# This GLP Editorial Team # This GLP | Which GLP-1 seller actually holds up. Independent reviews of GLP-1 telehealth sellers — semaglutide and tirzepatide, compounded and brand. We read what each seller publishes, check it against the trial record, and say what it does not tell you. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/ Updated: 2026-10-28 An independent GLP-1 price desk # 135 of 402 sellers advertise _a price you cannot pay_. We compare sellers’ published prices with mandatory membership, consultation and shipping fees included. 267 sellers need no correction at all. [See how the sellers rank](https://thisglp.com/best)[Work out your own cost →](https://thisglp.com/tools/glp1-cost-calculator) 580 sellers tracked 1,202 figures, each dated 580 reviews written here October 2026 prices last read The widest gap we hold Alloy advertises $199 what it bills $448 +$249/mo added Wegovy is billed by NovoCare at $199 a month for a new patient's first two fills only, then $349 a month at every standard dose; with the mandatory $99 Alloy Weight Care fee that is $448 a month. [Check your quote](https://thisglp.com/tools/glp1-price-check)[Read the Alloy review](https://thisglp.com/reviews/alloy) First on the [published rubric](https://thisglp.com/methodology) in more than one category ## Rivo Health Rivo Health ranks first in three of these four cuts, scoring 8.8 of 10 in each. - A price is published for each of the 4 molecule-and-form combinations this seller lists. The rubric that produced that position cannot read whether a seller pays us. [Read the Rivo Health review](https://thisglp.com/reviews/rivo-health) ### Compounded semaglutide $189.50 Median across the 368 sellers priced here, from $49. Its own figure here is $149. [See how the sellers rank](https://thisglp.com/best) ### Compounded tirzepatide $250 Median across the 355 sellers priced here, from $83. Its own figure here is $199. [See the tirzepatide sellers](https://thisglp.com/best) ### No membership required $181.50 Median across the 248 sellers priced here, from $83. Its own figure here is $149. [Work out your own all-in cost](https://thisglp.com/tools/glp1-cost-calculator) ## The branded products Wegovy, Zepbound and the manufacturer pharmacies, where the price is set above the seller. $298 Median monthly price across the 19 sellers priced here. The range runs from $119. Ranked first here by the [published rubric](https://thisglp.com/methodology), at 7.6 of 10 Maximus $449.99 a month A price is published for each of the 2 molecule-and-form combinations this seller lists. [Read the seller reviews](https://thisglp.com/reviews) Every price above is read off the seller’s own page, with the fees described in prose beside it added back before anything is ranked. [How a price is checked](https://thisglp.com/methodology) ## What this desk holds 580 Sellers we hold a published price for, across 1,202 separate figures, each carrying the date we read it. 135 Of the 402 sellers we price, that many advertise a figure you cannot actually pay. 65 of those corrections are a membership charged beside the medication. 267 Sellers whose advertised price is the one they bill. That is the number this site exists to find, and it is recomputed every time the roster moves. Everything on this site ## Four ways to get to an answer 580 ### [Seller reviews](https://thisglp.com/reviews) One page per seller: what the plan term really is, what a month costs with nothing prepaid, and which states it ships to. 36 ### [Head-to-head pages](https://thisglp.com/compare) Two sellers side by side on the figures that actually differ, rather than on the ones that are the same everywhere. 222 ### [Research write-ups](https://thisglp.com/research) What the trial record says about this drug class, with the effect sizes, the confidence intervals and the citations attached. 10 ### [Cost tools](https://thisglp.com/tools) Work out your own all-in monthly cost at your own dose, including the fees a headline price leaves out. ### The 10 calculators, by name - [What Sellers Publish](https://thisglp.com/tools/what-sellers-publish) - [Questions They Leave Open](https://thisglp.com/tools/questions-they-leave-open) - [When a Month Is Not a Month](https://thisglp.com/tools/billing-cadence-check) - [Published Dose Ladders](https://thisglp.com/tools/published-dose-ladders) - [Coverage by State](https://thisglp.com/tools/coverage-by-state) - [Molecule and Format Finder](https://thisglp.com/tools/molecule-and-format-finder) - [Cost Calculator](https://thisglp.com/tools/glp1-cost-calculator) - [Titration Planner](https://thisglp.com/tools/glp1-titration-planner) - [Expected Weight Loss](https://thisglp.com/tools/glp1-expected-weight-loss) - [Price Check](https://thisglp.com/tools/glp1-price-check) **Disclosure:** We are paid a commission by 31 sellers elsewhere on this site and by none of the sellers named above. Where a partner is named, it carries a Partner label and it sorts first. [How we make money](https://thisglp.com/disclosures) --- # About | This GLP This GLP is an independent review site for GLP-1 sellers, published under its own editorial byline and funded by affiliate commission. Here's how it works. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/about Updated: 2026-09-16 About # One molecule. Every way it is sold. This GLP reviews and ranks the telehealth providers and compounding pharmacies that sell GLP-1. We read the studies, price out a real month with each seller, and tell you plainly which ones are worth your money and which ones aren’t. We didn’t build this because GLP-1 is complicated to explain — we built it because the sellers make it complicated to compare, and because the evidence behind the marketing claims is thinner in most places than the marketing suggests. This GLP publishes the research and comparisons on this site. We are paid by affiliate commissions from some of the providers here, we [name every one of them](https://thisglp.com/disclosures), and a provider’s score never moves because of the commission. We attach no degrees or affiliations to our writers, and there is no licensed clinician on staff as a medical reviewer — we say so rather than implying otherwise, and that is why a medical disclaimer sits on our health pages. What we do instead is check everything against the primary source before it publishes, and date every price to the month we read it off the seller’s own page. ## Editorial coverage [ ### Evidence reviewer Coverage area What the trials measured, in whom, at what dose, and for how long. Explore coverage →](https://thisglp.com/authors/dana-sullivan)[ ### Outcomes writer Coverage area What the months actually look like — the plateau, the side effects, stopping. Explore coverage →](https://thisglp.com/authors/ruth-alvarez)[ ### Standards editor Coverage area The ranking rules, the corrections log, and what this site will not publish. Explore coverage →](https://thisglp.com/authors/glenn-torres) Read more about how we work in our [methodology](https://thisglp.com/methodology) and [disclosures](https://thisglp.com/disclosures). --- # Editorial Team | This GLP This GLP publishes sourced GLP-1 research and provider comparisons. Learn about the publisher, coverage areas, source standards and corrections. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/authors Updated: 2026-09-16 Editorial team # The publisher behind the research. Articles and reviews are published by This GLP. Coverage includes clinical evidence, provider comparisons and the practical cost of treatment. This GLP is responsible for the research and comparisons published here. Content draws on prescribing information, published studies and provider disclosures. It is informational and is not individualized medical advice. Publisher attribution does not imply a medical credential or an independent clinical review. Questions about a page or its sources can be sent through the [contact page](https://thisglp.com/contact). [ ## Evidence reviewer Coverage area What the trials measured, in whom, at what dose, and for how long. Explore coverage →](https://thisglp.com/authors/dana-sullivan)[ ## Outcomes writer Coverage area What the months actually look like — the plateau, the side effects, stopping. Explore coverage →](https://thisglp.com/authors/ruth-alvarez)[ ## Standards editor Coverage area The ranking rules, the corrections log, and what this site will not publish. Explore coverage →](https://thisglp.com/authors/glenn-torres) How we research and where we draw the line is set out in our [methodology](https://thisglp.com/methodology) and [editorial policy](https://thisglp.com/editorial-policy). --- # Evidence reviewer — This GLP | This GLP This GLP coverage of what the trials measured, in whom, at what dose, and for how long. Browse sourced articles and the publisher’s editorial standards. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/authors/dana-sullivan Updated: 2026-09-15 [← Editorial team](https://thisglp.com/authors) Coverage area # Evidence reviewer This GLP articles covering Randomized trial design and endpoints, FDA prescribing information and label changes, Reported adverse events and dropout rates, Dose-response and titration schedules, Compounded versus FDA-approved formulations, Reading a study's limitations section. Published by This GLP Editorial Team. This collection brings together sourced articles on what the trials measured, in whom, at what dose, and for how long. These pages explain available evidence; they do not provide a clinical opinion or claim firsthand treatment experience. ## Coverage - Randomized trial design and endpoints - FDA prescribing information and label changes - Reported adverse events and dropout rates - Dose-response and titration schedules - Compounded versus FDA-approved formulations - Reading a study's limitations section ## Articles in this collection 77 pieces - [Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show Evidence](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [Does Tirzepatide Cause Skin Sensitivity? The Allodynia Reports, Counted Safety](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity) - [Should You Stop Ozempic Before a Colonoscopy? What Bowel-Prep Studies Found Safety](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy) - [Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure Formats](https://thisglp.com/research/where-should-you-inject-ozempic) - [How Long Does Zepbound Stay in Your System? About a Month Safety](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system) - [How Do You Avoid Ozempic Face? No Tested Way to Prevent It Safety](https://thisglp.com/research/how-to-avoid-ozempic-face) - [Do GLP-1 Drugs Cause Depression or Anxiety? The Trials Say No, the Records Say Yes Safety](https://thisglp.com/research/do-glp1-drugs-cause-depression) - [GLP-1 Drugs in Pregnancy: What the Evidence Shows, and What It Cannot Safety](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows) - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?Evidence](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) - [Is CagriSema Better Than Semaglutide Alone? By 6.5 Points, Head to Head Evidence](https://thisglp.com/research/is-cagrisema-better-than-semaglutide) - [Do GLP-1 Drugs Prevent Stroke? The Composite Moves, Stroke Alone Is Thin Evidence](https://thisglp.com/research/do-glp1-drugs-prevent-stroke) - [Retatrutide in Type 2 Diabetes: Why TRANSCEND-T2D-1 Reads Lower Than Phase 2 Evidence](https://thisglp.com/research/retatrutide-transcend-t2d-1) - [Survodutide: What SYNCHRONIZE-1 Found, and Why It Reads Weaker Than Phase 2 Evidence](https://thisglp.com/research/survodutide-synchronize-1) - [Ozempic Teeth: What Has Actually Been Measured, and What Has Not Safety](https://thisglp.com/research/ozempic-teeth) - [Do GLP-1 Drugs Prevent Heart Attacks and Strokes? One, Not Both Evidence](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes) - [Weight-Loss Drugs in Hypertension: What the Cochrane Review Lacked Evidence](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths) - [Does Semaglutide Help Liver Cirrhosis? Not in the Trial That Tested It Evidence](https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis) - [Can You Take a GLP-1 With Epilepsy? Seizure Risk Did Not Rise Evidence](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy) - [How Many Heart Attacks Could Semaglutide Prevent in the US?Evidence](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent) - [GLP-1 Use and Knee Replacement: Absolute Risk at Eight Years Evidence](https://thisglp.com/research/fewer-knee-replacements-eight-years-on) - [Does Orforglipron Work for Type 2 Diabetes? Three Phase 3 Trials Evidence](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes) - [Respiratory Side Effects of Weight-Loss Drugs: A Review of 123 Studies Safety](https://thisglp.com/research/one-asthma-study-in-a-hundred-and-twenty-three) - [Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers Formats](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) - [Mortality in Serious Mental Illness: GLP-1 vs SGLT2 Inhibitors Evidence](https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness) - [Can a Drug Prevent Muscle Loss on a GLP-1? Two Antibodies Tested Evidence](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1) - [What Is Ecnoglutide? A Phase 3 Result You Cannot Compare to the Others Evidence](https://thisglp.com/research/what-is-ecnoglutide) - [Tirzepatide vs Semaglutide for Heart Failure, With and Without Diabetes Evidence](https://thisglp.com/research/bigger-relative-smaller-absolute) - [Semaglutide and Effort in Major Depression: A 72-Person Randomized Trial Evidence](https://thisglp.com/research/motivation-in-depression-a-secondary-finding) - [Obesity Drugs Ranked Across 262 Trials: Weight Lost vs Side-Effect Dropout Evidence](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated) - [Do GLP-1 Drugs Help Psoriasis? Clear Skin in 40.6% Against 29.0%Evidence](https://thisglp.com/research/do-glp1-drugs-help-psoriasis) - [Do GLP-1 Drugs Cause Glaucoma? Nobody Untreated Was Ever Compared Safety](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma) - [Frailty and Semaglutide's Cardiovascular Benefit in the SELECT Trial Evidence](https://thisglp.com/research/frailty-did-not-change-the-answer) - [BMI Above 30 and Type 2 Diabetes Drug Response: Weight vs HbA1c Evidence](https://thisglp.com/research/does-starting-weight-change-the-answer) - [Do GLP-1 Drugs Affect Breast Surgery? Implants Fared Worse, Flaps Did Not Evidence](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery) - [What Weight Loss Drugs Are There Besides Ozempic? Six Have Evidence Evidence](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic) - [Do GLP-1 Drugs Help Resistant Hypertension? The Pressure Matched Evidence](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension) - [Do GLP-1 Drugs Help COPD? Fewer Flare-Ups, Against One Comparator Evidence](https://thisglp.com/research/do-glp1-drugs-help-copd) - [GLP-1 Drugs in Psoriasis: Mortality, Heart Events and Substance Use Evidence](https://thisglp.com/research/glp1-psoriasis-comorbidities) - [Semaglutide and Reproductive Hormones in Rats: A Pair-Fed Study Evidence](https://thisglp.com/research/semaglutide-reproduction-pair-fed-rats) - [Tirzepatide and Cardiac Remodeling in HFpEF: A 50-Patient Echo Study Evidence](https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling) - [Smart Scale Body Composition on GLP-1 Drugs: Fat vs Muscle Lost Evidence](https://thisglp.com/research/glp1-body-composition-smart-scale) - [Do GLP-1 Drugs Improve Blood Vessel Function? The Same Number, Two Answers Evidence](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function) - [Frailty and Semaglutide in Heart Failure: The STEP-HFpEF Analysis Evidence](https://thisglp.com/research/glp1-heart-failure-frailty) - [Liver Cancer Risk on GLP-1 Drugs vs Other Diabetes Treatments Evidence](https://thisglp.com/research/glp1-liver-cancer-absolute-risk) - [GLP-1 Drugs in MASH: Deaths, Ascites and a Small Liver Cancer Signal Evidence](https://thisglp.com/research/glp1-liver-cancer-signal-dismissed) - [Can You Take a GLP-1 on Dialysis? 2,492 Patients, and No Trial Evidence](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis) - [Do GLP-1 Drugs Cause Pancreatic Cancer? Six Comparators, Five Answers Evidence](https://thisglp.com/research/do-glp1-drugs-cause-pancreatic-cancer) - [Do GLP-1 Drugs Help Parkinson's Disease? Prevention and Treatment Disagree Evidence](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease) - [GLP-1 Prescribing to Children Aged 8 to 11: Who Gets Them Evidence](https://thisglp.com/research/glp1-prescriptions-to-young-children) - [Real-World GLP-1 Weight Loss: Discontinuation, Dose and the Trial Gap Evidence](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) - [How Do You Take Oral Semaglutide? Empty Stomach, and Little Water Formats](https://thisglp.com/research/how-do-you-take-oral-semaglutide) - [Oral Semaglutide 50 mg in East Asian Adults: 14.3% Weight Loss Evidence](https://thisglp.com/research/oral-semaglutide-fifty-milligrams) - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide Evidence](https://thisglp.com/research/what-is-orforglipron) - [Do GLP-1 Drugs Help Heart Failure? Symptom Scores Rose 7.5 Points Evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure) - [Semaglutide and Fracture Risk: Type 2 Diabetes vs No Diabetes Evidence](https://thisglp.com/research/semaglutide-fractures-diabetes-only) - [Semaglutide in Knee Osteoarthritis: A Six-Month Cohort and Its Phenotypes Evidence](https://thisglp.com/research/semaglutide-knee-osteoarthritis-phenotypes) - [Semaglutide and Handgrip Strength: A 12-Month Body Composition Study Evidence](https://thisglp.com/research/semaglutide-muscle-mass-and-grip) - [Semaglutide and NAION: Optic Nerve Risk in Diabetes vs Obesity Safety](https://thisglp.com/research/semaglutide-optic-nerve-by-indication) - [Is a Higher Semaglutide Dose Worth It? Three Points, Four Times the Symptom Evidence](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it) - [What Else Comes Back When You Stop a GLP-1? Almost Everything Evidence](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1) - [Tirzepatide Dispensing by Dose in Japan: National Claims Data Formats](https://thisglp.com/research/tirzepatide-dose-mix-in-japan) - [SUMMIT Trial Composite Endpoint: Tirzepatide in HFpEF, Broken Down Evidence](https://thisglp.com/research/tirzepatide-heart-failure-composite) - [Tirzepatide vs Semaglutide: Major Adverse Liver Outcomes in Type 2 Diabetes Evidence](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver) - [UBT251 Triple Agonist: First-in-Human 12-Week Weight Loss Trial Evidence](https://thisglp.com/research/triple-agonist-first-in-human) - [Do GLP-1 Drugs Cause Kidney Cancer? Trials Say Probably Not Safety](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer) - [Gallstone Risk on GLP-1 Drugs: Weight-Loss vs Diabetes Trials Safety](https://thisglp.com/research/glp1-and-gallbladder-disease) - [Do GLP-1 Drugs Help Knee Pain? Yes, and Read the Placebo Arm Evidence](https://thisglp.com/research/do-glp1-drugs-help-knee-pain) - [Do GLP-1 Drugs Cause Pancreatitis? Risk and Warning Signs Safety](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis) - [Do GLP-1 Drugs Affect Sex Drive? Nobody Has Run That Trial Safety](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive) - [Tirzepatide Sleep Apnea Trial (SURMOUNT-OSA): AHI Results at 52 Weeks Evidence](https://thisglp.com/research/glp1-and-sleep-apnea) - [Residual Stomach Contents on GLP-1 Drugs: A Gastric Ultrasound Study Safety](https://thisglp.com/research/glp1-before-surgery) - [Semaglutide Lean Mass in the SMART Trial: −2.5 kg, Interval Crossing Zero Evidence](https://thisglp.com/research/muscle-loss-on-glp1) - [FLOW Trial: Semaglutide 1.0 mg in Diabetic Chronic Kidney Disease Evidence](https://thisglp.com/research/semaglutide-and-kidney-disease) - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded Evidence](https://thisglp.com/research/semaglutide-cochrane-review) - [Tirzepatide and Oral Contraceptive Levels: 55 to 66% Lower Peaks Safety](https://thisglp.com/research/tirzepatide-and-oral-contraception) - [GLP-1 Seller Disclosure Gaps: Dose Pricing, State Coverage, Formats Formats](https://thisglp.com/research/what-glp1-sellers-do-not-publish) - [GLP-1 Sellers That Publish a Dose Price Ladder, Counted Formats](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) [Browse all research](https://thisglp.com/research)[About This GLP](https://thisglp.com/about) --- # Standards editor — This GLP | This GLP This GLP coverage of the ranking rules, the corrections log, and what this site will not publish. Browse sourced articles and the publisher’s editorial standards. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/authors/glenn-torres Updated: 2026-09-15 [← Editorial team](https://thisglp.com/authors) Coverage area # Standards editor This GLP articles covering The provider scoring rubric, Corrections and how they are logged, Affiliate disclosure rules, Medical-claim language limits, Source requirements for a published figure, When a provider is excluded from a ranking. Published by This GLP Editorial Team. This collection brings together sourced articles on the ranking rules, the corrections log, and what this site will not publish. These pages explain available evidence; they do not provide a clinical opinion or claim firsthand treatment experience. ## Coverage - The provider scoring rubric - Corrections and how they are logged - Affiliate disclosure rules - Medical-claim language limits - Source requirements for a published figure - When a provider is excluded from a ranking ## Articles in this collection 68 pieces - [Can You Smoke Weed on Ozempic? What Cannabis-User Cohorts Found Safety](https://thisglp.com/research/can-you-smoke-weed-on-ozempic) - [Can You Take Ozempic With Levothyroxine? The Tablet Form Is the One Studied Safety](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine) - [Can You Take Phentermine With Ozempic? No Trial Has Tested It, One Tried Liraglutide Safety](https://thisglp.com/research/can-you-take-phentermine-with-ozempic) - [Can You Take Ozempic While Breastfeeding? 8 Mothers, No Drug Detected in Milk Safety](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding) - [Can a Pill Keep Weight Off After the Injection? ATTAIN-MAINTAIN, Read Carefully Evidence](https://thisglp.com/research/can-a-pill-keep-weight-off-after-the-injection) - [Tirzepatide Against Real Clinical Practice: What SURPASS-EARLY Found Evidence](https://thisglp.com/research/tirzepatide-vs-real-clinical-practice) - [Do GLP-1 Drugs Help Alzheimer's? The Trials and the Records Disagree Evidence](https://thisglp.com/research/do-glp1-drugs-help-alzheimers) - [Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes Formats](https://thisglp.com/research/semaglutide-starting-dose) - [VK2735 Phase 2 VENTURE Trial: 14.7% Weight Loss in 13 Weeks Evidence](https://thisglp.com/research/ninety-three-percent-in-thirteen-weeks) - [GLP-1 Use and Bowel Function After Lumbar Fusion: 117 Patients Safety](https://thisglp.com/research/the-bowels-woke-up-sooner) - [GLP-1 Drugs and ERCP Complications: A TriNetX Cohort of 21,818 Evidence](https://thisglp.com/research/when-a-drug-improves-everything) - [Is Semaglutide Safe for People With HIV? Four Studies So Far Safety](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv) - [Parkinson's Incidence and Motor Symptoms on GLP-1 Drugs: An 82-Study Review Evidence](https://thisglp.com/research/preventing-it-is-not-treating-it) - [Can a GLP-1 Cause Ketoacidosis? 470 Reports, Most of Them Hospitalized Safety](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis) - [FLOW Trial Cardiovascular Subgroups: Semaglutide's Numbers Needed to Treat Evidence](https://thisglp.com/research/twenty-two-thirteen-seventeen) - [Tirzepatide Sleep Apnea Results by Age, BMI and Severity Evidence](https://thisglp.com/research/apnea-improved-across-every-subgroup) - [Semaglutide Dose Escalation and Insulin Reduction in Type 2 Diabetes Evidence](https://thisglp.com/research/each-dose-step-took-insulin-away) - [GLP-1 Drugs at the Start of Hemodialysis: Hospitalization and Death Evidence](https://thisglp.com/research/dialysis-the-evidence-base-just-grew) - [Atrial Fibrillation Risk: GLP-1 vs SGLT-2 vs DPP-4 Inhibitors Evidence](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won) - [Can a GLP-1 Cause Thiamine Deficiency? Six Cases Say It Can Safety](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency) - [Do GLP-1 Drugs Raise the Risk of Aspiration Pneumonia?Safety](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia) - [Do GLP-1 Drugs Cause Acid Reflux? Three Databases Say More Reports Safety](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux) - [GLP-1 Drugs and Overdose Risk: Five Comparators in VA Data Evidence](https://thisglp.com/research/overdose-depends-on-the-comparator) - [Do GLP-1 Drugs Help Carpal Tunnel Syndrome? Fewer Diagnoses, Same Surgeries Evidence](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome) - [How Many People Use Compounded GLP-1 Drugs? Records Catch 8.2%Evidence](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs) - [Do GLP-1 Drugs Prevent Contrast Kidney Injury? 8.7% Against 25.7%Evidence](https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury) - [Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3 Formats](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease) - [Do GLP-1 Drugs Cause Arrhythmia? Three Intervals, Two Cross One Safety](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia) - [Do GLP-1 Drugs Help Antipsychotic Weight Gain? 9.8% Off, Half Back Evidence](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain) - [Depression Risk on GLP-1 Drugs vs DPP-4 and SGLT2 Inhibitors Evidence](https://thisglp.com/research/glp1-depression-depends-on-comparator) - [Do GLP-1 Drugs Cause Kidney Stones? Nobody Has Run That Comparison Evidence](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones) - [Is Tirzepatide Better Than Dulaglutide? One Trial Is 92% of the Answer Evidence](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide) - [GLP-1 Discounts vs Seller Disclosure: Dose Ladders and State Lists Formats](https://thisglp.com/research/do-discounting-sellers-disclose-less) - [Adolescent Suicidality on GLP-1 Drugs vs Lifestyle Intervention and Metformin Evidence](https://thisglp.com/research/glp1-adolescent-suicidality-comparators) - [Advertised vs Billed GLP-1 Prices: Every Correction, by Type Formats](https://thisglp.com/research/glp1-advertised-vs-billed-corrections) - [Do GLP-1 Drugs Help Ulcerative Colitis? Remission Was 66.7% Against 25.3%Evidence](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis) - [What BMI Do You Need for a GLP-1? The Cut-Off Is a Convention Evidence](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) - [What Should a GLP-1 Provider Actually Do? Five Pillars Formats](https://thisglp.com/research/what-should-a-glp1-provider-actually-do) - [Does Taking a GLP-1 Before Pregnancy Raise Preeclampsia Risk? The Studies Split Evidence](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk) - [GLP-1 Drugs in Children and Adolescents: 18 Randomized Trials Pooled Evidence](https://thisglp.com/research/glp1-in-children-all-eighteen-trials) - [Do You Lose Muscle on a GLP-1? And What Comes Back Is Fat Evidence](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1) - [GLP-1 Drugs and Mortality in Type 2 Diabetes With a BMI Under 27 Evidence](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own) - [Mortality on GLP-1 Drugs in Hidradenitis Suppurativa: A Record Study Evidence](https://thisglp.com/research/glp1-mortality-in-hidradenitis) - [Why Do GLP-1 Drugs Cause Nausea? And Why It Does Not Predict Weight Loss Safety](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea) - [Insulin Resistance in PCOS on GLP-1 Drugs: A Four-Trial Meta-Analysis Evidence](https://thisglp.com/research/glp1-pcos-insulin-resistance) - [GLP-1 Price Spread Across Sellers: The Range and the Middle Half Formats](https://thisglp.com/research/glp1-price-spread-across-sellers) - [Which GLP-1 Has the Worst Side Effects? It Depends on the Outcome Evidence](https://thisglp.com/research/which-glp1-has-the-worst-side-effects) - [GLP-1 Drugs and Rotator Cuff Repair Complications in Type 2 Diabetes Evidence](https://thisglp.com/research/glp1-shoulder-surgery-adjustment) - [Do GLP-1 Drugs Affect Spinal Fusion Surgery? It Depends on the Operation Evidence](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery) - [Atrial Fibrillation After Ablation on GLP-1 Drugs: An Umbrella Review Evidence](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) - [GLP-1 Prescribing After a Heart Attack or Stroke: Czech Registry Data Evidence](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke) - [Do You Need Vitamins on a GLP-1? Over 60% Eat Below the Iron Requirement Safety](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1) - [GLP-1 Dose Ladders: How Many Price Rungs Sellers Publish Formats](https://thisglp.com/research/how-deep-a-published-dose-ladder-goes) - [Promotional GLP-1 Pricing: First-Month Rates, Codes and Struck Prices Formats](https://thisglp.com/research/how-much-glp1-pricing-is-promotional) - [Is a GLP-1 Better Than Metformin? Nobody Has Run That Trial Evidence](https://thisglp.com/research/is-a-glp1-better-than-metformin) - [GLP-1 Price Changes Between Two Readings of the Same Sellers Formats](https://thisglp.com/research/rereading-glp1-prices) - [Does Semaglutide Reduce Alcohol Use? One Trial Found a 13.7-Point Gap Evidence](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use) - [Oral Semaglutide in Early Alzheimer's Disease: The evoke and evoke+ Trials Evidence](https://thisglp.com/research/semaglutide-and-alzheimers) - [Semaglutide in MASH: ESSENCE Phase 3 Results at 72 Weeks Evidence](https://thisglp.com/research/semaglutide-and-liver-disease) - [Do GLP-1 Drugs Help Migraine? Triptan Use Fell 7%, Which Is Not a Treatment Evidence](https://thisglp.com/research/do-glp1-drugs-help-migraine) - [Semaglutide and Cognitive Signs in Psychiatric Patients: 13,007 Records Evidence](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs) - [Can You Trust GLP-1 Advice on TikTok? Likes Do Not Track Quality Evidence](https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media) - [Do GLP-1 Drugs Affect Fertility? 25 Men, and No Trial Measured Pregnancy Evidence](https://thisglp.com/research/do-glp1-drugs-affect-fertility) - [Switching to Tirzepatide and Liver Fibrosis Scores: 182 Patients Evidence](https://thisglp.com/research/tirzepatide-fibrosis-worst-group) - [Tirzepatide 2.5 mg vs 5 mg in Japanese Adults Without Diabetes Evidence](https://thisglp.com/research/tirzepatide-low-dose-self-selected) - [Stopping Semaglutide in Type 1 Diabetes: Time in Range After Withdrawal Evidence](https://thisglp.com/research/type-1-diabetes-stopping-semaglutide) - [GLP-1 Seller State Coverage: Who Publishes Where They Ship Formats](https://thisglp.com/research/who-publishes-the-states-they-serve) - [GLP-1 Sellers Billing Every Four Weeks: Thirteen Charges a Year Formats](https://thisglp.com/research/glp1-four-week-billing-cycles) [Browse all research](https://thisglp.com/research)[About This GLP](https://thisglp.com/about) --- # Outcomes writer — This GLP | This GLP This GLP coverage of what the months actually look like — the plateau, the side effects, stopping. Browse sourced articles and the publisher’s editorial standards. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/authors/ruth-alvarez Updated: 2026-09-15 [← Editorial team](https://thisglp.com/authors) Coverage area # Outcomes writer This GLP articles covering Weight regain after discontinuation, Tolerability over the first six months, Plateaus and dose escalation decisions, Maintenance dosing and long-term cost, What continuation actually requires of a patient, Trial follow-up beyond the primary endpoint. Published by This GLP Editorial Team. This collection brings together sourced articles on what the months actually look like — the plateau, the side effects, stopping. These pages explain available evidence; they do not provide a clinical opinion or claim firsthand treatment experience. ## Coverage - Weight regain after discontinuation - Tolerability over the first six months - Plateaus and dose escalation decisions - Maintenance dosing and long-term cost - What continuation actually requires of a patient - Trial follow-up beyond the primary endpoint ## Articles in this collection 70 pieces - [Can You Take Metformin and Ozempic Together? Most Trials Required It Safety](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together) - [Does Ozempic Cause Constipation? What the Trials Counted, and When It Eases Safety](https://thisglp.com/research/does-ozempic-cause-constipation) - [Why Does Ozempic Cause Sulfur Burps? What the Adverse-Event Data Show Safety](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps) - [Can Tirzepatide Cause Anxiety or Depression? Trials Say No, Records Are Mixed Safety](https://thisglp.com/research/can-tirzepatide-cause-anxiety) - [Does Zepbound Cause Headaches? Headache Never Made Its Side-Effect Table Safety](https://thisglp.com/research/does-zepbound-cause-headaches) - [Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found Evidence](https://thisglp.com/research/semaglutide-in-type-1-diabetes) - [Do GLP-1 Drugs Work After Bariatric Surgery? Two Randomized Trials Say Yes Evidence](https://thisglp.com/research/glp1-after-bariatric-surgery-evidence) - [What Happens When You Stop Tirzepatide? SURMOUNT-4 Says 14% Comes Back Evidence](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide) - [Does Ozempic Cause Hair Loss? What 1,091,743 Records Show Safety](https://thisglp.com/research/does-ozempic-cause-hair-loss) - [Do GLP-1 Drugs Improve Your Quality of Life? 2.12 Points on the SF-36 Evidence](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life) - [Do GLP-1 Drugs Cause Blood Clots? No Untreated Group Was Ever Followed Evidence](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots) - [Do GLP-1 Drugs Work the Same in Asian Patients? The Percentages Match Evidence](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients) - [Do GLP-1 Drugs Help IBS? Coded Symptoms Fell by Two to Four Points Evidence](https://thisglp.com/research/do-glp1-drugs-help-ibs) - [Do GLP-1 Drugs Help Bipolar Disorder? One Drug Moved, Two Did Not Evidence](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder) - [Tirzepatide and Serum Uric Acid: A SURMOUNT-1 Post Hoc Analysis Evidence](https://thisglp.com/research/uric-acid-fell-and-most-of-it-was-weight) - [Tirzepatide in HFpEF by Sex: SUMMIT Trial Results in Women and Men Evidence](https://thisglp.com/research/same-benefit-different-route-by-sex) - [Can You Take a GLP-1 With a Heart Pump? 141 Pairs, and No Effect Sizes Evidence](https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump) - [Do GLP-1 Drugs Help Intracranial Hypertension? Probably, but Less Than Reported Evidence](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension) - [Are GLP-1 Drugs Safe for Older Adults? Seven Trials, and Who They Left Out Safety](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults) - [How Much Less Do You Eat on a GLP-1? About 271 Calories at One Meal Evidence](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1) - [Can You Take a GLP-1 With Sickle Cell Disease? One Cohort, 1,391 Pairs Evidence](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease) - [Survodutide in MASH: How Much of the Liver Benefit Was Weight Loss Evidence](https://thisglp.com/research/liver-repair-that-was-not-the-weight) - [Do GLP-1 Drugs Help Rheumatoid Arthritis? The Heart Result, Not the Joints Evidence](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis) - [Alcohol Admissions After Stopping a GLP-1: Swedish Within-Person Data Evidence](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it) - [Do GLP-1 Drugs Reduce Inflammation? hsCRP Fell 37.8% in SELECT Evidence](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation) - [Do GLP-1 Drugs Help Crohn's Disease? Hospitalization Halved, Steroids Unchanged Evidence](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease) - [Asthma Exacerbations on GLP-1 Drugs vs Other Weight Medications Evidence](https://thisglp.com/research/glp1-asthma-relative-and-absolute) - [Do GLP-1 Drugs Make You Tired? Daytime Sleepiness Improved by 0.20 Points Safety](https://thisglp.com/research/do-glp1-drugs-make-you-tired) - [Bone Mineral Density on GLP-1 Drugs in Type 2 Diabetes: 25 Trials Evidence](https://thisglp.com/research/glp1-bone-density-vs-fractures) - [Do GLP-1 Drugs Help Atrial Fibrillation? The Evidence Disagrees With Itself Evidence](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation) - [Why Isn't Obesity in Your Medical Record? One in Ten Had It Written Down Evidence](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record) - [Bariatric Surgery vs GLP-1 Drugs on Cardiovascular Events Evidence](https://thisglp.com/research/bariatric-surgery-vs-glp1-cardiovascular) - [GLP-1 Storefronts Sharing One Application Build, Matched by Hash Formats](https://thisglp.com/research/eight-storefronts-one-application) - [Do GLP-1 Drugs Cause Gastroparesis? Thirteen Cases, and Two Opposite Findings Safety](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis) - [Unexpected Pregnancy on a GLP-1: Why Weight Loss Makes It Likelier Safety](https://thisglp.com/research/glp1-and-pregnancy) - [Semaglutide and Suicidal Ideation: The Large Matched Cohort Studies Safety](https://thisglp.com/research/glp1-and-suicidal-ideation) - [Do GLP-1 Drugs Change Your Sense of Taste? Scores Fell From 40.63 to 28.61 Evidence](https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste) - [Do GLP-1 Drugs Cause Thyroid Cancer? A Bound, Not a Verdict Safety](https://thisglp.com/research/do-glp1-drugs-cause-thyroid-cancer) - [Does a GLP-1 Affect Surgery Outcomes? Four Procedures, Four Different Answers Evidence](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) - [Do GLP-1 Drugs Prevent Diabetic Foot Ulcers? The Database Cannot Say Evidence](https://thisglp.com/research/do-glp1-drugs-prevent-diabetic-foot-ulcers) - [GLP-1 Dosing Errors in FDA Adverse Event Reports Safety](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports) - [Are GLP-1 Drugs Bad for Your Liver? The Evidence Says Better Evidence](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver) - [High-Dose vs Standard-Dose GLP-1 Before Neck Fusion (ACDF) Surgery Evidence](https://thisglp.com/research/glp1-neck-fusion-high-dose) - [Exenatide for Smoking Cessation: Five Subgroups From One Pilot Trial Evidence](https://thisglp.com/research/glp1-smoking-cessation-subgroups) - [Do GLP-1 Drugs Cause Gout? The Study Everyone Cites Cannot Say Evidence](https://thisglp.com/research/do-glp1-drugs-cause-gout) - [GLP-1 Weight Loss Across 32 Trials: The 9.36% Average and Its Spread Evidence](https://thisglp.com/research/glp1-weight-loss-pooled-average) - [GLP-1 Price Freshness: How Old Published Seller Prices Are Formats](https://thisglp.com/research/how-old-is-the-price-you-are-reading) - [GLP-1 Seller Disclosures: Does Publishing One Predict Another?Formats](https://thisglp.com/research/is-seller-disclosure-a-trait) - [Do GLP-1 Drugs Raise Testosterone? Not in the Trials That Measured It Evidence](https://thisglp.com/research/do-glp1-drugs-raise-testosterone) - [Oral Semaglutide vs DPP-4 Inhibitors and Cognitive Impairment in HFpEF Evidence](https://thisglp.com/research/oral-semaglutide-cognitive-impairment) - [What New Weight Loss Drugs Are Coming? Retatrutide Leads at 22.1%Evidence](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming) - [Do GLP-1 Drugs Protect Against Dementia? A Predictor Moved Evidence](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia) - [Do GLP-1 Drugs Slow Aging? Three Clocks Moved, One Mouse Lifespan Did Evidence](https://thisglp.com/research/do-glp1-drugs-slow-aging) - [Does Semaglutide Make Diabetic Retinopathy Worse? In One Trial, Yes Safety](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse) - [Why Does Weight Loss Plateau on a GLP-1? The Drug Is Still Working Evidence](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1) - [Do GLP-1 Drugs Help Hidradenitis Suppurativa? Twenty People, No Control Group Evidence](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) - [Can You Take a GLP-1 With Polycystic Kidney Disease? Not as a Treatment Evidence](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease) - [Semaglutide Lifespan Study in Female Mice: 742 vs 834 Days Evidence](https://thisglp.com/research/semaglutide-lifespan-in-mice) - [Semaglutide Carbon Footprint: A UK Lifetime Emissions Model Evidence](https://thisglp.com/research/semaglutide-lifetime-carbon-emissions) - [Semaglutide for MASH in Japanese Patients: The ESSENCE Subgroup Evidence](https://thisglp.com/research/semaglutide-liver-japanese-subgroup) - [Semaglutide Psychiatric Risk Meta-Analysis: Trials Pooled With Report Counts Safety](https://thisglp.com/research/semaglutide-psychiatric-risk-pooling) - [Semaglutide vs Sleeve Gastrectomy: Liver Stiffness Over 72 Weeks Evidence](https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness) - [Telehealth Semaglutide and Tirzepatide Program: 12.3% at 24 Weeks Evidence](https://thisglp.com/research/telehealth-glp1-program-trial) - [Semaglutide vs Liraglutide After Bariatric Surgery: Weight and Lean Mass Evidence](https://thisglp.com/research/glp1-after-bariatric-surgery) - [Are GLP-1 Drugs Safe for Teens? The Trials, and What Is Outside Them Evidence](https://thisglp.com/research/are-glp1-drugs-safe-for-teens) - [Do GLP-1 Drugs Work in Menopause? The Subgroup Nobody Reported Safety](https://thisglp.com/research/do-glp1-drugs-work-in-menopause) - [Oral Semaglutide 25 mg: OASIS 4 Trial Results at 71 Weeks Formats](https://thisglp.com/research/oral-semaglutide-what-the-pill-does) - [Does Semaglutide Cause Vision Loss? The Signal Sits in Diabetes Safety](https://thisglp.com/research/does-semaglutide-cause-vision-loss) - [GLP-1 Withdrawal Trials: STEP 1, STEP 4 and SURMOUNT-4 Compared Evidence](https://thisglp.com/research/stopping-glp1-and-weight-regain) - [How Long Does Nausea Last on a GLP-1? Through the Escalation Evidence](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) [Browse all research](https://thisglp.com/research)[About This GLP](https://thisglp.com/about) --- # Buyer's guides | This GLP Every This GLP buyer's guide in one place — compounded semaglutide and tirzepatide, oral GLP-1, flat-dose pricing and the cheapest standing monthly rates. Ranked by molecule, by price and by who is asking. Affiliate-disclosed. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/best Updated: 2026-10-28 # Buyer’s guides Honest, evidence-first roundups of where to actually buy GLP-1. We disclose our affiliate relationships and order partners accordingly — but the assessment never changes based on who we earn from. Verify current pricing on each seller’s own site. **3** guides Reviewed against our [editorial methodology](https://thisglp.com/methodology) [How we make money](https://thisglp.com/disclosures) ## By molecule and form Sellers price semaglutide and tirzepatide independently, and a seller that is clear about one is often vague about the other. Start with the molecule — or the form — you are actually considering. [ ### Best compounded semaglutide sellers Sellers that publish a semaglutide price, ranked on whether they are usable by you: findable pricing, state coverage, and what else they carry. ](https://thisglp.com/best/compounded-semaglutide)[ ### GLP-1 sellers whose price holds at every dose Sellers that charge one figure whatever the dose. The axis is what the price does at month six, not what it is at month one — which is the part a reader cannot check quickly. ](https://thisglp.com/best/price-holds-at-every-dose)[ ### Best oral GLP-1 sellers Sellers offering a tablet rather than a weekly injection. A smaller field, and the ordering changes because breadth of form is the thing being asked for. ](https://thisglp.com/best/oral-glp1) ## Before you buy from anyone How these rankings are produced, and who pays us. [ ### How we score sellers The published rubric every score is computed from — price transparency, how a price behaves across the dose ladder, and access. It does not read commercial status. ](https://thisglp.com/methodology)[ ### How we make money Which links pay us, which do not, and how 31 sellers are partners on this site today. ](https://thisglp.com/disclosures)[ ### All seller reviews Every seller we have assessed, in full. ](https://thisglp.com/reviews) ## Faster paths If you would rather not read five guides to get to an answer. [ Torn between two? ### Head-to-head comparisons Found vs Ro, Hims vs Ro and more — the two services side by side, with an honest bottom line. ](https://thisglp.com/compare) --- # Best compounded semaglutide sellers | This GLP Compounded semaglutide sellers ranked on published pricing, state coverage and catalog breadth | every figure read off the seller's own page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/best/compounded-semaglutide Updated: 2026-10-28 Buyer's guide # Best compounded semaglutide sellers Every seller below publishes a semaglutide price. They are ordered on this site’s rubric, scoped to semaglutide, so a seller is judged on what it charges and covers for this molecule rather than on its cheapest line anywhere. By [This GLP Editorial Team](https://thisglp.com/about) **385** providers compared Reviewed against our [editorial methodology](https://thisglp.com/methodology) Partners listed first Updated September 2026 **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Top 5 for compounded semaglutide Every seller here is a partner — we may earn from these links 1. [ShedRx](https://thisglp.com/reviews/shedrx)Partner Readers willing to telephone a seller and ask which published fee is the real one From $149 2. [RxSpan MD](https://thisglp.com/reviews/rxspan-md)Partner Buyers who want the standing rate, the pharmacy and the prescriber named before signing up From $249 3. [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)Partner A reader unwilling to prepay a year before seeing how the drug goes From $179 4. [Lttl](https://thisglp.com/reviews/lttl)Partner Readers who want every prepay rung visible and know which dose line they need From $107 5. [Oak](https://thisglp.com/reviews/oak)Partner Readers who want a flat rate without a subscription and ignore the entry figure From $250 The shortlist ## 385 providers, side by side Sellers that publish a semaglutide figure on their own site. A seller with no published price cannot be ranked here, and is not listed. Sort | Provider | Access | Dose price | States | Go | | --- | --- | --- | --- | --- | | ShedRx Partner [Read review →](https://thisglp.com/reviews/shedrx) | From $149/mo | — | — | | | RxSpan MD Partner [Read review →](https://thisglp.com/reviews/rxspan-md) | From $249/mo | — | All 50 | | | Bodybuilding Health+Partner [Read review →](https://thisglp.com/reviews/bodybuilding-health-plus) | From $179/mo | — | — | | | Lttl Partner [Read review →](https://thisglp.com/reviews/lttl) | From $107/mo | Flat | — | | | Oak Partner [Read review →](https://thisglp.com/reviews/oak) | From $250/mo | Rises | — | | | Willow Partner [Read review →](https://thisglp.com/reviews/willow) | From $299/mo | — | — | | | Eden Partner [Read review →](https://thisglp.com/reviews/eden) | From $198/mo | Flat | All 50 | | | HumeCare+Partner [Read review →](https://thisglp.com/reviews/humecare) | From $199/mo | — | — | | | Direct Meds Partner [Read review →](https://thisglp.com/reviews/direct-meds) | From $249/mo | — | — | | | Found Partner [Read review →](https://thisglp.com/reviews/found) | From $313/mo | — | All 50 | | | Sprout Health Partner [Read review →](https://thisglp.com/reviews/sprout-health) | From $324/mo | — | 44 | | | CoreAge Rx Partner [Read review →](https://thisglp.com/reviews/coreage-rx) | From $99/mo | Flat | All 50 | | | HealthRX Partner [Read review →](https://thisglp.com/reviews/healthrx) | From $165/mo | Flat | — | | | PeterMD Partner [Read review →](https://thisglp.com/reviews/petermd) | From $270/mo | — | 42 | | | Luvo Health Partner [Read review →](https://thisglp.com/reviews/luvo-health) | From $271/mo | Flat | — | | | Sesame Care Partner [Read review →](https://thisglp.com/reviews/sesame-care) | From $208/mo | Rises | — | | | Embody Partner [Read review →](https://thisglp.com/reviews/embody) | From $199/mo | — | All 50 | | | Collective Partner [Read review →](https://thisglp.com/reviews/collective) | From $76/mo | Flat | — | | | SnagRx Partner [Read review →](https://thisglp.com/reviews/snagrx) | From $99/mo | Flat | — | | | Strut Health Partner [Read review →](https://thisglp.com/reviews/strut-health) | From $99/mo | — | 49 | | - ShedRx Partner— Readers willing to telephone a seller and ask which published fee is the real one Access From $149/mo Insurance — Visit — - RxSpan MD Partner— Buyers who want the standing rate, the pharmacy and the prescriber named before signing up Access From $249/mo Insurance — Visit All 50 - Bodybuilding Health+Partner— A reader unwilling to prepay a year before seeing how the drug goes Access From $179/mo Insurance — Visit — - Lttl Partner— Readers who want every prepay rung visible and know which dose line they need Access From $107/mo Insurance Flat Visit — - Oak Partner— Readers who want a flat rate without a subscription and ignore the entry figure Access From $250/mo Insurance Rises Visit — - Willow Partner— Readers who want a named physician roster and a tablet at the injection price Access From $299/mo Insurance — Visit — - Eden Partner— Buyers comparing what the two molecules actually cost Access From $198/mo Insurance Flat Visit All 50 - HumeCare+Partner— A reader who wants one number to survive a titration, consultation counted in Access From $199/mo Insurance — Visit — - Direct Meds Partner— A reader content to buy by the quarter who will redo the per-day math Access From $249/mo Insurance — Visit — - Found Partner— Readers who will commit to a longer term and want coaching and membership inside one figure Access From $313/mo Insurance — Visit All 50 - Sprout Health Partner— Readers taking the six-month plan, which is the one measured in calendar months Access From $324/mo Insurance — Visit 44 - CoreAge Rx Partner— A reader still at a starting dose, since that is the tier these rates price. Access From $99/mo Insurance Flat Visit All 50 - HealthRX Partner— Buyers who expect to escalate and want the later months priced Access From $165/mo Insurance Flat Visit — - PeterMD Partner— Readers who want a cancel-anytime subscription and will choose the monthly product over the quarterly offer Access From $270/mo Insurance — Visit 42 - Luvo Health Partner— Readers who want to price a full year before starting and can read a four-week interval Access From $271/mo Insurance Flat Visit — - Sesame Care Partner— Readers who want tirzepatide priced by dose and will read the FAQ before the headline Access From $208/mo Insurance Rises Visit — - Embody Partner— Readers who will establish the care arrangements and recurring agreement before enrollment Access From $199/mo Insurance — Visit All 50 - Collective Partner— A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. Access From $76/mo Insurance Flat Visit — - SnagRx Partner— Buyers who want to stay month to month without paying much for it Access From $99/mo Insurance Flat Visit — - Strut Health Partner— A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. Access From $99/mo Insurance — Visit 49 We never show a fabricated price or rating. Facts are shown only where a provider publishes them. ## How this board is built Across the 385 sellers here that publish a figure, the range runs from $49 to $525.42 a month, with a midpoint of $190. The spread is 10.7× from bottom to top, which is wider than most readers expect before they compare. Compounded semaglutide is prepared by a pharmacy rather than manufactured and reviewed as a finished product, so it is not FDA-approved and is not assessed for safety, efficacy or quality before it is dispensed. The published trial results a reader may have seen were generated with the approved product at labeled doses. See the [methodology](https://thisglp.com/methodology) for how each mark is derived. Semaglutide is the molecule almost every seller in this category leads with, so this board is close to the full field rather than a narrow cut of it. That makes the ordering the useful part: the sellers are broadly the same ones you will meet everywhere, and what separates them here is whether they say what they charge, where they will ship it, and what else they would sell you if the first choice does not suit. Two things a semaglutide price routinely omits. The first is the dose it applies to — an opening dose and a maintenance dose are different products at the same seller, and a single figure rarely says which one it is quoting. The second is what happens at week twelve, when most people have escalated at least once. Neither is visible in a headline, and neither is something this board can read off a page that does not state it. ## How we judge sellers - **Price transparency** — Can you find what a month costs — for the molecule and the form you want — before creating an account, and does the seller's own site agree with itself? - **Honest headline** — Is the figure the seller leads with the figure it bills? A price that needs a twelve-month prepay, or that is struck through from an anchor nobody pays, is a different number from a standing monthly rate. - **Dose-ladder pricing** — Does the price hold as your dose escalates, or is it re-set at every step? This is the difference most buyers only discover in month three. - **State coverage** — How much of the country the seller actually ships to. A seller that does not operate where you live is not an option, whatever it charges. - **Molecule and form breadth** — Whether the seller carries both molecules, and whether it offers an oral as well as an injection. Breadth is what lets you change course without changing provider. We never show a fabricated price or rating, and access notes appear only where a provider publishes them. Pricing and availability change often — confirm current details on the provider’s own site. ## Keep comparing [sellers offering an oral](https://thisglp.com/best/oral-glp1), and [what happens to the dose over twenty weeks](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## Common questions Why is the order different from the tirzepatide board? Because the marks are re-derived for the molecule the board is about. A seller that prices semaglutide clearly and tirzepatide vaguely ranks differently on the two, which is the point of scoping them. Is a compounded semaglutide the same as the branded product? It is the same molecule prepared by a compounding pharmacy rather than the finished product a manufacturer makes and the FDA reviews. Equivalence in content and purity is not established by that process. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Best oral GLP-1 sellers | This GLP Sellers offering a GLP-1 tablet rather than a weekly injection | ranked on published oral pricing, state coverage and catalog breadth. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/best/oral-glp1 Updated: 2026-09-16 Buyer's guide # Best oral GLP-1 sellers A smaller field than the injection boards: most sellers lead with a weekly shot, and a published oral price is the exception. Each seller below is marked on its ORAL line, not on its cheapest product. By [This GLP Editorial Team](https://thisglp.com/about) **79** providers compared Reviewed against our [editorial methodology](https://thisglp.com/methodology) Partners listed first Updated September 2026 **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Top 5 for oral glp-1 Every seller here is a partner — we may earn from these links 1. [ShedRx](https://thisglp.com/reviews/shedrx)Partner Readers willing to telephone a seller and ask which published fee is the real one From $274 2. [Lttl](https://thisglp.com/reviews/lttl)Partner Readers who want every prepay rung visible and know which dose line they need From $194 3. [Direct Meds](https://thisglp.com/reviews/direct-meds)Partner A reader content to buy by the quarter who will redo the per-day math From $249 4. [Luvo Health](https://thisglp.com/reviews/luvo-health)Partner Readers who want to price a full year before starting and can read a four-week interval From $303 5. [Sesame Care](https://thisglp.com/reviews/sesame-care)Partner Readers who want tirzepatide priced by dose and will read the FAQ before the headline From $208 The shortlist ## 79 providers, side by side Sellers that publish a price for an oral GLP-1 on their own site. Sellers offering only injections are not listed here. Sort | Provider | Access | Dose price | States | Go | | --- | --- | --- | --- | --- | | ShedRx Partner [Read review →](https://thisglp.com/reviews/shedrx) | From $274/mo | — | — | | | Lttl Partner [Read review →](https://thisglp.com/reviews/lttl) | From $194/mo | Flat | — | | | Direct Meds Partner [Read review →](https://thisglp.com/reviews/direct-meds) | From $249/mo | — | — | | | Luvo Health Partner [Read review →](https://thisglp.com/reviews/luvo-health) | From $303/mo | Flat | — | | | Sesame Care Partner [Read review →](https://thisglp.com/reviews/sesame-care) | From $208/mo | Rises | — | | | Strut Health Partner [Read review →](https://thisglp.com/reviews/strut-health) | From $99/mo | — | 49 | | | MyDrHank Partner [Read review →](https://thisglp.com/reviews/mydrhank) | From $171/mo | — | — | | | Rivo Health [Read review →](https://thisglp.com/reviews/rivo-health) | From $149/mo | Flat | All 50 | | | Zera Health [Read review →](https://thisglp.com/reviews/zera-health) | From $169/mo | Flat | All 50 | | | Breeze Meds [Read review →](https://thisglp.com/reviews/breeze-meds) | From $299/mo | — | All 50 | | | Revel Health [Read review →](https://thisglp.com/reviews/revel-health) | From $149/mo | Flat | 45 | | | Alan Meds [Read review →](https://thisglp.com/reviews/alan-meds) | From $215/mo | Flat | 46 | | | Edessa [Read review →](https://thisglp.com/reviews/edessa) | From $229/mo | Flat | All 50 | | | Idgie Health [Read review →](https://thisglp.com/reviews/idgie-health) | From $287/mo | Flat | All 50 | | | HealthSource [Read review →](https://thisglp.com/reviews/healthsource) | From $434/mo | — | All 50 | | | VirtualCare2Go [Read review →](https://thisglp.com/reviews/virtualcare2go) | From $599/mo | — | All 50 | | | BetterMe Rx [Read review →](https://thisglp.com/reviews/betterme-rx) | From $250/mo | — | All 50 | | | Midi Health [Read review →](https://thisglp.com/reviews/midi-health) | From $178/mo | — | All 50 | | | Synergy Rx [Read review →](https://thisglp.com/reviews/synergy-rx) | From $299/mo | — | All 50 | | | DoctorAdam [Read review →](https://thisglp.com/reviews/doctoradam) | From $129/mo | — | 44 | | - ShedRx Partner— Readers willing to telephone a seller and ask which published fee is the real one Access From $274/mo Insurance — Visit — - Lttl Partner— Readers who want every prepay rung visible and know which dose line they need Access From $194/mo Insurance Flat Visit — - Direct Meds Partner— A reader content to buy by the quarter who will redo the per-day math Access From $249/mo Insurance — Visit — - Luvo Health Partner— Readers who want to price a full year before starting and can read a four-week interval Access From $303/mo Insurance Flat Visit — - Sesame Care Partner— Readers who want tirzepatide priced by dose and will read the FAQ before the headline Access From $208/mo Insurance Rises Visit — - Strut Health Partner— A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. Access From $99/mo Insurance — Visit 49 - MyDrHank Partner— Readers who expect early nausea to be the hard part and will ask about plan terms before paying Access From $171/mo Insurance — Visit — - Rivo Health— Readers who want a flat rate and can ignore the seasonal framing Access From $149/mo Insurance Flat Visit All 50 - Zera Health— A reader who budgets from the monthly rate printed beside the first-month offer. Access From $169/mo Insurance Flat Visit All 50 - Breeze Meds— A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. Access From $299/mo Insurance — Visit All 50 - Revel Health— A reader who wants an oral and expects to pay less for it, which on this seller is what happens. Access From $149/mo Insurance Flat Visit 45 - Alan Meds— A reader ready to prepay six months who wants the full-dose price in view before the intake. Access From $215/mo Insurance Flat Visit 46 - Edessa— Readers who will read the plan table rather than the homepage banner Access From $229/mo Insurance Flat Visit All 50 - Idgie Health— A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. Access From $287/mo Insurance Flat Visit All 50 - HealthSource— Readers who want the compounding source identified and the contents itemized Access From $434/mo Insurance — Visit All 50 - VirtualCare2Go— Readers genuinely indifferent between three molecules who value plain speaking Access From $599/mo Insurance — Visit All 50 - BetterMe Rx— A reader willing to fund a quarter up front, once the sale is confirmed live Access From $250/mo Insurance — Visit All 50 - Midi Health— Readers who want every rung costed, with its milligram, before choosing a first dose Access From $178/mo Insurance — Visit All 50 - Synergy Rx— A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form. Access From $299/mo Insurance — Visit All 50 - DoctorAdam— A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. Access From $129/mo Insurance — Visit 44 We never show a fabricated price or rating. Facts are shown only where a provider publishes them. ## How this board is built Across the 79 sellers here that publish a figure, the range runs from $99 to $599 a month, with a midpoint of $225. The spread is 6.1× from bottom to top, which is wider than most readers expect before they compare. An oral is a daily tablet against a weekly injection, and on several sellers here it costs more rather than less — worth checking against whichever assumption you arrived with. See the [methodology](https://thisglp.com/methodology) for how each mark is derived. An oral changes the daily shape of treatment rather than its cost. A tablet is taken every day, usually on an empty stomach and with a wait before eating, against one injection a week that most people schedule and forget. Whether that is easier is a question about your week, not about the drug, and it is the reason this board exists separately from the molecule boards. What surprises most readers here is the direction of the price. On several sellers the tablet is the dearer product — sometimes by a hundred dollars a month — so a reader arriving to save money by avoiding needles will often find the opposite. Where that is the case the seller’s own figures say so on its page, and the rows below carry them. ## How we judge sellers - **Price transparency** — Can you find what a month costs — for the molecule and the form you want — before creating an account, and does the seller's own site agree with itself? - **Honest headline** — Is the figure the seller leads with the figure it bills? A price that needs a twelve-month prepay, or that is struck through from an anchor nobody pays, is a different number from a standing monthly rate. - **Dose-ladder pricing** — Does the price hold as your dose escalates, or is it re-set at every step? This is the difference most buyers only discover in month three. - **State coverage** — How much of the country the seller actually ships to. A seller that does not operate where you live is not an option, whatever it charges. - **Molecule and form breadth** — Whether the seller carries both molecules, and whether it offers an oral as well as an injection. Breadth is what lets you change course without changing provider. We never show a fabricated price or rating, and access notes appear only where a provider publishes them. Pricing and availability change often — confirm current details on the provider’s own site. ## Keep comparing [The semaglutide board](https://thisglp.com/best/compounded-semaglutide), and [what the dose does over twenty weeks](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## Common questions Is the oral cheaper than the injection? Not reliably. Several sellers on this board price the tablet above their own injection, so the form is a convenience decision here rather than a saving. Why are there fewer sellers on this board? Because a published oral price is the exception. A seller that offers an oral only after an intake cannot be ranked on it, and is not listed. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # GLP-1 sellers whose price holds at every dose | This GLP Sellers that charge one figure whatever the dose | read off their own pages, ranked, and set against the sellers that raise the price as you titrate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/best/price-holds-at-every-dose Updated: 2026-10-28 Buyer's guide # GLP-1 sellers whose price holds at every dose Most GLP-1 prices are quoted at the starting dose. The sellers below charge the same figure at 2.5 mg as at 0.25 mg, so the number on the page is the number you keep paying after you titrate up. By [This GLP Editorial Team](https://thisglp.com/about) **127** providers compared Reviewed against our [editorial methodology](https://thisglp.com/methodology) Partners listed first Updated September 2026 **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Top 5 for price holds at every dose Every seller here is a partner — we may earn from these links 1. [Lttl](https://thisglp.com/reviews/lttl)Partner Readers who want every prepay rung visible and know which dose line they need From $107 2. [Eden](https://thisglp.com/reviews/eden)Partner Buyers comparing what the two molecules actually cost From $198 3. [CoreAge Rx](https://thisglp.com/reviews/coreage-rx)Partner A reader still at a starting dose, since that is the tier these rates price. From $99 4. [HealthRX](https://thisglp.com/reviews/healthrx)Partner Buyers who expect to escalate and want the later months priced From $165 5. [Luvo Health](https://thisglp.com/reviews/luvo-health)Partner Readers who want to price a full year before starting and can read a four-week interval From $271 The shortlist ## 127 providers, side by side Sellers whose own pages state that the price does not change with the dose, and that publish a semaglutide injection figure. Sellers that say nothing about dose are not listed — an unrecorded stance is not a flat one. Sort | Provider | Access | Dose price | States | Go | | --- | --- | --- | --- | --- | | Lttl Partner [Read review →](https://thisglp.com/reviews/lttl) | From $107/mo | Flat | — | | | Eden Partner [Read review →](https://thisglp.com/reviews/eden) | From $198/mo | Flat | All 50 | | | CoreAge Rx Partner [Read review →](https://thisglp.com/reviews/coreage-rx) | From $99/mo | Flat | All 50 | | | HealthRX Partner [Read review →](https://thisglp.com/reviews/healthrx) | From $165/mo | Flat | — | | | Luvo Health Partner [Read review →](https://thisglp.com/reviews/luvo-health) | From $271/mo | Flat | — | | | Collective Partner [Read review →](https://thisglp.com/reviews/collective) | From $76/mo | Flat | — | | | SnagRx Partner [Read review →](https://thisglp.com/reviews/snagrx) | From $99/mo | Flat | — | | | Enhance MD Partner [Read review →](https://thisglp.com/reviews/enhance-md) | From $270/mo | Flat | 39 | | | Belle Health Partner [Read review →](https://thisglp.com/reviews/belle-health) | From $199/mo | Flat | All 50 | | | bmiMD Partner [Read review →](https://thisglp.com/reviews/bmimd) | From $119/mo | Flat | All 50 | | | Rivo Health [Read review →](https://thisglp.com/reviews/rivo-health) | From $149/mo | Flat | All 50 | | | Aspen [Read review →](https://thisglp.com/reviews/aspen-health) | From $179/mo | Flat | All 50 | | | EverSlim [Read review →](https://thisglp.com/reviews/everslim) | From $113/mo | Flat | All 50 | | | Rewinding RX [Read review →](https://thisglp.com/reviews/rewinding-rx) | From $139/mo | Flat | All 50 | | | NewSelf [Read review →](https://thisglp.com/reviews/newself) | From $100/mo | Flat | 49 | | | Bionomy Health [Read review →](https://thisglp.com/reviews/bionomy-health) | From $189/mo | Flat | 48 | | | Zera Health [Read review →](https://thisglp.com/reviews/zera-health) | From $179/mo | Flat | All 50 | | | Revel Health [Read review →](https://thisglp.com/reviews/revel-health) | From $199/mo | Flat | 45 | | | Cora Health [Read review →](https://thisglp.com/reviews/cora-health) | From $175/mo | Flat | All 50 | | | Gimme Care [Read review →](https://thisglp.com/reviews/gimme-care) | From $173.33/mo | Flat | All 50 | | - Lttl Partner— Readers who want every prepay rung visible and know which dose line they need Access From $107/mo Insurance Flat Visit — - Eden Partner— Buyers comparing what the two molecules actually cost Access From $198/mo Insurance Flat Visit All 50 - CoreAge Rx Partner— A reader still at a starting dose, since that is the tier these rates price. Access From $99/mo Insurance Flat Visit All 50 - HealthRX Partner— Buyers who expect to escalate and want the later months priced Access From $165/mo Insurance Flat Visit — - Luvo Health Partner— Readers who want to price a full year before starting and can read a four-week interval Access From $271/mo Insurance Flat Visit — - Collective Partner— A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. Access From $76/mo Insurance Flat Visit — - SnagRx Partner— Buyers who want to stay month to month without paying much for it Access From $99/mo Insurance Flat Visit — - Enhance MD Partner— A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. Access From $270/mo Insurance Flat Visit 39 - Belle Health Partner— Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. Access From $199/mo Insurance Flat Visit All 50 - bmiMD Partner— Readers who want a microdose and understand that is what the low figure buys Access From $119/mo Insurance Flat Visit All 50 - Rivo Health— Readers who want a flat rate and can ignore the seasonal framing Access From $149/mo Insurance Flat Visit All 50 - Aspen— Readers who want the escalation question closed and need no separate molecule price Access From $179/mo Insurance Flat Visit All 50 - EverSlim— A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. Access From $113/mo Insurance Flat Visit All 50 - Rewinding RX— Readers who want a fixed figure and the doses it covers listed Access From $139/mo Insurance Flat Visit All 50 - NewSelf— Buyers who want every dose step and its price visible before starting a quiz Access From $100/mo Insurance Flat Visit 49 - Bionomy Health— Readers who want to be able to stop by doing nothing Access From $189/mo Insurance Flat Visit 48 - Zera Health— A reader who budgets from the monthly rate printed beside the first-month offer. Access From $179/mo Insurance Flat Visit All 50 - Revel Health— A reader who wants an oral and expects to pay less for it, which on this seller is what happens. Access From $199/mo Insurance Flat Visit 45 - Cora Health— Buyers who want the prescriber and the pharmacy named before they pay, and who read past the annual headline Access From $175/mo Insurance Flat Visit All 50 - Gimme Care— Buyers who want the monthly price fixed while the dose climbs Access From $173.33/mo Insurance Flat Visit All 50 We never show a fabricated price or rating. Facts are shown only where a provider publishes them. ## How this board is built Of the 374 sellers ranked on a published semaglutide injection price, 157 have had their dose stance read off their own pages: 127 hold one figure at every dose, 30 raise it as the dose goes up. The 127 that hold open at a median of $175 a month against $199 for the ones that scale — so the sellers that hold are not the cheap ones on day one. They are the ones whose day-one figure is still true in month six. The remaining 217 say nothing either way on the pages we have read, and are not listed here. A starting dose is not where anyone stays. Titration schedules move a patient up over roughly the first four to five months, and a price that climbs with the milligrams means the figure that persuaded someone to sign up was true for the shortest part of their year. See the [methodology](https://thisglp.com/methodology) for how each mark is derived. This is the one seller behavior on this site that a reader cannot check quickly for themselves. An opening price sits on the homepage; what happens at maintenance is usually further in, on a dosing page or inside a plan selector, and on plenty of sellers it is not written down at all. That is why the count of sellers we have read is published above alongside the count that hold — the second number means little without the first. Holding at every dose is not automatically the better deal. A seller that scales can be cheaper for the months spent at a low dose, and a flat price set high is simply a high price stated honestly. What a flat figure removes is the surprise, which is a different thing from a saving, and the rows below carry each seller’s own number so the comparison is yours to make. ## How we judge sellers - **Price transparency** — Can you find what a month costs — for the molecule and the form you want — before creating an account, and does the seller's own site agree with itself? - **Honest headline** — Is the figure the seller leads with the figure it bills? A price that needs a twelve-month prepay, or that is struck through from an anchor nobody pays, is a different number from a standing monthly rate. - **Dose-ladder pricing** — Does the price hold as your dose escalates, or is it re-set at every step? This is the difference most buyers only discover in month three. - **State coverage** — How much of the country the seller actually ships to. A seller that does not operate where you live is not an option, whatever it charges. - **Molecule and form breadth** — Whether the seller carries both molecules, and whether it offers an oral as well as an injection. Breadth is what lets you change course without changing provider. We never show a fabricated price or rating, and access notes appear only where a provider publishes them. Pricing and availability change often — confirm current details on the provider’s own site. ## Keep comparing [The semaglutide board](https://thisglp.com/best/compounded-semaglutide), the [titration planner](https://thisglp.com/tools/glp1-titration-planner), and [what the dose does over twenty weeks](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## Common questions Does a flat price mean the cheapest price? No. The sellers here open at a higher median than the ones that scale. A flat figure buys predictability rather than a discount, and for a reader who will spend most of the year at a maintenance dose those are often the same thing — but not always. Why are so many sellers missing from this board? Because most sellers do not say what happens to the price as the dose rises, and we will not infer it. A seller appears here only where its own pages state that the figure holds. Where does the dose stance come from? From the seller's own pricing or dosing page, read directly. Where a seller states it in a plan selector rather than in prose, that is what was read. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Code of Conduct | This GLP This GLP's editorial code of conduct: no fabrication of data or citations, a strict conflicts-of-interest policy, an accuracy commitment, and an advertiser-influence prohibition on editorial verdicts. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/code-of-conduct Updated: 2026-09-16 Our Standards # Editorial Code of Conduct Effective September 15, 2026 People read this site before spending a few hundred dollars a month on a compounded drug that is not FDA-approved, often for a benefit no controlled trial has demonstrated. That is the decision our pages feed into, and it sets the standard below. These rules bind everyone who writes or edits here, and they sit alongside our [editorial policy](https://thisglp.com/editorial-policy) and [methodology](https://thisglp.com/methodology). ## 1\. No fabrication, and a citation from memory counts as one We do not invent or embellish data, results, quotes or sources. The specific failure this rule is written against is the plausible citation: real-sounding authors, a real journal, a year that fits, and no such paper. It is easy to produce and hard for a reader to catch, which is exactly why we treat writing a reference from memory as fabrication rather than as a shortcut. Every citation is confirmed in a primary database before publication or it does not publish. Fabricating a source is grounds for retracting the work it appears in. ## 2\. Say how thin the evidence is Accuracy in this category is mostly a matter of not overstating. We distinguish a randomized human trial from an animal model from a cell-culture result, and we never let one format borrow another’s evidence. We say when something is compounded, and therefore not FDA-approved and not reviewed by the FDA for safety, efficacy or quality before it is dispensed. We say when a trial measured a blood level rather than how anyone felt. Where the data are thin, the sentence says so rather than going quiet. ## 3\. Conflicts of interest Anyone contributing here must disclose to the editors any financial, personal or professional interest that could reasonably be seen to affect their coverage — a stake in a provider or pharmacy being reviewed, for instance. A material conflict means recusal from the verdict on that topic. No contributor may take personal payment, product or gifts from a company in exchange for coverage, and This GLP is not paid to hold an opinion. ## 4\. What a commercial relationship can and cannot buy This GLP is reader-supported and earns through labeled affiliate partnerships, mostly via the **Katalys** network, under the FTC’s endorsement guides (16 CFR Part 255). A partnership can buy _placement_ — being listed first, being featured — and where it does, the placement is labeled. **It cannot buy a verdict, a score, a ranking rationale, or the softening of a safety statement, and refusing to partner cannot be punished with a worse one.** That is not only a promise: the function that computes a score does not receive the provider’s commercial status at all, and a test asserts the score is identical either way. [Nature of reviews](https://thisglp.com/nature-of-reviews) shows the three pages on this site where that rule visibly cost us money. ## 5\. No manufactured urgency Longevity marketing runs on the idea that you are already behind and every month of delay is lost. We do not write that way. No countdowns, no “aging backwards”, no implying that a reader who waits to see better evidence has made a mistake. Waiting is frequently the correct decision here and we will say so when it is. ## 6\. Reporting a breach If you think something here breaks these rules — a citation that does not check out, an undisclosed conflict, a verdict that reads as bought — write to [editor@thisglp.com](mailto:editor@thisglp.com). We investigate and we answer. If you are right, the fix goes through [corrections](https://thisglp.com/corrections), in public. --- # Compare GLP-1 sellers head to head | This GLP Direct comparisons of GLP-1 sellers — what each one charges, which formats they ship, and who each is actually the better pick for. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare Updated: 2026-10-26 Head to head # Compare GLP-1 sellers head to head Direct comparisons of GLP-1 sellers — what each one charges, which formats they ship, and who each is actually the better pick for. Provider comparisons ## Compare GLP-1 sellers Build a comparison Pick two providers First providervsSecond provider 36 written comparisons so far. Search comparisons 36 of 36 - [Enhance MD vs EverSlim One bills every four weeks; the other puts the visit inside the price.](https://thisglp.com/compare/enhance-md-vs-everslim) - [Harper Meds vs Pallas Health A four-week fill against twelve-week billing, which are two different calendars.](https://thisglp.com/compare/harper-meds-vs-pallas-health) - [Fidelity Medical Clinic vs Pallas Health Four-week dosing against twelve-week billing at the same $216.](https://thisglp.com/compare/fidelity-medical-clinic-vs-pallas-health) - [Enhance MD vs Harper Meds Two sellers on a four-week cycle, twenty-three dollars apart.](https://thisglp.com/compare/enhance-md-vs-harper-meds) - [Pallas Health vs Apex MD Quarterly billing against a price that already contains the additives.](https://thisglp.com/compare/pallas-health-vs-apex-md) - [NextMeds vs Collective At one seller the membership is the price; at the other it is billed beside it.](https://thisglp.com/compare/nextmeds-vs-collective) - [Alloy vs EverSlim A required fee on top against a consultation already inside the number.](https://thisglp.com/compare/alloy-vs-everslim) - [KERNX Health vs EverSlim A consultation billed per event against one folded into the monthly price.](https://thisglp.com/compare/kernx-health-vs-everslim) - [NextMeds vs Alloy Two services that charge for the relationship, one inside the price and one outside it.](https://thisglp.com/compare/nextmeds-vs-alloy) - [Collective vs Alloy Two sellers that both bill something beside the medication.](https://thisglp.com/compare/collective-vs-alloy) - [Liberty vs Idgie Health Two sellers that each volunteer something most of the category does not.](https://thisglp.com/compare/liberty-vs-idgie-health) - [Liberty vs CoreAge Rx One names the facility behind the vial; the other does not.](https://thisglp.com/compare/liberty-vs-coreage-rx) - [Idgie Health vs PlushCare A seller that states the off-label position against one whose headline covers only the starting dose.](https://thisglp.com/compare/idgie-health-vs-plushcare) - [Liberty vs Apex MD Named sourcing against named inclusions, a hundred dollars apart.](https://thisglp.com/compare/liberty-vs-apex-md) - [Embody vs AVARA Rx A promotional rate against a rate that needs a code.](https://thisglp.com/compare/embody-vs-avara-rx) - [Embody vs Revel Health Two headline figures that expire in different ways.](https://thisglp.com/compare/embody-vs-revel-health) - [AVARA Rx vs Revel Health A code-dependent rate against an introductory month.](https://thisglp.com/compare/avara-rx-vs-revel-health) - [Embody vs Trimi Health A promotional monthly rate against an annual plan billed up front.](https://thisglp.com/compare/embody-vs-trimi-health) - [Trimi Health vs Lean Meds A disclosed annual commitment against an offer that needs a medication-specific quote.](https://thisglp.com/compare/trimi-health-vs-leanmeds) - [Trimi Health vs Pallas Health A year paid up front against a quarter at a time, at the same rate.](https://thisglp.com/compare/trimi-health-vs-pallas-health) - [Lean Meds vs Strut Health A general starting offer against a disclosed standing-order discount.](https://thisglp.com/compare/leanmeds-vs-strut-health) - [Trimi Health vs Harper Meds An annual plan against an all-inclusive four-week fill.](https://thisglp.com/compare/trimi-health-vs-harper-meds) - [Wholesome Clinic vs PlushCare Every dose rung published against a price that changes once, after the starting dose.](https://thisglp.com/compare/wholesome-clinic-vs-plushcare) - [Zera Health vs PlushCare A monthly rate behind a first-month offer, against a two-step dose price.](https://thisglp.com/compare/zera-health-vs-plushcare) - [Alan Meds vs Strut Health A flat rate stated outright against a rate conditional on a standing order.](https://thisglp.com/compare/alan-meds-vs-strut-health) - [KERNX Health vs Breeze Meds A flat rate with a one-off consult fee against four rates and no dose statement.](https://thisglp.com/compare/kernx-health-vs-breeze-meds) - [Idgie Health vs Synergy Rx Candor about the off-label position against candor about every price.](https://thisglp.com/compare/idgie-health-vs-synergy-rx) - [Synergy Rx vs Liberty Four published rates on one side, a named 503B facility on the other.](https://thisglp.com/compare/synergy-rx-vs-liberty) - [Care Bare Rx vs EverSlim A rate that rises with the dose against one with the visit already inside it.](https://thisglp.com/compare/care-bare-rx-vs-everslim) - [Nova vs EverSlim Two states against fifty-one, and two ways of counting the service in.](https://thisglp.com/compare/nova-vs-everslim) - [Wholesome Clinic vs Enhance MD Seven states with the ladder published against thirty-nine on a four-week cycle.](https://thisglp.com/compare/wholesome-clinic-vs-enhance-md) - [PreventiveMD vs Maximus Three molecules priced against branded and compounded priced side by side.](https://thisglp.com/compare/preventivemd-vs-maximus-tribe) - [Bayan Health vs DoctorAdam Two sellers where the route does not change the bill.](https://thisglp.com/compare/bayan-health-vs-doctoradam) - [PreventiveMD vs Strut Health Three molecules against two molecules in two formats.](https://thisglp.com/compare/preventivemd-vs-strut-health) - [Apex MD vs Maximus Additives inside the price against branded and compounded on one page.](https://thisglp.com/compare/apex-md-vs-maximus-tribe) - [EverSlim vs Trimi Health A visit inside the price against a year paid before the first shipment.](https://thisglp.com/compare/everslim-vs-trimi-health) --- # Alan Meds vs Strut Health: which GLP-1 seller is right for you? | This GLP A flat rate stated outright against a rate conditional on a standing order. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/alan-meds-vs-strut-health Updated: 2026-09-16 Head to head # Alan Meds vs Strut Health A flat rate stated outright against a rate conditional on a standing order. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Alan Meds Editorial $215/mo Alan Meds prices compounded tirzepatide by injection from $325 a month and an oral compounded GLP-1 from $215, each paid up front on a six-month plan. No month-to-month rate is published for either. Separate microdosing lines sit well below both, forty-six states are served, and no oral tirzepatide is listed. For - Full-dose and microdosing lines listed apart - The prepay term is printed in a footnote - Forty-six states served Against - No month-to-month rate on the full-dose lines - Six months are paid before the first dose - What the rate includes is not stated **Pick it for:** Readers who want no standing order and a stated flat rate [Read the full review](https://thisglp.com/reviews/alan-meds) ## Strut Health Partner $99/mo Strut Health advertises compounded semaglutide at $149 a month by injection and $99 as an oral, with compounded tirzepatide at $199 in either form. Each of those is the auto-refill rate; the page shows a higher one-off price beside the oral tirzepatide at $239, and a $325 compare-at figure beside the injection. Coverage runs to 49 states, with Alaska excluded. For - Four advertised rates, both forms of both molecules - Oral semaglutide priced at $99 a month - One-off prices shown beside refill rates Against - Advertised rates assume a standing auto-refill - Not available in Alaska - Dose-escalation pricing not stated **Pick it for:** Readers who want a tablet and will hold the refill to get it [Read the full review](https://thisglp.com/reviews/strut-health) ## Our verdict Alan Meds states its figures hold at every dose. Strut Health's headline requires a refill commitment and it publishes the one-off price beside it. Both are $99 and neither means the same thing. The formats differ too: Alan Meds quotes $99 for an injection, while Strut Health's $99 is the oral and its injection is $149. Strut also states the discount behind each line, so a reader can see what stepping outside the standing order costs. Alan Meds has no standing order to step outside of, which is why it publishes one figure per line and no alternative. ## What actually separates them Alan Meds and Strut Health state different things about published price. Everything else they publish, they publish the same way. Alan Meds costs $116 more than Strut Health — 117% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,188 at Strut Health against $2,580 at Alan Meds — a difference of $1,392. |   | Alan Meds | Strut Health | | --- | --- | --- | | Published price | $215/mo | $99/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Alloy vs EverSlim: which GLP-1 seller is right for you? | This GLP A required fee on top against a consultation already inside the number. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/alloy-vs-everslim Updated: 2026-09-16 Head to head # Alloy vs EverSlim A required fee on top against a consultation already inside the number. By [This GLP Editorial Team](https://thisglp.com/about) ## Alloy Editorial $169/mo Three compounded molecules at $70, $100 and $115 a month for the medication, each with a mandatory $99 care fee on top: $169, $199 and $214 all-in. Wegovy is listed from $199, but that is NovoCare's offer for a new patient's first two fills. At NovoCare's standing $349 plus the fee, it runs $448 a month. For - Three compounded molecules at one seller - Care fee amount published, not implied - Branded and compounded routes both listed Against - Care fee is $99 every month - Medication rate excludes that fee - Fee dominates a low medication rate - Wegovy's $199 covers two fills only **Pick it for:** Readers who want Alloy's specific program and will add the fee [Read the full review](https://thisglp.com/reviews/alloy) ## EverSlim Editorial $113/mo EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate. For - Provider visit and shipping included - Rate flat at every dose - One monthly charge, no prepay ladder Against - Visit frequency not published - Compounding pharmacy not named - No lower rung for a longer commitment **Pick it for:** Readers who want the published number to be the whole number [Read the full review](https://thisglp.com/reviews/everslim) ## Our verdict Alloy publishes a medication price with a required fee charged beside it. EverSlim publishes $113 and states the visit is included. Only one of these figures is the figure owed. ## What actually separates them Alloy and EverSlim state different things about published price. Everything else they publish, they publish the same way. Alloy costs $56 more than EverSlim — 50% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,356 at EverSlim against $2,028 at Alloy — a difference of $672. |   | Alloy | EverSlim | | --- | --- | --- | | Published price | $169/mo | $113/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Apex MD vs Maximus: which GLP-1 seller is right for you? | This GLP Additives inside the price against branded and compounded on one page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/apex-md-vs-maximus-tribe Updated: 2026-09-16 Head to head # Apex MD vs Maximus Additives inside the price against branded and compounded on one page. By [This GLP Editorial Team](https://thisglp.com/about) ## Apex MD Editorial $299/mo Apex MD prices compounded semaglutide at $299 a month by weekly injection and tirzepatide at $399. The injectable preparation is compounded with NAD, B-12 and L-carnitine in the same vial. Plans are described as month-to-month and the rate is stated as flat at every dose. Oral pills are sold on a separate microdosing line. For - Additives named on the product page - Rate stated as flat at every dose - Plans described as month-to-month Against - Additive combination not studied in trials - Figures sit high for compounded products - No prepay rung published **Pick it for:** Readers who want no separate additive charge [Read the full review](https://thisglp.com/reviews/apex-md) ## Maximus Editorial $249.99/mo Maximus lists compounded semaglutide at $249.99 a month on a one-month plan and the branded Wegovy pen at $449.99 a month ongoing, a $200 gap. On tirzepatide the gap is $190, at $359.99 compounded against $549.99 for Zepbound. Four-month and twelve-month plans cut the compounded semaglutide figure to $199.49 and $150.32. For - Branded and compounded on one plan page - Branded pen prices published by dose - Compounded rate stated as flat across doses Against - One-month rate is high for this category - Branded pens cost $190 to $200 more monthly - Best compounded rates need a twelve-month plan **Pick it for:** Readers who want to see the branded price before choosing compounded [Read the full review](https://thisglp.com/reviews/maximus-tribe) ## Our verdict Apex MD states the additives are contained in its figure. Maximus Tribe prices the branded product beside the compounded one. Both remove a question a reader would otherwise have to ask. ## What actually separates them Apex MD and Maximus state different things about published price. Everything else they publish, they publish the same way. Apex MD costs $49.01 more than Maximus — 20% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $3,000 at Maximus against $3,588 at Apex MD — a difference of $588. |   | Apex MD | Maximus | | --- | --- | --- | | Published price | $299/mo | $249.99/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # AVARA Rx vs Revel Health: which GLP-1 seller is right for you? | This GLP A code-dependent rate against an introductory month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/avara-rx-vs-revel-health Updated: 2026-09-16 Head to head # AVARA Rx vs Revel Health A code-dependent rate against an introductory month. By [This GLP Editorial Team](https://thisglp.com/about) ## AVARA Rx Editorial $229/mo AVARA Rx publishes compounded tirzepatide at $279 a month, or $229 with a discount code, and compounded semaglutide at $229 with no code attached. The provider consult and free shipping are stated as included in both figures, and no insurance is required. A code is a condition rather than a price, so $279 is the tirzepatide figure to budget against. For - Consult and shipping stated as included - Standing rate published beside the code rate - Coverage published as fifty states Against - Lower tirzepatide rate depends on a code - Dose-pricing model not published - Consult scope not described **Pick it for:** Readers who can confirm the code before ordering [Read the full review](https://thisglp.com/reviews/avara-rx) ## Revel Health Editorial $149/mo Revel Health advertises compounded semaglutide at $199 a month by injection and $149 as an oral dissolving tablet, with compounded tirzepatide at $249 and $199 on the same pattern. The oral is the cheaper route on both molecules, which reverses the usual order. Each line also carries a reduced first month, and the seller states that consultation, medication, supplies and shipping are included in the rate. Forty-five states. For - Oral priced below the injection on both molecules - Rate stated to include consultation and shipping - All four combinations carry a published figure Against - Headline first-month rates apply once - Five states are not served - Support at a dose step is not described **Pick it for:** Readers who want a single figure covering the whole service afterwards [Read the full review](https://thisglp.com/reviews/revel-health) ## Our verdict Avara Rx's lower figure is conditional on a code; Revel Health's is conditional on it being the first month. Both are real and neither is the ongoing price. ## What actually separates them AVARA Rx and Revel Health state different things about published price. Everything else they publish, they publish the same way. AVARA Rx costs $80 more than Revel Health — 54% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,788 at Revel Health against $2,748 at AVARA Rx — a difference of $960. |   | AVARA Rx | Revel Health | | --- | --- | --- | | Published price | $229/mo | $149/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Bayan Health vs DoctorAdam: which GLP-1 seller is right for you? | This GLP Two sellers where the route does not change the bill. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/bayan-health-vs-doctoradam Updated: 2026-09-16 Head to head # Bayan Health vs DoctorAdam Two sellers where the route does not change the bill. By [This GLP Editorial Team](https://thisglp.com/about) ## Bayan Health Editorial $99/mo Bayan Health prices a compounded semaglutide microdose at $99 a month and a compounded tirzepatide microdose at $119, and charges the same two figures for its oral drop formulations. The injectables are sold with vitamin B6 in the preparation. No pharmacokinetic data is published for the drop route. For - Injection and oral priced the same - Rate stated as flat at every dose - Two molecules on one page Against - No pharmacokinetic data published for the drops - State coverage not published - Entry tiers sit below label doses **Pick it for:** Readers who want the lower of two route-neutral figures [Read the full review](https://thisglp.com/reviews/bayan-health) ## DoctorAdam Editorial $129/mo DoctorAdam advertises compounded semaglutide at $129 a month as an injection or an oral, and compounded tirzepatide at $229 by injection or $199 as an oral. Choosing a tablet here never costs more, which is unusual. Forty-four states are served. For - Form carries no price penalty - All four combinations published - The tirzepatide tablet costs less Against - Six states are not served - Dose-escalation pricing not published - What the rate includes is not stated **Pick it for:** Readers who want both molecules priced the same way [Read the full review](https://thisglp.com/reviews/doctoradam) ## Our verdict Bayan Health prices the same figure across two routes; DoctorAdam charges one figure per molecule whether injected or swallowed. Neither makes format a money decision. ## What actually separates them Bayan Health and DoctorAdam state different things about published price. Everything else they publish, they publish the same way. DoctorAdam costs $30 more than Bayan Health — 30% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,188 at Bayan Health against $1,548 at DoctorAdam — a difference of $360. |   | Bayan Health | DoctorAdam | | --- | --- | --- | | Published price | $99/mo | $129/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Care Bare Rx vs EverSlim: which GLP-1 seller is right for you? | This GLP A rate that rises with the dose against one with the visit already inside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/care-bare-rx-vs-everslim Updated: 2026-09-16 Head to head # Care Bare Rx vs EverSlim A rate that rises with the dose against one with the visit already inside it. By [This GLP Editorial Team](https://thisglp.com/about) ## Care Bare Rx Editorial $199/mo Care Bare Rx advertises compounded semaglutide and compounded tirzepatide at the same $199 a month, both by injection. No oral form is listed for either molecule. All fifty states are served, and the catalog extends well past weight loss into hair, NAD+ and sexual health. For - Tirzepatide priced at the semaglutide rate - All fifty states served - One rate to understand, not four Against - No oral form for either molecule - Dose-escalation pricing not published - GLP-1 is one of six catalog categories **Pick it for:** Readers who want tirzepatide without the usual premium [Read the full review](https://thisglp.com/reviews/care-bare-rx) ## EverSlim Editorial $113/mo EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate. For - Provider visit and shipping included - Rate flat at every dose - One monthly charge, no prepay ladder Against - Visit frequency not published - Compounding pharmacy not named - No lower rung for a longer commitment **Pick it for:** Readers who want the consultation inside the figure [Read the full review](https://thisglp.com/reviews/everslim) ## Our verdict Care Bare Rx charges $199 for either molecule and its pricing climbs with the dose. EverSlim charges $113 and states the consultation is included. Both make a promise; they are different promises. ## What actually separates them Care Bare Rx and EverSlim state different things about published price. Everything else they publish, they publish the same way. Care Bare Rx costs $86 more than EverSlim — 76% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,356 at EverSlim against $2,388 at Care Bare Rx — a difference of $1,032. |   | Care Bare Rx | EverSlim | | --- | --- | --- | | Published price | $199/mo | $113/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Collective vs Alloy: which GLP-1 seller is right for you? | This GLP Two sellers that both bill something beside the medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/collective-vs-alloy Updated: 2026-09-16 Head to head # Collective vs Alloy Two sellers that both bill something beside the medication. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Collective Partner $76/mo Collective advertises $59 a month for compounded semaglutide and $69 for compounded tirzepatide, and charges a $199 annual membership beside both. Added together, a first year of semaglutide comes to $907, or $76 a month. The rate is stated as holding at every dose. For - Rate stated as flat at every dose - Both molecules priced on one page - Membership amount published, not implied Against - Membership is charged annually, up front - Advertised rate excludes that membership - Short course carries the whole year fee **Pick it for:** Readers who want the lower medication figure of the two [Read the full review](https://thisglp.com/reviews/collective) ## Alloy Editorial $169/mo Three compounded molecules at $70, $100 and $115 a month for the medication, each with a mandatory $99 care fee on top: $169, $199 and $214 all-in. Wegovy is listed from $199, but that is NovoCare's offer for a new patient's first two fills. At NovoCare's standing $349 plus the fee, it runs $448 a month. For - Three compounded molecules at one seller - Care fee amount published, not implied - Branded and compounded routes both listed Against - Care fee is $99 every month - Medication rate excludes that fee - Fee dominates a low medication rate - Wegovy's $199 covers two fills only **Pick it for:** Readers who want Alloy's program and treat the fee as part of it [Read the full review](https://thisglp.com/reviews/alloy) ## Our verdict Collective bills a membership separately and Alloy bills a required fee. Neither headline is what a buyer pays, and both sellers say so on their own pages. ## What actually separates them Collective and Alloy state different things about published price. Everything else they publish, they publish the same way. Alloy costs $93 more than Collective — 122% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $912 at Collective against $2,028 at Alloy — a difference of $1,116. |   | Collective | Alloy | | --- | --- | --- | | Published price | $76/mo | $169/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Embody vs AVARA Rx: which GLP-1 seller is right for you? | This GLP A promotional rate against a rate that needs a code. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/embody-vs-avara-rx Updated: 2026-09-16 Head to head # Embody vs AVARA Rx A promotional rate against a rate that needs a code. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Embody Partner $199/mo The Flat subscription schedule puts monthly semaglutide at $199 and tirzepatide at $299. Embody also promotes a separate offer, so the selected agreement matters more than the headline. Its disclosures now identify OpenLoop Health and four dispensing partners. The refund restriction on unused bundle months deserves attention before a long commitment. For - OpenLoop Health identified as the clinical network - Four dispensing partners disclosed - Separate subscription programs explained in legal terms Against - Promotional homepage and Flat terms quote different offers - The assigned pharmacy is not established before intake - Prepaid unused treatment is generally non-refundable **Pick it for:** Readers who will read past the promotional rate to the listed one [Read the full review](https://thisglp.com/reviews/embody) ## AVARA Rx Editorial $229/mo AVARA Rx publishes compounded tirzepatide at $279 a month, or $229 with a discount code, and compounded semaglutide at $229 with no code attached. The provider consult and free shipping are stated as included in both figures, and no insurance is required. A code is a condition rather than a price, so $279 is the tirzepatide figure to budget against. For - Consult and shipping stated as included - Standing rate published beside the code rate - Coverage published as fifty states Against - Lower tirzepatide rate depends on a code - Dose-pricing model not published - Consult scope not described **Pick it for:** Readers who have the code and will check it still applies [Read the full review](https://thisglp.com/reviews/avara-rx) ## Our verdict Embody's low figure is promotional and it lists a higher standing rate beside it. Avara Rx's lower figure requires a code. In both cases the advertised number is conditional. ## What actually separates them Embody and AVARA Rx state different things about published price. Everything else they publish, they publish the same way. AVARA Rx costs $30 more than Embody — 15% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $2,388 at Embody against $2,748 at AVARA Rx — a difference of $360. |   | Embody | AVARA Rx | | --- | --- | --- | | Published price | $199/mo | $229/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Embody vs Revel Health: which GLP-1 seller is right for you? | This GLP Two headline figures that expire in different ways. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/embody-vs-revel-health Updated: 2026-09-16 Head to head # Embody vs Revel Health Two headline figures that expire in different ways. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Embody Partner $199/mo The Flat subscription schedule puts monthly semaglutide at $199 and tirzepatide at $299. Embody also promotes a separate offer, so the selected agreement matters more than the headline. Its disclosures now identify OpenLoop Health and four dispensing partners. The refund restriction on unused bundle months deserves attention before a long commitment. For - OpenLoop Health identified as the clinical network - Four dispensing partners disclosed - Separate subscription programs explained in legal terms Against - Promotional homepage and Flat terms quote different offers - The assigned pharmacy is not established before intake - Prepaid unused treatment is generally non-refundable **Pick it for:** Readers comparing the standing rate rather than the promotion [Read the full review](https://thisglp.com/reviews/embody) ## Revel Health Editorial $149/mo Revel Health advertises compounded semaglutide at $199 a month by injection and $149 as an oral dissolving tablet, with compounded tirzepatide at $249 and $199 on the same pattern. The oral is the cheaper route on both molecules, which reverses the usual order. Each line also carries a reduced first month, and the seller states that consultation, medication, supplies and shipping are included in the rate. Forty-five states. For - Oral priced below the injection on both molecules - Rate stated to include consultation and shipping - All four combinations carry a published figure Against - Headline first-month rates apply once - Five states are not served - Support at a dose step is not described **Pick it for:** Readers who want consultation and shipping inside the ongoing figure [Read the full review](https://thisglp.com/reviews/revel-health) ## Our verdict Embody advertises a promotional rate against a higher listed one. Revel Health advertises a first month against a higher ongoing rate. Neither headline is what month two costs. ## What actually separates them Embody and Revel Health state different things about published price. Everything else they publish, they publish the same way. Embody costs $50 more than Revel Health — 34% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,788 at Revel Health against $2,388 at Embody — a difference of $600. |   | Embody | Revel Health | | --- | --- | --- | | Published price | $199/mo | $149/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Embody vs Trimi Health: which GLP-1 seller is right for you? | This GLP A promotional monthly rate against an annual plan billed up front. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/embody-vs-trimi-health Updated: 2026-09-16 Head to head # Embody vs Trimi Health A promotional monthly rate against an annual plan billed up front. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Embody Partner $199/mo The Flat subscription schedule puts monthly semaglutide at $199 and tirzepatide at $299. Embody also promotes a separate offer, so the selected agreement matters more than the headline. Its disclosures now identify OpenLoop Health and four dispensing partners. The refund restriction on unused bundle months deserves attention before a long commitment. For - OpenLoop Health identified as the clinical network - Four dispensing partners disclosed - Separate subscription programs explained in legal terms Against - Promotional homepage and Flat terms quote different offers - The assigned pharmacy is not established before intake - Prepaid unused treatment is generally non-refundable **Pick it for:** Readers who want to start without a year committed [Read the full review](https://thisglp.com/reviews/embody) ## Trimi Health Editorial Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide, and bills both as an annual plan: $1,188 and $1,500, charged up front or split through a buy-now-pay-later provider. The rate is stated as flat across doses. For - Rate stated as flat across doses - Annual cost published as a total - Ships to all fifty states Against - Monthly figure is an annual plan - Full year is charged at the start - Financing spreads payment, not the term **Pick it for:** Readers who will pay a year up front to hold the rate [Read the full review](https://thisglp.com/reviews/trimi-health) ## Our verdict Embody's headline is promotional and time-limited. Trimi Health's $99 comes on an annual plan billed in advance. One expires, the other has to be paid for in full first. ## What actually separates them Embody and Trimi Health state different things about published price. Everything else they publish, they publish the same way. Embody publishes a monthly rate and Trimi Health does not, so there is no gap between the two to measure. Over twelve months Embody's rate comes to about $2,388, and there is no figure from Trimi Health to set beside it. |   | Embody | Trimi Health | | --- | --- | --- | | Published price | $199/mo | Not published | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Enhance MD vs EverSlim: which GLP-1 seller is right for you? | This GLP One bills every four weeks; the other puts the visit inside the price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/enhance-md-vs-everslim Updated: 2026-09-18 Head to head # Enhance MD vs EverSlim One bills every four weeks; the other puts the visit inside the price. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Enhance MD Partner $270/mo Enhance MD charges $249 for a one-month plan of compounded semaglutide and $329 for full-dose compounded tirzepatide, each billed every four weeks, which is thirteen charges a calendar year: $270 and $356 a month. The $212 it leads with is the twelve-month rung. Labs, the consultation and two-day shipping are described as included, and the semaglutide rate is stated as flat at all doses. For - Labs and consultation inside the price - Semaglutide rate flat at every dose - Whole plan ladder published on one page Against - Cycle is four weeks, not a month - The lead figure needs a forty-eight-week term - Microdose tier is prepay only **Pick it for:** Readers who want the shorter refill interval and accept the extra fill [Read the full review](https://thisglp.com/reviews/enhance-md) ## EverSlim Editorial $113/mo EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate. For - Provider visit and shipping included - Rate flat at every dose - One monthly charge, no prepay ladder Against - Visit frequency not published - Compounding pharmacy not named - No lower rung for a longer commitment **Pick it for:** Readers who want the visit priced in and a calendar month that is a month [Read the full review](https://thisglp.com/reviews/everslim) ## Our verdict Enhance MD charges $249 for semaglutide on a four-week cycle, which is thirteen bills a year rather than twelve. EverSlim charges $113 and states the consultation sits inside it. The cadence and the inclusions move in opposite directions. ## What actually separates them Enhance MD and EverSlim state different things about published price. Everything else they publish, they publish the same way. Enhance MD costs $157 more than EverSlim — 139% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,356 at EverSlim against $3,240 at Enhance MD — a difference of $1,884. |   | Enhance MD | EverSlim | | --- | --- | --- | | Published price | $270/mo | $113/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Enhance MD vs Harper Meds: which GLP-1 seller is right for you? | This GLP Two sellers on a four-week cycle, twenty-three dollars apart. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/enhance-md-vs-harper-meds Updated: 2026-09-16 Head to head # Enhance MD vs Harper Meds Two sellers on a four-week cycle, twenty-three dollars apart. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Enhance MD Partner $270/mo Enhance MD charges $249 for a one-month plan of compounded semaglutide and $329 for full-dose compounded tirzepatide, each billed every four weeks, which is thirteen charges a calendar year: $270 and $356 a month. The $212 it leads with is the twelve-month rung. Labs, the consultation and two-day shipping are described as included, and the semaglutide rate is stated as flat at all doses. For - Labs and consultation inside the price - Semaglutide rate flat at every dose - Whole plan ladder published on one page Against - Cycle is four weeks, not a month - The lead figure needs a forty-eight-week term - Microdose tier is prepay only **Pick it for:** Readers comparing the lower of two four-week figures [Read the full review](https://thisglp.com/reviews/enhance-md) ## Harper Meds Editorial $161/mo Harper Meds prices compounded semaglutide at a flat $149 and compounded tirzepatide at a flat $196, with the consultation, the prescription, four weeks of medication and free shipping inside the charge. Both rates are stated as flat at every dose. Four weeks is not a calendar month, so thirteen fills land in a year and the figures ranked here are $161 and $212. For - Consultation and prescription inside the price - Rate flat at every dose - No prepay term required Against - A fill covers four weeks, not a month - State coverage not published - Compounding pharmacy not named **Pick it for:** Readers who want the inclusions stated rather than inferred [Read the full review](https://thisglp.com/reviews/harper-meds) ## Our verdict Both bill on four weeks rather than a calendar month, so both charge thirteen times a year. Harper Meds describes its fill as all-inclusive; Enhance MD does not make that claim. ## What actually separates them Enhance MD and Harper Meds state different things about published price. Everything else they publish, they publish the same way. Enhance MD costs $109 more than Harper Meds — 68% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,932 at Harper Meds against $3,240 at Enhance MD — a difference of $1,308. |   | Enhance MD | Harper Meds | | --- | --- | --- | | Published price | $270/mo | $161/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # EverSlim vs Trimi Health: which GLP-1 seller is right for you? | This GLP A visit inside the price against a year paid before the first shipment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/everslim-vs-trimi-health Updated: 2026-09-16 Head to head # EverSlim vs Trimi Health A visit inside the price against a year paid before the first shipment. By [This GLP Editorial Team](https://thisglp.com/about) ## EverSlim Editorial $113/mo EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate. For - Provider visit and shipping included - Rate flat at every dose - One monthly charge, no prepay ladder Against - Visit frequency not published - Compounding pharmacy not named - No lower rung for a longer commitment **Pick it for:** Readers who want the visit covered and no annual commitment [Read the full review](https://thisglp.com/reviews/everslim) ## Trimi Health Editorial Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide, and bills both as an annual plan: $1,188 and $1,500, charged up front or split through a buy-now-pay-later provider. The rate is stated as flat across doses. For - Rate stated as flat across doses - Annual cost published as a total - Ships to all fifty states Against - Monthly figure is an annual plan - Full year is charged at the start - Financing spreads payment, not the term **Pick it for:** Readers who will fund a year to hold the lower figure [Read the full review](https://thisglp.com/reviews/trimi-health) ## Our verdict EverSlim states the consultation is inside its $113. Trimi Health's $99 assumes an annual plan billed up front. One removes a charge, the other moves the whole year forward. ## What actually separates them EverSlim and Trimi Health state different things about published price. Everything else they publish, they publish the same way. EverSlim publishes a monthly rate and Trimi Health does not, so there is no gap between the two to measure. Over twelve months EverSlim's rate comes to about $1,356, and there is no figure from Trimi Health to set beside it. |   | EverSlim | Trimi Health | | --- | --- | --- | | Published price | $113/mo | Not published | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Fidelity Medical Clinic vs Pallas Health: which GLP-1 seller is right for you? Four-week dosing against twelve-week billing at the same $216. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/fidelity-medical-clinic-vs-pallas-health Updated: 2026-09-16 Head to head # Fidelity Medical Clinic vs Pallas Health Four-week dosing against twelve-week billing at the same $216. By [This GLP Editorial Team](https://thisglp.com/about) ## Fidelity Medical Clinic Editorial $216/mo Fidelity Medical Clinic sells compounded semaglutide at $199 for four doses and compounded tirzepatide at $349 for four, each order covering four weeks rather than a calendar month. Converted by month length, the figures ranked here are $216 and $379. The intro orders are $99 and $349 for eight doses, and both require a two-month commitment. For - Order contents stated as four doses - Supplies included with each order - Intro order priced and dated Against - Four weeks is not a calendar month - Dose-pricing model not published - Intro order requires two months **Pick it for:** Readers who want dose-by-dose pricing they can check [Read the full review](https://thisglp.com/reviews/fidelity-medical-clinic) ## Pallas Health Editorial $216/mo The $199 a month Pallas quotes comes from dividing a $597 twelve-week charge by three, and twelve weeks is 2.76 calendar months, so the figure ranked here is $216; the same correction puts the $897 tirzepatide block at $325. A first month of compounded semaglutide is $139 before either block begins. Provider care and check-ins are described as sitting inside the price, and the rate is stated as holding at every dose. For - Seller publishes its own averaging - Provider care and check-ins included - Rate stated as flat at every dose Against - Card is charged $597 at a time - First month is cheaper than the rest - Twelve weeks is the shortest commitment **Pick it for:** Readers who want fewer transactions and a longer paid term [Read the full review](https://thisglp.com/reviews/pallas-health) ## Our verdict The two publish the same figure on entirely different clocks. Fidelity prices four doses across four weeks; Pallas bills every twelve. The same number describes a very different year. ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Harper Meds vs Pallas Health: which GLP-1 seller is right for you? | This GLP A four-week fill against twelve-week billing, which are two different calendars. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/harper-meds-vs-pallas-health Updated: 2026-09-16 Head to head # Harper Meds vs Pallas Health A four-week fill against twelve-week billing, which are two different calendars. By [This GLP Editorial Team](https://thisglp.com/about) ## Harper Meds Editorial $161/mo Harper Meds prices compounded semaglutide at a flat $149 and compounded tirzepatide at a flat $196, with the consultation, the prescription, four weeks of medication and free shipping inside the charge. Both rates are stated as flat at every dose. Four weeks is not a calendar month, so thirteen fills land in a year and the figures ranked here are $161 and $212. For - Consultation and prescription inside the price - Rate flat at every dose - No prepay term required Against - A fill covers four weeks, not a month - State coverage not published - Compounding pharmacy not named **Pick it for:** Readers who want the shorter commitment between charges [Read the full review](https://thisglp.com/reviews/harper-meds) ## Pallas Health Editorial $216/mo The $199 a month Pallas quotes comes from dividing a $597 twelve-week charge by three, and twelve weeks is 2.76 calendar months, so the figure ranked here is $216; the same correction puts the $897 tirzepatide block at $325. A first month of compounded semaglutide is $139 before either block begins. Provider care and check-ins are described as sitting inside the price, and the rate is stated as holding at every dose. For - Seller publishes its own averaging - Provider care and check-ins included - Rate stated as flat at every dose Against - Card is charged $597 at a time - First month is cheaper than the rest - Twelve weeks is the shortest commitment **Pick it for:** Readers who would rather pay once a quarter than once a month [Read the full review](https://thisglp.com/reviews/pallas-health) ## Our verdict Harper Meds bills all-inclusive on a four-week fill; Pallas Health bills every twelve weeks. Neither interval is a calendar month, so neither headline is a monthly cost without arithmetic. ## What actually separates them Harper Meds and Pallas Health state different things about published price. Everything else they publish, they publish the same way. Pallas Health costs $55 more than Harper Meds — 34% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,932 at Harper Meds against $2,592 at Pallas Health — a difference of $660. |   | Harper Meds | Pallas Health | | --- | --- | --- | | Published price | $161/mo | $216/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Idgie Health vs PlushCare: which GLP-1 seller is right for you? | This GLP A seller that states the off-label position against one whose headline covers only the starting dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/idgie-health-vs-plushcare Updated: 2026-09-18 Head to head # Idgie Health vs PlushCare A seller that states the off-label position against one whose headline covers only the starting dose. By [This GLP Editorial Team](https://thisglp.com/about) ## Idgie Health Editorial $134/mo Idgie Health prices a compounded semaglutide microdose at $134 a month, a tirzepatide microdose at $179, and an orally dissolving semaglutide tablet at $287. Three-month purchases are charged in full at $377, $497 and $747. The product copy describes microdosing as an off-label approach, which few sellers print beside a price. For - Seller names microdosing as off-label - Monthly and three-month figures both published - Second active ingredient named on the tablet Against - Microdoses sit below the studied doses - Three-month price is charged in full - Tablet costs more than either injection **Pick it for:** Readers who want the regulatory framing stated [Read the full review](https://thisglp.com/reviews/idgie-health) ## PlushCare Editorial $149/mo PlushCare advertises compounded semaglutide at $149 a month cash-pay, and states that the figure buys the 0.25 mg starting dose only; every dose from 0.5 mg to 2.4 mg costs more. Its compounded tirzepatide page now redirects to a Mounjaro page that quotes no compounded price. Insurance is accepted on a separate basis. For - Says what the entry figure buys - Insurance accepted as a separate route - Prescription follows a clinician visit Against - Maintenance doses cost $299 a month - No compounded tirzepatide price published **Pick it for:** Readers who want a recognized clinical brand at the opening dose [Read the full review](https://thisglp.com/reviews/plushcare) ## Our verdict Idgie Health names the off-label parity question directly. PlushCare's $149 covers the starting dose, and one higher price covers every dose above it. Each is candid about a different thing. ## What actually separates them Idgie Health and PlushCare state different things about published price. Everything else they publish, they publish the same way. PlushCare costs $15 more than Idgie Health — 11% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,608 at Idgie Health against $1,788 at PlushCare — a difference of $180. |   | Idgie Health | PlushCare | | --- | --- | --- | | Published price | $134/mo | $149/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Idgie Health vs Synergy Rx: which GLP-1 seller is right for you? | This GLP Candor about the off-label position against candor about every price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/idgie-health-vs-synergy-rx Updated: 2026-09-16 Head to head # Idgie Health vs Synergy Rx Candor about the off-label position against candor about every price. By [This GLP Editorial Team](https://thisglp.com/about) ## Idgie Health Editorial $134/mo Idgie Health prices a compounded semaglutide microdose at $134 a month, a tirzepatide microdose at $179, and an orally dissolving semaglutide tablet at $287. Three-month purchases are charged in full at $377, $497 and $747. The product copy describes microdosing as an off-label approach, which few sellers print beside a price. For - Seller names microdosing as off-label - Monthly and three-month figures both published - Second active ingredient named on the tablet Against - Microdoses sit below the studied doses - Three-month price is charged in full - Tablet costs more than either injection **Pick it for:** Readers who want the off-label position stated and the rate held [Read the full review](https://thisglp.com/reviews/idgie-health) ## Synergy Rx Editorial $199/mo Synergy Rx advertises compounded semaglutide at $199 a month by injection and $299 as an oral, and compounded tirzepatide at $349 by injection and $399 as an oral. It is one of the few sellers to publish a rate for all four combinations rather than quoting the injection and leaving the oral to an enquiry. All fifty states are served. For - A published rate for all four combinations - Oral priced without requiring an intake - All fifty states served Against - Tirzepatide injection priced at $349 - Oral carries a premium on both molecules - Dose-escalation pricing not stated **Pick it for:** Readers who want to compare formats without an intake [Read the full review](https://thisglp.com/reviews/synergy-rx) ## Our verdict Idgie Health states the regulatory framing plainly and holds its rate. Synergy Rx publishes all four combinations and states nothing about dose. Two different kinds of openness. ## What actually separates them Idgie Health and Synergy Rx state different things about published price. Everything else they publish, they publish the same way. Synergy Rx costs $65 more than Idgie Health — 49% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,608 at Idgie Health against $2,388 at Synergy Rx — a difference of $780. |   | Idgie Health | Synergy Rx | | --- | --- | --- | | Published price | $134/mo | $199/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # KERNX Health vs Breeze Meds: which GLP-1 seller is right for you? | This GLP A flat rate with a one-off consult fee against four rates and no dose statement. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/kernx-health-vs-breeze-meds Updated: 2026-09-16 Head to head # KERNX Health vs Breeze Meds A flat rate with a one-off consult fee against four rates and no dose statement. By [This GLP Editorial Team](https://thisglp.com/about) ## KERNX Health Editorial $209/mo KERNX Health publishes $209 a month for compounded semaglutide and $299 for compounded tirzepatide, one flat price at every dose, with no membership fee and no required three-month plan. A provider consultation fee is billed apart from the medication rate and charged only when treatment is approved: $25 for a message-based review, $35 for a standard live visit and $60 for a complex one. For - Consultation fee published as three tiers - Fee charged only on approval - Rate flat at every dose Against - Tirzepatide costs $90 more a month - Visit fee at a dose change is unstated - Consultation billed apart from the rate **Pick it for:** Readers who want the dose behavior settled up front [Read the full review](https://thisglp.com/reviews/kernx-health) ## Breeze Meds Editorial $199/mo Breeze Meds advertises compounded semaglutide at $199 a month by injection and $299 as a daily dissolvable tablet, with compounded tirzepatide at $399 in either form. The oral semaglutide catalog also lists prepaid three-, six- and twelve-month blocks, each of which works out within a few dollars of the monthly rate. All fifty states are served. For - All fifty states served - Both molecules priced in both forms - Oral described as one tablet daily Against - Oral semaglutide costs more than the injection - Prepaid blocks save little against monthly - Dose-escalation pricing not published **Pick it for:** Readers who want every format priced before choosing one [Read the full review](https://thisglp.com/reviews/breeze-meds) ## Our verdict KernX states its tiers hold and charges the consultation once on approval. Breeze Meds publishes four figures and says nothing about the ladder. Each leaves a different question open. ## What actually separates them KERNX Health and Breeze Meds state different things about published price. Everything else they publish, they publish the same way. KERNX Health costs $10 more than Breeze Meds — 5% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $2,388 at Breeze Meds against $2,508 at KERNX Health — a difference of $120. |   | KERNX Health | Breeze Meds | | --- | --- | --- | | Published price | $209/mo | $199/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # KERNX Health vs EverSlim: which GLP-1 seller is right for you? | This GLP A consultation billed per event against one folded into the monthly price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/kernx-health-vs-everslim Updated: 2026-09-16 Head to head # KERNX Health vs EverSlim A consultation billed per event against one folded into the monthly price. By [This GLP Editorial Team](https://thisglp.com/about) ## KERNX Health Editorial $209/mo KERNX Health publishes $209 a month for compounded semaglutide and $299 for compounded tirzepatide, one flat price at every dose, with no membership fee and no required three-month plan. A provider consultation fee is billed apart from the medication rate and charged only when treatment is approved: $25 for a message-based review, $35 for a standard live visit and $60 for a complex one. For - Consultation fee published as three tiers - Fee charged only on approval - Rate flat at every dose Against - Tirzepatide costs $90 more a month - Visit fee at a dose change is unstated - Consultation billed apart from the rate **Pick it for:** Readers who want three tiers and a one-off consult charge [Read the full review](https://thisglp.com/reviews/kernx-health) ## EverSlim Editorial $113/mo EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate. For - Provider visit and shipping included - Rate flat at every dose - One monthly charge, no prepay ladder Against - Visit frequency not published - Compounding pharmacy not named - No lower rung for a longer commitment **Pick it for:** Readers who want no separate consultation line at all [Read the full review](https://thisglp.com/reviews/everslim) ## Our verdict KernX charges a consultation fee that applies on approval rather than every month; EverSlim states its visit is inside the $113. Both are honest arrangements, and they land differently on a first bill. ## What actually separates them KERNX Health and EverSlim state different things about published price. Everything else they publish, they publish the same way. KERNX Health costs $96 more than EverSlim — 85% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,356 at EverSlim against $2,508 at KERNX Health — a difference of $1,152. |   | KERNX Health | EverSlim | | --- | --- | --- | | Published price | $209/mo | $113/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Lean Meds vs Strut Health: which GLP-1 seller is right for you? | This GLP A general starting offer against a disclosed standing-order discount. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/leanmeds-vs-strut-health Updated: 2026-10-14 Head to head # Lean Meds vs Strut Health A general starting offer against a disclosed standing-order discount. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Lean Meds Editorial Leanmeds explains its clinician evaluation and coaching pathway, but the current starting offer does not identify separate recurring prices for semaglutide and tirzepatide. A countdown qualifies the headline. Confirm the prescribed product and payment terms before relying on older rates or prepayment ladders. For - Clinical review is described before prescribing - Coaching is advertised within the plan - State-dependent consultation process is explained Against - No verified current price for each molecule - A countdown accompanies the starting offer - Final medication details require confirmation **Pick it for:** Readers willing to confirm both dose pricing and renewal terms [Read the full review](https://thisglp.com/reviews/leanmeds) ## Strut Health Partner $99/mo Strut Health advertises compounded semaglutide at $149 a month by injection and $99 as an oral, with compounded tirzepatide at $199 in either form. Each of those is the auto-refill rate; the page shows a higher one-off price beside the oral tirzepatide at $239, and a $325 compare-at figure beside the injection. Coverage runs to 49 states, with Alaska excluded. For - Four advertised rates, both forms of both molecules - Oral semaglutide priced at $99 a month - One-off prices shown beside refill rates Against - Advertised rates assume a standing auto-refill - Not available in Alaska - Dose-escalation pricing not stated **Pick it for:** Readers who want to see the one-off price before committing [Read the full review](https://thisglp.com/reviews/strut-health) ## Our verdict Leanmeds describes consistent pricing across doses, but its current public offer does not establish a standing amount for each medication. Strut Health publishes a standing-order discount alongside a single-month option. Request a medication-specific Leanmeds quote before treating those offers as comparable. ## What actually separates them Lean Meds and Strut Health state different things about published price. Everything else they publish, they publish the same way. Strut Health publishes a monthly rate and Lean Meds does not, so there is no gap between the two to measure. Over twelve months Strut Health's rate comes to about $1,188, and there is no figure from Lean Meds to set beside it. |   | Lean Meds | Strut Health | | --- | --- | --- | | Published price | Not published | $99/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Liberty vs Apex MD: which GLP-1 seller is right for you? | This GLP Named sourcing against named inclusions, a hundred dollars apart. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/liberty-vs-apex-md Updated: 2026-09-16 Head to head # Liberty vs Apex MD Named sourcing against named inclusions, a hundred dollars apart. By [This GLP Editorial Team](https://thisglp.com/about) ## Liberty Editorial $129/mo Liberty prices compounded semaglutide at a flat $129 a month and compounded tirzepatide at a flat $219, and states that both are sourced from a 503B outsourcing facility after a clinician review. A three-month supply brings the semaglutide to $110 a month. A 503B registers with the FDA and compounds under current good manufacturing practice, which is not the same as approval. For - Pharmacy type named, not implied - Clinician review stated before prescribing - Rate flat at every dose Against - No state list published - Tirzepatide costs $90 more - Facility name itself not published **Pick it for:** Readers whose first question is where the medication comes from [Read the full review](https://thisglp.com/reviews/liberty) ## Apex MD Editorial $299/mo Apex MD prices compounded semaglutide at $299 a month by weekly injection and tirzepatide at $399. The injectable preparation is compounded with NAD, B-12 and L-carnitine in the same vial. Plans are described as month-to-month and the rate is stated as flat at every dose. Oral pills are sold on a separate microdosing line. For - Additives named on the product page - Rate stated as flat at every dose - Plans described as month-to-month Against - Additive combination not studied in trials - Figures sit high for compounded products - No prepay rung published **Pick it for:** Readers whose first question is what the figure already covers [Read the full review](https://thisglp.com/reviews/apex-md) ## Our verdict Liberty names its 503B source; Apex MD names what its price contains. Neither leaves the reader guessing, and they chose different things to be clear about. ## What actually separates them Liberty and Apex MD state different things about published price. Everything else they publish, they publish the same way. Apex MD costs $170 more than Liberty — 132% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,548 at Liberty against $3,588 at Apex MD — a difference of $2,040. |   | Liberty | Apex MD | | --- | --- | --- | | Published price | $129/mo | $299/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Liberty vs CoreAge Rx: which GLP-1 seller is right for you? | This GLP One names the facility behind the vial; the other does not. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/liberty-vs-coreage-rx Updated: 2026-09-16 Head to head # Liberty vs CoreAge Rx One names the facility behind the vial; the other does not. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Liberty Editorial $129/mo Liberty prices compounded semaglutide at a flat $129 a month and compounded tirzepatide at a flat $219, and states that both are sourced from a 503B outsourcing facility after a clinician review. A three-month supply brings the semaglutide to $110 a month. A 503B registers with the FDA and compounds under current good manufacturing practice, which is not the same as approval. For - Pharmacy type named, not implied - Clinician review stated before prescribing - Rate flat at every dose Against - No state list published - Tirzepatide costs $90 more - Facility name itself not published **Pick it for:** Readers who will pay more to know where the medication is made [Read the full review](https://thisglp.com/reviews/liberty) ## CoreAge Rx Partner $99/mo Two injectable lines and nothing else: compounded semaglutide at $99 a month and compounded tirzepatide at $149. No oral line is listed at any price, and all fifty states are served. For - Lowest advertised figures of the sellers wired here - Narrow $50 gap between the two molecules - All fifty states served Against - No oral form for either molecule - Prices carry the oldest check date in this group - Dose-escalation pricing not stated **Pick it for:** Readers optimizing on the published figure [Read the full review](https://thisglp.com/reviews/coreage-rx) ## Our verdict Liberty identifies a 503B outsourcing facility as its source. CoreAge Rx publishes two figures and names no pharmacy. At a hundred dollars of difference, that disclosure is what the money buys. ## What actually separates them Liberty and CoreAge Rx state different things about published price. Everything else they publish, they publish the same way. Liberty costs $30 more than CoreAge Rx — 30% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,188 at CoreAge Rx against $1,548 at Liberty — a difference of $360. |   | Liberty | CoreAge Rx | | --- | --- | --- | | Published price | $129/mo | $99/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Liberty vs Idgie Health: which GLP-1 seller is right for you? | This GLP Two sellers that each volunteer something most of the category does not. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/liberty-vs-idgie-health Updated: 2026-09-16 Head to head # Liberty vs Idgie Health Two sellers that each volunteer something most of the category does not. By [This GLP Editorial Team](https://thisglp.com/about) ## Liberty Editorial $129/mo Liberty prices compounded semaglutide at a flat $129 a month and compounded tirzepatide at a flat $219, and states that both are sourced from a 503B outsourcing facility after a clinician review. A three-month supply brings the semaglutide to $110 a month. A 503B registers with the FDA and compounds under current good manufacturing practice, which is not the same as approval. For - Pharmacy type named, not implied - Clinician review stated before prescribing - Rate flat at every dose Against - No state list published - Tirzepatide costs $90 more - Facility name itself not published **Pick it for:** Readers who want the compounding source named before ordering [Read the full review](https://thisglp.com/reviews/liberty) ## Idgie Health Editorial $134/mo Idgie Health prices a compounded semaglutide microdose at $134 a month, a tirzepatide microdose at $179, and an orally dissolving semaglutide tablet at $287. Three-month purchases are charged in full at $377, $497 and $747. The product copy describes microdosing as an off-label approach, which few sellers print beside a price. For - Seller names microdosing as off-label - Monthly and three-month figures both published - Second active ingredient named on the tablet Against - Microdoses sit below the studied doses - Three-month price is charged in full - Tablet costs more than either injection **Pick it for:** Readers who want the regulatory position spelled out [Read the full review](https://thisglp.com/reviews/idgie-health) ## Our verdict Liberty names the 503B facility its medication comes from. Idgie Health states the off-label position plainly. Different disclosures, and both are rarer than the prices beside them. ## What actually separates them Liberty and Idgie Health state different things about published price. Everything else they publish, they publish the same way. Idgie Health costs $5 more than Liberty — 4% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,548 at Liberty against $1,608 at Idgie Health — a difference of $60. |   | Liberty | Idgie Health | | --- | --- | --- | | Published price | $129/mo | $134/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # NextMeds vs Alloy: which GLP-1 seller is right for you? | This GLP Two services that charge for the relationship, one inside the price and one outside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/nextmeds-vs-alloy Updated: 2026-09-16 Head to head # NextMeds vs Alloy Two services that charge for the relationship, one inside the price and one outside it. By [This GLP Editorial Team](https://thisglp.com/about) ## NextMeds Editorial $49/mo NextMeds sells its GLP-1 treatment as a membership, and the membership price is the whole price: $49 a month for compounded semaglutide and $119 for compounded tirzepatide. Telehealth visits, a care coach, a dietitian and shipping sit inside it. Neither rate is described as moving with the dose, and neither is an introductory price: the site says a first order and a tenth cost the same. For - Membership price is the whole price - Visits, coaching and shipping bundled - Rate flat at every dose Against - Both rates printed as starting figures - Visit frequency not published - Compounding pharmacy not named **Pick it for:** Readers who want the bundled figure with nothing owed beside it [Read the full review](https://thisglp.com/reviews/nextmeds) ## Alloy Editorial $169/mo Three compounded molecules at $70, $100 and $115 a month for the medication, each with a mandatory $99 care fee on top: $169, $199 and $214 all-in. Wegovy is listed from $199, but that is NovoCare's offer for a new patient's first two fills. At NovoCare's standing $349 plus the fee, it runs $448 a month. For - Three compounded molecules at one seller - Care fee amount published, not implied - Branded and compounded routes both listed Against - Care fee is $99 every month - Medication rate excludes that fee - Fee dominates a low medication rate - Wegovy's $199 covers two fills only **Pick it for:** Readers comparing Alloy's medication rate specifically [Read the full review](https://thisglp.com/reviews/alloy) ## Our verdict NextMeds' figure is the membership and bundles the service into it. Alloy's figure is the medication with a required fee alongside. The difference shows up on the first statement, not on the pricing page. ## What actually separates them NextMeds and Alloy state different things about published price. Everything else they publish, they publish the same way. Alloy costs $120 more than NextMeds — 245% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $588 at NextMeds against $2,028 at Alloy — a difference of $1,440. |   | NextMeds | Alloy | | --- | --- | --- | | Published price | $49/mo | $169/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # NextMeds vs Collective: which GLP-1 seller is right for you? | This GLP At one seller the membership is the price; at the other it is billed beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/nextmeds-vs-collective Updated: 2026-09-16 Head to head # NextMeds vs Collective At one seller the membership is the price; at the other it is billed beside it. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## NextMeds Editorial $49/mo NextMeds sells its GLP-1 treatment as a membership, and the membership price is the whole price: $49 a month for compounded semaglutide and $119 for compounded tirzepatide. Telehealth visits, a care coach, a dietitian and shipping sit inside it. Neither rate is described as moving with the dose, and neither is an introductory price: the site says a first order and a tenth cost the same. For - Membership price is the whole price - Visits, coaching and shipping bundled - Rate flat at every dose Against - Both rates printed as starting figures - Visit frequency not published - Compounding pharmacy not named **Pick it for:** Readers who want one charge covering the whole service [Read the full review](https://thisglp.com/reviews/nextmeds) ## Collective Partner $76/mo Collective advertises $59 a month for compounded semaglutide and $69 for compounded tirzepatide, and charges a $199 annual membership beside both. Added together, a first year of semaglutide comes to $907, or $76 a month. The rate is stated as holding at every dose. For - Rate stated as flat at every dose - Both molecules priced on one page - Membership amount published, not implied Against - Membership is charged annually, up front - Advertised rate excludes that membership - Short course carries the whole year fee **Pick it for:** Readers who want the medication priced apart from the service [Read the full review](https://thisglp.com/reviews/collective) ## Our verdict NextMeds states the published figure IS the membership, bundling visits, coaching and shipping. Collective bills its membership separately from the medication. The word is the same and the arrangement is not. ## What actually separates them NextMeds and Collective state different things about published price. Everything else they publish, they publish the same way. Collective costs $27 more than NextMeds — 55% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $588 at NextMeds against $912 at Collective — a difference of $324. |   | NextMeds | Collective | | --- | --- | --- | | Published price | $49/mo | $76/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Nova vs EverSlim: which GLP-1 seller is right for you? | This GLP Two states against fifty-one, and two ways of counting the service in. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/nova-vs-everslim Updated: 2026-09-16 Head to head # Nova vs EverSlim Two states against fifty-one, and two ways of counting the service in. By [This GLP Editorial Team](https://thisglp.com/about) ## Nova Editorial $139/mo Nova advertises compounded semaglutide at $229 a month by injection and $139 as an oral, with compounded tirzepatide at $279 and $159. The injection figures are stated as all-in, covering medication, shipping and a required Nova Care fee. The orals carry the same membership, so the gap between forms is the medication alone. Two states are served. For - Required care fee folded into the price - Oral rates well below the injections - Sublingual dosing difference stated plainly Against - Two states only - The injections cost more than the orals - Price scales with the dose **Pick it for:** Readers in Texas or Florida who want the fee counted in [Read the full review](https://thisglp.com/reviews/nova) ## EverSlim Editorial $113/mo EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate. For - Provider visit and shipping included - Rate flat at every dose - One monthly charge, no prepay ladder Against - Visit frequency not published - Compounding pharmacy not named - No lower rung for a longer commitment **Pick it for:** Readers anywhere else who want the same kind of inclusion [Read the full review](https://thisglp.com/reviews/everslim) ## Our verdict Nova counts a mandatory care charge inside its injection figures but ships to Texas and Florida only. EverSlim includes the visit and ships nationally. For most readers this is decided by the map. ## What actually separates them Nova and EverSlim state different things about published price. Everything else they publish, they publish the same way. Nova costs $26 more than EverSlim — 23% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,356 at EverSlim against $1,668 at Nova — a difference of $312. |   | Nova | EverSlim | | --- | --- | --- | | Published price | $139/mo | $113/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Pallas Health vs Apex MD: which GLP-1 seller is right for you? | This GLP Quarterly billing against a price that already contains the additives. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/pallas-health-vs-apex-md Updated: 2026-09-16 Head to head # Pallas Health vs Apex MD Quarterly billing against a price that already contains the additives. By [This GLP Editorial Team](https://thisglp.com/about) ## Pallas Health Editorial $216/mo The $199 a month Pallas quotes comes from dividing a $597 twelve-week charge by three, and twelve weeks is 2.76 calendar months, so the figure ranked here is $216; the same correction puts the $897 tirzepatide block at $325. A first month of compounded semaglutide is $139 before either block begins. Provider care and check-ins are described as sitting inside the price, and the rate is stated as holding at every dose. For - Seller publishes its own averaging - Provider care and check-ins included - Rate stated as flat at every dose Against - Card is charged $597 at a time - First month is cheaper than the rest - Twelve weeks is the shortest commitment **Pick it for:** Readers who want the lower figure and can commit a quarter at a time [Read the full review](https://thisglp.com/reviews/pallas-health) ## Apex MD Editorial $299/mo Apex MD prices compounded semaglutide at $299 a month by weekly injection and tirzepatide at $399. The injectable preparation is compounded with NAD, B-12 and L-carnitine in the same vial. Plans are described as month-to-month and the rate is stated as flat at every dose. Oral pills are sold on a separate microdosing line. For - Additives named on the product page - Rate stated as flat at every dose - Plans described as month-to-month Against - Additive combination not studied in trials - Figures sit high for compounded products - No prepay rung published **Pick it for:** Readers who want additives priced in rather than added later [Read the full review](https://thisglp.com/reviews/apex-md) ## Our verdict Pallas Health bills every twelve weeks at $216. Apex MD charges $299 and states the additives are inside that figure. One spreads the commitment, the other removes a line item. ## What actually separates them Pallas Health and Apex MD state different things about published price. Everything else they publish, they publish the same way. Apex MD costs $83 more than Pallas Health — 38% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $2,592 at Pallas Health against $3,588 at Apex MD — a difference of $996. |   | Pallas Health | Apex MD | | --- | --- | --- | | Published price | $216/mo | $299/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # PreventiveMD vs Maximus: which GLP-1 seller is right for you? | This GLP Three molecules priced against branded and compounded priced side by side. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/preventivemd-vs-maximus-tribe Updated: 2026-09-16 Head to head # PreventiveMD vs Maximus Three molecules priced against branded and compounded priced side by side. By [This GLP Editorial Team](https://thisglp.com/about) ## PreventiveMD Editorial $119/mo PreventiveMD sells a one-month supply of compounded semaglutide for $119 and of compounded tirzepatide for $139, described as all-in and flat across doses; the $83 and $97 on its homepage are the twelve-month plans, paid in one charge up front. It also lists orforglipron, a third molecule few sellers carry, at $149 plus a $49 monthly membership. Thirty-six states. For - Carries a third molecule most sellers do not - Both compounded figures described as all-in - Brand and compounded routes priced separately Against - The headline figures need a year paid up front - A $49 membership applies on brand plans - Fourteen states are not served **Pick it for:** Readers who want the newer molecule priced at all [Read the full review](https://thisglp.com/reviews/preventivemd) ## Maximus Editorial $249.99/mo Maximus lists compounded semaglutide at $249.99 a month on a one-month plan and the branded Wegovy pen at $449.99 a month ongoing, a $200 gap. On tirzepatide the gap is $190, at $359.99 compounded against $549.99 for Zepbound. Four-month and twelve-month plans cut the compounded semaglutide figure to $199.49 and $150.32. For - Branded and compounded on one plan page - Branded pen prices published by dose - Compounded rate stated as flat across doses Against - One-month rate is high for this category - Branded pens cost $190 to $200 more monthly - Best compounded rates need a twelve-month plan **Pick it for:** Readers weighing a branded product against a compounded one [Read the full review](https://thisglp.com/reviews/maximus-tribe) ## Our verdict PreventiveMD prices a third molecule most sellers do not carry. Maximus Tribe prices branded against compounded on the same page. Both widen the comparison rather than narrowing it. ## What actually separates them PreventiveMD and Maximus state different things about published price. Everything else they publish, they publish the same way. Maximus costs $130.99 more than PreventiveMD — 110% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,428 at PreventiveMD against $3,000 at Maximus — a difference of $1,572. |   | PreventiveMD | Maximus | | --- | --- | --- | | Published price | $119/mo | $249.99/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # PreventiveMD vs Strut Health: which GLP-1 seller is right for you? | This GLP Three molecules against two molecules in two formats. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/preventivemd-vs-strut-health Updated: 2026-09-16 Head to head # PreventiveMD vs Strut Health Three molecules against two molecules in two formats. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## PreventiveMD Editorial $119/mo PreventiveMD sells a one-month supply of compounded semaglutide for $119 and of compounded tirzepatide for $139, described as all-in and flat across doses; the $83 and $97 on its homepage are the twelve-month plans, paid in one charge up front. It also lists orforglipron, a third molecule few sellers carry, at $149 plus a $49 monthly membership. Thirty-six states. For - Carries a third molecule most sellers do not - Both compounded figures described as all-in - Brand and compounded routes priced separately Against - The headline figures need a year paid up front - A $49 membership applies on brand plans - Fourteen states are not served **Pick it for:** Readers who want the newer molecule priced [Read the full review](https://thisglp.com/reviews/preventivemd) ## Strut Health Partner $99/mo Strut Health advertises compounded semaglutide at $149 a month by injection and $99 as an oral, with compounded tirzepatide at $199 in either form. Each of those is the auto-refill rate; the page shows a higher one-off price beside the oral tirzepatide at $239, and a $325 compare-at figure beside the injection. Coverage runs to 49 states, with Alaska excluded. For - Four advertised rates, both forms of both molecules - Oral semaglutide priced at $99 a month - One-off prices shown beside refill rates Against - Advertised rates assume a standing auto-refill - Not available in Alaska - Dose-escalation pricing not stated **Pick it for:** Readers who want a tablet and an injection priced side by side [Read the full review](https://thisglp.com/reviews/strut-health) ## Our verdict PreventiveMD prices a third molecule; Strut Health prices two molecules in both formats on a standing order. Breadth of molecule against breadth of format. ## What actually separates them PreventiveMD and Strut Health state different things about published price. Everything else they publish, they publish the same way. PreventiveMD costs $20 more than Strut Health — 20% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,188 at Strut Health against $1,428 at PreventiveMD — a difference of $240. |   | PreventiveMD | Strut Health | | --- | --- | --- | | Published price | $119/mo | $99/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Synergy Rx vs Liberty: which GLP-1 seller is right for you? | This GLP Four published rates on one side, a named 503B facility on the other. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/synergy-rx-vs-liberty Updated: 2026-09-16 Head to head # Synergy Rx vs Liberty Four published rates on one side, a named 503B facility on the other. By [This GLP Editorial Team](https://thisglp.com/about) ## Synergy Rx Editorial $199/mo Synergy Rx advertises compounded semaglutide at $199 a month by injection and $299 as an oral, and compounded tirzepatide at $349 by injection and $399 as an oral. It is one of the few sellers to publish a rate for all four combinations rather than quoting the injection and leaving the oral to an enquiry. All fifty states are served. For - A published rate for all four combinations - Oral priced without requiring an intake - All fifty states served Against - Tirzepatide injection priced at $349 - Oral carries a premium on both molecules - Dose-escalation pricing not stated **Pick it for:** Readers who want the format choice priced out [Read the full review](https://thisglp.com/reviews/synergy-rx) ## Liberty Editorial $129/mo Liberty prices compounded semaglutide at a flat $129 a month and compounded tirzepatide at a flat $219, and states that both are sourced from a 503B outsourcing facility after a clinician review. A three-month supply brings the semaglutide to $110 a month. A 503B registers with the FDA and compounds under current good manufacturing practice, which is not the same as approval. For - Pharmacy type named, not implied - Clinician review stated before prescribing - Rate flat at every dose Against - No state list published - Tirzepatide costs $90 more - Facility name itself not published **Pick it for:** Readers who want the sourcing question answered first [Read the full review](https://thisglp.com/reviews/liberty) ## Our verdict Synergy Rx prices all four combinations at the same opening figure Liberty charges for one. Liberty answers with the compounding facility named on the page. That trade is sharper than it sounds, because the two sellers are answering different questions rather than the same question differently. Breadth lets a reader price a format decision before making it; a named facility lets them check a supply chain that is otherwise invisible. Only one of those can be verified from outside the company, which is the argument for weighing the named facility more heavily than a menu. A reader who already knows which format they want gets less from the breadth than the comparison implies. ## What actually separates them Synergy Rx and Liberty state different things about published price. Everything else they publish, they publish the same way. Synergy Rx costs $70 more than Liberty — 54% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,548 at Liberty against $2,388 at Synergy Rx — a difference of $840. |   | Synergy Rx | Liberty | | --- | --- | --- | | Published price | $199/mo | $129/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Trimi Health vs Harper Meds: which GLP-1 seller is right for you? | This GLP An annual plan against an all-inclusive four-week fill. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/trimi-health-vs-harper-meds Updated: 2026-09-16 Head to head # Trimi Health vs Harper Meds An annual plan against an all-inclusive four-week fill. By [This GLP Editorial Team](https://thisglp.com/about) ## Trimi Health Editorial Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide, and bills both as an annual plan: $1,188 and $1,500, charged up front or split through a buy-now-pay-later provider. The rate is stated as flat across doses. For - Rate stated as flat across doses - Annual cost published as a total - Ships to all fifty states Against - Monthly figure is an annual plan - Full year is charged at the start - Financing spreads payment, not the term **Pick it for:** Readers who want the lowest figure and will commit a year [Read the full review](https://thisglp.com/reviews/trimi-health) ## Harper Meds Editorial $161/mo Harper Meds prices compounded semaglutide at a flat $149 and compounded tirzepatide at a flat $196, with the consultation, the prescription, four weeks of medication and free shipping inside the charge. Both rates are stated as flat at every dose. Four weeks is not a calendar month, so thirteen fills land in a year and the figures ranked here are $161 and $212. For - Consultation and prescription inside the price - Rate flat at every dose - No prepay term required Against - A fill covers four weeks, not a month - State coverage not published - Compounding pharmacy not named **Pick it for:** Readers who want inclusions stated and no annual commitment [Read the full review](https://thisglp.com/reviews/harper-meds) ## Our verdict Trimi Health's figure assumes a year paid in advance. Harper Meds bills every four weeks and describes the fill as all-inclusive. Neither is a plain calendar month at a plain monthly rate. ## What actually separates them Trimi Health and Harper Meds state different things about published price. Everything else they publish, they publish the same way. Harper Meds publishes a monthly rate and Trimi Health does not, so there is no gap between the two to measure. Over twelve months Harper Meds's rate comes to about $1,932, and there is no figure from Trimi Health to set beside it. |   | Trimi Health | Harper Meds | | --- | --- | --- | | Published price | Not published | $161/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Trimi Health vs Lean Meds: which GLP-1 seller is right for you? | This GLP A disclosed annual commitment against an offer that needs a medication-specific quote. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/trimi-health-vs-leanmeds Updated: 2026-10-14 Head to head # Trimi Health vs Lean Meds A disclosed annual commitment against an offer that needs a medication-specific quote. By [This GLP Editorial Team](https://thisglp.com/about) ## Trimi Health Editorial Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide, and bills both as an annual plan: $1,188 and $1,500, charged up front or split through a buy-now-pay-later provider. The rate is stated as flat across doses. For - Rate stated as flat across doses - Annual cost published as a total - Ships to all fifty states Against - Monthly figure is an annual plan - Full year is charged at the start - Financing spreads payment, not the term **Pick it for:** Readers ready to pay twelve months in advance [Read the full review](https://thisglp.com/reviews/trimi-health) ## Lean Meds Editorial Leanmeds explains its clinician evaluation and coaching pathway, but the current starting offer does not identify separate recurring prices for semaglutide and tirzepatide. A countdown qualifies the headline. Confirm the prescribed product and payment terms before relying on older rates or prepayment ladders. For - Clinical review is described before prescribing - Coaching is advertised within the plan - State-dependent consultation process is explained Against - No verified current price for each molecule - A countdown accompanies the starting offer - Final medication details require confirmation **Pick it for:** Readers prepared to clarify the medication and recurring charge before enrolling [Read the full review](https://thisglp.com/reviews/leanmeds) ## Our verdict Trimi Health labels its semaglutide offer as an annual plan, so the monthly equivalent does not describe the first charge. Leanmeds currently presents a general starting offer with a countdown. That offer does not identify a separate standing price for either injection. Its homepage describes clinical assessment and coaching before pharmacy fulfillment. Leanmeds also says consultation format depends on state requirements. Compare a written Leanmeds prescription and renewal quote with the full Trimi commitment before choosing. ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Trimi Health vs Pallas Health: which GLP-1 seller is right for you? | This GLP A year paid up front against a quarter at a time, at the same rate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/trimi-health-vs-pallas-health Updated: 2026-09-16 Head to head # Trimi Health vs Pallas Health A year paid up front against a quarter at a time, at the same rate. By [This GLP Editorial Team](https://thisglp.com/about) ## Trimi Health Editorial Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide, and bills both as an annual plan: $1,188 and $1,500, charged up front or split through a buy-now-pay-later provider. The rate is stated as flat across doses. For - Rate stated as flat across doses - Annual cost published as a total - Ships to all fifty states Against - Monthly figure is an annual plan - Full year is charged at the start - Financing spreads payment, not the term **Pick it for:** Readers who want the lowest rate and can fund the year [Read the full review](https://thisglp.com/reviews/trimi-health) ## Pallas Health Editorial $216/mo The $199 a month Pallas quotes comes from dividing a $597 twelve-week charge by three, and twelve weeks is 2.76 calendar months, so the figure ranked here is $216; the same correction puts the $897 tirzepatide block at $325. A first month of compounded semaglutide is $139 before either block begins. Provider care and check-ins are described as sitting inside the price, and the rate is stated as holding at every dose. For - Seller publishes its own averaging - Provider care and check-ins included - Rate stated as flat at every dose Against - Card is charged $597 at a time - First month is cheaper than the rest - Twelve weeks is the shortest commitment **Pick it for:** Readers who want commitment in shorter blocks [Read the full review](https://thisglp.com/reviews/pallas-health) ## Our verdict Trimi Health asks for the annual plan in advance; Pallas Health bills every twelve weeks. The question is how much of the year a reader wants to owe on day one. ## What actually separates them Trimi Health and Pallas Health state different things about published price. Everything else they publish, they publish the same way. Pallas Health publishes a monthly rate and Trimi Health does not, so there is no gap between the two to measure. Over twelve months Pallas Health's rate comes to about $2,592, and there is no figure from Trimi Health to set beside it. |   | Trimi Health | Pallas Health | | --- | --- | --- | | Published price | Not published | $216/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Wholesome Clinic vs Enhance MD: which GLP-1 seller is right for you? | This GLP Seven states with the ladder published against thirty-nine on a four-week cycle. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/wholesome-clinic-vs-enhance-md Updated: 2026-09-16 Head to head # Wholesome Clinic vs Enhance MD Seven states with the ladder published against thirty-nine on a four-week cycle. By [This GLP Editorial Team](https://thisglp.com/about) **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). ## Wholesome Clinic Editorial $159/mo Wholesome Clinic publishes a dose ladder rather than a single figure for each product: compounded semaglutide starts at $159 a month in either form and climbs with each dose stage, while compounded tirzepatide runs $349 to $549 by injection and $249 to $349 as an oral. All four are self-pay. The service covers seven states. For - Every dose rung published before you start - Oral tirzepatide below the injection - Self-pay terms stated plainly Against - Seven states only - Price rises with the dose - Tirzepatide reaches $549 at the top rung **Pick it for:** Readers inside its seven states who want the climb visible [Read the full review](https://thisglp.com/reviews/wholesome-clinic) ## Enhance MD Partner $270/mo Enhance MD charges $249 for a one-month plan of compounded semaglutide and $329 for full-dose compounded tirzepatide, each billed every four weeks, which is thirteen charges a calendar year: $270 and $356 a month. The $212 it leads with is the twelve-month rung. Labs, the consultation and two-day shipping are described as included, and the semaglutide rate is stated as flat at all doses. For - Labs and consultation inside the price - Semaglutide rate flat at every dose - Whole plan ladder published on one page Against - Cycle is four weeks, not a month - The lead figure needs a forty-eight-week term - Microdose tier is prepay only **Pick it for:** Readers who need wider coverage and can absorb the extra fill [Read the full review](https://thisglp.com/reviews/enhance-md) ## Our verdict Wholesome Clinic prints every rung but reaches seven states. Enhance MD reaches thirty-nine and bills every four weeks, which is thirteen charges a year. Availability and cadence, not price, decide this one. ## What actually separates them Wholesome Clinic and Enhance MD state different things about published price. Everything else they publish, they publish the same way. Enhance MD costs $111 more than Wholesome Clinic — 70% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,908 at Wholesome Clinic against $3,240 at Enhance MD — a difference of $1,332. |   | Wholesome Clinic | Enhance MD | | --- | --- | --- | | Published price | $159/mo | $270/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Wholesome Clinic vs PlushCare: which GLP-1 seller is right for you? | This GLP Every dose rung published against a price that changes once, after the starting dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/wholesome-clinic-vs-plushcare Updated: 2026-09-18 Head to head # Wholesome Clinic vs PlushCare Every dose rung published against a price that changes once, after the starting dose. By [This GLP Editorial Team](https://thisglp.com/about) ## Wholesome Clinic Editorial $159/mo Wholesome Clinic publishes a dose ladder rather than a single figure for each product: compounded semaglutide starts at $159 a month in either form and climbs with each dose stage, while compounded tirzepatide runs $349 to $549 by injection and $249 to $349 as an oral. All four are self-pay. The service covers seven states. For - Every dose rung published before you start - Oral tirzepatide below the injection - Self-pay terms stated plainly Against - Seven states only - Price rises with the dose - Tirzepatide reaches $549 at the top rung **Pick it for:** Readers in its seven states who want the climb priced [Read the full review](https://thisglp.com/reviews/wholesome-clinic) ## PlushCare Editorial $149/mo PlushCare advertises compounded semaglutide at $149 a month cash-pay, and states that the figure buys the 0.25 mg starting dose only; every dose from 0.5 mg to 2.4 mg costs more. Its compounded tirzepatide page now redirects to a Mounjaro page that quotes no compounded price. Insurance is accepted on a separate basis. For - Says what the entry figure buys - Insurance accepted as a separate route - Prescription follows a clinician visit Against - Maintenance doses cost $299 a month - No compounded tirzepatide price published **Pick it for:** Readers who want a recognized brand and a flat price past the starting dose [Read the full review](https://thisglp.com/reviews/plushcare) ## Our verdict Wholesome Clinic prints every rung on every line. PlushCare prints two steps: $149 at the starting dose and one higher price above it. Both answer what month four costs; they differ in how finely the price steps. ## What actually separates them Wholesome Clinic and PlushCare state different things about published price. Everything else they publish, they publish the same way. Wholesome Clinic costs $10 more than PlushCare — 7% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,788 at PlushCare against $1,908 at Wholesome Clinic — a difference of $120. |   | Wholesome Clinic | PlushCare | | --- | --- | --- | | Published price | $159/mo | $149/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Zera Health vs PlushCare: which GLP-1 seller is right for you? | This GLP A monthly rate behind a first-month offer, against a two-step dose price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/compare/zera-health-vs-plushcare Updated: 2026-09-18 Head to head # Zera Health vs PlushCare A monthly rate behind a first-month offer, against a two-step dose price. By [This GLP Editorial Team](https://thisglp.com/about) ## Zera Health Editorial $169/mo Zera Health charges $179 a month for compounded semaglutide and $255 for compounded tirzepatide, each billed monthly after a discounted first month. A separate microdose semaglutide line, described by the seller as low-dose, is priced below it, and a daily dissolving tablet is listed at $169. All fifty states are served. For - The monthly rate is printed beside the offer - All fifty states served - Narrow step between the two molecules Against - The lead figure is a first month only - Prices above the named vial strengths are not shown - The tablet's standing rate is not stated **Pick it for:** Readers who want the lower rate past the starting dose [Read the full review](https://thisglp.com/reviews/zera-health) ## PlushCare Editorial $149/mo PlushCare advertises compounded semaglutide at $149 a month cash-pay, and states that the figure buys the 0.25 mg starting dose only; every dose from 0.5 mg to 2.4 mg costs more. Its compounded tirzepatide page now redirects to a Mounjaro page that quotes no compounded price. Insurance is accepted on a separate basis. For - Says what the entry figure buys - Insurance accepted as a separate route - Prescription follows a clinician visit Against - Maintenance doses cost $299 a month - No compounded tirzepatide price published **Pick it for:** Readers who want the brand and a clinician visit in the loop [Read the full review](https://thisglp.com/reviews/plushcare) ## Our verdict Zera Health charges $179 a month for semaglutide after a discounted first month. PlushCare's $149 covers the starting dose only, and every dose above it costs more. Past the starting dose, Zera is the cheaper of the two. ## What actually separates them Zera Health and PlushCare state different things about published price. Everything else they publish, they publish the same way. Zera Health costs $20 more than PlushCare — 13% more for the same molecule. Whether that buys anything is what the rest of this page is for. Over twelve months that is about $1,788 at PlushCare against $2,028 at Zera Health — a difference of $240. |   | Zera Health | PlushCare | | --- | --- | --- | | Published price | $169/mo | $149/mo | ## Before you choose either Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against [every published price we hold](https://thisglp.com/best) rather than against each other alone. Our take is computed from a [published rubric](https://thisglp.com/methodology) that does not read commercial status, and [what is known about safety](https://thisglp.com/research) applies to both of them equally. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). [All head-to-head comparisons](https://thisglp.com/compare) · [The buyer’s guides](https://thisglp.com/best) --- # Contact This GLP | This GLP How to reach This GLP — corrections, provider and pricing updates, press, and partnership enquiries, each with a direct route. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/contact Updated: 2026-09-16 Contact # Get in touch A real person reads these. Pick the closest route below so the subject line tells us what it is about — everything lands in the same inbox either way. ## A correction If something on this site is wrong — a price, a dose, a claim about a provider, a citation that does not say what we said it says — tell us and we will check it against the source. Corrections we make are logged publicly. [Report a correction →](mailto:editor@thisglp.com?subject=Correction) ## A price or product change Prices in this category move constantly. If a provider has changed what it charges, what dose it offers, or which states it serves, send the page and we will re-read the seller's own site. [Send a pricing update →](mailto:editor@thisglp.com?subject=Price%20or%20product%20update) ## You are a provider we cover If we have described your service inaccurately, we want to fix it — send what is wrong and where it is stated on your own site. Note that a correction is not a negotiation over a score: scores are computed from a published rubric and do not change because a company asked. [Correct our review →](mailto:editor@thisglp.com?subject=Provider%20correction) ## Partnerships and affiliate programs We work with affiliate programs and disclose every commercial relationship. What we do not do is sell placement, sell a score, or accept sponsored posts — so if that is the enquiry, it saves us both time to say so here. [Partnership enquiries →](mailto:editor@thisglp.com?subject=Partnership%20enquiry) ## Press and research Happy to talk about how the rankings are produced, our methodology, or the state of evidence in this category. [Press enquiries →](mailto:editor@thisglp.com?subject=Press) ## What we cannot help with We are not a medical provider and cannot give advice about your treatment, your dose, or whether something is right for you — that is a conversation for a licensed clinician who knows your history. We also cannot help with an order, a refund or a prescription from a provider we review; those go to the provider directly. See our [medical disclaimer](https://thisglp.com/medical-disclaimer). [Corrections policy](https://thisglp.com/corrections) · [Editorial policy](https://thisglp.com/editorial-policy) · [How we make money](https://thisglp.com/disclosures) · [Who writes this](https://thisglp.com/authors) --- # Corrections Policy | This GLP This GLP's corrections policy: how to report an error, how we evaluate it, and how corrections are logged, dated, and disclosed on the affected page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/corrections Updated: 2026-09-16 Accountability # Corrections Policy Effective September 15, 2026 This site exists to be checked. Every citation here was verified against the source before it published, and every price was read off the seller’s own page rather than a program description — the two disagree more often than you would expect. That discipline lowers the error rate; it does not make it zero. When we get something wrong we would rather hear it and fix it in public than have it sit there being quietly wrong. ## 1\. What goes stale fastest here GLP-1 is sold almost entirely through compounding pharmacies and cash-pay telehealth, a market with no list prices and no announcements. In practice these are the things most likely to be out of date on a page, roughly in order: - **Price.** Monthly rates, intro offers and prepay tiers change without notice and without a changelog. Every price on this site carries the month it was read. - **States served.** Prescribing restrictions move, and a provider that shipped to your state last quarter may not now. - **Dose.** When a seller does publish a milligram figure, it can change underneath an unchanged price — which changes the cost per milligram without changing the number on the page. - **Whether the product is still sold at all.** Programs in this category get discontinued quietly. ## 2\. Telling us Email [editor@thisglp.com](mailto:editor@thisglp.com). What helps most: - The page, and the exact sentence or figure you think is wrong. - What it should say, and where you saw that — a link to the provider’s own page, a PubMed record, a DailyMed or FDA label. - For a price: a screenshot or the date you saw it. Prices here are dated on purpose, and “this is wrong now” and “this was wrong then” are different corrections. ## 3\. What we do with it We check it against the primary source rather than against our own page. If you are right, we fix it and date the change. If we think the original stands, we write back and say why, with the source — you are entitled to the reasoning, not just the verdict. Errors we catch ourselves are handled the same way; nothing is corrected more quietly because we found it first. ## 4\. If a provider asks for a change Providers write to us too, and a correction request from a company about its own product is a lead, not a fact. We verify it the same way we verify anything else — against the live page or the label — and a commercial relationship does not shorten that step. We will happily correct a price a provider says is wrong. We will not soften a verdict because they would prefer a different one. ## 5\. A correction is not an update A **correction** fixes something that was inaccurate when we published it. An **update** reflects something that has since changed — a new price, a new trial, a program that closed. Both move a page’s last-updated date; only the first is an error on our part, and where a correction changes a conclusion we say so on the page rather than editing it away. ## 6\. Related How we research and verify in the first place is in our [editorial policy](https://thisglp.com/editorial-policy) and [methodology](https://thisglp.com/methodology). What can and cannot influence a verdict is in [nature of reviews](https://thisglp.com/nature-of-reviews). Our rules on fabrication are in the [code of conduct](https://thisglp.com/code-of-conduct). --- # Disclosures | This GLP How This GLP earns revenue, our FTC affiliate disclosure under 16 CFR Part 255, and the firewall between commercial partnerships and editorial verdicts. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/disclosures Updated: 2026-10-28 Transparency # Disclosures Effective September 15, 2026 Nobody pays to read This GLP, so somebody else does. This page sets out who, what their money reaches, and what it does not reach. The standard it is written against is the FTC’s endorsement guides at 16 CFR Part 255, together with the agency’s guidance on making a disclosure clear and conspicuous rather than merely present. ## 1\. How we are paid **Commission, on outbound clicks.** Follow a link from here to a seller and sign up, and that seller may pay us. Your bill is unaffected: the figure you are quoted is the figure you would have been quoted arriving from a search result, an advert, or the address bar. The arrangement is a material connection in the FTC’s language, which is why it is stated here, on every page where it applies, and directly above the links rather than in a footer. What appears on a given page is derived from that page’s own links at build time. Where none of them earn, the page says so plainly instead of reciting a precaution it does not need. A notice printed everywhere regardless is a notice nobody reads, and it tells you nothing about the page in front of you. ## 2\. Who pays us Paid links are tracked by **Katalys (Katalys LLC)**, the affiliate network we work through. Some of the sellers reviewed on this site have a live commercial relationship with us; most do not, and several are covered precisely because they do not. We do not print the roster here, because a list on a policy page is the wrong place to learn it. Where a seller pays us, that is stated on the seller’s own review, on every board row it appears in, and on the link itself before you click it — which is where the Federal Trade Commission asks for it and where it is actually of use. Those labels are computed from the same records that decide which links earn, so a label cannot fall behind the wiring without the site itself breaking. ## 3\. What the money buys, and what it does not **Position, and only position.** A paying seller is grouped ahead of non-paying ones on a board and can appear in a promoted module. Wherever that happens the row carries a Partner label, so you can see the arrangement at the point it affects what you are looking at. **Not the assessment.** A score, the reasoning behind a rank, a note about a seller’s own contradictions — none of it moves with payment, and refusing to work with us costs a company nothing in how it is written up. This is enforced rather than promised: the scoring function is never handed a seller’s commercial status, and a test fails the build if the same seller scores differently with it flipped. [Nature of reviews](https://thisglp.com/nature-of-reviews) sets out the mechanism. ## 4\. Where the money stands today **31 of the sellers reviewed here are live partners today**, labeled Partner wherever they appear and sorted first on their board. Every other outbound link on this site remains editorial. A partnership buys placement only — the order beyond the partner block, and the score itself, are still produced by the rubric alone, which cannot read commercial status. Those labels change the same day a partnership does, because every one of them is generated from the wiring rather than typed in. A recommendation we cannot be paid for is the strongest signal of independence we are able to give you, so we would rather point at it than ask you to take the firewall on trust. ## 5\. Who we are, and what we do not cover An independent publisher. Not a medical provider, not a pharmacy, not a telehealth company, and not affiliated with any manufacturer beyond ordinary affiliate agreements. We do not cover every GLP-1 seller in existence — coverage follows what readers are actually choosing between and where there is evidence to choose on. ## 6\. Not medical advice This is research and education, not medical advice, and it creates no doctor–patient relationship. GLP-1 is not right for everyone, and everything sold through telehealth today is **compounded** — not FDA-approved, and not reviewed by the FDA for safety, efficacy or quality before it reaches you. Talk to a licensed clinician before starting, stopping or changing anything. Prices and availability move constantly; check the provider’s own page before you act. Full terms are in our [Terms of Use](https://thisglp.com/terms). ## 7\. Trademarks Provider and product names, logos and marks referenced here are the property of their respective owners and are used only to identify what is being discussed. Their use does not imply endorsement or affiliation. ## 8\. Privacy Following an affiliate link may pass a non-identifying referral code to the destination. It does not send them personal information about you from us, and our analytics do not load until you consent. See our [Privacy Policy](https://thisglp.com/privacy) for how we handle data and your rights under GDPR and CCPA/CPRA. ## 9\. Corrections and contact Found an error, or think something here is out of date? Write to [editor@thisglp.com](mailto:editor@thisglp.com). We fix things in public — see [corrections](https://thisglp.com/corrections). --- # Editorial Policy | This GLP How This GLP sources clinical claims, verifies them against primary literature, handles corrections, and keeps editorial calls independent of advertisers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/editorial-policy Updated: 2026-09-16 How We Work # Editorial Policy Effective September 15, 2026 This GLP covers the GLP-1 drugs sold online — semaglutide and tirzepatide, compounded and brand, by injection and by tablet. This is how we decide what goes on a page. It sits alongside our [methodology](https://thisglp.com/methodology) (the scoring rubric), [nature of reviews](https://thisglp.com/nature-of-reviews) (what can and cannot move a verdict), and our [disclosures](https://thisglp.com/disclosures) (how we are paid). ## 1\. Evidence does not transfer from the brand to the compound This is the rule that does the most work on this site, because the whole category is built on blurring it. The trials behind these drugs — STEP 1, SURMOUNT-1, SELECT — studied the approved products at the approved doses. A compounded preparation contains the same molecule by intent, but it was not in those trials, it is not FDA-approved, and the FDA does not review it for safety, efficacy or quality before it ships. A seller quoting a 15% or 20% weight-loss figure beside a compounded vial is citing a trial its own product was not in. So we say which product a number came from, every time. The same applies to dose: a “microdose” protocol is not the schedule any published trial used, and a result measured at 2.4 mg weekly is not evidence for a fraction of it. Where a claim has no trial behind it at all we say there is none, and we say what we searched to establish that — an absence claim is worth nothing without the census behind it. ## 2\. Primary sources, and no marketing language Every factual claim traces to the trial publication, the FDA or DailyMed label, or the paper of record. Press releases, program descriptions, affiliate one-sheets and AI-generated summaries are not evidence. We report effect sizes, intervals and durations rather than adjectives. We also do not repeat a seller’s claims in our own voice. “Clinically proven”, “scientifically proven” and “the fountain of youth peptide” are phrases we have read on real GLP-1 product pages this year. When we quote one it is in quotation marks and attributed, because it is a fact about the seller, not about the molecule. ## 3\. Citations are verified live, never from memory Before publication every reference is checked against the source of record — PubMed, DailyMed, ClinicalTrials.gov or the journal — to confirm the authors, the year, the journal and the specific figure being cited. A citation that cannot be located and confirmed does not publish, and a plausible-looking reference written from memory is treated as a fabrication rather than a shortcut. ## 4\. Prices are read off the seller’s page, and dated Not from a program description, not from an affiliate feed. Those routinely disagree with the live page, and in a cash-pay compounded market the live page is the only thing a reader can actually buy from. Each price carries the month it was read, because it will change and you should be able to tell how old ours is. Where a seller does not publish a milligram dose — which is most of them — we report that as a finding rather than quietly comparing prices as if it did not matter. A monthly rate is not a value judgment until you know what you get for it. ## 5\. Bylines and what we do not claim Articles and reviews are attributed to This GLP as publisher. This attribution does not claim a clinical credential or an independent medical review. Coverage areas and source standards are described on the [editorial team](https://thisglp.com/authors) page. ## 6\. No clinician on staff, and we will not imply otherwise This GLP does **not** have a licensed clinician as a named medical reviewer. We do not claim individualized clinical review and we do not present any of this as care guidance. Our standard is primary-source verification, disclosed rather than dressed up — which is also why a [medical disclaimer](https://thisglp.com/medical-disclaimer) appears on our health content. Saying so costs us something in perceived authority; claiming a reviewer we do not have would cost you more. ## 7\. AI assistance Where drafting tools including AI are used, the output is a draft and nothing more. Every claim is then verified by a human against the primary literature by the process above. Editorial responsibility for accuracy rests entirely with us, and an AI summary is never a source of fact. ## 8\. Corrections We fix errors in public and date the change. If you find a misread figure, a stale price or a broken source link, see our [corrections policy](https://thisglp.com/corrections) or write to [editor@thisglp.com](mailto:editor@thisglp.com). --- # Medical Disclaimer | This GLP This GLP is not medical advice. Compounded GLP-1 is not FDA-approved. Read this before making any decision based on content here. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/medical-disclaimer Updated: 2026-09-16 Important Notice # Medical Disclaimer Effective September 15, 2026 This GLP covers GLP-1 — a peptide people buy to change their energy, their body composition and their aging, largely on the strength of marketing rather than outcome data. That is consequential territory, so we want to be unambiguous about what this site is and is not. Please read this disclaimer carefully. By using This GLP, you acknowledge and agree to the statements below and to our [Terms of Use](https://thisglp.com/terms). ## 1\. For Education and Research Only All content on This GLP — including articles, reviews, comparisons, tools, charts, glossary entries, and newsletters — is provided for general informational, research, and educational purposes only. It represents our reading of the published evidence at the time of writing. It is **not** medical, clinical, pharmaceutical, nutritional, or other professional advice, and it is **not** a recommendation that you take, avoid, start, stop, or change any medication, supplement, dose, or course of treatment. ## 2\. Not a Substitute for Professional Care Nothing on this Site is a substitute for the individualized judgment of a qualified, licensed healthcare professional who knows your medical history. Always seek the advice of your physician, pharmacist, or other licensed clinician with any questions you have about a medical condition, a medication, or a therapy — and before acting on anything you read here. Never disregard professional medical advice, and never delay seeking it, because of something you read on This GLP. ## 3\. No Doctor–Patient Relationship This GLP is an independent research and review publisher. We are **not** a medical provider, telehealth company, pharmacy, or insurer. We do not diagnose conditions, prescribe or dispense medications, or provide treatment. Reading this Site, contacting us, or using our tools does **not** create a doctor–patient, pharmacist–patient, or any other professional-care relationship between you and This GLP or its writers. ## 4\. Individual Results and Risks Vary GLP-1 can cause side effects and is not appropriate for everyone. This matters more here than the marketing suggests: GLP-1 acetate was withdrawn from the U.S. market as an approved branded drug (GEREF), and **everything sold today is compounded by a licensed pharmacy under a prescription**, which means it is **not FDA-approved** and has not been reviewed by the FDA for safety, efficacy or quality before it reaches you. Regulatory status varies by jurisdiction and changes over time. Efficacy and safety data describe study populations, not individuals — your own response, risks, contraindications, and drug interactions may differ. Any decision you make based on information from this Site is made at your own risk. ## 5\. What the Evidence Does and Does Not Show We state this on the disclaimer page, not only in our articles, because the gap it describes is the one most commonly blurred in this category. **The drugs have a large, recent evidence base; the products most of these sellers dispense were not part of it.** STEP 1 randomized 1,961 adults to once-weekly semaglutide 2.4 mg or placebo and reported a mean weight change of −14.9% against −2.4% (PMID 33567185); SURMOUNT-1 randomized 2,539 adults and reached −20.9% at tirzepatide 15 mg against −3.1% (PMID 35658024). Those trials studied the _approved_ products. What a telehealth seller compounds is not FDA-approved and is not reviewed by the FDA for safety, efficacy or quality before it reaches you, and a “microdose” protocol is not the dose either trial used. The evidence also shows the effect is not durable without the drug: weight was regained after withdrawal in both STEP 4 (PMID 33755728) and SURMOUNT-4 (PMID 38078870). Treat a claim about a compounded product, a non-standard dose, or a result that outruns those trials with caution wherever you meet it — including on pages where we earn a commission. ## 6\. Medical Emergencies **If you think you may have a medical emergency, call your doctor or your local emergency number (such as 911 in the United States) immediately.** Do not rely on this Site, our email, or any online resource for urgent medical needs. This GLP does not provide emergency services and cannot respond to medical crises. ## 7\. Accuracy and Currency We work hard to source every claim to the primary literature and to verify it before publication — see our [methodology](https://thisglp.com/methodology) and [editorial policy](https://thisglp.com/editorial-policy). Even so, the science evolves, labels are updated, and provider details change frequently. Information may become outdated, and despite our care it may contain errors or omissions. We do not warrant that any content is complete, current, or error-free. Verify anything material with a licensed professional and with primary sources before acting on it. If you spot an error, please tell us through our [corrections](https://thisglp.com/corrections) process. ## 8\. Third-Party Content and Links The Site references and links to third-party sources — clinical trials, FDA and DailyMed labels, peer-reviewed papers, news, and provider websites. We do not control that content and are not responsible for its accuracy or for the practices of any third party. A link is not an endorsement of any treatment decision. ## 9\. Limitation of Liability To the fullest extent permitted by law, This GLP and its publisher disclaim all liability for any loss, injury, or damage of any kind arising from, or in connection with, your use of or reliance on the information on this Site. Your use of the Site is governed by our [Terms of Use](https://thisglp.com/terms), including the disclaimers and limitations of liability set out there. ## 10\. Contact Questions about this disclaimer can be sent to [notices@thisglp.com](mailto:notices@thisglp.com). For related transparency policies, see our [Disclosures](https://thisglp.com/disclosures), [Editorial Policy](https://thisglp.com/editorial-policy), and [Trademark](https://thisglp.com/trademarks) pages. --- # Methodology | This GLP Every score on This GLP is computed from a published rubric — evidence, price transparency, real monthly cost, formats, and prescribing process. Scores never move with commission. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/methodology Updated: 2026-10-28 The This GLP standard # Methodology We rank the companies selling GLP-1. Those rankings are worth something only if you can see how they are produced, so here is the whole thing: the scoring weights, the rules we hold ourselves to, and the one place commercial relationships are allowed to show up. ## How a score is calculated Every provider score is a weighted average of 5 marks. There is no field anywhere in this site’s data where a score can be typed in by hand — a rank is an output of the table below, and nothing else. - ### Price transparency 30% Can you find what a month costs — for the molecule and the form you want — before creating an account, and does the seller's own site agree with itself? - ### Honest headline 10% Is the figure the seller leads with the figure it bills? A price that needs a twelve-month prepay, or that is struck through from an anchor nobody pays, is a different number from a standing monthly rate. - ### Dose-ladder pricing 10% Does the price hold as your dose escalates, or is it re-set at every step? This is the difference most buyers only discover in month three. - ### State coverage 25% How much of the country the seller actually ships to. A seller that does not operate where you live is not an option, whatever it charges. - ### Molecule and form breadth 25% Whether the seller carries both molecules, and whether it offers an oral as well as an injection. Breadth is what lets you change course without changing provider. The score broken into twenty units of 5 percent each: price transparency takes six, honest headline takes two, dose-ladder pricing takes two, state coverage takes five, molecule and form breadth takes five, filling all twenty with no unit left for anything commercial. · WHAT MAKES UP A SCORE · Price transparency · 30% · Honest headline · 10% · Dose-ladder pricing · 10% · State coverage · 25% · Molecule and form breadth · 25% · Each unit is 5% of the score. 20 units is the whole of it. **The scoring function does not read commercial status.** It is not weighted low; it is not an input at all. Partners are shown first on category pages and labeled “Partner” — that is display order, and it never touches the number. **31 of the 580 sellers we rank pay us a commission.** The seller our rubric places first, **Rivo Health**, is not one of them — we earn nothing when you click through to it. That is the check we would want to make of a site like this one, so we publish it rather than describe it. Partner status changes where a row sits on a board, and never the number beside it. 1. 01 ## Primary sources, never summaries Every factual claim is tied to the trial publication, the FDA / DailyMed label, or the peer-reviewed paper of record. We do not cite press releases, secondary blogs, or AI-generated summaries as evidence. 2. 02 ## Citations are live-verified Before publication, each reference is checked against the source of record — PubMed, DailyMed, ClinicalTrials.gov — to confirm the authors, year, journal, and the specific figure being cited. Citations are never reconstructed from memory. 3. 03 ## Magnitude over vibes We report effect sizes, hazard ratios, confidence intervals, and durations — not adjectives. Where evidence is preclinical or thin, we say so plainly rather than implying more than the data supports. 4. 04 ## Independence, disclosed This GLP earns revenue through clearly labeled partnerships with vetted telehealth and pharmacy providers. Those relationships are disclosed and never determine a ranking, a verdict, or a safety statement. 5. 05 ## Research, not medical advice Our work is educational. It is not a substitute for an individualized consultation with a licensed clinician, and we say so on every page that discusses a medication or intervention. ## Frequently asked What sources does This GLP cite? Every factual claim is tied to a primary source — the trial publication, the FDA or DailyMed label, or the peer-reviewed paper of record. We do not treat press releases, secondary blogs, or AI-generated summaries as evidence. How are citations verified? Before publication, each reference is checked against the source of record — PubMed, DailyMed, or ClinicalTrials.gov — to confirm the authors, year, journal, and the specific figure being cited. Citations are never reconstructed from memory. Do commercial partnerships affect your verdicts? No. This GLP earns revenue through clearly labeled partnerships, but those relationships never determine a ranking, a verdict, or a safety statement. Placement can be commercial; the substance of the evidence review is not. Is anything on This GLP medical advice? No. Our work is educational research, not a substitute for individualized care from a licensed clinician. We say so on every page that discusses a medication or intervention. --- # Nature of Reviews | This GLP How This GLP assesses providers and products: the editorial criteria we use, why no provider can pay for a favorable verdict, and how monetized partners are labeled and ordered. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/nature-of-reviews Updated: 2026-10-28 How We Assess # Nature of Reviews Effective September 15, 2026 Every page on this site ranks something, and rankings are worth nothing if you cannot see how they were produced. This page describes exactly what goes into a GLP-1 verdict, what is structurally incapable of influencing it, and how to read the partner labels. It sits alongside our [disclosures](https://thisglp.com/disclosures) and [editorial policy](https://thisglp.com/editorial-policy). ## 1\. What we score Five inputs, applied identically to every provider, from the $29 patch to the $2,000 annual prepay: - **Evidence** — what human trials show for that specific format. The only placebo-controlled adult trial behind GLP-1 used a nightly injection; no format inherits that evidence just because it shares the molecule’s name. - **Price transparency** — whether the cost appears before an intake form, and whether a headline rate is a monthly price or a year billed at once. Those are not the same number and we do not let them be compared as if they were. - **Value** — what a month actually costs for the molecule and format you’d choose, since the same seller routinely prices semaglutide and tirzepatide, and injection against tablet, as separate products. - **Ordering experience** — what the intake actually asks, which states are excluded, and whether the path to GLP-1 runs through a weight-loss funnel that was not built for you. - **Clinical support** — whether a licensed clinician is involved beyond approving a form, and whether labs inform the dose. The standard behind those inputs — primary sources, citations verified live, effect sizes rather than adjectives — is in our [methodology](https://thisglp.com/methodology). ## 2\. The score cannot see who pays This is a property of the code, not a promise about our character. The function that produces a provider’s score never reads its commercial status; that field is not among its inputs, and a test asserts it. No score on this site was typed in by hand. That is no longer true of the whole site, and we would rather say so plainly than let an old sentence quietly go stale: **31 sellers we cover pay us today.** They are labeled Partner wherever they appear and sort ahead of non-partners on their board. What has not changed is the score beside them: still computed by a function that cannot read commercial status, on every provider alike. The place to check us is [the disclosure page](https://thisglp.com/disclosures), which lists what we earn from and what we have declined, and [the rubric itself](https://thisglp.com/methodology), which is published rather than described. A verdict that only ever flattered the people paying us would not produce those three pages. ## 3\. How partners appear This GLP is reader-supported. Some providers we review are commercial partners, reached through the **Katalys** network: if you start care through our link we may earn a commission, at no extra cost to you. Two consequences, both worth stating plainly: - **Commercial links are labeled where they appear**, not only in a policy page you would have to go looking for. - **A partnership can affect the order things are listed in. It cannot affect the verdict, the score, or a safety statement.** When a partner is shown first, that is placement. It is not a claim that they are better, and the review immediately below will tell you if they are not. Our affiliate disclosure is computed from the links actually present on the page you are reading, rather than asserted site-wide. A page that earns nothing does not claim to. ## 4\. Providers we earn nothing from We cover products with no commercial relationship to us, and link to them directly. Some of those are among our strongest recommendations. Not being a partner neither helps nor hurts an assessment — but it does mean we had no reason to write about them except that they belong in the comparison, which is worth knowing when you read the verdict. ## 5\. What we do not cover, and how fast it goes stale We do not review every GLP-1 seller in existence. Coverage follows what people are actually deciding between and where evidence exists to decide on. In a compounded market, prices, state availability and regulatory standing move without notice, and every price here was read off the seller’s own page on a stated date — not from a program description, which routinely disagrees with it. Check the current figure before you buy, and treat all of this as research rather than [medical advice](https://thisglp.com/medical-disclaimer). If something here is out of date, [tell us](https://thisglp.com/corrections) — we publish the correction. --- # Privacy Policy | This GLP How This GLP collects, uses, and protects your information, including our opt-out analytics, GDPR, and CCPA/CPRA practices. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/privacy Updated: 2026-09-16 Legal # Privacy Policy Effective September 15, 2026 This GLP is published independently, and [thisglp.com](https://thisglp.com/) (the “Site”) is built to need almost nothing from you. There is no account to create, no profile to fill in, and no reason for us to know who you are in order to show you a price. This policy covers the little we do collect, why, who else sees it, and what you can require us to do about it. Using the Site means accepting what follows; if it does not suit you, the remedy is not to use it. **How this is funded.** Certain outbound links pay us a commission if you follow them and sign up, which costs you nothing extra — a material connection in the sense the FTC’s Endorsement Guides use. A paying seller is grouped ahead of others on a board and labeled where it is; what is written about it does not change either way. The full account, including every seller that pays us by name, is on [Disclosures](https://thisglp.com/disclosures). ## 1\. Information We Collect We collect only the data we need to operate, secure, and improve our research and review service: **Things you send us.** Write in with a correction, a question or a newsletter signup and we hold your email address, whatever name you chose to give, and what you wrote. It is used to reply to you or to send the thing you asked for, and for nothing else. **Things recorded as you read.** The host, and our analytics unless you have declined it, log the ordinary details a web request carries: a shortened and anonymised IP, the city or region it suggests, your browser and operating system, which page sent you and which you left from, what you looked at, how long for, and when. **Cookies and similar technologies.** We use a single essential local setting to remember your cookie choice, and — unless you have opted out — analytics cookies set by Google Analytics 4. See Section 3 for the full breakdown and your choices. **What happens at an outbound link.** Following one hands you to the seller and to the network that tracks the referral, and both may record the click and any signup that follows so the commission can be attributed. Nothing identifying you travels from us in that handoff; what the seller collects once you are on their site is governed by their policy, not this one. **We do not** ask for, collect, or store special-category health information such as diagnoses, prescriptions, lab results, body measurements, genetic data, or insurance member IDs. Reading an article about GLP-1 tells us nothing about your own health. Any interactive tools or calculators on the Site run in your browser, and the values you enter are not transmitted to us or stored on our servers unless we explicitly say so. ## 2\. How We Use Your Information We use the information we collect to: operate, maintain, and secure the Site; send our email newsletter and reply to questions you send us; understand which articles, reviews, and tools are useful to readers so we can improve our research; allow affiliate partners to attribute outbound clicks they receive after you leave the Site; prevent fraud, abuse, and security incidents and enforce our [Terms of Use](https://thisglp.com/terms); and comply with applicable legal obligations. ## 3\. Cookies, Tracking Technologies, and Your Consent Choices **Analytics are on by default, and one click turns them off.** As a US-focused site we operate on an opt-out basis: Google Analytics loads with the page. On your first visit you will see a cookie banner with two choices — _Accept_ (analytics continue as described below) or _Decline_ (we deny analytics and advertising storage through Google Consent Mode and delete the Google Analytics cookies already on your device). Your decision is stored as a single setting in your browser's local storage. You can change your choice at any time by clearing this site's data for thisglp.com in your browser, which will cause the banner to reappear on your next visit. **Analytics cookies (opt-out).** We use Google Analytics 4 (GA4), Measurement ID G-R14JDVC28X, to measure traffic and understand reader behavior in aggregate. GA4 anonymizes IP addresses at the point of collection and does not allow us to identify individual visitors. Because analytics run by default, pages you view before choosing “Decline” are measured. Once you decline, we deny analytics and advertising storage and delete the Google Analytics cookies from your browser, and on every later visit the tag is set to denied before it loads — so no analytics identifier is stored on your device and no advertising-personalization signal is sent. Google still receives a basic, cookieless page-view signal; to stop that as well, use the browser add-on linked below. Data Google does process is governed by [Google's Privacy Policy](https://policies.google.com/privacy). You can also opt out of Google Analytics across all sites using Google's [browser add-on](https://tools.google.com/dlpage/gaoptout). **Affiliate tracking pixels.** When you click an outbound affiliate link and leave our Site, the destination partner (and its affiliate network, such as Katalys) may set its own tracking cookies to attribute the conversion. These are cookies of the destination site, not ours, and are governed by that partner's privacy policy. We do not set affiliate pixels on the This GLP domain itself. **Essential functional storage.** We use your browser's local storage to remember your cookie-consent choice and similar preferences. This is always active, stores no personal data, and never leaves your device. You can disable cookies in your browser settings, but parts of the Site may not work as intended. ## 4\. Third Parties We Share Data With We do not sell your personal information. We share limited data only with the service providers that make the Site run: **Email service provider (Kit / ConvertKit).** When you subscribe to our newsletter, your email address and subscription preferences are stored with Kit so we can send you emails. **Analytics (Google Analytics 4).** Pseudonymous traffic data is processed by GA4(Measurement ID G-R14JDVC28X) to help us understand site usage, unless you opt out via the “Decline” control on our cookie banner. GA4 anonymizes IP addresses by default. Google acts as a processor on our behalf and is bound by its own published terms; see [Google's Privacy Policy](https://policies.google.com/privacy). **Hosting and infrastructure (Vercel).** Our Site is hosted on Vercel, which processes server logs and stores some operational data on our behalf. **Affiliate networks and partners.** When you click an outbound affiliate link, the destination partner and its tracking network will receive referral data (the page you came from, the timestamp, and a non-identifying sub-tracking ID we generate to attribute the click). The network we principally work with is **Katalys (Katalys LLC)**, along with direct partnerships with telehealth and pharmacy providers we cover. Each network operates under its own privacy policy and is responsible for the data it collects after the click hands off. None of these partners receive any information you provided directly to us (for example, the email address you gave to our newsletter). See our [Disclosures](https://thisglp.com/disclosures) for the editorial framework that governs which providers we cover and how commercial relationships factor in. **Legal and safety.** We may share information when legally required (for example, in response to a valid subpoena) or when necessary to protect the rights, property, or safety of our readers or the public. ## 5\. Your Rights and How to Exercise Them Regardless of where you live, you may contact us at [notices@thisglp.com](mailto:notices@thisglp.com?subject=Privacy%20Request) to ask what personal information we hold about you, request that we correct or delete it, unsubscribe from our newsletter, or opt out of analytics. We aim to respond to verifiable requests within 30 days. If we need to verify your identity before acting on a request, we will ask only for the minimum information needed to match your request against records we already hold. Because we hold almost no personal data, most requests are straightforward. To opt out of analytics immediately, select “Decline” on the cookie banner; if you have already made a choice, clear this site's data for thisglp.com and the banner will reappear. Declining denies analytics and advertising storage and deletes the Google Analytics cookies on that visit and every subsequent one. ## 6\. California Residents (CCPA / CPRA) If you are a California resident, the California Consumer Privacy Act and California Privacy Rights Act give you the right to: know what personal information we have collected about you and how we use it; request deletion of your personal information; correct inaccurate personal information we maintain about you; opt out of the “sale” or “sharing” of your personal information; and exercise these rights without being discriminated against for doing so. **We do not sell personal information** as that term is defined under the CCPA/CPRA, and we do not knowingly share personal information of minors under 16 for cross-context behavioral advertising. To exercise any of the above rights, email [notices@thisglp.com](mailto:notices@thisglp.com?subject=California%20Privacy%20Request) with “California Privacy Request” in the subject line. ## 7\. EU / UK Residents (GDPR) **Jurisdictional scope.** This GLP is an independently published United States website. The telehealth providers, compounding pharmacies and GLP-1 products we review are **generally available only to patients located in the United States** and, in most cases, only to patients with a valid US prescription issued by a US-licensed healthcare provider. We do not market the Site to residents of the European Economic Area, the United Kingdom, or Switzerland, and the product information on the Site should not be construed as an offer of telehealth services or prescription medication to EU, UK, or Swiss residents. That said, if you are located in the EEA, the UK, or Switzerland and you do visit the Site, the General Data Protection Regulation (GDPR) and the UK GDPR still give you the rights of access, rectification, erasure (“right to be forgotten”), restriction of processing, data portability, and objection with respect to any data we process about you. You also have the right to withdraw any consent you previously gave (for example, by clearing your cookies and selecting “Decline” on our cookie banner to disable Google Analytics) and the right to lodge a complaint with your local data protection authority (for UK residents, the Information Commissioner's Office). We honor these rights regardless of whether you can actually use the products we review. **Our GDPR Article 6 lawful bases for processing.** We rely on the following lawful bases under GDPR Article 6(1): **Art. 6(1)(a) — Consent.** We rely on your freely-given, specific, informed, and unambiguous consent for subscribing you to our email newsletter. You can withdraw it at any time by clicking the unsubscribe link in any email or by emailing us. Withdrawal does not affect processing that already occurred before the withdrawal. Analytics do not run on this basis — the Site is operated for a US audience on an opt-out footing, described under Art. 6(1)(f) below and in Section 3. **Art. 6(1)(b) — Contract / pre-contractual steps.** When you email us with a question or submit a correction, we process your message to respond to your request. **Art. 6(1)(f) — Legitimate interests.** We rely on our legitimate interests in running a secure, high-quality research site for operating and securing the Site, including server logs and abuse prevention; for aggregate analytics measurement, which runs on the opt-out basis described in Section 3; and for replying to partner-relationship correspondence. We balance these interests against your rights and freedoms. You can object to analytics at any time by selecting “Decline” on the cookie banner, and to processing on this basis generally by contacting us at [notices@thisglp.com](mailto:notices@thisglp.com). **Art. 6(1)(c) — Legal obligation.** We process data where required by applicable law — for example, in response to a valid legal request from a competent authority. We do not process special categories of personal data (health data, biometric data, etc.) under GDPR Article 9. We do not make any decisions about you based solely on automated processing (including profiling) that produce legal or similarly significant effects within the meaning of GDPR Article 22. ## 8\. Children's Privacy The Site is intended for adults and is not directed to children under 18. In line with the Children's Online Privacy Protection Act (COPPA), we do not knowingly collect personal information from children under 13. If you believe a child has provided us with personal information, please contact us and we will delete it promptly. ## 9\. Data Retention We retain personal data only for as long as needed for the purposes described in this policy. Newsletter subscriber data is retained until you unsubscribe and is then purged from active lists. Google Analytics data is retained according to our GA4 configuration (no more than 26 months) and then automatically deleted. Server logs are typically rotated within 30 to 90 days. Correspondence sent to our contact address is retained as long as reasonably necessary to respond and for a reasonable period afterward for reference. ## 10\. Security We use industry-standard technical and organizational safeguards — including HTTPS encryption in transit, access controls, and reputable hosting providers — to protect the information we collect. However, no method of transmission or storage is 100% secure, and we cannot guarantee absolute security. Please use strong passwords and keep your devices up to date. ## 11\. International Data Transfers We are based in the United States, and the service providers we use may process data in the United States and other countries. Where required by law, we rely on appropriate safeguards such as standard contractual clauses for international data transfers. ## 12\. Changes to This Policy We may update this Privacy Policy from time to time. When we do, we will revise the “Effective” date at the top of the page. For material changes, we will take reasonable steps to notify users (for example, by posting a notice on the Site or emailing newsletter subscribers). Your continued use of the Site after the changes become effective constitutes acceptance of the updated policy. ## 13\. Contact For privacy questions, requests, or complaints, please email [notices@thisglp.com](mailto:notices@thisglp.com) or use the contact page. See also our [Terms of Use](https://thisglp.com/terms) and [Disclosures](https://thisglp.com/disclosures). **This GLP** Attn: Privacy [notices@thisglp.com](mailto:notices@thisglp.com) --- # Research | This GLP Evidence reviews of the GLP-1 drugs sold online — semaglutide, tirzepatide and what is coming next. Every claim traced to the trial that produced it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research Updated: 2026-09-16 Research # Research Evidence reviews of the drugs sold online — semaglutide, tirzepatide, and what the trials behind them actually measured. No secondary summaries: every claim traced to the trial, the label, or the paper of record. [ Interactive tool ## Head-to-head comparisons Two sellers side by side on price, dose disclosure, format and states served — scored on the same rubric. ](https://thisglp.com/compare)[ Interactive tool ## Expected Weight Loss Enter a starting weight and see the published distribution from STEP 1 and SURMOUNT-1 applied to it — not the arm mean every landing page quotes, but how many participants reached each threshold and how many did not. ](https://thisglp.com/tools/glp1-expected-weight-loss) Search research 222 articles - [Safety ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks Ozempic does not list a specific ibuprofen prohibition. Dehydration, kidney disease, and your other medicines can change the answer. 5 min read](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [Safety ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call Diarrhea affected about 9 in 100 adults in Ozempic trials. Learn what those figures mean, what to track, and which symptoms need prompt attention. 5 min read](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [Safety ### Does Ozempic Cause Dizziness? What to Check First Dizziness is listed in Ozempic prescribing information. Low glucose, fluid loss, and other causes need different responses. 5 min read](https://thisglp.com/research/does-ozempic-cause-dizziness) - [Safety ### Does Wegovy Increase Heart Rate? Understanding the Numbers Wegovy injection trials found a small average rise in resting pulse. Larger changes and symptoms still need individual assessment. 5 min read](https://thisglp.com/research/does-wegovy-increase-heart-rate) - [Evidence ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms Activity remains useful during semaglutide treatment. The evidence supports a sustainable routine, while injection-day workout rules remain unproven. 5 min read](https://thisglp.com/research/exercise-on-ozempic) - [Safety ### GLP-1 and Eating Disorders: What the Evidence Does and Does Not Show A smaller appetite is not the same as recovery. Learn why eating-disorder history, symptoms, and coordinated care matter before and during treatment. 5 min read](https://thisglp.com/research/glp1-and-eating-disorders) - [Safety ### GLP-1 Dehydration Symptoms: What to Watch For Fluid loss from vomiting or diarrhea can become more than a nuisance. Recognize warning signs and prepare a plan that fits your health history. 5 min read](https://thisglp.com/research/glp1-dehydration-symptoms) - [Safety ### Can You Smoke Weed on Ozempic? What Cannabis-User Cohorts Found No trial has tested cannabis with Ozempic, and the label does not mention it. Two large cohorts linked GLP-1 drugs to fewer cannabis use disorder diagnoses, which is not the same as measuring use. 6 min read](https://thisglp.com/research/can-you-smoke-weed-on-ozempic) - [Safety ### Can You Take Metformin and Ozempic Together? Most Trials Required It SUSTAIN 7, SUSTAIN 8 and SUSTAIN China enrolled only people already on metformin, and an interaction study found semaglutide left metformin levels unchanged. The stomach is where the two drugs overlap. 7 min read](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together) - [Safety ### Can You Take Ozempic With Levothyroxine? The Tablet Form Is the One Studied Thyroxine exposure rose 33% when levothyroxine was taken with oral semaglutide. The Ozempic injection label reports no clinically relevant effect on oral drugs, and weight loss is the other route to watch. 6 min read](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine) - [Safety ### Can You Take Phentermine With Ozempic? No Trial Has Tested It, One Tried Liraglutide No trial has combined phentermine with semaglutide, and the phentermine label advises against pairing it with any weight-loss drug. Added to liraglutide for 12 weeks, it took off 1.6% against 0.1% on placebo, not a significant gap. 6 min read](https://thisglp.com/research/can-you-take-phentermine-with-ozempic) - [Safety ### Does Ozempic Cause Constipation? What the Trials Counted, and When It Eases Yes: 5.0% on Ozempic 0.5 mg against 1.5% on placebo, and 24.2% on the 2.4 mg weight-loss dose against 11.1%. Nearly all of it was mild to moderate and clustered in the dose-escalation weeks. 7 min read](https://thisglp.com/research/does-ozempic-cause-constipation) - [Evidence ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show A little. On semaglutide 2.4 mg, LDL fell 2.5% from 110.3 mg/dL against a 1.3% rise on placebo, while triglycerides fell 21.9%. In type 2 diabetes the LDL effect was 0.16 mmol/L. 7 min read](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [Safety ### Does Tirzepatide Cause Skin Sensitivity? The Allodynia Reports, Counted Zepbound's trials recorded dysesthesia in 0.2% to 0.4% of people against 0.1% on placebo. Beyond that line, the tirzepatide evidence is one case report and reporting-database signals. 7 min read](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity) - [Safety ### Should You Stop Ozempic Before a Colonoscopy? What Bowel-Prep Studies Found No study has tested whether stopping improves the prep. In one matched cohort, inadequate prep was recorded for 125 of 503 GLP-1 users against 56 of 503 non-users, and three meta-analyses disagree on the size of the effect. 7 min read](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy) - [Formats ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure The label allows the abdomen, thigh or upper arm, and a model of 1,612 trial patients found no clinically relevant effect of injection site on semaglutide exposure. Body weight was the only factor that mattered. 6 min read](https://thisglp.com/research/where-should-you-inject-ozempic) - [Safety ### Why Does Ozempic Cause Sulfur Burps? What the Adverse-Event Data Show Burping reached 2.7% on Ozempic 0.5 mg and 7% on Wegovy 2.4 mg in the label trials, against 1% or less on placebo. It is semaglutide's strongest stomach signal in FDA reports. The sulfur smell itself has never been measured. 7 min read](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps) - [Safety ### Can Tirzepatide Cause Anxiety or Depression? Trials Say No, Records Are Mixed Across 4,056 adults in three SURMOUNT trials, depression scores fell slightly more on tirzepatide than placebo. Anxiety was never scored there, and the record studies split by comparator. 8 min read](https://thisglp.com/research/can-tirzepatide-cause-anxiety) - [Safety ### Can You Take Ozempic While Breastfeeding? 8 Mothers, No Drug Detected in Milk In the one milk study of injected semaglutide, none of eight mothers had detectable drug in milk. The Ozempic injection label still says there are no data, and the tablet labels advise against breastfeeding. 7 min read](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding) - [Safety ### Does Zepbound Cause Headaches? Headache Never Made Its Side-Effect Table Across 2,519 adults in the trials behind the label, headache did not reach the table of reactions at 2% or more above placebo. Dizziness did, and the reporting databases tell a louder story than the trials. 7 min read](https://thisglp.com/research/does-zepbound-cause-headaches) - [Safety ### How Long Does Zepbound Stay in Your System? About a Month Tirzepatide's half-life is 5 to 6 days, so five half-lives come to 25 to 30 days. The label's missed-dose, contraception and pregnancy rules all follow from that clock. 7 min read](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system) - [Safety ### How Do You Avoid Ozempic Face? No Tested Way to Prevent It The one direct measurement found midface volume down a median 9.0% in 20 people on a GLP-1, about 7% per 10 kg lost. Slower loss, protein and exercise have never been tested against the face. 7 min read](https://thisglp.com/research/how-to-avoid-ozempic-face) - [Evidence ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found Total daily insulin fell 22.6% and time in range rose 4.8 points without more hypoglycemia. It is off-label, both trials were small, and two people developed ketosis at normal glucose. 7 min read](https://thisglp.com/research/semaglutide-in-type-1-diabetes) - [Safety ### Do GLP-1 Drugs Cause Depression or Anxiety? The Trials Say No, the Records Say Yes Randomized trials found depression scores slightly better on semaglutide than placebo. Health records report the opposite, and the comparison group explains most of the gap. 7 min read](https://thisglp.com/research/do-glp1-drugs-cause-depression) - [Safety ### GLP-1 Drugs in Pregnancy: What the Evidence Shows, and What It Cannot Across 40,000 exposed pregnancies, malformations were not significantly raised. Both sets of authors call their estimates imprecise, and no GLP-1 drug is approved in pregnancy. 7 min read](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows) - [Evidence ### Tirzepatide vs Semaglutide: Which Works Better for Weight Loss? In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. 8 min read](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) - [Evidence ### Can a Pill Keep Weight Off After the Injection? ATTAIN-MAINTAIN, Read Carefully A daily tablet held about three quarters of the weight people had already lost. Placebo held about half, and no arm stayed on the injection. 6 min read](https://thisglp.com/research/can-a-pill-keep-weight-off-after-the-injection) - [Evidence ### Do GLP-1 Drugs Work After Bariatric Surgery? Two Randomized Trials Say Yes Semaglutide took off 18.0% where placebo gained 0.4%; liraglutide took off 8.8% where placebo gained 1.1%. Both trials are small, and both untreated groups were still gaining. 8 min read](https://thisglp.com/research/glp1-after-bariatric-surgery-evidence) - [Evidence ### Is CagriSema Better Than Semaglutide Alone? By 6.5 Points, Head to Head The trial built to answer it gave both arms 2.4 mg and found 18.4% against 11.9%. Against placebo the combination looks twice as impressive, which is the point. 7 min read](https://thisglp.com/research/is-cagrisema-better-than-semaglutide) - [Evidence ### Do GLP-1 Drugs Prevent Stroke? The Composite Moves, Stroke Alone Is Thin The headline cardiovascular results are composites that pool stroke with heart attack and cardiovascular death. Measured on its own, stroke has one small trial its own authors discount. 7 min read](https://thisglp.com/research/do-glp1-drugs-prevent-stroke) - [Evidence ### Tirzepatide Against Real Clinical Practice: What SURPASS-EARLY Found A rare trial whose control arm was care as doctors actually deliver it, other GLP-1 drugs included. The margin is 0.68 HbA1c points — smaller than a placebo trial, and far more useful. 7 min read](https://thisglp.com/research/tirzepatide-vs-real-clinical-practice) - [Evidence ### Retatrutide in Type 2 Diabetes: Why TRANSCEND-T2D-1 Reads Lower Than Phase 2 Weight fell 15.3% at the top dose here, against 24.2% in the phase 2 obesity trial. Different populations over different durations — not a weaker drug. 7 min read](https://thisglp.com/research/retatrutide-transcend-t2d-1) - [Evidence ### Survodutide: What SYNCHRONIZE-1 Found, and Why It Reads Weaker Than Phase 2 Weight fell 13.0% at the top dose over 76 weeks, against 14.9% in the earlier phase 2 trial. The drug did not get worse — the two trials measured different things. 7 min read](https://thisglp.com/research/survodutide-synchronize-1) - [Safety ### Ozempic Teeth: What Has Actually Been Measured, and What Has Not Dry mouth, altered taste, reflux and more cavities are all reported. No study reports a rate, and the route to damaged teeth runs through dryness and acid rather than the drug itself. 7 min read](https://thisglp.com/research/ozempic-teeth) - [Evidence ### Do GLP-1 Drugs Help Alzheimer's? The Trials and the Records Disagree Randomized trials have found no cognitive benefit. Health-record studies report Alzheimer's diagnoses at half the rate. The same records also halve all-cause mortality, which is the clue. 7 min read](https://thisglp.com/research/do-glp1-drugs-help-alzheimers) - [Evidence ### What Happens When You Stop Tirzepatide? SURMOUNT-4 Says 14% Comes Back The trial randomized 670 people to keep taking it or stop. Over the following year the ones who stopped regained 14.0%, and how much each person regained decided how much of the benefit they kept. 8 min read](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide) - [Safety ### Does Ozempic Cause Hair Loss? What 1,091,743 Records Show Pooled across 1,091,743 exposures, the odds are raised about 40%. The kind of hair loss that goes up points at the weight you lost, not the drug. 7 min read](https://thisglp.com/research/does-ozempic-cause-hair-loss) - [Formats ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes Four weeks at 0.25 mg, then a step every four weeks to 1.7 or 2.4 mg. What changes with a compounded vial is not the milligrams — it is who measures them. 7 min read](https://thisglp.com/research/semaglutide-starting-dose) - [Evidence ### VK2735 Phase 2 VENTURE Trial: 14.7% Weight Loss in 13 Weeks The GIP and GLP-1 dual agonist VK2735 took off up to 14.7% of body weight in a 13-week phase 2 trial. The approved drugs report figures from trials of 68 weeks or longer. 5 min read](https://thisglp.com/research/ninety-three-percent-in-thirteen-weeks) - [Evidence ### Do GLP-1 Drugs Prevent Heart Attacks and Strokes? One, Not Both A 52,971-person cohort with a neutral active comparator and two negative control outcomes. Heart attacks fell; strokes did not. 6 min read](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes) - [Evidence ### Weight-Loss Drugs in Hypertension: What the Cochrane Review Lacked Eight trials, 13,000 people with high blood pressure. The semaglutide and tirzepatide trials reported none of the outcomes the review was built to assess. 6 min read](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths) - [Safety ### GLP-1 Use and Bowel Function After Lumbar Fusion: 117 Patients Bowel function returned half a day sooner after spinal fusion in GLP-1 users, in 117 patients at one hospital. The direction contradicts the drug's best-known mechanism. 6 min read](https://thisglp.com/research/the-bowels-woke-up-sooner) - [Evidence ### Does Semaglutide Help Liver Cirrhosis? Not in the Trial That Tested It In 71 people with MASH cirrhosis, fibrosis improved in 11% on semaglutide and 29% on placebo. A larger 2026 trial mixed in earlier stages, and two cohorts disagree on what happens after cirrhosis. 7 min read](https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis) - [Evidence ### Do GLP-1 Drugs Improve Your Quality of Life? 2.12 Points on the SF-36 Cochrane graded the quality-of-life evidence moderate certainty and measured a 2.12-point gain in physical functioning, on a scale running to a hundred. The one place the effect is large is heart failure, and there it belongs almost entirely to the frailest participants. 9 min read](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life) - [Evidence ### Do GLP-1 Drugs Cause Blood Clots? No Untreated Group Was Ever Followed Every published comparison ranks one of these drugs against another, never against taking nothing. The effect is small, the method is unusually careful, and the lung clots moved while the leg clots did not. 8 min read](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots) - [Evidence ### Can You Take a GLP-1 With Epilepsy? Seizure Risk Did Not Rise A 452,766-person study found a clean, consistent association. Expressed as people rather than ratios, it is one case avoided per sixteen hundred treated. 8 min read](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy) - [Evidence ### GLP-1 Drugs and ERCP Complications: A TriNetX Cohort of 21,818 Pancreatitis, bleeding, sepsis, stricture, cholangitis, repeat procedures: every outcome after ERCP improved by about the same amount with GLP-1 exposure. No drug does that. 6 min read](https://thisglp.com/research/when-a-drug-improves-everything) - [Evidence ### How Many Heart Attacks Could Semaglutide Prevent in the US? Models put it between half a million and 2 million cardiovascular events over a decade, depending on who is counted. Nobody in them took a drug, and each assumes everyone eligible is treated. 8 min read](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent) - [Evidence ### Do GLP-1 Drugs Work the Same in Asian Patients? The Percentages Match Percentage weight loss came out at 18.16% against 17.92% across Asian and non-Asian trial populations, and the same comparison in kilograms ran 16.72 against 23.46. Only 148 Asian participants received the drug, which is why the authors refuse to call that first result equivalence. 9 min read](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients) - [Safety ### Is Semaglutide Safe for People With HIV? Four Studies So Far A 108-person trial and two routine-care cohorts found no new safety problem. Visceral fat fell 30.6%, weight fell 6.47 kg, and depression scores did not worsen. 7 min read](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv) - [Evidence ### GLP-1 Use and Knee Replacement: Absolute Risk at Eight Years A matched database study of people with knee osteoarthritis found 2.80 to 4.71 fewer knee replacements per hundred at eight years, with larger effects for longer use and newer drugs. 6 min read](https://thisglp.com/research/fewer-knee-replacements-eight-years-on) - [Evidence ### Parkinson's Incidence and Motor Symptoms on GLP-1 Drugs: An 82-Study Review In one review of 82 studies, GLP-1 use was linked to lower odds of developing Parkinson's in observational data, while randomized trials found no motor improvement in people who already had it. 7 min read](https://thisglp.com/research/preventing-it-is-not-treating-it) - [Evidence ### Do GLP-1 Drugs Help IBS? Coded Symptoms Fell by Two to Four Points Diarrhea, constipation, pain and bloating were all coded less often in treated IBS patients. Coded is doing a lot of work in that sentence. 8 min read](https://thisglp.com/research/do-glp1-drugs-help-ibs) - [Evidence ### Does Orforglipron Work for Type 2 Diabetes? Three Phase 3 Trials Yes, on blood sugar. HbA1c fell 1.23 to 1.91 points and the tablet beat placebo, dapagliflozin and oral semaglutide. More people stopped it than stopped either active comparator. 8 min read](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes) - [Evidence ### Do GLP-1 Drugs Help Bipolar Disorder? One Drug Moved, Two Did Not Comparing people against their own untreated periods, psychiatric admissions fell 21% on semaglutide. Liraglutide and dulaglutide showed nothing. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder) - [Safety ### Can a GLP-1 Cause Ketoacidosis? 470 Reports, Most of Them Hospitalized Two drugs, 470 reported cases, and hospitalization in roughly three quarters of them. The database cannot say how often it happens. 9 min read](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis) - [Safety ### Respiratory Side Effects of Weight-Loss Drugs: A Review of 123 Studies A meta-analysis of 123 studies found no excess respiratory adverse events on weight-loss drugs. One of those studies was conducted in people with asthma. 6 min read](https://thisglp.com/research/one-asthma-study-in-a-hundred-and-twenty-three) - [Evidence ### FLOW Trial Cardiovascular Subgroups: Semaglutide's Numbers Needed to Treat The FLOW subgroup analysis publishes numbers needed to treat of 22, 13 and 17, a hazard ratio translated into people. Every interaction test came back null. 6 min read](https://thisglp.com/research/twenty-two-thirteen-seventeen) - [Evidence ### Tirzepatide and Serum Uric Acid: A SURMOUNT-1 Post Hoc Analysis Serum urate dropped nearly a milligram per deciliter across 72 weeks on tirzepatide, about three quarters of it explained by weight loss. Gout flares were not an outcome. 6 min read](https://thisglp.com/research/uric-acid-fell-and-most-of-it-was-weight) - [Evidence ### Tirzepatide Sleep Apnea Results by Age, BMI and Severity Post hoc SURMOUNT-OSA analyses found apnea events fell in every subgroup. Age, sex, BMI and neck size made little difference; starting severity made a fourfold one, for arithmetic reasons worth understanding. 6 min read](https://thisglp.com/research/apnea-improved-across-every-subgroup) - [Evidence ### Tirzepatide in HFpEF by Sex: SUMMIT Trial Results in Women and Men Every treatment-effect comparison by sex in SUMMIT came back null. The one significant interaction was about how the benefit arrives, not who receives it. 7 min read](https://thisglp.com/research/same-benefit-different-route-by-sex) - [Formats ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers Yes, in two forms. Orforglipron cut weight 11.2% and won FDA approval in April 2026. Oral semaglutide cut weight 13.6%, but absorbs at under 1% and is not yet approved for it. 11 min read](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) - [Evidence ### Can You Take a GLP-1 With a Heart Pump? 141 Pairs, and No Effect Sizes Fewer driveline infections, lower mortality and more transplants, all of it reported as a direction with no magnitude attached, and all of it in people whose GLP-1 prescription predates the operation. 7 min read](https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump) - [Evidence ### Mortality in Serious Mental Illness: GLP-1 vs SGLT2 Inhibitors In people with schizophrenia, bipolar disorder or major depression, four-year mortality was 4.91% on a GLP-1 drug against 6.45% on an SGLT2 inhibitor. The one-year figure in the same paper is not believable. 7 min read](https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness) - [Evidence ### Semaglutide Dose Escalation and Insulin Reduction in Type 2 Diabetes In a 62-patient chart review, total daily insulin fell by 36.9% as semaglutide was escalated to 2 mg, and HbA1c improved rather than slipped. The published confidence intervals do not parse. 6 min read](https://thisglp.com/research/each-dose-step-took-insulin-away) - [Evidence ### Do GLP-1 Drugs Help Intracranial Hypertension? Probably, but Less Than Reported Two meta-analyses agree on direction: less papilledema, at risk ratios of 0.38 and 0.25. One also reports 80% fewer deaths in a condition that rarely kills anybody, which says its effect sizes are inflated. 8 min read](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension) - [Evidence ### Can a Drug Prevent Muscle Loss on a GLP-1? Two Antibodies Tested Not outside a trial. Apitegromab kept 1.9 kg more lean mass on tirzepatide without slowing weight loss, and bimagrumab added lean mass on its own. Neither is approved, and nobody measured strength. 7 min read](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1) - [Evidence ### What Is Ecnoglutide? A Phase 3 Result You Cannot Compare to the Others A GLP-1 drug engineered to favor one signaling pathway reached phase 3 and took off 13.2% at week 40. Its entry criteria mean the percentage is not comparable to the ones you have seen. 7 min read](https://thisglp.com/research/what-is-ecnoglutide) - [Evidence ### GLP-1 Drugs at the Start of Hemodialysis: Hospitalization and Death A matched cohort of 2,492 pairs starting in-center hemodialysis linked GLP-1 use to 9% lower hospitalization and 17% lower mortality. The prior literature was 388 patients, and a baseline gap is worth reading first. 6 min read](https://thisglp.com/research/dialysis-the-evidence-base-just-grew) - [Safety ### Are GLP-1 Drugs Safe for Older Adults? Seven Trials, and Who They Left Out Pooled across seven tirzepatide trials, adults 65 and over showed no clinically meaningful difference from placebo on falls, fractures or tolerability. Everyone in them had qualified for a phase 3 trial. 10 min read](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults) - [Evidence ### Atrial Fibrillation Risk: GLP-1 vs SGLT-2 vs DPP-4 Inhibitors Across 2,171,267 patients, GLP-1 drugs showed no detectable advantage over DPP-4 inhibitors on atrial fibrillation. SGLT-2 inhibitors beat both, and nothing helped recurrence. 6 min read](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won) - [Evidence ### Tirzepatide vs Semaglutide for Heart Failure, With and Without Diabetes In 217,920 matched adults, tirzepatide's heart failure risk ratio favored people without diabetes while the absolute risk difference favored people with it. Both come from the same table. 7 min read](https://thisglp.com/research/bigger-relative-smaller-absolute) - [Evidence ### How Much Less Do You Eat on a GLP-1? About 271 Calories at One Meal Pooled across three trials and 209 participants, energy intake at an observed lunch fell by 1,132 kJ against placebo. Nobody has measured a whole day properly. 9 min read](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1) - [Evidence ### Semaglutide and Effort in Major Depression: A 72-Person Randomized Trial In adults with major depression, semaglutide made people more willing to work for larger rewards. The outcome was a laboratory effort task, not a depression score. 6 min read](https://thisglp.com/research/motivation-in-depression-a-secondary-finding) - [Evidence ### Can You Take a GLP-1 With Sickle Cell Disease? One Cohort, 1,391 Pairs Vaso-occlusive crises ran 36% lower among GLP-1 users in the only matched cohort that exists, but kidney progression, which matters as much in this disease, was measured far too imprecisely to call either way. 8 min read](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease) - [Safety ### Can a GLP-1 Cause Thiamine Deficiency? Six Cases Say It Can Every published case began the same way. Prolonged vomiting first. Then rapid weight loss. Then neurological signs. The first two stages are the ones a reader can act on. 7 min read](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency) - [Safety ### Do GLP-1 Drugs Raise the Risk of Aspiration Pneumonia? Not at planned endoscopy, where 210,216 pooled patients showed no significant difference. After emergency stroke treatment, the rate was 26.8% against 10.3%, and the authors say treat anyway. 7 min read](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia) - [Evidence ### Survodutide in MASH: How Much of the Liver Benefit Was Weight Loss A mediation analysis of a phase 2 survodutide trial split its liver effects in two. Roughly three quarters of the fat reduction tracked weight loss; only a third of the fibrosis improvement did. 7 min read](https://thisglp.com/research/liver-repair-that-was-not-the-weight) - [Evidence ### Obesity Drugs Ranked Across 262 Trials: Weight Lost vs Side-Effect Dropout A network meta-analysis of 262 trials and 99,791 participants produces two rankings, biggest weight loss and highest rate of stopping for side effects. Four drugs appear on both. 7 min read](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated) - [Evidence ### Do GLP-1 Drugs Help Psoriasis? Clear Skin in 40.6% Against 29.0% Added to a biologic in 274 randomized adults, tirzepatide raised complete skin clearance from 29.0% to 40.6%. The trial's headline number is twice that, and half of it was settled at randomization. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-psoriasis) - [Safety ### Do GLP-1 Drugs Cause Acid Reflux? Three Databases Say More Reports Reporting ratios of 2.83, 2.91 and 4.76 across three countries. Exenatide, in the same class, ran inverse at 0.60. 8 min read](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux) - [Evidence ### Do GLP-1 Drugs Help Rheumatoid Arthritis? The Heart Result, Not the Joints Semaglutide was linked to fewer cardiovascular events in people with rheumatoid arthritis. Heart failure accounted for it; death, heart attack and stroke did not budge. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis) - [Safety ### Do GLP-1 Drugs Cause Glaucoma? Nobody Untreated Was Ever Compared A 51,540-person comparison found less open-angle glaucoma on tirzepatide than on other GLP-1 drugs. Both arms were treated. Neither figure says what either drug does against taking nothing. 7 min read](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma) - [Evidence ### GLP-1 Drugs and Overdose Risk: Five Comparators in VA Data The same GLP-1 drugs, the same veterans' database, the same twelve months, and five comparison groups that do not agree. One estimate points the other way. 6 min read](https://thisglp.com/research/overdose-depends-on-the-comparator) - [Evidence ### Alcohol Admissions After Stopping a GLP-1: Swedish Within-Person Data Comparing people against themselves, alcohol-related hospital admissions fell on a GLP-1 and stayed lower for 182 days after stopping. By a year, the difference was gone. 7 min read](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it) - [Evidence ### Frailty and Semaglutide's Cardiovascular Benefit in the SELECT Trial Split 17,604 trial participants three ways by a frailty index and the cardiovascular benefit holds across all three. The frailty scores themselves moved too. 7 min read](https://thisglp.com/research/frailty-did-not-change-the-answer) - [Evidence ### Do GLP-1 Drugs Reduce Inflammation? hsCRP Fell 37.8% in SELECT Semaglutide cut an inflammation marker by 37.8% over 104 weeks, and the fall began before major weight loss and appeared in people who lost none. A marker is still not a mechanism. 9 min read](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation) - [Evidence ### Do GLP-1 Drugs Help Carpal Tunnel Syndrome? Fewer Diagnoses, Same Surgeries Tirzepatide came with fewer carpal tunnel diagnoses than other GLP-1 drugs. The operation rate did not follow. That gap is the more telling half of the result. 7 min read](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome) - [Evidence ### Do GLP-1 Drugs Help Crohn's Disease? Hospitalization Halved, Steroids Unchanged In 9,766 matched pairs, hospitalization at one year was 10.0% against 24.7%. The same study reports a six-fold mortality difference its authors say is probably not real. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease) - [Evidence ### BMI Above 30 and Type 2 Diabetes Drug Response: Weight vs HbA1c In 1,016 adults with type 2 diabetes, those starting above BMI 30 were likelier to reach 5% weight loss (27.2% vs 15.5% at six months), while HbA1c improvement was comparable. 5 min read](https://thisglp.com/research/does-starting-weight-change-the-answer) - [Evidence ### How Many People Use Compounded GLP-1 Drugs? Records Catch 8.2% Primary care records documented compounded use in 8.2% of 153,044 patients, against about 23% in surveys. A compounded prescription leaves no structured record, so the true share cannot be counted. 6 min read](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs) - [Evidence ### Do GLP-1 Drugs Affect Breast Surgery? Implants Fared Worse, Flaps Did Not Implant failure had 1.70 times the odds in GLP-1 users, and breast reduction complications doubled from 1.3% to 2.6%. Free-flap reconstruction and cancer surgery did not show the same. 7 min read](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery) - [Evidence ### Asthma Exacerbations on GLP-1 Drugs vs Other Weight Medications In 2,423 matched pairs of adults with obesity and asthma, exacerbations ran 1.7% on GLP-1 therapy against 4.0% on other weight drugs: a ratio of 0.438, or a 2.2-point difference. 6 min read](https://thisglp.com/research/glp1-asthma-relative-and-absolute) - [Evidence ### Do GLP-1 Drugs Prevent Contrast Kidney Injury? 8.7% Against 25.7% One retrospective cohort found a third the rate of kidney injury after coronary angiography. The outcome is defined by a creatinine rise, and creatinine itself came out at p = 0.084. 8 min read](https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury) - [Evidence ### What Weight Loss Drugs Are There Besides Ozempic? Six Have Evidence Six obesity drugs have randomized evidence behind them and storefronts sell two. Across 56 trials and 60,307 patients, all six beat placebo, and only semaglutide and tirzepatide passed 10%. The cheapest respectable option reaches about eight. 9 min read](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic) - [Evidence ### Do GLP-1 Drugs Help Resistant Hypertension? The Pressure Matched Two fourth-line drugs lowered blood pressure by the same amount. One group then had a two-thirds lower risk of dying, which is a fact about who gets which drug rather than about the drug. No randomized trial has reported an outcome in this population. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension) - [Formats ### Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3 The liver indication is narrower than the phrase suggests. It covers fibrosis stages F2 to F3 without cirrhosis, and entry to it requires a test nobody can take at a checkout. 8 min read](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease) - [Safety ### Do GLP-1 Drugs Cause Arrhythmia? Three Intervals, Two Cross One Pooled across ten tirzepatide trials, the odds ratios for arrhythmia all sat above 1. Only the broadest category cleared significance, and barely. Ten meta-analyses of the same drug class point the other way, and none of them reached moderate confidence. 8 min read](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia) - [Safety ### Do GLP-1 Drugs Make You Tired? Daytime Sleepiness Improved by 0.20 Points No randomized trial of this drug class reported fatigue as an endpoint, and the nearest measured proxy moved a tenth of the distance a person can feel. The mechanisms that would explain feeling tired were measured, but never as tiredness. 9 min read](https://thisglp.com/research/do-glp1-drugs-make-you-tired) - [Evidence ### Do GLP-1 Drugs Help Antipsychotic Weight Gain? 9.8% Off, Half Back In 26 people with schizophrenia on clozapine or olanzapine, semaglutide took off about 10.1 kg over 24 weeks. A year after it stopped, roughly half had returned. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain) - [Evidence ### Depression Risk on GLP-1 Drugs vs DPP-4 and SGLT2 Inhibitors In Medicare adults aged 66 and over with type 2 diabetes, the depression hazard ratio was 0.90 against DPP-4 inhibitors and 1.07 against SGLT2 inhibitors. Which one gets quoted depends on the comparator. 5 min read](https://thisglp.com/research/glp1-depression-depends-on-comparator) - [Evidence ### Do GLP-1 Drugs Help COPD? Fewer Flare-Ups, Against One Comparator Against an older drug class, GLP-1 use came with fewer exacerbations. Against SGLT2 inhibitors the hazard ratio was 0.94, with an interval reaching 1.00. 8 min read](https://thisglp.com/research/do-glp1-drugs-help-copd) - [Evidence ### Bone Mineral Density on GLP-1 Drugs in Type 2 Diabetes: 25 Trials Twenty-five trials found higher bone density at every site measured. The fracture interval runs from 0.47 to 1.36 — consistent with a halving and with a rise. 6 min read](https://thisglp.com/research/glp1-bone-density-vs-fractures) - [Evidence ### Do GLP-1 Drugs Cause Kidney Stones? Nobody Has Run That Comparison Every published study ranks one diabetes drug against another. Stones ran at 21.3 per 1,000 person-years on a GLP-1 and 14.9 on an SGLT2 inhibitor. Neither figure is a risk. 7 min read](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones) - [Evidence ### GLP-1 Drugs in Psoriasis: Mortality, Heart Events and Substance Use A 3,048-pair cohort found lower mortality, fewer cardiac events and less alcohol and substance use. The mortality figure — a hazard ratio of 0.219 — is larger than any trial has produced. 5 min read](https://thisglp.com/research/glp1-psoriasis-comorbidities) - [Evidence ### Do GLP-1 Drugs Help Atrial Fibrillation? The Evidence Disagrees With Itself One ablation cohort found a hazard ratio of 0.82 for recurrence. Another found 1.04. A larger comparison found no advantage over a near-neutral drug at all. 8 min read](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation) - [Evidence ### Why Isn't Obesity in Your Medical Record? One in Ten Had It Written Down 42,243 hospitalized adults all had a BMI of 30 or more on the chart. It reached the discharge summary for 10.6% of them, against 59.7% for diabetes. 8 min read](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record) - [Evidence ### Is Tirzepatide Better Than Dulaglutide? One Trial Is 92% of the Answer A four-trial network meta-analysis of 14,348 participants. One study supplies 13,165 of them. Every published difference is measured against tirzepatide 5 mg, not against dulaglutide. 8 min read](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide) - [Evidence ### Semaglutide and Reproductive Hormones in Rats: A Pair-Fed Study A second group of obese rats was fed exactly what the treated ones ate, so it lost the same weight without the drug. The gap between those two arms is the molecule. 7 min read](https://thisglp.com/research/semaglutide-reproduction-pair-fed-rats) - [Evidence ### Tirzepatide and Cardiac Remodeling in HFpEF: A 50-Patient Echo Study Fifty patients, six months of tirzepatide, and every measured outcome moved the right way. BMI fell 5.8 kg/m² in the same period, and an echocardiogram reads a body as well as a heart. 7 min read](https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling) - [Evidence ### Bariatric Surgery vs GLP-1 Drugs on Cardiovascular Events Bariatric surgery beat GLP-1 drugs on every cardiovascular outcome in a 932,380-patient analysis. The drug side pools studies going back to 2000. 7 min read](https://thisglp.com/research/bariatric-surgery-vs-glp1-cardiovascular) - [Formats ### GLP-1 Discounts vs Seller Disclosure: Dose Ladders and State Lists A page covered in struck-through prices reads as less trustworthy than a plain one. Discounting GLP-1 sellers publish a dose ladder more often, not less, and the reason is structural. 5 min read](https://thisglp.com/research/do-discounting-sellers-disclose-less) - [Formats ### GLP-1 Storefronts Sharing One Application Build, Matched by Hash A group of GLP-1 storefronts serves a byte-identical application, matched by hash. A shortlist containing four of them contains one product configured four ways. 5 min read](https://thisglp.com/research/eight-storefronts-one-application) - [Evidence ### Adolescent Suicidality on GLP-1 Drugs vs Lifestyle Intervention and Metformin In 9,222 matched pairs of adolescents, incretin drugs looked protective against lifestyle intervention and made no difference against metformin. Neither comparison found harm. 6 min read](https://thisglp.com/research/glp1-adolescent-suicidality-comparators) - [Formats ### Advertised vs Billed GLP-1 Prices: Every Correction, by Type Most corrections to a published GLP-1 price exist for one reason: the advertised figure is not the billed one. A few exist because no figure could be published at all. 5 min read](https://thisglp.com/research/glp1-advertised-vs-billed-corrections) - [Safety ### Do GLP-1 Drugs Cause Gastroparesis? Thirteen Cases, and Two Opposite Findings Rarely: only thirteen cases of GLP-1-associated gastroparesis have ever been published. Two larger studies found the same drugs linked to fewer digestive symptoms, not more. 9 min read](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis) - [Safety ### Unexpected Pregnancy on a GLP-1: Why Weight Loss Makes It Likelier Weight loss restores ovulation, so unplanned pregnancy is a foreseeable consequence of these drugs working. Across 36 studies no consistent signal of harm has appeared — which is not the same as evidence of safety. 6 min read](https://thisglp.com/research/glp1-and-pregnancy) - [Safety ### Semaglutide and Suicidal Ideation: The Large Matched Cohort Studies Regulators opened investigations after reports of suicidal thoughts. Four matched cohorts published since — covering millions of patients — have all pointed the other way, and none of them is a randomized trial. 7 min read](https://thisglp.com/research/glp1-and-suicidal-ideation) - [Evidence ### Do GLP-1 Drugs Change Your Sense of Taste? Scores Fell From 40.63 to 28.61 People on a GLP-1 scored far lower on a standardized taste test than matched controls. Smell was untouched, and the people with the worst side effects tasted best. 8 min read](https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste) - [Safety ### Do GLP-1 Drugs Cause Thyroid Cancer? A Bound, Not a Verdict Across 437,077 patients the hazard ratio was 0.93, and the authors bound it: no more than a 31% increase in relative risk. For medullary cancer specifically, the interval runs from 0.37 to 3.86. 6 min read](https://thisglp.com/research/do-glp1-drugs-cause-thyroid-cancer) - [Evidence ### Do GLP-1 Drugs Help Ulcerative Colitis? Remission Was 66.7% Against 25.3% One matched cohort of 150 pairs put twelve-week symptomatic remission at 66.7% against 25.3%, at an adjusted odds ratio of 5.90. Nobody was randomized, and no seller offers anything for this. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis) - [Evidence ### Does a GLP-1 Affect Surgery Outcomes? Four Procedures, Four Different Answers It depends on the operation. Knee and neck surgery showed no difference, shoulder surgery's alarming signals vanished on adjustment, and spinal fusion went both ways depending on the database. 10 min read](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) - [Evidence ### What BMI Do You Need for a GLP-1? The Cut-Off Is a Convention A trial in China and Taiwan enrolled people at a BMI of 24 to 30, below where the Western trials start. The cut-off is a guideline, not a boundary in a body. 9 min read](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) - [Evidence ### Smart Scale Body Composition on GLP-1 Drugs: Fat vs Muscle Lost Connected bioimpedance scales recorded a 9.8% median weight reduction on GLP-1 drugs, split 7.5% fat and 2.3% muscle, in people who weigh themselves for years. 7 min read](https://thisglp.com/research/glp1-body-composition-smart-scale) - [Formats ### What Should a GLP-1 Provider Actually Do? Five Pillars A European specialist society set out what proper care around these drugs requires. It was not written about online sellers, which is what makes it useful against them. 5 min read](https://thisglp.com/research/what-should-a-glp1-provider-actually-do) - [Evidence ### Do GLP-1 Drugs Prevent Diabetic Foot Ulcers? The Database Cannot Say Diabetic foot took up half as much of the GLP-1 adverse event pile as of the comparison pile. That reads as protective until you notice what the method does. A reporting database can find harm appearing too often, and it can never find harm missing. 9 min read](https://thisglp.com/research/do-glp1-drugs-prevent-diabetic-foot-ulcers) - [Safety ### GLP-1 Dosing Errors in FDA Adverse Event Reports Among the terms reported most often for these drugs are incorrect dose, extra dose and off-label use. Those describe what somebody did, not what the drug did. 6 min read](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports) - [Evidence ### Do GLP-1 Drugs Improve Blood Vessel Function? The Same Number, Two Answers Blood-vessel function rose 0.11 against baseline and 0.11 against placebo. The first was significant and the second was not. Only the comparison changed. 9 min read](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function) - [Evidence ### Frailty and Semaglutide in Heart Failure: The STEP-HFpEF Analysis Re-cutting 1,145 heart failure participants by frailty separated the weight loss from the symptom benefit. The frailest gained the most, and the fittest gained nothing measurable. 6 min read](https://thisglp.com/research/glp1-heart-failure-frailty) - [Evidence ### Does Taking a GLP-1 Before Pregnancy Raise Preeclampsia Risk? The Studies Split Pooled, three cohorts showed no association. A JAMA cohort found 46% against 36% when the drug was stopped around conception, and a records study found 19.9% against 22.8%. 7 min read](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk) - [Evidence ### GLP-1 Drugs in Children and Adolescents: 18 Randomized Trials Pooled A meta-analysis pooled 18 randomized trials covering 1,402 children and adolescents aged six to seventeen. The pooled effects were modest, and the median treatment lasted about six months. 5 min read](https://thisglp.com/research/glp1-in-children-all-eighteen-trials) - [Evidence ### Liver Cancer Risk on GLP-1 Drugs vs Other Diabetes Treatments GLP-1 starters had less liver cancer than users of four other diabetes drugs. Every difference lands under 0.6 percentage points, because the cancer is rare. 6 min read](https://thisglp.com/research/glp1-liver-cancer-absolute-risk) - [Evidence ### GLP-1 Drugs in MASH: Deaths, Ascites and a Small Liver Cancer Signal In 168,733 matched pairs of adults with MASH, GLP-1 users had 2.2 fewer deaths per hundred. A liver-cancer signal cleared significance with a risk difference of zero, and the authors set it aside. 6 min read](https://thisglp.com/research/glp1-liver-cancer-signal-dismissed) - [Evidence ### Are GLP-1 Drugs Bad for Your Liver? The Evidence Says Better Eleven trials found liver enzymes falling on these drugs. The authors then refused to rank the drug classes, and said they could not compare safety at all. 6 min read](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver) - [Evidence ### Do You Lose Muscle on a GLP-1? And What Comes Back Is Fat Six to seven kilograms of lean mass goes during treatment. About 5.6 kg comes back after stopping, preferentially as fat. The scale can read the same either way. 6 min read](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1) - [Evidence ### GLP-1 Drugs and Mortality in Type 2 Diabetes With a BMI Under 27 A study found 39% lower all-cause mortality on GLP-1 drugs, then said in its conclusion that the number is probably confounding rather than benefit. 7 min read](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own) - [Evidence ### Mortality on GLP-1 Drugs in Hidradenitis Suppurativa: A Record Study A matched-record study found three quarters of deaths missing in GLP-1 users over two years. Randomized trials move mortality by about a fifth. 7 min read](https://thisglp.com/research/glp1-mortality-in-hidradenitis) - [Safety ### Why Do GLP-1 Drugs Cause Nausea? And Why It Does Not Predict Weight Loss The drugs act on a brainstem area that handles both appetite and nausea. In the trials, people with and without stomach side effects lost about the same weight. 6 min read](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea) - [Evidence ### High-Dose vs Standard-Dose GLP-1 Before Neck Fusion (ACDF) Surgery Neck fusion patients on a high-dose GLP-1 did no worse than those on a standard dose, across nine outcomes and two years. 7 min read](https://thisglp.com/research/glp1-neck-fusion-high-dose) - [Evidence ### Can You Take a GLP-1 on Dialysis? 2,492 Patients, and No Trial A matched cohort of 2,492 pairs starting hemodialysis found mortality 17% lower on these drugs. Before it, the entire world literature was 388 patients, and no trial has enrolled anyone on dialysis. 10 min read](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis) - [Evidence ### Do GLP-1 Drugs Cause Pancreatic Cancer? Six Comparators, Five Answers Against four rival drug classes the GLP-1 arm carried the lower hazard, and against SGLT2 inhibitors no difference. One of the six comparisons is printed in both directions in the same abstract. 9 min read](https://thisglp.com/research/do-glp1-drugs-cause-pancreatic-cancer) - [Evidence ### Do GLP-1 Drugs Help Parkinson's Disease? Prevention and Treatment Disagree Across 82 pooled studies the risk of developing Parkinson's was lower, at a hazard ratio of 0.70. In people who already have it, motor symptoms did not improve at all. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease) - [Evidence ### Insulin Resistance in PCOS on GLP-1 Drugs: A Four-Trial Meta-Analysis Pooled across four small trials in PCOS, waist, BMI and testosterone fell. Insulin resistance, the reason these drugs are supposed to help, did not. 6 min read](https://thisglp.com/research/glp1-pcos-insulin-resistance) - [Evidence ### GLP-1 Prescribing to Children Aged 8 to 11: Who Gets Them GLP-1 prescriptions to children aged 8 to 11 rose 310-fold in seven years, from a base of 0.03%. The children getting them are the least socially vulnerable. 6 min read](https://thisglp.com/research/glp1-prescriptions-to-young-children) - [Formats ### GLP-1 Price Spread Across Sellers: The Range and the Middle Half Published monthly GLP-1 prices for the same molecule run from the low double figures to the high hundreds. Most sellers sit nowhere near either end. 4 min read](https://thisglp.com/research/glp1-price-spread-across-sellers) - [Evidence ### Which GLP-1 Has the Worst Side Effects? It Depends on the Outcome Pooling 41,381 people, the two drugs looked alike on ordinary side effects and on quitting. Serious adverse events were 83% more frequent with tirzepatide. 6 min read](https://thisglp.com/research/which-glp1-has-the-worst-side-effects) - [Evidence ### GLP-1 Drugs and Rotator Cuff Repair Complications in Type 2 Diabetes GLP-1 users looked worse on three outcomes after shoulder surgery. Then the authors made the groups comparable and all three differences disappeared. 5 min read](https://thisglp.com/research/glp1-shoulder-surgery-adjustment) - [Evidence ### Exenatide for Smoking Cessation: Five Subgroups From One Pilot Trial A small trial found exenatide added to a nicotine patch helped smokers quit. A secondary analysis then found five different groups it helped most, which is what exploratory subgroup analysis reliably produces. 5 min read](https://thisglp.com/research/glp1-smoking-cessation-subgroups) - [Evidence ### Do GLP-1 Drugs Affect Spinal Fusion Surgery? It Depends on the Operation These drugs look protective in one database, neutral in another and harmful in a third. Pooling it all gives an interval from 0.35 to 4.70. That is not an answer. It is a warning. 8 min read](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery) - [Evidence ### Atrial Fibrillation After Ablation on GLP-1 Drugs: An Umbrella Review Two meta-analyses of the same six trials published pooled hazard ratios of 0.58 and 0.78. Nothing separated them but the choices their authors made. 7 min read](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) - [Evidence ### GLP-1 Prescribing After a Heart Attack or Stroke: Czech Registry Data Czech national registry data covered heart attack and stroke survivors with type 2 diabetes from 2015 to 2024. About 2 percent were started on a GLP-1 within a year, despite a guideline recommending it. 5 min read](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke) - [Safety ### Do You Need Vitamins on a GLP-1? Over 60% Eat Below the Iron Requirement Across six studies and 480,825 adults, vitamin D deficiency reached 13.6% at twelve months. Most users ate below the estimated requirement for calcium and iron. The answer is a blood test, not a supplement aisle. 10 min read](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1) - [Evidence ### Do GLP-1 Drugs Cause Gout? The Study Everyone Cites Cannot Say A 295,907-person comparison put gout at 7.8 events per 1,000 person-years on a GLP-1 against 4.9 on an SGLT2 inhibitor. Both arms were treated, so neither rate has a baseline to sit against. 9 min read](https://thisglp.com/research/do-glp1-drugs-cause-gout) - [Evidence ### Real-World GLP-1 Weight Loss: Discontinuation, Dose and the Trial Gap Weight loss on GLP-1 drugs in ordinary practice runs below the trial results and approaches them in people who keep taking the drug. Between a fifth and a half stop within the first year. 5 min read](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) - [Evidence ### GLP-1 Weight Loss Across 32 Trials: The 9.36% Average and Its Spread Thirty-two trials give a mean weight reduction of 9.36%. They also disagree with each other almost completely, which is the more useful number. 6 min read](https://thisglp.com/research/glp1-weight-loss-pooled-average) - [Formats ### GLP-1 Dose Ladders: How Many Price Rungs Sellers Publish Publishing a priced dose ladder is a rare disclosure among GLP-1 sellers. Publishing one deep enough to reach the dose you will actually end up on is rarer still. 5 min read](https://thisglp.com/research/how-deep-a-published-dose-ladder-goes) - [Formats ### Promotional GLP-1 Pricing: First-Month Rates, Codes and Struck Prices A fifth of published GLP-1 pricing notes carry the seller's own promotional language: a first month, an introductory rate, a code, or a struck-through figure nobody is charged. 5 min read](https://thisglp.com/research/how-much-glp1-pricing-is-promotional) - [Formats ### GLP-1 Price Freshness: How Old Published Seller Prices Are Every GLP-1 price here carries the month it was read. This page counts how old those readings are, and what changed when the same prices were read a second time. 5 min read](https://thisglp.com/research/how-old-is-the-price-you-are-reading) - [Formats ### GLP-1 Seller Disclosures: Does Publishing One Predict Another? A GLP-1 seller that publishes its full dose ladder is no likelier than average to publish the states it serves. Disclosure is a property of pages rather than of companies. 5 min read](https://thisglp.com/research/is-seller-disclosure-a-trait) - [Evidence ### Is a GLP-1 Better Than Metformin? Nobody Has Run That Trial Across 93 trials, metformin had the largest reduction in cardiovascular events of any diabetes drug. It also had the least reliable evidence behind it. 9 min read](https://thisglp.com/research/is-a-glp1-better-than-metformin) - [Evidence ### Do GLP-1 Drugs Raise Testosterone? Not in the Trials That Measured It Five strategies for obesity-related low testosterone across 23 trials, and the significant increases belong to the other four. Weight loss still helps the condition. 9 min read](https://thisglp.com/research/do-glp1-drugs-raise-testosterone) - [Formats ### How Do You Take Oral Semaglutide? Empty Stomach, and Little Water Oral semaglutide's bioavailability is about 0.4% to 1%, and only on an empty stomach with restricted water. Eat first and there is no measurable drug in the blood at all. 8 min read](https://thisglp.com/research/how-do-you-take-oral-semaglutide) - [Evidence ### Oral Semaglutide vs DPP-4 Inhibitors and Cognitive Impairment in HFpEF In 246 elderly patients with heart failure, obesity and type 2 diabetes, new cognitive impairment was 77% lower on oral semaglutide. A 13,007-patient study of the same comparison found no difference. 7 min read](https://thisglp.com/research/oral-semaglutide-cognitive-impairment) - [Evidence ### Oral Semaglutide 50 mg in East Asian Adults: 14.3% Weight Loss A 50 mg tablet produced a 14.3% mean weight reduction against 1.3% on placebo in 201 East Asian adults starting at 91.9 kg, at a dose several times the oral semaglutide already on the market. 5 min read](https://thisglp.com/research/oral-semaglutide-fifty-milligrams) - [Evidence ### What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. 8 min read](https://thisglp.com/research/what-is-orforglipron) - [Formats ### GLP-1 Price Changes Between Two Readings of the Same Sellers Published prices from dozens of GLP-1 sellers were read a second time. Most figures had moved, most of them downward, and the typical change was not small. 4 min read](https://thisglp.com/research/rereading-glp1-prices) - [Evidence ### What New Weight Loss Drugs Are Coming? Retatrutide Leads at 22.1% Across 58 trials and 24,214 adults, retatrutide took off 22.10% of body weight and tirzepatide 19.28%. Only one drug on that podium can actually be bought. 10 min read](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming) - [Evidence ### Do GLP-1 Drugs Protect Against Dementia? A Predictor Moved Semaglutide slowed the rise of a 25-protein dementia risk score in SELECT participants. Nobody in the analysis developed dementia, or avoided it. 7 min read](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia) - [Evidence ### Do GLP-1 Drugs Slow Aging? Three Clocks Moved, One Mouse Lifespan Did Median lifespan in female mice ran 834 days on semaglutide against 742 on vehicle. In people the strongest result is a biomarker over 32 weeks, and no trial has a prespecified aging endpoint. 10 min read](https://thisglp.com/research/do-glp1-drugs-slow-aging) - [Evidence ### Does Semaglutide Reduce Alcohol Use? One Trial Found a 13.7-Point Gap In a 26-week trial, yes: heavy drinking days fell 13.7 percentage points more than placebo. A register study found the benefit fades within a year of stopping. 8 min read](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use) - [Evidence ### Oral Semaglutide in Early Alzheimer's Disease: The evoke and evoke+ Trials Two phase 3 trials randomized 3,808 people with confirmed early Alzheimer's disease. At 104 weeks the estimated difference on the primary endpoint was -0.08, and both trials were discontinued. 6 min read](https://thisglp.com/research/semaglutide-and-alzheimers) - [Safety ### Does Semaglutide Make Diabetic Retinopathy Worse? In One Trial, Yes A randomized trial found more retinopathy complications on semaglutide than on placebo, and the effect concentrated almost entirely in people who already had retinopathy, had poor glycemic control at baseline, and were being treated with insulin. 8 min read](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse) - [Evidence ### Do GLP-1 Drugs Help Heart Failure? Symptom Scores Rose 7.5 Points In one trial population, yes: semaglutide improved heart-failure symptom scores by 7.5 points and tirzepatide cut a composite endpoint by 38%. Neither number transfers whole. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-heart-failure) - [Evidence ### Semaglutide in MASH: ESSENCE Phase 3 Results at 72 Weeks At 72 weeks, steatohepatitis resolved in 62.9% on semaglutide against 34.3% on placebo, and fibrosis improved in 36.8% against 22.4%. In compensated cirrhosis, the one trial available found neither. 6 min read](https://thisglp.com/research/semaglutide-and-liver-disease) - [Evidence ### Do GLP-1 Drugs Help Migraine? Triptan Use Fell 7%, Which Is Not a Treatment A Danish register of 189,392 people found triptan dispensing fell after semaglutide was started. The effect is real, small, and sits inside a study design with no control group. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-migraine) - [Evidence ### Semaglutide and Cognitive Signs in Psychiatric Patients: 13,007 Records Semaglutide starters had fewer recorded cognitive problems than three comparator groups, and no significant difference from the fourth, sitagliptin, which was the closest match. 6 min read](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs) - [Evidence ### Why Does Weight Loss Plateau on a GLP-1? The Drug Is Still Working Most people on tirzepatide plateaued between 24 and 36 weeks. At week 60 of a semaglutide trial, people still ate 269.5 kcal less than placebo, though they no longer felt it. 8 min read](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1) - [Evidence ### Semaglutide and Fracture Risk: Type 2 Diabetes vs No Diabetes Semaglutide was associated with fewer major fractures in people with type 2 diabetes and with no difference in people without it. The second group is most of the weight-loss market. 6 min read](https://thisglp.com/research/semaglutide-fractures-diabetes-only) - [Evidence ### Do GLP-1 Drugs Help Hidradenitis Suppurativa? Twenty People, No Control Group A small study reported that semaglutide improved every outcome it measured in a painful skin disease. Reading why that is not yet a finding is a skill worth having. 9 min read](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) - [Evidence ### Can You Take a GLP-1 With Polycystic Kidney Disease? Not as a Treatment One matched study of 320 pairs found a higher eGFR on semaglutide and no rise in kidney injury. The eGFR is calculated from creatinine, which falls when muscle does, and reviews say it is not a treatment. 7 min read](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease) - [Evidence ### Semaglutide in Knee Osteoarthritis: A Six-Month Cohort and Its Phenotypes Pain, function and inflammation markers all improved over six months on semaglutide in 88 patients. There was no untreated comparison group, and the authors say so in their methods. 6 min read](https://thisglp.com/research/semaglutide-knee-osteoarthritis-phenotypes) - [Evidence ### Semaglutide Lifespan Study in Female Mice: 742 vs 834 Days Semaglutide started late in life extended median lifespan from 742 to 834 days in female mice, and beat a calorie-restricted group matched to how much less they ate. 7 min read](https://thisglp.com/research/semaglutide-lifespan-in-mice) - [Evidence ### Semaglutide Carbon Footprint: A UK Lifetime Emissions Model A disease model found semaglutide lowered lifetime carbon emissions in two UK populations and raised them in a third, because the people in it survived longer. 7 min read](https://thisglp.com/research/semaglutide-lifetime-carbon-emissions) - [Evidence ### Semaglutide for MASH in Japanese Patients: The ESSENCE Subgroup Semaglutide resolved liver inflammation in 116 Japanese trial participants. On fibrosis, the endpoint the approval is written around, the interval ran from −11 to +26. 7 min read](https://thisglp.com/research/semaglutide-liver-japanese-subgroup) - [Evidence ### Semaglutide and Handgrip Strength: A 12-Month Body Composition Study Over twelve months on semaglutide, skeletal muscle mass fell from 29.9 to 28.7 kg while handgrip strength held, and the metabolic slowdown matched the lifestyle-only group. 7 min read](https://thisglp.com/research/semaglutide-muscle-mass-and-grip) - [Safety ### Semaglutide and NAION: Optic Nerve Risk in Diabetes vs Obesity A meta-analysis of six million people links semaglutide to optic nerve damage. In people taking it for weight rather than diabetes, the interval runs from 0.72 to 3.91. 7 min read](https://thisglp.com/research/semaglutide-optic-nerve-by-indication) - [Safety ### Semaglutide Psychiatric Risk Meta-Analysis: Trials Pooled With Report Counts A meta-analysis found no significant psychiatric risk with semaglutide. It reached that by pooling randomized trials with tallies from a spontaneous reporting database. 7 min read](https://thisglp.com/research/semaglutide-psychiatric-risk-pooling) - [Evidence ### Is a Higher Semaglutide Dose Worth It? Three Points, Four Times the Symptom A trial put semaglutide 7.2 mg against 2.4 mg in the same protocol. The higher dose bought three more points of weight, and nearly four times the rate of an unfamiliar nerve symptom. 6 min read](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it) - [Evidence ### Can You Trust GLP-1 Advice on TikTok? Likes Do Not Track Quality Four studies graded GLP-1 content on social media. The median video scored 2 out of 4 for saying who made it. Likes were a poor guide to accuracy. 7 min read](https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media) - [Evidence ### Semaglutide vs Sleeve Gastrectomy: Liver Stiffness Over 72 Weeks Sleeve gastrectomy took off more weight than semaglutide and improved liver stiffness no more than the drug did. Ninety-two people, nobody randomized. 7 min read](https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness) - [Evidence ### Do GLP-1 Drugs Affect Fertility? 25 Men, and No Trial Measured Pregnancy The only randomized comparison in men enrolled 25 people and moved normal sperm morphology from 2% to 4%. In women the pooled trial evidence is 176 participants, none of them followed to conception. 9 min read](https://thisglp.com/research/do-glp1-drugs-affect-fertility) - [Evidence ### What Else Comes Back When You Stop a GLP-1? Almost Everything Across eighteen trials, stopping reversed HbA1c, waist, blood pressure and fasting glucose as well as weight — and the rebound was roughly twice as large after semaglutide as after liraglutide. 6 min read](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1) - [Evidence ### Telehealth Semaglutide and Tirzepatide Program: 12.3% at 24 Weeks A single-arm telehealth program produced 12.3% weight loss in 24 weeks. Alongside the prescription, it supplied a behavioral program, a connected scale and a blood pressure cuff. 6 min read](https://thisglp.com/research/telehealth-glp1-program-trial) - [Formats ### Tirzepatide Dispensing by Dose in Japan: National Claims Data Japan publishes national dispensing quantities for every strength of tirzepatide. Doses of 7.5 mg and above went from 13.0% of the mix to 24.0% in ten months. 6 min read](https://thisglp.com/research/tirzepatide-dose-mix-in-japan) - [Evidence ### Switching to Tirzepatide and Liver Fibrosis Scores: 182 Patients Switching to tirzepatide improved a fibrosis score only in the patients whose scores were worst to begin with. That is a real effect or regression to the mean. 6 min read](https://thisglp.com/research/tirzepatide-fibrosis-worst-group) - [Evidence ### SUMMIT Trial Composite Endpoint: Tirzepatide in HFpEF, Broken Down Tirzepatide cut a composite of cardiovascular death or worsening heart failure by 38%. Almost all of that was the heart-failure half; the death half went the other way, on thirteen events. 6 min read](https://thisglp.com/research/tirzepatide-heart-failure-composite) - [Evidence ### Tirzepatide 2.5 mg vs 5 mg in Japanese Adults Without Diabetes Tirzepatide at 2.5 mg matched 5 mg on weight loss over six months in 112 adults. Patients picked their own dose, which is why the comparison cannot settle it. 6 min read](https://thisglp.com/research/tirzepatide-low-dose-self-selected) - [Evidence ### Tirzepatide vs Semaglutide: Major Adverse Liver Outcomes in Type 2 Diabetes In a matched analysis, tirzepatide and semaglutide showed nearly identical rates of major adverse liver outcomes. The reason to believe the null is that both beat a third drug in the same analysis. 7 min read](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver) - [Evidence ### UBT251 Triple Agonist: First-in-Human 12-Week Weight Loss Trial The GLP-1, GIP and glucagon receptor agonist UBT251 produced large early weight loss in its first human study. The 12-week clock is why that number cannot be set beside the drugs you can buy. 6 min read](https://thisglp.com/research/triple-agonist-first-in-human) - [Evidence ### Stopping Semaglutide in Type 1 Diabetes: Time in Range After Withdrawal Adults with type 1 diabetes lost about an hour a day of good glucose control in the twelve weeks after semaglutide stopped. Low blood sugar did not change. 6 min read](https://thisglp.com/research/type-1-diabetes-stopping-semaglutide) - [Formats ### GLP-1 Seller State Coverage: Who Publishes Where They Ship Publishing the states served costs nothing and cannot go stale. A count of how many GLP-1 sellers publish a state list, and how wide the ones that do reach. 5 min read](https://thisglp.com/research/who-publishes-the-states-they-serve) - [Evidence ### Semaglutide vs Liraglutide After Bariatric Surgery: Weight and Lean Mass Pooling eight studies and 557 patients, semaglutide outperformed liraglutide by 4.15 points at a year. The body-composition figures include a bone density reduction whose interval reaches zero. 5 min read](https://thisglp.com/research/glp1-after-bariatric-surgery) - [Safety ### Do GLP-1 Drugs Cause Kidney Cancer? Trials Say Probably Not Across 48 trials the kidney cancer odds ratio was 1.12, graded as little or no effect. One cohort's 1.38 signal and two drug-versus-drug comparisons point different ways. 7 min read](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer) - [Safety ### Gallstone Risk on GLP-1 Drugs: Weight-Loss vs Diabetes Trials Across 76 randomized trials the pooled risk ratio was 1.37. In the thirteen weight-loss trials it was 2.29, and that is the subgroup everyone buying from a telehealth seller is in. 5 min read](https://thisglp.com/research/glp1-and-gallbladder-disease) - [Evidence ### Do GLP-1 Drugs Help Knee Pain? Yes, and Read the Placebo Arm Semaglutide cut WOMAC pain by 41.7 points. Placebo plus diet and activity counseling cut it by 27.5. The drug's own share is the 14.2 between them. 5 min read](https://thisglp.com/research/do-glp1-drugs-help-knee-pain) - [Safety ### Do GLP-1 Drugs Cause Pancreatitis? Risk and Warning Signs Overall risk and recurrence are different questions. Studies disagree in people with pancreatic disease, and severe persistent pain needs prompt assessment. 6 min read](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis) - [Safety ### Do GLP-1 Drugs Affect Sex Drive? Nobody Has Run That Trial The weight-loss trials did not measure libido or erectile function. What exists is a reporting signal, a cohort analysis pointing the other way, and case reports. 6 min read](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive) - [Evidence ### Tirzepatide Sleep Apnea Trial (SURMOUNT-OSA): AHI Results at 52 Weeks SURMOUNT-OSA measured breathing events directly rather than weight alone. The reduction was large, the population was severe, and a year is not the whole question. 5 min read](https://thisglp.com/research/glp1-and-sleep-apnea) - [Safety ### Residual Stomach Contents on GLP-1 Drugs: A Gastric Ultrasound Study After identical fasting instructions, 56 percent of GLP-1 users had food still in the stomach against 19 percent of others. Pausing the drug for longer did not help. 5 min read](https://thisglp.com/research/glp1-before-surgery) - [Formats ### GLP-1 Sellers Billing Every Four Weeks: Thirteen Charges a Year Some GLP-1 sellers bill every four weeks rather than by the calendar month. That is a thirteenth charge a year, roughly an eight percent premium, and it never appears on the price tag. 4 min read](https://thisglp.com/research/glp1-four-week-billing-cycles) - [Evidence ### Are GLP-1 Drugs Safe for Teens? The Trials, and What Is Outside Them A 16.1 percent BMI reduction over 68 weeks, and 73 percent reaching five percent weight loss. The endpoint is BMI, not weight, and five participants developed gallstones. 5 min read](https://thisglp.com/research/are-glp1-drugs-safe-for-teens) - [Safety ### Do GLP-1 Drugs Work in Menopause? The Subgroup Nobody Reported Women were 79% of one trial population at a mean age of 46, and no published trial has reported outcomes by menopausal status. 6 min read](https://thisglp.com/research/do-glp1-drugs-work-in-menopause) - [Evidence ### Semaglutide Lean Mass in the SMART Trial: −2.5 kg, Interval Crossing Zero In a prespecified SMART trial analysis, the lean-mass change on semaglutide was −2.5 kg with a confidence interval that crosses zero. Lean mass is also not the same thing as muscle. 6 min read](https://thisglp.com/research/muscle-loss-on-glp1) - [Formats ### Oral Semaglutide 25 mg: OASIS 4 Trial Results at 71 Weeks A 71-week randomized trial put the 25 mg tablet at −13.6% body weight against −2.2% on placebo. Three quarters of the treated group had gastrointestinal side effects, and compounded orals are not this product. 5 min read](https://thisglp.com/research/oral-semaglutide-what-the-pill-does) - [Evidence ### FLOW Trial: Semaglutide 1.0 mg in Diabetic Chronic Kidney Disease A 24 percent reduction in major kidney events, with every secondary outcome agreeing, in a trial stopped early at an interim analysis. The dose was 1.0 mg, the diabetes dose, not the one sold for weight loss. 6 min read](https://thisglp.com/research/semaglutide-and-kidney-disease) - [Safety ### Does Semaglutide Cause Vision Loss? The Signal Sits in Diabetes One eye center counted 20 cases of sudden optic-nerve damage among 979 semaglutide patients against 3 on the comparator. Pooled across 5,916,559 people, the association holds in diabetes and not in the weight-loss group. 9 min read](https://thisglp.com/research/does-semaglutide-cause-vision-loss) - [Evidence ### Cochrane Review of Semaglutide for Obesity: 18 Trials Graded A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. 6 min read](https://thisglp.com/research/semaglutide-cochrane-review) - [Evidence ### GLP-1 Withdrawal Trials: STEP 1, STEP 4 and SURMOUNT-4 Compared Three randomized withdrawal studies measured what happens after the drug stops. In the STEP 1 extension, participants regained two thirds of the loss within a year. 7 min read](https://thisglp.com/research/stopping-glp1-and-weight-regain) - [Safety ### Tirzepatide and Oral Contraceptive Levels: 55 to 66% Lower Peaks A single pharmacokinetic study found tirzepatide cut peak contraceptive hormone levels by up to 66% and total exposure by around 20%. Those two numbers mean different things. 5 min read](https://thisglp.com/research/tirzepatide-and-oral-contraception) - [Evidence ### How Long Does Nausea Last on a GLP-1? Through the Escalation The first twenty weeks are where the dose climbs, where the side effects cluster, and where a dose-priced seller starts charging more. 6 min read](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [Formats ### GLP-1 Seller Disclosure Gaps: Dose Pricing, State Coverage, Formats Across several hundred GLP-1 sellers, a count of how many publish nothing about dose pricing, nothing about state coverage and nothing beyond a single format, and why silence is not the same as concealment. 5 min read](https://thisglp.com/research/what-glp1-sellers-do-not-publish) - [Formats ### GLP-1 Sellers That Publish a Dose Price Ladder, Counted A minority of GLP-1 sellers print three or more rungs of a dose price ladder. Far fewer state that the price scales at all, and the two groups are not the same sellers. 5 min read](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) --- # Mortality in Serious Mental Illness: GLP-1 vs SGLT2 Inhibitors | This GLP A 764,115-pair emulation found four-year mortality of 4.91% vs 6.45% on GLP-1 drugs against SGLT2 inhibitors in serious mental illness, an absolute gap of 1.54 points. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Mortality in Serious Mental Illness: GLP-1 vs SGLT2 Inhibitors In people with schizophrenia, bipolar disorder or major depression, four-year mortality was 4.91% on a GLP-1 drug against 6.45% on an SGLT2 inhibitor. The one-year figure in the same paper is not believable. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Four-year mortality, serious mental illness · on a GLP-1 · 4.91% · on an SGLT2 inhibitor · 6.45% · HR 0.76 — a gap of 1.54 percentage points. · Both arms were on an effective drug. 195,184 matched pairs. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A target trial emulation matched 764,115 pairs starting a GLP-1 drug or an SGLT2 inhibitor, including 195,184 pairs with serious mental illness. - Four-year mortality in the serious mental illness cohort was 4.91% against 6.45% — a hazard ratio of 0.76 and an absolute difference of 1.54 percentage points. - A separately matched one-year analysis reported 1.46% against 2.84%, a relative risk of 0.52. - The comparator is not placebo. SGLT2 inhibitors reduce mortality themselves, so this is one effective drug measured against another. People with schizophrenia, bipolar disorder and major depression die substantially earlier than everyone else, mostly of cardiovascular disease, and that gap has resisted decades of attention. A large emulation asked whether these drugs narrow it, comparing them against SGLT2 inhibitors [\[1\]](https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness#ref-1). The weight side of the same problem is covered in [clozapine weight gain and what came back](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain). At four years, mortality among participants with serious mental illness was 4.91% on a GLP-1 drug against 6.45% on an SGLT2 inhibitor — a hazard ratio of 0.76 with an absolute risk difference of 1.54 percentage points. Among those who also had type 2 diabetes, semaglutide was associated with lower rates of major cardiovascular events, myocardial infarction, stroke and heart failure. The one-year figure is too large to believe A separately matched one-year cohort reported mortality of 1.46% against 2.84%, a relative risk of 0.52. A drug halving deaths within twelve months of the first prescription is not something any randomized trial in this class has produced over much longer periods. What that number most likely measures is that people started on a weekly injectable are, at that moment, healthier and better engaged with care than people started on a tablet. The four-year estimate is the plausible one; the one-year estimate is a warning about the method. The comparator deserves emphasis because it cuts both ways. SGLT2 inhibitors are not inert — they reduce mortality in their own right — so a margin over them is a harder thing to achieve than a margin over nothing. That makes the direction more interesting. It also means both groups were under active treatment, which removes some of the usual objection that the treated group is simply the group receiving care. Read the absolute numbers alongside the ratios, as always. A hazard ratio of 0.76 on a four-year mortality of around 6% is a gap of about one and a half people per hundred. That is a real and meaningful difference in a population with excess mortality, and it is a much smaller thing than 0.76 sounds — the same arithmetic set out in [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute) and in [the intracranial pressure meta-analysis](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension). The authors ask for randomized trials, which is correct and also unlikely to happen soon in this population. In the meantime the useful conclusion is narrow: there is no signal here that these drugs are dangerous in serious mental illness, which matters because psychiatric safety concerns have circulated widely around them, as [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding) approaches from another direction. ## Frequently asked Do GLP-1 drugs reduce death in serious mental illness? This emulation found lower four-year mortality against SGLT2 inhibitors — 4.91% versus 6.45% — but it is observational, and the authors call for randomized trials. Why distrust the one-year result? It reports a 48% mortality reduction within twelve months of the first prescription, larger than any randomized trial of this class has produced over much longer periods. That pattern suggests the treated group was healthier when treatment started. What was the comparison drug? SGLT2 inhibitors, which reduce mortality themselves. This is not a comparison against placebo or against no treatment. ## Sources 1. \[1\] McIntyre RS, Zhang-James Y, Kwan ATH (2026). Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness JAMA Psychiatry. [PMID 42647034](https://pubmed.ncbi.nlm.nih.gov/42647034/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide Sleep Apnea Results by Age, BMI and Severity | This GLP Post hoc SURMOUNT-OSA analyses: tirzepatide cut apnea events in every subgroup, by 27.7 to 34.1 an hour across ages and by 12.1 to 52.2 across baseline severity. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/apnea-improved-across-every-subgroup Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Tirzepatide Sleep Apnea Results by Age, BMI and Severity Post hoc SURMOUNT-OSA analyses found apnea events fell in every subgroup. Age, sex, BMI and neck size made little difference; starting severity made a fourfold one, for arithmetic reasons worth understanding. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Fewer breathing events per hour, by subgroup · by age · 27.7–34.1 · by sex · 19.8–32.6 · by BMI · 25.2–34.4 · by neck size · 23.9–30.8 · by starting severity · 12.1–52.2 · The bottom row is four times as wide as the others. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Post hoc analyses of two phase 3 trials examined tirzepatide's effect on sleep apnea across subgroups defined by age, sex, BMI, baseline severity and neck circumference. - Reductions in the apnea-hypopnea index appeared in every subgroup, alongside improvements in weight, systolic blood pressure and hypoxic burden. - Ranges were narrow for age (-27.7 to -34.1 events per hour), sex, BMI and neck circumference — and wide for baseline severity, at -12.1 to -52.2. - The authors describe these analyses as descriptive. No interaction tests or subgroup confidence intervals are reported. Tirzepatide is approved for obstructive sleep apnea with obesity, and the obvious next question is whether it works as well for everyone. Post hoc analyses of the two trials behind that approval cut the results by age, sex, BMI, starting severity and neck circumference[\[1\]](https://thisglp.com/research/apnea-improved-across-every-subgroup#ref-1). What the trial measured in the first place is set out in [tirzepatide and sleep apnea](https://thisglp.com/research/glp1-and-sleep-apnea). The broad answer is yes. Reductions in the apnea-hypopnea index appeared in every subgroup examined, alongside improvements in body weight, systolic blood pressure and the sleep-apnea-specific hypoxic burden, which measures how much oxygen desaturation someone actually accumulates rather than just counting events. One range is four times wider than the others By age the reduction ran from 27.7 to 34.1 events per hour, by BMI from 25.2 to 34.4, by neck circumference from 23.9 to 30.8. By starting severity it ran from 12.1 to 52.2 — a 4.3-fold spread against roughly 1.3-fold for the others. That is not evidence of an unpredictable drug — it is arithmetic. Someone starting at 20 events an hour cannot lose 52 of them. The people with the most to lose lost the most, and the headline figure from a trial like this is driven substantially by how severe the enrolled population was. That matters for anyone converting a trial number into an expectation. A person with an AHI of 18 and a person with an AHI of 60 will both improve on this evidence, and they will not improve by the same amount, and the average reported for the trial describes neither of them. It is the same reason a percentage weight loss from a lighter starting population is not comparable to one from a heavier one, as [the ecnoglutide trial](https://thisglp.com/research/what-is-ecnoglutide) illustrates. The word to hold onto is the authors’ own: descriptive. No interaction tests are reported here and no confidence intervals accompany the subgroup estimates, so “consistent across subgroups” means the ranges overlap rather than that heterogeneity was tested and ruled out. That is a weaker statement than the prespecified sex analysis in [the HFpEF trial](https://thisglp.com/research/same-benefit-different-route-by-sex), where interaction P values were calculated and reported. None of this touches the question that follows from a good result, which is what happens to the machine beside the bed. Improving on a measurement is not the same as no longer needing treatment, and a sleep study is the only thing that establishes the difference — a practice gap covered in [the cardiac imaging evidence](https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling) from a different direction. ## Frequently asked Does it work equally well for everyone? Improvements appeared in every subgroup examined, with similar ranges by age, sex, BMI and neck circumference. By starting severity the range was much wider, from 12.1 to 52.2 fewer events per hour. Why does starting severity matter so much? Largely arithmetic. Someone with 20 breathing events an hour cannot lose 52 of them, so people who start worse have more room to improve and the trial average reflects how severe the enrolled group was. Were the subgroups formally compared? No. The authors describe these analyses as descriptive, and no interaction tests or subgroup confidence intervals are reported — so consistency here means overlapping ranges rather than tested equivalence. ## Sources 1. \[1\] Falcon B, Xie CC, Redline S, Grunstein R, et al. (2026). Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA Journal of Clinical Sleep Medicine. [PMID 42675225](https://pubmed.ncbi.nlm.nih.gov/42675225/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Are GLP-1 Drugs Bad for Your Liver? The Evidence Says Better | This GLP A meta-analysis of eleven trials in type 2 diabetes and fatty liver reported ALT and HbA1c effects with separate certainty grades — and declined to rank the drug classes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Are GLP-1 Drugs Bad for Your Liver? The Evidence Says Better Eleven trials found liver enzymes falling on these drugs. The authors then refused to rank the drug classes, and said they could not compare safety at all. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Effect, and how much to believe it · SGLT2 inhibitor · ALT · −7.56 U/L · moderate certainty · SGLT2 inhibitor · HbA1c · −0.09% · moderate certainty · GLP-1 agonist · ALT · −6.71 U/L · moderate certainty · GLP-1 agonist · HbA1c · −0.48% · low certainty · Eleven trials, 642 analyzed — and no class ranking offered **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Eleven randomized trials, 692 people randomized and 642 analyzed, in adults with type 2 diabetes and fatty liver disease. - Adding a GLP-1 lowered ALT by 6.71 U/L, 95% CI −11.53 to −1.89, at moderate certainty. - It lowered HbA1c by 0.48 percentage points, 95% CI −0.83 to −0.14 — at low certainty. - The authors state the evidence does not support ranking the drug classes against each other. - They also state that comparative safety could not be assessed, because adverse-event reporting was incomplete. On the measured evidence they look good for it rather than bad. Pooled across eleven randomized trials in adults with type 2 diabetes and fatty liver disease, adding a GLP-1 lowered ALT by 6.71 U/L at moderate certainty. HbA1c fell by 0.48 percentage points, graded low certainty — the two numbers do not carry equal weight, and the review says so. Liver cancer is the outcome people mean when they ask this, and it has been measured twice with the same shape of answer. A target trial emulation found five-year hepatocellular carcinoma risk LOWER on a GLP-1 than on every comparator, by 0.37 to 0.52 percentage points [\[2\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-2). Those differences stay under 0.6 points because the cancer is rare, which is the reading in [half a percentage point over five years](https://thisglp.com/research/glp1-liver-cancer-absolute-risk). A second study found liver cancer slightly HIGHER and dismissed it for being negligible, with a risk difference rounding to zero [\[3\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-3). That reasoning is right, and [applied to the same study’s benefits it makes those real and small rather than transformative](https://thisglp.com/research/glp1-liver-cancer-signal-dismissed). Most reviews end by telling you which option is best. This one ends by explaining why it will not, and the explanation is more useful than a ranking would have been. ## What was measured Eleven randomized trials in Asian study settings, in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease, all adding a study drug to comparable background glucose-lowering therapy. [\[1\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-1) 692 participants were randomized into eligible comparisons and 642 entered the coprimary analyses. The coprimary outcomes were change in ALT, a liver enzyme, and change in HbA1c. Adding a GLP-1 reduced ALT by 6.71 U/L, 95% CI −11.53 to −1.89, graded moderate certainty. It reduced HbA1c by 0.48 percentage points, 95% CI −0.83 to −0.14, graded low certainty. Adding an SGLT2 inhibitor reduced ALT by 7.56 U/L, 95% CI −11.24 to −3.88, at moderate certainty, with little or no clinically important further effect on HbA1c. ALT is a blood test, not a liver Alanine aminotransferase is an enzyme that leaks from damaged liver cells, so it tracks injury loosely and imperfectly. A fall of about 7 units is a change in a number. Whether it corresponds to less scarring, fewer people progressing to cirrhosis, or anybody living longer is what short trials with surrogate endpoints are least able to answer. This is also the same disease where an approved treatment [is defined by a fibrosis stage](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease), not by an enzyme. ## Where the endpoint was the liver itself A separate 2025 meta-analysis went past the enzyme to the tissue, pooling 13 phase 2 and phase 3 trials with 1,811 participants, four of which diagnosed the disease by biopsy and nine by MRI [\[4\]](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver#ref-4). In people with steatohepatitis and moderate to advanced fibrosis, GLP-1 drugs beat placebo at resolving the inflammation, an odds ratio of 3.48 across three trials. They also beat it at improving fibrosis, at 1.79, and the authors single out semaglutide 2.4 mg a week among the drugs tested. The same paper marks where the benefit stopped. In the one trial of people whose disease had already reached compensated cirrhosis, semaglutide did not resolve the steatohepatitis or improve fibrosis against placebo, and the authors say the effect on liver-related events over the long term still needs study. ## Two grades for one drug Notice that the GLP-1 estimates carry different certainty ratings. Moderate for the liver enzyme, low for the blood sugar measure. That is not an inconsistency; it reflects how many trials contributed to each comparison, how consistent they were, and how precise the pooled estimate is. A summary that reported both numbers without both grades would treat them as equally settled. They are not, and the authors went to the trouble of grading them separately — which is the sort of distinction [a pooled figure usually hides](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## The three refusals First, no class ranking. The authors state the available evidence does not support ranking SGLT2 inhibitors, GLP-1 agonists and pioglitazone against one another — several comparisons rested on sparse evidence, and the two classes were not tested head to head. Second, no claim about durability or clinical significance. Follow-up was short and the endpoints were surrogates, so the paper says both of those remain uncertain rather than projecting forward. Third, and most striking: comparative safety could not be assessed reliably, because adverse-event reporting across the trials was heterogeneous and incomplete. Eleven randomized trials, and the authors could not compare how safe the drugs were relative to each other. That is a statement about the literature rather than about the drugs, and it is the kind of thing that never survives into a summary. ## Why a refusal is worth reading Because the demand for rankings is what produces bad ones. A reader wants to know which drug to take, and a marketer wants to say theirs. A review that declines to answer is doing the harder and more honest thing — [a comparison nobody ran](https://thisglp.com/research/do-glp1-drugs-cause-gout) cannot be reconstructed from two separate ones. The practical version for anybody reading a claim about these drugs and the liver: ask which endpoint moved, how certain the authors were, and whether they compared the drug to the alternative or only to background care. Almost nothing published by a seller answers any of the three, which [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) measures from the other end. ## Frequently asked Do these drugs improve fatty liver disease? They lowered ALT, a liver enzyme, by about 6.71 U/L at moderate certainty in these trials. Whether that corresponds to less scarring or better long-term outcomes is what the authors say remains uncertain. Do GLP-1 drugs reverse liver scarring? In people with steatohepatitis and moderate to advanced fibrosis, a meta-analysis of randomized trials found fibrosis improved more often than on placebo, at an odds ratio of 1.79. In the one trial of compensated cirrhosis, semaglutide did not improve fibrosis. Which drug class is best for this? The authors decline to say, stating that the available evidence does not support a treatment-class ranking. The classes were not compared head to head and several comparisons rested on sparse evidence. Why do the two GLP-1 results have different certainty grades? Moderate for ALT and low for HbA1c. Certainty reflects how many trials contributed, how consistent they were and how precise the estimate is, so two findings from the same review can deserve different confidence. What about side effects? The review could not assess comparative safety, because adverse-event reporting across the eleven trials was heterogeneous and incomplete. ## Sources 1. \[1\] Zheng H, et al. (2026). Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis Frontiers in Endocrinology. [PMID 42745769](https://pubmed.ncbi.nlm.nih.gov/42745769/) 2. \[2\] Hernández-Pérez JG, et al. (2026). Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation Hepatology International. [PMID 42584814](https://pubmed.ncbi.nlm.nih.gov/42584814/) 3. \[3\] Khan SA, et al. (2026). Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study Medicine (Baltimore). [PMID 42736811](https://pubmed.ncbi.nlm.nih.gov/42736811/) 4. \[4\] Mantovani A, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials Liver International. [PMID 40736113](https://pubmed.ncbi.nlm.nih.gov/40736113/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Are GLP-1 Drugs Safe for Older Adults? Seven Trials, and Who They Left Out Are GLP-1 drugs safe for older adults? Seven pooled tirzepatide trials, 17,604 SELECT participants by frailty, and the body composition question nobody measured. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Are GLP-1 Drugs Safe for Older Adults? Seven Trials, and Who They Left Out Pooled across seven tirzepatide trials, adults 65 and over showed no clinically meaningful difference from placebo on falls, fractures or tolerability. Everyone in them had qualified for a phase 3 trial. [This GLP Editorial Team](https://thisglp.com/about)September 202610 min read Checked in adults 65+, none differed from placebo · stomach tolerability · falls · fractures · depression · pancreatitis · kidney, liver, gallbladder · In people well enough to enter a phase 3 trial. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). In the older people trials actually enroll, yes. A post hoc analysis pooled safety across seven tirzepatide trials and found no clinically meaningful difference against placebo in adults aged 65 and over for gastrointestinal tolerability, falls, fractures, depression, pancreatitis, or renal, hepatic, gallbladder and biliary events [\[1\]](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults#ref-1). Across 17,604 SELECT participants sorted by a 31-item frailty index, the cardiovascular benefit did not differ by frailty, and the odds of improving a frailty category by week 104 were 2.46 times higher on semaglutide than on placebo [\[2\]](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults#ref-2). Every one of those people had qualified for a phase 3 trial, which excludes most of what makes prescribing to an older patient difficult in the first place. ## Key takeaways - A post hoc analysis pooled safety data and compared efficacy across seven tirzepatide trials, splitting participants at age 65. - Weight reduction and cardiometabolic and quality-of-life results in adults 65 and over were described as broadly comparable to those under 65. - No clinically meaningful differences appeared between tirzepatide and placebo in older adults for gastrointestinal tolerability, falls, fractures, depression, pancreatitis, or renal, hepatic, gallbladder and biliary events. - In 17,604 SELECT participants, the cardiovascular effect did not vary by frailty (P = .09 for interaction), and discontinuation for adverse events was relatively lower at higher frailty. - In 1,145 STEP-HFpEF participants, weight loss was identical across frailty strata and the symptom benefit was not — the most frail gained 11.0 points. - Everyone analyzed had qualified for a phase 3 obesity trial, which excludes much of what makes prescribing to older adults difficult. Age is one of the commonest reasons a clinician hesitates over these drugs, and the evidence behind that hesitation has been thin in both directions. A post hoc analysis worked through the SURMOUNT trials, including the three-year extension, along with SURMOUNT-OSA and SUMMIT, comparing participants aged 65 and over against those under 65 [\[1\]](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults#ref-1). The related question of whether frailty changes that answer is taken up in [the frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer). The efficacy conclusion is that older participants did about as well as younger ones on weight, on cardiometabolic risk factors and on quality of life. No pooled number is attached to that: efficacy was analyzed study by study at whatever timepoint each trial used, so “broadly comparable” is the finding and there is no single figure to quote. The safety list is more useful than the summary, because it shows what was actually examined. Gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and renal, hepatic, gallbladder and biliary adverse events were each checked in the older group against placebo, and none showed a clinically meaningful difference. Falls and fractures appearing on that list matters, since those are the specific fears that attach to rapid weight loss in older people. Trial older adults are not clinic older adults Everyone in this analysis had qualified for and entered a phase 3 obesity trial. Those trials exclude recent cardiovascular events, significant organ impairment, cognitive problems and limited mobility. What the analysis establishes is that the drug behaved normally in relatively well 65-to-75-year-olds — which is a real finding, and close to the opposite of the population a geriatrician is worried about when they hesitate. ## What frailty did, in the largest sample that measured it A secondary analysis of SELECT built a 31-item frailty index across 17,604 adults with established cardiovascular disease and no diabetes [\[2\]](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults#ref-2). Thirty-one percent scored at or below 0.210, 47% between 0.211 and 0.310, and 22% at 0.311 or above. The treatment effect on major cardiovascular events did not track frailty, with the test for interaction at P = .09. Two results there carry more weight than any subgroup slice. Benefit on the EQ-5D-5L quality of life score was larger at higher frailty, interaction P = .02. And frailty was not fixed: participants on semaglutide were more likely to improve a frailty category by week 104 (OR 2.46, 95% CI 1.80 to 3.37) and less likely to worsen one (OR 0.47, 95% CI 0.34 to 0.65). The tolerability result runs against the intuition that drives the caution. Adverse events leading to permanent discontinuation were relatively lower, not higher, among participants with greater baseline frailty (P < .001 for interaction). The full reading, including why the three subgroup hazard ratios should not be compared against each other, is in [the SELECT frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer). ## The one trial where frailty changed the answer A prespecified pooled analysis of the two STEP-HFpEF trials sorted 1,145 participants by a cumulative-deficit frailty index, and most of them were frail: 692 people, 60.4%, fell in the most-frail group and only 110 were nonfrail [\[3\]](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults#ref-3). Weight loss was similar across every stratum, with a P value for interaction of 0.38. The symptom benefit was not similar at all. In the most frail the mean difference against placebo at 52 weeks was 11.0 points, 95% CI 8.1 to 13.8, with P for interaction below 0.001. In the nonfrail group it was −1.5, on an interval from −8.4 to 5.4, which demonstrates nothing in either direction on 110 people. The people who improved most were the ones in the worst shape at the start, which is set out in [the heart failure frailty analysis](https://thisglp.com/research/glp1-heart-failure-frailty). ## What none of these analyses measured Body composition over years, in an age group already losing muscle without any drug. Trials measured weight, and sarcopenia develops across years rather than appearing as a listed adverse event. The best-controlled body composition figure available comes from 101 adults over 24 weeks, where semaglutide changed lean body mass by −2.5 kg against placebo on an interval running from −6.6 to 1.6 [\[4\]](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults#ref-4). An interval that wide includes no change at all, and some of what a scan records as lost lean mass is fluid rather than muscle. Nothing there supports a claim that these drugs spare muscle, and nothing supports a claim that they destroy it. What it supports is measuring, and the full state of that question is in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1) and in [what comes back afterward](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). ## Where the evidence stops That boundary is where observational data has to take over, with its own weaknesses. A cohort can include the frail and the very old in a way a trial never will, at the cost of never knowing who was chosen for treatment and why. That trade-off is visible in [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute) and in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). For someone over 65 buying online, the practical gap is not the evidence. It is that an intake form cannot see mobility, cognition or the rest of a medication list, and a reassuring safety list drawn from trial participants should not be read as a complete one. What a seller asks before shipping, and who reviews the answers, is counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## Frequently asked Are GLP-1 drugs safe for older adults? In trial participants aged 65 and over, pooled safety across seven tirzepatide trials showed no clinically meaningful difference from placebo on gastrointestinal tolerability, falls, fractures, depression, pancreatitis or organ events. Do they work as well after 65? Weight, cardiometabolic risk factors and quality of life were described as broadly comparable to those under 65. Efficacy was analyzed study by study, so no single pooled figure exists to quote. Should frailty rule someone out? In 17,604 SELECT participants the cardiovascular benefit did not vary by frailty, and discontinuation for adverse events was relatively lower at higher frailty. Participants on semaglutide were 2.46 times more likely to improve a frailty category. What about muscle loss in older people? Nobody has measured it over the years that matter. The best-controlled figure, from 101 adults over 24 weeks, put the lean mass change at -2.5 kg on an interval from -6.6 to 1.6, which includes no change at all. Do these results describe an ordinary 75-year-old? Not closely. Phase 3 obesity trials exclude recent cardiovascular events, significant organ impairment, cognitive problems and limited mobility, which is most of what makes prescribing to an older patient difficult. ## Sources 1. \[1\] Alfaris N, Kushner RF, Li J, Chen KL, Fenimore M, Calderon B, Stefanski A (2026). Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials Diabetes, Obesity & Metabolism. [PMID 42303274](https://pubmed.ncbi.nlm.nih.gov/42303274/) 2. \[2\] Ostrominski JW, Plutzky J, Scirica BM, Hovingh GK, et al. (2026). Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial JAMA Cardiology. [PMID 42747817](https://pubmed.ncbi.nlm.nih.gov/42747817/) 3. \[3\] Pandey A, et al. (2025). Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program JACC: Heart Failure. [PMID 40956259](https://pubmed.ncbi.nlm.nih.gov/40956259/) 4. \[4\] Heerspink HJL, Soler M, Beernink JM, et al. (2026). Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial Clinical Journal of the American Society of Nephrology. [PMID 42308057](https://pubmed.ncbi.nlm.nih.gov/42308057/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Are GLP-1 Drugs Safe for Teens? The Trials, and What Is Outside Them | This GLP STEP TEENS randomized 201 adolescents to semaglutide 2.4 mg or placebo: mean BMI fell 16.1% against a 0.6% rise, with 73% versus 18% reaching 5% weight loss. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/are-glp1-drugs-safe-for-teens Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # Are GLP-1 Drugs Safe for Teens? The Trials, and What Is Outside Them A 16.1 percent BMI reduction over 68 weeks, and 73 percent reaching five percent weight loss. The endpoint is BMI, not weight, and five participants developed gallstones. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Mean BMI change at 68 weeks · Semaglutide 2.4 mg · −16.1% · Placebo · +0.6% · Reaching 5% weight loss: · 73% on drug · 18% on placebo **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). On the trial evidence they work, and the safety picture is thinner than the efficacy one. STEP TEENS randomized 201 participants aged 12 to under 18 with obesity, two to one, semaglutide 2.4 mg against placebo for 68 weeks, both arms receiving lifestyle intervention. One trial is not the evidence base. A systematic review and meta-analysis pooled every randomized trial in children and adolescents with obesity or type 2 diabetes [\[2\]](https://thisglp.com/research/are-glp1-drugs-safe-for-teens#ref-2), which is [the whole picture rather than the famous study](https://thisglp.com/research/glp1-in-children-all-eighteen-trials). On the psychiatric question specifically, an adolescent analysis found that the answer changed with the comparator [\[3\]](https://thisglp.com/research/are-glp1-drugs-safe-for-teens#ref-3) — two comparators produced [two different answers](https://thisglp.com/research/glp1-adolescent-suicidality-comparators), which is a reason to read any single reassurance carefully. Prescribing has meanwhile moved below the ages STEP TEENS studied. Prescriptions to children aged 8 to 11 rose 310-fold between 2019 and 2026 [\[4\]](https://thisglp.com/research/are-glp1-drugs-safe-for-teens#ref-4), and [that age band](https://thisglp.com/research/glp1-prescriptions-to-young-children) has one randomized trial behind it, of a different drug. SCALE Kids assigned 82 children aged 6 to under 12 to daily liraglutide 3.0 mg or placebo for 56 weeks, both with lifestyle support [\[5\]](https://thisglp.com/research/are-glp1-drugs-safe-for-teens#ref-5). BMI fell 5.8 percent on liraglutide and rose 1.6 percent on placebo, a difference of 7.4 percentage points, and 46 percent of the children on the drug cut their BMI by at least 5 percent against 9 percent on placebo. Gastrointestinal events came with it, in 80 percent against 54 percent, and serious adverse events were reported in 12 percent against 8. That trial tested the daily injection sold as Saxenda, and its results do not transfer automatically to the weekly drugs now being written for the same children. Adolescent prescribing is where this drug class gets least comfortable and least studied, and STEP TEENS is the trial people are arguing about. It randomized 201 participants aged 12 to under 18 with obesity, two to one, to semaglutide 2.4 mg or placebo for 68 weeks, both arms receiving lifestyle intervention [\[1\]](https://thisglp.com/research/are-glp1-drugs-safe-for-teens#ref-1). Ninety percent completed treatment. The effect is the largest in the literature for this age group, and the way it is measured is worth reading closely before it reaches [a purchasing decision](https://thisglp.com/best). ## What the trial measured The primary endpoint was the percentage change in BMI, not in body weight. Mean BMI fell 16.1 percent on semaglutide and rose 0.6 percent on placebo, an estimated difference of 16.7 percentage points (95% CI −20.3 to −13.2, P < 0.001). In a population still growing in height, BMI change and weight change are different quantities, and the trial chose the one that accounts for growth. The confirmatory secondary endpoint was weight loss of at least 5 percent. That was reached by 95 of 131 participants on semaglutide reached it, against 11 of 62 on placebo — 73 percent against 18 percent, an odds ratio of 14.0 (95% CI 6.3 to 31.0). Waist circumference, glycated hemoglobin, lipids other than HDL, and alanine aminotransferase all improved more on the drug. ## What it cost Gastrointestinal adverse events occurred in 62 percent on semaglutide against 42 percent on placebo. Serious adverse events were reported in 15 of 133 on the drug and 6 of 67 on placebo, 11 percent against 9. Five participants on semaglutide developed gallstones and none on placebo did. Five of 133 is a small number and it points the same way as the much larger [gallbladder meta-analysis](https://thisglp.com/research/glp1-and-gallbladder-disease), whose weight-loss subgroup carried nearly double the pooled risk. In adolescents that finding has a longer horizon attached to it than it does in adults. ## What this does not settle Sixty-eight weeks is not adolescence. The trial says nothing about what happens over the years a 14-year-old has ahead of them, nothing about stopping, and nothing about bone accrual during growth — a question the [post-surgical body-composition data](https://thisglp.com/research/glp1-after-bariatric-surgery) raises in adults with far less at stake. One practical note for anyone reading this as a parent. Adolescent prescribing is a specialist decision, and almost none of the telehealth sellers tracked here publish anything about age criteria, pediatric oversight or who reviews a case — the gap counted in [the disclosure census](https://thisglp.com/tools/what-sellers-publish). That absence is the relevant fact here, more than any figure in the trial. ## Frequently asked How much weight did adolescents lose? The primary endpoint was BMI, which fell 16.1 percent against a 0.6 percent rise on placebo. On the weight endpoint, 73 percent reached at least 5 percent loss against 18 percent on placebo. Why measure BMI rather than weight? Because adolescents are still growing in height, so BMI change accounts for growth in a way weight change does not. The two are different quantities in this population. What were the harms? Gastrointestinal events in 62 percent against 42 on placebo, serious adverse events in 11 percent against 9, and gallstones in five of 133 participants on the drug against none on placebo. Has a GLP-1 been tested in children under 12? Yes, in one randomized trial. SCALE Kids assigned 82 children aged 6 to under 12 to daily liraglutide or placebo for 56 weeks: BMI fell 5.8 percent on the drug and rose 1.6 percent on placebo, and gastrointestinal events occurred in 80 percent against 54 percent. ## Sources 1. \[1\] Weghuber D, et al. (2022). Once-Weekly Semaglutide in Adolescents with Obesity New England Journal of Medicine. [PMID 36322838](https://pubmed.ncbi.nlm.nih.gov/36322838/) 2. \[2\] Kotecha P, et al. (2025). Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis JAMA Pediatrics. [PMID 40952752](https://pubmed.ncbi.nlm.nih.gov/40952752/) 3. \[3\] Liu TH, et al. (2026). Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity Diabetes, Obesity and Metabolism. [PMID 42736027](https://pubmed.ncbi.nlm.nih.gov/42736027/) 4. \[4\] Orandi BJ, et al. (2026). Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026 Pediatrics. [PMID 42692477](https://pubmed.ncbi.nlm.nih.gov/42692477/) 5. \[5\] Fox CK, et al. (2025). Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial New England Journal of Medicine. [PMID 39258838](https://pubmed.ncbi.nlm.nih.gov/39258838/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Atrial Fibrillation Risk: GLP-1 vs SGLT-2 vs DPP-4 Inhibitors | This GLP A network meta-analysis of 2,171,267 patients found GLP-1 drugs no different from DPP-4 inhibitors on atrial fibrillation (RR 0.93), with SGLT-2 inhibitors ahead of both. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/atrial-fibrillation-the-other-drug-won Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Atrial Fibrillation Risk: GLP-1 vs SGLT-2 vs DPP-4 Inhibitors Across 2,171,267 patients, GLP-1 drugs showed no detectable advantage over DPP-4 inhibitors on atrial fibrillation. SGLT-2 inhibitors beat both, and nothing helped recurrence. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Atrial fibrillation risk · 1.0 · SGLT-2i vs GLP-1 · SGLT-2i vs DPP-4i · GLP-1 vs DPP-4i · The bottom row is the one about these drugs. It crosses the line. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A network meta-analysis of 4 randomized trials and 21 cohort studies, 2,171,267 patients, compared three diabetes drug classes on atrial fibrillation risk. - GLP-1 drugs were not significantly different from DPP-4 inhibitors, at a risk ratio of 0.93 (95% CI 0.84-1.03). - SGLT-2 inhibitors beat both — 0.86 (95% CI 0.79-0.95) against GLP-1 drugs and 0.80 (95% CI 0.74-0.87) against DPP-4 inhibitors. - For recurrence of atrial fibrillation in people who already have it, no class separated from any other. These drugs accumulate favorable cardiovascular findings steadily enough that it is worth marking where they do not. On atrial fibrillation, a network meta-analysis covering 2,171,267 patients across three drug classes puts them second [\[1\]](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won#ref-1). The heart failure picture, where the evidence runs the other way, is in [the heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure). Against DPP-4 inhibitors — the standard near-neutral comparator in diabetes research — GLP-1 drugs showed a risk ratio of 0.93 with a confidence interval of 0.84 to 1.03. That interval crosses 1, so the honest summary is no detectable difference. New-onset atrial fibrillation gave the same answer, at 0.93 (95% CI 0.83–1.04). SGLT-2 inhibitors separated from both. They beat GLP-1 drugs at 0.86 (95% CI 0.79–0.95) and DPP-4 inhibitors at 0.80 (95% CI 0.74–0.87), consistently across sensitivity analyses. For anyone whose main concern is atrial fibrillation specifically, this evidence points at a different drug class. For people who already have it, nothing separated Recurrence of atrial fibrillation showed no significant difference between any of the three classes, with every interval crossing 1. The question these comparisons answer is about developing the condition, not about managing it once present. The evidence grade deserves attention before the headcount does. Four randomized trials and 21 cohort studies means the bulk of that two million is observational, and a network meta-analysis compares treatments indirectly where trials did not test them against each other. Large numbers of observational patients do not substitute for randomization, and the confidence intervals here reflect statistical precision rather than freedom from bias — the same distinction that governs [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute). None of this argues against taking a GLP-1 drug. It argues against a particular kind of reasoning, in which a drug with real cardiovascular benefits is assumed to have every cardiovascular benefit. The benefits that do hold up are specific, and so are the absences, which is the same pattern visible in [the rheumatoid arthritis cohort](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis) where one component of a composite moved and three did not, and in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). ## Frequently asked Do GLP-1 drugs reduce atrial fibrillation risk? Not detectably in this analysis. Against DPP-4 inhibitors the risk ratio was 0.93 with an interval from 0.84 to 1.03, which crosses no difference. Which class did best? SGLT-2 inhibitors, which were associated with lower atrial fibrillation risk than both GLP-1 drugs (0.86) and DPP-4 inhibitors (0.80). What if I already have atrial fibrillation? Nothing here distinguishes the three classes on recurrence. Every comparison for recurrence had an interval crossing no difference. ## Sources 1. \[1\] Ye X, Wu Q, Hou L, Hou X, Yang Y, Yang C, Huang M, Wang S (2026). Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus Diabetes/Metabolism Research and Reviews. [PMID 42455922](https://pubmed.ncbi.nlm.nih.gov/42455922/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Bariatric Surgery vs GLP-1 Drugs on Cardiovascular Events | This GLP A network meta-analysis put bariatric surgery at 0.66 for major cardiovascular events against 0.85 for GLP-1 drugs, pooling studies from 2000 to 2024. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/bariatric-surgery-vs-glp1-cardiovascular Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Bariatric Surgery vs GLP-1 Drugs on Cardiovascular Events Bariatric surgery beat GLP-1 drugs on every cardiovascular outcome in a 932,380-patient analysis. The drug side pools studies going back to 2000. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Against controls — surgery above, GLP-1 below · major CV events · heart failure · not significant for GLP-1 · heart attack · not significant for GLP-1 · 43 studies, 932,380 patients, heterogeneity 66% to 93%. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A network meta-analysis of 43 studies and 932,380 patients comparing bariatric surgery and GLP-1 drugs. - Surgery against controls: major cardiovascular events 0.66, heart failure 0.45, heart attack 0.53. - GLP-1 drugs against controls: major cardiovascular events 0.85, 95% CI 0.77 to 0.94. - GLP-1 drugs did not reach significance for heart failure or heart attack. - The search ran from 2000 to 2024, and the authors ask for studies on newer GLP-1 drugs. The comparison is arresting and the date range is the part to read first. This pools studies published between January 2000 and September 2024, which means most of the drug side of it is exenatide, liraglutide and dulaglutide rather than what people take now — the same problem as [reading an older trial as evidence about a newer molecule](https://thisglp.com/research/semaglutide-cochrane-review). ## What the pooled figures say Bariatric surgery was associated with lower major adverse cardiovascular events, hazard ratio 0.66, 95% CI 0.60 to 0.74; lower heart failure, 0.45, 95% CI 0.38 to 0.53; and lower myocardial infarction, 0.53, 95% CI 0.45 to 0.63. [\[1\]](https://thisglp.com/research/bariatric-surgery-vs-glp1-cardiovascular#ref-1) GLP-1 drugs reduced major cardiovascular events, 0.85, 95% CI 0.77 to 0.94, and did not reach significance for heart failure or heart attack. Heterogeneity ran from 66% to 93%, which the authors flag themselves while noting the direction was consistent across studies — a spread that puts the pooled numbers closer to [a summary of disagreement](https://thisglp.com/research/glp1-weight-loss-pooled-average) than to a single estimate. Which GLP-1 drugs, and when A study published in 2012 is not evidence about semaglutide, and a cardiovascular literature reaching back to 2000 is dominated by agents that are substantially weaker on weight and were tested in different populations. The authors close by asking for future studies on newer GLP-1 drugs, which is an acknowledgment that the arm they pooled is not the current class. Whatever the drug side of this comparison measures, it is not a measurement of what a person starting today would take. ## The other half of the comparison Bariatric surgery has an eligibility process in front of it. Somebody has to be considered suitable, pass an anesthetic assessment, and be well enough to be operated on, and that selection happens before any outcome is counted. A network meta-analysis links the two arms largely through their shared comparison with controls rather than through head-to-head studies, so what is being compared is partly two different groups of people — which is the standing limit of [evidence assembled indirectly](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery). ## What the drug arm does establish A real reduction in major adverse cardiovascular events, at 0.85 with an interval clear of one, in a pooled population of that size. Not reaching significance on heart failure and heart attack is not the same as showing no effect on them, and with heterogeneity in this range the pooled estimates carry less than their intervals suggest. The authors’ own framing — GLP-1 drugs as an evidence-based option for people who are not surgical candidates — is the reasonable reading, and it is a clinical decision rather than [a ranking anyone shops from](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). ## Frequently asked Is bariatric surgery better than GLP-1 drugs for the heart? In this pooled analysis surgery showed larger and more consistent reductions. The drug arm pools studies back to 2000, so it is largely older GLP-1 agents rather than current ones. What did GLP-1 drugs achieve? A reduction in major adverse cardiovascular events, hazard ratio 0.85, 95% CI 0.77 to 0.94. They did not reach significance for heart failure or myocardial infarction. Were the two groups comparable? Not directly. Surgery candidates pass an eligibility and anesthetic assessment first, and the analysis links the arms largely through their shared comparison with controls. How consistent were the studies? Heterogeneity ran from 66% to 93%. The authors report directional consistency and ask for cautious interpretation. ## Sources 1. \[1\] Shirmohammadi E, et al. (2026). Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis Endocrinology, Diabetes & Metabolism. [PMID 42700367](https://pubmed.ncbi.nlm.nih.gov/42700367/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide vs Semaglutide for Heart Failure, With and Without Diabetes | This GLP A 217,920-person emulation found tirzepatide ahead of semaglutide on heart failure — relative risk 0.60 without diabetes against 0.82 with, but absolute differences of 0.9% and 1.5%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/bigger-relative-smaller-absolute Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Tirzepatide vs Semaglutide for Heart Failure, With and Without Diabetes In 217,920 matched adults, tirzepatide's heart failure risk ratio favored people without diabetes while the absolute risk difference favored people with it. Both come from the same table. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Heart failure at one year, tirzepatide vs semaglutide · risk ratio · absolute difference · with diabetes · 0.82 · 1.5% · without diabetes · 0.60 · 0.9% · Shorter bar wins on the left. Longer bar wins on the right. · They disagree about which group benefits more. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A target trial emulation matched 217,920 adults starting semaglutide or tirzepatide, splitting them by diabetes status: 48,507 pairs with, 60,453 pairs without. - Tirzepatide was associated with lower risk across every outcome measured at one and three years. - For heart failure at one year, the risk ratio was 0.82 with diabetes and 0.60 without — but the absolute risk differences were 1.5% and 0.9% respectively. - The relative figure favors the group without diabetes and the absolute figure favors the group with it. Both are correct. No trial has randomized semaglutide against tirzepatide on cardiovascular outcomes, so the comparison runs on claims data. A target trial emulation matched 217,920 adults starting one or the other and followed them for up to three years, reporting atrial fibrillation, heart failure and myocardial infarction as primary outcomes [\[1\]](https://thisglp.com/research/bigger-relative-smaller-absolute#ref-1). The same two drugs on a different endpoint are compared in [the liver comparison](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). Tirzepatide came out ahead on every outcome at both time points, and the associations strengthened over the three years. That is the finding most summaries will report, and taken at face value it is a straightforward win. One result, two numbers, opposite conclusions Heart failure at one year gave a risk ratio of 0.82 in people with diabetes and 0.60 in people without. Read relatively, the benefit is far larger for people without diabetes. The risk differences were 1.5 percentage points and 0.9 points respectively — read absolutely, the benefit is larger for people with diabetes. Nothing is contradictory here: a 40% reduction in a small risk removes fewer events than an 18% reduction in a large one. But a reader who meets only the 0.60 will draw the opposite conclusion from one who meets only the 1.5%. That asymmetry is worth internalizing because it recurs throughout this literature. Baseline risk determines how much a relative reduction is worth, which is why the same drug can look transformative in a high-risk population and marginal in a healthy one while behaving identically in both. The interaction tests here were significant for atrial fibrillation (P = 0.003), heart failure (P < 0.001) and myocardial infarction (P = 0.019), so the difference between the groups is not noise. The design carries the limitation that matters most. These are two drugs that entered the market at different times and get prescribed to different people for reasons a claims database records only partially, so the comparison is vulnerable to who was chosen for what rather than to what the drugs did. Propensity matching on recorded characteristics narrows that without closing it, the same caveat that applies to [the glaucoma comparison](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma) and [the carpal tunnel cohort](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome), both of which also found tirzepatide ahead of its class on an unexpected endpoint. Read alongside the randomized evidence on weight in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated), the picture is consistent in direction and much weaker in quality here. A pattern of tirzepatide outperforming across several unrelated outcomes could reflect a genuinely more effective drug, or it could reflect who gets prescribed the newer and more expensive option. ## Frequently asked Is tirzepatide better than semaglutide for the heart? This study found it associated with lower risk across every outcome, but it is observational rather than randomized. No trial has compared the two drugs head to head on cardiovascular outcomes. Why do the two heart failure numbers disagree? They measure different things. A risk ratio of 0.60 means a 40% relative reduction; a risk difference of 0.9% means fewer than one event avoided per hundred people. A large relative cut in a small risk prevents fewer events than a modest cut in a large one. Does diabetes status change the benefit? The interaction tests were significant for atrial fibrillation, heart failure and myocardial infarction, so yes — but which group benefits more depends on whether you read the relative or the absolute figures. ## Sources 1. \[1\] Azzam AY, Essibayi MA, Rai P, Salim HA, et al. (2026). Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation JACC: Advances. [PMID 42489387](https://pubmed.ncbi.nlm.nih.gov/42489387/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can a Drug Prevent Muscle Loss on a GLP-1? Two Antibodies Tested | This GLP No approved drug prevents muscle loss on a GLP-1 | apitegromab kept 1.9 kg of lean mass on tirzepatide, bimagrumab added 1.70 kg, and no trial measured strength. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1 Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can a Drug Prevent Muscle Loss on a GLP-1? Two Antibodies Tested Not outside a trial. Apitegromab kept 1.9 kg more lean mass on tirzepatide without slowing weight loss, and bimagrumab added lean mass on its own. Neither is approved, and nobody measured strength. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Week 24, both arms on tirzepatide · 1.9 kg less lean mass lost · 80% CI 1.2 to 2.7 — an 80% interval, not 95% · Total weight lost: similar in both arms. · Strength or physical function: not measured. · 102 participants · phase 2 · investigational, not on sale **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - No drug to prevent muscle loss is approved or on sale. Two investigational antibodies have been tested in phase 2 trials. - Apitegromab, added to tirzepatide in 102 adults, left 1.9 kg less lean mass lost than placebo at 24 weeks (80% CI 1.2-2.7), with similar total weight loss. - Bimagrumab, given alone to 75 adults with type 2 diabetes, raised lean mass 1.70 kg and cut fat mass 7.5 kg over 48 weeks. - Bimagrumab plus semaglutide 2.4 mg took off 17.8 kg at 48 weeks against 14.2 kg on semaglutide alone, in a 507-person trial. - None of these trials reports strength or physical function. Lean mass on a scan is a compartment, not an ability. Not yet, outside a trial. The closest result so far comes from apitegromab, an antibody given with tirzepatide to 102 adults. At 24 weeks it left 1.9 kg less lean mass lost than placebo, and total weight loss was similar in both arms [\[1\]](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1#ref-1). A second antibody, bimagrumab, has two phase 2 trials behind it [\[2\]](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1#ref-2) [\[3\]](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1#ref-3). Neither drug is approved, and neither can be bought. The problem both are aimed at is real. Lean mass is lost in proportion to total weight on drugs such as tirzepatide [\[1\]](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1#ref-1). The [muscle loss guide](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1) sets out how much goes and what comes back after stopping. The approaches with evidence today are protein and resistance training. A drug would be a third option, and a second prescription. ## Apitegromab: lean mass kept, weight loss unchanged Apitegromab blocks the activation of myostatin, the signal that limits how much muscle the body builds. In the EMBRAZE trial, adults with overweight or obesity all took tirzepatide and were randomized 1:1 to add apitegromab or placebo [\[1\]](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1#ref-1). At week 24 the apitegromab group had lost 1.9 kg less lean mass than placebo (P = 0.001). The authors describe that as retaining 54.9% of the lean mass that would otherwise have gone. The part that mattered most was the weight. Total weight loss was similar between the arms, so the lean mass was retained without blunting what tirzepatide took off. Adverse events ran 39 of 51 on apitegromab against 36 of 51 on placebo. The authors call it a proof-of-concept study, and 51 people per arm over 24 weeks can only detect common problems. That interval is 80%, not 95% The figure is reported as 1.9 kg with an 80% confidence interval of 1.2 to 2.7. An 80% interval is considerably narrower than the 95% interval used almost everywhere else. It is a phase 2 convention that reduces the number of participants a trial needs, and it is declared in the paper. A 95% interval on the same data would be wider on both sides. The bimagrumab trial below reports its body-composition figures the same way. ## Bimagrumab: fat down, lean mass up, and then a combination Bimagrumab blocks a different target, the activin type II receptor, and blocking that signal stimulates skeletal muscle growth. The first trial gave it alone, with no GLP-1, to 75 adults with type 2 diabetes and a BMI of 28 to 40 [\[3\]](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1#ref-3). After 48 weeks of monthly infusions, fat mass fell 20.5% (−7.5 kg) against 0.5% on placebo. Lean mass rose 3.6% (1.70 kg, 80% CI 1.1 to 2.3) against a 0.8% fall on placebo, and body weight fell 6.5%. That is a gain in lean mass while weight fell. Two limits sit beside it. Only 58 of the 75 completed the 48 weeks, and only participants who completed the full regimen were analyzed. Every interval is again 80%. The larger BELIEVE trial then paired bimagrumab with semaglutide [\[2\]](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1#ref-2). It randomized 507 adults with obesity across nine groups for 48 weeks. Body weight fell 9.3 kg on the higher bimagrumab dose alone, 14.2 kg on semaglutide 2.4 mg alone, and 17.8 kg on the high-dose combination, against 3.3 kg on placebo. Its primary endpoint was weight, not lean mass, so it answers whether the two drugs add up on the scale. They did. Muscle spasms, diarrhea and acne were the common side effects of bimagrumab. ## What none of these trials measured Lean mass on a DXA scan includes organs and body water alongside skeletal muscle. None of the three trials reports grip strength, walking speed or any measure of physical function. What was preserved is a compartment on a scan, not a demonstrated ability to lift or carry anything. The same gap runs through the field, as [the grip strength evidence](https://thisglp.com/research/semaglutide-muscle-mass-and-grip) shows: mass and strength do not always move together. The people most likely to need a muscle-sparing drug are older adults, and the trade-offs for them are set out in [the analysis in older adults](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults). For now the practical answer has not changed, and it starts with food: [how much less people eat](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1) shows the size of that fall. The broader case on muscle is in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). ## Frequently asked Is there a drug to prevent muscle loss on a GLP-1? Not one that is approved or on sale. Apitegromab and bimagrumab are investigational antibodies that have been tested in phase 2 trials. Protein intake and resistance training remain the approaches with evidence behind them. How much muscle did apitegromab save? In 102 adults on tirzepatide, the apitegromab group lost 1.9 kg less lean mass than placebo at 24 weeks, with an 80% confidence interval of 1.2 to 2.7 kg. Total weight loss was similar in both groups. Does bimagrumab work with semaglutide? On weight, yes. In a 507-person trial the combination took off 17.8 kg at 48 weeks against 14.2 kg on semaglutide 2.4 mg alone and 3.3 kg on placebo. That trial's primary endpoint was body weight rather than lean mass. Did either drug preserve strength? Unknown. The trials measured lean mass on a scan, which includes organs and body water, and reported no grip strength, walking speed or physical function outcome. ## Sources 1. \[1\] Pratley RE, Denham DS, Trivedi R, Watkins E, et al. (2026). Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Nature Medicine. [PMID 42260100](https://pubmed.ncbi.nlm.nih.gov/42260100/) 2. \[2\] Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, et al. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial Nature Medicine. [PMID 41772149](https://pubmed.ncbi.nlm.nih.gov/41772149/) 3. \[3\] Heymsfield SB, Coleman LA, Miller R, Rooks DS, et al. (2021). Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial JAMA Network Open. [PMID 33439265](https://pubmed.ncbi.nlm.nih.gov/33439265/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can a GLP-1 Cause Ketoacidosis? 470 Reports, Most of Them Hospitalized | This GLP Can a GLP-1 cause ketoacidosis? Reporting ratios of 3.15 and 1.22 across 470 cases in people without diabetes, over 70% hospitalized, and why none of it is a rate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-a-glp1-cause-ketoacidosis Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Can a GLP-1 Cause Ketoacidosis? 470 Reports, Most of Them Hospitalized Two drugs, 470 reported cases, and hospitalization in roughly three quarters of them. The database cannot say how often it happens. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Ketoacidosis reports, people without diabetes · semaglutide · 261 cases · 3.15 · tirzepatide · 209 cases · 1.22 · Hospitalization required: 74.3% and 71.3% of cases. · No denominator. This measures reporting, not risk. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). It has been reported, including in people who do not have diabetes. A disproportionality analysis covered 7,349,591 FDA reports [\[1\]](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis#ref-1). Semaglutide gave a reporting odds ratio of 3.15, 95% CI 2.78 to 3.56, from 261 cases. Tirzepatide gave 1.22, 95% CI 1.06 to 1.39, from 209 cases. Hospitalization was required in 74.3% and 71.3% of them. A reporting ratio is not a rate. Nothing in that database counts how many people took the drug. In a supervised type 1 diabetes trial, two episodes of euglycemic ketosis were recorded [\[2\]](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis#ref-2). ## Key takeaways - A disproportionality analysis of 7,349,591 FDA adverse event reports looked at ketoacidosis in people using these drugs for obesity, without diabetes. - Semaglutide showed a reporting odds ratio of 3.15 (95% CI 2.78-3.56) from 261 cases; tirzepatide 1.22 (95% CI 1.06-1.39) from 209 cases. - Hospitalization was required in 74.3% and 71.3% of those cases respectively. - Tirzepatide reports rose from 1-2 per quarter in 2022 to 28-34 by 2025 — over the period its use expanded enormously. Ketoacidosis is a metabolic emergency normally associated with type 1 diabetes. It is not something expected in a person without diabetes at all. That makes it an unusual thing to find in the adverse event database for a weight drug. This analysis asks how often it is being reported [\[1\]](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis#ref-1). The wider safety profile these drugs carry in people without diabetes is surveyed in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). Both drugs produced a signal among non-diabetic users. Semaglutide had a reporting odds ratio of 3.15 (95% CI 2.78–3.56) across 261 cases, and tirzepatide 1.22 (95% CI 1.06–1.39) across 209. Roughly three quarters of the cases in each group required hospitalization. A reporting ratio is not a risk These figures describe how often a term appears among reports relative to other terms. There is no count of how many people took the drug, so no incidence can be calculated and no individual can be told their chance of this happening. Two hundred and sixty-one cases across a drug taken by millions is, on any plausible denominator, rare — and the database cannot say how rare. What lifts this above the usual pharmacovigilance caveats is the population and the severity. Ketoacidosis in someone without diabetes cannot be explained away by the underlying condition. In a diabetes cohort, most adverse events can be. And the hospitalization rate, above 70% in both groups, is a severity marker. Disproportionality analysis does not usually supply one, and these are not minor coded events. The rising trend is the part most likely to be misread. Tirzepatide reports went from one or two a quarter in 2022 to 28 to 34 a quarter by 2025. That sounds like a worsening problem. It spans precisely the period in which tirzepatide went from newly launched to one of the most prescribed drugs in the country. More users generate more reports. Nothing in this design separates a rising rate from a rising denominator, the same trap set out in [the reflux reporting study](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux). ## Where it sits in the wider report pile These reports are a small part of a large file. A multi-source pharmacovigilance mapping took 243,114 GLP-1 records where the drug was the primary suspect, covering 2021 to 2026 [\[3\]](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis#ref-3). Tirzepatide accounted for 133,100 of them, semaglutide 55,619 and dulaglutide 38,406. Frequently reported terms included incorrect dose administered, off-label use and extra dose administered. The authors call those use-process issues rather than adverse drug reactions. They also state that no source in the study estimates incidence, comparative risk or causality. That is the same limit that applies here, and it is counted in [the dose error records](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). ## The one setting where it was measured inside a trial Type 1 diabetes is the population where ketoacidosis is expected, and it is not an approved indication for any of these drugs. A crossover trial added semaglutide to automated insulin delivery [\[2\]](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis#ref-2). Time in range rose 4.8 percentage points without more hypoglycemia, and two episodes of euglycemic ketosis were recorded. Two events is a count, not a rate, but it came from supervised randomized follow-up rather than a spontaneous report. The rest of that evidence is in [the type 1 diabetes trials](https://thisglp.com/research/semaglutide-in-type-1-diabetes). The practical content is a symptom list rather than a probability. Persistent vomiting, abdominal pain, rapid breathing and confusion during a period of very low food intake are reasons to seek urgent care. Waiting is worse, particularly during dose escalation when intake falls fastest. That is the same window in which the nutritional problems in [the thiamine cases](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency) arose. It is described from the tolerability side in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## Frequently asked Can a GLP-1 cause ketoacidosis? It has been reported in people without diabetes, at a reporting odds ratio of 3.15 for semaglutide across 261 cases and 1.22 for tirzepatide across 209. Roughly three quarters of those cases required hospitalization. A reporting ratio cannot produce a probability for any individual. How likely is ketoacidosis on one of these drugs? This analysis cannot say. Reporting ratios have no denominator of people taking the drug, so they produce no incidence figure. The case counts are small relative to how many people take these medicines. Why does it matter that these people did not have diabetes? Ketoacidosis in someone without diabetes cannot be attributed to the underlying condition, which is the usual explanation when it appears in diabetes cohorts. Are tirzepatide reports rising because it is more dangerous? Not demonstrably. Reports rose from 1-2 to 28-34 per quarter between 2022 and 2025, over exactly the period its use expanded enormously. More users produce more reports. ## Sources 1. \[1\] Makhmutov A, Qureshi F (2026). Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System Cureus. [PMID 42299163](https://pubmed.ncbi.nlm.nih.gov/42299163/) 2. \[2\] Karakus KE, Akturk HK, Kruger D, Ahmann A, Bharvaga A, Langel CR (2026). Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis Diabetes Care. [PMID 41429002](https://pubmed.ncbi.nlm.nih.gov/41429002/) 3. \[3\] Ren L, et al. (2026). Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study Diabetes, Obesity and Metabolism. [PMID 42687799](https://pubmed.ncbi.nlm.nih.gov/42687799/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can a GLP-1 Cause Thiamine Deficiency? Six Cases Say It Can | This GLP A systematic review found six published cases of Wernicke's encephalopathy after semaglutide for obesity | all six preceded by prolonged GI symptoms and rapid weight loss. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Can a GLP-1 Cause Thiamine Deficiency? Six Cases Say It Can Every published case began the same way. Prolonged vomiting first. Then rapid weight loss. Then neurological signs. The first two stages are the ones a reader can act on. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read The sequence in all six cases · prolonged GI symptoms · rapid, substantial weight loss · altered mental status, · eye movement abnormalities · The first two are the warning. The last two are the emergency. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A systematic review identified six published cases of Wernicke's encephalopathy, a thiamine deficiency disorder, following semaglutide treatment for obesity. - All six had prolonged gastrointestinal symptoms and substantial weight loss before any neurological signs appeared. - Presentations included altered mental status and abnormal eye movements. Outcomes were poor in several cases, including progression to Korsakoff syndrome and death. - Six case reports cannot produce a rate. They establish that it happens, not how often. It can, and six published cases prove it happens. A systematic review searched four databases for Wernicke’s encephalopathy after semaglutide prescribed for obesity. It found six [\[1\]](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency#ref-1). Wernicke’s is what severe thiamine deficiency does to the brain. Thiamine is stored for a matter of weeks. That is short next to how long someone can spend eating very little and vomiting. The broader nutrient picture is in [vitamins and minerals on a GLP-1](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1). A narrative review sets the wider context [\[2\]](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency#ref-2). Thiamine is one of several micronutrients this drug class is associated with depleting. The route is reduced intake, not impaired absorption. A separate meta-analysis measured what happens to nutritional intake during treatment [\[3\]](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency#ref-3). Intake is the mechanism. The drug does not consume thiamine. The person stops eating enough of it. Six cases is not a frequency Millions of people take these drugs. Six published reports establish that this can happen and say nothing whatever about how often it does. Case reports have no denominator, and reaching publication requires a clinician to have recognized the syndrome, written it up, and had it accepted — a filter that removes most of what occurs. Nobody should read this as a common event, and nobody should read it as a reason to stop treatment. The reason it is worth a reader’s attention anyway is the shape of the sequence, which was the same in every case. Prolonged gastrointestinal symptoms came first. Substantial and rapid weight loss followed. Only then did neurological deterioration appear, presenting as altered mental status and abnormalities of eye movement. The first two stages are visible to the person experiencing them, which makes this a rare harm with an early warning attached. The outcomes are the reason not to soften any of this. Several cases did badly. One progressed to Korsakoff syndrome, an irreversible amnesic disorder. One ended in death. Wernicke’s is treatable. Treated early with parenteral thiamine, the damage is largely preventable. Left late, it is not. The practical translation is narrow. Persistent vomiting for weeks is not a side effect to push through. Neither is an inability to keep food down. Rapid weight loss on top of either compounds the problem rather than signaling success. That combination is a reason to contact a prescriber. The dose-escalation period is when it is most likely to arise, as [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) describes. Nothing here is an argument for taking a supplement on your own initiative. Deficiency severe enough to reach the brain is a clinical emergency. It is treated with injections under supervision. A tablet from a shelf does not address it once symptoms have started. The general problem underneath is eating much less while needing the same nutrients. It sits beside the muscle question in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). The broader tolerability picture is in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). ## Frequently asked How common is this? Unknown, and this review cannot establish it. Six published case reports have no denominator, so they show the event is possible without indicating any rate. What are the warning signs? In every case, prolonged gastrointestinal symptoms and substantial rapid weight loss came first, followed by confusion or altered mental state and abnormal eye movements. The later signs are a medical emergency. Should I take a thiamine supplement? That is a question for a prescriber, not something to start independently. Deficiency severe enough to affect the brain is treated with injections under medical supervision, and the useful action is reporting persistent vomiting rather than self-supplementing. ## Sources 1. \[1\] Bidesie J, Oudman E (2026). Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence Obesity (Silver Spring, Md.). [PMID 42399213](https://pubmed.ncbi.nlm.nih.gov/42399213/) 2. \[2\] Urbina J, et al. (2026). Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review Clinical Obesity. [PMID 41549912](https://pubmed.ncbi.nlm.nih.gov/41549912/) 3. \[3\] Quan AT, Nguyen HL, Nguyen TMT (2026). Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis Diabetes & Metabolic Syndrome. [PMID 42508090](https://pubmed.ncbi.nlm.nih.gov/42508090/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can a Pill Keep Weight Off After the Injection? ATTAIN-MAINTAIN, Read Carefully In ATTAIN-MAINTAIN, an orforglipron tablet held 74.7% and 79.3% of earlier weight loss against 49.2% and 37.6% on placebo. No arm continued the injectable. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-a-pill-keep-weight-off-after-the-injection Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can a Pill Keep Weight Off After the Injection? ATTAIN-MAINTAIN, Read Carefully A daily tablet held about three quarters of the weight people had already lost. Placebo held about half, and no arm stayed on the injection. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Share of the earlier weight loss still held at one year · tablet, after tirzepatide · 74.7% · placebo, after tirzepatide · 49.2% · tablet, after semaglutide · 79.3% · placebo, after semaglutide · 37.6% · Share of prior loss kept — not a share of body weight. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - ATTAIN-MAINTAIN gave a daily orforglipron tablet or placebo to people who had already lost weight on an injectable, then followed them a year. - After tirzepatide, the tablet group held 74.7% of their earlier loss against 49.2% on placebo. After semaglutide, 79.3% against 37.6%. - Every figure is a share of weight already lost — not a share of body weight. - No arm stayed on the injection, so the trial never tested the tablet against simply continuing. Partly, and the trial does not answer the question most people are asking. It compared a tablet against nothing, not against staying on the injection. ## What the trial did Participants had already been treated with tirzepatide or semaglutide in an earlier trial [\[1\]](https://thisglp.com/research/can-a-pill-keep-weight-off-after-the-injection#ref-1). They were then randomized to a daily orforglipron tablet or placebo for 52 weeks. Cohort 1 followed tirzepatide and had 205 people. Cohort 2 followed semaglutide and had 171. Share of the earlier weight reduction still held at week 52. | Prior injectable | Kept on the tablet | Kept on placebo | Difference | | --- | --- | --- | --- | | Tirzepatide | 74.7% | 49.2% | 25.5 points (95% CI 14.5 to 36.5) | | Semaglutide | 79.3% | 37.6% | 41.7 points (95% CI 24.4 to 59.0) | Share of the earlier weight reduction still held at week 52. ATTAIN-MAINTAIN, model-based estimates Read what the percentage is a share of 74.7% is not 74.7% of body weight. It is the share of the weight a person had already lost that they still held a year later. Someone who had lost 20% and kept 74.7% of it is about 15% below their starting weight. A page printing these as weight-loss figures is off by a factor of five. This site keeps that distinction in [the same percentage in different kilograms](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients). ## The comparison the trial did not run The authors name it themselves. There was no arm that continued the injectable. So the trial shows a tablet beats nothing. It does not show a tablet matches the injection you were already on. Those are different claims, and only the first is supported. The authors also state the second limit: the trial ran one year. What happens in year two is untested. ## What the placebo arms did Placebo held 49.2% of the earlier loss in cohort 1. In cohort 2 it held 37.6%. So roughly half the loss persisted with no drug at all after tirzepatide. That is the baseline the tablet has to beat. It also explains why the two cohorts differ so much. The tablet added 25.5 points after tirzepatide and 41.7 after semaglutide, because the placebo floors were not the same. The withdrawal evidence behind those floors is in [what happens when you stop tirzepatide](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide). ## A different tablet, a different question Orforglipron is not oral semaglutide. They are separate molecules and the trials ask separate questions. Oral semaglutide 25 mg was tested from a standing start rather than as maintenance [\[2\]](https://thisglp.com/research/can-a-pill-keep-weight-off-after-the-injection#ref-2). Over 64 weeks weight fell 13.6% against 2.2% on placebo, a difference of 11.4 points with an interval from 13.9 to 9.0. Gastrointestinal adverse events ran 74.0% against 42.2%. That is what a tablet does when it is the treatment. ATTAIN-MAINTAIN asks what a tablet does after the treatment. The approval status of the oral route is in [the oral one is approved now](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection). What it costs is in [the fifty-milligram dose](https://thisglp.com/research/oral-semaglutide-fifty-milligrams). Neither trial priced anything. Orforglipron is not approved and not sold. ## Frequently asked Can a pill keep weight off after stopping the injection? It helped. A daily orforglipron tablet held 74.7% of earlier weight loss after tirzepatide and 79.3% after semaglutide, against 49.2% and 37.6% on placebo. Does 74.7% mean 74.7% of body weight? No. It is the share of the weight already lost that was still held a year later. Someone who had lost 20% and kept 74.7% of it is about 15% below their starting weight. Is the tablet as good as staying on the injection? The trial cannot say. Its authors list the absence of an arm that continued the injectable as a limitation, so the tablet was only ever compared against placebo. How much weight stays off with no drug at all? In this trial the placebo groups held 49.2% of the earlier loss after tirzepatide and 37.6% after semaglutide, over one year. Is this the same as oral semaglutide? No. Orforglipron is a different molecule. Oral semaglutide 25 mg was tested as a treatment from a standing start and produced 13.6% weight loss against 2.2% on placebo over 64 weeks. ## Sources 1. \[1\] Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B (2026). Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Nature Medicine. [PMID 42120723](https://pubmed.ncbi.nlm.nih.gov/42120723/) 2. \[2\] Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity The New England Journal of Medicine. [PMID 40934115](https://pubmed.ncbi.nlm.nih.gov/40934115/) ## Where to get it ### Oral GLP-1, ranked Tablets, troches and capsules priced on the oral product itself — never on a number borrowed from the same seller's injection page. [Compare providers →](https://thisglp.com/best/oral-glp1) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can Tirzepatide Cause Anxiety or Depression? Trials Say No, Records Are Mixed Can tirzepatide cause anxiety or depression? In SURMOUNT, 18.2% vs 24.3% on placebo shifted to worse depression scores. Anxiety rose slightly only against semaglutide. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-tirzepatide-cause-anxiety Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Can Tirzepatide Cause Anxiety or Depression? Trials Say No, Records Are Mixed Across 4,056 adults in three SURMOUNT trials, depression scores fell slightly more on tirzepatide than placebo. Anxiety was never scored there, and the record studies split by comparator. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Shifted to a worse PHQ-9 category by week 72 · 18.2% · tirzepatide · 24.3% · placebo · 4,056 adults, SURMOUNT-1, -2 and -3 pooled. · Suicidal ideation: 0.6% in each group. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Across three SURMOUNT trials pooling 4,056 adults, tirzepatide did not raise depression. Scores on the PHQ-9 questionnaire went from 2.7 to 1.9 on the drug and from 2.6 to 2.4 on placebo over 72 weeks, and 0.6% of each group reported suicidal thoughts [\[1\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-1). Anxiety is the less settled half of the question, because the trials did not score it and the health-record studies that did found a small rise against semaglutide and a fall against an older weight-loss pill. ## Key takeaways - Pooled across SURMOUNT-1, -2 and -3, depression scores fell slightly further on tirzepatide than on placebo, an estimated difference of -0.6 points. - 18.2% on tirzepatide and 24.3% on placebo moved into a more severe depression category by week 72. - Suicidal ideation was reported by 0.6% in each group, and nonfatal suicidal behavior by 0.1% on tirzepatide against none on placebo. - In US health records, adults without diabetes on tirzepatide had anxiety diagnoses at a hazard ratio of 1.12 against semaglutide users, and lower rates than naltrexone-bupropion users. - The Zepbound label removed its suicidal behavior and ideation warning in February 2026. For someone who asks it, the question can arrive a few weeks in, somewhere around the second or third pen. Appetite has gone quiet, and a person notices they feel flatter, or more on edge, than they did before the first dose. Whether the drug did that is a fair question, and it has a better answer for depression than for anxiety. The class-wide picture, drawn mostly from semaglutide, is set out in [whether GLP-1 drugs cause depression or anxiety](https://thisglp.com/research/do-glp1-drugs-cause-depression); this page stays with tirzepatide. ## What the SURMOUNT trials measured over 72 weeks A post hoc analysis went back through SURMOUNT-1, SURMOUNT-2 and SURMOUNT-3 and pulled out every psychiatric measure the trials had collected along the way [\[1\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-1). Depressive symptoms were scored with the PHQ-9, a nine-item questionnaire, and suicidal thoughts were asked about directly with the Columbia-Suicide Severity Rating Scale. Both groups started with scores around 2.7 and 2.6, which is the range of someone with essentially no depressive symptoms. By week 72 the tirzepatide group sat at 1.9 and the placebo group at 2.4, a treatment difference of 0.6 points in the drug's favor, a small gap that nonetheless points the reassuring way rather than the worrying one. The more useful number for someone counting their own weeks is who got worse. By the end, 18.2% of people on tirzepatide had moved into a more severe PHQ-9 category against 24.3% on placebo. That is fewer than one person in five on the drug drifting upward, against about one in four on the dummy injection. Suicidal ideation, mostly rated low risk, was reported by 0.6% of each group. Nonfatal suicidal behavior appeared in 0.1% of people on tirzepatide and in nobody on placebo, a difference too small to read either way at these numbers. The authors describe the rates as similar to those of other incretin drugs, a comparison this site follows further in [the cohorts on suicidal ideation](https://thisglp.com/research/glp1-and-suicidal-ideation). Who those trials left out The title of the paper carries the limit: people with obesity and no known major psychopathology. Anyone with significant existing mental illness was screened out, so these numbers describe people who started well, and the authors themselves say tirzepatide may warrant further study in people with significant psychiatric illness. Four of the seven authors are Eli Lilly employees, which is ordinary for a sponsor's post hoc analysis and worth knowing when you weigh it. ## Where anxiety shows up, and against what Anxiety was not scored on a scale in SURMOUNT; it appears in that analysis only inside the adverse event tallies, which the authors call generally similar between groups [\[1\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-1). The anxiety numbers people quote come from health-record studies instead, and each one depends heavily on which drug tirzepatide was being measured against. One US record network followed adults with obesity for 24 months after they started tirzepatide or semaglutide, and matched them one to one with people starting naltrexone-bupropion, phentermine, or phentermine-topiramate [\[2\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-2). Against naltrexone-bupropion, tirzepatide came with fewer new anxiety and depression diagnoses, whether or not a person had type 2 diabetes. First recorded diagnosis over 24 months after starting the drug. Below 1.0 favors tirzepatide. | Tirzepatide against | Outcome | Hazard ratio (95% CI) | | --- | --- | --- | | Naltrexone-bupropion, with diabetes | Anxiety disorder | 0.55 (0.40–0.76) | | Naltrexone-bupropion, without diabetes | Anxiety disorder | 0.78 (0.68–0.89) | | Naltrexone-bupropion, with diabetes | Depression | 0.49 (0.33–0.72) | | Naltrexone-bupropion, without diabetes | Depression | 0.57 (0.49–0.66) | | Semaglutide, without diabetes | Anxiety disorder | 1.12 (1.06–1.18) | | Semaglutide, without diabetes | Insomnia | 1.13 (1.05–1.21) | First recorded diagnosis over 24 months after starting the drug. Below 1.0 favors tirzepatide. US electronic health record network, 2020–2025 The row that matters to someone choosing between the two injections is the fifth one. Among adults without diabetes, tirzepatide users picked up an anxiety diagnosis about 12% more often than semaglutide users, and insomnia about 13% more often. The authors add that these findings do not show cause and remain open to residual confounding and to diagnoses being recorded wrongly. A second, larger record study matched 85,546 pairs of tirzepatide and semaglutide starters and found the two drugs level on a combined psychiatric outcome in both years, with hazard ratios of 0.984 and 1.002 [\[3\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-3). A nominally higher anxiety hazard of 1.052 surfaced in the second year only, with an interval running from 1.001 to 1.106, and the authors warn it should be read cautiously given how many comparisons they ran. Put together, the two studies suggest that any extra anxiety relative to semaglutide is small, if it is there at all, while the side-by-side on weight and tolerability is in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). The comparator problem is the same one this site traced in [a depression estimate that flipped with its comparison group](https://thisglp.com/research/glp1-depression-depends-on-comparator). People steered to a pill such as naltrexone-bupropion may differ from people handed an injection, in ways a diagnosis code never records. ## What the adverse event reports and the label say Spontaneous reports tell a similar story from a noisier angle. A search of the FDA's adverse event database from 2004 to 2024, with 15,597 reports for tirzepatide, found significant depression and suicide-related signals for semaglutide only, at reporting odds ratios of 1.87 and 1.73, and none for tirzepatide [\[4\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-4). Reports are counts without a denominator, so they flag questions rather than measure risk, which is why [pooling them with trial data](https://thisglp.com/research/semaglutide-psychiatric-risk-pooling) causes trouble. A cohort focused on suicide itself matched 16,321 pairs of adults with overweight or obesity, tirzepatide against non-GLP-1 weight-loss medicines, and followed them for a median of a year [\[5\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-5). Suicidal ideation or attempts were recorded in 17 people on tirzepatide and 33 on the other drugs, roughly one and two in every thousand, an adjusted hazard ratio of 0.52. The regulator has moved in the same direction. The current Zepbound prescribing information lists its suicidal behavior and ideation warning as removed in February 2026, among its recent major changes [\[6\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-6). ## The anxiety that may be low blood sugar One ordinary source of jitteriness is written into the label itself. The patient information lists anxiety, irritability, or mood changes among the signs of low blood sugar, alongside sweating, shakiness and a fast heartbeat [\[6\]](https://thisglp.com/research/can-tirzepatide-cause-anxiety#ref-6). The label puts the risk higher when Zepbound is taken with a medicine that can lower blood sugar, such as insulin or a sulfonylurea. So a person with type 2 diabetes who feels a wave of unease an hour after a missed lunch has a checkable explanation. That is a narrower thing than an anxiety disorder, and it has a meter reading attached. Tiredness and low mood can also travel with eating far less, a thread this site follows in [whether GLP-1 drugs make you tired](https://thisglp.com/research/do-glp1-drugs-make-you-tired). ## What is still unresolved The trial evidence covers people who began without a psychiatric diagnosis, and it measured depression carefully and anxiety barely at all. Nobody has randomized people with established depression, anxiety disorder or bipolar disorder to tirzepatide and followed their symptoms. That leaves the people most likely to be asking this question without trial evidence of their own, the same gap that runs through [the bipolar disorder cohort](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder). Until that trial exists, the honest reading is two-sided. Tirzepatide has not been shown to cause depression in people who start without it, and the anxiety signal against semaglutide is small and observational. Neither finding tells someone with an existing diagnosis what their own next six months on the drug will look like. ## Frequently asked Can tirzepatide cause anxiety? The trials did not score anxiety on a scale. In US health records, adults without diabetes starting tirzepatide received anxiety diagnoses slightly more often than semaglutide starters (hazard ratio 1.12) and less often than naltrexone-bupropion starters. None of those studies can show cause. Can tirzepatide cause depression? Not in the trials. Pooled across SURMOUNT-1, -2 and -3, PHQ-9 depression scores fell from 2.7 to 1.9 on tirzepatide and from 2.6 to 2.4 on placebo, and fewer people on the drug moved into a worse category (18.2% against 24.3%). Does tirzepatide cause suicidal thoughts? Suicidal ideation was reported by 0.6% of participants on tirzepatide and 0.6% on placebo in the pooled SURMOUNT analysis. The Zepbound label removed its suicidal behavior and ideation warning in February 2026. Why might I feel anxious on tirzepatide? The Zepbound patient information lists anxiety, irritability or mood changes among the signs of low blood sugar, which is more likely when it is taken with insulin or a sulfonylurea. Anyone with new or worsening anxiety or low mood should raise it with their prescriber. ## Sources 1. \[1\] Wadden TA, Oquendo MA, Kushner RF, Cao D, Karanikas CA, Kechter A, Murphy MA (2026). Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT Obesity (Silver Spring). [PMID 41537305](https://pubmed.ncbi.nlm.nih.gov/41537305/) 2. \[2\] Huang YN, Liu KW, Li PH, Chen JC, Meyerowitz-Katz G, Su PH, Huang CC (2026). Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes Communications Medicine. [PMID 42373755](https://pubmed.ncbi.nlm.nih.gov/42373755/) 3. \[3\] Chen SC, Wang TJ, Chou CK, Lee C (2026). Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists Diabetes, Obesity and Metabolism. [PMID 42420795](https://pubmed.ncbi.nlm.nih.gov/42420795/) 4. \[4\] Wang M, Yang Z, Yan M, Liu S, Xiao S (2025). Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database Journal of Affective Disorders. [PMID 40523410](https://pubmed.ncbi.nlm.nih.gov/40523410/) 5. \[5\] Yu WS, Huang JY, Lo SC, Huang CN, Yang YS, Kornelius E (2025). Association of tirzepatide and the risk of suicide in a real-world cohort Frontiers in Psychiatry. [PMID 41334076](https://pubmed.ncbi.nlm.nih.gov/41334076/) 6. \[6\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection — prescribing information and patient information, revised 08/2026 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can You Smoke Weed on Ozempic? What Cannabis-User Cohorts Found | This GLP Can you smoke weed on Ozempic? No trial has tested it and the label is silent | veterans starting a GLP-1 had 2.25 fewer cannabis use disorder diagnoses per 1,000. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-smoke-weed-on-ozempic Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Can You Smoke Weed on Ozempic? What Cannabis-User Cohorts Found No trial has tested cannabis with Ozempic, and the label does not mention it. Two large cohorts linked GLP-1 drugs to fewer cannabis use disorder diagnoses, which is not the same as measuring use. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Cannabis use disorder diagnoses, against another drug class · 1.0 = no difference · New diagnosis, obesity cohort · HR 0.56 · Repeat diagnosis, obesity cohort · HR 0.62 · New diagnosis, veterans · HR 0.86 · Observational cohorts. Diagnoses in health records, not measured use. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No trial has been designed to test cannabis with Ozempic. A 2026 review of registered GLP-1 substance-use trials found none on cannabis [\[5\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-5). The current Ozempic label does not mention cannabis or marijuana [\[6\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-6). The largest study to touch the question followed US veterans with type 2 diabetes for up to three years [\[2\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-2). Starting a GLP-1 drug was linked to 2.25 fewer cannabis use disorder diagnoses per 1,000 people than starting an SGLT-2 inhibitor. That was a hazard ratio of 0.86. ## Key takeaways - The only randomized cannabis result is a side outcome in a 50-person alcohol trial of oral semaglutide. - The Ozempic, Wegovy and Zepbound labels do not mention cannabis or marijuana. - Among veterans, a GLP-1 was linked to 2.25 fewer cannabis use disorder diagnoses per 1,000 over three years (HR 0.86). - In an obesity cohort, semaglutide was linked to fewer new (HR 0.56) and repeat (HR 0.62) cannabis use disorder diagnoses. - Of 33 registered GLP-1 trials in substance use disorders, searched to July 2025, none targeted cannabis. This page reports what studies measured. It does not advise on cannabis use, with or without a GLP-1. The evidence comes in three kinds, in this order of strength: 1. Randomized trials. One exists, and cannabis was a side outcome in it. 2. Cohort studies of health records. Two large ones exist. 3. Reports from users online. One analysis exists. The same kinds of evidence exist for alcohol, where a dedicated trial has been run. That result is in [whether semaglutide reduces alcohol use](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use). ## What the labels say The current Ozempic, Wegovy and Zepbound labels contain none of these words: cannabis, marijuana, THC or dronabinol [\[6\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-6) [\[8\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-8) [\[9\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-9). The labels list no interaction with cannabis, and none says one was studied. An absent warning is not a finding of safety. It means the question was not addressed. ## The cohort studies Both cohorts counted cannabis use disorder diagnoses in health records. A diagnosis is not the same as use. The 2024 study puts US cannabis users at more than 45 million, with about one-third meeting the diagnosis [\[1\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-1). 1. **Semaglutide, 2024.** The study drew on US electronic health records [\[1\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-1). It matched 85,223 patients with obesity on semaglutide or another anti-obesity drug. Over 12 months, semaglutide was linked to fewer new diagnoses (HR 0.56, 95% CI 0.42 to 0.75). Among people with a prior diagnosis, it was linked to fewer repeat diagnoses (HR 0.62, 95% CI 0.46 to 0.84). 2. **Veterans, 2026.** The trial emulation followed 524,817 veterans with type 2 diabetes [\[2\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-2). It compared starting a GLP-1 drug with starting an SGLT-2 inhibitor. The cannabis use disorder hazard ratio was 0.86 (95% CI 0.81 to 0.90). The absolute difference was 2.25 fewer diagnoses per 1,000 people over three years. The 2024 authors call their result preliminary evidence. They state that randomized trials are needed before semaglutide is used for cannabis use disorder [\[1\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-1). The veterans study describes its data as observational [\[2\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-2). Neither study measured how much cannabis anyone used. A pooled review that included cannabis outcomes is logged in [the 82-study substance-use review](https://thisglp.com/research/preventing-it-is-not-treating-it). ## The one randomized result A 2026 trial randomized 50 adults with moderate to severe alcohol use disorder [\[3\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-3). They took oral semaglutide, 3 mg then 7 mg a day, or placebo for 8 weeks. Cannabis use was an exploratory outcome. Cannabis use days fell significantly on semaglutide. The trial was built for alcohol, not cannabis. Its primary outcome, craving in a laboratory test, did not fall significantly. An exploratory result in 50 people is a lead for a future trial. It is not an answer. ## What users report A 2024 study coded Reddit posts about GLP-1 drugs and substance use [\[4\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-4). It drew on 5,859 threads and their comments. About 30% of alcohol-related comments described stopping alcohol. For cannabis, the results were mixed. Posts are self-selected, and none was verified. What has not been studied No study here measured nausea, dizziness, appetite or blood sugar in people using cannabis on a GLP-1. A 2026 review of ClinicalTrials.gov, searched to July 2025, found 33 registered GLP-1 trials in substance use disorders [\[5\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-5). Fifteen were for alcohol and nine for nicotine or tobacco. None was for cannabis. Compounded semaglutide is not FDA-approved, and none of these studies used it. ## Cannabis use disorder and mental health One more cohort bears on safety. A 2025 study of people with type 2 diabetes looked at suicide attempts [\[7\]](https://thisglp.com/research/can-you-smoke-weed-on-ozempic#ref-7). GLP-1 use was linked to lower risk overall (adjusted HR 0.63). Cannabis use disorder was linked to much higher risk (adjusted HR 5.50). Among people with cannabis use disorder, GLP-1 use showed no difference (adjusted HR 1.00, 95% CI 0.37 to 2.69). That is an association in records, not a drug effect. The broader cohort evidence on these drugs and suicidal thoughts is in [semaglutide and suicidal ideation](https://thisglp.com/research/glp1-and-suicidal-ideation). The nicotine side of the substance-use question is in [the exenatide smoking-cessation trial](https://thisglp.com/research/glp1-smoking-cessation-subgroups). ## Frequently asked Can you smoke weed on Ozempic? No trial has tested it, and the Ozempic label does not mention cannabis or marijuana. The evidence that exists comes from cohort studies of cannabis use disorder diagnoses, not from measured use. Do Ozempic and weed interact? No interaction is listed on the Ozempic, Wegovy or Zepbound labels, and none was studied for them. An absent warning is not a finding of safety; the question was not addressed. Does Ozempic reduce marijuana use? Cohorts link GLP-1 drugs to fewer cannabis use disorder diagnoses: HR 0.86 among veterans with type 2 diabetes, and HR 0.56 for new diagnoses in an obesity cohort on semaglutide. No trial has tested it in people who use cannabis. Has semaglutide been tested with THC? Not directly. In a 50-person trial of oral semaglutide for alcohol use disorder, cannabis use days fell significantly as an exploratory outcome. A 2026 review of 33 registered GLP-1 substance-use trials, searched to July 2025, found none targeting cannabis. ## Sources 1. \[1\] Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024). Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study Molecular Psychiatry. [PMID 38486046](https://pubmed.ncbi.nlm.nih.gov/38486046/) 2. \[2\] Cai M, Choi T, Xie Y, Al-Aly Z (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study BMJ. [PMID 41781010](https://pubmed.ncbi.nlm.nih.gov/41781010/) 3. \[3\] Schacht JP, Sakai JT, Raymond K, Shelton R (2026). Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial The American Journal of Psychiatry. [PMID 42522065](https://pubmed.ncbi.nlm.nih.gov/42522065/) 4. \[4\] Arillotta D, Floresta G, Papanti Pelletier GD, et al. (2024). Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach Brain Sciences. [PMID 38928616](https://pubmed.ncbi.nlm.nih.gov/38928616/) 5. \[5\] Patil S, Jha N, Jha MK (2026). Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov Addictive Behaviors Reports. [PMID 41696398](https://pubmed.ncbi.nlm.nih.gov/41696398/) 6. \[6\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 7. \[7\] Dhruva Y, Messias E, Lin PI (2025). Glucagon-like peptide-1 receptor agonists and suicide risk in individuals with diabetes and Cannabis use disorder Preventive Medicine Reports. [PMID 41050856](https://pubmed.ncbi.nlm.nih.gov/41050856/) 8. \[8\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 9. \[9\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can You Take a GLP-1 on Dialysis? 2,492 Patients, and No Trial | This GLP Can you take a GLP-1 on dialysis? A 388-patient pooled review, a 2,492-pair cohort and the FLOW subgroups | with the baseline imbalance behind the mortality figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-on-dialysis Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 on Dialysis? 2,492 Patients, and No Trial A matched cohort of 2,492 pairs starting hemodialysis found mortality 17% lower on these drugs. Before it, the entire world literature was 388 patients, and no trial has enrolled anyone on dialysis. [This GLP Editorial Team](https://thisglp.com/about)September 202610 min readUpdated September 2026 Pooled rates, and what the intervals allow · nausea · uninformative · any GI event · hypoglycemia · uninformative · stopped for side effects · 388 patients across 19 studies — about twenty per study **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No trial has tested it, and the observational evidence now runs to a few thousand people. A matched cohort at a large dialysis organization followed 2,492 patients who started in-center hemodialysis while on one of these drugs, against 2,492 who did not. Hospitalization ran 9% lower and mortality 17% lower [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis#ref-2). Before that cohort, the entire world literature was 388 patients across 19 studies [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis#ref-1). The groups in the larger study differed substantially before anyone was treated, so the honest summary is encouraging rather than established. ## Key takeaways - A review pooled 19 studies of GLP-1 drugs in people with end-stage kidney disease, 388 patients in total. - 91.5% were on dialysis or another form of renal replacement therapy — a population the major trials excluded. - Weight fell 7.00 kg at twelve months, 95% CI −11.38 to −2.61, with heterogeneity of 79.2%. - A later matched cohort of 2,492 pairs found hospitalization 9% lower (IRR 0.91) and mortality 17% lower (IRR 0.83). - 98% of GLP-1 users in that cohort had diagnosed diabetes against 73% of controls, and 76% had predialysis nephrology care against 67%. - FLOW, the trial that motivated the question, studied chronic kidney disease and enrolled nobody on dialysis. Everything known about these drugs comes from people whose kidneys work well enough to be in a trial. This is what the evidence looks like for people whose kidneys have failed, and the shape of it is the point. ## Who is missing from the trials The large cardiovascular and weight-loss trials exclude end-stage kidney disease, and the kidney trial that made news enrolled people with chronic kidney disease rather than people on dialysis. That is [a distinction the coverage rarely draws](https://thisglp.com/research/semaglutide-and-kidney-disease). So a patient on dialysis, who may need to lose weight to qualify for a transplant, is asking a question no randomized trial has answered. This review gathered what exists: 19 studies, 388 patients, 91.5% on renal replacement therapy [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis#ref-1). Semaglutide accounted for 266 of them, liraglutide 66, dulaglutide 47, and tirzepatide nine. Nine patients, in the world literature. ## What the pooled studies found On semaglutide, weight fell 3.09 kg at three months, 95% CI −5.95 to −0.24, and 3.68 kg at six months, 95% CI −5.71 to −1.65. At twelve months it was 7.00 kg, 95% CI −11.38 to −2.61, with heterogeneity of 79.2%. Glycated hemoglobin fell 0.75 percentage points at twelve months, 95% CI −1.07 to −0.43. Some estimates did not exclude no effect: BMI at three months, 95% CI −2.92 to 0.09, and HbA1c at six months, 95% CI −1.20 to 0.20. Both liraglutide weight estimates crossed zero as well. Two of these intervals contain no information Pooled nausea came out at 36% with a 95% CI from 3% to 91%. Pooled hypoglycemia at 9%, interval 0% to 82%. An interval that spans almost the entire possible range is not a measurement of anything. It is what happens when a handful of very small studies with different definitions are averaged. The point estimates are the numbers that will get quoted, and they are the least defensible part of the paper. ## The estimates that are usable Not all of it is like that. Any gastrointestinal event came in at 39%, 95% CI 25% to 55%, and discontinuation because of side effects at 9%, 95% CI 4% to 20%. Those are wide but they say something: side effects are common in this population and roughly one person in eleven stopped because of them. The twelve-month weight figure is similar: a real effect with an interval running from about two and a half to eleven kilograms. Heterogeneity was high enough that the studies disagreed substantially. It is enough to say the drug does something and not enough to say how much, which [a high heterogeneity statistic](https://thisglp.com/research/glp1-weight-loss-pooled-average) always implies. ## The cohort that multiplied the evidence base A matched cohort then followed 2,492 patients who began in-center hemodialysis while on one of these drugs, against an equal number who did not [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis#ref-2). Hospitalization ran 9% lower (incidence rate ratio 0.91, 95% CI 0.87 to 0.96) and mortality 17% lower (IRR 0.83, 95% CI 0.73 to 0.95). Both are incidence rate ratios rather than hazard ratios, because hospitalization recurs and the model counts episodes. The baseline table is the part to read first. Among patients on a GLP-1 drug at dialysis initiation, 98% had diagnosed diabetes against 73% of the comparison group. Predialysis nephrology care had reached 76% against 67%, and mean BMI was 33 against 30. Predialysis nephrology care is one of the best-established predictors of doing well on dialysis and has nothing to do with any drug. The full reading is in [the dialysis cohort](https://thisglp.com/research/dialysis-the-evidence-base-just-grew). ## What the trial evidence one stage earlier says FLOW enrolled people with type 2 diabetes and chronic kidney disease, at semaglutide 1.0 mg, and its subgroup analyses publish numbers needed to treat [\[3\]](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis#ref-3). To prevent one primary kidney outcome over three years you would treat 22 people with established atherosclerotic disease, 13 with heart failure, or 17 at high cardiovascular risk. Every interaction test came back null. Those numbers describe kidney protection in diabetic kidney disease at a diabetes dose. They do not transfer to someone taking a weight-management dose without either condition, and they do not transfer to dialysis. The arithmetic is in [the FLOW numbers needed to treat](https://thisglp.com/research/twenty-two-thirteen-seventeen). ## A measurement problem that runs through all of it Kidney function is usually reported as an estimated glomerular filtration rate, which is calculated from creatinine, and creatinine is a waste product of muscle. A drug that takes muscle mass off lowers creatinine and raises the calculated rate with the kidney doing exactly what it was doing before. A matched study in polycystic kidney disease shows the pattern cleanly. Both eGFR and a stage threshold defined off eGFR improved, while reaching end-stage disease, which does not depend on creatinine, did not [\[4\]](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis#ref-4). That is what a measurement artifact looks like, and also what an underpowered hard endpoint looks like in 320 pairs. The check is set out in [the eGFR and muscle analysis](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease). ## What the authors conclude That semaglutide may be considered in end-stage kidney disease, that the results are primarily hypothesis-generating, and that prospective randomized trials are urgently needed. All three clauses belong together. A drug can be reasonable to try in a population where nothing else works while the evidence for it remains this thin. ## Why it belongs on a site about buying Because nobody on this roster screens for kidney failure, and a person on dialysis filling out a telehealth intake form is in a category the whole evidence base excludes. Dosing, clearance and hypoglycemia risk are all different when kidneys have stopped working, and none of that is a question an online questionnaire is built to catch. The [census of what goes unasked](https://thisglp.com/tools/questions-they-leave-open) counts how much. More generally, this is the clearest example available of what [the gap between trial populations and real ones](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) actually costs. Exclusion criteria are written to protect a trial’s result. They also decide, years later, which patients have evidence and which have nineteen small studies. ## Frequently asked Can you take a GLP-1 on dialysis? No randomized trial has tested it. A matched cohort of 2,492 pairs starting in-center hemodialysis found hospitalization 9% lower and mortality 17% lower, and the two groups differed substantially before anyone was treated. How much evidence exists? A pooled review found 19 studies and 388 patients, 91.5% on renal replacement therapy. Tirzepatide accounted for nine of those patients. How much weight do people on dialysis lose? On semaglutide, 7.00 kg at twelve months with an interval from -11.38 to -2.61 and heterogeneity of 79.2%. That is enough to say the drug does something and not enough to say how much. Did the FLOW trial answer this? It did not. FLOW enrolled people with type 2 diabetes and chronic kidney disease at semaglutide 1.0 mg, and nobody in it was on dialysis. Will a telehealth seller catch it? Nobody on this roster screens for kidney failure. Dosing, clearance and hypoglycemia risk all change when kidneys have stopped working, and an online questionnaire is not built to catch that. ## Sources 1. \[1\] Dutta D, et al. (2026). Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis Endocrine Practice. [PMID 42551699](https://pubmed.ncbi.nlm.nih.gov/42551699/) 2. \[2\] Karpinski S, Qazi R, Bjordahl T, Sibbel S, Weinhandl E, Tentori F, Brunelli SM (2026). Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease Clinical Journal of the American Society of Nephrology. [PMID 42640716](https://pubmed.ncbi.nlm.nih.gov/42640716/) 3. \[3\] Tuttle KR, Bakris GL, Baeres FMM, Bang CN, et al. (2026). Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses Journal of the American College of Cardiology. [PMID 42233552](https://pubmed.ncbi.nlm.nih.gov/42233552/) 4. \[4\] Chen TP, et al. (2026). Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study Science Progress. [PMID 42648283](https://pubmed.ncbi.nlm.nih.gov/42648283/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can You Take a GLP-1 With a Heart Pump? 141 Pairs, and No Effect Sizes | This GLP A matched cohort of 141 pairs with left ventricular assist devices reported less driveline infection and lower mortality with prior GLP-1 exposure | but published no effect sizes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With a Heart Pump? 141 Pairs, and No Effect Sizes Fewer driveline infections, lower mortality and more transplants, all of it reported as a direction with no magnitude attached, and all of it in people whose GLP-1 prescription predates the operation. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read What the paper reports · driveline infection, 1 year · lower · — no figure · mortality, 3 years · lower · — no figure · transplant listing, 3 years · higher · — no figure · heart transplantation, 3 years · higher · — no figure · 141 matched pairs. No hazard ratios or intervals published. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Among 527 people with obesity who received a durable left ventricular assist device, 231 had documented GLP-1 exposure before implantation; 141 pairs were matched. - The abstract reports lower driveline infection at one year, and at three years lower mortality with more transplant listing and more transplantation. - No hazard ratios, confidence intervals or percentages accompany any of those outcomes. - Exposure was before the pump was implanted, which selects for people already well enough and engaged enough to be on the drug. There is one study, it covers 141 matched pairs, and it publishes no effect size for any outcome, so the answer is that nobody can tell you how much difference it makes. A left ventricular assist device is a mechanical pump implanted when a heart is failing badly enough to need one, often as a bridge to transplant. Obesity complicates the surgery, increases infection around the driveline that exits the skin, and at many centers blocks transplant listing outright. Among 527 people with obesity who received one, 231 had documented GLP-1 exposure before implantation, and 141 pairs were matched[\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump#ref-1). It sits among the growing set of results in populations trials never enroll, alongside [the sickle cell cohort](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease). The reported direction is favorable across the board: fewer driveline infections at one year, and at three years lower mortality along with more transplant listings and more transplants performed. In a population this sick, all of those would be meaningful. None of those outcomes comes with a number The abstract states directions and no effect sizes — no hazard ratios, no confidence intervals, no percentages for any outcome. That is unusual, and it means a reader cannot tell whether the mortality difference was large or marginal, or how precisely anything was estimated. This article reports the absence rather than filling it, because inventing magnitudes the paper did not publish is not an option. The exposure definition carries the heavier problem. Patients qualified by having a GLP-1 prescription _before_ implantation, so the comparison is between people who arrived at major cardiac surgery already on one and people who did not. Being on a GLP-1 drug beforehand means being stable enough to have been started on it, engaged enough to have continued, and managed in advance rather than arriving in crisis. In a group where reaching elective implantation in good condition largely determines what follows, that is close to selecting on the outcome — the same structure flagged in [the dialysis cohort](https://thisglp.com/research/dialysis-the-evidence-base-just-grew). One finding deserves separating from the rest because its mechanism is probably not cardiac at all. Transplant listing is a committee decision, and a BMI ceiling is a common explicit criterion. More listings among GLP-1 users may be recording that people crossed a threshold on a chart rather than that their hearts improved. That is a genuine and important benefit, because access to transplantation is the thing that changes survival here. It is still a different claim from the drug treating heart failure, which is examined on its own terms in [the heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure) and [the rheumatoid arthritis cohort](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis). A second cohort in a comparably sick population shows what this one is missing. Among patients with end-stage kidney disease on dialysis, GLP-1 use was studied for hospitalization and mortality with published risk estimates attached [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump#ref-2), which is what lets a reader judge whether a difference is large or marginal. Both studies select people well enough to have been started on the drug, and only one of them lets you see how big the resulting gap was. The authors describe their findings as observational and hypothesis-generating and ask for prospective evaluation, which is the right conclusion from 141 pairs with no published effect sizes. What it establishes is that the question deserves asking properly, in a population where weight is not a cosmetic concern but a gate to the treatment that would save them. ## Frequently asked How large were the benefits? Unstated. The paper reports directions — lower infection, lower mortality, more transplants — without hazard ratios, confidence intervals or percentages for any outcome. Were patients taking the drug after their implant? Exposure was defined before implantation. The comparison is between people who arrived at surgery already on a GLP-1 drug and people who did not, which selects for being stable and engaged with care beforehand. Why did more patients reach transplant? Possibly because obesity is an explicit barrier to transplant listing at many centers, so weight loss may move someone across a threshold. That is a real benefit, but a different mechanism from improving the heart itself. ## Sources 1. \[1\] Divya A, Dalal N, Yoshida Y, Kanwar M, Catarino P, D'Alessandro D (2026). Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study ASAIO Journal. [PMID 42497207](https://pubmed.ncbi.nlm.nih.gov/42497207/) 2. \[2\] Karpinski S, Qazi R, Bjordahl T, Sibbel S, Weinhandl E, Tentori F, Brunelli SM (2026). Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease Clinical Journal of the American Society of Nephrology. [PMID 42640716](https://pubmed.ncbi.nlm.nih.gov/42640716/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can You Take a GLP-1 With Epilepsy? Seizure Risk Did Not Rise | This GLP Can you take a GLP-1 with epilepsy? A 452,766-adult cohort found incident epilepsy at 2.35% against 2.41%, a hazard ratio of 0.84, and no trial in people who already have it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With Epilepsy? Seizure Risk Did Not Rise A 452,766-person study found a clean, consistent association. Expressed as people rather than ratios, it is one case avoided per sixteen hundred treated. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Cumulative epilepsy incidence · 2.35% · on a GLP-1 · 2.41% · on a DPP-4 drug · Reported as: 16% lower risk (HR 0.84). · Actual gap: 0.06 percentage points. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Nothing in this evidence says you cannot, and nothing says the drug will help the epilepsy. A matched cohort of 452,766 adults with type 2 diabetes recorded incident epilepsy in 2.35% of GLP-1 users against 2.41% of DPP-4 comparators [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-1). That is a hazard ratio of 0.84 (95% CI 0.78 to 0.90). The 16% relative reduction is an absolute difference of 0.06 percentage points, or roughly one case avoided per sixteen hundred people treated. Everyone in it was free of epilepsy at baseline, so it is a question about developing the condition rather than living with it. No trial has tested one of these drugs in people who already have it. ## Key takeaways - A matched cohort of 452,766 adults with type 2 diabetes compared new users of GLP-1 drugs against DPP-4 inhibitors for incident epilepsy. - Epilepsy developed in 1,670 GLP-1 users and 1,886 comparators — cumulative incidences of 2.35% and 2.41%. - The hazard ratio was 0.84 (95% CI 0.78-0.90), holding at one, three and five years and across age and sex subgroups. - A 16% relative reduction on those incidences is an absolute difference of 0.06 percentage points. This is a well-conducted study whose headline is nearly meaningless to an individual [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-1). It is the clearest example on this site of why both numbers must be printed. The general problem is set out in [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute). Across 452,766 matched patients, epilepsy developed in 1,670 people on a GLP-1 drug and 1,886 on a DPP-4 inhibitor. That is 2.35% against 2.41%. The hazard ratio of 0.84 (95% CI 0.78–0.90) accounts for follow-up time and is correctly calculated; it will be reported as a 16% reduction in epilepsy risk. Six hundredths of a percentage point The two cumulative incidences differ by 0.06 points. Expressed as people, that is roughly one case of epilepsy avoided for every sixteen hundred patients treated — set against a hazard ratio that sounds like a substantial protective effect. Neither figure is wrong. A reader deciding whether epilepsy risk should influence their choice of diabetes drug needs the second one, and will almost certainly be shown the first. The quality of the study and the size of its finding are separate judgments and should not be collapsed. This one is large, and the associations held at one, three and five years. They were consistent across age and sex, and sensitivity analyses supported them, comparable rigor to [the venous thromboembolism cohort](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots). Semaglutide showed the strongest association at a hazard ratio of 0.68. That rests on the same near-identical incidences, so it is a larger relative figure attached to the same tiny absolute one. Whether there is a mechanism is genuinely open. Epilepsy and metabolic disease share pathways that these drugs plausibly touch. This is not the first neurological association to appear in observational data while trial evidence stays quiet. The same pattern is described in [lower odds of getting Parkinson's, no help once you have it](https://thisglp.com/research/preventing-it-is-not-treating-it), where prevention signals and treatment nulls came from different study designs. ## Where the rest of the neurological evidence sits Two larger poolings frame this one. A systematic review screened 10,037 records and pooled 82 studies of neuropsychiatric outcomes, graded with GRADE [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-2). Risk of developing Parkinson’s disease was lower at a pooled hazard ratio of 0.70, 95% CI 0.53 to 0.92, from observational data. Motor symptoms in people who already had it did not improve, mean difference −3.29, 95% CI −7.84 to 1.26, from trials. A Bayesian network meta-analysis of 712,287 patients found no antidiabetic class with a significant difference in Parkinson’s risk [\[3\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-3). Its own conclusion nonetheless describes GLP-1 and SGLT2 drugs as consistently associated with lower risk. The gap between a paper’s results and its conclusion is set out in [the Parkinson's evidence](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease). The practical translation is short. Nobody should choose or avoid a diabetes drug on epilepsy grounds from this evidence, and nobody with epilepsy should expect a GLP-1 drug to do anything for it. What the study contributes is a reassurance: these drugs do not appear to raise seizure risk. That is useful to have measured at this scale, in the same way the respiratory null in [the respiratory adverse event review](https://thisglp.com/research/one-asthma-study-in-a-hundred-and-twenty-three) is useful. ## Frequently asked Can you take a GLP-1 if you have epilepsy? No study has tested one in people who already have epilepsy. The largest cohort available enrolled 452,766 adults free of it at baseline and found incident epilepsy at 2.35% against 2.41%, which is reassurance about seizure risk rather than evidence of a treatment effect. Do these drugs reduce epilepsy risk? The association is real and consistent, but tiny in absolute terms: 2.35% against 2.41%, or roughly one case avoided per sixteen hundred people treated. Why does the 16% figure sound so much larger? A hazard ratio expresses a proportional change. Sixteen percent of a 2.4% risk is a very small number of people, which is why absolute figures matter for any personal decision. Should this affect my choice of diabetes drug? No. The difference is too small to weigh against efficacy, tolerability or cost. Its value is as reassurance that these drugs do not appear to increase seizure risk. ## Sources 1. \[1\] Cheng CY, Lo SC, Huang CN, Yang YS, Wang YH, Kornelius E (2026). Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes Neurology. [PMID 41370744](https://pubmed.ncbi.nlm.nih.gov/41370744/) 2. \[2\] Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis Clinical Therapeutics. [PMID 41862354](https://pubmed.ncbi.nlm.nih.gov/41862354/) 3. \[3\] Lee SH, et al. (2026). Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis Journal of Global Health. [PMID 42626880](https://pubmed.ncbi.nlm.nih.gov/42626880/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can You Take a GLP-1 With Polycystic Kidney Disease? Not as a Treatment Can you take a GLP-1 with polycystic kidney disease? One 320-pair cohort found no rise in kidney injury | reviews say it is not a treatment for ADPKD. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With Polycystic Kidney Disease? Not as a Treatment One matched study of 320 pairs found a higher eGFR on semaglutide and no rise in kidney injury. The eGFR is calculated from creatinine, which falls when muscle does, and reviews say it is not a treatment. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Outcomes built on creatinine, and outcomes that are not · eGFR at follow-up · 57.52 vs 50.93, p = 0.013 · progression to stage 5 · HR 0.447 (0.230-0.872) · end-stage kidney disease · no significant difference · acute kidney injury · no significant difference · 320 matched pairs. Creatinine comes from muscle. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - No trial has yet published GLP-1 results in polycystic kidney disease; the human outcome evidence is one matched cohort of 320 pairs. - Semaglutide users had a higher follow-up eGFR, 57.52 against 50.93 mL/min/1.73 m2, and less progression to stage 5 disease, hazard ratio 0.447. - End-stage kidney disease, acute kidney injury and urinary tract infection showed no significant difference. - Both favorable outcomes are calculated from creatinine, which falls when muscle is lost, and the authors call the results hypothesis-generating. - A 2026 review says GLP-1 therapy should not currently be regarded as a treatment for the disease. People with polycystic kidney disease do take GLP-1 drugs, for weight or for diabetes, and the one matched study of them found no signal of kidney harm across 320 pairs [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-1). Acute kidney injury was no more common on semaglutide, and follow-up eGFR was higher, 57.52 against 50.93 mL/min/1.73 m2. What that study cannot show is that the drug protects the kidneys, and the reviews on the question are clear that a GLP-1 is not a treatment for the disease itself. The decision about taking one sits with a nephrologist, for the same reasons it does in [later-stage kidney disease on dialysis](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis). ## The study, and who was in it Autosomal dominant polycystic kidney disease is inherited, progressive, and short on treatment options, and semaglutide has shown kidney benefits in other populations, which is what prompted researchers to look [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-1). They searched a large research network for adults with the disease between 2000 and 2024 and excluded anyone on an SGLT2 inhibitor, tolvaptan or another GLP-1. Among 45,613 patients, 323 eligible semaglutide users remained, and 320 of them were matched one to one against non-users. Excluding tolvaptan matters, because tolvaptan is the drug that treatment of this disease is built around. The study compares semaglutide against no particular treatment rather than against the standard of care, and it says nothing at all about taking the two together. ## What moved, and what did not Follow-up eGFR came out higher on semaglutide, and progression to stage 5 chronic kidney disease was lower, with a hazard ratio of 0.447 and a confidence interval from 0.230 to 0.872. Volume depletion and death from any cause were also less common among the users. End-stage kidney disease, acute kidney injury and urinary tract infection showed no significant difference either way. Two readings of the same pattern The eGFR in this study is calculated from creatinine, a waste product of muscle, and semaglutide weight loss takes muscle off along with fat, so the number can rise with the kidney filtering exactly as before. The outcomes that moved are the ones built on creatinine, and end-stage disease, which is not, did not move. That fits a measurement artifact, and it also fits a hard endpoint too rare to show up in 320 pairs, and the authors themselves call their results hypothesis-generating. The same creatinine problem runs through other kidney results on this site, including [the contrast kidney injury cohort](https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury), and the muscle side of it is covered in [the muscle loss guide](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). A filtration marker that does not come from muscle, such as cystatin C, is the usual way to separate the two readings, and it is not among the outcomes the study reports. ## What the reviews say Two reviews have looked at whether these drugs could slow the disease. The first points to animal findings and to the metabolic changes the drugs produce, in weight, blood pressure and inflammation, as reasons for interest. It concludes that further clinical studies are needed on both efficacy and safety before the drugs could be used for it [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-2). The second goes further into the biology, arguing that obesity and visceral fat may shape how fast cysts grow and kidney function falls, which would make GLP-1 drugs plausible candidates alongside tolvaptan rather than substitutes for it [\[3\]](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease#ref-3). It describes early-phase trials in progress, lists co-administration with tolvaptan among the open questions, and states plainly that GLP-1 therapy should not currently be regarded as a treatment for the disease. ## Where that leaves someone with the disease For a person with polycystic kidney disease who is being offered a GLP-1 for weight or diabetes, this cohort flagged no kidney harm and the reviews promise no kidney benefit. The heavier kidney claims for this drug come from [the FLOW trial in diabetic kidney disease](https://thisglp.com/research/semaglutide-and-kidney-disease), a different condition. The question still unanswered is whether the drug changes the course of the cysts themselves, and that is what the trials now under way were designed to find out. ## Frequently asked Can you take a GLP-1 with polycystic kidney disease? People with the disease do take them for weight or diabetes. The one matched study of 320 pairs found no rise in acute kidney injury, but no trial has reported results and the decision belongs with a nephrologist. Does semaglutide slow polycystic kidney disease? Not shown. Follow-up eGFR was higher and stage 5 progression lower on semaglutide, but both are calculated from creatinine, which falls when muscle is lost, and end-stage kidney disease did not differ. Is a GLP-1 a treatment for ADPKD? No. A 2026 review states that GLP-1 therapy should not currently be regarded as a treatment for the disease, and early-phase trials are still in progress. Can you take a GLP-1 with tolvaptan? That has not been answered. The cohort excluded tolvaptan users, and a 2026 review lists co-administration with tolvaptan among the open questions for trials. ## Sources 1. \[1\] Chen TP, Tsai SF (2026). Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study Science Progress. [PMID 42648283](https://pubmed.ncbi.nlm.nih.gov/42648283/) 2. \[2\] Ali H, Alahmad B, Al-Mulla F (2025). Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease? BMC Nephrology. [PMID 40468228](https://pubmed.ncbi.nlm.nih.gov/40468228/) 3. \[3\] Corrêa LMA, Brandão LKV, Delmiro Silva YR, Ferreira GD, Mazur GR, Arruda SLP, et al. (2026). GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing Translational Research. [PMID 42398811](https://pubmed.ncbi.nlm.nih.gov/42398811/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can You Take a GLP-1 With Sickle Cell Disease? One Cohort, 1,391 Pairs | This GLP In 1,391 matched pairs with sickle cell disease and type 2 diabetes, GLP-1 use came with fewer cardiovascular events (HR 0.61) and fewer vaso-occlusive crises (HR 0.64). Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With Sickle Cell Disease? One Cohort, 1,391 Pairs Vaso-occlusive crises ran 36% lower among GLP-1 users in the only matched cohort that exists, but kidney progression, which matters as much in this disease, was measured far too imprecisely to call either way. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read 1,391 matched pairs, 12 months · cardiovascular events · 0.61 · stroke · 0.47 · pain crises · 0.64 · kidney disease · 1.26 · hypoglycemia · 1.10 · Dashed line marks no difference. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched cohort of 1,391 pairs with both sickle cell disease and type 2 diabetes compared GLP-1 users against non-users over 12 months. - Major cardiovascular events were lower (HR 0.61, 95% CI 0.49-0.76) and so were vaso-occlusive pain crises (HR 0.64, 95% CI 0.45-0.91). - Stroke came in at HR 0.47, with an interval of 0.23 to 0.97 that clears 1 by three hundredths. - No difference appeared in hypoglycemia or in progression to chronic kidney disease, where the interval reaches 1.95. Nobody has run a trial to find out, and the one matched cohort that exists points favorably rather than conclusively. Across 1,391 pairs with both sickle cell disease and type 2 diabetes, followed for a year, painful vaso-occlusive crises occurred 36% less often among GLP-1 users, at a hazard ratio of 0.64 [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease#ref-1). People with this disease are largely absent from the trials that built the evidence base for these drugs, and 84.5% of the cohort were Black. That is a group underrepresented in almost every study covered here, including the access picture in [uptake after a heart attack or stroke](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke). The cardiovascular findings are roughly what this drug class produces elsewhere. Major adverse cardiovascular events came in at a hazard ratio of 0.61 (95% CI 0.49–0.76), and stroke at 0.47 (95% CI 0.23–0.97). The novel result is the one specific to the disease. Vaso-occlusive crises — the painful episodes that define sickle cell disease and drive most of its hospital admissions — occurred 36% less often among GLP-1 users (HR 0.64, 95% CI 0.45–0.91). That is not a cardiovascular benefit restated; it is a claim about the mechanism of the underlying disease, and there is no obvious precedent for it in this drug class. Whether an anti-inflammatory route could plausibly carry such an effect is the open question. The SELECT inflammation substudy is where it is usually raised, because semaglutide cut high-sensitivity CRP by 37.8% at 104 weeks against placebo [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease#ref-2). That is a marker rather than an outcome, read here in [the inflammation substudy](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation). Two results did not move, and one of them matters a lot Hypoglycemia showed no difference (HR 1.10), which is reassuring in a group already managing diabetes. Progression to chronic kidney disease also showed no difference, at HR 1.26 with an interval running to 1.95. Kidney disease is a leading cause of death in sickle cell disease, and an interval whose upper bound approaches a doubling is not evidence of safety — it is an estimate too imprecise to rule much out in either direction. Two limits shape how far any of this travels. Everyone in the study had type 2 diabetes as well as sickle cell disease, which is an unusual combination and not the typical patient with either condition. The stroke interval is the other limit, because 0.23 to 0.97 excludes 1 by a margin thin enough that a modest amount of unmeasured confounding would erase it. The same caution applies with equal force to [the glaucoma comparison](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma), where the upper bound was 0.96. What makes this worth reporting despite those limits is that the alternative is nothing. Rare-disease populations rarely accumulate enough participants for a trial, and a matched cohort of 1,391 pairs is a substantial body of evidence by the standards of the field it sits in. A result that would be preliminary in type 2 diabetes is, here, among the better evidence available — which is also true of the disease-specific findings in [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease). ## Frequently asked Do GLP-1 drugs reduce sickle cell pain crises? This cohort found 36% fewer vaso-occlusive crises among users (HR 0.64, 95% CI 0.45-0.91). It is observational, so it establishes an association rather than an effect, but it is a disease-specific finding without obvious precedent. Is it safe for the kidneys? The study could not tell. Progression to chronic kidney disease showed no significant difference, but the interval ran from 0.82 to 1.95, which is too wide to rule out meaningful harm or benefit. Does this apply to sickle cell disease generally? Not directly. Every participant also had type 2 diabetes, which is an unusual combination and not representative of most people with sickle cell disease. ## Sources 1. \[1\] Nguefang GL, Boateng S, Gyabaah S, Issaka Y, et al. (2026). Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis Orphanet Journal of Rare Diseases. [PMID 41904481](https://pubmed.ncbi.nlm.nih.gov/41904481/) 2. \[2\] Plutzky J, Bogdański P, Colhoun HM, Dağdelen S, et al. (2026). Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis Circulation. [PMID 42610271](https://pubmed.ncbi.nlm.nih.gov/42610271/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks | This GLP Ozempic does not list a specific ibuprofen prohibition. Dehydration, kidney disease, and your other medicines can change the answer. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic Updated: 2026-10-13 Published: 2026-10-13 [← Research](https://thisglp.com/research) Safety # Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks Ozempic does not list a specific ibuprofen prohibition. Dehydration, kidney disease, and your other medicines can change the answer. [This GLP Editorial Team](https://thisglp.com/about)October 20265 min read Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Ozempic's prescribing information does not list ibuprofen as a specifically prohibited combination. But two issues still matter: your kidney health and whether you are dehydrated. Ibuprofen can contribute to acute kidney injury during dehydration or low blood pressure, according to NIDDK. [\[1\]](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic#ref-1)[\[2\]](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic#ref-2) That makes a blanket “yes, always safe” misleading. A pharmacist can review the reason you need pain relief, how long you expect to use it, and your full medication list. If diarrhea or vomiting prompted the question, start with our [GLP-1 dehydration guide](https://thisglp.com/research/glp1-dehydration-symptoms). ## Why vomiting or diarrhea changes the decision The Ozempic label warns about kidney injury associated with fluid loss from gastrointestinal reactions. [\[1\]](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic#ref-1) Separately, NSAIDs such as ibuprofen and naproxen can interfere with the kidneys' protective response when circulation is reduced. NIDDK specifically warns about NSAID use when sick and dehydrated. [\[2\]](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic#ref-2) This is a risk-factor discussion, not evidence that every person combining the medicines will have kidney injury. It also does not mean avoiding ibuprofen alone solves persistent vomiting. The cause of fluid loss still needs attention, particularly when you cannot drink normally. Our guides to [Ozempic-related diarrhea](https://thisglp.com/research/does-ozempic-cause-diarrhea) and [nausea during GLP-1 treatment](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) explain why symptom severity matters more than simply labeling a reaction “common.” ## Bring the whole medication list Include cold remedies, combination headache products, and nonprescription pain medicines. A product's brand name may not make its active ingredient obvious. Ask the pharmacist to check for duplicate NSAIDs and to consider your kidney function, blood pressure treatment, ulcer history, and other relevant risks before recommending an option. If you take an ACE inhibitor, an ARB, or a diuretic, ask your clinician for a written plan for illnesses that cause poor intake or fluid loss. NIDDK recommends planning these decisions before you get sick. Do not stop protective blood pressure medicines without instructions about which medicine, when, and how to restart it. [\[2\]](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic#ref-2) ## Would separating the doses fix the concern? There is no label-based rule saying an hour or a day between ibuprofen and the Ozempic injection removes kidney risk. Ozempic also delays stomach emptying and may affect absorption of oral medicines. [\[1\]](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic#ref-1) A spacing rule cannot substitute for checking whether ibuprofen is appropriate in the first place. Ask about the specific product and your circumstances rather than looking for a universal timing trick. The discussion is especially important when the pain itself is new, severe, or unexplained. ## When pain needs assessment instead of another painkiller Severe persistent abdominal pain deserves prompt medical evaluation, especially if it radiates to the back or comes with repeated vomiting. Our [pancreatitis guide](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis) explains the distinction between a recognized warning and the much more common experience of mild stomach upset. Very little urine, confusion, fainting, or an inability to keep fluids down also calls for urgent help rather than self-managing with pain medicine. MedlinePlus describes reduced urination and neurologic symptoms among important dehydration warning signs. [\[3\]](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic#ref-3) For a routine headache or familiar minor pain, the useful next step is simple: ask a pharmacist which option fits your medication list and health history. The safest choice may differ between someone eating and drinking normally and someone who has been vomiting all day. ## Frequently asked Is ibuprofen specifically banned with Ozempic? No specific ibuprofen prohibition appears in the Ozempic label. That does not establish that ibuprofen is appropriate for every patient. Should I take ibuprofen if Ozempic has caused vomiting? Check with a clinician or pharmacist first, particularly if you are dehydrated or have kidney disease. NSAIDs can increase kidney injury risk during fluid depletion. Can I avoid the risk by taking ibuprofen on a different day? Spacing doses is not a substitute for checking kidney risk, hydration, other medicines, and the reason for the pain. ## Sources 1. \[1\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection: U.S. prescribing information Novo Nordisk; revised May 2026. [Source](https://www.novo-pi.com/ozempic.pdf) 2. \[2\] National Institute of Diabetes and Digestive and Kidney Diseases (2018). Keeping Kidneys Safe: Smart Choices about Medicines NIDDK. [Source](https://www.niddk.nih.gov/health-information/kidney-disease/keeping-kidneys-safe) 3. \[3\] U.S. National Library of Medicine (2026). Dehydration MedlinePlus; accessed October 13, 2026. [Source](https://medlineplus.gov/dehydration.html) ## More in Safety - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) - [ 1–4 bpm · Mean rise vs placebo · Resting pulse · Track consistently · Persistent rise · Contact prescriber ### Does Wegovy Increase Heart Rate? Understanding the Numbers ](https://thisglp.com/research/does-wegovy-increase-heart-rate) --- # Can You Take Metformin and Ozempic Together? Most Trials Required It | This GLP Can you take metformin and Ozempic together? All 1,201 adults in SUSTAIN 7 were on metformin | semaglutide left metformin exposure unchanged in an interaction study. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-metformin-and-ozempic-together Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Can You Take Metformin and Ozempic Together? Most Trials Required It SUSTAIN 7, SUSTAIN 8 and SUSTAIN China enrolled only people already on metformin, and an interaction study found semaglutide left metformin levels unchanged. The stomach is where the two drugs overlap. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Semaglutide trials where every participant took metformin · SUSTAIN 8, 52 weeks · 788 adults · SUSTAIN China, 30 wks · 868 adults · SUSTAIN 7, 40 weeks · 1,201 adults · Adults with type 2 diabetes randomized after metformin alone was not enough. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, and most of the evidence for Ozempic was gathered in people doing exactly that. In SUSTAIN 7, all 1,201 adults were already on metformin when they were randomized, and those on semaglutide 1.0 mg lowered their HbA1c by 1.8 percentage points over 40 weeks [\[3\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-3). A separate interaction study gave healthy volunteers metformin before and alongside semaglutide 1.0 mg, and found no change in metformin exposure large enough to call for a different dose [\[1\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-1). ## Key takeaways - SUSTAIN 7 (1,201 adults), SUSTAIN 8 (788) and SUSTAIN China (868) enrolled only people already taking metformin. - In healthy volunteers, semaglutide 1.0 mg left metformin exposure inside the 0.80 to 1.25 no-interaction range. - Stomach side effects were common in the metformin trials: 43% to 47% of people on semaglutide reported one. - The Ozempic label's low-blood-sugar warning names sulfonylureas and insulin, not metformin. - Every trial here enrolled adults with type 2 diabetes; none of them tested the pair in people without it. The question usually arrives at the pharmacy counter, when the bag holds a bottle of metformin that has been in the kitchen cabinet for years and a new pen that needs a shelf in the refrigerator. The worry is reasonable: two drugs, both aimed at blood sugar, both with a reputation for upsetting the stomach. What follows is what the trials and the label actually recorded about taking them side by side, and where the record thins out. ## Most of the trials started with metformin already in the cabinet For people with type 2 diabetes, semaglutide was mostly tested as the second drug rather than the first. The Ozempic label lists trials of the drug alone and in combination with metformin, with metformin and a sulfonylurea, with metformin and/or a thiazolidinedione, and with basal insulin [\[6\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-6). Three of the head-to-head trials went further and required metformin as the entry ticket, so every person randomized was taking both drugs from the first week. SUSTAIN China randomized 868 adults whose HbA1c sat between 7.0% and 10.5% on metformin, and both semaglutide doses beat sitagliptin on HbA1c and body weight after 30 weeks [\[2\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-2). SUSTAIN 8 randomized 788 people on stable daily metformin to semaglutide 1.0 mg or canagliflozin, and 739 of them completed the year [\[4\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-4). In SUSTAIN 7 the weight fell by 6.5 kg on semaglutide 1.0 mg against 3.0 kg on the higher dulaglutide dose, again with metformin running underneath the whole time [\[3\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-3). Whether a weekly shot should replace metformin instead of joining it is a different question, and [whether a GLP-1 is better than metformin](https://thisglp.com/research/is-a-glp1-better-than-metformin) explains why no trial has settled it. ## What the interaction study measured The direct test of the pairing was a pharmacokinetic study in healthy subjects, funded by the manufacturer, with most of its authors on the company’s staff [\[1\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-1). Volunteers took metformin 500 mg twice daily for three and a half days, once before semaglutide and again once semaglutide 1.0 mg had reached steady state. The rule set in advance was that the ratio of metformin exposure with and without semaglutide had to fall between 0.80 and 1.25, and it did. That result is narrower than it sounds, and the scale matters. It shows that semaglutide does not push metformin levels up or down in the blood, which is the worry behind most interaction questions. It does not show how the two drugs feel together over months, it was not run at the 2 mg Ozempic dose, and it enrolled people without diabetes. The Wegovy label repeats the conclusion, listing metformin among drugs whose pharmacokinetics showed no clinically significant difference alongside semaglutide [\[7\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-7). ## The stomach is where the two overlap The practical concern is nausea, loose stools and the first bad week after a dose step, and here the metformin-background trials give a useful number without answering the whole question. In SUSTAIN 7, gastrointestinal disorders were the most common adverse event, reported by 43% of people on semaglutide 0.5 mg and 44% on 1.0 mg [\[3\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-3). In SUSTAIN 8 the figure was 47%, or 184 of 392 people, and 10% stopped semaglutide because of an adverse event against 5% on canagliflozin [\[4\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-4). Those percentages describe people taking both drugs, not the extra burden that combining them creates, because no one in those trials took semaglutide without metformin. The dulaglutide arms, on the same metformin background, landed at 33% and 48%, so the gap between arms followed the GLP-1 drug and its dose rather than the metformin every arm shared. How long the queasy stretch tends to last, dose step by dose step, is laid out in [how long nausea lasts on a GLP-1](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), and the mechanism behind it in [why GLP-1 drugs cause nausea](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea). ## Low blood sugar comes from a different partner The label’s interaction section warns about hypoglycemia when Ozempic is combined with an insulin secretagogue such as a sulfonylurea, or with insulin, and suggests lowering those doses when Ozempic starts [\[6\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-6). Metformin is not named in that warning. When Ozempic was taken with a sulfonylurea, severe hypoglycemia occurred in 0.8% on 0.5 mg and 1.2% on 1 mg, which is the combination the label singles out. SUSTAIN 4 shows the same pattern from the other side. Its 1,089 participants were on metformin, some with a sulfonylurea as well, and severe or glucose-confirmed hypoglycemia was reported by 4% on semaglutide 0.5 mg and 6% on 1.0 mg, against 11% on insulin glargine [\[5\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-5). For someone whose regimen includes insulin, the dose changes that follow a new GLP-1 are described in [how each semaglutide dose step took insulin away](https://thisglp.com/research/each-dose-step-took-insulin-away). Where the evidence stops Every trial above enrolled adults with type 2 diabetes, and the interaction study used one dose in healthy volunteers for a few days. None of these sources tested metformin with semaglutide in people without diabetes, or with compounded semaglutide, which is not FDA-approved and carries no label of its own. Whether to keep, lower or stop metformin after starting Ozempic is a prescriber’s decision, and none of these papers makes it. ## When there is no diabetes in the picture Many people asking about the pair do not have diabetes at all, and take metformin for insulin resistance or polycystic ovary syndrome. The Wegovy weight-loss program did include a trial of 807 people with type 2 diabetes, who could be taking up to three oral diabetes drugs with metformin among them [\[7\]](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together#ref-7). The small trial literature on GLP-1 drugs in polycystic ovary syndrome, where metformin is often the comparison, is gathered in [insulin resistance in PCOS on GLP-1 drugs](https://thisglp.com/research/glp1-pcos-insulin-resistance). What stays unresolved is the everyday version of the question: nobody has published how the pair behaves over a year in someone without diabetes, from the first pen to the maintenance dose. ## Frequently asked Can you take metformin and Ozempic together? Yes. In SUSTAIN 7, SUSTAIN 8 and SUSTAIN China, every participant was already taking metformin when semaglutide was added. In an interaction study, semaglutide 1.0 mg did not change metformin exposure enough to call for a dose change. Do Ozempic and metformin together cause more stomach problems? Stomach side effects were common in the metformin trials: 43% to 44% on semaglutide in SUSTAIN 7 and 47% in SUSTAIN 8. Because everyone took metformin, those trials cannot say how much of that the combination itself adds. Does metformin and Ozempic cause low blood sugar? The Ozempic label's hypoglycemia warning names sulfonylureas and insulin, not metformin. In SUSTAIN 4, on metformin with or without a sulfonylurea, severe or glucose-confirmed hypoglycemia occurred in 4% to 6% on semaglutide against 11% on insulin glargine. Should I stop metformin when I start Ozempic? The trials behind the label kept metformin running throughout. Changing or stopping it is a prescriber's decision; none of the studies here was designed to answer it. ## Sources 1. \[1\] Hausner H, Derving Karsbøl J, Holst AG, et al. (2017). Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects Clinical Pharmacokinetics. [PMID 28349387](https://pubmed.ncbi.nlm.nih.gov/28349387/) 2. \[2\] Ji L, Dong X, Li Y, et al. (2021). Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial Diabetes, Obesity and Metabolism. [PMID 33074557](https://pubmed.ncbi.nlm.nih.gov/33074557/) 3. \[3\] Pratley RE, Aroda VR, Lingvay I, et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial The Lancet Diabetes & Endocrinology. [PMID 29397376](https://pubmed.ncbi.nlm.nih.gov/29397376/) 4. \[4\] Lingvay I, Catarig AM, Frias JP, et al. (2019). Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial The Lancet Diabetes & Endocrinology. [PMID 31540867](https://pubmed.ncbi.nlm.nih.gov/31540867/) 5. \[5\] Aroda VR, Bain SC, Cariou B, et al. (2017). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial The Lancet Diabetes & Endocrinology. [PMID 28344112](https://pubmed.ncbi.nlm.nih.gov/28344112/) 6. \[6\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, sections 6.1, 7.1 and 14.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 7. \[7\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, sections 12.3 and 14 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can You Take Ozempic While Breastfeeding? 8 Mothers, No Drug Detected in Milk Eight mothers on injected semaglutide had no detectable drug in milk | what the Ozempic, Rybelsus and Zepbound labels say, and how small the lactation evidence is. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Can You Take Ozempic While Breastfeeding? 8 Mothers, No Drug Detected in Milk In the one milk study of injected semaglutide, none of eight mothers had detectable drug in milk. The Ozempic injection label still says there are no data, and the tablet labels advise against breastfeeding. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Every human milk study, by participant count · semaglutide, injected · 8 women · 0 samples with detectable drug · tirzepatide, one 5 mg dose · 11 women · 164 of 171 samples undetectable · No study measured drug levels in an infant. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The evidence is small. In the one milk study of injected semaglutide, eight mothers gave samples and none contained detectable drug [\[1\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-1). The worst-case estimate put the infant’s dose at 1.26% of the mother’s. The Ozempic injection label still says there are no data on semaglutide in human milk [\[7\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-7). The Ozempic and Rybelsus tablet labels say breastfeeding is not recommended [\[8\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-8). The reason is an additive in the tablet, not semaglutide itself. ## Key takeaways - Eight mothers on injected semaglutide gave milk samples. None had detectable semaglutide. - The study's worst-case estimate of the infant dose was 1.26% of the maternal dose. The usual threshold is 10%. - Eleven women took one 5 mg tirzepatide dose. Drug was undetectable in 164 of 171 milk samples. - The Ozempic injection label says there are no data on semaglutide in human milk. - The semaglutide tablet labels advise against breastfeeding because of SNAC, an absorption enhancer found in milk. - No study measured drug levels in an infant or measured milk production. This page covers lactation only. Exposure during pregnancy is a separate question with a larger literature, set out in [what the pregnancy evidence shows](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows). Why pregnancy becomes likelier on these drugs is in [the pregnancy log entry](https://thisglp.com/research/glp1-and-pregnancy). ## What each label says Labels are read in this order: the product, then section 8.2, then the data behind it. 1. **Ozempic injection.** There are no data on semaglutide in human milk, on the breastfed infant, or on milk production [\[7\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-7). Semaglutide was present in the milk of lactating rats. Rat milk levels were 3- to 12-fold lower than maternal plasma. The label says the clinical relevance of the rat data is not clear. 2. **Ozempic tablets and Rybelsus.** A clinical lactation study found semaglutide below the lower limit of quantification in milk [\[8\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-8). SNAC and its metabolites were present in milk. Infants may clear SNAC more slowly than adults. The label advises that breastfeeding is not recommended on these tablets. 3. **Zepbound (tirzepatide).** In a single-dose lactation study, tirzepatide in milk was undetectable or low [\[9\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-9). There are no data on effects in the breastfed infant or on milk production. The injection labels for Ozempic and Zepbound use the same closing sentence. The benefits of breastfeeding are weighed against the mother’s need for the drug and any potential effect on the infant. The label does not settle that weighing either way. The tablet format, and how it differs from the pen, is covered in [how oral semaglutide is taken](https://thisglp.com/research/how-do-you-take-oral-semaglutide). ## The semaglutide milk study A milk bank released samples from eight women taking injected semaglutide [\[1\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-1). Samples were taken at 0, 12 and 24 hours after a dose. The assay’s limit of detection was 1.7 ng/mL. Semaglutide was not detected in any sample. The authors then assumed milk held drug at the limit of quantification. That is a worst case, since nothing was found. On that assumption the maximum relative infant dose was 1.26%. The standard safety threshold they cite is 10%. LactMed adds the details the abstract leaves out [\[5\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-5). The mothers took 0.25 to 1 mg a week. Their infants were 4 to 23 months old and mixed fed. They received breastmilk for 3 to 9 weeks during treatment. Normal growth and development were reported by the mothers. The weekly doses sit at the start of the ladder described in [the semaglutide starting dose](https://thisglp.com/research/semaglutide-starting-dose). ## The tirzepatide data Eleven healthy lactating women took one 5 mg dose of tirzepatide [\[9\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-9). Milk was sampled over 28 days. Drug was undetectable in 164 of 171 samples. The other seven samples held less than 0.02% of the dose in total. The last measurable level came 5 days after the dose. One dose is not weekly use. LactMed says levels at steady state are probably higher than this study shows [\[6\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-6). It also reports a preprint of five women taking 2.5 to 5 mg weekly. No sample exceeded the limit of quantification. None of the mothers reported an adverse effect in the infant attributable to the drug. LactMed’s summary is conditional. Tirzepatide is not a reason to stop breastfeeding if a mother requires it [\[6\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-6). It should be used with caution until more data exist. The caution applies especially to a newborn or preterm infant. What “not detected” does not cover Every figure above is a milk measurement. No study measured drug in an infant’s blood. Nobody measured milk production. Infant growth was reported by mothers, not measured by a clinic. Both LactMed entries note that some experts recommend monitoring infant growth and the mother’s nutritional status [\[5\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-5) [\[6\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-6). The nutrition side is covered in [vitamins on a GLP-1](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1). ## How small the evidence is Three reviews count the same gap from different directions. 1. A 2026 systematic review included 36 studies of use around pregnancy and lactation [\[2\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-2). Lactation data were sparse. It found one pharmacokinetic study, which reported no detectable semaglutide in milk. 2. A 2026 scoping review with consensus guidance included 34 articles [\[4\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-4). One was about lactation. Its introduction describes breastfeeding on these drugs as contraindicated. 3. A 2026 review of diabetes drugs in breastmilk covered 20 drugs [\[3\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-3). Five had human milk transfer data. Semaglutide was the only GLP-1 among them. That third review also graded the guidelines. Most recommendations, 78%, were against glucose-lowering drugs while breastfeeding [\[3\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-3). Only 4.4% were based on clinical evidence. The authors describe published recommendations as largely inconsistent. So the sources point in different directions. LactMed lists semaglutide and tirzepatide as alternatives to each other. A consensus paper calls breastfeeding contraindicated. The injection labels leave the weighing open. The human milk data behind all three total 24 women. ## Where this meets pregnancy and fertility A breastfeeding mother may also be planning the next pregnancy. The Ozempic label says to stop at least 2 months before a planned pregnancy [\[7\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-7). The reason given is the long washout period. Fertility evidence is also thin, and is set out in [whether GLP-1 drugs affect fertility](https://thisglp.com/research/do-glp1-drugs-affect-fertility). Postpartum contraception has its own label rule. The Zepbound label says tirzepatide may reduce the efficacy of oral hormonal contraceptives [\[9\]](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding#ref-9). It advises a non-oral method, or an added barrier method, for 4 weeks after starting. The same applies for 4 weeks after each dose increase. The study behind that rule is in [tirzepatide and oral contraception](https://thisglp.com/research/tirzepatide-and-oral-contraception). ## How this site handles the question This site reports what the labels and studies say. It does not advise starting, stopping or continuing a drug while breastfeeding. That decision belongs to the prescriber, and the infant’s pediatrician is part of it. Compounded semaglutide and tirzepatide are not FDA-approved. They carry no label of their own, so no section 8.2 applies to them. Whether a seller publishes a lactation policy at all is tracked in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Can you take Ozempic while breastfeeding? The Ozempic injection label says there are no data on semaglutide in human milk and leaves the decision to the prescriber. In one study of eight mothers on injected semaglutide, no milk sample had detectable drug. Can you take a GLP-1 while breastfeeding? Human milk data exist for two: injected semaglutide in eight women and tirzepatide in eleven after one 5 mg dose. LactMed says tirzepatide is not a reason to stop breastfeeding if a mother requires it, with caution for newborn or preterm infants. Does Ozempic get into breast milk? In the one human study, semaglutide was not detected in any milk sample. The worst-case estimate put the infant dose at 1.26% of the maternal dose. In rats, semaglutide did appear in milk. Is the Ozempic pill different while breastfeeding? Yes. The Rybelsus and Ozempic tablet labels say breastfeeding is not recommended. The tablets contain SNAC, an absorption enhancer found in human milk that infants may clear more slowly. ## Sources 1. \[1\] Diab H, et al. (2024). Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk Nutrients. [PMID 39275201](https://pubmed.ncbi.nlm.nih.gov/39275201/) 2. \[2\] Ozbek L, et al. (2026). Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes Diabetes, Obesity and Metabolism. [PMID 41885132](https://pubmed.ncbi.nlm.nih.gov/41885132/) 3. \[3\] Richardson K, et al. (2026). Maternal-to-Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines Clinical Pharmacology and Therapeutics. [PMID 41670332](https://pubmed.ncbi.nlm.nih.gov/41670332/) 4. \[4\] Maslin K, et al. (2026). Incretin-Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice Obesity Reviews. [PMID 42528099](https://pubmed.ncbi.nlm.nih.gov/42528099/) 5. \[5\] National Institute of Child Health and Human Development (2026). Semaglutide. Drugs and Lactation Database (LactMed), updated 2026 Aug 15 NCBI Bookshelf, National Library of Medicine. [Source](https://www.ncbi.nlm.nih.gov/books/NBK500980/) 6. \[6\] National Institute of Child Health and Human Development (2026). Tirzepatide. Drugs and Lactation Database (LactMed), updated 2026 Aug 15 NCBI Bookshelf, National Library of Medicine. [Source](https://www.ncbi.nlm.nih.gov/books/NBK581488/) 7. \[7\] U.S. Food and Drug Administration (2026). Prescribing information for Ozempic (semaglutide) injection, accessed via DailyMed DailyMed, National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 8. \[8\] U.S. Food and Drug Administration (2026). Prescribing information for Rybelsus and Ozempic (oral semaglutide) tablets, accessed via DailyMed DailyMed, National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) 9. \[9\] U.S. Food and Drug Administration (2026). Prescribing information for Zepbound (tirzepatide) injection, accessed via DailyMed DailyMed, National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can You Take Ozempic With Levothyroxine? The Tablet Form Is the One Studied Ozempic and levothyroxine: thyroxine exposure rose 33% with oral semaglutide in 45 volunteers | the injection label reports no relevant effect on oral drugs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Can You Take Ozempic With Levothyroxine? The Tablet Form Is the One Studied Thyroxine exposure rose 33% when levothyroxine was taken with oral semaglutide. The Ozempic injection label reports no clinically relevant effect on oral drugs, and weight loss is the other route to watch. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Total T4 exposure after one levothyroxine 600 mcg dose · Levothyroxine alone · 100% · With oral semaglutide 14 mg · 133% (peak level unchanged) · 45 healthy volunteers. The tablet was tested; the weekly pen was not. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes. No label forbids the combination. The one interaction study used the tablet form of semaglutide [\[1\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-1). In 45 healthy volunteers, total thyroxine exposure rose 33% when levothyroxine was taken with oral semaglutide 14 mg. For the weekly injection, the Ozempic label reports no clinically relevant effect on the absorption of oral drugs [\[3\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-3). ## Key takeaways - Total thyroxine exposure rose 33% when levothyroxine was taken with oral semaglutide 14 mg. Peak level did not change. - That study used the tablet. The Ozempic injection label reports no clinically relevant effect on oral drug absorption. - The tablet label advises closer monitoring for oral drugs that need it, and gives levothyroxine's 33% rise as its example. - Weight loss can lower the dose of levothyroxine a person needs. Case reports describe excess thyroid hormone on semaglutide and tirzepatide. - In a Medicare study, about 83% of levothyroxine users had a TSH test within a year of starting a GLP-1. Two separate questions sit under this one. The first is absorption: whether the GLP-1 changes how much levothyroxine reaches the blood. The second is dose: whether losing weight changes how much levothyroxine a person needs. The labels answer the first. The second rests on thinner evidence. Thyroid cancer is a third question, answered in [whether GLP-1 drugs cause thyroid cancer](https://thisglp.com/research/do-glp1-drugs-cause-thyroid-cancer). ## What each label says Labels are read in this order: the product, then the interaction section. 1. **Ozempic injection.** Semaglutide delays gastric emptying, which could affect oral drugs [\[3\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-3). In clinical pharmacology trials, it did not affect their absorption to any clinically relevant degree. The label advises caution with oral drugs taken alongside it. 2. **Rybelsus and Ozempic tablets.** Levothyroxine exposure rose 33%, with a 90% confidence interval of 1.25 to 1.42 [\[2\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-2). For oral drugs with a narrow therapeutic index or that need clinical monitoring, the label says to consider more monitoring. 3. **Wegovy injection.** The label repeats both findings [\[4\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-4). The 1 mg injection did not affect oral drug absorption. The tablet raised levothyroxine exposure 33%. It advises monitoring oral drugs that have a narrow therapeutic index. So the rule differs by form. The tablet carries a measured interaction. The pen carries a general caution. The tablet’s own dosing rules are covered in [how oral semaglutide is taken](https://thisglp.com/research/how-do-you-take-oral-semaglutide). ## The tablet study Four of the trial’s five authors worked for the manufacturer [\[1\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-1). They note that levothyroxine has dosing conditions similar to the tablet’s. 1. 45 healthy subjects took one 600 mcg dose of levothyroxine alone. 2. They took it again with oral semaglutide 14 mg at steady state. 3. They also took it with SNAC 300 mg, the tablet’s absorption enhancer, alone. Total T4 exposure rose 33% with oral semaglutide. The baseline-corrected peak did not change. SNAC alone did not affect total exposure. The authors concluded that thyroid monitoring should be considered when both drugs are used. The same study tested the reverse direction. Five placebo tablets taken with oral semaglutide cut semaglutide exposure 34% [\[1\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-1). The tablet label handles this with a timing rule. Take it with up to 4 ounces of water. Then wait at least 30 minutes before food, drinks or other oral drugs [\[2\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-2). A 2025 review of GLP-1 drug interactions reached the same split [\[5\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-5). It found most gastric-emptying interactions clinically insignificant. It named levothyroxine with oral semaglutide as one of two exceptions needing close monitoring. The other was oral contraceptives with tirzepatide, covered in [tirzepatide and oral contraception](https://thisglp.com/research/tirzepatide-and-oral-contraception). ## The weight-loss route Levothyroxine doses are set partly by body weight. A 2025 case report estimates the average adult need at 1.6 micrograms per kilogram [\[7\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-7). The patient was stable on levothyroxine, started semaglutide and lost weight quickly. She developed palpitations and new hyperthyroidism. Her levothyroxine dose was reduced. A 2024 report described thyrotoxicosis from excess levothyroxine in a 62-year-old man whose weight fell quickly on tirzepatide [\[9\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-9). Those are two patients. The 2025 authors say the mechanism is unknown. It may be increased absorption, or the weight loss itself. They advise monitoring for hyperthyroidism and expecting that a dose reduction may be needed. A Medicare study looked at testing, not outcomes [\[6\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-6). It matched 5,370 adults aged 65 or older with type 2 diabetes on a stable levothyroxine dose. About 83% had a TSH test within one year, on either drug class. The mean time to that test was about 130.5 days. The authors call the lack of any difference a missed opportunity for monitoring. Where the evidence stops The 33% figure comes from one dose in healthy volunteers taking the tablet. No study here measured TSH changes in people with hypothyroidism on the Ozempic pen. A 2024 review found the thyroid-function evidence on GLP-1 drugs inconclusive, with conflicting results [\[8\]](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine#ref-8). It advised thyroid function tests in the routine screening of patients with diabetes. This site does not advise on levothyroxine dosing. That decision belongs to the prescriber. ## How this applies to each form 1. **Weekly pen.** The label reports no clinically relevant absorption effect. Weight loss is the route to watch. 2. **Daily tablet.** The label reports a 33% rise in exposure. Both routes apply. 3. **Compounded semaglutide.** It is not FDA-approved and carries no label. No interaction data apply to it directly. The pill and the pen are compared in [the pill-versus-injection evidence](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection). ## Frequently asked Can you take Ozempic with levothyroxine? No label forbids it. The Ozempic injection label reports no clinically relevant effect on the absorption of oral drugs. The tablet form raised thyroxine exposure 33% in an interaction study, and its label advises closer monitoring. Is Ozempic safe with hypothyroidism? Hypothyroidism is not a contraindication on the Ozempic label. Weight loss can lower the levothyroxine dose a person needs, and case reports describe excess thyroid hormone after rapid weight loss on semaglutide. Does Ozempic affect the thyroid? A 2024 literature review found the evidence on GLP-1 drugs and thyroid function inconclusive, with conflicting results, and advised thyroid function tests in routine screening. The cancer question is separate. How far apart should levothyroxine and the semaglutide tablet be taken? The tablet label says to take semaglutide with up to 4 ounces of water and wait at least 30 minutes before food, drinks or other oral drugs. It does not set a separate levothyroxine schedule. ## Sources 1. \[1\] Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Bækdal TA (2021). Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial Expert Opinion on Drug Metabolism & Toxicology. [PMID 34289755](https://pubmed.ncbi.nlm.nih.gov/34289755/) 2. \[2\] Novo Nordisk (2026). RYBELSUS and OZEMPIC (semaglutide) tablets, for oral use — prescribing information, sections 2.1, 7.2 and 12.3 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) 3. \[3\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, section 7.2 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 4. \[4\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, sections 7 and 12.3 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 5. \[5\] Min JS, Jo SJ, Lee S, et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist Drug Design, Development and Therapy. [PMID 40330819](https://pubmed.ncbi.nlm.nih.gov/40330819/) 6. \[6\] Chen Y, Du F, Singh Ospina NM, et al. (2026). Patterns of TSH test after GLP-1 RAs initiation in patients on levothyroxine: a trial emulation study The Journal of Clinical Endocrinology and Metabolism. [PMID 41902399](https://pubmed.ncbi.nlm.nih.gov/41902399/) 7. \[7\] Barnett MJL, Eidbo S, Rivadeneira A (2025). Semaglutide therapy and iatrogenic thyrotoxicosis Endocrinology, Diabetes & Metabolism Case Reports. [PMID 40638337](https://pubmed.ncbi.nlm.nih.gov/40638337/) 8. \[8\] Capuccio S, Scilletta S, La Rocca F, et al. (2024). Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels Biomolecules. [PMID 38927090](https://pubmed.ncbi.nlm.nih.gov/38927090/) 9. \[9\] Karakus KE, Shah VN, Akturk HK (2024). Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis JAMA Internal Medicine. [PMID 39102259](https://pubmed.ncbi.nlm.nih.gov/39102259/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can You Take Phentermine With Ozempic? No Trial Has Tested It, One Tried Liraglutide Can you take phentermine with Ozempic? No trial has tested it, and the label advises against it | added to liraglutide, it gave 1.6% vs 0.1% over 12 weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-phentermine-with-ozempic Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Can You Take Phentermine With Ozempic? No Trial Has Tested It, One Tried Liraglutide No trial has combined phentermine with semaglutide, and the phentermine label advises against pairing it with any weight-loss drug. Added to liraglutide for 12 weeks, it took off 1.6% against 0.1% on placebo, not a significant gap. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Extra weight lost over 12 weeks, on top of liraglutide · + phentermine 15 mg · −1.6% · + placebo · −0.1% · p = 0.073: not significant. 45 adults. · All had already lost 12.6% on liraglutide over a year. · Liraglutide, not semaglutide. No semaglutide trial found. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No trial has tested phentermine with Ozempic. The phentermine label says combining it with any other weight-loss drug is not recommended [\[1\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-1). The reason given is that safety and efficacy have not been established. The closest trial added phentermine to liraglutide, an older daily GLP-1 [\[2\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-2). Over 12 weeks, 45 adults lost 1.6 percent more on phentermine against 0.1 percent on placebo. That difference was not significant. ## Key takeaways - No randomized trial has combined phentermine with semaglutide (Ozempic, Wegovy) or tirzepatide. - The phentermine label says coadministration with other weight-loss drugs is not recommended. - One 12-week trial added phentermine 15 mg to liraglutide. Weight fell 1.6% against 0.1% on placebo (p = 0.073). - Phentermine is labeled for short-term use of a few weeks. Wegovy is labeled for long-term use. - Both drugs can raise heart rate, and phentermine can raise blood pressure. This page covers the pairing only. The full list of alternatives is in [what weight loss drugs there are besides Ozempic](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic). Stalled weight loss, the usual reason for asking, is covered in [why weight loss plateaus on a GLP-1](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1). ## What the phentermine label says The label sets four rules [\[1\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-1): 1. Phentermine is a short-term treatment, for a few weeks. 2. It is indicated as monotherapy. 3. Safety and efficacy with any other weight-loss drug are not established. That covers prescription drugs, over-the-counter products and herbal products. 4. Coadministration with those products is not recommended. Phentermine is a Schedule IV controlled substance. Its listed reactions include raised blood pressure, a fast heart rate and palpitations. The label advises caution in patients with even mild hypertension. The label does not name semaglutide or tirzepatide. The rule covers them because it covers every prescription weight-loss drug. ## The one trial: phentermine added to liraglutide The trial enrolled 45 adults who had already lost 12.6 percent of their weight [\[2\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-2). That loss came from a year of liraglutide 3.0 mg and intensive behavioral treatment. They were then randomized, double-blind, to add phentermine 15 mg or placebo for 12 weeks. Results at week 12: 1. Further weight loss: 1.6 percent on phentermine, 0.1 percent on placebo (p = 0.073). 2. A further 5 percent or more: 2 people (9.1%) against 1 (4.3%). 3. Kept the full earlier loss: 86.4 percent against 69.9 percent (p = 0.125). Hunger and food preoccupation fell more on phentermine in the first 8 weeks. The combination appeared well tolerated. The authors concluded it did not add clinically meaningful weight loss. Three limits apply. The GLP-1 was liraglutide, not semaglutide. The sample was 45 people. The trial ran 12 weeks, and safety over a longer course was not measured. ## How each drug performs alone The single-drug trials started from full weight, so their results do not compare directly with the add-on trial. A 2024 review pooled them against placebo [\[3\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-3). Semaglutide gave 11.4 percent more weight loss, across 5 trials and 4,421 people. Tirzepatide 15 mg gave 12.4 percent more. Phentermine-topiramate, the combination capsule, gave 8.0 percent more. A 2025 meta-analysis covered 56 trials and 60,307 patients [\[4\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-4). Semaglutide and tirzepatide each exceeded 10 percent total weight loss against placebo. Only two of those trials tested phentermine-topiramate. How weight loss trades against dropout across these drugs is in [the 262-trial ranking](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). A 2026 review of combination regimens reached a general finding [\[5\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-5). Adding an approved obesity drug to a GLP-1 was generally additive, not synergistic. It also brought more complexity, cost and adverse-event risk. ## Heart rate and blood pressure Semaglutide raises resting heart rate. On Wegovy, mean increases were 1 to 4 beats per minute against placebo [\[6\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-6). A rise of 20 beats or more at any visit occurred in 26 percent against 16 percent. The label says to monitor heart rate. Phentermine lists a fast heart rate and raised blood pressure among its reactions [\[1\]](https://thisglp.com/research/can-you-take-phentermine-with-ozempic#ref-1). No study reported heart rate or blood pressure on the two drugs together. How GLP-1 drugs behave in people with high blood pressure is covered in [the resistant hypertension evidence](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension). Where the evidence stops No trial has tested phentermine with semaglutide or tirzepatide, at any dose or for any length of time. The liraglutide trial is the nearest evidence and it is small. Compounded semaglutide is not FDA-approved, and no study has paired it with phentermine. ## Frequently asked Can you take Ozempic and phentermine together? No trial has tested it. The phentermine label says safety and efficacy with any other weight-loss drug are not established, and that coadministration is not recommended. Has phentermine and semaglutide been studied? Not in a randomized trial. The only randomized trial of phentermine with a GLP-1 used liraglutide. Adding phentermine 15 mg for 12 weeks gave 1.6% further weight loss against 0.1% on placebo, which was not significant. Does adding phentermine to Ozempic break a plateau? That has not been measured. In the liraglutide trial, people had already lost 12.6%, and adding phentermine did not produce clinically meaningful further loss. How long can phentermine be taken? The label indicates it for short-term use of a few weeks, as monotherapy. It is a Schedule IV controlled substance. ## Sources 1. \[1\] Calvin Scott & Co., Inc. (2026). LOMAIRA (phentermine hydrochloride) tablets, CIV — prescribing information, Indications, Warnings, Adverse Reactions and Drug Abuse and Dependence DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0718f0f3-77f2-45d7-be12-1ed718c8b806) 2. \[2\] Tronieri JS, Wadden TA, Walsh OA, Berkowitz RI, Alamuddin N, Gruber K, Leonard S, Chao AM (2019). Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial Metabolism: Clinical and Experimental. [PMID 30902750](https://pubmed.ncbi.nlm.nih.gov/30902750/) 3. \[3\] Gudzune KA, Kushner RF (2024). Medications for Obesity: A Review JAMA. [PMID 39037780](https://pubmed.ncbi.nlm.nih.gov/39037780/) 4. \[4\] McGowan B, Ciudin A, Baker JL, et al. (2025). A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults Nature Medicine. [PMID 41039116](https://pubmed.ncbi.nlm.nih.gov/41039116/) 5. \[5\] Kamrul-Hasan ABM, Kalra A, Kapoor N, Dutta D, Mahajan K, Maskey R, Raza SA (2026). Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions Endocrinology, Diabetes & Metabolism. [PMID 42581493](https://pubmed.ncbi.nlm.nih.gov/42581493/) 6. \[6\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, section 5.9 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Can You Trust GLP-1 Advice on TikTok? Likes Do Not Track Quality | This GLP Can you trust GLP-1 advice on TikTok? Four studies found likes a poor guide to quality | median transparency was 2 of 4, and medical creators scored higher. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Can You Trust GLP-1 Advice on TikTok? Likes Do Not Track Quality Four studies graded GLP-1 content on social media. The median video scored 2 out of 4 for saying who made it. Likes were a poor guide to accuracy. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 225 semaglutide videos, median score on each instrument · Global Quality Scale · is it useful · 4/5 · mDISCERN · is it reliable · 4/5 · JAMA benchmark · who wrote it, and from what · 2/4 · 82.2% were about weight loss. 2.7% were about blood sugar. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Four studies scored or analyzed GLP-1 content on TikTok, Instagram, YouTube and other platforms. In the two that tested it, likes did not reliably track quality. - In 225 semaglutide videos, the median transparency score was 2 out of 4. That score asks who made the video and from what sources. - In 200 TikTok and Instagram videos, 68.5% came from non-medical creators. The average DISCERN score was 28.0 out of 80. - Videos from medical professionals scored higher in both short-video studies. - A five-platform analysis found misstated side effects and indications were very common. Some posts under an Ozempic hashtag sold products with no semaglutide in them. Not on popularity. In the two studies that tested it, likes did not reliably track quality. Across 225 semaglutide videos, the median scored 2 out of 4 for saying who made it and where its claims came from. Who uploaded a video predicted its quality. The four studies measured different things. Two scored semaglutide videos on Chinese short-video apps. One scored TikTok and Instagram. One read posts across five platforms and compared them with the trial data. The trial data itself is summarized in [the side effect comparison](https://thisglp.com/research/which-glp1-has-the-worst-side-effects). ## Useful, but unsourced One study scored 225 semaglutide videos from Bilibili and the Chinese TikTok [\[1\]](https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media#ref-1). Two reviewers applied three tools. Median usefulness was 4 out of 5. Median reliability was 4 out of 5. Median transparency was 2 out of 4. Transparency is a separate question from accuracy. It asks four things: who wrote it, what sources it used, what the author’s interests are, and when it was updated. A video can be accurate and still fail all four. When it does, a wrong video looks the same as a right one. Of the 225 videos, 82.2% were about weight loss against 2.7% about blood sugar, the condition the drug was developed for. The eligibility rules are set out in [the BMI cut-off guide](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1). ## Popular is not the same as good In the same study, more likes went with lower usefulness and reliability scores. On TikTok, more comments went with lower quality too. On Bilibili, more shares went with higher scores. A second study scored the top 100 semaglutide videos on each of the same two apps [\[2\]](https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media#ref-2). Likes correlated only weakly with quality, r = 0.151. Longer videos scored higher on reliability but drew no more engagement. Both author groups reach the same conclusion. Engagement is a poor guide to quality. ## Who made it matters most In the first study, videos from medical professionals scored higher on all three tools. Commercial videos scored lower on usefulness and reliability. In the second, medical professionals and institutions produced the more reliable content. Medical information scored higher than personal experience videos. A third study looked at who was making the videos [\[3\]](https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media#ref-3). It covered 200 TikTok and Instagram videos on GLP-1 drugs and sleeve gastrectomy. 31.5% came from medical professionals. The average DISCERN quality score was 28.0 out of 80. Instagram GLP-1 videos scored highest of the four groups. ## What gets left out A German analysis read semaglutide posts on Instagram, TikTok, X, Facebook and YouTube [\[4\]](https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media#ref-4). It compared them with the adverse reactions reported in the STEP trials. Misstatements about mechanism, indication, side effects and drug interactions were very common. Cost and supply shortages were barely covered. Three findings from the five-platform analysis The common stomach side effects went unmentioned on Instagram. Some posts under the Ozempic hashtag advertised products that contained no semaglutide. Weight loss result videos showed a high probability of AI modification. Those stomach effects, and how long they usually last, are covered in [the nausea timeline](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The analysis rated YouTube the most reputable platform. Instagram carried the least medical knowledge. ## How to check a GLP-1 video 1. Find who made it. A named clinician or institution scored higher in both short-video studies. 2. Look for a source. A trial name or a label beats a personal result. 3. Check that side effects are mentioned. Their absence was a common failure. 4. Treat a product link under a brand hashtag as unverified. Some contained no semaglutide. 5. Ignore the like count. It did not track quality in either study that measured it. A provider should cover the same ground a good video does. The standard is in [what a GLP-1 provider should do](https://thisglp.com/research/what-should-a-glp1-provider-actually-do). ## Frequently asked Can you trust GLP-1 advice on TikTok? Not on popularity. In 225 semaglutide videos the median transparency score was 2 out of 4, and more likes went with lower usefulness and reliability scores. Is semaglutide information on social media accurate? It varies by creator. Videos from medical professionals scored higher in two short-video studies, while a five-platform analysis found misstated side effects and indications very common. Do popular GLP-1 videos give better information? No. One study linked more likes to lower quality scores and another found only a weak correlation, r = 0.151. Both concluded engagement is a poor guide to quality. Are products sold under the Ozempic hashtag real semaglutide? Not always. An analysis of posts on five platforms found some products advertised under the Ozempic hashtag contained no semaglutide. ## Sources 1. \[1\] Li H, Peng F, Wang H (2026). Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok Frontiers in Public Health. [PMID 42620396](https://pubmed.ncbi.nlm.nih.gov/42620396/) 2. \[2\] Zeng J, Leng C, Chen X, Tang R, Wang Q, Zhang L (2026). Quality and Reliability of Semaglutide-Related Short Videos on TikTok and Bilibili American Journal of Health Promotion. [PMID 42077173](https://pubmed.ncbi.nlm.nih.gov/42077173/) 3. \[3\] Lee S, Narula N, Weglarz M, Lee J, Kim D (2025). Evaluation of social media videos on weight-loss surgery and GLP-1 agonists: a content quality and reliability analysis Surgical Endoscopy. [PMID 40634725](https://pubmed.ncbi.nlm.nih.gov/40634725/) 4. \[4\] Propfe LE, Seifert R (2026). Misrepresentation of semaglutide in social media Naunyn-Schmiedeberg's Archives of Pharmacology. [PMID 40682686](https://pubmed.ncbi.nlm.nih.gov/40682686/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Drugs at the Start of Hemodialysis: Hospitalization and Death | This GLP A matched cohort of 2,492 pairs starting hemodialysis found GLP-1 use linked to 9% lower hospitalization and 17% lower mortality, against a prior literature of 388 patients. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/dialysis-the-evidence-base-just-grew Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs at the Start of Hemodialysis: Hospitalization and Death A matched cohort of 2,492 pairs starting in-center hemodialysis linked GLP-1 use to 9% lower hospitalization and 17% lower mortality. The prior literature was 388 patients, and a baseline gap is worth reading first. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Evidence in dialysis patients · previously, all studies combined · 388 patients · this one cohort · 2,492 matched pairs · Hospitalization 9% lower. Mortality 17% lower. · And 98% of the treated group had diabetes, against 73% of controls. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched cohort followed 2,492 patients who started in-center hemodialysis while on a GLP-1 drug, against 2,492 who did not. - Hospitalization was 9% lower (IRR 0.91, 95% CI 0.87-0.96) and mortality 17% lower (IRR 0.83, 95% CI 0.73-0.95). - The two groups differed substantially before treatment: 98% of GLP-1 users had diagnosed diabetes against 73% of controls, and 76% had predialysis nephrology care against 67%. - The FLOW trial that motivated the question studied chronic kidney disease and did not include people on dialysis. This site reported not long ago that [the entire world literature on these drugs in dialysis patients was 388 people](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis) across 19 studies. That is now out of date. A single matched cohort at a large dialysis organization has followed 2,492 patients who began in-center hemodialysis while on a GLP-1 drug, against an equal number who did not [\[1\]](https://thisglp.com/research/dialysis-the-evidence-base-just-grew#ref-1). The results point the same way as the rest of this literature. Hospitalization ran 9% lower (incidence rate ratio 0.91, 95% CI 0.87–0.96) and mortality 17% lower (IRR 0.83, 95% CI 0.73–0.95). Both are incidence rate ratios rather than hazard ratios, because hospitalization recurs and the model is counting episodes rather than time to a first one. Hospitalization as an outcome, and what it captures, is discussed further in [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease). Look at who was taking it before you read the effect Among patients on a GLP-1 drug at dialysis initiation, 98% had a diagnosis of diabetes against 73% of the comparison group, 76% had received predialysis nephrology care against 67%, and mean BMI was 33 against 30. Predialysis nephrology care is one of the best-established predictors of doing well on dialysis and has nothing to do with any drug — it means someone was seen, planned for and started in an orderly way. Matching and adjustment narrow a gap like that; they do not close it. The reason this question was open at all is worth stating precisely, because it is easy to assume it was already answered. The FLOW trial showed semaglutide reducing kidney and cardiovascular outcomes in chronic kidney disease with type 2 diabetes — but it studied people whose kidneys were failing, not people whose kidneys had failed. End-stage disease on dialysis is a different physiological state, a different drug-clearance situation and a different population, which is why an entire literature of 388 patients existed alongside a major positive trial. What this cohort supplies is scale rather than certainty. Thirteen times the previous evidence base, pointing in a plausible direction, from data an organization already held — and with a baseline imbalance large enough that the honest summary is encouraging rather than established. A randomized trial in dialysis patients remains the thing that would settle it, and the same structure of argument applies to every observational result on this site, including [the sickle cell cohort](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease) and [the kidney disease evidence](https://thisglp.com/research/semaglutide-and-kidney-disease). For anyone in this situation the practical point is narrow: the question is now one a nephrologist can discuss with actual numbers rather than with an admission that nothing has been studied. That is a meaningful change even though nothing has been proved. ## Frequently asked Did the FLOW trial not already cover this? No. FLOW studied chronic kidney disease with type 2 diabetes and did not include people on dialysis. End-stage kidney disease is a different physiological state with different drug clearance. How strong is this evidence? It is much larger than anything before it and observational. The treated group differed notably at baseline — 98% versus 73% with diagnosed diabetes, and more predialysis nephrology care — which matching narrows without eliminating. What did it find? Among patients starting in-center hemodialysis, GLP-1 use was associated with a 9% lower hospitalization rate and a 17% lower mortality rate. ## Sources 1. \[1\] Karpinski S, Qazi R, Bjordahl T, Sibbel S, Weinhandl E, Tentori F, Brunelli SM (2026). Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease Clinical Journal of the American Society of Nephrology. [PMID 42640716](https://pubmed.ncbi.nlm.nih.gov/42640716/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Discounts vs Seller Disclosure: Dose Ladders and State Lists | This GLP Do GLP-1 sellers using first-month rates, codes or struck-through prices disclose less? Compared on dose ladders, higher-dose pricing and state lists, the answer runs the other way. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-discounting-sellers-disclose-less Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Discounts vs Seller Disclosure: Dose Ladders and State Lists A page covered in struck-through prices reads as less trustworthy than a plain one. Discounting GLP-1 sellers publish a dose ladder more often, not less, and the reason is structural. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 solid = uses promotional wording · pale = does not · publishes a dose ladder · 80% · 28% · states what the price does at a higher dose · 43% · 35% · publishes a list of states · 47% · 32% · The top pair runs the opposite way from the intuition. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 99 rankable sellers use promotional wording in their recorded pricing; 481 do not. - Sellers who discount publish a dose ladder more often, not less: 80% against 28%. - On stating what the price does at a higher dose the two groups are level: 43% against 35%. - On publishing a state list they are close: 47% against 32%. - The intuition that a hard-selling page tells you less does not hold on this roster. A page covered in struck-through prices and first-month offers reads as less trustworthy than a plain one, and it is natural to expect that it also tells you less. That expectation is testable, and on this roster it is wrong — as wrong as the assumption tested in [is disclosure a trait](https://thisglp.com/research/is-seller-disclosure-a-trait), and in a more interesting direction. ## What the comparison shows 99 of the sellers this site can rank use promotional language somewhere in their recorded pricing — a first month, an introductory rate, a code, a struck-through anchor. The other 481 do not. On the hardest disclosure in this category, publishing a dose ladder, the promotional group does better: 80% against 28%. On stating what the price does at a higher dose the two are level at 43% and 35%, and on publishing a state list they sit at 47% and 32%. The boring explanation, before the interesting one ⛔ The likeliest reason is not that discounting makes a seller candid. It is that a page showing many figures has many figures to discount. A seller publishing a five-rung ladder has five prices to put a strike-through against; a seller publishing one starting price has one. Both behaviors follow from the same underlying thing — a page that shows a lot of numbers — which means this is a correlation with an obvious confounder rather than a finding about character. ## What it does not excuse Anything. A promotional figure is still not a standing rate, a struck-through anchor is still a number nobody has been charged, and a fifth of the pricing notes on this roster are offers rather than prices — which is the separate count in [how much of this pricing is a promotion](https://thisglp.com/research/how-much-glp1-pricing-is-promotional). What changes is the inference a reader draws from the style of a page. Marketing intensity is not a proxy for opacity here, so a plain-looking storefront has not thereby earned anything, and a loud one has not forfeited it. ## Where this sits beside the other cross-check This site has run one other test of whether a seller’s behavior predicts its behavior elsewhere, in [is disclosure a trait](https://thisglp.com/research/is-seller-disclosure-a-trait), and found nothing at all: publishing a ladder said nothing about publishing a state list. The two results fit together. Disclosure does not travel between dimensions, and the one association that does appear has a structural cause rather than a moral one. The practical conclusion is the same as it was: check the specific thing you care about, seller by seller, as listed in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). Corpus read October 2026. [Science & Co](https://thisglp.com/reviews/science-and-co) identifies its lowest advertised rate as a twelve-month-plan figure in its [FAQ](https://science.co/faq). That qualification is a disclosure worth preserving beside the price. Whether a discount exists and whether its commitment is clearly explained are separate questions, just as the aggregate comparison above suggests. ## Frequently asked Do promotional sellers disclose less? Not on this roster. They publish a dose ladder more often than sellers using no promotional wording, and the two groups are level on stating dose behavior and on publishing a state list. Does that mean discounting is a good sign? No. The likeliest explanation is structural: a page showing many figures has many figures to discount, so both behaviors follow from the same cause. Does it change anything about promotional pricing? Nothing. A promotional figure is still not a standing rate and an anchor is still a number nobody has been charged. What changes is only what a reader should infer from the style of a page. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Do GLP-1 Drugs Affect Breast Surgery? Implants Fared Worse, Flaps Did Not Do GLP-1 drugs affect breast surgery? Implant failure odds were 1.70, breast reduction complications 2.6% vs 1.3%, and free flaps fared no worse | four studies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Affect Breast Surgery? Implants Fared Worse, Flaps Did Not Implant failure had 1.70 times the odds in GLP-1 users, and breast reduction complications doubled from 1.3% to 2.6%. Free-flap reconstruction and cancer surgery did not show the same. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 GLP-1 users against matched non-users · Implant reconstruction · implant failure OR 1.70 · Breast reduction · 2.6% vs 1.3% complications · Cancer surgery · no significant difference · Free-flap reconstruction · 9.0% vs 17.1% complications **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The answer changes with the operation, and for two of the four studied the risk went up. In implant-based reconstruction, GLP-1 users had higher odds of implant failure, at 1.70 (95% CI 1.18 to 2.45) [\[3\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-3). After breast reduction, wound complications ran at 2.6% against 1.3% [\[4\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-4). Free-flap reconstruction showed fewer complications, 9.0% against 17.1% [\[2\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-2). Breast cancer surgery showed no significant difference, on 209 exposed patients [\[1\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-1). ## Key takeaways - Implant-based reconstruction, 326 matched GLP-1 users: implant failure OR 1.70, wound-healing complications OR 1.90, readmission or ED visit OR 1.80. - Breast reduction, in people without diabetes: surgical site complications 2.6% against 1.3% within 30 days. - Free-flap reconstruction: composite wound complications 9.0% against 17.1%, with the benefit confined to people without diabetes. - Breast cancer surgery, 750 patients: no significant difference, but every adjusted odds ratio sat above 1. - All four are retrospective record studies. None is a trial. ## Implant-based reconstruction A records study identified 57,987 reconstruction patients between 2014 and 2024, of whom 823 had used a GLP-1 before surgery [\[3\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-3). After matching on body mass index, comorbidities and timing, 326 implant patients were compared with controls. The odds of implant failure were 1.70 (95% CI 1.18 to 2.45). Wound-healing complications came in at an odds ratio of 1.90. Readmission or an emergency visit was 1.80 (95% CI 1.04 to 3.21). Hematoma, seroma and blood clots did not differ. In the same study, 51 matched patients having autologous reconstruction showed no increased risk. That is a small group, and it cannot rule out a moderate difference. The pattern of one operation faring worse than another echoes [the evidence across four other procedures](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## Free-flap reconstruction A second records study looked only at free-flap reconstruction from 2012 to 2025 [\[2\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-2). Anyone with a GLP-1 prescription in the year before surgery counted as a user. After matching, composite wound complications were 9.0% in users and 17.1% in non-users. Surgical site infection was 4.1% against 8.1%, and wound dehiscence 3.8% against 7.8%. The favorable result came from people without diabetes, at 7.9% against 18.6%. In people with diabetes, overall complication rates were comparable. The abstract does not give the size of either cohort. ## Breast reduction A third study excluded diabetes, cancer history and smoking, then matched GLP-1 users to non-users having breast reduction, abdominoplasty or panniculectomy [\[4\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-4). Wound infection, breakdown or dehiscence within 30 days ran at 2.6% against 1.3% after breast reduction. Both abdominal procedures showed higher rates too. The absolute gap after breast reduction is about one extra complication per 77 operations. ## Breast cancer surgery The fourth study covered 750 patients at one tertiary center between January 2024 and August 2025 [\[1\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-1). Of those, 209 had GLP-1 use in the 30 days before surgery, verified against pharmacy records. After adjustment, surgical site infection had an odds ratio of 1.28 (95% CI 0.81 to 2.03). Seroma was 1.22 (95% CI 0.83 to 1.79). Flap necrosis of grade II or worse was 1.41 (95% CI 0.83 to 2.40). A null on 209 patients None of the three is significant, because every interval crosses 1. Every point estimate also sits above 1, and two of the upper bounds run past 2. With 209 exposed patients, an increase of that size could go undetected. This result is the absence of a detected difference, not evidence that there is none. The exposed patients also had higher body mass index and more diabetes before surgery. The authors adjusted and weighted for that. Measured differences can be corrected; unmeasured ones cannot. The same limit runs through [the spinal fusion databases](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery). ## What none of these measured Anesthetists ask about these drugs for a different reason: slowed stomach emptying and the risk of inhaling stomach contents at induction. None of the four studies measured that. The digestive side of the question is covered in [the gastroparesis guide](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). The practical step does not depend on which way these results settle. Tell the surgical and anesthetic team you are taking one, and ask whether to pause it. That timing is their decision. Specialist guidance on what proper care around these drugs looks like is summarized in [what a GLP-1 provider should do](https://thisglp.com/research/what-should-a-glp1-provider-actually-do). ## Frequently asked Is it safe to take a GLP-1 before breast surgery? It depends on the operation. Implant-based reconstruction and breast reduction both had more complications in GLP-1 users. Free-flap reconstruction had fewer, and breast cancer surgery showed no significant difference on 209 exposed patients. Do GLP-1 drugs cause implant failure after reconstruction? In one matched records study of 326 implant patients, GLP-1 users had 1.70 times the odds of implant failure (95% CI 1.18 to 2.45). It is an association in retrospective data, not a trial result. Does a GLP-1 affect healing after breast reduction? Wound complications within 30 days ran at 2.6% in GLP-1 users against 1.3% in matched non-users, in a study that excluded people with diabetes. Should I stop my GLP-1 before breast surgery? That is a decision for the surgical and anesthetic team. Tell them you are taking one; the timing of any pause is theirs to set. ## Sources 1. \[1\] Alsaleh N, Seif-Eldein NA, El Malky AM, Al Hashem H, Idriss H (2026). Perioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study World Journal of Surgery. [PMID 42444315](https://pubmed.ncbi.nlm.nih.gov/42444315/) 2. \[2\] Ha J, Lester ER, De May H, Somers S, Eddington D, Agarwal JP, et al. (2026). GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction Journal of Reconstructive Microsurgery. [PMID 42013898](https://pubmed.ncbi.nlm.nih.gov/42013898/) 3. \[3\] Hamzeh BF, Orear CR, Mardourian M, Keeter C, Egan KG, Winocour J, et al. (2026). Effects of GLP-1 Receptor Agonists on Breast Reconstruction Outcomes: A Large-Database Retrospective Study Journal of Clinical Medicine. [PMID 42452504](https://pubmed.ncbi.nlm.nih.gov/42452504/) 4. \[4\] Lee CC, Newland M, Yau A, Chroneos R, Johnson TS (2026). Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis Plastic and Reconstructive Surgery. [PMID 41364427](https://pubmed.ncbi.nlm.nih.gov/41364427/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Affect Fertility? 25 Men, and No Trial Measured Pregnancy Do GLP-1 drugs affect fertility? A 25-man randomized trial, a 1,899-man network, a pair-fed rat study and 176 women in PCOS | what each design can support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-affect-fertility Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Affect Fertility? 25 Men, and No Trial Measured Pregnancy The only randomized comparison in men enrolled 25 people and moved normal sperm morphology from 2% to 4%. In women the pooled trial evidence is 176 participants, none of them followed to conception. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Morphologically normal sperm, median · 2% · baseline · 4% · 24 weeks · both values sit below · the reference range · 25 men, open-label, 24 weeks **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Almost nobody has studied it. The only randomized comparison in men enrolled 25 people, split two ways, and ran 24 weeks [\[1\]](https://thisglp.com/research/do-glp1-drugs-affect-fertility#ref-1). On semaglutide the median proportion of morphologically normal sperm rose from 2% to 4%. Both figures sit below the reference range. In women the pooled randomized evidence is [four trials and 176 participants](https://thisglp.com/research/glp1-pcos-insulin-resistance), all in PCOS, and no trial has measured conception [\[4\]](https://thisglp.com/research/do-glp1-drugs-affect-fertility#ref-4). Nobody on this roster sells anything for fertility. ## Key takeaways - A randomized open-label trial gave 25 men either semaglutide 1 mg weekly or testosterone replacement for 24 weeks. - On semaglutide, median morphologically normal sperm rose from 2% to 4%, p=0.012. Both numbers are below the reference range. - On testosterone, sperm concentration and total count fell significantly — which is what testosterone replacement does. - So the drug beat a comparator that suppresses sperm production. That is a lower bar than it sounds. - A 23-trial network of 1,899 men does not list a GLP-1 among the strategies shown to raise testosterone. - In women, four trials and 176 participants in PCOS. No pooled trial has measured pregnancy or live birth. Men with obesity and type 2 diabetes often have low testosterone, and the standard fix is to give them testosterone. That fix has a known cost: it suppresses the hormonal signal that tells the testes to make sperm. A man who wants both the symptom relief and the fertility is stuck. This trial asked whether a weight-loss drug could be the way out. ## The trial in men Twenty-five men with type 2 diabetes, obesity and functional hypogonadism were randomized. One arm took semaglutide 1 mg a week. The other took intramuscular testosterone undecanoate 1000 mg every ten to twelve weeks. It ran 24 weeks, open-label. Median age was 50 and median BMI 35.9. Semen analysis and hypogonadism measures were taken at baseline and at the end. Baseline semen quality was poor in both arms, below the 5th percentile of reference values. That matters for reading everything that follows. These were not men with normal parameters. ## What changed In the semaglutide arm, the median proportion of morphologically normal sperm rose from 2% to 4%, p=0.012. In the testosterone arm, sperm concentration and total sperm number both fell significantly. Head to head at 24 weeks, the semaglutide group had significantly more morphologically normal sperm, higher concentration and a higher total count. Both arms saw total testosterone rise and both improved on the Aging Symptoms scale. Only the testosterone arm improved significantly on erectile function. Read the comparator before the result Testosterone replacement lowers sperm production. That is established, expected, and the reason fertility specialists avoid it in men who want children. A trial showing semaglutide produces better semen parameters than testosterone is showing something real. It is not showing that semaglutide improves fertility. Half of that gap was created by the comparator going down. ## What the numbers actually say The within-arm change on semaglutide is the part that stands on its own, and it is small. A median of 2% morphologically normal sperm became 4%. Doubling sounds substantial. Two percentage points is a different impression of the same fact. Both numbers sit below the reference range. Twenty-five men, split two ways, is twelve or thirteen per arm. Open-label means everyone knew which drug they were on, and the two regimens are impossible to confuse. The design could not have blinded this. A placebo arm would settle it, and there was not one. Those are the same questions worth asking of [any small uncontrolled study](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa), and here at least there was randomization and a comparator. ## Where a GLP-1 sits among the alternatives A network meta-analysis pooled 23 randomized trials covering 1,899 men with obesity-related low testosterone, searched to April 2026 [\[2\]](https://thisglp.com/research/do-glp1-drugs-affect-fertility#ref-2). GLP-1-based therapy was one of the five interventions in that network. It does not appear among the results the abstract reports as significant, and the abstract gives no estimate for it either way. Testosterone replacement plus structured lifestyle therapy raised total testosterone most, MD 7.19 (95% CI 1.18 to 13.21). It was also the only strategy that significantly improved erectile function. No intervention significantly reduced glycated hemoglobin. The full comparison is in [the low testosterone network](https://thisglp.com/research/do-glp1-drugs-raise-testosterone). ## What the animal work separates Every human study here runs into the same confound: the people taking the drug are also losing weight. A rat study used a pair-fed control to break that apart [\[3\]](https://thisglp.com/research/do-glp1-drugs-affect-fertility#ref-3). One group was fed exactly what the treated group chose to eat. In male rats, both the drug and the matched restriction improved sperm motility, which points at the weight rather than the molecule. Restriction lowered androgens and semaglutide blunted that fall. In females, progesterone, pregnenolone and estradiol fell in a way the diet alone did not produce. Nobody measured whether any animal conceived, and four weeks in a rodent is not a year in a person. The design and its limits are in [the pair-fed rat study](https://thisglp.com/research/semaglutide-reproduction-pair-fed-rats). ## The evidence in women Four randomized trials, 176 participants in total, pooled for women with PCOS and obesity [\[4\]](https://thisglp.com/research/do-glp1-drugs-affect-fertility#ref-4). Waist circumference fell 5.16 cm and BMI 2.42 points. Total testosterone fell 1.33 (95% CI −2.55 to −0.12). HOMA-IR, the marker closest to the reason these drugs are supposed to help PCOS, did not move significantly. No pregnancy or live-birth outcome was pooled. Weight loss genuinely helps many PCOS symptoms, and that does not require this literature. What the trials do not establish is that the drug treats the underlying endocrinology. That reading is set out in [the PCOS pooled analysis](https://thisglp.com/research/glp1-pcos-insulin-resistance). ## What a buyer should do with this Nothing on this roster is sold for fertility, and no seller claims it. If fertility is the actual goal, that is a reproductive endocrinologist’s question and semen analysis is the measurement. What this trial supports is narrower. A man is already facing a choice between these two treatments. The semen parameters point one way and the erectile function score points the other. The broader sexual-function evidence is thin and [covered separately](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive). What sellers say about any of it is close to nothing, which [the census of silence](https://thisglp.com/tools/questions-they-leave-open) counts directly. ## Frequently asked Do GLP-1 drugs affect fertility? Almost nobody has studied it directly. The only randomized comparison in men enrolled 25 people and moved median normal sperm morphology from 2% to 4%. No trial in either sex has measured pregnancy or live birth. Does semaglutide improve sperm? In that trial it beat testosterone replacement, which suppresses sperm production. The within-arm change was two percentage points, from one figure below the reference range to another below it. Do these drugs raise testosterone? A network of 23 trials and 1,899 men does not list a GLP-1 among the strategies shown to raise it. The abstract gives no estimate for the GLP-1 arm either way. Do they help PCOS? Four trials and 176 participants found waist, BMI and total testosterone fell. HOMA-IR, the insulin-resistance marker the mechanism story rests on, did not move significantly. Can I buy one for fertility? No seller on this roster offers a fertility service or claims the indication. Semen analysis and a reproductive endocrinologist are the measurement here, not a weight-loss intake form. ## Sources 1. \[1\] Gregorič N, et al. (2025). Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism Diabetes, Obesity and Metabolism. [PMID 39511836](https://pubmed.ncbi.nlm.nih.gov/39511836/) 2. \[2\] Yang L, et al. (2026). Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis The Journal of Sexual Medicine. [PMID 42704281](https://pubmed.ncbi.nlm.nih.gov/42704281/) 3. \[3\] Sotzen MR, et al. (2026). Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats Molecular Metabolism. [PMID 42692145](https://pubmed.ncbi.nlm.nih.gov/42692145/) 4. \[4\] Austregésilo de Athayde De Hollanda Morais B, et al. (2024). The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials Journal of Diabetes and Its Complications. [PMID 39178623](https://pubmed.ncbi.nlm.nih.gov/39178623/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Affect Sex Drive? Nobody Has Run That Trial | This GLP No randomized trial of semaglutide or tirzepatide reported a sexual function endpoint. Here is the pharmacovigilance signal, the cohort data, and the limits of both. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-affect-sex-drive Updated: 2026-09-17 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Affect Sex Drive? Nobody Has Run That Trial The weight-loss trials did not measure libido or erectile function. What exists is a reporting signal, a cohort analysis pointing the other way, and case reports. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Randomized trials · Cohort analyses · Spontaneous reports · Longer is not stronger. Only the top bar can show cause. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Nobody has run the trial that would answer it. Libido, erectile function and orgasm are among the most searched questions about these drugs and among the least studied. The weight-loss trials that produced every figure people quote did not measure sexual function at all. What exists instead is a pharmacovigilance signal, two database analyses that disagree with each other, and a testosterone meta-analysis. None has sexual function as a primary endpoint. Reading them as an answer is reading more than they say. The adjacent questions have been measured better. [what obesity does to testosterone](https://thisglp.com/research/do-glp1-drugs-raise-testosterone) and [how semaglutide compares with testosterone on fertility](https://thisglp.com/research/do-glp1-drugs-affect-fertility) each have their own evidence. [The menopause subgroup](https://thisglp.com/research/do-glp1-drugs-work-in-menopause) has the same shape of gap as this one. Libido, erectile function and orgasm are among the most searched questions about these drugs and among the least studied. The weight-loss trials that produced the figures everyone quotes did not measure sexual function at all. What exists instead is a pharmacovigilance signal, a pair of database analyses that disagree with each other, and a handful of case reports. ## What the weight-loss trials measured STEP 1 randomized 1,961 adults with overweight or obesity to semaglutide 2.4 mg weekly or placebo for 68 weeks, and reported a mean weight change of −14.9% against −2.4%[\[1\]](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive#ref-1). SURMOUNT-1 randomized 2,539 adults to tirzepatide or placebo for 72 weeks and reported −20.9% at 15 mg against −3.1% [\[2\]](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive#ref-2). Neither trial listed a sexual function endpoint among its primary, secondary or prespecified exploratory outcomes. Those figures are the reason the drugs are prescribed, and they say nothing about this question. The same distinction runs through the [withdrawal evidence](https://thisglp.com/research/stopping-glp1-and-weight-regain), which measured weight and cardiometabolic variables and nothing else. ## The reporting signal, and what a reporting signal is A 2026 disproportionality analysis of the FDA Adverse Event Reporting System identified 49 semaglutide-associated reports of erectile dysfunction and calculated a reporting odds ratio of 1.53 (95% CI 1.16–2.03) [\[3\]](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive#ref-3). Sitagliptin and dapagliflozin returned almost identical figures, 1.52 and 1.51, while dulaglutide, linagliptin and metformin returned no significant signal. The authors describe their own finding as preliminary and hypothesis-generating, and that description is the important part: a reporting odds ratio counts what was reported, not what happened. Nobody knows the denominator. A time-to-onset analysis in the same paper found a random failure-type distribution rather than a cluster shortly after starting the drug. That is worth reading carefully. It means the reports do not line up with the moment a dose is introduced, which is what a drug-caused effect usually looks like. ## The cohort data points the other way A retrospective cohort study using the TriNetX network compared men aged 18 to 70 with type 2 diabetes and no prior erectile dysfunction, in three propensity-matched comparisons. Tirzepatide was associated with a lower risk of an erectile dysfunction diagnosis or a PDE-5 inhibitor prescription against three comparators. Against sitagliptin the risk ratio was 0.70 (95% CI 0.64–0.76), against injectable semaglutide 0.67 (0.62–0.72), and against dulaglutide 0.55 (0.51–0.59) [\[4\]](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive#ref-4). Its authors state that randomized trials are needed to confirm the finding. Two honest readings sit side by side here. Weight loss and better glycemic control improve erectile function through mechanisms that are well described, so a drug that produces both might reasonably reduce risk. And the same drug might cause a distinct problem in a small number of people, which a population-level risk ratio would not show. A narrative review of the mechanistic literature published in 2025 reaches the same unresolved position[\[5\]](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive#ref-5). ## Case reports are real, and they are not rates A 2025 case report in Sexual Medicine describes anorgasmia beginning after a GLP-1 agonist was started [\[6\]](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive#ref-6). One case is not a frequency. It is a documented event. That is more than an anecdote and much less than an incidence. The correct response to it is to recognize the symptom rather than to estimate how common it is. ## What was searched, and when The searches behind this page were run against PubMed in September 2026, covering semaglutide and tirzepatide against libido, sexual function, erectile function and anorgasmia. No randomized controlled trial reporting a sexual function endpoint for either molecule was found. That is a statement about what a search returned on a date, not a promise that no such trial exists or will exist. This page records its method here because an absence claim is only checkable if the search behind it is stated — the same standard the [editorial methodology](https://thisglp.com/methodology) applies to a price. ## What to do with this A reader who notices a change should treat it as reportable rather than as expected, and should raise it with whoever wrote the prescription. Which seller that is matters here. A service that bills a consultation separately is one case. A service that never says how often a patient is reviewed, is a harder place to raise a symptom than one where the visit sits inside the price. The [per-visit fee schedules](https://thisglp.com/reviews/kernx-health) and the [seller reviews](https://thisglp.com/reviews) record what each one publishes about that. ## Frequently asked Do GLP-1 drugs lower libido? No randomized trial has measured it. A 2026 analysis of spontaneous reports found a signal for erectile dysfunction with semaglutide, at a reporting odds ratio of 1.53 (95% CI 1.16–2.03), which its own authors call hypothesis-generating. Why does one study say the risk goes down? A retrospective cohort of men with type 2 diabetes found tirzepatide associated with a lower risk of erectile dysfunction than three comparator drugs. Weight loss and glycemic control both improve erectile function, so a population-level reduction and an individual adverse effect can both be true. Should a change be reported? Yes. A symptom that begins after a drug is started is reportable whether or not a trial has measured it, and the prescriber is the person to raise it with. ## Sources 1. \[1\] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/) 2. \[2\] Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine. [PMID 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/) 3. \[3\] Lin S, Ding X, Dang X, Zhan Q. (2026). Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis Andrology. [PMID 41883294](https://pubmed.ncbi.nlm.nih.gov/41883294/) 4. \[4\] Cowart K, Murphy C, Carris N. (2025). Association of tirzepatide with erectile dysfunction in people with type 2 diabetes Journal of Diabetes and Its Complications. [PMID 40614622](https://pubmed.ncbi.nlm.nih.gov/40614622/) 5. \[5\] Kounatidis D, Vallianou NG, Rebelos E, et al. (2025). The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? Biomolecules. [PMID 41008590](https://pubmed.ncbi.nlm.nih.gov/41008590/) 6. \[6\] Visvabharathy V, MacPhedran S, Shupp K, King B. (2025). Anorgasmia following initiation of GLP-1 agonist Sexual Medicine. [PMID 40666108](https://pubmed.ncbi.nlm.nih.gov/40666108/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Affect Spinal Fusion Surgery? It Depends on the Operation A review of twelve cohorts on GLP-1 drugs and cervical spine fusion found procedure-specific associations running in opposite directions | and overlapping source databases. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Affect Spinal Fusion Surgery? It Depends on the Operation These drugs look protective in one database, neutral in another and harmful in a third. Pooling it all gives an interval from 0.35 to 4.70. That is not an answer. It is a warning. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Odds of failed fusion, by operation · ACDF — one database · ACDF — another database · posterior fusion · everything pooled · 1.0 · The pooled row is what happens when you average studies that disagree this much **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Twelve retrospective cohorts published in 2025 and 2026 looked at GLP-1 use and failed fusion after cervical spine surgery. - For anterior fusion, one large database gave OR 0.52, 95% CI 0.40 to 0.67, and another gave a neutral 0.86, 95% CI 0.56 to 1.32. - A semaglutide-specific posterior fusion cohort gave OR 4.79, 95% CI 3.11 to 7.37 — the opposite direction. - Pooling everything produced OR 1.28 with a 95% CI of 0.35 to 4.70 and heterogeneity of 97.3%. - Several of the twelve studies query overlapping databases, so they are not twelve independent samples. Both ways, depending on which operation. Take anterior cervical fusion first. One large database put failed fusion lower among GLP-1 users, at OR 0.52 (95% CI 0.40 to 0.67)[\[1\]](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery#ref-1). A semaglutide-specific posterior fusion cohort found the opposite, at OR 4.79 (95% CI 3.11 to 7.37). Pooling everything gives an interval from 0.35 to 4.70, which is not a finding. The question is adjacent to [whether to pause them around an operation](https://thisglp.com/research/glp1-before-surgery) and separate from it. ## What was gathered Twelve retrospective cohorts, all published in 2025 or 2026. All cover GLP-1 exposure and outcomes after cervical fusion. Five databases were searched to June 2026. The primary outcome was pseudarthrosis, which is the fusion failing to knit. Take anterior cervical discectomy and fusion first. One large claims network put the odds of failed fusion lower among GLP-1 users, at OR 0.52, 95% CI 0.40 to 0.67. An independent estimate from a different network was neutral, at OR 0.86, 95% CI 0.56 to 1.32. The anterior subgroup as a whole came to 0.65, 95% CI 0.40 to 1.06, with heterogeneity of 74.5%. A semaglutide-specific posterior cervical fusion cohort went the other way entirely. Failed fusion at two years came in at OR 4.79, 95% CI 3.11 to 7.37. A dysphagia signal ran alongside it. The pooled number is the proof, not the answer Averaging all of it gives OR 1.28, 95% CI 0.35 to 4.70, with heterogeneity of 97.3%. That interval runs from a two-thirds reduction in failed fusions to a near-fivefold increase. It is not a finding about anything. The authors compute it and then reject the class-wide interpretation it invites, concluding that the associations are procedure-specific. A pooled estimate this wide is evidence that the studies should not have been pooled. ## Twelve studies, fewer than twelve samples This is the part worth carrying away. Several of the included cohorts query the same commercial claims networks. The same patient can appear in more than one apparently independent study. A reader counting twelve papers may be looking at far fewer distinct groups of people. The authors prespecified how to handle double counting. They used non-overlapping estimates for the primary synthesis. That is careful and it is rare, because most reviews in this literature simply count the papers. Large shared claims networks make the problem worse each year, and it affects [every study built on the same data](https://thisglp.com/research/semaglutide-fractures-diabetes-only). ## Why the direction might genuinely differ Anterior and posterior cervical fusion are different operations with different biology and different failure modes. A drug may affect one and not the other, or affect them oppositely. The authors take that position explicitly. The posterior finding may also reflect who gets a posterior fusion. That is generally more complex disease, more levels, more comorbidity. One cohort in one procedure is thin ground for a fourfold estimate. The review classes all of this as hypothesis-generating rather than actionable. The distance between [a pooled figure and a patient](https://thisglp.com/research/glp1-weight-loss-pooled-average) is rarely this visible. ## What the dose evidence adds One study sorted patients by prescription strength rather than by exposure [\[2\]](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery#ref-2). It set high-dose GLP-1 use against standard-dose use before neck fusion surgery. After matching, the two dose groups held together on readmission, emergency visits, complications and failed fusion. Both dose groups had less failed fusion than matched non-users. The higher dose added nothing on top. That is an absence of an obvious dose penalty, not a demonstration that no difference exists. This site reads it in [twice the dose, the same recovery](https://thisglp.com/research/glp1-neck-fusion-high-dose). The wider surgical picture is in [what a GLP-1 does to surgery outcomes](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## What it means before an operation That the question is live and unsettled, and that your surgeon should be told you are taking one of these drugs. Whether to pause it around surgery is a separate question, and the evidence there is mostly about anesthesia rather than about bone. No seller on this roster asks whether you have surgery scheduled. None would know what to do with the answer. [the census of what goes unasked](https://thisglp.com/tools/questions-they-leave-open) counts how much a prescription arrives without. Anybody facing a fusion should raise it with the surgeon who will do it. ## Frequently asked Do these drugs help or harm spinal fusion? Both answers appear in the evidence. Anterior fusion estimates ran from OR 0.52 to a neutral 0.86, while a posterior fusion cohort found OR 4.79 for failed fusion. The authors conclude the associations are procedure-specific and hypothesis-generating. What does the pooled estimate say? OR 1.28 with a 95% CI of 0.35 to 4.70 and heterogeneity of 97.3%. That range covers a large reduction and a near-fivefold increase, which means the studies should not be pooled rather than that the answer is neutral. Why does it matter that databases overlap? Because the same patient can appear in several apparently independent studies. Counting twelve papers can mean far fewer distinct groups of people, and this review prespecified how to handle that. Should I stop before spine surgery? That is a question for your surgeon, and this evidence does not answer it. Pausing around surgery is a separate issue, mostly concerning anesthesia rather than bone healing. ## Sources 1. \[1\] Yu X, et al. (2026). GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence European Spine Journal. [PMID 42635669](https://pubmed.ncbi.nlm.nih.gov/42635669/) 2. \[2\] Stirpe C, et al. (2026). Impact of GLP-1 Dose Intensity on Perioperative and Long-Term Fusion Outcomes Following ACDF The Spine Journal. [PMID 42705550](https://pubmed.ncbi.nlm.nih.gov/42705550/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Cause Acid Reflux? Three Databases Say More Reports | This GLP Do GLP-1 drugs cause acid reflux? Reporting ratios of 2.83, 2.91 and 4.76 across three national databases, gastric ultrasound in 124 fasted patients, and what a reporting ratio cannot tell you. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Acid Reflux? Three Databases Say More Reports Reporting ratios of 2.83, 2.91 and 4.76 across three countries. Exenatide, in the same class, ran inverse at 0.60. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Reflux reporting ratio, vs DPP-4 drugs · FAERS (US) · 9,245 vs 139 · 2.83 · Canada Vigilance · 206 vs 29 · 2.91 · JADER (Japan) · 19 vs 16 · 4.76 · The largest ratio rests on the fewest reports. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Reflux is reported more often on a GLP-1 than on its closest drug comparator. Across 260,417 GLP-1 reports in three national databases, the reporting odds ratio was 2.83 in the United States [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-1). Canada Vigilance gave 2.91 and Japan’s JADER gave 4.76. None of those three numbers is a risk. A reporting ratio counts reports, not patients. Exenatide, in the same class, ran the other way at 0.60. The slowed stomach underneath all of it is set out in [the gastroparesis evidence](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## Key takeaways - Across 260,417 GLP-1 reports in three national databases, reflux was reported disproportionately often against DPP-4 inhibitors as the comparator. - FAERS gave a reporting odds ratio of 2.83 (95% CI 2.39-3.35) from 9,245 reports against 139; Canada 2.91 from 206 against 29; Japan 4.76 from just 19 against 16. - Exenatide went the other way, at 0.60 (95% CI 0.46-0.77) — an inverse signal inside the same drug class. - A reporting odds ratio has no denominator of people taking the drug. It cannot tell you your chance of getting reflux. - Gastric ultrasound in 124 fasted patients found retained stomach contents in 56% against 19%, which is the mechanism reflux would run through. - Gastroparesis, the far end of the same mechanism, has thirteen published cases worldwide. ## What the three databases found One 2026 study ran the same analysis over the American, Japanese and Canadian adverse event databases [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-1). The comparator was DPP-4 inhibitors, not the whole database. All three sources produced a signal. FAERS gave 2.83 (95% CI 2.39–3.35). Canada Vigilance gave 2.91 (95% CI 1.97–4.31). Japan’s JADER gave 4.76 (95% CI 2.45–9.27). Semaglutide carried the strongest drug-specific signal in all three. The signal rose with age, reaching 3.01 at 65 and over. Age also tracks the rest of a person’s medication list, which [the frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer) sets out. Read the counts, not the ratios The Japanese figure is the largest number in the study. It rests on 19 reports against 16. The American figure is less than half as large and rests on 9,245 against 139. A ratio built on a few dozen events is unstable. That is why the Japanese interval runs from 2.45 to 9.27 while the American one spans barely a point. ## The one drug that ran the other way Exenatide is an older drug in the same class. In FAERS it returned a reporting odds ratio of 0.60 (95% CI 0.46–0.77). That is fewer reflux reports than the comparator, not more. Disagreement inside one class is hard to explain by notoriety. Attention should lift a famous class together, not push one member below the line. The objection still holds for the rest of the class. Semaglutide is the most discussed medicine on the market. Attention drives reporting, and the drug with the most attention carries the strongest signal. This design cannot separate those two facts. Consistency across three countries does not fix it, because the same drug is famous in all three. ## The mechanism has been measured directly Reflux would run through delayed gastric emptying. That has a measurement of its own. Gastric ultrasound was performed on 124 patients who had followed standard fasting instructions [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-2). Retained stomach contents were found in 56% against 19% of the unexposed group. The adjusted prevalence ratio was 2.48 (95% CI 1.23 to 4.97). Stopping the drug earlier did not help: the adjusted odds ratio for interruption length was 0.86 (95% CI 0.65 to 1.14). The procedural consequence is in [what to tell the anesthesiologist](https://thisglp.com/research/glp1-before-surgery). ## Where the far end of it sits Gastroparesis is delayed emptying severe enough to carry a diagnosis. A systematic review searched four databases to October 2025 and found twelve case reports covering thirteen patients [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-3). Onset ran from hours to several months. It usually followed a dose increase or a restart after a gap. Stopping the drug resolved it in every reported patient. Thirteen cases is not a rate, because a case series has no denominator. ## What a reader can do with this Take direction, not magnitude. Reflux belongs on the list of plausible effects of this class. Belching is a separate label entry, covered in [why Ozempic causes sulfur burps](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps). Exenatide means it is not obviously a class effect. Nothing here states how likely it is for any one person. Trial-based figures carry denominators and are the place to look. The escalation pattern behind most stomach complaints is in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The wider safety picture is in [the cancer risk evidence](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer). ## Frequently asked Do GLP-1 drugs cause acid reflux? Reflux is reported disproportionately often on them. Reporting odds ratios were 2.83 in the US database, 2.91 in Canada and 4.76 in Japan, against DPP-4 inhibitors as the comparator. Exenatide, in the same class, ran inverse at 0.60. How likely am I to get reflux on a GLP-1? This study cannot say. A reporting odds ratio compares how often a term appears among reports, with no count of how many people took the drug, so it produces no incidence or personal risk. Why did exenatide show the opposite result? It is unexplained, and it is the most interesting result in the paper. An inverse signal within the same drug class is difficult to attribute to reporting bias, which would tend to lift the whole class together. Is the Japanese figure the strongest evidence? It is the largest ratio and the weakest evidence. It rests on 19 reports against 16, which is why its confidence interval runs from 2.45 to 9.27. ## Sources 1. \[1\] Choi JG, Gong EJ, Bang CS, Lee JJ (2026). Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study Gut and Liver. [PMID 42682267](https://pubmed.ncbi.nlm.nih.gov/42682267/) 2. \[2\] Sen S, et al. (2024). Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia JAMA Surgery. [PMID 38446466](https://pubmed.ncbi.nlm.nih.gov/38446466/) 3. \[3\] Olubodun T, et al. (2026). Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes PLOS ONE. [PMID 42594084](https://pubmed.ncbi.nlm.nih.gov/42594084/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Cause Arrhythmia? Three Intervals, Two Cross One | This GLP Do GLP-1 drugs cause arrhythmia? Ten tirzepatide trials gave an atrial fibrillation odds ratio of 2.20, credible interval 0.81 to 6.75 | and ten reviews disagree. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Arrhythmia? Three Intervals, Two Cross One Pooled across ten tirzepatide trials, the odds ratios for arrhythmia all sat above 1. Only the broadest category cleared significance, and barely. Ten meta-analyses of the same drug class point the other way, and none of them reached moderate confidence. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Odds ratio vs comparator, 95% credible interval · atrial fibrillation · atrial arrhythmia · any arrhythmia · 1.0 · 10 trials, 6,515 people — intervals this wide mean few events **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The evidence points both ways. Pooled across ten randomized tirzepatide trials, atrial fibrillation came out at an odds ratio of 2.20 [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-1). Its credible interval runs from 0.81 to 6.75, which measures nothing. Ten meta-analyses of this drug class point the other way, toward less atrial fibrillation [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-2). None of them reached moderate confidence. A network comparison of 2,171,267 patients found no difference against a near-neutral drug [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-3). ## Key takeaways - A meta-analysis pooled 10 randomized trials of tirzepatide covering 6,515 people, 68.9% of them randomized to the drug. - Atrial fibrillation: odds ratio 2.20, 95% credible interval 0.81 to 6.75. - Atrial arrhythmia: 2.16, credible interval 0.90 to 5.87. Both intervals include no effect. - Any arrhythmia: 1.84, credible interval 1.04 to 3.90 — the only one that excludes it. - An umbrella review of ten meta-analyses pointing the other way rated five at low confidence and four at critically low. This is the safety question, not the treatment one. Whether a GLP-1 keeps atrial fibrillation from returning after ablation is a separate matter. The answer there is also unsettled, and it is set out in [the atrial fibrillation evidence](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation). ## What was pooled Ten randomized controlled trials of tirzepatide in adults with overweight or obesity [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-1). In total 6,515 people, of whom 4,491 — 68.9% — were randomized to the drug. The analysis was Bayesian, so its ranges are credible intervals rather than confidence intervals. It looked at three nested categories of rhythm problem. For atrial fibrillation the pooled odds ratio was 2.20, credible interval 0.81 to 6.75. For atrial arrhythmia more broadly, 2.16, credible interval 0.90 to 5.87. For any arrhythmia at all, 1.84, credible interval 1.04 to 3.90. ## How to read intervals that wide A range from 0.81 to 6.75 is not a measurement. It is consistent with a slight reduction and with a sevenfold rise. It cannot tell those apart. Intervals get that wide when there are very few events. That is what arrhythmia looks like in trials designed to measure weight. So the two narrower categories found nothing. The broadest one did, barely, at a lower bound of 1.04. One more trial in either direction could undo it. What an interval includes decides more here than the point estimate does, the same reading applied in [the vessel-function measurements](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). A composite collects events “Any arrhythmia” is a composite, and composites collect more events, which narrows intervals. There are two honest readings and this page picks neither. One: a real effect is spread across rhythm disturbances and only becomes visible when they are counted together. Two: three related analyses were run and the one with the most events came out significant, which is what multiplicity does. ## The literature that points the other way Ten meta-analyses have asked whether this drug class lowers atrial fibrillation. An umbrella review appraised them together [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-2). Two shared an identical six-study base and reported hazard ratios of 0.58 and 0.78. Identical evidence, different published answers. Overlap between the reviews was substantial: 43.8% for recurrence and 34.1% among the semaglutide-only incident reviews. So when these papers agree, the agreement is largely a shared base rather than independent replication. Five were rated low confidence and four critically low. None reached moderate or high. The full appraisal is in [the umbrella review](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials). The largest single comparison sits between the two positions. A network and pairwise meta-analysis covered 2,171,267 patients with type 2 diabetes [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-3). It found GLP-1 drugs no different from DPP-4 inhibitors on new-onset atrial fibrillation, at RR 0.93. SGLT2 inhibitors beat both. That is not a signal of harm and it is not a benefit either. ## What would make this more than a signal A trial with arrhythmia as a prespecified endpoint. Monitoring designed to catch it. Enough events to produce an interval narrower than a factor of eight. None of that exists. What exists is adverse-event reporting pooled after the fact. There is also a confounder running in an awkward direction. Rapid weight loss, electrolyte shifts and a rising heart rate all accompany these drugs. All three have some relationship to rhythm. A pooled adverse-event count cannot say whether any of it is doing the work. Nor can a trial population answer questions about a clinic population, the gap measured in [the ordinary-care results](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## What to do with it Not stop a prescribed drug on the strength of it. Three wide intervals from pooled adverse events are not a reason to change treatment. That decision belongs to a prescriber who knows your heart history. What it is worth is a question. A history of atrial fibrillation, palpitations or any rhythm diagnosis belongs on an intake form before starting. It is exactly the kind of history a telehealth questionnaire may not ask for. [The census of what sellers leave unasked](https://thisglp.com/research/what-glp1-sellers-do-not-publish) counts that from the other side. ## Frequently asked Do GLP-1 drugs cause arrhythmia? Nothing here settles it. Pooled across ten tirzepatide trials, atrial fibrillation came out at an odds ratio of 2.20 with a credible interval from 0.81 to 6.75, which is consistent with a small reduction and with a sevenfold rise. Which result was statistically significant? Only the broadest category. Any arrhythmia gave 1.84, credible interval 1.04 to 3.90. The two narrower categories both crossed no effect. Does other evidence disagree? Yes. Ten meta-analyses point toward less atrial fibrillation, though an umbrella review rated five of them low confidence and four critically low. A comparison of 2,171,267 patients found no difference against DPP-4 inhibitors. Should someone with a rhythm problem avoid these drugs? That is a prescriber's decision, not a conclusion from pooled adverse events. A history of atrial fibrillation or palpitations belongs on an intake form before starting. ## Sources 1. \[1\] Mansouri ES, et al. (2026). Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials Journal of the American Heart Association. [PMID 42714458](https://pubmed.ncbi.nlm.nih.gov/42714458/) 2. \[2\] Ramzy D, et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses Cureus. [PMID 42668799](https://pubmed.ncbi.nlm.nih.gov/42668799/) 3. \[3\] Ye X, Wu Q, Hou L, Hou X, Yang Y, Yang C, Huang M, Wang S (2026). Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus Diabetes/Metabolism Research and Reviews. [PMID 42455922](https://pubmed.ncbi.nlm.nih.gov/42455922/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Raise the Risk of Aspiration Pneumonia? | This GLP Pooled endoscopy data found aspiration in 0.16% of GLP-1 users against 0.12% | after emergency stroke thrombectomy it was 26.8% against 10.3% in 41 users. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Raise the Risk of Aspiration Pneumonia? Not at planned endoscopy, where 210,216 pooled patients showed no significant difference. After emergency stroke treatment, the rate was 26.8% against 10.3%, and the authors say treat anyway. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Aspiration pneumonia within 30 days · on a GLP-1 (n = 41) · 26.8% · not on one (n = 699) · 10.3% · 90-day functional outcome: no difference. · 26.8% of 41 patients is eleven pneumonias. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - At planned endoscopy, no. A pooled analysis of 210,216 patients found aspiration in 0.16% of GLP-1 users and 0.12% of non-users, a difference that was not significant. - A BMJ cohort of 43,365 adults with diabetes found 4.15 aspirations per 1,000 on a GLP-1 against 4.26 on an SGLT2 inhibitor. - Food left in the stomach is a different finding. The same BMJ cohort found endoscopies stopped about twice as often on a GLP-1. - The exception is emergency care. In 41 GLP-1 users having stroke thrombectomy, aspiration pneumonia reached 26.8% against 10.3%. - The thrombectomy authors state that the procedure should not be withheld because of GLP-1 use. At a planned endoscopy, the studies found no increase. A meta-analysis of twelve studies and 210,216 patients found pulmonary aspiration in 0.16% of GLP-1 users and 0.12% of non-users [\[4\]](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia#ref-4). The odds ratio was 1.23, and it was not statistically significant. Emergency care is the exception. After emergency stroke thrombectomy, aspiration pneumonia occurred in 26.8% of GLP-1 users against 10.3% of non-users [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia#ref-1). The reason for the concern is known. These drugs slow gastric emptying. Food can remain in the stomach after a normal fast, as [what to tell the anesthesiologist](https://thisglp.com/research/glp1-before-surgery) sets out. Food left in the stomach is not aspiration. Aspiration means stomach contents reach the lungs. The first is more common on these drugs. The second is what the studies below count. ## Planned endoscopy: no increase found Three analyses reach the same result. Alkabbani and colleagues compared 43,365 adults with type 2 diabetes in two US insurance databases [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia#ref-2). Everyone had used a GLP-1 or an SGLT2 inhibitor within 30 days of an upper endoscopy. Aspiration ran 4.15 per 1,000 on a GLP-1 and 4.26 per 1,000 on an SGLT2 inhibitor. The risk ratio was 0.98 (95% CI 0.73 to 1.31). Velji-Ibrahim and colleagues matched 46,948 patients with diabetes or obesity [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia#ref-3). Post-endoscopy aspiration pneumonitis had a hazard ratio of 0.92 (95% CI 0.54 to 1.56). Pneumonia had a hazard ratio of 1.01 (0.83 to 1.24). Neither differed between groups. The meta-analysis adds a warning inside its null result [\[4\]](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia#ref-4). Its case reports include three patients who aspirated despite stopping the drug more than six days earlier. All three had fasted for over eight hours. The Zepbound label carries a similar warning, covered in [how long Zepbound stays in the body](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system). Retained food still stops procedures The same BMJ cohort found a second result. Endoscopies were stopped 9.79 times per 1,000 on a GLP-1 against 4.91 on an SGLT2 inhibitor. That is a risk ratio of 1.99 (95% CI 1.56 to 2.53). The authors link it to a higher risk of retained gastric content. Whether to hold the drug before a procedure is the clinician’s decision. ## Emergency stroke treatment: a higher rate A stroke gives no notice. Nobody fasts, and nobody holds the drug. Sardana and colleagues reviewed 740 consecutive patients having thrombectomy at one center [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia#ref-1). Of these, 41 were on a GLP-1 at arrival. The authors state the rule first. Thrombectomy should not be withheld based on GLP-1 exposure alone. Their findings support targeted aspiration-prevention steps instead. An untreated large-vessel stroke is catastrophic. A pneumonia is treatable. Aspiration pneumonia within 30 days occurred in 26.8% of GLP-1 users and 10.3% of non-users. The absolute difference was 16.5 percentage points. The matched adjusted odds ratio was 3.25 (95% CI 1.43 to 7.40). Twenty-six point eight percent of 41 is eleven pneumonias. Every estimate rests on those eleven events, which is why the interval is wide. The same caution applies to [the overdose comparison](https://thisglp.com/research/overdose-depends-on-the-comparator). Two outcomes did not differ. Symptomatic brain bleeding occurred in 4.9% against 9.1%, with an odds ratio of 0.32 (95% CI 0.04 to 2.53). Function at 90 days was also similar, with a common odds ratio of 1.14 (0.58 to 2.25). A complication rose. Recovery did not measurably suffer. ## How the two settings fit together The mechanism is the same in both settings. The circumstances differ. Before a planned procedure, the patient fasts and the team knows the drug is on board. In an emergency, neither is true. The motility evidence is in [the gastroparesis guide](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). How other operations fare is in [the surgery outcomes guide](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## Frequently asked Do GLP-1 drugs cause aspiration during endoscopy? The studies found no increase. A meta-analysis of 210,216 patients found aspiration in 0.16% of GLP-1 users against 0.12% of non-users, which was not significant. A cohort of 43,365 adults found 4.15 against 4.26 per 1,000. Is food left in the stomach the same as aspiration? It is not. Retained food means the stomach has not emptied. Aspiration means stomach contents reach the lungs. On a GLP-1, endoscopies were stopped about twice as often, likely from retained food, while aspiration did not rise. Should someone on a GLP-1 avoid emergency stroke treatment? Do not delay it. The study authors state that thrombectomy should not be withheld on the basis of GLP-1 exposure. Their finding supports aspiration precautions during and after the procedure. Should I stop my GLP-1 before a procedure? That decision belongs to the clinician doing the procedure. Tell them you take it and when your last dose was. ## Sources 1. \[1\] Sardana S, Mateti N, Hackett CT, Singh R, et al. (2026). GLP-1 receptor agonist use and aspiration pneumonia risk following endovascular thrombectomy Journal of NeuroInterventional Surgery. [PMID 42248677](https://pubmed.ncbi.nlm.nih.gov/42248677/) 2. \[2\] Alkabbani W, Suissa K, Gu KD, Cromer SJ, et al. (2024). Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study BMJ. [PMID 39438043](https://pubmed.ncbi.nlm.nih.gov/39438043/) 3. \[3\] Velji-Ibrahim J, Nathani P, Patel HK, Sharma P (2025). GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy Endoscopy International Open. [PMID 39958662](https://pubmed.ncbi.nlm.nih.gov/39958662/) 4. \[4\] Elmati PR, Jagirdhar GSK, Qasba RK, Perez A, et al. (2025). GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis The Open Respiratory Medicine Journal. [PMID 41036293](https://pubmed.ncbi.nlm.nih.gov/41036293/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Cause Blood Clots? No Untreated Group Was Ever Followed A 701,374-person cohort put venous thromboembolism at HR 0.90 on tirzepatide against other GLP-1 drugs | negative controls and E-values tested how fragile that result is. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-blood-clots Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Cause Blood Clots? No Untreated Group Was Ever Followed Every published comparison ranks one of these drugs against another, never against taking nothing. The effect is small, the method is unusually careful, and the lung clots moved while the leg clots did not. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Tirzepatide vs other GLP-1 drugs, 1 year · blood clots overall · 0.90 · pulmonary embolism · 0.88 · deep vein thrombosis · 0.96 · death, any cause · 0.90 · Clots in the lung moved. Clots in the leg did not. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A cohort of 701,374 matched adults with obesity compared tirzepatide against other GLP-1 drugs for blood clots over one year. - Venous thromboembolism came in at a hazard ratio of 0.90 (95% CI 0.83-0.98), driven by pulmonary embolism (0.88) and accompanied by lower all-cause mortality (0.90). - Deep vein thrombosis showed no difference (0.96, 95% CI 0.86-1.07) — awkward, since most pulmonary emboli begin as leg clots. - The study used negative control outcomes and E-values to test its own vulnerability to confounding. No large study has compared GLP-1 users against untreated people for clots, so the honest answer is that nobody has measured it. The one big comparison that exists ranks two of these drugs against each other rather than against nothing. In 701,374 matched adults with obesity, venous thromboembolism over one year came in at a hazard ratio of 0.90 (95% CI 0.83 to 0.98) on tirzepatide against other GLP-1 drugs [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots#ref-1). Most claims studies report an association and leave the reader to guess how much unmeasured confounding would erase it, and this one tests that directly, which makes it worth reading for its method as much as its result. Other comparisons between the same two drugs are in [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute). Two instruments were used. A negative control outcome is something the drug could not plausibly affect: if the analysis finds an effect there, the method is manufacturing associations. An E-value asks how strong an unmeasured confounder would have to be, in association with both treatment and outcome, to explain away the result entirely. Together they convert “this might be confounded” from an objection into a quantity. The finding itself is modest. Venous thromboembolism over one year gave a hazard ratio of 0.90 with a confidence interval of 0.83 to 0.98. An upper bound that close to 1 across 701,374 people describes a small effect measured precisely — the precision comes from the sample size, not from the size of the difference. The lung clots moved and the leg clots did not Pulmonary embolism came in at 0.88 and deep vein thrombosis at 0.96, with an interval crossing no effect. The overwhelming majority of pulmonary emboli begin as deep vein thromboses that travel, so a treatment reducing the destination without reducing the origin is mechanistically awkward. That pattern is a reason for caution the abstract does not draw, and it is the kind of internal inconsistency worth more than the headline. A separate target trial emulation set semaglutide against tirzepatide on cardiovascular and cerebrovascular outcomes rather than clots [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots#ref-2). Between them the two studies make the same shape of claim. One of these drugs edges the other by a margin small enough that the choice of comparator and the coding of the records matter as much as the molecules do. Neither has an untreated arm, so neither can tell a reader whether taking a GLP-1 at all raises or lowers the chance of a clot. All-cause mortality also fell, at 0.90 — the same magnitude as the primary outcome. In a one-year study of blood clots, a mortality difference of equal size suggests the two arms differ in general health rather than specifically in clotting risk. That is the pattern described at greater length in [six unrelated complications all halved](https://thisglp.com/research/when-a-drug-improves-everything). That the authors ran negative controls makes this less likely than it otherwise would be, without eliminating it. For a reader the practical content is small and the methodological content is not. A 10% relative reduction in clots between two drugs in the same class is not a reason to choose between them. It sits alongside the other small tirzepatide advantages this site has covered in [the glaucoma comparison](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma) and [the carpal tunnel cohort](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome). What is genuinely useful is that a large claims study can quantify its own fragility, and that most do not. ## Frequently asked Is tirzepatide safer than other GLP-1 drugs for blood clots? The hazard ratio was 0.90 with an upper bound of 0.98 — a small difference measured precisely in 701,374 people. It is not large enough to drive a choice between the two. What is an E-value? A measure of how strong an unmeasured confounder would have to be, in its association with both the treatment and the outcome, to fully explain away a reported result. Why does the deep vein thrombosis result matter? Most pulmonary emboli begin as deep vein thromboses. A treatment that reduces lung clots without reducing leg clots is mechanistically difficult to explain, which is a reason for caution. ## Sources 1. \[1\] Wu JY, Lee KW, Huang SC, Chang HY, Lin YM (2026). Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study Frontiers in Medicine. [PMID 42239959](https://pubmed.ncbi.nlm.nih.gov/42239959/) 2. \[2\] Azzam AY, Essibayi MA, Rai P, Salim HA, et al. (2026). Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation JACC: Advances. [PMID 42489387](https://pubmed.ncbi.nlm.nih.gov/42489387/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Cause Depression or Anxiety? The Trials Say No, the Records Say Yes Pooled STEP trial data found PHQ-9 depression scores better on semaglutide than placebo (difference -0.56). A matched cohort reported psychiatric disorders at 2.02 instead. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-depression Updated: 2026-10-26 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Depression or Anxiety? The Trials Say No, the Records Say Yes Randomized trials found depression scores slightly better on semaglutide than placebo. Health records report the opposite, and the comparison group explains most of the gap. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Records above the line, randomized trials below · 1.0 · records: depression · records: anxiety · records: any psychiatric · trials: worsening · The trials found worsening LESS likely, not more. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Randomized trials found the opposite of what health records show. Pooled across STEP 1, 2 and 3, depression scores were slightly better on semaglutide than placebo. - Participants on semaglutide were less likely to shift into a worse depression category, at odds of 0.63 (95% CI 0.50 to 0.79). - A matched cohort in Korean hospitals reported higher rates instead: psychiatric disorders 2.02, anxiety 2.39, depressive disorder 3.42. - The cohort's comparison group was people who never started the drug — and starting one means more clinical contact, which means more recorded diagnoses. The two study designs point in opposite directions, and the reason is the comparison group. The randomized evidence is reassuring and narrow; the observational evidence is alarming and confounded. This site reads that split the same way in [what pooling does to psychiatric risk estimates](https://thisglp.com/research/semaglutide-psychiatric-risk-pooling). For the drug-specific question, the [tirzepatide anxiety and depression evidence](https://thisglp.com/research/can-tirzepatide-cause-anxiety) separates clinical-trial findings from medical-record associations. ## What the randomized trials found A post hoc analysis pooled the STEP 1, 2 and 3 trials — 3,377 participants — plus 304 from STEP 5 [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-depression#ref-1). Depression was measured with the PHQ-9 and suicidal ideation with the Columbia-Suicide Severity Rating Scale. Baseline scores were 2.0 and 1.8, which is no or minimal symptoms. At week 68 they were 2.0 on semaglutide and 2.4 on placebo, an estimated treatment difference of -0.56 with an interval from -0.81 to -0.32. Participants on semaglutide were also less likely to move into a more severe PHQ-9 category, at odds of 0.63. One percent or fewer of participants reported suicidal ideation or behavior, with no difference between groups. Who those trials excluded The paper's own title says it: people without known major psychopathology. Anyone with significant existing mental illness was not enrolled, so these results do not speak to that group. A reassuring number from a trial that screened out the people most at risk is a reassuring number about everyone else. This site set out the same population problem in [the mortality gap in serious mental illness](https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness). ## What the health records found A multicenter cohort across 13 South Korean hospitals compared 2,357 semaglutide and 6,953 liraglutide initiators against propensity-matched people who started neither [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-depression#ref-2). Hazard ratios against matched people who did not start a GLP-1 drug. | Outcome | Semaglutide | Liraglutide | | --- | --- | --- | | Psychiatric disorders overall | 2.02 (1.30–3.14) | 1.66 (1.36–2.03) | | Anxiety disorder | 2.39 (1.22–4.71) | 1.68 (1.45–1.96) | | Depressive disorder | 3.42 (1.51–7.74) | 1.51 (1.14–2.00) | | Gastrointestinal dysmotility | 3.91 (1.42–10.82) | — | Hazard ratios against matched people who did not start a GLP-1 drug. 13 South Korean hospitals, 2018–2025 Read the widths. An interval from 1.42 to 10.82 is compatible with a small effect and an enormous one, and the two largest point estimates are the two least precise. The liraglutide figures, drawn from three times as many initiators, are smaller and tighter. ## Why the designs disagree Someone who starts a weight-management drug has usually just seen a doctor, is being monitored, and is often distressed about their weight. Their matched non-initiator is not necessarily doing any of those things. Higher recorded rates of anxiety and depression in a group with more clinical contact can reflect more diagnosis rather than more disease. Matching on baseline variables does not remove that, because the contact happens after matching. This site set the general problem out in [the trials and the records disagreeing on Alzheimer's](https://thisglp.com/research/do-glp1-drugs-help-alzheimers), where the same shape appears with the signs reversed. A randomized trial removes the problem by construction: both arms are in the same study, seen on the same schedule, assessed with the same instrument. That is why the PHQ-9 result carries more weight here than the hazard ratios, despite the hazard ratios being larger and louder. ## When the comparison is another drug A Medicare target trial emulation removed the never-started group [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-depression#ref-3). It matched adults aged 66 or older with type 2 diabetes who started a GLP-1 against people starting another diabetes drug. Against DPP-4 inhibitors, across 13,711 matched pairs, the depression hazard ratio was 0.90 (0.82 to 0.98). Against SGLT2 inhibitors, across 14,665 pairs, it was 1.07 (0.98 to 1.18). Same drug class, same outcome, and the comparator decided the direction. A 2026 meta-analysis pooled trials, cohorts and pharmacovigilance studies of semaglutide [\[4\]](https://thisglp.com/research/do-glp1-drugs-cause-depression#ref-4). The pooled risk ratio for depression was 1.25, with an interval from 0.95 to 1.65. Anxiety came in at 1.22 (0.93 to 1.60). Heterogeneity was extreme, at an I² of 98 percent. The authors call the result an absence of detected risk, not proof of no risk. ## What is still open The authors of the cohort add their own caveat: semaglutide-associated vision impairment and liraglutide-associated hepatic impairment lost significance in some sensitivity analyses. And nobody has run a randomized trial in people with established serious mental illness, which is the group a reader worrying about this is most likely to belong to. Until somebody does, the honest position is narrow. The drug has not been shown to worsen mood in people without a psychiatric history, and it has not been properly tested in people with one. The adjacent question of motivation is in [a secondary finding on motivation](https://thisglp.com/research/motivation-in-depression-a-secondary-finding). ## Frequently asked Do GLP-1 drugs cause depression? Randomized trials say no. Pooled across STEP 1, 2 and 3, PHQ-9 depression scores were slightly better on semaglutide than placebo, and participants were less likely to shift into a worse category. Why do some studies report higher rates? Those are health-record studies comparing people who started the drug against people who did not. Starting one usually means more clinical contact, and more contact means more recorded diagnoses. Does the comparison group change the answer? Yes. In older Medicare patients with type 2 diabetes, the depression hazard ratio for a GLP-1 was 0.90 against DPP-4 inhibitors and 1.07 against SGLT2 inhibitors. Only the first was statistically significant. What about suicidal thoughts? In the pooled trials, one percent or fewer of participants reported suicidal ideation or behavior, with no difference between semaglutide and placebo. Does this apply if I already have depression? Not directly. The randomized analysis covered people without known major psychopathology, so it does not speak to anyone with established serious mental illness. No trial has tested that group properly. ## Sources 1. \[1\] Wadden TA, Brown GK, Egebjerg C, Frenkel O, Goldman B, Kushner RF (2024). Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials JAMA Internal Medicine. [PMID 39226070](https://pubmed.ncbi.nlm.nih.gov/39226070/) 2. \[2\] Park J, Kim JH, Kim YS, Lim G, Song HJ, Rhee SY (2026). GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study Diabetes, Obesity and Metabolism. [PMID 42410329](https://pubmed.ncbi.nlm.nih.gov/42410329/) 3. \[3\] Tang H, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study Annals of Internal Medicine. [PMID 39993315](https://pubmed.ncbi.nlm.nih.gov/39993315/) 4. \[4\] Bhaduri G, et al. (2026). Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis Clinical Obesity. [PMID 42584177](https://pubmed.ncbi.nlm.nih.gov/42584177/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Cause Gastroparesis? Thirteen Cases, and Two Opposite Findings Do GLP-1 drugs cause gastroparesis? Thirteen published cases worldwide, plus two studies finding fewer IBS symptoms and faster bowel recovery after surgery. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Gastroparesis? Thirteen Cases, and Two Opposite Findings Rarely: only thirteen cases of GLP-1-associated gastroparesis have ever been published. Two larger studies found the same drugs linked to fewer digestive symptoms, not more. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Meal still in the stomach at four hours · normal · mild · moderate · severe · 10% · diagnostic threshold **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Rarely, and the far more common effect on digestion runs the opposite way. A systematic review of published cases found exactly thirteen patients with GLP-1-associated gastroparesis, worldwide, ever reported [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis#ref-1). Two much larger studies found the same drugs associated with fewer coded digestive symptoms in people with irritable bowel syndrome, and with faster — not slower — return of bowel function after spinal surgery. None of the three findings contradicts the others; they describe the same slowing mechanism landing differently depending on the gut it meets. ## Key takeaways - A systematic review found twelve case reports describing thirteen patients with GLP-1-associated gastroparesis, worldwide, ever published. - Thirteen reports is not a rate. A case series has no denominator, so nothing here says how often this happens. - Onset ranged from hours to several months, and commonly followed a dose increase or a restart after a gap. - Stopping the drug resolved the symptoms in every reported patient. - In people who already have irritable bowel syndrome, coded rates of diarrhea, constipation, pain and bloating were all lower on a GLP-1 — the same symptoms the drugs are known for causing. - After spinal fusion surgery, bowel function returned faster in GLP-1 users than non-users, the opposite of what a gut-slowing drug should produce. These drugs work in part by slowing the stomach. That is the mechanism, not a side effect, and it is why a smaller meal feels like enough. This section is about what happens at the far end of that mechanism: the stomach slowing past the point of usefulness and into a diagnosis with a name, an imaging threshold and a treatment pathway of its own. That is a genuinely different question from the ordinary nausea of a dose increase, which [the titration page covers](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and which resolves on its own in most people. ## What the published cases show A systematic review published in 2026 searched PubMed, Embase, Scopus and Web of Science from inception to October 2025 for symptomatic gastroparesis associated with these drugs, and found twelve case reports describing thirteen patients. [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis#ref-1) Most were women, most had type 2 diabetes, and cases occurred in people without diabetes too. Semaglutide was the agent implicated most often, followed by liraglutide, dulaglutide and exenatide — which is roughly the order of how widely each is prescribed, so the ranking tells you less than it appears to. Symptom onset ranged from hours after a dose to several months into treatment, and it commonly followed either a dose escalation or a restart after a break in therapy — the same two moments that [a titration schedule](https://thisglp.com/tools/glp1-titration-planner) is built around. Reported symptoms were nausea, vomiting, abdominal pain, bloating, early satiety and an inability to keep food down. Imaging or endoscopy often showed a distended stomach still holding its contents, with no mechanical blockage to explain it. Thirteen patients is not a frequency A case series counts events that were noticed, written up, accepted for publication and then found by a search. It has no denominator, so it cannot say how often this occurs among the millions of people taking these drugs. What it can do is describe the shape of the event well enough to recognize it. Reading a count of thirteen as reassurance is as wrong as reading it as alarm. ## How the diagnosis is actually made Gastroparesis means delayed gastric emptying with no outlet obstruction, and the standard test is gastric emptying scintigraphy: a labeled meal, then a measurement of how much is still in the stomach four hours later. [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis#ref-2) More than 10% retained, in someone with the symptoms and without a blockage on endoscopy or a CT scan, meets the 2022 American College of Gastroenterology and 2025 American Gastroenterological Association definition. Severity is banded off the same measurement — 10% to 15% is mild, 16% to 35% moderate, and above 35% severe. A carbon-13 breath test is also FDA-approved for the diagnosis. The condition itself is uncommon. A 2018 claims analysis put the prevalence of documented gastroparesis at 21.5 per 100,000 people, and it runs two to four times more often in women than men. In a US epidemiological study of 82.6 million patients, the causes broke down as type 2 diabetes 51.7%, postsurgical 15%, medication-induced 11.8%, idiopathic 11.3%, type 1 diabetes 5.7% and other 4.5%. Medication-induced is the category these drugs fall into, alongside opioids, cannabis and anticholinergics. ## What happened to the reported patients Management in the published cases was mostly supportive — fluids, antiemetics, and letting the stomach recover. Discontinuing the drug resolved the symptoms in every patient reported. That is the most useful sentence in the review, and it is also the sentence most easily over-read: thirteen people all got better after stopping, which is encouraging and is not the same as a demonstrated reversibility rate. What it does establish is that stopping is the intervention, and that the outcomes published so far have been good. The general treatment ladder is unchanged by the cause. First-line for mild disease is a small-particle diet low in fat and indigestible fiber, plus antiemetics. Moderate adds prokinetics such as metoclopramide or erythromycin. Severe may need liquid or jejunal feeding, and refractory cases are sometimes treated with a pyloric myotomy or an implanted gastric stimulator. None of that is specific to a GLP-1, and almost none of the published cases needed any of it. ## The paradox: irritable bowel symptoms fell, not rose A matched analysis of people who already had irritable bowel syndrome compared those who started a GLP-1 drug against those who did not, with roughly 6,665 people in each arm[\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis#ref-3). Coded rates were lower on treatment for every symptom measured: chronic diarrhea 8.9% against 10.6%, constipation 19.8% against 22.0%, abdominal pain 31.6% against 35.8%, and bloating 8.3% against 10.9%. Those are the exact symptoms this drug class is best known for causing. The likely explanation is not that IBS improved. Every outcome here is a diagnostic code entered at a visit. Someone who develops new gut symptoms after starting a weight drug may describe them as a side effect rather than as their IBS, so the coded IBS symptom simply does not appear. A real effect from slower gastric emptying is plausible too, and this design cannot tell the two apart. The full breakdown is in [the irritable bowel syndrome analysis](https://thisglp.com/research/do-glp1-drugs-help-ibs). ## The other paradox: bowel function that returned faster, not slower A single-center chart review compared 57 patients on a GLP-1 drug against 60 who were not, all having elective spinal fusion surgery [\[4\]](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis#ref-4). Bowel function returned at a mean of 1.35 days in GLP-1 users against 1.90 days in non-users — faster, not slower, which runs against the mechanism these drugs are known for. Everything else measured was flat: no differences in length of stay, complications, wound problems or patient-reported outcomes. The measurement is soft (a chart note on whether someone passed gas), the groups differed by sex, and 117 patients at one hospital is not a lot. It is a signal worth watching rather than a settled finding, detailed in [the bowel-recovery study](https://thisglp.com/research/the-bowels-woke-up-sooner). ## What this means before ordering The practical content here is narrow and worth stating plainly. Dose increases and restarts are the moments to watch, vomiting that stops you eating is not the ordinary nausea of week three, and the drug is prescribed — which means there is a clinician to call. Whether the seller you are buying from makes that easy is a separate question, and [most of them publish very little about it](https://thisglp.com/tools/questions-they-leave-open). A discontinuation that goes through a support inbox is a slower discontinuation than one that goes through a prescriber. There is also a cost consequence that nobody prices. An emptying study, an endoscopy and an unplanned stop all sit outside the monthly figure, and [outside the trial protocols](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) that produced the efficacy numbers. Rare events are still expensive when they land on you. ## Frequently asked Do GLP-1 drugs cause gastroparesis? Rarely, on the published record. A systematic review found only thirteen case reports worldwide. Two much larger studies found the same drugs linked to fewer coded digestive symptoms in IBS and faster bowel recovery after surgery, not slower. How common is gastroparesis on a GLP-1? Nobody has published a rate. The systematic review that collected the cases found twelve reports describing thirteen patients, which is a description of the event rather than a measurement of how often it occurs. How is it different from normal nausea? Ordinary titration nausea is common, temporary, and does not stop you eating. Gastroparesis is a measured delay in emptying — more than 10% of a meal still in the stomach at four hours — with vomiting, early satiety and an inability to keep food down. Does it go away if you stop? In every patient reported so far, yes. Discontinuing the drug resolved the symptoms. Thirteen good outcomes is encouraging rather than a reversibility rate, and stopping is a decision for the prescriber. When is the risk highest? The published cases clustered after a dose increase or after restarting the drug following a gap. Both are moments a titration schedule is supposed to manage. Why did IBS symptoms fall on a drug known for causing them? Likely a coding effect. Someone who develops new gut symptoms on a GLP-1 may describe them as a drug side effect rather than as their IBS, so the coded IBS symptom does not appear. A real effect from slower gastric emptying is also plausible, and the study design cannot separate the two. Why did bowel function return faster after surgery, not slower? It is not fully explained. One possibility is that a treated patient's underlying metabolic state was healthier to begin with. The measurement was soft, and 117 patients at one hospital makes it a signal to watch rather than a settled finding. ## Sources 1. \[1\] Olubodun T, et al. (2026). Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes PLOS ONE. [PMID 42594084](https://pubmed.ncbi.nlm.nih.gov/42594084/) 2. \[2\] Camilleri M (2026). Gastroparesis: A Review JAMA. [PMID 42485161](https://pubmed.ncbi.nlm.nih.gov/42485161/) 3. \[3\] Khan SA, Marasini A, Shrestha A, Bharadwaj HR, et al. (2026). Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis Digestive Diseases and Sciences. [PMID 42570075](https://pubmed.ncbi.nlm.nih.gov/42570075/) 4. \[4\] Fano A, Oris RJ, Dalton J, Baidya J, Ng M, Baek G, Tarawneh O (2025). GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion Spine. [PMID 41400023](https://pubmed.ncbi.nlm.nih.gov/41400023/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Cause Glaucoma? Nobody Untreated Was Ever Compared A 51,540-person cohort links tirzepatide to less incident open-angle glaucoma than other GLP-1 drugs (HR 0.65, 95% CI 0.44-0.96) | and why a two-drug comparison has limits. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-glaucoma Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Glaucoma? Nobody Untreated Was Ever Compared A 51,540-person comparison found less open-angle glaucoma on tirzepatide than on other GLP-1 drugs. Both arms were treated. Neither figure says what either drug does against taking nothing. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Tirzepatide vs other GLP-1 drugs · open-angle glaucoma, 2 years, age 60+ · no difference · 0.65 · 0.44 · 0.96 · Both arms are on a drug. Neither is compared with none. · 51,540 matched participants across 21 countries. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Among 51,540 matched adults aged 60 and over with type 2 diabetes across 21 countries, tirzepatide was associated with less incident open-angle glaucoma than other GLP-1 drugs over two years. - The hazard ratio was 0.65, with a 95% confidence interval of 0.44 to 0.96 — excluding 1, but only just. - Both arms were taking a drug in this class. The study has no untreated comparison, so it cannot say whether either raises or lowers glaucoma risk in absolute terms. - The result held across several sensitivity analyses, including an intention-to-treat design. No study has compared a GLP-1 user against an untreated person for glaucoma. The one large comparison that exists ranks two of these drugs against each other. It covered 51,540 matched adults aged 60 and over. Incident open-angle glaucoma came in at a hazard ratio of 0.65 (95% CI 0.44 to 0.96) on tirzepatide against other GLP-1 drugs [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma#ref-1). Eye safety has followed this class since the first reports of optic nerve damage, examined here in [the optic nerve evidence by indication](https://thisglp.com/research/semaglutide-optic-nerve-by-indication). The cohort covered adults aged 60 and over with type 2 diabetes, newly prescribed tirzepatide or another GLP-1 drug between 2022 and 2024. Matching was one to one on age, sex, race, smoking history, HbA1c, BMI, prior glucose-lowering medication, corticosteroid use and comorbidities. Anyone with existing glaucoma or prior glaucoma medication was excluded, as was anyone using both drug types during follow-up. Follow-up ran two years, and the result survived several sensitivity analyses including an intention-to-treat design. The separate optic nerve literature runs the other way and should not be folded in. Pooling eight cohorts, semaglutide carried a relative effect of 1.93 for non-arteritic anterior ischemic optic neuropathy (95% CI 1.22 to 3.08) [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma#ref-2). That is a different structure, a different nerve and a different comparison. Glaucoma is not NAION. Nobody in this study was untreated Both arms were on a drug from the same class. That makes this a ranking, not a risk assessment: it can tell you which of two treated groups had fewer glaucoma diagnoses, and it cannot tell you whether taking either one leaves you better or worse off than taking neither. A reader who comes away thinking tirzepatide protects the eyes has drawn a conclusion the design cannot reach. The interval is worth reading rather than rounding. An upper bound of 0.96 clears 1 by four hundredths. That makes the result real by the usual convention and fragile under any reasonable amount of unmeasured confounding. Two years is also a short window for a disease that develops over decades. And a diagnosis of open-angle glaucoma depends on somebody having an eye examination at all, which is the same detection problem that shapes [the retinopathy evidence](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse). What would make this more than a curiosity is a mechanism, and the study supplies none. Intraocular pressure, blood sugar variability and weight change are all plausible routes. None was measured. Until an untreated comparison exists, the practical use of this finding is narrow. It is one more small difference between two drugs usually discussed as interchangeable, alongside [the carpal tunnel comparison](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome) and [the network comparison](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide). ## Frequently asked Does tirzepatide protect against glaucoma? The study cannot show that. Both groups were taking a GLP-1-class drug, so it compares two treatments with each other and has no untreated arm to measure absolute risk against. How strong is the result? The hazard ratio was 0.65 with a confidence interval of 0.44 to 0.96. It excludes 1 by a small margin, which makes it statistically significant by convention and sensitive to unmeasured confounding. Does this apply to younger people? It has not been shown to. The cohort was restricted to adults aged 60 and over, followed for two years, and measured only primary open-angle glaucoma. ## Sources 1. \[1\] Pan SY, Weng CH, Sheen YJ, Chen JP, et al. (2026). Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study Ophthalmology Science. [PMID 42383218](https://pubmed.ncbi.nlm.nih.gov/42383218/) 2. \[2\] Khani E, et al. (2026). Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis The Journal of Clinical Pharmacology. [PMID 42612051](https://pubmed.ncbi.nlm.nih.gov/42612051/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Cause Gout? The Study Everyone Cites Cannot Say | This GLP Do GLP-1 drugs cause gout? A 295,907-person comparison, a randomized urate analysis in 2,539 adults, and why an active-comparator design cannot answer it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-gout Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Cause Gout? The Study Everyone Cites Cannot Say A 295,907-person comparison put gout at 7.8 events per 1,000 person-years on a GLP-1 against 4.9 on an SGLT2 inhibitor. Both arms were treated, so neither rate has a baseline to sit against. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Gout, events per 1,000 person-years · SGLT2 inhibitor · 4.9 · GLP-1 agonist · 7.8 · no treatment · not in the study · Without the third bar, neither rate can be called high or low. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Nobody has run the study that could answer that. The comparison everyone cites followed 295,907 adults with type 2 diabetes and found gout at 7.8 events per 1,000 person-years on a GLP-1 drug against 4.9 on an SGLT2 inhibitor [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-gout#ref-1). Both arms were taking something, so the study establishes a difference between two treated rates and nothing about where either one sits against no treatment. Meanwhile the thing that produces gout moved the other way: across 2,539 adults in SURMOUNT-1, serum uric acid fell up to 0.95 mg/dL on tirzepatide against 0.18 on placebo [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-gout#ref-2). ## Key takeaways - In 295,907 adults with type 2 diabetes, gout occurred at 4.9 events per 1,000 person-years on SGLT2 inhibitors and 7.8 on GLP-1 agonists. - The hazard ratio was 0.64 (95% CI 0.57 to 0.72) in favor of the SGLT2 inhibitor, with a rate difference of 2.9 events per 1,000 person-years. - The study's conclusion is about SGLT2 inhibitors possibly reducing gout risk. It is routinely cited as though it showed GLP-1 drugs raising it. - ⛔ There was no untreated comparison group, so the study cannot say whether the GLP-1 rate is high, normal or low. - In SURMOUNT-1, serum uric acid fell 0.69 to 0.95 mg/dL on tirzepatide against 0.18 on placebo, with 72.7% of that attributed to weight loss. - That analysis counted no gout flares, no new diagnoses and no urate-lowering prescriptions. A study comparing two drugs produces one number and two possible readings, and only one of them is supported. This is a clean example, and it is worth working through because the misreading circulates. A reader who has heard that these drugs raise gout risk has probably met this study wearing the wrong label, the same way a composite gets over-heard in [what a composite endpoint hides](https://thisglp.com/research/tirzepatide-heart-failure-composite). ## What was compared Researchers identified 295,907 adults with type 2 diabetes newly prescribed either an SGLT2 inhibitor or a GLP-1 receptor agonist. Gout occurred at 4.9 events per 1,000 person-years in the SGLT2 group and 7.8 in the GLP-1 group. That is a hazard ratio of 0.64 (95% CI 0.57 to 0.72) and a rate difference of 2.9 events per 1,000 person-years (95% CI 2.1 to 3.6). The authors’ conclusion is that SGLT2 inhibitors may reduce the risk of gout, and they say further studies are needed to confirm it. SGLT2 inhibitors have a known mechanism for this: they increase urinary excretion of uric acid, which is what causes gout. The bar that is missing ⛔ Everyone in the study was taking something. There is no arm of comparable patients taking neither drug, which means the study establishes the difference between two rates and nothing about where either sits. If the untreated rate were 8 per 1,000 person-years, the GLP-1 result would be unremarkable and the SGLT2 result protective. If it were 5, the reading would change entirely. The study does not contain the information to choose between those, and neither does this page. ## What happened to uric acid itself The mechanism runs through urate, and that has been measured inside a randomized trial. A post hoc analysis of SURMOUNT-1 tracked serum uric acid in 2,539 adults with obesity or overweight across 72 weeks [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-gout#ref-2). It fell by 0.69, 0.92 and 0.95 mg/dL on the 5, 10 and 15 mg tirzepatide doses, against 0.18 mg/dL on placebo, all at P < .001. A mediation analysis attributed 72.7% of that reduction to weight loss, leaving roughly a quarter attributed to something else about the drug. The fall did not differ by baseline uric acid quartile (P = .610) or by baseline BMI (P = .362), which is unusual in this literature. The full reading, including why a mediation split is a model output rather than a measurement, is in [the SURMOUNT-1 urate analysis](https://thisglp.com/research/uric-acid-fell-and-most-of-it-was-weight). Uric acid is a blood test. Gout is an attack. That analysis measured a laboratory value. It reports no gout flares, no new gout diagnoses and no change in urate-lowering prescriptions, because those were not among the outcomes. Lowering serum urate is how gout treatment works, so the direction is encouraging — but a 0.95 mg/dL drop is not a count of attacks avoided. ## The same design problem, in a second condition Kidney stones were compared the same way and produced the same trap. A new-user study matched 358,203 pairs starting an SGLT2 inhibitor or a GLP-1 receptor agonist and followed them a median of 192 days [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-gout#ref-3). Nephrolithiasis occurred at 14.9 events per 1,000 person-years in the SGLT2 arm against 21.3 in the GLP-1 arm, a hazard ratio of 0.69 (95% CI 0.67 to 0.72). That is again a study about SGLT2 inhibitors, with the GLP-1 arm as the thing they were measured against. It cannot say whether a GLP-1 raises the stone rate above no treatment at all, because no untreated group was followed. The same reading is set out in [the kidney stone comparison](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones). ## Why the misreading is easy Because an active-comparator design is a good way to answer a clinical question — which of two drugs should this patient take — and a bad way to answer a safety question about either one alone. The output is a ratio, ratios have a numerator and a denominator, and a reader who cares about the denominator will read the ratio as being about it. The same structure appears throughout this literature. A result reported against another drug, or against people who were prescribed nothing for reasons nobody recorded, is answering a narrower question than its sentence suggests. That thread runs through [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review) and [the suicidal ideation cohorts](https://thisglp.com/research/glp1-and-suicidal-ideation). ## What this does and does not change If you have gout and type 2 diabetes and a choice between these two classes, the first study is directly relevant and points one way. If you have gout and are considering a GLP-1 drug for weight, it tells you almost nothing, because the population is different and the comparison you care about is absent. Your urate is likely to fall, which is the direction gout treatment aims for, and the trial that would count flares rather than measure blood has not been done. That is worth knowing before a seller’s page cites a study at you. Most storefronts tracked here publish no evidence summary at all, and the ones that do rarely name the comparator. It is a gap in the same family as the ones counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) and [what happens outside a trial](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## Frequently asked Do GLP-1 drugs cause gout? No study has tested that. The comparison usually cited found 7.8 gout events per 1,000 person-years on a GLP-1 against 4.9 on an SGLT2 inhibitor, with no untreated arm to say whether either rate is high or normal. What does the study actually show? That SGLT2 inhibitors came with fewer gout events than GLP-1 drugs in people with type 2 diabetes. The authors' own conclusion is about SGLT2 inhibitors possibly reducing risk. Do these drugs lower uric acid? In SURMOUNT-1, serum uric acid fell 0.69 to 0.95 mg/dL on tirzepatide against 0.18 mg/dL on placebo over 72 weeks. A mediation analysis attributed 72.7% of that to weight loss. Does lower uric acid mean fewer gout attacks? That analysis counted none. It reports no flares, no new diagnoses and no change in urate-lowering prescriptions, because those outcomes were not measured. Does the same problem affect the kidney stone comparison? It does. A 358,203-pair study found 21.3 stone events per 1,000 person-years on a GLP-1 against 14.9 on an SGLT2 inhibitor, again with no untreated group followed. ## Sources 1. \[1\] Fralick M, et al. (2020). Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study Annals of Internal Medicine. [PMID 31931526](https://pubmed.ncbi.nlm.nih.gov/31931526/) 2. \[2\] Sattar N, Scilletta S, Stefanski A, Wang H, Daly JW, Linetzky B (2026). Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial Annals of the Rheumatic Diseases. [PMID 41198460](https://pubmed.ncbi.nlm.nih.gov/41198460/) 3. \[3\] Paik JM, et al. (2024). Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes JAMA Internal Medicine. [PMID 38285598](https://pubmed.ncbi.nlm.nih.gov/38285598/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Cause Kidney Cancer? Trials Say Probably Not | This GLP Do GLP-1 drugs cause kidney cancer? 48 trials found an odds ratio of 1.12 (0.78 to 1.60), and one cohort's 1.38 signal crossed 1 | what four studies show. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Kidney Cancer? Trials Say Probably Not Across 48 trials the kidney cancer odds ratio was 1.12, graded as little or no effect. One cohort's 1.38 signal and two drug-versus-drug comparisons point different ways. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Kidney cancer, GLP-1 users vs comparison · 1.0 · 48 trials (OR) · 1.12 · One cohort (HR) · 1.38 · Both intervals reach 1.0. · Trials grade it: probably little or no effect. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Probably not, on the best evidence available. Across 48 placebo-controlled trials with 94,245 participants, the odds ratio for kidney cancer was 1.12 (95% CI 0.78 to 1.60) [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer#ref-1). In people, that is between 5 fewer and 13 more cases per 10,000 treated. The reviewers graded it as moderate-certainty evidence of little or no effect. The worry came from a matched cohort that put the hazard ratio at 1.38 (95% CI 0.99 to 1.93) [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer#ref-2). Its own authors called that marginally nonsignificant. ## Key takeaways - 48 randomized trials, 94,245 participants: kidney cancer odds ratio 1.12 (95% CI 0.78 to 1.60), graded moderate certainty of little or no effect. - One matched cohort of 86,632 adults with obesity found a kidney cancer hazard ratio of 1.38 (95% CI 0.99 to 1.93). - Against SGLT2 inhibitors in type 2 diabetes, renal cell carcinoma ran at 1.26 per 1,000 patient-years on a GLP-1 and 1.07 on an SGLT2 drug. - After bariatric surgery, starting a GLP-1 was linked to lower five-year kidney cancer risk than any of four other diabetes drugs. - None of the trials was designed to measure cancer, and follow-up was short. ## Where the kidney signal came from The cohort drew on 2014 to 2024 health records and matched 43,317 GLP-1 users to 43,315 eligible non-users [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer#ref-2). Everyone had obesity or overweight and no prior cancer. Mean age was 52.4, and 68.2% were women. Fourteen cancers were tracked. Overall, the picture favored the drug. The fourteen cancers ran at 13.6 per 1,000 person-years in users against 16.4 in non-users, a hazard ratio of 0.83 (95% CI 0.76 to 0.91). Endometrial cancer came in at 0.75, ovarian at 0.53 and meningioma at 0.69. Kidney cancer was the one estimate above 1. Its interval starts at 0.99, so it does not exclude no effect. The authors asked for longer follow-up rather than calling it a harm. Thyroid was among the fourteen, with no separate figure given; the thyroid evidence is set out in [the thyroid cancer guide](https://thisglp.com/research/do-glp1-drugs-cause-thyroid-cancer). ## What the randomized trials add Trials remove the question of who gets prescribed a drug, which a cohort cannot fully do. The meta-analysis pooled 48 placebo-controlled trials searched to August 2025 [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer#ref-1). For kidney cancer the odds ratio was 1.12, with an interval from 0.78 to 1.60. The same moderate-certainty grade applied to thyroid, pancreatic and breast cancer. Results held in trials of semaglutide or tirzepatide and across dose and duration subgroups. The limit on the trial evidence None of the 48 trials was built to count cancers, and their follow-up was short. Cancers take years to develop. So the trial result bounds the risk over the length of a trial. It does not reach the many years over which a cancer would develop. ## Two comparisons against SGLT2 drugs, pointing opposite ways A target-trial emulation matched 294,664 adults with type 2 diabetes starting an SGLT2 inhibitor against the same number starting a GLP-1 [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer#ref-3). Over a mean of 44.2 months, renal cell carcinoma ran at 1.07 per 1,000 patient-years on SGLT2 drugs and 1.26 on GLP-1 drugs. The reported hazard ratio for SGLT2 use was 0.85 (95% CI 0.79 to 0.92). Urothelial cancer showed the same pattern. That is a comparison between two treatments, not against no treatment. It cannot say whether GLP-1 drugs raise kidney cancer or SGLT2 drugs lower it. The same trade-off appears in [the kidney stone comparisons](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones), where every study ranks one diabetes drug against another. A second emulation looked only at adults with type 2 diabetes after bariatric surgery [\[4\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer#ref-4). Over five years, starting a GLP-1 was linked to lower kidney cancer risk than metformin, insulin, SGLT2 inhibitors or sulfonylureas. The risk differences ran from 0.18 to 0.22 percentage points. Against SGLT2 drugs it was 0.19 points lower, across 8,613 matched pairs. That is the opposite direction to the first comparison, in a different population. How these drugs work after surgery is covered in [the post-bariatric trials](https://thisglp.com/research/glp1-after-bariatric-surgery-evidence). ## How to read four answers at once The randomized evidence carries the most weight and sits closest to no effect. The cohort signal is real enough to watch and too uncertain to act on. The two SGLT2 comparisons disagree, and neither uses a placebo. Pancreatic cancer shows a similar pattern of comparator-dependent answers in [the pancreatic cancer guide](https://thisglp.com/research/do-glp1-drugs-cause-pancreatic-cancer). A personal or family history of kidney cancer is a reason to raise the question with a prescriber. It is not, on this evidence, a reason the drug was shown to be unsafe. Whether an online intake asks about it is one of [the questions sellers leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs cause kidney cancer? The randomized evidence says probably not. Across 48 placebo-controlled trials with 94,245 participants, the kidney cancer odds ratio was 1.12 (95% CI 0.78 to 1.60), graded as moderate certainty of little or no effect. Where did the kidney cancer concern come from? A matched cohort of 86,632 adults with obesity found a hazard ratio of 1.38 (95% CI 0.99 to 1.93). Its authors described it as marginally nonsignificant and asked for longer follow-up. Is kidney cancer risk lower on an SGLT2 inhibitor? In one comparison of 294,664 matched pairs with type 2 diabetes, renal cell carcinoma ran at 1.07 per 1,000 patient-years on SGLT2 drugs and 1.26 on GLP-1 drugs. After bariatric surgery, a second study found the opposite direction. Does the trial result hold for semaglutide and tirzepatide? Yes. The meta-analysis found consistent results in trials of semaglutide or tirzepatide. Those trials were not designed to measure cancer and followed people for a short time. ## Sources 1. \[1\] Ko A, Chang YC, Bahar F, Wang TH, Xanthavanij N, Yu CC, et al. (2026). Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis Annals of Internal Medicine. [PMID 41359966](https://pubmed.ncbi.nlm.nih.gov/41359966/) 2. \[2\] Dai H, Li Y, Lee YA, Lu Y, George TJ, Donahoo WT, et al. (2025). GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity JAMA Oncology. [PMID 40839273](https://pubmed.ncbi.nlm.nih.gov/40839273/) 3. \[3\] Huang CW, Lai EC, Wu VC, Hsieh MH, Li CJ, Chang R, et al. (2026). Renal and urothelial cancer risks with SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes: a target trial emulation Nephrology Dialysis Transplantation. [PMID 41665869](https://pubmed.ncbi.nlm.nih.gov/41665869/) 4. \[4\] Hernández-Pérez JG, Abdelgadir O, Albayyaa M, Ernest DK, Chen J, DeSantis SM, et al. (2026). GLP-1 receptor agonists are associated with lower kidney cancer risk after metabolic bariatric surgery Nephrology Dialysis Transplantation. [PMID 42644757](https://pubmed.ncbi.nlm.nih.gov/42644757/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Cause Kidney Stones? Nobody Has Run That Comparison | This GLP No study compares GLP-1 users against untreated people for kidney stones | one 358,203-pair cohort put stones at 21.3 per 1,000 person-years against 14.9 on an SGLT2 inhibitor. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Cause Kidney Stones? Nobody Has Run That Comparison Every published study ranks one diabetes drug against another. Stones ran at 21.3 per 1,000 person-years on a GLP-1 and 14.9 on an SGLT2 inhibitor. Neither figure is a risk. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Kidney stones per 1,000 person-years · 21.3 · GLP-1 arm · 14.9 · SGLT2 arm · 6.4 fewer · 358,203 matched pairs, median 192 days **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - No study has compared GLP-1 users against untreated people for kidney stones. The question has not been answered. - One 358,203-pair cohort put stones at 21.3 per 1,000 person-years on a GLP-1 and 14.9 on an SGLT2 inhibitor. - That is a hazard ratio of 0.69 in the SGLT2 arm's favor, and a difference of 6.4 events per 1,000 person-years. - The likely mechanism is urate. SGLT2 inhibitors push uric acid out in the urine and cut gout by 36%. - Tirzepatide lowers uric acid too, by up to 0.95 mg/dL over 72 weeks, and 72.7% of that tracked weight loss. Nobody has measured it. Every published comparison sets one diabetes drug against another. None follows an untreated group. The best evidence is a 358,203-pair cohort. In it, stones ran at 21.3 per 1,000 person-years on a GLP-1 and 14.9 on an SGLT2 inhibitor [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones#ref-1). That ranks two treatments. It does not price either against taking nothing, which is the same limit this site reads into [the glaucoma comparison](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma). ## What the cohort measured Adults with commercial insurance were matched on starting either drug class. Median follow-up was 192 days. Nephrolithiasis came in at a hazard ratio of 0.69 (95% CI 0.67 to 0.72) for the SGLT2 arm. The rate difference was 6.4 fewer events per 1,000 person-years. A second comparison, against DPP4 inhibitors, ran 14.6 against 19.9 per 1,000 person-years. The hazard ratio there was 0.74 (95% CI 0.71 to 0.77). The association held across sex, race and ethnicity, chronic kidney disease history and obesity. Age changed it. Under 70 the reduction was larger. At 70 and over the hazard ratio was 0.85. A pooled figure describes nobody in particular. ## The direction of the claim This is a study about SGLT2 inhibitors. GLP-1 drugs are the yardstick, not the subject. What it supports is that SGLT2 use came with fewer stones than GLP-1 use. Reading it backwards turns a ranking into a risk estimate, which is the error set out in [the gout comparison](https://thisglp.com/research/do-glp1-drugs-cause-gout). Why the SGLT2 arm probably won SGLT2 inhibitors increase uric acid excretion in the urine. A population-based cohort found gout diagnosed 36% less often on them than on GLP-1 drugs, at a hazard ratio of 0.64 [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones#ref-2). Urate is a stone-forming substance and it also acidifies the urine, which favors stone formation. So the stone result and the gout result are probably one finding about urate handling, reported twice. ## What weight loss does to urate GLP-1 drugs lower uric acid as well, by a different route. In a post hoc analysis of SURMOUNT-1, serum uric acid fell 0.69, 0.92 and 0.95 mg/dL on the three tirzepatide doses [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones#ref-3). Placebo gave 0.18 mg/dL. A mediation analysis attributed 72.7% of the fall to weight loss. Weight loss is slower than a diuretic effect. Nothing in the 192-day cohort window would capture much of it. The two classes may therefore look further apart at six months than at three years. It is the same follow-up problem raised in [the uric acid analysis](https://thisglp.com/research/uric-acid-fell-and-most-of-it-was-weight). ## What would settle it A cohort with an untreated arm, followed for years rather than months. The kidney trials already run that long. FLOW followed people with chronic kidney disease and stopped early for benefit [\[4\]](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones#ref-4), and stones were not among its endpoints. Until somebody counts them, the honest answer stands: unmeasured. If stones are part of your history, put it in the intake. Whether a seller makes a clinician reachable is a separate question. Most publish nothing about it. [what sellers do not publish](https://thisglp.com/research/what-glp1-sellers-do-not-publish) counts how little. The list worth sending is in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs cause kidney stones? This study cannot answer that. It compared two drug classes against each other with no untreated group, so it shows only that the SGLT2 arm had fewer stones than the GLP-1 arm. How big was the difference? 14.9 events per 1,000 person-years against 21.3, a hazard ratio of 0.69 (95% CI 0.67 to 0.72) and 6.4 fewer events per 1,000 person-years. Did age change it? Yes. The reduction was larger under 70. In adults 70 or older the hazard ratio was 0.85. ## Sources 1. \[1\] Paik JM, et al. (2024). Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes JAMA Internal Medicine. [PMID 38285598](https://pubmed.ncbi.nlm.nih.gov/38285598/) 2. \[2\] Fralick M, et al. (2020). Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study Annals of Internal Medicine. [PMID 31931526](https://pubmed.ncbi.nlm.nih.gov/31931526/) 3. \[3\] Sattar N, Scilletta S, Stefanski A, Wang H, Daly JW, Linetzky B (2026). Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial Annals of the Rheumatic Diseases. [PMID 41198460](https://pubmed.ncbi.nlm.nih.gov/41198460/) 4. \[4\] Perkovic V, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes New England Journal of Medicine. [PMID 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Cause Pancreatic Cancer? Six Comparators, Five Answers A TriNetX propensity-matched study compared GLP-1 users with six antidiabetic classes on pancreatic cancer | hazard ratios ran 1.08 to 1.39, on 0.04 to 0.15 point risk differences. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-pancreatic-cancer Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Cause Pancreatic Cancer? Six Comparators, Five Answers Against four rival drug classes the GLP-1 arm carried the lower hazard, and against SGLT2 inhibitors no difference. One of the six comparisons is printed in both directions in the same abstract. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Pancreatic cancer, comparator versus GLP-1 user · above 1.00 means the comparator drug carried the higher hazard · metformin · 1.39 (1.16–1.66) · +0.04 pts · sulfonylureas · 1.37 (1.13–1.65) · +0.07 pts · DPP-4 inhibitors · 1.31 (1.06–1.61) · +0.08 pts · thiazolidinediones · 1.30 (1.001–1.678) · +0.15 pts · SGLT2 inhibitors · 1.08 (0.87–1.34) · no difference · insulin — the abstract reports this one in both directions · HR 0.43 (0.35–0.53), risks 0.15% against 0.11%, conclusion: higher **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A new-user cohort study in the TriNetX record network, adults with type 2 diabetes starting a GLP-1 drug. - Six separate 1:1 propensity-matched comparisons, one per rival drug class, matched on 39 covariates. - The answer changed with the comparator: lower than four classes, no different from SGLT2 inhibitors. - The insulin comparison is printed in both directions in the same abstract. - Every absolute risk difference sits between 0.04 and 0.15 percentage points. Nothing here says they do. Across six separate matched comparisons, the GLP-1 arm carried a lower hazard than four rival drug classes and no different a hazard from SGLT2 inhibitors. Every absolute difference sits between 0.04 and 0.15 percentage points [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatic-cancer#ref-1). One comparison in the paper is printed three times, in two directions, and that is the part worth your attention. It sits inside a design that was otherwise careful, and beside [the larger matched-record study on cancer overall](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer). ## What was compared with what Adults with type 2 diabetes who started a GLP-1 drug were matched one-to-one against adults who started insulin, metformin, a DPP-4 inhibitor, an SGLT2 inhibitor, a sulfonylurea or a thiazolidinedione. Matching used 39 baseline variables covering demographics, conditions, procedures and other prescriptions. The outcome was a pancreatic cancer diagnosis recorded between 365 and 7,300 days after the first prescription. That first year is deliberately discarded, because pancreatic cancer often causes diabetes months before anyone finds the tumor. Without the gap, the drug someone was prescribed for their new diabetes would look like the cause of the cancer that produced it. ## Four lower, one level Against metformin the hazard ratio was 1.39, interval 1.16 to 1.66, in the comparator’s direction — so the metformin group carried the higher hazard. Sulfonylureas gave 1.37, DPP-4 inhibitors 1.31, thiazolidinediones 1.30 with an interval of 1.001 to 1.678. SGLT2 inhibitors gave 1.08, and that interval crosses one. Read one at a time, each is a separate observational study with its own matched population. We have [written about what that does to an answer](https://thisglp.com/research/glp1-adolescent-suicidality-comparators) and will not repeat it here. What is new is the sixth row. The insulin row disagrees with itself The results section says GLP-1 users had a lower hazard than insulin users, HR 0.43 with an interval of 0.35 to 0.53. The same sentence prints absolute risks of 0.15% on a GLP-1 against 0.11% on insulin, which runs the other way. The conclusions then describe a higher hazard relative to insulin. Those three statements cannot all be right. We cannot tell from the abstract which is the slip, so we are not going to pick one. What we can say is that the insulin comparison is the one nobody should quote yet. ## How large are these differences Small. The absolute risk differences run from 0.04 to 0.15 percentage points, on underlying risks of roughly one in a thousand. A hazard ratio of 1.39 sounds like a third more cancer. In this data it is about four extra diagnoses per ten thousand people over a period that can run twenty years. Ratios and counts are two different sentences, and [a large ratio on a small base](https://thisglp.com/research/glp1-prescriptions-to-young-children) is the easiest number on a page to misread. ## What matching does not fix Nobody here was randomized. People put on insulin have usually had diabetes longer and controlled it worse, and 39 covariates do not erase that. The comparison against insulin is the one most likely to be carrying it, which makes the contradiction in that row doubly awkward. The record network also only knows what was coded. A diagnosis appears when somebody wrote it down, and so do the conditions used to match on — the same limitation behind [the other large matched-record study on cancer](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer). ## What the wider cancer evidence adds A separate matched cohort of 86,632 adults looked at cancer overall rather than one organ[\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatic-cancer#ref-2). Incidence across fourteen cancers ran 13.6 per 1,000 person-years in GLP-1 users against 16.4 in non-users, a hazard ratio of 0.83 (95% CI 0.76 to 0.91). Pancreatic cancer is not reported separately there, so the two studies answer adjacent questions rather than the same one. Both are record studies and both share the coding problem. Neither is a trial. What they agree on is a direction, and the direction is away from harm. ## What to take from it No signal that GLP-1 drugs cause pancreatic cancer. That is the useful finding, and it is a negative one. Anything stronger runs into the comparator problem. “Lower risk” is not a property a drug has on its own, and a difference of [a fraction of a percentage point](https://thisglp.com/research/glp1-liver-cancer-absolute-risk) is not something a person can feel either way. ## Frequently asked Do GLP-1 drugs cause pancreatic cancer? This study found no signal that they do. Against four other drug classes the GLP-1 group carried the lower hazard, and against SGLT2 inhibitors there was no difference. Why does the answer change with the comparator? Because every result is a comparison. Each of the six analyses matched a different population, so the number describes the pair of drugs rather than the GLP-1 alone. How big were the differences? Between 0.04 and 0.15 percentage points, on underlying risks near one in a thousand. A hazard ratio of 1.39 here is about four extra diagnoses per ten thousand people. What is wrong with the insulin comparison? The published abstract reports it in both directions — a lower hazard in the results, absolute risks running the other way, and a higher hazard in the conclusions. It should not be quoted until that is resolved. ## Sources 1. \[1\] Kazi MAI, et al. (2026). Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network Journal of Gastrointestinal Cancer. [PMID 42745130](https://pubmed.ncbi.nlm.nih.gov/42745130/) 2. \[2\] Dai H, et al. (2025). GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity JAMA Oncology. [PMID 40839273](https://pubmed.ncbi.nlm.nih.gov/40839273/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Cause Pancreatitis? Risk and Warning Signs | This GLP Do GLP-1 drugs cause pancreatitis? What studies show about overall risk, prior pancreatitis, early symptoms and when to seek prompt medical care. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis Updated: 2026-10-15 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Pancreatitis? Risk and Warning Signs Overall risk and recurrence are different questions. Studies disagree in people with pancreatic disease, and severe persistent pain needs prompt assessment. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated October 2026 One diabetes cohort: GLP-1 vs matched controls · 1.0 · Complicated pancreatitis · 0.32 · Mechanical ventilation · 0.23 · All-cause mortality · 0.45 · Uncomplicated pancreatitis · 0.71 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Pancreatitis remains a possible serious adverse effect, even though several studies find no overall increase in risk. One matched diabetes cohort found less complicated pancreatitis, with a hazard ratio of 0.32 [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis#ref-1). That result does not establish safety for every patient, especially someone with previous pancreatic disease. The question needs three distinctions: pancreatitis from all causes, suspected medication-related cases, and recurrence after an earlier episode. Gallstones are another concern and can themselves cause pancreatitis. The separate [gallbladder evidence](https://thisglp.com/research/glp1-and-gallbladder-disease) found increased biliary disease in randomized trials [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis#ref-2). A reassuring pancreatic study does not cancel that finding. ## What the reassuring diabetes cohort found Researchers matched 20,459 GLP-1 users with 20,459 nonusers from a larger population with type 2 diabetes [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis#ref-1). Complicated pancreatitis was less frequent, with a hazard ratio of 0.32 and a 95% confidence interval of 0.14 to 0.74. Uncomplicated pancreatitis had a hazard ratio of 0.71, but its interval of 0.49 to 1.01 included no difference. The analysis excluded several competing causes, including alcohol-related, biliary and high-triglyceride pancreatitis. It therefore cannot settle risk across all causes or all patients. Matching also cannot remove every difference between people prescribed these drugs and those who were not. Lower complication rates are associations, not proof that treatment protects the pancreas. ## Why an overall neutral result can hide an early risk A separate VA study compared 333,687 people with diabetes starting a GLP-1 drug or a sulfonylurea [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis#ref-3). Overall pancreatitis rates at one year were similar. But suspected drug-induced pancreatitis increased, while alcohol-related and high-triglyceride cases decreased. The suspected medication-related excess clustered early in treatment. This was an observational analysis designed to emulate a trial, not randomized treatment. Its findings help explain why an overall average and a medication warning can coexist. Neither establishes an individual patient's risk, and neither means abdominal symptoms should be ignored. ## What if you have had pancreatitis before? The recurrence evidence is conflicting and needs its own discussion with your prescriber. A cohort of 46,186 patients with diabetes included 10,933 with pancreatitis and 35,253 with elevated lipase [\[4\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis#ref-4). GLP-1 use was associated with greater recurrence: hazard ratio 1.252, with a 95% confidence interval of 1.178 to 1.332. Elevated lipase alone is not the same as a confirmed previous attack. Another study of people with chronic pancreatitis without diabetes found lower recorded recurrence among GLP-1 users [\[5\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis#ref-5). The authors described a selected treatment group and cautioned against using the findings to guide prescribing. These studies differ in population and design; they cannot be combined into a personal risk estimate. Tell the clinician about previous attacks, their suspected cause, gallstones and any abnormal pancreatic tests before treatment starts. A prior episode deserves an individual benefit-risk assessment rather than reassurance based on a general diabetes cohort. This is separate from the question of [pancreatic cancer](https://thisglp.com/research/do-glp1-drugs-cause-pancreatic-cancer). ## Symptoms that need prompt assessment Wegovy's prescribing information warns about persistent or severe abdominal pain, sometimes spreading to the back [\[6\]](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis#ref-6). Nausea or vomiting may occur, but their absence does not rule out pancreatitis. Stop Wegovy and seek prompt medical care if pancreatitis is suspected, rather than waiting for a routine refill appointment. Follow the instructions for your own medicine and clinician. Mild nausea during dose increases is a different symptom pattern, discussed in [the nausea guide](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). Persistent severe pain should not be dismissed as ordinary nausea or assumed to be [delayed stomach emptying](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). Research averages cannot diagnose the cause of pain. ## Frequently asked Do GLP-1 drugs cause pancreatitis? Pancreatitis is a labeled warning. Some studies find similar overall rates, but that does not exclude medication-related cases or settle risk after previous pancreatic disease. Can you take a GLP-1 after pancreatitis? Discuss the previous attack and its cause with your prescriber. Recurrence studies conflict, and neither reassuring nor concerning observational results establish your individual risk. Which symptoms need medical attention? Persistent or severe abdominal pain, sometimes spreading to the back, needs prompt assessment. Vomiting may be absent. Wegovy labeling directs stopping treatment if pancreatitis is suspected. ## Sources 1. \[1\] Nieto LM, et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis The American Journal of Gastroenterology. [PMID 40358430](https://pubmed.ncbi.nlm.nih.gov/40358430/) 2. \[2\] He L, et al. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials JAMA Internal Medicine. [PMID 35344001](https://pubmed.ncbi.nlm.nih.gov/35344001/) 3. \[3\] Xie Y, et al. (2026). GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation. BMJ Medicine. [PMID 42046647](https://pubmed.ncbi.nlm.nih.gov/42046647/) 4. \[4\] Calvarysky B, et al. (2026). Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis Diabetes/Metabolism Research and Reviews. [PMID 41392524](https://pubmed.ncbi.nlm.nih.gov/41392524/) 5. \[5\] Dhali A, et al. (2026). Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study. Journal of Personalized Medicine. [PMID 42645931](https://pubmed.ncbi.nlm.nih.gov/42645931/) 6. \[6\] Novo Nordisk (2026). Wegovy prescribing information Novo Nordisk. [Source](https://www.novo-pi.com/wegovy.pdf) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Cause Thyroid Cancer? A Bound, Not a Verdict | This GLP What a three-country cohort of 437,077 patients found on GLP-1 drugs and thyroid cancer, why the bound matters more than the point estimate, and what it cannot settle. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-thyroid-cancer Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Thyroid Cancer? A Bound, Not a Verdict Across 437,077 patients the hazard ratio was 0.93, and the authors bound it: no more than a 31% increase in relative risk. For medullary cancer specifically, the interval runs from 0.37 to 3.86. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Thyroid cancer risk, against DPP-4 inhibitors · 1.0 · all thyroid cancer · medullary only · 437,077 patients. The second interval is the honest one. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Across 437,077 patients in three countries, thyroid cancer occurred at 1.33 events per 10,000 person-years on GLP-1 drugs and 1.46 on the comparator. - The hazard ratio was 0.93 (95% CI 0.66 to 1.31). - The authors' own conclusion is bounded: the upper limit was consistent with no more than a 31% increase in relative risk. - For medullary thyroid cancer — the one the boxed warning names — the hazard ratio was 1.19 with an interval from 0.37 to 3.86. - That interval is too wide to rule much in or out, and saying so is more useful than reassurance. Nothing in the published record shows that they do, and the honest form of the answer is a bound rather than a reassurance. Across 437,077 patients in three countries, thyroid cancer occurred at 1.33 events per 10,000 person-years on a GLP-1 and 1.46 on the comparator, a hazard ratio of 0.93. The authors put a ceiling on what their data could still be hiding: no more than a 31% increase in relative risk. For medullary thyroid cancer, the one the boxed warning actually names, the interval runs from 0.37 to 3.86 — too wide to rule much in or out, and saying so is more useful than reassurance. The broader cancer question has been asked separately, in 86,632 matched adults with obesity, where three obesity-associated cancers fell and none rose[\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-thyroid-cancer#ref-2); that reading is in [what the cancer cohort found](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer). The thyroid warning on these drugs comes from rodent studies, and it has followed the class into every patient leaflet since. Whether it translates to people has taken a decade and several very large datasets to address. And the answer is more interesting than either “yes” or “no” — it is a bound — the same discipline this site applies to a published price in [what happens when you read a price twice](https://thisglp.com/research/rereading-glp1-prices). ## What was compared A nationwide cohort study used registry data from three countries to compare 145,410 patients treated with GLP-1 receptor agonists against 291,667 treated with DPP-4 inhibitors[\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-thyroid-cancer#ref-1). Mean follow-up was 3.9 years in the first group and 5.4 in the second. Seventy-six thyroid cancers occurred in the GLP-1 group, an incidence rate of 1.33 per 10,000 person-years, against 184 in the comparator group at 1.46. The hazard ratio was 0.93 (95% CI 0.66 to 1.31), and the rate difference was −0.13 events per 10,000 person-years (95% CI −0.61 to 0.36). Both groups had type 2 diabetes, which is a different population from the one most sellers here serve — a gap that also limits the results in [GLP-1 and cancer risk](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer). Read the bound, not the point estimate A hazard ratio of 0.93 looks like a small protective effect and it is not one. What the study establishes is the ceiling: the upper limit of the interval is consistent with no more than a 31% increase in relative risk, which the authors state in exactly those terms. On a base rate of roughly one event per 10,000 person-years, a 31% relative increase is a very small absolute number. That framing — a bound on a rare outcome rather than a verdict — is what a large observational study is actually good for. ## The subgroup the warning is about Medullary thyroid cancer is the specific tumor the rodent data raised and the labeling names. In this study its hazard ratio was 1.19, with a confidence interval from 0.37 to 3.86. That interval spans a two-thirds reduction and a near-quadrupling. It is what happens when a very rare cancer is looked for in a cohort that is large but not large enough, and it means the study cannot settle the question the warning exists for. A comparison against SGLT-2 inhibitors gave 1.16 (0.65 to 2.05) for thyroid cancer overall, which is consistent and equally imprecise. ## What a buyer does with this The practical answer is unchanged by the study, because the labeling already says it: anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take these drugs. That is a contraindication rather than a risk calculation, and it is the sort of thing an intake form should ask about. Whether it does is a separate question. Most sellers tracked here publish nothing about what their intake asks or who reviews the answers, which we count in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) and list seller by seller in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). A contraindication only works if somebody checks for it, and the wider pattern of claims that outrun their evidence is in [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review). ## Frequently asked Do these drugs cause thyroid cancer? Across 437,077 patients the hazard ratio was 0.93 (95% CI 0.66 to 1.31). The authors bound their conclusion: the upper limit was consistent with no more than a 31% increase in relative risk. What about medullary thyroid cancer specifically? The hazard ratio was 1.19 with an interval from 0.37 to 3.86 — too wide to rule much in or out, on a cancer rare enough that this cohort could not resolve it. Who should avoid these drugs? The labeling contraindicates them for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. That is unchanged by this study. How common is thyroid cancer here at all? About 1.33 events per 10,000 person-years in the treated group, against 1.46 in the comparator — rare enough that relative risks translate to very small absolute numbers. ## Sources 1. \[1\] Pasternak B, et al. (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study BMJ. [PMID 38683947](https://pubmed.ncbi.nlm.nih.gov/38683947/) 2. \[2\] Dai H, et al. (2025). GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity JAMA Oncology. [PMID 40839273](https://pubmed.ncbi.nlm.nih.gov/40839273/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Change Your Sense of Taste? Scores Fell From 40.63 to 28.61 Do GLP-1 drugs change your sense of taste? 46 users against 46 matched controls scored 28.61 against 40.63, smell was untouched, and the side-effect pattern runs backwards. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Change Your Sense of Taste? Scores Fell From 40.63 to 28.61 People on a GLP-1 scored far lower on a standardized taste test than matched controls. Smell was untouched, and the people with the worst side effects tasted best. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Score on a 53-item taste test · on a GLP-1 · 28.61 · matched controls · 40.63 · 46 per group, cross-sectional — no baseline scores were taken **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, and the size of it has been measured. Forty-six people taking a GLP-1 scored 28.61 on a 53-item taste test against 40.63 in matched controls, at p<0.001 and an effect size of η²=0.37 [\[1\]](https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste#ref-1). Eighty-five percent of them scored worse than the specific control they were matched against, while smell barely moved at p=0.076. Nobody’s taste was measured before they started, so this is a large difference between two groups rather than a demonstrated cause. What changes alongside it is how much gets eaten: at a standardized test meal the gap ran 291.9, 240.2 and 269.5 kcal at weeks 20, 40 and 60 [\[2\]](https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste#ref-2). ## Key takeaways - 46 people taking a GLP-1 and 46 matched controls took a 53-item taste test and a 40-item smell test. - Taste scores averaged 28.61 (95% CI 25.66 to 31.56) against 40.63 (38.35 to 42.91), p<0.001, with a large effect size of η²=0.37. - 85% of the drug group scored worse than the specific control they were matched to. All five taste qualities were affected. - Smell was slightly lower and not significantly different, p=0.076. - Taste and smell scores were better, not worse, in the people reporting nausea and other side effects. Everybody taking these drugs is asked whether their appetite has changed. Almost nobody is asked whether food still tastes like food. It turns out to be a measurable question with a large answer, and one that sits outside every question [a seller thinks to answer](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## What was measured Forty-six people taking a GLP-1 and forty-six controls matched on age, sex, smoking and COVID-19 history each completed two standardized instruments: a 53-item waterless taste test covering the five basic qualities, and a 40-item smell identification test [\[1\]](https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste#ref-1). Taste scores in the drug group averaged 28.61, 95% CI 25.66 to 31.56, against 40.63, 95% CI 38.35 to 42.91, in controls. The difference was significant at p<0.001 with an effect size of η²=0.37, which is large. Eighty-five percent of the people on the drug scored worse than the specific control they had been matched against, and all five taste subtests moved together, each at p<0.001. Smell was a different story: it was slightly lower on average and the difference did not reach significance, at p=0.076. So this looks like a taste effect rather than a general chemosensory one, which is unusual, because most things that blunt flavor do it through smell. A cross-section cannot show a cause Nobody’s taste was measured before they started the drug. This compares two groups of people at one moment, matched on four characteristics, and finds a large difference. The paper’s own title says these drugs impair taste; the design supports saying that taste scores differ, substantially, in people taking them. Those are not the same claim, and the honest version is still interesting enough. ## The finding that points the wrong way Here is the part that stops this being a tidy story. Taste and smell scores were _higher_ — better — in the participants reporting nausea, diarrhea and other drug-related side effects, which the authors call remarkable and which it is. If the taste effect were simply a marker of how strongly the drug was acting on somebody, you would expect the people with the most side effects to have the worst taste scores; they had the best. That undercuts the simplest explanation and leaves the mechanism open — the authors suggest receptors in the brainstem and afferent taste pathways, and vagal processes, all of which is hypothesis rather than finding. It is also a reminder that [side effects are not a dose meter](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## Why it matters practically Because what you eat follows what you can taste. When food registers as flat, people drift toward salt, sugar, texture and convenience — the things that still deliver something. That is the opposite of the dietary pattern anybody would prescribe alongside rapid weight loss. It compounds a problem covered already on this site, that people on these drugs are [eating below requirements for several nutrients](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1) and largely not being tested for it. It also has a quieter effect on how people judge the drug. Someone who has stopped enjoying meals may read that as discipline, or as the drug working. It may just be that dinner has stopped tasting like dinner. ## Where the mechanism is being looked for The authors point at brainstem receptors, afferent taste pathways and vagal processing, and that is where the laboratory work has gone too. A 2026 circuit study mapped which brainstem neurons carry which effect of these drugs and found that neurons in the area postrema did nothing for ordinary feeding while carrying both the weight loss and the aversion [\[3\]](https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste#ref-3). Its conclusion is that the nauseating and weight-lowering effects cannot be separated at a circuit level. That is preclinical work in laboratory animals and the indexed abstract does not name the species, so it is a direction to look rather than an explanation of a human taste score. ## How much to lean on it Not far: ninety-two people, one time point, no baseline, and a title that overstates what the design can show. It is a strong enough signal to take seriously and far too thin to treat as established, which is roughly where [most small studies in this field](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) sit. What would settle it is measuring the same people before and after starting. In the meantime it is a question worth asking yourself and answering honestly, and one nobody selling you the drug will raise — [the list of things they leave to you](https://thisglp.com/tools/questions-they-leave-open) is long and this belongs on it. ## Frequently asked Do GLP-1 drugs change your sense of taste? Taste scores are substantially lower in people taking them: 28.61 against 40.63 on a 53-item test, p<0.001, with 85% scoring below the control they were matched to. All five taste qualities moved together. Do these drugs damage your sense of taste? This study shows taste scores are substantially lower in people taking them — 28.61 against 40.63 on a 53-item test. It is cross-sectional with no baseline measurements, so it cannot establish that the drug caused the difference. Is smell affected too? Not significantly. Smell scores were slightly lower on average at p=0.076, which makes this look like a taste-specific effect rather than a general chemosensory one. Does it mean the drug is working? Apparently not. Participants reporting nausea and other side effects had better taste and smell scores, not worse, which argues against reading dulled taste as a sign of a strong response. Is it permanent? Unknown. Nobody in this study was followed after stopping, and no baseline scores exist to compare against. ## Sources 1. \[1\] Khan R, et al. (2025). GLP-1 receptor agonists significantly impair taste function Physiology & Behavior. [PMID 39722367](https://pubmed.ncbi.nlm.nih.gov/39722367/) 2. \[2\] Tronieri JS, et al. (2026). Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial The American Journal of Clinical Nutrition. [PMID 42323166](https://pubmed.ncbi.nlm.nih.gov/42323166/) 3. \[3\] Yacawych WT, et al. (2026). A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists The Journal of Clinical Investigation. [PMID 42742987](https://pubmed.ncbi.nlm.nih.gov/42742987/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Alzheimer's? The Trials and the Records Disagree | This GLP Randomized trials including ELAD found no cognitive benefit from GLP-1 drugs in Alzheimer's. Health-record studies report a hazard ratio of 0.46. Why the two disagree. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-alzheimers Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Alzheimer's? The Trials and the Records Disagree Randomized trials have found no cognitive benefit. Health-record studies report Alzheimer's diagnoses at half the rate. The same records also halve all-cause mortality, which is the clue. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Two kinds of study, two answers · no effect · records: AD · records: dementia · trials: cognition · The same records also halve all-cause mortality. · No trial has ever done that. That is the clue. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Randomized trials have not shown a cognitive benefit. In the phase 3 evoke trials, 3,808 people with early Alzheimer's declined at the same rate on oral semaglutide as on placebo. - ELAD, a 204-person liraglutide trial, missed its primary outcome. - A meta-analysis of four randomized trials, 112 patients in total, found a pooled effect of -0.10 (95% CI -0.53 to 0.34). - Health-record studies report large benefits: one put an Alzheimer's diagnosis at a hazard ratio of 0.46. - The same record study halved all-cause mortality. No randomized trial has done that, which is a reason to discount its other numbers. No GLP-1 drug is approved to treat or prevent Alzheimer’s disease. The evidence splits by study design. Randomized trials find nothing. Health records find a lot. This page sets out both, and why they disagree. ## What the randomized trials found ELAD tested liraglutide. It gave 204 people with mild to moderate Alzheimer’s daily liraglutide or placebo for 52 weeks [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-alzheimers#ref-1). None had diabetes. The primary outcome was cerebral glucose metabolism. That outcome did not move. The difference was -0.17, with an interval from -0.39 to 0.06 and a P value of 0.14. The interval crosses zero. One secondary outcome favored liraglutide. The ADAS executive domain differed by 0.15, with an interval from 0.03 to 0.28. Its P value of 0.01 is reported as unadjusted. Unadjusted is the word doing the work A trial measuring many secondaries will produce some that clear 0.05 by chance. The standard correction was not applied here. Two other secondaries were flat: daily living at -0.58 (95% CI -3.13 to 1.97), and Clinical Dementia Rating-Sum of Boxes at -0.06 (-0.57 to 0.44). One positive among several nulls, uncorrected, is the pattern this site flagged in [the study that checked its own work](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots). Pooling helps less than it sounds. A meta-analysis found four randomized trials in non-diabetic patients with Alzheimer’s or mild cognitive impairment [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-alzheimers#ref-2). Together they enrolled 112 people. The pooled effect was -0.10, with an interval from -0.53 to 0.34. That is not evidence of absence. It is 112 patients. The correct statement is that a benefit has not been shown, not that it has been ruled out. ## The phase 3 trials of oral semaglutide The evoke and evoke+ trials tested oral semaglutide in early Alzheimer’s at phase 3 scale [\[4\]](https://thisglp.com/research/do-glp1-drugs-help-alzheimers#ref-4). Participants were 55 to 85 years old. Each had mild cognitive impairment or mild dementia due to Alzheimer’s. Amyloid had to be confirmed by PET scan or spinal fluid. The dose climbed over eight weeks to 14 mg a day. The primary endpoint was change in CDR-SB at week 104. The two trials randomized 3,808 people across 566 sites [\[5\]](https://thisglp.com/research/do-glp1-drugs-help-alzheimers#ref-5). In evoke, CDR-SB rose 2.3 points on semaglutide and 2.3 on placebo. In evoke+, it rose 2.2 against 2.1. The differences were -0.08 (95% CI -0.35 to 0.20) and 0.10 (-0.17 to 0.38). Both trials were discontinued for a negative outcome. The full reading is in [the trial that closed the question](https://thisglp.com/research/semaglutide-and-alzheimers). ## What the health records found A target-trial emulation used a federated record system of over 29 million patients [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-alzheimers#ref-3). It matched 28,901 GLP-1 starters against 28,901 people starting a different diabetes drug. Matching used 30 baseline variables, plus index year and age band. GLP-1 starters against other diabetes drug starters, matched. | Outcome | Hazard ratio | 95% CI | | --- | --- | --- | | First Alzheimer's diagnosis | 0.46 | 0.29 to 0.73 | | All-cause dementia | 0.66 | 0.55 to 0.79 | | Mild cognitive impairment | 0.76 | 0.61 to 0.94 | | All-cause mortality | 0.46 | 0.37 to 0.58 | GLP-1 starters against other diabetes drug starters, matched. Target-trial emulation, 28,901 per arm The semaglutide result reproduced at 0.56. The tirzepatide estimate was 0.60 and did not reach significance. ## Why the two disagree Read the mortality row first That study reports all-cause mortality at a hazard ratio of 0.46. A halving of death from any cause is larger than any randomized GLP-1 trial has produced. When a matched cohort reports an effect that size on mortality, the most likely explanation is who got the prescription, not what the drug did. The same selection sits underneath its Alzheimer’s number. This site set out the general problem in [what happens when the control group never started treatment](https://thisglp.com/research/do-glp1-drugs-cause-depression). Two more limits apply. People who start a newer drug see doctors more often, which changes how fast a diagnosis is recorded. And that analysis appeared in Biology Methods & Protocols, which is not a dementia journal. Matching on 30 variables does not fix this. It balances what was measured. It cannot balance the reason a prescriber chose one drug over another. ## What is settled, and what is not Settled: liraglutide was safe and tolerated over 52 weeks in this population. Daily injections in people with cognitive impairment had not been tested before. Not settled: whether any GLP-1 drug changes the course of Alzheimer’s. Larger randomized trials of oral semaglutide have reported, and it did not slow early Alzheimer’s. A record-based hazard ratio remains a hypothesis. One narrower question has its own page. The oral tablet was tested in cognitive impairment. It reached a similarly cautious place — see [what the oral tablet did for cognitive impairment](https://thisglp.com/research/oral-semaglutide-cognitive-impairment). The effect-size reading this site applies throughout is in [sixteen percent lower, six hundredths of a point](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy). ## Frequently asked Do GLP-1 drugs help Alzheimer's disease? No randomized trial has shown a cognitive benefit. In the phase 3 evoke trials of 3,808 people with early Alzheimer's, oral semaglutide did not slow decline on CDR-SB at 104 weeks. ELAD, with 204 people, missed its primary outcome, and a pooled analysis of four small trials found no effect. Why do some studies report a large benefit? Those are health-record studies rather than trials. One reported an Alzheimer's hazard ratio of 0.46, but it also reported all-cause mortality at 0.46 — larger than any randomized trial has produced, which points to who received the prescription. Is liraglutide safe in people with Alzheimer's? In ELAD it was generally safe and well tolerated over 52 weeks in people without diabetes. That is the trial's clearest result. Is any GLP-1 drug approved for dementia? No. None is approved to treat or prevent Alzheimer's disease or any other dementia. ## Sources 1. \[1\] Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z (2026). Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial Nature Medicine. [PMID 41326666](https://pubmed.ncbi.nlm.nih.gov/41326666/) 2. \[2\] O'Mara A, Mody BP, Mammi M, Simjian T, Ghattas K, Kaliki S (2026). The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or Alzheimer's disease: a systematic review and meta-analysis Neurological Sciences. [PMID 41524953](https://pubmed.ncbi.nlm.nih.gov/41524953/) 3. \[3\] Murugadoss K, Venkatakrishnan AJ, Soundararajan V (2026). GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk Biology Methods and Protocols. [PMID 42602880](https://pubmed.ncbi.nlm.nih.gov/42602880/) 4. \[4\] Cummings JL, et al. (2025). evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease Alzheimer's Research & Therapy. [PMID 39780249](https://pubmed.ncbi.nlm.nih.gov/39780249/) 5. \[5\] Cummings JL, et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials The Lancet. [PMID 41865758](https://pubmed.ncbi.nlm.nih.gov/41865758/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Antipsychotic Weight Gain? 9.8% Off, Half Back | This GLP Do GLP-1 drugs help antipsychotic weight gain? A 76-week schizophrenia study, a 764,115-pair mortality emulation and a 14,694-person bipolar cohort | what each shows. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Antipsychotic Weight Gain? 9.8% Off, Half Back In 26 people with schizophrenia on clozapine or olanzapine, semaglutide took off about 10.1 kg over 24 weeks. A year after it stopped, roughly half had returned. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Weight against baseline · 0% · −9.8% · −5.1% · start · week 24 (drug ends) · week 76 · 26 enrolled · 17 completed the intervention · open-label, no control **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, by about 10.1 kg, and roughly half of it came back. A 24-week open-label study gave nurse-administered semaglutide to people with schizophrenia taking clozapine or olanzapine [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain#ref-1). Weight fell 9.8% on an intention-to-treat basis (95% CI −12.7% to −6.8%). A year after the drug stopped, participants were 5.1% below baseline. Twenty-six people enrolled and fifteen finished the trial, with no control group. ## Key takeaways - An open-label study gave nurse-administered semaglutide for 24 weeks to people with schizophrenia taking clozapine or olanzapine, then followed them to week 76. - Weight fell 9.8% by the end of the intervention (95% CI -12.7% to -6.8%), about 10.1 kg. - A year after the drug stopped, weight was 5.1% below baseline (95% CI -8.3% to -1.9%) — roughly half of what was lost had returned. - Twenty-six enrolled, 17 completed the intervention, 15 completed the trial. No control group and no blinding. - In a 764,115-pair emulation, four-year mortality among people with serious mental illness was 4.91% against 6.45%. - In 14,694 people with bipolar disorder, semaglutide tracked lower psychiatric hospitalization; liraglutide and dulaglutide did not. Clozapine and olanzapine cause substantial weight gain. For many people they are also the antipsychotics that work, so they are not substitutable. That leaves a population carrying drug-induced obesity with no way to stop the cause. ## What the intervention produced Weight fell 9.8% on an intention-to-treat basis, around 10.1 kg. Waist circumference fell 7.3%. HbA1c fell too but did not reach significance (P = 0.055). The dose was 1.0 mg weekly. That is a diabetes dose, not the 2.4 mg used for weight management. These figures are therefore not comparable to obesity-trial numbers, a distinction that changes the ranking of these drugs. The ordering is set out in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). The number most studies do not publish At week 76, a year after the intervention ended, participants were 5.1% below their starting weight (95% CI -8.3% to -1.9%). Roughly half of what came off had come back. Most small open-label studies stop at the end of treatment and report the 9.8%. This one reported both, and the second number is the more useful one. ## How small the study is Twenty-six people enrolled. Seventeen completed the intervention and fifteen completed the trial. There was no control group and no blinding. In a population where medication adherence is the central clinical difficulty, a 65% completion rate is itself a finding. It means the weight figures describe those who stayed. One result points in an unexpected direction. Gut microbial alpha diversity decreased as time on semaglutide increased, with one species enriched. Lower diversity is usually characterized as unfavorable in metabolic research. Nobody measured a health outcome from it, so it is an observation rather than a harm. It belongs beside the other things these drugs turn out to do that nobody designed them for, as in [the inflammation substudy](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation). ## What happens to mortality in this population People with schizophrenia, bipolar disorder and major depression die substantially earlier than everyone else, mostly of cardiovascular disease. A target trial emulation matched 764,115 pairs starting a GLP-1 drug or an SGLT2 inhibitor. Of those pairs, 195,184 had serious mental illness [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain#ref-2). Four-year mortality in that cohort was 4.91% against 6.45%. The hazard ratio was 0.76 and the absolute difference 1.54 percentage points. The comparator is not placebo: SGLT2 inhibitors reduce mortality themselves, so this is one effective drug measured against another. The same paper's one-year figure is 1.46% against 2.84%. That is too large to believe, and the reasons are in [the four-year mortality gap](https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness). ## Whether the psychiatric course changes A nationwide cohort covered 14,694 people with bipolar disorder and diabetes or obesity. It compared each person against their own periods on and off these drugs [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain#ref-3). Semaglutide tracked a 21% lower risk of psychiatric hospitalization (adjusted HR 0.79, 95% CI 0.69 to 0.91). Liraglutide and dulaglutide showed no such association. One outcome did not move at all. Sick leave for psychiatric reasons showed no association with any of the drugs studied. Hospitalization depends on admission thresholds and bed availability; sick leave tracks whether someone can work. The full reading is in [the bipolar cohort](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder). One randomized psychiatric result exists. A trial in major depressive disorder found semaglutide reduced the felt cost of effort, measured on an effort-based decision-making task [\[4\]](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain#ref-4). It was a secondary finding, and it is described in [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding). ## What this establishes Feasibility, in a group usually excluded from obesity trials altogether. Nurse-administered treatment in a public mental health setting produced real weight loss in people taking the most metabolically damaging antipsychotics. Whether it should be continued indefinitely rather than for 24 weeks is the question the 76-week figure raises and cannot answer. The same question runs through [what comes back when you stop](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1). No seller on this roster prescribes for schizophrenia, and an intake form is not where a clozapine history belongs. ## Frequently asked Do GLP-1 drugs help antipsychotic weight gain? In a 24-week open-label study of people on clozapine or olanzapine, weight fell 9.8%, about 10.1 kg. Twenty-six people enrolled, fifteen finished, and there was no control group. Does the weight stay off after stopping? Not fully. A year after the drug stopped, participants were 5.1% below their starting weight, so roughly half of what came off had returned. What dose was used? 1.0 mg of semaglutide weekly. That is a diabetes dose rather than the 2.4 mg used for weight management, so the figures do not transfer to obesity-trial numbers. Do these drugs reduce deaths in serious mental illness? A 764,115-pair emulation put four-year mortality at 4.91% against 6.45%, a hazard ratio of 0.76. The comparator was an SGLT2 inhibitor, which lowers mortality itself, not a placebo. Do they change the psychiatric course? In 14,694 people with bipolar disorder, semaglutide tracked a 21% lower risk of psychiatric hospitalization. Liraglutide and dulaglutide did not, and sick leave for psychiatric reasons did not move for any of them. ## Sources 1. \[1\] Lappin JM, Bolton P, Smith G, Chua XY, et al. (2026). Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial Schizophrenia Research. [PMID 42372344](https://pubmed.ncbi.nlm.nih.gov/42372344/) 2. \[2\] McIntyre RS, Zhang-James Y, Kwan ATH (2026). Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness JAMA Psychiatry. [PMID 42647034](https://pubmed.ncbi.nlm.nih.gov/42647034/) 3. \[3\] Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A (2026). Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024 Acta Psychiatrica Scandinavica. [PMID 42324672](https://pubmed.ncbi.nlm.nih.gov/42324672/) 4. \[4\] Gill H, Badulescu S, Shah H, Brudner RM, et al. (2026). Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial JAMA Psychiatry. [PMID 42054055](https://pubmed.ncbi.nlm.nih.gov/42054055/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Atrial Fibrillation? The Evidence Disagrees With Itself Do GLP-1 drugs help atrial fibrillation? Two TriNetX cohorts disagree on recurrence after ablation, and a 2.17-million-patient comparison found no clear benefit. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Atrial Fibrillation? The Evidence Disagrees With Itself One ablation cohort found a hazard ratio of 0.82 for recurrence. Another found 1.04. A larger comparison found no advantage over a near-neutral drug at all. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Atrial fibrillation recurrence after ablation · 1.0 · 3,350 pairs, 2 years · 0.82 · 1,625 pairs, 1 year · 1.04 · Same research network. Different cohorts, different answer. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No clear answer yet, and the numbers explain why nobody can give one. Two analyses of the same research database asked whether a GLP-1 drug keeps atrial fibrillation from returning after catheter ablation. They landed on opposite conclusions: one found a hazard ratio of 0.82, the other found 1.04. A larger comparison, of 2,171,267 patients, found GLP-1 drugs no better than a near-neutral standard drug at preventing atrial fibrillation from developing in the first place, while a different drug class beat both — the full writeup is [here](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won)[\[3\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-3). Whatever a seller's landing page claims about heart rhythm, this is the record it would be drawing from. ## Key takeaways - A 2026 analysis of 3,350 matched pairs found GLP-1 use before ablation cut atrial fibrillation recurrence, hazard ratio 0.82 (95% CI 0.76-0.88). - A 2024 analysis of 1,625 matched pairs found no benefit on a similar composite endpoint, hazard ratio 1.04 (95% CI 0.92-1.19). - Both used the same TriNetX research network; the cohorts differed in BMI criteria, follow-up length and outcome definition. - A separate network meta-analysis of 2,171,267 patients found GLP-1 drugs no different from DPP-4 inhibitors on new-onset atrial fibrillation (RR 0.93), while SGLT-2 inhibitors beat both. - For people who already have atrial fibrillation, no drug class separated from the others on recurrence. Atrial fibrillation comes back in a substantial minority of the people who have it burned out by catheter ablation, and weight is one of the few things a patient can change that is known to matter. So the question of whether a GLP-1 drug lowers the recurrence rate is not academic: it is the kind of claim a seller could reasonably be tempted to put on a landing page. The evidence, as it stands, will not support one. The reason why is worth following, because it is the same reason so many claims about this drug class read as more settled than they are — a habit visible on most of the [seller pages ranked here](https://thisglp.com/best). ## Two studies, one research network, opposite conclusions A multicenter analysis published in 2026 drew obese adults without a diabetes requirement from the TriNetX network, matched 3,350 GLP-1 users to 3,350 nonusers across 82 clinical and demographic variables, and followed them a median of two years. Recurrence was 6.66% among users against 7.72% among nonusers, a hazard ratio of 0.82 (95% CI 0.76 to 0.88, P < 0.0001)[\[1\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-1). Progression to permanent atrial fibrillation was also lower at a hazard ratio of 0.77 (95% CI 0.63 to 0.93), as were all-cause mortality at 0.73 (95% CI 0.59 to 0.91) and heart-failure hospitalization at 0.80 (95% CI 0.71 to 0.90). An earlier analysis, published in 2024, used the same TriNetX network to ask a question that sounds identical. It matched 1,625 preablation GLP-1 users to 1,625 nonusers and followed a composite of cardioversion, a new antiarrhythmic drug, or a repeat ablation over twelve months after a three-month blanking period. The hazard ratio was 1.04 (95% CI 0.92 to 1.19, log-rank P = 0.51) [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-2), and stroke, hospitalization and mortality did not differ either. The authors concluded the evidence does not support a benefit and called for research that would settle it. ## What differs is who was counted, and for how long The two cohorts are not the same people asked the same question. The 2026 analysis required a body mass index above 30 and excluded nobody on the basis of diabetes; the 2024 analysis took every adult undergoing ablation in the window it covered. The follow-up differs by a factor of two, and the outcome definitions differ as well: one counted recurrence, the other counted a composite of three downstream interventions that a clinician chooses. Body mass index is doing work of its own here: it is the variable the newer cohort selected on, and the one every [pooled weight-loss estimate](https://thisglp.com/research/glp1-weight-loss-pooled-average) is built from. Either study could be right about its own population without contradicting the other, which is a more uncomfortable finding than a straightforward disagreement would be, because it means neither result generalizes cleanly to the person reading it. This shape recurs across the literature on these drugs, and we have written about it before where two meta-analyses drew [opposite conclusions from the same six trials](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) and where studies of blood-vessel function [returned two answers](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). The pattern is not fraud and it is rarely even error. It is what happens when a large observational database is asked a question the underlying data was not collected to answer. ## A larger comparison, and a different drug wins A network meta-analysis of 2,171,267 patients across four randomized trials and 21 cohort studies asked a related but separate question. Not whether a GLP-1 drug helps someone who already has atrial fibrillation, but whether it prevents the condition from developing at all, compared against two other diabetes drug classes [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation#ref-3). Against DPP-4 inhibitors, the standard near-neutral comparator in this literature, GLP-1 drugs showed a risk ratio of 0.93 with a confidence interval of 0.84 to 1.03. That interval crosses 1, so the honest reading is no detectable difference. SGLT-2 inhibitors separated from both, beating GLP-1 drugs at 0.86 and DPP-4 inhibitors at 0.80. For recurrence specifically — the same question the two ablation cohorts above were asking — no class separated from any other. The full comparison, including why the evidence grade matters more than the headcount, is in [the network meta-analysis writeup](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won). ## What a buyer should take from it Nothing on this page is a reason to start or stop a prescription, and nobody should be buying a GLP-1 drug in order to treat an arrhythmia. What it is useful for is calibration. If a seller's page ever cites a cardiac benefit as a reason to buy, the honest version of that claim carries the population it was measured in and the length of the follow-up. Almost none of them do — an absence we have counted across the market in [what sellers do not publish](https://thisglp.com/research/what-glp1-sellers-do-not-publish). The practical question a buyer can actually act on is a duller one: who is writing the prescription, what they know about your heart, and whether the service you are paying makes that person reachable. Those are the questions worth taking to an intake, and we keep a list of them in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs help atrial fibrillation? The evidence disagrees with itself. Two ablation-recurrence cohorts on the same database found a hazard ratio of 0.82 and 1.04. A separate 2,171,267-patient comparison found no significant advantage over a near-neutral drug class (risk ratio 0.93) at preventing new-onset atrial fibrillation, while SGLT-2 inhibitors did better. Why do the two ablation studies disagree? They studied different people for different lengths of time. The 2026 cohort required a body mass index above 30 and ran a median of two years; the 2024 cohort took all adults having an ablation and ran twelve months, counting a composite of cardioversion, a new antiarrhythmic drug or a repeat procedure. Which drug class did best for preventing atrial fibrillation? SGLT-2 inhibitors, in the largest of the three studies here — a risk ratio of 0.86 against GLP-1 drugs and 0.80 against DPP-4 inhibitors. Should this change what I buy? No. None of these studies was designed to guide a purchase, and no telehealth seller is prescribing for an arrhythmia. It is useful mainly as a check on any cardiac benefit a marketing page claims without naming its population or follow-up. ## Sources 1. \[1\] Venier S, et al. (2026). Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis Circulation: Arrhythmia and Electrophysiology. [PMID 41446932](https://pubmed.ncbi.nlm.nih.gov/41446932/) 2. \[2\] Satti DI, et al. (2024). Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation JACC: Clinical Electrophysiology. [PMID 38795099](https://pubmed.ncbi.nlm.nih.gov/38795099/) 3. \[3\] Ye X, Wu Q, Hou L, Hou X, Yang Y, Yang C, Huang M, Wang S (2026). Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus Diabetes/Metabolism Research and Reviews. [PMID 42455922](https://pubmed.ncbi.nlm.nih.gov/42455922/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Bipolar Disorder? One Drug Moved, Two Did Not | This GLP Do GLP-1 drugs help bipolar disorder? A within-individual cohort of 14,694 people found 21% lower psychiatric hospitalization on semaglutide and nothing on two sibling drugs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Bipolar Disorder? One Drug Moved, Two Did Not Comparing people against their own untreated periods, psychiatric admissions fell 21% on semaglutide. Liraglutide and dulaglutide showed nothing. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Psychiatric hospitalization, same person on vs off · semaglutide · 0.79 · liraglutide · no significant association · dulaglutide · no significant association · Sick leave from work: no association for any of them. · 14,694 people, 5,200 of them GLP-1 users. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). One drug in the class showed something, and the design is better than most. A nationwide cohort of 14,694 people with bipolar disorder and diabetes or obesity compared each person against their own periods on and off these drugs [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-1). Semaglutide came with a 21% lower risk of psychiatric hospitalization, adjusted HR 0.79, 95% CI 0.69 to 0.91. Bipolar relapse was 17% lower at 0.83, 95% CI 0.69 to 0.99, while liraglutide and dulaglutide showed no association at all. Sick leave for psychiatric reasons, the outcome closest to daily life, did not move for any of them. No randomized trial has tested one of these drugs as a psychiatric treatment, and the authors ask for exactly that. ## Key takeaways - A nationwide cohort of 14,694 people with bipolar disorder and diabetes or obesity compared each person against their own periods on and off these drugs. - Semaglutide was associated with 21% lower risk of psychiatric hospitalization (adjusted HR 0.79, 95% CI 0.69-0.91) and 17% lower risk of bipolar relapse (aHR 0.83, 95% CI 0.69-0.99). - Liraglutide and dulaglutide showed no such association, so the authors conclude this is not a class effect. - Sick leave for psychiatric reasons showed no association with any of the drugs studied. People with bipolar disorder carry a heavy burden of obesity and diabetes, much of it produced by the medications that control the illness. A nationwide cohort spanning 2009 to 2024 asked whether treating the metabolic problem changes the psychiatric course[\[1\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-1). The broader mortality picture in serious mental illness is in [a four-year mortality gap](https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness). The design is the reason to take it seriously. Rather than comparing treated people against untreated people, it compares each person against themselves across periods when they were and were not taking one of these drugs. Everything stable about someone — how severe their illness is, their genetics, their circumstances — is identical in both periods and cancels out. In a condition where severity drives both what gets prescribed and who gets admitted, that removes the dominant objection — the same instrument used to good effect in [the alcohol discontinuation study](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it). Semaglutide was associated with a 21% lower risk of psychiatric hospitalization (adjusted HR 0.79, 95% CI 0.69–0.91) and a 17% lower risk of bipolar relapse (aHR 0.83, 95% CI 0.69–0.99). Liraglutide and dulaglutide showed no such association. One drug moving and two not is not a clean finding The authors read this as evidence against a class effect, and that is one reading. The other is that semaglutide users differ from liraglutide and dulaglutide users — they started more recently, are more often taking it for weight, and were selected by a prescriber making a different decision. A within-individual design removes differences between people; it does not remove differences between the periods in which each drug was fashionable. One outcome did not move at all, and it is the one closest to daily life. Sick leave for psychiatric reasons showed no association with any of the drugs studied. Hospitalization is a severe endpoint that also depends on admission thresholds and bed availability; sick leave tracks whether someone can work. A benefit that appears in one and not the other is narrower than the headline suggests. ## The two neighboring psychiatric results Two other findings sit next to this one and neither is about bipolar disorder. A target trial emulation matched 764,115 pairs starting a GLP-1 drug or an SGLT2 inhibitor, including 195,184 pairs with serious mental illness, and four-year mortality in that cohort was 4.91% against 6.45% [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-2). That is a hazard ratio of 0.76 and an absolute difference of 1.54 percentage points, measured against another effective drug rather than against placebo. Separately, a 16-week double-blind trial randomized 72 adults with major depressive disorder to oral semaglutide 14 mg or placebo and found more willingness to exert effort as reward value rose, at P = .02 [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-3). Its outcome was a laboratory task rather than a depression rating scale, which is set out in [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding). The authors ask for a randomized trial, which is the right conclusion and an achievable one here — unlike many populations this site covers, people with bipolar disorder and obesity are numerous and already in regular contact with services. Until then this sits alongside the other psychiatric findings on this site, [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding) and [the clozapine cohort](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain), as a signal worth testing rather than a reason to prescribe. ## Frequently asked Do GLP-1 drugs help bipolar disorder? One nationwide cohort found semaglutide associated with 21% fewer psychiatric hospitalizations and 17% fewer relapses when people were taking it, compared with their own periods off it. Liraglutide and dulaglutide showed nothing, and no randomized trial has tested any of them. Does semaglutide help bipolar disorder? It was associated with fewer psychiatric hospitalizations and fewer relapses when people were taking it, compared with their own periods off it. The authors call for a randomized trial before treating that as an effect. Why did the other drugs show nothing? The authors read that as evidence against a class effect. An alternative is that people prescribed semaglutide differ from those prescribed liraglutide or dulaglutide, since the drugs became common at different times and for different reasons. Did anything else improve? No. Sick leave for psychiatric reasons showed no association with any of the drugs studied, which is the outcome closest to everyday functioning. ## Sources 1. \[1\] Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A (2026). Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024 Acta Psychiatrica Scandinavica. [PMID 42324672](https://pubmed.ncbi.nlm.nih.gov/42324672/) 2. \[2\] McIntyre RS, Zhang-James Y, Kwan ATH (2026). Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness JAMA Psychiatry. [PMID 42647034](https://pubmed.ncbi.nlm.nih.gov/42647034/) 3. \[3\] Gill H, Badulescu S, Shah H, Brudner RM, et al. (2026). Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial JAMA Psychiatry. [PMID 42054055](https://pubmed.ncbi.nlm.nih.gov/42054055/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Carpal Tunnel Syndrome? Fewer Diagnoses, Same Surgeries A TriNetX cohort put carpal tunnel diagnoses at HR 0.82 on tirzepatide against other GLP-1 drugs, while surgery showed no significant difference | what the gap means. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Carpal Tunnel Syndrome? Fewer Diagnoses, Same Surgeries Tirzepatide came with fewer carpal tunnel diagnoses than other GLP-1 drugs. The operation rate did not follow. That gap is the more telling half of the result. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Tirzepatide, hazard ratio · vs other GLP-1s · diagnosis · vs other GLP-1s · surgery · no significant difference · vs orlistat etc · diagnosis · vs orlistat etc · surgery · Dashed line marks no effect. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Fewer diagnoses, and no change in operations. Against other GLP-1 drugs, tirzepatide gave a carpal tunnel diagnosis hazard ratio of 0.82 (95% CI 0.71 to 0.95). - Carpal tunnel surgery against that same comparator showed no significant difference. The harder endpoint did not move. - Against orlistat and phentermine, both moved: diagnosis 0.75 (0.65 to 0.85) and surgery 0.64 (0.44 to 0.94). - No study compares any of these drugs against no treatment, so none of this is an absolute risk. - The authors raise a nerve-protecting effect. The study measures nothing about nerves. Fewer people were diagnosed. The same number were operated on. Against other GLP-1 drugs, tirzepatide gave a carpal tunnel diagnosis hazard ratio of 0.82 (95% CI 0.71 to 0.95) [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome#ref-1). Surgery showed no significant difference. Hand and wrist complaints recur across this literature, and the strength evidence sits in [grip strength on a GLP-1](https://thisglp.com/research/semaglutide-muscle-mass-and-grip). ## What the cohort did Carpal tunnel syndrome is more common with obesity and diabetes. A retrospective cohort used the TriNetX US network to test tirzepatide against two comparators. The design emulated a target trial, with one-to-one propensity matching. Matching covered demographics, BMI, comorbidities and socioeconomic variables. Adults starting tirzepatide, another GLP-1 drug, or an older anti-obesity medication were enrolled. The window ran from January 2022 to December 2024. Two outcomes were followed: a carpal tunnel diagnosis, and carpal tunnel surgery. The two endpoints disagree, and that is informative A diagnosis is a coded clinical encounter. It needs somebody to seek care and a clinician to code it. People on a newer drug are in front of a clinician more often. An operation is harder to explain away. The gentler endpoint moved and the harder one did not. That is the pattern detection produces, not the pattern disease produces. ## The other comparator Against orlistat and phentermine the picture was stronger. Diagnoses came in at 0.75 (95% CI 0.65 to 0.85). Surgery came in at 0.64 (95% CI 0.44 to 0.94). Both endpoints moved the same way. That comparison carries its own problem. People prescribed orlistat or phentermine are not people prescribed tirzepatide. Propensity matching works on recorded variables. It cannot fix a difference that was never recorded. ## What the study does not show The authors close by suggesting metabolic and neuroprotective benefits. Nothing in the study measures nerve structure or function. That is a hypothesis attached to an association. The simpler reading is that losing weight reduces pressure in a tunnel weight narrows. There is also no untreated arm anywhere in this design. Both comparisons rank one drug against another. Neither says whether a GLP-1 user has more or less carpal tunnel syndrome than someone taking nothing. ## Where it sits Tirzepatide beating other GLP-1 drugs turns up repeatedly, and each margin is small. Incident open-angle glaucoma came in at 0.65 (95% CI 0.44 to 0.96) in a 51,540-person cohort [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome#ref-2). Venous thromboembolism came in at 0.90 (95% CI 0.83 to 0.98) across 701,374 people [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome#ref-3). This site reads those in [the glaucoma comparison](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma) and [the clotting cohort](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots). The recurring question is whether these compare molecules or doses. The network comparison is in [tirzepatide against dulaglutide](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide). The mismatched-dose problem is in [the liver comparison](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). What the lost weight is made of is in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). ## Frequently asked Does tirzepatide prevent carpal tunnel syndrome? The study shows an association, not prevention. Diagnoses were lower than on other GLP-1 drugs, but carpal tunnel surgery was not significantly different against that comparator. Why does the surgery result matter more? A diagnosis depends on someone seeking care and a clinician coding it, so it partly measures contact with the health system. An operation is a harder endpoint to explain by detection alone. Is this a nerve-protecting effect? The authors raise that possibility but the study measures nothing about nerves. The simpler explanation is that weight loss reduces pressure in a space that excess weight narrows. ## Sources 1. \[1\] Su YJ, Gau SY, Shiue YL (2026). Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults Clinical Pharmacology and Therapeutics. [PMID 42572932](https://pubmed.ncbi.nlm.nih.gov/42572932/) 2. \[2\] Pan SY, Weng CH, Sheen YJ, Chen JP, et al. (2026). Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study Ophthalmology Science. [PMID 42383218](https://pubmed.ncbi.nlm.nih.gov/42383218/) 3. \[3\] Wu JY, Lee KW, Huang SC, Chang HY, Lin YM (2026). Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study Frontiers in Medicine. [PMID 42239959](https://pubmed.ncbi.nlm.nih.gov/42239959/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help COPD? Fewer Flare-Ups, Against One Comparator | This GLP Do GLP-1 drugs help COPD? 32,107 matched pairs, 9.89 exacerbations per 100 person-years against 11.49, and the head-to-head comparison that finds almost nothing. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-copd Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help COPD? Fewer Flare-Ups, Against One Comparator Against an older drug class, GLP-1 use came with fewer exacerbations. Against SGLT2 inhibitors the hazard ratio was 0.94, with an interval reaching 1.00. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Exacerbations per 100 person-years · GLP-1 · 9.89 · DPP-4 · 11.49 · SGLT2 · 9.26 · DPP-4 · 11.4 · SGLT2 · 9.47 · GLP-1 · 10 · The third pair is the head-to-head, and it is nearly a tie. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Against an older diabetes drug class, yes, and against the other new class, barely. In 32,107 matched pairs of adults with type 2 diabetes and COPD, GLP-1 users had 9.89 moderate or severe exacerbations per 100 person-years against 11.49 on DPP-4 inhibitors [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-copd#ref-1). That is a hazard ratio of 0.86 (95% CI 0.81 to 0.91). Put against SGLT2 inhibitors instead, the hazard ratio was 0.94 with an interval running to 1.00, which touches no effect. Everyone in the study had diabetes and coded COPD at a mean age near 70, which is not the population buying from [a telehealth page](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## Key takeaways - In 32,107 matched pairs, GLP-1 users had 9.89 COPD exacerbations per 100 person-years against 11.49 on DPP-4 inhibitors — a hazard ratio of 0.86 (95% CI 0.81 to 0.91). - SGLT2 inhibitors against the same comparator ran 9.26 against 11.4, a hazard ratio of 0.81 (95% CI 0.76 to 0.86) across 27,991 pairs. - Head to head, the two newer classes were 9.47 against 10.00 per 100 person-years — a hazard ratio of 0.94 whose interval reaches 1.00. - Mean age was near 70, every patient had type 2 diabetes and coded COPD, and median follow-up was 145 days. - A separate systematic review of 123 studies found no increase in respiratory adverse events on these drugs against placebo. - In asthma, a matched cohort recorded exacerbations in 1.7% against 4.0% — a ratio of 0.438 and a difference of 2.2 points. ## Two comparisons that favor the newer drugs The study emulated three target trials in US insurance claims, matching patients aged 40 and over who carried both diagnoses [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-copd#ref-1). Against DPP-4 inhibitors, GLP-1 receptor agonists came in at 9.89 exacerbations per 100 person-years against 11.49 across 32,107 matched pairs. SGLT2 inhibitors against the same comparator ran 9.26 against 11.4, a hazard ratio of 0.81 (95% CI 0.76 to 0.86) across 27,991 pairs. Both results held across the sensitivity and subgroup analyses the authors report. ## And one that finds almost nothing The third comparison put the two newer classes against each other in 36,218 matched pairs, and the difference nearly vanished. It was 9.47 against 10.00 per 100 person-years, a hazard ratio of 0.94 with a 95% confidence interval of 0.89 to 1.00. The upper bound touches no effect, and the rate difference says the same thing at −0.55 per 100 person-years with an interval running to −0.01. Both classes beat an older one and neither clearly beats the other. Quoting the first two comparisons alone would imply a ranking this study does not support, which is the shape taken apart in [two meta-analyses of the same six trials](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials). ## Do these drugs harm breathing in the first place That is a separate question and it has its own answer. A systematic review screened 9,086 records and included 123 studies of respiratory adverse events on weight-loss drugs [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-copd#ref-2). Liraglutide, semaglutide, tirzepatide and naltrexone-bupropion showed no increase against placebo, with the contributing randomized trials at low risk of bias. Of those 123 studies, 122 were in general populations and one was in people with asthma, so the reassurance mostly comes from people without a lung condition. The full reading of that gap is in [the respiratory safety review](https://thisglp.com/research/one-asthma-study-in-a-hundred-and-twenty-three). ## The nearest efficacy result in another lung disease Asthma has been measured with a tighter design. A propensity-matched cohort of 2,423 adults per group recorded an asthma exacerbation in 1.7% against 4.0% over the following year, a ratio of 0.438 (95% CI 0.306 to 0.626) [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-copd#ref-3). Stated as a difference that is 2.2 percentage points, and the difference is the number that tells a reader what it might mean for them. Systemic glucocorticoid exposure ran 16.4% against 23.1%. COPD and asthma are different diseases, so this is a neighbor rather than a substitute. The same gap between a ratio and a difference is set out in [the asthma cohort](https://thisglp.com/research/glp1-asthma-relative-and-absolute). ## Who was in it, and who was not The cohorts were old and sick by the standards of this market: a mean age near 70, type 2 diabetes, and COPD active enough to be coded as such. Median follow-up was 145 days, with an interquartile range of 61 to 355, which is short for a chronic lung condition. A person buying compounded semaglutide from a telehealth page at 45 with no lung disease sits outside the population these numbers describe. Nothing here is a reason to choose one seller over another. It is a reason to make sure whoever writes the prescription knows the rest of the history. That gap is counted in [what happens outside a trial](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) and put into [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs cause breathing problems? A systematic review of 123 studies found no increase in respiratory adverse events for liraglutide, semaglutide, tirzepatide or naltrexone-bupropion against placebo. Only one of the 123 studies was in people with a lung condition. Do GLP-1 drugs reduce COPD flare-ups? Against DPP-4 inhibitors, yes — 9.89 against 11.49 per 100 person-years, a hazard ratio of 0.86. Against SGLT2 inhibitors the difference was 0.94 with an interval reaching 1.00, which is close to nothing. Does this apply to me if I do not have diabetes? No. Every cohort required type 2 diabetes and active COPD, at a mean age near 70. That is not the population buying these drugs from a telehealth page. How long were people followed? A median of 145 days, with an interquartile range of 61 to 355 — short for a chronic lung condition. ## Sources 1. \[1\] Ray A, et al. (2025). Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes JAMA Internal Medicine. [PMID 39928303](https://pubmed.ncbi.nlm.nih.gov/39928303/) 2. \[2\] Zeng L, Zinmon-Htet C, Hundie T, Lin S, et al. (2026). Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis Annals of the American Thoracic Society. [PMID 42479131](https://pubmed.ncbi.nlm.nih.gov/42479131/) 3. \[3\] McCraw C, Grayeb D, Gupta N, Zafar P, et al. (2026). Association of GLP-1-based therapy with asthma-related outcomes in patients with obesity: a propensity-matched retrospective cohort study Expert Review of Respiratory Medicine. [PMID 42733229](https://pubmed.ncbi.nlm.nih.gov/42733229/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Crohn's Disease? Hospitalization Halved, Steroids Unchanged Do GLP-1 drugs help Crohn's disease? 9,766 matched pairs, hospitalization at 10.0% against 24.7%, steroid use unchanged, and authors who disown their own mortality result. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-crohns-disease Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Crohn's Disease? Hospitalization Halved, Steroids Unchanged In 9,766 matched pairs, hospitalization at one year was 10.0% against 24.7%. The same study reports a six-fold mortality difference its authors say is probably not real. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read One year, 9,766 matched pairs · on a GLP-1 · not on one · hospitalization · 10% · 24.7% · ED visit · 18.9% · 25.3% · TNF inhibitor use · 7.1% · 10.9% · Corticosteroid use at one year: unchanged. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Fewer of them went to hospital, and the study does not claim the disease improved. In 9,766 matched pairs of adults with Crohn’s disease and obesity, hospitalization at one year was 10.0% against 24.7% (RR 0.40, 95% CI 0.38 to 0.43) and emergency visits 18.9% against 25.3% [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease#ref-1). Corticosteroid use, the outcome closest to disease activity, was identical at RR 1.00 with an interval of 0.96 to 1.03. In ulcerative colitis a separate matched cohort did measure remission, at 66.7% against 25.3% at twelve weeks [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease#ref-2). No randomized trial has tested a GLP-1 in inflammatory bowel disease. ## Key takeaways - 9,766 matched pairs from 162 organizations, followed at one year and again at five. - Hospitalization at one year was 10.0% against 24.7% (RR 0.40, 95% CI 0.38 to 0.43); emergency visits 18.9% against 25.3%. - Corticosteroid use at one year was identical, RR 1.00 with an interval of 0.96 to 1.03 — the outcome a healthy-user effect should also have moved. - One-year mortality was 0.7% against 4.2%, and the authors say it is unlikely to be causal. - Recorded TNF inhibitor use was lower, but the database cannot separate starting one from continuing one. - In ulcerative colitis, symptomatic remission was 66.7% against 25.3%, and weight loss was not associated with it. Obesity affects between 15% and 40% of adults with Crohn’s disease, and a 2026 cohort study asked what happens to them on a GLP-1 drug [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease#ref-1). It drew on 162 organizations, matched 9,766 pairs on more than thirty covariates, and followed them for one year and again for five. The utilization results are substantial and consistent. Hospitalization at one year was 10.0% against 24.7% (RR 0.40, 95% CI 0.38–0.43), emergency visits 18.9% against 25.3% (RR 0.75, 95% CI 0.71–0.79), and both associations held at five years. These are the outcomes that show up on a bill as well as in a chart, which makes them worth more attention than they usually get beside the [weight figures](https://thisglp.com/research/glp1-weight-loss-pooled-average). The study also reports one-year mortality at 0.7% against 4.2% (RR 0.17, 95% CI 0.13–0.22), and then tells you not to believe it. Its authors write that the mortality difference is unlikely to reflect a true causal effect and should be treated as hypothesis-generating, and that healthy-user bias cannot be excluded. This is the second paper in this library to publish a dramatic mortality number and disown it in the same breath. The first is covered in [the authors do not believe their own hazard ratio](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own), and the reasoning there applies here unchanged. The TNF inhibitor result needs the same discipline. Use was 7.1% against 10.9% (RR 0.65, 95% CI 0.60–0.72), which reads like less need for biologic escalation. The authors state plainly that it should not be read that way, because their database cannot distinguish starting a TNF inhibitor from continuing one. A lower rate of recorded use is not the same fact as a lower rate of disease progression. The most informative number is the one that did not move. Corticosteroid use at one year was the same in both arms, RR 1.00 with a confidence interval of 0.96 to 1.03. If a healthy-user effect were driving everything, it should have dragged that outcome too. It did not, which is a point in the findings’ favor, and by five years steroid use was modestly lower at RR 0.91. ## The neighboring disease, where remission was measured Ulcerative colitis got the better endpoint. A matched cohort reported symptomatic remission at twelve weeks in 66.7% against 25.3%, an adjusted odds ratio of 5.90 (95% CI 3.52 to 9.86), with the remission definition requiring a rectal bleeding subscore of zero [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease#ref-2). Gut slowing does not stop rectal bleeding, which is the reason that definition matters, and weight loss was not associated with remission either. Crohn’s disease and ulcerative colitis are different illnesses with different patterns of inflammation, so this is a neighbor rather than a transfer, and the full reading is in [the ulcerative colitis cohort](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis). None of this makes a GLP-1 a Crohn’s treatment, and the paper does not claim it. What it supports is metabolic safety in a group whose disease is often cited as a reason for caution, with a call for prospective work. That caution is mostly about motility, and the evidence behind it is thinner than the warnings suggest — the [gastroparesis signal](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis) is worth reading before assuming it settles the question. In irritable bowel syndrome, a matched analysis of 6,665 people per arm found coded abdominal pain at 31.6% against 35.8% and bloating at 8.3% against 10.9%, which runs the other way from the warning [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease#ref-3). Anyone with inflammatory bowel disease weighing one of these drugs is in a conversation with a gastroenterologist, not an intake form — the same conclusion reached from a different direction in [the ulcerative colitis evidence](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis). ## Frequently asked Do GLP-1 drugs help Crohn's disease? This study does not show that, and does not claim it. It found lower hospitalization and emergency use among matched patients with Crohn's and obesity, and its authors present the work as supporting metabolic safety rather than treatment effect. Why dismiss the mortality result? Because the authors do. They write that the difference is unlikely to be causal, should be treated as hypothesis-generating, and that healthy-user bias cannot be excluded — people well enough to be started on a GLP-1 differ from those who are not. Did fewer patients need biologics? That cannot be concluded. Recorded TNF inhibitor use was lower, but the authors state their data cannot distinguish starting one from continuing one, so a lower recorded rate is not evidence of less escalation. ## Sources 1. \[1\] Ganju N, Ssebambulidde K, Gupta S, Adidam S, et al. (2026). GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study Scientific Reports. [PMID 42321339](https://pubmed.ncbi.nlm.nih.gov/42321339/) 2. \[2\] Alqinai B, et al. (2026). GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study Inflammatory Bowel Diseases. [PMID 42627215](https://pubmed.ncbi.nlm.nih.gov/42627215/) 3. \[3\] Khan SA, Marasini A, Shrestha A, Bharadwaj HR, et al. (2026). Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis Digestive Diseases and Sciences. [PMID 42570075](https://pubmed.ncbi.nlm.nih.gov/42570075/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Heart Failure? Symptom Scores Rose 7.5 Points | This GLP Do GLP-1 drugs help heart failure? Pooled trial data and cohorts from 50 to 217,920 patients, with the frailty, sex, and composite-endpoint caveats. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-heart-failure Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Heart Failure? Symptom Scores Rose 7.5 Points In one trial population, yes: semaglutide improved heart-failure symptom scores by 7.5 points and tirzepatide cut a composite endpoint by 38%. Neither number transfers whole. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Symptom score at 52 weeks, between-group difference · +7.5 points (95% CI 5.3 to 9.8) · Six-minute walk distance · +17.1 meters · Serious adverse events · 161 on semaglutide · 301 on placebo **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, in one specific population. Pooled data from two placebo-controlled trials found semaglutide improved heart-failure symptom scores by 7.5 points more than placebo. That was over 52 weeks, in 1,145 people with obesity-related heart failure with preserved ejection fraction [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-heart-failure#ref-1). A separate trial found tirzepatide cut a composite of cardiovascular death or worsening heart failure by 38%, from 15.3% to 9.9%. That was in a comparable population, followed for a median of 104 weeks [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-heart-failure#ref-2) — the full [component breakdown](https://thisglp.com/research/tirzepatide-heart-failure-composite) is below. Neither number transfers whole: one hides a death count that ran the wrong way, and both apply to a narrower group of patients than most readers asking this question. ## Key takeaways - Pooled STEP-HFpEF data: semaglutide improved symptom scores by 7.5 points more than placebo in 1,145 people with obesity-related HFpEF. - The SUMMIT trial: tirzepatide cut a composite of cardiovascular death or worsening heart failure by 38%, but cardiovascular death alone ran the other way on 13 events. - Weight loss was identical across frailty strata; the symptom benefit was not — the frailest gained the most, the fittest gained nothing measurable. - The benefit did not differ between women and men, though in men it arrived by a route other than weight loss. - In a small, sicker cohort with implanted heart pumps, directional benefits were reported with no effect sizes published. Heart failure with preserved ejection fraction is a condition with very little that works. The pooled analysis of STEP-HFpEF and STEP-HFpEF DM is one of the few trials to move it. It combined individual patient data from two randomized placebo-controlled trials across 129 sites in 18 countries, every participant with a BMI of at least 30 and heart failure symptoms. The effect sizes are modest in absolute terms and the direction is consistent across everything measured — including one number that looks wrong until you understand it. Before weighing it against [what a seller charges](https://thisglp.com/best), it is worth knowing who was studied. ## What improved in STEP-HFpEF The dual primary endpoints were symptom score and body weight at 52 weeks. The Kansas City Cardiomyopathy Questionnaire clinical summary score improved by 7.5 points more on semaglutide than placebo (95% CI 5.3 to 9.8). Body weight fell 8.4 percentage points further (95% CI −9.2 to −7.5). Both at P < 0.0001. Six-minute walk distance improved by 17.1 meters more (95% CI 9.2 to 25.0). A hierarchical composite of death, heart failure events and changes in those two measures gave a win ratio of 1.65 (95% CI 1.42 to 1.91). Effects held consistently across subgroups defined by age, race, sex, BMI, blood pressure, baseline CRP and ejection fraction. ## The number that looks like a typo There were 161 serious adverse events in the semaglutide group and 301 in the placebo group. That is not a transcription error, and it is not unusual in a sick population. A drug that prevents some of what the underlying illness would otherwise do can leave the treated arm with fewer serious events than the untreated one. It is also a reminder that the harms of a condition and the harms of its treatment are measured on the same page. ## A second trial, and a composite worth taking apart SUMMIT enrolled 731 patients with the same diagnosis and randomized them to tirzepatide or placebo for a median of 104 weeks. The composite of cardiovascular death or worsening heart failure fell from 15.3% on placebo to 9.9% on tirzepatide, a hazard ratio of 0.62. Almost all of that came from the worsening-heart-failure half: 14.2% against 8.0%, on its own. The death component ran the other way Cardiovascular death occurred in 8 patients on tirzepatide against 5 on placebo, a hazard ratio of 1.58 with a confidence interval from 0.52 to 4.83. Thirteen deaths cannot establish anything in either direction, and the interval crosses 1 comfortably. It matters because a composite headline reads as covering mortality, and here the trial did not show that. The full component table, and what a composite endpoint can hide more generally, is in [the SUMMIT composite breakdown](https://thisglp.com/research/tirzepatide-heart-failure-composite). ## What changed in the heart muscle SUMMIT counted events and symptoms. A prospective single-center cohort measured the heart itself [\[7\]](https://thisglp.com/research/do-glp1-drugs-help-heart-failure#ref-7). It followed 50 adults with obesity-related HFpEF who started tirzepatide in routine care, for a median of 5.8 months. Left ventricular mass fell 12.4 g (95% CI −15.4 to −9.4). The E/e′ ratio, a measure of diastolic filling, improved by 1.45. The symptom score rose 13.1 points and six-minute walk distance 43 m. NYHA class improved in 30 of the 50, and none worsened. Every change is measured against each patient’s own baseline, not against a placebo arm. ## Who inside these trials it worked for Re-cutting the 1,145 STEP-HFpEF participants by frailty separated two things that are usually assumed to move together. Weight loss was statistically the same across every frailty stratum (P for interaction 0.38). The symptom benefit was not (P for interaction below 0.001). The most frail gained 11.0 points against placebo. The nonfrail group gained nothing measurable, a mean difference of −1.5 with an interval from −8.4 to 5.4. The full breakdown, including why that negative point estimate is printed rather than dropped, is in [the frailty analysis](https://thisglp.com/research/glp1-heart-failure-frailty)[\[3\]](https://thisglp.com/research/do-glp1-drugs-help-heart-failure#ref-3). A separate, prespecified look at the SUMMIT population by sex found the opposite pattern: no difference at all in the headline benefit. Cardiovascular death or worsening heart failure gave hazard ratios of 0.66 in women and 0.61 in men, an interaction P of 0.81. The one difference that reached significance concerned mechanism, not size — among people on tirzepatide, weight loss tracked symptom improvement more closely in women than in men. That comparison is set out in [the sex-stratified SUMMIT analysis](https://thisglp.com/research/same-benefit-different-route-by-sex)[\[4\]](https://thisglp.com/research/do-glp1-drugs-help-heart-failure#ref-4). ## How this compares with semaglutide No trial has randomized semaglutide against tirzepatide on cardiovascular outcomes, so the comparison runs on claims data. A 217,920-person target trial emulation found tirzepatide ahead on heart failure at one year. The two ways of reading that result disagree about who benefits more. The risk ratio was 0.60 in people without diabetes against 0.82 with it. The absolute risk difference ran the other way: 0.9 percentage points without diabetes against 1.5 points with it. Both numbers are correct, and which one matters depends on baseline risk — the full working is in [the semaglutide-versus-tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute)[\[5\]](https://thisglp.com/research/do-glp1-drugs-help-heart-failure#ref-5). ## The sickest patients trials do not enroll None of the trials above included people with a heart failing badly enough to need a mechanical pump. A matched cohort of 141 pairs with implanted left ventricular assist devices found favorable directions for infection, mortality and transplant listing among those with prior GLP-1 exposure. The abstract publishes no hazard ratios, confidence intervals or percentages for any of it. Exposure was also recorded before implantation, which selects for people already stable enough to be on the drug. That gap between direction and magnitude is detailed in [the assist-device cohort](https://thisglp.com/research/can-you-take-a-glp1-with-a-heart-pump)[\[6\]](https://thisglp.com/research/do-glp1-drugs-help-heart-failure#ref-6). ## What it does not transfer to These were people with diagnosed heart failure, a BMI of 30 or more, and symptoms bad enough to score under 90 on the questionnaire. The dose was 2.4 mg weekly, which is the weight-management dose most compounded sellers titrate toward — so unlike [the kidney trial at 1.0 mg](https://thisglp.com/research/semaglutide-and-kidney-disease), the dose here does transfer. The population does not. If you have heart failure and are considering a telehealth purchase, the gap is not the evidence. It is that this is a condition needing monitoring. Most sellers tracked here publish nothing about who reviews a case — the census is in [what sellers publish](https://thisglp.com/tools/what-sellers-publish) and in [what they will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). A seller that cannot tell you who reads your history is not the right route into a cardiac diagnosis. ## Frequently asked Do GLP-1 drugs help heart failure? In obesity-related heart failure with preserved ejection fraction, yes: semaglutide improved symptom scores by 7.5 points more than placebo, and tirzepatide cut a composite of cardiovascular death or worsening heart failure by 38%. Neither trial showed a mortality benefit on its own. Why were there fewer serious events on semaglutide than on placebo? 161 against 301. In a population sick enough to have symptomatic heart failure, a treatment that prevents some of what the illness does can produce fewer serious events than placebo. Does frailty change how much someone benefits? It changed the symptom benefit, not the weight loss. The most frail participants gained 11.0 points on the symptom score against placebo; the least frail showed no measurable gain, though weight loss was identical across every stratum. Does tirzepatide change the heart itself in HFpEF? In a 50-person cohort followed for a median of 5.8 months, left ventricular mass fell 12.4 g and the E/e-prime ratio improved by 1.45. There was no placebo arm, so each change is against the patient's own baseline. Does the dose match what sellers offer? Yes. The trials used 2.4 mg weekly, which is the weight-management dose most compounded sellers titrate toward. The population, however, was people with diagnosed heart failure. ## Sources 1. \[1\] Butler J, et al. (2024). Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials The Lancet. [PMID 38599221](https://pubmed.ncbi.nlm.nih.gov/38599221/) 2. \[2\] Packer M, et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity New England Journal of Medicine. [PMID 39555826](https://pubmed.ncbi.nlm.nih.gov/39555826/) 3. \[3\] Pandey A, et al. (2025). Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program JACC: Heart Failure. [PMID 40956259](https://pubmed.ncbi.nlm.nih.gov/40956259/) 4. \[4\] Borlaug BA, Zile MR, Kramer CM, Litwin SE, et al. (2026). Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial JACC: Heart Failure. [PMID 42417681](https://pubmed.ncbi.nlm.nih.gov/42417681/) 5. \[5\] Azzam AY, Essibayi MA, Rai P, Salim HA, et al. (2026). Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation JACC: Advances. [PMID 42489387](https://pubmed.ncbi.nlm.nih.gov/42489387/) 6. \[6\] Divya A, Dalal N, Yoshida Y, Kanwar M, Catarino P, D'Alessandro D (2026). Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study ASAIO Journal. [PMID 42497207](https://pubmed.ncbi.nlm.nih.gov/42497207/) 7. \[7\] Karanxha J, et al. (2026). Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study International Journal of Cardiology. [PMID 42710812](https://pubmed.ncbi.nlm.nih.gov/42710812/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Hidradenitis Suppurativa? Twenty People, No Control Group Do GLP-1 drugs help hidradenitis suppurativa? A 20-patient open-label study, a matched cohort reporting a mortality hazard ratio of 0.24, and what neither design can establish. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Hidradenitis Suppurativa? Twenty People, No Control Group A small study reported that semaglutide improved every outcome it measured in a painful skin disease. Reading why that is not yet a finding is a skill worth having. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Where a claim can come from · case reports · a few patients, no design · single-arm cohort · everyone gets the drug · controlled trial · a group that does not · replication · somebody else finds it too **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). One 20-person study says yes and cannot prove it. Over six months on semaglutide above 1 mg a week, body weight fell 21.4 kg and Hurley stage improved in every single patient [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa#ref-1). The dermatology quality-of-life index improved 8.8 points, a pain scale 4.1 and a depression inventory 12.9, all at p<0.001. There was no control group and no blinding, so none of it separates the drug from six months of attention in a relapsing disease. A separate matched-record cohort in the same condition reports an all-cause mortality hazard ratio of 0.24 (95% CI 0.145 to 0.395), which is roughly four times the effect randomized trials of this class produce [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa#ref-2). ## Key takeaways - A six-month study of semaglutide in hidradenitis suppurativa reported large improvements in every outcome it measured. - It enrolled 20 adults, was open-label, and had no control group. Everyone received the drug and everyone knew it. - Weight fell 21.4 kg. Quality-of-life score improved 8.8 points, pain 4.1 points, and a depression score 12.9 points, all at p<0.001. - The authors report that several improvements held after adjusting for weight change — a calculation a single-arm study cannot support. - None of this is a reason to dismiss the finding. It is a reason to know what grade of finding it is. Every few weeks another condition joins the list of things these drugs are said to help. Some of those claims will turn out to be right — the [knee osteoarthritis result](https://thisglp.com/research/do-glp1-drugs-help-knee-pain) came out of a randomized trial of 407 people. The useful question is not which claims sound plausible but what kind of study produced them, and there is a small study of a painful skin disease that makes an unusually clean example of the problem. ## The study Hidradenitis suppurativa is a chronic inflammatory skin condition, strongly associated with obesity, that produces recurrent painful lesions. A prospective open-label cohort followed 20 adults with the condition and obesity for six months on semaglutide above 1 mg a week [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa#ref-1). It measured weight, body composition, skin severity, pain, mood, and metabolic and inflammatory markers at baseline and at the end. The results are striking: body weight fell 21.4 kg, and Hurley stage, the standard severity grading, decreased in every single patient. The dermatology quality-of-life index improved by 8.8 points, a pain visual analog scale by 4.1, and a depression inventory by 12.9, all at p<0.001. Blood pressure, waist circumference and fat measures all fell as well. If you read only that paragraph you would conclude the drug treats the disease. ## What is missing There was no control group: every participant got semaglutide, and each one’s six-month numbers were compared with their own baseline numbers. That design cannot separate the drug from everything else that happens in six months, including regression to the mean in a relapsing-remitting disease and the attention of a research team. Seasonal variation, other treatments and the simple fact that people enroll in studies when their condition is bad all sit inside the same window. It was also open-label, so participants knew they were taking the drug. Three of the four headline outcomes — quality of life, pain, and mood — are self-reported, which is where that matters most. A person who has lost 21 kg and knows why will answer a pain questionnaire differently. And there were 20 people, not 20 per arm but twenty in total, which is roughly the size at which a single unusual responder moves a mean. None of this is misconduct; it is what a pilot study is. The paper is honest about its design in its own methods section. The adjustment that cannot work The authors report that after adjusting for weight change, improvements in quality of life, pain, depressive symptoms, skin severity and several markers remained significant. That sentence will be quoted as evidence of a weight-independent anti-inflammatory effect, and it cannot be. In a single-arm study, there is no group that took the drug without losing weight, and no group that lost weight without the drug. A statistical adjustment cannot manufacture the comparison the design omitted. ## The record-linkage studies, and why their numbers are too large Two large matched cohorts sit beside the pilot and point the same way with implausible force. The hidradenitis cohort puts all-cause mortality at a hazard ratio of 0.24 over two years, while reporting hyperlipidemia at 1.25, fatty liver disease at 1.37 and nausea at 1.31 in the same table [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa#ref-2). Exposure required at least a year of therapy, so nobody who died inside that year could be counted as exposed. A 6,096-person matched cohort in psoriasis reports lower mortality and cardiac events at effect sizes no trial has produced [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa#ref-3). Three quarters of deaths not happening is what confounding looks like, and the full reading of that figure is in [a hazard ratio of 0.24](https://thisglp.com/research/glp1-mortality-in-hidradenitis). ## Why this shape of claim keeps appearing Because it is cheap to produce and genuinely interesting. Twenty patients, six months, no randomization and no placebo is a study a single clinic can run. It is the correct first step, and the correct thing to do with its result is to design the trial that would test it. The failure is downstream, when the pilot gets summarized as a finding and the finding gets summarized as an indication. There is a legitimate version of the weight-independent claim, and it looks different. A prespecified analysis of 1,145 randomized participants [found symptom benefit and weight loss moving apart](https://thisglp.com/research/glp1-heart-failure-frailty) inside a controlled trial, which is the kind of comparison that can support the inference. Same shape of conclusion, completely different grade of evidence. ## How to read the next one Three questions settle most of it: was there a group that did not get the drug, did anyone not know what they were taking, and how many people in total rather than per headline. Those take ten seconds against an abstract and they sort nearly every claim you will meet. Effect sizes and intervals matter too, and [what a comparator can tell you](https://thisglp.com/research/do-glp1-drugs-cause-gout) is the longer version of the first question. Nobody on this roster sells semaglutide for hidradenitis suppurativa, and no seller claims it. What sellers do carry is a general implication that the benefits keep extending outward, which is where a twenty-person pilot ends up doing commercial work it was never built for. The ordinary weight-loss evidence is strong and [worth reading on its own terms](https://thisglp.com/research/semaglutide-cochrane-review). It does not need help from studies like this one, and [what a seller declines to say](https://thisglp.com/tools/questions-they-leave-open) is usually more informative than what it implies. ## Frequently asked Does semaglutide treat hidradenitis suppurativa? Unknown. One open-label study of 20 people reported large improvements over six months, but with no control group it cannot separate the drug from time, attention and regression to the mean. Were the improvements real? The measurements were real. Weight fell 21.4 kg and severity grading improved in every patient. Whether the drug caused the skin improvement is the part the design cannot answer. What about the weight-adjusted analysis? It is the weakest claim in the paper. Adjusting for weight change in a single-arm study cannot isolate a weight-independent effect, because no participant took the drug without losing weight. What would settle it? A randomized controlled trial with a group that does not receive the drug, ideally blinded, and large enough that one unusual responder cannot move the result. ## Sources 1. \[1\] Nicolau J, et al. (2026). Semaglutide in patients with hidradenitis suppurativa and obesity Medicina Clínica. [PMID 41832804](https://pubmed.ncbi.nlm.nih.gov/41832804/) 2. \[2\] Brouer IC, et al. (2026). Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study Frontiers in Medicine. [PMID 42741157](https://pubmed.ncbi.nlm.nih.gov/42741157/) 3. \[3\] Olbrich H, et al. (2026). Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study British Journal of Dermatology. [PMID 40897378](https://pubmed.ncbi.nlm.nih.gov/40897378/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help IBS? Coded Symptoms Fell by Two to Four Points | This GLP Do GLP-1 drugs help IBS? A matched analysis of 6,665 per arm found lower coded rates of diarrhea, constipation, pain and bloating | and why coding may explain all of it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-ibs Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help IBS? Coded Symptoms Fell by Two to Four Points Diarrhea, constipation, pain and bloating were all coded less often in treated IBS patients. Coded is doing a lot of work in that sentence. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Coded in 90 days — on a GLP-1 vs not · on one · not on one · abdominal pain · 31.6 · 35.8 · constipation · 19.8 · 22 · diarrhea · 8.9 · 10.6 · bloating · 8.3 · 10.9 · Gaps of 2 to 4 points, in about 6,665 people per arm. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Coded symptoms fell, which is not the same thing as bowels settling. In a matched analysis of 6,665 people per arm who already had irritable bowel syndrome, abdominal pain was coded in 31.6% against 35.8%, constipation in 19.8% against 22.0% and bloating in 8.3% against 10.9% [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-1). Every one of those outcomes is a billing code entered at a visit, chronic diarrhea included at 8.9% against 10.6%, and the gaps run two to four percentage points. Nothing here was a symptom diary, and no randomized trial has tested a GLP-1 in irritable bowel syndrome. ## Key takeaways - A matched analysis compared people with irritable bowel syndrome who started a GLP-1 drug against those who did not, with 6,665 per arm in the 90-day cohort. - Coded rates were lower on treatment for chronic diarrhea (8.9% vs 10.6%), constipation (19.8% vs 22.0%), abdominal pain (31.6% vs 35.8%) and bloating (8.3% vs 10.9%). - These are the same symptoms the drugs are best known for causing. - Every outcome is a diagnostic code, and differences in symptom recurrence were smaller than differences in first occurrence. Nausea, diarrhea, [constipation](https://thisglp.com/research/does-ozempic-cause-constipation) and bloating are the defining side effects of this drug class, described from the mechanism side in [nausea and appetite on one circuit](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea). So a study finding fewer of those symptoms recorded in people who already have irritable bowel syndrome is worth reading carefully [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-1). The direction is consistent across every outcome measured. In the 90-day cohort, chronic diarrhea was coded in 8.9% of the treated group against 10.6% of controls, constipation in 19.8% against 22.0%, abdominal pain in 31.6% against 35.8%, and bloating in 8.3% against 10.9%. Similar patterns appeared in the diarrhea-predominant and constipation-predominant subtypes. A code is not a symptom Every outcome here is a diagnostic code entered at a visit. Irritable bowel syndrome is defined by fluctuating gut symptoms, so what gets coded depends heavily on what a patient raises and a clinician records on a given day. Someone who develops new gut symptoms shortly after starting a weight drug may reasonably describe them as a drug side effect rather than as their IBS — and the coded IBS symptom then does not appear. That mechanism would produce exactly this result without anyone's gut improving. The authors provide a clue that points the same way. They note that differences in outcome recurrence — how many separate episodes people had — were smaller than differences in incidence. If the drug were genuinely settling irritable bowels, you would expect ongoing symptom burden to fall at least as much as first occurrences. A gap concentrated in first coding is more consistent with a change in how symptoms are attributed than in how often they happen. ## Two other guts, measured the same year The same slowing mechanism has been read in two other settings and it lands differently in each. At the severe end, a systematic review searching four databases to October 2025 found twelve case reports covering thirteen patients with drug-associated gastroparesis worldwide [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-2). At the other end, a chart review of 117 patients having elective posterior lumbar fusion found bowel function returning sooner in GLP-1 users, at 1.35 days against 1.90 (P = 0.013) [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-ibs#ref-3). A drug that slows gut transit producing an earlier return of bowel function is the opposite of the expected direction, and the reading of it is in [the post-surgical cohort](https://thisglp.com/research/the-bowels-woke-up-sooner). None of the three findings contradicts the others; they describe one mechanism meeting three different guts. The absolute differences are also modest: two to four percentage points across the outcomes. With roughly 6,665 people in each arm, small differences reach significance easily, and the P values say nothing about whether a patient would notice — the distinction drawn in [the FLOW numbers needed to treat](https://thisglp.com/research/twenty-two-thirteen-seventeen) applies here too. A real effect is nonetheless plausible. Slower gastric emptying could genuinely help diarrhea-predominant IBS, and weight loss reduces the systemic inflammation that some IBS phenotypes involve. What this design cannot do is separate that from a coding artifact, and a prospective study with symptom diaries rather than billing codes would settle it — the same gap running through [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease) and [the gastroparesis evidence](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## Frequently asked Do GLP-1 drugs help IBS? Coded symptom rates were lower in a matched analysis of people who already had IBS — abdominal pain 31.6% against 35.8%, bloating 8.3% against 10.9%. No randomized trial has tested one in IBS, and every outcome here is a billing code. Do these drugs improve irritable bowel syndrome? Coded rates of IBS symptoms were lower among treated patients, but every outcome is a billing code rather than a measured symptom, and the pattern is also consistent with symptoms being attributed to the drug instead of the IBS. How large were the differences? Two to four percentage points across outcomes — for example abdominal pain in 31.6% against 35.8%. With about 6,665 people per arm, small gaps reach statistical significance readily. Is there a plausible mechanism? Yes. Slowed gastric emptying could help diarrhea-predominant IBS, and weight loss reduces inflammation relevant to some phenotypes. This study design cannot distinguish that from a coding effect. ## Sources 1. \[1\] Khan SA, Marasini A, Shrestha A, Bharadwaj HR, et al. (2026). Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis Digestive Diseases and Sciences. [PMID 42570075](https://pubmed.ncbi.nlm.nih.gov/42570075/) 2. \[2\] Olubodun T, et al. (2026). Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes PLOS ONE. [PMID 42594084](https://pubmed.ncbi.nlm.nih.gov/42594084/) 3. \[3\] Fano A, Oris RJ, Dalton J, Baidya J, Ng M, Baek G, Tarawneh O (2025). GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion Spine. [PMID 41400023](https://pubmed.ncbi.nlm.nih.gov/41400023/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Intracranial Hypertension? Probably, but Less Than Reported Two meta-analyses link GLP-1 use in idiopathic intracranial hypertension to less papilledema (RR 0.38 and 0.25) | one also reports an implausible 80% mortality cut. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Intracranial Hypertension? Probably, but Less Than Reported Two meta-analyses agree on direction: less papilledema, at risk ratios of 0.38 and 0.25. One also reports 80% fewer deaths in a condition that rarely kills anybody, which says its effect sizes are inflated. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Reported risk ratios · headache · 0.73 · needing surgery · 0.76 · visual worsening · 0.51 · papilledema · 0.38 · death · 0.20 · ← implausible · A condition that threatens sight, not life. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A meta-analysis of 9 studies and 13,257 participants compared GLP-1 drugs against conventional management in idiopathic intracranial hypertension. - Reported benefits: headache (RR 0.73), papilledema (RR 0.38), visual worsening (RR 0.51), and needing surgery (RR 0.76). - It also reports 80% lower mortality (RR 0.20, 95% CI 0.07-0.59) in a condition that threatens sight rather than life. - That mortality figure is not plausible as a drug effect, and whatever produced it is also acting on the other numbers. - A second meta-analysis of 1,550 patients, including one randomized trial, also found less papilledema (RR 0.25) and less visual disturbance (RR 0.41). Probably in direction, and not by the amounts the papers print. Idiopathic intracranial hypertension raises pressure inside the skull, causes severe headache and swells the optic nerve, and weight loss is one of the few things established to help it, so a drug producing large weight loss ought to work. A meta-analysis of nine studies covering 13,257 participants reports that it does, with papilledema at a risk ratio of 0.38 and headache at 0.73 [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension#ref-1). It also reports something that cannot be true, and that number is the reason to distrust the size of the rest. The eye is somewhere these drugs have produced mixed signals before, as [the optic nerve evidence by indication](https://thisglp.com/research/semaglutide-optic-nerve-by-indication) shows. The clinical outcomes go the expected way. Headache risk came in at a risk ratio of 0.73 (95% CI 0.61–0.86), papilledema at 0.38 (95% CI 0.25–0.56), visual worsening at 0.51 (95% CI 0.37–0.68), and needing surgical intervention at 0.76 (95% CI 0.65–0.89). Mechanistically this is about as plausible as findings in this field get. Then there is the mortality number The same analysis reports an 80% reduction in mortality: RR 0.20, 95% CI 0.07 to 0.59. Idiopathic intracranial hypertension is a condition that threatens vision, not life, and its annual death rate is very low. No weight-loss drug produces an eightfold difference in dying in a population like this over the follow-up these studies had. That figure is not a treatment effect — it is a measurement of how different the two groups were before anyone was treated. The reason to dwell on an implausible number rather than ignore it is that it calibrates the others. The mortality estimate and the papilledema estimate come from the same studies, comparing the same people. Whatever made the treated group so much less likely to die — being younger, healthier, better engaged with care, well enough to be offered an injection — was also making them less likely to lose vision. So the direction of the vision findings is probably right and the size of them is almost certainly inflated. A second meta-analysis, built from different sources, lands in the same direction [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension#ref-3). It pooled two clinical trials, one of them randomized, and two registries: 1,550 patients, 768 of them on a GLP-1 or dual GIP/GLP-1 drug. Against standard care, papilledema came in at a risk ratio of 0.25 (95% CI 0.15–0.43) and visual disturbance or blindness at 0.41 (95% CI 0.18–0.92). Headache, at 0.61 with an interval from 0.34 to 1.07, fell short of significance. The analysis detected no association between the drugs and body mass index, and its authors suspect the effect reaches beyond weight loss. Its abstract reports no mortality figure, so the calibration argument above belongs to the first analysis, not to this one. Two pools, with papilledema at 0.38 and 0.25, agree on which way it goes. What neither supplies is a large randomized trial. The first analysis excluded studies of patients with prior IIH treatment, which removes one source of confusion, and its abstract does not say how many of its nine studies were randomized. The second counted one among its four sources. Where a pooled study is observational, its risk ratio inherits every baseline difference that study carried. The separate optic nerve literature is worth keeping apart from this one. Pooling eight cohorts, semaglutide carried a relative effect of 1.93 for non-arteritic anterior ischemic optic neuropathy, with a 95% confidence interval of 1.22 to 3.08 [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension#ref-2). That is a different condition, a different mechanism and a different comparison, and it cuts against the idea that anything here is simply good for the optic nerve. For someone with this diagnosis the practical position is reasonable and the numbers are not. Weight loss helps intracranial pressure, these drugs produce weight loss, and a neuro-ophthalmologist weighing one is on defensible ground. Reading 0.38 as the papilledema benefit to expect is not defensible. It is the same reason [a mortality hazard ratio the authors disowned](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own) and [the dialysis cohort](https://thisglp.com/research/dialysis-the-evidence-base-just-grew) need their baseline tables read first, and the same reason [the overdose comparison](https://thisglp.com/research/overdose-depends-on-the-comparator) gave five different answers. ## Frequently asked Do these drugs help idiopathic intracranial hypertension? Probably, in direction. Two meta-analyses found less papilledema, at risk ratios of 0.38 and 0.25, and less visual worsening. The larger one's effect sizes are likely inflated by differences between treated and untreated groups. Why single out the mortality result? Because the condition threatens sight rather than life, so an 80% reduction in deaths cannot be a drug effect. It reveals how different the compared groups were, which affects every other estimate from the same studies. Is there randomized evidence? Very little. The larger meta-analysis pooled nine studies, and its abstract does not say how many were randomized. The second pooled four sources, one of them a randomized trial. ## Sources 1. \[1\] Ahmed W, Gandhi OH, Yu N, Brant J, et al. (2026). Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis Journal of the Neurological Sciences. [PMID 41468715](https://pubmed.ncbi.nlm.nih.gov/41468715/) 2. \[2\] Khani E, et al. (2026). Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis The Journal of Clinical Pharmacology. [PMID 42612051](https://pubmed.ncbi.nlm.nih.gov/42612051/) 3. \[3\] Stefanou MI, et al. (2025). Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis European Journal of Neurology. [PMID 40937960](https://pubmed.ncbi.nlm.nih.gov/40937960/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Knee Pain? Yes, and Read the Placebo Arm | This GLP STEP 9 measured knee osteoarthritis pain directly: a 41.7-point WOMAC reduction on semaglutide against 27.5 on placebo with diet and activity counseling. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-knee-pain Updated: 2026-10-26 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Knee Pain? Yes, and Read the Placebo Arm Semaglutide cut WOMAC pain by 41.7 points. Placebo plus diet and activity counseling cut it by 27.5. The drug's own share is the 14.2 between them. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 WOMAC pain reduction at 68 weeks · Semaglutide · 41.7 points · Placebo, diet and activity · 27.5 points · 14.2 points is the drug’s own share **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, and the placebo arm is the part to read first. STEP 9 randomized 407 people with obesity and moderate knee osteoarthritis to semaglutide 2.4 mg or placebo for 68 weeks, both arms receiving counseling. Pain improved in both. The [knee-osteoarthritis phenotype analysis](https://thisglp.com/research/semaglutide-knee-osteoarthritis-phenotypes) examines whether the response varies between patient groups rather than treating every painful knee as the same trial participant. Knee replacement, the harder outcome, has three database studies behind it, and they do not agree. One followed people who already had knee osteoarthritis out to eight years. Three years of semaglutide or tirzepatide gave an absolute risk difference of −4.71 percentage points [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-knee-pain#ref-2), which is [4.71 fewer operations per hundred people](https://thisglp.com/research/fewer-knee-replacements-eight-years-on). The other two found no gap in knee replacement. A five-year cohort started with people who had no hip or knee osteoarthritis [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-knee-pain#ref-3). Among diabetic patients with obesity, GLP-1 users were diagnosed with knee osteoarthritis more often, a hazard ratio of 1.52. They also had more joint injections, and knee replacement rates did not differ. A second cohort matched 452,445 adults with type 2 diabetes per arm against SGLT2 inhibitor users [\[4\]](https://thisglp.com/research/do-glp1-drugs-help-knee-pain#ref-4). Knee osteoarthritis was less common on the SGLT2 drugs, a hazard ratio of 0.831. Knee replacement again did not differ. None of the three was randomized, and each compared a different group over a different window. The eight-year figure is one reading of the record, not a settled effect on surgery. If the operation happens anyway, the two molecules look alike, though not on evidence strong enough to say so. Across 415 matched pairs no outcome differed significantly[\[5\]](https://thisglp.com/research/do-glp1-drugs-help-knee-pain#ref-5). The surgical complication interval ran from 0.845 to 3.152, consistent with one drug being slightly better and with it tripling the risk. That is [no difference found rather than no difference](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). Knee osteoarthritis is one of the reasons people want to lose weight rather than a side issue, and STEP 9 is the trial that measured it directly. It randomized 407 people with obesity and moderate knee osteoarthritis two to one, semaglutide 2.4 mg against placebo for 68 weeks. Both arms received counseling on physical activity and a reduced-calorie diet[\[1\]](https://thisglp.com/research/do-glp1-drugs-help-knee-pain#ref-1). The headline number is large. The number that describes the drug is smaller, and it is the one worth carrying into any decision about [what to pay for it](https://thisglp.com/best). ## Both arms improved Mean WOMAC pain score fell by 41.7 points on semaglutide and by 27.5 points on placebo (P < 0.001). The scale runs 0 to 100 with higher scores worse, and mean baseline pain was 70.9. So the placebo arm — which was not an inert arm, since it included diet and activity counseling — accounted for roughly two thirds of the improvement seen on the drug. The drug’s own contribution is the 14.2-point difference. That is a real and meaningful effect on a 100-point pain scale. It is not 41.7, and a page that quotes 41.7 without its comparator is quoting the trial rather than reporting it. ## The weight figures Body weight fell 13.7 percent on semaglutide against 3.2 percent on placebo. Physical function on the SF-36 improved by 12.0 points against 6.5. Serious adverse events were similar between groups. Discontinuation for adverse events ran 6.7 percent on the drug against 3.0 on placebo, gastrointestinal problems being the most common reason — which matches what the [titration literature](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) reports elsewhere. ## What it means for a purchase Two things. The trial used 2.4 mg semaglutide. That is the weight-management dose most compounded sellers titrate toward, so the dose here does transfer in a way the [kidney trial’s 1.0 mg](https://thisglp.com/research/semaglutide-and-kidney-disease) does not. The comparator matters too. The trial is evidence for the drug plus diet and activity counseling, not for the drug alone, and almost no telehealth seller includes structured counseling in what it sells. If pain relief is the reason for starting, that is worth asking a seller about directly. Most publish nothing about what support comes with the prescription, which is the gap we count in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked How much did semaglutide reduce knee pain? WOMAC pain fell 41.7 points on semaglutide and 27.5 on placebo, from a mean baseline of 70.9 on a 0-to-100 scale. The drug's own contribution is the 14.2-point difference. Why did the placebo group improve so much? Both arms received counseling on physical activity and a reduced-calorie diet, so the placebo arm was not inert. It also lost 3.2 percent of body weight. Does the dose match what sellers offer? Yes. The trial used 2.4 mg semaglutide, which is the weight-management dose most compounded sellers titrate toward. Do GLP-1 drugs prevent knee replacement? The database studies disagree. One found 4.71 fewer knee replacements per hundred people after three years of semaglutide or tirzepatide. Two five-year cohorts of people with type 2 diabetes found no difference in knee replacement, and both found more knee osteoarthritis among GLP-1 users than in the group they were compared with. ## Sources 1. \[1\] Bliddal H, et al. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis New England Journal of Medicine. [PMID 39476339](https://pubmed.ncbi.nlm.nih.gov/39476339/) 2. \[2\] Carter V, Desverreaux E, Amin I, Fogarty AE, et al. (2026). Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis Regional Anesthesia and Pain Medicine. [PMID 42229941](https://pubmed.ncbi.nlm.nih.gov/42229941/) 3. \[3\] Lavu MS, et al. (2024). The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists Journal of Arthroplasty. [PMID 38857711](https://pubmed.ncbi.nlm.nih.gov/38857711/) 4. \[4\] Jao WY, et al. (2026). Comparative effects of SGLT2 inhibitors and GLP-1 receptor agonists on osteoarthritis risk in patients with type 2 diabetes mellitus: A multi-institutional cohort study PLoS One. [PMID 42475344](https://pubmed.ncbi.nlm.nih.gov/42475344/) 5. \[5\] Wu KA, et al. (2026). Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysis The Knee. [PMID 42727208](https://pubmed.ncbi.nlm.nih.gov/42727208/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Migraine? Triptan Use Fell 7%, Which Is Not a Treatment Do GLP-1 drugs help migraine? A 189,392-person Danish register found triptan dispensing down 7% at twelve months, and an interrupted time series has no control group. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-migraine Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Migraine? Triptan Use Fell 7%, Which Is Not a Treatment A Danish register of 189,392 people found triptan dispensing fell after semaglutide was started. The effect is real, small, and sits inside a study design with no control group. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Triptan dispensing, defined daily doses · first dispensing · 24 months before · −7% at 12 months **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Not enough to buy one for headaches. A Danish register followed 189,392 adults starting semaglutide for weight management [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-1). Triptan dispensing had been rising. After initiation the trend reversed. The reduction was 7% at twelve months, RR = 0.93, 95% CI 0.88 to 0.97. It came from people already taking triptans, not from fewer people starting them. Women fell 8%. In men the change was not statistically significant. There is no control group in that design. ## Key takeaways - A Danish register study followed 189,392 adults starting semaglutide for weight management. - Triptan dispensing had been rising. After initiation the trend reversed. - The reduction was 7% at twelve months — a rate ratio of RR = 0.93, 95% CI 0.88 to 0.97. - It came from people already taking triptans, not from fewer people starting them. - Women showed an 8% reduction. In men the change was not statistically significant. Migraine and obesity are linked, and both are common. So the question is old and the data are new. Denmark keeps national prescription registers. Somebody used them. ## What was measured Everyone who started semaglutide for weight management between December 2022 and December 2024 was included. That is 189,392 adults, 68% women, median age 50. Each person’s first dispensing set the clock. The study looked back 24 months and forward 12. [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-1) The outcome was triptan consumption, counted in defined daily doses per 10,000 people per month. Note what that is. Triptans treat an attack that has already started. Dispensing them is a proxy for how often attacks happen. It is a good proxy and it is not the thing itself, a distinction [endpoint choice makes constantly](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## The result Before initiation, triptan use was climbing. After it, the trend reversed. The decline was 13 defined daily doses per month per 10,000 people (95% CI −25 to −1.3). At twelve months that came to a 7% relative reduction — a rate ratio of RR = 0.93, 95% CI 0.88 to 0.97. Where it came from matters more than the headline. Existing triptan users cut their consumption: RR = 0.86, 95% CI 0.82 to 0.90. The monthly rate of new triptan users barely moved. So this is people who already had migraine using less, not fewer people developing it. The subgroups split cleanly. Women fell 8%: RR = 0.92, 95% CI 0.88 to 0.97. Men showed no statistically significant change. The largest reductions were in people aged 18 to 35, at RR = 0.86, 95% CI 0.78 to 0.94. People who had previously taken a migraine preventive came in at RR = 0.88, 95% CI 0.82 to 0.94. Who wrote this Two of the authors are employed by Novo Nordisk, which manufactures semaglutide. A third reports sponsor-initiated research funded by the same company, paid to his institution. All of that is disclosed in the paper. It does not make a national register of 189,392 people wrong. It is a fact you should have before you weigh a seven percent finding published by a manufacturer’s employees. ## The two neighboring neurological readings Two other results sit beside this one. A meta-analysis of 9 studies and 13,257 participants looked at idiopathic intracranial hypertension [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-2). Its main symptom is headache, and the comparator was conventional management. Headache came in at RR 0.73 and papilledema at RR 0.38. The same analysis reports 80% lower mortality, RR 0.20, 95% CI 0.07 to 0.59. That figure is not plausible as a drug effect. Whatever produced it is also acting on the headache number, which is the reading in [the mortality number that cannot be right](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension). The wider neuropsychiatric pooling is more disciplined. A systematic review screened 10,037 records and pooled 82 studies, graded with GRADE [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-migraine#ref-3). Risk of developing Parkinson’s disease was lower, pooled HR 0.70, 95% CI 0.53 to 0.92, from observational studies. Motor symptoms in people who already had it did not improve, mean difference −3.29, 95% CI −7.84 to 1.26, from trials. Prevention and treatment are separate questions. That split is set out in [preventing it is not treating it](https://thisglp.com/research/preventing-it-is-not-treating-it). ## What the design cannot rule out An interrupted time series compares a population to its own past. There is no control group. Everything else that happens when somebody starts a weight-loss drug happens inside the measurement window. People who start these drugs lose weight. They often eat differently and sleep differently. Many are titrating upward through the same months, which [changes more than the dose](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it). Some stop other medications. Some are seeing a clinician regularly for the first time in years. Any of those could move triptan dispensing on its own. The study cannot separate them, and it does not claim to. There is also a plainer possibility. Nausea is common early on. A person feeling sick may fill fewer prescriptions of anything. The effect here was gradual rather than abrupt, which argues against that, but it is not excluded. ## Is seven percent worth anything On its own, no. Seven percent of triptan consumption is not a migraine treatment. The approved preventives do far better and they are cheap. Nobody should buy this drug for headaches. As a secondary benefit it is more interesting. If you are taking the drug anyway and you have migraine, this is a modest reason to expect less. That is the honest frame, and it is the frame [most real-world findings deserve](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). The money question is simpler. These drugs are priced for weight loss, and a headache benefit does not change what a month costs. You can see the range in [the price check](https://thisglp.com/tools/glp1-price-check). Nothing on this roster is sold for migraine, and no seller claims it. ## Frequently asked Do GLP-1 drugs help migraine? A Danish register of 189,392 people found triptan dispensing 7% lower at twelve months after semaglutide was started, RR = 0.93. That is a small secondary signal from a design with no control group, not a migraine treatment. Does semaglutide treat migraine? It is not a migraine drug and is not sold as one. A register study found 7% less triptan dispensing at twelve months, which is a small secondary signal rather than a treatment effect. Why triptans rather than migraine attacks? Registers record dispensing, not symptoms. Triptan consumption tracks how often attacks are treated, which follows attack frequency but is not the same measurement. Why did men show no effect? The study does not say. It reports an 8% reduction in women and no statistically significant change in men. The cohort was 68% female, so the male subgroup was also smaller. Who funded it? Two authors are employed by Novo Nordisk, which makes semaglutide, and a third reports sponsor-initiated research funded by the company. The paper discloses this. ## Sources 1. \[1\] Roland N, et al. (2026). Impact of semaglutide introduction on the use of triptans: an interrupted-time series The Journal of Headache and Pain. [PMID 42557547](https://pubmed.ncbi.nlm.nih.gov/42557547/) 2. \[2\] Ahmed W, Gandhi OH, Yu N, Brant J, et al. (2026). Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis Journal of the Neurological Sciences. [PMID 41468715](https://pubmed.ncbi.nlm.nih.gov/41468715/) 3. \[3\] Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis Clinical Therapeutics. [PMID 41862354](https://pubmed.ncbi.nlm.nih.gov/41862354/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Parkinson's Disease? Prevention and Treatment Disagree Do GLP-1 drugs help Parkinson's disease? 82 pooled studies and a 712,287-patient network analysis | why the prevention signal and the trial null point opposite ways. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Parkinson's Disease? Prevention and Treatment Disagree Across 82 pooled studies the risk of developing Parkinson's was lower, at a hazard ratio of 0.70. In people who already have it, motor symptoms did not improve at all. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Two sentences from the same abstract · RESULTS · no class showed a significant difference · CONCLUSION · consistently associated with lower risk · What changed between them was a ranking, not a test **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Not once you have it. A systematic review screened 10,037 records and pooled 82 studies. It found people on these drugs less likely to develop Parkinson’s disease, at a pooled hazard ratio of 0.70 (95% CI 0.53 to 0.92) [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease#ref-2). In people who already had it, motor symptoms did not improve: a mean difference of −3.29 points on the standard rating scale, on an interval from −7.84 to 1.26. The prevention figure comes from observational cohorts and the null comes from randomized trials, which is the wrong way round. A Bayesian network of nine cohorts covering 712,287 patients found no antidiabetic class with a statistically significant difference in risk at all [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease#ref-1). ## Key takeaways - 82 pooled studies: risk of developing Parkinson's was lower, pooled HR 0.70, 95% CI 0.53 to 0.92, from observational data. - Motor symptoms in people who already have Parkinson's did not improve: mean difference -3.29, 95% CI -7.84 to 1.26, from trials. - A Bayesian network meta-analysis of 712,287 patients found no antidiabetic class with a significant difference in Parkinson's risk. - That paper's conclusion describes GLP-1 and SGLT2 drugs as consistently associated with lower risk, which its own results section does not support. - In Alzheimer's disease, where the trials have now reported, oral semaglutide did not slow decline. Neuroprotection is the most exciting claim anyone makes about these drugs and the least established. The pattern below is the reason: prevention signals keep appearing in observational data, and treatment effects keep failing to appear in trials. The same split runs through [the dementia evidence](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia), where a risk score moved and no clinical outcome did. ## What the prevention evidence is made of The neuropsychiatric review applied GRADE across outcomes, which is more rigor than most syntheses in this field manage [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease#ref-2). Its Parkinson’s incidence figure of 0.70 rests on observational studies. People prescribed a GLP-1 differ from people not prescribed one in age, wealth, insurance, comorbidity and how recently they entered care. Parkinson’s develops over decades and is often preceded by years of subtle symptoms. A drug given more often to healthier, better-followed patients will look protective against a slow neurodegenerative disease whether or not it is. The split between prevention and treatment is set out in [the neuropsychiatric review](https://thisglp.com/research/preventing-it-is-not-treating-it). ## What was pooled in the network analysis Nine observational cohort studies, 712,287 patients, searched to August 2025, comparing Parkinson’s incidence across antidiabetic drug classes in a Bayesian network that allowed indirect comparisons [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease#ref-1). Results were expressed as risk ratios with 95% credible intervals, with prespecified subgroups by age, sex and cardiovascular disease. In the authors’ own words in the results section: no antidiabetic class demonstrated a statistically significant difference in Parkinson’s risk. What the analysis did produce was rank probabilities. SGLT2 inhibitors tended to rank lowest for Parkinson’s risk among people aged 75 and over, and GLP-1 agonists lowest among those under 75. Metformin, sulfonylureas and alpha-glucosidase inhibitors ranked consistently higher than the newer agents. A ranking is not a difference Rank probabilities describe how often a treatment comes out on top across simulated orderings. Something ranks first in every simulation while the actual differences between it and second place remain too small and uncertain to detect. That is precisely what happens when nothing reaches significance. So the ranking here is a description of the model’s uncertainty, not a finding about Parkinson’s disease. ## The sentence that does not follow The conclusion states that SGLT2 inhibitors and GLP-1 agonists were consistently associated with lower Parkinson’s risk, suggesting potential neuroprotective effects. That is a stronger claim than the results support, and it is the sentence that will travel. Nothing was statistically significant. The word doing the work is “consistently,” which describes the rankings rather than the estimates. Reporting rank probabilities is normal practice and not the problem. Converting them into an association is the step that does not follow, and it is the same move as reading [a result into an estimate the comparison cannot carry](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). ## What happened when a neurodegenerative trial did report Parkinson’s has no large completed randomized readout. Alzheimer’s does. Two phase 3 trials tested oral semaglutide 14 mg in early-stage symptomatic Alzheimer’s disease and did not slow cognitive decline [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease#ref-3). That is the closest thing this field has to a test of the neuroprotection story, and it failed. A post hoc analysis of the SELECT trial did move a proteomic dementia risk signature in older adults with obesity and cardiovascular disease [\[4\]](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease#ref-4). A signature is a predictor, not a diagnosis, and no clinical dementia outcome was measured. Both readouts are covered in [the Alzheimer’s trials](https://thisglp.com/research/semaglutide-and-alzheimers) and [the dementia risk score](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia). ## What to do with the neuroprotection story Wait for trials in Parkinson’s specifically. Until those report, the honest summary is that nobody has shown these drugs prevent neurodegenerative disease, and neither analysis here is an exception. The one result in the review that is both randomized and countable concerns binge eating disorder, where liraglutide cut binge frequency by 1.28 episodes (95% CI −1.67 to −0.89). No seller on this roster claims a neurological benefit, and none should. The tell to watch for, if one ever does, is the shape of this paper. A results section that found nothing sits beside a conclusion that found something. The other thing to look for is [whether anything is published at all](https://thisglp.com/tools/what-sellers-publish). ## Frequently asked Do GLP-1 drugs help Parkinson's disease? Not in people who already have it. Pooled randomized data put the change in motor symptoms at -3.29 points, on an interval from -7.84 to 1.26, which crosses no effect. Non-motor symptoms, quality of life and dyskinesia did not improve either. Do they prevent Parkinson's disease? Observational data suggest a lower incidence, at a pooled hazard ratio of 0.70 (95% CI 0.53 to 0.92). A separate Bayesian network of 712,287 patients found no drug class with a statistically significant difference. Why does the prevention finding deserve less weight? It comes from observational cohorts, where people prescribed newer drugs differ from people who are not in age, wealth, comorbidity and how closely they are followed. The null on motor symptoms comes from randomized trials. Has any neurodegenerative trial reported? Yes, in Alzheimer's disease. Two phase 3 trials of oral semaglutide 14 mg in early-stage symptomatic Alzheimer's did not slow cognitive decline. Does any seller claim a neurological benefit? None on this roster does, and none should. The shape to watch for is a results section that found nothing beside a conclusion that found something. ## Sources 1. \[1\] Lee SH, et al. (2026). Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis Journal of Global Health. [PMID 42626880](https://pubmed.ncbi.nlm.nih.gov/42626880/) 2. \[2\] Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis Clinical Therapeutics. [PMID 41862354](https://pubmed.ncbi.nlm.nih.gov/41862354/) 3. \[3\] Cummings JL, et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials The Lancet. [PMID 41865758](https://pubmed.ncbi.nlm.nih.gov/41865758/) 4. \[4\] Jiménez-Mausbach M, et al. (2026). Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial Alzheimer's & Dementia. [PMID 42571323](https://pubmed.ncbi.nlm.nih.gov/42571323/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Psoriasis? Clear Skin in 40.6% Against 29.0% | This GLP Do GLP-1 drugs help psoriasis? A 274-patient phase 3b trial, a 6,096-person matched cohort, and the hidradenitis evidence | what each design can support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-psoriasis Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Psoriasis? Clear Skin in 40.6% Against 29.0% Added to a biologic in 274 randomized adults, tirzepatide raised complete skin clearance from 29.0% to 40.6%. The trial's headline number is twice that, and half of it was settled at randomization. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read At week 36 · + tirzepatide · alone · skin clear AND 10% lost · 27.1% · 5.8% · skin clear (PASI 100) · 40.6% · 29% · 10% or more lost · 69.2% · 9.1% · Only one arm received a weight-loss drug. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). On the skin, modestly. A phase 3b trial randomized 274 adults with moderate to severe psoriasis and overweight or obesity. Complete skin clearance at week 36 was 40.6% on ixekizumab plus tirzepatide against 29.0% on the biologic alone [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-psoriasis#ref-1). That is a risk difference of 11.6%, on a confidence interval running from 0.3% to 22.9%. The trial’s headline endpoint was much larger, and half of it was settled before anyone was treated. No trial has tested a GLP-1 drug on psoriasis without a biologic alongside it. ## Key takeaways - A phase 3b open-label trial randomized 274 adults with moderate to severe psoriasis and overweight or obesity to ixekizumab with or without tirzepatide. - The primary endpoint combined complete skin clearance with 10% weight loss: 27.1% vs 5.8% (risk difference 21.2%, 95% CI 12.8%-29.7%). - Only one arm got a weight drug, so half that composite was settled at randomization. - On skin alone, PASI 100 was 40.6% vs 29.0% — a risk difference of 11.6% with a confidence interval running from 0.3% to 22.9%. - A separate 6,096-person matched cohort reported lower mortality and cardiac events in psoriasis, at effect sizes no trial has produced. - Nobody has randomized a GLP-1 drug against placebo in psoriasis. Every figure here is either a combination or a matched record. Between 60% and 78% of people with psoriasis carry overweight or obesity, and weight worsens both the disease and the response to treatment. That relationship is what makes the trial below worth running, and it is also what makes its headline number hard to read. The [comorbidity load in psoriasis](https://thisglp.com/research/glp1-psoriasis-comorbidities) is counted separately. A phase 3b trial at 72 US sites tested treating both at once, randomizing 274 adults to the biologic ixekizumab with or without tirzepatide [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-psoriasis#ref-1). The headline result is large. At week 36, 27.1% of the combination arm reached complete skin clearance and lost at least 10% of their weight. On the biologic alone it was 5.8%, a risk difference of 21.2% (95% CI 12.8%–29.7%). Half of that endpoint was decided before anyone was treated The primary outcome requires clear skin and 10% weight loss together. One arm received a drug that reliably produces 10% weight loss and the other did not — and indeed 69.2% against 9.1% hit the weight component. A composite that bundles a near-certainty with an open question will move, and the size of the movement says more about the design than about what tirzepatide does to psoriasis. The number that answers the actual question is the skin-only one. Complete clearance was 40.6% with tirzepatide against 29.0% without, a risk difference of 11.6% whose confidence interval runs from 0.3% to 22.9% (P = .04). The lower bound sits three tenths of a percent above zero. That is a positive result by convention and the most fragile figure in the trial. It is also the one a dermatologist weighing a second drug actually needs. Two design features deserve weight here. The trial was open-label, so everyone knew who was receiving what, and PASI scoring involves investigator judgment. That combination tends to favor the more intensively treated arm on a visually assessed endpoint. Gastrointestinal events were more frequent on the combination. The trial reports that as consistent with known safety profiles, and it is still a tolerability cost attached to the extra 11.6%. The same class of stomach complaints is described from the mechanism side in [nausea and appetite on one circuit](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea). ## What the record-based cohort adds, and what it cannot A US database cohort matched 3,048 psoriasis patients on a GLP-1 drug against 3,048 taking other antidiabetic or antiobesity drugs and followed both for two years [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-psoriasis#ref-2). All-cause mortality came out at a hazard ratio of 0.219 (95% CI 0.123 to 0.391) and major adverse cardiac events at 0.561 (95% CI 0.442 to 0.714). A hazard ratio of 0.219 describes a group dying at roughly a fifth the rate of its comparator. No randomized trial of this class has produced anything close to it. Neither arm measured whether anyone’s psoriasis improved. The full reading, including why the cardiac figure is easier to believe than the mortality one, is in [the psoriasis comorbidity cohort](https://thisglp.com/research/glp1-psoriasis-comorbidities). ## The adjacent skin disease, and the grade of its evidence Hidradenitis suppurativa is a different condition with the same obesity link, and it shows what this literature looks like without a randomized comparison. An open-label study of 20 adults on semaglutide for six months reported weight down 21.4 kg, quality of life up 8.8 points and pain down 4.1, all at p<0.001 [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-psoriasis#ref-3). There was no control group and no blinding, and three of those four outcomes are self-reported. A separate matched-record cohort in the same disease reported all-cause mortality at a hazard ratio of 0.24 (95% CI 0.145 to 0.395). Exposure required at least a year of therapy [\[4\]](https://thisglp.com/research/do-glp1-drugs-help-psoriasis#ref-4). Anybody who died inside that year could not be counted as exposed. Both studies are set out in [the twenty-person pilot](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) and [the hidradenitis mortality cohort](https://thisglp.com/research/glp1-mortality-in-hidradenitis). ## What the trial does establish The two drugs can be given together for a year without a new safety signal emerging, in a population where doing so was previously untested at this scale. Whether the skin benefit is worth a second injection is a judgment the confidence interval leaves genuinely open. The broader pattern of these drugs producing modest effects across many separate conditions runs through [the heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure) and [the carpal tunnel comparison](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome). No telehealth seller prescribes for psoriasis, and nothing here is a reason to start or stop a drug. The record cohort is useful for reading a marketing claim. The risk reductions were larger in the psoriasis group than in groups without it. That is the kind of subgroup finding a landing page quotes without its population attached. Before a first order, the more useful questions are about who is prescribing and what happens at a higher dose, and those are listed in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs help psoriasis? Added to a biologic in a 274-patient trial, tirzepatide raised complete skin clearance from 29.0% to 40.6%, a risk difference of 11.6% on an interval from 0.3% to 22.9%. No trial has tested one without a biologic alongside it. Why is the trial's headline number so much bigger? The primary endpoint required clear skin and 10% weight loss together. Only one arm received a drug that reliably produces 10% weight loss, so half the composite was settled at randomization. What about the cohort study reporting much lower mortality? A 6,096-person matched cohort reported all-cause mortality at a hazard ratio of 0.219. No randomized trial of this class has produced anything close to that, and neither arm measured whether psoriasis improved. Is there evidence in hidradenitis suppurativa? Only weak evidence. A twenty-person open-label study with no control group reported large improvements, and a matched-record cohort reported mortality at 0.24 under an exposure definition that excluded anyone who died inside the first year. Can I buy a GLP-1 for psoriasis? No telehealth seller on this roster prescribes for psoriasis. The trial evidence involves adding tirzepatide to a biologic already being prescribed by a dermatologist. ## Sources 1. \[1\] Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, et al. (2026). Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial JAMA Dermatology. [PMID 42139049](https://pubmed.ncbi.nlm.nih.gov/42139049/) 2. \[2\] Olbrich H, et al. (2026). Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study British Journal of Dermatology. [PMID 40897378](https://pubmed.ncbi.nlm.nih.gov/40897378/) 3. \[3\] Nicolau J, et al. (2026). Semaglutide in patients with hidradenitis suppurativa and obesity Medicina Clínica. [PMID 41832804](https://pubmed.ncbi.nlm.nih.gov/41832804/) 4. \[4\] Brouer IC, et al. (2026). Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study Frontiers in Medicine. [PMID 42741157](https://pubmed.ncbi.nlm.nih.gov/42741157/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Resistant Hypertension? The Pressure Matched | This GLP Do GLP-1 drugs help resistant hypertension? A 4,153-per-arm matched cohort found the same pressure fall as an MRA | and mortality at HR 0.34, which is not credible. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Resistant Hypertension? The Pressure Matched Two fourth-line drugs lowered blood pressure by the same amount. One group then had a two-thirds lower risk of dying, which is a fact about who gets which drug rather than about the drug. No randomized trial has reported an outcome in this population. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Systolic blood pressure change at 12 weeks · GLP-1 · −5.7 mmHg · MRA · −6.3 mmHg · All-cause mortality, same two groups · hazard ratio 0.34 — a two-thirds difference · The treated quantity matched. The outcomes did not. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No randomized trial has tested one for it. The evidence is a matched cohort of 4,153 patients per arm, and it found what a trial would not [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-1). Blood pressure fell 5.7 mmHg on a GLP-1 against 6.3 mmHg on a mineralocorticoid receptor antagonist. On the thing both drugs were prescribed to do, the two groups landed in the same place. Everything afterward differed: MACE at HR 0.63, kidney events at 0.64, all-cause mortality at 0.34. A two-thirds reduction in death with the treated quantity equalized is a signature of confounding. ## Key takeaways - A matched cohort compared GLP-1 drugs against mineralocorticoid receptor antagonists as fourth-line therapy for resistant hypertension. - After matching, 4,153 patients remained in each group, followed a median of 1.4 years. - Blood pressure fell by a similar amount in both: −5.7 mmHg against −6.3 mmHg at 12 weeks. - Outcomes did not match: MACE HR 0.63, kidney events HR 0.64, and all-cause mortality HR 0.34. - A Cochrane review found the semaglutide and tirzepatide trials in hypertension reported no mortality or cardiovascular results at all. Resistant hypertension means pressure still uncontrolled on three drugs at once. It is a specific diagnosis, not a description of a bad reading. The question here is whether a GLP-1 belongs as the fourth drug, and the general blood-pressure and vascular evidence is a different matter, set out in [the vessel-function measurements](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). ## What was compared Adults with overweight or obesity and resistant hypertension, across 67 US healthcare organizations, who started a fourth drug between 2017 and 2025 [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-1). Those starting semaglutide or tirzepatide were matched against those starting spironolactone or eplerenone, the guideline-recommended option. Of 213,309 eligible patients, 22,694 started a GLP-1 and 5,673 an MRA. Propensity matching left 4,153 in each group. Over a median 1.4 years the GLP-1 group had lower risks across the board. MACE HR 0.63, 95% CI 0.52 to 0.78. Cardiovascular events HR 0.74, 95% CI 0.59 to 0.92. Major adverse kidney events HR 0.64, 95% CI 0.46 to 0.88. Acute kidney injury HR 0.62, 95% CI 0.46 to 0.83. All-cause mortality HR 0.34, 95% CI 0.21 to 0.55. ## And the blood pressure Systolic pressure fell 5.7 mmHg on the GLP-1 and 6.3 mmHg on the MRA at twelve weeks, with overlapping intervals. On the thing both drugs were prescribed to do, the two groups were the same. The MRA arm did marginally better. The study undermines its own headline If GLP-1 therapy produced better cardiovascular and kidney outcomes because it controlled pressure better, the pressure data would show it. They do not. Something other than the treated quantity is separating these two groups, and a 66% lower risk of death from any cause over 1.4 years is far larger than any plausible pharmacological explanation for it. Consider what it takes to be in each group. Spironolactone is a decades-old generic costing a few dollars a month. A clinician can add it this afternoon. Getting semaglutide or tirzepatide approved as a fourth-line blood pressure drug takes an insurer’s cooperation, a prescriber willing to pursue it, documentation, and often the patient’s own money. The people who clear that are better insured, more engaged with their care, and well enough to be considered for an elective addition. Those characteristics predict survival on their own. Propensity matching adjusts for what was recorded, and none of that is recorded. It is the same shape of confounding visible from the access side in [the uptake registry](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke). ## What the trials reported, which is nothing A Cochrane review now in its fourth update pooled eight randomized trials of long-term weight drugs in adults with hypertension, about 13,000 participants [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-2). For both semaglutide and tirzepatide it records that no results were reported for all-cause mortality, cardiovascular morbidity, serious adverse events or adverse events. Liraglutide could not be entered at all, because no trial has published separate figures for hypertensive participants. That is not a safety finding. It says the trials did not report the outcomes a reviewer needs, in a population where the question is unusually live. The older drugs did report. Orlistat probably increases serious adverse events at RR 1.45, 95% CI 1.10 to 1.91, across three trials and 1,476 participants. The full reading is in [the Cochrane update](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths). ## What the randomized evidence does support In broader populations the hard outcomes are real and much smaller than the cohort suggests. A meta-analysis of 11 trials and 85,373 people found MACE at HR 0.87, 95% CI 0.81 to 0.93, alongside kidney benefits [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension#ref-3). That is a 13% relative reduction, not a 37% one, and it comes from randomization rather than from matching. Stroke measured on its own is thinner still, as [the stroke evidence](https://thisglp.com/research/do-glp1-drugs-prevent-stroke) sets out. So the practical position is narrow. A GLP-1 achieved about the same pressure reduction as the guideline drug in a population where pressure is hard to move. The outcome gap beside it is not credible at the size reported. The authors say prospective studies are needed to determine whether these drugs should be part of treatment for resistant hypertension, and that is the correct conclusion from their own data. Nobody on this roster sells anything for resistant hypertension. What sellers publish about who they will and will not prescribe to is thin. [The ordinary-care results](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) show what happens to trial figures once access decides who is in the sample. ## Frequently asked Do GLP-1 drugs help resistant hypertension? They lowered systolic pressure by 5.7 mmHg, about the same as the guideline fourth-line drug at 6.3 mmHg. No randomized trial has tested one in this population for any hard outcome. Why distrust the mortality result? All-cause mortality came out at HR 0.34 while both groups reached the same blood pressure. If the drug worked through pressure, the pressure data would show it. A two-thirds reduction in death over 1.4 years is larger than randomized evidence supports. What did the randomized trials report? In hypertension, nothing. A Cochrane review records that the semaglutide and tirzepatide trials reported no results for mortality, cardiovascular morbidity or adverse events. What is the credible size of the cardiovascular benefit? A meta-analysis of 11 trials and 85,373 people found MACE at HR 0.87, 95% CI 0.81 to 0.93 — a 13% relative reduction in broader populations, not the 37% the cohort reports. ## Sources 1. \[1\] Tian Z, et al. (2026). Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA eClinicalMedicine. [PMID 42701458](https://pubmed.ncbi.nlm.nih.gov/42701458/) 2. \[2\] Spary-Kainz U, Posch N, Radl-Karimi C, Jeitler K, Krenn C, Siebenhofer A (2026). Long-term effects of weight-reducing drugs in people with hypertension Cochrane Database of Systematic Reviews. [PMID 42318855](https://pubmed.ncbi.nlm.nih.gov/42318855/) 3. \[3\] Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT (2025). Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials The Lancet Diabetes & Endocrinology. [PMID 39608381](https://pubmed.ncbi.nlm.nih.gov/39608381/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Rheumatoid Arthritis? The Heart Result, Not the Joints Do GLP-1 drugs help rheumatoid arthritis? 1,017 matched pairs, a MACCE hazard ratio of 0.75 driven entirely by heart failure, and no measurement of joint disease. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Rheumatoid Arthritis? The Heart Result, Not the Joints Semaglutide was linked to fewer cardiovascular events in people with rheumatoid arthritis. Heart failure accounted for it; death, heart attack and stroke did not budge. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Semaglutide vs other second-line drugs · MACCE (composite) · 0.75 · heart failure · 0.69 · death, MI, stroke · no significant difference · 1,017 matched pairs, followed up to two years. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Not the joints, on this evidence. Among 1,017 matched pairs with type 2 diabetes, rheumatoid arthritis and obesity, semaglutide was associated with major adverse cardiac and cerebrovascular events in 12.7% against 16.5%, a hazard ratio of 0.75 (95% CI 0.60 to 0.94) [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-1). The composite moved because heart failure moved, at 8.9% against 12.5%, while death, heart attack and stroke showed no significant difference at all. Nothing in the study measured joint disease. The inflammation these drugs are shown to lower is a blood marker: high-sensitivity CRP fell 37.8% at 104 weeks in SELECT [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-2). ## Key takeaways - Among 1,017 matched pairs with type 2 diabetes, rheumatoid arthritis and obesity, semaglutide was associated with fewer major cardiovascular and cerebrovascular events: 12.7% vs 16.5% (HR 0.75, 95% CI 0.60-0.94). - The composite moved because heart failure moved: 8.9% vs 12.5% (HR 0.69, 95% CI 0.53-0.91). - All-cause mortality, myocardial infarction and stroke showed no significant differences. - Escalation to a disease-modifying antirheumatic drug was also lower (16.6% vs 21.6%), which is a prescribing observation rather than a measure of disease activity. Rheumatoid arthritis makes exercise painful and weight management harder, and it adds chronic inflammation on top, so cardiovascular risk in this group is elevated for several reasons at once. A target trial emulation in a US database asked whether semaglutide changes that, comparing 1,017 matched pairs who started it against other second-line glucose-lowering drugs[\[1\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-1). Everyone was free of prior stroke, heart failure and coronary events, making this a primary-prevention question, which is a harder one than the [established heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure) addresses. The composite outcome separated. Major adverse cardiovascular and cerebrovascular events occurred in 12.7% against 16.5%, a hazard ratio of 0.75 (95% CI 0.60–0.94, P = .01). One of four components did the work The composite bundles death, heart attack, heart failure and stroke. Heart failure came in at 8.9% against 12.5% (HR 0.69, 95% CI 0.53–0.91). Mortality, myocardial infarction and stroke showed no significant differences at all. Describing this as a reduction in cardiovascular events is technically accurate and practically misleading — it is a heart failure result wearing a composite's clothes. Heart failure is also the component where a weight drug has the clearest non-vascular route to an effect. It is diagnosed substantially on symptoms, breathlessness on exertion chief among them, and removing a tenth of someone's body weight changes how far they can walk before they are short of breath. A real reduction in cardiac strain and a change in what gets coded both produce this number, and two years of follow-up in a thousand pairs cannot separate them. The same detection problem, with the two endpoints disagreeing rather than agreeing, appears in [the carpal tunnel cohort](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome). ## What happens when a joint is measured directly Rheumatoid arthritis has not been measured that way, and the nearest thing is osteoarthritis. Ninety-three adults with knee osteoarthritis started semaglutide in routine rheumatology care and 88 completed six months, over which mean weight fell 10.88 kg, pain fell 2.47 points and the WOMAC total fell 22.50 points [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-rheumatoid-arthritis#ref-3). C-reactive protein fell 2.67 mg/L and the sedimentation rate 7.62 mm/h. There was no untreated comparison group, and the authors state in their own methods that the changes are therefore non-causal, which is rarer than the result and worth more. Osteoarthritis is mechanical and rheumatoid arthritis is autoimmune, so this is an adjacent measurement rather than a stand-in, and the randomized version of it sits in [the knee pain trial](https://thisglp.com/research/do-glp1-drugs-help-knee-pain). Escalation to a disease-modifying antirheumatic drug was lower as well, 16.6% against 21.6% (HR 0.75, 95% CI 0.60–0.90). The temptation is to read that as less active arthritis, and it should be resisted for the reason set out in [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease). There, a lower rate of recorded biologic use could not be distinguished from a change in prescribing patterns. A claims database sees the prescription, not the joint. The authors ask for prospective work and apply a Bonferroni correction for their secondary comparisons, both of which are the right instincts. What survives is a plausible, modest, single-component finding in a group that gets studied rarely. It is also a reminder that the weight itself does things a composite endpoint will happily absorb, including to muscle, as covered in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). ## Frequently asked Do GLP-1 drugs help rheumatoid arthritis? No study has measured joint disease activity. The one target trial emulation in this population measured cardiovascular events and found 12.7% against 16.5%, a hazard ratio of 0.75 carried entirely by the heart failure component. Did semaglutide prevent heart attacks and strokes here? No. Myocardial infarction, stroke and all-cause mortality showed no significant differences. The composite result was driven by the heart failure component alone. Why single out heart failure? It is the component most sensitive to weight, and it is diagnosed largely on symptoms like breathlessness. Losing a tenth of body weight changes those symptoms, so a coding shift and a real cardiac effect look alike in this data. Does it reduce arthritis activity? That is not established. Escalation to a disease-modifying drug was lower, but a claims database records prescriptions rather than joint disease, and cannot separate starting a drug from continuing one. ## Sources 1. \[1\] Malik F, Shah M, Chang Y, Chowdhury I, et al. (2026). Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation European Heart Journal. Cardiovascular Pharmacotherapy. [PMID 42334436](https://pubmed.ncbi.nlm.nih.gov/42334436/) 2. \[2\] Plutzky J, Bogdański P, Colhoun HM, Dağdelen S, et al. (2026). Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis Circulation. [PMID 42610271](https://pubmed.ncbi.nlm.nih.gov/42610271/) 3. \[3\] Conforti A, et al. (2026). Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis-Results from a Six-Month Real-World Cohort Journal of Clinical Medicine. [PMID 42589980](https://pubmed.ncbi.nlm.nih.gov/42589980/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Help Ulcerative Colitis? Remission Was 66.7% Against 25.3% Do GLP-1 drugs help ulcerative colitis? A 300-patient matched cohort, a 9,766-pair Crohn's cohort, and the motility caution | what each can and cannot support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Ulcerative Colitis? Remission Was 66.7% Against 25.3% One matched cohort of 150 pairs put twelve-week symptomatic remission at 66.7% against 25.3%, at an adjusted odds ratio of 5.90. Nobody was randomized, and no seller offers anything for this. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Symptomatic remission — drug vs matched controls · 4 weeks · 34.7% · 15.3% · 8 weeks · 54.7% · 18% · 12 weeks · 66.7% · 25.3% · 150 matched pairs, one center, retrospective **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). In one matched cohort of 300 patients, yes. Symptomatic remission at twelve weeks was 66.7% on a GLP-1 against 25.3% without one [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis#ref-1). The adjusted odds ratio was 5.90 (95% CI 3.52 to 9.86). That is 150 pairs at one center, with nobody randomized. A separate cohort of 9,766 matched pairs with Crohn’s disease put one-year hospitalization at 10.0% against 24.7% [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis#ref-2). Neither study makes a GLP-1 a treatment for inflammatory bowel disease, and neither set of authors says it does. ## Key takeaways - Ulcerative colitis: symptomatic remission 66.7% against 25.3% at twelve weeks, adjusted odds ratio 5.90, 95% CI 3.52 to 9.86. - The remission definition required a rectal bleeding subscore of zero, which gut slowing does not produce. - In an endoscopic subset, mucosal remission was 58% against 38% — objective evidence, in a subset, with no p-value given. - Crohn's disease: 9,766 matched pairs, hospitalization 10.0% against 24.7% at one year, and steroid use identical at RR 1.00. - Weight loss was not associated with remission, which argues against this being a weight effect. - Both studies are observational. No randomized trial has tested a GLP-1 in inflammatory bowel disease. This drug slows the gut. Ulcerative colitis is measured partly by how often a patient goes to the bathroom. The improvement in that measure was very large. The first question is whether the measure moved or the disease did. That is the question [every endpoint choice](https://thisglp.com/research/do-glp1-drugs-cause-gout) forces. ## What was found in ulcerative colitis The study covered one academic health system. Adults with ulcerative colitis who started liraglutide or semaglutide, and stayed on it at least 12 weeks, were eligible. They were started for metabolic reasons, not for the colitis. Each was matched one to one against a patient with the condition who did not. Symptomatic remission was 34.7% against 15.3% at four weeks, 54.7% against 18.0% at eight, and 66.7% against 25.3% at twelve. Mean partial Mayo scores fell from 5.8 at baseline to 2.1, against 4.6 in controls. Semaglutide did better than liraglutide, 72.5% against 60%, odds ratio 1.77, p=0.04. Weight loss was not associated with remission. ## The obvious objection Partial Mayo is a symptom score. Two of its components are stool frequency and rectal bleeding. These drugs slow gastric emptying and intestinal transit as their central mechanism. A person going less often scores lower on a scale that counts how often they go. Nothing need have changed in the colon. The study answers that twice Remission here required a rectal bleeding subscore of zero. Slowing transit does not stop bleeding, so the definition is not satisfiable by the mechanism alone. In the subset who had endoscopy, mucosal remission was 58% against 38%. Endoscopic improvement was 69% against 47%. Those are direct observations of the colon, not a questionnaire. That is a subset and the abstract quotes no p-values for it, so it is supportive rather than conclusive. But it is the right kind of evidence, and it means the objection cannot be the whole story. ## What the Crohn’s cohort adds The second study drew on 162 organizations and matched 9,766 pairs on more than thirty covariates [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis#ref-2). Hospitalization at one year was 10.0% against 24.7% (RR 0.40, 95% CI 0.38–0.43). Emergency visits were 18.9% against 25.3% (RR 0.75, 95% CI 0.71–0.79). Both associations held at five years. The most informative number is the one that did not move. Corticosteroid use at one year was the same in both arms, RR 1.00, 95% CI 0.96 to 1.03. A healthy-user effect driving everything should have dragged that outcome too. It did not. The full reading of that cohort, including a mortality figure its own authors disown, is in [the Crohn’s cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease). ## What still deserves suspicion An adjusted odds ratio of 5.90 is very large. Effect sizes that size in matched observational data usually shrink when somebody randomizes. The reasons are familiar. People prescribed a new drug for metabolic reasons differ from people not prescribed one. Records do not capture those differences, including how closely a patient’s gastroenterology is managed. That is the limit [every matched-records study runs into](https://thisglp.com/research/semaglutide-fractures-diabetes-only), and it does not shrink because the result is interesting. One hundred and fifty pairs at one tertiary center over two years is also a small, particular population. Everyone in it was well enough and metabolically unwell enough to be started on a GLP-1. ## The finding that cuts the other way Weight loss was not associated with remission. If the benefit were the downstream effect of losing weight, the people who lost most should have improved most. They did not. That points toward something more direct. GLP-1 receptors are present in the gut and these drugs have measurable anti-inflammatory effects. It is also the kind of mechanistic inference that [a study without randomization](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) can support only weakly, however sensible it sounds. ## The motility caution, and how strong it is Inflammatory bowel disease is often cited as a reason for caution with a drug that slows the gut. The evidence behind that caution is thinner than the warnings suggest. A systematic review of GLP-1-induced gastroparesis found thirteen published cases in total [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis#ref-3). A separate real-world analysis of patients with irritable bowel syndrome found fewer gastrointestinal events on the drug, not more [\[4\]](https://thisglp.com/research/do-glp1-drugs-help-ulcerative-colitis#ref-4). Both are set out in [the gastroparesis evidence](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## What this means for a reader Nothing to buy. No seller on this roster offers anything for ulcerative colitis, and none claims it. Nobody should start a GLP-1 for inflammatory bowel disease on one matched cohort. What it is worth is a conversation. Someone with ulcerative colitis who is considering one of these drugs for weight has a reason to raise it. The place to raise it is a gastroenterologist, not an intake form. Inflammatory bowel disease is exactly the kind of history [a telehealth questionnaire may never ask about](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs help ulcerative colitis? One matched cohort of 150 pairs found twelve-week symptomatic remission at 66.7% against 25.3%, an adjusted odds ratio of 5.90. It is observational, single-center, and no randomized trial has tested the question. Is that just the drug slowing the gut? Not entirely. Remission required a rectal bleeding subscore of zero, which slowed transit does not produce, and an endoscopic subset showed mucosal remission at 58% against 38%. What about Crohn's disease? A 9,766-pair cohort found one-year hospitalization at 10.0% against 24.7% and emergency visits at 18.9% against 25.3%. Corticosteroid use was identical at RR 1.00, which argues the result is not purely healthy-user bias. Is inflammatory bowel disease a reason to avoid these drugs? The motility caution is weaker than it sounds. A systematic review of GLP-1-induced gastroparesis found thirteen published cases, and a real-world irritable bowel syndrome analysis found fewer gastrointestinal events on the drug. Can I buy a GLP-1 for ulcerative colitis? No seller on this roster offers anything for it and none claims to. This is a conversation for a gastroenterologist, not a telehealth intake form. ## Sources 1. \[1\] Alqinai B, et al. (2026). GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study Inflammatory Bowel Diseases. [PMID 42627215](https://pubmed.ncbi.nlm.nih.gov/42627215/) 2. \[2\] Ganju N, Ssebambulidde K, Gupta S, Adidam S, et al. (2026). GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study Scientific Reports. [PMID 42321339](https://pubmed.ncbi.nlm.nih.gov/42321339/) 3. \[3\] Olubodun T, et al. (2026). Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes PLOS ONE. [PMID 42594084](https://pubmed.ncbi.nlm.nih.gov/42594084/) 4. \[4\] Khan SA, Marasini A, Shrestha A, Bharadwaj HR, et al. (2026). Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis Digestive Diseases and Sciences. [PMID 42570075](https://pubmed.ncbi.nlm.nih.gov/42570075/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Improve Blood Vessel Function? The Same Number, Two Answers Do GLP-1 drugs improve blood vessel function? An identical 0.11 estimate was significant against baseline and not against placebo, while hsCRP fell 37.8% in SELECT. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Improve Blood Vessel Function? The Same Number, Two Answers Blood-vessel function rose 0.11 against baseline and 0.11 against placebo. The first was significant and the second was not. Only the comparison changed. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Blood-vessel response, same estimate of 0.11 · vs baseline · p = 0.03 · vs placebo · p = 0.16 · no change · Only the comparison changed, not the measurement **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). One measurement, two answers, and the comparison decides which one you get. In a 32-week trial of 120 people with type 2 diabetes, blood-vessel responsiveness rose 0.11 against each participant’s own baseline, 95% CI 0.008 to 0.21, p=0.03 [\[1\]](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function#ref-1). Against the placebo group the estimate was the same 0.11, with a 95% CI of −0.04 to 0.24 and p=0.16. Four adhesion molecules were measured and they did not move together, with one rising against placebo. The marker in this family that does move reliably is inflammation: hsCRP fell 37.8% at 104 weeks in SELECT [\[2\]](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function#ref-2). ## Key takeaways - A 32-week trial randomized 120 people with type 2 diabetes to semaglutide, empagliflozin, both, or placebo. - Blood-vessel responsiveness rose by 0.11 against each person's own baseline, 95% CI 0.008 to 0.21, p=0.03. - Against placebo the estimate was the same 0.11, 95% CI −0.04 to 0.24, p=0.16 — not significant. - One adhesion molecule fell against placebo and another rose, at 12.3 and 16.2 in the semaglutide and combination groups. - The authors attribute the placebo-comparison null to limited power, which is fair with about 30 people per arm. Two sentences can describe one measurement. “Semaglutide improved blood vessel function, p=0.03.” And: “Semaglutide did not significantly improve blood vessel function versus placebo, p=0.16.” Both are accurate descriptions of the same number in the same study, and the difference between them is the entire subject of [choosing what to compare against](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## The study A post hoc analysis of a 32-week randomized trial that had been designed to look at cardio-renal organ damage. One hundred and twenty participants with type 2 diabetes, aged 50 or over, were randomized to semaglutide, empagliflozin, both together, or placebo. [\[1\]](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function#ref-1) The analysis looked at a measure of how well blood vessels widen in response to demand, and at four adhesion molecules the endothelium releases. ## The same estimate, twice In the semaglutide group the vessel-response index rose 0.11 from each participant’s own starting value, with a 95% confidence interval of 0.008 to 0.21 and p=0.03. Compared with the placebo group it also rose 0.11 — with a confidence interval of −0.04 to 0.24 and p=0.16. Nothing about the measurement changed. What changed is what it was held up against. People in a trial tend to improve for reasons that have nothing to do with the drug: closer monitoring, changed habits, regression to the mean, the season. A placebo group exists to absorb all of that, and when you subtract it the effect here stopped being distinguishable from noise. Not shown is not shown absent The authors say the placebo-comparison null likely reflects limited power, and they are probably right. One hundred and twenty people split four ways is about thirty per arm, which is very little for a biomarker with this much natural variation. So this page is not claiming the drug does nothing to the endothelium. It is claiming that the baseline comparison cannot tell you, and that the study which could have is too small. ## The markers disagreed with each other Four adhesion molecules were measured and they did not move together. E-Selectin fell against placebo, by 9 in both the semaglutide group, 95% CI −14.1 to −5.1, and the combination group, 95% CI −14.3 to −5.2, both at p<0.01. That is the direction usually read as healthier. VCAM-1 went the other way. It rose against placebo, by 12.3 in the semaglutide group, 95% CI 2.8 to 20.8, p=0.01, and by 16.2 in the combination group, 95% CI 7.2 to 24.3, p<0.01. P-Selectin and ICAM-1 did not move significantly in any group. The authors describe the responses as heterogeneous and suggest the molecules play distinct roles, which is an honest way of saying nobody knows what the pattern means. Note what a selective summary could do with that. Quote E-Selectin, omit VCAM-1, and this becomes a study showing improved endothelial health. It is the same move [a composite endpoint makes structurally](https://thisglp.com/research/tirzepatide-heart-failure-composite), performed by hand. ## The marker that does move, and one that moved too much Inflammation is the comparison worth having beside this one. A prespecified SELECT substudy reported high-sensitivity CRP down 37.8% at 104 weeks against placebo [\[2\]](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function#ref-2). The reduction was evident by weeks 4 and 8, and it appeared among participants who did not lose weight. That is a placebo comparison in a trial of 17,604 people, and its authors still describe reduced inflammation as contributing “in part” rather than as the mechanism. The reading is in [the hsCRP substudy](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation). A third study shows what happens when the comparison is right and the result is still too large. A matched cohort of 4,153 patients per arm compared these drugs against mineralocorticoid receptor antagonists as fourth-line therapy in resistant hypertension [\[3\]](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function#ref-3). Blood pressure fell by a similar amount in both arms, −5.7 mmHg against −6.3 mmHg at 12 weeks, while all-cause mortality came in at a hazard ratio of 0.34. A two-thirds reduction in death with the treated quantity equalized is a confounding signature, set out in [same blood pressure, different outcomes](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension). ## Why any of this matters to a reader Not because endothelial biomarkers should influence a purchase. They should not — these are laboratory measures in 120 people, not events in anybody. It matters because “improved from baseline” is everywhere. It appears in clinic testimonials, in single-arm studies, in before-and-after marketing, and in summaries of real trials that had a placebo group available and quoted the baseline comparison anyway. Once you notice the phrase you cannot stop seeing it, and it is the same weakness that makes [an uncontrolled study](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) unable to show what it appears to show. The test is one question: compared to what? If the answer is “to how they were before,” you have been told how a group of people changed over time, not what the drug did. Almost nothing a seller publishes survives that question, which [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) measures from the other direction. ## Frequently asked Do GLP-1 drugs improve blood vessel function? This trial cannot say. The same 0.11 estimate was significant against each person's own baseline and not significant against placebo, and the authors attribute that to limited power at about thirty people per arm. How can the same number be significant and not significant? Because significance depends on the comparison. Against each person's own baseline the interval was 0.008 to 0.21, which excludes zero. Against the placebo group it was −0.04 to 0.24, which does not. Does semaglutide improve blood vessel function? This study cannot say. The placebo comparison was not significant and the authors attribute that to limited power, with about thirty people per arm. Why did one marker get worse? VCAM-1 rose against placebo while E-Selectin fell. The authors call the responses heterogeneous and suggest the molecules have distinct roles. Nobody knows what the pattern means. Should this change what I buy? No. These are laboratory markers in 120 people, not clinical events. The transferable part is the question to ask of any result: compared to what? ## Sources 1. \[1\] Gullaksen S, et al. (2026). Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial Journal of Diabetes and Its Complications. [PMID 42679726](https://pubmed.ncbi.nlm.nih.gov/42679726/) 2. \[2\] Plutzky J, Bogdański P, Colhoun HM, Dağdelen S, et al. (2026). Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis Circulation. [PMID 42610271](https://pubmed.ncbi.nlm.nih.gov/42610271/) 3. \[3\] Tian Z, et al. (2026). Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA eClinicalMedicine. [PMID 42701458](https://pubmed.ncbi.nlm.nih.gov/42701458/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Improve Your Quality of Life? 2.12 Points on the SF-36 | This GLP Do GLP-1 drugs improve quality of life? Cochrane found SF-36 physical functioning up 2.12 points | EQ-5D utility rose 0.03, and KCCQ rose 11.0 in the most frail. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Improve Your Quality of Life? 2.12 Points on the SF-36 Cochrane graded the quality-of-life evidence moderate certainty and measured a 2.12-point gain in physical functioning, on a scale running to a hundred. The one place the effect is large is heart failure, and there it belongs almost entirely to the frailest participants. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Health utility, scale 0 to 1 · baseline 0.78 · +0.03 · Estimated difference 0.03 (95% CI 0.01 to 0.06). · Mapped from SF-36 answers, not asked directly. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Measurably, and by less than the weight loss would lead most readers to expect. Cochrane pooled fifteen randomized trials in 8,651 adults and found physical functioning on the SF-36 improving by 2.12 points against placebo, 95% CI 0.95 to 3.28, graded moderate certainty [\[1\]](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life#ref-1). In liver disease the mapped EQ-5D utility gain was 0.03 points from a baseline of about 0.78, which is the raw material every cost-per-QALY figure for this drug is built from [\[2\]](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life#ref-2). The exception is heart failure, where the most frail participants gained 11.0 points on a symptom questionnaire whose clinically meaningful threshold is about five [\[3\]](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life#ref-3). ## Key takeaways - Cochrane graded quality of life moderate certainty: SF-36 physical functioning improved 2.12 points (95% CI 0.95 to 3.28), on a 100-point scale. - In the ESSENCE liver trial, mapped EQ-5D utility rose 0.03 points against placebo at week 72, from a baseline around 0.78. - Those utilities were not measured — they were derived from SF-36 answers through a published mapping algorithm. - In obesity-related heart failure the effect was far larger and confined to the frail: 11.0 points on the KCCQ in the most frail, 3.7 in the more frail, −1.5 in the nonfrail. - The certainty grades fall as the outcome moves from the scale to the person. Health utility is the number that turns a clinical result into a reimbursement decision, and quality of life is the outcome most often claimed and least often measured well. It sits on a scale where 1 is perfect health and 0 is death, and multiplying it by years lived produces the quality-adjusted life years that payers price. What the drug does to the scale is a separate and much better-measured question, covered in [the Cochrane review of semaglutide](https://thisglp.com/research/semaglutide-cochrane-review). ## What Cochrane graded, and how the grades fall The 2025 Cochrane review pooled fifteen randomized trials in 8,651 adults and graded every outcome separately, which is the useful part [\[1\]](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life#ref-1). Percentage body weight is high certainty, at a mean difference of −10.73% against placebo. Quality of life is moderate certainty, and the measured difference on the SF-36 physical functioning score is 2.12 points, 95% CI 0.95 to 3.28. Serious adverse events are graded very low. The grades fall away as the outcome moves from the scale to the person, and that ordering is the finding rather than any single estimate inside it. Two points on a hundred-point scale SF-36 physical functioning runs from 0 to 100, so 2.12 points is a real but modest movement and the interval reaches only 3.28 at its upper end. It is statistically present and small enough that a reader should ask what two points would feel like. Nothing in the review converts it into an experience, and no threshold for a noticeable change on that subscale is applied there. ## The number payers actually use In the ESSENCE trial, 800 participants with metabolic dysfunction-associated steatohepatitis and F2 or F3 fibrosis were assessed at week 72 [\[2\]](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life#ref-2). Mapped utility improved by 0.03 points against placebo, 95% CI 0.01 to 0.06, from a baseline of about 0.78. Participants completed the SF-36, and EQ-5D utilities were derived from those answers using a published algorithm rather than measured directly. That makes every figure an estimate of an estimate, and a directly administered EQ-5D would have produced a different number that nobody can size. The size deserves attention because of what happens to it downstream. Three hundredths of a point is small on a scale whose whole range is one, and cost-effectiveness models multiply it by years of treatment and by population size, so a 0.03 input can produce impressive-looking totals. The authors label the analysis exploratory and the p value nominal, which places it outside the trial’s confirmatory hierarchy, and the population it describes is narrower than it sounds — the staging requirement is set out in [the liver approval](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease). ## Where the effect is large, and who it is large in The exception is instructive. A prespecified pooled analysis of the two STEP-HFpEF trials sorted 1,145 participants with obesity-related heart failure by frailty, and weight loss was similar across every stratum at a P for interaction of 0.38 [\[3\]](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life#ref-3). Symptom score was not. In the most frail the mean difference against placebo was 11.0 points on the Kansas City Cardiomyopathy Questionnaire, 95% CI 8.1 to 13.8, where roughly five points is usually treated as clinically meaningful. In the more-frail group it was 3.7, and in the nonfrail group it was −1.5 with an interval running from −8.4 to 5.4. That pattern is the answer to the question most readers are really asking. The same weight loss produced very different amounts of felt improvement depending on how much room there was to improve, and someone with little functional limitation to begin with should not expect the trial figures to describe them. The fuller reading of that analysis is in [the frailty strata](https://thisglp.com/research/glp1-heart-failure-frailty), and the trial it re-cuts is covered in [the heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure). ## What none of it measures No trial in this literature asked whether people felt better in the ways they most often describe: energy, mood, confidence, the ability to get through a day. Those show up in questionnaires only indirectly, and the instruments were chosen to be comparable across medicine rather than sensitive to this drug. What was measured of daytime tiredness sits in [the fatigue evidence](https://thisglp.com/research/do-glp1-drugs-make-you-tired), and it moved a tenth of the distance a person can feel. So the honest summary is three-part. Quality of life improves, the improvement is small in general populations and large in people with a great deal of functional limitation, and the instrument doing the measuring was not built for this question. A reader weighing what the drug is worth to them personally is better served by that structure than by any of the three headline numbers on its own. ## Frequently asked Do GLP-1 drugs improve quality of life? Yes, by a small amount in general populations. Cochrane graded the evidence moderate certainty and found SF-36 physical functioning improving by 2.12 points against placebo, 95% CI 0.95 to 3.28, on a 100-point scale. How large is the effect in heart failure? Much larger, and concentrated in the frail. The most frail participants gained 11.0 points on the KCCQ against placebo, 95% CI 8.1 to 13.8, while the nonfrail group showed −1.5 with an interval spanning zero. What is a quality-adjusted life year built from? A health utility between 0 and 1, multiplied by years lived. In the ESSENCE liver trial that utility rose 0.03 points, and it was mapped from SF-36 answers rather than measured directly. Was fatigue or energy measured? Not as an endpoint. The instruments used were general health questionnaires chosen to be comparable across medicine, not built to be sensitive to this drug. ## Sources 1. \[1\] Bracchiglione J, et al. (2025). Semaglutide for adults living with obesity Cochrane Database of Systematic Reviews. [PMID 41161683](https://pubmed.ncbi.nlm.nih.gov/41161683/) 2. \[2\] Augusto M, Bauer R, Clancy S, Poulsen AS, Tefos F, Long M (2026). EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE JHEP Reports. [PMID 42580587](https://pubmed.ncbi.nlm.nih.gov/42580587/) 3. \[3\] Pandey A, et al. (2025). Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program JACC: Heart Failure. [PMID 40956259](https://pubmed.ncbi.nlm.nih.gov/40956259/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Make You Tired? Daytime Sleepiness Improved by 0.20 Points Do GLP-1 drugs make you tired? No trial measured fatigue | daytime sleepiness improved 0.20 Epworth points, while ferritin ran 26% to 30% below a comparison group. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-make-you-tired Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Make You Tired? Daytime Sleepiness Improved by 0.20 Points No randomized trial of this drug class reported fatigue as an endpoint, and the nearest measured proxy moved a tenth of the distance a person can feel. The mechanisms that would explain feeling tired were measured, but never as tiredness. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Daytime sleepiness, Epworth points improved · measured effect · 0.20 points · noticeable · 2 points · 95% CI 0.14 to 0.26 — precisely measured, and invisible · Breathing events fell 15.28 an hour in the same analysis. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No trial of this drug class has measured fatigue as an endpoint, so the honest answer is assembled from adjacent measurements rather than read off a result. The closest direct one is daytime sleepiness, pooled across fifteen studies and 1,877 participants with sleep apnea, where the Epworth score improved by 0.20 points with a 95% confidence interval from 0.14 to 0.26 [\[1\]](https://thisglp.com/research/do-glp1-drugs-make-you-tired#ref-1). Two points is the smallest change on that scale anybody notices, so the measured effect is a tenth of the threshold of perception, and it runs toward less sleepiness rather than more. What the same literature does show is depletion: ferritin 26% to 30% below a comparison group on a different diabetes drug, and more than 60% of users eating below the estimated requirement for iron [\[2\]](https://thisglp.com/research/do-glp1-drugs-make-you-tired#ref-2). ## Key takeaways - No randomized trial of a GLP-1 drug has reported fatigue, tiredness or energy as a named endpoint. - Daytime sleepiness, the nearest measured proxy, improved by 0.20 Epworth points (95% CI 0.14 to 0.26) against a 2-point threshold for a noticeable change. - Ferritin ran 26% to 30% lower than in a comparison group on a different diabetes drug, and over 60% of users ate below the estimated iron requirement. - Resting energy expenditure fell further than body composition alone predicts — in the treated group and in the lifestyle-only group equally. - Skeletal muscle mass fell from 29.9 kg to 28.7 kg over twelve months while handgrip strength was preserved. Tiredness is one of the commonest things people report on these drugs and one of the least studied, which is an uncomfortable combination. The trials count nausea, vomiting, diarrhea and constipation, and the time course of those is set out in [the nausea timeline](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). Energy was not on the list. ## The one scale that touches it The Epworth Sleepiness Scale asks how likely someone is to doze off in eight ordinary situations, and it is the only instrument in this literature that measures anything close to how tired a person feels. A network meta-analysis of fifteen studies and 1,877 participants with moderate to severe obstructive sleep apnea pooled it, and GLP-1 drugs improved the score by 0.20 points against placebo [\[1\]](https://thisglp.com/research/do-glp1-drugs-make-you-tired#ref-1). In the same analysis, breathing events fell by 15.28 an hour, 95% CI 8.35 to 22.22, which is a large effect on the thing a machine counts. Significant, and a tenth of noticeable The minimal clinically important difference on the Epworth scale is two points — the smallest change patients said they had to feel before they would call it better. A measured improvement of 0.20 points is a tenth of that, and the interval is tight enough to say the true effect is also about a tenth of it. The authors say so themselves, in the abstract. Significance answers whether an effect exists; a minimal clinically important difference answers whether anybody could tell. The subgroup analyses behind the sleep apnea approval point the same way. Reductions in the apnea-hypopnea index appeared in every subgroup examined — by age from 27.7 to 34.1 events per hour, by body mass index from 25.2 to 34.4, by neck circumference from 23.9 to 30.8 [\[3\]](https://thisglp.com/research/do-glp1-drugs-make-you-tired#ref-3). Those analyses are descriptive, with no interaction tests and no subgroup confidence intervals reported, and the full reading is in [the subgroup post hoc](https://thisglp.com/research/apnea-improved-across-every-subgroup). For somebody whose tiredness comes from untreated apnea, this is the mechanism by which a GLP-1 would make them less tired rather than more. ## The mechanisms that would push the other way Three findings in this literature are consistent with feeling worse rather than better, and none of them was collected as a fatigue measurement. The first is iron. A narrative review covering six studies and 480,825 adults found ferritin running 26% to 30% below a comparison group taking an SGLT2 inhibitor, and more than 60% of users eating below the estimated requirement for iron and for calcium [\[2\]](https://thisglp.com/research/do-glp1-drugs-make-you-tired#ref-2). Low iron stores are among the most ordinary causes of tiredness there is, and the full nutritional picture is in [the micronutrient evidence](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1). The second is thiamine, at the severe end of the same mechanism, where prolonged vomiting and rapid weight loss have preceded every published case of Wernicke’s encephalopathy in this setting. Fatigue and confusion are early features, and the staging of it is in [the thiamine cases](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency). Six published cases cannot produce a rate, and nothing here says this is common. The third is energy expenditure itself. In 83 adults followed for twelve months at one obesity unit, skeletal muscle mass fell from 29.9 kg to 28.7 kg and fat-free mass from 53.8 kg to 52.7 kg, both at p < 0.001 [\[4\]](https://thisglp.com/research/do-glp1-drugs-make-you-tired#ref-4). Handgrip strength was preserved, in the treated group and in the lifestyle-only group alike. Resting energy expenditure fell further than the change in body composition predicts, and it did so equally in both groups, which makes it a feature of losing weight rather than of the drug. ## What to do with an answer this thin Someone who feels tired on one of these drugs is not contradicted by the evidence, because the evidence never asked. The measurable causes worth ruling out are the ones a blood test settles: iron and ferritin, vitamin B12, vitamin D, and thyroid function. A reader losing lean mass quickly has a second, separate question to ask, and it is laid out in [the muscle-loss evidence](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). The one thing this page will not do is convert an absence of data into a reassurance. A drug that reduces food intake by roughly 271 calories at a measured meal is reducing the intake of everything, as [the intake measurements](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1) show. The trials that would have detected a fatigue signal were not designed to collect one. ## Frequently asked Do GLP-1 drugs make you tired? No randomized trial reported fatigue as an endpoint. The nearest measured proxy, daytime sleepiness, improved by 0.20 Epworth points against a 2-point threshold for a change a person can notice. What would explain feeling tired on one? Iron depletion is the most ordinary candidate: ferritin ran 26% to 30% lower than in a comparison group, and over 60% of users ate below the estimated iron requirement. Lost lean mass and a fall in resting energy expenditure are the others. Does a GLP-1 improve daytime sleepiness? Slightly, and by less than anyone can feel. The pooled improvement was 0.20 Epworth points, 95% CI 0.14 to 0.26, where two points is the smallest noticeable change. What should be checked? The measurable causes a blood test settles — iron and ferritin, vitamin B12, vitamin D and thyroid function. Prolonged vomiting with rapid weight loss is the pattern that preceded every published thiamine case. ## Sources 1. \[1\] Zheng J, et al. (2026). Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysis Frontiers in Endocrinology. [PMID 42676363](https://pubmed.ncbi.nlm.nih.gov/42676363/) 2. \[2\] Urbina J, et al. (2026). Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review Clinical Obesity. [PMID 41549912](https://pubmed.ncbi.nlm.nih.gov/41549912/) 3. \[3\] Falcon B, Xie CC, Redline S, Grunstein R, et al. (2026). Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA Journal of Clinical Sleep Medicine. [PMID 42675225](https://pubmed.ncbi.nlm.nih.gov/42675225/) 4. \[4\] Filippi-Arriaga F, et al. (2026). Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide Obesity Facts. [PMID 42640861](https://pubmed.ncbi.nlm.nih.gov/42640861/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Prevent Contrast Kidney Injury? 8.7% Against 25.7% | This GLP Do GLP-1 drugs prevent contrast-induced kidney injury? In 336 adults having coronary angiography it was 8.7% against 25.7%, odds ratio 0.290 | creatinine did not differ. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Prevent Contrast Kidney Injury? 8.7% Against 25.7% One retrospective cohort found a third the rate of kidney injury after coronary angiography. The outcome is defined by a creatinine rise, and creatinine itself came out at p = 0.084. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Two readings of the same kidneys, 48 to 72 hours after contrast · The event, defined as a creatinine rise · 8.7% on a GLP-1 · 25.7% not · odds ratio 0.290, 95% CI 0.119 to 0.708 · The creatinine the definition rests on · 1.02 mg/dL against 1.17 — p = 0.084, not significant. · eGFR, which is calculated from creatinine, did differ: · 67.1 against 58.0 mL/min/1.73 m², p < 0.001. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). In one retrospective cohort, yes. Contrast-induced kidney injury occurred in 8.7% of GLP-1 users against 25.7% of non-users [\[1\]](https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury#ref-1). The adjusted odds ratio was 0.290, 95% CI 0.119 to 0.708. That outcome is defined by a creatinine rise. Creatinine itself did not differ significantly, at p = 0.084. Nobody was randomized, and the cohort is 336 people at one center. ## Key takeaways - 336 adults with type 2 diabetes undergoing coronary angiography or PCI at one center. - 149 were on a GLP-1 drug and 187 were not. Nobody was randomized or matched. - Contrast-induced kidney injury occurred in 8.7% against 25.7%, odds ratio 0.290, 95% CI 0.119 to 0.708. - That outcome is defined by a creatinine rise, and creatinine itself did not differ significantly (p = 0.084). - eGFR, which is calculated from creatinine, did differ: 67.1 against 58.0. A kidney injury here is not something anybody felt. It is a definition: creatinine up by at least 0.5 mg/dL, or by at least a quarter, within seventy-two hours. Hold that next to the fact that creatinine did not differ significantly between the two groups. The randomized kidney evidence for this drug class is a separate body of work, summarized in [the FLOW trial](https://thisglp.com/research/semaglutide-and-kidney-disease). ## Both numbers, side by side The event rate was 8.7% among GLP-1 users and 25.7% among non-users. Adjusted, the odds ratio came to 0.290 with an interval of 0.119 to 0.708. At the same timepoint, mean creatinine was 1.02 mg/dL in users and 1.17 in non-users, p = 0.084. Those standard deviations are wide, at 0.73 and 1.57. A difference in group means can be absent while a difference in how many people cross a threshold is large. That is not a contradiction and it is not nothing either. A threshold outcome and a mean are different questions about the same measurement. A paper reporting both has told you something a paper reporting only the first would not. That is how [a ratio and an absolute risk](https://thisglp.com/research/bigger-relative-smaller-absolute) describe one finding in two sizes. eGFR is calculated, not measured Estimated GFR is derived from creatinine, age and sex. It came out 67.1 against 58.0 with p below 0.001, while the creatinine it is built from sat at p = 0.084. Some of that is baseline: if the groups differed in kidney function before the procedure, the calculation carries the difference forward. The rest is what an equation built on muscle metabolism does when the people being compared differ in body composition, which on these drugs they reliably do. That last point is not theoretical. A propensity-matched study of semaglutide in polycystic kidney disease used eGFR as its outcome [\[2\]](https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury#ref-2). The same dependency applies wherever a drug changes lean mass. The fuller reading of that trap is in [the eGFR and muscle problem](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease). ## What the design can carry 336 people at one center, looked at afterwards. Users were compared with non-users by regression rather than by matching. Nobody chose who got what. An odds ratio of 0.29 is a large effect. Large effects from small retrospective cohorts are the ones that most often shrink when somebody randomizes. The usual reason is that the two groups differed in ways nobody recorded. [A hazard ratio its own authors distrust](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own) shows that at the extreme. ## What the randomized evidence says about kidneys The strongest kidney result for this drug class comes from a trial that stopped early. FLOW randomized people with type 2 diabetes and chronic kidney disease to semaglutide or placebo [\[3\]](https://thisglp.com/research/do-glp1-drugs-prevent-contrast-kidney-injury#ref-3). It was halted for efficacy on a composite of kidney failure, sustained eGFR decline and death. That is chronic disease progression over years, not a creatinine spike in seventy-two hours. The two questions are related and they are not the same. Nothing in the chronic evidence predicts what happens around a scheduled dose of contrast dye. Nothing in a 336-person cohort establishes it either. ## Why it is still worth reading Contrast injury is common, it is expensive, and it happens on a schedule somebody controls. A drug patients are already taking that reduced it would matter. There is a plausible route: better volume status, less inflammation, improved endothelial function. So this is a hypothesis with a mechanism, measured in a way that leaves room for doubt. The useful next step is a trial that randomizes around a scheduled procedure. Nothing here is a reason to start, stop or time a dose around an angiogram. Tell the team doing the procedure what you take and let them decide. ## Frequently asked Do GLP-1 drugs prevent contrast-induced kidney injury? One retrospective cohort of 336 adults found 8.7% against 25.7%, an adjusted odds ratio of 0.290. Nobody was randomized, and the creatinine measurement the outcome is built from did not differ significantly. Why does the creatinine result matter? Contrast-induced kidney injury is defined as a creatinine rise of at least 0.5 mg/dL or 25% within 72 hours. Mean creatinine came out at p = 0.084, so the threshold count moved while the underlying measurement did not separate. Should a dose be timed around an angiogram? Nothing here supports starting, stopping or timing a dose around a procedure. Tell the team doing the procedure what you take. What do the randomized kidney trials show? FLOW randomized people with type 2 diabetes and chronic kidney disease to semaglutide or placebo and was stopped early for efficacy on a composite of kidney failure, sustained eGFR decline and death. That is disease progression over years, not a creatinine spike in 72 hours. ## Sources 1. \[1\] Oksen D, et al. (2026). Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventions Frontiers in Endocrinology. [PMID 42723898](https://pubmed.ncbi.nlm.nih.gov/42723898/) 2. \[2\] Chen TP, et al. (2026). Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study Science Progress. [PMID 42648283](https://pubmed.ncbi.nlm.nih.gov/42648283/) 3. \[3\] Perkovic V, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England Journal of Medicine. [PMID 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Prevent Diabetic Foot Ulcers? The Database Cannot Say | This GLP A FAERS analysis put diabetic foot at 6.38 per 1,000 GLP-1 reports against 11.31 per 1,000 elsewhere, a ratio of 0.56 | a share of reports, not a rate in patients. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-prevent-diabetic-foot-ulcers Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Prevent Diabetic Foot Ulcers? The Database Cannot Say Diabetic foot took up half as much of the GLP-1 adverse event pile as of the comparison pile. That reads as protective until you notice what the method does. A reporting database can find harm appearing too often, and it can never find harm missing. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Share of each drug’s report pile, per 1,000 reports · GLP-1 drugs — 1,819 reports · 6.38 · other diabetes drugs — 17,206 · 11.31 · Reporting ratio 0.56 (0.54 to 0.59) · The method only runs one way · Above the expected share is a reason to investigate. · Below it has too many ordinary explanations to be a finding. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Disproportionality analysis finds problems reported more often than expected. It cannot find problems reported less often than they happen. - Diabetic foot appeared in 6.38 of every 1,000 GLP-1 reports against 11.31 per 1,000 for other diabetes drugs. - The reporting ratio is 0.56, 95% CI 0.54 to 0.59, and every individual drug pointed the same way. - A share can fall because a different symptom filled the pile — here, nausea from weight-loss users. - The authors call the evidence preliminary and ask for prospective validation. Nobody knows, and the study usually cited for it cannot say. Diabetic foot complications made up 6.38 of every 1,000 GLP-1 adverse event reports against 11.31 per 1,000 for other diabetes drugs, a ratio of 0.56 [\[1\]](https://thisglp.com/research/do-glp1-drugs-prevent-diabetic-foot-ulcers#ref-1). That is a share of a report pile, not a rate in patients. The question underneath is a good one, because people with diabetes lose toes and feet to ulcers that begin as small wounds. The trouble is that the instrument used here answers only whether harm appears more often than expected. It cannot be turned around and asked whether something appears less often than it should, which is the same asymmetry running under [the dose-error reports](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). ## What was measured The FDA’s adverse event database was queried for every report naming a GLP-1 drug between 2005 and 2024, and for every report naming one of the other diabetes drug classes. [\[1\]](https://thisglp.com/research/do-glp1-drugs-prevent-diabetic-foot-ulcers#ref-1) There were 1,819 of the former and 17,206 of the latter. Diabetic foot complications made up 6.38 per thousand of the GLP-1 pile. The comparison pile carried 11.31 per thousand. That gives a proportional reporting ratio of 0.56, with an interval from 0.54 to 0.59 narrow enough to look like certainty about something. Semaglutide came out at 0.45, dulaglutide at 0.49 and liraglutide at 0.30, and the pattern held across sensitivity analyses. The consistency is genuine. What it is consistent about is the part that needs care — and the mechanics of the database itself we have covered [in a separate piece](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). Why the share fell Every one of these figures has reports in the denominator rather than people. Nobody was enrolled, nobody was followed, and nothing in the calculation knows how many patients took either drug. So a term’s share can fall for two completely different reasons: because fewer people suffered it, or because the pile filled up with something else. GLP-1 report piles are dominated by nausea, vomiting and injection-site complaints. A great many of those come from people taking the drug for weight rather than diabetes, and they were never at risk of a diabetic foot ulcer in the first place. Add enough of those reports and every other term in the pile shrinks as a proportion, with nobody’s foot having improved at all. ## The direction the method runs A larger evidence map across several safety databases makes the same point from the other end [\[2\]](https://thisglp.com/research/do-glp1-drugs-prevent-diabetic-foot-ulcers#ref-2). What that kind of mapping surfaces is the terms reported unusually often — dosing errors, gastrointestinal events, [injection-site problems](https://thisglp.com/research/where-should-you-inject-ozempic) — because those are the only ones the arithmetic can find. Nothing in it is built to notice a complication that failed to turn up at all. Disproportionality analysis was designed to find signals: to notice when a drug’s reports contain a strange term far more often than the background does, so that somebody can go and investigate properly. Running above the expected share is a reason to look. Running below it is not a finding, because the things that suppress a share are so numerous and so ordinary that no ratio can separate them. This is the same asymmetry that makes [an absent result different from a negative one](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes), arriving through a different door. ## The genetic half The authors also ran a Mendelian randomization, using inherited variation in the GLP-1 receptor gene as a stand-in for the drug, and report that it broadly agreed with the database analysis. That is a genuinely independent instrument, which is worth more than another pass through the same reports. It also answers a different question. Small lifelong differences in a receptor are not eighteen months of a therapeutic dose in a fifty-year-old. A method that models a lifetime cannot tell you what happens after a year, much as [a model trained on one thing](https://thisglp.com/research/do-glp1-drugs-slow-aging) keeps getting read as evidence about another. ## What would settle it A cohort with feet in it. Count the people taking each drug, examine them, and record the ulcers — the trial evidence already exists for wound-adjacent outcomes in other conditions, so the design is not exotic. Until then, the honest summary is the one the authors themselves wrote: preliminary, requiring prospective validation. Weight loss and better glucose control ought to help a diabetic foot, so the hypothesis is reasonable on its face. Reasonable is not the same as demonstrated, and [a large database](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer) is not the same as a large study. ## Frequently asked Do GLP-1 drugs protect against diabetic foot ulcers? This analysis cannot answer that. It compares how large a share of each drug's adverse event reports mentioned diabetic foot, which depends on what else got reported alongside. What is a proportional reporting ratio? The share of one drug's reports naming a given problem, divided by that share for comparison drugs. Its denominator is reports rather than patients, so it measures reporting rather than risk. Why can it find harm but not safety? An unusually high share is a reason to investigate. A low share has too many ordinary explanations — chiefly that other symptoms crowded into the same pile — for any of them to be ruled out. Does the genetic analysis settle it? No. It uses inherited variation in the receptor as a proxy, which models a lifetime of small differences rather than a year or two of a therapeutic dose. ## Sources 1. \[1\] Zhang T, et al. (2026). Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization The International Journal of Lower Extremity Wounds. [PMID 42726083](https://pubmed.ncbi.nlm.nih.gov/42726083/) 2. \[2\] Ren L, et al. (2026). Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study Diabetes, Obesity and Metabolism. [PMID 42687799](https://pubmed.ncbi.nlm.nih.gov/42687799/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Prevent Heart Attacks and Strokes? One, Not Both | This GLP In 52,971 adults, MACE occurred in 2.9% on tirzepatide against 4.4% on sitagliptin at one year (HR 0.68, NNT 70), with stroke unchanged at HR 0.91. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Prevent Heart Attacks and Strokes? One, Not Both A 52,971-person cohort with a neutral active comparator and two negative control outcomes. Heart attacks fell; strokes did not. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Tirzepatide vs sitagliptin, hazard ratios at one year · 1.0 · MACE composite · heart attack · ischemic stroke · Stroke crosses 1.0. Two negative controls showed nothing. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A population-based cohort of 52,971 adults with type 2 diabetes and established cardiovascular disease compared tirzepatide initiators against sitagliptin, a cardiovascular-neutral comparator. - At one year, major adverse cardiovascular events occurred in 2.9% against 4.4% — a risk difference of -1.4% (95% CI -2.1 to -0.7), number needed to treat 70, hazard ratio 0.68 (95% CI 0.58 to 0.80). - Heart attack fell (HR 0.67, 95% CI 0.52 to 0.87) while ischemic stroke did not (HR 0.91, 95% CI 0.64 to 1.28, NNT 2500). - Two negative control outcomes showed no association, a check on residual confounding that most observational studies skip. Heart attacks, yes. Strokes, not in this cohort. Among 52,971 adults with type 2 diabetes and established cardiovascular disease, tirzepatide initiators had major adverse cardiovascular events in 2.9% against 4.4% on a cardiovascular-neutral comparator. That is a hazard ratio of 0.68 and a number needed to treat of 70. Split the composite and the two halves part company. Heart attack fell, at a hazard ratio of 0.67 (95% CI 0.52 to 0.87). Ischemic stroke did not, at 0.91 (95% CI 0.64 to 1.28), where the number needed to treat works out at 2,500. A composite that moves is not every component moving, and this one names which. A randomized trial reached a similar place from the other direction. Tirzepatide against dulaglutide in 13,299 people met noninferiority and missed superiority, at P=0.09 [\[2\]](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes#ref-2). Matching an older drug is not beating it. The study here also did something most observational work skips: it ran two negative control outcomes, and neither showed an association. That is a check on residual confounding rather than an assumption that none exists. Most observational drug comparisons on this site fail on the same problem: people who get the newer drug differ from people who do not, in ways no adjustment fully captures. This one built three defenses against that, and it is worth reading for the method as much as the result [\[1\]](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes#ref-1). It is the standard this site applied in [the study that checked its own work](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots). First, the comparator. Tirzepatide initiators, 35,353 of them, were not compared against untreated people. The comparator was sitagliptin initiators (17,618) — a drug chosen because its cardiovascular effect is neutral, making it a proxy for placebo among people who are being actively treated. Second, propensity score overlap weighting balanced baseline characteristics. Third, the authors tested two negative control outcomes, lumbar radiculopathy and abdominal hernia, which no drug in this class should affect. Neither showed an association. On the result, major adverse cardiovascular events occurred in 2.9% of the tirzepatide group and 4.4% of the sitagliptin group at one year. That is a risk difference of 1.4 percentage points, a number needed to treat of 70, and a hazard ratio of 0.68. Heart attack drove it, at a hazard ratio of 0.67 and an NNT of 130. That is an absolute gain of the kind this site keeps separating from relative ones in [sixteen percent lower, six hundredths of a point](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy). Stroke did not move, and the composite contains death Ischemic stroke came in at a hazard ratio of 0.91 with an interval from 0.64 to 1.28 and a number needed to treat of 2,500 — which is the paper’s way of saying no meaningful difference. And the MACE composite here is heart attack, stroke and all-cause mortality together. A composite carrying deaths from any cause is a different thing from a composite of cardiovascular events, and this site keeps that distinction in [the mortality number that could not be right](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension). Two findings sit outside the cardiovascular story and deserve reporting without explanation. Infections requiring hospital admission were lower on tirzepatide (HR 0.64, 95% CI 0.55 to 0.75, NNT 48), as was infection-related mortality (HR 0.40, 95% CI 0.26 to 0.61). All-cause mortality came in at 0.55 (95% CI 0.42 to 0.72). Those are large and this site will not speculate about why they appear. The limits are ordinary and real. Follow-up ran one year and was censored at discontinuation or switching, so this measures the first year of continuous use rather than a durable effect. And claims data records prescriptions and diagnoses, not people. What makes the study unusual is what its authors did next. They asked their own data to prove it was not lying — the practice this site wants more of, and rarely gets, as in [the result extrapolated to everyone](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent). ## Frequently asked How much did tirzepatide reduce cardiovascular events? Major adverse cardiovascular events occurred in 2.9% against 4.4% at one year, a hazard ratio of 0.68 with a number needed to treat of 70. Did it prevent strokes? Not measurably. Ischemic stroke came in at a hazard ratio of 0.91 with a confidence interval from 0.64 to 1.28 and a number needed to treat of 2,500. Why compare against sitagliptin rather than no drug? Because sitagliptin is cardiovascular-neutral, so it acts as a placebo proxy among people who are being actively treated, removing much of the difference between treated and untreated populations. ## Sources 1. \[1\] Krüger N, Schneeweiss S, Wang SV (2026). Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study The BMJ. [PMID 42556854](https://pubmed.ncbi.nlm.nih.gov/42556854/) 2. \[2\] Nicholls SJ, et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine. [PMID 41406444](https://pubmed.ncbi.nlm.nih.gov/41406444/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Prevent Stroke? The Composite Moves, Stroke Alone Is Thin SELECT found composite cardiovascular events at 6.5% vs 8.0% (HR 0.80). Stroke measured alone rests on one underpowered trial and a cohort where it did not move. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-prevent-stroke Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Prevent Stroke? The Composite Moves, Stroke Alone Is Thin The headline cardiovascular results are composites that pool stroke with heart attack and cardiovascular death. Measured on its own, stroke has one small trial its own authors discount. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Composite outcomes, then stroke on its own · 1.0 · MACE, SELECT · MACE, 11 trials · stroke recurrence · ischemic stroke · A composite moving is not stroke moving. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - The large trials report MACE — a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke. The composite moves. - SELECT found 6.5% against 8.0% in 17,604 people (HR 0.80, 95% CI 0.72 to 0.90). A meta-analysis of 11 trials and 85,373 people found MACE at HR 0.87. - Stroke measured on its own is far thinner. One dedicated trial found recurrence at 7.9% against 13.8%, and its authors call it underpowered. - A large matched cohort found ischemic stroke unchanged at HR 0.91 (95% CI 0.64 to 1.28) while heart attack fell. The honest answer depends on a distinction most summaries skip. The headline cardiovascular results are composites, and a composite moving is not the same as stroke moving. This site reads effect estimates the same way in [sixteen percent lower, six hundredths of a point](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy). ## What the big trials actually counted SELECT randomized 17,604 people with cardiovascular disease and a BMI of 27 or more, without diabetes, to semaglutide 2.4 mg or placebo [\[1\]](https://thisglp.com/research/do-glp1-drugs-prevent-stroke#ref-1). A primary event occurred in 6.5% of the semaglutide group against 8.0% on placebo, a hazard ratio of 0.80 with an interval from 0.72 to 0.90. That primary endpoint is death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke, counted as time to first event. Stroke is one of three components, and the trial was not designed to size stroke alone. A meta-analysis of 11 trials covering 85,373 participants reports the same shape [\[2\]](https://thisglp.com/research/do-glp1-drugs-prevent-stroke#ref-2). In the 67,769 participants with type 2 diabetes, GLP-1 drugs reduced MACE by 13% (HR 0.87, 95% CI 0.81 to 0.93). All-cause death fell 12% (HR 0.88, 0.83 to 0.93). The kidney half of that analysis sits alongside [the growing dialysis evidence base](https://thisglp.com/research/dialysis-the-evidence-base-just-grew). A composite can move on one component Three outcomes are pooled into MACE, and a drug that strongly reduces one of them will move the composite even if the others barely shift. This site has seen exactly that: a matched cohort of 52,971 adults found heart attack fell (HR 0.67) while ischemic stroke did not (HR 0.91, 95% CI 0.64 to 1.28, number needed to treat 2,500) — set out in [the cohort that tested its own bias](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes). Read the components, not the composite. ## The one trial built around stroke LAMP randomized 636 patients with type 2 diabetes who had a minor ischemic stroke or a high-risk transient ischemic attack, within 24 hours of symptom onset [\[3\]](https://thisglp.com/research/do-glp1-drugs-prevent-stroke#ref-3). One arm received liraglutide for 90 days on top of guideline care; the other received guideline care alone. Hazard ratio 0.56 (95% CI 0.34 to 0.91); odds ratio 1.95 (1.28 to 3.00). | Outcome at 90 days | Liraglutide + standard care | Standard care alone | | --- | --- | --- | | Stroke recurrence | 25 of 316 (7.9%) | 44 of 318 (13.8%) | | Excellent functional outcome | 87.3% | 77.8% | Hazard ratio 0.56 (95% CI 0.34 to 0.91); odds ratio 1.95 (1.28 to 3.00). LAMP, 27 hospitals in China Both outcomes favored liraglutide. The authors then state that, given the underpowered nature of the study, the findings should be interpreted with caution — a caveat this site usually has to supply itself. Underpowered means the trial enrolled fewer patients than needed to reliably detect the effect it tested. A positive result from such a trial is more likely to overstate the effect, and more likely to shrink on replication. Two further limits. The design was open-label with blinded endpoint assessment, so patients and treating doctors knew the assignment while outcome assessors did not. And participants were Chinese, which the authors note when framing their conclusion. ## Where that leaves the question Composite cardiovascular outcomes improve, consistently, across large trials and a large meta-analysis. Stroke measured on its own has one small dedicated trial that its own authors discount, and one large cohort in which it did not move. So the defensible statement is that these drugs reduce cardiovascular events overall, and that the stroke-specific contribution is not established. That is a narrower claim than most pages make, and it is the one the evidence supports. The distinction between preventing something and treating it is set out in [why preventing something is not treating it](https://thisglp.com/research/preventing-it-is-not-treating-it). Nothing here is a reason to start or stop a medication after a stroke. That decision involves blood pressure, anticoagulation, the cause of the stroke and much else, and it belongs to the clinicians managing it. ## Frequently asked Do GLP-1 drugs prevent stroke? They reduce composite cardiovascular events, which include stroke alongside heart attack and cardiovascular death. Stroke measured on its own is not established: one dedicated trial is underpowered by its authors' own account, and a large cohort found ischemic stroke unchanged. What did SELECT find? A primary event in 6.5% on semaglutide against 8.0% on placebo across 17,604 people, a hazard ratio of 0.80. That endpoint pools cardiovascular death, non-fatal heart attack and non-fatal stroke. What is MACE? A composite outcome — usually cardiovascular death, non-fatal myocardial infarction and non-fatal stroke counted together. A drug that strongly reduces one component moves the composite even if the others barely shift. Does liraglutide help after a minor stroke? In the LAMP trial, recurrence was 7.9% against 13.8% over 90 days. The authors describe the trial as underpowered and advise caution, and it was open-label with blinded endpoint assessment. ## Sources 1. \[1\] Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes The New England Journal of Medicine. [PMID 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/) 2. \[2\] Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT (2025). Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials The Lancet Diabetes & Endocrinology. [PMID 39608381](https://pubmed.ncbi.nlm.nih.gov/39608381/) 3. \[3\] Zhu H, Yang B, Lu L, Li Y, Sui R, Liu K (2026). Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial JAMA Internal Medicine. [PMID 41182740](https://pubmed.ncbi.nlm.nih.gov/41182740/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Protect Against Dementia? A Predictor Moved | This GLP A post hoc SELECT analysis found semaglutide reduced increases in a proteomic dementia risk score, odds ratio 0.74 at five years and 0.91 at twenty. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-protect-against-dementia Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Protect Against Dementia? A Predictor Moved Semaglutide slowed the rise of a 25-protein dementia risk score in SELECT participants. Nobody in the analysis developed dementia, or avoided it. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Effect on a predicted dementia score — not on dementia · 1.0 · 5-year signature · 26.0% lower predicted rate · 20-year signature · 8.8% lower · The score rose in both arms. It rose less on the drug. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A post hoc analysis of the SELECT trial in 2,970 adults aged 65 and over, semaglutide 2.4 mg against placebo. - The outcome is a validated 25-protein blood score that predicts dementia at 5 and 20 years. - Predicted risk rose in both groups. It rose less on semaglutide. - On the 5-year signature, odds ratio 0.74, 95% CI 0.65 to 0.85 — a 26.0% lower predicted event rate. - On the 20-year signature, odds ratio 0.91, 95% CI 0.88 to 0.94 — 8.8% lower. Nobody has measured that, and what has been measured is a predictor of it — a different thing, and worth keeping separate from the question people are actually asking. In a post hoc analysis of SELECT covering 2,970 adults aged 65 and over, a validated 25-protein blood score that forecasts dementia rose in both arms. It rose less on semaglutide, at an odds ratio of 0.74 on the five-year signature and 0.91 on the twenty-year one. A predictor moving is not the same as a disease not happening, and the gap between those two sentences is the whole of this page. One study that looked at cognitive impairment itself found 33 cases on oral semaglutide against 73 on a comparator in 246 elderly outpatients, a reduction its regression put at 77% with no confidence interval published[\[2\]](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia#ref-2). A larger study of the same drug against another DPP-4 inhibitor found nothing, which is why [those two results have to be read together](https://thisglp.com/research/oral-semaglutide-cognitive-impairment). Nobody in this analysis developed dementia, and nobody avoided it. What was measured is a blood score built to predict it, and the distance between moving a predictor and moving an outcome is the same distance [a biological clock](https://thisglp.com/research/do-glp1-drugs-slow-aging) sits at from a lifespan. ## What was measured Serum samples taken at baseline and at week 104 from 2,970 SELECT participants aged 65 and over with overweight or obesity and cardiovascular disease but no diabetes. [\[1\]](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia#ref-1) Those samples were run through a validated test that reads 25 proteins and returns a predicted risk of all-cause dementia over five and twenty years. This is a post hoc analysis. SELECT was designed to test whether semaglutide prevents cardiovascular events — a composite endpoint with [its own reading problems](https://thisglp.com/research/tirzepatide-heart-failure-composite) — not to answer anything about cognition, and the proteomic question was asked of its samples afterwards. ## Rate, not level Predicted dementia risk went up in both arms over the two years, which is what happens to a risk score as a cohort of 65-year-olds gets older. It went up less on semaglutide: 2.5-fold less on the five-year signature and 1.67-fold less on the twenty-year one. That is the paper’s own framing — reduced increases — and it is worth keeping, because “reduced dementia risk” describes something that did not happen here in two separate ways. The two horizons do not agree The five-year score moved substantially, odds ratio 0.74 with an interval of 0.65 to 0.85. The twenty-year score moved much less, 0.91 with an interval of 0.88 to 0.94 — a tight interval around a small effect. A signature built to read further ahead responded least. That is either a real statement about a short-term effect on a long-term process, or a sign that a two-year window moves the near-term proteins more readily than the ones carrying the distant signal. The analysis cannot tell you which. ## What a validated score validates That people with higher scores develop dementia more often than people with lower ones. That is what validation of a predictive test establishes, and it is a fact about the population the test was built on. It does not establish that lowering somebody’s score lowers their risk. A marker can track a disease faithfully and still be a passenger rather than a driver. In which case moving it changes the reading and not the future — the reason [the markers easiest to move](https://thisglp.com/research/glp1-pcos-insulin-resistance) are usually the ones proving least. ## Cognitive signs in a clinic record A US health-record cohort asked a closer question in a different group: 13,007 adults with a psychiatric diagnosis, 1,261 of whom started semaglutide [\[3\]](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia#ref-3). The outcome was a 0-to-100 score built from what clinicians wrote down in routine cognitive assessments of memory, attention and orientation, over the 12 months after a diabetes drug was started. Scores averaged 11.14 on semaglutide against 14.91 with no treatment, 13.46 on glipizide and 13.69 on empagliflozin. Against sitagliptin, at 12.52, the gap was not significant. Effect sizes were similar across diagnoses but consistently significant only in major depression. The authors say randomized trials are needed to show the drug caused it, which is the same limit [a score made of clinical notes](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs) carries on its own. ## What would settle it A trial with dementia as its endpoint, in people followed long enough to get it. That is expensive, slow, and the reason proteomic signatures are attractive in the first place. Until one exists, this is a promising result about a score. The trial it came from was asking about hearts, reported honestly by authors who say their drug slowed the progression of a signature rather than of a disease — which is more care than [most conclusions take](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease). ## Frequently asked Does semaglutide reduce dementia risk? This analysis measured a blood score that predicts dementia, not dementia itself. Nobody in it developed or avoided the disease. What does 'reduced increases' mean? Predicted risk rose in both groups over two years, as it does with age. It rose less on semaglutide — 2.5-fold less on the five-year signature. Why do the five and twenty-year results differ? The five-year score moved substantially, odds ratio 0.74, and the twenty-year one much less, 0.91. A signature built to read further ahead responded least, and the analysis cannot explain why. Does semaglutide help memory in people with depression or other psychiatric conditions? In a US health-record cohort of 13,007 adults with a psychiatric diagnosis, clinician-recorded cognitive signs scored 11.14 on semaglutide against 14.91 with no treatment. The association was consistently significant only in major depression, and it was not a randomized trial. Was the trial designed for this? No. SELECT tested whether semaglutide prevents cardiovascular events. This question was asked of its stored samples afterwards. ## Sources 1. \[1\] Jiménez-Mausbach M, et al. (2026). Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial Alzheimer's & Dementia. [PMID 42571323](https://pubmed.ncbi.nlm.nih.gov/42571323/) 2. \[2\] Armentaro G, et al. (2026). Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity Internal and Emergency Medicine. [PMID 42622752](https://pubmed.ncbi.nlm.nih.gov/42622752/) 3. \[3\] De Giorgi R, et al. (2026). Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA BMJ Mental Health. [PMID 42624612](https://pubmed.ncbi.nlm.nih.gov/42624612/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Raise Testosterone? Not in the Trials That Measured It | This GLP Do GLP-1 drugs raise testosterone? A 23-trial network in 1,899 men, a 25-man randomized head-to-head, and a matched cohort on erectile function. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-raise-testosterone Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Raise Testosterone? Not in the Trials That Measured It Five strategies for obesity-related low testosterone across 23 trials, and the significant increases belong to the other four. Weight loss still helps the condition. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 What each strategy actually moved · TRT + structured lifestyle · testosterone ↑, erectile function ↑, lean mass ↑ · endogenous restoration · testosterone ↑, lean mass ↑ · testosterone replacement · testosterone ↑, waist ↓, lean mass ↑, hematocrit ↑ · every intervention · HbA1c — no significant change · 23 trials, 1,899 men — and no single winner **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Weight loss does raise testosterone, and the trial evidence still does not put a GLP-1 among the strategies shown to do it. A network meta-analysis of 23 randomized trials in 1,899 men with obesity-related low testosterone tested five strategies, and GLP-1-based therapy was one of them [\[1\]](https://thisglp.com/research/do-glp1-drugs-raise-testosterone#ref-1). The increases it reports as significant belong to testosterone replacement with lifestyle therapy at MD 7.19, endogenous restoration at 4.14 and replacement alone at 2.53. The only randomized head-to-head enrolled 25 men for 24 weeks, and total testosterone rose in both arms [\[2\]](https://thisglp.com/research/do-glp1-drugs-raise-testosterone#ref-2). Nobody selling these drugs online measures the hormone, which is the gap running through [the sexual-function evidence](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive) as well. ## Key takeaways - A network meta-analysis pooled 23 randomized trials covering 1,899 men with obesity-related low testosterone. - Testosterone replacement plus structured lifestyle therapy raised total testosterone most, MD 7.19, 95% CI 1.18 to 13.21. - It was also the only strategy that significantly improved erectile function scores, MD 1.29, 95% CI 0.07 to 2.50. - GLP-1-based therapy was one of the five interventions and does not appear among the significant results the abstract reports. - In the one randomized comparison, 25 men took semaglutide or testosterone for 24 weeks and testosterone rose in both arms. - A matched cohort found tirzepatide associated with fewer erectile dysfunction diagnoses, risk ratio 0.67 against injectable semaglutide. - No intervention significantly reduced glycated hemoglobin, and the authors decline to name a best treatment. ## What was compared Randomized trials of structured lifestyle therapy, testosterone replacement, endogenous testosterone restoration, GLP-1-based therapy, or testosterone replacement combined with structured lifestyle therapy, searched to April 2026. [\[1\]](https://thisglp.com/research/do-glp1-drugs-raise-testosterone#ref-1) Twenty-three trials and 1,899 participants went into a frequentist network, with risk of bias assessed by RoB 2 and confidence in each comparison graded by CINeMA. Against usual care or placebo, testosterone replacement plus lifestyle therapy produced the largest increase in total testosterone, MD 7.19, 95% CI 1.18 to 13.21. Endogenous restoration followed at 4.14, 95% CI 0.74 to 7.54, and testosterone replacement alone at 2.53, 95% CI 0.26 to 4.81. Where the GLP-1 arm is GLP-1-based therapy was one of the five interventions in this network. It does not appear among the results the abstract reports as significant, and the abstract gives no estimate for it either way. That is an absence from a reported list rather than a published null, and the two cannot be separated from the abstract alone. The distinction matters, because a strategy that was estimated and found wanting is not the same as one that was never summarized. ## The one randomized comparison, and why it flatters the drug Twenty-five men with type 2 diabetes, obesity and functional hypogonadism were randomized to semaglutide 1 mg weekly or intramuscular testosterone undecanoate for 24 weeks, open-label [\[2\]](https://thisglp.com/research/do-glp1-drugs-raise-testosterone#ref-2). Total testosterone rose in both arms, and both improved on the Aging Symptoms scale, while only the testosterone arm improved significantly on erectile function. The semaglutide arm beat a comparator that suppresses sperm production, which is a lower bar than the headline suggests, and the full reading of that trial sits in [the fertility evidence](https://thisglp.com/research/do-glp1-drugs-affect-fertility). ## The nearest thing to an outcome Testosterone is a blood test, and the symptom most men actually bring in is erectile function. A retrospective cohort in the TriNetX network compared men aged 18 to 70 with type 2 diabetes and no prior erectile dysfunction, in three propensity-matched pairings. Tirzepatide was associated with a lower risk of a diagnosis or a PDE-5 prescription [\[3\]](https://thisglp.com/research/do-glp1-drugs-raise-testosterone#ref-3). Against sitagliptin the risk ratio was 0.70 (95% CI 0.64 to 0.76), against injectable semaglutide 0.67 (0.62 to 0.72), and against dulaglutide 0.55 (0.51 to 0.59). Its authors say randomized trials are needed to confirm it, and nothing in it measures the hormone itself. ## The outcomes disagree with each other Testosterone replacement plus lifestyle therapy was the only strategy that significantly improved erectile function on the International Index of Erectile Function, MD 1.29, 95% CI 0.07 to 2.50 — an interval that barely clears zero. Testosterone replacement alone reduced waist circumference and increased lean mass. It also increased hematocrit, which is the classic reason testosterone requires monitoring. Endogenous restoration and the combination also increased lean mass. And no intervention at all significantly reduced glycated hemoglobin. So the question “which treatment is best” has no answer here, and not for the usual reason. It is not that the evidence is too thin to separate them — though confidence in many comparisons was graded low or very low. It is that they genuinely do different things, and which one is best depends entirely on which symptom brought somebody in. ## Why that is the useful finding Because a man with obesity and low testosterone is usually presented with one option by whoever he happens to consult. A urologist reaches for testosterone. A weight clinic reaches for a GLP-1. A primary care physician reaches for lifestyle advice. Each is defensible and none is complete. The authors say explicitly that their findings should inform individualized decisions rather than a definitive ranking, and that longer head-to-head trials are needed. That is the correct conclusion from an analysis where the winner changes with the outcome — and it is a different situation from [a comparison too small to find a difference](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## What it means for someone buying online Nobody on this roster treats hypogonadism, and no seller here measures testosterone. What they sell is weight loss, and weight loss genuinely helps obesity-related low testosterone — that is why the condition is called functional and reversible. If low testosterone is the reason somebody is considering a weight-loss drug, that is a conversation for a clinician who will measure it before and after, and repeat it. What a seller asks about before shipping is [measurably little](https://thisglp.com/tools/questions-they-leave-open), and the same silence covers the menopause question set out in [the subgroup nobody reported](https://thisglp.com/research/do-glp1-drugs-work-in-menopause). ## Frequently asked Do GLP-1 drugs raise testosterone? Weight loss raises it, but the 23-trial network that compared five strategies does not list GLP-1-based therapy among the ones that significantly raised total testosterone. The significant increases were MD 7.19 for replacement plus lifestyle therapy, 4.14 for endogenous restoration and 2.53 for replacement alone. Which treatment is best for obesity-related low testosterone? The authors decline to name one, because each strategy improved a different set of outcomes. Testosterone replacement plus structured lifestyle therapy raised testosterone most and was the only one to improve erectile function significantly. Did GLP-1 therapy help? It was one of the five interventions compared, and it does not appear among the results the abstract reports as significant. The abstract gives no estimate for it, so this page cannot say whether it was found wanting or simply not summarized. Is testosterone replacement risky? It raised hematocrit in this analysis, which is the standard reason it requires monitoring. No significant differences in adverse events overall were detected across the strategies. Did any of it improve blood sugar? No. No intervention significantly reduced glycated hemoglobin compared with usual care or placebo. ## Sources 1. \[1\] Yang L, et al. (2026). Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis The Journal of Sexual Medicine. [PMID 42704281](https://pubmed.ncbi.nlm.nih.gov/42704281/) 2. \[2\] Gregorič N, et al. (2025). Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism Diabetes, Obesity and Metabolism. [PMID 39511836](https://pubmed.ncbi.nlm.nih.gov/39511836/) 3. \[3\] Cowart K, Murphy C, Carris N. (2025). Association of tirzepatide with erectile dysfunction in people with type 2 diabetes Journal of Diabetes and Its Complications. [PMID 40614622](https://pubmed.ncbi.nlm.nih.gov/40614622/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Reduce Inflammation? hsCRP Fell 37.8% in SELECT | This GLP Do GLP-1 drugs reduce inflammation? A prespecified SELECT substudy, a 120-person endothelial trial and a 4,153-pair hypertension cohort | and what each can support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-reduce-inflammation Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Reduce Inflammation? hsCRP Fell 37.8% in SELECT Semaglutide cut an inflammation marker by 37.8% over 104 weeks, and the fall began before major weight loss and appeared in people who lost none. A marker is still not a mechanism. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read When each one moved · wk 4 · wk 8 · wk 104 · inflammation (hsCRP) · body weight · hsCRP fell 37.8% by week 104 — and in people who lost no weight. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). On one marker, substantially. In a prespecified SELECT substudy, semaglutide reduced high-sensitivity C-reactive protein by 37.8% at 104 weeks against placebo, from baseline geometric means of 1.96 and 1.91 mg/L [\[1\]](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation#ref-1). The fall was already evident at weeks 4 and 8, before major weight loss, and it appeared among participants who lost no weight at all. What that does not establish is that lowering inflammation is how the drug works, and the authors are careful to say inflammation contributes in part rather than being the mechanism. ## Key takeaways - In a prespecified SELECT substudy, semaglutide reduced hsCRP by 37.8% at 104 weeks against placebo. - The reduction was evident by weeks 4 and 8, before major weight loss, and also appeared among participants who did not lose weight. - Baseline hsCRP predicted future events: risk rose across the <2, 2 to <10, and ≥10 mg/L subgroups. - The authors describe reduced inflammation as contributing 'in part', not as the mechanism. hsCRP is a marker, and the trial's outcome was cardiovascular events. - A 120-person endothelial trial produced the same 0.11 estimate twice: significant against each person's own baseline, not significant against placebo. - In resistant hypertension, blood pressure fell the same amount on both drugs and every other outcome differed — which is a confounding signature. The obvious explanation for a weight-loss drug preventing heart attacks is the weight loss. A prespecified substudy of SELECT tested that by following an inflammation marker, and found a pattern the weight explanation does not fit. The same trial, cut a different way, is covered in [the frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer). Baseline hsCRP was almost identical in the two arms, at a geometric mean of 1.96 mg/L on semaglutide and 1.91 mg/L on placebo, and it predicted what happened next. Event risk rose across the three baseline strata of below 2, 2 to below 10, and 10 mg/L or above, including significant associations with cardiovascular and all-cause death. Semaglutide then reduced hsCRP by 37.8% at 104 weeks, and reduced event risk in every one of those strata. The timing is the part that matters. Larger falls in hsCRP went with larger weight loss, which on its own would suggest the marker was simply tracking the scale. But the fall was already evident at 4 and 8 weeks, before major weight loss had happened, and it occurred among participants who did not lose weight at all. It was also independent of LDL cholesterol, of statin use, and of which cardiovascular entry criterion had let someone into the trial. A marker is not a mechanism hsCRP is a biomarker, and the trial’s actual outcome was cardiovascular events. The authors write that their modeling suggests decreased inflammation contributes in part to the benefit seen in SELECT. That is a careful sentence and it is worth keeping the hedges: nothing here establishes that lowering inflammation is how the drug works. ## What the blood vessels did, measured two ways A 32-week randomized trial gave 120 people with type 2 diabetes semaglutide, empagliflozin, both, or placebo, and measured how well blood vessels widen in response to demand [\[2\]](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation#ref-2). In the semaglutide group that index rose 0.11 from each participant’s own starting value, 95% CI 0.008 to 0.21, p=0.03. Against placebo it also rose 0.11, on an interval from −0.04 to 0.24, p=0.16. Nothing about the measurement changed between those two sentences. What changed is what it was held up against, and once the placebo group absorbed the ordinary improvement that happens inside a trial, the effect stopped being distinguishable from noise. The adhesion molecules disagreed with each other too, with E-Selectin falling against placebo and VCAM-1 rising. The full reading is in [the endothelial function analysis](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). ## The study where the treated quantity was equalized A matched cohort compared these drugs against mineralocorticoid receptor antagonists as fourth-line therapy for resistant hypertension, leaving 4,153 patients in each group followed a median of 1.4 years [\[3\]](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation#ref-3). Systolic pressure fell 5.7 mmHg on the GLP-1 and 6.3 mmHg on the comparator at twelve weeks, with overlapping intervals. Every other outcome differed sharply: major adverse cardiovascular events at a hazard ratio of 0.63, kidney events at 0.64, and all-cause mortality at 0.34. On the thing both drugs were prescribed to do, the groups were the same, so something other than the treated quantity is separating them. A 66% lower risk of death over 1.4 years is larger than any plausible pharmacological explanation, and what probably separates the groups is set out in [the resistant hypertension cohort](https://thisglp.com/research/do-glp1-drugs-help-resistant-hypertension). ## What the inflammation finding is good for It establishes that the cardiovascular benefit is not purely a function of pounds lost, which matters to anyone weighing whether a smaller response on the scale means a smaller cardiovascular return. The comparison with the other intervention that produces large sustained weight loss is drawn in [surgery against a GLP-1 on cardiovascular outcomes](https://thisglp.com/research/bariatric-surgery-vs-glp1-cardiovascular), and the older drug whose cardiovascular case rested on different reasoning is set out in [where metformin ranks](https://thisglp.com/research/is-a-glp1-better-than-metformin). One limit deserves stating plainly. SELECT enrolled people with established atherosclerotic disease, overweight or obesity, and no diabetes, most of them already well treated with statins, so these numbers describe a specific and fairly narrow population. Whether they extend to people starting the drug for weight alone, with no cardiovascular diagnosis, is not something this substudy can answer. The gap between who gets studied and who gets prescribed is a running problem examined in [uptake after a heart attack or stroke](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke). Nothing here is a reason to buy a drug for inflammation, and no seller on this roster offers an anti-inflammatory indication. What the pattern is useful for is reading a claim: ask which marker moved, what it was compared against, and whether anything happened to a person. ## Frequently asked Do GLP-1 drugs reduce inflammation? In a prespecified SELECT substudy, semaglutide reduced high-sensitivity CRP by 37.8% at 104 weeks against placebo. hsCRP is a marker, and the trial's own outcome was cardiovascular events. Is the effect just the weight loss? Not entirely. The fall was evident at weeks 4 and 8, before major weight loss, and it appeared among participants who lost no weight. Larger falls did go with larger weight loss. Does that mean inflammation is how the drug works? The authors say only that decreased inflammation contributes in part to the benefit seen in SELECT. Nothing in the substudy establishes the mechanism. What about blood vessel function? A 120-person trial produced the same 0.11 estimate twice: significant against each participant's own baseline, and not significant against placebo. Four adhesion molecules moved in different directions. Who do these numbers describe? SELECT enrolled people with established atherosclerotic disease, overweight or obesity and no diabetes, most already well treated with statins. Whether they extend to someone starting the drug for weight alone is not answerable from this substudy. ## Sources 1. \[1\] Plutzky J, Bogdański P, Colhoun HM, Dağdelen S, et al. (2026). Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis Circulation. [PMID 42610271](https://pubmed.ncbi.nlm.nih.gov/42610271/) 2. \[2\] Gullaksen S, et al. (2026). Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial Journal of Diabetes and Its Complications. [PMID 42679726](https://pubmed.ncbi.nlm.nih.gov/42679726/) 3. \[3\] Tian Z, et al. (2026). Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA eClinicalMedicine. [PMID 42701458](https://pubmed.ncbi.nlm.nih.gov/42701458/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Slow Aging? Three Clocks Moved, One Mouse Lifespan Did Do GLP-1 drugs slow aging? Methylation clocks over 32 weeks, a mouse lifespan trial with a calorie-restricted control, and what the mortality data can support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-slow-aging Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Slow Aging? Three Clocks Moved, One Mouse Lifespan Did Median lifespan in female mice ran 834 days on semaglutide against 742 on vehicle. In people the strongest result is a biomarker over 32 weeks, and no trial has a prespecified aging endpoint. [This GLP Editorial Team](https://thisglp.com/about)September 202610 min readUpdated September 2026 What a methylation clock measures · DNA methylation · a trained model · this is what moved · living longer, · or better · not measured · Three clocks decelerated over 32 weeks of semaglutide, per the review. · No trial has yet asked whether that predicts anything in the people it happened to. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). In mice, and only in mice so far. Female mice of one strain treated daily from 20 months of age reached a median lifespan of 834 days against 742 on vehicle, which is 92 days of difference by subtraction from the two published figures [\[2\]](https://thisglp.com/research/do-glp1-drugs-slow-aging#ref-2). In people, the strongest claim is that three validated DNA methylation clocks decelerated over 32 weeks of semaglutide, and a clock is a model trained to predict aging outcomes rather than a record of them [\[1\]](https://thisglp.com/research/do-glp1-drugs-slow-aging#ref-1). No trial with a prespecified aging endpoint has been conducted, and the review making the case says so itself. ## Key takeaways - A review argues these drugs deserve consideration as candidate anti-aging agents. - It cites SELECT's 19% reduction in all-cause mortality, hazard ratio 0.81, and FLOW's 24% reduction in a kidney composite, hazard ratio 0.76. - It reports that randomized evidence in 2025 showed three validated methylation clocks decelerating over 32 weeks of semaglutide. - A methylation clock is a model trained to predict aging outcomes. Moving it is not the same as changing them. - In female mice, median lifespan was 742 days on vehicle and 834 on semaglutide, against a calorie-restricted comparison group matched to the same 24% intake cut. - The review says definitive trials with prespecified aging endpoints have not been conducted. The longevity market is the next place these drugs are going, and it moves faster than evidence does — faster than [the trial evidence that exists](https://thisglp.com/research/semaglutide-cochrane-review) can support. This review is a careful version of the argument, which makes it a good place to see exactly where the argument currently stops. ## The case, as its authors put it These drugs reduce major cardiovascular events, all-cause mortality and systemic inflammation in randomized trials [\[1\]](https://thisglp.com/research/do-glp1-drugs-slow-aging#ref-1). The review cites SELECT’s 19% reduction in all-cause mortality, hazard ratio 0.81, in people with obesity and without diabetes, and FLOW’s 24% reduction in its primary kidney composite, hazard ratio 0.76. It then makes an inferential move worth marking: it describes those effect sizes as exceeding what glycemic and weight-related improvements alone would predict. That is a comparison against a model of how much benefit weight loss ought to produce, not a measurement of anything. It may well be right, and it is an argument rather than a result. ## The clocks The newest piece is the interesting one. The review reports that randomized evidence published in 2025 showed significant deceleration of three validated DNA methylation clocks — DunedinPACE, PCGrimAge and PhenoAge — over 32 weeks of semaglutide therapy. That finding is described here as the review describes it, and this desk has not read the underlying trial. A clock is a prediction, not a lifespan These clocks are statistical models. Researchers trained them on methylation patterns to predict aging-related outcomes, and they predict those outcomes reasonably well across populations. A drug that shifts a clock has shifted the model’s output. Whether it has changed what the model was built to predict is a separate question, answerable only by following people for years and counting what happens to them. Nobody has done that here. Thirty-two weeks of a biomarker is thirty-two weeks of a biomarker. ## The one place lifespan itself was measured Female mice of a single common laboratory strain were given daily semaglutide by injection from twenty months of age, which is late middle age for a mouse, and treatment continued for the rest of their lives [\[2\]](https://thisglp.com/research/do-glp1-drugs-slow-aging#ref-2). Median lifespan came out at 742 days on vehicle and 834 days on semaglutide. What makes that more than an appetite-suppression result is the comparison arm. Eating less is the oldest reliable way to extend life in a laboratory animal, so the authors measured how much less their mice ate, found 24%, and ran a separate group restricted by exactly that 24%. Against it, semaglutide tracked calorie restriction on most measures and did better on exploratory drive, spatial memory and glucose control. The strain, sex and schedule cautions are in [the mouse lifespan study](https://thisglp.com/research/semaglutide-lifespan-in-mice). ## What the human mortality evidence looks like up close A target trial emulation in adults with type 2 diabetes and a BMI below 27 found all-cause mortality 39% lower against DPP-4 inhibitors, hazard ratio 0.61 (95% CI 0.52 to 0.71) [\[3\]](https://thisglp.com/research/do-glp1-drugs-slow-aging#ref-3). Against SGLT2 inhibitors it did not differ at all: 0.89, 95% CI 0.76 to 1.05. The authors describe the first figure as likely residual confounding rather than a benefit of that size. That pattern is the tell, and it is what a longevity claim built on observational mortality has to get past. When a result is huge against a weak comparator and gone against a strong one, the comparator is doing the work. The reasoning is set out in [the hazard ratio its own authors disowned](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own). The other way the question gets answered is by modeling. A risk equation fitted in 610,789 people was applied to 200,012 survey participants twice, once as observed and once with five risk factors shifted by the amounts SELECT measured [\[4\]](https://thisglp.com/research/do-glp1-drugs-slow-aging#ref-4). Projected ten-year cardiovascular incidence fell from 13.82% to 10.83%, an absolute reduction of 2.99 percentage points. Nobody in that analysis took any drug, which is set out in [the emulated general population](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent). ## What the review itself says is missing Its own list is long and specific: definitive trials with prespecified epigenetic aging endpoints, durability follow-up, body-composition assessment, prespecified sex-stratified analyses, and adequate representation of diverse populations. None of those exist yet. It flags the pending EVOKE and EVOKE+ readouts in early Alzheimer’s disease as particularly consequential, which is fair, because a hard clinical endpoint in a neurodegenerative disease would say far more than any clock. [That question has its own page here](https://thisglp.com/research/semaglutide-and-alzheimers). ## Why this matters commercially before it matters clinically Because “slows biological aging” is a claim that can be made about a biomarker long before it can be made about a person, and there is an entire consumer longevity industry built on exactly that gap. Methylation clock tests are already sold direct to consumers, and the pairing of those two products is predictable. No seller on this roster offers a longevity indication and none claims one. If that changes, the question to ask is the one this review answers honestly about itself: which endpoint moved, and was it a thing that happened to people or a number that predicts things that happen to people? The mechanisms the review names are plausible and preclinical, and mechanistic plausibility is how every failed intervention in this field started. What sellers say now is the baseline, recorded in [the disclosure census](https://thisglp.com/tools/what-sellers-publish). ## Frequently asked Do GLP-1 drugs slow aging? In female mice of one strain, median lifespan was 834 days on semaglutide against 742 on vehicle. In people, three DNA methylation clocks decelerated over 32 weeks, and no trial with a prespecified aging endpoint has been run. What is a methylation clock? A statistical model trained on methylation patterns to predict aging-related outcomes. A drug that shifts a clock has shifted the model's output, not necessarily what the model was built to predict. Why does the mouse study matter more than most animal work? It included a group restricted to the same 24% intake cut the drug produced. That separates the molecule from the eating, and semaglutide still did better on exploratory drive, spatial memory and glucose control. Does the mortality evidence support a longevity claim? Weakly. A target trial emulation found mortality 39% lower against DPP-4 inhibitors and no different against SGLT2 inhibitors, and its own authors call the larger figure likely residual confounding. Can I buy one of these drugs for longevity? No seller on this roster offers a longevity indication and none claims one. The claim to watch for is one made about a biomarker and stated as though it were about a person. ## Sources 1. \[1\] Al-Ali D, et al. (2026). GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension Experimental Gerontology. [PMID 42735804](https://pubmed.ncbi.nlm.nih.gov/42735804/) 2. \[2\] Feng Y, et al. (2026). Late-life semaglutide treatment slows ageing and extends lifespan in female mice Nature. [PMID 42686906](https://pubmed.ncbi.nlm.nih.gov/42686906/) 3. \[3\] Chen SC, et al. (2026). Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial Emulation Diabetes, Obesity and Metabolism. [PMID 42642357](https://pubmed.ncbi.nlm.nih.gov/42642357/) 4. \[4\] Schrage B, Lackner MK, Hoshiyar A, de Lemos JA, et al. (2026). Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population Journal of the American College of Cardiology. [PMID 41811277](https://pubmed.ncbi.nlm.nih.gov/41811277/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Work in Menopause? The Subgroup Nobody Reported | This GLP Most participants in the GLP-1 weight trials were women in their forties, and none of the trials analyzed menopausal status. What is known, and what is not. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-work-in-menopause Updated: 2026-10-26 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Work in Menopause? The Subgroup Nobody Reported Women were 79% of one trial population at a mean age of 46, and no published trial has reported outcomes by menopausal status. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Women in STEP 4: 79 of every 100 · Prespecified analyses by menopausal status · Searched September 2026. The lower bar is empty. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Almost certainly, though no trial has reported the subgroup that would prove it. The same gap shows up around [sexual function](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive) and around [the hormonal questions next to it](https://thisglp.com/research/do-glp1-drugs-raise-testosterone). Women are the majority of every published weight-loss trial of these drugs, and the mean ages sit squarely in the years when the menopausal transition happens. So the evidence is full of menopausal women and empty of any analysis naming them as such. That is an unusual shape of gap. It is not that the drugs were tested only in men, or only in the young. A large and identifiable group was enrolled in quantity and never reported separately, so the question a reader is asking has an answer sitting inside the data that nobody has extracted. Women are the majority of every published weight-loss trial of these drugs. STEP 4 randomized 803 adults of whom 634, or 79%, were women, at a mean age of 46[\[1\]](https://thisglp.com/research/do-glp1-drugs-work-in-menopause#ref-1). SURMOUNT-4 randomized 670 adults of whom 473, or 71%, were women, at a mean age of 48 [\[2\]](https://thisglp.com/research/do-glp1-drugs-work-in-menopause#ref-2). Those mean ages sit squarely in the years when the menopausal transition happens, and neither trial reported menopausal status as a prespecified subgroup. ## What was searched, and when The searches behind this page were run against PubMed in September 2026, pairing semaglutide and tirzepatide with menopause, perimenopause, postmenopausal status, vasomotor symptoms and menopausal hormone therapy. No randomized controlled trial reporting outcomes by menopausal status was returned. What came back was a review of pharmacologic options written for a menopause readership [\[3\]](https://thisglp.com/research/do-glp1-drugs-work-in-menopause#ref-3), a case report [\[4\]](https://thisglp.com/research/do-glp1-drugs-work-in-menopause#ref-4), and a pharmacokinetic review about progestogens [\[5\]](https://thisglp.com/research/do-glp1-drugs-work-in-menopause#ref-5). That is a statement about a search on a date, not a claim that no such work exists anywhere. The rule this page follows is the one the [editorial methodology](https://thisglp.com/methodology) applies everywhere: an outcome may be stated only where a cited paper measured it. Where nothing measured it, the page says so. ## What can honestly be carried across A trial whose population is 79% women at a mean age of 46 has produced a result that applies to a population including many women in the transition, even though it did not analyze them separately. The weight outcomes in [the withdrawal studies](https://thisglp.com/research/stopping-glp1-and-weight-regain) were measured in those same populations. What cannot be carried across is anything specific to the transition — whether the response differs before and after the final period, whether the body-composition changes differ, whether vasomotor symptoms interact with the drug at all. None of that was measured. ## The hormone therapy question, which is real and unstudied Many women in this age group take oral progestogens, either for a gynecologic indication or for endometrial protection alongside estrogen. Tirzepatide delays gastric emptying, so an interaction with an oral hormone is biologically plausible. The only pharmacokinetic study available used a combined oral contraceptive rather than a menopausal regimen: a single 5 mg dose of tirzepatide reduced peak concentrations by 55 to 66% and total exposure by 20 to 23% [\[5\]](https://thisglp.com/research/do-glp1-drugs-work-in-menopause#ref-5). No equivalent data exists for the progestogens used in menopausal hormone therapy, and the review reporting the contraceptive figures says plainly that findings from one formulation cannot be extrapolated to structurally different agents. The [contraception page](https://thisglp.com/research/tirzepatide-and-oral-contraception) sets out the same study in more detail. Anyone taking both should treat this as a question for a prescriber rather than a settled matter in either direction. ## A single case report, labeled as one A 2025 case report in Menopause describes worsening vasomotor symptoms in a woman taking estradiol who started semaglutide [\[4\]](https://thisglp.com/research/do-glp1-drugs-work-in-menopause#ref-4). One case establishes that the combination was documented once. It does not establish a rate, a mechanism or a direction, and it should not be read as any of those. ## What this means when choosing a service The practical consequence of an unstudied question is that the person prescribing has to be reachable. A service that folds the clinician visit into the monthly price is a different proposition here from one that bills each contact separately or never says how often a patient is reviewed. Those differences are recorded per seller: the [visit-inclusive services](https://thisglp.com/reviews/everslim) state it on the pricing page, and the rest are set out across the [seller reviews](https://thisglp.com/reviews). For a care-setting comparison, [Midi Health](https://thisglp.com/reviews/midi-health) presents GLP-1 prescribing within women’s and hormonal healthcare on its [website](https://www.joinmidi.com/). That broader scope is a question to discuss with a clinician, not evidence that Midi’s program produces the study’s results or that menopause alone makes a GLP-1 appropriate. ## Frequently asked Do these drugs work differently after menopause? Not established. As of a PubMed search run in September 2026, no randomized trial of semaglutide or tirzepatide has reported outcomes by menopausal status. Were women included in the trials? In large numbers. STEP 4 randomized 803 adults of whom 79% were women, and SURMOUNT-4 randomized 670 of whom 71% were women, both at a mean age in the forties. Is there an interaction with hormone therapy? Untested. The only pharmacokinetic study used a combined oral contraceptive with tirzepatide and found peak concentrations fell by 55 to 66% and exposure by 20 to 23%. No equivalent data exists for menopausal regimens. ## Sources 1. \[1\] Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial JAMA. [PMID 33755728](https://pubmed.ncbi.nlm.nih.gov/33755728/) 2. \[2\] Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. [PMID 38078870](https://pubmed.ncbi.nlm.nih.gov/38078870/) 3. \[3\] Hurtado Andrade MD. (2025). Pharmacologic options for the treatment of overweight and obesity Menopause. [PMID 40554633](https://pubmed.ncbi.nlm.nih.gov/40554633/) 4. \[4\] Parker AE. (2025). Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report Menopause. [PMID 40729307](https://pubmed.ncbi.nlm.nih.gov/40729307/) 5. \[5\] Viana DPDC, Invitti AL, Jacobsen L, Schor E. (2026). Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy Maturitas. [PMID 42721915](https://pubmed.ncbi.nlm.nih.gov/42721915/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Do GLP-1 Drugs Work the Same in Asian Patients? The Percentages Match Do GLP-1 drugs work the same in Asian patients? Tirzepatide gave 18.16% against 17.92% across Asian and non-Asian trials | in kilograms it was 16.72 against 23.46. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Work the Same in Asian Patients? The Percentages Match Percentage weight loss came out at 18.16% against 17.92% across Asian and non-Asian trial populations, and the same comparison in kilograms ran 16.72 against 23.46. Only 148 Asian participants received the drug, which is why the authors refuse to call that first result equivalence. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Asian vs non-Asian trial populations · measured as a percentage · −18.16% vs −17.92% · p = 0.94 · no difference · measured in kilograms · −16.72 kg vs −23.46 kg · p = 0.03 · a real difference · Same people, same trials, two units. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Measured as a percentage the answer is yes, and measured in kilograms it is not, which is the single most useful fact on this page. A meta-analysis pooling five phase 3 tirzepatide trials found 18.16% weight loss in Asian populations against 17.92% in predominantly non-Asian ones, at a p value of 0.94 [\[1\]](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients#ref-1). The same participants measured in kilograms lost 16.72 kg against 23.46 kg, at a p value of 0.03, and the explanation is that the non-Asian trial populations started heavier. Only 148 Asian participants received tirzepatide across the two trials supplying them, and the authors state that an underpowered comparison of that size cannot confirm equivalence. ## Key takeaways - A meta-analysis pooled five phase 3 tirzepatide trials, 4,022 participants, splitting them into Asian and predominantly non-Asian populations. - Percentage weight loss was almost identical: -18.16% against -17.92% (p = 0.94). - Absolute weight loss differed: -16.72 kg against -23.46 kg (p = 0.03), reflecting higher starting weight in the non-Asian trials. - Only 148 Asian participants received tirzepatide, and the authors state the comparison cannot confirm equivalence. - The largest randomized trial run specifically in an East Asian population tested a tablet, not an injection, and started from a mean weight of 91.9 kg. Trials of these drugs report percentage weight loss, which is convenient and quietly consequential, and the disagreement between the two units is the reason this question is harder than it looks. The pooled figures across the whole literature are in [the weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average), where a single mean of 9.36% sits on top of trials that almost entirely disagree with each other. ## Why the two units disagree Measured as a percentage, the Asian and non-Asian trial populations lost essentially the same amount: 18.16% against 17.92%, with a p value of 0.94. Measured in kilograms they did not: 16.72 kg against 23.46 kg, with a p value of 0.03. Both statements describe the same participants in the same trials. The explanation is the starting weight People in the non-Asian trials weighed more to begin with, so the same proportional loss removes more kilograms. Neither figure is wrong and neither is the whole picture. Which one matters depends on the question: a percentage describes how the drug performs, and a kilogram figure describes what changes about a person — joints, sleep apnea and cardiovascular risk respond to mass, not to ratios. The authors are unusually careful about what their own null means. Only 148 Asian participants received tirzepatide, across two trials, and they state plainly that the comparison is underpowered and cannot confirm equivalence. A p value of 0.94 on a sample that small is absence of evidence rather than evidence of sameness — the distinction that governs [the frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer), where the sample was large enough for a null to mean something. The design carries a further limit. This compares across trials rather than within one, so the Asian and non-Asian groups differ in every way two separate trials differ — sites, era, baseline characteristics, background care — and ethnicity is only one of them. Heterogeneity on the headline effect was also substantial, at I² = 77%. ## The trial that was actually run in East Asia The strongest evidence about this population is not a subgroup at all but a randomized trial conducted in it. Two hundred and one East Asian adults with overweight or obesity were randomized to oral semaglutide at 50 mg daily or to placebo, and mean weight change came out at 14.3% against 1.3% [\[2\]](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients#ref-2). Some 84.3% of the treated group reached a 5% reduction against 17.2% on placebo, gastrointestinal adverse events affected 63.4% of them, and 4.5% stopped because of an adverse event. What that trial cannot settle is whether a tablet a reader can buy resembles the one it used, which is the problem set out in [the oral versus injectable comparison](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection). Mean starting weight in that trial was 91.9 kg, against roughly 113 kg in the large Western obesity trials, so a percentage taken off it is not the same quantity of body mass at all. That single line explains the kilogram gap in the tirzepatide pooling without invoking ethnicity, drug response or metabolism, and the fuller reading of the dose and its conditions sits in [the 50 mg trial](https://thisglp.com/research/oral-semaglutide-fifty-milligrams). ## What the Japanese data adds, and what it cannot Two Japanese records extend the picture in different directions. In a subgroup of 116 Japanese participants from the ESSENCE liver trial, steatohepatitis resolved without worsening fibrosis in 63.1% against 36.8%, a difference of 26.65 percentage points with a 95% confidence interval from 7.43 to 45.86 [\[3\]](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients#ref-3). The fibrosis endpoint in the same subgroup gave 7.07 points with an interval running from −11.48 to 25.62, which crosses zero and therefore answers nothing, and the reading of that pair is in [the Japanese ESSENCE subgroup](https://thisglp.com/research/semaglutide-liver-japanese-subgroup). The second record is national rather than clinical. Japan publishes dispensing quantities for every strength of tirzepatide, and strengths of 7.5 mg and above rose from 13.0% of the mix to 24.0% between June 2024 and March 2025 [\[4\]](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients#ref-4). That is a description of a market rather than of patients, because a market where new people keep starting low and one where existing people keep climbing produce the same aggregate shift, and [the dispensing file](https://thisglp.com/research/tirzepatide-dose-mix-in-japan) says so itself. ## What a reader should take from it The transferable lesson is about units rather than ethnicity, because any comparison between populations with different baseline weights will look different depending on whether it is reported as a percentage or an absolute. Trials almost always choose the percentage. The same trap sits behind cross-trial comparisons like [the ecnoglutide trial](https://thisglp.com/research/what-is-ecnoglutide), where entry criteria set a lighter starting population, and behind the subgroup ranges in [the sleep apnea subgroups](https://thisglp.com/research/apnea-improved-across-every-subgroup). None of this supports a claim that these drugs work differently by ethnicity, and none of it supports the opposite claim either. What exists is one underpowered indirect comparison, one randomized tablet trial in 201 people, one liver subgroup of 116, and a national dispensing file that counts kit units rather than patients. That is a thin evidence base for a question this frequently asked, and saying so is more useful than picking whichever number reads better. ## Frequently asked Do GLP-1 drugs work the same in Asian patients? Percentage weight loss was nearly identical in a pooled comparison — 18.16% against 17.92% — but only 148 Asian participants received the drug, and the authors state the comparison is underpowered and cannot confirm equivalence. Why did the kilogram figures differ? Participants in the non-Asian trials weighed more at baseline, so the same proportional loss removes more kilograms — 23.46 kg against 16.72 kg. Has any trial been run specifically in an East Asian population? Yes. OASIS 2 randomized 201 East Asian adults to oral semaglutide 50 mg or placebo and found a 14.3% mean weight reduction against 1.3%, from a mean starting weight of 91.9 kg. Which measure matters more? It depends on the question. A percentage describes drug performance; absolute mass is what joints, sleep apnea and cardiovascular risk actually respond to. ## Sources 1. \[1\] Kamrul-Hasan ABM, Khalil I, Dutta D, Mahajan K, Nagendra L, Pappachan JM (2026). Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis Endocrinology, Diabetes & Metabolism. [PMID 42487213](https://pubmed.ncbi.nlm.nih.gov/42487213/) 2. \[2\] Kadowaki T, et al. (2025). Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial JAMA Internal Medicine. [PMID 40758358](https://pubmed.ncbi.nlm.nih.gov/40758358/) 3. \[3\] Nakajima A, et al. (2026). Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial Journal of Gastroenterology. [PMID 42663669](https://pubmed.ncbi.nlm.nih.gov/42663669/) 4. \[4\] Omura T, et al. (2026). Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data Cureus. [PMID 42535213](https://pubmed.ncbi.nlm.nih.gov/42535213/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do You Lose Muscle on a GLP-1? And What Comes Back Is Fat | This GLP A review reports lean mass losses of 6 to 7 kg during incretin therapy and fat-preferential regain averaging 5.6 kg within a year of stopping. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-you-lose-muscle-on-a-glp1 Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Do You Lose Muscle on a GLP-1? And What Comes Back Is Fat Six to seven kilograms of lean mass goes during treatment. About 5.6 kg comes back after stopping, preferentially as fat. The scale can read the same either way. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 What comes off, and what comes back · on treatment · fat and 6–7 kg of lean mass · after stopping · 5.6 kg back, preferentially fat · The same weight, made of different tissue. · Figures gathered by a narrative review, not measured in it. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A narrative review of what happens to body composition during and after incretin therapy. - It cites lean mass losses averaging 6 to 7 kg during active treatment, alongside falls in bone mineral density. - It cites post-cessation weight regain averaging 5.6 kg within a year, and describes that regain as fat-preferential. - So the tissue lost and the tissue regained are not the same tissue. - It also cites 85% of patients discontinuing within the second year of real-world use. Yes, and the tissue that comes back is not the tissue that left. A review of body composition during and after incretin therapy cites lean mass losses averaging 6 to 7 kg. Bone mineral density falls alongside it. After stopping, regain averages 5.6 kg within a year, and the review describes that regain as fat-preferential. Body-composition findings also depend on the clinical population. The [semaglutide studies in people living with HIV](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv) address a distinct safety and fat-distribution question. So the scale can read the same at both ends of a course while the body underneath has changed. That is the finding, and it is not the one a weight chart shows. Several trials have tested a second drug to protect muscle. In 102 adults on tirzepatide, randomizing to add apitegromab held 1.9 kg more lean mass at 24 weeks [\[2\]](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1#ref-2). Total weight loss was similar in both arms, so [the lean mass was kept without blunting the loss](https://thisglp.com/research/can-a-drug-prevent-muscle-loss-on-a-glp1). Bimagrumab is the other candidate. It blocks the activin type II receptor, a signal that limits muscle growth. Given alone to 75 adults with type 2 diabetes, it added 1.70 kg of lean mass over 48 weeks [\[4\]](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1#ref-4). Lean mass on placebo fell 0.4 kg. No GLP-1 was used in that trial. A later trial paired it with semaglutide in 507 adults with obesity [\[5\]](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1#ref-5). At 48 weeks, weight fell 17.8 kg on the high-dose pair. It fell 14.2 kg on semaglutide 2.4 mg alone and 3.3 kg on placebo. The abstract reports weight as its endpoint. Lean mass is not among the results it gives. Two recent cohorts measured how the weight lost splits. In 35 adults on tirzepatide, fat made up 85.7 percent of the loss [\[6\]](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1#ref-6). Skeletal muscle fell 2.8 kg, or 8.3 percent. That clinic measured body composition by bioelectrical impedance. A second cohort matched 396 GLP-1 users to nonusers from connected-device data [\[7\]](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1#ref-7). Median weight fell 9.8 percent. Fat mass fell 7.5 percent and muscle mass 2.3 percent. Neither cohort was randomized. Bone runs the other way from what the review's density figures suggest. Pooled across twenty-five randomized trials, bone mineral density was higher on a GLP-1 at every site measured [\[3\]](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1#ref-3). Meanwhile [whether fractures fell is a question those trials cannot answer](https://thisglp.com/research/glp1-bone-density-vs-fractures). Weight coming back after stopping is well established and [covered elsewhere on this site](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1). This review is about something narrower and less discussed: what the returning weight is made of. ## What it gathers A narrative review searching three databases from 2005 to mid-2026, assembled under a standard framework for this kind of review. [\[1\]](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1#ref-1) Every number in it is drawn from other studies rather than measured. A narrative review chooses what to include. These are figures it found, presented as it read them. On treatment, lean mass fell by 6 to 7 kg on average, alongside reductions in bone mineral density. After stopping, weight rose by 5.6 kg on average within one year, described as fat-preferential, with observational reports of dose-dependent cardiometabolic worsening. Why that combination matters more than either half Losing six kilograms of lean mass and regaining 5.6 kg of mostly fat does not return a person to where they started. The scale can read the same while the body underneath has less muscle and more fat. Lean mass determines resting energy expenditure. That makes the next attempt harder than the last. That is the argument for treating cessation as a clinical event rather than the absence of one. It differs from [what happens to muscle during treatment alone](https://thisglp.com/research/semaglutide-muscle-mass-and-grip). ## The persistence figure The review cites 85% of patients discontinuing within the second year of real-world use. That is the premise of the whole paper. If most people stop, what happens after stopping is most of the story. That figure comes from the literature the review surveys, not its own data. Persistence estimates vary with how long a gap counts as stopping. The direction is not in dispute. Do not quote the exact number as though it were measured here, any more than [a multiplier quoted without its base](https://thisglp.com/research/glp1-prescriptions-to-young-children) should. ## What it recommends, and what this page will not Structured exercise. Exercise and pharmacotherapy produce different body composition outcomes. Exercise preserves lean mass where the drug does not. The review offers prescription guidance. This page does not, because what is appropriate depends on age, joints, cardiac fitness and what somebody is already doing. What is safe to say is that the cessation transition has no established framework. The authors say so. Nobody selling a subscription is planning one, and [it is not among the things sellers publish](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Is the weight that comes back the same as the weight that went? Not according to this review. Lean mass losses of 6 to 7 kg occur during treatment, while post-cessation regain averaging 5.6 kg is described as fat-preferential. Why does that matter if the scale reads the same? Because lean mass drives resting energy expenditure. Ending a cycle with less muscle and more fat than you started with makes the next attempt harder. How much of the weight lost on a GLP-1 is muscle? In two recent cohorts most of it was fat. On tirzepatide, fat made up 85.7 percent of the weight lost and skeletal muscle fell 8.3 percent. In connected-device data, median weight fell 9.8 percent, with fat mass down 7.5 percent and muscle mass down 2.3 percent. Can a second drug protect muscle? It has been tested. Adding apitegromab to tirzepatide held 1.9 kg more lean mass at 24 weeks. Bimagrumab alone added 1.70 kg of lean mass in adults with type 2 diabetes. Paired with semaglutide, it produced 17.8 kg of weight loss against 14.2 kg on semaglutide alone. How many people stop? The review cites 85% discontinuing within the second year of real-world use, drawn from the literature it surveys rather than measured in it. What should somebody do about it? The review argues for structured exercise, since exercise preserves lean mass where the drug does not. What is appropriate for a particular person is a clinical question. ## Sources 1. \[1\] Zeigler Z, et al. (2026). Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance Healthcare. [PMID 42588312](https://pubmed.ncbi.nlm.nih.gov/42588312/) 2. \[2\] Pratley RE, Denham DS, Trivedi R, Watkins E, et al. (2026). Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Nature Medicine. [PMID 42260100](https://pubmed.ncbi.nlm.nih.gov/42260100/) 3. \[3\] Tan Y, et al. (2025). Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis Acta Diabetologica. [PMID 39985672](https://pubmed.ncbi.nlm.nih.gov/39985672/) 4. \[4\] Heymsfield SB, et al. (2021). Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial JAMA Network Open. [PMID 33439265](https://pubmed.ncbi.nlm.nih.gov/33439265/) 5. \[5\] Heymsfield SB, et al. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial Nature Medicine. [PMID 41772149](https://pubmed.ncbi.nlm.nih.gov/41772149/) 6. \[6\] Corso H, et al. (2026). Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity Frontiers in Endocrinology. [PMID 42488012](https://pubmed.ncbi.nlm.nih.gov/42488012/) 7. \[7\] Chabassier A, et al. (2026). Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data Mayo Clinic Proceedings: Digital Health. [PMID 42746268](https://pubmed.ncbi.nlm.nih.gov/42746268/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do You Need Vitamins on a GLP-1? Over 60% Eat Below the Iron Requirement Do you need vitamins on a GLP-1? Deficiency rates across 480,825 adults, the 271-calorie intake drop behind them, and six cases of thiamine deficiency. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-you-need-vitamins-on-a-glp1 Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Do You Need Vitamins on a GLP-1? Over 60% Eat Below the Iron Requirement Across six studies and 480,825 adults, vitamin D deficiency reached 13.6% at twelve months. Most users ate below the estimated requirement for calcium and iron. The answer is a blood test, not a supplement aisle. [This GLP Editorial Team](https://thisglp.com/about)September 202610 min readUpdated September 2026 Vitamin D deficiency among users · 7.5% · 6 months · 13.6% · 12 months **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Ask a clinician what to measure, rather than buying a multivitamin. A structured review covered six studies and 480,825 adults on these drugs[\[1\]](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1#ref-1). Vitamin D deficiency ran 7.5% at six months and 13.6% at twelve. More than 60% were eating below the estimated requirement for calcium and for iron. Vitamin D intake averaged about a fifth of the recommended amount. Ferritin ran 26% to 30% lower than in a comparison group on a different diabetes drug. The data are observational, and the review says causality cannot be established. ## Key takeaways - A structured review found six studies covering 480,825 adults on these drugs. - Vitamin D deficiency was the commonest finding: 7.5% of users at six months, 13.6% at twelve. - Ferritin ran 26% to 30% lower than in people taking a different diabetes drug. - More than 60% of users ate below estimated requirements for calcium and iron. Vitamin D intake averaged a fifth of what is recommended. - Measured directly, intake at a standardized lunch fell about 271 kcal against placebo — the simplest explanation for all of the above. - Six published cases of Wernicke's encephalopathy followed prolonged vomiting and rapid weight loss. Six cases cannot produce a rate. - The data are observational. The review says causality cannot be established, and so does this page. These drugs work by making you eat less. Eating less means taking in less of everything, not only calories. That is obvious once stated and almost nobody states it. ## What the review found The search covered PubMed and the Cochrane Database from January 2019 to May 2025. It turned up six adult studies with nutritional endpoints, together covering 480,825 people. Vitamin D deficiency was the most common abnormality, in 7.5% of users at six months and 13.6% at twelve. Iron depletion was frequent. Ferritin ran 26% to 30% lower than in a comparison group taking SGLT2 inhibitors. That is a different diabetes drug, not an untreated control. Intake was worse than status. More than 60% of users were eating below estimated requirements for calcium and for iron. Vitamin D intake averaged about a fifth of the recommended amount. Thiamine and B12 deficits grew over time, and protein and calcium shortfalls contributed to loss of lean mass. This is association, not mechanism The review is explicit that its findings come mainly from observational datasets and that causality cannot be established. There is also a simpler explanation than drug pharmacology available throughout. Somebody eating half as much food takes in half as much iron. That would produce these numbers whatever caused the eating to fall. The practical consequence is the same either way; the mechanism claim is not earned. ## How much less is being eaten That simpler explanation has been measured. A meta-analysis pooled standardized test-meal data from four arms across three trials, 209 participants in total [\[3\]](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1#ref-3). Energy intake at an observed lunch fell 1,132 kJ against placebo, on an interval from −1,449 to −815. That is roughly 271 kcal at one meal. One lunch is not a diet, and the authors say habitual intake remains underreported. It is still the number that makes the nutrient findings unsurprising. The full reading is in [how much less you eat on a GLP-1](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1). ## Why it goes unnoticed The early symptoms are the symptoms of everything. Tiredness. Feeling cold. Thinning hair. Getting out of breath on stairs. A person who has lost twenty pounds attributes all of that to the diet, and so does everybody around them. Nausea makes it worse by narrowing what people can face eating, which tends to mean less meat, less dairy and fewer vegetables. That is a predictable consequence of [the titration period](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and nobody schedules a blood test around it. ## The rare version, and its warning sign Thiamine is stored for a matter of weeks. A systematic review found six published cases of Wernicke’s encephalopathy after semaglutide prescribed for obesity [\[2\]](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1#ref-2). Every case followed the same sequence: prolonged gastrointestinal symptoms first, then substantial rapid weight loss, then neurological deterioration. Six cases cannot produce a rate. Millions of people take these drugs, and case reports have no denominator. What the sequence gives is an early warning that the person experiencing it can see. Persistent vomiting for weeks is a reason to contact a prescriber rather than push through. The outcomes in several of those cases were poor. The detail is in [the six reported cases](https://thisglp.com/research/can-a-glp1-cause-thiamine-deficiency). ## What lean mass has to do with it Protein shortfalls and lean mass are linked in the review, and the body composition evidence is thinner than the argument around it. The best-controlled figure comes from 101 adults over 24 weeks. Semaglutide changed lean body mass by −2.5 kg against placebo, on an interval from −6.6 to 1.6 [\[4\]](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1#ref-4). That interval includes no change at all. Lean body mass is also not muscle. Bioimpedance measures fat-free tissue, which includes water and organ mass, and the same analysis recorded extracellular water down 0.9 L. Nothing there supports a claim that these drugs spare muscle or destroy it. The state of that question is in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1) and [what comes back afterward](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). ## What would actually catch it A blood test. Vitamin D, ferritin, B12 and a basic metabolic panel cover most of what the review flags, and they are cheap and ordinary. The review’s own recommendation is targeted nutritional assessment and individualized laboratory evaluation for people at higher risk of malnutrition. That is a clinician deciding what to measure, rather than a reader buying supplements on the strength of a percentage. Who is at higher risk is not mysterious. People losing weight fast. People who were already eating poorly. People with a restricted diet, and people who have had bariatric surgery. That last group is already monitored for exactly this. The medical system has a protocol for rapid weight loss and nutrition, and it exists on the surgical side of the market. ## What sellers say about it Close to nothing. A prescription arrives, a titration schedule arrives, and no seller on this roster publishes a monitoring plan or suggests a baseline panel. That absence is not unique to nutrition. It [runs across almost every clinical question](https://thisglp.com/research/what-glp1-sellers-do-not-publish) this market touches, and [the census counts how wide the silence runs](https://thisglp.com/tools/questions-they-leave-open). There is no accusation in that. A telehealth seller is not set up to run longitudinal labs, and most of them do not pretend to be. The point is that the gap is yours to close. You are buying a year of a drug that reduces how much you eat. Ask a clinician what to measure and when. Ask before the tiredness starts and gets attributed to the diet. ## Frequently asked Do you need vitamins on a GLP-1? Across six studies covering 480,825 adults, more than 60% of users ate below the estimated requirement for calcium and iron, and vitamin D deficiency reached 13.6% at twelve months. What that calls for is a blood test and a clinician's judgment, not a supplement bought on a percentage. Which deficiencies show up most? Vitamin D was the commonest, in 7.5% of users at six months and 13.6% at twelve. Ferritin ran 26% to 30% lower than in a comparison group on SGLT2 inhibitors, and thiamine and B12 deficits grew over time. Is the drug causing it, or the eating? The review says causality cannot be established. Intake at a standardized lunch fell about 271 kcal against placebo, and somebody eating much less food takes in less iron whatever caused the eating to fall. What about thiamine and Wernicke's encephalopathy? Six published cases followed semaglutide prescribed for obesity, each after prolonged gastrointestinal symptoms and rapid weight loss. Six case reports establish that it happens and say nothing about how often. What should I actually ask for? Vitamin D, ferritin, B12 and a basic metabolic panel cover most of what the review flags. No seller on this roster publishes a monitoring plan or suggests a baseline panel. ## Sources 1. \[1\] Urbina J, et al. (2026). Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review Clinical Obesity. [PMID 41549912](https://pubmed.ncbi.nlm.nih.gov/41549912/) 2. \[2\] Bidesie J, Oudman E (2026). Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence Obesity (Silver Spring, Md.). [PMID 42399213](https://pubmed.ncbi.nlm.nih.gov/42399213/) 3. \[3\] Quan AT, Nguyen HL, Nguyen TMT (2026). Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis Diabetes & Metabolic Syndrome. [PMID 42508090](https://pubmed.ncbi.nlm.nih.gov/42508090/) 4. \[4\] Heerspink HJL, Soler M, Beernink JM, et al. (2026). Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial Clinical Journal of the American Society of Nephrology. [PMID 42308057](https://pubmed.ncbi.nlm.nih.gov/42308057/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Does a GLP-1 Affect Surgery Outcomes? Four Procedures, Four Different Answers Does a GLP-1 affect surgery outcomes? Four studies on knee, shoulder, spinal, and neck surgery, and what each one actually found once you read past the headline. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Does a GLP-1 Affect Surgery Outcomes? Four Procedures, Four Different Answers It depends on the operation. Knee and neck surgery showed no difference, shoulder surgery's alarming signals vanished on adjustment, and spinal fusion went both ways depending on the database. [This GLP Editorial Team](https://thisglp.com/about)September 202610 min readUpdated September 2026 Semaglutide against tirzepatide, 415 pairs · 90-day medical · 180-day surgical · surgical site infection · acute kidney injury · no difference · Every interval spans about a halving to about a tripling **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). It depends on the procedure, and the four largest studies do not agree with each other. On knee replacement, a 415-pair comparison of semaglutide against tirzepatide found no significant difference on any outcome [\[1\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-1). On shoulder surgery, three alarming raw signals — up to a near-fourfold rise in urinary infection — vanished once the comparison was adjusted for who actually gets prescribed a GLP-1 [\[2\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-2). On spinal fusion, the same drug class looked protective in one database, neutral in another, and nearly five-times worse in a third [\[3\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-3). On neck fusion, doubling the dose changed nothing measured [\[4\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-4). No single answer covers all four, and that disagreement is itself the finding. The [breast-surgery evidence](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery) is another procedure-specific example; an overall surgical association should not be assumed to apply identically to every operation. ## Key takeaways - Knee replacement: 415 matched pairs on semaglutide or tirzepatide beforehand. No outcome differed significantly, but every interval was wide enough to hide a real difference. - Shoulder surgery: three raw signals (respiratory, urinary infection, stiffness) all disappeared after adjusting for who gets prescribed a GLP-1. - Spinal fusion: twelve cohorts gave odds ratios from 0.52 (protective) to 4.79 (worse), and pooling them produced an interval spanning both. - Neck fusion: 921 matched pairs per dose group, high dose against standard. Nothing differed across nine outcomes. - None of these studies answers whether to pause a GLP-1 before surgery — that is a separate, mostly anesthesia-related question. A study that finds nothing is often the most useful kind. The knee replacement comparison found nothing, and then described what it found in a way worth separating from the data. ## What was compared Adults with type 2 diabetes who had a primary knee replacement between mid-2022 and the end of 2024, and who had an active prescription for semaglutide or tirzepatide within the 90 days before surgery. [\[1\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-1) They were matched one to one on age, sex, race, BMI, glycated hemoglobin, comorbidity burden and concurrent diabetes medication, leaving 415 pairs. Outcomes were tracked to 90 and 180 days. Nothing reached significance. Medical complications at 90 days came in at OR 1.122, 95% CI 0.736 to 1.710. Surgical complications at 180 days at OR 1.632, 95% CI 0.845 to 3.152. Individual events — heart attack, stroke, pneumonia, sepsis, clots, kidney injury, wound problems, joint infection, death, revision — were all similar, every p above 0.05. Read the width, not the p-value The 180-day surgical complication interval runs from 0.845 to 3.152. That is consistent with tirzepatide being modestly safer and with it carrying triple the risk. Surgical site infection runs 0.782 to 3.810. These are not findings of similarity. They are the arithmetic of 415 pairs and a handful of events, and the correct summary is that the study could not tell — the same reading [a wide interval always demands](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia), whether it favors a drug or not. ## The sentence that goes further than the data The authors conclude that the two drugs demonstrated similar short-term safety and utilization profiles, and that the findings support continued perioperative use of either agent. The first half is a reasonable summary of a null result if you read “similar” loosely. The second half is a recommendation, and a failure to detect a difference among 830 patients does not establish that no difference exists. Concluding equivalence takes a study designed to rule out a difference of a stated size, and this was not one. It is the same distinction between [what a design was built to answer](https://thisglp.com/research/do-glp1-drugs-cause-gout) and what gets claimed from it. ## Not the opposite claim either None of this suggests either drug is risky around surgery. The point estimates cluster near no difference, nothing looked alarming, and the study is perfectly good evidence that no large difference was detected. The honest position is narrower than either headline: on this evidence nobody can tell the two apart for knee replacement, and the reason is that nobody has looked at enough patients. Whether these drugs should be paused before surgery at all is a separate question with [its own page here](https://thisglp.com/research/glp1-before-surgery), and it is the question a patient is more likely to face. ## Shoulder surgery: the alarming numbers that did not survive adjustment Among 5,876 people with type 2 diabetes having a rotator cuff repair, 233 were on a GLP-1 beforehand. Compared directly, they looked worse on three outcomes: respiratory complications at an odds ratio of 1.97, urinary tract infection at 3.85, and postoperative stiffness at 2.20 [\[2\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-2). Once the two groups were reweighted to resemble each other on measured characteristics, every one of those differences disappeared. Nothing about the patients had changed; only the comparison had. The raw figures were measuring who gets prescribed a GLP-1, not what the drug does — the full breakdown is in [the shoulder surgery adjustment](https://thisglp.com/research/glp1-shoulder-surgery-adjustment). ## Spinal fusion: protective in one database, worse in another Twelve retrospective cohorts on GLP-1 use and cervical spine fusion give three different answers depending on which database and which procedure [\[3\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-3). For anterior cervical fusion, one large claims network put the odds of failed fusion at 0.52 against non-users; a second, independent network found a neutral 0.86. A semaglutide-specific cohort of posterior cervical fusion went the other way entirely, at 4.79. Pooling all twelve gives an odds ratio of 1.28, with a confidence interval from 0.35 to 4.70. That range spans a two-thirds reduction and a near-fivefold increase. It is evidence the studies should not have been pooled, rather than a finding about the drugs. The procedure-by-procedure detail is in [the spinal fusion review](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery). ## Neck fusion: doubling the dose changed nothing A fourth study asked a narrower question: among people already on a GLP-1 before neck fusion surgery, does a higher dose change the outcome [\[4\]](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes#ref-4)? Comparing 921 matched pairs on a high dose against 921 on a standard dose, nothing differed across nine measures — readmission, emergency visits, complications, swallowing problems, opioid use, and failed fusion. Both dose groups also fared better than matched patients taking no GLP-1 at all, though that second comparison carries the weaker evidence, for the same reason the knee and shoulder comparisons above do. The full results are in [the neck fusion dose comparison](https://thisglp.com/research/glp1-neck-fusion-high-dose). ## Why this pattern matters beyond knees Because “no significant difference” is the most frequently over-read phrase in medical writing. It gets reported as reassurance, quoted as equivalence, and eventually cited as evidence that two things are the same. The test takes a moment: look at the interval rather than the p-value, and ask what the upper bound would mean if it were true. If it would matter, the study did not settle anything. Almost nothing a seller publishes includes an interval at all, which [the census of what goes unsaid](https://thisglp.com/tools/questions-they-leave-open) measures from the other end. ## Frequently asked Does a GLP-1 affect surgery outcomes? It depends on the procedure. Knee replacement and neck fusion showed no significant difference. Shoulder surgery's raw signals of higher complications vanished once the comparison was adjusted. Spinal fusion showed protective, neutral, and worse associations depending on the database and procedure. Is one drug safer before knee surgery? This study cannot tell you. Nothing reached significance, but the intervals are wide enough to contain meaningful differences in either direction — surgical complications ran from 0.845 to 3.152. Why did the shoulder surgery numbers change so much after adjustment? Because people prescribed a GLP-1 for type 2 diabetes differ from those who are not. The raw odds ratios of up to 3.85 were describing who gets the prescription, not what the drug did. Does a non-significant result mean the drugs are equivalent? No. Showing equivalence requires a study designed to rule out a difference of a stated size. Failing to detect one among a few hundred patients is a statement about the study's size, not proof of safety. Should either drug be stopped before surgery? That is a different question, about perioperative pausing rather than about outcomes, and it is one a surgical team decides. ## Sources 1. \[1\] Wu KA, et al. (2026). Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysis The Knee. [PMID 42727208](https://pubmed.ncbi.nlm.nih.gov/42727208/) 2. \[2\] Choudhury A, et al. (2026). The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repair Shoulder & Elbow. [PMID 42712738](https://pubmed.ncbi.nlm.nih.gov/42712738/) 3. \[3\] Yu X, et al. (2026). GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence European Spine Journal. [PMID 42635669](https://pubmed.ncbi.nlm.nih.gov/42635669/) 4. \[4\] Stirpe C, et al. (2026). Impact of GLP-1 Dose Intensity on Perioperative and Long-Term Fusion Outcomes Following ACDF The Spine Journal. [PMID 42705550](https://pubmed.ncbi.nlm.nih.gov/42705550/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Does Taking a GLP-1 Before Pregnancy Raise Preeclampsia Risk? The Studies Split Does a GLP-1 before pregnancy raise preeclampsia risk? A JAMA cohort found 46% vs 36% after stopping; another found 19.9% vs 22.8% | the pooled OR was 0.91. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk Updated: 2026-10-15 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Does Taking a GLP-1 Before Pregnancy Raise Preeclampsia Risk? The Studies Split Pooled, three cohorts showed no association. A JAMA cohort found 46% against 36% when the drug was stopped around conception, and a records study found 19.9% against 22.8%. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated October 2026 Hypertensive disorders of pregnancy, exposed vs unexposed · Stopped around conception · 46% · 36% · Prescribed in prior 2 years · 19.9% · 22.8% · Upper bar: exposed. Lower bar: unexposed. · Pooled across three cohorts: OR 0.91 (0.57 to 1.47). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The studies point both ways. A pooled review of three cohorts found an odds ratio of 0.91 (95% CI 0.57 to 1.47) [\[1\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-1). That is no significant association. A JAMA cohort found hypertensive disorders in 46% of exposed pregnancies against 36% [\[2\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-2). In that cohort the drug was stopped before or early in pregnancy. A larger records study found the opposite: 19.9% against 22.8% [\[3\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-3). ## Key takeaways - Pooled review, 10,880 pregnancies in three cohorts: odds ratio 0.91, 95% CI 0.57 to 1.47. - JAMA cohort, drug stopped around conception: 46% against 36%, risk ratio 1.29. - Records study, prescription in the two prior years: 19.9% against 22.8%, odds ratio 0.84. - Small cohort of 31 exposed pregnancies: more preeclampsia after prepregnancy exposure. - No study randomized anyone. The exposures differ from study to study. Preeclampsia is one of several hypertensive disorders of pregnancy. Most studies below count them together. Birth defects and other pregnancy outcomes are a separate question, covered in [the pregnancy evidence guide](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows). ## 1\. The pooled review The review searched five databases to December 2025 [\[1\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-1). It found three retrospective cohorts, all from the United States. Together they held 10,880 pregnancies: 4,942 exposed and 5,938 unexposed. Exposure meant a GLP-1 before conception or in the first trimester. Two of the three found lower risk. One found higher. Pooled, the odds ratio was 0.91. The interval runs from a 43% reduction to a 47% increase. The review rules out neither. ## 2\. When the drug was stopped around conception The JAMA cohort drew on 149,790 pregnancies in one academic health system [\[2\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-2). Exposure meant a GLP-1 order from three years before conception to 90 days after it. The weight-gain analysis matched 448 exposed pregnancies to 1,344 unexposed. Its population was mainly people with obesity. The obstetric analysis used a separate matched cohort. These are not interchangeable denominators. Hypertensive disorders reached 46% against 36%, a risk ratio of 1.29 (95% CI 1.12 to 1.49). Weight gain in pregnancy was 13.7 kg against 10.5 kg. Preterm delivery and gestational diabetes were also higher. The authors frame the result as following discontinuation of the drug. Association does not establish a stopping effect This was a comparison of prescription histories. It did not compare randomized stopping with continued treatment. Medication orders only estimated when treatment ended. Actual use could not be confirmed for every patient. Matching used BMI before pregnancy, not before GLP-1 treatment. Differences in earlier weight and health could still matter. The results do not show that continuing during pregnancy would prevent these outcomes. ## 3\. When the drug was prescribed in the two prior years A national records study matched 4,267 pregnancies with a GLP-1 prescription in the prior 24 months against 4,267 with none [\[3\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-3). Hypertensive disorders ran at 19.9% against 22.8%, an odds ratio of 0.84 (95% CI 0.76 to 0.94). Gestational diabetes and preterm delivery were also lower. This contrast is different. It compares ever being prescribed with never. It does not separate women who stopped early from women who stopped late. ## 4\. A small cohort pointing up A fourth cohort studied women with both obesity and diabetes [\[4\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-4). It found 31 exposed pregnancies and matched 29. Preeclampsia was more common after exposure in the 12 or 24 months before delivery. The abstract reports p-values of 0.023 and 0.018, not rates. Cesarean delivery was also more frequent. With 29 matched pairs, the estimate is fragile. ## What the differences mean The pooled review and individual cohorts are not independent evidence to add together. Exposure windows, patient histories and outcomes differ. Prescription records also do not prove that a medicine was taken. These results do not establish that earlier treatment prevents preeclampsia or that stopping causes it. Weight regain after stopping is a separate finding, covered in [the stopping evidence](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1). It does not prove the mechanism behind these pregnancy associations. ## What to do with this Weight-loss treatment should not continue during pregnancy. Wegovy labeling directs stopping when pregnancy is recognized for weight reduction [\[5\]](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk#ref-5). For planned pregnancy, its instructions specify stopping at least two months beforehand. This is semaglutide-specific advice, not a class-wide interval. Discuss the exact medicine and a transition plan with your prescriber before trying to conceive. Effects on conception itself are covered in [the fertility guide](https://thisglp.com/research/do-glp1-drugs-affect-fertility), and the period after birth in [the breastfeeding guide](https://thisglp.com/research/can-you-take-ozempic-while-breastfeeding). Tell the obstetric team which medicine you used and when it stopped. Discuss blood pressure, weight and glucose monitoring. If you have diabetes, arrange a pregnancy-appropriate treatment plan rather than leaving high blood sugar untreated. ## Frequently asked Does taking a GLP-1 before pregnancy raise preeclampsia risk? The studies disagree. A pooled review of three cohorts found an odds ratio of 0.91 (95% CI 0.57 to 1.47). A JAMA cohort found hypertensive disorders in 46% against 36% when the drug was stopped around conception. A records study found 19.9% against 22.8% after a prescription in the prior two years. Does stopping a GLP-1 before pregnancy raise blood pressure risk? The JAMA cohort found an association, not proof that stopping causes harm. It compared prescription histories and did not test continued treatment against stopping. Its 46% versus 36% result covers hypertensive disorders together, not preeclampsia alone. Can a GLP-1 prevent preeclampsia? That has not been shown. One records study found lower rates after a prescription in the prior two years, 19.9% against 22.8%. Other cohorts found higher rates, and none of these studies was a trial. Should I tell my obstetrician I took a GLP-1? Yes. Share the medicine, treatment dates and reason for taking it. Your team can plan blood pressure and glucose monitoring and appropriate treatment during pregnancy. ## Sources 1. \[1\] Pisani D, Lorenza D, Fordellone M, Cerillo A, Fatigati M, Hanulíková P, et al. (2026). Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis Endocrine. [PMID 42536323](https://pubmed.ncbi.nlm.nih.gov/42536323/) 2. \[2\] Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, et al. (2025). Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation JAMA. [PMID 41284263](https://pubmed.ncbi.nlm.nih.gov/41284263/) 3. \[3\] Imbroane MR, LeMoine F, Nau CT (2025). Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes American Journal of Obstetrics and Gynecology. [PMID 39848396](https://pubmed.ncbi.nlm.nih.gov/39848396/) 4. \[4\] Lemas DJ, Zapata R, Loy I, Mahadevan A, Wen T, Mkuu R, et al. (2026). Prepregnancy GLP-1RA Exposure and Risk of Hypertensive Disorders of Pregnancy Among Women With Obesity and Diabetes Obesity. [PMID 42120704](https://pubmed.ncbi.nlm.nih.gov/42120704/) 5. \[5\] Novo Nordisk (2026). Wegovy prescribing information Novo Nordisk. [Source](https://www.novo-pi.com/wegovy.pdf) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Does Orforglipron Work for Type 2 Diabetes? Three Phase 3 Trials | This GLP Orforglipron cut HbA1c 1.23 to 1.91 points in three phase 3 trials | it beat placebo, dapagliflozin and oral semaglutide, with more side effects and discontinuations. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes Updated: 2026-10-26 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Does Orforglipron Work for Type 2 Diabetes? Three Phase 3 Trials Yes, on blood sugar. HbA1c fell 1.23 to 1.91 points and the tablet beat placebo, dapagliflozin and oral semaglutide. More people stopped it than stopped either active comparator. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 HbA1c fall at week 40, percentage points · orforglipron 36 mg · −1.56 · orforglipron 12 mg · −1.50 · orforglipron 3 mg · −1.23 · dapagliflozin 10 mg · −0.81 · The trial only had to prove it was no worse. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Yes, on blood sugar. In three phase 3 trials, HbA1c fell 1.23 to 1.91 percentage points on orforglipron, and it beat placebo, dapagliflozin and oral semaglutide. - Against oral semaglutide over 52 weeks in 1,698 adults, HbA1c fell 1.71 and 1.91 points on orforglipron against 1.23 and 1.47 on semaglutide. - Against dapagliflozin over 40 weeks in 962 adults, a trial built only to show a tie, all three doses won outright. - The cost is tolerability: more gastrointestinal events and more people stopping than on either active comparator. - No severe hypoglycemia was reported in the placebo-controlled or dapagliflozin trials. Yes, on the measure diabetes trials are built around. Across three phase 3 trials in adults with type 2 diabetes, orforglipron lowered HbA1c by 1.23 to 1.91 percentage points. It beat every comparator it faced: placebo [\[2\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-2), dapagliflozin [\[1\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-1) and oral semaglutide [\[3\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-3). The price was more nausea-type side effects and more people stopping treatment. Orforglipron’s first US approval, in April 2026, was for weight management, covered in [what orforglipron is](https://thisglp.com/research/what-is-orforglipron). ## Against placebo, in early diabetes ACHIEVE-1 enrolled 559 adults whose diabetes was treated with diet and exercise alone, at a mean starting HbA1c of 8.0% [\[2\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-2). Over 40 weeks HbA1c fell 1.24, 1.47 and 1.48 percentage points on the 3, 12 and 36 mg doses, against 0.41 on placebo. Mean HbA1c ended at 6.5% to 6.7% on the drug. Weight fell 4.5% to 7.6% against 1.7% on placebo. Adverse events ended treatment for 4.4% to 7.8% on orforglipron against 1.4% on placebo. The phase 2 trial that set those doses ran 26 weeks in 383 adults [\[4\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-4). HbA1c fell by up to 2.10% on orforglipron, against 0.43% on placebo and 1.10% on injected dulaglutide. Body weight fell by up to 10.1 kg. ## Against dapagliflozin, added to metformin ACHIEVE-2 tested it where most diabetes drugs are actually decided: as the thing added when metformin is no longer enough [\[1\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-1). The design deserves a moment because the phrase appears constantly and is rarely explained. A non-inferiority trial does not set out to show a drug is better. It sets out to show the drug is not worse by more than an agreed margin, here 0.3 percentage points of HbA1c. It did considerably more than hold its own. In 962 adults at week 40, HbA1c fell 1.23, 1.50 and 1.56 percentage points on the three doses against 0.81 with dapagliflozin. The treatment differences were −0.42 (95% CI −0.62 to −0.23), −0.70 (−0.90 to −0.49) and −0.75 (−0.96 to −0.55). A trial built to show a tie produced a win, which is a stronger signal because nobody designed it to find one. Beating a drug on blood sugar is not beating it overall Dapagliflozin is an SGLT2 inhibitor, and its value is not confined to glucose. That class reduces heart failure hospitalization and slows kidney disease progression, benefits an HbA1c endpoint cannot see. On at least one outcome the same class outperforms GLP-1 drugs, as [the atrial fibrillation comparison](https://thisglp.com/research/atrial-fibrillation-the-other-drug-won) shows. ACHIEVE-2 answers a narrow question well. ## Against the other GLP-1 tablet ACHIEVE-3 is the comparison a tablet buyer would ask for: orforglipron against oral semaglutide, both once daily, in 1,698 adults on metformin for 52 weeks [\[3\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-3). From a starting HbA1c of 8.3%, it fell 1.71 and 1.91 points on orforglipron 12 and 36 mg, against 1.23 and 1.47 on semaglutide 7 and 14 mg. Both orforglipron doses beat both semaglutide doses, including 12 mg against 14 mg, by 0.24 points (95% CI −0.41 to −0.072). Oral semaglutide has to be taken on an empty stomach with little water, a routine set out in [what the pill does](https://thisglp.com/research/oral-semaglutide-what-the-pill-does). Orforglipron was designed to be taken without food or water restrictions [\[3\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-3). ## What it costs in tolerability Every trial reports the same trade. In ACHIEVE-2, gastrointestinal events affected 46% to 54% of the orforglipron groups against 12% on dapagliflozin. Between 15% and 20% stopped the study drug, against 6% [\[1\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-1). In ACHIEVE-3, 9% and 10% stopped because of adverse events against 4% and 5% on semaglutide. Pulse rose 3.7 and 4.7 beats per minute on orforglipron against 1.0 and 1.5 [\[3\]](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes#ref-3). One design choice makes these results more useful than they might have been. ACHIEVE-2 and ACHIEVE-3 counted each participant’s data whether or not they stopped the drug or added another. That measures what happens when someone is put on a drug, not what happens if they stay on it perfectly. Given how often people stop, that is the more honest question, and [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated) puts orforglipron among the highest for stopping because of adverse events. Both active-comparator trials were open-label, so everyone knew what they were taking. HbA1c is a laboratory measure and difficult to influence directly, but knowing you are on the new drug can change adherence and effort. Where orforglipron sits among the other tablets in development is in [the guide to GLP-1 pills](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection), and the wider pipeline includes [ecnoglutide](https://thisglp.com/research/what-is-ecnoglutide). ## Frequently asked Does orforglipron lower A1c? Yes. In three phase 3 trials HbA1c fell 1.23 to 1.91 percentage points on orforglipron, depending on dose, comparator and trial length. It was superior to placebo, dapagliflozin and oral semaglutide. Is orforglipron better than oral semaglutide for diabetes? On HbA1c, yes, in one 52-week trial of 1,698 adults: 1.71 and 1.91 points on orforglipron against 1.23 and 1.47 on oral semaglutide. More people stopped orforglipron because of side effects, 9% to 10% against 4% to 5%. What is a non-inferiority trial? One designed to show a drug is not worse than a comparator by more than an agreed margin, here 0.3 percentage points of HbA1c. Orforglipron cleared that margin in two trials and then showed it was better outright. Does beating dapagliflozin make it the better drug? Not necessarily. Dapagliflozin belongs to a class with benefits for heart failure and kidney disease that an HbA1c endpoint does not measure, so that trial answers a narrow question. ## Sources 1. \[1\] Welch M, Forst T, Jia W, Del Pino PO, et al. (2026). Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial The Lancet. [PMID 42259339](https://pubmed.ncbi.nlm.nih.gov/42259339/) 2. \[2\] Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes The New England Journal of Medicine. [PMID 40544435](https://pubmed.ncbi.nlm.nih.gov/40544435/) 3. \[3\] Rosenstock J, Yabe D, Cox D, Li J, et al. (2026). Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial The Lancet. [PMID 41765029](https://pubmed.ncbi.nlm.nih.gov/41765029/) 4. \[4\] Frias JP, Hsia S, Eyde S, Liu R, et al. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study The Lancet. [PMID 37369232](https://pubmed.ncbi.nlm.nih.gov/37369232/) ## Prescription access ### LillyDirect’s Foundayo pathway Understand the prescription requirements, pharmacy pathway and payment terms before arranging Foundayo treatment. [Read the LillyDirect review →](https://thisglp.com/reviews/lillydirect-foundayo) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Does Ozempic Cause Constipation? What the Trials Counted, and When It Eases Does Ozempic cause constipation? 5.0% on 0.5 mg vs 1.5% on placebo, and 24.2% vs 11.1% at the 2.4 mg dose | mostly mild and early, during dose steps. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-ozempic-cause-constipation Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Does Ozempic Cause Constipation? What the Trials Counted, and When It Eases Yes: 5.0% on Ozempic 0.5 mg against 1.5% on placebo, and 24.2% on the 2.4 mg weight-loss dose against 11.1%. Nearly all of it was mild to moderate and clustered in the dose-escalation weeks. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Constipation in label tables, drug against placebo · Ozempic 0.5 mg (T2D) · 5.0% vs 1.5% · Wegovy 2.4 mg · 24% vs 11% · Mounjaro 15 mg (T2D) · 7% vs 1% · Zepbound 5 mg · 17% vs 5% · Separate trials and populations. T2D = type 2 diabetes trials. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, and far more often at the weight-loss dose than at the diabetes doses. In the diabetes trials behind the Ozempic label, constipation affected 5.0 percent of people on 0.5 mg and 3.1 percent on 1 mg, against 1.5 percent on placebo [\[1\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-1). At 2.4 mg, the dose sold as Wegovy, it reached 24.2 percent of 2,117 adults against 11.1 percent of 1,262 on placebo across three 68-week trials, and nearly all of those stomach side effects were mild to moderate [\[2\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-2). ## Key takeaways - On Ozempic 0.5 mg in type 2 diabetes trials, 5.0% reported constipation against 1.5% on placebo. - At the 2.4 mg weight-loss dose, 24.2% reported it against 11.1% on placebo, so roughly one extra person in eight. - Of all stomach side effects on 2.4 mg, 99.5% were non-serious and 98.1% mild to moderate, and 4.3% of people stopped the drug because of them. - Tirzepatide shows the same side effect: 11% to 17% on Zepbound against 5%, and 6% to 7% on Mounjaro against 1%. - Stomach side effects cluster during dose escalation. No trial behind these labels published how long constipation lasts. It tends to arrive in the first months, in the weeks when the pen is being stepped up and a smaller plate at dinner has become the new normal, and the trials place it there too. The numbers below come from the placebo-controlled trials, because the placebo arm is the only way to tell how much of that constipation belongs to the drug. It turns out that about one person in nine on placebo reported it too. ## How often Ozempic causes constipation, dose by dose The Ozempic label draws its table from two placebo-controlled trials in type 2 diabetes, in which 521 people took the drug for a mean of 32.9 weeks [\[1\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-1). Constipation made the table at 5.0 percent on 0.5 mg and 3.1 percent on 1 mg, well behind nausea at 15.8 to 20.3 percent. At those diabetes doses it is one of the quieter side effects, and nausea is the one that sets the tone, as [how long nausea lasts on a GLP-1](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) describes. The weight-loss dose is a different picture. Pooling the STEP 1 to 3 trials, constipation ran at 24.2 percent on semaglutide 2.4 mg against 11.1 percent on placebo, the fourth most common stomach complaint after nausea, diarrhea and vomiting [\[2\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-2). The Wegovy label prints the same trials as 24 percent against 11 percent [\[3\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-3). Put plainly, about one extra person in eight became constipated because of the drug rather than the diet, the season or the travel that would have done it anyway. ## How bad it gets, and how many stop Most of it was mild. Across the stomach side effects in those trials, 99.5 percent of events were non-serious and 98.1 percent were mild to moderate, and 4.3 percent of people on semaglutide stopped the drug permanently because of them [\[2\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-2). The same analysis found that weight loss was about the same whether or not someone had stomach side effects. A constipated month is not a sign the drug is working harder, a point taken further in [why GLP-1 drugs cause nausea](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea). The labels also carry a rarer tail that the trial tables are too small to count. Since approval, reports have included severe constipation with fecal impaction, ileus and intestinal obstruction, listed as post-marketing reactions whose frequency cannot be estimated [\[1\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-1). Those belong in a different conversation from the usual slow week, and the closest cousin, a stomach that stops emptying, is covered in [whether GLP-1 drugs cause gastroparesis](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). Where the evidence stops The trial abstracts describe stomach side effects as transient as a group; none of the sources here reports how many weeks constipation alone lasted, or what helped. The labels list severe constipation among post-marketing reports without a rate. Compounded semaglutide is not FDA-approved and has no trial side-effect table of its own. ## Zepbound and Mounjaro: tirzepatide’s numbers Tirzepatide causes constipation too. The Zepbound label, from two obesity trials, lists it at 17 percent on 5 mg, 14 percent on 10 mg and 11 percent on 15 mg, against 5 percent on placebo, a row that falls as the dose rises [\[4\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-4). The Mounjaro label, from diabetes trials, lists it at 6 to 7 percent against 1 percent, and at 13 percent in a cardiovascular outcomes trial of 6,647 adults [\[5\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-5). The FDA database points in the same direction from the other side. In 123,145 reports for tirzepatide, constipation was reported with lower odds than for semaglutide, along with vomiting and decreased appetite [\[6\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-6). That is a comparison of reports, not users, and no trial has randomized people between the two drugs with constipation as the outcome; the head-to-head trial that exists measured weight, as [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) explains. ## When it tends to ease The trials place stomach side effects in the escalation weeks. The STEP analysis found they occurred most frequently during or shortly after dose escalation and were transient [\[2\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-2), and the tirzepatide obesity trial reported the same pattern across its 20-week escalation [\[7\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-7). A review of 26 randomized trials in 15,491 people without diabetes found stomach side effects in 47 to 84 percent of people on a GLP-1 against 13 to 63 percent on placebo. Constipation was among the most common [\[8\]](https://thisglp.com/research/does-ozempic-cause-constipation#ref-8). What is still missing is a timetable. None of these trials published constipation by week, so there is no measured answer to whether it settles a month after the last dose step or lingers through maintenance. People who already had bowel trouble before starting are asking a different question again, one with its own evidence in [whether GLP-1 drugs help IBS](https://thisglp.com/research/do-glp1-drugs-help-ibs). How side effects weigh against weight loss across every obesity drug is set out in [the 262-trial ranking of weight lost against dropout](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). ## Frequently asked Does Ozempic cause constipation? Yes. In the type 2 diabetes trials behind the label, 5.0% on 0.5 mg and 3.1% on 1 mg reported constipation against 1.5% on placebo. At the 2.4 mg weight-loss dose it was 24.2% against 11.1%. How common is Ozempic constipation compared with nausea? Less common. On Ozempic 0.5 to 1 mg, nausea affected 15.8% to 20.3% against constipation at 3.1% to 5.0%. At 2.4 mg, nausea affected 43.9% and constipation 24.2%. Does Zepbound cause constipation? Yes. The Zepbound label lists constipation at 17% on 5 mg, 14% on 10 mg and 11% on 15 mg, against 5% on placebo, in two 72-week obesity trials. Is Mounjaro constipation worse than Ozempic constipation? No trial has compared them on constipation. The Mounjaro label lists 6% to 7% against 1% on placebo in diabetes trials, and FDA reports for tirzepatide showed lower reporting odds of constipation than for semaglutide, which counts reports rather than users. ## Sources 1. \[1\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, Table 1 and sections 6.1 and 6.2 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 2. \[2\] Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity & Metabolism. [PMID 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682/) 3. \[3\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Table 3 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 4. \[4\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, Table 1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) 5. \[5\] Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information, Table 1 and section 6.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0) 6. \[6\] Guo X, Zhang J, Li Q, Ye Z, Yuan S (2026). Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database Diabetes, Obesity & Metabolism. [PMID 42443144](https://pubmed.ncbi.nlm.nih.gov/42443144/) 7. \[7\] Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity The New England Journal of Medicine. [PMID 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/) 8. \[8\] Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ (2025). Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials Annals of Internal Medicine. [PMID 39761578](https://pubmed.ncbi.nlm.nih.gov/39761578/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call | This GLP Diarrhea affected about 9 in 100 adults in Ozempic trials. Learn what those figures mean, what to track, and which symptoms need prompt attention. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-ozempic-cause-diarrhea Updated: 2026-10-13 Published: 2026-10-13 [← Research](https://thisglp.com/research) Safety # Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call Diarrhea affected about 9 in 100 adults in Ozempic trials. Learn what those figures mean, what to track, and which symptoms need prompt attention. [This GLP Editorial Team](https://thisglp.com/about)October 20265 min read 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes. In placebo-controlled Ozempic trials, diarrhea occurred in 8.5% of adults taking 0.5 mg and 8.8% taking 1 mg, versus 1.9% taking placebo. These are trial rates in adults with type 2 diabetes, not a prediction for every person using semaglutide. [\[1\]](https://thisglp.com/research/does-ozempic-cause-diarrhea#ref-1) A loose stool is different from repeated watery stools that leave you weak or unable to drink. The useful question is how severe the change is and whether you are losing fluids. Our guide to [GLP-1 dehydration symptoms](https://thisglp.com/research/glp1-dehydration-symptoms) explains that distinction. ## Why the dose and product matter The Ozempic label says most nausea, vomiting, and diarrhea reports occurred during dose escalation. It does not provide a reliable countdown for when an individual episode will stop. [\[1\]](https://thisglp.com/research/does-ozempic-cause-diarrhea#ref-1) A symptom that began after a dose change is worth reporting, but timing alone does not prove the medication caused it. Research on semaglutide 2.4 mg provides additional context. A pooled analysis of the STEP 1–3 weight-management trials found diarrhea in 29.7% of semaglutide participants and 15.9% of placebo participants. Gastrointestinal events were usually mild or moderate and clustered around escalation. Those studies used a different dose and population from the Ozempic trials. [\[2\]](https://thisglp.com/research/does-ozempic-cause-diarrhea#ref-2) Do not combine those percentages into one generic semaglutide rate. They answer different questions. The same caution applies when comparing [side effects across GLP-1 drugs](https://thisglp.com/research/which-glp1-has-the-worst-side-effects). ## What to record before contacting your prescriber A brief symptom note is more useful than guessing which food or injection caused the problem. Record when the diarrhea started, how often it happens, the date of your last dose, and whether your dose recently changed. Add any vomiting, fever, pain, recent travel, or new medications. Bring the medication list rather than stopping several treatments at once. A clinician can consider infection, food-related illness, and other medicines alongside semaglutide. NIDDK identifies these as common causes of acute diarrhea. [\[3\]](https://thisglp.com/research/does-ozempic-cause-diarrhea#ref-3) If you also take metformin, our [metformin and Ozempic guide](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together) covers why combination treatment needs its own review. ## When diarrhea needs medical attention Contact a healthcare professional promptly for dehydration symptoms, frequent vomiting, high fever, severe abdominal or rectal pain, or black or bloody stools. NIDDK also advises adults to seek care for diarrhea lasting more than two days or six or more loose stools in a day. These are reasons to call, not targets to wait for when you feel seriously unwell. [\[3\]](https://thisglp.com/research/does-ozempic-cause-diarrhea#ref-3) Persistent severe upper abdominal pain, especially if it reaches your back, needs urgent assessment. It should not be dismissed as ordinary stomach upset. Read the separate [pancreatitis evidence](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis) for context, rather than trying to diagnose it from stool changes alone. ## Does diarrhea mean the treatment is working? Feeling ill is not a treatment goal. In the pooled STEP analysis, gastrointestinal events explained less than one percentage point of semaglutide's additional weight loss versus placebo. Weight loss was not simply the result of people being too sick to eat. [\[2\]](https://thisglp.com/research/does-ozempic-cause-diarrhea#ref-2) Ask your prescriber how to handle your next dose if symptoms are ongoing. A useful plan should cover hydration, whether other causes need investigation, and whether the dosing schedule needs adjustment. Increasing the dose through persistent symptoms is not something to decide from a generic online schedule. ## Frequently asked Is diarrhea common with Ozempic? It occurred in 8.5% to 8.8% of adults receiving 0.5 mg or 1 mg in the placebo-controlled trials, compared with 1.9% on placebo. How long does Ozempic diarrhea last? The label does not give an individual recovery time. Contact your clinician for persistent or severe symptoms; do not assume all diarrhea is caused by Ozempic. Does diarrhea mean Ozempic is causing weight loss? Side effects are not needed for benefit. A semaglutide weight-management analysis found that gastrointestinal events explained very little of the additional weight loss versus placebo. ## Sources 1. \[1\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection: U.S. prescribing information Novo Nordisk; revised May 2026. [Source](https://www.novo-pi.com/ozempic.pdf) 2. \[2\] Wharton S, Calanna S, Davies M, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. [PMID 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682/) 3. \[3\] National Institute of Diabetes and Digestive and Kidney Diseases (2024). Symptoms & Causes of Diarrhea NIDDK. [Source](https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea/symptoms-causes) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) - [ 1–4 bpm · Mean rise vs placebo · Resting pulse · Track consistently · Persistent rise · Contact prescriber ### Does Wegovy Increase Heart Rate? Understanding the Numbers ](https://thisglp.com/research/does-wegovy-increase-heart-rate) --- # Does Ozempic Cause Dizziness? What to Check First | This GLP Dizziness is listed in Ozempic prescribing information. Low glucose, fluid loss, and other causes need different responses. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-ozempic-cause-dizziness Updated: 2026-10-13 Published: 2026-10-13 [← Research](https://thisglp.com/research) Safety # Does Ozempic Cause Dizziness? What to Check First Dizziness is listed in Ozempic prescribing information. Low glucose, fluid loss, and other causes need different responses. [This GLP Editorial Team](https://thisglp.com/about)October 20265 min read Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, dizziness is a recognized Ozempic adverse reaction. The label lists it among reactions reported at a frequency above 0.4%, without giving a separate exact rate. That figure does not tell you why you feel dizzy or whether your symptoms can safely wait. [\[1\]](https://thisglp.com/research/does-ozempic-cause-dizziness#ref-1) Sit or lie down if you feel faint, and avoid driving while unsteady. Describe whether you feel lightheaded, off balance, or as though the room is spinning. MedlinePlus distinguishes these sensations because they can point toward different causes. [\[2\]](https://thisglp.com/research/does-ozempic-cause-dizziness#ref-2) For ongoing tiredness without dizziness, see [GLP-1 fatigue](https://thisglp.com/research/do-glp1-drugs-make-you-tired). ## Check glucose when your diabetes plan calls for it If you use insulin or a sulfonylurea, low blood glucose deserves particular attention. Ozempic can increase hypoglycemia risk when combined with these medicines. [\[1\]](https://thisglp.com/research/does-ozempic-cause-dizziness#ref-1) Sweating, shaking, hunger, or confusion accompanying dizziness makes a glucose check especially useful, although symptoms alone cannot confirm the cause. NIDDK advises people with diabetes to check glucose when low-glucose symptoms begin. If it is below the person's target or below 70 mg/dL, an awake person who can swallow should follow their hypoglycemia treatment plan. Its general guidance uses 15 to 20 grams of rapid carbohydrate, followed by another check after 15 minutes. Severe confusion, seizure, or unconsciousness requires emergency help; do not give food or drink to someone who cannot swallow safely. [\[3\]](https://thisglp.com/research/does-ozempic-cause-dizziness#ref-3) Do not reduce insulin on your own because one dizzy episode seemed related to a smaller meal. Share the reading and timing with the clinician who manages your diabetes. ## Look for fluid loss, without assuming it is the answer Vomiting or [diarrhea on Ozempic](https://thisglp.com/research/does-ozempic-cause-diarrhea) changes the context. The label warns about kidney injury associated with volume depletion. [\[1\]](https://thisglp.com/research/does-ozempic-cause-dizziness#ref-1) Faintness after gastrointestinal symptoms belongs in a call to the prescriber, especially when drinking is difficult. Our [dehydration guide](https://thisglp.com/research/glp1-dehydration-symptoms) explains what to watch for. Dizziness by itself is not a hydration test, however. A normal-looking urine sample or a drink of water cannot rule out other causes. ## What a useful symptom record includes Write down whether the feeling starts when you stand up, during exercise, after a meal, or while resting. Include recent dose changes and any home blood pressure or glucose readings you already collect. List all prescription and nonprescription medicines, including treatments that can affect blood pressure. That record helps the clinician decide what to investigate. It also avoids turning an observation such as “I felt dizzy after my injection” into a conclusion that excludes an unrelated illness. New or recurrent symptoms deserve assessment even if earlier episodes settled. ## When to get urgent help Dizziness with chest pain, shortness of breath, a new irregular heartbeat, fainting, new weakness, or trouble speaking needs urgent medical evaluation. MedlinePlus identifies associated heart and neurologic symptoms as reasons to seek emergency care. [\[2\]](https://thisglp.com/research/does-ozempic-cause-dizziness#ref-2) Do not wait for the next injection appointment when these occur. A pulse change is a separate question from lightheadedness. The guide to [semaglutide and resting heart rate](https://thisglp.com/research/does-wegovy-increase-heart-rate) explains why a small average trial change does not make a racing heart harmless. A medication review should respond to your symptoms, not just the average experience in a safety table. ## Frequently asked Is dizziness an Ozempic side effect? Yes. The prescribing information lists dizziness among adverse reactions reported above 0.4%, but does not give a separate exact percentage. Does dizziness always mean low blood sugar? No. Glucose changes, fluid loss, blood pressure changes, and unrelated conditions can cause similar sensations. Check glucose according to your diabetes plan and seek assessment for severe or recurrent symptoms. ## Sources 1. \[1\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection: U.S. prescribing information Novo Nordisk; revised May 2026. [Source](https://www.novo-pi.com/ozempic.pdf) 2. \[2\] U.S. National Library of Medicine (2026). Dizziness and Vertigo MedlinePlus; accessed October 13, 2026. [Source](https://medlineplus.gov/dizzinessandvertigo.html) 3. \[3\] National Institute of Diabetes and Digestive and Kidney Diseases (2021). Low Blood Glucose (Hypoglycemia) NIDDK. [Source](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ 1–4 bpm · Mean rise vs placebo · Resting pulse · Track consistently · Persistent rise · Contact prescriber ### Does Wegovy Increase Heart Rate? Understanding the Numbers ](https://thisglp.com/research/does-wegovy-increase-heart-rate) --- # Does Ozempic Cause Hair Loss? What 1,091,743 Records Show | This GLP Pooled across 17 studies, GLP-1 use raised the odds of non-scarring hair loss to 1.40. Telogen effluvium rose to 1.76; autoimmune alopecia areata did not rise at all. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-ozempic-cause-hair-loss Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Does Ozempic Cause Hair Loss? What 1,091,743 Records Show Pooled across 1,091,743 exposures, the odds are raised about 40%. The kind of hair loss that goes up points at the weight you lost, not the drug. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Odds of each kind of hair loss, pooled · 1.0 · any non-scarring · telogen effluvium · androgenetic · alopecia areata · The autoimmune one is the one that does not move. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Yes, modestly. Pooled across 17 studies and 1,091,743 patient-exposures, the odds of non-scarring hair loss were 1.40 (95% CI 1.33 to 1.48). - The subtype matters: telogen effluvium — the shedding that follows rapid weight loss — was raised at 1.76, while autoimmune alopecia areata was not raised at all (1.08, 95% CI 0.87 to 1.34). - In a separate matched cohort, GLP-1 users who experienced hair loss had a LOWER follow-up BMI than those who did not. - Together those point at fast weight loss as the driver rather than anything specific to the molecule — though no trial has tested that directly. The short answer is yes, a little, and probably not for the reason people assume. A 2026 systematic review and meta-analysis pooled 17 studies covering 1,091,743 patient-exposures and found the odds of any non-scarring alopecia raised at 1.40, with a confidence interval from 1.33 to 1.48 and no measurable heterogeneity between the cohort studies [\[1\]](https://thisglp.com/research/does-ozempic-cause-hair-loss#ref-1). That is a real signal and a small one. It is also an average taken across very different conditions that happen to share the word “alopecia”, and splitting them apart is where the useful answer turns out to live. ## Which kind of hair loss actually goes up Pooled odds ratios by alopecia subtype, 17 studies. | Type of hair loss | Pooled odds at 12 months | Raised? | | --- | --- | --- | | Any non-scarring alopecia | 1.40 (95% CI 1.33–1.48) | Yes | | Telogen effluvium | 1.76 (95% CI 1.34–2.32) | Yes | | Androgenetic alopecia | 1.64 (95% CI 1.35–1.99) | Yes | | Alopecia areata | 1.08 (95% CI 0.87–1.34) | No — interval crosses 1 | Pooled odds ratios by alopecia subtype, 17 studies. Systematic review and meta-analysis, 1,091,743 patient-exposures Telogen effluvium is diffuse shedding that begins two to four months after a physiological stress, which is the detail that makes the timing recognizable to anyone it has happened to. Rapid weight loss is one of the classic triggers, alongside illness, surgery and childbirth — the same stress response behind the lean-mass changes in [what is lost and what returns](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). Alopecia areata, by contrast, is autoimmune and patchy, and it has nothing to do with how much weight somebody has lost or how quickly they lost it. The first of those is raised here and the second is not, and that split is the closest thing this literature has to an explanation. Two different studies used the same negative control, and both came back clean Alopecia areata was not merely unmeasured — a propensity-matched cohort study built on US health records deliberately used it as a _negative control_ outcome, on the reasoning that a drug causing weight-related shedding should not also cause an autoimmune patchy condition [\[2\]](https://thisglp.com/research/does-ozempic-cause-hair-loss#ref-2). It came back null there too. When a study names a control in advance and the control behaves, the rest of its findings get more credible — the practice this site praised in [the cohort that tested its own bias](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes). ## The clue that points at the weight, not the drug The same matched cohort reports one observation that does more work than any odds ratio in it: among GLP-1 users, the people who developed hair loss had a _lower_ follow-up BMI than the people who did not. The ones who lost more hair were the ones who lost more weight. That is consistent with telogen effluvium being the mechanism, because on that reading the shedding tracks the speed and the size of the weight change rather than anything about the molecule itself. It is an association found inside an observational cohort rather than a randomized comparison, which makes it a strong hint about the mechanism rather than proof of it. Nobody has run a trial that holds weight loss constant and varies the drug, which is the experiment that would settle it. It is the same reasoning problem this site worked through in [separating a drug effect from a weight effect](https://thisglp.com/research/liver-repair-that-was-not-the-weight). ## Why you will still find sources saying the evidence conflicts Because until very recently it genuinely did, and the pages saying so were describing the evidence accurately at the time they were written. A 2025 systematic review found only five primary studies covering 2,905 adults, and they disagreed with each other — some reported hair loss as an adverse event, others reported improvement and regrowth [\[3\]](https://thisglp.com/research/does-ozempic-cause-hair-loss#ref-3). That was an honest description of a thin evidence base. The 2026 meta-analysis is roughly 375 times larger by exposures, which is what changed. Pages written against that older review are not wrong about what it said, and it would be unfair to read them as careless. They are just describing the state of the field before the larger synthesis landed. ## Does it matter which drug you are on? On current evidence, not much. The matched cohort found higher odds of non-scarring alopecia with both semaglutide and tirzepatide compared with other GLP-1 drugs, and higher odds of telogen effluvium with tirzepatide across every follow-up window it examined [\[2\]](https://thisglp.com/research/does-ozempic-cause-hair-loss#ref-2). The published summary reports those as directions rather than as odds ratios, so this site will not attach numbers to them. Since semaglutide and tirzepatide are also the two that take off the most weight — the gap measured in [the real-world comparison of the two](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) — a difference between molecules and a difference in weight lost cannot be separated here either. What this article is not This is a summary of what has been measured across populations. It is not a diagnosis, and nothing here is a reason to stop or change a prescription on your own. Diffuse shedding that starts months after rapid weight loss, patchy round bald spots, and hair thinning at the crown are three different things with three different workups, and telling them apart is a clinician’s job. ## Frequently asked Does Ozempic cause hair loss? Pooled across 17 studies and over a million patient-exposures, GLP-1 use raised the odds of non-scarring hair loss to 1.40 (95% CI 1.33 to 1.48). That is a real but modest increase. What kind of hair loss is it? Mostly telogen effluvium — diffuse shedding that follows a physiological stress such as rapid weight loss — at pooled odds of 1.76. Autoimmune alopecia areata was not raised, at 1.08 with an interval crossing 1. Is it the drug or the weight loss? The evidence leans toward the weight loss. Users who developed hair loss had a lower follow-up BMI than those who did not, and the subtype raised is the one classically triggered by rapid weight change. No trial has separated the two directly. Does tirzepatide cause more hair loss than semaglutide? A matched cohort found higher odds of telogen effluvium with tirzepatide at every follow-up window, but reported directions rather than figures. Since tirzepatide also produces more weight loss, drug and weight effects cannot be separated. Will my hair grow back? That is a question for a clinician who can examine you, because diffuse shedding, patchy loss and crown thinning have different causes and different workups. Nothing here is a reason to stop a prescription on your own. ## Sources 1. \[1\] Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS (2026). GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms Skin Appendage Disorders. [PMID 42621629](https://pubmed.ncbi.nlm.nih.gov/42621629/) 2. \[2\] Katragadda R, Hayden J, Saltagi AK, Welschmeyer AF, Quereshy HA, Karasik D (2026). Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study The Laryngoscope. [PMID 42647098](https://pubmed.ncbi.nlm.nih.gov/42647098/) 3. \[3\] Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM (2025). Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review Cureus. [PMID 41111833](https://pubmed.ncbi.nlm.nih.gov/41111833/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show Does Ozempic lower cholesterol? A little: LDL fell 2.5% vs a 1.3% rise on placebo in STEP 1 | triglycerides fell 21.9%, and tirzepatide moved lipids further. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-ozempic-lower-cholesterol Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Evidence # Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show A little. On semaglutide 2.4 mg, LDL fell 2.5% from 110.3 mg/dL against a 1.3% rise on placebo, while triglycerides fell 21.9%. In type 2 diabetes the LDL effect was 0.16 mmol/L. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). A little, and triglycerides fall much more than LDL. In the 68-week STEP 1 trial of semaglutide 2.4 mg, LDL cholesterol fell 2.5 percent from an average of 110.3 mg/dL, roughly 3 mg/dL [\[1\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-1) [\[2\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-2). On placebo it rose 1.3 percent. Triglycerides fell 21.9 percent against 7.3 percent. At the lower Ozempic doses, a network meta-analysis of 76 diabetes trials put the LDL reduction at 0.16 mmol/L [\[3\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-3). ## Key takeaways - In STEP 1 (1,961 adults without diabetes, semaglutide 2.4 mg, 68 weeks), LDL changed −2.5% against +1.3% on placebo, from a baseline of 110.3 mg/dL. - Triglycerides moved most: −21.9% against −7.3%. HDL rose 5.2% against 1.4%. - Pooling four 2.4 mg trials, LDL fell by a mean 6.01 mg/dL and triglycerides by 14.75 mg/dL against placebo. - In type 2 diabetes, across 76 trials, semaglutide lowered LDL by 0.16 mmol/L and total cholesterol by 0.48 mmol/L. - Tirzepatide (Zepbound) lowered LDL 4.6% to 7.1% against 1.7% on placebo, and triglycerides 21.2% to 29.1%. Two cautions apply to every number below. First, the Ozempic label itself prints no cholesterol table; the trial percentages come from Wegovy, the 2.4 mg dose of the same drug. Second, lipids were secondary measures in these trials. How the two drugs compare on weight, the primary outcome, is in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). ## What STEP 1 measured on cholesterol STEP 1 randomized 1,961 adults with obesity or overweight and no diabetes, 2:1, to semaglutide 2.4 mg or placebo for 68 weeks [\[2\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-2). The label reports the lipid results as percent change from baseline [\[1\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-1): 1. Total cholesterol: −3.3 percent against +0.1 percent, from 189.6 mg/dL. 2. LDL cholesterol: −2.5 percent against +1.3 percent, a relative difference of −3.8 percent. 3. HDL cholesterol: +5.2 percent against +1.4 percent. 4. Triglycerides: −21.9 percent against −7.3 percent, from 126.2 mg/dL. The label notes that these measures were not part of the pre-specified testing order. The LDL change is small next to the triglyceride change. A pooled analysis of four 2.4 mg trials of at least 68 weeks gives the same shape in mg/dL [\[4\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-4). LDL fell by a mean 6.01 mg/dL, total cholesterol by 6.39 mg/dL and triglycerides by 14.75 mg/dL. HDL rose by 1.82 mg/dL. ## Does Ozempic lower cholesterol in type 2 diabetes? Ozempic is approved for type 2 diabetes at 0.5 to 2 mg. The best estimate for that population is a network meta-analysis of 76 trials, 15 GLP-1 drugs and 39,246 adults [\[3\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-3). Against placebo, the mean difference for semaglutide was −0.16 mmol/L for LDL (95% CI −0.30 to −0.02). For total cholesterol it was −0.48 mmol/L (95% CI −0.84 to −0.11). The LDL interval ends just short of zero. One trial in the Wegovy label shows the limit directly. In STEP 2, adults with type 2 diabetes on 2.4 mg saw LDL change by +0.5 percent against +0.1 percent on placebo [\[1\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-1). Triglycerides still fell, by 22 percent against 9.4 percent. In that trial, the triglyceride effect held and the LDL effect did not appear. Where the evidence stops None of these trials was designed to treat high cholesterol, and none tested semaglutide against a statin. Lipids were secondary or exploratory measures. The figures come from branded semaglutide; compounded semaglutide is not FDA-approved and has no trial lipid data. ## Does Zepbound lower cholesterol? Tirzepatide moved lipids further in its obesity trial. The Zepbound label reports 72-week results from SURMOUNT-1 by dose [\[5\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-5). LDL fell 4.6, 5.6 and 7.1 percent on 5, 10 and 15 mg, against 1.7 percent on placebo, from about 109 mg/dL. The relative difference at 5 mg had a confidence interval crossing zero. Triglycerides fell 21.2 to 29.1 percent against 5.6 percent, and HDL rose 6.9 to 9.2 percent. A meta-analysis of seven randomized trials found the same pattern with dose [\[6\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-6). Total cholesterol fell 3.76 percent on 5 mg, 4.63 percent on 10 mg and 5.93 percent on 15 mg. LDL and triglycerides fell and HDL rose. How much of this follows weight loss rather than the drug itself was not separated in these abstracts. A SURMOUNT-1 analysis of uric acid faced the same question, set out in [the uric acid log entry](https://thisglp.com/research/uric-acid-fell-and-most-of-it-was-weight). ## Cholesterol medicines and heart risk One pooled analysis looked at lipid-lowering prescriptions across five STEP trials [\[7\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-7). More people on semaglutide had their lipid-lowering treatment reduced, and fewer had it intensified, than on placebo. The abstract gives no counts. It is a post hoc analysis, and several authors are Novo Nordisk employees. In SELECT, 17,604 adults with established cardiovascular disease and no diabetes took semaglutide 2.4 mg or placebo [\[1\]](https://thisglp.com/research/does-ozempic-lower-cholesterol#ref-1). At baseline, 90 percent were on lipid-lowering therapy. At week 104, LDL changed −5.3 percent against −3.1 percent, from 78.5 mg/dL. The trial was built to measure a composite of cardiovascular death, heart attack and stroke, and the cholesterol change beside it was small. What drove the benefit is covered in [whether GLP-1 drugs prevent heart attacks and strokes](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes) and in [the inflammation evidence](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation). ## Frequently asked Does semaglutide lower cholesterol? Modestly. In STEP 1, semaglutide 2.4 mg changed LDL by −2.5% against +1.3% on placebo over 68 weeks, and triglycerides by −21.9% against −7.3%. Across 76 type 2 diabetes trials, semaglutide lowered LDL by 0.16 mmol/L. Does Zepbound lower cholesterol? Yes, somewhat more than semaglutide did in its own trials. In SURMOUNT-1, LDL fell 4.6% to 7.1% across doses against 1.7% on placebo, and triglycerides fell 21.2% to 29.1% against 5.6%. Does tirzepatide lower cholesterol in a dose-dependent way? A meta-analysis of seven trials found total cholesterol fell 3.76% on 5 mg, 4.63% on 10 mg and 5.93% on 15 mg. The two drugs have not been compared head to head on lipids. Can a GLP-1 replace a cholesterol medicine? No trial has tested that. The LDL changes on semaglutide were a few percent, and no study compared a GLP-1 with a statin. A post hoc STEP analysis found lipid-lowering treatment was reduced more often on semaglutide, without giving counts. ## Sources 1. \[1\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Tables 7 and 13 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 2. \[2\] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine. [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/) 3. \[3\] Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS (2024). Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis BMJ. [PMID 38286487](https://pubmed.ncbi.nlm.nih.gov/38286487/) 4. \[4\] Miranda S, Choudhari J, Chauhan N, Parmar MS (2025). Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials European Journal of Pharmacology. [PMID 40675357](https://pubmed.ncbi.nlm.nih.gov/40675357/) 5. \[5\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, Table 3 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) 6. \[6\] Kanbay M, Copur S, Siriopol D, Yildiz AB, Gaipov A, van Raalte DH, Tuttle KR (2023). Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials Diabetes, Obesity & Metabolism. [PMID 37700437](https://pubmed.ncbi.nlm.nih.gov/37700437/) 7. \[7\] Tchang BG, Knight MG, Adelborg K, Clements JN, Iversen AT, Traina A (2025). Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials Obesity (Silver Spring). [PMID 39756397](https://pubmed.ncbi.nlm.nih.gov/39756397/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) - [ Weight loss, tirzepatide against semaglutide · chart review, 12 mo · −16.6% · −13.4% · matched cohort, 2 yr · −14.7% · −10.8% · Randomized, SURMOUNT-5: 20.2% against 13.7% at 72 weeks. ### Tirzepatide vs Semaglutide: Which Works Better for Weight Loss? ](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) --- # Does Semaglutide Cause Vision Loss? The Signal Sits in Diabetes | This GLP Does semaglutide cause vision loss? NAION, retinopathy and glaucoma evidence across 5.9 million people | and why the signal concentrates in diabetes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-semaglutide-cause-vision-loss Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Does Semaglutide Cause Vision Loss? The Signal Sits in Diabetes One eye center counted 20 cases of sudden optic-nerve damage among 979 semaglutide patients against 3 on the comparator. Pooled across 5,916,559 people, the association holds in diabetes and not in the weight-loss group. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 NAION events, overweight or obese group · Prescribed semaglutide · 20 · Comparator · 3 · Everyone here was already referred to a · neuro-ophthalmology clinic. That is not the street. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Rarely, and almost all of the measured risk sits in people who have diabetes rather than in people taking the drug for weight alone. The largest single count comes from one academic eye center, where 20 cases of sudden optic-nerve vision loss appeared among 979 overweight or obese patients prescribed semaglutide, against 3 in the matched comparison group [\[1\]](https://thisglp.com/research/does-semaglutide-cause-vision-loss#ref-1). When [eight observational cohorts](https://thisglp.com/research/semaglutide-optic-nerve-by-indication) covering 5,916,559 people were pooled two years later, the association held among patients with diabetes at 1.84, on a confidence interval of 1.21 to 2.80 [\[2\]](https://thisglp.com/research/does-semaglutide-cause-vision-loss#ref-2). In the overweight and obese group it came to 1.68, on an interval running from 0.72 to 3.91, which is wide enough to hold both no association at all and a near-quadrupling of one. ## Key takeaways - One neuro-ophthalmology cohort: 20 NAION events among 979 overweight or obese patients on semaglutide, against 3 on the comparator. - Pooled across eight cohorts and 5,916,559 people, the NAION association was 1.84 in diabetes and 1.68, 95% CI 0.72 to 3.91, in the group taking it for weight. - Diabetic retinopathy is the one eye finding from a randomized trial, and it concentrated in people whose HbA1c fell fastest from the worst starting point. - A 51,540-person glaucoma comparison put tirzepatide ahead of other GLP-1 drugs at a hazard ratio of 0.65, with nobody untreated to measure either against. - In idiopathic intracranial hypertension the eye numbers run the other way, and the mortality figure in the same analysis shows why they are inflated. Sudden painless vision loss in one eye is the symptom behind the cohort above, and the finding is real enough to have changed labeling conversations worldwide. A retrospective matched study at one academic center searched 16,827 patients with no history of the condition and compared those prescribed semaglutide against those prescribed other treatments. The hazard ratios are large, and the population they came from is the part that decides what they mean for anyone reading [a seller’s page](https://thisglp.com/best). ## What one eye center counted Among 710 patients with type 2 diabetes, 17 events of nonarteritic anterior ischemic optic neuropathy occurred among those prescribed semaglutide against 6 in the comparator group. Cumulative incidence over 36 months was 8.9 percent (95% CI 4.5 to 13.1) against 1.8 percent (95% CI 0 to 3.5), a hazard ratio of 4.28 (95% CI 1.62 to 11.29, P < 0.001). Among 979 patients who were overweight or obese, 20 events occurred on semaglutide against 3 on the comparator. Cumulative incidence was 6.7 percent (95% CI 3.6 to 9.7) against 0.8 percent (95% CI 0 to 1.8), a hazard ratio of 7.64 (95% CI 2.21 to 26.36). ## Where those people came from Every patient in this study was evaluated by neuro-ophthalmologists at a single academic institution, which is to say a referral population of people already sent to specialists for eye problems. A cumulative incidence of 6.7 percent in that group says nothing like 6.7 percent for a general population, because the denominator has been filtered by the exact thing being measured. The interval widths say the same thing more quietly. A hazard ratio of 7.64 with a confidence interval running from 2.21 to 26.36 is built on 23 events in total. The direction is consistent and the magnitude is unsettled, which is what a large interval on small counts looks like. ## What happened when eight cohorts were pooled A later systematic review put eight observational studies together, 5,916,559 people of whom 1,870,346 were on semaglutide, and reported a pooled relative effect of 1.93 with an interval of 1.22 to 3.08 [\[2\]](https://thisglp.com/research/does-semaglutide-cause-vision-loss#ref-2). Splitting that by indication is where it stops being one number. Among people with diabetes it was 1.84 (95% CI 1.21 to 2.80), and among overweight or obese people 1.68 (95% CI 0.72 to 3.91), which is the row almost everybody buying these drugs online belongs to. Heterogeneity across those eight studies was 91 percent, close enough to the ceiling that they are not estimating one common number at all. The full reading of that pooled figure, and of the absolute rate the abstract never publishes, is in [the optic nerve evidence by indication](https://thisglp.com/research/semaglutide-optic-nerve-by-indication). ## The one eye finding that came from a randomized trial Everything above is observational. The only randomized eye signal in this literature is diabetic retinopathy, and it came out of SUSTAIN 6. That was a two-year pre-approval cardiovascular trial in type 2 diabetes, where semaglutide was associated with a significant increase in retinopathy complications against placebo [\[3\]](https://thisglp.com/research/does-semaglutide-cause-vision-loss#ref-3). Across SUSTAIN 1 through 5 and the Japanese trials there was no imbalance, so the signal sits in the longest trial of the sickest patients. A post hoc mediation analysis attributed most of the effect to how far and how fast HbA1c fell in the first sixteen weeks, among patients who already had retinopathy, had poor control at baseline, and were on insulin. Early worsening after a rapid improvement in glucose control is a documented phenomenon with insulin too, which makes it a screening instruction rather than a reassurance. The mechanism and its limits are set out in [the retinopathy evidence](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse). ## Glaucoma, and a comparison with nobody untreated A retrospective cohort matched 51,540 adults aged 60 and over with type 2 diabetes across 21 countries. Over two years it found less incident primary open-angle glaucoma on tirzepatide than on other GLP-1 drugs, at a hazard ratio of 0.65 (95% CI 0.44 to 0.96) [\[4\]](https://thisglp.com/research/does-semaglutide-cause-vision-loss#ref-4). Both arms were taking a drug from this class, which makes the result a ranking rather than a risk assessment. An upper bound of 0.96 clears 1 by four hundredths, and two years is a short window for a disease that develops over decades. What the design cannot reach is whether either drug leaves an eye better or worse off than taking nothing, which is the gap described in [the glaucoma comparison](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma). ## Where the eye numbers run the other way Idiopathic intracranial hypertension raises pressure inside the skull and swells the optic nerve, and weight loss is one of the few things established to help it. A meta-analysis of nine studies and 13,257 participants reported less papilledema on these drugs at a risk ratio of 0.38 (95% CI 0.25 to 0.56) and less visual worsening at 0.51 (95% CI 0.37 to 0.68) [\[5\]](https://thisglp.com/research/does-semaglutide-cause-vision-loss#ref-5). The same analysis reports an 80 percent reduction in mortality, in a condition that threatens sight rather than life. That is not a drug effect but a measurement of how different the two groups were before anyone was treated. That figure calibrates the eye results beside it: the direction is probably right and the size is almost certainly inflated. The full argument is in [the intracranial pressure analysis](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension). ## What to do with all of it NAION is uncommon and it is not reversible, so a small absolute risk is still worth knowing. The practical response is not to avoid the drug on the strength of one referral cohort, and it is not to dismiss the finding either. It is to treat sudden painless vision loss in one eye as an emergency, and to tell a clinician about it the same day rather than at the next refill. That is harder than it sounds when the prescription arrived through a website. Most of the sellers tracked here publish nothing about who to contact or how quickly, which is the gap counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) and listed in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). Knowing the route to a human before you need one is the part of this a buyer can actually control, and [the disclosure census](https://thisglp.com/tools/what-sellers-publish) shows who publishes it. ## Frequently asked Does semaglutide cause vision loss? One matched cohort found higher NAION risk at hazard ratios of 4.28 in patients with diabetes and 7.64 in those overweight or obese. Pooling eight cohorts of 5,916,559 people, the association reached significance in diabetes and not in the weight-loss group. Is my chance really 6.7 percent? It is not. That cumulative incidence comes from a population already referred to neuro-ophthalmologists at an academic center, so the denominator is filtered by the thing being measured. Does semaglutide worsen diabetic retinopathy? In SUSTAIN 6 it was associated with a significant increase in retinopathy complications against placebo. A post hoc analysis attributed most of that to how fast HbA1c fell, among people who already had retinopathy and were on insulin. Do these drugs affect glaucoma? A 51,540-person cohort found less incident open-angle glaucoma on tirzepatide than on other GLP-1 drugs, at a hazard ratio of 0.65. Both arms were treated, so it cannot say what either does against taking nothing. What should I actually do? Treat sudden painless vision loss in one eye as an emergency and report it the same day. Knowing how to reach a clinician quickly matters more here than any hazard ratio does. ## Sources 1. \[1\] Hathaway JT, et al. (2024). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide JAMA Ophthalmology. [PMID 38958939](https://pubmed.ncbi.nlm.nih.gov/38958939/) 2. \[2\] Khani E, et al. (2026). Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis The Journal of Clinical Pharmacology. [PMID 42612051](https://pubmed.ncbi.nlm.nih.gov/42612051/) 3. \[3\] Vilsbøll T, et al. (2018). Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy Diabetes, Obesity and Metabolism. [PMID 29178519](https://pubmed.ncbi.nlm.nih.gov/29178519/) 4. \[4\] Pan SY, Weng CH, Sheen YJ, Chen JP, et al. (2026). Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study Ophthalmology Science. [PMID 42383218](https://pubmed.ncbi.nlm.nih.gov/42383218/) 5. \[5\] Ahmed W, Gandhi OH, Yu N, Brant J, et al. (2026). Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis Journal of the Neurological Sciences. [PMID 41468715](https://pubmed.ncbi.nlm.nih.gov/41468715/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Does Semaglutide Help Liver Cirrhosis? Not in the Trial That Tested It | This GLP Does semaglutide help liver cirrhosis? In the cirrhosis trial, fibrosis improved in 11% on the drug vs 29% on placebo | cohort benefits appear earlier. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Does Semaglutide Help Liver Cirrhosis? Not in the Trial That Tested It In 71 people with MASH cirrhosis, fibrosis improved in 11% on semaglutide and 29% on placebo. A larger 2026 trial mixed in earlier stages, and two cohorts disagree on what happens after cirrhosis. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Fibrosis improved by one stage or more · 2023 trial, cirrhosis only · 71 people, 48 weeks · semaglutide · 11% · placebo · 29% · 2026 trial, F2 to F4c · 200 in these two arms, 52 weeks · semaglutide · 30% · placebo · 16% · Of the two, only the 2023 trial was limited to cirrhosis. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - In a 71-person trial limited to MASH cirrhosis, fibrosis improved in 11% on semaglutide 2.4 mg against 29% on placebo after 48 weeks. The difference was not significant. - A 2026 trial of 698 people with fibrosis stages F2 to F4c found semaglutide alone improved fibrosis in 30% against 16%. The authors call that nominally significant, and it was not the primary comparison. - In a large veterans cohort, GLP-1 use was linked to less progression to cirrhosis, hazard ratio 0.86. No association appeared in people who already had cirrhosis. - A single-center cohort found less hepatic encephalopathy in GLP-1 users with cirrhosis, but more among those who also had liver cancer. - The US approval for semaglutide in liver disease covers stages F2 to F3, without cirrhosis. Not in the trial that tested it. In 71 people with compensated MASH cirrhosis, semaglutide 2.4 mg did not improve liver scarring over 48 weeks [\[1\]](https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis#ref-1). Fibrosis improved in 11% on the drug and 29% on placebo, a difference that was not significant. The approved use stops at stage F3, before cirrhosis, as [the liver disease eligibility guide](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease) sets out. The broader question of liver safety is covered in [whether GLP-1 drugs are bad for the liver](https://thisglp.com/research/are-glp1-drugs-bad-for-your-liver). This page covers the last stage of the disease only. ## The cirrhosis trial The trial enrolled adults with biopsy-confirmed MASH cirrhosis and a BMI of 27 or more. Seventy-five percent had diabetes. They were randomized 2:1, 47 to semaglutide 2.4 mg weekly and 24 to placebo. The primary endpoint was fibrosis improving by at least one stage without the steatohepatitis worsening. That happened in 5 of 47 on semaglutide and 7 of 24 on placebo. The odds ratio was 0.28, with a 95% confidence interval from 0.06 to 1.24. Resolution of steatohepatitis did not differ either. With 71 people, the trial could miss a modest benefit. Safety held within the trial. There were no decompensating events or deaths, and liver and kidney function stayed stable. Nausea affected 45% on semaglutide against 17% on placebo, and vomiting 17% against none. ## The 2026 trial that included cirrhosis A larger phase 2 trial enrolled 698 people with MASH and fibrosis from stage F2 to compensated cirrhosis [\[2\]](https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis#ref-2). Its main question was whether adding zalfermin to semaglutide helped, and it did not. Zalfermin 30 mg plus semaglutide improved fibrosis in 24% against 16% on placebo, p = 0.19. Semaglutide 2.4 mg alone reached 30% against 16% at 52 weeks. The authors describe that as nominally significant, p = 0.024, and it sat outside the protected primary comparison. A cagrilintide plus semaglutide arm did not differ substantially from placebo, which matters for [the CagriSema comparison](https://thisglp.com/research/is-cagrisema-better-than-semaglutide). The 30% is not a cirrhosis result The trial mixed stages F2, F3 and compensated cirrhosis. Its abstract does not report the cirrhosis group separately. The authors say only that semaglutide might merit further testing in that group. Gastrointestinal events affected 73% on semaglutide against 51% on placebo. ## What the cohorts add A US veterans cohort compared GLP-1 drugs with DPP-4 inhibitors in people with fatty liver disease and diabetes [\[3\]](https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis#ref-3). In 14,606 users without cirrhosis, progression to cirrhosis ran 9.98 against 11.10 events per 1,000 person-years. The hazard ratio was 0.86. In 1,452 users who already had cirrhosis, no association appeared with any outcome. The authors read that as a case for treating earlier in the disease. Why scarring can respond differently from liver fat is examined in [the survodutide mediation analysis](https://thisglp.com/research/liver-repair-that-was-not-the-weight). A single-center cohort looked at hepatic encephalopathy, a brain complication of advanced liver disease [\[4\]](https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis#ref-4). Of 2,557 people with cirrhosis, 139 took a weight-loss dose for six months or more. They developed it less often, 3.6% against 18.7%, with an adjusted hazard ratio of 0.33, P = 0.048. The direction reversed in people who also had liver cancer, where the hazard ratio was 6.12, P = 0.024. The absolute cancer risk on these drugs is set out in [the liver cancer cohort](https://thisglp.com/research/glp1-liver-cancer-absolute-risk). ## What is not yet known Neither trial showed semaglutide reversing scarring once cirrhosis was present. Decompensated cirrhosis was excluded from both trials, so it is not measured. The encephalopathy finding comes from 139 treated people at one center. The earlier-stage evidence, where results are stronger, sits in [the phase 3 liver trial](https://thisglp.com/research/semaglutide-and-liver-disease). ## Frequently asked Does semaglutide help liver cirrhosis? It has not been shown to. In a 48-week trial of 71 people with MASH cirrhosis, fibrosis improved in 11% on semaglutide 2.4 mg and 29% on placebo, not a significant difference. Is semaglutide approved for cirrhosis? No. The US approval for semaglutide in MASH covers fibrosis stages F2 to F3, without cirrhosis. Can semaglutide prevent cirrhosis? A veterans cohort with fatty liver disease and diabetes found less progression to cirrhosis on GLP-1 drugs than on DPP-4 inhibitors, hazard ratio 0.86. That is an association, not a trial result. Does a GLP-1 reduce hepatic encephalopathy? One single-center cohort found it less often in 139 users with cirrhosis, 3.6% against 18.7%. Among people who also had liver cancer, the risk was higher, hazard ratio 6.12. Is semaglutide safe in cirrhosis? In the 71-person trial of compensated cirrhosis there were no decompensating events or deaths, and liver and kidney function stayed stable. Nausea affected 45% on the drug against 17% on placebo. ## Sources 1. \[1\] Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. (2023). Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial The Lancet Gastroenterology & Hepatology. [PMID 36934740](https://pubmed.ncbi.nlm.nih.gov/36934740/) 2. \[2\] Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A (2026). Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial The Lancet Gastroenterology & Hepatology. [PMID 42456707](https://pubmed.ncbi.nlm.nih.gov/42456707/) 3. \[3\] Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, et al. (2024). GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease JAMA Internal Medicine. [PMID 39283612](https://pubmed.ncbi.nlm.nih.gov/39283612/) 4. \[4\] Singh V, Wang M, Ebinger J, Velazquez A, Cheng S, Kwan AC, et al. (2026). Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis Journal of Clinical Gastroenterology. [PMID 42183591](https://pubmed.ncbi.nlm.nih.gov/42183591/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Does Semaglutide Make Diabetic Retinopathy Worse? In One Trial, Yes | This GLP SUSTAIN 6 found more diabetic retinopathy complications on semaglutide than placebo | who the signal applies to, and why a post hoc mechanism does not dismiss it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Does Semaglutide Make Diabetic Retinopathy Worse? In One Trial, Yes A randomized trial found more retinopathy complications on semaglutide than on placebo, and the effect concentrated almost entirely in people who already had retinopathy, had poor glycemic control at baseline, and were being treated with insulin. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Who the signal was concentrated in · already had retinopathy · poor glucose control · treated with insulin · All three, together, and a fast fall in HbA1c over sixteen weeks. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - In a two-year cardiovascular outcomes trial, semaglutide was associated with a significant increase in diabetic retinopathy complications against placebo. - Across the other trials in the same program there was no imbalance in retinopathy adverse events. - A post hoc analysis attributed most of the effect to how fast and how far HbA1c fell in the first sixteen weeks, in patients who already had retinopathy, had poor control at baseline, and were on insulin. - Rapid improvement in glucose control is a recognized trigger for early worsening of retinopathy — it happens with insulin too. - None of this describes someone without diabetes, which is most people reading about these drugs. In one randomized trial it did, and the people it happened to are a narrow group. SUSTAIN 6 was a two-year cardiovascular outcomes trial in type 2 diabetes, and in it semaglutide was associated with a significant increase in diabetic retinopathy complications against placebo [\[1\]](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse#ref-1). A post hoc analysis attributed most of that to how fast and how far HbA1c fell in the first sixteen weeks, among patients who already had retinopathy, had poor control at baseline and were on insulin. Almost every safety question in this library ends with the evidence not supporting the worry, and this one does not. What follows is an attempt to say exactly who it applies to, because the answer is narrow and the alarm is broad. That gap is the one this site keeps finding between [what a trial established](https://thisglp.com/research/semaglutide-cochrane-review) and what gets repeated about it. Other diabetes complications need their own outcomes and comparators, including the [evidence on diabetic foot ulcers](https://thisglp.com/research/do-glp1-drugs-prevent-diabetic-foot-ulcers); a finding about the eyes does not settle a claim about the feet. ## What the trial found SUSTAIN 6 was a two-year pre-approval cardiovascular outcomes trial in type 2 diabetes, and in it semaglutide was associated with a significant increase in the risk of diabetic retinopathy complications compared with placebo. That is the finding, stated as the investigators state it, and it is the only randomized retinopathy signal in the program. Across the rest of the program — SUSTAIN 1 through 5 and the Japanese trials — there was no imbalance in retinopathy adverse events. The signal sat in one trial, which is both reassuring and the reason the trial mattered: it was the longest and it enrolled the sickest. The same is true of the kidney trial covered in [semaglutide and kidney disease](https://thisglp.com/research/semaglutide-and-kidney-disease), where the sickest population is also where the effect showed up. ## The mechanism, and what it does not do A post hoc mediation analysis used the initial change in HbA1c at week 16 as a covariate. Most of the effect could be attributed to the magnitude and rapidity of that reduction, and it concentrated in patients who already had retinopathy, had poor glycemic control at baseline, and were being treated with insulin. Early worsening of retinopathy after a fast improvement in glucose control is a known phenomenon and is documented with insulin. Guidance exists for it there, and the authors suggest similar guidance may be appropriate for semaglutide. A mechanism is not a dismissal It is tempting to read this as the finding being explained away. It is not. A post hoc analysis identifies a plausible route from the drug to the outcome; it does not remove the outcome, and it was not the trial’s prespecified question. What it does is tell a clinician where to look: at people whose retinas are already affected, whose control is poor, and whose glucose is about to improve quickly. That is a screening instruction, not a reassurance. ## The other eye signal, and why it is separate Retinopathy is not the optic nerve question. A separate pooling of eight cohorts put the relative effect for non-arteritic anterior ischemic optic neuropathy at 1.93 against no semaglutide, with a 95% confidence interval of 1.22 to 3.08 [\[2\]](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse#ref-2). In overweight or obese people specifically it came in at 1.68 (95% CI 0.72 to 3.91). Two different structures, two different literatures, and the second one is read here in [the optic nerve evidence by indication](https://thisglp.com/research/semaglutide-optic-nerve-by-indication). Neither excuses the other, and neither is evidence about the other. ## Whether it applies to you Every participant in these trials had type 2 diabetes. Most people buying these drugs from the sellers tracked here do not, and for them there is no HbA1c to fall rapidly and no pre-existing retinopathy for it to worsen. The finding does not transfer to that population, and nothing in this literature suggests it should. If you do have diabetes and any degree of retinopathy, this is a conversation to have before starting rather than after — with someone who can look at your retinas. That is the part this market is worst equipped for. Most sellers publish nothing about who reviews a case or how to reach them, which we count in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) and list in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). A condition that needs monitoring is a poor fit for a service that does not describe any. ## Frequently asked Does semaglutide damage the eyes? In one two-year trial in type 2 diabetes it was associated with a significant increase in retinopathy complications against placebo. Across the other trials in the same program there was no imbalance. What explains it? A post hoc analysis attributed most of the effect to how fast and how far HbA1c fell in the first sixteen weeks, among patients who already had retinopathy, had poor control, and were on insulin. Does it apply without diabetes? Nothing in this literature suggests it does. Every participant had type 2 diabetes, and the proposed mechanism requires an HbA1c that falls rapidly from a poor starting point. What should someone with retinopathy do? Raise it before starting, with a clinician who can examine the retinas — and note that rapid improvement in glucose control triggers the same early worsening with insulin. ## Sources 1. \[1\] Vilsbøll T, et al. (2018). Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy Diabetes, Obesity and Metabolism. [PMID 29178519](https://pubmed.ncbi.nlm.nih.gov/29178519/) 2. \[2\] Khani E, et al. (2026). Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis The Journal of Clinical Pharmacology. [PMID 42612051](https://pubmed.ncbi.nlm.nih.gov/42612051/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Does Semaglutide Reduce Alcohol Use? One Trial Found a 13.7-Point Gap | This GLP Does semaglutide reduce alcohol use? Six studies, three of them randomized trials, with the doses and populations each one tested and the outcome one trial missed. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-semaglutide-reduce-alcohol-use Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Does Semaglutide Reduce Alcohol Use? One Trial Found a 13.7-Point Gap In a 26-week trial, yes: heavy drinking days fell 13.7 percentage points more than placebo. A register study found the benefit fades within a year of stopping. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Fall in heavy drinking days over 26 weeks · semaglutide 2.4 mg · 41.1 pts · placebo · 26.4 pts · Difference 13.7 points (95% CI 22.0 to 5.4). Both arms had therapy. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, in randomized trials. The size of the effect depends on which trial. In the largest one, heavy drinking days fell 13.7 percentage points more on semaglutide than on placebo. That was over 26 weeks, in 108 people with alcohol use disorder [\[1\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-1). A smaller trial of the daily tablet missed its primary outcome, craving in a laboratory test. Heavy drinking days still fell in that trial [\[6\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-6). A separate register study found alcohol-related hospital admissions ran lower on the drug, at a rate ratio of 0.55 [\[5\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-5). That association faded within a year of stopping — the full [discontinuation data](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it) is below. Nothing here is an approved use. The largest trial did use 2.4 mg weekly, the dose sold for weight loss, in adults with both alcohol use disorder and obesity. ## Key takeaways - A 26-week randomized trial in 108 people found heavy drinking days fell 13.7 percentage points further on semaglutide than on placebo — and both arms also received cognitive behavioral therapy. - An earlier 9-week trial in 48 people found lower laboratory drinking and lower craving, but no change in how many days people drank. - An 8-week trial of oral semaglutide in 50 people missed its primary outcome, laboratory craving. Heavy drinking days still fell. - A retrospective cohort of 83,825 people with obesity found a 50% to 56% lower rate of alcohol use disorder over 12 months. - A Swedish register study of 167,026 people found alcohol-related hospitalizations fell while on the drug (RR 0.55), and the benefit faded within a year of stopping. - The doses studied are brand semaglutide at 0.5 mg and 2.4 mg. Nobody is licensed to prescribe it for this. The claim started as an anecdote. It became a pharmacovigilance signal. It has now been tested in randomized trials of semaglutide. That progression is unusual, and the literature broadly agreed with the anecdote. None of it changes what these drugs are sold for. Every seller on [this site’s roundup](https://thisglp.com/best) prescribes them for weight. None prescribes for this. ## The larger trial A 26-week single-center trial randomized 108 treatment-seeking adults with alcohol use disorder and obesity. The drug was weekly semaglutide at 2.4 mg or placebo. Both arms also got cognitive behavioral therapy [\[1\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-1). Heavy drinking days fell 41.1 percentage points from baseline on semaglutide and 26.4 points on placebo. The treatment difference was 13.7 points (95% CI −22.0 to −5.4, p=0.0015). Eighty-one percent of participants completed the full intervention. The placebo arm is the part worth sitting with. It fell by more than a quarter on therapy alone. Semaglutide added to that; it did not replace it. The trial cannot say what the drug would do without therapy, because it never tested that. ## The smaller, earlier trial A phase 2 trial published a year earlier took a different population. It randomized 48 adults with alcohol use disorder who were _not_ seeking treatment. It gave nine weeks of low-dose semaglutide, topping out at 1.0 mg, and measured drinking in a laboratory task[\[2\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-2). It found medium to large effects on grams of alcohol consumed (β −0.48, 95% CI −0.85 to −0.11). Peak breath alcohol concentration also fell (β −0.46, 95% CI −0.87 to −0.06). Drinks per drinking day and weekly craving also fell. It also found nothing on two outcomes. Average drinks per calendar day did not move. Neither did the number of drinking days. People drank on the same days, and drank less when they did. That is a specific finding, not a weaker version of the big trial’s. ## The oral trial, which missed its primary outcome A third trial tested the daily tablet [\[6\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-6). It randomized 50 treatment-seeking adults with moderate to severe alcohol use disorder. The dose was oral semaglutide 3 mg a day for four weeks, then 7 mg for four weeks. The comparison was placebo. The primary outcome was craving in a laboratory cue test at week 6. It did not fall significantly. Drinks per day did not fall either. Heavy drinking days did fall, and they were a preregistered secondary outcome. So did drinks per drinking day, everyday craving and [cannabis use days](https://thisglp.com/research/can-you-smoke-weed-on-ozempic). A trial is read on its primary outcome first. This one missed it. Its secondary results point the same way as the 26-week trial, in a group less than half the size. Three RCTs, three molecules, three answers A 2025 systematic review found three trials, 48 to 151 participants each [\[3\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-3). Semaglutide reduced alcohol use. Dulaglutide lowered intake among current drinkers. Exenatide had no significant effect on heavy drinking days. This is a drug-class question only in the loosest sense. ## What the large observational data adds A retrospective cohort of electronic health records covered 83,825 patients with obesity[\[4\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-4). Semaglutide was associated with a 50% to 56% lower rate of both incidence and recurrence of alcohol use disorder over 12 months. The comparison was other anti-obesity medications. The direction was consistent across sex, age group, race, and diabetes status. It replicated in 598,803 patients with type 2 diabetes. Cohorts of that size are good at showing a small effect is real. They are bad at showing how big it is. People prescribed one drug differ from people prescribed another, in ways no adjustment fully removes. The trials are the evidence for the size. The cohort is the evidence that it generalizes past a single clinic. ## What happens after someone stops A Swedish register study asked a question the trials above could not. What happens to the effect once a person stops taking the drug? It compared 167,026 people with type 2 diabetes against themselves, across periods on and off treatment [\[5\]](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use#ref-5). While exposed, alcohol-related hospitalizations ran at a rate ratio of 0.55 against a person’s own unexposed periods. In the first 182 days after stopping, the association was weaker, at 0.70. By 183 to 364 days it was gone, at 1.07. That interval sits across no effect. DPP-4 inhibitors, used as a comparison, showed no such pattern. The full breakdown is in [the discontinuation study](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it). ## The part that matters for anyone buying online None of this is an approved use. The trials used brand semaglutide, at fixed doses, under supervision. The larger one added therapy. A reader who buys a compounded vial from a telehealth storefront hoping for this effect is buying a different thing. It is a preparation the FDA does not review before dispensing. The dose is often unstated. The escalation schedule is usually unpublished. We count how rarely that gets written down in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). We list every seller that does in [the published ladders tool](https://thisglp.com/tools/published-dose-ladders). The two injection trials also ran at doses on the escalation path, not at the starting rung. What a price does between those two points is the single most common silence in this market. It is counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). If the interest is appetite and reward more broadly, read the weight evidence first in [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review). ## Frequently asked Does semaglutide reduce drinking? In a 26-week randomized trial of 108 people, heavy drinking days fell 13.7 percentage points further than on placebo. Both arms also received cognitive behavioral therapy, and the placebo arm still improved substantially. Is it approved for alcohol use disorder? No. Every trial so far has been investigational, and the systematic review of the randomized evidence covers three trials of between 48 and 151 participants. Do all GLP-1 drugs do this? The randomized evidence does not say so. Semaglutide reduced alcohol use and dulaglutide lowered intake among current drinkers, but exenatide showed no significant effect on heavy drinking days. What dose was studied? The 26-week trial used 2.4 mg weekly. The earlier 9-week trial topped out at 1.0 mg. An 8-week trial used oral semaglutide at 3 mg and then 7 mg a day. All three used brand semaglutide at a fixed schedule under supervision. Does the semaglutide pill reduce drinking? One 8-week trial of 50 people tested it. It missed its primary outcome, craving in a laboratory cue test, and drinks per day did not fall. Heavy drinking days and drinks per drinking day did fall. Does the benefit last after stopping? Only briefly. A Swedish register study found alcohol-related hospital admissions stayed lower for the first 182 days after stopping and were back to baseline by 183 to 364 days. ## Sources 1. \[1\] Klausen MK, et al. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial The Lancet. [PMID 42070571](https://pubmed.ncbi.nlm.nih.gov/42070571/) 2. \[2\] Hendershot CS, et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial JAMA Psychiatry. [PMID 39937469](https://pubmed.ncbi.nlm.nih.gov/39937469/) 3. \[3\] Patel S, et al. (2025). GLP-1 receptor agonists and alcohol use disorder: a systematic review Alcohol and Alcoholism. [PMID 41273789](https://pubmed.ncbi.nlm.nih.gov/41273789/) 4. \[4\] Wang W, et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population Nature Communications. [PMID 38806481](https://pubmed.ncbi.nlm.nih.gov/38806481/) 5. \[5\] Bach P, Franck J, Hällgren J, Widing H, Gissler M, Westman J (2026). Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study The Lancet. Psychiatry. [PMID 42456704](https://pubmed.ncbi.nlm.nih.gov/42456704/) 6. \[6\] Schacht JP, et al. (2026). Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial American Journal of Psychiatry. [PMID 42522065](https://pubmed.ncbi.nlm.nih.gov/42522065/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # BMI Above 30 and Type 2 Diabetes Drug Response: Weight vs HbA1c | This GLP A 2026 study of 1,016 adults found higher baseline BMI predicted more weight loss on SGLT2 or GLP-1 therapy, while HbA1c improvement was comparable. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-starting-weight-change-the-answer Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # BMI Above 30 and Type 2 Diabetes Drug Response: Weight vs HbA1c In 1,016 adults with type 2 diabetes, those starting above BMI 30 were likelier to reach 5% weight loss (27.2% vs 15.5% at six months), while HbA1c improvement was comparable. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Reached 5% weight loss by month 6 · BMI 30 or above · 27.2% · BMI under 30 · 15.5% · HbA1c improvement: comparable in both groups. · Two drug classes pooled. Retrospective, three centers. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Does starting heavier change what these drugs do for you? A 2026 retrospective study of adults with type 2 diabetes at three centers in Riyadh looked at exactly that, splitting patients by whether their body mass index was above or below 30 and following them for a year (n=1,016, 73.4% obese) [\[1\]](https://thisglp.com/research/does-starting-weight-change-the-answer#ref-1). The weight answer is yes, and it needs a caveat the authors supply themselves. Obese patients lost more absolute weight and more BMI at 3, 6, 9 and 12 months, but they also started heavier, and the paper says plainly that this may account for the difference. That is the same arithmetic caution that applies to every headline weight figure, including the pooled averages in [what the trials actually found](https://thisglp.com/research/glp1-weight-loss-pooled-average). The proportional measure is harder to explain away. The share reaching at least 5% weight loss was 21.9% vs 12.0% at three months (p=0.0016) and 27.2% vs 15.5% at six months (p=0.0086), obese against non-obese. A percentage-of-body-weight threshold is not inflated by a higher starting point the way a kilogram count is, so that gap is a real signal rather than an artifact of where people began. The glycemic answer is no, and it is the half worth carrying away. After adjustment, HbA1c reductions and the proportions reaching HbA1c below 7.0% or dropping by at least 0.5% or 1.0% were statistically comparable between the groups. Whatever these drugs do to blood sugar, they appear to do it without much regard to how heavy someone was when they started. That separation between the two effects also runs through [the kidney evidence](https://thisglp.com/research/semaglutide-and-kidney-disease), where benefit does not track the scale either. Two limits matter before any of this is carried anywhere. Patients were started on either an SGLT2 inhibitor or a GLP-1 receptor agonist, and the comparison is obese against non-obese rather than drug against drug — so nothing here is a statement about GLP-1 on its own. And the authors call their own findings hypothesis-generating and ask for prospective work, which is the appropriate weight to give a retrospective record review. For a reader deciding whether to start, the useful version is narrow: a lower starting BMI is not a reason to expect nothing, and a higher one is not a promise. The variation between individuals still dwarfs the variation between these groups, which is the point made at length in [weight loss in ordinary care](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) and worth checking against the [expected weight loss tool](https://thisglp.com/tools/glp1-expected-weight-loss) rather than against a single trial number. ## Frequently asked Do heavier people lose more on these drugs? In this study they lost more absolute weight, and were likelier to reach a 5% threshold — 27.2% against 15.5% at six months. The authors note that a higher starting weight may itself account for part of the absolute difference. Does starting BMI change the blood sugar effect? It did not here. HbA1c reductions and the proportions reaching target were statistically comparable between obese and non-obese patients after adjustment. Does this tell me about GLP-1 specifically? No. Patients were started on either an SGLT2 inhibitor or a GLP-1 receptor agonist, and the comparison was between weight groups rather than between drugs. ## Sources 1. \[1\] Almohammed O, Alshaya O, Alduhayshi L, Alshaibani S, et al. (2026). Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists Frontiers in Endocrinology. [PMID 42741141](https://pubmed.ncbi.nlm.nih.gov/42741141/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers | This GLP Is there a GLP-1 pill that works? Orforglipron and oral semaglutide compared: what each trial found, what got approved, and the 50 mg dose sellers do not mean. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection Updated: 2026-10-26 Published: 2026-09-17 [← Research](https://thisglp.com/research) Formats # Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers Yes, in two forms. Orforglipron cut weight 11.2% and won FDA approval in April 2026. Oral semaglutide cut weight 13.6%, but absorbs at under 1% and is not yet approved for it. [This GLP Editorial Team](https://thisglp.com/about)September 202611 min read Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes, in two forms, with different numbers attached to each. Orforglipron, a small-molecule tablet, won US approval in April 2026 after a trial in which the top dose cut weight 11.2% against 2.1% on placebo [\[3\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-3). Oral semaglutide, a peptide tablet that needs an absorption enhancer and an empty stomach, is not yet approved for weight loss but produced 13.6% in its own 71-week trial [\[5\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-5). Neither number can be set directly against the other — different trials, different populations — and neither is what most sellers mean when they advertise "the oral option." Starting an oral medicine is a different question from [using a pill to maintain weight after an injection](https://thisglp.com/research/can-a-pill-keep-weight-off-after-the-injection); the maintenance evidence needs its own comparison. ## Key takeaways - Orforglipron, an oral non-peptide GLP-1 receptor agonist taken as a daily tablet, received its first approval in April 2026 in the United States for long-term weight management, after a trial showing 11.2% weight loss on the top dose. - Oral semaglutide, a peptide tablet, produced 13.6% weight loss in a 71-week trial but is absorbed at only 0.4% to 1% of the dose, and only if taken fasted. - A 50 mg oral semaglutide trial in East Asian adults found 14.3% weight loss — at a dose several times higher than what is sold for diabetes, in a population starting far lighter than Western trials. - A pooled analysis of seven orforglipron phase 3 trials covering 11,220 participants found mean reductions in liver enzymes and balanced rates of enzyme elevation against comparators. - Those trials excluded people whose liver enzymes were already substantially raised, so the safety finding does not extend to significant liver disease. When this site last covered orforglipron in [a pill without a needle](https://thisglp.com/research/what-is-orforglipron), it was a drug in development. It is now approved in the United States for long-term weight management, alongside reduced calorie intake and increased activity [\[1\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-1). What makes it different is chemical rather than clinical. Semaglutide and tirzepatide are peptides, which is why they are injected and why the oral semaglutide tablet needs an absorption enhancer and an empty stomach. Orforglipron is a small molecule, so it can be swallowed like an ordinary tablet without those constraints. On safety at scale, the most substantial evidence so far is a pooled analysis of seven phase 3 trials covering 11,220 participants for up to 104 weeks [\[2\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-2). Liver enzymes fell on average rather than rose, and categorical elevations were balanced against comparators. Six participants on orforglipron and six on comparators hit the laboratory threshold that triggers a drug-induced liver injury assessment. All six orforglipron cases had an alternative explanation, and none met Hy’s Law. Those trials screened out the livers you would worry about Eligibility required liver enzymes below three times the upper limit of normal in the weight management program and at or below five times in the diabetes program. Reassurance about liver safety drawn from people whose livers were working reasonably well does not transfer to people with significant fatty liver disease — a group that overlaps heavily with the people being prescribed this drug, as [the liver mediation analysis](https://thisglp.com/research/liver-repair-that-was-not-the-weight) describes. ## What orforglipron's own trial found Approval rests on ATTAIN-1, a 72-week trial in 3,127 adults with obesity and no diabetes[\[3\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-3). On the 36 mg dose, weight fell 11.2% against 2.1% on placebo. More than half the group on that dose, 54.6%, lost at least 10% of their body weight. Adverse events led 5.3% to 10.3% of the drug groups to stop, against 2.7% on placebo — mostly gastrointestinal, and mild to moderate. No trial has yet put orforglipron head to head against an injected GLP-1, so any comparison across separate studies is an eyeball, not a result. The full trial detail is in [the ATTAIN-1 breakdown](https://thisglp.com/research/what-is-orforglipron). ## The other pill: oral semaglutide Oral semaglutide is a different chemical problem with a different answer. It is a peptide, not a small molecule, so the tablet needs an absorption enhancer called SNAC and an empty stomach to work at all. Absolute bioavailability runs about 0.4% to 1% under fasting conditions, and in the fed state plasma concentrations stay below the limit of quantification — not reduced, unmeasurable [\[4\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-4). At a 25 mg dose, a 71-week trial found 13.6% weight loss against 2.2% on placebo, with gastrointestinal adverse events in 74.0% of the drug group. That figure sits in the same range as the injectable trials, though the two cannot be subtracted from each other directly [\[5\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-5). The full trial and the bioavailability science behind it are in [what the pill actually does](https://thisglp.com/research/oral-semaglutide-what-the-pill-does) and [what happens to the other 99%](https://thisglp.com/research/how-do-you-take-oral-semaglutide). ## A third number, and a dose that is not what sellers mean A separate oral semaglutide trial in 201 East Asian adults tested 50 mg daily. That is several times the 7 or 14 mg dose already approved for diabetes. It found 14.3% weight loss against 1.3% on placebo [\[6\]](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection#ref-6). Mean starting weight in that trial was 91.9 kg, well below the roughly 113 kg typical of the large Western trials. The percentage comes off a smaller base, so it should not be set beside the others uncorrected. It matters mainly because of the dose: a storefront advertising "oral semaglutide" is almost never selling 50 mg. Compounded sellers frequently do not publish the milligram at all. The trial detail is in [the 50 mg trial](https://thisglp.com/research/oral-semaglutide-fifty-milligrams). The list of conditions in phase 3 testing is worth reading as a commercial map: obstructive sleep apnea, hypertension, stress urinary incontinence, osteoarthritis pain and peripheral arterial disease. None is approved, and a trial running is not a result. It shows the strategy this class is pursuing: collecting indications that each unlock a different coverage pathway. That is how a drug excluded from weight-only reimbursement gets paid for anyway. For a reader the practical question is what a daily tablet changes. Not efficacy, on current evidence. The pooled comparison in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated) put orforglipron below tirzepatide and alongside injected semaglutide on weight. It also ranked among the highest for stopping because of side effects. What it changes is who will start — needles deter people — and how manufacturing scales, since a small molecule is not limited by peptide synthesis capacity. Whether that translates into lower prices is a separate question, examined in [the ecnoglutide trial](https://thisglp.com/research/what-is-ecnoglutide). ## Frequently asked Is there a GLP-1 pill that works? Yes, in two different forms. Orforglipron, a small-molecule tablet, won US approval in April 2026 after cutting weight 11.2% on its top dose. Oral semaglutide, a peptide tablet, is not yet approved for weight loss but produced 13.6% in its own trial at 25 mg. Is orforglipron available now? It received first US approval in April 2026 for long-term weight management. It is under regulatory review in the EU, Japan and Canada, and is not approved for the other conditions it is being tested in. How is orforglipron different from an oral semaglutide tablet? Orforglipron is a small molecule rather than a peptide, so it does not need an absorption enhancer or the fasting and timing requirements that oral semaglutide carries. Is it safe for the liver? Across 11,220 phase 3 participants, liver enzymes fell on average and elevations were balanced against comparators. But those trials excluded people whose enzymes were already substantially raised, so the finding does not cover significant liver disease. How much of an oral semaglutide tablet actually gets absorbed? About 0.4% to 1%, and only if taken fasted. In the fed state, plasma concentrations stay below the limit of quantification — not reduced, unmeasurable. Is the 'oral semaglutide' sold online the same as what was tested? Usually not. The efficacy trials tested a manufactured 25 mg tablet or, in one East Asian trial, 50 mg. Most oral semaglutide sold through telehealth is compounded, often at a dose the seller does not publish. ## Sources 1. \[1\] Shirley M (2026). Orforglipron: First Approval Drugs. [PMID 42479349](https://pubmed.ncbi.nlm.nih.gov/42479349/) 2. \[2\] Wharton S, Stefanski A, Chen J, Rao G, Twum EA, Denning M (2026). Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials Diabetes, Obesity & Metabolism. [PMID 42338042](https://pubmed.ncbi.nlm.nih.gov/42338042/) 3. \[3\] Wharton S, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment New England Journal of Medicine. [PMID 40960239](https://pubmed.ncbi.nlm.nih.gov/40960239/) 4. \[4\] Vahora S, et al. (2026). Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities Pharmaceutical Research. [PMID 42687069](https://pubmed.ncbi.nlm.nih.gov/42687069/) 5. \[5\] Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 40934115](https://pubmed.ncbi.nlm.nih.gov/40934115/) 6. \[6\] Kadowaki T, et al. (2025). Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial JAMA Internal Medicine. [PMID 40758358](https://pubmed.ncbi.nlm.nih.gov/40758358/) ## Where to get it ### Oral GLP-1, ranked Tablets, troches and capsules priced on the oral product itself — never on a number borrowed from the same seller's injection page. [Compare providers →](https://thisglp.com/best/oral-glp1) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Where the approval applies · F0 — no fibrosis · F1 — mild · F2 — significant · approved · F3 — advanced · approved · F4 — cirrhosis · Knowing which row you are in requires testing nobody does at a checkout ### Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3 ](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease) --- # Does Tirzepatide Cause Skin Sensitivity? The Allodynia Reports, Counted | This GLP Does tirzepatide cause skin sensitivity? Zepbound's trials found dysesthesia in 0.2% to 0.4% against 0.1% on placebo | the rest of the evidence is case reports. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Does Tirzepatide Cause Skin Sensitivity? The Allodynia Reports, Counted Zepbound's trials recorded dysesthesia in 0.2% to 0.4% of people against 0.1% on placebo. Beyond that line, the tirzepatide evidence is one case report and reporting-database signals. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Dysesthesia in placebo-controlled trials, drug against placebo · Tirzepatide 15 mg (Zepbound) · 0.4% vs 0.1% · Semaglutide 2.4 mg (Wegovy) · 2% vs 1% · Semaglutide 7.2 mg (STEP UP) · 22.9% vs 0.5% · Separate trials, different people. Not a head-to-head comparison. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Rarely, as far as the trials can tell. In the two placebo-controlled Zepbound trials, dysesthesia, meaning altered or painful skin sensation, was reported by 0.2% of people on 5 mg or 10 mg and 0.4% on 15 mg. On placebo the figure was 0.1% [\[1\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-1). Beyond that label line, the tirzepatide evidence is reports, not trials. One published case report describes it in a patient on tirzepatide [\[2\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-2). ## Key takeaways - Zepbound's pooled trials recorded dysesthesia in 0.2% to 0.4% of people on tirzepatide, against 0.1% on placebo. - One published case report describes a tirzepatide patient. The case series behind the term allodynia covers four people on semaglutide. - Reporting databases list hyperesthesia as a signal for tirzepatide, which shows the term recurs in reports, not how many users get it. - On semaglutide the pattern follows dose: 2% at 2.4 mg and 22.9% at 7.2 mg. - In the published cases, symptoms eased after stopping or, in some, with time on the drug. People describe it in plain terms. A shirt collar burns, a bedsheet hurts, skin feels sunburned without sun. The medical words are dysesthesia for altered sensation and allodynia for pain from a touch that should not hurt. The trials behind the Zepbound label were designed to measure weight, not either symptom. Hair shedding is the other body complaint that arrives in the same months, and [the hair-loss evidence](https://thisglp.com/research/does-ozempic-cause-hair-loss) is built on similar trial tables. ## What the Zepbound trials recorded The label pools Study 1 and Study 2, the placebo-controlled weight-reduction trials [\[1\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-1). Dysesthesia is not in the main side-effect table, which lists reactions at 2% or more. It appears in the text below it, dose by dose. The rates were 0.2% at 5 mg, 0.2% at 10 mg and 0.4% at 15 mg, against 0.1% on placebo. That is a small absolute gap. It is also a count of whatever investigators coded as dysesthesia, not a symptom survey. The label does not say how long the episodes lasted or how many people stopped the drug over them. Neither figure is published. The same limit applies to [headache on the Zepbound label](https://thisglp.com/research/does-zepbound-cause-headaches), where the table is the only randomized figure. ## The reports behind the term allodynia The case literature is short, and it is where the word allodynia entered the record. A 2025 case series from a Veterans Affairs system described four patients on semaglutide [\[3\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-3). All four took it for obesity and developed skin pain at the 2.4 mg weekly dose. The authors reported a clear link in time, and to dose, in each case. Two of the four stopped semaglutide, and their symptoms resolved. Two kept taking it, and one of them recovered after 4 months. The authors rated all four cases as probable on the Naranjo causality scale. They wrote that no drug mechanism had been identified. They also said it is not known whether this is a class effect. The tirzepatide case came later. A 2025 case report described dysesthesia on semaglutide and presented what the author called a novel report in a patient taking tirzepatide [\[2\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-2). The author describes the reaction as appearing dose dependent, resolving when the drug was stopped, and sometimes resolving on its own after several weeks. That is one patient. It shows the reaction can occur on tirzepatide, not how often. Reports, not trials A case report shows that something happened to someone. It cannot give a rate, and it cannot rule out a coincidence. The evidence in this section and the next is reports: one tirzepatide patient, four semaglutide patients, and two spontaneous-report databases. None of them is a controlled comparison. ## What the reporting databases add The World Health Organization database, VigiBase, was mined for these terms in a 2026 analysis [\[4\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-4). Semaglutide and tirzepatide were both significantly associated with hyperesthesia, an exaggerated skin sensation. Semaglutide was also associated with dysesthesia and burning sensation. The authors describe the effect as dose dependent, with discontinuation often followed by recovery, and cases of rechallenge observed. An analysis of the FDA’s reporting system found allodynia among 19 neurological signals for the GLP-1 class [\[5\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-5). Across all of those neurological reports, the median time from starting the drug was 32 days. The authors state that these are associations, not causal findings. The same caution runs through [what adverse-event reports actually list](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). ## The dose pattern, seen on semaglutide The clearest dose pattern comes from semaglutide, not tirzepatide. In the Wegovy 2.4 mg trials, dysesthesia occurred in 2% on the drug and 1% on placebo [\[6\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-6). The label’s grouping for that line includes allodynia, sensitive skin, pain of skin and skin burning sensation. STEP UP then tested 7.2 mg in 1,407 adults with obesity and without diabetes for 72 weeks [\[7\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-7). Dysesthesia was reported by 22.9% on 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo. The efficacy side of that trial is covered in [whether a higher semaglutide dose is worth it](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it). The Zepbound label’s own dose steps, 0.2% to 0.4%, show nothing on that scale. The Wegovy label adds what happened next at 7.2 mg [\[6\]](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity#ref-6). Among people who reported dysesthesia, 18% did not report recovering during the trial. Of 38 who recovered and were raised back to 7.2 mg, 17 reported it again. Those are semaglutide figures. They show a pattern worth knowing, not a tirzepatide rate. ## What remains unmeasured For tirzepatide, the label reports none of three things: how long an episode lasts, whether a lower dose ends it, and whether it returns on the same dose. They are not measured. Tirzepatide stays in the body for weeks after a last dose, as [how long Zepbound stays in your system](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system) explains. A report of improvement days after stopping should be read with that in mind. Compounded tirzepatide is not FDA-approved and has no trial safety data of its own. ## Frequently asked Does tirzepatide cause skin sensitivity? It has been reported, but rarely in the trials. Zepbound's pooled trials recorded dysesthesia in 0.2% on 5 mg and 10 mg and 0.4% on 15 mg, against 0.1% on placebo. One published case report describes it on tirzepatide. Is Zepbound skin sensitivity permanent? No study has followed it on tirzepatide. In the published reports, symptoms resolved after stopping the drug and sometimes eased on their own after several weeks. On semaglutide 7.2 mg, 18% of those affected did not report recovering during the trial. Is skin sensitivity on Wegovy more common? The Wegovy 2.4 mg trials recorded dysesthesia in 2% against 1% on placebo. At 7.2 mg in STEP UP it rose to 22.9%. These are separate trials from Zepbound's, so the figures are not a direct comparison. What is Ozempic allodynia? Allodynia is pain from a touch that should not hurt. A case series described it in four patients at the 2.4 mg semaglutide dose; two stopped and recovered, and one of two who continued recovered after 4 months. ## Sources 1. \[1\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, section 6.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) 2. \[2\] Ahern S (2025). Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide Cureus. [PMID 41210042](https://pubmed.ncbi.nlm.nih.gov/41210042/) 3. \[3\] Stark J, Klass MJ, Owen L (2025). Allodynia (skin tenderness) associated with semaglutide: A case series American Journal of Health-System Pharmacy. [PMID 39862389](https://pubmed.ncbi.nlm.nih.gov/39862389/) 4. \[4\] Laroche ML, Géniaux H, Jardou M (2026). Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review European Journal of Clinical Pharmacology. [PMID 42168638](https://pubmed.ncbi.nlm.nih.gov/42168638/) 5. \[5\] Chen H, Liu S, Gao S, et al. (2025). Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System Scientific Reports. [PMID 40413246](https://pubmed.ncbi.nlm.nih.gov/40413246/) 6. \[6\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Table 3 and section 6.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 7. \[7\] Wharton S, Freitas P, Hjelmesæth J, et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology. [PMID 40961952](https://pubmed.ncbi.nlm.nih.gov/40961952/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Does Wegovy Increase Heart Rate? Understanding the Numbers | This GLP Wegovy injection trials found a small average rise in resting pulse. Larger changes and symptoms still need individual assessment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-wegovy-increase-heart-rate Updated: 2026-10-13 Published: 2026-10-13 [← Research](https://thisglp.com/research) Safety # Does Wegovy Increase Heart Rate? Understanding the Numbers Wegovy injection trials found a small average rise in resting pulse. Larger changes and symptoms still need individual assessment. [This GLP Editorial Team](https://thisglp.com/about)October 20265 min read 1–4 bpm · Mean rise vs placebo · Resting pulse · Track consistently · Persistent rise · Contact prescriber **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Yes. Wegovy injection trials in adults found an average resting heart-rate increase of 1 to 4 beats per minute compared with placebo. An average is not a safety limit: some participants had larger changes, and persistent racing or pounding while resting should be reported. [\[1\]](https://thisglp.com/research/does-wegovy-increase-heart-rate#ref-1) This article concerns the injection trial figures in the prescribing information. It does not assume every semaglutide formulation produces the same measured change. Our guide to [GLP-1 drugs and arrhythmia](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia) addresses the separate question of abnormal heart rhythms. ## What the larger pulse changes actually measure In those adult trials, a maximum increase of at least 20 beats per minute at any visit occurred in 26% of Wegovy participants and 16% of placebo participants. That comparison describes each person's largest recorded change, not a sustained increase throughout treatment. [\[1\]](https://thisglp.com/research/does-wegovy-increase-heart-rate#ref-1) These two measures answer different questions. The average describes the overall group shift; the maximum captures a person's highest observed change. Neither establishes the cause of a particular episode. A single smartwatch alert also cannot identify an arrhythmia. ## Can a drug raise pulse and still protect the heart? Those findings are compatible. In SELECT, 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes, received semaglutide 2.4 mg or placebo. Major cardiovascular events occurred in 6.5% versus 8.0% over an average follow-up of about 40 months. [\[2\]](https://thisglp.com/research/does-wegovy-increase-heart-rate#ref-2) The outcome combined cardiovascular death, nonfatal heart attack, and nonfatal stroke. It did not mean every participant benefited, nor that palpitations could be ignored. The population matters: these were people who already had cardiovascular disease. Our article on [heart attack and stroke prevention](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes) examines how far those findings extend. ## What to bring to your appointment If you already monitor your pulse, record readings under comparable resting conditions. Include the time, symptoms, activity just beforehand, recent illness, and any medication changes. A short record of repeated symptoms is more informative than a screenshot of the highest number your watch has displayed. Tell your clinician whether the sensation is steady racing, skipped beats, or pounding, and whether it occurs at rest. Ask whether you need an examination, rhythm tracing, or a review of other medications. This is a discussion about an individual symptom, not an instruction to achieve a particular watch reading. The prescribing information calls for regular heart-rate monitoring and discontinuing Wegovy if a sustained increase in resting heart rate develops. That instruction belongs in a clinician-led assessment; it should not be replaced with an arbitrary online threshold. [\[1\]](https://thisglp.com/research/does-wegovy-increase-heart-rate#ref-1) ## Symptoms that change the urgency A fast or irregular heartbeat accompanied by fainting, chest discomfort, breathlessness, or marked dizziness needs urgent care. Do not use the small average increase as reassurance in that setting. MedlinePlus advises emergency assessment for dizziness with concerning cardiac symptoms. [\[3\]](https://thisglp.com/research/does-wegovy-increase-heart-rate#ref-3) Fluid loss can also complicate the picture, especially after repeated vomiting or diarrhea. The [dehydration warning signs](https://thisglp.com/research/glp1-dehydration-symptoms) and [dizziness guide](https://thisglp.com/research/does-ozempic-cause-dizziness) help you describe associated symptoms. They cannot determine which cause applies to you. Keep the focus on symptoms and clinical assessment rather than trying to explain every pulse change with the medication alone. ## Frequently asked How much can Wegovy raise resting heart rate? The injection trials reported a mean increase of 1 to 4 beats per minute versus placebo in adults. Individual changes were sometimes larger. Does a higher pulse mean Wegovy damages the heart? A pulse change does not by itself establish heart damage. SELECT found fewer major cardiovascular events in a specific high-risk population, while the label still requires attention to sustained resting heart-rate increases. Should I ignore palpitations if the average increase is small? No. Report a racing or pounding heart at rest. Seek urgent care when it accompanies chest pain, fainting, breathlessness, or severe dizziness. ## Sources 1. \[1\] Novo Nordisk (2026). WEGOVY (semaglutide): U.S. prescribing information Novo Nordisk. [Source](https://www.novo-pi.com/wegovy.pdf) 2. \[2\] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine. [PMID 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/) 3. \[3\] U.S. National Library of Medicine (2026). Dizziness and Vertigo MedlinePlus; accessed October 13, 2026. [Source](https://medlineplus.gov/dizzinessandvertigo.html) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Does Zepbound Cause Headaches? Headache Never Made Its Side-Effect Table Does Zepbound cause headaches? Headache is missing from its label table of 2,519 treated adults | tirzepatide trials in diabetes found a risk ratio of 1.00. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/does-zepbound-cause-headaches Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Does Zepbound Cause Headaches? Headache Never Made Its Side-Effect Table Across 2,519 adults in the trials behind the label, headache did not reach the table of reactions at 2% or more above placebo. Dizziness did, and the reporting databases tell a louder story than the trials. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Label side-effect tables, drug against placebo · Zepbound: nausea · 25–29% vs 8% · Zepbound: dizziness · 4–5% vs 2% · Zepbound: headache · not in the table · Wegovy: headache · 14% vs 10% · Tables list reactions at 2% or more and above placebo. Separate trials, not head to head. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Not often enough for the trials to separate it from placebo. Zepbound’s label pools two placebo-controlled trials in which 2,519 adults took the drug for up to 72 weeks, and its side-effect table lists every reaction that reached at least 2 percent and ran above placebo [\[1\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-1). Nausea made that table at 25 to 29 percent against 8 percent on placebo, and dizziness made it at 4 to 5 percent against 2 percent, but headache is not on it. Across twelve randomized trials of tirzepatide in 10,615 people with type 2 diabetes, the risk ratio for headache was 1.00, with a 95% confidence interval from 0.65 to 1.55 [\[2\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-2). ## Key takeaways - Headache does not appear in Zepbound's label table, which lists reactions at 2% or more and above placebo across 2,519 treated adults. - Twelve randomized trials of tirzepatide in 10,615 people with type 2 diabetes found a headache risk ratio of 1.00 (95% CI 0.65 to 1.55). - Dizziness is on the table, at 4% to 5% against 2% on placebo, and it was significantly raised in the diabetes trials too (RR 1.64). - Adverse-event databases do collect headache reports: a class-wide reporting odds ratio of 1.74 in the FDA system, and 2.51% of tirzepatide's European reports. - The label names two routes to feeling unwell that include headache: low blood sugar in people with diabetes, and dehydration with low blood pressure. The question is easy to picture: a few weeks in, the day after a dose step, when lunch was half a sandwich and the water bottle stayed full in the bag. Whether the pen caused the headache or the day did is exactly what a placebo arm exists to settle. That is why the answer here leans on trial tables first and on reports second, and why the reports get their own section rather than a vote. ## What the label table can and cannot say The table has a threshold with two parts, and headache could have failed either one. Its absence means headache was either under 2 percent on Zepbound or no more common than on placebo, and the label does not print a headache row that would say which [\[1\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-1). The table does show where the drug’s burden sits, and it sits in the gut: vomiting at 8 to 13 percent against 2 percent, [constipation](https://thisglp.com/research/does-ozempic-cause-constipation) at 11 to 17 percent against 5 percent. The same kind of table does catch a headache signal when one exists, which is the useful comparison. Wegovy’s label lists headache at 14 percent of 2,116 people on semaglutide 2.4 mg against 10 percent of 1,261 on placebo [\[6\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-6). That is four extra headaches per hundred people, and it also shows how common headache is without any drug, since one person in ten on placebo reported one. These were separate trials with different people, so the pair is a contrast between two labels rather than a head-to-head result, and the full comparison across every outcome sits in [which GLP-1 has the worst side effects](https://thisglp.com/research/which-glp1-has-the-worst-side-effects). The randomized figure for tirzepatide itself comes from diabetes trials, not the obesity program. The meta-analysis pooled twelve trials, grouped in its subgroups by comparator type, and headache landed at a risk ratio of exactly 1.00 [\[2\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-2). Dizziness did not: it rose significantly, to a risk ratio of 1.64 (95% CI 1.04 to 2.57), and the authors report the higher risk in patients aged 60 or younger. A reader who feels light-headed rather than head-sore is describing the side effect the trials did detect. ## Why the reports keep coming anyway Spontaneous reporting systems tell a louder story. In the FDA’s adverse event database, a study of 25,110 neuropsychiatric reports for the GLP-1 class found headache reported more often than expected, at a reporting odds ratio of 1.74 (95% CI 1.65 to 1.84) [\[3\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-3). The median time from starting the drug to the reported event was 16 days, with an interquartile range of 3 to 66 days, across those neuropsychiatric reports as a group rather than headache alone. The European database shows the same pattern for tirzepatide specifically. Headache made up 2.51 percent of tirzepatide’s reports there, a reaction its European product summary does not list, and the authors ask for cautious interpretation of reporting biases [\[4\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-4). On Facebook, headache was the adverse event mentioned most often in posts about tirzepatide, in 78 of 4,202 posts, or 1.86 percent [\[5\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-5). None of those numbers is a rate among people taking the drug. A reporting odds ratio compares how often headache shows up in reports for one drug against reports for all the others, and it can rise with attention as well as with harm. The gap between what trials count and what reports count has come up before on this site, in [the psychiatric-risk pooling](https://thisglp.com/research/semaglutide-psychiatric-risk-pooling) and in [what the adverse event reports actually list](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). Reports are where a signal is first noticed, and a placebo-controlled trial is where it is either confirmed or not. ## The two routes the label does name The first is low blood sugar, and it belongs mostly to people with type 2 diabetes. In the trial of adults with diabetes, blood glucose below 54 mg/dL was reported in 4.2 percent of people on Zepbound against 1.3 percent on placebo, and in 10.3 percent of those also taking a sulfonylurea [\[1\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-1). The patient information lists headache among the signs of low blood sugar, alongside sweating, shakiness and confusion. In the trial without diabetes the same reading appeared in 0.3 percent of people on the drug and in none on placebo. The second is fluid loss. The label ties nausea, vomiting and diarrhea to dehydration, and reports low blood pressure in 1.6 percent of people on Zepbound against 0.1 percent on placebo, higher in those also taking blood-pressure medicine [\[1\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-1). It says that hypotension also occurred alongside gastrointestinal side effects and dehydration. The stomach side of that story, and how long it lasts through each dose step, is covered in [how long nausea lasts on a GLP-1](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). Where the evidence stops None of these sources measured whether dehydration or low blood pressure produces headaches in people on Zepbound. The label connects them to dizziness and hypotension, and to headache only through low blood sugar, and anything further is inference. The figures here come from the branded drug’s trials; compounded tirzepatide is not FDA-approved and has no trial safety table of its own. ## A headache is not the same question as migraine Someone who already lives with migraine is asking something different, which is whether the drug changes attacks they were having before it. That question has its own evidence, mostly on semaglutide and triptan prescriptions, and it is laid out in [whether GLP-1 drugs help migraine](https://thisglp.com/research/do-glp1-drugs-help-migraine). The FDA database adds one awkward note to it, a small migraine signal for the class at a reporting odds ratio of 1.28 (95% CI 1.06 to 1.55) [\[3\]](https://thisglp.com/research/does-zepbound-cause-headaches#ref-3). Headache is also the main symptom of raised pressure around the brain, a condition these drugs are being studied to treat, as [the intracranial hypertension evidence](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension) explains. What remains open is the detail a person actually wants in week three. No trial behind the label published headache by dose step, by severity or by how many days it lasted, so there is nothing to say about whether a headache after the move to 10 mg fades by the next pen. Tiredness sits in the same gap, and [the fatigue evidence](https://thisglp.com/research/do-glp1-drugs-make-you-tired) shows how little the trials were built to catch. ## Frequently asked Does Zepbound cause headaches? Headache is not in Zepbound's label table, which lists reactions that reached 2% or more and ran above placebo across 2,519 treated adults. The label does not say whether headache fell under 2% or simply matched placebo. Does tirzepatide cause headaches? In twelve randomized trials of tirzepatide in 10,615 people with type 2 diabetes, the headache risk ratio was 1.00 (95% CI 0.65 to 1.55), meaning no difference from the comparison groups. Dizziness was raised, at a risk ratio of 1.64. Why do so many people report headaches on tirzepatide? Headache is common without any drug: one in ten placebo patients in the Wegovy trials reported one. Adverse-event databases count reports, not rates, and headache made up 2.51% of tirzepatide's European reports. Can low blood sugar on Zepbound cause a headache? The patient information lists headache among the signs of low blood sugar. In the trial of adults with type 2 diabetes, glucose below 54 mg/dL occurred in 4.2% on Zepbound against 1.3% on placebo, and in 10.3% of those also taking a sulfonylurea. ## Sources 1. \[1\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, Table 1 and sections 5.3, 5.7 and 6.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) 2. \[2\] Wu R, Xing B, Zhou Z, Yu L, Wang H (2025). Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis Neurological Sciences. [PMID 41402646](https://pubmed.ncbi.nlm.nih.gov/41402646/) 3. \[3\] Lu W, Wang S, Tang H, Yuan T, Zuo W, Liu Y (2025). Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database European Psychiatry. [PMID 39901452](https://pubmed.ncbi.nlm.nih.gov/39901452/) 4. \[4\] Popa Ilie IR, Ghibu S, Butuca A, et al. (2026). Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data Pharmaceuticals (Basel). [PMID 42356493](https://pubmed.ncbi.nlm.nih.gov/42356493/) 5. \[5\] Alibilli AS, Jain V, Mane H, et al. (2025). Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024 JMIR Infodemiology. [PMID 40706081](https://pubmed.ncbi.nlm.nih.gov/40706081/) 6. \[6\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Table 3 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Semaglutide Dose Escalation and Insulin Reduction in Type 2 Diabetes | This GLP In 62 patients, total daily insulin fell 5.6%, 22.2% and 36.9% across semaglutide dose steps while HbA1c dropped from 7.7% to 7.1%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/each-dose-step-took-insulin-away Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Semaglutide Dose Escalation and Insulin Reduction in Type 2 Diabetes In a 62-patient chart review, total daily insulin fell by 36.9% as semaglutide was escalated to 2 mg, and HbA1c improved rather than slipped. The published confidence intervals do not parse. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Total daily insulin, against baseline · at 1 mg · −5.6% · at 2 mg · −22.2% · 3 months at 2 mg · −36.9% · 62 patients, one VA center, no control group. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A chart review of 62 patients with type 2 diabetes tracked total daily insulin as semaglutide was escalated from 0.5 mg to 2 mg. - Insulin fell 5.6% by the 1 mg step (P = .008), 22.2% by the 2 mg step (P < .001), and 36.9% after at least three months at 2 mg (P < .001). - HbA1c fell from 7.7% to 7.1% over the same period, so glycemic control improved while insulin came down. - Confidence intervals as printed in the source do not bracket their own point estimates, so only the percentage changes and P values are reported here. Insulin is the treatment people most want to reduce: it requires more frequent dosing, it causes hypoglycemia, and it drives weight gain. Whether escalating a GLP-1 drug lets people take less of it is a practical question, and a chart review at a Veterans Affairs center followed 62 patients through the dose steps to find out [\[1\]](https://thisglp.com/research/each-dose-step-took-insulin-away#ref-1). Swapping mealtime doses entirely is a different question, and this chart review does not answer it. The pattern is stepwise. Total daily insulin fell 5.6% by the time the 1 mg dose started, and 22.2% by the 2 mg step, and 36.9% after at least three months at 2 mg. HbA1c went from 7.7% to 7.1% across the same period, which is the combination that matters: less insulin and better control, not one traded for the other. What the same drugs do to weight across that stretch is pooled in [the weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average). The intervals in the source do not parse The paper reports each change with a confidence interval that is positive while the estimate is negative, and in two cases the estimate falls outside its own interval. That is a sign or typesetting failure rather than data, so nothing is derived from those intervals here — the percentage changes and P values are reported and the intervals are not. A reader should treat the precision of these figures as unstated rather than as given. A monotonic relationship across three dose steps is more persuasive than a single before-and-after comparison would be, because a confounder would have to track the escalation schedule to produce it. That is the strongest thing about this study, and it is working against real limitations: 62 patients at one center, retrospective, with no control group and no way to separate the drug from everything else that changes over months of active diabetes management. One detail matters for anyone reading across from the weight literature. Semaglutide 2 mg is a diabetes dose with a diabetes label; the weight-management product is 2.4 mg and is a different prescription. The dose question generally is set out in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated), and what happens at the top of the ladder in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The practical implication is worth stating plainly because it is easy to miss: if insulin requirements fall by a third, insulin doses must be actively reduced as the GLP-1 dose rises, or hypoglycemia follows. That is a prescriber’s job and not a thing to manage alone, which is one more reason the variable clinical support described in [the analysis in older adults](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults) and the monitoring gaps in [vitamins and minerals on a GLP-1](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1) matter more than they appear to. ## Frequently asked Does a GLP-1 reduce how much insulin you need? In this small review, total daily insulin fell progressively with each semaglutide dose step, reaching 36.9% below baseline after three months at 2 mg, while HbA1c also improved. Is the finding reliable? It is suggestive rather than established. Sixty-two patients at one center, retrospective and without a control group — though the stepwise pattern across three dose levels is harder to explain by chance than a single comparison. Does insulin need adjusting when starting one? If requirements fall this much, doses have to come down alongside, or hypoglycemia follows. That is a prescriber's decision and not something to manage without supervision. ## Sources 1. \[1\] Halver A, Wiksen J, Larson A, Wegner A (2025). Efficacy of Subcutaneous Semaglutide Dose Escalation in Reducing Insulin in Patients With Type 2 Diabetes Federal Practitioner. [PMID 42666995](https://pubmed.ncbi.nlm.nih.gov/42666995/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Storefronts Sharing One Application Build, Matched by Hash | This GLP What it means for a comparison when several GLP-1 storefronts run the same compiled build, how it was established, and the rendering defect it also explains. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/eight-storefronts-one-application Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Storefronts Sharing One Application Build, Matched by Hash A group of GLP-1 storefronts serves a byte-identical application, matched by hash. A shortlist containing four of them contains one product configured four ways. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 8 storefronts, one compiled application · one build · Matched by hash on the app chunk and the testimonial images. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 8 storefronts on this roster serve a byte-identical compiled application. - The proof is a matching hash on the app chunk and on the testimonial images — two independent artifacts, not a resemblance. - A reader shortlisting four of them believes they are comparing four companies' judgment. They are comparing one product's per-tenant settings. - This is a recorded fact, not a merge and not an accusation: they remain separate sellers on this site. - Corpus read October 2026. Comparison assumes independence. Putting four storefronts side by side is only informative if four separate organizations made four separate decisions about pricing, dosing and what to tell a buyer. On this roster there is a group where that assumption fails completely — a different kind of failure from the per-seller silences counted in [who says where they can ship](https://thisglp.com/research/who-publishes-the-states-they-serve). ## What was found 8 storefronts serve the same compiled application. The evidence is a matching md5 hash on the application chunk the browser downloads, and a second matching hash on the testimonial images. Two independent artifacts agreeing to the byte is not something a genuinely separate build produces by coincidence. What this is and is not ⛔ It is not a merge. Separate brands under one parent stay separate sellers on this site, because collapsing them once cost a real company its own review. Each of these keeps its own row and its own page. ⛔ It is not an accusation either. Running several storefronts on one platform is a business model, not a deception, and nothing here alleges that anyone claimed otherwise. What is recorded is narrow and checkable: one application, several names. ## What it does to a comparison It removes the thing a shortlist is for. A reader who narrows the field to four of these names has not found four opinions about what a fair price is, or four judgments about how much to tell a buyer. They have found one product configured four ways, and the differences between the four are settings rather than decisions. That matters more here than it would in most categories, because what this site measures is precisely disclosure — whether a seller says where it ships, what the price does at a higher dose, which pharmacy fills the vial. Those are properties of the application in this group, not of eight independent editorial choices. ## The software explains a defect too The shared build’s own code accounts for something visible on several of these tenants: its pricing grid renders the first match for each molecule and truncates. A tenant that configures four priced programs therefore publishes two, and the rest sit in the shipped payload where no reader can see them. That is worth knowing because it looks exactly like concealment and is not. A page reading “available by consultation” above a price that exists in its own payload is a rendering bug, and writing it up as a seller hiding a figure would be wrong. The distinction between a silence and a defect is one this site has to keep making, and it is the same care taken over the counts in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## How to shortlist around it Treat the group as one option rather than 8. If one of them suits, take it; adding a second from the same build adds a name to the list and no information. The reviews of each say which group they belong to, and the broader question of whether disclosure travels between sellers at all is in [is disclosure a trait](https://thisglp.com/research/is-seller-disclosure-a-trait) and [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). Platform and practice are also distinct outside the group discussed above. [Sesame](https://thisglp.com/reviews/sesame-care) says its affiliated practices are independently owned and operated in its [provider notice](https://sesamecare.com/). This is a different arrangement, not evidence that Sesame belongs to this storefront group. Identify the treating practice before assuming two brands represent different clinical choices. ## Frequently asked How was this established? A matching md5 hash on the compiled application chunk and a second matching hash on the testimonial images. Two independent artifacts agreeing to the byte, rather than sites looking similar. Is this an accusation? No. Running several storefronts on one platform is a business model. What is recorded is narrow and checkable: one application, several names. Why not merge them into one entry? Because separate brands under one parent are separate sellers, and collapsing them once cost a real company its own review. Each keeps its own row and page. What should a reader do with it? Treat the group as one option. Adding a second name from the same build adds a line to a shortlist and no information. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Weight-Loss Drugs in Hypertension: What the Cochrane Review Lacked | This GLP A Cochrane review of long-term weight drugs in hypertension found the semaglutide and tirzepatide trials reported no mortality, cardiovascular or adverse event results. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Weight-Loss Drugs in Hypertension: What the Cochrane Review Lacked Eight trials, 13,000 people with high blood pressure. The semaglutide and tirzepatide trials reported none of the outcomes the review was built to assess. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Did the trial report deaths, events and harms? · orlistat · yes · phentermine/topiramate · yes · naltrexone/bupropion · yes · semaglutide · nothing · tirzepatide · nothing · Eight trials, about 13,000 people with hypertension. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A Cochrane review, now in its fourth update, pooled eight randomized trials of long-term weight drugs in adults with hypertension — roughly 13,000 participants. - The semaglutide trial (274 participants) and the tirzepatide trial reported no results at all for all-cause mortality, cardiovascular morbidity, serious adverse events or adverse events. - Among the older drugs, orlistat probably increases serious adverse events (RR 1.45, 95% CI 1.10 to 1.91, moderate certainty). - Liraglutide could not be included because no trial reported separate data for participants with hypertension. Hypertension and obesity travel together, so the people most likely to be prescribed a weight drug are disproportionately the people this review is about. After four updates and eight trials, its conclusion is that the evidence remains insufficient to say whether these drugs reduce death or cardiovascular events in that group [\[1\]](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths#ref-1). The reason is not that the trials found nothing. It is that the two newest trials measured nothing the review needed. For both semaglutide and tirzepatide, the review records that no results were reported for all-cause mortality, cardiovascular morbidity, serious adverse events or adverse events. Liraglutide could not be entered at all, because no trial has published separate figures for hypertensive participants — a gap of exactly the kind this site described in [who actually gets into trials](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults). This is an absence of evidence, not evidence of harm Nothing here says semaglutide or tirzepatide is dangerous in hypertension. It says the trials did not report the outcomes a reviewer would need to answer the question, in a population where the question is unusually live. Those are different claims and they get confused constantly — the distinction this site drew in [why preventing something is not treating it](https://thisglp.com/research/preventing-it-is-not-treating-it). The older drugs did report, and the reporting is mixed. Orlistat probably increases serious adverse events against placebo, at a risk ratio of 1.45 with a confidence interval from 1.10 to 1.91 across three trials and 1,476 participants, rated moderate certainty. Naltrexone with bupropion probably increases all adverse events at RR 1.69 (95% CI 1.58 to 1.80) in a single trial of 8,283 people, while showing no difference in serious ones. Phentermine with topiramate probably increases all adverse events at RR 1.13 (95% CI 1.08 to 1.20) — the tolerability ordering this site set out in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). Two facts about the evidence base frame the rest. Seven of the eight trials were funded by the pharmaceutical industry, which is ordinary and worth knowing. And the review itself had no dedicated funding, which is why its authors can end on a request rather than a conclusion: that completed trials enrolling both hypertensive and normotensive participants publish the hypertensive results separately. For a reader with high blood pressure weighing one of these drugs, the practical position is that the weight and blood-pressure numbers exist while the hard-outcome numbers do not, in this population. That is a narrower gap than it sounds, because the cardiovascular outcome trials in broader populations are real and this site has covered them — including [the surgery comparison on cardiovascular outcomes](https://thisglp.com/research/bariatric-surgery-vs-glp1-cardiovascular). It is still a gap, and it is four updates old. ## Frequently asked Does this review say GLP-1 drugs are unsafe in hypertension? No. It says the semaglutide and tirzepatide trials reported no results for mortality, cardiovascular morbidity, serious adverse events or adverse events, so the question cannot be answered from them. What did the older weight drugs show? Orlistat probably increases serious adverse events (RR 1.45, 95% CI 1.10 to 1.91). Naltrexone-bupropion and phentermine-topiramate probably increase all adverse events, at RR 1.69 and RR 1.13. Why was liraglutide left out entirely? Because no randomized trial has published separate results for participants with hypertension, so the review had nothing to pool. ## Sources 1. \[1\] Spary-Kainz U, Posch N, Radl-Karimi C, Jeitler K, Krenn C, Siebenhofer A (2026). Long-term effects of weight-reducing drugs in people with hypertension Cochrane Database of Systematic Reviews. [PMID 42318855](https://pubmed.ncbi.nlm.nih.gov/42318855/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Exercise on Ozempic: Building Strength Without Ignoring Symptoms | This GLP Activity remains useful during semaglutide treatment. The evidence supports a sustainable routine, while injection-day workout rules remain unproven. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/exercise-on-ozempic Updated: 2026-10-13 Published: 2026-10-13 [← Research](https://thisglp.com/research) Evidence # Exercise on Ozempic: Building Strength Without Ignoring Symptoms Activity remains useful during semaglutide treatment. The evidence supports a sustainable routine, while injection-day workout rules remain unproven. [This GLP Editorial Team](https://thisglp.com/about)October 20265 min read 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Exercise on Ozempic is generally part of treatment, not something the injection replaces. For adults who can safely do it, CDC guidance calls for at least 150 minutes of moderate activity each week plus muscle strengthening on 2 days. Those are general health goals, not a mandatory starting workload for someone feeling unwell. [\[1\]](https://thisglp.com/research/exercise-on-ozempic#ref-1) The goal should include function: walking comfortably, carrying groceries, or maintaining strength. Our guide to [muscle changes during GLP-1 treatment](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1) explains why the scale alone cannot describe progress. ## What direct exercise research shows A randomized trial assigned 195 adults who had completed an initial diet-induced weight loss to exercise, liraglutide, their combination, or placebo. After one year, the combination produced a 9.5 kg greater weight reduction than placebo, compared with 4.1 kg for exercise and 6.8 kg for liraglutide. [\[2\]](https://thisglp.com/research/exercise-on-ozempic#ref-2) This supports combining physical activity with treatment, but it was a liraglutide study after a structured initial program. It does not establish an exact Ozempic workout prescription or promise the same result for a person starting semaglutide today. The supervised intervention also differs from simply being told to “move more.” That distinction matters when reading claims about [weight maintenance after a GLP-1](https://thisglp.com/research/stopping-glp1-and-weight-regain). A beneficial habit is worth building without promising it will prevent every kilogram of regain. ## Start from your current ability CDC emphasizes that some activity is better than none and that activity can be spread through the week. [\[1\]](https://thisglp.com/research/exercise-on-ozempic#ref-1) A practical starting point may be a short walk or a manageable set of familiar strength exercises. Increase what you can sustain rather than trying to meet a full weekly target immediately. If you have mobility limits, cardiovascular disease, or complications of diabetes, ask which activities fit your situation. Discuss support from a physical therapist or an appropriately qualified exercise professional when needed. Choose a routine you can repeat without using exercise to compensate for eating. If that becomes difficult, read about [GLP-1 treatment and eating disorders](https://thisglp.com/research/glp1-and-eating-disorders) and discuss your concerns with your care team. ## Should you schedule workouts around injection day? The Ozempic label allows weekly dosing at any time of day, with or without meals. It does not prescribe a workout-free window after an injection. [\[3\]](https://thisglp.com/research/exercise-on-ozempic#ref-3) That absence is not evidence that every intense session will feel comfortable. Use your symptom pattern to plan, and let persistent symptoms trigger a medication review. There is no need to turn a drug concentration curve into a rigid seven-day training calendar. Read [the nausea evidence](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) if gastrointestinal symptoms keep interrupting activity. ## Glucose and hydration can change the plan People taking insulin or a sulfonylurea need an individualized exercise and glucose plan. NIDDK notes that activity can lower glucose during exercise and afterward, so the care team may recommend monitoring or changes to carbohydrate intake and medication. [\[4\]](https://thisglp.com/research/exercise-on-ozempic#ref-4) Do not assume all workout dizziness is low glucose, or dismiss it as ordinary fatigue. Pause activity if you become dizzy, faint, or unable to tolerate fluids. Chest pain, fainting, or severe breathlessness requires urgent evaluation. Our [dehydration guide](https://thisglp.com/research/glp1-dehydration-symptoms) covers fluid-loss symptoms that should not be pushed through. ## Track what the routine helps you do Record a few meaningful markers: how far you can comfortably walk, whether everyday tasks feel easier, and whether your usual strength is stable. Pair those observations with how well you are eating and recovering. If exercise capacity steadily worsens, bring the pattern to your clinician instead of treating greater exhaustion as proof of greater benefit. ## Frequently asked Can I exercise on the day I inject Ozempic? The prescribing information does not require avoiding exercise on injection day. Match activity to your symptoms, medical conditions, and clinician advice. How much exercise should I do on Ozempic? General adult guidance is at least 150 minutes of moderate activity weekly plus two muscle-strengthening days. Start from your ability and adapt with medical advice. Does exercise research prove the same benefits with every GLP-1? No. The cited combination trial used liraglutide after an initial weight-loss program. Its results support the value of activity but are not an exact semaglutide forecast. ## Sources 1. \[1\] Centers for Disease Control and Prevention (2023). Adult Activity: An Overview CDC. [Source](https://www.cdc.gov/physical-activity-basics/guidelines/adults.html) 2. \[2\] Lundgren JR, Janus C, Jensen SBK, et al. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined New England Journal of Medicine. [PMID 33951361](https://pubmed.ncbi.nlm.nih.gov/33951361/) 3. \[3\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection: U.S. prescribing information Novo Nordisk; revised May 2026. [Source](https://www.novo-pi.com/ozempic.pdf) 4. \[4\] National Institute of Diabetes and Digestive and Kidney Diseases (2021). Low Blood Glucose (Hypoglycemia) NIDDK. [Source](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) - [ Weight loss, tirzepatide against semaglutide · chart review, 12 mo · −16.6% · −13.4% · matched cohort, 2 yr · −14.7% · −10.8% · Randomized, SURMOUNT-5: 20.2% against 13.7% at 72 weeks. ### Tirzepatide vs Semaglutide: Which Works Better for Weight Loss? ](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) --- # GLP-1 Use and Knee Replacement: Absolute Risk at Eight Years | This GLP GLP-1 use and knee replacement in osteoarthritis: at eight years, risk was 2.80 percentage points lower after one year of any GLP-1 and 4.71 after three years of semaglutide or tirzepatide. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/fewer-knee-replacements-eight-years-on Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # GLP-1 Use and Knee Replacement: Absolute Risk at Eight Years A matched database study of people with knee osteoarthritis found 2.80 to 4.71 fewer knee replacements per hundred at eight years, with larger effects for longer use and newer drugs. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Fewer knee replacements at 8 years · 1 year, any GLP-1 · −2.8 pts · HR 0.90 · 3 years, semaglutide or tirzepatide · −4.71 pts · HR 0.72 · Longer exposure and newer drugs both did more. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A database analysis matched people with knee osteoarthritis on a GLP-1 drug against non-users, with cohorts from 13,351 to 42,062 patients. - One year of exposure to any GLP-1 drug gave an absolute risk difference for knee replacement of -2.80 percentage points at eight years (HR 0.90, 95% CI 0.83-0.98). - Three years of semaglutide or tirzepatide gave -4.71 percentage points (HR 0.72, 95% CI 0.67-0.78). - Effects grew with longer exposure and with newer agents, across every follow-up interval tested. Knee osteoarthritis is one of the conditions where weight loss has the clearest mechanical rationale, and the trial evidence on symptoms is covered in [the knee osteoarthritis evidence](https://thisglp.com/research/do-glp1-drugs-help-knee-pain). This analysis asked about the harder endpoint: whether people end up having the joint replaced [\[1\]](https://thisglp.com/research/fewer-knee-replacements-eight-years-on#ref-1). The first thing worth noting is how the results are reported. Alongside hazard ratios, the paper gives absolute risk differences — 2.80 percentage points fewer knee replacements at eight years after a single year of exposure to any GLP-1 drug, and 4.71 points fewer after three years of semaglutide or tirzepatide. Most papers this site covers publish only the ratio and leave the reader unable to work out what it means for a hundred people. The shape of the result is its strongest feature. Effects were larger with longer exposure and larger with the newer, more potent agents, consistently across four separate follow-up intervals. A confounder producing that pattern would have to track exposure duration and drug generation together, which is a much harder thing to arrange by accident than a single spurious difference — the concern that dominates [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute). A knee replacement is a decision, not an event Surgeons defer or decline knee replacement in patients above a BMI threshold, and many centers apply one explicitly. So weight loss can change the operation rate in either direction: by relieving pain enough that surgery is not wanted, or by making someone eligible who previously was not. This study found fewer operations, which is consistent with less disabling disease — and an avoided operation is not automatically avoided disease, because somebody decided not to do it. The matching deserves credit. Cohorts were balanced on age, sex, race, musculoskeletal diagnoses, obesity-related conditions, BMI and — unusually for a claims study — proxies for healthcare access. That last one addresses the objection that people on an expensive elective drug are people with better access to everything, which is a live concern in several other studies on this site, including [the thrombectomy cohort](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia). For someone with knee osteoarthritis the practical reading is reasonably direct: on this evidence, being on one of these drugs is associated with a meaningfully lower chance of needing the joint replaced within eight years, and the association is stronger the longer it is taken. It remains observational, and the parallel timing question — what happens to surgical outcomes when someone takes one before an operation — is covered in [before knee replacement](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## Frequently asked How much does it reduce the chance of knee replacement? At eight years, by 2.80 percentage points after one year of any GLP-1 drug and by 4.71 points after three years of semaglutide or tirzepatide — roughly three to five fewer operations per hundred people. Is the finding reliable? It is observational, but the effect grew with longer exposure and newer agents across every follow-up interval, which is a pattern that is hard for confounding to produce. Could fewer operations mean something other than better knees? Possibly. Surgeons defer knee replacement above certain BMI thresholds, so weight change can affect who is offered surgery as well as who needs it. ## Sources 1. \[1\] Carter V, Desverreaux E, Amin I, Fogarty AE, et al. (2026). Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis Regional Anesthesia and Pain Medicine. [PMID 42229941](https://pubmed.ncbi.nlm.nih.gov/42229941/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Frailty and Semaglutide's Cardiovascular Benefit in the SELECT Trial | This GLP A SELECT secondary analysis found no heterogeneity in semaglutide's cardiovascular benefit by frailty, and frailty category itself improved (OR 2.46, 95% CI 1.80-3.37). Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/frailty-did-not-change-the-answer Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Frailty and Semaglutide's Cardiovascular Benefit in the SELECT Trial Split 17,604 trial participants three ways by a frailty index and the cardiovascular benefit holds across all three. The frailty scores themselves moved too. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Semaglutide vs placebo, by frailty · no effect · not frail · 0.84 (0.65–1.07) · more frail · 0.70 (0.59–0.82) · most frail · 0.92 (0.76–1.10) **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Across 17,604 SELECT participants split three ways by a 31-item frailty index, semaglutide's effect on major cardiovascular events did not differ by frailty (P = .09 for interaction). - The three subgroup hazard ratios were 0.84, 0.70 and 0.92. Only the middle one excludes 1, which is what splitting one trial into thirds does, not a finding about middle-frail patients. - Quality-of-life benefit was larger at higher frailty (P = .02 for interaction), and frailty category itself was more likely to improve on semaglutide (OR 2.46, 95% CI 1.80-3.37). - Adverse events causing permanent discontinuation were relatively less common at higher frailty, not more (P < .001 for interaction). Frailty is the usual reason to withhold a drug from the people a trial says should get it. A secondary analysis of SELECT tested whether that caution has a basis here, building a 31-item frailty index across 17,604 adults with established cardiovascular disease and no diabetes [\[1\]](https://thisglp.com/research/frailty-did-not-change-the-answer#ref-1). It is a different question from the one asked in [the heart failure trial](https://thisglp.com/research/glp1-heart-failure-frailty), and a much larger sample. Thirty-one percent scored at or below 0.210 on the index, 47% between 0.211 and 0.310, and 22% at 0.311 or above. Events were more common as frailty rose, which is what a frailty index is for. The treatment effect did not track it: hazard ratios for the primary outcome ran 0.84 (95% CI 0.65–1.07) in the least frail, 0.70 (95% CI 0.59–0.82) in the middle group, and 0.92 (95% CI 0.76–1.10) in the frailest, with the test for interaction at P = .09. Do not read those three numbers against each other Only the middle interval excludes 1. That is not evidence the drug works best in middle-frail patients; it is what happens when one trial is cut into thirds and each third gets a wider interval than the whole. The interaction test is the number that answers the question asked, and at P = .09 it does not separate the groups. Two results are not subgroup slicing and carry more weight. Benefit on the EQ-5D-5L quality of life score was larger at higher frailty, with the interaction test reaching P = .02. And frailty was not a fixed trait in this trial: between baseline and week 104, participants on semaglutide were more likely to improve a frailty category (OR 2.46, 95% CI 1.80–3.37) and less likely to worsen one (OR 0.47, 95% CI 0.34–0.65). The safety result runs against the intuition that drives the caution. Adverse events leading to permanent discontinuation were relatively lower, not higher, among participants with greater baseline frailty (P < .001 for interaction). That does not mean frail patients tolerate the drug better in some absolute sense, since the comparison is against placebo within each stratum and frail placebo patients stop for their own reasons. It does mean the trial found no frailty-specific tolerability penalty, which is the thing the caution assumes. What none of this settles is whether people this sick are being offered the drug at all, which is a separate and worse-documented problem covered in [uptake after a heart attack or stroke](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke). SELECT enrolled people without diabetes and with treated cardiovascular disease, so it does not describe the frailest patients in a clinic, and the body composition question that frailty raises most sharply is handled on its own terms in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1) and in the wider cardiovascular results summarized in [the heart failure evidence](https://thisglp.com/research/do-glp1-drugs-help-heart-failure). ## Frequently asked Did semaglutide work better in some frailty groups than others? No. The test for interaction was P = .09, meaning the differences between the three subgroup estimates are not distinguishable from chance. Only the middle group's interval excluded 1, which reflects how a trial behaves when split into thirds. Can a drug change how frail someone is? In this trial frailty category moved. By week 104, participants on semaglutide were more likely to improve a category (OR 2.46) and less likely to worsen one (OR 0.47) than those on placebo. Were frail participants more likely to stop because of side effects? The opposite pattern appeared. Hazard ratios for adverse events leading to permanent discontinuation were lower at higher baseline frailty (P < .001 for interaction), so the trial found no frailty-specific tolerability penalty. ## Sources 1. \[1\] Ostrominski JW, Plutzky J, Scirica BM, Hovingh GK, et al. (2026). Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial JAMA Cardiology. [PMID 42747817](https://pubmed.ncbi.nlm.nih.gov/42747817/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Adolescent Suicidality on GLP-1 Drugs vs Lifestyle Intervention and Metformin A cohort of 9,222 matched adolescent pairs found no increased psychiatric risk with incretin drugs, a protective signal against lifestyle intervention, and none against metformin. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-adolescent-suicidality-comparators Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Adolescent Suicidality on GLP-1 Drugs vs Lifestyle Intervention and Metformin In 9,222 matched pairs of adolescents, incretin drugs looked protective against lifestyle intervention and made no difference against metformin. Neither comparison found harm. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Suicide-related events, same drugs, two comparisons · vs lifestyle intervention · HR 0.74 — 95% CI 0.57 to 0.95 · vs metformin, an active drug · no significant difference · Neither comparison found increased risk. Only one found a benefit. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched cohort of 9,222 adolescents per group compared incretin drugs against lifestyle intervention. - Neither comparison found increased psychiatric risk — which is the answer to the question people actually ask about this class in teenagers. - Against lifestyle intervention: suicide-related events HR 0.74, suicidal ideation HR 0.73, anxiety HR 0.92. - No differences for suicide attempt, insomnia, depression or eating disorders. - Against metformin, an active drug comparator, there was no significant difference — and the authors say to read the headline cautiously because of it. The most publicized worry about these drugs in young people is suicidality. This study addresses it directly in 9,222 matched pairs of adolescents, and the reassuring finding holds however you cut it: no increase. The more interesting part is what happened when the authors changed who they compared against. ## The reassuring answer first Adolescents with overweight or obesity starting semaglutide, liraglutide or tirzepatide were matched against adolescents receiving lifestyle interventions, using global electronic health records, and followed from 30 days to about three years after starting. [\[1\]](https://thisglp.com/research/glp1-adolescent-suicidality-comparators#ref-1) Incretin therapy was not associated with increased risk of any psychiatric outcome measured. Suicide attempt, insomnia, depression and eating disorders all showed no significant difference. That is the finding most families are looking for, and it is consistent with what [the pooled randomized evidence in children](https://thisglp.com/research/glp1-in-children-all-eighteen-trials) found over its much shorter follow-up. ## Then it looked protective Against lifestyle intervention, the drugs were associated with lower risks: suicide-related events HR 0.74, 95% CI 0.57 to 0.95; suicidal ideation HR 0.73, 95% CI 0.56 to 0.96; and anxiety HR 0.92, 95% CI 0.84 to 0.99. The reductions were significant among girls, HR 0.61, 95% CI 0.46 to 0.82, and among adolescents without type 2 diabetes, HR 0.63, 95% CI 0.47 to 0.85. They were not significant among boys or among those with type 2 diabetes. The study reports those splits without explaining them, and so does this page. And then it changed the comparator The authors also ran the analysis against metformin — another drug, prescribed to a more similar kind of adolescent through a more similar route. In that comparison there was no significant difference. They flag this themselves, along with potential selection bias, as the reason to interpret the protective finding cautiously. A benefit that appears against lifestyle advice and vanishes against a pill is a benefit that may belong to the patients rather than the molecule. ## Why the comparator decides so much An adolescent prescribed a GLP-1 and an adolescent enrolled in a lifestyle program differ before either starts. One has a prescriber willing to medicate, usually insurance, and a family navigating specialty care. The other may have been offered the cheaper option, or the only one available. Those differences predict mental health outcomes on their own. Metformin narrows that gap. It is also a prescription, also given for metabolic reasons, also requiring a clinician. When the difference disappears under that comparison, the most economical explanation is that some of what looked like a drug effect was a difference in who receives drugs — the point [comparator choice](https://thisglp.com/research/do-glp1-drugs-cause-gout) makes in almost every observational study this desk reads. ## What to carry away The safety question has a clear answer and the efficacy-adjacent claim does not. Nothing here suggests these drugs raise psychiatric risk in adolescents, across two comparators and seven outcomes. Nothing here establishes that they lower it either. For adults the picture is separate and has [its own longer history](https://thisglp.com/research/glp1-and-suicidal-ideation). And nobody on this roster ships to anyone under eighteen or offers a pediatric service, so this is a conversation for a family and a clinician — one in which the questions worth asking are the ones [no intake form covers](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do these drugs increase suicidality in teenagers? Not in this study. Across 9,222 matched pairs and seven psychiatric outcomes, incretin therapy was not associated with increased risk in either comparison the authors ran. Do they reduce it? Against lifestyle intervention the hazard ratio for suicide-related events was 0.74. Against metformin there was no significant difference, and the authors cite that as a reason to read the protective finding cautiously. Why did the answer change with the comparator? Adolescents who get prescribed a drug differ from those offered a lifestyle program in access, insurance and family circumstances. Metformin is also a prescription, which narrows that gap — and the difference vanished. Why were girls' results different from boys'? The reductions reached significance in girls and in adolescents without type 2 diabetes, and not in boys or those with it. The study reports the split without explaining it. ## Sources 1. \[1\] Liu TH, et al. (2026). Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity Diabetes, Obesity and Metabolism. [PMID 42736027](https://pubmed.ncbi.nlm.nih.gov/42736027/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Advertised vs Billed GLP-1 Prices: Every Correction, by Type | This GLP Every corrected GLP-1 seller price, sorted by outcome: restated upward for a fee, a four-week cycle or a prepay rung, withdrawn entirely, or corrected in a field other than the price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-advertised-vs-billed-corrections Updated: 2026-10-28 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # Advertised vs Billed GLP-1 Prices: Every Correction, by Type Most corrections to a published GLP-1 price exist for one reason: the advertised figure is not the billed one. A few exist because no figure could be published at all. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 What happened to 380 corrected price rows · 250 restated — the billed figure is higher · 95 withdrawn — no figure could be published · 35 corrected a field other than the price · Across 199 sellers. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The single most common thing wrong with a GLP-1 price is that it is not the price. Across the sellers this desk has worked through, 199 carry at least one correction, over 380 separate price rows — and the largest group by far, 250 of them, exists because the figure a seller advertises is not the figure a buyer is billed. Before comparing anything on [a board](https://thisglp.com/best), it is worth knowing what kinds of gap keep appearing. ## Three different outcomes A correction is arithmetic on what a seller publishes, and it has three possible endings. The commonest, 250 rows or 66% of the corrected set, restates the figure upward: a mandatory membership added, a four-week cycle converted to a calendar month, a prepay rung separated from the monthly rate it was standing in for. The second, 95 rows, withdraws the price entirely. Those are sellers whose published figures could not be resolved into anything a buyer could be held to — two pages giving one number different meanings, a savings line printed where a price goes, a default carried by a shared template. Publishing any of those would have put a number on a board that nobody is charged. The third and smallest, 35 rows, leaves the price alone and corrects something else — a product recorded as an injection that is an oral, a compounded row that is actually brand. Those change what a figure describes without changing the figure. ## What this is not a rate of This counts corrections written, not sellers audited. A row enters the count when somebody read the seller, found the gap and did the arithmetic, so the denominator is the worked set rather than the 580 sellers on the roster. It would be easy and wrong to turn these into a percentage of the market. What it does establish is the shape of the problem. The gaps are not random errors — they cluster into a small number of repeated structures, and once a reader can recognize those structures they can check for them on any page, including sellers nobody has corrected yet. ## The four that keep recurring A billing cycle that is four weeks rather than a month, which adds a thirteenth charge a year — counted separately in [a month that is not a month](https://thisglp.com/research/glp1-four-week-billing-cycles). A required fee outside the medication price. A first-month or promotional figure printed where the standing rate belongs. And a prepay rung presented as though it were the monthly rate. All four are checkable before paying, and all four are invisible if you read only the number. The questions that surface them are in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open), and the broader census of what goes unpublished is in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). Every figure above is computed from this site’s own correction records at the moment the page was built, most recently read October 2026. [Calibrate](https://thisglp.com/reviews/calibrate-health) makes another distinction explicit in its [pricing page](https://www.joincalibrate.com/pricing): program membership excludes lab tests and prescription medication and carries an initial commitment. The program price and an insured prescription copay are different expenses; neither should silently stand in for the other. ## Frequently asked How often is the advertised price wrong? This counts corrections written rather than sellers audited, so it is not a rate. What it shows is that the largest group of corrections by far exists because the advertised figure is not the billed one. Why would a price be withdrawn entirely? Because nothing publishable could be resolved — two pages giving one number different meanings, a savings line printed where a price goes, or a default carried by a shared template. What should I check on a seller's page? The billing interval, any required fee outside the medication, whether the figure is a first month or a promotion, and whether it belongs to a prepaid term rather than a month. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Semaglutide vs Liraglutide After Bariatric Surgery: Weight and Lean Mass A meta-analysis of eight studies in 557 post-bariatric patients: liraglutide −6.0 kg against placebo, semaglutide ahead by 4.15 points at a year, with lean mass and bone concerns. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-after-bariatric-surgery Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # Semaglutide vs Liraglutide After Bariatric Surgery: Weight and Lean Mass Pooling eight studies and 557 patients, semaglutide outperformed liraglutide by 4.15 points at a year. The body-composition figures include a bone density reduction whose interval reaches zero. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 What came off, after bariatric surgery · Fat mass · 4.78 kg · Lean mass · 3.01 kg · Bone density · small, and its interval reaches zero **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). A large number of people who have had bariatric surgery regain weight or never lose as much as expected, and GLP-1 drugs are increasingly prescribed into that gap. A 2024 meta-analysis pooled eight studies covering 557 individuals to ask whether it works and what it costs in body composition [\[1\]](https://thisglp.com/research/glp1-after-bariatric-surgery#ref-1). The answer to the first is yes. The answer to the second is where the interesting part is, and it overlaps with [what happens to lean mass generally](https://thisglp.com/research/muscle-loss-on-glp1). ## It works after surgery Against placebo, liraglutide produced greater weight loss at six months by a mean difference of 6.0 kg (95% CI −8.66 to −3.33, P < 0.001), though with substantial heterogeneity between studies at I² = 79 percent. Semaglutide outperformed liraglutide by 2.57 percentage points of body weight at six months (95% CI −3.91 to −1.23) and by 4.15 points at twelve (95% CI −6.96 to −1.34). One included study reported that after twelve months semaglutide patients were more likely to reach more than 15 percent weight loss (odds ratio 2.15, 95% CI 1.07 to 4.33) and more than 10 percent (odds ratio 2.10, 95% CI 1.19 to 3.71), in 207 people. ## What came off besides fat On liraglutide, the pooled changes were a fat mass reduction of 4.78 kg (95% CI −7.11 to −2.45), a lean mass reduction of 3.01 kg (95% CI −4.80 to −1.22), and a whole-body bone mineral density reduction of 0.02 kg/m² (95% CI −0.04 to −0.00). Read the last interval carefully. Its upper bound is zero, which means the analysis cannot rule out no bone effect at all — and it also cannot rule out a real one. The authors do not treat it as noise: their conclusion names deterioration of bone health and muscle mass as a concern needing further evaluation. In a post-surgical population, where bone density is already a known long-term issue, that combination matters more than it would in someone starting from scratch. ## What this means for buying Nothing about a post-bariatric prescription is visible in the way these drugs are sold online. A seller’s intake decides whether surgical history is asked about at all, and most of the sellers tracked here publish nothing about what a clinician reviews — the census is in [what sellers publish](https://thisglp.com/tools/what-sellers-publish). If you have had bariatric surgery, that is a reason to want a clinician who knows it, not just a prescription that arrives. The practical points are bone and muscle rather than the drug. Resistance training and adequate protein are the standard advice for lean mass, and post-surgical patients usually already have a bone monitoring plan worth continuing. And a dose ladder is worth knowing in advance here too, since these are long courses — [very few sellers publish one](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). Which molecule a seller carries also decides what is available to you at all, and the [molecule and format finder](https://thisglp.com/tools/molecule-and-format-finder) lists who offers what. ## Frequently asked Do GLP-1 drugs work after bariatric surgery? Yes. Pooled across eight studies in 557 people, liraglutide produced 6.0 kg more weight loss than placebo at six months, and semaglutide outperformed liraglutide by 4.15 percentage points at twelve. What happened to bone density? Whole-body bone mineral density fell by 0.02 kg/m² with liraglutide, with a 95% confidence interval from −0.04 to −0.00. The upper bound is zero, so a bone effect is neither established nor ruled out. How much lean mass came off? 3.01 kg on liraglutide (95% CI −4.80 to −1.22), alongside 4.78 kg of fat. The authors name muscle and bone as concerns needing further evaluation. ## Sources 1. \[1\] Dutta D, et al. (2024). Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis Obesity Surgery. [PMID 38502519](https://pubmed.ncbi.nlm.nih.gov/38502519/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Do GLP-1 Drugs Work After Bariatric Surgery? Two Randomized Trials Say Yes Two randomized trials tested GLP-1 drugs after bariatric surgery underdelivered. Semaglutide: -18.0% vs +0.4%. Liraglutide after gastric bypass: -8.8% vs +1.1%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-after-bariatric-surgery-evidence Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Work After Bariatric Surgery? Two Randomized Trials Say Yes Semaglutide took off 18.0% where placebo gained 0.4%; liraglutide took off 8.8% where placebo gained 1.1%. Both trials are small, and both untreated groups were still gaining. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Weight change after surgery had underdelivered · semaglutide, 68 weeks · -18% · its placebo arm · +0.4% · liraglutide, 56 weeks · -8.8% · its placebo arm · +1.1% · Both placebo arms gained. That is most of the gap. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Two randomized trials have tested a GLP-1 drug in people whose weight loss after bariatric surgery fell short, and both found a large effect. - Semaglutide 2.4 mg: weight fell 18.0% against a 0.4% gain on placebo over 68 weeks, an adjusted difference of 19.18 points (95% CI -23.4 to -14.8). - Liraglutide 3.0 mg after gastric bypass: 8.8% lost against a 1.1% gain, with 76% reaching at least 5% loss against 17% on placebo. - Both trials are small — 70 and 132 people — and both placebo arms gained weight, which is most of why the gaps look so wide. Yes, in both trials that have asked, and by a margin wide enough that the more interesting question is what the untreated group was doing. Surgery that has underdelivered is one of the few places in this field where somebody has actually run the randomized comparison, rather than looking back at records afterwards. ## The semaglutide trial A double-blind trial randomized 70 people whose weight loss after bariatric surgery had been suboptimal to semaglutide 2.4 mg or placebo, and followed them for 68 weeks [\[1\]](https://thisglp.com/research/glp1-after-bariatric-surgery-evidence#ref-1). Sixty-three were in the intention-to-treat sample, with 34 and 29 contributing data at the final visit. Weight fell 18.0% on semaglutide and rose 0.4% on placebo, an adjusted difference of 19.18 percentage points with an interval running from 23.4 to 14.8. Metabolic parameters and quality of life improved alongside it, measured with the kind of instrument this site examined in [the health utility analysis](https://thisglp.com/research/do-glp1-drugs-improve-quality-of-life). ## The liraglutide trial, in a narrower group An earlier randomized trial gave liraglutide 3.0 mg or placebo to people 18 to 120 months past a Roux-en-Y gastric bypass specifically, with lifestyle counseling for everyone, over 56 weeks [\[2\]](https://thisglp.com/research/glp1-after-bariatric-surgery-evidence#ref-2). Eighty-nine received the drug and 43 the placebo. Fifty-six weeks after a Roux-en-Y gastric bypass, 18 to 120 months post-operation. | | Liraglutide 3.0 mg | Placebo | | --- | --- | --- | | Total body weight change | −8.8% | +1.1% | | Lost at least 5% | 76% | 17% | | Lost at least 10% | 51% | none | | Lost at least 15% | 26% | none | | Went below their post-operative low | 21% | none | Fifty-six weeks after a Roux-en-Y gastric bypass, 18 to 120 months post-operation. Randomized, double-blind, placebo-controlled trial, 132 participants That last row is the one worth sitting with. A fifth of the people on liraglutide ended up below the lowest weight their operation had ever taken them to, and nobody on placebo did. ## What the pooled studies add A 2024 meta-analysis gathered eight studies and 557 people treated with a GLP-1 drug after bariatric surgery, from a search that took in trials and observational studies, and it went to press before the semaglutide trial above was published [\[3\]](https://thisglp.com/research/glp1-after-bariatric-surgery-evidence#ref-3). Against placebo, liraglutide took off 6.0 kg more over six months. Against liraglutide, semaglutide took off 2.57 percentage points more at six months and 4.15 points more at twelve. It also carried the cost that the headline figures leave out. On liraglutide, fat mass fell 4.78 kg, but lean mass fell 3.01 kg with it, and whole-body bone mineral density dropped slightly. The authors call bone and muscle a concern that still needs evaluating, and it is the same [body-composition question](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1) that follows these drugs outside surgery too. ## Read the placebo arms before the headlines Untreated, both comparison groups gained The placebo arm gained 0.4% in one trial and 1.1% in the other, which is why the differences — 19.18 points and roughly ten — look so enormous next to what the drugs did on their own. This is not a trick; it is the natural history of weight regain after surgery, and it is the thing the operation was supposed to prevent. But a reader comparing 18.0% here against the 15% of a placebo-controlled obesity trial elsewhere is comparing against two different floors, which is the reasoning this site sets out in [the ladder of comparators](https://thisglp.com/research/tirzepatide-vs-real-clinical-practice). ## What these two trials do not establish They are small. Seventy people and 132 people, with 63 contributing to the analysis in one of them, is not the scale at which safety signals appear or subgroups separate. The semaglutide trial recorded eight serious adverse events and one suspected unexpected serious adverse reaction, which is what a trial that size can tell you about harm: very little. The liraglutide trial also lost a lot of people. Only 65% of the drug group and 53.4% of the placebo group completed, which the authors attribute to the pandemic. Serious adverse events occurred less often on liraglutide than on placebo. They also tested different drugs after different operations. One enrolled mixed bariatric procedures and the other only Roux-en-Y gastric bypass, so they are two answers to adjacent questions rather than a replication. Nobody has compared a GLP-1 drug against a revision operation, which is the choice a person in this position is actually weighing — and the broader surgery-against-drug comparison is in [surgery against a GLP-1 on cardiovascular outcomes](https://thisglp.com/research/bariatric-surgery-vs-glp1-cardiovascular). What the trials do support is narrow and useful: when an operation has underdelivered, adding one of these drugs moves weight substantially, and doing nothing does not hold the line. What happens if the drug is later stopped is a separate question, answered in [what happens when you stop tirzepatide](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide). ## Frequently asked Do GLP-1 drugs work after bariatric surgery? In both randomized trials that have tested it, yes. Semaglutide produced 18.0% weight loss against a 0.4% gain on placebo, and liraglutide 8.8% against a 1.1% gain after gastric bypass. Can you get below the lowest weight your surgery reached? Some did. In the liraglutide trial, 21% of participants went below their post-operative nadir weight, and nobody on placebo did. Why are the differences so large? Partly because both placebo groups gained weight — 0.4% and 1.1%. The comparison is against continued regain, not against a stable weight. How strong is this evidence? Directionally consistent but small: 70 and 132 participants, with 63 analyzed in one trial. That is not a scale at which safety signals appear or subgroups separate. Does semaglutide work better than liraglutide after surgery? In a 2024 meta-analysis of eight studies and 557 people, semaglutide took off 2.57 percentage points more body weight than liraglutide at six months and 4.15 points more at twelve. Is a drug better than revision surgery? Nobody has compared them in a trial, which is the comparison a person in this position is actually weighing. ## Sources 1. \[1\] Stanley C, Mallik R, Hamid N, Jassil FC, Reuven V, Ruwona T (2026). Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Nature Medicine. [PMID 42174253](https://pubmed.ncbi.nlm.nih.gov/42174253/) 2. \[2\] Lofton HF, Maranga G, Hold R, Fielding G, Youn H, Gujral A (2025). A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass Surgery for Obesity and Related Diseases. [PMID 39401933](https://pubmed.ncbi.nlm.nih.gov/39401933/) 3. \[3\] Dutta D, et al. (2024). Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis Obesity Surgery. [PMID 38502519](https://pubmed.ncbi.nlm.nih.gov/38502519/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 and Eating Disorders: What the Evidence Does and Does Not Show | This GLP A smaller appetite is not the same as recovery. Learn why eating-disorder history, symptoms, and coordinated care matter before and during treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-and-eating-disorders Updated: 2026-10-13 Published: 2026-10-13 [← Research](https://thisglp.com/research) Safety # GLP-1 and Eating Disorders: What the Evidence Does and Does Not Show A smaller appetite is not the same as recovery. Learn why eating-disorder history, symptoms, and coordinated care matter before and during treatment. [This GLP Editorial Team](https://thisglp.com/about)October 20265 min read Appetite · One part of eating · Recovery · More than weight · Care team · Share your history **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). GLP-1 treatment is not an established replacement for eating-disorder care. In one small randomized trial involving 27 adults with binge-eating disorder, liraglutide did not significantly outperform placebo on the primary binge-episode outcome. Weight loss and recovery from an eating disorder are different outcomes. [\[1\]](https://thisglp.com/research/glp1-and-eating-disorders#ref-1) If you have a current or past eating disorder, tell the prescriber before starting or escalating treatment. This is relevant at any body size. NIMH explains that people with eating disorders may be underweight, average weight, or overweight, and can be medically unwell despite appearing healthy. [\[2\]](https://thisglp.com/research/glp1-and-eating-disorders#ref-2) ## What the small trial can actually tell us The liraglutide trial lasted 17 weeks. Both groups reported fewer binge episodes. Remission rates of 44% with liraglutide and 36% with placebo did not differ significantly, although weight loss was greater with liraglutide. A pharmacy dispensing error was an important limitation. [\[1\]](https://thisglp.com/research/glp1-and-eating-disorders#ref-1) These findings justify further study, not a claim that appetite suppression treats every eating disorder. They also cannot establish safety for anorexia nervosa, bulimia nervosa, or avoidant restrictive food intake disorder. The diagnoses involve different patterns and risks. Our article on [how GLP-1 treatment changes food intake](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1) describes an appetite outcome. It should not be read as a measure of psychological recovery or nutritional adequacy. ## Why a quieter appetite can be complicated A specialist review concludes that evidence is insufficient to establish how GLP-1 medicines should be used in eating-disorder populations. It highlights uncertainty about whether they may improve, worsen, or contribute to symptoms. [\[3\]](https://thisglp.com/research/glp1-and-eating-disorders#ref-3) A person feeling less driven to eat may welcome the change, while another may find that it reinforces restrictive behavior. The useful question is not simply whether you feel less hungry. It is whether you can nourish yourself reliably and whether thoughts or behaviors around food are becoming more distressing or rigid. Those changes warrant discussion with a qualified clinician rather than praise for a lower number on the scale. ## What to tell your care team Share any history of eating-disorder treatment, recurrent loss-of-control eating, purging, fear-driven food avoidance, or compulsive exercise. Explain changes that began after starting treatment, including difficulty eating enough or anxiety about eating despite needing nourishment. NIMH describes these kinds of behaviors as reasons for professional assessment. [\[2\]](https://thisglp.com/research/glp1-and-eating-disorders#ref-2) Medication-related nausea can complicate the picture without automatically meaning a new eating disorder. Our guide to [why GLP-1 drugs cause nausea](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea) discusses the physical symptom. A clinician should consider both physical intolerance and the emotional or behavioral response to it. ## Coordinate treatment instead of choosing between concerns An eating-disorder-informed clinician, prescriber, and dietitian can help assess whether treatment fits your situation and what monitoring is needed. NIMH describes care that can include psychotherapy, nutrition support, and medical monitoring. [\[2\]](https://thisglp.com/research/glp1-and-eating-disorders#ref-2) Do not change medication solely because an online story sounds similar to yours. Activity should support health and function, not become punishment for eating. Our [exercise guide](https://thisglp.com/research/exercise-on-ozempic) uses general health goals rather than calorie-compensation targets. Similarly, [vitamins and supplements](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1) cannot replace adequate food or specialist assessment. ## What this evidence cannot answer yet Small studies cannot tell us which individuals will improve, who may worsen, or how risk changes over years. Larger weight-loss trials are not interchangeable with trials designed to measure eating-disorder recovery. Future studies need to assess eating behavior, nutritional health, distress, and functioning, alongside weight. If you are struggling now, you do not need to wait for that research to ask for help. Tell your primary care clinician or existing treatment team what has changed and ask for an eating-disorder assessment. ## Frequently asked Are GLP-1 medicines proven treatments for eating disorders? The evidence is not sufficient to replace established eating-disorder care. A small liraglutide trial did not significantly improve the primary binge-episode outcome compared with placebo. Should I mention a past eating disorder before starting a GLP-1? Yes. Share your history and any current symptoms so the prescriber and eating-disorder care team can assess treatment and monitoring together. Does reduced appetite mean an eating disorder has resolved? No. Recovery involves eating behavior, nutritional health, distress, and functioning; appetite and weight alone do not establish it. ## Sources 1. \[1\] Allison KC, Chao AM, Bruzas MB, et al. (2023). A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder Obesity Science & Practice. [PMID 37034559](https://pubmed.ncbi.nlm.nih.gov/37034559/) 2. \[2\] National Institute of Mental Health (2024). Eating Disorders: What You Need to Know NIMH. [Source](https://www.nimh.nih.gov/health/publications/eating-disorders) 3. \[3\] Bartel S, McElroy SL, Levangie D, Keshen A (2024). Use of glucagon-like peptide-1 receptor agonists in eating disorder populations International Journal of Eating Disorders. [PMID 38135891](https://pubmed.ncbi.nlm.nih.gov/38135891/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Gallstone Risk on GLP-1 Drugs: Weight-Loss vs Diabetes Trials | This GLP A 76-trial meta-analysis found GLP-1 drugs raise gallbladder and biliary disease risk, with a relative risk of 2.29 in weight-loss trials against 1.27 in diabetes trials. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-and-gallbladder-disease Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Gallstone Risk on GLP-1 Drugs: Weight-Loss vs Diabetes Trials Across 76 randomized trials the pooled risk ratio was 1.37. In the thirteen weight-loss trials it was 2.29, and that is the subgroup everyone buying from a telehealth seller is in. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Risk of gallbladder or biliary disease · 1.0 · Diabetes trials · 1.27 · Weight-loss trials · 2.29 · Same drug class. Different populations, different risk. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Gallstones are the side effect most likely to turn into surgery, and the pooled evidence on them is stronger than for most things attributed to this drug class. A meta-analysis of 76 randomized trials in 103,371 patients found that randomization to a GLP-1 receptor agonist was associated with an increased risk of gallbladder or biliary disease, at a relative risk of 1.37 (95% CI 1.23 to 1.52) [\[1\]](https://thisglp.com/research/glp1-and-gallbladder-disease#ref-1). That is the figure usually quoted. It is not the figure that applies to most people reading a [GLP-1 seller’s page](https://thisglp.com/best). ## The weight-loss subgroup is nearly twice as high The analysis split trials by what they were studying. In the 63 trials for type 2 diabetes or other conditions, the relative risk was 1.27 (95% CI 1.14 to 1.43). In the thirteen trials for weight loss, it was 2.29 (95% CI 1.64 to 3.18), with a formal test for interaction at P < 0.001 — meaning the difference between those two groups is unlikely to be chance. Everyone buying from a telehealth seller is in the second group. A doubled relative risk on an uncommon event is still an uncommon event, but it is the number that describes this population, and it is roughly twice the one that travels. ## Dose and duration both moved it Two further subgroup findings sharpen the picture. At higher doses the relative risk was 1.56 (95% CI 1.36 to 1.78); at lower doses it was 0.99 (95% CI 0.73 to 1.33), which includes no effect at all, with interaction at P = 0.006. With longer use it was 1.40 (95% CI 1.26 to 1.56) and with shorter use 0.79 (95% CI 0.48 to 1.31), interaction at P = 0.03. Read together: the risk concentrates at higher doses held for longer, which is precisely the shape of a maintenance prescription. It is also why a seller’s silence about what happens at a higher dose is a clinical gap and not only a pricing one — a question we have counted across the market in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). ## What the components were Broken out, the pooled risks were 1.27 for cholelithiasis (95% CI 1.10 to 1.47), 1.36 for cholecystitis (95% CI 1.14 to 1.62) and 1.55 for biliary disease (95% CI 1.08 to 2.22). These are gallstones, an inflamed gallbladder, and disease of the bile ducts. The cholecystectomy figure is the one that ends in an operating room. ## What to do with it This is an association measured in randomized trials, which is the strongest design available, and the authors are explicit that the risk is greatest at higher doses, for longer durations, and for weight loss. It is worth raising with whoever writes your prescription — and worth noticing how little most sellers publish about who that clinician is, which we have measured in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) and listed as [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked How much does GLP-1 raise gallbladder risk? Pooled across 76 randomized trials, the relative risk was 1.37 (95% CI 1.23 to 1.52). In the thirteen weight-loss trials specifically it was 2.29 (95% CI 1.64 to 3.18). Does the dose matter? Yes. Higher doses carried a relative risk of 1.56 (95% CI 1.36 to 1.78) while lower doses carried 0.99 (95% CI 0.73 to 1.33), which includes no effect. The interaction test was significant at P = 0.006. Is this gallstones or something worse? Both are reported. Cholelithiasis was 1.27, cholecystitis 1.36 and biliary disease 1.55. Some of these end in gallbladder removal. ## Sources 1. \[1\] He L, et al. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials JAMA Internal Medicine. [PMID 35344001](https://pubmed.ncbi.nlm.nih.gov/35344001/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Unexpected Pregnancy on a GLP-1: Why Weight Loss Makes It Likelier | This GLP What 36 studies show about GLP-1 exposure around conception and in early pregnancy, why the reviews stop short of calling it safe, and the mechanism that makes exposure likelier. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-and-pregnancy Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Unexpected Pregnancy on a GLP-1: Why Weight Loss Makes It Likelier Weight loss restores ovulation, so unplanned pregnancy is a foreseeable consequence of these drugs working. Across 36 studies no consistent signal of harm has appeared — which is not the same as evidence of safety. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Where the evidence is, and where it stops · around conception · and first trimester · 36 studies · continued use through · the whole pregnancy · limited · One pharmacokinetic study found no semaglutide in human milk. · No pooled risk estimate has been published for any of it. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Weight loss restores ovulation in women whose cycles had stopped, so unplanned pregnancies while taking these drugs are a recognized and foreseeable consequence. - Across 36 studies, exposure around conception or in early pregnancy has not been consistently linked to major congenital malformations, growth restriction, stillbirth or neonatal death. - That is not the same as a finding of safety, and one review says so explicitly. - Data on continued use through the whole pregnancy remain limited. Animal studies at high exposure did show harm. - One pharmacokinetic study found no detectable semaglutide transfer into human milk. This is the question where the gap between what a buyer is told and what is known is widest. It is also the one where the drug working is what creates the situation — which makes the silence around it harder to excuse than most of the silences counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## Why it comes up at all Many women with irregular or absent periods who had been unable to conceive become pregnant unexpectedly after losing weight on these drugs [\[1\]](https://thisglp.com/research/glp1-and-pregnancy#ref-1). The mechanism is ordinary reproductive physiology: sustained weight loss restores ovulation. Someone who has spent years being told conception is unlikely is the person least likely to be using contraception and least likely to test early. There is a second route to the same place. Tirzepatide can reduce the absorption of oral contraceptives around dose changes, which we cover separately in [tirzepatide and oral contraception](https://thisglp.com/research/tirzepatide-and-oral-contraception). Two independent mechanisms both raise the chance of an exposure nobody planned. ## What the human data shows A 2026 systematic review searched four databases and included 36 human studies of exposure before conception, during pregnancy, or during lactation [\[2\]](https://thisglp.com/research/glp1-and-pregnancy#ref-2). Across large observational cohorts, exposure around conception or in early pregnancy was not consistently associated with a higher risk of major congenital malformations in adjusted analyses, nor with fetal growth restriction, stillbirth, or neonatal death, compared with insulin-treated or disease-matched controls. Maternal outcomes — gestational diabetes, hypertensive disorders, preterm birth, gestational weight gain — were described as heterogeneous, with no reproducible safety signal in either direction. Lactation data were sparse: one pharmacokinetic study reported no detectable semaglutide transfer into human milk. What “no consistent signal” is not The 2025 review is blunter about the limits. It notes that the large cohort most often cited — 938 pregnancies affected by type 2 diabetes, comparing periconceptional exposure against insulin — carried no information on maternal glycemic control. Because diabetic embryopathy tracks the degree of hyperglycemia rather than the diagnosis itself, that omission makes the comparison hard to interpret. Its conclusion is that patients should be counseled there is not enough evidence to predict adverse effects _or the lack of them_, and that anyone taking these drugs should use contraception to prevent unintended pregnancy. That is a stronger statement than “probably fine” and a weaker one than “shown to be harmful”. ## The animal data, in proportion Some small-animal studies of exposure during pregnancy reported decreased fetal growth, skeletal and visceral anomalies, and embryonic death. Those findings are why the label advises stopping before a planned pregnancy, and they are also why the human cohorts were assembled. So far the human data has not reproduced the pattern — which is reassuring without being conclusive, because the doses, species and exposure windows differ. ## What to do with this If pregnancy is possible, the practical answer is contraception while taking the drug and a conversation with a clinician about timing before stopping it. If an exposure has already happened, the useful thing to know is that the large cohorts have not found a pattern of anomalies — and that this is a conversation for an obstetric clinician rather than a storefront chat window. That last part is the constraint this market makes hardest. Most sellers tracked here publish nothing about who reviews a case or how to reach them, which is listed seller by seller in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). A question that has to be answered in days is a bad fit for a service that answers in weeks, and the related question of what stopping does is in [stopping and weight regain](https://thisglp.com/research/stopping-glp1-and-weight-regain). ## Frequently asked Can these drugs make pregnancy more likely? Yes, and it is a recognized pattern. Sustained weight loss restores ovulation in women whose cycles had stopped, so people previously told conception was unlikely become pregnant unexpectedly. Is exposure in early pregnancy harmful? Across 36 studies, exposure around conception or in early pregnancy has not been consistently associated with major congenital malformations, growth restriction, stillbirth or neonatal death. The reviews stop short of calling that a finding of safety. What do the reviews actually recommend? That patients be counseled there is not enough evidence to predict adverse effects or their absence, and that anyone taking these drugs use contraception to prevent unintended pregnancy. What about breastfeeding? Lactation data are sparse. One pharmacokinetic study reported no detectable semaglutide transfer into human milk, which is a single study rather than a settled answer. ## Sources 1. \[1\] Drummond RF, et al. (2025). Glucagon-like peptide-1 receptor agonist use in pregnancy: a review American Journal of Obstetrics and Gynecology. [PMID 39181497](https://pubmed.ncbi.nlm.nih.gov/39181497/) 2. \[2\] Ozbek L, et al. (2026). Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes Diabetes, Obesity and Metabolism. [PMID 41885132](https://pubmed.ncbi.nlm.nih.gov/41885132/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Tirzepatide Sleep Apnea Trial (SURMOUNT-OSA): AHI Results at 52 Weeks SURMOUNT-OSA: tirzepatide cut the apnea–hypopnea index by 20 to 24 events an hour against placebo over 52 weeks, in adults with severe apnea and obesity. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-and-sleep-apnea Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # Tirzepatide Sleep Apnea Trial (SURMOUNT-OSA): AHI Results at 52 Weeks SURMOUNT-OSA measured breathing events directly rather than weight alone. The reduction was large, the population was severe, and a year is not the whole question. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Apnea–hypopnea events per hour, trial 1 · 51.5 · baseline · −5.3 · placebo · −25.3 · tirzepatide **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Obstructive sleep apnea is one of the few conditions where a GLP-1 drug has been tested against the thing itself rather than against the weight underneath it. SURMOUNT-OSA randomized adults with moderate-to-severe apnea and obesity to tirzepatide at the maximum tolerated dose of 10 or 15 mg, or placebo, for 52 weeks, and measured the apnea–hypopnea index directly [\[1\]](https://thisglp.com/research/glp1-and-sleep-apnea#ref-1). If you are weighing [one seller’s tirzepatide against another’s](https://thisglp.com/compare), this is the trial behind the molecule. ## Two trials, two populations The published work is two phase 3 trials, not one, and the split matters. Trial 1 enrolled participants not receiving positive airway pressure at baseline; trial 2 enrolled those who were. Mean baseline AHI was 51.5 events an hour in trial 1 and 49.5 in trial 2, with mean BMI of 39.1 and 38.7. These were people with severe apnea and substantial obesity, not a general population. In trial 1, the mean change in AHI at week 52 was −25.3 events an hour (95% CI −29.3 to −21.2) with tirzepatide and −5.3 (95% CI −9.4 to −1.1) with placebo, a treatment difference of −20.0 events an hour (95% CI −25.8 to −14.2). In trial 2, the change was −29.3 against −5.5, a difference of −23.8 events an hour (95% CI −29.6 to −17.9). Both results were significant at P < 0.001. ## What twenty events an hour means Severity thresholds for apnea are conventionally set at 5, 15 and 30 events an hour. A participant starting at 51.5 and falling by 25 is moving from severe to moderate, not to nothing. The trial did not show that the drug resolves apnea; it showed a large reduction in a population with a great deal of it to lose. Hypoxic burden, high-sensitivity CRP, systolic blood pressure and patient-reported sleep measures all improved as well. ## What it does not settle Fifty-two weeks is one year, and apnea is a chronic condition. The trial does not describe what happens to AHI when the drug stops, which is the same open question that follows [weight regain after discontinuation](https://thisglp.com/research/stopping-glp1-and-weight-regain). The most frequently reported adverse events were gastrointestinal and mostly mild to moderate, which matches what the [titration literature](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) reports elsewhere. And the trial was funded by the manufacturer, as most trials of these drugs are. A practical note for anyone buying: a seller pricing tirzepatide for weight loss is selling the same molecule, but an apnea indication is a clinical decision rather than a product tier. Nothing in a [seller’s published disclosures](https://thisglp.com/tools/what-sellers-publish) speaks to it. ## Frequently asked How much did tirzepatide reduce apnea events? By 20.0 events an hour against placebo in participants not on positive airway pressure (95% CI −25.8 to −14.2), and by 23.8 in those already using it (95% CI −29.6 to −17.9), over 52 weeks. Does it cure sleep apnea? The trial does not show that. Participants started at a mean of about 50 events an hour and fell by around 25, which moves severe apnea toward moderate rather than resolving it. Does the effect last after stopping? Unknown from this trial. It ran 52 weeks and did not follow participants after treatment ended. ## Sources 1. \[1\] Malhotra A, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity New England Journal of Medicine. [PMID 38912654](https://pubmed.ncbi.nlm.nih.gov/38912654/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide and Suicidal Ideation: The Large Matched Cohort Studies | This GLP What the large matched cohorts found on GLP-1 drugs and suicidal ideation, why every one of them is observational, and where the systematic review still disagrees. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-and-suicidal-ideation Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Semaglutide and Suicidal Ideation: The Large Matched Cohort Studies Regulators opened investigations after reports of suicidal thoughts. Four matched cohorts published since — covering millions of patients — have all pointed the other way, and none of them is a randomized trial. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Hazard ratios for suicidal ideation, four cohorts · 1.0 · no difference · 0.27 · 0.44 · 0.49 · 0.75 · All four are observational. None is a randomized trial. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - European regulators opened an investigation after reports of suicidal thoughts on these drugs. The large matched cohorts published since have pointed the other way. - In 240,618 patients with overweight or obesity, semaglutide was associated with a hazard ratio of 0.27 for incident suicidal ideation and 0.44 for recurrent ideation against other anti-obesity drugs. - Against earlier GLP-1 drugs, semaglutide showed a hazard ratio of 0.49 for suicidal ideation and 0.81 for depression. - Tirzepatide and semaglutide looked the same as each other over two years. - Every one of these is observational. A systematic review of 37 studies still calls the psychiatric picture preliminary and mixed. This is the safety question with the widest gap between what a reader has heard and what has been measured. The reports came first, the regulatory investigations followed, and the large studies arrived afterwards and mostly disagreed with the premise. That sequence is worth understanding before reading any single number below — the same three stages ran for [sudden vision loss](https://thisglp.com/research/does-semaglutide-cause-vision-loss), and knowing which stage a question has reached tells you how much weight its headline deserves. ## The cohort that answered the regulators A study of electronic health records assembled 240,618 patients with overweight or obesity who were prescribed either semaglutide or a non-GLP-1 anti-obesity medication, matched them on propensity score, and followed them for six months [\[1\]](https://thisglp.com/research/glp1-and-suicidal-ideation#ref-1). Incident suicidal ideation carried a hazard ratio of 0.27 on semaglutide, and recurrent ideation 0.44 (95% CI 0.32 to 0.60). The finding held across sex, age and ethnicity, and replicated in a separate population of 1,589,855 patients with type 2 diabetes. A hazard ratio below 1.0 means the event happened less often in the semaglutide group. The authors’ own conclusion is phrased negatively — the findings do not support a higher risk — which is the correct strength of claim for this design. ## Semaglutide against the rest of its own class A 2026 analysis of a global records network covering more than 192 million patients ran two matched comparisons [\[2\]](https://thisglp.com/research/glp1-and-suicidal-ideation#ref-2). Semaglutide against earlier GLP-1 receptor agonists, across 80,115 matched pairs, showed lower first-year rates of depression (HR 0.811, 95% CI 0.770 to 0.855), anxiety (HR 0.915, 95% CI 0.871 to 0.961) and suicidal ideation (HR 0.488, 95% CI 0.339 to 0.702). Tirzepatide against semaglutide, across 85,546 matched pairs, showed no meaningful difference on the composite psychiatric outcome in either year one (HR 0.984, 95% CI 0.950 to 1.019) or year two (HR 1.002, 95% CI 0.960 to 1.046). A nominally higher anxiety hazard appeared for tirzepatide in year two (HR 1.052, 95% CI 1.001 to 1.106), and the authors themselves flag it as fragile given the number of comparisons made. ## People who were already at risk A 2026 target-trial emulation in 606,434 US veterans with type 2 diabetes looked specifically at patients who already had a substance use disorder [\[3\]](https://thisglp.com/research/glp1-and-suicidal-ideation#ref-3). Among them, starting a GLP-1 receptor agonist rather than an SGLT-2 inhibitor was associated with a lower rate of suicidal ideation or attempt (HR 0.75, 95% CI 0.67 to 0.83), a difference of roughly 10 fewer events per 1,000 people over three years. What the systematic review says, which is less tidy A 2026 systematic review screened 342 papers and included 37 [\[4\]](https://thisglp.com/research/glp1-and-suicidal-ideation#ref-4). Its summary is that semaglutide is effective and well tolerated across psychiatric populations, with possible benefit in binge eating disorder and alcohol use disorder — and that it is also linked to depressive symptoms and suicidal ideation, alongside possible antidepressant effects, with the evidence described as preliminary and its use in depression still controversial. Four cohorts pointing one way and a review calling the picture unsettled are not a contradiction. The cohorts measure average rates across very large groups. The review is describing what happens to individuals, which averages are poor at showing. ## What to do with this None of these studies randomized anybody to semaglutide to find out. People who get prescribed one drug differ from people who get prescribed another, and propensity matching reduces that problem without eliminating it. The honest summary is that the signal which prompted the investigations has not reproduced in large matched populations, and that this is not the same as proof it does not exist for any individual. Practically, this is a reason to want a prescriber you can reach. Most of the sellers tracked here publish nothing about who reviews a case or how often, which is the silence counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) and enumerated in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). Anyone with a psychiatric history should be raising it with a clinician who can act on it rather than an intake form, and anyone deciding whether to stop should read [what happens after stopping](https://thisglp.com/research/stopping-glp1-and-weight-regain) first. The related question of whether these drugs affect drinking is covered in [semaglutide and alcohol use](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use). ## Frequently asked Do GLP-1 drugs cause suicidal thoughts? The large matched cohorts published since the regulatory investigations found lower rates on semaglutide, not higher — a hazard ratio of 0.27 for incident ideation in one study of 240,618 patients. All of them are observational rather than randomized. Why did regulators investigate then? Reports of suicidal thoughts during treatment prompted European agencies to look. A reporting signal is a reason to investigate rather than a finding, and the studies run since have not reproduced it at population scale. Is tirzepatide different from semaglutide here? Across 85,546 matched pairs the two looked the same on the composite psychiatric outcome over two years. A slightly higher anxiety hazard appeared for tirzepatide in year two, which the authors describe as fragile. Does any of this settle the question? No. A 2026 systematic review of 37 studies still describes the psychiatric evidence as preliminary and mixed, and reports links in both directions. Anyone with a psychiatric history should be discussing it with a clinician who can act on it. ## Sources 1. \[1\] Wang W, et al. (2024). Association of semaglutide with risk of suicidal ideation in a real-world cohort Nature Medicine. [PMID 38182782](https://pubmed.ncbi.nlm.nih.gov/38182782/) 2. \[2\] Chen SC, et al. (2026). Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists Diabetes, Obesity and Metabolism. [PMID 42420795](https://pubmed.ncbi.nlm.nih.gov/42420795/) 3. \[3\] Cai M, et al. (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study BMJ. [PMID 41781010](https://pubmed.ncbi.nlm.nih.gov/41781010/) 4. \[4\] Carminati M, et al. (2026). Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks International Clinical Psychopharmacology. [PMID 40577093](https://pubmed.ncbi.nlm.nih.gov/40577093/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Asthma Exacerbations on GLP-1 Drugs vs Other Weight Medications | This GLP A 2026 propensity-matched cohort found asthma exacerbations in 1.7% of GLP-1 patients versus 4.0% on other weight drugs — a risk ratio of 0.438 and a 2.2-point difference. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-asthma-relative-and-absolute Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Asthma Exacerbations on GLP-1 Drugs vs Other Weight Medications In 2,423 matched pairs of adults with obesity and asthma, exacerbations ran 1.7% on GLP-1 therapy against 4.0% on other weight drugs: a ratio of 0.438, or a 2.2-point difference. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Recorded asthma exacerbation, one year · GLP-1 therapy · 1.7% · Other weight drugs · 4.0% · Difference: 2.2 points. Ratio: 0.438. · Same result, two very different-sounding numbers. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Obesity makes asthma harder to control, so the question of whether a weight drug also improves breathing is a reasonable one to ask, and a 2026 cohort study is the largest attempt at an answer so far [\[1\]](https://thisglp.com/research/glp1-asthma-relative-and-absolute#ref-1). It drew on the TriNetX US network across 72 healthcare organizations, took adults with a body mass index of 30 or above and repeated asthma documentation, and compared those subsequently prescribed a GLP-1-based therapy against those prescribed other weight-management drugs. After one-to-one propensity-score matching, 2,423 patients remained in each group, and outcomes were counted over the following year. Recorded asthma exacerbation occurred in 1.7% of the GLP-1 group against 4.0% of the comparator group. Stated as a ratio that is 0.438, with a confidence interval of 0.306 to 0.626, and a reader could fairly summarize it as more than half the exacerbations gone. Stated as a difference it is 2.2 percentage points, with a confidence interval of 1.3 to 3.2. Both descriptions are of the same result, and the second is the one that tells someone what it might mean for them, because the baseline risk was already low. The other outcomes move the same way and are worth reading with the same care. Systemic glucocorticoid exposure was 16.4% against 23.1%, emergency or critical-care use 7.1% against 13.0%, and acute respiratory failure 0.7% against 1.8%. The steroid figure is arguably the most meaningful of the four, since oral steroid courses carry their own long-run costs and a reduction there is a benefit beyond the breathing itself. The same caution about baselines applies to the [COPD exacerbation trials](https://thisglp.com/research/do-glp1-drugs-help-copd), where the ratio again outruns the difference. What lifts this above most observational GLP-1 work is the comparator. Patients were measured against others receiving an active weight-management drug rather than against people receiving nothing, which removes the most obvious confound in this literature: that anyone prescribed a weight medication differs systematically from anyone who is not. The authors are nonetheless explicit that residual confounding and uncertainty about how long patients actually stayed on treatment both remain, and they note that GLP-1-specific adverse events were not systematically assessed — so this is a measurement of one side of the ledger, and the article should not be read as though both sides were counted. A companion review published the same year argues the mechanism may not be weight at all, pointing to evidence that improving insulin resistance can improve asthma control independently of how much weight is lost, and describing the underlying pathways as poorly understood [\[2\]](https://thisglp.com/research/glp1-asthma-relative-and-absolute#ref-2). Its authors call for randomized and pragmatic trials before GLP-1 drugs are placed anywhere in an asthma treatment pathway, which is the correct position: nothing here establishes that these drugs treat asthma, only that a large matched cohort recorded fewer respiratory events over twelve months. A weight-independent mechanism would also fit what the [sleep apnea evidence](https://thisglp.com/research/glp1-and-sleep-apnea) suggests about breathing outcomes that do not track the scale. The pattern is familiar from the rest of this library: a relative figure that sounds decisive sitting on top of an absolute one that is modest. The same discipline applies to harms, which is why the [pooled serious adverse events](https://thisglp.com/research/which-glp1-has-the-worst-side-effects) are worth reading beside any benefit, and why the [Cochrane review](https://thisglp.com/research/semaglutide-cochrane-review) remains the more conservative summary of what these drugs have actually been shown to do. ## Frequently asked Do GLP-1 drugs treat asthma? No study shows that. A matched cohort recorded fewer asthma exacerbations over one year among patients on GLP-1 therapy than among patients on other weight-management drugs, which is an association in observational data rather than a demonstrated treatment effect. How large was the difference? Exacerbations occurred in 1.7% against 4.0% over twelve months. That is a risk ratio of 0.438 and an absolute difference of 2.2 percentage points, because the starting risk in both groups was low. Were side effects measured too? Not systematically. The authors state that GLP-1-specific adverse events were not assessed, so the study measures one side of the ledger and should not be read as a full accounting. ## Sources 1. \[1\] McCraw C, Grayeb D, Gupta N, Zafar P, et al. (2026). Association of GLP-1-based therapy with asthma-related outcomes in patients with obesity: a propensity-matched retrospective cohort study Expert Review of Respiratory Medicine. [PMID 42733229](https://pubmed.ncbi.nlm.nih.gov/42733229/) 2. \[2\] O'Brien H, Franciosi A, Butler M (2026). GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads Current Opinion in Pulmonary Medicine. [PMID 41664500](https://pubmed.ncbi.nlm.nih.gov/41664500/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Residual Stomach Contents on GLP-1 Drugs: A Gastric Ultrasound Study | This GLP Gastric ultrasound found increased residual stomach contents in 56% of GLP-1 users versus 19% of non-users after standard fasting, with no benefit from longer drug interruption. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-before-surgery Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Residual Stomach Contents on GLP-1 Drugs: A Gastric Ultrasound Study After identical fasting instructions, 56 percent of GLP-1 users had food still in the stomach against 19 percent of others. Pausing the drug for longer did not help. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Increased stomach contents after standard fasting · Taking a GLP-1 · 56% · Not taking one · 19% · Pausing the drug for longer did not change this. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). These drugs slow the stomach down. That is part of how they work, and it has a consequence that matters exactly once: on the morning of a procedure under anesthesia, when everyone involved is assuming an empty stomach. A cross-sectional study used gastric ultrasound on 124 patients who had followed standard preprocedural fasting instructions, and found increased residual gastric content in 56 percent of those taking a once-weekly GLP-1 drug against 19 percent of those who were not [\[1\]](https://thisglp.com/research/glp1-before-surgery#ref-1). If you are starting on one of these, this belongs on the same page as [the questions your seller has not answered](https://thisglp.com/tools/questions-they-leave-open). ## The numbers Among 124 participants (median age 56, 60 percent female), increased residual gastric content was present in 35 of 62 in the exposed group and 12 of 62 in the control group. After adjustment for confounding, GLP-1 use was associated with a 30.5 percentage point higher prevalence (95% CI 9.9 to 51.2), an adjusted prevalence ratio of 2.48 (95% CI 1.23 to 4.97). Increased content was defined as solids, thick liquids, or more than 1.5 mL/kg of clear liquids on ultrasound. ## The part that changes what you should do The intuitive response is to stop the drug for a while beforehand, and the study looked at that directly. There was no association between the duration of interruption and the prevalence of increased gastric content: adjusted odds ratio 0.86, 95 percent CI 0.65 to 1.14, an interval comfortably spanning no effect. That is a single cross-sectional study and it is not the last word. But it means the correct action is not to quietly skip a dose and say nothing. It is to tell the anesthesiologist you are taking the drug, and let them decide on the airway plan and the fasting window. The study’s own conclusion is that current fasting guidance may be inadequate for this group. ## Why your seller probably will not raise it A telehealth seller that never learns you are having surgery cannot warn you about it, and most of the sellers tracked here publish very little about the clinical relationship at all — a gap measured across the market in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). Delayed gastric emptying also affects [bowel preparation for colonoscopy](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy), which is the other place this comes up, and it applies to both molecules on the [seller comparisons](https://thisglp.com/compare). Two practical notes. Tell every clinician who asks what you take, including the ones who only ask about “medications” and not about weight-loss injections. And if a procedure is coming, raise it early enough that the plan can change — not on the day. The same delayed emptying underlies the [nausea most people meet during titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), and it is worth understanding as one mechanism rather than two unrelated problems. ## Frequently asked Should I stop my GLP-1 before surgery? That is a decision for the clinician doing the procedure, not one to make quietly. In this study, a longer interruption was not associated with less residual gastric content (adjusted OR 0.86, 95% CI 0.65 to 1.14). How much higher is the risk? After adjustment, GLP-1 use was associated with a 30.5 percentage point higher prevalence of increased residual gastric content (95% CI 9.9 to 51.2), an adjusted prevalence ratio of 2.48. Does this affect colonoscopy too? Delayed gastric emptying has also been raised as a problem for bowel preparation. Tell the team doing the procedure what you are taking. ## Sources 1. \[1\] Sen S, et al. (2024). Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia JAMA Surgery. [PMID 38446466](https://pubmed.ncbi.nlm.nih.gov/38446466/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Smart Scale Body Composition on GLP-1 Drugs: Fat vs Muscle Lost | This GLP Connected-scale data showed a 9.8% median weight reduction on GLP-1 drugs, 7.5% fat and 2.3% muscle, with systolic pressure down 2.5 mm Hg in 148 exposed users. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-body-composition-smart-scale Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Smart Scale Body Composition on GLP-1 Drugs: Fat vs Muscle Lost Connected bioimpedance scales recorded a 9.8% median weight reduction on GLP-1 drugs, split 7.5% fat and 2.3% muscle, in people who weigh themselves for years. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Median weight change at 10 to 14 months: −9.8% · fat 7.5% · muscle 2.3% · The two shares sum to the total, so both are shares of body weight. · 2.3 of 9.8 is 23% of the weight lost. · What measured it · A connected bathroom scale, reading bioimpedance through the legs. · Not DXA. Everybody in both groups owned one and used it for years. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A retrospective cohort built from connected-scale data, 396 people starting a GLP-1 against matched non-users. - Median weight reduction over months 10 to 14: 9.8%, made of 7.5% fat and 2.3% muscle. - Those two figures sum to the total, so the muscle share of the weight lost works out at about a quarter. - Blood pressure fell 2.5 mm Hg systolic and 1.5 diastolic, in a smaller group of 148 exposed. - Fat and muscle were estimated by household bioimpedance, not by DXA. A study of body composition is only as good as the thing doing the composing. Here that thing is a bathroom scale that sends a small current through your legs and infers what is between them. That is a real measurement and a useful one. It is not the measurement the phrase “body composition” usually implies, and the difference matters more than the percentages do. [\[1\]](https://thisglp.com/research/glp1-body-composition-smart-scale#ref-1) ## What the numbers say Over months 10 to 14, the GLP-1 group showed a median weight reduction of 9.8% against matched non-users. The paper attributes 7.5% to fat mass and 2.3% to muscle mass. Those two add to 9.8 exactly, which tells you both are expressed as shares of body weight rather than of each tissue. Work it through and muscle accounts for roughly a quarter of everything lost — close to the range [the imaging studies keep landing in](https://thisglp.com/research/muscle-loss-on-glp1), which is at least a point in the method’s favor. Systolic blood pressure fell 2.5 mm Hg, interval 1.5 to 2.9. Diastolic fell 1.5, interval 1.2 to 1.9. Those came from 148 exposed people rather than 396. Intervals this tight are telling you about the method The headline reduction is reported as 9.8% with a 95% interval of 9.8 to 9.9. No clinical effect is known to a tenth of a percentage point. What is being estimated is a distributional quantity across a very large number of daily weigh-ins, and its precision describes the arithmetic rather than any individual’s result. ## Who is in a study made of scale data People who bought a connected scale, linked it to an app, weighed themselves regularly for years, and then answered a survey about their medications. Both groups. That is a population already engaged with measuring itself. Matching happens inside it, so it controls for differences between the people who are there and tells you nothing about the people who are not — the same structural limit as [a study whose sample defines its own conclusion](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa), arriving by a different route. ## The prediction that may be a floor The strongest predictor of what the authors call weight-loss quality was the muscle-to-fat ratio somebody started with. People with less muscle relative to fat lost more fat and kept more muscle. Which is worth sitting with. Somebody carrying little muscle has little muscle available to lose, so a measure of how much muscle came off will look favorable for them almost by construction. Whether that is a clinical insight or an artifact of the ratio is not something this design can separate, and [what muscle loss does to strength](https://thisglp.com/research/semaglutide-muscle-mass-and-grip) is a different question again. ## What it is good for Scale data has one genuine advantage over a trial: it keeps going. Nobody schedules a DXA scan for a Tuesday in month thirteen, and daily home weights across years are a record no clinic produces. So read this as a long, noisy, densely sampled look at a self-selected group, and not as a body-composition study. It agrees roughly with better instruments on the split, which is reassuring, and it says nothing about [what comes back afterward](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). ## Frequently asked How much of the weight lost was muscle? The paper reports 7.5% fat and 2.3% muscle against a 9.8% total, so muscle is about a quarter of what came off. That figure follows from the published numbers rather than being stated. Is a bathroom scale accurate for body composition? It estimates rather than measures. Bioimpedance infers tissue from electrical resistance and shifts with hydration and time of day, so it is not comparable to a DXA scan. Why are the confidence intervals so narrow? Because the quantity being estimated is a distributional one computed across a very large number of daily weigh-ins. The precision describes the arithmetic, not any individual result. Did blood pressure improve? Systolic fell 2.5 mm Hg and diastolic 1.5 mm Hg, sustained over months 10 to 14. That part of the analysis had 148 exposed people rather than 396. ## Sources 1. \[1\] Chabassier A, et al. (2026). Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data Mayo Clinic Proceedings: Digital Health. [PMID 42746268](https://pubmed.ncbi.nlm.nih.gov/42746268/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Bone Mineral Density on GLP-1 Drugs in Type 2 Diabetes: 25 Trials | This GLP A 25-trial meta-analysis found GLP-1 agonists raised lumbar spine, hip neck and total hip bone density, while pooled fracture risk was 0.80 (95% CI 0.47 to 1.36). Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-bone-density-vs-fractures Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Bone Mineral Density on GLP-1 Drugs in Type 2 Diabetes: 25 Trials Twenty-five trials found higher bone density at every site measured. The fracture interval runs from 0.47 to 1.36 — consistent with a halving and with a rise. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Fracture risk ratio, 25 trials · 1.0 · 0.47 · 1.36 · Bone density gain, grams per square centimeter · Lumbar spine · +0.07 · Hip neck · +0.05 · Total hip · +0.06 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Losing weight quickly takes bone with it, which is why the skeleton keeps coming up around this drug class and why a reader who intends to stay on one for a year has a fair reason to ask about it. A meta-analysis of twenty-five randomized trials in type 2 diabetes gathered what has actually been measured [\[1\]](https://thisglp.com/research/glp1-bone-density-vs-fractures#ref-1), and the answer separates into two parts that point in different directions — a separation worth keeping straight before any of it reaches a claim on a [seller’s page](https://thisglp.com/best). ## Density went up Bone mineral density was higher on a GLP-1 receptor agonist than in the control arms at every site measured: the lumbar spine by 0.07 g/cm² (95% CI 0.06 to 0.09, P < 0.00001), the hip neck by 0.05 g/cm² (95% CI 0.03 to 0.08, P = 0.0001) and the total hip by 0.06 g/cm² (95% CI 0.04 to 0.07, P < 0.00001). The turnover markers moved consistently with that: formation markers rose — P1NP at a standardized mean difference of 0.33 (95% CI 0.07 to 0.59), osteocalcin by 1.46 µg/L (95% CI 1.10 to 1.83), bone-specific alkaline phosphatase by 0.91 µg/L (95% CI 0.19 to 1.63) — while β-CTX, which tracks resorption, fell at a standardized mean difference of −0.34 (95% CI −0.54 to −0.14). Calcium, phosphate and total alkaline phosphatase did not move at all. ## Fractures did not answer The outcome that matters to a person rather than to a scan is whether bones break, and there the pooled risk ratio was 0.80 with a 95% confidence interval of 0.47 to 1.36 (P = 0.41). The authors summarize that as no significant association, which is accurate, but the interval is the part to read: it is compatible with fractures falling by more than half and with them rising by more than a third. That is not reassurance. It is a set of trials too small, and followed for too little time, to distinguish between those two worlds — the same problem we found where [two meta-analyses of the same six trials](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) reached opposite conclusions. ## And the cohort is not this market Every trial pooled here enrolled people with type 2 diabetes, whose bone behaves oddly: density often reads normal or high while fracture risk is raised anyway, so density is a worse proxy in that group than in anyone else. A buyer without diabetes — most of the people reading a telehealth seller’s page — is outside the population these numbers describe. We have written before about a fracture finding that [stopped at the edge of the diabetes cohort](https://thisglp.com/research/semaglutide-fractures-diabetes-only), and this is the same boundary seen from the other side. The practical version is dull and unchanged: resistance training and enough protein are what the evidence supports for protecting lean tissue and bone during weight loss, and neither is something a seller charges for. What a seller does control is whether a clinician is reachable to raise it with, which is the gap we count in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs weaken bone? In these twenty-five trials bone density was higher on the drug, not lower, at the lumbar spine, hip neck and total hip. Whether that translates into fewer broken bones is not established. What does the fracture result actually say? A pooled risk ratio of 0.80 with a 95% confidence interval of 0.47 to 1.36. That spans a near-halving and a rise of more than a third, so it distinguishes nothing. Does this apply to me if I do not have diabetes? Not directly. Every trial pooled here enrolled people with type 2 diabetes, in whom bone density is a poorer guide to fracture risk than it is in anyone else. ## Sources 1. \[1\] Tan Y, et al. (2025). Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis Acta Diabetologica. [PMID 39985672](https://pubmed.ncbi.nlm.nih.gov/39985672/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Dehydration Symptoms: What to Watch For | This GLP Fluid loss from vomiting or diarrhea can become more than a nuisance. Recognize warning signs and prepare a plan that fits your health history. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-dehydration-symptoms Updated: 2026-10-13 Published: 2026-10-13 [← Research](https://thisglp.com/research) Safety # GLP-1 Dehydration Symptoms: What to Watch For Fluid loss from vomiting or diarrhea can become more than a nuisance. Recognize warning signs and prepare a plan that fits your health history. [This GLP Editorial Team](https://thisglp.com/about)October 20265 min read Notice · Fluid loss and intake · Call · Persistent symptoms · Act urgently · Confusion or fainting **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). GLP-1 dehydration symptoms can include thirst, dry mouth, darker urine, urinating less, and lightheadedness. They are not specific to the medication. The Ozempic label identifies nausea, vomiting, and diarrhea as routes to fluid depletion and warns that kidney injury can follow. A single symptom cannot establish the diagnosis. [\[1\]](https://thisglp.com/research/glp1-dehydration-symptoms#ref-1)[\[2\]](https://thisglp.com/research/glp1-dehydration-symptoms#ref-2) Think about two parts of the picture: what you are losing and what you can replace. Repeated vomiting with difficulty drinking is different from a brief dry mouth after waking. The guide to [diarrhea on Ozempic](https://thisglp.com/research/does-ozempic-cause-diarrhea) explains when bowel symptoms themselves need assessment. ## Which signs need a faster response? Confusion, fainting, a rapid heartbeat, or little to no urine can accompany serious dehydration. Seek urgent medical help when these occur, particularly if you cannot keep fluids down. MedlinePlus distinguishes these from milder symptoms that may respond to oral fluids. [\[2\]](https://thisglp.com/research/glp1-dehydration-symptoms#ref-2) Do not wait for every sign to appear. Someone may need assessment without meeting a checklist, and dizziness can have causes besides fluid loss. Our [dizziness guide](https://thisglp.com/research/does-ozempic-cause-dizziness) explains why glucose, blood pressure, and other possibilities matter. ## Why there is no universal water target here A fixed number of liters is not a personalized hydration plan. Fluid needs depend on illness, activity, weather, and medical conditions. If a clinician has prescribed a fluid restriction, ask for guidance before substantially increasing intake. Severe losses may require assessment and treatment beyond drinking more water. For mild fluid loss when you can drink, ask whether an oral rehydration solution is appropriate. MedlinePlus notes that replacing electrolytes may be necessary as well as water. [\[2\]](https://thisglp.com/research/glp1-dehydration-symptoms#ref-2) A branded electrolyte powder is not automatically the right product for every medical situation. Keep a practical record of vomiting or loose stools and whether you can tolerate fluids. If you already measure your weight or blood pressure for medical reasons, share those readings too. The point is to give the care team context, not to self-diagnose from a single urine color or scale change. ## Review medicines before an illness becomes a problem NIDDK advises people at kidney risk to plan for vomiting, diarrhea, and poor intake with a clinician or pharmacist. NSAIDs, including ibuprofen, deserve special attention during dehydration. Certain blood pressure medicines may also need a clinician-directed illness plan. [\[3\]](https://thisglp.com/research/glp1-dehydration-symptoms#ref-3) Our guide to [ibuprofen and Ozempic](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) covers that decision. Do not improvise by stopping every medicine labeled as affecting the kidneys; some are prescribed precisely to protect them. ## Does kidney benefit remove this risk? A medicine's longer-term benefits and an acute illness are different questions. A favorable kidney outcome in a trial does not mean persistent fluid loss is harmless. See [semaglutide and kidney disease](https://thisglp.com/research/semaglutide-and-kidney-disease) for the evidence behind treatment benefits. Ask the prescribing team whom to contact after hours, what to do if symptoms persist before the next injection, and whether kidney testing is needed. A clear response plan is more useful than reassurance that stomach symptoms are expected. Any dose change should be based on that discussion and the actual product you receive. ## Frequently asked What are early signs of dehydration on a GLP-1? Thirst, dry mouth, darker urine, reduced urination, and lightheadedness may occur. They are clues rather than proof, and other causes may need assessment. Do all GLP-1 users need electrolyte drinks? No universal requirement is established. The need depends on fluid losses and health conditions; ask whether oral rehydration is appropriate when vomiting or diarrhea occurs. When is dehydration urgent? Seek urgent help for confusion, fainting, very little urine, or inability to keep fluids down, especially with a fast heartbeat or significant weakness. ## Sources 1. \[1\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection: U.S. prescribing information Novo Nordisk; revised May 2026. [Source](https://www.novo-pi.com/ozempic.pdf) 2. \[2\] U.S. National Library of Medicine (2026). Dehydration MedlinePlus; accessed October 13, 2026. [Source](https://medlineplus.gov/dehydration.html) 3. \[3\] National Institute of Diabetes and Digestive and Kidney Diseases (2018). Keeping Kidneys Safe: Smart Choices about Medicines NIDDK. [Source](https://www.niddk.nih.gov/health-information/kidney-disease/keeping-kidneys-safe) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Depression Risk on GLP-1 Drugs vs DPP-4 and SGLT2 Inhibitors | This GLP A Medicare target trial emulation found a depression hazard ratio of 0.90 for GLP-1 against DPP-4 inhibitors and 1.07 against SGLT2 inhibitors. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-depression-depends-on-comparator Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Depression Risk on GLP-1 Drugs vs DPP-4 and SGLT2 Inhibitors In Medicare adults aged 66 and over with type 2 diabetes, the depression hazard ratio was 0.90 against DPP-4 inhibitors and 1.07 against SGLT2 inhibitors. Which one gets quoted depends on the comparator. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Risk of depression, against each comparator · 1.0 · vs DPP-4 · 0.82 · 0.98 · vs SGLT2 · 0.98 · 1.18 · Same data, same method, same paper. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Whether these drugs move mood in either direction has been argued over for two years, and most of the argument is conducted without naming a comparator. A target trial emulation in US Medicare data makes the point unavoidable: it asked the same question twice, against two different drug classes, and got two different answers [\[1\]](https://thisglp.com/research/glp1-depression-depends-on-comparator#ref-1). It is a useful corrective to the way this claim usually reaches [a seller’s page](https://thisglp.com/best). ## Two comparisons, two answers Adults aged 66 and over with type 2 diabetes were matched on propensity score. Against DPP-4 inhibitors, across 13,711 matched pairs, the rate difference was −5.78 cases of depression per 1,000 person-years (95% CI −10.49 to −1.07), a hazard ratio of 0.90 (95% CI 0.82 to 0.98). That interval clears 1. Against SGLT2 inhibitors, across 14,665 pairs, the rate difference was 3.48 per 1,000 person-years (95% CI −0.81 to 7.78), a hazard ratio of 1.07 (95% CI 0.98 to 1.18). That interval spans 1. So the honest sentence is that GLP-1 use carried a modestly lower depression risk than one comparator and no detectable difference against another. ## Why the comparator is the finding A drug is never tested against nothing in this kind of study. Everyone in both arms was being treated. So a hazard ratio here describes a choice between two treatments, not the effect of taking one. Reading 0.90 as “GLP-1 drugs protect against depression” drops the clause that carries the meaning — the same omission we found where [gout was compared across classes](https://thisglp.com/research/do-glp1-drugs-cause-gout) and where a kidney-stone comparison [ran the other way](https://thisglp.com/research/do-glp1-drugs-cause-kidney-stones). ## The authors rule this market out themselves The stated limitations include unmeasured confounders such as HbA1c and body mass index, and limited generalizability to younger people and to those taking the drug for obesity rather than diabetes. That second clause is this market, named by the paper as out of scope. Everyone studied was 66 or older with type 2 diabetes. Which leaves the same practical point as the rest of the mood evidence, including the [suicidality signal](https://thisglp.com/research/glp1-and-suicidal-ideation): what matters is whether the service you are paying can be reached by someone qualified if your mood changes. That is a question about the seller, and most of them do not answer it — a gap counted in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs lower depression risk? Against DPP-4 inhibitors the hazard ratio was 0.90 (95% CI 0.82 to 0.98). Against SGLT2 inhibitors it was 1.07 (95% CI 0.98 to 1.18), which includes no difference. The answer depends on the comparator. Does this apply to someone taking it for weight loss? The authors say not. Their stated limitations include limited generalizability to younger people and to those without type 2 diabetes taking the drug for obesity. How common was depression in the study? The authors describe the incidence as relatively low. The absolute differences were 5.78 fewer cases per 1,000 person-years against DPP-4 inhibitors, and 3.48 more against SGLT2 inhibitors. ## Sources 1. \[1\] Tang H, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study Annals of Internal Medicine. [PMID 39993315](https://pubmed.ncbi.nlm.nih.gov/39993315/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Dosing Errors in FDA Adverse Event Reports | This GLP Across 243,114 GLP-1 adverse event records, frequently reported terms included incorrect dose administered and extra dose administered alongside nausea and vomiting. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-dose-errors-in-adverse-reports Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # GLP-1 Dosing Errors in FDA Adverse Event Reports Among the terms reported most often for these drugs are incorrect dose, extra dose and off-label use. Those describe what somebody did, not what the drug did. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Frequently reported terms — use-process shaded · incorrect dose administered · how it was used · nausea · injection-site pain · diarrhea · vomiting · off-label use · how it was used · extra dose administered · how it was used · 243,114 records. The list is not ranked, and none of it is a rate. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 243,114 GLP-1 records where the drug was the primary suspect, from the FDA's reporting system, 2021 to 2026. - Frequently reported terms included incorrect dose administered, off-label use and extra dose administered, alongside nausea, vomiting and diarrhea. - The authors call those first three use-process issues rather than adverse drug reactions. - Tirzepatide accounted for 133,100 records, semaglutide 55,619, dulaglutide 38,406. - None of this is a rate. The authors say no source here estimates incidence, comparative risk or causality. Three of the terms turning up repeatedly in these reports are not descriptions of what the drug did to somebody. They are descriptions of what somebody did with the drug, and the authors separate the two explicitly — a distinction [a product page never makes](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## What a record is A case-product entry in the FDA’s Adverse Event Reporting System where a GLP-1 drug was named the primary suspect, after removing deleted cases, keeping only the latest version of each, and deduplicating. [\[1\]](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports#ref-1) That produced 243,114 records inside a background of 8,995,547 reports covering everything else. Somebody — a patient, a clinician, a manufacturer — decided each of those was worth submitting. There is no denominator of users anywhere in it. ## Two different kinds of thing in one list Nausea, vomiting, diarrhea and [injection-site pain](https://thisglp.com/research/where-should-you-inject-ozempic) are effects of a drug. Incorrect dose administered, extra dose administered and off-label use are events in the handling of a product. The authors put it as medication-use terms reflecting use-process rather than conventional adverse-drug-reaction issues, and they build a whole prioritized domain around medication-use and device events alongside the clinical ones — gastrointestinal intolerance, impaired gastric emptying, pancreatobiliary, renal and dehydration events, and hypoglycemia. Why that distinction matters more here than for most drugs A weekly self-injected drug with a dose that escalates on a schedule puts the administration in the hands of the person taking it, every week, for as long as they take it. Getting the dose wrong is a failure mode built into the product rather than into the molecule — and it is the failure mode a leaflet, a pharmacist or a follow-up appointment exists to prevent. Where a product arrives without those, [what happens outside a controlled setting](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) includes this. ## The counts by drug are not a comparison Tirzepatide accounted for 133,100 records, semaglutide 55,619 and dulaglutide 38,406. That ordering says nothing about which drug is riskier. Reporting volume follows how many people take something, how long it has been on the market, how much press it has had, and who is being prompted to report — which is why [a count of reports is not a count of events](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes), and why the authors say explicitly that none of their sources estimates incidence, comparative risk or causality. ## What it is actually for Deciding what to look at next. The authors describe their output as signal prioritization and medication-safety evidence, cross-checked against Canadian reports and against the FDA’s own labeling changes. Read that way it is useful and modest: a map of where to point a proper study. Read as a league table of harm it is worthless, and it will be read that way, which is the standing fate of [every spontaneous reporting analysis](https://thisglp.com/research/glp1-and-suicidal-ideation) that reaches a headline. ## Frequently asked What gets reported most often for these drugs? The published list includes incorrect dose administered, nausea, injection-site pain, diarrhea, vomiting, off-label use and extra dose administered. The abstract does not rank them. Why separate dose errors from side effects? Because they are different failures. The authors describe medication-use terms as reflecting the use process rather than conventional adverse drug reactions — what somebody did with the product, not what the product did. Does tirzepatide having more reports mean it is riskier? No. Reporting volume follows how many people take a drug, how long it has been sold and how much attention it has had. The authors state no source here estimates comparative risk. Can you get a rate out of this? No. There is no count of how many people took anything, and the authors say the findings are signal prioritization rather than incidence. ## Sources 1. \[1\] Ren L, et al. (2026). Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study Diabetes, Obesity and Metabolism. [PMID 42687799](https://pubmed.ncbi.nlm.nih.gov/42687799/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # GLP-1 Sellers Billing Every Four Weeks: Thirteen Charges a Year | This GLP How many GLP-1 sellers bill on four-week rather than calendar-month intervals, what the thirteenth charge costs, and why two prices are not comparable without it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-four-week-billing-cycles Updated: 2026-10-26 Published: 2026-09-15 [← Research](https://thisglp.com/research) Formats # GLP-1 Sellers Billing Every Four Weeks: Thirteen Charges a Year Some GLP-1 sellers bill every four weeks rather than by the calendar month. That is a thirteenth charge a year, roughly an eight percent premium, and it never appears on the price tag. [This GLP Editorial Team](https://thisglp.com/about)September 20264 min readUpdated September 2026 Calendar months billed in a year · Four-week periods billed in the same year · +1 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 34 sellers on this roster record a billing interval that is not a calendar month. - 24 of them bill every four weeks, which is thirteen charges a year rather than twelve. - At the median published figure of $190, that thirteenth charge is $190 a year nobody sees on the price tag. - Longer intervals exist too — eight weeks, twelve weeks, and a handful billing weekly. - Counts come from each seller's own recorded note, read most recently October 2026. A price quoted “monthly” is usually a price per calendar month. Sometimes it is not, and the difference is invisible at the point a reader compares two numbers. ## Thirteen is not twelve A seller billing every four weeks charges thirteen times across a year, because fifty-two weeks divides into thirteen four-week periods rather than twelve. That is roughly an eight percent premium over an identical figure billed by the calendar month, and it never appears on the price tag — the same class of gap that [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) marks sellers on. At this corpus’s median published figure of $190 a month, the thirteenth charge is $190 a year. 24 sellers here record a four-week interval in their own pricing notes. 34 record some non-monthly interval in total, including 3 every week, 1 every eight weeks, 6 every twelve weeks. These counts are a floor There is no billing-interval field on this roster. A seller appears in these counts only when its own recorded note names the interval, so a seller absent from them has not been shown to bill by the calendar month — it has simply not written the interval down anywhere this desk has read. Inventing a value from that silence is the error this site refuses to make. ## The longer intervals cut the other way Twelve-week billing is the mirror image: fewer, larger charges rather than more, smaller ones. It is not a premium, but it is a commitment, and a reader who stops treatment partway through a quarter has usually already paid for it. Neither interval is dishonest. Both make two published figures non-comparable until the interval is read alongside them, which is why [the questions worth asking](https://thisglp.com/tools/questions-they-leave-open) start with the terms rather than the number. ## Reading the interval first [The billing cadence check](https://thisglp.com/tools/billing-cadence-check) lists every seller whose own note names an interval, with the charges a year each implies. It is the first thing worth reading on any seller whose figure looks competitive, because a number that turns out to be per four weeks is not the number it appeared to be. For the sellers that publish every rung of a ladder instead, see [published dose ladders](https://thisglp.com/tools/published-dose-ladders). Counts are computed from this site’s own records at build time, most recently read October 2026. Not every nonmonthly supply is a recurring four-week charge. [Henry Meds’ review](https://thisglp.com/reviews/henry-meds) distinguishes monthly billing from shipment allowances: its [program terms](https://henrymeds.com/legal/programs) describe semaglutide quantities over 70- or 90-day windows. Read the payment frequency and shipment window separately rather than deriving one from the other. ## Frequently asked How much does four-week billing actually add? About eight percent over a year, because thirteen four-week periods fit into fifty-two weeks rather than twelve. At this corpus's median figure that is roughly one extra monthly charge annually. Is a seller missing from the list billing monthly? Not established. There is no billing-interval field; a seller appears only when its own note names the interval. Absence means nothing was written down, not that the interval is a calendar month. Is twelve-week billing better? It is fewer, larger charges rather than more, smaller ones — not a premium, but a commitment. A reader stopping partway through a quarter has usually already paid for it. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Frailty and Semaglutide in Heart Failure: The STEP-HFpEF Analysis | This GLP A prespecified analysis of the STEP-HFpEF trials found semaglutide's weight loss was identical across frailty strata while symptom improvement was not. What that decoupling means. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-heart-failure-frailty Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Frailty and Semaglutide in Heart Failure: The STEP-HFpEF Analysis Re-cutting 1,145 heart failure participants by frailty separated the weight loss from the symptom benefit. The frailest gained the most, and the fittest gained nothing measurable. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Symptom score vs placebo at 52 weeks · nonfrail · n=110 · more frail · n=343 · most frail · n=692 · no difference **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A prespecified pooled analysis of the two STEP-HFpEF trials sorted 1,145 participants by frailty. - Most of them were frail: 692 people, 60.4%, fell in the most-frail group and only 110 were nonfrail. - Weight loss was similar whatever the frailty stratum — P for interaction 0.38. - Symptom improvement was not. The most frail gained 11.0 points against placebo, 95% CI 8.1 to 13.8, with P for interaction below 0.001. - Frailty itself fell: the odds of being nonfrail at 52 weeks were 3.16 times higher, 95% CI 2.44 to 4.09. Nearly every claim made for these drugs runs through the weight. Lose the weight, the argument goes, and the knees, the sleep, the blood pressure and the breathlessness all follow. It is a reasonable argument and this analysis is the most interesting reason to doubt that it is the whole story — because it found a trial population where the weight loss was the same for everybody and the benefit was not. ## How the trials were re-cut The STEP-HFpEF program randomized people with obesity-related heart failure with preserved ejection fraction to once-weekly semaglutide 2.4 mg or placebo for 52 weeks, with two co-primary endpoints: change in body weight and change in the Kansas City Cardiomyopathy Questionnaire clinical summary score, a patient-reported measure of heart failure symptoms and physical limitation. Whether the drug worked there is the subject of [a separate page](https://thisglp.com/research/do-glp1-drugs-help-heart-failure). This analysis asked a narrower question of the same 1,145 participants. [\[1\]](https://thisglp.com/research/glp1-heart-failure-frailty#ref-1) Frailty was scored with a cumulative-deficit index built from 34 variables, at baseline and at follow-up, and participants were sorted into three strata. The distribution is worth pausing on: 110 people, 9.6%, were nonfrail. 343, or 30.0%, were more frail. 692, or 60.4%, were most frail. A trial of an obesity drug in heart failure turns out to have enrolled a mostly frail population, which is not how these trials are usually pictured. ## The weight moved the same for everyone Semaglutide-mediated weight loss was similar across all three strata, with a P value for interaction of 0.38. Nothing about being frail made the drug less effective at the thing it is sold for. That is a useful negative finding on its own, and it sets up the contrast. ## The symptoms did not The effect on symptom score varied sharply by frailty, with P for interaction below 0.001. In the most frail, the mean difference against placebo at 52 weeks was 11.0 points, 95% CI 8.1 to 13.8 — a large improvement on a scale where roughly five points is usually treated as clinically meaningful. In the more-frail group it was 3.7, 95% CI −0.2 to 7.6. In the nonfrail group it was −1.5, 95% CI −8.4 to 5.4. That last number is the one worth sitting with. The point estimate is negative, which means the nonfrail participants on semaglutide reported slightly worse symptom scores than the nonfrail participants on placebo. The interval runs from −8.4 to 5.4 and the group is 110 people, so it demonstrates nothing in either direction. It is printed here because omitting an unflattering estimate while quoting the flattering ones is how a result gets sold rather than reported — the same problem [composite endpoints create](https://thisglp.com/research/tirzepatide-heart-failure-composite) when nobody looks at the components. ## Frailty itself improved The analysis also measured whether the frailty index moved. It did. The odds of being classified nonfrail at 52 weeks were 3.16 times higher on semaglutide than on placebo, 95% CI 2.44 to 4.09, with P below 0.0001. A cumulative-deficit index counts accumulated problems across many domains, so a shift of that size over a year is substantial, and it is a different claim from losing weight. Who ran this The STEP-HFpEF trials are the manufacturer’s own and Novo Nordisk appears among the author affiliations on this analysis. The analysis was prespecified rather than assembled afterward, which is the safeguard that matters most here, and the frailty index was defined in advance. Both facts belong beside the result. ## What to distrust The primary symptom endpoint is a questionnaire. Participants score their own breathlessness and physical limitation. In a trial where one arm visibly loses weight and the other does not, blinding holds less well in practice than on paper, and a patient who suspects they are on the active drug may score themselves differently. That is a real limitation of every symptom endpoint in this literature and it does not make an 11-point difference disappear. There is also a subgroup caution. Three strata from one pooled population, with the smallest holding 110 people, is the kind of cut where an interaction can be real and can also be noise. This one was prespecified and the P value is small, which is the better version of that situation rather than an exemption from it. Body composition is a related and separate question, and [what the weight is made of](https://thisglp.com/research/muscle-loss-on-glp1) matters more in a frail population than in a robust one. ## What a buyer should take from it Two things, both modest. The benefit these drugs produce is not a simple function of pounds lost, so a seller’s weight-loss figure is not a proxy for how you will feel. And the people who improved most here were the ones in the worst shape at the start — which is the opposite of the marketing, and a reason to be skeptical of any pitch aimed at people who are basically well. Almost none of that appears on a product page, and [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) shows how little does. ## Frequently asked Did frail people lose less weight? No. Weight loss was similar across all three frailty strata, with a P value for interaction of 0.38. Frailty did not blunt the drug's main effect. Why did the fittest participants show no symptom benefit? The analysis does not say, and with 110 people and an interval from −8.4 to 5.4 the estimate shows nothing either way. One plausible reading is that people with few symptoms have little room to improve on a symptom score. Is an 11-point change large? Yes. On the KCCQ clinical summary score, roughly five points is usually treated as clinically meaningful, and the interval here ran from 8.1 to 13.8. Does this apply outside heart failure? Not directly. These were people with obesity-related HFpEF, most of them frail. The useful transferable point is that symptom benefit and weight loss moved independently, which nothing on a product page acknowledges. ## Sources 1. \[1\] Pandey A, et al. (2025). Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program JACC: Heart Failure. [PMID 40956259](https://pubmed.ncbi.nlm.nih.gov/40956259/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Drugs in Children and Adolescents: 18 Randomized Trials Pooled | This GLP Meta-analysis of 18 GLP-1 trials in 1,402 children and adolescents: body weight down 3.02 kg, BMI down 1.45, and a median treatment duration of 0.51 years. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-in-children-all-eighteen-trials Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs in Children and Adolescents: 18 Randomized Trials Pooled A meta-analysis pooled 18 randomized trials covering 1,402 children and adolescents aged six to seventeen. The pooled effects were modest, and the median treatment lasted about six months. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Median treatment duration across 18 pediatric trials · 0.51 years · five years, for scale · Pooled effects, 1,402 participants · body weight · −3.02 kg · BMI · −1.45 · HbA1c · −0.44% **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A meta-analysis pooled 18 randomized trials of GLP-1 drugs in under-18s, covering 1,402 participants. - Pooled effects: body weight −3.02 kg (95% CI −4.98 to −1.06), BMI −1.45 (−2.40 to −0.49), HbA1c −0.44 percentage points (−0.68 to −0.21). - Systolic blood pressure fell 2.73 mm Hg (95% CI −4.04 to −1.43). Gastrointestinal adverse events rose. - Median treatment duration across the whole evidence base was 0.51 years. - Suicidal ideation and behaviors were not significantly different — over that same short window. One trial in adolescents gets quoted everywhere. It is a good trial and [this site has its own page on it](https://thisglp.com/research/are-glp1-drugs-safe-for-teens). This is what the rest of the evidence looks like when you pool all of it. ## What was pooled Eighteen randomized controlled trials — eleven in obesity, six in type 2 diabetes, one in prediabetes — covering 1,402 participants, of whom 838 received a GLP-1 and 564 placebo. [\[1\]](https://thisglp.com/research/glp1-in-children-all-eighteen-trials#ref-1) Mean age was 13.7, with a range from six to seventeen. Fifty-nine percent were girls. The pooled results: HbA1c fell 0.44 percentage points, 95% CI −0.68 to −0.21. Fasting glucose fell 9.92 mg/dL, 95% CI −16.20 to −3.64. Body weight fell 3.02 kg, 95% CI −4.98 to −1.06. BMI fell 1.45 points, 95% CI −2.40 to −0.49, with BMI standard deviation score down 0.20 and BMI percentile down 7.24. Systolic blood pressure fell 2.73 mm Hg, 95% CI −4.04 to −1.43. Gastrointestinal adverse events rose. This is not a rebuttal of the big trial Three kilograms sounds small next to a sixteen percent BMI reduction, and the two numbers are not in conflict. This pool mixes several different drugs at several different doses, across obesity, prediabetes and type 2 diabetes, with a median duration of about six months. The famous trial is one drug at its highest dose in one population over sixty-eight weeks. Pooling heterogeneous trials answers a different question than running a big clean one — which is [the same lesson comparators teach](https://thisglp.com/research/do-glp1-drugs-cause-gout) in a different key. ## Half a year The number that should stop you is the duration. Median treatment across the entire randomized evidence base in children was 0.51 years, with an interquartile range of 0.25 to 1.00. A thirteen-year-old starting one of these drugs is not making a six-month decision. Obesity in adolescence is a chronic condition and the drugs work while taken. So the relevant exposure is years, possibly decades, and there is essentially no randomized evidence at that horizon in this age group. Not bad evidence. Absent evidence. ## The safety signal people ask about Suicidal ideation and behaviors were not significantly different between drug and placebo in this pool. That is genuinely reassuring and it is bounded by the same half-year median, in trials that were not designed or powered to detect it. The adult version of the question has [its own longer story](https://thisglp.com/research/glp1-and-suicidal-ideation). Gastrointestinal effects did rise, which the authors flag as warranting attention in long-term management. In a population that has to keep eating enough to finish growing, that is a more consequential side effect than it is in adults. ## Why this page exists on a site that cannot sell to them Nothing on this roster ships to anybody under eighteen, and no seller here offers a pediatric service. This page is not a buying guide. It is here because the adolescent evidence base is the clearest available example of something this market does constantly: one strong trial becomes the whole story, and the thinness behind it stops being visible. Grown-up buyers meet the same pattern in [much weaker form](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) all the time. Parents being asked to decide deserve the full picture, and [nobody in this market is in the business of providing it](https://thisglp.com/tools/what-sellers-publish). ## Frequently asked Why are the pooled numbers smaller than the famous trial's? Because the pool mixes several drugs at several doses across obesity, prediabetes and type 2 diabetes, with a median duration near six months. The large trial used one drug at its top dose for sixty-eight weeks. They are different questions, not contradictory answers. How long has this been studied in children? Not long. Median treatment duration across all eighteen randomized trials was 0.51 years, interquartile range 0.25 to 1.00. What about suicidal thoughts? Not significantly different from placebo in this pool. That result is bounded by the same short follow-up and by trials that were not designed to detect it. Can a teenager get these drugs from a telehealth seller? Not from anyone on this roster. No seller here ships to minors or offers a pediatric service. ## Sources 1. \[1\] Kotecha P, et al. (2025). Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis JAMA Pediatrics. [PMID 40952752](https://pubmed.ncbi.nlm.nih.gov/40952752/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Drugs in Pregnancy: What the Evidence Shows, and What It Cannot | This GLP Pooled across 40,000+ exposed pregnancies, congenital malformations were not significantly raised (OR 1.11). Continuing into the first trimester gave a nonlive birth ratio of 1.09. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows Updated: 2026-10-26 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # GLP-1 Drugs in Pregnancy: What the Evidence Shows, and What It Cannot Across 40,000 exposed pregnancies, malformations were not significantly raised. Both sets of authors call their estimates imprecise, and no GLP-1 drug is approved in pregnancy. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Every main estimate crosses no-difference · 1.0 · any malformation · major, 1st trimester · major, continuing · nonlive birth · Wide intervals are not the same as reassurance. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - No GLP-1 drug is approved for use in pregnancy, and nothing here is a reason to take one. - Pooled across seven cohorts and more than 40,000 exposed pregnancies, congenital malformations were not significantly raised (OR 1.11, 95% CI 0.82 to 1.51). - A separate study of continuing the drug into the first trimester found nonlive birth at 29.7% against 27.1% (adjusted risk ratio 1.09). - Both sets of authors call their estimates imprecise. Wide intervals that cross one are not evidence of safety. Start with what this is not. These drugs are not approved in pregnancy, and none of the evidence below is a reason to take one while pregnant or trying to conceive. Every study here describes pregnancies that were already exposed, usually before anyone knew about them. The size of that group is set by the contraception question in [what tirzepatide does to oral contraception](https://thisglp.com/research/tirzepatide-and-oral-contraception). Exposure during pregnancy is also distinct from [GLP-1 use before pregnancy and later preeclampsia risk](https://thisglp.com/research/does-a-glp1-before-pregnancy-raise-preeclampsia-risk); timing changes the question being studied. ## What the pooled cohorts found A systematic review and meta-analysis covered seven cohort studies and more than 40,000 exposed pregnancies [\[1\]](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows#ref-1). Exposure at any point was not associated with congenital malformations overall, at an odds ratio of 1.11 with an interval from 0.82 to 1.51. First-trimester exposure and major malformations came in at 1.39, with an interval from 0.73 to 2.65. Stillbirth, spontaneous abortion, small for gestational age and preterm birth all showed no significant increase. One outcome cleared significance. Urinary malformations came in at 1.24 with an interval from 1.05 to 1.47 — and that estimate rests exclusively on unadjusted data. The authors read it as likely residual confounding rather than a real effect, which is a stronger caveat than most papers attach to their own positive finding. ## What two reviews add A 2026 systematic review read 36 human studies without pooling them [\[3\]](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows#ref-3). It covered exposure before conception, during pregnancy and after birth. Across large cohorts, early exposure was not consistently tied to major malformations in adjusted analyses. The same held for fetal growth restriction, stillbirth and newborn death. Maternal outcomes were mixed from study to study. Those included gestational diabetes, hypertensive disorders of pregnancy and preterm birth. The authors add that data on continuing the drug through a whole pregnancy remain limited. A 2025 clinical review set out the counseling position [\[4\]](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows#ref-4). In small animals, exposure in pregnancy was linked to decreased fetal growth, skeletal anomalies and embryonic death. Human case reports and cohorts had not shown a pattern of congenital anomalies. The authors found too little evidence to predict harm, or its absence. They recommend contraception for everyone taking these drugs. ## The question of continuing versus stopping A target trial emulation asked something narrower and more practical: among pregnancies already exposed, what happens if the prescription continues into the first trimester [\[2\]](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows#ref-2). It used US insurance claims from 2011 to 2024 and covered 3,572 pregnancies, 41.1% of them in women with type 2 diabetes. Continuing a GLP-1 prescription into the first trimester, against not continuing. | Outcome | Continuing vs not | 95% CI | | --- | --- | --- | | Nonlive birth | 29.7% vs 27.1% (aRR 1.09) | 0.98 to 1.23 | | Major congenital malformation | 1.21 | 0.83 to 1.82 | | Small for gestational age | 1.29 | 0.82 to 2.06 | | Large for gestational age | 1.08 | 0.84 to 1.40 | Continuing a GLP-1 prescription into the first trimester, against not continuing. Target trial emulation, 3,572 pregnancies The authors' own words are the finding They conclude that risks were not definitively higher with continuation — and then say the estimates for malformation and small-for-gestational-age were imprecise, and compatible with both no increased risk and clinically relevant differences in risk. That is a study telling you it cannot answer the question, which is different from a study telling you the answer is no. This site keeps that distinction in [the review that found no outcome data at all](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths). ## Why confounding is especially hard here People taking these drugs into a pregnancy have higher baseline BMI, more diabetes and more cardiometabolic disease than the general obstetric population. Every one of those independently affects pregnancy outcomes. The target trial emulation names its own version of the problem: potential residual confounding by prior glycemic control. Separating the drug from the reason it was prescribed is the same difficulty this site set out in [what happens when the control group never started treatment](https://thisglp.com/research/do-glp1-drugs-cause-depression). ## What a reader can actually take from this If a pregnancy was exposed before it was known about, the pooled evidence so far does not show an increase in the outcomes that question usually concerns. That is worth knowing and it is genuinely the most common situation. It is a different statement from the drug being safe in pregnancy, which nobody has established and no randomized trial is likely to test. The same "not shown" reading applies in [the Alzheimer's evidence](https://thisglp.com/research/do-glp1-drugs-help-alzheimers). The contraception interaction that puts people in this position is covered in [what tirzepatide does to oral contraception](https://thisglp.com/research/tirzepatide-and-oral-contraception). ## Frequently asked Is it safe to take a GLP-1 drug while pregnant? That is not established. No GLP-1 drug is approved in pregnancy, the pooled certainty of evidence is graded low, and both sets of authors describe their estimates as imprecise. What if I was already taking one when I found out? Across seven cohorts and more than 40,000 exposed pregnancies, congenital malformations were not significantly raised (OR 1.11, 95% CI 0.82 to 1.51), and neither were stillbirth, spontaneous abortion, small for gestational age or preterm birth. Does continuing into the first trimester change anything? In a target trial emulation of 3,572 pregnancies, nonlive birth was 29.7% with continuation against 27.1% without (adjusted risk ratio 1.09). The authors call the malformation and growth estimates imprecise. Should I use contraception while taking a GLP-1? A 2025 clinical review recommends it for everyone taking these drugs, because there is not enough evidence to predict harm, or its absence, after exposure around conception. What about the urinary malformation finding? It reached significance at OR 1.24 but rests entirely on unadjusted estimates, and the authors attribute it to likely residual confounding. ## Sources 1. \[1\] Uysal N, Horoz E, Gungor M, Timarci I, Sozmen MK, Karadas B (2026). Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis Scientific Reports. [PMID 42420519](https://pubmed.ncbi.nlm.nih.gov/42420519/) 2. \[2\] Brown JP, Huybrechts KF, Straub L, Patorno E, Seely EW, Bateman BT (2026). Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information Annals of Internal Medicine. [PMID 42258827](https://pubmed.ncbi.nlm.nih.gov/42258827/) 3. \[3\] Ozbek L, et al. (2026). Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes Diabetes, Obesity and Metabolism. [PMID 41885132](https://pubmed.ncbi.nlm.nih.gov/41885132/) 4. \[4\] Drummond RF, et al. (2025). Glucagon-like peptide-1 receptor agonist use in pregnancy: a review American Journal of Obstetrics and Gynecology. [PMID 39181497](https://pubmed.ncbi.nlm.nih.gov/39181497/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Liver Cancer Risk on GLP-1 Drugs vs Other Diabetes Treatments | This GLP A target trial emulation found five-year liver cancer risk 0.37 to 0.52 percentage points lower among GLP-1 initiators than four comparator treatments. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-liver-cancer-absolute-risk Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Liver Cancer Risk on GLP-1 Drugs vs Other Diabetes Treatments GLP-1 starters had less liver cancer than users of four other diabetes drugs. Every difference lands under 0.6 percentage points, because the cancer is rare. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Five-year liver cancer risk, percentage points lower · vs insulin · −0.52% · vs sulfonylureas · −0.39% · vs metformin · −0.37% · vs DPP-4 inhibitors · −0.37% · Four comparators, one answer, all under 0.6 points. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Adults with type 2 diabetes starting a GLP-1 drug, compared against four other glucose-lowering treatments. - Five-year liver cancer risk was lower by 0.37 percentage points against metformin, 95% CI 0.08 to 0.59. - Against insulin, 0.52 points; against sulfonylureas, 0.39; against DPP-4 inhibitors, 0.37. - Every comparison lands under 0.6 percentage points, because liver cancer is rare. - The mortality analysis was limited by small numbers and the authors call it inconclusive. This study does something most do not: it publishes its results as absolute risk differences rather than as ratios. That decision is why the numbers look small, and it is why they are useful — a hazard ratio on a rare cancer tells you almost nothing about how many people are involved, which is [the gap a relative figure always leaves](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## What was compared Adults with type 2 diabetes starting a GLP-1 drug in one academic center’s clinical research network between 2010 and 2025, set against new users of metformin, insulin, SGLT2 inhibitors, DPP-4 inhibitors and sulfonylureas. [\[1\]](https://thisglp.com/research/glp1-liver-cancer-absolute-risk#ref-1) The primary outcome was a first diagnosis of hepatocellular carcinoma, the commonest form of liver cancer, over five years. ## The numbers Against insulin, five-year liver cancer risk was 0.52 percentage points lower, 95% CI 0.35 to 0.74. Against sulfonylureas, 0.39 points, 95% CI 0.13 to 0.64. Against metformin, 0.37 points, 95% CI 0.08 to 0.59. Against DPP-4 inhibitors, 0.37 points, 95% CI 0.06 to 0.70. Per-protocol analyses, which account for whether people kept taking the drug, were stronger — which is expected, and is also why [who keeps taking it](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1) is never a neutral variable. Results held across subgroups, sensitivity analyses and individual agents. What 0.37 percentage points is worth knowing as It means roughly one fewer liver cancer for every few hundred people treated over five years. That is a small number and it is a real one, and the two are not in tension: a disease that affects a small fraction of people cannot be prevented in a large fraction of them. Reported as a relative reduction the same finding would sound far more dramatic and would tell a reader much less. ## Why four comparators matter The estimates against metformin, insulin, DPP-4 inhibitors and sulfonylureas sit inside a narrow band, between 0.37 and 0.52 points. That consistency is the strongest thing here. Confounding by who gets prescribed what tends to produce a large gap against a weak comparator and a small one against a strong one — which is exactly [the pattern that made another study distrust its own mortality result](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own). Four comparators agreeing is a different shape. ## What is not established Survival. A secondary analysis looked at death after a liver cancer diagnosis and the authors describe it as limited by small sample sizes, inconclusive and exploratory, suggesting a potential benefit without demonstrating one. Nothing in this is a reason to take a GLP-1 drug for cancer prevention, and nobody sells them for that. It sits alongside [what these drugs do to a liver](https://thisglp.com/research/semaglutide-and-liver-disease) more generally — where the fatty liver findings are stronger and the outcomes further away. ## Frequently asked Do GLP-1 drugs prevent liver cancer? This study found five-year risk lower by 0.37 to 0.52 percentage points against four comparator drugs. It is an observational comparison, and nobody prescribes these drugs for cancer prevention. Why are the numbers so small? Because liver cancer is rare. A condition affecting a small fraction of people cannot be prevented in a large fraction of them, whatever the relative reduction looks like. Why does using four comparators help? Confounding by who receives which prescription usually produces a big gap against a weak comparator and a small one against a strong one. Four estimates landing in a narrow band is a different pattern. Did it improve survival? Unknown. The mortality analysis was limited by small numbers, and the authors describe it as inconclusive and exploratory. ## Sources 1. \[1\] Hernández-Pérez JG, et al. (2026). Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation Hepatology International. [PMID 42584814](https://pubmed.ncbi.nlm.nih.gov/42584814/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Drugs in MASH: Deaths, Ascites and a Small Liver Cancer Signal | This GLP A matched cohort of 168,733 adults with MASH found 2.2 fewer deaths per hundred on a GLP-1, and a liver-cancer signal too small to mean anything. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-liver-cancer-signal-dismissed Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs in MASH: Deaths, Ascites and a Small Liver Cancer Signal In 168,733 matched pairs of adults with MASH, GLP-1 users had 2.2 fewer deaths per hundred. A liver-cancer signal cleared significance with a risk difference of zero, and the authors set it aside. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Difference in percentage points, GLP-1 exposed against matched · ascites · -1.3 points · all-cause death · -2.2 points · liver cancer · 0.0 — and statistically significant · 168,733 matched patients per group. Follow-up window not stated. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A claims-database study matched 168,733 adults with MASH taking a GLP-1 against the same number who were not. - Ascites was lower by 1.3 percentage points and death by 2.2 points, both at p < 0.001. - Liver cancer was higher, at p = 0.025, with a risk difference of 0.000. - The authors set the cancer signal aside because its absolute size was negligible. That reasoning is right. - The same reasoning, run on the benefits, makes them real and small rather than transformative. This is a study with an unusual virtue and one blind spot, and they are the same feature seen from two sides. ## What it found Adults with metabolic dysfunction-associated steatohepatitis were pulled from a large real-world health database and split by whether they had a documented GLP-1 prescription. [\[1\]](https://thisglp.com/research/glp1-liver-cancer-signal-dismissed#ref-1) Propensity matching on demographics, coexisting conditions and concomitant drugs left 168,733 patients on each side, out of 168,740 exposed. Three outcomes were reported, all as absolute risk differences. Ascites was lower among GLP-1 users by 0.013, a 1.3-point difference, 95% CI 0.014 to 0.012 lower, p < 0.001. All-cause death was lower by 0.022, or 2.2 points, 95% CI 0.023 to 0.021 lower, p < 0.001. Liver cancer went the other way: higher among users, p = 0.025, risk difference 0.000, 95% CI 0.000 to 0.001. ## The good part Reporting all three on one scale is better practice than most papers manage. A relative figure would have made the cancer result sound alarming and the mortality result sound heroic, and both would have been the same numbers dressed differently — which is [how a statistical result usually gets oversold](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). The authors then looked at the cancer signal, saw a difference of zero at three decimal places, and declined to treat a p-value of 0.025 as a clinical finding. In a matched sample this size, tiny differences clear significance easily. That judgment is correct. Run it in the other direction The same standard applied to the benefits gives 1.3 fewer cases of ascites and 2.2 fewer deaths per hundred people. Those are real. They are also modest, and the paper’s closing description of GLP-1s as beneficial and hepatically safe carries a weight the risk differences do not. Nothing in the arithmetic is inconsistent; the language around it is. ## Nobody said over how long The indexed abstract gives no follow-up duration. A risk difference without a window is not a rate. Two point two points of mortality across one year and the same figure across eight years describe very different drugs, and a reader cannot tell which this is. ## Prescribed is not randomized Everyone here chose, or was offered, their treatment. Being prescribed a GLP-1 for MASH and filling it repeatedly selects for people healthy enough to be considered, insured enough to afford it, and engaged enough to keep going. Matching on codes cannot see any of that. It is the standing weakness of every database comparison on this site, and it pushes in the direction that flatters the treated group — the same shape as [a conclusion stated more confidently than its design allows](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease). ## What to do with it Read it as reassurance about liver safety rather than as a reason to buy. The liver-cancer result is the kind of signal that would matter if it were larger, and it is not. The survival result points the right way and is small. If liver disease is the reason someone is considering one of these drugs, the relevant page is [the trial evidence in that population](https://thisglp.com/research/semaglutide-and-liver-disease), not a claims cohort — and [which events a study counts](https://thisglp.com/research/which-glp1-has-the-worst-side-effects) decides most of what its numbers can mean. ## Frequently asked Do GLP-1 drugs cause liver cancer? This study found more cases among users at p = 0.025, but the absolute difference was 0.000 — nothing a person could act on. The authors treated it as clinically irrelevant, which is the right reading of a difference that size. How much did it reduce deaths? By 2.2 percentage points against matched patients, at p < 0.001. The abstract does not say over what period, so the figure has no rate attached to it. Is this as good as a trial? No. Treatment was not randomized, and being prescribed a GLP-1 selects for people already healthier and better insured. Matching on database codes cannot correct for that. What was the population? Adults with metabolic dysfunction-associated steatohepatitis in a multinational health database, 168,733 matched on each side of the comparison. ## Sources 1. \[1\] Khan SA, et al. (2026). Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study Medicine (Baltimore). [PMID 42736811](https://pubmed.ncbi.nlm.nih.gov/42736811/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Drugs and Mortality in Type 2 Diabetes With a BMI Under 27 | This GLP In adults with type 2 diabetes and BMI under 27, GLP-1 drugs showed mortality HR 0.61 against DPP-4 inhibitors and 0.89 against SGLT2 inhibitors. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-mortality-authors-doubt-their-own Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs and Mortality in Type 2 Diabetes With a BMI Under 27 A study found 39% lower all-cause mortality on GLP-1 drugs, then said in its conclusion that the number is probably confounding rather than benefit. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Hazard ratios, BMI under 27 with type 2 diabetes · vs DPP-4i · death, any cause · 0.61 · vs SGLT2i · death, any cause · 0.89 · vs DPP-4i · coded heart failure · 0.71 · vs SGLT2i · coded heart failure · 0.56 · The mortality benefit disappears against the stronger comparator. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Adults with type 2 diabetes and a body mass index under 27 — the group the weight trials exclude. - Against DPP-4 inhibitors, GLP-1 drugs were linked to 39% lower all-cause mortality, hazard ratio 0.61, 95% CI 0.52 to 0.71. - Against SGLT2 inhibitors, mortality did not differ: 0.89, 95% CI 0.76 to 1.05. - Coded heart failure was lower across all three comparisons — the authors' own most consistent finding. - The authors say the mortality result likely reflects residual confounding rather than a benefit of that size. A 39% reduction in death from any cause is the kind of number that ends up in a headline, and the people who calculated it wrote a sentence asking you not to treat it that way. It is worth understanding why they did, because the reasoning is visible inside their own results — the same kind of internal check as [a comparison run where a difference is expected](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). ## Who was studied Adults with type 2 diabetes and a body mass index below 27, starting a GLP-1 drug, compared separately against new users of DPP-4 inhibitors, SGLT2 inhibitors and usual care. [\[1\]](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own#ref-1) Matching left 7,389, 8,969 and 8,610 GLP-1 users in the three comparisons, followed up to 24 months. That population is the reason the study exists. The cardiovascular evidence for these drugs comes almost entirely from trials in people with overweight or obesity, and a person with diabetes and a body mass index of 25 has been largely absent from it — the same gap between a trial population and a treated one that [eligibility figures](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke) keep exposing. ## What the three comparisons gave Against DPP-4 inhibitors: all-cause mortality 0.61, 95% CI 0.52 to 0.71. Major adverse cardiovascular events 0.83, 95% CI 0.71 to 0.98. Coded heart failure 0.71, 95% CI 0.60 to 0.85. Against SGLT2 inhibitors: cardiovascular events 0.81, 95% CI 0.69 to 0.95, and coded heart failure 0.56, 95% CI 0.47 to 0.65 — but all-cause mortality 0.89, 95% CI 0.76 to 1.05, which crosses one. Why that pattern is the tell SGLT2 inhibitors are an active comparator with a mortality benefit of their own, so a drug effect would not be expected to disappear entirely against them — it might shrink. A confounding effect behaves differently: if the people started on a GLP-1 are systematically healthier or better cared for than the people started on a DPP-4 inhibitor or left on usual care, the gap will be largest against the weakest comparator and smallest against the one prescribed to a similar population. That is what happened, and it is why the authors describe a 39% mortality reduction as likely residual confounding rather than a benefit of that magnitude. ## What they do stand behind Coded heart failure, which was lower across all three comparisons. That consistency is the thing a confounding explanation has more trouble with, and it is what the authors present as their most reliable result. It is still a coded event — a diagnosis appearing in a record rather than an adjudicated one — so it carries the same caveat as [any outcome assembled from what somebody wrote down](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs). ## And a harm in the same study Gastroparesis was more frequent on GLP-1 drugs than on DPP-4 inhibitors. Slowed stomach emptying is the mechanism these drugs work partly through, so a rise in its clinical extreme is coherent rather than surprising, and it belongs in the same summary as the benefits — alongside [what is already known about that](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## What a reader takes from it Not a result about weight-loss buyers. Everybody here had type 2 diabetes and a body mass index under 27, which is nobody this site’s sellers are writing prescriptions for. What travels is the method: when an observational result is huge against a weak comparator and gone against a strong one, the comparator is doing the work. Authors who say so about their own headline are rarer than the finding. ## Frequently asked Do GLP-1 drugs reduce death in people who are not overweight? This study found a hazard ratio of 0.61 against DPP-4 inhibitors, and the authors state that result likely reflects residual confounding rather than a benefit of that size. Why does the SGLT2 comparison matter? Because mortality did not differ against it, 0.89, 95% CI 0.76 to 1.05. A real drug effect would be expected to shrink rather than disappear; confounding produces exactly this pattern. What result do the authors stand behind? Lower coded heart failure, which was consistent across all three comparisons. Consistency is harder for a confounding explanation to account for. Was anything worse? Gastroparesis was more frequent on GLP-1 drugs than on DPP-4 inhibitors in the same analysis. ## Sources 1. \[1\] Chen SC, et al. (2026). Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial Emulation Diabetes, Obesity and Metabolism. [PMID 42642357](https://pubmed.ncbi.nlm.nih.gov/42642357/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Mortality on GLP-1 Drugs in Hidradenitis Suppurativa: A Record Study | This GLP A TriNetX cohort reported all-cause mortality at HR 0.24 in GLP-1 users with hidradenitis suppurativa. The size of the effect is the reason to doubt it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-mortality-in-hidradenitis Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Mortality on GLP-1 Drugs in Hidradenitis Suppurativa: A Record Study A matched-record study found three quarters of deaths missing in GLP-1 users over two years. Randomized trials move mortality by about a fifth. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 One matched cohort, eight outcomes, two years · no difference · all-cause death · 0.24 · suicidal ideation · 0.38 · substance use disorder · 0.58 · major cardiac events · 0.61 · depression · 0.78 · hyperlipidemia · 1.25 · nausea and vomiting · 1.31 · fatty liver disease · 1.37 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched-record cohort of adults with hidradenitis suppurativa plus diabetes or obesity, two years of follow-up. - All-cause mortality: hazard ratio 0.24, 95% CI 0.145 to 0.395. - That is three quarters of deaths not happening. Randomized trials of these drugs move mortality by about a fifth. - Exposure required at least a year of therapy. Nobody who died in that year could be exposed. - The same table reports hyperlipidemia at 1.25, fatty liver disease at 1.37 and nausea at 1.31. Some results are too good to believe. This is one. The finding is not wrong because it is large. It is doubtful because of how large it is, and where it came from. ## What the study did Adults with hidradenitis suppurativa and either type 2 diabetes or obesity were pulled from a US record network. [\[1\]](https://thisglp.com/research/glp1-mortality-in-hidradenitis#ref-1) Those on a GLP-1 drug or tirzepatide were matched one-to-one against those on other metabolic medicines. Outcomes were followed two years. The skin disease defines who is in the study. It is not an outcome. Nothing here measured whether anyone’s hidradenitis got better. ## The number that stops you All-cause mortality came out at 0.24, interval 0.145 to 0.395. Three quarters of deaths, gone. Compare that to a randomized trial. SELECT moved all-cause death by roughly a fifth over four years, and that is the largest properly randomized read we have — the same body of evidence that a [Cochrane review of eighteen trials](https://thisglp.com/research/semaglutide-cochrane-review) graded. A four-fold larger effect, in two years, in unrandomized records, is not a discovery. It is what we should expect when the people who get a drug differ from the people who do not. Who can be counted as exposed Exposure here required at least one year of therapy. Somebody who died in month three never completes that year, so they cannot join the treated group. They can only appear among the controls. That alone can manufacture a mortality benefit out of nothing. Whether it did depends on when the follow-up clock starts, and the abstract does not say. It is the first question to ask of the full paper, and it is not a small one. ## The rest of the table Major cardiac events came out at 0.61. Stroke and heart failure both fell. Depression came out at 0.78, substance use disorder at 0.58, suicidal ideation at 0.38. These cannot be separated from the mortality figure. They are the same people, matched the same way, over the same two years. If the design can produce 0.24 for death, it can produce 0.38 for suicidal ideation, and nobody gets to keep the reassuring rows and discard the implausible one — the problem [every large matched-record study](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer) carries. Three things went up: hyperlipidemia at 1.25, fatty liver disease at 1.37, nausea and vomiting at 1.31. Those come with the same caveat and deserve the same weight. ## Why healthy people get prescriptions Doctors do not start an expensive injectable in somebody who is dying. They start it in people well enough to benefit, who show up, and who can pay. Everyone in the comparison group was on some other metabolic drug, which helps. It does not fix it. Matching handles what got recorded, and how sick somebody looks in clinic is mostly not recorded — the same gap behind [who ends up meeting an indication](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease). ## What to do with it Read it as a hypothesis about a population nobody studies much. That is a real contribution. Do not read 0.24 as a mortality benefit. A ratio needs its absolute counts before it means anything, and [the counts are usually smaller than the ratio sounds](https://thisglp.com/research/glp1-liver-cancer-absolute-risk). An effect this size showing up only outside a trial is the oldest warning sign in observational medicine, and [the reverse error](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) is just as common. ## Frequently asked Do GLP-1 drugs cut the risk of death by three quarters? No trial has shown anything like that. This is an unrandomized record study, and an effect four times larger than the randomized evidence is a reason to doubt the design rather than to believe the drug. What is wrong with requiring a year of treatment? Anybody who dies before completing it cannot be counted as exposed, so early deaths fall to the control group. That can create a survival benefit on its own, depending on when follow-up starts. Did anything get worse in this study? Yes. Hyperlipidemia came out at 1.25, fatty liver disease at 1.37 and nausea with vomiting at 1.31, in the same matched data. Did the study measure hidradenitis suppurativa itself? No. The skin disease defines who was included. No outcome in the analysis describes whether it improved. ## Sources 1. \[1\] Brouer IC, et al. (2026). Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study Frontiers in Medicine. [PMID 42741157](https://pubmed.ncbi.nlm.nih.gov/42741157/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # High-Dose vs Standard-Dose GLP-1 Before Neck Fusion (ACDF) Surgery | This GLP A matched study of 921 patients per group found high-dose GLP-1 therapy before neck fusion surgery produced no more complications, readmissions or failed fusions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-neck-fusion-high-dose Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # High-Dose vs Standard-Dose GLP-1 Before Neck Fusion (ACDF) Surgery Neck fusion patients on a high-dose GLP-1 did no worse than those on a standard dose, across nine outcomes and two years. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 High dose above, standard dose below — no p-value under 0.2 · readmitted · 11.4 / 10.0% · ED visit · 11.4 / 12.3% · complication · 9.6 / 8.9% · failed fusion · 4.0 / 3.8% · 921 matched patients per group, neck fusion surgery. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Patients having neck fusion surgery were split by whether their GLP-1 prescription was a high or standard dose. - After matching, 921 remained in each group, drawn from 112,065 screened across three comparisons. - Nothing differed: readmission, emergency visits, complications, swallowing problems, opioid use, failed fusion. - Both dose groups had less failed fusion than matched non-users, with no extra gain from the higher dose. - No funding was received and the authors declare no study-specific conflicts. The question this study asks is one a buyer has to answer every time a titration schedule moves up a rung, and the answer here is that a stronger prescription did not change anything the surgeons measured — which is not the same as saying [a higher dose adds nothing](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it), since the outcomes counted here are surgical rather than metabolic. ## What was compared Anterior cervical discectomy and fusion is the operation that removes a damaged disc in the neck and fuses the two vertebrae together, and it has a well-known failure mode: the bones do not knit, which is called pseudarthrosis and often means a second operation. Adults who had one were pulled from a research network and sorted by the strength of the GLP-1 prescription recorded for them between one year and one week before surgery. [\[1\]](https://thisglp.com/research/glp1-neck-fusion-high-dose#ref-1) Three pairwise comparisons were run, covering 112,065 patients in total. The one the paper treats as primary sets high dose against standard dose, and after matching it holds 921 people on each side. ## What it found Readmission within ninety days ran 11.4% against 10.0%, p = 0.327. Emergency visits 11.4% against 12.3%, p = 0.564. Composite medical complications 9.6% against 8.9%, p = 0.629. Difficulty swallowing, a characteristic complication of this operation, ran 10.6% against 11.2%, p = 0.709. Opioid exposure was 85.2% against 83.1%, p = 0.202, and out at 180 to 720 days failed fusion ran 4.0% against 3.8%, p = 0.822, with second-stage posterior fusion at 3.0% against 3.7%, p = 0.398. There is no result in that list that a reader could mistake for a signal. A null on 921 people A clean set of non-findings across nine outcomes is genuinely reassuring about large effects and says very little about small ones, because 921 patients per arm can only rule out differences of a certain size — and none of these p-values comes close enough to the threshold to look like a study that nearly found something. Read it as an absence of any obvious dose penalty, which is what the authors claim, rather than as [a demonstration that no difference exists](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## The comparison against non-users Both dose groups had lower failed-fusion rates than matched patients taking no GLP-1 at all, and the higher dose added nothing further on top of that. That second comparison is the weaker of the two, because people on a GLP-1 and people on nothing differ in ways a database records imperfectly, and this section has already watched [three significant differences vanish](https://thisglp.com/research/glp1-shoulder-surgery-adjustment) when that gap was closed properly. The dose comparison does not have that problem, since everyone in it was taking the same drug. ## Why the dose field matters here This study could sort patients by dose because a prescription record carries a strength. The dose is a field somebody wrote down, and the analysis exists because of it. Most sellers publish a monthly figure and say nothing about what happens to it as the dose climbs, which is the gap [the dose-ladder tool](https://thisglp.com/tools/published-dose-ladders) was built to count. Nothing in this paper is about pricing. It is a reminder that the distinction between a starting dose and a maintenance dose is real enough for researchers to build a study on, and vague enough on a checkout page to be unanswerable. ## Frequently asked Is a higher GLP-1 dose riskier before surgery? Not in this study. Across readmission, emergency visits, complications, swallowing problems, opioid use and failed fusion, no outcome differed between high-dose and standard-dose patients. How many people were compared? 921 in each arm of the dose comparison, matched one to one, out of 112,065 patients screened across three comparisons. Did being on a GLP-1 at all help the fusion? Both dose groups had lower failed-fusion rates than matched non-users, but that comparison is between people on the drug and people not on it, which database matching handles poorly. Who paid for the study? Nobody. The authors report no funding and no study-specific conflicts of interest. ## Sources 1. \[1\] Stirpe C, et al. (2026). Impact of GLP-1 Dose Intensity on Perioperative and Long-Term Fusion Outcomes Following ACDF The Spine Journal. [PMID 42705550](https://pubmed.ncbi.nlm.nih.gov/42705550/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Insulin Resistance in PCOS on GLP-1 Drugs: A Four-Trial Meta-Analysis | This GLP A meta-analysis of four randomized trials in PCOS found significant falls in waist, BMI and testosterone, and no significant change in HOMA-IR. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-pcos-insulin-resistance Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Insulin Resistance in PCOS on GLP-1 Drugs: A Four-Trial Meta-Analysis Pooled across four small trials in PCOS, waist, BMI and testosterone fell. Insulin resistance, the reason these drugs are supposed to help, did not. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Pooled across four trials, 176 participants · waist circumference · −5.16 cm · BMI · −2.42 · triglycerides · −0.20 · total testosterone · −1.33 · total cholesterol · no difference · HOMA-IR · no difference **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Four randomized trials, 176 participants in total, pooled for women with PCOS and obesity. - Waist circumference fell 5.16 cm (95% CI −6.11 to −4.21) and BMI 2.42 points (−3.10 to −1.74). - Total testosterone fell by 1.33 (95% CI −2.55 to −0.12, p=0.03) and triglycerides by 0.20. - Total cholesterol did not move significantly, and neither did HOMA-IR (−0.30, 95% CI −0.92 to 0.32, p=0.35). - HOMA-IR is the marker closest to the reason these drugs are supposed to help PCOS. Polycystic ovary syndrome is tangled up with insulin resistance, and that is the usual explanation for why a drug like this should help — the same kind of mechanism story that [gets told about other hormonal conditions](https://thisglp.com/research/do-glp1-drugs-work-in-menopause). The pooled trial evidence supports part of it and not the part everyone names. ## What exists A meta-analysis searched four databases for randomized trials of a GLP-1 against placebo in women diagnosed with PCOS by the Rotterdam criteria, and found four. [\[1\]](https://thisglp.com/research/glp1-pcos-insulin-resistance#ref-1) Together they contributed 176 participants — not per arm, in total. Liraglutide accounted for 103 of them, 58 percent, and semaglutide for 23, or 13 percent. That composition matters before any result. Most of what is known here comes from a drug that is not what most people are prescribed now, in a pooled sample smaller than a single modest trial. ## What moved Waist circumference fell by 5.16 cm, 95% CI −6.11 to −4.21, p<0.00001. BMI fell 2.42 points, 95% CI −3.10 to −1.74. Serum triglycerides fell 0.20, 95% CI −0.30 to −0.11. Total testosterone fell by 1.33, 95% CI −2.55 to −0.12, p=0.03 — a real result whose interval comes close to zero. Adverse event information was available for 112 patients, of whom 49 reported light side effects such as nausea and abdominal pain. ## What did not Total cholesterol showed no significant difference, at −0.04, 95% CI −0.10 to 0.01, p=0.15. Neither did HOMA-IR, at −0.30, 95% CI −0.92 to 0.32, p=0.35. The null is on the mechanism HOMA-IR estimates insulin resistance, and insulin resistance is the reason usually given for why these drugs ought to treat PCOS rather than merely reduce weight in women who have it. It did not move significantly here. Meanwhile waist, BMI and triglycerides — the things a GLP-1 improves in almost anybody — did. On this evidence the effect looks general rather than PCOS-specific, and the honest summary says so. ## How much weight to give a null this small Not much, in either direction. With 176 people across four trials, a real moderate effect on HOMA-IR could easily go undetected. The interval runs from −0.92 to 0.32, which is wide enough to contain a meaningful improvement and a slight worsening at once. So the correct reading is not that these drugs fail to address insulin resistance in PCOS. It is that nobody has shown they do, on a sample this size, and that the results being quoted as evidence for PCOS treatment are mostly results about weight. That distinction is the same one that separates [a famous trial from a thin literature](https://thisglp.com/research/glp1-in-children-all-eighteen-trials) in other corners of this field. ## The testosterone question Hyperandrogenism is what many women with PCOS most want treated — the hair, the skin, the cycles. Total testosterone did fall, significantly. But the pooled estimate is a single laboratory number whose interval nearly reaches zero, drawn from four small trials, and no clinical outcome was pooled alongside it. Whether that translates into anything a person would notice is a different endpoint, and [which endpoint a study chose](https://thisglp.com/research/do-glp1-drugs-cause-gout) decides what it can tell you. ## What this means before ordering No seller on this roster offers a PCOS service or claims the indication. What is being sold is weight loss, and weight loss genuinely helps many PCOS symptoms — that is not in dispute and does not require this literature. What would be misleading is a purchase made on the belief that the drug is treating the underlying endocrinology. Four trials and 176 women do not establish that, and the marker closest to the claim is the one that did not move. PCOS care is a gynecologist or endocrinologist’s territory, and [the questions a seller leaves unanswered](https://thisglp.com/tools/questions-they-leave-open) include every one that matters here. [Allara Health](https://thisglp.com/reviews/allara-health) describes care for PCOS and insulin resistance on its [website](https://www.allarahealth.com/). That is a relevant practice scope to compare. It does not establish that a GLP-1 is the right treatment for every patient with PCOS. Ask which evaluation and ongoing care your plan includes. ## Frequently asked Do these drugs treat PCOS? They reduce weight, waist and BMI in women with PCOS, which helps many symptoms. The pooled evidence does not show a significant effect on insulin resistance, which is the mechanism usually invoked for a PCOS-specific benefit. How much evidence is there? Four randomized trials contributing 176 participants in total. Liraglutide accounts for 58% of them and semaglutide for 13%. Does testosterone come down? Total testosterone fell by 1.33 with a 95% CI of −2.55 to −0.12 and p=0.03. That is a laboratory result from four small trials, and no clinical outcome such as hair or cycle regularity was pooled alongside it. Can I buy one for PCOS here? No seller on this roster offers a PCOS service or claims the indication. What is sold is weight loss. ## Sources 1. \[1\] Austregésilo de Athayde De Hollanda Morais B, et al. (2024). The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials Journal of Diabetes and Its Complications. [PMID 39178623](https://pubmed.ncbi.nlm.nih.gov/39178623/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Prescribing to Children Aged 8 to 11: Who Gets Them | This GLP Among 3.5 million children aged 8 to 11 with obesity, 0.6% received a GLP-1 prescription, and prescribing skewed toward less socially vulnerable families. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-prescriptions-to-young-children Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Prescribing to Children Aged 8 to 11: Who Gets Them GLP-1 prescriptions to children aged 8 to 11 rose 310-fold in seven years, from a base of 0.03%. The children getting them are the least socially vulnerable. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Prescriptions per 10,000 children with obesity · age · 79.5 (11 years) · 41.5 (8 years) · sex · 75.9 (girls) · 42.8 (boys) · social vulnerability · 76.1 (low) · 49.2 (high) · With an obesity-related condition: 188.9 per 10,000. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 3,520,531 children aged 8 to 11 with obesity and no diabetes were counted from 2019 to 2026. - 0.6% of them received a GLP-1 prescription. - Prevalent prescribing rose from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase, P < .001. - Children with obesity-related conditions were prescribed at 188.9 per 10,000, far above the overall rate. - Children with less social vulnerability were prescribed more: 76.1 against 49.2 per 10,000. Nothing on this site can be bought for a child — every seller in this roster serves adults only, and a prescription for an eight-year-old comes from a pediatrician, not a subscription form. The study is here because the growth figure attached to it is going to be quoted without its base, which is how [most real-world prescribing data](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) gets used. ## The headline and the base Prescribing to this age group rose 310-fold between 2019 and 2026. [\[1\]](https://thisglp.com/research/glp1-prescriptions-to-young-children#ref-1) The starting point was 0.03% of children, so the multiplier is doing what a multiplier does to a very small number. Across the whole cohort of 3.5 million children, 0.6% ever received a prescription. That is uncommon by any reading. Two figures the abstract does not reconcile The published record states that 0.6% of the cohort received a prescription, and separately that prevalent prescribing reached 9.3% in 2026. The second pair is internally consistent, since 0.03% multiplied by 310 is 9.3%. What the indexed abstract does not supply is the denominator that lets a 2026 figure of 9.3% sit beneath a cohort-wide 0.6%. Both are printed here as published. Neither has been adjusted to agree with the other. ## Who is getting them Older children more than younger: 79.5 per 10,000 at age eleven against 41.5 at age eight. Girls more than boys: 75.9 against 42.8. The paper does not explain the second gap and neither will this page. The largest difference is clinical. Children who already had an obesity-related condition were prescribed at 188.9 per 10,000, which the authors read as clinicians reserving these drugs for the highest cardiometabolic risk. That looks like appropriate targeting, and it is the same logic as [an eligibility threshold](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) applied by judgment rather than by rule. ## The finding that runs the wrong way Children with less social vulnerability received more prescriptions: 76.1 per 10,000 against 49.2 among the most vulnerable. Childhood obesity is commoner, not rarer, in the groups getting fewer prescriptions. So access here is tracking resources rather than need, which is the ordinary pattern for an expensive drug and is worth naming when the figure appears inside a paper about prescribing trends. ## What it means for an adult reader Two things, neither of them about children. The first is that a fold-change is not a prevalence, and any number of that shape should send you looking for the base. The second is that who gets a prescription is decided by cost and coverage as much as by clinical need, which is visible in [how few eligible adults ever receive one](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke) and in [where sellers will and will not ship](https://thisglp.com/tools/coverage-by-state). ## Frequently asked How many young children are on these drugs? Few. Across 3,520,531 children aged 8 to 11 with obesity and no diabetes, 0.6% ever received a prescription between 2019 and 2026. What does a 310-fold increase mean? That prevalent prescribing went from 0.03% in 2019 to 9.3% in 2026. The multiplier is large because the starting number was very small. Who is most likely to be prescribed one? Children who already have an obesity-related condition, at 188.9 per 10,000 — well above the rate for any other group measured. Can I buy one for my child from a telehealth seller? No. Every seller covered on this site serves adults only. Prescribing at this age happens through pediatric care. ## Sources 1. \[1\] Orandi BJ, et al. (2026). Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026 Pediatrics. [PMID 42692477](https://pubmed.ncbi.nlm.nih.gov/42692477/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Price Spread Across Sellers: The Range and the Middle Half | This GLP How far apart GLP-1 monthly prices sit across every seller that publishes a figure: the lowest, the highest, the median and the middle-half band, derived when the page renders. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-price-spread-across-sellers Updated: 2026-10-28 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Price Spread Across Sellers: The Range and the Middle Half Published monthly GLP-1 prices for the same molecule run from the low double figures to the high hundreds. Most sellers sit nowhere near either end. [This GLP Editorial Team](https://thisglp.com/about)September 20264 min readUpdated September 2026 $49 · low · $149 · 25th · $190 · median · $234.50 · 75th · $525.42 · high **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 402 sellers on this roster publish a monthly figure this site can read. - They run from $49 to $525.42 — a factor of 10.7. - The middle half is much tighter: $149 to $234.50, a band $85.50 wide. - Over a year the same middle half is $1,788 against $2,814. - Figures were read most recently October 2026. The molecule does not change. The price does, by a factor of 10.7. ## What the range actually looks like 402 sellers here publish a figure. The lowest is $49. The highest is $525.42. Stated that way the market looks chaotic. It is not, quite. Most of the roster clusters. Half of it sits between $149 and $234.50, which is a band $85.50 wide. The median is $190. You can check any single seller against that band in [the price check](https://thisglp.com/tools/glp1-price-check). So the extremes are thin and the middle is crowded. That shape matters. A reader who finds two quotes far apart has probably found one outlier, not a real market spread. ## A factor of six is not a discount It is tempting to read the floor as a bargain and stop. Resist that. A low figure buys a different thing at different sellers. Some price one dose and let the rest rise. Some quote a rate that assumes a standing order. Some quote a period that is not a calendar month. Those are separate questions and [a single figure answers none of them](https://thisglp.com/research/glp1-advertised-vs-billed-corrections). The ceiling deserves the same suspicion in reverse. A high figure is not evidence of a better product. It may include a consultation, a scale, or a longer supply. It may simply be higher. What this range excludes 178 sellers on this roster publish no figure this site can read. They are not in the range above, so the true market is wider than the chart in at least one direction and nobody can say which. [The disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) counts who those sellers are. ## The number moves These quartiles are computed when the page loads. They are not stored. That is deliberate, because a published price is a perishable fact. This desk re-reads figures and [a second reading often disagrees with the first](https://thisglp.com/research/rereading-glp1-prices). Every movement shifts the band a little. 580 of the 580 rankable sellers carry a written review here. The rest are counted, not assessed. A figure in the range above is a figure somebody published, nothing more. ## How to use the band Do not shop for the floor. Shop for a figure inside the middle half that comes with the dose stated, the interval stated, and the states stated. That is a narrower search than it sounds. It is also the one where the answer holds for longer than a week. [Ro](https://thisglp.com/reviews/ro) and [Mochi Health](https://thisglp.com/reviews/mochi-health) show why care costs need their own line. [Ro’s FAQ](https://ro.co/weight-loss/) excludes medication from membership, while [Mochi’s self-pay description](https://joinmochi.com/) separates membership from medication. Neither care fee alone is a comparable all-in drug price. ## Frequently asked Why not just take the cheapest price? Because a low figure and a high figure are often not describing the same purchase. One may price a single dose, or assume a standing order, or bill on a period that is not a calendar month. The floor is only a bargain once those three things match. Is the middle half a fair price? It is the ordinary price, which is not the same claim. This site measures what sellers publish; it does not price the drug. A figure inside the band is unremarkable rather than endorsed. Do these numbers change? Yes. Every figure here is computed from the roster when the page renders, so a re-read price moves the quartiles the same day. Nothing on this page is stored. ## Sources ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # GLP-1 Drugs in Psoriasis: Mortality, Heart Events and Substance Use | This GLP A TriNetX cohort of 3,048 matched pairs found GLP-1 use in psoriasis carried a mortality hazard ratio of 0.219 and a cardiac hazard ratio of 0.561 against other obesity drugs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-psoriasis-comorbidities Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs in Psoriasis: Mortality, Heart Events and Substance Use A 3,048-pair cohort found lower mortality, fewer cardiac events and less alcohol and substance use. The mortality figure — a hazard ratio of 0.219 — is larger than any trial has produced. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Hazard ratio against other obesity and diabetes drugs · Death, any cause · 0.22 · Alcohol use · 0.35 · Substance use · 0.51 · Major cardiac event · 0.56 · 1.0 · 3,048 matched pairs, two years **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Psoriasis carries a heavier load of heart disease and metabolic illness than the skin lesions suggest, so a drug class aimed at weight and glucose has an obvious reason to be studied in it. A population cohort drawn from the US TriNetX database matched 3,048 psoriasis patients taking a GLP-1 receptor agonist against 3,048 taking other antidiabetic or antiobesity drugs, and followed both for two years [\[1\]](https://thisglp.com/research/glp1-psoriasis-comorbidities#ref-1). The comparator matters more than the result: everybody here was being treated for something, which makes this a question about which drug, not about whether to take one — the same distinction that separates a real price from a headline on the [sellers ranked here](https://thisglp.com/best). Comorbidity outcomes should be separated from [whether GLP-1 treatment improves psoriasis itself](https://thisglp.com/research/do-glp1-drugs-help-psoriasis); they do not answer the same clinical question. ## What the cohort reported All-cause mortality was lower in the GLP-1 arm, at a hazard ratio of 0.219 (95% CI 0.123 to 0.391, P < 0.001). Major adverse cardiac events came in at 0.561 (95% CI 0.442 to 0.714, P < 0.001). Two psychiatric outcomes also fell: alcohol use at 0.346 (95% CI 0.174 to 0.685, P = 0.009) and substance use at 0.510 (95% CI 0.350 to 0.743, P = 0.002). The authors report that typical adverse drug events were no more frequent in the GLP-1 arm. ## The mortality figure is the one to distrust A hazard ratio of 0.219 describes a group dying at roughly a fifth the rate of its comparator. No randomized trial of this drug class has produced anything close to that, and the gap between a trial estimate and an observational one is usually the study design rather than the drug. Sicker patients are prescribed differently, and a matched cohort can only balance what was recorded. We have written about this shape before, where authors of a mortality analysis [doubted their own result](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own) for the same reason. The cardiac figure is easier to believe, because it sits closer to what the cardiovascular outcome trials found, and the psychiatric figures are interesting mainly because the debate about this class has run in the opposite direction — a question we have followed through the [suicidality signal](https://thisglp.com/research/glp1-and-suicidal-ideation) and its comparators. ## What it does not tell a buyer No telehealth seller prescribes for psoriasis, and nothing here is a reason to start or stop a drug. What the study is useful for is reading a marketing claim: the risk reductions here were larger in the psoriasis cohort than in cohorts without it, which is precisely the kind of subgroup finding a landing page will quote without its population attached. Before a first order, the more useful questions are about who is prescribing and what happens at a higher dose — the ones we keep listed in [questions they leave open](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Do GLP-1 drugs help psoriasis? This study did not measure the skin. It measured death, cardiac events and psychiatric outcomes in people who have psoriasis, against other diabetes and obesity drugs. Why distrust the mortality number? A hazard ratio of 0.219 means a fifth the death rate, which no randomized trial of this class has shown. In a matched cohort that size of effect usually reflects who gets prescribed what, not what the drug does. What was the comparison group? Psoriasis patients taking other antidiabetic or antiobesity drugs — not untreated people. That makes it a question of which drug rather than whether to treat. ## Sources 1. \[1\] Olbrich H, et al. (2026). Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study British Journal of Dermatology. [PMID 40897378](https://pubmed.ncbi.nlm.nih.gov/40897378/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Drugs and Rotator Cuff Repair Complications in Type 2 Diabetes | This GLP Among 5,876 rotator cuff repairs, raw odds ratios of 3.85, 2.20 and 1.97 against GLP-1 users all vanished once the comparison was adjusted. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-shoulder-surgery-adjustment Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs and Rotator Cuff Repair Complications in Type 2 Diabetes GLP-1 users looked worse on three outcomes after shoulder surgery. Then the authors made the groups comparable and all three differences disappeared. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Before adjustment — odds ratio against no GLP-1 · urinary tract infection · 3.85 · stiffness · 2.20 · respiratory · 1.97 · After adjustment: none of them survived. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 5,876 adults with type 2 diabetes had a rotator cuff repair. 233 were on a GLP-1 beforehand. - Raw comparison: respiratory complications OR 1.97, urinary tract infection OR 3.85, stiffness OR 2.20. - After inverse propensity weighting, no outcome differed. - The raw figures measured who takes these drugs, not what the drugs did. - With 233 exposed patients, the adjusted nulls are weak reassurance rather than proof of safety. A near-fourfold rise in infections is the kind of number that travels. This one did not survive its own paper, and watching it die is more useful than any of the results. ## The raw pass Adults with type 2 diabetes undergoing rotator cuff repair between 2018 and 2024 were pulled from a research network and split by whether they filled a GLP-1 before surgery. [\[1\]](https://thisglp.com/research/glp1-shoulder-surgery-adjustment#ref-1) Compared directly, the users looked worse on three of the ninety-day outcomes. Respiratory complications came in at an odds ratio of 1.97, 95% CI 1.32 to 2.86, p = 0.0006. Urinary tract infection at 3.85, 95% CI 1.31 to 9.12, p = 0.0055. Postoperative stiffness at 2.20, 95% CI 1.31 to 3.49, p = 0.0016. Three significant results pointing the same way — which is what [an unmatched comparison](https://thisglp.com/research/do-glp1-drugs-cause-gout) usually looks like. ## The adjusted pass The authors then reweighted the sample so the two groups resembled each other on measured characteristics. Every difference vanished. Nothing about the patients changed. Only the question did. The first pass asked whether GLP-1 users have more complications. The second asked whether taking one causes them. Those are [two answers from one dataset](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). What the raw numbers were measuring People with type 2 diabetes who are prescribed a GLP-1 tend to be heavier, further along, and carrying more other conditions than people with diabetes who are not. Line them up against each other untouched and you are comparing two different patient populations. The odds ratios were real. They were describing who gets the prescription. ## Do not flip it into reassurance Only 233 patients were exposed. That is a thin base for detecting a complication that happens to a small percentage of people. So the honest reading is that this study found nothing, not that there is nothing to find. The authors say prospective work is needed, and they are right, because [finding no difference is not the same as showing none exists](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## What it is good for A reader will meet the raw version of a number like this before the adjusted one. Social posts carry the 3.85. Papers carry the null. The question to ask of any alarming figure about these drugs is whether the comparison group was built or just found. Most of what gets circulated about real-world GLP-1 use is the found kind, which is [the whole difficulty with evidence collected outside a trial](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## Frequently asked Do GLP-1 drugs raise complication risk after shoulder surgery? Not in this study once the comparison was adjusted. The raw figures showed more respiratory complications, urinary infections and stiffness, and none of it held up after propensity weighting. Why did the numbers change so much? Because people prescribed a GLP-1 for type 2 diabetes differ from those who are not. The unadjusted comparison was measuring who receives the prescription. Does this prove the drugs are safe before surgery? No. Only 233 of 5,876 patients were exposed, which is too few to rule out an uncommon complication. The authors call for prospective studies. Is this about anesthesia risk? No. This study counted complications over 90 days after surgery. Concerns about delayed stomach emptying during sedation are a separate question with its own evidence. ## Sources 1. \[1\] Choudhury A, et al. (2026). The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repair Shoulder & Elbow. [PMID 42712738](https://pubmed.ncbi.nlm.nih.gov/42712738/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Exenatide for Smoking Cessation: Five Subgroups From One Pilot Trial | This GLP How a secondary analysis of a pilot trial generated five answers to who a drug works for, why posterior probabilities are not significance, and what that means for any 'works best for' claim. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-smoking-cessation-subgroups Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Exenatide for Smoking Cessation: Five Subgroups From One Pilot Trial A small trial found exenatide added to a nicotine patch helped smokers quit. A secondary analysis then found five different groups it helped most, which is what exploratory subgroup analysis reliably produces. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Posterior probability of benefit, by subgroup · smoked >20 a day · 81.7% · no prediabetes · 76% · no obesity · 94.4% · no depression symptoms · 91.2% · one genotype · 88.6% · Posterior probabilities, from a secondary analysis of a pilot trial. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A pilot trial found that adding exenatide to a nicotine patch improved smoking abstinence compared with the patch alone. - A secondary analysis then asked who it worked for, and found five different answers. - Benefit appeared stronger in heavier smokers, in people without prediabetes, in people without obesity, in people without depression symptoms, and in carriers of one genotype. - ⛔ These are posterior probabilities rather than p-values, and they come from questions asked after the data existed. - The authors' own conclusion is that larger prospective investigations are needed to confirm and extend the findings. This page is not really about smoking. It is about what happens when a small positive trial is asked who it worked for, because the answer is almost always “several different groups” and that answer is almost always less informative than it looks — a cousin of the problem in [what happens outside a trial](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## What the original trial found In a pilot trial, exenatide added to a nicotine patch improved smoking abstinence compared with the patch alone [\[1\]](https://thisglp.com/research/glp1-smoking-cessation-subgroups#ref-1). That is the primary result, and it is the one with a design built to support it. ## What the secondary analysis found Exploring baseline characteristics, the analysis reported stronger benefit among participants smoking more than twenty cigarettes a day (posterior probability 81.7%), among those without prediabetes (76.0%), among those without obesity (94.4%), among those with no or minimal depression symptoms (91.2%), and among carriers of one genotype at a nicotinic receptor gene (88.6%). Read quickly, that is five findings. Read carefully, it is five ways of dividing one small sample, each producing a smaller group than the trial was sized for. Two words that do most of the work ⛔ _Secondary_ means the questions were asked after the data existed. A prespecified subgroup is a hypothesis; an exploratory one is a search, and a search through enough baseline characteristics will find differences in data with none. ⛔ _Pilot_ means the trial was sized to establish feasibility rather than to answer these questions. Splitting such a sample five ways produces groups too small to settle anything, which is why the authors call for larger prospective investigation rather than presenting a patient profile. ⛔ And the numbers are posterior probabilities — statements of belief under a model — not p-values. Describing an 81.7% posterior probability as statistical significance would be a category error. ## Why this pattern matters beyond one trial Because subgroup findings are the raw material of marketing. “Works best for people who...” is a persuasive sentence, and it can be sourced to a real analysis of a real trial while resting on a group of a few dozen people identified after the fact. The same caution applies to every claim about who these drugs suit. When a result is presented as applying especially to some readers, the question is whether that group was named before the data arrived or after — which is a version of the reading discipline in [what a composite endpoint hides](https://thisglp.com/research/tirzepatide-heart-failure-composite) and [what a comparator can and cannot tell you](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## What is actually established That a GLP-1 drug added to a nicotine patch improved abstinence in one pilot trial. That is a genuine and interesting result, and it is the only one here with a design behind it. Everything after it is a direction for the next study. None of this is available to buy for smoking cessation, and no seller tracked on this site prescribes for it — the same distance between a trial result and a purchasable product that runs through [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review). ## Frequently asked Does a GLP-1 drug help people stop smoking? In one pilot trial, adding exenatide to a nicotine patch improved abstinence compared with the patch alone. That is the primary result and the only one with a design built to support it. Who did it work best for? The secondary analysis reported five different answers — heavier smokers, people without prediabetes, without obesity, without depression symptoms, and carriers of one genotype. Five ways of dividing one small sample is not five findings. Are those percentages significance levels? No. They are posterior probabilities — statements of belief under a model — and describing them as statistical significance would be a category error. Can I buy this for smoking cessation? No. It is not an approved use and no seller tracked on this site prescribes for it. ## Sources 1. \[1\] Yammine L, et al. (2025). Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation Nicotine & Tobacco Research. [PMID 39780397](https://pubmed.ncbi.nlm.nih.gov/39780397/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Atrial Fibrillation After Ablation on GLP-1 Drugs: An Umbrella Review | This GLP An umbrella review of ten GLP-1 and atrial fibrillation meta-analyses found substantial overlap, low confidence throughout, and identical evidence bases giving different answers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Atrial Fibrillation After Ablation on GLP-1 Drugs: An Umbrella Review Two meta-analyses of the same six trials published pooled hazard ratios of 0.58 and 0.78. Nothing separated them but the choices their authors made. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Two reviews. The same six trials. 100% overlap. · review A · 0.58 · review B · 0.78 · 1.0 · The difference is analytic choices, not data. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Ten meta-analyses of GLP-1 drugs and atrial fibrillation were appraised together in an umbrella review. - Two of them shared an identical six-study base and reported pooled hazard ratios of 0.58 and 0.78. - Across reviews, incident AF estimates ranged from an odds ratio of 0.54 to 0.83. - Overlap between reviews was substantial: 43.8% for recurrence, 34.1% among the semaglutide-only incident reviews. - Confidence was low in five reviews and critically low in four. None reached moderate or high. Ten meta-analyses agreeing with each other looks like a settled question. This umbrella review went and checked what they were made of, and the answer is that they are largely made of the same trials — which is the difference between [counting studies and counting independent observations](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery). ## The pair that settles it Two of the three reviews of post-ablation atrial fibrillation recurrence included exactly the same six primary studies — a pairwise corrected covered area of 100%. [\[1\]](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials#ref-1) One reported a pooled hazard ratio of 0.58, 95% CI 0.42 to 0.79. The other reported 0.78, 95% CI 0.61 to 0.99. Identical evidence, different published answers. Nothing separates them except what their authors chose: which comparator, which statistical model, which population. A reader who found one of those papers would come away with a meaningfully different impression from a reader who found the other — which is what [a conclusion detached from its data](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease) looks like when it happens twice from one dataset. What the gradient was made of The umbrella review traced where the disagreement came from, and it tracked three analytic features. Estimates were smaller against an active comparator than against placebo, smaller under a fixed-effect model than a random-effects one, and smaller in type 2 diabetes populations than in obesity populations. Each of those is a defensible decision and none of them is a finding about the drug. The spread between meta-analyses is partly a map of the decisions their authors made. ## How much of the literature is one literature Corrected covered area measures how much the primary studies inside a set of reviews overlap. It came to 43.8% across the three recurrence reviews, 34.1% across the five semaglutide-only reviews of incident AF, and 22.5% across all six incident-AF reviews. So when these papers agree, that agreement is substantially a shared base rather than independent replication, which is the authors’ own conclusion. Ten citations pointing the same way is not ten pieces of evidence — the same illusion as [a pooled figure standing in for consensus](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## The quality appraisal Every review was independently appraised twice on a standard instrument. Five came out at low confidence and four at critically low. None reached moderate or high. That is a striking result for a question with ten published syntheses. Quantity of reviews has no relationship to the certainty they can deliver, and the effect estimates still spread from an odds ratio of 0.54, 95% CI 0.39 to 0.77, up to 0.83, 95% CI 0.70 to 0.98 — intervals that overlap but describe quite different sized benefits, as [the underlying trial-level evidence](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia) also shows. ## What this does not say That the effect is not real. The authors’ conclusion is that GLP-1 drugs are plausibly associated with lower atrial fibrillation burden, with certainty low for new cases and very low for recurrence after ablation. What they ask for is adequately powered randomized trials with AF endpoints that are adjudicated and systematically monitored — because a rhythm problem that is often silent is only counted when somebody looks for it, and how hard a study looks is another choice that moves the number. ## Frequently asked How can two meta-analyses of the same studies disagree? Through analytic choices. The estimates tracked which comparator was used, whether a fixed or random-effects model was applied, and which population was studied — none of which is a finding about the drug. Do GLP-1 drugs reduce atrial fibrillation? Plausibly, according to the authors, with certainty rated low for new cases and very low for recurrence after ablation. Adequately powered trials with monitored AF endpoints are what they ask for. Why does overlap between reviews matter? Because agreement between reviews that share most of their primary trials is not independent replication. Overlap ran to 43.8% across the recurrence reviews. How good were the reviews? Five were rated low confidence and four critically low on a standard appraisal instrument. None reached moderate or high. ## Sources 1. \[1\] Ramzy D, et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses Cureus. [PMID 42668799](https://pubmed.ncbi.nlm.nih.gov/42668799/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Prescribing After a Heart Attack or Stroke: Czech Registry Data | This GLP Czech registry data on GLP-1 prescribing after heart attack and stroke in type 2 diabetes: about 2 percent uptake, lower MACE in matched users, and a mortality figure that points to healthy-user bias. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Prescribing After a Heart Attack or Stroke: Czech Registry Data Czech national registry data covered heart attack and stroke survivors with type 2 diabetes from 2015 to 2024. About 2 percent were started on a GLP-1 within a year, despite a guideline recommending it. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Eligible survivors started on a GLP-1 within a year · ≈2% started · Each block is one in fifty. Guidelines recommend the drug for all of them. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Czech national registry data covered more than 300,000 heart attack and stroke survivors from 2015 to 2024. - Among those with type 2 diabetes, about 2% were started on a GLP-1 within a year of the event. - In matched cohorts, users had lower MACE: HR 0.70, 95% CI 0.52 to 0.93 after heart attack; 0.71, 0.54 to 0.94 after stroke. - All-cause death was HR 0.61 and 0.59 — as large as the cardiovascular effect, which is a warning sign rather than a bonus. - The treated arms were 401 and 385 people. Guidelines recommend these drugs after a heart attack or stroke in people with type 2 diabetes. A national registry can check whether that happens. It mostly does not. ## The number that does not need a causal claim Czech registry data from 2015 to 2024 identified 126,845 people surviving a first nonfatal heart attack, of whom 28,206 had confirmed type 2 diabetes, and 177,115 surviving an ischemic stroke, of whom 73,750 had it. [\[1\]](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke#ref-1) Roughly 2% of those survivors were started on a GLP-1 within twelve months. Use was lowest among women and older adults. That finding stands whatever you conclude about effectiveness. A recommended therapy reached one eligible patient in fifty. Nothing about study design changes it, and it is a different kind of gap from [the access limits sellers publish](https://thisglp.com/research/who-publishes-the-states-they-serve). ## What the matched comparison found Users were propensity-matched to non-users. After heart attack, the matched cohort was 2,271 people, 401 of them on a GLP-1, followed a median of 35 months. Major adverse cardiovascular events came in at HR 0.70, 95% CI 0.52 to 0.93. All-cause death was HR 0.61, 95% CI 0.47 to 0.80. Cardiovascular death was HR 0.54, 95% CI 0.36 to 0.80. After stroke, the matched cohort was 2,235 people, 385 on a GLP-1, median follow-up 27 months. MACE was HR 0.71, 95% CI 0.54 to 0.94. All-cause death HR 0.59, 95% CI 0.46 to 0.76. Cardiovascular death HR 0.55, 95% CI 0.37 to 0.81. Look at the all-cause number A drug that prevents heart attacks should move cardiovascular death more than it moves death from every cause combined. Here the all-cause figures are as large as the cardiovascular ones. That pattern is the fingerprint of healthy-user bias: the people who got started on a new drug in the year after a major event were the ones well enough, insured enough and engaged enough to be started on it. Matching cannot remove that, because being the sort of patient who gets offered a new therapy is not a variable anybody records. ## How much to believe The direction is almost certainly right. Randomized trials already established that these drugs reduce cardiovascular events in people with diabetes and existing disease, and [those trials are the reason to believe it](https://thisglp.com/research/semaglutide-cochrane-review). This registry is consistent with them. The magnitude is another matter. Four hundred treated patients, matched out of tens of thousands, with a mortality benefit that spills past the mechanism, is not a number to quote as an effect size. It is the same caution that applies to [any matched-records analysis](https://thisglp.com/research/semaglutide-fractures-diabetes-only), and it applies harder here because the treated group is small. ## Why a two percent figure matters here This site sells nothing to people recovering from a heart attack, and none of the clinical findings above transfer to a weight-loss purchase. The transferable part is about supply and attention. In a country with universal coverage and a recommending guideline, 98% of eligible patients did not get the drug — while a large commercial market sells the same molecules to people at far lower risk. That is not hypocrisy on anyone’s part and it is worth noticing. The gap between who a drug is proven to help and who actually buys it is the widest fact in this market, and [it is invisible from inside a trial](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). What sellers record about who they ship to is thin, [measurably so](https://thisglp.com/tools/what-sellers-publish). ## Frequently asked Why did so few eligible patients get the drug? The study reports the shortfall rather than its causes, noting use was lowest among women and older adults. Cost, prescribing habit, specialty boundaries and competing priorities after a major event are all plausible and none is measured here. Does this prove the drug prevents death? No. All-cause mortality fell as much as cardiovascular events did, which is the pattern you expect when treated patients were healthier to begin with. Randomized trials, not this registry, are the reason to believe the cardiovascular benefit. How large was the treated group? 401 people in the heart attack cohort and 385 in the stroke cohort, matched from populations of 28,206 and 73,750 with diabetes. Does this apply to buying for weight loss? Not clinically. These were people with type 2 diabetes recovering from a major cardiovascular event. The transferable point is about access rather than effect. ## Sources 1. \[1\] Sedova P, et al. (2026). GLP-1 Receptor Agonists for Secondary Prevention After Myocardial Infarction and Stroke in Type 2 Diabetes: Nationwide Real-World Evidence European Journal of Preventive Cardiology. [PMID 41499432](https://pubmed.ncbi.nlm.nih.gov/41499432/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Real-World GLP-1 Weight Loss: Discontinuation, Dose and the Trial Gap | This GLP Real-world GLP-1 weight loss runs below the trial results. The gap comes from 20 to 50 percent stopping in the first year and from lower doses, not from the drug behaving differently. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-weight-loss-in-ordinary-care Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Real-World GLP-1 Weight Loss: Discontinuation, Dose and the Trial Gap Weight loss on GLP-1 drugs in ordinary practice runs below the trial results and approaches them in people who keep taking the drug. Between a fifth and a half stop within the first year. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Stopping within the first year, real-world · 20% to 50% · The literature reports a range, not a figure. · Weight loss in practice runs below trial results — · and approaches them among the highly adherent. · Doses used are lower than those the trials evaluated. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Weight reduction in ordinary practice tends to run below what the randomized trials reported. - It approaches trial levels among patients who are highly adherent — the gap is largely about who keeps taking it. - Real-world studies report discontinuation of 20% to 50% within the first year, and doses well below those the trials evaluated. - Gastrointestinal disturbance is frequent, as in the trials. - No clear real-world increase was seen in pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm. A trial is a description of what a drug can do under conditions almost nobody experiences: selected patients, free medication, study staff, a protocol for escalation and a schedule for checking in. The question a reader actually has is what it does without any of that. This review is the best available summary, and its answer is a shortfall with a specific cause — one that speaks directly to what is counted in [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review). ## What the gap is Observed weight reduction in clinical practice tends to be lower than in the randomized trials [\[1\]](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care#ref-1). The interesting part is the qualifier: outcomes approach trial levels when the analysis focuses on highly adherent patients. That locates the gap. It is not that the drug behaves differently outside a trial; it is that people take it differently. Two mechanisms are named — high discontinuation, reported at 20% to 50% within the first year, and the use of much lower doses than the trials evaluated. Ranges, kept as ranges ⛔ “20% to 50%” is what the literature reports, and this page does not collapse it into a single number. A range that wide reflects genuine disagreement between studies about what counts as stopping and over what window, and inventing a point estimate would manufacture a precision the source does not have. This is also a narrative review rather than a meta-analysis. It summarizes a literature instead of pooling it, so nothing here carries a confidence interval. ## One cohort, for scale A single matched study puts a concrete figure inside that range. In a cohort of 18,386 propensity-matched adults starting one of these drugs in ordinary care, follow-up ended in discontinuation for 55.9% of those on tirzepatide against 52.5% of those on semaglutide[\[2\]](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care#ref-2). More than half of each group stopped. That is one study rather than the literature, and it sits at the upper end of the range the review describes. It is included because a range from a fifth to a half is hard to hold, and a single well-matched number gives it a shape. ## The half that is reassuring The same review reports that observational studies in diabetes and obesity populations found frequent gastrointestinal disturbance — consistent with the trials — but no clear increase in the risks that generate the most alarm: pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm. That belongs in the same summary as the shortfall. An article reporting only that the drug underperforms outside a trial, while omitting that the feared harms did not materialize outside one either, would be selecting evidence rather than reporting it. The eye-disease question is named as still needing evidence, and we cover the two strands of it in [sudden vision loss](https://thisglp.com/research/does-semaglutide-cause-vision-loss) and [diabetic retinopathy](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse). ## What it means for someone buying online The two named causes of the gap are both worse in this market than in ordinary care. Doses are frequently unpublished, so a buyer often cannot tell where on the ladder they are — the silence counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). And discontinuation is driven substantially by cost, which is the whole subject of this category. The practical reading is that trial figures are a ceiling rather than an expectation, and that most of the distance between the ceiling and the floor is decided by whether a person keeps taking the drug at an adequate dose. That is a question about price and about supervision, neither of which most sellers here describe. [knownwell](https://thisglp.com/reviews/knownwell) describes both virtual and in-person obesity care on its [website](https://www.knownwell.co/). Those settings are worth comparing when travel or continuity affects access. They are not interchangeable with this study population, and the service description alone does not establish how long patients remain on treatment. ## Frequently asked Do people lose as much weight as the trials reported? Generally less. Outcomes approach trial levels among highly adherent patients, which locates the gap in how the drug is taken rather than in what it does. How many stop in the first year? Real-world studies report 20% to 50%. That range is what the literature says, and collapsing it to one figure would invent a precision it does not have. Did the feared harms show up in practice? Not clearly. The same review reports no clear real-world increase in pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm, alongside frequent gastrointestinal disturbance. ## Sources 1. \[1\] Thomsen RW, et al. (2025). Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Diabetes, Obesity and Metabolism. [PMID 40196933](https://pubmed.ncbi.nlm.nih.gov/40196933/) 2. \[2\] Rodriguez PJ, et al. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity JAMA Internal Medicine. [PMID 38976257](https://pubmed.ncbi.nlm.nih.gov/38976257/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Weight Loss Across 32 Trials: The 9.36% Average and Its Spread | This GLP A meta-regression of 32 trials and 40,408 participants found 9.36% mean weight reduction with I² of 99.6% — and what actually explained the spread between trials. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-weight-loss-pooled-average Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Weight Loss Across 32 Trials: The 9.36% Average and Its Spread Thirty-two trials give a mean weight reduction of 9.36%. They also disagree with each other almost completely, which is the more useful number. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Pooled across 32 trials, 40,408 participants · 9.36% · 7.92 · 10.80 · I² = 99.6% — the trials do not agree with each other · A tight interval around a mean that almost no trial reported **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A meta-regression pooled 32 trials covering 40,408 participants, searched to February 2026. - The weighted mean weight reduction was 9.36%, 95% CI 7.92% to 10.80%. - Heterogeneity between trials was I² = 99.6%, meaning the trials almost entirely disagree. - Trials with more baseline anxiety or depression reported larger weight loss — a study-level association, not a fact about individuals. - Trials in people with type 2 diabetes, sleep apnea or fatty liver disease reported smaller responses. A single number for how much weight these drugs take off is the most requested figure in this market and the least reliable one. Here is a pooled estimate built from forty thousand people, and the statistic that tells you not to use it. ## The number, and the number beside it Thirty-two trials, 40,408 participants, searched across four databases to February 2026. [\[1\]](https://thisglp.com/research/glp1-weight-loss-pooled-average#ref-1) The weighted mean weight reduction was 9.36%, with a 95% confidence interval from 7.92% to 10.80%. That looks precise. The heterogeneity statistic was I² = 99.6%, p<0.001. I² estimates how much of the variation between trial results is real rather than chance. At 99.6%, essentially all of it is real. The trials are not noisy measurements of one underlying number — they are measurements of different numbers. What a tight interval means when I² is that high The confidence interval describes uncertainty about the average. It does not describe the spread of what happened. With this much heterogeneity, an individual trial could sit far outside 7.92% to 10.80% and be entirely consistent with the pooled result, and an individual person sits further out still. A narrow interval around a meaningless average is a familiar trap, and it is a cousin of [the same estimate answering two questions](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). ## What explained the spread Subgroup analysis found larger weight reduction with the dual GLP-1 and GIP agonist, tirzepatide, and with treatment lasting 72 weeks or more. Neither is surprising and both come from subgrouping rather than from a designed comparison, which makes them weaker than they look. The meta-regression found something less expected. Baseline anxiety or depression was positively associated with weight-loss efficacy, β = 2.44, p<0.001, with study-level R² of 81.34%. Type 2 diabetes, obstructive sleep apnea and metabolic dysfunction-associated fatty liver disease were each negatively correlated with response, all at p<0.05; the abstract gives no coefficients for those, so none appear here. This does not say anxious people lose more weight Meta-regression works on trials, not people. The finding is that trials whose participants had more baseline anxiety or depression reported larger average weight loss. Concluding from that what will happen to any individual with anxiety is the ecological fallacy — the classic example being that a country’s average income predicts nothing reliable about the person next to you. Thirty-two data points also make an R² of 81% fragile. It is a hypothesis about why trials differ, not a trait that predicts your result. ## Why the negative correlations are more useful Because they are consistent with what individual trials already show. Weight loss on these drugs is reliably smaller in people with type 2 diabetes than in people without it, which is why the landmark obesity and diabetes trials report different headline figures and are not interchangeable — [reading the right trial for your situation](https://thisglp.com/research/semaglutide-cochrane-review) matters more than the pooled average does. Sleep apnea and fatty liver disease pointing the same way is a newer observation and carries the same study-level caveat. All three travel together with metabolic disease, so whether any one of them is doing something on its own is not answerable here. ## What to do with a number like 9.36% Use it as a floor for what the class does, not as a forecast for what you will do. Any estimate a seller or a calculator produces — including [the one on this site](https://thisglp.com/tools/glp1-expected-weight-loss) — is drawn from trial averages and inherits this spread. It is an estimate, and this study is the clearest available measure of how wide the real distribution around it is. The broader lesson is one this desk keeps arriving at from different directions: a pooled figure is a summary of a literature, not a description of a person, and the literature here is far less settled than the marketing suggests — the same distance [between one famous trial and everything behind it](https://thisglp.com/research/glp1-in-children-all-eighteen-trials). ## Frequently asked How much weight will I lose? No study can tell you. The pooled average across 32 trials was 9.36%, but heterogeneity between those trials was I² = 99.6%, meaning they were measuring genuinely different numbers rather than one number imprecisely. Does anxiety or depression make the drug work better? Nothing here shows that. The association is between trials — studies with more baseline anxiety or depression reported larger average weight loss — and applying a study-level pattern to an individual is the ecological fallacy. Why did people with diabetes lose less? The analysis reports the correlation and not its cause. Smaller weight loss in type 2 diabetes is a consistent finding across individual trials too, which is why obesity and diabetes trial results are not interchangeable. Is a narrow confidence interval reassuring here? Not in the way it looks. The interval describes uncertainty about the average, not the spread of individual results, which this analysis shows is very wide. ## Sources 1. \[1\] Lu D, et al. (2026). Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis Clinical Obesity. [PMID 42733128](https://pubmed.ncbi.nlm.nih.gov/42733128/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Dose Ladders: How Many Price Rungs Sellers Publish | This GLP Among GLP-1 sellers that publish a dose ladder, how many priced rungs each one shows, and why a three-rung table runs out before titration settles. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-deep-a-published-dose-ladder-goes Updated: 2026-10-28 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Dose Ladders: How Many Price Rungs Sellers Publish Publishing a priced dose ladder is a rare disclosure among GLP-1 sellers. Publishing one deep enough to reach the dose you will actually end up on is rarer still. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 216 sellers with a published ladder, by rungs shown · 85 · 3 · 55 · 4 · 32 · 5 · 17 · 6 · 8 · 7 · 12 · 8 · 5 · 9 · 1 · 10 · 1 · 11 · Rungs published. Median 4; deepest 11. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 216 sellers this site can rank publish three or more distinct figures in one pricing note — a ladder rather than a starting price. - The median ladder has 4 rungs. The deepest has 11. - 140 of them stop at three or four rungs; 44 publish six or more. - The test is mechanical — distinct dollar figures in one note — so every count is a floor rather than an estimate. - Corpus read October 2026. Publishing a dose ladder at all is the rarer disclosure, and we count how many sellers manage it in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). This page asks the follow-up question: once a seller decides to show its rungs, how many does it show? ## How deep they go Of 216 rankable sellers publishing a ladder, the median shows 4 rungs. 140 stop at three or four, and 44 publish six or more. One publishes 11, which is a complete escalation schedule with a price against every step. Three rungs is enough to establish that the price moves and not enough to plan a year against. A buyer starting at the opening dose and titrating upward will pass the end of a three-rung table well before treatment settles, and at that point is back to asking. Every number here is a floor ⛔ The test is distinct dollar figures inside one recorded pricing note. It is deliberately dumb: it cannot be gamed by wording and it credits nobody for merely saying the price changes. It also cannot see a seller whose published table this desk recorded only the first rows of, so a seller credited with three rungs may well publish six. ⛔ This count is scoped to sellers this site can rank, which is why it is smaller than the roster-wide figure in the other census. Two counts of the same phenomenon with different denominators is worth stating rather than leaving a reader to trip over. ## Why depth matters more than existence A ladder is useful in proportion to how far it reaches. The disclosure that changes a purchase is not “the price rises” but “here is what it becomes at the dose you are likely to end up on”, and most of the real-world evidence suggests people settle in the middle of the range rather than at the bottom — which is what the dose comparison in [what a higher dose actually adds](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it) implies about where climbing stops. A three-rung table that stops before the middle answers the easy part of the question. A six-rung one priced to the top of the labeled range answers the whole thing, and the sellers doing that are a minority of a minority — roughly 20% of those who publish anything. ## What to do with a shallow ladder Treat the last published rung as the beginning of the unknown rather than the end of the price. If a seller shows three figures and your likely maintenance dose is above the third, the figure you will actually pay is not on the page — and that is a question to settle in writing before starting, not after. Which sellers publish anything at all is listed in [published dose ladders](https://thisglp.com/tools/published-dose-ladders), and the wider pattern of what this market declines to write down is in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). An alternative to a ladder is the same-price claim on [Next Vial’s storefront](https://thisglp.com/reviews/next-vial), which [advertises the same price across doses](https://www.nextvial.com/). That answers one pricing question, not the entire bill. Confirm the supplied amount, treatment interval and renewal terms for your prescription before treating the claim as a complete quote. ## Frequently asked How many rungs does a typical published ladder have? The median is four. A minority publish six or more, and one seller publishes a complete escalation schedule with a price against every step. Is three rungs enough? Enough to establish that the price moves, not enough to plan a year against. A buyer titrating upward will pass the end of a three-rung table before treatment settles. Could a seller be publishing more than you counted? Yes. The test is distinct figures in one recorded note, which cannot see a table this desk captured only part of, so every count is a floor. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # How Do You Take Oral Semaglutide? Empty Stomach, and Little Water | This GLP A pharmacokinetics review puts oral semaglutide's absolute bioavailability at 0.4% to 1% fasted | and below the limit of quantification in the fed state, which is why the rules exist. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-do-you-take-oral-semaglutide Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # How Do You Take Oral Semaglutide? Empty Stomach, and Little Water Oral semaglutide's bioavailability is about 0.4% to 1%, and only on an empty stomach with restricted water. Eat first and there is no measurable drug in the blood at all. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Of an oral semaglutide dose, what reaches the blood · fasted · 0.4 to 1% · after food · below the limit of quantification · The conditions are not advice. They are the dose. · The injection route does not have this problem. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Oral semaglutide's absolute bioavailability is about 0.4% to 1% under optimized fasting conditions with restricted water. - Taken in the fed state, plasma concentrations stay below the limit of quantification. - The tablet is paired with an absorption enhancer called SNAC, which is doing specific chemical work. - Absorption varies widely between people and between days. - Steady levels hold anyway, because the drug's week-long half-life and albumin binding smooth out the variation. On an empty stomach, with restricted water, and nothing to eat afterwards for a while. That is not a preference. Absolute bioavailability is about 0.4% to 1% under those conditions, and in the fed state plasma concentrations stay below the limit of quantification [\[1\]](https://thisglp.com/research/how-do-you-take-oral-semaglutide#ref-1). A price page lists a tablet beside an injection as two ways to buy the same molecule. That is true and it hides the interesting part. The clinical result of the tablet is covered in [what the 25 mg trial showed](https://thisglp.com/research/oral-semaglutide-what-the-pill-does). This is the part underneath it. ## The number Absolute bioavailability of oral semaglutide is approximately 0.4% to 1%, under optimized fasting conditions with restricted water intake. So between roughly 99% and 99.6% of the tablet never reaches the bloodstream at all. The injection does not have this problem. That is why the oral dose is so much larger than the injected one for the same molecule. The sizes differ because the routes differ, not because the products are different strengths of the same thing. ## Where the rest goes Four losses, according to the review. The peptide is broken down by enzymes in the gut. It crosses the gut lining poorly. The stomach’s own physiology limits what can be absorbed. And some of what survives is metabolized before it reaches circulation. Peptides are food, structurally speaking. The digestive tract is extremely good at taking them apart, and getting one through intact is the whole engineering problem. What SNAC actually does The tablet is formulated with sodium N-(8-\[2-hydroxybenzoyl\]amino) caprylate, and its job is chemical rather than inert. It raises the pH immediately around the tablet in the stomach, which stops acid from unfolding the peptide and keeps pepsin from activating against it. It holds the semaglutide in the single-molecule form that can cross a cell membrane, instead of clumping. And it helps the molecule move through the stomach lining. It is part of the product, not packaging around it. ## Food closes the window In the fed state, the review reports, plasma semaglutide concentrations remain below the limit of quantification. Not reduced. Not less effective. Unmeasurable. Whatever the instructions say about fasting and water, they are the difference between taking the drug and not taking it. The tablet has been tested [alongside levothyroxine](https://thisglp.com/research/can-you-take-ozempic-with-levothyroxine), a drug with similar dosing conditions. A reader comparing a tablet to an injection on price alone is comparing [two things that are not interchangeable](https://thisglp.com/research/eight-storefronts-one-application). ## What the dose has to be, because of all this The trials show the size of the correction. Oral semaglutide at 25 mg over 64 weeks produced a mean weight reduction of 13.6% against 2.2% on placebo [\[2\]](https://thisglp.com/research/how-do-you-take-oral-semaglutide#ref-2). A 50 mg dose in 201 East Asian adults gave a mean reduction of 14.3% against 1.3% on placebo [\[3\]](https://thisglp.com/research/how-do-you-take-oral-semaglutide#ref-3). The injected doses for the same molecule are measured in single-digit milligrams. Those two results are read separately in [the 50 mg trial](https://thisglp.com/research/oral-semaglutide-fifty-milligrams) and against the injection in [the pill against the needle](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection). Neither is a reason to skip the fasting rules, because both were measured under them. ## Variable, and stable anyway Absorption swings a lot, between people and from day to day in the same person, and the usable dose range is narrow. Steady-state levels still come out reasonably even. Semaglutide has a half-life of about a week and binds extensively to albumin, so a low day is buffered by the drug already in circulation. That is a real advantage of a long-acting molecule. It is also why a missed window does not announce itself. ## Why this belongs on a disclosure site Because the delivery system is part of what you are buying, and it is the part least likely to appear on a product page. A seller can publish a molecule, a format and a figure without ever saying what the tablet is formulated with or under what conditions the number was established. That gap is the same one this site counts everywhere else — what gets published against what gets left out. Which sellers list formats at all is in [the format finder](https://thisglp.com/tools/molecule-and-format-finder), and what happens to price when the same molecule changes route is in [the six-times-the-price comparison](https://thisglp.com/research/glp1-price-spread-across-sellers). ## Frequently asked How much of an oral semaglutide tablet is absorbed? About 0.4% to 1%, under fasting conditions with restricted water. The rest is broken down or never crosses the gut lining. What happens if I take it with food? The review reports that plasma concentrations remain below the limit of quantification in the fed state — not reduced, but unmeasurable. What is SNAC? An absorption enhancer formulated into the tablet. It raises the local pH in the stomach, protects the peptide from acid and pepsin, keeps it in its absorbable single-molecule form, and helps it cross the stomach lining. Why is the oral dose so much bigger than the injection? Because so little of it gets in. The two routes need different amounts of the same molecule to produce comparable exposure. ## Sources 1. \[1\] Vahora S, et al. (2026). Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities Pharmaceutical Research. [PMID 42687069](https://pubmed.ncbi.nlm.nih.gov/42687069/) 2. \[2\] Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 40934115](https://pubmed.ncbi.nlm.nih.gov/40934115/) 3. \[3\] Kadowaki T, et al. (2025). Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial JAMA Internal Medicine. [PMID 40758358](https://pubmed.ncbi.nlm.nih.gov/40758358/) ## Where to get it ### Oral GLP-1, ranked Tablets, troches and capsules priced on the oral product itself — never on a number borrowed from the same seller's injection page. [Compare providers →](https://thisglp.com/best/oral-glp1) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # How Long Does Nausea Last on a GLP-1? Through the Escalation | This GLP Semaglutide and tirzepatide both escalate over about twenty weeks. Here are the reported gastrointestinal event and discontinuation rates, and what they mean for a plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1 Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # How Long Does Nausea Last on a GLP-1? Through the Escalation The first twenty weeks are where the dose climbs, where the side effects cluster, and where a dose-priced seller starts charging more. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Escalation · Maintenance · Most discontinuation happens inside the shaded part. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Mostly through the escalation window, which runs about twenty weeks. The dose climbs on a fixed schedule over that period, the gastrointestinal events cluster inside it, and the people who stop mostly stop there rather than later. Whether the nausea is doing the work is a fair question, and in the trials it mostly was not. Pooling STEP 1 to 3, mean weight loss on semaglutide 2.4 mg ran 11.4 to 17.7 percent in people who had gastrointestinal events and 9.6 to 17.1 percent in people who did not. Under one percentage point of the extra loss over placebo ran through those events [\[5\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-5). In three head-to-head semaglutide trials, nausea and vomiting accounted for less than 0.1 kg of its advantage over other GLP-1 drugs [\[6\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-6). Across SURPASS-1 to -5 they explained under 6 percent of tirzepatide’s difference from its comparators [\[7\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-7). So the nausea is not what takes the weight off, and the escalation window is something to get through rather than a sign of progress. Dose errors are their own category, and [the adverse event reports list what those actually are](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). Where the slowing does not resolve, the question becomes [gastroparesis](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis), which is measured separately. And [what returns after stopping](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1) is a different window again. The biology underneath is less tidy. A circuit-mapping study found that neurons in the area postrema carried both the weight loss and the aversion, while neurons in the nucleus of the solitary tract restrained normal eating and did not mediate drug-induced loss [\[4\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-4). Its authors conclude the two effects cannot be separated at a circuit level, which is [one neuron population carrying both](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea). That is preclinical work, and the indexed abstract does not name the species. A shared circuit is not the same as a shared outcome, and in the people who took the drugs the weight loss arrived with or without the nausea. The first four months of one of these prescriptions are not the same experience as the ones that follow. The dose climbs on a fixed schedule, the side effects cluster in that window, and the people who stop mostly stop there. Every number below comes from a trial that recorded it, and the window they describe is the same window a seller’s pricing model either holds still through or does not. ## What the escalation schedule actually is STEP 4 ran a twenty-week lead-in to reach the 2.4 mg semaglutide maintenance dose, of which sixteen weeks were dose escalation and four were maintenance, and 89.0% of the 902 people who began it reached the maintenance dose [\[1\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-1). SURMOUNT-1 used a twenty-week escalation period for tirzepatide across its three dose arms [\[2\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-2). Twenty weeks is close to five months, which is longer than most readers expect when they buy a first month. That is why the [titration planner](https://thisglp.com/tools/glp1-titration-planner) plots the schedule against weeks rather than listing it. The opening dose is the one a patient is on for the fewest weeks, so a seller’s price at the top of the ladder governs most of a year. ## How often the gastrointestinal effects show up In STEP 1, nausea and diarrhea were the most common adverse events with semaglutide. Gastrointestinal events caused discontinuation in 4.5% against 0.8% on placebo[\[3\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-3). STEP 4 reported gastrointestinal events in 49.1% against 26.1% on placebo, among participants who continued semaglutide, with similar discontinuation rates in the two arms at 2.4% and 2.2% [\[1\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-1). Hold those two figures next to each other. Roughly half the treated group reported a gastrointestinal event, and roughly one in twenty-two stopped the drug because of one. The gap between those numbers is the thing a reader planning a course of treatment needs: the common outcome is discomfort that is managed, not discontinuation. SURMOUNT-1 reported the most common adverse events with tirzepatide as gastrointestinal, mostly mild to moderate. They occurred primarily during dose escalation, with discontinuation for adverse events in 4.3%, 7.1% and 6.2% of the 5 mg, 10 mg and 15 mg groups against 2.6% on placebo [\[2\]](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1#ref-2). The rate rises with the dose, which is the clearest argument in the record for escalating no faster than the schedule requires. Belching is a smaller entry on the same labels, and it has its own account in [the sulfur burps explainer](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps). ## Where the escalation window meets the bill A seller whose price is tied to the milligram charges more at exactly the point the drug is hardest to tolerate. That is not a coincidence or a trick; it is what a dose-priced ladder does. A reader on a rising dose at a seller like [one that publishes the whole ladder](https://thisglp.com/reviews/rixa-health) can see what month four costs before month one is paid for. A reader at a seller that publishes only its entry rung finds out at the refill. The opposite arrangement is a flat rate held at every dose, which removes the financial pressure to escalate faster or slower than the schedule says. That property is scored directly by the [published rubric](https://thisglp.com/methodology), and it is worth more across a year than most of the gaps between headline prices. ## What none of this tells an individual These are group rates from trial populations, and a trial population is not a general population: participants were screened, monitored and followed on a protocol. A rate of 49.1% does not mean a coin flip for any particular person, and 4.5% does not promise anything either. What the numbers support is a plan. Expect the escalation window to be the hard part, and expect most of the discomfort to be manageable, and have a way to reach a prescriber during it — which the [seller reviews](https://thisglp.com/reviews) record for each service. ## Frequently asked How long does the dose take to reach maintenance? STEP 4 used a twenty-week lead-in for semaglutide, sixteen weeks of which were escalation, and SURMOUNT-1 used a twenty-week escalation for tirzepatide. Close to five months, not one. How many people stop because of nausea? In STEP 1, 4.5% of the semaglutide group discontinued because of gastrointestinal events, against 0.8% on placebo. In SURMOUNT-1, discontinuation for adverse events ran from 4.3% to 7.1% across the tirzepatide dose arms. Does nausea mean the drug is working? No. In STEP 1 to 3, weight loss on semaglutide 2.4 mg was similar with and without gastrointestinal events, and under one percentage point of the extra loss over placebo ran through them. The SURPASS trials found the same pattern for tirzepatide. Does the rate depend on the dose? In SURMOUNT-1 the discontinuation rate was higher at 10 mg and 15 mg than at 5 mg, and the trial reported that gastrointestinal events occurred primarily during dose escalation. ## Sources 1. \[1\] Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial JAMA. [PMID 33755728](https://pubmed.ncbi.nlm.nih.gov/33755728/) 2. \[2\] Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine. [PMID 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/) 3. \[3\] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/) 4. \[4\] Yacawych WT, et al. (2026). A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists The Journal of Clinical Investigation. [PMID 42742987](https://pubmed.ncbi.nlm.nih.gov/42742987/) 5. \[5\] Wharton S, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. [PMID 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682/) 6. \[6\] Lingvay I, et al. (2020). Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events BMJ Open Diabetes Research & Care. [PMID 33115821](https://pubmed.ncbi.nlm.nih.gov/33115821/) 7. \[7\] Patel H, et al. (2024). Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials Diabetes, Obesity and Metabolism. [PMID 37853960](https://pubmed.ncbi.nlm.nih.gov/37853960/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # How Long Does Zepbound Stay in Your System? About a Month | This GLP How long Zepbound stays in your system | a 5-6 day half-life, about a month to clear, and what the label says on missed doses, the pill, pregnancy and surgery. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # How Long Does Zepbound Stay in Your System? About a Month Tirzepatide's half-life is 5 to 6 days, so five half-lives come to 25 to 30 days. The label's missed-dose, contraception and pregnancy rules all follow from that clock. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Share of one dose left, at a five-day half-life · 100% · 50% · 0 · 5 · 10 · 15 · 20 · 25 · 30 · 35 · day 25: about 3% · Days after the last injection. The label range is 5 to 6 days. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). About a month. The Zepbound label puts tirzepatide’s elimination half-life at 5 to 6 days [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). Five half-lives, the rule of thumb for a drug being cleared, comes to 25 to 30 days. By then about 3% of the last dose remains. A review of preconception planning puts the tirzepatide washout at 25 to 35 days [\[4\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-4). ## Key takeaways - A population model pooled 19 studies and put tirzepatide's half-life at about 5 days; the label gives 5 to 6 days. - Five half-lives is 25 to 30 days, after which roughly 3% of the last dose is left. - Steady state takes 4 weeks of weekly dosing, so building up and clearing out run on the same clock. - After one radiolabeled dose, most of what was excreted was recovered within 480 hours, about 20 days. - The label's missed-dose window is 4 days, and it tells people on oral contraceptives to add a backup method for 4 weeks. - The label sets no washout before surgery or conception; a review suggests stopping 25 to 35 days before trying to conceive. The same numbers apply to Mounjaro, which is the same molecule under a different label. What follows is how long the drug itself lasts. How long its effect on weight lasts after stopping is a separate question, answered by a withdrawal trial in [what happens when you stop tirzepatide](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide). ## Where the five-day figure comes from Eli Lilly’s population model pooled 19 studies and described tirzepatide with a two-compartment model [\[1\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-1). It put the half-life at about 5 days. The authors found no demographic group that needed a different dose regimen. Both authors are Lilly employees and shareholders. The label adds the details a patient can use [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). A dose peaks in the blood at a median of 24 hours, with a range of 8 to 72 hours. Tirzepatide is 99% bound to albumin, which is what keeps it in circulation. Steady-state concentrations were reached after 4 weeks of once-weekly injections. That last figure is the useful one. Four weeks to build up to a stable level and roughly four weeks to clear out are the same arithmetic run in opposite directions. ## What “five half-lives” means in days Each half-life removes half of what is left. At 5 days, half the last dose remains on day 5, a quarter on day 10, and one eighth on day 15. On day 25 the share is one thirty-second, about 3%. At a 6-day half-life, the same point arrives on day 30. That is a calculation from the label’s half-life, not a measurement in anyone’s blood. Half-life also varies between people. The label reports clearance with a coefficient of variation of about 20% [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). ## What a radiolabel study measured One study followed a tagged dose directly [\[3\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-3). Healthy men received a single injection of about 2.9 mg tirzepatide carrying a radioactive label. Most of the excreted dose was recovered within 480 hours, which is 20 days. About 66% came out in urine and 33% in feces. Intact tirzepatide was not found in urine or feces at all. What leaves the body is broken down first, by cleavage of the peptide chain and oxidation of its fatty-acid side chain. The study used one small dose in healthy men. It did not measure the higher doses used for weight loss. ## Does it stay longer with kidney or liver disease? Not by a clinically relevant amount. In a single-dose study of 45 people given 5 mg, exposure in mild, severe and dialysis-dependent kidney disease matched normal kidneys [\[5\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-5). Blood was sampled for up to 648 hours, about 27 days. The moderate group ran 25 to 29% higher, and the authors judged no effect clinically relevant. A matching study in 32 people with liver impairment found exposure and half-life similar to healthy controls [\[6\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-6). Both studies gave one 5 mg dose, so neither measured repeated weekly dosing. What the evidence shows for people on dialysis more broadly is set out in [can you take a GLP-1 on dialysis](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis). ## A missed dose The label’s rule follows from the half-life [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). Take a missed dose as soon as possible within 4 days, or 96 hours. After 4 days, skip it and take the next dose on the usual day. The injection day can move, as long as doses are at least 3 days apart. The label gives no schedule for restarting after a longer break. That decision belongs to a prescriber. The pattern of nausea at each new dose is covered in [how long nausea lasts on a GLP-1](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). A long half-life cuts both ways A drug that lasts is forgiving of a late dose and slow to leave after a mistake. One case report describes a 53-year-old woman who injected 7.5 mg, 10 mg and 15 mg on three consecutive days [\[7\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-7). She developed paralytic ileus, a stalled bowel, and it took three weeks of treatment to resolve. The label says the same thing in its overdose section: observation may need to account for the roughly 5-day half-life [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). One case describes one patient, and the wider pattern of dosing mistakes is in [the adverse event reports on dose errors](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). ## Oral contraceptives: the 4-week window The label tells people on the pill to switch to a non-oral method, or add a barrier method [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). The backup covers 4 weeks after starting Zepbound and 4 weeks after each dose increase. Hormonal methods that are not swallowed should not be affected. This window is not about how long tirzepatide stays in the body. The cause is slower stomach emptying, which the label says is largest after the first dose and then diminishes. The pharmacokinetic study behind it is read in [tirzepatide and oral contraception](https://thisglp.com/research/tirzepatide-and-oral-contraception). ## Stopping before conception The label does not set a washout before trying to conceive. It says to stop Zepbound when a pregnancy is recognized, and calls the human data insufficient to evaluate risk [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). The concern comes from animal studies, where fetal growth reductions appeared at clinical exposures. A 2025 narrative review filled that gap with the half-life [\[4\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-4). It recommends stopping tirzepatide 25 to 35 days before conception, against at least 35 days for semaglutide. That is one author’s synthesis of 9 studies, not a trial result. The human pregnancy data are in [GLP-1 drugs in pregnancy](https://thisglp.com/research/glp1-in-pregnancy-what-the-evidence-shows), and effects on fertility in [do GLP-1 drugs affect fertility](https://thisglp.com/research/do-glp1-drugs-affect-fertility). ## Breastfeeding In a single-dose study of 11 lactating women given 5 mg, tirzepatide was undetectable in 164 of 171 milk samples [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). The amount found in the other 7 was under 0.02% of the dose. The last measurable level appeared 5 days after the injection. Effects on a breastfed infant were not measured. ## Stopping before surgery The label warns that people on these drugs have aspirated stomach contents under anesthesia, despite fasting as instructed [\[2\]](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system#ref-2). It also states that the data are insufficient to say whether pausing the drug reduces retained stomach contents. That is a month-long washout meeting a question nobody has answered. What one anesthesia study found is in [GLP-1 drugs and an empty stomach](https://thisglp.com/research/glp1-before-surgery), and the label tells patients to report the drug before any planned procedure. ## Compounded tirzepatide Every figure here comes from studies of Lilly’s product. Compounded tirzepatide is not FDA-approved, and its pharmacokinetics were not measured in these studies. The molecule is the same, so the half-life would be expected to match. Whether a given compounded product delivers the stated dose is a separate question. ## Frequently asked How long does Zepbound stay in your system? About a month. The label gives a half-life of 5 to 6 days, and five half-lives come to 25 to 30 days, when roughly 3% of the last dose remains. That is a calculation from the half-life, not a blood measurement. How long does tirzepatide stay in your system? The same as Zepbound, because Zepbound and Mounjaro are both tirzepatide. A population model pooling 19 studies put the half-life at about 5 days, and steady state takes 4 weeks of weekly dosing. How long should you stop tirzepatide before trying to get pregnant? The label sets no washout and says to stop when pregnancy is recognized. A 2025 narrative review recommends stopping 25 to 35 days before conception, based on the half-life. What if you miss a Zepbound dose? The label says to take it within 4 days (96 hours). After 4 days, skip it and take the next dose on the usual day, keeping at least 3 days between doses. ## Sources 1. \[1\] Schneck K, Urva S (2024). Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide CPT: Pharmacometrics & Systems Pharmacology. [PMID 38356317](https://pubmed.ncbi.nlm.nih.gov/38356317/) 2. \[2\] U.S. Food and Drug Administration (2026). Zepbound (tirzepatide) injection prescribing information, accessed via DailyMed DailyMed, National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) 3. \[3\] Martin JA, Czeskis B, Urva S, Cassidy KC (2024). Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys European Journal of Pharmaceutical Sciences. [PMID 39243911](https://pubmed.ncbi.nlm.nih.gov/39243911/) 4. \[4\] Saad Alfaiz A (2025). GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review Annals of Medicine and Surgery. [PMID 41377305](https://pubmed.ncbi.nlm.nih.gov/41377305/) 5. \[5\] Urva S, Quinlan T, Landry J, Martin J, Loghin C (2021). Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide Clinical Pharmacokinetics. [PMID 33778934](https://pubmed.ncbi.nlm.nih.gov/33778934/) 6. \[6\] Urva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT (2022). Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide Clinical Pharmacokinetics. [PMID 35674880](https://pubmed.ncbi.nlm.nih.gov/35674880/) 7. \[7\] Asada K, Tsujimoto Y, Hoshino Y, Tomiki M, Sekiguchi K, Yamashiro K, Nishimura R (2026). A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa Internal Medicine. [PMID 42144326](https://pubmed.ncbi.nlm.nih.gov/42144326/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # How Many Heart Attacks Could Semaglutide Prevent in the US? | This GLP US models project semaglutide preventing 496,400 to 1.93 million cardiovascular events over 10 years | every figure is a model output that assumes full treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent Updated: 2026-10-26 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # How Many Heart Attacks Could Semaglutide Prevent in the US? Models put it between half a million and 2 million cardiovascular events over a decade, depending on who is counted. Nobody in them took a drug, and each assumes everyone eligible is treated. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Cardiovascular events prevented, US models · 0.50 to 1.93 million · over 10 years, adults with heart disease · 1.50 million · over 10 years, eligible adults without it · 75,681 a year · adults with type 2 diabetes · Every figure assumes everyone eligible is treated. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Four US modeling studies put the answer between tens of thousands of cardiovascular events a year and about 2 million over a decade, depending on who is treated. - In 22.7 million adults with heart disease eligible under the label, one model projects 1,934,493 major cardiovascular events prevented over 10 years. - For a person at elevated risk without heart disease, one model projects ten-year risk falling from 13.82% to 10.83%, an absolute drop of 2.99 points. - The counts are composite events (heart attack, stroke and cardiovascular death together), not heart attacks alone. - Nobody in these studies took a drug, and every model assumes everyone eligible is treated and stays treated. Modeling studies put it in the millions over a decade, and none of those figures was observed in a patient. One model covers US adults who already have cardiovascular disease. It projects semaglutide 2.4 mg preventing between 496,400 and 1,934,493 major cardiovascular events over 10 years, depending on how eligibility is drawn [\[2\]](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent#ref-2). Those events are a composite of heart attack, stroke and cardiovascular death. Whether the drug prevents each of those separately is a different question, taken up in [whether GLP-1 drugs prevent heart attacks and strokes](https://thisglp.com/research/do-glp1-drugs-prevent-heart-attacks-and-strokes). National-scale projections also depend on what is counted: a separate [UK lifetime carbon-emissions model](https://thisglp.com/research/semaglutide-lifetime-carbon-emissions) examines environmental consequences, not observed cardiovascular events. Every model here takes a trial result and multiplies it across survey records. Nobody was treated. The answer therefore depends on three choices: which trial supplies the effect, which people are counted as eligible, and whether they are assumed to take the drug for ten years. ## In people who already have heart disease Nanna and colleagues applied SELECT’s hazard ratio for major cardiovascular events to US census projections and national survey data [\[2\]](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent#ref-2). Of 6,164,019 adults meeting SELECT’s entry criteria, 2,523,218 (40.9%) were projected to have at least one new event in 10 years without further treatment. Semaglutide 2.4 mg may prevent 496,400 of them, a 16% relative reduction. Widening the pool to the 22,653,158 adults who meet the label for cardiovascular risk reduction raised the projection to 1,934,493 events. The model applied the same 16% relative reduction to deaths, giving 1,231,295 deaths avoided. ## In people without heart disease Wong and colleagues started from the weight-loss trial rather than the heart trial [\[3\]](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent#ref-3). They applied STEP 1’s eligibility criteria to national survey data and found 93.0 million eligible US adults, 38% of the adult population. Feeding STEP 1’s weight change into a BMI-based Framingham risk score, among those without cardiovascular disease, moved ten-year risk from 10.15% to 8.34%. That is 1.81 points absolute and 17.8% relative, or 1.50 million preventable events over 10 years. Weight is the only route this model allows. Schrage and colleagues used a wider set of inputs [\[1\]](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent#ref-1). A risk equation fitted in 610,789 people was applied to 200,012 survey participants twice. The first run used their real values. The second shifted BMI, HbA1c, systolic blood pressure, C-reactive protein and [non-HDL cholesterol](https://thisglp.com/research/does-ozempic-lower-cholesterol) by the amounts SELECT recorded. Among 21,720 people with a BMI of 27 or above and elevated baseline risk, projected ten-year incidence fell from 13.82% to 10.83%. Absolute reductions were larger in men (3.14 points) than in women (2.70). Nobody here took anything These are arithmetic exercises. Each asks what a risk model predicts if a trial’s effect is applied to everyone who qualifies. Each inherits every assumption in its risk equation, and every question about whether a trial’s effect carries over to people it did not enroll. The four studies also use four different inputs, so their totals cannot be added together. ## In people with type 2 diabetes Karthikeyan and colleagues used SUSTAIN-6, the semaglutide trial in type 2 diabetes [\[4\]](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent#ref-4). Of an estimated 33.6 million US adults with type 2 diabetes, 6.9 million fit the trial’s criteria. Applying its event rates, the model projects 75,681 primary-outcome cardiovascular events prevented each year if all of them were treated. The eligible sample was more often female and Black, and less likely to have prior cardiovascular disease, than the trial itself. ## What the per-person number looks like Large totals come from large denominators. Schrage’s 2.99-point drop is roughly three fewer events per hundred people over a decade: a meaningful public health quantity and a modest personal one. The same relative-versus-absolute distinction runs through [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute) and [the FLOW numbers needed to treat](https://thisglp.com/research/twenty-two-thirteen-seventeen). Every total also assumes that everyone eligible starts treatment and stays on it. Schrage’s modeled benefit diminished further under lower compliance assumptions [\[1\]](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent#ref-1). Persistence is the weak point. The drugs that take off the most weight are also the ones people stop soonest, per [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). How many eligible people are actually prescribed one after a heart attack or stroke is its own question, covered in [the uptake data](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke). One assumption could cut the other way. The Schrage model routes the whole benefit through five risk factors. SELECT’s inflammation findings, covered in [inflammation fell before the weight](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation), suggest part of the effect may arrive by another route, which that model cannot capture. ## Frequently asked How many heart attacks could semaglutide prevent? Modeling studies project between 496,400 and 1,934,493 major cardiovascular events prevented over 10 years among US adults with heart disease, depending on who counts as eligible. Those events combine heart attack, stroke and cardiovascular death, and nobody in the models took a drug. What about people who have never had a heart attack? One model found 93.0 million US adults eligible under the STEP 1 criteria and projected 1.50 million events prevented over 10 years among those without cardiovascular disease. Another projected ten-year risk falling from 13.82% to 10.83% in people at elevated risk. How much does it lower one person's risk? In one model, by 2.99 percentage points over ten years for people at elevated risk, or roughly three events per hundred people per decade. The big national totals come from multiplying a modest personal benefit across millions of people. Why might the real number be lower? Every model assumes everyone eligible is treated and stays on the drug. In one model the benefit diminished under lower compliance assumptions, and many people stop these drugs. ## Sources 1. \[1\] Schrage B, Lackner MK, Hoshiyar A, de Lemos JA, et al. (2026). Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population Journal of the American College of Cardiology. [PMID 41811277](https://pubmed.ncbi.nlm.nih.gov/41811277/) 2. \[2\] Nanna MG, Doan QV, Fabricatore A, Faurby M, et al. (2025). Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial Diabetes, Obesity and Metabolism. [PMID 40183412](https://pubmed.ncbi.nlm.nih.gov/40183412/) 3. \[3\] Wong ND, Karthikeyan H, Fan W (2025). US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events Cardiovascular Drugs and Therapy. [PMID 37578663](https://pubmed.ncbi.nlm.nih.gov/37578663/) 4. \[4\] Karthikeyan H, Fan W, Wong ND (2025). US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes Diabetes & Vascular Disease Research. [PMID 40908778](https://pubmed.ncbi.nlm.nih.gov/40908778/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # How Many People Use Compounded GLP-1 Drugs? Records Catch 8.2% | This GLP Compounded GLP-1 use was documented in 8.2% of 153,044 primary care patients, against about 23% in surveys | a compounded prescription leaves no structured record. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # How Many People Use Compounded GLP-1 Drugs? Records Catch 8.2% Primary care records documented compounded use in 8.2% of 153,044 patients, against about 23% in surveys. A compounded prescription leaves no structured record, so the true share cannot be counted. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Where each number came from · Brand name: · structured records · Compounded: only · free-text notes · 8.2% of 153,044 patients documented as compounded. · Counted only where a clinician wrote a sentence about it. · That makes 8.2% a floor, not a rate. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - No reliable count exists. Medical records capture only the compounded use a clinician wrote down. - In 153,044 US primary care patients on semaglutide or tirzepatide, 8.2% had compounded use documented, from 2021 through 2024. - Surveys cited by the same authors put the share near 23% of users, well above the documented figure. - A second records study found compounded use often appeared in notes before the first structured prescription. - In one state in 2024, 93 business websites advertised compounded GLP-1 drugs from 188 physical locations. Nobody has a reliable count. The largest records study found compounded semaglutide or tirzepatide documented in 8.2% of 153,044 US primary care patients using those drugs [\[1\]](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs#ref-1). Surveys cited by the same authors put the share near 23% of users. The gap is the point. A compounded prescription does not create the record a brand-name one does. It appears in a chart only if a clinician writes it down. The same visibility problem runs through the sellers themselves. What they leave off their pages is counted in [what GLP-1 sellers do not publish](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## What the medical record catches Hendrix and colleagues used a national database of primary care records [\[1\]](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs#ref-1). The window ran from January 2021 to December 2024. Brand-name prescriptions came from structured data. That means the coded fields every system records automatically. Compounded use could not be found that way. It was found in clinical notes instead: free text, typed by a clinician. So 8.2% is not the share of people using compounded drugs. It is the share whose clinician recorded it. A buyer who never told their doctor is not in it. Neither is one whose doctor did not write it down. The authors conclude that many patients may get these drugs outside coordinated care. Longer on treatment is not better treatment Compounded-only patients stayed on treatment 10.0 months on average. Brand-name-only patients stayed 7.8 months. That is an association in retrospective data. Cost and refill mechanics can produce it. It is not evidence that compounded drugs work better. The documented users also differed. They were more likely to be female, non-Hispanic White and without diabetes. They were also more likely to live in less deprived areas. Their share of semaglutide and tirzepatide use rose over the study window. ## Reading the notes more closely A second study used a language model to read clinical notes at scale [\[2\]](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs#ref-2). It covered a US records platform of over 29 million patients. It found compounded exposure in 1,696 patients who started treatment without a documented barrier. For about half of them, the first compounding signal came on or before the first structured prescription. That was 50.8% for semaglutide and 57.9% for tirzepatide. The same study shows why structured records mislead in general. Over 18 months, persistence on semaglutide was 55.4% by prescription records against 42.3% by the notes. For tirzepatide the figures were 58.3% and 43.1%. How long people really stay on these drugs is covered in [what happens when they stop](https://thisglp.com/research/stopping-glp1-and-weight-regain). ## Counting sellers instead of users The supply side is easier to count than the buyers. DiStefano and colleagues searched for websites advertising compounded GLP-1 drugs in Colorado in March and April 2024 [\[3\]](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs#ref-3). They found 93 businesses at 188 physical locations. Medical or health spas were the largest group, at 33. Weight loss services were next, at 26. Semaglutide was advertised by 92 of the 93. Tirzepatide was advertised by 40. Of the 93, 41 referred to FDA approval when describing compounded products, and 5 called them generic. This is a count of places selling, not of people buying. What a compounded vial changes about dosing is in [the semaglutide starting dose guide](https://thisglp.com/research/semaglutide-starting-dose). What a buyer should expect from a provider is in [the care standards comparison](https://thisglp.com/research/what-should-a-glp1-provider-actually-do). ## Frequently asked How many people use compounded GLP-1 drugs? Nobody has a reliable count. One study documented it in 8.2% of 153,044 primary care patients on semaglutide or tirzepatide. Surveys cited by the same authors put it near 23% of users. Why can't compounded use be counted from medical records? A compounded preparation does not create the structured prescription record that a brand-name drug does. It appears in the chart only if a clinician types a note about it. Do compounded patients stay on treatment longer? In one dataset, compounded-only patients averaged 10.0 months against 7.8 for brand-name-only. That is an association in retrospective data, and cost and refill mechanics can explain it. How many businesses sell compounded GLP-1 drugs? One state-level count has been published. A 2024 search in Colorado found 93 business websites advertising compounded GLP-1 products, at 188 physical locations. ## Sources 1. \[1\] Hendrix N, Velásquez EE, Pham H, Bazemore A (2025). Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset Pharmacoepidemiology and Drug Safety. [PMID 41024632](https://pubmed.ncbi.nlm.nih.gov/41024632/) 2. \[2\] Varma G, Murugadoss K, Kurian ME, Varghese J, et al. (2026). Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records Biology Methods and Protocols. [PMID 42433615](https://pubmed.ncbi.nlm.nih.gov/42433615/) 3. \[3\] DiStefano MJ, Dardouri M, Moore GD, Saseen JJ, et al. (2025). Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado Journal of Pharmaceutical Policy and Practice. [PMID 39776466](https://pubmed.ncbi.nlm.nih.gov/39776466/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Promotional GLP-1 Pricing: First-Month Rates, Codes and Struck Prices | This GLP How much published GLP-1 pricing is an offer rather than a standing rate, counted from sellers' own words, and why a struck-through anchor distorts a comparison differently from an intro rate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-much-glp1-pricing-is-promotional Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # Promotional GLP-1 Pricing: First-Month Rates, Codes and Struck Prices A fifth of published GLP-1 pricing notes carry the seller's own promotional language: a first month, an introductory rate, a code, or a struck-through figure nobody is charged. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 1200 recorded pricing notes · 165 · carry promotional wording · What kind (a note can be in more than one): · a first month · 81 · a struck-through anchor · 33 · an introductory rate · 28 · a discount code · 24 · a sale · 18 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 165 of 1200 recorded pricing notes — 14% — carry the seller's own promotional language. - The commonest form is a first month, appearing in 81 notes. - 33 notes describe a struck-through figure nobody is charged. - A note without promotional wording has not been shown to carry a standing rate. It has been shown not to advertise a promotion in the text recorded. - Corpus read most recently October 2026. A price is meant to be a fact. In this market a fifth of them are an offer, and the difference is entirely invisible when two figures sit side by side in a comparison. This page counts how much of the published pricing is a promotion rather than a rate, using the sellers’ own words rather than any inference about their intent — the same method as the disclosure counts in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). ## How much of it Of 1200 pricing notes this desk has recorded, 165 contain promotional language — 14% of them. The commonest is a first month, in 81 notes. A figure described that way is not necessarily wrong; it is describing a different thing from the figure beside it. What the other four-fifths are not ⛔ A note without promotional wording has not been shown to carry a standing rate. It has been shown not to advertise a promotion in the text recorded here. Some of those sellers run promotions this desk did not capture; others publish a plain rate and always have. The census counts what was written, not what is true. The phrase counts also overlap on purpose. A note reading “intro price with code SAVE50” lands in two buckets, so adding the categories together produces a number larger than the total, and it means nothing. ## The anchors are the worst of it 33 notes describe a struck-through figure sitting above the price. An anchor is not a price anyone has ever paid — it exists to make the number beneath it feel smaller — and in this market almost none of them is sourced to anything. That is worth separating from a genuine introductory rate, which at least corresponds to a real transaction for a real month. Both distort a comparison, but only one of them is a number a buyer could ever be charged. ## What it changes about comparing It means the two most useful questions about any figure are what it applies to and for how long. A first-month rate answers a different question from a standing rate, and a comparison that places them side by side is not a comparison. We follow that through seller by seller in [when the headline is not the bill](https://thisglp.com/research/glp1-advertised-vs-billed-corrections) and count the structural version of it in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). It also means a figure read once may not survive a second reading — which is why every price on this site carries the month it was taken, and why [reading a price twice](https://thisglp.com/research/rereading-glp1-prices) found so much movement. [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) illustrates why the payment period belongs beside a headline: its [homepage](https://orderlymeds.com/) presents introductory monthly equivalents alongside a two-month total. Compare the amount due for that initial order and the later terms separately. The opening equivalent is not evidence of a standing month-to-month rate. ## Frequently asked How much published pricing is promotional? About a fifth of the recorded pricing notes on this roster contain the seller's own promotional language, most commonly a discounted first month. Does that mean the rest are standing rates? No. It means the rest did not advertise a promotion in the text recorded here. Some run promotions this desk did not capture. Why single out struck-through figures? Because an anchor is not a price anyone has ever been charged. An introductory rate at least corresponds to a real transaction for a real month. ## Sources ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # How Much Less Do You Eat on a GLP-1? About 271 Calories at One Meal | This GLP How much less do you eat on a GLP-1? A 209-participant test-meal meta-analysis, a 60-week trial, and what happens to taste | with the limits of a single lunch. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1 Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # How Much Less Do You Eat on a GLP-1? About 271 Calories at One Meal Pooled across three trials and 209 participants, energy intake at an observed lunch fell by 1,132 kJ against placebo. Nobody has measured a whole day properly. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Measured: one lunch, under observation · −271 kcal · −1,132 kJ (95% CI −1,449 to −815), I² = 0% · Not measured: the rest of the day · breakfast, dinner, snacks, the other six days · habitual intake remains underreported **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). About 271 calories at one observed meal, and nobody has measured a whole day properly. A systematic review pooled standardized test-meal data from four arms across three trials, 209 participants in total, and found energy intake fell by 1,132 kJ against placebo, on a confidence interval from −1,449 to −815 [\[1\]](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1#ref-1). In more familiar units that is roughly 271 kcal at a single lunch. A separate 60-week trial in 120 adults measured the same thing four times and found the gap held: 291.9 kcal at week 20, 240.2 at week 40 and 269.5 at week 60 [\[2\]](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1#ref-2). What faded over those months was the feeling of it, not the eating. ## Key takeaways - A meta-analysis pooled standardized test-meal data from four arms across three trials, 209 participants in total. - At that meal, energy intake fell by 1,132 kJ (95% CI -1,449 to -815), roughly 271 kcal, with no heterogeneity between trials (I² = 0%). - The outcome is a single observed lunch, not daily or habitual eating, which the authors note remains underreported. - In a 60-week trial, the gap at a measured lunch was 291.9, 240.2 and 269.5 kcal at weeks 20, 40 and 60 — it did not fade. - Self-rated appetite and hunger differed from placebo at week 20 and not at weeks 40 or 60. The sensation faded and the behavior did not. - Taste scores were substantially lower in people on these drugs, which changes what gets eaten rather than how much. Everyone knows these drugs make people eat less. Almost nobody has measured how much, because asking people what they ate produces unreliable answers and weighing it is expensive. A systematic review searched six databases for trials that measured eating directly, under observation, and pooled what it found. The nutritional consequences of eating less are set out in [vitamins and minerals on a GLP-1](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1). The pooled result is precise. At a standardized ad libitum lunch, participants on a GLP-1 or dual agonist ate 1,132 kJ less than on placebo, with a confidence interval from −1,449 to −815 and an I² of 0%, meaning the contributing trials agreed almost exactly. One lunch is not a diet An ad libitum test meal is food provided in excess and eaten under observation in a research setting. It measures appetite at a moment, reproducibly, which is exactly why the trials agree so well. It does not measure breakfast, dinner, snacking, compensation later in the day, or what happens on a Tuesday at home — and the authors say directly that real-world habitual intake remains underreported. A reader who turns 271 kcal into a daily deficit has manufactured a number this analysis does not contain. The pooled figure is also thinner than the paper’s scope suggests. Sixteen studies entered the systematic review, and four arms from three trials, 209 participants in total, contributed to the meta-analysis. Adding an exploratory three-week phase 1 tirzepatide trial raised the estimate to −1,421 kJ and pushed heterogeneity from zero to 70%, which shows how much a single study can move a pool this size. No significant difference appeared between semaglutide and tirzepatide (P = 0.154). ## Whether it lasts, and what stops lasting The longest measurement of the same thing ran 60 weeks and randomized 120 adults 3:2 to semaglutide 2.4 mg or placebo [\[2\]](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1#ref-2). At a laboratory lunch the semaglutide group ate 291.9 kcal less than placebo at week 20, 240.2 kcal less at week 40 and 269.5 kcal less at week 60, with standard errors of 64.4, 87.8 and 83.6. All three differences were significant, so fourteen months in, the gap was about where it started. The self-reported measures did not hold. At week 20 the semaglutide group reported greater appetite suppression, less hunger over the past week and less preoccupation with food. At weeks 40 and 60 the groups did not differ significantly on any appetite measure at all. Why that combination is not a contradiction, and what it means for the common complaint that the drug stopped working, is in [appetite at fourteen months](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1). ## The mechanism, and why it is hard to separate from nausea What the analysis establishes is that the appetite effect is real, immediate and measurable rather than a matter of self-report. That matters because the alternative explanation, that people on these drugs simply report eating less, has never been ruled out by questionnaire studies. Work in mice traced the anorectic response and the aversive one to a single circuit in the dorsal vagal complex [\[4\]](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1#ref-4), which is a finding about rodents and a reason the two effects are hard to prise apart. It is described in [nausea and appetite on one circuit](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea). ## What gets eaten, not only how much A cross-sectional study gave a 53-item taste test and a 40-item smell test to 46 people on a GLP-1 and 46 matched controls [\[3\]](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1#ref-3). Taste scores averaged 28.61 (95% CI 25.66 to 31.56) against 40.63 (38.35 to 42.91), at p<0.001 and an effect size of η²=0.37, while smell was slightly lower and not significantly different at p=0.076. Nobody’s taste was measured before they started, so this shows that taste scores differ substantially rather than that the drug caused it. What makes it matter for intake is what people do when food registers as flat, which tends to be drifting toward salt, sugar and texture. The study and its one result that points the wrong way are in [the taste-function study](https://thisglp.com/research/do-glp1-drugs-change-your-sense-of-taste). ## What follows from a smaller plate The authors of the pooled analysis close by arguing for structured nutritional support with attention to adequate protein, which follows from their own finding. If intake drops by this much at a single meal, composition matters more than it did before, and nothing about the drug ensures that what remains is well chosen. That connects directly to the body composition question in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). For a buyer the useful translation is that the effect is sustained while the drug is taken, which is a different claim from the effect being permanent. What happens to intake after stopping has [its own uncomfortable answer](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1), and no seller on this roster publishes a nutrition plan to go with the prescription. ## Frequently asked How much less do you eat on a GLP-1? At a standardized observed lunch, about 1,132 kJ less than placebo, roughly 271 kcal, pooled across three trials and 209 participants. No pooled analysis has measured habitual daily intake. Does the effect fade over time? The eating did not. In a 60-week trial the gap at a measured lunch was 291.9, 240.2 and 269.5 kcal at weeks 20, 40 and 60. Self-rated appetite differed from placebo only at week 20. Why do people say the drug stopped working? Appetite ratings are relative to a recent normal, which by month ten is already the drug's normal. The sensation of suppression fades while the measured intake gap stays. Does food taste different? Taste scores in people on these drugs averaged 28.61 against 40.63 in matched controls, with smell almost unchanged. Nobody was measured before starting, so it shows a difference rather than a cause. Can I turn 271 calories into a daily deficit? No arithmetic supports that. The figure describes one observed meal, and the authors state that real-world habitual intake remains underreported. ## Sources 1. \[1\] Quan AT, Nguyen HL, Nguyen TMT (2026). Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis Diabetes & Metabolic Syndrome. [PMID 42508090](https://pubmed.ncbi.nlm.nih.gov/42508090/) 2. \[2\] Tronieri JS, et al. (2026). Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial The American Journal of Clinical Nutrition. [PMID 42323166](https://pubmed.ncbi.nlm.nih.gov/42323166/) 3. \[3\] Khan R, et al. (2025). GLP-1 receptor agonists significantly impair taste function Physiology & Behavior. [PMID 39722367](https://pubmed.ncbi.nlm.nih.gov/39722367/) 4. \[4\] Yacawych WT, et al. (2026). A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists The Journal of Clinical Investigation. [PMID 42742987](https://pubmed.ncbi.nlm.nih.gov/42742987/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Price Freshness: How Old Published Seller Prices Are | This GLP How many recorded GLP-1 seller prices were read this month, how many are older, and how often a second reading found the price had moved up or down. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-old-is-the-price-you-are-reading Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Price Freshness: How Old Published Seller Prices Are Every GLP-1 price here carries the month it was read. This page counts how old those readings are, and what changed when the same prices were read a second time. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 580 recorded prices, by the month each was read · October 2026 · 83 · September 2026 · 420 · August 2026 · 25 · July 2026 · 2 · 50 rows carry no reading date at all. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 580 recorded prices sit behind this site, and 50 of them carry no reading date. - 83 were read in October 2026. The remaining 447 — 77% — are older than that. - When 217 of them were re-read, 217 had moved: 155 down and 62 up. - The median move was 13% and the largest fall was 79%. - A price with no reading date beside it is not a price. It is a memory. Every figure on this site carries the month it was read, and that is not decoration. A published price in this market is a snapshot of a page that its owner can change without telling anyone, and the interval between the reading and your reading of it is the part nobody usually discloses. This page puts a number on that interval for our own data — the same instinct behind counting what sellers leave out in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish), turned around and pointed here. ## How old the corpus is There are 580 recorded prices behind the comparisons on this site, covering 580 sellers. 50 of them carry no reading date. 83 were read in October 2026, and the remaining 447 are older. That second group is the honest weakness here, and it is stated rather than averaged away. The oldest rows are the ones to treat most carefully. A figure read several months ago has had several months in which a promotion could end, a fee could be added, or a product could be withdrawn — and none of those produce a notification. What a re-read actually finds 217 rows across 219 sellers have been walked a second time. 217 of them had changed: 155 downward and 62 upward. The median move was 13%, the largest fall 79% and the largest rise 131%. The direction is the surprise. More prices came down than went up, which is not what a reader braced for inflation expects, and it is a reason to re-read rather than to assume either way. The full record of what moved is in [what happens when you read a price twice](https://thisglp.com/research/rereading-glp1-prices). ## Why the date has to be visible A comparison site that publishes a figure without saying when it was read is asking you to trust an unstated interval. The figure may have been collected this week or last year, and nothing on the page distinguishes the two. Attaching the month is the cheapest honest thing a publisher can do, and it is the reason every price on this site carries one. It also makes the site checkable. If a figure here is wrong, the date says which page to go and look at, and the [corrections record](https://thisglp.com/corrections) says what has already been found wrong and fixed. A claim that cannot be checked against its own source is a claim that has to be taken on faith, which is what this whole category runs on. ## What to do with this as a reader Read the date beside any figure here, and treat an older one as a lead rather than a price — something to confirm on the seller’s own page before it decides anything. That advice applies with more force to the figures most likely to move: promotional rates, first-month offers and anything described as starting at. The structural version of the same problem is that a headline can be true and still not be the bill, which is counted in [when the headline is not the bill](https://thisglp.com/research/glp1-advertised-vs-billed-corrections) and in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). A fresh reading of a misleading figure is still a misleading figure. Rereading the footnote matters as much as rereading the headline. [Hers](https://thisglp.com/reviews/hers) currently separates a required weight-loss membership from medication prices on its [homepage](https://www.forhers.com/). An old drug-only figure cannot answer the present total-cost question without the associated membership and renewal terms. ## Frequently asked Why does a price need a date? Because a seller can change its page without telling anyone. The interval between the reading and your reading of it is the part that decides whether a figure is still true, and it is the part most comparison sites leave unstated. Are older figures wrong? Not necessarily, but they are less reliable. When rows here were walked a second time, more of them had moved down than up, and the median move was substantial in both directions. What should I do with an older reading? Treat it as a lead rather than a price. Confirm it on the seller's own page before it decides anything, especially where the figure is promotional or described as starting at. ## Sources ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # How Do You Avoid Ozempic Face? No Tested Way to Prevent It | This GLP How to avoid Ozempic face: midface volume fell a median 9.0% in 20 GLP-1 users, about 7% per 10 kg lost | no prevention has been tested against the face. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/how-to-avoid-ozempic-face Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # How Do You Avoid Ozempic Face? No Tested Way to Prevent It The one direct measurement found midface volume down a median 9.0% in 20 people on a GLP-1, about 7% per 10 kg lost. Slower loss, protein and exercise have never been tested against the face. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Median midface volume lost, 20 people · Superficial fat · 11.0% · Total midface · 9.0% · Deep fat · 7.0% · About 7% of midface volume per 10 kg lost. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - No method has been tested to prevent Ozempic face. No trial has imaged the face while testing diet, protein, exercise or dosing. - The one direct measurement found midface volume down a median 9.0% in 20 people, about 7% per 10 kg of weight lost. - The loss sat mainly in superficial fat, and it tracked the weight lost rather than anything else measured. - Slower loss and lean-mass protection are reasonable levers for the body. Neither has been measured against the face. No method has been tested to prevent it, because the one measured predictor is how much weight comes off. In 20 people scanned before and after starting a GLP-1, midface volume fell by a median 9.0% [\[1\]](https://thisglp.com/research/how-to-avoid-ozempic-face#ref-1). That worked out to about 7% of midface volume for every 10 kg lost. No trial has tested slower loss, protein or exercise against the face. That makes Ozempic face mostly a question about weight loss rather than about one drug. The same pattern appears with [the hair shedding that follows rapid loss](https://thisglp.com/research/does-ozempic-cause-hair-loss), where the subtype that rises points at the weight lost rather than the molecule. ## What was actually measured A facial plastic surgery group at one academic center searched its records for GLP-1 prescriptions [\[1\]](https://thisglp.com/research/how-to-avoid-ozempic-face#ref-1). It kept patients with head and neck CT or MR imaging both before and after the prescription. Twenty qualified, with a median age of 54. They had been on the drug for an average of 321 days and lost an average of 11.0 kg. Total midface volume fell by a median 9.0%, with an interquartile range of 3% to 14%. Superficial fat fell 11.0%. Deep fat fell 7.0%, but its range ran from minus 20% to 15%. Weight lost correlated with superficial volume loss, at rho 0.590. It did not correlate with deep volume loss. The authors describe it as one of the first quantitative assessments of the phenomenon, which is accurate, and it is also most of what exists. Twenty people, one hospital, no comparison group The study was retrospective, and nobody was scanned in order to measure the face. It had no group losing the same weight without a drug. So it cannot say whether a GLP-1 changes the face differently from a diet producing the same loss. Not measured is the accurate description. ## Why age changes the trade Facial fat is not only a cost of excess weight. In 186 pairs of identical twins, a panel rated age from photographs [\[2\]](https://thisglp.com/research/how-to-avoid-ozempic-face#ref-2). A 4-point higher BMI made a twin look older before age 40 and younger after it. An 8-point higher BMI made a twin look older before 55 and younger after. Smoking and sun exposure made twins look older at every age. The study measured appearance at one moment, not change during weight loss, so it explains the direction rather than the size. The practical reading is narrow. The same weight loss is likely to show more in the face of a 60-year-old than a 30-year-old. That is a reason to expect it, not a reason to avoid treatment. ## The levers, and what each rests on Only the amount of weight lost has been measured against facial volume. | Lever | What is measured | Measured on the face? | | --- | --- | --- | | Losing less weight | About 7% midface volume per 10 kg lost, in 20 people | Yes, once | | Losing it more slowly | More fat-free mass lost during fast loss, mostly gone after 2 to 4 weeks of stability | Not measured | | Protein and resistance training | Lean mass held in trials of the body | Not measured | | Hydration and nutrition | Listed as risk factors in a review of 40 studies, without effect sizes | Not measured | Only the amount of weight lost has been measured against facial volume. References 1, 3, 4 and 5 ### Losing it more slowly Slowing loss is the most repeated advice, and its evidence comes from the body. A review gathered 13 studies that produced the same percentage loss at slow or fast rates [\[3\]](https://thisglp.com/research/how-to-avoid-ozempic-face#ref-3). Rates ranged from 0.2 to 3.2 kg a week. Faster loss may take more fat-free mass during the losing phase. Those differences shrank after 2 to 4 weeks of holding the new weight. The review judged the remaining differences unlikely to matter clinically. One randomized trial in that literature shows the size. In 57 adults, a 500 kcal diet for 5 weeks and a 1,250 kcal diet for 12 weeks produced similar losses, of 9.0 kg and 8.2 kg [\[4\]](https://thisglp.com/research/how-to-avoid-ozempic-face#ref-4). Fat-free mass loss was 8.8% on the fast diet against 1.3% on the slow one. None of these studies used a GLP-1, and none imaged a face. On a GLP-1 the rate is set largely by the dose schedule. That is covered in [the four-week titration steps](https://thisglp.com/research/semaglutide-starting-dose), and the trade between more loss and more symptoms is in [whether a higher dose is worth it](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it). ### Protein and resistance training These protect lean mass, and the case for them on a GLP-1 is set out in [how much muscle goes during treatment](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). The single-trial detail is in [what happened to muscle mass and grip](https://thisglp.com/research/semaglutide-muscle-mass-and-grip). The difficulty is anatomical. The measured facial loss sat mainly in superficial fat, and resistance training builds muscle rather than facial fat. Nobody has shown that holding lean mass protects the cheeks. It is still worth doing for the body, and the face is not the reason. ### Nutrition and hydration A 2026 review of 40 studies on GLP-1 drugs and skin quality listed risk factors for more severe changes [\[5\]](https://thisglp.com/research/how-to-avoid-ozempic-face#ref-5). They were advanced age, a long history of obesity, rapid weight loss, poor hydration and insufficient protein intake. The included studies mixed clinical trials, case reports and observational work. The abstract gives no effect size for any factor. A list like this is where to look, not a measured risk. What a reduced intake does to micronutrients is covered in [whether you need vitamins on a GLP-1](https://thisglp.com/research/do-you-need-vitamins-on-a-glp1). ## Prevention plans are still hypotheses A 2026 paper proposes a risk-stratification model and a four-phase prevention algorithm keyed to the pace of weight loss [\[6\]](https://thisglp.com/research/how-to-avoid-ozempic-face#ref-6). Its own methods call it hypothesis-generating. It rates itself Level V evidence and says future studies are needed to validate it. Most of the remaining literature concerns injectable correction after the fact, much of it written by practitioners who provide it. That is treatment, not avoidance, and this page does not assess it. The mouth has a parallel gap, described in [what has been measured about Ozempic teeth](https://thisglp.com/research/ozempic-teeth). ## What nobody has measured No randomized trial has imaged the face while testing any intervention. No study compares facial change on a GLP-1 with the same loss by diet. Nobody has measured how much volume returns after stopping, or at what rate. So the answer a reader can act on is limited. The amount of weight lost drives most of the measured change. Age makes it more visible. Slower loss and lean-mass protection are sensible for the body, and untested for the face. ## Frequently asked How do you prevent Ozempic face? No method has been tested. The only direct measurement found midface volume fell about 7% for every 10 kg lost, so the amount of weight lost is the one measured driver. Slower loss and protecting lean mass are reasonable for the body but untested for the face. What causes Ozempic face? Mainly the loss of facial fat that comes with weight loss. In 20 people scanned before and after a GLP-1, superficial midface fat fell a median 11.0%, and that loss correlated with the weight lost. Is Ozempic face real? Facial volume loss is real and has been measured, at a median 9.0% of midface volume in one small study. Whether a GLP-1 changes the face differently from a diet producing the same loss has not been measured. Does Ozempic face age you more after 40? Probably more visibly. In 186 pairs of identical twins, a 4-point higher BMI looked older before 40 and younger after it, so the same loss is likely to show more in an older face. ## Sources 1. \[1\] Sharma RK, Vittetoe KL, Barna AJ, Takkouche S, et al. (2025). Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists Otolaryngology–Head and Neck Surgery. [PMID 40407186](https://pubmed.ncbi.nlm.nih.gov/40407186/) 2. \[2\] Guyuron B, Rowe DJ, Weinfeld AB, Eshraghi Y, et al. (2009). Factors contributing to the facial aging of identical twins Plastic and Reconstructive Surgery. [PMID 19337100](https://pubmed.ncbi.nlm.nih.gov/19337100/) 3. \[3\] Fogarasi A, Gonzalez K, Dalamaga M, Magkos F (2022). The Impact of the Rate of Weight Loss on Body Composition and Metabolism Current Obesity Reports. [PMID 35133628](https://pubmed.ncbi.nlm.nih.gov/35133628/) 4. \[4\] Vink RG, Roumans NJ, Arkenbosch LA, Mariman EC, van Baak MA (2016). The effect of rate of weight loss on long-term weight regain in adults with overweight and obesity Obesity (Silver Spring, Md.). [PMID 26813524](https://pubmed.ncbi.nlm.nih.gov/26813524/) 5. \[5\] Barone M, Brunetti B, D'Emilio R, Caputo MG, et al. (2026). Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review Aesthetic Plastic Surgery. [PMID 42162206](https://pubmed.ncbi.nlm.nih.gov/42162206/) 6. \[6\] Castrellon R, Maita K, Witt E, Young V, et al. (2026). Preventing GLP-1-Associated Facial Aging: An Anatomy-Driven Risk Stratification Model and Prevention Algorithm in the “Ozempic Face” Era Aesthetic Plastic Surgery. [PMID 42260145](https://pubmed.ncbi.nlm.nih.gov/42260145/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Is a GLP-1 Better Than Metformin? Nobody Has Run That Trial | This GLP Is a GLP-1 better than metformin? A 93-trial network puts metformin at OR 0.69 and GLP-1 agonists at 0.87, with overlapping intervals and no head-to-head trial. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-a-glp1-better-than-metformin Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Is a GLP-1 Better Than Metformin? Nobody Has Run That Trial Across 93 trials, metformin had the largest reduction in cardiovascular events of any diabetes drug. It also had the least reliable evidence behind it. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Major cardiovascular events vs placebo · metformin · lower-quality evidence · SGLT2 inhibitors · tirzepatide · GLP-1 agonists · 1.0 · 93 studies — and four intervals that mostly overlap **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Nobody has run that trial. A network meta-analysis pooled 93 randomized trials of every approved type 2 diabetes class [\[1\]](https://thisglp.com/research/is-a-glp1-better-than-metformin#ref-1). Against placebo, metformin had the lowest odds ratio for major cardiovascular events. It was 0.69, 95% CI 0.53 to 0.89. GLP-1 agonists came in at 0.87, 95% CI 0.83 to 0.92. Tirzepatide and SGLT2 inhibitors were both 0.82. Those four intervals overlap. The authors grade the metformin evidence as lower quality. Every trial pooled here enrolled people with type 2 diabetes. That is also the population in [the kidney failure numbers needed to treat](https://thisglp.com/research/twenty-two-thirteen-seventeen). ## Key takeaways - A pairwise and network meta-analysis pooled 93 randomized trials of every approved class of type 2 diabetes drug. - Against placebo, metformin came in at OR 0.69 for major cardiovascular events, 95% CI 0.53 to 0.89. - SGLT2 inhibitors were 0.82, tirzepatide 0.82, and GLP-1 agonists 0.87. - The authors grade the metformin and pioglitazone evidence as lower quality, and the four intervals overlap heavily. - Sulfonylureas were the only class associated with more cardiovascular events. - A separate network of four trials found no difference in mortality or cardiovascular events between tirzepatide and dulaglutide. - The strongest single GLP-1 result, FLOW, was run against placebo at the 1.0 mg diabetes dose. ## What was pooled Ninety-three randomized trials of at least 40 weeks. [\[1\]](https://thisglp.com/research/is-a-glp1-better-than-metformin#ref-1) Each compared a diabetes medication against placebo or an active comparator. Cardiovascular events and deaths were formally adjudicated. Both pairwise and network methods were used. That lets drugs never tested against each other be compared indirectly. In the network against placebo, metformin came in at OR 0.69, 95% CI 0.53 to 0.89. SGLT2 inhibitors were 0.82, 95% CI 0.75 to 0.90. Tirzepatide was 0.82, 95% CI 0.72 to 0.93. GLP-1 agonists were 0.87, 95% CI 0.83 to 0.92. Insulin, DPP-4 inhibitors and sulfonylureas showed no significant effect on events. On all-cause mortality, tirzepatide came in at 0.72, 95% CI 0.64 to 0.82. SGLT2 inhibitors and GLP-1 agonists were both 0.85, 95% CI 0.80 to 0.91. In the pairwise analyses, sulfonylureas were associated with increased cardiovascular events. That was the only class moving the wrong way. Metformin is first and least certain, at once The authors attach lower quality of evidence to metformin and pioglitazone. It shows in the interval. Metformin runs 0.53 to 0.89; GLP-1 agonists run 0.83 to 0.92. Much of the metformin evidence comes from older trials run to different standards. A cheap generic has the largest point estimate and the least reliable one. Reporting either half alone misleads in opposite directions. ## Why this is not a ranking Read the four intervals, not the four point estimates. Metformin runs 0.53 to 0.89. SGLT2 inhibitors run 0.75 to 0.90. Tirzepatide runs 0.72 to 0.93. GLP-1 agonists run 0.83 to 0.92. Almost all of that overlaps. An analysis can produce an ordering it cannot defend. The ordering is the part that gets quoted. That is the same failure as [a pooled average that describes nobody](https://thisglp.com/research/glp1-weight-loss-pooled-average). These numbers support four classes reducing events and three reducing death. They do not support a first place. ## An indirect comparison is not a head-to-head The same limit shows up inside the GLP-1 class. A network of four randomized trials covering 14,348 participants compared tirzepatide with dulaglutide [\[2\]](https://thisglp.com/research/is-a-glp1-better-than-metformin#ref-2). One trial supplies 13,165 of them, or 91.8% of the evidence. Every published difference is measured against tirzepatide 5 mg, not against dulaglutide directly. No difference appeared in all-cause mortality or major cardiovascular events. The full reading is in [one trial that is 92% of a network](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide). ## Where the GLP-1 evidence is strongest It is strongest against placebo, not against metformin. FLOW randomized 3,533 people with type 2 diabetes and chronic kidney disease [\[3\]](https://thisglp.com/research/is-a-glp1-better-than-metformin#ref-3). The primary composite hazard ratio was 0.76, 95% CI 0.66 to 0.88. Major cardiovascular events were 0.82, 95% CI 0.68 to 0.98. All-cause death was 0.80, 95% CI 0.67 to 0.95. The dose was 1.0 mg weekly, which is the diabetes dose. The condition attached to all of it is set out in [the trial that stopped early](https://thisglp.com/research/semaglutide-and-kidney-disease). Several semaglutide trials in type 2 diabetes added it to metformin rather than replacing it. That pairing is covered in [taking metformin and Ozempic together](https://thisglp.com/research/can-you-take-metformin-and-ozempic-together). ## The population, and who is reading Everyone in these 93 trials had type 2 diabetes. A person buying a GLP-1 for weight loss without diabetes is not in this evidence. The cardiovascular case for that group rests on different trials in different populations. Metformin is not a weight-loss drug and is not sold as one. A table where it leads on cardiovascular events is a table about diabetes care. It is not a shopping list. The menu a seller does carry is counted in [the six obesity drugs on sale](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic). ## What a reader can use One rule. When a comparison puts an old generic near the top, read it as a statement about evidence. Old drugs have old trials. Old trials have wider intervals and looser methods. It cuts both ways. The generic’s apparent advantage should be discounted. The newer drug’s advantage over it has also not been demonstrated, because nobody ran that trial. And [an active comparator](https://thisglp.com/research/do-glp1-drugs-cause-gout) answers a narrower question than its sentence suggests. Almost nothing a seller publishes distinguishes the two, which [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) counts. ## Frequently asked Is a GLP-1 better than metformin? No trial has compared them directly. In a 93-trial network against placebo, metformin's odds ratio for major cardiovascular events was 0.69 and the GLP-1 class was 0.87, with intervals that overlap and lower-quality evidence behind the metformin figure. Is metformin better than a GLP-1 for the heart? This analysis cannot show that. Metformin had the lowest point estimate, OR 0.69, with an interval from 0.53 to 0.89 that overlaps the others, and the authors grade its evidence as lower quality. Which drug reduced deaths most? Tirzepatide, at OR 0.72 with a 95% CI of 0.64 to 0.82, with SGLT2 inhibitors and GLP-1 agonists both at 0.85. Did anything make outcomes worse? Sulfonylureas were associated with increased cardiovascular events in the pairwise analyses — the only class that moved in that direction. Does this apply to someone without diabetes? No. Every trial pooled here enrolled people with type 2 diabetes, and the cardiovascular case for weight-loss buyers rests on separate trials. ## Sources 1. \[1\] Silverii GA, et al. (2026). Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis Diabetes, Obesity and Metabolism. [PMID 42530338](https://pubmed.ncbi.nlm.nih.gov/42530338/) 2. \[2\] Hageen AW, et al. (2026). Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials Endocrinology, Diabetes & Metabolism. [PMID 42706739](https://pubmed.ncbi.nlm.nih.gov/42706739/) 3. \[3\] Perkovic V, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes New England Journal of Medicine. [PMID 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Is a Higher Semaglutide Dose Worth It? Three Points, Four Times the Symptom What the 7.2 mg semaglutide trial found against the existing dose, what the extra dose cost in side effects, and the one number that does not fit a dose-response story. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Is a Higher Semaglutide Dose Worth It? Three Points, Four Times the Symptom A trial put semaglutide 7.2 mg against 2.4 mg in the same protocol. The higher dose bought three more points of weight, and nearly four times the rate of an unfamiliar nerve symptom. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read weight lost · had GI side effects · 7.2 mg · 18.7% · 70.8% · 2.4 mg · 15.6% · 61.2% · placebo · 3.9% · 42.8% · 1,407 people, randomized against each other in one trial. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A trial randomized 1,407 people to semaglutide at 7.2 mg, at 2.4 mg, or to placebo — so the doses were compared inside one protocol rather than across separate trials. - Weight fell 18.7% at the higher dose against 15.6% at the existing one: an estimated treatment difference of 3.1 percentage points. - Gastrointestinal adverse events rose from 61.2% to 70.8%, and dysesthesia from 6.0% to 22.9%. - Serious adverse events were highest in the 2.4 mg arm (10.9%), not the 7.2 mg arm (6.8%) — which does not fit a simple dose-response story. - Three more points of weight, bought with roughly four times the rate of an unfamiliar symptom. Three more points of weight, bought with roughly four times the rate of an unfamiliar symptom. A trial randomized 1,407 people to semaglutide at 7.2 mg, at 2.4 mg, or to placebo, so the doses were compared inside one protocol rather than across separate trials. Weight fell 18.7% at the higher dose against 15.6% at the existing one. The cost side is not only gastrointestinal. Those events rose from 61.2% to 70.8%, but [dysesthesia](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity) — altered sensation — rose from 6.0% to 22.9%. Serious adverse events were highest in the 2.4 mg arm at 10.9%, not the 7.2 mg arm at 6.8%, which does not fit a simple dose-response story. Whether a bigger starting weight changes the trade is a separate question with its own answer. Heavier patients lost more weight and reached the same HbA1c [\[2\]](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it#ref-2), which is [more weight lost and the same glucose result](https://thisglp.com/research/does-starting-weight-change-the-answer). Every seller on this roster has a dose ladder, published or not, and the reason a reader cares is that climbing it costs money. This trial answers the other half of the question: what climbing it buys. It is unusually well designed for that purpose. It put the two doses against each other rather than leaving the comparison to be assembled from separate studies. That is the weakness undermining most such claims, discussed in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). ## What was compared Between January 2023 and November 2024, 1,407 adults with obesity were randomized to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo [\[1\]](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it#ref-1). Nearly three-quarters were female, mean age was 47, mean weight 113 kg and mean BMI 39.9. ## What the higher dose added Mean weight change was −18.7% on 7.2 mg against −15.6% on 2.4 mg, an estimated treatment difference of 3.1 percentage points (95% CI −4.7 to −1.6). Against placebo the difference was 14.8 points. The thresholds show where the extra dose earns its keep. Compared with 2.4 mg, the 7.2 mg arm was 1.8 times likelier to reach a 20% reduction and 2.4 times likelier to reach 25%. At the lower thresholds the two doses were not far apart; the difference is concentrated at the far end. What it cost, in the same table Gastrointestinal adverse events affected 70.8% of the 7.2 mg arm, 61.2% of the 2.4 mg arm and 42.8% of placebo. Dysesthesia — altered or unpleasant sensation, usually tingling or burning — affected 22.9% at the higher dose against 6.0% at the lower and 0.5% on placebo. That last figure is the one worth sitting with. Nearly a quarter of people on the higher dose reported a symptom that barely existed in the other two arms. It is not one most readers will have been warned about. ## The number that does not fit Serious adverse events were reported by 6.8% of the 7.2 mg arm, 10.9% of the 2.4 mg arm and 5.5% of placebo. The highest rate was in the middle dose, which is not what a dose-response relationship looks like. With 201 participants in that arm against 1,004 in the other, the comparison is fragile and the difference may be noise. It is reported here because leaving it out would tidy the result in the drug’s disfavor. A page that only prints the numbers that fit its argument is doing the thing this site exists to catch. ## What a buyer takes from it That the ladder has a top, that the top is worth about three points of weight, and that it costs a substantially higher rate of side effects to stand on. Whether a seller will tell you what the top rung costs in money is a separate matter. It is counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) and listed seller by seller in [published dose ladders](https://thisglp.com/tools/published-dose-ladders). It is also worth knowing that most people never reach a dose like this. Real-world prescribing settles lower and slower than trial protocols. A large share stop before the question arises at all — which is the context for everything above, and the subject of [stopping and weight regain](https://thisglp.com/research/stopping-glp1-and-weight-regain). ## Frequently asked How much more weight does the higher dose produce? 18.7% against 15.6% at 2.4 mg — an estimated treatment difference of 3.1 percentage points, measured inside one trial rather than across separate ones. What does it cost in side effects? Gastrointestinal events rose from 61.2% to 70.8%, and dysesthesia — altered or unpleasant sensation — from 6.0% to 22.9%. Were serious events higher at the higher dose? No, and this is reported rather than omitted: serious adverse events were 6.8% at 7.2 mg against 10.9% at 2.4 mg. With 201 participants in that arm the comparison is fragile. Where does the extra dose earn its keep? At the far end. Against 2.4 mg it was 1.8 times likelier to reach a 20% reduction and 2.4 times likelier to reach 25%, while the lower thresholds were close. ## Sources 1. \[1\] Wharton S, et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology. [PMID 40961952](https://pubmed.ncbi.nlm.nih.gov/40961952/) 2. \[2\] Almohammed O, Alshaya O, Alduhayshi L, Alshaibani S, et al. (2026). Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists Frontiers in Endocrinology. [PMID 42741141](https://pubmed.ncbi.nlm.nih.gov/42741141/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Is CagriSema Better Than Semaglutide Alone? By 6.5 Points, Head to Head A 331-person randomized trial found cagrilintide-semaglutide cut weight 18.4% against 11.9% for semaglutide alone, with adverse events of 87% vs 84%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-cagrisema-better-than-semaglutide Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Is CagriSema Better Than Semaglutide Alone? By 6.5 Points, Head to Head The trial built to answer it gave both arms 2.4 mg and found 18.4% against 11.9%. Against placebo the combination looks twice as impressive, which is the point. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Weight change at week 68 · CagriSema, head-to-head · −18.4% · semaglutide alone, same trial · −11.9% · CagriSema, REDEFINE 1 · −20.4% · The gap between the top two is the answer: 6.5 points. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A randomized trial in 331 adults in east Asia gave both arms 2.4 mg and compared the combination directly against semaglutide alone. - Weight fell 18.4% on the combination against 11.9% on semaglutide alone — a difference of 6.5 percentage points (95% CI -8.4 to -4.6). - Adverse events were 87% against 84%, so the extra weight loss did not cost measurably more side effects. - REDEFINE 1, the larger placebo-controlled trial, reached 20.4% against 3.0% on placebo in 3,417 people. Yes, by about 6.5 percentage points, in the one trial built to answer it directly. The useful part is how small that margin is beside the headline figures, and what it cost in tolerability. ## The trial that compared them head to head A randomized, masked trial gave 331 adults in east Asia either cagrilintide-semaglutide or semaglutide alone, both escalated to 2.4 mg, for 68 weeks [\[1\]](https://thisglp.com/research/is-cagrisema-better-than-semaglutide#ref-1). Weight fell 18.4% on the combination and 11.9% on semaglutide alone. The estimated treatment difference was 6.5 percentage points, with an interval from 8.4 to 4.6. Both arms reached the same dose, so this is not the mismatched-dose comparison this site keeps finding elsewhere — the problem set out in [the tirzepatide network comparison](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide). The extra weight loss did not cost extra side effects Adverse events occurred in 87% of the combination group against 84% on semaglutide alone, and gastrointestinal events in 53% against 51%. Discontinuation ran 10% against 6%. Adding a second agent for 6.5 more points without a clear tolerability penalty is the commercially important part of this trial, and the part most in need of replication — it is the opposite of the trade in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). Adding phentermine to a GLP-1 drug has been tested only with liraglutide, in [one 12-week trial](https://thisglp.com/research/can-you-take-phentermine-with-ozempic). ## A correction to what this site previously said This site has twice described the head-to-head comparison as missing from the CagriSema program. That was not accurate, and the record is worth correcting. REDEFINE 1 randomized 3,417 participants in a 21:3:3:7 ratio: 2,108 to the combination, 302 to semaglutide alone, 302 to cagrilintide alone and 705 to placebo [\[2\]](https://thisglp.com/research/is-cagrisema-better-than-semaglutide#ref-2). A semaglutide-alone arm was there from the start. What was true is narrower. REDEFINE 1’s co-primary endpoints were both stated against placebo. The comparison against semaglutide alone therefore sat in the trial as a secondary question, not the one it was powered to answer. The 2026 trial made that comparison its primary purpose. ## What REDEFINE 1 found The same combination, measured against two different things. | Trial | Compared against | Result | | --- | --- | --- | | REDEFINE 1, n=3,417 | Placebo | −20.4% vs −3.0%, difference −17.3 (95% CI −18.1 to −16.6) | | Head-to-head, n=331 | Semaglutide 2.4 mg alone | −18.4% vs −11.9%, difference −6.5 (95% CI −8.4 to −4.6) | The same combination, measured against two different things. REDEFINE 1 and the 2026 head-to-head trial Gastrointestinal adverse events affected about 79% of the combination group in REDEFINE 1. Its analysis used a treatment-policy estimand, consistent with intention to treat, which counts what happened to everyone randomized rather than only those who stayed on the drug. Read the two rows together and the shape is clear. Against nothing, the combination looks enormous. Against the drug you would otherwise take, it is worth about 6.5 points. That is the same lesson as [the ladder of comparators](https://thisglp.com/research/tirzepatide-vs-real-clinical-practice): the harder the comparator, the smaller the claim. ## What does not transfer The head-to-head enrolled participants from east Asia and the authors frame their conclusion that way. Its semaglutide-alone arm reached 11.9%, noticeably below the figures Western trials report for the same dose in [the pooled weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average). So the 6.5-point gap is the trial’s finding and should travel. The 18.4% is not a number to promise anyone elsewhere. The trial was also 68% male, unusual for an obesity trial, and funded by Novo Nordisk, which the paper states. Whether stacking a second agent helps at all appears to depend entirely on which second agent. In [the zalfermin trial](https://thisglp.com/research/does-semaglutide-help-liver-cirrhosis), every combination failed and the single agent won. ## Frequently asked Is CagriSema better than semaglutide on its own? In the trial built to compare them, yes — 18.4% against 11.9% over 68 weeks with both arms at 2.4 mg, a difference of 6.5 percentage points. Why do some figures say 20% and others 18%? Different comparators. REDEFINE 1 reported 20.4% against placebo in 3,417 people; the head-to-head reported 18.4% against semaglutide alone in 331 people. Against nothing, the combination looks far larger. Does the combination cause more side effects? Not measurably in the head-to-head: adverse events were 87% against 84% and gastrointestinal events 53% against 51%, though discontinuation was 10% against 6%. Do the weight figures apply everywhere? The 6.5-point gap should travel; the absolute numbers may not. Participants were from east Asia and the semaglutide arm reached 11.9%, below what Western trials report at the same dose. ## Sources 1. \[1\] Yamauchi T, Becker NP, Hagemann CA, Huang KC, Kiyosue A, Lim S (2026). Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity The Lancet Diabetes & Endocrinology. [PMID 42009015](https://pubmed.ncbi.nlm.nih.gov/42009015/) 2. \[2\] Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine. [PMID 40544433](https://pubmed.ncbi.nlm.nih.gov/40544433/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Seller Disclosures: Does Publishing One Predict Another? | This GLP Testing whether GLP-1 sellers that disclose one thing disclose others, across four disclosures: a state list, higher-dose pricing, a rankable price and a full dose ladder. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-seller-disclosure-a-trait Updated: 2026-10-28 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Seller Disclosures: Does Publishing One Predict Another? A GLP-1 seller that publishes its full dose ladder is no likelier than average to publish the states it serves. Disclosure is a property of pages rather than of companies. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 580 sellers, four things they could publish · 116 · 0 · 118 · 1 · 168 · 2 · 137 · 3 · 41 · 4 · Number of the four disclosures made. Most sellers make two or three. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Four things a seller can publish, across 580 rankable sellers: a state list, what the price does at a higher dose, a rankable figure, and a full dose ladder. - 41 sellers publish all four. 116 publish none. - Of the 216 sellers publishing a dose ladder, 101 also publish a state list — 47%. - Across every seller, 35% publish a state list. - Those two numbers are the same. Disclosing one thing tells you nothing about whether a seller discloses another. It would be convenient if honesty were a property of companies rather than of pages. A seller that tells you what happens at a higher dose would then be a seller worth trusting about shipping, about fees, about everything else it did not happen to mention. This page tests that assumption against the roster, and it does not hold — which changes how the individual silences counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) ought to be read. ## What each seller could publish Four disclosures, each a separate act and none requiring any of the others: a list of states served, a statement about what the price does as the dose climbs, a figure this site can rank at all, and a full dose ladder with its rungs priced. 201 publish a list of states it serves; 210 publish what the price does at a higher dose; 402 publish a figure this site can rank; 216 publish a published dose ladder. 41 sellers manage all four and 116 manage none, with the bulk sitting on two or three. The comparison that matters Of the 216 sellers who publish a dose ladder — the most demanding of the four — 101 also publish a list of states, which is 47% of them. Across the whole roster, 35% publish a state list. The two figures are effectively identical. Publishing the hardest disclosure in this category makes a seller no likelier than average to publish the easiest one. ## What that rules out It rules out the inference every reader wants to make. Having found one thing a seller is forthcoming about, there is no basis for assuming it is forthcoming generally — and equally, a seller silent on one point has not been shown to be evasive on others. The likelier explanation is mundane. Each disclosure has its own cost and its own reason to be absent: a state list is cheap and dull, a dose ladder is commercially awkward, a rankable price commits to something. Different sellers make different trades, and the trades do not correlate because they are not the same decision. ## How to read a storefront given that One answer at a time. The question you care about has to be asked directly rather than inferred from an unrelated one the seller happened to answer well, which is why [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open) lists them per seller rather than scoring anyone overall. It is also why this site publishes counts of specific silences rather than a trust rating. The dose version is in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder), the shipping version in [who says where they can ship](https://thisglp.com/research/who-publishes-the-states-they-serve), and the rest in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). Corpus read October 2026. [Bodi Envi](https://thisglp.com/reviews/bodi-envi) names Wasef Health as its clinical organization and VialsRx as its dispensing pharmacy in its [FAQ](https://bodienvi.com/faq). Those named relationships answer who is involved. The separate analysis of [discounting and disclosure](https://thisglp.com/research/do-discounting-sellers-disclose-less) asks whether promotional pricing is associated with fewer published details. They do not answer every separate question about the purchase, refund terms or the clinical appropriateness of treatment. ## Frequently asked Do forthcoming sellers tend to be forthcoming about everything? No. Sellers publishing a full dose ladder publish a state list at almost exactly the rate of the roster as a whole, so one disclosure predicts nothing about another. How many sellers publish all four disclosures? A small minority. Most make two or three of the four, and a handful make none at all. What does that mean for choosing? Ask the question you care about directly. A good answer on an unrelated point is not evidence about the one that matters to you. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Is Semaglutide Safe for People With HIV? Four Studies So Far | This GLP Is semaglutide safe for people with HIV? Four studies found no new safety problem | visceral fat fell 30.6% in a trial and depression scores did not worsen. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Is Semaglutide Safe for People With HIV? Four Studies So Far A 108-person trial and two routine-care cohorts found no new safety problem. Visceral fat fell 30.6%, weight fell 6.47 kg, and depression scores did not worsen. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Semaglutide in people with HIV, four reports · Trial, 108 people · visceral fat · -30.6% · Same trial · visuospatial score · improved · Cohort, 222 people · weight at 1 year · -6.47 kg · Cohort, 354 people · depression score · -0.1 · The largest group is 354 people. A rare harm needs far more. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Four published studies of semaglutide in people with HIV have found no new safety problem. The largest followed 354 people. - In a 32-week randomized trial of 108 people, visceral fat fell 30.6% against placebo. Adverse event rates did not differ significantly. - The same trial recorded one semaglutide-related grade 4 lipase elevation and two possibly related gallstone cases. - In a cohort of 222 people, 97% on antiretroviral therapy, weight fell 6.47 kg at one year. - Depression scores did not worsen overall: a change of -0.1 points across 354 people. So far, yes, within limits. Four published studies have found no new safety problem. The largest followed 354 people. That is enough to see common effects. It is not enough to see rare ones. The evidence comes in two kinds. One randomized trial compared semaglutide with placebo. It was reported twice, once for body fat and once for cognition. Two cohorts followed people starting semaglutide in routine HIV care. Mood is covered for the general population in [the depression and anxiety guide](https://thisglp.com/research/do-glp1-drugs-cause-depression). This page covers the HIV-specific record. ## The trial: 108 people, 32 weeks The trial enrolled people with controlled HIV-1 and a BMI of 25 or more [\[1\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-1). All had lipohypertrophy, a build-up of abdominal fat. Nobody had diabetes. Participants were randomized 1:1. The semaglutide dose rose over 8 weeks and then held at 1.0 mg weekly for 24 weeks. Visceral fat fell 30.6% against placebo. Total body fat fell 18.9%. Eight people in each arm, 15%, withdrew early. Adverse event rates did not differ significantly between arms. Three events are named in the results. One grade 4 lipase elevation was judged related to semaglutide. Two cases of gallstones, grades 1 and 2, were judged possibly related. Pancreas and gallbladder events across the drug class are covered in [the pancreatitis guide](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis) and [the gallbladder evidence](https://thisglp.com/research/glp1-and-gallbladder-disease). The authors call for larger trials to examine serious adverse events. ## Cognition in the same trial A second report measured thinking skills in the same 108 people [\[2\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-2). Against placebo, three scores rose at 32 weeks. They were visuospatial, naming and language, and delayed recall. After adjusting for sex and CD4 count, only visuospatial stayed significant. The wider question sits in [the dementia evidence](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia). ## Routine care: weight and blood sugar A US cohort followed 222 people with HIV who started semaglutide [\[3\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-3). At baseline, 97% were on antiretroviral therapy. 89% had a suppressed viral load. 77% had diabetes. Mean follow-up was 1.1 years. Weight fell 6.47 kg at one year. HbA1c fell 1.07 points in the 157 people with a follow-up test. The authors call both results comparable to the general population. ## Routine care: depression scores Depression is common in people with HIV. A second cohort asked whether semaglutide made it worse [\[4\]](https://thisglp.com/research/is-semaglutide-safe-for-people-with-hiv#ref-4). It followed 354 people across nine clinic sites. Scores came from a standard nine-item questionnaire collected at routine visits. The overall change was -0.1 points. The 95% confidence interval ran from -0.7 to 0.5. No subgroup worsened by BMI, diabetes or antidepressant use. The subgroups moved toward the middle Scores rose 1.2 points in people who started with few symptoms. They fell 4.7 points in people who started severe. The study had no control group. Extreme scores drift toward the average on a second measurement with or without a drug. Neither figure is a treatment effect. That limit matches other psychiatric evidence on this site. See [the bipolar cohort](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder) and [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding). ## What the four studies do not cover The trial excluded people with diabetes. Every study group had controlled or treated HIV. The largest group was 354 people. A harm affecting one person in a thousand would likely go unseen. A prescriber who knows the full medication list is the right check before starting. ## Frequently asked Is semaglutide safe for people with HIV? Four published studies found no new safety problem. The randomized trial had 108 people and the largest cohort 354, which is too small to detect a rare harm. Does semaglutide help HIV-associated belly fat? In a 32-week randomized trial of people with HIV-associated lipohypertrophy, visceral fat fell 30.6% against placebo and total body fat fell 18.9%. What side effects were seen in people with HIV? Adverse event rates did not differ significantly from placebo. The trial recorded one grade 4 lipase elevation judged related to semaglutide and two possibly related gallstone cases. Does semaglutide make depression worse in people with HIV? Not in a 354-person routine-care cohort. The overall change in depression score was -0.1 points, 95% CI -0.7 to 0.5, and no subgroup worsened. Does semaglutide work for weight loss in people with HIV? In a cohort of 222 people, 97% on antiretroviral therapy, weight fell 6.47 kg at one year. The authors called that comparable to the general population. ## Sources 1. \[1\] Eckard AR, Wu Q, Sattar A, Ansari-Gilani K, Labbato D, Foster T, et al. (2024). Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial The Lancet Diabetes & Endocrinology. [PMID 38964353](https://pubmed.ncbi.nlm.nih.gov/38964353/) 2. \[2\] Atieh O, Daher J, Abboud M, Wu Q, Sattar A, Baissary J, et al. (2026). Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial Clinical Infectious Diseases. [PMID 41098140](https://pubmed.ncbi.nlm.nih.gov/41098140/) 3. \[3\] Haidar L, Crane HM, Nance RM, Webel A, Ruderman SA, Whitney BM, et al. (2024). Weight loss associated with semaglutide treatment among people with HIV AIDS. [PMID 37976053](https://pubmed.ncbi.nlm.nih.gov/37976053/) 4. \[4\] Haidar L, Ruderman SA, Leong C, Doupe MB, Lesko C, Delaney JAC (2026). Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care AIDS. [PMID 42558052](https://pubmed.ncbi.nlm.nih.gov/42558052/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Is Tirzepatide Better Than Dulaglutide? One Trial Is 92% of the Answer | This GLP A network meta-analysis put tirzepatide 15 mg 2.68 kg ahead of 5 mg at week 16 | one of its four trials contributes 91.8% of the 14,348 participants it pools. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Is Tirzepatide Better Than Dulaglutide? One Trial Is 92% of the Answer A four-trial network meta-analysis of 14,348 participants. One study supplies 13,165 of them. Every published difference is measured against tirzepatide 5 mg, not against dulaglutide. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 A four-trial network, by participant · Nicholls 2025 — 13,165 · the other three: 1,183 between them · 91.8% of the participants come from one study. · Every difference below is measured against tirzepatide 5 mg · TZP 15 mg −2.68 kg · TZP 1 mg +4.39 kg · DULA 0.75 mg +3.10 kg **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A network meta-analysis of four randomized trials, 14,348 participants in total. - One trial supplies 13,165 of them — 91.8% of the evidence. - Every published difference is measured against tirzepatide 5 mg, not against dulaglutide directly. - Tirzepatide 15 mg gave the largest weight and HbA1c reductions; nausea rose with dose. - No difference in all-cause mortality or major cardiovascular events between any treatment. On weight and HbA1c, yes, and the margin is dose-dependent. At week 16 tirzepatide 15 mg took off 2.68 kg more than tirzepatide 5 mg[\[1\]](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide#ref-1). Dulaglutide 0.75 mg took off 3.10 kg less. Four trials went into that network. One of them is almost all of it. ## Where the weight sits The headline number is 14,348 participants. Of those, 13,165 came from a single 2025 trial. The remaining three studies contributed 1,183 people between them. So this is one large trial with three small ones attached. That is not a criticism of the method. It describes what the method had to work with. It also limits a seven-node network, for the same reason [one famous trial and a whole evidence base](https://thisglp.com/research/glp1-in-children-all-eighteen-trials) give different answers. ## The results, with their reference arm Every difference is published against tirzepatide 5 mg. At week 16, tirzepatide 15 mg took off 2.68 kg more, 95% CI −4.98 to −0.38. Tirzepatide 1 mg took off 4.39 kg less and dulaglutide 0.75 mg 3.10 kg less. On HbA1c at week 24, tirzepatide 15 mg gave 0.40 points more reduction and 10 mg gave 0.23 more. Dulaglutide 1.5 mg came in at +0.67%, which reads as a worse reduction, not a better one. Drop the reference arm from any of those sentences and they stop meaning anything. The authors' own four cautions They list them plainly. Several comparisons are indirect. Many participants had not reached their maintenance dose. Several safety outcomes rest on limited event counts. Significant inconsistency was observed for the early body-weight outcomes. The dose one matters most for a reader. Comparing drugs before people reach the dose they settle on measures the titration schedule as much as the molecule. That is a different question from [what these drugs do at their maintenance doses](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). ## What did not differ All-cause mortality and major cardiovascular events showed no significant difference between any treatment in the network. With 446 fewer events than you would want, that null is uninformative rather than reassuring. The authors say as much when they flag limited event counts. A pooled figure built this way carries the same problem as [two poolings of the same trials disagreeing](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials). ## The head-to-head that does exist Dulaglutide is not the only comparator with a direct trial behind it. SURPASS-2 randomized adults with type 2 diabetes to tirzepatide or semaglutide 1 mg once weekly [\[2\]](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide#ref-2). That is a head-to-head, not an indirect estimate. It is also a different question. This site reads it in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). Nothing in it speaks to dulaglutide. ## The split the title promises The paper is titled for patients with and without established atherosclerotic cardiovascular disease. The abstract reports no such split. The full text may carry it. This page has read the abstract only. Anyone quoting this as evidence about the ASCVD subgroup is quoting something the abstract does not contain. ## What to take More tirzepatide does more, and costs more nausea. That is the finding, and it was not much in doubt. The dose-by-dose ranking is the new part. It is also the part resting on indirect comparisons and pre-maintenance doses. Read it as an ordering to test, not one to buy on. The same applies to [a pooled average almost nobody experienced](https://thisglp.com/research/glp1-weight-loss-pooled-average) is a summary rather than a forecast. ## Frequently asked Is tirzepatide better than dulaglutide? At higher doses it produced larger weight and HbA1c reductions in this network. Every comparison is against tirzepatide 5 mg rather than head to head, and several are indirect. Why does one trial matter so much here? It supplies 13,165 of the 14,348 participants, or 91.8%. The other three trials contribute 1,183 people between them, so the network is one large study with three small ones attached. Were there safety differences? No significant difference in all-cause mortality or major cardiovascular events. Gastrointestinal side effects rose with tirzepatide dose, particularly nausea at 15 mg. What does the paper say about established heart disease? Its title names that stratification, but the abstract reports no such split. Anyone citing it as evidence about that subgroup is citing something the abstract does not contain. ## Sources 1. \[1\] Hageen AW, et al. (2026). Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials Endocrinology, Diabetes & Metabolism. [PMID 42706739](https://pubmed.ncbi.nlm.nih.gov/42706739/) 2. \[2\] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine. [PMID 34170647](https://pubmed.ncbi.nlm.nih.gov/34170647/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Survodutide in MASH: How Much of the Liver Benefit Was Weight Loss | This GLP A mediation analysis of a phase 2 MASH trial found 77.4% of survodutide's liver fat effect ran through weight loss, against 36.3% for fibrosis improvement. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/liver-repair-that-was-not-the-weight Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Survodutide in MASH: How Much of the Liver Benefit Was Weight Loss A mediation analysis of a phase 2 survodutide trial split its liver effects in two. Roughly three quarters of the fat reduction tracked weight loss; only a third of the fibrosis improvement did. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 How much of the effect ran through weight loss · liver fat (FibroScan CAP) · 77.4% · MASH improvement · 71.8% · MASH resolution · 66.7% · liver fat (MRI) · 58.2% · fibrosis improvement · 36.3% · AST · 16.5% · Remainder is attributed to a direct drug effect. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A post hoc mediation analysis of a phase 2 MASH trial split survodutide's liver effects into a part running through weight loss and a part not. - Fat responded to weight: 77.4% and 58.2% of the effect on the two steatosis measures was weight-mediated. - Scarring largely did not: only 36.3% of the effect on fibrosis improvement, and 16.5% to 38.6% for the inflammation and fibrosis blood markers. - Mediation analysis apportions an effect using assumptions that cannot be checked against the data. Survodutide is investigational and not on sale. If a drug improves a fatty liver, the interesting question is whether it did anything the weight loss would not have done by itself. A post hoc analysis of a phase 2 trial in MASH tried to answer it directly, taking participants (n = 170) with stage F2 to F3 fibrosis and paired biopsies and apportioning each liver outcome between a weight-dependent and a weight-independent path [\[1\]](https://thisglp.com/research/liver-repair-that-was-not-the-weight#ref-1). The comparison between the marketed drugs on liver endpoints is in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). The pattern that emerged is cleaner than these analyses usually produce. Liver fat behaved like a weight problem: 77.4% of the effect on the FibroScan attenuation measure and 58.2% of the effect on MRI-measured fat fraction ran through weight reduction. So did most of the effect on MASH itself, at 66.7% for resolution and 71.8% for improvement. Fibrosis behaved differently. Only 36.3% of the effect on fibrosis improvement was attributed to weight, leaving the majority to a direct action of the drug. The blood markers pointed the same way, with weight mediating between 16.5% for AST and 38.6% for the Enhanced Liver Fibrosis score. The authors suggest glucagon receptor agonism as the route, which is what distinguishes survodutide from a pure GLP-1 drug, and places it among the multi-receptor agents surveyed in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). A mediation percentage is a model output This kind of analysis divides an observed effect between two paths by assuming, among other things, that nothing unmeasured causes both the weight change and the liver change. That assumption cannot be tested against the data it is applied to. "66.7% mediated by weight reduction" is therefore a statement about a model, not a measurement anyone made, and a different set of covariates would produce a different split. Three further limits keep this in proportion. It is post hoc, so the questions were chosen after the results were known. It pools the dose arms, discarding the dose-response information that is the main output of a phase 2 trial. And 170 participants with biopsies at both ends is a small number on which to divide six separate effects in two. Survodutide is investigational and cannot be bought, so nothing here is a recommendation about anything currently available. What it contributes is a mechanistic claim worth testing properly: that in the liver, the fat and the scarring may respond to different things, and a drug that only removes weight may do less for the second. That would matter for the marketed drugs too, whose liver results are usually reported without this separation — as are their effects on body composition generally, covered in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1) and in [the pooled weight figures](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## Frequently asked Does this mean the drug helps the liver beyond weight loss? It suggests so for scarring specifically, where only 36.3% of the effect was attributed to weight. But a mediation analysis apportions effects using assumptions that cannot be verified, so this is a hypothesis with numbers attached. Can I get survodutide? No. It is investigational and not approved or on sale anywhere as of this writing. Why did liver fat and fibrosis behave differently? The authors propose direct glucagon receptor agonism, which survodutide has and pure GLP-1 drugs do not. That would act on the liver independently of how much weight someone loses. ## Sources 1. \[1\] Noureddin M, Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2026). Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH Hepatology. [PMID 42545725](https://pubmed.ncbi.nlm.nih.gov/42545725/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide and Effort in Major Depression: A 72-Person Randomized Trial A randomized trial in 72 adults with major depressive disorder found semaglutide reduced effort discounting on a reward task (β = -1.737, P = .03), with no change in probability sensitivity. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/motivation-in-depression-a-secondary-finding Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Semaglutide and Effort in Major Depression: A 72-Person Randomized Trial In adults with major depression, semaglutide made people more willing to work for larger rewards. The outcome was a laboratory effort task, not a depression score. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Two parameters, one model · sensitivity to effort · β = −1.737, P = .03 · the perceived cost of trying, reduced · sensitivity to probability · β = −0.776, P = .51 · how likely the reward is, unchanged **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - In a 16-week double-blind trial, 72 adults with major depressive disorder and a BMI of 25 or above were randomized to oral semaglutide 14 mg or placebo, added to their usual treatment. - The preregistered outcome was a laboratory task measuring willingness to work harder for larger rewards — not a depression rating scale. - Participants on semaglutide showed more willingness to exert effort as reward value rose (P = .02), attributed by modeling to reduced effort discounting (β = -1.737, P = .03). - Sensitivity to the probability of reward was unchanged (β = -0.776, P = .51), which is what makes the effort finding interpretable rather than general. Anhedonia — the loss of drive rather than the presence of sadness — is the part of depression that responds worst to existing drugs. A randomized trial at a Toronto mood disorders unit tested whether semaglutide changes it, in 72 adults with major depressive disorder and a BMI of 25 or above, randomized to oral semaglutide 14 mg or placebo alongside whatever treatment they were already on [\[1\]](https://thisglp.com/research/motivation-in-depression-a-secondary-finding#ref-1). The observational literature on these drugs and mood is messier, as [depression risk against two comparators](https://thisglp.com/research/glp1-depression-depends-on-comparator) shows. The measure was the Effort-Expenditure for Rewards Task, in which people repeatedly choose between an easy option for a small payout and a hard one for a larger payout at some stated probability. Participants on semaglutide became more willing to take the hard option as the expected value rose, with a treatment by visit by expected value interaction reaching P = .02. Computational modeling then split that into parts, and this is where the result becomes interesting rather than merely positive. Sensitivity to effort fell significantly on semaglutide (β = -1.737, P = .03), meaning the cost of trying felt lower. Sensitivity to probability did not move (β = -0.776, P = .51). A drug that simply made people press more buttons, or feel generally better, would be expected to shift both. Nobody measured depression here The outcome is a button-pressing task, and it is a proxy for motivation. This analysis reports no depression scores, no remission rates and nothing about how participants felt. Whether a change in effort discounting on a laboratory task translates into a person getting out of bed, returning to work, or feeling better is exactly the step that has defeated many promising psychiatric findings. The scale deserves equal weight. Seventy-two people at one center, split 35 and 37, with the result coming from a secondary analysis — preregistered, which matters a great deal, but still one task in one small trial. The journal's title calls it a randomized clinical trial and the abstract calls it a secondary analysis; both are accurate and the second is the one that should govern how much is built on it. What makes it worth reporting anyway is that it is a mechanism claim with a null attached, tested prospectively against placebo, in a population where the drug was not being given for weight. That is a rarer thing in this field than the volume of publication suggests, and it sits alongside the other evidence that these drugs act on reward circuitry rather than only on the stomach — the appetite side of which is in [nausea and appetite on one circuit](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea), and the substance-use side in [what happens when you stop](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it) and [the overdose comparison](https://thisglp.com/research/overdose-depends-on-the-comparator). ## Frequently asked Does semaglutide treat depression? This trial does not show that. It measured performance on a laboratory effort-and-reward task and reported no depression scores or remission rates at all. What did it actually find? Participants on semaglutide were more willing to work harder for larger rewards, and modeling attributed this to a reduced perceived cost of effort rather than to any change in how they judged the odds of being paid. How big was the trial? Seventy-two participants at a single center, 35 on semaglutide and 37 on placebo, over 16 weeks. The finding comes from a preregistered secondary analysis. ## Sources 1. \[1\] Gill H, Badulescu S, Shah H, Brudner RM, et al. (2026). Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial JAMA Psychiatry. [PMID 42054055](https://pubmed.ncbi.nlm.nih.gov/42054055/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide Lean Mass in the SMART Trial: −2.5 kg, Interval Crossing Zero A prespecified SMART trial analysis measured lean and fat mass on semaglutide in 101 adults: a −2.5 kg lean-mass change whose interval crosses zero, and why lean mass is not muscle. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/muscle-loss-on-glp1 Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # Semaglutide Lean Mass in the SMART Trial: −2.5 kg, Interval Crossing Zero In a prespecified SMART trial analysis, the lean-mass change on semaglutide was −2.5 kg with a confidence interval that crosses zero. Lean mass is also not the same thing as muscle. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Total change, 24 weeks · Split: fat, then lean · The interval on the lean estimate crosses zero. · n=101, twenty-four weeks, chronic kidney disease. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Weight loss of any kind takes some lean tissue with the fat. The question that matters is whether these drugs take more than a diet producing the same loss would, and the published record is thinner and less certain than the confidence of the argument around it suggests. ## The best-controlled figures available A prespecified analysis of the SMART trial measured body composition by bioimpedance spectroscopy in 101 adults with chronic kidney disease, overweight or obesity and no type 2 diabetes, randomized to semaglutide 2.4 mg weekly or placebo for 24 weeks. Against placebo, semaglutide changed total body weight by −9.1 kg (95% CI −11.0 to −7.2), lean body mass by −2.5 kg (95% CI −6.6 to 1.6) and fat mass by −3.9 kg (95% CI −7.8 to 0.0)[\[1\]](https://thisglp.com/research/muscle-loss-on-glp1#ref-1). Read the intervals rather than the point estimates. The lean mass interval runs from −6.6 to +1.6 kg, which includes no change at all, and the fat mass interval reaches zero at its upper end. The study is small, it is short, and its population has kidney disease. It is the most carefully controlled measurement available and it does not settle the question. A reader who has seen a confident figure for how much muscle these drugs cost has seen something the data does not support. ## What the large trials measured instead STEP 1 randomized 1,961 adults and reported a mean weight change of −14.9% against −2.4% on placebo over 68 weeks [\[2\]](https://thisglp.com/research/muscle-loss-on-glp1#ref-2). Body composition was not a coprimary endpoint, and the trial’s reported outcomes are weight, weight-loss thresholds and cardiometabolic risk factors. The same holds for the [withdrawal extension](https://thisglp.com/research/stopping-glp1-and-weight-regain), which followed weight and cardiometabolic variables after the drug stopped and did not report what happened to lean tissue. An observational analysis of tirzepatide published in 2026 reports body weight and body composition changes in adults with overweight and obesity [\[3\]](https://thisglp.com/research/muscle-loss-on-glp1#ref-3). It is not randomized, so it describes what happened to the people it followed rather than what the drug caused. ## Why the question is hard to answer at all Lean body mass is not muscle. Bioimpedance and dual-energy absorptiometry both measure fat-free tissue, which includes water, glycogen and organ mass. Semaglutide reduced extracellular water by 0.9 L (95% CI −1.6 to −0.1) in the same SMART analysis[\[1\]](https://thisglp.com/research/muscle-loss-on-glp1#ref-1). Some of what a scan records as lost lean mass is fluid, and no bedside method separates the two. The second difficulty is the comparator. Any intervention producing a 9 kg loss takes lean tissue with it, so the honest question is whether these drugs take a larger share than an equivalent loss by other means. Answering that needs a trial designed around it, and the trials were designed around weight. The same design gap runs through the [escalation data](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), where the reported outcomes are the ones the protocol happened to collect. ## What follows from that Nothing here supports a claim that these drugs spare muscle, and nothing here supports a claim that they destroy it. What it supports is measuring: resistance training and protein intake are the standard advice for preserving lean tissue during any weight loss, and they are advice a prescriber gives rather than a product a seller sells. Whether a service includes that kind of support, or sells medication alone, is recorded per seller in the [bundled-care reviews](https://thisglp.com/reviews/nextmeds) and across the [full set](https://thisglp.com/reviews). What none of them can offer is a figure for how much muscle you will lose, because that figure has not been established. ## Frequently asked How much muscle do these drugs cost? No figure is established. The best-controlled measurement reported a lean mass change of −2.5 kg against placebo with a 95% confidence interval of −6.6 to 1.6 kg, which includes no change. Is lean body mass the same as muscle? No. It is fat-free tissue, which includes water, glycogen and organ mass. The same analysis found extracellular water fell by 0.9 L, and no bedside method separates that from muscle. Do these drugs take more lean tissue than dieting? That comparison has not been made in a trial designed to answer it. Any weight loss takes some lean tissue, and the published trials were designed around weight rather than composition. ## Sources 1. \[1\] Heerspink HJL, Soler M, Beernink JM, et al. (2026). Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial Clinical Journal of the American Society of Nephrology. [PMID 42308057](https://pubmed.ncbi.nlm.nih.gov/42308057/) 2. \[2\] Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/) 3. \[3\] Corso H, Graybeal AJ, Hoelscher E, et al. (2026). Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity Frontiers in Endocrinology. [PMID 42488012](https://pubmed.ncbi.nlm.nih.gov/42488012/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # VK2735 Phase 2 VENTURE Trial: 14.7% Weight Loss in 13 Weeks | This GLP In the 13-week VENTURE phase 2 trial, weight fell 9.1% to 14.7% on VK2735 against 1.7% on placebo, and 93% of treated participants lost at least 5% | why a 13-week figure is not a 68-week one. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/ninety-three-percent-in-thirteen-weeks Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # VK2735 Phase 2 VENTURE Trial: 14.7% Weight Loss in 13 Weeks The GIP and GLP-1 dual agonist VK2735 took off up to 14.7% of body weight in a 13-week phase 2 trial. The approved drugs report figures from trials of 68 weeks or longer. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Weight change at week 13 — not week 68 · 15 mg · −14.7% · 2.5 mg · −9.1% · placebo · −1.7% · 93% of treated participants lost at least 5%. · 174 people, one quarter of a year, phase 2. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - VENTURE was a 13-week phase 2 dose-ranging trial of weekly injected VK2735, another GIP and GLP-1 dual agonist, in adults with obesity or overweight and at least one comorbidity. - Weight fell 9.2 kg (9.1%) at 2.5 mg and 14.6 kg (14.7%) at 15 mg, against 1.8 kg (1.7%) on placebo. - At least 5% of body weight was lost by 93% of treated participants (130 of 140) against 12% on placebo (4 of 34). - Gastrointestinal events were the common adverse events and became less frequent after titration reached steady state. Read the timeline before the numbers. This trial ran 13 weeks [\[1\]](https://thisglp.com/research/ninety-three-percent-in-thirteen-weeks#ref-1). Every approved drug figure on this site — the ones in [the pooled weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average) — comes from trials of 68 weeks or longer. A 14.7% result at three months and a 15% result at sixteen months are not the same claim, and setting them side by side is the single easiest way to mislead a reader about a pipeline drug. With that established, the numbers are striking. Weight fell 9.2 kg at the 2.5 mg dose and 14.6 kg at 15 mg, against 1.8 kg on placebo. In proportional terms that is 9.1% and 14.7% against 1.7%. Losing at least 5% of body weight was achieved by 130 of 140 treated participants — 93% — against 4 of 34 on placebo. A 93% response rate in 174 people is a phase 2 finding Dose-ranging trials are designed to find which doses do something, not to establish how much. The arms here are small, the population excluded anyone with diabetes, and a quarter of a year is short enough that the weight curve on every drug in this class is still steep. What VENTURE establishes is that all tested doses work; what it cannot establish is where any of them land. VK2735 pairs GLP-1 with GIP, the same combination as tirzepatide, which makes it a competitor rather than a new mechanism. That distinguishes it from the glucagon pairing this site covered in [the survodutide phase 3 result](https://thisglp.com/research/survodutide-synchronize-1) and from the amylin pairing in CagriSema. The pipeline is now several molecules deep on each of three mechanisms. On tolerability, the adverse events were predominantly gastrointestinal and their reported frequency fell once titration reached steady state. That pattern — worst during escalation, better after — recurs across this class and is the reason dose ladders exist, as this site set out in [what titration does to the nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). None of this is purchasable. VK2735 completed a phase 2 study and has no approval anywhere. The reason to record it is that the pipeline determines what the market looks like in three years, and a drug that clears phase 2 cleanly is the kind that eventually changes what the approved options cost — the pipeline this site tracks in [what is not for sale](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). ## Frequently asked Is 14.7% comparable to what semaglutide or tirzepatide achieve? No. This trial ran 13 weeks; the approved-drug figures come from trials of 68 weeks or more. The curves are still steep at three months in every drug in this class. How many people were in the trial? 174 — 140 across the active dose arms and 34 on placebo. It was a phase 2 dose-ranging study, and people with diabetes were not eligible. Can I buy VK2735? No. It has completed a phase 2 study and is not approved or sold anywhere. ## Sources 1. \[1\] Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J (2026). Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Obesity. [PMID 41508550](https://pubmed.ncbi.nlm.nih.gov/41508550/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Respiratory Side Effects of Weight-Loss Drugs: A Review of 123 Studies | This GLP A systematic review and meta-analysis of 123 studies found no increase in respiratory adverse events on weight-loss drugs | 122 were in general populations and one in people with asthma. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/one-asthma-study-in-a-hundred-and-twenty-three Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Respiratory Side Effects of Weight-Loss Drugs: A Review of 123 Studies A meta-analysis of 123 studies found no excess respiratory adverse events on weight-loss drugs. One of those studies was conducted in people with asthma. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 123 studies included · One study was conducted in people with asthma. · The review exists because obesity and asthma coexist. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A systematic review screened 9,086 records and included 123 studies of respiratory adverse events on weight-loss drugs. - Liraglutide, semaglutide, tirzepatide and naltrexone-bupropion showed no increase in respiratory adverse events against placebo, with the randomized trials at low risk of bias. - Of the 123 studies, 122 were in general populations and one was specifically in people with asthma. - Data were insufficient to assess orlistat, phentermine-topiramate and setmelanotide, which means unmeasured rather than cleared. Obesity and asthma occur together often, each makes the other worse, and losing weight improves asthma outcomes. That is the stated reason this review was conducted, and the exacerbation evidence on the efficacy side is in [a ratio of 0.438, a difference of 2.2 points](https://thisglp.com/research/glp1-asthma-relative-and-absolute). The safety question is separate: do these drugs themselves cause breathing problems[\[1\]](https://thisglp.com/research/one-asthma-study-in-a-hundred-and-twenty-three#ref-1). The answer is no, as far as the data goes. Across 123 studies, liraglutide, semaglutide, tirzepatide and naltrexone-bupropion were not associated with increased respiratory adverse events compared with placebo, and the randomized trials contributing carried a low risk of bias. For a class taken by tens of millions of people, that is a useful null. One hundred and twenty-two of the studies were not about asthma Of the 123 included studies, 122 evaluated general populations and exactly one evaluated people with asthma — in a review whose entire premise is that obesity and asthma coexist and compound each other. So the reassurance applies to people who mostly did not have the condition the question was asked about, and the specific worry — that a drug might worsen breathing in someone whose breathing is already compromised — is addressed by a single study. What counts as a respiratory adverse event in a weight-loss trial is worth knowing too. These are dominated by upper respiratory tract infections, which is to say colds. A null result on that measure says these drugs do not make people catch more colds. It is a weaker statement than “these drugs do not affect the lungs”, and the two will be reported as the same thing. Three drugs could not be assessed at all. Insufficient data limited comparisons for orlistat, phentermine-topiramate and setmelanotide, which means they are unmeasured rather than cleared — a distinction that matters given phentermine-topiramate’s position in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated), where it ranked among both the more effective and the less tolerated. For anyone with asthma weighing one of these drugs, the practical position is that nothing suggests harm and almost nothing has been measured in people like them. That is a common shape in this literature, and it recurs in [the COPD flare-up comparisons](https://thisglp.com/research/do-glp1-drugs-help-copd) and [the analysis in older adults](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults), where the population studied and the population asking are not the same people. ## Frequently asked Do these drugs cause breathing problems? No increase in respiratory adverse events appeared for liraglutide, semaglutide, tirzepatide or naltrexone-bupropion across 123 studies, with the randomized trials at low risk of bias. Does that reassurance cover people with asthma? Barely. Of the 123 included studies, 122 evaluated general populations and one evaluated people with asthma specifically. What about other weight-loss drugs? Orlistat, phentermine-topiramate and setmelanotide could not be assessed because the data were insufficient, which means unmeasured rather than shown to be safe. ## Sources 1. \[1\] Zeng L, Zinmon-Htet C, Hundie T, Lin S, et al. (2026). Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis Annals of the American Thoracic Society. [PMID 42479131](https://pubmed.ncbi.nlm.nih.gov/42479131/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Oral Semaglutide vs DPP-4 Inhibitors and Cognitive Impairment in HFpEF | This GLP In 246 elderly HFpEF patients with obesity and type 2 diabetes, 33 new cases of cognitive impairment on oral semaglutide against 73 on DPP-4 inhibitors, a result a larger US study did not reproduce. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/oral-semaglutide-cognitive-impairment Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Oral Semaglutide vs DPP-4 Inhibitors and Cognitive Impairment in HFpEF In 246 elderly patients with heart failure, obesity and type 2 diabetes, new cognitive impairment was 77% lower on oral semaglutide. A 13,007-patient study of the same comparison found no difference. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 New cognitive impairment over one year · oral semaglutide · 33 cases · 26.8 per 100 patient-years · DPP-4 inhibitor · 73 cases · 59.3 per 100 patient-years · 106 of 246 people, in twelve months. p < 0.0001. · A larger study of the same comparison found no difference. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 246 elderly outpatients with heart failure, obesity and type 2 diabetes, on oral semaglutide or a DPP-4 inhibitor. - Over one year, 106 developed cognitive impairment — 33 on semaglutide against 73 on the comparator, p < 0.0001. - A logistic regression put the reduction at 77%. No confidence interval is published in the abstract. - That is 43.1 new cases per 100 patients per year across the whole cohort. - A larger study of the same drug against sitagliptin, also a DPP-4 inhibitor, found no significant difference. This is the largest effect on cognition anybody has reported for these drugs, and it points the opposite way from the other study in this section that ran the same comparison. Both cannot be describing the same reality, and working out why is more useful than either number. ## What this study found Elderly outpatients with heart failure with preserved ejection fraction, obesity and type 2 diabetes were given oral semaglutide or a DPP-4 inhibitor as an add-on, matched on age, sex and body mass index, and followed a year. [\[1\]](https://thisglp.com/research/oral-semaglutide-cognitive-impairment#ref-1) New cognitive impairment appeared in 33 of the semaglutide group and 73 of the comparator group, p < 0.0001, which a logistic regression rendered as a 77% lower risk. The abstract publishes that 77% without a confidence interval, so how precisely it is estimated cannot be read off the record. The other study, and what separates them A US study of 13,007 patients compared semaglutide against sitagliptin — a DPP-4 inhibitor — and found [no significant difference on cognitive signs](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs). The comparison is the same; almost nothing else is. That study scored signs recorded in routine notes across a psychiatric population; this one counted formally incident cognitive impairment in a cardiology clinic. Different outcome, different ascertainment, different patients — and a 77% reduction against a null is too large a gap for both to be measuring one thing. ## The incidence is the tell 106 new cases among 246 people in twelve months, or 43.1 per 100 patients per year. Nearly half the cohort acquired a cognitive impairment diagnosis inside a year. That is far above what a general elderly population would produce, which means either the population was already close to the threshold or the threshold was set low. Neither is wrong — a cardiology clinic full of elderly patients with heart failure, obesity and diabetes is a high-risk group — but it does mean the outcome being counted here is not the outcome most readers picture, in the same way [an entry criterion set locally](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) changes what a trial is about. ## What the matching covers Age, sex and body mass index. Those are the three variables the abstract names. The strongest predictors of a new cognitive impairment diagnosis are baseline cognition and education, and neither appears in that list. In a non-randomized comparison where a clinician chose who got which drug, that gap matters — it is the same structural weakness as every [real-world comparison assembled after the fact](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## How to hold both results As an open question, not a settled benefit. One study found a very large effect in a small, high-risk, narrowly matched cohort; a much larger one found nothing against the closest available comparator. Nobody is selling these drugs for cognition and nothing here is a reason to buy one. What the pair demonstrates is that a single striking percentage is worth very little until somebody has asked what else was published on the same question — the habit [reading any body of literature](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials) requires. ## Frequently asked Does semaglutide protect against cognitive decline? This study found 33 new cases against 73 over a year, a 77% lower risk. A much larger study comparing semaglutide with sitagliptin found no significant difference, so the question is open. Why is the incidence so high? 106 cases among 246 people in a year is 43.1 per 100 patient-years. That reflects a high-risk cardiology population, a low diagnostic threshold, or both. How precise is the 77%? Unknown from the published abstract, which reports the point estimate from a logistic regression without a confidence interval. Were the groups comparable? They were matched on age, sex and body mass index. Baseline cognition and education — the strongest predictors of a new diagnosis — are not among the matching variables named. ## Sources 1. \[1\] Armentaro G, et al. (2026). Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity Internal and Emergency Medicine. [PMID 42622752](https://pubmed.ncbi.nlm.nih.gov/42622752/) ## Where to get it ### Oral GLP-1, ranked Tablets, troches and capsules priced on the oral product itself — never on a number borrowed from the same seller's injection page. [Compare providers →](https://thisglp.com/best/oral-glp1) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Oral Semaglutide 50 mg in East Asian Adults: 14.3% Weight Loss | This GLP What the 50 mg oral semaglutide trial in 201 East Asian adults found (14.3% against 1.3% on placebo), the conditions the headline drops, and why a storefront's 'oral semaglutide' is probably not this. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/oral-semaglutide-fifty-milligrams Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Oral Semaglutide 50 mg in East Asian Adults: 14.3% Weight Loss A 50 mg tablet produced a 14.3% mean weight reduction against 1.3% on placebo in 201 East Asian adults starting at 91.9 kg, at a dose several times the oral semaglutide already on the market. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Weight change, 201 East Asian adults · 50 mg daily · 14.3% · placebo · 1.3% · Mean starting weight 91.9 kg, not the 113 kg of the big trials. · A percentage of a different number is a different thing. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Oral semaglutide at 50 mg daily produced a mean weight reduction of 14.3% against 1.3% on placebo, in 201 East Asian adults with overweight or obesity. - 84.3% of the treated group lost at least 5% of their body weight, against 17.2% on placebo. - Mean starting weight was 91.9 kg — well below the 113 kg of the large Western trials — so the percentages come off a different base. - Gastrointestinal adverse events affected 63.4% of the drug arm, and 4.5% stopped because of adverse events. - ⛔ 50 mg daily is not the oral semaglutide sold for diabetes at 7 or 14 mg, and almost certainly not what a storefront means by 'oral semaglutide'. A tablet that works as well as an injection is the thing most readers actually want, and this is one of the trials that decides whether it exists. The answer is encouraging and comes with three conditions attached, all of which get dropped when the headline travels — the same fate as the trial figures collected in [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review). ## What was tested Two hundred and one adults with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to oral semaglutide 50 mg daily or placebo [\[1\]](https://thisglp.com/research/oral-semaglutide-fifty-milligrams#ref-1). Mean age was 49, 43.3% were female, a quarter had type 2 diabetes, and mean body weight was 91.9 kg. ## What it found Mean weight change was −14.3% on the drug against −1.3% on placebo, an estimated treatment difference of 13.07 percentage points (95% CI −15.61 to −10.52). More of the treated group reached a 5% reduction: 84.3% against 17.2%, an odds ratio of 23.00. Gastrointestinal adverse events were reported by 63.4% of the semaglutide arm against 34.8% on placebo, and adverse events led 4.5% of the treated group to discontinue. That discontinuation figure is lower than the injectable trials generally report, though with 134 people on the drug it is not a precise estimate. Three conditions the headline drops The trial enrolled East Asian adults with a mean starting weight of 91.9 kg. The large Western obesity trials started around 113 kg. A percentage taken off a smaller number is not the same quantity, and setting −14.3% beside a STEP or SURMOUNT figure compares populations as much as drugs. It is also a small trial by this field’s standards — 201 randomized, 134 on the drug — and the dose is 50 mg daily, which is several times the 7 or 14 mg oral semaglutide approved for type 2 diabetes. ## The part that matters on a storefront That last condition is the one with commercial consequences. A seller offering “oral semaglutide” is almost certainly not offering 50 mg daily of the product this trial used, and in the compounded market the milligram is frequently not published at all — the silence counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). A reader who has seen this result and gone looking for a tablet may be sold something at an unstated fraction of the dose, with no way to tell from the page. What an oral formulation does and does not deliver is covered in [what the pill actually does](https://thisglp.com/research/oral-semaglutide-what-the-pill-does), and the chemically different small-molecule tablet now in trials is a separate matter again, covered in [orforglipron, a pill without a needle](https://thisglp.com/research/what-is-orforglipron). ## What it establishes That a peptide tablet at a high enough dose can produce double-digit weight reduction in a randomized trial. That is a real advance and it is worth stating plainly. What it does not establish is that any particular tablet a reader can buy will do it, which depends entirely on a dose most sellers decline to name. ## Frequently asked How much weight did the tablet produce? A mean of 14.3% against 1.3% on placebo, with 84.3% of the treated group losing at least 5% of their body weight. Is that comparable to the injection trials? Not directly. This trial enrolled East Asian adults starting at a mean of 91.9 kg, against roughly 113 kg in the large Western trials, so the percentages come off a different base. Is this the oral semaglutide sold online? Almost certainly not. The trial used 50 mg daily, several times the 7 or 14 mg approved for type 2 diabetes, and compounded sellers frequently do not publish a milligram at all. ## Sources 1. \[1\] Kadowaki T, et al. (2025). Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial JAMA Internal Medicine. [PMID 40758358](https://pubmed.ncbi.nlm.nih.gov/40758358/) ## Where to get it ### Oral GLP-1, ranked Tablets, troches and capsules priced on the oral product itself — never on a number borrowed from the same seller's injection page. [Compare providers →](https://thisglp.com/best/oral-glp1) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Oral Semaglutide 25 mg: OASIS 4 Trial Results at 71 Weeks | This GLP OASIS 4 tested oral semaglutide 25 mg for 71 weeks: −13.6% body weight against −2.2% on placebo, with GI adverse events in 74% versus 42%. Compounded oral products are a different thing. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/oral-semaglutide-what-the-pill-does Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Formats # Oral Semaglutide 25 mg: OASIS 4 Trial Results at 71 Weeks A 71-week randomized trial put the 25 mg tablet at −13.6% body weight against −2.2% on placebo. Three quarters of the treated group had gastrointestinal side effects, and compounded orals are not this product. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Mean body-weight change at week 64 · Oral semaglutide 25 mg · −13.6% · Placebo · −2.2% · Gastrointestinal adverse events · 74.0% on drug · 42.2% on placebo **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). A pill that works as well as an injection is the thing most readers want to exist, and the trial evidence now goes some way toward it. OASIS 4 randomized 307 adults with overweight or obesity and no diabetes, two to one, to oral semaglutide 25 mg once daily or placebo for 71 weeks [\[1\]](https://thisglp.com/research/oral-semaglutide-what-the-pill-does#ref-1). The result is real and the caveats are specific, and both matter before you compare [what any seller lists as an oral](https://thisglp.com/tools/molecule-and-format-finder). ## The result Estimated mean change in body weight from baseline to week 64 was −13.6 percent with oral semaglutide and −2.2 percent with placebo, an estimated difference of 11.4 percentage points (95% CI −13.9 to −9.0, P < 0.001). Participants on the drug were significantly more likely to reach reductions of 5, 10, 15 and 20 percent or more, and to report improved physical function on the IWQOL-Lite-CT scale. Set against the pooled injectable figure of about −10.7 percent from [the Cochrane review](https://thisglp.com/research/semaglutide-cochrane-review), this is not a lesser product. It is a different trial in a different population, so the two numbers should not be subtracted from one another, but the pill is clearly in the same range. ## The gastrointestinal cost Gastrointestinal adverse events occurred in 74.0 percent of the oral semaglutide group against 42.2 percent on placebo. That is a high rate in absolute terms and a wide gap against placebo, and it is the number most likely to describe your first three months. What the trial reports is frequency, not severity; the practical shape of it is covered in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## What you are buying is probably not this This is the part a seller’s page will not make clear. OASIS 4 tested a specific manufactured 25 mg tablet. Most oral semaglutide sold through telehealth is compounded — a sublingual drop or a dissolving tablet prepared by a pharmacy, often at a dose the seller does not publish. The FDA does not review a compounded preparation before it is dispensed, and no compounded oral product has been through a trial like this one. Two practical consequences. An oral price cannot be set against an injection price as though the milligrams meant the same thing. And a seller that publishes no dose beside an oral figure has published a number you cannot interpret at all — which is common enough that we counted it across the market in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## What the trial does not settle Three hundred and seven participants is a small trial by the standards of this drug class, it ran 71 weeks, and it was funded by the manufacturer. It says nothing about what happens after stopping, and nothing about compounded preparations at all. ## Frequently asked Does the pill work as well as the injection? In its own trial, oral semaglutide 25 mg produced −13.6 percent body weight against −2.2 on placebo over 64 weeks. That is in the same range as pooled injectable figures, though the trials are not directly comparable. Is the oral semaglutide I can buy the same thing? Usually not. The trial tested a manufactured 25 mg tablet. Most oral semaglutide sold through telehealth is compounded, often at a dose the seller does not publish, and no compounded oral has been tested this way. How common were side effects? Gastrointestinal adverse events occurred in 74.0 percent of the treated group against 42.2 percent on placebo. ## Sources 1. \[1\] Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 40934115](https://pubmed.ncbi.nlm.nih.gov/40934115/) ## Where to get it ### Oral GLP-1, ranked Tablets, troches and capsules priced on the oral product itself — never on a number borrowed from the same seller's injection page. [Compare providers →](https://thisglp.com/best/oral-glp1) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # GLP-1 Drugs and Overdose Risk: Five Comparators in VA Data | This GLP A VA target trial emulation found lower drug overdose risk on GLP-1 drugs against insulin (HR 0.32) and SGLT2 inhibitors, but not against metformin, sulfonylureas or DPP4 inhibitors. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/overdose-depends-on-the-comparator Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs and Overdose Risk: Five Comparators in VA Data The same GLP-1 drugs, the same veterans' database, the same twelve months, and five comparison groups that do not agree. One estimate points the other way. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Same drug, five comparison groups · 1.0 · vs insulin · vs SGLT2 · vs metformin · vs sulfonylurea · vs DPP4 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Veterans with type 2 diabetes and opioid use disorder were followed for 12 months after starting a GLP-1 drug or a comparison diabetes medication. - Against insulin, overdose risk was lower (HR 0.32, 95% CI 0.14-0.71). Against SGLT2 inhibitors, also lower (HR 0.25, 95% CI 0.09-0.68). - Against metformin (0.75), sulfonylureas (0.82) and DPP4 inhibitors (1.20), there was no significant difference — and the DPP4 estimate points the other way. - Insulin users are the sickest group in any diabetes cohort, so the two comparisons that worked are the two most vulnerable to confounding. Preclinical work suggested GLP-1 drugs might reduce opioid craving, and observational studies have reported fewer overdoses. A target trial emulation in Veterans Health Administration data tested it again in people carrying both type 2 diabetes and opioid use disorder, who started semaglutide or tirzepatide against one of five other diabetes medications between 2020 and 2024 [\[1\]](https://thisglp.com/research/overdose-depends-on-the-comparator#ref-1). The trial evidence in this area is covered separately in [the alcohol trials](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use), which asked a related question with a randomized design. Against insulin, the hazard ratio for all-cause overdose over 12 months was 0.32 (95% CI 0.14–0.71). Against SGLT2 inhibitors it was 0.25 (95% CI 0.09–0.68). Both are large reductions and both are statistically significant. Against the other three comparators, nothing. Metformin gave 0.75 (95% CI 0.38–1.45), sulfonylureas 0.82 (95% CI 0.33–1.96), and DPP4 inhibitors 1.20 (95% CI 0.52–2.78), an estimate that sits on the wrong side of 1 entirely. Same drug, same outcome, same database, same 12 months. Which comparison a study picks decides what it finds Insulin is what people get when other drugs have failed or their diabetes is advanced, so insulin users are sicker on average than anyone else in a diabetes cohort. SGLT2 inhibitors sit closer to the middle. The two comparisons where the GLP-1 arm won are the two where the comparison group had most reason to fare badly for reasons unrelated to overdose, and propensity matching on recorded variables does not fix that. The intervals themselves say something worth noticing. An interval running from 0.09 to 0.68 is not a precise estimate; it is a small number of rare events in a matched set of a few hundred people. Overdose is uncommon even in this population, and the width of every interval in the study reflects that. The authors conclude by calling for randomized controlled trials, which is the correct reading of their own result, and puts them in the same position as the team in [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease) who published a dramatic number and then told readers not to believe it. None of this makes the hypothesis wrong. A real effect on craving could plausibly show up first against the comparators with the most room to move, and two of five estimates landing below 1 with three inconclusive is not evidence of absence. It is evidence that the question is still open, and that a headline built from the insulin comparison alone would be describing a choice of control group rather than a property of the drug. The same reasoning applies whenever a study picks its own comparator, as in [the tirzepatide network comparison](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide) and in [the carpal tunnel cohort](https://thisglp.com/research/do-glp1-drugs-help-carpal-tunnel-syndrome), where two comparison groups gave two different answers about the same drug. ## Frequently asked Do GLP-1 drugs reduce overdose risk? This study cannot settle that. Risk was lower against insulin and SGLT2 inhibitors but not against metformin, sulfonylureas or DPP4 inhibitors, and the authors call for randomized trials. Why does the comparison drug matter so much? Insulin is prescribed when diabetes is advanced or other drugs have failed, so insulin users are sicker on average. A comparison group with more underlying risk makes any drug look better. Were these large studies? No. The matched sets ranged from a few hundred to about a thousand people and overdose is rare, which is why the confidence intervals are wide — one runs from 0.09 to 0.68. ## Sources 1. \[1\] Kennedy KP, Bremseth-Vining R, Lynch KG, Reville N, et al. (2026). GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder The Journal of Clinical Psychiatry. [PMID 42474323](https://pubmed.ncbi.nlm.nih.gov/42474323/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Ozempic Teeth: What Has Actually Been Measured, and What Has Not | This GLP Dry mouth is the oral effect most consistently reported with semaglutide, alongside taste change, reflux and caries. No study pools a prevalence, and no trial has counted cavities. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/ozempic-teeth Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Ozempic Teeth: What Has Actually Been Measured, and What Has Not Dry mouth, altered taste, reflux and more cavities are all reported. No study reports a rate, and the route to damaged teeth runs through dryness and acid rather than the drug itself. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read What the literature contains · dry mouth · taste change · reflux · more cavities · a measured rate · Reported is not the same as common. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Dry mouth is the oral effect most consistently reported with semaglutide, across reviews and adverse-event reporting systems. - Altered taste, reflux, dry throat, bad breath and more dental caries also appear in the literature. - No study reports a prevalence. Three narrative reviews describe these effects; none pools a rate, and no randomized trial has counted cavities. - The likely route to tooth damage is indirect — dry mouth and reflux — which is what makes it something a dentist can act on. “Ozempic teeth” is not a diagnosis, and no trial has measured it. What exists is a set of oral effects reported consistently enough to take seriously, with no study yet attaching a rate to any of them. That is a different kind of gap from the one in [the pooled serious adverse events](https://thisglp.com/research/which-glp1-has-the-worst-side-effects), where the trials counted and the total was small. ## What is actually reported A narrative review of semaglutide and the mouth drew on clinical trials, pharmacovigilance analyses, observational studies, case reports and laboratory work [\[1\]](https://thisglp.com/research/ozempic-teeth#ref-1). Dry mouth — xerostomia or hyposalivation — is the effect it found reported most consistently. The review states that rates vary across studies and does not combine them. That is the same unpooled shape this site described in [two meta-analyses built on the same six trials](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials). Alongside dry mouth it lists altered taste, dry throat, reduced sensation in the mouth, bad breath, frothy saliva and more dental caries. Reporting systems show signals for dry mouth and taste change, and case series confirm reduced saliva, though a reporting signal measures what was reported rather than how often it happens. A second review, covering the oral and maxillofacial region specifically, adds reflux, nasopharyngitis and taste disturbance to the same list [\[2\]](https://thisglp.com/research/ozempic-teeth#ref-2). Its authors ask clinicians to keep these drugs in the differential diagnosis, because the effects overlap with conditions that have entirely different causes. ## Why teeth, when the drug does not touch them The reported route from a GLP-1 drug to dental damage is indirect. | What happens | Why it follows | What it does to teeth | | --- | --- | --- | | Less saliva | Nausea, eating and drinking less, slower gastric emptying | Saliva buffers acid and clears sugar; less of it raises caries risk | | Reflux | Delayed gastric emptying pushes acid upward | Acid reaches enamel directly | | Altered taste | Reported directly with the drug | Can change what and how often someone eats | The reported route from a GLP-1 drug to dental damage is indirect. Narrative reviews of oral adverse effects The first review is careful about the order of events: dry mouth often arrives secondary to gastrointestinal symptoms rather than from the drug acting on salivary glands directly. That matters for what a reader can do about it. A mouth that is dry because someone is drinking less is a different problem from a gland that has stopped working. Indirect is the useful finding, not a reassurance None of this says the risk is imaginary. It says the mechanism runs through dryness and acid, both of which a dentist can see and both of which have standard management. It also means the effect should track how strong the gastrointestinal symptoms are — which is the same pattern this site described in [what titration does to the nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## One study points the other way A 2026 review of the oral microbiome in obstructive sleep apnea argues that these drugs introduce competing influences [\[3\]](https://thisglp.com/research/ozempic-teeth#ref-3). Untreated sleep apnea drives mouth breathing, salivary drying and acid challenge on its own. So a drug that reduces apnea severity may improve the oral environment, even while its salivary effects push the other way. That review is a synthesis of mechanisms rather than a measurement of outcomes, so it does not settle the question. It does mean a blanket claim in either direction is unsupported. The apnea evidence itself is in [what happened across every apnea subgroup](https://thisglp.com/research/apnea-improved-across-every-subgroup). ## What nobody has measured No randomized trial has counted cavities in people taking these drugs. No study reports what share of users develop dry mouth, or how long it lasts, or whether it resolves when the dose stops climbing. Those are not gaps this site can close by reading harder; they are measurements nobody has taken. One of the reviews also records that these drugs promote a gaunt facial appearance, which is the observation behind a much larger volume of searching than the dental one. What has actually been measured about facial volume, and what is only proposed, is set out in [how to avoid Ozempic face](https://thisglp.com/research/how-to-avoid-ozempic-face). For a reader currently on one of these drugs, the practical implication is narrow. Dryness and reflux are both worth raising at a dental appointment, as medication effects rather than as unrelated symptoms. What a seller will tell you about any of this is covered in [whether disclosure is a trait of the seller](https://thisglp.com/research/is-seller-disclosure-a-trait). ## Frequently asked Does Ozempic damage your teeth? No trial has counted cavities in people taking it. Reviews report more dental caries alongside dry mouth and reflux, but no study reports a rate, so the size of the risk is unmeasured. Why would a GLP-1 drug affect teeth at all? Indirectly. Nausea and reduced intake lower saliva, which normally buffers acid and clears sugar, and delayed gastric emptying can push acid up as reflux. Both damage enamel without the drug touching it. How common is dry mouth on semaglutide? Not established. It is the oral effect most consistently reported, and adverse-event systems show a signal for it, but the review that gathered the literature states rates vary across studies and does not pool them. Does it get better? Nobody has measured that. No study reports how long these effects last or whether they resolve once the dose stops escalating. What should I do about it? Raise dryness and reflux at a dental appointment and say they began with the medication, since both have standard management and both overlap with conditions that have other causes. ## Sources 1. \[1\] Al-Zawawi AS (2024). Oral Adverse Effects of Semaglutide Therapy: A Narrative Review Journal of International Society of Preventive and Community Dentistry. [PMID 42730115](https://pubmed.ncbi.nlm.nih.gov/42730115/) 2. \[2\] Brooks JK, Sultan AS (2026). Potential oral and maxillofacial adverse events associated with glucagon-like peptide-1 receptor agonist administration: a narrative review Quintessence International. [PMID 42334501](https://pubmed.ncbi.nlm.nih.gov/42334501/) 3. \[3\] Comisi JC (2026). Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring Clinical Oral Investigations. [PMID 42734711](https://pubmed.ncbi.nlm.nih.gov/42734711/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Parkinson's Incidence and Motor Symptoms on GLP-1 Drugs: An 82-Study Review A systematic review of 82 studies linked GLP-1 use to lower Parkinson's incidence (HR 0.70) in observational data, with no improvement in motor symptoms in randomized trials. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/preventing-it-is-not-treating-it Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Parkinson's Incidence and Motor Symptoms on GLP-1 Drugs: An 82-Study Review In one review of 82 studies, GLP-1 use was linked to lower odds of developing Parkinson's in observational data, while randomized trials found no motor improvement in people who already had it. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Risk of DEVELOPING Parkinson’s — observational studies · HR 0.70 · (95% CI 0.53–0.92) · lower · Motor symptoms in ESTABLISHED Parkinson’s — trials · −3.29 · (95% CI −7.84 to 1.26) · no improvement · The positive result uses the weaker design. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A systematic review screened 10,037 records and pooled 82 studies of neuropsychiatric outcomes, graded with GRADE. - Risk of developing Parkinson's disease was lower (pooled HR 0.70, 95% CI 0.53-0.92), from observational studies. - Motor symptoms in people who already have Parkinson's did not improve (mean difference -3.29, 95% CI -7.84 to 1.26), from trials. - Cannabis use disorder risk was lower (HR 0.55) but opioid use disorder was not (HR 0.61, 95% CI 0.24-1.52, I² = 91%). Eighty-two studies across a field this scattered will produce results pointing in several directions at once, and this review does. The cleanest way to read it is to separate claims about preventing a condition from claims about treating one [\[1\]](https://thisglp.com/research/preventing-it-is-not-treating-it#ref-1). The dementia version of the same split is in [the dementia risk score](https://thisglp.com/research/do-glp1-drugs-protect-against-dementia). On Parkinson’s disease both appear, and they disagree. People taking these drugs were less likely to develop Parkinson’s, at a pooled hazard ratio of 0.70 (95% CI 0.53–0.92). Among people who already had it, motor symptoms did not improve — a mean difference of -3.29 points on the standard rating scale with a confidence interval running from -7.84 to 1.26, which crosses no effect. Nor did non-motor symptoms, quality of life or dyskinesia. The positive result rests on the weaker evidence The lower incidence figure comes from observational studies, where people who take these drugs differ from people who do not in ways nobody fully measures. The null on motor symptoms comes from randomized trials. So the encouraging claim is supported by the design most prone to confounding, and the discouraging one by the design built to avoid it. Any summary reporting that these drugs "help Parkinson's disease" has collapsed two findings of very different quality into one sentence. The substance use results split the same way and carry a further problem. Cannabis use disorder risk was lower at a pooled hazard ratio of 0.55 (95% CI 0.39–0.77), while opioid use disorder showed nothing (HR 0.61, 95% CI 0.24–1.52). The heterogeneity statistics are the part to notice: 71% for cannabis and 91% for opioids. An I² of 91% means the contributing studies disagree so profoundly that the pooled number describes none of them — a related caution to the comparator problem in [the overdose comparison](https://thisglp.com/research/overdose-depends-on-the-comparator). One result is cleaner than the rest. Liraglutide reduced binge frequency in binge eating disorder against placebo, by 1.28 episodes (95% CI -1.67 to -0.89) with moderate heterogeneity. That is a randomized comparison, a specific drug, and a countable outcome, which makes it the most actionable line in the review. The review applied GRADE to assess certainty across outcomes, which is more rigor than most syntheses in this field manage. What it leaves is a field where prevention signals keep appearing in observational data and treatment effects keep failing to appear in trials — a shape also visible in [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding) and [the bipolar cohort](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder). ## Frequently asked Do these drugs help Parkinson's disease? Two different answers. Observational studies link them to lower risk of developing it, while randomized trials show no improvement in motor symptoms among people who already have it. Why does that distinction matter? Because the encouraging finding comes from the study design most vulnerable to confounding and the null comes from the design built to avoid it. They are not equally reliable. What about substance use? Cannabis use disorder risk was lower (HR 0.55) and opioid use disorder showed no effect. Heterogeneity was severe in both — 71% and 91% — meaning the contributing studies disagreed substantially. ## Sources 1. \[1\] Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis Clinical Therapeutics. [PMID 41862354](https://pubmed.ncbi.nlm.nih.gov/41862354/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Price Changes Between Two Readings of the Same Sellers | This GLP How often published GLP-1 prices change between two readings of the same sellers, which direction they move and by how much, measured on the sellers' own pages. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/rereading-glp1-prices Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Price Changes Between Two Readings of the Same Sellers Published prices from dozens of GLP-1 sellers were read a second time. Most figures had moved, most of them downward, and the typical change was not small. [This GLP Editorial Team](https://thisglp.com/about)September 20264 min readUpdated September 2026 Price rows re-read, and which way they moved · 155 fell · 62 rose · Across 219 sellers, 217 rows in all · Median move -13.4% · Largest fall -79% · largest rise 131% **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Every price list on the internet is a photograph. This one included. The interesting question is how fast the thing being photographed moves, and that can only be answered by going back and looking again — which this desk did, on 219 sellers, covering 217 separate price rows. It is the one measurement a reader cannot take for themselves without doing the same work twice, and it changes how much weight any figure on [a comparison page](https://thisglp.com/best) deserves. ## Most of them fell Of the 217 rows re-read, 155 had gone down and 62 had gone up. The median move was \-13.4%, so the typical change was not a rounding adjustment — it was a meaningful cut. The extremes ran from \-79% at one end to 131% at the other, which means a single seller’s figure both halved and doubled somewhere in this set. A market where most published prices fall between two readings is a market under competitive pressure. That is good news for a buyer and bad news for a price list, because it means the list is wrong in a predictable direction: too high, more often than not. ## What this is not These are not a random sample. A seller gets re-read when something prompts it — a figure that looked stale, a page that changed, a review being written. So this describes the rows this desk went back to, not the market as a whole, and the true rate of change across all 580 rostered sellers is unknown. It also says nothing about which direction any particular seller will move next. A price that fell \-79% between two readings is not on a trend; it is a business making a decision, and the next decision is not predictable from the last. ## What to do with it The practical rule is short. Confirm the figure on the seller’s own page on the day you order, not from any list — including this one. A quote more than a few weeks old is more likely wrong than right, and the direction of the error usually favors you. The second rule follows from what a changed price does to everything attached to it. A seller that moves its headline may not have moved its [dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) or its billing interval, so a re-read should cover the terms as well as the number — the questions we keep in [what they leave open](https://thisglp.com/tools/questions-they-leave-open). And where a figure has changed twice, the useful conclusion is about the seller rather than the price: see [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish) for the disclosures that tend to move with it. Every figure above is computed from this site’s own re-reading record at the moment the page was built. The most recent reading in the corpus is October 2026. [Hims](https://thisglp.com/reviews/hims) provides a specific reason to revisit the surrounding text: its [weight-loss offer](https://www.hims.com/) requires membership in addition to the listed medication price. The [age of a recorded price](https://thisglp.com/research/how-old-is-the-price-you-are-reading) is another reason to confirm the offer before ordering. A second reading should capture both charges and their renewal conditions, even if the prominent drug figure appears unchanged. ## Frequently asked Do GLP-1 prices really change that often? Among the rows this desk went back and re-read, most had changed, and most of those had fallen. That describes the rows re-read rather than the whole market, because sellers are re-read when something prompts it. Which direction do they move? Downward more often than upward in this set, with a median move that is a real cut rather than a rounding adjustment. Individual sellers moved both ways. So what should I do? Confirm the figure on the seller's own page on the day you order rather than from any list, and check the billing terms at the same time — a changed price does not mean the terms changed with it. ## Sources ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Retatrutide in Type 2 Diabetes: Why TRANSCEND-T2D-1 Reads Lower Than Phase 2 TRANSCEND-T2D-1 randomized 537 adults with type 2 diabetes to retatrutide or placebo. HbA1c fell up to 1.94 points against 0.81 on placebo, and weight 15.3% against 2.6%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/retatrutide-transcend-t2d-1 Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Retatrutide in Type 2 Diabetes: Why TRANSCEND-T2D-1 Reads Lower Than Phase 2 Weight fell 15.3% at the top dose here, against 24.2% in the phase 2 obesity trial. Different populations over different durations — not a weaker drug. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Weight change at 12 mg, two different populations · obesity, no diabetes · −24.2% · type 2 diabetes · −15.3% · 48 weeks against 40. Not the same comparison. · Weight loss runs smaller in diabetes across this whole class. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Retatrutide targets three receptors — GIP, GLP-1 and glucagon. TRANSCEND-T2D-1 is its first phase 3 readout in type 2 diabetes. - In 537 adults over 40 weeks, HbA1c fell 1.69, 1.86 and 1.94 points at 4, 9 and 12 mg, against 0.81 on placebo. - The treatment differences are about half those figures: -0.88, -1.04 and -1.12 points, all at p<0.0001. - Weight fell 15.3% at 12 mg here, against 24.2% in the phase 2 obesity trial — different populations, not a weaker drug. Retatrutide has been the most-hyped molecule in the pipeline for two years. That rests on a phase 2 obesity trial which took off nearly a quarter of body weight. Its first phase 3 result in type 2 diabetes reports 15.3%, and the gap between those two numbers is the thing most likely to be misread. This site covered the molecule’s [first-in-human data](https://thisglp.com/research/triple-agonist-first-in-human) when it appeared. ## What TRANSCEND-T2D-1 measured The trial randomized 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone, at 48 sites across the USA, Mexico and India [\[1\]](https://thisglp.com/research/retatrutide-transcend-t2d-1#ref-1). Average age was 48.8, average HbA1c 7.9%, average BMI 35.8, and average diabetes duration 2.5 years. These were people early in the disease, which is the easiest setting for a glucose drug. HbA1c fell 1.69 points at 4 mg, 1.86 at 9 mg and 1.94 at 12 mg. The placebo arm fell 0.81 points over the same 40 weeks. That is large for a placebo, and it changes what the drug can be said to have done on its own. The arm change and the treatment difference are different numbers Against placebo the estimated treatment differences were 0.88, 1.04 and 1.12 points, roughly half the raw arm change at every dose. A page quoting “nearly two points of HbA1c” is quoting the arm rather than the drug’s effect. This site set out the same slippage in [a trial result extrapolated to everyone](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent). ## Why the weight number looks smaller than you remember The two headline figures come from different trials in different people. | | Phase 2 | TRANSCEND-T2D-1 | | --- | --- | --- | | Population | Obesity, no diabetes | Type 2 diabetes | | Participants | 338 | 537 | | Duration | 48 weeks | 40 weeks | | Weight at 12 mg | −24.2% | −15.3% | | Placebo arm | −2.1% | −2.6% | The two headline figures come from different trials in different people. Phase 2 obesity trial and TRANSCEND-T2D-1 The phase 2 trial enrolled adults with obesity and without diabetes. It reported 8.7%, 17.1%, 22.8% and 24.2% across 1, 4, 8 and 12 mg at 48 weeks, against 2.1% on placebo [\[2\]](https://thisglp.com/research/retatrutide-transcend-t2d-1#ref-2). At 12 mg, 83% of participants lost at least 15% of their body weight, against 2% on placebo. Setting 24.2% beside 15.3% therefore compares two different populations over two different durations. Weight loss runs consistently smaller in people with type 2 diabetes across this entire drug class, which is the established explanation rather than a sign that this drug underperformed. The molecule-by-molecule version of that pattern is in [the pooled weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## Safety, as reported Discontinuation for adverse events ran 2% to 5% on retatrutide and 0% on placebo, with gastrointestinal events most common and generally mild to moderate. No severe hypoglycemia was reported. Two deaths occurred during the study, both in the 4 mg group, and the paper describes both as unrelated to the study drug. That is what the record says. It is not evidence of a dose-related hazard, since the two higher doses had none, and two events in a 537-person trial cannot establish a rate either way. The phase 2 trial also recorded dose-dependent increases in heart rate that peaked at 24 weeks and declined afterwards. It found gastrointestinal events were partly mitigated by starting at 2 mg rather than 4 mg. That is the same escalation logic set out in [what titration does to the nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## What this does not settle Retatrutide is not approved and is not sold, a point worth repeating because the name circulates in gray-market listings — covered in [what is not for sale](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). This trial also used placebo rather than an active comparator, so it establishes that a third receptor does not obviously break anything at 40 weeks in an easy population. Whether it beats the drugs already on pharmacy shelves is a different question, and nobody has run it. ## Frequently asked How much weight did retatrutide take off in type 2 diabetes? 15.3% at 12 mg over 40 weeks, against 2.6% on placebo, in 537 adults whose diabetes was inadequately controlled by diet and exercise. Why is that lower than the 24% everyone quotes? The 24.2% came from a phase 2 trial in adults with obesity and without diabetes, over 48 weeks. Weight loss runs consistently smaller in people with type 2 diabetes across this whole drug class. How much did it lower HbA1c? Arm changes were 1.69, 1.86 and 1.94 points at 4, 9 and 12 mg. Because placebo fell 0.81 points, the treatment differences were 0.88, 1.04 and 1.12 points. Were there deaths in the trial? Two, both in the 4 mg group, which the paper reports as unrelated to the study drug. The two higher doses had none. Can I buy retatrutide? No. It is investigational, not approved anywhere, and not sold by any seller this site tracks. ## Sources 1. \[1\] Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial The Lancet. [PMID 42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/) 2. \[2\] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England Journal of Medicine. [PMID 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide in HFpEF by Sex: SUMMIT Trial Results in Women and Men | This GLP A prespecified SUMMIT analysis found tirzepatide's benefit in obesity-related HFpEF did not differ by sex (HR 0.66 vs 0.61), while weight loss tracked symptom improvement more closely in women. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/same-benefit-different-route-by-sex Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Tirzepatide in HFpEF by Sex: SUMMIT Trial Results in Women and Men Every treatment-effect comparison by sex in SUMMIT came back null. The one significant interaction was about how the benefit arrives, not who receives it. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 SUMMIT, 731 patients with HFpEF and obesity · Did the benefit differ by sex? · HR 0.66 (women) vs 0.61 (men) · interaction P = 0.81 — no · Did weight loss track symptom relief differently? · more closely in women · interaction P = 0.0058 — yes · Same destination, apparently different road. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A prespecified secondary analysis of the SUMMIT trial split its 731 participants by sex: 393 women and 338 men with obesity-related heart failure with preserved ejection fraction. - The effect on cardiovascular death or worsening heart failure did not differ (HR 0.66 in women, 0.61 in men, interaction P = 0.81), nor did symptom score or walking distance. - Among those taking tirzepatide, weight loss was more strongly associated with symptom improvement in women than men (interaction P = 0.0058). - Women and men differed substantially at baseline: women had higher BMI and worse symptoms, men more left ventricular remodeling and paracardiac fat. Women outnumber men in heart failure with preserved ejection fraction, and the way body fat relates to the disease is not the same in both. A prespecified analysis of the SUMMIT trial asked whether tirzepatide works differently in each [\[1\]](https://thisglp.com/research/same-benefit-different-route-by-sex#ref-1). The trial's main result is covered in [the heart failure composite](https://thisglp.com/research/tirzepatide-heart-failure-composite). The starting points really were different. Women had greater BMI, a higher waist-to-height ratio, worse symptoms on the Kansas City questionnaire, more severe functional class and shorter six-minute walk distances. Men had more left ventricular remodeling and more fat deposited around the heart. Higher waist-to-height ratio was associated with poorer kidney function in women only (interaction P = 0.043). Despite all that, the drug behaved identically. Cardiovascular death or worsening heart failure gave hazard ratios of 0.66 in women and 0.61 in men with an interaction P of 0.81. Symptom scores improved by 8.1 and 5.5 placebo-corrected points (interaction P = 0.43), and walking distance by 18 and 15 meters (interaction P = 0.76). Because sex was a planned analysis rather than one dredged up afterwards, those nulls carry real weight. One interaction did reach significance, and it is about mechanism Among participants taking tirzepatide, how much weight someone lost was more tightly linked to how much better they felt in women than in men (interaction P = 0.0058). That is not a claim that women benefited more — the benefit was the same. It suggests the benefit may arrive by a different route in each: more through weight reduction in women, more through something else in men. If that holds up it has a practical edge. In a man with this condition, a modest weight response would not necessarily predict a modest symptom response, so stopping early because the scale is disappointing could mean stopping something that was working. In a woman the scale tracks the symptoms more closely. That is a hypothesis from one trial and not a prescribing rule, and it is the kind of finding that needs replication before anyone acts on it — the same caution applied in [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute) and [the frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer), which similarly found no heterogeneity where people expected some. The broader point is worth keeping. Subgroup analyses usually get attention when they find a difference, and this one is more useful for what it failed to find: a disease that looks different in women and men responded to the same drug in the same way, which is a reason to treat rather than to hesitate. The body composition differences underlying it connect to [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). ## Frequently asked Does tirzepatide work better for women or men with heart failure? Neither. Hazard ratios were 0.66 in women and 0.61 in men with an interaction P of 0.81, and symptom and walking outcomes showed no heterogeneity either. What was the one significant difference? Among people taking tirzepatide, weight loss was more strongly associated with symptom improvement in women than in men. That concerns how the benefit arrives rather than how large it is. Did women and men start out the same? No. Women had higher BMI, worse symptoms and shorter walking distance, while men had more left ventricular remodeling and more fat around the heart. ## Sources 1. \[1\] Borlaug BA, Zile MR, Kramer CM, Litwin SE, et al. (2026). Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial JACC: Heart Failure. [PMID 42417681](https://pubmed.ncbi.nlm.nih.gov/42417681/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Oral Semaglutide in Early Alzheimer's Disease: The evoke and evoke+ Trials The evoke and evoke+ trials tested oral semaglutide in 3,808 people with early Alzheimer's disease and found no effect | what that means for the observational evidence that preceded them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-and-alzheimers Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Oral Semaglutide in Early Alzheimer's Disease: The evoke and evoke+ Trials Two phase 3 trials randomized 3,808 people with confirmed early Alzheimer's disease. At 104 weeks the estimated difference on the primary endpoint was -0.08, and both trials were discontinued. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Dementia rating, change over 104 weeks (higher is worse) · 0 · semaglutide 2.3 · placebo 2.3 · 3,808 participants. Estimated difference −0.08. Trials stopped. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Two phase 3 trials randomized 3,808 people with amyloid-confirmed early Alzheimer's disease to oral semaglutide 14 mg daily or placebo for up to 156 weeks. - At 104 weeks, dementia rating scores had worsened by 2.3 points on semaglutide and 2.3 on placebo. The estimated difference was -0.08 (95% CI -0.35 to 0.20). - The second trial found the same: 2.2 against 2.1, a difference of 0.10 (95% CI -0.17 to 0.38). - Both trials were discontinued for a negative clinical outcome. - The observational literature that motivated them had pointed the other way. Most of what this library covers is a question the evidence has not settled. This one it has. A drug class widely reported to protect the brain was tested in the population that matters, at scale, for two years, and it did nothing measurable. That is a more useful result than a positive one, and it is also the kind that gets far less coverage — which is itself a pattern worth recognizing when reading any claim on [a seller’s page](https://thisglp.com/best). ## What was tested evoke and evoke+ ran across 566 sites in 40 countries [\[1\]](https://thisglp.com/research/semaglutide-and-alzheimers#ref-1). Participants were aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer’s disease, confirmed by amyloid imaging or cerebrospinal fluid analysis — not self-reported memory complaints. They were randomized 1:1 to once-daily oral semaglutide at up to 14 mg or placebo for up to 156 weeks. evoke+ additionally included people with significant small vessel pathology. Between May 2021 and September 2023, 9,981 people were screened and 3,808 randomized: 1,855 in evoke and 1,953 in evoke+. Mean age was 72.2 years and the mean baseline dementia rating score was 3.7. ## What they found The primary endpoint was the change in the Clinical Dementia Rating – Sum of Boxes score from baseline to week 104. In evoke, scores worsened by 2.3 points on semaglutide and 2.3 on placebo, an estimated difference of −0.08 (95% CI −0.35 to 0.20, p=0.57). In evoke+, 2.2 against 2.1, a difference of 0.10 (95% CI −0.17 to 0.38, p=0.46). Both intervals sit symmetrically around zero. This is not an underpowered trial that missed a small effect; it is a very large trial that found no effect. The investigators’ own conclusion is that oral semaglutide was not efficacious in slowing clinical progression, and both trials were discontinued. Why the earlier evidence said otherwise Animal work, clinical studies and real-world data in people with type 2 diabetes or obesity had all suggested a lower rate of dementia after exposure to this drug class. That is what justified spending two years and 3,808 participants on the question. The likeliest explanation for the gap is that people prescribed these drugs differ from people who are not, in ways that also predict dementia — and no statistical adjustment removes a difference you did not measure. The trial exists precisely because that possibility cannot be ruled out from the outside. ## What it did not find, either Safety was unremarkable. Treatment-emergent adverse events were reported in 91.2% of 1,896 participants on semaglutide against 84.8% of 1,902 on placebo, and the investigators judged five deaths treatment-related — one in the semaglutide group and four in the placebo group. Tolerability was consistent with what the drug does in its other indications, described in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## How to use a negative trial A well-run trial that finds nothing closes a question, and closing questions is the scarcer service. It means anyone still telling you these drugs help with memory is working from evidence that has been superseded — and, on current publishing incentives, may not know it. It also tells you what to do with the next observational headline in this category. The pattern here is exactly the pattern that ran for other outcomes: a real correlation, a plausible mechanism, and no effect when tested. That is worth holding onto while reading [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review), and while reading any seller’s summary of them — most publish nothing about which claims rest on trials and which on cohorts, a silence counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## Frequently asked Does semaglutide slow Alzheimer's disease? No. Two phase 3 trials in 3,808 people with amyloid-confirmed early Alzheimer's disease found estimated differences of -0.08 and 0.10 on the primary endpoint at 104 weeks. Both trials were discontinued for a negative clinical outcome. Why did earlier studies suggest it might? Animal work and observational data in people with diabetes or obesity had shown lower dementia rates after exposure. People prescribed a drug differ from people who are not in ways that can also predict the outcome, which is what a randomized trial exists to rule out. Was the dose too low? The trials used oral semaglutide at up to 14 mg once daily for up to 156 weeks, with an eight-week escalation. Both confidence intervals sit symmetrically around zero rather than pointing toward an effect the trial narrowly missed. Were there safety problems? Nothing unusual. Treatment-emergent adverse events occurred in 91.2% on semaglutide against 84.8% on placebo, and of five deaths judged treatment-related, four were in the placebo group. ## Sources 1. \[1\] Cummings JL, et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials The Lancet. [PMID 41865758](https://pubmed.ncbi.nlm.nih.gov/41865758/) 2. \[2\] Cummings JL, et al. (2025). evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease Alzheimer's Research & Therapy. [PMID 39780249](https://pubmed.ncbi.nlm.nih.gov/39780249/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # FLOW Trial: Semaglutide 1.0 mg in Diabetic Chronic Kidney Disease | This GLP The FLOW trial randomized 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg or placebo and found a hazard ratio of 0.76 for major kidney events. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-and-kidney-disease Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # FLOW Trial: Semaglutide 1.0 mg in Diabetic Chronic Kidney Disease A 24 percent reduction in major kidney events, with every secondary outcome agreeing, in a trial stopped early at an interim analysis. The dose was 1.0 mg, the diabetes dose, not the one sold for weight loss. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 FLOW: hazard ratios against placebo · 1.0 · Major kidney events · 0.76 · Cardiovascular death · 0.71 · Major cardiac events · 0.82 · Death from any cause · 0.80 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). FLOW is the trial that stopped early because it was working. It randomized 3,533 people with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg weekly or placebo, and an interim analysis recommended cessation before the planned end, after a median follow-up of 3.4 years [\[1\]](https://thisglp.com/research/semaglutide-and-kidney-disease#ref-1). The result is one of the strongest in this drug class, and it comes with a condition almost nobody mentions when quoting it — a condition that matters before you compare [what any seller charges](https://thisglp.com/best). ## What it found The primary outcome was a composite of kidney failure, a 50 percent or greater fall in eGFR, or death from kidney or cardiovascular causes. Risk was 24 percent lower on semaglutide, at 331 first events against 410, a hazard ratio of 0.76 (95% CI 0.66 to 0.88, P = 0.0003). Every confirmatory secondary outcome moved the same way. The kidney-specific composite was 0.79 (95% CI 0.66 to 0.94). Death from cardiovascular causes was 0.71 (95% CI 0.56 to 0.89). Major cardiovascular events were 18 percent lower at 0.82 (95% CI 0.68 to 0.98), and death from any cause 20 percent lower at 0.80 (95% CI 0.67 to 0.95). The mean annual eGFR slope was less steep by 1.16 ml per minute per 1.73 m². Serious adverse events were reported in fewer participants on the drug than on placebo, 49.6 percent against 53.8. ## The condition on all of it The dose was 1.0 mg weekly. That is the type 2 diabetes dose, and it is not the 2.4 mg weight-management dose that most compounded semaglutide sold online is titrated toward. The population was people with diabetes and established kidney disease, defined by specific eGFR and albumin-to-creatinine thresholds — not a general weight-loss population. None of that makes the result less real. It means the result belongs to a drug at a dose in a population, and moving it onto a different dose in a different population is an assumption rather than a finding. If a seller’s page cites kidney benefits, the question to ask is which trial and at what dose — and most sellers publish nothing about dose at all, which we have counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). ## Why early cessation is worth understanding Stopping a trial early for benefit is the right thing to do for the participants and it systematically inflates effect estimates, because trials stop at a moment when the data happen to look good. The effect here is large, consistent across every secondary outcome, and prespecified — which is about as reassuring as an early stop gets. It is still a reason to expect the real-world effect to be somewhat smaller. For anyone with kidney disease considering a telehealth purchase, the practical gap is not the evidence. It is that this is a condition requiring monitoring, and most of the sellers tracked here publish nothing about who reviews a case or how often — a census we keep in [what sellers publish](https://thisglp.com/tools/what-sellers-publish) and in [what they will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## Frequently asked How much did semaglutide reduce kidney events? By 24 percent against placebo — 331 first events against 410, a hazard ratio of 0.76 (95% CI 0.66 to 0.88) over a median 3.4 years. Does this apply to the dose I would be sold? Not directly. FLOW used 1.0 mg weekly, the type 2 diabetes dose. Most compounded semaglutide sold online is titrated toward the 2.4 mg weight-management dose. Why did the trial stop early? A prespecified interim analysis recommended cessation for benefit. That is correct for participants and it tends to inflate effect estimates, so expect the real-world effect to be somewhat smaller. ## Sources 1. \[1\] Perkovic V, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes New England Journal of Medicine. [PMID 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide in MASH: ESSENCE Phase 3 Results at 72 Weeks | This GLP The ESSENCE phase 3 interim results for semaglutide in MASH, the 13-trial meta-analysis behind them, and the one randomized cirrhosis result that went the other way. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-and-liver-disease Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide in MASH: ESSENCE Phase 3 Results at 72 Weeks At 72 weeks, steatohepatitis resolved in 62.9% on semaglutide against 34.3% on placebo, and fibrosis improved in 36.8% against 22.4%. In compensated cirrhosis, the one trial available found neither. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Week 72, first 800 patients · steatohepatitis resolved · 62.9% · 34.3% · fibrosis improved · 36.8% · 22.4% · Semaglutide 2.4 mg weekly against placebo. Accent bar is the drug. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - At 72 weeks, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide against 34.3% on placebo — a 28.7 point difference. - Fibrosis improved without worsening steatohepatitis in 36.8% against 22.4%, a 14.4 point difference. - A meta-analysis of 13 trials in 1,811 people put MASH resolution at a pooled odds ratio of 3.48, with no heterogeneity between studies. - In the one trial of MASH-related compensated cirrhosis, semaglutide did neither. - Every one of these results used brand semaglutide at 2.4 mg weekly for over a year. Fatty liver disease is the condition most likely to be sitting underneath a reader’s interest in these drugs without either of them knowing it. More than half the participants in the largest trial also had type 2 diabetes, and almost all met at least one cardiometabolic criterion [\[3\]](https://thisglp.com/research/semaglutide-and-liver-disease#ref-3). It is a common disease that produces no symptoms until it produces serious ones. ## What the phase 3 trial found ESSENCE randomized 1,197 patients with biopsy-defined MASH and fibrosis at stage 2 or 3 in a 2:1 ratio to weekly semaglutide at 2.4 mg or placebo for 240 weeks. A planned interim analysis at week 72, covering the first 800 patients, reported both primary endpoints[\[1\]](https://thisglp.com/research/semaglutide-and-liver-disease#ref-1). Steatohepatitis resolved without worsening of fibrosis in 62.9% of the 534 patients on semaglutide and 34.3% of the 266 on placebo, an estimated difference of 28.7 percentage points (95% CI 21.1 to 36.2). Fibrosis improved without worsening of steatohepatitis in 36.8% against 22.4%, a difference of 14.4 points (95% CI 7.5 to 21.3). Both outcomes together were reached by 32.7% against 16.1%, a difference of 16.5 points (95% CI 10.2 to 22.8). Weight fell 10.5% on semaglutide and 2.0% on placebo. Mean changes in bodily pain scores did not differ between the groups, and gastrointestinal adverse events were more common on the drug — the same pattern the dose-escalation literature describes, which we cover in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## Whether the rest of the class does the same A 2025 meta-analysis pooled 13 phase 2 and phase 3 randomized trials covering 1,811 participants [\[2\]](https://thisglp.com/research/semaglutide-and-liver-disease#ref-2). Among people with MASH and moderate to advanced fibrosis, GLP-1 receptor agonists over up to 72 weeks beat placebo on MASH resolution with a pooled odds ratio of 3.48 (95% CI 2.69 to 4.51) and on fibrosis improvement at 1.79 (95% CI 1.37 to 2.35). Both pooled estimates had an I² of 0%, meaning the trials agreed with each other to an unusual degree. Liver fat measured by magnetic resonance fell by a pooled mean of 4.50% (95% CI 6.60 to 2.40). That estimate came from nine trials with an I² of 95.9% — the studies did not agree, and the pooled number should be read as a direction rather than a quantity. The result that went the other way The same meta-analysis found one randomized trial in people with MASH-related compensated cirrhosis. In that trial semaglutide produced neither MASH resolution nor improved fibrosis against placebo. One trial is not a settled answer, but it is the only randomized evidence there is for that group, and it does not point the same way as everything above. ## What this does and does not tell a buyer Every figure on this page came from 2.4 mg of brand semaglutide given weekly for at least 72 weeks. That is the top of the approved escalation, held for well over a year. Most of the sellers tracked here publish an opening figure and say nothing about what the price becomes at the doses these trials ran at — the gap counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) and listed seller by seller in [published dose ladders](https://thisglp.com/tools/published-dose-ladders). It also tells a buyer what to ask about rather than what to buy. A liver result is not something a telehealth intake form establishes, and the trials selected patients by biopsy. If you are reading this because of a scan result or an enzyme panel, the useful next step is a clinician who can see the panel, not a storefront. The wider question of what the weight trials themselves support is in [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review), and the kidney outcome data in [semaglutide and kidney disease](https://thisglp.com/research/semaglutide-and-kidney-disease). ## Frequently asked Does semaglutide treat fatty liver disease? In the phase 3 interim analysis, steatohepatitis resolved without worsening fibrosis in 62.9% of patients on semaglutide 2.4 mg against 34.3% on placebo at 72 weeks — a difference of 28.7 percentage points. Does it help if the disease has already reached cirrhosis? The one randomized trial available in MASH-related compensated cirrhosis found neither resolution nor fibrosis improvement against placebo. That is a single trial, and it is the only randomized evidence for that group. What dose did the trials use? Semaglutide 2.4 mg by weekly injection, for 72 weeks in the interim analysis and 240 weeks in the full trial. That is the top of the approved escalation, held for over a year. Do other GLP-1 drugs show the same thing? A meta-analysis of 13 trials in 1,811 people found a pooled odds ratio of 3.48 for MASH resolution and 1.79 for fibrosis improvement, with no heterogeneity between the pooled trials. ## Sources 1. \[1\] Sanyal AJ, et al. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis New England Journal of Medicine. [PMID 40305708](https://pubmed.ncbi.nlm.nih.gov/40305708/) 2. \[2\] Mantovani A, et al. (2025). Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials Liver International. [PMID 40736113](https://pubmed.ncbi.nlm.nih.gov/40736113/) 3. \[3\] Newsome PN, et al. (2024). Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial Alimentary Pharmacology & Therapeutics. [PMID 39412509](https://pubmed.ncbi.nlm.nih.gov/39412509/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide and Cognitive Signs in Psychiatric Patients: 13,007 Records | This GLP Among 13,007 patients with psychiatric diagnoses, semaglutide was linked to fewer recorded cognitive signs than no treatment but not versus sitagliptin | how a score built from clinical notes works. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide and Cognitive Signs in Psychiatric Patients: 13,007 Records Semaglutide starters had fewer recorded cognitive problems than three comparator groups, and no significant difference from the fourth, sitagliptin, which was the closest match. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Cognitive signs recorded over 12 months (lower is fewer) · semaglutide · 11.14 · sitagliptin · 12.52 · difference not significant · glipizide · 13.46 · empagliflozin · 13.69 · no antidiabetic drug · 14.91 · 13,007 patients, 1,261 of them on semaglutide. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 13,007 adults with a psychiatric diagnosis who started an antidiabetic drug, 1,261 of them semaglutide. - The outcome is a 0-100 score built from cognitive signs a clinician recorded in routine notes. - Semaglutide scored 11.14 against 14.91 on no treatment — mean ratio 0.75, 95% CI 0.65 to 0.85. - Against sitagliptin, the other incretin-system drug here, the difference was not significant. - Effect sizes looked similar across disorders but held consistently only in major depression. Before any of the numbers, what was measured: not a cognitive test, but whether somebody writing up an appointment noted a problem with memory, attention or orientation. That is a real signal and it is also a record of how often a person was seen and how carefully they were written up — the sort of measurement question that decides what [a comparison can be asked to carry](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## The setup Adults with any psychiatric diagnosis in a multicenter US electronic health record, each with at least one clinician-rated cognitive assessment in the year before starting an antidiabetic drug and at least one in the year after. [\[1\]](https://thisglp.com/research/semaglutide-and-recorded-cognitive-signs#ref-1) Scores run 0 to 100, where 0 means no signs recorded and 100 means signs across every domain. Mean age 62.0, 48.4% women. Semaglutide starters were compared against four alternatives: sitagliptin, empagliflozin, glipizide and no antidiabetic treatment at all. ## What the four comparisons gave Against no treatment, semaglutide scored 11.14 to 14.91, a mean ratio of 0.75, 95% CI 0.65 to 0.85, p = 0.00002 after Bonferroni correction. Against glipizide, 0.83. Against empagliflozin, 0.81. Against sitagliptin: 11.14 to 12.52, a mean ratio of 0.89, 95% CI 0.77 to 1.02, p = 0.50. Not significant. The comparator that did not separate Sitagliptin is a DPP-4 inhibitor, which works by preventing the breakdown of the body’s own incretin hormones — the same system semaglutide acts on from the other end. It is the closest thing in this list to an active control, and it is the one comparison where the difference disappeared. That is compatible with an incretin effect rather than a semaglutide effect, and it is compatible with the other three gaps being about who gets which drug. The study cannot tell those apart. ## The weakest arm gives the biggest number “No antidiabetic treatment” produced the largest ratio, and it is the arm to trust least. Somebody with a psychiatric diagnosis and no antidiabetic prescription differs from somebody just started on one — in how sick they are, how engaged with care, and how often anybody writes anything down about them. That is the standing problem with a comparison drawn from records rather than built by randomization, and it runs the same way every time: it flatters the treated group, the way [three significant differences vanished once the groups were made comparable](https://thisglp.com/research/glp1-shoulder-surgery-adjustment) elsewhere in this section. ## Where it held and where it did not Associations were strongest for memory and for broader cognitive function. Across the disorder groups the effect sizes looked similar, but statistical significance held consistently only in major depression. The authors’ own closing line asks for randomized trials to establish whether any of this is causal or useful, which is the correct request and worth more than the headline ratio — and it is the same request [every observational result on this site](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) ought to end with. ## What a reader should take Not a reason to buy anything. Nobody in this study was taking semaglutide for cognition, and no seller on this site sells it for that. What is worth keeping is the shape: an outcome assembled from clinical notes, four comparators, and a result that survives three of them and not the closest one. When a finding depends on which comparator you pick, the comparator is the finding — the same lesson as [a trial that gave two answers depending on what it was measured against](https://thisglp.com/research/glp1-adolescent-suicidality-comparators). ## Frequently asked Does semaglutide improve cognition? This study cannot say. It found fewer clinician-recorded cognitive signs than with no treatment, glipizide or empagliflozin, and no significant difference from sitagliptin, and the authors ask for randomized trials. What was actually measured? A 0 to 100 composite built from cognitive signs and symptoms recorded in routine clinical assessments — not a cognitive test administered for the study. Why does the sitagliptin result matter most? Because sitagliptin also acts on the incretin system, making it the closest active comparator in the study. It is the one comparison where semaglutide did not separate. Who was in the study? 13,007 adults with a psychiatric diagnosis, mean age 62, starting an antidiabetic drug, of whom 1,261 started semaglutide. ## Sources 1. \[1\] De Giorgi R, et al. (2026). Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA BMJ Mental Health. [PMID 42624612](https://pubmed.ncbi.nlm.nih.gov/42624612/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Cochrane Review of Semaglutide for Obesity: 18 Trials Graded | This GLP Cochrane's 2025 review of semaglutide for adults with obesity: −10.73% body weight against placebo at high certainty, with lower grades for quality of life, mortality and adverse events. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-cochrane-review Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # Cochrane Review of Semaglutide for Obesity: 18 Trials Graded A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Certainty of the evidence, by outcome · Body weight · 5% weight loss · Quality of life · Mortality · High for the scale. Low for the outcomes people care about. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The number everyone quotes for semaglutide is around fifteen percent of body weight. The number a 2025 Cochrane review actually reports, pooling fifteen randomized trials in 8,651 adults, is a mean difference of −10.73 percent against placebo, with a 95 percent confidence interval from −12.24 to −9.21 [\[1\]](https://thisglp.com/research/semaglutide-cochrane-review#ref-1). That is a large effect, it carries high-certainty evidence, and it is smaller than the figure a seller’s landing page will show you. Before comparing what any of them [charge for it](https://thisglp.com/best), it is worth knowing what the drug was measured to do. ## What is certain, and what is not The review graded each outcome separately, and the grades fall away sharply as the outcome moves from the scale to the person. Percentage body weight is high certainty. So is the proportion reaching five percent weight loss, a risk ratio of 2.68 (95% CI 2.30 to 3.12) across twelve studies and 7,458 participants. Quality of life is moderate certainty, and the measured difference on the SF-36 physical functioning score is 2.12 points (95% CI 0.95 to 3.28) — statistically present and small enough that a reader should ask what two points feel like. Serious adverse events are graded very low certainty, with a risk ratio of 1.01 and an interval from 0.78 to 1.29 that includes no difference in either direction. This is the shape of the evidence base, and it is not the shape of the marketing. The thing measured best is the number on the scale. ## The long-term figures are thinner than they look At 26 months the review reports a mean difference of −11.11 percent (95% CI −16.47 to −5.75), which sounds like confirmation until you read what sits beside it: two studies, and an I² of 94 percent. That statistic describes how much of the variation between the two results is more than chance, and ninety-four percent is close to the ceiling. Two trials that disagree that strongly are not a settled long-term answer, and the review grades this outcome moderate rather than high for exactly that reason. What happens after the drug stops is a different question again, and one the trials mostly do not follow. We have written separately about [what the regain data shows](https://thisglp.com/research/stopping-glp1-and-weight-regain). ## Who paid for the evidence Seventeen of the eighteen included trials reported that the drug’s manufacturer had a major role in their design, conduct, analysis or writing. The review names this explicitly in its conclusions as raising important concerns about conflicts of interest, and it identifies 46 ongoing studies that may change the picture. This is not a reason to disregard the findings. Industry-run trials are how most drugs are tested, and a high-certainty grade from Cochrane already accounts for a great deal. It is a reason to notice that the independent replication most readers assume exists behind a number this famous has, so far, largely not happened. ## A note on the cardiovascular figures The review reports major adverse cardiovascular events at a risk ratio of 0.63 (95% CI 0.44 to 0.90) at medium-term follow-up and still describes the effect as possibly little to no absolute difference. That reads like a contradiction and is not one. The ratio is relative; the absolute number of events in a mostly healthy trial population is small, and the certainty grade is low. A thirty-seven percent relative reduction in a rare outcome can be a handful of events either way. ## What to do with this Take the ten to eleven percent figure as the honest central estimate for what the trials measured, expect less certainty the further an outcome sits from body weight, and treat the long-term numbers as provisional. Then look at what a seller will actually tell you about the product before you buy it — our census of [what goes unpublished](https://thisglp.com/research/what-glp1-sellers-do-not-publish) and the [questions left open](https://thisglp.com/tools/questions-they-leave-open) are the practical half of this. ## Frequently asked Why is the trial figure lower than the fifteen percent I have seen? Different sources report different things. The Cochrane pooled estimate across fifteen trials and 8,651 adults is −10.73 percent against placebo (95% CI −12.24 to −9.21). Single trials in selected populations can report more. Does semaglutide reduce heart attacks and strokes? The review reports a risk ratio of 0.63 (95% CI 0.44 to 0.90) at medium-term follow-up but grades the certainty low and describes the absolute difference as possibly little to none. The relative reduction is on a small number of events. Were these trials independent? Mostly not. Seventeen of the eighteen included trials reported that the manufacturer had a major role in their design, conduct, analysis or writing, which the review names as a concern in its conclusions. ## Sources 1. \[1\] Bracchiglione J, et al. (2025). Semaglutide for adults living with obesity Cochrane Database of Systematic Reviews. [PMID 41161683](https://pubmed.ncbi.nlm.nih.gov/41161683/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide and Fracture Risk: Type 2 Diabetes vs No Diabetes | This GLP A target trial emulation found lower fracture risk on semaglutide only in the type 2 diabetes cohort | what a null in the cohort without diabetes means for someone taking it for weight loss. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-fractures-diabetes-only Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide and Fracture Risk: Type 2 Diabetes vs No Diabetes Semaglutide was associated with fewer major fractures in people with type 2 diabetes and with no difference in people without it. The second group is most of the weight-loss market. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Fracture risk, cohort WITH type 2 diabetes · vs empagliflozin · vs glipizide · vs usual care · 1.0 · Cohort WITHOUT diabetes: no comparison reached significance **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A target trial emulation matched people with obesity starting semaglutide to comparators 1:1 on 215 covariates. - In the cohort with type 2 diabetes, major osteoporotic fracture risk was lower: HR 0.69 against empagliflozin, 0.72 against glipizide, 0.84 against usual care. - In the cohort without type 2 diabetes, no comparison reached significance on fracture at all. - Osteoporosis diagnosis did not differ in most comparisons in either cohort. - The stratum that came back null is the one most people buying from this roster belong to. A result that holds in one group and vanishes in another is more informative than a result that holds everywhere, because the boundary tells you something about the mechanism. This study has that shape, and the boundary falls in an awkward place for anyone reading it as a reason to buy. ## How it was built The analysis used a federated network of electronic health records and a target trial emulation design: define the trial you would run, then assemble it from records that already exist. [\[1\]](https://thisglp.com/research/semaglutide-fractures-diabetes-only#ref-1) People with obesity starting semaglutide were matched one to one, on 215 covariates, against people starting an active comparator or receiving usual care. The diabetes cohort ran to between 19,824 and 93,519 matched pairs depending on the comparison and was followed three years. The non-diabetes cohort ran between 10,323 and 56,225 pairs over two years. The primary outcome was major osteoporotic fracture. Two comparators and a control condition is an unusually careful setup, and the reason it matters is visible in the results — the answer changes depending on [what you compare against](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## The diabetes cohort Against empagliflozin, the hazard ratio for major osteoporotic fracture was 0.69, 95% CI 0.61 to 0.77. Against glipizide it was 0.72, 95% CI 0.63 to 0.83. Against usual care it was 0.84, 95% CI 0.76 to 0.93. All three intervals sit below one, so all three point the same way, and the spread between them is the interesting part. The weakest effect came from the comparison against usual care — the contrast where the two groups differ most in everything other than the drug. ## The cohort without diabetes Nothing. Across every comparison, no significant association with fracture was observed, all p above 0.05. Osteoporosis diagnosis did not differ significantly in most comparisons in either cohort, and exploratory looks at osteoarthritis and gout produced inconsistent patterns across comparators. That is the finding to carry away, and it is the one least likely to be repeated anywhere else. Most people buying these drugs from a telehealth seller do not have type 2 diabetes. They are in the stratum where the fracture result did not appear. Matching is not randomizing Two hundred and fifteen covariates is a lot of covariates. It is still a list somebody wrote down, and the confounders that matter in this kind of analysis are the ones nobody thought to record — how sick a patient looked, why a clinician reached for one drug rather than another, who was steady enough to keep a prescription going. A protective hazard ratio from matched records is a hypothesis with a large sample attached, not a demonstrated effect. ## Why the boundary might be real There is a plausible story, and it is worth stating as a story rather than a conclusion. Diabetes damages bone quality in ways that do not show up on a density scan, and it raises fracture risk at any given density. A drug that improves glycemic control in people with diabetes has a pathway to bone that simply does not exist in people without it. If that is what is happening, the null in the non-diabetes cohort is not a failure of power. It is the correct answer. There is an equally plausible story in which the diabetes result is confounding — sicker comparator patients, different monitoring, different falls risk — and the non-diabetes null is the honest one throughout. This study cannot separate those, and body composition is a live question in both directions, since [what the weight is made of](https://thisglp.com/research/muscle-loss-on-glp1) bears on falls as much as on bone. ## What to do with it Do not treat bone as a reason to buy or a reason not to. On the best current evidence there is no fracture signal in either direction for a person without diabetes taking these drugs, which is a genuinely reassuring kind of nothing. The people who should pay attention are those with existing osteoporosis or a fracture history, and that is a prescriber conversation rather than a product-page one — a conversation [almost no seller here gives you a way to have](https://thisglp.com/tools/what-sellers-publish). And treat the strength of this design carefully. It is far better than [a single-arm cohort](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa) and it is not a randomized trial. A large matched database can produce a very precise estimate of the wrong quantity. ## Frequently asked Does semaglutide protect your bones? Only the diabetes cohort showed a lower fracture risk, and that came from matched health records rather than a randomized trial. In people with obesity but no type 2 diabetes, no comparison reached significance. Why would diabetes change the answer? One plausible explanation is that diabetes harms bone quality in ways a density scan does not capture, giving a glucose-lowering drug a pathway to bone that does not exist otherwise. The study cannot confirm that. Is a null result reassuring? Here, moderately. It means no fracture signal appeared in either direction over two years in the cohort without diabetes, across every comparison the study ran. How reliable is a target trial emulation? It is a strong observational design and not a substitute for randomization. Matching on 215 covariates cannot adjust for the reasons a clinician chose one drug over another, which is the confounding that matters most. ## Sources 1. \[1\] Huang YN, et al. (2026). Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation Diabetes, Obesity and Metabolism. [PMID 42010367](https://pubmed.ncbi.nlm.nih.gov/42010367/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found | This GLP In ADJUST-T1D, semaglutide cut total daily insulin 22.6% in type 1 diabetes. A crossover trial raised time in range 4.8 points without more hypoglycemia. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-in-type-1-diabetes Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found Total daily insulin fell 22.6% and time in range rose 4.8 points without more hypoglycemia. It is off-label, both trials were small, and two people developed ketosis at normal glucose. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Type 1 diabetes is not an approved indication for any GLP-1 drug, and both trials below ran under close supervision. - Adding semaglutide to automated insulin delivery cut total daily insulin by 22.6%, driven more by bolus (-30.5%) than basal (-15.6%) doses. - Early on, the reduction was mostly a direct drug effect rather than a consequence of weight loss: 83% at week four, falling to 52% by week 26. - A separate crossover trial raised time in range by 4.8 percentage points without more hypoglycemia — but recorded two episodes of euglycemic ketosis. Two small randomized trials have now tested a GLP-1 drug alongside modern insulin therapy in type 1 diabetes, and both found something worth knowing. Neither makes it an approved treatment, and the reason to read them carefully is that the changes they describe involve taking insulin away from people who cannot live without it. ## What happened to the insulin A post hoc analysis of the ADJUST-T1D trial followed adults with type 1 diabetes and obesity who were using automated insulin delivery systems, and who took semaglutide 1 mg weekly or placebo for 26 weeks [\[1\]](https://thisglp.com/research/semaglutide-in-type-1-diabetes#ref-1). Total daily insulin fell 22.6%, with an interval running from 28.3 to 17.0 — a change of the kind this site sizes carefully in [what each dose step took away](https://thisglp.com/research/each-dose-step-took-insulin-away). The reduction was not spread evenly across the two kinds of insulin a person takes. Bolus doses, the ones covering meals, fell 30.5%, while basal doses covering the background requirement fell 15.6%. The share of the total that was basal therefore rose from 0.56 to 0.62, and insulin per kilogram per day fell from 0.72 to 0.60. Daily carbohydrate intake fell from 137 g to 107 g over the same period. Read the units, not the percentages At week four the drug’s direct effect accounted for 11.1 units a day and weight loss for 2.3. At week 26 the direct effect accounted for 11.4 units and weight loss for 10.5. The split moved from 83/17 to 52/48, but the drug’s own contribution barely changed in absolute terms — what grew was the weight side. A reader given only the percentages would conclude the drug effect faded, and it did not. This site separates the two the same way in [the liver repair that was not the weight](https://thisglp.com/research/liver-repair-that-was-not-the-weight). ## What happened to the glucose A separate double-blind crossover trial gave weekly semaglutide or placebo to people using automated insulin delivery, randomizing 28 participants of whom 24 completed [\[2\]](https://thisglp.com/research/semaglutide-in-type-1-diabetes#ref-2). Time in the target glucose range rose by a mean 4.8 percentage points against placebo. Semaglutide added to automated insulin delivery, against placebo. | Outcome | Result | Significance | | --- | --- | --- | | Time in target range | +4.8 points (SD 7.6) | P = 0.006 | | Time below 3.9 mmol/L | no increase | P = 0.19 | | Time below 3.0 mmol/L | no increase | P = 0.65 | Semaglutide added to automated insulin delivery, against placebo. Double-blind randomized crossover trial, 28 randomized Improving time in range without buying it back in low readings is the combination that matters in type 1 diabetes, because a drug that flattens glucose by pushing people toward hypoglycemia has not helped them at all. ## The safety signal a type 1 reader needs Two episodes of ketosis at normal glucose No diabetic ketoacidosis and no severe hypoglycemia occurred during any intervention. But the crossover trial recorded two episodes of recurrent euglycemic ketosis without acidosis during semaglutide use. Ketosis while blood glucose looks normal is the version that is easy to miss, because the number on the meter is reassuring while the problem is developing — and it is a recognized hazard when insulin comes down. This site covered the broader picture in [ketoacidosis without diabetes](https://thisglp.com/research/can-a-glp1-cause-ketoacidosis). ## How far this goes Not far, and the numbers are the reason. Twenty-eight people were randomized in one trial, and the other is a post hoc analysis of a larger but still modest study. Neither is the scale at which a safety signal separates from chance, or at which subgroups become visible. Both trials also enrolled people already using automated insulin delivery, which is a system that adjusts doses continuously and catches drift that a fixed regimen would not. Whether the same reductions would be safe on injections and finger-sticks is untested, and it is the setting most people with type 1 diabetes are actually in. ## What happened when it stopped The ADJUST-T1D team kept continuous glucose monitors on after the 26-week trial ended and followed people for a 12-week extension [\[3\]](https://thisglp.com/research/semaglutide-in-type-1-diabetes#ref-3). Sixteen had come off semaglutide, and 22 had been on placebo and started no GLP-1 drug afterwards, which is a small group on either side. Time in range fell by a median 3.6 percentage points in the people who stopped, against a 1.5-point rise in the placebo group. Glucose also swung more: the standard deviation rose 6.0 mg/dL against 1.2. Time above range crept up but lost significance after adjustment, and hypoglycemia measures did not differ between the groups. The authors read it as benefits that may not fully survive withdrawal, which is the story told at more length in [what happened when type 1 patients stopped](https://thisglp.com/research/type-1-diabetes-stopping-semaglutide). Nothing here is a reason to change an insulin dose, which is a decision that belongs to the clinician managing it. ## Frequently asked Is semaglutide approved for type 1 diabetes? No. Type 1 diabetes is not an approved indication for any GLP-1 drug, and both trials described here ran off-label under close supervision. How much did insulin needs fall? Total daily insulin fell 22.6% over 26 weeks, with bolus doses down 30.5% and basal doses down 15.6%. Insulin per kilogram per day went from 0.72 to 0.60 units. Was that just the weight loss? Not early on. At week four, 83% of the reduction was attributed to a direct drug effect and 17% to weight loss. By week 26 the two contributions were about equal in units per day. Did glucose control improve? Time in the target range rose by 4.8 percentage points against placebo, without more time spent below 3.9 or 3.0 mmol/L. What happens to glucose after stopping semaglutide in type 1 diabetes? In a 12-week extension of ADJUST-T1D, time in range fell a median 3.6 percentage points in 16 people who stopped, against a 1.5-point rise in 22 who had been on placebo, and glucose variability rose. What is the main safety concern? Two episodes of recurrent euglycemic ketosis without acidosis occurred during semaglutide use. Ketosis while glucose reads normal is easy to miss, and it is a recognized hazard when insulin doses come down. ## Sources 1. \[1\] Karakus KE, Akturk HK, Kruger D, Ahmann A, Bharvaga A, Langel CR (2026). Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis Diabetes Care. [PMID 41429002](https://pubmed.ncbi.nlm.nih.gov/41429002/) 2. \[2\] Pasqua MR, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A (2025). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial Nature Medicine. [PMID 39794615](https://pubmed.ncbi.nlm.nih.gov/39794615/) 3. \[3\] Montaser E, et al. (2026). Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study Diabetes, Obesity and Metabolism. [PMID 42675550](https://pubmed.ncbi.nlm.nih.gov/42675550/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Weight loss, tirzepatide against semaglutide · chart review, 12 mo · −16.6% · −13.4% · matched cohort, 2 yr · −14.7% · −10.8% · Randomized, SURMOUNT-5: 20.2% against 13.7% at 72 weeks. ### Tirzepatide vs Semaglutide: Which Works Better for Weight Loss? ](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) --- # Semaglutide in Knee Osteoarthritis: A Six-Month Cohort and Its Phenotypes In 88 knee osteoarthritis patients, six months of semaglutide came with 10.88 kg lost and WOMAC down 22.50 points, in a retrospective cohort with no comparison group and exploratory phenotype clusters. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-knee-osteoarthritis-phenotypes Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide in Knee Osteoarthritis: A Six-Month Cohort and Its Phenotypes Pain, function and inflammation markers all improved over six months on semaglutide in 88 patients. There was no untreated comparison group, and the authors say so in their methods. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Mean change at six months — everything moved · weight · −10.88 kg · pain, 0–10 scale · −2.47 points · WOMAC total · −22.50 points · C-reactive protein · −2.67 mg/L · sedimentation rate · −7.62 mm/h · Nobody was untreated, so nothing here is attributable. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 93 adults with knee osteoarthritis started semaglutide in routine rheumatology care; 88 completed six months. - Mean weight fell 10.88 kg, pain 2.47 points, WOMAC total 22.50 points. - Inflammatory markers fell too: C-reactive protein 2.67 mg/L, sedimentation rate 7.62 mm/h. - There was no untreated comparison group, and the authors say their results are therefore non-causal. - An exploratory clustering analysis sorted the 88 into response phenotypes. Every number in this study went the right way, and the authors wrote a sentence in their own methods that stops any of it being read as the drug’s doing. That sentence is worth more than the results, and it is the thing [the randomized knee trial](https://thisglp.com/research/do-glp1-drugs-help-knee-pain) has and this does not. ## What was measured A retrospective, self-controlled cohort of 93 adults with knee osteoarthritis and overweight or obesity, treated in routine rheumatology care. [\[1\]](https://thisglp.com/research/semaglutide-knee-osteoarthritis-phenotypes#ref-1) 88 completed six months. Pain on a visual analog scale, WOMAC function, anthropometry, inflammatory markers, glycated hemoglobin, lipids, dose exposure and safety were all tracked. At six months, mean weight had fallen 10.88 kg, pain by 2.47 points, WOMAC total by 22.50 points, C-reactive protein by 2.67 mg/L and sedimentation rate by 7.62 mm/h — the last two being inflammation markers rather than symptoms, and so [the easiest things here to move](https://thisglp.com/research/glp1-pcos-insulin-resistance). The methods section says it plainly “There was no untreated concurrent comparator; within-patient changes and exposure-outcome associations were therefore interpreted as non-causal.” Papers rarely disqualify their own headline that directly. It matters here more than usual, because every one of these outcomes moves on its own: knee pain fluctuates, people arrive at a clinic when they are at their worst, and taking 10.88 kg off a knee would improve WOMAC scores through mechanics alone. ## The phenotypes The authors also ran an exploratory K-means clustering across dose, weight loss, body mass index change, pain and WOMAC improvement, C-reactive protein, sedimentation rate and glycated hemoglobin, to sort patients into response patterns. K-means always returns clusters. Give it eight variables and 88 people and it will partition them, whether or not the groups mean anything. The authors call the analysis exploratory and examined how stable the solutions were under resampling, which is the right precaution — and a set of phenotypes found once in 88 people is a hypothesis, not a taxonomy, in the same way [a subgroup effect found once](https://thisglp.com/research/tirzepatide-fibrosis-worst-group) is. ## What it is good for Describing what happened to a real clinic’s patients over six months, which is genuinely useful and is not the same as showing what caused it. If you have knee osteoarthritis and are considering one of these drugs, the pain and function evidence worth weighing comes from the trial with a placebo arm. This cohort adds inflammatory markers and a picture of routine care, and it adds them with the caveat its own authors attached — which is more than [most real-world reports](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) manage. ## Frequently asked Did semaglutide improve knee pain here? Pain fell 2.47 points and WOMAC total 22.50 points over six months. The authors state there was no untreated comparator, so the changes are reported as non-causal. Why does a missing comparison group matter so much? Because knee pain fluctuates, people attend a clinic when they are worst, and losing 10.88 kg would improve knee scores mechanically. Without an untreated group, none of that can be separated from the drug. What are the response phenotypes? Clusters produced by an exploratory K-means analysis across eight variables in 88 patients. The method always returns clusters, and the authors treat the result as exploratory. Did inflammation improve? C-reactive protein fell 2.67 mg/L and sedimentation rate 7.62 mm/h, alongside the weight loss, in the same uncontrolled design. ## Sources 1. \[1\] Conforti A, et al. (2026). Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis-Results from a Six-Month Real-World Cohort Journal of Clinical Medicine. [PMID 42589980](https://pubmed.ncbi.nlm.nih.gov/42589980/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide Lifespan Study in Female Mice: 742 vs 834 Days | This GLP A Nature study found late-life semaglutide extended median lifespan in female mice from 742 to 834 days, outperforming a matched 24% calorie restriction on several measures. No human data exists. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-lifespan-in-mice Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide Lifespan Study in Female Mice: 742 vs 834 Days Semaglutide started late in life extended median lifespan from 742 to 834 days in female mice, and beat a calorie-restricted group matched to how much less they ate. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Median lifespan, female mice · vehicle · 742 days · semaglutide · 834 days · 92 days apart — and the comparison arm ate 24% less too · Treatment started at 20 months of age. No human data exists. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - This is a mouse study. Female C57BL/6 mice, one strain, treated daily from 20 months of age. - Median lifespan was 742 days on vehicle and 834 days on semaglutide. - The semaglutide regimen cut food intake by 24%, and a comparison group was calorie-restricted by the same 24%. - Against that matched restriction, semaglutide did better on exploration, spatial memory and glucose control. - No trial has asked whether any of this happens in a person. Nothing in this paper is a reason to buy a GLP-1, and it is going to be reported as one. What it is, is the first careful attempt to separate a drug’s effect on aging from the effect of simply eating less — and it is the outcome that [the surrogate-marker literature keeps standing in for](https://thisglp.com/research/do-glp1-drugs-slow-aging), measured directly, in animals. ## What was done Female mice of a single common laboratory strain were given daily semaglutide by injection starting at twenty months of age, which is late middle age for a mouse rather than the start of life. [\[1\]](https://thisglp.com/research/semaglutide-lifespan-in-mice#ref-1) Treatment continued for the rest of their lives. Median lifespan came out at 742 days in the vehicle group and 834 days on semaglutide, compared by log-rank test. The gap of 92 days, about 12%, is this desk’s subtraction from those two published figures rather than a number the paper prints. Why the calorie-restriction arm matters so much Eating less is the oldest and most reliable way known to extend life in a laboratory animal, and a drug that suppresses appetite will do that by default — so a lifespan result from an appetite suppressant tells you nothing on its own about the drug. The authors measured how much less their mice ate, found 24%, and then ran a separate group restricted by exactly that 24% for five months as the comparison. Against it, semaglutide preserved baseline function, tracked calorie restriction on most measures, and did better on exploratory drive, spatial memory and glucose control. That is the part of the paper that is actually new. ## What it also found Three months of treatment improved physiological function, attenuated recognized hallmarks of aging, and shifted nutrient-sensing pathways and conserved genetic regulators of aging in the direction calorie restriction shifts them. The authors read the whole picture as semaglutide acting like a calorie-restriction mimetic, with some effects beyond what reduced intake explains — which is a mechanistic claim about mice, and a different kind of evidence from [a biomarker moving in people](https://thisglp.com/research/glp1-pcos-insulin-resistance). ## Every reason to hold it loosely Female mice only, one strain, one laboratory. Strain and sex both change lifespan results in this field routinely, and a finding in female C57BL/6 mice is a finding in female C57BL/6 mice until somebody repeats it elsewhere. The schedule is not a human schedule either. These animals were injected daily; people take semaglutide weekly, at doses that do not map across species by any simple ratio. Drugs that extend rodent lifespan have a long history of not doing so in humans, and there is no registered trial asking this question in people. ## What a reader should take from it That the mechanism question is now genuinely open, and that it was mostly closed before this — the reasonable default was that any longevity effect of these drugs is a weight effect wearing a lab coat. This is real evidence against that default, in mice. What it is not is a purchase. The drugs on this site are sold for weight, at prices set by sellers, to people who will take them for a year or two at most, and [what happens outside a controlled study](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) looks nothing like a mouse facility. A first-in-class result has to survive a long way before it means anything at a checkout — the same distance [an early-phase weight figure](https://thisglp.com/research/triple-agonist-first-in-human) has to travel. ## Frequently asked Does semaglutide extend lifespan? In female mice of one strain, started at twenty months, median lifespan went from 742 to 834 days. Nothing equivalent has been measured in people, and no trial is asking. Is it just because the mice ate less? That is the question the study was built to answer. Semaglutide cut food intake by 24%, and a separate group was restricted by the same 24% — against it, the drug still did better on exploration, spatial memory and glucose control. How much longer is 92 days for a mouse? About 12% on the vehicle group's median. That percentage is arithmetic from the two published figures, not a number the paper reports. Should this change what I do? No. It was daily injection in mice at doses that do not translate across species, and rodent lifespan results have a long record of not carrying over to people. ## Sources 1. \[1\] Feng Y, et al. (2026). Late-life semaglutide treatment slows ageing and extends lifespan in female mice Nature. [PMID 42686906](https://pubmed.ncbi.nlm.nih.gov/42686906/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide Carbon Footprint: A UK Lifetime Emissions Model | This GLP A UK disease model gave semaglutide lower lifetime carbon emissions in two groups and higher in a third (14,700 against 14,444 kg CO2e) because patients lived longer. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-lifetime-carbon-emissions Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide Carbon Footprint: A UK Lifetime Emissions Model A disease model found semaglutide lowered lifetime carbon emissions in two UK populations and raised them in a third, because the people in it survived longer. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Modeled change in lifetime carbon emissions · BMI 30+, or 27+ with a complication · 1.8% lower · BMI 27+ with a complication · 1.8% lower · BMI 27+ with heart disease · about 1.8% higher · The third group lived longer. 14,700 against 14,444 kg CO2e. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A Markov model estimated the lifetime carbon footprint of semaglutide against diet and exercise alone in the UK. - In two populations, modeled emissions fell by 1.8%, alongside 0.30 and 0.25 extra life-years. - In the population with established heart disease, emissions rose: 14,700 against 14,444 kg CO2e. - The reason they rose is that people lived longer and were monitored more. - Every author is a Novo Nordisk employee, adviser, IQVIA employee, or works for a consultancy Novo has funded. Somebody had to ask this question eventually, because health systems buying at national scale now have emissions targets attached to their procurement, and a weekly injection manufactured, refrigerated and shipped for years is not a small object in that arithmetic. The answer the model returns is interesting mostly for the part that does not fit the conclusion, which is a pattern this site keeps meeting in [modeled evidence generally](https://thisglp.com/research/telehealth-glp1-program-trial). ## What was modeled A cohort state-transition model, fed with results from the STEP and SELECT trials, estimated per-patient emissions across a lifetime for semaglutide 2.4 mg added to diet and exercise, against diet and exercise on their own, in three UK populations. [\[1\]](https://thisglp.com/research/semaglutide-lifetime-carbon-emissions#ref-1) Nothing here was weighed or metered; every figure is an output of the model’s assumptions about how obesity-related complications would otherwise have unfolded. In the two populations defined by body mass index and complications, the drug came out ahead on everything the model tracked: 0.30 and 0.25 additional life-years, 0.51 and 0.46 additional quality-adjusted life-years, and lifetime emissions lower by 1.8%. The manufacturing footprint of the drug was more than offset by the complications the model expected it to prevent. ## The third population Among people with a body mass index over 27 and established cardiovascular disease, the clinical results were the best of the three — 0.56 additional life-years and 0.59 additional quality-adjusted life-years — and the carbon result went the other way, with modeled lifetime emissions of 14,700 kg CO2e against 14,444 for the comparator. The gap of 256 kilograms, about 1.8% higher, is this desk’s subtraction from the paper’s two published figures. The stated reason is longer survival and more monitoring. People who do not die of a heart attack go on consuming healthcare, and healthcare emits. What that reversal actually means It means the environmental result is a function of how the model prices survival, not a property of the drug, because any therapy that keeps people alive longer will add years of emissions to its own ledger — and a model that counts those years as a cost will find every life-extending treatment environmentally worse the better it works. The paper does not say that; it reports the reversal accurately and then concludes that semaglutide offers clinical and environmental benefits supporting the UK’s net-zero goals, which is true of two populations out of three and is [stated more broadly than the results support](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease). ## Who wrote it Two of the authors are employees and shareholders of Novo Nordisk, which makes semaglutide. One sits on the company’s Sustainability Advisory Council under contract. Five are employees of IQVIA, and one works for a health-economics consultancy that has received Novo Nordisk funding in the past three years. That is the entire author list, and the disclosure is published in full, which is the right way to do it. None of it makes the model wrong — a manufacturer usually holds the data nobody else has — but a reader deciding how much weight to give a favorable environmental conclusion is entitled to know that no independent party checked the assumptions that produced it. ## What it has to do with buying one Almost nothing, which is worth saying plainly on a site whose readers are paying for these drugs out of pocket. This paper argues to a health system deciding what to stock, and a life-year in a model is not a promise to any individual, for the same reason [a modeled clock is not a lifespan](https://thisglp.com/research/do-glp1-drugs-slow-aging). What it is good for is calibration. When a study arrives showing that a drug is good on an axis nobody was arguing about, the question to ask first is who needed that answer — the same question worth asking about [any ranking that flatters a seller](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). ## Frequently asked Does semaglutide lower carbon emissions? In this model, in two of three populations, by 1.8% over a lifetime. In the third, people with established heart disease, modeled emissions rose from 14,444 to 14,700 kg CO2e. Why did emissions go up in one group? Because those patients lived longer and were monitored more. Any treatment that extends life adds years of healthcare emissions to its own account. Was this measured or estimated? Estimated. It is a cohort state-transition model fed with STEP and SELECT trial results. No emissions were metered. Who funded it? The author list consists of Novo Nordisk employees and shareholders, a contracted adviser to the company's sustainability council, IQVIA employees, and a consultant whose firm has received Novo Nordisk funding. All of it is disclosed in the paper. ## Sources 1. \[1\] Lund N, et al. (2026). Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach PharmacoEconomics. [PMID 42722807](https://pubmed.ncbi.nlm.nih.gov/42722807/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide for MASH in Japanese Patients: The ESSENCE Subgroup | This GLP In 116 Japanese ESSENCE participants, steatohepatitis resolved in 63.1% against 36.8% on placebo, while the fibrosis endpoint gave 7.07 points, 95% CI −11.48 to 25.62. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-liver-japanese-subgroup Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide for MASH in Japanese Patients: The ESSENCE Subgroup Semaglutide resolved liver inflammation in 116 Japanese trial participants. On fibrosis, the endpoint the approval is written around, the interval ran from −11 to +26. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 116 Japanese participants: 78 on semaglutide, 38 on placebo · steatohepatitis resolved · 63.1% drug · 36.8% placebo · +26.65 (7.43 to 45.86) · fibrosis improved · 36.5% drug · 28.9% placebo · +7.07 (−11.48 to 25.62) · Differences in percentage points. The second interval crosses zero. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 116 Japanese participants from the first 800 randomized in the ESSENCE trial: 78 on semaglutide, 38 on placebo. - Steatohepatitis resolved without worsening fibrosis in 63.1% against 36.8% — a difference of 26.65 points, 95% CI 7.43 to 45.86. - Fibrosis improved without worsening steatohepatitis in 36.5% against 28.9% — 7.07 points, 95% CI −11.48 to 25.62. - That second interval crosses zero, so the fibrosis endpoint did not separate in this subgroup. - The Japanese participants were older with a lower body mass index than the overall trial population. Two endpoints, two very different results, and the one that did not hold is the one the drug’s liver approval is written around — which makes the order they are read in the whole of what this page has to get right, since [the indication is defined by a fibrosis stage](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease). ## What this is A subgroup analysis. Of the first 800 people randomized in the interim efficacy analysis of the ESSENCE trial, 116 were Japanese — 78 given semaglutide and 38 given placebo. [\[1\]](https://thisglp.com/research/semaglutide-liver-japanese-subgroup#ref-1) They were older and lighter than the trial population as a whole. That difference is why somebody looked, and it is also why the numbers should not be carried far. A subgroup is not designed to answer a question; it is a slice reported after the fact, and 38 people in a placebo arm is a narrow base for a proportion. ## The endpoint that separated Resolution of steatohepatitis with no worsening of fibrosis reached 63.1% on semaglutide against 36.8% on placebo. The estimated difference in responder proportions is 26.65 percentage points, 95% CI 7.43 to 45.86. That is a wide interval around a large effect, which is what a subgroup of this size produces, and it clears zero comfortably — unlike [the intervals that do not](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia). And the endpoint that did not Improvement in fibrosis with no worsening of steatohepatitis reached 36.5% against 28.9% — a difference of 7.07 points, 95% CI −11.48 to 25.62. That interval starts below zero, meaning the data are compatible with semaglutide doing slightly worse than placebo here, and it ends at 25.62, meaning they are equally compatible with a large benefit. In 116 people, this endpoint simply was not answered. ## What “directionally consistent” means That is the authors’ phrase for the whole comparison, and it is well chosen. Both point estimates favor the drug, and both are consistent with the overall trial. It is not a claim that the subgroup confirmed anything. A subgroup that agrees in direction with a larger trial adds reassurance about generalizability and does not independently establish an effect — the difference between [not detecting a difference and showing there is none](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes), applied to a slice rather than a whole study. ## Why it is worth reading anyway Because trial populations are rarely the population buying the drug, and a subgroup that differs on age and body size is a small test of whether the result travels. Here it traveled on one endpoint and was untested on the other. That is a more useful summary than either the headline or the caveat alone, and it is the same reading that [the main liver evidence](https://thisglp.com/research/semaglutide-and-liver-disease) deserves — a drug with a real effect on inflammation whose effect on scarring is the harder, slower, less settled question. ## Frequently asked Did semaglutide work in this subgroup? On steatohepatitis resolution, yes — 63.1% against 36.8%, a difference of 26.65 points with a confidence interval clear of zero. On fibrosis improvement the interval ran from −11.48 to 25.62 and did not separate. How many people were in it? 116 — 78 on semaglutide and 38 on placebo — drawn from the first 800 randomized in an interim analysis. What does 'directionally consistent' mean? That both estimates favored the drug and agreed with the overall trial. It is not a claim that the subgroup independently confirmed the effect. Why look at Japanese participants separately? They were older and had a lower body mass index than the overall trial population, which makes them a small test of whether the result travels across body size and age. ## Sources 1. \[1\] Nakajima A, et al. (2026). Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial Journal of Gastroenterology. [PMID 42663669](https://pubmed.ncbi.nlm.nih.gov/42663669/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide and Handgrip Strength: A 12-Month Body Composition Study | This GLP Semaglutide and handgrip strength in 83 adults with obesity: 11.0 kg more weight loss and less muscle mass at 12 months, with grip strength preserved in both groups. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-muscle-mass-and-grip Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide and Handgrip Strength: A 12-Month Body Composition Study Over twelve months on semaglutide, skeletal muscle mass fell from 29.9 to 28.7 kg while handgrip strength held, and the metabolic slowdown matched the lifestyle-only group. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Twelve months on semaglutide — what moved · skeletal muscle · 29.9 kg · → · 28.7 kg · fat-free mass · 53.8 kg · → · 52.7 kg · handgrip strength · preserved · Metabolic rate fell past prediction — in both groups alike · 44 on semaglutide, 39 on lifestyle alone. One center, not randomized. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 44 adults with obesity on semaglutide plus a lifestyle program, against 39 on the program alone, followed 12 months. - Weight fell 11.0 kg further on semaglutide, p = 0.001, with waist down 7.0 cm. - Skeletal muscle mass fell from 29.9 to 28.7 kg and fat-free mass from 53.8 to 52.7 kg, p < 0.001. - Handgrip strength was preserved — in both groups. - Resting energy expenditure fell further than body composition predicts, equally in both groups. Two measurements in this study disagree with each other, and the disagreement is more useful than either one alone: the muscle got smaller and the hand did not get weaker. [What the lean-mass numbers mean](https://thisglp.com/research/muscle-loss-on-glp1) is covered elsewhere on this site; this is about what happens when somebody also measures what the muscle can do. ## The setup A single obesity unit in Barcelona, looking back at routine care between January 2024 and December 2025. [\[1\]](https://thisglp.com/research/semaglutide-muscle-mass-and-grip#ref-1) Adults with a body mass index of 30 or more and no diabetes, 44 on semaglutide alongside a lifestyle program and 39 on the program alone, each with a baseline and a twelve-month assessment. Nobody was randomized. In routine care the people who end up on a drug differ from the people who do not, and 83 patients at one center is a small base for any of it. ## What came off Weight fell 11.0 kg further in the semaglutide group, p = 0.001, with body mass index down 4.0 and waist circumference down 7.0 cm, p = 0.002. Fat mass fell. So did skeletal muscle mass, from 29.9 to 28.7 kg, and fat-free mass, from 53.8 to 52.7 kg, both at p < 0.001. That is the finding people argue about, and it is real here. Losing weight costs lean tissue by whatever route it happens; what a drug adds on top is the open question, and it is the same shape of question as [what a higher dose buys and what it costs](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it). The grip test says something the scale cannot Absolute handgrip strength was preserved, in the semaglutide group and the lifestyle group alike. A smaller muscle that pulls as hard as it did before is a different event from a weaker one, and a body-composition scale cannot tell them apart — it reports kilograms. The authors also ran a reference-standardized muscle index, which compares a person against age- and body-size-matched norms rather than against their own earlier kilograms, and on that measure the semaglutide group improved. Both things are true: less muscle by mass, better standing relative to people of the same size. ## The adaptation that was not the drug Resting energy expenditure fell in both groups by more than fat-free mass, fat mass, age and sex would predict — the phenomenon called adaptive thermogenesis, the body spending less than its new size implies. There was no significant difference between the groups. The semaglutide patients lost far more weight and their metabolic rate adapted no differently from the people who lost less without the drug. That is worth stating carefully, because it would be easy and wrong to file it as a GLP-1 side effect. It is what losing weight does, and this study found the drug neither caused it nor prevented it. ## What a reader takes from it That the muscle question needs a strength test attached to it, and almost never gets one. A study reporting kilograms of lean mass and stopping there has measured half of the thing people actually care about. And that the metabolic adaptation is going to be there whatever route you take down, which is part of why [weight comes back after stopping](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1). None of this is settled by 83 people at one hospital, and the authors’ own conclusion is a request for better monitoring rather than a claim — the appropriate weight for [an observation from routine care](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## Frequently asked Does semaglutide cost you muscle? Skeletal muscle mass fell from 29.9 to 28.7 kg over twelve months here. Handgrip strength did not change, so the mass and the function moved differently. Does it slow your metabolism? Resting energy expenditure fell further than body composition predicts — but equally in the group losing weight without the drug. This study found no difference between them. How big was the study? 83 patients at one hospital, 44 on semaglutide and 39 on lifestyle alone, looked at retrospectively rather than randomized. Why did one muscle measure improve while mass fell? The improving measure is a reference-standardized score comparing a person against norms for their age and body size, not against their own earlier kilograms. ## Sources 1. \[1\] Filippi-Arriaga F, et al. (2026). Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide Obesity Facts. [PMID 42640861](https://pubmed.ncbi.nlm.nih.gov/42640861/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide and NAION: Optic Nerve Risk in Diabetes vs Obesity | This GLP Pooling eight cohorts, semaglutide carried a relative effect of 1.93 for NAION, an optic nerve injury, overall and 1.68 (95% CI 0.72 to 3.91) in people with overweight or obesity. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-optic-nerve-by-indication Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Semaglutide and NAION: Optic Nerve Risk in Diabetes vs Obesity A meta-analysis of six million people links semaglutide to optic nerve damage. In people taking it for weight rather than diabetes, the interval runs from 0.72 to 3.91. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Relative effect for NAION, against no semaglutide · 1.0 · everyone pooled · with diabetes · overweight or obese · The eight studies agree almost not at all: I² 91%. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Eight observational cohorts, 5,916,559 people, 1,870,346 of them on semaglutide. - Pooled relative effect for NAION: 1.93, 95% CI 1.22 to 3.08, P = .01. - Among people with diabetes: 1.84, 95% CI 1.21 to 2.80. - Among overweight or obese people: 1.68, 95% CI 0.72 to 3.91, P = .23 — not significant. - Heterogeneity was 91%, and no absolute rate is published in this abstract. NAION is a sudden, usually painless loss of vision in one eye, caused by interrupted blood supply to the optic nerve, and it is usually permanent. That is a serious enough outcome that the numbers below deserve reading in full rather than as a headline — starting with which population each one describes, which is the distinction [most figures about these drugs lose](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke) on the way to being quoted. ## Where a weight-loss reader sits The pooled figure across all eight studies is a relative effect of 1.93, 95% CI 1.22 to 3.08. [\[1\]](https://thisglp.com/research/semaglutide-optic-nerve-by-indication#ref-1) Split by population, the association held among people with diabetes — 1.84, 95% CI 1.21 to 2.80 — and did not reach significance among overweight or obese people: 1.68, 95% CI 0.72 to 3.91, P = .23. Almost everybody reading a price page for these drugs is in that third row. So the honest summary for this audience is that the association is not established in people like them — which is the opposite of what [a headline drawn from the pooled figure](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease) would say. A wide interval is not reassurance 0.72 to 3.91 contains 1.0, which is why it is not significant. It also contains 3.91, which would be close to four times the risk. An interval that wide says the data cannot distinguish between no effect and a large one, and the correct reading is that nobody knows yet — not that nothing is there. The subgroup is smaller than the diabetes one, which is part of why it is wide. ## The studies disagree with each other Heterogeneity was 91% overall and above 83% in both subgroups. That is close to the ceiling: it means the eight studies are not estimating one common number, they are producing genuinely different answers. A random-effects pooled figure in that situation is an average of results that conflict, and it may be a number no individual study found — the same problem as [an average nobody in the trials experienced](https://thisglp.com/research/glp1-weight-loss-pooled-average), and a reason to treat 1.93 as a summary of disagreement rather than as a measurement. ## The number that is missing How many people this would actually affect. NAION is rare in the general population, so even a doubled relative risk can amount to a small number of extra cases. This abstract publishes no baseline rate and no absolute difference, so the arithmetic cannot be done here, and this desk will not invent a denominator to do it with. That absence is the single most important limitation on the page, for the same reason [a relative figure alone settles nothing](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## What this supports Every one of the eight studies is observational, and the authors describe the finding as a possible association and ask for randomized trials. If you have diabetes, this is the subgroup where the signal held, and it is worth raising with whoever prescribes for you — particularly alongside any existing eye disease. If you are taking it for weight without diabetes, the honest position is an open question rather than a finding, which is a different thing from [a settled real-world result](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## Frequently asked Does semaglutide cause sudden vision loss? Eight observational cohorts pooled to a relative effect of 1.93, which the authors call a possible association. They ask for randomized trials before anyone draws a conclusion. Does that apply if I am taking it for weight? In the overweight and obese subgroup the result was 1.68, 95% CI 0.72 to 3.91, which is not significant. That interval also reaches nearly four times the risk, so it means unknown rather than safe. How many extra cases would that be? The abstract publishes no baseline rate, so the absolute figure cannot be worked out from it. NAION is rare, which means a doubled relative risk may be a small number of people. What is NAION? Nonarteritic anterior ischemic optic neuropathy — sudden, usually painless loss of vision in one eye from interrupted blood supply to the optic nerve. It is usually permanent. ## Sources 1. \[1\] Khani E, et al. (2026). Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis The Journal of Clinical Pharmacology. [PMID 42612051](https://pubmed.ncbi.nlm.nih.gov/42612051/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Semaglutide Psychiatric Risk Meta-Analysis: Trials Pooled With Report Counts A semaglutide meta-analysis gave pooled risk ratios of 1.25 for depression, 1.22 for anxiety and 1.20 for suicidal ideation, all non-significant, with heterogeneity of 98%, 99% and 92%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-psychiatric-risk-pooling Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Semaglutide Psychiatric Risk Meta-Analysis: Trials Pooled With Report Counts A meta-analysis found no significant psychiatric risk with semaglutide. It reached that by pooling randomized trials with tallies from a spontaneous reporting database. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Pooled risk ratio, and how much the studies disagreed · 1.0 · depression · I² 98% · anxiety · I² 99% · suicidal ideation or attempt · I² 92% · Randomized trials and report tallies, averaged together. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A meta-analysis of semaglutide and psychiatric outcomes, searched to January 2026. - Depression: pooled risk ratio 1.25, 95% CI 0.95 to 1.65. Anxiety: 1.22, 0.93 to 1.60. Suicidal ideation or attempt: 1.20, 0.90 to 1.62. - None is statistically significant. All three point estimates sit above 1. - Heterogeneity was 98%, 99% and 92% — the studies barely agree at all. - Randomized trials were pooled together with spontaneous-reporting analyses. Three reassuring-looking nulls, and a methods section that explains why the word “pooled” is doing more work here than usual — the same distinction between [what different designs can be asked](https://thisglp.com/research/do-glp1-drugs-cause-gout) that decides how much any average is worth. ## What went into the pool The eligible studies were randomized controlled trials, observational studies, large database analyses and pharmacovigilance disproportionality studies. [\[1\]](https://thisglp.com/research/semaglutide-psychiatric-risk-pooling#ref-1) All four were combined into single risk ratios. Those are not the same measurement. A randomized trial compares what happened to two groups assigned by chance. A disproportionality analysis divides one kind of report by other reports inside a spontaneous database, with no count of how many people took anything. The first estimates a risk; the second estimates how a database looks, which is why [the cohort evidence on this question](https://thisglp.com/research/glp1-and-suicidal-ideation) is worth separating from the report counts rather than averaged with them. Which is why the heterogeneity is what it is I² of 98%, 99% and 92% means the included studies are not producing scattered estimates of one underlying number — they are producing different numbers, near-completely. Some of that is populations and follow-up. A large part of it is that the inputs are answers to different questions. A random-effects model will still return an average, and the average of a risk ratio and a reporting ratio is neither. ## What the numbers say Depression 1.25, 95% CI 0.95 to 1.65. Anxiety 1.22, 95% CI 0.93 to 1.60. Suicidal ideation or attempt 1.20, 95% CI 0.90 to 1.62. Every interval crosses 1, so none is significant. All three point estimates sit above 1, which is worth saying plainly and worth not over-reading. It is not evidence of harm. It is also not the same picture as three estimates landing on either side of 1, and with intervals this wide the data cannot distinguish between the two. ## The sentence the authors close on They describe their own findings as reassuring, and then write that they should be interpreted as the absence of a detected increased risk in the available evidence rather than definitive proof of no psychiatric risk. That is a precise and unusually honest closing line, and it is the whole of [why not finding something is not finding nothing](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) written by the people who did the work. ## What to carry away That regulators on both sides of the Atlantic have looked at this question and not confirmed a causal link, and that this analysis does not contradict them. And that when a meta-analysis reports heterogeneity in the nineties, the first thing to check is what it pooled. An average of incompatible designs is a summary of a literature, not a measurement of a risk — the same caution that applies to [any pooled figure no individual study reported](https://thisglp.com/research/glp1-weight-loss-pooled-average). Anyone experiencing thoughts of harming themselves should speak to a doctor now, not weigh an interval. ## Frequently asked Does semaglutide increase depression risk? This analysis found a pooled risk ratio of 1.25, 95% CI 0.95 to 1.65 — not statistically significant. The authors call it the absence of a detected increase rather than proof of no risk. Why is the heterogeneity so high? Partly populations and follow-up, and partly because randomized trials were pooled with spontaneous-reporting analyses, which measure a different thing entirely. What about anxiety and suicidal ideation? Pooled risk ratios of 1.22, 95% CI 0.93 to 1.60, and 1.20, 95% CI 0.90 to 1.62. Neither is significant, and both intervals are wide. Should this change anything? It does not contradict what regulators have concluded. Anyone having thoughts of self-harm should speak to a doctor rather than weigh a confidence interval. ## Sources 1. \[1\] Bhaduri G, et al. (2026). Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis Clinical Obesity. [PMID 42584177](https://pubmed.ncbi.nlm.nih.gov/42584177/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Semaglutide and Reproductive Hormones in Rats: A Pair-Fed Study | This GLP Semaglutide in diet-induced obese rats against pair-fed controls: androgens fell on food restriction and less on the drug, while female hormones fell in a treatment-specific way. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-reproduction-pair-fed-rats Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide and Reproductive Hormones in Rats: A Pair-Fed Study A second group of obese rats was fed exactly what the treated ones ate, so it lost the same weight without the drug. The gap between those two arms is the molecule. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Why a pair-fed arm exists · fed freely · no weight loss, no drug · pair-fed to match · same weight loss, no drug · semaglutide · same weight loss, plus drug · The difference between the last two rows is the drug itself. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Diet-induced obese rats, four weeks of semaglutide, with a pair-fed control group. - The pair-fed animals ate exactly what the treated ones ate, so they lost weight without the drug. - In males, weight loss lowered androgens and semaglutide blunted that reduction. - In females, progesterone, pregnenolone and estradiol fell in a way the diet alone did not produce. - GLP-1 receptor expression was four-fold higher in testes than in ovaries. These are rats — 4 weeks of treatment in diet-induced obese animals. Nothing below is a finding about a person, and 4 weeks in a rodent is not a year in a human being. What makes the study worth reading anyway is a control group most studies skip. [\[1\]](https://thisglp.com/research/semaglutide-reproduction-pair-fed-rats#ref-1) ## The arm that does the work Every question about these drugs runs into the same confound: the people taking them are also losing weight, and weight loss changes almost everything you might want to measure. A pair-fed control settles it. One group gets the drug; a second group is fed exactly the amount the first group chose to eat, so it loses the same weight with no drug in it. Anything that differs between those two arms is the molecule. Anything they share is the eating. That is the design human studies almost never manage, which is why so much of this field cannot separate the two — the same trouble behind [measurements taken on a shrinking body](https://thisglp.com/research/glp1-body-composition-smart-scale). ## What separated, and which way In male rats, both the drug and the matched restriction improved sperm motility and mucus penetration. That shared result points at the weight rather than the molecule. The hormones went the other way. Restriction lowered androgens, and semaglutide attenuated that fall — so here the drug partly offset something the weight loss caused. In females, progesterone, pregnenolone and estradiol fell in a treatment-specific way, meaning the diet alone did not do it. Folliculogenesis increased in both arms. Pituitary hormones shifted in both sexes. Two different kinds of finding A drug that blunts a weight-loss effect and a drug that causes an effect of its own are not the same discovery, and this study found one of each in different sexes. That is worth holding onto, because summaries will flatten it into “semaglutide affects reproductive hormones”, which is true of both and useful about neither. ## What the receptor count does and does not say GLP-1 receptor expression measured 4-fold higher in testes than in ovaries — a ratio of 4.0 between two tissues in the same animals. The authors describe this as supporting a potential male bias for the drug’s potency. Expression is not potency. A tissue can carry many receptors and respond little, or few and respond strongly, and this study did not test the link. Keep it as the hedge they wrote it as, the way [a marker close to the mechanism](https://thisglp.com/research/glp1-pcos-insulin-resistance) still has to be shown to move. ## What nobody measured Whether any animal conceived. The morphology is described as largely suggesting increased fertility, which is a statement about tissue under a microscope. In humans the direct evidence remains thin in both directions — small and narrow on the male side, as [a twenty-five-man comparison](https://thisglp.com/research/do-glp1-drugs-affect-fertility) shows, and almost absent for anything a rodent can only gesture at. Animal work of this quality tells you which human study to run. It does not substitute for one, any more than [ninety-two more days in mice](https://thisglp.com/research/semaglutide-lifespan-in-mice) settles anything about a lifespan. ## Frequently asked Does semaglutide affect fertility? This study was in rats and measured hormones and gonad structure, not conception. The findings differ by sex and cannot be read across to people. What is a pair-fed control? A group fed exactly the amount the treated group ate, so it loses the same weight without receiving the drug. Differences between the two arms are the drug; shared results are the eating. What differed between the sexes? In males the drug blunted a fall in androgens that weight loss caused. In females several hormones fell in a way calorie restriction alone did not produce. Does higher receptor expression mean a stronger effect? Not on its own. Testes carried four-fold more GLP-1 receptor than ovaries, but expression is not potency and this study did not test the link. ## Sources 1. \[1\] Sotzen MR, et al. (2026). Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats Molecular Metabolism. [PMID 42692145](https://pubmed.ncbi.nlm.nih.gov/42692145/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes | This GLP The starting dose is 0.25 mg weekly for four weeks, escalating every four weeks to 1.7 or 2.4 mg. What compounding changes, and the measurement error that causes harm. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-starting-dose Updated: 2026-10-26 Published: 2026-09-17 [← Research](https://thisglp.com/research) Formats # Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes Four weeks at 0.25 mg, then a step every four weeks to 1.7 or 2.4 mg. What changes with a compounded vial is not the milligrams — it is who measures them. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - The labeled starting dose is 0.25 mg once weekly for four weeks — a dose chosen for tolerability, not for weight loss. - Escalation steps every four weeks: 0.5 mg, then 1 mg, then 1.7 mg, reaching a maintenance dose of 1.7 or 2.4 mg at week 17. - No compounded semaglutide carries an FDA-approved label, so the ladder above is the approved product's, borrowed by convention. - The real difference with a compounded vial is not the milligrams. It is that you measure them yourself, in units, on a syringe. The short answer is 0.25 mg once weekly for the first four weeks. The longer answer has three parts. The number comes from the approved product’s label. No compounded vial has a label of its own. And the step that goes wrong is not choosing the dose. It is drawing it. ## What the labeled ladder actually is The prescribing information for the approved injection sets a fixed escalation schedule and tells prescribers to titrate every four weeks [\[5\]](https://thisglp.com/research/semaglutide-starting-dose#ref-5). Every rung below is four weeks long. Recommended starting dosage and escalation, approved semaglutide injection. | Weeks | Weekly dose | What this rung is for | | --- | --- | --- | | 1–4 | 0.25 mg | Starting dosage. Not a treatment dose. | | 5–8 | 0.5 mg | First escalation step. | | 9–12 | 1 mg | Second escalation step. | | 13–16 | 1.7 mg | Third step — also a valid maintenance dose. | | 17 and onward | 1.7 mg or 2.4 mg | Maintenance for weight reduction. | Recommended starting dosage and escalation, approved semaglutide injection. FDA prescribing information via DailyMed, read September 2026 Two provisions matter more than the numbers. If a dose is not tolerated, the label says to consider delaying escalation by four weeks rather than pushing on. Miss two or more consecutive weekly doses and escalation restarts at a lower dose. You do not resume where you left off. That second rule catches people who travel, run out, or wait on a refill. ## Why it starts so low 0.25 mg is not a weight-loss dose. It exists to get the gut used to the drug — the reasoning behind [every published ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). The STEP 1 to 3 trials pooled their gastrointestinal events at 2.4 mg. Nausea ran 43.9% against 16.1% on placebo. Vomiting ran 24.5% against 6.3%. Diarrhea ran 29.7% against 15.9% [\[2\]](https://thisglp.com/research/semaglutide-starting-dose#ref-2). Those events clustered during and shortly after escalation, and 98.1% were mild to moderate. 43.9% had nausea on 2.4 mg (16.1% on placebo) STEP 1–3 pooled 98.1% of gut side effects were mild or moderate STEP 1–3 pooled 4.3% stopped permanently because of them STEP 1–3 pooled <1 pt of the weight loss was explained by them mediation analysis You do not have to feel sick for it to be working The same analysis ran a mediation model and found that of the extra 7.6% to 14.4% of weight lost on semaglutide against placebo, less than one percentage point was mediated by gastrointestinal side effects. People who had no side effects lost 9.6% to 17.1%; people who had them lost 11.4% to 17.7%. Feeling unwell is not the mechanism, and tolerating a slower climb costs you very little — which is the reasoning behind [the titration schedule](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## What changes when the product is compounded The milligrams do not change. The delivery does. An approved product arrives as a pen, with the dose selected for you. A compounded product typically arrives as a vial with syringes. The arithmetic moves to your kitchen table. A poison-control case series describes what that costs. Of three cases of compounded semaglutide administration errors, two were ten-fold overdoses. All three patients had nausea, vomiting and abdominal pain lasting days. One received a vial and syringes with no pharmacist counseling. One reported dosing in milliliters and units rather than milligrams [\[3\]](https://thisglp.com/research/semaglutide-starting-dose#ref-3). The authors’ conclusion is about the format. Vials do not carry the safety features of a prefilled pen. Syringes not intended for semaglutide make the unit ambiguous. Your vial's concentration is the number that matters “How many units is 0.25 mg” has no fixed answer, because it depends entirely on the concentration of the vial in front of you. The same 0.25 mg is a different mark on the syringe at 2.5 mg/mL than at 5 mg/mL. Never carry a unit count over from a previous vial, a forum post or a friend — read the concentration on the label you were dispensed, every time it changes. This is the failure mode behind [the dose errors that reach adverse-event reports](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). ## Is the compounded version riskier? One study read the FDA’s adverse event database from 2018 to 2024. It compared 707 reports involving compounded products against 81,078 GLP-1 reports in total [\[4\]](https://thisglp.com/research/semaglutide-starting-dose#ref-4). Compounded products carried higher reporting odds on four counts. Preparation errors: ROR 48.92 (95% CI 12.63 to 189.6). Contamination: 19.00 (4.24 to 85.03). Compounding or manufacturing issues: 8.51 (5.17 to 14.0). Hospitalization: 2.35 (1.94 to 2.83). The same study found _lower_ reporting odds for administration errors (0.29) and dosing errors (0.24). That runs against the case-series picture. It is worth stating rather than hiding. Reporting odds ratios measure what gets reported, not what happens. A disproportionality signal is not an incidence rate. Read the direction and the intervals, not the point estimates. ## So what should you actually do in week one Start at the dose your prescriber wrote, which for a first course is almost always 0.25 mg weekly. Read the concentration printed on your vial and have whoever dispensed it confirm the mark on the syringe before the first injection. Hold each rung four weeks. If a rung is rough, the label advises staying there another four weeks rather than climbing. Miss two weeks in a row and expect to step back down. What happens at the top of the ladder is a separate question, covered in [how deep a published dose ladder goes](https://thisglp.com/research/how-deep-a-published-dose-ladder-goes). This guide will not tell you which concentration to buy. It will not convert milligrams to units for a specific vial. That calculation has a wrong answer, and the wrong answer sends people to hospital. The person dispensing your medication should do it with you. The [Coby Health review](https://thisglp.com/reviews/coby-health) illustrates how a seller’s [dose and bundle menu](https://www.cobyhealth.com/treatments/weight-loss/semaglutide) differs from a prescription. Prices can be compared before enrollment, but the prescriber must determine your regimen. A package label or discount is not a reason to choose a higher dose or change the instructions supplied with medication. ## Frequently asked What is the starting dose of compounded semaglutide? Almost always 0.25 mg once weekly for four weeks, following the approved product's labeled schedule. No compounded semaglutide has an FDA-approved label of its own, so that ladder is borrowed by convention rather than required. How many units is 0.25 mg? There is no single answer. It depends on the concentration of your vial — the same 0.25 mg sits at a different mark at 2.5 mg/mL than at 5 mg/mL. Have the pharmacy that dispensed it confirm the mark before your first injection. How long before I move up to the next dose? Four weeks on each rung: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then maintenance at 1.7 or 2.4 mg from week 17. If a dose is not tolerated, the label advises delaying escalation by another four weeks. What if I miss a couple of weeks? If two or more consecutive weekly doses are missed, the label says to reinitiate escalation at a lower dose rather than resume where you stopped. Is compounded semaglutide more dangerous than the branded product? Adverse event reports show higher reporting odds of preparation errors, contamination and hospitalization for compounded products, though lower odds of dosing errors. These are disproportionality signals in a voluntary reporting system, not incidence rates. ## Sources 1. \[1\] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine. [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/) 2. \[2\] Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. [PMID 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682/) 3. \[3\] Lambson JE, Flegal SC, Johnson AR (2023). Administration errors of compounded semaglutide reported to a poison control center-Case series Journal of the American Pharmacists Association. [PMID 37392810](https://pubmed.ncbi.nlm.nih.gov/37392810/) 4. \[4\] McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Expert Opinion on Drug Safety. [PMID 40285721](https://pubmed.ncbi.nlm.nih.gov/40285721/) 5. \[5\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Table 1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) - [ Where the approval applies · F0 — no fibrosis · F1 — mild · F2 — significant · approved · F3 — advanced · approved · F4 — cirrhosis · Knowing which row you are in requires testing nobody does at a checkout ### Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3 ](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease) --- # Semaglutide vs Sleeve Gastrectomy: Liver Stiffness Over 72 Weeks | This GLP Over 72 weeks, liver stiffness fell 2.8 kPa on semaglutide and 4.9 kPa after sleeve gastrectomy, with no significant difference in relative reduction between them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Semaglutide vs Sleeve Gastrectomy: Liver Stiffness Over 72 Weeks Sleeve gastrectomy took off more weight than semaglutide and improved liver stiffness no more than the drug did. Ninety-two people, nobody randomized. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Over 72 weeks — liver fat signal, then stiffness · lifestyle · −17.9 dB/m · −0.8 kPa · semaglutide · −46.0 dB/m · −2.8 kPa · surgery · −83.7 dB/m · −4.9 kPa · Stiffness: no significant difference between drug and surgery, p = 0.428. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 92 adults with obesity and fatty liver, followed 72 weeks on lifestyle therapy, semaglutide, or sleeve gastrectomy. - Liver fat signal fell 17.9, 46.0 and 83.7 dB/m across the three groups. - Liver stiffness fell 0.8, 2.8 and 4.9 kPa — but drug and surgery did not differ significantly in relative reduction, p = 0.428. - Surgery produced more weight loss than semaglutide, and no more stiffness improvement. - The semaglutide dose was 1.0 mg a week, a diabetes dose rather than the 2.4 mg sold for weight. The interesting line in this study is the one where the bigger intervention stopped buying a bigger result. Surgery took off more weight than the drug did and the liver stiffness improved about the same, which is either a measurement limit or a hint that the liver effect is not purely a weight effect — [the question the trial evidence has been circling](https://thisglp.com/research/semaglutide-and-liver-disease). ## What was compared Ninety-two adults at one center, watched prospectively for 72 weeks. [\[1\]](https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness#ref-1) Thirty on a lifestyle program, thirty on that plus semaglutide at 1.0 ± 0.4 mg a week, and thirty-two who had a laparoscopic sleeve gastrectomy. Everyone had hepatic steatosis at baseline. Nobody was randomized. People who choose an operation differ from people who choose a weekly injection, in ways no covariate list holds. ## Fat first The controlled attenuation parameter, which estimates how much fat is in the liver, fell by 17.9 dB/m on lifestyle, 46.0 on semaglutide and 83.7 after surgery, overall p = 0.002. That ordering is what anybody would expect, and it tracks the weight loss — fat comes out of a liver when weight comes off a body, which is why [a marker close to the mechanism](https://thisglp.com/research/glp1-pcos-insulin-resistance) moves most readily and proves least. ## Then stiffness Liver stiffness fell 0.8, 2.8 and 4.9 kPa across the same three groups, overall p < 0.001. In relative terms the semaglutide and surgery groups did not differ significantly, p = 0.428. The authors are careful about this and so is the page: they call it hypothesis-generating and say it warrants investigation into weight-independent mechanisms. It is 92 people, it is not randomized, and a non-significant difference between two small groups is a weak instrument for claiming they are equivalent. A FibroScan does not see fibrosis Every outcome here is a non-invasive marker. The device measures how fast a shear wave travels through the liver and infers stiffness; the scores are calculated from that and from blood tests. They correlate with what a biopsy finds and they are not the same thing, which matters on a site whose readers are being offered a drug [approved against a fibrosis stage](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease) that has to be established some other way. ## The result nobody explained FIB-4, a score built from age, platelet count and two liver enzymes, rose modestly after surgery — up 0.29, p < 0.001 — while staying stable in both other groups. A fibrosis score moving in the wrong direction after an operation that improved every other marker is the sort of thing worth an explanation, and the published abstract does not offer one. This desk is not going to invent a mechanism for it either. It is on the page because a reader deserves to know the results did not all point one way. ## The dose is not the dose you are buying One milligram a week is a type 2 diabetes dose. The sellers on this roster price 2.4 mg for weight, and most price something different again as the dose climbs. So this study does not tell you what the dose you would actually pay for does to a liver, and it does not tell you that a smaller dose is sufficient either. It tells you what 1.0 mg did to 30 people over 72 weeks, which is the kind of specificity [observational work outside a trial](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) usually loses in the retelling. ## Frequently asked Did surgery beat semaglutide for the liver? On liver fat, yes — 83.7 against 46.0 dB/m. On stiffness the two did not differ significantly in relative reduction, p = 0.428, despite surgery producing more weight loss. What dose of semaglutide was used? 1.0 ± 0.4 mg a week, a type 2 diabetes dose rather than the 2.4 mg sold for weight management. Were the liver findings from biopsies? No. All outcomes are non-invasive markers — FibroScan measurements and scores calculated from blood tests — which correlate with biopsy findings without being the same thing. Did anything get worse? FIB-4 rose by 0.29 after surgery while staying stable in the other groups. The published abstract does not explain why. ## Sources 1. \[1\] Lünswilken P, et al. (2026). Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD The Journal of Clinical Endocrinology and Metabolism. [PMID 42657770](https://pubmed.ncbi.nlm.nih.gov/42657770/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Should You Stop Ozempic Before a Colonoscopy? What Bowel-Prep Studies Found Ozempic and colonoscopy: inadequate bowel prep in 125 of 503 GLP-1 users against 56 of 503 non-users | no study has tested whether stopping first improves the prep. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Should You Stop Ozempic Before a Colonoscopy? What Bowel-Prep Studies Found No study has tested whether stopping improves the prep. In one matched cohort, inadequate prep was recorded for 125 of 503 GLP-1 users against 56 of 503 non-users, and three meta-analyses disagree on the size of the effect. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read One matched cohort, 503 people in each group · Inadequate prep, on a GLP-1 · 125 of 503 · Inadequate prep, not on one · 56 of 503 · Repeat procedure, on a GLP-1 · 26 of 503 · Repeat procedure, not on one · 9 of 503 · Everyone here was on the drug or not. Nobody was tested after stopping it. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). No study has tested whether stopping Ozempic improves the bowel prep for a colonoscopy. What has been measured is the prep in people still taking a GLP-1 drug. In one matched cohort, inadequate prep was recorded for 125 of 503 GLP-1 users and 56 of 503 non-users [\[1\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-1). A repeat procedure followed for 26 against 9. Pooled studies disagree on how large the effect is. ## Key takeaways - In a matched cohort, inadequate bowel prep was recorded for 125 of 503 GLP-1 users against 56 of 503 non-users (OR 2.6). - Two meta-analyses found worse prep on GLP-1 drugs (OR 2.10 and OR 1.55). A third found no difference (OR 1.00). - In 49,987 patients having colonoscopy, adenoma detection was unaffected; the prep gap was largest in people with diabetes. - No study has tested a washout period before colonoscopy. One review names it as the open question. - In a randomized trial, 25 people having both scopes drank clear liquids the day before, and none had a clinically significant amount of stomach contents. The worry follows from how the drug works. GLP-1 drugs slow the stomach, and a colonoscopy depends on a gut that has emptied. For the upper scope, the concern is food left in the stomach under sedation. That is covered in [the gastric ultrasound study of residual stomach contents](https://thisglp.com/research/glp1-before-surgery). This page is about the lower scope, where the concern is a colon the camera cannot see. ## What a single large cohort found A multicenter Veterans Affairs cohort matched 503 GLP-1 users with 503 non-users [\[1\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-1). The groups were matched for diabetes and cirrhosis. The main outcome combined several signs of inadequate prep, taken from procedure reports. Users had higher odds of that outcome: 125 against 56, an odds ratio of 2.6 (95% CI 1.9 to 3.7). They also had higher odds of a repeat procedure: 26 against 9, an odds ratio of 3.0. The study was retrospective. It cannot say whether the drug, the diabetes behind it, or something else explains the gap. ## Four meta-analyses, no agreement The pooled evidence does not agree with itself. That disagreement is the finding. The first pooled 5 studies and 10,833 patients [\[2\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-2). Inadequate prep was more likely on a GLP-1 drug, at an odds ratio of 2.10 (95% CI 1.41 to 3.13). The mean prep score was lower by 0.34 points. The second pooled 12 studies and 123,858 patients, including conference abstracts [\[3\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-3). The unadjusted odds ratio was 1.55 (95% CI 1.11 to 2.16). Adjusted for age, sex, body mass index and diabetes, it was 2.35. It found no association with repeat colonoscopy (OR 1.5, 95% CI 0.88 to 2.56). The third pooled 6 studies and found no difference [\[4\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-4). Its odds ratio was 1.00 (95% CI 0.73 to 1.37). Its authors advised against stopping GLP-1 drugs before colonoscopy, and asked for more evidence. A fourth pooled 8,778 users and 8,290 controls [\[6\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-6). It put the gap in absolute terms: about 6 percentage points more inadequate prep on a GLP-1 drug. It named the washout period before colonoscopy as the question still to be answered. What was not measured Every study above compared people on a GLP-1 drug with people not on one. None randomized people to stop the drug, or to an extended prep, and measured the result. How long to hold Ozempic before a colonoscopy has not been measured. ## Does worse prep mean missed polyps? That is what a poor prep risks, so one cohort checked it directly [\[5\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-5). It included 49,987 patients having outpatient screening or surveillance colonoscopy, 4,269 of them GLP-1 users. Users had modestly higher odds of inadequate prep, at an odds ratio of 1.23. Adenoma detection did not differ. The subgroup with diabetes had the largest prep gap, at an odds ratio of 1.88. It also had lower detection of sessile serrated polyps, at 0.71. The authors called for bowel-prep protocols tailored to this group, tested prospectively. Observational procedure studies need care in both directions. A cohort can also make a drug look protective across every outcome, as in [the ERCP cohort of 21,818](https://thisglp.com/research/when-a-drug-improves-everything). ## The one randomized trial nearby OCULUS randomized people on a GLP-1 or GLP-1/GIP drug before an upper endoscopy [\[7\]](https://thisglp.com/research/should-you-stop-ozempic-before-a-colonoscopy#ref-7). They either held one dose or kept taking it. It was stopped early after 60 patients. Clinically significant residual stomach contents occurred in 3.1% who held against 25.0% who continued. Its colonoscopy finding is one subgroup. Among 25 people having both scopes, all on clear liquids the day before, none had clinically significant stomach contents. The authors suggest clear liquids may reduce that risk whether or not the drug is taken. The trial did not measure bowel prep quality. Aspiration itself is covered in [whether GLP-1 drugs raise aspiration risk](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia). ## What this leaves the person booked for a scope The endoscopy team sets the prep and any pause, and needs to know the drug, dose and date of the last injection. The evidence supports telling them. It does not support a particular number of days off the drug. The bowel-prep studies report GLP-1 drugs as a class, not Ozempic alone. Compounded semaglutide is not FDA-approved and was not studied as such. Slow emptying as a lasting problem is a separate question, set out in [whether GLP-1 drugs cause gastroparesis](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## Frequently asked Should you stop Ozempic before a colonoscopy? No study has tested whether stopping improves the result, and the endoscopy team sets any pause. What is measured is prep quality on the drug: in one matched cohort, 125 of 503 GLP-1 users had inadequate prep against 56 of 503 non-users. Does Ozempic affect colonoscopy prep? Most pooled studies say yes: odds ratios of 2.10 and 1.55 for inadequate prep. One meta-analysis found no difference (OR 1.00). A fourth put the gap at about 6 percentage points. Does a GLP-1 cause missed polyps at colonoscopy? In 49,987 colonoscopies, adenoma detection did not differ between GLP-1 users and non-users. Users with diabetes had lower detection of sessile serrated polyps (OR 0.71). Does a clear liquid diet help on a GLP-1 before a scope? In the OCULUS trial, none of 25 people having both an upper endoscopy and a colonoscopy, on clear liquids the day before, had clinically significant stomach contents. That subgroup did not measure bowel prep quality. ## Sources 1. \[1\] Cole JL, Stark JE (2026). Impact of Glucagon-like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Large, Matched Regional Cohort Annals of Pharmacotherapy. [PMID 40583805](https://pubmed.ncbi.nlm.nih.gov/40583805/) 2. \[2\] Beran A, Nayfeh T, Akhras A, et al. (2025). Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis The American Journal of Gastroenterology. [PMID 39933910](https://pubmed.ncbi.nlm.nih.gov/39933910/) 3. \[3\] Abdulraheem A, Abujaber B, Ayers L, et al. (2026). Impact of glucagon-like peptide-1 receptor agonists on colonoscopy outcomes: a systematic review and meta-analysis Clinical Endoscopy. [PMID 41943648](https://pubmed.ncbi.nlm.nih.gov/41943648/) 4. \[4\] Ahmed Z, Iqbal A, Arif SF, et al. (2026). Bowel preparation quality in patients using glucagon-like peptide-1 agonists: a systematic review and meta-analysis Gastrointestinal Endoscopy. [PMID 40846241](https://pubmed.ncbi.nlm.nih.gov/40846241/) 5. \[5\] Garg S, Hoxha D, Long D, et al. (2025). Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists Clinical and Translational Gastroenterology. [PMID 40874603](https://pubmed.ncbi.nlm.nih.gov/40874603/) 6. \[6\] Chiu YT, Chen YT, Lee FJ, Chang CY (2025). The impact of glucagon-like peptide-1 receptor agonists on the quality indicators of colonoscopy - a systematic review and meta-analysis Digestive and Liver Disease. [PMID 40121157](https://pubmed.ncbi.nlm.nih.gov/40121157/) 7. \[7\] Ahmad AI, Garg S, Jacobs J, et al. (2026). Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial JAMA Internal Medicine. [PMID 41837981](https://pubmed.ncbi.nlm.nih.gov/41837981/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # GLP-1 Withdrawal Trials: STEP 1, STEP 4 and SURMOUNT-4 Compared | This GLP STEP 1, STEP 4 and SURMOUNT-4 each measured what happens when a GLP-1 drug is withdrawn: the regain figures, the spread behind them, and what they mean for a prepaid plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/stopping-glp1-and-weight-regain Updated: 2026-10-26 Published: 2026-09-15 [← Research](https://thisglp.com/research) Evidence # GLP-1 Withdrawal Trials: STEP 1, STEP 4 and SURMOUNT-4 Compared Three randomized withdrawal studies measured what happens after the drug stops. In the STEP 1 extension, participants regained two thirds of the loss within a year. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 On treatment · Stopped · Two thirds of the loss came back within a year. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Everything a reader is asked to decide about price — a month at a time or a year up front, a three-month bundle or a rolling plan — turns on one question that the pricing pages never answer. Is this a course of treatment that ends, or a medication taken indefinitely? Three randomized withdrawal studies have asked it directly, and they agree with each other more closely than most bodies of evidence ever do. ## STEP 1, one year after the drug stopped The STEP 1 extension followed 327 participants for a year after semaglutide 2.4 mg and lifestyle support were withdrawn. Mean weight loss to week 68 had been 17.3% on semaglutide against 2.0% on placebo. By week 120, the semaglutide group had regained 11.6 percentage points of what they lost, leaving a net loss of 5.6% from where they started[\[1\]](https://thisglp.com/research/stopping-glp1-and-weight-regain#ref-1). Cardiometabolic improvements reverted toward baseline for most variables over the same period. Two thirds of the loss came back in twelve months. The third that stayed is real, and it matters, and it is not what the headline figure describes. A reader deciding whether to buy a year at a [prepaid rate](https://thisglp.com/reviews/leanmeds) is deciding in month one about a trajectory that is only visible at month 120. ## STEP 4 separated continuing from stopping STEP 4 ran a 20-week open-label lead-in on semaglutide, then randomized the 803 participants who reached the 2.4 mg maintenance dose to continue or to switch to placebo for 48 weeks. From week 20 to week 68, the continuing group lost a further 7.9% while the placebo group gained 6.9%, a difference of 14.8 percentage points (95% CI −16.0 to −13.5)[\[2\]](https://thisglp.com/research/stopping-glp1-and-weight-regain#ref-2). Both groups kept the same lifestyle support throughout. That design is what makes the finding hard to argue with. The two arms had the same starting weight, the same behavior program and the same twenty weeks of history behind them, and the only difference after randomization was whether the drug continued. Those twenty weeks are the escalation window the [titration evidence](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) describes. ## SURMOUNT-4 found the same thing with tirzepatide SURMOUNT-4 gave 783 adults an open-label 36-week lead-in on the maximum tolerated dose of tirzepatide, producing a mean reduction of 20.9%, then randomized 670 of them to continue or to switch to placebo for 52 weeks. From week 36 to week 88 the continuing group changed by −5.5% and the placebo group by +14.0%, a difference of 19.4 percentage points[\[3\]](https://thisglp.com/research/stopping-glp1-and-weight-regain#ref-3). At week 88, 89.5% of those still on tirzepatide had kept at least 80% of the lead-in loss, against 16.6% of those switched to placebo. ## What the three studies together do and do not establish They establish that stopping is followed by regain, on both molecules, in randomized conditions, with lifestyle support held constant. They do not establish that everyone regains, that the rate is the same for everyone, or that a person who stops after reaching a goal cannot hold any of it. Group means are group means, and the STEP 1 extension’s standard deviation of 7.7 percentage points on the regain figure says plainly that the spread was wide. They also do not tell a reader how long to stay on. That is a clinical decision made with a prescriber, and the practical version of it is often about cost rather than medicine. The [cost calculator](https://thisglp.com/tools/glp1-cost-calculator) is the honest place to work out what an indefinite prescription costs at the dose you expect to sit on, rather than at the entry dose the advertisement is written around. ## What this means for a prepay decision If the evidence said treatment was a course, buying twelve months at a discount would be buying the whole thing. It says the opposite, so a twelve-month prepay is a discount on the first part of something longer, taken before the reader knows whether they tolerate the drug or reach a plateau. A month-to-month rate costs more per month and keeps that decision open, which is why the [seller reviews](https://thisglp.com/reviews) record the standing rate rather than the prepaid rung wherever a seller publishes both. The billing model can leave more or less room to reassess. [Contour Health](https://thisglp.com/reviews/contour-health) says in its [FAQ](https://www.contourhealthrx.com/faqs) that weight-loss medication is purchased by the vial without a subscription. That is a purchasing distinction, not evidence that stopping treatment is easier or that its patients avoid regain. ## Frequently asked How much weight comes back after stopping? In the STEP 1 extension, participants regained 11.6 of the 17.3 percentage points they had lost within a year of withdrawal, leaving a net 5.6% below their starting weight. Does continuing treatment prevent it? In STEP 4 the continuing group lost a further 7.9% while the placebo group gained 6.9% over the same 48 weeks. In SURMOUNT-4, 89.5% of those continuing tirzepatide kept at least 80% of the lead-in loss, against 16.6% on placebo. Does everyone regain? The studies report group means, and the spread around them is wide. The STEP 1 extension reported a standard deviation of 7.7 percentage points on the regain figure, so individual results varied considerably. ## Sources 1. \[1\] Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Diabetes, Obesity and Metabolism. [PMID 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/) 2. \[2\] Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial JAMA. [PMID 33755728](https://pubmed.ncbi.nlm.nih.gov/33755728/) 3. \[3\] Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. [PMID 38078870](https://pubmed.ncbi.nlm.nih.gov/38078870/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Survodutide: What SYNCHRONIZE-1 Found, and Why It Reads Weaker Than Phase 2 SYNCHRONIZE-1 randomized 725 adults to survodutide 3.6 mg, 6.0 mg or placebo. Weight fell 12.2% and 13.0% against 5.4%, with gastrointestinal events at 80.9% and 89.7%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/survodutide-synchronize-1 Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Survodutide: What SYNCHRONIZE-1 Found, and Why It Reads Weaker Than Phase 2 Weight fell 13.0% at the top dose over 76 weeks, against 14.9% in the earlier phase 2 trial. The drug did not get worse — the two trials measured different things. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Weight change — but not the same measurement · phase 2, 4.8 mg · −14.9% · phase 3, 6.0 mg · −13% · phase 3, 3.6 mg · −12.2% · Placebo moved too: −2.8% then −5.4%. · Compare the gaps, never the bars. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Survodutide pairs GLP-1 with glucagon — a different second mechanism from the GIP in tirzepatide or the amylin in CagriSema. - In phase 3, weight fell 12.2% on 3.6 mg and 13.0% on 6.0 mg over 76 weeks, against 5.4% on placebo. - The phase 2 trial had reached 14.9% at 4.8 mg over 46 weeks, so the phase 3 figure looks lower at a higher dose. - The two trials measured different things: phase 3 used an estimand that counts discontinuation against the drug, and its placebo arm lost nearly twice as much. Survodutide is the glucagon entry in a field that has mostly paired GLP-1 with something else. Its phase 3 result arrived looking slightly weaker than the phase 2 result that made people interested in it. That comparison is the thing worth getting right, because the obvious reading of it is wrong. The mechanism it competes against is set out in [the head-to-head that was finally run](https://thisglp.com/research/is-cagrisema-better-than-semaglutide). ## What the phase 3 trial found SYNCHRONIZE-1 randomized 725 adults with obesity and without diabetes to survodutide at 3.6 mg, 6.0 mg or placebo, and followed them for 76 weeks [\[1\]](https://thisglp.com/research/survodutide-synchronize-1#ref-1). Weight fell 12.2% on the lower dose and 13.0% on the higher one, against 5.4% on placebo. At least 5% of body weight was lost by 72.6%, 71.9% and 46.3% of each group respectively. Read the two active arms against each other and the dose step bought 0.8 percentage points. Over that same step, gastrointestinal events rose from 80.9% of participants to 89.7%. Nearly nine in ten people on the higher dose reported one, for less than a point of extra result. ## Why it looks weaker than phase 2 The same drug, measured two different ways. | | Phase 2 | Phase 3 (SYNCHRONIZE-1) | | --- | --- | --- | | Participants | 386 | 725 | | Duration | 46 weeks | 76 weeks | | Top dose tested | 4.8 mg → −14.9% | 6.0 mg → −13.0% | | Placebo arm | −2.8% | −5.4% | | Gap to placebo at top dose | about 12 points | about 7.6 points | | Analysis | Planned treatment, COVID discontinuations censored | Treatment-regimen estimand | The same drug, measured two different ways. Phase 2 dose-finding trial and SYNCHRONIZE-1 The phase 2 trial found a clean dose-response, with weight falling 6.2%, 12.5%, 13.2% and 14.9% across 0.6, 2.4, 3.6 and 4.8 mg against 2.8% on placebo [\[2\]](https://thisglp.com/research/survodutide-synchronize-1#ref-2). Set beside 13.0% at 6.0 mg in phase 3, that looks like a drug losing ground as it moved into a larger trial, and it almost certainly is not. The two trials asked different questions Phase 3 reports a treatment-regimen estimand, which deliberately counts early discontinuation, prohibited medication use and a prolonged escalation period against the drug rather than excluding them. Phase 2 reported the dose people were assigned, with COVID-related discontinuations censored out. The first is a harder test than the second, and neither paper decomposes how much of the difference that accounts for — so the honest statement is that the measurements differ, not that the effect shrank. The same distinction is why this site quotes gaps rather than arms, as in [the same percentage in different kilograms](https://thisglp.com/research/do-glp1-drugs-work-the-same-in-asian-patients). There is a second reason to compare gaps rather than headline figures. The placebo arm lost 2.8% in phase 2 and 5.4% in phase 3. The distance between drug and no drug therefore fell from about twelve points to about 7.6, before anything else is considered. A page quoting 14.9% and 13.0% side by side is comparing two numbers that were never measured against the same floor. One further limit sits underneath the phase 2 figure. Only 60.4% of its participants completed the 46-week treatment period. That is a lot of people to lose from the trial whose top-dose result everyone remembers. ## What it costs to tolerate Tolerability is where this drug has consistently been expensive. In phase 2, adverse events occurred in 91% of survodutide recipients against 75% on placebo, and gastrointestinal events specifically in 75% against 42%. In phase 3 the gastrointestinal figures reached 80.9% and 89.7% across the two doses. That is the pattern this site has found across the class. The agents taking off the most weight are generally the ones people find hardest to stay on, as set out in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). Whether the glucagon arm eventually earns its place will depend on outcomes nobody has measured yet rather than on the weight column. No deaths were reported in the phase 3 trial, and it was funded by Boehringer Ingelheim, which the paper states and which is ordinary for a phase 3 program. Survodutide is not approved and is not sold, so no price exists for it anywhere. This site keeps making that point about the whole pipeline in [what is not for sale](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). It is worth holding on to whenever a seller mentions a drug you cannot buy. ## Frequently asked How much weight did survodutide take off? In the phase 3 trial, 12.2% at 3.6 mg and 13.0% at 6.0 mg over 76 weeks, against 5.4% on placebo in 725 adults with obesity and without diabetes. Why was the phase 2 number higher? Phase 2 reached 14.9% at 4.8 mg, but it reported the assigned dose with COVID discontinuations censored, while phase 3 used an estimand that counts discontinuation against the drug. Its placebo arm also lost nearly twice as much. Is the higher dose worth taking? On these numbers it bought 0.8 percentage points of weight while gastrointestinal events rose from 80.9% to 89.7%, and the share of people losing at least 5% was essentially the same at both doses. Can I buy survodutide? No. It is investigational, not approved anywhere, and not sold by any seller this site tracks. ## Sources 1. \[1\] le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A (2026). Survodutide Once Weekly for the Treatment of Adults with Obesity The New England Journal of Medicine. [PMID 42253238](https://pubmed.ncbi.nlm.nih.gov/42253238/) 2. \[2\] le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial The Lancet Diabetes & Endocrinology. [PMID 38330987](https://pubmed.ncbi.nlm.nih.gov/38330987/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Telehealth Semaglutide and Tirzepatide Program: 12.3% at 24 Weeks | This GLP A 180-person single-arm study of telemedicine semaglutide and tirzepatide prescribing found 12.3% weight loss at 24 weeks | what the intervention included beyond the prescription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/telehealth-glp1-program-trial Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Telehealth Semaglutide and Tirzepatide Program: 12.3% at 24 Weeks A single-arm telehealth program produced 12.3% weight loss in 24 weeks. Alongside the prescription, it supplied a behavioral program, a connected scale and a blood pressure cuff. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 What the 12.3% result was produced by · the drug · the part sellers ship · behavioral program · connected scale · blood pressure cuff · Single arm, 180 participants, 24 weeks **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A 24-week single-arm study followed 180 people prescribed semaglutide or tirzepatide through a telehealth program. - Weight loss was 7.2% at twelve weeks and 12.3% at twenty-four, p<0.0001. - Blood pressure fell from a mean of 131.0/83.8 to 120.0/78.2. - The intervention was not just a prescription: it included a behavioral program, a connected scale and a blood pressure cuff. - There was no control group, and side effects were compared informally against published trials rather than measured against a comparator. Nearly all the evidence for these drugs comes from trials run through clinics. Almost all the buying happens through websites. The gap between those two sentences is where most of this market lives, so a study of telemedicine prescribing is worth reading carefully — and this one rewards the care, because the thing it studied is not quite the thing being sold. ## What happened One hundred and eighty people recruited from a telehealth medical obesity program received semaglutide or tirzepatide along with a virtual behavioral program designed for long-acting obesity medications, a Bluetooth scale and a blood pressure cuff. [\[1\]](https://thisglp.com/research/telehealth-glp1-program-trial#ref-1) Participants averaged 44 years old and 102.8 kg; 91% were women and 81% were white. Weight, blood pressure, eating habits, diet quality, activity and side effects were assessed at baseline, twelve weeks and twenty-four. Weight fell 7.2% at twelve weeks and 12.3% at twenty-four, both at p<0.0001. Mean blood pressure went from 131.0/83.8 to 122.5/78.7 at twelve weeks and 120.0/78.2 at twenty-four. Eating habits, diet quality and activity all improved significantly. Those are good numbers, comparable to what the trials report, obtained without anybody walking into a clinic. Four things were delivered. Sellers ship one. The intervention included a structured behavioral program, hardware for weighing yourself, and a cuff for tracking blood pressure between visits. A result produced by that package cannot be attributed to the prescription inside it. Almost nothing on this roster comes with a behavioral program, and [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) shows how few sellers describe any ongoing support at all. ## What the design cannot tell you There was no control group. Everyone received everything, so there is no way to know what the behavioral program added over the drug alone, or what the drug added over the program alone, or what either added over the kind of person who signs up for a structured twenty-four-week study and owns a connected scale. The analysis also carried the last observation forward for people who stopped contributing data. On a weight endpoint that is a generous convention — somebody who dropped out at week thirteen keeps their week-twelve loss on the books at week twenty-four, and a person who left because it was not working is recorded at their best point rather than their last. Real-world persistence is poor enough that this matters, as [the gap between trials and practice](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care) keeps showing. ## The claim not to repeat The paper reports that side effects were markedly lower than in previously reported trials. That comparison is the weakest thing in it, and it is the line most likely to be quoted by somebody selling this delivery model. Randomized trials capture adverse events systematically, with scheduled questioning and predefined categories, from participants who did not choose their treatment. An unblinded single-arm program collects what people volunteer between virtual visits. Lower numbers from the second method are what you would expect whether or not fewer things happened. Nothing here establishes that telehealth delivery is gentler, and the study did not set out to. ## What it does support Something real and narrower. A well-built remote program, with structured behavioral support and simple home monitoring, produced trial-comparable weight loss and meaningful blood pressure improvement over six months in people who stayed with it. That is a useful thing to know, and it is an argument for the package rather than for the convenience. It also sets a standard a buyer can hold a seller to. If a site is selling remote weight management, does it provide anything beyond a prescription and a refill schedule? Most here do not say, which is its own kind of answer — [the pattern runs across every clinical question](https://thisglp.com/research/what-glp1-sellers-do-not-publish) this market touches, right down to [which states they will ship to](https://thisglp.com/research/who-publishes-the-states-they-serve). Published service descriptions provide a separate shopping comparison, not a replication of this study. [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) offers phone, video or e-consult appointments on its [website](https://lavenderskyhealth.com/). Ask which contact format and follow-up schedule your own plan includes; the availability of telehealth alone does not establish the support used in this trial. ## Frequently asked Does telehealth work as well as a clinic? This study cannot answer that, because it had no comparison group. It showed that one well-supported remote program produced 12.3% weight loss at 24 weeks in the people who stayed in it. Why does the behavioral program matter? Because it was part of what produced the result, along with a connected scale and a blood pressure cuff. A prescription on its own was not what was studied. Were side effects really lower? Unknown. The paper compares its self-reported tallies against published randomized trials, which capture adverse events systematically. The two methods do not produce comparable numbers. Who was in it? 180 people averaging 44 years and 102.8 kg, of whom 91% were women and 81% were white, recruited from an existing telehealth obesity program. ## Sources 1. \[1\] Heinberg LJ, et al. (2026). Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study Obesity. [PMID 41253738](https://pubmed.ncbi.nlm.nih.gov/41253738/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Obesity Drugs Ranked Across 262 Trials: Weight Lost vs Side-Effect Dropout A network meta-analysis of 262 trials ranks tirzepatide at -14.9% and CagriSema at -14.8% against lifestyle alone, and finds four top performers also lead on discontinuation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/the-best-losers-are-the-worst-tolerated Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Obesity Drugs Ranked Across 262 Trials: Weight Lost vs Side-Effect Dropout A network meta-analysis of 262 trials and 99,791 participants produces two rankings, biggest weight loss and highest rate of stopping for side effects. Four drugs appear on both. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Weight loss vs lifestyle alone, one year · tirzepatide · 14.9% · CagriSema · 14.8% · ● · oral semaglutide · 10.9% · ● · orforglipron · 9.9% · ● · semaglutide (injected) · 9.8% · phentermine-topiramate · 8.1% · ● · ● also among the highest rates of stopping for side effects. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A network meta-analysis pooled 262 randomized trials and 99,791 participants across 19 drugs. - At one year against lifestyle modification alone: tirzepatide -14.9%, CagriSema -14.8%, oral semaglutide -10.9%, orforglipron -9.9%, injected semaglutide -9.8%, phentermine-topiramate -8.1%. - Stopping because of adverse events was highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema and oral semaglutide — risk ratios from 1.9 to 4.2. - Four drugs appear on both lists. The efficacy ranking and the tolerability ranking are not independent of each other. This is the largest comparison of obesity drugs assembled so far: 262 randomized trials, 99,791 participants, 19 drugs, 24 outcomes, with certainty of evidence graded throughout[\[1\]](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated#ref-1). It supersedes the pooled figures reported in [the earlier weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average) on coverage, though not on the caveats. On weight at one year, measured against lifestyle modification alone, tirzepatide led at -14.9% (95% CI -16.0% to -13.9%), followed by cagrilintide-semaglutide at -14.8%, oral semaglutide at -10.9%, orforglipron at -9.9%, injected semaglutide at -9.8%, and phentermine-topiramate at -8.1%. All of those carry moderate to high certainty. The newer agents are a separate category and should be read as one. Ecnoglutide, mazdutide and retatrutide may produce similar or larger reductions, in the range of 13.1% to 14.6%, but the certainty attached is very low to low. A number with low certainty and a number with high certainty are not two entries on the same list, and the drugs that have not yet reached the market are covered in [what is not for sale yet](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). The two league tables share four names Discontinuation because of adverse events was highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema and oral semaglutide, at risk ratios between 1.9 and 4.2. Gastrointestinal events were most increased with naltrexone-bupropion, oral semaglutide, orforglipron and tirzepatide, at 3.1 to 4.2. Oral semaglutide, orforglipron, CagriSema and phentermine-topiramate each sit on both lists. The drug that takes off the most weight is disproportionately likely to be the drug people quit. That overlap is the practical finding, and it reframes what a top-of-table position means. A ranking built on weight loss among the people who completed a trial answers a different question from the one a person starting treatment is asking, which is closer to how much weight they will have lost in a year given some chance of stopping along the way. The tolerability route out of treatment is described from the dosing side in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). Two structural limits apply to every figure above. The comparator is lifestyle modification, so these are not head-to-head contests, and most differences between two drugs here are inferred through the network rather than measured in a trial that randomized people between them. And trial follow-up ran from 12 to 172 weeks, which for a condition managed over decades is short — the question of what the weight is made of, and what returns, sits outside this analysis entirely and is taken up in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1). ## Frequently asked Which obesity drug produces the most weight loss? Tirzepatide, at -14.9% against lifestyle modification alone at one year, with cagrilintide-semaglutide essentially level at -14.8%. Both carry moderate to high certainty of evidence. Are the newer drugs better? Possibly, but the evidence is weaker. Ecnoglutide, mazdutide and retatrutide showed reductions of 13.1% to 14.6% at very low to low certainty, which is not comparable to a high-certainty estimate. Which drugs do people stop taking? Discontinuation for adverse events was highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema and oral semaglutide, at risk ratios from 1.9 to 4.2 — a list that overlaps heavily with the most effective drugs. ## Sources 1. \[1\] Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. (2026). Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ. [PMID 42419792](https://pubmed.ncbi.nlm.nih.gov/42419792/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Use and Bowel Function After Lumbar Fusion: 117 Patients | This GLP After posterior lumbar fusion, bowel function returned at 1.35 days in GLP-1 users against 1.90 in non-users, with no differences in complications or hospital length of stay. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/the-bowels-woke-up-sooner Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # GLP-1 Use and Bowel Function After Lumbar Fusion: 117 Patients Bowel function returned half a day sooner after spinal fusion in GLP-1 users, in 117 patients at one hospital. The direction contradicts the drug's best-known mechanism. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Days until bowel function returned · 0 · 1 · 2 · 1.35 · on a GLP-1 · 1.90 · not on one · Opposite of what a gut-slowing drug should do. · 57 and 60 patients, one center, chart review. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A single-center chart review compared 57 patients on a GLP-1 drug against 60 who were not, all having elective posterior lumbar fusion. - Bowel function returned sooner in GLP-1 users — 1.35 days against 1.90 (P = 0.013), with a regression rate ratio of 0.69. - No differences appeared in length of stay, discharge disposition, inpatient complications, wound abnormalities or patient-reported outcomes. - These drugs slow gut transit, so a faster return of bowel function is the opposite of the expected direction. After spinal fusion the gut is expected to be sluggish, and the complication surgeons watch for is ileus — bowel function failing to restart. Since these drugs slow gastric emptying and transit, as [the gastroparesis evidence](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis) describes, the reasonable prediction is that patients taking one would take longer. They took less[\[1\]](https://thisglp.com/research/the-bowels-woke-up-sooner#ref-1). Bowel function, defined as passing flatus or having a bowel movement, returned at a mean of 1.35 days in GLP-1 users against 1.90 days in non-users, a difference of about half a day that held in regression (rate ratio 0.69, P = 0.028). Everything else was flat: no differences in length of stay, discharge destination, inpatient complications, wound problems, or patient-reported outcomes at follow-up. Half a day, in 117 patients, measured by asking The outcome is whether someone passed gas or had a bowel movement, recorded by whoever was on the ward and noted in a chart later reviewed by hand. That is a soft measurement, and the difference is twelve hours. With 57 patients in one arm and 60 in the other at a single center, this is a signal to check rather than a finding to act on — and the groups differed, with GLP-1 users far more often female (54.4% against 30.5%), which matters because postoperative bowel recovery is not the same in men and women. If the effect is real, the explanation is not obvious. One possibility is that the relevant comparison is not the drug against nothing but the drug against the metabolic state it treats: people with poorly controlled diabetes have autonomic gut dysfunction of their own, and a treated patient may simply be in better shape. Another is that chronic exposure produces tolerance to the motility effect, so the slowing seen on starting does not persist. The nulls are the more useful part of this paper and will get less attention. In a field where perioperative caution around these drugs has grown quickly — the fasting question in [what to tell the anesthesiologist](https://thisglp.com/research/glp1-before-surgery) and the aspiration findings in [the thrombectomy cohort](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia) — a study finding no excess complications, no longer stays and no worse recovery scores after major spinal surgery is worth having, even at this size. The pattern of small perioperative studies reaching reassuring conclusions is itself examined in [bile duct procedures and every complication halved](https://thisglp.com/research/when-a-drug-improves-everything). ## Frequently asked Do these drugs delay recovery after spinal surgery? Not in this study. Bowel function returned about half a day sooner in GLP-1 users, and there were no differences in complications, length of stay or patient-reported outcomes. Is that not the opposite of what the drugs do? It is. They slow gastric emptying and gut transit, so a faster return of bowel function runs against the mechanism — which is a reason to treat a 117-patient single-center result cautiously. How solid is the measurement? Soft. The outcome was whether a patient passed flatus or had a bowel movement, recorded on the ward and later reviewed by hand, and the difference was about twelve hours. ## Sources 1. \[1\] Fano A, Oris RJ, Dalton J, Baidya J, Ng M, Baek G, Tarawneh O (2025). GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion Spine. [PMID 41400023](https://pubmed.ncbi.nlm.nih.gov/41400023/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Tirzepatide and Oral Contraceptive Levels: 55 to 66% Lower Peaks | This GLP Tirzepatide reduced peak oral contraceptive hormone levels by 55 to 66% and total exposure by about 20% | what that difference means for the pill, and where the evidence stops. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-and-oral-contraception Updated: 2026-09-18 Published: 2026-09-15 [← Research](https://thisglp.com/research) Safety # Tirzepatide and Oral Contraceptive Levels: 55 to 66% Lower Peaks A single pharmacokinetic study found tirzepatide cut peak contraceptive hormone levels by up to 66% and total exposure by around 20%. Those two numbers mean different things. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Alone · With tirzepatide · Peak falls by more than total exposure does. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Tirzepatide slows gastric emptying. Anything swallowed alongside it therefore leaves the stomach later, and a drug that depends on being absorbed quickly can behave differently as a result. Oral contraception is the case where that matters most, and it is the case where the published data is thinnest. ## The one pharmacokinetic study, and its actual numbers A single 5 mg dose of tirzepatide given with a combined oral contraceptive reduced the peak plasma concentration of ethinylestradiol by 59%, of norgestimate by 66% and of its active metabolite norelgestromin by 55% [\[1\]](https://thisglp.com/research/tirzepatide-and-oral-contraception#ref-1). Total exposure fell by much less: 20%, 21% and 23% respectively. Time to peak was delayed by 2.5 to 4.5 hours. Those two sets of figures are the whole of this question. A 59% fall in peak concentration sounds alarming and a 20% fall in exposure does not, and they describe the same event. The review reporting them makes the point directly: a fall in peak concentration cannot be equated with reduced efficacy. Contraceptive effect depends far more on exposure across the day than on how high the curve gets in hour two. Whether a 20% reduction in exposure is enough to matter has not been measured in a clinical outcome study, and the honest answer to the question is that nobody has tested it. That is the same shape as the gap the [sexual function evidence](https://thisglp.com/research/do-glp1-drugs-affect-sex-drive) has, for the same reason: the trials were designed to measure weight. ## Why the risk is concentrated at the start The slowing of gastric emptying is greatest after a first dose and diminishes with continued treatment [\[1\]](https://thisglp.com/research/tirzepatide-and-oral-contraception#ref-1). Any interaction is therefore concentrated during initiation and during each dose escalation, rather than spread evenly across a course of treatment. This is the practical consequence of the finding, and it is why the labeling advice is framed around the four weeks after starting and after every increase rather than around the whole prescription. That timing matters commercially as well as clinically. A seller whose price rises at each dose step is a seller whose escalation schedule a reader has a financial reason to compress, and the escalation is the window this interaction lives in. The [titration evidence](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) covers the same window from the tolerability side. ## What this does and does not extend to The study used one combined oral contraceptive formulation. A pharmacokinetic review of the approved GLP-1 and dual agonists notes that interaction findings are formulation-specific and are not automatically transferable between structurally different agents[\[2\]](https://thisglp.com/research/tirzepatide-and-oral-contraception#ref-2). No equivalent data exists for progestogens prescribed for gynecologic indications or for endometrial protection during menopausal hormone therapy[\[1\]](https://thisglp.com/research/tirzepatide-and-oral-contraception#ref-1). A reader taking one of those is in a position the published record does not cover, which is a different statement from being at no risk. Semaglutide is a separate question with a separate answer, and this page does not extend the tirzepatide finding to it. The two molecules slow gastric emptying to different degrees and have been studied separately. ## The label is the document that governs The prescribing information for tirzepatide carries the contraception advice that a prescriber acts on, and it is the primary source here rather than any review of it[\[3\]](https://thisglp.com/research/tirzepatide-and-oral-contraception#ref-3). A review can describe a study; only the label sets out what the manufacturer and the FDA agreed the advice should be. Read it before deciding anything on the strength of a percentage. ## What to ask a prescriber The question worth asking is not whether the interaction exists but what to do during the four weeks after starting and after each increase. A service that makes a clinician reachable in that window is worth more here than one that is cheaper by $20 a month, and what each seller publishes about clinician access is recorded in the [seller reviews](https://thisglp.com/reviews) and applied by the [editorial methodology](https://thisglp.com/methodology). ## Frequently asked Does tirzepatide make oral contraception fail? That has not been measured. The one pharmacokinetic study found peak hormone concentrations fell by 55 to 66% while total exposure fell by about 20%, and no clinical outcome study has tested whether that matters. When is the interaction largest? After a first dose and after each escalation. The slowing of gastric emptying is greatest at initiation and diminishes with continued treatment, so the effect is concentrated in those windows. Does this apply to semaglutide? This page does not extend the finding. The study was of tirzepatide with one combined oral contraceptive, and interaction data is formulation-specific and molecule-specific. ## Sources 1. \[1\] Viana DPDC, Invitti AL, Jacobsen L, Schor E. (2026). Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy Maturitas. [PMID 42721915](https://pubmed.ncbi.nlm.nih.gov/42721915/) 2. \[2\] Min JS, et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist Drug Design, Development and Therapy. [PMID 40330819](https://pubmed.ncbi.nlm.nih.gov/40330819/) 3. \[3\] U.S. Food and Drug Administration (2026). Prescribing information for tirzepatide, accessed via DailyMed DailyMed, National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Tirzepatide Dispensing by Dose in Japan: National Claims Data | This GLP National Japanese claims data show tirzepatide strengths of 7.5 mg and above rising from 13.0% to 24.0% of dispensed units between June 2024 and March 2025. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-dose-mix-in-japan Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # Tirzepatide Dispensing by Dose in Japan: National Claims Data Japan publishes national dispensing quantities for every strength of tirzepatide. Doses of 7.5 mg and above went from 13.0% of the mix to 24.0% in ten months. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Share of the dispensing mix, June 2024 to March 2025 · 2.5 mg · 40.6% in June · 27.1% in March · 7.5 mg and above · 13% in June · 24% in March · Kit units, not patients. The 2.5 mg quantity rose while its share fell. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Japan publishes national dispensing quantities by product strength. This is one year of them, for tirzepatide. - In Japan the product is approved for type 2 diabetes, so this is a diabetes market's record. - Monthly quantity rose from 392,354 to 1,027,955 kit units between June 2024 and March 2025. - Strengths of 7.5 mg and above went from 13.0% of the mix to 24.0% against that 13.0% start. - The 2.5 mg quantity rose, from 159,318 to 278,540 kit units, while its share fell from 40.6% to 27.1%. The interesting thing here is not any of the numbers. It is that a country publishes them at all: every strength of one product, dispensed nationally, month by month, auditable by anybody. Nothing equivalent exists for the market this site covers, which is why [counting what sellers choose to disclose](https://thisglp.com/tools/published-dose-ladders) is the best available substitute. ## What the record shows Across the fiscal year the primary outpatient total was 7,829,974.7 kit units, of which 6,748,743.5 — 86.2% — were dispensed outside medical institutions rather than within them. [\[1\]](https://thisglp.com/research/tirzepatide-dose-mix-in-japan#ref-1) Over the fully observable months, that share rose from 84.0% to 87.6%. Monthly quantity rose from 392,354 to 1,027,955 kit units. The strength mix moved with it: 7.5 mg and above went from 50,902 kit units to 246,316, which is 24.0% of the mix against 13.0% at the start — the population-level version of [the dose decision made one patient at a time](https://thisglp.com/research/tirzepatide-low-dose-self-selected). What a rising strength mix is not It is not evidence that individual patients escalated. A market where new people keep starting at the lowest dose and a market where existing people keep moving up produce the same aggregate shift, and national dispensing data cannot separate them. The authors say so directly: this is a description of dispensing-setting and product-mix dynamics rather than an analysis of patient uptake, adherence, clinical outcomes or individual titration. Kit units are not people. ## The 2.5 mg figure went both ways Its quantity rose, from 159,318 to 278,540 kit units. Its share of the mix fell, from 40.6% to 27.1%. Both are true and they describe different things. More of the starting strength was dispensed in March than in June; it was a smaller slice of a much larger total. The 5 mg product accounted for 50.5% of the absolute increase and the higher strengths together for 30.7% — which is what growth in a titrating market looks like from the outside, and is the kind of distinction [a fold-change quoted without its base](https://thisglp.com/research/glp1-prescriptions-to-young-children) erases. ## Why this belongs on a disclosure site Because the question this data answers for Japan — what dose is the market actually on — is one nobody can answer for the US telehealth market at all. Sellers there publish a starting price and, mostly, nothing about what happens to it as the dose climbs. That silence is measurable in one direction only: this site can count who publishes a ladder, not what anybody dispenses. A national claims file makes the second visible, and the comparison worth drawing is between a market that can be audited and one that cannot — the same gap behind [every unanswered question in the census](https://thisglp.com/tools/questions-they-leave-open). ## Frequently asked Does this show patients escalating their dose? No. National dispensing data cannot separate new patients starting low from existing patients moving up, and the authors say the study is not an analysis of individual titration. What happened to the lowest strength? Its quantity rose from 159,318 to 278,540 kit units while its share of the mix fell from 40.6% to 27.1%. Both are true of the same period. Does this apply to weight-loss buyers? Not directly. In Japan the product is approved for type 2 diabetes, so this is a diabetes market's dispensing record. Why does a US-focused site cover Japanese claims data? Because it answers a question nobody can answer for the US telehealth market: what dose the market is actually on. Here, only what sellers choose to publish can be counted. ## Sources 1. \[1\] Omura T, et al. (2026). Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data Cureus. [PMID 42535213](https://pubmed.ncbi.nlm.nih.gov/42535213/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Switching to Tirzepatide and Liver Fibrosis Scores: 182 Patients | This GLP In 182 patients switching to tirzepatide, a liver fibrosis index fell significantly only in the high-risk group, with baseline severity correlated to the size of the change. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-fibrosis-worst-group Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Switching to Tirzepatide and Liver Fibrosis Scores: 182 Patients Switching to tirzepatide improved a fibrosis score only in the patients whose scores were worst to begin with. That is a real effect or regression to the mean. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 After switching to tirzepatide, six months · steatosis index · low risk · high risk · fell in both groups · fibrosis index · low risk · high risk · fell in the high-risk group only · 182 patients, all of whom switched. No one stayed put. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 182 people with type 2 diabetes at high risk of fatty liver disease switched from a GLP-1 drug to tirzepatide. - Over six months, blood sugar, weight and liver enzymes all improved. - The steatosis index fell in both risk groups; the fibrosis index fell significantly only in the high-risk group, P < 0.001. - Baseline steatosis correlated with the change in the fibrosis index, rho 0.234, P = 0.005. - Nobody stayed on their original drug, so there is no comparison group. A result that shows up only in the group with the worst starting numbers is the one to slow down on, because two very different things produce exactly that picture — and this study has no arm that could tell them apart, which is [what a missing comparator costs](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## What was done A secondary analysis of a multicenter Japanese cohort, looking at the 182 patients at high risk of metabolic dysfunction-associated steatotic liver disease who switched from a GLP-1 receptor agonist to tirzepatide. [\[1\]](https://thisglp.com/research/tirzepatide-fibrosis-worst-group#ref-1) Two calculated scores were tracked over six months: the Hepatic Steatosis Index and the Fibrosis-4 index, both assembled from routine measurements rather than from imaging or a biopsy. Patients were split into low- and high-risk groups by baseline fibrosis status. Everyone switched. There is no group that stayed on the original drug, which is the design difference between this and [a study that checked whether its own method could detect anything](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver). ## What improved Glycated hemoglobin, body weight and liver enzymes all fell significantly. The steatosis index fell in both risk groups. The fibrosis index fell significantly only in the high-risk group, P < 0.001. And baseline steatosis was positively correlated with the change in the fibrosis index, rho = 0.234, P = 0.005 — the worse a person started, the more their score moved. Two things that look identical here The first is a real effect concentrated in sicker patients, which is plausible: there is more fibrosis to improve when there is more of it to begin with. The second is regression to the mean — pick out the people whose scores were most extreme at one measurement and they will, on average, be less extreme at the next, whatever you do to them in between. A correlation of 0.234 is weak in either case, significant across 182 patients and explaining a small share of what happened. With no group that stayed put, nothing in this design separates the two. ## The claim worth noting The authors report that improvements in the hepatic indices were not correlated with changes in body mass index or glycated hemoglobin, and describe the benefit as not clearly explained by weight change. That is their phrasing and it is the interesting part, because it points at something the weight loss does not account for. It also sits in a study with no control arm, which is a weak place to establish a mechanism — the same limit as [the surgery comparison where more weight bought no more stiffness improvement](https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness). ## What a reader takes from it Not a reason to switch. Nobody in this study chose tirzepatide from a price page, and a before-and-after in 182 people who all did the same thing is the weakest form of comparison there is. What is worth keeping is the check: when an effect appears only in the subgroup that started worst, ask what the people who started worst would have done anyway. It applies here, and it applies to every [index calculated from routine bloods](https://thisglp.com/research/glp1-pcos-insulin-resistance) that somebody has sorted patients by. ## Frequently asked Does switching to tirzepatide help the liver? Scores improved over six months in these 182 patients, but nobody stayed on their original drug, so there is no comparison group and no way to know what would have happened anyway. Why does 'only in the high-risk group' matter? Because selecting people with the most extreme scores guarantees that, on average, their next measurement is less extreme. That looks identical to a real effect concentrated in sicker patients. Was the improvement due to weight loss? The authors report it was not correlated with changes in body mass index or glycated hemoglobin, and describe it as not clearly explained by weight change. Were these liver scans? No. Both the steatosis and fibrosis measures are indices calculated from routine clinical measurements, not imaging or biopsy. ## Sources 1. \[1\] Takiyama T, et al. (2026). Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study Journal of Diabetes and Its Complications. [PMID 42618422](https://pubmed.ncbi.nlm.nih.gov/42618422/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # SUMMIT Trial Composite Endpoint: Tirzepatide in HFpEF, Broken Down | This GLP The SUMMIT trial of tirzepatide in HFpEF with obesity: how a 38% cut in a composite endpoint splits between worsening heart failure and cardiovascular death. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-heart-failure-composite Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # SUMMIT Trial Composite Endpoint: Tirzepatide in HFpEF, Broken Down Tirzepatide cut a composite of cardiovascular death or worsening heart failure by 38%. Almost all of that was the heart-failure half; the death half went the other way, on thirteen events. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Event rates: tirzepatide (solid) against placebo (pale) · the composite · 9.9% · 15.3% · worsening heart failure · 8% · 14.2% · cardiovascular death · 2.2% · 1.4% · The third row runs the other way. It is 13 events in total. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - In 731 patients with heart failure with preserved ejection fraction and obesity, the composite of cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide against 15.3% on placebo (HR 0.62). - Worsening heart failure alone drove it: 8.0% against 14.2%, a hazard ratio of 0.54. - ⛔ Cardiovascular death alone went the other way — 8 patients against 5, a hazard ratio of 1.58 with an interval from 0.52 to 4.83. - Thirteen deaths cannot establish anything, and that is the point: a composite reports a result its components cannot individually support. - Adverse events led 6.3% of the tirzepatide arm to discontinue, against 1.4% on placebo. Composite endpoints exist because rare events are hard to study, and they are honest arithmetic. They also produce a sentence — “reduced death from cardiovascular causes or worsening heart failure” — that a reader hears as two claims when the trial supports one. This is a clean example, and worth reading before the next time that sentence appears on a product page — a habit this site has already had to apply to a hazard ratio in [semaglutide and kidney disease](https://thisglp.com/research/semaglutide-and-kidney-disease). ## What the trial did Seven hundred and thirty-one patients with heart failure with preserved ejection fraction and obesity were randomized to tirzepatide or placebo and followed for a median of 104 weeks[\[1\]](https://thisglp.com/research/tirzepatide-heart-failure-composite#ref-1). ## What it found The composite of adjudicated cardiovascular death or a worsening heart-failure event occurred in 36 patients on tirzepatide (9.9%) against 56 on placebo (15.3%) — a hazard ratio of 0.62 (95% CI 0.41 to 0.95, p=0.026). Health status improved too: the mean change on the symptom score at 52 weeks was 19.5 against 12.7, a between-group difference of 6.9 (95% CI 3.3 to 10.6). Worsening heart-failure events alone accounted for nearly all of the composite: 29 patients (8.0%) against 52 (14.2%), a hazard ratio of 0.54 (95% CI 0.34 to 0.85). That is a substantial result on an outcome patients experience directly. The component that runs the other way Adjudicated cardiovascular death occurred in 8 patients on tirzepatide (2.2%) and 5 on placebo (1.4%) — a hazard ratio of 1.58, with a confidence interval from 0.52 to 4.83. ⛔ That interval contains 1 comfortably, and thirteen deaths across 731 patients cannot establish anything in either direction. This is not evidence of harm and the page is not claiming it is. It is printed because a reader who hears the composite as covering death is hearing a claim the trial did not make, and because leaving a component inside a composite is the commonest way a true sentence misleads. ## What the trial does establish That in this population, tirzepatide reduced how often people had a worsening heart-failure event and made them feel meaningfully better. Both are real, both are useful, and neither is a claim about mortality. It cost something: adverse events, mainly gastrointestinal, led 6.3% of the tirzepatide arm to stop the drug against 1.4% of placebo — a fourfold difference in a trial with study staff and no bill to pay, which is the context for the discontinuation figures in [stopping and weight regain](https://thisglp.com/research/stopping-glp1-and-weight-regain). ## How to read the next composite Ask which component moved. A composite is a legitimate way to study rare events and a convenient way to describe a narrow result broadly, and the difference is visible only in the component table. The same discipline applies to every large claim in this field, which is the subject of [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review) and of [semaglutide and heart failure](https://thisglp.com/research/do-glp1-drugs-help-heart-failure). And notice which population was studied. Everyone here had heart failure with preserved ejection fraction and obesity, which is not the person buying a compounded vial to lose weight — the transferability problem this site keeps running into, counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## Frequently asked What did the trial find? The composite of cardiovascular death or worsening heart failure fell from 15.3% to 9.9%, and symptom scores improved by 6.9 points more than placebo. Did it reduce deaths? No. Cardiovascular deaths were 8 on tirzepatide against 5 on placebo, a hazard ratio of 1.58 with an interval from 0.52 to 4.83. Thirteen events cannot establish anything in either direction. So is the composite misleading? Not dishonest, but easy to over-hear. Almost all the benefit came from the worsening-heart-failure component, and a reader who takes the phrase as covering mortality is taking a claim the trial did not make. Who was studied? Patients with heart failure with preserved ejection fraction and obesity, followed for a median of 104 weeks — not people buying a compounded vial for weight loss. ## Sources 1. \[1\] Packer M, et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity New England Journal of Medicine. [PMID 39555826](https://pubmed.ncbi.nlm.nih.gov/39555826/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide and Cardiac Remodeling in HFpEF: A 50-Patient Echo Study | This GLP A 50-patient cohort found left ventricular mass down 12.4 g and E/e' improved by 1.45 on tirzepatide in obesity-related HFpEF, with no control group and BMI down 5.8 kg/m². Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Tirzepatide and Cardiac Remodeling in HFpEF: A 50-Patient Echo Study Fifty patients, six months of tirzepatide, and every measured outcome moved the right way. BMI fell 5.8 kg/m² in the same period, and an echocardiogram reads a body as well as a heart. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Fifty patients, six months, every measure · left ventricular mass · −12.4 g · E/e' (diastolic filling) · −1.45 · symptom score (KCCQ) · +13.1 · six-minute walk · +43 m · BMI · −5.8 kg/m² · NT-proBNP, hs-CRP, hs-TnT · all down · NYHA class · 60% better, 0% worse · Nothing to compare against. Nobody got worse. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A prospective single-center cohort of 50 adults with obesity-related HFpEF starting tirzepatide. - Left ventricular mass fell 12.4 g and the E/e' filling ratio improved by 1.45 over about six months. - Symptom scores rose 13.1 points and six-minute walk distance by 43 meters. - BMI fell 5.8 kg/m² in the same period, which changes how a heart images. - There was no control group, and NYHA class worsened in nobody. Eight things were measured here and eight things improved. That is worth pausing on before reading any of them, because a study where nothing goes the wrong way is usually telling you about its design. ## What was found Fifty adults with preserved-ejection-fraction heart failure and obesity started tirzepatide in ordinary care and were followed a median of 5.8 months. [\[1\]](https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling#ref-1) Left ventricular mass fell by 12.4 g, 95% CI −15.4 to −9.4. The E/e’ ratio, a measure of how stiffly the heart fills, improved by 1.45. Symptom scores gained 13.1 points, walk distance 43 meters, and three blood markers — NT-proBNP, hs-CRP and hs-TnT — all fell. NYHA class improved in thirty patients and worsened in none — an outcome pattern worth setting beside [a small uncontrolled study where everything also improved](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa). An echocardiogram reads a body as well as a heart BMI fell 5.8 kg/m² over the same six months. That is a large change in the thing an ultrasound has to see through, and both co-primary endpoints are measurements taken across it. This is the same problem as [a kidney measure calculated from muscle](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease) and we will not restate it here. The question to carry is whether the heart changed, the image changed, or both — and a cohort of this shape cannot separate them. ## What the symptom scores carry KCCQ is a questionnaire and NYHA class is a clinician’s judgment. Everyone in this study knew they had started a new drug, and most had watched their weight fall. Thirteen points is a real improvement if it is real. It is also exactly the size of thing expectation produces in an unblinded study, which is why [reading the placebo arm first](https://thisglp.com/research/do-glp1-drugs-help-knee-pain) matters so much wherever an outcome is something a person reports. ## What the numbers in brackets mean The paper reports standardized response means of −1.16 and −1.08. Those are large, and they are easy to mistake for effect sizes against a comparator. They are not. An SRM measures change relative to the variability of that same change inside one group. With no control arm there is no between-group effect to size, which is a different thing from a small one. ## Where it fits Randomized evidence already exists for this drug class in heart failure with preserved ejection fraction, and it is better evidence than this. What a real-world cohort adds is whether the same direction shows up outside a protocol. It did. That is genuinely useful, and it is all this design can deliver — the effect still needs separating from the weight, as [re-cutting the trial populations by frailty](https://thisglp.com/research/glp1-heart-failure-frailty) showed when everyone lost the same weight and not everyone felt better. The authors say their findings complement the randomized evidence and call for further evaluation, which is the right verb for fifty people in one center. ## Frequently asked Does tirzepatide improve heart function in HFpEF? This cohort found left ventricular mass down 12.4 g and diastolic filling improved over six months. Nobody was randomized, so the effect cannot be separated from the weight loss that happened alongside. Why does weight loss complicate an echocardiogram? Both main endpoints are measurements read through the body. BMI fell 5.8 kg/m² over the same period, which changes the image as well as the heart. What is a standardized response mean? A measure of change relative to how variable that change was within one group. It is not an effect size against a comparator, and this study had no comparator. How reliable are the symptom scores? KCCQ is self-reported and NYHA class is a clinician's judgment, both collected unblinded in people who knew they had started a new drug and had lost weight. ## Sources 1. \[1\] Karanxha J, et al. (2026). Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study International Journal of Cardiology. [PMID 42710812](https://pubmed.ncbi.nlm.nih.gov/42710812/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide 2.5 mg vs 5 mg in Japanese Adults Without Diabetes | This GLP In 112 non-diabetic Japanese adults, tirzepatide 2.5 mg produced 15.3% weight loss against 16.1% at 5 mg, with adverse events of 35% against 50%, and no randomization. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-low-dose-self-selected Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Tirzepatide 2.5 mg vs 5 mg in Japanese Adults Without Diabetes Tirzepatide at 2.5 mg matched 5 mg on weight loss over six months in 112 adults. Patients picked their own dose, which is why the comparison cannot settle it. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 2.5 mg against 5 mg, six months · weight lost · 15.3% at 2.5 mg · 16.1% at 5 mg · had an adverse event · 35% at 2.5 mg · 50% at 5 mg · 112 adults. Nobody was assigned a dose — each was chosen. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 112 non-diabetic Japanese adults on tirzepatide, 58 staying at 2.5 mg and 54 moving to 5 mg after four weeks. - The dose was decided between patient and clinician, not randomly assigned. - At six months the primary outcome was met by 62.1% against 63.0%, hazard ratio 0.93, 95% CI 0.58 to 1.49. - Mean weight loss was 15.3% against 16.1%, p = 0.563. - Adverse events were more frequent at 5 mg: 50% against 35%, mostly gastrointestinal. A study suggesting the lowest maintenance dose does almost as much as the next one up would matter on a market where the dose is what the price is attached to. This one cannot establish it, and the reason is in the methods rather than the results — the same place [the randomized dose comparison](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it) has its answer. ## How the two groups were formed Everyone started at 2.5 mg weekly. After four weeks, the dose was either held or increased to 5 mg, based on shared decision-making between the patient and their clinician. [\[1\]](https://thisglp.com/research/tirzepatide-low-dose-self-selected#ref-1) That produced 58 people at 2.5 mg and 54 at 5 mg. Nobody was randomized. A person doing well at four weeks has little reason to escalate, and a person struggling with nausea has a reason not to — so the low-dose group is enriched for good early responders and for people who would have tolerated more poorly. Both push the comparison the same way. Which findings survive that, and which do not The efficacy comparison does not. 62.1% against 63.0% and 15.3% against 16.1% are exactly what you would expect if the people who stayed low were the ones already on track, and no statistical adjustment recovers a randomization that never happened. The tolerability comparison is sturdier: adverse events ran 50% at 5 mg against 35% at 2.5 mg, and if anything the selection works against that finding, since people who reacted badly early were the ones who stayed at the lower dose — the mirror of [a null that cannot be trusted](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes), where the bias runs toward the result rather than away from it. ## Why 15.3% is higher than you have seen Mean body mass index at entry was 30.8 — considerably lower than the Western obesity trials — in a Japanese cohort, alongside standardized dietary and exercise counseling. Dietary adherence was 96.4%. Exercise adherence was 37.5%. So the lifestyle arm of this was very largely a diet arm, which is worth knowing before reading the weight figures as the drug’s alone — and it makes the result hard to carry to a reader at a different body size with no dietitian attached, in the same way [a trial run at locally defined entry criteria](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) does not transfer. ## What it is good for Two things. The tolerability gap is real and useful: half the people at 5 mg had an adverse event against a third at 2.5 mg, almost all gastrointestinal. And it establishes that low-dose maintenance is a strategy clinicians are actually using, which is a fact about practice rather than about efficacy. Whether a seller’s price follows the dose upward is a separate question and one this site can answer — [who publishes a ladder at all](https://thisglp.com/tools/published-dose-ladders) decides whether a buyer can even see the difference. Nothing here is a reason to choose a dose; that is a prescriber’s call. ## Frequently asked Does 2.5 mg work as well as 5 mg? This study found 15.3% against 16.1% weight loss, but patients chose their own dose with their clinician. The low-dose group is enriched for people already doing well, so the comparison cannot answer it. Which finding is reliable? The tolerability difference: 50% of the 5 mg group had an adverse event against 35% at 2.5 mg. Selection works against that result rather than for it. Why was the weight loss so high? Mean body mass index at entry was 30.8 in a Japanese cohort, with standardized dietary counseling at 96.4% adherence. Exercise adherence was 37.5%. Should I ask to stay on a lower dose? That is a prescriber's decision. What this study shows is that low-dose maintenance is a strategy in use, not that it produces equal results. ## Sources 1. \[1\] Amioka M, et al. (2026). Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults Diabetes, Obesity and Metabolism. [PMID 42521631](https://pubmed.ncbi.nlm.nih.gov/42521631/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide Against Real Clinical Practice: What SURPASS-EARLY Found | This GLP SURPASS-EARLY randomized 794 adults to tirzepatide or intensified conventional care for two years. HbA1c fell 1.99 points against 1.32, with 60.2% vs 24.0% reaching under 5.7%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-vs-real-clinical-practice Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Tirzepatide Against Real Clinical Practice: What SURPASS-EARLY Found A rare trial whose control arm was care as doctors actually deliver it, other GLP-1 drugs included. The margin is 0.68 HbA1c points — smaller than a placebo trial, and far more useful. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read What a trial compares the drug against · placebo · most trials · another drug · SURPASS-2 · real practice · SURPASS-EARLY · a whole population · running · Each rung answers a harder question than the one below. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - SURPASS-EARLY compared tirzepatide against intensified conventional care — real practice, which could include other GLP-1 drugs. - HbA1c fell 1.99 points against 1.32 over two years: a difference of 0.68 points (95% CI -0.84 to -0.51). - Weight differed by 8.0 kg and waist by 6.2 cm. 60.2% reached an HbA1c below 5.7%, against 24.0%. - Margins against real practice are smaller than margins against placebo. That is the point of measuring them. Almost every trial on this site uses placebo. That answers whether a drug does something. It does not answer the question a patient and a doctor face: is this better than what we would have done anyway. ## Four kinds of comparator Each rung is a harder test than the one below it. | Compared against | Example | What it tells you | | --- | --- | --- | | Placebo | Most trials on this site | Whether the drug works at all | | Another drug | SURPASS-2 | Which of two drugs works better | | Real practice | SURPASS-EARLY | Whether it beats what you would otherwise get | | A whole population | SURMOUNT-REAL UK, running | What it does to a health system | Each rung is a harder test than the one below it. ## What SURPASS-EARLY did It randomized 794 adults with early type 2 diabetes at 78 sites in 10 countries [\[1\]](https://thisglp.com/research/tirzepatide-vs-real-clinical-practice#ref-1). One arm got tirzepatide. The other got intensified conventional care, delivered as clinicians actually deliver it and guided by local guidelines. That comparator arm could include other GLP-1 drugs. Only tirzepatide itself was excluded. So this is a drug against real practice, including practice that reaches for the same family. Over two years HbA1c fell 1.99 points against 1.32. The estimated treatment difference was 0.68 points, with an interval from 0.84 to 0.51. Weight differed by 8.0 kg. Waist circumference differed by 6.2 cm. An HbA1c below 5.7% was reached by 60.2% against 24.0%. Below 5.7% is a lab value, not a cure That threshold is the level below which a person would not be diagnosed with diabetes today. It is not remission. Remission requires the number to hold after the drug stops. Nothing here tested that, and what this site has found about stopping is in [what happens when you stop tirzepatide](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide). The trial was open-label. Everyone knew their arm. For a lab value and a scale reading that matters less than it would for a symptom score. It still colors how hard each arm was intensified. ## The rung below: a drug against a drug SURPASS-2 compared tirzepatide against semaglutide directly [\[2\]](https://thisglp.com/research/tirzepatide-vs-real-clinical-practice#ref-2). HbA1c fell 2.01, 2.24 and 2.30 points at 5, 10 and 15 mg, against 1.86 on semaglutide. The differences were 0.15, 0.39 and 0.45 points. Weight differences ran 1.9 kg, 3.6 kg and 5.5 kg. Note the comparator dose. It was semaglutide 1 mg, the diabetes dose, not the 2.4 mg used for weight management. A reader setting those figures beside the STEP trials is comparing different doses. That mismatch keeps recurring here, set out in [the tirzepatide network comparison](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide). Read the three margins in order. Against placebo, arms fall by two points or more. Against another drug, 0.45. Against real practice, 0.68. The harder the comparator, the smaller the claim. ## The rung above, still running SURMOUNT-REAL UK is a five-year pragmatic trial in UK primary care [\[3\]](https://thisglp.com/research/tirzepatide-vs-real-clinical-practice#ref-3). It plans to enroll about 3,000 adults with class I obesity and no diabetes. They are randomized to tirzepatide plus standard care, or standard care alone. Its endpoints go past the scale. Time to onset of type 2 diabetes at month 60. Healthcare resource use. Employment and sickness absence. ⚠ It has reported nothing. The primary endpoint is month 24 and the key secondary is month 60. Treat it as a design that now exists, not as evidence. That is the distinction this site applies to every unreported study, as in [the review that found no outcome data at all](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths). For a reader, the rule is simple. Check what a figure was measured against before comparing it to anything. A 0.68-point margin over real care is smaller than the placebo-controlled arms this site usually reports. It is also more useful. The same reasoning applies to the older drugs in [where metformin lands when ranked](https://thisglp.com/research/is-a-glp1-better-than-metformin). ## Frequently asked What was tirzepatide compared against in SURPASS-EARLY? Intensified conventional care as clinicians deliver it across 10 countries, which could include other GLP-1 receptor agonists. Only tirzepatide itself was excluded from that arm. How large was the advantage? 0.68 HbA1c percentage points over two years, plus 8.0 kg of weight and 6.2 cm of waist circumference. 60.2% reached an HbA1c below 5.7% against 24.0%. Does an HbA1c below 5.7% mean the diabetes is gone? No. It means the value sits below the diagnostic threshold while on treatment. Remission requires it to hold after the drug stops, which this trial did not test. How does that compare with tirzepatide against semaglutide? In SURPASS-2 the margin over semaglutide 1 mg was 0.15 to 0.45 HbA1c points depending on dose. Note that is the diabetes dose of semaglutide, not the 2.4 mg used for weight management. Is anyone testing this at population scale? SURMOUNT-REAL UK is a five-year pragmatic trial planning about 3,000 participants in UK primary care. It has reported nothing yet — its primary endpoint is month 24. ## Sources 1. \[1\] Del Prato S, Heine RJ, Pérez Manghi FC, Hsia SH, Gomez-Valderas E, Zeytinoglu M (2026). Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial Annals of Internal Medicine. [PMID 42184419](https://pubmed.ncbi.nlm.nih.gov/42184419/) 2. \[2\] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine. [PMID 34170647](https://pubmed.ncbi.nlm.nih.gov/34170647/) 3. \[3\] Rutter MK, Mount J, Gibson JM, Webb J, Marler C, Reed C (2026). SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity Obesity. [PMID 42297568](https://pubmed.ncbi.nlm.nih.gov/42297568/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide vs Semaglutide: Major Adverse Liver Outcomes in Type 2 Diabetes A matched study found major adverse liver outcomes at 4.05 against 4.04 per 1,000 person-years for tirzepatide and semaglutide in adults with obesity and type 2 diabetes, hazard ratio 1.04. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-vs-semaglutide-liver Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Tirzepatide vs Semaglutide: Major Adverse Liver Outcomes in Type 2 Diabetes In a matched analysis, tirzepatide and semaglutide showed nearly identical rates of major adverse liver outcomes. The reason to believe the null is that both beat a third drug in the same analysis. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Tirzepatide against semaglutide — liver outcomes · 1.0 · all patients · with fatty liver · as treated · Both drugs did beat sitagliptin — so the method can see a difference. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - New users of tirzepatide and injectable semaglutide, matched, followed a median of about 17 months. - Major adverse liver outcomes ran at 4.05 against 4.04 per 1000 person-years, hazard ratio 1.04, 95% CI 0.88 to 1.23. - The same null held among patients with fatty liver and in an as-treated analysis. - Both drugs did outperform sitagliptin in the study's own internal check. - Tirzepatide produced about 1.1 kg/m2 more reduction in body mass index, p < 0.001 — and no fewer liver events. Most of what makes this study worth reading is a check the authors ran on themselves. [Finding no difference](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) has two explanations — there is not one, or the study could not have seen one — and almost nothing published bothers to separate them. ## What was compared Adults with overweight or obesity and type 2 diabetes starting tirzepatide or injectable semaglutide, drawn from a global research network and matched on baseline characteristics. [\[1\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver#ref-1) The outcome was time to a first major adverse liver outcome: cirrhosis, a decompensating event, or liver cancer. This is a target trial emulation — an observational comparison built to behave like a trial, with eligibility and follow-up rules fixed in advance. It still does not randomize anyone. ## The result Over a median of roughly 17 months, incidence ran at 4.05 per 1000 person-years on tirzepatide and 4.04 on semaglutide — a hazard ratio of 1.04, 95% CI 0.88 to 1.23. Among patients with fatty liver the rates were 9.97 and 10.03 per 1000 person-years, hazard ratio 1.03, 95% CI 0.75 to 1.42. An as-treated analysis gave 0.98, 95% CI 0.80 to 1.21. Three ways of asking, three intervals sitting squarely across one. Why the sitagliptin check matters A study that cannot detect anything will report no difference between any two things you give it, and it will look identical to a study that found a real absence. So the authors ran both drugs against sitagliptin, where a difference is expected, and both significantly outperformed it. That does not prove the main comparison is right. It does establish that the data, the matching and the outcome definition are capable of producing a difference when one is there — which is the single thing most null results never demonstrate about themselves. ## More weight, same liver Tirzepatide achieved about 1.1 kg/m2 more reduction in body mass index, p < 0.001. It did not produce fewer liver events. Over seventeen months that is not a contradiction — it takes years for cirrhosis or liver cancer to arrive, and a difference in weight would have to work through a long causal chain to show up in those counts. It does sit alongside [the study where surgery lost more weight and improved liver stiffness no further](https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness), and the two together make the weight-to-liver link look less automatic than it is usually described. ## What the window can carry Seventeen months is short for these endpoints and the authors say so, describing their conclusion as short- to medium-term. What the study supports is that neither drug is worse than the other on liver outcomes over that stretch. That is genuinely useful for anyone weighing the two, and it is not the same as either drug having been shown to prevent liver disease — a claim that needs [the trial evidence in that population](https://thisglp.com/research/semaglutide-and-liver-disease) and, for the approval that exists, [a fibrosis stage somebody has actually measured](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease). ## Frequently asked Is one of these drugs better for the liver? Not over this window. Major adverse liver outcomes ran at 4.05 against 4.04 per 1000 person-years, with every sensitivity analysis giving an interval crossing one. Why should a null result be believed? Because the authors also compared both drugs against sitagliptin, where a difference was expected, and found one. That shows the method can detect a difference when it exists. Did the extra weight loss help? Tirzepatide produced about 1.1 kg/m2 more reduction in body mass index and no fewer liver events. Seventeen months is short for outcomes like cirrhosis and liver cancer. Was this a trial? No. It is a target trial emulation — an observational comparison with trial-like eligibility and follow-up rules set in advance — and nobody was randomized. ## Sources 1. \[1\] Banerjee M, et al. (2026). Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes Obesity. [PMID 42618523](https://pubmed.ncbi.nlm.nih.gov/42618523/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide vs Semaglutide: Which Works Better for Weight Loss? | This GLP In the randomized SURMOUNT-5 trial, weight fell 20.2% on tirzepatide and 13.7% on semaglutide at 72 weeks | routine-care studies found a three-to-four-point gap. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Tirzepatide vs Semaglutide: Which Works Better for Weight Loss? In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Weight loss, tirzepatide against semaglutide · chart review, 12 mo · −16.6% · −13.4% · matched cohort, 2 yr · −14.7% · −10.8% · Randomized, SURMOUNT-5: 20.2% against 13.7% at 72 weeks. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - In SURMOUNT-5, a randomized trial at weight-management doses, weight fell 20.2% on tirzepatide and 13.7% on semaglutide over 72 weeks. - Participants knew which drug they took, and Eli Lilly, tirzepatide's maker, paid for the trial. - A 511-patient chart review found 16.6% against 13.4% at twelve months; a matched cohort found 14.7% against 10.8% over two years. - An earlier randomized trial, SURPASS-2, compared them in type 2 diabetes against semaglutide 1 mg, the diabetes dose. - Previous obesity medication blunted both drugs, but semaglutide far more: 14.4% down to 10.4%, against 17.1% down to 16.1%. Tirzepatide, on current evidence. In SURMOUNT-5, a randomized trial at weight-management doses, weight fell 20.2% on tirzepatide and 13.7% on semaglutide over 72 weeks [\[5\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better#ref-5). Participants knew which drug they were on, and the sponsor was Eli Lilly, tirzepatide's manufacturer. Routine-care studies point the same way, by three to four percentage points. ## The randomized comparisons, and their limits SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes [\[5\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better#ref-5). Each took the maximum tolerated dose of one drug: tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg, weekly for 72 weeks. Weight fell 20.2% (95% CI −21.4 to −19.1) against 13.7% (−14.9 to −12.6). Waists shrank by 18.4 cm on tirzepatide and 13.0 cm on semaglutide. Two limits sit beside that result. Participants knew which drug they were taking, and the sponsor makes one of them. Gastrointestinal events were the most common adverse events in both arms, mostly mild to moderate and mostly during dose escalation. An earlier trial compared them in type 2 diabetes. SURPASS-2 randomized people with type 2 diabetes to tirzepatide at 5, 10 or 15 mg, or semaglutide at 1 mg [\[1\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better#ref-1). HbA1c fell 2.01, 2.24 and 2.30 points against 1.86, and weight differed by 1.9 kg, 3.6 kg and 5.5 kg. The comparator matters. Semaglutide 1 mg is the diabetes dose; weight management uses 2.4 mg. A reader setting the SURPASS-2 figures beside the STEP trials is comparing different doses — the mismatch this site keeps finding, set out in [the tirzepatide network comparison](https://thisglp.com/research/is-tirzepatide-better-than-dulaglutide). ## What routine practice shows Two observational comparisons, neither randomized. | Study | Tirzepatide | Semaglutide | Design | | --- | --- | --- | --- | | Chart review, 511 patients, 12 months | 16.6% | 13.4% | Retrospective, multicenter | | Matched cohort, 2 years | 14.7% | 10.8% | Propensity-matched records | | Reached ≥15% (chart review) | 56.8% | 40.7% | — | | Reached ≥15% in year 1 (cohort) | 42.6% | 21.6% | — | Two observational comparisons, neither randomized. Multicenter chart review and a propensity-matched cohort The matched cohort also measured pace: 2.54% of body weight a month against 2.18% [\[4\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better#ref-4). Among patients without diabetes in the chart review, the gap widened to 18.5% against 14.2% [\[2\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better#ref-2). A third and much larger matched cohort points the same way. Among 18,386 propensity-matched adults in routine US care, tirzepatide was significantly more likely to reach every weight-loss threshold [\[3\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better#ref-3). It also recorded something the smaller studies do not: follow-up ended in discontinuation for 55.9% of the tirzepatide group and 52.5% of the semaglutide group. More than half of each arm stopped. ## The finding most likely to change a decision Previous obesity medication blunted one drug far more than the other Patients who had used an obesity medication before did worse on both, but unevenly: semaglutide fell from 14.4% to 10.4%, a loss of four points, while tirzepatide fell from 17.1% to 16.1%, a loss of one. If that holds up, treatment history should inform which drug comes next — and it currently does not. ## Side effects: the direction is unusual, the evidence is weak The chart review recorded gastrointestinal side effects in 28.5% of tirzepatide patients against 50.7% on semaglutide, which runs against the usual pattern where the stronger drug is harder to tolerate. Read how that was collected. In a randomized trial, adverse events are solicited from everyone on a schedule; in a chart review they appear when a patient raised them and a clinician wrote them down. The cohort study reached a similar conclusion using AI curation of clinical notes, a method it reports no validation for here. So the tolerability claim is directionally interesting and weakly evidenced. It sits against the network meta-analysis pattern in [the drugs that lose most and are tolerated worst](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). ## Who responded, and who did not The two-year matched cohort reports a demographic pattern it does not explain. Women were over-represented among high responders for both drugs, as were White patients. Black and Hispanic patients were over-represented among the group losing less than 5%. The paper offers no mechanism and this site will not invent one. It is a description of who did well in the records examined. It is also the kind of finding that ought to shape who future trials enroll — a representativeness problem this site set out in [who actually gets into trials](https://thisglp.com/research/are-glp1-drugs-safe-for-older-adults). What none of this prices. Which of the two is cheaper depends entirely on the seller, and the stopping question applies to both — see [what happens when you stop tirzepatide](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide). ## Frequently asked Which works better, tirzepatide or semaglutide? Tirzepatide. In the randomized SURMOUNT-5 trial, weight fell 20.2% on tirzepatide and 13.7% on semaglutide over 72 weeks. In routine care the gap was three to four points: 16.6% against 13.4% in one study, 14.7% against 10.8% in another. Has anyone compared them in a randomized trial? Yes. SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of each drug for 72 weeks: 20.2% weight loss on tirzepatide against 13.7% on semaglutide. Both groups knew their assigned drug, and Eli Lilly, which sells tirzepatide, sponsored it. SURPASS-2 compared them earlier in type 2 diabetes, against the 1 mg diabetes dose of semaglutide. Does it matter if I have taken a weight drug before? It appeared to, unevenly. Prior obesity medication dropped semaglutide results from 14.4% to 10.4% but tirzepatide only from 17.1% to 16.1%. Which causes more side effects? A chart review recorded gastrointestinal effects in 28.5% of tirzepatide patients against 50.7% on semaglutide. Those were chart-reported rather than systematically collected, which limits how much the difference can carry. ## Sources 1. \[1\] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine. [PMID 34170647](https://pubmed.ncbi.nlm.nih.gov/34170647/) 2. \[2\] Ghusn W, Fansa S, Tama E, Anazco D, Espinosa MA, Villamarin J (2026). Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study Mayo Clinic Proceedings. [PMID 42383938](https://pubmed.ncbi.nlm.nih.gov/42383938/) 3. \[3\] Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity JAMA Internal Medicine. [PMID 38976257](https://pubmed.ncbi.nlm.nih.gov/38976257/) 4. \[4\] Venkatakrishnan AJ, Murugadoss K, Soundararajan V (2026). Weight-loss dynamics with tirzepatide versus semaglutide PNAS Nexus. [PMID 42311474](https://pubmed.ncbi.nlm.nih.gov/42311474/) 5. \[5\] Aronne LJ, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine. [PMID 40353578](https://pubmed.ncbi.nlm.nih.gov/40353578/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # UBT251 Triple Agonist: First-in-Human 12-Week Weight Loss Trial | This GLP A phase 1 study of the GLP-1/GIP/glucagon agonist UBT251 reported mean losses of 8.96 to 13.48 kg in 12 weeks against a 1.57 kg gain on placebo. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/triple-agonist-first-in-human Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # UBT251 Triple Agonist: First-in-Human 12-Week Weight Loss Trial The GLP-1, GIP and glucagon receptor agonist UBT251 produced large early weight loss in its first human study. The 12-week clock is why that number cannot be set beside the drugs you can buy. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Mean weight change over 12 weeks · 0 · UBT251 · 8.96 to 13.48 kg lost · placebo · 1.57 kg gained · Twelve weeks. The trials you know about ran sixty-eight. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - UBT251 targets three receptors at once: GLP-1, GIP and glucagon. - In a first-in-human study, weekly doses of 1, 3 and 6 mg for 12 weeks produced mean losses of 8.96 to 13.48 kg. - Placebo gained 1.57 kg over the same period. - Safety and tolerability were the primary endpoints. Weight was a secondary readout. - Twelve weeks is not comparable to the 68-week trials that produced the figures people quote for semaglutide. A number this large, this early, is going to be quoted against drugs people can actually buy. The comparison does not work, and the reason is worth understanding before the headline arrives — it is the same problem as [reading an early-phase result as a verdict](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa). ## What was tested UBT251 is a peptide that activates the GLP-1 receptor, the GIP receptor and the glucagon receptor together. This was its first study in humans: a single-dose escalation from 0.1 to 4.5 mg, then a multiple-dose arm giving weekly injections for twelve weeks to participants with overweight or obesity and no diabetes. [\[1\]](https://thisglp.com/research/triple-agonist-first-in-human#ref-1) Safety and tolerability were the primary endpoints, which is what a Phase 1 study is for. The common adverse effects were laboratory findings, reduced appetite and gastrointestinal events — the familiar list for this class. ## The weight numbers At 1, 3 and 6 mg weekly, mean body weight fell between 8.96 and 13.48 kg over twelve weeks. The placebo group gained 1.57 kg, so the gap against placebo is larger than the drug figure by itself. Pharmacokinetics were roughly linear from 1.0 to 6.0 mg, and fasting glucose, hemoglobin A1c and lipids all improved. Why you cannot line this up against semaglutide The weight-loss curve for these drugs is steepest at the start and flattens as the months go on, so twelve weeks captures the fast part and nothing else. The 68-week trials that produced the semaglutide and tirzepatide figures include the flat part, where most of the difference between agents actually shows up. Putting a twelve-week number beside a sixty-eight-week number compares two different segments of two different curves. ## What is not in the abstract How many people were in each dose arm. The indexed record does not say, and a dose-escalation cohort is normally a handful of participants per level rather than the hundreds a later trial enrolls. That is the ordinary shape of first-in-human work, not a criticism of it. It does mean a mean weight change carries a wide uncertainty nobody has published here, which is the difference between [a result you can price](https://thisglp.com/research/semaglutide-cochrane-review) and one you cannot. ## Nobody can buy it UBT251 is not approved. This study was registered in China and the paper supports continued development, which is a long way from a prescription. The practical value of reading it now is calibration for the next announcement. A triple agonist adding a glucagon target is a real mechanistic step, and whether a third receptor translates into more weight lost at a dose people tolerate is exactly the question [dose-response data](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it) has to answer — the same test [every new entrant](https://thisglp.com/research/what-is-orforglipron) faces on its way to a pharmacy. ## Frequently asked How much weight did people lose on UBT251? A mean of 8.96 to 13.48 kg across the 1, 3 and 6 mg weekly doses over twelve weeks, while the placebo group gained 1.57 kg. Is that better than semaglutide? The study cannot say. Weight loss is fastest in the first months, and the semaglutide figures people quote come from 68-week trials. Twelve weeks and sixty-eight weeks measure different parts of the curve. Can I get it? No. UBT251 is an investigational drug with no approval anywhere, studied here for the first time in humans. What does a triple agonist do differently? It activates the glucagon receptor as well as GLP-1 and GIP. Whether that third target adds weight loss at a tolerable dose is what later trials have to establish. ## Sources 1. \[1\] Yang GP, et al. (2026). Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study Diabetes, Obesity and Metabolism. [PMID 42712041](https://pubmed.ncbi.nlm.nih.gov/42712041/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # FLOW Trial Cardiovascular Subgroups: Semaglutide's Numbers Needed to Treat FLOW cardiovascular subgroup analyses give numbers needed to treat of 22, 13 and 17 over three years to prevent one kidney outcome, with null interaction tests across cardiovascular status. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/twenty-two-thirteen-seventeen Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # FLOW Trial Cardiovascular Subgroups: Semaglutide's Numbers Needed to Treat The FLOW subgroup analysis publishes numbers needed to treat of 22, 13 and 17, a hazard ratio translated into people. Every interaction test came back null. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 People treated for 3 years to prevent one kidney outcome · heart failure · 13 · high CV risk · 17 · established ASCVD · 22 · Every subgroup interaction test came back null. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Subgroup analyses of the FLOW trial split participants with type 2 diabetes and chronic kidney disease by baseline cardiovascular status. - Numbers needed to treat over three years to prevent one primary kidney outcome were 22 with established atherosclerotic disease, 13 with heart failure, and 17 at high cardiovascular risk. - Every interaction test was null — 0.62, 0.40 and 0.99 for the kidney outcome and 0.79, 0.74 and 0.63 for all-cause death. - FLOW used semaglutide 1.0 mg, a diabetes dose, in people with diabetes and kidney disease. It is not a weight-management trial. Most results on this site arrive as hazard ratios, which describe a proportion and not a person. This analysis of the FLOW trial publishes numbers needed to treat, which is the same information in a form somebody can act on [\[1\]](https://thisglp.com/research/twenty-two-thirteen-seventeen#ref-1). The broader kidney evidence is in [the kidney disease evidence](https://thisglp.com/research/semaglutide-and-kidney-disease). To prevent one primary kidney outcome over three years, you would treat 22 people with established atherosclerotic cardiovascular disease, 13 with heart failure, or 17 at high cardiovascular risk without established disease. The primary outcome is a composite: a fall in kidney function of 50% or more, an eGFR below 15, dialysis, transplantation, or death from kidney or cardiovascular causes. Thirteen is a striking figure for a chronic disease outcome. It means that in a heart failure clinic, treating a room of thirteen people for three years prevents one of them from reaching dialysis, transplant or death from these causes — and the people in that room are the ones most likely to get there. Some subgroup intervals cross 1, and that is not a failure The ASCVD subgroup gave a hazard ratio of 0.80 with an interval from 0.63 to 1.02, and all-cause death in the heart failure subgroup gave 0.75 (0.54–1.05). Both cross no effect. Subgroups are smaller than whole trials and have less power by construction, so reading them as “it worked here and not there” is the error the interaction test exists to prevent. Every interaction test here came back null, which is the finding: the benefit did not depend on cardiovascular status. That pattern — dramatic-looking subgroup differences dissolving into null interaction tests — is the same one described in [the frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer) and [the HFpEF sex analysis](https://thisglp.com/research/same-benefit-different-route-by-sex). It keeps recurring because trials are powered for their whole population and journalism is drawn to the slices. One boundary is worth marking clearly. FLOW enrolled people with type 2 diabetes and chronic kidney disease, and used semaglutide at 1.0 mg — the diabetes dose, not the 2.4 mg weight product. These numbers describe kidney protection in diabetic kidney disease and do not transfer to someone taking a weight-management dose without either condition, nor to people already on dialysis, which is a separate question covered in [the dialysis cohort](https://thisglp.com/research/dialysis-the-evidence-base-just-grew). ## Frequently asked What does a number needed to treat of 13 mean? Treating thirteen people for three years prevents one of them reaching the primary kidney outcome — a 50% fall in kidney function, an eGFR below 15, dialysis, transplantation, or kidney or cardiovascular death. Did it work better in some groups than others? No. Every interaction test comparing subgroups was null, so the benefit did not depend on whether someone had atherosclerotic disease, heart failure, or high cardiovascular risk. Does this apply to weight-management doses? No. FLOW used semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease, which is a different dose, indication and population from weight management. ## Sources 1. \[1\] Tuttle KR, Bakris GL, Baeres FMM, Bang CN, et al. (2026). Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses Journal of the American College of Cardiology. [PMID 42233552](https://pubmed.ncbi.nlm.nih.gov/42233552/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Stopping Semaglutide in Type 1 Diabetes: Time in Range After Withdrawal | This GLP After semaglutide stopped, time in range fell a median 3.6 points against a 1.5-point rise on placebo in adults with type 1 diabetes using an insulin pump. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/type-1-diabetes-stopping-semaglutide Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Stopping Semaglutide in Type 1 Diabetes: Time in Range After Withdrawal Adults with type 1 diabetes lost about an hour a day of good glucose control in the twelve weeks after semaglutide stopped. Low blood sugar did not change. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Median change in time in range, 12 weeks after stopping · semaglutide · −3.6 points · placebo · +1.5 points · Adjusted p = 0.044. Low blood sugar did not differ between groups. · Adults with type 1 diabetes on an automated insulin pump. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Adults with type 1 diabetes and obesity had been taking semaglutide alongside an automated insulin pump. - Twelve weeks after stopping, time in range fell by a median 3.6 points against a 1.5-point rise on placebo. - Glucose variability rose too, on both measures reported. - Time spent too high increased but did not survive adjustment, p = 0.064. - Low blood sugar did not differ, which is the risk people worry about when a GLP-1 is added to insulin. Semaglutide is not approved for type 1 diabetes. Everyone in this study was in a trial, and the question it answers is narrow: what happens to blood sugar control in the twelve weeks after the drug is taken away. On the weight side that question already has a well-established answer, since [regain after discontinuation](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1) is the rule rather than the exception. This is the glucose version, in a different population. ## The setup Participants were adults with type 1 diabetes and obesity using an automated insulin delivery system — a pump that adjusts insulin itself, minute by minute, from a continuous glucose sensor. [\[1\]](https://thisglp.com/research/type-1-diabetes-stopping-semaglutide#ref-1) The extension phase followed them after semaglutide or placebo stopped. Time in range means the share of the day spent between 70 and 180 mg/dL. It is the number that matters most to somebody wearing a sensor. ## What changed Time in range fell by a median 3.6 points in the group that had been on semaglutide. Placebo went up 1.5 points. Adjusted p = 0.044. Variability rose as well. The standard deviation of glucose went up 6.0 mg/dL against 1.2. The coefficient of variation went up 3.1% against 1.1%. Both at adjusted p = 0.044. Three identical p-values Three outcomes reporting exactly 0.044 after adjustment is the signature of a multiplicity correction applied across a family of results, which is why the fourth outcome — time spent above range — comes back at 0.064 and is reported as not holding. The published record does not name the method used, so this page does not name one either. What the pattern does tell you is that these results sit close to the line, and that the authors applied a correction rather than reporting four raw comparisons. ## What did not change Nothing in the low-blood-sugar measures moved. That is the finding worth holding onto. The standing worry about combining a GLP-1 with insulin is that the two together drive glucose too low. Stopping the GLP-1 did not shift those metrics in either direction here, which is a null result rather than a reassurance — and [a null in a small extension study](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) carries the weight its sample allows. ## How big is 3.6 points A little under an hour a day. That is the honest translation of three and a half percentage points of a twenty-four-hour clock. Whether an hour a day out of range matters is a clinical judgment, not a statistical one, and it is the same distinction as [an effect that clears significance and sits below perception](https://thisglp.com/research/do-glp1-drugs-make-you-tired). Here the direction is clear and the size is modest. ## What it says about stopping generally That the benefit was not retained. Twelve weeks off the drug and the measurements drifted back toward where they started. That matches the weight side exactly: different population, different endpoint, same shape. A placebo arm is what makes the comparison mean anything, which is [not true of every study that reports a before and an after](https://thisglp.com/research/do-glp1-drugs-cause-gout). ## Frequently asked Is semaglutide approved for type 1 diabetes? No. Everyone in this study was taking it inside a trial, alongside an automated insulin delivery system. What happened after people stopped? Time in range fell by a median 3.6 points over twelve weeks, against a 1.5-point rise in the placebo group, and glucose variability increased. How much is 3.6 points in real terms? A little under an hour a day outside the 70 to 180 mg/dL range. Did stopping affect low blood sugar? No. None of the hypoglycemia measures from the continuous sensor differed between the groups. ## Sources 1. \[1\] Montaser E, et al. (2026). Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study Diabetes, Obesity and Metabolism. [PMID 42675550](https://pubmed.ncbi.nlm.nih.gov/42675550/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Tirzepatide and Serum Uric Acid: A SURMOUNT-1 Post Hoc Analysis | This GLP A SURMOUNT-1 post hoc analysis found serum uric acid fell up to 0.95 mg/dL on tirzepatide against 0.18 on placebo, with 72.7% of the reduction attributed to weight loss. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/uric-acid-fell-and-most-of-it-was-weight Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Tirzepatide and Serum Uric Acid: A SURMOUNT-1 Post Hoc Analysis Serum urate dropped nearly a milligram per deciliter across 72 weeks on tirzepatide, about three quarters of it explained by weight loss. Gout flares were not an outcome. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Serum uric acid at week 72, mg/dL lower · tirzepatide 15 mg · −0.95 · tirzepatide 10 mg · −0.92 · tirzepatide 5 mg · −0.69 · placebo · −0.18 · A blood level moved. Gout attacks were not counted. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A post hoc analysis of SURMOUNT-1 tracked serum uric acid in 2,539 adults with obesity or overweight across 72 weeks. - Uric acid fell 0.69, 0.92 and 0.95 mg/dL on the three tirzepatide doses against 0.18 mg/dL on placebo (all P < .001). - Mediation analysis attributed 72.7% of the reduction to weight loss, leaving about a quarter unexplained. - The fall did not differ by baseline uric acid quartile (P = .610) or baseline BMI (P = .362). High uric acid is what produces gout, and obesity raises it, so a drug that removes a fifth of someone's body weight ought to lower it. A post hoc analysis of SURMOUNT-1 confirmed that and then asked the more interesting question of why [\[1\]](https://thisglp.com/research/uric-acid-fell-and-most-of-it-was-weight#ref-1). The comparison between drug classes on gout itself is in [what a comparator can and cannot tell you](https://thisglp.com/research/do-glp1-drugs-cause-gout). Across 72 weeks, serum uric acid fell by 0.69, 0.92 and 0.95 mg/dL on the 5, 10 and 15 mg doses, against 0.18 mg/dL on placebo. Weight fell by up to 20.9% over the same period, broadly in line with the pooled figures in [the weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average). Uric acid is a blood test. Gout is an attack. This analysis measured a laboratory value. It reports no gout flares, no new gout diagnoses and no change in urate-lowering prescriptions, because those were not among the outcomes. Lowering serum urate is how gout treatment works, so the direction is encouraging — but a 0.95 mg/dL drop is not a count of attacks avoided, and anyone with gout should read it as a mechanism finding rather than a result about their symptoms. The mediation analysis attributed 72.7% of the uric acid reduction to weight loss. That leaves roughly a quarter attributed to something else about the drug, which is the part worth following up — though as with every mediation analysis, the split is the output of a model resting on assumptions that cannot be tested against the data, the same caution set out in [the liver mediation analysis](https://thisglp.com/research/liver-repair-that-was-not-the-weight). Two nulls in this paper are easy to skim past and shouldn’t be. The reduction did not differ by baseline uric acid quartile (P = .610), so people who started with the highest levels did not drop further than those who started lower. Nor did it differ by baseline BMI (P = .362). That is unusual: most outcomes in this literature show bigger changes in people with more room to move, as [the sleep apnea subgroups](https://thisglp.com/research/apnea-improved-across-every-subgroup) illustrate, and the absence of that pattern here suggests a fairly uniform effect. The practical translation is narrow. If you have gout and are taking one of these drugs for other reasons, your urate is likely to fall, which is the direction gout treatment aims for. If you are considering one specifically for gout, nothing here supports that yet — the trial that would, counting flares rather than measuring blood, has not been done. ## Frequently asked Does tirzepatide treat gout? Not on this evidence. The analysis measured serum uric acid and reported no gout flares, diagnoses or urate-lowering prescriptions, so it shows a mechanism rather than a symptom result. How much did uric acid fall? By 0.69, 0.92 and 0.95 mg/dL on the 5, 10 and 15 mg doses over 72 weeks, against 0.18 mg/dL on placebo. Is it just the weight loss? Mostly. Mediation analysis attributed 72.7% of the reduction to weight loss, leaving about a quarter unexplained — though that split is a model estimate rather than a measurement. ## Sources 1. \[1\] Sattar N, Scilletta S, Stefanski A, Wang H, Daly JW, Linetzky B (2026). Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial Annals of the Rheumatic Diseases. [PMID 41198460](https://pubmed.ncbi.nlm.nih.gov/41198460/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # What BMI Do You Need for a GLP-1? The Cut-Off Is a Convention | This GLP What BMI do you need for a GLP-1? STEP 12 enrolled at 24 to 30 and found 12.1% against 2.2%, while only 10.6% of hospitalized adults over BMI 30 were coded for obesity at all. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1 Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # What BMI Do You Need for a GLP-1? The Cut-Off Is a Convention A trial in China and Taiwan enrolled people at a BMI of 24 to 30, below where the Western trials start. The cut-off is a guideline, not a boundary in a body. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min readUpdated September 2026 Body mass index at trial entry · STEP 12 entry (China, Taiwan) · typical Western trial entry · 24 · 27 · 30 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The number depends on which guideline your prescriber uses. A phase 3b trial in China and Taiwan enrolled adults at a BMI of 24 to under 28 [\[1\]](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1#ref-1). That band required a weight-related condition, and a second ran 28 to under 30. Weight fell 12.1% against 2.2% on placebo over 44 weeks. East Asian guidelines set the cut-points lower because risk rises at lower BMI there. A cut-off is a convention adopted by a committee. It is not a line where a body changes. Nothing on this page tells you that you qualify. ## Key takeaways - A phase 3b trial in mainland China and Taiwan randomized 242 adults 2:1 to semaglutide 2.4 mg or placebo for 44 weeks. - Entry required a BMI of 24 to under 28 with a weight-related condition, or 28 to under 30 — below the thresholds used in the Western trials. - Weight fell 12.1% against 2.2% on placebo, an estimated treatment difference of 9.9 percentage points, 95% CI −11.8 to −8.0. - 80.5% reached at least 5% weight loss against 24.4%, an odds ratio of 14.8, 95% CI 7.4 to 29.6. - Adverse events were reported by 87.6% on the drug and 75.3% on placebo. Every intake form asks for a height and a weight. Behind it sits a number that decides whether anything is offered. That number is not a fact about bodies. It is a guideline, and guidelines differ. It is a different kind of gate from [the state lists sellers publish](https://thisglp.com/research/who-publishes-the-states-they-serve), and it works the same way. ## A trial run at lower numbers STEP 12 enrolled adults across 19 sites in mainland China and Taiwan [\[1\]](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1#ref-1). It used locally defined BMI thresholds. Entry was 24 to under 28 with at least one weight-related condition. The second band was 28 to under 30, with or without type 2 diabetes. Of 242 participants, 161 received semaglutide 2.4 mg weekly and 81 placebo. The trial ran 44 weeks alongside lifestyle intervention. Half were women and 19.4% had type 2 diabetes. Those entry criteria sit below where the well-known trials began. The rationale is not novel. East Asian guidelines set overweight and obesity cut-points lower, because cardiometabolic risk rises at lower BMI in these populations. The trial was designed around the local definition rather than the American one. ## What it found Body weight fell 12.1% on semaglutide against 2.2% on placebo. The estimated treatment difference was 9.9 percentage points, 95% CI −11.8 to −8.0, p<0.0001. The proportion reaching at least 5% weight loss was 80.5% against 24.4%, an odds ratio of 14.8, 95% CI 7.4 to 29.6. Adverse events were reported by 141 of 161 participants on the drug, 87.6%, and 61 of 81 on placebo, 75.3%. Both figures are high. The difference between them is smaller than the drug figure alone suggests. That is the reason to ask what the placebo arm reported. This page is not telling you that you qualify A trial run under one country’s guidelines does not change the criteria a prescriber elsewhere works to. Nothing here is a reason to present yourself differently on an intake form. The point is only about how to read a number. The BMI cut-off you meet or miss is a convention adopted by a guideline committee. It is not a line where a body changes. Where the line should sit is a question for clinicians and regulators. ## What the threshold does after you clear it Meeting the number is not the same as being coded for it. A decade-long analysis looked at 42,243 hospitalized adults with a measured BMI of 30 or above and no prior obesity code [\[2\]](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1#ref-2). Obesity appeared in the discharge summary for 10.6% of them. Each additional BMI unit raised the odds of being coded by 17%. The threshold behaves as a gradient rather than a gate. Documented patients had 3.44 times the odds of a GLP-1 prescription. That is an association, not a cause, and the full reading is in [measured in everyone, written down in one in ten](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record). ## Below the threshold entirely One study went under it. A target trial emulation took adults with type 2 diabetes and a BMI below 27, the group the weight trials exclude [\[3\]](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1#ref-3). Against DPP-4 inhibitors, all-cause mortality was 39% lower, hazard ratio 0.61, 95% CI 0.52 to 0.71. Against SGLT2 inhibitors it did not differ: 0.89, 95% CI 0.76 to 1.05. The authors say the mortality figure likely reflects residual confounding. Coded heart failure was lower across all three comparisons, which was their most consistent result. The reading is in [the authors who doubt their own hazard ratio](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own). ## How it compares The 12.1% reduction is smaller than the headline figures from the large Western trials. The comparison is not straightforward. This cohort started at a lower BMI, so there was less weight available to lose. The trial also ran 44 weeks rather than 68. Percentage weight loss behaves differently depending on where you start. That is one reason [expected-loss estimates](https://thisglp.com/tools/glp1-expected-weight-loss) should never be read as a promise. What travels is the shape. Both co-primary endpoints separated clearly from placebo. That is consistent with [what the wider trial evidence shows](https://thisglp.com/research/semaglutide-cochrane-review). A drug that worked only where it was first tested would be the surprising result. This is not that. ## Why a single trial in one region matters here Most readers meet this drug through trials run in the United States and Europe. The generalization outward is usually assumed rather than demonstrated. Trials like this one test the assumption. They arrive years later and attract a fraction of the attention. The published evidence is also narrower than the marketing implies at any moment. That is the gap separating [a famous trial from the literature behind it](https://thisglp.com/research/glp1-in-children-all-eighteen-trials). The trial was funded by Novo Nordisk, which makes the drug. Study enrollment and a clinic’s intake rules are separate. [Form Health](https://thisglp.com/reviews/form-health) publishes its own adult BMI and health-condition criteria in its [FAQ](https://www.formhealth.co/faqs). Meeting a threshold permits consideration; it does not guarantee a prescription, insurance approval or the result reported in this trial. ## Frequently asked What BMI do you need for a GLP-1? It depends on the guideline your prescriber follows. STEP 12 enrolled at a BMI of 24 to under 28 with a weight-related condition, or 28 to under 30, under East Asian cut-points that sit below the ones used in the Western trials. Why did this trial enroll people at a lower BMI? It used locally defined thresholds. East Asian guidelines set overweight and obesity cut-points lower because cardiometabolic risk rises at lower BMI in these populations, and the trial was designed around that definition. Does that mean I qualify at a lower BMI? No. A trial run under one country's guidelines does not change the criteria a prescriber elsewhere works to, and nothing here is a reason to describe yourself differently on an intake form. Why was the weight loss smaller than in the famous trials? Participants started at a lower BMI, so there was less weight available to lose, and the trial ran 44 weeks rather than 68. Percentage weight loss is not comparable across different starting points. Were side effects worse? Adverse events were reported by 87.6% on semaglutide and 75.3% on placebo. Both are high, and the gap is narrower than the drug figure alone suggests. ## Sources 1. \[1\] Guo L, et al. (2026). Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial The Lancet Diabetes & Endocrinology. [PMID 42575111](https://pubmed.ncbi.nlm.nih.gov/42575111/) 2. \[2\] Avivi I, et al. (2026). From measured BMI to documented obesity in hospitalized adults: a decade-long analysis and implications for cardiometabolic care International Journal of Obesity. [PMID 42687002](https://pubmed.ncbi.nlm.nih.gov/42687002/) 3. \[3\] Chen SC, et al. (2026). Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial Emulation Diabetes, Obesity and Metabolism. [PMID 42642357](https://pubmed.ncbi.nlm.nih.gov/42642357/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # What Else Comes Back When You Stop a GLP-1? Almost Everything | This GLP What a meta-analysis of eighteen discontinuation trials found returning after GLP-1 treatment stopped, how it differed by drug, and why its heterogeneity limits every figure in it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1 Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # What Else Comes Back When You Stop a GLP-1? Almost Everything Across eighteen trials, stopping reversed HbA1c, waist, blood pressure and fasting glucose as well as weight — and the rebound was roughly twice as large after semaglutide as after liraglutide. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read What returned after stopping, by drug · weight (kg) · systolic (mmHg) · semaglutide · 8.21 · 7.09 · liraglutide · 4.29 · 1.56 · Eighteen trials, 3,771 people, and they disagreed enormously. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Across eighteen randomized trials and 3,771 participants, stopping these drugs reversed more than weight. - In people with obesity, HbA1c rose 0.25% and waist circumference, BMI, systolic blood pressure and fasting glucose all deteriorated. - The rebound was larger after semaglutide than liraglutide: 8.21 kg against 4.29, and systolic pressure up 7.09 mmHg against 1.56. - It also grew with time — 7.31 kg beyond 26 weeks against 2.51 kg in shorter follow-ups. - Heterogeneity reached 99.57%, meaning the eighteen trials disagreed with each other almost entirely. More than the weight. Pooled across eighteen randomized trials and 3,771 participants, stopping reversed HbA1c, waist circumference, BMI, systolic blood pressure and fasting glucose together. In people with obesity HbA1c rose 0.25 percentage points. The rebound differed by drug. It ran 8.21 kg after semaglutide against 4.29 kg after liraglutide, and systolic pressure rose 7.09 mmHg against 1.56. It also grew with time: 7.31 kg beyond 26 weeks against 2.51 kg in shorter follow-ups. ⛔ Heterogeneity reached 99.57%. The eighteen trials disagreed with each other almost entirely, so the pooled figures describe a direction rather than an amount. The randomized withdrawal studies behind the weight half of this are STEP 1 [\[2\]](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1#ref-2) and STEP 4 [\[3\]](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1#ref-3). That weight returns after stopping is well established, and we cover it in [stopping and weight regain](https://thisglp.com/research/stopping-glp1-and-weight-regain). What is less discussed is that the scale is not the only thing that reverses, and that the size of the reversal depends on which drug was stopped. ## What was pooled A 2025 systematic review searched five databases without language restriction and included eighteen randomized trials with at least twelve weeks of follow-up after treatment ended, covering 3,771 participants [\[1\]](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1#ref-1). Every included study was rated low risk of bias. ## What came back Among people with obesity, body weight rose 5.63 kg after stopping (95% CI 3.52 to 7.73) and HbA1c by 0.25% (95% CI 0.18 to 0.32). Waist circumference, BMI, systolic blood pressure and fasting plasma glucose all deteriorated significantly. In the type 2 diabetes studies the pattern differed. Weight rose less, at 2.03 kg (95% CI 1.63 to 2.42), while HbA1c rose more, at 0.65% (95% CI 0.22 to 1.08). Fasting glucose remained stable there. The two populations lose different things and get different things back, which is the same lesson as the dose-response gradient in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). The number that limits every other number Heterogeneity on the weight outcome reached an I² of 99.57%, and on HbA1c 98.45%. That is close to the theoretical maximum. The eighteen trials did not agree with one another, and the pooled mean sits in the middle of results that point in very different directions. A figure like 5.63 kg is therefore a statement about the direction of travel across a literature, not a prediction about a person. Anyone told they will regain a specific amount is being told something this analysis does not support. ## The differences worth noticing Two subgroup findings stand out. The rebound was larger after semaglutide than after liraglutide — 8.21 kg against 4.29 — with waist circumference up 3.80 cm against 2.69 and systolic blood pressure up 7.09 mmHg against 1.56. And it grew with time: studies following people beyond 26 weeks reported 7.31 kg against 2.51 kg in shorter ones. The blood pressure figure is the one least likely to be mentioned by anyone selling the drug. Seven millimeters of mercury is a clinically meaningful move. It is the kind of thing a person who stopped six months ago would have no reason to connect to a decision they made then. ## What it means before buying It means the purchase is longer than it looks. The authors conclude that guidelines need to address discontinuation and maintenance, not only initiation and titration. That is a polite way of saying that the exit is unplanned for. On the seller side that gap is total. Nothing in this market describes what happens after, and most of it does not describe what happens during, which is the silence counted in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). It also means a year of purchases is the realistic unit of decision, not a month. and the prices that decide whether a year is affordable are the ones this site measures in [when the headline is not the bill](https://thisglp.com/research/glp1-advertised-vs-billed-corrections). ## Frequently asked Does anything besides weight come back? Yes. In people with obesity, HbA1c rose 0.25% and waist circumference, BMI, systolic blood pressure and fasting glucose all deteriorated significantly after stopping. Does the drug make a difference? In the subgroup analysis it did: 8.21 kg regained after semaglutide against 4.29 after liraglutide, with systolic pressure up 7.09 mmHg against 1.56. How reliable are these numbers? As a direction, well supported. As a prediction for an individual, not at all — heterogeneity reached 99.57% on the weight outcome, meaning the pooled trials disagreed almost entirely. Does the rebound stop? It grew with follow-up length rather than settling: 7.31 kg beyond 26 weeks against 2.51 kg in shorter studies. ## Sources 1. \[1\] Tzang CC, et al. (2025). Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis EClinicalMedicine. [PMID 41399474](https://pubmed.ncbi.nlm.nih.gov/41399474/) 2. \[2\] Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Diabetes, Obesity and Metabolism. [PMID 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/) 3. \[3\] Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial JAMA. [PMID 33755728](https://pubmed.ncbi.nlm.nih.gov/33755728/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Seller Disclosure Gaps: Dose Pricing, State Coverage, Formats | This GLP How many GLP-1 sellers leave dose pricing, state coverage and catalog breadth unpublished, counted across several hundred sellers, and three questions to ask one before ordering. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-glp1-sellers-do-not-publish Updated: 2026-10-28 Published: 2026-09-15 [← Research](https://thisglp.com/research) Formats # GLP-1 Seller Disclosure Gaps: Dose Pricing, State Coverage, Formats Across several hundred GLP-1 sellers, a count of how many publish nothing about dose pricing, nothing about state coverage and nothing beyond a single format, and why silence is not the same as concealment. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Says nothing about dose · 370 · No coverage list · 379 · One format only · 467 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 370 of 580 sellers on this roster — 64% — publish nothing about what their price does at a higher dose. - 379 record no list of states they ship to. - 467 offer one format only, and 105 one molecule. - Every count here is 'published nothing on this point'. None of them is a finding that a seller is concealing anything. - Corpus: 580 sellers, read most recently October 2026. Most of what decides whether a GLP-1 service suits a particular reader is not on its pricing page. That is not a scandal — it is a pattern, and it is consistent enough across several hundred sellers to count rather than assert. ## The four common silences **What happens at a higher dose.** 370 sellers of 580 publish nothing either way. 166 state the rate holds and 44 state it rises. Since almost everyone escalates inside the first sixteen weeks, this is the silence that costs the most — and [the sellers that do publish a ladder](https://thisglp.com/tools/published-dose-ladders) are a small minority of the roster. **Where they can ship.** 379 sellers record no state list at all. A reader in a licensing-thin state cannot tell from the page whether the service is available to them, and a price that cannot be bought is not a price. [Coverage by state](https://thisglp.com/tools/coverage-by-state) shows how unevenly that falls. **What else they sell.** 467 offer a single format, so a reader who wants a tablet rather than an injection is choosing from a much smaller field than the headline count suggests. 105 carry a single molecule, which [the molecule and format finder](https://thisglp.com/tools/molecule-and-format-finder) breaks down seller by seller. An unfilled field is not a refusal A seller counted in any of these groups has not been shown to be withholding anything. It has been shown not to have written the sentence down on a page this desk has read. Most will answer the question in a message; the point of counting is that the answer is worth having in writing before money changes hands, and that the industry norm is to leave it unwritten. ## What to send before ordering One message covers most of it: _does this figure change as my dose goes up, and if so what does it become; can you ship to my state; and is there any charge outside the figure on the page?_ A seller that answers all three in writing has done more than most of this market does in public. [The open-questions tool](https://thisglp.com/tools/questions-they-leave-open) keeps the current counts, and [the scorecard](https://thisglp.com/tools/what-sellers-publish) shows how each ranked seller does on the five things this site marks. Counts are computed from this site’s own records at build time, most recently read October 2026. Nothing is modeled or taken from a third party. One useful disclosure is who actually provides the care. [Embody](https://thisglp.com/reviews/embody) distinguishes its platform from independent medical groups in its [terms](https://joinem.co/pages/terms-conditions). A storefront name alone therefore does not identify the prescriber. Ask which practice will hold your records and handle a problem after dispensing. ## Frequently asked Does a missing answer mean a seller is hiding something? No. Every count here means 'published nothing on this point' on the pages this desk has read. Most sellers will answer in a message; the finding is that the norm is to leave it unwritten. Which silence matters most? What the price does at a higher dose. Almost everyone escalates inside sixteen weeks, so an opening figure with no stated dose behavior describes the cheapest month of a course. Where do these counts come from? This site's own seller records, computed when the page was built. No third-party dataset is involved. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Alcohol Admissions After Stopping a GLP-1: Swedish Within-Person Data | This GLP A Swedish within-individual study of 167,026 people found alcohol-related hospital admissions fell on GLP-1 drugs (RR 0.55), and the benefit faded within a year of stopping. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Alcohol Admissions After Stopping a GLP-1: Swedish Within-Person Data Comparing people against themselves, alcohol-related hospital admissions fell on a GLP-1 and stayed lower for 182 days after stopping. By a year, the difference was gone. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Alcohol-related hospitalization, same people · on the drug · 0.55 · days 1–182 after · 0.70 · days 183–364 after · 1.07 · Dashed line marks no change. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A Swedish register study of 167,026 people with type 2 diabetes compared each person against themselves, across periods on and off the drug. - While exposed, alcohol-related hospitalization rates were lower (RR 0.55, 95% CI 0.43-0.70), as were substance-related ones (RR 0.61, 95% CI 0.50-0.74). - After stopping, the alcohol association persisted for the first 182 days (RR 0.70, 95% CI 0.50-0.98) and was gone by days 183-364 (RR 1.07, 95% CI 0.71-1.63). - DPP-4 inhibitors, used as a comparison, showed no consistent reductions. Whether these drugs reduce drinking has been asked several times, including in the trials covered in [two trials that asked different questions](https://thisglp.com/research/does-semaglutide-reduce-alcohol-use). What had not been asked is what happens when people stop taking them, and a Swedish register study built specifically to answer that [\[1\]](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it#ref-1). The design deserves a moment. Rather than matching people on a drug to different people not on it, this study compared each person with themselves, contrasting periods when they were taking a GLP-1 drug against periods when they were not. Everything stable about a person — their genetics, their social circumstances, their baseline relationship with alcohol — cancels out by construction, which removes the confounding that troubles most of this literature. Across 167,026 residents of Stockholm County with type 2 diabetes, 41,109 received a GLP-1 drug at some point during the study period. While people were taking one, alcohol-related hospitalizations ran at a rate ratio of 0.55 (95% CI 0.43–0.70) against their own unexposed periods, and substance-related hospitalizations at 0.61 (95% CI 0.50–0.74). DPP-4 inhibitors, included as a comparison treatment, produced no consistent reductions, which suggests what was measured is not simply the effect of being under active medical care. How much that conclusion depends on the comparison chosen is the subject of [the overdose study with five comparators](https://thisglp.com/research/overdose-depends-on-the-comparator). The discontinuation windows are the new information. In the first 182 days after stopping, the alcohol association was still there but weaker, at 0.70 (95% CI 0.50–0.98). In days 183 to 364 it had gone, at 1.07 (95% CI 0.71–1.63), an interval sitting squarely across no effect. For substance use disorder more broadly, neither post-discontinuation window reached significance at all. Hospitalization is not drinking Nobody in this study was asked how much they drank. The outcome is an admission to hospital with an alcohol or substance code attached, which captures the severe end and misses everything below it. A fall in admissions is compatible with drinking less, and also with drinking the same amount with fewer crises. The practical reading the authors themselves draw is that substance use deserves clinical monitoring when one of these drugs is stopped. That matters more than it might sound, because stopping is the normal outcome rather than the exception, as [other register studies of this kind](https://thisglp.com/research/glp1-mortality-authors-doubt-their-own) and the discontinuation literature both show. If a benefit exists and fades within a year of stopping, then the population most exposed to that fade is large, and largely unwatched. The weight side of the same stopping problem is covered in [what happens to muscle](https://thisglp.com/research/muscle-loss-on-glp1). ## Frequently asked Why is comparing people with themselves better? It removes everything stable about a person from the comparison — genetics, social circumstances, baseline drinking — because those are identical in both periods. That is confounding most matched-cohort studies cannot eliminate. Does the benefit last after stopping? Partly and briefly. For alcohol-related admissions it persisted through the first 182 days (RR 0.70) and was gone by days 183 to 364 (RR 1.07). For substance use disorder generally, no post-stop window reached significance. Does this mean people drank less? It is not what was measured. The outcome was hospital admission with an alcohol or substance code, which captures severe events only. Fewer admissions is consistent with less drinking and also with fewer crises at the same level. ## Sources 1. \[1\] Bach P, Franck J, Hällgren J, Widing H, Gissler M, Westman J (2026). Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study The Lancet. Psychiatry. [PMID 42456704](https://pubmed.ncbi.nlm.nih.gov/42456704/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # What Happens When You Stop Tirzepatide? SURMOUNT-4 Says 14% Comes Back In SURMOUNT-4, people who stopped tirzepatide regained 14.0% over a year while those who continued lost a further 5.5%. What returned depended on how much weight came back. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-happens-when-you-stop-tirzepatide Updated: 2026-10-26 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # What Happens When You Stop Tirzepatide? SURMOUNT-4 Says 14% Comes Back The trial randomized 670 people to keep taking it or stop. Over the following year the ones who stopped regained 14.0%, and how much each person regained decided how much of the benefit they kept. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Waist gained after stopping, by share of loss regained · +0.8 · <25% · +5.4 · 25–50% · +10.1 · 50–75% · +14.7 · 75%+ · Centimeters, week 36 to 88. Everyone shown had stopped. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - In SURMOUNT-4, everyone spent 36 weeks on tirzepatide and lost 20.9% on average, then half were switched to placebo for a year. - Over that year the placebo group regained 14.0% of their week-36 weight while those who stayed on the drug lost a further 5.5% — a difference of 19.4 percentage points. - Regaining is not all-or-nothing: sorted by how much came back, waist circumference rose 0.8, 5.4, 10.1 and 14.7 cm across four bands. - Blood pressure rose in every band, including among people who held nearly all of their loss. The weight comes back gradually, and how much of it comes back varies enormously between one person and the next. The amount you keep off appears to decide how much of the health benefit you keep with it. SURMOUNT-4 is the trial that measured this, and it was built for the purpose rather than stumbling on it afterwards [\[1\]](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide#ref-1). Everyone in the trial took tirzepatide for the first 36 weeks, openly and without a placebo group, which is how 783 people came to lose an average of 20.9% of their body weight before the real experiment began. At that point 670 of them were randomly assigned either to carry on with the drug or to switch to a placebo injection for another 52 weeks. Neither they nor their doctors knew which they had been given. That is a withdrawal design, set against the observational stopping this site examined in — a withdrawal design rather than the observational stopping this site examined in [what happens in ordinary care](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## What the scale did over the following year The group that stayed on tirzepatide lost a further 5.5% on top of everything they had already lost, while the group switched to placebo gained 14.0% back. That leaves a gap of 19.4 percentage points between the two arms, with a confidence interval running from 21.2 to 17.7 [\[1\]](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide#ref-1). Regaining 14% is not the same as ending up where you started Somebody who had lost 20.9% and then regained 14.0% of their week-36 weight is still a long way below the weight they walked in at, because the second percentage is measured against the lighter body they had become rather than against their original one. The trial does not show that stopping undoes everything, and a page telling you it does is either misreading the arithmetic or hoping you will not check it. ## Why two people who both stop can end up in very different places A later analysis took the 308 people from the placebo arm who had lost at least 10% during the lead-in and sorted them by how much of that loss had returned by the end. That turns a single average into something far more useful for anyone actually deciding whether to stop [\[2\]](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide#ref-2). The bands are shares of the weight each person had lost, so somebody in the largest band had regained three quarters or more of their own result rather than three quarters of their body weight. Change from week 36 to week 88 among people who stopped tirzepatide. | Share of lost weight regained | Waist gained | Systolic blood pressure | | --- | --- | --- | | Under 25% | +0.8 cm (95% CI −1.0 to 2.6) | +6.8 mm Hg | | 25% to under 50% | +5.4 cm | +7.3 mm Hg | | 50% to under 75% | +10.1 cm | +9.6 mm Hg | | 75% or more | +14.7 cm | +10.4 mm Hg | Change from week 36 to week 88 among people who stopped tirzepatide. Post hoc analysis of the SURMOUNT-4 placebo arm, 308 participants The people who held on to most of their loss showed no measurable change in waist circumference at all, since 0.8 cm carries an interval running from minus 1.0 to 2.6. The people who regained the most put 14.7 cm back on. [Non-HDL cholesterol](https://thisglp.com/research/does-ozempic-lower-cholesterol) behaved the same way, staying flat in the two smaller bands and rising 8.4% and 10.8% in the two larger ones. ## The exception that is worth knowing about before you stop Blood pressure did not follow that pattern. Systolic pressure rose in every single band, from 6.8 mm Hg among the people who barely regained anything to 10.4 mm Hg among those who regained the most. It came back even for the people who did best on the scale. Whatever the drug was doing to blood pressure, holding on to the weight loss did not preserve it. One limit governs how hard any of this can be pushed, and it is worth being plain about: nobody was randomly assigned to a regain band. Everyone in that analysis received placebo, and which band a person landed in was an outcome rather than an allocation. So people who regained little may differ from people who regained a lot in ways that have nothing to do with the drug — the same problem this site set out in [what happens when the control group never started treatment](https://thisglp.com/research/do-glp1-drugs-cause-depression). ## Is this specific to tirzepatide? No, and the semaglutide evidence points the same way. When the STEP 1 extension followed people who had come off semaglutide, weight and the cardiometabolic markers both moved back toward where they had started. That is the pattern this site went through in [the withdrawal evidence](https://thisglp.com/research/stopping-glp1-and-weight-regain) and again, across drug classes, in [what comes back besides the weight](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1) [\[3\]](https://thisglp.com/research/what-happens-when-you-stop-tirzepatide#ref-3). What none of these trials can tell you is what happens to somebody who stops deliberately and carefully, with a plan, rather than because a prescription lapsed or a trial protocol switched them to saline. That trial has not been run, which is worth remembering the next time a page promises you a safe way off. — and the composition question underneath it, of what exactly is lost and what exactly returns, is in [what is lost and what returns](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). Continuity is a practical question to ask before treatment, not a promise of a successful exit. [PlushCare](https://thisglp.com/reviews/plushcare) describes ongoing weight management and the ability to keep the same doctor on its [website](https://plushcare.com/). Ask how follow-up would work if medication becomes unaffordable or must be discontinued; the withdrawal trials do not evaluate that service. ## Frequently asked What happens when you stop taking tirzepatide? In SURMOUNT-4, people switched to placebo regained 14.0% of their week-36 weight over the following year, while those who stayed on the drug lost a further 5.5%. Do you regain all the weight? Not in this trial. Participants had lost 20.9% before the withdrawal period began, and the 14.0% regained is measured against that lighter weight, so the group remained well below where they started. Does it matter how much weight comes back? It appears to. Sorted into four bands by how much of their loss returned, waist circumference rose 0.8, 5.4, 10.1 and 14.7 cm, and non-HDL cholesterol only rose once regain passed about half. Does anything come back even if you keep the weight off? Systolic blood pressure rose in every band, from 6.8 to 10.4 mm Hg, including among people who regained less than a quarter of what they had lost. Is semaglutide any different? The pattern looks the same. The STEP 1 trial extension found weight and cardiometabolic markers moved back toward baseline after semaglutide was withdrawn. ## Sources 1. \[1\] Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA. [PMID 38078870](https://pubmed.ncbi.nlm.nih.gov/38078870/) 2. \[2\] Horn DB, Linetzky B, Davies MJ, Laffin LJ, Wang H, Murphy MA (2026). Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial JAMA Internal Medicine. [PMID 41284285](https://pubmed.ncbi.nlm.nih.gov/41284285/) 3. \[3\] Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Diabetes, Obesity and Metabolism. [PMID 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # What Is Ecnoglutide? A Phase 3 Result You Cannot Compare to the Others | This GLP A phase 3 trial of ecnoglutide in 664 Chinese adults found 13.2% weight loss at week 40 against 0.1% on placebo | and entry criteria well below Western obesity trials. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-is-ecnoglutide Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # What Is Ecnoglutide? A Phase 3 Result You Cannot Compare to the Others A GLP-1 drug engineered to favor one signaling pathway reached phase 3 and took off 13.2% at week 40. Its entry criteria mean the percentage is not comparable to the ones you have seen. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Weight lost at week 40 · 2.4 mg · 13.2% · 1.8 mg · 10.9% · 1.2 mg · 9.1% · placebo · 0.1% · 664 adults in China. Entry BMI ≥ 28, or ≥ 24 with a comorbidity. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Ecnoglutide, a cAMP-biased GLP-1 receptor agonist, was tested against placebo in 664 adults with overweight or obesity and no diabetes, at 36 centers in China. - At week 40, weight fell 13.2% on the 2.4 mg dose against 0.1% on placebo — a treatment difference of -13.3% (97% CI -15.3 to -11.3). - 87% of the 2.4 mg group lost at least 5% of their weight, against 16% on placebo. - Entry required a BMI of 28, or 24 with a comorbidity — thresholds well below those used in the Western trials, so the percentages are not directly comparable. Ecnoglutide is a once-weekly GLP-1 receptor agonist engineered to favor one signaling pathway, and it is not approved or sold outside China. In its phase 3 trial, weight fell 13.2% at week 40 on the 2.4 mg dose against 0.1% on placebo [\[1\]](https://thisglp.com/research/what-is-ecnoglutide#ref-1). It appeared first as one of the thinly evidenced agents in a network meta-analysis of drugs for overweight and obesity[\[2\]](https://thisglp.com/research/what-is-ecnoglutide#ref-2). This site reads that analysis in [the network meta-analysis of nineteen drugs](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). It now has a completed trial behind it. It is described as a cAMP-biased GLP-1 receptor agonist. The engineering favors one downstream signaling pathway over another, with the intention of separating the metabolic effects from the gastrointestinal ones. Whether that worked is the interesting question, and the trial provides a partial answer. On weight it performed well. Across 664 randomized adults at 36 Chinese centers, week-40 weight loss was 9.1%, 10.9% and 13.2% at the three doses against 0.1% on placebo. The top dose gave a treatment difference of -13.3% (97% CI -15.3 to -11.3). Eighty-seven percent of that group lost at least 5% of their body weight, against 16% on placebo. These percentages are not comparable to the ones you know Eligibility required a BMI of 28 or above, or 24 or above with a weight-related condition. The Western obesity trials use 30, or 27 with a comorbidity. A trial starting from a lighter population is not measuring the same thing when it reports a percentage, and comparing 13.2% here against a figure from SURMOUNT or STEP would be comparing different denominators in different bodies. Ecnoglutide is also not approved or available outside China. On tolerability the picture is less distinctive than the design promised. Treatment-emergent adverse events occurred in 93% of each ecnoglutide group against 84% on placebo, most commonly mild to moderate gastrointestinal events, and ten participants stopped because of them. That is broadly the profile of the existing drugs rather than an escape from it. Tolerability is what drives most discontinuation in this class, as [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) describes. The trial was funded by Hangzhou Sciwind Biosciences, which makes the drug. That is ordinary for a phase 3 trial and worth stating rather than implying. Almost every pivotal obesity trial is sponsor-funded, including the ones behind the drugs people take today. The thing to weigh is the follow-up rather than the funding. Forty weeks says nothing about year three, which is where the questions in [what these drugs do to muscle](https://thisglp.com/research/muscle-loss-on-glp1) and [the measured lunch](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1) actually live. ## Frequently asked Can I get ecnoglutide? No. It is not approved or available outside China, and this trial was conducted entirely at Chinese centers. Is 13.2% better than what existing drugs achieve? Not comparable. This trial enrolled people at a BMI of 28, or 24 with a comorbidity, against 30 or 27 in the Western obesity trials, so the percentages are calculated from different starting points. Did the biased design reduce side effects? Not visibly. Treatment-emergent adverse events occurred in 93% of each ecnoglutide group against 84% on placebo, mostly mild to moderate gastrointestinal events. ## Sources 1. \[1\] Ji L, Gao L, Xue H, Tian J, et al. (2025). Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Diabetes & Endocrinology. [PMID 40555243](https://pubmed.ncbi.nlm.nih.gov/40555243/) 2. \[2\] Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. (2026). Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ. [PMID 42419792](https://pubmed.ncbi.nlm.nih.gov/42419792/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide | This GLP What orforglipron is, what ATTAIN-1 found at 72 weeks in 3,127 adults, and why a small-molecule tablet is chemically different from oral semaglutide | plus its tolerability. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-is-orforglipron Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Weight change at 72 weeks, once-daily tablet · placebo · 2.1% · 6 mg · 7.5% · 12 mg · 8.4% · 36 mg · 11.2% · 3,127 patients with obesity and no diabetes. No injection. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Orforglipron is a small-molecule tablet, not a peptide — a different chemical class from every other drug covered here, which is why it needs no injection and no absorption enhancer. - Over 72 weeks in 3,127 adults with obesity and no diabetes, weight fell 11.2% on the 36 mg dose against 2.1% on placebo. - On that dose, 54.6% lost at least 10% of their weight, 36.0% at least 15% and 18.4% at least 20%. - Adverse events ended treatment for 5.3% to 10.3% of the drug groups against 2.7% on placebo. - No trial has compared it against an injected GLP-1, so any such comparison is an eyeball across two studies. Orforglipron is a once-daily tablet that acts on the GLP-1 receptor and is not a peptide. In a 72-week phase 3 trial of 3,127 adults with obesity, weight fell 11.2% on the 36 mg dose against 2.1% on placebo [\[1\]](https://thisglp.com/research/what-is-orforglipron#ref-1). Everything else in this library is a peptide, either injected or put into a tablet with an absorption enhancer to survive the stomach. Orforglipron is neither. Being a small molecule is a chemistry difference with practical consequences: no cold chain, no needle, and none of the food-timing rules the existing pill requires. That last one is covered in [what the pill actually does](https://thisglp.com/research/oral-semaglutide-what-the-pill-does). For the diabetes-specific results, see the [three phase 3 orforglipron trials in type 2 diabetes](https://thisglp.com/research/does-orforglipron-work-for-type-2-diabetes), rather than assuming that weight-loss and glucose-control endpoints are interchangeable. ## What the trial did ATTAIN-1 was a phase 3, multinational, double-blind trial in adults who had obesity and did not have diabetes. Patients were randomized in a 3:3:3:4 ratio to once-daily orforglipron at 6 mg, 12 mg or 36 mg, or to placebo, alongside diet and activity advice, for 72 weeks. The primary endpoint was percent change in body weight at week 72, analyzed in the intention-to-treat population. ## What it found Among the 3,127 patients randomized, mean weight change at 72 weeks was −7.5% at 6 mg (95% CI −8.2 to −6.8). The 12 mg dose gave −8.4% (95% CI −9.1 to −7.7). The 36 mg dose gave −11.2% (95% CI −12.0 to −10.4). Placebo gave −2.1% (95% CI −2.8 to −1.4). The thresholds are the more legible version of the same result. On 36 mg, 54.6% of patients lost 10% or more of their body weight, 36.0% lost 15% or more and 18.4% lost 20% or more. The placebo figures were 12.9%, 5.9% and 2.8%. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol all improved against placebo as well. The comparison this page will not make It is tempting to set −11.2% beside the number you remember from a semaglutide or tirzepatide trial and rank them. Don’t. Those trials enrolled different people under different protocols, and no study has yet randomized anyone between a small-molecule tablet and an injected peptide. What can be said is narrower and still useful. A daily tablet with no absorption enhancer produced a double-digit mean reduction over 72 weeks, in a trial of more than three thousand people. That is a real result about this drug, and the only kind this trial supports. ## How it sits beside the other pill The nearest comparison is oral semaglutide, and it is not a randomized one. At 25 mg over 64 weeks, oral semaglutide produced a mean weight reduction of 13.6% against 2.2% on placebo in adults with overweight or obesity [\[2\]](https://thisglp.com/research/what-is-orforglipron#ref-2). Different trial, different population, different duration. A network meta-analysis of drugs for overweight and obesity places the whole class rather than ranking these two [\[3\]](https://thisglp.com/research/what-is-orforglipron#ref-3). Its finding is that the agents taking off the most weight are also the ones people stop soonest. Orforglipron’s discontinuation figures below are the same trade in miniature. ## What it costs in tolerability Adverse events led to discontinuation in 5.3% to 10.3% of patients across the three orforglipron groups, against 2.7% on placebo. The most common were gastrointestinal and mostly mild to moderate — the same pattern the injected drugs produce, described in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The dose-response runs both ways: the arm that lost most weight was also the arm people left most often. ## Where a reader will meet it It is already being sold. Several storefronts tracked here list the branded tablet. It is usually routed through the manufacturer’s own pharmacy with a membership charged beside it, which makes the advertised medication figure only part of the bill. That structure is the subject of [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). The dose question applies here as much as anywhere. 36 mg is the dose that produced the headline, and a seller quoting a starter price is quoting a different rung. Which sellers publish the rungs at all is counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). ## Frequently asked How is orforglipron different from the semaglutide pill? It is a small molecule rather than a peptide, so it does not need an absorption enhancer or the food-timing rules that come with one. Chemically it is a different class of drug acting on the same receptor. How much weight did people lose? A mean of 11.2% at 72 weeks on the 36 mg dose against 2.1% on placebo. On that dose, 54.6% lost at least 10% of their weight and 18.4% lost at least 20%. Is it better than an injection? Nobody knows. No trial has randomized patients between orforglipron and an injected GLP-1, so comparing numbers across separate trials compares populations as much as drugs. How many people stopped because of side effects? Between 5.3% and 10.3% across the three dose groups, against 2.7% on placebo, mostly for gastrointestinal effects that were mild to moderate. ## Sources 1. \[1\] Wharton S, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment New England Journal of Medicine. [PMID 40960239](https://pubmed.ncbi.nlm.nih.gov/40960239/) 2. \[2\] Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity New England Journal of Medicine. [PMID 40934115](https://pubmed.ncbi.nlm.nih.gov/40934115/) 3. \[3\] Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. (2026). Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ. [PMID 42419792](https://pubmed.ncbi.nlm.nih.gov/42419792/) ## Prescription access ### LillyDirect’s Foundayo pathway Understand the prescription requirements, pharmacy pathway and payment terms before arranging Foundayo treatment. [Read the LillyDirect review →](https://thisglp.com/reviews/lillydirect-foundayo) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # What New Weight Loss Drugs Are Coming? Retatrutide Leads at 22.1% | This GLP What new weight loss drugs are coming? Retatrutide, CagriSema, VK2735, UBT251 and ecnoglutide, with the trial length behind each figure | and what is buyable. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-new-weight-loss-drugs-are-coming Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # What New Weight Loss Drugs Are Coming? Retatrutide Leads at 22.1% Across 58 trials and 24,214 adults, retatrutide took off 22.10% of body weight and tirzepatide 19.28%. Only one drug on that podium can actually be bought. [This GLP Editorial Team](https://thisglp.com/about)September 202610 min readUpdated September 2026 Weight loss vs placebo, 58 trials · retatrutide · not on sale · tirzepatide · on sale · CagriSema · not on sale · Two of the top three are investigational, and intervals overlap besides **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Four with published results, and only one of them is buyable. A network meta-analysis of 58 randomized trials covering 24,214 adults put retatrutide at the top, at 22.10% of body weight against placebo (95% CI −25.60 to −18.60) [\[1\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-1). Tirzepatide came second at 19.28% and CagriSema third at 17.32%, and behind them sit VK2735, UBT251 and ecnoglutide. VK2735 took off 14.7% in 13 weeks [\[2\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-2), UBT251 up to 13.48 kg in 12 [\[3\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-3), and ecnoglutide reached 13.2% at week 40 in a trial run entirely in China [\[4\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-4). Of all of those, tirzepatide is the only one anyone can obtain, which makes the podium a description of the field rather than a set of choices. The [TRANSCEND-T2D-1 retatrutide analysis](https://thisglp.com/research/retatrutide-transcend-t2d-1) also shows why results in type 2 diabetes should not be compared directly with a different trial population. ## Key takeaways - A network meta-analysis pooled 58 randomized trials and 24,214 adults with overweight or obesity and without diabetes. - Retatrutide produced the most weight loss against placebo: −22.10%, 95% CI −25.60 to −18.60. - Tirzepatide followed at −19.28%, 95% CI −20.39 to −18.16, and CagriSema at −17.32%, −19.32 to −15.32. - VK2735 reached 14.7% in 13 weeks and UBT251 up to 13.48 kg in 12 — both far shorter than the 68-week trials everyone quotes. - Ecnoglutide reached 13.2% at week 40, from a Chinese trial whose BMI entry threshold was lower than the Western trials use. - Two of the three leaders are investigational drugs nobody can buy, and one of them had worse tolerability. This is the most complete ranking of these drugs published so far, and reading it as a shopping list produces a strange result: most of the podium is unavailable. It is a map of [a menu that is still being written](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic), and the drugs on it arrive years apart. ## What was pooled Fifty-eight randomized trials covering 24,214 adults, searched across three databases from 2000 to March 2026, all in people with overweight or obesity and without diabetes. Trials enrolling people with diabetes, or where diabetes status was unclear, were excluded, which makes the comparison cleanly about weight and means none of it describes a diabetes population [\[1\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-1). Against placebo, retatrutide produced the largest reduction at 22.10%, 95% CI −25.60 to −18.60. Tirzepatide came next at 19.28%, 95% CI −20.39 to −18.16, and CagriSema, a combination of cagrilintide and semaglutide, at 17.32%, 95% CI −19.32 to −15.32. The conventional GLP-1 receptor agonists were more modest, and waist circumference and lipid outcomes followed similar patterns. Only one of the three is on a shelf Retatrutide is in trials, CagriSema is in trials, and so are danuglipron and mazdutide, which appear in the tolerability findings. Of everything at the top of this table, only tirzepatide can actually be obtained, and the drugs most people are taking sit in the modest tier below. A ranking is useful for understanding where the field is going, and it is not a list of options anybody has. ## The trade at the top Retatrutide produced the most weight loss and, on low-certainty evidence, also had higher rates of stopping treatment; danuglipron showed the same pattern, while mazdutide was better tolerated. That is worth registering before anybody concludes the next generation is simply better. A drug that takes off more weight and that more people stop taking has not obviously beaten a gentler one, and the tolerability evidence here is explicitly graded low. ## The drugs behind the podium, and how long each was tested VK2735 pairs GLP-1 with GIP, the same combination as tirzepatide, which makes it a competitor rather than a new mechanism. In a 13-week phase 2 dose-ranging trial, weight fell 14.6 kg (14.7%) at 15 mg against 1.8 kg (1.7%) on placebo, and 130 of 140 treated participants lost at least 5% against 4 of 34 on placebo [\[2\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-2). Thirteen weeks is a quarter of the 68 weeks behind every approved-drug figure on this site, and the full caution is in [the VENTURE result](https://thisglp.com/research/ninety-three-percent-in-thirteen-weeks). UBT251 activates three receptors at once, adding glucagon to GLP-1 and GIP, which is a real mechanistic step rather than another pairing of the same two. Its first-in-human study gave weekly doses for twelve weeks and reported mean losses of 8.96 to 13.48 kg, against a 1.57 kg gain on placebo [\[3\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-3). Safety was the primary endpoint and weight a secondary readout, and the abstract does not say how many people were in each dose arm, all of which is set out in [the first-in-human study](https://thisglp.com/research/triple-agonist-first-in-human). Ecnoglutide is engineered to favor one downstream signaling pathway, with the intention of separating the metabolic effects from the gastrointestinal ones. Across 664 adults at 36 Chinese centers, week-40 weight loss reached 13.2% against 0.1% on placebo [\[4\]](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming#ref-4). Adverse events occurred in 93% of each treated group against 84% on placebo, which is broadly the profile of the existing drugs rather than an escape from it. Why its percentages are not comparable to the ones you know is in [the ecnoglutide trial](https://thisglp.com/research/what-is-ecnoglutide). ## What the authors say about their own ranking That confidence intervals overlapped for several comparisons, that head-to-head evidence is limited, and that residual uncertainty should be considered when interpreting comparative effects. Their framing is a probabilistic hierarchy rather than an order of merit. The intervals are worth reading. Tirzepatide runs from −20.39 to −18.16, which is tight, while retatrutide runs from −25.60 to −18.60, wide enough to reach down into tirzepatide’s range. The difference between first and second place is less settled than the order suggests, which is the standing problem with [any pooled ordering](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## What a reader can use today Two things, and the first is that tirzepatide’s position is solid — second place with the narrowest interval on the board, from the largest body of trials, and it is buyable. That is a stronger practical statement than retatrutide’s first place. The modest tier is where most purchasing actually happens, because semaglutide and the older agonists are what this market sells, and [their own evidence](https://thisglp.com/research/semaglutide-cochrane-review) is the relevant evidence for almost everybody reading. What is available in which molecule and format is [a separate question with a concrete answer](https://thisglp.com/tools/molecule-and-format-finder). ## Frequently asked What new weight loss drugs are coming? Retatrutide and CagriSema lead the published rankings, with VK2735, UBT251 and ecnoglutide behind them. Retatrutide produced 22.10% weight loss against placebo across the pooled trials. Can I buy any of them? Only tirzepatide, which came second at 19.28%. Retatrutide, CagriSema, VK2735 and UBT251 are investigational, and ecnoglutide is not approved or available outside China. Is retatrutide better than tirzepatide? Its point estimate is higher and its interval is wider, reaching down into tirzepatide's range. It also had higher rates of stopping treatment, on evidence the authors grade as low certainty. Why are the early-phase numbers not comparable? VK2735 ran 13 weeks and UBT251 ran 12. The weight curve for this class is steepest at the start, and the 68-week trials behind the approved figures include the flat part where agents separate. What should someone buying today use? The evidence for semaglutide and the older agonists, because that is what this market sells. A pipeline ranking describes where the field is going, not what is on a shelf. ## Sources 1. \[1\] Chen D, et al. (2026). Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials BMJ Medicine. [PMID 42688617](https://pubmed.ncbi.nlm.nih.gov/42688617/) 2. \[2\] Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J (2026). Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Obesity. [PMID 41508550](https://pubmed.ncbi.nlm.nih.gov/41508550/) 3. \[3\] Yang GP, et al. (2026). Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study Diabetes, Obesity and Metabolism. [PMID 42712041](https://pubmed.ncbi.nlm.nih.gov/42712041/) 4. \[4\] Ji L, Gao L, Xue H, Tian J, et al. (2025). Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Diabetes & Endocrinology. [PMID 40555243](https://pubmed.ncbi.nlm.nih.gov/40555243/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # What Should a GLP-1 Provider Actually Do? Five Pillars | This GLP The EASO position statement on integrating incretin-based therapies names five pillars of good care — and a reader can hold any seller to all five. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-should-a-glp1-provider-actually-do Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # What Should a GLP-1 Provider Actually Do? Five Pillars A European specialist society set out what proper care around these drugs requires. It was not written about online sellers, which is what makes it useful against them. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min read The EASO Integration Framework · Right · Patient · Right · Care · Right · Workforce · Right · Data · Right · Access · Interdependent, in the authors’ description — not a menu to pick from **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - The European Association for the Study of Obesity published a position statement on how these drugs should be delivered. - It names an Integration Paradox: the therapies have advanced faster than the systems needed to use them well. - Its framework has five interdependent pillars — Right Patient, Right Care, Right Workforce, Right Data, Right Access. - The statement is about European health systems, not about telehealth sellers, and says nothing about this market. - Read as a checklist, it is a useful one, and most sellers here publish nothing against most of it. There is a published answer, and it was not written with this market in mind. The European Association for the Study of Obesity set out five interdependent pillars. Right Patient. Right Care. Right Workforce. Right Data. Right Access. It names an Integration Paradox. The therapies advanced faster than the systems needed to use them well. That is a statement about health systems, not about telehealth sellers. Read as a checklist it is still useful. Most sellers here publish nothing against most of it. That silence is measured three ways. There is [whether disclosure is a trait a seller has](https://thisglp.com/research/is-seller-disclosure-a-trait). There is [how invisible compounded use is in the record](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs) [\[2\]](https://thisglp.com/research/what-should-a-glp1-provider-actually-do#ref-2), and in [what the dose-error reports list](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). A specialist society has written down what it thinks good care around these drugs requires. It is not addressed to anybody selling them online. That is part of why it is worth reading here. It describes a standard set without this market in mind, and [what sellers publish](https://thisglp.com/research/what-glp1-sellers-do-not-publish) can be laid against it. ## The paradox they name European health systems vary in workforce capability, multidisciplinary care, reimbursement, access and monitoring infrastructure. [\[1\]](https://thisglp.com/research/what-should-a-glp1-provider-actually-do#ref-1) The authors argue that therapeutic innovation has outpaced the structures needed to use it well. They call that mismatch the EASO Integration Paradox. Their closing position is unambiguous. Worth stating before anything else. The question is no longer whether incretin-based therapies should be used. It is how to implement them responsibly, inside comprehensive obesity care pathways. This is a document in favor of the drugs. ## The five pillars Right Patient. Right Care. Right Workforce. Right Data. Right Access. The authors describe them as interdependent. That is the load-bearing word. The framework is not a menu a provider picks two from. Alongside it they set out a research and implementation agenda: real-world evidence, harmonized monitoring, workforce development, pharmacovigilance, and equitable access. What follows is ours, not theirs EASO is writing about national health systems. It makes no claim about telehealth sellers, and this page is not putting one in its mouth. But a reader choosing where to buy has five headings here. Nobody wrote them for a marketing department, and they answer a question a price comparison cannot: what should surround this prescription? ## Reading the pillars against a checkout Right Patient asks whether the person in front of you should be on this drug at all. An intake form can do a version of that. How good a version is not something a buyer can inspect from outside. Right Care and Right Workforce are about what surrounds the prescription — dietetic input, behavioral support, someone to call. This site has covered [a remote program that supplied several of those](https://thisglp.com/research/telehealth-glp1-program-trial) and produced results comparable to trials. It can be done remotely. It usually is not, and almost no seller here describes what they provide. Right Data means monitoring and follow-up that goes somewhere. Right Access is the one this market arguably improves on a national system. It makes the drug obtainable to people no insurer would cover — while leaving the other four pillars to the buyer. ## What to do with a framework Use it as five questions rather than as a verdict. Who decided I should take this, and on what basis? What comes with it besides the drug? Who do I contact when something changes? What is being measured, and by whom? And what happens when I cannot pay? Most sellers on this roster answer none of those. That is measurable rather than rhetorical. [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) counts what each one says, and [the census of silence](https://thisglp.com/tools/questions-they-leave-open) counts what they leave to you. A framework written for health ministries turns out to be a decent shopping list. For a concrete care model, [Form Health](https://thisglp.com/reviews/form-health) describes monthly clinician and dietitian video visits plus messaging in its [FAQ](https://www.formhealth.co/faqs). Those are services a reader can ask about elsewhere. They do not establish that any particular program meets every EASO pillar or delivers the same outcomes. ## Frequently asked What are the five pillars? Right Patient, Right Care, Right Workforce, Right Data and Right Access. The authors describe them as interdependent rather than as separate options. Does the statement criticize telehealth? No. It is addressed to European health systems and says nothing about online sellers. The comparison to a checkout on this page is this site's, not EASO's. Is it opposed to the drugs? The opposite. Its closing position is that the question is no longer whether these therapies should be used but how to implement them responsibly. How do I use it as a buyer? As five questions: who decided I should take this, what comes with it besides the drug, who do I contact when something changes, what is being measured, and what happens if I cannot pay. ## Sources 1. \[1\] Correia JC, et al. (2026). Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement The Lancet Regional Health. Europe. [PMID 42733510](https://pubmed.ncbi.nlm.nih.gov/42733510/) 2. \[2\] Hendrix N, Velásquez EE, Pham H, Bazemore A (2025). Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset Pharmacoepidemiology and Drug Safety. [PMID 41024632](https://pubmed.ncbi.nlm.nih.gov/41024632/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # What Weight Loss Drugs Are There Besides Ozempic? Six Have Evidence | This GLP What weight loss drugs are there besides Ozempic? Six have randomized evidence across 56 trials and 60,307 patients | only two exceeded 10% of body weight. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # What Weight Loss Drugs Are There Besides Ozempic? Six Have Evidence Six obesity drugs have randomized evidence behind them and storefronts sell two. Across 56 trials and 60,307 patients, all six beat placebo, and only semaglutide and tirzepatide passed 10%. The cheapest respectable option reaches about eight. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read 56 trials, 60,307 patients, six drugs · orlistat · 22 · semaglutide · 14 · liraglutide · 11 · tirzepatide · 6 · naltrexone/bupropion · 5 · phentermine/topiramate · 2 · ⛔ Trial count is not effect size. The order nearly inverts. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Six obesity drugs have randomized evidence behind them. Storefronts sell two. Across 56 trials and 60,307 patients, all six beat placebo on weight loss, and only semaglutide and tirzepatide exceeded 10% [\[1\]](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic#ref-1). The other four are orlistat, liraglutide, naltrexone with bupropion, and phentermine with topiramate. A larger network meta-analysis of 262 trials and 99,791 participants puts phentermine-topiramate at −8.1% against lifestyle alone [\[2\]](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic#ref-2). ## Key takeaways - A systematic review pooled 56 trials of six obesity medications, enrolling 60,307 patients — 32,598 on a drug and 27,709 on placebo. - Every one of the six beat placebo on total body weight loss. Only semaglutide and tirzepatide exceeded 10%. - ⛔ Trial counts run almost opposite to effect sizes: orlistat has 22 trials and the smallest effect, tirzepatide 6 and the largest. - A 262-trial network meta-analysis puts phentermine-topiramate at -8.1% at one year, against tirzepatide at -14.9%. - The older drugs carry their own adverse-event records: orlistat raises serious adverse events at RR 1.45 in hypertensive patients. The drugs this site tracks are two of six with randomized evidence behind them, and the other four are almost never mentioned on a storefront. This review places all six in one frame. That is the only honest way to answer whether the expensive option is the right one. The trial-by-trial reading in [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review) can only half answer it. ## What was pooled A search to 31 January 2025 identified 56 randomized trials comparing obesity medications against placebo or an active comparator, enrolling 60,307 patients [\[1\]](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic#ref-1). Orlistat appeared in 22 trials, semaglutide in 14, liraglutide in 11, tirzepatide in 6, naltrexone with bupropion in 5, and phentermine with topiramate in 2. All six produced significantly greater total body weight loss than placebo. Only semaglutide and tirzepatide exceeded 10%. Trial count is not certainty The two lists run in nearly opposite orders. Orlistat has the most trials and the smallest effect; tirzepatide has among the fewest and the largest. A reader treating the number of studies as a measure of how sure we are will get this backwards. What the trial count measures is how long a drug has existed and how hard anyone bothered to study it. ## The ranking, from the largest comparison The biggest synthesis so far pooled 262 randomized trials and 99,791 participants across 19 drugs [\[2\]](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic#ref-2). At one year against lifestyle modification alone, tirzepatide led at −14.9%, 95% CI −16.0% to −13.9%. Cagrilintide-semaglutide came next at −14.8%, oral semaglutide at −10.9%, orforglipron at −9.9%, injected semaglutide at −9.8%, and phentermine-topiramate at −8.1%. All of those carry moderate to high certainty. So the cheapest drug with a respectable result is phentermine with topiramate, at a little over half what tirzepatide achieves. Taking phentermine alongside semaglutide is a separate question, and [no trial has tested that pairing](https://thisglp.com/research/can-you-take-phentermine-with-ozempic). That is the trade a reader is actually being asked to make, and it is never framed that way on a storefront. The tolerability side of the same analysis is in [the discontinuation ranking](https://thisglp.com/research/the-best-losers-are-the-worst-tolerated). ## What the older drugs cost in side effects A Cochrane review of long-term weight drugs in people with hypertension reports the harms in a way the efficacy reviews do not [\[3\]](https://thisglp.com/research/what-weight-loss-drugs-are-there-besides-ozempic#ref-3). Orlistat probably increases serious adverse events at RR 1.45, 95% CI 1.10 to 1.91, across three trials and 1,476 participants. Naltrexone with bupropion probably increases all adverse events at RR 1.69, 95% CI 1.58 to 1.80. Phentermine with topiramate probably increases them at RR 1.13, 95% CI 1.08 to 1.20. None of that makes the older drugs unusable. It means the cheaper option is cheaper partly because it is older and partly because it does less, and its side-effect record is not blank. The same review found the semaglutide and tirzepatide trials reported no adverse-event results at all in that population, which is a different problem, set out in [the Cochrane update](https://thisglp.com/research/eight-trials-and-nobody-counted-the-deaths). ## What none of this establishes Which drug is better than which, for a particular person. Fifty-six trials with different populations, durations and comparators can establish that each beats placebo. They cannot substitute for putting two drugs in one protocol. The review’s own conclusion is that the choice should be individualized rather than ranked, and the one head-to-head that does exist is read in [the tirzepatide against semaglutide comparison](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). The drugs still in trials are a separate category again. Ecnoglutide, mazdutide and retatrutide may produce reductions of 13.1% to 14.6%, with certainty graded very low to low, and none of them can be bought. What is coming and what is buyable are separated in [the pipeline reading](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). ## Why the other four matter to a buyer Because they are cheaper, and because nobody selling a GLP-1 will mention them. Four drugs with randomized evidence of real weight loss exist outside this market entirely, at a fraction of what this roster charges. They have smaller effects and their own side-effect profiles. That does not make them the right choice. The effect sizes really are smaller, and for many people the difference between 5% and 15% is the difference between a result and none. It does mean a reader comparing only the two drugs a storefront sells is comparing a shortlist somebody else wrote. ## Frequently asked What weight loss drugs are there besides Ozempic? Five others carry randomized evidence: tirzepatide, liraglutide, orlistat, naltrexone with bupropion, and phentermine with topiramate. All six beat placebo, and only semaglutide and tirzepatide exceeded 10% of body weight. Which is the cheapest drug that actually works? Phentermine with topiramate reached −8.1% at one year against lifestyle modification alone, in a network meta-analysis of 262 trials, against tirzepatide at −14.9%. Do the older drugs have worse side effects? They have their own records. Orlistat probably increases serious adverse events at RR 1.45, and naltrexone with bupropion increases all adverse events at RR 1.69, both in hypertensive populations. Does more trials mean more certainty? Not here. Orlistat has 22 trials and the smallest effect; tirzepatide has 6 and the largest. Trial count measures how long a drug has existed, not how well it works. ## Sources 1. \[1\] McGowan B, et al. (2025). A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults Nature Medicine. [PMID 41039116](https://pubmed.ncbi.nlm.nih.gov/41039116/) 2. \[2\] Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. (2026). Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ. [PMID 42419792](https://pubmed.ncbi.nlm.nih.gov/42419792/) 3. \[3\] Spary-Kainz U, Posch N, Radl-Karimi C, Jeitler K, Krenn C, Siebenhofer A (2026). Long-term effects of weight-reducing drugs in people with hypertension Cochrane Database of Systematic Reviews. [PMID 42318855](https://pubmed.ncbi.nlm.nih.gov/42318855/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Drugs and ERCP Complications: A TriNetX Cohort of 21,818 | This GLP A matched TriNetX analysis of 21,818 ERCP patients found every 30-day complication roughly halved with GLP-1 exposure | why uniform improvement signals selection, not effect. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/when-a-drug-improves-everything Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs and ERCP Complications: A TriNetX Cohort of 21,818 Pancreatitis, bleeding, sepsis, stricture, cholangitis, repeat procedures: every outcome after ERCP improved by about the same amount with GLP-1 exposure. No drug does that. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Risk ratios, 30 days after the procedure · acute pancreatitis · 0.47 · GI bleeding · 0.49 · sepsis · 0.51 · biliary stricture · 0.52 · repeat procedure · 0.53 · cholangitis · 0.56 · Everything improved by about half. That is the problem. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched analysis of 21,818 patients compared 30-day outcomes after ERCP, a bile duct procedure, by prior GLP-1 exposure. - Every major complication was roughly halved: pancreatitis 0.47, GI bleeding 0.49, sepsis 0.51, biliary stricture 0.52, repeat procedure 0.53, cholangitis 0.56. - Those outcomes have unrelated mechanisms. A drug producing all six effects at once is implausible. - ERCP is performed urgently in unstable patients and electively in stable ones, and people on a maintenance prescription are disproportionately the latter. ERCP threads an endoscope into the bile duct, and its best-known complication is pancreatitis — which makes a drug associated with fewer cases worth examining, given the long-running pancreatitis question covered in [the pancreatitis evidence](https://thisglp.com/research/do-glp1-drugs-cause-pancreatitis). This analysis reports exactly that, and then keeps going [\[1\]](https://thisglp.com/research/when-a-drug-improves-everything#ref-1). Acute pancreatitis came in at a risk ratio of 0.47 (95% CI 0.43–0.51). Cholangitis 0.56 (95% CI 0.50–0.62). Sepsis 0.51 (95% CI 0.46–0.57). Gastrointestinal bleeding 0.49. Biliary stricture 0.52. Repeat ERCP 0.53. Every major 30-day outcome the study measured was approximately halved. A drug that improves everything is measuring the patient These complications have nothing mechanistically in common. Post-procedure pancreatitis is about duct irritation and enzyme activation; bleeding is about sphincterotomy and clotting; sepsis is about infection and drainage; biliary stricture is an anatomical outcome that develops over weeks. No metabolic drug has six separate routes to halving all of them. When every outcome moves by the same amount, the thing being measured is usually the patient rather than the treatment. The likeliest explanation is visible in how the procedure is used. ERCP is done urgently in people who are acutely unwell with obstructed, infected bile ducts, and electively in stable outpatients with stones or strictures. Someone on an ongoing GLP-1 prescription is disproportionately in the second group: well enough to be on maintenance medication, engaged with care, scheduled rather than admitted. Urgency of indication is not something propensity matching on recorded covariates can capture. That is not a reason to dismiss the paper so much as to read it as a description of who is taking these drugs. The same signature — uniform improvement across outcomes with unrelated mechanisms — is what makes the mortality figures in [the intracranial pressure meta-analysis](https://thisglp.com/research/do-glp1-drugs-help-intracranial-hypertension) implausible, and it is why the negative-control approach used in [the FLOW subgroup analysis](https://thisglp.com/research/twenty-two-thirteen-seventeen) and elsewhere matters so much in claims research. If there is a real effect here it is most likely on pancreatitis specifically, where a mechanism exists and where the concern started. Establishing it would need a design that separates elective from urgent procedures, or a randomized comparison — and 21,818 matched patients, however well balanced on paper, cannot substitute for either. The general difficulty of reading procedure outcomes in this literature runs through [the thrombectomy cohort](https://thisglp.com/research/do-glp1-drugs-cause-aspiration-pneumonia). ## Frequently asked Do these drugs make bile duct procedures safer? The study reports every complication roughly halved, which is implausible as a drug effect because those complications have unrelated mechanisms. It more likely reflects which patients were on a maintenance prescription. Why is uniform improvement suspicious? Pancreatitis, bleeding, sepsis and stricture arise through completely different processes. A single metabolic drug halving all of them at once would require several unconnected mechanisms. Is any part of it likely real? Possibly the pancreatitis finding, where a plausible mechanism exists. Establishing it would need a design separating elective from urgent procedures, which this analysis does not do. ## Sources 1. \[1\] Kazi MAI, Khan J, Mufarrih SM, Widmer J, Al-Sabban A, Irani SS, Baron TH (2026). Protective Impact of GLP-1 Therapy on Post-ERCP Outcomes: A TriNetX Retrospective Cohort Analysis Journal of Clinical Gastroenterology. [PMID 42084951](https://pubmed.ncbi.nlm.nih.gov/42084951/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure Where to inject Ozempic: abdomen, thigh or upper arm | the label reports similar exposure at all three, and 1,612 trial patients showed no site effect. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/where-should-you-inject-ozempic Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Formats # Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure The label allows the abdomen, thigh or upper arm, and a model of 1,612 trial patients found no clinically relevant effect of injection site on semaglutide exposure. Body weight was the only factor that mattered. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). In the abdomen, the thigh or the upper arm, and the choice does not change how much drug reaches the blood. The Ozempic label names those three areas and states that similar exposure is achieved at each [\[1\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-1). A model built on 1,612 people with type 2 diabetes in five trials found no clinically relevant effect of injection site on exposure [\[2\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-2). Body weight was the only factor that mattered. ## Key takeaways - The Ozempic label allows the abdomen, thigh or upper arm, and says exposure is similar at all three. - In 1,612 trial patients, injection site had no clinically relevant effect on semaglutide exposure. Body weight did. - A second model, from 353 people and 10,573 blood samples, found only minor differences in bioavailability between sites. - The labels ask for a new spot with each dose, and the abdominal site at least 2 inches from the belly button. - One published case linked abdominal injections to a trapped skin nerve. Pain eased after injections moved away from the abdomen. The pen itself sets the timing, not the site. How the first doses are stepped up is covered in [the semaglutide starting dose](https://thisglp.com/research/semaglutide-starting-dose). The tablet form skips injection entirely, and [how oral semaglutide is taken](https://thisglp.com/research/how-do-you-take-oral-semaglutide) explains its own rules. ## What the Ozempic label says about injection sites The dosing section is short. Ozempic goes under the skin of the abdomen, thigh or upper arm [\[1\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-1). When the same body region is used each week, a different spot within it is used each time. The pharmacology section adds the key sentence: similar exposure is achieved in all three areas. The Medication Guide and instructions for use add three practical limits [\[1\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-1): 1. In the abdomen, stay at least 2 inches from the belly button. 2. Inject under the skin, never into a muscle or a vein. 3. Insulin may go in the same body area, but not right next to the Ozempic injection, and never mixed in one syringe. The Wegovy label, for the 2.4 mg dose of the same drug, says the site and the time of day can change without any change in dose [\[3\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-3). It also names the same three areas. ## Does the injection site change how well Ozempic works? Not in the blood levels that were measured. The population model pooled 1,612 people from five phase 3 trials that ran 30 to 104 weeks [\[2\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-2). Each person gave up to seven blood samples. Sex, age, race, kidney function and injection site had no clinically relevant effect on exposure. Only body weight did. A second model used denser sampling from nine clinical pharmacology trials: 353 people and 10,573 concentration values [\[4\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-4). It found minor differences between injection sites in bioavailability. The authors still describe semaglutide’s behavior as predictable across populations and routes. Minor and not clinically relevant are the two findings side by side. What neither model measured is weight loss or blood sugar by site. No trial randomized people to the arm or the abdomen and compared outcomes. The exposure result is the closest evidence, and it is a blood-level result. ## Zepbound and Mounjaro: where to inject tirzepatide The tirzepatide labels list the same three areas with one condition. You or another person can inject the abdomen or thigh, and the back of the upper arm is for another person to inject [\[5\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-5) [\[7\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-7). The Zepbound label also states that similar exposure was achieved in the abdomen, thigh or upper arm. Mean absolute bioavailability after an injection under the skin is 80 percent. How long the drug then lingers is set out in [how long Zepbound stays in your system](https://thisglp.com/research/how-long-does-zepbound-stay-in-your-system). Skin reactions at the site are counted separately from exposure. Injection site reactions affected 0.2 percent of people on Ozempic in placebo-controlled trials [\[1\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-1). On Zepbound they reached 6 to 8 percent against 2 percent on placebo [\[5\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-5). They were more frequent in people who developed antibodies to tirzepatide, at 11.3 percent against 1 percent. ## Why rotate injection sites Every label asks for a new spot with each dose [\[1\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-1) [\[3\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-3) [\[5\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-5). None of the sources here reports a trial that tested rotation against repeated use of one spot. The instruction is a labeling rule, and its benefit has not been measured for these drugs. One published case shows a site-specific problem. A 44-year-old man developed focal, nerve-type abdominal pain that began with his tirzepatide injections [\[6\]](https://thisglp.com/research/where-should-you-inject-ozempic#ref-6). Examination found anterior cutaneous nerve entrapment, a trapped nerve in the abdominal wall. The pain improved after injections moved away from the abdomen and medication was started. It is one case, and no rate can be drawn from it. Where the evidence stops Both exposure models come from branded semaglutide in people with type 2 diabetes or in pharmacology trials. Neither measured weight loss or side effects by site. Compounded semaglutide is not FDA-approved, and its vials carry no label data on injection sites. Dose errors, a separate risk with vials, appear in [the adverse event reports](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). ## Frequently asked What are the semaglutide injection sites? The abdomen, the thigh and the upper arm, under the skin. The Ozempic and Wegovy labels state that similar semaglutide exposure is achieved at all three, and ask for a different spot with each dose. What is the best injection site for Ozempic? None has been shown to be better. A model of 1,612 trial patients found no clinically relevant effect of injection site on exposure. No trial compared weight loss or blood sugar by site. Where do you inject Zepbound? In the abdomen or thigh, or in the back of the upper arm if another person gives the injection. The Zepbound label states that exposure is similar across the three areas. How far from the belly button should you inject Ozempic? At least 2 inches, according to the Ozempic instructions for use. The Wegovy and Zepbound instructions give the same distance. ## Sources 1. \[1\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, sections 2.1, 6.1 and 12.3, Medication Guide and Instructions for Use DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 2. \[2\] Carlsson Petri KC, Ingwersen SH, Flint A, Zacho J, Overgaard RV (2018). Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis Diabetes Therapy. [PMID 29907893](https://pubmed.ncbi.nlm.nih.gov/29907893/) 3. \[3\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, sections 2.1 and 12.3 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 4. \[4\] Overgaard RV, Delff PH, Petri KCC, Anderson TW, Flint A, Ingwersen SH (2019). Population Pharmacokinetics of Semaglutide for Type 2 Diabetes Diabetes Therapy. [PMID 30788808](https://pubmed.ncbi.nlm.nih.gov/30788808/) 5. \[5\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, sections 2, 6.1 and 12.3 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) 6. \[6\] Singh N, Chaparro E, Shapiro JM, Husu EN (2026). Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection ACG Case Reports Journal. [PMID 42326458](https://pubmed.ncbi.nlm.nih.gov/42326458/) 7. \[7\] Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information, section 2.2 and Instructions for Use DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) - [ Where the approval applies · F0 — no fibrosis · F1 — mild · F2 — significant · approved · F3 — advanced · approved · F4 — cirrhosis · Knowing which row you are in requires testing nobody does at a checkout ### Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3 ](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease) --- # Which GLP-1 Has the Worst Side Effects? It Depends on the Outcome | This GLP A meta-analysis of ten studies found tirzepatide produced 4.28 points more weight loss than semaglutide — and a higher rate of serious adverse events. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/which-glp1-has-the-worst-side-effects Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Which GLP-1 Has the Worst Side Effects? It Depends on the Outcome Pooling 41,381 people, the two drugs looked alike on ordinary side effects and on quitting. Serious adverse events were 83% more frequent with tirzepatide. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read Tirzepatide against semaglutide, by event category · overall adverse events · similar · gastrointestinal events · similar · stopped for adverse events · RR 1.28, p = 0.54 · serious adverse events · RR 1.83, p = 0.007 · Ten studies, 41,381 participants — and no interval published for the one that moved **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A meta-analysis pooled ten studies and 41,381 participants comparing tirzepatide with semaglutide over at least 24 weeks. - Tirzepatide produced 4.28 percentage points more weight loss, 95% CI −5.28 to −3.28, and 4.43 kg more in absolute terms. - It was likelier to reach 10%, 15% and 20% weight loss. At 5% there was no difference — both drugs get most people there. - Overall adverse events, gastrointestinal events and discontinuation for side effects were all similar. - Serious adverse events were more frequent with tirzepatide: risk ratio 1.83, p=0.007, with no interval published in the abstract. On serious events, they stop looking alike, and the answer depends on which outcome you pick. The pooled analysis below is where the two drugs separate. For claims encountered outside a study, see the [analysis of GLP-1 advice on social media](https://thisglp.com/research/can-you-trust-glp1-advice-on-social-media). It asks whether popularity is a useful signal of information quality. Direction can also flip with the comparator. In veterans with type 2 diabetes and opioid use disorder, overdose risk fell against two comparator drugs and not against three [\[2\]](https://thisglp.com/research/which-glp1-has-the-worst-side-effects#ref-2). So [the answer changed with what the drug was set beside](https://thisglp.com/research/overdose-depends-on-the-comparator). That is true of most claims in this class. This site already covers the largest single cohort comparing these two drugs. It found tirzepatide ahead on weight and [most of each group gone before the end](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). This is the pooled version, and it adds one finding the cohort did not report. ## The efficacy side, briefly Ten studies, randomized and observational, with at least 24 weeks of follow-up, covering 41,381 participants. [\[1\]](https://thisglp.com/research/which-glp1-has-the-worst-side-effects#ref-1) Tirzepatide produced 4.28 percentage points more weight reduction, 95% CI −5.28 to −3.28. Absolute loss ran 4.43 kg greater, 95% CI −5.56 to −3.30. Glycated hemoglobin fell 0.29 percentage points further. It was likelier to get people past 10%, 15% and 20% weight loss. At the 5% threshold there was no difference. Both drugs get most people that far. The separation is entirely in the deeper end. Pooling randomized trials with observational studies invites an obvious objection. The authors addressed it. Subgroup analyses by study design produced consistent findings, as did subgroups by diabetes status. ## The finding that is new here Three safety comparisons came back level. Overall adverse events were similar. Gastrointestinal adverse events were similar. Discontinuation because of adverse events was similar, at a risk ratio of 1.28 with p=0.54. Serious adverse events were not. They were more frequent with tirzepatide, risk ratio 1.83, p=0.007. What that category means, and what the abstract omits A serious adverse event is a regulatory classification. Death, hospitalization, significant disability, a life-threatening episode. Recorded whether or not anybody thinks the drug caused it. So this is not 83% more harm; it is 83% more events in a bucket defined by severity rather than by attribution. The abstract publishes no confidence interval for that risk ratio, only the point estimate and the p-value. The finding cannot be sized. It is a real signal that cannot be measured from what was reported. ## Why the pattern is the interesting part If tirzepatide were simply harder to tolerate, it should show up in the ordinary adverse events and in people quitting. It did not. The two drugs looked alike on everything except the most severe category. That could mean several things. It could reflect the greater metabolic effect of the stronger drug producing more events at the tail. It could be a consequence of who receives which drug in the observational studies. It could be a chance finding in a category with few events. That is exactly why the missing interval matters, and why [a signal without its uncertainty](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia) is so hard to use. ## What a reader should take from it The efficacy gap is well established and this adds to it. Tirzepatide takes off more weight, and the advantage is concentrated among people aiming past ten percent rather than at modest loss. The safety gap is a question rather than an answer, and it is one nobody selling either drug will raise. A seller comparing the two has every reason to quote the weight difference and none to mention a serious adverse event ratio. and [almost nothing about safety appears there at all](https://thisglp.com/tools/what-sellers-publish). Where the two drugs genuinely look alike, that is worth knowing too, because [similar is not the same as identical](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). Unlike most comparisons in this field, these studies put the two drugs against each other directly. ## Frequently asked How much more weight does tirzepatide take off? 4.28 percentage points more than semaglutide, 95% CI −5.28 to −3.28, or 4.43 kg in absolute terms across ten studies. What does a higher serious adverse event rate mean? A serious adverse event is a regulatory category — death, hospitalization, significant disability, a life-threatening episode — logged whether or not the drug is thought to have caused it. The risk ratio was 1.83 with p=0.007, and the abstract publishes no confidence interval for it. Were ordinary side effects worse? No. Overall adverse events, gastrointestinal events and discontinuation because of side effects were all similar between the two drugs. Does the weight advantage apply to everyone? Not evenly. There was no difference at the 5% weight-loss threshold, and the advantage appeared at 10%, 15% and 20%. ## Sources 1. \[1\] Paccola GP, et al. (2026). Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies Clinical Obesity. [PMID 42670242](https://pubmed.ncbi.nlm.nih.gov/42670242/) 2. \[2\] Kennedy KP, Bremseth-Vining R, Lynch KG, Reville N, et al. (2026). GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder The Journal of Clinical Psychiatry. [PMID 42474323](https://pubmed.ncbi.nlm.nih.gov/42474323/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # GLP-1 Sellers That Publish a Dose Price Ladder, Counted | This GLP How many GLP-1 sellers publish a dose price ladder rather than an opening figure, counted across the whole roster, and why a printed ladder beats a promise that the price rises. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/who-publishes-a-glp1-dose-ladder Updated: 2026-10-28 Published: 2026-09-15 [← Research](https://thisglp.com/research) Formats # GLP-1 Sellers That Publish a Dose Price Ladder, Counted A minority of GLP-1 sellers print three or more rungs of a dose price ladder. Far fewer state that the price scales at all, and the two groups are not the same sellers. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Sellers publishing three or more rungs · 216 · The rest publish an opening figure and stop · rung 1 · rung 2 · rung 3 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 216 of 580 sellers — 37% — print three or more distinct figures on at least one line. - That is a different and rarer disclosure than saying the price rises, which only 44 sellers state at all. - A published ladder is the only version of that disclosure a buyer can plan a course against. - The test used here is mechanical: three or more distinct figures in one recorded pricing note. - Corpus: 580 sellers, read most recently October 2026. There are two quite different things a seller can do about dose pricing. It can tell you the price changes as the dose climbs. Or it can tell you what it changes to. Only the second is something a reader can budget against, and the gap between how often each happens is the subject of this page — one of several silences counted in [what sellers do not put on the page](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## How many actually print the numbers 216 sellers of 580 on this roster publish three or more distinct figures on at least one line — a ladder rather than a headline with a warning attached. That is 37% of the corpus. By contrast only 44 sellers state anywhere that their price scales with the dose, and 370 say nothing either way. The two numbers do not overlap as neatly as they should. A seller can publish a ladder without ever writing the sentence “the price rises with your dose”, and several do. The ladder is the better disclosure in that case, because it answers the question the sentence only raises. [Every seller printing a ladder](https://thisglp.com/tools/published-dose-ladders) is listed with its own note. A mechanical test, with a known blind spot A seller qualifies here by printing three or more distinct dollar figures in one recorded pricing note. That is deliberately dumb: it cannot be gamed by wording, and it credits nobody for merely saying the price changes. It will, however, miss a seller whose ladder lives in a table this desk recorded only the opening rung of. The count is a floor. ## Why a ladder beats a promise A flat-rate promise is worth more than a ladder if it holds, because it removes the question entirely. But a flat rate is a claim about the future and a ladder is a published fact about the present, and the second can be checked before ordering. [The disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) marks both, and [the open-questions census](https://thisglp.com/tools/questions-they-leave-open) counts how often neither is offered. Counts are computed from this site’s own records at build time, most recently read October 2026. Nothing is modeled or taken from a third party. [Coby Health](https://thisglp.com/reviews/coby-health) makes this question tangible: its [semaglutide page](https://www.cobyhealth.com/treatments/weight-loss/semaglutide) separates dose options and purchase lengths. Read the dose and supply together before comparing figures. A table describes what is offered for sale; it does not tell you which dose a clinician will prescribe. ## Frequently asked What counts as publishing a ladder? Three or more distinct dollar figures in one recorded pricing note. It is a deliberately mechanical test: it cannot be gamed by wording, and it credits nobody for merely saying the price changes. Is a flat rate better than a ladder? If it holds, yes — it removes the question. But a flat rate is a claim about the future and a ladder is a published fact about the present, and only the second can be checked before ordering. Could a seller be missed by this count? Yes. A ladder living in a table where only the opening rung was recorded would not qualify, so the count is a floor rather than a census. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # GLP-1 Seller State Coverage: Who Publishes Where They Ship | This GLP A census of which GLP-1 sellers publish the states they serve, how many states those lists cover, and why an absent list is not a coverage claim. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/who-publishes-the-states-they-serve Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # GLP-1 Seller State Coverage: Who Publishes Where They Ship Publishing the states served costs nothing and cannot go stale. A count of how many GLP-1 sellers publish a state list, and how wide the ones that do reach. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 580 sellers: who says where they ship · 201 publish a list · 379 do not · Of those that do: · 50 states or more · 110 · 40 to 49 · 33 · 20 to 39 · 18 · 2 to 19 · 27 · a single state · 13 **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 379 of 580 sellers on this roster publish no list of the states they serve — 65% of them. - Of the 201 that do publish one, the median is 50 states. - 110 of them reach 50 or more; 40 reach fewer than twenty. - A seller absent from this count has not been shown to serve nowhere. It has been shown not to have written it down. - Corpus read most recently October 2026. Whether a seller can legally ship to your address is the first question that matters and one of the last most storefronts answer. It is also the cheapest possible disclosure — a list of states costs nothing to publish and cannot go stale in an interesting way — which makes the silence worth counting. It sits alongside the other silences in [what sellers will not tell you](https://thisglp.com/research/what-glp1-sellers-do-not-publish). ## How many say Of 580 sellers this site can rank, 201 publish a list of states and 379 do not. That is 65% of the market giving no answer to the question a reader has to resolve before any price matters. Silence is not a coverage claim ⛔ A seller in the 379 has not been shown to serve nowhere, or to serve everywhere. It has been shown not to have published the list. Several of them almost certainly ship nationally and simply never wrote it down. That distinction matters because this site has already found the opposite error made three times elsewhere — an unrecorded field read as a recorded negative, about named businesses. A census of what is missing is only honest if it keeps saying what missing means. ## How wide the ones that answer reach Among the 201 sellers that publish a list, the median is 50 states, and 110 of them reach 50 or more. Publication and breadth travel together: a seller with near-national coverage has an easy thing to say, and says it. The tail is the more interesting end. 40 sellers publish a list covering fewer than twenty states, and 13 serve a single state. Those are the ones for whom the disclosure costs something — it disqualifies most readers immediately — and they make it anyway, which is worth crediting rather than penalizing. ## What to do with it Check coverage before price, not after. A cheaper seller that cannot ship to you is not a cheaper seller, and a storefront that will not say is a storefront you have to ask — which means finding someone to ask, and most of this market publishes nothing about that either, as listed in [the questions they leave open](https://thisglp.com/tools/questions-they-leave-open). The state-by-state view of who has said they serve where is in [coverage by state](https://thisglp.com/tools/coverage-by-state), and the wider question of which figures survive contact with a real purchase is in [when the headline is not the bill](https://thisglp.com/research/glp1-advertised-vs-billed-corrections). [Contour Health](https://thisglp.com/reviews/contour-health) publishes a concrete exclusion list in its [FAQ](https://www.contourhealthrx.com/faqs): Arkansas, Kentucky, Michigan and Mississippi. That is more useful for an initial shortlist than a general nationwide claim. It remains a provider statement, not independent license verification or a promise that an individual prescription will be approved. ## Frequently asked How many sellers publish a state list? The count is derived on the page when it builds. A large number of sellers give no answer at all to the question a reader has to resolve before any price is relevant. Does a missing list mean the seller cannot ship to me? No. It means the seller has not written the answer down. Several of them almost certainly ship nationally and never published it. How wide are the ones that do publish? The median is fifty states, and most of them reach fifty or more. A handful serve fewer than twenty, and a few serve one. ## Sources ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3 | This GLP Who qualifies for semaglutide for liver disease? The conditional approval covers MASH with fibrosis stages F2 to F3, without cirrhosis | staging requires a test. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Formats # Who Qualifies for Semaglutide for Liver Disease? Fibrosis Stage F2 to F3 The liver indication is narrower than the phrase suggests. It covers fibrosis stages F2 to F3 without cirrhosis, and entry to it requires a test nobody can take at a checkout. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Where the approval applies · F0 — no fibrosis · F1 — mild · F2 — significant · approved · F3 — advanced · approved · F4 — cirrhosis · Knowing which row you are in requires testing nobody does at a checkout **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Fibrosis stages F2 to F3, without cirrhosis. That is the whole of the approved population [\[1\]](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease#ref-1). Semaglutide 2.4 mg holds conditional US approval for metabolic dysfunction-associated steatohepatitis with significant fibrosis. Earlier stages are not included, and neither is F4. Entry requires non-invasive testing — elastography, or a blood-based fibrosis score — to establish the stage. No telehealth intake stages a liver. ## Key takeaways - Semaglutide 2.4 mg and resmetirom hold conditional FDA approval for MASH with significant fibrosis, stages F2 to F3, without cirrhosis. - It is the first pharmacological treatment for a disease that previously had none. - Entry to the indication requires non-invasive testing to establish the fibrosis stage. - The approval is not written around weight: in a mediation analysis, only 36.3% of a drug's effect on fibrosis improvement ran through weight loss. - No telehealth intake stages a liver, and most products on this roster are compounded with no approved indication at all. These drugs have acquired a formal liver indication, which is genuinely new. It is narrower than the sentence “approved for liver disease” suggests, and the narrowness is the useful part. The trial behind it is read in [the phase 3 liver evidence](https://thisglp.com/research/semaglutide-and-liver-disease). ## What was approved, and for whom Two drugs now hold conditional US approval for metabolic dysfunction-associated steatohepatitis with significant fibrosis [\[1\]](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease#ref-1). They are resmetirom, a liver-directed thyroid hormone receptor-beta agonist, and semaglutide 2.4 mg. The population is fibrosis stage F2 to F3, without cirrhosis. Earlier stages are not included. Neither is F4. An international expert panel has consolidated the phase 3 data, the FDA labels and early clinical experience into one care pathway. It covers how to diagnose MASH with significant fibrosis using non-invasive tests. It covers how to choose and start a therapy, and how to monitor it. And it defines response, non-response, and when to switch or combine the two agents. ## Who the phase 3 trial enrolled ESSENCE is the phase 3 trial of semaglutide 2.4 mg in MASH [\[4\]](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease#ref-4). Entry required a biopsy showing MASH with fibrosis stage 2 or 3. Of the first 800 randomized, 250 were at stage 2. The other 550, or 68.8 percent, were at stage 3. Mean age was 56 and mean BMI was 34.6. Type 2 diabetes was present in 55.5 percent. More than 99 percent met at least one cardiometabolic criterion. That was not an entry rule. Part 1 of the trial measures liver tissue. Part 2 measures clinical outcomes. Nobody knows their own fibrosis stage Being in the approved population is not something a patient knows about themselves. It requires non-invasive testing — elastography, blood-based fibrosis scores — to establish a stage between F2 and F3. Nobody arrives at that from a symptom, because this disease does not reliably produce one. A checkout page cannot put a reader inside the indication, and no intake form on this roster asks. ## Why the stage is the eligibility criterion Because fibrosis is the endpoint that predicts outcomes, and it is also the one the drugs move least reliably. A mediation analysis of a phase 2 MASH trial split the liver effects in two [\[2\]](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease#ref-2). One part ran through weight loss, and one did not. Liver fat behaved like a weight problem. Weight reduction carried 77.4% of the effect on one steatosis measure and 58.2% on another. Fibrosis did not. Only 36.3% of the effect on fibrosis improvement was attributed to weight. The blood markers pointed the same way, with weight mediating between 16.5% and 38.6%. That is the mechanistic reason the indication is staged rather than written around a weight threshold. The fuller reading is in [the mediation analysis](https://thisglp.com/research/liver-repair-that-was-not-the-weight). The same pattern shows up in clinical cohorts. In 182 Japanese patients with type 2 diabetes who switched to tirzepatide, the steatosis index fell in both risk groups [\[3\]](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease#ref-3). The fibrosis index fell significantly only in the high-risk group. Nobody stayed on the original drug, so there is no comparison arm, and [the switching cohort](https://thisglp.com/research/tirzepatide-fibrosis-worst-group) sets out what that costs. ## Monitoring is part of the indication The panel devotes substantial attention to on-treatment monitoring and response assessment. That includes what counts as non-response, and when to switch or combine. It is a treatment relationship with a clinician who is tracking something over time. It is also the part of the framework a website transaction is least equipped to supply. A drug with a monitoring protocol, sold without one, is not the same treatment the approval describes. What a remote prescriber should actually be doing is set out in [the standard of care](https://thisglp.com/research/what-should-a-glp1-provider-actually-do). ## What to take from it Risk factors for fatty liver disease include type 2 diabetes, obesity and high triglycerides. If you have them, there is now a reason to ask about fibrosis staging that did not exist three years ago. The tests are non-invasive. That is a conversation with a clinician, not a purchase. And if you are already on one of these drugs for weight, the panel addresses that case too. Somebody who started for one reason and turns out to qualify for another is a case the specialists have now written down. The answer is not the same as continuing unchanged. The eligibility question for weight itself is a different threshold again, read in [the BMI cut-off](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1). ## Frequently asked Who qualifies for semaglutide for liver disease? People with metabolic dysfunction-associated steatohepatitis and fibrosis at stage F2 or F3, without cirrhosis. Earlier stages and F4 are both outside the conditional approval. How is the fibrosis stage established? By non-invasive testing — elastography or a blood-based fibrosis score. It is not something a patient knows from symptoms, because the disease does not reliably produce any. Who was in the semaglutide liver trial? ESSENCE required biopsy-proven MASH at fibrosis stage 2 or 3. Of the first 800 randomized, 68.8 percent were at stage 3, mean BMI was 34.6 and 55.5 percent had type 2 diabetes. Is the liver benefit just the weight loss? Not entirely. In a mediation analysis of a phase 2 MASH trial, 77.4% of the effect on one steatosis measure ran through weight reduction, against only 36.3% of the effect on fibrosis improvement. Can a telehealth seller prescribe for this indication? Nothing on this roster stages a liver. Most products sold here are compounded and carry no approved indication at all, and the approval also assumes on-treatment monitoring and a defined response assessment. ## Sources 1. \[1\] Mironova M, et al. (2026). International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update Gut. [PMID 42728029](https://pubmed.ncbi.nlm.nih.gov/42728029/) 2. \[2\] Noureddin M, Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2026). Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH Hepatology. [PMID 42545725](https://pubmed.ncbi.nlm.nih.gov/42545725/) 3. \[3\] Takiyama T, et al. (2026). Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study Journal of Diabetes and Its Complications. [PMID 42618422](https://pubmed.ncbi.nlm.nih.gov/42618422/) 4. \[4\] Newsome PN, et al. (2024). Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial Alimentary Pharmacology & Therapeutics. [PMID 39412509](https://pubmed.ncbi.nlm.nih.gov/39412509/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection) --- # Why Do GLP-1 Drugs Cause Nausea? And Why It Does Not Predict Weight Loss Why do GLP-1 drugs cause nausea? They act on the brainstem's area postrema. In STEP 1 to 3, weight loss was similar with or without it | under 1 point ran through it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/why-do-glp1-drugs-cause-nausea Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Safety # Why Do GLP-1 Drugs Cause Nausea? And Why It Does Not Predict Weight Loss The drugs act on a brainstem area that handles both appetite and nausea. In the trials, people with and without stomach side effects lost about the same weight. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Mean weight loss on semaglutide 2.4 mg, STEP 1 to 3 · No GI side effects · 9.6–17.1% · With GI side effects · 11.4–17.7% · Under 1 point of the drug's effect ran through · nausea, vomiting and other GI events. · Darker segment: range across the three trials. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). GLP-1 drugs act on a small brainstem area that, in animal studies, carries both appetite loss and nausea. On semaglutide 2.4 mg, 43.9% of trial participants had nausea, against 16.1% on placebo [\[1\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-1). Feeling sick does not mean the drug is working better. In the same trials, people without stomach side effects lost 9.6% to 17.1% of their weight. People with them lost 11.4% to 17.7%. ## Key takeaways - STEP 1 to 3: nausea in 43.9% on semaglutide 2.4 mg against 16.1% on placebo, mostly mild to moderate and during dose escalation. - Weight loss was similar with or without stomach side effects. Under 1 percentage point of the drug's extra loss ran through them. - SUSTAIN 3, 7 and 10: nausea and vomiting accounted for under 0.1 kg of semaglutide's advantage over other GLP-1 drugs. - SURPASS 1 to 5: tirzepatide weight loss was consistent with or without nausea, vomiting or diarrhea. - In laboratory animals, one brainstem neuron population carried both the weight loss and the aversion. ## Where the nausea comes from Two brainstem areas carry the GLP-1 receptor. One is the nucleus of the solitary tract. The other is the area postrema. A 2026 study silenced each neuron population in turn [\[4\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-4). It also restored the receptor in each on a background where it was otherwise missing. The results split cleanly. Solitary tract neurons restrained normal eating. They did not carry the drug's weight loss. Area postrema neurons played no part in normal eating. They carried both the drug's weight loss and its aversive effect. The authors conclude the two cannot be separated at a circuit level. These are genetic methods in laboratory animals. The abstract does not name the species. How appetite changes at a meal in people is covered in [the food intake guide](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1). ## Why more nausea does not mean more weight loss A shared circuit is not a dose-for-dose link a person can feel. Three sets of human trials tested the link directly. 1. STEP 1 to 3 pooled 2,117 people on semaglutide 2.4 mg and 1,262 on placebo for 68 weeks [\[1\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-1). Weight loss was similar with or without stomach side effects. Semaglutide added 7.6% to 14.4% over placebo. Under 1 percentage point of that ran through those side effects. 2. SUSTAIN 3, 7 and 10 compared semaglutide with other GLP-1 drugs in type 2 diabetes [\[2\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-2). Nausea and vomiting accounted for under 0.1 kg of semaglutide’s extra loss. In SUSTAIN 3 that was 0.09 kg of 3.78 kg. 3. SURPASS 1 to 5 enrolled 6,263 people with type 2 diabetes [\[3\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-3). Tirzepatide weight loss was 6.2 to 14.9 kg with nausea, vomiting or diarrhea. It was 6.2 to 13.3 kg without. Under 6% of tirzepatide’s advantage over comparators ran through stomach side effects. The rule the trials support Nausea is a side effect, not a progress marker. Someone without it is not getting a weaker drug. Someone with a lot of it is not getting a stronger one. ## How long it lasts, and what reduces it In STEP 1 to 3, 99.5% of stomach side events were non-serious. 98.1% were mild to moderate [\[1\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-1). Most were transient and clustered during dose escalation. 4.3% of semaglutide participants stopped the drug because of them. The time course is set out in [how long nausea lasts](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The tools that exist are the dose and the pace of escalation. Both are the prescriber’s decision. The standard semaglutide schedule is in [the starting dose guide](https://thisglp.com/research/semaglutide-starting-dose), and [the titration planner](https://thisglp.com/tools/glp1-titration-planner) maps the steps. ## Whether a drug without nausea is possible One route under study adds a second hormone. In mice, rats and musk shrews, GIP receptor activation blocked vomiting from a GLP-1 drug [\[5\]](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea#ref-5). Reduced food intake and weight loss were kept. That is the preclinical rationale for dual-agonist drugs. It is not a human result. Cross-trial comparisons of nausea rates mix different doses and populations. Head-to-head side-effect data are covered in [the side-effect comparison](https://thisglp.com/research/which-glp1-has-the-worst-side-effects). A product sold as a gentler version needs its own trial data before the claim holds. ## Frequently asked Why do GLP-1 drugs make you nauseous? They act on GLP-1 receptors in the brainstem, including the area postrema, which governs both appetite and nausea. In laboratory animals, the same area postrema neurons carried the weight loss and the aversive effect. Does nausea mean the GLP-1 is working? Not on the trial evidence. In STEP 1 to 3, people without stomach side effects lost 9.6% to 17.1% of their weight and people with them lost 11.4% to 17.7%. Under 1 percentage point of the drug's effect ran through those side effects. If I have no nausea, is my dose too low? Nausea is not a dose gauge. The trials found similar weight loss with or without it, so dose changes are a prescriber decision based on results and tolerability. Does tirzepatide cause less nausea than semaglutide? In animals, GIP receptor activation blocked vomiting from a GLP-1 drug. That does not settle the human question, and nausea rates from separate trials are not directly comparable. ## Sources 1. \[1\] Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. [PMID 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682/) 2. \[2\] Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R, et al. (2020). Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events BMJ Open Diabetes Research & Care. [PMID 33115821](https://pubmed.ncbi.nlm.nih.gov/33115821/) 3. \[3\] Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, et al. (2024). Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials Diabetes, Obesity and Metabolism. [PMID 37853960](https://pubmed.ncbi.nlm.nih.gov/37853960/) 4. \[4\] Yacawych WT, Wang Y, Zhou G, Hassan S, Bodur C, Walters E, et al. (2026). A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists The Journal of Clinical Investigation. [PMID 42742987](https://pubmed.ncbi.nlm.nih.gov/42742987/) 5. \[5\] Borner T, Geisler CE, Fortin SM, Cosgrove R, Alsina-Fernandez J, Dogra M, et al. (2021). GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models Diabetes. [PMID 34380697](https://pubmed.ncbi.nlm.nih.gov/34380697/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Why Does Ozempic Cause Sulfur Burps? What the Adverse-Event Data Show Why does Ozempic cause sulfur burps? Burping hit 2.7% on Ozempic and 7% on Wegovy vs 1% or less on placebo | the smell itself has never been measured. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps Updated: 2026-09-18 Published: 2026-09-18 [← Research](https://thisglp.com/research) Safety # Why Does Ozempic Cause Sulfur Burps? What the Adverse-Event Data Show Burping reached 2.7% on Ozempic 0.5 mg and 7% on Wegovy 2.4 mg in the label trials, against 1% or less on placebo. It is semaglutide's strongest stomach signal in FDA reports. The sulfur smell itself has never been measured. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Eructation (burping) in label tables, drug against placebo · Ozempic 0.5 mg · 2.7% vs 0% · Wegovy 2.4 mg · 7% vs under 1% · Mounjaro 15 mg · 3.3% vs 0.4% · Zepbound 15 mg · 5% vs 1% · Separate trials and populations, not head to head. No table records the smell. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Nobody has measured why the burps smell of sulfur, but the burping itself is a counted side effect. In the diabetes trials behind the Ozempic label, 2.7 percent of people on 0.5 mg reported burping against none of the 262 on placebo [\[1\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-1). At the 2.4 mg dose sold as Wegovy, 7 percent of 2,116 adults burped more than usual against under 1 percent on placebo [\[2\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-2). In the FDA’s adverse-event database, burping was the stomach complaint most out of proportion for semaglutide, with a reporting odds ratio whose lower bound was 42.03 [\[3\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-3). ## Key takeaways - Burping (eructation) is on the Ozempic, Wegovy, Mounjaro and Zepbound labels: 2.7% on Ozempic 0.5 mg against 0% on placebo, and 7% on Wegovy 2.4 mg against under 1%. - Tirzepatide shows the same pattern: 3.0% to 3.3% on Mounjaro against 0.4%, and 4% to 5% on Zepbound against 1%. - Among 45 stomach-related signals for semaglutide in the FDA database, burping had the strongest, and the signals clustered in the first weeks. - No study has sampled the gas, so the sulfur smell has no measured cause; a trial of 72 adults found no delayed stomach emptying at week 20. - The labels say these stomach reactions were reported most often during dose escalation. Picture the evening it usually starts, a few weeks after the first pen or the day after a step up in dose, when a heavy dinner comes back up as a burp that tastes like a rotten egg. That detail, the smell, is the part the labels never record, because a trial form has one box for burping and none for what the burp was like. So the answer below runs in two halves, the burping that trials and databases counted, and the sulfur that nobody has yet put a number on. ## How often Ozempic and Wegovy cause burping The Ozempic label lists burping among the less common stomach reactions, at 2.7 percent on 0.5 mg and 1.1 percent on 1 mg, drawn from two placebo-controlled trials in people with type 2 diabetes [\[1\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-1). The same pool puts all stomach reactions together at 32.7 to 36.4 percent on the drug against 15.3 percent on placebo. That gives burping its scale, a small slice of a large pie and one that nausea dominates, as [why GLP-1 drugs cause nausea](https://thisglp.com/research/why-do-glp1-drugs-cause-nausea) explains. The obesity dose moves the number up. In the Wegovy weight trials, burping reached 7 percent on 2.4 mg against under 1 percent on placebo, close to dyspepsia at 9 percent and abdominal distension at 7 percent [\[2\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-2). The label adds that these reactions were reported most often during dosage escalation, the weeks when each new, higher pen arrives. The full comparison of side effects across the drugs, burping included, sits in [which GLP-1 has the worst side effects](https://thisglp.com/research/which-glp1-has-the-worst-side-effects). ## Mounjaro and Zepbound: the same symptom in the tirzepatide tables Tirzepatide carries the same side effect under both of its brand names. The Mounjaro label, from diabetes trials, lists burping at 3.0 percent on 5 mg, 2.5 percent on 10 mg and 3.3 percent on 15 mg, against 0.4 percent on placebo [\[4\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-4). The Zepbound label, from obesity trials, lists it at 4 to 5 percent across the three doses against 1 percent of 958 people on placebo [\[5\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-5), high enough that it appears in the label’s own list of most common reactions. The tirzepatide reports in the FDA database line up with those tables. An analysis of reports from 2022 to 2024 found burping and impaired gastric emptying carried the highest disproportionality of any stomach event, with most events arriving within three months and a median onset of 16 days [\[6\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-6). The tables and the reports were built differently, but they point to the same early window. ## What the FDA reports add, and what they cannot The largest semaglutide analysis took 5,442 reports of stomach side effects filed to the FDA between 2018 and 2022 and found 45 signals, ranging from a lower bound of 1.01 for oral numbness to 42.03 for burping [\[3\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-3). The authors describe every signal as an early failure type, meaning the risk of a new report fell as time on the drug went on, and the median onset for the strongest-priority signal was 23 days. That is a comparison of reports against reports, so it shows how distinctive burping is to semaglutide, not how many users get it. The label rates and the database signal describe the same thing from two sides. Burping is uncommon in absolute terms, at a few percent, and it is also unusually specific to these drugs, which is why it stands out so sharply once people compare notes. The same gap between a strong reporting signal and a modest trial rate runs through [the acid reflux evidence](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux), which is the other upper-stomach complaint these drugs share. ## Why the burps might smell of sulfur The explanation that circulates is that food sits in a slowed stomach long enough for protein to break down into hydrogen sulfide, the gas that smells of rotten eggs. It is a plausible idea, and none of the sources here tested it: no study has sampled the burps of people on these drugs, and the labels count burping without recording its smell. The slow-stomach half of the story is also less settled than it sounds. In a trial of 72 adults with obesity, 20 weeks of semaglutide 2.4 mg raised a paracetamol-absorption measure of stomach emptying by 8 percent, a difference that was no longer significant once body weight was accounted for [\[7\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-7). The authors concluded there was no evidence of delayed gastric emptying at week 20, while the same people ate 35 percent less at a free lunch. The rarer, more serious version of a slowed stomach is covered in [whether GLP-1 drugs cause gastroparesis](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis), and a study that found food still in the stomach after fasting is in [the gastric ultrasound log entry](https://thisglp.com/research/glp1-before-surgery). Where the evidence stops The counts here are for burping of any kind; none of the sources separates sulfur burps from ordinary ones. Paracetamol absorption is an indirect measure taken at one point in time, so it cannot rule out slower emptying in the first weeks, when the reports cluster. The figures come from the branded drugs’ trials; compounded semaglutide is not FDA-approved and has no trial side-effect table of its own. ## When it tends to fade Both lines of evidence put the burping early and point to it easing. The labels tie stomach reactions to dose escalation, and the FDA analyses found reports concentrated in the first weeks, with a median onset of 23 days for semaglutide’s strongest signal and 16 days for tirzepatide [\[3\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-3) [\[6\]](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps#ref-6). The dose ladder that sets those escalation weeks is laid out in [the semaglutide starting dose](https://thisglp.com/research/semaglutide-starting-dose), and the time course of the commoner stomach complaint is in [how long nausea lasts on a GLP-1](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). What remains unanswered is the question a person actually has at the kitchen table: whether a smaller dinner, less protein late in the day, or a slower dose step shortens the sulfur phase. No trial behind these labels reported burping by week, by meal or by how long each episode lasted, so the fading is a pattern in the reports, not a timetable anyone has measured. ## Frequently asked Why does Ozempic cause sulfur burps? No study has measured it. Burping itself is a labeled side effect, reported by 2.7% on Ozempic 0.5 mg against 0% on placebo. The idea that slowed digestion produces hydrogen sulfide is plausible but untested, and one 20-week trial found no delayed stomach emptying. Do people get sulfur burps on Mounjaro too? Burping is on the tirzepatide labels as well: 3.0% to 3.3% on Mounjaro against 0.4% on placebo, and 4% to 5% on Zepbound against 1%. In FDA reports for tirzepatide, burping had one of the highest disproportionality scores of any stomach event. Are egg burps on Ozempic a sign of something serious? Burping is common and usually early; FDA reports for semaglutide clustered in the first weeks, with a median onset of 23 days for the strongest signal. The labels warn separately about severe stomach reactions, pancreatitis and gallbladder disease, which come with pain or vomiting rather than burping alone. Does Ozempic burping go away? The labels say stomach reactions were reported most often during dose escalation, and the FDA analyses found the risk of new reports fell over time. No trial measured how many weeks burping lasts for an individual. ## Sources 1. \[1\] Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, Table 1 and section 6.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) 2. \[2\] Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use — prescribing information, Table 3 and section 6.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b) 3. \[3\] Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q (2022). Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system Frontiers in Public Health. [PMID 36339230](https://pubmed.ncbi.nlm.nih.gov/36339230/) 4. \[4\] Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information, section 6.1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0) 5. \[5\] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, Table 1 DailyMed, U.S. National Library of Medicine. [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) 6. \[6\] Shen P, Peng MS, Kim SJ, Joung KI, Kim KJ (2026). Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis PLoS One. [PMID 41894422](https://pubmed.ncbi.nlm.nih.gov/41894422/) 7. \[7\] Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Diabetes, Obesity & Metabolism. [PMID 33269530](https://pubmed.ncbi.nlm.nih.gov/33269530/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness) --- # Why Does Weight Loss Plateau on a GLP-1? The Drug Is Still Working | This GLP Why does weight loss plateau on a GLP-1? Appetite feedback catches up | median plateau came at 24 to 36 weeks on tirzepatide, and intake stayed lower at week 60. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1 Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Why Does Weight Loss Plateau on a GLP-1? The Drug Is Still Working Most people on tirzepatide plateaued between 24 and 36 weeks. At week 60 of a semaglutide trial, people still ate 269.5 kcal less than placebo, though they no longer felt it. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Median weeks until weight stopped falling · overweight · 24.3 wk · class I · 26 wk · class II · 36.1 wk · class III · 36.1 wk · By week 72, about 88% to 90% had reached a plateau. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Weight loss on a GLP-1 slows and stops because the body's appetite feedback catches up with the drug, not because the drug has stopped working. - In a SURMOUNT-1 analysis, median time to a plateau on tirzepatide ran from 24.3 to 36.1 weeks, and about 88% to 90% had plateaued by week 72. - At week 60 of a semaglutide trial, people still ate 269.5 kcal less than placebo at a measured meal, although self-rated appetite no longer differed. - Higher doses, younger age and female sex went with a later plateau. Weight loss on a GLP-1 slows and then stops because the body pushes back, and for most people that happens within the first year and a half. In a large tirzepatide analysis, the median time to a plateau ran from 24.3 to 36.1 weeks depending on starting weight, and about nine in ten had plateaued by week 72 [\[1\]](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1#ref-1). The plateau is the expected shape of treatment, and the trial evidence says the drug is still doing its job while the scale sits still, which is a different thing from [what happens when it is stopped](https://thisglp.com/research/stopping-glp1-and-weight-regain). ## When the plateau arrives The timing comes from a post hoc analysis of SURMOUNT-1 and SURMOUNT-4, the tirzepatide obesity trials, which defined a plateau as less than 5% weight change across a twelve-week window and every window after it [\[1\]](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1#ref-1). It included only people who stayed on treatment and had already lost at least 5% by the trial’s main endpoint, 1,438 of them in SURMOUNT-1 and 259 in SURMOUNT-4, so it describes people for whom the drug was working. Among them, the median plateau arrived at 24.3 weeks for people who started overweight, 26.0 for class I obesity, and 36.1 for classes II and III. By week 72, between 87.6% and 90.2% of each group had reached one. Higher doses of 10 or 15 mg, younger age and female sex all went with a later plateau, and SURMOUNT-4 showed the same pattern. Diabetes trials show the same curve. A network meta-analysis of 55 placebo-controlled trials in 18,876 people with type 2 diabetes found the largest weight difference against placebo at 24 to 30 weeks, 2.42 kg, followed by a plateau period [\[4\]](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1#ref-4). The effect on blood sugar held for at least 104 weeks, though by then the HbA1c reduction was about 0.36 points smaller than at its early peak, and the authors advise accounting for that weakening after two years. ## Why the body stops the loss Body weight behaves like a system with a thermostat: as weight falls, appetite rises, and intake creeps back toward what the new, lighter body needs. A published mathematical model of energy metabolism fitted that idea to the average weight curves from diet restriction, semaglutide 2.4 mg, tirzepatide 10 mg and gastric bypass [\[2\]](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1#ref-2). In the model, every intervention except dieting substantially weakened the appetite feedback circuit, which is why the drugs and surgery produce a longer stretch of loss before the plateau. Gastric bypass also shifted the body’s equilibrium about twice as far as either drug. The author calls the results preliminary, and a model fitted to averages says nothing about a particular person’s curve, but it gives the plateau a mechanism that does not require the drug to wear off. ## The drug is still working at the plateau A direct test is a 60-week trial that randomized 120 adults 3:2 to semaglutide 2.4 mg or placebo [\[3\]](https://thisglp.com/research/why-does-weight-loss-plateau-on-a-glp1#ref-3). At weeks 20, 40 and 60 the participants came into a laboratory and ate as much as they wanted from a provided lunch, with the calories measured. The semaglutide group ate 291.9, 240.2 and 269.5 kcal less than placebo at those three visits, so the gap at week 60 was about where it had been at week 20. What changed was the feeling. Self-rated appetite, hunger and preoccupation with food all differed from placebo at week 20, and none of them did at weeks 40 or 60. Someone fourteen months in is probably comparing today’s hunger with their recent normal, which is already the drug’s normal. The sense that the medicine has stopped working can be sincere and still be wrong about what the drug is doing. How much less people eat in the first place is covered in [the pooled intake evidence](https://thisglp.com/research/how-much-less-do-you-eat-on-a-glp1). A plateau is not a failure to respond Not losing much in the first months is a different problem from stopping after a good run. The plateau analyses above include only people who had already lost at least 5%, and the same distinction, between a curve that flattened and one that never fell, is worth making before changing anything. ## What people do at a plateau Because higher doses went with a later plateau in SURMOUNT, the dose is the obvious question to raise with a prescriber. The [the higher-dose evidence for semaglutide](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it) sets out what a step up buys and what it costs in side effects. The other thing worth watching through a long plateau is what the lost weight was made of, which is the subject of [the muscle loss guide](https://thisglp.com/research/do-you-lose-muscle-on-a-glp1). Stopping at a plateau carries the clearest risk, because the weight the drug is holding off tends to return, and it brings more than weight with it, as [the stopping evidence](https://thisglp.com/research/what-else-comes-back-when-you-stop-a-glp1) shows. What none of these studies can yet say is how a plateau behaves beyond two years, or whether it drifts, because the trials that measured it did not run that long. ## Frequently asked Why does weight loss plateau on a GLP-1? As weight falls, appetite feedback pushes intake back up until it matches what the lighter body needs. A published model found GLP-1 drugs weaken that feedback, which lengthens the period of loss, but a plateau still arrives. When does weight loss stop on a GLP-1? In a SURMOUNT-1 analysis of tirzepatide, the median plateau came at 24.3 to 36.1 weeks depending on starting BMI, and about 88% to 90% had plateaued by week 72. Does a plateau mean the drug stopped working? The trial evidence says no. At week 60, people on semaglutide still ate 269.5 kcal less than placebo at a measured meal, even though self-rated appetite no longer differed. Does a higher dose delay the plateau? In the SURMOUNT analysis, tirzepatide 10 or 15 mg went with a later plateau, as did younger age and female sex. That is an association in a post hoc analysis, not a dose trial. ## Sources 1. \[1\] Horn DB, Kahan S, Batterham RL, Cao D, Lee CJ, Murphy M, et al. (2025). Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials Clinical Obesity. [PMID 39800653](https://pubmed.ncbi.nlm.nih.gov/39800653/) 2. \[2\] Hall KD (2024). Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery Obesity (Silver Spring). [PMID 38644683](https://pubmed.ncbi.nlm.nih.gov/38644683/) 3. \[3\] Tronieri JS, et al. (2026). Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial The American Journal of Clinical Nutrition. [PMID 42323166](https://pubmed.ncbi.nlm.nih.gov/42323166/) 4. \[4\] Li Z, Han Z, Sun R, Xuan X, Huang C (2025). Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis Diabetes, Metabolic Syndrome and Obesity. [PMID 41019499](https://pubmed.ncbi.nlm.nih.gov/41019499/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Why Isn't Obesity in Your Medical Record? One in Ten Had It Written Down Why isn't obesity in your medical record? Among 42,243 adults with BMI 30 or more, 10.6% had it documented at discharge vs 59.7% for diabetes | four studies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/why-isnt-obesity-in-your-medical-record Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Why Isn't Obesity in Your Medical Record? One in Ten Had It Written Down 42,243 hospitalized adults all had a BMI of 30 or more on the chart. It reached the discharge summary for 10.6% of them, against 59.7% for diabetes. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min readUpdated September 2026 Written into the discharge summary, of those who met the criterion · obesity, BMI ≥ 30 · 10.6% · measured with a scale · severe dyslipidemia, LDL-C ≥ 190 · 39% · measured with a blood test · diabetes, HbA1c ≥ 6.5% · 59.7% · measured with a blood test · 42,243 hospitalized adults, 2013 to 2023, all with a BMI already on the chart. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Because a measured weight and a written diagnosis are two different events, and the second one is skipped far more often than the first. In a decade of hospital records covering 42,243 adults whose BMI of 30 or more was already on the chart, only 10.6% left with obesity documented in the discharge summary [\[1\]](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record#ref-1). Diabetes, by contrast, was written down for 59.7% of the patients whose HbA1c met its criterion, and that difference matters to anyone hoping to be treated. ## Key takeaways - 42,243 hospitalized adults with a BMI of 30 or more: obesity documented at discharge for 10.6%. - Diabetes was documented for 59.7% of those with HbA1c at or above 6.5%, and severe dyslipidemia for 39.0%. - Documented patients had 3.44 times the odds of a GLP-1 prescription, an association rather than a proven cause. - In one primary care practice, obesity was documented for 27.5% of patients who had it, against 83.3% for hypertension. - A standard electronic template raised documentation in young children from 34% to 47%. ## What the hospital study found Everyone in the study was admitted between 2013 and 2023 with a BMI of 30 or above and no earlier obesity code [\[1\]](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record#ref-1). Every one of them had been weighed and measured before a doctor wrote a word. Their mean BMI was 33.9 and their mean age 60.9, and nine in ten of them went home with a discharge summary that never named the condition the scale had recorded. The comparison with the laboratory conditions is what makes the gap hard to explain away. Diabetes needs a blood sample and a result coming back, and it reached the summary for 59.7% of patients whose HbA1c was 6.5% or higher; severe dyslipidemia, with an LDL-C of 190 or more, reached it for 39.0%. Each additional BMI unit raised the odds of coding by 17%, so the higher the number, the likelier someone was to write it down. That is a gradient of judgment rather than a line at 30, much as [the BMI cut-off for these drugs](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) is a convention rather than a boundary in the body. ## The same gap in a primary care office An older, smaller study went through a year of records from one community practice, where 22 physicians between them cared for more than 13,000 patients with obesity [\[2\]](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record#ref-2). Obesity made it into the record for 27.5% of those patients, while hypertension in the same charts was documented 83.3% of the time. The authors also sorted the physicians by their own BMI, and the pattern was not a tidy one: 23.2% for the six normal-weight doctors, 33.5% for the ten who were overweight, and 21.7% for the six with obesity themselves. It is one practice, and the sample of doctors is small enough that no single number in it should be carried very far, but the headline gap against hypertension is the same shape as the hospital finding. Measured is not the same as written down A third study looked a step earlier, at whether the measurement itself reaches the chart. In the records of 707,819 Canadian adults aged 40 and over, 48.7% had at least one BMI recorded and 11.5% had a waist measurement [\[4\]](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record#ref-4). So in routine primary care the number that a diagnosis would rest on is missing for about half of patients before the diagnosis question even comes up. ## What helped, where anything did The one intervention in this set was modest and practical. At a pediatric primary care clinic, researchers followed 585 children under six with a BMI above the 99th percentile and compared well-child visits that used a standardized electronic template with visits that did not [\[3\]](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record#ref-3). Documentation of obesity rose from 34% to 47% with the template, and with obesity in the chart, nutrition counseling rose from 44% to 66% and physical activity counseling from 9% to 23%. Young children are a separate question for treatment, covered in [the guide to teenagers](https://thisglp.com/research/are-glp1-drugs-safe-for-teens), but the lesson about templates travels. ## Why it matters if you want treatment In the hospital study, patients whose obesity was coded had 2.26 times the odds of a metabolic clinic visit and 3.51 times the odds of bariatric surgery. Their odds of a GLP-1 prescription were 3.44 times higher, with a 95% CI of 2.76 to 4.28 [\[1\]](https://thisglp.com/research/why-isnt-obesity-in-your-medical-record#ref-1). That is an association, and the arrow can run either way, since a doctor who has already decided to treat has a reason to write the diagnosis, but it shows how closely the paperwork and the prescription travel together. The practical version is short. If your weight has been measured and never discussed, it is reasonable to ask at the next visit whether obesity is on your problem list. You would expect a high blood pressure reading to end up there too. Whether a condition is on record also shapes who counts as eligible for the narrower approvals, like [semaglutide for liver disease](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease), and what good care around these drugs should include is set out in [what a GLP-1 provider should do](https://thisglp.com/research/what-should-a-glp1-provider-actually-do). What none of these studies answers is whether writing the diagnosis down, on its own, changes what happens to a patient afterwards, and that is the question a trial would have to settle. The hospital authors’ own conclusion is narrower and fair: closing the documentation gap is a prerequisite for turning a measured BMI into care. ## Frequently asked Why isn't obesity listed as a diagnosis in my chart? Measuring a BMI and writing obesity down as a diagnosis are separate steps, and the second is often skipped. In 42,243 hospitalized adults with a BMI of 30 or more, only 10.6% had obesity documented at discharge. How often do doctors document obesity compared with other conditions? In the hospital study, 10.6% for obesity against 59.7% for diabetes and 39.0% for severe dyslipidemia. In one primary care practice, 27.5% for obesity against 83.3% for hypertension. Does having obesity documented make a GLP-1 prescription more likely? Documented patients had 3.44 times the odds of a GLP-1 prescription. That is an association: a clinician who already plans to treat also has a reason to write the diagnosis. Can I ask my doctor to add obesity to my problem list? Yes. If your BMI has been measured, it is reasonable to ask whether obesity is recorded, just as you would for a high blood pressure reading. ## Sources 1. \[1\] Avivi I, Zelmanoff DD, Golan N, Arbel Y (2026). From measured BMI to documented obesity in hospitalized adults: a decade-long analysis and implications for cardiometabolic care International Journal of Obesity. [PMID 42687002](https://pubmed.ncbi.nlm.nih.gov/42687002/) 2. \[2\] Berry AC, Berry NA, Myers TS, Reznicek J, Berry BB (2018). Physician Body Mass Index and Bias Toward Obesity Documentation Patterns Ochsner Journal. [PMID 29559873](https://pubmed.ncbi.nlm.nih.gov/29559873/) 3. \[3\] Thaker VV, Lee F, Bottino CJ, Perry CL, Holm IA, Hirschhorn JN, et al. (2016). Impact of an Electronic Template on Documentation of Obesity in a Primary Care Clinic Clinical Pediatrics. [PMID 26676994](https://pubmed.ncbi.nlm.nih.gov/26676994/) 4. \[4\] Lindeman C, Jones A, Klein D, Prado CM, Pham ANQ, Spence JC, et al. (2022). Measurement of obesity in primary care practice: chronic conditions matter Family Practice. [PMID 35104851](https://pubmed.ncbi.nlm.nih.gov/35104851/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes) --- # Provider reviews: honest, evidence-first telehealth assessments | This GLP Independent reviews of the GLP-1 sellers we track — compounded semaglutide and tirzepatide, injection and oral. What the plan term really is, what it costs month to month, and who each seller is for. No fabricated scores. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews Updated: 2026-10-28 Independent assessments # Provider reviews Honest, evidence-first reviews of the telehealth providers we track — what each service actually is, how the care model works, how transparent the pricing is, and who it’s (and isn’t) for. No fabricated scores; where we have a partnership we say so, and it never changes the verdict. **580** providers reviewed Reviewed against our [editorial methodology](https://thisglp.com/methodology) Updated October 2026 **Disclosure:** This GLP is reader-supported. We earn nothing from the links on this page, but the order above is still commercial: partners are listed first, non-partners after — that never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Find a provider Showing all 580 reviews - [ Willow Partner Two prices, four products Four compounded GLP-1 products at two monthly prices, with a dozen named physicians and a program aimed at women. Read our review](https://thisglp.com/reviews/willow) - [ Belle Health Partner Care included, supply length matters Belle includes clinician oversight, nurse support and group dietitian coaching in its compounded injection plans. Longer supplies lower the advertised monthly equivalent, but the one-month rates remain higher. Read our review](https://thisglp.com/reviews/belle-health) - [ RxSpan MD Partner Regular price printed first The catalog leads with the standing rate, not the discounted one. Read our review](https://thisglp.com/reviews/rxspan-md) - [ Eden Partner The premium is all drug The membership costs the same on either molecule, so the hundred dollars between them is the medication and nothing else. Read our review](https://thisglp.com/reviews/eden) - [ HealthRX Partner The rate does not follow the dose Both molecules are stated flat at every dose, which on a medication designed to be escalated is the disclosure worth more than the headline. Read our review](https://thisglp.com/reviews/healthrx) - [ SnagRx Partner A year buys thirty dollars Four billing cycles are published on each molecule, and the gap between the shortest and the longest is only thirty dollars a month. Read our review](https://thisglp.com/reviews/snagrx) - [ bmiMD Partner Microdose, both molecules Both products are sold explicitly as microdose lines, which puts them below the doses every trial in this field used. Read our review](https://thisglp.com/reviews/bmimd) - [ Bodybuilding Health+Partner You can leave after thirty days Nothing here has a term attached, so the advertised number is the one an uncommitted buyer pays. Read our review](https://thisglp.com/reviews/bodybuilding-health-plus) - [ SkinnyRx Partner A first month, and no second The semaglutide injection publishes an opening month and no standing rate anywhere, while tirzepatide publishes a standing rate after its first month. Read our review](https://thisglp.com/reviews/skinnyrx) - [ ShedRx Partner One page, two answers, twice The same page quotes the medication at $149 and at $349-499, and the membership at $99 and at $125, without ever reconciling either pair. Read our review](https://thisglp.com/reviews/shedrx) - [ Wellorithm Partner Marketing and checkout differ The landing page and the checkout catalog publish different figures, and the bundle price is a first cycle only. Read our review](https://thisglp.com/reviews/wellorithm) - [ YourEra Partner Six months behind the headline Both advertised figures need six months, and no month-to-month rate is published for either. Read our review](https://thisglp.com/reviews/yourera) - [ Sprout Health Partner Two clocks, one seller The monthly plan bills every four weeks and the six-month plan bills by the calendar, which are different years. Read our review](https://thisglp.com/reviews/sprout-health) - [ Oak Partner Flat, no subscription Flat at every dose with no subscription, beside an advertised figure whose terms are never published. Read our review](https://thisglp.com/reviews/oak) - [ PeterMD Partner Monthly products behind a quarterly offer Both molecules have a cancel-anytime monthly product, while the tirzepatide landing page leads with a quarterly plan. Read our review](https://thisglp.com/reviews/petermd) - [ Live Vital Partner Ten weeks, not three months Both plans are ten-week protocols, and the page's own framing calls one of them a three-month program. Read our review](https://thisglp.com/reviews/live-vital) - [ Gala Partner Two lines, one market apart A brand cash price near thirteen hundred dollars sits beside a compounded yearly plan at a fraction of it. Read our review](https://thisglp.com/reviews/gala) - [ Sesame Care Partner Promo past its own end date The advertised introductory rate covers two months at the two lowest doses, and it is still displayed past the end date its own terms give. Read our review](https://thisglp.com/reviews/sesame-care) - [ HumeCare+Partner Flat rate, device included The rate is stated to hold at every dose, and what it covers includes a physical device as well as the medication. Read our review](https://thisglp.com/reviews/humecare) - [ Luvo Health Partner Weekly rate, four blocks Everything is priced per four weeks and per week at once, with twelve, twenty-four and fifty-two week blocks published beside it. Read our review](https://thisglp.com/reviews/luvo-health) - [ MEDGm Partner Membership plus an unstated cost All three figures are memberships. The medication cost is written as a word, not a number. Read our review](https://thisglp.com/reviews/medgm) - [ Direct Meds Partner A daily rate on the wrong page Everything is sold by the quarter and quoted by the day. One of the daily figures is the other molecule's. Read our review](https://thisglp.com/reviews/direct-meds) - [ Found Partner Priced per 28-day cycle Each molecule has its own four-rung ladder, and every rung is billed per 28-day cycle rather than per month. Read our review](https://thisglp.com/reviews/found) - [ Lttl Partner Four rungs, two dose lines Every line publishes a four-rung prepay ladder, and the low-dose and standard-dose products are priced separately rather than blended. Read our review](https://thisglp.com/reviews/lttl) - [ CoreAge Rx Partner $99 advertised, and the oldest figures here Semaglutide is advertised at $99 a month, on a row checked earlier than the rest of this group. Read our review](https://thisglp.com/reviews/coreage-rx) - [ Strut Health Partner Both molecules, both forms Four advertised rates across two molecules, with an oral semaglutide at $99 a month. Read our review](https://thisglp.com/reviews/strut-health) - [ Enhance MD Partner Four-week cycle, not a month Everything here is billed in four-week cycles, so a plan advertised by the month lands thirteen times a year rather than twelve. Read our review](https://thisglp.com/reviews/enhance-md) - [ Collective Partner Membership billed separately The advertised rate is $59 a month, and the required annual membership brings the monthly figure to $76. Read our review](https://thisglp.com/reviews/collective) - [ Embody Partner Read the program name before the price Embody names its clinical network and dispensing partners. Its promotion and monthly Flat terms still describe different purchase decisions. Read our review](https://thisglp.com/reviews/embody) - [ MyDrHank Partner Blended formulas, term unstated Three compounded GLP-1 products, each blended with a second ingredient, and a starting monthly figure on every one with no plan length printed beside it. Read our review](https://thisglp.com/reviews/mydrhank) - [ EverPrime Partner Verify your care team Named clinical groups, video visits and ongoing support; confirm the pharmacy and the full cost of your chosen care plan. Read our review](https://thisglp.com/reviews/everprime) - [ Coby Health Medical review, pharmacy unnamed Coby connects patients with independent prescribers for compounded injections. The care relationship deserves as much attention as the starting price. Read our review](https://thisglp.com/reviews/coby-health) - [ Form Health Ongoing clinician and dietitian care Form combines medical visits, nutrition support and primary-care coordination. Medication is one part of the program, with eligibility and coverage assessed separately. Read our review](https://thisglp.com/reviews/form-health) - [ TeleDocs360 Clinical portal, dose-based tier TeleDocs360 describes the evaluation and follow-up pathway, with a higher tirzepatide price at the top two doses. Read our review](https://thisglp.com/reviews/teledocs360) - [ 1st Optimal Membership priced, medication not A lab-led coaching membership with GLP-1 prescribing inside it, where the membership has a price and the drug does not. Read our review](https://thisglp.com/reviews/1st-optimal) - [ 24hrDOC Figures without a period A general online clinic with a weight-loss page that prints two semaglutide figures and never says what period either covers. Read our review](https://thisglp.com/reviews/24hrdoc) - [ AbundRX Entry figure, renewal unstated Two starting figures for compounded semaglutide and tirzepatide, and a signup screen that talks about a first-month discount without saying what month two costs. Read our review](https://thisglp.com/reviews/abundrx) - [ Alinwell Offer on the homepage, none on the product A GLP-1 service for women whose homepage advertises a new-patient offer, while both product pages say the price is set at consultation. Read our review](https://thisglp.com/reviews/alinwell) - [ Allara Health Specialist care, drug billed apart A women's hormone and metabolic practice that prescribes branded GLP-1s and prices only its own care. Read our review](https://thisglp.com/reviews/allara-health) - [ altRX Named pharmacies, monthly prices Compounded semaglutide and tirzepatide with named dispensing pharmacies, a published dose schedule, and monthly product prices. Read our review](https://thisglp.com/reviews/altrx) - [ Amazon One Medical Visit and drug billed apart Pay-as-you-go prescribing for branded GLP-1s, where the visit, the medication and the labs are three separate bills. Read our review](https://thisglp.com/reviews/amazon-one-medical) - [ AM Rx Membership first, medication second Insurance coordination for brand-name drugs, plus a cash route for compounded semaglutide and tirzepatide. Read our review](https://thisglp.com/reviews/amrx) - [ Ark Health Three plans, one monthly charge Three bundled monthly GLP-1 plans, and an oral option whose page does not name the drug inside it. Read our review](https://thisglp.com/reviews/ark-health) - [ BeyondMD Starting figures, no billing period A peptide practice that added GLP-1 programs, with starting figures that name no billing period. Read our review](https://thisglp.com/reviews/beyondmd) - [ BiltRx Low card, fees apart Card prices for two compounded drugs, with a membership and a consultation billed separately. Read our review](https://thisglp.com/reviews/biltrx) - [ Bliv An estimate, not a rate An asynchronous GLP-1 service whose headline figures depend on plan structure and eligibility. Read our review](https://thisglp.com/reviews/bliv) - [ BloomWell Rx Pharmacy and network named Monthly figures on both molecules, with the dispensing pharmacy and the provider network named in the FAQ. Read our review](https://thisglp.com/reviews/bloomwell-rx) - [ CaliberRx One figure, three payees A single starting figure covers both molecules, and billing splits across three parties. Read our review](https://thisglp.com/reviews/caliberrx) - [ Call-On-Doc Two routes, one prescriber An online prescriber that now sells an all-in home-delivery GLP-1 program beside its care-only plan. Read our review](https://thisglp.com/reviews/call-on-doc) - [ Dollar Dad Club Dose-proof injection price One injection price at every dose, a printed oral price, and a card charged when the plan is picked rather than after the doctor has looked at the case. Read our review](https://thisglp.com/reviews/dollar-dad-club) - [ Eclipse Medical Wellness A care fee, with the drug billed apart A Colorado nurse practitioner's weight-loss practice that prices the care and sends the prescription to a pharmacy the patient pays directly. Read our review](https://thisglp.com/reviews/eclipse-medical-wellness) - [ ElixaMD Separate branded and compounded offers ElixaMD offers compounded injections and branded GLP-1 treatment. Clarify the medication bill, prescribing decision and refund conditions before paying. Read our review](https://thisglp.com/reviews/elixamd) - [ eMI Aesthetics Plan length left unpriced Four plan lengths on offer and one starting figure, with no way to tell which plan the figure belongs to until a gated intake has been completed. Read our review](https://thisglp.com/reviews/emi-aesthetics) - [ Eve Email before anything An unpriced GLP-1 program and three branded names, behind an intake that asks for an email before the first health question. Read our review](https://thisglp.com/reviews/eve) - [ Everlywell (Weight Care+) A membership, not a drug sale A monthly membership on a three- or twelve-month term. The brand medication is billed by a pharmacy. Read our review](https://thisglp.com/reviews/everlywell-weight-care-plus) - [ Eviora MD Priced at consultation Three GLP-1 programs, each marked available by consultation, from a Virginia telehealth practice that quotes a flat rate only after a provider has reviewed the case. Read our review](https://thisglp.com/reviews/eviora-md) - [ Fella Health Cost stated per day A men's weight-loss program that states its cost per day, not per month, and backs it with a conditional six-month refund. Read our review](https://thisglp.com/reviews/fella-health) - [ Fitness RX Floor stated, product unstated A subscription GLP-1 service that prints one medication-inclusive floor and leaves the product behind it to the intake. Read our review](https://thisglp.com/reviews/fitness-rx) - [ FitRx Two paths, one bundled price An insurance-first service with a bundled cash plan for compounded GLP-1s and a cheaper route that adds a membership. Read our review](https://thisglp.com/reviews/fitrx) - [ Garcia Weight Loss, Aesthetics & Hormone Therapy Tampa Bay clinic, office visits A Tampa Bay clinic group that runs GLP-1 injections through weekly or monthly office visits and prices them only at a consultation. Read our review](https://thisglp.com/reviews/garcia-weight-loss) - [ GoodRx Brand drugs, membership on top The prescription-coupon company's telehealth plan, which prescribes FDA-approved GLP-1s only and bills a monthly membership apart from the medication. Read our review](https://thisglp.com/reviews/goodrx) - [ Heally Brand only, no membership A telehealth marketplace that prescribes brand semaglutide and tirzepatide after a live video visit, with no membership and no compounded option. Read our review](https://thisglp.com/reviews/heally) - [ HelloWellness Checkout before the questionnaire A longevity-branded online seller of compounded semaglutide and tirzepatide, sold as three-month plans that renew every eleven weeks and are paid before any intake. Read our review](https://thisglp.com/reviews/hellowellness) - [ Heva Health One price at every dose A functional-medicine practice that sells compounded semaglutide and tirzepatide at a flat rate across doses, with the month-to-month rung printed beside the commitment discounts. Read our review](https://thisglp.com/reviews/heva-health) - [ Independent Wellness One nurse practitioner, named A single-provider telehealth practice selling compounded semaglutide and tirzepatide, with a semaglutide rate its own pricing page states two ways. Read our review](https://thisglp.com/reviews/independent-wellness) - [ InstaRX Only month one priced One flat price is stated for both molecules. Only the first month carries a figure. Read our review](https://thisglp.com/reviews/instarx) - [ Iron Med RX Three plan lengths, one floor An injection from $149 and a tablet from $196, each printed under a list of three plan lengths that the page never matches to a price. Read our review](https://thisglp.com/reviews/iron-med-rx) - [ Ivy Rx Floors that change by page Every figure Ivy Rx prints is a floor, and the floor depends on which page a buyer lands on. Read our review](https://thisglp.com/reviews/ivy-rx) - [ JRNYS Membership priced, drug later A coaching membership with a published price, and brand-name drugs priced after a consultation. Read our review](https://thisglp.com/reviews/jrnys) - [ JumpstartMD Fourteen clinics, one start fee A California clinic network that prices the act of joining and leaves the medication to be priced after the clinician visit. Read our review](https://thisglp.com/reviews/jumpstartmd) - [ JustAnswer Weight Loss Annual-plan rates only Both published figures are annual-plan rates, and the monthly plan is priced behind a sign-up form. Read our review](https://thisglp.com/reviews/justanswer-weight-loss) - [ Lean Rx Four-week fills, shipping extra Every plan is billed in four-week fills. The one rung without a lock-in adds shipping. Read our review](https://thisglp.com/reviews/lean-rx) - [ LifeRx.md One figure, no dose upcharge One starting figure for a GLP-1 plan, a pledge not to charge more as the dose climbs, and a refund policy with no exceptions for dispensed medication. Read our review](https://thisglp.com/reviews/liferx) - [ LifespanningRx A peptide store, weight loss behind a consult A Miami peptide and longevity platform whose weight-loss program is sold through a clinician evaluation, with no GLP-1 price on the program page. Read our review](https://thisglp.com/reviews/lifespanningrx) - [ LillyDirect Foundayo The maker's own pill, priced by dose Eli Lilly's direct pharmacy channel for its orforglipron tablet, with a self-pay price for every strength and a separate insured figure. Read our review](https://thisglp.com/reviews/lillydirect-foundayo) - [ 50 Stars Health Three plans, one price per dose Compounded semaglutide is $146 on the monthly plan, the same at every dose. Read our review](https://thisglp.com/reviews/livv) - [ Loop Health A free club with a pharmacy counter A peptide community whose membership is free for now, with GLP-1 prescriptions priced flat at every dose and sold on top of it. Read our review](https://thisglp.com/reviews/loop-health) - [ Marek Health Labs first, prescription later A lab-led optimization service that tests before it prescribes, and publishes no price for the GLP-1 medication itself. Read our review](https://thisglp.com/reviews/marek-health) - [ Medi-Weightloss Clinic visits, first month priced A franchise of in-person clinics. Only the first month of medication is priced online. Read our review](https://thisglp.com/reviews/medi-weightloss) - [ Metaboost Rx Low figures, unlabeled term An Oklahoma City telehealth brand whose headline GLP-1 figures sit under a new-patient banner, with nothing on the page saying what follows the offer. Read our review](https://thisglp.com/reviews/metaboost-rx) - [ Neo Soma Healthcare Texas only, ladder published A Texas clinic that publishes its full semaglutide dose ladder, names its compounding pharmacy, and prices refills by dose band. Read our review](https://thisglp.com/reviews/neo-soma-healthcare) - [ New Wave Health Priced only after review Two compounded injections from a Virginia Beach storefront, with no monthly price shown before an intake. Read our review](https://thisglp.com/reviews/new-wave-health) - [ Nirwana Health Two blocks, two readings Each product page prints two price blocks, and one of them calls the monthly figure introductory. Read our review](https://thisglp.com/reviews/nirwana-health) - [ Omnia TeleHealth Visit priced, medicine not A general telehealth practice in coastal Alabama that prescribes GLP-1s through a flat-fee visit and leaves the medication price unpublished. Read our review](https://thisglp.com/reviews/omnia-telehealth) - [ Raeliva Flat monthly rate, named pharmacies Raeliva prices each product at one monthly rate, whatever the dose. Read our review](https://thisglp.com/reviews/onlinesemaglutideorg) - [ PauseRX Flat semaglutide, open tirzepatide Semaglutide carries one price for all doses. Tirzepatide is worded two ways. Read our review](https://thisglp.com/reviews/pauserx) - [ QuickMD A visit, not a program An online clinic that charges per visit and sends brand GLP-1 prescriptions to the patient's own pharmacy, after withdrawing its compounded versions. Read our review](https://thisglp.com/reviews/quickmd) - [ Refills Discount shown, plan withheld Two compounded injections, a daily rate labeled as low as, and plans behind a date-of-birth question. Read our review](https://thisglp.com/reviews/refills) - [ Ro Brand pills and pens, plus membership Brand GLP-1s only, with the membership billed as a second monthly charge. Read our review](https://thisglp.com/reviews/ro) - [ RxSaludable Bilingual care, refill rate in the FAQ A Spanish and English telehealth brand whose semaglutide refill rate sits in its FAQ, not on its price cards. Read our review](https://thisglp.com/reviews/rxsaludable) - [ TD Tele-Doc Weight Loss Insurance first, Virginia physicians A Richmond weight-loss practice that runs its GLP-1 prescribing through insurance and weekly video visits rather than a cash price list. Read our review](https://thisglp.com/reviews/td-teledoc) - [ TeleHealth Med Flat price promised, not printed A compounded GLP-1 storefront that promises one price for every dose and shows no figure before checkout. Read our review](https://thisglp.com/reviews/telehealth-med) - [ TeleSlim Clinic Obesity doctors, drug billed apart A Chicago obesity-medicine practice that sells a monthly doctor subscription and sends the prescription to whichever pharmacy the patient chooses. Read our review](https://thisglp.com/reviews/teleslim-clinic) - [ Tell Her Doc Clinicians by NPI, price term unstated Four physicians listed by NPI and four pharmacies by phone, beside one starting figure whose billing period is never given. Read our review](https://thisglp.com/reviews/tellherdoc) - [ The Virtual NP One named NP, brand drugs only A nurse practitioner's telehealth practice that charges for the visit and bills brand-name medication separately. Read our review](https://thisglp.com/reviews/the-virtual-np) - [ Tyde Wellness Five pharmacies named, two strengths A women's weight-loss program that names every compounding pharmacy it uses and prices each molecule with a single floor across two strengths. Read our review](https://thisglp.com/reviews/tyde-wellness) - [ UR Meds One figure, no drug named A single starting figure for GLP-1 care, labeled limited-time, with no drug, dose or end date attached to it. Read our review](https://thisglp.com/reviews/ur-meds) - [ Valhalla Vitality A free account is needed to see prices A broad telehealth catalog that shows its GLP-1 prices only to account holders, after sign-up. Read our review](https://thisglp.com/reviews/valhalla-vitality) - [ Velvet Rx First fill priced, renewal not Three GLP-1 cards priced for the first four weeks, with no renewal rate printed beside any of them. Read our review](https://thisglp.com/reviews/velvet-rx) - [ Vitara RX Flat by dose, unclear by plan Three figures for one semaglutide program on one site, and nothing that says which of them a buyer will be charged. Read our review](https://thisglp.com/reviews/vitara-rx) - [ ZipHealth Brands with provisional prices Four brand-name GLP-1 medicines with starting estimates, a separate clinical fee and final pricing from the pharmacy. Read our review](https://thisglp.com/reviews/ziphealth) - [ ZYP Medical One named prescriber, seven states A one-provider clinic near Omaha that prices each order by how long the vial will last, and prints the arithmetic. Read our review](https://thisglp.com/reviews/zyp-medical) - [ Superpower Membership before medication Semaglutide is sold only to members of a lab-testing service, and the membership fee is printed two different ways. Read our review](https://thisglp.com/reviews/superpower-health) - [ Cabana Named physician, named pharmacy Cabana names its supervising physician and its pharmacy, and prices its weight-loss plans from one figure. Read our review](https://thisglp.com/reviews/cabana) - [ Dr. Gillis' Wellness Center Walk-in clinic, named physician A physician-owned clinic in Oakland, Maine, with walk-in consultations and no contracts. Read our review](https://thisglp.com/reviews/dr-gillis-wellness-center) - [ EllieMD Three months in one box A build-your-own formula that ships twelve weeks of injections at once and bills for them month by month. Read our review](https://thisglp.com/reviews/elliemd) - [ Emerge Weight Loss Tirzepatide only, priced per dose A tirzepatide-only clinic that prints every dose's price and bills every four weeks, not every month. Read our review](https://thisglp.com/reviews/emerge-weight-loss) - [ Factor Health MD One flat rate, four plan lengths A flat price at every dose, with the lowest headline figure belonging to a twelve-month plan. Read our review](https://thisglp.com/reviews/factor-health-md) - [ Fierce Health Checkout first, intake after The order is paid before the medical intake, and a nurse practitioner sets the dose afterward. Read our review](https://thisglp.com/reviews/fierce-health) - [ Fitish Full dose or fixed microdose Two lanes per molecule, one monthly supply price each, and a microdose lane that stays at one dose. Read our review](https://thisglp.com/reviews/fitish) - [ Fitstry Four-week billing, clinician first The cards start at $149, the FAQ bills $249 every four weeks, and a clinician reads a long profile before anything ships. Read our review](https://thisglp.com/reviews/fitstry) - [ FormBlends Every rung on one page FormBlends describes clinical screening, check-ins before dose changes and shipment replacement rules alongside its public plan prices. Read our review](https://thisglp.com/reviews/formblends) - [ FormidableMD Visits billed, ladder published A priced ladder for each molecule, a paid visit at every dose change, and medical care in four states. Read our review](https://thisglp.com/reviews/formidablemd) - [ Fresh Day Meds Twenty-three day renewals The low storefront figures are three-month plans, and the one-month plans renew every 23 days. Read our review](https://thisglp.com/reviews/fresh-day) - [ Freya Meds Quarterly figure, monthly rate Monthly plans cost more than the quarterly figures, and the dose does not change the price. Read our review](https://thisglp.com/reviews/freya-meds) - [ Gaya Wellness Medication inside a tier A physician-led midlife program with the medication priced inside one tier, in five states. Read our review](https://thisglp.com/reviews/gaya-wellness) - [ GetRelief Rx Under the tongue, dose-priced A daily liquid held under the tongue, sold on two-month plans at prices that move with the dose. Read our review](https://thisglp.com/reviews/getrelief-rx) - [ Gimme Care Two rungs, one dose rule Each product card prints a monthly rate and a three-month rate, and states the price holds at every dose. Read our review](https://thisglp.com/reviews/gimme-care) - [ HealthOn Headline tied to a year The product pages lead with a twelve-month figure. The monthly plan in the cart bills differently. Read our review](https://thisglp.com/reviews/healthon) - [ Henry Meds Priced by the milligram allowance A monthly rate here buys a quantity of drug per shipment window, and the window stretches as the allowance grows. Read our review](https://thisglp.com/reviews/henry-meds) - [ Heros Health Named physicians, flat fee The program names its prescribing physicians and publishes dose check-ins at weeks 2, 4 and 8. Read our review](https://thisglp.com/reviews/heros-health) - [ Hims Brand pens, plus membership Every GLP-1 price is medication only. The membership is billed separately and cannot be skipped. Read our review](https://thisglp.com/reviews/hims) - [ Immortals Longevity framing, quarterly billing Every monthly figure on the GLP-1 pages is a share of a three-month charge taken at the start. Read our review](https://thisglp.com/reviews/immortals) - [ Intimate Rose Provider picks, one floor One advertised floor covers both molecules, and the prescribing is done by a named clinician network. Read our review](https://thisglp.com/reviews/intimate-rose) - [ Invigor Medical Four-week billing, unnamed molecules The plan pages say GLP-1 and GLP-1 + GIP. The checkout bills every four weeks. Read our review](https://thisglp.com/reviews/invigor-medical) - [ Invyncible Dearer at each dose step Every step up the dose ladder is a separate program with its own higher price. Read our review](https://thisglp.com/reviews/invyncible) - [ iThriveMD Clinic-led, flat by dose A clinic network in two states, with a flat price at every dose and a 28-day billing cycle. Read our review](https://thisglp.com/reviews/ithrivemd) - [ Jently Named pharmacy, month to month A New York telehealth platform that names its compounding pharmacy and opens on a no-commitment month. Read our review](https://thisglp.com/reviews/jently) - [ Joey Med Four-week plans, molecule unnamed Two GLP-1 plans priced per four weeks, with the drug in each named only on the hub page. Read our review](https://thisglp.com/reviews/joey-med) - [ Jyra Health Flat by dose, three pharmacies named A flat price that holds through every dose step, from a seller that names all three of its pharmacies. Read our review](https://thisglp.com/reviews/jyra-health) - [ Knownwell Insurance-first obesity clinic An obesity-medicine practice that bills insurance for visits and prescribes brand-name drugs only. Read our review](https://thisglp.com/reviews/knownwell) - [ Kongo All-inclusive, flat by dose Two all-inclusive monthly rates, no membership, and a provider review within a day. Read our review](https://thisglp.com/reviews/kongo) - [ Lavender Sky Health Every pharmacy named and priced Every compounding pharmacy is named beside its own price, and a new patient's first order is a one-month starter plan. Read our review](https://thisglp.com/reviews/lavender-sky-health) - [ Layla Oral drops, injection-trial footnote Oral semaglutide drops at $237 a month after a discounted first month, beside a footnote about a different form. Read our review](https://thisglp.com/reviews/layla) - [ Lemonaid Health Membership on top, clinicians named Medication at $299 a month plus a required $49 membership, from a clinic that names its clinicians. Read our review](https://thisglp.com/reviews/lemonaid-health) - [ LIV by WellNow Five states, printed dose path One compounded semaglutide membership at $195 a month, sold in five states, with its dose schedule printed on the page. Read our review](https://thisglp.com/reviews/liv-by-wellnow) - [ LovelyMeds Flat by dose, priced by term Compounded semaglutide at $175 and tirzepatide at $235 on one-month plans, each flat across doses. Read our review](https://thisglp.com/reviews/lovelymeds) - [ Luma Health Co Priced per dose, per four weeks A price for every milligram strength, each buying four weeks, with no subscription attached. Read our review](https://thisglp.com/reviews/luma-health) - [ Lumen Meds Flat rates, cancel any time Two compounded programs at flat monthly rates that hold at every dose, with no membership fee and no term to sign. Read our review](https://thisglp.com/reviews/lumen-meds) - [ LunaRx Three stacks, one floor One headline figure spans three bundled stacks, and the page never says which stack it prices. Read our review](https://thisglp.com/reviews/lunarx-health) - [ Lyfe Rx One price, no membership Each price includes the provider review, medication, supplies and shipping, with no membership fee. Read our review](https://thisglp.com/reviews/lyfe-rx) - [ Maves A discounted first month The $89 on the page is a first month with a $100 discount applied, and every month after it costs $189. Read our review](https://thisglp.com/reviews/maves) - [ Measured Every rung in writing The lead figure is a twelve-month rate, and the struck figure beside it is the monthly one. Read our review](https://thisglp.com/reviews/measured) - [ Medro A code on the lead The lead figure has a one-time code applied. The standing rates are $199 and $299. Read our review](https://thisglp.com/reviews/medro) - [ Medsol RX A ladder of commitments Month-to-month semaglutide is $199 after a $169 first month, and three prepaid plans trade the whole term up front for a lower monthly figure. Read our review](https://thisglp.com/reviews/medsol-rx) - [ Mevo Health A floor, term unstated Both figures read as low as. The plan length each one prices is not stated. Read our review](https://thisglp.com/reviews/mevo-health) - [ Mint Med One rate across the ladder The monthly figure is written into the product name, and the listing says it holds at every dose for as long as the order runs. Read our review](https://thisglp.com/reviews/mint-med) - [ Mint Medical Clinic Utah clinic, one printed floor A Utah clinic prints one starting price for both molecules, and the GLP-1 page itself carries no price at all. Read our review](https://thisglp.com/reviews/mint-medical) - [ Mojoon Chinese-language, price rises with dose A Chinese-language telehealth service prices each monthly course by dose, from a starting figure up to a published ceiling. Read our review](https://thisglp.com/reviews/mojoon) - [ MyFastRx Second month printed up front An introductory first month sits on top of each product page, and the rate for every month after it is printed on the same card. Read our review](https://thisglp.com/reviews/myfastrx) - [ RNK Health Coupon price, then the regular rate The headline rate carries a $50 coupon that the seller's own data applies once. Read our review](https://thisglp.com/reviews/myrnk) - [ NewSelf Doses listed, one price each Every milligram step is listed on the homepage, and the seller says each one costs the same. Read our review](https://thisglp.com/reviews/newself) - [ Nex Gen Health Rx Totals printed per plan Four supply lengths on one selector, each with a strength and an upfront total beside it. Read our review](https://thisglp.com/reviews/nex-gen-health-rx) - [ Next Vial Year preselected, month on top The selector opens on the twelve-month card, and the month-to-month rate sits at the top of the same ladder. Read our review](https://thisglp.com/reviews/next-vial) - [ NiceRx Discount first, rate after Each product card prints a discounted opening month and, on the same line, the monthly rate that replaces it. Read our review](https://thisglp.com/reviews/nicerx) - [ Novi Four cycles, one dose price A billing-cycle table on each product page, with the one-month rate listed first and no membership charged on top. Read our review](https://thisglp.com/reviews/novi) - [ NP2GO Priced by month and dose An Oklahoma nurse practitioner practice that prints a separate price for every month of the dose ladder. Read our review](https://thisglp.com/reviews/np2go) - [ NuviaRx Annual rate up front The product page prices the annual plan; the checkout prints every term, a single month included. Read our review](https://thisglp.com/reviews/nuviarx) - [ Optimized Health A Joplin clinic, named clinician A Missouri clinic with a named prescribing clinician, lab panels when indicated, and telehealth in five states. Read our review](https://thisglp.com/reviews/optimized-health) - [ OrderlyMeds Two-month offer, then the monthly plan The advertised figures belong to a new-patient starter program. The monthly plans are printed on the same page. Read our review](https://thisglp.com/reviews/orderlymeds) - [ OurView Health Assessment before final payment OurView offers dose-independent monthly pricing, an authorization before clinical approval, and a patient portal for follow-up. Read our review](https://thisglp.com/reviews/ourview-health) - [ PCOS Sisters PCOS clinic, membership first A nurse practitioner clinic for polycystic ovary syndrome, where a GLP-1 prescription requires an active membership. Read our review](https://thisglp.com/reviews/pcos-sisters) - [ Peak Wellness First month first, rate after The monthly plan quotes a first month. The rate after it is printed on the same card. Read our review](https://thisglp.com/reviews/peak-wellness) - [ Pomegranate Health A starting price, then a pharmacy menu Each product page quotes one starting figure; the pricing app behind it changes the price with the pharmacy, the dose tier and the package. Read our review](https://thisglp.com/reviews/pomegranate-health) - [ Precision Telemed Named clinicians, flat dose pricing Both product pages publish the full dose range and name the clinicians, down to their NPI numbers. Read our review](https://thisglp.com/reviews/precision-telemed) - [ Premium Health Base rate, dose surcharge A monthly membership that includes medication. A higher dose adds a stated monthly charge. Read our review](https://thisglp.com/reviews/premium-health) - [ PrescribedRX Refill timing needs clarification Provider messaging and included supplies are described, but the three-month plan renews every ten weeks. Read our review](https://thisglp.com/reviews/prescribedrx) - [ ReadyRx Flat rate after month one A discounted first month, then a flat rate that ReadyRx applies to every dose. Read our review](https://thisglp.com/reviews/readyrx) - [ Remi Meds Five dose steps, five prices Two dose selectors, five priced steps on each, and every step up costs more. Read our review](https://thisglp.com/reviews/remi-meds) - [ Reset Solutions Local clinic, two bills A program fee and a separate medication bill, with an in-person start near The Woodlands. Read our review](https://thisglp.com/reviews/reset-solutions) - [ Roen Rx Two routes, one membership Insurance coordination for brand drugs, and a compounded bundle for everyone else. Read our review](https://thisglp.com/reviews/roen-rx) - [ RX Bella Monthly only, shared storefront One monthly price per drug, sold from a storefront that shares its software with seven other brands. Read our review](https://thisglp.com/reviews/rx-bella) - [ RxION Health Six-month headline, monthly plan beside it The headline rate is the six-month rung, and the monthly plan asks for no term. Read our review](https://thisglp.com/reviews/rxion-health) - [ Rylo Health One rate at every dose The no-contract rate holds at every dose, and the filling pharmacy is named. Read our review](https://thisglp.com/reviews/rylo-health) - [ Ryze Rx Each vial strength priced Semaglutide is sold vial by vial, and the price climbs with the strength the prescriber writes. Read our review](https://thisglp.com/reviews/ryze-rx) - [ Semaglutide Online Four rungs in one table Four billing rungs sit in one table, and the headline figure belongs to the five-month commitment. Read our review](https://thisglp.com/reviews/semaglutide-online) - [ SexyMD Four-week fills, intro first The no-commitment plan ships four weeks at a time, which is thirteen fills a year. Read our review](https://thisglp.com/reviews/sexymd) - [ ShapeIn Rx Priced in dose bands Semaglutide is priced in two dose bands, and the product page adds an appointment fee and a shipping charge. Read our review](https://thisglp.com/reviews/shapein-rx) - [ Signos GLP-1 with a glucose sensor A compounded GLP-1 comes bundled with a glucose sensor, sold only on three- or six-month terms. Read our review](https://thisglp.com/reviews/signos) - [ Southern Vitality and Weight Loss Prepaid packages, no renewal Every plan is a one-time package, and none of them renews on its own. Read our review](https://thisglp.com/reviews/southern-vitality-weight-loss) - [ SynergenX Health Clinic chain, visit fees on top A hormone clinic chain that sells compounded semaglutide online, with each visit priced apart from the medication. Read our review](https://thisglp.com/reviews/synergenx) - [ TeleZen MD Four rungs, one price per dose A four-rung plan ladder on both molecules, with the month-to-month rate printed at the bottom of each card. Read our review](https://thisglp.com/reviews/telezen-md) - [ The Aesthetic Concierge Five-week cycles, physician-led A physician-led practice that bills semaglutide in five-week cycles, after a kick-off appointment that carries its own price. Read our review](https://thisglp.com/reviews/the-aesthetic-concierge) - [ Oxford's Medical Weight Loss (The Calibrate Clinic) Local clinic, first month discounted A Lafayette practice that quotes a new-patient first month, then bills a flat rate that it says covers every dose. Read our review](https://thisglp.com/reviews/the-calibrate-clinic) - [ TOM Weight Loss One doctor, two states A one-physician obesity medicine practice in Texas and Utah, with medication inside the monthly price. Read our review](https://thisglp.com/reviews/tom-weight-loss) - [ Tonik Wellness Three terms, lab work first A hormone and longevity clinic that prices both molecules on three terms, with a month-to-month card beside the yearly one it advertises. Read our review](https://thisglp.com/reviews/tonik-wellness) - [ Trava Health A published price at every dose Each product page prints a monthly price for every dose on the ladder, so the cost of titration is visible before intake. Read our review](https://thisglp.com/reviews/trava-health) - [ Trellis Vitality Named pharmacy, named medical group A three-term price table at one price per dose, with the pharmacy and the medical group both named. Read our review](https://thisglp.com/reviews/trellis-vitality) - [ Trillium Meds Pick the pharmacy, then the plan A pharmacy picker with its own table of plan totals under every pharmacy it lists. Read our review](https://thisglp.com/reviews/trillium-meds) - [ Trinity Meds One rate, every dose A flat monthly rate at every dose, printed beside a countdown and a promise of pricing for life. Read our review](https://thisglp.com/reviews/trinity-meds) - [ TRT Nation Three months, one rate One tirzepatide rate, fixed at every dose, sold in three-month blocks. Read our review](https://thisglp.com/reviews/trt-nation) - [ VitaFusions IV Texas only, any dose A Dallas IV practice selling two injectables across Texas, one price per drug at any dose. Read our review](https://thisglp.com/reviews/vitafusions-iv) - [ Vyora Wellness One rate through the dose ladder Two monthly figures, one per molecule, and a written promise that neither moves with the dose. Read our review](https://thisglp.com/reviews/vyora-wellness) - [ Vytora Health Same bill at every dose A monthly price that stays put as the dose climbs, with prescribing handled by a named Florida medical group. Read our review](https://thisglp.com/reviews/vytora-health) - [ WeightCare Four terms, one without commitment The monthly plan carries no commitment, and the longer tirzepatide terms cap the dose they cover. Read our review](https://thisglp.com/reviews/weightcare) - [ WeightlessRx Quarterly supply, charged after approval Every plan is a three-month supply, and the card is charged only after a clinician approves. Read our review](https://thisglp.com/reviews/weightlessrx) - [ WePeptideRx Priced by the dose tier The starting price is the first dose tier, and the monthly figure climbs with each step up the ladder. Read our review](https://thisglp.com/reviews/wepeptiderx) - [ Wisp Daily drops, untested in people A daily sublingual drop at $225 a month, which the seller says has not yet been tested in the human body. Read our review](https://thisglp.com/reviews/wisp) - [ Zealthy Membership plus medication The ranked figure adds a recurring membership to a medication rate bought three months at a time. Read our review](https://thisglp.com/reviews/zealthy) - [ Zeuss Sixty days at a time Two compounded injections sold as single 60-day purchases, with nothing renewed unless the buyer orders again. Read our review](https://thisglp.com/reviews/zeuss) - [ AHBARx Three supply lengths, no prescriber named Compounded semaglutide and tirzepatide in one, three and six-month supplies, with a physician founder named and no prescriber. Read our review](https://thisglp.com/reviews/ahbarx) - [ Always Wellness and Recovery Every stage priced upfront Three-month titration bundles priced stage by stage, and single-month vials priced by strength. Read our review](https://thisglp.com/reviews/always-wellness-and-recovery) - [ Andrew Meds Four plan lengths, month to month first Compounded semaglutide and tirzepatide at four plan lengths, prescribed through an independent medical practice the footer names. Read our review](https://thisglp.com/reviews/andrew-meds) - [ Arc-1 Priced by the milligram Compounded semaglutide and tirzepatide sold as dose-priced variants on a longevity storefront, with checkout before the intake. Read our review](https://thisglp.com/reviews/arc-1) - [ AskRx Brand-name only, fee itemized Brand-name Wegovy and Zepbound billed at pharmacy cost, plus a flat monthly care fee shown on its own line. Read our review](https://thisglp.com/reviews/ask-rx) - [ Avono Health Two programs, two flat rates Compounded semaglutide and tirzepatide at flat monthly rates across two dose programs, with the prescribing team and the pharmacies named. Read our review](https://thisglp.com/reviews/avono-health) - [ AZ Health Two tirzepatide figures One tirzepatide injection carries two monthly figures on the same page, and screening is a nurse practitioner phone call. Read our review](https://thisglp.com/reviews/az-health) - [ Better U Care A psychiatry clinic's GLP-1 line A mental-health telehealth practice whose checkout charges one monthly figure for compounded GLP-1s, medication and consultation together, at every dose. Read our review](https://thisglp.com/reviews/better-u-care) - [ Blis MD A price for every dose Each rung is a one-month vial, with the weekly dose it delivers printed beside the price. Read our review](https://thisglp.com/reviews/blis-md) - [ Bloom MD Flat semaglutide, laddered tirzepatide Semaglutide at one price for any dose; tirzepatide priced step by step, with each weekly dose printed. Read our review](https://thisglp.com/reviews/bloommd) - [ Boston Medical Group A men's clinic, one price per drug A men's health telemedicine brand selling compounded GLP-1s on a four-rung plan ladder, with the one-month plan selected by default. Read our review](https://thisglp.com/reviews/boston-medical-group) - [ Brightmeds Flat price, new starters only A flat price at any dose, stated to apply to patients who are new to GLP-1 treatment. Read our review](https://thisglp.com/reviews/brightmeds) - [ California Trim Clinic A named doctor, a discovery call A Westlake Village clinic that now treats by video, with its prices kept on a page of their own. Read our review](https://thisglp.com/reviews/california-trim-clinic) - [ Carocare Wellness Six doses, six prices A Houston clinic that prints the milligram dose beside every monthly price for the first six months. Read our review](https://thisglp.com/reviews/carocare-wellness) - [ Clinic Secret Month one is $100 off The bold figure is the first month. The struck figure beside it is every month after. Read our review](https://thisglp.com/reviews/clinic-secret) - [ Cora Health Named doctors, named pharmacies Every prescriber, both pharmacies and all four commitment terms are printed where a buyer can read them. Read our review](https://thisglp.com/reviews/cora-health) - [ Dr. Arevitalize A year-long bundle rate The injection figures are twelve-month bundle rates; the capsules are quoted month by month. Read our review](https://thisglp.com/reviews/dr-arevitalize) - [ Elevate Health Monthly first, discounts below The checkout starts on the monthly plan, and every cheaper line beneath it asks for months in advance. Read our review](https://thisglp.com/reviews/elevate-health) - [ ElitePhysiqMD A member rate plus a membership The headline is a member rate; the $89 monthly membership that unlocks it is priced separately. Read our review](https://thisglp.com/reviews/elitephysiqmd) - [ ElleS Doctors and pharmacies named Four monthly GLP-1 rates, two named physicians, four named pharmacies, and one price at every dose. Read our review](https://thisglp.com/reviews/elles) - [ Cielo Three numbers, one vial The asterisk on the home page card does the work most sites leave out. Read our review](https://thisglp.com/reviews/cielo) - [ CLYR Health Priced by the dose The charge rises with the dose, and every tier is published before the intake. Read our review](https://thisglp.com/reviews/clyr-health) - [ EOS Health The renewal rate, printed Each plan shows what it costs now and what it costs when it renews. Read our review](https://thisglp.com/reviews/eos) - [ FitFlow A year, in the page title The rate in the browser tab is the twelve-month plan paid upfront. Read our review](https://thisglp.com/reviews/fitflow) - [ FMmeds Two numbers, no ladder The whole pricing section is two figures and a pharmacy name. Read our review](https://thisglp.com/reviews/fmmeds) - [ Piper Renamed, pharmacies named The brand has changed; the company behind it and the prices have not. Read our review](https://thisglp.com/reviews/piper) - [ Science & Co Follow-up described, monthly quote unresolved Science & Co describes ongoing provider contact and dose adjustments, but its current headline prices require a twelve-month plan. Read our review](https://thisglp.com/reviews/science-and-co) - [ Shapely Insurance first, four states The membership and the medication are two separate charges, and the site says so. Read our review](https://thisglp.com/reviews/shapely) - [ SkyRx A year, priced as a month The asterisk on $199 resolves at the foot of the page, among the citations. Read our review](https://thisglp.com/reviews/skyrx) - [ TrueMe Pay first, intake after The product page says no intake form is required before payment. Read our review](https://thisglp.com/reviews/trueme) - [ Tryozi Half off, once The opening figure is the first four weeks, at half the standing rate. Read our review](https://thisglp.com/reviews/tryozi) - [ VevaRX One page, two prices The cards and the paragraph beneath them quote different numbers. Read our review](https://thisglp.com/reviews/vevarx) - [ Zappy Health A starter dose, for a quarter Its lowest-priced plan holds the starting dose for three months. Read our review](https://thisglp.com/reviews/zappy-health) - [ Care Clinics Same money, fewer weeks The price never moves as the dose climbs, because the number of weeks does instead. Read our review](https://thisglp.com/reviews/care-clinics) - [ CoraDoc A program, not a month There is no monthly option here, and the headline figure is half a year. Read our review](https://thisglp.com/reviews/coradoc) - [ Elara Health and Wellness Thirteen months, one charge Two figures sit on every card, and the lower one is a prepayment for thirteen months. Read our review](https://thisglp.com/reviews/elara-health-and-wellness) - [ Fifty 410 Three catalogs, three floors A page with three starting-at figures on it, only one of which is a GLP-1. Read our review](https://thisglp.com/reviews/fifty-410) - [ Joi + Blokes First month, then quarterly The card prints the introductory rate and the standing one in the same line. Read our review](https://thisglp.com/reviews/joi-and-blokes) - [ MyStart Health Frozen rate, four-week month The price is guaranteed never to rise, and the month it applies to is four weeks. Read our review](https://thisglp.com/reviews/mystart-health) - [ Nu Image Medical Four cards, four units Four products sit on one page, and the figure that draws the eye is a year bought at once. Read our review](https://thisglp.com/reviews/nu-image-medical) - [ Ondra Health A year in the title The rate in the page title is a year bought in a single payment. Read our review](https://thisglp.com/reviews/ondra-health) - [ Potere Health MD A vial, priced as a month The clinic sells a vial and then divides its price by three to reach a monthly figure. Read our review](https://thisglp.com/reviews/potere-health-md) - [ Primary Clinic (Direct GLP) Members-only wholesale rate The medication tables carry a condition printed across them: active members only. Read our review](https://thisglp.com/reviews/primary-clinic) - [ TRYM Health Priced by the day The menu leads to a daily rate, and the daily rate belongs to a twelve-month plan. Read our review](https://thisglp.com/reviews/trym-health) - [ Vita Bella The asterisk does the work The hero figure carries an asterisk, and the asterisk names two charges beside it. Read our review](https://thisglp.com/reviews/vita-bella) - [ Welling Health At cost, plus a membership The medication carries no markup, and the margin is charged as a separate track. Read our review](https://thisglp.com/reviews/welling-health) - [ Yucca Health Lifetime rate, six-month term A banner promises a rate for life, and the asterisk names the plan it belongs to. Read our review](https://thisglp.com/reviews/yucca-health) - [ Hello Alpha Approved drugs, unpriced Everything Alpha dispenses has an FDA approval behind it. Nothing it dispenses has a published cost. Read our review](https://thisglp.com/reviews/hello-alpha) - [ Ivim Health A membership, then a medicine Ivim charges for care and for the drug on separate lines, and says so on its own pricing page. Read our review](https://thisglp.com/reviews/ivim-health) - [ NuuVim One price per molecule, either form Injection and oral cost the same on each molecule, which is unusual. The seller states no membership and one price at any dose. Read our review](https://thisglp.com/reviews/nuuvim) - [ Believe Health One price for both drugs Tirzepatide and semaglutide cost the same to the dollar, at every dose. Read our review](https://thisglp.com/reviews/believe-health) - [ Big Easy Weight Loss Twelve weeks is not three months Dividing a twelve-week package by three understates every figure here, because twelve weeks is 2.76 calendar months. Read our review](https://thisglp.com/reviews/big-easy-weight-loss) - [ Bionomy Health Nothing renews by itself There is no subscription to cancel here, which matters more than it sounds when most people stop within a year. Read our review](https://thisglp.com/reviews/bionomy-health) - [ Bioverse Two anchors, two stories The struck-through figures imply a fifty-five percent cut on one line and eleven on the other, with nothing explaining either. Read our review](https://thisglp.com/reviews/bioverse) - [ Blue Haven RX It defines the unit, then mislabels it The card states that the rate buys four weeks and then advertises that same rate as a month, which are two different things the page itself distinguishes. Read our review](https://thisglp.com/reviews/blue-haven-rx) - [ Blue Sky MD A real rate behind an unpriced gate The weekly figures are stated plainly and neither can be reached without joining a program whose cost the practice declines to publish. Read our review](https://thisglp.com/reviews/blue-sky-md) - [ Bodi Envi Named care partners, restrictive returns Bodi Envi identifies Wasef Health for clinical care and VialsRx for dispensing. Its cancellation and replacement rules need attention before enrollment. Read our review](https://thisglp.com/reviews/bodi-envi) - [ boostAGErx Division dressed as a price Ninety-five dollars is three months paid at once, divided by three. No invoice ever reads that figure. Read our review](https://thisglp.com/reviews/boostagerx) - [ Society of You First months only, rate behind the intake Both injection cards lead with a first-month figure, and the standing rate is shown only after contact details are entered. Read our review](https://thisglp.com/reviews/society-of-you) - [ Edessa The homepage figure is a prepay The number on the front of the site is the six-month rate. A single month costs forty-four dollars more. Read our review](https://thisglp.com/reviews/edessa) - [ He & She MD A year up front, or a renewal Both injection rates are annual plans billed in a single payment, and the oral figure is an introductory rate that renews twenty percent higher. Read our review](https://thisglp.com/reviews/he-and-she-md) - [ MedLeanRx Almost nobody can buy it The pricing is reasonable and the catalog is sensible. Forty-nine states cannot reach either. Read our review](https://thisglp.com/reviews/medleanrx) - [ MEDVi One price, two memberships Only one of three lines publishes what the medicine costs; on the other two the figure on the card is the membership and the drug is unpriced. Read our review](https://thisglp.com/reviews/medvi) - [ Nolu All three fell, all per four weeks Every line came down a month apart, and every line is labeled per four weeks by the seller itself. Read our review](https://thisglp.com/reviews/nolu) - [ Recovery Delivered It tells you the bad news A seller that prints the expensive end of its own price ladder is telling you something about itself. Read our review](https://thisglp.com/reviews/recovery-delivered) - [ Roboclinic Advertised at the annual rate All three headline figures require a year committed, and buying by the month costs a hundred dollars more. Read our review](https://thisglp.com/reviews/roboclinic) - [ Try Ageless Two doors, two prices The same product carries one price in the shop and a different one in the plan funnel, and which is cheaper depends on the line. Read our review](https://thisglp.com/reviews/try-ageless) - [ Aspen One rate, either molecule Both molecules cost the same here, every dosage costs the same, and the vial carries an additive the trials never measured. Read our review](https://thisglp.com/reviews/aspen-health) - [ Aspire Health Vials by the week, fee by the month The vial is measured in weeks and the care fee in months, so neither published number is a month of treatment. Read our review](https://thisglp.com/reviews/aspire-health) - [ Auren Rx Two rates per molecule, both published Tirzepatide costs $80 a month more than semaglutide, and both commitment rates are published. Read our review](https://thisglp.com/reviews/auren-rx) - [ Balanced Hormone Health Sold by the milligram A package here is a quantity of drug rather than a length of time, so how long it lasts is decided by the dose a buyer titrates to. Read our review](https://thisglp.com/reviews/balanced-hormone-health) - [ Corsica Health The low rate is a block rate Both advertised figures sit inside a three-month plan paid in advance, and the monthly rate is printed beside each. Read our review](https://thisglp.com/reviews/corsica-health) - [ Pepton Health Two cards name no drug The two cheaper products are sold as GLP-1 without saying which one, and refill pricing needs an account. Read our review](https://thisglp.com/reviews/pepton-health) - [ Silhouette MD Tablets cost far more Both injections are advertised as a lowest tier. Both tablets cost substantially more and carry no such qualifier. Read our review](https://thisglp.com/reviews/silhouette-md) - [ Somi Health ANY DOSE, in capitals The seller states the flat-dose claim in its own capital letters, and prices its tablet at more than double the shot. Read our review](https://thisglp.com/reviews/somi-health) - [ VirtualCare2Go Supply picks the drug, and says so One card covers three different molecules and tells you outright that which one arrives depends on what is in stock — a disclosure almost nobody else in this market volunteers. Read our review](https://thisglp.com/reviews/virtualcare2go) - [ WeightWatchers Clinic A membership quoted as a range Every self-pay figure is footnoted to a separate membership the buyer cannot decline and whose price is given as a span rather than a number. Read our review](https://thisglp.com/reviews/weight-watchers) - [ Luci Priced from, and it says so Four figures, all of them asterisked. The seller's own note says the real monthly cost may be higher. Read our review](https://thisglp.com/reviews/luci) - [ Midi Health Every rung, with its milligram All four lines publish a complete dose ladder with the milligram beside each rung — and every table is a four-week supply rather than a month. Read our review](https://thisglp.com/reviews/midi-health) - [ Navio MD Tiered, with no tiers shown Two tirzepatide figures, one compounded and one branded. Both are floors, and the dose that earns either is never named. Read our review](https://thisglp.com/reviews/navio-md) - [ NowPatient Brand names, plus a duties line Four manufactured products priced by pack, each with a shipment-and-duties charge that sits in the buy box rather than the headline. Read our review](https://thisglp.com/reviews/nowpatient) - [ Pepti Thirteen fills a year Each fill runs 28 days, so a year carries thirteen charges rather than twelve. Read our review](https://thisglp.com/reviews/pepti) - [ Rivo Health Four figures, all on a seasonal sale Four flat figures, all of them attributed to a seasonal sale that was still running out of season. Read our review](https://thisglp.com/reviews/rivo-health) - [ TelePeptide Four terms, four lines, no dose Every line publishes a month-to-month figure and three commitment rates, each stated as covering the evaluation, the prescription, the medication and the shipping — and no figure anywhere states a dose. Read our review](https://thisglp.com/reviews/telepeptide) - [ TrimRx Sold by mechanism, not molecule The compounded tiles name a mechanism rather than a drug, the bundle prices have gone behind a quiz, and the first-month discount lands on the same figure as the standing rate. Read our review](https://thisglp.com/reviews/trimrx) - [ Tru2u Two molecules in one vial Flat pricing across four lines, plus a combined product that pairs both molecules for $275. Read our review](https://thisglp.com/reviews/tru2u) - [ Vitalex Health One price, either molecule One starting figure covers both molecules, and the site says the plan price is confirmed after provider review. Read our review](https://thisglp.com/reviews/vitalex-health) - [ VitaStir A kit, not a month The lowest listing covers one week, and the ladder above it climbs to nearly four hundred dollars. Read our review](https://thisglp.com/reviews/vitastir) - [ Voxy Headline is the annual tier The figure in the headline belongs to the twelve-month plan, and every other rung is published beside it. Read our review](https://thisglp.com/reviews/voxy) - [ VyrarX Entry tier, no ceiling Both figures are entry-tier, and maintenance-dose pricing is not disclosed. Read our review](https://thisglp.com/reviews/vyrarx) - [ Walgreens Weight Management A fill is twenty-eight days The pharmacy states each fill is a 28-day supply, which is thirteen fills a year rather than twelve. Read our review](https://thisglp.com/reviews/walgreens-weight-management) - [ WeightRx Tirzepatide is the cheap one Tirzepatide costs $83 and semaglutide costs $250, which reverses the usual order. Read our review](https://thisglp.com/reviews/weightrx) - [ Wellspring Longevity Clinic Two starting figures Both lines are described as personalized and both figures say starts at. Read our review](https://thisglp.com/reviews/wellspring-longevity-clinic) - [ Whoosh Wellness No charge until prescribed Nothing is billed unless a prescription is approved, and the prepay tabs print totals where monthly rates appear. Read our review](https://thisglp.com/reviews/whoosh-wellness) - [ Woodwork Forty-eight weeks in an asterisk The advertised figure carries an asterisk, and the asterisk says forty-eight weeks. Read our review](https://thisglp.com/reviews/woodwork) - [ YourHealthRx Flat, wide coverage One flat price regardless of dose, an oral option, and coverage in every jurisdiction. Read our review](https://thisglp.com/reviews/yourhealthrx) - [ Somira Health Locked as you titrate The price is stated as locked while the dose rises, on both plan lengths. Read our review](https://thisglp.com/reviews/somira-health) - [ StackMD Every rung on the page Five priced rungs on one molecule and six on the other, printed where a reader can find them before starting. Read our review](https://thisglp.com/reviews/stackmd) - [ Sumbare Wellness One price for three products A single from-price covers two molecules and a microdose plan, so it describes none of them in particular. Read our review](https://thisglp.com/reviews/sumbare-wellness) - [ Sunlight Same price forever, per fill A price-forever guarantee attached to a four-week fill rather than a calendar month. Read our review](https://thisglp.com/reviews/sunlight) - [ Superior Remedies One figure, no molecule The only number on screen names neither a drug nor a term, and the figures in the page data belong to a shared template. Read our review](https://thisglp.com/reviews/superior-remedies) - [ SurpassMD Three conditions on one figure The figure depends on eligibility, medication, dose and provider approval, all stated. Read our review](https://thisglp.com/reviews/surpassmd) - [ TeleCareSpot Consult fee, credited back A separate consult fee applies and is credited toward the package if the patient is approved. Read our review](https://thisglp.com/reviews/telecarespot) - [ TeleClinic Intro quarter, then the standard rate Each molecule starts on a discounted first quarter billed quarterly, and the standard monthly rate is stated beside it. Read our review](https://thisglp.com/reviews/teleclinic) - [ TeleHealth Weight Solutions Ten weeks, then refills The opening charge buys about ten weeks, and refills afterwards depend on vial size. Read our review](https://thisglp.com/reviews/telehealth-weight-solutions) - [ Telos Rx Longest plan, no monthly rate The advertised figures belong to the longest plan, and no monthly rate is published for either molecule. Read our review](https://thisglp.com/reviews/telos-rx) - [ The Edit A first-month price, once The first month is priced below the standing rate for a limited time, and only once. Read our review](https://thisglp.com/reviews/the-edit) - [ TMates Oral or injection, one price The format does not change the price, and every rung of the term ladder is published with its total. Read our review](https://thisglp.com/reviews/tmates) - [ Prime Health Four weeks, thirteen times The program ships four weeks at a time, which is one more charge a year than the figure implies. Read our review](https://thisglp.com/reviews/prime-health) - [ Regenics Membership renews every 28 days A required membership renews on a four-week clock, which is thirteen charges a year on top of the medication. Read our review](https://thisglp.com/reviews/regenics) - [ Rehydra+ Wellness Every dose tier priced Three dose tiers on each molecule, each with its own figure, and a separate price for buying without a subscription. Read our review](https://thisglp.com/reviews/rehydra-plus) - [ Rejuve Meds Most Affordable, prepaid The label says Most Affordable and the figure under it needs twelve months paid up front. Read our review](https://thisglp.com/reviews/rejuve-meds) - [ Remedy Meds Four-week fill, price behind a quiz A four-week fill billed monthly, and no figure a reader can see before the quiz. Read our review](https://thisglp.com/reviews/remedy-meds) - [ REMEVi Fifty-two weeks, not twelve months The advertised rates belong to a fifty-two week plan, and the site promises no titration hikes. Read our review](https://thisglp.com/reviews/remevi) - [ Remote Pharmacy Same figure, two meanings The same number appears on two of this seller's pages meaning two different things, so no rate can be established at all. Read our review](https://thisglp.com/reviews/remote-pharmacy) - [ Renlo Health Same figure at every dose Each dose tier is listed with the same price beside it, which is a stronger claim than the word flat. Read our review](https://thisglp.com/reviews/renlo-health) - [ RENN Health Homepage and drug page differ The homepage and the semaglutide page give different figures for the same product. Read our review](https://thisglp.com/reviews/renn-health) - [ RestorLife Med A blood test each quarter The figures are high and they include a quarterly blood test, which almost nothing else here does. Read our review](https://thisglp.com/reviews/restorlife-med) - [ Revel RX Low, flat, cold-shipped Two of the lowest flat figures published, with consultation and overnight cold shipping inside them. Read our review](https://thisglp.com/reviews/revel-rx) - [ Revive Meds No subscription, no posted price No subscription and no membership fee, and no price a reader can see before handing over an email. Read our review](https://thisglp.com/reviews/revive-meds) - [ Rewinding RX Fixed price, any dose A fixed figure at any dose, four strengths listed, and no membership. Read our review](https://thisglp.com/reviews/rewinding-rx) - [ Rex MD Brand pill, priced; pen, not The tablet is an approved brand product with a published figure. The injection is too, and its price belongs to someone else. Read our review](https://thisglp.com/reviews/rex-md) - [ NovoCare Pharmacy The manufacturer, direct This is the drug company selling its own approved product, and the month it quotes is twenty-eight days. Read our review](https://thisglp.com/reviews/novocare-pharmacy) - [ NuBloom Six doses, one price Six dose strengths are listed on the product page and every one of them costs the same. Read our review](https://thisglp.com/reviews/nubloom) - [ Nucore Health Floors, no membership Three figures, all floors, with no membership fee and health-account eligibility stated. Read our review](https://thisglp.com/reviews/nucore-health) - [ NuDay Rx Tablets cost more The semaglutide tablet matches the injection, and the tirzepatide tablet costs seventy dollars more. Read our review](https://thisglp.com/reviews/nuday-rx) - [ Obu Health Both pages agree The homepage card and the product tile print the same figure, which several sellers here cannot manage. Read our review](https://thisglp.com/reviews/obu-health) - [ Onyx Weight Loss The cheap card is another drug The ninety-nine dollar plan on the weight-loss page is a different medication entirely. Read our review](https://thisglp.com/reviews/onyx-weight-loss) - [ Open Water Rx Flat and all-inclusive Both figures are stated as flat monthly prices, and no code is needed to reach either. Read our review](https://thisglp.com/reviews/open-water-rx) - [ Options Medical Weight Loss No monthly rate exists The only semaglutide figure is a twelve-month plan paid in full, so no monthly rate exists to rank at all. Read our review](https://thisglp.com/reviews/options-medical-weight-loss) - [ Oria Meds Ships every three months The tirzepatide figure belongs to a six-month prepay, and the line ships quarterly rather than monthly. Read our review](https://thisglp.com/reviews/oria-meds) - [ Ozari Health A starter you can use once The lowest figure is a starter block for people new to GLP-1, and the full plan table sits behind it. Read our review](https://thisglp.com/reviews/ozari-health) - [ PepHaūs One line has two prices The semaglutide rungs are clear. The tirzepatide line carries two prices and nothing says which applies. Read our review](https://thisglp.com/reviews/pephaus) - [ PlexusDx Entry plan picks your drug The lowest figure is a microdose protocol where the provider chooses both the molecule and the route. Read our review](https://thisglp.com/reviews/plexusdx) - [ PrideRx Brand drugs, plus a membership Three approved products routed through the manufacturers' own channels, each with a required monthly membership beside it. Read our review](https://thisglp.com/reviews/priderx) - [ Prime Doctor RX Billed every four weeks The published figure is charged every four weeks, which is thirteen times a year rather than twelve. Read our review](https://thisglp.com/reviews/prime-doctor-rx) - [ LeanDose Month one, and then silence Both published figures are labeled first-month prices, and no ongoing rate appears anywhere. Read our review](https://thisglp.com/reviews/leandose) - [ LevelsRx Two floors, no ceiling Two starting prices on a seller whose cost rises with the dose, and no ceiling published. Read our review](https://thisglp.com/reviews/levelsrx) - [ LevelUp Rx Flat, with totals shown Every plan length is priced as a total, and the rate is stated flat across doses. Read our review](https://thisglp.com/reviews/levelup-rx) - [ Levers Health Priced by dose band Each advertised figure buys a capped weekly dose, and the next band up costs more. Read our review](https://thisglp.com/reviews/levers-health) - [ Liv Body A floor with an asterisk No membership and no contract, and an asterisk saying the real price depends on what is prescribed. Read our review](https://thisglp.com/reviews/liv-body) - [ Livea Medication plus a program fee The medication figure and the program fee live on different pages, and the site says the relationship between them is settled at a consultation. Read our review](https://thisglp.com/reviews/livea) - [ Longevixx Two flat rates, one menu Both prices sit on one treatment menu, flat across doses, with no anchor beside them. Read our review](https://thisglp.com/reviews/longevixx) - [ Luma Meds New patient and prepaid The headline figure requires being new and paying for three months, and a continuing patient on monthly billing pays half as much again. Read our review](https://thisglp.com/reviews/luma-meds) - [ Lumora Full pricing, after the form The site promises to show visit fees, medication, labs and follow-up before you commit, and publishes an amount for none of them. Read our review](https://thisglp.com/reviews/lumora) - [ LVNG RX Confirmed after review The card figures are stated to be confirmed after a provider review, which makes them provisional. Read our review](https://thisglp.com/reviews/lvng-rx) - [ MANÜ Telehealth Starter and full dose, priced Two plans per molecule, split by dose rather than by term, with both figures published. Read our review](https://thisglp.com/reviews/manu-telehealth) - [ MaxLife A starting price tied to a kit Both headline figures are asterisked to a Starter Kit Plan that the page never describes. Read our review](https://thisglp.com/reviews/maxlife) - [ MDExam Two pages, two prices The same product carries different figures on two of the seller's own pages, and only one of them is ever given a billing period. Read our review](https://thisglp.com/reviews/mdexam) - [ Fridays Two pages, two answers The pricing page and the treatment page give different annual rates for the same plan, and the discount figure needs a coupon. Read our review](https://thisglp.com/reviews/fridays) - [ Genesis Health Four rungs, both molecules Every commitment length is priced and every total is printed beside it. Read our review](https://thisglp.com/reviews/genesis) - [ Get Thin MD Sale price needs a term The sale figures apply to the first month of a three-month plan, not to a month bought alone. Read our review](https://thisglp.com/reviews/get-thin-md) - [ Glam Health Starting at, and little else Two floors are published with B12 formulations named. Almost nothing else is. Read our review](https://thisglp.com/reviews/glam-health) - [ Go Vida Plena Spanish-first, annual rung A Spanish-language program whose advertised figures are annual rungs, with installment plans offered on top. Read our review](https://thisglp.com/reviews/go-vida-plena) - [ Goldspan Health A month that is four weeks The word monthly appears beside a supply that arrives every four weeks, and the price is not on the seller's own site. Read our review](https://thisglp.com/reviews/goldspan-health) - [ Good Life Meds Same price at every dose One figure holds across every dose level, with no membership and no fees stated on top. Read our review](https://thisglp.com/reviews/good-life-meds) - [ Green Cap Health One state, low figures Two unusually low published figures, available in a single state. Read our review](https://thisglp.com/reviews/green-cap-health) - [ Harbor Bundled, and a floor Each plan states what it covers. Each figure carries the words as low as. Read our review](https://thisglp.com/reviews/harbor) - [ Harmony Wellness Clinic Every dose tier printed Five priced levels on one molecule and six on the other, printed on the services page rather than discovered later. Read our review](https://thisglp.com/reviews/harmony-wellness-clinic) - [ Healthicare An itemized monthly charge Two injections at low monthly rates, with the charge broken into its parts and a three-month plan beside it. Read our review](https://thisglp.com/reviews/healthicare) - [ Concierge MD LA Membership is the price The monthly figure is a membership that includes the medication, and the page disagrees with itself about how often it ships. Read our review](https://thisglp.com/reviews/concierge-md-la) - [ Contour Health Provider continuity, pay by vial Contour Health offers a free video consultation, continued access to the same provider and medication ordered by vial rather than automatic monthly refills. Read our review](https://thisglp.com/reviews/contour-health) - [ DadVantage Men's Health Blocks of weeks, plus fees Nothing here is sold by the month, and two charges sit outside whichever block a buyer picks. Read our review](https://thisglp.com/reviews/dadvantage-mens-health) - [ DrBrainRx A price plus a required fee A single medication price per molecule, and a required monthly care fee that sits outside it. Read our review](https://thisglp.com/reviews/drbrainrx) - [ DreamHug Medical A floor, not a rate Both figures are the longest-plan tier. The one-month rate is higher and is not published. Read our review](https://thisglp.com/reviews/dreamhug-medical) - [ DudeMeds Monthly rate behind a commit kit Each lower figure is a commitment kit that strikes the month-to-month rate through beside it. Read our review](https://thisglp.com/reviews/dudemeds) - [ EdgeRx Names the pharmacy, not selling A seller that names who compounds its medication also says its protocols are not currently available to buy. Read our review](https://thisglp.com/reviews/edgerx) - [ Effecty Four plan lengths, one ladder Semaglutide is sold at four plan lengths. Monthly billing is the dearest rung. Read our review](https://thisglp.com/reviews/effecty) - [ Elevated Health Every rung published Four plan lengths on each molecule, with every figure printed rather than revealed at checkout. Read our review](https://thisglp.com/reviews/elevated-health) - [ AquaVita NextGen Two one-month prices Each molecule is sold as a one-month supply at a single published price, with no dose named beside it. Read our review](https://thisglp.com/reviews/aquavita-nextgen) - [ ARSYNL Rx A price that has already moved One of these figures has already moved once, which makes either worth confirming on the day. Read our review](https://thisglp.com/reviews/arsynl-rx) - [ Ascend Medical A price with no period Two package prices are published and neither states what period they cover. Read our review](https://thisglp.com/reviews/ascend-medical) - [ Bon Health Four terms, fifty states Four term lengths are published for each molecule, and the coverage list runs to every state. Read our review](https://thisglp.com/reviews/bon-health) - [ Brello Health A month that is eleven weeks The card advertises a monthly figure. Renewals bill every eleven weeks, not every three months. Read our review](https://thisglp.com/reviews/brello-health) - [ Candor Rx Flat at every dose The promise of a rate that never moves with the dose is the rare kind worth wanting, and both molecules carry it. Read our review](https://thisglp.com/reviews/candor-rx) - [ Citizen Meds Says the price climbs The entry figure is stated, and so is the fact that it rises with the dose. Most sellers state only the first half. Read our review](https://thisglp.com/reviews/citizen-meds) - [ Clume Health One price, two molecules Both molecules carry one monthly figure, and the lower advertised figure requires a twelve-week prepaid term. Read our review](https://thisglp.com/reviews/clume-health) - [ Coivas A figure and little else One monthly number is published. Almost nothing surrounding it is. Read our review](https://thisglp.com/reviews/coivas) - [ Curex Oral only, wide coverage An oral line at $199 across forty-five states, with no injection offered at any price. Read our review](https://thisglp.com/reviews/curex) - [ Actin Three cadences, one page Every commitment length is printed on the product page, but the help center says the dose can move the cost. Read our review](https://thisglp.com/reviews/actin) - [ AgelessRx Coupon built into the start price The $139 semaglutide figure already has a first-term coupon applied; the same option reads $239 without it. Read our review](https://thisglp.com/reviews/agelessrx) - [ AlyveRx Two routes for tirzepatide Tirzepatide comes as an injection and as needle-free sublingual drops, and the two are priced as different products. Read our review](https://thisglp.com/reviews/alyverx) - [ CeliaRx Monthly figure, single charge The per-month figure is arithmetic on a four-month vial. The charge is the whole vial, once. Read our review](https://thisglp.com/reviews/celia-rx) - [ HealthSource Four-week billing, pharmacy named Every figure is quoted per four weeks rather than per month, and the dispensing pharmacy type is stated. Read our review](https://thisglp.com/reviews/healthsource) - [ LifeMD Program fee sits outside Each published figure is medication only, with a $149 monthly program fee charged alongside it. Read our review](https://thisglp.com/reviews/lifemd) - [ NEUVÉ Health Site disagrees with itself Whether the medication is inside the program fee depends on which part of the page you read. Read our review](https://thisglp.com/reviews/neuve-md) - [ NoBsRx Low-dose programs, flat rate Every program is named low-dose, and all three twelve-week blocks cost the same regardless of molecule. Read our review](https://thisglp.com/reviews/no-bs-rx) - [ BetterMe Rx Sale-dependent headline The advertised rate holds while a sitewide sale runs, and the pricing page carries no notice of what happens when it stops. Read our review](https://thisglp.com/reviews/betterme-rx) - [ FORM No medication price anywhere Four lines, four published figures, and not one of them is the price of a medication. Read our review](https://thisglp.com/reviews/form) - [ GobyMeds One month, any dosage A one-month price at any dosage, beside a starter bundle with its inclusions spelled out. Read our review](https://thisglp.com/reviews/gobymeds) - [ Good Girl Rx The headline is a year, paid up front Each "from" figure is the twelve-month rung of a prepaid plan, and the one-month rate sits on the same selector. Read our review](https://thisglp.com/reviews/good-girl-rx) - [ Hers Membership you cannot decline Every medication price here is missing $149, and Hers states plainly that the membership behind it is not optional. Read our review](https://thisglp.com/reviews/hers) - [ June Health Ladders published in full Each line publishes its whole tier structure, and the milligram doses are stated on the oral ones. Read our review](https://thisglp.com/reviews/june-health) - [ Kin Meds Three molecules, one checkable One figure can be checked against a manufacturer's own published price. Two cannot, and sit at about half cash-pay. Read our review](https://thisglp.com/reviews/kin-meds) - [ MadeMed Headline is the longer term The advertised figure belongs to the six-month plan, and every line publishes the shorter term's rate beside it. Read our review](https://thisglp.com/reviews/mademed) - [ Alan Meds Six-month prepay floors Full-dose lines priced as six-month prepayments, beside cheaper microdosing lines. Read our review](https://thisglp.com/reviews/alan-meds) - [ DoctorAdam The tablet never costs more Semaglutide costs the same in either form, and the tirzepatide tablet costs less than its injection. Read our review](https://thisglp.com/reviews/doctoradam) - [ Nova Two states, care fee inside Every figure includes a required care fee, and each oral is priced below its injection. Read our review](https://thisglp.com/reviews/nova) - [ PreventiveMD Three molecules, not two It carries orforglipron alongside the usual pair, and its lowest figures are twelve-month plans paid up front. Read our review](https://thisglp.com/reviews/preventivemd) - [ Revel Health Oral is the cheaper route The tablet undercuts the injection on both molecules, which is the reverse of the usual order. Read our review](https://thisglp.com/reviews/revel-health) - [ Wholesome Clinic Publishes the whole ladder Four products, each with its dose ladder printed rather than a single opening figure. Read our review](https://thisglp.com/reviews/wholesome-clinic) - [ Zera Health Standing rates behind a first-month offer Each product page leads with a first-month figure and prints the monthly rate that follows it. Read our review](https://thisglp.com/reviews/zera-health) - [ Breeze Meds Four rates, fifty states Semaglutide starts at $199 by injection, and the oral tablet is priced above it rather than below. Read our review](https://thisglp.com/reviews/breeze-meds) - [ Care Bare Rx Same price, both molecules Semaglutide and tirzepatide cost the same $199 here. That is unusual. Read our review](https://thisglp.com/reviews/care-bare-rx) - [ Synergy Rx All four rates published Both molecules are priced in both forms, which most sellers in this category do not do. Read our review](https://thisglp.com/reviews/synergy-rx) - [ Apex MD Additives inside the price The weekly injection is sold with three additives, and what those additives do was not measured in the trials behind the drug. Read our review](https://thisglp.com/reviews/apex-md) - [ AVARA Rx Lower rate needs a code The lower tirzepatide figure requires a discount code, which makes it a condition rather than a standing rate. Read our review](https://thisglp.com/reviews/avara-rx) - [ Bayan Health Same price, two routes An injection and an oral drop carry the same monthly figure here, which is the reverse of the usual pattern. Read our review](https://thisglp.com/reviews/bayan-health) - [ EverSlim Visit inside the price The monthly figure covers the medication, the provider visit and the shipping, and it does not move as the dose does. Read our review](https://thisglp.com/reviews/everslim) - [ Fidelity Medical Clinic Four doses, four weeks Each order buys four doses over four weeks, so thirteen of them land in a calendar year. Read our review](https://thisglp.com/reviews/fidelity-medical-clinic) - [ Harper Meds All-inclusive, four-week fill One charge covers the consultation, the prescription and the shipping, and the fill it buys runs four weeks rather than a calendar month. Read our review](https://thisglp.com/reviews/harper-meds) - [ Idgie Health Seller names the off-label part This seller calls its own microdosing approach off-label on the page that sells it, which few in this category do. Read our review](https://thisglp.com/reviews/idgie-health) - [ KERNX Health Consult fee, three tiers The consultation is priced as three named tiers and is charged only when treatment is approved. Read our review](https://thisglp.com/reviews/kernx-health) - [ Liberty 503B facility named as source The preparation is sourced from a 503B outsourcing facility, which is a different regulatory category from a retail compounding pharmacy. Read our review](https://thisglp.com/reviews/liberty) - [ NextMeds The membership is the product The membership here is the product rather than a fee charged beside one, and it bundles four services. Read our review](https://thisglp.com/reviews/nextmeds) - [ Pallas Health Billed every twelve weeks The monthly figure is an average the seller publishes itself: one discounted first month, then a charge every twelve weeks. Read our review](https://thisglp.com/reviews/pallas-health) - [ PlushCare Starting dose only at $149 The advertised cash-pay figure buys the 0.25 mg starting dose, and every maintenance dose is priced above it. Read our review](https://thisglp.com/reviews/plushcare) - [ Alloy Medication plus required fee Every figure at this seller is a medication rate plus a $99 monthly care fee charged alongside it. Read our review](https://thisglp.com/reviews/alloy) - [ Lean Meds Care described, price unresolved Leanmeds describes clinician review and coaching, but its current starting offer does not identify a separate price for each molecule. Read our review](https://thisglp.com/reviews/leanmeds) - [ Maximus Branded and compounded priced together Compounded preparations and the manufacturers' pens are listed side by side on this seller's plans. Read our review](https://thisglp.com/reviews/maximus-tribe) - [ Trimi Health Annual plan, billed up front Both monthly figures here are an annual plan divided by twelve, charged in a single payment at the start. Read our review](https://thisglp.com/reviews/trimi-health) - [ Rx.com Six months in the headline The figure set in the largest type is a six-month plan charged once. Read our review](https://thisglp.com/reviews/rx-com) - [ NexLife A year behind the headline The rate set in the largest type belongs to a year-long plan, and the asterisk beside it says so. Read our review](https://thisglp.com/reviews/nexlife) - [ RxPros Two rates, neither monthly One advertised figure needs a year paid ahead, and the other is a first-month discount. Read our review](https://thisglp.com/reviews/rxpros) - [ HeliMeds Twelve weeks called three months Every plan runs twelve weeks, and every monthly figure beside one divides by three. Read our review](https://thisglp.com/reviews/helimeds) - [ MultiMedRx A consultation fee, not a price The single published figure is a refundable consultation fee, and the medication is billed elsewhere. Read our review](https://thisglp.com/reviews/multimedrx) - [ Framework Quoted weekly, paid monthly A figure quoted by the week reads cheaper than the same money quoted by the month. Read our review](https://thisglp.com/reviews/framework) - [ Calibrate Health Two charges, only one certain The program fee is fixed and published; the medication figure beside it depends on an insurance plan. Read our review](https://thisglp.com/reviews/calibrate-health) - [ RxPepsDirect Priced by the vial, billed by the order The vial price is the smaller half of what an order costs, because a visit fee lands on every one. Read our review](https://thisglp.com/reviews/rxpepsdirect) - [ Noom Three clocks in one footnote The intro runs three weeks, the medication four, and the recurring charge answers to twelve. Read our review](https://thisglp.com/reviews/noom) - [ Injectco A subscription beside a package A monthly subscription for each molecule, beside long packages quoted only at the starting dose. Read our review](https://thisglp.com/reviews/injectco) - [ Rivas Medical Weight Loss A weekly appointment, or telehealth The clinic gives the injection on site every seven days, and a telehealth program prices the same drugs by the month. Read our review](https://thisglp.com/reviews/rivas-medical) - [ Queen RX One quarterly product There is no monthly plan to choose, because the catalog holds a single quarterly one. Read our review](https://thisglp.com/reviews/queen-rx) - [ Alegro Health A starter with no sequel The figure buys eight weeks outright, and the page stops before saying what week nine costs. Read our review](https://thisglp.com/reviews/alegro-health) - [ LaSara Medical Group A ladder paid at the top Each step down the price ladder is bought with the whole term's money at the start. Read our review](https://thisglp.com/reviews/lasara) - [ Ivologist A term shorter than its label The paid-in-full plan runs eleven weeks and is priced as though a quarter had gone by. Read our review](https://thisglp.com/reviews/ivologist) - [ Ascend Vitality One panel, two molecules The tirzepatide tablets page prints the semaglutide price panel. Read our review](https://thisglp.com/reviews/ascend-vitality) - [ OnlyRx A sale at list price The promotional banner offers the price the product card already charges. Read our review](https://thisglp.com/reviews/onlyrx) - [ Vital Edge Capsule undercuts the shot The daily capsule costs $151 less a month than the weekly injection. Read our review](https://thisglp.com/reviews/vital-edge) - [ Näky A panel hides the monthly The rate on each injection card is the six-month plan, not the monthly one. Read our review](https://thisglp.com/reviews/naky) - [ Rixa Health Every dose has its own price The price rises at each dose level, and the ladder is published in full. Read our review](https://thisglp.com/reviews/rixa-health) - [ VigorMeds The needle is the premium Taking it under the tongue costs less here than taking it by injection. Read our review](https://thisglp.com/reviews/vigormeds) - [ MediRX Two grids, one homepage The same two products are priced twice on one page, at different rates. Read our review](https://thisglp.com/reviews/medirx) - [ Claya Tile and product page differ The homepage advertises one semaglutide rate and the product page charges another. Read our review](https://thisglp.com/reviews/claya) - [ HealthHub The tile overstates the price The homepage tile quotes more than the injection behind it actually costs. Read our review](https://thisglp.com/reviews/healthhub) - [ Vaylen Priced only by the year Every figure on the page is a twelve-month program paid upfront. Read our review](https://thisglp.com/reviews/vaylen) - [ Center for Medical Weight Loss (CMWL) The page picks the longer plan Both product pages open with the three-month plan already chosen. Read our review](https://thisglp.com/reviews/center-for-medical-weight-loss) - [ Alternate Health Club A month, or twenty-eight days The rate reads per month and the vial is stated to cover twenty-eight days. Read our review](https://thisglp.com/reviews/alternate-health-club) - [ Amble Flat at every dose, three terms Two compounded lines, three plan lengths each, and one rate that holds at every dose. Read our review](https://thisglp.com/reviews/amble) - [ Eloria The refill doubles it The headline rate covers a first month, and the figure that follows it lives only in the FAQ. Read our review](https://thisglp.com/reviews/eloria) - [ Kina Named clinic, four routes One population, four delivery routes, and the clinical provider named with a street address. Read our review](https://thisglp.com/reviews/kina) - [ LumiMeds Labeled product, unlabeled term The ingredient, route and pharmacy type are all stated; the plan behind the price is not. Read our review](https://thisglp.com/reviews/lumimeds) - [ Mochi Health Every dose priced in milligrams The full dose ladder is published in milligrams, and the care fee is billed separately from it. Read our review](https://thisglp.com/reviews/mochi-health) - [ Mondae Cheap, and short on detail Among the lowest published compounded rates here, on pages that state very little else. Read our review](https://thisglp.com/reviews/mondae) - [ NativeMed A prepay that saves nothing Two compounded injections, priced monthly, with a three-month plan that costs the same per month. Read our review](https://thisglp.com/reviews/nativemed) - [ Nova MD The long plan is preselected Four plan lengths per drug, with the twelve-month prepay already chosen when the page loads. Read our review](https://thisglp.com/reviews/nova-md) - [ Omzo A catalog still being built Two GLP-1 rates are published, and four of the six advertised categories are not open yet. Read our review](https://thisglp.com/reviews/omzo) - [ ReflexMD Priced on the front page Three products, three flat rates, and one of them never says what is in it. Read our review](https://thisglp.com/reviews/reflexmd) - [ Spry Four weeks, not a month Two GLP-1 rates on the front page, billed on a four-week cycle the cards never mention. Read our review](https://thisglp.com/reviews/spry) - [ T2D.com Two doors, one priced by dose One price includes the prescriber; a second, lower one is for buyers who already have a prescription. Read our review](https://thisglp.com/reviews/t2d) - [ Transparent Meds Six programs, one row Two GLP-1 lines priced beside four peptide programs, each card carrying its own pair of figures. Read our review](https://thisglp.com/reviews/transparent-meds) - [ Tuyo Health Compounded beside brand Two columns, compounded against brand-name, with the membership fee attached to only one of them. Read our review](https://thisglp.com/reviews/tuyo-health) - [ 10Rx Quarterly care needs an exit plan 10Rx advertises a quarterly package that holds its price across available strengths. Its terms make the selected subscription period and prescription stage important when stopping treatment. Read our review](https://thisglp.com/reviews/10rx) - [ Ambiante Health & Wellness Women-focused concierge platform Ambiante combines metabolic, longevity and aesthetic marketing with independent clinician access. Its semaglutide page and terms give different cancellation notice periods. Read our review](https://thisglp.com/reviews/ambiante-health-wellness) - [ Aurelius Health Group A microdose-focused proposition Aurelius markets clinician-monitored, compounded tirzepatide microdosing. Its promised check-ins are distinct from the evidence needed to support its broader wellness claims. Read our review](https://thisglp.com/reviews/aurelius-health-group) - [ AVArx Named clinical organization AVArx identifies Arora Health & Aesthetics as its clinical organization and describes real-time visits when state rules require them. Read our review](https://thisglp.com/reviews/avarx) - [ Basal Health Separate microdose and weight care Basal’s GLP-One offers clinician-prescribed compounded tirzepatide in microdose and weight-loss plans. Those programs should be assessed separately rather than treated as interchangeable. Read our review](https://thisglp.com/reviews/basal-health) - [ Better MedSpa Better Med Spa offers supervised semaglutide and tirzepatide care in Chicago, with Illinois telehealth described. Its aesthetic memberships are a separate financial decision. Read our review](https://thisglp.com/reviews/better-medspa) - [ Broose Wellness Oral and injectable products separated Broose separates oral semaglutide, injectable semaglutide and tirzepatide. The follow-up plan needs to fit the supply term. Read our review](https://thisglp.com/reviews/broose-wellness) - [ CAPO Health Pharmacy partner identified CAPO identifies The Pharmacy Hub and describes monthly check-ins. Confirm the medical practice responsible for the prescription. Read our review](https://thisglp.com/reviews/capo-health) - [ Chia Ingredients and compounded status disclosed Chia combines weight-loss prescribing with a wider longevity menu. A focused care plan matters more than adding extra protocols. Read our review](https://thisglp.com/reviews/chia-health) - [ Chronos Body Health & Wellness Chronos offers in-person weight care in Metairie and telehealth pathways for Louisiana and Texas. Its GLP-1 pages explain individual assessment and optional compounded treatment. Read our review](https://thisglp.com/reviews/chronos-bhw) - [ CVS MinuteClinic CVS MinuteClinic offers a $29 online GLP-1 eligibility consultation with later medication support. The first assessment, ongoing visits and pharmacy purchase are separate decisions. Read our review](https://thisglp.com/reviews/cvs-minuteclinic) - [ Elara MD Ask for the actual ingredient Elara MD publishes dose-linked prices for personalized GLP-1 products, but generic product labels leave the exact medicine and a conflicting starting-price claim unresolved. Read our review](https://thisglp.com/reviews/elara-md) - [ Enhanced Enhanced now lists clinician-guided semaglutide and tirzepatide within its Weight Rx pathway. Prescription assessment and the supplement storefront are different services. Read our review](https://thisglp.com/reviews/enhanced) - [ EverFit Medical Clinic and telehealth routes EverFit combines an Ohio clinic with online weight-management evaluation. Its public program names semaglutide and tirzepatide, with treatment conditional on a clinician’s assessment. Read our review](https://thisglp.com/reviews/everfit-medical) - [ Evergreen Telehealth Named medical partner, renewal cutoff Evergreen Lean describes continuing GLP-1 care through a team, while the terms name NVP Medical Group and impose a seven-day cancellation deadline. Read our review](https://thisglp.com/reviews/evergreen-telehealth) - [ Evernow Evernow places GLP-1 assessment within menopause-focused care, with membership or individual visits. Medication costs and suitability remain separate from access to the care team. Read our review](https://thisglp.com/reviews/evernow) - [ FeelGood Support is not the prescriber FeelGood offers compounded weight-care products and branded options through independent medical groups. Its round-the-clock support claim should be separated from access to the clinician managing treatment. Read our review](https://thisglp.com/reviews/feelgood-meds) - [ Florida Weight Loss MD Florida evaluation before prescribing Florida Weight Loss MD presents care through Florida Surgery & Weight Loss Center, with separate branded-drug and compounded-treatment pathways. Read our review](https://thisglp.com/reviews/florida-weight-loss-md) - [ Found Youth Physician-guided, flat-dose claim Found Youth describes weekly compounded GLP-1 programs with provider-directed adjustments. Its editorial guide is more informative than the storefront’s broad price ranges. Read our review](https://thisglp.com/reviews/found-youth) - [ FuturHealth Branded care with nutrition tools FuturHealth brings clinical prescribing and nutrition tools together. Before enrolling, distinguish ongoing clinical follow-up from the app’s everyday food and activity features. Read our review](https://thisglp.com/reviews/futurhealth) - [ Genesis Lifestyle Medicine Genesis Lifestyle Medicine combines weight-management assessment, laboratory review and adjustable follow-up. Its brand-name and compounded pathways need separate pharmacy and cost checks. Read our review](https://thisglp.com/reviews/genesis-lifestyle-medicine) - [ Gide Health Provider-network partner identified Gide identifies a provider-network partner, while its broad GLP-1 labels leave the exact ingredient and formulation unclear. Read our review](https://thisglp.com/reviews/gide-health) - [ Glow AI coaching and prescription care Glow combines an AI-led diet service with a separate clinician-reviewed prescription program. Medical decisions and pharmacy responsibilities need to remain clear. Read our review](https://thisglp.com/reviews/glow) - [ GOAL.MD Physician care and nutrition support Physician supervision, nutrition coaching and a phone-accessible team are included. The question is how that support translates into your own follow-up plan. Read our review](https://thisglp.com/reviews/goal-md) - [ GoodLife Health Metabolic care with included labs GoodLife puts repeated lab review and cardiometabolic care ahead of a medicine-only offer. The monthly membership and the pharmacy prescription remain separate. Read our review](https://thisglp.com/reviews/goodlife-health) - [ Happy Care Meds Clinical platform named in the terms Happy Care Meds identifies a clinical-service platform and offers weekly compounded weight-loss protocols. Read our review](https://thisglp.com/reviews/happy-care-meds) - [ HealFastRx Care bundle with upfront options HealFastRx includes supplies, clinical care and shipping in its compounded injection offer, with separate introductory, monthly and prepaid prices. Read our review](https://thisglp.com/reviews/healfast) - [ Helix Wellness Rx Concierge claims, conflicting notice periods Helix Wellness Rx describes direct clinician messaging and flat-rate semaglutide care. Its public pages disagree about how much cancellation notice is required. Read our review](https://thisglp.com/reviews/helix-wellness-rx) - [ Hone Health Hone Health combines biomarker testing and physician visits with a separate medication bill. Its listed GLP-1 option is compounded liraglutide, within a broader hormone and longevity service. Read our review](https://thisglp.com/reviews/hone-health) - [ Hormonally Balanced Hormonally Balanced lists a monthly tirzepatide program with a physician-assistant consultation, medication delivery and coach check-ins. Pharmacy and stopping terms need clarification. Read our review](https://thisglp.com/reviews/hormonally-balanced) - [ KairoRx Clinical messaging versus AI advice KairoRx offers clinician-reviewed weight treatment and a separate AI health-advisor feature. Its branded-drug access fees are distinct from the medication bill. Read our review](https://thisglp.com/reviews/kairorx) - [ KIN Health Bundled support, formulation questions KIN advertises a single price including medication, provider care and messaging. Its GLP-1 menu groups several formulations without fully defining every drug-and-form option. Read our review](https://thisglp.com/reviews/kin-health) - [ Klarity Health Klarity Health offers a choice of independent weight-loss clinicians, insurance or self-pay visits and medication assessment. Continuity depends on the particular practice selected. Read our review](https://thisglp.com/reviews/klarity-health) - [ Klinic Klinic connects patients with independent medical practices for weight-management assessment. Consultation fees, prescription costs and insurer access are separate decisions. Read our review](https://thisglp.com/reviews/klinic) - [ Kova Care tracking with contract commitments Kova combines clinician-reviewed treatment with an app for tracking progress. Its plan billing can continue independently of refill and review timing. Read our review](https://thisglp.com/reviews/kova) - [ LifeVine Wellness Nurse-founded platform, independent care LifeVine’s nurse-founded identity sits alongside a clear legal distinction: independent medical groups provide treatment. Renewal charges may be processed early. Read our review](https://thisglp.com/reviews/lifevine-wellness) - [ Livbetr Clinical network identified A care coach and AI-assisted check-ins accompany clinician-reviewed treatment. Ask which contacts involve the prescriber. Read our review](https://thisglp.com/reviews/livbetr) - [ Longevity Meds A readable screening route Longevity Meds names compounded semaglutide and tirzepatide, lists available strengths and describes care-team support. Its public screening shows the information requested before evaluation. Read our review](https://thisglp.com/reviews/longevity-meds) - [ Loozy Three-month care membership Loozy’s approachable storefront describes asynchronous support, while its terms establish a prepaid three-month telehealth membership. Read our review](https://thisglp.com/reviews/loozy) - [ Male Excel Male Excel includes GLP-1 options within a broader men’s hormone and metabolic program. Regular provider reviews are described, while the drug-specific costs need clarification. Read our review](https://thisglp.com/reviews/male-excel) - [ MangoRx MangoRx offers Slim, a compounded semaglutide dissolving tablet. Its clinical process, pharmacy terms and formulation deserve separate consideration from the low starting price. Read our review](https://thisglp.com/reviews/mangorx) - [ MD Trim Clinic MD Trim Clinic offers physician-directed semaglutide and tirzepatide assessment with a free screening call. Its dose-based payment model and dispensing details need a direct conversation. Read our review](https://thisglp.com/reviews/md-trim-clinic) - [ MDLive MDLIVE offers anti-obesity prescriptions through eligible Primary Care Routine Care visits. Its urgent-care service and wellness screening are different pathways. Read our review](https://thisglp.com/reviews/mdlive) - [ MD Total Wellness MD Total Wellness offers in-office GLP-1 care in Brea, California, with monthly visits, body-composition tracking and direct clinical messaging in its published package. Read our review](https://thisglp.com/reviews/mdtw) - [ Medical Health Institute Medical Health Institute describes laboratory-guided GLP-1 care and ongoing monitoring. Its general program page leaves the exact medicine, pharmacy and complete cost to assessment. Read our review](https://thisglp.com/reviews/medical-health-institute) - [ Medivive AI intake, clinician decisions Medivive starts with an AI conversation, then assigns prescribing decisions to TrueEval Medical Group. The weight program describes 30-day monitoring. Read our review](https://thisglp.com/reviews/medivive) - [ MEDVidi Video visits, separate pharmacy access MEDvidi offers scheduled online assessment and follow-up, with a weight-care page naming branded GLP-1 options. It is not a bundled medication storefront. Read our review](https://thisglp.com/reviews/medvidi) - [ Meli Health Named care and pharmacy partners Meli identifies an independent clinician network and a dispensing pharmacy for its compounded weight-care service. The platform itself does not practice medicine. Read our review](https://thisglp.com/reviews/meli-health) - [ Metabolic Rx Direct care, conflicting stop rules Metabolic Rx describes provider check-ins and direct messaging for compounded weight care. Its product FAQ and general terms give different cancellation notice periods. Read our review](https://thisglp.com/reviews/metabolic-rx) - [ Metabolyz Coaching alongside prescribing Metabolyz combines clinician review with nutrition, movement and lifestyle coaching, but keeps program prices inside consultation. Read our review](https://thisglp.com/reviews/metabolyz) - [ Mixx Health & Wellness Mixx Health & Wellness identifies a medical director and pharmacy for its compounded GLP-1/GIP pathway. Confirm the actual ingredient, prescription and cancellation conditions. Read our review](https://thisglp.com/reviews/mixx-health-and-wellness) - [ Modern Age Modern Age describes assessment-led weight management with a six-month support program and separate medication costs. Clarify current availability and the proposed prescription first. Read our review](https://thisglp.com/reviews/modern-age) - [ Novera MD Biomarker-led marketing, network care Novera MD promotes testing and ongoing optimization, while its terms identify independent providers affiliated with WizDoc as the clinical decision-makers. Read our review](https://thisglp.com/reviews/novera-md) - [ Nuform Health Assigned team, multi-month kits Nuform describes an assigned provider and follow-ups every four weeks. Its multi-month kits make a slower dose increase or early treatment change worth discussing first. Read our review](https://thisglp.com/reviews/nuform-health) - [ Nurx Ongoing care, separate pharmacy Nurx offers a licensed-provider relationship and ongoing messaging. Injectable medication fulfillment is separate from its familiar home-delivery model. Read our review](https://thisglp.com/reviews/nurx) - [ Olleve Care Visits and pharmacy choice Olleve Care offers scheduled virtual consultations and names semaglutide and tirzepatide as possible treatment options. Prescriptions can go to a preferred pharmacy when appropriate. Read our review](https://thisglp.com/reviews/ollevecare) - [ Omada Health Omada pairs GLP-1 support with behavior change, coaching and selected prescribing through a provider partner. The exact employer or health-plan benefit determines access. Read our review](https://thisglp.com/reviews/omada-health) - [ Prescriva Standard and microdose categories separated Prescriva separates standard weight-loss treatment from low-dose longevity programs and describes ongoing provider support. Read our review](https://thisglp.com/reviews/prescriva) - [ PrescrYbe Clinical partners behind the platform PrescrYbe offers online GLP-1 assessment through independent clinical partners. Its program page and general terms describe recurring billing differently. Read our review](https://thisglp.com/reviews/prescrybe) - [ PRIMO Health Partners Weight care within broader telehealth PRIMO offers online weight-loss plans alongside virtual primary and urgent care. Its semaglutide page describes monitoring but leaves the plan price and visit cadence unspecified. Read our review](https://thisglp.com/reviews/primo-health-partners) - [ Push Health Push Health connects patients with independent prescribers and sends approved prescriptions to a chosen pharmacy. Its GLP-1 pathway is not an all-inclusive medication subscription. Read our review](https://thisglp.com/reviews/push-health) - [ Ravia Health Psychiatry and partner-delivered weight care Ravia’s Florida psychiatric practice and its Lyv Health weight-care partnership are different routes. Confirm which team will manage the GLP-1 assessment. Read our review](https://thisglp.com/reviews/ravia-health) - [ Red Mountain Weight Loss Red Mountain Weight Loss offers clinician-guided GLP-1 care through regional offices and telemedicine. Promotional pricing needs to be separated from the individual treatment plan. Read our review](https://thisglp.com/reviews/red-mountain-weight-loss) - [ RegenCen RegenCen offers several weight-management and maintenance programs with clinician check-ins. Distinguish GLP-1 prescribing from the additional injections included in some packages. Read our review](https://thisglp.com/reviews/regencen) - [ Rese Wellness No automatic billing or reorder Rese combines portal support with a three-month medication shipment and no automatic reorder. Read our review](https://thisglp.com/reviews/rese-wellness) - [ Revive Longevity Four-week product, wider memberships Revive offers a tirzepatide program and separate wellness membership tiers. The named product is billed every four weeks, not every calendar month. Read our review](https://thisglp.com/reviews/revive-longevity) - [ Rila Medical group and pharmacies identified Rila names its medical group and pharmacy partners and describes check-ins during the first month. Read our review](https://thisglp.com/reviews/rila) - [ Robinhood Telehealth Concentration needs context The program describes physician review and structured check-ins. Its dosing concentrations and cancellation language need careful reading. Read our review](https://thisglp.com/reviews/robinhood-telehealth) - [ Royal Medical Center Royal Medical Center describes a compounded GLP-1 weight-loss program with laboratory assessment, individualized dosing and follow-up. Confirm the precise medication and pharmacy. Read our review](https://thisglp.com/reviews/royal-medical-center) - [ Sipra Injection additives and oral formats disclosed Sipra publishes the ingredients and formats in its compounded weight-loss range and describes ongoing side-effect support. Read our review](https://thisglp.com/reviews/sipra) - [ Sommar Club Compounded ingredients identified Sommar markets online compounded care for women. Confirm the clinical follow-up and dispensing pharmacy for the chosen program. Read our review](https://thisglp.com/reviews/sommar-club) - [ Steady State Health Named clinician, regional care Steady State Health places GLP-1 treatment within Josie Cowburn’s women’s health practice in Oregon and Washington. Medication is billed separately from membership. Read our review](https://thisglp.com/reviews/steady-state-health) - [ Super Healthy Rx Super Healthy Rx publishes compounded semaglutide and tirzepatide plans with physician review and ongoing support. The care relationship and subscription terms need equal attention. Read our review](https://thisglp.com/reviews/super-healthy-rx) - [ Tablet Health Formulation matters more than format Tablet Health lists oral and injected GLP-1 products. Its oral tirzepatide offering should not be mistaken for an FDA-approved version of an injectable brand. Read our review](https://thisglp.com/reviews/tablet-health) - [ Teladoc Health Teladoc Health combines weight-management support with GLP-1 assessment where the member’s program includes prescribing. Coverage and care eligibility must be checked first. Read our review](https://thisglp.com/reviews/teladoc-health) - [ TeleWellnessMD State-dependent prescription access TeleWellnessMD offers a GLP-1 assessment and a location-dependent formulary. Its terms allow patients to request an outside pharmacy before completing an order. Read our review](https://thisglp.com/reviews/telewellnessmd) - [ The Protocole A consultation before the protocol The Protocole lists compounded semaglutide and tirzepatide as four-week supplies, with a consultation credited toward an order if treatment proceeds. Read our review](https://thisglp.com/reviews/the-protocole) - [ TideMedix TideMedix offers online GLP-1 assessment with semaglutide and tirzepatide pathways. Clinical approval, the actual formulation and ongoing costs must be confirmed after the opening offer. Read our review](https://thisglp.com/reviews/tidemedix) - [ Tomorrow A clear product, tighter terms Tomorrow names its compounded preparations and separates monthly from quarterly semaglutide purchases. Its order-cancellation terms deserve equal attention. Read our review](https://thisglp.com/reviews/tomorrow) - [ TotalRx Selected-rate renewal promise is explicit TotalRx describes a medication-inclusive program with independent prescribing networks and ongoing support. Read our review](https://thisglp.com/reviews/totalrx) - [ Totara Health State-dependent video visits described Oral and injectable programs sit inside a broader telehealth marketplace. The intake format depends on the patient’s state. Read our review](https://thisglp.com/reviews/totara-health) - [ TRT Kingdom TRT Kingdom offers lab-informed weight-management care alongside hormone services. Its compounded GLP-1 categories need a named prescription and clear continuing-care terms. Read our review](https://thisglp.com/reviews/trt-kingdom) - [ Tummala Health Introductory and later pricing separated Tummala offers compounded semaglutide with nutrition guidance and support. The treating practice and monitoring schedule need confirming. Read our review](https://thisglp.com/reviews/tummala-health) - [ Vea Health App features versus clinical care Vea lists standard and microdose GLP-1 options alongside an iPhone app. Its own terms make the independent clinical practice responsible for prescribing decisions. Read our review](https://thisglp.com/reviews/vea-health) - [ Vela Rx Clarify clinical follow-up Vela offers compounded injections and provider messaging. Its product FAQ and terms disagree about cancellation notice. Read our review](https://thisglp.com/reviews/vela-rx) - [ Verge Review before dispensing Verge names Telegra MD as its clinical group. Pharmacy transmission creates an important deadline for changing a prescription. Read our review](https://thisglp.com/reviews/verge) - [ Virgo-Meds Clinical group identified Virgo names OpenLoop and describes four-week check-ins while the dose is being established. Read our review](https://thisglp.com/reviews/virgo-meds) - [ Virta Health Virta Health offers nutrition-centered metabolic care with GLP-1 prescribing in selected programs. Its medication and deprescribing pathways depend on the individual care plan. Read our review](https://thisglp.com/reviews/virta-health) - [ Vitakey Same-provider continuity is described Vitakey promises continuity with the same provider. Verify the responsible practice, prescription and follow-up arrangements. Read our review](https://thisglp.com/reviews/vitakey) - [ Vital Step Clinician-selected formats Vital Step identifies Dr. TelX as a clinical group and offers oral and injectable compounded treatment. Read our review](https://thisglp.com/reviews/vital-step) - [ Vivanta Care Clinical evaluation precedes prescribing Vivanta identifies a consultation step and a pharmacy partner. The public GLP-1 category leaves the actual treatment to be confirmed. Read our review](https://thisglp.com/reviews/vivanta-care) - [ VivioMD Named pharmacies, follow-up questions VivioMD names its pharmacy partners and offers care-team messaging. Its clinical follow-up schedule is less specific than the promise of access. Read our review](https://thisglp.com/reviews/viviomd) - [ welludr. Two subscriptions need attention The wellmedr.com site now presents itself as welludr. Its weight-care offering includes compounded semaglutide and tirzepatide, with important differences between membership and medication-plan cancellation. Read our review](https://thisglp.com/reviews/wellmedr) - [ YOURx Health Clarify the consultation format YOURx offers physician-directed semaglutide within a wider longevity service. Its public pages describe different consultation formats, a detail worth resolving before enrollment. Read our review](https://thisglp.com/reviews/yourx-health) - [ AJ Peptide A prescription peptide storefront naming semaglutide and tirzepatide, with a strong emphasis on pharmacy sourcing and batch testing. AJ Peptide presents its GLP-1 products as patient prescriptions. Its testing claims need to be connected to the actual dispensed product. Read our review](https://thisglp.com/reviews/aj-peptide) - [ Docberry An app-supported telehealth storefront offering multi-month semaglutide and tirzepatide supplies rather than a single simple monthly plan. Docberry’s supply commitments deserve as much attention as its clinical intake. Read our review](https://thisglp.com/reviews/docberry) - [ Freeley A compounded GLP-1 program advertising monthly clinical check-ins, laboratory monitoring and a named pharmacy partner. Freeley publishes more of its care process than a simple medication storefront, but its long-plan pricing needs clarification. Read our review](https://thisglp.com/reviews/freeley) - [ Lighter You An online program advertising weekly semaglutide and tirzepatide injections, with coaching and other GLP-1 formats listed separately. Lighter You combines medication access with advertised support. Verify the plan’s clinical follow-up and the conditions behind its satisfaction guarantee. Read our review](https://thisglp.com/reviews/lighter-you) - [ One80Rx A prescription weight-loss platform advertising compounded GLP-1 treatment with clinical messaging, but inconsistent cancellation deadlines. One80Rx describes a supervised semaglutide program. Its product FAQ and general terms need to be reconciled before enrollment. Read our review](https://thisglp.com/reviews/one80rx) - [ Pillar Health A clinician-reviewed GLP-1 storefront that distinguishes monthly ongoing care from other prescription purchases. Pillar Health’s plan type affects both the care included and the payment commitment. Read our review](https://thisglp.com/reviews/pillar-health) - [ StaveMD A compounded GLP-1 platform with a clear distinction between free eligibility checking and paid clinical review. StaveMD advertises flat-dose treatment and a refund if no prescription is issued. Its introductory period and ongoing plan should be read separately. Read our review](https://thisglp.com/reviews/stavemd) - [ Yes Clinic A semaglutide program with a clearly identified compounded injectable and a choice of monthly or longer supply purchases. Yes Clinic makes the product and price structure relatively easy to identify. Clinical follow-up still deserves a direct conversation. Read our review](https://thisglp.com/reviews/yes-clinic) - [ Youth & Soul A broad GLP-1 storefront with branded pens, compounded options and several administration formats. The specific prescription matters more than the shared weight-loss category. Youth & Soul brings injections, lozenges and a spray into one menu. They are not interchangeable versions of a single medicine. Read our review](https://thisglp.com/reviews/youth-and-soul) - [ BodyLogicMD BodyLogicMD offers practitioner-led weight assessment within a broader hormone-focused network. Its semaglutide discussion should lead to a specific prescription and monitoring plan. Read our review](https://thisglp.com/reviews/bodylogicmd) - [ Defy Medical Broader medical assessment Defy places GLP-1 treatment within a broader medical weight-management practice. Its consultation and follow-up model deserve more attention than the list of available therapies. Read our review](https://thisglp.com/reviews/defy-medical) - [ EmbraceRX EmbraceRX lists compounded injections and oral capsules, with medical services through independent networks including Samaritan MD. Formulation and follow-up need a careful review. Read our review](https://thisglp.com/reviews/embrace-rx) - [ eMed Structured screening and monitoring eMed combines its own screening kit with licensed-clinician review, monthly consultations and brief weekly check-ins. Employer access and the public patient pathway should not be treated as identical programs. Read our review](https://thisglp.com/reviews/emed) - [ Enara Health Team-based clinic care Enara combines medical weight management with dietitian, movement and behavioral support through partner clinics. Medication is one part of the program rather than its entire purpose. Read our review](https://thisglp.com/reviews/enara-health) - [ Evolve Telemed Evolve discusses semaglutide within men’s weight-management care. Its separate women’s page emphasizes hormones, so clarify the actual treatment pathway before enrolling. Read our review](https://thisglp.com/reviews/evolve-telemed) - [ G-Plans A medication-access and nutrition program that names independent clinical care and combines it with meal planning, tracking and progress support. G-Plans offers prescription treatment alongside nutrition tools. Confirm the exact medicine and clinical follow-up rather than relying on the quiz’s metabolic-type framing. Read our review](https://thisglp.com/reviews/g-plans) - [ Gatlan A consultation-led medical weight-loss service within a broader hormone and wellness platform. The public product page identifies GLP-1 and GLP-1/GIP treatment classes, but not a complete named-drug offer. Gatlan describes individualized care and ongoing contact. Ask for the exact prescription, treating practice and monitoring plan before judging the program. Read our review](https://thisglp.com/reviews/gatlan) - [ JM Integrated Health A named nurse-practitioner-led program with separate clinical and medication charges, baseline laboratory work and monthly follow-up options. JM Integrated Health makes the cost boundary clear: its program fee pays for care, while the pharmacy charges separately for medication. Read our review](https://thisglp.com/reviews/jm-integrated-health) - [ Risen Labs Risen Labs requires a live video evaluation for compounded semaglutide or tirzepatide and identifies Olympia Pharmacy. The service is limited to New York and Colorado patients. Read our review](https://thisglp.com/reviews/risen-labs) - [ Teleios Health A platform arranging compounded semaglutide and tirzepatide injections with independent clinician review and pharmacy delivery. Teleios Health advertises continuing support, but its exact monitoring schedule and narrow refund window need attention before treatment starts. Read our review](https://thisglp.com/reviews/teleios-health) - [ Trally Meds Confirm the actual prescription Trally describes clinical approval before the first charge and check-ins before later treatment orders. The public price and dose cards need careful confirmation for the actual prescription. Read our review](https://thisglp.com/reviews/trally-meds) - [ Transcarent Benefit-dependent weight care Transcarent provides weight-management support through employer and benefit arrangements. GLP-1 medication management depends on both clinical suitability and the coverage selected for the program. Read our review](https://thisglp.com/reviews/transcarent) - [ Vida Health Vida Health combines clinical assessment, dietitian care and behavioral support. GLP-1 prescribing depends on the available program, benefits and individual medical assessment. Read our review](https://thisglp.com/reviews/vida-health) - [ Zenbody Named route-specific pharmacies Zenbody identifies different pharmacies for its injections and tablets and describes continuing clinical contact. Route and monitoring deserve as much attention as the first-month discount. Read our review](https://thisglp.com/reviews/zenbody) Not sure which to pick? Compare every seller side by side in the [head-to-head comparisons](https://thisglp.com/compare), or browse [the buyer’s guides](https://thisglp.com/best). --- # 10Rx reviews (2026): GLP-1 telehealth sellers | This GLP 10Rx advertises a quarterly package that holds its price across available strengths. Its terms make the selected subscription period and prescription stage important when stopping treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/10rx Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Quarterly care needs an exit plan # 10Rx review 10Rx advertises a quarterly package that holds its price across available strengths. Its terms make the selected subscription period and prescription stage important when stopping treatment. ## The verdict 10Rx publishes a more useful dose-pricing promise than a low introductory headline alone. The tradeoff is commitment: its terms restrict ending an active fixed-term plan. Discuss side-effect follow-up and the consequences of an early stop before choosing a quarterly purchase. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved 10Rx offers online prescription weight care with semaglutide and tirzepatide, alongside unrelated wellness treatments. A quiz and medical consultation precede an individualized plan. The product menu is not a clinical recommendation to combine therapies. 1. ## Who writes the prescription, and what do they see? The homepage identifies Wasef Health physicians and describes a doctor consultation reviewing history and treatment options. A named team is a useful starting point for verification, but does not establish which clinician will see you or guarantee a prescription. 10Rx describes clinical assessment, a personalized plan, pharmacy fulfillment and ongoing support. Its pricing page includes consultations and support. Ask how clinical messages are triaged and how promptly the prescriber reviews a problem between scheduled fills. 2. ## What happens when the dose goes up? Dose changes are said not to increase the selected medication’s package price. That does not specify a clinically suitable dose for every patient. Ask what happens to the remaining supply and payment if the clinician pauses, reduces or changes treatment. 3. ## What the price includes The pricing page describes one quarterly package for the selected medication, with the rate unchanged across its available strengths. The headline’s low monthly language does not establish a flexible monthly purchase. Confirm the actual charge and included quantity on the order. 4. ## What it claims, and what it cites [Semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are offered, and the terms cover compounded prescriptions and identify several potential dispensing pharmacies. A named pharmacy list is not a patient-specific assignment. Confirm the actual preparation, concentration and label; compounded products are not FDA approved. ## Where it holds up, and where it does not - Strength: Doctor team identified publicly - Strength: Price-hold claim across available strengths - Strength: Potential pharmacy partners listed - Limitation: Fixed-term stopping restrictions - Limitation: Individual clinician response time not promised - Limitation: Quarterly commitment differs from monthly flexibility ## What the evidence says about this kind of treatment The assessment above is about 10Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants predictable dose pricing and understands the selected package’s commitment and clinical follow-up. Wrong for Someone who may need to stop after an early fill and expects a refund for the rest of a fixed-term plan. ## The evidence behind what 10Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How 10Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Belle Health](https://thisglp.com/reviews/belle-health) [bmiMD](https://thisglp.com/reviews/bmimd) [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)[Collective](https://thisglp.com/reviews/collective) [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) [Direct Meds](https://thisglp.com/reviews/direct-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise when the dose changes? 10Rx says its selected medication package stays at the same price across available strengths. Confirm the medication and quantity covered by your offer. Can I cancel a refill after pharmacy submission? The terms say orders cannot be canceled once sent to the pharmacy, and refill cancellation must arrive at least forty-eight hours beforehand. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official program](https://www.take10rx.com/) - [Program terms](https://www.take10rx.com/pricing) - [Service and cancellation terms](https://www.take10rx.com/terms-and-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # 1st Optimal reviews (2026): GLP-1 telehealth sellers | This GLP A lab-led coaching membership with GLP-1 prescribing inside it, where the membership has a price and the drug does not. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/1st-optimal Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership priced, medication not # 1st Optimal review A lab-led coaching membership with GLP-1 prescribing inside it, where the membership has a price and the drug does not. ## The verdict 1st Optimal publishes $99 a month for its Weight Loss Care membership. The medication is invoiced separately, and no figure for it appears anywhere on the site. That makes the membership the only cost a reader can know before joining. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Prescription Required Labs Included 1st Optimal is a Michigan-based functional medicine service that sells monthly care memberships. Weight loss is one of several plans, beside hormone, menopause and peptide care. GLP-1 therapy is offered within that weight-loss plan. 1. ## Who writes the prescription, and what do they see? The site states that a licensed provider reviews lab results and discusses a treatment plan after an initial consultation. A prescription, if one is written, goes electronically to a partner pharmacy. The individual prescriber is not named on the plan pages, though a nurse practitioner appears in the site's podcast. Labs come first. The membership covers consultations, lab testing, shipping and medical supplies, plus monthly coaching on nutrition and exercise. Billing is month to month, drafted on the 1st or the 16th, with no long-term contract stated. The FAQ says pharmacy partners typically ship within 14 business days, which is slower than most mail-order GLP-1 sellers state. 2. ## What happens when the dose goes up? The weight-loss page describes protocols that use minimum effective doses, adjusted against labs and symptoms. No dose schedule is published. Because the medication price is not published either, what a dose increase does to the monthly cost is not stated. 3. ## What the price includes $99 a month buys the membership. Prescriptions, labs and supplements are invoiced separately, about three weeks before each refill for existing patients. The FAQ promises a reduced members-only rate on treatments but prints no rate. A total monthly cost cannot be worked out from the site. 4. ## What it claims, and what it cites The plan pages describe GLP-1s as FDA-approved medications and list weekly injections, daily tablets and combination therapies. They do not name the molecule, say whether it is branded or compounded, or name the partner pharmacy. Compounded preparations are not FDA-approved. ## Where it holds up, and where it does not - Strength: Month-to-month billing, no contract stated - Strength: Labs and consultations sit inside the membership - Strength: Coaching is part of the plan, not an add-on - Strength: Cancellation is described step by step - Limitation: No medication price is published - Limitation: The molecule is not named on the plan pages - Limitation: Shipping can take 14 business days - Limitation: States are given only on request ## What the evidence says about this kind of treatment The assessment above is about 1st Optimal. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants labs and coaching around a prescription, and will ask for the drug price before paying. Wrong for A reader comparing all-in monthly GLP-1 prices, since only the membership has one here. ## The evidence behind what 1st Optimal prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How 1st Optimal compares | Seller | Who it suits | Go | | --- | --- | --- | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Measured | Readers ready to commit to a term who know which rung the lead figure is | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Eden](https://thisglp.com/reviews/eden) [Embody](https://thisglp.com/reviews/embody) [Enhance MD](https://thisglp.com/reviews/enhance-md) [Gala](https://thisglp.com/reviews/gala) [HealthRX](https://thisglp.com/reviews/healthrx) [HumeCare+](https://thisglp.com/reviews/humecare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $99 a month include the GLP-1? No. The $99 is the Weight Loss Care membership. The FAQ says prescriptions are invoiced separately, and no medication price is published. Which states does 1st Optimal cover? It does not list them. The FAQ asks readers to email member support for the current list. Is there a commitment? The FAQ says the membership is month to month and renews until a change request is filed. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # 24hrDOC reviews (2026): GLP-1 telehealth sellers | This GLP A general online clinic with a weight-loss page that prints two semaglutide figures and never says what period either covers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/24hrdoc Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Figures without a period # 24hrDOC review A general online clinic with a weight-loss page that prints two semaglutide figures and never says what period either covers. ## The verdict 24hrDOC lists semaglutide injection at $299 and oral semaglutide at $309. Neither figure states a billing period. Tirzepatide is named but not priced. This site ranks none of the three. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose published No Prescription Required 24hrDOC is a Houston telehealth practice treating many conditions. Weight loss has its own page. That page is not in the main menu or the conditions list. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews a 10-minute questionnaire. No office visit is required. The page promises a prescription within 45 minutes. It does not name the prescriber or state credentials. The FAQ says prescriptions go electronically to a pharmacy of the patient's choice. The process has three steps: questionnaire, provider review, prescription. Monthly sessions with a licensed nutritionist are offered as Care Coaching. The site states it is not a pharmacy and does not ship medicines. Yet the pricing answer describes a visit that includes the medication. The two statements conflict. 2. ## What happens when the dose goes up? The provider writes a low-dose protocol, per the page. No dose ladder is published. Whether the price changes at a higher dose is not stated. The page offers the ability to pause or adjust at any time. 3. ## What the price includes Each figure sits beside the words "6 months subscription is recommended." That line describes a length, not a unit. The figure could be a month, a fill or six months. The page offers 15 percent off a first order. Insurance is not accepted for weight-loss care. FSA and HSA payment is described as possible. 4. ## What it claims, and what it cites The FAQ describes compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and states it is not FDA-approved as a formulation. The page does not say which product each figure buys. [Tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is named in the page copy only. ## Where it holds up, and where it does not - Strength: Both semaglutide forms carry a printed figure - Strength: The FAQ states compounded is not FDA-approved - Strength: Nutritionist sessions are described - Limitation: No billing period on either figure - Limitation: Tirzepatide is unpriced - Limitation: Medication-included answer conflicts with the pharmacy statement - Limitation: The weight-loss page is hard to find from the menu ## What the evidence says about this kind of treatment The assessment above is about 24hrDOC. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will ask in writing what the $299 covers before starting. Wrong for A reader who needs a monthly figure to compare against other sellers. ## The evidence behind what 24hrDOC prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How 24hrDOC compares | Seller | Who it suits | Go | | --- | --- | --- | | Sesame Care | Readers who want tirzepatide priced by dose and will read the FAQ before the headline | | | TeleClinic | Readers who want the standard rate stated beside the introductory one before they sign up | | | NowPatient | Readers who want a named manufactured product and will read the buy box first | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HumeCare+](https://thisglp.com/reviews/humecare)[Live Vital](https://thisglp.com/reviews/live-vital) [Lttl](https://thisglp.com/reviews/lttl) [Luvo Health](https://thisglp.com/reviews/luvo-health) [MEDGm](https://thisglp.com/reviews/medgm) [Oak](https://thisglp.com/reviews/oak) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $299 a monthly price? The page does not say. It prints the figure beside a note that a six-month subscription is recommended, with no billing period. Does 24hrDOC ship the medication? The site states it is not a pharmacy and sends prescriptions to the patient's pharmacy. One FAQ answer also says the visit includes the medication. Is tirzepatide available? It is named on the weight-loss page. No price is printed for it. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AbundRX reviews (2026): GLP-1 telehealth sellers | This GLP Two starting figures for compounded semaglutide and tirzepatide, and a signup screen that talks about a first-month discount without saying what month two costs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/abundrx Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Entry figure, renewal unstated # AbundRX review Two starting figures for compounded semaglutide and tirzepatide, and a signup screen that talks about a first-month discount without saying what month two costs. ## The verdict AbundRX opens at $99 for semaglutide-based care and $149 for tirzepatide-based care. Its own intake then greets a new patient with a discount on the first month and never prints the rate that follows, so what a reader pays by the third renewal is a question the site leaves open. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider AbundRX, trading as Abundant Wellness from a West Palm Beach address, sells two compounded GLP-1 care options through a short online intake, one built on semaglutide and one on tirzepatide, each billed as a recurring subscription. 1. ## Who writes the prescription, and what do they see? The site pictures three physicians by name as providers who may support patient care, and it describes a licensed provider reviewing the intake and deciding whether treatment is appropriate. Nearly every sentence about that review is hedged with may, and nothing says whether it happens by video, by phone or only in writing. A patient starts with height, weight and goal weight, and the next screen asks for a date of birth, which is where the identifying part of the intake begins. After approval, medication is described as prepared by a licensed pharmacy and shipped home, with follow-up support that the page again says may be available rather than will be. 2. ## What happens when the dose goes up? Nothing on the page describes a dose schedule or says whether the monthly figure holds as a dose climbs through the first few months. That is the stretch where most people on either molecule are stepping up, so what the fourth or fifth month costs is still an open question. 3. ## What the price includes The homepage says programs begin at $99 and $149, and that pricing may include provider review, care planning, follow-up and medication if prescribed, before adding that final pricing may vary with the treatment path chosen at clinical review. The intake frames its entry offer as a first-month saving. The refund policy confirms a subscription that renews unless it is canceled at least 72 hours before the next billing date, but no renewal amount appears on any page a reader can see before handing over identifying details. 4. ## What it claims, and what it cites Both options are compounded, and the site says so plainly: compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. The compounding pharmacy is not named. ## Where it holds up, and where it does not - Strength: Both molecules show an entry figure before signup - Strength: The compounded status is disclosed in the seller's own words - Strength: Shipping is described as free - Strength: Cancellation terms are written out in the refund policy - Limitation: No renewal figure is printed anywhere - Limitation: The intake treats the entry figure as a first-month saving - Limitation: Whether medication is inside the price is hedged - Limitation: No dose schedule is published ## What the evidence says about this kind of treatment The assessment above is about AbundRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to ask for the month-two price in writing before the first charge goes through. Wrong for A reader who wants to know the standing monthly cost before sharing a date of birth. ## The evidence behind what AbundRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AbundRX compares | Seller | Who it suits | Go | | --- | --- | --- | | Claya | Buyers who click through to the product page before trusting a homepage rate | | | MEDVi | Readers who want the injected line, where the card figure is the medicine's figure | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PeterMD](https://thisglp.com/reviews/petermd) [RxSpan MD](https://thisglp.com/reviews/rxspan-md) [Sesame Care](https://thisglp.com/reviews/sesame-care) [ShedRx](https://thisglp.com/reviews/shedrx) [SkinnyRx](https://thisglp.com/reviews/skinnyrx) [SnagRx](https://thisglp.com/reviews/snagrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 what semaglutide costs every month? The site does not say. The homepage calls it a starting figure, and the intake describes its offer as a saving on the first month without printing what follows. Does the price include the medication? The FAQ says pricing may include provider review, care planning, follow-up and medication fulfillment if prescribed. It does not state that it always does. How is a subscription canceled? By emailing support or using the portal chat at least 72 hours before the next billing date. Service continues to the end of the paid cycle. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Actin reviews (2026): GLP-1 telehealth sellers | This GLP Every commitment length is printed on the product page, but the help center says the dose can move the cost. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/actin Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three cadences, one page # Actin review Every commitment length is printed on the product page, but the help center says the dose can move the cost. ## The verdict Actin prints three rates for compounded semaglutide on one page. They are $169 month to month, $143 on three months and $116 on six. Tirzepatide runs $269, $209 and $166. Its own FAQ says the final cost depends on the prescribed dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $169/mo Prescription Required Compounded Yes — not FDA-approved Actin sells both molecules by injection. Two lines carry figures. Each publishes three commitment lengths on the product page rather than at checkout. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The product page carries rates and dose behavior rather than clinician detail. The intake is not documented. Every cadence is on the page a reader lands on. Most sellers hold the longer terms back for checkout. The product page adds "Same price, forever", which describes the plan rate, not the dose. 2. ## What happens when the dose goes up? The help center answers the dose question directly. It says "The final cost depends on your treatment plan and prescribed dose". No dose-by-dose figure is published. The listed rates are therefore opening figures until a higher dose is priced. 3. ## What the price includes $116 a month is the six-month rate. Month to month is $169. The commitment saves $53 a month, which is 31 percent. On tirzepatide the saving is $103, or 38 percent. Both ladders are steeper than most. Nothing is hidden behind an intake. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: All three cadences printed on the page - Strength: No hidden fees, per its own FAQ - Strength: The commitment discount is unusually steep - Limitation: The low rate requires six months - Limitation: Cost can change with the dose - Limitation: No oral line is offered - Limitation: No pharmacy is named - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Actin. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader comparing commitment lengths who will confirm the price at each dose step. Wrong for A reader who wants a tablet, or who cannot commit past a month. ## The evidence behind what Actin prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Actin compares | Seller | Who it suits | Go | | --- | --- | --- | | AlyveRx | Readers who want a needle-free route named as such rather than implied | | | Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sprout Health](https://thisglp.com/reviews/sprout-health) [Strut Health](https://thisglp.com/reviews/strut-health) [Wellorithm](https://thisglp.com/reviews/wellorithm) [Willow](https://thisglp.com/reviews/willow) [YourEra](https://thisglp.com/reviews/yourera) [EverPrime](https://thisglp.com/reviews/everprime) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the six-month plan save? $53 a month on semaglutide and $103 on tirzepatide, against the month-to-month rates. Both are printed on the product page. Does the rate change as the dose rises? It can. Actin's FAQ says the final cost depends on the treatment plan and the prescribed dose. No higher-dose figure is published. Is there a tablet? No. Both lines are weekly injections. Is Actin expensive compared with other GLP-1 telehealth sellers? Actin publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Actin below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AgelessRx reviews (2026): GLP-1 telehealth sellers | This GLP The $139 semaglutide figure already has a first-term coupon applied; the same option reads $239 without it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/agelessrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Coupon built into the start price # AgelessRx review The $139 semaglutide figure already has a first-term coupon applied; the same option reads $239 without it. ## The verdict AgelessRx leads with compounded semaglutide at $139 a month, a four-month plan with a first-term coupon applied. Without the coupon the same option reads $239. Full-dose compounded tirzepatide reads $279 with the coupon and $349 without. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $239/mo Prescription Required Compounded Yes — not FDA-approved AgelessRx sells compounded semaglutide and tirzepatide by injection, in microdosing and full-dose plans, with brand Wegovy alongside them. The microdosing tirzepatide is a separate, lower-dose product at $159 a month. The seller's own page states that it is not a full-dose GLP-1. Full-dose tirzepatide has no product page and is priced only inside the intake. 1. ## Who writes the prescription, and what do they see? The $65 monthly membership is attached to brand Wegovy, where AgelessRx bills the clinical side and NovoCare bills the drug. No membership is named on the compounded lines. Whether a consultation is billed separately there is not something the pages settle. The coupon is the arrangement worth understanding here. Every Get Started button opens the intake with a first-term coupon already attached, so the first figure a reader meets is discounted. The discount applies to the first term of a four-month plan, not to every month that follows. On its microdose lines the seller says so in words: the lower figure is a four-month plan price, and $159 a month follows. 2. ## What happens when the dose goes up? Nothing is published about what either compounded figure does as the dose climbs. The monthly and two-month plans are priced only after intake answers are submitted. That makes $239 and $349 floors, not month-to-month rates. Wegovy is the one line with a stated schedule: a lower rate for a new patient's first two months, then $349 at every dose. 3. ## What the price includes The figures this site compares are $239 for semaglutide and $349 for full-dose tirzepatide, the options with no coupon applied. Both are four-month plan prices, the only term published before intake. The month-to-month rate is at least that and not published. Wegovy totals $414 a month: $349 of drug billed through NovoCare plus the $65 membership, and the page adds the two itself. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) lines are compounded, so neither has been through the FDA review an approved product completes before dispensing. The microdosing tirzepatide is a lower-dose product, and the seller's own page says it is not a full-dose GLP-1. Wegovy is the manufacturer's finished product, billed through NovoCare. ## Where it holds up, and where it does not - Strength: Microdosing and full-dose plans both offered - Strength: The microdose is labeled as not full-dose - Strength: The Wegovy total includes the membership - Strength: No membership named on compounded lines - Limitation: Starting figures carry a first-term coupon - Limitation: Full-dose tirzepatide priced only in intake - Limitation: No monthly rate published before intake - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about AgelessRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit to four months who wants to choose between a microdose and a full dose. Wrong for A reader who needs a month-to-month price before answering intake questions, since none is published. ## The evidence behind what AgelessRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AgelessRx compares | Seller | Who it suits | Go | | --- | --- | --- | | AVARA Rx | A reader who wants the consult inside the price, and who plans against the standing rate rather than a code that can be withdrawn. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | | Maximus | A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [1st Optimal](https://thisglp.com/reviews/1st-optimal) [24hrDOC](https://thisglp.com/reviews/24hrdoc) [AbundRX](https://thisglp.com/reviews/abundrx) [Actin](https://thisglp.com/reviews/actin) [AHBARx](https://thisglp.com/reviews/ahbarx) [Alan Meds](https://thisglp.com/reviews/alan-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $139 the real price of semaglutide here? It is the four-month plan with a first-term coupon that the seller's own link applies. The same option reads $239 without the coupon, and that is the figure this site ranks. Is the $159 microdosing tirzepatide a full dose? No. It is the microdosing product, which the seller's page says is not a full-dose GLP-1. Full-dose tirzepatide reads $349 without the coupon, or $279 with it. What does Wegovy cost through AgelessRx? $414 a month once the first two months pass: $349 for the drug, billed through NovoCare, plus the $65 AgelessRx membership. The page totals the two itself. Does the price rise with the dose? Not stated on the compounded lines. On Wegovy the drug is $349 at every dose once a new patient's first two months are used. Is AgelessRx expensive compared with other GLP-1 telehealth sellers? AgelessRx publishes a starting figure of $239/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AgelessRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AHBARx reviews (2026): GLP-1 telehealth sellers | This GLP Compounded semaglutide and tirzepatide in one, three and six-month supplies, with a physician founder named and no prescriber. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ahbarx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three supply lengths, no prescriber named # AHBARx review Compounded semaglutide and tirzepatide in one, three and six-month supplies, with a physician founder named and no prescriber. ## The verdict AHBARx charges $249 for one month of compounded semaglutide. Tirzepatide is $349 for the same supply. Three and six-month supplies cost less per month. Every refill passes a follow-up consultation first. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider AHBARx is the online prescribing arm of AHBA, a wellness practice. It sells weight loss, longevity, anti-aging, sexual health and skin care treatments. Semaglutide and tirzepatide are its two GLP-1 products. B12, NAD+, glutathione and sermorelin make up most of the rest. 1. ## Who writes the prescription, and what do they see? The FAQ states that licensed, board-certified clinicians review every plan. None of them is named. The about page names the founder, Dr. Nima Yazdanpanah, DO, a pain medicine physician. It does not say he reviews weight-loss requests. The review is described as a health intake followed by a consultation. The sequence is intake, consultation, then home delivery. Each monthly refill is reviewed in a follow-up consultation before it ships. The service is cash-pay and needs no insurance. The footer states service in all 50 states. An email sign-up offers 35 percent off a first eligible treatment. 2. ## What happens when the dose goes up? No milligram appears on either product page. The pages do not say whether the price changes as the dose rises. Dosing guidance is assigned to the provider, with injection technique and site rotation. The monthly refill consultation is the stated checkpoint for a change. 3. ## What the price includes Semaglutide is $249 for one month, $649 for three and $1,199 for six. Tirzepatide is $349, $949 and $1,799 on the same ladder. Each card prints its saving: $98 on three months, $295 on six. No card is preselected. The six-month card is marked most popular. It is charged every six months and ships every three. 4. ## What it claims, and what it cites Both products are compounded. The FAQ says they come from U.S.-based, FDA-registered compounding pharmacies. None is named. Each product page states that compounded medications are not reviewed or approved by the FDA. No formulation detail is given beyond a subcutaneous injection. ## Where it holds up, and where it does not - Strength: One-month rate printed beside each longer supply - Strength: Savings on longer supplies printed in dollars - Strength: Every refill reviewed in a follow-up consultation - Strength: FDA status of compounding stated on both pages - Limitation: No prescribing clinician is named - Limitation: No milligram appears beside any price - Limitation: The compounding pharmacy is not named - Limitation: Price at higher doses is not addressed ## What the evidence says about this kind of treatment The assessment above is about AHBARx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to start on one month and choose a longer supply later. Wrong for A buyer who needs the dose and the pharmacy named before paying. ## The evidence behind what AHBARx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AHBARx compares | Seller | Who it suits | Go | | --- | --- | --- | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Mondae | Buyers who want a low published compounded rate and few other details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Alan Meds](https://thisglp.com/reviews/alan-meds) [Alegro Health](https://thisglp.com/reviews/alegro-health) [Alinwell](https://thisglp.com/reviews/alinwell) [Allara Health](https://thisglp.com/reviews/allara-health) [Alloy](https://thisglp.com/reviews/alloy) [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $249 an introductory price? No. It is the one-month supply rate, delivered monthly. Lower monthly rates require buying three or six months at once. Who reviews the request? The FAQ says licensed, board-certified clinicians. No prescriber is named anywhere on the site. Does the six-month supply ship at once? No. It is charged every six months. Medication is delivered every three months. Is AHBARx legit? AHBARx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is AHBARx expensive compared with other GLP-1 telehealth sellers? AHBARx publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AHBARx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AJ Peptide reviews (2026): GLP-1 telehealth sellers | This GLP AJ Peptide presents its GLP-1 products as patient prescriptions. Its testing claims need to be connected to the actual dispensed product. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/aj-peptide Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A prescription peptide storefront naming semaglutide and tirzepatide, with a strong emphasis on pharmacy sourcing and batch testing. # Does AJ Peptide sell a GLP-1? AJ Peptide presents its GLP-1 products as patient prescriptions. Its testing claims need to be connected to the actual dispensed product. ## The verdict The prescription requirement distinguishes this offer from a research-only chemical sale. Before enrolling, ask for the clinical follow-up plan and actual pharmacy and batch documentation; testing claims do not establish FDA approval. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved AJ Peptide LLC markets compounded prescription treatments following a licensed provider’s medical evaluation. GLP-1 products sit alongside several other peptide and wellness categories. 1. ## Who writes the prescription, and what do they see? The site requires a valid prescription after medical evaluation. Ask which clinical organization performs that evaluation and who remains responsible for treatment questions and monitoring. The public overview explains evaluation and fulfillment more clearly than continuing GLP-1 care. Confirm scheduled follow-up, message access and how side effects or a treatment change are handled. 2. ## What happens when the dose goes up? A separate microdose category appears alongside named semaglutide and tirzepatide products. Its marketing does not establish a suitable regimen for an individual or an interchangeable substitute for another prescription. 3. ## What the price includes Product cards contain coupon-reduced prices and crossed-out figures, but do not establish a clear monthly supply interval for every offer. Obtain the complete prescription quantity, duration and renewal total. 4. ## What it claims, and what it cites The site names compounded semaglutide and tirzepatide and describes pharmacy sourcing and testing. A registered ingredient supplier or a batch certificate is not FDA approval of the finished compounded medicine. ## Where it holds up, and where it does not - Strength: States a prescription and clinical-evaluation requirement - Strength: Names semaglutide and tirzepatide - Limitation: Ongoing clinical care is not fully described - Limitation: Testing claims need product-specific documentation ## What the evidence says about this kind of treatment The assessment above is about AJ Peptide. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults prepared to ask detailed questions about the prescriber, dispensing pharmacy and actual batch documentation. Wrong for Anyone treating supplier registration, a coupon or a testing badge as proof of a complete clinical treatment program. ## The evidence behind what AJ Peptide prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AJ Peptide compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AlyveRx](https://thisglp.com/reviews/alyverx) [AM Rx](https://thisglp.com/reviews/amrx) [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) [Amble](https://thisglp.com/reviews/amble) [Andrew Meds](https://thisglp.com/reviews/andrew-meds) [Apex MD](https://thisglp.com/reviews/apex-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is this presented as a research-only peptide seller? No. Its public statement says products are compounded under a valid prescription following licensed medical evaluation. Confirm the actual prescriber and pharmacy. Does an FDA-registered supplier mean the medicine is FDA-approved? No. Supplier registration does not establish FDA approval of the finished compounded product. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://ajpeptide.com/) - [Official program and terms](https://ajpeptide.com/terms-of-service) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Alan Meds reviews (2026): GLP-1 telehealth sellers | This GLP Full-dose lines priced as six-month prepayments, beside cheaper microdosing lines. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/alan-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Six-month prepay floors # Alan Meds review Full-dose lines priced as six-month prepayments, beside cheaper microdosing lines. ## The verdict Alan Meds prices compounded tirzepatide from $325 a month and its oral compounded GLP-1 from $215. Both figures are paid up front on a six-month plan. Forty-six states are served. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 46 Injection From $315/mo Oral From $215/mo Prescription Required Compounded Yes — not FDA-approved Alan Meds sells compounded semaglutide and compounded tirzepatide at full dose. Separate microdosing lines sit at lower prices. The full-dose oral is $215 a month. Injectable tirzepatide is $325. Injectable semaglutide is $315 a month, shown at $158 on a two-month plan paid up front. No oral tirzepatide is listed. The service covers forty-six states. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely. A prescription is issued before shipping. The pricing page states the rates. It does not describe the clinician who writes them. Remote service, compounded products, full-dose and microdosing lines side by side. The pages carry the figures and little else. That is a choice about presentation, not a gap in what is sold. 2. ## What happens when the dose goes up? No month-to-month rate is published for either full-dose line. Six months are paid before the first dose step. The pages do not say whether the rate changes as the dose climbs. 3. ## What the price includes Six months of injectable tirzepatide is $1,950, paid at once. The oral is $1,290 on the same term. Those are the only figures published for either line. Whether shipping or a consultation sits inside them is not stated. Put that to the intake before the first order. 4. ## What it claims, and what it cites Both products are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. Trial results for these molecules came from the approved products at labeled doses. A compounded vial is not measured against that. ## Where it holds up, and where it does not - Strength: Full-dose and microdosing lines listed apart - Strength: The prepay term is printed in a footnote - Strength: Forty-six states served - Limitation: No month-to-month rate on the full-dose lines - Limitation: Six months are paid before the first dose - Limitation: What the rate includes is not stated ## What the evidence says about this kind of treatment The assessment above is about Alan Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to prepay six months who wants the full-dose price before the intake. Wrong for A reader who wants to pay month to month, or wants tirzepatide as a tablet. ## The evidence behind what Alan Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Alan Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | PreventiveMD | A reader interested in orforglipron, which most sellers in this category do not offer at all. | | | Revel Health | A reader who wants an oral and expects to pay less for it, which on this seller is what happens. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Andrew Meds](https://thisglp.com/reviews/andrew-meds) [Apex MD](https://thisglp.com/reviews/apex-md) [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) [Arc-1](https://thisglp.com/reviews/arc-1) [Ark Health](https://thisglp.com/reviews/ark-health) [ARSYNL Rx](https://thisglp.com/reviews/arsynl-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I pay month to month? Not on the full-dose tirzepatide or oral lines. Each is priced on a six-month plan paid up front. Is there an oral tirzepatide? No. The oral line is a compounded GLP-1 at $215 a month. Tirzepatide is listed as an injection only. What does the price include? The page does not say. Whether shipping and a consultation sit inside the rate is not stated, so ask before ordering. Is Alan Meds expensive compared with other GLP-1 telehealth sellers? Alan Meds publishes a starting figure of $215/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Alan Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Alegro Health reviews (2026): GLP-1 telehealth sellers | This GLP The figure buys eight weeks outright, and the page stops before saying what week nine costs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/alegro-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A starter with no sequel # Alegro Health review The figure buys eight weeks outright, and the page stops before saying what week nine costs. ## The verdict Alegro Health advertises an eight-week semaglutide starter with B12 for $199, and that $199 is the total for the whole eight weeks rather than a rate charged every month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Alegro Health is a clinic-led weight-loss service offering a fixed starter course in selected states, where the medication is paired with B12 and sold as a single block of treatment rather than as an open-ended plan. 1. ## Who writes the prescription, and what do they see? The starter is presented as a course a clinician puts a patient on, and booking rather than checkout is how a buyer begins, which suggests a consultation sits in front of the purchase. The pages do not name the clinician or describe what the consultation covers, and they do not say whether it is charged separately. Everything is scoped to the starter. There is no membership, no monthly fee and no subscription, and the clinic says so plainly. What that clarity costs is any view of the second course, because nothing published says what a continuing patient pays once the first eight weeks are gone. 2. ## What happens when the dose goes up? Eight weeks is roughly the span of the early escalation, when a starting dose is stepped up for the first time, so this course covers exactly the stretch where a price is most likely to move. Alegro publishes no dose figures and no second-course rate, which leaves the step that usually changes the bill entirely unpriced. 3. ## What the price includes Paid once for the eight weeks it covers, $199 is the whole of what a buyer spends in that window, and no part of it recurs. The figure is not comparable with a standing monthly rate, because a standing rate keeps going and this one runs out. Anyone budgeting a six-month course has two months priced and four months unknown. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is a compounded preparation rather than a manufactured product, prepared by a pharmacy the clinic does not name, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: The eight-week term is stated up front - Strength: No monthly fee attached to the starter - Strength: B12 included in the course - Strength: A low total for a first trial - Limitation: The figure is a total, not a monthly rate - Limitation: Nothing is published about week nine onward - Limitation: Availability limited to selected states - Limitation: No dose figures anywhere on the page ## What the evidence says about this kind of treatment The assessment above is about Alegro Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer trying a GLP-1 for two months before committing to a rate. Wrong for A buyer pricing a six-month course, since only the first eight weeks are published. ## The evidence behind what Alegro Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Alegro Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Queen RX | Buyers content to commit a quarter at a time in one payment | | | Injectco | Buyers who want to pay month by month and keep a longer package as an option | | | Ivologist | Buyers who check a printed monthly equivalent against the term it covers | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ascend Medical](https://thisglp.com/reviews/ascend-medical) [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) [AskRx](https://thisglp.com/reviews/ask-rx) [Aspen](https://thisglp.com/reviews/aspen-health) [Aspire Health](https://thisglp.com/reviews/aspire-health) [Auren Rx](https://thisglp.com/reviews/auren-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 charged every month? No. It is the total for the full eight-week starter, paid once, and nothing published says what a patient pays after those eight weeks. What happens after eight weeks? Nothing on the page states a continuing rate, so the cost of staying on treatment is not published. Is it available everywhere? No. Alegro states the starter is offered in selected states. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Alinwell reviews (2026): GLP-1 telehealth sellers | This GLP A GLP-1 service for women whose homepage advertises a new-patient offer, while both product pages say the price is set at consultation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/alinwell Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Offer on the homepage, none on the product # Alinwell review A GLP-1 service for women whose homepage advertises a new-patient offer, while both product pages say the price is set at consultation. ## The verdict Alinwell's homepage runs a new-patient offer: semaglutide from $149 a month and tirzepatide from $199. Its own semaglutide and tirzepatide pages print no price at all, only "Available by consultation". No standing monthly rate is published for either molecule. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Alinwell sells compounded semaglutide and tirzepatide by injection, marketed to women, plus a microdose program. The site runs the same compiled application as seven other GLP-1 brands, down to the testimonial photographs. Each brand configures its own products and prices inside that shared software. 1. ## Who writes the prescription, and what do they see? The site says licensed providers review each patient's health and make every dosing decision. It does not name a clinician, a medical group or a state license. A patient who is not approved pays nothing, per the homepage. The program page lists a dedicated provider, portal messaging and structured check-ins. Medication ships from partner compounding pharmacies in temperature-controlled packaging. The FAQ says no long-term commitment is required. Service is stated as available in all 50 states. 2. ## What happens when the dose goes up? The semaglutide page describes [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) in month one and a therapeutic dose by month three. It cites trial averages, not Alinwell patients. No milligram schedule is published, and nothing says whether the monthly charge changes with dose. 3. ## What the price includes The two homepage figures carry the words "from" and sit under a new-patient banner. The footer adds "Plans from $149/mo · confirmed after provider review". The product pages, which would normally carry the binding figure, defer to the consultation. A reader cannot tell from the site what month two costs. 4. ## What it claims, and what it cites Both molecules are compounded. The homepage states that compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are not FDA-approved and are not the same as the branded medications. Certificates of analysis are posted for several batches, with the vial concentration. The pharmacies themselves are not named. ## Where it holds up, and where it does not - Strength: Batch certificates of analysis are published - Strength: Compounded status is stated plainly - Strength: No charge if a patient is not approved - Strength: No long-term commitment required - Limitation: Product pages print no price - Limitation: Homepage figures are a new-patient offer - Limitation: Shares one build with seven other brands - Limitation: No clinician or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Alinwell. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A woman who wants a provider-led compounded program and will get the post-consultation price in writing. Wrong for A reader who needs a published standing rate to compare before starting an intake. ## The evidence behind what Alinwell prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Alinwell compares | Seller | Who it suits | Go | | --- | --- | --- | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | | ElleS | Buyers who want the prescribing physicians and pharmacies named before they pay | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AVARA Rx](https://thisglp.com/reviews/avara-rx) [Avono Health](https://thisglp.com/reviews/avono-health) [AZ Health](https://thisglp.com/reviews/az-health) [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) [Bayan Health](https://thisglp.com/reviews/bayan-health) [Believe Health](https://thisglp.com/reviews/believe-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 the monthly price of semaglutide? It is the homepage's new-patient offer. The semaglutide page itself reads "Available by consultation", so the standing rate is not published. Is Alinwell a separate company from other GLP-1 sites? It is its own brand, but the site runs the same compiled application as seven other GLP-1 brands. Each sets its own products and prices within it. Does Alinwell publish lab results for its medication? It posts certificates of analysis for named batches, showing concentration and test month. It does not name the pharmacy. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Allara Health reviews (2026): GLP-1 telehealth sellers | This GLP A women's hormone and metabolic practice that prescribes branded GLP-1s and prices only its own care. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/allara-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Specialist care, drug billed apart # Allara Health review A women's hormone and metabolic practice that prescribes branded GLP-1s and prices only its own care. ## The verdict Allara charges $149 a month for its Complete Care Program when insurance is out of network. That fee covers care, not medication. No GLP-1 price is published. This site ranks no figure for Allara. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 46 Prescription Required Compounded No Availability 45 states and D.C. Allara is a telehealth practice for hormonal, metabolic and gynecological conditions. PCOS and insulin resistance are its core. Weight care is one service among many. GLP-1s are prescribed inside that care. 1. ## Who writes the prescription, and what do they see? Each patient keeps one medical provider and one Registered Dietitian. The same pair handles every visit. The site lists OB-GYNs, endocrinologists and women's health nurse practitioners. Visits are scheduled video calls. The individual clinician is not named before signup. Insurance comes first. Allara is in network with Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare and GEHA in some states. Without coverage, the cash subscription applies. Labs are ordered to build the plan. Medication is optional and decided with the patient. 2. ## What happens when the dose goes up? The prescription page says providers monitor progress and adjust the dose. No schedule is published. The drug is billed through a pharmacy or an insurer. So a dose step does not move the care fee. What it does to the drug bill is not stated. 3. ## What the price includes The $149 is billed monthly with no long-term commitment. A card must be kept on file. With in-network insurance, copays, coinsurance and deductibles apply instead. Labs and prescriptions may be covered by insurance, per the seller. An uninsured buyer has no published drug figure. 4. ## What it claims, and what it cites The GLP-1s named are branded and FDA-approved: Zepbound, [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) pen and tablet, and Foundayo. The page also names Ozempic, Mounjaro and Saxenda. No compounded GLP-1 is offered on the pages read. ## Where it holds up, and where it does not - Strength: Branded, FDA-approved GLP-1s only - Strength: Same clinician and dietitian at every visit - Strength: In network with several major insurers - Strength: No long-term commitment on the cash plan - Limitation: No medication price is published - Limitation: The cash fee buys care, not the drug - Limitation: Insurance status decides the cost - Limitation: Full care is not offered in every state ## What the evidence says about this kind of treatment The assessment above is about Allara Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A woman with PCOS or insulin resistance who wants a specialist team and may have coverage. Wrong for A cash buyer who wants one monthly figure that includes the medication. ## The evidence behind what Allara Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Allara Health compares | Seller | Who it suits | Go | | --- | --- | --- | | PCOS Sisters | Women with PCOS in a covered state who want a named specialist and monthly visits | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | | Knownwell | Insured patients who want ongoing care from one obesity-medicine clinician | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Better U Care](https://thisglp.com/reviews/better-u-care) [BetterMe Rx](https://thisglp.com/reviews/betterme-rx) [BeyondMD](https://thisglp.com/reviews/beyondmd) [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) [BiltRx](https://thisglp.com/reviews/biltrx) [Bionomy Health](https://thisglp.com/reviews/bionomy-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $149 a month include a GLP-1? No. It is the Complete Care Program fee for patients whose insurance is out of network. Medication is billed separately. Does Allara prescribe compounded semaglutide? The pages read name only branded products, such as Wegovy, Zepbound and Foundayo. No compounded GLP-1 is listed. Where is Allara available? Full medical and nutrition care is listed for 45 states and D.C. Five more states get a nutrition-only membership. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Alloy reviews (2026): GLP-1 telehealth sellers | This GLP Every figure at this seller is a medication rate plus a $99 monthly care fee charged alongside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/alloy Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Medication plus required fee # Alloy review Every figure at this seller is a medication rate plus a $99 monthly care fee charged alongside it. ## The verdict Alloy charges $70 a month for compounded semaglutide, $100 for compounded tirzepatide and $115 for compounded liraglutide. A $99 monthly care fee sits on top of each, making the real figures $169, $199 and $214. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Liraglutide · Semaglutide · Tirzepatide Form Injection From From $169/mo Prescription Required Alloy sells three compounded GLP-1 molecules and both branded weekly injections through an online weight-care service. The compounded medication rates are $70, $100 and $115 a month, for semaglutide, tirzepatide and liraglutide. A separate care fee of $99 a month applies to every row. Wegovy is listed from $199 and Zepbound from $299, both before that fee. 1. ## Who writes the prescription, and what do they see? The $99 line is labeled ongoing treatment and support, the closest this seller comes to pricing clinician access. It is charged monthly and is the same across all five medication rows. Whether it buys a scheduled visit, a message thread or a review of an intake form is not stated on the seller’s own pages. The medication rate and the care fee are billed as two lines, so the reader can at least see which is which. The care fee is the structure here, and it is charged every month rather than once a year. It does not vary with the molecule, so compounded tirzepatide stays $30 above compounded semaglutide on either basis. The branded rows are where the medication line itself can move, since both are printed as starting figures. Zepbound is $299 for the medication, or $398 with the fee. 2. ## What happens when the dose goes up? The compounded rows carry one medication rate each, with no per-dose ladder published beside them. Wegovy is the exception, and its schedule is set by the pharmacy rather than by Alloy. Alloy routes the prescription to NovoCare, which bills $199 a month for a new patient's first two fills, at 0.25 and 0.5 mg. From the third fill, NovoCare's published rate is $349 a month at every standard dose up to 2.4 mg. Liraglutide is dosed daily rather than weekly, so its escalation runs on a different schedule from the other two. 3. ## What the price includes A reader comparing sellers on the medication rate alone would put Alloy near the low end of this market. Adding the fee moves compounded semaglutide to $169, which is a different position entirely. The fee is the same whichever molecule is taken, so it weighs heaviest where the medication rate is smallest. On semaglutide it is more than half the total. Wegovy is the price most likely to mislead. Alloy prints “Starting at $199” with $499 struck, and that $199 is NovoCare's new-patient offer, limited to two fills through December 31, 2026. At NovoCare's standing $349 plus the care fee, Wegovy here costs $448 a month. A $50 first-month code runs across the site; it lowers one bill, not the monthly rate. 4. ## What it claims, and what it cites Three of the five rows are compounded preparations, made by a pharmacy rather than a manufacturer, and not FDA-approved. [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are the manufacturers' finished products. Liraglutide is the older molecule of the three and is dosed daily rather than weekly. The trial evidence for each was generated with the approved products at label doses, and compounded preparations were not studied. ## Where it holds up, and where it does not - Strength: Three compounded molecules at one seller - Strength: Care fee amount published, not implied - Strength: Branded and compounded routes both listed - Limitation: Care fee is $99 every month - Limitation: Medication rate excludes that fee - Limitation: Fee dominates a low medication rate - Limitation: Wegovy's $199 covers two fills only ## What the evidence says about this kind of treatment The assessment above is about Alloy. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader comparing three molecules at a single seller, where the same fixed fee sits on top of each of them. Wrong for A reader who wants one charge a month, since the medication and the care fee are billed as two separate lines here. ## The evidence behind what Alloy prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Alloy compares | Seller | Who it suits | Go | | --- | --- | --- | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | | Maximus | A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Blis MD](https://thisglp.com/reviews/blis-md) [Bliv](https://thisglp.com/reviews/bliv) [Bloom MD](https://thisglp.com/reviews/bloommd) [BloomWell Rx](https://thisglp.com/reviews/bloomwell-rx) [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) [Blue Sky MD](https://thisglp.com/reviews/blue-sky-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can the $99 care fee be declined? It is charged alongside every medication row on this seller's page, so the figures this site ranks on include it. A reader should treat $169 rather than $70 as the monthly cost of compounded semaglutide here. Which molecule is cheapest once the fee is counted? Compounded semaglutide, at $169 a month. Compounded tirzepatide is $199 and compounded liraglutide $214, because the fee is identical across all three. What does Wegovy cost here after the first two fills? NovoCare, the pharmacy Alloy sends the prescription to, bills $349 a month at every standard dose once a new patient's two $199 fills are used. With the care fee, that is $448 a month. How does Zepbound compare? Zepbound starts at $299 for the medication, or $398 with the care fee. Alloy prints it as a starting figure, so the $299 may not hold at every dose. Does the $50 first-month code change the price? It lowers the first bill only. The monthly figures on this page are the standing rates, before any first-month code. Is Alloy expensive compared with other GLP-1 telehealth sellers? Alloy publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Alloy below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Alternate Health Club reviews (2026): GLP-1 telehealth sellers | This GLP The rate reads per month and the vial is stated to cover twenty-eight days. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/alternate-health-club Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A month, or twenty-eight days # Alternate Health Club review The rate reads per month and the vial is stated to cover twenty-eight days. ## The verdict Alternate Health Club charges $129 a month for compounded semaglutide and $169 for compounded tirzepatide, both paired with vitamin B12 and both promised at flat pricing whatever the dose, which is about as legible as this category gets. The one thing worth holding onto is in its own product copy: each vial is described as designed to cover twenty-eight days, while the price beside it reads per month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $129/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Alternate Health Club is a telehealth storefront whose GLP-1 line runs compounded semaglutide and compounded tirzepatide as weekly subcutaneous injections, with separate microdose versions of each sold as their own products. Longevity treatments including glutathione, NAD+ and sermorelin sit beside them at their own monthly rates, as do migraine and erectile dysfunction products. 1. ## Who writes the prescription, and what do they see? The product pages describe a licensed provider clinically reviewing the intake and issuing a prescription only where they find it medically appropriate, which is stated as a condition rather than a formality. Dosage instructions are emailed after approval rather than printed on the product page, and dose support is offered through live chat or a support address. No individual provider or medical group is named. What the care plan includes is set out item by item rather than summarized: clinical review, a treatment plan built from the health history, the prescription itself, cold-chain express shipping, emailed dosing instructions, and dose support on request. Cold-chain handling is specified rather than assumed, which matters for a medication that has to stay refrigerated in transit. A separate eligibility check runs before the full intake. 2. ## What happens when the dose goes up? Flat pricing at every dose is stated on both product pages, so the climb itself carries no surcharge, and the microdose products sit outside that ladder as separate purchases at their own rates. Dosing instructions arrive by email after a provider approves the plan rather than being published up front, so a buyer cannot see the schedule before paying. No milligram figure appears on either product page. 3. ## What the price includes Semaglutide is $129 a month and tirzepatide is $169, both quoted as a from-price on the product page and both repeated on the homepage tile without contradiction. The longevity line is priced in the same style and on the same pages, which makes the whole catalog readable in one pass. The detail that complicates the arithmetic is the vial's stated twenty-eight-day coverage against a rate written per month. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded rather than manufactured, prepared to order by a pharmacy, which means the FDA does not review the preparation before it is dispensed. Each formula is described as pairing the active ingredient with vitamin B12 in a single weekly injection. No compounding pharmacy is named. No LegitScript certification is claimed. ## Where it holds up, and where it does not - Strength: Flat pricing at every dose is stated on both products - Strength: Cold-chain express shipping is specified - Strength: The care plan is itemized rather than summarized - Strength: Both rates appear on the tile and the product page unchanged - Strength: Microdose versions are sold and priced separately - Limitation: Each vial is stated to cover twenty-eight days, not a month - Limitation: The dosing schedule arrives only after approval - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published on either product page ## What the evidence says about this kind of treatment The assessment above is about Alternate Health Club. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants cold-chain shipping and one rate across the whole dose ladder. Wrong for A buyer who wants the titration schedule in hand before paying. ## The evidence behind what Alternate Health Club prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Alternate Health Club compares | Seller | Who it suits | Go | | --- | --- | --- | | CoreAge Rx | A reader still at a starting dose, since that is the tier these rates price. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | | SnagRx | Buyers who want to stay month to month without paying much for it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [boostAGErx](https://thisglp.com/reviews/boostagerx) [Boston Medical Group](https://thisglp.com/reviews/boston-medical-group) [Breeze Meds](https://thisglp.com/reviews/breeze-meds) [Brello Health](https://thisglp.com/reviews/brello-health) [Brightmeds](https://thisglp.com/reviews/brightmeds) [Cabana](https://thisglp.com/reviews/cabana) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does a higher dose cost more? No. Both product pages state flat pricing at every dose, and the microdose products are sold separately at their own rates. How long does one vial last? The product page states each vial is designed to cover twenty-eight days, which is four weekly injections rather than a calendar month. What is in the injection besides the GLP-1? Vitamin B12. Both the semaglutide and the tirzepatide formulas are described as pairing the active ingredient with it. Is Alternate Health Club expensive compared with other GLP-1 telehealth sellers? Alternate Health Club publishes a starting figure of $129/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Alternate Health Club below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # altRX reviews (2026): GLP-1 telehealth sellers | This GLP Compounded semaglutide and tirzepatide with named dispensing pharmacies, a published dose schedule, and monthly product prices. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/altrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named pharmacies, monthly prices # altRX review Compounded semaglutide and tirzepatide with named dispensing pharmacies, a published dose schedule, and monthly product prices. ## The verdict altRx identifies its prescribing practice and four pharmacies, giving readers more of the care pathway to check before they enroll. The current product pages list semaglutide at $89 a month and tirzepatide at $149, without the earlier dated promotional banner. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $89/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states altRx sells compounded semaglutide and compounded tirzepatide in multi-dose vials through a self-pay membership, and lists brand-name Zepbound, Wegovy and Ozempic as further options on its homepage. It describes itself as the technology and administrative platform rather than the medical practice. 1. ## Who writes the prescription, and what do they see? Prescribing is done by clinicians of OpenLoop Healthcare Partners and its affiliated practices, which the footer names as independently owned. The evaluation can be a live video visit or an asynchronous review, depending on what the treating provider and the patient's state allow. After a free two-minute assessment, a provider decides whether treatment fits, and the prescription goes to a pharmacy in the altRx network. The vial ships with syringes, needles and alcohol swabs. The membership is described as covering consultations, messaging support and shipping, and it can be paused or canceled at any time. 2. ## What happens when the dose goes up? The semaglutide page gives the schedule in plain numbers: 0.25mg weekly for four weeks, then stepping up to a maintenance dose between 1.0mg and 2.4mg. The site's own line on price across that climb is 'Same price at every dose', which matters most in the second and third months when the steps come quickly. The FAQ adds that stopping may mean a taper, and that regain after discontinuation is common. 3. ## What the price includes The semaglutide product page displays $89 a month, while the tirzepatide page displays $149. The homepage says there are no membership fees or price hikes and that patients can cancel anytime. Confirm the specific prescription and renewal terms before completing enrollment. 4. ## What it claims, and what it cites Both molecules are compounded by state-licensed 503A pharmacies and are not FDA-approved; the FAQ says the compounded versions have not been evaluated for safety, efficacy or quality. The pharmacies are named in the FAQ, with addresses: RedRock Pharmacy in Utah, Health Warehouse in Kentucky, Precision Medicine in New York and Triad Rx in Alabama. ## Where it holds up, and where it does not - Strength: Four filling pharmacies named, with addresses - Strength: A milligram dose schedule is published - Strength: Prescribing practice is identified - Strength: Available in all 50 states per the FAQ - Limitation: Compounded preparations are not FDA-approved - Limitation: Final prescription depends on clinical evaluation - Limitation: Weight-loss claims rest on self-reported member data - Limitation: Some testimonials are from paid endorsers, per the site ## What the evidence says about this kind of treatment The assessment above is about altRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who values a named prescribing practice and pharmacy network alongside the dose schedule. Wrong for Someone seeking trial results for the compounded preparations themselves rather than evidence from approved products. ## The evidence behind what altRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How altRX compares | Seller | Who it suits | Go | | --- | --- | --- | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | Eden | Buyers comparing what the two molecules actually cost | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Brightmeds](https://thisglp.com/reviews/brightmeds) [Cabana](https://thisglp.com/reviews/cabana) [CaliberRx](https://thisglp.com/reviews/caliberrx) [Calibrate Health](https://thisglp.com/reviews/calibrate-health) [California Trim Clinic](https://thisglp.com/reviews/california-trim-clinic) [Call-On-Doc](https://thisglp.com/reviews/call-on-doc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What monthly prices does altRx publish? Its current product pages list $89 for compounded semaglutide and $149 for compounded tirzepatide. The earlier September promotion is no longer displayed. Which pharmacies fill altRx prescriptions? The FAQ names RedRock Pharmacy, Health Warehouse, Precision Medicine and Triad Rx, all state-licensed compounding pharmacies. Who actually prescribes? Clinicians with OpenLoop Healthcare Partners and affiliated practices. The seller describes itself as the platform that connects patients to them. Is altRX legit? altRX is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is altRX expensive compared with other GLP-1 telehealth sellers? altRX publishes a starting figure of $89/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts altRX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Always Wellness and Recovery reviews (2026): GLP-1 telehealth sellers | This GLP Three-month titration bundles priced stage by stage, and single-month vials priced by strength. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/always-wellness-and-recovery Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every stage priced upfront # Always Wellness and Recovery review Three-month titration bundles priced stage by stage, and single-month vials priced by strength. ## The verdict Always Wellness and Recovery sells a single-month vial of compounded semaglutide from $210. Tirzepatide vials start at $280. Three-month titration bundles cost less per month. Every stage of those bundles is priced before checkout. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $210/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Always Wellness and Recovery is a telehealth clinic for weight loss, peptides and hormone therapy. Its weight-loss line is compounded semaglutide and tirzepatide. Each is sold two ways: as three-month titration bundles and as single-month vials. 1. ## Who writes the prescription, and what do they see? A licensed physician reviews each intake in an asynchronous appointment. The patient does not attend it. The physician makes contact before prescribing if anything needs clarifying. A providers page names six physicians and their specialties. No license numbers are given. The home page quotes a medical director, Dr. M. Reyes, who is not on that page. The providers page gives the title to Dr. Amanda Chen. Checkout comes first. A medical intake of about ten minutes follows. The physician reviews it and the pharmacy ships. The weight-loss page says the card is charged at checkout and refunded if nothing is prescribed. The FAQ says no charge is taken before approval. No lab work is required for weight loss. Messaging runs through a patient portal. 2. ## What happens when the dose goes up? The [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) path is the part this seller publishes in full. Semaglutide bundles run $349 for months one to three, then $429 for months four to six. After that the price is $499 per three months. Tirzepatide runs $499, then $699, then $849. The FAQ gives the reason: later bundles hold higher-strength vials. After month six, dose and price hold steady. The first semaglutide bundle lists its vials: 1 mg, 2 mg, then 4 mg. 3. ## What the price includes Single-month vials are priced by strength. Semaglutide runs from $210 for a 1 mg vial to $295 for 10 mg. Tirzepatide runs from $280 for 5 mg to $460 for 30 mg. The bundles cost less per month but are three-month purchases. There is no membership fee. Nothing renews automatically. HSA and FSA cards are accepted, and insurance is not. 4. ## What it claims, and what it cites Both products are compounded by a licensed 503A pharmacy. The pharmacy is not named. The site states that compounded medications are not FDA-approved. It adds that the FDA does not review them for safety, effectiveness or quality. The general FAQ notes the active ingredients are FDA-approved. ## Where it holds up, and where it does not - Strength: Every titration stage priced before checkout - Strength: Vial strengths printed on the starter bundle - Strength: No membership fee and no automatic billing - Strength: Single-month vials sold without a bundle - Limitation: Two pages disagree on when the card is charged - Limitation: Two different medical directors are named - Limitation: The compounding pharmacy is not named - Limitation: Single-vial price climbs with strength ## What the evidence says about this kind of treatment The assessment above is about Always Wellness and Recovery. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the first six months costed before starting. Wrong for A buyer who wants one flat monthly rate at every dose. ## The evidence behind what Always Wellness and Recovery prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Always Wellness and Recovery compares | Seller | Who it suits | Go | | --- | --- | --- | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | | Tuyo Health | Buyers weighing a compounded plan against brand Wegovy or Zepbound at the same clinic | | | Amble | Buyers who want a multi-month rate that holds at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Candor Rx](https://thisglp.com/reviews/candor-rx) [Care Bare Rx](https://thisglp.com/reviews/care-bare-rx) [Care Clinics](https://thisglp.com/reviews/care-clinics) [Carocare Wellness](https://thisglp.com/reviews/carocare-wellness) [CeliaRx](https://thisglp.com/reviews/celia-rx) [Center for Medical Weight Loss (CMWL)](https://thisglp.com/reviews/center-for-medical-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does the bundle price rise at month four? The seller says later bundles contain higher-strength vials. After month six, the dose and the price hold steady. Is there a month-to-month option? Yes. Single-month vials are sold separately and priced by strength. Semaglutide starts at $210 and tirzepatide at $280. Is lab work required? Not for weight loss. The physician works from the medical history in the intake. Is Always Wellness and Recovery legit? Always Wellness and Recovery is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Always Wellness and Recovery expensive compared with other GLP-1 telehealth sellers? Always Wellness and Recovery publishes a starting figure of $210/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Always Wellness and Recovery above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AlyveRx reviews (2026): GLP-1 telehealth sellers | This GLP Tirzepatide comes as an injection and as needle-free sublingual drops, and the two are priced as different products. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/alyverx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two routes for tirzepatide # AlyveRx review Tirzepatide comes as an injection and as needle-free sublingual drops, and the two are priced as different products. ## The verdict AlyveRx publishes $183 a month for a compounded semaglutide injection and $283 for a compounded tirzepatide injection. Needle-free sublingual tirzepatide drops are a separate product at $249. AlyveRx states the rate is lower on longer plans and holds at every dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $183/mo Prescription Required Compounded Yes — not FDA-approved AlyveRx sells compounded injections of both molecules. Tirzepatide is also sold as sublingual drops. The route differs between them, which the pages state rather than leave to be assumed. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe the route and the billing rather than the clinician. What the intake asks is not published. Naming the route on each line is the disclosure. A reader comparing the $249 drops against another seller's tirzepatide injection is comparing two different products. AlyveRx says which is which. 2. ## What happens when the dose goes up? The rate is stated to hold at every dose. Longer plans are said to lower it, without the figures being published. So the dose question is answered and the term question is not. 3. ## What the price includes $183 is the monthly semaglutide injection rate. Six months at it is $1,098. The tirzepatide injection is $283, or $1,698 over six months. The drops are $249. Whether a drop at $249 is dearer than an injection is not a question a price answers. The milligrams do not read across. What longer plans cost is not published. 4. ## What it claims, and what it cites Both lines are compounded. The FDA does not review them before dispensing. Sublingual drops and a weekly injection are not interchangeable milligram for milligram, and no absorption data is published for the drop route. ## Where it holds up, and where it does not - Strength: The route is named on each line - Strength: Rate stated to hold at every dose - Strength: All three figures published without an intake - Limitation: Longer-plan rates are not published - Limitation: No absorption data for the drops - Limitation: Only two molecules are offered - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about AlyveRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a needle-free route named as such rather than implied. Wrong for A reader comparing the drops against an injection on milligrams. ## The evidence behind what AlyveRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AlyveRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Actin | A reader weighing term lengths who will confirm the price at each dose step | | | Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | | | Idgie Health | A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Citizen Meds](https://thisglp.com/reviews/citizen-meds) [Claya](https://thisglp.com/reviews/claya) [Clinic Secret](https://thisglp.com/reviews/clinic-secret) [Clume Health](https://thisglp.com/reviews/clume-health) [CLYR Health](https://thisglp.com/reviews/clyr-health) [Coivas](https://thisglp.com/reviews/coivas) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are the drops equivalent to an injection? Not established. Sublingual and injected milligrams do not read across, and AlyveRx publishes no absorption data for the drop route. What do longer plans cost? Not published. AlyveRx states the rate is lower on longer plans without giving the figures. Does the price rise with the dose? AlyveRx states it does not, on both lines. Is AlyveRx expensive compared with other GLP-1 telehealth sellers? AlyveRx publishes a starting figure of $183/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AlyveRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Amazon One Medical reviews (2026): GLP-1 telehealth sellers | This GLP Pay-as-you-go prescribing for branded GLP-1s, where the visit, the medication and the labs are three separate bills. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/amazon-one-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Visit and drug billed apart # Amazon One Medical review Pay-as-you-go prescribing for branded GLP-1s, where the visit, the medication and the labs are three separate bills. ## The verdict Amazon One Medical sells the visit, not the drug. Care starts from $39, and medication is bought separately at a pharmacy. The lowest cash figure shown, $149 for a starting-dose tablet, depends on a manufacturer coupon and eligibility. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron Form Injection · Oral States 50 Dose published Yes Prescription Required Compounded No Labs Extra cost Amazon One Medical offers GLP-1 weight care two ways. On-Demand Care is cash-only telehealth, paid per treatment. Scheduled Visits run through One Medical's membership and can bill insurance. The prices below are the On-Demand route's. 1. ## Who writes the prescription, and what do they see? A licensed One Medical clinician reviews an online intake and decides whether a GLP-1 fits. Eligibility is set out plainly: adults 18 to 64, meeting FDA criteria, without diabetes. Recent labs showing creatinine, eGFR and fasting glucose are required. Clinicians will not prescribe a compounded medication. After a treatment, a patient can message the care team for 14 days. Past that window, a new treatment request is needed. Prescriptions go to any pharmacy, with Amazon Pharmacy shown as an option. On-Demand Care does not handle prior authorizations. 2. ## What happens when the dose goes up? The page says treatment begins at a starter dose and steps up at check-ins. Every cash figure it shows is for the starting dose only. Prices at maintenance doses are not published. The page adds that meaningful loss, above 5%, usually appears around week 12. 3. ## What the price includes Three costs apply. The visit starts from $39 and varies by state. The medication is bought separately; the cash tablet price of $149 includes a manufacturer coupon, if eligible. Labs are purchased separately too. With insurance, the page estimates $25, but that applies only after prior authorization. 4. ## What it claims, and what it cites Only branded, FDA-approved GLP-1s are offered: Foundayo and Wegovy tablets, and Wegovy and Zepbound injections. Each price card names the supply length and the starting dose in milligrams. ## Where it holds up, and where it does not - Strength: Branded, FDA-approved medicines only - Strength: Doses and supply lengths printed on each card - Strength: Lab and eligibility rules stated up front - Strength: No membership needed for On-Demand Care - Limitation: Visit, drug and labs are billed separately - Limitation: Cash drug prices rely on a coupon - Limitation: Messaging closes after 14 days - Limitation: Only starting-dose prices are shown ## What the evidence says about this kind of treatment The assessment above is about Amazon One Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A cash payer who wants a branded GLP-1 and is comfortable arranging labs and a pharmacy. Wrong for A reader who wants one monthly fee covering care and medication together. ## The evidence behind what Amazon One Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. ## How Amazon One Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | | LifeMD | Readers with insurance that may cover the medication, leaving the fee as the main cost | | | Walgreens Weight Management | Readers who want the approved product and count fills rather than months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [CLYR Health](https://thisglp.com/reviews/clyr-health) [Coivas](https://thisglp.com/reviews/coivas) [Concierge MD LA](https://thisglp.com/reviews/concierge-md-la) [Contour Health](https://thisglp.com/reviews/contour-health) [Cora Health](https://thisglp.com/reviews/cora-health) [CoraDoc](https://thisglp.com/reviews/coradoc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $25 the price of Foundayo? Only with insurance and an approved prior authorization, and the page calls it an estimate. The cash figure is higher and depends on a coupon. Does the visit fee include the drug? No. The page states that medication and lab costs are not included in the price of care. Can I get compounded semaglutide here? No. The FAQ says clinicians will not write a prescription for a compounded medication. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ambiante Health & Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Ambiante combines metabolic, longevity and aesthetic marketing with independent clinician access. Its semaglutide page and terms give different cancellation notice periods. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ambiante-health-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Women-focused concierge platform # Ambiante Health & Wellness review Ambiante combines metabolic, longevity and aesthetic marketing with independent clinician access. Its semaglutide page and terms give different cancellation notice periods. ## The verdict The direct-care description may appeal to someone seeking a continuing relationship, but the contract needs clarification. The treatment page asks for 30 days’ notice while the general terms describe a 48-hour auto-refill cutoff. Neither should be silently preferred. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Ambiante Health & Wellness is a women-focused telehealth platform with semaglutide and tirzepatide pathways alongside other wellness services. 1. ## Who writes the prescription, and what do they see? The platform identifies Lilly Baptiste as founder and clinical director, while its legal disclaimer assigns treatment to independent licensed providers. Confirm the actual practice and clinician before assuming the founder personally manages care. A consultation is followed by provider review, pharmacy preparation if authorized and ongoing contact. The semaglutide page describes direct messaging and structured check-ins without a fixed universal visit frequency. 2. ## What happens when the dose goes up? The program describes dose adjustment under provider supervision and flat-rate pricing. Ask what a check-in involves and how promptly a clinician responds when tolerance changes. 3. ## What the price includes Public pages promise flat rates confirmed after clinical review rather than a full published amount. No complete monthly medication-and-care total is established before the consultation quote. 4. ## What it claims, and what it cites The platform describes pharmacy-compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) care. Compounded products are not FDA-approved; longevity and microdose language should not be treated as established benefits beyond the evidence for the exact prescribed product. ## Where it holds up, and where it does not - Strength: Direct messaging described - Strength: Clinical and platform roles separated - Limitation: Cancellation deadlines conflict - Limitation: No specified visit frequency ## What the evidence says about this kind of treatment The assessment above is about Ambiante Health & Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants women-focused care and will verify clinical access and contract terms first. Wrong for Someone expecting a public fixed quote and one consistent cancellation deadline. ## The evidence behind what Ambiante Health & Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ambiante Health & Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) [DoctorAdam](https://thisglp.com/reviews/doctoradam) [Dollar Dad Club](https://thisglp.com/reviews/dollar-dad-club) [Dr. Arevitalize](https://thisglp.com/reviews/dr-arevitalize) [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) [DrBrainRx](https://thisglp.com/reviews/drbrainrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the founder necessarily my prescriber? No. The site names a founder but says independent licensed providers make treatment decisions; confirm the assigned clinician. Is longevity marketing evidence of a proven GLP-1 benefit? Not by itself. Discuss the evidence and risks for the precise formulation and intended use with the clinician. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://ambiantehealthandwellness.com/) - [Official program and terms](https://ambiantehealthandwellness.com/terms) - [Official program and terms](https://ambiantehealthandwellness.com/treatments/semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Amble reviews (2026): GLP-1 telehealth sellers | This GLP Two compounded lines, three plan lengths each, and one rate that holds at every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/amble Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat at every dose, three terms # Amble review Two compounded lines, three plan lengths each, and one rate that holds at every dose. ## The verdict Amble charges $179 for one month of compounded semaglutide, $160 a month on three and $135 on six, and $329 for one month of compounded tirzepatide, falling to $255 and $235. Both rates are stated to hold at every dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $179/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Amble is a weight-loss telehealth program selling two once-weekly compounded injections, reached from navigation tabs that name them as compounded semaglutide and compounded tirzepatide. Anti-aging, medical kits and skin categories share the same menu, and a separate landing page offers a GLP-1 and GIP combination bundled with NAD+ at $250 for a one-month supply. 1. ## Who writes the prescription, and what do they see? A licensed medical provider reviews the online medical intake and determines whether the medication is right for the patient, and secure messaging with scheduled check-ins runs afterwards at any hour. What the provider reads before writing is not described, and no clinician, medical group or medical director is named. The buyer picks the molecule by picking the page, and the provider then decides whether that medication is right for them. Every plan is stated to include supplies, shipping and ongoing clinical monitoring, with medication cold-shipped to the door and no pharmacy trip involved. A fast-acting anti-nausea medication is offered as an add-on to eligible patients rather than included, which is at least stated rather than left to be discovered later. There is no insurance requirement and no separate membership charge on any of the three plans. 2. ## What happens when the dose goes up? Amble publishes a step-by-step dose-escalation schedule as one of the things a plan includes, and describes dose adjustments as available where clinically appropriate, which is more than a flat promise that nothing changes. The rate is stated to stay the same at every dose, so climbing does not cost more. What neither page carries is a milligram at any rung, so the escalation is described in the abstract and cannot be checked against a label schedule. 3. ## What the price includes Each plan table is three rows and reads cleanly: semaglutide at $135, $160 and $179, tirzepatide at $235, $255 and $329, for six, three and one month. Nothing is struck through and no first-month rate is layered on top, which puts Amble ahead of several sellers charging similar figures. Six months of semaglutide on the longest plan is $810, and the same term of tirzepatide is $1,410. A promotional banner across the top of the site offers a GLP-1 at $150 with NAD+ at $100, on terms the banner itself does not explain. 4. ## What it claims, and what it cites The product is compounded, and Amble's own disclosure states that compounded products are not approved or evaluated for safety, efficacy or quality by the FDA and that no efficacy claims are made for them. The compounding pharmacy is not named. The outcome statistics on the page come from a May 2025 survey of more than sixteen thousand members, using their own scale and tape-measure readings, and the disclosure notes that participants were compensated for taking part. ## Where it holds up, and where it does not - Strength: Three plan lengths priced with nothing struck through - Strength: Rate stated to hold at every dose - Strength: Supplies, shipping and monitoring included in every plan - Strength: A dose-escalation schedule is named as part of the plan - Strength: The survey behind the outcome figures is disclosed in full - Limitation: No milligram appears on either plan - Limitation: Tirzepatide costs $150 more for a single month - Limitation: Anti-nausea support is an add-on rather than included - Limitation: The compounding pharmacy and the clinicians are unnamed - Limitation: The banner offer states no terms ## What the evidence says about this kind of treatment The assessment above is about Amble. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a six-month rate that holds as the dose climbs. Wrong for A reader who needs the milligram schedule or the pharmacy named before ordering. ## The evidence behind what Amble prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Amble compares | Seller | Who it suits | Go | | --- | --- | --- | | Eloria | Buyers who read the refill rate before the first-month rate | | | Mondae | Buyers who want a low published compounded rate and few other details | | | Nova MD | Buyers who will read which plan is already selected before they press start | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) [DrBrainRx](https://thisglp.com/reviews/drbrainrx) [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) [DudeMeds](https://thisglp.com/reviews/dudemeds) [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) [Edessa](https://thisglp.com/reviews/edessa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Amble sell both semaglutide and tirzepatide? Yes. Each has its own page and plan table: semaglutide from $179 a month and tirzepatide from $329 a month, both lower on longer plans. Does the price rise as the dose rises? No. Amble states the same price applies at every dose across all three plan lengths. Where do the weight-loss figures come from? A May 2025 survey of more than sixteen thousand members, using their own scale and tape readings, whose participants were compensated. Is Amble expensive compared with other GLP-1 telehealth sellers? Amble publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Amble below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AM Rx reviews (2026): GLP-1 telehealth sellers | This GLP Insurance coordination for brand-name drugs, plus a cash route for compounded semaglutide and tirzepatide. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/amrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership first, medication second # AM Rx review Insurance coordination for brand-name drugs, plus a cash route for compounded semaglutide and tirzepatide. ## The verdict AM Rx is a membership service first. The standard membership is $135 a month. GLP-1 medication is billed on top, except in two bundles. No figure is ranked here. The cash rates are quarterly or first-month figures, and the membership sits outside them. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Prescription Required AM Rx is an online clinic. It covers weight loss, primary care, mental health and several other services. The weight-loss program has two routes. One coordinates insurance for Wegovy, Ozempic, Zepbound and Mounjaro. The other sells compounded semaglutide or tirzepatide for cash. 1. ## Who writes the prescription, and what do they see? A licensed AM Rx provider reviews the intake and medical history. The provider then prescribes, or declines to. The FAQ says a stated preference is considered, not guaranteed. Visits run by video, phone or secure message. One provider group named in the membership terms is Bruno Health. The membership is the core product. It covers insurance navigation, messaging with the care team and coaching. Per the FAQ, GLP-1 medication is typically not included in it. A prior authorization stays active only while the membership does. A denied request can be resubmitted up to three times. Medicare and Medicaid members are not eligible. 2. ## What happens when the dose goes up? The bundles carry one dose rule. A dose above standard [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) may add fees. Those fees are not priced anywhere. The supply rates carry no dose schedule either. The cost of escalation is set after prescribing. 3. ## What the price includes Several figures matter, and none stands alone. The standard membership is $135 a month. Compounded semaglutide starts at $106 a month on a three-month supply. Compounded tirzepatide starts at $216 a month on the same terms. Both supply rates include a 20% discount for buying three months. The all-in bundles are $297 a month for semaglutide and $449 for tirzepatide. Each opens with a lower first month, $217 and $349. The $25 figure applies only to insured brand-name copays. 4. ## What it claims, and what it cites Brand-name drugs are FDA-approved and reached through insurance. The cash preparations are compounded. Compounded drugs are not FDA-approved. The FDA does not review them before dispensing. The partner pharmacy is not named on the public pages. ## Where it holds up, and where it does not - Strength: Insurance coordination for brand-name GLP-1 drugs - Strength: Up to three prior authorization attempts - Strength: All-in bundles include medication and care - Strength: Refund if found clinically ineligible - Limitation: Membership billed apart from medication - Limitation: Lowest supply rates require a quarterly purchase - Limitation: Higher-dose fees carry no published amount - Limitation: Government insurance members are not eligible ## What the evidence says about this kind of treatment The assessment above is about AM Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader with commercial insurance who wants help getting a brand-name drug covered. Wrong for A reader on Medicare or Medicaid, whom the weight-loss program does not accept. ## The evidence behind what AM Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How AM Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Knownwell | Insured patients who want ongoing care from one obesity-medicine clinician | | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Effecty](https://thisglp.com/reviews/effecty) [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) [Elevate Health](https://thisglp.com/reviews/elevate-health) [Elevated Health](https://thisglp.com/reviews/elevated-health) [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) [ElixaMD](https://thisglp.com/reviews/elixamd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the membership include the medication? Not for GLP-1 drugs. The FAQ says they are typically not included in the membership fee. The two bundles are the exception. What does the $25 figure mean? It is the lowest insured copay the seller cites for a covered brand-name drug. It is not a cash price. Is there a month-to-month cash option? Yes, the bundles. Semaglutide runs $297 a month after a $217 first month. Tirzepatide runs $449 after a $349 first month. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Andrew Meds reviews (2026): GLP-1 telehealth sellers | This GLP Compounded semaglutide and tirzepatide at four plan lengths, prescribed through an independent medical practice the footer names. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/andrew-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four plan lengths, month to month first # Andrew Meds review Compounded semaglutide and tirzepatide at four plan lengths, prescribed through an independent medical practice the footer names. ## The verdict Andrew Meds charges $199 a month for compounded semaglutide and $299 for tirzepatide on its month-to-month plan. A buyer who commits to twelve months pays $149 and $229 a month instead, with the whole year billed as one total at the start. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 51 From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states and DC Andrew Meds is a Houston-based telehealth platform whose weight-loss program, which its own FAQ describes as the launch offering, is compounded semaglutide and tirzepatide by weekly injection. A GHK-Cu skin cream, a CJC-1295 and ipamorelin peptide, and an oral sexual health treatment sit on the menu around that core program. 1. ## Who writes the prescription, and what do they see? The footer names the clinical side outright: care is provided by Dr Tel X, an independent professional medical practice in Kennewick, Washington, with its own support address and phone line. Individual clinicians are not named, and the FAQ describes them only as licensed clinicians in the patient's state who review the intake, talk with the patient and write the prescription if a medication is appropriate. A buyer fills out an intake of about five minutes and then books a consultation, which is a video visit or an online assessment depending on where the buyer lives. The footer spells out the split: questionnaire-based care runs in 44 states, while the District of Columbia and six states, among them Kansas, Louisiana and West Virginia, require a live consultation before treatment. After approval the pharmacy typically ships within a few business days, and Andrew Meds says it will reach out about refill timing. 2. ## What happens when the dose goes up? The FAQ says doses usually start low and are adjusted over time, and that the provider sets the starting dose from the intake and the consultation. What happens to the bill as the dose climbs is not stated, because no milligram appears beside any plan and the pricing table never says whether $199 still covers the stronger doses later in a course. 3. ## What the price includes The table on each product page runs month to month first, and it reads plainly: semaglutide at $199, three months at $549 in total, six at $999 and twelve at $1,788, which the page converts to $149 a month. Tirzepatide follows the same four columns at $299, $797, $1,494 and $2,748, ending at $229 a month. Each longer column prints its saving in dollars, and the page states that the figures cover medication and supplies, with nothing charged for a medication that is never prescribed. 4. ## What it claims, and what it cites Both products are compounded by a licensed pharmacy the site does not name, and the FAQ is direct that they are not the same as [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review), Wegovy, [Mounjaro](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) or Zepbound, which are FDA-approved finished products. Compounded medications are not FDA-approved as finished products, a line the footer repeats on every page of the site. ## Where it holds up, and where it does not - Strength: Month-to-month rate listed first, before any discount - Strength: Every plan total printed beside its saving - Strength: The prescribing medical practice is named - Strength: State consultation rules published in the footer - Limitation: No milligram appears beside any plan - Limitation: Silent on whether higher doses cost more - Limitation: The compounding pharmacy is not named - Limitation: Refunds are handled case by case ## What the evidence says about this kind of treatment The assessment above is about Andrew Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to start month to month and see every longer commitment priced before choosing one. Wrong for A reader who needs the dose and the dispensing pharmacy named before paying anything. ## The evidence behind what Andrew Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Andrew Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EllieMD](https://thisglp.com/reviews/elliemd) [Eloria](https://thisglp.com/reviews/eloria) [Emerge Weight Loss](https://thisglp.com/reviews/emerge-weight-loss) [eMI Aesthetics](https://thisglp.com/reviews/emi-aesthetics) [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 the monthly price for semaglutide? Only on the twelve-month plan, which is billed as $1,788 at the start, while the month-to-month price is $199 for semaglutide and $299 for tirzepatide. Who actually writes the prescription? A licensed clinician working through Dr Tel X, the independent medical practice named in the footer, decides after the intake and the consultation whether any medication is appropriate, though no individual clinician is named. Is a live visit required? In 44 states the consultation can be an online assessment, while the District of Columbia and six states, including Kansas and West Virginia, require a live consultation before any treatment begins. Is Andrew Meds legit? Andrew Meds is a GLP-1 telehealth sellers service. Its stated availability: All 50 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Andrew Meds expensive compared with other GLP-1 telehealth sellers? Andrew Meds publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Andrew Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Apex MD reviews (2026): GLP-1 telehealth sellers | This GLP The weekly injection is sold with three additives, and what those additives do was not measured in the trials behind the drug. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/apex-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Additives inside the price # Apex MD review The weekly injection is sold with three additives, and what those additives do was not measured in the trials behind the drug. ## The verdict Apex MD prices compounded semaglutide at $299 a month by injection and tirzepatide at $399. The injectable preparation includes NAD, B-12 and L-carnitine, none of which the outcome trials studied. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 51 From From $299/mo Prescription Required Compounded Yes — not FDA-approved Apex MD sells compounded semaglutide and compounded tirzepatide as weekly injections. Oral pills appear only on a separate microdosing line. The injectable plans are described as month-to-month. Coverage extends to fifty states and the District of Columbia. 1. ## Who writes the prescription, and what do they see? A prescription is required for both products and treatment is arranged online. The plans are sold as month-to-month, so a reader is not committed past the first fill. What an intake asks before a prescription is written is not published. Nor is how often a patient is reviewed once the plan is running. The injectable preparation is not plain semaglutide. It is compounded with NAD, B-12 and L-carnitine in the same vial. That combination is the product Apex MD is selling, and it is priced as one thing. Whether the additives change the result is a separate question from whether the semaglutide does. 2. ## What happens when the dose goes up? The rate is stated as flat across doses on every plan. An escalation therefore does not move the monthly figure. That matters most between month one and month four, when the dose usually rises. Whether the additive quantities scale with the GLP-1 dose is not stated beside the price. 3. ## What the price includes These are among the higher figures in the compounded market, and the additives are part of what the price buys. A month-to-month plan is what is being priced, with no prepay rung published against it. The gap between the two molecules is $100 a month. 4. ## What it claims, and what it cites Both products are compounded, so a pharmacy prepares them and no regulator reviews the finished vial. The trial evidence a reader may have seen for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) came from the approved products at label doses. Those trials studied the molecule alone. A combination with NAD, B-12 and L-carnitine was not measured. ## Where it holds up, and where it does not - Strength: Additives named on the product page - Strength: Rate stated as flat at every dose - Strength: Plans described as month-to-month - Limitation: Additive combination not studied in trials - Limitation: Figures sit high for compounded products - Limitation: No prepay rung published ## What the evidence says about this kind of treatment The assessment above is about Apex MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a month-to-month plan with no prepay commitment, and who is told what is in the vial before ordering. Wrong for A reader who wants the preparation to match what the trials tested, since the injection here carries three additives the trials did not include. ## The evidence behind what Apex MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Apex MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Maximus | A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus)[Eviora MD](https://thisglp.com/reviews/eviora-md) [Factor Health MD](https://thisglp.com/reviews/factor-health-md) [Fella Health](https://thisglp.com/reviews/fella-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What are the additives in the injection? NAD, B-12 and L-carnitine, compounded into the same weekly injection as the semaglutide. They are described on the product page rather than added at checkout. Do the additives change what the drug does? That was not measured. The published outcome trials for semaglutide and tirzepatide used the approved products at label doses, with no additives. A combination product is a different preparation from the one those trials studied. Is there an oral version? Not in the GLP-1 program. Oral pills are sold on a separate microdosing line, which is a different product from the full-dose injection. Is Apex MD expensive compared with other GLP-1 telehealth sellers? Apex MD publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Apex MD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AquaVita NextGen reviews (2026): GLP-1 telehealth sellers | This GLP Each molecule is sold as a one-month supply at a single published price, with no dose named beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/aquavita-nextgen Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two one-month prices # AquaVita NextGen review Each molecule is sold as a one-month supply at a single published price, with no dose named beside it. ## The verdict Aquavita NextGen publishes $215 for a one-month supply of compounded semaglutide and $320 for tirzepatide, and nothing on the pages says what dose either figure covers. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 5 From From $215/mo Prescription Required Compounded Yes — not FDA-approved Aquavita NextGen sells both molecules by injection, one month at a time, and the catalog is short enough that the two product pages are the whole of what a buyer has to go on before a first order. 1. ## Who writes the prescription, and what do they see? A prescription is issued before anything ships, and the published pages describe products and rates rather than the clinician who writes it, so nothing here says what is reviewed before a first order or a fifth. Remote and price-led, with the two molecule lines carrying the whole of what the site says about itself, and no description of a course of care running underneath them. 2. ## What happens when the dose goes up? Nothing on the pages states what either figure covers in milligrams, so a buyer climbing from a starting dose toward a maintenance one cannot tell from the shop whether the $215 follows them up the ladder. That question belongs in the intake, before the second month rather than after it. 3. ## What the price includes At $215 a month, six months of semaglutide is $1,290, and tirzepatide at $320 runs to $1,920 over the same span. Those totals hold only if the one-month price holds at every dose, which the pages neither promise nor rule out, so the figure is worth confirming on the seller's own page before a first charge. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product would be. ## Where it holds up, and where it does not - Strength: Each price is tied to a one-month supply - Strength: Both molecules carry a published price - Limitation: No care program is described beside the drug - Limitation: No milligram dose beside either figure - Limitation: Nothing published about dose pricing - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about AquaVita NextGen. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a one-month price with no plan attached and will confirm the dose it covers. Wrong for A reader who needs the cost at a maintenance dose settled before ordering. ## The evidence behind what AquaVita NextGen prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AquaVita NextGen compares | Seller | Who it suits | Go | | --- | --- | --- | | ARSYNL Rx | Readers who want both molecules priced on one page and will confirm the figure on the day | | | Clume Health | Readers who want both molecules at one rate and will re-check the figure before paying | | | Candor Rx | Readers who value a bill that does not move with the dose and will confirm the figure first | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Fifty 410](https://thisglp.com/reviews/fifty-410) [FitFlow](https://thisglp.com/reviews/fitflow) [Fitish](https://thisglp.com/reviews/fitish) [Fitness RX](https://thisglp.com/reviews/fitness-rx) [FitRx](https://thisglp.com/reviews/fitrx) [Fitstry](https://thisglp.com/reviews/fitstry) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost? $215 for a one-month supply, the figure printed on both the shop grid and the product page. Does the price change with the dose? The pages do not say, because neither product lists a milligram figure beside its price, so the question belongs in the intake before a first charge rather than after it. What about tirzepatide? That line is $320 a month, and nothing on the pages states what dose either figure covers. Is AquaVita NextGen expensive compared with other GLP-1 telehealth sellers? AquaVita NextGen publishes a starting figure of $215/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AquaVita NextGen above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Arc-1 reviews (2026): GLP-1 telehealth sellers | This GLP Compounded semaglutide and tirzepatide sold as dose-priced variants on a longevity storefront, with checkout before the intake. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/arc-1 Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by the milligram # Arc-1 review Compounded semaglutide and tirzepatide sold as dose-priced variants on a longevity storefront, with checkout before the intake. ## The verdict Arc-1 charges $199.99 for the entry dose of compounded semaglutide and the same for compounded tirzepatide. Each higher dose is sold as a separate variant at a higher price. The product pages show only a starting figure, and the cart is where each dose gets its price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $199.99/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider Arc-1 is a longevity storefront selling B12, NAD+, rapamycin, sermorelin, metformin and erectile dysfunction drugs. Two GLP-1 products sit among them, and both are compounded weekly injections bought like any other item in the cart. 1. ## Who writes the prescription, and what do they see? Checkout comes first, and the medical intake follows it once the order is placed. Licensed practitioners then review the intake and approve or decline the prescription. A practitioner may follow up by chat, phone or video when clarification is needed. The founder is named as Dr. Todd Stearns, DO, a board-certified OB/GYN practicing in Nevada. The site does not say he reviews weight-loss orders, and no other clinician is named. The consultation fee at checkout is listed as $0, and shipping is described as free and expedited. A 30-day window to request a return is stated beside the product. Semaglutide is not offered in Arkansas, Indiana, Minnesota, South Carolina or Puerto Rico. Tirzepatide excludes California, Arkansas, Indiana, Minnesota and South Carolina. The site's process page currently carries an under-construction notice. 2. ## What happens when the dose goes up? The buyer selects a dose on the product page, before any clinician is involved. Semaglutide is offered at 0.5 mg, 1 mg and 2.5 mg weekly, and tirzepatide at 2.5 mg, 5 mg and 7.5 mg. How a patient moves from one rung to the next is not described. The top tirzepatide rung sits at half the 15 mg maximum on the Zepbound label. 3. ## What the price includes Semaglutide costs $199.99 at 0.5 mg, $249.99 at 1 mg and $549.99 at 2.5 mg. Tirzepatide costs $199.99 at 2.5 mg, $249.99 at 5 mg and $399.99 at 7.5 mg. The tirzepatide headline reads starting at $149 a month, yet its entry dose goes into the cart at $199.99. No subscription or multi-month plan is offered on either product page. 4. ## What it claims, and what it cites Both products are compounded by U.S.-licensed pharmacies, and none of those pharmacies is named. The [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is compounded with glycine and B12, at 10 mg, 5 mg and 500 mcg per mL. The weight-loss FAQ calls [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and tirzepatide FDA-approved without qualification. That describes the branded drugs, not the compounded versions sold here, which are not FDA-approved. ## Where it holds up, and where it does not - Strength: Every dose priced as its own variant - Strength: Tirzepatide concentration printed per mL - Strength: Founder named with training and specialty - Strength: No consultation fee at checkout - Limitation: Checkout comes before any clinician review - Limitation: Tirzepatide headline figure differs from the cart - Limitation: FAQ calls the drugs FDA-approved - Limitation: The compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Arc-1. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer expecting to stay at a low dose who wants each dose priced. Wrong for A buyer planning to reach a maintenance dose at one flat rate. ## The evidence behind what Arc-1 prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Arc-1 compares | Seller | Who it suits | Go | | --- | --- | --- | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | | Tuyo Health | Buyers weighing a compounded plan against brand Wegovy or Zepbound at the same clinic | | | Omzo | Buyers who want the medication cost inside one fee rather than billed by a pharmacy | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [FitRx](https://thisglp.com/reviews/fitrx) [Fitstry](https://thisglp.com/reviews/fitstry) [FMmeds](https://thisglp.com/reviews/fmmeds) [FORM](https://thisglp.com/reviews/form) [FormBlends](https://thisglp.com/reviews/formblends) [FormidableMD](https://thisglp.com/reviews/formidablemd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change with the dose? Yes. Each dose is a separate variant, running from $199.99 up to $549.99 for semaglutide at 2.5 mg. Is there a multi-month discount? No multi-month plan is offered on either product, so each purchase is a single one-off order. Is the tirzepatide plain tirzepatide? No. It is compounded with glycine and vitamin B12, at 10 mg, 5 mg and 500 mcg per mL. Is Arc-1 expensive compared with other GLP-1 telehealth sellers? Arc-1 publishes a starting figure of $199.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Arc-1 above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ark Health reviews (2026): GLP-1 telehealth sellers | This GLP Three bundled monthly GLP-1 plans, and an oral option whose page does not name the drug inside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ark-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three plans, one monthly charge # Ark Health review Three bundled monthly GLP-1 plans, and an oral option whose page does not name the drug inside it. ## The verdict Ark Health sells three bundled monthly plans: compounded semaglutide by injection at $169, compounded tirzepatide at $249, and an oral plan at $125. Each bundle folds the consultation, the medication and the follow-up support into that one monthly charge, but the oral plan's own page never names the drug it contains. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $169/mo Oral From $125/mo Prescription Required Compounded Yes — not FDA-approved Ark Health LLC runs a technology platform from Dover, Delaware, and its footer says clinical services come from Beluga Health and affiliated professional entities rather than from Ark. Beyond the three weight plans it lists injectable sermorelin and MIC/B12 on the same treatments page, and its terms name Mississippi as an excluded state. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the health history submitted online and makes the prescribing decision, and the FAQ is careful to say that finishing an intake does not guarantee a prescription will be issued. Ark itself does not provide medical services, so the person who writes the prescription works for the provider group rather than for the company taking the payment. Every plan is sold as a bundle with monthly pricing that covers an online consultation, a personalized care plan, the medication if prescribed and ongoing follow-up support, with free expedited shipping on eligible orders. The part to plan around is the cancellation window, because a request has to arrive at least 15 days before the next order date to stop the next scheduled charge. 2. ## What happens when the dose goes up? Nothing on the three plan pages ties the price to a dose, and the formulation notes say the prescriber and the dispensing pharmacy settle the strength, the quantity and the directions after the review. The semaglutide page adds that a formulation may also contain vitamin B12, vitamin B6 or glycine, though not every formulation does. Whether a higher dose later in the year changes the monthly charge is not stated anywhere on the public pages. 3. ## What the price includes The semaglutide card shows $169 a month beside a struck-through $250, and nothing on the page says the lower figure ends, so $169 reads as the standing rate rather than a first-month promotion. Six months at that rate comes to $1,014, against $1,494 for tirzepatide at $249 and $750 for the oral plan at $125, and the FAQ repeats all three monthly figures as the prices currently displayed. 4. ## What it claims, and what it cites All three plans are compounded preparations, which are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality before they reach a patient, and the site says so on every product page. The oral plan is the one to ask about, since its page says only that the exact active ingredient must be confirmed by the provider and the dispensing pharmacy. ## Where it holds up, and where it does not - Strength: Consultation and follow-up included in each plan - Strength: Standing monthly rates on every plan - Strength: Clinical provider group named in the footer - Strength: Free expedited shipping on eligible orders - Limitation: Oral plan page does not name its drug - Limitation: Cancellation needs fifteen days' notice - Limitation: No milligram dose beside any rate - Limitation: Dispensing pharmacy goes unnamed ## What the evidence says about this kind of treatment The assessment above is about Ark Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the visit, the medication and the follow-up billed together as one monthly charge, and who will set a reminder well ahead of each order date. Wrong for A reader drawn to the cheaper oral plan who needs to know which molecule is in it before the intake begins. ## The evidence behind what Ark Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ark Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Cabana | Readers who want the prescribing practice and pharmacy named up front | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Framework](https://thisglp.com/reviews/framework) [Fresh Day Meds](https://thisglp.com/reviews/fresh-day) [Freya Meds](https://thisglp.com/reviews/freya-meds) [Fridays](https://thisglp.com/reviews/fridays) [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) [Gaya Wellness](https://thisglp.com/reviews/gaya-wellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What drug is in the oral plan? The page does not say; it states that the exact active ingredient, formulation and strength must be confirmed by the prescribing provider and the dispensing pharmacy, and that oral and injectable forms are not interchangeable. Is the $169 semaglutide price a promotion? Nothing on the product page or in the FAQ says it ends, and the FAQ lists $169 among the plan prices currently displayed, so the struck $250 beside it reads as an anchor rather than a future rate. How do I avoid the next charge? Send the cancellation request at least 15 days before the next order date, because the site states that a later request will not stop the scheduled charge and that processed payments are generally non-refundable. Is Ark Health expensive compared with other GLP-1 telehealth sellers? Ark Health publishes a starting figure of $125/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ark Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ARSYNL Rx reviews (2026): GLP-1 telehealth sellers | This GLP One of these figures has already moved once, which makes either worth confirming on the day. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/arsynl-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A price that has already moved # ARSYNL Rx review One of these figures has already moved once, which makes either worth confirming on the day. ## The verdict Arsynl Rx publishes $219 a month for compounded semaglutide and $269 for tirzepatide, and neither figure has held steady long enough to budget from without checking it first. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $219/mo Prescription Required Compounded Yes — not FDA-approved Arsynl Rx sells both molecules by injection, each with its own published monthly figure, and the fifty-dollar step between them is the ordinary shape of this market rather than anything unusual to this seller. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping, and the pages set out rates rather than describing the clinician behind them, so a reader learns what a month costs long before learning anything about who decides that a month is appropriate. Remote, and organized around the two product lines rather than around a course of care, with nothing published about what a clinician looks at between the first order and the fourth. 2. ## What happens when the dose goes up? Consider the four months most buyers actually spend escalating. Nothing Arsynl Rx publishes says whether $219 is the figure at 0.25 milligrams or at 1.0, nor what it becomes at either end. A reader planning a winter of dose increases is planning against a number with no stated dose attached to it. 3. ## What the price includes Six months of semaglutide at $219 is $1,314 and the tirzepatide line runs to $1,614 over the same span, and both totals hold only for a buyer whose dose stays where it started. More useful than either total: this is a price that has already moved once, so confirm it on the seller's own page on the day you order, including against this one. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy that is not named on any page here, and not reviewed by the FDA before dispensing in the way an approved product is. ## Where it holds up, and where it does not - Strength: Both molecules carry a published figure - Strength: The tirzepatide premium is modest - Limitation: No milligram dose stated beside either - Limitation: Nothing published about dose pricing - Limitation: No state coverage list recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about ARSYNL Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants both molecules priced on one page and will confirm the figure on the day. Wrong for A reader who needs the dose behind a figure before treating it as comparable. ## The evidence behind what ARSYNL Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How ARSYNL Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Candor Rx | Readers who value a bill that does not move with the dose and will confirm the figure first | | | AquaVita NextGen | Readers who re-check a price on the day of ordering and will benefit from the lower one | | | Clume Health | Readers who want both molecules at one rate and will re-check the figure before paying | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [GetRelief Rx](https://thisglp.com/reviews/getrelief-rx) [Gimme Care](https://thisglp.com/reviews/gimme-care) [Glam Health](https://thisglp.com/reviews/glam-health) [Go Vida Plena](https://thisglp.com/reviews/go-vida-plena) [GobyMeds](https://thisglp.com/reviews/gobymeds) [Goldspan Health](https://thisglp.com/reviews/goldspan-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What do the two lines cost? Semaglutide is $219 a month and tirzepatide is $269. Does either figure hold at a higher dose? Arsynl Rx publishes nothing on that question, and an absence of a statement is not a promise that the figure holds, nor evidence that it climbs. Will this price hold? It has already moved once, so there is no reason to assume it will. Confirm either figure on the seller's own page before the first charge. Is ARSYNL Rx expensive compared with other GLP-1 telehealth sellers? ARSYNL Rx publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ARSYNL Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ascend Medical reviews (2026): GLP-1 telehealth sellers | This GLP Two package prices are published and neither states what period they cover. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ascend-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A price with no period # Ascend Medical review Two package prices are published and neither states what period they cover. ## The verdict Ascend Medical publishes a Starting Package at $225 for semaglutide and $240 for tirzepatide. Neither states a period. Not per month, not per supply. Neither figure is ranked here. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 2 Prescription Required Compounded Yes — not FDA-approved Ascend Medical sells both molecules by injection. Two packages carry a figure. Coverage is recorded in two states. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages name packages rather than clinicians. The intake is not documented. Nor is the duration of what is being sold. A package price without a period is not comparable to anything. Two sellers quoting $225 are quoting different products if one covers four weeks and the other twelve. Ascend does not say which it is. 2. ## What happens when the dose goes up? Nothing is published about dose. That question sits underneath the first one. Neither the duration nor the dose is stated. A package like that cannot be priced per milligram or per month. 3. ## What the price includes No figure here can be turned into a monthly cost. $225 might be a month, a supply, or a starting block. The pages do not say. Ask before ordering, and get the answer in writing. Until then, treat both numbers as quotes rather than prices. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Two packages carry a published figure - Strength: Both molecules are offered - Strength: The word Starting is at least stated - Limitation: No billing period appears anywhere - Limitation: Neither figure can be compared - Limitation: Coverage is recorded in two states - Limitation: No dose information is published ## What the evidence says about this kind of treatment The assessment above is about Ascend Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader prepared to ask what period the package covers before ordering. Wrong for A reader who needs a monthly figure to compare against another seller. ## The evidence behind what Ascend Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ascend Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | Balanced Hormone Health | Readers who would rather see a dose increase priced than hidden in a monthly figure | | | CeliaRx | Readers who prefer a one-time purchase to a subscription and can fund it at once | | | Blue Sky MD | Patients near the practice who will ask what enrollment costs before joining | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Good Girl Rx](https://thisglp.com/reviews/good-girl-rx) [Good Life Meds](https://thisglp.com/reviews/good-life-meds) [GoodRx](https://thisglp.com/reviews/goodrx) [Green Cap Health](https://thisglp.com/reviews/green-cap-health) [Harbor](https://thisglp.com/reviews/harbor) [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $225 a monthly price? Unknown. Ascend states no period beside either figure — not per month, not per supply. Why is nothing ranked here? A price with no period cannot be compared. Ranking it would put a number on a board that means something different from every other number on it. Where does Ascend operate? Coverage is recorded in two states. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ascend Vitality reviews (2026): GLP-1 telehealth sellers | This GLP The tirzepatide tablets page prints the semaglutide price panel. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ascend-vitality Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One panel, two molecules # Ascend Vitality review The tirzepatide tablets page prints the semaglutide price panel. ## The verdict Ascend Vitality charges $199 a month for semaglutide and $299 for tirzepatide. Its tirzepatide tablets page prints $199 instead, the semaglutide figure. The discount line on its tirzepatide injection page carries no number at all. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $199/mo Oral From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider Ascend Vitality sells compounded semaglutide and compounded tirzepatide. Each molecule comes as a weekly injection or a daily tablet. Sermorelin, NAD+ and men's health products share the same catalog. Coverage is stated as all fifty states. 1. ## Who writes the prescription, and what do they see? A plan is prescribed after an asynchronous review of the intake form. The stated window for that review is 24 to 48 hours. No clinic visit is required. No prescriber is named, and what one reads before writing is not described. One rate covers the provider evaluation, shipping, unlimited messaging and dose adjustments. A six-month term lowers it. A patient community with coaching, meal plans and weekly check-ins is included. The site states there is no membership fee. 2. ## What happens when the dose goes up? Dose adjustments are listed inside the price on every product panel. The rate does not move as the dose climbs. No milligram figure appears beside any rate. Nothing published names who approves a step up. 3. ## What the price includes Semaglutide is $199 a month, injected or as a tablet. Tirzepatide is $299 injected. The tirzepatide tablets page prints $199. Its own comparison table describes the six-month rate as a membership, four lines under a panel promising no membership fee. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. The pharmacies are described as licensed 503A and 503B facilities and none is named. The site states that compounded medications are not reviewed or approved by the FDA. LegitScript certification is claimed on each product page. ## Where it holds up, and where it does not - Strength: The tablet costs the same as the injection on semaglutide - Strength: Provider evaluation, shipping and messaging sit inside the rate - Strength: No membership fee is charged alongside the medication - Strength: Coaching and a patient community are included - Strength: LegitScript certification is stated - Limitation: The tirzepatide tablets page prints the semaglutide price - Limitation: The tirzepatide discount line renders with no figure in it - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published beside any rate ## What the evidence says about this kind of treatment The assessment above is about Ascend Vitality. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer comparing the tablet price against the injection before picking a format. Wrong for A buyer who needs a milligram dose printed beside the rate. ## The evidence behind what Ascend Vitality prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ascend Vitality compares | Seller | Who it suits | Go | | --- | --- | --- | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | | Breeze Meds | A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. | | | CoraDoc | Buyers who would rather pay a program once than carry a subscription they have to remember to cancel | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) [Harper Meds](https://thisglp.com/reviews/harper-meds) [He & She MD](https://thisglp.com/reviews/he-and-she-md) [Heally](https://thisglp.com/reviews/heally) [HealthHub](https://thisglp.com/reviews/healthhub) [Healthicare](https://thisglp.com/reviews/healthicare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the tablet cost more than the injection? Not on semaglutide. Both the weekly injection and the daily tablet are priced from $199 a month. What does the six-month plan change? It lowers the semaglutide rate to $176 a month. The tirzepatide injection page states a six-month plan exists but prints no figure for it. Is a compounding pharmacy named? No. The site says its pharmacies are licensed 503A and 503B facilities and does not name one. Is Ascend Vitality legit? Ascend Vitality is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Ascend Vitality expensive compared with other GLP-1 telehealth sellers? Ascend Vitality publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ascend Vitality above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AskRx reviews (2026): GLP-1 telehealth sellers | This GLP Brand-name Wegovy and Zepbound billed at pharmacy cost, plus a flat monthly care fee shown on its own line. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ask-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand-name only, fee itemized # AskRx review Brand-name Wegovy and Zepbound billed at pharmacy cost, plus a flat monthly care fee shown on its own line. ## The verdict AskRx prescribes brand-name GLP-1 medicines only. Wegovy at the starting dose totals $299 a month. Zepbound at 2.5 mg totals $399. Both totals include a mandatory $100 monthly care fee. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $299/mo Dose published Yes Prescription Required Compounded No Pharmacy Not named Availability All 50 states AskRx is a telehealth membership for weight loss. It offers Wegovy as a pen or a tablet, Zepbound and Foundayo. Mental health, sexual health and hormone therapy are listed as coming soon. The site states it never prescribes compounded GLP-1s. 1. ## Who writes the prescription, and what do they see? AskRx states that its physicians are board-certified and trained in obesity medicine. None is named. The first consultation runs by interactive messaging. Video visits are offered in select states. The intake invites uploads of existing labs or records. The physician confirms the starting dose at consultation. The membership covers the physician, unlimited messaging and a monthly titration review. Medication is dispensed through an affiliated pharmacy. AskRx states it bills medication at that pharmacy's cost. Insurance is not billed. Cancellation is allowed at any time. 2. ## What happens when the dose goes up? A short dose check sets the starting point before checkout. A new patient starts Wegovy at 0.25 mg and Zepbound at 2.5 mg. The medication line changes with the dose. Wegovy is $199 at 0.25 mg and 0.5 mg. It is $349 at 1 mg and 1.7 mg. Zepbound is $299 at 2.5 mg and $399 at 5 mg. The $100 fee stays the same. 3. ## What the price includes The care fee is a $90 physician fee plus $10 for fulfillment. It is charged every month. Medication is added on top at cost. The home page leads with the $90 alone. The starting monthly total for Wegovy injections is $299. Wegovy tablets start at $249 all in. 4. ## What it claims, and what it cites Every product is brand-name and FDA-approved. [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) comes from Novo Nordisk; [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and Foundayo come from Eli Lilly. No compounded product is offered. The site describes Foundayo as oral tirzepatide. Foundayo's active ingredient is orforglipron, a different molecule. ## Where it holds up, and where it does not - Strength: Brand-name drugs only, nothing compounded - Strength: Care fee shown on its own line - Strength: Medication stated to be billed at cost - Strength: Starting-dose totals visible before checkout - Limitation: Headline $90 excludes medication and fulfillment - Limitation: No prescribing physician is named - Limitation: Foundayo is described as oral tirzepatide - Limitation: Medication cost rises with the dose ## What the evidence says about this kind of treatment The assessment above is about AskRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants brand-name Wegovy or Zepbound with every fee itemized. Wrong for A buyer shopping on compounded prices. ## The evidence behind what AskRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AskRx compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | | WeightWatchers Clinic | Readers who want a familiar brand and will add the membership at its ceiling | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Healthicare](https://thisglp.com/reviews/healthicare) [HealthOn](https://thisglp.com/reviews/healthon) [HealthSource](https://thisglp.com/reviews/healthsource) [HeliMeds](https://thisglp.com/reviews/helimeds) [Hello Alpha](https://thisglp.com/reviews/hello-alpha) [HelloWellness](https://thisglp.com/reviews/hellowellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $90 a month include the medication? No. The $90 is the physician fee. A $10 fulfillment fee and the medication are added every month. What does Wegovy cost to start? The dose check shows $199 for Wegovy 0.25 mg. The $100 care fee brings it to $299. Does AskRx offer compounded semaglutide? No. Its FAQ states its physicians prescribe only FDA-approved brand-name medicines. Is AskRx legit? AskRx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is AskRx expensive compared with other GLP-1 telehealth sellers? AskRx publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AskRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Aspen reviews (2026): GLP-1 telehealth sellers | This GLP Both molecules cost the same here, every dosage costs the same, and the vial carries an additive the trials never measured. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/aspen-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One rate, either molecule # Aspen review Both molecules cost the same here, every dosage costs the same, and the vial carries an additive the trials never measured. ## The verdict Aspen publishes as low as $179 a month for a compounded GLP-1 with glycine or B12. The same figure covers both molecules. All dosages are stated at one price, across 51 jurisdictions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $179/mo Prescription Required Compounded Yes — not FDA-approved Availability 51 jurisdictions Aspen sells a compounded GLP-1 injection with an additive, describing a semaglutide path and a tirzepatide path but publishing one figure for both. Coverage runs to 51 jurisdictions. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe the paths and the price rather than the clinician or the review schedule behind them. Declining to charge more for the dual agonist is unusual and it removes a decision most sellers monetize. The cost of that simplicity is that the two paths are not priced separately, so a reader cannot see what either would cost alone. 2. ## What happens when the dose goes up? All dosages are the same price, stated plainly. That answers the escalation question completely, and it is the strongest disclosure on the page. 3. ## What the price includes Six months at $179 is $1,074, and the flat-dosage statement makes that a real total rather than an opening one. The figure is still qualified as low as, so something unpublished can lift it. 4. ## What it claims, and what it cites The preparation is compounded with glycine or B12 rather than being the molecule alone. A pharmacy makes it to order and no agency reviews it before dispensing. The trials behind [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) studied neither additive. ## Where it holds up, and where it does not - Strength: A single figure spans both molecules - Strength: All dosages priced identically - Strength: Coverage in 51 jurisdictions - Strength: The additive is disclosed on the card - Limitation: The two paths are not priced separately - Limitation: The figure is still an as-low-as - Limitation: No trial measured the additive - Limitation: The pharmacy behind it is not identified ## What the evidence says about this kind of treatment The assessment above is about Aspen. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the escalation question closed and does not need the two molecules priced apart. Wrong for A reader who wants plain semaglutide without anything else in the vial. ## The evidence behind what Aspen prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Aspen compares | Seller | Who it suits | Go | | --- | --- | --- | | Auren Rx | Readers who want a cancel-anytime subscription with the no-commitment rate printed beside it | | | Aspire Health | Readers who want the dose stated beside the vial and will do the arithmetic | | | Balanced Hormone Health | Readers who would rather see a dose increase priced than hidden in a monthly figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Hers](https://thisglp.com/reviews/hers) [Heva Health](https://thisglp.com/reviews/heva-health) [Hims](https://thisglp.com/reviews/hims) [Idgie Health](https://thisglp.com/reviews/idgie-health) [Immortals](https://thisglp.com/reviews/immortals) [Independent Wellness](https://thisglp.com/reviews/independent-wellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the dual agonist priced higher? No. Aspen publishes one figure and describes both paths under it. What happens when the dose goes up? Nothing, according to the seller: all dosages are stated at the same price. What is glycine or B12 doing in it? It is part of the compounded preparation Aspen sells. The trials behind either molecule tested the molecule alone. Is Aspen legit? Aspen is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Aspen expensive compared with other GLP-1 telehealth sellers? Aspen publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Aspen below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Aspire Health reviews (2026): GLP-1 telehealth sellers | This GLP The vial is measured in weeks and the care fee in months, so neither published number is a month of treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/aspire-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Vials by the week, fee by the month # Aspire Health review The vial is measured in weeks and the care fee in months, so neither published number is a month of treatment. ## The verdict Aspire Health publishes $129 for a five-week semaglutide vial and $149 for a four-week tirzepatide vial, with a $49 monthly medical-care fee charged apart from the medication. A calendar month is $161 and $210. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $161/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Aspire Health sells both molecules as compounded vials sized in weeks rather than months, with a separate monthly fee covering the medical side. The seller states plainly that medication is not included in the program fee. 1. ## Who writes the prescription, and what do they see? The $49 is what the clinical relationship costs and it is disclosed as separate, which is a clearer arrangement than most bundles. What the fee buys is described less precisely than what it costs. Sizing a vial in weeks and a fee in months guarantees the two never line up, and the arithmetic is left entirely to the reader. Stating that medication sits outside the program fee is nonetheless the disclosure that makes the arithmetic possible. 2. ## What happens when the dose goes up? The five-week semaglutide vial is quoted at 0.5 mg weekly and the four-week tirzepatide vial at 2.5 mg, so the supply length is tied to the dose. A higher dose empties the same vial faster, and nothing published says what that does to the bill. 3. ## What the price includes The semaglutide vial works out at about $112 a calendar month, plus $49, giving $161. Tirzepatide is about $161 plus $49, giving $210. Six months is therefore $966 and $1,260. Both medication figures came down sharply a month apart. 4. ## What it claims, and what it cites Both vials are compounded with B6 rather than being the molecule alone. A pharmacy prepares them to order, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: The fee is disclosed as separate, in writing - Strength: The milligram is stated beside each vial - Strength: Both medication figures fell - Strength: Longer supplies are published as well - Limitation: Vials are five and four weeks, not months - Limitation: A $49 monthly fee sits outside both figures - Limitation: A higher dose empties the vial sooner - Limitation: An enrollment fee has applied on top ## What the evidence says about this kind of treatment The assessment above is about Aspire Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the dose stated beside the vial and will do the weekly-to-monthly arithmetic. Wrong for A reader comparing $129 against another seller's monthly all-in figure. ## The evidence behind what Aspire Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Aspire Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Aspen | Readers who want the escalation question closed and need no separate molecule price | | | Corsica Health | Readers who want the monthly rate and the prepay discount on one selector | | | Balanced Hormone Health | Readers who would rather see a dose increase priced than hidden in a monthly figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Injectco](https://thisglp.com/reviews/injectco) [InstaRX](https://thisglp.com/reviews/instarx) [Intimate Rose](https://thisglp.com/reviews/intimate-rose) [Invigor Medical](https://thisglp.com/reviews/invigor-medical) [Invyncible](https://thisglp.com/reviews/invyncible) [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a calendar month actually cost? About $161 for semaglutide and $210 for tirzepatide, once the vial length and the $49 fee are both counted. Does the program fee cover the drug? No, and Aspire says so directly: medication costs are not included in either program fee. How long does a vial last? Five weeks for semaglutide at 0.5 mg weekly and four weeks for tirzepatide at 2.5 mg. A higher dose shortens both. Is Aspire Health expensive compared with other GLP-1 telehealth sellers? Aspire Health publishes a starting figure of $161/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Aspire Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Aurelius Health Group reviews (2026): GLP-1 telehealth sellers | This GLP Aurelius markets clinician-monitored, compounded tirzepatide microdosing. Its promised check-ins are distinct from the evidence needed to support its broader wellness claims. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/aurelius-health-group Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A microdose-focused proposition # Aurelius Health Group review Aurelius markets clinician-monitored, compounded tirzepatide microdosing. Its promised check-ins are distinct from the evidence needed to support its broader wellness claims. ## The verdict Aurelius is a microdose service, so it should not be treated as equivalent to a conventional obesity-treatment program. The site describes physician contact and monthly monitoring, but claims about muscle retention, nausea and metabolic benefits need stronger context than a branded-drug trial or a testimonial. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Aurelius Health Group offers a compounded GLP-1 microdose protocol, with optional formulations involving other ingredients. The homepage presents it as clinician-guided metabolic care. Readers seeking standard-dose weight-loss treatment should establish whether that is actually offered before enrolling. 1. ## Who writes the prescription, and what do they see? The offer describes review by board-certified MD or DO physicians. Its terms distinguish independent professional judgment from the platform’s administrative role. A review-speed claim does not establish that an individual patient should receive tirzepatide. Monthly physician check-ins, adjustments and secure messaging are included in the advertised subscription. Ask whether a visit is live or asynchronous, how urgent symptoms are handled and which medical conditions would prompt a referral instead of online treatment. 2. ## What happens when the dose goes up? The service emphasizes physician-directed microdosing and adjustment. That approach is not interchangeable with the regimens studied in major obesity trials. Ask the clinician what evidence supports your proposed dose and how response, adverse effects and discontinuation will be assessed. 3. ## What the price includes The homepage separates a reduced first month from a continuing monthly subscription covering physician care, the protocol and monitoring. Those are microdose-plan terms, not evidence of a comparable full-dose medication price. Confirm any changes for a different prescribed preparation. 4. ## What it claims, and what it cites The advertised protocol is compounded [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). Additional ingredients are named in the broader protocol description; confirm the exact prescription instead of assuming every order contains the same mixture. Compounded products are not FDA approved, and their quality is not established by branded-product trial outcomes. ## Where it holds up, and where it does not - Strength: Physician check-ins included in the offer - Strength: Secure clinical messaging described - Strength: Introductory and continuing periods distinguished - Limitation: Microdose outcomes require separate evidence - Limitation: Protocol may include additional ingredients - Limitation: Not a substitute for standard-dose trial evidence ## What the evidence says about this kind of treatment The assessment above is about Aurelius Health Group. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone specifically discussing microdose tirzepatide with a clinician and prepared to examine the evidence and alternatives. Wrong for A patient seeking an FDA-approved weight-loss brand or assuming microdosing delivers conventional obesity-trial results. ## The evidence behind what Aurelius Health Group prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Aurelius Health Group compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) [iThriveMD](https://thisglp.com/reviews/ithrivemd) [Ivim Health](https://thisglp.com/reviews/ivim-health) [Ivologist](https://thisglp.com/reviews/ivologist) [Ivy Rx](https://thisglp.com/reviews/ivy-rx) [Jently](https://thisglp.com/reviews/jently) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Aurelius a standard-dose weight-loss plan? The reviewed homepage centers on microdosing. Confirm the actual prescribed regimen and available alternatives. Does a named pharmacy list identify my prescription? No. The terms name possible partner pharmacies, but the individual prescription should identify the actual dispenser and ingredients. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://www.aureliushealthgroup.com/) - [Service and cancellation terms](https://www.aureliushealthgroup.com/terms-of-use) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Auren Rx reviews (2026): GLP-1 telehealth sellers | This GLP Tirzepatide costs $80 a month more than semaglutide, and both commitment rates are published. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/auren-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two rates per molecule, both published # Auren Rx review Tirzepatide costs $80 a month more than semaglutide, and both commitment rates are published. ## The verdict Auren Rx publishes $149 a month for semaglutide and $229 for tirzepatide on a subscription. The rate without one is $30 higher on each. Coverage is 50 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $149/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states Auren Rx sells both molecules by weekly injection. Each carries two rates, one subscribed and one not. A separate microdose track is priced lower. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state rates rather than describe care. No clinician is named. The subscription can be paused or canceled at any time. Publishing the no-commitment rate beside it removes the usual guesswork. 2. ## What happens when the dose goes up? Nothing published says what either figure does at a higher dose. That is the gap in an otherwise plain page. 3. ## What the price includes Six months of semaglutide is $894 subscribed or $1,074 without. Tirzepatide is $1,374 subscribed or $1,554 without. The $30 gap is the cost of declining the subscription. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them to order. The FDA does not review a compounded preparation before dispensing. ## Where it holds up, and where it does not - Strength: Both commitment rates published - Strength: The subscription cancels at any time - Strength: The gap between them is $30 - Strength: Coverage in 50 states - Limitation: Tirzepatide costs $80 a month more - Limitation: Dose behavior is not published - Limitation: No milligram appears beside a figure - Limitation: The pharmacy is not identified ## What the evidence says about this kind of treatment The assessment above is about Auren Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a subscription that cancels at any time, with the no-commitment rate in view. Wrong for A reader who needs to know what happens to $149 at a higher dose. ## The evidence behind what Auren Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Auren Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Aspen | Readers who want the escalation question closed and need no separate molecule price | | | Somi Health | Readers who want the dose question answered in writing before anything else | | | Silhouette MD | Readers who want an unqualified number and will pay the tablet premium for one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Jently](https://thisglp.com/reviews/jently) [Joey Med](https://thisglp.com/reviews/joey-med) [Joi + Blokes](https://thisglp.com/reviews/joi-and-blokes) [JRNYS](https://thisglp.com/reviews/jrnys) [JumpstartMD](https://thisglp.com/reviews/jumpstartmd) [June Health](https://thisglp.com/reviews/june-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does tirzepatide cost more? Yes. It is $229 subscribed against $149 for semaglutide, an $80 step. What does declining the subscription cost? $30 a month on either molecule, or $180 over six. Which states are served? Fifty. Is Auren Rx legit? Auren Rx is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Auren Rx expensive compared with other GLP-1 telehealth sellers? Auren Rx publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Auren Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AVARA Rx reviews (2026): GLP-1 telehealth sellers | This GLP The lower tirzepatide figure requires a discount code, which makes it a condition rather than a standing rate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/avara-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Lower rate needs a code # AVARA Rx review The lower tirzepatide figure requires a discount code, which makes it a condition rather than a standing rate. ## The verdict AVARA Rx publishes compounded tirzepatide at $279 a month, or $229 with a code. The standing rate is $279. Compounded semaglutide is $229. The provider consult and shipping are stated as included in both. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $229/mo Prescription Required Compounded Yes — not FDA-approved AVARA Rx sells compounded semaglutide and compounded tirzepatide. Both are weekly injections. The rates read $229 and $279 a month. A code lowers the tirzepatide rate to $229. Coverage is published as fifty states. No insurance is required. 1. ## Who writes the prescription, and what do they see? The provider consult is stated as included in the price. It is not billed as a separate line. What the consult covers is not published beside either figure. Neither is how often it repeats. A prescription is required before the first shipment. Care is arranged remotely. Shipping is described as free and discreet. One charge covers the medication, the consult and the postage. The two molecules are priced $50 apart at the standing rates. A code closes that gap on tirzepatide. 2. ## What happens when the dose goes up? The dose-pricing model is not published on either row. Neither rate is described as flat. A reader should not assume the figure holds as the dose rises. The first sixteen weeks are an escalation for most patients. What a higher dose costs here is not stated. 3. ## What the price includes $279 is the standing tirzepatide rate. $229 is the rate with the code. A code can be withdrawn without notice. The standing rate is the one to budget against. Semaglutide is $229 with no code attached. Nothing else was recorded beside either figure. 4. ## What it claims, and what it cites Both products are compounded. A pharmacy prepares them. No regulator reviews the finished vial. A compounded preparation is not FDA-approved. The published trial results used the approved products at label doses. A compounded vial was not what those trials measured. ## Where it holds up, and where it does not - Strength: Consult and shipping stated as included - Strength: Standing rate published beside the code rate - Strength: Coverage published as fifty states - Limitation: Lower tirzepatide rate depends on a code - Limitation: Dose-pricing model not published - Limitation: Consult scope not described ## What the evidence says about this kind of treatment The assessment above is about AVARA Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the consult inside the price. Both figures include it. Wrong for A reader budgeting on the code rate. A code is a condition, not a price. ## The evidence behind what AVARA Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AVARA Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | KERNX Health | A reader who wants the clinician charge stated as a number before intake, and a medication rate that holds at every dose. | | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [June Health](https://thisglp.com/reviews/june-health) [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) [Jyra Health](https://thisglp.com/reviews/jyra-health) [Kin Meds](https://thisglp.com/reviews/kin-meds) [Kina](https://thisglp.com/reviews/kina) [Knownwell](https://thisglp.com/reviews/knownwell) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which tirzepatide figure should a reader plan on? $279. That is the standing rate. The $229 figure requires a discount code, and a code can be withdrawn at any time. Is the consult charged separately? No. The provider consult and free shipping are stated as included in the published figures for both molecules. Does the price rise with the dose? Not published. Neither row describes the rate as flat, and no per-dose ladder is stated beside either figure. Is AVARA Rx expensive compared with other GLP-1 telehealth sellers? AVARA Rx publishes a starting figure of $229/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AVARA Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AVArx reviews (2026): GLP-1 telehealth sellers | This GLP AVArx identifies Arora Health & Aesthetics as its clinical organization and describes real-time visits when state rules require them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/avarx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named clinical organization # AVArx review AVArx identifies Arora Health & Aesthetics as its clinical organization and describes real-time visits when state rules require them. ## The verdict Naming the clinical organization makes the platform easier to investigate. The remaining gaps concern the assigned clinician, pharmacy and follow-up schedule; round-the-clock messaging access should not be read as an instant clinical response guarantee. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved AVArx LLC is a telehealth technology platform based in Glendale, California. It explicitly says it is not a pharmacy or medical practice and is not affiliated with similarly named businesses. 1. ## Who writes the prescription, and what do they see? Its FAQ attributes medical services to licensed providers affiliated with Arora Health & Aesthetics, LLC. The clinical organization makes prescribing decisions independently of the platform. Patients complete a medical questionnaire, followed by provider review and any required synchronous visit before prescribing. Approved medication is sent from a pharmacy partner, with messaging offered afterward. 2. ## What happens when the dose goes up? The site describes access to dose adjustments and refills but does not define one review interval for every patient. Ask which symptoms prompt a live visit and who authorizes changes before the next shipment. 3. ## What the price includes The program publishes a generic starting GLP-1 figure rather than a complete molecule-and-dose table. It says there is no membership fee and no direct insurance billing, but the specific plan total remains a checkout question. 4. ## What it claims, and what it cites The weight-care page identifies compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), and the menu labels injections. Compounded medicines are not FDA-approved; provider access and pharmacy licensing do not change that distinction. ## Where it holds up, and where it does not - Strength: Clinical organization named - Strength: Real-time visit requirements explained - Limitation: Assigned pharmacy not established - Limitation: Follow-up interval needs confirmation ## What the evidence says about this kind of treatment The assessment above is about AVArx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants a disclosed clinical organization and clarity about state-specific visit requirements. Wrong for Someone needing a named dispenser and fixed recurring clinical schedule before completing assessment. ## The evidence behind what AVArx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AVArx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LaSara Medical Group](https://thisglp.com/reviews/lasara) [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) [Layla](https://thisglp.com/reviews/layla) [Lean Meds](https://thisglp.com/reviews/leanmeds) [Lean Rx](https://thisglp.com/reviews/lean-rx) [LeanDose](https://thisglp.com/reviews/leandose) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is AVArx the prescriber? No. It identifies itself as a platform and names Arora Health & Aesthetics as the clinical organization. Is it available everywhere? The site ties availability to provider and pharmacy authorization. Confirm the specific service for your state. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://www.getavarx.com/) - [Official program and terms](https://www.getavarx.com/terms) - [Official program and terms](https://www.getavarx.com/online-glp-1-weight-loss-care) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Avono Health reviews (2026): GLP-1 telehealth sellers | This GLP Compounded semaglutide and tirzepatide at flat monthly rates across two dose programs, with the prescribing team and the pharmacies named. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/avono-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two programs, two flat rates # Avono Health review Compounded semaglutide and tirzepatide at flat monthly rates across two dose programs, with the prescribing team and the pharmacies named. ## The verdict Avono Health charges $219 a month for compounded semaglutide and $299 for tirzepatide in its Standard Dose Program, billed month to month and stated to hold at every dose inside that program. A separate Microdose Program, for dosing up to 2.5 mg, starts lower, at $159 and $219. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $219/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Avono Health is a telehealth platform selling weight management, wellness, hair growth and sexual health treatments, and its weight-loss catalog is split into two programs rather than laid out as one ladder. The Standard Dose Program covers the doses most patients go on to reach, and the Microdose Program covers clinician-guided dosing up to 2.5 mg, with an injection and an oral option in each. 1. ## Who writes the prescription, and what do they see? Avono says plainly that it does not practice medicine, and its medical oversight page names who does. The prescribing is done by independent clinicians through Lion MD, a nationwide team led by Dr. Ana Lisa Carr and Dr. Kelly Tenbrink, whose NPI numbers are printed beside their names. The intake runs through a platform called CareValidate, and a clinician may approve, decline, ask for more information, require a video visit or recommend lab work before writing anything. A card goes on file during the intake and is authorized rather than charged, with the charge landing only if a clinician approves, and the statement reads CARE VALIDATE for both the hold and the charge. Medication, clinician care, follow-up messaging and shipping are stated to sit inside the one monthly price, with no membership fee and no clinician fee on top, and questions reach the care team through a patient portal. 2. ## What happens when the dose goes up? The FAQ answers the escalation question directly: inside a program the monthly price does not move as the clinician raises the dose, so a patient on standard-dose semaglutide pays $219 at the first step and at the last. The bill changes only if a clinician moves a patient from the Microdose Program up to the Standard Dose Program, and the page says Microdose is not a required first step. No milligram is published for any of the standard-dose rungs, so the ladder a patient climbs stays out of view. 3. ## What the price includes The weight-management page is built around the month-to-month figures and states that Avono offers no three, six, nine or twelve-month bundles and never asks for prepayment. The home page says otherwise, showing a three-month semaglutide injection bundle at $699 set against a month-to-month rate of $269, a figure that appears nowhere on the program page. Oral capsules run $289 and $349 on the standard program, and orally dissolving tablets in the Microdose Program run $219 and $239. 4. ## What it claims, and what it cites Both lines are compounded by state-licensed pharmacies, and Avono names its current network outright: Belmar Pharmacy, Strive Pharmacy and Casa Pharma Rx. The site states that compounded medications are not FDA-approved, are not reviewed by the FDA before they are dispensed, and are not interchangeable with any FDA-approved medication. ## Where it holds up, and where it does not - Strength: Monthly rate stated flat across doses - Strength: Prescribing team named with NPI numbers - Strength: Three dispensing pharmacies named - Strength: Card charged only after clinician approval - Limitation: Home page bundle contradicts the no-bundles FAQ - Limitation: No milligram given for standard-dose rungs - Limitation: Two programs with overlapping price figures - Limitation: Which pharmacy fills an order is not stated ## What the evidence says about this kind of treatment The assessment above is about Avono Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who expects to climb through several doses and wants the monthly bill to stay where it started. Wrong for A reader hoping for a prepaid multi-month discount, since the program page says none is offered. ## The evidence behind what Avono Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Avono Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Amble | Buyers who want a multi-month rate that holds at every dose | | | Mondae | Buyers who want a low published compounded rate and few other details | | | Candor Rx | Readers who value a bill that does not move with the dose and will confirm the figure first | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lemonaid Health](https://thisglp.com/reviews/lemonaid-health) [LevelsRx](https://thisglp.com/reviews/levelsrx) [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) [Levers Health](https://thisglp.com/reviews/levers-health) [Liberty](https://thisglp.com/reviews/liberty) [LifeMD](https://thisglp.com/reviews/lifemd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price go up as the dose goes up? Not within a program, because the monthly price stays flat as the clinician adjusts the dose, and it changes only if a patient is moved from the Microdose Program to the Standard Dose Program. Is the $159 figure for the full dose? No, since $159 is the starting price of the Microdose Program, which covers dosing up to 2.5 mg, while standard-dose semaglutide is $219 a month. Who writes the prescription? Independent clinicians through Lion MD, a medical team led by Dr. Ana Lisa Carr and Dr. Kelly Tenbrink, whose NPI numbers appear on the medical oversight page. Is Avono Health expensive compared with other GLP-1 telehealth sellers? Avono Health publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Avono Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # AZ Health reviews (2026): GLP-1 telehealth sellers | This GLP One tirzepatide injection carries two monthly figures on the same page, and screening is a nurse practitioner phone call. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/az-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two tirzepatide figures # AZ Health review One tirzepatide injection carries two monthly figures on the same page, and screening is a nurse practitioner phone call. ## The verdict AZ Health lists compounded semaglutide at $179 a month and compounded tirzepatide from $199 on its injection cards. Its own cost FAQ, further down the same page, gives the tirzepatide injection as $249 a month. Which of the two figures a new patient actually pays is not stated anywhere on the page. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $179/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider AZ Health is a single-page telehealth storefront based in the Phoenix and Chandler area of Arizona. It sells compounded semaglutide and tirzepatide both as weekly injections and as daily dissolving tablets. An NAD+ injection is offered in the same row of product cards as the weight-loss treatments. The footer describes the whole service as weight loss for men and women in Arizona. 1. ## Who writes the prescription, and what do they see? The page names the prescriber's role but never the person who holds it. Every screening is described as a 20-minute phone call with a licensed nurse practitioner. That clinician reviews the full health history and says whether either molecule is a fit. A personalized plan is promised within 24 hours of the initial health quiz. Physician-guided and board-certified labels also appear on the page, but no physician is named. The stated path is a five-minute health quiz, then the phone screening, then shipment from a pharmacy. Ongoing care is described as regular check-ins with dose adjustments made along the way. Shipping is free, and the page says a patient can cancel at any time without a contract. How often a check-in actually happens during treatment is not stated. 2. ## What happens when the dose goes up? The injection cards promise personalized dosing, but no milligram figure appears for either molecule. The oral tablets are sold at one flat price across all doses, and the page says so outright. For the injections, whether the monthly figure moves as the dose climbs is not stated anywhere. The word "From" printed on both injection cards leaves that question open for the reader. 3. ## What the price includes Four GLP-1 figures appear on the cards: $179 and $199 for the injections, $219 and $249 for the tablets. The cost FAQ lower on the page repeats three of those four figures exactly. For injectable tirzepatide it gives $249 a month rather than the $199 on the card. Screening is described as free, and no membership or program fee is named anywhere. Every card carries an asterisk that ties its price to medical qualification. 4. ## What it claims, and what it cites Both molecules are compounded, and the footnote under the cards says compounded medications are not FDA-approved. Compounded preparations are not reviewed by the FDA for safety, effectiveness or quality before they are dispensed. The dispensing pharmacy is described only as FDA-registered and is not named on the page. ## Where it holds up, and where it does not - Strength: Semaglutide injection priced the same in two places - Strength: Oral tablets priced flat across every dose - Strength: Screening is described as free - Strength: Screening is a 20-minute nurse practitioner call - Strength: States it holds LegitScript certification - Limitation: Tirzepatide injection carries two different monthly figures - Limitation: No milligram dose published for the injections - Limitation: Neither the prescriber nor the pharmacy is named - Limitation: Check-in frequency is not stated ## What the evidence says about this kind of treatment The assessment above is about AZ Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An Arizona buyer who wants a phone screening with a nurse practitioner before starting. Wrong for A buyer who needs one confirmed tirzepatide price before the intake. ## The evidence behind what AZ Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How AZ Health compares | Seller | Who it suits | Go | | --- | --- | --- | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | SkyRx | Buyers ready to prepay a year who want the medication, visit and shipping in one figure | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LifeMD](https://thisglp.com/reviews/lifemd) [LifeRx.md](https://thisglp.com/reviews/liferx) [LifespanningRx](https://thisglp.com/reviews/lifespanningrx) [LillyDirect Foundayo](https://thisglp.com/reviews/lillydirect-foundayo) [Liv Body](https://thisglp.com/reviews/liv-body) [LIV by WellNow](https://thisglp.com/reviews/liv-by-wellnow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How much is tirzepatide at AZ Health? The injection card says from $199 a month, while the cost FAQ on the same page says $249 a month. The page does not say which figure applies to a new patient. Who does the screening? A licensed nurse practitioner, on a 20-minute phone call after the online quiz. The page gives neither the clinician's name nor the state that issued the license. Is there an oral option? Yes. Oral semaglutide is $219 a month and oral tirzepatide $249, each as 30 dissolving tablets at one flat price for every dose. Is AZ Health expensive compared with other GLP-1 telehealth sellers? AZ Health publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts AZ Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Balanced Hormone Health reviews (2026): GLP-1 telehealth sellers | This GLP A package here is a quantity of drug rather than a length of time, so how long it lasts is decided by the dose a buyer titrates to. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/balanced-hormone-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Sold by the milligram # Balanced Hormone Health review A package here is a quantity of drug rather than a length of time, so how long it lasts is decided by the dose a buyer titrates to. ## The verdict Balanced Hormone Health publishes a compounded tirzepatide starter of 60 mg as a twelve-week supply at $499, which works out near $181 a calendar month. A semaglutide package runs from $197 for roughly ten weeks. The branded Zepbound route is a paid telehealth consult for a Lilly Direct prescription, so Lilly rather than this seller prices the medication. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $181/mo Prescription Required Compounded Yes — not FDA-approved Balanced Hormone Health sells compounded injections by total milligram rather than by month, so a package is a quantity that empties at a rate the buyer's own titration decides, with a branded product listed beside the compounded ones. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing, and the pages price packages rather than describing the clinician, the intake or how often a case is reviewed. That matters more here than usual, because the titration is what decides how long a purchase lasts. Pricing by quantity is arguably the honest way to sell a drug whose dose climbs, because it stops a fixed monthly figure from quietly buying less each month. The cost is that no published figure here is comparable against a monthly rate anywhere else without arithmetic the buyer has to do themselves. 2. ## What happens when the dose goes up? This is the seller whose pricing model makes the dose question unavoidable, and it deserves credit for not pretending otherwise. The semaglutide card writes its own tilde into the duration, conceding that a package's length is a function of the dose rather than a promise anyone can make. 3. ## What the price includes The 60 mg tirzepatide starter at $499 works out near $181 a calendar month across its twelve weeks, or about $1,086 over six months if the titration holds where it starts. The semaglutide package from $197 covers roughly ten weeks, which is nearer $85 a month at the opening dose — and both figures shorten as the dose rises, because the milligrams run out sooner. 4. ## What it claims, and what it cites The starter packages are compounded rather than manufactured, prepared to order by a pharmacy the pages do not name, while the [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) line is an approved manufactured product. The FDA does not review a compounded preparation before it is dispensed, and the two routes are not comparable on regulation any more than on price. ## Where it holds up, and where it does not - Strength: The total milligram is published, not just a rate - Strength: The duration carries the seller's own tilde - Strength: A branded route is listed beside the compounded ones - Strength: Pricing by quantity survives a dose increase honestly - Limitation: No figure here is a monthly rate - Limitation: A package empties faster at a higher dose - Limitation: The Zepbound line states no period at all - Limitation: The states served are not published ## What the evidence says about this kind of treatment The assessment above is about Balanced Hormone Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who understands that a dose increase costs money and would rather see it priced in milligrams than hidden inside a monthly figure. Wrong for A reader who needs a single monthly number to set beside another seller's, since nothing here is quoted that way. ## The evidence behind what Balanced Hormone Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Balanced Hormone Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Aspire Health | Readers who want the dose stated beside the vial and will do the arithmetic | | | Aspen | Readers who want the escalation question closed and need no separate molecule price | | | VirtualCare2Go | Readers genuinely indifferent between three molecules who value plain speaking | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [50 Stars Health](https://thisglp.com/reviews/livv) [Longevixx](https://thisglp.com/reviews/longevixx) [Loop Health](https://thisglp.com/reviews/loop-health) [LovelyMeds](https://thisglp.com/reviews/lovelymeds) [Luci](https://thisglp.com/reviews/luci) [Luma Health Co](https://thisglp.com/reviews/luma-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How long does the tirzepatide starter last? Twelve weeks at the opening dose, as 60 mg in total. At a higher dose the same 60 mg is consumed sooner, which is why the package is sold by quantity rather than by month. What is that per month? About $181 a calendar month, since twelve weeks is 2.76 months rather than three. Why does the semaglutide card say about ten weeks? Because the seller cannot know the answer in advance. The tilde is its own, and it concedes that duration depends on the dose the buyer titrates to. Is Balanced Hormone Health expensive compared with other GLP-1 telehealth sellers? Balanced Hormone Health publishes a starting figure of $181/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Balanced Hormone Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Basal Health reviews (2026): GLP-1 telehealth sellers | This GLP Basal’s GLP-One offers clinician-prescribed compounded tirzepatide in microdose and weight-loss plans. Those programs should be assessed separately rather than treated as interchangeable. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/basal-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Separate microdose and weight care # Basal Health review Basal’s GLP-One offers clinician-prescribed compounded tirzepatide in microdose and weight-loss plans. Those programs should be assessed separately rather than treated as interchangeable. ## The verdict Basal describes continued clinician contact and a patient portal, which matter more than its broad metabolic-wellness claims. For weight management, confirm the prescribed strength and treatment goal: a microdose offer does not establish the expected results of a conventional obesity-treatment regimen. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection Dose pricing Flat across doses From From $323.92/mo Prescription Required Compounded Yes — not FDA-approved GLP-One is Basal’s tirzepatide care program, with clinical assessment, individualized dosing and progress follow-up. The site markets two distinct approaches, microdose and weight loss. Claims about metabolic optimization extend beyond a simple prescription service and deserve their own evidence. 1. ## Who writes the prescription, and what do they see? The terms describe independent medical groups and professionals licensed where the patient is located. Basal itself provides the platform rather than practicing medicine. Clinical approval precedes charging under the homepage offer; a patient may be declined or directed to other care. The portal brings treatment information, communication and follow-up together. Basal describes regular check-ins and monitoring, but the pages reviewed do not promise one consultation frequency for every patient. Ask whether any diagnostic testing is included and how an adverse reaction reaches the clinician. 2. ## What happens when the dose goes up? Basal says its clinician selects a starting dose and adjusts treatment according to response. Its microdose and weight-loss pathways should not be compared solely on their shared ingredient. Request your actual dose range, refill instructions and plan for pauses before enrolling. 3. ## What the price includes The advertised introductory period differs from continuing treatment, and billing repeats every four weeks. That creates more charges over a year than calendar-month billing. The site says the price holds across doses and that there is no membership fee; confirm which GLP-One plan that offer covers. 4. ## What it claims, and what it cites GLP-One is described as compounded [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), not an FDA-approved finished medicine. Basal acknowledges that distinction. Published trials of approved tirzepatide products cannot establish the quality of a particular compounded shipment or validate all microdosing claims. ## Where it holds up, and where it does not - Strength: Charging follows clinical approval - Strength: Patient portal and ongoing monitoring - Strength: Four-week billing stated openly - Limitation: Microdose evidence differs from standard obesity trials - Limitation: Exact testing inclusions need confirmation - Limitation: Four-week renewal can be mistaken for monthly billing ## What the evidence says about this kind of treatment The assessment above is about Basal Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking clinician-supervised tirzepatide who can distinguish the weight-loss plan from the microdose proposition. Wrong for A patient expecting FDA-approved branded medication or trial-level evidence for every claimed microdose benefit. ## The evidence behind what Basal Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Basal Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Luma Meds](https://thisglp.com/reviews/luma-meds) [Lumen Meds](https://thisglp.com/reviews/lumen-meds) [LumiMeds](https://thisglp.com/reviews/lumimeds) [Lumora](https://thisglp.com/reviews/lumora) [LunaRx](https://thisglp.com/reviews/lunarx-health) [LVNG RX](https://thisglp.com/reviews/lvng-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is GLP-One an FDA-approved brand? No. Basal describes a compounded tirzepatide program and states that compounded products are not FDA approved. Does four-week billing mean twelve annual charges? No. Four-week supply cycles recur thirteen times in fifty-two weeks. Review the recurring amount rather than comparing only the introductory period. Is Basal Health expensive compared with other GLP-1 telehealth sellers? Basal Health publishes a starting figure of $323.92/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Basal Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official program](https://basal.health/) - [Service and cancellation terms](https://basal.health/terms) - [Treatment information](https://basal.health/about) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bayan Health reviews (2026): GLP-1 telehealth sellers | This GLP An injection and an oral drop carry the same monthly figure here, which is the reverse of the usual pattern. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bayan-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same price, two routes # Bayan Health review An injection and an oral drop carry the same monthly figure here, which is the reverse of the usual pattern. ## The verdict Bayan Health prices compounded semaglutide at $99 and compounded tirzepatide at $119, and charges the same for the injectable microdose as for the oral drops. Both entry tiers are microdoses rather than the doses the approved labels describe. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $129/mo Oral From $99/mo Prescription Required Compounded Yes — not FDA-approved Bayan Health sells compounded semaglutide and compounded tirzepatide in two delivery routes. The injectable microdose tiers read $99 and $119 a month. The oral drop formulations carried the same two figures on the same day. Both injectables are sold with vitamin B6 in the preparation. Billing is described as a monthly subscription. 1. ## Who writes the prescription, and what do they see? A prescription stands behind every tier, and the subscription is the unit that is billed. The pages priced here describe the formulation and the route in detail. Who reviews an intake, and how often afterwards, is not published. No list of states served is published either, so eligibility is settled at intake rather than before it. Treatment is arranged remotely and the medication arrives by mail. The microdose tier is the entry product on both routes. A microdose is a fraction of the maintenance dose each label describes. The published trial results for these molecules were produced at label doses. 2. ## What happens when the dose goes up? The rate is stated as flat across doses, on both molecules and both routes. A [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) therefore leaves the monthly figure where it started. What a dose step means on the oral route is a separate question from what it means by injection. Sublingual milligrams and injected milligrams are not interchangeable, and no conversion between them is published beside the price. 3. ## What the price includes $99 buys either the injectable microdose or the oral drops, which inverts the usual order. Most sellers price an oral preparation above the injection. Tirzepatide is $119 by either route, so the $20 step between molecules holds whichever is chosen. No second charge sits beside either figure. 4. ## What it claims, and what it cites Both molecules are compounded, so a pharmacy prepares them and no regulator reviews the finished product before it ships. The oral drops are the weaker case on evidence. Bayan publishes no pharmacokinetic data for that route. How much of a sublingual drop reaches the bloodstream is therefore not measured. ## Where it holds up, and where it does not - Strength: Injection and oral priced the same - Strength: Rate stated as flat at every dose - Strength: Two molecules on one page - Limitation: No pharmacokinetic data published for the drops - Limitation: State coverage not published - Limitation: Entry tiers sit below label doses ## What the evidence says about this kind of treatment The assessment above is about Bayan Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader weighing an injection against an oral preparation at one seller, where the two routes carry the same monthly figure. Wrong for A reader who wants the dose to match what the trials used, because both entry tiers here are microdoses rather than label doses. ## The evidence behind what Bayan Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bayan Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Idgie Health | A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. | | | Apex MD | A reader who wants a month-to-month plan with no prepay commitment, and who is told what is in the vial before ordering. | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MadeMed](https://thisglp.com/reviews/mademed) [MANÜ Telehealth](https://thisglp.com/reviews/manu-telehealth) [Marek Health](https://thisglp.com/reviews/marek-health) [Maves](https://thisglp.com/reviews/maves) [Maximus](https://thisglp.com/reviews/maximus-tribe) [MaxLife](https://thisglp.com/reviews/maxlife) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are the oral drops equivalent to the injection? Equivalence is not established. No pharmacokinetic data for the drop route is published beside the price. Sublingual milligrams and injected milligrams are not interchangeable. What does a microdose tier mean here? It is a dose below the maintenance doses the approved labels describe. The trial results published for semaglutide and tirzepatide were produced at those label doses. A microdose was not what those trials measured. Does the price move as the dose rises? Bayan states one rate at every dose, on both molecules and both routes. The monthly figure therefore holds through a titration. Is Bayan Health expensive compared with other GLP-1 telehealth sellers? Bayan Health publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bayan Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Believe Health reviews (2026): GLP-1 telehealth sellers | This GLP Tirzepatide and semaglutide cost the same to the dollar, at every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/believe-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price for both drugs # Believe Health review Tirzepatide and semaglutide cost the same to the dollar, at every dose. ## The verdict Believe Health charges $129 for either drug, at any dose. Tirzepatide carries no premium over semaglutide. Eight storefronts ship the same software under different names, and this is one. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $129/mo Prescription Required Compounded Yes — not FDA-approved Two injected lines, identically priced. The tirzepatide card is marked MOST CHOSEN. The storefront itself is a tenant on a platform serving seven others. 1. ## Who writes the prescription, and what do they see? Nothing identifies who prescribes. The same absence appears on all seven sibling sites, which is what you would expect from one codebase. Watch what a brand here can change. On a platform shared by eight storefronts, the price card is the one thing each tenant configures for itself. 2. ## What happens when the dose goes up? Neither figure moves with the dose, and the page says so outright. That single sentence is what turns $129 into something a reader can multiply. 3. ## What the price includes Half a year costs $774 whichever drug is chosen, and the dose claim makes that number survive an escalation. Two struck figures, $249 and $299, sit overhead explaining nothing. 4. ## What it claims, and what it cites Made to order, not manufactured. Nobody at the FDA sees the finished vial. None of the eight sites will tell you which pharmacy fills it. ## Where it holds up, and where it does not - Strength: One low figure covers either drug - Strength: The dose claim is written on the page - Strength: Tirzepatide costs no more than semaglutide - Limitation: Eight names run one shipped bundle - Limitation: A shortlist of these compares settings - Limitation: The overhead figures explain nothing - Limitation: No pharmacy is disclosed on any sibling ## What the evidence says about this kind of treatment The assessment above is about Believe Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a cheap fixed rate and understands what this storefront is. Wrong for A reader treating several of these brand names as separate businesses. ## The evidence behind what Believe Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Believe Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Bioverse | Readers who want semaglutide cheaply and ignore the struck figure beside it | | | Bodi Envi | Patients who value named care partners and can monitor refill notices | | | bmiMD | Readers who want a microdose and understand that is what the low figure buys | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDExam](https://thisglp.com/reviews/mdexam) [Measured](https://thisglp.com/reviews/measured) [Medi-Weightloss](https://thisglp.com/reviews/medi-weightloss) [MediRX](https://thisglp.com/reviews/medirx) [MedLeanRx](https://thisglp.com/reviews/medleanrx) [Medro](https://thisglp.com/reviews/medro) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does tirzepatide cost more than semaglutide? No. Both are $129 a month, each shown under its own struck figure. Is this an independent business? It is one tenant among eight sharing a single shipped bundle, established by hashing it rather than by how the sites look. Will a higher dose cost more? No. The page states one price at any dosage. Is Believe Health expensive compared with other GLP-1 telehealth sellers? Believe Health publishes a starting figure of $129/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Believe Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Belle Health reviews (2026): GLP-1 telehealth sellers | This GLP Belle includes clinician oversight, nurse support and group dietitian coaching in its compounded injection plans. Longer supplies lower the advertised monthly equivalent, but the one-month rates remain higher. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/belle-health Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Care included, supply length matters # Belle Health review Belle includes clinician oversight, nurse support and group dietitian coaching in its compounded injection plans. Longer supplies lower the advertised monthly equivalent, but the one-month rates remain higher. ## The verdict Belle is worth considering for its stated clinical oversight and nutrition support, particularly if you want a consistent medication price as the prescribed dose changes. Choose the supply length cautiously: the lowest headline is a longer-plan equivalent, and shipped prescriptions cannot be refunded under its terms. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $199/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states, subject to clinical eligibility Belle offers compounded semaglutide and tirzepatide injections, with a separate tirzepatide microdose listing and broader wellness products. Those categories should not be mixed when deciding whether the program suits a conventional weight-management regimen. 1. ## Who writes the prescription, and what do they see? A licensed clinician reviews the written screening and decides whether treatment is appropriate. The site names its medical leadership and describes access to care by phone or text. A named team does not identify the clinician assigned to an individual patient; confirm that relationship during enrollment. The pricing page includes clinician oversight, nurse support, injection supplies, delivery and weekly group dietitian sessions. Group nutrition coaching differs from an individual medical appointment. Ask how follow-up is scheduled and how urgent or persistent side effects reach the treating clinician. 2. ## What happens when the dose goes up? The product pages describe starting low and adjusting gradually, without publishing a universal milligram schedule. Belle says the selected plan’s price holds as the dose increases. Dose changes still require the clinician; clarify what happens to an already supplied package if treatment is paused or changed. 3. ## What the price includes A one-month supply remains $199 for compounded semaglutide and $249 for tirzepatide. The current rendered pricing cards show lower equivalents for longer supplies. Confirm the actual payment schedule and amount charged upfront; a monthly equivalent does not establish a monthly cancellation opportunity. 4. ## What it claims, and what it cites The injection pages identify compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and compounded [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and state that finished compounded medicines are not FDA approved. Public pharmacy lists differ between the pricing page and terms, so confirm the actual dispensing pharmacy on the prescription and label rather than assuming every listed partner fills every order. ## Where it holds up, and where it does not - Strength: Clinical oversight and nurse support included - Strength: Weekly group dietitian coaching listed - Strength: One-month and longer-supply options distinguished - Strength: No membership fee advertised - Limitation: Lowest rate requires a longer supply choice - Limitation: No public patient-specific dose schedule - Limitation: Shipped medication is non-refundable - Limitation: Actual pharmacy assignment requires confirmation ## What the evidence says about this kind of treatment The assessment above is about Belle Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. Wrong for A patient who needs guaranteed video appointments or expects unused shipped medication to be refunded. ## The evidence behind what Belle Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Belle Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Medsol RX](https://thisglp.com/reviews/medsol-rx) [MEDVi](https://thisglp.com/reviews/medvi) [Metaboost Rx](https://thisglp.com/reviews/metaboost-rx) [Mevo Health](https://thisglp.com/reviews/mevo-health) [Midi Health](https://thisglp.com/reviews/midi-health) [Mint Med](https://thisglp.com/reviews/mint-med) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the lowest monthly figure the one-month price? No. The rendered pricing cards attach their lower rates to longer supplies; one month is $199 for semaglutide and $249 for tirzepatide. Does Belle raise the price when the dose rises? Its public pricing page says the chosen plan’s price does not increase with dose. Confirm the prescribed preparation and supply included. Does cancel anytime guarantee a medication refund? No. The terms exclude refunds for shipped prescriptions and require stopping subscriptions before renewal. Is Belle Health legit? Belle Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states, subject to clinical eligibility. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Belle Health expensive compared with other GLP-1 telehealth sellers? Belle Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Belle Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Current supply-length prices and inclusions](https://www.joinbelle.com/treatments) - [Semaglutide preparation and care](https://www.joinbelle.com/treatments/weight-loss/compounded-semaglutide) - [Tirzepatide product details](https://www.joinbelle.com/treatments/weight-loss/compounded-tirzepatide) - [Renewal, clinical partners and refund rules](https://www.joinbelle.com/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Better MedSpa reviews (2026): GLP-1 telehealth sellers | This GLP Better Med Spa offers supervised semaglutide and tirzepatide care in Chicago, with Illinois telehealth described. Its aesthetic memberships are a separate financial decision. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/better-medspa Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Better MedSpa sell a GLP-1? Better Med Spa offers supervised semaglutide and tirzepatide care in Chicago, with Illinois telehealth described. Its aesthetic memberships are a separate financial decision. ## The verdict The most useful clinical commitment is that follow-up should accompany refills. Better describes individual plans, check-ins and Illinois telehealth, alongside its Lincoln Park clinic. Decide whether that care model suits you without assuming that accompanying spa or contouring services are medically necessary. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Better Med Spa is a Chicago medical-aesthetic practice with GLP-1 weight-management services. The public pages describe weekly semaglutide and tirzepatide injections, personalized planning and lifestyle support. Other advertised aesthetic treatments are separate interventions. 1. ## Who writes the prescription, and what do they see? The medical team assesses health history and goals before treatment. The clinic’s general terms require medical screening and examination by an authorized provider. Ask who will prescribe and manage the ongoing course rather than assuming the professional performing an aesthetic service fills that role. The weight-management description includes regular check-ins and explicitly rejects automatic refills without follow-up. Lincoln Park visits and Illinois telehealth are described. Confirm the actual appointment format and route for contacting a prescriber about symptoms between reviews. 2. ## What happens when the dose goes up? Treatment is personalized and should be adjusted through the clinician. The public materials do not establish one universal dose ladder or a guaranteed visit interval. Ask what information is required before each refill and what happens if a follow-up appointment is delayed. 3. ## What the price includes The public treatment description does not establish one complete recurring GLP-1 price. Aesthetic membership discounts and financed services are not the same as a medication-and-care quote. Clarify whether any membership is optional and which services carry a longer commitment. 4. ## What it claims, and what it cites Semaglutide and tirzepatide are named, but the precise branded or compounded prescription and pharmacy must be established for the patient’s plan. Trial findings and broad body-composition claims should not be interpreted as proof of every proposed combination with aesthetic services. ## Where it holds up, and where it does not - Strength: Refill follow-up is explicitly emphasized - Strength: Local clinic and Illinois telehealth are described - Strength: Individual medical screening precedes treatment - Limitation: Actual drug and pharmacy need confirmation - Limitation: Spa memberships can introduce separate commitments - Limitation: No complete public dose-price schedule ## What the evidence says about this kind of treatment The assessment above is about Better MedSpa. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Chicago or Illinois patient wanting local clinical follow-up and able to separate weight care from optional aesthetic services. Wrong for Someone seeking verified nationwide care or assuming a spa membership defines a complete GLP-1 package. ## The evidence behind what Better MedSpa prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Better MedSpa compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Mint Med](https://thisglp.com/reviews/mint-med) [Mint Medical Clinic](https://thisglp.com/reviews/mint-medical) [Mochi Health](https://thisglp.com/reviews/mochi-health) [Mojoon](https://thisglp.com/reviews/mojoon) [Mondae](https://thisglp.com/reviews/mondae) [MultiMedRx](https://thisglp.com/reviews/multimedrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are automatic refills provided without follow-up? The public weight-care description says no; ask what reassessment is required before each refill. Where is remote care described? The site describes Illinois telehealth in addition to its Lincoln Park clinic. Must aesthetic services accompany the drug? Do not assume they must. Ask for a clinical explanation and a separate quote for each proposed service. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.bettermedspa.com/) - [Tirzepatide program details](https://www.bettermedspa.com/treatments/tirzepatide) - [Terms of service and payment conditions](https://www.bettermedspa.com/terms-and-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Better U Care reviews (2026): GLP-1 telehealth sellers | This GLP A mental-health telehealth practice whose checkout charges one monthly figure for compounded GLP-1s, medication and consultation together, at every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/better-u-care Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A psychiatry clinic's GLP-1 line # Better U Care review A mental-health telehealth practice whose checkout charges one monthly figure for compounded GLP-1s, medication and consultation together, at every dose. ## The verdict Better U Care charges $298 a month for compounded semaglutide and $397 for compounded tirzepatide, and its checkout pages describe each figure as covering the medication and the provider consultation together. Because the same figure is stated to hold at every dose, the charge for the first month is a fair guide to the charge for the sixth. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 21 From From $298/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 21 states Better U Care is a telehealth practice built around mental health, with at-home ketamine therapy, psychiatry and talk therapy at the front of its site and weight management added as a separate line. Its weight-loss page sells brand-name Ozempic, Wegovy and Mounjaro appointments for a clinical fee with the drug bought separately at a pharmacy. Beside those sit two compounded injections priced with the medication included. 1. ## Who writes the prescription, and what do they see? Payment goes to Better U Clinical, P.A., the practice named at the top of both checkout pages, and the team page names a medical director, Janette Leal, MD, alongside a second psychiatrist. Neither is presented as the clinician who reviews weight-loss patients, and the weight page quotes a third physician on the program without saying who writes the prescription. What a clinician reads before prescribing is described only as the intake and health history form. A patient picks a package, fills in the intake and health history form, and a licensed clinician reviews it and builds a plan, all from a phone or a computer without a clinic visit. The site describes a companion app with progress tracking and live chat, plus licensed wellness coaches for habits, though how often anyone checks in during a course is not stated. Both checkout pages ask for any labs from the last six months to be uploaded to the member portal. 2. ## What happens when the dose goes up? The FAQ answers the dose question directly: whatever the medication dose in a treatment plan, the price remains the same, and the semaglutide card repeats that the cost is uniform for all doses. A patient stepping up from a starting dose toward maintenance over the first months should therefore see the same $298 or $397 at each refill. No milligram schedule is published, and the page does not say who approves each step up. 3. ## What the price includes The two compounded figures, $298 and $397 a month, are the amounts the checkout pages charge, and each is labeled there as medication plus provider consultation. The FAQ says patients are not billed automatically and can choose a subscription or pay one month at a time, which leaves the next charge in the buyer's hands rather than a renewal date's. One practical note before comparing: the compounded price cards appear in the page's mobile layout, while a desktop visitor mainly sees the brand-name appointment packages. 4. ## What it claims, and what it cites Both GLP-1 lines are sold as a custom compounded prescription rather than a manufactured product, and compounded preparations are not FDA-approved or reviewed by the FDA for safety, effectiveness or quality before dispensing. The compounding pharmacy is not named on the weight-loss page or at checkout. The brand-name route works differently, with the prescription sent to a pharmacy of the patient's choice and the drug paid for there. ## Where it holds up, and where it does not - Strength: Medication and consultation included in one charge - Strength: Price stated to hold at every dose - Strength: Choice of subscription or one month at a time - Strength: Practice and medical director named - Limitation: Compounding pharmacy is not named - Limitation: Compounded prices shown only in the mobile layout - Limitation: No dose schedule appears on the page - Limitation: Two different state lists on one page ## What the evidence says about this kind of treatment The assessment above is about Better U Care. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer in one of its listed states who wants the same monthly price from the first dose through maintenance. Wrong for A buyer who wants to know which pharmacy compounds the medication before paying for it. ## The evidence behind what Better U Care prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Better U Care compares | Seller | Who it suits | Go | | --- | --- | --- | | Tuyo Health | Buyers weighing a compounded plan against brand Wegovy or Zepbound at the same clinic | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | | Eden | Buyers comparing what the two molecules actually cost | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MyFastRx](https://thisglp.com/reviews/myfastrx) [MyStart Health](https://thisglp.com/reviews/mystart-health) [Näky](https://thisglp.com/reviews/naky) [NativeMed](https://thisglp.com/reviews/nativemed) [Navio MD](https://thisglp.com/reviews/navio-md) [Neo Soma Healthcare](https://thisglp.com/reviews/neo-soma-healthcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the medication included in the $298? Yes, according to the checkout page, which describes the semaglutide charge as medication and provider consultation included. An FAQ answer saying packages cover only the virtual visit is written for the brand-name appointment packages, where the drug is bought separately at a pharmacy. Which states does Better U Care serve for weight loss? The FAQ lists twenty-one states, among them Arizona, California, Florida, New York and Texas, while a second list lower on the same page names eighteen and leaves out Connecticut, Idaho and Oregon. Will I be charged automatically each month? Not unless you choose it, since the FAQ says there is no automatic billing by default and offers a subscription or a single month at a time as the two options. Is Better U Care legit? Better U Care is a GLP-1 telehealth sellers service. Its stated availability: 21 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Better U Care expensive compared with other GLP-1 telehealth sellers? Better U Care publishes a starting figure of $298/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Better U Care above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # BetterMe Rx reviews (2026): GLP-1 telehealth sellers | This GLP The advertised rate holds while a sitewide sale runs, and the pricing page carries no notice of what happens when it stops. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/betterme-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Sale-dependent headline # BetterMe Rx review The advertised rate holds while a sitewide sale runs, and the pricing page carries no notice of what happens when it stops. ## The verdict BetterMe Rx puts two numbers on the same page for the same product and never says which one a buyer will meet. The advertised rate holds only while a sitewide sale runs; the undiscounted rate is printed beside it, fifty dollars a month higher. Publishing both is more honest than most sellers manage. Saying nothing about which applies today undoes much of that. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $249/mo Oral From $250/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states BetterMe Rx sells compounded semaglutide and compounded tirzepatide across injected and oral forms, stated across fifty states. All four lines are quoted as monthly figures but sold as three-month plans, and every one of those figures depends on a sitewide sale being live at the moment a buyer arrives. 1. ## Who writes the prescription, and what do they see? The prescription is arranged remotely and precedes shipping, and the pages describe plans rather than clinicians. The intake is not documented, so what a prescriber sees before writing is not something a reader can establish from the site. That is common enough here. It sits alongside a pricing structure that already asks for a good deal of trust. A sale that has run continuously is still a sale, and that is the thing to hold onto. The advertised figure is real while it lasts, the regular figure is also published, and nothing on the pricing page tells a buyer which one will apply on the day they order. The three-month plan then converts whichever rate applies into a single charge at the start. 2. ## What happens when the dose goes up? Nothing is published about what either rate does as the dose rises, and the three-month structure makes that gap wider than it looks. A buyer commits a quarter at one figure, without knowing whether the next quarter carries the same one at a higher dose. 3. ## What the price includes Two conditions sit on every figure and neither is hidden. The first is the sale. The second is the term: a quarter is bought at once, so the opening charge is nearly three times the quoted monthly rate. Both oral lines inherit the same arrangement as their injections. What a reader cannot establish from the pages is the only thing that decides the bill, which is whether the discount is live on the day they order. 4. ## What it claims, and what it cites Every line is compounded, so none has been assessed by the FDA for safety or quality before reaching a buyer. BetterMe Rx does not name the pharmacy that prepares them. ## Where it holds up, and where it does not - Strength: Both rates appear on the same page - Strength: Coverage is enumerated, not asserted - Strength: Sale condition is named in the copy - Limitation: The page never says which rate applies today - Limitation: The term is a quarter, not a month - Limitation: Escalation is undocumented on every line - Limitation: Figures older than most on this site ## What the evidence says about this kind of treatment The assessment above is about BetterMe Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will confirm the sale is running and is content to commit three months at once. Wrong for A reader budgeting from the advertised figure without checking which rate applies today. ## The evidence behind what BetterMe Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How BetterMe Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | MadeMed | A reader who can commit to six months, the term the lower rate is priced for | | | GobyMeds | A reader who wants a monthly price that holds at any dose, with a cheaper starter bundle as the alternative | | | Lttl | Readers who want every prepay rung visible and know which dose line they need | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [New Wave Health](https://thisglp.com/reviews/new-wave-health) [NewSelf](https://thisglp.com/reviews/newself) [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) [NexLife](https://thisglp.com/reviews/nexlife) [Next Vial](https://thisglp.com/reviews/next-vial) [NextMeds](https://thisglp.com/reviews/nextmeds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 the real price? Only while a sitewide sale is running. The undiscounted rate is published alongside it and is fifty dollars a month higher. Is billing monthly? No. A quarter is purchased at once, so the first charge is close to three times the figure quoted as monthly. What does half a year cost? It depends entirely on whether the sale is live when you order, and the pricing page gives a reader no way to tell. Is BetterMe Rx legit? BetterMe Rx is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is BetterMe Rx expensive compared with other GLP-1 telehealth sellers? BetterMe Rx publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts BetterMe Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # BeyondMD reviews (2026): GLP-1 telehealth sellers | This GLP A peptide practice that added GLP-1 programs, with starting figures that name no billing period. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/beyondmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Starting figures, no billing period # BeyondMD review A peptide practice that added GLP-1 programs, with starting figures that name no billing period. ## The verdict BeyondMD lists its compounded semaglutide program as "Starting at $125" and tirzepatide as "Starting at $199". Neither page states whether that figure covers a month, a single fill or a whole program. Membership itself is described on both pages as free. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved BeyondMD is a telehealth practice in Greenville, Michigan, built around peptide programs. Weight management is one of eight program categories on the site. It lists compounded semaglutide by injection, a semaglutide and B12 version, and compounded tirzepatide. Oral versions of both molecules and consultation programs for Wegovy and Zepbound sit on the same grid. 1. ## Who writes the prescription, and what do they see? A U.S.-licensed clinician reviews each intake, and in some states approval also requires a short video consultation. The process page says no decision is automated and that approval typically takes three to five business days. A patient who is not approved for treatment is not charged, per the same page. The semaglutide program lists its contents: the drug, a provider consultation, optional specialist and nutritionist access, coaching, and an order of Zofran. Zofran is an anti-nausea medicine, which matters most during dose increases. Check-ins run through a patient portal, and labs are requested case by case rather than required up front. 2. ## What happens when the dose goes up? The semaglutide page describes gradual [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) based on response and tolerance. It outlines expected effects for weeks one to four and four to eight. It gives no doses in milligrams, and it does not say whether the charge changes as the dose rises. 3. ## What the price includes The figures are $125 for semaglutide and $199 for tirzepatide, each labeled as a starting figure. No billing period is printed beside either one, on the product pages or on the category grid. A reader cannot tell a monthly rate from a first fill on these pages, so neither figure is ranked here. 4. ## What it claims, and what it cites Both injections are compounded by licensed 503A pharmacies, per the site's disclosure. Compounded preparations are not FDA-approved and are not reviewed before dispensing. The pharmacies themselves go unnamed anywhere on the program pages. [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are offered as consultation programs, which is a different product from a compounded vial. ## Where it holds up, and where it does not - Strength: Zofran included in the semaglutide program - Strength: No charge if not approved - Strength: Video visit where the state requires one - Strength: Titration described in plain stages - Limitation: No billing period beside either figure - Limitation: No milligram doses published - Limitation: Compounding pharmacy goes unnamed - Limitation: State coverage stated two different ways ## What the evidence says about this kind of treatment The assessment above is about BeyondMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants nausea support built into the program and will confirm the billing period first. Wrong for A reader comparing monthly rates, since neither figure states the period it covers. ## The evidence behind what BeyondMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How BeyondMD compares | Seller | Who it suits | Go | | --- | --- | --- | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | LifeMD | Readers with insurance that may cover the medication, leaving the fee as the main cost | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NiceRx](https://thisglp.com/reviews/nicerx) [Nirwana Health](https://thisglp.com/reviews/nirwana-health) [NoBsRx](https://thisglp.com/reviews/no-bs-rx) [Nolu](https://thisglp.com/reviews/nolu) [Noom](https://thisglp.com/reviews/noom) [Nova](https://thisglp.com/reviews/nova) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $125 a monthly price? The page does not say. It reads Starting at $125 with no period attached, and the FAQs on the same page do not address billing at all. What comes with the semaglutide program? A provider consultation, weight-loss coaching, optional specialist and nutritionist access, and an order of Zofran for nausea. Is BeyondMD available in every state? The footer says all 50 states, while the process page says most U.S. states. Availability depends on provider licensure where the reader lives. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Big Easy Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP Dividing a twelve-week package by three understates every figure here, because twelve weeks is 2.76 calendar months. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/big-easy-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Twelve weeks is not three months # Big Easy Weight Loss review Dividing a twelve-week package by three understates every figure here, because twelve weeks is 2.76 calendar months. ## The verdict Big Easy Weight Loss sells only in twelve-week packages: $495 for semaglutide and $599 for tirzepatide, discounted to $399 and $499 for new patients. Those work out at $179 and $217 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $179/mo Prescription Required Compounded Yes — not FDA-approved Availability 51 jurisdictions Big Easy Weight Loss sells both molecules by injection in twelve-week blocks with no monthly option, across 51 jurisdictions. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages price packages rather than describing the clinical relationship. The new-patient figure is a genuine reduction on the block rather than a first-month rate that ends, which is a cleaner offer than most in this comparison. 2. ## What happens when the dose goes up? The rates are recorded as flat across doses, so a block bought at one dose holds if the dose rises. No milligram appears on either package. 3. ## What the price includes A twelve-week semaglutide block is $495, or $179 a calendar month; the new-patient block at $399 is $144. Tirzepatide is $599 and $217, or $499 and $181 for new patients. Reading either as three months understates the monthly figure by about eight percent. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. A pharmacy prepares them, and the FDA does not review a compounded preparation before dispensing. ## Where it holds up, and where it does not - Strength: The new-patient price is a real reduction - Strength: Coverage in 51 jurisdictions - Strength: Flat across doses within a block - Strength: Package totals are published - Limitation: No monthly purchase exists - Limitation: Twelve weeks is under three months - Limitation: The whole block falls due at the start - Limitation: Refunds inside a block are unstated ## What the evidence says about this kind of treatment The assessment above is about Big Easy Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who can pay a block up front and wants the new-patient reduction. Wrong for A reader dividing a twelve-week package by three to compare it. ## The evidence behind what Big Easy Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Big Easy Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | Blue Haven RX | Readers who read the term definition rather than the word beside the price | | | bmiMD | Readers who want a microdose and understand that is what the low figure buys | | | Believe Health | Readers who want a low flat rate and know what this storefront actually is | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nova MD](https://thisglp.com/reviews/nova-md) [Novi](https://thisglp.com/reviews/novi) [NovoCare Pharmacy](https://thisglp.com/reviews/novocare-pharmacy) [NowPatient](https://thisglp.com/reviews/nowpatient) [NP2GO](https://thisglp.com/reviews/np2go) [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a calendar month cost? $179 for semaglutide and $217 for tirzepatide, or $144 and $181 at the new-patient rates. Is there a monthly option? No. Everything is sold in twelve-week packages. Is the new-patient price introductory? It is a reduction on the block rather than a first-month rate that then ends. Is Big Easy Weight Loss legit? Big Easy Weight Loss is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Big Easy Weight Loss expensive compared with other GLP-1 telehealth sellers? Big Easy Weight Loss publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Big Easy Weight Loss below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # BiltRx reviews (2026): GLP-1 telehealth sellers | This GLP Card prices for two compounded drugs, with a membership and a consultation billed separately. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/biltrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Low card, fees apart # BiltRx review Card prices for two compounded drugs, with a membership and a consultation billed separately. ## The verdict BiltRx lists compounded semaglutide at $81 a month and tirzepatide at $129. Each product page adds one line: consultation and shipping apply separately. The FAQ also names a monthly membership. With it, a month costs at least $90.99 and $138.99. Even those are not the full monthly cost. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $90.99/mo Prescription Required Compounded Yes — not FDA-approved BiltRx is a telehealth brand based in Houston. It sells GLP-1 drugs beside NAD+, glutathione, hormone therapy and supplements. Its weight-loss grid lists two compounded drugs. It also lists four brand-name drugs. 1. ## Who writes the prescription, and what do they see? A licensed U.S. provider runs the consultation. The FAQ describes phone and video visits. The provider decides whether to prescribe. The provider group behind the visits is not named. Three charges stack here. The FAQ states that "BiltRx has a 9.99 monthly membership". It then says consultation fees and medication are billed separately. The consultation fee has no published amount. Partner compounding pharmacies fill the prescriptions. 2. ## What happens when the dose goes up? Each card shows one rate per drug and names no dose. Whether the rate rises during escalation is not stated. The product pages give no dose ladder. 3. ## What the price includes Start with the card: $81 for semaglutide, $129 for tirzepatide. Add the $9.99 monthly membership stated in the FAQ. That gives $90.99 and $138.99, the floors ranked here. Add a consultation fee, which has no published amount. Add shipping, which is also unpublished. The full monthly total cannot be computed from the public pages. The brand-name cards run $1,449 for Ozempic and $1,849 for Wegovy. Mounjaro and Zepbound are $1,499 each. 4. ## What it claims, and what it cites Both compounded lines carry a NOT FDA APPROVED tag on their cards. The FDA does not review compounded drugs before dispensing. [Mounjaro](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), Zepbound, [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) and Ozempic are FDA-approved brand products. The partner pharmacies are not identified. ## Where it holds up, and where it does not - Strength: Compounded cards state a monthly figure - Strength: Compounded status tagged on each card - Strength: Brand-name drugs priced on the same grid - Strength: Phone and video consultations offered - Limitation: Consultation fee has no published amount - Limitation: Membership billed on top of medication - Limitation: Shipping charged separately, amount unstated - Limitation: No dose attached to either rate ## What the evidence says about this kind of treatment The assessment above is about BiltRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will get the consultation fee in writing before paying. Wrong for A reader who needs the full monthly cost before starting an intake. ## The evidence behind what BiltRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How BiltRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | Rex MD | Readers who want an approved oral product with the clinician's cost stated inside it | | | Maximus | A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) [NuBloom](https://thisglp.com/reviews/nubloom) [Nucore Health](https://thisglp.com/reviews/nucore-health) [NuDay Rx](https://thisglp.com/reviews/nuday-rx) [NuuVim](https://thisglp.com/reviews/nuuvim) [NuviaRx](https://thisglp.com/reviews/nuviarx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $81 the full monthly cost? No. The product page says consultation and shipping apply separately. The FAQ adds a $9.99 monthly membership, so at least $90.99. What does the membership cover? Care coordination, priority support and member savings on supplements, per the FAQ. Consultation fees and medication are billed apart from it. Which brand-name drugs are listed? Mounjaro, Zepbound, Wegovy and Ozempic. Each carries its own monthly figure on the weight-loss grid. Is BiltRx expensive compared with other GLP-1 telehealth sellers? BiltRx publishes a starting figure of $90.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts BiltRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bionomy Health reviews (2026): GLP-1 telehealth sellers | This GLP There is no subscription to cancel here, which matters more than it sounds when most people stop within a year. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bionomy-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Nothing renews by itself # Bionomy Health review There is no subscription to cancel here, which matters more than it sounds when most people stop within a year. ## The verdict Bionomy Health publishes $189 a month for semaglutide and $249 for tirzepatide. Payment is per prescription with no subscription. Coverage is 48 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 48 From From $189/mo Prescription Required Compounded Yes — not FDA-approved Availability 48 states Bionomy Health sells both molecules by weekly injection, billed monthly against each prescription rather than on a standing plan. 1. ## Who writes the prescription, and what do they see? A prescription precedes each fill, which is what the billing model rests on. No clinician is described on the pages read. Most sellers here make stopping an administrative act. This one makes it the default: nothing continues unless a prescription is written again. 2. ## What happens when the dose goes up? The rates are recorded as flat across doses, so an escalation should not move them. No milligram appears beside either figure. 3. ## What the price includes Six months is $1,134 and $1,494, and neither total assumes a commitment. Neither figure is low against this comparison, and the absence of a subscription is what is being paid for. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them, and the FDA reviews neither before dispensing. ## Where it holds up, and where it does not - Strength: No subscription to cancel - Strength: Flat across doses - Strength: Coverage in 48 states - Limitation: Neither figure is low - Limitation: No oral route is offered - Limitation: No milligram published - Limitation: The pharmacy is not identified ## What the evidence says about this kind of treatment The assessment above is about Bionomy Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to be able to stop by doing nothing. Wrong for A reader shopping on price alone. ## The evidence behind what Bionomy Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bionomy Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Bioverse | Readers who want semaglutide cheaply and ignore the struck figure beside it | | | Society of You | Readers willing to hand over contact details before seeing the monthly rate | | | Bodi Envi | Patients who value named care partners and can monitor refill notices | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Obu Health](https://thisglp.com/reviews/obu-health) [Omnia TeleHealth](https://thisglp.com/reviews/omnia-telehealth) [Omzo](https://thisglp.com/reviews/omzo) [Ondra Health](https://thisglp.com/reviews/ondra-health) [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) [OnlyRx](https://thisglp.com/reviews/onlyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a subscription? No. Payment is per prescription, billed monthly. Does a higher dose cost more? The rates are recorded as flat across doses. Which states are covered? Forty-eight. Is Bionomy Health legit? Bionomy Health is a GLP-1 telehealth sellers service. Its stated availability: 48 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Bionomy Health expensive compared with other GLP-1 telehealth sellers? Bionomy Health publishes a starting figure of $189/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bionomy Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bioverse reviews (2026): GLP-1 telehealth sellers | This GLP The struck-through figures imply a fifty-five percent cut on one line and eleven on the other, with nothing explaining either. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bioverse Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two anchors, two stories # Bioverse review The struck-through figures imply a fifty-five percent cut on one line and eleven on the other, with nothing explaining either. ## The verdict Bioverse publishes $129 a month for semaglutide against a struck $289, and $399 for tirzepatide against a struck $449. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $129/mo Prescription Required Compounded Yes — not FDA-approved Bioverse sells both molecules by weekly injection. Each carries a price and an anchor above it, and the gap between them differs sharply by line. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. Nothing describes who writes it or how often a case is reviewed. An anchor is only useful if something explains it. Here one line implies a saving five times the size of the other, and neither anchor is sourced. 2. ## What happens when the dose goes up? Nothing published says what either figure does at a higher dose. No milligram appears beside either. 3. ## What the price includes Six months is $774 on semaglutide and $2,394 on tirzepatide. That is a gap of $1,620 between molecules, which is far wider than most sellers here maintain. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them, and the FDA does not review a compounded preparation before dispensing. ## Where it holds up, and where it does not - Strength: Semaglutide is priced low - Strength: Both anchors are shown, not hidden - Strength: Both molecules carry a figure - Limitation: The two anchors imply unequal discounts - Limitation: Neither anchor is explained - Limitation: Tirzepatide costs three times semaglutide - Limitation: Nothing lists the states served ## What the evidence says about this kind of treatment The assessment above is about Bioverse. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants semaglutide cheaply and ignores the struck figure beside it. Wrong for A reader treating either anchor as a price anyone has been charged. ## The evidence behind what Bioverse prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bioverse compares | Seller | Who it suits | Go | | --- | --- | --- | | Bionomy Health | Readers who want to be able to stop by doing nothing | | | Society of You | Readers willing to hand over contact details before seeing the monthly rate | | | Believe Health | Readers who want a low flat rate and know what this storefront actually is | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Onyx Weight Loss](https://thisglp.com/reviews/onyx-weight-loss) [Open Water Rx](https://thisglp.com/reviews/open-water-rx) [Optimized Health](https://thisglp.com/reviews/optimized-health) [Options Medical Weight Loss](https://thisglp.com/reviews/options-medical-weight-loss) [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) [Oria Meds](https://thisglp.com/reviews/oria-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What do the struck prices mean? Nothing published explains them. They imply a 55% cut on one line and 11% on the other. Why is tirzepatide so much dearer? The page does not say. The gap is $270 a month. What does six months cost? $774 for semaglutide or $2,394 for tirzepatide. Is Bioverse expensive compared with other GLP-1 telehealth sellers? Bioverse publishes a starting figure of $129/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bioverse below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Blis MD reviews (2026): GLP-1 telehealth sellers | This GLP Each rung is a one-month vial, with the weekly dose it delivers printed beside the price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/blis-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A price for every dose # Blis MD review Each rung is a one-month vial, with the weekly dose it delivers printed beside the price. ## The verdict Blis MD prints the weekly dose each price buys, which makes its figures checkable against a titration schedule. Semaglutide starts at $109 a month for 0.25 mg weekly and reaches $189 at 2.5 mg. Tirzepatide runs from $159 a month at 2.5 mg weekly to $270 at 15 mg. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $109/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 29 states Blis MD is a Florida-based virtual clinic that sells compounded semaglutide and tirzepatide one vial at a time. Testosterone, sermorelin, NAD+ and erectile dysfunction tablets share the same online shop. An oral semaglutide tablet combined with vitamin B6 is also listed, sold as 30 tablets. Checkout is a one-time purchase for each vial, not a recurring subscription. 1. ## Who writes the prescription, and what do they see? The founder and medical director is described as a primary care physician with over 17 years of practice. She is not named anywhere on the About page or elsewhere on the site. After checkout, a licensed clinician reviews the intake forms and approves or declines treatment. The FAQ says no charge is made unless a patient is approved for treatment. Messages to the practitioner through the account chat are answered within 24 hours, per the same FAQ. Ordering runs through the shop: choose a vial, check out, then complete the medical intake forms. A free consultation can be booked beforehand, but the home page says one is not required to order. Each vial is a one-month supply, shipped free and described as temperature-controlled. The three-month kits add syringes and alcohol prep pads to the vials. Once approved, a patient re-orders at any time along the personalized dosing plan. 2. ## What happens when the dose goes up? The price follows the dose, rung by rung, and every rung names its weekly dose. Semaglutide steps through $109, $129, $149, $169 and $189 at 0.25, 0.5, 1, 1.5 and 2.5 mg weekly. Tirzepatide steps from $159 at 2.5 mg weekly to $270 at 15 mg across six rungs. Two three-month kits bundle the early and the later vials at a stated discount. Who decides when to step up is described only as the patient's personalized dosing plan. 3. ## What the price includes The pricing page lists semaglutide at $109 a month and tirzepatide at $159 a month. Those are the starting-dose vials, not a flat monthly rate that holds through maintenance. A patient who has reached 1 mg of semaglutide weekly pays $149 for that month's vial. The weight-loss page quotes $139 and $199 as starting prices, figures that do not match the product pages. The product pages state that no doctor's fee or subscription fee is charged on top. 4. ## What it claims, and what it cites Both injections are compounded, and the site footer says plainly that compounded medications are not FDA-approved. Compounded preparations are not reviewed by the FDA for safety, effectiveness or quality before they are dispensed. Sourcing is described as accredited 503A compounding pharmacies, and none of them is named. ## Where it holds up, and where it does not - Strength: Weekly dose printed beside every price - Strength: Charged only after approval, per the FAQ - Strength: No subscription or doctor's fee - Strength: Three-month kits discount the early doses - Strength: Twenty-nine states listed by name - Limitation: Price climbs with each dose step - Limitation: Medical director described but not named - Limitation: Weight-loss page quotes different starting prices - Limitation: Compounding pharmacy not named ## What the evidence says about this kind of treatment The assessment above is about Blis MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to know the cost at each dose before starting. Wrong for A buyer expecting one flat price through maintenance. ## The evidence behind what Blis MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Blis MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | VevaRX | Buyers who will read a product page twice before believing the number on the card | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Oria Meds](https://thisglp.com/reviews/oria-meds) [OurView Health](https://thisglp.com/reviews/ourview-health) [Oxford's Medical Weight Loss (The Calibrate Clinic)](https://thisglp.com/reviews/the-calibrate-clinic)[Ozari Health](https://thisglp.com/reviews/ozari-health) [Pallas Health](https://thisglp.com/reviews/pallas-health) [PauseRX](https://thisglp.com/reviews/pauserx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change as the dose goes up? Yes. Each vial carries its own price, from $109 to $189 for semaglutide and from $159 to $270 for tirzepatide. Is a consultation required? Not a scheduled one. A licensed clinician still reviews the intake after checkout, and no charge is made unless treatment is approved. Which states does Blis MD serve? Twenty-nine, listed by abbreviation in the FAQ, with Florida, Texas, California and New York among them. Is Blis MD legit? Blis MD is a GLP-1 telehealth sellers service. Its stated availability: 29 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Blis MD expensive compared with other GLP-1 telehealth sellers? Blis MD publishes a starting figure of $109/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Blis MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bliv reviews (2026): GLP-1 telehealth sellers | This GLP An asynchronous GLP-1 service whose headline figures depend on plan structure and eligibility. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bliv Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 An estimate, not a rate # Bliv review An asynchronous GLP-1 service whose headline figures depend on plan structure and eligibility. ## The verdict Bliv approves prescriptions without a phone call or a video visit, and it advertises compounded semaglutide at as low as $116 a month and tirzepatide at as low as $199, each footnoted "based on plan structure and eligibility". What a single order actually costs is set inside the intake, so neither figure is ranked as a price here. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $116/mo Prescription Required Compounded Yes — not FDA-approved Bliv Wellness LLC sells GLP-1 treatment alongside erectile dysfunction, hair loss and peptide care, and its weight-loss page leads with an online intake reviewed by a U.S.-licensed provider, usually within a day. Medication is filled by a U.S. pharmacy and shipped in discreet packaging, typically within three to five days of approval. 1. ## Who writes the prescription, and what do they see? The whole clinical exchange happens in writing: a patient answers a medical questionnaire, a licensed clinician reads it, and if the treatment fits, the prescription is written without the two ever speaking. That suits someone who already knows what they want, though it means questions about side effects go through support after approval rather than into a visit before it. Bliv sells a subscription that renews automatically each billing period, and its terms put the refill on the patient, who must request a prescription refill once a month through a form, web chat or a link. Support runs by phone, email and text, and a community forum on Skool offers nutrition guidance the site says a dietician leads. 2. ## What happens when the dose goes up? The public page publishes no dose schedule and no milligram figures, only the line that semaglutide comes with gradual dose increases, so a reader cannot tell whether the monthly charge climbs as the dose climbs over the first four months. That question is worth asking directly, because the headline figures are described as depending on plan structure. 3. ## What the price includes The semaglutide card reads as low as $116 per month and the tirzepatide card as low as $199, both beneath a banner advertising a limited-time 50% discount, and both carry the same footnote about plan structure and eligibility. The home page also promises no contracts and no cancellation fees, yet the refund terms allow a full refund only within 72 hours of purchase. 4. ## What it claims, and what it cites Both products are compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), which are not FDA-approved and are not reviewed by the FDA before dispensing, and the site does not name the U.S. pharmacy that fills them. A pay-later route through CareCredit or Klarna is offered on eligible plans, and the terms say the CareCredit service fee is not refundable. ## Where it holds up, and where it does not - Strength: No phone call or video visit required - Strength: Approval usually within a day - Strength: Pay-later financing on eligible plans - Strength: Dietician-led community forum included - Limitation: Headline figures depend on plan structure - Limitation: Refill requests fall to the patient - Limitation: Full refund window is 72 hours - Limitation: Filling pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Bliv. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader already comfortable with a GLP-1, who wants a prescription without scheduling a call and will confirm the per-order charge before paying. Wrong for A first-time patient who wants to talk through side effects with a clinician before the first dose arrives. ## The evidence behind what Bliv prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bliv compares | Seller | Who it suits | Go | | --- | --- | --- | | Lemonaid Health | Readers who want named clinicians and a price that holds through dose changes | | | Wisp | Readers who will not inject and accept a form without human data | | | Fridays | Readers who will get the annual rate confirmed in writing before paying | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Peak Wellness](https://thisglp.com/reviews/peak-wellness) [PepHaūs](https://thisglp.com/reviews/pephaus) [Pepti](https://thisglp.com/reviews/pepti) [Piper](https://thisglp.com/reviews/piper) [PlexusDx](https://thisglp.com/reviews/plexusdx) [PlushCare](https://thisglp.com/reviews/plushcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $116 what I pay each month? Not necessarily. The card says as low as $116 per month, footnoted to plan structure and eligibility, and the per-order charge appears only inside the intake, so ask for it in writing first. Can I get a refund if I change my mind? Only within 72 hours of purchase and only if no services have been rendered and no medication has gone to the pharmacy, and even then the terms deduct a consultation fee and a clinical coordination charge from what is returned. Do I ever speak with a clinician? Not as part of approval, since the intake is reviewed in writing. The terms do describe booking an appointment with the clinic by email, and support can be reached by phone or text at the number on the site. Is Bliv expensive compared with other GLP-1 telehealth sellers? Bliv publishes a starting figure of $116/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bliv below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bloom MD reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide at one price for any dose; tirzepatide priced step by step, with each weekly dose printed. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bloommd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat semaglutide, laddered tirzepatide # Bloom MD review Semaglutide at one price for any dose; tirzepatide priced step by step, with each weekly dose printed. ## The verdict BloomMD charges $270 a month for compounded semaglutide on subscription, at any dose. Compounded tirzepatide starts at $244 on subscription at 2.2 mg weekly and costs more at each higher dose. Payment comes before the medical intake, with a full refund if a provider declines. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Liraglutide · Semaglutide · Tirzepatide Form Injection From From $244/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named BloomMD is an online clinic selling weight-loss, longevity, hormone, skin and hair treatments alongside supplements. Its GLP-1 shelf carries compounded semaglutide, compounded tirzepatide, a microdose tirzepatide line and compounded liraglutide, with brand-name Wegovy and Zepbound as separate listings. 1. ## Who writes the prescription, and what do they see? BloomMD states that it does not practice medicine, and that care comes from independent licensed providers contracted through MDI Medical Group PC. No individual clinician is named. The provider reviews an intake form that arrives after checkout, not before it. A free consultation can be booked in advance, and a text line reaches a practitioner. What the provider reviews beyond the form is not stated. The order runs in a fixed sequence: choose a plan, pay, complete the medical form, then wait for review. If a provider does not approve, BloomMD states the order is refunded in full. Approved orders are compounded in five to seven business days and shipped overnight, with supplies, shipping and unlimited provider messaging included. 2. ## What happens when the dose goes up? The two main molecules handle the dose ladder in opposite ways. Semaglutide is sold as one monthly figure for any dose, so a step up costs nothing extra. Tirzepatide is priced per weekly dose: $249 at 2.2 mg, $319 at 4.4 mg, $379 at 7 mg, $409 at 10 mg and $459 at 13 mg. Those are one-time prices, before the subscription takes its saving off. A twelve-week new-patient starter steps from 2.2 to 4.4 to 7 mg for $749. Higher doses may require documentation of recent treatment, subject to provider approval. 3. ## What the price includes Semaglutide is $275 as a one-time purchase and $270 on the month-to-month subscription. A 90-day block is $750, and a ten-week starter for new patients who have not taken it before is $395. The dose selector labels the monthly option at $295, which disagrees with the $275 shown beside it. Tirzepatide's subscription figure is $244 at the lowest dose, because both subscriptions take $5 off the one-time price. Liraglutide runs $375.25 on subscription for the smallest vial. 4. ## What it claims, and what it cites All four GLP-1 lines are compounded, and the product page states the FDA does not review or approve them. The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) program is described as a preparation that combines semaglutide with glycine and B12. BloomMD calls its preparations pharmacy-inspected and lab-tested for potency and purity. The compounding pharmacy is not named. Semaglutide dosing may differ in California, Indiana and Minnesota. ## Where it holds up, and where it does not - Strength: Every tirzepatide dose printed with its price - Strength: Semaglutide priced the same at any dose - Strength: Full refund if a provider declines - Strength: Liraglutide offered beside the usual two molecules - Strength: The contracted medical group is named - Limitation: Payment is taken before the medical intake - Limitation: Tirzepatide reaches $459 a month at 13 mg - Limitation: No individual clinician is named - Limitation: The compounding pharmacy goes unnamed - Limitation: The semaglutide dose label disagrees with its price ## What the evidence says about this kind of treatment The assessment above is about Bloom MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to see the tirzepatide price at each weekly dose before starting. Wrong for A buyer who wants a provider to review their history before any payment is taken. ## The evidence behind what Bloom MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bloom MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | VigorMeds | Buyers who would rather take a daily sublingual than a weekly shot | | | Tuyo Health | Buyers weighing a compounded plan against brand Wegovy or Zepbound at the same clinic | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PlushCare](https://thisglp.com/reviews/plushcare) [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) [Potere Health MD](https://thisglp.com/reviews/potere-health-md) [Precision Telemed](https://thisglp.com/reviews/precision-telemed) [Premium Health](https://thisglp.com/reviews/premium-health) [PrescribedRX](https://thisglp.com/reviews/prescribedrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does semaglutide cost more at a higher dose? No. The monthly plan is sold for any dose at $270 on subscription, or $275 as a one-time purchase. How much is tirzepatide at 10 mg? $409 for a thirty-day supply, before the $5 subscription saving. The page prints a figure for each of five weekly doses. What if a provider does not approve me? BloomMD states the order is refunded in full, though payment is taken first and the medical intake follows checkout. Is Bloom MD expensive compared with other GLP-1 telehealth sellers? Bloom MD publishes a starting figure of $244/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bloom MD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # BloomWell Rx reviews (2026): GLP-1 telehealth sellers | This GLP Monthly figures on both molecules, with the dispensing pharmacy and the provider network named in the FAQ. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bloomwell-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Pharmacy and network named # BloomWell Rx review Monthly figures on both molecules, with the dispensing pharmacy and the provider network named in the FAQ. ## The verdict BloomWell Rx prices compounded semaglutide at $199 a month and tirzepatide at $249. Both are the default one-month rate on each product page, and the FAQ names DiRx Health as the pharmacy and Beluga Health as the provider network. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named BloomWell Rx is a Grand Rapids telehealth brand selling weight-loss, wellness and hormone treatments. Its two compounded GLP-1 products are labeled Personalized GLP-1 and GLP-1/GIP. The small print on each page names the molecules: semaglutide and tirzepatide. Brand-name drugs are offered as consultations only, not as shipped products. 1. ## Who writes the prescription, and what do they see? Prescribing runs through Beluga Health, which the FAQ calls a physician-led virtual care platform. A provider reviews the quiz answers within 24 hours, and some states require a live video visit or a secure chat. A photo ID and a selfie are required before any treatment starts. Refills are not charged automatically on this service. The FAQ says a renewal notice arrives each month and the provider reviews the patient's information before continuing. Payment is taken only when the patient confirms the order, and insurance is not accepted. 2. ## What happens when the dose goes up? The tirzepatide product is described as a GLP-1/GIP and B12 blend. Neither page gives a milligram dose, although the product copy says dosing is adjusted over time. Whether the price moves with the dose is not stated beside either figure. 3. ## What the price includes Each product page shows a one-month tab, selected by default, beside a three-month tab. The default reads $199 a month for semaglutide and $249 for tirzepatide. The gap between the molecules is $50 a month at the default rate. Orders cannot be changed or canceled once placed, and medication cannot be returned. 4. ## What it claims, and what it cites Both products are compounded and dispensed by a licensed third-party pharmacy. Compounded drugs are not FDA-approved and are not reviewed by the FDA before dispensing. DiRx Health, in Fort Lauderdale, is named in the FAQ as the pharmacy partner. [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), the Wegovy pill and Foundayo are offered as consultations. ## Where it holds up, and where it does not - Strength: Dispensing pharmacy named in the FAQ - Strength: Beluga Health named as prescribing network - Strength: No automatic monthly charge - Strength: One-month rate is the default tab - Limitation: No milligram dose on either page - Limitation: Orders cannot be canceled once placed - Limitation: Insurance is not accepted - Limitation: Tirzepatide vial adds B12 to the blend ## What the evidence says about this kind of treatment The assessment above is about BloomWell Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to know which pharmacy fills the order before paying. Wrong for A reader who may need to cancel an order after placing it. ## The evidence behind what BloomWell Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How BloomWell Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Eden | Buyers comparing what the two molecules actually cost | | | Sprout Health | Readers taking the six-month plan, which is the one measured in calendar months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Primary Clinic (Direct GLP)](https://thisglp.com/reviews/primary-clinic)[Prime Doctor RX](https://thisglp.com/reviews/prime-doctor-rx) [Prime Health](https://thisglp.com/reviews/prime-health) [Queen RX](https://thisglp.com/reviews/queen-rx) [QuickMD](https://thisglp.com/reviews/quickmd) [ReadyRx](https://thisglp.com/reviews/readyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which pharmacy fills BloomWell Rx orders? DiRx Health, which the FAQ names along with a Fort Lauderdale address. Am I charged automatically each month? No. The FAQ says a renewal notice arrives monthly, and payment is taken only when the patient chooses to process it. Does the tirzepatide product contain anything else? Yes. The product page describes a GLP-1/GIP and B12 blend rather than tirzepatide on its own, with the vitamin presented as support for energy. Is BloomWell Rx expensive compared with other GLP-1 telehealth sellers? BloomWell Rx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts BloomWell Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Blue Haven RX reviews (2026): GLP-1 telehealth sellers | This GLP The card states that the rate buys four weeks and then advertises that same rate as a month, which are two different things the page itself distinguishes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/blue-haven-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 It defines the unit, then mislabels it # Blue Haven RX review The card states that the rate buys four weeks and then advertises that same rate as a month, which are two different things the page itself distinguishes. ## The verdict Blue Haven RX publishes $179 for four weeks of semaglutide and $259 for tirzepatide, with consultation, medication and free shipping stated as included. Thirteen fills a year make those $194 and $281 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $194/mo Prescription Required Compounded Yes — not FDA-approved Blue Haven RX sells both molecules by weekly injection at a flat rate that covers the consultation, the medicine and the shipping, sold in four-week fills and advertised monthly. 1. ## Who writes the prescription, and what do they see? The consultation is named as part of the price rather than charged beside it, which puts the clinician inside the figure. How often a case is revisited afterwards is not described anywhere on the pages read. Bundling three charges into one figure is genuinely good practice and this seller does it on both lines. What undoes some of it is a card that states its own term as four weeks and then presents that term as a month, because a reader who trusts the label reaches a figure the same card contradicts. 2. ## What happens when the dose goes up? Nothing published states what either rate becomes at a higher dose, which is the second unknown sitting on a figure whose interval is already doing quiet work. 3. ## What the price includes A year of semaglutide is $2,327 rather than the $2,148 twelve payments of $179 would suggest, and tirzepatide $3,367 rather than $3,108. An introductory rate from $149 is available on a three-month plan, which commits a buyer to a quarter before the standing rate applies. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the pages do not name, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: Consultation, medication and shipping all included - Strength: The four-week term is stated on the card - Strength: An introductory rate is published - Strength: Both molecules carry a flat figure - Limitation: A four-week fill is advertised as a month - Limitation: Thirteen fills a year, not twelve - Limitation: Reaching the opener means signing for three months - Limitation: No milligram appears beside either rate ## What the evidence says about this kind of treatment The assessment above is about Blue Haven RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who reads the term definition on the card rather than the word beside the price. Wrong for A reader comparing $179 against another seller's calendar-month figure without converting it. ## The evidence behind what Blue Haven RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Blue Haven RX compares | Seller | Who it suits | Go | | --- | --- | --- | | Blue Sky MD | Patients near the practice who will ask what enrollment costs before joining | | | Big Easy Weight Loss | Readers who can pay a block up front and want the new-patient reduction | | | bmiMD | Readers who want a microdose and understand that is what the low figure buys | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Recovery Delivered](https://thisglp.com/reviews/recovery-delivered) [Refills](https://thisglp.com/reviews/refills) [ReflexMD](https://thisglp.com/reviews/reflexmd) [Regenics](https://thisglp.com/reviews/regenics) [Rehydra+ Wellness](https://thisglp.com/reviews/rehydra-plus) [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a calendar month cost? $194 for semaglutide and $281 for tirzepatide, once thirteen four-week fills a year are counted rather than twelve. What is included in the rate? The consultation, the medication and free shipping, on both lines, which is three charges that commonly sit outside a headline elsewhere. What does the introductory rate require? A three-month plan, after which the standing rate applies. Is Blue Haven RX expensive compared with other GLP-1 telehealth sellers? Blue Haven RX publishes a starting figure of $194/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Blue Haven RX above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Blue Sky MD reviews (2026): GLP-1 telehealth sellers | This GLP The weekly figures are stated plainly and neither can be reached without joining a program whose cost the practice declines to publish. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/blue-sky-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A real rate behind an unpriced gate # Blue Sky MD review The weekly figures are stated plainly and neither can be reached without joining a program whose cost the practice declines to publish. ## The verdict Blue Sky MD quotes $40 a week for semaglutide and $60 for tirzepatide in office. Both require enrollment in a medical weight-loss program that the practice states varies in cost and prices nowhere, so this site ranks no figure for it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 1 Prescription Required Compounded Yes — not FDA-approved Availability 1 state Blue Sky MD is a clinical practice rather than a mail-order storefront, dispensing compounded injections in office or shipping them, with the medication priced by the week and the program around it priced only on request. 1. ## Who writes the prescription, and what do they see? This is the part that distinguishes it: treatment happens inside a medical weight-loss program at a physical practice, with the prescriber seen rather than inferred. That is a different proposition from most of this comparison, and the reason the program exists at all. Pricing the drug by the week and the care by an unpublished amount inverts the usual problem. Most sellers here hide the care behind the medication figure; this one publishes the medication figure and hides the care, and the result is the same — no total can be built before committing. 2. ## What happens when the dose goes up? Nothing published states what the weekly rate does as a dose rises. In a practice-based model that question is usually settled in the room rather than on the page, which helps a patient and does nothing for a reader comparing options beforehand. 3. ## What the price includes There is nothing to total. $40 and $60 a week are the medication figures and they are not the purchase: the program enrollment is mandatory, its cost is stated to vary, and no range appears anywhere. Multiplying the weekly rate by four produces a number that describes part of a bill, which is worse than producing none. Ask for the program cost in writing before enrolling. 4. ## What it claims, and what it cites Both preparations are compounded rather than manufactured, dispensed in office or shipped, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: A physical practice with a seen prescriber - Strength: The weekly medication rates are stated plainly - Strength: Medication can be dispensed in office - Limitation: The mandatory program cost is unpublished - Limitation: No total can be built before enrolling - Limitation: One state appears in the coverage record - Limitation: Prices here are older than most on this site ## What the evidence says about this kind of treatment The assessment above is about Blue Sky MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient near the practice who wants an in-person program and will ask what the enrollment costs before joining it. Wrong for Anyone comparing on price, since the figure that decides the bill is not published anywhere. ## The evidence behind what Blue Sky MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Blue Sky MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Blue Haven RX | Readers who read the term definition rather than the word beside the price | | | Big Easy Weight Loss | Readers who can pay a block up front and want the new-patient reduction | | | Bionomy Health | Readers who want to be able to stop by doing nothing | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Remedy Meds](https://thisglp.com/reviews/remedy-meds) [REMEVi](https://thisglp.com/reviews/remevi) [Remi Meds](https://thisglp.com/reviews/remi-meds) [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) [Renlo Health](https://thisglp.com/reviews/renlo-health) [RENN Health](https://thisglp.com/reviews/renn-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does this site publish no price? Because the weekly medication rate cannot be reached without a mandatory program enrollment whose cost the practice states varies and never states, so no total exists to rank. What are the medication rates? $40 a week for semaglutide and $60 for tirzepatide, quoted in office, which are real figures for part of the purchase rather than the purchase. What should a patient establish first? The cost of the program enrollment, in writing, before joining — because that is the number the weekly rate depends on. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # bmiMD reviews (2026): GLP-1 telehealth sellers | This GLP Both products are sold explicitly as microdose lines, which puts them below the doses every trial in this field used. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bmimd Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Microdose, both molecules # bmiMD review Both products are sold explicitly as microdose lines, which puts them below the doses every trial in this field used. ## The verdict bmiMD's compounded semaglutide card reads $119 a month under a struck $199.80. Its tirzepatide card reads $179 under a struck $299.70. Coverage is 50 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $119/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states bmiMD sells a semaglutide microdose and a dual-agonist microdose by injection, each card showing a monthly rate under a struck-through anchor. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe plans and discounts rather than the clinician or the review schedule. Naming the tier microdose is honest labeling, and it is the fact a reader most needs. No trial has tested a dose below the licensed range, so the evidence behind either molecule does not transfer to what is being sold here. 2. ## What happens when the dose goes up? Microdose is the seller's own framing on both lines, and it locates these products below the trial range rather than at its opening rung. Nothing published says what moving up the ladder costs, or whether it is offered. 3. ## What the price includes A year of the semaglutide line at $119 is $1,428. The tirzepatide line at $179 is $2,148. The struck figures of $199.80 and $299.70 sit above those rates and are not charged. 4. ## What it claims, and what it cites Both lines are compounded and both are microdoses, meaning a smaller quantity of the same molecule rather than a different drug. The FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: The microdose framing is stated openly - Strength: Coverage in 50 states - Strength: Both card rates shown before intake - Limitation: No trial has tested a dose below the licensed range - Limitation: Nothing published on dose escalation cost - Limitation: The strike-throughs are never charged ## What the evidence says about this kind of treatment The assessment above is about bmiMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a microdose and understands that is what the low figure buys. Wrong for A reader expecting the doses the trial results were produced at. ## The evidence behind what bmiMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How bmiMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Bodi Envi | Patients who value named care partners and can monitor refill notices | | | Believe Health | Readers who want a low flat rate and know what this storefront actually is | | | Big Easy Weight Loss | Readers who can pay a block up front and want the new-patient reduction | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Reset Solutions](https://thisglp.com/reviews/reset-solutions) [RestorLife Med](https://thisglp.com/reviews/restorlife-med) [Revel Health](https://thisglp.com/reviews/revel-health) [Revel RX](https://thisglp.com/reviews/revel-rx) [Revive Meds](https://thisglp.com/reviews/revive-meds) [Rewinding RX](https://thisglp.com/reviews/rewinding-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is a microdose here? A smaller quantity of the same molecule, below the doses the trials used. The seller names both lines that way. Are the struck figures charged? No. $199.80 and $299.70 sit above the $119 and $179 rates as anchors. Is there trial evidence at these doses? No trial has tested a dose below the licensed range. Is bmiMD legit? bmiMD is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is bmiMD expensive compared with other GLP-1 telehealth sellers? bmiMD publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts bmiMD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bodi Envi reviews (2026): care and monthly plans | This GLP Bodi Envi identifies Wasef Health for clinical care and VialsRx for dispensing. Its cancellation and replacement rules need attention before enrollment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bodi-envi Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named care partners, restrictive returns # Bodi Envi review Bodi Envi identifies Wasef Health for clinical care and VialsRx for dispensing. Its cancellation and replacement rules need attention before enrollment. ## The verdict Bodi Envi now identifies the organizations behind prescribing and pharmacy fulfillment, with patient-portal access for ongoing care. Its monthly plans are stated as unchanged across doses. The main tradeoff is its strict treatment of processed orders, prepaid balances and packages marked delivered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $155/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states LegitScript Claimed by provider Bodi Envi is a telehealth platform, not the pharmacy or medical practice. Its FAQ identifies Wasef Health, PC as the clinical organization and Michael Wasef, MD as medical director. The service describes nationwide telehealth availability. These organizational disclosures help a patient know whom to contact, without establishing who will personally review an individual case. 1. ## Who writes the prescription, and what do they see? A licensed physician or nurse practitioner assesses the medical information and decides whether treatment is appropriate. The site says most consultations use a questionnaire and secure chat, with audio or video when required. Paying does not guarantee a prescription. Patients who are not eligible after provider review receive a refund under the policy. Current patients can contact their care team through the patient portal. The service promotes ongoing support, but that does not establish a guaranteed immediate clinical response. Refills receive advance text and email notice. Use that notice to discuss tolerability or request changes before pharmacy processing; the policy says changes cannot be made once the prescription has been sent. 2. ## What happens when the dose goes up? Bodi Envi says dose changes do not increase the price. The clinician may adjust treatment for response and tolerability, and patients can request review through their care team. A lower price or smaller prescribed dose does not remove the need for a clear concentration, injection instruction and follow-up plan. 3. ## What the price includes The monthly plan is $155 for semaglutide and $229 for tirzepatide. Longer prepaid terms can lower the monthly equivalent. The cancellation policy excludes partial refunds for three-, six- and twelve-month purchases. Canceling future orders is possible, but a prescription already issued after medical review may make the current order nonrefundable. 4. ## What it claims, and what it cites Bodi Envi names VialsRx in Tomball, Texas as its 503A dispensing pharmacy. The injections are compounded, not FDA-approved products. The pharmacy contact should also appear on the prescription label. Report a suspected dispensing error to the pharmacy within the policy’s 48-hour window and retain the packaging and label. ## Where it holds up, and where it does not - Strength: Clinical organization and dispensing pharmacy identified - Strength: Patient portal provides an ongoing contact route - Strength: Dose changes do not raise the advertised plan price - Limitation: Prepaid plans lack partial refunds - Limitation: Processed prescriptions cannot ordinarily be canceled - Limitation: Packages marked delivered are not replaced without another purchase ## What the evidence says about this kind of treatment The assessment above is about Bodi Envi. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who values identifiable care partners and can monitor refill notices before processing. Wrong for Someone who needs generous prepaid refunds or replacement coverage for a package marked delivered but missing. ## The evidence behind what Bodi Envi prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bodi Envi compares | Seller | Who it suits | Go | | --- | --- | --- | | bmiMD | Readers who want a microdose and understand that is what the low figure buys | | | Believe Health | Readers who want a low flat rate and know what this storefront actually is | | | Bionomy Health | Readers who want to be able to stop by doing nothing | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rex MD](https://thisglp.com/reviews/rex-md) [Rivas Medical Weight Loss](https://thisglp.com/reviews/rivas-medical) [Rivo Health](https://thisglp.com/reviews/rivo-health) [Rixa Health](https://thisglp.com/reviews/rixa-health) [RNK Health](https://thisglp.com/reviews/myrnk) [Ro](https://thisglp.com/reviews/ro) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who provides Bodi Envi’s care? The FAQ identifies Wasef Health, PC for clinical services and VialsRx in Texas for dispensing. A licensed clinician makes the individual treatment decision. Does two-day shipping mean two days from signup? No. The shipping policy starts that interval after pharmacy preparation and dispatch. It excludes weekends and holidays, and carrier delays can add time. What happens if the carrier says delivered but the package is missing? The replacement policy says a delivered scan completes fulfillment and a replacement requires another purchase. Contact support and the carrier promptly. Can I cancel before the next refill? Request cancellation through the portal or email. Act before processing; issued prescriptions and processed refills are subject to restrictive refund rules. Is Bodi Envi legit? Bodi Envi is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Bodi Envi expensive compared with other GLP-1 telehealth sellers? Bodi Envi publishes a starting figure of $155/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bodi Envi below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 14, 2026. Terms can change. - [Monthly and prepaid prices](https://bodienvi.com/pricing) - [Clinical team and pharmacy FAQ](https://bodienvi.com/faq) - [Cancellation and refunds](https://bodienvi.com/refund-policy) - [Shipping policy](https://bodienvi.com/shipping-policy) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bodybuilding Health+ reviews (2026): GLP-1 telehealth sellers | This GLP Nothing here has a term attached, so the advertised number is the one an uncommitted buyer pays. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bodybuilding-health-plus Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 You can leave after thirty days # Bodybuilding Health+ review Nothing here has a term attached, so the advertised number is the one an uncommitted buyer pays. ## The verdict Bodybuilding Health+ charges $179 for semaglutide and $209 for tirzepatide, with no term attached to either. A year bought at once brings semaglutide to $139. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $179/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states claimed; no list published Two injected products, each buyable thirty days at a time. Longer bundles exist underneath the headline figures. 1. ## Who writes the prescription, and what do they see? A prescription comes first. Nothing on the pages says who issues it or when a case is looked at again. Elsewhere in this comparison the advertised number usually hides a term. Here it does not, which removes the commonest reason a published figure misleads. 2. ## What happens when the dose goes up? Neither product says what a climbing dose does to its price. That silence is the page's weak point. 3. ## What the price includes Half a year costs $1,074 and $1,254, with nothing signed. Buying twelve months of semaglutide at once is $1,668 against $2,148 paid as you go, so the year saves $480. 4. ## What it claims, and what it cites Compounded to order, not manufactured. No regulator sees the finished vial, and no pharmacy is identified. ## Where it holds up, and where it does not - Strength: No term hides behind the headline - Strength: Bundles exist for anyone who wants one - Strength: Each drug carries a thirty-day figure - Limitation: Neither number is cheap - Limitation: Dose effects go unmentioned - Limitation: No milligram appears anywhere - Limitation: No served-states list appears ## What the evidence says about this kind of treatment The assessment above is about Bodybuilding Health+. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to begin without signing for a year. Wrong for A reader who needs the escalated price before ordering. ## The evidence behind what Bodybuilding Health+ prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bodybuilding Health+ compares | Seller | Who it suits | Go | | --- | --- | --- | | boostAGErx | Readers certain of the molecule who can pay three months at once | | | Bodi Envi | Patients who value named care partners and can monitor refill notices | | | Bionomy Health | Readers who want to be able to stop by doing nothing | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Roboclinic](https://thisglp.com/reviews/roboclinic) [Roen Rx](https://thisglp.com/reviews/roen-rx) [RX Bella](https://thisglp.com/reviews/rx-bella) [Rx.com](https://thisglp.com/reviews/rx-com) [RxION Health](https://thisglp.com/reviews/rxion-health) [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is a term required to get $179? No. That is the thirty-day figure. What does buying a year save? Forty dollars monthly on semaglutide — $480 across the year. What does a climbing dose cost? The pages do not say. Is Bodybuilding Health+ expensive compared with other GLP-1 telehealth sellers? Bodybuilding Health+ publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bodybuilding Health+ below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # BodyLogicMD reviews (2026): weight-loss clinics | This GLP BodyLogicMD offers practitioner-led weight assessment within a broader hormone-focused network. Its semaglutide discussion should lead to a specific prescription and monitoring plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bodylogicmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does BodyLogicMD sell a GLP-1? BodyLogicMD offers practitioner-led weight assessment within a broader hormone-focused network. Its semaglutide discussion should lead to a specific prescription and monitoring plan. ## The verdict BodyLogicMD is worth considering when weight concerns need a broader clinical discussion, but its hormone-centered explanation should not be accepted as a diagnosis by itself. The useful next step is a practitioner who can distinguish a genuine hormonal condition from other causes and explain the evidence for each proposed treatment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category weight-loss clinics Prescription Required The network connects patients with practitioners offering integrative and hormone-related care. Its weight page specifically discusses semaglutide, alongside testing, nutrition planning and ongoing support. It does not establish the same medication or bundle for every practice and patient. 1. ## Who writes the prescription, and what do they see? A symptom quiz and contact form lead to a Wellness Advocate, then testing and a practitioner consultation. The advocate is an intake role, not the person making a prescription decision. Ask for the clinical professional’s credentials, state eligibility and responsibility for ongoing care. The published process includes testing through a preferred lab partner, review of results and a tailored wellness plan. A practitioner and concierge team provide continuing support. That description does not establish a universal clinical visit interval or a guaranteed response time for every network location. 2. ## What happens when the dose goes up? Semaglutide suitability and follow-up need a medication-specific discussion rather than an assumption based on a hormone quiz. Ask how tolerance is reviewed, which changes require a visit and whether the same practitioner handles dose decisions and refills. 3. ## What the price includes The weight-management page does not give one complete recurring semaglutide price. It describes labs, medicine and delivery while allowing complementary products or optional services. Clarify which components are required for the proposed care and which are choices that can be declined. 4. ## What it claims, and what it cites The program discusses semaglutide without establishing one brand, route or dispensing pharmacy for every individual. Ask for the exact prescription before comparing clinical results. A claim that hormonal change can affect weight does not establish that hormone therapy is appropriate for every person seeking a GLP-1. ## Where it holds up, and where it does not - Strength: Testing is reviewed with a practitioner - Strength: Intake and medical consultation are separate steps - Strength: Continuing support is described - Limitation: Hormone-focused framing needs individual clinical justification - Limitation: No uniform public medication package - Limitation: Follow-up details vary with the chosen practice ## What the evidence says about this kind of treatment The assessment above is about BodyLogicMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking an assessment of weight concerns alongside possible hormone symptoms and willing to evaluate each proposed treatment separately. Wrong for A patient seeking an immediate standardized GLP-1 shipment or assuming a symptom quiz identifies the cause of weight gain. ## The evidence behind what BodyLogicMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How BodyLogicMD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) [RxPros](https://thisglp.com/reviews/rxpros) [RxSaludable](https://thisglp.com/reviews/rxsaludable) [Rylo Health](https://thisglp.com/reviews/rylo-health) [Ryze Rx](https://thisglp.com/reviews/ryze-rx) [Science & Co](https://thisglp.com/reviews/science-and-co) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does a Wellness Advocate prescribe? The published sequence places practitioner consultation after intake and testing. Confirm who provides the medical assessment. Must every optional product be purchased? The weight page explicitly describes complementary products and optional services; ask which, if any, are medically required. Is one semaglutide formulation guaranteed? No universal product is specified on the weight-management page. Obtain the actual medicine and pharmacy details. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Medical weight management and semaglutide discussion](https://www.bodylogicmd.com/symptoms/weight-loss/) - [Network and website terms](https://www.bodylogicmd.com/terms-and-conditions/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Bon Health reviews (2026): GLP-1 telehealth sellers | This GLP Four term lengths are published for each molecule, and the coverage list runs to every state. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/bon-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four terms, fifty states # Bon Health review Four term lengths are published for each molecule, and the coverage list runs to every state. ## The verdict Bon Health publishes $220 a month for semaglutide and $285 for tirzepatide without a commitment, across 50 states. Four term lengths are published beside them, which is more structure than most compounded sellers publish. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $220/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Bon Health sells compounded semaglutide and compounded tirzepatide by injection. Tirzepatide costs more at every term. Coverage is recorded in all fifty states. 1. ## Who writes the prescription, and what do they see? A prescription is issued before shipping and the pages name terms rather than clinicians. The intake is not described anywhere on the site. The pricing structure is documented in detail; the clinical one is not documented at all. Remote, with the commitment length as the main variable a buyer chooses. Four terms are offered, and the monthly figure falls as the term lengthens. 2. ## What happens when the dose goes up? Nothing is published about what the figure does at a higher dose, and the term structure makes that gap matter more. A buyer choosing the longest term fixes a commitment across an escalation whose cost behavior is unstated. 3. ## What the price includes Month to month, semaglutide is $220 and tirzepatide $285. Six months at those rates is $1,320 and $1,710. The annual plan is billed once, at $1,140 and $1,620, which is $95 and $135 a month. 4. ## What it claims, and what it cites Both lines are compounded, not manufactured. A pharmacy prepares them and the FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Coverage recorded in all fifty states - Strength: Every rung priced for both molecules - Strength: Four term lengths published, not one - Limitation: The lower figures require longer locks - Limitation: No dose behavior published anywhere - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Bon Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer in a state few sellers reach who wants every commitment length priced up front. Wrong for A buyer unwilling to trade term length for a lower monthly figure. ## The evidence behind what Bon Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Bon Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Citizen Meds | Readers who want the escalation named up front rather than discovered on a statement | | | Coivas | Readers comparing headline figures who will ask about dose and coverage before ordering | | | Avono Health | Buyers who expect to titrate and want one monthly price at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SexyMD](https://thisglp.com/reviews/sexymd) [ShapeIn Rx](https://thisglp.com/reviews/shapein-rx) [Shapely](https://thisglp.com/reviews/shapely) [Signos](https://thisglp.com/reviews/signos) [Silhouette MD](https://thisglp.com/reviews/silhouette-md) [SkyRx](https://thisglp.com/reviews/skyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is tirzepatide more expensive here? Yes. Month to month it is $285 against $220 for semaglutide, a $65 step. How do the four terms differ? The monthly figure falls as the term lengthens. The trade is a longer commitment for a lower rate, and the structure is published rather than hidden. Where does Bon Health ship? All fifty states are recorded in its coverage list. Is Bon Health legit? Bon Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Bon Health expensive compared with other GLP-1 telehealth sellers? Bon Health publishes a starting figure of $220/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Bon Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # boostAGErx reviews (2026): GLP-1 telehealth sellers | This GLP Ninety-five dollars is three months paid at once, divided by three. No invoice ever reads that figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/boostagerx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Division dressed as a price # boostAGErx review Ninety-five dollars is three months paid at once, divided by three. No invoice ever reads that figure. ## The verdict boostAGErx leads with from $95 monthly, which is what three months bought outright work out to per month. Anyone paying as they go is billed $225 per 28-day cycle, landing at $244 against the calendar. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $244/mo Prescription Required Compounded Yes — not FDA-approved Two injected products sold either as three months handed over at once or in 28-day cycles at a considerably higher rate. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages sell plans; nothing describes the clinical side. Dividing a lump sum by three produces a number, not a price. Nobody is billed $95 in a month, and the term behind it sits in a footnote. 2. ## What happens when the dose goes up? The seller writes that the real price varies by product and plan. That admits the figure moves and stops short of saying where. 3. ## What the price includes Buying three months outright works out at $95 monthly on semaglutide and $145 on tirzepatide. A buy-now, pay-later program can carry that charge. Going cycle by cycle costs $225 and $265 every 28 days, landing thirteen times annually. Against the calendar that is $244 and $287. Roughly $1,800 a year separates the two routes on semaglutide. 4. ## What it claims, and what it cites Compounded to order rather than manufactured. Nobody at the FDA inspects the finished vial before it ships. ## Where it holds up, and where it does not - Strength: Both routes appear on the page - Strength: Buying outright genuinely saves a lot - Strength: Each drug carries a figure - Limitation: The lead figure is arithmetic, not a bill - Limitation: 28-day cycles land thirteen times annually - Limitation: Three months are handed over before dose one - Limitation: Nothing addresses getting money back ## What the evidence says about this kind of treatment The assessment above is about boostAGErx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader sure of the drug who can hand over three months at once. Wrong for A reader who takes $95 for what a month costs. ## The evidence behind what boostAGErx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How boostAGErx compares | Seller | Who it suits | Go | | --- | --- | --- | | Bodybuilding Health+ | A reader unwilling to prepay a year before seeing how the drug goes | | | bmiMD | Readers who want a microdose and understand that is what the low figure buys | | | Blue Haven RX | Readers who read the term definition rather than the word beside the price | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Society of You](https://thisglp.com/reviews/society-of-you) [Somi Health](https://thisglp.com/reviews/somi-health) [Somira Health](https://thisglp.com/reviews/somira-health) [Southern Vitality and Weight Loss](https://thisglp.com/reviews/southern-vitality-weight-loss) [Spry](https://thisglp.com/reviews/spry) [StackMD](https://thisglp.com/reviews/stackmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does anyone pay $95 in a month? No. It is a three-month total divided by three. What does going cycle by cycle cost? $244 against the calendar on semaglutide, $287 on tirzepatide. Can money be recovered? The pages do not address it. Is boostAGErx expensive compared with other GLP-1 telehealth sellers? boostAGErx publishes a starting figure of $244/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts boostAGErx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Boston Medical Group reviews (2026): GLP-1 telehealth sellers | This GLP A men's health telemedicine brand selling compounded GLP-1s on a four-rung plan ladder, with the one-month plan selected by default. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/boston-medical-group Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A men's clinic, one price per drug # Boston Medical Group review A men's health telemedicine brand selling compounded GLP-1s on a four-rung plan ladder, with the one-month plan selected by default. ## The verdict Boston Medical Group's store preselects the one-month plan, which costs $190 for compounded semaglutide and $239 for compounded tirzepatide, and it states that the figure does not change as the dose climbs. The lower numbers on the same selector, down to $99 and $149, belong to a twelve-month plan billed as $1,188 or $1,788 in one charge. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 7 From From $190/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Boston Medical Group describes itself in its footer as a men's health network for erectile dysfunction and premature ejaculation, and its storefront still lists those treatments ahead of weight loss, testosterone, NAD+ and PT-141. The weight-loss product is a single page with a switch between semaglutide and tirzepatide and a plan selector beneath it. The company calls itself a marketplace that connects patients with independently licensed providers. 1. ## Who writes the prescription, and what do they see? The prescriber is an independent licensed provider, and the company says every clinical decision is that provider's alone and that payment does not guarantee a prescription. In California, Massachusetts, Rhode Island and Vermont the FAQ names the physicians a patient will be assigned, Dr Jeffrey Shellenberger and Dr Marc Serota, with a license number beside each state. Elsewhere the reviewing doctor is not named, and some states require a video visit or live chat before a prescription is finalized. A patient answers a medical questionnaire, uploads a photo ID and a picture of themselves as state rules require, and hears back from a doctor within about 24 hours. Each shipment carries four weeks of medication with syringes and alcohol pads, the card is charged when the order ships, and the company says it makes contact before each refill is billed. Reordering and canceling both happen inside the patient account. 2. ## What happens when the dose goes up? The store states its pricing rule plainly: the rate is set by which GLP-1 is prescribed, and whether the provider raises the dose or holds it, the monthly charge stays the same. For a patient moving from a starting dose toward maintenance over the first four months, the bill should read the same at each step. The store prints no milligram schedule, though an older program page on the main domain lays out a semaglutide ladder from 0.25 mg weekly to 2.5 mg over twenty weeks. 3. ## What the price includes Semaglutide is $190 for one month, $399 for three, $714 for six and $1,188 for twelve, and tirzepatide is $239, $589, $1,074 and $1,788 on the same terms. The per-month equivalents printed on the longer plans fall as low as $99 and $149, which is what a buyer sees if the eye goes to the smallest number rather than the selected one. Older SlimFitRx pages on the main domain still quote $199 to $299 a month plus a telemedicine platform fee, and they do not match the store. 4. ## What it claims, and what it cites Both drugs are compounded, and the store says compounded medications are not reviewed or approved by the FDA for safety or efficacy and are prepared by licensed 503A compounding pharmacies. The FAQ names two pharmacies that may fill a prescription depending on the therapy, Manifest Pharmacy in Greer, South Carolina, and RX Compounding Store in Miami. The older program FAQ adds that its compounded version carries vitamin B6 against nausea. ## Where it holds up, and where it does not - Strength: One-month plan preselected at checkout - Strength: Price stated not to change with dose - Strength: Two dispensing pharmacies named with addresses - Strength: Physicians named for four states - Limitation: Longer plans billed as one upfront charge - Limitation: Reviewing doctor unnamed in most states - Limitation: Older program pages quote conflicting prices - Limitation: No milligram schedule on the store page ## What the evidence says about this kind of treatment The assessment above is about Boston Medical Group. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the one-month price fixed across every dose, and the dispensing pharmacy named before paying. Wrong for A buyer who needs a named prescriber outside California, Massachusetts, Rhode Island and Vermont. ## The evidence behind what Boston Medical Group prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Boston Medical Group compares | Seller | Who it suits | Go | | --- | --- | --- | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [StackMD](https://thisglp.com/reviews/stackmd) [Sumbare Wellness](https://thisglp.com/reviews/sumbare-wellness) [Sunlight](https://thisglp.com/reviews/sunlight) [Superior Remedies](https://thisglp.com/reviews/superior-remedies) [Superpower](https://thisglp.com/reviews/superpower-health) [SurpassMD](https://thisglp.com/reviews/surpassmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Boston Medical Group's semaglutide $99 a month? Only on the twelve-month plan, which is billed as $1,188 in one charge, while the plan the store selects by default is one month at $190. Does the price go up with the dose? No, according to the store, which says the monthly rate depends only on which GLP-1 is prescribed, whether the provider raises the dose or keeps it where it is. When is the card charged? When the medication ships, per the FAQ, and the company says it contacts the patient before each refill is billed so there is a chance to cancel first. Is Boston Medical Group expensive compared with other GLP-1 telehealth sellers? Boston Medical Group publishes a starting figure of $190/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Boston Medical Group right at the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Breeze Meds reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide starts at $199 by injection, and the oral tablet is priced above it rather than below. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/breeze-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four rates, fifty states # Breeze Meds review Semaglutide starts at $199 by injection, and the oral tablet is priced above it rather than below. ## The verdict Breeze Meds publishes four advertised rates and serves all fifty states, and the ordering of those rates is the thing worth noticing, because the oral semaglutide at $299 sits a hundred dollars above the injection rather than beneath it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $199/mo Oral From $299/mo Prescription Required Compounded Yes — not FDA-approved Breeze Meds sells compounded semaglutide and compounded tirzepatide through an online service, and it publishes a rate for each molecule in each of two forms. Injectable semaglutide was advertised at $199 a month and the daily dissolvable tablet at $299, while tirzepatide was $399 in either form. All fifty states are listed, which is a wider footprint than several sellers priced beside it here. 1. ## Who writes the prescription, and what do they see? The service arranges treatment remotely and a prescription is issued before anything ships. The pricing cards describe the product and the rate rather than the clinician who signs for it, and what an intake asks beforehand is not something the seller publishes. Everything Breeze Meds sells in this category is compounded rather than the manufacturer's approved pen, and the service is delivered entirely at distance. The oral semaglutide is described on the seller's own card as one dissolvable tablet per day, which is a different daily commitment from a weekly injection and is worth weighing against the hundred-dollar premium it carries here. 2. ## What happens when the dose goes up? Whether these rates hold as the dose rises is not stated beside them, and since almost every patient escalates across the first sixteen weeks, that is the question its pages leave open. A reader should put it to the intake rather than assume the advertised figure is the one that persists. 3. ## What the price includes The oral semaglutide is the line that inverts the usual pattern: at $299 against $199 for the injection, paying more buys a daily tablet rather than a weekly shot, which is a convenience trade rather than a saving. Tirzepatide is $399 in both forms, so the same decision carries no price difference at all on that molecule. Prepaid three-, six- and twelve-month blocks are also listed for the oral, and each works out within a few dollars of the monthly rate, so the block buys commitment rather than a discount. 4. ## What it claims, and what it cites Both molecules are compounded, prepared by a pharmacy rather than manufactured and reviewed as a finished product, which means neither is FDA-approved and neither is assessed for safety, efficacy or quality before it is dispensed. The trial evidence a reader may have seen for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) was generated with the approved products at labeled doses, and whether a compounded preparation matches those in content or purity is not measured. ## Where it holds up, and where it does not - Strength: All fifty states served - Strength: Both molecules priced in both forms - Strength: Oral described as one tablet daily - Limitation: Oral semaglutide costs more than the injection - Limitation: Prepaid blocks save little against monthly - Limitation: Dose-escalation pricing not published ## What the evidence says about this kind of treatment The assessment above is about Breeze Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a daily tablet rather than a weekly injection and is willing to pay a premium for that difference. Wrong for A reader choosing the oral form expecting it to be the cheaper of the two, which on this seller it is not. ## The evidence behind what Breeze Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Breeze Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Synergy Rx | A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form. | | | Care Bare Rx | A reader choosing between the two molecules on grounds other than price, since this seller charges the same for both. | | | Strut Health | A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SynergenX Health](https://thisglp.com/reviews/synergenx) [T2D.com](https://thisglp.com/reviews/t2d) [TD Tele-Doc Weight Loss](https://thisglp.com/reviews/td-teledoc) [TeleCareSpot](https://thisglp.com/reviews/telecarespot) [TeleClinic](https://thisglp.com/reviews/teleclinic) [TeleDocs360](https://thisglp.com/reviews/teledocs360) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does the oral cost more than the injection here? That is how Breeze Meds prices it, and both figures are advertised on the same page. The oral semaglutide is $299 a month against $199 for the injectable, so on this seller the tablet is the premium option rather than the economy one. Do the prepaid blocks save money? Very little. The three-, six- and twelve-month blocks on the oral each work out within a few dollars of simply paying monthly, so what the block buys is a fixed commitment rather than a meaningful discount. Is compounded tirzepatide the same as the branded product? It is the same molecule prepared by a compounding pharmacy rather than the finished product a manufacturer makes and the FDA reviews, and equivalence in content and purity is neither established by that process nor measured here. Is Breeze Meds expensive compared with other GLP-1 telehealth sellers? Breeze Meds publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Breeze Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Brello Health reviews (2026): GLP-1 telehealth sellers | This GLP The card advertises a monthly figure. Renewals bill every eleven weeks, not every three months. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/brello-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A month that is eleven weeks # Brello Health review The card advertises a monthly figure. Renewals bill every eleven weeks, not every three months. ## The verdict Brello Health advertises semaglutide at $133 a month on a three-month minimum. Renewals bill $399 every eleven weeks. Eleven weeks is 2.53 calendar months, not three. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 35 From From $133/mo Prescription Required Compounded Yes — not FDA-approved Availability 35 states Brello Health sells both molecules by injection across 35 states. Two lines carry figures. There is no one-month option. A three-month prepay is mandatory. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe plans rather than clinicians. The intake is not documented. What is documented is the billing cycle, in the checkout rather than on the card. Two terms sit behind the advertised figure. Renewals run every eleven weeks, not every calendar quarter. And the prepay is mandatory, so nobody buys a single month. Both sit in a footnote under the headline figure. 2. ## What happens when the dose goes up? Nothing is published about what the figure does at a higher dose. On an eleven-week cycle that gap is wider than usual. A buyer commits most of a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) window at a price whose behavior is unstated. 3. ## What the price includes The advertised $133 is $399 divided by three months. Renewals then bill $399 every eleven weeks, which is 2.53 calendar months. A year of renewals bills more often than a quarterly reading suggests. Tirzepatide follows the same pattern: $166 advertised, $499 every eleven weeks. The $599 and $749 strikethroughs are anchors and are never charged. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The billing cycle appears at checkout - Strength: Coverage stated across 35 states - Strength: Both molecules carry a figure - Limitation: Renewals bill every eleven weeks - Limitation: The headline divides by three, not 2.53 - Limitation: A three-month prepay is mandatory - Limitation: Anchor prices are never charged ## What the evidence says about this kind of treatment The assessment above is about Brello Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who reads the checkout before the card and can prepay a quarter. Wrong for A reader taking the advertised monthly figure at face value. ## The evidence behind what Brello Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Brello Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | | Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. | | | Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TeleHealth Med](https://thisglp.com/reviews/telehealth-med) [TeleHealth Weight Solutions](https://thisglp.com/reviews/telehealth-weight-solutions) [TelePeptide](https://thisglp.com/reviews/telepeptide) [TeleSlim Clinic](https://thisglp.com/reviews/teleslim-clinic) [TeleZen MD](https://thisglp.com/reviews/telezen-md) [Tell Her Doc](https://thisglp.com/reviews/tellherdoc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the advertised figure a monthly price? Not quite. The first $399 covers the three-month minimum. Renewals then bill every eleven weeks, which is 2.53 calendar months rather than three. Can I buy one month? No. There is no one-month option and the three-month prepay is mandatory. Are the strikethrough prices real? No. $599 and $749 are anchors. Nothing on the pages indicates either is charged. Is Brello Health legit? Brello Health is a GLP-1 telehealth sellers service. Its stated availability: 35 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Brello Health expensive compared with other GLP-1 telehealth sellers? Brello Health publishes a starting figure of $133/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Brello Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Brightmeds reviews (2026): GLP-1 telehealth sellers | This GLP A flat price at any dose, stated to apply to patients who are new to GLP-1 treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/brightmeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat price, new starters only # Brightmeds review A flat price at any dose, stated to apply to patients who are new to GLP-1 treatment. ## The verdict Brightmeds charges $129 a month for compounded semaglutide and $149 for compounded tirzepatide on its month-to-month plan. Both prices are stated to hold at any dose the provider prescribes. The footnote limits that promise to new patients who start at the lowest available dose. Anyone already taking a GLP-1 medication is told to contact support for pricing instead. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 47 From From $129/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 38 states + DC Brightmeds describes itself as a platform that partners with physicians and pharmacies rather than practicing medicine itself. Its GLP-1 line is compounded semaglutide and tirzepatide, plus microdosing versions of each molecule. Brand-name Zepbound is offered through LillyDirect for a $100 Brightmeds consult fee. Testosterone, sermorelin, glutathione and NAD+ complete the catalog. 1. ## Who writes the prescription, and what do they see? Prescriptions come from board-certified, U.S.-licensed physicians affiliated with Brightmeds, none of whom is named. A physician reviews the health profile submitted through the online intake before anything ships. Patients can message a licensed doctor during treatment, and the site says this costs nothing extra. If the intake is not approved, the page promises a full refund of the payment. The price bundles the medication, the clinical evaluation, clinician follow-up, dose adjustments, support and standard shipping. The page states there is no laboratory fee and no separate consultation or prescribing fee. Month-to-month plans renew automatically until they are canceled from the account or by email. The three-month pack is billed once, upfront, and covers three months of treatment. 2. ## What happens when the dose goes up? New patients begin at the lowest available dose, and the flat price is stated to apply as that dose is raised. The page does not publish the milligram steps themselves or how many weeks each one lasts. For a patient transferring an existing prescription, the flat price is not promised on the page. That group is directed to email customer support, and no figure is given for it. 3. ## What the price includes Each molecule has two rungs: a month-to-month rate and a three-month pack. Month-to-month is $129 for semaglutide and $149 for tirzepatide, cancelable at any time. The three-month pack works out to $99 and $119 a month, billed as $297 and $357 at once. The page headline and hero both lead with the lower pack rates. The page is titled a summer special, and no end date for the pricing is printed on it. 4. ## What it claims, and what it cites Both molecules are compounded by state-licensed pharmacies, and those pharmacies are not named. The page states that compounded medications are not reviewed or approved by the FDA for safety or effectiveness. The FAQ describes the source as either 503A or 503B facilities, without saying which one fills a given order. ## Where it holds up, and where it does not - Strength: Month-to-month rate stated beside the pack rate - Strength: No lab, consultation or membership fee - Strength: Refund if the intake is not approved - Strength: Price stated flat at any dose - Limitation: Flat price covers new starters only - Limitation: California and New Jersey excluded from the offer - Limitation: Prescribing physicians and pharmacies unnamed - Limitation: Summer framing with no stated end date ## What the evidence says about this kind of treatment The assessment above is about Brightmeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer new to GLP-1s in one of the listed states. Wrong for A patient transferring an existing GLP-1 prescription. ## The evidence behind what Brightmeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Brightmeds compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Tell Her Doc](https://thisglp.com/reviews/tellherdoc) [Telos Rx](https://thisglp.com/reviews/telos-rx) [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) [The Edit](https://thisglp.com/reviews/the-edit) [The Virtual NP](https://thisglp.com/reviews/the-virtual-np) [TMates](https://thisglp.com/reviews/tmates) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Brightmeds charge per month without a pack? $129 for semaglutide and $149 for tirzepatide, month to month. The lower $99 and $119 rates require the three-month pack, billed once. Does the flat price apply if I already take a GLP-1? Not as stated on the page. The footnote directs current GLP-1 users and anyone transferring a prescription to support for pricing. Which states can use this offer? Thirty-eight states plus Washington, D.C., all listed in the footnote. California, New Jersey, Massachusetts and Michigan are not on that list. Is Brightmeds legit? Brightmeds is a GLP-1 telehealth sellers service. Its stated availability: 38 states + DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Brightmeds expensive compared with other GLP-1 telehealth sellers? Brightmeds publishes a starting figure of $129/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Brightmeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Broose Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Broose separates oral semaglutide, injectable semaglutide and tirzepatide. The follow-up plan needs to fit the supply term. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/broose-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Oral and injectable products separated # Broose Wellness review Broose separates oral semaglutide, injectable semaglutide and tirzepatide. The follow-up plan needs to fit the supply term. ## The verdict Broose’s product distinctions are useful, but a substantial prepaid order needs a more concrete follow-up plan than the storefront alone establishes. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Broose Wellness markets clinician-guided weight-management treatment through a platform and affiliated medical groups. Its product page separates oral semaglutide, injected semaglutide and tirzepatide. 1. ## Who writes the prescription, and what do they see? Independent licensed healthcare professionals and affiliated medical groups make treatment decisions. The platform’s terms make them responsible for evaluation, suitability and prescribing rather than treating the storefront itself as the clinician. Broose describes medically guided care but does not establish a universal follow-up appointment cadence on the pages reviewed. Ask which clinician handles side effects, how dose reviews are scheduled and what support continues after the first shipment. 2. ## What happens when the dose goes up? The chosen formulation and dose require a clinical plan. Before a long package, clarify how the prescriber can slow an increase or stop treatment and what that means for medicine already supplied. 3. ## What the price includes The weight-management page prices four-, twelve-, twenty-four- and fifty-two-week supplies. Those are not interchangeable calendar-month bills. The terms generally make sales final and exclude returns of medication that has been dispensed or shipped. 4. ## What it claims, and what it cites The prescriptions are compounded preparations and are not FDA-approved. The product menu distinguishes their routes and term lengths. A low-dose or longevity-oriented offer should not be assumed to match an established branded obesity-treatment regimen. ## Where it holds up, and where it does not - Strength: Oral and injectable products separated - Strength: Exact supply terms are shown - Strength: Medical decisions assigned to independent providers - Limitation: Week-based terms need careful comparison - Limitation: Dispensed medicine is generally nonreturnable - Limitation: Universal follow-up schedule is not stated ## What the evidence says about this kind of treatment The assessment above is about Broose Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded care who will agree on monitoring and a dose-change plan before selecting a long supply. Wrong for Someone who may need to stop soon and cannot accept the refund exposure of a long medication package. ## The evidence behind what Broose Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Broose Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) [Tonik Wellness](https://thisglp.com/reviews/tonik-wellness) [Transparent Meds](https://thisglp.com/reviews/transparent-meds) [Trava Health](https://thisglp.com/reviews/trava-health) [Trellis Vitality](https://thisglp.com/reviews/trellis-vitality) [Trillium Meds](https://thisglp.com/reviews/trillium-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Broose describes medically guided care but does not establish a universal follow-up appointment cadence on the pages reviewed. Ask which clinician handles side effects, how dose reviews are scheduled and what support continues after the first shipment. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-management products and terms](https://broosewellness.com/weight-management) - [Medical, pharmacy and refund terms](https://broosewellness.com/terms-of-use) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Cabana reviews (2026): GLP-1 telehealth sellers | This GLP Cabana names its supervising physician and its pharmacy, and prices its weight-loss plans from one figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/cabana Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Named physician, named pharmacy # Cabana review Cabana names its supervising physician and its pharmacy, and prices its weight-loss plans from one figure. ## The verdict Cabana is a cash-pay telehealth brand whose weight-loss plans start at $249 a month, billed as a monthly subscription. It names the physician practice behind its prescriptions and the pharmacy it partners with. It does not say which product or dose the $249 buys. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection From From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Cabana sells compounded semaglutide injections, tirzepatide injections and a semaglutide tablet from one weight-loss hub. An NAD+ injection sits beside them under an energy heading. The brand frames itself as aesthetic medicine with concierge support. Every product page lists the same inclusions: prescription, membership, shipping and cancellation at any time. 1. ## Who writes the prescription, and what do they see? Cabana's medical-care FAQ names its clinical providers as Wasef Health, PC, care of Michael Wasef, MD. The terms describe Cabana itself as a technology platform rather than a medical practice. A licensed provider reviews the online assessment and prescribes only if treatment is judged appropriate. The hub promises same-day provider review. What the assessment asks, and whether labs are required, is not stated. Care runs through a patient portal, with provider messaging and a concierge team for logistics. Refill requests go through the dashboard and are reviewed by a provider before processing. The FAQ says the medical visit, ongoing shipments and provider messaging sit inside one price. Shipping is stated as free two-day delivery. 2. ## What happens when the dose goes up? The semaglutide page describes gentle starting doses and says providers often fine-tune the dose in months two and three. Any change must be approved by the provider first. Whether the monthly price moves with the dose is not stated. No milligram figure appears on any product page. 3. ## What the price includes One figure is published: $249 a month on the weight-loss hub, labeled as a starting price. The subscription auto-renews monthly and can be canceled in the portal. The semaglutide, tirzepatide and tablet pages carry no price of their own. A buyer learns the cost of a specific product and dose only after the assessment. 4. ## What it claims, and what it cites The footer states that compounded medications are not FDA-approved and are not evaluated by the FDA. The FAQ names F&F Pharmacies Inc, doing business as Jungle Jim's Pharmacy, as the partner pharmacy. The same FAQ says that pharmacy does not dispense sterile compounds, and lists ten states where it is not licensed. Which pharmacy fills the injectable products is not stated separately. ## Where it holds up, and where it does not - Strength: Supervising physician practice is named - Strength: Partner pharmacy is named, with its licensed states - Strength: Monthly subscription, cancellable in the portal - Strength: Compounded status stated on every page - Limitation: The $249 is not tied to a product - Limitation: Product pages print no price - Limitation: No milligram dose is published - Limitation: The named pharmacy does not do sterile compounding ## What the evidence says about this kind of treatment The assessment above is about Cabana. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the prescribing practice and pharmacy named before starting an assessment. Wrong for A reader who needs a per-product, per-dose price before handing over health details. ## The evidence behind what Cabana prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Cabana compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TrimRx](https://thisglp.com/reviews/trimrx) [Trinity Meds](https://thisglp.com/reviews/trinity-meds) [TRT Nation](https://thisglp.com/reviews/trt-nation) [Tru2u](https://thisglp.com/reviews/tru2u) [TrueMe](https://thisglp.com/reviews/trueme) [Try Ageless](https://thisglp.com/reviews/try-ageless) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $249 a month buy at Cabana? It is the starting figure on the weight-loss hub. The hub does not tie it to semaglutide, tirzepatide or the tablet, or to a dose. Who writes the prescription? Cabana names Wasef Health, PC, care of Michael Wasef, MD, as its clinical providers. Cabana itself describes its role as a technology platform. Which pharmacy fills the order? The FAQ names F&F Pharmacies Inc, doing business as Jungle Jim's Pharmacy. The same answer says it does not dispense sterile compounds. Is Cabana expensive compared with other GLP-1 telehealth sellers? Cabana publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Cabana above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # CaliberRx reviews (2026): GLP-1 telehealth sellers | This GLP A single starting figure covers both molecules, and billing splits across three parties. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/caliberrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One figure, three payees # CaliberRx review A single starting figure covers both molecules, and billing splits across three parties. ## The verdict CaliberRx shows "Starting at $199/Month" for semaglutide and for tirzepatide. Its billing consent splits charges three ways. What that figure covers is not stated on any public page. It is not ranked here for that reason. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved Availability 46 states and DC CaliberRx is a telehealth platform based in Dallas. It offers compounded semaglutide and tirzepatide by weekly injection. Service covers 46 states and the District of Columbia. Alabama, Massachusetts, Rhode Island and Vermont are excluded. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews an online intake. The provider writes the treatment plan, if there is one. CaliberRx calls itself a management services organization. The provider group bills its own consultation fee. The home page lists chat with a provider around the clock. The billing consent names three payees. CaliberRx charges membership and coordination fees. The provider group charges for consultations. The dispensing pharmacy charges for medication and shipping. Membership billing is "typically monthly or quarterly, depending on the plan you select". 2. ## What happens when the dose goes up? No dose appears beside either figure. The page does not say whether the rate moves with the dose. The offer terms add one rule on price. A promotional rate renews at the then-current standard rate. 3. ## What the price includes One figure appears on the public pages: $199 a month, starting, for either drug. The pages do not say which of the three charges it covers. Plans appear only inside the intake, after identity questions. Treat $199 as a floor, not a total. 4. ## What it claims, and what it cites Both drugs are compounded and not FDA-approved. The FDA does not review them before dispensing. The dispensing pharmacy bills the patient directly. It is not named on the public pages. ## Where it holds up, and where it does not - Strength: Service area published state by state - Strength: Billing parties named in the consent - Strength: Both molecules share one starting figure - Strength: Round-the-clock provider chat listed - Limitation: Starting figure does not say what it covers - Limitation: Plans shown only inside the intake - Limitation: Promotional rates renew at standard pricing - Limitation: Four states excluded from service ## What the evidence says about this kind of treatment The assessment above is about CaliberRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader outside the four excluded states who will read the billing consent first. Wrong for A reader who wants a complete monthly total before creating an account. ## The evidence behind what CaliberRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How CaliberRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Measured | Readers ready to commit to a term who know which rung the lead figure is | | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | Mint Med | Buyers planning to move up the dose ladder who want one monthly figure throughout | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TRYM Health](https://thisglp.com/reviews/trym-health) [Tryozi](https://thisglp.com/reviews/tryozi) [Tuyo Health](https://thisglp.com/reviews/tuyo-health) [Tyde Wellness](https://thisglp.com/reviews/tyde-wellness) [UR Meds](https://thisglp.com/reviews/ur-meds) [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 the monthly total? That is not established. The consent splits charges among membership, consultation and pharmacy. The $199 is not tied to any one of them. Where is CaliberRx available? In 46 states and the District of Columbia. Alabama, Massachusetts, Rhode Island and Vermont are excluded. Can a promotional price rise? Yes. The offer terms say a promotional membership renews at the then-current standard rate unless canceled. Is CaliberRx legit? CaliberRx is a GLP-1 telehealth sellers service. Its stated availability: 46 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is CaliberRx expensive compared with other GLP-1 telehealth sellers? CaliberRx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts CaliberRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Calibrate Health reviews (2026): GLP-1 telehealth sellers | This GLP The program fee is fixed and published; the medication figure beside it depends on an insurance plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/calibrate-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two charges, only one certain # Calibrate Health review The program fee is fixed and published; the medication figure beside it depends on an insurance plan. ## The verdict Calibrate charges $199 a month for its Metabolic Reset program, with an initial three-month commitment stated on the same page. The $25 quoted for medication is what members with commercial insurance should expect after a deductible, not a cash price, and it sits on top of the program fee. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 50 Prescription Required Compounded No Calibrate sells a year-long metabolic program built around coaching, clinician prescribing and insurance advocacy. The medication is prescribed to a member and filled through their own pharmacy benefit. 1. ## Who writes the prescription, and what do they see? Calibrate clinicians prescribe GLP-1 medications and the program names the branded ones they work with. The clinician relationship is the product here rather than an add-on to a shipment, though the individual clinician is not named before signup. A member gets one-to-one coaching, a welcome kit with a smart scale, and staff who work the insurance claim on their behalf. That advocacy is the reason the program fee exists, and it is also why the drug cost is out of Calibrate's hands. 2. ## What happens when the dose goes up? [Dose escalation](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) runs through a prescribing clinician and a pharmacy benefit rather than a price list, so a step up does not move the program fee. What it does to the copay depends on the plan. Calibrate publishes no figure for a member whose insurer declines the drug. 3. ## What the price includes The three-month commitment brings the published total to $597, billed in monthly installments of $199. Medication is extra, and the $25 estimate applies only after a deductible has been met on a commercial plan. An uninsured buyer has no published number to work from at all. 4. ## What it claims, and what it cites The medicines named are manufacturer-branded rather than compounded, so they are FDA-approved and dispensed as the approved product. Availability depends on what a member's insurer will cover. ## Where it holds up, and where it does not - Strength: The program fee is stated plainly - Strength: Insurance advocacy is part of the service - Strength: Branded medication rather than compounded - Strength: Coaching included in the fee - Limitation: A three-month commitment is required - Limitation: $25 assumes commercial insurance and a met deductible - Limitation: No cash medication price is published - Limitation: The fee and the drug are two separate bills ## What the evidence says about this kind of treatment The assessment above is about Calibrate Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An insured buyer who wants coaching and help with a claim. Wrong for A cash buyer looking for one all-in monthly figure. ## The evidence behind what Calibrate Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Calibrate Health compares | Seller | Who it suits | Go | | --- | --- | --- | | MultiMedRx | A reader with insurance who needs a branded GLP-1 covered rather than sold | | | Noom | Buyers who read the footnote before the headline | | | Queen RX | Buyers content to commit a quarter at a time in one payment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vaylen](https://thisglp.com/reviews/vaylen) [Velvet Rx](https://thisglp.com/reviews/velvet-rx) [VevaRX](https://thisglp.com/reviews/vevarx) [VigorMeds](https://thisglp.com/reviews/vigormeds) [VirtualCare2Go](https://thisglp.com/reviews/virtualcare2go) [Vita Bella](https://thisglp.com/reviews/vita-bella) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $25 the price of the medication? It is an estimate for members with commercial insurance after any deductible. It is not a cash price, and it is charged on top of the $199 program fee. What is the minimum commitment? Three months, which Calibrate states brings the program cost to $597 paid in monthly installments. What if my insurer will not cover the drug? No cash medication figure is published, so the cost in that case cannot be worked out from the site. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # California Trim Clinic reviews (2026): GLP-1 telehealth sellers | This GLP A Westlake Village clinic that now treats by video, with its prices kept on a page of their own. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/california-trim-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A named doctor, a discovery call # California Trim Clinic review A Westlake Village clinic that now treats by video, with its prices kept on a page of their own. ## The verdict California Trim Clinic keeps an office on Thousand Oaks Boulevard in Westlake Village, says it has gone national, and sells compounded semaglutide at $199 a month and compounded tirzepatide at $299 by telemedicine in every state. What sets it apart is the first step, a free video or phone call of about twenty minutes with a clinician, and a physician whose name and specialty appear on the site. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states The clinic runs two businesses under one name: a medical weight loss program delivered by telemedicine nationwide, and an in-person practice in Westlake Village offering body contouring and cryoslimming to people who can drive there. Around the GLP-1 program sits a long peptide catalog, hormone replacement, and a weight loss track for teenagers from age twelve with a parent involved. The GLP-1 menu lists compounded semaglutide and tirzepatide as injections, plus a tirzepatide capsule taken by mouth. 1. ## Who writes the prescription, and what do they see? Dr. Lynda A. Szczech, a board-certified nephrologist with more than twenty years in practice, is presented on the telemedicine page as one of the clinic's medical providers. The phrasing matters, because it names one prescriber without saying how many others there are or which of them a new patient will actually meet. The site says the clinician reviews health history, screens for contraindications and prescribes only when treatment is appropriate, and the GLP-1 page adds that lab results are part of that review. A new patient books a discovery call, which the clinic describes as a real conversation of about twenty minutes by video or phone, free and with no obligation, before any plan is written. If a clinician prescribes, the medication ships free from a licensed pharmacy in plain packaging, and the care team takes messages on any day of the week. Check-ins are described as weekly to monthly depending on the plan, and payment runs cash-only, with HSA and FSA funds, Affirm and Cherry all accepted. 2. ## What happens when the dose goes up? The site says doses adjust as a patient progresses and that regular check-ins exist to make those adjustments, which fits the escalation that fills the first sixteen weeks of treatment. What it never says is whether the monthly charge moves when the dose does, and the words starting at in front of both figures leave room for it to. No milligram schedule appears on either product page, so the ladder itself stays out of view until the discovery call. 3. ## What the price includes Neither the semaglutide page nor the tirzepatide page prints a price, which surprises a reader who has scrolled both from top to bottom. The figures sit on a separate page about keeping costs low, where semaglutide starts at $199 a month and tirzepatide at $299, each followed by an asterisk that the page never resolves. The same page promises no membership fees and no automatic renewals, and the unexplained asterisk is the one open question left beside those two numbers. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded, prepared by state-licensed 503A and 503B pharmacies that the site does not name, and the [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) program is described as injections paired with vitamin B12. Compounded preparations are not FDA-approved and are not reviewed by the FDA before they are dispensed, a point the clinic makes itself in several places. ## Where it holds up, and where it does not - Strength: A prescribing physician is named with her specialty - Strength: A free discovery call comes before any charge - Strength: No membership fee and no automatic renewal stated - Strength: Cash-pay with Affirm, Cherry, HSA and FSA - Limitation: Neither product page shows a price - Limitation: The asterisk after both figures goes unexplained - Limitation: No compounding pharmacy is named - Limitation: No milligram schedule is published for either molecule ## What the evidence says about this kind of treatment The assessment above is about California Trim Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to talk to a clinician before paying anything and likes seeing a doctor's name on the site. Wrong for A buyer who wants the dose ladder and its price in writing before the first phone call. ## The evidence behind what California Trim Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How California Trim Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [VitaFusions IV](https://thisglp.com/reviews/vitafusions-iv) [Vital Edge](https://thisglp.com/reviews/vital-edge) [Vitalex Health](https://thisglp.com/reviews/vitalex-health) [Vitara RX](https://thisglp.com/reviews/vitara-rx) [VitaStir](https://thisglp.com/reviews/vitastir) [Voxy](https://thisglp.com/reviews/voxy) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does California Trim Clinic charge for semaglutide and tirzepatide? Its cost page lists semaglutide from $199 a month and tirzepatide from $299, with no membership fee and no automatic renewal, though an asterisk beside each figure is never explained. Do I have to live in California? No, the clinic says it treats weight loss patients by telemedicine across all fifty states, while its body contouring services stay at the Westlake Village office. Who prescribes the medication? A licensed clinician after a discovery call and a review of health history, and the site names Dr. Lynda A. Szczech, a board-certified nephrologist, as one of its providers. Is California Trim Clinic legit? California Trim Clinic is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is California Trim Clinic expensive compared with other GLP-1 telehealth sellers? California Trim Clinic publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts California Trim Clinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Call-On-Doc reviews (2026): GLP-1 telehealth sellers | This GLP An online prescriber that now sells an all-in home-delivery GLP-1 program beside its care-only plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/call-on-doc Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two routes, one prescriber # Call-On-Doc review An online prescriber that now sells an all-in home-delivery GLP-1 program beside its care-only plan. ## The verdict Call-On-Doc now sells compounded semaglutide at $250.00 and tirzepatide at $375.00 as an all-in home-delivery program, which is the tab its weight-loss page opens on. Its older care-only route still charges $75.00 for the prescription alone and sends it to the buyer's own pharmacy, where the drug is priced separately. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $250/mo Prescription Required Call-On-Doc, Inc. is a general online clinic treating more than 150 conditions, open seven days a week including nights and holidays, and weight loss is one of its categories rather than the whole business. Its weight-loss page offers three care options: a full-strength all-in-one program, a microdosing all-in-one program, and a care-only plan with pharmacy pick-up. 1. ## Who writes the prescription, and what do they see? A licensed provider reads a medical triage intake that takes five to ten minutes, may come back through the portal for more history, photographs or lab results, and then either writes a prescription or recommends an in-person evaluation instead. The consultation itself runs through the secure portal, by phone or by video, depending on the state and the provider. The home-delivery program ships medication every month and, per the weight-loss FAQ, includes the prescribed drug, ongoing provider management, dose adjustments and round-the-clock medical support. The pick-up route is thinner by design: the provider sends the prescription to a local pharmacy and the patient pays there, with insurance if the plan covers it or in cash. 2. ## What happens when the dose goes up? The FAQ says dose adjustments are part of the monthly home-delivery program, and a separate microdosing tab exists for patients the provider judges suited to smaller doses, such as those sensitive to [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). Neither program page publishes a milligram schedule, so whether the monthly charge holds steady once the dose climbs past the starting months is not stated. 3. ## What the price includes The all-in figures are $250.00 for compounded semaglutide and $375.00 for compounded tirzepatide, with microdosing versions at $185.00 and $285.00, and the FAQ describes these as monthly programs that ship each month. The care-only plan charges the same $75.00 across eight drugs, from Zepbound to oral semaglutide, which marks it as a plan fee rather than a medication price. The full-strength figures are the ones ranked here; the microdosing versions are a separate product and are described rather than ranked. 4. ## What it claims, and what it cites The home-delivery programs supply compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), which are not FDA-approved and are not reviewed by the FDA before dispensing, and the pharmacy that compounds them is not named on the program pages. The pick-up route covers FDA-approved brands such as Zepbound, Wegovy and Mounjaro, which the patient buys at whichever pharmacy fills the prescription. ## Where it holds up, and where it does not - Strength: All-in program covers care and medication - Strength: Microdosing option for smaller doses - Strength: Pharmacy pick-up can use insurance - Strength: Open nights, weekends and holidays - Limitation: No milligram schedule on program pages - Limitation: Compounding pharmacy goes unnamed - Limitation: Care-only fee excludes the medication - Limitation: Brand drugs priced only at the pharmacy ## What the evidence says about this kind of treatment The assessment above is about Call-On-Doc. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one monthly charge covering the prescriber and a compounded vial, or an insured reader who only needs the prescription written. Wrong for A reader who wants the milligram schedule and the dispensing pharmacy named before the first order ships. ## The evidence behind what Call-On-Doc prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Call-On-Doc compares | Seller | Who it suits | Go | | --- | --- | --- | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | | Sesame Care | Readers who want tirzepatide priced by dose and will read the FAQ before the headline | | | LifeMD | Readers with insurance that may cover the medication, leaving the fee as the main cost | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vyora Wellness](https://thisglp.com/reviews/vyora-wellness) [VyrarX](https://thisglp.com/reviews/vyrarx) [Vytora Health](https://thisglp.com/reviews/vytora-health) [Walgreens Weight Management](https://thisglp.com/reviews/walgreens-weight-management) [WeightCare](https://thisglp.com/reviews/weightcare) [WeightlessRx](https://thisglp.com/reviews/weightlessrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the $250.00 include the medication? Yes; the home-delivery program is described as including the prescribed medication, ongoing provider management and dose adjustments, with the drug shipped to the patient's door each month. What does the $75.00 care-only plan cover? The consultation and the prescription only, since the same figure appears beside eight different drugs and the medication is then bought at the patient's chosen pharmacy, with insurance where the plan covers it. What happens if I am not approved? The FAQ says the order is simply not processed, and the provider may recommend other treatment options that suit the patient's health needs better than a GLP-1 would. Is Call-On-Doc expensive compared with other GLP-1 telehealth sellers? Call-On-Doc publishes a starting figure of $250/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Call-On-Doc above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Candor Rx reviews (2026): GLP-1 telehealth sellers | This GLP The promise of a rate that never moves with the dose is the rare kind worth wanting, and both molecules carry it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/candor-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat at every dose # Candor Rx review The promise of a rate that never moves with the dose is the rare kind worth wanting, and both molecules carry it. ## The verdict Candor Rx advertises compounded semaglutide as low as $99 a month and tirzepatide as low as $149, each printed beside the words same price at every dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $99/mo Prescription Required Compounded Yes — not FDA-approved Candor Rx sells compounded semaglutide and tirzepatide by injection, and the thing it sells hardest is not the molecule but the shape of the bill — a rate the seller says will not move when the milligrams do. 1. ## Who writes the prescription, and what do they see? A prescription is written before anything ships, but the pages are given over almost entirely to the pricing promise, and the clinician who signs that prescription is never described, named, or characterized anywhere this desk could find. The whole model is arranged around one claim, which is that the escalation a buyer is about to spend four months inside will not change what the card is charged, and everything else on the site sits behind that sentence. 2. ## What happens when the dose goes up? Here is what the promise is worth if it holds. A buyer starting at 0.25 milligrams in October and reaching 2.4 by spring will, with most compounded sellers, watch the monthly charge climb at every step. The rungs are almost never published in advance, and Candor Rx says that climb does not happen here at all. The claim is checkable only by living it, and the words as low as in front of each figure are the part to settle first. 3. ## What the price includes At $99 a month held flat, six months of semaglutide comes to $594 and a year to $1,188, and neither total needs an asterisk about the dose. That is precisely what makes a flat rate worth wanting in a category where the monthly figure usually rises with the dose. Tirzepatide at $149 comes to $894 over six months, and the as low as in front of both figures is the one qualifier a reader should get explained in writing before the first charge. 4. ## What it claims, and what it cites The line is compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before it is dispensed the way an approved product is. ## Where it holds up, and where it does not - Strength: A flat rate is promised at any dose - Strength: The promise is stated plainly, not buried - Strength: Six-month totals need no dose asterisk - Limitation: Each figure is printed as low as - Limitation: What lifts a figure above the floor is unstated - Limitation: No clinician is described anywhere - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Candor Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who values a bill that does not move with the dose, and who will confirm which figure applies before ordering. Wrong for A reader who would treat the advertised figure as settled without asking. ## The evidence behind what Candor Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Candor Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | ARSYNL Rx | Readers who want both molecules priced on one page and will confirm the figure on the day | | | Clume Health | Readers who want both molecules at one rate and will re-check the figure before paying | | | Brello Health | Readers who can prepay a quarter and want the billing cycle read before the price tag | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [WeightRx](https://thisglp.com/reviews/weightrx) [WeightWatchers Clinic](https://thisglp.com/reviews/weight-watchers) [Welling Health](https://thisglp.com/reviews/welling-health) [Wellspring Longevity Clinic](https://thisglp.com/reviews/wellspring-longevity-clinic) [WePeptideRx](https://thisglp.com/reviews/wepeptiderx) [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which figure should I expect to pay? As low as $99 a month for semaglutide and $149 for tirzepatide, and because both are printed as floors, the honest answer is that a reader should get the applicable figure confirmed in writing before the first charge. Does the price really stay flat as the dose rises? That is what Candor Rx says, and it is the claim the whole site is arranged around, which is worth something in a category where most sellers publish nothing at all about what happens at a higher milligram. What does a year cost? At $99 held flat, a year of semaglutide is $1,188 with no adjustment for escalation, and tirzepatide at $149 comes to $1,788. Is Candor Rx expensive compared with other GLP-1 telehealth sellers? Candor Rx publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Candor Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # CAPO Health reviews (2026): GLP-1 telehealth sellers | This GLP CAPO identifies The Pharmacy Hub and describes monthly check-ins. Confirm the medical practice responsible for the prescription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/capo-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Pharmacy partner identified # CAPO Health review CAPO identifies The Pharmacy Hub and describes monthly check-ins. Confirm the medical practice responsible for the prescription. ## The verdict CAPO provides a named pharmacy and a monthly monitoring claim, both useful details to confirm for the individual treatment plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved CAPO Health offers online prescription care with compounded semaglutide and tirzepatide weight-loss programs. Its public process combines clinical evaluation, pharmacy fulfillment, patient-portal access and monthly check-ins. 1. ## Who writes the prescription, and what do they see? An independent medical group supplies licensed providers who review the health assessment. The clinical decision remains with the provider, not the platform. Ask which practice and clinician will be responsible for the selected program. CAPO explicitly describes monthly check-ins to adjust the plan as treatment progresses. The patient portal supports ongoing contact. Confirm whether those check-ins are scheduled clinical reviews and what response to expect between contacts. 2. ## What happens when the dose goes up? Monthly review does not require increasing the dose each month. Agree with the clinician on how response, [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and other medicines determine whether to maintain, change or stop the prescription. 3. ## What the price includes The public program does not establish one standing total for every selected plan. It says patients can cancel online without a cancellation fee, while dispensed medicine follows a separate refund policy. A denial-of-treatment refund and cancellation of an existing medication order are different situations. 4. ## What it claims, and what it cites The treatments are compounded and are not FDA-approved. The site identifies The Pharmacy Hub as its pharmacy partner and describes Section 503A patient-specific compounding. Confirm that pharmacy on the actual prescription and review the vial instructions with the pharmacist. ## Where it holds up, and where it does not - Strength: Pharmacy partner identified - Strength: Monthly check-ins described - Strength: Online cancellation is available - Limitation: Individual medical practice needs confirming - Limitation: No single standing total established - Limitation: Dispensed medicine follows separate refund rules ## What the evidence says about this kind of treatment The assessment above is about CAPO Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values a named pharmacy and a described monthly review process and will confirm the treating practice. Wrong for Someone requiring a single published total for every medication, testing and outside-care expense. ## The evidence behind what CAPO Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How CAPO Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) [Whoosh Wellness](https://thisglp.com/reviews/whoosh-wellness) [Wisp](https://thisglp.com/reviews/wisp) [Woodwork](https://thisglp.com/reviews/woodwork) [YourHealthRx](https://thisglp.com/reviews/yourhealthrx) [Yucca Health](https://thisglp.com/reviews/yucca-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? CAPO explicitly describes monthly check-ins to adjust the plan as treatment progresses. The patient portal supports ongoing contact. Confirm whether those check-ins are scheduled clinical reviews and what response to expect between contacts. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-loss care and included services](https://capohealth.com/weight-loss/) - [Clinical network and pharmacy](https://capohealth.com/) - [Service and subscription terms](https://capohealth.com/terms/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Care Bare Rx reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide and tirzepatide cost the same $199 here. That is unusual. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/care-bare-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same price, both molecules # Care Bare Rx review Semaglutide and tirzepatide cost the same $199 here. That is unusual. ## The verdict Care Bare Rx charges $199 a month for both molecules. Tirzepatide normally costs more. Here it does not. Injection only, and all fifty states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 50 From From $199/mo Prescription Required Compounded Yes — not FDA-approved Care Bare Rx sells compounded semaglutide and compounded tirzepatide. Both are weekly injections. Both were advertised at $199 a month. No oral form is listed for either. The service covers all fifty states. Its wider catalog runs to hair, NAD+ and sexual health. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely. A prescription is issued before shipping. The pricing page states the rate. It does not describe the prescriber. What the intake asks is not published. The service is remote and the products are compounded. The catalog is broad rather than weight-loss specific. That is worth knowing. A seller covering six categories is not automatically weaker on one. It does mean the GLP-1 line is not the whole business. 2. ## What happens when the dose goes up? Whether $199 holds as the dose rises is not stated. Most patients escalate within sixteen weeks. That makes it the question to ask. The seller does not answer it. 3. ## What the price includes The flat $199 across both molecules is the whole story. Tirzepatide usually carries a premium over semaglutide. Sellers priced beside it here charge $149 against $199, or $199 against $399. Care Bare Rx charges neither more nor less. A reader who wants tirzepatide pays the semaglutide rate. That is the reason to look at this one. 4. ## What it claims, and what it cites Both products are compounded. A pharmacy prepares them. A manufacturer does not. Neither is FDA-approved. Neither is reviewed for safety, efficacy or quality before dispensing. The trial evidence for these molecules used the approved products at labeled doses. A compounded vial is not measured against that. ## Where it holds up, and where it does not - Strength: Tirzepatide priced at the semaglutide rate - Strength: All fifty states served - Strength: One rate to understand, not four - Limitation: No oral form for either molecule - Limitation: Dose-escalation pricing not published - Limitation: GLP-1 is one of six catalog categories ## What the evidence says about this kind of treatment The assessment above is about Care Bare Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants tirzepatide and does not want to pay the premium it usually carries. Wrong for A reader who wants an oral, since neither molecule is offered in that form here. ## The evidence behind what Care Bare Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Care Bare Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | CoreAge Rx | A reader still at a starting dose, since that is the tier these rates price. | | | Synergy Rx | A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form. | | | Breeze Meds | A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Zealthy](https://thisglp.com/reviews/zealthy) [Zera Health](https://thisglp.com/reviews/zera-health) [Zeuss](https://thisglp.com/reviews/zeuss) [ZipHealth](https://thisglp.com/reviews/ziphealth) [ZYP Medical](https://thisglp.com/reviews/zyp-medical) [10Rx](https://thisglp.com/reviews/10rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is tirzepatide really the same price as semaglutide? Yes. Both are $199 a month. Most sellers charge more for tirzepatide. Can I get an oral here? No. Both molecules are sold as weekly injections. No oral line was advertised. Does the wide catalog matter? Only as context. Care Bare Rx also sells hair, NAD+ and sexual health products. That does not change the GLP-1 rate. Is Care Bare Rx expensive compared with other GLP-1 telehealth sellers? Care Bare Rx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Care Bare Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Care Clinics reviews (2026): GLP-1 telehealth sellers | This GLP The price never moves as the dose climbs, because the number of weeks does instead. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/care-clinics Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same money, fewer weeks # Care Clinics review The price never moves as the dose climbs, because the number of weeks does instead. ## The verdict Care Clinics publishes a grid of dose against duration in which the charge stays fixed and the supply falls. $399 buys sixteen weeks of semaglutide at 1.5 mg and ten weeks of it at 2.5 mg, which is $108 a calendar month at the bottom and $173 at the top. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 32 From From $108/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider Care Clinics is a telehealth weight-loss practice selling compounded semaglutide as its GLP-1 program and compounded tirzepatide as its GLP-1 and GIP program. Extended plans run several months on a single charge, and shorter programs of seven weeks and four weeks sit beside them. 1. ## Who writes the prescription, and what do they see? Treatment begins with a booked consultation rather than a form submitted into a queue, and the clinic lists its providers on a page of their own. What a provider reviews before approving a plan is not described, and no prescriber is named against a particular program. Medication ships within three to five business days of that consultation. Each program is a single charge covering a fixed block of weeks, with the medication included rather than billed separately by a pharmacy. The published semaglutide course steps a patient from 0.5 mg through 0.75 mg and 1 mg to 1.7 mg across twelve weeks, and the tirzepatide course runs 2.5 mg to 5 mg to 7.5 mg over the same span. Klarna financing is offered against the larger totals. 2. ## What happens when the dose goes up? The dose ladder is published in unusual detail here, and it is also where the cost hides, because escalation is what shortens every plan. The extended semaglutide grid holds $399 across four doses while the supply falls from sixteen weeks to ten, and the extended tirzepatide grid holds $599 from sixteen weeks at 7.5 mg down to eight weeks at 15 mg. A patient who climbs the ladder pays the same figure more often rather than a larger one. 3. ## What the price includes Every headline here is a block total rather than a monthly rate, and the clinic does the reader the service of printing the week count beside each one. Converted to calendar months, the semaglutide floor is $108 and its ceiling $173; tirzepatide runs from $163 to $326 on the same basis. The shorter seven-week and four-week programs at $259 and $299 are priced by the block in exactly the same way. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, which means a pharmacy prepares them to order and the FDA does not review the preparation before it is dispensed. No compounding pharmacy is named anywhere on the site. The clinic states that it is LegitScript certified. ## Where it holds up, and where it does not - Strength: Dose and duration are published together in one grid - Strength: The medication is inside the program price - Strength: A full titration schedule is written out week by week - Strength: LegitScript certified - Strength: Financing is offered against the block totals - Limitation: A higher dose buys fewer weeks for the same charge - Limitation: Nothing is priced as a calendar month - Limitation: The compounding pharmacy is not named - Limitation: The whole block is paid before the first injection ## What the evidence says about this kind of treatment The assessment above is about Care Clinics. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to divide a block total by its own week count before comparing it. Wrong for A buyer who wants a monthly bill that holds steady as the dose climbs. ## The evidence behind what Care Clinics prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Care Clinics compares | Seller | Who it suits | Go | | --- | --- | --- | | Potere Health MD | Utah patients who want one named physician through titration and can price a vial rather than a month | | | Primary Clinic (Direct GLP) | Buyers who want unlimited primary care alongside the prescription and will use enough of it to earn the membership back | | | Nu Image Medical | Buyers comparing the injectable and the dissolving tablet who will read which card a figure sits on | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AJ Peptide](https://thisglp.com/reviews/aj-peptide) [Ambiante Health & Wellness](https://thisglp.com/reviews/ambiante-health-wellness) [Aurelius Health Group](https://thisglp.com/reviews/aurelius-health-group) [AVArx](https://thisglp.com/reviews/avarx) [Basal Health](https://thisglp.com/reviews/basal-health) [Better MedSpa](https://thisglp.com/reviews/better-medspa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price go up when the dose goes up? No, and that is the catch. The charge holds at $399 or $599 while the number of weeks it covers falls, so the cost per month rises instead. What does $399 actually buy? Sixteen weeks of semaglutide at 1.5 mg, or ten weeks at 2.5 mg, which is $108 and $173 a calendar month respectively. Is the medication included? Yes. Each program is described as including medication rather than leaving it to be billed separately by a pharmacy. Is Care Clinics expensive compared with other GLP-1 telehealth sellers? Care Clinics publishes a starting figure of $108/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Care Clinics below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Carocare Wellness reviews (2026): GLP-1 telehealth sellers | This GLP A Houston clinic that prints the milligram dose beside every monthly price for the first six months. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/carocare-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Six doses, six prices # Carocare Wellness review A Houston clinic that prints the milligram dose beside every monthly price for the first six months. ## The verdict Carocare Wellness publishes its whole escalation in one table. Compounded semaglutide opens at $180 for a 0.25 mg month and reaches $330 at 2.5 mg by month six. Compounded tirzepatide runs from $200 at 2.5 mg to $350 at 15 mg. The price rises with the dose, and the page says so plainly. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 1 From From $180/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability Houston area, Texas Carocare Wellness is a clinic on Harwin Drive in Houston, Texas. Its weight loss program sells compounded semaglutide and tirzepatide by injection. IV hydration, NAD+ injections, an annual wellness exam with blood work, and hair-growth gummies share the menu. The site describes its patients as Houston and the surrounding area. 1. ## Who writes the prescription, and what do they see? The site refers to a team of licensed providers who design each plan. No clinician is named anywhere on it, and no medical director appears. A plan is said to follow a thorough consultation covering health, lifestyle and goals. Which conditions or labs that consultation reviews is not stated. A free consultation is booked through an online calendar before anything is sold. Each monthly package is stated to include ongoing provider support, supplies and delivery. How often a provider checks in between packages is not stated. The FAQ says a program runs from a few weeks to several months. 2. ## What happens when the dose goes up? The escalation is written out month by month. Semaglutide steps through 0.25, 0.5, 1.0, 1.5, 2.0 and 2.5 mg, one step per month. Tirzepatide steps through 2.5, 5, 7.5, 10, 12.5 and 15 mg on the same schedule. Each step carries its own price, so the cost of escalating is known in advance. What happens when a patient needs to hold a dose, or step back, is not stated. 3. ## What the price includes Semaglutide is $180, $210, $240, $270, $300 and $330 across months one to six. Tirzepatide is $200, $250, $280, $300, $325 and $350. Three-month bundles cover each half of that ladder: $500 then $600 for semaglutide, $600 then $800 for tirzepatide. No membership fee appears beside any package, and no price is published past month six. 4. ## What it claims, and what it cites Both lines are compounded; the services page calls the medications GLP-1 compounds. The preparing pharmacy is not named. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. ## Where it holds up, and where it does not - Strength: A milligram dose sits beside every monthly price - Strength: The cost of each escalation step is published - Strength: Three-month bundles are priced for both halves - Strength: A free consultation comes before any purchase - Limitation: The monthly charge rises at every dose step - Limitation: No clinician or medical director is named - Limitation: No compounding pharmacy is named - Limitation: No price is published beyond month six ## What the evidence says about this kind of treatment The assessment above is about Carocare Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Houston-area buyer who wants to know the cost of every dose step before starting. Wrong for A buyer outside the Houston area, or one who wants one flat rate at every dose. ## The evidence behind what Carocare Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Carocare Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [BodyLogicMD](https://thisglp.com/reviews/bodylogicmd) [Broose Wellness](https://thisglp.com/reviews/broose-wellness) [CAPO Health](https://thisglp.com/reviews/capo-health) [Chia](https://thisglp.com/reviews/chia-health) [Chronos Body Health & Wellness](https://thisglp.com/reviews/chronos-bhw) [CVS MinuteClinic](https://thisglp.com/reviews/cvs-minuteclinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the first month of semaglutide cost at Carocare Wellness? $180, for the 0.25 mg starting dose. Each later month is priced at its own dose, up to $330 at 2.5 mg in month six. Does the price go up as the dose goes up? Yes, and the pricing page prints every step. Tirzepatide goes from $200 at 2.5 mg to $350 at 15 mg. Is there a cheaper way to buy the first three months? The clinic sells three-month bundles. Months one to three are $500 for semaglutide and $600 for tirzepatide. Is Carocare Wellness legit? Carocare Wellness is a GLP-1 telehealth sellers service. Its stated availability: Houston area, Texas. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Carocare Wellness expensive compared with other GLP-1 telehealth sellers? Carocare Wellness publishes a starting figure of $180/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Carocare Wellness below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # CeliaRx reviews (2026): GLP-1 telehealth sellers | This GLP The per-month figure is arithmetic on a four-month vial. The charge is the whole vial, once. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/celia-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Monthly figure, single charge # CeliaRx review The per-month figure is arithmetic on a four-month vial. The charge is the whole vial, once. ## The verdict CeliaRx shows $125 a month for compounded semaglutide. The actual charge is $499 for one vial lasting about four months. Tirzepatide shows $225 a month against a single $899 charge. No recurring billing was observed. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose From From $199/mo Prescription Required Compounded Yes — not FDA-approved CeliaRx sells both molecules, injected and oral. The injections are vials covering roughly four months. The orals are one-time bottle purchases. Four lines carry a figure. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages do not name the clinician. The intake is not documented. What they do document is the purchasing unit, which most sellers leave vague. No subscription was observed in the cart or at checkout. Each purchase stands alone. That is unusual here and it cuts both ways: nothing renews without a decision, and nothing spreads the cost either. 2. ## What happens when the dose goes up? CeliaRx states the price scales with the dose. It does not publish the steps. A four-month vial bought at one dose does not adjust if a prescriber raises it partway through. 3. ## What the price includes The displayed monthly figure is a division. A buyer pays $499 at once for semaglutide, or $899 for tirzepatide. Both are struck against no other figure. The orals are per-bottle purchases at $199 and $299. Read the unit before the number: a four-month vial and a monthly subscription are different commitments at the same arithmetic. 4. ## What it claims, and what it cites Every line is compounded. None is FDA-approved. No agency reviews them before dispensing. A single vial covering four months raises storage and stability questions the pages do not address. ## Where it holds up, and where it does not - Strength: The supply length is stated beside the price - Strength: No subscription renews without a decision - Strength: One-time purchase terms are disclosed - Limitation: The monthly figure is never billed - Limitation: A single charge is four figures on one line - Limitation: Dose steps are not published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about CeliaRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who prefers a one-time purchase to a subscription and can fund it at once. Wrong for A reader budgeting monthly, since no line is billed that way. ## The evidence behind what CeliaRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How CeliaRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | | | Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. | | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Defy Medical](https://thisglp.com/reviews/defy-medical) [Docberry](https://thisglp.com/reviews/docberry) [Elara MD](https://thisglp.com/reviews/elara-md) [EmbraceRX](https://thisglp.com/reviews/embrace-rx) [eMed](https://thisglp.com/reviews/emed) [Enara Health](https://thisglp.com/reviews/enara-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Will I be charged $125 a month? No. The charge is $499 for a vial lasting about four months. The monthly figure is arithmetic on that. Does anything auto-renew? No recurring subscription was observed in the cart or at checkout. Each purchase stands alone. What happens if my dose goes up? CeliaRx states the price scales with the dose but publishes no steps. A vial already bought does not adjust. Is CeliaRx expensive compared with other GLP-1 telehealth sellers? CeliaRx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts CeliaRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Center for Medical Weight Loss (CMWL) reviews (2026): GLP-1 telehealth sellers Both product pages open with the three-month plan already chosen. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/center-for-medical-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The page picks the longer plan # Center for Medical Weight Loss (CMWL) review Both product pages open with the three-month plan already chosen. ## The verdict CMWL charges $149 a month for compounded semaglutide and $239 for compounded tirzepatide with no commitment. Both product pages arrive with the cheaper three-month plan already selected, so the no-commitment rate is the one sitting unselected beside it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states CMWL is a physician-led medical weight-loss network selling compounded semaglutide and compounded tirzepatide as weekly injections, with a separate microdosing line. It states it has operated since 2006 and served more than half a million members. Coverage is stated as all fifty US states. 1. ## Who writes the prescription, and what do they see? A chief medical officer is named on the product page with his medical school, which is rare in this category. The site states a US board-certified physician sets the starting dose and adjusts it, and that a clinician reviews the intake within twenty-four to forty-eight hours. Nothing is charged unless a prescription is approved. One charge covers the virtual visit, the medication from a licensed US pharmacy, injection supplies, provider-managed dose adjustments and a behavioral education program. The site states a patient can pause or cancel at any time with no penalty. Shipping is free and quoted at three to five days after approval. A patient already on semaglutide is stated not to have to start over. 2. ## What happens when the dose goes up? [Titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) is described as deliberate rather than automatic. The physician sets a starting dose and raises it as the body responds, and the site says a patient is not left to work it out alone. The compounded formulation is described as sometimes carrying B vitamins or glycine to ease gastrointestinal effects. One charge applies at every dose, so climbing the ladder costs nothing extra. 3. ## What the price includes The no-commitment rate is $149 for semaglutide and $239 for tirzepatide. The three-month plan sits beside each at a lower monthly figure and is the option the page preselects. Both pages state one transparent price with no membership fee and no hidden costs. Switching from semaglutide to tirzepatide later is described as permitted where the physician recommends it. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, and the FAQ answers the question directly: the active ingredient is FDA-approved and the compounded medication is not. Preparation is described as by a US-licensed partner pharmacy, which is not named. No LegitScript certification is claimed. ## Where it holds up, and where it does not - Strength: A chief medical officer is named with his credential - Strength: One charge holds at every dose - Strength: Medication, supplies and visit sit inside the price - Strength: A behavioral education program is included - Strength: Pause or cancel is offered with no penalty - Limitation: The page preselects the three-month plan, not the monthly one - Limitation: The three-month rate is billed as a block - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published beside either rate ## What the evidence says about this kind of treatment The assessment above is about Center for Medical Weight Loss (CMWL). These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a named medical director and a rate that holds at every dose. Wrong for A buyer who would rather the page defaulted to the plan with no commitment. ## The evidence behind what Center for Medical Weight Loss (CMWL) prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Center for Medical Weight Loss (CMWL) compares | Seller | Who it suits | Go | | --- | --- | --- | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Enhanced](https://thisglp.com/reviews/enhanced) [EverFit Medical](https://thisglp.com/reviews/everfit-medical) [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) [Evernow](https://thisglp.com/reviews/evernow) [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) [FeelGood](https://thisglp.com/reviews/feelgood-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which plan is selected when I arrive? The three-month plan, on both product pages. The monthly plan sits beside it at $149 for semaglutide and $239 for tirzepatide. Does the price change with the dose? No. Both pages state one price at every dose, with no separate membership fee. Can I switch molecules later? The FAQ says many patients start on semaglutide and move to tirzepatide where the physician recommends it. Is Center for Medical Weight Loss (CMWL) legit? Center for Medical Weight Loss (CMWL) is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Center for Medical Weight Loss (CMWL) expensive compared with other GLP-1 telehealth sellers? Center for Medical Weight Loss (CMWL) publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Center for Medical Weight Loss (CMWL) below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Chia reviews (2026): GLP-1 telehealth sellers | This GLP Chia combines weight-loss prescribing with a wider longevity menu. A focused care plan matters more than adding extra protocols. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/chia-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Ingredients and compounded status disclosed # Chia review Chia combines weight-loss prescribing with a wider longevity menu. A focused care plan matters more than adding extra protocols. ## The verdict Chia offers an ongoing refill relationship; the clinical question is what its check-ins involve and whether extra marketed treatments are necessary. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Chia combines online prescribing with weight-management and longevity-oriented programs. Its current menu names compounded semaglutide and tirzepatide; other marketed protocols address different goals and should be evaluated separately. 1. ## Who writes the prescription, and what do they see? Chia says a U.S.-licensed clinician reviews the health information and can decline treatment. The reviewed pages describe a provider network without establishing which individual clinician or pharmacy will handle a particular patient. The tirzepatide page describes doctor check-ins, tracking and continuing support. Shipments contain a four-week supply and refill check-ins are part of the process. Ask how often a clinician actually reviews the information and what requires a live visit. 2. ## What happens when the dose goes up? Chia describes individualized protocols and support around refills. Ask how the dose is reassessed and what happens if the next prepared shipment no longer matches a slower [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) plan. 3. ## What the price includes The product page contains discounted starting and higher comparison figures. The exact selected plan, billed term and renewal price need confirming. The homepage distinguishes cancellation before a consultation or shipment from an order already prepared for the pharmacy. 4. ## What it claims, and what it cites The products are compounded prescriptions and are not FDA-approved. Claims about combining GLP-1 medicines with other longevity treatments do not establish that the combination has the evidence or approved uses of either branded drug alone. ## Where it holds up, and where it does not - Strength: Ingredients and compounded status disclosed - Strength: Four-week shipment length described - Strength: Refill check-ins are part of the process - Limitation: Extra longevity protocols need separate scrutiny - Limitation: Discounted headline is not a complete bill - Limitation: Assigned clinician and pharmacy need confirming ## What the evidence says about this kind of treatment The assessment above is about Chia. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants online compounded care and will keep the treatment plan focused on a clear clinical need. Wrong for Someone who wants a narrowly defined prescription program without weighing additional longevity protocols. ## The evidence behind what Chia prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Chia compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Florida Weight Loss MD](https://thisglp.com/reviews/florida-weight-loss-md) [Found Youth](https://thisglp.com/reviews/found-youth) [Freeley](https://thisglp.com/reviews/freeley) [FuturHealth](https://thisglp.com/reviews/futurhealth) [G-Plans](https://thisglp.com/reviews/g-plans) [Gatlan](https://thisglp.com/reviews/gatlan) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The tirzepatide page describes doctor check-ins, tracking and continuing support. Shipments contain a four-week supply and refill check-ins are part of the process. Ask how often a clinician actually reviews the information and what requires a live visit. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Treatment overview and FAQ](https://chia.health/) - [Tirzepatide program](https://chia.health/product/tirzepatide) - [Service terms](https://chia.health/legal/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Chronos Body Health & Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Chronos offers in-person weight care in Metairie and telehealth pathways for Louisiana and Texas. Its GLP-1 pages explain individual assessment and optional compounded treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/chronos-bhw Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Chronos Body Health & Wellness sell a GLP-1? Chronos offers in-person weight care in Metairie and telehealth pathways for Louisiana and Texas. Its GLP-1 pages explain individual assessment and optional compounded treatment. ## The verdict Chronos gives patients a concrete choice between local office care and defined telehealth routes. Its pages also distinguish approved drug brands from possible compounded preparations. That is a useful starting point, but the exact prescription and follow-up package still need to be settled at consultation. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Chronos Body Health & Wellness combines medical weight management with other wellness and aesthetic services. Its semaglutide and tirzepatide programs are described separately, with in-person Metairie care and telemedicine for Louisiana and Texas. 1. ## Who writes the prescription, and what do they see? The program materials identify Mace Scott, MD, as medical director and medical reviewer of the treatment information. That is a disclosure about the practice’s oversight, not a guarantee that he will personally conduct every appointment. Confirm your assigned clinician and their prescribing role. The described approach considers medical history, goals, progress and treatment response. Consultation and medication packages are purchased as needed, with no mandatory monthly membership stated. Ask how the chosen package translates into actual visits and between-visit communication. 2. ## What happens when the dose goes up? Dosing is individualized rather than prescribed by the website’s general explanation. Determine what follow-up is required before increasing strength, whether [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) change the plan and how a current prescription is managed if the next supply is delayed. 3. ## What the price includes The public information does not establish a single monthly price for every medicine and care route. It says consultation and medication packages can be paid as needed without a compulsory membership. Request the actual prescription and follow-up quote for the Louisiana, Texas or office pathway you will use. 4. ## What it claims, and what it cites The pages identify approved semaglutide and tirzepatide brands and state that compounded formulations may also be considered when clinically appropriate. These are distinct products. A branded trial result should not be interpreted as evidence that a particular compounded preparation has the same performance. ## Where it holds up, and where it does not - Strength: Local and telehealth pathways are distinguished - Strength: Medical oversight is identified - Strength: No compulsory monthly membership is described - Limitation: Complete recurring costs require a quote - Limitation: Provider assignment needs confirmation - Limitation: Brand and compounded options must be separated ## What the evidence says about this kind of treatment The assessment above is about Chronos Body Health & Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient in the stated service region wanting a medical practice with both office and remote weight-management options. Wrong for Someone needing verified nationwide prescribing or a fully public drug-and-follow-up price ladder. ## The evidence behind what Chronos Body Health & Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Chronos Body Health & Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Lifestyle Medicine](https://thisglp.com/reviews/genesis-lifestyle-medicine) [Gide Health](https://thisglp.com/reviews/gide-health) [Glow](https://thisglp.com/reviews/glow) [GOAL.MD](https://thisglp.com/reviews/goal-md) [GoodLife Health](https://thisglp.com/reviews/goodlife-health) [Happy Care Meds](https://thisglp.com/reviews/happy-care-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Where is telehealth described? The weight-loss materials provide Louisiana and Texas telemedicine pathways, plus in-person Metairie care. Is membership compulsory? The treatment information says consultation and medication packages can be purchased as needed without mandatory monthly membership. Does the practice only use branded drugs? No. Its pages discuss approved brands and the possible use of compounded formulations when appropriate. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.chronosbhw.com/) - [Tirzepatide program details](https://www.chronosbhw.com/wellness/weight-loss/tirzepatide) - [Semaglutide program details](https://www.chronosbhw.com/wellness/weight-loss/semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Cielo reviews (2026): GLP-1 telehealth sellers | This GLP The asterisk on the home page card does the work most sites leave out. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/cielo Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three numbers, one vial # Cielo review The asterisk on the home page card does the work most sites leave out. ## The verdict Cielo Health leads with $89 a month for compounded semaglutide and puts the condition in an asterisk immediately below it, where the words say a six-month plan and all doses. Open the semaglutide page itself and the ladder appears in full, with a shorter term between the headline and a monthly plan that carries its own figure and the regular rate printed beside it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $139/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Cielo Health sells compounded semaglutide and compounded tirzepatide as weekly injections, entirely online, with the intake reviewed the same day and the medication described as arriving within a few days. The company states that ten percent of every dollar it earns goes to charitable organizations, and it repeats that on a page of its own rather than as a badge. The site is published in English and Spanish. No other product line shares the catalog. 1. ## Who writes the prescription, and what do they see? The intake is described as secure and reviewed by licensed physicians who take time with a health history before treatment starts, and that sentence is as close as the site comes to naming anyone. No physician, medical group or medical director appears on the about page, the product pages or the footer. The FAQ list runs to eleven questions, several of which would carry the answer, and the headings render without any text beneath them. What a physician weighs before writing the first prescription is left entirely unstated. Each molecule has its own page, and each page opens on a plan table rather than a quiz, which means a buyer can price the whole thing before answering a single medical question. Free physician consultation and shipping are described as inside the rate, and the site says care plans are adjusted as the body changes, with an eye on preserving muscle mass. Unlimited provider access, refill help and ongoing follow-up are listed as included. A patient portal sits behind a separate login. 2. ## What happens when the dose goes up? The asterisk under every price says all doses, and the plan table repeats it, so the figure a buyer starts on is the figure they stay on as the dose climbs through the first sixteen weeks. That removes the most common unpleasant surprise in this category, where a step up quietly moves a patient into a higher tier. What it does not do is say who approves the step, or how quickly. No milligram figure appears anywhere beside a plan, so the ladder itself is invisible until a provider describes it. 3. ## What the price includes The semaglutide page prints three rungs in one table, headed by the six-month plan and closing on a monthly plan with the regular rate struck through beside it. Tirzepatide is built identically, one tier higher at every rung. The home page card shows the six-month figure against the regular rate, and a sale banner runs across the top of every page. Nothing on either page states what the six-month plan costs as a single charge, only what it works out to each month. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by pharmacy partners the site calls FDA-regulated without naming any of them. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. Every batch is described as tested, and the claim is not attributed to a named laboratory. ## Where it holds up, and where it does not - Strength: The commitment is printed in the asterisk - Strength: The regular rate sits beside the sale rate - Strength: One price at every titration dose - Strength: The plan table comes before the quiz - Strength: No membership fee sits beside any rung - Limitation: The headline rate needs six months - Limitation: The FAQ headings render without answers - Limitation: No prescriber or medical group is named - Limitation: No compounding pharmacy is named - Limitation: No milligram dose appears beside a plan ## What the evidence says about this kind of treatment The assessment above is about Cielo. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the term behind a headline rate stated in the line under it. Wrong for A buyer who needs to know who will be writing the prescription. ## The evidence behind what Cielo prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Cielo compares | Seller | Who it suits | Go | | --- | --- | --- | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealFastRx](https://thisglp.com/reviews/healfast) [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) [Hone Health](https://thisglp.com/reviews/hone-health) [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) [KairoRx](https://thisglp.com/reviews/kairorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $89 a month what a new patient pays? Only on the six-month plan. The asterisk under the figure says so, and the product page's monthly rung is higher. Does a higher dose cost more? No. Every plan on both product pages is marked as covering all doses, so a step up does not move the charge. Who reviews the intake? Licensed physicians, according to the site. None is named, and no medical group or medical director appears anywhere on it. Is Cielo expensive compared with other GLP-1 telehealth sellers? Cielo publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Cielo below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Citizen Meds reviews (2026): GLP-1 telehealth sellers | This GLP The entry figure is stated, and so is the fact that it rises with the dose. Most sellers state only the first half. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/citizen-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Says the price climbs # Citizen Meds review The entry figure is stated, and so is the fact that it rises with the dose. Most sellers state only the first half. ## The verdict Citizen Meds publishes $135 a month for compounded semaglutide at the entry dose. It states plainly that the figure rises as the dose does, which is a disclosure most sellers here do not make. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $135/mo Prescription Required Compounded Yes — not FDA-approved Citizen Meds sells compounded semaglutide and compounded tirzepatide by injection. Each carries an entry figure and a stated intention to rise. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping, and the pages describe the plan rather than the clinician writing it. The intake is not documented. What the seller does document is the pricing behavior, which is the thing a buyer meets second. The service is remote. The pages are organized around dose tiers rather than around a care relationship, and nothing describes what a clinician reviews between one tier and the next. 2. ## What happens when the dose goes up? This is the field Citizen Meds actually answers. The entry figure is for the starting dose and the seller says the charge moves upward with the milligrams. It does not publish every rung, so a buyer knows the direction without knowing the destination. Direction is more than silence and less than a ladder. 3. ## What the price includes $135 buys the first dose tier and nothing here fixes it there. Six months at the entry figure is $810, and that total holds only for a buyer who does not escalate — which describes almost nobody in the first four months. Tirzepatide starts at $157 under the same rule. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. A pharmacy prepares them and the FDA does not review them before dispensing. No pharmacy is named on the pages. ## Where it holds up, and where it does not - Strength: States that the price rises with dose - Strength: Entry figures published for both molecules - Strength: Tirzepatide costs only $22 more to start - Limitation: The upper rungs are not published - Limitation: No state coverage list is recorded - Limitation: The entry total misleads anyone escalating - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Citizen Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the escalation named rather than discovered on a card statement. Wrong for A buyer who needs to know the cost at 2.4 milligrams before committing. ## The evidence behind what Citizen Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Citizen Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Bloom MD | Buyers who want each tirzepatide dose priced in advance, with liraglutide as an option | | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | Bon Health | Readers who can pick a commitment length and want every rung priced before they choose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [KIN Health](https://thisglp.com/reviews/kin-health) [Klarity Health](https://thisglp.com/reviews/klarity-health) [Klinic](https://thisglp.com/reviews/klinic) [Kova](https://thisglp.com/reviews/kova) [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) [Lighter You](https://thisglp.com/reviews/lighter-you) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $135 hold at a higher dose? No, and Citizen Meds says so. The figure is the entry dose and the charge rises with the milligrams. What it rises to is not published. What does tirzepatide cost? $157 at the entry dose, under the same rising structure as the semaglutide line. Is a rising price a bad sign? Not by itself. Saying so is a disclosure, and most compounded sellers publish nothing about what happens at a higher dose. Is Citizen Meds expensive compared with other GLP-1 telehealth sellers? Citizen Meds publishes a starting figure of $135/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Citizen Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Claya reviews (2026): GLP-1 telehealth sellers | This GLP The homepage advertises one semaglutide rate and the product page charges another. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/claya Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Tile and product page differ # Claya review The homepage advertises one semaglutide rate and the product page charges another. ## The verdict Claya's semaglutide page prices the weekly injection at $179 a month and the tablets at $279. The homepage a click earlier advertises a lower figure for the same injection, and attributes it to multi-month plans in one place and to the monthly plan in another. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $179/mo Oral From $279/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Claya is a cash-pay GLP-1 service selling compounded semaglutide as a weekly injection and as a tablet, with compounded tirzepatide offered by injection. A daily drop format is described on the semaglutide page but not priced. Coaching and a patient portal are sold alongside the medication. 1. ## Who writes the prescription, and what do they see? Every assessment is stated to be reviewed by a licensed provider, and medication is described as shipping only if a provider deems it appropriate. The intake is a three-minute form rather than a scheduled visit. No prescriber or medical group is named on the page. What a provider reads before approving is not described. Plans are described as monthly with options shown before checkout, and the site states there is no lock-in. Refill reminders, shipping support and care-team messaging are included rather than billed. A separate membership page and a coaching program sit beside the medication. Shipping is offered same-day where a prescription clears before the pharmacy cutoff. 2. ## What happens when the dose goes up? Claya states that dosing is adjusted as the body responds and that the same price applies regardless of dosage. That covers the money, but not the clinical side of a step up. No milligram figure appears beside either plan. Nothing published names who signs off on an increase. 3. ## What the price includes The semaglutide product page prices the injection at $179 and the tablets at $279, and those are the figures a buyer reaches. Tirzepatide has no product page of its own and is priced only in the homepage plan block, at $199. The oral tirzepatide the catalog once carried is no longer sold. Three semaglutide formats are described and two are priced. 4. ## What it claims, and what it cites Both molecules are offered compounded. A required safety notice states that compounded medications are regulated by state boards of pharmacy, and not evaluated by the FDA for safety or efficacy. Pharmacies are described as licensed United States facilities rather than named. The same notice sets out the thyroid warnings carried by the drug class. ## Where it holds up, and where it does not - Strength: A required safety notice states the FDA position plainly - Strength: The same price applies at every dose - Strength: Refill support and care-team messaging are included - Strength: Plan options are shown before checkout - Strength: Same-day shipping is offered where a prescription clears early - Limitation: The homepage and the product page quote different semaglutide rates - Limitation: Tirzepatide has no product page of its own - Limitation: A third semaglutide format is described but never priced - Limitation: No pharmacy or prescriber is named ## What the evidence says about this kind of treatment The assessment above is about Claya. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who opens the product page before trusting a homepage rate. Wrong for A buyer who wants tirzepatide documented as thoroughly as semaglutide. ## The evidence behind what Claya prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Claya compares | Seller | Who it suits | Go | | --- | --- | --- | | Breeze Meds | A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | HealthRX | Buyers who expect to escalate and want the later months priced | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Livbetr](https://thisglp.com/reviews/livbetr) [Longevity Meds](https://thisglp.com/reviews/longevity-meds) [Loozy](https://thisglp.com/reviews/loozy) [Male Excel](https://thisglp.com/reviews/male-excel) [MangoRx](https://thisglp.com/reviews/mangorx) [MD Trim Clinic](https://thisglp.com/reviews/md-trim-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which semaglutide price is right? The product page figure of $179 a month. The homepage tile quotes a lower rate and ties it to multi-month plans. Can I get tirzepatide as a tablet? Not now. Claya prices tirzepatide only as an injection, and lists no oral tirzepatide product. Does a higher dose cost more? No. The plan cards state the same price regardless of dosage, with dosing adjusted as the body responds. Is Claya expensive compared with other GLP-1 telehealth sellers? Claya publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Claya below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Clinic Secret reviews (2026): GLP-1 telehealth sellers | This GLP The bold figure is the first month. The struck figure beside it is every month after. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/clinic-secret Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Month one is $100 off # Clinic Secret review The bold figure is the first month. The struck figure beside it is every month after. ## The verdict Clinic Secret prints "Plans starting at $297 $197" with the $297 struck through. A banner on every page names the gap: $100 off the first month. So $297 is the standing monthly rate. The site states the rate does not rise with the dose. No prescriber or pharmacy is named. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $297/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Clinic Secret is an online weight loss service run by Clinic Secret, LLC. It sells compounded semaglutide and compounded tirzepatide. Sermorelin and a pentadeca arginate line for joint and knee recovery share the catalog. No in-person visit is required. 1. ## Who writes the prescription, and what do they see? The site states its team includes 17 prescribing physicians. It also states clinical services come from partner doctor networks. A board-certified physician reviews the intake within 24 hours. The provider may decline, and a declined buyer is refunded in full. No physician or network is named. The process has three steps. 1. The buyer completes an online health assessment. 2. A physician reviews it and prescribes if the buyer qualifies. 3. The order ships, with delivery stated at three days. Identity checks require a photo ID and a clothed full-body image. 2. ## What happens when the dose goes up? The site states the monthly price does not rise with the dose. No milligram schedule is published. Who approves a dose step, and when, is not stated. The refund policy says physicians customize the plan over six months. 3. ## What the price includes The weight loss page shows $297 struck and $197 in bold. The site-wide banner reads "New Member Promo - $100 Off 1st Month". The $197 is therefore month one only. From month two the rate is $297. The page does not split the figure by molecule. No membership fee is charged. 4. ## What it claims, and what it cites Both lines are compounded at 503A pharmacies regulated by state boards of pharmacy. None is named. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The site states nothing is added to the GLP-1, such as B12. ## Where it holds up, and where it does not - Strength: The promo mechanism is printed on every page - Strength: Price stated flat at every dose - Strength: Full refund if the prescription is declined - Strength: No membership fee - Limitation: The bold figure lasts one month - Limitation: No prescriber or pharmacy is named - Limitation: Refunds close one hour after purchase - Limitation: No milligram schedule is published ## What the evidence says about this kind of treatment The assessment above is about Clinic Secret. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who budgets from the struck $297, not the bold $197. Wrong for A buyer who wants a named physician or pharmacy before ordering. ## The evidence behind what Clinic Secret prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Clinic Secret compares | Seller | Who it suits | Go | | --- | --- | --- | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDLive](https://thisglp.com/reviews/mdlive) [MD Total Wellness](https://thisglp.com/reviews/mdtw) [Medical Health Institute](https://thisglp.com/reviews/medical-health-institute) [Medivive](https://thisglp.com/reviews/medivive) [MEDVidi](https://thisglp.com/reviews/medvidi) [Meli Health](https://thisglp.com/reviews/meli-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Clinic Secret cost after the first month? $297 a month. The $197 shown in bold is that rate less a $100 first-month promotion. Can I cancel after ordering? Within one hour of purchase, for a full refund. After that, sales are final except under the stated guarantee or a declined prescription. What is the weight loss guarantee? The refund policy requires six full months on treatment. A buyer who loses no weight in that time is refunded. Is Clinic Secret expensive compared with other GLP-1 telehealth sellers? Clinic Secret publishes a starting figure of $297/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Clinic Secret above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Clume Health reviews (2026): GLP-1 telehealth sellers | This GLP Both molecules carry one monthly figure, and the lower advertised figure requires a twelve-week prepaid term. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/clume-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price, two molecules # Clume Health review Both molecules carry one monthly figure, and the lower advertised figure requires a twelve-week prepaid term. ## The verdict Clume Health publishes $259 a month for both molecules. It is printed as a starting figure. A lower figure of $200 appears on the pages and requires a twelve-week prepaid term. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $259/mo Prescription Required Compounded Yes — not FDA-approved Clume Health sells both molecules by injection. Two lines carry figures. Both carry the same figure. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state prices and terms rather than clinician detail. The intake is not documented. Two things matter here. Both molecules carry one figure. And the attractive figure carries a twelve-week prepay. Neither is hidden; the prepay is easy to miss beside the lower number. 2. ## What happens when the dose goes up? Nothing is published about what either figure does at a higher dose. $259 is a starting figure. Ask what it becomes at your dose before the second month. 3. ## What the price includes $259 is the current monthly figure on both lines. Six months at it is $1,554. The $200 figure needs twelve weeks paid up front. Confirm the figure on the seller's own page before ordering. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Both molecules at the same figure - Strength: The prepay condition is stated - Limitation: $259 is printed as a starting figure - Limitation: The low figure needs twelve weeks prepaid - Limitation: No dose behavior is published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Clume Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will confirm the figure on the day before ordering. Wrong for A reader relying on a quote more than a few weeks old. ## The evidence behind what Clume Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Clume Health compares | Seller | Who it suits | Go | | --- | --- | --- | | AVARA Rx | A reader who wants the consult inside the price, and who plans against the standing rate rather than a code that can be withdrawn. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | | ARSYNL Rx | Readers who want both molecules priced on one page and will confirm the figure on the day | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Metabolic Rx](https://thisglp.com/reviews/metabolic-rx) [Metabolyz](https://thisglp.com/reviews/metabolyz) [Mixx Health & Wellness](https://thisglp.com/reviews/mixx-health-and-wellness) [Modern Age](https://thisglp.com/reviews/modern-age) [Novera MD](https://thisglp.com/reviews/novera-md) [Nuform Health](https://thisglp.com/reviews/nuform-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the current price? $259 a month on both lines, printed as a starting figure. How do I get $200? That figure requires a twelve-week prepaid term. The monthly rate is $259. Does the price change with the dose? Not published. Confirm the rate at your dose on the seller's own page before acting. Is Clume Health expensive compared with other GLP-1 telehealth sellers? Clume Health publishes a starting figure of $259/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Clume Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # CLYR Health reviews (2026): GLP-1 telehealth sellers | This GLP The charge rises with the dose, and every tier is published before the intake. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/clyr-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by the dose # CLYR Health review The charge rises with the dose, and every tier is published before the intake. ## The verdict CLYR Health charges by weekly dose rather than at one flat rate, which sounds like bad news until you see that all three semaglutide tiers are printed on the product page before anyone asks a medical question. The page says as much in its own words, promising no ladder hidden behind a five-minute intake form, and the tirzepatide page carries a starter month, a three-month plan and a month-to-month rung laid out the same way. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $169/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider CLYR Health sells compounded semaglutide and compounded tirzepatide with B12, prepared by a state-licensed 503A pharmacy, alongside brand-name Zepbound, Wegovy tablets and the orforglipron tablet at their own published rates. A lipotropic add-on, daily wellness and sexual health lines share the catalog, and an ivermectin category sits in the main navigation. Payment is described as a single charge rather than a subscription, and the site states there is no membership fee. 1. ## Who writes the prescription, and what do they see? A provider confirms the right dose during the visit, and the page is explicit that a patient only ever pays the tier they are prescribed, which ties the money to a clinical decision rather than to a checkout selection. That is a meaningful sentence in a category where the tier is usually chosen before anyone has looked at a chart. What the provider reads first is still not described, and no clinician, medical group or medical director is named anywhere on the site. A full refund is promised where a buyer is found not eligible. The tirzepatide page splits its plans by where a buyer is starting from, offering one path for someone new to a GLP-1 and another for someone who has already found their dose. Almost nobody else on this shelf draws that distinction at all. Each plan lists what arrives in the box: the vial, an injection homekit with syringes, alcohol pads and a sharps container, the provider consultation and cold-chain shipping. Refills on the tirzepatide starter run on eight-week cycles. Stripe handles payment, and the site says the price shown is the price paid. 2. ## What happens when the dose goes up? The starter program is built around the climb rather than around a single dose, covering a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) from twenty to seventy units a week under one price so that no mid-titration jump lands on a patient halfway through. Above that, the published ladder continues to ninety and a hundred and twenty units, and the vial's concentration is printed beside it, so the milligrams behind each step can be worked out from the page itself. The semaglutide line is tiered the same way across three published rates. What is left unresolved is timing: nothing says how long a tier is held before the next one is offered. 3. ## What the price includes Semaglutide is quoted from one figure per dose tier, with the three rates named on the category page rather than hidden behind a consultation. Tirzepatide opens on a reduced starter month that reverts to a stated refill rate, sits in the middle at a three-month starter billed once, and tops out at a month-to-month rung. Brand-name products are listed beside the compounded ones at their own monthly rates. Nothing is charged as a recurring membership. 4. ## What it claims, and what it cites Both compounded lines are prepared with vitamin B12 by a state-licensed 503A pharmacy, and compounded preparations are not FDA-approved or reviewed by the FDA before dispensing. The brand-name products are described as factory-sealed and FDA-approved, which is a real distinction and one the page draws clearly. The pharmacy is identified by type rather than by name. ## Where it holds up, and where it does not - Strength: Every dose tier is published before the intake - Strength: The weekly unit ladder is printed with the concentration - Strength: One starter price covers the early titration - Strength: Brand and compounded options sit on one page - Strength: No membership fee and no subscription - Limitation: The charge rises as the dose climbs - Limitation: The starter month reverts to a higher rate - Limitation: The compounding pharmacy is not named - Limitation: No clinician or medical group is named - Limitation: Nothing states how long a tier is held ## What the evidence says about this kind of treatment The assessment above is about CLYR Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants every dose tier priced on the page before answering a medical question. Wrong for A buyer whose budget cannot absorb a higher charge at each step up the ladder. ## The evidence behind what CLYR Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How CLYR Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nurx](https://thisglp.com/reviews/nurx) [Olleve Care](https://thisglp.com/reviews/ollevecare) [Omada Health](https://thisglp.com/reviews/omada-health) [One80Rx](https://thisglp.com/reviews/one80rx) [Pillar Health](https://thisglp.com/reviews/pillar-health) [Prescriva](https://thisglp.com/reviews/prescriva) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price go up with the dose? Yes. CLYR prices semaglutide across three dose tiers and tirzepatide by plan, and states a patient pays only the tier they are prescribed. Is the starter rate the ongoing rate? No. The tirzepatide starter month reverts to a stated refill rate, printed on the same line as the opening figure. Is the dose published in milligrams? Indirectly. The page prints the weekly unit ladder and the vial's concentration, so the milligrams behind each step can be derived from it. Is CLYR Health expensive compared with other GLP-1 telehealth sellers? CLYR Health publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts CLYR Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Coby Health reviews (2026): care and dose costs | This GLP Coby connects patients with independent prescribers for compounded injections. The care relationship deserves as much attention as the starting price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/coby-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Medical review, pharmacy unnamed # Coby Health review Coby connects patients with independent prescribers for compounded injections. The care relationship deserves as much attention as the starting price. ## The verdict Coby identifies its medical group and offers on-demand support, but does not identify the dispensing pharmacy on the public pages reviewed. Before ordering, establish who will handle side effects, dose changes and the next refill. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $199/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Not stated Availability Excludes AR, LA, MS and NM Coby is a telehealth platform rather than the medical practice or pharmacy itself. Its weight-loss products are compounded semaglutide and tirzepatide injections. Payment does not guarantee a prescription. 1. ## Who writes the prescription, and what do they see? The terms name Beluga Health and affiliated independent professionals as the medical group. A licensed provider reviews the health assessment and decides whether treatment is appropriate. The public terms allow several communication formats; they do not promise every patient a scheduled video visit. The product pages include on-demand medical support. Current members are directed to the patient portal for clinical questions. No fixed follow-up appointment frequency or guaranteed clinical response time is established on the reviewed pages. Ask how to reach the prescriber if nausea or another problem appears before the next order. 2. ## What happens when the dose goes up? The semaglutide page describes gradual clinician-directed increases and prints doses from 0.25 to 2.4 mg. Tirzepatide runs from 2.5 to 15 mg. A printed monthly sequence is a sales schedule, not an instruction to increase your own dose. Ask whether a prepaid shipment can accommodate a slower increase or a treatment change. 3. ## What the price includes The monthly schedules start with introductory prices of $159 for semaglutide and $239 for tirzepatide. The next listed rungs are $199 and $299. At the highest listed doses, prices reach $249 and $439. Consultation, medication, support and shipping are included; prepaid packages carry separate terms. 4. ## What it claims, and what it cites Both injections are compounded and are not FDA-approved. Coby states they are not generic versions of the branded products. Its public pages refer to partner pharmacies without establishing which pharmacy will fill an individual prescription. ## Where it holds up, and where it does not - Strength: Medical group named in the terms - Strength: Dose schedules and included services are visible - Strength: Monthly orders do not require a subscription - Limitation: Dispensing pharmacy not identified publicly - Limitation: No promised follow-up frequency - Limitation: Prices increase along the listed dose schedule ## What the evidence says about this kind of treatment The assessment above is about Coby Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded treatment who can clarify the pharmacy and follow-up arrangements before paying. Wrong for Someone seeking an FDA-approved brand or a program with scheduled dietitian visits. ## The evidence behind what Coby Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Coby Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Prescriva](https://thisglp.com/reviews/prescriva) [PrescrYbe](https://thisglp.com/reviews/prescrybe) [PRIMO Health Partners](https://thisglp.com/reviews/primo-health-partners) [Push Health](https://thisglp.com/reviews/push-health) [Ravia Health](https://thisglp.com/reviews/ravia-health) [Red Mountain Weight Loss](https://thisglp.com/reviews/red-mountain-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who prescribes through Coby Health? Coby names Beluga Health in its terms. An independent licensed provider evaluates eligibility; the platform itself does not practice medicine. Is Coby available in every state? The help center excludes Arkansas, Louisiana, Mississippi and New Mexico. Treatment-specific availability can change. Can an order be canceled? Cancellation is not guaranteed after a prescription reaches the pharmacy. A successful cancellation carries a $50 clinical deduction; shipped orders are not refundable. Optional subscriptions require 30 days of notice. Is Coby Health legit? Coby Health is a GLP-1 telehealth sellers service. Its stated availability: Excludes AR, LA, MS and NM. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Coby Health expensive compared with other GLP-1 telehealth sellers? Coby Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Coby Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 14, 2026. Terms can change. - [Semaglutide plans](https://www.cobyhealth.com/treatments/weight-loss/semaglutide) - [Tirzepatide plans](https://www.cobyhealth.com/treatments/weight-loss/tirzepatide) - [Coverage and cancellation](https://www.cobyhealth.com/help) - [Clinical and service terms](https://www.cobyhealth.com/policies/terms-of-service) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Coivas reviews (2026): GLP-1 telehealth sellers | This GLP One monthly number is published. Almost nothing surrounding it is. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/coivas Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A figure and little else # Coivas review One monthly number is published. Almost nothing surrounding it is. ## The verdict Coivas publishes $149 a month for compounded semaglutide. No dose, no coverage list and no statement about what the figure does as the dose rises. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $149/mo Prescription Required Compounded Yes — not FDA-approved Coivas sells compounded semaglutide by injection. One figure is published. The catalog beyond that line is thin. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the pages describe the offer rather than the person writing it. The intake is not documented, and neither is what a clinician reviews before approving a refill. Remote and lightly described. The published material is a price and a product, which is a smaller disclosure than most compounded sellers make even at higher figures. 2. ## What happens when the dose goes up? Nothing is published on dose at all — not a milligram figure, not a statement about the price at a higher one. A reader cannot tell whether $149 buys 0.25 milligrams or 2.4, which makes the figure hard to set beside any other. 3. ## What the price includes $149 is competitive against the median here, and six months at it comes to $894. Both statements assume the dose does not move and that nothing is added at checkout, and Coivas publishes nothing that confirms either assumption. 4. ## What it claims, and what it cites Compounded rather than manufactured. A pharmacy prepares it and the FDA does not review it before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: A monthly figure is published up front - Strength: Published figure sits under $150 - Limitation: No milligram dose stated anywhere - Limitation: No state coverage list recorded - Limitation: Nothing published about dose pricing - Limitation: One molecule, one format ## What the evidence says about this kind of treatment The assessment above is about Coivas. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer comparing headline figures who will ask the rest before ordering. Wrong for A buyer who needs the dose behind a price before treating it as comparable. ## The evidence behind what Coivas prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Coivas compares | Seller | Who it suits | Go | | --- | --- | --- | | Bon Health | Readers who can pick a commitment length and want every rung priced before they choose | | | Bloom MD | Buyers who want each tirzepatide dose priced in advance, with liraglutide as an option | | | Bioverse | Readers who want semaglutide cheaply and ignore the struck figure beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rese Wellness](https://thisglp.com/reviews/rese-wellness) [Revive Longevity](https://thisglp.com/reviews/revive-longevity) [Rila](https://thisglp.com/reviews/rila) [Risen Labs](https://thisglp.com/reviews/risen-labs) [Robinhood Telehealth](https://thisglp.com/reviews/robinhood-telehealth) [Royal Medical Center](https://thisglp.com/reviews/royal-medical-center) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What dose does $149 buy? Coivas does not say. No milligram figure appears beside the price, which means the number cannot be compared against a seller that publishes one. Does the price rise with the dose? Nothing is published either way. That is silence rather than a rising price, and the two should not be read as the same thing. Which states are served? No coverage list is recorded. Ask before ordering. Is Coivas expensive compared with other GLP-1 telehealth sellers? Coivas publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Coivas below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Collective reviews (2026): GLP-1 telehealth sellers | This GLP The advertised rate is $59 a month, and the required annual membership brings the monthly figure to $76. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/collective Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership billed separately # Collective review The advertised rate is $59 a month, and the required annual membership brings the monthly figure to $76. ## The verdict Collective advertises $59 a month for compounded semaglutide and charges a $199 annual membership beside it. Spread across twelve months that is $76, and $76 is the figure this site ranks the seller on. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $76/mo Prescription Required Compounded Yes — not FDA-approved Collective sells compounded semaglutide and compounded tirzepatide, both as weekly injections, through an online service. Its pricing page carried $59 a month for the semaglutide and $69 a month for the tirzepatide. The same page stated a $199 annual membership charge alongside each rate. A first year of semaglutide therefore came to $907, and a first year of tirzepatide to $1,027. 1. ## Who writes the prescription, and what do they see? Collective arranges treatment remotely and a prescription is issued before the first shipment. The pricing page describes the product and the membership, and it does not describe the clinician who signs for either one. What an intake asks before a prescription is written is not published. The $199 charge is published as an annual membership rather than as a fee for clinician time. The service operates remotely, and both products are compounded preparations rather than the manufacturer's approved pen. Collective states that the rate holds at every dose for semaglutide and at any dose for tirzepatide. A rate that does not move during titration is worth more over a year than most headline gaps between sellers. The dose rises for almost everyone within the first four months. What the intake asks of a patient before a prescription is issued is not something the seller publishes. 2. ## What happens when the dose goes up? The rate is stated as flat at every dose, on both molecules. Almost everyone escalates across the first sixteen weeks, so a flat rate holds the monthly figure through the part that usually moves it. The saving is larger than most headline gaps between sellers. What clinical support accompanies a dose step is not stated beside the price. 3. ## What the price includes The membership is the part that changes the arithmetic, and it is charged once a year rather than monthly. At $59 plus $199 a year, twelve months of semaglutide runs $907, which is $75.58 a month and rounds to $76 on the boards here. Tirzepatide on the same terms runs $1,027, or $85.58 a month. A reader who stops after four months pays the whole membership anyway, so the effective monthly rate on a short course is higher than either figure above. 4. ## What it claims, and what it cites Both molecules are compounded, which means they are prepared by a pharmacy rather than manufactured and reviewed as a finished product. A compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not an FDA-approved drug and is not assessed for safety or efficacy before it is dispensed. The trial evidence a reader may have seen quoted for semaglutide was generated with the approved product at the doses the label describes, not with a compounded preparation. Whether a compounded vial matches that product in content or purity is not measured. ## Where it holds up, and where it does not - Strength: Rate stated as flat at every dose - Strength: Both molecules priced on one page - Strength: Membership amount published, not implied - Limitation: Membership is charged annually, up front - Limitation: Advertised rate excludes that membership - Limitation: Short course carries the whole year fee ## What the evidence says about this kind of treatment The assessment above is about Collective. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who expects to stay on treatment for a full twelve months, which is the term the annual membership is priced against. Wrong for A reader who wants to try one or two months before committing, since the $199 membership is charged in full regardless of how long the course runs. ## The evidence behind what Collective prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Collective compares | Seller | Who it suits | Go | | --- | --- | --- | | Lean Meds | Readers willing to clarify the prescription and renewal details | | | Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sipra](https://thisglp.com/reviews/sipra) [Sommar Club](https://thisglp.com/reviews/sommar-club) [StaveMD](https://thisglp.com/reviews/stavemd) [Steady State Health](https://thisglp.com/reviews/steady-state-health) [Super Healthy Rx](https://thisglp.com/reviews/super-healthy-rx) [Tablet Health](https://thisglp.com/reviews/tablet-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $59 a month what Collective actually bills? It is the medication rate, and it is accurate as far as it goes. The $199 annual membership is charged in addition, so twelve months of semaglutide comes to $907 rather than $708. The monthly equivalent is $76. Does the price rise as the dose goes up? Collective states that it does not, for either molecule. That is a meaningful claim in this category, because a dose escalation over the first sixteen weeks is the normal path and many sellers reprice at each step. Is compounded semaglutide the same drug as the branded product? It is the same molecule prepared by a compounding pharmacy, not the finished product a manufacturer makes and the FDA reviews. Equivalence in content and purity is not established by that process, and it is not measured here. Is Collective expensive compared with other GLP-1 telehealth sellers? Collective publishes a starting figure of $76/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Collective below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Concierge MD LA reviews (2026): GLP-1 telehealth sellers | This GLP The monthly figure is a membership that includes the medication, and the page disagrees with itself about how often it ships. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/concierge-md-la Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership is the price # Concierge MD LA review The monthly figure is a membership that includes the medication, and the page disagrees with itself about how often it ships. ## The verdict Concierge MD LA publishes $199 a month for semaglutide and $299 for tirzepatide, as memberships that include the medication rather than fees beside it. A four-month minimum applies. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved Concierge MD LA sells both molecules by injection through a membership. The consultation and the medication sit inside the monthly figure. A four-month commitment is required. 1. ## Who writes the prescription, and what do they see? The membership is the clinical relationship here, and the seller frames it that way rather than pricing a visit separately. What it does not do is describe the clinician, the intake, or what a renewal review covers. One published figure covering consultation and medication is a cleaner structure than a price with fees attached. The four-month minimum is the cost of it: $796 on semaglutide before a reader can stop. 2. ## What happens when the dose goes up? Nothing is published about what either figure does at a higher dose. Inside a four-month commitment that gap covers most of an escalation. A buyer locks in before the dose settles, with no stated rule for what happens when it moves. 3. ## What the price includes $199 a month with a four-month minimum is a $796 commitment, and $299 is $1,196. Neither is a rate a reader can leave after thirty days. The membership framing is honest; the minimum is the part to read twice. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Consultation and medication in one figure - Strength: The membership framing is stated plainly - Strength: No separate fee sits outside the price - Limitation: A four-month minimum, so $796 committed - Limitation: The page disagrees on shipping cadence - Limitation: Nothing published about dose pricing - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Concierge MD LA. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one number covering care and medication and can commit four months. Wrong for A reader who needs to stop after a month, or who needs the shipping cadence settled. ## The evidence behind what Concierge MD LA prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Concierge MD LA compares | Seller | Who it suits | Go | | --- | --- | --- | | DrBrainRx | Readers in the 21 prescribing states who will add the care fee to the headline | | | CoraDoc | Buyers who would rather pay a program once than carry a subscription they have to remember to cancel | | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Teladoc Health](https://thisglp.com/reviews/teladoc-health) [Teleios Health](https://thisglp.com/reviews/teleios-health) [TeleWellnessMD](https://thisglp.com/reviews/telewellnessmd) [The Protocole](https://thisglp.com/reviews/the-protocole) [TideMedix](https://thisglp.com/reviews/tidemedix) [Tomorrow](https://thisglp.com/reviews/tomorrow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the membership a fee on top of the medication? No. The seller's own wording is that the $299 monthly membership includes a shipment, with the consultation and medication inside it. How often does medication arrive? The page contradicts itself. Its product copy describes a monthly supply, while the FAQ on the same page says every 60 days for tirzepatide and every 90 for semaglutide. That changes what arrives, not what is billed. What is the real commitment? $796 on semaglutide or $1,196 on tirzepatide, because a four-month minimum applies to both. Is Concierge MD LA expensive compared with other GLP-1 telehealth sellers? Concierge MD LA publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Concierge MD LA above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Contour Health reviews (2026): care and vial pricing | This GLP Contour Health offers a free video consultation, continued access to the same provider and medication ordered by vial rather than automatic monthly refills. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/contour-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Provider continuity, pay by vial # Contour Health review Contour Health offers a free video consultation, continued access to the same provider and medication ordered by vial rather than automatic monthly refills. ## The verdict Contour Health’s strongest distinction is continuity: its FAQ promises the same provider, a video visit to begin and direct contact during treatment. Its medication bill depends on dose and vial size. The public weekly estimates do not support a single standing monthly price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 46 Prescription Required Compounded Yes — not FDA-approved Availability 46 states Contour Health describes itself as provider-owned remote care for weight management and other treatments. Its team page identifies co-founder Melissa Musso as a family nurse practitioner overseeing clinical operations and Laarni Gonzales-Naval as medical director. These are the seller’s disclosed roles, not a guarantee that either will be your assigned clinician. 1. ## Who writes the prescription, and what do they see? The first consultation is a Zoom video visit with a provider licensed in your state. Contour says the same provider remains involved throughout treatment. It does not require labs before starting, although an individual patient may need additional assessment. The FAQ lists 46 states, excluding Michigan, Mississippi, Kentucky and Arkansas. After the initial video visit, most communication uses messaging, with follow-up video available on request. The stated usual response is within about 24 hours on weekdays. Contact the provider when roughly two weeks of medication remain: progress and the next vial size are reviewed before payment and reorder. This requires the patient to initiate refills rather than rely on an automatic shipment. 2. ## What happens when the dose goes up? The provider adjusts the dose based on response and tolerability. Because medication is billed by vial, changing the prescribed amount can change both cost and how long a vial lasts. Ask for the amount in the vial, prescribed weekly dose and beyond-use instructions together; duration calculated from milligrams alone is not permission to use medication past its label date. 3. ## What the price includes Consultations and ongoing provider support are included without a membership fee. The current page advertises weekly starting estimates, while another calculator shows a different semaglutide starting amount. Medication is sold by vial and its duration depends on dose. Obtain a written vial quote before paying instead of converting the website’s weekly estimate into a promised monthly bill. 4. ## What it claims, and what it cites Contour uses compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), which are not FDA-approved. It describes an accredited 503A pharmacy partner but does not name the dispenser in the treatment summary. Ask for the pharmacy identity, formulation and storage directions before accepting a prescription. The site’s accreditation claims are not evidence of FDA approval for the medication. ## Where it holds up, and where it does not - Strength: Named clinical leadership - Strength: Initial video visit and provider continuity described - Strength: No weight-loss subscription or automatic refill - Strength: Dose and refill reviewed before reorder - Limitation: Vial price varies with the treatment plan - Limitation: Weekly semaglutide estimates conflict across the page - Limitation: Routine provider messaging is weekday-based - Limitation: Four states excluded ## What the evidence says about this kind of treatment The assessment above is about Contour Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who prefers a continuing clinician relationship and wants control over when a refill is ordered. Wrong for Someone needing one guaranteed monthly charge or automatic medication delivery. ## The evidence behind what Contour Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Contour Health compares | Seller | Who it suits | Go | | --- | --- | --- | | DadVantage Men's Health | Readers who want the cost at a higher dose stated and will add the two outside charges | | | EdgeRx | Readers who want a named compounding pharmacy and will check availability first | | | Curex | Readers who have ruled out injections and want a single published oral figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TotalRx](https://thisglp.com/reviews/totalrx) [Totara Health](https://thisglp.com/reviews/totara-health) [Trally Meds](https://thisglp.com/reviews/trally-meds) [Transcarent](https://thisglp.com/reviews/transcarent) [TRT Kingdom](https://thisglp.com/reviews/trt-kingdom) [Tummala Health](https://thisglp.com/reviews/tummala-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Contour charge for the first consultation? The current site advertises a free provider consultation without payment that day. Medication is quoted separately by vial. Will I keep the same provider? Contour’s FAQ says yes. Follow-up generally uses messaging, and a video appointment can be requested. How are refills arranged? Contact your provider with about two weeks of medication left. You review progress and select the next vial before payment and ordering. Does Contour accept insurance? It does not bill insurance. It says documentation can be provided for an HSA or FSA reimbursement request. ## Sources for this review Provider information checked October 14, 2026. Terms can change. - [Treatment and vial pricing](https://www.contourhealthrx.com/weight-loss) - [Appointments and refill FAQ](https://www.contourhealthrx.com/faqs) - [Clinical leadership](https://www.contourhealthrx.com/about) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Cora Health reviews (2026): GLP-1 telehealth sellers | This GLP Every prescriber, both pharmacies and all four commitment terms are printed where a buyer can read them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/cora-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Named doctors, named pharmacies # Cora Health review Every prescriber, both pharmacies and all four commitment terms are printed where a buyer can read them. ## The verdict Cora Health leads with $99 a month, but its plans page shows that figure belongs to a year paid in one charge. A buyer who wants the freedom to stop after any month pays $175 for compounded semaglutide or $225 for compounded tirzepatide. Around those numbers the disclosure runs deep: the medical group, three of its physicians, and both compounding pharmacies are named on the home page itself. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $175/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states LegitScript Claimed by provider Cora Health is a telehealth platform that connects buyers in all fifty states with an independent medical group, which then prescribes compounded semaglutide or compounded tirzepatide where it judges treatment appropriate. The company says plainly that it does not prescribe, diagnose or manufacture anything itself, and a peptide line is listed as coming soon. Diet and workout plans come with every plan, and the platform takes HSA and FSA cards alongside Affirm, Klarna and Afterpay. 1. ## Who writes the prescription, and what do they see? Prescriptions are written by Wasef Health, PC, a medical group in Pinellas Park, Florida, whose medical director, Dr. Michael Wasef, is described as board-certified in internal medicine and licensed in all fifty states. Two more physicians appear by name, Dr. Ozita Cooper, board-certified in obesity medicine and emergency medicine, and Dr. Andrew Sakla. A provider reviews the online questionnaire and decides within about a day, and the site gives the medical group's own contact address rather than routing everything through the platform. The path runs from a five-minute questionnaire to a provider decision in under a day and a shipment in under three, with messaging to the care team open around the clock after that. Every plan is described as covering the consultation, the medication, pharmacy fulfillment, expedited shipping and ongoing provider monitoring, with no separate membership fee on top. A new patient already on a GLP-1 can share that history and, where the provider agrees, continue at an equivalent dose rather than starting over. 2. ## What happens when the dose goes up? Cora states the same price applies at any dose, with no per-dose surcharge on either plan, so the steps of the first sixteen weeks do not change the bill. A provider makes each adjustment, and the site describes ongoing provider monitoring as part of every plan rather than an extra visit to book and pay for. What the site does not publish is a milligram schedule, so a patient learns the ladder from the provider rather than from the page. 3. ## What the price includes The plans page prints four rungs for each molecule, from an annual commitment through six and three months to a plain monthly plan, and the monthly rung is labeled no commitment. Semaglutide runs from $99 on the annual plan, billed as $1,188 at once, up to $175 month to month; tirzepatide runs from $135, billed as $1,620, up to $225. A code for $15 off the first month sits in a banner at the top of every page. 4. ## What it claims, and what it cites Both lines are compounded by one of two named 503A pharmacies, Hallandale Pharmacy in Fort Lauderdale, which the site describes as PCAB-accredited, and VialsRx, and each patient's label says which one filled it. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing, and Cora prints that sentence on its own home page. ## Where it holds up, and where it does not - Strength: Three physicians and the medical group are named - Strength: Both compounding pharmacies are named outright - Strength: Every commitment term is priced on one page - Strength: One price at every dose on both plans - Limitation: The headline rate needs a year paid upfront - Limitation: No milligram schedule is published - Limitation: The first-month code sits beside the headline ## What the evidence says about this kind of treatment The assessment above is about Cora Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to know which doctor and which pharmacy stand behind the vial before paying. Wrong for A buyer who reads the $99 as a monthly rate without looking at the plans page. ## The evidence behind what Cora Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Cora Health compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vea Health](https://thisglp.com/reviews/vea-health) [Vela Rx](https://thisglp.com/reviews/vela-rx) [Verge](https://thisglp.com/reviews/verge) [Vida Health](https://thisglp.com/reviews/vida-health) [Virgo-Meds](https://thisglp.com/reviews/virgo-meds) [Virta Health](https://thisglp.com/reviews/virta-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Cora Health cost without a long commitment? The monthly plan, which Cora labels no commitment and cancel anytime, is $175 for compounded semaglutide and $225 for compounded tirzepatide, with the lower figures reserved for three, six and twelve months paid up front. Who actually prescribes at Cora Health? Physicians at Wasef Health, PC, an independent medical group in Florida led by Dr. Michael Wasef, and Cora itself states that it does not prescribe medication. Which pharmacy makes the medication? Either Hallandale Pharmacy in Fort Lauderdale or VialsRx, both 503A compounding pharmacies, and the label on each patient's medication names the one that filled it. Is Cora Health legit? Cora Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Cora Health expensive compared with other GLP-1 telehealth sellers? Cora Health publishes a starting figure of $175/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Cora Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # CoraDoc reviews (2026): GLP-1 telehealth sellers | This GLP There is no monthly option here, and the headline figure is half a year. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/coradoc Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A program, not a month # CoraDoc review There is no monthly option here, and the headline figure is half a year. ## The verdict CoraDoc sells programs paid once and says so: no subscription, ever. The $99 beside its name is a six-month semaglutide program. The shortest commitment on the page is a three-month starter at $165 a month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider CoraDoc sells doctor-prescribed compounded semaglutide and tirzepatide, delivered nationwide. Peptides and supplements sit in the same catalog. Every GLP-1 plan is a fixed term rather than a rolling charge. 1. ## Who writes the prescription, and what do they see? A licensed US physician or nurse practitioner reviews the intake one to one, and the visit is free. The provider sends the prescription to a pharmacy partner within a day if it is appropriate. That pharmacy is not named. Four programs are published. Semaglutide runs six months at $99 and tirzepatide six months at $149. A three-month semaglutide starter exists for a shorter commitment. Provider visit, two-day shipping and supplies are stated as included at every tier. 2. ## What happens when the dose goes up? Nothing on the program cards ties a price to a dose. The maintenance tier is described as covering any prescribed dosage, which implies the rate holds. Who approves a step is not stated. A term is paid before the first injection. 3. ## What the price includes The six-month semaglutide program works out at $99 a month and the tirzepatide one at $149. Three months of semaglutide is $165 a month, and the three-month maintenance tier is $199. A buyer unwilling to commit half a year meets $165, not $99. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded rather than manufactured. A pharmacy prepares them to order, and the FDA does not review a compounded preparation before it is dispensed. No pharmacy is named. ## Where it holds up, and where it does not - Strength: No subscription and no auto-renewal - Strength: Provider visit, shipping and supplies included - Strength: LegitScript certified - Strength: A maintenance tier is published, not quoted later - Strength: Full refund if a provider declines - Limitation: The headline rate needs six months up front - Limitation: The shortest term still runs three months - Limitation: No compounding pharmacy is named - Limitation: A sale banner on the homepage has already expired ## What the evidence says about this kind of treatment The assessment above is about CoraDoc. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who would rather pay once than cancel later. Wrong for A buyer who wants to stop after a single month. ## The evidence behind what CoraDoc prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How CoraDoc compares | Seller | Who it suits | Go | | --- | --- | --- | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vitakey](https://thisglp.com/reviews/vitakey) [Vital Step](https://thisglp.com/reviews/vital-step) [Vivanta Care](https://thisglp.com/reviews/vivanta-care) [VivioMD](https://thisglp.com/reviews/viviomd) [welludr.](https://thisglp.com/reviews/wellmedr)[Yes Clinic](https://thisglp.com/reviews/yes-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I buy a single month? No. CoraDoc states there is no subscription option, and its shortest program is a three-month starter at $165 a month. What does the $99 actually buy? Six months of compounded semaglutide, paid in one charge, with the provider visit, shipping and supplies included. What happens after the starter program? A three-month maintenance tier is published at $199 a month for patients holding a dose. Is CoraDoc legit? CoraDoc is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is CoraDoc expensive compared with other GLP-1 telehealth sellers? CoraDoc publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts CoraDoc below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # CoreAge Rx reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide is advertised at $99 a month, on a row checked earlier than the rest of this group. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/coreage-rx Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026$99 advertised, and the oldest figures here # CoreAge Rx review Semaglutide is advertised at $99 a month, on a row checked earlier than the rest of this group. ## The verdict CoreAge Rx advertises compounded semaglutide at $99 a month and compounded tirzepatide at $149, both injectable, which are low figures in this category, though these are the oldest figures carried for any seller wired here. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $99/mo Prescription Required Compounded Yes — not FDA-approved CoreAge Rx sells compounded semaglutide and compounded tirzepatide as weekly injections through an online service, and it advertises $99 for the semaglutide and $149 for the tirzepatide. No oral form is listed for either molecule. All fifty states are served. 1. ## Who writes the prescription, and what do they see? The service arranges treatment remotely and a prescription is issued before anything ships, but the page states the rates rather than describing the clinician who writes for them, and what an intake asks beforehand is not something the seller publishes. Everything here is compounded and the service runs at a distance, with two products rather than four, so there is less to compare than at sellers offering both forms. The narrower catalog is not in itself a weakness; it does mean a reader who wants an oral will have to look elsewhere. 2. ## What happens when the dose goes up? Neither rate carries a statement about what happens as the dose rises. Escalation across the first sixteen weeks is the normal path, so a reader should treat $99 as a starting figure rather than an annual one until the intake confirms otherwise. 3. ## What the price includes The two advertised figures are $99 and $149, and the $50 between them is a narrower gap than this category usually puts between the molecules. The qualification worth carrying is the date: these figures were checked roughly ten days before the others in this group, so it is the one most likely to have moved since. A price with an older verification date is not wrong, but it is the first one to re-check. 4. ## What it claims, and what it cites Both products are compounded preparations made by a pharmacy rather than finished products manufactured and reviewed by the FDA, which means neither is approved and neither is assessed for safety, efficacy or quality before it is dispensed. The trial evidence quoted for these molecules was generated with the approved products at labeled doses, and whether a compounded vial matches them in content or purity is not measured. ## Where it holds up, and where it does not - Strength: Lowest advertised figures of the sellers wired here - Strength: Narrow $50 gap between the two molecules - Strength: All fifty states served - Limitation: No oral form for either molecule - Limitation: Prices carry the oldest check date in this group - Limitation: Dose-escalation pricing not stated ## What the evidence says about this kind of treatment The assessment above is about CoreAge Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader starting at a low dose, which is the tier these advertised rates are quoted against. Wrong for A reader who needs an oral, and a reader who wants the most recently verified figure on the page. ## The evidence behind what CoreAge Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How CoreAge Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Strut Health | A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. | | | Care Bare Rx | A reader choosing between the two molecules on grounds other than price, since this seller charges the same for both. | | | Synergy Rx | A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [YOURx Health](https://thisglp.com/reviews/yourx-health) [Youth & Soul](https://thisglp.com/reviews/youth-and-soul) [Zenbody](https://thisglp.com/reviews/zenbody) [Coby Health](https://thisglp.com/reviews/coby-health) [Form Health](https://thisglp.com/reviews/form-health) [Pepton Health](https://thisglp.com/reviews/pepton-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a month current? CoreAge Rx advertises it, and its figures carry an earlier check date than the rest of this group. That is an earlier date than the other sellers in this group carry, so it is the figure most worth confirming on the seller's own page before you act on it. Can I get tirzepatide as a tablet here? No. Both molecules are sold as weekly injections and no oral line is advertised. Why is the gap between the molecules so small? Tirzepatide usually carries a larger premium over semaglutide than the $50 charged here, CoreAge Rx publishes the two figures and no explanation for the gap between them. Is CoreAge Rx expensive compared with other GLP-1 telehealth sellers? CoreAge Rx publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts CoreAge Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Corsica Health reviews (2026): GLP-1 telehealth sellers | This GLP Both advertised figures sit inside a three-month plan paid in advance, and the monthly rate is printed beside each. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/corsica-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The low rate is a block rate # Corsica Health review Both advertised figures sit inside a three-month plan paid in advance, and the monthly rate is printed beside each. ## The verdict Corsica Health publishes $149 a month for semaglutide and $249 for tirzepatide, and both are the per-month figures of a three-month plan. Bought a month at a time the same products are $199 and $299. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved Corsica Health sells both molecules by weekly injection, with a three-month plan billed up front and a monthly option fifty dollars higher on each line. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe plans and their discounts rather than the clinician behind them. The plan selector puts the block rate and the monthly rate side by side. That is honest. Advertising only the block rate elsewhere is the part a comparison will pick up. 2. ## What happens when the dose goes up? Nothing published says what either plan does at a higher dose. A block bought in advance carries that question through all three months. 3. ## What the price includes The three-month semaglutide plan is $447 paid at once, which is $149 a month; the same product bought monthly is $199. Tirzepatide is $747 up front or $299 monthly. Six months of semaglutide runs $894 in blocks or $1,194 by the month. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. A pharmacy prepares them to order, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: Both the block and monthly rates are published - Strength: The upfront totals are shown, not just the rates - Strength: Both monthly rates came down in September - Limitation: The advertised rate needs three months paid at once - Limitation: Buying monthly costs $50 more on each line - Limitation: Refunds inside a paid block are unstated - Limitation: Dose behavior is not published ## What the evidence says about this kind of treatment The assessment above is about Corsica Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who can pay three months at once and wants the discount that buys. Wrong for A reader budgeting six months from the advertised figure while intending to pay monthly. ## The evidence behind what Corsica Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Corsica Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Pepton Health | Readers who will create an account before deciding anything | | | Aspire Health | Readers who want the dose stated beside the vial and will do the arithmetic | | | Somi Health | Readers who want the dose question answered in writing before anything else | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Belle Health](https://thisglp.com/reviews/belle-health) [bmiMD](https://thisglp.com/reviews/bmimd) [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)[Collective](https://thisglp.com/reviews/collective) [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) [Direct Meds](https://thisglp.com/reviews/direct-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I buy a single month at $149? No. One month of the same product is $199; $149 exists only inside the $447 block. What does the three-month plan cost up front? $447 for semaglutide and $747 for tirzepatide. Did the price change? Yes. The monthly rates fell by fifty dollars on each line, to $199 for semaglutide and $299 for tirzepatide. Is Corsica Health expensive compared with other GLP-1 telehealth sellers? Corsica Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Corsica Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Curex reviews (2026): GLP-1 telehealth sellers | This GLP An oral line at $199 across forty-five states, with no injection offered at any price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/curex Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Oral only, wide coverage # Curex review An oral line at $199 across forty-five states, with no injection offered at any price. ## The verdict Curex publishes $199 a month for oral semaglutide across 45 states. It sells no injection, which makes the figure hard to compare against an injectable price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Oral States 45 From From $199/mo Prescription Required Compounded Yes — not FDA-approved Availability 45 states Curex sells oral semaglutide. There is no injectable line. Coverage is recorded in forty-five states, which is wide for this category. 1. ## Who writes the prescription, and what do they see? A prescription is issued before shipping, and the published material describes the product rather than the clinician. The intake is not documented. Nothing states what review happens before a repeat order goes out. Remote, built around a single product rather than a menu. Committing to one format is itself a choice, and it is the clearest thing Curex publishes about how it works. 2. ## What happens when the dose goes up? Oral dosing escalates on its own schedule, and Curex publishes nothing about what $199 covers as that happens. The gap is the same one most sellers leave, on a format where the rungs differ from the injectable ones. 3. ## What the price includes $199 a month is $1,194 over six months at a steady dose. Setting that against an injectable figure compares two different products: the formats differ in what a milligram delivers, so the cheaper number is not automatically the cheaper treatment. 4. ## What it claims, and what it cites Compounded rather than manufactured. A pharmacy prepares it and the FDA does not review it before dispensing. The oral route is not the one the approved weight-loss products use. ## Where it holds up, and where it does not - Strength: Coverage recorded across 45 states - Strength: A single published figure, no tiers to decode - Strength: No injection means no format upsell - Limitation: Oral only — no injectable option - Limitation: Not comparable against injection prices - Limitation: Nothing published about dose behavior - Limitation: Five states are not served ## What the evidence says about this kind of treatment The assessment above is about Curex. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who has decided against injections and wants one published figure. Wrong for A buyer comparing against injectable prices, or one who may want to switch formats later. ## The evidence behind what Curex prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Curex compares | Seller | Who it suits | Go | | --- | --- | --- | | Coivas | Readers comparing headline figures who will ask about dose and coverage before ordering | | | Bon Health | Readers who can pick a commitment length and want every rung priced before they choose | | | Amble | Buyers who want a multi-month rate that holds at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Eden](https://thisglp.com/reviews/eden) [Embody](https://thisglp.com/reviews/embody) [Enhance MD](https://thisglp.com/reviews/enhance-md) [Found](https://thisglp.com/reviews/found) [Gala](https://thisglp.com/reviews/gala) [HealthRX](https://thisglp.com/reviews/healthrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 comparable to an injection price? Not directly. The formats deliver a milligram differently, so a lower or higher number across formats is not by itself the cheaper treatment. Does Curex sell an injection? No. Oral semaglutide is the only line published. How many states are covered? Forty-five are recorded. Five are not served. Is Curex legit? Curex is a GLP-1 telehealth sellers service. Its stated availability: 45 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Curex expensive compared with other GLP-1 telehealth sellers? Curex publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Curex above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # CVS MinuteClinic reviews (2026): weight-management clinical care | This GLP CVS MinuteClinic offers a $29 online GLP-1 eligibility consultation with later medication support. The first assessment, ongoing visits and pharmacy purchase are separate decisions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/cvs-minuteclinic Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # CVS MinuteClinic review CVS MinuteClinic offers a $29 online GLP-1 eligibility consultation with later medication support. The first assessment, ongoing visits and pharmacy purchase are separate decisions. ## The verdict The strongest feature is a clearly described assessment-to-follow-up pathway, without a mandatory subscription. It includes refill management and possible dose adjustments. The low consultation entry should still be read as access to a clinician, not confirmation that a medicine will be prescribed or affordable. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category weight-management clinical care Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required MinuteClinic offers weight-management assessment alongside its wider clinical services. The GLP-1 page lists Wegovy injections and tablets and Zepbound injections, with prescribing conditional on eligibility. These are specific prescription products rather than a single generic program medicine. 1. ## Who writes the prescription, and what do they see? The online consultation is reviewed by a licensed provider. MinuteClinic’s broader clinical information describes nurse practitioners and physician assistants, with professional arrangements varying by state. Confirm who is responsible for continuing medication management in the pathway you select. After the initial eligibility assessment, the service describes a personalized plan, refill management, dosage adjustments and additional care navigation when needed. Progress can be followed through later visits. Ask whether those appointments are online or in person and how to reach the team about side effects. 2. ## What happens when the dose goes up? A provider may adjust treatment in response to progress and tolerance. The public description does not make one [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule or response time universal. A prescription is not a direction to use the highest dose or a promise that every future refill will be approved. 3. ## What the price includes The online consultation is advertised at $29 with no subscription required. Medication is separate: advertised low cash prices or copays depend on a selected product, manufacturer coupon and eligibility restrictions. Later visits and other required services should be priced before beginning. 4. ## What it claims, and what it cites The listed options include approved [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) products. Their route, indication and prescribing requirements differ. Product trial results on the page describe studied populations and do not predict an individual patient’s outcome. ## Where it holds up, and where it does not - Strength: Initial assessment price is clearly separated - Strength: Refill management and dose support are described - Strength: No mandatory subscription - Limitation: Drug savings depend on restrictions and coupons - Limitation: Later visit costs require confirmation - Limitation: Prescription approval remains clinical ## What the evidence says about this kind of treatment The assessment above is about CVS MinuteClinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a recognizable outpatient care pathway with GLP-1 assessment and ongoing follow-up options. Wrong for A patient interpreting the initial consult charge or a coupon headline as a guaranteed all-in treatment price. ## The evidence behind what CVS MinuteClinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How CVS MinuteClinic compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HumeCare+](https://thisglp.com/reviews/humecare)[Live Vital](https://thisglp.com/reviews/live-vital) [Lttl](https://thisglp.com/reviews/lttl) [Luvo Health](https://thisglp.com/reviews/luvo-health) [MEDGm](https://thisglp.com/reviews/medgm) [Oak](https://thisglp.com/reviews/oak) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the consultation include medication? No. The $29 figure is for the online eligibility consultation, while drug prices and coupon conditions are described separately. Is a subscription required? The GLP-1 page says no subscription is required for the consultation. Is follow-up available? The service describes ongoing care, refill management and provider-directed dosage adjustments; verify appointment arrangements and charges. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.cvs.com/minuteclinic) - [Weight-management program](https://www.cvs.com/minuteclinic/services/weight-loss-program?icid=mchome-mcservices-weightloss) - [Official provider and care overview](https://www.cvs.com/minuteclinic/info?icid=mchome-mcfaq-mcallfaq) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # DadVantage Men's Health reviews (2026): GLP-1 telehealth sellers | This GLP Nothing here is sold by the month, and two charges sit outside whichever block a buyer picks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/dadvantage-mens-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Blocks of weeks, plus fees # DadVantage Men's Health review Nothing here is sold by the month, and two charges sit outside whichever block a buyer picks. ## The verdict DadVantage Men's Health sells both molecules in blocks of weeks rather than months, at about $217 a calendar month before a $250 consultation and a $50 monthly follow-up that the seller states excludes medication. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 1 From From $267/mo Prescription Required Compounded Yes — not FDA-approved DadVantage sells both molecules by injection, priced by the block: four weeks at $200, eight at $350, ten at $400, twelve at $500 and twenty at $650, with coverage recorded in a single state. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing, and the $250 consultation is the closest thing to a description of who writes it, since the pages set out blocks and fees rather than the clinician behind either. The $50 monthly follow-up is the interesting disclosure here, because the seller says plainly that it does not include medication. That is a clinical relationship priced separately from the drug, where one bundled number would not say which parts it covers. 2. ## What happens when the dose goes up? The tirzepatide line prices by dose as well as by block, which is more than most publish. At 2.5 milligrams a week it runs $400 for eight weeks or $700 for sixteen, and at 5 milligrams it is $700 for six weeks or $1,200 for twelve. At that upper rung the cost is about $505 a month, well over double the entry figure, and a buyer can see that before starting rather than after. 3. ## What the price includes A four-week block at $200 is $216.67 a calendar month, because thirteen four-week fills fit into a year rather than twelve. Add the $50 follow-up and the all-in figure is $267 on either molecule. The $250 consultation lands once. None of that is hidden; all of it needs working out from three separate statements. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The tirzepatide dose ladder is published - Strength: Block prices stated at five lengths - Strength: The follow-up fee's exclusion is stated - Limitation: Nothing is priced by the month - Limitation: A $250 consultation lands on top - Limitation: A $50 monthly fee excludes medication - Limitation: Coverage is recorded in one state ## What the evidence says about this kind of treatment The assessment above is about DadVantage Men's Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the cost at a higher dose stated, and will add the two outside charges. Wrong for A reader comparing monthly figures, since nothing here is one. ## The evidence behind what DadVantage Men's Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How DadVantage Men's Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Contour Health | Patients who prefer clinician continuity and control over each refill | | | DrBrainRx | Readers in the 21 prescribing states who will add the care fee to the headline | | | Elevated Health | Readers who want to see every rung before choosing a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PeterMD](https://thisglp.com/reviews/petermd) [RxSpan MD](https://thisglp.com/reviews/rxspan-md) [Sesame Care](https://thisglp.com/reviews/sesame-care) [ShedRx](https://thisglp.com/reviews/shedrx) [SkinnyRx](https://thisglp.com/reviews/skinnyrx) [SnagRx](https://thisglp.com/reviews/snagrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month actually cost? About $267 on either molecule at the entry rung — $216.67 for a four-week block converted to a calendar month, plus the $50 monthly follow-up, with the $250 consultation landing once. Why is a four-week block not a month? Because thirteen four-week fills fit into a year rather than twelve, so a $200 block is $216.67 a calendar month rather than $200. What happens at a higher tirzepatide dose? The 5 milligram rung is $700 for six weeks or $1,200 for twelve, which works out at about $505 a month, and the seller publishes those figures rather than leaving them to an invoice. Is DadVantage Men's Health expensive compared with other GLP-1 telehealth sellers? DadVantage Men's Health publishes a starting figure of $267/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts DadVantage Men's Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Defy Medical reviews (2026): GLP-1 telehealth sellers | This GLP Defy places GLP-1 treatment within a broader medical weight-management practice. Its consultation and follow-up model deserve more attention than the list of available therapies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/defy-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Broader medical assessment # Does Defy Medical sell a GLP-1? Defy places GLP-1 treatment within a broader medical weight-management practice. Its consultation and follow-up model deserve more attention than the list of available therapies. ## The verdict Defy may suit someone who wants a wider assessment and continuing provider contact. Before starting, establish which medical professional will manage the prescription, how often reviews occur and which exact drug product the pharmacy will supply. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Defy Medical offers online weight-management consultations alongside hormone and other medical services. Its dedicated treatment pages discuss semaglutide and tirzepatide, and the patient portal supports enrollment and ongoing care. 1. ## Who writes the prescription, and what do they see? The treatment pathway starts with a consultation with a Defy provider. The company describes tailoring treatment to health factors affecting weight. A website’s discussion of a medication does not identify the individual clinician assigned to a new patient; confirm that relationship during enrollment. The published model describes personalized treatment and regular follow-up to refine the plan. It also offers other therapies. Ask which elements are medically necessary for the stated goal and whether the same clinician will review response and side effects over time. 2. ## What happens when the dose goes up? Defy describes adjusting the plan through continued provider contact, without establishing a universal dose-increase schedule on the pages reviewed. The prescriber should decide whether a dose is maintained, increased or changed based on the individual assessment. 3. ## What the price includes A comparable standing medication-inclusive monthly amount is not established on the treatment pages. The terms say Defy does not accept insurance, and clinical services, medicines and testing can involve separate costs. Clarify the complete care plan before agreeing to additional therapies. 4. ## What it claims, and what it cites The semaglutide page describes a weekly injection; tirzepatide has a separate prescribing pathway. The reviewed material does not clearly establish the exact brand or compounded preparation supplied to every patient. Request that identity and the dispensing pharmacy before treatment. ## Where it holds up, and where it does not - Strength: Dedicated GLP-1 treatment pathways - Strength: Regular provider follow-up described - Strength: A broader clinical assessment is available - Limitation: The exact supplied product needs confirming - Limitation: No fixed universal follow-up cadence established - Limitation: Cash costs can extend beyond the prescription ## What the evidence says about this kind of treatment The assessment above is about Defy Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a clinical weight-management assessment with continuing contact rather than a medicine-only storefront. Wrong for Someone who needs an established all-in monthly amount and a specified drug product before arranging a consultation. ## The evidence behind what Defy Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Defy Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Willow](https://thisglp.com/reviews/willow) [YourEra](https://thisglp.com/reviews/yourera) [EverPrime](https://thisglp.com/reviews/everprime) [MyDrHank](https://thisglp.com/reviews/mydrhank) [1st Optimal](https://thisglp.com/reviews/1st-optimal) [24hrDOC](https://thisglp.com/reviews/24hrdoc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Defy accept insurance for this care? Its terms say it does not accept insurance. A receipt does not guarantee reimbursement from an insurer. Does the treatment page establish which pharmacy product I will receive? No single brand or compounded formulation is established for every patient by the pages reviewed. Confirm the exact prescription with the treating provider. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Semaglutide care pathway](https://www.defymedical.com/services/semaglutide-for-weight-loss/) - [Tirzepatide consultation and follow-up](https://www.defymedical.com/tirzepatide-online/) - [Clinical services, payment and refund terms](https://www.defymedical.com/about-us/terms-of-service/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Direct Meds reviews (2026): GLP-1 telehealth sellers | This GLP Everything is sold by the quarter and quoted by the day. One of the daily figures is the other molecule's. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/direct-meds Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A daily rate on the wrong page # Direct Meds review Everything is sold by the quarter and quoted by the day. One of the daily figures is the other molecule's. ## The verdict Direct Meds contradicts itself in public. Its tirzepatide page carries two daily rates. Only one agrees with the price beside it. The other is the semaglutide figure, transplanted. Every headline is hedged 'as low as' on top of that. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $297/mo Oral From $249/mo Prescription Required Compounded Yes — not FDA-approved Availability Not published by the provider Direct Meds runs a portal rather than a storefront. Both molecules appear in both routes. Every line is sold as a multi-month supply. The pages state which: twelve weeks for the injections, thirteen for the tablets. 1. ## Who writes the prescription, and what do they see? The prescription is arranged through the portal. A clinician reviews an intake before dispensing. The pages state flow codes and supply lengths rather than describing the clinician. What the intake asks is not published. No line is sold by the calendar month, though every figure is presented as one. What is bought is a supply block. The pages disclose its length beside a flow code rather than in the price. The daily framing shrinks the number a reader sees. It also conceals what is owed at purchase. 2. ## What happens when the dose goes up? No line says what its figure does at a higher dose. One oral tier runs against the category's habit. Certain dosages fall below the advertised number rather than above it. That makes the headline a ceiling. Unusual, and disclosed rather than discovered. 3. ## What the price includes Check the daily figures before trusting any of them. Only one of the two on the tirzepatide page reconciles with that page's own price; the other reproduces the semaglutide arithmetic. A pricing page carrying an error about its own product is a reason to confirm every number on it directly. 4. ## What it claims, and what it cites Each line is compounded. Nothing here is FDA-approved, and no agency examines it before it ships. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Supply length appears beside every figure - Strength: Flow codes are visible in the portal - Strength: One oral tier undercuts its own headline - Limitation: One published daily rate contradicts its own price - Limitation: The quoted unit is not the billed unit - Limitation: Every figure carries an unexplained hedge - Limitation: Nothing describes a higher dose ## What the evidence says about this kind of treatment The assessment above is about Direct Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will verify each number against the portal before ordering. Wrong for A reader who wants to buy a single month of anything. ## The evidence behind what Direct Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Direct Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | GobyMeds | A reader who wants a monthly price that holds at any dose, with a cheaper starter bundle as the alternative | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | NuBloom | Readers who want the top dose priced before starting the lowest | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [1st Optimal](https://thisglp.com/reviews/1st-optimal) [24hrDOC](https://thisglp.com/reviews/24hrdoc) [AbundRX](https://thisglp.com/reviews/abundrx) [Actin](https://thisglp.com/reviews/actin) [AgelessRx](https://thisglp.com/reviews/agelessrx) [AHBARx](https://thisglp.com/reviews/ahbarx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which daily figure is correct for tirzepatide? The higher of the two. It reconciles with that page's own price; the lower one reproduces the semaglutide arithmetic. Is a month available? No line is sold by the calendar month. Each is a multi-month supply block, and the pages state the length beside a flow code. Why does the oral price below its headline? Certain dosages fall below the advertised number rather than above it, which makes that headline a ceiling on the line. Is Direct Meds expensive compared with other GLP-1 telehealth sellers? Direct Meds publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Direct Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Docberry reviews (2026): GLP-1 telehealth sellers | This GLP Docberry’s supply commitments deserve as much attention as its clinical intake. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/docberry Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 An app-supported telehealth storefront offering multi-month semaglutide and tirzepatide supplies rather than a single simple monthly plan. # Does Docberry sell a GLP-1? Docberry’s supply commitments deserve as much attention as its clinical intake. ## The verdict The service may suit someone comfortable managing care online, but a longer supply should follow a clear follow-up and adjustment plan. Published medication bundles do not establish how unused treatment is handled. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Docberry facilitates online consultations and access to independent physicians. Its website markets medication delivery and an app for appointments and account management. 1. ## Who writes the prescription, and what do they see? The terms distinguish the platform from the healthcare provider and pharmacy. Payment does not guarantee a prescription. Confirm who will supervise the treatment and how to reach that practice. The app supports access to the account and scheduling. The reviewed public pages do not define a standard GLP-1 follow-up interval or clinical response time, so ask about both before committing to a supply bundle. 2. ## What happens when the dose goes up? A multi-month purchase needs a plan for dose changes, [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and stopping treatment. Ask how prescription changes affect medication already dispensed and whether later shipments require a fresh clinical review. 3. ## What the price includes The storefront lists semaglutide in four- and twelve-month supply bundles and tirzepatide as a three-month supply. Displayed monthly equivalents spread a larger total over time; they do not establish cancel-any-month billing. 4. ## What it claims, and what it cites Semaglutide and tirzepatide are named products. The overview does not sufficiently identify the exact formulation, route and dispensing pharmacy for each bundle. Obtain those details rather than inferring them from educational articles. ## Where it holds up, and where it does not - Strength: Offers app-based scheduling and account access - Strength: Names medication supply lengths - Limitation: Follow-up cadence is not clearly specified - Limitation: Exact formulation and pharmacy require confirmation ## What the evidence says about this kind of treatment The assessment above is about Docberry. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults who want online account management and can obtain a clear clinical plan before purchasing a longer supply. Wrong for Anyone who needs documented month-to-month flexibility or a fully specified product before intake. ## The evidence behind what Docberry prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Docberry compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Alinwell](https://thisglp.com/reviews/alinwell) [Allara Health](https://thisglp.com/reviews/allara-health) [Alloy](https://thisglp.com/reviews/alloy) [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) [altRX](https://thisglp.com/reviews/altrx) [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does a twelve-month supply replace clinical follow-up? No. Ask how the clinician monitors treatment and manages changes during the advertised supply period. Is a prescription guaranteed after payment? No. The terms make prescribing subject to clinical judgment. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://docberry.com/) - [Official program and terms](https://docberry.com/understanding-semaglutide-weight-loss-safety-and-more/) - [Official program and terms](https://docberry.com/terms-and-agreement/) - [Official program and terms](https://docberry.com/semaglutide-for-weight-loss-in-non-diabetics/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # DoctorAdam reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide costs the same in either form, and the tirzepatide tablet costs less than its injection. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/doctoradam Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The tablet never costs more # DoctorAdam review Semaglutide costs the same in either form, and the tirzepatide tablet costs less than its injection. ## The verdict DoctorAdam charges $129 a month for semaglutide in either form. Tirzepatide is $229 by injection and $199 as a tablet. Choosing a tablet here never costs more. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 44 Injection From $129/mo Oral From $129/mo Prescription Required Compounded Yes — not FDA-approved DoctorAdam sells compounded semaglutide and compounded tirzepatide, each as an injection and as an oral, through an online service covering forty-four states. Semaglutide is $129 a month in either form. Tirzepatide is $229 as an injection and $199 as an oral. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely and a prescription precedes shipping. The product pages carry the four figures. They do not describe the clinician or what the intake asks before a prescription is written. The service runs at a distance and every product is compounded. The pricing decision is the informative part. Most sellers price the two forms apart, in one direction or the other, which means a reader is weighing routine against cost. Here semaglutide costs the same either way, and the tirzepatide tablet costs $30 less. The decision is mostly about whether a daily tablet or a weekly injection suits the week. 2. ## What happens when the dose goes up? What happens to either figure as the dose rises is not stated. Escalation across the first sixteen weeks is the normal path, so both numbers should be treated as opening rates until the intake confirms otherwise. 3. ## What the price includes The step from semaglutide to tirzepatide is $100 by injection and $70 as a tablet. Nothing on the pages describes what sits inside either rate. Whether shipping and a consultation are included is a question for the intake. 4. ## What it claims, and what it cites All four products are compounded, prepared by a pharmacy rather than manufactured and reviewed as finished products. None is FDA-approved and none is assessed for safety, efficacy or quality before dispensing. The published trial evidence for these molecules used the approved products at labeled doses. ## Where it holds up, and where it does not - Strength: Form carries no price penalty - Strength: All four combinations published - Strength: The tirzepatide tablet costs less - Limitation: Six states are not served - Limitation: Dose-escalation pricing not published - Limitation: What the rate includes is not stated ## What the evidence says about this kind of treatment The assessment above is about DoctorAdam. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. Wrong for A reader shopping on the lowest opening figure, which is not what this seller competes on. ## The evidence behind what DoctorAdam prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How DoctorAdam compares | Seller | Who it suits | Go | | --- | --- | --- | | Revel Health | A reader who wants an oral and expects to pay less for it, which on this seller is what happens. | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Alan Meds | A reader ready to prepay six months who wants the full-dose price in view before the intake. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [altRX](https://thisglp.com/reviews/altrx) [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) [AlyveRx](https://thisglp.com/reviews/alyverx) [AM Rx](https://thisglp.com/reviews/amrx) [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) [Amble](https://thisglp.com/reviews/amble) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the tablet really the same price? On semaglutide, yes: $129 either way. On tirzepatide the tablet is cheaper, $199 against $229 for the injection. Why does that matter? Because most sellers price the forms apart, so a reader is usually trading routine against cost. Here the tablet never costs more. Does the price hold as the dose rises? Not stated. Treat both figures as opening rates and confirm the ladder at the intake. Is DoctorAdam expensive compared with other GLP-1 telehealth sellers? DoctorAdam publishes a starting figure of $129/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts DoctorAdam below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Dollar Dad Club reviews (2026): GLP-1 telehealth sellers | This GLP One injection price at every dose, a printed oral price, and a card charged when the plan is picked rather than after the doctor has looked at the case. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/dollar-dad-club Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Dose-proof injection price # Dollar Dad Club review One injection price at every dose, a printed oral price, and a card charged when the plan is picked rather than after the doctor has looked at the case. ## The verdict Dollar Dad Club prints $299 for a month of compounded oral semaglutide, or $199 once the code DAD100 is entered, and it promises the injection price will not move as the dose climbs. The $89 a month on the injection page is a twelve-month plan that checkout totals at $1,068, and the one-month injection plan is shown only after a name and an email have been handed over. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection · Oral Dose pricing Flat across doses From From $299/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Dollar Dad Club is a telehealth storefront pitched at fathers, although its FAQ says women use it too, and it sells compounded semaglutide as a weekly injection and as a daily tablet alongside compounded tirzepatide by injection. Hair-loss and erectile-dysfunction lines share the site, and the business does not take insurance for any of them. 1. ## Who writes the prescription, and what do they see? The prescription comes from a U.S.-licensed doctor who reviews a medical intake the buyer completes after checkout, with a reply promised within roughly 24 hours, and some states require a video, phone or chat consultation first. For patients in California, Massachusetts, Rhode Island and Vermont, the FAQ names the two physicians who will be assigned, Dr Jeffrey Shellenberger and Dr Marc Serota, with a license number beside each state. The order of events matters more here than on most storefronts, because the FAQ says the card is charged when a plan is selected, which is before the intake and before any doctor has read it. Orders can be canceled until they ship and not afterward, and returns are refused on the ground that medication sales are final, so the decision to stop has to be made before the box leaves the pharmacy. 2. ## What happens when the dose goes up? The injection page answers the dose question in its own FAQ: the price stays the same at every dose, so the month spent at the top of the ladder costs what the first month cost. A patient switching from another prescriber can name a current dose during the intake and continue from it, though the pages say little about how each step up is decided beyond ongoing support from the care team. 3. ## What the price includes The oral line carries the plainest figure on the site, $299 for one month, with $100 taken off when the code DAD100 is entered, which is a coupon rather than the standing rate. On the injection side, $89 is the twelve-month plan, billed as $1,068 against an original $2,868, and the one-month plan of $189 against $339 appears only after the name and email steps. A today-only banner with a countdown sits across every page, but the timer is computed in the visitor's own browser rather than set to any fixed end date. 4. ## What it claims, and what it cites Every GLP-1 line here is compounded, prepared by accredited, state-licensed U.S. compounding pharmacies that the FAQ describes but never names, with the pharmacy chosen by the buyer's location. Compounded preparations are not FDA-approved and are not reviewed by the agency before they are dispensed, a point worth holding beside the homepage's talk of trusted, U.S.-made medication. ## Where it holds up, and where it does not - Strength: Price stated as flat at every dose - Strength: Oral one-month price printed on the page - Strength: Physicians named for four states - Strength: Medication, supplies and shipping in one price - Limitation: Card is charged before the medical intake - Limitation: Injection headline is a twelve-month rate - Limitation: One-month injection price needs name and email - Limitation: No returns once an order ships ## What the evidence says about this kind of treatment The assessment above is about Dollar Dad Club. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who expects to climb several doses, wants the monthly figure to stay where it started, and is comfortable paying before the doctor's review. Wrong for A buyer who wants the one-month injection price, or a way back after shipping, settled before handing over any details. ## The evidence behind what Dollar Dad Club prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Dollar Dad Club compares | Seller | Who it suits | Go | | --- | --- | --- | | Vytora Health | Buyers expecting several dose steps who want the bill to stay flat | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Amble](https://thisglp.com/reviews/amble) [Andrew Meds](https://thisglp.com/reviews/andrew-meds) [Apex MD](https://thisglp.com/reviews/apex-md) [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) [Arc-1](https://thisglp.com/reviews/arc-1) [Ark Health](https://thisglp.com/reviews/ark-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the $89 injection figure buy? Twelve months of treatment, which checkout totals at $1,068 in one charge. The one-month injection plan, $189 against an original $339, appears after the name and email steps of the intake. When is the card charged? When a plan is selected, according to the FAQ, which comes before the medical intake that a doctor reviews. An order can be canceled until it ships, and after that it cannot be canceled or refunded. Does the price rise with the dose? Not for the injection, whose page says the price stays the same at every dose and includes medication, supplies and cold-packed shipping in that one figure. Is Dollar Dad Club legit? Dollar Dad Club is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Dollar Dad Club expensive compared with other GLP-1 telehealth sellers? Dollar Dad Club publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Dollar Dad Club above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Dr. Arevitalize reviews (2026): GLP-1 telehealth sellers | This GLP The injection figures are twelve-month bundle rates; the capsules are quoted month by month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/dr-arevitalize Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A year-long bundle rate # Dr. Arevitalize review The injection figures are twelve-month bundle rates; the capsules are quoted month by month. ## The verdict Dr. Arevitalize quotes compounded semaglutide injections from $179 a month and tirzepatide injections from $269, but both figures are tied to a twelve-month bundle and no one-month injection rate is printed beside them. The oral capsules are quoted plainly at $299 and $349 a month, and behind all four products stands a named medical group and a list of four named pharmacies. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $179/mo Oral From $299/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Dr. Arevitalize is a cash-pay telehealth storefront operated by Dr.Arevitalize Health, Inc., and its only open category is weight loss, even though its FAQ also mentions skin care, men's health and hair care. The weight-loss page carries four GLP-1 products, semaglutide and tirzepatide each as a weekly injection or an oral capsule, plus a separately priced lab-test bundle. The footer describes the company's work as wellness education and care coordination, and calls the site itself informational. 1. ## Who writes the prescription, and what do they see? The FAQ assigns prescribing to Lion MD, a nationwide group led by Dr. Ana Lisa Carr, MD and Dr. Kelly Tenbrink, MD, each printed with an NPI number a patient can look up. A licensed clinician reads the two-minute assessment, and the FAQ says plainly that many members are approved on that questionnaire alone, with a short telehealth visit booked only when the clinician wants more information. What the clinician weighs before approving, and whether any bloodwork is requested, is not stated anywhere on the page. In the first week the sequence is short: the questions, a clinician's review and, if approved, a thirty-day supply shipped to the door. The product note lists the reviewed intake, the medication, round-the-clock live support and shipping inside the price. The FAQ promises no long-term commitments, which sits awkwardly beside injection prices quoted only on a twelve-month bundle. The intake itself opens by asking for a name, an email address and a phone number before it reaches a single health question. 2. ## What happens when the dose goes up? No milligram figure appears beside any of the four products, so a reader cannot see what a thirty-day supply holds in the first month or in the fourth, when most schedules have climbed. Whether the $179 bundle rate or the capsule rates hold as the dose rises is not stated either way. No page describes who approves a step up, how often a patient is reviewed, or what happens to the price when the dose changes, so the ladder is simply blank here. 3. ## What the price includes Each card offers one-, three-, six- and twelve-month plans and marks twelve months as the largest saving. For the injections, the twelve-month figure stands alone on the card, $179 a month for semaglutide and $269 for tirzepatide, and it is a term rate. The page does not say whether the bundle is paid at once or month by month. The capsules are quoted at $299 and $349 a month with no term attached. A buyer who wants a single month of injections will not find that price on the product page. 4. ## What it claims, and what it cites All four GLP-1 products are compounded, which means none of them is FDA-approved and none was reviewed by the agency before being dispensed. The FAQ names four partner pharmacies, Belmar Pharmacy, Strive Pharmacy, Epiq Scripts and Casa Pharma Rx, each with a phone number, though it never says which of them fills a particular prescription. The capsules are pharmacy-made preparations, and they should not be mistaken for an FDA-approved oral GLP-1 tablet. ## Where it holds up, and where it does not - Strength: Prescribing physicians printed with NPI numbers - Strength: Four pharmacies named, each with a phone - Strength: Capsule rates quoted by the month - Strength: Intake, medication, support and shipping in one price - Limitation: Injection rates appear only on a twelve-month bundle - Limitation: No one-month injection price on the page - Limitation: No milligram figure beside any product - Limitation: Approval can rest on the questionnaire alone - Limitation: Contact details requested before any health question ## What the evidence says about this kind of treatment The assessment above is about Dr. Arevitalize. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who plans a full year of injections and wants the prescribing group named up front. Wrong for A reader who wants to price a single month of injections before handing over contact details. ## The evidence behind what Dr. Arevitalize prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Dr. Arevitalize compares | Seller | Who it suits | Go | | --- | --- | --- | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [ARSYNL Rx](https://thisglp.com/reviews/arsynl-rx) [Ascend Medical](https://thisglp.com/reviews/ascend-medical) [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) [AskRx](https://thisglp.com/reviews/ask-rx) [Aspen](https://thisglp.com/reviews/aspen-health) [Aspire Health](https://thisglp.com/reviews/aspire-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $179 a month the price of one month of semaglutide? No. The card ties that figure to a twelve-month bundle, so it is the monthly equivalent of a year-long plan, and the product page prints no one-month injection rate at all. Who writes the prescription? Lion MD, a medical group that the FAQ says is led by Dr. Ana Lisa Carr, MD and Dr. Kelly Tenbrink, MD, with both physicians listed alongside their NPI numbers. Is there a long-term commitment? The FAQ says there is none and describes the plans as flexible, although the injection prices it shows are the rates for a twelve-month bundle rather than for a single month. Is Dr. Arevitalize expensive compared with other GLP-1 telehealth sellers? Dr. Arevitalize publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Dr. Arevitalize below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Dr. Gillis' Wellness Center reviews (2026): GLP-1 telehealth sellers | This GLP A physician-owned clinic in Oakland, Maine, with walk-in consultations and no contracts. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/dr-gillis-wellness-center Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Walk-in clinic, named physician # Dr. Gillis' Wellness Center review A physician-owned clinic in Oakland, Maine, with walk-in consultations and no contracts. ## The verdict Dr. Gillis' Wellness Center prices semaglutide at $200 a month. It is an in-person clinic first. The physician who runs it is named, and consultations are free. Visits are weekly, biweekly or monthly, at the patient's choice. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $200/mo Dose published Yes Prescription Required Pharmacy Not named The center is a private clinic at 8 Water Street in Oakland, Maine. Its weight-loss pages describe semaglutide and tirzepatide injections. The site also markets retatrutide, which is investigational, not FDA-approved; FDA says it cannot be used in compounding under federal law. It also sells oral weight-loss medicines, peptides and testosterone therapy. Telehealth appointments are offered alongside clinic visits. The clinic does not bill insurance. It takes HSA and FSA cards. 1. ## Who writes the prescription, and what do they see? The prescriber is Dr. Gillis, an osteopathic physician and surgeon licensed in Maine. The site states he holds privileges at MaineGeneral and St. Mary's. Consultations are free, every Wednesday afternoon, with no appointment needed. The patient brings pre-screening and consent forms to that visit. The evaluation for tirzepatide is stated to happen on site. Treatment can start the same day as the consultation. Staff teach the first injection in the clinic and observe briefly afterward. The remaining injections go home with the patient. Staff will give the weekly injection in the office on request. A follow-up visit comes before the last injection in each supply. 2. ## What happens when the dose goes up? Dose changes are made at the follow-up visit, after weight is reviewed. The site states a micro-dosing approach: the lowest dose for the shortest time. A linked pricing sheet lists higher charges at higher semaglutide and tirzepatide doses. The sheet does not specify how much treatment time each charge covers. Confirm the prescribed dose, supply and refill cost with the clinic. 3. ## What the price includes Semaglutide is $200 a month on the Medication Info & Pricing page. No long-term contract is required. Tirzepatide starts at $300 a month on the same page. A linked sheet lists semaglutide from $225 and tirzepatide from $325, with a $25 cash discount. That arithmetic matches the page headlines, but the sheet does not independently state a billing interval. Confirm the payment method and total before treating either headline as your ongoing bill. The FAQ lists a discount for paying in cash, a referral credit and a rewards program. A lower figure on the homepage is a Seize the Deal voucher. Treat that voucher as a promotion, not the monthly price. 4. ## What it claims, and what it cites The site does not say on the pricing page whether its [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded or branded. The FAQ says compounded [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) can be discussed for eligible patients. Compounded medications are not FDA-approved. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The prescribing physician is named - Strength: Free walk-in consultations every Wednesday - Strength: No long-term contracts are required - Strength: Injection teaching in the clinic - Limitation: No pharmacy is named - Limitation: Semaglutide supply type is not stated - Limitation: Clinic visits are in Oakland, Maine - Limitation: Dose-price sheet does not state the supply interval ## What the evidence says about this kind of treatment The assessment above is about Dr. Gillis' Wellness Center. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Central Maine patient who wants a named physician and in-person follow-up. Wrong for A buyer outside Maine who wants a fully remote service with published dose pricing. ## The evidence behind what Dr. Gillis' Wellness Center prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Dr. Gillis' Wellness Center compares | Seller | Who it suits | Go | | --- | --- | --- | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Auren Rx](https://thisglp.com/reviews/auren-rx) [AVARA Rx](https://thisglp.com/reviews/avara-rx) [Avono Health](https://thisglp.com/reviews/avono-health) [AZ Health](https://thisglp.com/reviews/az-health) [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) [Bayan Health](https://thisglp.com/reviews/bayan-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost at Dr. Gillis' Wellness Center? $200 a month is the page headline. Its linked dose-price sheet starts at $225 with a $25 cash discount; higher doses cost more. Confirm your supply and payment terms. No contract is required. Is the homepage starting-dose offer the monthly price? No. It is a Seize the Deal voucher. The pricing page states the monthly figure. Do I have to go to the clinic? Consultations are held in Oakland, Maine. Telehealth appointments are also offered. Is Dr. Gillis' Wellness Center expensive compared with other GLP-1 telehealth sellers? Dr. Gillis' Wellness Center publishes a starting figure of $200/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Dr. Gillis' Wellness Center above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 15, 2026. Terms can change. - [Clinic medication pricing](https://www.drgilliswellnesscenter.com/Medication-information-pricing) - [Clinic dose and cash-discount sheet](https://irp.cdn-website.com/a0f63d22/files/uploaded/Pricing_+%28__CASH+DISCOUNT+ON+SEMAGLUTIDE+-+TIRZEPATIDE%29+_Prices+subject+to+change-800a3a3b.pdf) - [FDA: unapproved GLP-1 medicines](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # DrBrainRx reviews (2026): GLP-1 telehealth sellers | This GLP A single medication price per molecule, and a required monthly care fee that sits outside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/drbrainrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A price plus a required fee # DrBrainRx review A single medication price per molecule, and a required monthly care fee that sits outside it. ## The verdict On the product pages, one month of semaglutide is $199 and one month of tirzepatide is $299. A required $25 monthly Care Access plan makes the real figures $224 and $324. The homepage's $129 and $249 are prepaid six-month rates. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 21 From From $224/mo Prescription Required Compounded Yes — not FDA-approved Availability 21 states DrBrainRx sells both molecules by injection. Each figure covers a four-week vial. The stated dose ranges are 0.25 to 2.5 milligrams weekly and 2.5 to 15. 1. ## Who writes the prescription, and what do they see? The Care Access plan is what the pages say the prescriber relationship costs. It buys dose titration and support, is stated as required, and is cancellable at any time. That is more detail about the clinical side than most sellers publish. Two things are separated here that are usually blended. The medication has a price and the clinical support has its own. A reader can see what each costs, which is unusual, and must add them to get a monthly figure. 2. ## What happens when the dose goes up? Each product page names its weekly dose range and sells one price. Neither page now says whether that price holds as the dose rises. A single listed price is not the same as a stated flat rate, so the dose question is not answered. 3. ## What the price includes $199 plus the required $25 is $224 a month, and $299 plus $25 is $324. Six months paid monthly comes to $1,344 or $1,944. The homepage figures of $129 and $249 assume a six-month prepayment, $774 or $1,494 upfront, and exclude the plan fee. Each figure covers a four-week vial rather than a calendar month, so a heavy year would carry a thirteenth fill. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named on the pages. ## Where it holds up, and where it does not - Strength: Prescribing states named on the page - Strength: Milligram ranges published for both - Strength: The required fee is disclosed, not hidden - Strength: Care Access is cancellable at any time - Limitation: The headline omits a required $25 - Limitation: A four-week vial is not a calendar month - Limitation: Prescribing limited to 21 states - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about DrBrainRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in one of the 21 prescribing states who will add the care fee to the headline. Wrong for A reader comparing headline figures without adding the required fee. ## The evidence behind what DrBrainRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How DrBrainRx compares | Seller | Who it suits | Go | | --- | --- | --- | | EdgeRx | Readers who want a named compounding pharmacy and will check availability first | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | Concierge MD LA | Readers who want one number covering care and medication and can commit four months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Believe Health](https://thisglp.com/reviews/believe-health) [Better U Care](https://thisglp.com/reviews/better-u-care) [BetterMe Rx](https://thisglp.com/reviews/betterme-rx) [BeyondMD](https://thisglp.com/reviews/beyondmd) [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) [BiltRx](https://thisglp.com/reviews/biltrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 the whole cost? No. A $25 monthly Care Access plan is stated as required, which makes the real figure $224 a month. Why does the homepage show $129 and $249? Those are per-month equivalents of the six-month prepaid bundles, $774 for semaglutide and $1,494 for tirzepatide. Bought a month at a time, the rates are $199 and $299. Does the price rise as my dose goes up? The pages do not say. Each lists one price beside a dose range of 0.25 to 2.5 milligrams on semaglutide and 2.5 to 15 on tirzepatide. What does the Care Access plan buy? Dose titration and support, per the product page. It is cancellable at any time, though the medication price assumes it is held. Is DrBrainRx legit? DrBrainRx is a GLP-1 telehealth sellers service. Its stated availability: 21 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is DrBrainRx expensive compared with other GLP-1 telehealth sellers? DrBrainRx publishes a starting figure of $224/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts DrBrainRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # DreamHug Medical reviews (2026): GLP-1 telehealth sellers | This GLP Both figures are the longest-plan tier. The one-month rate is higher and is not published. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/dreamhug-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A floor, not a rate # DreamHug Medical review Both figures are the longest-plan tier. The one-month rate is higher and is not published. ## The verdict DreamHug Medical publishes from $188 a month for semaglutide and from $238 for tirzepatide. Both are the longest-plan tier. The one-month rate is not itemized anywhere. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $188/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states DreamHug Medical sells both molecules by injection. Semaglutide is combined with cyanocobalamin and tirzepatide with L-carnitine. Fifty states are covered. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages name formulations rather than clinicians. The intake is not documented. The word to read is from. A figure with from in front of it is a floor. The rate a monthly buyer pays is higher and the pages do not say by how much. 2. ## What happens when the dose goes up? Nothing is published about dose. No milligram figure appears beside either price. A floor price with no dose attached cannot be compared against a rate that carries one. 3. ## What the price includes $188 buys the longest plan, not a month. Six months at it is $1,128 and only for a buyer on that plan. A reader on a shorter term pays an unpublished figure. Ask for it in writing before ordering. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Coverage in all fifty states - Strength: Both formulations described by name - Strength: The word from is used honestly - Limitation: The one-month rate is not published - Limitation: Both figures are a floor, not a rate - Limitation: No milligram dose stated anywhere - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about DreamHug Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader on the longest plan who wants a wide coverage list. Wrong for A reader buying one month, since that price is not published. ## The evidence behind what DreamHug Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How DreamHug Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | Effecty | Readers ready to commit a year for the lowest rung, or to pay more for a monthly bill | | | DudeMeds | Readers who want a 503B facility and will commit to a kit to reach the lower rate | | | Concierge MD LA | Readers who want one number covering care and medication and can commit four months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Bionomy Health](https://thisglp.com/reviews/bionomy-health) [Bioverse](https://thisglp.com/reviews/bioverse) [Blis MD](https://thisglp.com/reviews/blis-md) [Bliv](https://thisglp.com/reviews/bliv) [Bloom MD](https://thisglp.com/reviews/bloommd) [BloomWell Rx](https://thisglp.com/reviews/bloomwell-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $188 what a month costs? Only on the longest plan. The one-month rate is higher and is not itemized on any page. What dose does it buy? No milligram figure is published beside either price. Where does DreamHug ship? All fifty states are recorded. Is DreamHug Medical legit? DreamHug Medical is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is DreamHug Medical expensive compared with other GLP-1 telehealth sellers? DreamHug Medical publishes a starting figure of $188/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts DreamHug Medical below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # DudeMeds reviews (2026): GLP-1 telehealth sellers | This GLP Each lower figure is a commitment kit that strikes the month-to-month rate through beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/dudemeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Monthly rate behind a commit kit # DudeMeds review Each lower figure is a commitment kit that strikes the month-to-month rate through beside it. ## The verdict DudeMeds charges $295 a month for semaglutide and $433 for tirzepatide, month to month. Commitment kits bring those to $175 and $233. Both lines are 503B compounded. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $295/mo Prescription Required Compounded Yes — not FDA-approved DudeMeds sells both molecules by injection. Both are 503B compounded. Each line is sold month to month or in a commitment kit billed as a block. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages list products and totals. The intake is not documented anywhere. Naming a 503B outsourcing facility is a real disclosure. A 503B registers with the FDA and is inspected on a schedule a 503A is not. That is a fact about the supply chain, not about the clinician. 2. ## What happens when the dose goes up? Nothing is published about dose on the semaglutide line. The tirzepatide refill kit names a steady-state dose of 5 mg a week. No other milligram figure appears. 3. ## What the price includes Semaglutide is $295 month to month. The six-month commit kit starts at $175 a month, billed $525 for its first part. Tirzepatide is $433 month to month, or $233 a month on a twelve-week refill billed $699. New tirzepatide patients start on a three-month kit billed $747. 4. ## What it claims, and what it cites Both lines are 503B compounded. A registered outsourcing facility prepares them. The FDA does not review a compounded preparation before dispensing. The facility itself is not named. ## Where it holds up, and where it does not - Strength: 503B compounding is stated plainly - Strength: The monthly rate is printed beside every kit - Strength: Block totals published, not just rates - Limitation: The lower rates need a commitment kit - Limitation: The advertised $149 is on no product page - Limitation: No semaglutide milligram dose stated - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about DudeMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a 503B facility and will commit to a kit to reach the lower rate. Wrong for A reader expecting the advertised figure, or the kit rate without the commitment. ## The evidence behind what DudeMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How DudeMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | EdgeRx | Readers who want a named compounding pharmacy and will check availability first | | | Effecty | Readers ready to commit a year for the lowest rung, or to pay more for a monthly bill | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) [Blue Sky MD](https://thisglp.com/reviews/blue-sky-md) [Bodi Envi](https://thisglp.com/reviews/bodi-envi) [Bon Health](https://thisglp.com/reviews/bon-health) [boostAGErx](https://thisglp.com/reviews/boostagerx) [Boston Medical Group](https://thisglp.com/reviews/boston-medical-group) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I get the advertised $149? Not from any product page. The lowest published figure is the $175 semaglutide commit kit. What does a single month cost? $295 for semaglutide and $433 for tirzepatide. Those are the figures struck through beside each kit. What does 503B mean? A registered outsourcing facility, inspected by the FDA on a schedule a 503A is not. The preparation itself is still not FDA-reviewed before dispensing. Is DudeMeds expensive compared with other GLP-1 telehealth sellers? DudeMeds publishes a starting figure of $295/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts DudeMeds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Eclipse Medical Wellness reviews (2026): GLP-1 telehealth sellers | This GLP A Colorado nurse practitioner's weight-loss practice that prices the care and sends the prescription to a pharmacy the patient pays directly. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/eclipse-medical-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A care fee, with the drug billed apart # Eclipse Medical Wellness review A Colorado nurse practitioner's weight-loss practice that prices the care and sends the prescription to a pharmacy the patient pays directly. ## The verdict Eclipse Medical Wellness sells clinician-led weight-loss care to Colorado residents, not medication. Its three-month starter program costs $500 and covers an evaluation, baseline labs and follow-up. The drug goes to a pharmacy and is paid for separately, so no all-in monthly figure exists. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 1 Prescription Required Pharmacy Named Labs Included Availability Colorado Eclipse is a small virtual practice offering medical weight loss and urgent care for minor illness. It serves Colorado only. The weight-loss program pairs telehealth visits with quarterly labs, medication management and nutrition support. 1. ## Who writes the prescription, and what do they see? The practice names its clinician: Jeriah-Travis Mendaro, a board-certified family nurse practitioner. His stated background spans emergency medicine, medical-surgical care and wound care. The medications page states that a prescription is not guaranteed and depends on the evaluation. Three care plans are published. The starter program runs three months, with follow-up by video or phone. A monthly-visit plan and a text-based plan for stable patients each charge an initial visit fee plus a monthly fee. A stable patient who needs real-time follow-up moves to the monthly-visit plan. Every plan includes one prior authorization attempt. 2. ## What happens when the dose goes up? Dose adjustment support and side-effect monitoring appear in every plan. The care fee does not change with dose. What the drug costs at each step depends on the pharmacy and on insurance, which sit outside the care fee. 3. ## What the price includes The $500 starter works out to $166.67 a month of care, before any medication. The monthly plans add a one-time initial visit fee. The practice's cost resource page lists a named 503A compounding pharmacy's monthly figures for compounded semaglutide and tirzepatide, stated as flat across doses. Those are the pharmacy's prices, billed by the pharmacy, not by the practice. 4. ## What it claims, and what it cites The practice discusses FDA-approved options by brand, including [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), Zepbound, Saxenda and Foundayo. It also states that compounded options are available. Compounded medications are not FDA-approved, and the resource page says so about the pharmacy it lists. Which product a patient receives is decided at evaluation. ## Where it holds up, and where it does not - Strength: Prescribing clinician named on the site - Strength: Baseline and quarterly labs included - Strength: One prior authorization attempt included - Strength: Branded and compounded options both discussed - Limitation: Serves Colorado residents only - Limitation: Medication is paid separately to a pharmacy - Limitation: No all-in monthly figure is published - Limitation: Care fee and drug bill arrive separately ## What the evidence says about this kind of treatment The assessment above is about Eclipse Medical Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Colorado resident who wants labs and a named clinician, and may use insurance for the drug. Wrong for Anyone outside Colorado, or a buyer looking for one all-in monthly price. ## The evidence behind what Eclipse Medical Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Eclipse Medical Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | MultiMedRx | A reader with insurance who needs a branded GLP-1 covered rather than sold | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Breeze Meds](https://thisglp.com/reviews/breeze-meds) [Brello Health](https://thisglp.com/reviews/brello-health) [Brightmeds](https://thisglp.com/reviews/brightmeds) [Cabana](https://thisglp.com/reviews/cabana) [CaliberRx](https://thisglp.com/reviews/caliberrx) [California Trim Clinic](https://thisglp.com/reviews/california-trim-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is medication included in the $500? No. The $500 covers three months of care, labs and follow-up. The prescription goes to a pharmacy, which bills the patient directly. Who will I see? Jeriah-Travis Mendaro, a board-certified family nurse practitioner, named on the practice's about page. Can insurance pay for the drug? Possibly. Each plan includes one prior authorization attempt, and coverage depends on the patient's plan. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Eden reviews (2026): GLP-1 sellers by price | This GLP The membership costs the same on either molecule, so the hundred dollars between them is the medication and nothing else. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/eden Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The premium is all drug # Eden review The membership costs the same on either molecule, so the hundred dollars between them is the medication and nothing else. ## The verdict Eden bills $198 a month for compounded semaglutide and $298 for tirzepatide. Each figure is $99 of medication plus a $99 membership the GLP-1 page states is required. The membership does not change between molecules. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 sellers by price Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $198/mo Prescription Required Compounded Yes — not FDA-approved Eden sells both molecules by injection. There is no oral line. The catalog around them is wide, covering hair, skin and peptide products, but the GLP-1 lines are priced on their own. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe the products and the membership rather than the clinician behind either. Who writes the prescription is not stated. A prescription is required. The membership is the part worth understanding. It is charged monthly whether or not a fill goes out, and it is the same $99 on either molecule. 2. ## What happens when the dose goes up? Nothing on either line states what happens to the price as the dose climbs. The membership half will not move, because it is flat. The medication half is unstated. 3. ## What the price includes Six months of semaglutide comes to $1,188 and tirzepatide to $1,788. Half of each total is membership. Because that half is identical on both lines, the $100 gap between them is pure drug cost. That is unusually legible. Most sellers here fold a service fee into the headline and leave the premium unreadable. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them to order. The FDA does not review a compounded preparation before it is dispensed. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The membership is disclosed on the product page - Strength: The same fee applies to both molecules - Strength: The drug premium is readable as a result - Limitation: The advertised figure is half the bill - Limitation: The fee is charged whether or not a fill goes out - Limitation: No pharmacy named on either line - Limitation: No state coverage list recorded ## What the evidence says about this kind of treatment The assessment above is about Eden. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer comparing the true cost of the two molecules. Wrong for A buyer who wants one charge a month. ## The evidence behind what Eden prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Eden compares | Seller | Who it suits | Go | | --- | --- | --- | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | PCOS Sisters | Women with PCOS in a covered state who want a named specialist and monthly visits | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 sellers by price reviews: [Belle Health](https://thisglp.com/reviews/belle-health) [bmiMD](https://thisglp.com/reviews/bmimd) [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)[Collective](https://thisglp.com/reviews/collective) [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) [Direct Meds](https://thisglp.com/reviews/direct-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month at Eden really cost? $198 for compounded semaglutide and $298 for tirzepatide. Each is $99 of medication plus the $99 membership. Can I skip the membership? No. The GLP-1 page states it is required to be prescribed. Why is tirzepatide exactly $100 more? Because the membership half is identical. The whole difference sits in the medication. Is Eden expensive compared with other GLP-1 sellers by price? Eden publishes a starting figure of $198/mo. Across the 402 GLP-1 sellers by price we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Eden above the median. The other 178 GLP-1 sellers by price we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller by price](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Edessa reviews (2026): GLP-1 telehealth sellers | This GLP The number on the front of the site is the six-month rate. A single month costs forty-four dollars more. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/edessa Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The homepage figure is a prepay # Edessa review The number on the front of the site is the six-month rate. A single month costs forty-four dollars more. ## The verdict Edessa publishes $179 a month for injected semaglutide, $160 on three months and $135 on six. The tablet is $229 to $199 and tirzepatide $239 to $209. Coverage is 51 jurisdictions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 51 Injection From $179/mo Oral From $229/mo Prescription Required Compounded Yes — not FDA-approved Availability 51 jurisdictions Edessa sells both molecules by injection and semaglutide as a tablet. Each line publishes three plan lengths in one table. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages present plan tables rather than describing a clinician or a review schedule. Publishing all three rungs in one table is the useful act. Putting the six-month rate on the homepage without its condition is the misleading one. 2. ## What happens when the dose goes up? The rates are recorded as flat across doses, so an escalation should not move them. No milligram appears beside any figure. 3. ## What the price includes Six months of the injection is $810 prepaid or $1,074 paid monthly, a difference of $264. The tablet is $1,194 or $1,374 and tirzepatide $1,254 or $1,434. Committing six months saves most on the injection and least on tirzepatide. 4. ## What it claims, and what it cites All three lines are compounded. A pharmacy prepares them to order, and the FDA does not review a compounded preparation before dispensing. ## Where it holds up, and where it does not - Strength: All three plan lengths in one table - Strength: Coverage in 51 jurisdictions - Strength: Flat across doses on every line - Strength: The monthly option is priced too - Limitation: The homepage figure needs six months - Limitation: A single month costs $44 more - Limitation: No milligram published anywhere - Limitation: The pharmacy is not identified ## What the evidence says about this kind of treatment The assessment above is about Edessa. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will read the plan table rather than the homepage banner. Wrong for A reader budgeting from $135 while intending to pay monthly. ## The evidence behind what Edessa prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Edessa compares | Seller | Who it suits | Go | | --- | --- | --- | | Roboclinic | Readers ready to commit a full year and wanting the discount that buys | | | MedLeanRx | Readers who happen to live where this seller operates | | | Recovery Delivered | Readers who reward a seller for publishing the number that costs it sales | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [California Trim Clinic](https://thisglp.com/reviews/california-trim-clinic) [Call-On-Doc](https://thisglp.com/reviews/call-on-doc) [Candor Rx](https://thisglp.com/reviews/candor-rx) [Care Bare Rx](https://thisglp.com/reviews/care-bare-rx) [Care Clinics](https://thisglp.com/reviews/care-clinics) [Carocare Wellness](https://thisglp.com/reviews/carocare-wellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $135 the monthly price? No. It is the six-month prepay rate. A single month is $179. What does committing six months save? $44 a month on the injection, or $264 over the period. Does the price rise with the dose? It is recorded as flat across doses on every line. Is Edessa legit? Edessa is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Edessa expensive compared with other GLP-1 telehealth sellers? Edessa publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Edessa below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # EdgeRx reviews (2026): GLP-1 telehealth sellers | This GLP A seller that names who compounds its medication also says its protocols are not currently available to buy. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/edgerx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Names the pharmacy, not selling # EdgeRx review A seller that names who compounds its medication also says its protocols are not currently available to buy. ## The verdict EdgeRx publishes $199 a month for semaglutide and $225 for tirzepatide, names Strive Pharmacy as the 503A that compounds both, and states on each protocol page that the protocol is not currently available for purchase. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 46 From From $199/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability 46 states EdgeRx sells both molecules by injection, each formulated with glycine and B12, with coverage recorded across 46 states and a named compounding pharmacy behind both lines. 1. ## Who writes the prescription, and what do they see? The prescriber is not described, but the pharmacy is, and on a question about who stands behind the medicine that is the rarer half of the answer. A buyer can look up a 503A registration in a way they cannot look up an unnamed one. Naming Strive Pharmacy is a real disclosure and it deserves saying plainly, because a compounded vial from an unnamed facility is a product whose chain of custody a reader has no way to check. The availability notice sits awkwardly beside it: the published rates describe something the pages say cannot currently be bought. 2. ## What happens when the dose goes up? Nothing is published about what either figure does at a higher dose. The glycine and B12 formulation is described in more detail than the dose ladder is, which inverts the usual priority for a buyer about to spend four months escalating. 3. ## What the price includes Semaglutide is $199 a month and tirzepatide $225, each for a one-month supply with free shipping. Six months at those rates is $1,194 and $1,350. Those totals assume the protocols become purchasable, which the pages currently say they are not, so treat both as quoted rather than available. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured and are prepared by Strive Pharmacy, a 503A facility the seller names. The FDA does not review a compounded preparation before it is dispensed, and a named pharmacy does not change that — it changes only whether a reader can find out who made it. ## Where it holds up, and where it does not - Strength: Names Strive Pharmacy as the compounder - Strength: Coverage recorded across 46 states - Strength: Free shipping stated on both lines - Strength: The formulation is described in detail - Limitation: Both protocols say not available to purchase - Limitation: Nothing published about dose pricing - Limitation: The availability notice is easy to miss ## What the evidence says about this kind of treatment The assessment above is about EdgeRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a named compounding pharmacy and will check availability first. Wrong for A reader who needs to order today. ## The evidence behind what EdgeRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How EdgeRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Contour Health | Patients who prefer clinician continuity and control over each refill | | | DrBrainRx | Readers in the 21 prescribing states who will add the care fee to the headline | | | Elevated Health | Readers who want to see every rung before choosing a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [CeliaRx](https://thisglp.com/reviews/celia-rx) [Center for Medical Weight Loss (CMWL)](https://thisglp.com/reviews/center-for-medical-weight-loss)[Cielo](https://thisglp.com/reviews/cielo) [Citizen Meds](https://thisglp.com/reviews/citizen-meds) [Claya](https://thisglp.com/reviews/claya) [Clinic Secret](https://thisglp.com/reviews/clinic-secret) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I actually buy this? The protocol pages for both molecules state the protocol is not currently available for purchase, so the published rates describe something a reader should confirm is buyable before planning around it. Who compounds the medication? Strive Pharmacy, a 503A facility, which EdgeRx names on its own pages, and a named 503A is checkable against a public registration. What do the two lines cost? $199 a month for semaglutide and $225 for tirzepatide, each a one-month supply with free shipping. Is EdgeRx legit? EdgeRx is a GLP-1 telehealth sellers service. Its stated availability: 46 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is EdgeRx expensive compared with other GLP-1 telehealth sellers? EdgeRx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts EdgeRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Effecty reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide is sold at four plan lengths. Monthly billing is the dearest rung. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/effecty Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four plan lengths, one ladder # Effecty review Semaglutide is sold at four plan lengths. Monthly billing is the dearest rung. ## The verdict Effecty publishes $170 a month for semaglutide and $235 for tirzepatide, billed monthly. Longer semaglutide plans run down to $130 a month billed yearly. Coverage is all fifty states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $170/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Effecty sells both molecules by injection. Both rates are stated flat across doses. Fifty states are covered. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe plans, not clinicians. The intake is not documented. The structure is a ladder, not one plan. A reader picks a term. Each longer term lowers the monthly figure. 2. ## What happens when the dose goes up? Both rows are flat, so the rate holds as the dose rises. Nothing describes what a clinician reviews at a dose increase. The price question is answered and the care question is not. 3. ## What the price includes Semaglutide is $170 billed monthly, $150 on three months, $140 on six and $130 on twelve. A year is $2,040 month to month or $1,560 billed yearly. Tirzepatide is $235 billed monthly, or $2,820 a year. Its longer terms are cheaper per month too. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Flat across doses on both molecules - Strength: Coverage in all fifty states - Strength: Four plan lengths published on semaglutide - Limitation: The lowest rate needs a year billed at once - Limitation: Monthly billing is the dearest rung - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Effecty. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit a year and wanting the rate fixed across it. Wrong for A reader expecting the yearly rate on a monthly bill. ## The evidence behind what Effecty prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Effecty compares | Seller | Who it suits | Go | | --- | --- | --- | | Direct Meds | A reader content to buy by the quarter who will redo the per-day math | | | Elevated Health | Readers who want to see every rung before choosing a term | | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [CLYR Health](https://thisglp.com/reviews/clyr-health) [Coivas](https://thisglp.com/reviews/coivas) [Concierge MD LA](https://thisglp.com/reviews/concierge-md-la) [Contour Health](https://thisglp.com/reviews/contour-health) [Cora Health](https://thisglp.com/reviews/cora-health) [CoraDoc](https://thisglp.com/reviews/coradoc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $130 the monthly price? Only billed yearly, on semaglutide. Billed monthly it is $170. What does a year cost? $1,560 for semaglutide billed yearly, or $2,040 month to month. Tirzepatide is $2,820 month to month. Can I pay month to month? Yes. Semaglutide is $170 and tirzepatide $235, billed monthly. Is Effecty legit? Effecty is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Effecty expensive compared with other GLP-1 telehealth sellers? Effecty publishes a starting figure of $170/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Effecty below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Elara Health and Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Two figures sit on every card, and the lower one is a prepayment for thirteen months. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elara-health-and-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Thirteen months, one charge # Elara Health and Wellness review Two figures sit on every card, and the lower one is a prepayment for thirteen months. ## The verdict Elara Health bills compounded semaglutide at $249 a month and tirzepatide at $339, with a cheaper equivalent printed beside each. Those equivalents are $2,327 and $3,497 taken in a single charge covering thirteen months, and the term is stated rather than buried. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 51 From From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Labs Included Elara Health sells physician-guided GLP-1 treatment with medication, labs and coaching in one program. Compounded semaglutide comes as an injection or an oral tablet, and tirzepatide as an injection. Supplements are sold separately and excluded from the plan price. 1. ## Who writes the prescription, and what do they see? A board-certified physician reviews the intake, prescribes when appropriate, and stays available for dose adjustments through the program. Every prescription is reviewed before dispensing. The care team is reachable by phone or email during business hours rather than around the clock. One program covers medication, physician care, quarterly metabolic labs and certified health coaching. Labs are drawn twice a year and read alongside the health history. Medication ships monthly from one of four named pharmacy partners. 2. ## What happens when the dose goes up? Dose adjustment is described as something the prescribing physician handles as the program runs, with labs due each quarter to inform it. No milligram figure or dose ladder is published on the pricing cards. Nothing states whether the monthly figure moves as the dose does, so a buyer cannot price the ladder in advance. 3. ## What the price includes The monthly rungs are $249 for the semaglutide injection, $279 for the oral tablet and $339 for tirzepatide. Each card also shows a per-month equivalent that only exists if the whole term is paid at once, and that term is thirteen months rather than twelve. A welcome code takes $50 off the first month. 4. ## What it claims, and what it cites Every GLP-1 line is compounded rather than manufactured, prepared by one of four state-licensed 503A partners the site names: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy and Triad Rx. The site states directly that compounded medications are not FDA-approved. Naming the compounder at all is rare in this category. ## Where it holds up, and where it does not - Strength: Four compounding pharmacies are named - Strength: Quarterly metabolic labs are included - Strength: Certified health coaching is inside the price - Strength: The thirteen-month term is stated on the card - Strength: Compounded status is disclosed in plain words - Limitation: The cheaper rate needs $2,327 in one charge - Limitation: The prepaid term runs thirteen months, not twelve - Limitation: No dose ladder or milligram figure is published - Limitation: Care team hours are business hours only ## What the evidence says about this kind of treatment The assessment above is about Elara Health and Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants labs and coaching bundled and can read a prepaid term for what it is. Wrong for A buyer comparing the equivalent figure against another seller's monthly bill. ## The evidence behind what Elara Health and Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Elara Health and Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Joi + Blokes | Buyers who want coaching bundled in and are budgeting for the quarter rather than the first month | | | Vita Bella | Buyers who will use the wider catalog the membership unlocks rather than a GLP-1 alone | | | Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [CoraDoc](https://thisglp.com/reviews/coradoc) [Corsica Health](https://thisglp.com/reviews/corsica-health) [Curex](https://thisglp.com/reviews/curex) [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) [DoctorAdam](https://thisglp.com/reviews/doctoradam) [Dollar Dad Club](https://thisglp.com/reviews/dollar-dad-club) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the $179 equivalent require? A single payment of $2,327 covering thirteen months. The figure billed monthly is $249. Are labs included? Yes. Quarterly metabolic labs are described as part of every plan, alongside physician care and coaching. Which pharmacy prepares the medication? One of four named 503A partners: RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy or Triad Rx. Is Elara Health and Wellness expensive compared with other GLP-1 telehealth sellers? Elara Health and Wellness publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Elara Health and Wellness above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Elara MD reviews (2026): GLP-1 telehealth sellers | This GLP Elara MD publishes dose-linked prices for personalized GLP-1 products, but generic product labels leave the exact medicine and a conflicting starting-price claim unresolved. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elara-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Ask for the actual ingredient # Does Elara MD sell a GLP-1? Elara MD publishes dose-linked prices for personalized GLP-1 products, but generic product labels leave the exact medicine and a conflicting starting-price claim unresolved. ## The verdict Elara’s published dose ladder is useful, but it cannot replace a clear ingredient name and a consistent quote. Ask which active drug, preparation and pharmacy apply to the proposed prescription. The product-page starting figure differs from the homepage ladder, so neither should be treated as a settled continuation offer. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Dose pricing Rises with dose Prescription Required Compounded Yes — not FDA-approved Elara MD markets medical weight management and other wellness treatments. Its weight-loss products use personalized GLP-1 and GLP-1/GIP labels, including B12 combinations. Those category names describe a treatment approach without fully identifying the prescribed medicine. 1. ## Who writes the prescription, and what do they see? The product page describes a consultation reviewing medical history, lifestyle and underlying conditions, available in person or virtually. The terms distinguish participating providers and pharmacies. Confirm the responsible clinician and state availability before paying for treatment. Elara says it develops a treatment plan with nutritional guidance and schedules follow-up visits to assess progress. Public information does not establish one visit frequency or urgent-response arrangement. Ask how to reach the prescriber if tolerability changes between appointments. 2. ## What happens when the dose goes up? Publishing weekly strengths offers more detail than a bare starting-price banner. It is still not a patient-specific [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule, particularly when the active drug is not clearly named. Discuss the formulation and each proposed adjustment with the clinician rather than interpreting the storefront’s ladder as dosing advice. 3. ## What the price includes The homepage links higher weekly doses with higher monthly tiers. A separate product-page starting amount does not match the first homepage tier. Obtain one written price for your actual prescription, including the next refill and any professional or delivery charge, before comparing costs. 4. ## What it claims, and what it cites Elara describes personalized preparations made by specialty pharmacies and combinations with B12. The reviewed pages do not clearly name the active molecule behind each generic GLP-1 label. Do not assume it is a particular branded medicine; compounded products are not FDA approved. ## Where it holds up, and where it does not - Strength: Weekly strengths and price tiers shown - Strength: Follow-up visits described - Strength: Terms allow requesting a different pharmacy - Limitation: Exact active drug not clearly identified on reviewed pages - Limitation: Starting-price descriptions conflict - Limitation: Follow-up timing requires confirmation ## What the evidence says about this kind of treatment The assessment above is about Elara MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient willing to clarify the medicine, clinician and complete dose-specific quote before starting. Wrong for Someone who needs an unambiguous named drug and consistent public price before contacting the service. ## How Elara MD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) [DudeMeds](https://thisglp.com/reviews/dudemeds) [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) [Edessa](https://thisglp.com/reviews/edessa) [EdgeRx](https://thisglp.com/reviews/edgerx) [Effecty](https://thisglp.com/reviews/effecty) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does GLP-1 identify the exact medication? No. It is a drug-class label. Ask for the active ingredient, formulation and prescription details. Can I request my own pharmacy? The terms say to contact Elara before completing an order if you want a different pharmacy. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Treatment and dose pricing](https://elaramd.com/) - [Treatment information](https://elaramd.com/glp1/) - [Service and cancellation terms](https://elaramd.com/terms-of-use/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Elevate Health reviews (2026): GLP-1 telehealth sellers | This GLP The checkout starts on the monthly plan, and every cheaper line beneath it asks for months in advance. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elevate-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Monthly first, discounts below # Elevate Health review The checkout starts on the monthly plan, and every cheaper line beneath it asks for months in advance. ## The verdict Elevate Health sells compounded semaglutide at $299 a month and compounded tirzepatide at $449, and those are the plans its own checkout has already selected when a buyer arrives. The lower rungs listed beneath them are real, but each one is a three, six or twelve month plan, so the discount is bought with a commitment rather than handed out. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $299/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Included Elevate Health and Wellness is a New York company on Fifth Avenue that describes itself as a patient management platform, handling the administrative side for physicians who work under contract elsewhere. The catalog carries compounded semaglutide, compounded tirzepatide and a branded Zepbound program, alongside B12, NAD+ and glutathione, and the home page claims more than 35,000 patients and offers a free lab panel. 1. ## Who writes the prescription, and what do they see? The physicians are contracted by two telehealth networks, MDIntegrations and TelegraMD, which the footer names, while Elevate itself only supports them administratively. No individual clinician is named anywhere on the site, and nothing describes who a patient will speak with or how often. The provider is said to review the medical intake and decide the treatment route, and the FAQ sets the bar at a BMI of 30, or 27 with certain conditions. A patient fills in a medical intake, a provider reviews it, and medication arrives within seven to ten business days of approval, which puts close to two weeks between a decision and a first dose. Each shipment is described as a multi-dose vial with syringes, alcohol wipes and a supply of anti-nausea medication. Support is offered seven days a week, and the site says there are no long-term contracts and a patient can cancel at any time. 2. ## What happens when the dose goes up? The anti-[nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) supply packed in every box is the one concrete sign of how the site expects the early weeks of a rising dose to feel. The site says nothing about whether the monthly charge changes at a higher dose, and no milligram schedule appears anywhere, so the step from one dose to the next is left entirely to the provider's review. 3. ## What the price includes The semaglutide checkout lists $299 monthly, then $232, $183 and $158 a month on three, six and twelve month plans, with Affirm and Klarna offered for the longer terms. Tirzepatide follows at $449 monthly, then $296, $269 and $248. A $200 discount code is attached to the home page button, and cancellation is by email or phone, with a stated exception for a twelve-week program the site does not otherwise describe. 4. ## What it claims, and what it cites The two main lines are compounded by state-licensed pharmacies the site does not name, and the footer states they are not generic versions of [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review), Wegovy, [Mounjaro](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) or Zepbound. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The Zepbound program is the branded product, priced separately at $1,289 a month. ## Where it holds up, and where it does not - Strength: The monthly plan is the default at checkout - Strength: Anti-nausea medication ships in every box - Strength: A free lab panel is offered - Strength: Full refund if a provider declines treatment - Limitation: No clinician is named anywhere - Limitation: Delivery runs seven to ten business days - Limitation: No compounding pharmacy is named - Limitation: No milligram schedule is published ## What the evidence says about this kind of treatment The assessment above is about Elevate Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a month-to-month plan with anti-nausea medication in the box. Wrong for A buyer who needs medication within a few days, or wants to know the prescriber by name. ## The evidence behind what Elevate Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Elevate Health compares | Seller | Who it suits | Go | | --- | --- | --- | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EdgeRx](https://thisglp.com/reviews/edgerx) [Effecty](https://thisglp.com/reviews/effecty) [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) [Elevated Health](https://thisglp.com/reviews/elevated-health) [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) [ElixaMD](https://thisglp.com/reviews/elixamd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Elevate Health cost without a longer plan? The monthly subscription, which checkout selects by default, is $299 for compounded semaglutide and $449 for compounded tirzepatide, and the cheaper rungs all require three, six or twelve months. Who are the prescribers? Physicians contracted through MDIntegrations and TelegraMD, according to the footer, while Elevate handles administration and names no individual clinician. What comes in the shipment? A multi-dose vial, syringes, alcohol wipes and a supply of anti-nausea medication, delivered within seven to ten business days of approval. Is Elevate Health expensive compared with other GLP-1 telehealth sellers? Elevate Health publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Elevate Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Elevated Health reviews (2026): GLP-1 telehealth sellers | This GLP Four plan lengths on each molecule, with every figure printed rather than revealed at checkout. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elevated-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every rung published # Elevated Health review Four plan lengths on each molecule, with every figure printed rather than revealed at checkout. ## The verdict Elevated Health publishes a complete plan ladder on both molecules: semaglutide runs from $296 a month down to $187 on twelve months, and tirzepatide from $359 to $235. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $296/mo Prescription Required Compounded Yes — not FDA-approved Elevated Health sells both molecules by injection across four commitment lengths each, with a discounted first month at $196 or $259 before the standing rate begins. 1. ## Who writes the prescription, and what do they see? A prescription is issued before shipping and the pages are given over to the plan ladder rather than to the clinician, so a reader learns exactly what every commitment costs and nothing at all about who reviews the intake. The published ladder is the disclosure worth crediting here, because a seller that prints all four rungs has taken away the usual reason a buyer discovers the real rate only after the first month has been charged. 2. ## What happens when the dose goes up? Both rows are marked flat, which on a ladder like this one means the rung a buyer picks is the rate for the whole term regardless of where the dose goes. Nothing states what happens if a dose increase needs a larger vial mid-term, which is the one question the ladder does not answer. 3. ## What the price includes Semaglutide is $196 for a first month, then $296 month to month, $242 on three months, $229 on six and $187 on twelve. Tirzepatide follows the same shape at $259, then $359, $304, $281 and $235. The spread between the month-to-month rate and the annual one is $109 on semaglutide and $124 on tirzepatide, which is a large enough gap to be the real decision a reader makes here. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: All four rungs published on both lines - Strength: A discounted first month, stated as one - Strength: Flat at every dose within a term - Limitation: The month-to-month rate is high - Limitation: The best rate needs a twelve-month lock - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Elevated Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to see every rung before choosing a term. Wrong for A reader who wants a low rate without committing to a year. ## The evidence behind what Elevated Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Elevated Health compares | Seller | Who it suits | Go | | --- | --- | --- | | CoraDoc | Buyers who would rather pay a program once than carry a subscription they have to remember to cancel | | | Effecty | Readers ready to commit a year for the lowest rung, or to pay more for a monthly bill | | | DadVantage Men's Health | Readers who want the cost at a higher dose stated and will add the two outside charges | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Eloria](https://thisglp.com/reviews/eloria) [Emerge Weight Loss](https://thisglp.com/reviews/emerge-weight-loss) [eMI Aesthetics](https://thisglp.com/reviews/emi-aesthetics) [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the real monthly rate? It depends entirely on the term: $296 month to month for semaglutide, $242 on three months, $229 on six and $187 on twelve, with the first month discounted to $196. Is the first-month price the ongoing one? No, and the pages say so. $196 covers the first month and $296 is the standing month-to-month rate after it. How much does committing save? $109 a month on semaglutide between the month-to-month rate and the annual one, and $124 on tirzepatide, which over a year is the largest decision on offer here. Is Elevated Health expensive compared with other GLP-1 telehealth sellers? Elevated Health publishes a starting figure of $296/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Elevated Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ElitePhysiqMD reviews (2026): GLP-1 telehealth sellers | This GLP The headline is a member rate; the $89 monthly membership that unlocks it is priced separately. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elitephysiqmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A member rate plus a membership # ElitePhysiqMD review The headline is a member rate; the $89 monthly membership that unlocks it is priced separately. ## The verdict ElitePhysiqMD quotes compounded semaglutide from $179.10 a month, which is the member refill price. Membership itself is $89 a month, so a member pays about $268 in total. A one-time order skips the membership and comes to $278 with the exam and shipping. Tirzepatide follows the same shape: $315 plus membership, or $429 one-time. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $268/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider ElitePhysiqMD is a telehealth platform, trading at myepmd.com, selling compounded semaglutide and tirzepatide by weekly injection. Testosterone, erectile dysfunction, hair loss, peptide and supplement lines share the catalog. Coverage is stated for all fifty states. Payment accepts HSA and FSA cards. 1. ## Who writes the prescription, and what do they see? A board-certified physician meets each patient on a live video visit before prescribing. The medical director is named: Dr. Hridayesh Nat, an internist stated to be licensed in 51 U.S. jurisdictions. The platform states it does not employ the prescribing physicians or make prescribing decisions. The other physicians in the network are not named. A three-minute assessment leads to the video visit, and a prescription ships only after approval. Membership covers visit fees, overnight cold-pack shipping and 10% off every item while active. It renews automatically until canceled, and cancellation is stated to carry no penalty. The hub page adds a $39 activation charge. 2. ## What happens when the dose goes up? The product page describes a once-weekly injection titrated by the physician. No milligram schedule is published. Whether the refill price moves with the dose is not stated. The care team is said to monitor progress and adjust the plan. 3. ## What the price includes Semaglutide is $179.10 per refill for members, or $199 one-time plus a $49 exam and $30 shipping. Tirzepatide is $315 for members, or $350 one-time plus the same two charges. The $89 membership sits outside both member figures. The auto-refill button also states it adds a $49 visit to the cart, which the member column shows as waived. 4. ## What it claims, and what it cites Both lines are compounded by U.S.-licensed 503A and 503B pharmacies, none of them named. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The site prints the GLP-1 boxed warning on thyroid C-cell tumors in rodents. ## Where it holds up, and where it does not - Strength: The medical director is named with credentials - Strength: A live video visit precedes every prescription - Strength: The non-member total is printed per order - Strength: Cancellation is stated to carry no penalty - Limitation: The headline excludes the $89 membership - Limitation: A $49 visit charge appears at auto-refill - Limitation: The 503A and 503B pharmacies go unnamed - Limitation: No milligram schedule is published ## What the evidence says about this kind of treatment The assessment above is about ElitePhysiqMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a live video visit with a physician before any prescription. Wrong for A buyer who wants one monthly figure with nothing added at checkout. ## The evidence behind what ElitePhysiqMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How ElitePhysiqMD compares | Seller | Who it suits | Go | | --- | --- | --- | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus)[EverSlim](https://thisglp.com/reviews/everslim) [Eviora MD](https://thisglp.com/reviews/eviora-md) [Factor Health MD](https://thisglp.com/reviews/factor-health-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost at ElitePhysiqMD each month? About $268 for a member: $179.10 per refill plus the $89 membership. A one-time order is $278 with the exam and shipping. Is the membership required? No. One-time orders are allowed, but each carries a $49 exam fee and $30 shipping, and member pricing does not apply. Do I see a doctor? Yes, by live video. A board-certified physician reviews the assessment on that visit and decides whether to prescribe. Is ElitePhysiqMD legit? ElitePhysiqMD is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is ElitePhysiqMD expensive compared with other GLP-1 telehealth sellers? ElitePhysiqMD publishes a starting figure of $268/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ElitePhysiqMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ElixaMD reviews (2026): GLP-1 telehealth sellers | This GLP ElixaMD offers compounded injections and branded GLP-1 treatment. Clarify the medication bill, prescribing decision and refund conditions before paying. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elixamd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Separate branded and compounded offers # ElixaMD review ElixaMD offers compounded injections and branded GLP-1 treatment. Clarify the medication bill, prescribing decision and refund conditions before paying. ## The verdict ElixaMD has two different buying propositions: compounded treatment and access to branded medication. A membership amount is not the full cost of a branded prescription. Obtain the exact product, recurring total and refund terms together before comparing it with a medication-inclusive plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Prescription Required Compounded Yes — not FDA-approved Pharmacy Named The treatment lineup includes compounded injections, Wegovy pills and injections, and Zepbound injections. OpenLoop Health and CareGLP-affiliated practices provide the medical care; ElixaMD coordinates access. 1. ## Who writes the prescription, and what do they see? The initial assessment does not establish a doctor-patient relationship. An OpenLoop clinician evaluates the patient after checkout and can decline a prescription. Buying access is therefore different from being approved for medication. Ask how a prescriber handles a dose change, an adverse effect or an interruption in supply. A general support channel cannot by itself answer whether a clinician will be available when treatment needs to change. A delivery estimate should start from clinical approval and dispensing, rather than the moment you pay. Ask whom to contact if your existing supply will run out before the next shipment. 2. ## What happens when the dose goes up? The public pricing page does not establish a confirmed charge at every dose. Ask the clinician how reassessment works before escalation and who can advise you if [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) make the proposed increase unsuitable. A subscription should not be read as a promise that the same prescription will continue. 3. ## What the price includes The branded cards advertise a membership charge plus medication cost. A current compounded refill quote is still needed. An earlier advertised rate is not confirmed. Request the full recurring quote rather than budgeting from an old promotion. The payment terms allow the final charge to vary with the prescribed medication and dispensing pharmacy. They also describe the medical practices as out of network. Obtain any lab and visit charges before relying on insurance reimbursement. 4. ## What it claims, and what it cites Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding are listed partners. That list does not identify your assigned dispenser. Compounded medication is not FDA-approved; request the actual formulation and pharmacy before accepting fulfillment. ## Where it holds up, and where it does not - Strength: Prescribing organization identified - Strength: Branded and compounded treatment distinguished - Strength: Written cancellation and refund policy - Limitation: Medication is additional on branded plans - Limitation: Current compounded renewal total needs confirmation - Limitation: Refund wording needs clarification for bundles ## What the evidence says about this kind of treatment The assessment above is about ElixaMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone willing to confirm the exact prescription and subscription total before purchasing. Wrong for A reader who needs a publicly confirmed all-in compounded refill price before considering an intake. ## The evidence behind what ElixaMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How ElixaMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Vytora Health | Buyers expecting several dose steps who want the bill to stay flat | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Fella Health](https://thisglp.com/reviews/fella-health) [Fidelity Medical Clinic](https://thisglp.com/reviews/fidelity-medical-clinic) [Fierce Health](https://thisglp.com/reviews/fierce-health) [Fifty 410](https://thisglp.com/reviews/fifty-410) [Fitish](https://thisglp.com/reviews/fitish) [Fitness RX](https://thisglp.com/reviews/fitness-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is a membership amount the complete branded medication price? No. The branded treatment cards separate membership from the medication charge. Ask for both parts of the recurring bill. Can paying guarantee a prescription? No. The clinician makes the prescribing decision after the assessment and checkout. Will canceling recover the current monthly payment? The policy generally excludes refunds for the month already billed. Its early unused-service and medical-disqualification provisions are separate exceptions. When should cancellation reach support? Support or portal chat must receive a cancellation at least 72 hours before the next billing date. Keep the confirmation with the original subscription agreement. Stopping renewal and recovering a payment are separate questions. What should I clarify before buying multiple months? The refund policy provides an early 72-hour refund only if no subscription services have been received, and describes refunds for medical disqualification. It also discusses unshipped months in multi-month subscriptions but contains restrictive language elsewhere. Obtain written clarification before prepaying. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Treatment options and prescribing partners](https://glp1.elixamd.com/) - [Service availability and payment terms](https://elixamd.com/terms-and-conditions) - [Cancellation and refund conditions](https://elixamd.com/cancellation-and-refund-policy) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ElleS reviews (2026): GLP-1 telehealth sellers | This GLP Four monthly GLP-1 rates, two named physicians, four named pharmacies, and one price at every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elles Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Doctors and pharmacies named # ElleS review Four monthly GLP-1 rates, two named physicians, four named pharmacies, and one price at every dose. ## The verdict ElleS charges $269 a month for compounded semaglutide injections and $359 for tirzepatide injections. The oral capsules are $299 and $349 a month, and the site names both its physicians and its pharmacies, which most of this category leaves blank. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $269/mo Oral From $299/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named ElleS is a cash-pay telehealth brand run by ElleS Care LLC, selling weight-loss, hair-loss, longevity and sexual-health treatments. Its weight-loss catalog lists eight GLP-1 products. Four are standard lines: semaglutide and tirzepatide, each as a weekly injection or an oral capsule. The other four are microdose versions, sold on one-month plans only. 1. ## Who writes the prescription, and what do they see? Prescribing sits with Lion MD, which the FAQ calls a nationwide medical group led by Dr. Ana Lisa Carr, MD and Dr. Kelly Tenbrink, MD. Each physician is printed with an NPI number, so a reader can check the license record. A licensed clinician reviews the online assessment, and many patients are approved on the questionnaire alone. A short telehealth visit is scheduled only when the clinician needs more information. What the clinician checks before approving is not stated. Four steps are published: a two-minute assessment, clinician review, free tracked delivery, then ongoing monitoring with dose adjustments when appropriate. The FAQ states that no long-term commitment is required. If no medication is prescribed, the semaglutide injection's product note charges a $50 medical review fee. Whether that fee applies to the other lines is not stated. 2. ## What happens when the dose goes up? ElleS states that treatment cost stays steady as the dose changes, under a heading it calls guaranteed pricing. That settles the price half of the question, not the clinical half. The semaglutide injection note names a thirty-day supply of 3 mg, given as four weekly injections. What supply is sent at a higher weekly dose is not published. The clinical process for a step up is described only as adjustment when appropriate. 3. ## What the price includes The four standard lines are quoted per month: $269 and $359 for the injections, $299 and $349 for the capsules. For semaglutide injections, the figure covers the consult, the medication and shipping. Every card lists one-, three-, six- and twelve-month plans and marks twelve months as the largest saving. The longer-plan rates are not printed on the cards. The microdose lines carry lower monthly figures, on one-month plans only. 4. ## What it claims, and what it cites Every GLP-1 line here is compounded, so none is FDA-approved and none is reviewed by the FDA before dispensing. ElleS states that it does not manufacture compounded medications itself. The FAQ names four partner pharmacies: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts and Casa Pharma Rx. Which one fills a given order is not stated. The oral capsules are pharmacy-made, and no oral [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) has FDA approval. ## Where it holds up, and where it does not - Strength: Prescribing physicians named, with NPI numbers - Strength: Four partner pharmacies named in the FAQ - Strength: Price stated to hold as the dose changes - Strength: Both molecules offered as injection or capsule - Strength: Consult and shipping inside the semaglutide injection rate - Limitation: Longer-plan rates are missing from the cards - Limitation: A $50 fee applies if nothing is prescribed - Limitation: The filling pharmacy for an order is unstated - Limitation: Approval can happen without any clinician call - Limitation: Semaglutide injection is unavailable in Alabama ## What the evidence says about this kind of treatment The assessment above is about ElleS. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the prescribing physicians and the pharmacies named before paying. Wrong for A buyer who wants a live visit with a clinician before any prescription is written. ## The evidence behind what ElleS prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How ElleS compares | Seller | Who it suits | Go | | --- | --- | --- | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [FitRx](https://thisglp.com/reviews/fitrx) [Fitstry](https://thisglp.com/reviews/fitstry) [FORM](https://thisglp.com/reviews/form) [FormBlends](https://thisglp.com/reviews/formblends) [FormidableMD](https://thisglp.com/reviews/formidablemd) [Framework](https://thisglp.com/reviews/framework) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who prescribes at ElleS? Lion MD, a medical group led by Dr. Ana Lisa Carr, MD and Dr. Kelly Tenbrink, MD, both listed in the FAQ with NPI numbers. Does the price rise with the dose? ElleS states the treatment cost remains steady as the dose changes, and each weight-loss card quotes one monthly figure per product. What happens if a clinician declines? The semaglutide injection's product note says a $50 medical review fee applies when medication is not prescribed. Is ElleS expensive compared with other GLP-1 telehealth sellers? ElleS publishes a starting figure of $269/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ElleS above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # EllieMD reviews (2026): GLP-1 telehealth sellers | This GLP A build-your-own formula that ships twelve weeks of injections at once and bills for them month by month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/elliemd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three months in one box # EllieMD review A build-your-own formula that ships twelve weeks of injections at once and bills for them month by month. ## The verdict EllieMD charges $299 a month for its full-dose injectable formula, whether the base is semaglutide or tirzepatide, and ships the whole twelve-week course in a single box. The plan is sold only in twelve-week blocks, $897 across the three months, so the commitment is made at checkout rather than at each refill. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $299/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states EllieMD is a telehealth program built around a configurator. The buyer picks an injection or oral drops, a GLP-1 or GLP-1/GIP base, and an additive such as glycine, B12, L-carnitine or NAD+, and the page assembles a formula with a price. A lower-dose microdose line, hormone therapy, protein and skincare share the same storefront, and a brand-partner program runs alongside the retail shop. 1. ## Who writes the prescription, and what do they see? The site says a state-licensed, board-certified MD, DO or qualified medical provider reviews the intake and writes a plan, and that a phone call may be required. No individual prescriber or medical group is named on the weight-loss pages, which describe a doctor network rather than a practice. The order of events is worth noting: the health assessment is completed and paid for first, and if the provider finds the buyer ineligible, the payment is refunded. After approval the whole twelve-week supply arrives in one shipment, typically within two to ten business days, which puts three months of vials in the refrigerator on the first day. Provider chat runs through the patient portal, described as round-the-clock access, and first-time buyers get a digital guide, a progress journal and a measuring tape in a welcome kit. 2. ## What happens when the dose goes up? A new patient starts on Tier 1, and the site's example twelve-week plan climbs from 0.25 mg a week to 0.5 mg and then 1 mg inside that first box, labeled as a visualization rather than a prescription. A switch of tier or of GLP-1 product happens only every twelve weeks, after a reassessment, so a patient who struggles in week six is working within a supply that has already shipped. What the higher tiers cost is not shown on the configurator before the intake is completed. 3. ## What the price includes Semaglutide and tirzepatide are the same $299 a month at the first tier, billed monthly against a twelve-week supply, which totals $897 for the three months. There is no one-month plan on the page that would let a buyer try the medication for four weeks before committing to three months. The site states no separate membership, shipping or consultation fee, and says the program is available in all fifty states. 4. ## What it claims, and what it cites The formulas are compounded to order with the additive the buyer chooses, and compounded medications are not FDA-approved. The weight-loss page names Cloverx as its dedicated pharmacy, and the home page describes its pharmacy partners as 503A-compliant, state-licensed facilities. Compounded products are not reviewed by the FDA for safety or effectiveness before they are dispensed. ## Where it holds up, and where it does not - Strength: Semaglutide and tirzepatide share one price - Strength: The dispensing pharmacy is named - Strength: No membership, shipping or consultation fee stated - Strength: The twelve-week total is printed beside the rate - Limitation: Only twelve-week plans are sold - Limitation: Payment is taken before the medical review - Limitation: Higher dose tiers are not priced up front - Limitation: No prescriber or medical group is named ## What the evidence says about this kind of treatment The assessment above is about EllieMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer already sure about treatment who wants three months of medication on hand and one flat monthly bill at the starting tier. Wrong for Someone who wants to try a single month first, or who needs to know what the higher dose tiers cost before paying. ## The evidence behind what EllieMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How EllieMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | Eden | Buyers comparing what the two molecules actually cost | | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Framework](https://thisglp.com/reviews/framework) [Fresh Day Meds](https://thisglp.com/reviews/fresh-day) [Freya Meds](https://thisglp.com/reviews/freya-meds) [Fridays](https://thisglp.com/reviews/fridays) [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) [Gaya Wellness](https://thisglp.com/reviews/gaya-wellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How is EllieMD billed? Monthly, at $299 for the first dose tier, against a twelve-week supply that ships all at once, which comes to $897 over the three months. Is tirzepatide more expensive than semaglutide here? Not at the first tier, where both bases are $299 a month; what the higher tiers cost is not shown on the configurator before the intake. Which pharmacy fills the prescription? The weight-loss page names Cloverx as EllieMD's dedicated pharmacy, and the formulas it dispenses are compounded, which means they are not FDA-approved. Is EllieMD legit? EllieMD is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is EllieMD expensive compared with other GLP-1 telehealth sellers? EllieMD publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts EllieMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Eloria reviews (2026): GLP-1 telehealth sellers | This GLP The headline rate covers a first month, and the figure that follows it lives only in the FAQ. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/eloria Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The refill doubles it # Eloria review The headline rate covers a first month, and the figure that follows it lives only in the FAQ. ## The verdict Eloria leads with $149 for its GLP-1 injection plan, and its own FAQ states that refills are then locked in at $299, which is a little over double. No card on the page carries the second figure, and the dissolving tablet line is $249 with no opening rate attached. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection · Oral Injection From $299/mo Oral From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Eloria is a cash-pay weight-care service whose product row holds five cards: a weekly GLP-1 injection, a daily GLP-1 dissolving tablet, and brand Wegovy as either a pill or an injection alongside brand Zepbound. The three brand cards are priced as a $99 membership plus whatever the medication costs, with availability described as subject to change, so a reader cannot learn from this page what a brand month would actually cost. 1. ## Who writes the prescription, and what do they see? A board-certified provider licensed in the patient's own state reviews a health questionnaire that Eloria says takes about five minutes, and the prescription then goes to a partner pharmacy. Unlimited appointments, messaging and support are described as available at any hour, with a dedicated team of specialists behind them. No clinician, medical group or medical director is named anywhere, and no list of covered states appears. The program is cash-pay by design, which Eloria presents as the reason its pricing stays simple, and health savings and flexible spending cards are accepted for most visits and medications. There are no contracts. The FAQ answers are unusually complete for a page this short, and they are also where the price actually lives, which is the opposite of how most sellers arrange the same information. 2. ## What happens when the dose goes up? Nothing on the page describes what happens across the dose ladder. There is no milligram, no escalation schedule and no statement about whether the charge moves as the dose rises, which leaves a buyer unable to tell whether the $299 refill rate is the ceiling or the first rung of one. The only movement the page documents is the step from the first month to every month after it. 3. ## What the price includes The injection card says starting at $149 and the tablet card says starting at $249. The FAQ answering what the program costs says a patient starts from $149 for the first month and that refills are locked in at $299 with the same benefits included. That makes $149 an opening rate rather than a price, and $299 the figure a reader budgeting for a year should be using. 4. ## What it claims, and what it cites The compounded preparations are made in FDA-regulated facilities for individual patients and are not FDA-approved, which Eloria states in the FAQ rather than in a footnote. The partner pharmacies are described as state-licensed and are not named. The compounded molecule is never identified: the cards read GLP-1 injections and GLP-1 tablets, and neither [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) nor tirzepatide appears anywhere on the page, though both Wegovy and Zepbound are named on the brand cards. ## Where it holds up, and where it does not - Strength: The refill rate is published, even if only in the FAQ - Strength: Brand and compounded options sit on one row - Strength: Cash-pay with no contract and no insurance step - Strength: Unlimited messaging and appointments included - Limitation: The headline $149 covers one month only - Limitation: Refills are $299, and no card shows it - Limitation: The compounded molecule is never named - Limitation: The three brand cards carry no medication price at all - Limitation: Every FAQ link points at the site template's designer ## What the evidence says about this kind of treatment The assessment above is about Eloria. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will budget on the refill rate rather than the opening one. Wrong for A reader who needs to know which molecule a $299 month is buying. ## The evidence behind what Eloria prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Eloria compares | Seller | Who it suits | Go | | --- | --- | --- | | Amble | Buyers who want a multi-month rate that holds at every dose | | | Mondae | Buyers who want a low published compounded rate and few other details | | | ReflexMD | Buyers who want the compounded rate on the homepage rather than after an intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Health](https://thisglp.com/reviews/genesis) [Get Thin MD](https://thisglp.com/reviews/get-thin-md) [GetRelief Rx](https://thisglp.com/reviews/getrelief-rx) [Gimme Care](https://thisglp.com/reviews/gimme-care) [Glam Health](https://thisglp.com/reviews/glam-health) [Go Vida Plena](https://thisglp.com/reviews/go-vida-plena) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a second month cost? $299. Eloria's FAQ states the program starts from $149 for the first month and that refills are then locked in at that rate. Which GLP-1 is prescribed? Not named. The compounded cards say GLP-1 injections and GLP-1 tablets, and neither molecule appears on the page. What do the brand options cost? A $99 membership plus the cost of the medication, which is not published. Availability is described as subject to change. Is Eloria expensive compared with other GLP-1 telehealth sellers? Eloria publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Eloria above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Embody reviews (2026): care, dosing and costs | This GLP Embody names its clinical network and dispensing partners. Its promotion and monthly Flat terms still describe different purchase decisions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/embody Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Read the program name before the price # Embody review Embody names its clinical network and dispensing partners. Its promotion and monthly Flat terms still describe different purchase decisions. ## The verdict The relevant distinction is between Embody Start and Embody Flat. Flat's unbundled terms list $199 for a month of semaglutide and $299 for tirzepatide. A lower homepage promotion does not establish which renewal agreement a patient receives. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 From From $199/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Embody connects patients with remote clinical care for compounded GLP-1 injections. The homepage presents semaglutide and tirzepatide. Although the terms also mention gum formulations, a legal price schedule alone is not evidence that an oral product can currently be ordered. 1. ## Who writes the prescription, and what do they see? OpenLoop Health is identified in the footer as the clinical network. The preliminary assessment screens eligibility, while the prescribing decision comes from a clinician after checkout. Neither completing the form nor paying is proof that treatment will be prescribed. The public pages identify the care network and four possible dispensing partners. They do not assign a named pharmacy to a particular visitor before intake. Ask who will supply the medication and how follow-up works; a published partner list establishes disclosure, not the quality of an individual encounter. 2. ## What happens when the dose goes up? A program described as fixed monthly pricing is not a published dosing schedule. Confirm the prescribed concentration, supply and charge at a higher dose with the care team rather than assuming the advertised vial represents every treatment stage. 3. ## What the price includes Under the Flat heading, the legal terms give semaglutide a monthly rate of $199 and add $100 for injectable tirzepatide. Longer commitments have their own discounts. The separate Start schedule changes after the introductory month. These are the published Flat monthly terms; the current promotion may have different conditions. A patient-specific checkout quote has not been verified. 4. ## What it claims, and what it cites The website lists Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx. Their appearance in the disclosure does not confirm which one will dispense a patient's medication. Compounded drugs are not FDA-approved, and results from trials of approved formulations do not validate a particular compounded preparation. ## Where it holds up, and where it does not - Strength: OpenLoop Health identified as the clinical network - Strength: Four dispensing partners disclosed - Strength: Separate subscription programs explained in legal terms - Limitation: Promotional homepage and Flat terms quote different offers - Limitation: The assigned pharmacy is not established before intake - Limitation: Prepaid unused treatment is generally non-refundable ## What the evidence says about this kind of treatment The assessment above is about Embody. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader prepared to confirm the prescribing arrangements and the selected subscription agreement before enrolling. Wrong for A reader who needs prepaid treatment to remain refundable when circumstances change. ## The evidence behind what Embody prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Embody compares | Seller | Who it suits | Go | | --- | --- | --- | | Lean Meds | Readers willing to clarify the prescription and renewal details | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | | Maximus | A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [GobyMeds](https://thisglp.com/reviews/gobymeds) [Goldspan Health](https://thisglp.com/reviews/goldspan-health) [Good Girl Rx](https://thisglp.com/reviews/good-girl-rx) [Good Life Meds](https://thisglp.com/reviews/good-life-meds) [GoodRx](https://thisglp.com/reviews/goodrx) [Green Cap Health](https://thisglp.com/reviews/green-cap-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the promotional figure the monthly Flat rate? The published Flat schedule sets semaglutide at $199, with another $100 for tirzepatide. That is the terms-based rate used here. A separate homepage offer and the introductory Start program should not be treated as interchangeable. Does Embody identify its pharmacies? Yes. Its disclosures list four partners, alongside OpenLoop Health for clinical care. Confirm the pharmacy attached to your prescription because the list describes possible partners rather than your individual dispensing arrangement. What happens if I stop treatment early? Its policy generally does not refund the remainder of a bundle. Medical disqualification is the stated exception. Cancellation must reach the service at least 72 hours ahead of the next billing date; ask for confirmation that future renewal has stopped. Is Embody expensive compared with other GLP-1 telehealth sellers? Embody publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Embody above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # EmbraceRX reviews (2026): GLP-1 care platforms | This GLP EmbraceRX lists compounded injections and oral capsules, with medical services through independent networks including Samaritan MD. Formulation and follow-up need a careful review. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/embrace-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # EmbraceRX review EmbraceRX lists compounded injections and oral capsules, with medical services through independent networks including Samaritan MD. Formulation and follow-up need a careful review. ## The verdict EmbraceRX clearly separates the storefront from medical care and names a physician network. The bigger clinical question is the product: its compounded injections and oral capsules are different preparations. Convenience of a capsule should not be confused with evidence that it performs like an approved injectable or tablet. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 care platforms Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved The weight-loss catalog offers semaglutide with B12 and tirzepatide injections, plus oral semaglutide and tirzepatide capsules. It also lists an anti-nausea medicine, which is a separate treatment decision. A catalog entry does not establish eligibility for every product. 1. ## Who writes the prescription, and what do they see? The footer describes independent physician networks, including Samaritan MD, as providing care through the platform. EmbraceRX itself does not provide medical or pharmacy services. Ask which practice and clinician will take responsibility for the actual prescription and ongoing questions. The service starts with an assessment and requires provider approval. The public material does not establish one universal appointment interval or clinical message-response deadline. Determine how monitoring and refill review operate after the first order rather than assuming that access to a portal guarantees continuous clinician availability. 2. ## What happens when the dose goes up? Any strength, route or dose change requires the prescriber’s judgment. Ask how tolerance is assessed and whether a refill is held pending review. An anti-[nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) product in the catalog is not a substitute for investigating persistent symptoms or an instruction to add medication without assessment. 3. ## What the price includes The public treatment catalog does not supply a complete recurring dose-and-care price. Confirm the medicine, supply duration, clinical fees and renewal conditions before payment. The terms allow pharmacy choice, but using another dispenser may change the quoted arrangement. 4. ## What it claims, and what it cites The site explicitly describes compounded preparations from state-licensed pharmacies and says it does not supply the trademarked brands named in its disclaimer. These products are not FDA-approved. Oral compounded capsules especially need formulation-specific evidence; approved-product trial results should not be borrowed as proof for a different preparation. ## Where it holds up, and where it does not - Strength: Medical network is named in the platform disclosure - Strength: Compounded product types are distinguished - Strength: Terms acknowledge pharmacy choice - Limitation: Oral capsules require separate evidence scrutiny - Limitation: No complete public monitoring timetable - Limitation: Prescription refunds are restricted after fulfillment ## What the evidence says about this kind of treatment The assessment above is about EmbraceRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded care who will verify the actual clinician, pharmacy and evidence for the chosen formulation before enrolling. Wrong for A patient seeking a named approved brand or assuming an oral capsule is equivalent to an approved semaglutide tablet. ## The evidence behind what EmbraceRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How EmbraceRX compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) [Harper Meds](https://thisglp.com/reviews/harper-meds) [He & She MD](https://thisglp.com/reviews/he-and-she-md) [Heally](https://thisglp.com/reviews/heally) [HealthHub](https://thisglp.com/reviews/healthhub) [Healthicare](https://thisglp.com/reviews/healthicare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does EmbraceRX itself provide medical care? Its disclosures say independent physician networks, including Samaritan MD, provide medical services. Can another pharmacy be requested? The terms say patients may direct prescriptions to a pharmacy of their choosing; confirm the practical process and financial effect. Are the listed capsules FDA-approved? No. The site describes compounded treatment and explicitly distinguishes it from the named approved brands. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-loss medicines and clinical network disclosure](https://embracerx.co/category/weight-loss) - [Provider and pharmacy-choice terms](https://embracerx.co/terms-of-use) - [Prescription returns and shipment policies](https://embracerx.co/returns-and-refund-policy) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # eMed reviews (2026): GLP-1 telehealth sellers | This GLP eMed combines its own screening kit with licensed-clinician review, monthly consultations and brief weekly check-ins. Employer access and the public patient pathway should not be treated as identical programs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/emed Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Structured screening and monitoring # Does eMed sell a GLP-1? eMed combines its own screening kit with licensed-clinician review, monthly consultations and brief weekly check-ins. Employer access and the public patient pathway should not be treated as identical programs. ## The verdict eMed may suit someone who wants a structured monitoring program, provided the specific enrollment and payment route is clear. Its weekly check-ins are short support contacts, not evidence of a weekly scheduled medical consultation. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded No eMed offers U.S. GLP-1 program access through patient enrollment and organizational arrangements. The clinical pathway uses a screening kit, medical-history review and continuing support when treatment is approved. 1. ## Who writes the prescription, and what do they see? The U.S. FAQ says eMed partners with licensed clinicians and is not itself the medical provider. Those professionals assess eligibility after reviewing the history and required lab report. Ask for the independent practice and clinician responsible for the individual prescription. The FAQ describes monthly clinical consultations, a monthly questionnaire supporting refills, side-effect support and weekly check-ins taking less than a minute. Clarify what is automated, what receives clinician review and how an urgent treatment concern is escalated. 2. ## What happens when the dose goes up? eMed describes ongoing assessment supporting refills. Dose changes should follow the treating clinician’s review of tolerance and response; brief check-ins are not a reason to advance a dose independently. 3. ## What the price includes The public patient route separates an application-and-screening charge from medication. Employer arrangements can have different membership coverage and eligibility rules. Confirm the applicable program rather than applying another organization’s promotional terms. 4. ## What it claims, and what it cites The U.S. FAQ states that the program provides access to FDA-approved GLP-1 medicines. That does not guarantee a particular product or insurance approval. The exact prescription, pharmacy and current availability should be established after evaluation. ## Where it holds up, and where it does not - Strength: Monthly clinical consultations are described - Strength: Required screening is clearly part of enrollment - Strength: Refill monitoring continues after the first prescription - Limitation: The program requires its own screening kit - Limitation: Weekly check-ins are not weekly clinical visits - Limitation: Eligibility and charges differ across enrollment routes ## What the evidence says about this kind of treatment The assessment above is about eMed. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a structured clinical-and-monitoring program who can verify the relevant patient or employer pathway. Wrong for Someone who expects existing outside lab reports to replace the program’s required screening kit. ## How eMed compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealthOn](https://thisglp.com/reviews/healthon) [HealthSource](https://thisglp.com/reviews/healthsource) [HeliMeds](https://thisglp.com/reviews/helimeds) [Hello Alpha](https://thisglp.com/reviews/hello-alpha) [HelloWellness](https://thisglp.com/reviews/hellowellness) [Henry Meds](https://thisglp.com/reviews/henry-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can an existing laboratory report replace eMed’s kit? The U.S. FAQ says the eMed GLP-1 Screening Kit is required and outside lab reports are not currently accepted. Are weekly check-ins scheduled clinician visits? The FAQ describes them as brief contacts available at any time. It lists monthly clinical consultations separately. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [U.S. patient program](https://www.emed.com/join/home) - [Screening, clinical support and returns FAQ](https://glp1.us.emed.com/join/faq) - [Program and benefit access overview](https://www.emed.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Emerge Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP A tirzepatide-only clinic that prints every dose's price and bills every four weeks, not every month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/emerge-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Tirzepatide only, priced per dose # Emerge Weight Loss review A tirzepatide-only clinic that prints every dose's price and bills every four weeks, not every month. ## The verdict Emerge Weight Loss sells compounded tirzepatide from $224 per four-week fill at the 2.5 mg starting dose. Billed thirteen times a year, that comes to about $243 a calendar month. Each step up the dose ladder has its own printed price, higher than the one before. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection Dose pricing Rises with dose From From $243/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved LegitScript Claimed by provider Emerge is a cash-pay telehealth clinic that prescribes one injectable molecule, compounded tirzepatide, with no semaglutide line. It also markets tirzepatide care for sleep apnea and for PCOS and endometriosis. A dissolvable tirzepatide tablet is sold separately on its own page. The clinic states that it does not serve patients in California. 1. ## Who writes the prescription, and what do they see? The site names its medical director, Sherryl Ashberg, MD, board-certified in family medicine. Nurse practitioners and a cardiologist are named beside her on the About page. The site states that a licensed provider reviews each intake before any prescription is written. Some patients are asked to submit a short intake video as part of that review. The questions on the intake form itself are not published anywhere on the site. Contact runs by text and email only, with published hours and a queue answered oldest message first. Virtual wellness sessions and nutrition guidance are included in the plan price. Emerge contacts the patient before each reorder, so the supply does not lapse between fills. The subscription can be canceled at any time, and the site states no minimum term. 2. ## What happens when the dose goes up? This is where Emerge publishes more than most. Everyone starts at 2.5 mg, and the clinic moves a patient to 5 mg automatically unless asked not to. From 5 mg onward, patients reply to a reorder message to request a step up or down. The 5, 7.5 and 10 mg fills cost $239, $249 and $269, so the automatic first step also raises the bill. Two higher strengths are listed for existing patients only. 3. ## What the price includes Four-week fills run $224, $239, $249 and $269 from 2.5 to 10 mg. The site says each fill includes medication, prescription, supplies, medical oversight and overnight shipping, with no signup or consultation fee. A four-week cycle means thirteen charges a year, about $243 a calendar month at the starting dose. A separate, lower maintenance rate applies once a goal weight is reached. 4. ## What it claims, and what it cites The [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is compounded for each patient by a state-licensed 503A pharmacy in the United States. The site states plainly that compounded medications themselves are not FDA-approved. The pricing page does not name the pharmacy that fills a given order. The FAQ warns that concentration differs between partner pharmacies, so the strength on the label is not the dose. ## Where it holds up, and where it does not - Strength: Every dose strength has a printed price - Strength: Medical director named with credentials - Strength: Titration schedule is described in writing - Strength: No minimum commitment is stated - Limitation: Billed every four weeks, not monthly - Limitation: Automatic step to 5 mg raises the bill - Limitation: No semaglutide option is offered - Limitation: California is not served ## What the evidence says about this kind of treatment The assessment above is about Emerge Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader set on tirzepatide who wants each dose priced before starting. Wrong for A reader who wants semaglutide, or who lives in California. ## The evidence behind what Emerge Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Emerge Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Hers](https://thisglp.com/reviews/hers) [Heva Health](https://thisglp.com/reviews/heva-health) [Hims](https://thisglp.com/reviews/hims) [Idgie Health](https://thisglp.com/reviews/idgie-health) [Immortals](https://thisglp.com/reviews/immortals) [Independent Wellness](https://thisglp.com/reviews/independent-wellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $224 a monthly price? No. It is billed every four weeks, thirteen times a year, which is about $243 per calendar month. Does the price rise with the dose? Yes. The 2.5 mg fill is $224, and the 5, 7.5 and 10 mg fills are $239, $249 and $269. Will my dose go up without my asking? The first step, from 2.5 to 5 mg, is automatic unless you ask Emerge not to. Later steps are by request. Is Emerge Weight Loss expensive compared with other GLP-1 telehealth sellers? Emerge Weight Loss publishes a starting figure of $243/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Emerge Weight Loss above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # eMI Aesthetics reviews (2026): GLP-1 telehealth sellers | This GLP Four plan lengths on offer and one starting figure, with no way to tell which plan the figure belongs to until a gated intake has been completed. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/emi-aesthetics Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Plan length left unpriced # eMI Aesthetics review Four plan lengths on offer and one starting figure, with no way to tell which plan the figure belongs to until a gated intake has been completed. ## The verdict eMI Aesthetics lists compounded semaglutide, injected or taken as a tablet, as "Starting at $179", but it sells the program in 4, 12, 24 and 52-week lengths and puts a price on none of them. Which of those plans the $179 describes is settled inside an intake that opens on a robot check, so the figure is a floor of unknown term rather than a monthly bill a reader can plan around. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Rises with dose States 51 From From $179/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states and DC eMI began as an aesthetics platform known for its AI simulators, and the GLP-1 program is a newer arm delivered through an outside telehealth network. Its medications page lists compounded semaglutide by injection and by mouth, compounded tirzepatide, and the branded Zepbound and Ozempic, each with its own starting figure, beside a separate lower-dose longevity path. 1. ## Who writes the prescription, and what do they see? Prescriptions are issued by independent licensed providers after a telehealth consultation, which the FAQ says in those words, and every intake link leads to forms hosted by OpenLoop Health. No individual clinician is named anywhere on the public pages, and the visit with a provider is booked only after the online form has been submitted and judged eligible. After the intake, an eligible patient books an online visit, receives a plan if the provider judges it appropriate, and has the medication shipped from a U.S. pharmacy, with a personal care app for tracking progress and asking medical questions. The body-simulation tool that the brand leads with sits inside that app, so the service a buyer is paying for is part prescription and part progress-tracking software. 2. ## What happens when the dose goes up? Nothing on the public pages says whether the monthly figure moves as a dose climbs from the starting strength toward maintenance. The plan selector names lengths and molecules without attaching a number to either, which leaves the second and third months impossible to cost from outside the intake, and that is the stretch where most dose steps happen. 3. ## What the price includes The public figure is the FAQ's "Start as low as $179/month", repeated on the medications page as "Starting at $179" for both semaglutide forms. Clicking through the 4, 12, 24 and 52-week options in the plan selector brings up no price at all, and every price link leads into the same captcha-gated intake. A long plan and a single month could each be the source of that $179, nothing public says which, and so it is quoted here as the seller's own floor rather than ranked as a monthly rate. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and tirzepatide lines are compounded, and compounded preparations are neither FDA-approved nor reviewed by the agency before dispensing, which the FAQ acknowledges while noting they come from FDA-regulated facilities. The homepage badge reading "FDA-approved medications from trusted pharmacies" is accurate only for the branded Zepbound and Ozempic. The site's terms name four partner pharmacies, among them RedRock Pharmacy and Precision Compounding Pharmacy. ## Where it holds up, and where it does not - Strength: Four partner pharmacies named in the terms - Strength: Coverage stated for all 50 states and DC - Strength: Semaglutide offered by injection and by mouth - Strength: Compounded status acknowledged in the FAQ - Limitation: No plan length carries a published price - Limitation: Intake opens behind a robot check - Limitation: No individual clinician is named - Limitation: Price at each dose step not described ## What the evidence says about this kind of treatment The assessment above is about eMI Aesthetics. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer willing to finish an intake before learning which plan the starting figure actually buys. Wrong for A buyer who needs a month-to-month rate in hand before sharing any health details. ## The evidence behind what eMI Aesthetics prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How eMI Aesthetics compares | Seller | Who it suits | Go | | --- | --- | --- | | Vytora Health | Buyers expecting several dose steps who want the bill to stay flat | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Independent Wellness](https://thisglp.com/reviews/independent-wellness) [Injectco](https://thisglp.com/reviews/injectco) [InstaRX](https://thisglp.com/reviews/instarx) [Intimate Rose](https://thisglp.com/reviews/intimate-rose) [Invigor Medical](https://thisglp.com/reviews/invigor-medical) [Invyncible](https://thisglp.com/reviews/invyncible) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost? The seller's own answer is "Start as low as $179/month". It does not say which of its four plan lengths that figure belongs to, and the plan selector on the site shows no prices for any of them. Who writes the prescription? Independent licensed providers, after a telehealth consultation that follows the online intake, which is hosted by OpenLoop Health. Which pharmacies fill the order? The terms list RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy and Triad Rx as partner pharmacies, and say a prescription may be moved between them for availability or pricing reasons. Is eMI Aesthetics legit? eMI Aesthetics is a GLP-1 telehealth sellers service. Its stated availability: All 50 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is eMI Aesthetics expensive compared with other GLP-1 telehealth sellers? eMI Aesthetics publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts eMI Aesthetics below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Enara Health reviews (2026): GLP-1 telehealth sellers | This GLP Enara combines medical weight management with dietitian, movement and behavioral support through partner clinics. Medication is one part of the program rather than its entire purpose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/enara-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Team-based clinic care # Enara Health review Enara combines medical weight management with dietitian, movement and behavioral support through partner clinics. Medication is one part of the program rather than its entire purpose. ## The verdict Enara is worth investigating if you want a continuing care team and can access a participating clinic. Confirm the individual providers, insurance terms and medication plan before interpreting an in-network program as guaranteed GLP-1 coverage. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Liraglutide Form Injection Prescription Required Compounded No Enara supports a weight-management program delivered with partner care clinics. Enrollment includes an insurance check and app-based appointment scheduling, followed by a medical assessment and an individualized plan. 1. ## Who writes the prescription, and what do they see? A medical provider evaluates the patient’s health and goals before selecting treatment. The program can involve a registered dietitian and behavioral support as well. Verify the participating clinic and clinician who would be responsible for the prescription in your location. Enara describes a team approach incorporating nutrition, movement, emotional well-being and medication when indicated. That broader model may be useful for someone who wants sustained support, but the actual appointment schedule and accessibility need checking with the partner clinic. 2. ## What happens when the dose goes up? The medication plan is selected by the clinical team rather than determined by a price ladder. Ask how the prescriber monitors tolerance, when a review is scheduled and how coverage problems are handled if a prescribed product needs changing. 3. ## What the price includes The published program figure depends on insurance coverage. It is not a universal cash price for a GLP-1 prescription. Confirm program fees, copays, drug coverage and any testing costs before enrollment. 4. ## What it claims, and what it cites The public medication page names branded [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and Saxenda injections. It also describes non-GLP alternatives if brand coverage is unavailable. Insurance assistance does not guarantee that every insurer will approve the requested medicine. ## Where it holds up, and where it does not - Strength: Medical and nutrition care are coordinated - Strength: Named branded injection options are listed - Strength: Prior-authorization assistance is described - Limitation: Access depends on participating care arrangements - Limitation: Coverage is not guaranteed by an in-network listing - Limitation: The individual appointment plan needs confirming ## What the evidence says about this kind of treatment The assessment above is about Enara Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants a multidisciplinary weight-care program and can verify the clinic and insurance pathway before starting. Wrong for Someone who wants unrestricted direct purchasing of a particular GLP-1 brand without a clinic or insurance assessment. ## The evidence behind what Enara Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Enara Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) [iThriveMD](https://thisglp.com/reviews/ithrivemd) [Ivim Health](https://thisglp.com/reviews/ivim-health) [Ivologist](https://thisglp.com/reviews/ivologist) [Ivy Rx](https://thisglp.com/reviews/ivy-rx) [Jently](https://thisglp.com/reviews/jently) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Enara a medication-only subscription? No. It describes a broader program with medical, nutrition, activity and behavioral support. Can prior authorization guarantee the requested brand? No. The insurer’s rules and the clinician’s assessment still apply. Enara describes other medication plans when branded treatment is not covered. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Patient program and clinical team](https://enarahealth.com/for-patients) - [Medication options and prior authorization](https://enarahealth.com/for-patients/medications) - [Participating care clinics](https://enarahealth.com/for-patients/clinics) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Enhance MD reviews (2026): GLP-1 telehealth sellers | This GLP Everything here is billed in four-week cycles, so a plan advertised by the month lands thirteen times a year rather than twelve. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/enhance-md Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week cycle, not a month # Enhance MD review Everything here is billed in four-week cycles, so a plan advertised by the month lands thirteen times a year rather than twelve. ## The verdict Enhance MD charges $249 for a one-month plan of compounded semaglutide and $329 for full-dose compounded tirzepatide, each billed every four weeks. Thirteen charges land in a calendar year, so those are $270 and $356 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 39 From From $270/mo Prescription Required Compounded Yes — not FDA-approved Labs Included Enhance MD sells compounded semaglutide and compounded tirzepatide as weekly injections across thirty-nine states, and the thing a reader has to hold on to is that its cycle is four weeks rather than a calendar month. The semaglutide plan ladder runs $249 month to month, $237 at three months, $224 at six and $212 at twelve. Labs, the consultation and two-day shipping are described as included at every rung. 1. ## Who writes the prescription, and what do they see? Labs and a consultation sit inside the price rather than beside it, which is the shape a reader should want and the shape that makes a like-for-like comparison hard. A seller charging less and billing the consultation separately can look cheaper on a landing page and cost more across a year. How often the consultation repeats, and whether labs are drawn again after the first set, is not something the priced row establishes. Treatment is arranged remotely and the medication arrives on a four-week rhythm, which sounds like a monthly subscription and is not one. Thirteen deliveries land in a calendar year rather than twelve, so the advertised figure understates the annual cost by roughly one fill. The first order carries a discount, larger on the twelve-month plan, which is also the point at which a reader commits to the term. 2. ## What happens when the dose goes up? The semaglutide plan is flat at all doses, so an escalation does not move the bill, and that is worth more across a year than most of the headline gaps between sellers. Tirzepatide comes in two products: the full-dose GLP-1 Advanced plan this site ranks, and a separate low-dose microdosing tier sold only on three, six and twelve-month prepay terms. 3. ## What the price includes The twelve-month rung is the figure the page leads with, at $212, and it buys a forty-eight-week term rather than a calendar year. The one-month plan is $249 per four-week fill, which is $270 a calendar month once thirteen fills are counted. Full-dose tirzepatide is $329 per fill on the same one-month plan, or $356 a calendar month. 4. ## What it claims, and what it cites Both products are compounded, so a pharmacy prepares them and no regulator reviews the finished vial before it ships. The published results for [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) came from the approved label doses over seventy-two weeks. The microdosing tier sits below those doses, which is why this site prices the full-dose plan instead. ## Where it holds up, and where it does not - Strength: Labs and consultation inside the price - Strength: Semaglutide rate flat at every dose - Strength: Whole plan ladder published on one page - Limitation: Cycle is four weeks, not a month - Limitation: The lead figure needs a forty-eight-week term - Limitation: Microdose tier is prepay only ## What the evidence says about this kind of treatment The assessment above is about Enhance MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. Wrong for A reader comparing the advertised $212 against another seller's month-to-month rate, because it is the twelve-month rung of a four-week cycle. ## The evidence behind what Enhance MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Enhance MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. | | | Idgie Health | A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Joey Med](https://thisglp.com/reviews/joey-med) [Joi + Blokes](https://thisglp.com/reviews/joi-and-blokes) [JRNYS](https://thisglp.com/reviews/jrnys) [JumpstartMD](https://thisglp.com/reviews/jumpstartmd) [June Health](https://thisglp.com/reviews/june-health) [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does this site show $270 rather than the advertised $212? Two reasons. $212 is the twelve-month rung, and a one-month plan is $249. And the plan bills every four weeks, so thirteen charges land in a calendar year: $249 a fill is $269.75 a calendar month. What does the price include? Labs, the consultation and two-day shipping are described as included at every rung of the semaglutide plan. That is worth holding on to when comparing it with a seller that bills a consultation separately. Can the microdosing tirzepatide plan be bought monthly? No. The low-dose tier is sold on three, six and twelve-month prepay terms only. The full-dose tirzepatide plan does offer a one-month option, at $329 per four-week fill. Is Enhance MD expensive compared with other GLP-1 telehealth sellers? Enhance MD publishes a starting figure of $270/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Enhance MD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Enhanced reviews (2026): GLP-1 telehealth sellers | This GLP Enhanced now lists clinician-guided semaglutide and tirzepatide within its Weight Rx pathway. Prescription assessment and the supplement storefront are different services. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/enhanced Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Enhanced sell a GLP-1? Enhanced now lists clinician-guided semaglutide and tirzepatide within its Weight Rx pathway. Prescription assessment and the supplement storefront are different services. ## The verdict The current site goes beyond supplements by describing clinician-guided GLP-1 treatment and laboratory review. That is worth evaluating as a distinct service, but it should not inherit trust from the supplement brand automatically. Clarify the medical practice, prescriber and pharmacy responsible for your care. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved Enhanced’s Weight Rx pathway lists semaglutide and tirzepatide among personalized protocols. Its general catalog also includes nonprescription products. A supplement purchase and a prescription medical evaluation have different eligibility, safety and financial rules. 1. ## Who writes the prescription, and what do they see? A licensed clinician decides whether a prescription treatment is appropriate after medical history and relevant lab review. The terms describe an initial consultation that may be video or asynchronous depending on the service. Ask which medical practice provides it and whether that clinician manages subsequent care. The Blood Test and Physician Consult fee covers testing or review of supplied results and an initial evaluation. Confirm what continuing appointments or messaging accompany a prescription, because that initial-service description does not establish a universal ongoing follow-up package. 2. ## What happens when the dose goes up? The weight pathway describes matching treatment to labs and clinical needs. A standard dose ladder, repeat testing interval and response deadline are not fully established by the treatment pages. Obtain the plan for [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and refill review before relying on a continuing course. 3. ## What the price includes The linked sources do not establish one standing all-in GLP-1 price. The clinical evaluation fee and prescription costs need to be separated from supplement or storefront discounts. The terms treat testing and consultation as services rather than guaranteeing that every purchase produces medication. 4. ## What it claims, and what it cites The prescription pathway includes compounded-treatment disclosures. Such preparations are not FDA-approved. Advertising a personalized protocol does not establish evidence for every proposed combination or equivalence to an approved branded medicine. ## Where it holds up, and where it does not - Strength: Prescription care is separately described - Strength: Clinical review can include laboratory results - Strength: Compounding disclosures are visible - Limitation: Initial assessment is not a complete follow-up specification - Limitation: Total medication price requires a quote - Limitation: Supplement-brand reputation does not identify the medical team ## What the evidence says about this kind of treatment The assessment above is about Enhanced. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone already considering the brand who wants to investigate its separate medical pathway and obtain the prescriber and pharmacy details. Wrong for A patient assuming a supplement order or general discount guarantees a suitable prescription. ## The evidence behind what Enhanced prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Enhanced compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Jyra Health](https://thisglp.com/reviews/jyra-health) [KERNX Health](https://thisglp.com/reviews/kernx-health) [Kin Meds](https://thisglp.com/reviews/kin-meds) [Kina](https://thisglp.com/reviews/kina) [Knownwell](https://thisglp.com/reviews/knownwell) [Kongo](https://thisglp.com/reviews/kongo) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Enhanced list GLP-1 treatment? Its Weight Rx pathway names semaglutide and tirzepatide under clinician-guided care. What does the consultation fee describe? The terms say it covers lab access or supplied-result review and an initial clinician consultation, with the format depending on the service. Are compounded products approved by the FDA? No. The site’s own prescription disclosures distinguish compounded preparations from FDA-approved products. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.enhanced.com/) - [Weight-management program](https://www.enhanced.com/live-enhanced/pathways/weight) - [Terms of service and payment conditions](https://www.enhanced.com/agreements/terms-of-service) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # EOS Health reviews (2026): GLP-1 telehealth sellers | This GLP Each plan shows what it costs now and what it costs when it renews. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/eos Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The renewal rate, printed # EOS Health review Each plan shows what it costs now and what it costs when it renews. ## The verdict EOS Health prints the renewal rate beside the opening rate on every rung of its semaglutide ladder, so the second term is visible before the first is bought. The month-to-month plan renews at $169, and the three- and six-month plans are written the same way. Almost nothing else on this shelf tells a buyer the second number without making them find it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 40 From From $169/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 40 states EOS Health is a cash-pay telehealth service whose weight-loss line runs physician-supervised GLP-1 protocols, with longevity, men's health, women's health and skincare on the same platform. Semaglutide and tirzepatide are offered in a standard formulation and in versions compounded with glycine or B12, chosen from the same plan picker. Insurance is not billed. A welcome credit for new patients is advertised across the top of every page. 1. ## Who writes the prescription, and what do they see? The plan picker carries a line stating that nothing is charged unless a clinician prescribes, which puts the clinical decision before the payment rather than after it. Protocols are described as physician-supervised, and the intake is a questionnaire rather than a booked appointment. No clinician, medical group or medical director is named on the weight-loss page. What a clinician reviews before writing is not set out anywhere on it. A patient portal carries tracking and messaging, and the site describes the program as personalized around the intake rather than assembled from a menu. The formulation is a choice made inside the plan picker alongside the molecule and the term, which is a small thing that makes the whole ladder visible in one place. Shipping is described as free and expedited. The welcome credit is stated to apply to a first order only, one per patient. 2. ## What happens when the dose goes up? The picker states the same price at any dose, so a step up the ladder costs nothing extra inside a plan, and the line sits beside the cancel-anytime promise rather than in a footnote. That covers the money half of the [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) question and leaves the clinical half open. Nothing on the page describes who approves a dose increase, how often a patient is reviewed, or what a clinician looks at before raising it. No milligram figure appears next to any plan or formulation. 3. ## What the price includes Three semaglutide rungs sit side by side, each with its opening rate and its renewal rate printed together, and the six-month plan is marked best value. The six-month total is shown both before and after the welcome credit, so the credit's size is derivable from the page rather than asserted. Tirzepatide is priced through the same picker once the molecule is switched. The renewal figure is the one to budget from on every rung. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, and compounded preparations are not FDA-approved or reviewed by the FDA before dispensing. The glycine and B12 versions are additions to the compounded preparation rather than different drugs. No compounding pharmacy is named. ## Where it holds up, and where it does not - Strength: The renewal rate is printed on every rung - Strength: Nothing is charged unless a clinician prescribes - Strength: The welcome credit's size is derivable - Strength: Same price at every titration dose - Strength: Three formulations sit in one picker - Limitation: The headline rate is a first-term rate - Limitation: The lowest rung needs six months paid at once - Limitation: No clinician or medical group is named - Limitation: The preparing pharmacy is left unnamed - Limitation: No milligram dose appears beside a plan ## What the evidence says about this kind of treatment The assessment above is about EOS Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the renewal rate printed beside the introductory one. Wrong for A buyer who wants a booked appointment before a prescription is written. ## The evidence behind what EOS Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How EOS Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Kongo](https://thisglp.com/reviews/kongo) [LaSara Medical Group](https://thisglp.com/reviews/lasara) [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) [Layla](https://thisglp.com/reviews/layla) [Lean Meds](https://thisglp.com/reviews/leanmeds) [Lean Rx](https://thisglp.com/reviews/lean-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the monthly plan renew at? $169. EOS prints the renewal rate beside the opening rate on every rung, so the second term is visible before the first is bought. Is anything charged before approval? No. The plan picker states a patient is not charged unless a clinician prescribes, and the welcome credit applies to a first order only. Does a higher dose cost more? No. The same line that carries the cancel-anytime promise states the price is the same at any dose. Is EOS Health legit? EOS Health is a GLP-1 telehealth sellers service. Its stated availability: 40 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is EOS Health expensive compared with other GLP-1 telehealth sellers? EOS Health publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts EOS Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Eve reviews (2026): GLP-1 telehealth sellers | This GLP An unpriced GLP-1 program and three branded names, behind an intake that asks for an email before the first health question. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/eve Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Email before anything # Eve review An unpriced GLP-1 program and three branded names, behind an intake that asks for an email before the first health question. ## The verdict Eve publishes no price for its GLP-1 program or for the branded Mounjaro, Ozempic and Wegovy it also lists. The single figure on the site is "You pay $0 unless approved by a licensed physician." The intake asks for an email before any health question, so cost stays unknown until an account exists. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Pharmacy Not named Eve is a telehealth brand selling weight loss beside longevity and hair-health lines. Its weight-loss catalog shows a GLP-1 Therapy card and three branded cards. Plans are sold as a subscription that can be canceled at any time. 1. ## Who writes the prescription, and what do they see? Eve states that it provides no medical services itself. Care comes from providers employed by or contracted with third-party professional entities, none named on the site. The homepage promises a match with a board-certified obesity medicine physician. Registration comes first, then a scheduled telehealth appointment, then the consultation and any prescription. Messaging with the assigned provider runs through a secure portal. Follow-up check-ins are described as scheduled across treatment. 2. ## What happens when the dose goes up? The FAQ says check-ins are used to adjust dosage as needed. It does not say whether the price changes at a higher dose. With no price published, a dose step cannot be costed in advance. 3. ## What the price includes No monthly figure is published for any line. The GLP-1 Therapy card and the branded cards carry stock labels, not prices. The intake opens by promising to find the right plan, then requires an email to continue. The no-charge-before-approval promise is the one public cost statement. 4. ## What it claims, and what it cites The site states that physicians may prescribe compounded medications, and that the FDA does not review or approve them for safety or effectiveness. [Mounjaro](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) and Wegovy appear as branded options. Prescriptions ship through what the terms call the Eve Pharmacy Network, whose members are not named. ## Where it holds up, and where it does not - Strength: Nothing charged before physician approval - Strength: Compounded status disclosed on the homepage - Strength: Portal messaging with the assigned provider - Strength: Branded options listed beside compounded - Limitation: No price published for any line - Limitation: Email required before any health question - Limitation: No prescriber or medical group named - Limitation: No dispensing pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Eve. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer willing to create an account before seeing any figure. Wrong for A buyer who wants monthly prices to compare before sharing an email. ## The evidence behind what Eve prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Eve compares | Seller | Who it suits | Go | | --- | --- | --- | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | | MultiMedRx | A reader with insurance who needs a branded GLP-1 covered rather than sold | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lean Rx](https://thisglp.com/reviews/lean-rx) [LeanDose](https://thisglp.com/reviews/leandose) [Lemonaid Health](https://thisglp.com/reviews/lemonaid-health) [LevelsRx](https://thisglp.com/reviews/levelsrx) [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) [Levers Health](https://thisglp.com/reviews/levers-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Eve charge per month? It does not say publicly. No card on the site carries a price, and the intake requires an email before continuing. Is anything charged before approval? Not according to the homepage, which says payment depends on a licensed physician approving treatment. Who prescribes? Providers employed by or contracted with third-party professional entities. The site does not name them or their medical group. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # EverFit Medical reviews (2026): GLP-1 telehealth sellers | This GLP EverFit combines an Ohio clinic with online weight-management evaluation. Its public program names semaglutide and tirzepatide, with treatment conditional on a clinician’s assessment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/everfit-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinic and telehealth routes # Does EverFit Medical sell a GLP-1? EverFit combines an Ohio clinic with online weight-management evaluation. Its public program names semaglutide and tirzepatide, with treatment conditional on a clinician’s assessment. ## The verdict EverFit offers a useful distinction from an online-only storefront: local patients can seek in-person support, while others use telehealth. Confirm which team follows you remotely and which optional clinic services are unavailable outside Ohio before choosing the program. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required EverFit Medical Clinic provides medical weight management from Macedonia, Ohio, and advertises a separate national telehealth route. Its local services include nutrition support and body-composition assessment. Those clinic features should not be treated as included benefits of every online prescription. 1. ## Who writes the prescription, and what do they see? The weight-management page requires a licensed provider’s evaluation of medical history, current medication and treatment suitability. The footer identifies Dr. Telx as its provider group. Ask who is responsible for your ongoing prescription and whether that clinician can practice where you are located. An intake precedes provider assessment and a treatment plan. EverFit describes progress monitoring and adjustments afterward. Public information supports ongoing care, but does not establish one appointment timetable or response-time guarantee for every remote patient. Its telehealth page advertises national care, while a footer says the clinic provides services exclusively in Ohio. Obtain confirmation that the remote route is available in your state; the conflicting wording does not establish a nationwide service footprint. 2. ## What happens when the dose goes up? Its care description allows treatment changes based on progress and tolerance. It does not provide a public schedule connecting every dose to the following refill charge. Request both the clinical follow-up plan and the cost at later prescribed strengths. 3. ## What the price includes A complete standing medication-and-follow-up price was not established from the reviewed program pages. Ask for the medication, consultation, lab and delivery components in writing. Local body scans or other wellness services should be priced separately unless the specific offer includes them. 4. ## What it claims, and what it cites The clinical page explicitly names semaglutide and tirzepatide and describes pharmacy partners. It does not establish the exact brand or preparation an individual patient receives. Verify the prescription label, formulation and dispensing pharmacy instead of inferring them from a molecule name. ## Where it holds up, and where it does not - Strength: In-person option in Ohio - Strength: Medical history considered before prescribing - Strength: Public distinction between local and remote care - Limitation: Online package price needs a quote - Limitation: Remote follow-up schedule not fully specified - Limitation: National telehealth and Ohio-only footer wording conflict ## What the evidence says about this kind of treatment The assessment above is about EverFit Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An Ohio patient who values a clinic option, or a remote patient who first confirms the follow-up arrangements. Wrong for Someone seeking a fully published, identical bundle of local services and medication regardless of location. ## The evidence behind what EverFit Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How EverFit Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LifeRx.md](https://thisglp.com/reviews/liferx) [LifespanningRx](https://thisglp.com/reviews/lifespanningrx) [LillyDirect Foundayo](https://thisglp.com/reviews/lillydirect-foundayo) [Liv Body](https://thisglp.com/reviews/liv-body) [LIV by WellNow](https://thisglp.com/reviews/liv-by-wellnow) [Livea](https://thisglp.com/reviews/livea) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is medication guaranteed after intake? No. EverFit states that a medical review determines whether treatment is appropriate. What if the provider declines treatment? Its policy says charges are not captured, or an earlier authorization is refunded. Consultation and filled-prescription refund rules differ. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official program](https://www.everfitmedical.com/) - [Treatment information](https://www.everfitmedical.com/weight-loss) - [Service and cancellation terms](https://www.everfitmedical.com/termsandconsitions) - [Consultation and care process](https://www.everfitmedical.com/how-it-works) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Evergreen Telehealth reviews (2026): GLP-1 telehealth sellers | This GLP Evergreen Lean describes continuing GLP-1 care through a team, while the terms name NVP Medical Group and impose a seven-day cancellation deadline. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/evergreen-telehealth Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named medical partner, renewal cutoff # Does Evergreen Telehealth sell a GLP-1? Evergreen Lean describes continuing GLP-1 care through a team, while the terms name NVP Medical Group and impose a seven-day cancellation deadline. ## The verdict The clinical partner and patient app are tangible parts of the model. Confirm the visit schedule and pharmacy rather than relying on continuity language alone; the seven-day renewal cutoff is especially important if treatment is being reassessed. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Evergreen Telehealth is operated by ConsultRX LLC and offers an active weight program alongside other treatments being introduced. Its Lean program names semaglutide and tirzepatide. 1. ## Who writes the prescription, and what do they see? The terms identify NVP Medical Group, P.A., and affiliates as the clinical partner. Evergreen’s site describes a continuous team, but patients should confirm the assigned provider and coverage when that clinician is unavailable. Patients complete an assessment, receive clinical review and use the Evie app for ongoing contact. The public model includes medication delivery and provider-guided adjustment rather than a one-time prescription alone. 2. ## What happens when the dose goes up? The program says dosing changes with progress, but does not establish a universal cadence for live visits or refill reviews. Ask which information must be submitted before another prescription is approved. 3. ## What the price includes Public pages do not establish a complete drug-specific price. The subscription terms govern the chosen term and describe prepaid amounts as nonrefundable through the current period. 4. ## What it claims, and what it cites Evergreen Lean names semaglutide and tirzepatide and the site discloses compounded preparation for certain products. Confirm the exact formulation; a molecule name does not establish a branded medicine or an approved product. ## Where it holds up, and where it does not - Strength: Medical partner named - Strength: Evie app for continuing contact - Limitation: Visit cadence not fixed publicly - Limitation: Medication and price scope need confirmation ## What the evidence says about this kind of treatment The assessment above is about Evergreen Telehealth. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants app-based access to a continuing clinical team and understands the renewal notice. Wrong for Someone relying on a last-minute cancellation or expecting public medication pricing before assessment. ## The evidence behind what Evergreen Telehealth prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Evergreen Telehealth compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [50 Stars Health](https://thisglp.com/reviews/livv) [Longevixx](https://thisglp.com/reviews/longevixx) [Loop Health](https://thisglp.com/reviews/loop-health) [LovelyMeds](https://thisglp.com/reviews/lovelymeds) [Luci](https://thisglp.com/reviews/luci) [Luma Health Co](https://thisglp.com/reviews/luma-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who provides the clinical service? The terms name NVP Medical Group, P.A., and affiliated practices as the clinical partner. Is every advertised treatment already available? The homepage identifies weight care as open while describing rollout of additional treatments. Confirm the specific service before enrolling. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://helloevergreen.com/) - [Official program and terms](https://helloevergreen.com/terms-conditions) - [Official program and terms](https://helloevergreen.com/support-guides/how-long-until-glp1-starts-working) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Everlywell (Weight Care+) reviews (2026): GLP-1 telehealth sellers | This GLP A monthly membership on a three- or twelve-month term. The brand medication is billed by a pharmacy. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/everlywell-weight-care-plus Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A membership, not a drug sale # Everlywell (Weight Care+) review A monthly membership on a three- or twelve-month term. The brand medication is billed by a pharmacy. ## The verdict Weight Care+ is a monthly program fee, not a medication price. A three-month term costs $139 a month. A twelve-month term costs $99 a month. The drug is billed separately, so nothing here is ranked as a GLP-1 price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Flat across doses Dose published No Prescription Required Compounded No Labs Extra cost Everlywell is an at-home lab testing company. Weight Care+ is its virtual weight-management membership. Everlywell's main site has no enrollment page for it. The purchase route on the web is Quest's page for its weight-loss blood panel. That page lists the program as a $99 add-on. 1. ## Who writes the prescription, and what do they see? A licensed, board-certified physician runs the first virtual consult. The patient picks from providers licensed in their state. Follow-ups are usually with that same provider. Everlywell says continuity cannot be guaranteed. A prescription is at the provider's discretion and is not promised. The first visit covers medical history, weight goals and any recent labs. The provider then writes a care plan, which may include a prescription. The prescription goes to a local pharmacy the patient chooses. Monthly check-ins follow once medication starts. Staff also help with insurance prior authorization. The term is binding once signed. 2. ## What happens when the dose goes up? Everlywell publishes no dose schedule. Each monthly check-in reviews progress and tolerance, and the provider adjusts the plan. Refills are renewed at those check-ins. The drug's cost at each dose is set by the pharmacy and the member's insurer. 3. ## What the price includes Three costs apply, and Everlywell sets only one of them. The program fee has two rungs: $139 a month for three months, or $99 a month for twelve. Medication is billed by the pharmacy that fills it. Without insurance or a discount card, Everlywell estimates $900 to $1,400 for one month of the drug. Lab work also falls outside the fee. Virtual visits are not covered by insurance. 4. ## What it claims, and what it cites Everlywell prescribes brand GLP-1s only. Its FAQ rules out compounded GLP-1 prescriptions, and the company dispenses no medication itself. The brands it names include [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) and Zepbound, both FDA-approved for weight management. The FAQ notes that Ozempic and Mounjaro are approved only for type 2 diabetes. If prior authorization is denied, naltrexone-bupropion, orlistat or metformin may be offered instead. ## Where it holds up, and where it does not - Strength: Program fee and both terms are published - Strength: Compounded GLP-1s are not prescribed - Strength: Patients choose a provider licensed in their state - Strength: Prior-authorization help is part of the membership - Limitation: Medication is billed by the filling pharmacy - Limitation: Minimum term of three or twelve months - Limitation: Early exit refunds nothing already charged - Limitation: No enrollment page on Everlywell's own site - Limitation: No dose schedule is published ## What the evidence says about this kind of treatment The assessment above is about Everlywell (Weight Care+). These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An insured adult who wants a clinician to prescribe a brand GLP-1 and handle prior authorization. Wrong for A cash buyer, or anyone unwilling to commit to at least three months. ## The evidence behind what Everlywell (Weight Care+) prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Everlywell (Weight Care+) compares | Seller | Who it suits | Go | | --- | --- | --- | | Knownwell | Insured patients who want ongoing care from one obesity-medicine clinician | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | WeightWatchers Clinic | Readers who want a familiar brand and will add the membership at its ceiling | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Luma Meds](https://thisglp.com/reviews/luma-meds) [Lumen Meds](https://thisglp.com/reviews/lumen-meds) [LumiMeds](https://thisglp.com/reviews/lumimeds) [Lumora](https://thisglp.com/reviews/lumora) [LunaRx](https://thisglp.com/reviews/lunarx-health) [LVNG RX](https://thisglp.com/reviews/lvng-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 the price of the medication? No. It is the monthly program fee on the twelve-month term. The medication is billed by the pharmacy that fills it. Can a member cancel early? Only in two cases. The member turns out to be ineligible, or the drug is uncovered or unaffordable. Prior charges are not refunded either way. Who is eligible? Adults aged 18 to 74 with a BMI of 30 or more, or 27 or more with a related condition. The provider makes the final call. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Evernow reviews (2026): GLP-1 telehealth sellers | This GLP Evernow places GLP-1 assessment within menopause-focused care, with membership or individual visits. Medication costs and suitability remain separate from access to the care team. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/evernow Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Evernow review Evernow places GLP-1 assessment within menopause-focused care, with membership or individual visits. Medication costs and suitability remain separate from access to the care team. ## The verdict Evernow’s distinction is context: weight concerns can be discussed alongside perimenopause and menopause symptoms. That does not mean a GLP-1 or hormone treatment is necessary for every patient. The useful question is how the provider evaluates the whole picture without turning access to a broad menu into a preset treatment plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required The platform offers menopause, hormone and weight-related care. Its treatment menu names Ozempic, Wegovy, Zepbound and Mounjaro. These products have different labeled uses; the presence of a brand in a menu does not establish suitability for every midlife weight concern. 1. ## Who writes the prescription, and what do they see? Care is provided by a matched professional, while the platform terms distinguish Evernow from the medical provider. The service advertises matching within 24 hours. That is an access statement, not a guarantee of a prescription, insurance approval or a particular clinician assignment. Patients can choose pay-per-visit access or ongoing membership. Membership describes secure messaging, prescription access, automated refills and optional insurance-covered video visits. Clarify what is covered by the selected arrangement and how medical concerns reach the provider between scheduled contacts. 2. ## What happens when the dose goes up? Personalized care plans may include a GLP-1 when clinically appropriate. Ask how follow-up, tolerance assessment and refill authorization are handled for that medicine. Automated refill functionality should not be confused with automatic clinical approval for an increased dose. 3. ## What the price includes Membership starts at $35 per month, and the site also offers individual video visits. This is a care-access figure, not a medicine-inclusive drug price. Insurance acceptance for certain video visits does not establish coverage for a weight-loss prescription. 4. ## What it claims, and what it cites The public menu names approved [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) brands. Medications can be sent to a pharmacy or delivered according to the plan. Confirm the actual product and indication with the prescriber, especially when coordinating weight treatment with hormone therapy or other existing medicines. ## Where it holds up, and where it does not - Strength: Menopause-related concerns can be considered together - Strength: Membership and individual visits are separate options - Strength: Messaging and refill functions are described - Limitation: Care price does not establish medication cost - Limitation: Insurance depends on the service and plan - Limitation: Provider matching does not guarantee treatment ## What the evidence says about this kind of treatment The assessment above is about Evernow. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient seeking menopause-informed clinical discussion of weight concerns and other midlife symptoms. Wrong for Someone seeking a guaranteed GLP-1 prescription or assuming membership includes the medicine. ## The evidence behind what Evernow prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Evernow compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lyfe Rx](https://thisglp.com/reviews/lyfe-rx) [MadeMed](https://thisglp.com/reviews/mademed) [MANÜ Telehealth](https://thisglp.com/reviews/manu-telehealth) [Marek Health](https://thisglp.com/reviews/marek-health) [Maves](https://thisglp.com/reviews/maves) [Maximus](https://thisglp.com/reviews/maximus-tribe) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is GLP-1 treatment available within the care plan? Evernow includes GLP-1s among possible personalized treatments and lists approved brand options; the provider still determines appropriateness. Does membership pay for the drug? The starting membership figure describes care access. Medication price and coverage must be established separately. Must every patient subscribe? The current service description also offers individual pay-per-visit video care. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.evernow.com/) - [How assessment and follow-up work](https://www.evernow.com/how-it-works) - [Terms of service and payment conditions](https://www.evernow.com/legal/terms) - [GLP-1 care and prescribing options](https://www.evernow.com/learn/how-glp-1s-work-to-support-weight-loss-and-hunger-management) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # EverPrime reviews (2026): GLP-1 telehealth sellers | This GLP Named clinical groups, video visits and ongoing support; confirm the pharmacy and the full cost of your chosen care plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/everprime Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Verify your care team # EverPrime review Named clinical groups, video visits and ongoing support; confirm the pharmacy and the full cost of your chosen care plan. ## The verdict EverPrime describes more of the clinical relationship than a checkout-only seller. Its product pages name video visits, lab intervals and support. Confirm your assigned practice and pharmacy before paying, and resolve the separate membership bill first. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Availability Availability varies by state and treatment; confirm eligibility during intake. EverPrime is a prescription-care platform operated by Enhance.MD, LLC. Its membership options and treatment selections have their own terms. An Enhance.MD package should not be assumed to cover the same visits, medication supply or subscription period. 1. ## Who writes the prescription, and what do they see? EverPrime’s contract separates the platform operator from the clinicians. Enhance Wellness, PC, EnhanceMD CA, PC and iThriveMD, PC provide medical services through licensed professionals. The website lists Erik Stark as medical director; that does not identify your personal prescriber. Ask which practice will treat you in your state. The semaglutide page includes an initial video consultation, continued treatment reviews and metabolic testing every six months. The tirzepatide page specifies a video visit every 90 days. These are published service descriptions, not a guarantee of an immediate reply. Ask how to reach a clinician between scheduled visits. 2. ## What happens when the dose goes up? Both full-dose injection pages advertise the same price across doses. They describe deliveries every four weeks. Dose increases still require the treating clinician’s assessment. The separate microdosing product should not be treated as the usual weight-loss dose ladder. 3. ## What the price includes On the one-month selection, the live calculator shows standard medication rates of $249 for semaglutide and $329 for tirzepatide. Member medicine costs are $150 and $230, plus a separate $99 Core membership. The membership page also offers Peak at $199 per month. Longer medication terms change the displayed rates. Request the exact prepaid charge, visit fees and renewal schedule before comparing totals. 4. ## What it claims, and what it cites The offered [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) injections are compounded, rather than FDA-approved finished products. EverPrime says a licensed 503A pharmacy prepares them. Its contract names Rite-Away, Vios and TruMedsRx among pharmacy partners. Some directory labels and links conflict, so establish the actual dispenser on your prescription. ## Where it holds up, and where it does not - Strength: Clinical groups identified in the contract - Strength: Treatment pages specify video visits and lab intervals - Strength: A nonmember purchase route is available - Limitation: The individual dispensing pharmacy needs confirmation - Limitation: Medication and membership commitments can differ - Limitation: State eligibility requires intake confirmation ## What the evidence says about this kind of treatment The assessment above is about EverPrime. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values a published visit schedule and wants to compare continuing care with or without membership. Wrong for Someone expecting the lowest member medication figure to include every care and subscription charge. ## The evidence behind what EverPrime prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How EverPrime compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDExam](https://thisglp.com/reviews/mdexam) [Measured](https://thisglp.com/reviews/measured) [Medi-Weightloss](https://thisglp.com/reviews/medi-weightloss) [MediRX](https://thisglp.com/reviews/medirx) [MedLeanRx](https://thisglp.com/reviews/medleanrx) [Medro](https://thisglp.com/reviews/medro) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is EverPrime connected with Enhance.MD? Yes. EverPrime’s own terms name Enhance.MD, LLC as the operator. Its service choices and prices should still be evaluated separately from an Enhance.MD offer. What happens if I need to stop? The shipping policy asks for notice at least 24 hours before the next billing date. An order cannot be canceled or refunded once pharmacy preparation begins. It promises a full refund if the provider finds treatment unsuitable. Membership payments have separate prepaid conditions; confirm both cancellation steps. Does two-day shipping mean treatment starts in two days? No. The delivery window starts after dispatch. Clinical review, any required consultation or labs, and pharmacy preparation happen first. Report an incorrect, damaged or incomplete delivery within 48 hours. ## Sources for this review Provider information checked October 28, 2026. Terms can change. - [Semaglutide options and selected pricing](https://joineverprime.com/products/glp-1-semaglutide) - [Tirzepatide treatment and care schedule](https://joineverprime.com/products/glp-1-gip-tirzepatide-) - [Optional membership, fees and prepaid terms](https://joineverprime.com/membership-plan) - [Operator, medical groups and pharmacy partners](https://joineverprime.com/terms-of-service) - [Delivery, cancellation and refund policy](https://joineverprime.com/shipping-and-returns) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # EverSlim reviews (2026): GLP-1 telehealth sellers | This GLP The monthly figure covers the medication, the provider visit and the shipping, and it does not move as the dose does. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/everslim Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Visit inside the price # EverSlim review The monthly figure covers the medication, the provider visit and the shipping, and it does not move as the dose does. ## The verdict EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the provider visit and shipping described as included in both. It covers fifty states and the District of Columbia. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $113/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named EverSlim sells compounded semaglutide and compounded tirzepatide as weekly injections, reaching fifty states and the District of Columbia, and its two figures were $113 and $136 a month. Both are described as flat monthly prices, and both are stated to include the medication, the provider visit and shipping. The tirzepatide product is described by its mechanism, as a dual GLP-1 and GIP agonist. 1. ## Who writes the prescription, and what do they see? A provider visit sits inside the monthly figure rather than beside it, which is the arrangement that makes a comparison with a cheaper headline elsewhere worth doing carefully. A seller charging $99 and billing a consultation separately can cost more across a year than one charging $113 with the visit inside. How often that visit repeats across a course of treatment is not something the priced row establishes. Treatment is arranged remotely and the medication arrives by mail on a monthly rhythm, which is the plain version of this category rather than a point of difference. What is different is how little the reader has to keep track of: one charge, one date, and no second line for a visit or for postage. The $23 gap between the two molecules is narrow enough that a clinician's choice between them is unlikely to be made on price. 2. ## What happens when the dose goes up? Both rates are described as flat monthly prices, so the escalation across the first sixteen weeks does not change the charge. That is the part of a course of treatment where a bill most often surprises a reader, and it is the part this seller has taken off the table. What the included visit covers at a dose change, and whether a change requires one, is not published beside the price. 3. ## What the price includes $113 and $136 are low figures for a product with a visit and shipping folded into them, and the honest comparison is against an all-in figure elsewhere rather than against a medication-only headline. Nothing beside either figure was recorded as a separate charge. No prepay ladder is published, so a reader is not being asked to buy a year to reach the rate on the page. 4. ## What it claims, and what it cites Both molecules are compounded, so a pharmacy prepares them and no regulator reviews the finished vial before it ships. Describing [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) as a dual GLP-1 and GIP agonist is accurate — that is what the molecule is, and it is why it is priced above [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) almost everywhere. The published results for both came from the approved products at label doses, and a compounded preparation was not what those trials studied. ## Where it holds up, and where it does not - Strength: Provider visit and shipping included - Strength: Rate flat at every dose - Strength: One monthly charge, no prepay ladder - Limitation: Visit frequency not published - Limitation: Compounding pharmacy not named - Limitation: No lower rung for a longer commitment ## What the evidence says about this kind of treatment The assessment above is about EverSlim. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. Wrong for A reader who wants to know who compounds the vial, since the facility is not named beside either figure. ## The evidence behind what EverSlim prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How EverSlim compares | Seller | Who it suits | Go | | --- | --- | --- | | Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Medro](https://thisglp.com/reviews/medro) [Medsol RX](https://thisglp.com/reviews/medsol-rx) [MEDVi](https://thisglp.com/reviews/medvi) [Metaboost Rx](https://thisglp.com/reviews/metaboost-rx) [Mevo Health](https://thisglp.com/reviews/mevo-health) [Midi Health](https://thisglp.com/reviews/midi-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the monthly figure cover? The medication, the provider visit and shipping are all described as included at both $113 and $136. No separate consultation or postage charge was recorded beside either figure. Does the price rise with the dose? Both rates are described as flat monthly prices, so an escalation through the first sixteen weeks leaves the charge where it started. Why is tirzepatide more expensive? Tirzepatide is a dual GLP-1 and GIP agonist and is priced above semaglutide almost everywhere. Here the gap is $23 a month, which is narrower than most. Is EverSlim expensive compared with other GLP-1 telehealth sellers? EverSlim publishes a starting figure of $113/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts EverSlim below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Eviora MD reviews (2026): GLP-1 telehealth sellers | This GLP Three GLP-1 programs, each marked available by consultation, from a Virginia telehealth practice that quotes a flat rate only after a provider has reviewed the case. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/eviora-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced at consultation # Eviora MD review Three GLP-1 programs, each marked available by consultation, from a Virginia telehealth practice that quotes a flat rate only after a provider has reviewed the case. ## The verdict Eviora MD offers compounded semaglutide, compounded tirzepatide and a lower-dose GLP-1 microdose program, and each treatment page says "Available by consultation" in the place where a buyer would look for a price. A new-patient banner on the homepage carries a monthly from-figure, but it names no drug and says the plan is confirmed after provider review, so nothing on the site works as a price for either molecule. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Eviora MD describes itself as a concierge telehealth platform based in Henrico, Virginia, connecting patients with independent board-certified providers and state-licensed compounding pharmacies. Next to its three GLP-1 programs it lists NAD+ and other peptide therapies, and its about page claims service in all 50 states. The site runs on software shared with other GLP-1 storefronts, which is why its pages may look familiar. 1. ## Who writes the prescription, and what do they see? The platform says plainly that it does not practice medicine or write prescriptions, and that every clinical decision rests with an independent licensed practitioner. No practitioner or medical group is named on the treatment pages, so a patient finds out who is prescribing only once the consultation itself begins. A patient starts with a short online eligibility check, moves on to a consultation, and, if a provider authorizes treatment, receives a protocol prepared by a partner pharmacy, with structured check-ins and secure messaging after it arrives. Memberships can be canceled with 30 days' notice before the next billing cycle, while consultations and filled prescriptions become non-refundable once they begin. 2. ## What happens when the dose goes up? The treatment pages call every program flat-rate, with "no dose-change surcharges", which would mean the monthly figure holds as the dose is stepped up over the first several months. Because that figure is never published, the promise can only be tested after the consultation, when the quote arrives and can be kept in writing for the months that follow. 3. ## What the price includes No rate is published for any GLP-1 line, and the pages come close to saying so outright, promising that the quoted price is the price paid. The banner's from-figure covers GLP-1 programs in general and is confirmed only after provider review, so it cannot be pinned to semaglutide, tirzepatide or the microdose line. Someone comparing sellers has nothing from this one to set beside the others until a consultation has been booked and held. 4. ## What it claims, and what it cites Every GLP-1 program is prepared by partner compounding pharmacies in the United States, none of which is named. The site's own disclaimer says compounded medications are not FDA-approved, and that their safety, efficacy and quality have not been independently verified by the agency. That disclaimer sits at the foot of every page rather than only in the terms. ## Where it holds up, and where it does not - Strength: No dose-change surcharge is promised - Strength: Nothing charged if a patient is not approved - Strength: Cancellation notice period stated up front - Strength: Compounded status disclosed on every page - Limitation: No price published for any GLP-1 line - Limitation: No prescriber or medical group named - Limitation: Compounding pharmacy is not named - Limitation: Filled prescriptions cannot be refunded ## What the evidence says about this kind of treatment The assessment above is about Eviora MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer prepared to sit through a consultation before seeing any figure for the drug, and to hold the practice to its flat-rate promise afterward. Wrong for A buyer who wants to line up published monthly prices across several sellers before starting anything. ## The evidence behind what Eviora MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Eviora MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Superior Remedies | Readers willing to book a consultation before learning any figure | | | MultiMedRx | A reader with insurance who needs a branded GLP-1 covered rather than sold | | | Vytora Health | Buyers expecting several dose steps who want the bill to stay flat | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Mevo Health](https://thisglp.com/reviews/mevo-health) [Midi Health](https://thisglp.com/reviews/midi-health) [Mint Med](https://thisglp.com/reviews/mint-med) [Mint Medical Clinic](https://thisglp.com/reviews/mint-medical) [Mochi Health](https://thisglp.com/reviews/mochi-health) [Mojoon](https://thisglp.com/reviews/mojoon) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How much does semaglutide cost here? Eviora MD does not publish it. The semaglutide page says "Available by consultation", and a quote follows once a provider has reviewed the case. What does the homepage banner's price cover? It is a new-patient offer for GLP-1 programs in general. It names no molecule, and the site says plans are confirmed after provider review. Can a membership be canceled? Yes, with 30 days' notice before the next billing cycle. Consultations, visits and prescriptions already processed are not refunded. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Evolve Telemed reviews (2026): weight-care programs | This GLP Evolve discusses semaglutide within men’s weight-management care. Its separate women’s page emphasizes hormones, so clarify the actual treatment pathway before enrolling. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/evolve-telemed Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Evolve Telemed sell a GLP-1? Evolve discusses semaglutide within men’s weight-management care. Its separate women’s page emphasizes hormones, so clarify the actual treatment pathway before enrolling. ## The verdict Evolve offers a broader clinical assessment rather than a medication-only checkout. Its men’s page specifically discusses semaglutide, while the women’s weight-management page focuses on hormones. Those are different offers: do not assume every weight consultation leads to the same medicine or that hormone treatment is necessary for GLP-1 care. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category weight-care programs Prescription Required Evolve Telemed is a technology and care-coordination platform connecting patients with independent providers. Weight management sits alongside hormone and other wellness services. The men’s program names semaglutide as an option for discussion after medical assessment. 1. ## Who writes the prescription, and what do they see? The legal terms distinguish E-Volve Company from independent clinicians who make treatment decisions. Assessment considers health history and, when needed, laboratory information. Confirm the medical practice and assigned professional before assuming that the platform’s concierge description defines the clinician relationship. The published approach combines health history, goals and lifestyle review with an individualized plan. The terms emphasize monitoring and informed consent. They do not specify one weight-care appointment interval or guaranteed message-response time, so ask how support continues after the initial consultation. 2. ## What happens when the dose goes up? The semaglutide FAQ tells patients to follow the prescribed regimen and consult a professional about progress and tolerability. It does not establish one dose-price ladder for every patient. Obtain the plan for reassessment, refill approval and [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) rather than using a general FAQ as personal dosing advice. 3. ## What the price includes The public weight pages do not provide a complete recurring semaglutide-and-care bill. The terms discuss laboratory services and an annual care plan, which becomes nonrefundable after the initial physician consultation. Confirm which of those arrangements applies to the selected weight-management service. 4. ## What it claims, and what it cites Semaglutide is explicitly discussed, including approved brand examples, but the individual prescription’s brand, formulation and pharmacy are not established by the program overview. The women’s hormone discussion should not be treated as evidence of an identical GLP-1 pathway or as a reason to start hormone therapy for weight alone. ## Where it holds up, and where it does not - Strength: Semaglutide is named in a dedicated clinical pathway - Strength: Independent provider responsibility is disclosed - Strength: Assessment includes broader health context - Limitation: Men’s and women’s program descriptions differ - Limitation: No complete public dose-price schedule - Limitation: Annual-care refund cutoff needs attention ## What the evidence says about this kind of treatment The assessment above is about Evolve Telemed. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a wider medical discussion of weight and metabolic symptoms who first confirms the intended medication and continuing-care pathway. Wrong for A patient expecting every weight program to include semaglutide or needing a fully public cancelable monthly package. ## The evidence behind what Evolve Telemed prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Evolve Telemed compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MyFastRx](https://thisglp.com/reviews/myfastrx) [MyStart Health](https://thisglp.com/reviews/mystart-health) [Näky](https://thisglp.com/reviews/naky) [NativeMed](https://thisglp.com/reviews/nativemed) [Navio MD](https://thisglp.com/reviews/navio-md) [Neo Soma Healthcare](https://thisglp.com/reviews/neo-soma-healthcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does every weight-management page describe GLP-1 care? No. The men’s page discusses semaglutide; the separate women’s page primarily describes hormones and lifestyle factors. Does the platform make prescribing decisions? Its terms place those decisions with independent medical providers. When can an annual care plan become nonrefundable? The terms identify the initial physician consultation as the cutoff. Confirm the applicable arrangement before committing. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Men’s weight-management and semaglutide assessment](https://evolvetelemed.com/weight-management-men/) - [Separate women’s weight-management pathway](https://evolvetelemed.com/weight-loss/) - [Clinical roles, eligibility and financial terms](https://evolvetelemed.com/terms-conditions/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Factor Health MD reviews (2026): GLP-1 telehealth sellers | This GLP A flat price at every dose, with the lowest headline figure belonging to a twelve-month plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/factor-health-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One flat rate, four plan lengths # Factor Health MD review A flat price at every dose, with the lowest headline figure belonging to a twelve-month plan. ## The verdict Factor Health MD charges one flat rate at every dose, which removes the usual rise in the bill as the dose climbs, and on a month-to-month plan that rate is $99.99 for compounded semaglutide and $189.99 for compounded tirzepatide. The $79.99 and $149.99 the site leads with are the twelve-month plans, printed on the pricing page beside their annual totals. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $99.99/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Factor Health MD is a Florida-based telehealth service that prescribes compounded semaglutide and tirzepatide, sold as Semaglutide Plus and Tirzepatide Plus, alongside liraglutide, vitamin injections, erectile dysfunction pills and a hair-regrowth topical. The weight-loss products are the center of the site, and a banner across the top announces that plans now start at a new lower price. 1. ## Who writes the prescription, and what do they see? Every patient has a two-way video consultation with a licensed provider before a prescription is written, and the FAQ says the video visit is required rather than offered, which is a firmer standard than an asynchronous questionnaire. The consultation is described as free, and providers are assigned by state licensing and availability. No individual provider or medical group is named on the site, though the FAQ says a patient can ask for a different one. After the video visit, prescriptions go to a network of licensed pharmacies that ship directly to the patient, since Factor Health MD states it does not dispense medication itself. Refills run automatically each month, virtual physician appointments are available as needed, and syringes, alcohol swabs and shipping are included. Canceling is possible at any time through the account, but it takes fourteen days' notice before the next billing date to avoid another charge. 2. ## What happens when the dose goes up? The strongest thing on this site is the promise that the price does not move with the dose: every plan says all doses are included, and the semaglutide page adds that the price will not increase. That page also prints an example schedule, two weeks at each step from 0.2 mg to 1.5 mg and then four-week steps up to 2.64 mg, which the provider may change. Additives such as glycine, B12 or B6 may be mixed into the same vial, depending on the provider's choice and the pharmacy's formulation. 3. ## What the price includes The pricing page sets out four plan lengths for each molecule, from one month to twelve, and each carries its own monthly rate. Month to month, semaglutide is $99.99 and tirzepatide $189.99, and the rate falls as the commitment lengthens, down to $79.99 and $149.99 a month on the twelve-month plans, where semaglutide is printed as $959.88 for the year. The FAQ says all charges are billed monthly and that no long-term contract is required, while the pricing page sells the cheaper rungs as three-, six- and twelve-month supplies. 4. ## What it claims, and what it cites Both GLP-1 products are compounded and patient-specific, with additives chosen by the provider, and compounded medications are not FDA-approved. The site does not name a pharmacy; it says medications ship from third-party compounding pharmacies and that a pharmacy outside its recommended network may not honor its pricing. ## Where it holds up, and where it does not - Strength: One flat rate at every dose - Strength: Video consultation required before prescribing - Strength: Every plan length is priced on one page - Strength: Supplies and shipping are included - Limitation: The headline rate is the twelve-month plan - Limitation: No pharmacy is named - Limitation: Fourteen days' notice needed to cancel - Limitation: Additives vary by pharmacy formulation ## What the evidence says about this kind of treatment The assessment above is about Factor Health MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who expects to climb the dose ladder and wants a video visit with the prescriber before the first shipment. Wrong for Someone who reads the headline figure as the month-to-month price, or who wants to know which pharmacy fills the order. ## The evidence behind what Factor Health MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Factor Health MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Navio MD](https://thisglp.com/reviews/navio-md) [Neo Soma Healthcare](https://thisglp.com/reviews/neo-soma-healthcare) [NEUVÉ Health](https://thisglp.com/reviews/neuve-md) [New Wave Health](https://thisglp.com/reviews/new-wave-health) [NewSelf](https://thisglp.com/reviews/newself) [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Factor Health MD cost without a long commitment? The month-to-month plans are $99.99 for semaglutide and $189.99 for tirzepatide, with all doses included at that rate. Where does the $79.99 figure come from? It is the twelve-month semaglutide plan, which the pricing page prints as $959.88 for a year's supply. Do I have to see a provider on video? Yes, the FAQ says every patient must have a two-way audio and video consultation with a provider before a prescription is issued, and describes that visit as free. Is Factor Health MD expensive compared with other GLP-1 telehealth sellers? Factor Health MD publishes a starting figure of $99.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Factor Health MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FeelGood reviews (2026): GLP-1 telehealth sellers | This GLP FeelGood offers compounded weight-care products and branded options through independent medical groups. Its round-the-clock support claim should be separated from access to the clinician managing treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/feelgood-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Support is not the prescriber # Does FeelGood sell a GLP-1? FeelGood offers compounded weight-care products and branded options through independent medical groups. Its round-the-clock support claim should be separated from access to the clinician managing treatment. ## The verdict FeelGood’s useful distinctions are its separate injection, tablet and original-product categories. Its broad weight-loss promises are less informative than the exact formulation and follow-up arrangement. Ask who reviews side effects and what its money-back offer actually covers before treating marketing assurances as a clinical service guarantee. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved FeelGood is a platform facilitating access to prescription weight management through affiliated medical groups and pharmacies. It advertises compounded injections, dissolving tablets and original injections in different price categories. The platform itself says it does not diagnose or treat patients. 1. ## Who writes the prescription, and what do they see? Independent practitioners working with medical groups deliver care and must be licensed where the patient is located. The terms reserve diagnosis and prescribing to those professionals. A patient should obtain the responsible practice’s details rather than assuming a support specialist is the prescriber. The homepage outlines evaluation, a personalized treatment plan and continuing support. It advertises access to specialists at any time. The reviewed information does not establish that a licensed clinician answers every message immediately or publishes one universal refill-review schedule. 2. ## What happens when the dose goes up? A personalized plan does not establish a published escalation ladder. Before ordering, clarify how treatment is reassessed, what happens when tolerance changes and whether dose adjustments alter the next bill. Never infer a dose from a price category. 3. ## What the price includes The public figures are starting amounts across several product categories. They do not establish one universal dose-independent continuation total. Ask for the selected medicine, formulation, supply period and later-dose charge, including how any first-order offer changes. 4. ## What it claims, and what it cites Compounded injection and tablet options are marketed separately from original injections, and the footer names tirzepatide microdosing. Confirm the exact active ingredient and formulation for the proposed prescription. Compounded drugs are not FDA approved, and oral products need formulation-specific evidence. ## Where it holds up, and where it does not - Strength: Product-format categories separated - Strength: Professional medical role explained in terms - Strength: Continuing support described - Limitation: Support hours do not establish clinician response time - Limitation: Starting prices do not settle the later-dose total - Limitation: Money-back conditions require examination ## What the evidence says about this kind of treatment The assessment above is about FeelGood. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient willing to confirm the exact product and medical follow-up behind a convenient online service. Wrong for Someone relying on guaranteed weight-loss language instead of an individualized clinician discussion. ## How FeelGood compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NextMeds](https://thisglp.com/reviews/nextmeds) [NiceRx](https://thisglp.com/reviews/nicerx) [Nirwana Health](https://thisglp.com/reviews/nirwana-health) [NoBsRx](https://thisglp.com/reviews/no-bs-rx) [Nolu](https://thisglp.com/reviews/nolu) [Noom](https://thisglp.com/reviews/noom) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does FeelGood itself provide medical care? Its terms say independent medical groups and practitioners provide healthcare; the platform facilitates access. Are compounded tablets equivalent to approved injections? That cannot be assumed. Ask about evidence for the actual formulation rather than borrowing outcomes from a different product. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://www.feelgoodmeds.com/) - [Service and cancellation terms](https://www.feelgoodmeds.com/terms-of-use) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fella Health reviews (2026): GLP-1 telehealth sellers | This GLP A men's weight-loss program that states its cost per day, not per month, and backs it with a conditional six-month refund. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fella-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Cost stated per day # Fella Health review A men's weight-loss program that states its cost per day, not per month, and backs it with a conditional six-month refund. ## The verdict Fella Health publishes no monthly rate for its GLP-1 program. The FAQ says the core program "starts at less than $10 per day" and covers medication, assessments and medical support. A money-back guarantee applies at six months, under strict conditions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 20 Prescription Required Pharmacy Not named Labs Included Fella Health is a men's telehealth program for weight loss, with testosterone and longevity treatments sold beside it. Its GLP-1 plans come in three kinds: compounded, microdose, and branded Zepbound through LillyDirect. 1. ## Who writes the prescription, and what do they see? Prescribing sits with Fella Medical Group, P.A., a Florida professional medical corporation named in the membership terms. The homepage calls its clinicians board-certified. No individual clinician is named on the treatment pages. A member completes a medical form, then gets free lab work locally or with an at-home kit. Labs from the past 24 months can be used instead. Clinicians then build a plan that may include a GLP-1. The membership fee is charged in advance and can change with 90 days' written notice. 2. ## What happens when the dose goes up? The FAQ states that the cost won't change with the dose a member requires. That covers the program fee across escalation. For branded Zepbound, the drug is paid directly to the pharmacy, outside the program fee. 3. ## What the price includes The per-day figure is a ceiling, not a rate, and no molecule or plan is attached to it. The priced cards on the treatments page belong to the testosterone and longevity lines. The membership terms say the fee is stated at sign-up, after the eligibility quiz. 4. ## What it claims, and what it cites The standard and microdose plans may use compounded medication, which the site says is not FDA-approved. The microdose plan is described as not intended for weight loss. [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), an FDA-approved tirzepatide, is offered through LillyDirect. No compounding pharmacy is named. ## Where it holds up, and where it does not - Strength: Program fee stated as flat across doses - Strength: Prescribing medical group named in the terms - Strength: Free lab work included at the start - Strength: Six-month money-back guarantee on GLP-1 plans - Limitation: No monthly GLP-1 rate is published - Limitation: Guarantee requires strict tracking and adherence - Limitation: Compounding pharmacy is not named - Limitation: Branded drug costs fall outside refunds ## What the evidence says about this kind of treatment The assessment above is about Fella Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A man who wants labs, a named medical group and a refund backstop, and will log his weight weekly. Wrong for A buyer who needs a monthly figure before starting the quiz. ## The evidence behind what Fella Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fella Health compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nova](https://thisglp.com/reviews/nova) [Nova MD](https://thisglp.com/reviews/nova-md) [Novi](https://thisglp.com/reviews/novi) [NovoCare Pharmacy](https://thisglp.com/reviews/novocare-pharmacy) [NowPatient](https://thisglp.com/reviews/nowpatient) [NP2GO](https://thisglp.com/reviews/np2go) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost? No monthly figure is public. The FAQ puts the core program at less than $10 per day, medication included. How does the guarantee work? A member who stays 180 days and loses less than 5% of starting weight can claim a refund in month seven. Logging weight in 21 of the first 26 weeks is one condition. Does the refund cover branded Zepbound? Only the membership fee. Medication paid directly to the pharmacy is excluded. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fidelity Medical Clinic reviews (2026): GLP-1 telehealth sellers | This GLP Each order buys four doses over four weeks, so thirteen of them land in a calendar year. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fidelity-medical-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four doses, four weeks # Fidelity Medical Clinic review Each order buys four doses over four weeks, so thirteen of them land in a calendar year. ## The verdict Fidelity Medical Clinic sells semaglutide at $199 for four doses and tirzepatide at $349 for four. Four weeks is not a calendar month. Converted by month length, the figures ranked here are $216 and $379. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $216/mo Prescription Required Compounded Yes — not FDA-approved Fidelity Medical Clinic sells compounded semaglutide and compounded tirzepatide. Both are weekly injections. Maintenance orders cover four doses across four weeks. The published order prices are $199 and $349. Coverage is listed as fifty states. 1. ## Who writes the prescription, and what do they see? A prescription is required before the first order. The intro order is labeled an initial prescription. It requires a two-month commitment. The maintenance order follows it. What the clinic asks before prescribing is not published. Neither is how often a patient is reviewed afterwards. Care is arranged remotely. Supplies are included with each order. The intro semaglutide order is $99 for eight doses. That works out at $49.50 a month for two months. The tirzepatide intro is $349 for eight doses, or $174.50 a month. 2. ## What happens when the dose goes up? The dose-pricing model is not published. Neither rate is described as flat. A reader should not assume the figure holds as the dose rises. The intro order runs two months. The first escalation usually falls inside it. What the next order costs at a higher dose is not stated. 3. ## What the price includes Four-week orders are the unit here. A calendar month is longer than four weeks. Converted by month length, $199 becomes $216 and $349 becomes $379. That conversion is used rather than a thirteen-fills approximation. The intro figures are lower and last two months. Budget from the maintenance figure, not the intro one. 4. ## What it claims, and what it cites Both products are compounded. A pharmacy prepares them. No regulator reviews the finished vial. A compounded preparation is not FDA-approved. The published trial results used the approved products at label doses. A compounded vial was not what those trials measured. ## Where it holds up, and where it does not - Strength: Order contents stated as four doses - Strength: Supplies included with each order - Strength: Intro order priced and dated - Limitation: Four weeks is not a calendar month - Limitation: Dose-pricing model not published - Limitation: Intro order requires two months ## What the evidence says about this kind of treatment The assessment above is about Fidelity Medical Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who counts fills rather than months. The order unit is published in doses. Wrong for A reader comparing monthly rates directly. Thirteen fills a year make that comparison wrong. ## The evidence behind what Fidelity Medical Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fidelity Medical Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) [NuBloom](https://thisglp.com/reviews/nubloom) [Nucore Health](https://thisglp.com/reviews/nucore-health) [NuDay Rx](https://thisglp.com/reviews/nuday-rx) [NuuVim](https://thisglp.com/reviews/nuuvim) [NuviaRx](https://thisglp.com/reviews/nuviarx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is the figure here $216 rather than $199? Because an order covers four weeks and a calendar month is longer. Converting $199 by month length gives $216. The tirzepatide order converts the same way, from $349 to $379. What does the intro order cover? Eight doses across two months. Semaglutide is $99 and tirzepatide is $349. A two-month order is required at that price. Does the price rise with the dose? Not published. The dose-pricing model is not stated on either row, so a higher dose may or may not carry a higher order price. Is Fidelity Medical Clinic expensive compared with other GLP-1 telehealth sellers? Fidelity Medical Clinic publishes a starting figure of $216/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fidelity Medical Clinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fierce Health reviews (2026): GLP-1 telehealth sellers | This GLP The order is paid before the medical intake, and a nurse practitioner sets the dose afterward. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fierce-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Checkout first, intake after # Fierce Health review The order is paid before the medical intake, and a nurse practitioner sets the dose afterward. ## The verdict Fierce Health sells its full-dose compounded semaglutide program at $297 a month and tirzepatide at $497. Payment comes first, and the intake form arrives after checkout. A refund is promised if a provider finds the treatment unsuitable. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $297/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider Fierce Health is a cash-pay online store for compounded GLP-1 programs and other prescription products. The weight-loss menu has two tracks: full-dose programs and lower-priced microdose programs. Ivermectin, methylene blue, NAD+ and lab panels are sold from the same shop. Each program is a monthly subscription, with three- and six-month options paid in full. 1. ## Who writes the prescription, and what do they see? The home page says a board-certified, US-licensed provider reviews the intake and prescribes, or declines. The semaglutide page says the dose is set from the intake and approved by a licensed nurse practitioner. A telemedicine appointment is scheduled only if the intake leaves questions open. No individual provider or medical group is named anywhere on the product pages. Messaging runs through the Fierce Portal, and access to a registered nurse is listed as included. Meal plans, a workout library and a monthly progress check-in are bundled into every program. Medication ships from a partner pharmacy, and the product page estimates about two weeks from checkout. Subscriptions can be adjusted, paused or canceled at any time without a cancellation fee. 2. ## What happens when the dose goes up? Doses are written in syringe units, not milligrams, so the strength behind a unit is not stated. Patients start at 5 to 10 units and move up as the body adjusts. One vial ships each month, and the page asks patients to email support once the dose passes 50 units. What that change does to the monthly price is not stated. A maintenance program is described for tapering off the medication. 3. ## What the price includes The full-dose programs are $297 a month for semaglutide and $497 for tirzepatide, each labeled as the regular price. The three- and six-month options are each paid in a single upfront charge. Separate microdose programs cost less and are sold beside them on the same menu. No separate membership or consultation fee is listed on either product page. 4. ## What it claims, and what it cites Both molecules are compounded and come from a licensed partner pharmacy, which is not named. The site footer states that compounded medications are not reviewed by the FDA for safety or efficacy, and they are not FDA-approved. The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) page quotes the STEP and cardiovascular trials, which studied the approved product at labeled doses. ## Where it holds up, and where it does not - Strength: Refund promised if treatment is declined - Strength: Monthly plan with no long-term contract - Strength: Nurse access through the patient portal - Strength: LegitScript certification is stated - Limitation: Payment is taken before the intake - Limitation: Doses are written in units, not milligrams - Limitation: No pharmacy or prescriber is named - Limitation: Shipping coverage is stated two different ways ## What the evidence says about this kind of treatment The assessment above is about Fierce Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a monthly plan with meal and workout material bundled in. Wrong for A reader who wants a clinician's review before paying, or a dose in milligrams. ## The evidence behind what Fierce Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fierce Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Obu Health](https://thisglp.com/reviews/obu-health) [Omnia TeleHealth](https://thisglp.com/reviews/omnia-telehealth) [Omzo](https://thisglp.com/reviews/omzo) [Ondra Health](https://thisglp.com/reviews/ondra-health) [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) [OnlyRx](https://thisglp.com/reviews/onlyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Fierce Health charge for semaglutide and tirzepatide? The full-dose programs are $297 a month for semaglutide and $497 for tirzepatide. The microdose programs are separate and cost less. When does the medical review happen? After checkout, when an intake form is sent for the paid order. If treatment is not suitable, the money is refunded. Which states does Fierce Health ship to? The product page says all 50 states, while the home page FAQ says most states, with a refund where it cannot ship. No state list is published. Is Fierce Health expensive compared with other GLP-1 telehealth sellers? Fierce Health publishes a starting figure of $297/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fierce Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fifty 410 reviews (2026): GLP-1 telehealth sellers | This GLP A page with three starting-at figures on it, only one of which is a GLP-1. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fifty-410 Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three catalogs, three floors # Fifty 410 review A page with three starting-at figures on it, only one of which is a GLP-1. ## The verdict Fifty 410 prints three starting-at prices within a screen of each other. The GLP-1 card is $199 a month, the $99 beneath it is a minoxidil hair formula for women, and $75 belongs to sermorelin and its neighbors. Both GLP-1s are $199 month to month; tirzepatide also comes in three-month programs from $133 a month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Fifty 410 is a telehealth platform selling compounded semaglutide and tirzepatide alongside hair-care, NAD+, sermorelin, glutathione and methylene blue. It states that it does not compound, manufacture or distribute anything itself. Independent pharmacies prepare what a provider prescribes. 1. ## Who writes the prescription, and what do they see? Every intake is reviewed by a licensed provider, and the platform is explicit that it makes no prescribing decision of its own. No card is charged until that provider issues a prescription, which puts the clinical decision genuinely before the payment. What the provider reviews, and whether a patient ever speaks to one, is not described. An online intake goes to a provider, and medication ships in one to two days if it is prescribed. There is no membership, and an order can be canceled up to the point compounding begins. Payments can be split through Afterpay or Affirm, or paid from an FSA or HSA. 2. ## What happens when the dose goes up? The month-to-month tirzepatide plan is stated to include all dosages at $199. The three-month programs are banded by dose instead, with the starting tier at $133 a month and higher tiers above it. No milligram figure appears beside either molecule. 3. ## What the price includes The pricing pages answer the homepage card. Semaglutide is $199 a month, pay as you go. Tirzepatide is $199 a month with no commitment, or $133 a month on a three-month starter program billed $399 up front. Reading the $99 card as a GLP-1 price understates it by half. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded by independent pharmacies rather than manufactured, prepared only once a provider prescribes. The FDA does not review a compounded preparation before it is dispensed. No pharmacy is named, and the platform states it is not the compounder. ## Where it holds up, and where it does not - Strength: Nothing is charged until a provider prescribes - Strength: An order can be canceled before compounding starts - Strength: No membership fee - Strength: Dose tiers are published with their totals - Strength: Free shipping in one to two days - Limitation: Three unrelated starting-at figures share one page - Limitation: The homepage GLP-1 card names two molecules at once - Limitation: The lowest tirzepatide rate needs three months paid up front - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Fifty 410. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants no charge before a prescription exists and will check which card a figure belongs to. Wrong for A buyer who read $99 as the price of a GLP-1. ## The evidence behind what Fifty 410 prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fifty 410 compares | Seller | Who it suits | Go | | --- | --- | --- | | TRYM Health | Buyers who will go looking for the plan table rather than price a program by the day | | | CoraDoc | Buyers who would rather pay a program once than carry a subscription they have to remember to cancel | | | Nu Image Medical | Buyers comparing the injectable and the dissolving tablet who will read which card a figure sits on | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Onyx Weight Loss](https://thisglp.com/reviews/onyx-weight-loss) [Open Water Rx](https://thisglp.com/reviews/open-water-rx) [Optimized Health](https://thisglp.com/reviews/optimized-health) [Options Medical Weight Loss](https://thisglp.com/reviews/options-medical-weight-loss) [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) [Oria Meds](https://thisglp.com/reviews/oria-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $99 buy here? A minoxidil hair formula for women. The GLP-1 card on the same page starts at $199 a month. What does tirzepatide cost? $199 a month with no commitment and all dosages included. The three-month starter program is $133 a month, billed as $399 up front. When am I charged? Only after a licensed provider issues a prescription. No credit card is required to start the intake. Is Fifty 410 expensive compared with other GLP-1 telehealth sellers? Fifty 410 publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fifty 410 above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FitFlow reviews (2026): GLP-1 telehealth sellers | This GLP The rate in the browser tab is the twelve-month plan paid upfront. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fitflow Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A year, in the page title # FitFlow review The rate in the browser tab is the twelve-month plan paid upfront. ## The verdict FitFlow puts $99 a month in the title of its own semaglutide page. The footnote at the bottom of that page fixes the figure to a twelve-month plan paid upfront. Month to month the same vial is $175, with quarterly and six-month rungs published in between. Tirzepatide runs the same shape from $134 to $235. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $175/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider FitFlow is a cash-pay telehealth platform selling compounded semaglutide and compounded tirzepatide by weekly injection. Sermorelin, NAD+, a lipotropic blend, glutathione and a skin-care line share the catalog. Coverage is stated for all fifty states, with treatment availability varying by state regulation. A page of its own separates FitFlow from a similarly named unrelated business. 1. ## Who writes the prescription, and what do they see? Care is delivered by an independent medical group named on a page of its own, and the site states that no approval is automated. A provider licensed in the buyer's state reviews the intake individually and declines where treatment is not appropriate. Dosing is described as selected by that provider. No individual clinician is named beside the group. Three steps run from intake to delivery, with the prescription dispensed by a licensed U.S. pharmacy. Messaging with the care team is offered at any point. LegitScript certification is stated, and the site links its own listing. Plans are bought per molecule rather than as a membership. 2. ## What happens when the dose goes up? The plan price is flat within a term, so a step up the ladder does not change the charge. The site states dosing is selected by the reviewing provider, with ongoing check-ins as the plan progresses. No milligram figure appears beside any plan. What a provider weighs before raising a dose is not published. 3. ## What the price includes Semaglutide is $175 billed monthly, $435 quarterly, $720 for six months and $1,188 for a year. Tirzepatide is $235, $597, $1,050 and $1,608 on the same four terms. The per-month equivalent is printed beside each prepay total, and the six-month rung is marked popular on both pages. The headline figure on each page is the annual rung. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, and FitFlow states it neither manufactures nor compounds. A banner at the top of every product page repeats that compounded drugs are not FDA-approved. The dispensing pharmacies are described as licensed and U.S.-based but are not named. ## Where it holds up, and where it does not - Strength: The billed total is printed beside every rate - Strength: One price at every dose inside a term - Strength: The medical group is named on its own page - Strength: LegitScript certification is stated and linked - Strength: A page disambiguates a similar company name - Limitation: The page title quotes the twelve-month rung - Limitation: $1,188 is charged in a single payment - Limitation: The prepay footnote sits below the fold - Limitation: No compounding pharmacy is named - Limitation: No milligram dose appears beside a plan ## What the evidence says about this kind of treatment The assessment above is about FitFlow. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who reads the plan table before the page title. Wrong for A buyer who will not hand over $1,188 in a single charge. ## The evidence behind what FitFlow prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How FitFlow compares | Seller | Who it suits | Go | | --- | --- | --- | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | | SkyRx | Buyers ready to prepay a year who want the medication, visit and shipping in one figure | | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Oria Meds](https://thisglp.com/reviews/oria-meds) [OurView Health](https://thisglp.com/reviews/ourview-health) [Oxford's Medical Weight Loss (The Calibrate Clinic)](https://thisglp.com/reviews/the-calibrate-clinic)[Ozari Health](https://thisglp.com/reviews/ozari-health) [Pallas Health](https://thisglp.com/reviews/pallas-health) [PauseRX](https://thisglp.com/reviews/pauserx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a month what a new patient pays? Only on the twelve-month plan paid upfront, which is $1,188 in one charge. Billed monthly, semaglutide is $175. Does a higher dose cost more? No. The plan rate is flat within its term, and the site states dosing is set by the reviewing provider. Is FitFlow the same as the similarly named company? No. FitFlow publishes a page stating it is unaffiliated with fitflow.ai and that its checkout runs only on its own domain. Is FitFlow legit? FitFlow is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is FitFlow expensive compared with other GLP-1 telehealth sellers? FitFlow publishes a starting figure of $175/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts FitFlow below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fitish reviews (2026): GLP-1 telehealth sellers | This GLP Two lanes per molecule, one monthly supply price each, and a microdose lane that stays at one dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fitish Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Full dose or fixed microdose # Fitish review Two lanes per molecule, one monthly supply price each, and a microdose lane that stays at one dose. ## The verdict Fitish charges $219 a month for compounded semaglutide with B6. Tirzepatide is $339. Each price covers the consult, the medication and shipping. A cheaper microdose lane exists and does not titrate up. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $219/mo Prescription Required Compounded Yes — not FDA-approved Fitish RX is the prescription side of a store that also sells skin care. It sells both molecules as weekly injections. Each comes in a full-dose lane and a microdose lane. The product pages describe the injections as built for women. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the online intake. A live consult happens only where a state requires one. Otherwise the provider reads the form and messages with questions. The providers are described as board-certified. They work through a telehealth platform the site does not name. Approval triggers the charge and sends the prescription to a pharmacy. The medication ships monthly. The care team answers through a patient portal at no added cost. The clinic FAQ states that all sales are final once a purchase completes. 2. ## What happens when the dose goes up? The provider titrates the full-dose lane over time. The tirzepatide page calls its $339 flat for a monthly supply. The semaglutide page states $219 per monthly supply and lists no dose tier. Dose questions go through the portal at no added cost. The microdose lane is fixed and never steps up. 3. ## What the price includes Six months of full-dose semaglutide is $1,314. Tirzepatide over the same span is $2,034. No membership or consult fee sits outside either figure. The microdose lanes cost less on both molecules. They are a separate plan held at one low dose. 4. ## What it claims, and what it cites Both lines are prepared by a state-licensed sterile compounding pharmacy. That pharmacy is not named. Compounded preparations are not FDA-approved. They receive no FDA review before they ship. ## Where it holds up, and where it does not - Strength: Consult and shipping inside the price - Strength: A microdose lane labeled as fixed - Strength: Portal dose support at no added cost - Strength: Live consult only where a state requires - Limitation: All sales final once a purchase completes - Limitation: No milligram dose beside either price - Limitation: The compounding pharmacy is not named - Limitation: The telehealth platform is not named ## What the evidence says about this kind of treatment The assessment above is about Fitish. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one monthly price with the consult and shipping inside it. Wrong for A reader who may want a refund after paying, since all sales are final. ## The evidence behind what Fitish prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fitish compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | ElleS | Buyers who want the prescribing physicians and pharmacies named before they pay | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Peak Wellness](https://thisglp.com/reviews/peak-wellness) [PepHaūs](https://thisglp.com/reviews/pephaus) [Pepti](https://thisglp.com/reviews/pepti) [Piper](https://thisglp.com/reviews/piper) [PlexusDx](https://thisglp.com/reviews/plexusdx) [PlushCare](https://thisglp.com/reviews/plushcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a membership fee? No. The price covers the consult, the medication and shipping. Does the microdose lane step up? No. It stays at one low dose. A higher dose needs the full-dose lane. Can I cancel after paying? The clinic FAQ states all sales are final once a purchase completes. Is Fitish expensive compared with other GLP-1 telehealth sellers? Fitish publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fitish above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fitness RX reviews (2026): GLP-1 telehealth sellers | This GLP A subscription GLP-1 service that prints one medication-inclusive floor and leaves the product behind it to the intake. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fitness-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Floor stated, product unstated # Fitness RX review A subscription GLP-1 service that prints one medication-inclusive floor and leaves the product behind it to the intake. ## The verdict Fitness RX advertises treatment from $119 a month with medication included. That floor is not attached to a named product. Six products are listed, brand and compounded, and none carries its own figure. What a given molecule costs is set inside an intake that opens with a date of birth. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $119/mo Dose published No Prescription Required Pharmacy Not named Availability All 50 states and DC Fitness RX is a subscription service built around GLP-1 medication, with a fitness app added later in the program. Its homepage lists Ozempic, Wegovy and Zepbound beside injectable semaglutide, injectable tirzepatide and sublingual semaglutide. The support pages describe a three-phase plan: medication first, then behavior coaching, then short workouts. 1. ## Who writes the prescription, and what do they see? The support center says prescribing decisions rest with an independent licensed clinician. It also states that Fitness RX does not employ or supervise those clinicians. No clinician is named on the public pages, and no credential type is given. The first review is described as asynchronous, usually within minutes, with video only if the clinician asks for it. A patient completes an online intake, is matched to a clinician licensed in their state, and receives medication from a partner pharmacy in two to four business days. Follow-ups run every four weeks through a fresh intake form. The support pages state availability in all 50 states and the District of Columbia. 2. ## What happens when the dose goes up? The terms say the patient is told of any cost increase if a clinician prescribes a higher dose. They also say no added charge is applied without consent. So the price can move with the dose, but the size of any step is not published. No milligram figure appears beside the $119 floor. 3. ## What the price includes The only figure on the public pages is the $119 floor, stated to include medication. The support center says medication, visits and support share one monthly price with no hidden fees. The terms separately describe a shipping fee calculated at checkout. A six-month course at the floor would be $714, if the floor applied to the product prescribed. 4. ## What it claims, and what it cites The support center lists brand [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review), Wegovy and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) alongside sublingual semaglutide and compounded tirzepatide. The compounded lines are not FDA-approved, a point the support center makes itself, and the FDA does not review them before dispensing. The partner pharmacy is not named. ## Where it holds up, and where it does not - Strength: Medication included in the advertised monthly floor - Strength: Service stated in all 50 states and DC - Strength: Notice promised before any dose-driven price change - Limitation: The floor is not tied to any one product - Limitation: Clinicians are unnamed and not employed by the seller - Limitation: Checkout shipping fee sits outside the no-hidden-fees answer - Limitation: No refunds once an order has shipped ## What the evidence says about this kind of treatment The assessment above is about Fitness RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who is content to learn the product-specific price inside the intake and wants medication folded into one monthly charge. Wrong for A reader who needs a semaglutide or tirzepatide price before sharing a date of birth. ## The evidence behind what Fitness RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fitness RX compares | Seller | Who it suits | Go | | --- | --- | --- | | TeleZen MD | Readers who want the monthly rate and every term discount on one card | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PlushCare](https://thisglp.com/reviews/plushcare) [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) [Potere Health MD](https://thisglp.com/reviews/potere-health-md) [Precision Telemed](https://thisglp.com/reviews/precision-telemed) [Premium Health](https://thisglp.com/reviews/premium-health) [PrescribedRX](https://thisglp.com/reviews/prescribedrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the $119 buy? The site says it includes medication. It does not say which product or dose it covers, and no product card prints its own price. Who prescribes at Fitness RX? An independent licensed clinician. The support center states that Fitness RX neither employs nor supervises its clinicians, and none is named. Can the price change as the dose rises? The terms allow it. They promise notice of any increase and no extra charge without consent, but publish no amount. Is Fitness RX legit? Fitness RX is a GLP-1 telehealth sellers service. Its stated availability: All 50 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Fitness RX expensive compared with other GLP-1 telehealth sellers? Fitness RX publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fitness RX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FitRx reviews (2026): GLP-1 telehealth sellers | This GLP An insurance-first service with a bundled cash plan for compounded GLP-1s and a cheaper route that adds a membership. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fitrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two paths, one bundled price # FitRx review An insurance-first service with a bundled cash plan for compounded GLP-1s and a cheaper route that adds a membership. ## The verdict FitRx's FAQ prices a semaglutide bundle at $297 a month after a $217 first month. The tirzepatide bundle is $449 after $349. Both include medication and care. But the bundle pages it links to do not load, so no FitRx price is ranked here. The $25 figure on the page is an insurance copay, not a cash price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 51 Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named FitRx is a telehealth service with a weight-loss line among several others. It works insurance first for brand Wegovy, Ozempic, Zepbound and Mounjaro. Members without coverage are offered compounded semaglutide or tirzepatide. Government insurance is not accepted. 1. ## Who writes the prescription, and what do they see? The FAQ says providers are licensed physicians and nurse practitioners. It calls them board-certified. No clinician is named on the public pages. The FAQ describes monthly video or phone visits and unlimited messaging. First, the member completes an intake. Next, a provider reviews it within one to two business days. If approved, a partner pharmacy ships the medication. For brand drugs, a coordinator files prior authorizations, up to three attempts. Memberships bill monthly. They cannot be paused. Shipments can be delayed in the portal. 2. ## What happens when the dose goes up? The bundle price covers the standard [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule. The FAQ states that a dose above that schedule may carry additional fees. The amount is not published. No milligram dose is printed beside either bundle. 3. ## What the price includes Two cash paths are described. The bundle is $297 a month for semaglutide and $449 for tirzepatide, medication included. The first month is $217 and $349. Those figures appear only in the FAQ, and its bundle links lead to missing pages, so they are not ranked. The second path is a membership plus medication. The first membership month is $39. The standing membership fee is not stated. Medication on that path starts at $151 a month for semaglutide and $216 for tirzepatide. Both of those need a three-month supply. The page also runs a sale banner with a closing date. A first-month discount is not the price. 4. ## What it claims, and what it cites The cash products are compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and compounded tirzepatide. Compounded drugs are not FDA-approved. The FDA does not review them before dispensing. The pharmacy is not named. Brand drugs are billed through the member's insurance. ## Where it holds up, and where it does not - Strength: FAQ bundle includes medication and care in one charge - Strength: Prior authorizations filed for brand drugs - Strength: Refund stated if found clinically ineligible - Limitation: Standing membership fee not published - Limitation: Lowest medication rates need a three-month supply - Limitation: Doses above standard titration may cost extra - Limitation: No compounding pharmacy named - Limitation: Bundle pages linked from the FAQ do not load ## What the evidence says about this kind of treatment The assessment above is about FitRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader with commercial insurance who wants brand coverage pursued, with a bundled cash fallback. Wrong for A reader on Medicare or Medicaid, which the program does not accept. ## The evidence behind what FitRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How FitRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Good Girl Rx | A reader who will read the one-month rung rather than the headline, and wants microdoses labeled as such | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Lemonaid Health | Readers who want named clinicians and a price that holds through dose changes | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Primary Clinic (Direct GLP)](https://thisglp.com/reviews/primary-clinic)[Prime Doctor RX](https://thisglp.com/reviews/prime-doctor-rx) [Prime Health](https://thisglp.com/reviews/prime-health) [Queen RX](https://thisglp.com/reviews/queen-rx) [QuickMD](https://thisglp.com/reviews/quickmd) [ReadyRx](https://thisglp.com/reviews/readyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does compounded semaglutide cost at FitRx? The FAQ says $297 a month on the bundle, after a $217 first month, with medication and care included. The bundle pages it links to do not load, so the figure is not ranked here. Is the $25 a cash price? No. It is the lowest insurance copay the site describes for covered brand drugs. Can a membership be paused? No. The FAQ says memberships cannot be paused. Medication shipments can be delayed in the portal. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fitstry reviews (2026): GLP-1 telehealth sellers | This GLP The cards start at $149, the FAQ bills $249 every four weeks, and a clinician reads a long profile before anything ships. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fitstry Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week billing, clinician first # Fitstry review The cards start at $149, the FAQ bills $249 every four weeks, and a clinician reads a long profile before anything ships. ## The verdict Fitstry's product cards start compounded semaglutide at $149 and tirzepatide at $199, but the FAQ further down the same page bills month-to-month plans at $249 and $339, with a charge landing every four weeks. Thirteen of those charges land in a year, which works out to about $270 and $367 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $270/mo Prescription Required Compounded Yes — not FDA-approved Labs Included Availability 49 states LegitScript Claimed by provider Fitstry is a GLP-1 program run on Weightstry, a LegitScript-certified telehealth practice, and it prescribes compounded semaglutide and tirzepatide injections along with a dissolvable daily tablet. Licensing covers 49 states, with Louisiana listed on a waitlist rather than open. 1. ## Who writes the prescription, and what do they see? The first step is a four-minute assessment that the site turns into what it calls a Living Profile, and a licensed clinician in the patient's state reads it, usually within about four hours, before deciding whether to prescribe. A board-certified physician sets the protocols those clinicians follow, and the page is careful to say he is not anyone's personal provider. Once a prescription is written, the medication ships free every four weeks and the pharmacy bills the saved card separately from the program. Around it sits a coach every two weeks, unlimited clinician messaging, a round-the-clock care line, and labs ordered through Quest or Labcorp at no extra cost. For now there is no program fee at all, which the page frames as a limited-time offer without saying what the fee would be later. 2. ## What happens when the dose goes up? The page says the Living Profile shapes which medication a clinician tries first and at what starting dose, and it lists adjustments over time as part of ongoing care, with a clinician reachable between steps. What it does not publish is whether the four-week charge changes as the dose climbs, so a patient three months in has no stated price for the higher step. 3. ## What the price includes The FAQ puts month-to-month semaglutide at $249 and tirzepatide at $339, with each charge falling every four weeks instead of on a calendar date. Over a year that is thirteen charges, so the fair monthly comparison is about $270 for semaglutide and $367 for tirzepatide, and six months of semaglutide comes to roughly $1,620. The $149 and $199 on the cards are labeled as starting figures, and nothing on the page says which plan they belong to. 4. ## What it claims, and what it cites Both injectables are compounded for the individual patient by a licensed compounding pharmacy that the page does not name. Compounded preparations are not FDA-approved, and the page itself notes that the trial results it cites describe the branded drugs rather than its own formulations. ## Where it holds up, and where it does not - Strength: Labs through Quest or Labcorp included - Strength: Clinician review usually within four hours - Strength: A coach every two weeks - Strength: First month refunded if not approved - Limitation: Charges recur every four weeks - Limitation: Card figures belong to no named plan - Limitation: The program fee waiver is time-limited - Limitation: The compounding pharmacy goes unnamed ## What the evidence says about this kind of treatment The assessment above is about Fitstry. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants a coach, labs and a reachable clinician wrapped around the prescription, and who can budget from the four-week rate. Wrong for A buyer planning from the figure on the product card, since the recurring charge is a four-week one at a higher rate. ## The evidence behind what Fitstry prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fitstry compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Recovery Delivered](https://thisglp.com/reviews/recovery-delivered) [Refills](https://thisglp.com/reviews/refills) [ReflexMD](https://thisglp.com/reviews/reflexmd) [Regenics](https://thisglp.com/reviews/regenics) [Rehydra+ Wellness](https://thisglp.com/reviews/rehydra-plus) [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost each month? The FAQ gives $249 month-to-month, and because the plan bills every four weeks, thirteen charges fall in a year, so the calendar-month equivalent comes to about $270. The $149 on the card is a starting figure that the page does not tie to any named plan. Is there a program fee? Not at present. The page calls the waiver a limited-time offer and does not say what the fee would be once it ends. What happens if a clinician declines me? According to the page, the first month is refunded in full, automatically, and the treatment order is canceled without any form to fill in. Is Fitstry legit? Fitstry is a GLP-1 telehealth sellers service. Its stated availability: 49 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Fitstry expensive compared with other GLP-1 telehealth sellers? Fitstry publishes a starting figure of $270/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fitstry above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Florida Weight Loss MD reviews (2026): GLP-1 telehealth sellers | This GLP Florida Weight Loss MD presents care through Florida Surgery & Weight Loss Center, with separate branded-drug and compounded-treatment pathways. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/florida-weight-loss-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Florida evaluation before prescribing # Florida Weight Loss MD review Florida Weight Loss MD presents care through Florida Surgery & Weight Loss Center, with separate branded-drug and compounded-treatment pathways. ## The verdict The site makes the evaluation-versus-medication distinction unusually visible and names its clinical team. Its broader surgical and wellness menu should not distract from verifying the exact prescription, dispensing pharmacy and follow-up for the selected program. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved The service belongs to a Florida medical and surgical weight-loss practice offering telehealth and clinic-based options. The reviewed tirzepatide pages distinguish branded Mounjaro evaluation from a compounded program. 1. ## Who writes the prescription, and what do they see? The site names a clinical team including Sergey Terushkin, MD, Janna Goldfeld, PA-C, and Karla Mioduchoski, FNP-BC. It says the assigned clinician can vary with scheduling and clinical need. The consultation reviews history, current medication, previous treatment and safety considerations. A prescription is not automatic. The site describes follow-up according to treatment needs rather than promising the same visit frequency to everyone. 2. ## What happens when the dose goes up? The compounded page says dose, supply and final pricing can vary after evaluation. Ask how changes are authorized and whether the next order is reviewed by the same clinical team. 3. ## What the price includes The consultation is priced separately from branded medication. The compounded page distinguishes weekly, monthly and longer packages, explicitly identifying its lowest monthly equivalent as a longer-program calculation. 4. ## What it claims, and what it cites The [Mounjaro](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) page concerns a branded prescription pathway, while the other page addresses compounded tirzepatide. Compounded products are not FDA-approved and must not be represented as the same product as Mounjaro or Zepbound. ## Where it holds up, and where it does not - Strength: Clinical team named - Strength: Brand and compounded routes separated - Limitation: Assigned clinician can vary - Limitation: No universal follow-up cadence ## What the evidence says about this kind of treatment The assessment above is about Florida Weight Loss MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Florida patient comparing clinic access with telehealth within a named practice. Wrong for Someone wanting a nationwide medication-only seller or assuming the evaluation charge buys the drug. ## The evidence behind what Florida Weight Loss MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Florida Weight Loss MD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) [Remedy Meds](https://thisglp.com/reviews/remedy-meds) [REMEVi](https://thisglp.com/reviews/remevi) [Remi Meds](https://thisglp.com/reviews/remi-meds) [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) [Renlo Health](https://thisglp.com/reviews/renlo-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the consultation an automatic medication order? No. The clinic describes a medical and prescription evaluation with treatment contingent on clinical judgment. Are the compounded and Mounjaro programs identical? No. The site separates these pathways, and compounded tirzepatide is not an FDA-approved branded product. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://floridaweightlossmd.com/) - [Official program and terms](https://floridaweightlossmd.com/medical-weight-loss/tirzepatide/compounded/) - [Official program and terms](https://floridaweightlossmd.com/florida/mounjaro-weight-loss/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FMmeds reviews (2026): GLP-1 telehealth sellers | This GLP The whole pricing section is two figures and a pharmacy name. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fmmeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two numbers, no ladder # FMmeds review The whole pricing section is two figures and a pharmacy name. ## The verdict FMmeds publishes two prices and stops: $95 a month for compounded semaglutide, $145 for compounded tirzepatide. Each is stated to cover the physician review, the plan, the clinician visit and the medication. No ladder, dose tier or renewal rate appears anywhere. The compounding pharmacy is named, which most of this category does not do. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $95/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named LegitScript Claimed by provider FMmeds is a cash-pay telehealth service selling compounded semaglutide and compounded tirzepatide by weekly injection. Both are prepared with vitamin B12. Nothing else is sold. Buy-now-pay-later financing is offered at checkout. 1. ## Who writes the prescription, and what do they see? A questionnaire is the entry point, and the price is stated to include a physician review and an online clinician visit. No provider, medical group or medical director is named. The site states it does not manufacture medication and ships from a licensed pharmacy. What a prescriber assesses before writing is not set out. One figure per molecule covers the program. Support runs through a member portal, and response times are stated to vary. A LegitScript listing is linked from the footer. Delivery is described as shipped from the named pharmacy. 2. ## What happens when the dose goes up? No dose tier is published, and no milligram figure appears beside either price. Nothing states whether the rate moves as the dose climbs. The medication is described only as compounded with vitamin B12. Who approves a step up is not addressed. 3. ## What the price includes Semaglutide is quoted as starting at $95 and tirzepatide as starting at $145. The FAQ repeats both figures verbatim as the program cost. Nothing on the page says what a longer term costs, or whether one exists. The word "starting" is the only signal that a higher figure is possible. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, and the preparing pharmacy is named. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The site warns that the medication received may not match the images shown. ## Where it holds up, and where it does not - Strength: The compounding pharmacy is named outright - Strength: Two figures cover the entire catalog - Strength: The visit is stated to be inside the price - Strength: Financing is offered at checkout - Limitation: A no-membership badge sits above two memberships - Limitation: No dose tier or milligram figure is published - Limitation: No longer-term rate appears anywhere - Limitation: No prescriber or medical group is named ## What the evidence says about this kind of treatment The assessment above is about FMmeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants one all-in figure and the pharmacy named beside it. Wrong for A buyer comparing multi-month rates before committing. ## The evidence behind what FMmeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How FMmeds compares | Seller | Who it suits | Go | | --- | --- | --- | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Renlo Health](https://thisglp.com/reviews/renlo-health) [RENN Health](https://thisglp.com/reviews/renn-health) [Reset Solutions](https://thisglp.com/reviews/reset-solutions) [RestorLife Med](https://thisglp.com/reviews/restorlife-med) [Revel Health](https://thisglp.com/reviews/revel-health) [Revel RX](https://thisglp.com/reviews/revel-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a membership fee on top? The site says no, in a badge near the top. The two products under it are both named Weight Management Membership. What does $95 include? FMmeds states it covers the physician review, the personalized plan, the online clinician visit and the medication shipped to the door. Is a cheaper multi-month plan offered? None is published. The pricing section is two figures, and no term, renewal rate or ladder appears beside either. Is FMmeds expensive compared with other GLP-1 telehealth sellers? FMmeds publishes a starting figure of $95/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts FMmeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FORM reviews (2026): GLP-1 telehealth sellers | This GLP Four lines, four published figures, and not one of them is the price of a medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/form Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 No medication price anywhere # FORM review Four lines, four published figures, and not one of them is the price of a medication. ## The verdict FORM publishes a figure on every line and a medication price on none of them. Two lines quote a self-pay care plan that FORM states excludes the medication. The other two quote an access membership, with the drug obtained through NovoCare or LillyDirect. In all four cases the number on the page buys the service, not the treatment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded No FORM covers semaglutide and tirzepatide, injected and oral. All four lines are service charges. None carries a medication cost, so no line on this seller can be ranked on price here. 1. ## Who writes the prescription, and what do they see? The $95 buys the clinical relationship. A prescriber reviews the request and writes the prescription. The manufacturer's channel fills it. FORM names those channels, which is more than most services that route a prescription do. Two service shapes sit on one site. One is a care plan, one is an access membership. Both leave the medication to a third party and neither states its cost. That is a consistent model, and it is disclosed rather than buried. It also means the site publishes no price a buyer can budget from. 2. ## What happens when the dose goes up? Neither shape states what happens as the dose climbs. The manufacturer sets that, not FORM. So the answer is not FORM's to give — but the pages do not say where to find it either. 3. ## What the price includes Nothing here can be set against another seller's price, because no line states what the medication costs. The care plan figure excludes it and FORM says so. The membership figure excludes it too. A reader has to find the drug price at the manufacturer and add it themselves. FORM at least names which manufacturer, which many services routing a prescription do not. 4. ## What it claims, and what it cites The access lines lead to the manufacturers' own channels, which dispense approved products rather than compounded ones. That is a real difference in what arrives: an approved product has passed the review a compounded preparation never enters. It also means the price is set somewhere FORM does not control. ## Where it holds up, and where it does not - Strength: The fulfilling channel is named outright - Strength: Membership and medication are kept distinct - Strength: Both service shapes are labeled - Limitation: No line states a drug cost - Limitation: The decisive number belongs to a third party - Limitation: Access is charged before disclosure - Limitation: Coverage is nowhere enumerated ## What the evidence says about this kind of treatment The assessment above is about FORM. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who already knows the manufacturer price and wants a named route to a prescriber. Wrong for A reader who needs to know what the treatment costs before committing. ## The evidence behind what FORM prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How FORM compares | Seller | Who it suits | Go | | --- | --- | --- | | Kin Meds | Anyone building a shortlist around orforglipron, a molecule almost nobody prices | | | Nucore Health | A reader paying from an FSA or HSA who will ask to be quoted a real figure | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rex MD](https://thisglp.com/reviews/rex-md) [Rivas Medical Weight Loss](https://thisglp.com/reviews/rivas-medical) [Rivo Health](https://thisglp.com/reviews/rivo-health) [Rixa Health](https://thisglp.com/reviews/rixa-health) [RNK Health](https://thisglp.com/reviews/myrnk) [Ro](https://thisglp.com/reviews/ro) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked So what is the money actually for? The service. A care plan on two lines, an access membership on the other two. The medication is billed separately and FORM publishes no figure for it. Can any line here be compared on price? No. Every figure excludes the medication, so there is nothing whole to set against another seller. Is this compounded? The access lines are not. They lead to manufacturer channels dispensing approved products, which is a different thing entirely. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Form Health reviews (2026): clinicians and coverage | This GLP Form combines medical visits, nutrition support and primary-care coordination. Medication is one part of the program, with eligibility and coverage assessed separately. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/form-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Ongoing clinician and dietitian care # Form Health review Form combines medical visits, nutrition support and primary-care coordination. Medication is one part of the program, with eligibility and coverage assessed separately. ## The verdict Form suits people seeking a continuing care team rather than prescription access alone. Its physician-led model and registered dietitian support are clear strengths; enrollment requires records and coordination before appointments can begin. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Liraglutide Form Injection Prescription Required Compounded No Form Health is a virtual obesity and cardiometabolic care program. Its team addresses nutrition, activity, behavioral health and medication when appropriate. It is distinct from the seller called Form at formbygby.com. 1. ## Who writes the prescription, and what do they see? Form describes a physician-led team with an American Board of Obesity Medicine clinician, advanced practice providers and registered dietitians. Florencia Halperin, MD, is its chief medical officer, not a promise about the individual assigned to you. The site names the professional practices delivering medical care. Onboarding requires a medical release, identification, insurance information and a questionnaire. Form collects primary-care records before scheduling and matches the team to state licensing and insurance. Initial appointments need roughly an hour reserved. This process may take longer than an immediate prescription assessment. 2. ## What happens when the dose goes up? Video follow-up and app messaging provide routes for discussing tolerance and treatment changes. Dose decisions depend on the clinician and chosen drug; Form does not publish one universal escalation or refill schedule. Ask how refill requests are handled between appointments and during a coverage appeal. 3. ## What the price includes Self-pay care costs $299 per month, excluding medication and labs. With insurance, visits and other services depend on benefits and patient cost-sharing. Acceptance of Medicare or an insurer does not establish coverage for a particular weight-loss prescription. 4. ## What it claims, and what it cites Form’s FAQ names [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and Saxenda among its FDA-approved options and says it only prescribes FDA-approved medicines. Its support center says Form does not fill prescriptions or sell medication discounts. Pharmacy availability and coverage remain separate from the clinical decision. ## Where it holds up, and where it does not - Strength: Medical and nutrition care in one program - Strength: Primary-care records inform treatment - Strength: Insurance authorization assistance - Limitation: Records must arrive before scheduling - Limitation: Medication and labs add separate costs - Limitation: No universal refill turnaround promised ## What the evidence says about this kind of treatment The assessment above is about Form Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants continued obesity care with a dietitian and coordination with an existing primary-care practice. Wrong for Someone seeking medication without ongoing visits or a single cash price including the drug. ## The evidence behind what Form Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Form Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ro](https://thisglp.com/reviews/ro) [Roboclinic](https://thisglp.com/reviews/roboclinic) [Roen Rx](https://thisglp.com/reviews/roen-rx) [RX Bella](https://thisglp.com/reviews/rx-bella) [Rx.com](https://thisglp.com/reviews/rx-com) [RxION Health](https://thisglp.com/reviews/rxion-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who can enroll in Form Health? Its FAQ requires adults with BMI at least 30, or at least 27 with weight-related risks, and a primary-care visit in the previous year. Clinical screening can identify other exclusions. Can Form guarantee a GLP-1 prescription? No. A clinician assesses appropriateness, and insurance approval is a separate decision. What happens when membership ends? The FAQ offers help creating a transition plan. Subscription terms require cancellation before renewal and close access at the end of the billing period; a refund is not promised. ## Sources for this review Provider information checked October 14, 2026. Terms can change. - [Care, pricing and eligibility](https://www.formhealth.co/faqs) - [Medication costs](https://help.formhealth.co/article/481-what-is-the-cost-of-medication) - [Getting started](https://help.formhealth.co/article/429-onboarding) - [Subscription terms](https://www.formhealth.co/legal/terms-of-use) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FormBlends reviews (2026): prescribing and pharmacy | This GLP FormBlends describes clinical screening, check-ins before dose changes and shipment replacement rules alongside its public plan prices. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/formblends Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Every rung on one page # FormBlends review FormBlends describes clinical screening, check-ins before dose changes and shipment replacement rules alongside its public plan prices. ## The verdict FormBlends charges $190 a month for compounded semaglutide and $239 for tirzepatide once the introductory month is over. That first month costs $99 and $149 and applies only once. The page states the price is identical at every dose, and lab work is not included. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $190/mo Prescription Required Compounded Yes — not FDA-approved Labs Extra cost FormBlends sells compounded semaglutide and tirzepatide injections and prices both on a single public page. Each molecule carries four plan lengths and an optional renewal discount called Subscribe & Save. The same site also lists a wider catalog of peptide products. 1. ## Who writes the prescription, and what do they see? FormBlends says an independent clinician checks medical history, medications, allergies, pregnancy status, height and weight, contraindications, identity and any submitted records. The clinician can decline treatment, request labs, or require a phone or video visit. State licensure determines who can treat the patient. A provider-network description does not identify the individual who will review a particular intake. The pharmacy-and-quality page requests a check-in before dose changes and offers secure messages to the treating clinician. It explicitly says the portal is not an emergency service. Billing support has separate weekday hours. This makes it worth confirming both the clinical contact route and expected response time before the first injection, rather than assuming a customer-service reply is clinical advice. 2. ## What happens when the dose goes up? The seller says dose changes do not increase the plan price. Its example compares 2.5 mg with 15 mg; those numbers should not be treated as a semaglutide schedule. The clinician determines the actual prescription. Check-ins before changing dose provide a stated opportunity to discuss response and tolerability, while labs and care outside the program remain extra. 3. ## What the price includes Semaglutide is listed at $190 monthly after the one-time $99 opening month; tirzepatide is $239 after its $149 introduction. Subscribe & Save changes the monthly renewals to $165 and $214. Longer plans are charged upfront. Medication, clinician review, supplies and shipping are included, but laboratory work is excluded. A declined prescription receives a full refund. 4. ## What it claims, and what it cites FormBlends describes patient-specific dispensing from licensed U.S. compounding pharmacies. The pharmacy assigned depends on the medication, patient location and capacity, and appears on the label and shipping paperwork. The site says lot-specific potency and sterility certificates can be requested. These disclosures do not make the preparations FDA-approved or interchangeable with approved brands. ## Where it holds up, and where it does not - Strength: Clinical screening and dose-change check-ins described - Strength: Replacement policy covers damaged or incorrect medication - Strength: No separate membership or consultation fee - Strength: Public price table distinguishes introduction and renewal - Limitation: Lab work and outside medical care cost extra - Limitation: Dispensed medication is not ordinarily refundable - Limitation: Assigned pharmacy depends on the prescription - Limitation: Longer plans require upfront payment ## What the evidence says about this kind of treatment The assessment above is about FormBlends. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants a stated follow-up process and clear shipment-problem rules before beginning remote care. Wrong for A patient needing routine laboratory monitoring bundled into the advertised medication price. ## The evidence behind what FormBlends prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How FormBlends compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) [RxPros](https://thisglp.com/reviews/rxpros) [RxSaludable](https://thisglp.com/reviews/rxsaludable) [Rylo Health](https://thisglp.com/reviews/rylo-health) [Ryze Rx](https://thisglp.com/reviews/ryze-rx) [Science & Co](https://thisglp.com/reviews/science-and-co) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I contact the clinician between fills? The seller describes patient-portal messaging and a check-in before dose changes. The portal is not monitored as an emergency service. What if medication arrives damaged or incorrect? The return policy offers replacement without charge. Report the problem within seven days, including the order number and package and label photos. Do not use a vial you suspect is compromised. How does a renewal stop? For Subscribe & Save, email support before the next billing date and retain its written cancellation confirmation. An already dispensed refill is not ordinarily refundable. Are laboratories included? No. The pricing page excludes lab work and outside medical visits, even though clinical review, supplies and shipping are included. Is FormBlends expensive compared with other GLP-1 telehealth sellers? FormBlends publishes a starting figure of $190/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts FormBlends right at the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 14, 2026. Terms can change. - [Plan prices and inclusions](https://formblends.com/pricing) - [Clinical review and pharmacy quality](https://formblends.com/pharmacy-and-quality) - [Provider network](https://formblends.com/about/provider-network) - [Refunds and replacements](https://formblends.com/returns) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FormidableMD reviews (2026): GLP-1 telehealth sellers | This GLP A priced ladder for each molecule, a paid visit at every dose change, and medical care in four states. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/formidablemd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Visits billed, ladder published # FormidableMD review A priced ladder for each molecule, a paid visit at every dose change, and medical care in four states. ## The verdict FormidableMD publishes a four-rung price list for each molecule and a required visit schedule. Counting the visits, entry semaglutide is $235 a month. Entry tirzepatide is $265. Medical care covers four states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 4 From From $235/mo Prescription Required Compounded Yes — not FDA-approved Availability FL, GA, NY, NJ FormidableMD is a telehealth practice focused on women in midlife. It prescribes semaglutide and tirzepatide, compounded or FDA-approved. Coaching is sold separately in all fifty states. Medical care covers Florida, Georgia, New York and New Jersey. 1. ## Who writes the prescription, and what do they see? Every visit is with a provider. The first is a one-on-one video visit after the intake questionnaire. The provider reviews that questionnaire beforehand. Labs may be ordered at the first visit. This is a pay-per-visit model with no membership. The initial consultation is $199 and each follow-up is $99. The pharmacy bills medication separately. The practice does not contract with insurers and issues a superbill instead. 2. ## What happens when the dose goes up? Each change of dose requires a follow-up visit. Patients on medication see a provider monthly for three months. Once the dose is stable, visits move to every three months for the first year. The price list rises with the milligram label: $169 to $269 for semaglutide, $199 to $319 for tirzepatide. 3. ## What the price includes All in, the first year works out to $235 a month for semaglutide and $265 for tirzepatide. Each figure adds the required visits to the lowest rung. Those visits total $793 in year one, or $66.08 a month. A higher rung raises only the medication part. 4. ## What it claims, and what it cites Compounded lines come from 503A pharmacies the practice does not name. Compounded drugs are not FDA-approved or FDA-reviewed before dispensing. Where insurance covers a brand product, the practice prescribes that instead. ## Where it holds up, and where it does not - Strength: Every dose rung carries a price - Strength: A provider visit before each dose change - Strength: No monthly membership fee - Strength: Brand prescribed where insurance covers it - Limitation: Visits cost $793 in year one - Limitation: Medical care in four states only - Limitation: Pharmacies are described, not named - Limitation: A late cancellation carries a fee ## What the evidence says about this kind of treatment The assessment above is about FormidableMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in Florida, Georgia, New York or New Jersey who wants a provider at each dose step. Wrong for A reader outside those four states, or one who wants visits folded into the medication price. ## The evidence behind what FormidableMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How FormidableMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SexyMD](https://thisglp.com/reviews/sexymd) [ShapeIn Rx](https://thisglp.com/reviews/shapein-rx) [Shapely](https://thisglp.com/reviews/shapely) [Signos](https://thisglp.com/reviews/signos) [Silhouette MD](https://thisglp.com/reviews/silhouette-md) [SkyRx](https://thisglp.com/reviews/skyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the visit fee part of the medication price? No. The practice bills visits, and the pharmacy bills medication. How often are visits required? Monthly for the first three months on medication. Then every three months for the first year once the dose is stable. Which states are covered? Medical care covers Florida, Georgia, New York and New Jersey. Coaching covers all fifty states. Is FormidableMD legit? FormidableMD is a GLP-1 telehealth sellers service. Its stated availability: FL, GA, NY, NJ. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is FormidableMD expensive compared with other GLP-1 telehealth sellers? FormidableMD publishes a starting figure of $235/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts FormidableMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Found reviews (2026): GLP-1 telehealth sellers | This GLP Each molecule has its own four-rung ladder, and every rung is billed per 28-day cycle rather than per month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/found Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced per 28-day cycle # Found review Each molecule has its own four-rung ladder, and every rung is billed per 28-day cycle rather than per month. ## The verdict Found charges $289 per 28-day cycle for compounded semaglutide month to month, after a $179 first month, and $359 for tirzepatide after a $219 first month. Thirteen cycles land in a year, so those are $313 and $389 a calendar month. Medication, membership and coaching are included. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $313/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states Found sells compounded semaglutide and compounded tirzepatide, each on its own store page with its own price ladder. It also offers branded products through a separate track. Coverage is stated across fifty states. 1. ## Who writes the prescription, and what do they see? A prescriber is reached through the plan and the membership is bundled into the figure rather than billed separately. The buyer now chooses the molecule on the store page, and the prescriber decides whether it is appropriate. The bundle is the model. Medication, membership and coaching sit inside one figure, which removes the separate charges that complicate most comparisons. What remains is the billing unit: a 28-day cycle, not a calendar month. 2. ## What happens when the dose goes up? Both store pages say the price is the same at every dose. The term moves the price instead: each ladder runs from one month to twelve. 3. ## What the price includes Semaglutide cash is $289 a cycle month to month, $249 on three months, $219 on six and $169 on twelve. Tirzepatide is $359, $309, $289 and $239. Each figure is per 28-day cycle. Thirteen cycles a year make the month-to-month rates $313 and $389 a calendar month. Six cycles of semaglutide month to month is $1,734. 4. ## What it claims, and what it cites The plan lines are compounded, which means they are not FDA-approved and are not reviewed by the agency before dispensing. The branded track dispenses approved products. Its plan price is not published before the intake. ## Where it holds up, and where it does not - Strength: Medication, membership and coaching bundled - Strength: Each molecule has its own published ladder - Strength: Same price at every dose - Strength: Coverage stated across 50 states - Limitation: Every price is per 28-day cycle, not per month - Limitation: The headline needs twelve months committed - Limitation: The first month is discounted, not the rate - Limitation: The branded track's plan price is unpublished ## What the evidence says about this kind of treatment The assessment above is about Found. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will commit to a longer term and wants coaching and membership inside one figure. Wrong for A reader comparing the $169 headline against another seller's monthly rate. ## The evidence behind what Found prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Found compares | Seller | Who it suits | Go | | --- | --- | --- | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Society of You](https://thisglp.com/reviews/society-of-you) [Somi Health](https://thisglp.com/reviews/somi-health) [Somira Health](https://thisglp.com/reviews/somira-health) [Southern Vitality and Weight Loss](https://thisglp.com/reviews/southern-vitality-weight-loss) [Spry](https://thisglp.com/reviews/spry) [StackMD](https://thisglp.com/reviews/stackmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $169 available monthly? No. It is the twelve-month cash rung for semaglutide. Month to month is $289 per 28-day cycle, after a $179 first month. Why does this site show $313 rather than $289? Found bills per 28-day cycle, and thirteen cycles land in a year. $289 a cycle is $313.08 a calendar month. Can I choose semaglutide or tirzepatide? Yes. Each has its own store page and price ladder. Tirzepatide is $359 per cycle month to month, after a $219 first month. Is Found legit? Found is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Found expensive compared with other GLP-1 telehealth sellers? Found publishes a starting figure of $313/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Found above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Found Youth reviews (2026): GLP-1 telehealth sellers | This GLP Found Youth describes weekly compounded GLP-1 programs with provider-directed adjustments. Its editorial guide is more informative than the storefront’s broad price ranges. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/found-youth Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Physician-guided, flat-dose claim # Found Youth review Found Youth describes weekly compounded GLP-1 programs with provider-directed adjustments. Its editorial guide is more informative than the storefront’s broad price ranges. ## The verdict The comparison guide explains the two treatments and claims unchanged prices across doses. The remaining care question is what ongoing contact actually includes: the reviewed pages do not establish a scheduled visit frequency or response time. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Found Youth is a physician-guided wellness storefront with weight-loss programs alongside skin and other treatments. Its journal identifies Dr. Yanilis Diaz as founder. 1. ## Who writes the prescription, and what do they see? The GLP-1 guide says prescriptions follow a licensed provider’s review of health history. A named founder does not establish who will treat each patient; request the assigned practice and follow-up contact. The site directs prospective patients through intake and says treatment selection considers medical history and prior response. It describes pharmacy fulfillment but does not provide a full care calendar in the reviewed guides. 2. ## What happens when the dose goes up? The comparison page says prices remain the same as the prescribed dose changes. That is a commercial promise, not a universal escalation schedule; confirm the review required before refills or adjustments. 3. ## What the price includes The journal distinguishes month-to-month rates from savings on longer plans. The storefront presents broad product ranges, so match the selected variant and duration rather than comparing the lowest range endpoint. 4. ## What it claims, and what it cites The guide says these are compounded weekly injections from a state-licensed 503A pharmacy partner, not branded medicines. Compounded products are not FDA-approved, and the site’s brand-trial discussion does not prove its own outcomes. ## Where it holds up, and where it does not - Strength: Provider review precedes treatment - Strength: Dose-price policy is stated - Limitation: Assigned practice needs confirmation - Limitation: No defined visit frequency ## What the evidence says about this kind of treatment The assessment above is about Found Youth. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone comparing provider-guided compounded options who will verify continuing-care access. Wrong for Someone needing a fully specified appointment and refill schedule before enrollment. ## The evidence behind what Found Youth prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Found Youth compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [StackMD](https://thisglp.com/reviews/stackmd) [Sumbare Wellness](https://thisglp.com/reviews/sumbare-wellness) [Sunlight](https://thisglp.com/reviews/sunlight) [Superior Remedies](https://thisglp.com/reviews/superior-remedies) [Superpower](https://thisglp.com/reviews/superpower-health) [SurpassMD](https://thisglp.com/reviews/surpassmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the founder necessarily my prescriber? No. The public guide names a founder but says treatment is reviewed by a licensed provider; confirm the clinician assigned to you. Are these branded medicines? The journal explicitly describes compounded injections rather than brand-name products. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://foundyouth.com/) - [Official program and terms](https://foundyouth.com/journal-glp1/) - [Official program and terms](https://foundyouth.com/journal-semaglutide-vs-tirzepatide/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Framework reviews (2026): GLP-1 telehealth sellers | This GLP A figure quoted by the week reads cheaper than the same money quoted by the month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/framework Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Quoted weekly, paid monthly # Framework review A figure quoted by the week reads cheaper than the same money quoted by the month. ## The verdict Framework advertises GLP-1 treatment from $25 a week and states there are no membership fees. A year of those charges totals $1,300, which across twelve calendar months is $108.33 rather than the $100 a weekly headline invites. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $108.33/mo Prescription Required Compounded Yes — not FDA-approved Framework describes itself as a precision wellness platform. Compounded semaglutide and compounded tirzepatide sit inside a wider longevity offer rather than making up the whole catalog. 1. ## Who writes the prescription, and what do they see? US-licensed clinicians are named as the source of treatment, and a prescription comes before any shipment. Past that, the pages describe the platform rather than the clinical relationship. Nothing states what a clinician examines, or when they look again. The proposition is one clear price with no membership, repeated across the homepage rather than expanded anywhere. What the weekly charge covers beyond the drug is left unsaid, so a reader cannot tell whether supplies and delivery sit inside it. 2. ## What happens when the dose goes up? No milligram quantity appears next to the weekly rate. That absence bites hardest across the first four months, when the dose normally climbs several times. Without a starting quantity there is nothing to check the price against, and Framework does not say whether the rate survives an escalation. 3. ## What the price includes Multiplying by four is the error a weekly price invites. An average calendar month holds 4.33 weeks, so $25 a week is $108.33, and six months is $650. Framework also applies one rate to a single agonist and a dual agonist alike, which is not how the category usually prices them, and no explanation appears. 4. ## What it claims, and what it cites Both lines are compounded preparations rather than manufactured products. The pharmacy preparing them is not identified. A compounded preparation is not reviewed by the FDA before it is dispensed. ## Where it holds up, and where it does not - Strength: Framework prints the weekly rate itself - Strength: No membership charge, stated plainly - Strength: One rate spans both molecules - Limitation: A weekly figure understates the calendar month - Limitation: No milligram quantity beside the price - Limitation: Silent on what happens as the dose rises - Limitation: The compounding pharmacy goes unnamed ## What the evidence says about this kind of treatment The assessment above is about Framework. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who multiplies by 4.33 before shortlisting anything. Wrong for A buyer who needs a milligram quantity behind a figure. ## The evidence behind what Framework prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Framework compares | Seller | Who it suits | Go | | --- | --- | --- | | Rivas Medical Weight Loss | Buyers within reach of a clinic who want a clinician present every week | | | RxPepsDirect | Buyers at a starting dose who want per-vial pricing and no subscription | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Synergy Rx](https://thisglp.com/reviews/synergy-rx) [T2D.com](https://thisglp.com/reviews/t2d) [TD Tele-Doc Weight Loss](https://thisglp.com/reviews/td-teledoc) [TeleCareSpot](https://thisglp.com/reviews/telecarespot) [TeleClinic](https://thisglp.com/reviews/teleclinic) [TeleDocs360](https://thisglp.com/reviews/teledocs360) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the weekly rate come to in a month? $108.33. A calendar month averages 4.33 weeks rather than four, and the annual total is $1,300. Is a dose published? No milligram quantity appears beside the rate on any page. Why do both molecules cost the same? Framework applies one weekly figure to semaglutide and tirzepatide. Nothing published accounts for the equivalence. Is Framework expensive compared with other GLP-1 telehealth sellers? Framework publishes a starting figure of $108.33/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Framework below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Freeley reviews (2026): GLP-1 telehealth sellers | This GLP Freeley publishes more of its care process than a simple medication storefront, but its long-plan pricing needs clarification. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/freeley Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A compounded GLP-1 program advertising monthly clinical check-ins, laboratory monitoring and a named pharmacy partner. # Does Freeley sell a GLP-1? Freeley publishes more of its care process than a simple medication storefront, but its long-plan pricing needs clarification. ## The verdict The stated monitoring and named pharmacy are useful starting points. Confirm that the proposed follow-up and laboratory schedule apply to the selected plan, and resolve inconsistent promotional price displays before paying. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved Freeley arranges physician-guided treatment and pharmacy delivery across several wellness categories. Its weight-loss offering names compounded semaglutide or tirzepatide. 1. ## Who writes the prescription, and what do they see? The process describes a physician licensed in the patient’s state reviewing intake and requesting further information or tests where needed. A free assessment is not an assurance of prescription approval. The published process includes monthly check-ins, quarterly laboratory monitoring and physician messaging. Ask which tests are included and how abnormal results or symptoms are escalated; marketing access language is not a response-time commitment. 2. ## What happens when the dose goes up? Dosage adjustments are described as part of ongoing care. Confirm who authorizes a change, whether a new shipment is needed and how the pharmacy instructions are communicated. 3. ## What the price includes The homepage and comparison display show different figures tied to an annual plan, while the pricing page uses a longer plan for its lowest rate. These offers need a written plan-specific total rather than a single assumed monthly cost. 4. ## What it claims, and what it cites The site names compounded semaglutide and tirzepatide and identifies Strive Pharmacy as its partner. Compounded products are not FDA-approved; the named pharmacy does not by itself establish which formulation will be prescribed. ## Where it holds up, and where it does not - Strength: Names a pharmacy partner - Strength: Describes check-ins and laboratory monitoring - Limitation: Care inclusions need plan-specific confirmation - Limitation: Price displays need reconciliation ## What the evidence says about this kind of treatment The assessment above is about Freeley. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults who value a published monitoring process and will verify its practical inclusions. Wrong for Anyone who needs an unambiguous short-term price before speaking to the service. ## The evidence behind what Freeley prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Freeley compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TeleDocs360](https://thisglp.com/reviews/teledocs360) [TeleHealth Med](https://thisglp.com/reviews/telehealth-med) [TeleHealth Weight Solutions](https://thisglp.com/reviews/telehealth-weight-solutions) [TelePeptide](https://thisglp.com/reviews/telepeptide) [TeleSlim Clinic](https://thisglp.com/reviews/teleslim-clinic) [TeleZen MD](https://thisglp.com/reviews/telezen-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Freeley name its pharmacy? Its pricing page identifies Strive Pharmacy. Confirm the actual dispensing pharmacy and formulation on the prescription. What follow-up is advertised? The care process describes monthly check-ins, quarterly laboratory monitoring and physician messaging. Confirm which tests and services apply to your plan. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://freeley.com/) - [Official program and terms](https://freeley.com/terms/) - [Official program and terms](https://freeley.com/how-it-works/) - [Official program and terms](https://freeley.com/pricing/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fresh Day Meds reviews (2026): GLP-1 telehealth sellers | This GLP The low storefront figures are three-month plans, and the one-month plans renew every 23 days. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fresh-day Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Twenty-three day renewals # Fresh Day Meds review The low storefront figures are three-month plans, and the one-month plans renew every 23 days. ## The verdict Fresh Day's month-to-month plans are $140 for compounded semaglutide and $179 for tirzepatide, and the lower storefront figures of $99 and $140 belong to three-month plans. Its own subscription terms add the detail a budget needs: one-month plans renew every 23 days, so across a year they work out to $185.14 and $236.72 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $185.14/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named LegitScript Claimed by provider Fresh Day Meds is a telehealth storefront that sells weekly compounded semaglutide and tirzepatide injections beside a catalog of B12, NAD+, hair, sexual-health and testosterone products, each on its own card. The GLP-1 lines are sold as subscriptions, with separate plans for new patients and for patients transferring an existing prescription. 1. ## Who writes the prescription, and what do they see? A licensed physician reviews the online assessment, and a transferring patient uploads a current label so the physician can decide whether to continue that dose rather than restart at the bottom. Where a phone consultation is needed, the order waits in the physician's queue for a callback, and the FAQ warns that a missed call can cost a non-refundable consultation fee. Checkout places a hold for the plan total and captures it only after a clinician approves, so a declined patient is never charged. After that the plan renews on its own cadence until it is canceled through the patient portal, and an approved term is not refunded, though canceling future renewals carries no fee. 2. ## What happens when the dose goes up? This is where the seller's pages are strongest for a patient who expects to climb. Both product pages state that the price holds while the dose rises, as long as the same plan stays active, and the new-patient three-month plans list three rising doses across their three shipments. Changing plans, medications or billing cadence ends that lock. 3. ## What the price includes Month to month, semaglutide is $140 and tirzepatide is $179, and the $99 and $140 figures at the top of the storefront are the three-month rates. The cadence matters as much as the figure: the subscription terms state that one-month plans renew every 23 days, which puts about sixteen charges into a year instead of twelve. Spread over a calendar month, that is $185.14 for semaglutide and $236.72 for tirzepatide, the figures to hold against a seller that bills once a month. Three-month plans renew every 83 days. 4. ## What it claims, and what it cites Both lines are compounded, and the site names its pharmacy partners: Boudreaux's New Drug Store or Promise Pharmacy. Compounded medications are not FDA-approved, and the FDA does not check them for safety or effectiveness before they reach the patient. ## Where it holds up, and where it does not - Strength: Price holds as the dose rises - Strength: Both pharmacy partners are named - Strength: No charge until a clinician approves - Strength: Transfer plans avoid restarting the dose - Limitation: One-month plans renew every 23 days - Limitation: Storefront figures need a three-month plan - Limitation: Approved terms are not refundable - Limitation: A missed callback can cost a fee ## What the evidence says about this kind of treatment The assessment above is about Fresh Day Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient planning to stay on one plan for months who values a price that holds through the dose climb and named pharmacies. Wrong for A buyer who budgets by the calendar month, since the one-month plan renews every 23 days. ## The evidence behind what Fresh Day Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fresh Day Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Revel RX | A reader drawn to a low flat rate who also wants the handling described | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | SkyRx | Buyers ready to prepay a year who want the medication, visit and shipping in one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Telos Rx](https://thisglp.com/reviews/telos-rx) [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) [The Edit](https://thisglp.com/reviews/the-edit) [The Virtual NP](https://thisglp.com/reviews/the-virtual-np) [TMates](https://thisglp.com/reviews/tmates) [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost without a commitment? $140 for semaglutide and $179 for tirzepatide per charge on the one-month plans, which the subscription terms say renew every 23 days. Averaged over a calendar month, that is $185.14 and $236.72. Does a higher dose cost more? Not while the same plan stays active, since both product pages say the price holds as the dose rises; switching plans or medications is what ends that lock. Which pharmacy fills the order? The site names Boudreaux's New Drug Store or Promise Pharmacy as its pharmacy partners, and describes the medication as prepared in licensed U.S. compounding pharmacies. Is Fresh Day Meds expensive compared with other GLP-1 telehealth sellers? Fresh Day Meds publishes a starting figure of $185.14/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fresh Day Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Freya Meds reviews (2026): GLP-1 telehealth sellers | This GLP Monthly plans cost more than the quarterly figures, and the dose does not change the price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/freya-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Quarterly figure, monthly rate # Freya Meds review Monthly plans cost more than the quarterly figures, and the dose does not change the price. ## The verdict On its monthly plans, Freya Meds charges $297 for compounded semaglutide and $390 for tirzepatide. The lower $250 and $332 figures apply only with quarterly billing. Monthly dose increases are stated as included at no extra cost. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $297/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved LegitScript Claimed by provider Freya Meds sells compounded semaglutide and tirzepatide as weekly injections, each on a monthly or a quarterly plan. Every plan bundles the medication with clinician access, monthly group calls and a one-on-one dietitian consultation. 1. ## Who writes the prescription, and what do they see? A U.S.-licensed doctor reviews the intake quiz and confirms the prescription, which the site says happens the same day. It promises the same practitioner from start to finish. It does not name its clinicians or say whether any live visit takes place. Care runs through unlimited messaging with the clinician and the wider care team. The product pages also list weekly check-ins for monitoring progress and adjusting the dose. Cancellation is stated as available at any time, with no lock-in. 2. ## What happens when the dose goes up? The published starting doses are 0.20 mg weekly for semaglutide and 2 mg weekly for tirzepatide, with maximums of 2.4 mg and 15 mg. The FAQ says monthly dose increases are built into the plan at no extra cost. How each step is decided for an individual patient is not described. 3. ## What the price includes Monthly plans are $297 for semaglutide and $390 for tirzepatide, and quarterly billing lowers them to $250 and $332. Six months on the monthly semaglutide plan total $1,782. The homepage advertises a lower starting figure that neither product page carries or explains. 4. ## What it claims, and what it cites Both lines are compounded preparations. Compounded drugs are not FDA-approved and get no FDA review before a pharmacy dispenses them, and this site does not name its pharmacy. ## Where it holds up, and where it does not - Strength: Dose increases included at no extra cost - Strength: Starting and maximum doses are published - Strength: A dietitian session is included - Strength: The same practitioner throughout - Limitation: Lower figures need quarterly billing - Limitation: Homepage figure missing from product pages - Limitation: Clinicians and pharmacy are not named ## What the evidence says about this kind of treatment The assessment above is about Freya Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to pay quarterly who wants the monthly dose increases priced in from the start. Wrong for A reader budgeting from the homepage's starting figure, which the product pages do not support. ## The evidence behind what Freya Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Freya Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | YourEra | Readers committing six months who have read which figure belongs to which plan | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | SkyRx | Buyers ready to prepay a year who want the medication, visit and shipping in one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Tonik Wellness](https://thisglp.com/reviews/tonik-wellness) [Transparent Meds](https://thisglp.com/reviews/transparent-meds) [Trava Health](https://thisglp.com/reviews/trava-health) [Trellis Vitality](https://thisglp.com/reviews/trellis-vitality) [Trillium Meds](https://thisglp.com/reviews/trillium-meds) [Trimi Health](https://thisglp.com/reviews/trimi-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a monthly plan cost? $297 for semaglutide and $390 for tirzepatide, and quarterly billing lowers those to $250 and $332. Does the price rise with the dose? No. The FAQ states the cost stays the same whatever dose the clinician sets, including monthly increases. What is the starting dose? 0.20 mg weekly for semaglutide and 2 mg weekly for tirzepatide, according to the product pages. Is Freya Meds expensive compared with other GLP-1 telehealth sellers? Freya Meds publishes a starting figure of $297/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Freya Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Fridays reviews (2026): GLP-1 telehealth sellers | This GLP The pricing page and the treatment page give different annual rates for the same plan, and the discount figure needs a coupon. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/fridays Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two pages, two answers # Fridays review The pricing page and the treatment page give different annual rates for the same plan, and the discount figure needs a coupon. ## The verdict Fridays publishes $249 a month for compounded semaglutide and $359 for tirzepatide on a month-to-month plan, alongside an annual rate that two of its own pages state differently. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $249/mo Prescription Required Compounded Yes — not FDA-approved Fridays sells both molecules by injection on month-to-month and annual plans, and the figures a reader meets depend on which of two pages they land on first. 1. ## Who writes the prescription, and what do they see? A prescription is issued before shipping and neither page describes the clinician who writes it, which is a smaller gap than it would normally be, because the pages cannot yet agree on what the treatment costs. One page puts the annual plan at $150 a month and another at $279, and a reader has no way to tell which is current. That is not a hidden fee or a clever framing — it is the same company publishing two answers to one question, and a buyer who plans around the lower one has been misled by a page the seller wrote itself. 2. ## What happens when the dose goes up? Nothing is published about what either figure does at a higher dose. On a plan whose headline rate is already in dispute across two pages, a reader should treat the dose question as unanswered rather than assume the rate holds. 3. ## What the price includes The month-to-month rates are the only figures both pages agree on: $249 for semaglutide and $359 for tirzepatide. The annual rate is either $150 or $279 depending on the page, a $129 spread. And the two discount figures, $117 and $198, are gated behind promo codes rather than standing rates, so neither is available to a reader who simply signs up. Get the applicable annual rate confirmed in writing before paying anything. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Month-to-month rates agree across pages - Strength: Both molecules carry published figures - Strength: The promo codes are shown, not hidden - Limitation: Two pages give different annual rates - Limitation: The lowest figures need a promo code - Limitation: Nothing published about dose pricing - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Fridays. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will get the annual rate confirmed in writing before paying. Wrong for A reader planning a year from whichever page they happened to open. ## The evidence behind what Fridays prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Fridays compares | Seller | Who it suits | Go | | --- | --- | --- | | Genesis Health | Readers who want the billed amount, not just the monthly rate, before committing | | | Get Thin MD | Readers taking the three-month plan who read what the sale actually covers | | | Harmony Wellness Clinic | Readers who want to cost out a full escalation before starting one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TrimRx](https://thisglp.com/reviews/trimrx) [Trinity Meds](https://thisglp.com/reviews/trinity-meds) [TRT Nation](https://thisglp.com/reviews/trt-nation) [Tru2u](https://thisglp.com/reviews/tru2u) [TrueMe](https://thisglp.com/reviews/trueme) [Try Ageless](https://thisglp.com/reviews/try-ageless) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the annual plan cost? Fridays gives two answers. Its treatment page states $150 a month and its pricing page states $279, and nothing on either explains the difference. Can I get the $117 rate? Only with a promo code. The advertised $117 and $198 figures are coupon-gated rather than standing rates. What is the month-to-month price? $249 for semaglutide and $359 for tirzepatide, which is the one figure both pages agree on. Is Fridays expensive compared with other GLP-1 telehealth sellers? Fridays publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Fridays above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # FuturHealth reviews (2026): GLP-1 telehealth sellers | This GLP FuturHealth brings clinical prescribing and nutrition tools together. Before enrolling, distinguish ongoing clinical follow-up from the app’s everyday food and activity features. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/futurhealth Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Branded care with nutrition tools # FuturHealth review FuturHealth brings clinical prescribing and nutrition tools together. Before enrolling, distinguish ongoing clinical follow-up from the app’s everyday food and activity features. ## The verdict FuturHealth is a reasonable program to investigate if branded medication and nutrition support matter to you. The deciding care question is how often the prescriber reviews your treatment and how quickly side-effect concerns reach that clinician. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Orforglipron Form Injection · Oral Prescription Required Compounded No FuturHealth combines online weight-management care with access to FDA-approved medication and a nutrition-focused app. The current program page lists Wegovy injection and pill, Zepbound and Foundayo. 1. ## Who writes the prescription, and what do they see? A licensed clinician reviews the intake, discusses the patient’s health and recommends a treatment plan when appropriate. The published medical advisory team helps describe the program’s expertise; it does not identify which clinician will personally treat a new patient. The care process describes online consultation, medication delivery, ongoing support and progress tracking. The app includes meal tracking and nutrition resources. A fixed appointment frequency and guaranteed response time were not established on the program pages reviewed. 2. ## What happens when the dose goes up? The prescriber should determine the medication and any dose changes. Before a refill, ask how tolerance and response are reviewed, whether a visit is needed and what happens if a slower increase changes the prescription. 3. ## What the price includes The displayed drug offers are introductory: $198 monthly for Foundayo or Wegovy pill, $299 for Wegovy injection and $395 for Zepbound. These are not established standing, medication-inclusive monthly totals. Ask for the ongoing care and drug charges together. 4. ## What it claims, and what it cites The current program describes FDA-approved branded medicines rather than a compounded injection bundle. The choice depends on the licensed clinician’s assessment. Do not assume every listed medicine has the same eligibility criteria, format or cost. ## Where it holds up, and where it does not - Strength: Current program specifies branded medicines - Strength: Clinical and nutrition support are described - Strength: App supports tracking between contacts - Limitation: No universal follow-up cadence established - Limitation: Introductory figures do not establish ongoing total cost - Limitation: Medical advisory team is not the assigned prescriber ## What the evidence says about this kind of treatment The assessment above is about FuturHealth. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering a branded prescription who wants nutrition tools alongside online clinical care. Wrong for Someone seeking a known all-in compounded price or guaranteed access to a particular brand. ## The evidence behind what FuturHealth prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. ## How FuturHealth compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Try Ageless](https://thisglp.com/reviews/try-ageless) [TRYM Health](https://thisglp.com/reviews/trym-health) [Tryozi](https://thisglp.com/reviews/tryozi) [Tuyo Health](https://thisglp.com/reviews/tuyo-health) [Tyde Wellness](https://thisglp.com/reviews/tyde-wellness) [UR Meds](https://thisglp.com/reviews/ur-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does FuturHealth currently describe compounded medication? The program pages reviewed describe FDA-approved branded options. Confirm the exact drug on the proposed treatment plan. Are the results and testimonials a personal prediction? No. Trial results and individual testimonials do not establish what a particular patient will lose or how quickly. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Care process and current medicines](https://fh.co/how-it-works) - [Clinical and nutrition team](https://fh.co/about-us) - [Medication offers](https://landing.fh.co/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # G-Plans reviews (2026): GLP-1 telehealth sellers | This GLP G-Plans offers prescription treatment alongside nutrition tools. Confirm the exact medicine and clinical follow-up rather than relying on the quiz’s metabolic-type framing. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/g-plans Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A medication-access and nutrition program that names independent clinical care and combines it with meal planning, tracking and progress support. # Does G-Plans sell a GLP-1? G-Plans offers prescription treatment alongside nutrition tools. Confirm the exact medicine and clinical follow-up rather than relying on the quiz’s metabolic-type framing. ## The verdict The combination of medication access and practical nutrition support may appeal to someone wanting both. The central question is what the selected plan actually includes: a named prescription, appropriate follow-up and clearly separated membership and medical charges. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required G-Plans is a platform combining weight-loss programs, nutrition guidance and access to prescription care. Its terms identify OpenLoop Healthcare Partners and affiliated medical groups as independent providers of clinical services. 1. ## Who writes the prescription, and what do they see? Licensed clinicians assess the patient’s health profile and decide whether to prescribe. The platform says it does not control clinical decisions. A quiz result is not a diagnosis or a promise of access to a requested medication. The public FAQ describes ongoing medical support, personalized nutrition guidance, tracking and progress check-ins. Ask how frequently clinical reviews occur, whether messages reach a clinician or coach and what happens if treatment is not tolerated. 2. ## What happens when the dose goes up? The service says providers monitor response and adjust plans when needed. Obtain the prescription-specific schedule and contact process; the public menu does not establish a universal dose ladder or monitoring protocol. 3. ## What the price includes The FAQ describes medication as included if eligible, but does not supply a complete product-specific price. The legal policies distinguish membership, provider and medication fees, and some partners bill directly. Ask for a breakdown before paying. 4. ## What it claims, and what it cites The FAQ names Ozempic and Zepbound and also mentions other GLP-1 treatments and pills. That establishes named semaglutide and tirzepatide options, not that every pill contains either drug or that either brand is guaranteed for a particular patient. ## Where it holds up, and where it does not - Strength: Identifies independent clinical groups in the terms - Strength: Combines nutrition tools with medical support - Limitation: Public overview does not specify a complete medication price - Limitation: Clinical follow-up cadence requires clarification ## What the evidence says about this kind of treatment The assessment above is about G-Plans. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults seeking clinician-guided medication access together with structured nutrition and tracking tools. Wrong for Anyone who needs a guaranteed drug, proof that metabolic-type matching improves outcomes, or a blanket refund covering every service. ## The evidence behind what G-Plans prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How G-Plans compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) [Vaylen](https://thisglp.com/reviews/vaylen) [Velvet Rx](https://thisglp.com/reviews/velvet-rx) [VevaRX](https://thisglp.com/reviews/vevarx) [VigorMeds](https://thisglp.com/reviews/vigormeds) [VirtualCare2Go](https://thisglp.com/reviews/virtualcare2go) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the quiz guarantee a prescription? No. Independent clinicians determine treatment based on the health assessment. A quiz category does not guarantee a particular medicine or outcome. Which pills does G-Plans offer? The reviewed FAQ says pill options are available but does not identify their ingredients. Ask for the actual medication rather than assuming an oral version of a named injectable. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://g-plans.com/) - [Official program and terms](https://g-plans.com/new/pages/terms/) - [Official program and terms](https://g-plans.com/new/pages/refunds-policy/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Gala reviews (2026): GLP-1 telehealth sellers | This GLP A brand cash price near thirteen hundred dollars sits beside a compounded yearly plan at a fraction of it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/gala Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two lines, one market apart # Gala review A brand cash price near thirteen hundred dollars sits beside a compounded yearly plan at a fraction of it. ## The verdict Gala publishes $1,299 a month as a cash price for branded Ozempic and $179 a month for compounded tirzepatide on a yearly subscription. Both are stated flat across doses, across fifty states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $179/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Gala sells branded semaglutide and compounded tirzepatide by injection, on terms that differ sharply by line. The Ozempic figure is a cash price that insurance may reduce. The tirzepatide figure requires a year's subscription. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe the two products rather than the clinician. That insurance may apply to one line implies a billing relationship the pages do not otherwise explain. The gap between the two figures is not a discount and should not be read as one. A brand cash price and a compounded yearly plan describe different products on different terms. Comparing them against each other, or against another seller's monthly rate, compares things that are not alike. 2. ## What happens when the dose goes up? Both lines are marked flat, so neither figure moves with the dose. The compounded page states all doses are included. What changes the tirzepatide price is the term, not the dose. 3. ## What the price includes $1,299 a month is a cash figure and the pages state insurance may reduce it, which means the number a reader pays is unknown until a claim is run. Compounded tirzepatide is $179 a month on a yearly subscription, or $2,148 across twelve months. A three-month plan is $199 a month. No month-to-month rate is published before checkout. 4. ## What it claims, and what it cites [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) is an FDA-approved brand product made by Novo Nordisk. The [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is compounded: a pharmacy prepares it, and the FDA does not review it before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Coverage across all fifty states - Strength: Both lines stated flat across doses - Strength: Insurance is named as a possible reducer - Limitation: The Ozempic cash price is $1,299 a month - Limitation: The tirzepatide rate needs a yearly subscription - Limitation: No month-to-month rate is published - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Gala. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader with insurance that may apply to Ozempic, or one ready to commit a year to compounded tirzepatide. Wrong for A reader who wants to pay month to month without a commitment. ## The evidence behind what Gala prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Gala compares | Seller | Who it suits | Go | | --- | --- | --- | | Green Cap Health | Readers in Texas wanting the lowest published figures | | | Harbor | Readers who value a bundled plan and will ask what raises the floor | | | Glam Health | Readers who will ask what the plan costs at their own dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [VitaFusions IV](https://thisglp.com/reviews/vitafusions-iv) [Vital Edge](https://thisglp.com/reviews/vital-edge) [Vitalex Health](https://thisglp.com/reviews/vitalex-health) [Vitara RX](https://thisglp.com/reviews/vitara-rx) [VitaStir](https://thisglp.com/reviews/vitastir) [Voxy](https://thisglp.com/reviews/voxy) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is semaglutide $1,299? It is the cash price of branded Ozempic, and Gala states insurance may reduce it. What a reader pays is not established until a claim is run. Can I buy one month of tirzepatide at $179? No. The $179 is calculated on a yearly subscription. A three-month plan is $199 a month, and the month-to-month rate appears only at checkout. Does either price change with the dose? No. Both lines are stated flat across doses. Is Gala legit? Gala is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Gala expensive compared with other GLP-1 telehealth sellers? Gala publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Gala below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Garcia Weight Loss, Aesthetics & Hormone Therapy reviews (2026) | This GLP A Tampa Bay clinic group that runs GLP-1 injections through weekly or monthly office visits and prices them only at a consultation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/garcia-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Tampa Bay clinic, office visits # Garcia Weight Loss, Aesthetics & Hormone Therapy review A Tampa Bay clinic group that runs GLP-1 injections through weekly or monthly office visits and prices them only at a consultation. ## The verdict Garcia Weight Loss runs its GLP programs out of clinics in North and South Tampa, Brandon and Palm Harbor, built around office visits every week or every month. The site names neither the molecule nor a price. The figure a patient will pay, along with the start fees it mentions, is settled at a free fifteen-minute consultation rather than on the page. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 1 Dose published No Prescription Required Pharmacy Not named Labs Included Availability Florida (clinic visits) Garcia Weight Loss, Aesthetics and Hormone Therapy is a Florida clinic group that says it has run medically directed weight-loss programs in Tampa Bay since 2000, alongside hormone pellets and a long aesthetics menu. Its GLP injections sit next to phentermine on the weight-loss page, and the site's blog was still publishing articles on GLP-1 plateaus through the summer. 1. ## Who writes the prescription, and what do they see? The provider page lists a medical director, Michael J. Garcia, MD, described there as an orthopedic surgeon, and an OB/GYN, Randy Armstrong, MD, who is also called a medical weight-loss physician. Three nurse practitioners with FNP credentials are named beside them, one a member of the Obesity Medicine Association. Which of them sees a given GLP patient is not stated, and nothing on the site describes an online-only route. The Premier program brings the patient into the office four times in its first month, each visit paired with a lipotropic injection, while the Standard program is one visit a month with a B12 shot. Both include a full metabolic and hormone lab panel, a first month of multivitamin and thermogenic supplement, and medication shipped by a pharmacy to the patient's door. 2. ## What happens when the dose goes up? The FAQ describes the familiar ladder in plain terms: a low starting dose, raised every four weeks until the right level is found, with an injection on the same day each week. What the page does not say is whether the program's cost moves as the dose climbs, and no milligram figure appears anywhere on it. 3. ## What the price includes No price is published on the site for either GLP program. Premier's list says new or returning patient fees are included, while Standard's says patient start fees still apply, so the two plans differ on an upfront charge the site never quantifies. A financing option is offered, and the consultation that would settle the monthly figure is described as free. 4. ## What it claims, and what it cites The site calls the medication GLPs throughout and never says whether it is [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review), tirzepatide, a brand product or a compounded preparation. It names no pharmacy either, describing only a pharmacy that ships to the patient's door. A patient who needs to know whether the drug is FDA-approved has to ask at the consultation, which is the one place the site says the plan is set. ## Where it holds up, and where it does not - Strength: In-person visits weekly or monthly - Strength: Metabolic and hormone lab panel included - Strength: Named nurse practitioners and physicians - Strength: Free fifteen-minute consultation - Limitation: Neither program lists a price - Limitation: Molecule and brand-or-compounded status not stated - Limitation: Start fees mentioned but not quantified - Limitation: Clinic visits limit it to the Tampa Bay area ## What the evidence says about this kind of treatment The assessment above is about Garcia Weight Loss, Aesthetics & Hormone Therapy. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader living near Tampa Bay who wants a GLP-1 program with a nurse practitioner in the room every week and is comfortable getting the price at a consultation. Wrong for A reader who wants to know the molecule and the monthly cost before booking anything, or anyone outside driving distance of the four clinics. ## The evidence behind what Garcia Weight Loss, Aesthetics & Hormone Therapy prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Garcia Weight Loss, Aesthetics & Hormone Therapy compares | Seller | Who it suits | Go | | --- | --- | --- | | SynergenX Health | Readers near a clinic metro who want a live video visit and can budget for visit fees | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vyora Wellness](https://thisglp.com/reviews/vyora-wellness) [VyrarX](https://thisglp.com/reviews/vyrarx) [Vytora Health](https://thisglp.com/reviews/vytora-health) [Walgreens Weight Management](https://thisglp.com/reviews/walgreens-weight-management) [WeightCare](https://thisglp.com/reviews/weightcare) [WeightlessRx](https://thisglp.com/reviews/weightlessrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How much does the Garcia GLP program cost? The site does not publish a price for either program. It mentions patient start fees without an amount and points to a free fifteen-minute consultation to set the plan. Is it semaglutide or tirzepatide? The site does not say. It uses the word GLPs throughout, and it does not say whether the drug is a brand product or compounded. Can the program be done online? Nothing on the site describes an online-only route. Both programs are built around office visits at the clinics in North and South Tampa, Brandon and Palm Harbor. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Gatlan reviews (2026): GLP-1 telehealth sellers | This GLP Gatlan describes individualized care and ongoing contact. Ask for the exact prescription, treating practice and monitoring plan before judging the program. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/gatlan Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A consultation-led medical weight-loss service within a broader hormone and wellness platform. The public product page identifies GLP-1 and GLP-1/GIP treatment classes, but not a complete named-drug offer. # Does Gatlan sell a GLP-1? Gatlan describes individualized care and ongoing contact. Ask for the exact prescription, treating practice and monitoring plan before judging the program. ## The verdict The intake, possible laboratory review and continuing support form a useful outline. Important details remain consultation-dependent, including the medicine, pharmacy and cost. Its generic starting figure is not a complete treatment specification. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Gatlan, identified in its terms as Immortal Male, Inc., operates a platform connecting users with healthcare and pharmacy services. Medical weight loss is one category alongside hormone, hair and other wellness treatments. 1. ## Who writes the prescription, and what do they see? The platform’s terms expressly distinguish it from the clinicians providing diagnosis and treatment. They also say Gatlan does not independently confirm every professional’s credentials. Ask who will prescribe and confirm that clinician’s authority to treat you in your state. The published journey starts with medical history, then provider review to determine whether laboratory work is needed. A personalized plan and continuing contact for questions and adjustments follow if appropriate. Confirm how often visits occur and who responds between appointments. 2. ## What happens when the dose goes up? Gatlan advertises ongoing refinement, but does not publish a medicine-specific [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule in the reviewed product overview. The proposed drug and clinician’s instructions should determine monitoring and changes; the broader optimization menu is not a GLP-1 protocol. 3. ## What the price includes The medical weight-loss category has a generic monthly starting figure and a free-consultation invitation. Neither establishes a named medicine’s complete cost. Ask whether testing, follow-up, pharmacy charges and supplies are included. Refunds are generally not offered under the terms, with exceptions left to the company’s discretion. 4. ## What it claims, and what it cites The product FAQ says weight management uses FDA-approved GLP-1 and GLP-1/GIP therapies. It does not name the specific products there. Treat that as the seller’s description and obtain the actual brand, ingredient, route and dispensing pharmacy before treatment. ## Where it holds up, and where it does not - Strength: Describes intake and possible laboratory review - Strength: Explains continuing provider contact - Limitation: Exact medicine and pharmacy are not specified in the product overview - Limitation: Follow-up frequency must be confirmed ## What the evidence says about this kind of treatment The assessment above is about Gatlan. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults who want a consultation-led program and will verify its clinical and pharmacy arrangements before enrolling. Wrong for Anyone needing a fully specified drug, follow-up schedule and medicine-inclusive price before a consultation. ## How Gatlan compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [WeightlessRx](https://thisglp.com/reviews/weightlessrx) [WeightRx](https://thisglp.com/reviews/weightrx) [WeightWatchers Clinic](https://thisglp.com/reviews/weight-watchers) [Welling Health](https://thisglp.com/reviews/welling-health) [Wellspring Longevity Clinic](https://thisglp.com/reviews/wellspring-longevity-clinic) [WePeptideRx](https://thisglp.com/reviews/wepeptiderx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Gatlan identify a specific GLP-1 on its product overview? The reviewed FAQ identifies GLP-1 and GLP-1/GIP treatment classes and describes them as FDA-approved therapies. Ask for the exact brand, ingredient and route in the proposed prescription. Who provides the medical care? Gatlan’s terms distinguish its platform from healthcare professionals. Confirm the treating practice, clinician and state authorization before care begins. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://www.gatlan.com/health-optimization-products/) - [Official program and terms](https://www.gatlan.com/) - [Official program and terms](https://www.gatlan.com/terms-of-service/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Gaya Wellness reviews (2026): GLP-1 telehealth sellers | This GLP A physician-led midlife program with the medication priced inside one tier, in five states. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/gaya-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Medication inside a tier # Gaya Wellness review A physician-led midlife program with the medication priced inside one tier, in five states. ## The verdict Gaya Wellness includes compounded semaglutide or tirzepatide in a $399 monthly tier. A quarterly commitment lowers the tier to $349. A board-certified OB/GYN leads the program, which is licensed in five states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 5 From From $399/mo Prescription Required Compounded Yes — not FDA-approved Availability FL, NC, VA, IN, TN Gaya Wellness is a virtual OB/GYN practice based in Winter Garden, Florida. Its weight program has three tiers. Only the middle tier includes a GLP-1 medication, and the top tier adds hormone therapy. 1. ## Who writes the prescription, and what do they see? The founder is a board-certified OB/GYN. The page states the program is physician-led, not handed to coaches or nurse practitioners. The first consultation is with a physician, and weekly check-ins with a board-certified MD are asynchronous. Enrollment starts with a physician consultation and lab orders, drawn at a facility near the patient. Medication ships to the door. Weekly check-ins and custom meal plans follow. The page states that patients can cancel anytime. 2. ## What happens when the dose goes up? Dosing is physician-managed, and the tier price assumes standard dosing. Tirzepatide above 10 mg a week may cost more. The physician discusses any added cost before the change is made. 3. ## What the price includes The GLP-1 tier is $399 a month without a commitment. A three-month billing cycle brings it to $349. Six months at $399 is $2,394. The surcharge for tirzepatide above 10 mg is not published. 4. ## What it claims, and what it cites Both molecules are compounded, and compounded preparations are not FDA-approved. They get no FDA review before dispensing, and the pharmacy is not named. ## Where it holds up, and where it does not - Strength: A board-certified OB/GYN leads the program - Strength: Weekly check-ins with a physician - Strength: Medication included in one tier price - Strength: The tirzepatide dose surcharge is disclosed - Limitation: Licensed in five states only - Limitation: The surcharge amount is not published - Limitation: The lower rate needs a quarterly commitment - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Gaya Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A woman in midlife living in one of the five licensed states who wants a physician at the center of care. Wrong for A reader outside those five states, or one who wants medication without a care program. ## The evidence behind what Gaya Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Gaya Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | ElleS | Buyers who want the prescribing physicians and pharmacies named before they pay | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Whoosh Wellness](https://thisglp.com/reviews/whoosh-wellness) [Wisp](https://thisglp.com/reviews/wisp) [Woodwork](https://thisglp.com/reviews/woodwork) [YourHealthRx](https://thisglp.com/reviews/yourhealthrx) [Yucca Health](https://thisglp.com/reviews/yucca-health) [Zappy Health](https://thisglp.com/reviews/zappy-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the medication tier cost? $399 a month, or $349 on a three-month billing cycle. Does a higher dose cost more? Tirzepatide above 10 mg a week may. The physician discusses the cost first. Which states are served? Florida, North Carolina, Virginia, Indiana and Tennessee. Is Gaya Wellness legit? Gaya Wellness is a GLP-1 telehealth sellers service. Its stated availability: FL, NC, VA, IN, TN. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Gaya Wellness expensive compared with other GLP-1 telehealth sellers? Gaya Wellness publishes a starting figure of $399/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Gaya Wellness above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Genesis Health reviews (2026): GLP-1 telehealth sellers | This GLP Every commitment length is priced and every total is printed beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/genesis Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four rungs, both molecules # Genesis Health review Every commitment length is priced and every total is printed beside it. ## The verdict Genesis Health publishes four plan lengths on each molecule. Semaglutide runs from $175 a month down to $91.67 on an annual plan, and tirzepatide from $225 down to $125. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $175/mo Prescription Required Compounded Yes — not FDA-approved Genesis Health sells both molecules by injection across four commitment lengths. Each figure includes a physician consult, the medication and free shipping. 1. ## Who writes the prescription, and what do they see? A physician consult is stated as included in every figure, which is more than most sellers commit to in writing. The clinician is not described and the intake is not documented, so what the consult covers is left open. The published ladder prints both the monthly figure and the billed amount at each rung. A reader can see that a quarterly semaglutide plan is $350 rather than three separate charges, which removes the most common surprise in this category. 2. ## What happens when the dose goes up? Nothing is published about what happens at a higher dose. The ladder answers how long a buyer commits, not what the milligrams do to the figure, and those are different questions. 3. ## What the price includes Semaglutide is $175 month to month, $116.67 quarterly at $350 billed, $108.33 on six months at $650, and $91.67 annually at $1,100. Tirzepatide is $225, $188.33 at $565, $175 at $1,050 and $125 at $1,500. Every total is printed, so nothing needs working out. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: All four rungs and totals published - Strength: Physician consult stated as included - Strength: Free shipping inside every figure - Strength: Semaglutide commitment rungs were cut - Limitation: The best rate needs a $1,100 prepay - Limitation: Nothing published about dose pricing - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Genesis Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the billed amount, not just the monthly rate, before committing. Wrong for A reader who needs to know the cost at a higher dose first. ## The evidence behind what Genesis Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Genesis Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Harmony Wellness Clinic | Readers who want to cost out a full escalation before starting one | | | Healthicare | A reader outside California who wants a low monthly injection price with every component listed | | | Get Thin MD | Readers taking the three-month plan who read what the sale actually covers | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Zealthy](https://thisglp.com/reviews/zealthy) [Zera Health](https://thisglp.com/reviews/zera-health) [Zeuss](https://thisglp.com/reviews/zeuss) [ZipHealth](https://thisglp.com/reviews/ziphealth) [ZYP Medical](https://thisglp.com/reviews/zyp-medical) [10Rx](https://thisglp.com/reviews/10rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is billed on the quarterly plan? $350 every three months for semaglutide, which the page states as $116.67 a month. Tirzepatide is $565. What is included? A physician consult, the medication and free shipping, stated as inside every figure. How much does the annual plan save? $83.33 a month on semaglutide and $100 on tirzepatide, against the month-to-month rates. Is Genesis Health expensive compared with other GLP-1 telehealth sellers? Genesis Health publishes a starting figure of $175/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Genesis Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Genesis Lifestyle Medicine reviews (2026): medical weight-loss clinics | This GLP Genesis Lifestyle Medicine combines weight-management assessment, laboratory review and adjustable follow-up. Its brand-name and compounded pathways need separate pharmacy and cost checks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/genesis-lifestyle-medicine Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Genesis Lifestyle Medicine sell a GLP-1? Genesis Lifestyle Medicine combines weight-management assessment, laboratory review and adjustable follow-up. Its brand-name and compounded pathways need separate pharmacy and cost checks. ## The verdict The useful detail is a described follow-up process: appointments may be weekly, every other week or monthly according to need. Genesis also distinguishes approved brand prescriptions from compounded options. That makes it important to establish the exact care and dispensing pathway at the chosen location. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category medical weight-loss clinics Prescription Required Genesis is a clinic network offering weight management, hormone and other services. The weight-loss materials cover Wegovy, Zepbound and compounded semaglutide or tirzepatide. A general network menu is not a promise that every treatment is appropriate or available at every office. 1. ## Who writes the prescription, and what do they see? The initial consultation reviews medical history, previous weight-loss attempts, symptoms and lifestyle. A provider may recommend laboratory tests for metabolic health, kidney and liver function or other relevant markers. The purpose is individualized suitability, not automatic prescribing after a quiz. The program describes nutrition and behavior support plus regular clinical visits. Follow-ups can be weekly, biweekly or monthly according to need and preference. The separate medical-weight-loss page also describes body-composition assessment; confirm which services your location and plan include. 2. ## What happens when the dose goes up? Dosing is adjusted according to appetite, gastrointestinal tolerance, energy and progress rather than a single universal schedule. Ask how to contact the team between appointments and how refill decisions are handled if a prescribed product is unavailable. 3. ## What the price includes For brand-name prescriptions, Genesis states that a monthly weight-management fee applies and that insurance coverage is not guaranteed. The treatment pages do not establish one complete recurring price across locations, formulations and clinical services. 4. ## What it claims, and what it cites Approved Wegovy and Zepbound may be sent to a pharmacy of the patient’s choice, including appropriate manufacturer pathways. Compounded preparations are different products and are not FDA-approved. Clarify which is proposed and why before comparing the expected benefit or cost. ## Where it holds up, and where it does not - Strength: Follow-up frequency is discussed explicitly - Strength: Brand-name pharmacy choice is acknowledged - Strength: Dose adjustment considers symptoms and progress - Limitation: Prices vary with the selected pathway - Limitation: A monthly management fee can accompany brand prescriptions - Limitation: Network availability must be checked locally ## What the evidence says about this kind of treatment The assessment above is about Genesis Lifestyle Medicine. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient wanting a clinic-based care plan with flexible follow-up and a discussion of approved versus compounded options. Wrong for Someone needing a single nationwide all-in price or guaranteed insurance approval. ## The evidence behind what Genesis Lifestyle Medicine prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Genesis Lifestyle Medicine compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [10Rx](https://thisglp.com/reviews/10rx) [AJ Peptide](https://thisglp.com/reviews/aj-peptide) [Ambiante Health & Wellness](https://thisglp.com/reviews/ambiante-health-wellness) [Aurelius Health Group](https://thisglp.com/reviews/aurelius-health-group) [AVArx](https://thisglp.com/reviews/avarx) [Basal Health](https://thisglp.com/reviews/basal-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How often are follow-ups? The GLP-1 program describes weekly, biweekly or monthly visits based on the patient’s needs and preferences. Can a brand prescription go to another pharmacy? Genesis states that patients may have the listed brand-name prescriptions sent to a pharmacy of their choice. Does the practice guarantee coverage? No. Its public information explicitly distinguishes prescribing from insurance approval. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.genesislifestylemedicine.com/) - [Weight-management program](https://www.genesislifestylemedicine.com/medical-weight-loss/) - [GLP-1 care and prescribing options](https://www.genesislifestylemedicine.com/glp-1-weight-loss/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Get Thin MD reviews (2026): GLP-1 telehealth sellers | This GLP The sale figures apply to the first month of a three-month plan, not to a month bought alone. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/get-thin-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Sale price needs a term # Get Thin MD review The sale figures apply to the first month of a three-month plan, not to a month bought alone. ## The verdict Get Thin MD publishes $169 a month for semaglutide and $299 for tirzepatide. Sale figures of $119 and $179 are a first-month discount on the three-month plan. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $169/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Get Thin MD sells both molecules by injection. Both figures are stated flat across doses. Fifty states are covered. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state rates and plans. The intake is not documented. Two conditions attach to the low figures. They need the three-month plan, and they cover its first month. Neither is hidden. Both are easy to read past. 2. ## What happens when the dose goes up? Both lines are flat, so the rate holds as the dose rises. Nothing describes what a clinician reviews at an increase. The price question is answered and the care question is not. 3. ## What the price includes Six months of semaglutide at $169 is $1,014. The $119 sale figure covers one month of a three-month plan, so the plan is $119 plus two at $169, or $457. Tirzepatide works the same way from $179 against $299. Neither sale figure is a rate. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Flat across doses on both molecules - Strength: Coverage in all fifty states - Strength: The sale terms are stated in the FAQ - Limitation: Sale figures cover one month only - Limitation: They require the three-month plan - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Get Thin MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader taking the three-month plan who reads what the sale covers. Wrong for A reader budgeting from the sale figure. ## The evidence behind what Get Thin MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Get Thin MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Genesis Health | Readers who want the billed amount, not just the monthly rate, before committing | | | Good Life Meds | Readers escalating to a high dose who want the figure fixed across it | | | Harbor | Readers who value a bundled plan and will ask what raises the floor | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [BodyLogicMD](https://thisglp.com/reviews/bodylogicmd) [Broose Wellness](https://thisglp.com/reviews/broose-wellness) [CAPO Health](https://thisglp.com/reviews/capo-health) [Chia](https://thisglp.com/reviews/chia-health) [Chronos Body Health & Wellness](https://thisglp.com/reviews/chronos-bhw) [CVS MinuteClinic](https://thisglp.com/reviews/cvs-minuteclinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $119 the monthly price? No. It is the first month of a three-month plan. The standing rate is $169. What does the three-month plan cost? $457 for semaglutide: one month at $119 and two at $169. Does the price rise with the dose? No. Both lines are stated flat across doses. Is Get Thin MD legit? Get Thin MD is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Get Thin MD expensive compared with other GLP-1 telehealth sellers? Get Thin MD publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Get Thin MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # GetRelief Rx reviews (2026): GLP-1 telehealth sellers | This GLP A daily liquid held under the tongue, sold on two-month plans at prices that move with the dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/getrelief-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Under the tongue, dose-priced # GetRelief Rx review A daily liquid held under the tongue, sold on two-month plans at prices that move with the dose. ## The verdict As a daily liquid held under the tongue, GetRelief Rx offers compounded semaglutide and tirzepatide starting at $209 and $359 a month on its shortest plan, which runs two months. Both figures are marked as starting prices that depend on the dose, and neither page says what a higher dose costs. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Oral Dose pricing Rises with dose From From $209/mo Prescription Required Compounded Yes — not FDA-approved GetRelief Rx is a telehealth brand whose GLP-1 products are compounded sublingual suspensions, a minty liquid taken once a day under the tongue, and it sells no injection of either molecule. The same storefront carries sermorelin, tadalafil and a tirzepatide-and-tadalafil combination. 1. ## Who writes the prescription, and what do they see? A licensed clinician reviews the online medical assessment and decides whether treatment is appropriate, and the site states that prescribing decisions rest with the clinician while dispensing decisions rest with the pharmacy. Who the clinicians are, and whether a patient ever speaks to one, is not described anywhere on the product pages. Plans are subscriptions of two or six months, and the refund policy describes renewals on a recurring 30-day cycle with refills that can ship up to seven days early, so a cancellation has to land before processing starts. Once a bottle has been dispensed it cannot be returned or refunded. 2. ## What happens when the dose goes up? The product pages describe a microdosing approach built on lower, steady daily doses rather than an automatic climb toward a maintenance level, with the clinician adjusting the pace. Because every figure carries the note that pricing depends on dosing, a patient whose dose does rise should expect the bill to follow, by an amount the pages leave unstated. 3. ## What the price includes The shortest plan is two months, at $209 a month for semaglutide and $359 for tirzepatide, charged as a two-month total, and a six-month plan lowers the monthly figure on both. Held for six months at the shorter plan's rate, semaglutide comes to $1,254 and tirzepatide to $2,154. Those are floors rather than quotes, since the page ties the real charge to the prescribed dose. 4. ## What it claims, and what it cites Both are compounded under Section 503A for an individual patient, and the pages state plainly that compounded drugs are not FDA-approved or reviewed for safety, effectiveness or quality before marketing. No FDA-approved product delivers either molecule under the tongue. The site footer lists GetRelief Pharmacy in Billings, Montana, but the product pages do not say which pharmacy prepares the order. ## Where it holds up, and where it does not - Strength: No injection, a daily liquid instead - Strength: Free shipping and HSA/FSA accepted - Strength: Clinician adjusts the pace of dosing - Strength: Compounding status stated on each page - Limitation: Shortest plan runs two months - Limitation: Price depends on dose, amount unstated - Limitation: No refund once a bottle ships - Limitation: No sublingual form is FDA-approved ## What the evidence says about this kind of treatment The assessment above is about GetRelief Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who will not inject, accepts a lower-dose daily routine, and can commit to at least two months at a time. Wrong for A buyer who wants one fixed monthly price or a month-to-month plan, since the seller offers neither. ## The evidence behind what GetRelief Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How GetRelief Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | Breeze Meds | A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Defy Medical](https://thisglp.com/reviews/defy-medical) [Docberry](https://thisglp.com/reviews/docberry) [Elara MD](https://thisglp.com/reviews/elara-md) [EmbraceRX](https://thisglp.com/reviews/embrace-rx) [eMed](https://thisglp.com/reviews/emed) [Enara Health](https://thisglp.com/reviews/enara-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a one-month plan? No. The shortest subscription is two months, starting at $209 a month for semaglutide and $359 for tirzepatide, and a six-month plan lowers both monthly figures. Will a higher dose cost more? It can, since both product pages mark every figure as dependent on dosing, but the price attached to any particular higher dose is not published. Is this an injection? No. It is a liquid held under the tongue once a day, and the site sells no injectable version of either molecule. Is GetRelief Rx expensive compared with other GLP-1 telehealth sellers? GetRelief Rx publishes a starting figure of $209/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts GetRelief Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Gide Health reviews (2026): GLP-1 telehealth sellers | This GLP Gide identifies a provider-network partner, while its broad GLP-1 labels leave the exact ingredient and formulation unclear. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/gide-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Provider-network partner identified # Does Gide Health sell a GLP-1? Gide identifies a provider-network partner, while its broad GLP-1 labels leave the exact ingredient and formulation unclear. ## The verdict Gide identifies a clinical network, but product identity and follow-up details should be settled before choosing a GLP-1 format. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Gide Health is an online platform marketing weight-loss and wellness prescriptions through a clinical partner network. Its weight-loss material uses general GLP-1 injection and drop labels, rather than clearly establishing the ingredient of every listed product. 1. ## Who writes the prescription, and what do they see? The terms point to Beluga Health as a provider-network partner and say Gide does not itself practice medicine. The clinician must assess the patient and decide whether a prescription is appropriate. Confirm the specific medical practice on the clinical consent. The site markets doctor-prescribed treatment and home delivery. A fixed follow-up schedule and clinical response deadline were not established in the public offer. Ask how to reach the prescriber and how a change in symptoms is reviewed before refilling. 2. ## What happens when the dose goes up? The clinician should identify the exact ingredient, concentration and dose before any schedule can be evaluated. Do not treat a generic product label or a drop count as equivalent to a prescribed injection dose. 3. ## What the price includes The homepage displays different starting figures for what appear to be similarly labeled GLP-1 injections. The relationship between those offers is not established. Its terms make purchases final after services begin or a prescription goes to the pharmacy; request a definitive product-specific quote first. 4. ## What it claims, and what it cites A generic GLP-1 label does not establish the active ingredient, formulation or evidence for oral drops. Obtain the proposed prescription and pharmacy details before comparing a drop with an injection or an FDA-approved branded medicine. ## Where it holds up, and where it does not - Strength: Provider-network partner identified - Strength: Clinical evaluation is required - Strength: Purchase-finality terms are public - Limitation: Exact ingredient is not established for every category - Limitation: Injection starting labels differ - Limitation: Follow-up and pharmacy details need confirming ## What the evidence says about this kind of treatment The assessment above is about Gide Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone willing to verify the exact medicine, medical group and monitoring relationship before agreeing to treatment. Wrong for Someone ready to buy an injection or drop before the active ingredient and formulation have been clarified. ## How Gide Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Enara Health](https://thisglp.com/reviews/enara-health) [Enhanced](https://thisglp.com/reviews/enhanced) [EverFit Medical](https://thisglp.com/reviews/everfit-medical) [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) [Evernow](https://thisglp.com/reviews/evernow) [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The site markets doctor-prescribed treatment and home delivery. A fixed follow-up schedule and clinical response deadline were not established in the public offer. Ask how to reach the prescriber and how a change in symptoms is reviewed before refilling. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Current weight-loss offer](https://www.gide.health/weight-loss) - [Medical-network and purchase terms](https://www.gide.health/terms-of-service) - [Homepage treatment labels](https://www.gide.health/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Gimme Care reviews (2026): GLP-1 telehealth sellers | This GLP Each product card prints a monthly rate and a three-month rate, and states the price holds at every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/gimme-care Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two rungs, one dose rule # Gimme Care review Each product card prints a monthly rate and a three-month rate, and states the price holds at every dose. ## The verdict Gimme Care charges $160 for compounded semaglutide and $199 for compounded tirzepatide with no term attached, and refills ship every 28 days. Thirteen refills fall in a year, so a calendar month costs $173.33 and $215.58. Each card also carries a three-month rung, and its FAQ says that rung is billed every three months. The price is stated to hold at every dose, which is the claim most worth reading before the dose rises. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $173.33/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states + DC Gimme Care is a cash-pay telehealth program that sells two compounded GLP-1 injections beside sermorelin, NAD+, B12 and glutathione. The company named in its footer is Start Gimme LLC. Service is stated for all 50 states and the District of Columbia. No insurance is billed, and no membership fee is charged. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews an online questionnaire and prescribes only if treatment is judged appropriate. No clinician, medical group or medical director is named on the product pages. The site describes itself as not a pharmacy, connecting patients with licensed professionals who decide eligibility. Whether a video or phone visit ever takes place is not stated. Follow-ups, dose adjustments and questions go through an online portal with unlimited provider messaging. Refills ship every 28 days after a short check-in, and delivery is stated to be free. The monthly price is said to include consultation, medication, supplies, shipping and support. A dedicated care team handles non-clinical questions. 2. ## What happens when the dose goes up? "Same price at every dose" is printed on both product cards, so the rate does not rise as the dose climbs. The page describes a step-by-step escalation schedule meant to limit [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The physician sets the starting dose after the intake. A patient already on a GLP-1 may ask to continue the current dose. The milligram steps themselves are not published. 3. ## What the price includes Semaglutide is $160 per refill month to month and $130 a month on the three-month plan. Tirzepatide is $199 and $163 on the same two terms. The month-to-month refill ships every 28 days, which is $173.33 and $215.58 per calendar month. The three-month rung is billed in one charge every quarter, so it is $390 or $489 upfront. No figure on either card is struck through or marked as a first-month offer. 4. ## What it claims, and what it cites Both products are compounded by U.S. pharmacies, and the page states compounded medications are not FDA-approved and were not evaluated by the FDA for safety, quality or efficacy. The compounding pharmacy is not named. Brand [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), Ozempic, [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and Mounjaro are not sold. ## Where it holds up, and where it does not - Strength: One price stated to hold at every dose - Strength: A month-to-month rung is published beside the term rate - Strength: All 50 states and DC are named - Strength: No membership fee is charged - Strength: Unlimited provider messaging is included - Limitation: The lower rung is billed a quarter at a time - Limitation: No clinician or medical group is named - Limitation: The compounding pharmacy is not named - Limitation: Milligram steps are not published - Limitation: Refills run on a 28-day cycle ## What the evidence says about this kind of treatment The assessment above is about Gimme Care. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who expects to climb the dose ladder and wants the monthly price fixed while it happens. Wrong for A buyer who wants a named prescriber or pharmacy before paying. ## The evidence behind what Gimme Care prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Gimme Care compares | Seller | Who it suits | Go | | --- | --- | --- | | Good Life Meds | Readers escalating to a high dose who want the figure fixed across it | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | ElleS | Buyers who want the prescribing physicians and pharmacies named before they pay | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Florida Weight Loss MD](https://thisglp.com/reviews/florida-weight-loss-md) [Found Youth](https://thisglp.com/reviews/found-youth) [Freeley](https://thisglp.com/reviews/freeley) [FuturHealth](https://thisglp.com/reviews/futurhealth) [G-Plans](https://thisglp.com/reviews/g-plans) [Gatlan](https://thisglp.com/reviews/gatlan) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does compounded semaglutide cost without a commitment? $160 per refill, and refills ship every 28 days, so $173.33 per calendar month. The $130 figure beside it is the three-month plan, which is billed every three months. Does the price go up at higher doses? Not according to the product cards, which state the same price at every dose for both molecules. Is there a membership fee? No. The site states there is no membership or hidden fee, and that the price covers consultation, medication, supplies and shipping. Is Gimme Care legit? Gimme Care is a GLP-1 telehealth sellers service. Its stated availability: All 50 states + DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Gimme Care expensive compared with other GLP-1 telehealth sellers? Gimme Care publishes a starting figure of $173.33/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Gimme Care below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Glam Health reviews (2026): GLP-1 telehealth sellers | This GLP Two floors are published with B12 formulations named. Almost nothing else is. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/glam-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Starting at, and little else # Glam Health review Two floors are published with B12 formulations named. Almost nothing else is. ## The verdict Glam Health publishes starting figures of $149 a month for compounded semaglutide and $175 for tirzepatide. Both are formulated with B12. No dose or coverage list is published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $149/mo Prescription Required Compounded Yes — not FDA-approved Glam Health sells both molecules by injection with B12. Each plan is described as including steady follow-up. Two floors are published. 1. ## Who writes the prescription, and what do they see? The pages state a licensed provider reviews the tirzepatide plan. No clinician is named. The intake is not documented. Steady follow-up is the phrase used and it is not defined. No cadence, no format, no charge is attached to it. A reader cannot tell what it costs or how often it happens. 2. ## What happens when the dose goes up? Nothing is published about dose. No milligram figure appears beside either price. Starting at leaves the ceiling unstated as well as the floor's dose. 3. ## What the price includes $149 and $175 are floors. Six months at them is $894 and $1,050 at best. A reader escalating pays an unpublished figure. Ask what the plan costs at a therapeutic dose before ordering. 4. ## What it claims, and what it cites Both lines are compounded with B12. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Both molecules carry a published floor - Strength: B12 formulation named on both lines - Strength: A licensed provider review is stated - Limitation: Both figures are a floor, not a rate - Limitation: Steady follow-up is never defined - Limitation: No milligram dose stated anywhere - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Glam Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will ask what the plan costs at their dose. Wrong for A reader who needs a settled monthly figure. ## The evidence behind what Glam Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Glam Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Green Cap Health | Readers in Texas wanting the lowest published figures | | | Harbor | Readers who value a bundled plan and will ask what raises the floor | | | Gala | Readers with insurance that may apply to Ozempic, or those ready to commit a year to compounded tirzepatide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Lifestyle Medicine](https://thisglp.com/reviews/genesis-lifestyle-medicine) [Gide Health](https://thisglp.com/reviews/gide-health) [Glow](https://thisglp.com/reviews/glow) [GOAL.MD](https://thisglp.com/reviews/goal-md) [GoodLife Health](https://thisglp.com/reviews/goodlife-health) [Happy Care Meds](https://thisglp.com/reviews/happy-care-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 what I will pay? It is a starting figure. No dose is attached to it and no ceiling is published. What is steady follow-up? The phrase is used and not defined. No cadence, format or charge is attached to it. Which states are served? No coverage list is recorded. Ask before ordering. Is Glam Health expensive compared with other GLP-1 telehealth sellers? Glam Health publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Glam Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Glow reviews (2026): GLP-1 telehealth sellers | This GLP Glow combines an AI-led diet service with a separate clinician-reviewed prescription program. Medical decisions and pharmacy responsibilities need to remain clear. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/glow Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 AI coaching and prescription care # Glow review Glow combines an AI-led diet service with a separate clinician-reviewed prescription program. Medical decisions and pharmacy responsibilities need to remain clear. ## The verdict Glow may interest someone seeking food-planning support alongside medication, but its AI interface is not the prescribing clinician. The prescription-specific terms are more informative than the general site’s refund language, and the selected drug’s continuation cost still needs confirmation. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Glow is a diet and weight-care platform with a prescription service offering compounded semaglutide and tirzepatide, including oral options. Its AI nutrition tools and medical program are distinct services; using one does not establish eligibility for the other. 1. ## Who writes the prescription, and what do they see? The prescription pathway requires assessment by a licensed professional. Glow says it does not compound the medicines; partner pharmacies prepare and dispense them. The public site names Epiq Scripts and CraftedRx as possible dispensing partners. An intake precedes physician review and pharmacy fulfillment. Ongoing support and follow-ups are listed in prescription pricing. Ask which medical practice takes responsibility for side effects and how to contact it outside general coaching support. 2. ## What happens when the dose goes up? A clinician reviews suitability and treatment risks. The public pricing explanation does not provide a full dose-by-dose continuation schedule. Request the planned follow-up and charges at later strengths before basing a decision on the opening month. 3. ## What the price includes First-month offers are separated from later semaglutide and tirzepatide amounts. The FAQ also says price varies with product and dose, so the later headline should not be assumed to cover every strength or oral formulation. 4. ## What it claims, and what it cites The site names compounded injections and oral preparations, including B-vitamin combinations. These finished compounded products are not FDA approved. Ask for the exact formulation and evidence relevant to its route rather than extrapolating from an injectable-brand trial. ## Where it holds up, and where it does not - Strength: Potential pharmacies named - Strength: Prescription terms separate from general coaching - Strength: Initial and continuation prices distinguished - Limitation: AI coaching is not clinical access - Limitation: Dose can affect price - Limitation: General and prescription refund policies differ ## What the evidence says about this kind of treatment The assessment above is about Glow. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values nutrition-planning tools but also checks the separate medical and pharmacy arrangements. Wrong for A patient seeking guaranteed results from an AI program or interchangeable evidence across oral and injected products. ## The evidence behind what Glow prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Glow compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealFastRx](https://thisglp.com/reviews/healfast) [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) [Hone Health](https://thisglp.com/reviews/hone-health) [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) [KairoRx](https://thisglp.com/reviews/kairorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Glow’s AI prescribe medication? No. The prescription service describes review by licensed healthcare professionals. Which refund policy applies to prescriptions? Read the prescription-specific terms. They discuss possible consultation refunds if a visit does not occur or prescribing is declined, while medication questions go to the dispenser. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://www.glowdiet.com/) - [Service and cancellation terms](https://www.glowdiet.com/legal/terms.html) - [Service and cancellation terms](https://www.glowdiet.com/prescription/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Go Vida Plena reviews (2026): GLP-1 telehealth sellers | This GLP A Spanish-language program whose advertised figures are annual rungs, with installment plans offered on top. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/go-vida-plena Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Spanish-first, annual rung # Go Vida Plena review A Spanish-language program whose advertised figures are annual rungs, with installment plans offered on top. ## The verdict Go Vida Plena advertises compounded semaglutide from $179 a month, which is the twelve-month rung billed at $2,148. Month to month the same injection is $269, and tirzepatide is $359. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $269/mo Prescription Required Compounded Yes — not FDA-approved Go Vida Plena is a Spanish-first telehealth program selling both molecules by injection, with installment payment offered through Klarna, Afterpay and Affirm. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described, but the program's distinguishing feature is the language it operates in rather than anything it publishes about who reviews an intake. Serving a Spanish-speaking reader in Spanish is a real service, and it makes the pricing structure matter more rather than less. A buyer comparing an advertised figure against an English-language competitor's monthly rate is comparing an annual rung against a month, and the language of the page does not change that arithmetic. 2. ## What happens when the dose goes up? Nothing is published about what either figure does at a higher dose. An oral semaglutide line is also offered with no price attached, so a reader considering a format change cannot cost it out either. 3. ## What the price includes The advertised $179 requires twelve months, billed at $2,148, and month to month the same injection is $269 — a $90 gap. Tirzepatide's $269 is the annual rung at $3,228 against $359 month to month, a $90 gap again. Installments through Klarna, Afterpay or Affirm spread the payment without lowering it, which is a different thing from a discount and worth keeping separate. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Spanish-language service throughout - Strength: Installment options published plainly - Strength: Both molecules carry a figure - Limitation: The advertised rate needs twelve months - Limitation: Month to month costs $90 more on both - Limitation: Oral semaglutide is offered without a price - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Go Vida Plena. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Spanish-speaking reader ready to commit a year and wanting the language served properly. Wrong for A reader who wants to pay monthly at the advertised figure. ## The evidence behind what Go Vida Plena prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Go Vida Plena compares | Seller | Who it suits | Go | | --- | --- | --- | | Goldspan Health | Readers who count the charges rather than the months | | | Genesis Health | Readers who want the billed amount, not just the monthly rate, before committing | | | Good Life Meds | Readers escalating to a high dose who want the figure fixed across it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [KIN Health](https://thisglp.com/reviews/kin-health) [Klarity Health](https://thisglp.com/reviews/klarity-health) [Klinic](https://thisglp.com/reviews/klinic) [Kova](https://thisglp.com/reviews/kova) [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) [Lighter You](https://thisglp.com/reviews/lighter-you) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $179 a monthly rate? Only on the twelve-month plan, which is billed at $2,148. Paying month to month the same injection is $269. What does tirzepatide cost? $269 a month on the annual plan, billed at $3,228, or $359 month to month. Do the installment plans lower the price? No. Klarna, Afterpay and Affirm spread the payment across time. The total stays the same. Is Go Vida Plena expensive compared with other GLP-1 telehealth sellers? Go Vida Plena publishes a starting figure of $269/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Go Vida Plena above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # GOAL.MD reviews (2026): GLP-1 telehealth sellers | This GLP Physician supervision, nutrition coaching and a phone-accessible team are included. The question is how that support translates into your own follow-up plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/goal-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Physician care and nutrition support # GOAL.MD review Physician supervision, nutrition coaching and a phone-accessible team are included. The question is how that support translates into your own follow-up plan. ## The verdict GOAL.MD describes more than a medication shipment: physician supervision and unlimited nutrition coaching are part of the compounded program. Before enrolling, establish who will review side effects and when you will next speak with the prescriber. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $179/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved GOAL.MD offers physician-supervised compounded injections and a separate program for access to brand-name GLP-1 medicines. The two programs have different billing arrangements; a prescription depends on a medical evaluation. 1. ## Who writes the prescription, and what do they see? A licensed U.S. physician reviews the medical history and decides whether to prescribe. GOAL.MD says it serves all 50 states, while also making the particular medication conditional on state rules, pharmacy eligibility and the clinical assessment. The public program includes ongoing physician supervision, nutrition coaching and telephone access to the care team. Contact hours are weekdays, 9 a.m.–5 p.m. Central. A published promise of support does not establish a scheduled clinical appointment interval. 2. ## What happens when the dose goes up? The tirzepatide page lists doses from 2.5 to 15 mg at the same price. Semaglutide also has a published dose list. The physician determines your prescription; a price table is not a reason to advance a dose before symptoms and response are reviewed. 3. ## What the price includes Month-to-month compounded care is advertised at $179 for semaglutide and $249 for tirzepatide, including medication, supervision, coaching and shipping. The $99 and $159 headlines require 12 months paid upfront. Brand access costs $95 a month for physician care, with medication and labs separate. 4. ## What it claims, and what it cites Its personalized [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are compounded preparations, which are not FDA-approved. Brand-name access is a separate service with medication bought through a manufacturer program or participating pharmacy. ## Where it holds up, and where it does not - Strength: Physician evaluation and nutrition coaching included - Strength: Telephone contact hours are published - Strength: Compounded refills require your confirmation - Limitation: No fixed clinical follow-up interval established - Limitation: Prepaid compounded orders become nonrefundable after payment - Limitation: Brand access does not include the medicine ## What the evidence says about this kind of treatment The assessment above is about GOAL.MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values physician supervision and nutrition coaching and can confirm the clinical follow-up arrangements before ordering. Wrong for Someone who expects a medicine-only transaction or needs a publicly guaranteed appointment schedule. ## The evidence behind what GOAL.MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How GOAL.MD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Livbetr](https://thisglp.com/reviews/livbetr) [Longevity Meds](https://thisglp.com/reviews/longevity-meds) [Loozy](https://thisglp.com/reviews/loozy) [Male Excel](https://thisglp.com/reviews/male-excel) [MangoRx](https://thisglp.com/reviews/mangorx) [MD Trim Clinic](https://thisglp.com/reviews/md-trim-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are compounded refills automatic? GOAL.MD says they are not. The care team contacts you before renewal and charges only after you confirm. Is the brand-name membership the same arrangement? No. It renews automatically and covers physician services rather than the medicine. Cancellation must precede the next prescription or refill authorization. Is GOAL.MD expensive compared with other GLP-1 telehealth sellers? GOAL.MD publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts GOAL.MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Semaglutide treatment and billing](https://goal.md/weight-loss/semaglutide-injection) - [Tirzepatide treatment and billing](https://goal.md/weight-loss/tirzepatide-injection) - [Membership and refund terms](https://goal.md/terms-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # GobyMeds reviews (2026): GLP-1 telehealth sellers | This GLP A one-month price at any dosage, beside a starter bundle with its inclusions spelled out. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/gobymeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One month, any dosage # GobyMeds review A one-month price at any dosage, beside a starter bundle with its inclusions spelled out. ## The verdict GobyMeds prices one month at any dosage: $169 for semaglutide and $299 for tirzepatide. A starter bundle for first-time patients costs less per month and is paid in full at the start. The bundle names four things it covers. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $169/mo Prescription Required Compounded Yes — not FDA-approved Both molecules are sold as injections only, by the month or as a starter bundle. Two further entries sit far higher and correspond to branded products the promotional terms specifically exclude, which the terms state. 1. ## Who writes the prescription, and what do they see? The consultation is inside the bundle price rather than billed apart. A prescription precedes shipping. The pages do not name the clinician or describe the intake. The enumerated inclusions are the strong point. Four separate charges that normally sit outside a headline are each named as covered, individually rather than as a vague 'all-inclusive'. That is the difference between a claim a reader can check and one they must take on trust. 2. ## What happens when the dose goes up? The one-month price holds at any dosage, and the page says so. The starter bundle covers roughly the escalation window. After it, the one-month price is the figure to plan against. 3. ## What the price includes One month is $169 on semaglutide and $299 on tirzepatide. The starter bundles are $299 for twelve weeks of semaglutide and $399 for three months of tirzepatide. Each is paid in full at the start. Codes on the promotions page apply to the starter bundles only. 4. ## What it claims, and what it cites The two priced lines are compounded preparations, made to order rather than manufactured and reviewed as finished products. The four-figure entries correspond to branded products the promotional terms exclude. ## Where it holds up, and where it does not - Strength: Four bundle inclusions named one by one - Strength: A one-month price at any dosage - Strength: Exclusions on the branded lines are stated - Limitation: The bundle is paid in full at the start - Limitation: The one-month price sits well above the bundle - Limitation: Nothing names the prescriber - Limitation: The compounder is unidentified ## What the evidence says about this kind of treatment The assessment above is about GobyMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a monthly price that holds at any dose, or a cheaper bundle paid at once. Wrong for A reader who expects the bundle's monthly figure to continue after it ends. ## The evidence behind what GobyMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How GobyMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | Direct Meds | A reader content to buy by the quarter who will redo the per-day math | | | BetterMe Rx | A reader willing to fund a quarter up front, once the sale is confirmed live | | | NuDay Rx | Readers wanting an oral semaglutide at the injection price | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDLive](https://thisglp.com/reviews/mdlive) [MD Total Wellness](https://thisglp.com/reviews/mdtw) [Medical Health Institute](https://thisglp.com/reviews/medical-health-institute) [Medivive](https://thisglp.com/reviews/medivive) [MEDVidi](https://thisglp.com/reviews/medvidi) [Meli Health](https://thisglp.com/reviews/meli-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the starter bundle cheaper per month? Yes, for first-time patients: $299 covers twelve weeks of semaglutide, paid in full at the start. One month on its own is $169. Does the price rise with the dose? Not on the one-month plan, which the page prices at any dosage. What is covered? In the starter bundle, four things, each named separately: the drug, the delivery, the visit and the kit. Is GobyMeds expensive compared with other GLP-1 telehealth sellers? GobyMeds publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts GobyMeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Goldspan Health reviews (2026): GLP-1 telehealth sellers | This GLP The word monthly appears beside a supply that arrives every four weeks, and the price is not on the seller's own site. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/goldspan-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A month that is four weeks # Goldspan Health review The word monthly appears beside a supply that arrives every four weeks, and the price is not on the seller's own site. ## The verdict Goldspan Health advertises $229 a month for compounded semaglutide and $299 for tirzepatide, on a cycle its own copy describes as every four weeks — about $248 and $324 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $248/mo Prescription Required Compounded Yes — not FDA-approved Goldspan Health sells both molecules by injection with prices stated flat across doses, though neither figure is published on its own domain. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described, but the more unusual gap is upstream of that: a reader on goldspanhealth.com cannot find out what anything costs without following a link to a different company's storefront. The seller's own sentence is the whole finding: a new monthly supply arrives automatically every four weeks. Those two units are not the same, and calling the second one monthly is what turns a $229 charge into a $248 calendar month without anything on the page appearing to change. 2. ## What happens when the dose goes up? Both figures are stated flat across doses, so the rate holds as the milligrams climb. What does not hold is the calendar: thirteen four-week fills land in a year rather than twelve, which is the escalation a buyer does not see coming because it has nothing to do with the dose. 3. ## What the price includes Thirteen renewals at $229 is $2,977 a year rather than the $2,748 that twelve would give, which is $248.08 a calendar month. Tirzepatide at $299 comes to $3,887 rather than $3,588, or $323.92. The gap is one extra charge a year on each line, and a reader who budgets twelve months finds it in the thirteenth. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy neither site names, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The four-week cycle is stated verbatim - Strength: Both figures are flat across doses - Strength: Renewal is automatic and described as such - Limitation: A four-week cycle is billed as monthly - Limitation: Thirteen charges a year, not twelve - Limitation: No price appears on its own domain - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Goldspan Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who counts the charges rather than the months. Wrong for A reader budgeting a year from the advertised figure. ## The evidence behind what Goldspan Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Goldspan Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Go Vida Plena | Spanish-speaking readers ready to commit a year and wanting the language served properly | | | Fridays | Readers who will get the annual rate confirmed in writing before paying | | | Healthicare | A reader outside California who wants a low monthly injection price with every component listed | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Metabolic Rx](https://thisglp.com/reviews/metabolic-rx) [Metabolyz](https://thisglp.com/reviews/metabolyz) [Mixx Health & Wellness](https://thisglp.com/reviews/mixx-health-and-wellness) [Modern Age](https://thisglp.com/reviews/modern-age) [Novera MD](https://thisglp.com/reviews/novera-md) [Nuform Health](https://thisglp.com/reviews/nuform-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $229 what a month costs? Not a calendar month. The seller's own copy says a supply arrives every four weeks, and thirteen of those land in a year, which makes the real figure about $248.08. Where is the price published? Not on goldspanhealth.com. Both figures appear only on the altroapp.com storefront the product links through to. Does the price change with the dose? No. Both lines are stated flat across doses. The extra cost comes from the billing cycle rather than the milligrams. Is Goldspan Health expensive compared with other GLP-1 telehealth sellers? Goldspan Health publishes a starting figure of $248/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Goldspan Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Good Girl Rx reviews (2026): GLP-1 telehealth sellers | This GLP Each "from" figure is the twelve-month rung of a prepaid plan, and the one-month rate sits on the same selector. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/good-girl-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The headline is a year, paid up front # Good Girl Rx review Each "from" figure is the twelve-month rung of a prepaid plan, and the one-month rate sits on the same selector. ## The verdict Good Girl Rx leads every product with its twelve-month rung. The footnote says so. One month of compounded semaglutide is $179. Tirzepatide is $329. Microdose lines are sold separately and labeled as microdoses. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $179/mo Oral From $300/mo Prescription Required Compounded Yes — not FDA-approved Both molecules are sold by injection and as tablets, at full dose. Separate microdose lines sit beside them. Brand Ozempic is listed at $1,580. Every compounded plan offers one, three, six and twelve months. 1. ## Who writes the prescription, and what do they see? The service is remote. A prescription precedes shipping. The pages do not name the clinician. The intake is not described. The footnote states the rule: the figure shown is the average monthly cost of a multi-month plan paid up front. The one-month rate is the price without that commitment. This site ranks the one-month rate. 2. ## What happens when the dose goes up? No line states what happens as the dose rises. No milligram appears beside any plan. The microdose lines are labeled, but their contents are not. 3. ## What the price includes Semaglutide by injection runs $179 for one month, then $159, $145 and $134 a month on longer plans. Tirzepatide runs $329, then $255, $248 and $235. The tablets are $300 and $397 for one month. The tablets cost more than the injections. 4. ## What it claims, and what it cites Every compounded line is prepared by a pharmacy. None is FDA-approved. No agency examines them before they ship. [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) is the one approved product listed. ## Where it holds up, and where it does not - Strength: The prepay basis is footnoted on every page - Strength: One-month rates are published beside the ladder - Strength: Microdose lines are labeled as microdoses - Limitation: Every headline is a twelve-month prepaid rung - Limitation: No milligram accompanies any figure - Limitation: The oral premium goes unexplained ## What the evidence says about this kind of treatment The assessment above is about Good Girl Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the one-month rate and will not prepay a year. Wrong for A reader comparing the headline against another seller's monthly rate. ## The evidence behind what Good Girl Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Good Girl Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Luci | Readers who take an asterisk seriously and plan to ask what it hides | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nurx](https://thisglp.com/reviews/nurx) [Olleve Care](https://thisglp.com/reviews/ollevecare) [Omada Health](https://thisglp.com/reviews/omada-health) [One80Rx](https://thisglp.com/reviews/one80rx) [Pillar Health](https://thisglp.com/reviews/pillar-health) [Prescriva](https://thisglp.com/reviews/prescriva) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the "from" figure what one month costs? No. It is the twelve-month rung paid up front. One month of compounded semaglutide is $179, and tirzepatide is $329. Why does the tablet cost more here? The seller prices it that way and offers no reason. One month of the semaglutide tablet is $300, against $179 by injection. What are the microdose lines? Separate products, labeled as microdoses by the seller. They are not the starting dose of the full-dose plans, and no milligram is stated for either. Is Good Girl Rx expensive compared with other GLP-1 telehealth sellers? Good Girl Rx publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Good Girl Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Good Life Meds reviews (2026): GLP-1 telehealth sellers | This GLP One figure holds across every dose level, with no membership and no fees stated on top. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/good-life-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same price at every dose # Good Life Meds review One figure holds across every dose level, with no membership and no fees stated on top. ## The verdict Good Life Meds publishes $199 a month for semaglutide and $297 for tirzepatide. Both are stated as the same price at every dose level, with no additional fees or membership costs. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $199/mo Prescription Required Compounded Yes — not FDA-approved Good Life Meds sells both molecules by injection. A one-month supply is the unit the product pages price. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state prices and supply lengths rather than describing the clinician. The intake is not documented anywhere a reader can reach. Two statements do the work. The price is the same at every dose level, and no additional fees or membership costs apply. Both are the seller's own words, and together they make $199 a figure a reader can plan against. 2. ## What happens when the dose goes up? This is answered directly. The page states the same price at every dose level for a one-month supply, so escalation does not move the figure. Nothing describes what clinical support accompanies an increase. 3. ## What the price includes Six months of semaglutide at $199 is $1,194, and of tirzepatide at $297 is $1,782. The $99 and $149 figures a reader may see first are promotional prices on a first order, tagged as limited-time, not standing rates. The longer prepaid supplies the product pages once listed no longer appear on them. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Same price at every dose, stated plainly - Strength: No fees or membership, in writing - Strength: The standing rate is printed beside the promotion - Strength: The promo mechanism is disclosed - Limitation: The low figures are first-order only - Limitation: Only one supply length is priced - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Good Life Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader escalating to a high dose who wants the figure fixed across it. Wrong for A reader expecting the promotional figure to continue past a first order. ## The evidence behind what Good Life Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Good Life Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Genesis Health | Readers who want the billed amount, not just the monthly rate, before committing | | | Get Thin MD | Readers taking the three-month plan who read what the sale actually covers | | | Harbor | Readers who value a bundled plan and will ask what raises the floor | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrescrYbe](https://thisglp.com/reviews/prescrybe) [PRIMO Health Partners](https://thisglp.com/reviews/primo-health-partners) [Push Health](https://thisglp.com/reviews/push-health) [Ravia Health](https://thisglp.com/reviews/ravia-health) [Red Mountain Weight Loss](https://thisglp.com/reviews/red-mountain-weight-loss) [RegenCen](https://thisglp.com/reviews/regencen) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with my dose? No. The page states the same price at every dose level, at $199 for a one-month semaglutide supply. Can I keep the $99 price? No. It is a $100 first-order discount redeemed with a code. The standing rate is $199. What does tirzepatide cost after the first order? $297 a month. The $149 beside it is a limited-time first-order price. Is Good Life Meds expensive compared with other GLP-1 telehealth sellers? Good Life Meds publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Good Life Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # GoodLife Health reviews (2026): GLP-1 telehealth sellers | This GLP GoodLife puts repeated lab review and cardiometabolic care ahead of a medicine-only offer. The monthly membership and the pharmacy prescription remain separate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/goodlife-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Metabolic care with included labs # GoodLife Health review GoodLife puts repeated lab review and cardiometabolic care ahead of a medicine-only offer. The monthly membership and the pharmacy prescription remain separate. ## The verdict GoodLife may suit someone who wants broader metabolic care rather than a quick prescription. Its included quarterly labs and described monthly check-ins are meaningful features, but establish how that plan fits an existing primary-care relationship and the actual medication budget. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded No Labs Included GoodLife Health offers a cardiometabolic direct-primary-care membership with clinical support and included laboratory panels. Its weight-loss pathway uses branded GLP-1 medicines when clinically appropriate, with medication paid separately to the pharmacy. 1. ## Who writes the prescription, and what do they see? The terms name Beluga Health, P.A., an independent medical corporation working under GoodLife’s protocols. A clinical relationship begins only when an authorized clinician accepts the patient. The platform and its technology do not themselves practice medicine. GoodLife describes monthly check-ins and comprehensive lab panels every 90 days. The membership covers clinician review of those results and ongoing support. Ask which tests are included and how urgent symptoms are handled between scheduled contacts. 2. ## What happens when the dose goes up? GoodLife frames dose changes as part of clinical monitoring. A check-in and lab schedule do not mean every patient should increase doses monthly. Agree on the plan for [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), a plateau or switching medicines with the treating clinician. 3. ## What the price includes The membership is $299 a month with an initial two-month commitment. The pricing page says $598 is held at checkout and charged when a clinician accepts the patient. Branded medication is additional; included labs do not turn the membership into an all-in drug price. 4. ## What it claims, and what it cites The site lists [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), Mounjaro and Ozempic and says it uses branded, FDA-approved medicines rather than compounded GLP-1s. The prescribed product and its approved indication still matter. Membership is not a guarantee of a particular prescription. ## Where it holds up, and where it does not - Strength: Quarterly laboratory panels included - Strength: Monthly check-ins described - Strength: Independent medical group identified - Limitation: Medication costs are separate - Limitation: Initial two-month commitment - Limitation: Broader membership may exceed what a prescription-only buyer needs ## What the evidence says about this kind of treatment The assessment above is about GoodLife Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values continuing cardiometabolic care, lab interpretation and coordination around a branded prescription. Wrong for Someone seeking the lowest medication-only bill or a one-month trial without an initial commitment. ## The evidence behind what GoodLife Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How GoodLife Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rese Wellness](https://thisglp.com/reviews/rese-wellness) [Revive Longevity](https://thisglp.com/reviews/revive-longevity) [Rila](https://thisglp.com/reviews/rila) [Risen Labs](https://thisglp.com/reviews/risen-labs) [Robinhood Telehealth](https://thisglp.com/reviews/robinhood-telehealth) [Royal Medical Center](https://thisglp.com/reviews/royal-medical-center) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is GoodLife the prescribing medical practice? The terms identify the independent clinical entity as Beluga Health, P.A. Confirm the clinician responsible for your own care. Does membership cover GLP-1 medication? No. GoodLife separates its care-and-lab membership from the pharmacy’s medication charge. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Membership pricing and initial commitment](https://goodlifehealth.ai/pricing) - [Clinical and billing terms](https://goodlifehealth.ai/legal/terms) - [Weight-loss care](https://goodlifehealth.ai/medical-weight-loss) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # GoodRx reviews (2026): GLP-1 telehealth sellers | This GLP The prescription-coupon company's telehealth plan, which prescribes FDA-approved GLP-1s only and bills a monthly membership apart from the medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/goodrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand drugs, membership on top # GoodRx review The prescription-coupon company's telehealth plan, which prescribes FDA-approved GLP-1s only and bills a monthly membership apart from the medication. ## The verdict GoodRx Care Direct charges $39 a month for care, and the medication is billed on top. Foundayo is as low as $149 a month at its two lowest doses, so $188 all in. Zepbound KwikPen is as low as $299, so $338 all in. Every medication figure is tied to a dose, and several carry an end date. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron · Tirzepatide Form Injection · Oral Dose pricing Rises with dose States 48 Injection From $338/mo Oral From $188/mo Dose published Yes Prescription Required Compounded No Availability US except AL and LA GoodRx is best known for pharmacy discount coupons. GoodRx Care Direct is its subscription telehealth program. The weight-loss plan lists four brand products: the Wegovy pill, Wegovy and Wegovy HD pens, Foundayo tablets and the Zepbound KwikPen. Patients who already hold a prescription can use a GoodRx coupon at a pharmacy instead. 1. ## Who writes the prescription, and what do they see? Licensed healthcare professionals write the prescription, according to the page, after an online consultation. None is named, and no credential type is given. The membership buys unlimited online care, described as help reaching the most effective dose. Whether visits are live or asynchronous is not stated on the product page. A patient starts an online consultation, receives a prescription if it is deemed appropriate, and checks in with the care team afterward. Medication is offered by delivery or pickup. The subscription renews automatically and can be canceled from the dashboard a day before renewal. Weight-loss care is not available in Alabama or Louisiana. 2. ## What happens when the dose goes up? This is where the figures are most limited. GoodRx's footnote limits the Foundayo price to the 0.8 mg and 2.5 mg doses, and only until December 31, 2026; higher doses cost more. The Wegovy pen offer covers only the first two fills at the two lowest doses. So the advertised floor describes the start of the ladder, not maintenance. 3. ## What the price includes Care is $39 a month and does not include medication. Foundayo from $149 makes $188 all in; Zepbound from $299 makes $338. A year of care alone is $468. The footnotes list higher prices for [higher doses](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) and a step-up on the Wegovy pen after two fills. GoodRx states that it is not insurance. 4. ## What it claims, and what it cites Every product on the plan is FDA-approved; the page says so and lists nothing compounded. Foundayo is [orforglipron](https://thisglp.com/research/what-is-orforglipron), taken as a daily tablet. [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is tirzepatide by weekly pen. Wegovy is semaglutide, as a pill or a pen. Dispensing runs through pharmacy delivery or pickup, and no single pharmacy is named. ## Where it holds up, and where it does not - Strength: FDA-approved products only - Strength: Milligram doses printed beside each offer - Strength: Membership fee stated plainly - Strength: Cancel from the dashboard before renewal - Limitation: Medication billed on top of the membership - Limitation: Lowest prices cover only the lowest doses - Limitation: Several offers end on a stated date - Limitation: Alabama and Louisiana residents are excluded ## What the evidence says about this kind of treatment The assessment above is about GoodRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants brand medication with the dose-by-dose terms in writing and accepts a separate care fee. Wrong for A reader planning past the starting doses on a fixed budget, since the lowest figures stop there. ## The evidence behind what GoodRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How GoodRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Hims | Buyers set on brand Wegovy or Zepbound who accept a monthly membership on top | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sipra](https://thisglp.com/reviews/sipra) [Sommar Club](https://thisglp.com/reviews/sommar-club) [StaveMD](https://thisglp.com/reviews/stavemd) [Steady State Health](https://thisglp.com/reviews/steady-state-health) [Super Healthy Rx](https://thisglp.com/reviews/super-healthy-rx) [Tablet Health](https://thisglp.com/reviews/tablet-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Zepbound cost through GoodRx? The KwikPen is as low as $299 a month for medication. The $39 care membership is added, so $338 a month all in at the lowest price. Is the $39 membership optional? No. The footnotes say the $39 monthly fee applies and does not include medication. Does GoodRx sell compounded GLP-1s? No. The page states it offers only FDA-approved medications. Is GoodRx legit? GoodRx is a GLP-1 telehealth sellers service. Its stated availability: US except AL and LA. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is GoodRx expensive compared with other GLP-1 telehealth sellers? GoodRx publishes a starting figure of $188/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts GoodRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Green Cap Health reviews (2026): GLP-1 telehealth sellers | This GLP Two unusually low published figures, available in a single state. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/green-cap-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One state, low figures # Green Cap Health review Two unusually low published figures, available in a single state. ## The verdict Green Cap Health publishes $79 a month for compounded semaglutide and $119 for tirzepatide with B12. Service is recorded in Texas only. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 1 From From $179/mo Prescription Required Compounded Yes — not FDA-approved Availability Texas only Green Cap Health sells both molecules by injection. The tirzepatide line is described as a GLP-1 and GIP with B12. Coverage is one state. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages state prices. No clinician is described and no intake is documented. Coverage decides everything here. A reader outside Texas cannot buy at any price. A reader inside it meets two figures and very little else. 2. ## What happens when the dose goes up? Nothing is published about dose. The tirzepatide line is quoted at about $3.96 a day, which is a framing rather than a dose. No milligram figure appears. 3. ## What the price includes Six months at $79 is $474 and tirzepatide is $714. Both totals assume the figures are rates rather than floors, which the pages do not confirm. A daily framing of $3.96 describes the same $119 differently and adds nothing a reader can act on. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Two unusually low published figures - Strength: The tirzepatide formulation is described - Strength: The single-state limit is recorded - Limitation: Texas only, so most readers cannot buy - Limitation: No milligram dose stated anywhere - Limitation: A daily framing adds nothing - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Green Cap Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in Texas wanting an unusually low published figure. Wrong for Anyone outside Texas. ## The evidence behind what Green Cap Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Green Cap Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Harbor | Readers who value a bundled plan and will ask what raises the floor | | | Glam Health | Readers who will ask what the plan costs at their own dose | | | Gala | Readers with insurance that may apply to Ozempic, or those ready to commit a year to compounded tirzepatide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Teladoc Health](https://thisglp.com/reviews/teladoc-health) [Teleios Health](https://thisglp.com/reviews/teleios-health) [TeleWellnessMD](https://thisglp.com/reviews/telewellnessmd) [The Protocole](https://thisglp.com/reviews/the-protocole) [TideMedix](https://thisglp.com/reviews/tidemedix) [Tomorrow](https://thisglp.com/reviews/tomorrow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I buy outside Texas? No. Coverage is recorded in Texas only. What does tirzepatide cost? $119 a month, also framed as about $3.96 a day. The two describe the same figure. What dose does $79 buy? No milligram figure is published beside either price. Is Green Cap Health legit? Green Cap Health is a GLP-1 telehealth sellers service. Its stated availability: Texas only. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Green Cap Health expensive compared with other GLP-1 telehealth sellers? Green Cap Health publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Green Cap Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Happy Care Meds reviews (2026): GLP-1 telehealth sellers | This GLP Happy Care Meds identifies a clinical-service platform and offers weekly compounded weight-loss protocols. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/happy-care-meds Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinical platform named in the terms # Happy Care Meds review Happy Care Meds identifies a clinical-service platform and offers weekly compounded weight-loss protocols. ## The verdict Happy Care Meds identifies a clinical-service route, but its patient-specific monitoring plan should be clarified beyond the testimonials. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Happy Care Meds offers online compounded weight-management prescriptions and other treatments. Its semaglutide and tirzepatide categories are described as weekly protocols prescribed and monitored by licensed providers. 1. ## Who writes the prescription, and what do they see? The terms describe clinical services through medical groups using Qualiphy. The site also identifies a medical director, but the medical director is not necessarily the person treating a new patient. Ask for the assigned clinician and relevant practice. The homepage describes ongoing support and a prescribing review. A testimonial about check-ins does not establish a promised clinical cadence. Confirm when the provider will review the treatment and how to report side effects before another shipment is prepared. 2. ## What happens when the dose goes up? Weekly dosing requires an individual prescription and a plan for reassessment. Check how a package can accommodate a slower [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) or stopped treatment; a long supply should not force a dose increase. 3. ## What the price includes The lowest monthly equivalents belong to longer packages. The site says there is no membership fee. It also offers a refund when a patient is not approved. Neither promise establishes unconditional refunds after clinical work or dispensing. Request the full package total and order-specific terms. 4. ## What it claims, and what it cites The injections are compounded and are not FDA-approved. The site describes state-licensed U.S. pharmacies, without establishing the dispensing pharmacy for an individual order in the materials reviewed. Confirm the pharmacy on the actual prescription. ## Where it holds up, and where it does not - Strength: Clinical platform named in the terms - Strength: Compounded drug status disclosed - Strength: No-membership-fee model stated - Limitation: Lowest equivalents require longer packages - Limitation: Actual dispensing pharmacy needs confirming - Limitation: Testimonials do not establish follow-up commitments ## What the evidence says about this kind of treatment The assessment above is about Happy Care Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants online compounded care and will verify the assigned clinician, dispensing pharmacy and check-in plan. Wrong for Someone who expects the lowest long-package equivalent to buy one independently cancelable month. ## The evidence behind what Happy Care Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Happy Care Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TotalRx](https://thisglp.com/reviews/totalrx) [Totara Health](https://thisglp.com/reviews/totara-health) [Trally Meds](https://thisglp.com/reviews/trally-meds) [Transcarent](https://thisglp.com/reviews/transcarent) [TRT Kingdom](https://thisglp.com/reviews/trt-kingdom) [Tummala Health](https://thisglp.com/reviews/tummala-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The homepage describes ongoing support and a prescribing review. A testimonial about check-ins does not establish a promised clinical cadence. Confirm when the provider will review the treatment and how to report side effects before another shipment is prepared. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Current treatments and care model](https://happycaremeds.com/) - [Clinical and purchase terms](https://happycaremeds.com/terms-conditions/) - [Semaglutide package](https://happycaremeds.com/product/semaglutide-4/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Harbor reviews (2026): GLP-1 telehealth sellers | This GLP Each plan states what it covers. Each figure carries the words as low as. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/harbor Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Bundled, and a floor # Harbor review Each plan states what it covers. Each figure carries the words as low as. ## The verdict Harbor publishes as low as $89 a month for compounded semaglutide and $119 for tirzepatide. Each plan covers medication, provider consultations, refill management and shipping. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $89/mo Prescription Required Compounded Yes — not FDA-approved Harbor sells both molecules as a weekly injection. Each figure is bundled. Four things are named as included. 1. ## Who writes the prescription, and what do they see? Provider consultations are named as included in both plans. No clinician is described. The intake is not documented. Naming four inclusions is a real disclosure. Refill management is unusual to see itemized. What the words as low as do to all of it is the offsetting problem. 2. ## What happens when the dose goes up? Nothing is published about dose. A bundled floor with no milligram attached cannot be compared against a rate that carries one. The inclusions are stated; the dose is not. 3. ## What the price includes $89 and $119 are floors rather than rates. Six months at them is $534 and $714 at best. The site states no price increases, but what sets the floor is not published. Ask for the figure at a therapeutic dose before ordering. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Four inclusions named in each plan - Strength: Refill management itemized explicitly - Strength: Both molecules carry a figure - Limitation: Both figures are a floor, not a rate - Limitation: No milligram dose stated anywhere - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Harbor. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who values a bundled plan and will ask what raises the floor. Wrong for A reader budgeting six months from $89. ## The evidence behind what Harbor prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Harbor compares | Seller | Who it suits | Go | | --- | --- | --- | | Green Cap Health | Readers in Texas wanting the lowest published figures | | | Glam Health | Readers who will ask what the plan costs at their own dose | | | Get Thin MD | Readers taking the three-month plan who read what the sale actually covers | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vea Health](https://thisglp.com/reviews/vea-health) [Vela Rx](https://thisglp.com/reviews/vela-rx) [Verge](https://thisglp.com/reviews/verge) [Vida Health](https://thisglp.com/reviews/vida-health) [Virgo-Meds](https://thisglp.com/reviews/virgo-meds) [Virta Health](https://thisglp.com/reviews/virta-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is included? Medication, provider consultations, refill management and shipping, named in both plans. Is $89 a rate? No. It is a floor. Both figures carry the words as low as, and what sets them is not published. What dose does it cover? No milligram figure is published beside either price. Is Harbor expensive compared with other GLP-1 telehealth sellers? Harbor publishes a starting figure of $89/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Harbor below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Harmony Wellness Clinic reviews (2026): GLP-1 telehealth sellers | This GLP Five priced levels on one molecule and six on the other, printed on the services page rather than discovered later. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/harmony-wellness-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every dose tier printed # Harmony Wellness Clinic review Five priced levels on one molecule and six on the other, printed on the services page rather than discovered later. ## The verdict Harmony Wellness Clinic publishes a priced dose tier for every level it offers. Semaglutide runs from $200 at Level 1 to $300 at Level 5, and tirzepatide from $250 to $450 across six levels, in 36 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 36 From From $200/mo Prescription Required Compounded Yes — not FDA-approved Availability 36 states Harmony Wellness Clinic sells both molecules by injection, each formulated with B12, and prices every dose level separately rather than quoting one figure and leaving the rest to an invoice. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the services page names levels rather than the clinician who moves a patient between them, so a reader learns exactly what each step costs and nothing about who decides to take it. Publishing eleven priced tiers is the substantive disclosure here, and it changes what a reader can actually plan. Most of this category answers the dose question with silence or with a single word like flat. This seller answers it with a number at every rung, so a buyer can cost out a year of escalation before starting one. 2. ## What happens when the dose goes up? This is the field Harmony answers better than almost anything else a reader will meet. Semaglutide runs $200, $225, $250, $275 and $300 across its five levels, and tirzepatide runs from $250 to $450 across six. A buyer who expects to reach the top rung knows the number today, which is the difference between a budget and a hope. 3. ## What the price includes The entry figures of $200 and $250 are the ones a comparison will pick up, and they describe Level 1 rather than a course of treatment. A year spent climbing to the top semaglutide tier costs more than a year at the bottom by $100 a month, and the pages say so. Coverage runs to 36 states, so fourteen are not served. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Every dose level carries its own price - Strength: Eleven priced tiers published in total - Strength: Coverage recorded across 36 states - Strength: B12 formulation described on both lines - Limitation: The entry figures describe Level 1 only - Limitation: The top tirzepatide tier reaches $450 - Limitation: Fourteen states are not served - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Harmony Wellness Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to cost out a full escalation before starting one. Wrong for A reader comparing entry figures as though they were rates, when the tirzepatide ladder here runs to $450 at its top level. ## The evidence behind what Harmony Wellness Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Harmony Wellness Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | Genesis Health | Readers who want the billed amount, not just the monthly rate, before committing | | | Fridays | Readers who will get the annual rate confirmed in writing before paying | | | Healthicare | A reader outside California who wants a low monthly injection price with every component listed | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vitakey](https://thisglp.com/reviews/vitakey) [Vital Step](https://thisglp.com/reviews/vital-step) [Vivanta Care](https://thisglp.com/reviews/vivanta-care) [VivioMD](https://thisglp.com/reviews/viviomd) [welludr.](https://thisglp.com/reviews/wellmedr)[Yes Clinic](https://thisglp.com/reviews/yes-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the price do as my dose rises? It rises with it, and every step is published: semaglutide at $200, $225, $250, $275 and $300, and tirzepatide across six levels from $250 to $450. Is $200 what most people pay? It is Level 1. A reader who escalates pays the tier they reach, and the pages state each one rather than leaving it to an invoice. Where does Harmony operate? Thirty-six states are recorded in its coverage list. Is Harmony Wellness Clinic legit? Harmony Wellness Clinic is a GLP-1 telehealth sellers service. Its stated availability: 36 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Harmony Wellness Clinic expensive compared with other GLP-1 telehealth sellers? Harmony Wellness Clinic publishes a starting figure of $200/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Harmony Wellness Clinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Harper Meds reviews (2026): GLP-1 telehealth sellers | This GLP One charge covers the consultation, the prescription and the shipping, and the fill it buys runs four weeks rather than a calendar month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/harper-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 All-inclusive, four-week fill # Harper Meds review One charge covers the consultation, the prescription and the shipping, and the fill it buys runs four weeks rather than a calendar month. ## The verdict Harper Meds prices compounded semaglutide at a flat $149 and compounded tirzepatide at a flat $196, with the consultation, the prescription and free shipping described as included. Each charge buys four weeks rather than a calendar month, so thirteen land in a year and the figures ranked here are $161 and $212. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $161/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Harper Meds sells compounded semaglutide and compounded tirzepatide as weekly injections, and its two figures are $149 and $196. Both are described as flat at every dose and as all-inclusive: the consultation, the prescription, four weeks of medication and shipping sit inside the charge. No list of states served is published beside either figure. 1. ## Who writes the prescription, and what do they see? The consultation is inside the price, which means a reader is not choosing between a cheap medication rate and a clinician they can reach — a choice several sellers in this market do make them face. What the consultation consists of, how it is delivered, and whether it repeats after the first fill is not something the priced row establishes. The prescription follows it rather than the checkout. Treatment is arranged remotely and each charge sends four weeks of medication, which is the unit worth writing down before comparing this seller with anything else. Four weeks is not a calendar month, and over a year the difference is close to one extra fill. A reader who budgets twelve charges and receives thirteen has not been misled about the rate, but they have been comparing two different units. 2. ## What happens when the dose goes up? Both figures are stated as flat at every dose, so the escalation that runs through the first four months leaves the charge alone. That is the single most useful thing a seller can do for a reader on a rising dose, and it is worth more across a year than the gap between most headline rates. What support the included consultation offers at a dose step is not published beside the price. 3. ## What the price includes $149 and $196 sit in the middle of the compounded market, and what they buy is wider than a medication-only rate at the same number. The four-week cycle is the adjustment a reader has to make before comparing them with anything: thirteen fills a year makes the semaglutide $161.42 a calendar month and the tirzepatide $212.33. There is no prepay ladder published, so nothing here asks a reader to commit to a term before reaching the rate on the page — the trade is a four-week cycle rather than a twelve-month one. 4. ## What it claims, and what it cites Both products are compounded, so a pharmacy prepares them and no regulator reviews the finished vial before it is dispensed. The published weight-change results for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) were produced with the approved products at the doses their labels describe. Whether a compounded vial matches those products in content or purity is not measured, and an all-inclusive price does not change that. ## Where it holds up, and where it does not - Strength: Consultation and prescription inside the price - Strength: Rate flat at every dose - Strength: No prepay term required - Limitation: A fill covers four weeks, not a month - Limitation: State coverage not published - Limitation: Compounding pharmacy not named ## What the evidence says about this kind of treatment The assessment above is about Harper Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. Wrong for A reader comparing annual costs across sellers without adjusting for the cycle, since four-week fills land thirteen times a year rather than twelve. ## The evidence behind what Harper Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Harper Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [YOURx Health](https://thisglp.com/reviews/yourx-health) [Youth & Soul](https://thisglp.com/reviews/youth-and-soul) [Zenbody](https://thisglp.com/reviews/zenbody) [Coby Health](https://thisglp.com/reviews/coby-health) [Form Health](https://thisglp.com/reviews/form-health) [Pepton Health](https://thisglp.com/reviews/pepton-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is inside the $149? The consultation, the prescription, four weeks of medication and free shipping are all described as included. No separate consultation or postage charge was recorded beside the figure. Why does the four-week fill matter? Because thirteen four-week fills land in a calendar year rather than twelve. The rate is what it says it is, and the calendar-month equivalents are $161.42 and $212.33, which is what the boards here rank on. Does the price rise as the dose goes up? Both figures are stated as flat at every dose, so the escalation through the first four months does not change what is charged. Is Harper Meds expensive compared with other GLP-1 telehealth sellers? Harper Meds publishes a starting figure of $161/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Harper Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # He & She MD reviews (2026): GLP-1 telehealth sellers | This GLP Both injection rates are annual plans billed in a single payment, and the oral figure is an introductory rate that renews twenty percent higher. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/he-and-she-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A year up front, or a renewal # He & She MD review Both injection rates are annual plans billed in a single payment, and the oral figure is an introductory rate that renews twenty percent higher. ## The verdict He & She MD advertises $99 a month for injected semaglutide and $159 for tirzepatide, and both require a year paid at once — $1,188 and $1,908. Its oral line runs $199 for six months and then renews at $239. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $199/mo Oral From $239/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states He & She MD sells both molecules by injection on annual plans billed up front, alongside an oral program priced as an introductory half-year that renews at a higher rate, with coverage across 50 states. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing, and the pages present program cards and footnotes rather than describing who reviews a case or how often. The oral line's renewal terms live in a footnote rather than on the card. Annual prepay at a low headline is a defensible offer, and the totals are published rather than hidden. What the pages do less well is separate the two numbers in the banner, where a struck-through monthly figure and an annual one sit in the same sentence as though they were alternatives. 2. ## What happens when the dose goes up? Nothing published states what any of these figures does as a dose climbs, which matters most on the annual plans: a buyer has committed twelve months before discovering whether the rate survives an escalation. 3. ## What the price includes A year of injected semaglutide is $1,188 and tirzepatide $1,908, both due at signup rather than monthly. The oral program is $1,194 for its first six months and $1,434 for every six after, so a full year at the renewal rate is $2,868. Budgeting the oral at its introductory figure understates a second year by $480. 4. ## What it claims, and what it cites The lines are compounded rather than manufactured, prepared to order by a pharmacy the pages do not name, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: Annual totals are published, not just rates - Strength: Coverage across 50 states - Strength: An oral program is offered separately - Strength: The renewal rate appears in a footnote - Limitation: Both injection rates need a year at once - Limitation: The oral renews about 20% higher - Limitation: The banner shows two prices in one line - Limitation: Refunds inside an annual term are unstated ## What the evidence says about this kind of treatment The assessment above is about He & She MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who can pay a year in advance and wants the annual total published rather than implied. Wrong for A reader reading the oral $199 as a rate that holds, or anyone who cannot commit twelve months at signup. ## The evidence behind what He & She MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How He & She MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Try Ageless | Readers willing to price the same product twice before buying it once | | | MEDVi | Readers who want the injected line, where the card figure is the medicine's figure | | | Roboclinic | Readers ready to commit a full year and wanting the discount that buys | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Belle Health](https://thisglp.com/reviews/belle-health) [bmiMD](https://thisglp.com/reviews/bmimd) [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)[Collective](https://thisglp.com/reviews/collective) [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) [Direct Meds](https://thisglp.com/reviews/direct-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $99 a month actually require? A year paid in a single payment of $1,188. There is no month-to-month route to that figure. Does the oral price hold? No. $199 covers six months, after which the program renews at $1,434 per six months, which is $239 a month. What does a full year of tirzepatide cost? $1,908, billed up front at signup rather than spread across the year. Is He & She MD legit? He & She MD is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is He & She MD expensive compared with other GLP-1 telehealth sellers? He & She MD publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts He & She MD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HealFastRx reviews (2026): GLP-1 telehealth sellers | This GLP HealFastRx includes supplies, clinical care and shipping in its compounded injection offer, with separate introductory, monthly and prepaid prices. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/healfast Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Care bundle with upfront options # HealFastRx review HealFastRx includes supplies, clinical care and shipping in its compounded injection offer, with separate introductory, monthly and prepaid prices. ## The verdict HealFastRx’s stated inclusions and later monthly rates are useful for evaluating ongoing care. Confirm the medical practice and response arrangements behind the support promise. Longer prepayments may be less suitable if treatment changes, because the initial order can enter a noncancelable stage at medical review. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $199/mo Prescription Required Compounded Yes — not FDA-approved HealFastRx connects patients to licensed independent providers and pharmacies for compounded GLP-1 care. Some branded offers are marked coming soon, so they should not be treated as currently available prescriptions. 1. ## Who writes the prescription, and what do they see? The platform separates its role from independent medical groups and dispensing pharmacies. A provider reviews health information and may request a consultation, further information or testing before starting or continuing treatment. The injection offer includes supplies, provider care, support and coaching material. Support is advertised around the clock, but ask how that translates into access to a licensed clinician rather than administrative help. 2. ## What happens when the dose goes up? The plan includes dose support and follow-ups, with prescribing decisions reserved to the clinician. A flat-price claim does not establish a fixed dose ladder for every patient. Ask how monitoring, prescription changes and treatment pauses are handled. 3. ## What the price includes Semaglutide has a discounted first month, a distinct continuing monthly charge and longer prepaid packages. Dose-independent pricing is advertised on the product page. The lowest monthly equivalent belongs to an annual upfront payment rather than an unrestricted monthly plan. 4. ## What it claims, and what it cites The active injection offering names compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). These are not FDA-approved finished medicines. The product page correctly directs measuring and dose instructions to the pharmacist and prescribing professional. ## Where it holds up, and where it does not - Strength: Ongoing monthly rate distinguished from intro - Strength: Included support and supplies listed - Strength: Dose-independent offer stated - Limitation: Prepaid plans require larger commitments - Limitation: Initial order may become noncancelable at review - Limitation: Advertised support hours need clinical clarification ## What the evidence says about this kind of treatment The assessment above is about HealFastRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient seeking an included-care injection plan who understands the payment term and clinical follow-up route. Wrong for Someone choosing an annual equivalent while expecting easy refunds if the medication is unsuitable. ## The evidence behind what HealFastRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HealFastRx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Eden](https://thisglp.com/reviews/eden) [Embody](https://thisglp.com/reviews/embody) [Enhance MD](https://thisglp.com/reviews/enhance-md) [Found](https://thisglp.com/reviews/found) [Gala](https://thisglp.com/reviews/gala) [HealthRX](https://thisglp.com/reviews/healthrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are all branded options currently available? The homepage marks several branded products coming soon. Confirm actual availability before relying on those listings. Does twenty-four-hour support guarantee an immediate clinician response? The public promise does not establish that. Ask how medical questions are escalated and answered. Is HealFastRx expensive compared with other GLP-1 telehealth sellers? HealFastRx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HealFastRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://healfastrx.com/) - [Service and cancellation terms](https://healfastrx.com/terms) - [Treatment information](https://healfastrx.com/treatments/compounded-semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Heally reviews (2026): GLP-1 telehealth sellers | This GLP A telehealth marketplace that prescribes brand semaglutide and tirzepatide after a live video visit, with no membership and no compounded option. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/heally Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand only, no membership # Heally review A telehealth marketplace that prescribes brand semaglutide and tirzepatide after a live video visit, with no membership and no compounded option. ## The verdict Heally prescribes brand GLP-1s only. Zepbound starts at $299 a month through Eli Lilly Direct. The semaglutide pill starts at $149. No compounded product is sold. No membership is charged. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $299/mo Dose published No Prescription Required Compounded No Pharmacy Not named Availability All 50 states LegitScript Claimed by provider Heally is a telehealth platform covering weight loss, longevity, hormones and lab testing. Its weight-loss line lists Ozempic, Wegovy, the Wegovy pill, Rybelsus, Zepbound and Mounjaro. It also lists liraglutide and metformin. The site states service in all 50 states. 1. ## Who writes the prescription, and what do they see? A board-certified physician writes the prescription, according to the product pages. The visit is a 15-minute video appointment. Same-day slots are advertised. Prescriptions are issued the same day on approval. The FAQ says the platform also lists nurses and specialists. The patient answers a questionnaire and books a video visit. The card is held about 48 hours before the appointment. It is charged only if the doctor approves. Medication ships in 24 to 48 hours. Refills and follow-ups stay online. There is no subscription; the patient pays per reorder. 2. ## What happens when the dose goes up? Tirzepatide starts at 2.5 mg and steps up, per the product page. Brand prices are set by the manufacturer channel, and Heally prints only the starting figure. The Wegovy block says self-pay starts at $200 depending on dose. What each higher step costs is not published. 3. ## What the price includes The product pages call the consultation free. The FAQ says consultation cost varies by type and is shown at booking. Those two statements do not match. Zepbound starts at $299 a month. The semaglutide pill starts at $149. Insurance is not accepted. HSA and FSA cards are. 4. ## What it claims, and what it cites Every GLP-1 listed is an FDA-approved brand product. [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is dispensed through Eli Lilly Direct, per the site. Compounded tirzepatide appears only as something a patient may switch away from. No compounded GLP-1 is offered. ## Where it holds up, and where it does not - Strength: FDA-approved brands only - Strength: Live video visit before any prescription - Strength: No membership or subscription - Strength: LegitScript certification stated - Limitation: Consultation fee described two different ways - Limitation: Only starting prices published - Limitation: No insurance billing - Limitation: Clinicians are not named on the product pages ## What the evidence says about this kind of treatment The assessment above is about Heally. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a brand GLP-1 prescribed after a live visit and paid per refill. Wrong for A reader looking for compounded medication, which Heally does not sell. ## The evidence behind what Heally prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Heally compares | Seller | Who it suits | Go | | --- | --- | --- | | Hims | Buyers set on brand Wegovy or Zepbound who accept a monthly membership on top | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HumeCare+](https://thisglp.com/reviews/humecare)[Live Vital](https://thisglp.com/reviews/live-vital) [Lttl](https://thisglp.com/reviews/lttl) [Luvo Health](https://thisglp.com/reviews/luvo-health) [MEDGm](https://thisglp.com/reviews/medgm) [Oak](https://thisglp.com/reviews/oak) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Heally's semaglutide compounded? No. It prescribes brand semaglutide products only. What does tirzepatide cost at Heally? Zepbound starts at $299 a month through Eli Lilly Direct. Higher doses are not priced on the page. Is the consultation free? The product pages say so. The FAQ says the fee varies and is shown at booking. Is Heally legit? Heally is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Heally expensive compared with other GLP-1 telehealth sellers? Heally publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Heally above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HealthHub reviews (2026): GLP-1 telehealth sellers | This GLP The homepage tile quotes more than the injection behind it actually costs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/healthhub Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The tile overstates the price # HealthHub review The homepage tile quotes more than the injection behind it actually costs. ## The verdict HealthHub sells its semaglutide injection at $99 a month and says so twice, once on the plan card and again in a FAQ sentence. That makes it the unusual seller whose homepage tile overstates rather than understates what a reader will pay. Getting there is the hard part, because the weight-loss category page in between prints no price at all on any of its five products. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $99/mo Oral From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability 46 states LegitScript Claimed by provider HealthHub is a prescription telehealth service whose weight-loss line runs compounded semaglutide and compounded tirzepatide as weekly injections and as orally dissolving tablets, with a sublingual semaglutide and a sermorelin program alongside them. Hair loss, sexual health, testosterone and anti-aging catalogs share the same storefront, and the site states it is licensed in forty-six states. 1. ## Who writes the prescription, and what do they see? A board-certified provider is stated to review the intake and send back a tailored plan by video or secure message, which is a fuller description of the first contact than most sellers offer. No individual clinician or medical group is named. What the provider examines before deciding, and how long that takes, are not published anywhere on the product pages. There is no subscription, and the site makes a point of it: a patient chooses when to reorder rather than being billed on a cycle, and the FAQ states a clear total appears before checkout with no hidden fees. Medication is described as shipping from an in-house pharmacy, though the FAQ further down the same product pages names outside compounding pharmacies the service works with. Delivery is quoted at forty-eight hours. 2. ## What happens when the dose goes up? Each product page states that a licensed provider determines the appropriate dose from the patient's goals and health profile, and that dosing is monitored and adjusted as treatment continues. What none of them publishes is a milligram figure, or what a step up the ladder costs, or whether the stated rate holds when the dose doubles. Every price is written as a starting figure. 3. ## What the price includes The semaglutide injection is $99 a month and the two needle-free semaglutide formats, sublingual and dissolving tablet, are both $149, which makes the needle the cheap option by $50. Tirzepatide is $199 whether injected or taken as a tablet. The weight-loss tile on the homepage quotes a figure higher than any of the injections behind it, and the category page it leads to prices nothing at all. 4. ## What it claims, and what it cites The FAQ states that some medications may be compounded within pharmacy guidelines and that a provider will explain the options, which is softer than the flat statement most sellers make about FDA review. Compounding pharmacies are named with contact details on the product pages. A LegitScript listing is linked from the footer. ## Where it holds up, and where it does not - Strength: The injection price is stated twice, on the card and in the FAQ - Strength: Compounding pharmacies are named with contact details - Strength: There is no subscription and reordering is patient-led - Strength: A clear total is promised before checkout - Strength: Delivery is quoted at forty-eight hours - Limitation: The category page prints no price on any product - Limitation: The homepage tile quotes more than its own $99 injection - Limitation: Both needle-free semaglutide formats cost $50 more than the shot - Limitation: An in-house pharmacy is claimed while outside pharmacies are named ## What the evidence says about this kind of treatment The assessment above is about HealthHub. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to skip the category page and open each product to find a price. Wrong for A buyer who wants the medication's regulatory status stated plainly on the page. ## The evidence behind what HealthHub prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HealthHub compares | Seller | Who it suits | Go | | --- | --- | --- | | CoreAge Rx | A reader still at a starting dose, since that is the tier these rates price. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | | Strut Health | A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sesame Care](https://thisglp.com/reviews/sesame-care) [ShedRx](https://thisglp.com/reviews/shedrx) [SkinnyRx](https://thisglp.com/reviews/skinnyrx) [SnagRx](https://thisglp.com/reviews/snagrx) [Sprout Health](https://thisglp.com/reviews/sprout-health) [Wellorithm](https://thisglp.com/reviews/wellorithm) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the tablet cheaper than the injection? No. Both needle-free semaglutide formats are $149 a month against $99 for the weekly injection. Why does the category page show no prices? It lists five products with a consultation request instead of a figure. The prices live on the individual product pages. Whose pharmacy fills the prescription? The homepage describes an in-house pharmacy, and the product FAQ names outside compounding pharmacies the service works with. Is HealthHub legit? HealthHub is a GLP-1 telehealth sellers service. Its stated availability: 46 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is HealthHub expensive compared with other GLP-1 telehealth sellers? HealthHub publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HealthHub below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Healthicare reviews (2026): GLP-1 telehealth sellers | This GLP Two injections at low monthly rates, with the charge broken into its parts and a three-month plan beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/healthicare Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 An itemized monthly charge # Healthicare review Two injections at low monthly rates, with the charge broken into its parts and a three-month plan beside it. ## The verdict Healthicare publishes $126 a month for injected semaglutide and $144 for tirzepatide, billed monthly and cancelable at any time. The prices apply in every state except California. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses From From $126/mo Prescription Required Compounded Yes — not FDA-approved Healthicare sells compounded semaglutide and compounded tirzepatide by injection. Its only oral product is the brand Wegovy pill. Three-month plans are published beside the monthly rates. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe plans and billing rather than clinicians. What a provider reviews before a refill is not documented. The semaglutide page itemizes the monthly charge: medication, consultation, preparation, shipping, platform and service, summed to $126. No separate membership fee sits outside that figure. 2. ## What happens when the dose goes up? Neither page states what the monthly charge does at a higher dose. The itemized list names a medication component with no dose attached to it. 3. ## What the price includes Injected semaglutide is $126 monthly or $107.10 on the three-month plan, billed as $321.30 every three months. Tirzepatide is $144 or $122.40, billed as $367.20. Six months at the monthly rate is $756 and $864. 4. ## What it claims, and what it cites Both injected lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Low monthly rates on both injections - Strength: Three-month totals published, not just rates - Strength: The monthly charge is itemized - Limitation: Prices exclude California - Limitation: Dose behavior is not stated - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Healthicare. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader outside California who wants the monthly charge broken into its parts. Wrong for A reader in California, or one who wants a compounded oral. ## The evidence behind what Healthicare prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Healthicare compares | Seller | Who it suits | Go | | --- | --- | --- | | Genesis Health | Readers who want the billed amount, not just the monthly rate, before committing | | | Harmony Wellness Clinic | Readers who want to cost out a full escalation before starting one | | | Good Life Meds | Readers escalating to a high dose who want the figure fixed across it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sprout Health](https://thisglp.com/reviews/sprout-health) [Strut Health](https://thisglp.com/reviews/strut-health) [Wellorithm](https://thisglp.com/reviews/wellorithm) [Willow](https://thisglp.com/reviews/willow) [YourEra](https://thisglp.com/reviews/yourera) [EverPrime](https://thisglp.com/reviews/everprime) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a compounded oral? No. The only oral sold is the brand Wegovy pill. What is billed on the three-month plans? $321.30 for semaglutide and $367.20 for tirzepatide, every three months. Is there a membership fee? No separate one. The seller lists every component inside the monthly charge. Is Healthicare expensive compared with other GLP-1 telehealth sellers? Healthicare publishes a starting figure of $126/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Healthicare below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HealthOn reviews (2026): GLP-1 telehealth sellers | This GLP The product pages lead with a twelve-month figure. The monthly plan in the cart bills differently. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/healthon Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Headline tied to a year # HealthOn review The product pages lead with a twelve-month figure. The monthly plan in the cart bills differently. ## The verdict HealthOn leads with $189 for semaglutide and $290 for tirzepatide. Each figure carries an asterisk. The footnote reads "Paid upfront with a 12-month plan." The monthly plan in the cart bills $155 for the first order. Every order after that is $255. Tirzepatide follows the same pattern at $275, then $375. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $255/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named HealthOn is a cash-pay telehealth platform. It sells compounded semaglutide and compounded tirzepatide by injection. NAD+ and sermorelin sit in a longevity line beside them. The footer describes a patient management platform working with independent licensed providers. Purchases are stated to be FSA and HSA eligible. 1. ## Who writes the prescription, and what do they see? A licensed provider assesses each patient after an online consultation. The page states that provider decides whether compounded medication is appropriate. No provider, medical group or medical director is named. Eligibility follows general BMI guidelines, as the tirzepatide page describes them. What the provider reviews is not listed. Plans are subscriptions that renew automatically until canceled. Cancellation requires 30 days' written notice to the care email. Service and billing continue through that notice period. A six-month money-back guarantee exists with conditions. The conditions include 150 minutes of weekly exercise, proven through a linked device. Medication cost is excluded from any refund. 2. ## What happens when the dose goes up? Each subscription names a dose ceiling rather than a dose. Semaglutide is sold "Up to 1.5mg" and tirzepatide "Up to 10mg". The price does not change below that ceiling. No step schedule is published. Nothing states what happens to the price above the ceiling. 3. ## What the price includes Three figures apply to each molecule. The headline, $189 or $290, is tied to a twelve-month plan paid upfront. The monthly plan bills $155 or $275 on the first order. It bills $255 or $375 on every order after. The standing monthly rate is the last pair. A quarterly plan is also offered in the cart. 4. ## What it claims, and what it cites Both products are compounded by state-licensed pharmacies. The site states compounded medications are not reviewed or approved by the FDA for safety or effectiveness. Third-party lab testing of each prescription is described. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Each plan names its dose ceiling in milligrams - Strength: Third-party lab testing is described - Strength: Purchases are FSA and HSA eligible - Strength: A money-back guarantee is published with terms - Limitation: The headline figure requires a year paid upfront - Limitation: The standing monthly rate is not on the product page - Limitation: Cancellation needs 30 days' written notice - Limitation: No provider or pharmacy is named - Limitation: The guarantee excludes medication cost ## What the evidence says about this kind of treatment The assessment above is about HealthOn. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who reads the cart before the product page and plans to stay under the dose ceiling. Wrong for A buyer who wants to cancel on short notice. ## The evidence behind what HealthOn prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HealthOn compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | LaSara Medical Group | Buyers who can pay a full term at once and want the lowest rung | | | AgelessRx | Readers ready to commit to four months who want a choice between a microdose and a full dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MyDrHank](https://thisglp.com/reviews/mydrhank) [1st Optimal](https://thisglp.com/reviews/1st-optimal) [24hrDOC](https://thisglp.com/reviews/24hrdoc) [AbundRX](https://thisglp.com/reviews/abundrx) [Actin](https://thisglp.com/reviews/actin) [AHBARx](https://thisglp.com/reviews/ahbarx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost month to month? $255 an order after a $155 first order. The $189 headline is footnoted to a twelve-month plan paid upfront. What does tirzepatide cost month to month? $375 an order after a $275 first order. The $290 headline carries the same twelve-month footnote. How much notice does cancellation need? Thirty days, in writing, to the care email address. Billing continues until the notice period ends. Is HealthOn expensive compared with other GLP-1 telehealth sellers? HealthOn publishes a starting figure of $255/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HealthOn above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HealthRX reviews (2026): GLP-1 sellers by price | This GLP Both molecules are stated flat at every dose, which on a medication designed to be escalated is the disclosure worth more than the headline. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/healthrx Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The rate does not follow the dose # HealthRX review Both molecules are stated flat at every dose, which on a medication designed to be escalated is the disclosure worth more than the headline. ## The verdict HealthRX charges $165 a month for compounded semaglutide month to month and $214 for tirzepatide. Committing three months brings those to $133 and $209, and twelve months to $99 and $179. Every figure is stated to hold at any dose, so the number a buyer starts at is the number they are still paying at the top of the ladder. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 sellers by price Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $165/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Availability All 50 states claimed; no list published HealthRX sells both molecules by injection alongside a wide catalog of other peptide and men's-health products, and the GLP-1 lines are priced independently of the rest of it. The figure the pages lead with belongs to a three-month term rather than to a month. 1. ## Who writes the prescription, and what do they see? A prescription is issued before anything ships, and the pages set out the plans and the products rather than the clinician who writes them. Nothing names the prescriber or describes what the intake asks. A prescription is written before anything ships, and the plan length is chosen at purchase rather than renewed month to month. What deserves weight in a comparison is not that structure, which is common, but the flat-dose statement attached to it. Almost every seller in this category prices by milligram or declines to say, so a buyer escalating from 0.25 mg to 2.4 mg over sixteen weeks usually has no way to know what the later months cost. 2. ## What happens when the dose goes up? This is the part HealthRX does better than most of the market. Both molecules are stated flat at every dose, so the first sixteen weeks of escalation carry no price consequence at all, and the rate agreed at 0.25 mg is still the rate at the top of the ladder. Almost every seller in this comparison either prices by milligram or says nothing. 3. ## What the price includes Six months bought month to month is $990 on semaglutide and $1,284 on tirzepatide. On the three-month plan the same span is $798 and $1,254, and at the annual rate it would be $594 and $1,074, though that rung requires the whole year paid as one term. The distance between paying monthly and committing a year is $66 a month on semaglutide and $35 on tirzepatide — a real discount on the first line and a thin one on the second. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy to order, and the FDA does not review a compounded preparation before it is dispensed. No pharmacy is named on either line. ## Where it holds up, and where it does not - Strength: Both molecules stated flat at every dose - Strength: Term rates published beside each other - Strength: The dose disclosure is the rarest one in this category - Limitation: The lowest rungs need a full year - Limitation: The advertised $133 is a prepay rate, not the standing one - Limitation: Nothing published about stopping partway - Limitation: No pharmacy named and no state list recorded ## What the evidence says about this kind of treatment The assessment above is about HealthRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who expects to escalate and wants the later months priced. Wrong for A buyer who wants to pay month to month. ## The evidence behind what HealthRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HealthRX compares | Seller | Who it suits | Go | | --- | --- | --- | | Somi Health | Readers who want the dose question answered in writing before anything else | | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Trellis Vitality | Readers who want the pharmacy and the medical group named before starting | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 sellers by price reviews: [Eden](https://thisglp.com/reviews/eden) [Embody](https://thisglp.com/reviews/embody) [Enhance MD](https://thisglp.com/reviews/enhance-md) [Found](https://thisglp.com/reviews/found) [Gala](https://thisglp.com/reviews/gala) [HumeCare+](https://thisglp.com/reviews/humecare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change as my dose goes up? No. Both molecules are stated flat at every dose, so the rate at 2.4 mg is the rate at 0.25 mg. What does the lowest published rate require? Twelve months. Semaglutide is $99 a month on that term, $133 on the three-month plan and $165 month to month; tirzepatide is $179, $209 and $214. Is the annual plan worth committing to? On semaglutide it saves $66 a month against the month-to-month rate, which is substantial. On tirzepatide it saves $35, so the flexibility may be worth more than the discount there. Is HealthRX expensive compared with other GLP-1 sellers by price? HealthRX publishes a starting figure of $165/mo. Across the 402 GLP-1 sellers by price we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HealthRX below the median, toward the cheaper end. The other 178 GLP-1 sellers by price we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller by price](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HealthSource reviews (2026): GLP-1 telehealth sellers | This GLP Every figure is quoted per four weeks rather than per month, and the dispensing pharmacy type is stated. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/healthsource Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week billing, pharmacy named # HealthSource review Every figure is quoted per four weeks rather than per month, and the dispensing pharmacy type is stated. ## The verdict HealthSource publishes $199 every four weeks for compounded semaglutide, with tirzepatide at $299 and its sublingual tablet at $399 on the same interval. Each figure is the entry tier of several, and the tirzepatide line states it is dispensed through a 503A partner pharmacy. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $216/mo Oral From $434/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states HealthSource sells both molecules by injection and tirzepatide as a sublingual tablet, across a stated fifty states. The semaglutide is supplied as a vial with syringes and alcohol pads, combined with B12, and the pages list several dose tiers of which the published figure is the lowest. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the pages describe the product in unusual detail — what is in the vial, what ships with it, and which class of pharmacy fills it. Naming the 503A partner is the disclosure worth noting, because the compounding source is the thing most sellers in this category leave unstated. The billing interval is the quiet detail. Every figure is quoted every four weeks, which is thirteen charges across a year rather than twelve. HealthSource states the interval plainly on each product page rather than presenting the figure as monthly. A careful reader is therefore not misled. A reader comparing headline numbers against a monthly seller will be. 2. ## What happens when the dose goes up? Multiple dose tiers exist on each line and the published figure is the entry one. HealthSource names the tiers: full dose, and starter blocks of four, six and eight weeks. What each costs is not published. A reader knows the ladder exists and not what climbing it involves. 3. ## What the price includes Read the interval before the figure. $199 every four weeks is more expensive across a year than $199 a month, by roughly one extra charge. The sublingual tirzepatide at $399 is the dearest line and ships in five to ten business days, which the page states. Each figure is a floor, since dose tiers sit above it. 4. ## What it claims, and what it cites The lines are compounded, so none has been through FDA review for safety or quality before dispensing. The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is combined with B12, a formulation the approved product does not use. The sublingual tablet is taken once daily before bed, and sublingual milligrams do not read across to injected ones. ## Where it holds up, and where it does not - Strength: The dispensing pharmacy class is named - Strength: Billing interval stated on every page - Strength: What ships with the vial is itemized - Strength: Coverage stated across fifty states - Limitation: Four-week billing means thirteen charges - Limitation: Tier prices above the entry one are unpublished - Limitation: Every figure is an entry-tier floor - Limitation: B12 combination effect is not described ## What the evidence says about this kind of treatment The assessment above is about HealthSource. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the compounding source identified and the contents itemized. Wrong for A reader comparing against monthly sellers without adjusting for the interval. ## The evidence behind what HealthSource prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HealthSource compares | Seller | Who it suits | Go | | --- | --- | --- | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | | KERNX Health | A reader who wants the clinician charge stated as a number before intake, and a medication rate that holds at every dose. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Alan Meds](https://thisglp.com/reviews/alan-meds) [Alegro Health](https://thisglp.com/reviews/alegro-health) [Alinwell](https://thisglp.com/reviews/alinwell) [Allara Health](https://thisglp.com/reviews/allara-health) [Alloy](https://thisglp.com/reviews/alloy) [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 a monthly price? No. It is quoted every four weeks, which is thirteen charges across a year rather than twelve. Who compounds the medication? The tirzepatide line states it is dispensed through a 503A partner pharmacy. That is more than most sellers here disclose about their source. What do the higher tiers cost? Not published. HealthSource names full-dose and starter tiers of four, six and eight weeks without pricing them, so the published figure is a floor. Is HealthSource legit? HealthSource is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is HealthSource expensive compared with other GLP-1 telehealth sellers? HealthSource publishes a starting figure of $216/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HealthSource above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HeliMeds reviews (2026): GLP-1 telehealth sellers | This GLP Every plan runs twelve weeks, and every monthly figure beside one divides by three. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/helimeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Twelve weeks called three months # HeliMeds review Every plan runs twelve weeks, and every monthly figure beside one divides by three. ## The verdict HeliMeds sells twelve-week plans as one-time charges and prints a monthly rate next to each. The starter tirzepatide plan is $447, shown as $149 a month. Twelve weeks is 2.77 calendar months, so that plan is $161.42 a month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $216/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved HeliMeds sells compounded semaglutide and compounded tirzepatide, with branded products listed alongside. Plans are paid once. The site states there is no recurring billing and no automatic charge. 1. ## Who writes the prescription, and what do they see? Treatment begins with a five-minute online survey rather than a described consultation. Licensed providers are said to prescribe. None is named, and nothing states what is reviewed before a plan is approved. One upfront payment covers twelve weeks of medication, which arrives in a single vial. Reorders are separate purchases. A four-week semaglutide supply after the plan is $239. 2. ## What happens when the dose goes up? The starter tirzepatide dose is $447 and any other dose is $697. The price rises with the ladder rather than holding flat, which is the less common arrangement. HeliMeds does not describe who approves a step, and a step taken mid-plan sits against a vial already dispensed. 3. ## What the price includes $697 across twelve weeks is $251.63 a calendar month rather than the $232 printed beside it. Semaglutide behaves the same way at $99 and $199. Once a plan ends, a $239 four-week reorder is $258.92 a calendar month, because thirteen four-week supplies fit inside a year. 4. ## What it claims, and what it cites The compounded lines are prepared by a pharmacy rather than manufactured, and no pharmacy is named. The FDA does not review a compounded preparation before it is dispensed. The branded lines are the manufacturer's products. ## Where it holds up, and where it does not - Strength: No recurring billing, stated plainly - Strength: Twelve weeks of medication in one purchase - Strength: Branded products listed beside compounded - Strength: The reorder rate is published - Limitation: A twelve-week plan is priced as three months - Limitation: The rate rises at doses above the starter - Limitation: The whole term is paid before a first dose - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about HeliMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer converting a twelve-week term into calendar months first. Wrong for A buyer budgeting twelve payments from the printed monthly figure. ## The evidence behind what HeliMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HeliMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | RxPros | A reader able to fund a year at signing and collect deliveries by the quarter | | | Ivologist | Buyers who check a printed monthly equivalent against the term it covers | | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) [altRX](https://thisglp.com/reviews/altrx) [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) [AlyveRx](https://thisglp.com/reviews/alyverx) [AM Rx](https://thisglp.com/reviews/amrx) [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is the real monthly rate higher than the printed one? A twelve-week plan covers 2.77 calendar months, not three. HeliMeds divides by three, which understates the monthly cost of every plan it sells. What happens after the twelve weeks? Reorders are separate. A four-week semaglutide supply is $239, which works out at $258.92 a calendar month across a year. Does the price change with the dose? Yes. The starter tirzepatide plan is $447 and every other dose is $697. Is HeliMeds expensive compared with other GLP-1 telehealth sellers? HeliMeds publishes a starting figure of $216/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HeliMeds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Helix Wellness Rx reviews (2026): GLP-1 telehealth sellers | This GLP Helix Wellness Rx describes direct clinician messaging and flat-rate semaglutide care. Its public pages disagree about how much cancellation notice is required. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/helix-wellness-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Concierge claims, conflicting notice periods # Helix Wellness Rx review Helix Wellness Rx describes direct clinician messaging and flat-rate semaglutide care. Its public pages disagree about how much cancellation notice is required. ## The verdict The service explains ongoing access more clearly than a bare product listing, but the conflicting cancellation language needs resolution before enrollment. A named assigned practice and pharmacy would also make its concierge promise easier to evaluate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Helix Wellness Rx LLC operates a telehealth platform connecting patients with independent clinicians and compounding pharmacies. Semaglutide and tirzepatide sit within a broader wellness menu. 1. ## Who writes the prescription, and what do they see? The terms distinguish Helix from the medical groups and pharmacies. The treatment page promises a dedicated provider; confirm that person’s practice and the continuity arrangements for absences or transfers. The semaglutide page describes consultation, pharmacy fulfillment, structured check-ins and direct provider messaging. It does not establish a precise recurring visit schedule, so ask what is scheduled versus available on request. 2. ## What happens when the dose goes up? The program says dose adjustments carry no surcharge. Clinical review remains separate from that pricing promise: ask how tolerability is assessed and whether refill approval requires a new encounter. 3. ## What the price includes The treatment page claims flat-rate pricing without consultation or dose-change charges, but directs patients to consultation rather than publishing a complete amount. The claim cannot establish the size of the recurring bill. 4. ## What it claims, and what it cites The program describes custom-compounded GLP-1 treatment. These products are not FDA-approved. Trial averages shown on the page should not be treated as verified outcomes for Helix’s formulations or service. ## Where it holds up, and where it does not - Strength: Direct provider messaging described - Strength: No dose-change surcharge claimed - Limitation: Cancellation pages disagree - Limitation: No complete public recurring quote ## What the evidence says about this kind of treatment The assessment above is about Helix Wellness Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking provider messaging who will obtain a detailed care and billing agreement first. Wrong for Someone unwilling to enroll until pricing and cancellation conditions agree across the public pages. ## The evidence behind what Helix Wellness Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Helix Wellness Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) [Arc-1](https://thisglp.com/reviews/arc-1) [Ark Health](https://thisglp.com/reviews/ark-health) [ARSYNL Rx](https://thisglp.com/reviews/arsynl-rx) [Ascend Medical](https://thisglp.com/reviews/ascend-medical) [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Helix name the assigned prescriber publicly? The reviewed pages describe independent providers and a dedicated relationship, but do not identify the clinician who would receive an individual case. Is the flat-rate claim a clinical dosing plan? No. It concerns charges; the clinician still determines the prescription and any changes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://helixwellnessrx.com/) - [Official program and terms](https://helixwellnessrx.com/terms) - [Official program and terms](https://helixwellnessrx.com/treatments/semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Hello Alpha reviews (2026): GLP-1 telehealth sellers | This GLP Everything Alpha dispenses has an FDA approval behind it. Nothing it dispenses has a published cost. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/hello-alpha Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Approved drugs, unpriced # Hello Alpha review Everything Alpha dispenses has an FDA approval behind it. Nothing it dispenses has a published cost. ## The verdict Alpha prescribes approved medicines only. Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza. No compounded line exists, which settles most questions this desk asks. The one it cannot settle is what any of them cost. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Prescription Required Compounded No A practice spanning a hundred conditions, with weight among them. Diabetes, mental health, menopause, fertility and hormone care sit under the same subscription. GLP-1 prescribing is one service, not the business. 1. ## Who writes the prescription, and what do they see? Visits are online, with a board-certified team. The subscription tier sets the cadence rather than the treatment: four visits monthly on the upper tier, two on the lower. Individual clinicians are not named. Breadth is the argument here. A patient on a GLP-1 often has a second condition being managed elsewhere, and this model puts both in one place. The lower tier excludes weight entirely, so that choice is made for the reader. 2. ## What happens when the dose goes up? No dose ladder is described. Nothing links the subscription to a milligram, and the escalation happens at a pharmacy counter that sets its own price. A reader should expect the cost of month six to differ from month one for reasons this site cannot show. 3. ## What the price includes Subscriptions are $79 and $29 monthly, quoted per day as well. Both are transparent. Neither is a medication cost. Free delivery is offered on anything prescribed, which is a real saving on a product that ships cold. The drug price appears on no page. 4. ## What it claims, and what it cites Every product named carries an FDA approval and a manufacturer behind it. That removes the compounding question most sellers raise here. No 503A or 503B preparation, no unnamed pharmacy, no regulatory gap around quality. The trade is cost, since approved GLP-1s are the expensive ones. ## Where it holds up, and where it does not - Strength: Approved medicines only, with no compounded alternative - Strength: A hundred conditions under one subscription - Strength: Cancellation at any time, with no term - Strength: Visit counts stated per tier, in plain figures - Limitation: No page states what any medication costs - Limitation: A subscription fee reads as a treatment price - Limitation: Weight is excluded from the cheaper tier - Limitation: Approved products carry the highest list prices in the category ## What the evidence says about this kind of treatment The assessment above is about Hello Alpha. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants an approved medicine, manages another condition alongside it, and has already priced their pharmacy. Wrong for A reader whose decision turns on a monthly figure. ## The evidence behind what Hello Alpha prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Hello Alpha compares | Seller | Who it suits | Go | | --- | --- | --- | | Ivim Health | Readers who want continuous clinician contact and will price both lines together | | | Sesame Care | Readers who want tirzepatide priced by dose and will read the FAQ before the headline | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) [AskRx](https://thisglp.com/reviews/ask-rx) [Aspen](https://thisglp.com/reviews/aspen-health) [Aspire Health](https://thisglp.com/reviews/aspire-health) [Auren Rx](https://thisglp.com/reviews/auren-rx) [AVARA Rx](https://thisglp.com/reviews/avara-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What will the medication actually cost here? Alpha does not say. The subscription covers visits and delivery. The medicine is dispensed by a pharmacy, at that pharmacy's price, which varies by product and coverage. Why is weight loss missing from the cheaper plan? The lower tier covers eighty conditions and lists weight loss outside them. Weight sits on the upper tier, which is why a reader here is on that one. Does Alpha compound anything? No. Every GLP-1 it names is an approved, manufactured product, so the questions this desk asks about compounding pharmacies do not arise. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HelloWellness reviews (2026): GLP-1 telehealth sellers | This GLP A longevity-branded online seller of compounded semaglutide and tirzepatide, sold as three-month plans that renew every eleven weeks and are paid before any intake. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/hellowellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Checkout before the questionnaire # HelloWellness review A longevity-branded online seller of compounded semaglutide and tirzepatide, sold as three-month plans that renew every eleven weeks and are paid before any intake. ## The verdict HelloWellness labels compounded semaglutide at $133 a month and tirzepatide at $166, but a buyer is actually charged once for a three-month plan, $399 or $499 at checkout, and that plan renews every eleven weeks rather than every three months. Across a calendar year that comes to $157.18 a month for semaglutide and $196.58 for tirzepatide. The health intake comes only after payment, with a refund promised if a provider declines. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $157.18/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named HelloWellness sells compounded GLP-1s beside NAD+, sermorelin and glutathione, and markets them through fitness trainers and athletes as a longevity routine. Its terms name the operator as HelloWellness, LLC, a technology platform that connects buyers with unaffiliated providers and a pharmacy rather than employing clinicians itself. 1. ## Who writes the prescription, and what do they see? The product pages say a healthcare provider reviews the intake and decides whether the plan is appropriate, and that an approved patient can message that provider at no extra cost. No provider is named anywhere on the pages, no credential is given, and nothing says whether any part of the review happens on video rather than in writing. The order runs in reverse of most telehealth: the buyer picks a plan and pays, then completes the intake with a government ID ready. If a provider approves, a kit with syringes and an injection guide ships in five to seven business days; if not, the payment is refunded. Once a prescription is written, a cancellation keeps a professional services fee. 2. ## What happens when the dose goes up? Neither product page prints a milligram dose, and nothing on the site says whether a renewal costs more once the dose climbs past the starting weeks. The checkout charge is one figure with no dose attached to it, so what a later plan costs at a higher dose is left open. 3. ## What the price includes The start page lists compounded semaglutide at $133 a month and tirzepatide at $166, each with a three-month minimum, and those labels are simply the plan charge divided by three. The product pages bill $399 today for semaglutide and $499 for tirzepatide, each renewing at the same figure every eleven weeks, so a year holds closer to five charges than four. Spread over the calendar, that is $157.18 a month for semaglutide and at least $196.58 for tirzepatide, whose page footer also mentions a ten-week cycle that would cost more; those calendar-month figures are the ones ranked here. A struck higher figure sits beside each plan as the original price. 4. ## What it claims, and what it cites Both GLP-1s are compounded and shipped from a US-based 503A pharmacy, which the terms identify as AP Max, Inc., doing business as Southend Pharmacy. The site's own disclaimer states that compounded drugs are not FDA-approved and that the FDA does not evaluate their safety, effectiveness or quality before they reach a patient. ## Where it holds up, and where it does not - Strength: Refund stated if a provider declines - Strength: Dispensing pharmacy named in the terms - Strength: Provider messaging included at no extra cost - Limitation: Payment is taken before any intake - Limitation: Plans renew every eleven weeks, not every three months - Limitation: Monthly figures are a three-month charge divided - Limitation: No provider named or credentialed on the pages ## What the evidence says about this kind of treatment The assessment above is about HelloWellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who already knows they want compounded semaglutide, is comfortable paying for a three-month plan up front, and values a named dispensing pharmacy. Wrong for A reader who wants a provider to assess eligibility before any money changes hands, or who budgets by the calendar month and would be caught out by an eleven-week renewal. ## The evidence behind what HelloWellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HelloWellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Auren Rx](https://thisglp.com/reviews/auren-rx) [AVARA Rx](https://thisglp.com/reviews/avara-rx) [Avono Health](https://thisglp.com/reviews/avono-health) [AZ Health](https://thisglp.com/reviews/az-health) [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) [Bayan Health](https://thisglp.com/reviews/bayan-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does HelloWellness charge for semaglutide? The product page bills $399 at checkout for a three-month plan, renewing at $399 every eleven weeks until canceled, which is $157.18 a calendar month. The start page's $133 a month is that charge divided by three. Do I fill in the health intake before paying? No. The product page says no intake form is required before payment. The intake follows checkout, and the payment is refunded if a provider does not approve the plan. Which pharmacy fills the prescription? The terms name AP Max, Inc., doing business as Southend Pharmacy, and the product pages describe it as a US-based 503A pharmacy. Is HelloWellness expensive compared with other GLP-1 telehealth sellers? HelloWellness publishes a starting figure of $157.18/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HelloWellness below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Henry Meds reviews (2026): GLP-1 telehealth sellers | This GLP A monthly rate here buys a quantity of drug per shipment window, and the window stretches as the allowance grows. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/henry-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by the milligram allowance # Henry Meds review A monthly rate here buys a quantity of drug per shipment window, and the window stretches as the allowance grows. ## The verdict Henry Meds charges $297 a month for compounded semaglutide injections and $249 for sublingual semaglutide tablets, and both figures sit on a programs page reached through the legal links at the foot of the site. What the money buys is written in milligrams per shipment window rather than as a weekly dose, which is the detail that decides how long a patient's supply lasts once the dose starts climbing. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose Injection From $297/mo Oral From $249/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Henry Meds is a cash-pay telehealth service operated by Adonis Health, which runs weight management beside testosterone therapy, women's hormone therapy and erectile dysfunction care, with no insurance billed for any of it. Its GLP-1 shelf holds compounded semaglutide as an injection and as sublingual tablets, plus a compounded liraglutide program and phentermine, and an oral tirzepatide supply appears on the same programs page. 1. ## Who writes the prescription, and what do they see? After a medical form of about five minutes, a patient either books a video visit with a provider or, depending on the home state, chooses an independent provider review without a call, and messaging continues through a patient portal afterward. Care is delivered by licensed professionals employed by or contracted with independent professional entities, with Henry Meds describing itself as the administrative platform, and no clinician or medical group is named. Eligibility runs from 18 to 70. One monthly bill is stated to cover the provider visits, medication, supplies and ongoing care, and most people receive a first shipment eight to ten business days after the provider visit, longer in California because of extra compound testing there. The FAQ says injectables then ship every 45 days while the programs page describes 60-, 70- and 90-day windows, so the refrigerator schedule a patient plans around depends on which page is read. 2. ## What happens when the dose goes up? The injection plan comes in two shapes at the same $297 a month: up to 10 mg of semaglutide every 70 days, or up to 12.5 mg every 90 days, each with needles, syringes and swabs. Because the price is fixed to an allowance rather than a dose, a patient stepping up the ladder uses the allowance faster, and the page does not say what happens when a higher dose exhausts it before the window closes. The FAQ says the provider raises the dose gradually to limit [nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and bloating. 3. ## What the price includes The injection plan's six-month term is listed at $1,782 and its twelve-month term at $3,564, each shipped every 60 days, and each carries a lower figure beside it for a buyer who pays in full at the start. The sublingual tablet plan is $249 a month for up to 180 mg every 60 days. The oral tirzepatide supply is listed at $1,047, or $891 paid in full, under a heading that says three months while its own description says delivery runs for six, so no monthly rate can be read from it. 4. ## What it claims, and what it cites Every GLP-1 product here is compounded, prepared in a licensed 503A pharmacy or a 503B outsourcing facility. The site states compounded medications do not undergo pre-market review or FDA approval and may differ from approved drugs in efficacy and safety. The pharmacies are not named. No brand [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), Ozempic or [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is offered. ## Where it holds up, and where it does not - Strength: Every program's milligram allowance is published - Strength: Longer terms show their paid-in-full totals - Strength: A video visit or asynchronous review, depending on state - Strength: One bill covers visits, medication and supplies - Limitation: The price list sits in the legal menu - Limitation: Shipping intervals differ between the FAQ and the programs page - Limitation: The oral tirzepatide listing contradicts its own term - Limitation: Multi-month plans may require paying out the balance on cancellation - Limitation: No clinician or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Henry Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient comfortable reading dose in milligrams per shipment who wants a fixed monthly bill. Wrong for A buyer who wants a multi-month plan they can leave early without owing the remainder. ## The evidence behind what Henry Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Henry Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Believe Health](https://thisglp.com/reviews/believe-health) [Better U Care](https://thisglp.com/reviews/better-u-care) [BetterMe Rx](https://thisglp.com/reviews/betterme-rx) [BeyondMD](https://thisglp.com/reviews/beyondmd) [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) [BiltRx](https://thisglp.com/reviews/biltrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Where is the full price list? On the programs page linked from the legal section of the footer, which lists each plan's monthly rate, milligram allowance and shipping window. Can a multi-month plan be canceled early? Cancellation is available through the portal, email or phone, but the FAQ says a multi-month plan may require paying the remaining balance unless a provider finds a medical reason to stop. Does the injection price rise with the dose? The monthly rate stays at $297, but it buys a fixed milligram allowance per shipment window, so a higher dose uses that allowance sooner. Is Henry Meds expensive compared with other GLP-1 telehealth sellers? Henry Meds publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Henry Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Heros Health reviews (2026): GLP-1 telehealth sellers | This GLP The program names its prescribing physicians and publishes dose check-ins at weeks 2, 4 and 8. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/heros-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Named physicians, flat fee # Heros Health review The program names its prescribing physicians and publishes dose check-ins at weeks 2, 4 and 8. ## The verdict Heros Health prices its GLP-1 program at $199 a month after a $149 first month, and the same figure covers compounded semaglutide or compounded tirzepatide. A three-month plan lowers the rate to $165. Three prescribing physicians are named with their specialties, and the dose review schedule is published in weeks. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Heros Health is a cash-pay telehealth company selling compounded GLP-1s beside erectile dysfunction treatment, NAD+, sermorelin and PT-141. Its weight-loss page states service in all 50 states. The program describes itself as a platform, not a healthcare provider, working with partner clinicians and 503A pharmacies. No insurance is billed. 1. ## Who writes the prescription, and what do they see? A U.S.-licensed physician reviews each intake, and the page says this happens within 24 hours. Prescriptions are described as signed by board-certified physicians in a partner clinical network. Three are named on the weight-loss page, two in family medicine and one in emergency medicine. The quiz takes about a minute, and no card is charged until a physician approves. After approval, medication ships in two to four business days from a 503A pharmacy, in temperature-controlled packaging. Asynchronous check-ins are scheduled at weeks 2, 4 and 8, with direct messaging to the clinician between them. A buyer who is not medically approved is refunded in full. The home page also advertises a 90-day money-back guarantee, whose terms are not set out on the program page. 2. ## What happens when the dose goes up? Treatment starts at the lowest [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) dose, and the clinician adjusts it every two to four weeks based on response and tolerability. Dose changes are stated to be included in the monthly price, with no extra appointment and no upcharge. The milligram steps are not published. The clinician may also switch a patient between molecules, at no stated change in price. 3. ## What the price includes One fee covers either molecule: $149 for the first month, then $199 a month. The three-month plan is $165 a month, which is $495 for the quarter. The FAQ does not say whether that plan is billed upfront or monthly. No separate membership, visit or shipping charge is listed. 4. ## What it claims, and what it cites Both molecules are compounded by U.S.-licensed 503A pharmacies, which the page says meet USP 797 sterile-preparation standards. The footer states compounded medications are not FDA-approved and the FDA does not verify their safety, effectiveness or quality. The pharmacy itself is not named. ## Where it holds up, and where it does not - Strength: Three prescribing physicians are named - Strength: Check-ins are scheduled at weeks 2, 4 and 8 - Strength: Dose changes are included in the fee - Strength: One price covers either molecule - Strength: Full refund if not medically approved - Limitation: The first figure a buyer meets is a first month - Limitation: Milligram steps are not published - Limitation: The three-month plan's billing cadence is not stated - Limitation: Guarantee terms are not on the program page - Limitation: The compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Heros Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to know who signs the prescription and when the dose will be reviewed. Wrong for A buyer who wants published milligram steps before starting. ## The evidence behind what Heros Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Heros Health compares | Seller | Who it suits | Go | | --- | --- | --- | | DudeMeds | Readers who want a 503B facility and will commit to a kit to reach the lower rate | | | Strut Health | A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. | | | Rex MD | Readers who want an approved oral product with the clinician's cost stated inside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Bioverse](https://thisglp.com/reviews/bioverse) [Blis MD](https://thisglp.com/reviews/blis-md) [Bliv](https://thisglp.com/reviews/bliv) [Bloom MD](https://thisglp.com/reviews/bloommd) [BloomWell Rx](https://thisglp.com/reviews/bloomwell-rx) [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does tirzepatide cost more than semaglutide here? No. The program FAQ prices both at one figure: $149 for the first month, then $199 a month, or $165 a month on the three-month plan. Who prescribes? Board-certified, U.S.-licensed physicians in a partner clinical network. Three are named on the weight-loss page with their specialties. How often is the dose reviewed? Check-ins are scheduled at weeks 2, 4 and 8, and the FAQ says the clinician adjusts the dose every two to four weeks. Is Heros Health legit? Heros Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Heros Health expensive compared with other GLP-1 telehealth sellers? Heros Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Heros Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Hers reviews (2026): GLP-1 telehealth sellers | This GLP Every medication price here is missing $149, and Hers states plainly that the membership behind it is not optional. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/hers Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership you cannot decline # Hers review Every medication price here is missing $149, and Hers states plainly that the membership behind it is not optional. ## The verdict Hers prices compounded semaglutide at $199 by injection and $149 as an oral, with compounded tirzepatide at $299 and oral orforglipron at $149, — and none of those figures is what a buyer pays. A Hers Weight Loss Membership is required alongside them at $39 for the first month and $149 a month afterwards, and the company states in its own words that medication is not available without one. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron · Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $348/mo Oral From $298/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states Hers is the women's arm of a large consumer telehealth brand, and it carries an unusually wide GLP-1 catalog: two compounded molecules across injection and oral forms, plus oral orforglipron, which very few sellers price at all. What it sells alongside all of them is a membership, and that membership is the part that decides what the service actually costs. 1. ## Who writes the prescription, and what do they see? The membership is how a reader reaches a prescriber at all, so the clinical relationship and the recurring charge are the same thing here rather than two separable purchases. Hers is clear about that arrangement. The sentence about medication being unavailable without a membership is on its own pages, not inferred from a footnote, which puts it ahead of the sellers that let a reader discover a standing fee at checkout. What a buyer is really choosing is a subscription with a pharmacy attached, and the first month is priced to make that easy to start: $39 rather than $149, which softens the largest recurring charge exactly once. From month two the membership costs more than three of the four medication lines it unlocks, which is an unusual shape for a service to have and the single most important thing to understand before enrolling. 2. ## What happens when the dose goes up? Hers does not publish what happens to a medication figure as the dose climbs, and on the compounded lines that leaves the larger question open. The membership at least does not move: $149 a month is stated flatly, so a buyer escalating through a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule knows one of the two components will hold even if the other does not. 3. ## What the price includes The arithmetic is the review. Oral semaglutide at $149 becomes $298 a month once the membership is counted, and the injection at $199 becomes $348. Tirzepatide at $299 becomes $448. Six months on the oral line is therefore $1,788 rather than $894, and a reader comparing the medication figure against a seller that quotes an all-in rate is comparing half a price against a whole one. The orforglipron line, flagged as new on the page, carries the same $149 membership on top of its own $149. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) lines are compounded preparations, which means they are not FDA-approved and the agency does not review them for safety or quality before they are dispensed. The orforglipron line is a newer molecule and its presence here is notable in itself, since a published price for it is rare anywhere. ## Where it holds up, and where it does not - Strength: The requirement is written in the seller's own words - Strength: Orforglipron priced, which is rare - Strength: Membership rate holds at $149 monthly - Strength: Coverage stated across 50 states - Limitation: No medication figure is the real cost - Limitation: Membership exceeds three of four drug prices - Limitation: The $39 first month applies once - Limitation: Dose behavior is not published ## What the evidence says about this kind of treatment The assessment above is about Hers. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a large brand and a wide catalog, and who will budget the membership as the main charge. Wrong for A reader comparing medication prices across sellers without adding a required fee to each. ## The evidence behind what Hers prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Hers compares | Seller | Who it suits | Go | | --- | --- | --- | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Bodi Envi](https://thisglp.com/reviews/bodi-envi) [Bon Health](https://thisglp.com/reviews/bon-health) [boostAGErx](https://thisglp.com/reviews/boostagerx) [Boston Medical Group](https://thisglp.com/reviews/boston-medical-group) [Breeze Meds](https://thisglp.com/reviews/breeze-meds) [Brello Health](https://thisglp.com/reviews/brello-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Hers actually cost a month? The medication figure plus $149. Oral semaglutide at $149 becomes $298, the injection at $199 becomes $348, and tirzepatide at $299 becomes $448. Can the membership be skipped? No. Hers states on its own pages that medication is not available without a membership, which is why every figure here is quoted as a component rather than a price. Is the $39 first month a discount on the medication? No, it applies to the membership and only once. From the second month the membership charge is $149 alongside whatever the medication costs. Why does orforglipron matter here? It is a newer GLP-1 and very few sellers publish a figure for it at all. Hers lists it as an oral at $149, with the same membership required on top. Is Hers legit? Hers is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Hers expensive compared with other GLP-1 telehealth sellers? Hers publishes a starting figure of $298/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Hers above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Heva Health reviews (2026): GLP-1 telehealth sellers | This GLP A functional-medicine practice that sells compounded semaglutide and tirzepatide at a flat rate across doses, with the month-to-month rung printed beside the commitment discounts. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/heva-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price at every dose # Heva Health review A functional-medicine practice that sells compounded semaglutide and tirzepatide at a flat rate across doses, with the month-to-month rung printed beside the commitment discounts. ## The verdict Heva Health charges $199 a month for compounded semaglutide with no commitment. The three-month program drops that to $189 and the six-month program to $174. The page states the price does not change as the dose rises. Longer plans carry a possible early-cancellation charge. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Included LegitScript Claimed by provider Heva Health is an online functional-medicine practice offering weight loss, hormone optimization and lab testing. Compounded semaglutide and compounded tirzepatide are its weight-loss products. Full-service care is listed in twelve states, while its direct-to-door treatments are listed as available nationwide. 1. ## Who writes the prescription, and what do they see? The weight-loss page names four clinicians: a naturopathic doctor, a physician assistant, a doctor of nursing practice and a family nurse practitioner. No MD or DO appears among them. The page says a U.S.-licensed provider reviews every intake and that prescriptions are not computer-generated. Which clinician signs a given prescription is not stated. A patient starts with a free consultation or a short intake, and a provider reviews it before any prescription. Medication ships overnight in cold-chain packaging at no charge. The homepage says treatment plans include any necessary labs and provider dose adjustments. Plans can be paused or canceled from the member portal. 2. ## What happens when the dose goes up? This is where Heva is specific. The page says any dose costs the same and that the price never changes as the dose increases. It describes smart [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), with the provider adjusting the dose to response. What it does not publish is the milligram schedule itself. 3. ## What the price includes Semaglutide is $199 month to month, $189 on the three-month program and $174 on the six-month program, each billed monthly. Six months at the lowest rung comes to $1,044. The page says the three- and six-month plans may carry an early-cancellation fee or the remaining balance. Tirzepatide sits higher on the same three-rung ladder. 4. ## What it claims, and what it cites Both products are compounded by licensed U.S. compounding pharmacies, described as FDA-regulated 503A facilities. The page states that compounded medications are not FDA-approved and are not evaluated by the FDA for safety or efficacy. No pharmacy is named. [Tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is not dispensed in Alaska, Arkansas, Indiana or South Carolina. ## Where it holds up, and where it does not - Strength: Flat price across every dose - Strength: Month-to-month rung printed beside the discounts - Strength: Four clinicians named with credentials - Strength: LegitScript certification stated - Limitation: Commitment plans may charge an early-exit fee - Limitation: No physician among the named clinicians - Limitation: No compounding pharmacy named - Limitation: Tirzepatide unavailable in four states ## What the evidence says about this kind of treatment The assessment above is about Heva Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one fixed semaglutide price through the whole dose ladder and a month-to-month option. Wrong for A reader who wants a physician, rather than a naturopath or advanced-practice clinician, writing the prescription. ## The evidence behind what Heva Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Heva Health compares | Seller | Who it suits | Go | | --- | --- | --- | | TeleZen MD | Readers who want the monthly rate and every term discount on one card | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Breeze Meds](https://thisglp.com/reviews/breeze-meds) [Brello Health](https://thisglp.com/reviews/brello-health) [Brightmeds](https://thisglp.com/reviews/brightmeds) [Cabana](https://thisglp.com/reviews/cabana) [CaliberRx](https://thisglp.com/reviews/caliberrx) [Calibrate Health](https://thisglp.com/reviews/calibrate-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost at Heva Health? $199 a month with no commitment, $189 on the three-month program and $174 on the six-month program. Will a higher dose raise the Heva price? No. The page states that any dose costs the same and that the price never changes as the dose increases. Can a commitment plan be canceled early? The page says early termination of a three- or six-month plan may bring a cancellation fee or the remaining balance. Is Heva Health expensive compared with other GLP-1 telehealth sellers? Heva Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Heva Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Hims reviews (2026): GLP-1 telehealth sellers | This GLP Every GLP-1 price is medication only. The membership is billed separately and cannot be skipped. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/hims Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand pens, plus membership # Hims review Every GLP-1 price is medication only. The membership is billed separately and cannot be skipped. ## The verdict Hims sells brand GLP-1s only. Wegovy Pen starts at $199 a month and Zepbound at $299. Both figures exclude the Hims Weight Loss Membership. The membership is $39 for the first month, then $149 a month. Medication is not sold without it. The standing cost is $348 for Wegovy Pen and $448 for Zepbound. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $348/mo Dose published Yes Prescription Required Compounded No Pharmacy Not named Hims is a telehealth company whose weight-loss catalog lists manufacturer products only. The shelf carries Wegovy as a pen and a pill, Zepbound as a vial and a KwikPen, Foundayo, and Ozempic. No compounded GLP-1 is listed. The medication fee is FSA and HSA eligible. The membership fee is not. 1. ## Who writes the prescription, and what do they see? A provider reviews an intake and decides what, if anything, to prescribe. The membership includes 24/7 messaging with licensed providers. No clinician or medical group is named on the product pages. The page states the membership does not guarantee a prescription. What the provider reviews is not described beyond medical history. The membership carries the care: a treatment plan, provider messaging, a care team and weight tracking in the app. A smart scale ships separately if the buyer opts in. Canceling the membership also cancels any active medication plan. Membership and medication are billed as two separate charges. 2. ## What happens when the dose goes up? The Wegovy Pen page publishes the ladder: 0.25 mg, 0.5 mg, 1 mg, then 1.7 to 2.4 mg for maintenance. It lists a range up to 7.2 mg. Each price is written "Starts at" or "From". The price at each higher step is not published. Dose adjustments are listed as a membership benefit. 3. ## What the price includes Two charges apply every month. The medication starts at $199 for Wegovy Pen or $299 for Zepbound. The membership adds $149 after a $39 first month. The all-in standing figures are $348 and $448. The higher rungs of either medication are not priced on the page. 4. ## What it claims, and what it cites Every GLP-1 here is an FDA-approved manufacturer product, not a compounded preparation. Hims states it is not affiliated with or endorsed by Eli Lilly. [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) is listed with a note that it is approved for type 2 diabetes and prescribed only to eligible patients. ## Where it holds up, and where it does not - Strength: Only FDA-approved brand products are sold - Strength: The Wegovy Pen dose ladder is published in milligrams - Strength: The membership requirement is stated beside every price - Strength: The medication fee is FSA and HSA eligible - Limitation: Every medication price excludes a $149 membership - Limitation: Prices above the starting dose are not published - Limitation: Canceling the membership cancels the medication - Limitation: No clinician or medical group is named - Limitation: The membership fee is not FSA or HSA eligible ## What the evidence says about this kind of treatment The assessment above is about Hims. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer set on brand Wegovy or Zepbound who wants care and medication from one account. Wrong for A buyer comparing medication prices without adding the membership. ## The evidence behind what Hims prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Hims compares | Seller | Who it suits | Go | | --- | --- | --- | | LifeMD | Readers with insurance that may cover the medication, leaving the fee as the main cost | | | WeightWatchers Clinic | Readers who want a familiar brand and will add the membership at its ceiling | | | Eden | Buyers comparing what the two molecules actually cost | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Call-On-Doc](https://thisglp.com/reviews/call-on-doc) [Candor Rx](https://thisglp.com/reviews/candor-rx) [Care Bare Rx](https://thisglp.com/reviews/care-bare-rx) [Care Clinics](https://thisglp.com/reviews/care-clinics) [Carocare Wellness](https://thisglp.com/reviews/carocare-wellness) [CeliaRx](https://thisglp.com/reviews/celia-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Wegovy Pen cost at Hims all in? $348 a month at the starting price: $199 for the medication plus the $149 membership. The first month's membership is $39. Is a compounded GLP-1 on the Hims shelf? No. The weight-loss catalog lists brand products only, and no compounded GLP-1 appears on it. Can the medication be bought without the membership? No. The footnote under every price states medication is not available without an active membership. Is Hims expensive compared with other GLP-1 telehealth sellers? Hims publishes a starting figure of $348/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Hims above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Hone Health reviews (2026): GLP-1 telehealth sellers | This GLP Hone Health combines biomarker testing and physician visits with a separate medication bill. Its listed GLP-1 option is compounded liraglutide, within a broader hormone and longevity service. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/hone-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Hone Health review Hone Health combines biomarker testing and physician visits with a separate medication bill. Its listed GLP-1 option is compounded liraglutide, within a broader hormone and longevity service. ## The verdict Hone has a more structured testing and follow-up pathway than a bare prescription checkout. Hone sells a broad collection of therapies. Focus the initial conversation on why a particular medicine is appropriate. Ask how its benefits and risks will be assessed. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Liraglutide Form Injection Prescription Required Compounded Yes — not FDA-approved The service covers hormone, metabolic and longevity care. Its men’s weight-loss page lists compounded liraglutide alongside non-GLP-1 medicines. Testing and membership are entry points to care, not evidence that each treatment in the catalog is needed. 1. ## Who writes the prescription, and what do they see? Hone describes consultations with licensed physicians after biomarker testing. Medical services are delivered through independently operated medical practices using the platform. A clinician should interpret the results together with symptoms, history and existing medicines rather than treating a panel as a prescription decision by itself. The published process starts with testing across more than 50 biomarkers, then a private video consultation. The Premium pathway includes repeat testing and clinician follow-up every three months and unlimited care-team messaging. Basic has a different service scope, so compare the plan before relying on those features. 2. ## What happens when the dose goes up? Compounded liraglutide is described as a daily injection. The prescriber sets the regimen and should explain its escalation and monitoring requirements. The page’s monthly price does not identify one universal dose or establish that every patient is an appropriate candidate. 3. ## What the price includes Weight-loss liraglutide is listed at $160 monthly plus membership. The broader service lists Premium at $155 per month plus medication, with a $65 initial testing offer; Basic is $25 monthly and has different access. Do not assume that Basic membership includes the desired treatment. 4. ## What it claims, and what it cites The named GLP-1 product is compounded liraglutide. It should not be described as an FDA-approved generic of Saxenda or as equivalent to an approved product. Other listed weight therapies, including naltrexone and topiramate, act differently and need their own clinical justification. ## Where it holds up, and where it does not - Strength: Biomarker review precedes a treatment plan - Strength: Premium specifies recurring clinician follow-up - Strength: Medication and membership are distinguished - Limitation: Treatment access differs by membership tier - Limitation: Daily compounded injection has separate evidence questions - Limitation: Broad wellness catalog can complicate the choice ## What the evidence says about this kind of treatment The assessment above is about Hone Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking physician interpretation of metabolic and hormone symptoms who is comfortable evaluating membership and medicine separately. Wrong for A buyer seeking a standalone approved GLP-1 with no continuing membership expense. ## How Hone Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Citizen Meds](https://thisglp.com/reviews/citizen-meds) [Claya](https://thisglp.com/reviews/claya) [Clinic Secret](https://thisglp.com/reviews/clinic-secret) [Clume Health](https://thisglp.com/reviews/clume-health) [CLYR Health](https://thisglp.com/reviews/clyr-health) [Coivas](https://thisglp.com/reviews/coivas) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which GLP-1 does the weight-loss page name? Compounded liraglutide, described as a daily injection, at $160 monthly plus membership. Are all treatments included in Basic? No. The membership comparison distinguishes Basic-labeled treatments from the broader Premium catalog. How often does Premium reassess care? The published process describes retesting and clinician follow-up every three months, with messaging between visits. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://honehealth.com/) - [Terms of service and payment conditions](https://honehealth.com/terms/) - [How assessment and follow-up work](https://honehealth.com/how-it-works/) - [Weight-management program](https://honehealth.com/mens/weight-loss/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Hormonally Balanced reviews (2026): GLP-1 telehealth sellers | This GLP Hormonally Balanced lists a monthly tirzepatide program with a physician-assistant consultation, medication delivery and coach check-ins. Pharmacy and stopping terms need clarification. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/hormonally-balanced Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Hormonally Balanced sell a GLP-1? Hormonally Balanced lists a monthly tirzepatide program with a physician-assistant consultation, medication delivery and coach check-ins. Pharmacy and stopping terms need clarification. ## The verdict The described service includes more than a refill: a medical consultation and weight-loss coaching are both named. The limitation is the prescription detail. Confirm the precise product, pharmacy and ongoing clinical access rather than interpreting a bundled monthly price as a complete medication specification. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Hormonally Balanced is a private-pay practice based in Burlington, Massachusetts, with a telehealth weight-management offering. The dedicated tirzepatide page describes a monthly program after a screening consultation. Other hormone services are separate from the weight-loss decision. 1. ## Who writes the prescription, and what do they see? The initial assessment is described as a one-to-one telehealth visit with a licensed physician assistant. Medical history and goals inform suitability. The page states BMI screening criteria, but a calculator does not establish that prescribing is safe for an individual. The subscription lists medication delivery and individual coach check-ins. Coaching can support habits and progress, while medication questions still need a medical professional. Ask who handles clinical concerns between visits and what level of direct prescriber access accompanies the program. 2. ## What happens when the dose goes up? The provider selects treatment after the consultation. A dose-by-dose clinical or price ladder is not established on the reviewed page. Before enrolling, obtain the starting regimen, how changes are approved and the route for discussing tolerance before another supply is sent. 3. ## What the price includes The page publishes a monthly program fee and a refundable consultation deposit. The practice states that it does not accept insurance. Establish the deposit’s refund conditions and whether laboratory tests or any additional visits fall outside the stated program. 4. ## What it claims, and what it cites Tirzepatide delivery is described, but the precise branded or compounded product and dispensing pharmacy are not established by the reviewed program description. Do not infer either from the price. Ask for the prescription identity and formulation before consenting. ## Where it holds up, and where it does not - Strength: Clinical consultation and coaching are distinguished - Strength: Monthly program inclusions are described - Strength: Private-pay status is explicit - Limitation: Dispensed product and pharmacy need confirmation - Limitation: No public dose-price ladder - Limitation: Refundable deposit conditions need checking ## What the evidence says about this kind of treatment The assessment above is about Hormonally Balanced. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone eligible for the practice’s telehealth service who values a combination of medical assessment and ongoing coaching. Wrong for A patient needing insurance billing or a fully specified prescription and stopping policy before an initial conversation. ## The evidence behind what Hormonally Balanced prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Hormonally Balanced compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Concierge MD LA](https://thisglp.com/reviews/concierge-md-la) [Contour Health](https://thisglp.com/reviews/contour-health) [Cora Health](https://thisglp.com/reviews/cora-health) [CoraDoc](https://thisglp.com/reviews/coradoc) [Corsica Health](https://thisglp.com/reviews/corsica-health) [Curex](https://thisglp.com/reviews/curex) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who conducts the first visit? The program page describes a consultation with a licensed physician assistant. Does the practice accept insurance? Its weight-loss page describes private-pay concierge care and says insurance is not accepted. Does the quote stay the same at every dose? The page does not establish a detailed dose-price ladder. Confirm the cost of the actual prescribed course. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://hormonallybalanced.com/) - [Tirzepatide program details](https://hormonallybalanced.com/medical-weight-loss-in-ma-with-tirzepatide/) - [Terms of service and payment conditions](https://hormonallybalanced.com/terms-of-service/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # HumeCare+ reviews (2026): GLP-1 telehealth sellers | This GLP The rate is stated to hold at every dose, and what it covers includes a physical device as well as the medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/humecare Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat rate, device included # HumeCare+ review The rate is stated to hold at every dose, and what it covers includes a physical device as well as the medication. ## The verdict HumeCare+ publishes a flat $199 a month for compounded semaglutide by injection and states that the figure holds at every dose, while its pill and tirzepatide lines are priced only after an assessment. The semaglutide figure covers the medication, the provider consultation and a device the company calls the Hume Pod, against an anchor price of $299 that nobody appears to pay. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral From From $199/mo Prescription Required Compounded Yes — not FDA-approved Availability 47 states, list published HumeCare+ sells semaglutide as a once-weekly injection or a pill and tirzepatide by injection only, with the tirzepatide line sold exclusively as a B12 and glycine combination rather than as plain tirzepatide. Only the injection carries a published figure, shown against a higher anchor number; the company's own comparison pages describe the other two as not published until an assessment. 1. ## Who writes the prescription, and what do they see? The provider consultation sits inside the monthly figure rather than beside it, so the clinical relationship is not a separate charge a buyer discovers later. What the pages do not describe is how often that consultation happens or what a prescriber reviews before writing, which is the same gap almost every seller in this category leaves. Two things here are worth more than the price. The first is the flat-rate statement, made explicitly at every dose rather than left to be discovered during a titration. The second is the inclusion list, which extends past medication and consultation to a physical device. That is an unusual thing to fold into a monthly rate, and it makes the figure harder to compare against a plain medication price elsewhere. 2. ## What happens when the dose goes up? HumeCare+ states plainly that the rate is flat at every dose. That is among the most useful sentences a seller in this category can publish. Escalation across the first sixteen weeks is the normal path, and a rate that moves at each step costs more over a year than any gap between competitors. What the pages do not state is the milligram range the flat rate covers. 3. ## What the price includes The anchor prices are the part to treat carefully. Semaglutide is presented at $199 against a $299 anchor, and nothing on the pages suggests the higher figure is ever charged. An anchor nobody pays is a framing device rather than a price. What gives the real figures their weight is the flat-rate statement beside them: $199 a month that genuinely holds through a titration is a different proposition from $199 that resets at every step. 4. ## What it claims, and what it cites All three lines are compounded, which places them outside the FDA review an approved product completes before dispensing. The [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is available only as a combination with B12 and glycine, with no plain line offered. A buyer wanting the molecule alone cannot get it here, and the pages do not explain why the combination is the only option. ## Where it holds up, and where it does not - Strength: Flat rate stated explicitly at every dose - Strength: Consultation sits inside the figure - Strength: A device is included rather than sold apart - Strength: The injection price is published before an assessment - Limitation: Tirzepatide comes only as a combination - Limitation: The anchor price appears to be nominal - Limitation: The pill and tirzepatide are priced only after an assessment - Limitation: No milligram range is published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about HumeCare+. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the rate pinned across a titration and the consultation counted in. Wrong for A reader who wants tirzepatide on its own rather than as a combination product. ## The evidence behind what HumeCare+ prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How HumeCare+ compares | Seller | Who it suits | Go | | --- | --- | --- | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Idgie Health | A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. | | | Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Curex](https://thisglp.com/reviews/curex) [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) [DoctorAdam](https://thisglp.com/reviews/doctoradam) [Dollar Dad Club](https://thisglp.com/reviews/dollar-dad-club) [Dr. Arevitalize](https://thisglp.com/reviews/dr-arevitalize) [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price really hold at every dose? HumeCare+ states it does. That is worth confirming at intake, because it is the claim that decides what a year costs. What is the Hume Pod? A device the company includes in the monthly figure alongside the medication and the provider consultation. The pages do not price it separately. Can I get tirzepatide without the additives? Not here. The tirzepatide line is sold only as a B12 and glycine combination, with no plain version offered and no explanation given. Is HumeCare+ expensive compared with other GLP-1 telehealth sellers? HumeCare+ publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HumeCare+ above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Idgie Health reviews (2026): GLP-1 telehealth sellers | This GLP This seller calls its own microdosing approach off-label on the page that sells it, which few in this category do. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/idgie-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Seller names the off-label part # Idgie Health review This seller calls its own microdosing approach off-label on the page that sells it, which few in this category do. ## The verdict Idgie Health prices a compounded semaglutide microdose at $134 a month, a tirzepatide microdose at $179, and an oral semaglutide tablet at $287. Its own product copy describes microdosing as an off-label approach rather than leaving the reader to work that out. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 50 Injection From $134/mo Oral From $287/mo Prescription Required Compounded Yes — not FDA-approved Idgie Health sells compounded semaglutide and compounded tirzepatide as microdose injections, and semaglutide as an orally dissolving tablet. The three figures read $134, $179 and $287 a month. Each is billed monthly and described as flexible. Three-month purchases were $377, $497 and $747 charged on the day of order. 1. ## Who writes the prescription, and what do they see? A prescription is required and the plans are sold as month-to-month with a three-month alternative. The tablet is listed on the program menu as a semaglutide and ondansetron combination, which names a second active ingredient rather than implying one. What an intake asks before a prescription is issued is not published. Coverage is published as fifty states. Treatment is arranged remotely and the products are described by dose class rather than by milligram. Microdosing means a weekly dose below the maintenance doses the approved labels set out. The ondansetron in the tablet is an antiemetic, included against the nausea that accompanies these molecules. Whether it reduces that nausea at the quantity used was not measured in the outcome trials. 2. ## What happens when the dose goes up? The published figure is one rate for the microdose product rather than a ladder. A reader who escalates past the microdose range is buying a different product rather than a higher tier of this one. What the next rung costs is not published beside these three. The three-month purchases are charged in full on the day they are placed. 3. ## What the price includes The monthly and the three-month routes are both published, which lets a reader see the whole choice. Semaglutide runs $134 monthly against $125 a month across three, and tirzepatide $179 against $165. The tablet is the expensive route at $287 monthly, or $249 a month across three. Every three-month figure is a single charge rather than a lower monthly bill. 4. ## What it claims, and what it cites All three products are compounded, so a pharmacy prepares them and no regulator reviews the finished dose form. Naming microdosing as off-label is accurate and unusual to print. The published weight-change results for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) came from label doses over sixty-eight and seventy-two weeks. What a microdose produces over the same period was not measured. ## Where it holds up, and where it does not - Strength: Seller names microdosing as off-label - Strength: Monthly and three-month figures both published - Strength: Second active ingredient named on the tablet - Limitation: Microdoses sit below the studied doses - Limitation: Three-month price is charged in full - Limitation: Tablet costs more than either injection ## What the evidence says about this kind of treatment The assessment above is about Idgie Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. Wrong for A reader looking for the doses the outcome trials used, since every product priced here is a microdose or a tablet rather than a label-dose injection. ## The evidence behind what Idgie Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Idgie Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DrBrainRx](https://thisglp.com/reviews/drbrainrx) [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) [DudeMeds](https://thisglp.com/reviews/dudemeds) [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) [Edessa](https://thisglp.com/reviews/edessa) [EdgeRx](https://thisglp.com/reviews/edgerx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does off-label mean on this page? It means the dose is used in a way the approved label does not describe. Idgie Health applies the phrase to its own microdosing approach, on the page that sells it. Why is the tablet dearer than the injection? The tablet is $287 a month against $134 for the microdose injection. It is listed as a semaglutide and ondansetron combination, which is a different preparation rather than the same drug in another form. Is the three-month price a lower monthly rate? No. $377 is charged on the day of order and works out at $125 a month. The monthly plan bills $134 at a time and can be stopped sooner. Is Idgie Health expensive compared with other GLP-1 telehealth sellers? Idgie Health publishes a starting figure of $134/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Idgie Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Immortals reviews (2026): GLP-1 telehealth sellers | This GLP Every monthly figure on the GLP-1 pages is a share of a three-month charge taken at the start. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/immortals Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Longevity framing, quarterly billing # Immortals review Every monthly figure on the GLP-1 pages is a share of a three-month charge taken at the start. ## The verdict Immortals lists compounded semaglutide from $196 a month and compounded tirzepatide from $255, and the asterisk under both figures says the plan is billed quarterly with a three-month commitment paid up front. That makes the first charge $588 or $765, and nothing on either product page offers a way to pay for a single month instead. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $196/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Immortals is Bryan Johnson's longevity company, and its prescription arm sells GLP-1s as part of a catalog that also runs to metformin, acarbose, peptides, tadalafil and skin compounds, beside biomarker testing and the Blueprint supplement line. The GLP-1 shelf holds compounded semaglutide and tirzepatide, each mixed with glycine and B12, and separate listings for brand Wegovy, Zepbound and Foundayo, with GLP-1s framed as much for longevity as for weight. 1. ## Who writes the prescription, and what do they see? A medical intake of a few minutes goes to a U.S.-licensed, board-certified physician, who recommends a medication within 72 hours if one is appropriate. The page notes that some states require an audio or video consultation before a prescription is approved. One physician on Bryan Johnson's team is named on the home page with his training, though the product pages do not say whether he is among the doctors who review intakes. Approved medication ships in two to five business days, and the doctor stays reachable by chat, with video consults available, for up to twelve months under the same purchase. No membership fee is charged and payment is taken only after a doctor prescribes, so the quarterly charge is the whole of what a patient pays for those three months. Purchases are stated to be reimbursable through an HSA or FSA account. 2. ## What happens when the dose goes up? Each compounded product offers two dosage types, a Personalized Dose and a Microdose, and the tirzepatide page opens with the Microdose already selected. The first figure a visitor meets there therefore belongs to the smaller product, not to the $255 treatment plan. No milligram ladder is published for the Personalized Dose, and the page does not say whether the price holds as the dose climbs inside a quarter or at the next renewal. 3. ## What the price includes The Personalized Dose is $196 a month for semaglutide and $255 for tirzepatide, each billed as a quarter at a time, so $588 and $765 leave the account together at the start of every three months. The Microdose option sits lower on both products. Brand Wegovy, Zepbound and Foundayo are listed on their own pages, and the compounded plans carry no month-to-month rung to compare against. 4. ## What it claims, and what it cites The compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are prepared by licensed U.S. pharmacies with glycine and B12 added, and the page states compounded medications are not evaluated by the FDA for safety, quality or efficacy. The pharmacy is not named. The brand products are the manufacturers' own and are listed separately. ## Where it holds up, and where it does not - Strength: No membership fee on top of the medication - Strength: Physician messaging runs for up to twelve months - Strength: Brand and compounded routes are both listed - Strength: HSA and FSA reimbursable - Limitation: Every compounded plan is a three-month commitment paid up front - Limitation: The tirzepatide page opens on the Microdose option - Limitation: No milligram ladder is published - Limitation: The compounding pharmacy is not named - Limitation: Reviewing physicians are not named on the product pages ## What the evidence says about this kind of treatment The assessment above is about Immortals. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient already sure of a GLP-1 who wants it inside a broader longevity program and can pay a quarter at once. Wrong for A first-time patient who wants to try one month before committing to three. ## The evidence behind what Immortals prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Immortals compares | Seller | Who it suits | Go | | --- | --- | --- | | Try Ageless | Readers willing to price the same product twice before buying it once | | | AgelessRx | Readers ready to commit to four months who want a choice between a microdose and a full dose | | | Gala | Readers with insurance that may apply to Ozempic, or those ready to commit a year to compounded tirzepatide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Effecty](https://thisglp.com/reviews/effecty) [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) [Elevate Health](https://thisglp.com/reviews/elevate-health) [Elevated Health](https://thisglp.com/reviews/elevated-health) [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) [ElixaMD](https://thisglp.com/reviews/elixamd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I pay for one month at a time? Not on the compounded plans. The footnote under each price says billing is quarterly with a three-month commitment paid up front, so semaglutide is $588 and tirzepatide $765 at the start of each quarter. What is the Microdose option? A second dosage type on both compounded products, priced below the Personalized Dose. The tirzepatide page shows it by default, so check which option is selected before reading the figure. Is there a membership fee? No. The product pages state there are no membership fees and that payment is taken only after a doctor prescribes. Is Immortals expensive compared with other GLP-1 telehealth sellers? Immortals publishes a starting figure of $196/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Immortals above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Independent Wellness reviews (2026): GLP-1 telehealth sellers | This GLP A single-provider telehealth practice selling compounded semaglutide and tirzepatide, with a semaglutide rate its own pricing page states two ways. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/independent-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One nurse practitioner, named # Independent Wellness review A single-provider telehealth practice selling compounded semaglutide and tirzepatide, with a semaglutide rate its own pricing page states two ways. ## The verdict Compounded tirzepatide is $299 a month after a $199 first month. Semaglutide opens with a $99 month. After that, the page prints its rate as $299 on the plan card and $199 in the table below it. That conflict is not resolved on the page. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 20 From From $299/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named LegitScript Claimed by provider Independent Wellness runs weight-loss care online. Both compounded semaglutide and compounded tirzepatide are on its menu. It also offers microdosing and peptides such as NAD, glutathione and sermorelin. There is no membership fee. 1. ## Who writes the prescription, and what do they see? One clinician is named: Bonnie Lea Davis, FNP-C, a board-certified nurse practitioner. The pricing page says the patient works with her throughout the program. No physician is named. Visit one happens over live video. Monthly visits are required. The first is a video visit. The second and third months may be refill-only and asynchronous. A video visit is required every three months. Annual labs are recommended before starting. Medication ships monthly. 2. ## What happens when the dose goes up? The plan cards say the agreed price never changes. The FAQ says tirzepatide pricing varies by plan and dose. The two statements are not reconciled. Dose adjustments are made by the same provider. No milligram dose is published. 3. ## What the price includes Tirzepatide is $199 for the first month, then $299 a month. Semaglutide's opening month is $99. Its later rate is $299 on the card and $199 in the comparison table. A first-month offer is not the standing price. Unlimited provider visits are included. No payment is taken until approval. 4. ## What it claims, and what it cites Both products are compounded. They are not FDA-approved. The FDA does not review them before dispensing. The site names three partner pharmacies: DCA Pharmacy, Link Pharmacy and Boudreaux's New Drug Store. Each is listed with its address and the states it serves. ## Where it holds up, and where it does not - Strength: Same named provider for the whole program - Strength: Three partner pharmacies named with addresses - Strength: No membership fee - Strength: LegitScript certification stated - Limitation: Two different semaglutide ongoing rates on one page - Limitation: Fixed-price promise conflicts with the FAQ - Limitation: Monthly visits are mandatory - Limitation: One clinician carries the whole practice ## What the evidence says about this kind of treatment The assessment above is about Independent Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the same nurse practitioner at every visit and the pharmacy named in advance. Wrong for A reader who needs a settled semaglutide rate before starting. ## The evidence behind what Independent Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Independent Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SynergenX Health | Readers near a clinic metro who want a live video visit and can budget for visit fees | | | Good Girl Rx | A reader who will read the one-month rung rather than the headline, and wants microdoses labeled as such | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [ElixaMD](https://thisglp.com/reviews/elixamd) [ElleS](https://thisglp.com/reviews/elles) [EllieMD](https://thisglp.com/reviews/elliemd) [Eloria](https://thisglp.com/reviews/eloria) [Emerge Weight Loss](https://thisglp.com/reviews/emerge-weight-loss) [eMI Aesthetics](https://thisglp.com/reviews/emi-aesthetics) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the semaglutide rate from month two? The pricing page states it two ways: $299 on the plan card and $199 in the comparison table. What does tirzepatide cost? $199 for the first month, then $299 a month. The card and the table agree. Which pharmacy fills the prescription? One of three named partners: DCA Pharmacy, Link Pharmacy or Boudreaux's New Drug Store, depending on state. Is Independent Wellness expensive compared with other GLP-1 telehealth sellers? Independent Wellness publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Independent Wellness above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Injectco reviews (2026): GLP-1 telehealth sellers | This GLP A monthly subscription for each molecule, beside long packages quoted only at the starting dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/injectco Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A subscription beside a package # Injectco review A monthly subscription for each molecule, beside long packages quoted only at the starting dose. ## The verdict Injectco prices a compounded semaglutide subscription from $249 a month and tirzepatide from $425. It also sells six-to-eight month packages, and those are quoted at the starting dose only. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $249/mo Prescription Required Compounded Yes — not FDA-approved Injectco is a Texas medical aesthetics clinic that sells compounded semaglutide and tirzepatide alongside its other treatments. Each molecule has a monthly price and a longer package. 1. ## Who writes the prescription, and what do they see? A virtual consultation with an Injectco clinician sets the medication and the dosing, and the package price is stated to include that consultation. The clinic is a physical practice rather than a mail-order brand, which is worth knowing before a first call. The semaglutide subscription delivers medication monthly with a home kit. A single payment instead buys a long run of medication and the consultation that starts it. Payment plans are offered. The clinic states no membership costs and no hidden fees. 2. ## What happens when the dose goes up? The package supply is stated at the starting dose, and that qualifier does the real work. A [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) draws the same vial down faster, so the eight-month end of the range belongs to a buyer who does not escalate. Nothing published says what a step up costs on either route. 3. ## What the price includes Six months of the subscription is $1,494 for semaglutide and $2,550 for tirzepatide. Package prices of $1,249 and $1,620 for a six-to-eight month supply both appear on the site, the lower on a page that names no molecule. A buyer who escalates on schedule will exhaust a package nearer the short end of its range. 4. ## What it claims, and what it cites The GLP-1 line is a compounded preparation rather than a manufactured product, and the compounding pharmacy is not named. The FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: A monthly subscription with a home kit - Strength: Provider consult included in the package - Strength: Payment plans offered - Strength: No membership fee stated - Limitation: Package supply quoted at the starting dose only - Limitation: A dose increase shortens a package - Limitation: Two package prices appear on the site - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Injectco. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to pay monthly and keep a long package as an option. Wrong for A buyer escalating on schedule who is counting on a package to last eight months. ## The evidence behind what Injectco prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Injectco compares | Seller | Who it suits | Go | | --- | --- | --- | | RxPepsDirect | Buyers at a starting dose who want per-vial pricing and no subscription | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | | Alegro Health | Buyers trying a GLP-1 for two months before committing to a rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus)[EverSlim](https://thisglp.com/reviews/everslim) [Eviora MD](https://thisglp.com/reviews/eviora-md) [Factor Health MD](https://thisglp.com/reviews/factor-health-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a cheaper way to buy semaglutide? A $1,249 package covers six to eight months at the starting dose. The subscription starts at $249 a month. Does a dose increase change the supply? The supply is quoted at the starting dose, so escalating draws it down faster. Nothing published states the cost of topping it up. What does tirzepatide cost? $425 a month on its own program. Is Injectco expensive compared with other GLP-1 telehealth sellers? Injectco publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Injectco above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # InstaRX reviews (2026): GLP-1 telehealth sellers | This GLP One flat price is stated for both molecules. Only the first month carries a figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/instarx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Only month one priced # InstaRX review One flat price is stated for both molecules. Only the first month carries a figure. ## The verdict InstaRX sells compounded semaglutide and tirzepatide at one stated flat price. It prints one figure, a first month at $148. A struck $248 sits beside it. No page states what month two costs. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 Prescription Required Compounded Yes — not FDA-approved Availability All 50 states + DC InstaRX describes itself as a platform that connects patients with licensed clinicians. It sells both molecules as injections, compounded. No oral form is listed. It serves all 50 states and the District of Columbia. 1. ## Who writes the prescription, and what do they see? InstaRX states that it is not a healthcare provider. Clinicians work for third-party physician practices. A provider reviews each intake and decides whether to prescribe. The seller says its doctors are obesity certified. No clinician is named. The intake is a short online form. A provider evaluation follows. A plan is issued only if the provider prescribes. Online follow-ups and dose adjustments are listed as ongoing care. There is no monthly membership, and cancellation is allowed at any time. 2. ## What happens when the dose goes up? The FAQ says the price does not rise as the dose goes up. That applies to both molecules. The physician sets the [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and adjusts it over time. No milligram doses are published. 3. ## What the price includes A first-month offer is not a price on this site. InstaRX prints nothing else. One landing page shows $148 for month one, with $248 struck and $100 off. Another version of the page offers a different discount. The homepage shows no figure at all. No standing monthly rate is ranked until month two is published. 4. ## What it claims, and what it cites Both products are compounded by 503A pharmacies, per the FAQ. Compounded drugs are not FDA-approved. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: One stated price for either molecule - Strength: The rate is stated flat across doses - Strength: No membership fee and cancel anytime - Strength: Served in all 50 states and DC - Limitation: No month after the first is priced - Limitation: Month two's cost is not published - Limitation: The discount varies by landing page - Limitation: No oral form and no named pharmacy ## What the evidence says about this kind of treatment The assessment above is about InstaRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who may move to tirzepatide and wants one price throughout. Wrong for A buyer who needs a standing monthly rate before the intake. ## The evidence behind what InstaRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How InstaRX compares | Seller | Who it suits | Go | | --- | --- | --- | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | Ivim Health | Readers who want continuous clinician contact and will price both lines together | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Factor Health MD](https://thisglp.com/reviews/factor-health-md) [Fella Health](https://thisglp.com/reviews/fella-health) [Fidelity Medical Clinic](https://thisglp.com/reviews/fidelity-medical-clinic) [Fierce Health](https://thisglp.com/reviews/fierce-health) [Fifty 410](https://thisglp.com/reviews/fifty-410) [FitFlow](https://thisglp.com/reviews/fitflow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $148 the monthly price? No. It is labeled as the first month. What follows it is not published. Does tirzepatide cost more? No. InstaRX states one flat price for either molecule, at every dose. Where is InstaRX available? In all 50 states and the District of Columbia, per its FAQ. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Intimate Rose reviews (2026): GLP-1 telehealth sellers | This GLP One advertised floor covers both molecules, and the prescribing is done by a named clinician network. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/intimate-rose Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Provider picks, one floor # Intimate Rose review One advertised floor covers both molecules, and the prescribing is done by a named clinician network. ## The verdict Intimate Rose advertises GLP-1 treatment from $169 a month and says there are no memberships, no monthly fees and no price changes. The buyer does not choose a product. The provider picks compounded semaglutide or compounded tirzepatide, the form and the dose, and the page does not say which of those the $169 buys. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $169/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Intimate Rose is a pelvic-health products company, known for dilators and Kegel weights, that added a telehealth weight-loss program. Clinical care runs through OpenLoop Health, which the page names as its network of U.S.-licensed clinicians and state-licensed compounding pharmacies. Intimate Rose states it does not practice medicine, dispense medication or operate a pharmacy. Insurance is not accepted. 1. ## Who writes the prescription, and what do they see? An OpenLoop Health provider reviews an online assessment of about five minutes and prescribes only if treatment seems appropriate. That provider selects the molecule, the formulation and the dose from the health profile. Individual clinicians are not named. The page points to OpenLoop's terms of use for the full list of providers and pharmacies. The monthly price is stated to include provider oversight, medication, free delivery, and unlimited support and check-ins. The consent page describes a monthly subscription charged when the intake is completed. Cancellation needs 72 hours' notice before the billing date. A buyer found medically ineligible is refunded in full. Multi-month prepaid bundles are mentioned in the refund terms without a price. 2. ## What happens when the dose goes up? No dose ladder or milligram figure is published. The FAQ says medication may be taken by mouth daily or injected weekly, depending on what the provider prescribes. Plan adjustments are listed as included, and the banner promises no price changes. Whether that holds when the provider moves a patient up the ladder or from one molecule to the other is not stated. 3. ## What the price includes $169 a month is the only figure published, written as the floor treatment plans start from. It is not tied to a molecule, a form or a dose. Nothing on the page marks it as a first-month rate. A buyer learns the actual price of what is prescribed only after the provider has chosen it. 4. ## What it claims, and what it cites Both molecules are compounded by state-licensed pharmacies in OpenLoop's network. The page states compounded medications are not FDA-approved and were not evaluated by the FDA for safety, effectiveness or quality. It also says they are not generic versions of, or therapeutically equivalent to, the brand products. No pharmacy is named on the page itself. ## Where it holds up, and where it does not - Strength: The clinician network is named - Strength: No membership or monthly fee is stated - Strength: Full refund if medically ineligible - Strength: Check-ins and adjustments are included - Limitation: The buyer cannot choose a priced product - Limitation: The $169 floor is not tied to a molecule or dose - Limitation: No dose ladder is published - Limitation: Cancellation needs 72 hours' notice - Limitation: Insurance is not accepted ## What the evidence says about this kind of treatment The assessment above is about Intimate Rose. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who would rather a clinician choose the molecule and form than compare them. Wrong for A buyer who wants to know the price of a specific molecule and dose before the intake. ## The evidence behind what Intimate Rose prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Intimate Rose compares | Seller | Who it suits | Go | | --- | --- | --- | | ElleS | Buyers who want the prescribing physicians and pharmacies named before they pay | | | Luci | Readers who take an asterisk seriously and plan to ask what it hides | | | Good Life Meds | Readers escalating to a high dose who want the figure fixed across it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Fitness RX](https://thisglp.com/reviews/fitness-rx) [FitRx](https://thisglp.com/reviews/fitrx) [Fitstry](https://thisglp.com/reviews/fitstry) [FMmeds](https://thisglp.com/reviews/fmmeds) [FORM](https://thisglp.com/reviews/form) [FormBlends](https://thisglp.com/reviews/formblends) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the medication a pill or an injection? Either, depending on the prescription. The FAQ says oral options are taken daily and weekly injections are given in the abdomen, thigh or upper arm. Who prescribes? A provider in OpenLoop Health's network of U.S.-licensed clinicians. Intimate Rose states it does not practice medicine itself. What does $169 buy? It is the floor treatment plans start from. The page does not say which molecule, form or dose is priced at that figure. Is Intimate Rose expensive compared with other GLP-1 telehealth sellers? Intimate Rose publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Intimate Rose below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Invigor Medical reviews (2026): GLP-1 telehealth sellers | This GLP The plan pages say GLP-1 and GLP-1 + GIP. The checkout bills every four weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/invigor-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week billing, unnamed molecules # Invigor Medical review The plan pages say GLP-1 and GLP-1 + GIP. The checkout bills every four weeks. ## The verdict Invigor Medical's GLP-1 plan starts at $225. Its GLP-1 + GIP plan starts at $350. The checkout bills each amount every four weeks. That is thirteen charges a year, not twelve. In calendar months the cost is $244 and $379. Neither plan page names semaglutide or tirzepatide. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $244/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Invigor Medical now trades as Try Invigor, and its old domain forwards there. It sells compounded weight-loss medication beside testosterone, sexual-health and longevity treatments. The site states it is licensed in 50 states. It does not supply FDA-approved brand medications. 1. ## Who writes the prescription, and what do they see? The buyer chooses a plan and completes medical forms first. One of the site's doctors then contacts the buyer about health goals. The plan pages describe U.S. doctors prescribing online. No doctor or medical group is named. The checkout lists access to the prescribing doctor as needed. Each plan includes a prescription consultation, supplies and support from medical staff. A dedicated treatment specialist is assigned to each patient. The medication ships cold and must be refrigerated on arrival. The checkout lists no commitment. Partner pharmacies send every lot to a third-party lab for sterility, potency, endotoxin and pH testing. 2. ## What happens when the dose goes up? No dose ladder is published. Both prices are written "Starting at". The pages do not say whether the charge rises as the dose climbs. Clinicians are described as monitoring dosing and adjusting the plan as needed. The starting dose is not named. 3. ## What the price includes The GLP-1 plan is $225 per four-week fill. The GLP-1 + GIP plan is $350 per fill. Thirteen fills fall in a year. Per calendar month that is $244 and $379. No membership or consultation fee is added. Each plan page prints only its starting figure. 4. ## What it claims, and what it cites Every product is compounded by licensed 503A pharmacies, and the checkout notes a B vitamin is added. The site states compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness or manufacturing quality. The molecules are described by receptor, not by name. The pharmacies are not named. ## Where it holds up, and where it does not - Strength: Consultation and supplies are inside the price - Strength: Third-party lot testing is described by test - Strength: No commitment is required - Strength: A treatment specialist is assigned - Limitation: Billing runs every four weeks, not monthly - Limitation: Neither plan page names its molecule - Limitation: No dose ladder is published - Limitation: No doctor or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Invigor Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants no commitment and reads a four-week price as a four-week price. Wrong for A buyer who wants the molecule and dose named before checkout. ## The evidence behind what Invigor Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Invigor Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [FormidableMD](https://thisglp.com/reviews/formidablemd) [Framework](https://thisglp.com/reviews/framework) [Fresh Day Meds](https://thisglp.com/reviews/fresh-day) [Freya Meds](https://thisglp.com/reviews/freya-meds) [Fridays](https://thisglp.com/reviews/fridays) [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $225 a monthly price? No. The checkout bills it every four weeks, which is thirteen charges a year and $244 per calendar month. Which molecules are these? The pages say GLP-1 and GLP-1 + GIP. They do not name semaglutide or tirzepatide. Is there a contract? No. The checkout lists no commitments and flexible payments. Is Invigor Medical expensive compared with other GLP-1 telehealth sellers? Invigor Medical publishes a starting figure of $244/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Invigor Medical above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Invyncible reviews (2026): GLP-1 telehealth sellers | This GLP Every step up the dose ladder is a separate program with its own higher price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/invyncible Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Dearer at each dose step # Invyncible review Every step up the dose ladder is a separate program with its own higher price. ## The verdict Invyncible's lowest figures belong to its starting vials: $192.50 for the Starter semaglutide vial and $210 for the first tirzepatide program, which the page labels four weeks. The dose ladder is sold as a series of programs, each rung dearer than the last, so the figure that opens the first month is rarely the one a patient pays by the fourth. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 40 From From $192.50/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Invyncible is a telemedicine brand of Nationwide Telemedicine, based in St. Petersburg, Florida, and its weight-loss shelf carries compounded semaglutide in three formulas and compounded tirzepatide in two. The site states plainly that it does not compound, dispense or sell medication itself, and that prescriptions are filled by independent compounding pharmacies once a licensed provider has approved them. 1. ## Who writes the prescription, and what do they see? The sequence the page describes runs from an online intake to a provider consultation, where a licensed provider reviews the history, answers questions and decides whether semaglutide or tirzepatide is appropriate before a prescription goes to a pharmacy. The footer says the affiliated practices are independently owned and run by licensed physicians on the Nationwide Telemedicine platform, but no individual clinician or medical director is named on either product page. After approval the provider chooses the vial size and dosing pathway, and the page promises that providers remain available for check-ins and adjustments throughout treatment. Support runs Monday to Friday, nine to five Eastern, by phone, chat or email, and the site makes a point of saying a missed call gets a follow-up rather than silence. Nine states are excluded, and the lists differ slightly between the two products. 2. ## What happens when the dose goes up? This is where the programs matter most. A first tirzepatide fill at 2.5 mg a week is the $210 program, and the page offers five programs in all, climbing to 12.5 mg a week. The price rises at every step, until the top program costs roughly twice the first. Semaglutide works the same way through three vial sizes, the starter vial lasting about five weeks on the page's own example of 0.5 mg a week. A patient who titrates on schedule will cross into a dearer program within the first few months, and nothing on the page says whether a provider or the patient initiates that switch. 3. ## What the price includes Both headline figures sit beside a struck higher price, $275 for semaglutide and $300 for tirzepatide, with no end date attached, so the lower figures read as the current price rather than a promotion. Because each tirzepatide program covers four weeks rather than a calendar month, thirteen fills land in a year, which puts the $210 program at about $228 a month. Six months on the first program alone comes to $1,368, though few patients stay on the first program that long. 4. ## What it claims, and what it cites Every line is compounded, and the product page says outright that compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not FDA-approved and has not been reviewed by the FDA or any other regulator for safety, quality or effectiveness. The standard formulas contain the drug alone, and the alternatives add glycine or B12. The compounding pharmacy is not named. ## Where it holds up, and where it does not - Strength: Vial sizes and example doses are printed - Strength: Each program's price shows before intake - Strength: States it does not dispense medication itself - Strength: Human support by phone, chat or email - Limitation: Price rises at every dose step - Limitation: Tirzepatide programs cover four weeks, not months - Limitation: No clinician or medical director is named - Limitation: Nine states cannot be served - Limitation: The compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Invyncible. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants to see what each dose step will cost before the first fill. Wrong for A buyer looking for one flat monthly price that holds through titration. ## The evidence behind what Invyncible prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Invyncible compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Rehydra+ Wellness | Readers who want to price a full escalation before committing to a first dose | | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) [Gaya Wellness](https://thisglp.com/reviews/gaya-wellness) [Genesis Health](https://thisglp.com/reviews/genesis) [Get Thin MD](https://thisglp.com/reviews/get-thin-md) [GetRelief Rx](https://thisglp.com/reviews/getrelief-rx) [Gimme Care](https://thisglp.com/reviews/gimme-care) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price go up as the dose goes up? Yes. Each tirzepatide program is a larger weekly dose at a higher price, and the semaglutide vials are priced the same way, so the $210 and $192.50 figures cover the starting rungs only. Is $210 a monthly price? It buys a program the page labels four weeks, so a year of fills is thirteen charges rather than twelve, or about $228 a calendar month. Does Invyncible fill the prescription itself? No. The site says it provides telemedicine consultations and coordinates with licensed pharmacies, and that independent compounding pharmacies fill the prescriptions. Is Invyncible expensive compared with other GLP-1 telehealth sellers? Invyncible publishes a starting figure of $192.5/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Invyncible above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Iron Med RX reviews (2026): GLP-1 telehealth sellers | This GLP An injection from $149 and a tablet from $196, each printed under a list of three plan lengths that the page never matches to a price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/iron-med-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three plan lengths, one floor # Iron Med RX review An injection from $149 and a tablet from $196, each printed under a list of three plan lengths that the page never matches to a price. ## The verdict Iron Med RX prices its compounded semaglutide injection from $149 a month and its oral semaglutide tablets from $196, with each figure printed directly beneath a line offering monthly, three-month and six-month plans. Which of those lengths the figure belongs to is not stated anywhere before the intake, and the intake asks for a date of birth early on. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection · Oral Injection From $149/mo Oral From $196/mo Prescription Required Compounded Yes — not FDA-approved Iron Med RX, which also trades as IRON Rx, is a telehealth storefront whose weight-management shelf holds six GLP-1 lines, from semaglutide and tirzepatide injections to tablets of each and a lower-dose semaglutide microdosing protocol. Next to that shelf the same storefront sells peptides, NAD+ and other longevity products. 1. ## Who writes the prescription, and what do they see? A US-licensed provider reviews the health history and goals before anything is prescribed, and where a state requires it, a video consultation is added first. The seller says that call carries no extra cost and usually takes five to ten minutes, and it asks for a photo ID and a selfie to confirm age and identity. No clinician is named on the product pages. After the first shipment the model is a subscription, one the FAQ says can be paused or canceled at any time with no long-term commitment, and members keep unlimited provider messaging, refills and dose adjustments as the months go on. Iron Med RX does not take insurance directly, though the pages list HSA and FSA payment and free, discreet shipping. 2. ## What happens when the dose goes up? The pages promise dose guidance as the body responds, but they print no milligram figures and say nothing about whether the monthly charge changes when a starting dose is stepped up in the second or third month. That leaves the escalation weeks, when a dose is usually raised, with no stated price at all. 3. ## What the price includes Taken at face value, $149 a month comes to $894 across half a year of injections, and the tablet's $196 comes to $1,176 over the same stretch, a gap of $47 every month. Both figures read as starting points, though, and the plan list printed above them means either could be the six-month rung rather than a rate a buyer pays month to month. Until the intake shows the ladder, neither number can be treated as the no-commitment price. 4. ## What it claims, and what it cites Both products are compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review), prepared by pharmacy partners the seller describes as US-licensed and LegitScript-certified but does not name. A compounded preparation is not FDA-approved, and the FDA does not review it before it is dispensed. ## Where it holds up, and where it does not - Strength: Semaglutide as an injection or a tablet - Strength: Pause or cancel at any time, per the FAQ - Strength: Free, discreet shipping - Strength: Video visit, where required, at no extra cost - Limitation: Plan length behind each figure not stated - Limitation: No milligram doses on the product pages - Limitation: Pharmacy partners are not named - Limitation: Photo ID and a selfie are required ## What the evidence says about this kind of treatment The assessment above is about Iron Med RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone choosing between a semaglutide tablet and a shot who is willing to confirm the plan term during the intake. Wrong for Anyone who needs a month-to-month rate in writing before handing over a date of birth. ## The evidence behind what Iron Med RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Iron Med RX compares | Seller | Who it suits | Go | | --- | --- | --- | | Alan Meds | A reader ready to prepay six months who wants the full-dose price in view before the intake. | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | LifeMD | Readers with insurance that may cover the medication, leaving the fee as the main cost | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Go Vida Plena](https://thisglp.com/reviews/go-vida-plena) [GobyMeds](https://thisglp.com/reviews/gobymeds) [Goldspan Health](https://thisglp.com/reviews/goldspan-health) [Good Girl Rx](https://thisglp.com/reviews/good-girl-rx) [Good Life Meds](https://thisglp.com/reviews/good-life-meds) [GoodRx](https://thisglp.com/reviews/goodrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $149 require a longer plan? Possibly, since it is printed as the opening figure under a list of monthly, 3-month and 6-month plans, and nothing on the page ties it to one of them. Can I stop at any time? The FAQ describes the treatment as a subscription that can be paused or canceled at any time, with no long-term commitment attached to it. Does Iron Med RX take insurance? Not directly, although it accepts HSA and FSA payment and asks members to contact its support team about out-of-network reimbursement. Is Iron Med RX expensive compared with other GLP-1 telehealth sellers? Iron Med RX publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Iron Med RX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # iThriveMD reviews (2026): GLP-1 telehealth sellers | This GLP A clinic network in two states, with a flat price at every dose and a 28-day billing cycle. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ithrivemd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Clinic-led, flat by dose # iThriveMD review A clinic network in two states, with a flat price at every dose and a 28-day billing cycle. ## The verdict Two rates apply after the first charge: $299 for compounded semaglutide and $399 for compounded tirzepatide. The billing cycle is 28 days. At thirteen cycles a year, the calendar-month cost is about $324 and $432. Only patients in California and Arizona are eligible. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $324/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability California and Arizona iThriveMD runs longevity, hormone and weight-loss services. Its FAQ names eight clinic sites. Seven are in California and one is in Scottsdale. 1. ## Who writes the prescription, and what do they see? The process has four steps. A patient completes an online intake first. A clinical consultation follows, which includes a review of diagnostic labs. The clinic then builds a plan and starts treatment in clinic or at home. No individual prescriber is named on either product page. Treatment can be delivered in person or by telehealth. Home delivery is offered where eligible. The clinic states that it tracks progress and adjusts the plan. The first consultation is described as free. 2. ## What happens when the dose goes up? The price does not change with the dose. Both product pages state this in the FAQ. The dosing schedule is twice a week, not once. The clinic says this keeps medication levels steadier. Dose adjustments are described as managed by its medical team. 3. ## What the price includes Each Monthly card leads with a reduced first charge: $199 for semaglutide, $299 for tirzepatide. A footnote says the $100 reduction is used once. From the second cycle, the rates are $299 and $399. Prepaid packages run 12, 24 or 48 weeks and cost less per cycle. They are paid upfront and renew on their own. Semaglutide packages cut the rate by 10 to 20 percent. Tirzepatide packages cut it by 25 to 50 percent. 4. ## What it claims, and what it cites Both drugs are compounded preparations. A site footnote says compounded drugs have no FDA review or approval for safety or effectiveness. The site says a LegitScript-certified facility dispenses them. That facility is unnamed. ## Where it holds up, and where it does not - Strength: Dose increases do not raise the price - Strength: Standing rate printed beside the reduction - Strength: Clinic visits available beside home delivery - Strength: Lab review is part of the consultation - Limitation: Billing runs every 28 days - Limitation: Only California and Arizona are served - Limitation: No prescriber is named - Limitation: Packages auto-renew at their own interval ## What the evidence says about this kind of treatment The assessment above is about iThriveMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Californian or Arizonan who may want to walk into a clinic. Wrong for A patient outside those two states. ## The evidence behind what iThriveMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How iThriveMD compares | Seller | Who it suits | Go | | --- | --- | --- | | California Trim Clinic | Buyers who want a free call with a clinician, and a prescriber's name on the site, before paying anything | | | Concierge MD LA | Readers who want one number covering care and medication and can commit four months | | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) [Harper Meds](https://thisglp.com/reviews/harper-meds) [He & She MD](https://thisglp.com/reviews/he-and-she-md) [Heally](https://thisglp.com/reviews/heally) [HealthHub](https://thisglp.com/reviews/healthhub) [Healthicare](https://thisglp.com/reviews/healthicare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the first charge cost? $199 for semaglutide and $299 for tirzepatide. Each carries $100 off, once. After that the rates are $299 and $399. Does the price rise with the dose? No. Both product pages say the price holds at any dose. How often is the medication injected? Twice a week. The clinic uses a split schedule instead of one weekly dose. Where is care available? California and Arizona, at eight clinic locations or by telehealth. Is iThriveMD legit? iThriveMD is a GLP-1 telehealth sellers service. Its stated availability: California and Arizona. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is iThriveMD expensive compared with other GLP-1 telehealth sellers? iThriveMD publishes a starting figure of $324/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts iThriveMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ivim Health reviews (2026): GLP-1 telehealth sellers | This GLP Ivim charges for care and for the drug on separate lines, and says so on its own pricing page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ivim-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A membership, then a medicine # Ivim Health review Ivim charges for care and for the drug on separate lines, and says so on its own pricing page. ## The verdict Ivim is a membership practice that happens to prescribe GLP-1s, rather than a GLP-1 seller with care attached. The membership is billed monthly and the medication is billed beside it on a six-month commitment. The seller states that the medication figure varies with the treatment plan, which means there is no single number to compare against an all-in competitor. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved A clinic selling continuity rather than a product. Compounded semaglutide and tirzepatide are prescribed by injection, and an oral line is offered separately. The membership is the thing being sold and the prescription follows from it. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing, and the seller describes the clinician relationship at unusual length: unlimited visits, named care roles, and a patient experience team. It does not name individual prescribers. The membership covers unlimited provider visits, functional health coaches, a dedicated patient experience team, and a discount on supplements. That is a substantially larger care offering than most sellers this desk reads, and it is the reason the cost is structured in two parts rather than one. 2. ## What happens when the dose goes up? The seller states nothing about what the dose ladder does to the medication figure. That figure is already described as varying by treatment plan, so an escalation is one of several things that could move it. The membership half does not move. 3. ## What the price includes The structure is disclosed clearly and the arithmetic is left to the reader. A membership is charged monthly; the medication is charged separately, on a six-month footing, at a rate the seller describes as a starting point. Because that second figure is stated to vary by individualized treatment plan, this site publishes no ranked price for Ivim. Financing through Klarna is offered, which is itself a statement about the size of the commitment. 4. ## What it claims, and what it cites The injectable lines are compounded, prepared to order by a pharmacy rather than manufactured under an approved application. The FDA does not review a compounded preparation for safety, efficacy or quality before it is dispensed, and the seller does not name the pharmacy. The oral product is presented as an approved medicine, which is a different regulatory position and should not be read across. ## Where it holds up, and where it does not - Strength: The two-part cost is disclosed on the seller's own pricing page rather than after an intake - Strength: Unlimited provider visits and coaching are included in the membership rather than billed per visit - Strength: A published six-month rate exists, which many sellers withhold until an intake is complete - Limitation: The figure that travels off the site is the medication half, not the cost of treatment - Limitation: The medication rate is described as a starting point that varies by plan - Limitation: Both published medication rates are conditioned on a six-month commitment - Limitation: No pharmacy is named for the compounded lines ## What the evidence says about this kind of treatment The assessment above is about Ivim Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants continuous clinician contact and is willing to price the membership and the medication together before comparing. Wrong for A reader who needs one fixed monthly figure before committing to half a year. ## The evidence behind what Ivim Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ivim Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Hello Alpha | A reader set on brand Wegovy or Zepbound with a pharmacy quote already in hand | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Sesame Care | Readers who want tirzepatide priced by dose and will read the FAQ before the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Healthicare](https://thisglp.com/reviews/healthicare) [HealthOn](https://thisglp.com/reviews/healthon) [HealthSource](https://thisglp.com/reviews/healthsource) [HeliMeds](https://thisglp.com/reviews/helimeds) [HelloWellness](https://thisglp.com/reviews/hellowellness) [Henry Meds](https://thisglp.com/reviews/henry-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What stops Ivim from being ranked here? Its own footnote. Medication cost is stated to vary with the individualized treatment plan, so the medicine half is not a fixed rate. The half that is fixed buys care. What does the membership pay for? Unlimited provider visits, functional health coaches, a dedicated patient experience team and a supplement discount, according to the seller's own page. It does not pay for the medication. Are the medications compounded? The injectable semaglutide and tirzepatide are compounded. The oral line is presented as an approved product, which is a different regulatory footing. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ivologist reviews (2026): GLP-1 telehealth sellers | This GLP The paid-in-full plan runs eleven weeks and is priced as though a quarter had gone by. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ivologist Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A term shorter than its label # Ivologist review The paid-in-full plan runs eleven weeks and is priced as though a quarter had gone by. ## The verdict Ivologist runs its semaglutide program over eleven weeks and its tirzepatide program over twelve, then prints a monthly equivalent beside each that divides the total by three, which overstates how much treatment the money buys. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $149/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Availability 50 states Ivologist is a clinician-guided telehealth practice selling GLP-1 programs alongside hormone therapy and IV care, and its weight pages sell a fixed titration program rather than an open-ended monthly supply. 1. ## Who writes the prescription, and what do they see? Every program is described as overseen by board-certified licensed providers, with the dose adjusted to tolerance and clinical response rather than to a fixed protocol, and the price is stated to include the clinician review. That is a clearer commitment to supervision than most pages at this level make, even though no individual clinician is named. A buyer chooses between a subscription and a single payment for the whole program, and both routes include the medication, the supplies and the provider oversight. The program is bounded rather than rolling, so a patient reaches the end of it and has to decide again, which is a more honest shape than an auto-renewal even if it is less convenient. 2. ## What happens when the dose goes up? The semaglutide program is sold as a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) from 0.25mg to 0.75mg and the tirzepatide program from 2.5mg to 7.5mg, with the milligram range printed on the page, and that is the single most useful thing here. A buyer can see what the money buys in drug rather than in weeks, which is rare enough to be worth choosing a seller for. 3. ## What the price includes The subscription route is $124 for a first month and $149 thereafter on semaglutide, with tirzepatide at $249, and the paid-in-full route is $397 for the eleven-week semaglutide program. Eleven weeks is 2.53 calendar months, so $397 is $156.86 a month rather than the figure a division by three produces. The tirzepatide program behaves the same way across twelve weeks. 4. ## What it claims, and what it cites Both programs use compounded preparations rather than manufactured products, prepared by a pharmacy the practice does not name, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: Milligram ranges printed beside the price - Strength: Clinician oversight stated as included - Strength: A bounded program rather than an auto-renewal - Strength: Coverage stated across 50 states - Limitation: An eleven-week term priced as three months - Limitation: The printed monthly equivalent flatters the plan - Limitation: The whole program is paid before a first dose - Limitation: The compounding pharmacy goes unnamed ## What the evidence says about this kind of treatment The assessment above is about Ivologist. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who checks a printed monthly equivalent against the term it covers. Wrong for A buyer comparing the paid-in-full figure against another seller's calendar month. ## The evidence behind what Ivologist prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ivologist compares | Seller | Who it suits | Go | | --- | --- | --- | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | | Alegro Health | Buyers trying a GLP-1 for two months before committing to a rate | | | Queen RX | Buyers content to commit a quarter at a time in one payment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Henry Meds](https://thisglp.com/reviews/henry-meds) [Heros Health](https://thisglp.com/reviews/heros-health) [Hers](https://thisglp.com/reviews/hers) [Heva Health](https://thisglp.com/reviews/heva-health) [Hims](https://thisglp.com/reviews/hims) [Idgie Health](https://thisglp.com/reviews/idgie-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How long is the semaglutide program? Eleven weeks, which is 2.53 calendar months rather than a quarter. What does the paid-in-full plan really cost per month? $397 across eleven weeks is $156.86 a calendar month, above the equivalent printed beside it. What dose does the program cover? Semaglutide is titrated from 0.25mg to 0.75mg and tirzepatide from 2.5mg to 7.5mg, both printed on the product pages. Is Ivologist legit? Ivologist is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Ivologist expensive compared with other GLP-1 telehealth sellers? Ivologist publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ivologist below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ivy Rx reviews (2026): GLP-1 telehealth sellers | This GLP Every figure Ivy Rx prints is a floor, and the floor depends on which page a buyer lands on. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ivy-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Floors that change by page # Ivy Rx review Every figure Ivy Rx prints is a floor, and the floor depends on which page a buyer lands on. ## The verdict The Ivy Rx product page opens at $77 for four doses a month, covering both compounded molecules. Its paid landing pages print $77 or $97 for semaglutide, and $157 or $197 for tirzepatide. None of those is stated as a fixed rate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 Prescription Required Compounded Yes — not FDA-approved Ivy Rx is a telehealth seller of compounded semaglutide and tirzepatide, both as weekly injections. It also sells NAD+, sermorelin, glutathione and B12 injections. A lower-dose GLP-1 microdose line sits beside the full-dose one. 1. ## Who writes the prescription, and what do they see? The seller states that a physician reviews each questionnaire the same day. It describes its affiliated doctors as board-certified and US-licensed. The reviewing clinician is not named, and what the review covers is not stated. Labwork is described as not needed before a prescription. Care runs through a patient portal, where members message their providers. No insurance is required, and HSA or FSA cards are accepted. Shipping is described as free and temperature-controlled. Cancellation terms are not stated on the product page. 2. ## What happens when the dose goes up? The product page states the same price applies at every dose. On that statement, escalation carries no price step. The starting dose, the steps and the milligram amounts are not stated. Whether a floor marks a dose or a plan is not stated either. 3. ## What the price includes Four figures are published, and each one is a floor. Semaglutide pages print $77 on one ad channel and $97 on another. The tirzepatide landers show $157 and $197, again per four doses. No plan term is attached to any of them. Six months of either molecule cannot be priced from the site. 4. ## What it claims, and what it cites Both molecules are compounded preparations, not FDA-approved products. The seller says they are made in pharmacies meeting 503B and USP <797> standards. It also describes potency, sterility and endotoxin testing in FDA-registered labs. The pharmacy is not named. ## Where it holds up, and where it does not - Strength: Dose increases are stated not to raise the price - Strength: Potency and sterility testing described - Strength: No insurance and no labwork required - Strength: HSA and FSA cards accepted - Limitation: Every published figure is a floor - Limitation: Floors differ between ad landing pages - Limitation: No plan term attached to any figure - Limitation: Compounding pharmacy not named ## What the evidence says about this kind of treatment The assessment above is about Ivy Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a stated flat price across doses and will see the actual rate at checkout. Wrong for A reader comparing standing monthly rates before starting a questionnaire. ## The evidence behind what Ivy Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ivy Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | NiceRx | Buyers who want one flat monthly rate per molecule, whatever the dose | | | Sprout Health | Readers taking the six-month plan, which is the one measured in calendar months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Immortals](https://thisglp.com/reviews/immortals) [Independent Wellness](https://thisglp.com/reviews/independent-wellness) [Injectco](https://thisglp.com/reviews/injectco) [InstaRX](https://thisglp.com/reviews/instarx) [Intimate Rose](https://thisglp.com/reviews/intimate-rose) [Invigor Medical](https://thisglp.com/reviews/invigor-medical) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $77 buy? The page labels it as four doses a month. Whether that is a starting dose or a plan rate is not stated. Is tirzepatide priced separately? Its landing pages print their own floors, $157 and $197, each per four doses. The main product page shows $77 for both molecules. Is bloodwork required? No. The product page states that labwork is not needed. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Jently reviews (2026): GLP-1 telehealth sellers | This GLP A New York telehealth platform that names its compounding pharmacy and opens on a no-commitment month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/jently Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Named pharmacy, month to month # Jently review A New York telehealth platform that names its compounding pharmacy and opens on a no-commitment month. ## The verdict Jently sells compounded semaglutide at $199 and compounded tirzepatide at $259 for a single month, the tab each product page opens on, and it names the pharmacy that makes both. The lower figures on its homepage belong to prepaid terms, and a reader who plans a year from those cards will be planning around a lump-sum commitment rather than a monthly bill. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Jently is a New York-based telehealth platform whose shelf runs from compounded semaglutide and tirzepatide injections to NAD+, sermorelin, glutathione and metformin. It describes itself as a platform that arranges clinical evaluations rather than a pharmacy or a manufacturer, and every weight-management page carries the same disclosure about who makes the medication. 1. ## Who writes the prescription, and what do they see? Clinical care runs through a partnership with MD Integrations and its network of licensed providers, and the page says every clinician is a licensed physician practicing within the patient's state. A provider reviews the intake and decides whether any prescription is written at all; the page is careful to say that completing the assessment does not guarantee medication. No individual physician is named. The path is an online intake, a provider review, a prescription decision and then shipment from the pharmacy, with follow-up support described as ongoing so a provider can adjust treatment. Card details are collected during the questionnaire, but the refund policy says payment is taken only after a provider approves. A subscription can be paused for up to sixty days without penalty, and lost or damaged shipments are reshipped at no charge. 2. ## What happens when the dose goes up? Neither product page prints a dose or says whether the monthly figure changes as the dose climbs, so a patient moving up the ladder in month three cannot tell from the page whether the $199 still holds. The page says only that the provider sets an individualized plan and adjusts it during follow-up. That leaves the costliest question of the first four months unanswered in writing, and it is the one worth asking before the first fill. 3. ## What the price includes Each product page offers four tabs, one, three, six and twelve months, and opens on the single month, billed as a one-time purchase with free cold-chain shipping. The three prepaid tabs are labeled as a founding-member price lock and are each charged as one lump sum. A consultation fee is stated as included in the monthly figure. Three single months of semaglutide come to $597, and six months of tirzepatide to $1,554. 4. ## What it claims, and what it cites Both lines are compounded by Precision Compounding Pharmacy in Bellmore, New York, which the page describes as a state-licensed 503A pharmacy. Jently states that compounded drugs are not FDA-approved and that the FDA does not review them for safety, effectiveness or quality. ## Where it holds up, and where it does not - Strength: The compounding pharmacy is named with its address - Strength: Opens on a no-commitment single month - Strength: Payment taken only after provider approval - Strength: Subscriptions can pause for sixty days - Limitation: No dose is printed on either page - Limitation: Dose-step pricing is not stated - Limitation: Homepage cards show the twelve-month equivalent - Limitation: No refund once a consultation is completed ## What the evidence says about this kind of treatment The assessment above is about Jently. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants to know which pharmacy compounds the medication before paying for it. Wrong for A buyer who needs the price at each dose step written down in advance. ## The evidence behind what Jently prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Jently compares | Seller | Who it suits | Go | | --- | --- | --- | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Invigor Medical](https://thisglp.com/reviews/invigor-medical) [Invyncible](https://thisglp.com/reviews/invyncible) [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) [iThriveMD](https://thisglp.com/reviews/ithrivemd) [Ivim Health](https://thisglp.com/reviews/ivim-health) [Ivologist](https://thisglp.com/reviews/ivologist) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does the homepage show a lower price? The homepage cards quote the twelve-month prepaid rung. The single-month tab each product page opens on is $199 for semaglutide and $259 for tirzepatide. Who makes the medication? Precision Compounding Pharmacy in Bellmore, New York, which the page describes as a state-licensed 503A compounding pharmacy. Can I get a refund? Only before a consultation is completed or a prescription is dispensed, and the request must be made within 24 hours of the order. Is Jently expensive compared with other GLP-1 telehealth sellers? Jently publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Jently above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # JM Integrated Health reviews (2026): GLP-1 telehealth sellers | This GLP JM Integrated Health makes the cost boundary clear: its program fee pays for care, while the pharmacy charges separately for medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/jm-integrated-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A named nurse-practitioner-led program with separate clinical and medication charges, baseline laboratory work and monthly follow-up options. # JM Integrated Health review JM Integrated Health makes the cost boundary clear: its program fee pays for care, while the pharmacy charges separately for medication. ## The verdict The named clinical lead, initial lab inclusion and defined monthly follow-up are useful disclosures. Compare the full care-plus-pharmacy cost and confirm treatment availability in your state before enrolling. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Liraglutide Form Injection States 8 Prescription Required Compounded Yes — not FDA-approved JM Integrated Health provides virtual medical care, including a weight-management program alongside primary and urgent care. The program combines clinical assessment, nutrition and lifestyle guidance, and prescription treatment when appropriate. 1. ## Who writes the prescription, and what do they see? The weight-loss page identifies John Meyer, FNP-C, as a family nurse practitioner. It lists eight service states. Those are the practice’s published credentials and coverage claims, not an independent license verification; confirm the assigned provider and current eligibility. Enrollment includes provider evaluation, baseline labs and a treatment plan. Ongoing program fees cover visits, monitoring and support; the structured three-month option specifies three monthly follow-ups. Ask how between-visit medication questions are handled. 2. ## What happens when the dose goes up? The program describes individualized adjustments rather than a fixed public dose ladder. A clinician reviews response and treatment needs. Confirm whether new tests or an additional pharmacy order are required when a prescription changes. 3. ## What the price includes Enrollment and ongoing care have separate charges, and medication is explicitly excluded. The page says a compounding pharmacy contacts the patient for payment when that route is prescribed. A free introductory consultation does not make the later evaluation and treatment free. 4. ## What it claims, and what it cites The menu names compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) injections, plus branded Wegovy, Zepbound, Ozempic, Mounjaro and Saxenda as possible options. Oral therapies are mentioned without specific ingredients. The clinician determines which, if any, is appropriate. ## Where it holds up, and where it does not - Strength: Names the clinical lead - Strength: Specifies baseline labs and monthly follow-up options - Limitation: Medication cost requires a separate quote - Limitation: Service is limited to listed states ## What the evidence says about this kind of treatment The assessment above is about JM Integrated Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults in a listed service state who want identified clinical leadership and a structured follow-up plan. Wrong for Anyone interpreting the program fee as an all-in medication price or assuming that a listed branded option is automatically covered by insurance. ## The evidence behind what JM Integrated Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How JM Integrated Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Joey Med](https://thisglp.com/reviews/joey-med) [Joi + Blokes](https://thisglp.com/reviews/joi-and-blokes) [JRNYS](https://thisglp.com/reviews/jrnys) [JumpstartMD](https://thisglp.com/reviews/jumpstartmd) [June Health](https://thisglp.com/reviews/june-health) [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is medication included in the care program? No. The program explicitly excludes medication. When a compound is prescribed, a pharmacy contacts the patient directly for payment. What does the three-month option provide? The page specifies three monthly follow-up visits. Confirm the ongoing monitoring and any additional testing for your treatment. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://www.jmintegratedhealth.com/medical-weight-loss) - [Official program and terms](https://www.jmintegratedhealth.com/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Joey Med reviews (2026): GLP-1 telehealth sellers | This GLP Two GLP-1 plans priced per four weeks, with the drug in each named only on the hub page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/joey-med Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week plans, molecule unnamed # Joey Med review Two GLP-1 plans priced per four weeks, with the drug in each named only on the hub page. ## The verdict Joey Med's GLP-1 Core costs $199 and GLP-1 Plus Core costs $275, and each charge buys a four-week fill. Thirteen fills a year put the calendar-month cost near $216 for Core and $298 for Plus Core. Only the weight-loss hub says which drug each plan contains. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $216/mo Dose published No Prescription Required Availability All 50 states Joey Med is a cash-pay telehealth platform in Florida, run by MD Telehealth Platform LLC, whose catalog covers weight, sexual health, wellness and hair. Its GLP-1 shelf has three plans, Core, Plus Core and a high-dose Plus Core, and it says it ships to every state. 1. ## Who writes the prescription, and what do they see? The site says every consultation is with a board-certified U.S. provider, who reviews an online intake and prescribes only if clinically appropriate. The refund policy puts that chart review at five to seven business days, though no provider is named anywhere on the weight-loss pages. Core is described as weekly injections with clinician-guided check-ins, and Plus Core as the same program with extra provider check-ins and coaching on lifestyle. How often those check-ins happen is not stated. Once a prescription is written, medication is described as shipping within two days. 2. ## What happens when the dose goes up? The Core page tells a patient to begin on a starter dose and then follow a provider-guided [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule, but no milligram figure appears at any step. Whether the four-week price changes as the dose rises is not stated. A separate high-dose Plus Core plan costs more than the standard one, so the top of the tirzepatide ladder is priced differently. 3. ## What the price includes Each figure sits beside a struck higher price, and neither anchor carries an end date, so the lower figure reads as the current price. The four-week plan is the default selection on each page, and longer prepaid blocks, out to twelve months, appear in the plan menu. A banner offers up to ten percent off through a chat with the team, with no terms printed. 4. ## What it claims, and what it cites [Semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are named on the weight-loss hub, and a homepage answer describes Plus Core as a dual-action formulation. Neither the product pages nor the hub say whether a plan is compounded or brand-name. A compounded preparation would not be FDA-approved, and the dispensing pharmacy is called licensed but left unnamed. ## Where it holds up, and where it does not - Strength: A price is shown for every plan - Strength: The refund policy is published in full - Strength: Ships to every U.S. state - Strength: Plus Core includes extra provider check-ins - Limitation: The drug is unnamed on product pages - Limitation: Each charge buys four weeks - Limitation: Compounded or brand-name is never said - Limitation: No milligram dose appears anywhere ## What the evidence says about this kind of treatment The assessment above is about Joey Med. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who already knows which molecule they want and budgets in four-week fills. Wrong for A patient who wants the drug and its source named on the page they buy from. ## The evidence behind what Joey Med prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Joey Med compares | Seller | Who it suits | Go | | --- | --- | --- | | VevaRX | Buyers who will read a product page twice before believing the number on the card | | | GobyMeds | A reader who wants a monthly price that holds at any dose, with a cheaper starter bundle as the alternative | | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) [Jyra Health](https://thisglp.com/reviews/jyra-health) [KERNX Health](https://thisglp.com/reviews/kernx-health) [Kin Meds](https://thisglp.com/reviews/kin-meds) [Kina](https://thisglp.com/reviews/kina) [Knownwell](https://thisglp.com/reviews/knownwell) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which drug is in GLP-1 Core? The weight-loss hub lists Core as semaglutide and Plus Core as tirzepatide. On the product pages, only the GLP-1 label is used. What does $199 buy? Four weeks of Core. Over thirteen fills a year, the calendar-month cost is near $216. What happens to a refund once medication ships? The policy withholds a shipping charge and a $199 practitioner consultation fee. On an entry-level order, that leaves little or nothing to refund. Is Joey Med legit? Joey Med is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Joey Med expensive compared with other GLP-1 telehealth sellers? Joey Med publishes a starting figure of $216/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Joey Med above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Joi + Blokes reviews (2026): GLP-1 telehealth sellers | This GLP The card prints the introductory rate and the standing one in the same line. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/joi-and-blokes Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 First month, then quarterly # Joi + Blokes review The card prints the introductory rate and the standing one in the same line. ## The verdict Joi + Blokes writes the whole thing on the card: $179 a month, with $99 for the first month, billed quarterly. Tirzepatide runs the same shape at $149 and $249. The second charge is a quarter at the standing rate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $179/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Joi + Blokes sells a compounded GLP-1 containing semaglutide and a compounded GLP-1 and GIP containing tirzepatide. Both are weekly injections. Health coaching and functional labs sit alongside them. 1. ## Who writes the prescription, and what do they see? A partner clinician reviews the health history and decides whether a compounded GLP-1 is appropriate. Consults can be scheduled rather than left to a form. Labs are offered but not required, so the clinician may be writing without them. Plans are billed quarterly and include medication, dosing support, clinician access and unlimited health coach visits. There is no membership fee beside the plan. The site states that a plan can be adjusted or canceled at any time. 2. ## What happens when the dose goes up? Nothing on the product page ties the rate to a dose, and no milligram figure is published. Dosing support is named as part of the plan. A step taken mid-quarter sits inside a term already charged. 3. ## What the price includes Semaglutide is $99 for the first month and $179 a month after it. Tirzepatide is $149 and then $249. Because billing is quarterly, the introductory saving lands once and the next charge covers three months at the full rate. 4. ## What it claims, and what it cites Both lines are compounded and dispensed through US-licensed pharmacies. The site states that compounded medications are not evaluated by the FDA for safety, quality or efficacy. It also names the brands it is not selling. ## Where it holds up, and where it does not - Strength: Month two onward is printed on the same card as the offer - Strength: Unlimited health coach visits are included - Strength: No membership fee - Strength: Compounded status is stated in plain words - Strength: Cancellation is described as open-ended - Limitation: Billing is quarterly, so month two is a three-month charge - Limitation: The advertised figure buys one month - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published ## What the evidence says about this kind of treatment The assessment above is about Joi + Blokes. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer budgeting by the quarter rather than the first fill. Wrong for A buyer comparing $99 against another seller's standing rate. ## The evidence behind what Joi + Blokes prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Joi + Blokes compares | Seller | Who it suits | Go | | --- | --- | --- | | Vita Bella | Buyers who will use the wider catalog the membership unlocks rather than a GLP-1 alone | | | Elara Health and Wellness | Buyers who want labs and coaching inside the price and can read a thirteen-month prepay for what it is | | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Kongo](https://thisglp.com/reviews/kongo) [LaSara Medical Group](https://thisglp.com/reviews/lasara) [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) [Layla](https://thisglp.com/reviews/layla) [Lean Meds](https://thisglp.com/reviews/leanmeds) [Lean Rx](https://thisglp.com/reviews/lean-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How long does the $99 last? One month. The same card reads $179 a month after that, and the plan is billed quarterly. Is there a membership fee on top? There is none. Joi + Blokes states that a plan can be adjusted or canceled at any time. Are labs required before a prescription? No. Labs are offered for people who want them, and the site describes them as optional rather than a condition. Is Joi + Blokes expensive compared with other GLP-1 telehealth sellers? Joi + Blokes publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Joi + Blokes below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # JRNYS reviews (2026): GLP-1 telehealth sellers | This GLP A coaching membership with a published price, and brand-name drugs priced after a consultation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/jrnys Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership priced, drug later # JRNYS review A coaching membership with a published price, and brand-name drugs priced after a consultation. ## The verdict JRNYS sells a membership from $89 to $169 a month. The drug is billed separately. Its price is confirmed only after a provider consultation. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Prescription Required JRNYS is a telemedicine platform for weight loss, longevity and sexual health. Its weight-loss catalog lists Ozempic, Mounjaro, Zepbound and Wegovy. It also lists a compounded tirzepatide microdose, sold as cash pay. Membership tiers differ by the amount of one-to-one coaching. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the intake within 24 hours. No office visit is required. The site names its founding chief medical officer. The clinician who prescribes for a given member is not named. Members weigh in at least three times a week. Coaching sessions run every two weeks, for 20 minutes. The membership covers medical visits, daily monitoring and coaching. Follow-up messages to a provider are free. Programs follow six- and twelve-month curriculums. 2. ## What happens when the dose goes up? Each member gets a custom protocol. No dose schedule is published. Medication is priced after the consultation, so no price per dose step is stated. Membership tiers are set by coaching level, not by dose. 3. ## What the price includes A membership fee is not a medication price on this site. JRNYS publishes the membership only. The drug cost depends on the prescription and on insurance. JRNYS sends prescriptions and helps with prior authorizations. It does not bill insurance; the pharmacy does. A site banner offers a code for half off the first month of membership. No medication figure is ranked here. 4. ## What it claims, and what it cites [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review), Mounjaro, Zepbound and Wegovy are FDA-approved brand products. The site notes that Ozempic and Mounjaro are approved for type 2 diabetes. Weight-loss use of those two is off-label. The tirzepatide microdose is compounded and is not FDA-approved. ## Where it holds up, and where it does not - Strength: Membership tiers are published - Strength: Provider review within 24 hours - Strength: Weigh-ins and coaching built into the plan - Strength: Insurance navigation offered to members - Limitation: No medication figure published - Limitation: Drug cost depends on coverage - Limitation: Membership billed on top of the drug - Limitation: Weigh-ins required three times a week ## What the evidence says about this kind of treatment The assessment above is about JRNYS. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer with insurance coverage who wants coaching alongside a brand-name GLP-1. Wrong for A cash buyer who needs the medication price before joining. ## The evidence behind what JRNYS prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How JRNYS compares | Seller | Who it suits | Go | | --- | --- | --- | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Knownwell | Insured patients who want ongoing care from one obesity-medicine clinician | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LevelsRx](https://thisglp.com/reviews/levelsrx) [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) [Levers Health](https://thisglp.com/reviews/levers-health) [Liberty](https://thisglp.com/reviews/liberty) [LifeMD](https://thisglp.com/reviews/lifemd) [LifeRx.md](https://thisglp.com/reviews/liferx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the drug inside the $89? No. Membership starts at $89 a month. The drug is priced on its own, after the consultation. What decides the $169 tier? The level of one-to-one coach support. Visits, monitoring and coaching sit in the base price. Is anything compounded? One line is. A compounded tirzepatide microdose is sold as cash pay. The rest of the catalog is brand. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # JumpstartMD reviews (2026): GLP-1 telehealth sellers | This GLP A California clinic network that prices the act of joining and leaves the medication to be priced after the clinician visit. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/jumpstartmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Fourteen clinics, one start fee # JumpstartMD review A California clinic network that prices the act of joining and leaves the medication to be priced after the clinician visit. ## The verdict JumpstartMD advertises a $379 program start with a limited-time discount beside it, and that start fee is all the public site prices, because the medication itself carries no published figure anywhere. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 1 Prescription Required Pharmacy Named Availability California only JumpstartMD is a medical weight-loss practice with fourteen California locations and online visits for California residents, and it also runs menopause, low-testosterone and vitamin therapy programs out of the same clinics. Its GLP-1 shelf names Wegovy, oral Wegovy, Zepbound, Ozempic and Mounjaro, and the FAQ adds that compounded prescriptions can be filled through a partner pharmacy when a provider judges them appropriate. 1. ## Who writes the prescription, and what do they see? The first visit is with a health coach who collects biometrics, and only after laboratory work does a member sit down with a clinician, who discusses medication options and may prescribe if the member is a candidate. Later visits alternate between clinicians and health coaches, and the practice suggests weekly visits, which it calls the route to optimal results. Most of the model is the visit itself: the practice suggests seeing a clinician or coach every week, prices membership by how often a member meets the team, and takes payment at the time of service. A PPO member with out-of-network benefits who attends at least two weekly visits a month can have claims filed on their behalf, though reimbursement is not guaranteed and HMO and Medicare plans are excluded. 2. ## What happens when the dose goes up? Dose changes happen at the weekly or near-weekly visits where the team fine-tunes the program and adjusts medication, which puts a person in front of every step up through the escalation months. What those steps cost is another matter, because medication is billed apart from the membership and its price is never published. 3. ## What the price includes The $379 start fee is the regular figure and the discounted one changes as offers run, so neither is a rate for treatment. Medication costs are not included in membership fees, in the FAQ's own words, and membership pricing itself depends on visit frequency, so a buyer cannot price six months of care from the site. For a Californian with a PPO the out-of-network claims service may bring some of that back, but the practice guarantees no amount. 4. ## What it claims, and what it cites The brand products are FDA-approved, with [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) and Mounjaro approved for type 2 diabetes rather than weight loss, while the compounded prescriptions filled through PerfectRx are not FDA-approved or reviewed by the FDA before dispensing. Which of the two a member receives is decided by the clinician after the visit. ## Where it holds up, and where it does not - Strength: Face-to-face care at fourteen California clinics - Strength: Compounding pharmacy partner named in the FAQ - Strength: Brand and compounded options both offered - Strength: Out-of-network claims filed for PPO members - Limitation: Medication is priced only after joining - Limitation: Membership price depends on visit frequency - Limitation: California residents only - Limitation: The start-fee discount changes with the offer ## What the evidence says about this kind of treatment The assessment above is about JumpstartMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Californian who wants weekly in-person check-ins while starting a GLP-1, and who has a PPO or the budget to pay per visit. Wrong for Anyone outside California, or a buyer who needs a monthly medication figure before booking a first visit. ## The evidence behind what JumpstartMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How JumpstartMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | | California Trim Clinic | Buyers who want a free call with a clinician, and a prescriber's name on the site, before paying anything | | | Knownwell | Insured patients who want ongoing care from one obesity-medicine clinician | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LifespanningRx](https://thisglp.com/reviews/lifespanningrx) [LillyDirect Foundayo](https://thisglp.com/reviews/lillydirect-foundayo) [Liv Body](https://thisglp.com/reviews/liv-body) [LIV by WellNow](https://thisglp.com/reviews/liv-by-wellnow) [Livea](https://thisglp.com/reviews/livea) [50 Stars Health](https://thisglp.com/reviews/livv) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $379 the monthly cost? No, it is the fee to start the program, shown against a limited-time discount, and the medication is billed separately at a price the site does not publish. Does JumpstartMD prescribe compounded GLP-1s? It can, since the FAQ says compounded prescriptions are filled through its partner pharmacy, PerfectRx, when a provider decides one is appropriate, alongside brand-name options. Can insurance help with the cost? PPO members with out-of-network benefits can have claims filed for program costs if they attend at least two visits a month, with reimbursement paid to the member and never guaranteed. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # June Health reviews (2026): GLP-1 telehealth sellers | This GLP Each line publishes its whole tier structure, and the milligram doses are stated on the oral ones. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/june-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Ladders published in full # June Health review Each line publishes its whole tier structure, and the milligram doses are stated on the oral ones. ## The verdict June Health answers the question almost every seller leaves open. It does not merely say the price rises with the dose; it prints the dose and the price at each step, on all four lines. That turns the escalation from something a buyer discovers into something they can read before enrolling. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose From From $187/mo Prescription Required Compounded Yes — not FDA-approved June Health sells compounded semaglutide and compounded tirzepatide in injected and oral forms. The injections are supplied in solution with either vitamin B12 or glycine. Every line is priced as a published ladder rather than a single figure. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely and a prescription precedes dispensing. The pages state doses and tiers rather than describing the clinician, and the intake is not documented. What is documented is the schedule of prices a prescriber's decisions will move a buyer along. Publishing the ladder is the distinguishing act. Most sellers state that a price scales with the dose; June Health states what it scales to, which is the version a reader can plan against. The additives are part of the formulation rather than an extra charge, and they are not separately priced. 2. ## What happens when the dose goes up? This is the seller's strongest disclosure. The oral semaglutide ladder runs from 1mg with 10mg pyridoxine at $187 up to 24mg at $329. A buyer can see both the dose and the cost at each step before enrolling. The injected lines carry five and six tiers on the same basis. What is not stated is how quickly a prescriber moves between them. 3. ## What the price includes The advertised number is the bottom of a ladder, and the ladder is printed, which is the whole point. On the oral semaglutide line a reader looking only at the opening tier is well below where the line finishes, and can see exactly how far. The injected lines run five and six tiers on the same basis. What is not published is how quickly a prescriber moves a patient between them, which is the remaining unknown. 4. ## What it claims, and what it cites Every line is a compounded preparation. Nothing here has been through FDA review for safety or quality, because compounding sits outside that process. The injections are formulated with B12 or glycine and the oral [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) with pyridoxine — combinations the approved products do not use, and whose effect on absorption is not stated. ## Where it holds up, and where it does not - Strength: Dose and price appear together at each tier - Strength: The ladder is printed rather than described - Strength: Formulation additives are disclosed - Limitation: The advertised figure is the bottom rung - Limitation: The top rung is far above the headline - Limitation: What the additives do is unexplained - Limitation: Coverage is nowhere enumerated ## What the evidence says about this kind of treatment The assessment above is about June Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the escalation priced before enrolling rather than met in month three. Wrong for A reader who needs a rate that holds at every dose. ## The evidence behind what June Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How June Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Bioverse | Readers who want semaglutide cheaply and ignore the struck figure beside it | | | Wholesome Clinic | A reader who wants to see what a higher dose costs before starting, rather than discovering it in month three. | | | Lttl | Readers who want every prepay rung visible and know which dose line they need | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [50 Stars Health](https://thisglp.com/reviews/livv) [Longevixx](https://thisglp.com/reviews/longevixx) [Loop Health](https://thisglp.com/reviews/loop-health) [LovelyMeds](https://thisglp.com/reviews/lovelymeds) [Luci](https://thisglp.com/reviews/luci) [Luma Health Co](https://thisglp.com/reviews/luma-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the oral semaglutide cost at a higher dose? The pages print every tier with its milligram dose, from the 1mg opening rung up to the 24mg top one. What are B12 and glycine doing in the injection? That is how June Health formulates them. The approved products do not use those combinations, and what they do to absorption is not stated. Is $179 a monthly cost? At the opening tier only. The published ladder is what shows a reader how far that assumption travels before it stops holding. Is June Health expensive compared with other GLP-1 telehealth sellers? June Health publishes a starting figure of $187/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts June Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # JustAnswer Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP Both published figures are annual-plan rates, and the monthly plan is priced behind a sign-up form. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/justanswer-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Annual-plan rates only # JustAnswer Weight Loss review Both published figures are annual-plan rates, and the monthly plan is priced behind a sign-up form. ## The verdict JustAnswer Weight Loss prints $112.49 a month for compounded semaglutide and $195.82 for compounded tirzepatide. Both figures are marked as applying with an annual plan. A no-commitment rate is not published before the questionnaire asks for contact details. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved The weight-loss service is a branch of JustAnswer, which also runs a pharmacy for other conditions. It sells both molecules compounded, by injection. Delivery is free and comes from its accredited pharmacies. 1. ## Who writes the prescription, and what do they see? A licensed physician holds an online consultation after a five-minute health questionnaire. The page says medication is issued only when clinically appropriate. State rules are cited for a selfie and photo ID check. The physician is not named. The service is remote, with an online platform for tracking progress and managing refills. An online consultation is listed as included in both plans. A subscription can be canceled from the account before the next shipment. Refunds are not given once medication is dispensed. 2. ## What happens when the dose goes up? The product pages say physicians monitor progress and adjust the dose as needed. No dose ladder is published. Whether the monthly charge changes with dose is not stated. 3. ## What the price includes The two figures are rates for a twelve-month commitment. A year of semaglutide at that rate is $1,349.88; tirzepatide is $2,349.84. The difference between the molecules is $83.33 a month. A monthly plan exists, but its price appears only after the questionnaire asks for name, email and phone. A commitment rate is not treated as a monthly price here. 4. ## What it claims, and what it cites Both lines are compounded, so they are not FDA-approved and not reviewed by the FDA for safety, effectiveness or quality. The seller prints that statement on every product page. The compounding pharmacy is not named. ## Where it holds up, and where it does not - Strength: Both molecules carry a published figure - Strength: Online consultation included in both plans - Strength: Free delivery from accredited pharmacies - Strength: The seller prints its own compounding disclaimer - Limitation: Both figures need an annual plan - Limitation: Monthly plan priced only after contact details - Limitation: All sales final once dispensed - Limitation: Compounding pharmacy not named ## What the evidence says about this kind of treatment The assessment above is about JustAnswer Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit a year who wants the per-month figure before starting. Wrong for A reader who wants to try a single month before committing. ## The evidence behind what JustAnswer Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How JustAnswer Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | Woodwork | Readers ready to commit forty-eight weeks who read asterisks | | | Hims | Buyers set on brand Wegovy or Zepbound who accept a monthly membership on top | | | Lemonaid Health | Readers who want named clinicians and a price that holds through dose changes | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Luma Meds](https://thisglp.com/reviews/luma-meds) [Lumen Meds](https://thisglp.com/reviews/lumen-meds) [LumiMeds](https://thisglp.com/reviews/lumimeds) [Lumora](https://thisglp.com/reviews/lumora) [LunaRx](https://thisglp.com/reviews/lunarx-health) [LVNG RX](https://thisglp.com/reviews/lvng-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Do the published prices need a commitment? Yes. The $112.49 and $195.82 figures apply to a twelve-month plan. The monthly plan's price is not shown on the public pages. Can I get a refund? Not for dispensed medication. The pharmacy terms say sales are final once an order ships. A subscription can be canceled before that. How much more is tirzepatide? On the annual plan it is $83.33 a month more than semaglutide. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Jyra Health reviews (2026): GLP-1 telehealth sellers | This GLP A flat price that holds through every dose step, from a seller that names all three of its pharmacies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/jyra-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat by dose, three pharmacies named # Jyra Health review A flat price that holds through every dose step, from a seller that names all three of its pharmacies. ## The verdict Jyra Health charges $169 for a month of compounded semaglutide and $229 for tirzepatide, and its FAQ promises that neither figure moves as the dose climbs or the plan renews. The product page opens on a cheaper three-month card paid in one charge, which is worth recognizing as a prepayment before it is read as the monthly rate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $169/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Jyra Health is an online clinic selling compounded semaglutide and tirzepatide injections alongside a small longevity shelf of NAD+, sermorelin and glutathione. It bills no insurance and charges no membership, and every plan is described as including the consultation, the prescription and free express shipping. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the intake questionnaire and decides whether to prescribe, and the site says most approvals come within about a day and that providers are licensed in all 50 states. The initial consultation is free, and if the provider decides a patient is not eligible, no medication is charged. Individual prescribers are not named. Once approved, the medication ships in a kit with the vial, syringes, alcohol pads, a sharps container and written dosing instructions, and the page says the provider stays available for support as the dose is adjusted. Cancellation can happen at any time and takes effect at the end of the paid period. A subscription can be paused for up to three months. 2. ## What happens when the dose goes up? This is the part Jyra answers more directly than most. Its FAQ says the price stays the same at every dose and at every renewal, so the month a provider moves a patient up the ladder costs the same as the month before it. What the page does not print is a milligram schedule, so a patient learns the doses only from the provider after approval. 3. ## What the price includes The semaglutide page pre-selects a three-month plan at $99 a month, billed as a single $297 charge, and the one-month plan beside it is $169. Tirzepatide follows the same pattern, $133 a month on three months billed as $399, or $229 for a single month. A patient who wants to stop after one month pays the higher figure, which is the only rate that carries no commitment. 4. ## What it claims, and what it cites Both injections are compounded, and the site states that compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. The FAQ names three pharmacy partners with their addresses: VialsRX in Houston, White Label Pharmacy in Katy, Texas, and Hallandale Pharmacy Compounding in Fort Lauderdale, two of which list states they cannot serve. ## Where it holds up, and where it does not - Strength: Price stated flat at every dose - Strength: Three pharmacy partners named with addresses - Strength: No medication charge if found ineligible - Strength: Pausing for up to three months allowed - Limitation: Product page pre-selects the prepaid rung - Limitation: No milligram schedule is published - Limitation: Shipped medication cannot be refunded - Limitation: No individual prescriber is named ## What the evidence says about this kind of treatment The assessment above is about Jyra Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who expects to titrate and wants the monthly cost fixed through every step. Wrong for A buyer who reads the pre-selected card as the monthly price without checking the term. ## The evidence behind what Jyra Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Jyra Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | TrimRx | Readers who already know which molecule they want and will hunt for which tile holds it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LVNG RX](https://thisglp.com/reviews/lvng-rx) [Lyfe Rx](https://thisglp.com/reviews/lyfe-rx) [MadeMed](https://thisglp.com/reviews/mademed) [MANÜ Telehealth](https://thisglp.com/reviews/manu-telehealth) [Marek Health](https://thisglp.com/reviews/marek-health) [Maves](https://thisglp.com/reviews/maves) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a month the semaglutide price? Only on the three-month plan, charged as $297 up front. A single month is $169. Does the price rise as the dose goes up? No. The FAQ says the price stays the same at every dose and every renewal. Which pharmacies fill the prescriptions? VialsRX in Houston, White Label Pharmacy in Katy, Texas, and Hallandale Pharmacy Compounding in Fort Lauderdale, all named in the site's FAQ. Is Jyra Health legit? Jyra Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Jyra Health expensive compared with other GLP-1 telehealth sellers? Jyra Health publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Jyra Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # KairoRx reviews (2026): GLP-1 telehealth sellers | This GLP KairoRx offers clinician-reviewed weight treatment and a separate AI health-advisor feature. Its branded-drug access fees are distinct from the medication bill. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/kairorx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinical messaging versus AI advice # KairoRx review KairoRx offers clinician-reviewed weight treatment and a separate AI health-advisor feature. Its branded-drug access fees are distinct from the medication bill. ## The verdict KairoRx describes provider messaging and personalized dose review, useful features to verify before starting care. Its AI advisor should not be mistaken for the treating clinician. If a brand is proposed, the quoted access fee does not include the pharmacy’s drug cost. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved KairoRx arranges telehealth and pharmacy access for several prescription services, including semaglutide and tirzepatide weight care. Some offers are compounded, while branded listings use a separate access-fee model. 1. ## Who writes the prescription, and what do they see? The terms say KairoRx is neither the medical practice nor the pharmacy. Licensed providers independently determine whether treatment is appropriate, with charging described as occurring after approval. Ask which practice will manage your ongoing prescription. The process includes online consultation, pharmacy fulfillment and messaging between visits. Baseline and ongoing laboratory guidance are advertised without establishing that every test is free. The AI advisor is an additional interface, not evidence of physician review of each answer. 2. ## What happens when the dose goes up? Personalized dosing and [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) support are listed among the service features. Ask who authorizes each adjustment and whether the selected therapy’s price changes as treatment progresses. A starting-price table does not establish every later-strength cost. 3. ## What the price includes The pricing page distinguishes discounted first months from subsequent semaglutide and tirzepatide amounts. For Ozempic and Zepbound, the listed charge is an access fee with medication billed separately. Several therapies vary by dose, so confirm your prescription-specific continuation quote. 4. ## What it claims, and what it cites Both compounded and brand-name GLP-1 options are advertised. Compounded preparations are not FDA approved. Confirm the medicine, formulation and pharmacy on the clinical proposal rather than assuming an access-fee listing buys a particular quantity of branded medication. ## Where it holds up, and where it does not - Strength: Platform and clinical roles distinguished - Strength: Provider messaging described - Strength: Branded medication cost separated from access fee - Limitation: AI feature is not clinical oversight - Limitation: Some pricing depends on dose - Limitation: Testing costs not fully established ## What the evidence says about this kind of treatment The assessment above is about KairoRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants online clinical messaging and can distinguish the prescription plan from optional digital advice. Wrong for A patient interpreting an AI response or a low access fee as a complete branded-drug treatment plan. ## The evidence behind what KairoRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How KairoRx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MaxLife](https://thisglp.com/reviews/maxlife) [MDExam](https://thisglp.com/reviews/mdexam) [Measured](https://thisglp.com/reviews/measured) [Medi-Weightloss](https://thisglp.com/reviews/medi-weightloss) [MediRX](https://thisglp.com/reviews/medirx) [MedLeanRx](https://thisglp.com/reviews/medleanrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the branded access fee buy the medication? No. The pricing page says brand-name medication is billed separately. Is the AI advisor the prescribing clinician? No. Treatment decisions require a licensed provider’s consultation and independent assessment. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official treatment program](https://kairorx.com/) - [Service and cancellation terms](https://kairorx.com/terms/) - [Care, product and billing information](https://kairorx.com/pricing/) - [Consultation and care process](https://kairorx.com/how-it-works/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # KERNX Health reviews (2026): GLP-1 telehealth sellers | This GLP The consultation is priced as three named tiers and is charged only when treatment is approved. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/kernx-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Consult fee, three tiers # KERNX Health review The consultation is priced as three named tiers and is charged only when treatment is approved. ## The verdict KERNX Health publishes $209 a month for compounded semaglutide and $299 for tirzepatide. Each is one flat price at every dose. A provider consultation fee of $25 to $60 is charged separately, and only on approval. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $209/mo Prescription Required Compounded Yes — not FDA-approved KERNX Health sells compounded semaglutide and compounded tirzepatide. Both are weekly injections. The rates read $209 and $299 a month. No membership fee or three-month plan is required. Coverage is published as fifty states. 1. ## Who writes the prescription, and what do they see? The consultation fee is billed apart from the medication rate. It is charged only when treatment is approved. Three tiers are published. A message-based review is $25. A standard live visit is $35. A complex live visit is $60. An applicant who is declined pays none of them. Care is arranged remotely. Two charges apply rather than one. The medication rate is monthly. The consultation fee is charged at approval. The site states that no membership fee applies. Nothing else was recorded beside either figure. 2. ## What happens when the dose goes up? Both rates are stated as flat at every dose. An escalation does not move the medication charge. The first sixteen weeks are an escalation for most patients. Whether a dose change triggers a further visit fee is not published. A second visit inside that window is therefore possible. 3. ## What the price includes $209 is the semaglutide rate. $299 is the tirzepatide rate. The gap is $90 a month. Neither requires a three-month plan. Add $25 to $60 once, at approval. 4. ## What it claims, and what it cites Both products are compounded. A pharmacy prepares them. No regulator reviews the finished vial. A compounded preparation is not FDA-approved. The published trial results used the approved products at label doses. A compounded vial was not what those trials measured. ## Where it holds up, and where it does not - Strength: Consultation fee published as three tiers - Strength: Fee charged only on approval - Strength: Rate flat at every dose - Limitation: Tirzepatide costs $90 more a month - Limitation: Visit fee at a dose change is unstated - Limitation: Consultation billed apart from the rate ## What the evidence says about this kind of treatment The assessment above is about KERNX Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the clinician charge stated as a number before intake. Three tiers are published. Wrong for A reader who wants one charge rather than two. The consultation is billed apart from the rate. ## The evidence behind what KERNX Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How KERNX Health compares | Seller | Who it suits | Go | | --- | --- | --- | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | | AVARA Rx | A reader who wants the consult inside the price, and who plans against the standing rate rather than a code that can be withdrawn. | | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Medro](https://thisglp.com/reviews/medro) [Medsol RX](https://thisglp.com/reviews/medsol-rx) [MEDVi](https://thisglp.com/reviews/medvi) [Metaboost Rx](https://thisglp.com/reviews/metaboost-rx) [Mevo Health](https://thisglp.com/reviews/mevo-health) [Midi Health](https://thisglp.com/reviews/midi-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the consultation fee charged before approval? No. KERNX states that it applies only when treatment is approved. A declined applicant pays nothing. Is there a membership or a minimum term? No. The page states no membership fee and no required three-month plan. Does the price rise with the dose? No. Both rates are stated as flat at every dose. A dose change may still require a visit, and that visit is priced separately. Is KERNX Health expensive compared with other GLP-1 telehealth sellers? KERNX Health publishes a starting figure of $209/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts KERNX Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # KIN Health reviews (2026): GLP-1 telehealth sellers | This GLP KIN advertises a single price including medication, provider care and messaging. Its GLP-1 menu groups several formulations without fully defining every drug-and-form option. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/kin-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Bundled support, formulation questions # Does KIN Health sell a GLP-1? KIN advertises a single price including medication, provider care and messaging. Its GLP-1 menu groups several formulations without fully defining every drug-and-form option. ## The verdict The stated inclusion of ongoing provider care is useful, as is the explicit warning that KIN’s formulations have not been independently studied. Clarify the exact formulation and clinical review schedule before treating the broad product menu as a prescription plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved KIN Health, operated under Purpose Medical, Inc., offers telehealth weight and wellness treatment. Its homepage names semaglutide and tirzepatide within a wider GLP-1 category. 1. ## Who writes the prescription, and what do they see? Licensed providers review the intake and make prescribing decisions. The page describes independent U.S. pharmacies but does not establish the individual clinician or dispensing pharmacy for a prospective patient. The published sequence is quiz, clinician review, shipment if prescribed and ongoing support. Provider messaging and check-ins are advertised as included rather than an extra membership. 2. ## What happens when the dose goes up? The site promises the same monthly price regardless of prescribed dose. It does not define a uniform check-in interval, so confirm when a clinician reviews tolerability and authorizes the next prescription. 3. ## What the price includes Separate semaglutide and tirzepatide monthly figures are displayed, with no membership surcharge claimed. The exact formulation and supply attached to each must be confirmed before turning them into comparable injection or oral prices. 4. ## What it claims, and what it cites KIN describes compounded treatment and groups injection, nasal and dissolvable-tablet formats in the GLP-1 menu. Compounded products are not FDA-approved; the site acknowledges that its formulations were not independently studied. ## Where it holds up, and where it does not - Strength: Ongoing care described as included - Strength: Own-formulation evidence limit acknowledged - Limitation: Format-to-product mapping incomplete - Limitation: Visit frequency not specified ## What the evidence says about this kind of treatment The assessment above is about KIN Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants a bundled support model and will confirm the prescribed formulation in writing. Wrong for Someone assuming every route in a broad menu has the evidence or approval of a branded injection. ## The evidence behind what KIN Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How KIN Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Mint Med](https://thisglp.com/reviews/mint-med) [Mint Medical Clinic](https://thisglp.com/reviews/mint-medical) [Mochi Health](https://thisglp.com/reviews/mochi-health) [Mojoon](https://thisglp.com/reviews/mojoon) [Mondae](https://thisglp.com/reviews/mondae) [MultiMedRx](https://thisglp.com/reviews/multimedrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are the formulations proven by the cited brand trials? KIN itself says its compounded formulations have not been independently studied. Brand trials should not be treated as direct evidence for every listed route. Is provider support a separate membership? The homepage describes provider care and messaging as included without an additional membership fee. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://trykin.health/) - [Official program and terms](https://trykin.health/terms) - [Official program and terms](https://trykin.health/tools/glp1-dose-check) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Kin Meds reviews (2026): GLP-1 telehealth sellers | This GLP One figure can be checked against a manufacturer's own published price. Two cannot, and sit at about half cash-pay. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/kin-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three molecules, one checkable # Kin Meds review One figure can be checked against a manufacturer's own published price. Two cannot, and sit at about half cash-pay. ## The verdict One of Kin Meds' three figures can be checked against the manufacturer that supplies it, and two cannot. The orforglipron price matches LillyDirect's own published starter rate, which is a rare thing on this subject: a number a reader can verify without trusting the seller. The other two sit at roughly half what those channels charge for cash, and nothing on the pages explains who reaches them. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron · Semaglutide · Tirzepatide Form Injection · Oral From From $199/mo Prescription Required Compounded No Kin Meds prices three molecules, which is one more than nearly any seller here carries. Orforglipron is the newest and rarely carries a published figure at all. The lines reference the manufacturers' own direct channels. 1. ## Who writes the prescription, and what do they see? A prescription is arranged before dispensing and the fulfillment runs through manufacturer channels. What is not stated is the condition attached to the two low figures. Whether a buyer reaches them depends on insurance or a savings card. The pages do not say which, or who qualifies. The service is an access route to manufacturer products rather than a compounding operation. That has a real advantage: these are approved, FDA-reviewed products. It also has a consequence. The price a buyer meets is set by a program they may not be eligible for. 2. ## What happens when the dose goes up? Nothing is published about what these figures become at a higher dose, and on manufacturer-supplied products that is largely the manufacturer's schedule rather than Kin Meds'. The pages do not point a reader to where it is published. 3. ## What the price includes Verifiability is the axis this seller should be judged on. One figure agrees with its own supplier's published rate and can be confirmed in a minute. Two sit far under what those same suppliers charge a cash buyer, which means a condition applies, and the pages name neither the condition nor who satisfies it. A first-order discount is disclosed separately and affects one bill rather than the standing rate. 4. ## What it claims, and what it cites These lines reference approved products supplied through manufacturer channels rather than compounded preparations. An approved product has been reviewed by the FDA for safety and quality, which the compounded lines elsewhere on this site have not. ## Where it holds up, and where it does not - Strength: One figure can be checked against its source - Strength: A rarely priced molecule appears at all - Strength: The supplying channel is identified - Limitation: Two figures carry an unnamed condition - Limitation: Eligibility is never described - Limitation: The published rate sits far under cash pay - Limitation: Coverage is nowhere enumerated ## What the evidence says about this kind of treatment The assessment above is about Kin Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader pricing orforglipron, which almost no seller publishes a figure for. Wrong for A reader assuming the semaglutide and tirzepatide figures are cash-pay prices. ## The evidence behind what Kin Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Kin Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | PreventiveMD | A reader interested in orforglipron, which most sellers in this category do not offer at all. | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MyFastRx](https://thisglp.com/reviews/myfastrx) [MyStart Health](https://thisglp.com/reviews/mystart-health) [Näky](https://thisglp.com/reviews/naky) [NativeMed](https://thisglp.com/reviews/nativemed) [Navio MD](https://thisglp.com/reviews/navio-md) [Neo Soma Healthcare](https://thisglp.com/reviews/neo-soma-healthcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Will I pay $199 for semaglutide? Only if the tier applies to you. NovoCare's cash-pay standard pen is $299 a month, and the condition behind the lower figure is not published. What is orforglipron? A newer GLP-1 sold as Foundayo through LillyDirect. Kin Meds' $149 matches that channel's published starter cash price, making it the most checkable figure here. Are these compounded? No. The lines reference manufacturer channels supplying approved products, which have been FDA-reviewed. Is Kin Meds expensive compared with other GLP-1 telehealth sellers? Kin Meds publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Kin Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Kina reviews (2026): GLP-1 telehealth sellers | This GLP One population, four delivery routes, and the clinical provider named with a street address. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/kina Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Named clinic, four routes # Kina review One population, four delivery routes, and the clinical provider named with a street address. ## The verdict Kina treats women in menopause and midlife and prices four GLP-1 routes on the page. Semaglutide injection is $199 a month and tirzepatide injection $249. The rate is stated to hold at every dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $199/mo Oral From $229/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Kina is a GLP-1 program for women in menopause and midlife, and it says that is all it treats. Two molecules are offered in four forms: semaglutide by weekly injection or as a daily dissolving tablet, tirzepatide by weekly injection or as sublingual drops. Energy, sleep, hormone and NAD+ lines sit elsewhere in the catalog. 1. ## Who writes the prescription, and what do they see? The clinical provider is named in full, which is unusual here. Services are supplied by independently licensed providers affiliated with Arora Health & Aesthetics, LLC, of 300 Lenora Street, Seattle, with a compliance contact and an outside website. A clinical lead is named as a pharmacist. Clinicians are described as menopause-trained, and review runs within twenty-four hours of intake. One five-minute questionnaire covers all four routes, and the clinician recommends which fits. Medication ships from a licensed United States pharmacy in two to three days. Dose adjustments, side-effect support and unlimited messaging are included rather than billed. Zofran for nausea is free for the first two months. 2. ## What happens when the dose goes up? Kina states the price is the same at every dose, so the money question is closed. The clinical half is partly answered: dose adjustments are named as part of ongoing care, and [nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) is described as most likely in the first one to two months. No milligram is printed anywhere, so a reader cannot see where the ladder starts or ends. 3. ## What the price includes Four rates are published before any intake: semaglutide injection $199, tirzepatide injection $249, tirzepatide sublingual $229, semaglutide tablet $279. A first month is $169, with $30 taken off automatically. Kina states it covers the $25 physician consultation fee rather than adding it, and charges no membership. 4. ## What it claims, and what it cites All four are compounded preparations made by licensed United States pharmacies, and compounded medications are not FDA-approved. The pharmacies are called trusted and highly rated rather than being named. Kina's own FAQ explains why it charges less for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) than [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), which is an honest way to frame a price gap. ## Where it holds up, and where it does not - Strength: The medical group is named with a street address - Strength: Four delivery routes priced before the intake - Strength: The $25 consult fee is covered, not added - Strength: Anti-nausea medication included for two months - Strength: Same price stated at every dose - Limitation: No milligram appears beside any of the four rates - Limitation: The compounding pharmacies are not named - Limitation: No state coverage list is published - Limitation: The $169 opening rate lasts one month ## What the evidence says about this kind of treatment The assessment above is about Kina. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A woman in menopause who wants the prescribing group named and four routes priced. Wrong for A buyer who needs to know the milligrams behind each rate before choosing. ## The evidence behind what Kina prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Kina compares | Seller | Who it suits | Go | | --- | --- | --- | | Tuyo Health | Buyers weighing a compounded plan against brand Wegovy or Zepbound at the same clinic | | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | T2D.com | Buyers who already hold a GLP-1 prescription and want a dose-labeled cash rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Neo Soma Healthcare](https://thisglp.com/reviews/neo-soma-healthcare) [NEUVÉ Health](https://thisglp.com/reviews/neuve-md) [New Wave Health](https://thisglp.com/reviews/new-wave-health) [NewSelf](https://thisglp.com/reviews/newself) [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) [NexLife](https://thisglp.com/reviews/nexlife) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who actually writes the prescription? Independently licensed providers affiliated with Arora Health & Aesthetics, LLC, of Seattle, which Kina names in its own FAQ. Is the consultation fee extra? No. Kina states the $25 physician consultation fee is covered rather than added to the monthly rate. Does the price go up as the dose goes up? Kina states the price is the same at every dose, with no surprise increases. Is Kina expensive compared with other GLP-1 telehealth sellers? Kina publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Kina above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Klarity Health reviews (2026): GLP-1 telehealth sellers | This GLP Klarity Health offers a choice of independent weight-loss clinicians, insurance or self-pay visits and medication assessment. Continuity depends on the particular practice selected. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/klarity-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Klarity Health review Klarity Health offers a choice of independent weight-loss clinicians, insurance or self-pay visits and medication assessment. Continuity depends on the particular practice selected. ## The verdict Choosing a dedicated provider is the main attraction here. Klarity describes ongoing visits with the same clinician and side-effect management rather than a single anonymous prescription request. The marketplace structure means that provider availability, services and accepted insurance still need to be checked individually. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Liraglutide Form Injection Prescription Required Klarity is a technology marketplace connecting patients with independent private practices. Its weight-loss service lists approved GLP-1 options including Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda. It does not itself practice medicine or promise that every clinician offers every medicine. 1. ## Who writes the prescription, and what do they see? Licensed professionals within the selected practice provide medical care. The platform lets patients choose a dedicated provider and describes consistency across visits. Verify the clinician’s state eligibility and the practice’s approach to treating any relevant conditions alongside weight management. The service advertises remote appointments, often within 24 hours, and insurance or self-pay options. Some states can require an in-person assessment, and laboratory testing may require a separate trip. The convenience of booking online does not remove those clinical or legal steps. 2. ## What happens when the dose goes up? The weight-loss description includes side-effect management and a personalized treatment plan. The actual visit interval and dose-adjustment process are practice-specific. Discuss the route for reporting [nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) or treatment interruption and ask whether that contact requires an additional appointment. 3. ## What the price includes The weight-loss page starts self-pay care at $51, while general platform offers can differ. This is visit pricing, not a monthly medication package. Insurance acceptance must be checked for the chosen provider, and coverage of a consultation does not establish coverage of the prescription. 4. ## What it claims, and what it cites The named brands include [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review), [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and liraglutide products. Their labeled indications differ. Selection remains the clinician’s decision; the platform’s product list should not be read as a guarantee of an obesity indication or an approved insurance claim. ## Where it holds up, and where it does not - Strength: Dedicated provider choice - Strength: Pay-as-you-go visits without a compulsory subscription - Strength: Side-effect support is part of the care description - Limitation: Fees and coverage depend on the practice - Limitation: Some care may require in-person steps - Limitation: Medication is a separate purchase ## What the evidence says about this kind of treatment The assessment above is about Klarity Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values choosing a continuing clinician and wants to compare insurance and self-pay appointments. Wrong for A person needing one nationally uniform inclusive price or guaranteed access to a particular prescription. ## The evidence behind what Klarity Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Klarity Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NextMeds](https://thisglp.com/reviews/nextmeds) [NiceRx](https://thisglp.com/reviews/nicerx) [Nirwana Health](https://thisglp.com/reviews/nirwana-health) [NoBsRx](https://thisglp.com/reviews/no-bs-rx) [Nolu](https://thisglp.com/reviews/nolu) [Noom](https://thisglp.com/reviews/noom) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Klarity provide the medical care itself? No. Its public disclosures identify independent private practices as the providers of professional services. Is the self-pay starting figure a drug price? No. The weight-loss page’s starting figure concerns care; medication costs and coverage are separate. Can every step happen online? Not necessarily. Some states may require an in-person visit, and needed laboratory work may require a facility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.helloklarity.com/) - [Terms of service and payment conditions](https://www.helloklarity.com/terms-conditions) - [Terms of service and payment conditions](https://www.helloklarity.com/provider-terms-conditions) - [Weight-management program](https://www.helloklarity.com/service/weight-loss/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Klinic reviews (2026): GLP-1 telehealth sellers | This GLP Klinic connects patients with independent medical practices for weight-management assessment. Consultation fees, prescription costs and insurer access are separate decisions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/klinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Klinic review Klinic connects patients with independent medical practices for weight-management assessment. Consultation fees, prescription costs and insurer access are separate decisions. ## The verdict Klinic’s marketplace model can help patients find a provider who accepts their insurance. The clinical relationship is with the independent practice, not the technology platform. That distinction matters for continuity, side-effect support and follow-up fees after the initial appointment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Orforglipron Form Injection · Oral Prescription Required The platform supports several conditions, including obesity, and describes individualized plans that may include Wegovy, Zepbound, oral Wegovy or Foundayo. These are possible treatments, not a guarantee that every clinician or patient can use each option. 1. ## Who writes the prescription, and what do they see? The terms identify Klinic Medical practices and independent prescribing providers as responsible for care. The initial consultation evaluates medical need and eligibility. Confirm the individual clinician’s state authority and whether the selected practice provides the intended weight-management service. Patients choose a service and book a consultation through the platform. Later care and prescriptions are managed by the provider. Ask whether the same clinician handles reviews, how side effects are communicated and whether messaging between appointments is included. 2. ## What happens when the dose goes up? The prescriber decides dose and suitability. The public homepage does not establish a universal escalation ladder or refill policy across independent practices. Agree on the follow-up schedule before moving ongoing treatment to the service. 3. ## What the price includes The homepage lists self-pay initial visits from $99 and follow-ups from $75, with medication extra. Insurance options can depend on the practice and plan. A low or covered visit does not establish coverage for a particular weight-loss medicine. 4. ## What it claims, and what it cites Named GLP-1 options span [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review), [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and orforglipron products. Route and indication matter, and a provider should explain the exact prescription. The platform’s general medicine menu is not evidence that every product will be available locally or approved by an insurer. ## Where it holds up, and where it does not - Strength: Independent clinical responsibility is disclosed - Strength: Insurance and self-pay options can be compared - Strength: Follow-up fees are distinguished from first visits - Limitation: Care arrangements vary by practice - Limitation: Medication is outside visit prices - Limitation: No single platform-wide refill policy ## What the evidence says about this kind of treatment The assessment above is about Klinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone looking for an insurance-compatible clinician and willing to verify continuity and ongoing weight-care services. Wrong for A patient needing one universal medicine-inclusive price or an automatic prescription. ## The evidence behind what Klinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. ## How Klinic compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nova](https://thisglp.com/reviews/nova) [Nova MD](https://thisglp.com/reviews/nova-md) [Novi](https://thisglp.com/reviews/novi) [NovoCare Pharmacy](https://thisglp.com/reviews/novocare-pharmacy) [NowPatient](https://thisglp.com/reviews/nowpatient) [NP2GO](https://thisglp.com/reviews/np2go) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who provides the medical care? Independent Klinic Medical practices and prescribing providers, as distinguished in the platform terms. Does the visit price include medication? No. The homepage explicitly adds medication cost if a prescription is issued. Are follow-ups automatically identical across providers? The public information does not establish one universal schedule or policy; clarify it with the chosen practice. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://klinic.com/) - [Terms of service and payment conditions](https://klinic.com/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Knownwell reviews (2026): GLP-1 telehealth sellers | This GLP An obesity-medicine practice that bills insurance for visits and prescribes brand-name drugs only. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/knownwell Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Insurance-first obesity clinic # Knownwell review An obesity-medicine practice that bills insurance for visits and prescribes brand-name drugs only. ## The verdict Knownwell is an in-network obesity-medicine practice, not a medication seller. It prescribes brand-name GLP-1s and publishes the manufacturers' cash prices, with Zepbound at $299 a month at the 2.5 mg starting dose. The visits are billed to insurance where a plan covers them, or paid out of pocket. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection States 50 From From $299/mo Dose published Yes Prescription Required Compounded No Knownwell runs weight-management, nutrition and primary care, with clinics in several states and virtual visits nationwide. It is in-network with most major commercial plans and with Medicare. Its pricing page states that it does not dispense medication, does not set drug prices and gains nothing from which drug a patient chooses. 1. ## Who writes the prescription, and what do they see? Prescribing is done by the practice's own clinicians, described as obesity-medicine certified. A patient sees the same clinician across visits, virtually or in a clinic. The site links a clinician directory by state, but the product-level pages name no individual prescriber. Visits are monthly while a patient is starting treatment, with registered dietitians available and health coaching listed as coming soon. Out of pocket, a first weight-management visit is $299 and a follow-up is $149. There is no membership fee. A team handles prior authorization and looks for copay cards and pharmacy discounts on the patient's behalf. 2. ## What happens when the dose goes up? The pricing page lists each drug at its starting dose only: Zepbound at 2.5 mg, the Wegovy pen at 0.25 mg. The cost at higher doses is not printed and is set by the manufacturer, not by knownwell. Dose decisions sit with the clinician at the monthly visits. 3. ## What the price includes Two separate costs apply. The visit is billed by knownwell, as a copay under a covered plan or at the self-pay rate. The drug is bought at manufacturer list price: Zepbound vial and KwikPen at $299 a month at 2.5 mg, and the Wegovy pen at $349 at 0.25 mg. Several listings carry new-patient offers or end dates, so the long-run cost can differ from the first fill. 4. ## What it claims, and what it cites Every GLP-1 on the list is an FDA-approved brand product: [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), Wegovy, Ozempic, Saxenda and Foundayo, alongside non-GLP-1 pills such as Contrave and Qsymia. No compounded preparation appears on the list. The site's weight-loss outcome figures are its own patient averages, and how they were measured is not described. ## Where it holds up, and where it does not - Strength: Prescribes brand-name medication only - Strength: In-network with major plans and Medicare - Strength: Same clinician across visits - Strength: No membership fee is charged - Strength: Prior authorization handled for the patient - Limitation: Visits and medication are billed separately - Limitation: Drug prices shown at starting doses only - Limitation: Self-pay visits add a separate cost - Limitation: Outcome figures lack a stated method ## What the evidence says about this kind of treatment The assessment above is about Knownwell. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient with commercial insurance or Medicare who wants ongoing care from one obesity-medicine clinician. Wrong for A cash buyer looking for one monthly price that covers both the visit and the drug. ## The evidence behind what Knownwell prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Knownwell compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) [NuBloom](https://thisglp.com/reviews/nubloom) [Nucore Health](https://thisglp.com/reviews/nucore-health) [NuDay Rx](https://thisglp.com/reviews/nuday-rx) [NuuVim](https://thisglp.com/reviews/nuuvim) [NuviaRx](https://thisglp.com/reviews/nuviarx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does knownwell sell the medication? No. It prescribes, and the drug is filled by a pharmacy or the manufacturer at list price. The pricing page says knownwell does not set those prices. What does a visit cost without insurance? A first weight-management visit is $299 and a follow-up is $149, according to the FAQ. Does knownwell offer compounded semaglutide or tirzepatide? None appears on its pricing page. Every GLP-1 listed there is a brand-name, FDA-approved product. Is Knownwell expensive compared with other GLP-1 telehealth sellers? Knownwell publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Knownwell above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Kongo reviews (2026): GLP-1 telehealth sellers | This GLP Two all-inclusive monthly rates, no membership, and a provider review within a day. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/kongo Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 All-inclusive, flat by dose # Kongo review Two all-inclusive monthly rates, no membership, and a provider review within a day. ## The verdict Kongo charges $119 a month for compounded semaglutide and $229 for tirzepatide. The provider review, supplies and shipping sit inside both. No membership fee applies. The FAQ states the price does not rise with the dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $119/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider Kongo sells compounded semaglutide and tirzepatide as weekly injections. It also sells NAD+, sermorelin and glutathione. It states coverage in all 50 states. 1. ## Who writes the prescription, and what do they see? A licensed US provider reviews a four-minute online form. Most reviews finish within 24 hours, per the FAQ. No video call is required, though one is available. Some states may require a short phone call first. One physician is named as leading the clinical team. Care is asynchronous by default. Questions go to the clinical team through a patient portal. Pausing and canceling run through the same portal. The FAQ states there are no long-term commitments. 2. ## What happens when the dose goes up? The rule is stated plainly. The FAQ says the price never increases as the dosage is adjusted. The product page gives the order of steps. Weeks one to four stay at the starting dose. The dose rises gradually from week five. No milligram figures sit beside those steps. 3. ## What the price includes $119 is the standing semaglutide rate on the one-month plan. That plan is the default. Tirzepatide is $229 on the same plan. A three-month plan is billed once, upfront, at a lower monthly rate. A coded first-month discount carries a countdown. Budget from the standing rate: six months is $714 for semaglutide and $1,374 for tirzepatide. 4. ## What it claims, and what it cites Both lines are compounded by a licensed US pharmacy that the site does not name. Compounded drugs are not FDA-approved, and the site footer says so. ## Where it holds up, and where it does not - Strength: Provider review and shipping inside the price - Strength: Price stated flat across dose changes - Strength: No membership fee on either line - Strength: LegitScript certification stated on the site - Limitation: The compounding pharmacy goes unnamed - Limitation: No milligram doses beside the steps - Limitation: The lower rate needs three months upfront ## What the evidence says about this kind of treatment The assessment above is about Kongo. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one all-inclusive monthly figure that holds as the dose rises. Wrong for A reader who needs the compounding pharmacy named before paying. ## The evidence behind what Kongo prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Kongo compares | Seller | Who it suits | Go | | --- | --- | --- | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Obu Health](https://thisglp.com/reviews/obu-health) [Omnia TeleHealth](https://thisglp.com/reviews/omnia-telehealth) [Omzo](https://thisglp.com/reviews/omzo) [Ondra Health](https://thisglp.com/reviews/ondra-health) [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) [OnlyRx](https://thisglp.com/reviews/onlyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Kongo's price rise with the dose? No. The FAQ states one flat price as the dosage is adjusted. What does the first month cost? A coded discount lowers the first month. From month two, semaglutide is $119 and tirzepatide is $229. Is a membership required? No. The site states no membership, platform or consultation fee. Is Kongo legit? Kongo is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Kongo expensive compared with other GLP-1 telehealth sellers? Kongo publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Kongo below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Kova reviews (2026): GLP-1 telehealth sellers | This GLP Kova combines clinician-reviewed treatment with an app for tracking progress. Its plan billing can continue independently of refill and review timing. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/kova Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Care tracking with contract commitments # Kova review Kova combines clinician-reviewed treatment with an app for tracking progress. Its plan billing can continue independently of refill and review timing. ## The verdict The tracking tools may support a continuing conversation, but they are not the clinician. Pay particular attention to the separation between recurring billing and clinical reviews: delayed intake or an unused refill does not automatically pause the plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Kova is a telehealth platform with semaglutide and tirzepatide programs and a companion app for weight, nutrition and symptom tracking. 1. ## Who writes the prescription, and what do they see? Independent providers make prescription and renewal decisions. The terms say the company and app cannot prescribe, recommend or change a dose; patient-entered logs do not by themselves amend a treatment plan. Patients complete an assessment and access a provider portal. The program describes ongoing check-ins, while its legal terms make patients responsible for completing required refill and review steps. 2. ## What happens when the dose goes up? Clinical eligibility and later prescription decisions remain separate from the subscription. Ask how frequently a clinician reviews tracking entries and what happens to billing when treatment is paused or changed. 3. ## What the price includes The site separates introductory one-month prices from renewal rates and discounted longer plans. The contract also permits fixed-term commitments paid monthly, so monthly billing does not necessarily mean month-to-month cancellation. 4. ## What it claims, and what it cites The public program identifies [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and discusses compounded versions. Compounded medicines are not FDA-approved; branded-trial averages on the site are not proof of equivalent program outcomes. ## Where it holds up, and where it does not - Strength: App supports symptom and progress tracking - Strength: Independent clinical decisions stated - Limitation: Billing can precede refill review - Limitation: Tracking is not a clinical response guarantee ## What the evidence says about this kind of treatment The assessment above is about Kova. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants app-based tracking and is willing to read the full plan commitment. Wrong for Someone expecting that skipping a refill automatically stops their charges. ## The evidence behind what Kova prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Kova compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Onyx Weight Loss](https://thisglp.com/reviews/onyx-weight-loss) [Open Water Rx](https://thisglp.com/reviews/open-water-rx) [Optimized Health](https://thisglp.com/reviews/optimized-health) [Options Medical Weight Loss](https://thisglp.com/reviews/options-medical-weight-loss) [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) [Oria Meds](https://thisglp.com/reviews/oria-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does entering a symptom in the app change my prescription? No. Kova’s terms distinguish tracking tools from independent provider decisions. Contact the care team about treatment changes. Does a missed refill request pause the plan? The terms say it does not, by itself, stop the billing cycle. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://trykova.com/) - [Official program and terms](https://trykova.com/terms/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LaSara Medical Group reviews (2026): GLP-1 telehealth sellers | This GLP Each step down the price ladder is bought with the whole term's money at the start. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lasara Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A ladder paid at the top # LaSara Medical Group review Each step down the price ladder is bought with the whole term's money at the start. ## The verdict LaSara Medical Group prices compounded semaglutide at $299 month to month and compounded tirzepatide at $399, with ladders beneath each reaching $233 and $325 a month on twelve-month plans billed as one charge of $2,795 or $3,895. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $289/mo Prescription Required Compounded Yes — not FDA-approved LaSara is a physician-guided telehealth practice that sells weight management alongside hormone and men's health care, and its GLP-1 pages publish the full plan ladder rather than a single headline figure. 1. ## Who writes the prescription, and what do they see? The practice presents itself as physician-guided and describes a treatment plan built for the patient, which is more than most sellers at this price say about the clinical side. Who the physician is, and what they review before a first prescription, is still not published on the product pages. A buyer picks a term and pays for it, and support is described as available at every step with cancellation or pausing allowed at any time. The pause language matters more than it looks, because a reader who has paid $2,795 for a year has a different question about pausing than a reader billed monthly does. 2. ## What happens when the dose goes up? LaSara describes tirzepatide dosing as starting low and increasing gradually over the first eight to twelve weeks under physician supervision, which is a clearer account of the escalation than most pages carry. The plan price is not stated to change with the dose, so the ladder a buyer chooses at signup is the ladder they stay on while the dose climbs. 3. ## What the price includes Three months of semaglutide is $849, six is $1,495 and twelve is $2,795, which are $283, $249 and $233 a month. Tirzepatide runs $1,100, $1,995 and $3,895, or $367, $333 and $325. Each of those is a single charge rather than a smaller monthly bill, so the saving at the bottom of the ladder is bought with roughly $2,800 of exposure before a second injection. 4. ## What it claims, and what it cites Both lines are compounded preparations rather than manufactured products, prepared by a pharmacy the practice does not name, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: The whole ladder is published, not just a headline - Strength: Cancel or pause stated as available anytime - Strength: The escalation schedule is described - Strength: Both molecules carry every rung - Limitation: Longer plans are billed in one charge - Limitation: The year plan exposes $2,795 up front - Limitation: Nothing published about refunding a paid term - Limitation: The compounding pharmacy is not identified ## What the evidence says about this kind of treatment The assessment above is about LaSara Medical Group. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who can pay a full term at once and wants the lowest rung. Wrong for A buyer who wants the ladder rate without the single payment behind it. ## The evidence behind what LaSara Medical Group prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LaSara Medical Group compares | Seller | Who it suits | Go | | --- | --- | --- | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | | Rivas Medical Weight Loss | Buyers within reach of a clinic who want a clinician present every week | | | Noom | Buyers who read the footnote before the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Oria Meds](https://thisglp.com/reviews/oria-meds) [OurView Health](https://thisglp.com/reviews/ourview-health) [Oxford's Medical Weight Loss (The Calibrate Clinic)](https://thisglp.com/reviews/the-calibrate-clinic)[Ozari Health](https://thisglp.com/reviews/ozari-health) [Pallas Health](https://thisglp.com/reviews/pallas-health) [PauseRX](https://thisglp.com/reviews/pauserx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the twelve-month rate billed monthly? No. It is $2,795 for semaglutide or $3,895 for tirzepatide, taken as one charge, which is what produces the $233 and $325 figures. What does month to month cost? $299 for compounded semaglutide and $399 for compounded tirzepatide. Can a plan be paused? LaSara states cancellation or pausing is available at any time, though nothing published says what happens to money already paid on a longer plan. Is LaSara Medical Group expensive compared with other GLP-1 telehealth sellers? LaSara Medical Group publishes a starting figure of $289/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LaSara Medical Group above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lavender Sky Health reviews (2026): GLP-1 telehealth sellers | This GLP Every compounding pharmacy is named beside its own price, and a new patient's first order is a one-month starter plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lavender-sky-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every pharmacy named and priced # Lavender Sky Health review Every compounding pharmacy is named beside its own price, and a new patient's first order is a one-month starter plan. ## The verdict Lavender Sky Health prices its compounded GLP-1s pharmacy by pharmacy, and a new patient's first order is a one-month Monthly Starter: $139 for Southend Pharmacy's semaglutide with B6, or $149 for ReviveRx Pharmacy's tirzepatide with B6. Consults are billed separately as a flat fee per visit, and no subscription runs underneath either figure. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 50 From From $139/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Labs Extra cost Availability All 50 states and DC A remote practice that consults by phone, video or asynchronous e-consult, then sends the prescription to a partner compounding pharmacy the patient picks from a published list. Branded Zepbound and Wegovy are offered as a separate route, with the medication itself bought at a pharmacy rather than inside the plan. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the intake by phone, by video, or through portal messages, and the FAQ says an e-consult is answered within three business days of payment. Ordering anything beyond a starting dose requires documentation of a current prescription, so a patient new to these drugs begins on the lowest-dose Monthly Plan whichever pharmacy they choose. Nothing here renews on its own. The FAQ is explicit that there are no subscriptions and no recurring billing, so a patient pays for a consult when one is due and for medication when it is ordered. Refills between required follow-ups carry no consult fee, and those follow-ups fall due every six months on an active plan and every twelve months on maintenance dosing. 2. ## What happens when the dose goes up? The price here moves with the dose, and the page shows exactly how. Where a pharmacy offers Monthly Plans, it lists a Starter rung and then dearer Mid, Advanced and Advanced Plus rungs, each tied to a weekly milligram range. A patient stepping up past 2.5 mg of tirzepatide a week therefore pays more for the next month's vial than for the first one, and the longer packs are priced by dose band in the same way. 3. ## What the price includes The Monthly Starter is the figure to plan a first month around: $139 for semaglutide through Southend and $149 for tirzepatide through ReviveRx, each a single vial intended for use within five weeks. The lower "FROM" figures at the top of each pharmacy card are per-month equivalents of eight-to-ten-week packs paid once, up front, and the page labels them as a comparison rather than a payment schedule. A new patient also pays a one-time consult fee before the first order, billed apart from the medication. 4. ## What it claims, and what it cites Everything priced here is compounded, and the page says so itself: its partner pharmacies are vetted and accredited, but compounded medications are not FDA-approved, and the availability of any one formulation can shift. Several options add B6, B12, glycine, niacinamide or levocarnitine to the base drug, so the product name on each card is worth reading before the price. ## Where it holds up, and where it does not - Strength: Each compounding pharmacy named beside its price - Strength: One-month starter plans before longer packs - Strength: No subscription or recurring billing - Strength: Bloodwork not required, in-home labs optional - Limitation: Separate consult fee before the first order - Limitation: Price rises with each dose band - Limitation: Many formulations add ingredients to the drug ## What the evidence says about this kind of treatment The assessment above is about Lavender Sky Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to know which pharmacy compounds the vial before paying for it. Wrong for A reader who wants one flat monthly figure that stays put as the dose climbs. ## The evidence behind what Lavender Sky Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lavender Sky Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Fidelity Medical Clinic | A reader who counts fills rather than months, and who budgets from the maintenance order instead of the discounted intro one. | | | MyStart Health | Buyers who titrate quickly and want the rate frozen before the dose climbs | | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Peak Wellness](https://thisglp.com/reviews/peak-wellness) [PepHaūs](https://thisglp.com/reviews/pephaus) [Pepti](https://thisglp.com/reviews/pepti) [PlexusDx](https://thisglp.com/reviews/plexusdx) [PlushCare](https://thisglp.com/reviews/plushcare) [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What will the first month cost me? A Monthly Starter vial is $139 for Southend's semaglutide with B6 and $149 for ReviveRx's tirzepatide with B6, plus the new-patient consult fee, which is billed separately. Is there a subscription to cancel? No. The FAQ says nothing bills on a schedule; you pay for a consult when one is due and for medication when you order it, so stepping away needs no cancellation. Is bloodwork required? No. The FAQ says labs are not required before starting, and in-home wellness labs are offered as an optional extra for anyone who wants a baseline. Is Lavender Sky Health legit? Lavender Sky Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Lavender Sky Health expensive compared with other GLP-1 telehealth sellers? Lavender Sky Health publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lavender Sky Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Layla reviews (2026): GLP-1 telehealth sellers | This GLP Oral semaglutide drops at $237 a month after a discounted first month, beside a footnote about a different form. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/layla Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Oral drops, injection-trial footnote # Layla review Oral semaglutide drops at $237 a month after a discounted first month, beside a footnote about a different form. ## The verdict Layla's weight-loss line is now a monthly plan of oral semaglutide drops, $237 a month from the second month. The first month is discounted. The results footnote describes 68 weeks of once-weekly semaglutide, not drops. Compounded tirzepatide is no longer listed. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses From From $237/mo Dose published No Prescription Required Pharmacy Not named Layla is an online weight-loss service selling oral semaglutide drops on a monthly plan. Its treatment list also names branded Ozempic, Zepbound, Wegovy and Mounjaro. The drops ship as a monthly supply with a dropper. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews an online intake. The drops page describes a consult with a licensed physician via secure telehealth. One clinician is quoted by name on the page, without a stated role. The plan lists an initial telehealth visit, the prescription, monthly check-ins and 24/7 medical support. Subscriptions can be canceled at any time with 30 days' notice. Canceling an order already sent to the pharmacy costs a nonrefundable visit and clinical fee. 2. ## What happens when the dose goes up? No dose is stated for the drops, in milligrams or in drops. The page does not say whether the monthly price changes as the dose rises. Ask both before the first charge. 3. ## What the price includes $237 a month is the standing rate; the page says the discounted rate applies to the first month only. Six months at the standing rate is $1,422, less that one discount. The branded products carry separate prices, well above the drops. 4. ## What it claims, and what it cites The page calls the product oral [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) drops and cites FDA-approved ingredients. It does not say the drops are compounded, and it names no pharmacy. No semaglutide drop is itself an FDA-approved product. ## Where it holds up, and where it does not - Strength: Standing rate printed beside the discount - Strength: Cancel any time with notice - Strength: Needle-free option for injection-averse buyers - Limitation: No dose stated for the drops - Limitation: Trial footnote does not describe drops - Limitation: No pharmacy named for the drops - Limitation: Canceling after dispatch carries a fee ## What the evidence says about this kind of treatment The assessment above is about Layla. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a needle-free semaglutide plan and will ask about dose at intake. Wrong for A reader who wants trial evidence for the exact form they will take. ## The evidence behind what Layla prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Layla compares | Seller | Who it suits | Go | | --- | --- | --- | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | | LumiMeds | Buyers who want the ingredient, route and pharmacy type labeled before they pay | | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) [Potere Health MD](https://thisglp.com/reviews/potere-health-md) [Precision Telemed](https://thisglp.com/reviews/precision-telemed) [Premium Health](https://thisglp.com/reviews/premium-health) [PrescribedRX](https://thisglp.com/reviews/prescribedrx) [PreventiveMD](https://thisglp.com/reviews/preventivemd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Layla charge after the first month? $237 a month. The page says the discounted rate applies only to the first month. Does the weight-loss figure on the page apply to the drops? Not measured. The footnote describes once-weekly semaglutide over 68 weeks, a mean change of −14.9% against −2.4% on placebo. It does not describe drops. Is compounded tirzepatide still offered? It is not listed. The treatment list names Ozempic, Zepbound, Wegovy and Mounjaro, and the drops page sells semaglutide. Is Layla expensive compared with other GLP-1 telehealth sellers? Layla publishes a starting figure of $237/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Layla above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lean Rx reviews (2026): GLP-1 telehealth sellers | This GLP Every plan is billed in four-week fills. The one rung without a lock-in adds shipping. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lean-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week fills, shipping extra # Lean Rx review Every plan is billed in four-week fills. The one rung without a lock-in adds shipping. ## The verdict Lean Rx charges $450 for four weeks of compounded semaglutide, plus $35 shipping. That is $485 per fill. Tirzepatide is $599 plus shipping, or $634 per fill. Fills come every four weeks, thirteen a year. So a calendar month costs $525.42 and $686.83. Both are paid in full with no commitment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $525.42/mo Prescription Required Compounded Yes — not FDA-approved Lean Rx sells compounded semaglutide and tirzepatide by injection. It sells compounded medications only. Every plan is billed in four-week fills. Longer prepaid plans lower the average cost per vial. 1. ## Who writes the prescription, and what do they see? The first step is a brief online consultation. A medical history form follows. A licensed provider then holds a telehealth call. The provider prescribes a plan if appropriate. No provider is named. The buyer picks a program length after the call. Four options are offered per molecule. A pay-as-you-go subscription bills every four weeks. It cannot be canceled until 24 weeks. The single four-week fill carries no commitment. Longer plans are prepaid and ship free. 2. ## What happens when the dose goes up? A typical tirzepatide schedule is published in units, not milligrams. It runs 25 units a week for weeks one to four, then 50 units. A dose above 50 units a week needs an extra vial. That vial is billed on top, every four weeks. Dose is a price variable here. 3. ## What the price includes This site ranks the rate a buyer pays without committing. For Lean Rx that is the four-week fill. Each fill is charged $485 for semaglutide and $634 for tirzepatide, shipping included. Thirteen fills fall in a year. Per calendar month that is $525.42 and $686.83, the figures ranked here. The pay-as-you-go rate is lower but locks in 24 weeks. The 12- and 48-week plans are lower again, paid up front. Tirzepatide costs $149 more per fill. 4. ## What it claims, and what it cites Both products are compounded, per the seller's own FAQ. They come from state-licensed compounding pharmacies or 503B outsourcing facilities. Compounded drugs are not FDA-approved. The pharmacy is not named. ## Where it holds up, and where it does not - Strength: A no-commitment fill on both molecules - Strength: Dosing schedule published in units - Strength: Longer plans ship free - Strength: The seller says outright the drugs are compounded - Limitation: Shipping adds $35 to the no-commitment fill - Limitation: Pay-as-you-go locks in 24 weeks - Limitation: Higher doses cost an extra vial - Limitation: Billing runs on four weeks, not months ## What the evidence says about this kind of treatment The assessment above is about Lean Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a single fill with no subscription before choosing a plan. Wrong for A buyer on a high dose, where the extra vial raises every fill. ## The evidence behind what Lean Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lean Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Alegro Health | Buyers trying a GLP-1 for two months before committing to a rate | | | Gimme Care | Buyers who want the monthly price fixed while the dose climbs | | | Spry | Buyers who can read a four-week billing cycle as thirteen charges rather than twelve | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrideRx](https://thisglp.com/reviews/priderx) [Primary Clinic (Direct GLP)](https://thisglp.com/reviews/primary-clinic)[Prime Doctor RX](https://thisglp.com/reviews/prime-doctor-rx) [Prime Health](https://thisglp.com/reviews/prime-health) [Queen RX](https://thisglp.com/reviews/queen-rx) [QuickMD](https://thisglp.com/reviews/quickmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why $525.42 and not $450? The four-week fill is $450 plus a required $35 overnight shipping charge, so each fill is $485. Fills come every four weeks, thirteen a year, which is $525.42 a calendar month. Is there a cheaper recurring plan? Yes, pay-as-you-go. It bills every four weeks and cannot be canceled before 24 weeks. Does a higher dose cost more? Yes. Above 50 units a week, an extra vial is billed every four weeks. Is Lean Rx expensive compared with other GLP-1 telehealth sellers? Lean Rx publishes a starting figure of $525.42/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lean Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LeanDose reviews (2026): GLP-1 telehealth sellers | This GLP Both published figures are labeled first-month prices, and no ongoing rate appears anywhere. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/leandose Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Month one, and then silence # LeanDose review Both published figures are labeled first-month prices, and no ongoing rate appears anywhere. ## The verdict LeanDose publishes first-month prices from $159 for semaglutide and $279 for tirzepatide. Both are labeled as first-month figures. No ongoing monthly rate is published on the site or in the intake. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved LeanDose sells both molecules by injection and describes its pricing as transparent first-month all-inclusive. It states the medication is prepared by an FDA-registered compounding pharmacy. 1. ## Who writes the prescription, and what do they see? The pages name the pharmacy's registration status rather than the clinician. Registration is a real fact about a facility and it is not a statement about who writes the prescription or what they review. The seller uses the word transparent and applies it to one month. Its own copy adds that the ongoing monthly cost may differ, which is an honest sentence and the only thing said about month two. A reader cannot get further than that without starting. 2. ## What happens when the dose goes up? Nothing is published about dose. Since the ongoing rate is also unpublished, both variables that decide a year's cost are unavailable before signing up. That is a rarer gap than an unstated dose alone. 3. ## What the price includes $159 buys a first month and nothing establishes the second. Six months cannot be computed from anything on the site. Treat both figures as introductory and ask for the ongoing rate in writing before ordering. 4. ## What it claims, and what it cites Both lines are compounded. An FDA-registered compounding pharmacy is stated to prepare them. Registration is not FDA review of the preparation, which does not happen before dispensing. ## Where it holds up, and where it does not - Strength: A registered compounding pharmacy is named as such - Strength: The first-month label is explicit - Strength: The seller states the ongoing cost may differ - Limitation: No ongoing rate is published anywhere - Limitation: The intake does not reveal it either - Limitation: No milligram dose stated - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about LeanDose. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will get the month-two rate in writing before the first charge. Wrong for A reader who needs to price six months before starting. ## The evidence behind what LeanDose prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LeanDose compares | Seller | Who it suits | Go | | --- | --- | --- | | Lumora | Readers willing to complete an assessment and hold the seller to its own promise | | | MANÜ Telehealth | Readers who want the cost of a full dose stated before starting a low one | | | Levers Health | Readers who know which dose band they will stay in | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Recovery Delivered](https://thisglp.com/reviews/recovery-delivered) [Refills](https://thisglp.com/reviews/refills) [ReflexMD](https://thisglp.com/reviews/reflexmd) [Regenics](https://thisglp.com/reviews/regenics) [Rehydra+ Wellness](https://thisglp.com/reviews/rehydra-plus) [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does month two cost? LeanDose does not publish it. Both figures are labeled first-month prices and the site states the ongoing monthly cost may differ. Does FDA-registered mean FDA-approved? No. Registration describes the facility. The FDA does not review a compounded preparation before it is dispensed. Can I find the ongoing rate in the intake? It does not appear there either, which is why it has to be asked for directly. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lean Meds reviews (2026): GLP-1 telehealth sellers | This GLP Leanmeds describes clinician review and coaching, but its current starting offer does not identify a separate price for each molecule. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/leanmeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Care described, price unresolved # Lean Meds review Leanmeds describes clinician review and coaching, but its current starting offer does not identify a separate price for each molecule. ## The verdict Leanmeds now presents a general starting offer rather than the older public price ladder. Its care description is clearer than its product-level pricing: readers can see the evaluation pathway, but should request the prescribed medication and recurring amount before enrolling. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 Prescription Required Leanmeds offers online weight-management evaluations and pharmacy fulfillment when a provider prescribes. The homepage describes a care coach as part of the plan. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the assessment. The site says a live video or phone consultation occurs when state rules require it. The prescribing decision remains with that clinician. Patients complete an online assessment before clinical review. If a prescription is issued, a licensed pharmacy handles fulfillment. The homepage advertises shipping without a separate charge and describes ongoing support. 2. ## What happens when the dose goes up? The homepage says the price remains consistent across doses. It does not expose a current product-specific dose and price ladder before the initial health questionnaire. Ask how follow-up and dose changes are handled for the medication actually prescribed. 3. ## What the price includes The general starting offer carries a countdown. It is not clearly assigned to semaglutide or tirzepatide on the inspected public screens. The earlier separate rates and prepayment ladder could not be reverified, so no monthly comparison is shown here. 4. ## What it claims, and what it cites Confirm the exact molecule, formulation, dispensing pharmacy, and compounded or branded status in the proposed prescription. A generic GLP-1 offer does not establish those details for an individual patient. ## Where it holds up, and where it does not - Strength: Clinical review is described before prescribing - Strength: Coaching is advertised within the plan - Strength: State-dependent consultation process is explained - Limitation: No verified current price for each molecule - Limitation: A countdown accompanies the starting offer - Limitation: Final medication details require confirmation ## What the evidence says about this kind of treatment The assessment above is about Lean Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader prepared to clarify the exact prescription and recurring cost before committing. Wrong for Someone needing a complete public medication-by-medication price comparison. ## The evidence behind what Lean Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lean Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | | Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) [Remedy Meds](https://thisglp.com/reviews/remedy-meds) [REMEVi](https://thisglp.com/reviews/remevi) [Remi Meds](https://thisglp.com/reviews/remi-meds) [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) [Renlo Health](https://thisglp.com/reviews/renlo-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is no Leanmeds monthly price shown? The current public offer is generic and time-qualified. Separate standing semaglutide and tirzepatide rates were not verified. Is the older prepay ladder still current? It did not appear in the pages inspected in October. Ask for current written terms rather than relying on the previous ladder. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lemonaid Health reviews (2026): GLP-1 telehealth sellers | This GLP Medication at $299 a month plus a required $49 membership, from a clinic that names its clinicians. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lemonaid-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership on top, clinicians named # Lemonaid Health review Medication at $299 a month plus a required $49 membership, from a clinic that names its clinicians. ## The verdict Lemonaid bills compounded semaglutide at $299 a month. A $49 monthly membership is required beside it. The monthly total is therefore $348. The membership is free for the first month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $348/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Lemonaid Health is a national online doctor's office. Its weight-loss service offers compounded semaglutide and tirzepatide, microdose versions of each, and branded Wegovy and Ozempic. Zepbound vials are billed separately through LillyDirect. 1. ## Who writes the prescription, and what do they see? A U.S. licensed provider reviews an online intake and decides eligibility. The weight-loss page names twelve team members. Seven are nurse practitioners and four are physicians. One is listed as Head of Medical. Care runs as a membership. Every treatment option requires it. The membership covers clinical care and support. Medication is billed separately. Insurance is not accepted for membership, medication or medical fees. 2. ## What happens when the dose goes up? Treatment starts low and rises to a maintenance dose. Each increase comes with a provider check-in. The page states no additional fees for dosage changes on the same medication. Microdose versions are separate products at their own price. 3. ## What the price includes $348 is the figure to budget: $299 for medication and $49 for membership. Six months is $2,088. A three-month semaglutide plan lowers the medication rate. A site banner advertises a limited-time starting price. Neither removes the membership. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded in FDA-inspected 503(b) outsourcing facilities, per the product page. The page states it is the base form, not a salt. Compounded drugs are not FDA-approved. No facility is named. ## Where it holds up, and where it does not - Strength: Clinicians listed by name and role - Strength: No added fee for dose changes - Strength: 503(b) outsourcing facilities stated - Strength: Membership free for the first month - Limitation: A $49 membership is always required - Limitation: Medication and membership billed separately - Limitation: Not yet available in every state - Limitation: No compounding facility is named ## What the evidence says about this kind of treatment The assessment above is about Lemonaid Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants named clinicians and a price that holds through dose changes. Wrong for A reader comparing medication-only prices, since $49 a month sits on top. ## The evidence behind what Lemonaid Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lemonaid Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | | Sesame Care | Readers who want tirzepatide priced by dose and will read the FAQ before the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Reset Solutions](https://thisglp.com/reviews/reset-solutions) [RestorLife Med](https://thisglp.com/reviews/restorlife-med) [Revel Health](https://thisglp.com/reviews/revel-health) [Revel RX](https://thisglp.com/reviews/revel-rx) [Revive Meds](https://thisglp.com/reviews/revive-meds) [Rewinding RX](https://thisglp.com/reviews/rewinding-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is the price $348 and not $299? Every treatment requires the $49 monthly membership. Medication is billed separately at $299. Does the price change with the dose? Not on the same medication. The page states no additional fees for dosage changes. Does Lemonaid serve every state? Not yet. The weight-loss FAQ says it is not available in all 50 states. Is Lemonaid Health expensive compared with other GLP-1 telehealth sellers? Lemonaid Health publishes a starting figure of $348/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lemonaid Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LevelsRx reviews (2026): GLP-1 telehealth sellers | This GLP Two starting prices on a seller whose cost rises with the dose, and no ceiling published. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/levelsrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two floors, no ceiling # LevelsRx review Two starting prices on a seller whose cost rises with the dose, and no ceiling published. ## The verdict LevelsRx publishes starting prices of $150 a month for semaglutide and $240 for tirzepatide. An oral liposomal liquid is offered alongside the injection. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $150/mo Prescription Required Compounded Yes — not FDA-approved LevelsRx sells both molecules. Semaglutide comes as an injection or an oral liposomal liquid. Both figures are starting prices. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages name products. No clinician is described and no intake is documented. Two formats on one line is the structure here. Which one a buyer takes is not priced separately on the pages read. 2. ## What happens when the dose goes up? The cost rises with the dose. What it rises to is not published. Direction without a destination is half an answer. 3. ## What the price includes $150 and $240 are floors. Six months at them is $900 and $1,440 at best. A rising price makes both totals a minimum rather than an estimate. Ask what the figure is at a therapeutic dose. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: An oral and an injectable option - Strength: Both molecules carry a figure - Strength: The rising price is on the record - Limitation: Both figures are starting prices - Limitation: The upper rungs are not published - Limitation: No milligram dose stated - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about LevelsRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the oral option and will ask what the ladder costs. Wrong for A reader who needs a ceiling, since neither figure has one. ## The evidence behind what LevelsRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LevelsRx compares | Seller | Who it suits | Go | | --- | --- | --- | | LevelUp Rx | Readers who want the billed total before committing to a term | | | Longevixx | Readers wanting a flat rate in any state | | | LVNG RX | Readers who want a bundle and accept the figure is confirmed later | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rex MD](https://thisglp.com/reviews/rex-md) [Rivas Medical Weight Loss](https://thisglp.com/reviews/rivas-medical) [Rivo Health](https://thisglp.com/reviews/rivo-health) [Rixa Health](https://thisglp.com/reviews/rixa-health) [RNK Health](https://thisglp.com/reviews/myrnk) [Ro](https://thisglp.com/reviews/ro) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with the dose? Yes, and what it rises to is not published. Ask before ordering. What is the oral option? A liposomal liquid semaglutide, offered alongside the injection. Is $150 a rate? No. It is a starting price on a line that scales with dose. Is LevelsRx expensive compared with other GLP-1 telehealth sellers? LevelsRx publishes a starting figure of $150/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LevelsRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LevelUp Rx reviews (2026): GLP-1 telehealth sellers | This GLP Every plan length is priced as a total, and the rate is stated flat across doses. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/levelup-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat, with totals shown # LevelUp Rx review Every plan length is priced as a total, and the rate is stated flat across doses. ## The verdict LevelUp Rx publishes $149.97 a month for semaglutide and $249.97 for tirzepatide. Six months is $809.95 and twelve is $1,349.97. Both lines are flat across all doses. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $149.97/mo Prescription Required Compounded Yes — not FDA-approved LevelUp Rx sells both molecules by injection. Three plan lengths are priced on each. Totals are published rather than rates alone. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state plans. No clinician is described and no intake is documented. Publishing the billed total at each length removes the usual guesswork. A reader can see what a card is charged, not just a monthly figure. 2. ## What happens when the dose goes up? Both lines are stated flat across all doses. The rate holds as the dose rises. Nothing describes clinical support at an increase. 3. ## What the price includes Semaglutide is $149.97 monthly, $809.95 for six months and $1,349.97 for twelve. That is $135 and $112.50 a month. Tirzepatide is $249.97, $1,349.82 and $2,349.88, or $225 and $195.82. The annual rung is 25 percent below the monthly on both. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Flat across all doses, both molecules - Strength: Billed totals published at each length - Strength: Three plan lengths on each line - Limitation: The best rate needs a $1,349.97 prepay - Limitation: No milligram dose stated - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about LevelUp Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the billed total before committing to a term. Wrong for A reader unwilling to prepay for the lowest figure. ## The evidence behind what LevelUp Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LevelUp Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | LevelsRx | Readers who want the oral option and will ask what the ladder costs | | | MaxLife | Readers who will ask what the starter kit covers and what follows it | | | Longevixx | Readers wanting a flat rate in any state | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Roboclinic](https://thisglp.com/reviews/roboclinic) [Roen Rx](https://thisglp.com/reviews/roen-rx) [RX Bella](https://thisglp.com/reviews/rx-bella) [Rx.com](https://thisglp.com/reviews/rx-com) [RxION Health](https://thisglp.com/reviews/rxion-health) [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with the dose? No. Both lines are stated flat across all doses. What is billed on the annual plan? $1,349.97 for semaglutide and $2,349.88 for tirzepatide, charged as totals. What does six months cost? $809.95 for semaglutide, which is about $135 a month. Is LevelUp Rx expensive compared with other GLP-1 telehealth sellers? LevelUp Rx publishes a starting figure of $149.97/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LevelUp Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Levers Health reviews (2026): GLP-1 telehealth sellers | This GLP Each advertised figure buys a capped weekly dose, and the next band up costs more. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/levers-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by dose band # Levers Health review Each advertised figure buys a capped weekly dose, and the next band up costs more. ## The verdict Levers Health charges $247 a month for compounded semaglutide up to 1.25 mg a week, and $297 up to 2.5 mg. Tirzepatide is $296 up to 5 mg a week, or $396 at any dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $247/mo Prescription Required Compounded Yes — not FDA-approved Levers Health sells both molecules by injection on monthly subscriptions, each split into dose bands. A separate low and microdose GLP-1 line is sold on a two-month cycle. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe products and dose bands rather than clinicians. The intake is not documented. Pricing by dose band is a fair way to sell a drug whose dose climbs. It also means the advertised figure describes the lower band. The product pages name the milligram cap beside each rung, which most sellers do not. 2. ## What happens when the dose goes up? The cost rises with the dose here, in named steps. Semaglutide moves from $247 to $297 above 1.25 mg a week. Tirzepatide moves from $296 to $396 above 5 mg a week. 3. ## What the price includes Six months of semaglutide on the Regular rung is $1,482. On tirzepatide, the $296 low-dose plan sits $100 below the any-dose plan. A reader expecting to reach a full maintenance dose should price the higher band. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The milligram cap is stated beside each rung - Strength: Both dose bands are priced on the product page - Strength: Monthly billing on the main subscriptions - Limitation: The advertised figures are the lower dose bands - Limitation: The any-dose tirzepatide plan costs $100 more - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Levers Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who knows which dose band they will stay in. Wrong for A reader who expects the advertised figure to hold at a full maintenance dose. ## The evidence behind what Levers Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Levers Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Live Vital | Readers who work from the protocol total rather than the monthly figure beside it | | | LeanDose | Readers who will get the month-two rate in writing before the first charge | | | LevelsRx | Readers who want the oral option and will ask what the ladder costs | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RxPros](https://thisglp.com/reviews/rxpros) [RxSaludable](https://thisglp.com/reviews/rxsaludable) [Rylo Health](https://thisglp.com/reviews/rylo-health) [Ryze Rx](https://thisglp.com/reviews/ryze-rx) [Science & Co](https://thisglp.com/reviews/science-and-co) [Semaglutide Online](https://thisglp.com/reviews/semaglutide-online) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost at a higher dose? $297 a month on the Max rung, up to 2.5 mg a week. The $247 Regular rung is capped at 1.25 mg a week. Is $296 the full tirzepatide price? It is the low-dose plan, capped at 5 mg a week. The any-dose plan is $396. What is the line billed every other month? A separate low and microdose GLP-1 product on a two-month cycle. It is not the semaglutide subscription this site ranks. Is Levers Health expensive compared with other GLP-1 telehealth sellers? Levers Health publishes a starting figure of $247/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Levers Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Liberty reviews (2026): GLP-1 telehealth sellers | This GLP The preparation is sourced from a 503B outsourcing facility, which is a different regulatory category from a retail compounding pharmacy. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/liberty Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 503B facility named as source # Liberty review The preparation is sourced from a 503B outsourcing facility, which is a different regulatory category from a retail compounding pharmacy. ## The verdict Liberty prices compounded semaglutide at a flat $129 a month and compounded tirzepatide at a flat $219. Both are stated to come from a 503B outsourcing facility, after a clinician review. The facility type is the fact worth reading here. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $129/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Liberty sells compounded semaglutide and compounded tirzepatide as weekly injections. The two figures read $129 and $219 a month. A three-month supply brings the semaglutide to $110 a month. Both rates are described as flat at every dose. 1. ## Who writes the prescription, and what do they see? The prescription follows a clinician review rather than an automatic approval at checkout. That sequence is stated on the product pages for both molecules. What the review consists of, and whether it is live or asynchronous, is not published. The rate does not change with the outcome of the review. Treatment is arranged remotely and the injection is weekly. The tirzepatide is described as a dual GIP and GLP-1 agonist, which is what the molecule is. Liberty prices the two molecules $90 apart. Liberty describes no coaching or check-in program alongside the medication. 2. ## What happens when the dose goes up? Both rates are stated as flat at every dose. A reader who reaches a maintenance dose in month four pays the same as in month one. Whether a dose change requires a further clinician review is not stated beside the price. The three-month supply is a prepay rather than a different rate. 3. ## What the price includes $129 and $219 are month-to-month figures, and the three-month route drops the semaglutide to $110 and the tirzepatide to $186. The $90 step between molecules is the widest part of this seller's pricing. No state list is published, so a reader confirms coverage at intake. Nothing beside either figure was recorded as a separate charge. 4. ## What it claims, and what it cites A 503B outsourcing facility registers with the FDA and makes products under current good manufacturing practice, which a 503A pharmacy does not. That is a real distinction, and it is not the same as approval: a compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) from a 503B is still not an FDA-approved drug. The outcome trials used the approved products at label doses. Whether a 503B preparation matches them in content or purity is not measured here. ## Where it holds up, and where it does not - Strength: Pharmacy type named, not implied - Strength: Clinician review stated before prescribing - Strength: Rate flat at every dose - Limitation: No state list published - Limitation: Tirzepatide costs $90 more - Limitation: Facility name itself not published ## What the evidence says about this kind of treatment The assessment above is about Liberty. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. Wrong for A reader shopping the compounded market on price alone, since flat pricing and a named facility type are what the higher figure buys. ## The evidence behind what Liberty prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Liberty compares | Seller | Who it suits | Go | | --- | --- | --- | | Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | | | Apex MD | A reader who wants a month-to-month plan with no prepay commitment, and who is told what is in the vial before ordering. | | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SexyMD](https://thisglp.com/reviews/sexymd) [ShapeIn Rx](https://thisglp.com/reviews/shapein-rx) [Shapely](https://thisglp.com/reviews/shapely) [Signos](https://thisglp.com/reviews/signos) [Silhouette MD](https://thisglp.com/reviews/silhouette-md) [SkyRx](https://thisglp.com/reviews/skyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is a 503B outsourcing facility? It is a compounder registered with the FDA that makes products in batches under current good manufacturing practice. A 503A pharmacy compounds for individual prescriptions and is not held to that standard. Does that make the medication FDA-approved? No. A compounded preparation from a 503B facility is still not an FDA-approved drug and is not reviewed for safety or efficacy before it is dispensed. Does the price rise with the dose? Liberty states a flat rate at every dose on both molecules. A three-month supply lowers the semaglutide figure to $110 a month, billed $329 up front. Is Liberty expensive compared with other GLP-1 telehealth sellers? Liberty publishes a starting figure of $129/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Liberty below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LifeMD reviews (2026): GLP-1 telehealth sellers | This GLP Each published figure is medication only, with a $149 monthly program fee charged alongside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lifemd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Program fee sits outside # LifeMD review Each published figure is medication only, with a $149 monthly program fee charged alongside it. ## The verdict LifeMD publishes $199 for the Wegovy pen, $149 for the Wegovy pill and $299 for the Zepbound vial, and every one of those is described as medication only. A $149 monthly program fee is charged alongside. The pages also state the medication can fall to $0 to $25 a month with insurance. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $348/mo Oral From $298/mo Prescription Required Compounded No Availability 50 states LifeMD is a telehealth practice covering a stated fifty states, selling FDA-approved brand semaglutide and tirzepatide across injected and oral forms. What separates its pricing from most here is that the medication and the service are quoted as separate lines rather than as one figure, and both are published. 1. ## Who writes the prescription, and what do they see? The program fee buys the clinical relationship, and LifeMD prices it openly rather than folding it into a headline. That makes the service cost visible in a way a bundled figure never is. What the fee covers in practice — how often a prescriber is seen, what is reviewed — the pages do not describe. Two charges, both disclosed, is a more honest structure than one charge that hides the other. The consequence is that no published figure here is what a buyer pays. The semaglutide injection at $199 is $348 a month once the program fee is counted, and the oral at $149 is $298. 2. ## What happens when the dose goes up? Nothing is published about what the medication charge does as the dose rises. The program fee is stated as a flat monthly amount, so at least one half of the bill is known to hold. On the medication half a reader has only the entry figure. 3. ## What the price includes Read both lines together. Six months on the semaglutide injection is $2,088 with the fee included, against $1,194 if the fee is ignored — which is why it cannot be. The insurance path changes the arithmetic most. LifeMD states the medication can reach $0 to $25 a month for a buyer whose plan covers it. The program fee then becomes the dominant cost rather than a surcharge. 4. ## What it claims, and what it cites Every line is an FDA-approved brand product: [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) by pen or pill, and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) by vial. None is a compounded preparation. The $199 pen figure is labeled an initial price, and what it becomes after the first fills is not stated on the page. ## Where it holds up, and where it does not - Strength: Medication and service priced separately - Strength: The program fee amount is published - Strength: An insurance path is priced, not just implied - Strength: Coverage stated across fifty states - Limitation: No published figure is the full cost - Limitation: The fee exceeds one medication line - Limitation: Dose behavior is not published - Limitation: Which route a buyer lands on is unstated ## What the evidence says about this kind of treatment The assessment above is about LifeMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader with insurance that may cover the medication, leaving the fee as the main cost. Wrong for A reader comparing medication headlines across sellers without adding a standing fee. ## The evidence behind what LifeMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LifeMD compares | Seller | Who it suits | Go | | --- | --- | --- | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Society of You](https://thisglp.com/reviews/society-of-you) [Somi Health](https://thisglp.com/reviews/somi-health) [Somira Health](https://thisglp.com/reviews/somira-health) [Southern Vitality and Weight Loss](https://thisglp.com/reviews/southern-vitality-weight-loss) [Spry](https://thisglp.com/reviews/spry) [StackMD](https://thisglp.com/reviews/stackmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does LifeMD actually cost? The medication figure plus $149 a month. The semaglutide injection at $199 becomes $348, and the oral at $149 becomes $298. Can the medication really be $0? LifeMD states it can fall to $0 to $25 a month with insurance. The program fee still applies, so it becomes the main charge rather than a surcharge. Is the program fee avoidable? Nothing on the pages suggests it is. Every medication figure is described as medication only, with the fee charged alongside. Is LifeMD legit? LifeMD is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is LifeMD expensive compared with other GLP-1 telehealth sellers? LifeMD publishes a starting figure of $298/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LifeMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LifeRx.md reviews (2026): GLP-1 telehealth sellers | This GLP One starting figure for a GLP-1 plan, a pledge not to charge more as the dose climbs, and a refund policy with no exceptions for dispensed medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/liferx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One figure, no dose upcharge # LifeRx.md review One starting figure for a GLP-1 plan, a pledge not to charge more as the dose climbs, and a refund policy with no exceptions for dispensed medication. ## The verdict LifeRx.md prices its GLP-1 weight-management plan from $200 a month, with an asterisk pointing to terms that apply, and it promises that the figure will not rise as a prescribed dose is stepped up. The plan page never names the medication in its headline, although its disclaimer about compounded drugs refers to semaglutide. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $200/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states LegitScript Claimed by provider LifeRx.md is a New Jersey telehealth company that treats weight, hair loss and erectile dysfunction, and its weight-loss line is a compounded GLP-1 plan supervised by a provider, with no insurance needed and HSA or FSA cards accepted. The FAQ says it serves all 50 states and holds LegitScript certification. 1. ## Who writes the prescription, and what do they see? A licensed provider in the patient's state reviews the intake, and for weight-loss treatment an initial video consultation is required before anything is prescribed, after which the provider sets the medication and the dose. The providers are described as independent contractors, and none is named on the weight-loss page. There is no subscription: the refund policy says each month of service is started by the patient and nothing renews automatically, which means a missed reorder is a missed month rather than a surprise charge. Medication ships from licensed 503A partner pharmacies in three to five business days, and check-ins with the care team continue as the plan is adjusted. 2. ## What happens when the dose goes up? The page makes one promise about escalation: a higher prescribed dose will not be used as a reason to charge more. If that holds, the step from a starting dose to a maintenance dose over the first few months leaves the $200 where it started, though no milligram figures are published to show what the plan covers. 3. ## What the price includes The $200 is a starting figure with an asterisk, and the terms behind the asterisk are not spelled out on the page beyond a line saying that pricing, eligibility and other terms apply. Six months at that figure would be $1,200. The refund policy also describes consultation fees charged separately from medication for each visit with a provider, and no amount for them is published anywhere. Every medication sale is final once it is dispensed, with no exception for an unopened package. 4. ## What it claims, and what it cites The plan uses compounded medication, which is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness or quality, as the seller's own disclaimer says in plain terms. The 503A pharmacies that fill it are licensed by state boards, and none of them is named. ## Where it holds up, and where it does not - Strength: Price stated not to rise with dose - Strength: No subscription or membership fee - Strength: Served in all 50 states - Strength: LegitScript certification stated in the FAQ - Limitation: Medication not named in the plan headline - Limitation: Terms behind the asterisk not spelled out - Limitation: Consultation fees billed separately, amount unstated - Limitation: No refunds once medication is dispensed ## What the evidence says about this kind of treatment The assessment above is about LifeRx.md. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone expecting to climb to a higher dose over the first months who wants the price to stay put while they do. Wrong for A buyer who wants the exact medication, the consultation cost and the fine print settled before paying anything. ## The evidence behind what LifeRx.md prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LifeRx.md compares | Seller | Who it suits | Go | | --- | --- | --- | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | TrimRx | Readers who already know which molecule they want and will hunt for which tile holds it | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Spry](https://thisglp.com/reviews/spry) [StackMD](https://thisglp.com/reviews/stackmd) [Sumbare Wellness](https://thisglp.com/reviews/sumbare-wellness) [Sunlight](https://thisglp.com/reviews/sunlight) [Superior Remedies](https://thisglp.com/reviews/superior-remedies) [Superpower](https://thisglp.com/reviews/superpower-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price go up with the dose? The page says it does not, stating that a prescribed dosage will not be used as a reason to charge more and that there are no higher-dose upcharges. Is it a subscription? No, the refund policy says each month of service is started by the patient and there is no automatic renewal, so nothing is billed until the next month is ordered. Can I get a refund? Not for medication once it has been dispensed or shipped, and consultation fees are non-refundable once the visit has taken place. Is LifeRx.md legit? LifeRx.md is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is LifeRx.md expensive compared with other GLP-1 telehealth sellers? LifeRx.md publishes a starting figure of $200/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LifeRx.md above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LifespanningRx reviews (2026): GLP-1 telehealth sellers | This GLP A Miami peptide and longevity platform whose weight-loss program is sold through a clinician evaluation, with no GLP-1 price on the program page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lifespanningrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A peptide store, weight loss behind a consult # LifespanningRx review A Miami peptide and longevity platform whose weight-loss program is sold through a clinician evaluation, with no GLP-1 price on the program page. ## The verdict LifespanningRx offers medical weight loss as one program inside a much larger peptide and longevity catalog, and the program page names FDA-approved options such as Wegovy and Zepbound without attaching a price to any of them. A buyer who wants to know the monthly cost before starting will not find it in the store's navigation, and the program says outright that nothing is prescribed before a clinician has evaluated the patient. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Dose published No Prescription Required Pharmacy Not named LifespanningRx is a Florida telehealth platform, operated from Brickell Avenue in Miami, that sells more than fifty clinician-guided therapies. Most of them are peptides such as NAD+, glutathione and sermorelin, sold alongside at-home diagnostic kits and a blood test marketed as peptide readiness. Medical weight loss sits in its menu beside cellular rejuvenation, detox, longevity and brain health, and the platform says it charges no membership fee. 1. ## Who writes the prescription, and what do they see? The program page says a licensed provider evaluates eligibility, reviews risks and benefits, and decides whether treatment is medically appropriate. Elsewhere the site describes itself as a telehealth platform rather than a pharmacy, with prescriptions dispensed by licensed pharmacies after an independent clinical evaluation. It links to a provider network page, but the weight-loss program itself names no prescribing clinician, and the four-step process ends with a virtual consultation before anything ships. A patient starts with a screening of two or three minutes, browses therapies or uses the site's simulator to find possible matches, then meets a provider in a virtual consultation that confirms what is appropriate. If approved, the prescription is prepared and sent by refrigerated overnight delivery. The program stresses muscle preservation and metabolic health over the number on the scale, and promises ongoing follow-up to watch tolerance and response over time. 2. ## What happens when the dose goes up? Nothing on the program page describes a dose schedule, how often a dose is reviewed, or whether the cost moves as a patient climbs from a starting dose toward maintenance. The FAQ does raise the part most programs leave out, noting that weight can return after treatment stops and that maintenance should be planned at the start rather than treated as an afterthought. It stops short of saying what that maintenance involves or costs. 3. ## What the price includes The weight-loss program page publishes no price for any medication, and following the site's own menus leads to that page rather than to a priced GLP-1 product. The store says programs are available without a membership fee and without commitment, and that a purchase includes the medical evaluation and treatment access. Even so, a reader comparing monthly costs across sellers has no LifespanningRx figure to set beside the others until the evaluation is done. 4. ## What it claims, and what it cites The program page lists GLP-1 and GIP/GLP-1 treatments, naming FDA-approved [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) for chronic weight management and noting that Ozempic and Mounjaro carry different approved uses, along with oral prescription options for some patients. It also says prescriptions are filled by U.S. 503A pharmacies, which compound medications; compounded preparations are not FDA-approved, and the page does not say which products a patient would receive in which form. ## Where it holds up, and where it does not - Strength: No membership fee, per the site - Strength: FDA-approved brands named on the program page - Strength: Weight regain after stopping addressed in the FAQ - Strength: Muscle preservation built into the program - Limitation: No GLP-1 price on the program page - Limitation: No dose schedule published - Limitation: Prescribing clinician not named for the program - Limitation: Brand versus compounded supply not specified ## What the evidence says about this kind of treatment The assessment above is about LifespanningRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer already using the platform's peptide or longevity programs who wants weight loss handled in the same place. Wrong for A buyer comparing published monthly GLP-1 prices before sharing any health information. ## The evidence behind what LifespanningRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LifespanningRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Boston Medical Group | Buyers who want a one-month price that holds at every dose and a named dispensing pharmacy | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Synergy Rx](https://thisglp.com/reviews/synergy-rx) [T2D.com](https://thisglp.com/reviews/t2d) [TD Tele-Doc Weight Loss](https://thisglp.com/reviews/td-teledoc) [TeleCareSpot](https://thisglp.com/reviews/telecarespot) [TeleClinic](https://thisglp.com/reviews/teleclinic) [TeleDocs360](https://thisglp.com/reviews/teledocs360) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How much does LifespanningRx charge for semaglutide or tirzepatide? The weight-loss program page does not publish a price, and the store's menus do not lead to a priced GLP-1 product, so the cost is set out only once the clinician evaluation is under way. Does LifespanningRx prescribe Ozempic for weight loss? Its FAQ says Ozempic is approved for type 2 diabetes rather than chronic weight management, and that a clinician may instead consider Wegovy or Zepbound for eligible patients. Is there a membership fee? No, according to the site, which advertises no membership fees and cancellation at any time. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LifeVine Wellness reviews (2026): GLP-1 telehealth sellers | This GLP LifeVine’s nurse-founded identity sits alongside a clear legal distinction: independent medical groups provide treatment. Renewal charges may be processed early. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lifevine-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Nurse-founded platform, independent care # Does LifeVine Wellness sell a GLP-1? LifeVine’s nurse-founded identity sits alongside a clear legal distinction: independent medical groups provide treatment. Renewal charges may be processed early. ## The verdict The online workflow and continuing portal access are understandable, but the assigned practice, pharmacy and visit cadence need confirmation. A nurse-founded platform is not itself a promise that a particular nurse will manage the prescription. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved LifeVine Wellness LLC is a virtual-care platform based in Greensboro. It advertises GLP-1 care through independent licensed providers and identifies its mailing location as administrative, not a public clinic. 1. ## Who writes the prescription, and what do they see? Its public disclaimer assigns medical services to providers affiliated with independent medical groups. Ask who receives the intake and who takes over when the usual clinician is unavailable. The site describes an online history, clinical review and pharmacy delivery when appropriate, followed by messaging through a patient portal. It says medication availability may differ by state even while advertising broad service access. 2. ## What happens when the dose goes up? Ongoing support is described, but a fixed clinical review interval is not established in the reviewed pages. Confirm the refill authorization process and how symptoms are escalated beyond routine messages. 3. ## What the price includes The service is cash-pay and does not bill commercial insurance, Medicare or Medicaid. A complete public monthly drug total was not established; the terms allow some renewal charges to occur ahead of the displayed cycle. 4. ## What it claims, and what it cites Semaglutide and tirzepatide are named within the weight program, with a compounded-drug disclosure. Compounded medicines are not FDA-approved; the actual formulation and pharmacy should be identified before fulfillment. ## Where it holds up, and where it does not - Strength: Independent clinical role disclosed - Strength: Portal support after intake - Limitation: Provider assignment needs confirmation - Limitation: No complete public recurring quote ## What the evidence says about this kind of treatment The assessment above is about LifeVine Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone comfortable with asynchronous portal care who wants to verify the independent practice and billing schedule. Wrong for Someone seeking in-person care at the published mailing address or an insurance-billed medication bundle. ## The evidence behind what LifeVine Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LifeVine Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TeleDocs360](https://thisglp.com/reviews/teledocs360) [TeleHealth Med](https://thisglp.com/reviews/telehealth-med) [TeleHealth Weight Solutions](https://thisglp.com/reviews/telehealth-weight-solutions) [TelePeptide](https://thisglp.com/reviews/telepeptide) [TeleSlim Clinic](https://thisglp.com/reviews/teleslim-clinic) [TeleZen MD](https://thisglp.com/reviews/telezen-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does nurse-founded identify my clinician? No. The platform says independent medical groups provide care; confirm the clinician assigned to your case. Does general nationwide language guarantee a product in my state? No. The site says specific medications and options can vary with provider and pharmacy authorization. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://www.lifevinewellness.com/) - [Official program and terms](https://www.lifevinewellness.com/weight-loss) - [Official program and terms](https://www.lifevinewellness.com/how-it-works) - [Official program and terms](https://www.lifevinewellness.com/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lighter You reviews (2026): GLP-1 telehealth sellers | This GLP Lighter You combines medication access with advertised support. Verify the plan’s clinical follow-up and the conditions behind its satisfaction guarantee. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lighter-you Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 An online program advertising weekly semaglutide and tirzepatide injections, with coaching and other GLP-1 formats listed separately. # Lighter You review Lighter You combines medication access with advertised support. Verify the plan’s clinical follow-up and the conditions behind its satisfaction guarantee. ## The verdict Potentially useful for someone wanting medication and coaching together, but the public guarantee needs to be read alongside the refund policy. Availability is expressly not universal across states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Lighter You offers online prescription wellness services through healthcare-provider and pharmacy partners. Weight-loss products sit alongside peptide, microdosing and other wellness categories. 1. ## Who writes the prescription, and what do they see? A licensed healthcare provider reviews individual health needs and decides whether to prescribe. Ask for the treating practice and clinician’s state authorization before care begins. The site advertises dietitian and coaching support with an asterisk, plus access to care. Confirm the included sessions, eligibility conditions and whether a clinical professional handles medication questions. 2. ## What happens when the dose goes up? Weekly injections are listed for both named molecules. Separate tablets and microdose categories should not be treated as equivalent plans. Ask how the clinician reviews symptoms and changes a prescription over time. 3. ## What the price includes The storefront mixes a limited-time offer with product starting prices and separate microdose pricing. Its FAQ describes month-to-month membership and a satisfaction guarantee, while terms say sales are final except under the applicable refund policy. 4. ## What it claims, and what it cites [Semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) injections are explicitly named. Other GLP-1 tablets are listed without a clear molecule-to-format match in the reviewed overview. Compounding disclosures do not make these FDA-approved products. ## Where it holds up, and where it does not - Strength: Names both weekly injection options - Strength: Advertises coaching alongside medication access - Limitation: Support inclusions need clarification - Limitation: Guarantee depends on the applicable refund policy ## What the evidence says about this kind of treatment The assessment above is about Lighter You. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults seeking an injection program who will verify the promised coaching and state availability. Wrong for Anyone relying on an unconditional refund or assuming every listed tablet contains the same drug as an injection. ## The evidence behind what Lighter You prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lighter You compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Tell Her Doc](https://thisglp.com/reviews/tellherdoc) [Telos Rx](https://thisglp.com/reviews/telos-rx) [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) [The Edit](https://thisglp.com/reviews/the-edit) [The Virtual NP](https://thisglp.com/reviews/the-virtual-np) [TMates](https://thisglp.com/reviews/tmates) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Lighter You available in every state? No universal coverage is established. The site expressly says it is not available in all fifty states; confirm eligibility for your location. Does the guarantee override every sales condition? The terms defer to the applicable refund policy. Ask which charges and circumstances qualify before purchasing. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://www.lighteryou.co/) - [Official program and terms](https://shop.lighteryou.co/intake?productId=UHJvZHVjdDoxNDQ%3D) - [Official program and terms](https://www.lighteryou.co/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LillyDirect Foundayo reviews (2026): manufacturer direct pharmacy | This GLP Eli Lilly's direct pharmacy channel for its orforglipron tablet, with a self-pay price for every strength and a separate insured figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lillydirect-foundayo Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The maker's own pill, priced by dose # LillyDirect Foundayo review Eli Lilly's direct pharmacy channel for its orforglipron tablet, with a self-pay price for every strength and a separate insured figure. ## The verdict LillyDirect sells Foundayo, the FDA-approved orforglipron tablet, straight from the manufacturer. Self-pay starts at $149 a month for the 0.8 mg starting dose and rises with the strength. The $25 figure applies only with commercial insurance that covers the drug. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category manufacturer direct pharmacy Molecule Orforglipron Form Injection · Oral Dose pricing Rises with dose States 51 Dose published Yes Prescription Required Compounded No LillyDirect is Eli Lilly's own pharmacy and support service. Foundayo is a once-daily oral GLP-1 tablet approved for chronic weight management in adults with obesity, or with overweight and a weight-related condition. It comes in six strengths, from 0.8 mg to 17.2 mg. LillyDirect delivers to the home or supports pickup at a retail pharmacy. 1. ## Who writes the prescription, and what do they see? LillyDirect does not prescribe. A patient's own clinician sends the prescription to LillyDirect Pharmacy in Indianapolis. For patients without a doctor, the page links to independent telehealth services and to Healthgrades for in-person care. Those clinicians are not Lilly's, and none is named here. Once the prescription arrives, a pharmacy partner contacts the patient. It confirms details, checks for savings, and offers delivery or retail pickup. Insured patients get help with coverage checks and prior authorization. Beyond that, the channel supplies the drug and savings support; ongoing clinical care stays with the prescriber. 2. ## What happens when the dose goes up? Price follows the dose, and every strength is printed. Self-pay is $149 a month at 0.8 mg and at 2.5 mg, $199 at 5.5 mg, and $299 at 9 mg. The 2.5 mg and 5.5 mg prices are temporary reductions through December 31, 2026; the regular prices are $199 and $299. At 14.5 mg and 17.2 mg the regular price is $349, or $299 when each refill is bought within 45 days of the last delivery. A month is defined as 30 days. 3. ## What the price includes Three prices apply, depending on how the patient pays. Self-pay runs from $149 to $349 for a 30-day supply by strength. Commercially insured patients whose plan covers Foundayo may pay as little as $25 with the savings card; government beneficiaries are excluded. Eligible Medicare Part D patients are pointed to a $50-a-month bridge program. The savings figures carry monthly caps, and Lilly may change or end them at any time. 4. ## What it claims, and what it cites Foundayo is an FDA-approved brand product, dispensed by the manufacturer's own pharmacy. It is not compounded. It is taken by mouth once a day, with or without food, and should not be combined with other GLP-1 medicines. The label carries a warning about thyroid C-cell tumors seen in rodents. ## Where it holds up, and where it does not - Strength: FDA-approved tablet from the manufacturer - Strength: Self-pay price printed for every strength - Strength: No injection and no food timing - Strength: Home delivery or retail pickup - Limitation: Two strengths are temporarily discounted - Limitation: $25 needs covering commercial insurance - Limitation: Top-strength price depends on refill timing - Limitation: Prescriber must be found separately ## What the evidence says about this kind of treatment The assessment above is about LillyDirect Foundayo. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient with a prescriber who wants an approved oral GLP-1 at a published cash price. Wrong for A buyer looking for one service that supplies both the clinician and the medication. ## The evidence behind what LillyDirect Foundayo prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. ## How LillyDirect Foundayo compares | Seller | Who it suits | Go | | --- | --- | --- | | NovoCare Pharmacy | Readers who want the approved product and will count thirteen boxes a year rather than twelve | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Tonik Wellness](https://thisglp.com/reviews/tonik-wellness) [Transparent Meds](https://thisglp.com/reviews/transparent-meds) [Trava Health](https://thisglp.com/reviews/trava-health) [Trellis Vitality](https://thisglp.com/reviews/trellis-vitality) [Trillium Meds](https://thisglp.com/reviews/trillium-meds) [Trimi Health](https://thisglp.com/reviews/trimi-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Foundayo $25 a month? Only with commercial insurance that covers it, through the savings card. The self-pay price starts at $149 a month for the 0.8 mg dose. Does the price go up with the dose? Yes. Self-pay is $149 at the two lowest strengths, $199 at 5.5 mg and $299 at 9 mg, with two of those rates temporary through the end of 2026. Does LillyDirect write the prescription? No. A patient's own clinician prescribes, and LillyDirect links to independent telehealth and in-person options for anyone without one. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Liv Body reviews (2026): GLP-1 telehealth sellers | This GLP No membership and no contract, and an asterisk saying the real price depends on what is prescribed. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/liv-body Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A floor with an asterisk # Liv Body review No membership and no contract, and an asterisk saying the real price depends on what is prescribed. ## The verdict Liv Body publishes $99 a month for compounded semaglutide and $149 for tirzepatide. An asterisk states the actual price depends on the product and plan prescribed. No membership or contract applies. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $99/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Liv Body sells both molecules by injection. No membership or contract is required. Expedited shipping is free. New patients are offered $150 in supplements. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and decides the price. The asterisk says so directly. No clinician is described. Two disclosures point opposite ways. There is no membership and no contract, which removes the usual hidden charge. And the figure is conditional on what a prescriber decides, which removes the certainty. 2. ## What happens when the dose goes up? Nothing is published about dose. The asterisk covers the same ground from the other side. The plan prescribed sets the price, and the plan is decided after intake. 3. ## What the price includes $99 and $149 are floors rather than rates. Six months at them is $594 and $894 at best. What raises them is not published. The $150 in supplements is a new-patient offer, not a discount on medication. 4. ## What it claims, and what it cites Both lines are compounded. The FDA does not review them before dispensing. The disclaimer names four pharmacies. They are RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy and Triad Rx. ## Where it holds up, and where it does not - Strength: No membership and no contract, stated - Strength: Free expedited shipping included - Strength: The conditional pricing is disclosed - Strength: Four dispensing pharmacies named - Limitation: Both figures are a floor, not a rate - Limitation: The real price depends on the prescription - Limitation: No milligram dose stated - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Liv Body. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants no contract and will ask what their plan costs. Wrong for A reader budgeting from $99 without asking what the prescription adds. ## The evidence behind what Liv Body prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Liv Body compares | Seller | Who it suits | Go | | --- | --- | --- | | Longevixx | Readers wanting a flat rate in any state | | | LVNG RX | Readers who want a bundle and accept the figure is confirmed later | | | LevelsRx | Readers who want the oral option and will ask what the ladder costs | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TrimRx](https://thisglp.com/reviews/trimrx) [Trinity Meds](https://thisglp.com/reviews/trinity-meds) [TRT Nation](https://thisglp.com/reviews/trt-nation) [Tru2u](https://thisglp.com/reviews/tru2u) [TrueMe](https://thisglp.com/reviews/trueme) [Try Ageless](https://thisglp.com/reviews/try-ageless) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Will I pay $99? Only if the prescribed product and plan carry that figure. The asterisk states the actual price depends on both. Is there a membership fee? No. The seller states there is no membership and no contract. What are the free supplements? A $150 supplement offer for new patients. It does not change the medication price. Is Liv Body expensive compared with other GLP-1 telehealth sellers? Liv Body publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Liv Body below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LIV by WellNow reviews (2026): GLP-1 telehealth sellers | This GLP One compounded semaglutide membership at $195 a month, sold in five states, with its dose schedule printed on the page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/liv-by-wellnow Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Five states, printed dose path # LIV by WellNow review One compounded semaglutide membership at $195 a month, sold in five states, with its dose schedule printed on the page. ## The verdict LIV by WellNow sells one thing, compounded semaglutide, as a membership at $195 a month that includes the medication, supplies and unlimited virtual visits, and it prints the average dose schedule beside that price. Paying for three months at once brings the rate to $175 a month, and a higher dose costs more once a provider approves it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 5 From From $195/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability IL, IN, MI, NY, PA A weight-loss membership from a sister brand of WellNow Urgent Care, open only to adults in Illinois, Indiana, Michigan, New York and Pennsylvania who meet a BMI threshold of 30, or 27 alongside a condition like hypertension. 1. ## Who writes the prescription, and what do they see? An online health assessment comes first, with height and weight, and some applicants are asked to meet a provider to go over history and goals before the membership is approved. The providers are described as board-certified and online, and same-day approval is offered, though the site does not name any of them. Once approved, the medication arrives at home once a month with instructions, and the weekly doses run alongside unlimited virtual visits for questions or advice. Payment is out of pocket because no insurance is accepted, though an FSA or HSA may cover the membership depending on the individual plan. 2. ## What happens when the dose goes up? The page prints the schedule: 0.25 mg weekly for weeks one to four, 0.5 mg for weeks five to eight, and 1 mg from week nine, held there as maintenance. The $195 covers that average path; a patient whose provider moves them above it pays a published higher-dose rate, which needs provider approval, and that is the part of the year a budget should leave room for. 3. ## What the price includes Month to month the membership is $195, so six months at that rate comes to $1,170, and paying a quarter at a time in one charge lowers it to $175 a month, or $525 per payment. Both figures belong to the average dose, and the higher-dose tier costs more on either schedule. 4. ## What it claims, and what it cites The medication is compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review), and the site states plainly that it is not approved or evaluated by the FDA for safety, efficacy or quality. No compounding pharmacy is named anywhere on the pages, and no tirzepatide option is offered alongside it. ## Where it holds up, and where it does not - Strength: Dose schedule printed in milligrams - Strength: Medication, supplies and visits in one price - Strength: Quarterly payment lowers the monthly rate - Limitation: Available in five states only - Limitation: Higher doses move to a dearer tier - Limitation: No compounding pharmacy is named - Limitation: No tirzepatide option is offered ## What the evidence says about this kind of treatment The assessment above is about LIV by WellNow. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in one of the five states who wants to see the dose path before paying. Wrong for A reader outside Illinois, Indiana, Michigan, New York and Pennsylvania, or one who wants tirzepatide. ## The evidence behind what LIV by WellNow prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How LIV by WellNow compares | Seller | Who it suits | Go | | --- | --- | --- | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TRYM Health](https://thisglp.com/reviews/trym-health) [Tryozi](https://thisglp.com/reviews/tryozi) [Tuyo Health](https://thisglp.com/reviews/tuyo-health) [Tyde Wellness](https://thisglp.com/reviews/tyde-wellness) [UR Meds](https://thisglp.com/reviews/ur-meds) [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Where is LIV by WellNow available? Only in Illinois, Indiana, Michigan, New York and Pennsylvania, for adults who meet the BMI criteria the page sets out. Does the price change with the dose? Yes, above the average dose. The $195 rate covers the published schedule, and a higher dose, which needs provider approval, carries a higher monthly rate. Is there a discount for paying ahead? Paying three months at once, in a single charge, brings the average-dose rate down to $175 a month. Is LIV by WellNow legit? LIV by WellNow is a GLP-1 telehealth sellers service. Its stated availability: IL, IN, MI, NY, PA. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is LIV by WellNow expensive compared with other GLP-1 telehealth sellers? LIV by WellNow publishes a starting figure of $195/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LIV by WellNow above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Livbetr reviews (2026): GLP-1 telehealth sellers | This GLP A care coach and AI-assisted check-ins accompany clinician-reviewed treatment. Ask which contacts involve the prescriber. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/livbetr Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinical network identified # Livbetr review A care coach and AI-assisted check-ins accompany clinician-reviewed treatment. Ask which contacts involve the prescriber. ## The verdict Livbetr combines coaching and automated check-ins with clinical review; the key question is how those different kinds of support connect when a medical issue appears. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Livbetr offers online compounded semaglutide and tirzepatide care. Its public offer combines clinician review, medication delivery, a care coach and AI-assisted check-ins, with a promotional price tied to remaining on the plan. 1. ## Who writes the prescription, and what do they see? Livbetr’s terms identify licensed clinicians through OpenLoop or other partner networks. Those clinicians review the intake and can decline treatment. Accurate disclosure of medical history and current medicines is part of the clinical evaluation. The homepage advertises an ongoing care coach, clinical review and AI-powered check-ins. A coach or automated check-in is not necessarily a prescribing clinician. Clarify which symptoms go directly to a provider and how to obtain a clinical response between refills. 2. ## What happens when the dose goes up? Livbetr markets a flat price at different doses, with dosing adjusted as the body responds. The prescriber should decide changes; ask whether pausing an increase changes a prepaid shipment or the terms of the promotion. 3. ## What the price includes The current homepage emphasizes a continuing promotional discount for as long as the patient remains on the plan. The terms allow different plan cycles and make the consultation nonrefundable once intake is submitted and medicine nonrefundable once the pharmacy processes it. Confirm the full cycle total and what ends the discount. 4. ## What it claims, and what it cites The medicines are compounded injections, not FDA-approved products. The clinical partner may be OpenLoop or another licensed network. Confirm the dispensing pharmacy and the exact prescription rather than treating the storefront’s medication categories as a completed care plan. ## Where it holds up, and where it does not - Strength: Clinical network identified - Strength: Coaching accompanies treatment - Strength: Dose-based price claim is stated - Limitation: AI check-ins are not a substitute for a clinician - Limitation: Promotion depends on remaining enrolled - Limitation: Consultation and pharmacy refund cutoffs differ ## What the evidence says about this kind of treatment The assessment above is about Livbetr. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants coaching alongside prescribing and can confirm when a licensed clinician personally reviews progress or symptoms. Wrong for Someone who needs every check-in to be a scheduled clinician appointment rather than a mix of coaching and automated support. ## The evidence behind what Livbetr prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Livbetr compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) [Vaylen](https://thisglp.com/reviews/vaylen) [Velvet Rx](https://thisglp.com/reviews/velvet-rx) [VevaRX](https://thisglp.com/reviews/vevarx) [VigorMeds](https://thisglp.com/reviews/vigormeds) [VirtualCare2Go](https://thisglp.com/reviews/virtualcare2go) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The homepage advertises an ongoing care coach, clinical review and AI-powered check-ins. A coach or automated check-in is not necessarily a prescribing clinician. Clarify which symptoms go directly to a provider and how to obtain a clinical response between refills. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Current treatment and promotion](https://www.livbetr.com/) - [Medical, payment and refund terms](https://www.livbetr.com/terms) - [GLP-1 safety information](https://www.livbetr.com/glp-1-safety-information) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Live Vital reviews (2026): GLP-1 telehealth sellers | This GLP Both plans are ten-week protocols, and the page's own framing calls one of them a three-month program. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/live-vital Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Ten weeks, not three months # Live Vital review Both plans are ten-week protocols, and the page's own framing calls one of them a three-month program. ## The verdict Live Vital sells semaglutide as a ten-week protocol at $299 and tirzepatide at $549. Ten weeks is 2.3 calendar months, which makes the real figures about $130 and $239 a month rather than the thirds those totals suggest. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $130/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Live Vital sells both molecules by injection as fixed protocols rather than subscriptions, across fifty states, with the whole cost stated up front and the duration stated in weeks. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the clinician is not described, which matters more on a fixed protocol than on a subscription: a buyer commits to the full term at the outset rather than to a month they can leave. The protocol framing is honest in one respect and misleading in another. Publishing a total and a duration is better than publishing a monthly figure with no term behind it. Describing ten weeks as a three-month program is the part that costs a reader money, because it makes a $299 total look like a $100 month. 2. ## What happens when the dose goes up? Nothing is published about what happens at a higher dose, and a fixed ten-week protocol raises the question sharply. Most people are still escalating at week ten, so a reader needs to know what the next protocol costs before the first one ends. The pages do not say. 3. ## What the price includes A year holds 5.2 ten-week periods rather than four, so $299 is about $130 a calendar month and not the $99 a month the page prints, which divides the total by three. Tirzepatide is worse: the page prints $183 a month against a $549 total, and ten weeks makes the real figure about $239 — a thirty percent understatement on the seller's own arithmetic. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The protocol total is published up front - Strength: The duration is stated in weeks - Strength: Coverage across all fifty states - Limitation: Ten weeks is framed as three months - Limitation: The tirzepatide monthly figure is 30% low - Limitation: Nothing published about the next protocol - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Live Vital. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who works from the protocol total rather than the monthly figure beside it. Wrong for A reader taking the page's own per-month arithmetic at face value. ## The evidence behind what Live Vital prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Live Vital compares | Seller | Who it suits | Go | | --- | --- | --- | | Levers Health | Readers who know which dose band they will stay in | | | Livea | Readers in a served state who will get the fee relationship confirmed in writing | | | Luma Meds | Readers who are new, will prepay three months, and know what month four costs | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [VitaFusions IV](https://thisglp.com/reviews/vitafusions-iv) [Vital Edge](https://thisglp.com/reviews/vital-edge) [Vitalex Health](https://thisglp.com/reviews/vitalex-health) [Vitara RX](https://thisglp.com/reviews/vitara-rx) [VitaStir](https://thisglp.com/reviews/vitastir) [Voxy](https://thisglp.com/reviews/voxy) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $183 the monthly tirzepatide price? No. The protocol is ten weeks at $549 in total, and ten weeks is 2.3 calendar months, so the real figure is about $239 a month. Why does a ten-week protocol not equal three months? Because a year holds 5.2 ten-week periods rather than four. Dividing a ten-week total by three understates the monthly cost by about thirty percent. What happens after ten weeks? Nothing is published about the cost of a following protocol, which matters because most people are still escalating at week ten. Is Live Vital legit? Live Vital is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Live Vital expensive compared with other GLP-1 telehealth sellers? Live Vital publishes a starting figure of $130/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Live Vital below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Livea reviews (2026): GLP-1 telehealth sellers | This GLP The medication figure and the program fee live on different pages, and the site says the relationship between them is settled at a consultation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/livea Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Medication plus a program fee # Livea review The medication figure and the program fee live on different pages, and the site says the relationship between them is settled at a consultation. ## The verdict Livea publishes compounded semaglutide starting at $99 a month and tirzepatide at $199, with a separate $69 monthly program fee disclosed on another page — which makes the real figures $168 and $268. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 4 From From $168/mo Prescription Required Compounded Yes — not FDA-approved Availability 4 states Livea sells both molecules by injection in four states, running a program fee covering consultation and supervision alongside a medication charge that is quoted separately. 1. ## Who writes the prescription, and what do they see? The $69 program fee is described as covering consultation and supervision, which is a clearer statement of what a clinical relationship costs than most sellers offer. It is also on a different page from the price a reader arrives at. Livea's own FAQ says whether the $99 is inclusive of or additive to the program fee is clarified at a free consultation. That is an unusual admission: the seller knows the question is open and has chosen to answer it in a call rather than in writing. The medical page describes the fee as covering program access and supervision with medication stated as separate, which is why this desk treats the two as additive. 2. ## What happens when the dose goes up? Nothing is published about what the medication figure does at a higher dose. Livea also states that the end of the FDA shortage affects compounded tirzepatide availability and that it monitors eligibility, offering branded alternatives — so both the price and the supply of that line are conditional. 3. ## What the price includes Adding the fee gives $168 a month for semaglutide and $268 for tirzepatide, and six months is $1,008 or $1,608. Budgeting from $99 would give $594, which is $414 short. The starting-at wording on both medication figures leaves a further gap on top of that. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing. The [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) line's availability is stated to depend on compounding status. ## Where it holds up, and where it does not - Strength: The program fee is disclosed in writing - Strength: What the fee covers is described - Strength: Compounding-status risk is stated openly - Limitation: The fee is on a different page from the price - Limitation: The site defers the question to a call - Limitation: Coverage is recorded in four states - Limitation: Tirzepatide availability is conditional ## What the evidence says about this kind of treatment The assessment above is about Livea. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in a served state who will get the fee relationship confirmed in writing. Wrong for A reader budgeting from the $99. ## The evidence behind what Livea prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Livea compares | Seller | Who it suits | Go | | --- | --- | --- | | Luma Meds | Readers who are new, will prepay three months, and know what month four costs | | | Live Vital | Readers who work from the protocol total rather than the monthly figure beside it | | | LeanDose | Readers who will get the month-two rate in writing before the first charge | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vyora Wellness](https://thisglp.com/reviews/vyora-wellness) [VyrarX](https://thisglp.com/reviews/vyrarx) [Vytora Health](https://thisglp.com/reviews/vytora-health) [Walgreens Weight Management](https://thisglp.com/reviews/walgreens-weight-management) [WeightCare](https://thisglp.com/reviews/weightcare) [WeightlessRx](https://thisglp.com/reviews/weightlessrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $99 include the program fee? Livea's own FAQ says that is clarified at a free consultation. Its medical page describes the $69 fee as covering program access and supervision with medication separate, so the figures are treated here as additive: $168 a month. What does the $69 buy? Program access and supervision, including the consultation, per the medical page. Medication is stated separately. Is tirzepatide available? Conditionally. Livea states the end of the FDA shortage affects compounded tirzepatide and that it monitors eligibility, offering branded alternatives. Is Livea legit? Livea is a GLP-1 telehealth sellers service. Its stated availability: 4 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Livea expensive compared with other GLP-1 telehealth sellers? Livea publishes a starting figure of $168/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Livea below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # 50 Stars Health reviews (2026): GLP-1 telehealth sellers | This GLP Compounded semaglutide is $146 on the monthly plan, the same at every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/livv Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three plans, one price per dose # 50 Stars Health review Compounded semaglutide is $146 on the monthly plan, the same at every dose. ## The verdict 50 Stars Health charges $146 a month for compounded semaglutide. Compounded tirzepatide is $220 a month. Both are monthly-plan rates. Three- and six-month plans cost less per month. The price does not change with the dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $146/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability Puerto Rico plus 44 states 50 Stars Health sells compounded GLP-1 injections for weight loss. It also sells longevity, hormone, sexual-health, hair and pain treatments. 1. ## Who writes the prescription, and what do they see? A U.S.-licensed provider reviews the intake and decides whether to prescribe. Review takes up to 48 hours. The provider messages the patient in the portal before prescribing. The patient can ask questions at that point. The product pages name one physician, Dr. Gidon Akler, MD. The site does not say he reviews every intake. Step 1 is a written intake of about two to five minutes. Step 2 is the provider review. Step 3 is compounding and processing, about five business days. Step 4 is free two-day shipping. There is no fee for the assessment or the consultation. Insurance is neither required nor accepted. Follow-up runs through unlimited portal messaging. 2. ## What happens when the dose goes up? The provider sets the dose. Patients do not select it. Semaglutide comes in 0.2, 0.4, 0.75, 1.0 and 1.2 mg. Tirzepatide comes in 2, 3, 5, 6, 9, 11 and 14 mg. Every strength is priced the same. A dose change does not change the bill. [Nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) or constipation medication may be added and is reassessed at the three-month follow-up. 3. ## What the price includes Semaglutide is $146 a month on the monthly plan. It is $133 a month on the three-month plan and $124 on the six-month plan. Tirzepatide is $220, $201 and $183 on the same three plans. The monthly plan is the rate paid without a longer commitment. Consultation, follow-ups, supplies and shipping are included. Plans renew automatically. Cancellation must come at least two days before the billing date. Refunds are not typically offered. 4. ## What it claims, and what it cites Both drugs are compounded by licensed U.S. pharmacies. The site states compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not FDA-approved. Compounded drugs get no FDA review before dispensing. Semaglutide is compounded with vitamin B12. The site describes third-party testing for sterility, endotoxins, pH and potency. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Same price at every dose - Strength: Every available strength published - Strength: Consultation and shipping included - Strength: Monthly plan without a longer term - Limitation: Not available in six states - Limitation: Refunds not typically offered - Limitation: No compounding pharmacy named - Limitation: Auto-renews unless canceled two days ahead ## What the evidence says about this kind of treatment The assessment above is about 50 Stars Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants one price at every dose and a published list of strengths. Wrong for A buyer in Alabama, Arkansas, California, Indiana, South Carolina or West Virginia. ## The evidence behind what 50 Stars Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How 50 Stars Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | Boston Medical Group | Buyers who want a one-month price that holds at every dose and a named dispensing pharmacy | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [WeightRx](https://thisglp.com/reviews/weightrx) [WeightWatchers Clinic](https://thisglp.com/reviews/weight-watchers) [Welling Health](https://thisglp.com/reviews/welling-health) [Wellspring Longevity Clinic](https://thisglp.com/reviews/wellspring-longevity-clinic) [WePeptideRx](https://thisglp.com/reviews/wepeptiderx) [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does 50 Stars Health serve every state? No. It serves Puerto Rico plus 44 states. It does not serve Alabama, Arkansas, California, Indiana, South Carolina or West Virginia. What does semaglutide cost month to month? $146 a month on the monthly plan. The three- and six-month plans are $133 and $124 a month. Will the price change as the dose climbs? No. The site states every strength is priced the same. Is 50 Stars Health legit? 50 Stars Health is a GLP-1 telehealth sellers service. Its stated availability: Puerto Rico plus 44 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is 50 Stars Health expensive compared with other GLP-1 telehealth sellers? 50 Stars Health publishes a starting figure of $146/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts 50 Stars Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Longevity Meds reviews (2026): GLP-1 telehealth sellers | This GLP Longevity Meds names compounded semaglutide and tirzepatide, lists available strengths and describes care-team support. Its public screening shows the information requested before evaluation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/longevity-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A readable screening route # Longevity Meds review Longevity Meds names compounded semaglutide and tirzepatide, lists available strengths and describes care-team support. Its public screening shows the information requested before evaluation. ## The verdict Longevity Meds provides more visible screening detail than a bare product page, including medical-history questions and current treatment. The remaining issue is the individual care arrangement: confirm the clinician, dispensing pharmacy and refill-review schedule rather than interpreting fast-shipping or weight-loss guarantees as medical assurances. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Longevity Meds is an online weight-care service offering compounded GLP-1 treatment after provider assessment. Its intake asks about existing medicines and relevant conditions. Reviewing a public form is not evidence that any particular applicant will be approved. 1. ## Who writes the prescription, and what do they see? The service describes licensed professionals evaluating health history and issuing an appropriate prescription. The reviewed public material does not identify the clinician who will manage a given patient. Ask for the treating practice and the pharmacy assigned to your plan. An assessment precedes medical review, pharmacy shipment and ongoing care-team communication. The intake includes questions about pregnancy, current GLP-1 treatment and medical conditions. Confirm how follow-up is scheduled and how to reach clinical help if symptoms develop. 2. ## What happens when the dose goes up? Several strengths are shown beside each medication, and the intake asks about current dosing. Those details support a discussion with a clinician, not self-directed switching. Ask whether the quote holds at the strength ultimately prescribed and how changing health status affects refills. 3. ## What the price includes The homepage lists separate semaglutide and tirzepatide amounts with doctor visits and shipping included, and advertises no membership fee. It also labels the prices with an asterisk, so confirm the exact order, renewal and supply period before relying on an all-dose claim. 4. ## What it claims, and what it cites The site and intake identify compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). These finished preparations are not FDA approved. Ask the prescriber to identify any added ingredients, concentration and dispensing instructions; a generic injection image cannot establish those details. ## Where it holds up, and where it does not - Strength: Medical-history screening visible - Strength: Drug names and strengths published - Strength: Care and delivery described in the offer - Limitation: Individual clinician and pharmacy need confirmation - Limitation: Asterisked price terms need checking - Limitation: Guarantee is not a promised clinical outcome ## What the evidence says about this kind of treatment The assessment above is about Longevity Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants to understand the screening process and will verify the specific clinical and pharmacy arrangements. Wrong for Someone assuming a fast-delivery claim or weight-loss guarantee establishes treatment suitability. ## The evidence behind what Longevity Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Longevity Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) [Whoosh Wellness](https://thisglp.com/reviews/whoosh-wellness) [Wisp](https://thisglp.com/reviews/wisp) [Woodwork](https://thisglp.com/reviews/woodwork) [YourHealthRx](https://thisglp.com/reviews/yourhealthrx) [Yucca Health](https://thisglp.com/reviews/yucca-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is a completed intake an approved prescription? No. A licensed professional must evaluate the information and decide whether treatment is appropriate. Does the weight-loss guarantee mean everyone responds? No. The site describes a conditional claim process after sustained treatment; individual outcomes still vary. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official treatment program](https://www.longevitymeds.com/) - [Service and cancellation terms](https://www.longevitymeds.com/legal/terms-of-use) - [Care, product and billing information](https://www.longevitymeds.com/glp-male-4/v4/intake) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Longevixx reviews (2026): GLP-1 telehealth sellers | This GLP Both prices sit on one treatment menu, flat across doses, with no anchor beside them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/longevixx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two flat rates, one menu # Longevixx review Both prices sit on one treatment menu, flat across doses, with no anchor beside them. ## The verdict Longevixx publishes $149 a month for semaglutide and $299 for tirzepatide. Both are flat across doses. Fifty states are covered. No dose or pharmacy is named. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $149/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Longevixx sells both molecules by injection across fifty states. Both prices are stated flat across doses. A treatment menu carries the figures. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The menu lists treatments. No clinician is described and no intake is documented. The menu states two rates and nothing else. There is no struck-through comparison price and no popularity label. That leaves the figures easy to read. It also leaves the dose and the pharmacy unstated. 2. ## What happens when the dose goes up? Both lines are stated flat across doses, so the rate holds as the dose rises. Nothing describes clinical support at an increase. 3. ## What the price includes Six months at $149 is $894 and tirzepatide at $299 is $1,794. Both totals hold at any dose. The menu prints no plan ladder, so no longer term lowers either rate. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Flat across doses, both molecules - Strength: Coverage in all fifty states - Strength: Both figures published on one menu - Limitation: No plan ladder or longer-term rate - Limitation: No milligram dose stated - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Longevixx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader wanting a flat rate in any state. Wrong for A reader who needs the dose or the pharmacy named before paying. ## The evidence behind what Longevixx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Longevixx compares | Seller | Who it suits | Go | | --- | --- | --- | | Liv Body | Readers who want no contract and will ask what their own plan costs | | | LevelUp Rx | Readers who want the billed total before committing to a term | | | LVNG RX | Readers who want a bundle and accept the figure is confirmed later | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Zealthy](https://thisglp.com/reviews/zealthy) [Zera Health](https://thisglp.com/reviews/zera-health) [Zeuss](https://thisglp.com/reviews/zeuss) [ZipHealth](https://thisglp.com/reviews/ziphealth) [ZYP Medical](https://thisglp.com/reviews/zyp-medical) [10Rx](https://thisglp.com/reviews/10rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 a promotional price? Nothing on the menu marks it as one. It is printed as the semaglutide rate, with no end date and no comparison price. Does the price rise with the dose? No. Both lines are stated flat across doses. Which pharmacy prepares the medication? The menu does not name one. Both lines are compounded, and the pharmacy is not identified before purchase. Is Longevixx legit? Longevixx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Longevixx expensive compared with other GLP-1 telehealth sellers? Longevixx publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Longevixx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Loop Health reviews (2026): GLP-1 telehealth sellers | This GLP A peptide community whose membership is free for now, with GLP-1 prescriptions priced flat at every dose and sold on top of it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/loop-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A free club with a pharmacy counter # Loop Health review A peptide community whose membership is free for now, with GLP-1 prescriptions priced flat at every dose and sold on top of it. ## The verdict Loop Health gives its membership away for now and charges for the medication: $199 a month for semaglutide, as an injection or a dissolving tablet, and $299 a month for tirzepatide injections. The shop states that each figure holds at every dose. Both figures are printed plainly, but the shop sells the whole line under a microdosed GLP-1 heading, so neither is ranked here against full-dose programs. The shop also does not say how the monthly charge is billed or what the membership will cost once the free period ends. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 44 states Loop Health describes itself as an independent health research collective built around peptide protocols, and the membership reads that way, with weekly live sessions, a protocol library, a peptide tracker and community rooms for GLP-1, perimenopause and longevity. The telehealth shop sits beside all of that, split into a women's and a men's storefront that carry the same four weight-loss products, alongside NAD+, sermorelin, sexual-health and hair treatments. 1. ## Who writes the prescription, and what do they see? The telehealth consent is explicit that Loop Health is a technology platform rather than a medical practice. The licensed clinicians a member reaches are described as independent practitioners who decide, on their own judgment, whether a prescription is written at all. None of those clinicians is named on the shop or the product pages, and the consent describes asynchronous review, video or audio visits and secure messaging as possible formats without saying which one a GLP-1 patient should expect. A new patient starts with a short intake about goals, history and what has already been tried, and from it Loop builds a protocol that pairs a product with bloodwork and a coach matched to those goals. What sets the service apart from a plain prescription shop is everything around the injection: weekly live coaching calls with replays, group calls on reconstitution and a first injection, and a dashboard for bloodwork and wearable data. A member who wants one-to-one time can book a private coaching call at $149. 2. ## What happens when the dose goes up? Every weight-loss product page carries the same short line, all doses at one monthly figure, so a patient climbing from a starting dose toward maintenance should see the bill stay flat. That is how the shop describes the escalation months, at least. The shop does not publish a milligram schedule or say how often a dose is reviewed. It also files every weight-loss card under a microdosed GLP-1 heading, which leaves open how far up the ladder a Loop protocol is meant to go. 3. ## What the price includes Semaglutide is $199 a month whether injected or taken as a dissolving tablet, tirzepatide injections are $299 a month, and a tirzepatide tablet is listed higher on the same shelf. The membership itself is described as free for now with monthly billing and cancellation at any time, and the terms say medication costs are separate from membership fees. What the shop does not state is whether the monthly figure is charged monthly, whether shipping is included, or what happens to the price when the free membership ends. That last point is the question a patient a year in will want answered. Because the line is sold as microdosed, these figures are not set beside full-dose prices on this site's boards. 4. ## What it claims, and what it cites Loop's refund policy names compounded semaglutide and compounded [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), and states that compounded medications are not FDA-approved and have not been through FDA review for safety, effectiveness or quality. It says each compound comes from a licensed compounding pharmacy with a third-party certificate of analysis, though no pharmacy is named. ## Where it holds up, and where it does not - Strength: One monthly figure at every dose - Strength: Membership currently free, cancel anytime - Strength: Weekly live coaching sessions included - Strength: Oral semaglutide at the injection price - Limitation: Sold as a microdosed line, so not ranked - Limitation: No compounding pharmacy named - Limitation: Clinicians are not named anywhere - Limitation: Billing cadence for medication unstated - Limitation: No end date given for the free membership ## What the evidence says about this kind of treatment The assessment above is about Loop Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants coaching and a peer community around a flat-priced GLP-1, and is comfortable with an unnamed clinician. Wrong for Someone who needs the prescriber and the pharmacy named, or a full dose schedule, before the first order. ## The evidence behind what Loop Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Loop Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Boston Medical Group | Buyers who want a one-month price that holds at every dose and a named dispensing pharmacy | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AJ Peptide](https://thisglp.com/reviews/aj-peptide) [Ambiante Health & Wellness](https://thisglp.com/reviews/ambiante-health-wellness) [Aurelius Health Group](https://thisglp.com/reviews/aurelius-health-group) [AVArx](https://thisglp.com/reviews/avarx) [Basal Health](https://thisglp.com/reviews/basal-health) [Better MedSpa](https://thisglp.com/reviews/better-medspa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Loop Health still sell an annual membership plan? No. The site now describes membership as free for now, billed monthly and cancelable at any time, and the medication is charged separately at $199 or $299 a month depending on the drug. Does the price rise as the dose goes up? The shop says no: each weight-loss product page lists one monthly figure for all doses, though it publishes no milligram schedule to go with it. Is Loop's semaglutide compounded? Loop's refund policy names compounded semaglutide and compounded tirzepatide and states they are not FDA-approved; the product pages themselves do not say so beside the price. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Loozy reviews (2026): GLP-1 telehealth sellers | This GLP Loozy’s approachable storefront describes asynchronous support, while its terms establish a prepaid three-month telehealth membership. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/loozy Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Three-month care membership # Does Loozy sell a GLP-1? Loozy’s approachable storefront describes asynchronous support, while its terms establish a prepaid three-month telehealth membership. ## The verdict The support channel is clear, but the financial commitment begins before the provider’s final decision. Review the full refund policy and ask how care is escalated beyond messages before buying a three-month term. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved Loozy LLC is a technology platform for weight-management care through independent licensed providers and compounding pharmacies. Its homepage specifically advertises compounded semaglutide. 1. ## Who writes the prescription, and what do they see? Independent providers review the intake and determine treatment. The terms say the platform is not a medical provider or pharmacy, and completing prequalification does not guarantee a prescription. Patients prequalify, pay the membership upfront and then undergo provider review. The terms include support, messaging and approved treatment fulfillment, with follow-up check-ins every three months before further treatment may be authorized. 2. ## What happens when the dose goes up? The homepage advertises dose check-ins and asynchronous messaging. Ask how problems are handled between the formal three-month reviews and whether a live consultation is available when messages are insufficient. 3. ## What the price includes The displayed monthly figure is a starting equivalent billed as a three-month plan, not a standalone month. The terms generally make membership nonrefundable once intake is submitted for review, subject to the separate refund policy. 4. ## What it claims, and what it cites Compounded semaglutide is named on the homepage. Compounded drugs are not FDA-approved, and the reviewed pages do not establish a specific additional GLP-1 product or a universal prescription schedule. ## Where it holds up, and where it does not - Strength: Asynchronous support explicitly described - Strength: Formal check-in interval in terms - Limitation: Upfront payment before final review - Limitation: Live follow-up access needs confirmation ## What the evidence says about this kind of treatment The assessment above is about Loozy. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone comfortable with asynchronous care and a three-month membership after clarifying refund conditions. Wrong for Someone who needs month-to-month purchasing or a scheduled live follow-up model. ## The evidence behind what Loozy prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Loozy compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Better MedSpa](https://thisglp.com/reviews/better-medspa) [BodyLogicMD](https://thisglp.com/reviews/bodylogicmd) [Broose Wellness](https://thisglp.com/reviews/broose-wellness) [CAPO Health](https://thisglp.com/reviews/capo-health) [Chia](https://thisglp.com/reviews/chia-health) [Chronos Body Health & Wellness](https://thisglp.com/reviews/chronos-bhw) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is prequalification a prescription approval? No. The terms place provider review after prequalification and membership payment. How often are formal check-ins required? The terms specify follow-up check-ins every three months before additional treatment may be approved. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://loozy.care/) - [Official program and terms](https://loozy.care/faq) - [Official program and terms](https://loozy.care/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LovelyMeds reviews (2026): GLP-1 telehealth sellers | This GLP Compounded semaglutide at $175 and tirzepatide at $235 on one-month plans, each flat across doses. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lovelymeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat by dose, priced by term # LovelyMeds review Compounded semaglutide at $175 and tirzepatide at $235 on one-month plans, each flat across doses. ## The verdict LovelyMeds charges $175 a month for compounded semaglutide and $235 for compounded tirzepatide on its one-month plans. Longer commitments lower both, to $99 and $150 on twelve months. Every dose costs the same, by the seller's statement. The weight-loss claims come from trials of semaglutide and tirzepatide, not this kit. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $175/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability US except KS, LA, MS, NM LovelyMeds is an online clinic selling compounded semaglutide and tirzepatide injection kits with B12. It also lists oral drops, dissolving tablets, troches and branded products. It does not operate in Kansas, Louisiana, Mississippi or New Mexico. 1. ## Who writes the prescription, and what do they see? An online form is reviewed by an independent licensed clinician. Most evaluations are reviewed within one business day, per the page. No clinician is named. Prescriptions go to partner pharmacies unless the patient asks otherwise. The model is an order form, a clinician review and shipment in plain packaging. The pages describe no scheduled check-ins. The eligibility section calls a BMI of 27 obesity; the usual threshold for obesity is 30. 2. ## What happens when the dose goes up? Price does not move with dose. Both product pages state flat pricing with no increases while titrating. Neither page publishes a dose schedule or a milligram strength. Vial strengths are described as chosen from the prescribed plan. 3. ## What the price includes Plan length sets the price. Semaglutide runs $175, $145, $120 and $99 a month across one, three, six and twelve months. Tirzepatide runs $235, $199, $175 and $150. Six months on the six-month semaglutide plan is $720. The one-month tirzepatide rate is $60 above semaglutide. A first-month promotion and a new-customer code appear on both pages; neither is the standing rate. 4. ## What it claims, and what it cites Both kits are compounded with B12 by state-licensed U.S. compounding pharmacies. The pages say compounded medications are not FDA-approved. No pharmacy is named. Four batch checks are listed; the potency check, within ±10%, is labeled a sterility check. ## Where it holds up, and where it does not - Strength: Same price at every dose - Strength: Four plan lengths published per molecule - Strength: One-month rate shown beside longer plans - Limitation: No compounding pharmacy is named - Limitation: No dose schedule is published - Limitation: Twelve months required for the $99 rate - Limitation: Not offered in four states ## What the evidence says about this kind of treatment The assessment above is about LovelyMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a price that holds through titration and can pick a plan length. Wrong for A reader in Kansas, Louisiana, Mississippi or New Mexico. ## The evidence behind what LovelyMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LovelyMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | YourEra | Readers committing six months who have read which figure belongs to which plan | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Defy Medical](https://thisglp.com/reviews/defy-medical) [Docberry](https://thisglp.com/reviews/docberry) [Elara MD](https://thisglp.com/reviews/elara-md) [EmbraceRX](https://thisglp.com/reviews/embrace-rx) [eMed](https://thisglp.com/reviews/emed) [Enara Health](https://thisglp.com/reviews/enara-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with the dose? No. Both product pages state all doses cost the same; only plan length changes the price. What is the one-month price? $175 a month for semaglutide and $235 for tirzepatide. Does the 15% weight-loss figure apply to this kit? Not measured. The page attributes it to published clinical trial data for semaglutide, not to a compounded kit with B12. Is LovelyMeds legit? LovelyMeds is a GLP-1 telehealth sellers service. Its stated availability: US except KS, LA, MS, NM. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is LovelyMeds expensive compared with other GLP-1 telehealth sellers? LovelyMeds publishes a starting figure of $175/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LovelyMeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lttl reviews (2026): GLP-1 telehealth sellers | This GLP Every line publishes a four-rung prepay ladder, and the low-dose and standard-dose products are priced separately rather than blended. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lttl Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four rungs, two dose lines # Lttl review Every line publishes a four-rung prepay ladder, and the low-dose and standard-dose products are priced separately rather than blended. ## The verdict Lttl prices its low-dose semaglutide injection at $149 month to month and publishes the whole prepay ladder beneath it: $129 quarterly, $119 every six months and $109 annually. A separate standard-dose line, up to 2.4mg, runs $99 per four-week fill on auto-refill, where a fifty-two-week block bills $1,068. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $107/mo Oral From $194/mo Prescription Required Compounded Yes — not FDA-approved Lttl splits its catalog by dose rather than only by molecule, which is unusual and useful. A low-dose line marketed for tolerability sits beside a standard-dose line going up to 2.4mg, and each carries its own price and its own ladder. Both molecules appear, with tirzepatide described as a low-dose GLP-1 and GIP product on the same ladder as the microdose semaglutide. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the service runs remotely. What the pages give a reader instead of clinician detail is dose framing, which is the rarer of the two. Knowing that a line is a low-dose product marketed for tolerability tells a buyer something about what they will be taking. A clinician's name usually does not. The prepay ladder is the mechanism the whole service is built around, and Lttl publishes all four rungs rather than advertising the deepest one and leaving the rest to checkout. There is also a first-month special at $119 on the low-dose lines and $149 on the oral, which is a separate device again — it lowers one bill without touching any of the four ongoing rates. 2. ## What happens when the dose goes up? Lttl states the rate holds at every dose, and the two-line structure is what makes that claim legible. The low-dose product is priced as a low-dose product. A buyer moving to standard dosing moves to the separate $99 line rather than climbing a hidden ladder on the first. The standard line's own note caps it at 2.4mg, so the range each figure covers is stated. 3. ## What the price includes The month-to-month figure is $149 and the annual rung is $109, so committing a year takes $40 a month off the same product — and the pages show every step between. The oral runs the same shape at $179 month to month down to $139 annually. The standard-dose line is the one to read carefully: $99 per four-week fill is thirteen fills a year, which is why the fifty-two-week block bills $1,068 rather than $1,188. 4. ## What it claims, and what it cites Every line is a compounded preparation, which places all of them outside the FDA review that an approved product completes before dispensing. The low-dose products are marketed for tolerability rather than for a different clinical effect, and the pages do not claim otherwise. ## Where it holds up, and where it does not - Strength: All four prepay rungs published - Strength: Low-dose and standard-dose priced separately - Strength: Rate stated to hold at every dose - Strength: The four-week fill cycle is disclosed - Limitation: The lowest rung needs a year committed - Limitation: Standard line bills thirteen times a year - Limitation: First-month special applies once - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Lttl. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to see every prepay rung before choosing a term, and who knows which dose line they need. Wrong for A reader who wants a single monthly figure with no term to choose. ## The evidence behind what Lttl prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lttl compares | Seller | Who it suits | Go | | --- | --- | --- | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | | Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Enhanced](https://thisglp.com/reviews/enhanced) [EverFit Medical](https://thisglp.com/reviews/everfit-medical) [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) [Evernow](https://thisglp.com/reviews/evernow) [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) [FeelGood](https://thisglp.com/reviews/feelgood-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the difference between the $149 and $99 lines? Dose. The $149 is a low-dose product marketed for tolerability; the $99 is the standard-dose line running up to 2.4mg, billed per four-week fill on auto-refill. What does the annual plan save? $40 a month against the month-to-month rate on the low-dose injection, taking $149 down to $109, with $129 quarterly and $119 half-yearly in between. Why does a year cost $1,068 rather than twelve times $99? Because the standard line bills per four-week fill, which is thirteen fills across fifty-two weeks. Lttl publishes the block figure rather than leaving the arithmetic to the buyer. Is Lttl expensive compared with other GLP-1 telehealth sellers? Lttl publishes a starting figure of $107/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lttl below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Luci reviews (2026): GLP-1 telehealth sellers | This GLP Four figures, all of them asterisked. The seller's own note says the real monthly cost may be higher. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/luci Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced from, and it says so # Luci review Four figures, all of them asterisked. The seller's own note says the real monthly cost may be higher. ## The verdict Luci publishes $99 a month for semaglutide and $145 for tirzepatide. Both are asterisked as a lowest rate. The oral kits carry the same two figures. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $99/mo Oral From $99/mo Prescription Required Compounded Yes — not FDA-approved Luci sells both molecules as an injection and as an oral pill kit. All four lines are priced. The two orals match the two injections exactly. 1. ## Who writes the prescription, and what do they see? A prescription is issued before anything ships. No clinician is described anywhere on the pages read. The pricing is an opening rate with a caveat attached. Luci writes the caveat itself, which is more than most do. 2. ## What happens when the dose goes up? Nothing states what happens at a higher dose. The asterisk implies the figure moves without saying where to. 3. ## What the price includes Six months at $99 is $594 and at $145 is $870, both assuming the lowest rate holds. The seller has already said it may not. No milligram is published beside either number. 4. ## What it claims, and what it cites Both molecules are compounded. A pharmacy makes them to order. The FDA does not review a compounded preparation before it ships. ## Where it holds up, and where it does not - Strength: All four lines carry a figure - Strength: The caveat is the seller's own words - Strength: Oral and injection priced the same - Limitation: Every figure is a lowest rate - Limitation: No milligram dose published - Limitation: No state coverage list recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Luci. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who takes an asterisk seriously and plans to ask what it hides. Wrong for A reader budgeting from $99 without reading the asterisk beside it. ## The evidence behind what Luci prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Luci compares | Seller | Who it suits | Go | | --- | --- | --- | | Rivo Health | Readers who want a flat rate and can ignore the seasonal framing | | | Tru2u | Readers who want a flat rate and will ask what the combined product contains | | | TrimRx | Readers who already know which molecule they want and will hunt for which tile holds it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Florida Weight Loss MD](https://thisglp.com/reviews/florida-weight-loss-md) [Found Youth](https://thisglp.com/reviews/found-youth) [Freeley](https://thisglp.com/reviews/freeley) [FuturHealth](https://thisglp.com/reviews/futurhealth) [G-Plans](https://thisglp.com/reviews/g-plans) [Gatlan](https://thisglp.com/reviews/gatlan) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 the price? It is the lowest rate. Luci's own note says the actual monthly cost may be higher. Does the pill cost more? No. The oral kits are $99 and $145, matching the injections. Which dose does $99 buy? No milligram is published beside it. Is Luci expensive compared with other GLP-1 telehealth sellers? Luci publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Luci below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Luma Health Co reviews (2026): GLP-1 telehealth sellers | This GLP A price for every milligram strength, each buying four weeks, with no subscription attached. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/luma-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced per dose, per four weeks # Luma Health Co review A price for every milligram strength, each buying four weeks, with no subscription attached. ## The verdict Luma Health Co. prices each dose separately. The starting semaglutide dose is $115 per four-week supply, about $125 a calendar month. Tirzepatide starts at $180, or $195 a month. The price rises at every step up. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 31 From From $125/mo Dose published Yes Prescription Required Pharmacy Not named Availability 30 states and DC Luma Health Co. is a virtual clinic with an address in Livingston, Louisiana. It prescribes semaglutide and tirzepatide by injection. It also sells NAD+ and B12 injections. 1. ## Who writes the prescription, and what do they see? Every consultation is virtual. A provider builds a plan from goals, labs and health history. Treatment often begins within three to four business days of the consult. The site does not name its providers. There is no subscription. The FAQ states no monthly subscriptions, monthly fees or points. Insurance is not accepted. Invoices are provided for HSA and FSA claims. Initial consult visits are free for a limited time. The standard consult price is not published. 2. ## What happens when the dose goes up? Each dose has its own price. Semaglutide is listed at five strengths, 0.25 mg to 2.5 mg. Tirzepatide is listed at six, 2.5 mg to 15 mg. Each step up costs more than the one before. Budget for the dose you will reach, not the one you start on. 3. ## What the price includes Every line is a four-week supply. Thirteen fills make a year, not twelve. $115 every four weeks is $124.58 a calendar month. $180 every four weeks is $195 a month. Both are starting-dose figures only. 4. ## What it claims, and what it cites The site names each drug by molecule and milligram strength. Whether a fill is compounded or branded is not stated. Compounded drugs carry no FDA approval. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Each milligram strength carries its own price - Strength: Milligram strengths published on the pricing page - Strength: No subscription or recurring fee stated - Strength: Invoices available for HSA or FSA claims - Limitation: Price rises at every dose step - Limitation: Each fill covers four weeks, not a month - Limitation: Silent on compounded versus branded supply - Limitation: Standard consult price is not published ## What the evidence says about this kind of treatment The assessment above is about Luma Health Co. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to see the cost of each dose before starting. Wrong for A reader who wants one flat monthly price through titration. ## The evidence behind what Luma Health Co prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Luma Health Co compares | Seller | Who it suits | Go | | --- | --- | --- | | MyStart Health | Buyers who titrate quickly and want the rate frozen before the dose climbs | | | NovoCare Pharmacy | Readers who want the approved product and will count thirteen boxes a year rather than twelve | | | Fidelity Medical Clinic | A reader who counts fills rather than months, and who budgets from the maintenance order instead of the discounted intro one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Lifestyle Medicine](https://thisglp.com/reviews/genesis-lifestyle-medicine) [Gide Health](https://thisglp.com/reviews/gide-health) [Glow](https://thisglp.com/reviews/glow) [GOAL.MD](https://thisglp.com/reviews/goal-md) [GoodLife Health](https://thisglp.com/reviews/goodlife-health) [Happy Care Meds](https://thisglp.com/reviews/happy-care-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does $115 become $125 a month? Each fill lasts four weeks. Thirteen fills a year works out to $124.58 a calendar month. Does the price rise with the dose? Yes. Every higher strength carries a higher price on the pricing page. Is Luma a subscription? No. The FAQ states no monthly subscriptions, monthly fees or points. Is Luma Health Co legit? Luma Health Co is a GLP-1 telehealth sellers service. Its stated availability: 30 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Luma Health Co expensive compared with other GLP-1 telehealth sellers? Luma Health Co publishes a starting figure of $125/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Luma Health Co below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Luma Meds reviews (2026): GLP-1 telehealth sellers | This GLP The headline figure requires being new and paying for three months, and a continuing patient on monthly billing pays half as much again. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/luma-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 New patient and prepaid # Luma Meds review The headline figure requires being new and paying for three months, and a continuing patient on monthly billing pays half as much again. ## The verdict Luma Meds shows $99 a month for compounded semaglutide, a figure that is both a new-patient rate and a three-month rung. A continuing patient billed monthly pays $149, or $119 on three months. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $149/mo Prescription Required Compounded Yes — not FDA-approved Luma Meds sells both molecules by injection with pricing that varies on two axes at once — how long a buyer commits, and whether they are new — which is why one advertised number cannot describe it. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. What the pages do describe in detail is the plan structure, and a reader has to work through two conditions before the headline figure means anything. Most sellers attach one condition to a low figure. Luma Meds attaches two, and they compound: a reader who is new but pays monthly does not get $99, and a reader who prepays three months but has been a patient for a year does not get it either. Only the intersection does. 2. ## What happens when the dose goes up? Nothing is published about what any of these figures do at a higher dose, and that matters more here than usual. A new-patient rate expires by definition, so the figure a reader pays in month four is a continuing rate at a dose that may have moved twice. 3. ## What the price includes The continuing monthly rate is $149 for semaglutide and $219 for tirzepatide, with three-month rungs at $119 and $179. Six months at the continuing monthly rate is $894 and $1,314. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Both continuing and new rates are published - Strength: Three-month rungs stated on both lines - Limitation: The headline needs two conditions at once - Limitation: The continuing monthly rate is 50% higher - Limitation: Two conditions stack on the $99 - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Luma Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who is new, will prepay three months, and knows what month four costs. Wrong for A reader planning a year from the advertised figure. ## The evidence behind what Luma Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Luma Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Livea | Readers in a served state who will get the fee relationship confirmed in writing | | | Lumora | Readers willing to complete an assessment and hold the seller to its own promise | | | Live Vital | Readers who work from the protocol total rather than the monthly figure beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealFastRx](https://thisglp.com/reviews/healfast) [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) [Hone Health](https://thisglp.com/reviews/hone-health) [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) [KairoRx](https://thisglp.com/reviews/kairorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I get $99? Only as a new patient paying for three months at once. A continuing patient billed monthly pays $149. What will I pay after the first quarter? $149 a month for semaglutide or $219 for tirzepatide on monthly billing, or $119 and $179 on three-month rungs. What does a year cost on monthly billing? $1,788 for semaglutide and $2,628 for tirzepatide at the continuing monthly rate. Is Luma Meds expensive compared with other GLP-1 telehealth sellers? Luma Meds publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Luma Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lumen Meds reviews (2026): GLP-1 telehealth sellers | This GLP Two compounded programs at flat monthly rates that hold at every dose, with no membership fee and no term to sign. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lumen-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat rates, cancel any time # Lumen Meds review Two compounded programs at flat monthly rates that hold at every dose, with no membership fee and no term to sign. ## The verdict Lumen Meds charges $191.99 a month for compounded tirzepatide with B6 and $114.99 for compounded semaglutide with B12, and it states the same price holds at every dose. The monthly charge covers the provider consultations, the medication and cold-packed shipping, and a patient can cancel before the next billing date without a further charge. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection Dose pricing Flat across doses From From $191.99/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named A marketplace platform, in its own description, that connects patients with independently licensed providers through a patient portal, while prescriptions go to partner compounding pharmacies registered as 503A or 503B facilities. Lumen Meds itself states that it does not dispense medication or provide medical services. 1. ## Who writes the prescription, and what do they see? A ten-minute health quiz comes first, then an online meeting with a licensed provider who reviews the history, orders labs if needed and finalizes the prescription. The site describes its physicians as board-certified but names none of them, and it is clear that paying does not guarantee a prescription will be written. After the prescription, the pattern is regular check-ins, dose adjustments with the provider, and diet and lifestyle coaching, with mild nausea flagged as common early on and optional prescription relief offered for it. Shipping is described as expedited and cold-packed, usually within two to three business days of approval. 2. ## What happens when the dose goes up? The dose ladder is printed on the product cards, 0.25 mg to 2.5 mg for semaglutide and 2.5 mg to 15 mg for tirzepatide, and the page repeats that the price is the same at every rung. That settles the cost side of [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1); how quickly a patient climbs is left to the provider, and the site publishes no week-by-week schedule for it. 3. ## What the price includes Half a year of tirzepatide at $191.99 totals $1,151.94, while semaglutide at $114.99 totals $689.94 over the same stretch, with no membership fee and no separate charge for visits on either line. There is no long-term commitment to sign, so those totals are simply six consecutive monthly charges rather than a plan anyone has to prepay. 4. ## What it claims, and what it cites Both programs are compounded, and the page says in plain terms that compounded formulations are not reviewed or approved by the FDA and are not a replacement for approved medications. The pharmacies are described as licensed U.S. 503A or 503B facilities with batch testing for potency, purity and sterility, but none is named. ## Where it holds up, and where it does not - Strength: Same price stated at every dose - Strength: No membership fee on either program - Strength: Cancel before the next billing date - Strength: Milligram ladder printed on each card - Limitation: Pharmacies described but never named - Limitation: No providers are named on the site - Limitation: Headline results percentages carry no named source ## What the evidence says about this kind of treatment The assessment above is about Lumen Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a flat monthly rate through titration and the freedom to stop. Wrong for A reader who wants to know which pharmacy compounds the medication before signing up. ## The evidence behind what Lumen Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lumen Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | | Kina | Women in menopause who want the medical group named and four routes priced up front | | | Eden | Buyers comparing what the two molecules actually cost | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [KIN Health](https://thisglp.com/reviews/kin-health) [Klarity Health](https://thisglp.com/reviews/klarity-health) [Klinic](https://thisglp.com/reviews/klinic) [Kova](https://thisglp.com/reviews/kova) [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) [Lighter You](https://thisglp.com/reviews/lighter-you) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise as the dose goes up? No. Lumen Meds states the same price applies at every dose, on both the semaglutide and the tirzepatide program. What happens if I cancel? The FAQ says a patient can cancel at any time, and canceling before the next billing date means no further charge. What does semaglutide cost? $114.99 a month for the compounded semaglutide program, with the doctor's visit and shipping included in that figure. Is Lumen Meds expensive compared with other GLP-1 telehealth sellers? Lumen Meds publishes a starting figure of $191.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lumen Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LumiMeds reviews (2026): GLP-1 telehealth sellers | This GLP The ingredient, route and pharmacy type are all stated; the plan behind the price is not. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lumimeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Labeled product, unlabeled term # LumiMeds review The ingredient, route and pharmacy type are all stated; the plan behind the price is not. ## The verdict LumiMeds publishes semaglutide as low as $89 a month and tirzepatide as low as $125. Four plan lengths are offered. Which one the figure belongs to is never said. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $89/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider LumiMeds sells two compounded GLP-1 lines and an NAD+ line. Each has a product page of its own. The pages are built as spec sheets rather than sales copy. 1. ## Who writes the prescription, and what do they see? A licensed clinician reviews the intake and prescribes only where appropriate. LumiMeds states there are no auto-approvals and promises a full refund where a buyer is not eligible. Providers are described as United States licensed. None is named, and no state list is published. Dose changes, refills and questions are described as part of the plan rather than add-ons. Shipping is cold-chain and included. Klarna will split any plan into payments, and FSA and HSA cards are accepted on some of them. 2. ## What happens when the dose goes up? LumiMeds states there is no upcharge when the dose goes up, which settles the money question. The product page calls the dosing provider-titrated and once weekly. No milligram is printed, so the ladder itself stays out of view. 3. ## What the price includes The floor is $89 for semaglutide and $125 for tirzepatide. Above those figures sits one line: monthly, three, six and twelve-month options are available. Nothing connects the figure to a term. A buyer cannot tell from the page whether $89 is a month-to-month rate or a year bought at once. 4. ## What it claims, and what it cites Both lines are compounded by a 503A pharmacy against an individual prescription. Compounded drugs are not FDA-approved as a finished product, which LumiMeds states itself. The pharmacy is identified by type rather than by name. The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) page names the active ingredient, its receptor class, the subcutaneous route and the multi-dose vial it ships in. ## Where it holds up, and where it does not - Strength: Active ingredient and drug class named on the page - Strength: Route, frequency and vial format labeled - Strength: The 503A pharmacy type is stated - Strength: LegitScript certification is claimed - Strength: No upcharge when the dose rises - Limitation: The plan term behind the price is not stated - Limitation: No milligram appears on either product page - Limitation: The pharmacy is named by type only - Limitation: A three-week onset claim carries no source ## What the evidence says about this kind of treatment The assessment above is about LumiMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the ingredient, route and pharmacy type stated before paying. Wrong for A buyer who needs to know what a single month costs before committing. ## The evidence behind what LumiMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LumiMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | Mondae | Buyers who want a low published compounded rate and few other details | | | NativeMed | Buyers who want to see the prepay arithmetic before deciding it is a saving | | | Spry | Buyers who can read a four-week billing cycle as thirteen charges rather than twelve | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Livbetr](https://thisglp.com/reviews/livbetr) [Longevity Meds](https://thisglp.com/reviews/longevity-meds) [Loozy](https://thisglp.com/reviews/loozy) [Male Excel](https://thisglp.com/reviews/male-excel) [MangoRx](https://thisglp.com/reviews/mangorx) [MD Trim Clinic](https://thisglp.com/reviews/md-trim-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $89 a monthly price? Not established. The page offers monthly, three, six and twelve-month plans and does not say which the figure buys. Does the charge rise with the dose? No. LumiMeds states there is no upcharge when the dose goes up. Is the pharmacy named? It is identified as a state-licensed 503A compounding pharmacy. No name is given. Is LumiMeds expensive compared with other GLP-1 telehealth sellers? LumiMeds publishes a starting figure of $89/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LumiMeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lumora reviews (2026): GLP-1 telehealth sellers | This GLP The site promises to show visit fees, medication, labs and follow-up before you commit, and publishes an amount for none of them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lumora Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Full pricing, after the form # Lumora review The site promises to show visit fees, medication, labs and follow-up before you commit, and publishes an amount for none of them. ## The verdict Lumora publishes estimated starting prices of $245 a month for compounded semaglutide and $325 for tirzepatide. Exact pricing is shown after a free online assessment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $245/mo Prescription Required Compounded Yes — not FDA-approved Lumora sells both molecules by injection with five dose tiers on one line and six on the other. Sublingual forms are also offered. Both figures are described as estimated starting prices. 1. ## Who writes the prescription, and what do they see? A free online assessment precedes any exact figure. The pages describe what the assessment will reveal rather than who conducts it. Five and six dose tiers exist, which implies a clinical ladder the pages do not otherwise describe. The promise is specific and worth quoting: a reader will see full pricing — visit fees, medication, labs, follow-up — before committing. That is a better commitment than most sellers make. It is also a commitment to disclose later rather than a disclosure now, and no amount for any of the four appears anywhere on the site. 2. ## What happens when the dose goes up? Tiers exist and their prices do not. Five semaglutide tiers and six tirzepatide tiers are named, which is more structure than most sellers admit to, and the figure attached to each arrives after the assessment. 3. ## What the price includes Six months at $245 is $1,470 if the estimate holds, and the word estimated is doing real work there. A starting price on a five-tier ladder is the bottom rung, so a reader escalating should expect to leave it. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Dose tiers acknowledged, five and six - Strength: A specific disclosure promise in writing - Strength: Sublingual forms offered as well - Limitation: No amount published for any of the four items - Limitation: Longer supplies priced only at checkout - Limitation: Starting price is the bottom of a ladder - Limitation: Exact pricing requires an assessment ## What the evidence says about this kind of treatment The assessment above is about Lumora. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to complete an assessment and hold the seller to its own promise. Wrong for A reader who needs a settled figure before creating an account. ## The evidence behind what Lumora prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lumora compares | Seller | Who it suits | Go | | --- | --- | --- | | LeanDose | Readers who will get the month-two rate in writing before the first charge | | | MDExam | Readers who will get the applicable figure confirmed in writing before paying | | | MANÜ Telehealth | Readers who want the cost of a full dose stated before starting a low one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDLive](https://thisglp.com/reviews/mdlive) [MD Total Wellness](https://thisglp.com/reviews/mdtw) [Medical Health Institute](https://thisglp.com/reviews/medical-health-institute) [Medivive](https://thisglp.com/reviews/medivive) [MEDVidi](https://thisglp.com/reviews/medvidi) [Meli Health](https://thisglp.com/reviews/meli-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What will I actually pay? Lumora shows exact pricing after a free online assessment. The published $245 and $325 are described as estimated starting prices. Does the price rise with the dose? The site names five semaglutide tiers and six tirzepatide tiers without publishing a figure for any of them, so a starting price is the bottom rung. What does tirzepatide cost? An estimated $325 a month to start, on a ladder the seller says runs to six dose tiers. Is Lumora expensive compared with other GLP-1 telehealth sellers? Lumora publishes a starting figure of $245/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lumora above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LunaRx reviews (2026): GLP-1 telehealth sellers | This GLP One headline figure spans three bundled stacks, and the page never says which stack it prices. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lunarx-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three stacks, one floor # LunaRx review One headline figure spans three bundled stacks, and the page never says which stack it prices. ## The verdict LunaRx publishes from $199 a month across three GLP-1 stacks. The page does not attach that figure to a named stack. Each stack's price is confirmed after a provider review, so the headline is a floor rather than a quote. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LunaRx sells compounded GLP-1 injections bundled with peptides, with care in English and Spanish. The entry Foundation stack pairs semaglutide with a CJC-1295 and ipamorelin blend. The two higher stacks are built on tirzepatide. 1. ## Who writes the prescription, and what do they see? The platform states that it does not practice medicine or write prescriptions. Independent, board-certified clinical providers make every prescribing decision, according to its disclaimer. The founder is identified as a registered nurse. No prescribing physician is named on the homepage or the treatment pages. The Foundation stack lists a monthly asynchronous physician check-in. The Premier stack lists a monthly consult, synchronous or asynchronous. Direct messaging through a patient portal is described between check-ins. A buyer who is not approved is not charged, the page states. 2. ## What happens when the dose goes up? Each stack lists dose [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) as needed, with no schedule attached. The six-month Elite stack describes four active months, then a two-month taper. Whether the monthly price moves as the dose rises is not stated. No milligram dose is published for any stack. 3. ## What the price includes One figure is published: from $199 a month. Six months at that floor would be $1,194, if a buyer's stack is the one it prices. Which stack that is goes unstated. The three stack prices are confirmed after the provider review, not before it. 4. ## What it claims, and what it cites Every stack is compounded by a 503A pharmacy, which the page states. Compounded preparations are not FDA-approved, and the seller's own disclaimer says so. The pharmacy is not named. The peptides in each stack are named, but their doses are not. ## Where it holds up, and where it does not - Strength: The contents of each stack are named - Strength: Care offered in English and Spanish - Strength: No charge when a buyer is not approved - Strength: A taper is written into one stack - Limitation: The headline figure is not tied to a stack - Limitation: Stack prices arrive after the provider review - Limitation: No milligram dose appears for any stack - Limitation: Its partner pharmacies go unnamed ## What the evidence says about this kind of treatment The assessment above is about LunaRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a peptide stack and a planned taper, and will ask for the stack price at review. Wrong for A reader comparing single-molecule prices, since each stack bundles the GLP-1 with peptides. ## The evidence behind what LunaRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How LunaRx compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | MaxLife | Readers who will ask what the starter kit covers and what follows it | | | Vitalex Health | Readers wanting tirzepatide who will confirm the figure applies to it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Metabolic Rx](https://thisglp.com/reviews/metabolic-rx) [Metabolyz](https://thisglp.com/reviews/metabolyz) [Mixx Health & Wellness](https://thisglp.com/reviews/mixx-health-and-wellness) [Modern Age](https://thisglp.com/reviews/modern-age) [Novera MD](https://thisglp.com/reviews/novera-md) [Nuform Health](https://thisglp.com/reviews/nuform-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $199 buy semaglutide on its own? Not stated. The page does not price semaglutide apart from the stacks, and the figure is a from-price across all three. When is the price confirmed? After the provider review, according to the page. A buyer who is not approved is not charged. Where does LunaRx provide care? Its FAQ states service across all 50 states, in English or Spanish. Is LunaRx legit? LunaRx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is LunaRx expensive compared with other GLP-1 telehealth sellers? LunaRx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LunaRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Luvo Health reviews (2026): GLP-1 telehealth sellers | This GLP Everything is priced per four weeks and per week at once, with twelve, twenty-four and fifty-two week blocks published beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/luvo-health Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Weekly rate, four blocks # Luvo Health review Everything is priced per four weeks and per week at once, with twelve, twenty-four and fifty-two week blocks published beside it. ## The verdict Luvo Health publishes $249 per four weeks for compounded semaglutide by injection, and states the same figure as $62 a week alongside it. Three longer commitments are published in full: $657 for twelve weeks, $1,194 for twenty-four and $2,327 for fifty-two, each cutting the weekly rate a little further. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $271/mo Oral From $303/mo Prescription Required Compounded Yes — not FDA-approved Luvo Health sells both molecules, with semaglutide available as an injection or an oral and tirzepatide by injection. Every line carries four figures — a four-week price and three block prices — which means a reader can see the entire commitment ladder on one screen rather than discovering it at checkout. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the pages concentrate on terms rather than on the clinician behind them. The intake is not documented, so what a prescriber reviews before writing is not something a reader can establish here — a gap that sits oddly beside pricing this thoroughly disclosed. The four-week interval is the thing to register before comparing anything. A year at Luvo is thirteen four-week periods rather than twelve months, and the fifty-two-week block price is where that becomes visible: $2,327 against what thirteen separate four-week charges at $249 would cost. Publishing the annual block is what lets a reader do that arithmetic at all. 2. ## What happens when the dose goes up? Luvo states its rates hold at every dose. Combined with the published block prices, that makes a full-year calculation genuinely possible here. The two unknowns that usually defeat the exercise, [dose escalation](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and term pricing, are both addressed on the page. 3. ## What the price includes The weekly framing is unusually honest here because Luvo gives both numbers rather than only the small one. Semaglutide runs $249 per four weeks or $62 a week; the oral is $279 and $70; tirzepatide is $339 and $85. Each longer block lowers the weekly rate, so the ladder rewards commitment in a visible, checkable way rather than an advertised one. 4. ## What it claims, and what it cites Every line is compounded, which means none has been through the FDA review an approved product completes before dispensing. The oral [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) carries the highest four-week figure of the three lines, which runs against the usual pattern where a tablet undercuts an injection. ## Where it holds up, and where it does not - Strength: Four commitment lengths published on each line - Strength: Both the weekly and four-week figure given - Strength: Rate stated to hold at every dose - Strength: A full year can actually be calculated - Limitation: Four-week billing means thirteen periods - Limitation: The oral costs more than the injection - Limitation: No milligram dose is published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Luvo Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to price a full year before starting and can read a four-week interval correctly. Wrong for A reader comparing against monthly sellers without adjusting for the shorter period. ## The evidence behind what Luvo Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Luvo Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. | | | Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nurx](https://thisglp.com/reviews/nurx) [Olleve Care](https://thisglp.com/reviews/ollevecare) [Omada Health](https://thisglp.com/reviews/omada-health) [One80Rx](https://thisglp.com/reviews/one80rx) [Pillar Health](https://thisglp.com/reviews/pillar-health) [Prescriva](https://thisglp.com/reviews/prescriva) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $249 a monthly price? No. It covers four weeks, so a year is thirteen such periods rather than twelve. Luvo publishes a fifty-two-week block at $2,327, which is the figure to compare against an annual total elsewhere. Do the longer blocks actually save money? Yes, and visibly: each block lowers the stated weekly rate, from $62 on the four-week price down across the twelve, twenty-four and fifty-two week commitments. Why is the tablet more expensive? That is how Luvo prices it, at $279 per four weeks against $249 for the injection. The pages offer no reason, and the direction runs against most of the category. Is Luvo Health expensive compared with other GLP-1 telehealth sellers? Luvo Health publishes a starting figure of $271/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Luvo Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # LVNG RX reviews (2026): GLP-1 telehealth sellers | This GLP The card figures are stated to be confirmed after a provider review, which makes them provisional. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lvng-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Confirmed after review # LVNG RX review The card figures are stated to be confirmed after a provider review, which makes them provisional. ## The verdict LVNG RX publishes from $149 a month for semaglutide and from $249 for tirzepatide. The site states the plan price is confirmed after provider review. A microdose program is offered with no published price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $149/mo Prescription Required Compounded Yes — not FDA-approved LVNG RX sells both molecules by injection. Each bundle covers the online provider visit, the prescription, delivery and check-ins. A third microdose program carries no figure. 1. ## Who writes the prescription, and what do they see? An online provider visit is named as included, and the provider also sets the final price. Both facts are stated. Neither the clinician nor the intake is described. Four inclusions are named, which is a real disclosure. The price attached to them is provisional until a provider reviews the case, which the site says plainly. 2. ## What happens when the dose goes up? Nothing is published about dose. The provider review that confirms the price is where a dose is set. The two unknowns resolve together, and neither is available first. 3. ## What the price includes $149 and $249 are floors and are also subject to confirmation. Six months at them is $894 and $1,494 at best. Struck-through figures of $249 and $299 appear beside them with no stated basis. The microdose program has no published price at all. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Four inclusions named in each bundle - Strength: The confirmation step is disclosed - Strength: Both main lines carry a figure - Limitation: The card price is provisional - Limitation: Struck-through figures have no basis - Limitation: The microdose program has no price - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about LVNG RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a bundle and accepts the figure is confirmed later. Wrong for A reader who needs a settled price before intake. ## The evidence behind what LVNG RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How LVNG RX compares | Seller | Who it suits | Go | | --- | --- | --- | | Liv Body | Readers who want no contract and will ask what their own plan costs | | | LevelsRx | Readers who want the oral option and will ask what the ladder costs | | | Longevixx | Readers wanting a flat rate in any state | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrescrYbe](https://thisglp.com/reviews/prescrybe) [PRIMO Health Partners](https://thisglp.com/reviews/primo-health-partners) [Push Health](https://thisglp.com/reviews/push-health) [Ravia Health](https://thisglp.com/reviews/ravia-health) [Red Mountain Weight Loss](https://thisglp.com/reviews/red-mountain-weight-loss) [RegenCen](https://thisglp.com/reviews/regencen) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 what I will pay? Not necessarily. The site states the plan price is confirmed after provider review. What is included? The online provider visit, the prescription, delivery and check-ins. What does the microdose program cost? No price is published for it. Is LVNG RX expensive compared with other GLP-1 telehealth sellers? LVNG RX publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts LVNG RX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Lyfe Rx reviews (2026): GLP-1 telehealth sellers | This GLP Each price includes the provider review, medication, supplies and shipping, with no membership fee. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/lyfe-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price, no membership # Lyfe Rx review Each price includes the provider review, medication, supplies and shipping, with no membership fee. ## The verdict Lyfe RX lists compounded semaglutide at $225 and tirzepatide at $299 as one-time purchases. Each price includes the provider review, medication, supplies and shipping. No membership is charged. Subscription options cost less but renew automatically. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $225/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider Lyfe RX is a telehealth storefront. It sells compounded GLP-1s alongside hormone and longevity products. The buyer checks out first. The medical intake follows checkout. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews every intake before anything ships. The providers page names twelve licensed providers, including a medical director. Listed credentials are MD, DO and NP. Review takes about four hours, the site states. Provider messaging is included. The prescription goes to a 503A pharmacy by e-script. Pharmacy turnaround is stated as one to three days. Some protocols require recent labs before authorization. 2. ## What happens when the dose goes up? The product page states a low starting dose, raised gradually. A licensed provider oversees the schedule. The price is shown without a dose. Whether it changes as the dose rises is not stated. 3. ## What the price includes Each product page shows three purchase options. The pre-selected one is a monthly subscription at ten percent off. A three-month order takes fifteen percent off. The one-time purchase is $225 for semaglutide and $299 for tirzepatide. That is the price without a recurring charge. 4. ## What it claims, and what it cites Both lines are compounded by U.S.-licensed 503A pharmacies. The product page states they are not FDA-approved. No pharmacy is named. The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) line is sold as Compounded GLP-1, and the page confirms the molecule. ## Where it holds up, and where it does not - Strength: Provider review and shipping included in price - Strength: No membership fee on any order - Strength: Twelve named providers, including a medical director - Strength: LegitScript certification is displayed on-site - Limitation: Checkout comes before the medical intake - Limitation: The pre-selected option is a subscription - Limitation: No milligram dose beside the price - Limitation: The dispensing pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Lyfe Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one all-in figure and no membership. Wrong for A reader who wants eligibility settled before paying. ## The evidence behind what Lyfe Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Lyfe Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Good Girl Rx | A reader who will read the one-month rung rather than the headline, and wants microdoses labeled as such | | | LevelUp Rx | Readers who want the billed total before committing to a term | | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rese Wellness](https://thisglp.com/reviews/rese-wellness) [Revive Longevity](https://thisglp.com/reviews/revive-longevity) [Rila](https://thisglp.com/reviews/rila) [Risen Labs](https://thisglp.com/reviews/risen-labs) [Robinhood Telehealth](https://thisglp.com/reviews/robinhood-telehealth) [Royal Medical Center](https://thisglp.com/reviews/royal-medical-center) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Lyfe RX charge a membership on top? No. The page states the price covers review, medication, supplies and shipping. Why is a lower figure selected first? The monthly subscription is pre-selected at ten percent off. The one-time semaglutide price is $225. What if I am not approved? The order is not authorized. Refund terms sit in the cancellation and refund policy. Is Lyfe Rx legit? Lyfe Rx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Lyfe Rx expensive compared with other GLP-1 telehealth sellers? Lyfe Rx publishes a starting figure of $225/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Lyfe Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MadeMed reviews (2026): GLP-1 telehealth sellers | This GLP The advertised figure belongs to the six-month plan, and every line publishes the shorter term's rate beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mademed Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Headline is the longer term # MadeMed review The advertised figure belongs to the six-month plan, and every line publishes the shorter term's rate beside it. ## The verdict MadeMed's advertised rate is attached to a commitment rather than to a month, and the seller prints the shorter term's rate beside it on every line. That is the disclosure worth crediting: a reader can see what the headline assumes without starting a checkout. What it cannot tell them is whether either rate survives a rising dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $239/mo Oral From $219/mo Prescription Required Compounded Yes — not FDA-approved Availability Not published by the provider MadeMed sells compounded semaglutide and compounded tirzepatide in injected and oral forms, on plans rather than by the month. What distinguishes it from the many sellers that advertise a term rate is that it publishes both tiers on every line, so the discount for committing longer is visible rather than implied. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the service is remote. The pages describe plan structures rather than the clinician behind them, and the intake is not documented. A reader therefore learns a great deal about the commercial terms and very little about the clinical ones, which is the reverse of what a first-time buyer needs. Pricing by term is a reasonable way to sell a treatment most people stay on for months, and MadeMed discloses it rather than burying it. The consequence a reader has to carry is that the advertised figure describes the deeper commitment, so setting it beside a monthly rate from another seller compares two different kinds of promise. 2. ## What happens when the dose goes up? Nothing is published about what either tier costs as the dose climbs, which leaves the plan structure doing work it cannot do. A six-month commitment at $199 is only a six-month cost if the figure survives a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule, and the pages do not say. 3. ## What the price includes Each line carries two rates and MadeMed shows both, so the discount for committing longer is a visible number rather than an inference. The gap runs to forty dollars a month on semaglutide and thirty on tirzepatide. Billing happens in blocks either way, which means the commitment and the payment arrive together. Nothing states what either tier becomes at a higher dose, so neither is a half-year cost so much as a half-year rate. 4. ## What it claims, and what it cites All four lines are compounded preparations rather than manufactured ones, which places them outside the FDA review an approved product passes before it is dispensed. The oral line adds vitamin B6 to the formulation. The approved product contains no such addition, and the pages do not say what it is there to do. ## Where it holds up, and where it does not - Strength: Each line shows both of its tiers - Strength: The commitment behind the rate is named - Strength: The additive in the oral is disclosed - Limitation: The advertised rate needs six months - Limitation: Quarterly costs $40 a month more - Limitation: Billed in blocks rather than monthly - Limitation: No dose behavior is published ## What the evidence says about this kind of treatment The assessment above is about MadeMed. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit six months, which is the commitment the advertised figure assumes. Wrong for A reader who needs to leave without a term still running. ## The evidence behind what MadeMed prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MadeMed compares | Seller | Who it suits | Go | | --- | --- | --- | | BetterMe Rx | A reader willing to fund a quarter up front, once the sale is confirmed live | | | Lttl | Readers who want every prepay rung visible and know which dose line they need | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sipra](https://thisglp.com/reviews/sipra) [Sommar Club](https://thisglp.com/reviews/sommar-club) [StaveMD](https://thisglp.com/reviews/stavemd) [Steady State Health](https://thisglp.com/reviews/steady-state-health) [Super Healthy Rx](https://thisglp.com/reviews/super-healthy-rx) [Tablet Health](https://thisglp.com/reviews/tablet-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can $199 be had on the shorter plan? No. It belongs to the six-month plan; the quarterly tier is the higher of the two. What is the real difference between the two plans? Forty dollars a month on semaglutide. The longer commitment is what buys it, and MadeMed publishes both tiers so the trade is visible. What is the B6 doing there? The oral line adds it to the formulation. The approved product contains none, and the pages neither price the addition nor explain its purpose. Is MadeMed expensive compared with other GLP-1 telehealth sellers? MadeMed publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MadeMed above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Male Excel reviews (2026): GLP-1 telehealth sellers | This GLP Male Excel includes GLP-1 options within a broader men’s hormone and metabolic program. Regular provider reviews are described, while the drug-specific costs need clarification. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/male-excel Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Male Excel review Male Excel includes GLP-1 options within a broader men’s hormone and metabolic program. Regular provider reviews are described, while the drug-specific costs need clarification. ## The verdict The clinical structure is more useful than the broad promises about restoring performance. Male Excel describes symptom reviews, provider check-ins and recurring laboratory panels. A prospective weight-loss patient should establish whether those processes apply to a standalone GLP-1 plan and which other treatments are optional. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved The Excel Advantage model combines assessment, ongoing monitoring and personalized treatment for men. The site names semaglutide injections, semaglutide pills and tirzepatide among its metabolic options. Hormone therapy and thyroid treatment are separate prescriptions, not automatic companions to a weight-loss drug. 1. ## Who writes the prescription, and what do they see? Providers assess symptoms, laboratory information and medical suitability. The program describes prescription adjustments every 60 days, but that does not establish a universal GLP-1 titration schedule. Ask who will prescribe and what monitoring is specific to the medicine being proposed. The public model includes regular symptom reviews, 60-day provider check-ins and hormone and health panels every six months. Those are concrete service features to discuss. Verify which apply to the selected weight-loss program rather than assuming every treatment receives the entire hormone-care package. 2. ## What happens when the dose goes up? Dose decisions must account for the individual medicine and response. A general 60-day review cadence should not be interpreted as an instruction to wait that long with significant [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). Establish the contact route for problems between scheduled reviews and the refill plan during dose changes. 3. ## What the price includes The treatment pages do not establish one standing monthly bill for each GLP-1 option. The Excel Advantage guarantee concerns membership fees during an initial 90-day protocol and has adherence and claim requirements. It is not a general promise to refund every prescribed product. 4. ## What it claims, and what it cites The site describes US-compounded, pharmacy-dispensed treatment and lists [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) options. An oral semaglutide preparation cannot be assumed equivalent to an approved tablet. Discuss the actual formulation, dispensing pharmacy and evidence without relying on the wider program’s testimonials. ## Where it holds up, and where it does not - Strength: Regular provider reviews are described - Strength: Repeat laboratory monitoring is explicit - Strength: Named GLP-1 options extend beyond hormone therapy - Limitation: Drug-specific prices are not established publicly - Limitation: The guarantee is limited to membership fees - Limitation: Broader hormone services may not fit a weight-only goal ## What the evidence says about this kind of treatment The assessment above is about Male Excel. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A man interested in a wider medically supervised metabolic assessment who wants to discuss whether GLP-1 care is appropriate within it. Wrong for A patient seeking a clearly priced standalone approved medicine with no interest in a broader program. ## The evidence behind what Male Excel prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Male Excel compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Teladoc Health](https://thisglp.com/reviews/teladoc-health) [Teleios Health](https://thisglp.com/reviews/teleios-health) [TeleWellnessMD](https://thisglp.com/reviews/telewellnessmd) [The Protocole](https://thisglp.com/reviews/the-protocole) [TideMedix](https://thisglp.com/reviews/tidemedix) [Tomorrow](https://thisglp.com/reviews/tomorrow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Male Excel offer GLP-1 options? Its site explicitly names semaglutide injections and pills, plus tirzepatide, within metabolic care. Does the guarantee cover all drug spending? No. The published guarantee is limited to qualifying initial membership fees and imposes adherence and claim requirements. Is testosterone mandatory for weight treatment? Do not assume it is. Ask which parts of the individualized plan are clinically indicated and separately optional. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://maleexcel.com/) - [Terms of service and payment conditions](https://maleexcel.com/terms-conditions/) - [Terms of service and payment conditions](https://maleexcel.com/terms-conditions-excel-advantage-guarantee/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MangoRx reviews (2026): GLP-1 telehealth sellers | This GLP MangoRx offers Slim, a compounded semaglutide dissolving tablet. Its clinical process, pharmacy terms and formulation deserve separate consideration from the low starting price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mangorx Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # MangoRx review MangoRx offers Slim, a compounded semaglutide dissolving tablet. Its clinical process, pharmacy terms and formulation deserve separate consideration from the low starting price. ## The verdict MangoRx makes the route of administration clear: Slim is a daily dissolving tablet rather than a weekly injection. That convenience is a practical distinction, but evidence for an approved semaglutide product cannot establish how this compounded formulation performs. The pharmacy-choice restriction also deserves attention before enrollment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Oral Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Slim combines semaglutide with vitamin B6 in a 30-day supply. MangoRx describes an entirely online assessment and prescription pathway aimed at people who prefer to avoid injections. It is medication requiring clinical approval, not a supplement available without screening. 1. ## Who writes the prescription, and what do they see? A licensed healthcare provider reviews the health questionnaire and decides whether treatment is appropriate. The terms distinguish the technology platform, contracted medical groups and Epiq Scripts pharmacy. They do not make a particular named doctor your guaranteed prescriber. The sequence is a medical questionnaire, provider evaluation and pharmacy fulfillment if approved. MangoRx advertises free provider visits and shipping. The terms require patients to continue appropriate primary care; this service should not be treated as a replacement for an existing clinician managing other conditions. 2. ## What happens when the dose goes up? The product FAQ lists oral doses from 1 to 6 mg, chosen by the physician. It does not publish a universal follow-up calendar or a complete price for every dose. Establish how to reach the prescriber about tolerance, missed doses and the next supply before starting. 3. ## What the price includes The advertised entry figure is $67 per month, with a 30-day pack described. That does not establish every dose, renewal condition or longer commitment. Automatic renewal must be stopped at least 48 hours ahead under the terms; prescription returns and refunds are generally unavailable. 4. ## What it claims, and what it cites This is compounded oral [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) with B6. It is not an FDA-approved generic version of an approved tablet or injection. An orally dissolving preparation should not be assumed interchangeable with a swallowed approved tablet; ask the prescriber to explain the formulation and supporting evidence. ## Where it holds up, and where it does not - Strength: Daily tablet option is explicitly described - Strength: Pharmacy role is identified in the terms - Strength: Provider assessment precedes dispensing - Limitation: Dissolving formulation has separate evidence questions - Limitation: Terms restrict pharmacy choice - Limitation: No public universal follow-up timetable ## What the evidence says about this kind of treatment The assessment above is about MangoRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An adult who wants to discuss a non-injectable option with a prescriber and understands the distinction between compounded and approved oral medicines. Wrong for Someone seeking an approved medicine with a transferable prescription or a published appointment schedule before paying. ## The evidence behind what MangoRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How MangoRx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TotalRx](https://thisglp.com/reviews/totalrx) [Totara Health](https://thisglp.com/reviews/totara-health) [Trally Meds](https://thisglp.com/reviews/trally-meds) [Transcarent](https://thisglp.com/reviews/transcarent) [TRT Kingdom](https://thisglp.com/reviews/trt-kingdom) [Tummala Health](https://thisglp.com/reviews/tummala-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Slim an injection? No. MangoRx describes a daily orally dissolving tablet containing compounded semaglutide and vitamin B6. Who chooses the dose? The prescribing clinician does. The listed 1–6 mg range is not a self-directed dosing instruction. Can the prescription be filled elsewhere? The platform terms contain a pharmacy-choice waiver. Resolve that condition directly before consenting. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://mangorx.com/) - [Weight-management program](https://mangorx.com/weight-loss) - [Terms of service and payment conditions](https://mangorx.com/terms-and-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MANÜ Telehealth reviews (2026): GLP-1 telehealth sellers | This GLP Two plans per molecule, split by dose rather than by term, with both figures published. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/manu-telehealth Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Starter and full dose, priced # MANÜ Telehealth review Two plans per molecule, split by dose rather than by term, with both figures published. ## The verdict MANÜ Telehealth publishes a Semaglutide Starter Plan from $199 and a Full Dose Plan at $299, with tirzepatide at $297 and $397. The split is by dose rather than by commitment length. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved MANÜ Telehealth sells both molecules by injection across two plans each. The Starter Plan is described as entry pricing for patients starting or staying on lower doses. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. The plan names do the work instead, and they describe a clinical position rather than a billing term, which is unusual. Almost every seller that varies price by term publishes the ladder; almost none that varies by dose does. MANÜ publishes the dose split directly, so a reader can see what escalating costs before they escalate. The distinction between starting and staying on lower doses is also stated, which acknowledges that some people do not move up. 2. ## What happens when the dose goes up? This is the field MANÜ answers. Moving from the Starter Plan to the Full Dose Plan costs $100 a month on semaglutide and $100 on tirzepatide. A reader who expects to reach a full dose should price the second figure, not the first. 3. ## What the price includes Six months on the Starter Plan is $1,194 for semaglutide and $1,782 for tirzepatide. On the Full Dose Plan the same spans are $1,794 and $2,382. The word starting attaches to both entry figures, so the Starter Plan has a floor of its own. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Both dose plans priced, not just the entry one - Strength: The split is by dose, stated plainly - Strength: Staying on a low dose is acknowledged - Limitation: Full dose costs $100 more a month - Limitation: Both entry figures say starting at - Limitation: No milligram thresholds published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about MANÜ Telehealth. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the cost of a full dose stated before starting a low one. Wrong for A reader budgeting a year from the Starter Plan figure. ## The evidence behind what MANÜ Telehealth prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MANÜ Telehealth compares | Seller | Who it suits | Go | | --- | --- | --- | | MaxLife | Readers who will ask what the starter kit covers and what follows it | | | LeanDose | Readers who will get the month-two rate in writing before the first charge | | | LevelUp Rx | Readers who want the billed total before committing to a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vea Health](https://thisglp.com/reviews/vea-health) [Vela Rx](https://thisglp.com/reviews/vela-rx) [Verge](https://thisglp.com/reviews/verge) [Vida Health](https://thisglp.com/reviews/vida-health) [Virgo-Meds](https://thisglp.com/reviews/virgo-meds) [Virta Health](https://thisglp.com/reviews/virta-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a full dose cost? $299 a month for semaglutide and $397 for tirzepatide, against Starter Plan figures of $199 and $297. Where is the line between the two plans? MANÜ describes the Starter Plan as entry pricing for patients starting or staying on lower doses, without publishing a milligram threshold. Is $199 a fixed rate? It is a starting figure for the Starter Plan, so it is a floor within the lower tier rather than a settled rate. Is MANÜ Telehealth expensive compared with other GLP-1 telehealth sellers? MANÜ Telehealth publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MANÜ Telehealth above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Marek Health reviews (2026): GLP-1 telehealth sellers | This GLP A lab-led optimization service that tests before it prescribes, and publishes no price for the GLP-1 medication itself. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/marek-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Labs first, prescription later # Marek Health review A lab-led optimization service that tests before it prescribes, and publishes no price for the GLP-1 medication itself. ## The verdict Marek Health starts every patient with a coach, a lab panel and a physician consult, and only then a prescription. The $299 on its pages is the entry to that program, shown the same way for testosterone and hair loss. No price for semaglutide or tirzepatide is published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 50 Dose published No Prescription Required Pharmacy Not named Labs Extra cost Availability All 50 states Marek Health is a telehealth platform built around what it calls Guided Optimization. Weight loss sits beside testosterone, fertility, hair, sleep and heart-health programs. Its weight-loss page names tirzepatide injections, and its FAQ discusses both semaglutide and tirzepatide. The site says it serves U.S. residents only, in all 50 states, with some treatments limited by state. 1. ## Who writes the prescription, and what do they see? Marek states that it is not a clinic and does not prescribe. Partnered physicians write the prescriptions. The program includes a 25-minute consultation with a licensed medical provider after the labs are back. Individual prescribers are not named on the treatment pages. Coaches are the day-to-day contact. The first step is an intake with a health coach, who builds a custom lab panel. Discounted testing is open only once the patient buys at least $450 of labs. A written lab report and the provider consultation follow. The FAQ also requires a copy of an in-person annual physical before starting and continuing treatment. After that come monthly coach check-ins and refills. 2. ## What happens when the dose goes up? No dose schedule or dose-by-dose price is published. What the FAQ does fix is the monitoring around the dose. A follow-up provider visit comes 6 to 12 weeks after starting, with basic labs in the same window. Routine visits and repeat labs then run every six months. Whether a dose increase changes the medication cost is not stated. 3. ## What the price includes Two figures are published, and neither is a medication price. The first is $299 to start treatment online, printed identically on the weight-loss page and across other programs. The second is the $450 minimum for the first lab panel. Medication, follow-up labs and repeat visits are not priced publicly. The site says there are no set subscription plans and cancellation is open. Insurance is not billed, though the FAQ says many clients pay with FSA or HSA funds. 4. ## What it claims, and what it cites The FAQ says prescriptions are filled by 503A and 503B compounding pharmacies, which prepare each order on receipt. Compounded drugs are not FDA-approved, and the site does not say whether a GLP-1 order is compounded or branded. No pharmacy is named. The FAQ puts fulfillment at up to 48 hours for compounding alone. ## Where it holds up, and where it does not - Strength: Lab panel before any prescription - Strength: Scheduled follow-up labs at 6 to 12 weeks - Strength: No set subscription plan, per the FAQ - Strength: FSA and HSA payment accepted - Limitation: No GLP-1 medication price published - Limitation: $450 lab minimum before treatment - Limitation: In-person annual physical required - Limitation: Dispensing pharmacy not named ## What the evidence says about this kind of treatment The assessment above is about Marek Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants blood work and a coach wrapped around a GLP-1, and will get the drug price from the coach. Wrong for A buyer who wants to compare a published monthly GLP-1 price before booking anything. ## The evidence behind what Marek Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Marek Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | MultiMedRx | A reader with insurance who needs a branded GLP-1 covered rather than sold | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vitakey](https://thisglp.com/reviews/vitakey) [Vital Step](https://thisglp.com/reviews/vital-step) [Vivanta Care](https://thisglp.com/reviews/vivanta-care) [VivioMD](https://thisglp.com/reviews/viviomd) [welludr.](https://thisglp.com/reviews/wellmedr)[Yes Clinic](https://thisglp.com/reviews/yes-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $299 what Marek Health charges for a GLP-1? No. It is the figure to start treatment online, and it appears the same way beside other programs. The medication is not priced on the site. What does it cost before any prescription? At least $450 of lab work, bought through the coach, and a provider consultation follows the results. Is an in-person exam required? Yes. The FAQ asks for a copy of an annual physical from an in-person clinician before starting and while continuing treatment. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Maves reviews (2026): GLP-1 telehealth sellers | This GLP The $89 on the page is a first month with a $100 discount applied, and every month after it costs $189. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/maves Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A discounted first month # Maves review The $89 on the page is a first month with a $100 discount applied, and every month after it costs $189. ## The verdict Maves sells compounded semaglutide at $189 a month, and the $89 that leads its product page is that same monthly plan with a $100 first-order discount applied automatically at checkout. From the second month onward the page's own figure is $189, with no membership fee on top and cancellation allowed at any time through the patient portal. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $189/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Maves is a telehealth brand selling compounded semaglutide and tirzepatide alongside sermorelin and NAD+, and it frames weight loss as a sequence of phases that runs from an induction period through active fat loss to a taper toward maintenance. 1. ## Who writes the prescription, and what do they see? The page says licensed clinicians prescribe every treatment after an online assessment, and that a provider writes a plan only when medication is judged appropriate for the patient. No prescriber, medical group or licensing state is named on the product pages, so a buyer first meets the clinician somewhere inside the intake rather than on the page. Once a prescription is written, the care described is built around messaging: clinicians reachable at any hour without booking an appointment, dose adjustments made through that same channel, and ondansetron prescribed for nausea when a patient needs it. The medication ships free by expedited delivery, and the formulation may include vitamin B12 or L-carnitine alongside the semaglutide, which the page presents as part of personalizing the treatment. 2. ## What happens when the dose goes up? The page says Maves starts low and titrates for comfort, and it describes a later step down toward maintenance, but it does not publish a milligram schedule in either direction. The $189 is a single monthly figure with no dose attached, and whether it holds as the dose climbs through the first few months is not stated anywhere on the page. 3. ## What the price includes The plan is monthly, and no longer commitment rung is published, so the arithmetic is simple once the first month is set aside as the exception it is. Six months at the standing $189 would come to $1,134, and the first-order discount takes $100 off that total once rather than every month. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded by licensed U.S. pharmacies, which the page describes as state-licensed or FDA-registered outsourcing facilities whose products are tested by a third party for purity and potency, though none of them is named. Compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not FDA-approved, and a reader should know that the page's own FAQ calls semaglutide FDA-approved, which is true of the branded medicine rather than the compounded one sold here. ## Where it holds up, and where it does not - Strength: The first-month condition is printed beside the price - Strength: No membership fee on top of $189 - Strength: Anti-nausea prescribing is named in the FAQ - Strength: Cancellation at any time, stated in writing - Limitation: The headline $89 lasts a single month - Limitation: No milligram dose or schedule is published - Limitation: Pharmacies are described but never named - Limitation: The FAQ blurs compounded and FDA-approved semaglutide ## What the evidence says about this kind of treatment The assessment above is about Maves. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who budgets on $189 a month and treats the $89 as a one-time discount on the first order. Wrong for A reader who wants a published dose schedule, or a named prescriber, before placing the first order. ## The evidence behind what Maves prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Maves compares | Seller | Who it suits | Go | | --- | --- | --- | | Regenics | Readers who will add the membership to the medication before comparing anything | | | Sprout Health | Readers taking the six-month plan, which is the one measured in calendar months | | | Rivas Medical Weight Loss | Buyers within reach of a clinic who want a clinician present every week | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [YOURx Health](https://thisglp.com/reviews/yourx-health) [Youth & Soul](https://thisglp.com/reviews/youth-and-soul) [Zenbody](https://thisglp.com/reviews/zenbody) [Coby Health](https://thisglp.com/reviews/coby-health) [Form Health](https://thisglp.com/reviews/form-health) [Pepton Health](https://thisglp.com/reviews/pepton-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $89 the monthly price? It is the first month only, with a $100 first-order discount applied automatically at checkout, and the same pricing block states $189 a month for every month after that. Is there a contract? The FAQ says plans are subscriptions that can be canceled at any time through the patient portal, with no long-term contract and no cancellation fee, although an order already sent to the pharmacy still goes out. Does Maves sell tirzepatide? Yes, on its own product page, and that page carries the same $100 first-order discount structure, with a higher monthly figure than the semaglutide plan once the first month has passed. Is Maves expensive compared with other GLP-1 telehealth sellers? Maves publishes a starting figure of $189/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Maves below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Maximus reviews (2026): sellers of the branded GLP-1 products | This GLP Compounded preparations and the manufacturers' pens are listed side by side on this seller's plans. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/maximus-tribe Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Branded and compounded priced together # Maximus review Compounded preparations and the manufacturers' pens are listed side by side on this seller's plans. ## The verdict Maximus prices compounded semaglutide at $249.99 a month on a one-month plan and the branded Wegovy pen at $449.99 ongoing. On tirzepatide the gap is similar, at $359.99 compounded against $549.99 for the Zepbound pen. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category sellers of the branded GLP-1 products Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $249.99/mo Prescription Required Maximus sells both compounded preparations and the manufacturers' finished products, on plans of one, four and twelve months. The one-month plan carried $249.99 for semaglutide and $359.99 for compounded tirzepatide. The branded pens are billed monthly at $449.99 for Wegovy and $549.99 for Zepbound at the lowest dose, each $100 lower in the first month. Coverage extends to all fifty states and the District of Columbia. 1. ## Who writes the prescription, and what do they see? Treatment is arranged online and the plan a reader buys sets the rate. The branded rows are dispensed as the manufacturer's finished product, which requires a prescription written against the approved label. The compounded rows require one as well, written for a preparation the label does not cover. What the intake asks before either is issued is not published. Treatment is arranged online and the plan term sets the rate rather than the dose. Maximus states a flat rate across doses, so an escalation does not move the monthly figure. The longer plans cut it substantially: compounded semaglutide falls to $199.49 on four months and $150.32 on twelve. Compounded tirzepatide follows the same shape, at $298.99 and $240.66. 2. ## What happens when the dose goes up? Maximus states a flat rate across doses, so the escalation does not move the monthly figure. What moves it is the plan length chosen at the start. A twelve-month plan is bought before the first dose step, and a one-month plan keeps that decision open at $249.99. The branded pens are priced by dose instead. Wegovy runs from $449.99 at 0.25 mg to $599.99 at 2.4 mg. Zepbound runs from $549.99 at 2.5 mg to $749.99 at 15 mg. 3. ## What the price includes On semaglutide the branded pen costs $200 a month more than the compounded preparation on a one-month plan. On tirzepatide the gap is $190. Each pen's first month is $100 lower, and the ongoing rate is the one to budget against. Whether the longer plans apply to the branded rows is not recorded here. 4. ## What it claims, and what it cites The branded rows are the manufacturer's own product, reviewed and approved as a finished medicine. The compounded rows are prepared by a pharmacy and are not FDA-approved. That distinction is most of what the price gap buys. Trial results for these molecules were generated with the approved products at label doses, and compounded preparations were not what was studied. ## Where it holds up, and where it does not - Strength: Branded and compounded on one plan page - Strength: Branded pen prices published by dose - Strength: Compounded rate stated as flat across doses - Limitation: One-month rate is high for this category - Limitation: Branded pens cost $190 to $200 more monthly - Limitation: Best compounded rates need a twelve-month plan ## What the evidence says about this kind of treatment The assessment above is about Maximus. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. Wrong for A reader shopping the compounded market on price alone, since the one-month rate here sits well above what compounded-only sellers charge. ## The evidence behind what Maximus prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Maximus compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Belle Health](https://thisglp.com/reviews/belle-health) [bmiMD](https://thisglp.com/reviews/bmimd) [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)[Collective](https://thisglp.com/reviews/collective) [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) [Direct Meds](https://thisglp.com/reviews/direct-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the branded product priced near the compounded one? No. On a one-month plan compounded semaglutide was $249.99 against $449.99 ongoing for the Wegovy pen. Compounded tirzepatide was $359.99 against $549.99 for Zepbound. How much do the longer plans save? Compounded semaglutide drops from $249.99 to $199.49 on a four-month plan and $150.32 on twelve months. Compounded tirzepatide drops to $298.99 and $240.66 on the same terms. Does the price rise with the dose? Maximus states a flat rate across doses for its compounded plans. The branded pens are priced by dose, so an escalation there does raise the monthly figure. Is Maximus expensive compared with other GLP-1 telehealth sellers? Maximus publishes a starting figure of $249.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Maximus above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MaxLife reviews (2026): GLP-1 telehealth sellers | This GLP Both headline figures are asterisked to a Starter Kit Plan that the page never describes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/maxlife Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A starting price tied to a kit # MaxLife review Both headline figures are asterisked to a Starter Kit Plan that the page never describes. ## The verdict MaxLife publishes starting at $89 a month for semaglutide and $120 for tirzepatide. Both figures are asterisked to a Starter Kit Plan. The page never says what the kit is or what follows it. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $89/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states MaxLife sells both molecules by injection as a membership. The headline figures belong to a starter kit. Coverage is all fifty states. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The membership framing describes what is included rather than who provides it. The intake is not documented. The asterisk is the part to read. Each headline figure is tied to a Starter Kit Plan, and the phrase appears once on each product page, in the footnote itself. What a buyer pays once the kit ends is not published. 2. ## What happens when the dose goes up? Nothing on the product pages states what either figure does as the dose rises. Nor do they state the rate after the starter kit. Both questions belong in the intake, before the first charge. 3. ## What the price includes $89 and $120 are starter-kit figures, not standing rates. Six months at them would be $534 and $720. That holds only if the kit runs six months, which the page does not say. The rate after the kit is not published. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Both figures shown before intake - Strength: The asterisk sits beside each figure - Strength: Coverage in all fifty states - Strength: Both molecules carry a published figure - Limitation: The kit behind the figure is undescribed - Limitation: No milligram dose is published - Limitation: No rate after the kit is published - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about MaxLife. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will ask what the starter kit covers and what follows it. Wrong for A reader who needs a standing monthly rate before intake. ## The evidence behind what MaxLife prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MaxLife compares | Seller | Who it suits | Go | | --- | --- | --- | | MANÜ Telehealth | Readers who want the cost of a full dose stated before starting a low one | | | Longevixx | Readers wanting a flat rate in any state | | | LevelUp Rx | Readers who want the billed total before committing to a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Eden](https://thisglp.com/reviews/eden) [Embody](https://thisglp.com/reviews/embody) [Enhance MD](https://thisglp.com/reviews/enhance-md) [Found](https://thisglp.com/reviews/found) [Gala](https://thisglp.com/reviews/gala) [HealthRX](https://thisglp.com/reviews/healthrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the asterisk refer to? A Starter Kit Plan. The page names it once, in that footnote, and never describes it. Does the price change as my dose rises? Not stated on the product pages. Ask at intake, together with the rate after the kit. Where does tirzepatide start? At $120 a month, carrying the same asterisk as semaglutide. Is MaxLife legit? MaxLife is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is MaxLife expensive compared with other GLP-1 telehealth sellers? MaxLife publishes a starting figure of $89/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MaxLife below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MD Trim Clinic reviews (2026): GLP-1 telehealth sellers | This GLP MD Trim Clinic offers physician-directed semaglutide and tirzepatide assessment with a free screening call. Its dose-based payment model and dispensing details need a direct conversation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/md-trim-clinic Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # MD Trim Clinic review MD Trim Clinic offers physician-directed semaglutide and tirzepatide assessment with a free screening call. Its dose-based payment model and dispensing details need a direct conversation. ## The verdict The practice emphasizes a clinician relationship instead of a faceless refill service. That is a useful aim, but the practical test is who handles a dose change or side effect after screening. Public price categories are organized by medicine and weekly dose, so ask for both the care plan and its changing cost. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose Prescription Required Compounded Yes — not FDA-approved MD Trim Clinic markets medically supervised GLP-1 and GLP-1/GIP weight management. Its site lists semaglutide and tirzepatide and describes compounded treatment as well as branded-drug trial results. Those categories should not be conflated. 1. ## Who writes the prescription, and what do they see? The site describes physician-directed care and names a nurse practitioner within the team. A free consultation helps determine candidacy. Establish who will actually assess and prescribe for you; a statement about physician oversight does not identify every patient’s assigned professional. The public process begins with a free screening call and treatment selection. The FAQ discusses tolerability and contacting the clinician about persistent symptoms. It does not establish one universal appointment cadence or a guaranteed response time for every patient. 2. ## What happens when the dose goes up? The FAQ advises beginning at a low dose and changing it only under physician guidance. The monthly payment depends on medicine and weekly dose. Ask how each escalation is clinically approved and whether the next strength changes the bill before authorizing another supply. 3. ## What the price includes Published categories describe monthly payments by medication and weekly dose, but the public material does not establish a complete comparable price ladder. The free screening does not resolve medication, refill and additional-service charges. 4. ## What it claims, and what it cites The clinic describes compounded preparations and says medications come from LegitScript-certified pharmacies, without that statement identifying the pharmacy for your particular order. Its claims about trial weight loss concern studied products and do not guarantee the response to an individual compounded prescription. ## Where it holds up, and where it does not - Strength: Screening precedes treatment - Strength: Physician-directed dosing is emphasized - Strength: Dose-related billing is acknowledged - Limitation: Full price ladder needs a quote - Limitation: Assigned prescriber and pharmacy require confirmation - Limitation: Follow-up timing is not fully defined publicly ## What the evidence says about this kind of treatment The assessment above is about MD Trim Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants to discuss a clinician-directed injection plan and can obtain the dose and follow-up terms before beginning. Wrong for A patient needing a verified flat-price drug package or a public guaranteed monitoring schedule. ## The evidence behind what MD Trim Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MD Trim Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HumeCare+](https://thisglp.com/reviews/humecare)[Live Vital](https://thisglp.com/reviews/live-vital) [Lttl](https://thisglp.com/reviews/lttl) [Luvo Health](https://thisglp.com/reviews/luvo-health) [MEDGm](https://thisglp.com/reviews/medgm) [Oak](https://thisglp.com/reviews/oak) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is screening free? The site advertises a free patient screening or consultation call. Does the payment depend on dose? Yes. The public service description says the monthly payment depends on medication and weekly dose. Are branded trial results a guarantee? No. They describe study populations and products, not a guaranteed individual response or proof for a compounded formulation. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.mdtrimclinic.com/) - [Patient questions and care arrangements](https://www.mdtrimclinic.com/faq) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MDExam reviews (2026): GLP-1 telehealth sellers | This GLP The same product carries different figures on two of the seller's own pages, and only one of them is ever given a billing period. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mdexam Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two pages, two prices # MDExam review The same product carries different figures on two of the seller's own pages, and only one of them is ever given a billing period. ## The verdict MDExam publishes $225 a month for injectable semaglutide, and $192 for the identical product on a different page of its own site. Only the $225 is ever attached to a period. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $225/mo Prescription Required Compounded Yes — not FDA-approved MDExam sells both molecules by injection as a program that it describes as including telemedicine visits, nutrition and exercise coaching alongside the medication. 1. ## Who writes the prescription, and what do they see? Telemedicine visits and coaching are named as inside the program, which is a more specific description of the clinical relationship than most sellers offer. What is not specific is what any of it costs, because the site gives two answers. One page renders a price of $192 for the semaglutide program and another renders $225 for the same thing, and no sentence on either reconciles them. The site-wide framing — a program priced as low as $225 per month including visits, coaching and medication — is the only place a period appears at all, which is why that is the figure a reader should plan against. 2. ## What happens when the dose goes up? Nothing is published about what the figure does at a higher dose. The tirzepatide card compounds the problem by stating $258 with no billing period beside it, so its monthly status is an inference from the program framing rather than something the seller wrote down. 3. ## What the price includes Take $225 as the figure and six months is $1,350. Treat $192 as an unlabeled promotional number until someone can walk a checkout, which this desk could not — the checkout page renders an empty body without a session. The tirzepatide figure of $258 sits above the stated program floor, which is consistent with a monthly rate and is not the same as a published one. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Visits and coaching named as included - Strength: A period is stated in the site-wide framing - Strength: Both molecules carry a figure - Limitation: Two different prices for one product - Limitation: Neither product card states a period - Limitation: The tirzepatide period is inferred, not stated - Limitation: The checkout could not be walked ## What the evidence says about this kind of treatment The assessment above is about MDExam. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will get the applicable figure confirmed in writing before paying. Wrong for A reader taking the lower number on faith. ## The evidence behind what MDExam prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MDExam compares | Seller | Who it suits | Go | | --- | --- | --- | | LevelUp Rx | Readers who want the billed total before committing to a term | | | Lumora | Readers willing to complete an assessment and hold the seller to its own promise | | | MANÜ Telehealth | Readers who want the cost of a full dose stated before starting a low one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PeterMD](https://thisglp.com/reviews/petermd) [RxSpan MD](https://thisglp.com/reviews/rxspan-md) [Sesame Care](https://thisglp.com/reviews/sesame-care) [ShedRx](https://thisglp.com/reviews/shedrx) [SkinnyRx](https://thisglp.com/reviews/skinnyrx) [SnagRx](https://thisglp.com/reviews/snagrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is it $192 or $225? The site says both, on different pages, for the same product. Only $225 is ever attached to a period, in the site-wide framing of the program as priced as low as $225 per month. Is $258 a monthly tirzepatide price? The card states no period. It sits above the program's stated floor, which is consistent with a monthly rate, but that is an inference rather than something the seller published. What does the program include? Telemedicine visits, nutrition and exercise coaching, and the medication, per the site's own description. Is MDExam expensive compared with other GLP-1 telehealth sellers? MDExam publishes a starting figure of $225/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MDExam above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MDLive reviews (2026): GLP-1 telehealth sellers | This GLP MDLIVE offers anti-obesity prescriptions through eligible Primary Care Routine Care visits. Its urgent-care service and wellness screening are different pathways. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mdlive Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # MDLive review MDLIVE offers anti-obesity prescriptions through eligible Primary Care Routine Care visits. Its urgent-care service and wellness screening are different pathways. ## The verdict The crucial distinction is the appointment type. MDLIVE lists anti-obesity medicines as possible through Primary Care Routine Care, with clinical discretion and state exclusions. Booking urgent care simply because it is available sooner does not provide the same weight-management service. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Liraglutide Form Injection Prescription Required MDLIVE is a virtual-care platform whose independent professional entities provide clinical services. Its public medication policy names options such as Zepbound, Wegovy and Saxenda within the primary-care pathway. That is a broader care model than a standalone medication storefront. 1. ## Who writes the prescription, and what do they see? A medical provider decides whether an anti-obesity prescription is medically appropriate. MDLIVE’s terms separate the platform from the independent clinicians. The medicine list is not a guarantee of a particular drug, dose or an approved claim. Weight-management prescribing is limited to a Primary Care Routine Care visit. It is not offered through Urgent Care or a Primary Care Wellness Screening. Before booking, verify that the account benefit includes the correct service and that the provider can address the intended condition. 2. ## What happens when the dose goes up? Continuing dose and monitoring decisions sit with the primary-care clinician. The public medication policy does not define one universal GLP-1 escalation or refill schedule. Ask how later appointments are arranged, who reviews [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and whether the same care team can follow the course. 3. ## What the price includes Visit costs depend on the service and benefit arrangement; the public pages do not establish an all-in monthly GLP-1 bill. Pharmacy medication, laboratory requirements and plan cost-sharing must be considered separately. Cancellation fees may apply and are disclosed before booking. 4. ## What it claims, and what it cites The published anti-obesity examples include [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review), [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and liraglutide brands. They are unavailable through this pathway in Florida, Louisiana, Mississippi and New Jersey under the posted policy. A general statement about nationwide virtual care does not override that restriction. ## Where it holds up, and where it does not - Strength: Clear prescribing eligibility by appointment type - Strength: Primary-care context for ongoing conditions - Strength: Medication exclusions are disclosed - Limitation: Urgent care cannot substitute for Routine Care - Limitation: Four states excluded from this prescribing pathway - Limitation: No public inclusive medication price ## What the evidence says about this kind of treatment The assessment above is about MDLive. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone whose benefits include MDLIVE primary care and who wants a clinician to assess weight treatment in that setting. Wrong for A patient in an excluded state or someone trying to obtain weight-loss medication through a rapid urgent-care appointment. ## The evidence behind what MDLive prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MDLive compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Willow](https://thisglp.com/reviews/willow) [YourEra](https://thisglp.com/reviews/yourera) [EverPrime](https://thisglp.com/reviews/everprime) [MyDrHank](https://thisglp.com/reviews/mydrhank) [1st Optimal](https://thisglp.com/reviews/1st-optimal) [24hrDOC](https://thisglp.com/reviews/24hrdoc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can urgent care prescribe these weight-loss drugs? MDLIVE says anti-obesity medication is available only through Primary Care Routine Care, not its other visit types. Which states are excluded? The posted policy excludes Florida, Louisiana, Mississippi and New Jersey for this anti-obesity prescribing pathway. Is the medication included in a visit? The public information does not establish a bundled medicine price. Check the visit benefit and pharmacy charges separately. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.mdlive.com/) - [Terms of service and payment conditions](https://www.mdlive.com/terms-of-use) - [Practice and clinical team](https://www.mdlive.com/about-us) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MD Total Wellness reviews (2026): medical weight-loss clinics | This GLP MD Total Wellness offers in-office GLP-1 care in Brea, California, with monthly visits, body-composition tracking and direct clinical messaging in its published package. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mdtw Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # MD Total Wellness review MD Total Wellness offers in-office GLP-1 care in Brea, California, with monthly visits, body-composition tracking and direct clinical messaging in its published package. ## The verdict This is a local continuing-care option, not a nationwide prescription-delivery service. Monthly visits and body-composition assessment make the follow-up model tangible. Its statements about eventually tapering treatment should still be discussed as an individual clinical possibility, not a promise of permanent maintenance without medication. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category medical weight-loss clinics Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $299/mo Prescription Required Compounded Yes — not FDA-approved MD Total Wellness is a physician-owned Brea practice serving Orange County. Its weight-loss program offers compounded semaglutide and tirzepatide, alongside nutrition and lifestyle guidance. A separate comprehensive evaluation is optional rather than required for every weight-loss patient. 1. ## Who writes the prescription, and what do they see? The practice describes a dedicated clinician and in-office assessment. Its public materials name Dr. Oliak and clinical team members, but an individual’s appointment assignment must be confirmed. A free consultation determines candidacy; it does not guarantee that prescribing is appropriate. The monthly package lists visits in the Brea office, prescribed medication, 3D body-composition analysis, direct messaging and nutrition guidance. That combination is useful for patients who want measurable follow-up beyond the scale. It also means travel and appointment availability form part of the practical commitment. 2. ## What happens when the dose goes up? The practice describes personalized dosing, monitoring of lean mass and gradual changes based on tolerance. Ask what the contact process is for [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) between monthly visits. Its weaning guidance does not establish that a particular patient can stop treatment without weight regain. 3. ## What the price includes Published monthly prices are $299 for semaglutide and $399 for tirzepatide, with medication and the stated visits included. The page says no long-term contract or mandatory membership. Optional comprehensive testing and any additional services should be distinguished from the core package. 4. ## What it claims, and what it cites The FAQ explicitly describes compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) from US compounding pharmacies. A claim about an identical active molecule does not make the finished preparation FDA-approved or establish equivalence to a branded medicine. Ask which pharmacy and formulation would supply your prescription. ## Where it holds up, and where it does not - Strength: Monthly in-person follow-up is explicit - Strength: Body-composition tracking is included - Strength: Dedicated-team messaging accompanies visits - Limitation: Local office access is a real requirement - Limitation: Compounded formulation needs pharmacy-specific questions - Limitation: Long-term maintenance is not guaranteed ## What the evidence says about this kind of treatment The assessment above is about MD Total Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An Orange County patient who prefers continuing in-person monitoring and wants medication and visits in one published package. Wrong for Someone needing nationwide home delivery or an assurance of successful medication withdrawal. ## The evidence behind what MD Total Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MD Total Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AbundRX](https://thisglp.com/reviews/abundrx) [Actin](https://thisglp.com/reviews/actin) [AgelessRx](https://thisglp.com/reviews/agelessrx) [AHBARx](https://thisglp.com/reviews/ahbarx) [Alan Meds](https://thisglp.com/reviews/alan-meds) [Alegro Health](https://thisglp.com/reviews/alegro-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Where does ongoing care take place? The package specifies monthly visits in the Brea office. Is the comprehensive evaluation compulsory? No. The weight-loss FAQ describes it as optional, separate from the initial consultation. Do the prices include the medicine? The published package says medication is included, together with monthly visits and the listed monitoring. Is MD Total Wellness expensive compared with other GLP-1 telehealth sellers? MD Total Wellness publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MD Total Wellness above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://mdtw.co/) - [Terms of service and payment conditions](https://mdtw.co/terms-of-services/) - [GLP-1 care and prescribing options](https://mdtw.co/glp-1-weight-loss-orange-county/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Measured reviews (2026): GLP-1 telehealth sellers | This GLP The lead figure is a twelve-month rate, and the struck figure beside it is the monthly one. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/measured Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every rung in writing # Measured review The lead figure is a twelve-month rate, and the struck figure beside it is the monthly one. ## The verdict Measured charges $199 a month for compounded semaglutide and $299 for tirzepatide, month to month. The From figure on each product page is the twelve-month rate, billed annually. The full commitment ladder is written out on the same page. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Measured is a telehealth program offering compounded semaglutide and tirzepatide with medication included. Branded GLP-1s sit under a separate plan with medication paid separately. A lower-dose microdose line is sold as its own product. 1. ## Who writes the prescription, and what do they see? An obesity-trained provider reviews the intake and prescribes if treatment is appropriate. The practices are described as independently owned and operated by licensed physicians. No individual prescriber is named on the product pages. Lab work may be requested, and when it is required is not stated. The care team is named by role: a provider, a Registered Dietitian and a care coordinator. Messaging with that team is described as unlimited. Monthly check-ins are the stated point at which the dose is revisited. Shipping is free and two-day, if prescribed. 2. ## What happens when the dose goes up? Monthly check-ins are where the dose is adjusted, the page states. Whether the monthly rate changes with the dose is not stated. The ladder is priced by commitment length, not by milligram. No milligram dose is printed beside any rung. 3. ## What the price includes Semaglutide is $199 month to month, $139 on a three-month plan, $129 on six and $119 on twelve. Tirzepatide is $299, $239, $229 and $219 on the same terms. Each longer plan is billed once per term. The $960 saving in the hero is twelve months at the gap between $199 and $119. 4. ## What it claims, and what it cites Both lines are compounded, and each product page states they are not FDA-approved. A licensed compounding pharmacy prepares them; it is not named. Branded [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are offered under a separate plan, with medication paid separately. ## Where it holds up, and where it does not - Strength: Every commitment rung is priced in writing - Strength: The month-to-month rate is printed on-page - Strength: A dietitian is part of the named team - Strength: Medication is included in the compounded price - Limitation: The lead figure needs a twelve-month commitment - Limitation: No milligram dose beside any rung - Limitation: The preparing pharmacy is left unnamed - Limitation: No named prescriber on the product pages ## What the evidence says about this kind of treatment The assessment above is about Measured. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit to a term, who knows which rung the lead figure is. Wrong for A reader expecting $119 a month without a twelve-month commitment. ## The evidence behind what Measured prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Measured compares | Seller | Who it suits | Go | | --- | --- | --- | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Alan Meds](https://thisglp.com/reviews/alan-meds) [Alegro Health](https://thisglp.com/reviews/alegro-health) [Alinwell](https://thisglp.com/reviews/alinwell) [Allara Health](https://thisglp.com/reviews/allara-health) [Alloy](https://thisglp.com/reviews/alloy) [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I pay $119 a month? Only on the twelve-month plan, billed annually. Month to month, compounded semaglutide is $199. What is the $79 product? A separate microdose line, described as weekly lower-dose semaglutide or tirzepatide. It is not the full-dose program priced above. Can I cancel? The product pages state cancel anytime. How that applies partway through a prepaid term is not stated. Is Measured expensive compared with other GLP-1 telehealth sellers? Measured publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Measured above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MEDGm reviews (2026): GLP-1 telehealth sellers | This GLP All three figures are memberships. The medication cost is written as a word, not a number. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medgm Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership plus an unstated cost # MEDGm review All three figures are memberships. The medication cost is written as a word, not a number. ## The verdict MEDGm publishes $171, $99 and $99 across three lines. Each is labeled 'Membership + Cost'. The cost half is not published anywhere. Coverage is stated across 51 jurisdictions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 51 Prescription Required Compounded No Availability 51 jurisdictions MEDGm sells semaglutide and tirzepatide, injected and oral. Three lines carry a figure. Every one of them prices the membership and leaves the medication open. 1. ## Who writes the prescription, and what do they see? The membership is the route to a prescriber. A prescription follows. MEDGm notes that Ozempic is FDA-approved for type 2 diabetes and prescribed off-label for weight here. Few sellers state the off-label position that plainly. The pricing formula is printed on the page: membership plus cost. Naming the structure is a disclosure. Leaving the second term blank is the opposite. A buyer knows exactly what they will owe and exactly what they will not. 2. ## What happens when the dose goes up? Nothing is published about what either half does at a higher dose. The membership is presumably fixed. The medication cost is unknown at any dose, so the question cannot be answered even in principle. 3. ## What the price includes No line here can be totaled. $99 is what the membership costs, not what treatment costs. MEDGm also states availability is subject to change on two lines. A figure that is explicitly one term of a sum is not a price, and it is not ranked here as one. 4. ## What it claims, and what it cites The lines reference approved products prescribed off-label rather than compounded preparations. Off-label prescribing is lawful and common. MEDGm states it directly, which is worth more than most disclosure on this subject. ## Where it holds up, and where it does not - Strength: The off-label position is stated outright - Strength: The pricing formula is printed, not implied - Strength: Coverage stated across 51 jurisdictions - Limitation: No medication cost appears anywhere - Limitation: No line can be totaled - Limitation: Availability is flagged as changeable - Limitation: Dose behavior is unknowable here ## What the evidence says about this kind of treatment The assessment above is about MEDGm. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who values a plain statement of the off-label position and will price the drug elsewhere. Wrong for A reader who needs to know what treatment costs before joining. ## The evidence behind what MEDGm prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MEDGm compares | Seller | Who it suits | Go | | --- | --- | --- | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AlyveRx](https://thisglp.com/reviews/alyverx) [AM Rx](https://thisglp.com/reviews/amrx) [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) [Amble](https://thisglp.com/reviews/amble) [Andrew Meds](https://thisglp.com/reviews/andrew-meds) [Apex MD](https://thisglp.com/reviews/apex-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $99 buy? The membership. MEDGm writes the formula as 'Membership + Cost' and does not publish the second term. Is the drug approved? MEDGm states Ozempic is FDA-approved for type 2 diabetes and prescribed off-label here for weight. That is a plainer statement than most sellers make. Can six months be estimated? No. Half the sum is missing at every dose, so no total is available at any commitment length. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Medi-Weightloss reviews (2026): in-person weight-loss clinics | This GLP A franchise of in-person clinics. Only the first month of medication is priced online. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medi-weightloss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Clinic visits, first month priced # Medi-Weightloss review A franchise of in-person clinics. Only the first month of medication is priced online. ## The verdict Medi-Weightloss prices compounded semaglutide at $99 for the first month. Compounded tirzepatide is $199 for the first month. No price after the first month is published. The program fee is set by each clinic. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category in-person weight-loss clinics Molecule Semaglutide Form Injection Dose pricing Flat across doses Dose published No Prescription Required Pharmacy Not named Labs Included Medi-Weightloss is a network of in-person weight-loss clinics. Each clinic is independently operated. The program is medically supervised and built around weekly visits. It also offers hormone therapy, IV therapy and vitamin injections. The medication list names Wegovy, Zepbound, Saxenda and compounded semaglutide and tirzepatide. 1. ## Who writes the prescription, and what do they see? A licensed provider at the local clinic evaluates the patient in person. Prescription medication follows only after that evaluation and approval. The first visit includes a medical assessment, lab work and a GLP-1 eligibility review. Clinicians are not named on the national site. Each clinic's own page is the place to look. The first step is a free assessment. The second is a New Patient Visit, $199 on the self-pay membership. Most patients then visit weekly. Visits drop to monthly in the wellness phase. Follow-up visits are included in the membership. The program is not contract-based, and payment in advance is not required. 2. ## What happens when the dose goes up? No dose schedule is published. The pricing page states that membership pricing stays consistent across dosages. That line covers the program fee. It does not state that medication cost holds at every dose. Weekly visits give the provider a set point to review the dose. 3. ## What the price includes Two tracks exist. With insurance, most patients pay $0 to $50 per visit. Brand-name GLP-1s are used if the plan covers them. Self-pay starts with the $199 New Patient Visit. A monthly membership follows, on a one-, three- or six-month plan. The membership includes no medication. Membership fees vary by program and location and are not published. Compounded semaglutide is $99 and compounded tirzepatide $199 for the first month. The price after that is not stated. Local clinics give a quote before starting. 4. ## What it claims, and what it cites Both brand and compounded GLP-1s are offered. [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), Zepbound and Saxenda are FDA-approved. The site states that compounded drug products are not approved or evaluated by the FDA for safety, effectiveness or quality. The compounding pharmacy is not named. ## Where it holds up, and where it does not - Strength: In-person weekly supervision - Strength: Brand GLP-1s billed to insurance where covered - Strength: Lab work included in the first visit - Strength: FSA and HSA eligible - Limitation: Only first-month medication prices published - Limitation: Each clinic sets its own program fee - Limitation: Medication billed on top of membership - Limitation: Requires travel to a clinic ## What the evidence says about this kind of treatment The assessment above is about Medi-Weightloss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants weekly in-person visits and may have insurance that covers a brand GLP-1. Wrong for A buyer who wants a published ongoing monthly price before contacting a clinic. ## The evidence behind what Medi-Weightloss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Medi-Weightloss compares | Seller | Who it suits | Go | | --- | --- | --- | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | WeightWatchers Clinic | Readers who want a familiar brand and will add the membership at its ceiling | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Amble](https://thisglp.com/reviews/amble) [Andrew Meds](https://thisglp.com/reviews/andrew-meds) [Apex MD](https://thisglp.com/reviews/apex-md) [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) [Arc-1](https://thisglp.com/reviews/arc-1) [Ark Health](https://thisglp.com/reviews/ark-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Medi-Weightloss semaglutide $99 a month? No. $99 is the first-month price for compounded semaglutide. The ongoing price is set with the local clinic. Is the medication included in the membership? No. The site states the monthly program includes no medication. Medication is priced separately. What does the first visit cost? The initial assessment is free. The New Patient Visit is $199 on self-pay and includes labs. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Medical Health Institute reviews (2026): GLP-1 telehealth sellers | This GLP Medical Health Institute describes laboratory-guided GLP-1 care and ongoing monitoring. Its general program page leaves the exact medicine, pharmacy and complete cost to assessment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medical-health-institute Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Medical Health Institute sell a GLP-1? Medical Health Institute describes laboratory-guided GLP-1 care and ongoing monitoring. Its general program page leaves the exact medicine, pharmacy and complete cost to assessment. ## The verdict MHI’s stated approach emphasizes medical review and laboratory information rather than a questionnaire leading straight to dispensing. The public treatment page is less specific about the prescription itself. A useful consultation should resolve the actual medicine, monitoring schedule and clinician access before any ongoing payment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Medical Health Institute provides weight-management, hormone and other health services. Its dedicated weight page describes GLP-1 support within a personalized clinical program. It does not establish one named molecule or finished product for every patient. 1. ## Who writes the prescription, and what do they see? Licensed providers make prescription decisions after an appropriate evaluation. The terms state that not everyone qualifies and that geographic eligibility depends on where providers are licensed. The platform’s general availability is not proof of prescribing access in a particular state. The weight-loss description includes physician oversight, blood-work-guided treatment, regular check-ins and dose adjustments. These features need an operational definition: ask which tests are required, who reviews them and whether a continuing clinician remains responsible for the case. 2. ## What happens when the dose goes up? Dosing is described as individualized by medical needs and laboratory information. No universal escalation ladder or contact deadline is established. Ask how the team handles [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) or a change in health status before approving the next supply. 3. ## What the price includes The site advertises entry pricing, but the weight page does not attach a complete recurring bill to one specified prescription. Services are not covered by health insurance according to the page. Checkout and the program agreement determine the fees and renewal cadence. 4. ## What it claims, and what it cites The public offer names the GLP-1 class without establishing a specific drug or formulation for every patient. The terms say no medication or formulation is guaranteed. Obtain the proposed product and pharmacy directly; a general reference to licensed pharmacy partners is not the same as identifying your dispenser. ## Where it holds up, and where it does not - Strength: Medical and laboratory review are emphasized - Strength: Continuing check-ins are described - Strength: Geographic and clinical eligibility are acknowledged - Limitation: Specific prescription is not public for every plan - Limitation: No uniform monitoring schedule is established - Limitation: Insurance does not cover the service ## What the evidence says about this kind of treatment The assessment above is about Medical Health Institute. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a personalized metabolic-care discussion who is prepared to clarify the proposed treatment before enrolling. Wrong for A patient needing a fully specified branded or compounded drug quote before an assessment. ## How Medical Health Institute compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AskRx](https://thisglp.com/reviews/ask-rx) [Aspen](https://thisglp.com/reviews/aspen-health) [Aspire Health](https://thisglp.com/reviews/aspire-health) [Auren Rx](https://thisglp.com/reviews/auren-rx) [AVARA Rx](https://thisglp.com/reviews/avara-rx) [Avono Health](https://thisglp.com/reviews/avono-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is a GLP-1 guaranteed after applying? No. The terms reserve prescribing to the clinician and state that no medication or formulation is guaranteed. Does the service take insurance? The weight-management page says MHI services are not covered by health insurance. Can every state use it? Eligibility depends on the states where MHI or affiliated providers can legally practice; verify your location directly. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://medicalhealthinstitute.com/) - [Weight-management program](https://medicalhealthinstitute.com/goals/weight-loss) - [Terms of service and payment conditions](https://medicalhealthinstitute.com/terms-and-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MediRX reviews (2026): GLP-1 telehealth sellers | This GLP The same two products are priced twice on one page, at different rates. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medirx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two grids, one homepage # MediRX review The same two products are priced twice on one page, at different rates. ## The verdict MediRX publishes two price grids on a single homepage. One prices semaglutide injections at $149 and tirzepatide injections at $199. The other prices the same two names higher, and its tirzepatide figure is double the one below. A brand-name card in the upper grid also names the wrong molecule. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $149/mo Oral From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named MediRX is a cash-pay weight-loss service selling compounded semaglutide and compounded tirzepatide. Both come as weekly injections and as dissolvable oral tablets. A brand-name injection is listed beside them. Medical services are provided by an external clinician network named in the footer. 1. ## Who writes the prescription, and what do they see? The footer states the online assessment creates no doctor-patient relationship by itself. All medical services are provided by a named network of US-licensed clinicians. No individual prescriber appears on the page. What a clinician reviews before approving is not described. One rate is stated to cover the program, with free delivery and no membership fee. The oral tablets carry a stock warning that availability is subject to change. Support runs by email and phone. Nothing on the page locks a patient to a term. 2. ## What happens when the dose goes up? Every figure is written as a starting price. No milligram dose appears beside any of the four products. Nothing published states what a step up the ladder costs. Nothing names who authorizes it. 3. ## What the price includes The lower grid prices the injections at $149 and $199 and the tablets at $249 and $279. The upper grid prices the same two injection names higher. A banner above both announces a promotion under a season that has passed. The figure it quotes matches neither injection card in the upper grid. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. No compounding pharmacy is named. The brand-name card in the upper grid names two [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) products as sharing its active ingredient. That is the wrong molecule for the brand on the card. ## Where it holds up, and where it does not - Strength: Four format prices are published without an intake - Strength: Free delivery is included - Strength: No membership fee is charged - Strength: The clinician network is named in the footer - Strength: Nothing binds a patient to a term - Limitation: Two grids on one page price the same products differently - Limitation: A brand-name card names the wrong active ingredient - Limitation: The banner promotion cites a season that has passed - Limitation: No compounding pharmacy or milligram dose is published ## What the evidence says about this kind of treatment The assessment above is about MediRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who scrolls to the second grid before believing the first. Wrong for A buyer who needs one published price per product. ## The evidence behind what MediRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MediRX compares | Seller | Who it suits | Go | | --- | --- | --- | | CoreAge Rx | A reader still at a starting dose, since that is the tier these rates price. | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | SnagRx | Buyers who want to stay month to month without paying much for it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AZ Health](https://thisglp.com/reviews/az-health) [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) [Bayan Health](https://thisglp.com/reviews/bayan-health) [Believe Health](https://thisglp.com/reviews/believe-health) [Better U Care](https://thisglp.com/reviews/better-u-care) [BetterMe Rx](https://thisglp.com/reviews/betterme-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which grid carries the real price? The lower one matches the oral tablet pricing and is the cheaper of the two. The upper grid prices the same injection names higher. Is there a membership fee? No. The footer states free delivery, no membership fees and physician-led programs. Who writes the prescription? An external network of US-licensed clinicians named in the footer. No individual prescriber is listed. Is MediRX expensive compared with other GLP-1 telehealth sellers? MediRX publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MediRX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Medivive reviews (2026): GLP-1 telehealth sellers | This GLP Medivive starts with an AI conversation, then assigns prescribing decisions to TrueEval Medical Group. The weight program describes 30-day monitoring. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medivive Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 AI intake, clinician decisions # Medivive review Medivive starts with an AI conversation, then assigns prescribing decisions to TrueEval Medical Group. The weight program describes 30-day monitoring. ## The verdict A named clinical group and a stated monitoring interval make the model easier to examine. The AI and biomarker claims should not substitute for checking who reviews your case, what testing is required and how to reach a clinician. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Medivive offers bilingual virtual care across weight management, hormones and other services. Its weight program names compounded semaglutide and tirzepatide. 1. ## Who writes the prescription, and what do they see? The site identifies TrueEval Medical Group and says a clinician licensed in the patient’s state reviews the case. The assistant proposes candidate protocols but does not independently prescribe. The initial conversation gathers goals and history before a provider reviews the proposed treatment. Medivive also markets at-home blood collection and wearable data; confirm which of those services your weight plan actually includes. 2. ## What happens when the dose goes up? The weight page specifies provider check-ins every 30 days for tolerability and progress, with individualized dose adjustment. Ask how to report symptoms that cannot wait for the scheduled review. 3. ## What the price includes The public pages describe self-pay treatment without a membership fee. The exact price appears after protocol matching; a public, dose-specific recurring total was not established. 4. ## What it claims, and what it cites The weight page explicitly identifies compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) from a 503A pharmacy. These products are not FDA-approved, and a sophisticated intake system does not change that status. ## Where it holds up, and where it does not - Strength: Named medical group - Strength: Thirty-day weight-care monitoring - Limitation: AI performance claims are not outcome evidence - Limitation: Exact price appears after matching ## What the evidence says about this kind of treatment The assessment above is about Medivive. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone comfortable with an AI-assisted intake who wants a clinician to retain prescribing authority. Wrong for Someone seeking a human-only intake or a complete published price table before assessment. ## The evidence behind what Medivive prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Medivive compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [BeyondMD](https://thisglp.com/reviews/beyondmd) [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) [BiltRx](https://thisglp.com/reviews/biltrx) [Bionomy Health](https://thisglp.com/reviews/bionomy-health) [Bioverse](https://thisglp.com/reviews/bioverse) [Blis MD](https://thisglp.com/reviews/blis-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can the AI prescribe? Medivive says no: a licensed clinician reviews the case and can revise the proposed protocol. Is bloodwork always included? The platform advertises extensive testing, but patients should confirm the requirement and included costs for their specific weight program. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://mymedivive.com/) - [Official program and terms](https://mymedivive.com/weight) - [Official program and terms](https://mymedivive.com/how-it-works) - [Official program and terms](https://mymedivive.com/about) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MedLeanRx reviews (2026): GLP-1 telehealth sellers | This GLP The pricing is reasonable and the catalog is sensible. Forty-nine states cannot reach either. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medleanrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Almost nobody can buy it # MedLeanRx review The pricing is reasonable and the catalog is sensible. Forty-nine states cannot reach either. ## The verdict MedLeanRx prices semaglutide at $149 a month as a vial or a tablet and tirzepatide at $269. Its recorded coverage is a single state, and the tirzepatide discount narrows further to Texas. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 1 Injection From $149/mo Oral From $149/mo Prescription Required Compounded Yes — not FDA-approved Availability 1 state MedLeanRx offers semaglutide two ways at one price and tirzepatide by injection. A short-term tirzepatide bundle runs alongside, geographically restricted. 1. ## Who writes the prescription, and what do they see? A prescription comes before dispensing. Who writes it, and how often anything is reviewed afterwards, is not described. Charging the same for the needle and the tablet is genuinely good practice. It matters to whoever lives in the one state where it applies. 2. ## What happens when the dose goes up? The seller writes that plans start at $149 for the starting dose, and that pricing may vary with medication and dosage. That sentence concedes movement and declines to quantify it. 3. ## What the price includes Half a year of semaglutide comes to $894 by either route, and tirzepatide to $1,614. The Texas bundle is $325 for two months at 2 mg weekly, near $163 a month, and it lasts while stock does. 4. ## What it claims, and what it cites All lines are compounded to order by an unnamed pharmacy. Nothing is inspected by a regulator before it ships. ## Where it holds up, and where it does not - Strength: Needle and tablet share one price - Strength: The bundle states 2 mg weekly - Strength: Two semaglutide routes are offered - Limitation: Recorded coverage is a single state - Limitation: The bundle narrows to Texas and to stock - Limitation: The seller concedes the price may vary - Limitation: No pharmacy is identified ## What the evidence says about this kind of treatment The assessment above is about MedLeanRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who happens to live where this seller operates. Wrong for Almost everyone else, on coverage alone. ## The evidence behind what MedLeanRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MedLeanRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Edessa | Readers who will read the plan table rather than the homepage banner | | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | Recovery Delivered | Readers who reward a seller for publishing the number that costs it sales | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Bioverse](https://thisglp.com/reviews/bioverse) [Blis MD](https://thisglp.com/reviews/blis-md) [Bliv](https://thisglp.com/reviews/bliv) [Bloom MD](https://thisglp.com/reviews/bloommd) [BloomWell Rx](https://thisglp.com/reviews/bloomwell-rx) [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the tablet dearer than the vial? No. Both semaglutide routes are $149. Who qualifies for the bundle? Texas clients, while stock lasts, at $325 for two months. How wide is coverage? One state. Is MedLeanRx legit? MedLeanRx is a GLP-1 telehealth sellers service. Its stated availability: 1 state. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is MedLeanRx expensive compared with other GLP-1 telehealth sellers? MedLeanRx publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MedLeanRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Medro reviews (2026): GLP-1 telehealth sellers | This GLP The lead figure has a one-time code applied. The standing rates are $199 and $299. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medro Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A code on the lead # Medro review The lead figure has a one-time code applied. The standing rates are $199 and $299. ## The verdict Medro leads with $99 for semaglutide and $199 for tirzepatide. Both carry a flat first-order code. Without it, the rates are $199 and $299. The page strikes those through beside the lead. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Medro is a telehealth brand covering weight loss, skin, hair and more. It sells compounded semaglutide and tirzepatide by weekly injection. Brand-name GLP-1s are also offered. Coverage is stated as all 50 states. 1. ## Who writes the prescription, and what do they see? A partner medical group provides the clinical care. Licensed clinicians review each intake. Neither the group nor its clinicians are named. A prescription precedes shipping. Support is stated as unlimited and available around the clock. Follow-up and care coordination are listed as included. No membership is required. A licensed pharmacy partner fills the order and is not named. 2. ## What happens when the dose goes up? The page states the same price at every dose. Its footnote then lists dose among seven factors that may change the final price. Those two statements conflict. The final price is shown before checkout, after a prescription. 3. ## What the price includes The code applies to the first plan only. After that, semaglutide is $199 and tirzepatide is $299. Six months of semaglutide at $199 is $1,194. Six months of tirzepatide at $299 is $1,794. Supply duration is named as a price factor but not priced. 4. ## What it claims, and what it cites Both lines are compounded in the U.S. The page states the FDA does not evaluate compounded medications. Each formulation includes glycine and vitamin B12. The pharmacy is not named. ## Where it holds up, and where it does not - Strength: The struck standing rate sits beside the lead - Strength: Same price at every dose, per the page - Strength: No membership is required to buy - Strength: Coverage stated as all 50 states - Limitation: The lead figure includes a one-time code - Limitation: The footnote lists dose as a price factor - Limitation: Clinical group and pharmacy go unnamed - Limitation: Supply-duration pricing is not published ## What the evidence says about this kind of treatment The assessment above is about Medro. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who budgets on $199 or $299 and treats the lower lead as a first-order discount. Wrong for A reader who needs the final price before the prescription step. ## The evidence behind what Medro prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Medro compares | Seller | Who it suits | Go | | --- | --- | --- | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | | EdgeRx | Readers who want a named compounding pharmacy and will check availability first | | | Citizen Meds | Readers who want the escalation named up front rather than discovered on a statement | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) [Blue Sky MD](https://thisglp.com/reviews/blue-sky-md) [Bodi Envi](https://thisglp.com/reviews/bodi-envi) [Bon Health](https://thisglp.com/reviews/bon-health) [boostAGErx](https://thisglp.com/reviews/boostagerx) [Boston Medical Group](https://thisglp.com/reviews/boston-medical-group) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 the monthly price? No. It is the first plan with a code applied. The struck $199 is the standing semaglutide rate. Does the price rise with the dose? The page says no. Its footnote lists dose as a factor. Confirm before checkout. Who prescribes? A partner medical group. The page does not name it. Is Medro legit? Medro is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Medro expensive compared with other GLP-1 telehealth sellers? Medro publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Medro above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Medsol RX reviews (2026): GLP-1 telehealth sellers | This GLP Month-to-month semaglutide is $199 after a $169 first month, and three prepaid plans trade the whole term up front for a lower monthly figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medsol-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A ladder of commitments # Medsol RX review Month-to-month semaglutide is $199 after a $169 first month, and three prepaid plans trade the whole term up front for a lower monthly figure. ## The verdict Medsol RX prices compounded semaglutide at $199 a month and tirzepatide at $259 once the first month has passed, and it prints the first month, the standing rate and every prepaid plan together in one table. A buyer can see the whole price structure before the intake begins, which is more than the page reveals about dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider Medsol RX sells compounded semaglutide and tirzepatide by weekly injection, along with an oral semaglutide, lower-dose microdose options and branded pens, and it bundles one-on-one care coaching into every weight-loss plan it lists. 1. ## Who writes the prescription, and what do they see? The footer names the clinicians: final prescribing decisions are made by Open Loop's licensed U.S. clinicians after a telehealth consultation and a review of the patient's medical history. The site's own assessment, it says, only screens for initial eligibility and does not establish a doctor-patient relationship, so the clinical relationship begins with that network rather than with Medsol itself. Each plan card lists the same four inclusions, an injection supply, a dedicated care coach, a custom treatment plan and medical oversight, with priority check-ins added on the six-month and twelve-month plans. The coach is the distinctive piece here, written into the price on every card rather than sold as an add-on after the prescription arrives. 2. ## What happens when the dose goes up? Nothing on the packages page ties a figure to a dose, and no milligram amounts are printed beside any plan, so whether the $199 holds as a patient climbs from the starting dose is not stated. The month-to-month table shows that same figure from the second month through the fifth and beyond, which reads as flat, though the page never says so in words. 3. ## What the price includes A buyer paying month to month spends $169 on semaglutide in the first month and $199 in each month after, and the page says that buyer can switch to a plan at any point. The three longer plans lower the monthly figure in exchange for paying the whole term up front, down to $129 a month on twelve months, and tirzepatide follows the same pattern from a $239 first month to its standing $259. 4. ## What it claims, and what it cites Both injectable lines are compounded by certified U.S. pharmacies that the site describes as operating in FDA-regulated facilities, though none of those pharmacies is named on the packages page. The same footer states plainly that compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality. Branded [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) pens are sold separately, with coaching included, for a buyer who wants the approved product instead of a compounded one. ## Where it holds up, and where it does not - Strength: First month, standing rate and plans in one table - Strength: Care coaching included on every plan - Strength: The prescribing clinician network is named - Strength: Switching to a plan is allowed anytime - Limitation: No milligram dose beside any figure - Limitation: Lower rates require paying the term up front - Limitation: Dose-linked price changes are never addressed - Limitation: Dispensing pharmacies are described, not named ## What the evidence says about this kind of treatment The assessment above is about Medsol RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants coaching bundled into the price and can weigh a month-to-month rate against prepaid plans laid out on one page. Wrong for A reader who needs dose-by-dose pricing before starting treatment, since the packages page prints no milligram amounts at all. ## The evidence behind what Medsol RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Medsol RX compares | Seller | Who it suits | Go | | --- | --- | --- | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | YourEra | Readers committing six months who have read which figure belongs to which plan | | | Clume Health | Readers who want both molecules at one rate and will re-check the figure before paying | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Brightmeds](https://thisglp.com/reviews/brightmeds) [Cabana](https://thisglp.com/reviews/cabana) [CaliberRx](https://thisglp.com/reviews/caliberrx) [Calibrate Health](https://thisglp.com/reviews/calibrate-health) [California Trim Clinic](https://thisglp.com/reviews/california-trim-clinic) [Call-On-Doc](https://thisglp.com/reviews/call-on-doc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the first month cost? $169 for semaglutide and $239 for tirzepatide on the month-to-month path, after which the packages page lists $199 and $259 a month for every month that follows. Who writes the prescription? Clinicians in Open Loop's licensed U.S. network, after a telehealth consultation, according to the footer, which also describes the site's own questionnaire as an initial eligibility screen and nothing more. Is Medsol RX LegitScript certified? The packages page displays a LegitScript Approved badge beside its financing and shipping notes, which is the seller's own statement of that certification. Is Medsol RX expensive compared with other GLP-1 telehealth sellers? Medsol RX publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Medsol RX above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MEDVi reviews (2026): GLP-1 telehealth sellers | This GLP Only one of three lines publishes what the medicine costs; on the other two the figure on the card is the membership and the drug is unpriced. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medvi Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price, two memberships # MEDVi review Only one of three lines publishes what the medicine costs; on the other two the figure on the card is the membership and the drug is unpriced. ## The verdict MEDVi charges $179 for a first month of injected semaglutide and $299 a month for every refill after it, and that is the only line here carrying a medication price. Its other two show a $99 membership with the drug cost unstated, so this site ranks no figure for either. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 48 From From $299/mo Prescription Required Compounded Yes — not FDA-approved Availability 48 states MEDVi sells injected semaglutide at a published refill rate alongside a Wegovy pill line and a branded Zepbound line, both of which advertise a membership rather than a price. A compounded tablet card names no molecule, and coverage runs across 48 states. 1. ## Who writes the prescription, and what do they see? The $99 is what the clinical relationship costs on two of the three lines, and the pages state it plainly. What they do not state is what the medication then costs, which leaves the membership priced and the purchase unpriced. A membership model is legitimate and several sellers here use it well. What separates this one is that the medication figure is absent rather than merely separate, so a buyer pays $99 to discover a number that decides the whole purchase. 2. ## What happens when the dose goes up? The semaglutide refill is described as locked in at $299, and the program states it includes the same benefits at every refill, though no milligram is attached to that promise. On the membership lines the dose question cannot even be asked, because no medication figure exists to move. 3. ## What the price includes Six months of injected semaglutide is $1,674 at the published rates: $179 for the first month and five refills at $299. For the other two lines there is nothing to compute: $99 buys access and the drug is billed at a figure the pages describe as varying, with insurance possibly reimbursing some of it. Ask for that number before paying a membership, and treat a refusal as information. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) line is compounded, prepared to order by a pharmacy the pages do not name, and not reviewed by the FDA before dispensing. A compounded [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) product previously published at $349 no longer appears anywhere on the seller's sites, so this site carries no figure for it rather than repeating a stale one. ## Where it holds up, and where it does not - Strength: One line publishes a flat medication rate - Strength: The membership amount is stated clearly - Strength: Coverage across 48 states - Strength: The refill rate is printed beside the first-month offer - Limitation: Two lines publish no medication cost - Limitation: The membership is paid before the number appears - Limitation: A previously published line has disappeared - Limitation: Availability is described as subject to change ## What the evidence says about this kind of treatment The assessment above is about MEDVi. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the injected semaglutide line, where the figure on the card is the figure for the medicine. Wrong for A reader considering the oral or branded routes, where nothing published says what the treatment itself costs. ## The evidence behind what MEDVi prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MEDVi compares | Seller | Who it suits | Go | | --- | --- | --- | | He & She MD | A reader with a year's cost available who wants the annual total printed | | | Try Ageless | Readers willing to price the same product twice before buying it once | | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Call-On-Doc](https://thisglp.com/reviews/call-on-doc) [Candor Rx](https://thisglp.com/reviews/candor-rx) [Care Bare Rx](https://thisglp.com/reviews/care-bare-rx) [Care Clinics](https://thisglp.com/reviews/care-clinics) [Carocare Wellness](https://thisglp.com/reviews/carocare-wellness) [CeliaRx](https://thisglp.com/reviews/celia-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does this site show no price on two lines? Because the $99 on those cards is a membership fee and the medication cost is not stated anywhere, so no total can be built from what is published. What does injected semaglutide cost? $179 for the first month and $299 for each refill after it. The refill rate is the one figure here a reader can plan against. What happened to the compounded tirzepatide? It is no longer published anywhere on the seller's sites or intake flow, so this site treats it as discontinued rather than carrying an older figure forward. Is MEDVi legit? MEDVi is a GLP-1 telehealth sellers service. Its stated availability: 48 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is MEDVi expensive compared with other GLP-1 telehealth sellers? MEDVi publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MEDVi above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MEDVidi reviews (2026): GLP-1 telehealth sellers | This GLP MEDvidi offers scheduled online assessment and follow-up, with a weight-care page naming branded GLP-1 options. It is not a bundled medication storefront. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/medvidi Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Video visits, separate pharmacy access # Does MEDVidi sell a GLP-1? MEDvidi offers scheduled online assessment and follow-up, with a weight-care page naming branded GLP-1 options. It is not a bundled medication storefront. ## The verdict The appointment-based model makes clinician contact more concrete than an anonymous checkout. Confirm the weight-care visit price and refill schedule rather than assuming the general mental-health service terms describe every part of the GLP-1 program. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded No MEDvidi is a broader telehealth service with a dedicated medical weight-loss offering. It lists semaglutide, tirzepatide and liraglutide brands alongside non-GLP-1 options. 1. ## Who writes the prescription, and what do they see? The company publishes a clinician roster and describes doctors, nurse practitioners and physician assistants. A named roster member is not a promise about who will conduct the patient’s appointment. The general service describes an initial video assessment and shorter follow-ups. The weight page also lets patients manage prescriptions and change pharmacies through a portal; availability and prescribing depend on the case. 2. ## What happens when the dose goes up? Follow-up appointments provide a route to assess response and adjust treatment. Ask how refills are handled between visits and whether a pharmacy shortage requires another paid encounter. 3. ## What the price includes Published appointment charges and a separate follow-up membership are not medication prices. The weight page advertises no required membership, while the payment terms describe an optional follow-up subscription after an initial visit. 4. ## What it claims, and what it cites The dedicated weight page names Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro and Saxenda among options. Indications and eligibility differ; listing a brand does not guarantee its prescription or insurance coverage. ## Where it holds up, and where it does not - Strength: Video assessment and follow-up described - Strength: Provider roster publicly available - Limitation: Visit charges do not establish total treatment cost - Limitation: Weight-specific follow-up terms need confirmation ## What the evidence says about this kind of treatment The assessment above is about MEDVidi. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants scheduled video visits and the ability to manage a prescription through a chosen pharmacy. Wrong for Someone who expects the appointment fee to include medication delivery. ## The evidence behind what MEDVidi prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MEDVidi compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Citizen Meds](https://thisglp.com/reviews/citizen-meds) [Claya](https://thisglp.com/reviews/claya) [Clinic Secret](https://thisglp.com/reviews/clinic-secret) [Clume Health](https://thisglp.com/reviews/clume-health) [CLYR Health](https://thisglp.com/reviews/clyr-health) [Coivas](https://thisglp.com/reviews/coivas) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the clinician roster my assigned care team? Not necessarily. Confirm the provider and appointment availability for the weight-loss service. Does the medication list guarantee access? No. Prescribing requires clinical review, and pharmacy availability and coverage are separate questions. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://medvidi.com/) - [Official program and terms](https://medvidi.com/payment-terms/) - [Official program and terms](https://medvidi.com/terms-and-conditions/) - [Official program and terms](https://medvidi.com/terms-of-use/) - [Official program and terms](https://medvidi.com/services/weight-loss-treatment/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Meli Health reviews (2026): GLP-1 telehealth sellers | This GLP Meli identifies an independent clinician network and a dispensing pharmacy for its compounded weight-care service. The platform itself does not practice medicine. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/meli-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named care and pharmacy partners # Meli Health review Meli identifies an independent clinician network and a dispensing pharmacy for its compounded weight-care service. The platform itself does not practice medicine. ## The verdict Meli gives useful information about who provides clinical care and fulfillment. That is more informative than its broad around-the-clock support promise. Confirm how to contact the treating clinician, the later prescription charge and the cancellation cutoff before choosing the program. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $299/mo Prescription Required Compounded Yes — not FDA-approved Meli Health provides technology and administration for telehealth, prescription coordination and ongoing support. Its weight-care menu names semaglutide and tirzepatide. The broader wellness catalog should not be treated as a necessary part of GLP-1 treatment. 1. ## Who writes the prescription, and what do they see? The tirzepatide page identifies independent providers through LocumTele, while other material distinguishes the platform from the professional providing the consultation. Treatment is conditional on that clinician’s assessment, not a decision made by a website calculator. An online intake covers medical history and medications before review. The process includes care-team messaging, dose questions and follow-up. Rush Pharmacy is identified for fulfillment. Ask how a clinical concern is escalated from general support to the prescriber. 2. ## What happens when the dose goes up? Meli states that dosing and subsequent care are directed by the provider. Public information does not establish a complete dose-linked cost schedule. Ask what review precedes a change, whether additional visits cost more and how a pause affects the next shipment. 3. ## What the price includes The tirzepatide product page separates its first-month starting offer from the later monthly amount. The overview’s lower starting figure is not an ongoing quote for every dose. Obtain the prescribed strength, supply period and next payment before comparing costs. 4. ## What it claims, and what it cites Compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are part of the offering, with the non-approval distinction disclosed. The product page names Rush Pharmacy and describes clinical oversight. A pharmacy name and testing claim do not establish FDA approval of a compounded preparation. ## Where it holds up, and where it does not - Strength: Clinical network identified - Strength: Dispensing pharmacy named - Strength: Product page distinguishes renewal pricing - Limitation: Dose-specific total needs confirmation - Limitation: Support availability is not a clinician response guarantee - Limitation: Stopping and refund terms require a close read ## What the evidence says about this kind of treatment The assessment above is about Meli Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who values knowing the care and pharmacy partners and will verify the continuing treatment arrangement. Wrong for Someone choosing on a low starting amount without checking the next prescription and professional-care access. ## The evidence behind what Meli Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Meli Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Concierge MD LA](https://thisglp.com/reviews/concierge-md-la) [Contour Health](https://thisglp.com/reviews/contour-health) [Cora Health](https://thisglp.com/reviews/cora-health) [CoraDoc](https://thisglp.com/reviews/coradoc) [Corsica Health](https://thisglp.com/reviews/corsica-health) [Curex](https://thisglp.com/reviews/curex) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who provides medical care through Meli? Independent licensed professionals supply care; the tirzepatide page identifies the LocumTele network. Does pharmacy regulation mean the medicine is FDA approved? No. Meli’s compounded products are not FDA-approved finished drugs. Is Meli Health expensive compared with other GLP-1 telehealth sellers? Meli Health publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Meli Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official treatment program](https://www.melihealth.co/) - [Service and cancellation terms](https://www.melihealth.co/terms/) - [Treatment information](https://www.melihealth.co/treatments/tirzepatide/) - [Consultation and care process](https://www.melihealth.co/how-it-works/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Metabolic Rx reviews (2026): GLP-1 telehealth sellers | This GLP Metabolic Rx describes provider check-ins and direct messaging for compounded weight care. Its product FAQ and general terms give different cancellation notice periods. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/metabolic-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Direct care, conflicting stop rules # Metabolic Rx review Metabolic Rx describes provider check-ins and direct messaging for compounded weight care. Its product FAQ and general terms give different cancellation notice periods. ## The verdict Metabolic Rx’s stated follow-up model is relevant for patients wanting more than an initial prescription. The public cancellation discrepancy needs resolution first: a product FAQ requests thirty days’ notice while general terms describe a forty-eight-hour processing cutoff. Get the applicable rule in writing. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Metabolic Rx connects patients to independent medical professionals and pharmacies for weight and metabolic care. Its catalog includes compounded semaglutide and tirzepatide injections, lower-dose semaglutide and an oral option. 1. ## Who writes the prescription, and what do they see? The platform expressly says it does not practice medicine or dispense medication. A licensed clinician must evaluate and accept the patient before a clinical relationship is established. Ask for that practice’s identity and your supported location. The semaglutide program describes check-ins and direct secure provider messaging. Public outcome projections borrow from broader trials rather than establishing results for this service. Discuss realistic goals, tolerability and who reviews a changing health condition. 2. ## What happens when the dose goes up? The care model allows the provider to adjust a regimen through follow-up. That is different from a universal promise to reach a certain dose or result by a specific month. Ask how a pause or medication change affects monitoring and fulfillment. 3. ## What the price includes The program claims flat-rate pricing without consultation or dose-change surcharges, but no complete standing amount was established from the reviewed pages. A first-order percentage promotion does not resolve future charges. Request the actual prescription-and-care total. 4. ## What it claims, and what it cites The catalog explicitly names compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). These preparations are not FDA approved. The standard, microdose and oral options need separate clinical justification; a molecule name does not establish comparable absorption, dose or outcomes. ## Where it holds up, and where it does not - Strength: Direct provider messaging described - Strength: Consultation and dose-change surcharges excluded in the offer - Strength: Clinical and platform roles separated - Limitation: Cancellation notice periods conflict - Limitation: Standing total requires a quote - Limitation: Trial-based projections are not provider outcomes ## What the evidence says about this kind of treatment The assessment above is about Metabolic Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient seeking continued clinical messaging who first resolves the financial and cancellation terms. Wrong for Someone relying on a projected weight curve or assuming every format has the same evidence. ## The evidence behind what Metabolic Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Metabolic Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) [DoctorAdam](https://thisglp.com/reviews/doctoradam) [Dollar Dad Club](https://thisglp.com/reviews/dollar-dad-club) [Dr. Arevitalize](https://thisglp.com/reviews/dr-arevitalize) [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) [DrBrainRx](https://thisglp.com/reviews/drbrainrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which cancellation notice applies? The product FAQ says thirty days before the next cycle; general terms describe forty-eight hours before processing. Ask the provider to resolve the discrepancy before purchase. Does a flat-rate promise identify the total? No. It describes price behavior, not the actual amount or all inclusions of your prescription. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official treatment program](https://joinmetabolicrx.com/) - [Service and cancellation terms](https://joinmetabolicrx.com/terms) - [Treatment information](https://joinmetabolicrx.com/treatments/semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Metabolyz reviews (2026): GLP-1 telehealth sellers | This GLP Metabolyz combines clinician review with nutrition, movement and lifestyle coaching, but keeps program prices inside consultation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/metabolyz Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Coaching alongside prescribing # Metabolyz review Metabolyz combines clinician review with nutrition, movement and lifestyle coaching, but keeps program prices inside consultation. ## The verdict The coaching model is more specific than prescription delivery alone. Its value depends on the actual contact schedule and the total quoted fee; neither the projected weight curve nor testimonials establish durable results for an individual. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Metabolyz is a telehealth access platform operated by The Westview Drive Co Inc. It describes semaglutide and tirzepatide programs with ongoing coaching. 1. ## Who writes the prescription, and what do they see? The terms separate the platform from independent clinicians and pharmacies. Ask for the treating practice and dispenser before consenting; the platform’s medical-supervision language is not the name of your prescriber. An online consultation precedes clinical authorization. The site describes structured check-ins and direct messages to the care team, with nutrition and movement support alongside medication. 2. ## What happens when the dose goes up? The semaglutide page describes provider-directed adjustments and messaging between check-ins. It does not specify a universal appointment frequency. Establish how symptoms and refill requests are reviewed before each shipment. 3. ## What the price includes The FAQ explicitly withholds public pricing and says the quote depends on protocol and program length. A monthly membership description alone does not reveal the total or whether a dose change changes it. 4. ## What it claims, and what it cites The site identifies compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) pathways. Compounded drugs are not FDA-approved. Its separate microdose and longevity marketing does not establish additional proven benefits. ## Where it holds up, and where it does not - Strength: Nutrition and movement coaching described - Strength: Direct care-team messaging - Limitation: Prices withheld until consultation - Limitation: Visit frequency needs confirmation ## What the evidence says about this kind of treatment The assessment above is about Metabolyz. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone comparing a medication-plus-coaching service and willing to obtain a detailed quote first. Wrong for Someone who needs a published dose-specific price and a fixed visit schedule before sharing an intake. ## The evidence behind what Metabolyz prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Metabolyz compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) [DudeMeds](https://thisglp.com/reviews/dudemeds) [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) [Edessa](https://thisglp.com/reviews/edessa) [EdgeRx](https://thisglp.com/reviews/edgerx) [Effecty](https://thisglp.com/reviews/effecty) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who makes prescribing decisions? Independent licensed clinicians, rather than the platform company, decide whether and what to prescribe. Does the projected weight curve predict my outcome? No. A marketing projection is not an individualized clinical assessment or verified program outcome. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://metabolyz.com/) - [Official program and terms](https://metabolyz.com/treatments/semaglutide) - [Official program and terms](https://metabolyz.com/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Metaboost Rx reviews (2026): GLP-1 telehealth sellers | This GLP An Oklahoma City telehealth brand whose headline GLP-1 figures sit under a new-patient banner, with nothing on the page saying what follows the offer. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/metaboost-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Low figures, unlabeled term # Metaboost Rx review An Oklahoma City telehealth brand whose headline GLP-1 figures sit under a new-patient banner, with nothing on the page saying what follows the offer. ## The verdict Metaboost Rx advertises compounded semaglutide from $149 a month and compounded tirzepatide from $199, the second printed beside a struck $299, and the banner above both reads New Patient Offer. A reader planning past the first few months has no published figure to plan with, because nowhere on the public pages does the seller say whether those rates continue after the offer or what they become. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Metaboost Rx describes itself as a physician-directed telehealth practice for medical weight loss, based in Oklahoma City and serving patients nationwide, and its footer calls it a concierge platform that connects patients with independent providers and state-licensed compounding pharmacies. It runs three GLP-1 programs, semaglutide, tirzepatide and a lower-dose microdose track, plus a newer peptide therapy line for recovery and energy. Its website runs on a platform shared with seven other GLP-1 brands, down to the same compiled code and the same member photographs, and each brand configures its own programs and prices on top of it. 1. ## Who writes the prescription, and what do they see? The platform says plainly that it does not practice medicine or write prescriptions itself, and that every evaluation and prescribing decision belongs to an independent, board-certified U.S. provider who reviews the intake. No provider is named on the homepage, the program pages or the about page, and the only contact listed is a Gmail address, so a patient meets the clinician only after the assessment is under way. A patient fills in an online assessment of about five to ten minutes covering history, goals and baseline measurements, and a provider reads it and builds a plan. Medication then ships in temperature-controlled, unmarked packaging, with check-ins and secure messaging continuing afterward. The site says nothing is charged if the provider does not approve treatment, and its FAQ answers the commitment question in one word: no long-term commitment is required. 2. ## What happens when the dose goes up? The tirzepatide page sketches the first year as careful [dose escalation](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) in month one, a therapeutic dose by month three, and titration handled by the provider at every step, with each dose change listed as included in the flat-rate program. The FAQ adds that a patient switching from another provider may continue at the same or an equivalent dose, while a new patient starts at an introductory one. No milligram schedule is published, so a patient cannot see in advance where the ladder stops. 3. ## What the price includes The homepage pricing block shows semaglutide from $149 a month and tirzepatide from $199 a month, the latter with $299 struck through, and each card lists the online provider visit, the prescription, home delivery and ongoing check-ins as included. The banner over the page calls the $149 a new-patient offer, and the eligibility tool repeats it as plans from $149 confirmed after provider review. What the page never states is the rate after a patient stops being new, which leaves the question a buyer most needs answered, the cost of month four, without an answer anywhere public. 4. ## What it claims, and what it cites The program pages describe the medication as compounded and prepared by partner compounding pharmacies, and the footer states that compounded medications are not FDA-approved and that the FDA has not independently verified their safety, efficacy or quality. No compounding pharmacy is named on any page. ## Where it holds up, and where it does not - Strength: No long-term commitment, per the FAQ - Strength: No charge if treatment is not approved - Strength: Provider visit and delivery listed as included - Strength: Dose changes included in the program - Limitation: Headline figure labeled a new-patient offer - Limitation: Rate after the offer is not published - Limitation: No provider or pharmacy named - Limitation: No milligram schedule published ## What the evidence says about this kind of treatment The assessment above is about Metaboost Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer willing to start at the advertised figure and ask the rate after the offer before the first refill. Wrong for Someone who needs a published standing monthly rate before committing to any GLP-1 seller. ## The evidence behind what Metaboost Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Metaboost Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EdgeRx](https://thisglp.com/reviews/edgerx) [Effecty](https://thisglp.com/reviews/effecty) [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) [Elevate Health](https://thisglp.com/reviews/elevate-health) [Elevated Health](https://thisglp.com/reviews/elevated-health) [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 a month Metaboost Rx's regular semaglutide price? The seller does not say. The homepage banner calls it a new-patient offer, and no page states what a patient pays after that offer ends. What does tirzepatide cost? The pricing card shows from $199 a month, with $299 struck through beside it, and the same unanswered question about what follows the new-patient offer applies. Do I have to commit to a long plan? No, according to the FAQ, which says treatment length varies by patient and no long-term commitment is required. Is Metaboost Rx legit? Metaboost Rx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Metaboost Rx expensive compared with other GLP-1 telehealth sellers? Metaboost Rx publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Metaboost Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Mevo Health reviews (2026): GLP-1 telehealth sellers | This GLP Both figures read as low as. The plan length each one prices is not stated. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mevo-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A floor, term unstated # Mevo Health review Both figures read as low as. The plan length each one prices is not stated. ## The verdict Mevo Health publishes semaglutide as low as $199 a month. Tirzepatide is as low as $259. Plans come in monthly, quarterly and six-month lengths. The page does not say which length each figure prices. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Mevo Health is a direct-pay telemedicine service. It sells compounded semaglutide and tirzepatide by injection. Insurance is not required. 1. ## Who writes the prescription, and what do they see? Four board-certified physicians are named on the homepage. One is named head of the Mevo Provider Network. Their fields are internal, family and emergency medicine. A network physician reviews each intake before prescribing. Care starts with a secure online questionnaire. Physician review follows it. Ongoing access to the provider team is stated. A patient community group is also offered. 2. ## What happens when the dose goes up? The page states physicians may adjust treatment. No dose schedule is published. Whether the price changes with the dose is not stated. Ask for the rate at your expected dose. 3. ## What the price includes Each drug shows one figure against three plan lengths. The page does not match the figure to a length. A monthly buyer may pay more than the floor. Further pricing sits behind an email sign-in. Six months at $199 is $1,194, on whichever plan it belongs to. 4. ## What it claims, and what it cites Both lines are compounded by licensed 503A U.S. pharmacies. The pharmacy varies by location and physician, and none is named. The site states the FDA does not review compounded drugs before dispensing. ## Where it holds up, and where it does not - Strength: Four prescribing physicians are named - Strength: Plan lengths are listed in the FAQ - Strength: Cancellation before the next cycle is stated - Strength: Direct-pay, with no insurance needed - Limitation: The figure's plan length is not stated - Limitation: No product page beyond the homepage - Limitation: Pricing detail requires an email sign-in - Limitation: No dose schedule is published ## What the evidence says about this kind of treatment The assessment above is about Mevo Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will confirm which plan length the figure belongs to. Wrong for A reader who needs a month-to-month rate before signing in. ## The evidence behind what Mevo Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Mevo Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Woodwork | Readers ready to commit forty-eight weeks who read asterisks | | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) [ElixaMD](https://thisglp.com/reviews/elixamd) [ElleS](https://thisglp.com/reviews/elles) [EllieMD](https://thisglp.com/reviews/elliemd) [Eloria](https://thisglp.com/reviews/eloria) [Emerge Weight Loss](https://thisglp.com/reviews/emerge-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 the monthly rate? Not stated. Plans come in three lengths. The figure reads as low as. Can I cancel? Yes, before the next billing cycle, per the FAQ. Who are the physicians? Four board-certified physicians, named on the homepage. Is Mevo Health expensive compared with other GLP-1 telehealth sellers? Mevo Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Mevo Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Midi Health reviews (2026): GLP-1 telehealth sellers | This GLP All four lines publish a complete dose ladder with the milligram beside each rung — and every table is a four-week supply rather than a month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/midi-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every rung, with its milligram # Midi Health review All four lines publish a complete dose ladder with the milligram beside each rung — and every table is a four-week supply rather than a month. ## The verdict Midi Health publishes ladders on all four of its lines, opening at $180 a calendar month for injected semaglutide. The tables are priced per four-week supply, which is thirteen fills a year rather than twelve. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $180/mo Oral From $178/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Availability 50 states Midi Health sells both molecules as an injection and as an oral. Every line carries a published ladder rather than a single starting figure, and coverage runs to 50 states. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing, and the pricing page leads with the absence of a membership fee. The clinical side is described less than the commercial side. Publishing the milligram beside the money lets a reader cost a whole escalation before starting one. That is worth more than a low opening figure, and it is the reason to read this seller carefully. 2. ## What happens when the dose goes up? This is the disclosure almost nobody makes. Injected semaglutide runs from $165.90 at 0.1 to 0.5 mg up to $355.00 at 2.5 mg; the oral runs $164.00 at 0.075 mg to $275.00 at 0.8 mg. Injected tirzepatide runs $210.00 at 1.25 to 2.5 mg up to $434.00 at 13.75 to 15 mg, and its oral $209.00 at 1 mg to $460.00 at 7 mg. 3. ## What the price includes The opening rungs are $165.90, $164.00, $210.00 and $209.00, each buying four weeks. Thirteen of those in a year works out at $179.73, $177.67, $227.50 and $226.42 a calendar month. Six months of injected semaglutide at the opening rung is therefore about $1,078 rather than the $995 a twelve-payment year would suggest. 4. ## What it claims, and what it cites The lines are compounded rather than manufactured, and a pharmacy prepares them to order. The FDA does not review a compounded preparation before it is dispensed, and no pharmacy is named. ## Where it holds up, and where it does not - Strength: Complete dose ladders on all four lines - Strength: Milligram thresholds published beside each rung - Strength: The four-week cycle is stated, not hidden - Strength: Coverage in 50 states - Limitation: A year holds thirteen of these fills - Limitation: The top injected rungs roughly double the opener - Limitation: The oral tirzepatide ladder reaches $460 - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Midi Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants every rung costed, with its milligram, before a first dose is chosen. Wrong for A reader budgeting the opening rung as a twelve-payment calendar year. ## The evidence behind what Midi Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Midi Health compares | Seller | Who it suits | Go | | --- | --- | --- | | TelePeptide | Readers who want the whole commitment ladder priced in advance | | | Pepti | Readers who want labs and physician care inside one figure and count fills rather than months | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus)[EverSlim](https://thisglp.com/reviews/everslim) [Eviora MD](https://thisglp.com/reviews/eviora-md) [Factor Health MD](https://thisglp.com/reviews/factor-health-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $165.90 a monthly price? No. It buys a four-week supply, and thirteen of those in a year comes to $179.73 a calendar month. What does the price do at a higher dose? It climbs, and the page says by how much. Injected semaglutide reaches $355.00 at 2.5 mg and injected tirzepatide $434.00 at the top band. Which is cheaper, the pill or the injection? The orals open slightly lower on both molecules, but the oral tirzepatide ladder tops out higher, at $460.00 against $434.00. Is Midi Health legit? Midi Health is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Midi Health expensive compared with other GLP-1 telehealth sellers? Midi Health publishes a starting figure of $178/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Midi Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Mint Med reviews (2026): GLP-1 telehealth sellers | This GLP The monthly figure is written into the product name, and the listing says it holds at every dose for as long as the order runs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mint-med Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One rate across the ladder # Mint Med review The monthly figure is written into the product name, and the listing says it holds at every dose for as long as the order runs. ## The verdict Compounded semaglutide costs $106 a month at Mint Med and compounded tirzepatide costs $145, and the seller labels both a lifetime price with every dose included. On the seller's own wording, then, the figure paid in the first month is also the figure paid in the fifth, after the dose has climbed. The clinical side of the page is thinner: the review that comes before a prescription is described in outline, and neither a prescriber nor a pharmacy is named. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 36 From From $106/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Mint Med works like a shop, with compounded semaglutide and compounded tirzepatide each sold as one listing whose price is part of the product name. The same catalog carries NAD+, sermorelin, an MIC and B12 injection and bremelanotide. A buyer pays at checkout and is reviewed afterwards, and the site promises a refund straight away if a clinician decides the medication is not appropriate. 1. ## Who writes the prescription, and what do they see? The listing says a licensed provider reviews the intake within 24 business hours and sends the prescription on if it is approved. The homepage adds that a board-certified clinician makes that call, by live video or audio in states that require it and by a chart review answered in the patient inbox where asynchronous care is allowed. No clinician, medical group or medical director is named anywhere a buyer would look before paying, so who is actually signing the prescription is not stated. After the first order the relationship runs through a patient portal, where the site promises unlimited messaging with the care team and ongoing access to the provider for questions about dosage and symptoms. A 24/7 care team is listed on every product page. Cancellation needs 48 business hours of notice before the next order, and the homepage states plainly that no long-term subscription is required. 2. ## What happens when the dose goes up? This is where the listing is at its strongest, because the dose ladder is exactly the part that usually costs more by the fourth month. Every plan on both molecules says all doses are included and that the price is locked with no increases, so a step from the starting dose to a higher one should not change the bill. What the page does not describe is the clinical side of each step: who decides it, and what a patient reports before it is made. 3. ## What the price includes Month to month, semaglutide is $106 and tirzepatide is $145, a difference of $39 that stays the same at every dose. Each listing also offers two-, three-, six- and twelve-month prepaid terms, and every longer term lowers the monthly figure a little further, but each is charged in full at the start. A year of semaglutide at the monthly rate comes to $1,272, which is the useful number to hold beside a prepaid term before committing to one. 4. ## What it claims, and what it cites Both products are compounded preparations, not branded medicines. The product page says compounded medications are not reviewed or approved by the FDA before they are dispensed, and that the medication ships from a state-licensed compounding pharmacy it does not name. ## Where it holds up, and where it does not - Strength: Price labeled locked at every dose - Strength: Monthly figure printed in the product name - Strength: Refund stated if a clinician declines - Strength: Neither listing carries a membership fee - Limitation: No prescriber or medical group is named - Limitation: The compounding pharmacy is not named - Limitation: Payment is taken before clinical review - Limitation: Prepaid terms are charged in full upfront ## What the evidence says about this kind of treatment The assessment above is about Mint Med. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who expects to climb the dose ladder and wants the bill to stay where it started. Wrong for A buyer who wants to know which clinician is responsible before paying. ## The evidence behind what Mint Med prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Mint Med compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Voxy | Readers who want check-ins included and will pick a cadence deliberately | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Factor Health MD](https://thisglp.com/reviews/factor-health-md) [Fella Health](https://thisglp.com/reviews/fella-health) [Fidelity Medical Clinic](https://thisglp.com/reviews/fidelity-medical-clinic) [Fierce Health](https://thisglp.com/reviews/fierce-health) [Fifty 410](https://thisglp.com/reviews/fifty-410) [FitFlow](https://thisglp.com/reviews/fitflow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise when the dose goes up? Not on the seller's wording. Every plan on both listings says all doses are included and the price is locked with no increases. Is payment taken before a provider has reviewed the intake? Yes. The site collects payment at checkout, and says it refunds the order straight away if a clinician finds the patient is not eligible. Is Mint Med the same company as Mint Medical Clinic? No. Mint Med sells online from mintmed.com, while Mint Medical Clinic is a clinic in Utah with a different website and its own pricing, so the two should not be compared as one seller. Is Mint Med expensive compared with other GLP-1 telehealth sellers? Mint Med publishes a starting figure of $106/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Mint Med below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Mint Medical Clinic reviews (2026): GLP-1 telehealth sellers | This GLP A Utah clinic prints one starting price for both molecules, and the GLP-1 page itself carries no price at all. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mint-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Utah clinic, one printed floor # Mint Medical Clinic review A Utah clinic prints one starting price for both molecules, and the GLP-1 page itself carries no price at all. ## The verdict Mint Medical Clinic prints a single figure for GLP-1 care: starting at $299 a month, on one homepage card covering semaglutide and tirzepatide. What that figure buys, at which dose, is not stated. The physician-led structure is described in more detail than the price is. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 1 From From $299/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Mint Medical Clinic is an in-person clinic with two Utah locations, in Sandy and Layton. Its main lines are intimacy health, hormone therapy and body contouring. GLP-1 weight loss is one service among these, offered at the clinic or by telehealth. The weight-loss page names semaglutide and tirzepatide as weekly injections. 1. ## Who writes the prescription, and what do they see? A physician runs the evaluation, by the site's account, reviewing medical history and current medications before prescribing. The FAQ describes that consultation as a telehealth visit, and in-person care is offered at both locations. No physician is named on the GLP-1 pages or the About page. The GLP-1 page lays out four steps: a telehealth visit, a medical evaluation, a dosing schedule and shipped medication. Regular physician check-ins are described as part of the program. How often they happen is not stated. The first consultation is free, and the site says its staff speak Spanish. 2. ## What happens when the dose goes up? The site says dosing starts low and increases gradually, with the physician adjusting it to limit [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). No milligram doses are published for either molecule. Whether the monthly price changes as the dose rises is not stated. The homepage figure is a floor, so a higher price at a higher dose is not ruled out. 3. ## What the price includes One card on the homepage carries the only GLP-1 price: starting at $299 a month, for semaglutide and tirzepatide together. Neither the weight-loss service page nor the medication page prints a figure. At that floor, six months comes to $1,794. The card does not say whether the two molecules cost the same. 4. ## What it claims, and what it cites The medication page describes the program as using compounded GLP-1 medications. The same page calls [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) FDA-approved for weight management, an approval that belongs to the branded product rather than to a compounded preparation. Compounded medicines are not FDA-approved. The pharmacy that prepares them is not named. ## Where it holds up, and where it does not - Strength: In-person care at two Utah clinics - Strength: Physician check-ins described as routine - Strength: First consultation is free - Strength: Telehealth offered alongside clinic visits - Limitation: One price printed for two molecules - Limitation: No milligram doses published - Limitation: No physician named on the GLP-1 pages - Limitation: Compounding pharmacy not named ## What the evidence says about this kind of treatment The assessment above is about Mint Medical Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Utah resident who wants a clinic they can visit in person during the dose escalation. Wrong for A buyer who needs a per-molecule, per-dose price before the first consultation. ## The evidence behind what Mint Medical Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Mint Medical Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | CoraDoc | Buyers who would rather pay a program once than carry a subscription they have to remember to cancel | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [FitRx](https://thisglp.com/reviews/fitrx) [Fitstry](https://thisglp.com/reviews/fitstry) [FMmeds](https://thisglp.com/reviews/fmmeds) [FORM](https://thisglp.com/reviews/form) [FormBlends](https://thisglp.com/reviews/formblends) [FormidableMD](https://thisglp.com/reviews/formidablemd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does GLP-1 treatment cost here? The homepage card says starting at $299 a month, for semaglutide and tirzepatide together. No other GLP-1 price is printed. Is the weight-loss figure on the card from this clinic's patients? The card names a loss of 10 to 20 percent of body weight, and the FAQ attributes that range to clinical studies. Outcomes among this clinic's own patients are not reported. Is Mint Medical Clinic the same as Mint Med? No. Mint Medical Clinic is a Utah clinic at mintmedicalclinic.com, and Mint Med is an online seller at mintmed.com with its own prices. Is Mint Medical Clinic expensive compared with other GLP-1 telehealth sellers? Mint Medical Clinic publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Mint Medical Clinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Mixx Health & Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Mixx Health & Wellness identifies a medical director and pharmacy for its compounded GLP-1/GIP pathway. Confirm the actual ingredient, prescription and cancellation conditions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mixx-health-and-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Mixx Health & Wellness sell a GLP-1? Mixx Health & Wellness identifies a medical director and pharmacy for its compounded GLP-1/GIP pathway. Confirm the actual ingredient, prescription and cancellation conditions. ## The verdict Mixx publishes more operational detail than many generic GLP-1 storefronts: a named pharmacy, medical director and service-state list. The remaining essential detail is the precise medicine. A dual-receptor category description should not be substituted for the ingredient and concentration on a prescription. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth States 41 Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Mixx coordinates remote evaluation and delivery for a compounded weekly GLP-1/GIP injection program. The public page uses the drug-class description without clearly establishing a specific ingredient for every order. That limitation matters when evaluating both evidence and price. 1. ## Who writes the prescription, and what do they see? The treatment FAQ names Dr. James David Lawrence III as medical director. The prescribing relationship remains an individual medical assessment, not a guarantee that the named director personally sees every patient. Confirm the clinician responsible for the proposed prescription. The service describes complimentary consultations and follow-up contact through a patient-provider system. Its FAQ encourages continued check-ins. It also provides an explicit state list, which is more useful than assuming all-state access; verify eligibility for your location before submitting an order. 2. ## What happens when the dose goes up? Prescriptions and duration are at the physician’s discretion, with no guaranteed course. Ask how dose changes are authorized and how an existing pharmacy order is handled when the clinician needs to alter treatment. A flat consultation description does not establish a flat medication cost at every dose. 3. ## What the price includes The homepage and dedicated treatment page advertise different starting contexts. The latter should not be treated as a universal continuing quote. The FAQ says no separate subscription is required, while legal terms discuss nonrefundable payments and a possible cancellation or prescription-change charge. 4. ## What it claims, and what it cites Promise Pharmacy in Palm Harbor, Florida, is identified as the source in the FAQ. The preparation is described as compounded and therefore not FDA-approved. Obtain the exact ingredient and concentration directly; neither the pharmacy name nor GLP-1/GIP wording establishes the contents of an individual vial. ## Where it holds up, and where it does not - Strength: Dispensing pharmacy and medical director are named - Strength: A specific service-state list is published - Strength: Continuing provider contact is described - Limitation: Public class wording does not fully identify the prescription - Limitation: Starting-price contexts differ - Limitation: Cancellation and prescription changes can carry restrictions ## What the evidence says about this kind of treatment The assessment above is about Mixx Health & Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient in a listed service state willing to verify the exact compounded prescription and follow-up arrangements. Wrong for Someone satisfied with a drug-class label in place of a named ingredient or expecting unrestricted order cancellation. ## How Mixx Health & Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Fresh Day Meds](https://thisglp.com/reviews/fresh-day) [Freya Meds](https://thisglp.com/reviews/freya-meds) [Fridays](https://thisglp.com/reviews/fridays) [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) [Gaya Wellness](https://thisglp.com/reviews/gaya-wellness) [Genesis Health](https://thisglp.com/reviews/genesis) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which pharmacy is named? The treatment FAQ identifies Promise Pharmacy in Palm Harbor, Florida. Does GLP-1/GIP identify the exact vial? No. Ask for the ingredient, concentration and prescribed dose rather than inferring them from the receptor-class description. Is every state served? No all-state assumption is justified. The FAQ publishes an explicit list that should be checked for your location. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://mixxhealthandwellness.com/) - [Terms of service and payment conditions](https://mixxhealthandwellness.com/terms-of-service/) - [GLP-1 care and prescribing options](https://mixxhealthandwellness.com/glp1-gip/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Mochi Health reviews (2026): GLP-1 telehealth sellers | This GLP The full dose ladder is published in milligrams, and the care fee is billed separately from it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mochi-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every dose priced in milligrams # Mochi Health review The full dose ladder is published in milligrams, and the care fee is billed separately from it. ## The verdict Mochi Health prints a milligram ladder beside every product it sells, from $60 for compounded semaglutide. Care is a separate $79 monthly membership that the medication price does not include. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 15 From From $139/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Mochi Health is a telehealth membership covering weight care, hormones, hair and skin. Its weight line runs compounded semaglutide by injection, a compounded semaglutide pill, compounded tirzepatide and compounded orforglipron, with metformin alongside. Brand products appear at their own rates. Every one is listed with the weekly or daily doses it is available in. 1. ## Who writes the prescription, and what do they see? Mochi describes providers who listen and a plan built around the patient's goals. What a provider reviews before prescribing is not published, and no clinician, medical group or medical director is named. Eligibility and pricing are both stated to vary by state without a list of which states. The membership bundles provider access, coaching and support into one guided experience. Its own terms are explicit that medications and diagnostic services are not part of it. Prepaid multi-month memberships are offered, and terms are said to vary by state. A patient therefore holds two costs: the membership and whatever the prescribed dose costs. 2. ## What happens when the dose goes up? This is where Mochi is better than its shelf. Compounded semaglutide is listed across eight weekly doses, from 0.22 mg to 6.48 mg. Tirzepatide runs across seven, from 2.2 mg to 16.6 mg. Orforglipron runs across eight, from 1 mg to 16.5 mg. A patient can see the whole climb before starting. What each rung costs above the floor is not published, and nothing states how long a dose is held. 3. ## What the price includes The medication floors are $60 for compounded semaglutide, $90 for tirzepatide, $62 for the semaglutide pill and $31 for orforglipron. The membership is $79 a month, cut to $39 for a first month for new subscribers. Adding the two gives $139 for a semaglutide month at the foot of the ladder, which is arithmetic on Mochi's own published figures rather than a rate Mochi quotes. A banner records both injectable floors as recent cuts, from $99 and $199. 4. ## What it claims, and what it cites The compounded lines are not FDA-approved and the FDA has not evaluated them for safety, effectiveness or quality, which Mochi states. Metformin is identified as FDA-approved for type 2 diabetes. The compounding pharmacy is not named. Availability is said to vary by state. ## Where it holds up, and where it does not - Strength: Every product lists its full milligram ladder - Strength: Four molecules and two routes on one shelf - Strength: The membership terms state what they exclude - Strength: Recent price cuts shown against the old figures - Limitation: The medication price excludes the mandatory membership - Limitation: The $39 opening membership rate lasts one month - Limitation: No compounding pharmacy or clinician is named - Limitation: Dose-by-dose rates above the floor are not published ## What the evidence says about this kind of treatment The assessment above is about Mochi Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to see the milligrams behind a GLP-1 plan before paying for one. Wrong for A buyer comparing headline prices, because $60 is not what a month costs here. ## The evidence behind what Mochi Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Mochi Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Kina | Women in menopause who want the medical group named and four routes priced up front | | | Tuyo Health | Buyers weighing a compounded plan against brand Wegovy or Zepbound at the same clinic | | | Nova MD | Buyers who will read which plan is already selected before they press start | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) [Gaya Wellness](https://thisglp.com/reviews/gaya-wellness) [Genesis Health](https://thisglp.com/reviews/genesis) [Get Thin MD](https://thisglp.com/reviews/get-thin-md) [GetRelief Rx](https://thisglp.com/reviews/getrelief-rx) [Gimme Care](https://thisglp.com/reviews/gimme-care) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $60 cover a month of care? No. It is the medication floor. Mochi's membership terms state that medications are not included in the $79 monthly fee. Is the dose published? Yes. Each product lists its weekly or daily milligram options, from 0.22 mg for semaglutide to 16.6 mg for tirzepatide. Is $39 the membership rate? Only for a first month, for new subscribers. Mochi states the standard rate is $79 a month afterwards. Is Mochi Health expensive compared with other GLP-1 telehealth sellers? Mochi Health publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Mochi Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Modern Age reviews (2026): GLP-1 telehealth sellers | This GLP Modern Age describes assessment-led weight management with a six-month support program and separate medication costs. Clarify current availability and the proposed prescription first. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/modern-age Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Modern Age sell a GLP-1? Modern Age describes assessment-led weight management with a six-month support program and separate medication costs. Clarify current availability and the proposed prescription first. ## The verdict The care model starts with a broader assessment rather than a medication questionnaire alone. Its weight-loss page describes monitoring and prescription adjustment over six months. Before purchasing, confirm current service availability and whether that broader assessment answers a real clinical need for you. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Modern Age’s weight-management pathway begins with its Aging Wellness Assessment, followed by a possible Optimization Program. Treatment may include a GLP-1 or metformin when a clinician considers it appropriate. The wider wellness catalog does not make every test or treatment necessary. 1. ## Who writes the prescription, and what do they see? A clinician evaluates assessment results, history and goals before recommending prescription treatment. Eligibility is not established by purchasing an assessment. Ask who will manage the weight plan and how any existing primary-care clinician will be kept informed. The weight-loss page describes regular virtual or in-person check-ins, BMI tracking and prescription adjustments. Optional in-person injections are also mentioned. Confirm which visits are included in the six-month plan and where they can actually take place. 2. ## What happens when the dose goes up? The proposed medicine and response determine changes. There is no single public GLP-1 [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule applicable to every participant. A headline statement about possible weight loss is not an individualized forecast or a reason to escalate without medical advice. 3. ## What the price includes The page lists separate assessment and six-month Optimization Program fees, with medication excluded. Insurance assistance is described, but coverage is not guaranteed. Confirm current fees and services directly, particularly because a page’s availability does not itself establish appointment availability. 4. ## What it claims, and what it cites The program page discusses GLP-1 treatment and metformin without establishing one specific medicine for every patient. The actual product, formulation and pharmacy should be named in the clinical plan. Do not infer a particular molecule from a general weight-loss promise. ## Where it holds up, and where it does not - Strength: Assessment and ongoing support are distinct - Strength: Virtual and in-person monitoring are described - Strength: Medication exclusion is explicit - Limitation: Broader assessment may not suit every weight-loss goal - Limitation: Current appointment availability needs confirmation - Limitation: Drug identity and cost require a clinical plan ## What the evidence says about this kind of treatment The assessment above is about Modern Age. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone interested in a broader assessment-led approach who can verify current access and the relevance of the proposed testing. Wrong for A patient seeking a clearly priced standalone GLP-1 prescription without a wider wellness assessment. ## How Modern Age compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Goldspan Health](https://thisglp.com/reviews/goldspan-health) [Good Girl Rx](https://thisglp.com/reviews/good-girl-rx) [Good Life Meds](https://thisglp.com/reviews/good-life-meds) [GoodRx](https://thisglp.com/reviews/goodrx) [Green Cap Health](https://thisglp.com/reviews/green-cap-health) [Harbor](https://thisglp.com/reviews/harbor) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is medication included in the program price? No. The weight-loss page explicitly excludes GLP-1 or metformin medication cost. Does buying an assessment guarantee prescribing? No. A clinician must determine whether treatment is appropriate. Can the program be refunded? The program page describes a refund before the first prescription purchase through its pharmacy partner; confirm the current applicable agreement. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://modern-age.com/) - [Terms of service and payment conditions](https://modern-age.com/legal/terms-and-conditions) - [Weight-management program](https://modern-age.com/category/weight-loss) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Mojoon reviews (2026): GLP-1 telehealth sellers | This GLP A Chinese-language telehealth service prices each monthly course by dose, from a starting figure up to a published ceiling. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mojoon Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Chinese-language, price rises with dose # Mojoon review A Chinese-language telehealth service prices each monthly course by dose, from a starting figure up to a published ceiling. ## The verdict Mojoon sells compounded semaglutide at $350 to $520 per monthly course. The price rises with the dose. The site is written in Chinese, with bilingual service stated. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection From From $350/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Mojoon is a Chinese-language telehealth platform. Its menu also covers sexual health, hair loss, antivirals and wellness injections. Compounded semaglutide is sold as an injection with B12. Tirzepatide and an oral semaglutide are listed too. 1. ## Who writes the prescription, and what do they see? The site states that licensed doctors write each prescription. It says its doctors hold licenses in 48 states. It also states that its pharmacy holds licenses in all 50. No doctor is named. The online consultation is stated to be free. One course is four weekly injections. After each course, the patient completes a follow-up questionnaire. The doctor then decides whether to prescribe the next course. The site says patient information is protected under HIPAA. 2. ## What happens when the dose goes up? The starting dose is 0.25 mg. It rises month by month until it reaches the 2.4 mg maintenance dose. The price is adjusted each month as the dose rises. The page publishes the range, not the price at each step. 3. ## What the price includes The product page prints $350 to $520 per course, with a struck figure of $1000 beside it. A course is counted as one month. Three months at the starting price is $1,050. A patient who reaches the upper dose pays up to $520. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded, and the page labels it that way. Compounded preparations are not FDA-approved. The site says its medications come from a 503B pharmacy it describes as FDA-certified. That pharmacy is not named. ## Where it holds up, and where it does not - Strength: The full price range is published - Strength: The dose schedule is stated in milligrams - Strength: Each course is prescribed after a check-in - Strength: Consultation stated as free - Limitation: Price per dose step not published - Limitation: No doctor or pharmacy named - Limitation: Site content is in Chinese - Limitation: A BMI above 27 is required ## What the evidence says about this kind of treatment The assessment above is about Mojoon. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Chinese-speaking reader who wants a doctor's check-in before each monthly course. Wrong for A reader who wants one fixed monthly price across the dose ladder. ## The evidence behind what Mojoon prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Mojoon compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [GoodRx](https://thisglp.com/reviews/goodrx) [Green Cap Health](https://thisglp.com/reviews/green-cap-health) [Harbor](https://thisglp.com/reviews/harbor) [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) [Harper Meds](https://thisglp.com/reviews/harper-meds) [He & She MD](https://thisglp.com/reviews/he-and-she-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change with the dose? Yes. The page says the price is adjusted each month as the dose rises, within a range of $350 to $520 per course. How long does one course last? One month. A course is four weekly injections, and the next course needs a follow-up questionnaire first. Is the site available in English? The pages are in Chinese. The site states that it offers service in both Chinese and English. Is Mojoon expensive compared with other GLP-1 telehealth sellers? Mojoon publishes a starting figure of $350/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Mojoon above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Mondae reviews (2026): GLP-1 telehealth sellers | This GLP Among the lowest published compounded rates here, on pages that state very little else. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mondae Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Cheap, and short on detail # Mondae review Among the lowest published compounded rates here, on pages that state very little else. ## The verdict Mondae opens compounded semaglutide at $87 a month and compounded tirzepatide at $126. Both are the one-month rung, which the page selects by default. Three months drops semaglutide to $75. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $87/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Mondae is a telehealth platform with four treatment pages. Two are GLP-1 medicines. NAD and sermorelin and glutathione make up the rest. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the questionnaire and holds a consultation before prescribing. Messaging through a portal is offered afterwards. No clinician, medical group or medical director is named on either GLP-1 page. What the provider sees before writing is not described. Intake, provider review, then shipping with tracking. Follow-up consultations and dose adjustments are requested through the portal. Each product page carries three claims and stops: same price every dose, no membership fees, one-to-one provider guidance. 2. ## What happens when the dose goes up? Mondae says the price a patient starts on is the price they keep for life. Other programs, it adds, raise theirs as doses rise. The sentence carries a condition: as long as your membership remains active. The card above it says there are no membership fees. Those two statements cannot both be complete. The dose chart beside them is labeled a stylized representation rather than a real schedule. 3. ## What the price includes The plan selector opens on one month. Semaglutide is $87 there and $75 on three months, billed as $225 once. Tirzepatide is $126 and $124, billed as $372. The three-month saving is real on semaglutide and almost nothing on tirzepatide. A struck-through anchor figure sits above both. 4. ## What it claims, and what it cites Both lines are compounded, prescribed only where a provider judges it appropriate, and dispensed by a licensed pharmacy. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The pharmacy is not named and no milligram is published. ## Where it holds up, and where it does not - Strength: Among the lowest published compounded rates here - Strength: The one-month rung is the one preselected - Strength: Three-month totals are printed in full - Strength: Price stated to hold at every dose - Limitation: The price lock is conditional on a membership - Limitation: The same card says there are no membership fees - Limitation: No milligram, pharmacy name or clinician appears - Limitation: The dose chart is a stylized illustration ## What the evidence says about this kind of treatment The assessment above is about Mondae. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer whose first filter is the number and who will ask the rest later. Wrong for A buyer who wants the pharmacy, the dose and the care team on the page. ## The evidence behind what Mondae prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Mondae compares | Seller | Who it suits | Go | | --- | --- | --- | | LumiMeds | Buyers who want the ingredient, route and pharmacy type labeled before they pay | | | NativeMed | Buyers who want to see the prepay arithmetic before deciding it is a saving | | | Omzo | Buyers who want the medication cost inside one fee rather than billed by a pharmacy | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Heally](https://thisglp.com/reviews/heally) [HealthHub](https://thisglp.com/reviews/healthhub) [Healthicare](https://thisglp.com/reviews/healthicare) [HealthOn](https://thisglp.com/reviews/healthon) [HealthSource](https://thisglp.com/reviews/healthsource) [HeliMeds](https://thisglp.com/reviews/helimeds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $87 the monthly rate or a prepay? It is the one-month plan, which the page has already selected. Three months is $225, or $75 a month. Is there a membership fee? The product card says there is none. The price-lock promise below it holds only while a membership stays active. Does the price rise with the dose? Mondae states it does not. No milligram is published, so nothing on the page lets a buyer check it. Is Mondae expensive compared with other GLP-1 telehealth sellers? Mondae publishes a starting figure of $87/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Mondae below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MultiMedRx reviews (2026): GLP-1 telehealth sellers | This GLP The single published figure is a refundable consultation fee, and the medication is billed elsewhere. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/multimedrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A consultation fee, not a price # MultiMedRx review The single published figure is a refundable consultation fee, and the medication is billed elsewhere. ## The verdict MultiMedRx publishes $100, and it is a fully refundable consultation fee. The visit buys a provider consultation, a GLP-1 prescription, insurance coverage paperwork and phone support. No medication price appears anywhere on the site. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Prescription Required Compounded No MultiMedRx routes patients toward branded GLP-1 products. Wegovy, Zepbound and Ozempic are named throughout. The prescription is filled and billed by a pharmacy elsewhere. 1. ## Who writes the prescription, and what do they see? A medical healthcare provider conducts the consultation the fee pays for. MultiMedRx does not name that provider or describe what the visit covers clinically. The stated output is a prescription and the paperwork to support an insurance claim. The service ends at the prescription. Everything after it is a pharmacy transaction this site does not price. The fee is stated to be refundable, which is unusual and worth having in writing. 2. ## What happens when the dose goes up? Nothing is published about dose. Because the drug is dispensed and billed elsewhere, a dose change is a pharmacy matter rather than a priced step here. No follow-up schedule is described. 3. ## What the price includes $100 is the entire published cost of dealing with MultiMedRx. What a buyer spends each month depends on a plan document and a pharmacy counter. Neither figure appears on these pages. A reader budgeting from $100 is budgeting for paperwork. 4. ## What it claims, and what it cites The products named are manufacturer-branded rather than compounded, so they are FDA-approved and dispensed as the approved product. What a pharmacy charges for them is not stated here. ## Where it holds up, and where it does not - Strength: The fee is stated to be fully refundable - Strength: What the visit buys is itemized - Strength: Insurance paperwork is part of the service - Strength: Branded products rather than compounded - Limitation: No medication price is published - Limitation: The monthly cost depends on a plan document - Limitation: No provider is named - Limitation: No dose or follow-up schedule is described ## What the evidence says about this kind of treatment The assessment above is about MultiMedRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An insured buyer who wants help getting a branded GLP-1 covered. Wrong for A cash buyer trying to price a month of medication before starting. ## The evidence behind what MultiMedRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How MultiMedRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Queen RX | Buyers content to commit a quarter at a time in one payment | | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HelloWellness](https://thisglp.com/reviews/hellowellness) [Henry Meds](https://thisglp.com/reviews/henry-meds) [Heros Health](https://thisglp.com/reviews/heros-health) [Hers](https://thisglp.com/reviews/hers) [Heva Health](https://thisglp.com/reviews/heva-health) [Hims](https://thisglp.com/reviews/hims) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is any medicine included in the $100? No. It is a refundable consultation fee covering the visit, the prescription and the insurance paperwork. The drug is billed separately by a pharmacy. How much is the drug itself? MultiMedRx does not say. The figure depends on a buyer's insurance plan and the pharmacy that fills the prescription. Are the medicines compounded? No. The products named are the branded ones, which are FDA-approved and dispensed as the approved product. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MyDrHank reviews (2026): GLP-1 telehealth sellers | This GLP Three compounded GLP-1 products, each blended with a second ingredient, and a starting monthly figure on every one with no plan length printed beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mydrhank Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Blended formulas, term unstated # MyDrHank review Three compounded GLP-1 products, each blended with a second ingredient, and a starting monthly figure on every one with no plan length printed beside it. ## The verdict MyDrHank sells compounded tirzepatide from $240 a month, a compounded semaglutide injection from $178 and a daily semaglutide tablet from $171. Each figure is printed as a starting price, and none of the three product pages names the dose it buys or how long a plan has to run to get it. The consultation and the delivery are both advertised as free, which takes two common charges off the table before the first month begins. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $178/mo Oral From $171/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider MyDrHank is a telehealth platform covering weight, sexual health, hair loss and longevity. Its weight-loss shelf holds three compounded GLP-1 products: a weekly tirzepatide injection, a weekly semaglutide injection and a daily semaglutide tablet. The injections come in two versions, one compounded with vitamin B-12 and one with the amino acid glycine, and the product pages say both carry the same active ingredient at the same dose. The tablet is compounded with a low dose of ondansetron, an anti-nausea drug, which the seller says is there to help patients stay on therapy through the early weeks. The site says it has treated more than 10,000 patients. 1. ## Who writes the prescription, and what do they see? A U.S.-licensed clinician reads an online questionnaire of roughly five minutes and writes a prescription only when it is judged appropriate. The terms add that providers hold licenses in the states where they treat, and that a completed intake may still end without any prescription at all. No clinician is named on the weight-loss pages. The terms also state that using the service does not create a provider-patient relationship with the platform itself, which places MyDrHank as the company that arranges the visit rather than the one practicing medicine. The intake lays out three stages, from creating an account to a physician's review to a shipment at the door. After that, the homepage promises check-ins, dose adjustments and unlimited messaging with a care team for as long as treatment lasts. Refills and what the reorder page calls subscription changes go through that team by email or phone, with a reply promised within one business day. Nothing in the terms of use covers how a plan renews, how it is canceled, or whether a shipped order can be refunded, so those answers have to come from the care team before the first charge. 2. ## What happens when the dose goes up? The semaglutide page sketches the first half-year as a timeline, calling months two through five the dose-escalation phase and saying the provider reviews and adjusts the dose in weeks eight through sixteen. The tablet page says most patients have reached a maintenance dose somewhere between weeks eight and twelve. The ondansetron in the tablet is the one part of the plan built for those weeks, since the seller names [nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) as the most common side effect early on. What none of the three pages says is whether the starting figure holds as the dose climbs, because no milligram amount is printed beside any price. 3. ## What the price includes The three figures, $240 for tirzepatide, $178 for the semaglutide injection and $171 for the tablet, are each introduced with the word From and a per-month sign. The B-12 and glycine versions of each injection show the same amount. No plan length, [dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) or month-two price sits beside them, so the public pages leave open whether the starting figure is a month-to-month rate or one tied to a longer plan. The homepage places the words No commitment next to the button that opens the questionnaire. No insurance is required, the consultation is advertised as free, and the product pages say shipping is included. 4. ## What it claims, and what it cites All three GLP-1 products are compounded, and the site's own footer says compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality. The product pages say they are prepared in FDA-registered U.S. pharmacies, but none is named. The terms say a current list of pharmacy partners is available on request, and they warn that orders do not come in child-resistant packaging. The weight-loss calculators project results from trials of the branded drugs, and the footnotes beneath them say results with the compounded versions may differ. ## Where it holds up, and where it does not - Strength: Free consultation and free delivery advertised - Strength: Two injection formulas at one price - Strength: Anti-nausea drug compounded into the tablet - Strength: LegitScript seal displayed on the site - Limitation: Every price is a From figure with no term - Limitation: No dose printed beside any price - Limitation: Pharmacy partners named only on request - Limitation: No renewal, cancellation or refund terms published ## What the evidence says about this kind of treatment The assessment above is about MyDrHank. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who expects nausea to be the hard part of the first months, wants a tablet built around that, and is prepared to ask about the plan length before paying. Wrong for A reader who wants the month-two price, the plan length and the name of the pharmacy settled before starting an account. ## The evidence behind what MyDrHank prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MyDrHank compares | Seller | Who it suits | Go | | --- | --- | --- | | Revel Health | A reader who wants an oral and expects to pay less for it, which on this seller is what happens. | | | Luci | Readers who take an asterisk seriously and plan to ask what it hides | | | TrimRx | Readers who already know which molecule they want and will hunt for which tile holds it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Idgie Health](https://thisglp.com/reviews/idgie-health) [Immortals](https://thisglp.com/reviews/immortals) [Independent Wellness](https://thisglp.com/reviews/independent-wellness) [Injectco](https://thisglp.com/reviews/injectco) [InstaRX](https://thisglp.com/reviews/instarx) [Intimate Rose](https://thisglp.com/reviews/intimate-rose) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Do the B-12 and glycine versions cost the same? Yes. Both versions of the tirzepatide injection show a starting figure of $240 a month, both semaglutide versions show $178, and the pages say each pair carries the same active ingredient at the same dose. How long does a plan run at the starting price? The product pages do not say. Each figure reads From, per month, with no plan length, dose or later-month rate printed beside it. Which pharmacy fills the prescription? None is named on the site. The product pages describe an FDA-registered U.S. pharmacy, and the terms say a current list of pharmacy partners is available on request. Is MyDrHank expensive compared with other GLP-1 telehealth sellers? MyDrHank publishes a starting figure of $171/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MyDrHank below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MyFastRx reviews (2026): GLP-1 telehealth sellers | This GLP An introductory first month sits on top of each product page, and the rate for every month after it is printed on the same card. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/myfastrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Second month printed up front # MyFastRx review An introductory first month sits on top of each product page, and the rate for every month after it is printed on the same card. ## The verdict MyFastRx charges $139 a month for compounded semaglutide and $199 for compounded tirzepatide once the first month is over. Both pages lead with a cheaper introductory figure, but they say in the same line what the second month costs, which spares a buyer the surprise that usually arrives with the second charge. The price is also stated to stay flat at every dose, so the months of titration should not move it either. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $139/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named MyFastRx is a cash-pay telehealth service selling compounded semaglutide and compounded tirzepatide as weekly injections, with an NAD+ line alongside them. Each molecule has its own product page carrying the introductory month, the standing rate and three prepaid terms in a single row of cards. Insurance is not accepted, and the price is described as including the provider review, the medication and express shipping. 1. ## Who writes the prescription, and what do they see? A short online intake goes to a licensed U.S. provider, who the site says reviews it within 24 hours and prescribes only when treatment is medically appropriate. The consultation is described as always included at no extra charge. No clinician, medical group or medical director is named on either product page, and what the provider sees beyond the intake answers is not described. The pages promise unlimited access to the clinical team for dosage adjustments and questions, and name that support as free. Medication ships from a U.S.-licensed pharmacy in unmarked packaging, usually Monday through Thursday so a cold package does not sit over a weekend. The introductory card says there is no subscription or automatic billing, and the footer adds that a patient cancels before the next shipment. 2. ## What happens when the dose goes up? The seller's answer to the fourth-month question is written in plain terms: the price does not change from the first week to the sixth month and after, and there are no dosage upcharges. Its FAQ adds that a provider reviews progress before any dose change and that an approved change costs nothing extra. How often that review happens, and what a patient reports into it, is not stated, which leaves the clinical half of each step unexplained. 3. ## What the price includes Semaglutide opens at $69 for a new customer's first month with code MY70, and the same card says the rate becomes $139 a month after that. Three months prepaid is $297, six is $534 and twelve is $948, and the page prints each as a monthly equivalent of $99, $89 and $79 beside the upfront total. Tirzepatide follows the same pattern, opening at $129 and then $199 a month, with $498, $894 and $1,488 for the three prepaid terms. 4. ## What it claims, and what it cites Both lines are compounded, and each product page marks them as not FDA-approved. The site says it does not manufacture medication and that prescriptions are filled by U.S.-licensed pharmacies, none of which is named. A compounded preparation is not reviewed by the FDA before it is dispensed. ## Where it holds up, and where it does not - Strength: Standing rate printed beside the intro month - Strength: Price stated as flat at every dose - Strength: Dose changes stated to cost nothing extra - Strength: Each prepaid term shows its full upfront charge - Limitation: The headline figure covers one month only - Limitation: No prescriber or medical group is named - Limitation: The dispensing pharmacy is not named - Limitation: A year of tirzepatide costs $1,488 at once ## What the evidence says about this kind of treatment The assessment above is about MyFastRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to know what the second month costs before starting the first. Wrong for A buyer who reads the introductory figure as the ongoing monthly price. ## The evidence behind what MyFastRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MyFastRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Voxy | Readers who want check-ins included and will pick a cadence deliberately | | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Intimate Rose](https://thisglp.com/reviews/intimate-rose) [Invigor Medical](https://thisglp.com/reviews/invigor-medical) [Invyncible](https://thisglp.com/reviews/invyncible) [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) [iThriveMD](https://thisglp.com/reviews/ithrivemd) [Ivim Health](https://thisglp.com/reviews/ivim-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $69 the monthly price for semaglutide? Only for a new customer's first month with code MY70. The same card says the rate is $139 a month after that. Does the price change when the dose goes up? No, on the seller's wording. The page rules out dosage upcharges and says an approved dose change costs nothing extra. How are the longer plans billed? In full at the start. Semaglutide is $297 for three months, $534 for six and $948 for twelve, and tirzepatide is $498, $894 and $1,488. Is MyFastRx expensive compared with other GLP-1 telehealth sellers? MyFastRx publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MyFastRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RNK Health reviews (2026): GLP-1 telehealth sellers | This GLP The headline rate carries a $50 coupon that the seller's own data applies once. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/myrnk Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Coupon price, then the regular rate # RNK Health review The headline rate carries a $50 coupon that the seller's own data applies once. ## The verdict RNK Health's landing page lists semaglutide at $197 a month and tirzepatide at $297, both compounded. Its product data sets the regular prices at $247 and $347. The $50 difference is a coupon that its own records say applies once. The regular rate is the figure to budget from. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $247/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named RNK Health is a cash-pay telehealth brand. Its weight-loss line is compounded semaglutide and compounded tirzepatide by injection. NAD+, sermorelin, B12, naltrexone, enclomiphene and a DNA panel share the catalog. The terms name RNK Health LLC as the operator. 1. ## Who writes the prescription, and what do they see? Prescribing sits with outside professional entities named in the terms. They include OpenLoop Healthcare Partners and its state affiliates, and Reliant MD Medical Associates. The consent form states that a provider may be a nurse practitioner or physician assistant. The product page describes a US clinician approving the plan online after a short quiz. What the quiz asks is not published. The monthly price is described as covering the medication supply, the consultation and prescription, syringes and wipes, and shipping. Cancellation is stated as open at any time. The refund policy is narrower than that line suggests. Once the intake form is submitted, the fee is non-refundable except for medical disqualification or a damaged or incorrect delivery. 2. ## What happens when the dose goes up? The product pages print one price per drug and no milligram strength. Whether the price changes as the dose rises is not stated. The FAQ says pricing depends on the selected plan and medication, with full details shown during checkout. Any multi-month option sits behind that step, and none is published before it. 3. ## What the price includes The landing and product pages show $197 for semaglutide and $297 for tirzepatide. The seller's product feed gives $247 and $347 as the regular prices for the same injections. Each carries a coupon named '$50 off once', and each landing figure equals the regular price minus that coupon. On that data, month two costs $247 or $347. 4. ## What it claims, and what it cites Both GLP-1 lines are described as compounded in the United States. The telehealth consent states that the FDA does not approve or review compounded products for safety, effectiveness or quality. A dispensing pharmacy's address in Springville, Utah, is printed in the footer. The pharmacy itself is not named. ## Where it holds up, and where it does not - Strength: Supplies and shipping sit inside the stated price - Strength: The prescribing entities are named in the terms - Strength: Compounded status is stated in the consent form - Strength: Cancellation is stated as open at any time - Limitation: The headline figure includes a one-time coupon - Limitation: Fees are non-refundable once the intake is submitted - Limitation: No milligram strength is printed - Limitation: The pharmacy is identified by address only ## What the evidence says about this kind of treatment The assessment above is about RNK Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who budgets from the regular rate and wants supplies bundled into it. Wrong for A reader who expects the landing figure to recur, or who wants a refund window after intake. ## The evidence behind what RNK Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RNK Health compares | Seller | Who it suits | Go | | --- | --- | --- | | MEDVi | Readers who want the injected line, where the card figure is the medicine's figure | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ivy Rx](https://thisglp.com/reviews/ivy-rx) [Jently](https://thisglp.com/reviews/jently) [Joey Med](https://thisglp.com/reviews/joey-med) [Joi + Blokes](https://thisglp.com/reviews/joi-and-blokes) [JRNYS](https://thisglp.com/reviews/jrnys) [JumpstartMD](https://thisglp.com/reviews/jumpstartmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Will the price stay at $197? The seller's own product data sets the regular semaglutide price at $247, with a $50 coupon named as applying once. Tirzepatide follows the same pattern, $297 against $347. Who is the prescriber? A provider from an outside professional entity named in the terms, such as OpenLoop Healthcare Partners. That provider may be a nurse practitioner or physician assistant. Can I get a refund after starting? Only in narrow cases. The policy allows one for medical disqualification, and a replacement for a damaged or incorrect delivery. Is RNK Health expensive compared with other GLP-1 telehealth sellers? RNK Health publishes a starting figure of $247/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RNK Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # MyStart Health reviews (2026): GLP-1 telehealth sellers | This GLP The price is guaranteed never to rise, and the month it applies to is four weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/mystart-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Frozen rate, four-week month # MyStart Health review The price is guaranteed never to rise, and the month it applies to is four weeks. ## The verdict MyStart Health charges a flat $299 for either molecule and promises the figure will never rise, even as the dose does. The monthly plan ships a four-week supply, and thirteen of those fit inside a year. That makes a calendar month $324. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $324/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Included MyStart Health is a platform that connects patients to independent providers and pharmacies for compounded GLP-1 treatment. Semaglutide and tirzepatide are both offered. One program price covers either. 1. ## Who writes the prescription, and what do they see? A licensed clinician reviews the intake quiz and either writes the prescription or books a video visit, usually within a day. Payment is taken after the quiz and before that clinical review. A patient deemed ineligible is refunded. One all-inclusive program covers consultations, unlimited clinician access, medication, bloodwork and shipping. Monthly plans auto-bill and auto-ship each month. A three-month plan ships its whole supply at once. 2. ## What happens when the dose goes up? The rate is stated as never increasing from the base plan amount, even if the dose rises in later months. That is an unusually firm commitment in this category. Dose changes can be discussed with a clinician at no extra charge. 3. ## What the price includes The program starts at $299 a month before discounts, and the FAQ describes the monthly shipment as a four-week supply. Thirteen four-week shipments land in a calendar year, so the program costs $324 a month. Per-plan pricing beyond the starting figure is gated behind the intake quiz. 4. ## What it claims, and what it cites The GLP-1 lines are compounded rather than manufactured, prepared in US facilities described as meeting USP standards. The FDA does not review a compounded preparation before it is dispensed. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The rate is guaranteed not to rise with the dose - Strength: Bloodwork, shipping and unlimited clinician access included - Strength: Same figure for either molecule - Strength: A refund is promised if a provider declines - Limitation: A shipped order cannot be refunded under any circumstance - Limitation: The hero says no membership fees and the refund policy calls it a membership - Limitation: Payment is taken before the clinical review - Limitation: Plan-level pricing appears only after the quiz ## What the evidence says about this kind of treatment The assessment above is about MyStart Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who expects to titrate high and wants the rate frozen first. Wrong for A buyer who needs to be able to send a shipment back. ## The evidence behind what MyStart Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How MyStart Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Welling Health | Buyers who want bloodwork read by the prescriber and are comparing the medication line separately from the fee | | | Nu Image Medical | Buyers comparing the injectable and the dissolving tablet who will read which card a figure sits on | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [June Health](https://thisglp.com/reviews/june-health) [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) [Jyra Health](https://thisglp.com/reviews/jyra-health) [KERNX Health](https://thisglp.com/reviews/kernx-health) [Kin Meds](https://thisglp.com/reviews/kin-meds) [Kina](https://thisglp.com/reviews/kina) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $299 a calendar month? The monthly plan ships a four-week supply rather than a calendar one. Thirteen of those fall inside a year, which is $324 a month. Does the price rise as the dose does? MyStart states it does not. The price of medication and ongoing care is described as never increasing from the base plan amount. Is there a membership fee? The homepage says there is none. The refund policy describes the same charge as a membership fee and refuses refunds for partially completed membership periods. Is MyStart Health expensive compared with other GLP-1 telehealth sellers? MyStart Health publishes a starting figure of $324/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MyStart Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Näky reviews (2026): GLP-1 telehealth sellers | This GLP The rate on each injection card is the six-month plan, not the monthly one. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/naky Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A panel hides the monthly # Näky review The rate on each injection card is the six-month plan, not the monthly one. ## The verdict Näky's compounded semaglutide and tirzepatide cards both advertise a rate a buyer reaches only by paying for six months at once. The month-to-month figures of $185 and $295 sit inside a pricing panel that stays shut until you open it. The daily drops are the honest exception, because $145 is the only plan they have. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $185/mo Oral From $145/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Näky sells compounded semaglutide and compounded tirzepatide as weekly injections, a daily semaglutide drop taken under the tongue, and a branded oral semaglutide pill, with a separate microdosing line and a longevity line running NAD+ and sermorelin alongside them. The trading entity names itself on the product pages and states that it is not affiliated with the manufacturer whose brands it references. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the free medical intake before anything is charged, and the site is explicit that a patient pays only if a prescription is written. Someone arriving already on a GLP-1 is asked for their current dose during intake, so the provider can continue it rather than start them over. Most sellers leave that to a support ticket after the first vial has already arrived. Each injection is sold as a one, three or six month plan, and the longer the plan the lower the monthly figure, with the six-month rate being the one the card advertises. The drops are sold monthly and only monthly. Shipping is free and stated as two-day, the pharmacies are described as United States based and FDA-regulated rather than named, and the trust bar running across every page promises the same price at every dose. 2. ## What happens when the dose goes up? Näky states that the price holds at every dose, so the ladder itself costs nothing extra, and a new patient is started on a low dose to ease the first weeks. A transferring patient keeps their existing dose rather than dropping back to the bottom. What the site does not publish is a milligram figure against any plan, or who signs off on the step from one dose to the next. 3. ## What the price includes The semaglutide injection is $185 a month and the tirzepatide injection is $295, and neither number appears on the card a reader lands on. Both sit behind a collapsed panel headed Pricing Details, while the card above it quotes the six-month rate. Three-month plans sit between the two, and the daily drops carry one plan at $145 with no ladder behind it, which means the drops and the six-month injection rung meet at the same figure from opposite directions. 4. ## What it claims, and what it cites Both injections are compounded rather than manufactured, and the page states that compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not FDA-approved and that the agency does not evaluate compounded products for safety, effectiveness or quality. A branded oral pill is sold alongside them. No compounding pharmacy is named anywhere on the site. ## Where it holds up, and where it does not - Strength: The whole plan ladder is published, once the panel is opened - Strength: One price at every dose is stated across the site - Strength: A transferring patient keeps their current dose - Strength: Nothing is charged unless a prescription is written - Strength: Free two-day shipping is included - Limitation: Each injection card quotes the six-month rate as its headline - Limitation: The month-to-month figures sit inside a collapsed panel - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published against any plan ## What the evidence says about this kind of treatment The assessment above is about Näky. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who opens the pricing panel before deciding what a headline rate means. Wrong for A buyer who wants the month-to-month figure on the first screen they see. ## The evidence behind what Näky prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Näky compares | Seller | Who it suits | Go | | --- | --- | --- | | SnagRx | Buyers who want to stay month to month without paying much for it | | | HealthRX | Buyers who expect to escalate and want the later months priced | | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LaSara Medical Group](https://thisglp.com/reviews/lasara) [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) [Layla](https://thisglp.com/reviews/layla) [Lean Meds](https://thisglp.com/reviews/leanmeds) [Lean Rx](https://thisglp.com/reviews/lean-rx) [LeanDose](https://thisglp.com/reviews/leandose) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $145 a month what a new semaglutide patient pays? Only on the six-month plan. The one-month supply is $185, and the three-month plan sits between the two. Do the drops have a multi-month discount? No. The oral semaglutide drops are sold as a single one-month plan at $145, with no longer term offered. Does the price rise as the dose goes up? Näky states the same price applies at every dose, and repeats that promise in the bar running across every page. Is Näky expensive compared with other GLP-1 telehealth sellers? Näky publishes a starting figure of $145/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Näky below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NativeMed reviews (2026): GLP-1 telehealth sellers | This GLP Two compounded injections, priced monthly, with a three-month plan that costs the same per month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nativemed Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A prepay that saves nothing # NativeMed review Two compounded injections, priced monthly, with a three-month plan that costs the same per month. ## The verdict NativeMed charges $149 a month for compounded semaglutide and $183 for compounded tirzepatide. Both product pages also offer a three-month plan. It is $447 and $549, which is three months at the monthly rate exactly. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named NativeMed sells two compounded weekly injections. There is a longevity line as well. Weight loss is the front door. Each drug has its own page and its own price. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the intake and decides whether treatment is appropriate. The dose is set after that review. What the intake asks is not published. No clinician, medical group or medical director is named. One questionnaire, one review, then shipping. Orders ship within one to three business days once the pharmacy processes them. In-person appointments are offered as an alternative to the questionnaire. Insurance is not billed. HSA and FSA cards may be accepted. 2. ## What happens when the dose goes up? The rate is stated to hold at any dose. That answers half the question. The other half is unanswered: no milligram appears on either page, and the escalation schedule is left entirely to the provider. 3. ## What the price includes Semaglutide is $149 a month, tirzepatide $183. The prepay is the finding. Three months of semaglutide is $447 and three of tirzepatide is $549. Divide either by three and the monthly rate comes back unchanged. A prepay usually buys a discount. This one buys a larger charge today. 4. ## What it claims, and what it cites Both lines are compounded and neither is FDA-approved. The FDA does not review compounded preparations before they are dispensed. NativeMed states its own limits plainly: it does not manufacture medications, practice medicine or decide what is appropriate. The pharmacies are described by license, not by name. ## Where it holds up, and where it does not - Strength: Both rates published before any intake - Strength: Rate stated to hold at any dose - Strength: Shipping free where a prescription is written - Strength: The prepay total is printed, so the arithmetic is visible - Limitation: The three-month plan carries no discount - Limitation: No milligram is published on either page - Limitation: The compounding pharmacy is not named - Limitation: No clinician or medical group is named ## What the evidence says about this kind of treatment The assessment above is about NativeMed. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a flat monthly rate and no reason to prepay. Wrong for A buyer looking for a multi-month discount, because there is not one here. ## The evidence behind what NativeMed prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NativeMed compares | Seller | Who it suits | Go | | --- | --- | --- | | Omzo | Buyers who want the medication cost inside one fee rather than billed by a pharmacy | | | Mondae | Buyers who want a low published compounded rate and few other details | | | LumiMeds | Buyers who want the ingredient, route and pharmacy type labeled before they pay | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lean Meds](https://thisglp.com/reviews/leanmeds) [Lean Rx](https://thisglp.com/reviews/lean-rx) [LeanDose](https://thisglp.com/reviews/leandose) [Lemonaid Health](https://thisglp.com/reviews/lemonaid-health) [LevelsRx](https://thisglp.com/reviews/levelsrx) [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the three-month plan cost less per month? No. It is $447 for semaglutide and $549 for tirzepatide, which is three months at $149 and $183. Does the price rise as the dose rises? NativeMed states the rate is the same at any dose. No milligram is published to check it against. Is the pharmacy named? No. Fulfillment is described as licensed United States compounding pharmacies, without naming one. Is NativeMed expensive compared with other GLP-1 telehealth sellers? NativeMed publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NativeMed below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Navio MD reviews (2026): GLP-1 telehealth sellers | This GLP Two tirzepatide figures, one compounded and one branded. Both are floors, and the dose that earns either is never named. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/navio-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Tiered, with no tiers shown # Navio MD review Two tirzepatide figures, one compounded and one branded. Both are floors, and the dose that earns either is never named. ## The verdict Navio MD publishes tirzepatide from $189 compounded and from $445 branded. Both are stated as tiered by dose. Coverage is 48 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 48 From From $189/mo Prescription Required Compounded Yes — not FDA-approved Availability 48 states Navio MD sells compounded tirzepatide and a branded tirzepatide pen. Both carry a floor price. This site publishes no semaglutide figure for Navio MD. 1. ## Who writes the prescription, and what do they see? A prescription is issued before dispensing. The pages price products rather than describing care. Naming the mechanism is useful. Leaving the thresholds unpublished undoes most of the benefit of having named it. 2. ## What happens when the dose goes up? The seller states the price is tiered by dose. It does not state the tiers. That is half a disclosure and the half that cannot be planned against. 3. ## What the price includes Six months from $189 is $1,134, and only at whatever dose earns the floor. The branded line starts at $445, or $2,670 over the same period. Neither figure states which milligram it belongs to. 4. ## What it claims, and what it cites One line is compounded and one is a manufactured pen. A compounded preparation is not reviewed by the FDA before it is dispensed. The two are not interchangeable on price or on regulation. ## Where it holds up, and where it does not - Strength: Says plainly that the price is tiered - Strength: Coverage in 48 states - Strength: Compounded and branded priced separately - Limitation: The tiers themselves are not published - Limitation: Both figures are a floor - Limitation: Neither floor says which dose earns it - Limitation: The compounding pharmacy goes unnamed ## What the evidence says about this kind of treatment The assessment above is about Navio MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the branded and compounded routes priced side by side. Wrong for A reader who needs to know which dose each floor figure applies to. ## The evidence behind what Navio MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Navio MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Tru2u | Readers who want a flat rate and will ask what the combined product contains | | | TrimRx | Readers who already know which molecule they want and will hunt for which tile holds it | | | NowPatient | Readers who want a named manufactured product and will read the buy box first | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Levers Health](https://thisglp.com/reviews/levers-health) [Liberty](https://thisglp.com/reviews/liberty) [LifeMD](https://thisglp.com/reviews/lifemd) [LifeRx.md](https://thisglp.com/reviews/liferx) [LifespanningRx](https://thisglp.com/reviews/lifespanningrx) [LillyDirect Foundayo](https://thisglp.com/reviews/lillydirect-foundayo) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does tirzepatide cost here? From $189 compounded, or from $445 branded. Both are floors tiered by dose. Which dose gets $189? The tiers are not published. Does Navio MD sell semaglutide? This site publishes no semaglutide figure for it. There is no product page, price or dose menu for either the compounded or the branded version. Is Navio MD legit? Navio MD is a GLP-1 telehealth sellers service. Its stated availability: 48 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Navio MD expensive compared with other GLP-1 telehealth sellers? Navio MD publishes a starting figure of $189/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Navio MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Neo Soma Healthcare reviews (2026): GLP-1 telehealth sellers | This GLP A Texas clinic that publishes its full semaglutide dose ladder, names its compounding pharmacy, and prices refills by dose band. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/neo-soma-healthcare Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Texas only, ladder published # Neo Soma Healthcare review A Texas clinic that publishes its full semaglutide dose ladder, names its compounding pharmacy, and prices refills by dose band. ## The verdict Neo Soma charges $199 for each four-week refill of compounded semaglutide up to 1 mg a week, after a $99 first fill. That is $215.58 a calendar month. From 1.5 mg the refill is $299. Tirzepatide has no single monthly figure: a $330 first purchase, then refills of $495 to $680 by dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $215.58/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability Texas only Neo Soma Healthcare is a clinic in Leander, Texas that sells weight-loss, sexual-health and anti-aging prescriptions online. Its weight-loss line is compounded semaglutide and compounded tirzepatide, both injected weekly. The FAQ adds liraglutide to the list its providers may prescribe. Service is limited to Texas, according to the same FAQ. 1. ## Who writes the prescription, and what do they see? The site names its chief medical director, Dr. Stephen Bunker, an Austin physician it says graduated from Creighton in 1976. The refill page prints the doctor's name and a license number beside each dose band. Each product popup says the prescription is reviewed and written by an on-staff physician. No video visit is described at any stage. The order runs in four stated steps: payment, a short questionnaire, prescriber review, then shipping. The site says the whole process takes under 20 minutes. Stated criteria are a BMI of 30 or more, age 18 or over, and blood pressure under 170/100. Semaglutide ships by FedEx Express on Mondays and Wednesdays. Tirzepatide ships from the pharmacy in three to five business days. Follow-up runs through unlimited messaging with the doctor. 2. ## What happens when the dose goes up? The FAQ prints the semaglutide ladder in full: 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 and 2.4 mg a week. Steps come at four- to six-week intervals, at the provider's discretion. A patient cannot ask to climb faster, or higher, than that protocol. The price changes once on the way up, from $199 to $299 per refill at 1.5 mg. Tirzepatide is listed from 2.5 mg to 15 mg a week, with each refill tier priced separately. 3. ## What the price includes Semaglutide costs $99 for the first four weeks and $199 per four-week refill through 1 mg. From 1.5 mg to 2.4 mg the refill is $299. Each purchase is four weeks of injections, so a year holds thirteen refills rather than twelve. Spread over a calendar month, the $199 refill is $215.58, and that is the figure ranked here. Tirzepatide is listed at $330 as an "Initial Purchase", and the site does not say that figure repeats. The FAQ says tirzepatide refills start at $495 every four weeks for the lowest dose. The refill page sells four- and six-week supplies, priced $495 to $680 by dose. Shipping is free on both drugs. 4. ## What it claims, and what it cites Both drugs are compounded, and the site's own disclaimer states that compounded medications are not FDA-approved. [Semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded with cyanocobalamin, a form of vitamin B12, which the FAQ says turns it pink. [Tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) carries glycine and B12. The FAQ names the compounding pharmacy as Strive Pharmacy in San Antonio. ## Where it holds up, and where it does not - Strength: Full semaglutide dose ladder printed in the FAQ - Strength: Compounding pharmacy named with its address - Strength: Chief medical director named on the site - Strength: Refill price stated for each semaglutide dose band - Limitation: Serves Texas residents only, per the FAQ - Limitation: Semaglutide refill rises to $299 at 1.5 mg - Limitation: No single monthly figure for tirzepatide - Limitation: Four-week refills mean thirteen charges a year ## What the evidence says about this kind of treatment The assessment above is about Neo Soma Healthcare. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Texas resident who wants the whole semaglutide dose ladder, and its prices, before paying. Wrong for Anyone outside Texas, or a buyer who needs one fixed monthly figure for tirzepatide. ## The evidence behind what Neo Soma Healthcare prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Neo Soma Healthcare compares | Seller | Who it suits | Go | | --- | --- | --- | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [50 Stars Health](https://thisglp.com/reviews/livv) [Longevixx](https://thisglp.com/reviews/longevixx) [Loop Health](https://thisglp.com/reviews/loop-health) [LovelyMeds](https://thisglp.com/reviews/lovelymeds) [Luci](https://thisglp.com/reviews/luci) [Luma Health Co](https://thisglp.com/reviews/luma-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Neo Soma's semaglutide $99 a month? Only for the first four weeks. After that each four-week refill is $199 through 1 mg a week, and $299 from 1.5 mg. What does tirzepatide cost at Neo Soma? The first purchase is listed at $330. Refills cost $495 to $680 depending on dose, sold as four- or six-week supplies, so no single monthly figure is published. Which states does Neo Soma serve? Texas only, according to its FAQ. Is Neo Soma Healthcare legit? Neo Soma Healthcare is a GLP-1 telehealth sellers service. Its stated availability: Texas only. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Neo Soma Healthcare expensive compared with other GLP-1 telehealth sellers? Neo Soma Healthcare publishes a starting figure of $215.58/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Neo Soma Healthcare above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NEUVÉ Health reviews (2026): GLP-1 telehealth sellers | This GLP Whether the medication is inside the program fee depends on which part of the page you read. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/neuve-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Site disagrees with itself # NEUVÉ Health review Whether the medication is inside the program fee depends on which part of the page you read. ## The verdict NEUVÉ Health publishes $179, $240 and $160 across three lines. Each is a program fee. On two of them the site contradicts itself about whether medication is included. On the third the fine print says it is billed separately. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose Prescription Required Compounded Yes — not FDA-approved NEUVÉ Health sells semaglutide and tirzepatide, injected and oral. Three lines carry a figure. All three are program fees rather than medication prices. 1. ## Who writes the prescription, and what do they see? The program fee is the route to a prescriber. The $240 tirzepatide line is described as the recommended plan at intake. What the clinician sees before recommending it is not published. A program fee is a defensible way to sell this. What is not defensible is a page that answers the inclusion question twice, differently. A reader cannot tell what they are buying, and the ambiguity sits on the largest component of the bill. 2. ## What happens when the dose goes up? NEUVÉ states pricing scales with the dose. No steps are published. On a line where the medication may or may not be included, a scaling fee raises a second unanswerable question. 3. ## What the price includes None of these figures is rankable as a price. Two carry a contradiction about what they cover. The third states the medication is billed separately, which makes it a fee rather than a cost. Ask which it is in writing before paying anything, and get the medication figure at the same time. 4. ## What it claims, and what it cites The lines are compounded. None is FDA-approved. No agency reviews them before dispensing. A page that is unclear about what is included is not a reason to assume anything about what is dispensed. ## Where it holds up, and where it does not - Strength: The recommended plan is identified at intake - Strength: Three lines carry a published figure - Strength: Fine print exists and states a position - Limitation: The site answers inclusion two ways - Limitation: No line states a medication cost - Limitation: Dose steps are not published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about NEUVÉ Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader prepared to get the inclusion question answered in writing first. Wrong for A reader who needs the pages to agree with themselves. ## The evidence behind what NEUVÉ Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NEUVÉ Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | NextMeds | A reader who wants one charge covering medication and care, at a rate stated to hold from the first order. | | | MEDGm | A reader who values the off-label disclosure and will find the drug price elsewhere | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Luma Health Co](https://thisglp.com/reviews/luma-health) [Luma Meds](https://thisglp.com/reviews/luma-meds) [Lumen Meds](https://thisglp.com/reviews/lumen-meds) [LumiMeds](https://thisglp.com/reviews/lumimeds) [Lumora](https://thisglp.com/reviews/lumora) [LunaRx](https://thisglp.com/reviews/lunarx-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the fee include the medication? The site says both. Two lines carry a contradiction, and the third states in fine print that medication is billed separately. What is the $240 line? A tirzepatide program fee described as the recommended plan at intake. Its fine print puts the medication outside it. Can a total be calculated? No. On no line is the medication cost published, so no figure here is a whole cost. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # New Wave Health reviews (2026): GLP-1 telehealth sellers | This GLP Two compounded injections from a Virginia Beach storefront, with no monthly price shown before an intake. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/new-wave-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced only after review # New Wave Health review Two compounded injections from a Virginia Beach storefront, with no monthly price shown before an intake. ## The verdict New Wave Health sells compounded semaglutide and tirzepatide as weekly injections, and neither treatment page prints a monthly price. Each reads "AVAILABLE BY CONSULTATION", and plans appear only after an intake that asks for a name. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named A concierge telehealth storefront offering semaglutide, tirzepatide, a GLP-1 microdose and NAD+. Its footer calls it a platform connecting patients with independent clinicians and state-licensed compounding pharmacies. The software underneath is shared with other GLP-1 storefronts trading under different names. 1. ## Who writes the prescription, and what do they see? Independent, U.S. board-certified providers make every prescribing decision, according to the footer, and the platform itself writes no prescriptions. No clinician or medical group is named on either treatment page. What the reviewing provider sees beyond the intake questionnaire is not stated. Six inclusions are listed: compounded medication, a dedicated provider, provider-directed dosing, portal messaging, structured check-ins and cold-chain delivery. The homepage says all 50 states are served, while the FAQ narrows that to Virginia and the states where its providers hold licenses. Cancellation needs 30 days' notice before the next billing cycle. 2. ## What happens when the dose goes up? The FAQ promises no dose-change surcharges, which is a claim about escalation with no base figure to escalate from. The product cards carry strength labels rather than a weekly schedule, and the steps are described only as provider-directed. 3. ## What the price includes No monthly figure appears on the semaglutide or tirzepatide page. The FAQ says pricing is reviewed with the patient before anything is charged. The eligibility flow reaches name fields before it shows a plan. Consultations and fulfilled prescriptions become non-refundable once services begin. 4. ## What it claims, and what it cites Both drugs are compounded by partner pharmacies in the United States, none of them named. The footer states that compounded medications are not FDA-approved, so no FDA review happens before one is dispensed. ## Where it holds up, and where it does not - Strength: No dose-change surcharge is promised - Strength: Cancellation terms are written in the FAQ - Strength: A street address and phone number are published - Strength: The compounding disclaimer is in the footer - Limitation: No monthly price appears before the intake - Limitation: The software is shared with other storefronts - Limitation: No pharmacy or clinician is named - Limitation: State coverage is described two ways ## What the evidence says about this kind of treatment The assessment above is about New Wave Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer willing to finish an intake before seeing a price, who wants a provider on a message thread. Wrong for A buyer comparing monthly figures before handing over a name. ## The evidence behind what New Wave Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How New Wave Health compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LunaRx](https://thisglp.com/reviews/lunarx-health) [LVNG RX](https://thisglp.com/reviews/lvng-rx) [Lyfe Rx](https://thisglp.com/reviews/lyfe-rx) [MadeMed](https://thisglp.com/reviews/mademed) [MANÜ Telehealth](https://thisglp.com/reviews/manu-telehealth) [Marek Health](https://thisglp.com/reviews/marek-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does New Wave Health charge per month? The treatment pages do not say. Each reads "AVAILABLE BY CONSULTATION", and the FAQ says pricing is reviewed with you before any charge. Is New Wave Health a stand-alone business? It trades under its own name from a Virginia Beach address, on software shared with other GLP-1 storefronts. That shared build is why several such sites look alike. Does a higher dose cost more? The FAQ says there are no dose-change surcharges, but with no base price published the promise has no figure attached yet. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NewSelf reviews (2026): GLP-1 telehealth sellers | This GLP Every milligram step is listed on the homepage, and the seller says each one costs the same. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/newself Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Doses listed, one price each # NewSelf review Every milligram step is listed on the homepage, and the seller says each one costs the same. ## The verdict NewSelf prices compounded semaglutide at $99.97 and compounded tirzepatide at $144.49, and states that the price does not change with the dose. Both figures are framed as starting prices. Which billing plan they belong to is not stated before the intake. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 49 From From $100/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named NewSelf is an online platform that connects buyers with independent providers and pharmacies. It describes itself as a technology company that does not provide medical or pharmacy services itself. Semaglutide comes with B12 or glycine, and tirzepatide with B6 or glycine. Both are weekly injections. 1. ## Who writes the prescription, and what do they see? After a short quiz, a board-certified doctor reviews the patient by telehealth, according to the homepage. More than 1,000 physicians are claimed across all 50 states. No individual prescriber or medical group is named. The site states that a buyer declined by the doctor receives a full refund. The listed steps are a quiz, a tele-doctor visit, next-day cold shipping and ongoing support. That support is described as AI assistance plus nurses. How often a clinician checks in after the first prescription is not stated. The homepage also offers three months of medication upfront. 2. ## What happens when the dose goes up? The homepage lists the doses: 0.25, 0.50, 1.0, 2 and 2.5 mg for semaglutide, and 2.5 to 15 mg for tirzepatide. Each molecule is stated to cost the same at every one of them. An asterisk adds that dosing may vary on a doctor's recommendation. How each step up is decided is not described. 3. ## What the price includes Semaglutide is $99.97 and tirzepatide is $144.49, a gap of about $44 a month. The homepage labels both as low as, monthly. The product pages print the same figures with no term attached. No membership fee is charged, by the seller's statement. 4. ## What it claims, and what it cites Both lines are compounded by licensed pharmacies, and the site says so beside the prices. Compounded drugs are not FDA-approved and are not evaluated by the FDA for safety or effectiveness. The pharmacies are described as tested and trusted but are not named. ## Where it holds up, and where it does not - Strength: Every milligram step is published - Strength: One price stated for all doses - Strength: No membership fee charged - Strength: Full refund stated if declined - Limitation: Billing plan behind the figure not stated - Limitation: No prescriber or medical group named - Limitation: The pharmacies are not named - Limitation: Follow-up schedule not described ## What the evidence says about this kind of treatment The assessment above is about NewSelf. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the milligram ladder and its price on one page before the intake. Wrong for A buyer who needs to know the billing term before starting the quiz. ## The evidence behind what NewSelf prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NewSelf compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Voxy | Readers who want check-ins included and will pick a cadence deliberately | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Marek Health](https://thisglp.com/reviews/marek-health) [Maves](https://thisglp.com/reviews/maves) [Maximus](https://thisglp.com/reviews/maximus-tribe) [MaxLife](https://thisglp.com/reviews/maxlife) [MDExam](https://thisglp.com/reviews/mdexam) [Measured](https://thisglp.com/reviews/measured) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price go up at a higher dose? Not by the seller's statement. Each molecule is listed at one price across every dose on the homepage. Is $99.97 a month-to-month price? The homepage calls it as low as, monthly. Which billing plan it belongs to is not stated before the intake. What weight loss does the seller report? The homepage gives an average of 34 lbs in one line and 36 lbs in the next. The population and follow-up period behind either figure are not stated. Is NewSelf expensive compared with other GLP-1 telehealth sellers? NewSelf publishes a starting figure of $100/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NewSelf below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nex Gen Health Rx reviews (2026): GLP-1 telehealth sellers | This GLP Four supply lengths on one selector, each with a strength and an upfront total beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nex-gen-health-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Totals printed per plan # Nex Gen Health Rx review Four supply lengths on one selector, each with a strength and an upfront total beside it. ## The verdict Nex Gen Health Rx charges $190 for a 30-day supply of compounded semaglutide. Tirzepatide is $239 on the same terms. Longer supplies are billed upfront as one total. The page states the cost does not change with the dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $190/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Nex Gen Health Rx is an online prescribing service with a wide catalog. Weight loss is one of six categories. It sells compounded semaglutide and compounded tirzepatide as weekly injections. Metformin is listed beside them. 1. ## Who writes the prescription, and what do they see? The FAQ describes an independent network of U.S. board-certified physicians and nurse practitioners. No individual clinician is named. A physician reviews the online intake before anything is prescribed. The patient also submits a photo ID and a picture of themselves. The card is charged only after a provider approves the prescription. The process has three steps: an online assessment, a physician review, then shipping if a prescription is written. A provider who needs more information messages the patient on the platform. Refills run automatically on the chosen cadence. Pausing or canceling is done from the account. 2. ## What happens when the dose goes up? The semaglutide page states a flat monthly rate while the dose is titrated. Each supply option still prints a strength beside it. The 90-day option reads 0.25 mg and the others read 0.5 mg. Every tirzepatide option reads 2.5 mg. The strength after the first supply is set by the provider. 3. ## What the price includes The 30-day supply is $190 for semaglutide and $239 for tirzepatide. Consultation and shipping are included. The 90-, 180- and 360-day semaglutide plans are billed upfront at $399, $714 and $1,188. The matching tirzepatide totals are $589, $1,074 and $1,788. Each longer plan also prints a larger figure labeled as savings. That figure is not a price. Unused months on a multi-month plan are refundable under the seller's policy. 4. ## What it claims, and what it cites Both molecules are compounded. The product page says they come from 503A pharmacies. Compounded medications are not FDA-approved, and the page says so. The FAQ answer on pharmacies names none. The footer address pairs the company name with Manifest Pharmacy in Greer, South Carolina. ## Where it holds up, and where it does not - Strength: Every plan total printed before checkout - Strength: Strength printed beside each supply option - Strength: Card charged only after approval - Strength: Unused plan months are refundable - Limitation: No individual prescriber is named - Limitation: Savings lines sit where prices usually sit - Limitation: Service states are not listed - Limitation: Pharmacy FAQ answer names no pharmacy ## What the evidence says about this kind of treatment The assessment above is about Nex Gen Health Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants each plan's upfront total before starting an intake. Wrong for A buyer who needs a named prescriber or a published list of states. ## The evidence behind what Nex Gen Health Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nex Gen Health Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MedLeanRx](https://thisglp.com/reviews/medleanrx) [Medro](https://thisglp.com/reviews/medro) [Medsol RX](https://thisglp.com/reviews/medsol-rx) [MEDVi](https://thisglp.com/reviews/medvi) [Metaboost Rx](https://thisglp.com/reviews/metaboost-rx) [Mevo Health](https://thisglp.com/reviews/mevo-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are the larger figures under each plan prices? No. They are labeled as savings. The semaglutide plan totals are $399, $714 and $1,188. When is the card charged? After a licensed provider reviews the intake and approves a prescription. An ineligible patient is not charged for medication. Does a dose increase raise the price? The product page states it does not. The rate is described as flat while the dose is titrated. Is Nex Gen Health Rx expensive compared with other GLP-1 telehealth sellers? Nex Gen Health Rx publishes a starting figure of $190/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Nex Gen Health Rx right at the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NexLife reviews (2026): GLP-1 telehealth sellers | This GLP The rate set in the largest type belongs to a year-long plan, and the asterisk beside it says so. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nexlife Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A year behind the headline # NexLife review The rate set in the largest type belongs to a year-long plan, and the asterisk beside it says so. ## The verdict NexLife leads with compounded semaglutide as low as $119, footnoted as a twelve-month rate. Starting without that commitment costs $139. Tirzepatide begins at $169. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $139/mo Prescription Required Compounded Yes — not FDA-approved LegitScript Claimed by provider NexLife sells both molecules by injection. It states LegitScript certification. Expedited shipping carries no charge. 1. ## Who writes the prescription, and what do they see? NexLife calls itself a patient management platform, with clinicians prescribing where that is clinically appropriate. No clinician is named. What they examine before writing is not set out. The gap between platform and prescriber is worth noticing before a first order. Each molecule has two rungs. The difference between them lives in a footnote rather than in a plan picker. Shipping is free and no membership sits beside either figure. 2. ## What happens when the dose goes up? Flat pricing at every dose is stated for both molecules, so climbing the ladder leaves the bill alone. Who signs off on a step, and how fast, is not published. Against four months of escalation, a fixed figure is the more useful half of that pair. 3. ## What the price includes A short plan costs $139 for semaglutide and $169 for tirzepatide. Reaching $119 or $139 takes a year of commitment. The gap is $20 a month on one molecule and $30 on the other. That gap is what the advertised figure costs in term length. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy NexLife does not identify. A compounded preparation is not reviewed by the FDA before it is dispensed. ## Where it holds up, and where it does not - Strength: The year-long condition sits in the footnote - Strength: A shorter plan is genuinely offered - Strength: One rate at every dose - Strength: LegitScript certification stated - Limitation: The advertised rate needs a full year - Limitation: Starting without that commitment costs more - Limitation: The compounding pharmacy goes unnamed - Limitation: No state coverage list is published ## What the evidence says about this kind of treatment The assessment above is about NexLife. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer settled on a year rather than testing a month. Wrong for A buyer unsure of lasting beyond a first quarter. ## The evidence behind what NexLife prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NexLife compares | Seller | Who it suits | Go | | --- | --- | --- | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | | RxPros | A reader able to fund a year at signing and collect deliveries by the quarter | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Mevo Health](https://thisglp.com/reviews/mevo-health) [Midi Health](https://thisglp.com/reviews/midi-health) [Mint Med](https://thisglp.com/reviews/mint-med) [Mint Medical Clinic](https://thisglp.com/reviews/mint-medical) [Mochi Health](https://thisglp.com/reviews/mochi-health) [Mojoon](https://thisglp.com/reviews/mojoon) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can a new buyer pay $119 straight away? Only by taking the twelve-month plan. Without it the semaglutide rate is $139. What does tirzepatide cost? $169 on the shorter plan, or $139 across twelve months. Does a higher dose cost more? No. NexLife states the rate is flat at every dose, so escalation leaves the bill unchanged. Is NexLife expensive compared with other GLP-1 telehealth sellers? NexLife publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NexLife below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Next Vial reviews (2026): care, dosing and costs | This GLP The selector opens on the twelve-month card, and the month-to-month rate sits at the top of the same ladder. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/next-vial Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Year preselected, month on top # Next Vial review The selector opens on the twelve-month card, and the month-to-month rate sits at the top of the same ladder. ## The verdict Next Vial prices compounded semaglutide at $199 for a month billed monthly, while the selector a buyer lands on has already chosen the twelve-month card at $99 a month, paid as $1,188 at once. Both numbers sit side by side on the product page, so the cost of declining a year's commitment is visible before a single medical question is asked. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 49 From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability 49 states Next Vial is a telehealth marketplace that sells compounded semaglutide and compounded tirzepatide as weekly injections, alongside a catalog that runs from hormone therapy and peptides to hair loss, cold sores and smoking cessation. Its footer describes the company as a platform connecting patients with independently licensed providers, and says it neither dispenses medication nor provides medical care itself. 1. ## Who writes the prescription, and what do they see? The FAQ names the clinician network plainly as MD Integrations, and it describes US-based physicians who review each questionnaire and reply within roughly a day of it being submitted. In certain states a video consultation or a live chat has to happen before a prescription is written. No individual physician is named anywhere on the site, and in most states the review rests on the written intake rather than a scheduled visit. A buyer chooses the medication and the plan length first, answers the medical questions second, and then uploads a photo with an ID, which the FAQ puts down to state rules on identifying patients. The card is billed when the medication ships, and the FAQ says a patient is contacted before each refill is charged, the ordinary courtesy that keeps an automatic renewal from arriving unannounced on a statement. 2. ## What happens when the dose goes up? Nothing on the product page prints a milligram beside any plan, so the dose a buyer starts on, and the doses that follow through the first four months of escalation, are left entirely to the provider. The page describes provider-personalized dosages at one all-in price without saying outright that a higher dose keeps the same figure. What the fifth month costs is a question to put to the provider before the first vial is opened. 3. ## What the price includes The semaglutide ladder runs from $199 billed monthly to $507 for three months, $894 for six and $1,188 for twelve, which work out to $169, $149 and $99 a month. Tirzepatide has its own ladder in the same selector once it is chosen, and no monthly membership fee is charged on either. A separate banner lower on the same page advertises plans at a monthly figure that matches no card in the selector above it. 4. ## What it claims, and what it cites Both lines are compounded, and the product page says so twice, adding that compounded medications are not FDA-approved and that the FDA has not verified their safety or effectiveness. The FAQ names the dispensing pharmacy as Manifest Pharmacy in Greer, South Carolina, with a phone number and weekday hours, which gives a buyer something concrete to check against a state pharmacy board before the first shipment arrives. ## Where it holds up, and where it does not - Strength: Clinician network named as MD Integrations - Strength: Dispensing pharmacy named with its address - Strength: Every rung printed with its upfront total - Strength: No monthly membership fee - Limitation: The default card is a twelve-month prepay - Limitation: No milligram dose printed beside any plan - Limitation: A banner figure matches no plan card - Limitation: No individual physician is named ## What the evidence says about this kind of treatment The assessment above is about Next Vial. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to see the full cost of each commitment length, and the name of the pharmacy, before answering a single medical question. Wrong for A buyer who wants a milligram schedule, and what each month of it will cost, laid out before signing up. ## The evidence behind what Next Vial prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Next Vial compares | Seller | Who it suits | Go | | --- | --- | --- | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MultiMedRx](https://thisglp.com/reviews/multimedrx) [MyFastRx](https://thisglp.com/reviews/myfastrx) [MyStart Health](https://thisglp.com/reviews/mystart-health) [Näky](https://thisglp.com/reviews/naky) [NativeMed](https://thisglp.com/reviews/nativemed) [Navio MD](https://thisglp.com/reviews/navio-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a month what semaglutide costs? Only on the twelve-month plan, which is paid as $1,188 up front; the same selector prices a single month at $199, billed monthly, with no commitment beyond that month. Who writes the prescription? A physician from MD Integrations, the network that the Next Vial FAQ names, and in some states a video consultation or live chat has to take place before that prescription is written. Where does Next Vial ship? The FAQ lists forty-nine states by name, leaving Alaska off that list and making no mention of the District of Columbia, so a buyer in either place should ask before starting an intake. Is Next Vial legit? Next Vial is a GLP-1 telehealth sellers service. Its stated availability: 49 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Next Vial expensive compared with other GLP-1 telehealth sellers? Next Vial publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Next Vial above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NextMeds reviews (2026): GLP-1 telehealth sellers | This GLP The membership here is the product rather than a fee charged beside one, and it bundles four services. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nextmeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The membership is the product # NextMeds review The membership here is the product rather than a fee charged beside one, and it bundles four services. ## The verdict NextMeds sells its GLP-1 treatment as a membership. The membership price is the whole price: $49 a month for compounded semaglutide and $119 for compounded tirzepatide. Telehealth visits, a care coach, a dietitian and shipping sit inside it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $49/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named NextMeds sells compounded semaglutide and compounded tirzepatide. Both are weekly injections. The rates read $49 and $119 a month. Each is sold as a membership. Coverage is published as fifty states. Both rates are described as the same at every dose. 1. ## Who writes the prescription, and what do they see? Telehealth visits are inside the membership price. So are a care coach and a dietitian. None of the three is billed separately. How often each is available is not published beside the price. A prescription is required before the first shipment. Care is arranged remotely. One charge covers medication, visits, coaching and shipping. A reader is not choosing between a low rate and clinician access. That choice is the common one in this market. Here the bundle is the product being sold. 2. ## What happens when the dose goes up? Both rates are stated as flat at every dose. An escalation does not move the charge. The first sixteen weeks are an escalation for most patients. The bundled visits are the stated route for a dose change. What a visit covers at that point is not published. 3. ## What the price includes $49 is the semaglutide membership rate. $119 is the tirzepatide rate. The gap is $70 a month. The site states the same price every month. That covers the first order and every order after. A rate that holds from the first order is not an intro rate. 4. ## What it claims, and what it cites Both products are compounded. A pharmacy prepares them. No regulator reviews the finished vial. A compounded preparation is not FDA-approved. The published trial results used the approved products at label doses. A compounded vial was not what those trials measured. ## Where it holds up, and where it does not - Strength: Membership price is the whole price - Strength: Visits, coaching and shipping bundled - Strength: Rate flat at every dose - Limitation: Both rates printed as starting figures - Limitation: Visit frequency not published - Limitation: Compounding pharmacy not named ## What the evidence says about this kind of treatment The assessment above is about NextMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one charge covering medication and care. Four services sit inside it. Wrong for A reader who wants medication alone at the lowest rate. The bundle is not separable. ## The evidence behind what NextMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NextMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | KERNX Health | A reader who wants the clinician charge stated as a number before intake, and a medication rate that holds at every dose. | | | Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NEUVÉ Health](https://thisglp.com/reviews/neuve-md) [New Wave Health](https://thisglp.com/reviews/new-wave-health) [NewSelf](https://thisglp.com/reviews/newself) [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) [NexLife](https://thisglp.com/reviews/nexlife) [Next Vial](https://thisglp.com/reviews/next-vial) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the membership charged on top of the medication? No. The membership is the product. $49 and $119 are the whole published figures, and telehealth visits, a care coach, a dietitian and shipping sit inside them. Is $49 an intro rate? No. The site states the same price every month, for the first order and every order after. Does the price rise with the dose? No. Both rates are described as the same at every dose, so an escalation leaves the charge where it started. Is NextMeds expensive compared with other GLP-1 telehealth sellers? NextMeds publishes a starting figure of $49/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NextMeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NiceRx reviews (2026): GLP-1 telehealth sellers | This GLP Each product card prints a discounted opening month and, on the same line, the monthly rate that replaces it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nicerx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Discount first, rate after # NiceRx review Each product card prints a discounted opening month and, on the same line, the monthly rate that replaces it. ## The verdict NiceRx charges $199 a month for compounded semaglutide and $299 for compounded tirzepatide, at every dose. The first month of each is discounted by $100. The card states the ongoing rate beside the discount rather than below the fold. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 46 From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 46 states NiceRx sells compounded semaglutide and compounded tirzepatide as weekly injections, plus microdose versions and a starter bundle. The wider catalog covers NAD+, sermorelin, glutathione and B12. Everything is ordered online, and insurance is not accepted. 1. ## Who writes the prescription, and what do they see? The FAQ says each patient is treated by a U.S.-licensed clinician licensed in the patient's own state. No clinician, medical group or medical director is named. The fine print calls the reviewer an independent licensed medical professional. The two-minute quiz is described as a pre-approval, and a provider consultation follows before any prescription. The monthly rate covers the initial provider visit, the medication, syringes and shipping. It also covers up to one follow-up visit a month, a limit the product pages state and the homepage omits. Delivery is quoted at three to five business days after approval. Cancellation is by email, and medication cannot be returned. 2. ## What happens when the dose goes up? The FAQ states the same price for all doses, so escalation does not move the charge. Dosing is described as starting low and rising gradually to a maintenance dose. The schedule is set by the provider after approval and is not published. Clinical contact at each step is bounded by the one monthly follow-up the plan includes. 3. ## What the price includes Both product pages lead with the discounted first month and state the following rate on the same line. From month two, semaglutide is $199 and tirzepatide $299, with no term to commit to. Six months of semaglutide at the ongoing rate comes to $1,194, before the first-month discount is taken off. 4. ## What it claims, and what it cites Both molecules come from state-licensed compounding pharmacies in the company's network, none of them named. The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is described as the base form, not a salt. Compounded preparations are not FDA-approved or reviewed for safety or effectiveness, which the site also states. A quality panel reports passed potency, sterility, pH and endotoxin tests, without naming a laboratory or a batch. ## Where it holds up, and where it does not - Strength: Ongoing rate printed beside the discount - Strength: Same price stated for all doses - Strength: Semaglutide described as the base form - Strength: Follow-up visit limit stated plainly - Limitation: No clinician or medical group named - Limitation: Compounding pharmacies are not named - Limitation: Cancellation only by email - Limitation: Four states are not served ## What the evidence says about this kind of treatment The assessment above is about NiceRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants one flat monthly figure per molecule, whatever the dose turns out to be. Wrong for A buyer in Alaska, Kansas, Mississippi or New Jersey, or one who wants a named prescriber. ## The evidence behind what NiceRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NiceRx compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Next Vial](https://thisglp.com/reviews/next-vial) [NextMeds](https://thisglp.com/reviews/nextmeds) [Nirwana Health](https://thisglp.com/reviews/nirwana-health) [NoBsRx](https://thisglp.com/reviews/no-bs-rx) [Nolu](https://thisglp.com/reviews/nolu) [Noom](https://thisglp.com/reviews/noom) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the first-month figure the real price? No. It is a one-time $100 discount. From the second month, semaglutide is $199 and tirzepatide is $299. How many follow-up visits are included? Up to one a month, according to the product pages. The initial provider visit is included as well. Which states are excluded? Alaska, Kansas, Mississippi and New Jersey. Residents there can join a waiting list. Is NiceRx legit? NiceRx is a GLP-1 telehealth sellers service. Its stated availability: 46 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is NiceRx expensive compared with other GLP-1 telehealth sellers? NiceRx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NiceRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nirwana Health reviews (2026): GLP-1 telehealth sellers | This GLP Each product page prints two price blocks, and one of them calls the monthly figure introductory. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nirwana-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two blocks, two readings # Nirwana Health review Each product page prints two price blocks, and one of them calls the monthly figure introductory. ## The verdict Nirwana Health sells compounded semaglutide and tirzepatide. Each product page carries two price blocks. The blocks disagree about the monthly figure. Neither page states what a subscription costs after month one. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $229/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Nirwana Health is a cash-pay telehealth storefront. Its catalog covers weight loss, hair, sexual health, testosterone and peptide therapies. Both GLP-1s come as a weekly injection or a daily tablet. Checkout runs on a separate patient platform. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews a short questionnaire. No clinician or medical group is named. The site does not describe what the provider reads beyond the questionnaire. Unlimited doctor chat is advertised in the header. The pricing block lists five inclusions: a consultation, a dosing plan, the medication, free shipping and unlimited check-ins. No membership is charged and no insurance is taken. The FAQ calls the one-month supply "great for getting started". 2. ## What happens when the dose goes up? No dose schedule is published. No milligram figure appears beside any price. The pages do not say whether a higher dose changes the rate. The FAQ says a provider may taper the dose when treatment stops. 3. ## What the price includes The semaglutide selector lists "Monthly Subscription" and "Cancel anytime" at $149. The pricing block below labels $149 an "Introductory rate". A three-month plan is $399, billed every three months. A one-time month is $199. On tirzepatide, the selector shows $229 month to month. Its pricing block shows $199 as introductory and $499 per quarter. A summer sale banner offers a $50 checkout code. No end date is shown. 4. ## What it claims, and what it cites Both drugs are compounded. The footer says Nirwana Health does not manufacture compounded medications and that treatments ship from US licensed pharmacies. No pharmacy is named. Compounded preparations are not FDA-approved. ## Where it holds up, and where it does not - Strength: A one-time single month is priced - Strength: The quarterly total is printed beside the rate - Strength: Injection and tablet forms are both listed - Strength: No membership fee is charged - Limitation: Two blocks give different monthly readings - Limitation: One block calls the monthly rate introductory - Limitation: No dose schedule is published - Limitation: No prescriber or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Nirwana Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who will confirm the second-month charge at checkout before subscribing. Wrong for A buyer who needs a settled monthly rate before starting. ## The evidence behind what Nirwana Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nirwana Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | Green Cap Health | Readers in Texas wanting the lowest published figures | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nova](https://thisglp.com/reviews/nova) [Nova MD](https://thisglp.com/reviews/nova-md) [Novi](https://thisglp.com/reviews/novi) [NovoCare Pharmacy](https://thisglp.com/reviews/novocare-pharmacy) [NowPatient](https://thisglp.com/reviews/nowpatient) [NP2GO](https://thisglp.com/reviews/np2go) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 the ongoing semaglutide price? The page does not settle it. The selector calls $149 a cancel-anytime subscription. The pricing block calls it an introductory rate. What does tirzepatide cost month to month? The selector shows $229. A separate block shows $199 as an introductory rate. Can one month be bought without subscribing? Yes. The semaglutide selector lists a one-time month at $199. Is Nirwana Health expensive compared with other GLP-1 telehealth sellers? Nirwana Health publishes a starting figure of $229/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Nirwana Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NoBsRx reviews (2026): GLP-1 telehealth sellers | This GLP Every program is named low-dose, and all three twelve-week blocks cost the same regardless of molecule. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/no-bs-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Low-dose programs, flat rate # NoBsRx review Every program is named low-dose, and all three twelve-week blocks cost the same regardless of molecule. ## The verdict NoBsRx publishes $140 a month for injectable semaglutide, $179 for the oral and $140 for injectable tirzepatide. Each program is labeled low-dose. All three twelve-week blocks are $409. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $179/mo Oral From $199/mo Prescription Required Compounded Yes — not FDA-approved NoBsRx sells both molecules, injected and oral, as named low-dose programs. Three lines carry a monthly figure. Each also carries a twelve-week price, and those are identical across the three. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages name the program rather than the clinician. What the intake asks is not published. The dose framing is stated, which is the rarer disclosure of the two. Calling the programs low-dose on the product itself is the notable act. It stops the rate reading as a standard starting dose. NoBsRx states the rate holds at every dose, which on a low-dose program is the claim worth confirming at intake. 2. ## What happens when the dose goes up? The rate is stated to hold. The programs are low-dose by name. A buyer moving to standard dosing is not covered by anything published. The pages do not say whether that move exists. 3. ## What the price includes $140 a month is the injectable figure on both molecules, which removes the usual tirzepatide premium entirely. The oral runs $179. The twelve-week block is $409 whichever program is chosen, so the block is priced by term rather than by molecule. That is an unusual structure and it is published rather than inferred. 4. ## What it claims, and what it cites Every line is compounded. None is FDA-approved. No agency reviews them before dispensing. A low-dose program is a smaller quantity of the same molecule, not a different one. ## Where it holds up, and where it does not - Strength: Every program is labeled low-dose - Strength: Tirzepatide carries no premium here - Strength: The twelve-week price is published too - Limitation: All programs are low-dose only - Limitation: No milligram figure is published - Limitation: Standard dosing is not addressed - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about NoBsRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a low-dose program named as one and priced the same either molecule. Wrong for A reader who expects to move to a standard dose. ## The evidence behind what NoBsRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NoBsRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | | | Good Girl Rx | A reader who will read the one-month rung rather than the headline, and wants microdoses labeled as such | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) [NuBloom](https://thisglp.com/reviews/nubloom) [Nucore Health](https://thisglp.com/reviews/nucore-health) [NuDay Rx](https://thisglp.com/reviews/nuday-rx) [NuuVim](https://thisglp.com/reviews/nuuvim) [NuviaRx](https://thisglp.com/reviews/nuviarx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does tirzepatide cost the same as semaglutide? NoBsRx prices both injectable programs at $140 a month. Most sellers charge a premium for tirzepatide; this one does not. What is a low-dose program? A smaller quantity of the same molecule. NoBsRx names all three programs that way rather than leaving the rate to read as a standard dose. Is twelve weeks cheaper? It is $409 on every program. That sits below three months of the oral at its monthly rate, and above three months of either injection. Is NoBsRx expensive compared with other GLP-1 telehealth sellers? NoBsRx publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NoBsRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nolu reviews (2026): GLP-1 telehealth sellers | This GLP Every line came down a month apart, and every line is labeled per four weeks by the seller itself. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nolu Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 All three fell, all per four weeks # Nolu review Every line came down a month apart, and every line is labeled per four weeks by the seller itself. ## The verdict Nolu publishes $199 per four weeks for injected semaglutide, $239 for the tablet and $279 for tirzepatide. Thirteen cycles a year make those $216, $259 and $302 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $216/mo Oral From $259/mo Prescription Required Compounded Yes — not FDA-approved Nolu sells both molecules by injection and semaglutide as a tablet. Every line is priced against a four-week cycle rather than a calendar month, and the pricing page says so. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state rates and cycles rather than describing who writes the prescription or how often a case is reviewed. Labeling the cycle honestly is the disclosure most sellers skip, and Nolu makes it on all three lines. The arithmetic is still left to the reader. 2. ## What happens when the dose goes up? The rates are recorded as flat across doses. A four-week cycle is the variable that moves instead, because thirteen of them arrive in a year rather than twelve. 3. ## What the price includes A year of injected semaglutide is $2,587 rather than the $2,388 twelve payments would suggest. The tablet is $3,107 and tirzepatide $3,627. All three figures fell — by $50, $40 and $60 — so any older quote is now high. 4. ## What it claims, and what it cites All three lines are compounded rather than manufactured. A pharmacy prepares them, and the FDA does not review a compounded preparation before dispensing. ## Where it holds up, and where it does not - Strength: The four-week cycle is labeled plainly - Strength: All three lines came down - Strength: Flat across doses on every line - Strength: A tablet route is priced separately - Limitation: Thirteen cycles a year, not twelve - Limitation: Each figure reads about 8% low - Limitation: No milligram published on any line - Limitation: The states served are not recorded ## What the evidence says about this kind of treatment The assessment above is about Nolu. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who counts cycles rather than months and wants a flat rate at any dose. Wrong for A reader comparing $199 against another seller's calendar-month figure. ## The evidence behind what Nolu prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nolu compares | Seller | Who it suits | Go | | --- | --- | --- | | Roboclinic | Readers ready to commit a full year and wanting the discount that buys | | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | Try Ageless | Readers willing to price the same product twice before buying it once | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NuviaRx](https://thisglp.com/reviews/nuviarx) [Obu Health](https://thisglp.com/reviews/obu-health) [Omnia TeleHealth](https://thisglp.com/reviews/omnia-telehealth) [Omzo](https://thisglp.com/reviews/omzo) [Ondra Health](https://thisglp.com/reviews/ondra-health) [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a calendar month cost? $216, $259 and $302 across the three lines, once thirteen cycles a year are counted. Did the prices change? All three fell a month apart, by $50, $40 and $60. Does a higher dose cost more? No. The rates are recorded as flat across doses. Is Nolu expensive compared with other GLP-1 telehealth sellers? Nolu publishes a starting figure of $216/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Nolu above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Noom reviews (2026): GLP-1 telehealth sellers | This GLP The intro runs three weeks, the medication four, and the recurring charge answers to twelve. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/noom Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three clocks in one footnote # Noom review The intro runs three weeks, the medication four, and the recurring charge answers to twelve. ## The verdict Noom's own footnote sets an initial three-week subscription bundled with four weeks of medication from $79, then $179 a month against a twelve-week subscription thereafter. The tirzepatide program is built identically at $149 and $349. The recurring figure is not a cancel-anytime monthly rate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $195/mo Prescription Required Compounded Yes — not FDA-approved Noom sells a behavior-change program with compounded GLP-1 prescribing attached. The medication and the subscription are separate products billed on different schedules. 1. ## Who writes the prescription, and what do they see? A prescription follows an eligibility review, and the program is presented as coaching first with medication as one component. Who writes the prescription is not named on the pricing pages, and what a clinician reviews before approving a dose is not described. The coaching program is the thing Noom is known for, and the GLP-1 offer is layered onto it. That layering is why the terms run on different clocks: the subscription and the medication were never one product. 2. ## What happens when the dose goes up? Nothing published ties a dose to either figure, so what four weeks of medication contains at the start and at maintenance is not stated. A buyer stepping up inside a twelve-week subscription cannot tell from the pages whether the medication charge moves with them. 3. ## What the price includes Three weeks of subscription plus four weeks of medication is $79 to begin, which covers neither a calendar month nor a matching pair of terms. After that the charge is $179 a month, but the commitment underneath it is twelve weeks. Tirzepatide follows at $149 and $349. A reader comparing $179 against another seller's monthly rate is comparing a twelve-week term against a one-month one. Spread over the 84 days it buys, it is $195 a calendar month. 4. ## What it claims, and what it cites The GLP-1 lines are compounded rather than manufactured, and no compounding pharmacy is named. The FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: The terms are disclosed in a footnote - Strength: Coaching is built in rather than sold apart - Strength: Both molecules are offered - Limitation: Three different term lengths in one sentence - Limitation: The recurring charge assumes twelve weeks - Limitation: Intro subscription and medication run unequal terms - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Noom. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who reads the footnote before the headline. Wrong for A buyer who needs a cancel-anytime monthly rate. ## The evidence behind what Noom prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Noom compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Queen RX | Buyers content to commit a quarter at a time in one payment | | | LaSara Medical Group | Buyers who can pay a full term at once and want the lowest rung | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Onyx Weight Loss](https://thisglp.com/reviews/onyx-weight-loss) [Open Water Rx](https://thisglp.com/reviews/open-water-rx) [Optimized Health](https://thisglp.com/reviews/optimized-health) [Options Medical Weight Loss](https://thisglp.com/reviews/options-medical-weight-loss) [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) [Oria Meds](https://thisglp.com/reviews/oria-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $179 a month cancel-anytime? Noom's footnote charges it against a twelve-week subscription, so the commitment underneath the monthly figure is a quarter. What does the intro price cover? A three-week subscription bundled with four weeks of medication, from $79 for semaglutide and $149 for tirzepatide. Why do the terms not line up? The subscription and the medication are separate products on separate schedules, and the footnote prices them in one sentence. Is Noom expensive compared with other GLP-1 telehealth sellers? Noom publishes a starting figure of $195/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Noom above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nova reviews (2026): GLP-1 telehealth sellers | This GLP Every figure includes a required care fee, and each oral is priced below its injection. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nova Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two states, care fee inside # Nova review Every figure includes a required care fee, and each oral is priced below its injection. ## The verdict Nova covers two states. Its injection rates include a required care fee. Each oral is priced below its injection. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose States 2 Injection From $229/mo Oral From $139/mo Prescription Required Compounded Yes — not FDA-approved Nova sells compounded semaglutide and compounded tirzepatide in two forms. Injectable semaglutide is $229 a month. The oral is $139. Injectable tirzepatide is $279 and its oral is $159. Two states are served. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely. A prescription precedes the first shipment. The oral ships on provider approval. The pages do not describe who gives it. The service is remote and every product is compounded. The injection rates are described as all-in: medication, shipping and a required Nova Care fee. A required fee named inside the price is better than one added at checkout. 2. ## What happens when the dose goes up? The price scales with the dose. Nova says so. Most patients escalate inside sixteen weeks, so the opening figure is a starting point rather than a monthly cost. 3. ## What the price includes Two things matter more than the headline. The first is the care fee. It is required, and Nova folds it into the injection figures rather than adding it at checkout. So $229 is closer to a real monthly cost than a bare medication rate. The second is the form. Each oral costs less than its injection, by $90 on semaglutide and $120 on tirzepatide. Every figure includes the same $99 membership. 4. ## What it claims, and what it cites Both molecules are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. The oral [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is described as a sublingual microdose, and sublingual milligrams are not interchangeable with injectable milligrams. Nova states that itself. ## Where it holds up, and where it does not - Strength: Required care fee folded into the price - Strength: Oral rates well below the injections - Strength: Sublingual dosing difference stated plainly - Limitation: Two states only - Limitation: The injections cost more than the orals - Limitation: Price scales with the dose ## What the evidence says about this kind of treatment The assessment above is about Nova. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in one of the two states Nova covers who wants the service fee already inside the figure. Wrong for A reader outside those two states, and a reader who wants the medication priced without a membership. ## The evidence behind what Nova prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nova compares | Seller | Who it suits | Go | | --- | --- | --- | | Wholesome Clinic | A reader who wants to see what a higher dose costs before starting, rather than discovering it in month three. | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Revel Health | A reader who wants an oral and expects to pay less for it, which on this seller is what happens. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) [Oria Meds](https://thisglp.com/reviews/oria-meds) [OurView Health](https://thisglp.com/reviews/ourview-health) [Oxford's Medical Weight Loss (The Calibrate Clinic)](https://thisglp.com/reviews/the-calibrate-clinic)[Ozari Health](https://thisglp.com/reviews/ozari-health) [Pallas Health](https://thisglp.com/reviews/pallas-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the Nova Care fee? A required charge Nova folds into its injection rates rather than adding at checkout. It is why $229 is closer to a real monthly cost than a bare medication figure elsewhere. What is inside each figure? A medication price plus the $99 Nova membership. Semaglutide medication starts at $130 by injection and $40 as an oral. Is the sublingual dose the same as the injection? No, and Nova says so. Sublingual milligrams are not interchangeable with injectable milligrams. Is Nova expensive compared with other GLP-1 telehealth sellers? Nova publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Nova below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nova MD reviews (2026): GLP-1 telehealth sellers | This GLP Four plan lengths per drug, with the twelve-month prepay already chosen when the page loads. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nova-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The long plan is preselected # Nova MD review Four plan lengths per drug, with the twelve-month prepay already chosen when the page loads. ## The verdict Nova MD prices compounded semaglutide from $175 month to month down to $109 on twelve months. The page opens with the twelve-month rung selected, which is $1,308 charged at once. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $109/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Nova MD sells compounded semaglutide with B12 and compounded tirzepatide with B12, both ready to use and already reconstituted. Strength and anti-aging lines sit beside weight loss. The site trades under three names on one page: Nova MD, Try Nova and Try Nova MD. 1. ## Who writes the prescription, and what do they see? The prescribing network is named, which matters more than it looks. Beluga, a network of United States licensed doctors, holds the prescribing decision, and Nova states that a Beluga clinician meets the patient after checkout to decide whether they qualify. Payment therefore precedes the medical decision. If the provider declines, Nova says the patient is not charged. The intake is a questionnaire, the review is included, and shipping is overnight and free. Unlimited follow-ups and refills are described as part of the plan with no membership fee. Cancellation between provider review and shipping carries a $25 provider fee, which is stated on the product page rather than buried in terms. 2. ## What happens when the dose goes up? Nothing on either product page describes how the dose is escalated or how long a rung is held. No milligram is published. What the pages do settle is the money: one rate covers the plan term whatever dose is prescribed, so a mid-plan step up does not change the charge. 3. ## What the price includes Semaglutide is $175 month to month, $129 on three months, $119 on six and $109 on twelve. Tirzepatide is $199, $169, $159 and $149. Each figure carries its full charge beside it, so the twelve-month rung reads $1,308 and $1,788 rather than only a monthly average. The rung the page preselects is the twelve-month one. 4. ## What it claims, and what it cites Both lines are compounded with vitamin B12 and neither is FDA-approved. The FDA does not review compounded medications for safety, effectiveness or quality before they are marketed, which Nova prints twice on each page. The dispensing pharmacies are described as independent and licensed rather than named, and Nova states it neither compounds nor dispenses. ## Where it holds up, and where it does not - Strength: Every plan length shows its full charge, not just a monthly average - Strength: The prescribing network is named - Strength: Free overnight shipping and no membership fee - Strength: One rate holds across the plan whatever the dose - Strength: The $25 cancellation fee is disclosed on the product page - Limitation: The twelve-month prepay is already selected when the page loads - Limitation: A No Commitment badge sits on the same screen as that prepay - Limitation: The clinician meeting happens after checkout - Limitation: No milligram or titration schedule is published - Limitation: Three trading names appear on one page ## What the evidence says about this kind of treatment The assessment above is about Nova MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the whole plan charge printed beside the monthly figure. Wrong for A buyer who wants a clinician's decision before any money changes hands. ## The evidence behind what Nova MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nova MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | Spry | Buyers who can read a four-week billing cycle as thirteen charges rather than twelve | | | LumiMeds | Buyers who want the ingredient, route and pharmacy type labeled before they pay | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Peak Wellness](https://thisglp.com/reviews/peak-wellness) [PepHaūs](https://thisglp.com/reviews/pephaus) [Pepti](https://thisglp.com/reviews/pepti) [Piper](https://thisglp.com/reviews/piper) [PlexusDx](https://thisglp.com/reviews/plexusdx) [PlushCare](https://thisglp.com/reviews/plushcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which plan is selected by default? The twelve-month one, on both product pages. That is $1,308 for semaglutide and $1,788 for tirzepatide, charged at once. When does a clinician review the case? After checkout. Nova states a Beluga clinician meets the individual after checkout to determine whether they qualify. What does canceling cost? Nothing once shipped, because orders cannot be canceled then. Canceling after provider review but before shipping carries a $25 provider fee. Is Nova MD expensive compared with other GLP-1 telehealth sellers? Nova MD publishes a starting figure of $109/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Nova MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Novera MD reviews (2026): GLP-1 telehealth sellers | This GLP Novera MD promotes testing and ongoing optimization, while its terms identify independent providers affiliated with WizDoc as the clinical decision-makers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/novera-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Biomarker-led marketing, network care # Does Novera MD sell a GLP-1? Novera MD promotes testing and ongoing optimization, while its terms identify independent providers affiliated with WizDoc as the clinical decision-makers. ## The verdict The named network is more useful than the broad precision-medicine language. Ask what tests and follow-ups are actually included in weight care; marketing about extensive diagnostics does not establish an individualized plan or proven superior outcomes. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Novera MD is a telehealth platform with weight-loss, hormone and wellness offerings. The weight page names semaglutide and tirzepatide without a complete public formulation or price table. 1. ## Who writes the prescription, and what do they see? The terms say Novera does not employ healthcare providers or make clinical decisions. Prescribing belongs to independent licensed providers affiliated with the WizDoc network. The marketing sequence includes intake, diagnostic testing, protocol design and later monitoring. Confirm which steps apply to the chosen GLP-1 program rather than assuming every advertised biomarker panel is required or included. 2. ## What happens when the dose goes up? The site describes ongoing check-ins and refinements but does not establish a universal visit or refill schedule. Ask how a clinician reviews [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and what happens when treatment needs to change. 3. ## What the price includes The weight page says pricing is clear and insurance is not needed, but a drug-specific recurring amount was not established. Testing and follow-up scope should accompany the quote before enrollment. 4. ## What it claims, and what it cites Semaglutide and tirzepatide appear in the program menu. The terms include a compounded-drug disclosure, but the reviewed pages do not establish the exact branded or compounded formulation for each individual offer. ## Where it holds up, and where it does not - Strength: Clinical network identified in terms - Strength: Ongoing monitoring described - Limitation: Diagnostic scope not defined per program - Limitation: Exact GLP-1 formulation unconfirmed ## What the evidence says about this kind of treatment The assessment above is about Novera MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone interested in a broader assessment who will verify the actual testing and clinician arrangements. Wrong for Someone who needs a fully specified GLP-1 product, visit schedule and price without an intake. ## The evidence behind what Novera MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Novera MD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) [Potere Health MD](https://thisglp.com/reviews/potere-health-md) [Precision Telemed](https://thisglp.com/reviews/precision-telemed) [Premium Health](https://thisglp.com/reviews/premium-health) [PrescribedRX](https://thisglp.com/reviews/prescribedrx) [PreventiveMD](https://thisglp.com/reviews/preventivemd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Novera directly employ the prescriber? Its terms say independent WizDoc-affiliated providers make the clinical decisions and are not employed by the platform. Does the diagnostic marketing guarantee every panel is included? No. Confirm the tests required and paid for within the exact weight-care program. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://noveramd.com/) - [Official program and terms](https://noveramd.com/weight-loss) - [Official program and terms](https://noveramd.com/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Novi reviews (2026): GLP-1 telehealth sellers | This GLP A billing-cycle table on each product page, with the one-month rate listed first and no membership charged on top. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/novi Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four cycles, one dose price # Novi review A billing-cycle table on each product page, with the one-month rate listed first and no membership charged on top. ## The verdict Novi charges $149 a month for compounded semaglutide and $179 for compounded tirzepatide on its one-month billing cycle, and both product pages say the figure holds whatever the dose. Longer cycles bring the monthly number down, to $88 for semaglutide over twelve months, which is the figure each page title leads with rather than the rate most new patients will actually start on. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states and DC Novi is an online weight-loss service built around compounded semaglutide and compounded tirzepatide as weekly injections, with Mounjaro, Ozempic, Wegovy and Zepbound also shown on the home page without a price beside any of them. It serves all fifty states and the District of Columbia, takes no insurance, and offers pay-later financing through the usual installment services at checkout. 1. ## Who writes the prescription, and what do they see? The product pages say a licensed US physician reviews the questionnaire and decides eligibility, and that the patient can then message that physician without limit through the online portal. No physician or medical group is named anywhere on the pages. In Kansas, Louisiana, Mississippi, New Mexico and West Virginia a brief video or audio visit comes first, and everywhere else treatment can begin on the written intake alone. After approval the first shipment is described as arriving within two to three business days, and refills ship every twenty-eight days after a short check-in, tracked through the same portal where a patient messages support and logs weight. Novi also offers what it calls a Progress Promise, a full refund for a patient who completes four months of treatment without meaningful progress, with the conditions held in the terms of service. 2. ## What happens when the dose goes up? Both pages state the same price no matter the dose, so the climb through the first sixteen weeks does not change the charge on the card. The pages describe a step-by-step escalation meant to support tolerance, though no milligram schedule is printed, and the FAQ lets a patient already on a GLP-1 ask to continue at the current dose. The side-effect answer also tells the patient not to step up to a higher dose while [nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) or other symptoms are still present, advice a buyer can act on in the second month. 3. ## What the price includes The semaglutide table reads $149 for one month, then $130, $129 and $88 a month on the three-, six- and twelve-month cycles, and tirzepatide reads $179, $149, $133 and $129. Every figure is stated to include the consultation, care, medication, supplies and shipping, and the home page repeats that no monthly membership is charged. A promotional amount off the first order runs on the home page, separately from either table. 4. ## What it claims, and what it cites Both molecules are compounded and filled by pharmacies the site describes as FDA-regulated, none of which is named, and compounded preparations are not FDA-approved. The home page's safety answer refers to GLP-1s as FDA-approved for weight management, a description that fits the brand-name products and not the compounded versions sold from these two tables. ## Where it holds up, and where it does not - Strength: One price at every dose - Strength: One-month rate listed first in each table - Strength: No membership fee on any cycle - Strength: Refund promise after four months - Limitation: Page titles lead with the twelve-month rate - Limitation: No physician or medical group is named - Limitation: The filling pharmacies go unnamed - Limitation: No milligram schedule is printed ## What the evidence says about this kind of treatment The assessment above is about Novi. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to start on a single month without a membership, and to keep paying the same figure as the dose rises. Wrong for A buyer who wants the pharmacy or the prescribing physician named before paying anything. ## The evidence behind what Novi prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Novi compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrideRx](https://thisglp.com/reviews/priderx) [Primary Clinic (Direct GLP)](https://thisglp.com/reviews/primary-clinic)[Prime Doctor RX](https://thisglp.com/reviews/prime-doctor-rx) [Prime Health](https://thisglp.com/reviews/prime-health) [Queen RX](https://thisglp.com/reviews/queen-rx) [QuickMD](https://thisglp.com/reviews/quickmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does the page title say $88? Because $88 is the monthly figure on the twelve-month cycle; on the one-month cycle, which carries no longer commitment, semaglutide is $149 and tirzepatide is $179. Is a video visit required? Only in Kansas, Louisiana, Mississippi, New Mexico and West Virginia, where a brief video or audio visit comes before treatment, although a patient anywhere can request one through the portal at any time. What is the Progress Promise? A full refund for a patient who completes the first four months of treatment without meaningful progress toward their goals, subject to conditions set out in the terms of service rather than on the product page. Is Novi legit? Novi is a GLP-1 telehealth sellers service. Its stated availability: All 50 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Novi expensive compared with other GLP-1 telehealth sellers? Novi publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Novi below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NovoCare Pharmacy reviews (2026): GLP-1 telehealth sellers | This GLP This is the drug company selling its own approved product, and the month it quotes is twenty-eight days. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/novocare-pharmacy Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The manufacturer, direct # NovoCare Pharmacy review This is the drug company selling its own approved product, and the month it quotes is twenty-eight days. ## The verdict NovoCare Pharmacy is Novo Nordisk's own direct-purchase channel for FDA-approved brand semaglutide. The self-pay rate is $349 for a box of four pens, which the page calls a month and which is 28 days, so $378 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection · Oral Dose pricing Rises with dose States 50 From From $149/mo Prescription Required Compounded No Availability All 50 states NovoCare Pharmacy dispenses the manufacturer's approved products directly, across fifty states, in pen and tablet form. Nothing here is compounded. 1. ## Who writes the prescription, and what do they see? A prescription is required as it would be at any pharmacy, and the channel is the manufacturer rather than a telehealth seller. That changes who stands behind the product, not who decides you should have it. Buying from the company that makes the drug removes a whole category of question. There is no compounding pharmacy to identify, no unreviewed preparation, and no ambiguity about what is in the pen. What replaces those questions is a different one about arithmetic. 2. ## What happens when the dose goes up? The cost scales with the dose, and the pen box is the reason: four pens is four weekly doses at whatever strength was prescribed. A higher dose does not stretch a box further, so the cost follows the milligrams in a way the page does not spell out. 3. ## What the price includes Four weekly pens is 28 days, and a year holds 13.04 of those rather than twelve. So $349 is $4,552 a year, or $378 a calendar month. The $25 figure is a commercial-insurance copay subject to a $100 monthly savings cap, which means it describes what insurance pays down rather than what the product costs. The oral tablets are priced by strength: $149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg, with a bottle of thirty tablets counted as one month. 4. ## What it claims, and what it cites These are FDA-approved brand products dispensed by the manufacturer's own channel. The usual caution about a compounded preparation the FDA has not reviewed does not apply here at all. ## Where it holds up, and where it does not - Strength: FDA-approved product from the maker - Strength: Coverage across all fifty states - Strength: Pen and tablet forms both available - Strength: No compounding pharmacy question at all - Limitation: A four-pen box is 28 days, not a month - Limitation: The $25 figure requires commercial insurance - Limitation: That copay is capped at $100 of savings - Limitation: The tablet price climbs with the strength ## What the evidence says about this kind of treatment The assessment above is about NovoCare Pharmacy. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the approved product and will count 13 boxes a year rather than 12. Wrong for A reader comparing $25 against a compounded monthly figure. ## The evidence behind what NovoCare Pharmacy prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How NovoCare Pharmacy compares | Seller | Who it suits | Go | | --- | --- | --- | | PrideRx | Readers who want an approved product and have added the membership to the ladder | | | PeterMD | Readers who want a cancel-anytime subscription and will choose the monthly product over the quarterly offer | | | PlexusDx | A reader who will scroll past the entry card to find a product with a name | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Recovery Delivered](https://thisglp.com/reviews/recovery-delivered) [Refills](https://thisglp.com/reviews/refills) [ReflexMD](https://thisglp.com/reviews/reflexmd) [Regenics](https://thisglp.com/reviews/regenics) [Rehydra+ Wellness](https://thisglp.com/reviews/rehydra-plus) [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $25 a month what I would pay? Only with commercial insurance, and the savings are capped at $100 a month. The self-pay rate is $349 per box of four pens. Why is $349 not the monthly cost? A box of four weekly pens covers 28 days. A year holds 13.04 of those rather than twelve, so the real figure is about $378 a calendar month. Is this compounded semaglutide? No. NovoCare Pharmacy is the manufacturer's own channel dispensing FDA-approved brand products, in both pen and tablet form. Is NovoCare Pharmacy legit? NovoCare Pharmacy is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is NovoCare Pharmacy expensive compared with other GLP-1 telehealth sellers? NovoCare Pharmacy publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NovoCare Pharmacy below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NowPatient reviews (2026): GLP-1 telehealth sellers | This GLP Four manufactured products priced by pack, each with a shipment-and-duties charge that sits in the buy box rather than the headline. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nowpatient Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand names, plus a duties line # NowPatient review Four manufactured products priced by pack, each with a shipment-and-duties charge that sits in the buy box rather than the headline. ## The verdict NowPatient publishes $215.98 for the smallest Wegovy pen and $251.98 for the Mounjaro KwikPen. A separate $75.00 shipment-and-duties line applies, taking them to $291 and $327. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Liraglutide · Semaglutide · Tirzepatide Form Injection · Oral Injection From $291/mo Oral From $119/mo Prescription Required Compounded No NowPatient sells manufactured GLP-1 products rather than compounded ones: Wegovy, Mounjaro, Saxenda and a Wegovy tablet. Each is priced by pack size and strength. 1. ## Who writes the prescription, and what do they see? A prescription is required before dispensing. The catalog is organized by product and pack rather than by a described course of care. Naming the actual product, at a stated strength and pack size, is a real advantage over a compounded vial. The duties line is the cost of that advantage and it is disclosed, if not prominently. 2. ## What happens when the dose goes up? Price follows strength and pack size rather than a published ladder. Moving up a strength means a different product listing, not a stated step on a schedule. 3. ## What the price includes The lowest strength and smallest pack of Wegovy is $215.98, which becomes $291 once the $75.00 line is added. Mounjaro is $251.98 and $327. The five-pen Saxenda pack is $440.82 and $516. The thirty-tablet oral Wegovy is $99.00 with a $20.00 line, or $119. 4. ## What it claims, and what it cites These are FDA-approved manufactured medicines, not compounded preparations. That is a meaningful difference: the product in the pen is the product that was tested, at the strength printed on it. ## Where it holds up, and where it does not - Strength: Named manufactured products, not compounds - Strength: The additional line is shown before checkout - Strength: Four distinct products carry a figure - Strength: The oral line carries a lower added charge - Limitation: No headline figure includes the $75.00 - Limitation: Prices are for the smallest pack and lowest strength - Limitation: Nothing records which states it serves - Limitation: Cost rises with strength by product, not by a published schedule ## What the evidence says about this kind of treatment The assessment above is about NowPatient. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a named manufactured product and will read the buy box before deciding. Wrong for A reader comparing these headlines against a compounded seller's all-in figure. ## The evidence behind what NowPatient prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NowPatient compares | Seller | Who it suits | Go | | --- | --- | --- | | Navio MD | Readers who want the branded and compounded routes priced side by side | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | | TrimRx | Readers who already know which molecule they want and will hunt for which tile holds it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) [Remedy Meds](https://thisglp.com/reviews/remedy-meds) [REMEVi](https://thisglp.com/reviews/remevi) [Remi Meds](https://thisglp.com/reviews/remi-meds) [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) [Renlo Health](https://thisglp.com/reviews/renlo-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the $75.00 line? A shipment-and-duties charge shown in the buy box. It applies to the three injection products; the oral carries $20.00 instead. Are these compounded? No. Wegovy, Mounjaro and Saxenda are manufactured products, so the compounding caveats elsewhere on this site do not apply. What does a Wegovy pen actually come to? $291 for the lowest strength and smallest pack, once the duties line is included. Is NowPatient expensive compared with other GLP-1 telehealth sellers? NowPatient publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NowPatient below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NP2GO reviews (2026): GLP-1 telehealth sellers | This GLP An Oklahoma nurse practitioner practice that prints a separate price for every month of the dose ladder. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/np2go Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by month and dose # NP2GO review An Oklahoma nurse practitioner practice that prints a separate price for every month of the dose ladder. ## The verdict NP2GO's pay-as-you-go semaglutide starts at $150 a month at the first dose, with a $99 provider visit every three months. Spread monthly, that visit adds $33, so the entry cost is $183. Tirzepatide starts at $250 on the same terms, or $283 with the visit. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 40 From From $183/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider NP2GO is a nurse practitioner practice in Edmond, Oklahoma, offering telehealth alongside in-person visits. It sells compounded semaglutide and compounded tirzepatide on two plans, month-to-month and pay-as-you-go. Hormone therapy, peptides and IV hydration sit in the same catalog. 1. ## Who writes the prescription, and what do they see? The FAQ says all care is provided by licensed nurse practitioners. The founder, Kara De La Pena, is named on the site as a board-certified family nurse practitioner. The first visit is a face-to-face video appointment rather than a questionnaire. The site states LegitScript verification. Its count of states served differs by page, from 38 to 40. The month-to-month plan carries no visit fee and uses monthly provider check-in forms. The pay-as-you-go plan instead charges the $99 provider visit every three months. A nurse text line is staffed every day, twelve hours a day, on Central time. In-person visits are available at the Edmond office. 2. ## What happens when the dose goes up? The price rises with the dose, and the page prints each month's figure beside its milligram range. Pay-as-you-go semaglutide climbs every month for five months. The month-to-month plan holds its opening rate for three months, then steps up once. Tirzepatide follows the same pattern across six months. A buyer can price the whole escalation before booking. 3. ## What the price includes Pay-as-you-go semaglutide is $150 at the first dose, plus the $99 visit every three months. Tirzepatide is $250 at the first dose on the same terms. [Higher doses](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) cost more on both plans, and high-concentration vials are sold as a separate option. The month-to-month plan opens higher but drops the visit fee. 4. ## What it claims, and what it cites Both molecules are compounded, and the pricing page states that neither is FDA-approved. The pharmacy is described only as a reputable partner and is not named. For brand-name medications on pay-as-you-go, the practice offers to run prior authorizations. ## Where it holds up, and where it does not - Strength: Every month's price printed with its dose - Strength: Founder and credentials named on the site - Strength: First visit is a live video appointment - Strength: Daily nurse text line - Limitation: Price rises at most dose steps - Limitation: Visit fee sits outside the monthly figure - Limitation: Compounding pharmacy is not named - Limitation: State count differs between pages ## What the evidence says about this kind of treatment The assessment above is about NP2GO. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to see what each escalation month will cost before the first visit. Wrong for A buyer who wants one flat price for the whole course of treatment. ## The evidence behind what NP2GO prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NP2GO compares | Seller | Who it suits | Go | | --- | --- | --- | | Nova | A reader in one of the two states Nova covers who wants a figure with the service fee already inside it. | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Reset Solutions](https://thisglp.com/reviews/reset-solutions) [RestorLife Med](https://thisglp.com/reviews/restorlife-med) [Revel Health](https://thisglp.com/reviews/revel-health) [Revel RX](https://thisglp.com/reviews/revel-rx) [Revive Meds](https://thisglp.com/reviews/revive-meds) [Rewinding RX](https://thisglp.com/reviews/rewinding-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the first month really cost? $150 for semaglutide on pay-as-you-go, plus the $99 visit, which recurs every three months. Spread monthly, that is $183. Does the price rise as the dose rises? Yes, on both plans. Each month of the escalation has its own printed price. Who sees the patient? A licensed nurse practitioner, by face-to-face video for the first visit. Is NP2GO expensive compared with other GLP-1 telehealth sellers? NP2GO publishes a starting figure of $183/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NP2GO below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nu Image Medical reviews (2026): GLP-1 telehealth sellers | This GLP Four products sit on one page, and the figure that draws the eye is a year bought at once. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nu-image-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four cards, four units # Nu Image Medical review Four products sit on one page, and the figure that draws the eye is a year bought at once. ## The verdict Nu Image Medical prices four weight-loss products on a single page and labels each as an as-low-as figure. The $99 semaglutide injection carries the words twelve-month supply on its own card, and the tirzepatide injection is $289 rather than the $269 that belongs to the rapid-dissolve tablet beside it. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $289/mo Oral From $269/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Nu Image Medical is a telehealth practice that has been selling online since 2008, offering compounded semaglutide and tirzepatide as weekly injections and as daily rapid-dissolve tablets. A structured nutrition program is sold alongside them. Testosterone, peptides and several other lines share the same catalog. 1. ## Who writes the prescription, and what do they see? A licensed provider determines eligibility before anything is dispensed, which the page states in the same paragraph as its prices rather than in a footer. Beyond that the clinical model is thinly described: no prescriber is named, and nothing sets out what is reviewed, or when a patient next speaks to anyone. Ongoing support is listed as a feature without being defined. The four products are bought as programs of differing length rather than as a uniform monthly plan, which is why their headline figures are not comparable with one another. The injection sold at the lowest rate is explicitly a year's supply. Shipping is described as discreet, and the practice reports a 4.4 rating across roughly a thousand public reviews. 2. ## What happens when the dose goes up? Nothing on the weight-loss page ties a figure to a milligram, and no dose ladder is published for either molecule or either format. A buyer therefore cannot tell whether an escalation changes the charge, shortens the supply, or neither. That silence matters more here than elsewhere, because the $99 card commits a patient for twelve months before the first step is taken. 3. ## What the price includes The page's own summary sentence is the clearest thing on it: weekly injections from $99 and $289 a month. The $99 is the twelve-month semaglutide commitment and no month-to-month figure for that injection is published anywhere, while $269 and $314 price the semaglutide and tirzepatide tablets rather than a needle. Reading the tablet figure onto the injection understates the injection by $20 a month. 4. ## What it claims, and what it cites Every line on the page is marked as compounded and prescription-only, prepared by a pharmacy rather than manufactured. The hero states that compounded medications are not FDA-approved, which puts the disclosure beside the prices instead of underneath them. No compounding pharmacy is named. ## Where it holds up, and where it does not - Strength: Both an injection and a dissolving tablet are offered - Strength: The compounded disclosure sits next to the prices - Strength: A long trading history is stated and dated - Strength: The summary line names the injection rates directly - Limitation: The lowest figure is a twelve-month supply - Limitation: No month-to-month rate is published for the injection - Limitation: Tablet and injection prices sit side by side without a unit - Limitation: No milligram dose appears anywhere ## What the evidence says about this kind of treatment The assessment above is about Nu Image Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer choosing between a weekly injection and a daily tablet from one practice. Wrong for A buyer who wants to pay month to month for the injection. ## The evidence behind what Nu Image Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nu Image Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | MyStart Health | Buyers who titrate quickly and want the rate frozen before the dose climbs | | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rewinding RX](https://thisglp.com/reviews/rewinding-rx) [Rex MD](https://thisglp.com/reviews/rex-md) [Rivas Medical Weight Loss](https://thisglp.com/reviews/rivas-medical) [Rivo Health](https://thisglp.com/reviews/rivo-health) [Rixa Health](https://thisglp.com/reviews/rixa-health) [RNK Health](https://thisglp.com/reviews/myrnk) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a monthly rate? No. That card states a twelve-month supply, and Nu Image publishes no month-to-month figure for the semaglutide injection. What does the tirzepatide injection cost? $289 a month. The $269 and $314 figures belong to the rapid-dissolve tablets rather than to an injection. Are these FDA-approved medications? No. Every GLP-1 line here is compounded, and the page says compounded medications are not FDA-approved. Is Nu Image Medical expensive compared with other GLP-1 telehealth sellers? Nu Image Medical publishes a starting figure of $269/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Nu Image Medical above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NuBloom reviews (2026): GLP-1 telehealth sellers | This GLP Six dose strengths are listed on the product page and every one of them costs the same. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nubloom Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Six doses, one price # NuBloom review Six dose strengths are listed on the product page and every one of them costs the same. ## The verdict NuBloom publishes $149 a month for compounded semaglutide, on a month-to-month subscription. Six dose strengths are listed at that figure. Coverage is 49 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 49 From From $149/mo Prescription Required Compounded Yes — not FDA-approved Availability 49 states NuBloom sells both molecules by injection. Doses of 0.25, 0.5, 1, 1.7, 2 and 2.4 mg are listed. A BMI of 27 or above is required. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The BMI threshold is published. The clinician is not described. Listing every dose beside one price answers the escalation question without a ladder. A reader can see the top of the range and what it costs. 2. ## What happens when the dose goes up? This is answered plainly. Six strengths run from 0.25 to 2.4 mg at the same monthly figure. Nothing describes clinical support at a step. 3. ## What the price includes Six months at $149 is $894 and that total holds at any listed dose. Tirzepatide is $249 on a microdose product page, which is a narrower plan than the semaglutide line. Both are month to month. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Six dose strengths listed with one price - Strength: Coverage recorded across 49 states - Strength: Month to month on both lines - Strength: The BMI threshold is published - Limitation: The tirzepatide line is a microdose product - Limitation: One state is not served - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about NuBloom. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the top dose priced before starting the lowest. Wrong for A reader wanting a full-dose tirzepatide plan. ## The evidence behind what NuBloom prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NuBloom compares | Seller | Who it suits | Go | | --- | --- | --- | | Nucore Health | A reader paying from an FSA or HSA who will ask to be quoted a real figure | | | Obu Health | Readers who value a site that agrees with itself | | | NuDay Rx | Readers wanting an oral semaglutide at the injection price | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Roboclinic](https://thisglp.com/reviews/roboclinic) [Roen Rx](https://thisglp.com/reviews/roen-rx) [RX Bella](https://thisglp.com/reviews/rx-bella) [Rx.com](https://thisglp.com/reviews/rx-com) [RxION Health](https://thisglp.com/reviews/rxion-health) [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change by dose? No. Six strengths from 0.25 to 2.4 mg are listed at $149 a month. Is the tirzepatide line the same? No. It is a microdose product at $249 a month. Is there a BMI requirement? Yes. A BMI of 27 or above is stated. Is NuBloom legit? NuBloom is a GLP-1 telehealth sellers service. Its stated availability: 49 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is NuBloom expensive compared with other GLP-1 telehealth sellers? NuBloom publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NuBloom below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nucore Health reviews (2026): GLP-1 telehealth sellers | This GLP Three figures, all floors, with no membership fee and health-account eligibility stated. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nucore-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Floors, no membership # Nucore Health review Three figures, all floors, with no membership fee and health-account eligibility stated. ## The verdict Nucore Health publishes as low as $179 a month for compounded semaglutide. The oral is $209 and tirzepatide is $269. All three are floors. No membership fee applies. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $179/mo Oral From $209/mo Prescription Required Compounded Yes — not FDA-approved Nucore Health sells semaglutide as an injection and an oral, plus tirzepatide by injection. All three figures use as-low-as wording. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state prices and eligibility. The clinician is not described. The fee position is clear and the price position is not. There is no membership. What raises a floor is unstated. 2. ## What happens when the dose goes up? Nothing is published about dose. As low as covers the bottom of a range whose top is not given. Both unknowns sit on the same figure. 3. ## What the price includes Six months at $179 is $1,074 at best. The oral is $1,254 and tirzepatide $1,614, also at best. FSA and HSA eligibility is stated, which affects tax treatment rather than price. 4. ## What it claims, and what it cites All three lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: No membership fee, stated in writing - Strength: FSA and HSA eligibility published - Strength: An oral option priced separately - Limitation: All three figures are floors - Limitation: What raises them is not published - Limitation: No milligram dose stated - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Nucore Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader using a health account who will ask what their own figure is. Wrong for A reader who needs a settled monthly price. ## The evidence behind what Nucore Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nucore Health compares | Seller | Who it suits | Go | | --- | --- | --- | | NuBloom | Readers who want the top dose priced before starting the lowest | | | NuDay Rx | Readers wanting an oral semaglutide at the injection price | | | Obu Health | Readers who value a site that agrees with itself | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RxPros](https://thisglp.com/reviews/rxpros) [RxSaludable](https://thisglp.com/reviews/rxsaludable) [Rylo Health](https://thisglp.com/reviews/rylo-health) [Ryze Rx](https://thisglp.com/reviews/ryze-rx) [Science & Co](https://thisglp.com/reviews/science-and-co) [Semaglutide Online](https://thisglp.com/reviews/semaglutide-online) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a membership fee? No. The site states there is none. Is $179 a rate? No. It is an as-low-as figure and the top of the range is not published. Can I use an HSA? FSA and HSA eligibility is stated on the injection and tirzepatide lines. Is Nucore Health expensive compared with other GLP-1 telehealth sellers? Nucore Health publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Nucore Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NuDay Rx reviews (2026): GLP-1 telehealth sellers | This GLP The semaglutide tablet matches the injection, and the tirzepatide tablet costs seventy dollars more. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nuday-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Tablets cost more # NuDay Rx review The semaglutide tablet matches the injection, and the tirzepatide tablet costs seventy dollars more. ## The verdict NuDay Rx publishes $249 for compounded semaglutide and $329 for tirzepatide. Oral semaglutide is the same $249. The tirzepatide tablet is $399. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $249/mo Prescription Required Compounded Yes — not FDA-approved NuDay Rx sells both molecules as injections and as tablets. Four figures are published. Two of them match. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages name products and prices. The clinician is not described. Pricing an oral at the same figure as an injection is unusual. Pricing the other oral $70 higher is more usual. Nothing explains either choice. 2. ## What happens when the dose goes up? Nothing is published about dose on any of the four lines. An oral milligram and an injected milligram are not the same thing, so the matching figures compare two different products. 3. ## What the price includes Six months of injected semaglutide at $249 is $1,494 and the tablet is the same. Tirzepatide is $1,974 injected and $2,394 as tablets. All four figures are flat monthly prices with no ladder published. 4. ## What it claims, and what it cites All four lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Four molecule and format combinations priced - Strength: The semaglutide tablet matches the injection - Strength: No ladder to decode - Limitation: The tirzepatide tablet is $70 dearer - Limitation: No milligram dose stated anywhere - Limitation: No state coverage list is recorded - Limitation: The compounding pharmacy goes unnamed ## What the evidence says about this kind of treatment The assessment above is about NuDay Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader wanting an oral semaglutide at the injection price. Wrong for A reader choosing the tablet on price, since tirzepatide costs $70 more. ## The evidence behind what NuDay Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NuDay Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Nucore Health | A reader paying from an FSA or HSA who will ask to be quoted a real figure | | | NuBloom | Readers who want the top dose priced before starting the lowest | | | PepHaūs | Readers who will commit a quarter for a modest saving | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SexyMD](https://thisglp.com/reviews/sexymd) [ShapeIn Rx](https://thisglp.com/reviews/shapein-rx) [Shapely](https://thisglp.com/reviews/shapely) [Signos](https://thisglp.com/reviews/signos) [Silhouette MD](https://thisglp.com/reviews/silhouette-md) [SkyRx](https://thisglp.com/reviews/skyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Do the tablets cost the same? Oral semaglutide is $249, matching the injection. Oral tirzepatide is $399 against $329 injected. What dose do these buy? No milligram figure is published on any of the four lines. Is there a plan ladder? None is published. All four figures are monthly. Is NuDay Rx expensive compared with other GLP-1 telehealth sellers? NuDay Rx publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NuDay Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nuform Health reviews (2026): GLP-1 telehealth sellers | This GLP Nuform describes an assigned provider and follow-ups every four weeks. Its multi-month kits make a slower dose increase or early treatment change worth discussing first. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nuform-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Assigned team, multi-month kits # Nuform Health review Nuform describes an assigned provider and follow-ups every four weeks. Its multi-month kits make a slower dose increase or early treatment change worth discussing first. ## The verdict Nuform supplies a more specific follow-up cadence than a vague promise of support, but the care plan and the package duration need to work together. Ask what happens to the next shipment and unused medicine if your clinician changes treatment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Nuform is a telehealth platform covering weight management, hormone care and other treatments. The weight-loss page markets compounded GLP and GLP/GIP vitamin blends in multi-month kits rather than a standard monthly drug subscription. 1. ## Who writes the prescription, and what do they see? The terms name independent providers employed or contracted by Christopher Elia, D.O. P.C., doing business as Nuform Health and Wellness, P.C. Physicians, nurse practitioners and physician assistants can provide care through synchronous or asynchronous communication. Nuform says a specialist responds within 24–48 hours after intake. Its weight-loss page then describes an assigned provider and specialist, treatment delivery and follow-ups every four weeks. That is a stated service model, not a guarantee that every message receives an immediate clinical answer. 2. ## What happens when the dose goes up? Nuform says kit formulations and dosing are individualized. Some packages include dose increases. Confirm the prescribed dose, vial concentration, beyond-use date and how the clinician will adapt a prepaid kit if escalation needs to pause. 3. ## What the price includes The homepage lists a one-time $170 physician fee. The weight-loss page uses kit prices and monthly equivalents: the GLP starter kit is $389 for three months, while other maintenance and GLP/GIP kits have different lengths. Do not treat the displayed equivalent as a month-to-month drug bill. 4. ## What it claims, and what it cites Its weight-loss materials refer to [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review); the FAQ also mentions oral semaglutide. The specific compounded formulation can depend on the prescriber. Compounded products are not FDA-approved, and a compounded oral product should not be confused with an approved branded tablet. ## Where it holds up, and where it does not - Strength: Medical practice identified in the terms - Strength: Four-week follow-up cadence described - Strength: Kit duration and supplies are addressed publicly - Limitation: Medication and care costs need reconciling before enrollment - Limitation: Multi-month kits reduce flexibility - Limitation: Specific dispensing pharmacy not established on the pages reviewed ## What the evidence says about this kind of treatment The assessment above is about Nuform Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants continued provider contact and can confirm an individualized plan before committing to a kit. Wrong for Someone who needs a simple, medication-inclusive monthly subscription or a specific FDA-approved brand. ## The evidence behind what Nuform Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nuform Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SkyRx](https://thisglp.com/reviews/skyrx) [Society of You](https://thisglp.com/reviews/society-of-you) [Somi Health](https://thisglp.com/reviews/somi-health) [Somira Health](https://thisglp.com/reviews/somira-health) [Southern Vitality and Weight Loss](https://thisglp.com/reviews/southern-vitality-weight-loss) [Spry](https://thisglp.com/reviews/spry) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How often does Nuform describe follow-up? The weight-loss page says the assigned team follows up every four weeks. Confirm what that contact includes for your plan. Can medicine be returned after a treatment change? The terms state that medication orders are final and nonrefundable once placed. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-loss program and package prices](https://www.nuformhealth.com/weight-loss) - [Clinical, payment and refund terms](https://www.nuformhealth.com/terms-condition) - [Enrollment and physician fee](https://www.nuformhealth.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Nurx reviews (2026): GLP-1 telehealth sellers | This GLP Nurx offers a licensed-provider relationship and ongoing messaging. Injectable medication fulfillment is separate from its familiar home-delivery model. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nurx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Ongoing care, separate pharmacy # Nurx review Nurx offers a licensed-provider relationship and ongoing messaging. Injectable medication fulfillment is separate from its familiar home-delivery model. ## The verdict Nurx is worth considering for someone who wants ongoing online weight-management care and can use a local pharmacy. Its injection-specific instructions matter: generic Nurx shipping promises do not mean your GLP-1 will arrive from Nurx. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Liraglutide Form Injection Prescription Required Compounded No Nurx is an online care platform with a weight-management service. Its GLP-1 injection page lists FDA-approved brand-name medicines; a licensed provider determines which treatment, if any, fits the patient. 1. ## Who writes the prescription, and what do they see? A provider licensed in your state evaluates the online medical consultation, current weight and health history. Treatment is conditional on clinical suitability; the list of available drugs is not a promise that a particular prescription will be issued. The program describes regular check-ins, progress tracking, unlimited messaging and help with side effects. A care team can recommend changes when appropriate. The pages reviewed do not establish one appointment interval or a guaranteed clinical response time for every patient. 2. ## What happens when the dose goes up? Nurx says its care team may periodically adjust the dose and treatment plan. Ask how that decision is made if symptoms persist, and how a changed prescription reaches the pharmacy before the next refill. 3. ## What the price includes The program FAQ states a $79 initial medical consultation and $79 a month for provider support, with medication costs separate. Injection-page estimates vary by brand, pharmacy and insurance. They are not an all-in Nurx medication price. 4. ## What it claims, and what it cites Listed injection options include [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), Saxenda, Ozempic, Mounjaro and Victoza. These have different approved uses. The injection page specifically says the medicines are picked up through an outside pharmacy rather than shipped by Nurx. ## Where it holds up, and where it does not - Strength: Licensed-state-provider evaluation - Strength: Ongoing messaging and side-effect support - Strength: Brand-name options listed explicitly - Limitation: Outside pharmacy handles injectable medication - Limitation: Care fees and medication charges are separate - Limitation: No universal clinical response time stated ## What the evidence says about this kind of treatment The assessment above is about Nurx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking ongoing remote weight-management support who can arrange and afford the prescribed medicine through a pharmacy. Wrong for Someone expecting a single medication-inclusive subscription with injectable medicine shipped by Nurx. ## The evidence behind what Nurx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Nurx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [StackMD](https://thisglp.com/reviews/stackmd) [Sumbare Wellness](https://thisglp.com/reviews/sumbare-wellness) [Sunlight](https://thisglp.com/reviews/sunlight) [Superior Remedies](https://thisglp.com/reviews/superior-remedies) [Superpower](https://thisglp.com/reviews/superpower-health) [SurpassMD](https://thisglp.com/reviews/surpassmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Nurx ship GLP-1 injections? The injection product page says these medicines require outside pharmacy pickup and are not shipped through Nurx. Do oral weight-loss pills mean oral GLP-1 treatment? Not necessarily. Nurx also describes non-GLP-1 oral weight-management medicines. Confirm the actual prescription rather than treating all pills as interchangeable. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [GLP-1 injection service](https://www.nurx.com/weight-management/glp1-injections/) - [Weight-management fee FAQ](https://www.nurx.com/weight-management/orals/) - [Insurance information](https://www.nurx.com/faq/does-nurx-accept-health-insurance-for-medication/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NuuVim reviews (2026): GLP-1 sellers by price | This GLP Injection and oral cost the same on each molecule, which is unusual. The seller states no membership and one price at any dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nuuvim Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price per molecule, either form # NuuVim review Injection and oral cost the same on each molecule, which is unusual. The seller states no membership and one price at any dose. ## The verdict NuuVim's standard rates are $133 a month for compounded semaglutide and $199.67 for compounded tirzepatide. Each is billed as a three-month plan. The figure does not change between the injection and the oral. Brand Ozempic is listed separately at $1,498 a month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 sellers by price Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $133/mo Oral From $133/mo Prescription Required Compounded Yes — not FDA-approved NuuVim sells both molecules in two forms each. That is four compounded lines. A branded line sits beside them at a cash price. 1. ## Who writes the prescription, and what do they see? A prescription is written before anything ships, and the pages describe the plan rather than the clinician. Who writes it is not stated. The pricing is the clear part. Four lines, two numbers, and the form does not move either one. The seller also prints a table comparing itself with unnamed rivals at $279 to $325. 2. ## What happens when the dose goes up? NuuVim states the price is the same at any dose. That claim is printed in its own comparison table, beside a claim of no membership fee. Both are the seller's words rather than anything measured here, and both are worth confirming in writing before a first charge. 3. ## What the price includes Semaglutide is $399 per three months, or $133 a month. Tirzepatide is $599, or $199.67 a month. Six months is $798 and $1,198. New GLP-1 users are shown a lower introductory tab. The standard rate is what a returning patient pays. 4. ## What it claims, and what it cites The four cheaper lines are compounded rather than manufactured. A pharmacy prepares them, the FDA does not review a compounded preparation before it is dispensed, and no pharmacy is named. The [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) line is the branded product at a cash price. ## Where it holds up, and where it does not - Strength: The same figure whether injected or taken orally - Strength: Four compounded lines all priced openly - Strength: A branded option priced beside them rather than hidden - Limitation: Billing runs in three-month blocks - Limitation: The intro tab is for new GLP-1 users only - Limitation: The no-membership and any-dose claims are unverified - Limitation: No pharmacy named and no state list recorded ## What the evidence says about this kind of treatment The assessment above is about NuuVim. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer weighing the oral against the injection on price alone. Wrong for A buyer who wants to pay one month at a time. ## The evidence behind what NuuVim prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NuuVim compares | Seller | Who it suits | Go | | --- | --- | --- | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 sellers by price reviews: [HumeCare+](https://thisglp.com/reviews/humecare)[Live Vital](https://thisglp.com/reviews/live-vital) [Lttl](https://thisglp.com/reviews/lttl) [Luvo Health](https://thisglp.com/reviews/luvo-health) [MEDGm](https://thisglp.com/reviews/medgm) [Oak](https://thisglp.com/reviews/oak) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the oral cost more than the injection? No. NuuVim prices both forms of each molecule identically — $133 for semaglutide and $199.67 for tirzepatide at the standard rate. Is $133 the price I will pay? It is the standard rate, billed $399 per three months. New GLP-1 users are shown a lower introductory tab, so confirm which figure applies before the first charge. How is it billed? In three-month blocks: $399 for semaglutide and $599 for tirzepatide, in either form. Is NuuVim expensive compared with other GLP-1 sellers by price? NuuVim publishes a starting figure of $133/mo. Across the 402 GLP-1 sellers by price we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NuuVim below the median, toward the cheaper end. The other 178 GLP-1 sellers by price we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller by price](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # NuviaRx reviews (2026): GLP-1 telehealth sellers | This GLP The product page prices the annual plan; the checkout prints every term, a single month included. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/nuviarx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Annual rate up front # NuviaRx review The product page prices the annual plan; the checkout prints every term, a single month included. ## The verdict NuviaRx leads with $140 a month for compounded semaglutide and $170 for tirzepatide. Both carry an asterisk: with purchase of an annual plan. A single month costs $214.95 and $259.95. The checkout preselects three months. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $214.95/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named NuviaRx is a telehealth platform based in Jacksonville, Florida. It sells compounded semaglutide and compounded tirzepatide as weekly injections. B12 is listed as a compounding option. The site calls itself a technology platform, not a medical provider. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the intake within 24 hours, per the product page. No provider is named. No medical group is named. The site publishes no state list. Its disclaimer says the program is not available in all states. The intake is online. The provider selects the medication, the dose and a titration schedule. Medication ships from a licensed pharmacy. Monthly check-ins are included. Cancel, pause or switch is allowed at any time without penalty. The card is held, not charged, until a doctor writes the prescription. 2. ## What happens when the dose goes up? The product page states one price at every dose. The FAQ repeats it: no increase as the dose goes up. The provider sets the [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule after the intake. The schedule itself is not published. 3. ## What the price includes The checkout lists four terms. Semaglutide is $214.95 for one month, $524.95 for three, $979.95 for six and $1,684.95 for twelve. Tirzepatide is $259.95, $639.95, $1,184.95 and $2,044.95. The three-month term is preselected. The product page shows only the annual rate. No membership fee is listed. 4. ## What it claims, and what it cites Both molecules are compounded by a licensed 503A pharmacy. The pharmacy is not named. Compounded drugs are not FDA-approved, and the page states this. B12 is offered as an added ingredient. ## Where it holds up, and where it does not - Strength: Every term priced at checkout - Strength: One price at every dose - Strength: Card held until prescribed - Strength: No membership fee listed - Limitation: Product page shows only the annual rate - Limitation: Three-month term preselected at checkout - Limitation: No provider or pharmacy named - Limitation: States served are not listed ## What the evidence says about this kind of treatment The assessment above is about NuviaRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer prepared to prepay a year of treatment at the annual rate. Wrong for A buyer who wants the month-to-month price shown before checkout. ## The evidence behind what NuviaRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How NuviaRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Synergy Rx](https://thisglp.com/reviews/synergy-rx) [T2D.com](https://thisglp.com/reviews/t2d) [TD Tele-Doc Weight Loss](https://thisglp.com/reviews/td-teledoc) [TeleCareSpot](https://thisglp.com/reviews/telecarespot) [TeleClinic](https://thisglp.com/reviews/teleclinic) [TeleDocs360](https://thisglp.com/reviews/teledocs360) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $140 a month the price? Only on the annual plan, charged as $1,684.95. One month of semaglutide is $214.95. What is preselected at checkout? The three-month term. Semaglutide is $524.95 for three months. Tirzepatide is $639.95. When is the card charged? After a doctor writes the prescription. Until then the checkout places a temporary hold. Is NuviaRx expensive compared with other GLP-1 telehealth sellers? NuviaRx publishes a starting figure of $214.95/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NuviaRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Oak reviews (2026): GLP-1 telehealth sellers | This GLP Flat at every dose with no subscription, beside an advertised figure whose terms are never published. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/oak Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat, no subscription # Oak review Flat at every dose with no subscription, beside an advertised figure whose terms are never published. ## The verdict Oak publishes $250 a month for compounded semaglutide and $300 for tirzepatide. Both are flat at every dose and no subscription is required. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $250/mo Prescription Required Compounded Yes — not FDA-approved Oak sells both molecules by injection at one price per dose level. No subscription is required. A code lowers the tirzepatide figure. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state rates and terms. The intake is not documented anywhere a reader can reach. Two terms are unusually clean: one price at every dose, and no subscription. Against them sits an advertised figure the site never explains, which a reader meets before either. 2. ## What happens when the dose goes up? Both lines are flat at every dose, which answers the price question directly. Nothing describes what clinical support accompanies an increase, and the advertised entry figure has no dose attached at all. 3. ## What the price includes Six months at $250 is $1,500 and tirzepatide at $300 is $1,800. A code brings tirzepatide to $199 against a struck $300. Oak also advertises from $119, and the terms behind that figure are quiz-gated and never published, so it cannot be planned against. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: One price at every dose, both molecules - Strength: No subscription required - Strength: A code is published with its figure - Limitation: Tirzepatide costs $50 more a month - Limitation: The advertised from figure is quiz-gated - Limitation: Its terms are never published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Oak. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a flat rate without a subscription and ignores the entry figure. Wrong for A reader planning from the advertised $119. ## The evidence behind what Oak prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Oak compares | Seller | Who it suits | Go | | --- | --- | --- | | Open Water Rx | Readers who want one all-inclusive figure with no code attached | | | Obu Health | Readers who value a site that agrees with itself | | | Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TeleHealth Med](https://thisglp.com/reviews/telehealth-med) [TeleHealth Weight Solutions](https://thisglp.com/reviews/telehealth-weight-solutions) [TelePeptide](https://thisglp.com/reviews/telepeptide) [TeleSlim Clinic](https://thisglp.com/reviews/teleslim-clinic) [TeleZen MD](https://thisglp.com/reviews/telezen-md) [Tell Her Doc](https://thisglp.com/reviews/tellherdoc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I get $119 a month? The terms behind that figure are quiz-gated and never published, so nothing on the site establishes how. Is a subscription required? No. Oak states no subscription is required on either line. Does the price rise with the dose? No. Both lines are stated flat at every dose. Is Oak expensive compared with other GLP-1 telehealth sellers? Oak publishes a starting figure of $250/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Oak above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Obu Health reviews (2026): GLP-1 telehealth sellers | This GLP The homepage card and the product tile print the same figure, which several sellers here cannot manage. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/obu-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Both pages agree # Obu Health review The homepage card and the product tile print the same figure, which several sellers here cannot manage. ## The verdict Obu Health publishes starting figures of $190 a month for compounded semaglutide and $239 for tirzepatide. The homepage card and the product tile agree on both. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $190/mo Prescription Required Compounded Yes — not FDA-approved Obu Health sells both molecules by injection. Two figures are published. Both use starting-from wording. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state prices. The clinician is not described and the intake is not documented. Agreement between two pages is a low bar and several sellers do not clear it. Obu does. What it does not do is say what raises the figure. 2. ## What happens when the dose goes up? Nothing is published about dose. Starting from leaves the ceiling unstated. The floor is at least consistent across the site. 3. ## What the price includes Six months at $190 is $1,140 and tirzepatide at $239 is $1,434, both at the floor. What a higher dose costs is not published. Ask before ordering. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Card and tile print the same figure - Strength: Both molecules carry a price - Strength: No fees described beside either - Limitation: Both figures are a floor - Limitation: No milligram dose stated - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Obu Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who values a site that agrees with itself. Wrong for A reader who needs a settled figure at their dose. ## The evidence behind what Obu Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Obu Health compares | Seller | Who it suits | Go | | --- | --- | --- | | NuDay Rx | Readers wanting an oral semaglutide at the injection price | | | Open Water Rx | Readers who want one all-inclusive figure with no code attached | | | PepHaūs | Readers who will commit a quarter for a modest saving | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Telos Rx](https://thisglp.com/reviews/telos-rx) [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) [The Edit](https://thisglp.com/reviews/the-edit) [The Virtual NP](https://thisglp.com/reviews/the-virtual-np) [TMates](https://thisglp.com/reviews/tmates) [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $190 a rate? It is a starting figure. What raises it is not published. Do the two pages agree? Yes. The homepage card and the product tile print the same figure on both lines. What dose does it buy? No milligram figure is published. Is Obu Health expensive compared with other GLP-1 telehealth sellers? Obu Health publishes a starting figure of $190/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Obu Health right at the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Olleve Care reviews (2026): GLP-1 telehealth sellers | This GLP Olleve Care offers scheduled virtual consultations and names semaglutide and tirzepatide as possible treatment options. Prescriptions can go to a preferred pharmacy when appropriate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ollevecare Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Visits and pharmacy choice # Does Olleve Care sell a GLP-1? Olleve Care offers scheduled virtual consultations and names semaglutide and tirzepatide as possible treatment options. Prescriptions can go to a preferred pharmacy when appropriate. ## The verdict Olleve Care is worth considering if you want an appointment-based medical discussion and control over where a prescription is filled. It is less suited to someone expecting a published all-in medication subscription: visit fees appear during booking, and the reviewed site does not establish one drug-inclusive monthly package. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth States 13 Prescription Required Olleve Care is a virtual healthcare practice with medical weight-management services. Its FAQ describes medication alongside nutrition, activity and lifestyle guidance. The service should be understood as clinician access, not an automatic entitlement to a chosen weight-loss drug. 1. ## Who writes the prescription, and what do they see? The site describes consultations with board-certified providers who assess symptoms and discuss treatment. It lists a limited set of service jurisdictions rather than promising universal access. Confirm that your current location is supported before booking. A scheduled visit uses a device with a camera, microphone and stable internet. When appropriate, the provider sends a prescription electronically to the patient’s chosen pharmacy. Ask how subsequent reviews are arranged and whom to contact between appointments. 2. ## What happens when the dose goes up? The reviewed page does not specify a universal dose-escalation timetable or refill-visit schedule. Discuss monitoring and treatment changes with the clinician before the first fill, including how another appointment is booked if [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) interrupt treatment. 3. ## What the price includes The consultation fee is shown during booking. The public FAQ does not establish a combined continuing charge for visits, medication and laboratory work. Separate the appointment cost from the pharmacy’s prescription bill when comparing the program. 4. ## What it claims, and what it cites Olleve Care names semaglutide and tirzepatide among medications its program may include. It discusses FDA-approved and off-label prescribing, but does not identify one guaranteed brand or compounded formulation. The exact prescription and pharmacy determine what is dispensed. ## Where it holds up, and where it does not - Strength: Scheduled clinician consultation - Strength: Preferred-pharmacy prescriptions described - Strength: Supported jurisdictions publicly listed - Limitation: Medication-inclusive total not published - Limitation: Refill follow-up frequency unspecified - Limitation: Availability is not nationwide ## What the evidence says about this kind of treatment The assessment above is about Olleve Care. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient in a supported jurisdiction who wants a virtual visit and to use a local or preferred pharmacy. Wrong for Someone seeking one nationwide medication-delivery bundle with a fully published recurring price. ## The evidence behind what Olleve Care prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Olleve Care compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) [Tonik Wellness](https://thisglp.com/reviews/tonik-wellness) [Transparent Meds](https://thisglp.com/reviews/transparent-meds) [Trava Health](https://thisglp.com/reviews/trava-health) [Trellis Vitality](https://thisglp.com/reviews/trellis-vitality) [Trillium Meds](https://thisglp.com/reviews/trillium-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Olleve Care dispense the medication itself? Its FAQ describes sending an appropriate prescription to a preferred pharmacy; ask that pharmacy about filling and delivery. What happens if I miss an appointment? The site says a missed visit or cancellation within one hour can incur a fee disclosed in the booking policy. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official program](https://www.ollevecare.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Omada Health reviews (2026): weight-management care programs | This GLP Omada pairs GLP-1 support with behavior change, coaching and selected prescribing through a provider partner. The exact employer or health-plan benefit determines access. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/omada-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Omada Health sell a GLP-1? Omada pairs GLP-1 support with behavior change, coaching and selected prescribing through a provider partner. The exact employer or health-plan benefit determines access. ## The verdict Omada’s strongest feature is the support around medication: nutrition, activity and longer-term habits. Its current GLP-1 materials also describe integrated prescribing through a third-party provider. Confirm which arrangement your benefit offers rather than assuming that a support program automatically supplies a prescription. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category weight-management care programs Prescription Required Omada provides digital programs for weight health, diabetes and other chronic conditions. Its GLP-1 pathway can combine coaching, lifestyle support and partner prescribing. Enrollment begins with coverage and clinical-eligibility checks, not a universally available retail medicine order. 1. ## Who writes the prescription, and what do they see? The GLP-1 page expressly attributes prescriptions to a third-party provider partner. That distinction matters when asking who makes dose decisions or handles a side effect. A coach or peer group should not be treated as a substitute for the prescriber. Eligible participants are paired with a health coach and peer group, with connected tools depending on the program. Exercise-specialist access has a safety-screening condition. Ask which professionals are included, how they coordinate and where clinical questions are escalated. 2. ## What happens when the dose goes up? Omada emphasizes support during treatment and after discontinuation. Its reported member outcomes do not establish that an individual can stop safely or maintain the same result. Any reduction should be planned with the prescribing professional and followed by monitoring appropriate to the patient. 3. ## What the price includes Access commonly depends on employer or health-plan coverage, with program options varying by sponsor. No public single monthly drug-inclusive cost applies to every member. A covered support program does not by itself establish coverage of the prescribed medicine. 4. ## What it claims, and what it cites The public GLP-1 description does not guarantee one medication or formulation to every enrollee. Clarify the prescribing partner, covered products and pharmacy arrangement. Study or marketing comparisons between member outcomes and separate trials should not be interpreted as direct randomized evidence. ## Where it holds up, and where it does not - Strength: Behavioral support is central to the program - Strength: Prescribing partner role is disclosed - Strength: Coverage and clinical eligibility are checked - Limitation: Benefit configurations can differ - Limitation: Coaching access is not synonymous with prescribing - Limitation: No universal medication-inclusive price ## What the evidence says about this kind of treatment The assessment above is about Omada Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A person with an eligible Omada benefit who wants coordinated lifestyle support alongside an appropriately supervised GLP-1 course. Wrong for Someone seeking an immediately purchasable medication subscription without employer or plan eligibility checks. ## How Omada Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Trimi Health](https://thisglp.com/reviews/trimi-health) [TrimRx](https://thisglp.com/reviews/trimrx) [Trinity Meds](https://thisglp.com/reviews/trinity-meds) [TRT Nation](https://thisglp.com/reviews/trt-nation) [Tru2u](https://thisglp.com/reviews/tru2u) [TrueMe](https://thisglp.com/reviews/trueme) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who writes a prescription? The GLP-1 page says prescriptions are supplied by a third-party provider partner, not by the coaching team. Is every program feature available to everyone? No. Omada explains that program and clinical eligibility determine features and connected devices. Can reported results predict mine? No. Outcomes depend on the population, participation and treatment; they do not guarantee a personal response. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.omadahealth.com/) - [GLP-1 care and prescribing options](https://www.omadahealth.com/glp-1-care-track) - [Terms of service and payment conditions](https://www.omadahealth.com/terms-of-use) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Omnia TeleHealth reviews (2026): GLP-1 telehealth sellers | This GLP A general telehealth practice in coastal Alabama that prescribes GLP-1s through a flat-fee visit and leaves the medication price unpublished. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/omnia-telehealth Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Visit priced, medicine not # Omnia TeleHealth review A general telehealth practice in coastal Alabama that prescribes GLP-1s through a flat-fee visit and leaves the medication price unpublished. ## The verdict Omnia TeleHealth charges a flat $69 for a weight-loss consultation, and that visit fee is the only weight-loss figure the practice publishes anywhere on its site. The compounded semaglutide or tirzepatide a provider may prescribe afterwards is priced separately, and the FAQ answers the cost question by asking readers to get in touch for current pricing. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability 17 states Omnia is a cash-pay telehealth practice in Spanish Fort, Alabama, treating more than seventy conditions from urgent care to hair loss, with weight loss offered as one service among many. It takes no insurance, and its providers are licensed in seventeen states that the site asks patients to confirm by phone before booking. 1. ## Who writes the prescription, and what do they see? The weight-loss page says it was medically reviewed by the practice's founder and primary provider, Blair Carmichael-Lober, whose credentials are listed as DNP and CRNP, and the service list describes virtual consultations with licensed nurse practitioners. During the visit the provider decides whether a prescription goes to the patient's own pharmacy or to the partner pharmacy for a compounded version. Care is bought one visit at a time rather than through a membership, so a new patient books the weight-loss consultation and comes back later for a refill visit. That second visit, also $69, is where the provider reviews progress and side effects, adjusts the plan and renews the prescription when continuing makes sense, and same-day or next-day appointments are described as typical. 2. ## What happens when the dose goes up? Dose changes happen at those refill visits, so each step up the ladder passes through a provider and another $69 fee rather than through a published price table. No milligram schedule appears on the weight-loss pages, and what the medication costs at a higher dose is as unpublished as what it costs at the first one. 3. ## What the price includes The visit fee is stated plainly on the weight-loss page, the refill page and the general FAQ, which compares it to the cost of a typical copay. The medication is another matter, because the FAQ question about compounded semaglutide's cost is answered with a comparison to brand-name prices and an invitation to call. That leaves a reader with no monthly figure to plan around before the first visit is paid for. 4. ## What it claims, and what it cites Compounded prescriptions are filled by Belmar Pharma Solutions, which the site names as its partner pharmacy in the footer with a phone number beside it. The weight-loss page also names brand products, [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review), Wegovy, Mounjaro and Zepbound, which a provider can send to any pharmacy, and compounded preparations are not FDA-approved or reviewed by the FDA before they are dispensed. ## Where it holds up, and where it does not - Strength: The visit fee is flat and published - Strength: Belmar is named as the partner pharmacy - Strength: The reviewing clinician is named on the page - Strength: Brand or compounded, at the provider's choice - Limitation: The medication itself carries no listed price - Limitation: Seventeen states are served but not listed - Limitation: Each refill visit carries its own fee - Limitation: No dose schedule appears on the site ## What the evidence says about this kind of treatment The assessment above is about Omnia TeleHealth. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in one of Omnia's seventeen states who wants a named nurse practitioner and is willing to ask for the medication price. Wrong for A reader who wants to know what the medicine costs each month before paying for a visit. ## The evidence behind what Omnia TeleHealth prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Omnia TeleHealth compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | LifeMD | Readers with insurance that may cover the medication, leaving the fee as the main cost | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TRYM Health](https://thisglp.com/reviews/trym-health) [Tryozi](https://thisglp.com/reviews/tryozi) [Tuyo Health](https://thisglp.com/reviews/tuyo-health) [Tyde Wellness](https://thisglp.com/reviews/tyde-wellness) [UR Meds](https://thisglp.com/reviews/ur-meds) [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How much does the medication cost at Omnia TeleHealth? The site does not publish it. Its FAQ on compounded semaglutide ends by asking readers to get in touch for current pricing, so the figure arrives only by asking the practice directly or after the consultation has taken place. What does the $69 cover? One weight-loss consultation with a licensed provider, paid in cash with no insurance involved, and an established patient's later refill visit is priced at the same flat $69 on the practice's refill page. Which pharmacy fills a compounded prescription? Belmar Pharma Solutions, which the site names as its partner pharmacy for compounded medications, while a brand-name prescription can be sent to whichever pharmacy the patient already uses instead. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Omzo reviews (2026): GLP-1 telehealth sellers | This GLP Two GLP-1 rates are published, and four of the six advertised categories are not open yet. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/omzo Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A catalog still being built # Omzo review Two GLP-1 rates are published, and four of the six advertised categories are not open yet. ## The verdict Omzo prices compounded semaglutide at $179 a month and compounded tirzepatide at $279. The medication cost sits inside that fee. A branded prescription, if written instead, is the patient's to fill and fund. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $179/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Omzo runs six categories. Weight loss and sexual health are live. Hormone health, hair, skin and daily health are marked coming soon. A reader is looking at a partly finished catalog. 1. ## Who writes the prescription, and what do they see? Omzo states it is not a medical practice and employs no providers. Clinicians come from third-party networks and make the prescribing decision. The site says the assessment creates no doctor-patient relationship. No clinician is named and no state licensure list is published. A short intake, a clinician review, then delivery in discreet packaging. Support runs through an app. Omzo says it collects the medication cost in its own fee and pays the pharmacies itself. That is cleaner than a separate pharmacy bill. 2. ## What happens when the dose goes up? Nothing on the site describes what happens as the dose climbs. No milligram is published beside either figure. Whether $179 holds at a higher dose is not stated either way, so the ladder is simply absent here. 3. ## What the price includes $179 starts compounded semaglutide and $279 starts compounded tirzepatide, both as one weekly injection. Both are described as starting figures rather than flat ones. The branded route is the exception to that framing. Omzo does not sell, dispense or ship branded drugs. Their cost falls outside anything quoted here. 4. ## What it claims, and what it cites The primary program is compounded, prepared by a state-licensed sterile compounding pharmacy, and not FDA-approved. The FDA has not reviewed it for safety, effectiveness or quality. The pharmacy is not named. Omzo also states that 95 percent of its ingredients are quality-tested for purity and potency, which leaves the remainder unaccounted for. ## Where it holds up, and where it does not - Strength: Both GLP-1 rates published without an intake - Strength: Medication cost stated to be inside the fee - Strength: The branded exclusion is disclosed in writing - Strength: Compounding status stated in plain terms - Limitation: Four of six categories are not open yet - Limitation: No milligram appears beside either price - Limitation: The compounding pharmacy is not named - Limitation: A branded prescription leaves the buyer paying twice over - Limitation: The 95 percent testing claim leaves 5 percent unexplained ## What the evidence says about this kind of treatment The assessment above is about Omzo. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants one fee covering the consult, the medication and the shipping. Wrong for A buyer who expects a branded drug to be supplied by the site that prescribes it. ## The evidence behind what Omzo prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Omzo compares | Seller | Who it suits | Go | | --- | --- | --- | | NativeMed | Buyers who want to see the prepay arithmetic before deciding it is a saving | | | LumiMeds | Buyers who want the ingredient, route and pharmacy type labeled before they pay | | | Mondae | Buyers who want a low published compounded rate and few other details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vaylen](https://thisglp.com/reviews/vaylen) [Velvet Rx](https://thisglp.com/reviews/velvet-rx) [VevaRX](https://thisglp.com/reviews/vevarx) [VigorMeds](https://thisglp.com/reviews/vigormeds) [VirtualCare2Go](https://thisglp.com/reviews/virtualcare2go) [Vita Bella](https://thisglp.com/reviews/vita-bella) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the $179 include the medication? Omzo states medication costs are included in the fees it collects and that it pays the pharmacies itself. What if a provider prescribes a branded drug? Omzo does not sell, dispense or ship branded medications. Filling and paying for that prescription is the patient's responsibility. Is the dose published? No. Neither product page carries a milligram, and no rate is given for a higher dose. Is Omzo expensive compared with other GLP-1 telehealth sellers? Omzo publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Omzo below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ondra Health reviews (2026): GLP-1 telehealth sellers | This GLP The rate in the page title is a year bought in a single payment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ondra-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A year in the title # Ondra Health review The rate in the page title is a year bought in a single payment. ## The verdict Ondra Health puts $96 a month in its own page title. That rung is the twelve-month plan, charged as $1,149 up front. Month to month, semaglutide is $149 and tirzepatide is $219. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states LegitScript Claimed by provider Ondra Health sells compounded semaglutide and compounded tirzepatide by weekly injection. Care runs through Wasef Health, PC. Coverage is stated across all fifty states. 1. ## Who writes the prescription, and what do they see? Prescriptions are issued at provider discretion through Wasef Health, PC, and the medical director is named beside that sentence. The site says approvals are not automated. What a provider reads before writing one is not described anywhere. Four plan lengths sit in one table per molecule. Each prints the billed total beside the monthly rate. The two longest terms are a single payment. A buyer selects the dispensing pharmacy at checkout. 2. ## What happens when the dose goes up? The same price applies at every [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) dose inside a plan. A step up costs nothing extra. Nothing published says who approves the step. No milligram figure appears beside any plan. 3. ## What the price includes Monthly is $149 and $219. Three months is $339 and $549, billed quarterly. Six months is $649 and $999, taken up front. Twelve months is $1,149 and $1,699. The advertised rates are the bottom rung of that ladder. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. The site states plainly that compounded medications are not FDA-approved. Five pharmacies are named, and which ones a buyer can use depends on the state. ## Where it holds up, and where it does not - Strength: The billed total is printed beside every rate - Strength: One price at every dose inside a plan - Strength: The dispensing pharmacy is picked by name - Strength: No membership fee sits beside the plan - Strength: The medical director is named - Limitation: The page title quotes the twelve-month rung - Limitation: $1,149 is charged in one payment - Limitation: The longest terms run through two pharmacies only - Limitation: No milligram dose is published ## What the evidence says about this kind of treatment The assessment above is about Ondra Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who reads the billed total before the monthly figure. Wrong for A buyer who wants the headline rate without committing a year. ## The evidence behind what Ondra Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ondra Health compares | Seller | Who it suits | Go | | --- | --- | --- | | CoraDoc | Buyers who would rather pay a program once than carry a subscription they have to remember to cancel | | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vita Bella](https://thisglp.com/reviews/vita-bella) [VitaFusions IV](https://thisglp.com/reviews/vitafusions-iv) [Vital Edge](https://thisglp.com/reviews/vital-edge) [Vitalex Health](https://thisglp.com/reviews/vitalex-health) [Vitara RX](https://thisglp.com/reviews/vitara-rx) [VitaStir](https://thisglp.com/reviews/vitastir) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $96 a month what a new patient pays? Only on the twelve-month plan, which is billed as $1,149 in a single payment. The monthly plan is $149. Does a higher dose cost more? No. Ondra states that the same price applies across every titration dose within a plan. Can any pharmacy fill the longer plans? No. The six- and twelve-month plans are available only through Hallandale Pharmacy and Vials RX, and availability varies by state. Is Ondra Health legit? Ondra Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Ondra Health expensive compared with other GLP-1 telehealth sellers? Ondra Health publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ondra Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # One80Rx reviews (2026): GLP-1 telehealth sellers | This GLP One80Rx describes a supervised semaglutide program. Its product FAQ and general terms need to be reconciled before enrollment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/one80rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A prescription weight-loss platform advertising compounded GLP-1 treatment with clinical messaging, but inconsistent cancellation deadlines. # Does One80Rx sell a GLP-1? One80Rx describes a supervised semaglutide program. Its product FAQ and general terms need to be reconciled before enrollment. ## The verdict The treatment page explains weekly semaglutide and clinician access, but the thirty-day notice in its FAQ conflicts with the shorter cutoff in general terms. Get the applicable rule in writing before paying. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved One80Rx markets online weight-loss and wellness treatment through licensed clinical care and pharmacy fulfillment. The menu includes semaglutide, tirzepatide and a separate microdose category. 1. ## Who writes the prescription, and what do they see? The service describes licensed clinical review and direct messaging. Ask for the treating practice and clinician, and confirm that the clinician is authorized to treat you where you live. Direct messaging is advertised, but the public description does not define a guaranteed response time or standard follow-up schedule. Clarify how symptoms are reviewed and when a live appointment is available. 2. ## What happens when the dose goes up? The semaglutide page describes weekly treatment and individualized clinical care. A microdose category is not a substitute for a personal prescription; changes should come from the clinician. 3. ## What the price includes The semaglutide page describes a flat monthly cost without extra fees, but the homepage’s generic starting rate is not a complete quote for every medicine. Confirm the medication, supply and follow-up included. 4. ## What it claims, and what it cites The menu names semaglutide and tirzepatide, with compounded treatment disclosures. The detailed semaglutide page supports a weekly injectable program. Confirm the specific tirzepatide formulation and pharmacy rather than assuming the same product terms. ## Where it holds up, and where it does not - Strength: Describes licensed care and direct messaging - Strength: Publishes a detailed semaglutide treatment page - Limitation: Cancellation deadlines conflict across pages - Limitation: Follow-up cadence is not fully specified ## What the evidence says about this kind of treatment The assessment above is about One80Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults who want direct clinical messaging and can obtain a clear written treatment and billing plan. Wrong for Anyone who needs a single unambiguous cancellation deadline before committing. ## The evidence behind what One80Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How One80Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Voxy](https://thisglp.com/reviews/voxy) [Vyora Wellness](https://thisglp.com/reviews/vyora-wellness) [VyrarX](https://thisglp.com/reviews/vyrarx) [Vytora Health](https://thisglp.com/reviews/vytora-health) [Walgreens Weight Management](https://thisglp.com/reviews/walgreens-weight-management) [WeightCare](https://thisglp.com/reviews/weightcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which cancellation period applies? The semaglutide FAQ says thirty days; general terms say forty-eight hours before processing. Ask the service to identify the controlling rule for the exact plan. Does messaging mean immediate clinical access? No response-time guarantee is established by the reviewed description. Confirm how clinical questions and urgent symptoms are handled. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://one80rx.com/) - [Official program and terms](https://one80rx.com/terms) - [Official program and terms](https://one80rx.com/treatments/semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Raeliva reviews (2026): GLP-1 telehealth sellers | This GLP Raeliva prices each product at one monthly rate, whatever the dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/onlinesemaglutideorg Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat monthly rate, named pharmacies # Raeliva review Raeliva prices each product at one monthly rate, whatever the dose. ## The verdict Raeliva charges $219 a month for compounded semaglutide injection on the monthly plan, and $299 for tirzepatide. Each product page states the price does not rise when the dose does. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $219/mo Oral From $260/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states A telehealth storefront selling compounded semaglutide by injection or dissolving tablet, and compounded tirzepatide by injection. Pacific Shores Research Group, LLC, a San Diego company, runs the website and the intake form. 1. ## Who writes the prescription, and what do they see? Clinicians practice through Lion MDs, an independent medical practice with licenses in all 50 states. CareValidate Incorporated runs the consultation, the medical record and billing. The storefront states it employs no clinicians and writes no prescriptions, and the treating practice is confirmed during intake. A provider decides eligibility after the intake, and nothing is charged if the provider declines. Medication ships refrigerated, usually overnight, and check-ins, dosing guidance and refill timing run through the clinical team. Plans are subscriptions that can be canceled at any time. 2. ## What happens when the dose goes up? "Same price at every dose" is printed on each product page. The starting dose is described as low and adjusted gradually, but no milligram schedule is published. So the price claim covers escalation, while the escalation itself is not described. 3. ## What the price includes Semaglutide injection is $219 month to month. Three months cost $500 billed at once, and six months $900, which the page shows as $167 and $150 a month. The dissolving tablet is $260 monthly, or $550 per quarter. Tirzepatide is $299 monthly, $800 per quarter, and $242 a month on six months. 4. ## What it claims, and what it cites Both molecules are compounded, and the legal page names six fulfilling pharmacies, among them Belmar Pharmacy and Strive Pharmacy. Compounded preparations are not FDA-approved, and the product pages say so. Trial figures on those pages come from the approved drugs, a limit the pages state themselves. ## Where it holds up, and where it does not - Strength: One price at every dose, stated per product - Strength: The fulfilling pharmacies are named - Strength: The prescribing practice is named - Strength: No charge if the provider declines - Limitation: The lowest rates need an upfront term charge - Limitation: No milligram schedule is published - Limitation: Billing runs through a separate company - Limitation: Three companies divide one patient's care ## What the evidence says about this kind of treatment The assessment above is about Raeliva. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a flat monthly rate and a named prescribing practice. Wrong for A buyer who wants the storefront itself to be the clinical provider. ## The evidence behind what Raeliva prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Raeliva compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | MEDVi | Readers who want the injected line, where the card figure is the medicine's figure | | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [WeightRx](https://thisglp.com/reviews/weightrx) [WeightWatchers Clinic](https://thisglp.com/reviews/weight-watchers) [Welling Health](https://thisglp.com/reviews/welling-health) [Wellspring Longevity Clinic](https://thisglp.com/reviews/wellspring-longevity-clinic) [WePeptideRx](https://thisglp.com/reviews/wepeptiderx) [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does tirzepatide cost? $299 a month on the monthly plan, $800 per quarter, or $242 a month on the six-month plan. What does semaglutide cost month to month? $219 for the injection and $260 for the dissolving tablet, at any dose. Who writes the prescription? Clinicians practicing through Lion MDs, while CareValidate handles the consultation record and billing. Is Raeliva legit? Raeliva is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Raeliva expensive compared with other GLP-1 telehealth sellers? Raeliva publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Raeliva above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # OnlyRx reviews (2026): GLP-1 telehealth sellers | This GLP The promotional banner offers the price the product card already charges. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/onlyrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A sale at list price # OnlyRx review The promotional banner offers the price the product card already charges. ## The verdict OnlyRx runs a promotional banner quoting $179, and $179 is what its semaglutide injection card charges without it. The four prices are otherwise plainly stated, and going needle-free costs $70 more rather than less. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $179/mo Oral From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states OnlyRx is a cash-pay telehealth service selling compounded semaglutide and compounded tirzepatide. Each molecule is offered as a weekly injection and as a daily orally dissolving tablet. The service states it operates in all fifty US states. 1. ## Who writes the prescription, and what do they see? OnlyRx describes itself as a platform connecting patients to independent licensed providers who make the prescribing decisions. A medical group is named on the page. The full flow from intake to delivery is stated as roughly two to three weeks. What a provider reviews before approving is not described. One rate is stated to cover the consult, the prescription process and shipping, with no membership charged on top. Reordering is patient-initiated rather than locked to a term. Buy-now-pay-later financing is offered. Support runs by email rather than a scheduled visit. 2. ## What happens when the dose goes up? No dose schedule is published beside any of the four prices. The rates are quoted as starting figures, which leaves room for a higher dose to cost more. Nothing on the page states who authorizes a step up, or when. 3. ## What the price includes Semaglutide is $179 injected and $249 as a tablet. Tirzepatide is $249 injected and $279 as a tablet. The needle-free option is therefore the more expensive one on both molecules. A banner above all four quotes $179, which is the semaglutide injection card's own figure. 4. ## What it claims, and what it cites Both lines may be compounded, and the page states plainly that compounded medications are not FDA-approved. It also states a provider may instead prescribe a branded product. Four compounding pharmacies are named with phone numbers and web addresses. ## Where it holds up, and where it does not - Strength: Four compounding pharmacies are named outright - Strength: All four format prices are published on one page - Strength: Consult, prescription and shipping sit inside the rate - Strength: No membership fee is charged - Strength: Financing is offered at checkout - Limitation: The advertised promotion matches the standing price - Limitation: Both needle-free formats cost more than the injections - Limitation: No milligram dose is published - Limitation: Every rate is a starting figure rather than a ceiling ## What the evidence says about this kind of treatment The assessment above is about OnlyRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the dispensing pharmacy named before paying. Wrong for A buyer expecting a promotional banner to beat the listed rate. ## The evidence behind what OnlyRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How OnlyRx compares | Seller | Who it suits | Go | | --- | --- | --- | | CoreAge Rx | A reader still at a starting dose, since that is the tier these rates price. | | | SnagRx | Buyers who want to stay month to month without paying much for it | | | Strut Health | A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Whoosh Wellness](https://thisglp.com/reviews/whoosh-wellness) [Wisp](https://thisglp.com/reviews/wisp) [Woodwork](https://thisglp.com/reviews/woodwork) [YourHealthRx](https://thisglp.com/reviews/yourhealthrx) [Yucca Health](https://thisglp.com/reviews/yucca-health) [Zappy Health](https://thisglp.com/reviews/zappy-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the tablet cheaper than the injection? No. Semaglutide is $249 as a tablet against $179 injected, and tirzepatide is $279 against $249. Which pharmacies fill the prescription? Belmar Pharmacy, Strive Pharmacy, Epiq Scripts and Casa Pharma Rx are each named on the page with contact details. Is the medication FDA-approved? Compounded medications are not, and the page says so. A provider may alternatively prescribe an FDA-approved branded product. Is OnlyRx legit? OnlyRx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is OnlyRx expensive compared with other GLP-1 telehealth sellers? OnlyRx publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts OnlyRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Onyx Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP The ninety-nine dollar plan on the weight-loss page is a different medication entirely. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/onyx-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The cheap card is another drug # Onyx Weight Loss review The ninety-nine dollar plan on the weight-loss page is a different medication entirely. ## The verdict Onyx Weight Loss publishes a standard GLP-1 plan at $228 a month and a dual GLP-1 and GIP plan from $280. The $99 card on the same page is Amlexanox, which is not a GLP-1. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 8 From From $228/mo Prescription Required Compounded Yes — not FDA-approved Availability 8 states Onyx Weight Loss sells GLP-1 and dual-agonist plans across eight states. A third plan on the same page uses a different drug class. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages name plans rather than clinicians. What the plans contain is named, which is how the mismatch on the lowest card becomes visible. Three cards sit together and one of them is a different treatment. A reader scanning for a price sees $99 first. Nothing on the layout separates the drug classes. 2. ## What happens when the dose goes up? A GLP-1 microdosing plan is offered as a low-dose gradual start. Nothing states what either main plan costs at a higher dose. The dual-agonist figure is described as an entry tier. 3. ## What the price includes The standard GLP-1 plan is $228 a month, which is $1,368 over six months. The dual-agonist plan starts at $280 and includes medication and supplies. The $99 card belongs to Amlexanox and should not enter a GLP-1 comparison at all. 4. ## What it claims, and what it cites The GLP-1 lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. Amlexanox is a different drug with a different purpose. ## Where it holds up, and where it does not - Strength: Medication and supplies inside the dual plan - Strength: A low-dose gradual-start option exists - Strength: Coverage recorded across eight states - Limitation: A non-GLP-1 card sits beside the GLP-1 plans - Limitation: Its $99 is the first figure a reader meets - Limitation: The dual figure is an entry tier only - Limitation: Forty-two states are not served ## What the evidence says about this kind of treatment The assessment above is about Onyx Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in a served state who checks which drug a card names. Wrong for A reader comparing the $99 against a GLP-1 price. ## The evidence behind what Onyx Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Onyx Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | PlexusDx | A reader who will scroll past the entry card to find a product with a name | | | Open Water Rx | Readers who want one all-inclusive figure with no code attached | | | Oak | Readers who want a flat rate without a subscription and ignore the entry figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Zealthy](https://thisglp.com/reviews/zealthy) [Zera Health](https://thisglp.com/reviews/zera-health) [Zeuss](https://thisglp.com/reviews/zeuss) [ZipHealth](https://thisglp.com/reviews/ziphealth) [ZYP Medical](https://thisglp.com/reviews/zyp-medical) [10Rx](https://thisglp.com/reviews/10rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the $99 plan? Amlexanox, which is not a GLP-1. The standard GLP-1 plan on the same page is $228 a month. What does the dual-agonist plan cost? From $280 a month, with medication and supplies included. That figure is an entry tier. Where does Onyx operate? Eight states are recorded in its coverage list. Is Onyx Weight Loss legit? Onyx Weight Loss is a GLP-1 telehealth sellers service. Its stated availability: 8 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Onyx Weight Loss expensive compared with other GLP-1 telehealth sellers? Onyx Weight Loss publishes a starting figure of $228/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Onyx Weight Loss above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Open Water Rx reviews (2026): GLP-1 telehealth sellers | This GLP Both figures are stated as flat monthly prices, and no code is needed to reach either. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/open-water-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat and all-inclusive # Open Water Rx review Both figures are stated as flat monthly prices, and no code is needed to reach either. ## The verdict Open Water Rx publishes $169 a month for compounded semaglutide and $219 for tirzepatide. The site calls the tirzepatide figure the flat all-inclusive price. No code is needed for either. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $169/mo Prescription Required Compounded Yes — not FDA-approved Open Water Rx sells both molecules by injection, with an all-inclusive framing covering provider review, medication if prescribed, and shipping. 1. ## Who writes the prescription, and what do they see? Provider review is named as included, and the figure is conditional on medication being prescribed. Both are stated. The clinician is not otherwise described. An all-inclusive figure is a stronger commitment than a headline rate usually carries. Provider review, medication if prescribed and shipping are named inside it, so a reader can hold the seller to the list. 2. ## What happens when the dose goes up? Nothing is published about dose on either main line. Two further programs exist — a lower-dose [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) plan at $179 and an oral option at $279 — and neither names its molecule, so neither can be priced as a drug. 3. ## What the price includes Six months at $169 is $1,014 and tirzepatide at $219 is $1,314. Neither figure depends on a code. The site states the tirzepatide figure is all-inclusive, and the semaglutide line carries the same framing. 4. ## What it claims, and what it cites Both main lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: No code needed for either figure - Strength: Provider review and shipping included - Strength: Tirzepatide stated flat and all-inclusive - Limitation: No compounding pharmacy is named - Limitation: Two further programs name no molecule - Limitation: No dose behavior is published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Open Water Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one all-inclusive figure with no code attached. Wrong for A reader who needs the cost at a maintenance dose stated in advance. ## The evidence behind what Open Water Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Open Water Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Oak | Readers who want a flat rate without a subscription and ignore the entry figure | | | Obu Health | Readers who value a site that agrees with itself | | | Onyx Weight Loss | A reader inside the eight-state footprint who reads what each card actually names | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AJ Peptide](https://thisglp.com/reviews/aj-peptide) [Ambiante Health & Wellness](https://thisglp.com/reviews/ambiante-health-wellness) [Aurelius Health Group](https://thisglp.com/reviews/aurelius-health-group) [AVArx](https://thisglp.com/reviews/avarx) [Basal Health](https://thisglp.com/reviews/basal-health) [Better MedSpa](https://thisglp.com/reviews/better-medspa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What are the current figures? $169 a month for semaglutide and $219 for tirzepatide. Do I need a code? No. Both figures are base prices, and the site calls $219 the flat all-inclusive price for tirzepatide. What are the other two programs? A lower-dose titration plan at $179 and an oral option at $279. Neither names its molecule. Is Open Water Rx expensive compared with other GLP-1 telehealth sellers? Open Water Rx publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Open Water Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Optimized Health reviews (2026): GLP-1 telehealth sellers | This GLP A Missouri clinic with a named prescribing clinician, lab panels when indicated, and telehealth in five states. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/optimized-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A Joplin clinic, named clinician # Optimized Health review A Missouri clinic with a named prescribing clinician, lab panels when indicated, and telehealth in five states. ## The verdict Optimized Health prices compounded semaglutide from $200 a month and tirzepatide from $250, with medication included and no contract, and it names the clinician who writes every prescription. The figures are starting rates that the page says may vary with a patient's protocol, and lab work, when the clinician orders it, is billed on top of them. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 5 From From $200/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Extra cost Availability MO, IA, KS, UT, WA Optimized Health is a weight-loss and hormone clinic in Joplin, Missouri, that sees patients in person and by telehealth in Missouri, Iowa, Kansas, Utah and Washington. Its weight-loss program covers compounded semaglutide and tirzepatide injections, oral medications such as phentermine on a separate visit fee, and brand-name prescriptions sent to a patient's own pharmacy for insurance to cover. 1. ## Who writes the prescription, and what do they see? The page names Mathew Hammons, a physician assistant it describes as the practice's prescribing clinician, with more than fifteen years in obesity medicine, and it states that every protocol, adjustment and follow-up runs through him directly. A single named prescriber for the whole program gives a patient continuity from the first visit onward, though the page does not say who covers his patients when he is away. Treatment begins with a consultation, then a clinical evaluation that can include a lab panel the page puts at up to forty-plus biomarkers when the clinician decides it is indicated, and every visit includes an InBody body-composition scan. Between visits a patient can call the Joplin clinic directly or drop in for a free weigh-in during clinic hours, and the page describes a taper plan built into the program from the start. 2. ## What happens when the dose goes up? The page describes regular check-ins and dose adjustments made to a patient's progress rather than refills on a fixed schedule, and it says the clinician starts low and raises the dose gradually to keep [nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) down. What it does not say is whether the starting monthly figure holds at higher doses, and its own line that prices may vary with the protocol leaves that open until the first consultation. 3. ## What the price includes Compounded semaglutide starts at $200 a month and tirzepatide at $250, each described as including the medication, monitoring and provider care, with no contract and HSA or FSA cards accepted. Lab retesting is billed separately when clinically indicated, a condition the page repeats under each medication card, and the oral and brand-name programs carry a clinical supervision fee in place of an all-in monthly rate. 4. ## What it claims, and what it cites The injectables are prepared by licensed compounding pharmacies that the page does not name, and compounded preparations are not FDA-approved. The FAQ describes [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) as FDA-approved, which is true of Wegovy and Zepbound but not of the compounded versions priced on this page. For patients whose insurance covers a brand-name drug, the practice submits the prior authorization and appeals denials where it can. ## Where it holds up, and where it does not - Strength: Prescribing clinician named on the page - Strength: In-person visits available in Joplin - Strength: Body-composition scan at every visit - Strength: Taper plan described from the start - Limitation: Telehealth limited to five states - Limitation: Labs billed separately when ordered - Limitation: Starting prices may vary by protocol - Limitation: Compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Optimized Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient in Missouri, Iowa, Kansas, Utah or Washington who wants a named clinician and the option of walking into a clinic. Wrong for A buyer outside those five states, or one who wants a single monthly figure that covers any lab work. ## The evidence behind what Optimized Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Optimized Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | | Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | | | Fidelity Medical Clinic | A reader who counts fills rather than months, and who budgets from the maintenance order instead of the discounted intro one. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [BodyLogicMD](https://thisglp.com/reviews/bodylogicmd) [Broose Wellness](https://thisglp.com/reviews/broose-wellness) [CAPO Health](https://thisglp.com/reviews/capo-health) [Chia](https://thisglp.com/reviews/chia-health) [Chronos Body Health & Wellness](https://thisglp.com/reviews/chronos-bhw) [CVS MinuteClinic](https://thisglp.com/reviews/cvs-minuteclinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Are labs included in the monthly price? No. The monthly figure includes medication, monitoring and provider care, and lab work is billed separately whenever the clinician decides it is clinically indicated for that patient. Can the whole program be done by telehealth? Yes, for patients in Missouri, Iowa, Kansas, Utah and Washington, with blood drawn at a local lab site and medication shipped to the door, while the Joplin clinic stays open for in-person visits. Who prescribes? Mathew Hammons, a physician assistant whom the practice identifies as its prescribing clinician, and through whom it says every protocol, dose adjustment and follow-up is run. Is Optimized Health legit? Optimized Health is a GLP-1 telehealth sellers service. Its stated availability: MO, IA, KS, UT, WA. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Optimized Health expensive compared with other GLP-1 telehealth sellers? Optimized Health publishes a starting figure of $200/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Optimized Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Options Medical Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP The only semaglutide figure is a twelve-month plan paid in full, so no monthly rate exists to rank at all. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/options-medical-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 No monthly rate exists # Options Medical Weight Loss review The only semaglutide figure is a twelve-month plan paid in full, so no monthly rate exists to rank at all. ## The verdict Options Medical Weight Loss states its semaglutide figure as $199 per month for a twelve-month plan paid in full — $2,388 charged at signup. No monthly rate is published, so no semaglutide price is ranked here. Tirzepatide is $299. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Options Medical Weight Loss sells both molecules by injection on annual plans, with higher tiers on the tirzepatide line and eligibility for health-account spending stated. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the clinician is not described. The commitment being annual makes that gap larger: a buyer is committing a year before meeting whoever will manage it. The seller states the term twice on its own pages, which is more than many do, and it does not offer the alternative at all. A reader who wants to try a month cannot, at any price, because no month-to-month figure exists to quote. 2. ## What happens when the dose goes up? Nothing states what the figure does at a higher dose on the semaglutide line. Tirzepatide is published as a band from $339 to $399 with the same twelve-month structure, so the ladder there is at least bounded. 3. ## What the price includes $2,388 is the number to plan against on the semaglutide line, and it lands at once. The $199 monthly framing describes how that total divides rather than how it is billed, which is why no monthly figure is ranked for it here. Tirzepatide is the line that carries a rankable price: $299 a month, down from $399, with higher tiers previously published at $339 to $399. Health-account eligibility is stated, which helps with the tax treatment and not with the cash flow. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The twelve-month term is stated on two pages - Strength: HSA and FSA eligibility is published - Strength: The tirzepatide band is bounded - Strength: Tirzepatide fell $100 - Limitation: The whole year is charged at signup - Limitation: No month-to-month rate is published - Limitation: The monthly framing is arithmetic, not billing - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Options Medical Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader certain of a year who can pay $2,388 at once. Wrong for A reader who wants to start with one month. ## The evidence behind what Options Medical Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Options Medical Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | Ozari Health | A reader new to the drug class who will check the plan table before quarter two | | | Oria Meds | Readers who will commit six months and know which rung the headline is | | | Oak | Readers who want a flat rate without a subscription and ignore the entry figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Defy Medical](https://thisglp.com/reviews/defy-medical) [Docberry](https://thisglp.com/reviews/docberry) [Elara MD](https://thisglp.com/reviews/elara-md) [EmbraceRX](https://thisglp.com/reviews/embrace-rx) [eMed](https://thisglp.com/reviews/emed) [Enara Health](https://thisglp.com/reviews/enara-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 billed monthly? No. Two of the seller's own pages state it is per month for a twelve-month plan paid in full, which is $2,388 charged at signup. Can I pay month to month? No month-to-month rate is published anywhere on the site. What does tirzepatide cost? $299 a month, down from $399, with higher tiers previously published between $339 and $399. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # OrderlyMeds reviews (2026): GLP-1 telehealth sellers | This GLP The advertised figures belong to a new-patient starter program. The monthly plans are printed on the same page. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/orderlymeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two-month offer, then the monthly plan # OrderlyMeds review The advertised figures belong to a new-patient starter program. The monthly plans are printed on the same page. ## The verdict OrderlyMeds charges $149 a month for compounded semaglutide and $299 for compounded tirzepatide on its monthly plans. The $74 in its headline applies to new patients only. It covers a two-month starter program at the starting dose, paid upfront. The FAQ states the standing rates in plain figures. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $149/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states OrderlyMeds is an online GLP-1 service selling compounded semaglutide and compounded tirzepatide by weekly injection. Brand Wegovy and Zepbound plans are listed beside them at four-figure monthly prices. NAD+ and sermorelin sit in a separate longevity line. Coverage is stated as all 50 states. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews a medical form, and the pricing page describes a text-based telehealth visit. A video call is added only where the patient's state requires one. Dr. Brian Spears is named as chief medical officer, with an emergency medicine background. The individual prescriber for a given patient is not named before intake. Approval is stated to come within 24 hours, with delivery in five to six business days. Provider messaging, virtual consults and a coaching bundle are listed inside the price. No membership fee is charged. HSA and FSA cards are accepted. 2. ## What happens when the dose goes up? New patients start at 0.25 mg for four weeks, per the compounded product FAQ. A patient already on a GLP-1 can start at the last prescribed dose with proof of the prescription. The FAQ states that the price does not rise with the dose. The Zepbound page gives 2.5 mg as the starting dose for tirzepatide. 3. ## What the price includes Two tabs sit above the plans. New patients see the starter offer: $74 a month for semaglutide and $149 for tirzepatide, each billed as two months at once. Patients already on a GLP-1 see a smaller discount on the same two-month shape. Beneath both tabs, the monthly plans read $149 and $299. Six months at the monthly rate is $894 for semaglutide. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded rather than manufactured. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing, which the site's own footnote says. The FAQ names three pharmacies: SmartPharmaRx, Casa and PerfectRx. Each is described as a licensed 503A pharmacy. ## Where it holds up, and where it does not - Strength: Monthly plan rates printed beside the offer - Strength: Price stated as the same at every dose - Strength: Three dispensing pharmacies named in the FAQ - Strength: A chief medical officer is named - Strength: No membership fee on either molecule - Limitation: The headline is a two-month new-patient offer - Limitation: The starter program is paid upfront - Limitation: Visits are text-based unless a state requires video - Limitation: The homepage and pricing page disagree on starter length ## What the evidence says about this kind of treatment The assessment above is about OrderlyMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who reads past the starter offer to the monthly plan beneath it. Wrong for A buyer who expects the headline figure to recur after the second month. ## The evidence behind what OrderlyMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How OrderlyMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Enhanced](https://thisglp.com/reviews/enhanced) [EverFit Medical](https://thisglp.com/reviews/everfit-medical) [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) [Evernow](https://thisglp.com/reviews/evernow) [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) [FeelGood](https://thisglp.com/reviews/feelgood-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost after the starter program? $149 a month. The FAQ says the next month is billed at the standard monthly rate, and names $149 for semaglutide and $299 for tirzepatide. Who qualifies for the $74 figure? New patients who begin at the starting dose. It is sold as a two-month program paid in full upfront. Does the price change as the dose goes up? Not according to the FAQ, which states that all medication is the same price per dosage. Is the pharmacy named? Yes. SmartPharmaRx, Casa and PerfectRx are listed as the pharmacies the service works with. Is OrderlyMeds legit? OrderlyMeds is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is OrderlyMeds expensive compared with other GLP-1 telehealth sellers? OrderlyMeds publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts OrderlyMeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Oria Meds reviews (2026): GLP-1 telehealth sellers | This GLP The tirzepatide figure belongs to a six-month prepay, and the line ships quarterly rather than monthly. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/oria-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Ships every three months # Oria Meds review The tirzepatide figure belongs to a six-month prepay, and the line ships quarterly rather than monthly. ## The verdict Oria Meds publishes $199 a month for compounded semaglutide as an ongoing rate, with a first month at $89. Its $299 tirzepatide figure is the six-month prepay rung; month to month is $369. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $199/mo Prescription Required Compounded Yes — not FDA-approved Oria Meds sells both molecules by injection, with the semaglutide line billed monthly and the tirzepatide line shipping every three months across a three-rung ladder. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. The quarterly shipping cadence on the tirzepatide line is the kind of operational detail that usually implies a review schedule, and none is published. The semaglutide side is straightforward: an introductory month, then a stated ongoing rate. The tirzepatide side needs reading twice, because the figure a reader meets belongs to the longest commitment on the ladder rather than to the product itself. 2. ## What happens when the dose goes up? Both lines are recorded as flat, so the rate holds as the dose rises. What moves instead is the term, and on tirzepatide the term is what the advertised figure is really describing. 3. ## What the price includes Semaglutide is $89 for a first month then $199, so six months is $1,084. Tirzepatide month to month is $369 after a $129 introductory month, the three-month plan is $316 a month, and the six-month rung is $299, billed $1,794 per six months. A reader comparing $299 against another seller's monthly rate is comparing half a year against thirty days. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: All three tirzepatide rungs are published - Strength: Introductory months labeled as such - Strength: Both lines stated flat across doses - Limitation: The tirzepatide headline is a six-month rung - Limitation: Month to month costs $70 more - Limitation: The line ships every three months - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Oria Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will commit six months and knows which rung the headline is. Wrong for A reader reading $299 as a monthly tirzepatide rate. ## The evidence behind what Oria Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Oria Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Ozari Health | A reader new to the drug class who will check the plan table before quarter two | | | Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | | | PeterMD | Readers who want a cancel-anytime subscription and will choose the monthly product over the quarterly offer | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Florida Weight Loss MD](https://thisglp.com/reviews/florida-weight-loss-md) [Found Youth](https://thisglp.com/reviews/found-youth) [Freeley](https://thisglp.com/reviews/freeley) [FuturHealth](https://thisglp.com/reviews/futurhealth) [G-Plans](https://thisglp.com/reviews/g-plans) [Gatlan](https://thisglp.com/reviews/gatlan) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $299 the monthly tirzepatide price? No. It is the six-month prepay rung, billed $1,794 per six months. Month to month is $369. What does semaglutide cost? $89 for a first month as a limited offer, then $199 a month ongoing. How often does tirzepatide ship? Every three months, which is a different cadence from the monthly billing on the semaglutide line. Is Oria Meds expensive compared with other GLP-1 telehealth sellers? Oria Meds publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Oria Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # OurView Health reviews (2026): care and follow-up | This GLP OurView offers dose-independent monthly pricing, an authorization before clinical approval, and a patient portal for follow-up. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ourview-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Assessment before final payment # OurView Health review OurView offers dose-independent monthly pricing, an authorization before clinical approval, and a patient portal for follow-up. ## The verdict OurView charges $109 a month for compounded semaglutide and $129 for compounded tirzepatide. Both are month-to-month rates. Paying three months at once lowers each by ten dollars. No membership fee applies. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $109/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 46 states and DC LegitScript Claimed by provider OurView is an online platform for weight loss, hormone and wellness care. The GLP-1 line is compounded semaglutide and compounded tirzepatide. The footer calls OurView a patient management platform. Independent physician networks and a licensed U.S. pharmacy deliver the care. 1. ## Who writes the prescription, and what do they see? OurView separates its platform from the independent clinicians who deliver care. A U.S.-licensed provider reviews health history and determines suitability after intake. Checkout authorizes the payment method, but the FAQ says the charge is finalized only after treatment approval. If treatment is declined, the authorization is released. A payment hold is therefore not a promise that a prescription will follow. The patient portal is the route for account details and messages to the care team. The published sequence is treatment selection, health assessment, provider review, then pharmacy fulfillment. Each supply is described as 30 days. OurView lists service in 46 states plus DC, excluding Arkansas, Connecticut, Hawaii and New Jersey. Confirm availability before transferring care, particularly when a move would put you in an excluded state. 2. ## What happens when the dose goes up? The price is stated to hold at any prescribed dose. The homepage repeats this on both product cards. No milligram dose is published for either molecule. Who approves a dose change is described only as the provider. 3. ## What the price includes The monthly prices remain $109 for semaglutide and $129 for tirzepatide. A prepaid quarter reduces each monthly equivalent by ten dollars; semaglutide costs $297 upfront. Membership and delivery carry no separate charge. Prescription sales become final after payment and handoff to the carrier. Cancel through the account before shipment. The policy does not promise a refund for unused portions of a prepaid quarter. 4. ## What it claims, and what it cites The treatments are compounded and are not FDA-approved products. OurView describes licensed pharmacy fulfillment but does not identify the assigned dispenser on its treatment cards. Its return policy names Boudreaux’s New Drug Store as a return address; that alone does not establish who fills every GLP-1 order. Ask for the pharmacy name and follow the storage directions supplied with the actual prescription. ## Where it holds up, and where it does not - Strength: Month-to-month rates on both molecules - Strength: Price stated as the same at any dose - Strength: No membership fee and no shipping fee - Strength: Prepay saving stated in dollars - Strength: LegitScript approval displayed - Limitation: Assigned clinician and pharmacy need confirmation - Limitation: No complete milligram schedule beside pricing - Limitation: Four states excluded from service - Limitation: Unused prepaid months lack an explicit refund promise ## What the evidence says about this kind of treatment The assessment above is about OurView Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient comfortable with remote assessment who wants the prescribed dose to leave the monthly bill unchanged. Wrong for Someone needing in-person follow-up or a guaranteed refund for unused prepaid medication. ## The evidence behind what OurView Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How OurView Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Lifestyle Medicine](https://thisglp.com/reviews/genesis-lifestyle-medicine) [Gide Health](https://thisglp.com/reviews/gide-health) [Glow](https://thisglp.com/reviews/glow) [GOAL.MD](https://thisglp.com/reviews/goal-md) [GoodLife Health](https://thisglp.com/reviews/goodlife-health) [Happy Care Meds](https://thisglp.com/reviews/happy-care-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked When does OurView charge the card? The FAQ describes an initial authorization followed by a finalized charge after treatment approval. A declined treatment releases the authorization. Does the monthly price change at higher doses? OurView advertises $109 for semaglutide and $129 for tirzepatide at any prescribed dose. The clinician still determines which dose is appropriate. Is OurView available in every state? No. Its FAQ excludes Arkansas, Connecticut, Hawaii and New Jersey, while listing the remaining states and DC. What happens if a package is lost? Contact the patient care team. The return policy says OurView first works with the carrier to locate the shipment and will reship a lost order. Is OurView Health legit? OurView Health is a GLP-1 telehealth sellers service. Its stated availability: 46 states and DC. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is OurView Health expensive compared with other GLP-1 telehealth sellers? OurView Health publishes a starting figure of $109/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts OurView Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 14, 2026. Terms can change. - [Current treatment prices](https://ourviewhealth.com/) - [Care, approval and availability](https://ourviewhealth.com/faq/) - [Returns and lost shipments](https://ourviewhealth.com/return-refund-policy/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ozari Health reviews (2026): GLP-1 telehealth sellers | This GLP The lowest figure is a starter block for people new to GLP-1, and the full plan table sits behind it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ozari-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A starter you can use once # Ozari Health review The lowest figure is a starter block for people new to GLP-1, and the full plan table sits behind it. ## The verdict Ozari Health advertises semaglutide from $86 a month, which is a three-month starter restricted to first-time GLP-1 users and charged $257 up front. Its own plan table lists monthly at $175. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $175/mo Prescription Required Compounded Yes — not FDA-approved Ozari Health sells both molecules by injection across four plan lengths, with a separate entry block that only some readers are eligible for. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. The eligibility rule on the starter block is clinical in form and commercial in effect: it sorts buyers by whether they have taken a GLP-1 before. The compare-all-plans table is the honest document here, and it is the one a reader has to find. It lists monthly, quarterly, semi-annual and annual rates for both molecules, and the advertised figure appears on none of them because it belongs to a block sold once. 2. ## What happens when the dose goes up? Nothing states what any rung does at a higher dose, though the site notes figures range upward by dose and plan. So two variables move and only one of them is published as a ladder. 3. ## What the price includes The semaglutide table reads $175 monthly, $145 quarterly, $120 semi-annual and $99 annual. Tirzepatide reads $235, $199, $175 and $140. The starter blocks are $257 and $375 charged at once, and both are first-time only. A returning buyer should plan from $175 or $235, not from the advertised figure. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: A full four-rung table for both molecules - Strength: Shipping stated as included - Strength: The starter block's total is published - Limitation: The advertised figure is first-time only - Limitation: Monthly costs twice the headline - Limitation: Figures also range upward by dose - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Ozari Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader new to GLP-1 who will read the plan table before the second quarter. Wrong for A returning buyer, who cannot reach the advertised figure at all. ## The evidence behind what Ozari Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ozari Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Oria Meds | Readers who will commit six months and know which rung the headline is | | | Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | | | Open Water Rx | Readers who want one all-inclusive figure with no code attached | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealFastRx](https://thisglp.com/reviews/healfast) [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) [Hone Health](https://thisglp.com/reviews/hone-health) [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) [KairoRx](https://thisglp.com/reviews/kairorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I get $86 a month? Only as a first-time GLP-1 user, and only as a three-month starter charged $257 up front. What does the monthly plan cost? $175 for semaglutide and $235 for tirzepatide, per the compare-all-plans table. How low do the longer plans go? $99 a month for semaglutide on the annual rung and $140 for tirzepatide. Is Ozari Health expensive compared with other GLP-1 telehealth sellers? Ozari Health publishes a starting figure of $175/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ozari Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Pallas Health reviews (2026): GLP-1 telehealth sellers | This GLP The monthly figure is an average the seller publishes itself: one discounted first month, then a charge every twelve weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pallas-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Billed every twelve weeks # Pallas Health review The monthly figure is an average the seller publishes itself: one discounted first month, then a charge every twelve weeks. ## The verdict Pallas Health charges $139 for a first month of compounded semaglutide and $597 every twelve weeks after it, which the seller averages to $199 a month. Twelve weeks is 2.76 calendar months rather than three, so the figure ranked here is $216. Tirzepatide works out at $325 on the same arithmetic. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 51 From From $216/mo Prescription Required Compounded Yes — not FDA-approved Pallas Health sells compounded semaglutide and compounded tirzepatide as weekly injections across fifty states and the District of Columbia, and the billing shape is the first thing worth understanding. A reader pays $139 to start on semaglutide, and from then on the card is charged $597 at a time, twelve weeks apart. Provider care and check-ins are described as included in that figure, and the rate is stated as the same at every dose. 1. ## Who writes the prescription, and what do they see? Check-ins are inside the price rather than billed against a visit, which changes what the twelve-week charge is actually buying — it is a quarter of care rather than a quarter of medication. That distinction matters most in the second quarter, when a reader is usually deciding whether to stay at a dose or move up. How often the check-ins happen, and whether they are live or asynchronous, is not something the priced row establishes. Treatment is arranged remotely and the medication arrives on a schedule tied to the twelve-week block rather than to a calendar month. The first month is deliberately cheap, which is a good thing for a reader who wants to find out how the drug suits them, and a slightly awkward thing when it is averaged into a headline. The seller does the averaging in public, on the page, rather than leaving the reader to discover the real cadence at the second charge. 2. ## What happens when the dose goes up? The rate is stated as the same at every dose on both molecules, so the escalation that runs through the first sixteen weeks does not move the bill. What does move is the timing: the first dose increase usually lands inside the first twelve-week block, and the second charge arrives whether or not the drug has suited the reader. A quarter is a long commitment at the exact point most people are still deciding. 3. ## What the price includes The averaging is where the seller and this desk part company, and the gap is small but real. Twelve weeks is 2.76 calendar months rather than three, so $597 every twelve weeks is $216 a calendar month and not the $199 the page advertises. The tirzepatide block at $897 works out at $325 on the same arithmetic rather than $299. The first-month figures of $139 and $179 make the opening quarter cheaper than the ones after it, so a reader budgeting from the first charge will underestimate the second. 4. ## What it claims, and what it cites Both products are compounded, which means a pharmacy prepares them rather than a manufacturer, and no regulator reviews the finished vial before it is dispensed. A reader who has seen the published weight-change figures for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) should know those came from the approved product at the doses on its label. Whether a compounded vial matches that product in content or purity is not measured, and no billing arrangement changes that. ## Where it holds up, and where it does not - Strength: Seller publishes its own averaging - Strength: Provider care and check-ins included - Strength: Rate stated as flat at every dose - Limitation: Card is charged $597 at a time - Limitation: First month is cheaper than the rest - Limitation: Twelve weeks is the shortest commitment ## What the evidence says about this kind of treatment The assessment above is about Pallas Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who expects to stay past the first quarter and wants provider check-ins inside the price rather than billed against each visit. Wrong for A reader who wants to pay by the month, because after the discounted start the smallest charge available is twelve weeks at a time. ## The evidence behind what Pallas Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Pallas Health compares | Seller | Who it suits | Go | | --- | --- | --- | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [KIN Health](https://thisglp.com/reviews/kin-health) [Klarity Health](https://thisglp.com/reviews/klarity-health) [Klinic](https://thisglp.com/reviews/klinic) [Kova](https://thisglp.com/reviews/kova) [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) [Lighter You](https://thisglp.com/reviews/lighter-you) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 a month what the card is charged? No. After a $139 first month the card is charged $597 every twelve weeks. Pallas divides that by three and advertises $199; twelve weeks is 2.76 calendar months, so the figure ranked here is $216. What happens if the treatment does not suit me? The first month is $139, and the next charge is a full twelve-week block. A reader who stops in month two has paid the lowest figure on the page; one who stops in month four has already paid for a quarter. Does the price change as the dose rises? Pallas states the same price at every dose on both molecules, so the escalation across the first sixteen weeks leaves the figure alone. Is Pallas Health expensive compared with other GLP-1 telehealth sellers? Pallas Health publishes a starting figure of $216/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Pallas Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PauseRX reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide carries one price for all doses. Tirzepatide is worded two ways. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pauserx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat semaglutide, open tirzepatide # PauseRX review Semaglutide carries one price for all doses. Tirzepatide is worded two ways. ## The verdict PauseRX sells compounded semaglutide at $199 a month for all doses. Compounded tirzepatide is $249 a month. The homepage calls $249 an all-doses price, while the product page calls it a starting price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named PauseRX is a cash-pay patient management platform. Its catalog covers weight loss, hormones, testosterone, peptides and sexual health. Brand Wegovy, Zepbound and Foundayo are sold as consultations. The compounded injections are sold as monthly programs. 1. ## Who writes the prescription, and what do they see? Independent licensed physician networks provide the medical services. PauseRX states it provides no medical or pharmacy services itself. No physician or network is named anywhere on the site. A free physician consult is listed, and payment does not guarantee a prescription. The steps are a questionnaire, a physician review, shipping, then monthly check-ins. Shipping and the check-ins are both described as free. Service is described as nationwide, with no state list. 2. ## What happens when the dose goes up? Semaglutide does not change price with dose, and its product page reads "All doses at $199/month". Tirzepatide's product page reads "Starting at" instead. A higher tirzepatide dose may therefore cost more. No dose schedule is published for either drug. 3. ## What the price includes Two figures carry the compounded line: $199 a month for semaglutide and $249 for tirzepatide. No membership fee and no term discount are published. The brand consultations carry a separate provider fee. Brand medication is billed after the provider approves it. 4. ## What it claims, and what it cites A licensed 503(A) pharmacy compounds the injections. The pharmacy is not named. The footer states compounded medications are not FDA-approved. Brand medication ships through NovoCare, per the consultation pages. ## Where it holds up, and where it does not - Strength: Semaglutide costs the same at every dose - Strength: Shipping and check-ins are free - Strength: Brand and compounded options sit side by side - Strength: No membership fee is stated - Limitation: Tirzepatide pricing is worded two ways - Limitation: No physician network is named - Limitation: No compounding pharmacy is named - Limitation: No dose schedule is published ## What the evidence says about this kind of treatment The assessment above is about PauseRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants compounded semaglutide at one flat monthly figure. Wrong for A buyer who needs the tirzepatide rate fixed before the dose rises. ## The evidence behind what PauseRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PauseRX compares | Seller | Who it suits | Go | | --- | --- | --- | | Hims | Buyers set on brand Wegovy or Zepbound who accept a monthly membership on top | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | SkyRx | Buyers ready to prepay a year who want the medication, visit and shipping in one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Livbetr](https://thisglp.com/reviews/livbetr) [Longevity Meds](https://thisglp.com/reviews/longevity-meds) [Loozy](https://thisglp.com/reviews/loozy) [Male Excel](https://thisglp.com/reviews/male-excel) [MangoRx](https://thisglp.com/reviews/mangorx) [MD Trim Clinic](https://thisglp.com/reviews/md-trim-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does semaglutide cost more at a higher dose? No. The product page reads "All doses at $199/month". Is tirzepatide fixed at $249? Not clearly. The homepage says all doses, while the product page says starting at. Who prescribes at PauseRX? Independent licensed physician networks. None is named on the site. Is PauseRX expensive compared with other GLP-1 telehealth sellers? PauseRX publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PauseRX above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PCOS Sisters reviews (2026): GLP-1 telehealth sellers | This GLP A nurse practitioner clinic for polycystic ovary syndrome, where a GLP-1 prescription requires an active membership. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pcos-sisters Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 PCOS clinic, membership first # PCOS Sisters review A nurse practitioner clinic for polycystic ovary syndrome, where a GLP-1 prescription requires an active membership. ## The verdict PCOS Sisters prices GLP-1 prescriptions from $150 a month and requires a membership to hold one. The lower-priced membership plans are $99 a month, so the pair comes to $249. What the $150 buys is not itemized. The FAQ bills medication through the pharmacy, outside membership fees. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 8 From From $249/mo Dose published No Prescription Required Pharmacy Named Labs Extra cost Availability 8 states PCOS Sisters is a telehealth clinic for women with polycystic ovary syndrome, headquartered in St. Petersburg, Florida. GLP-1 care is one service among several, beside fertility, acne and hair-loss care. Semaglutide is named on the GLP-1 page, and a patient case there mentions tirzepatide. Its FAQ names eleven states and its service-area page names nine, and eight appear on both. 1. ## Who writes the prescription, and what do they see? Care is delivered by nurse practitioners the clinic describes as board-certified PCOS specialists. A patient chooses a named provider before paying, and the membership price is set per provider. The first appointment is a video visit, with same-week slots stated. Lynsey Johnson, DNP, is named in the clinic's legal entity. The membership includes monthly virtual visits and ongoing care, plus a fitness app. A one-time evaluation visit is sold separately for patients not ready to join. Prepaid membership terms of three, six and twelve months carry stated monthly savings. Insurance is accepted for evaluation visits in Georgia only. 2. ## What happens when the dose goes up? The GLP-1 page describes individualized dosing, including microdosing, rather than a standard protocol. No milligram dose is published. The $150 figure is written as a starting price, and what a higher dose costs is not stated. Dose decisions sit with the assigned nurse practitioner. 3. ## What the price includes The GLP-1 page states $150 a month with the membership required. The lower-priced membership plans are $99 a month, and one provider's standard plan is priced higher. At $150 plus $99, six months comes to $1,494. The FAQ says labs, medications and imaging are billed by the lab or pharmacy. Whether the $150 already includes the drug is not stated. 4. ## What it claims, and what it cites Two dispensing pharmacies are named in the footer: Strive Pharmacy in Gilbert, Arizona, and Striker Pharmacy in Katy, Texas. The site does not say whether the GLP-1 dispensed is compounded or a branded product. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. Oral GLP-1 options are mentioned without a price. ## Where it holds up, and where it does not - Strength: Care built around polycystic ovary syndrome - Strength: Nurse practitioners are named and chosen by the patient - Strength: Two dispensing pharmacies are named - Strength: Monthly video visits sit inside the membership - Limitation: A membership is required for any GLP-1 prescription - Limitation: Medication cost is not itemized - Limitation: Labs are billed separately - Limitation: Its two state lists disagree; eight states appear on both - Limitation: Compounded or branded is not stated ## What the evidence says about this kind of treatment The assessment above is about PCOS Sisters. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A woman with PCOS in a covered state who wants a named specialist and monthly visits. Wrong for A buyer who needs the full monthly cost, drug included, before enrolling. ## The evidence behind what PCOS Sisters prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PCOS Sisters compares | Seller | Who it suits | Go | | --- | --- | --- | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDLive](https://thisglp.com/reviews/mdlive) [MD Total Wellness](https://thisglp.com/reviews/mdtw) [Medical Health Institute](https://thisglp.com/reviews/medical-health-institute) [Medivive](https://thisglp.com/reviews/medivive) [MEDVidi](https://thisglp.com/reviews/medvidi) [Meli Health](https://thisglp.com/reviews/meli-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a GLP-1 cost at PCOS Sisters? Prescriptions start at $150 a month, and a membership is required. On a $99 membership plan the two come to $249. Is the medication included? Not stated for the $150. The FAQ says medications, labs and imaging are billed by the pharmacy or lab, not inside membership fees. Which states are covered? Two pages answer differently. The FAQ names eleven states and the service-area page names nine. The eight on both are Arizona, Florida, Georgia, New Mexico, Texas, Utah, Virginia and Washington. Who prescribes? Nurse practitioners the clinic describes as board-certified PCOS specialists. The patient selects one before the first visit. Is PCOS Sisters legit? PCOS Sisters is a GLP-1 telehealth sellers service. Its stated availability: 8 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is PCOS Sisters expensive compared with other GLP-1 telehealth sellers? PCOS Sisters publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PCOS Sisters above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Peak Wellness reviews (2026): GLP-1 telehealth sellers | This GLP The monthly plan quotes a first month. The rate after it is printed on the same card. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/peak-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 First month first, rate after # Peak Wellness review The monthly plan quotes a first month. The rate after it is printed on the same card. ## The verdict Peak Wellness charges $249 a month for compounded semaglutide on its monthly plan. Compounded tirzepatide is $349. The first month on that plan is $179 or $279. Both rates are stated as flat at every dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Peak Wellness sells compounded semaglutide and compounded tirzepatide by weekly injection. It serves all 50 states. Medical consultations and prescriptions run through a named telehealth group, Dr. TelX. 1. ## Who writes the prescription, and what do they see? The site says a board-certified physician reviews each profile. One section gives four hours for that review. The FAQ gives 24 hours and names obesity medicine as the specialty. No individual physician is named. What the physician sees beyond the questionnaire is not described. A 90-second questionnaire gives a pre-approval. Physician review comes next, and shipping follows within 48 to 72 hours. Supplies and expedited shipping are included. A patient can pause, skip or cancel through the portal. Changes apply at the next billing cycle. 2. ## What happens when the dose goes up? Every plan lists flat-rate pricing no matter the dose. A dose assistant in the patient portal gives the amount to draw. The FAQ lists dose adjustments as part of regular check-ins. No milligram dose is published on the pricing card. 3. ## What the price includes The monthly plan carries no commitment. Semaglutide is $179 for the first month, then $249. Tirzepatide is $279, then $349. Three- and six-month plans bill the whole term at once at lower monthly rates. The step between molecules is $100 a month. 4. ## What it claims, and what it cites Both products are compounded. The FAQ names four dispensing pharmacies: EmeraldsRx, Epiq Scripts, Southend Pharmacy and AbsoluteRX. The footer states that compounded medications are not FDA-approved. The FDA does not review them before dispensing. ## Where it holds up, and where it does not - Strength: The rate after month one is on the card - Strength: Flat pricing stated at every dose - Strength: Four dispensing pharmacies named - Strength: The telehealth group is named - Strength: Pause, skip or cancel in the portal - Limitation: The headline figure is a first month - Limitation: Two different review times are published - Limitation: No individual physician is named - Limitation: No milligram dose on the pricing card ## What the evidence says about this kind of treatment The assessment above is about Peak Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the pharmacy and the medical group named before starting. Wrong for A buyer budgeting a year from the first-month figure. ## The evidence behind what Peak Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Peak Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Metabolic Rx](https://thisglp.com/reviews/metabolic-rx) [Metabolyz](https://thisglp.com/reviews/metabolyz) [Mixx Health & Wellness](https://thisglp.com/reviews/mixx-health-and-wellness) [Modern Age](https://thisglp.com/reviews/modern-age) [Novera MD](https://thisglp.com/reviews/novera-md) [Nuform Health](https://thisglp.com/reviews/nuform-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is billed after the first month? $249 for semaglutide and $349 for tirzepatide on the monthly plan. Who prescribes? Physicians working through Dr. TelX, the telehealth group the FAQ names. No individual is named. Which pharmacies fill the order? EmeraldsRx, Epiq Scripts, Southend Pharmacy and AbsoluteRX are listed in the FAQ. Can I stop without a fee? Yes. The FAQ states no contracts and no cancellation fees. Is Peak Wellness legit? Peak Wellness is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Peak Wellness expensive compared with other GLP-1 telehealth sellers? Peak Wellness publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Peak Wellness above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PepHaūs reviews (2026): GLP-1 telehealth sellers | This GLP The semaglutide rungs are clear. The tirzepatide line carries two prices and nothing says which applies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pephaus Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One line has two prices # PepHaūs review The semaglutide rungs are clear. The tirzepatide line carries two prices and nothing says which applies. ## The verdict PepHaūs publishes from $152 a month for compounded semaglutide on the quarterly plan, against $179 otherwise. Its tirzepatide line carries two figures that cannot be reconciled, so no price for it is published here. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $179/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states PepHaūs sells both molecules by injection across fifty states. The semaglutide line carries a quarterly rate and a higher one outside it. The tirzepatide line does not resolve. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state plans. The clinician is not described. On semaglutide the structure is a two-rung ladder and both rungs are published. On tirzepatide two different figures appear and nothing states which one a buyer meets. 2. ## What happens when the dose goes up? Nothing is published about dose. The semaglutide figures carry from wording, so the quarterly rate is itself a floor. 3. ## What the price includes Six months of semaglutide at $152 is $912 on the quarterly plan and $1,074 otherwise, a gap of $27 a month. The tirzepatide line shows $215 in one place and $246 in another, with nothing to say which is the rate. Two prices for one product is not a rounding difference, so no figure for that line is carried here. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Coverage across all fifty states - Strength: Both rungs published on each line - Strength: The semaglutide rungs are both published - Limitation: The tirzepatide line shows two prices - Limitation: No milligram dose stated - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about PepHaūs. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will commit a quarter for a modest saving. Wrong for A reader needing a settled figure at their dose. ## The evidence behind what PepHaūs prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PepHaūs compares | Seller | Who it suits | Go | | --- | --- | --- | | Obu Health | Readers who value a site that agrees with itself | | | NuDay Rx | Readers wanting an oral semaglutide at the injection price | | | Prime Doctor RX | Readers who count charges rather than months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nurx](https://thisglp.com/reviews/nurx) [Olleve Care](https://thisglp.com/reviews/ollevecare) [Omada Health](https://thisglp.com/reviews/omada-health) [One80Rx](https://thisglp.com/reviews/one80rx) [Pillar Health](https://thisglp.com/reviews/pillar-health) [Prescriva](https://thisglp.com/reviews/prescriva) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the quarterly plan save? $27 a month on semaglutide, at $152 against $179. What does tirzepatide cost? Unresolved. The seller shows $215 in one place and $246 in another. Nothing states which applies, so no tirzepatide figure is carried here. Where does PepHaūs ship? All fifty states are recorded. Is PepHaūs legit? PepHaūs is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is PepHaūs expensive compared with other GLP-1 telehealth sellers? PepHaūs publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PepHaūs below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Pepti reviews (2026): GLP-1 telehealth sellers | This GLP Each fill runs 28 days, so a year carries thirteen charges rather than twelve. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pepti Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Thirteen fills a year # Pepti review Each fill runs 28 days, so a year carries thirteen charges rather than twelve. ## The verdict Pepti publishes $119 per fill for semaglutide and $139 for tirzepatide. Fills run 28 days, so a calendar month is $129 and $151. Coverage is 36 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 36 From From $129/mo Prescription Required Compounded Yes — not FDA-approved Availability 36 states Pepti sells both molecules as a weekly injection on a subscription that covers medication, physician care, labs and shipping. This site publishes no oral figure for Pepti. 1. ## Who writes the prescription, and what do they see? The subscription is described as covering physician care and labs alongside the medication, which is a fuller statement of what is included than a bare medication price gives. Bundling labs and physician care into one figure removes the two charges that most often appear later. The 28-day cycle is the detail that puts some of it back. 2. ## What happens when the dose goes up? The rate is recorded as flat, so an escalation should not move it. No milligram is published beside either figure. 3. ## What the price includes Six months of semaglutide at $129 a calendar month is $774, and tirzepatide at $151 is $906. The 28-day cycle is what lifts each fill price to its calendar-month figure. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name. The FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: Physician care and labs stated as included - Strength: Flat across doses - Strength: Both fill prices published before intake - Strength: Coverage in 36 states - Limitation: Thirteen fills a year, not twelve - Limitation: Fill prices understate a calendar month - Limitation: No milligram dose is published - Limitation: The pharmacy behind both lines is unnamed ## What the evidence says about this kind of treatment The assessment above is about Pepti. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants labs and physician care inside one figure and counts fills rather than months. Wrong for A reader budgeting fills as if they were months. ## The evidence behind what Pepti prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Pepti compares | Seller | Who it suits | Go | | --- | --- | --- | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | | TelePeptide | Readers who want the whole commitment ladder priced in advance | | | Rivo Health | Readers who want a flat rate and can ignore the seasonal framing | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrescrYbe](https://thisglp.com/reviews/prescrybe) [PRIMO Health Partners](https://thisglp.com/reviews/primo-health-partners) [Push Health](https://thisglp.com/reviews/push-health) [Ravia Health](https://thisglp.com/reviews/ravia-health) [Red Mountain Weight Loss](https://thisglp.com/reviews/red-mountain-weight-loss) [RegenCen](https://thisglp.com/reviews/regencen) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost? $129 for semaglutide and $151 for tirzepatide, once the 28-day cycle is converted to a calendar month. Why is a month more than a fill? Each fill covers 28 days, so thirteen land in a year. $119 a fill is $129 a calendar month, and $139 is $151. Is there an oral option? This site publishes no oral figure for Pepti. Its weight-loss category lists six injectable treatments, and the page that carried orals returns a 404. Is Pepti legit? Pepti is a GLP-1 telehealth sellers service. Its stated availability: 36 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Pepti expensive compared with other GLP-1 telehealth sellers? Pepti publishes a starting figure of $129/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Pepti below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Pepton Health reviews (2026): GLP-1 telehealth sellers | This GLP The two cheaper products are sold as GLP-1 without saying which one, and refill pricing needs an account. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pepton-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two cards name no drug # Pepton Health review The two cheaper products are sold as GLP-1 without saying which one, and refill pricing needs an account. ## The verdict Pepton Health publishes starting figures of $179 for an injection, $99 for a tablet and $299 for tirzepatide. Only the third names its molecule. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $179/mo Oral From $99/mo Prescription Required Compounded Yes — not FDA-approved Pepton Health sells three products: a weekly injection, a daily dissolvable tablet and a tirzepatide injection. Two are described only as GLP-1. 1. ## Who writes the prescription, and what do they see? A prescription is issued before dispensing. The cards describe a schedule rather than a clinician. Naming a category instead of a drug makes the two cheaper products hard to compare against anything. Refill pricing sitting behind account creation compounds it. 2. ## What happens when the dose goes up? Every figure is a starting price and none states a dose. The refill rate, which is the one that matters after month one, requires an account to see. 3. ## What the price includes Six months from $179 is $1,074 and from $99 is $594, if the starting figures hold past the first fill. Whether they do is the question account creation is standing in front of. 4. ## What it claims, and what it cites The lines are compounded. A pharmacy prepares them. No agency reviews a compounded preparation before it is dispensed, and the unnamed molecule question sits on top of that. ## Where it holds up, and where it does not - Strength: Three distinct products carry a figure - Strength: The tirzepatide card names its drug - Strength: A tablet route is priced openly - Limitation: Two cards name no molecule - Limitation: Refill pricing needs an account - Limitation: Every figure is a starting price - Limitation: The states served are not listed ## What the evidence says about this kind of treatment The assessment above is about Pepton Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will create an account before deciding anything. Wrong for A reader who wants to know which drug they are buying from the storefront. ## The evidence behind what Pepton Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Pepton Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Silhouette MD | Readers who want an unqualified number and will pay the tablet premium for one | | | Somi Health | Readers who want the dose question answered in writing before anything else | | | Corsica Health | Readers who want the monthly rate and the prepay discount on one selector | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RegenCen](https://thisglp.com/reviews/regencen) [Rese Wellness](https://thisglp.com/reviews/rese-wellness) [Revive Longevity](https://thisglp.com/reviews/revive-longevity) [Rila](https://thisglp.com/reviews/rila) [Risen Labs](https://thisglp.com/reviews/risen-labs) [Robinhood Telehealth](https://thisglp.com/reviews/robinhood-telehealth) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What drug does $179 actually buy? The card does not say. It reads GLP-1 Injections. What does a refill cost? The refill pricing sits behind account creation. Is the tablet the same drug? The card names no molecule for it either. Is Pepton Health expensive compared with other GLP-1 telehealth sellers? Pepton Health publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Pepton Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PeterMD reviews (2026): GLP-1 telehealth sellers | This GLP Both molecules have a cancel-anytime monthly product, while the tirzepatide landing page leads with a quarterly plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/petermd Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Monthly products behind a quarterly offer # PeterMD review Both molecules have a cancel-anytime monthly product, while the tirzepatide landing page leads with a quarterly plan. ## The verdict PeterMD publishes $270 a month for compounded semaglutide, struck from $417, with medicine included and the same price at every dose. Month-to-month tirzepatide is $299, and the $249 on its landing page is billed quarterly. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 42 From From $270/mo Prescription Required Compounded Yes — not FDA-approved Availability 42 states PeterMD sells both molecules by injection across 42 states, each as a month-to-month subscription, with a quarterly tirzepatide plan offered beside the monthly one. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. What the pages do describe is a subscription that can be canceled at any time, which is a term rather than a clinical fact. The useful disclosures here are real: medicine included, the same price at every dose, cancel anytime. The tirzepatide landing page is the exception, since its lead figure is a start charge followed by a quarterly bill, and the monthly product sits on a separate page. 2. ## What happens when the dose goes up? The semaglutide line is stated to cost the same at every dose, which answers the question directly. The quarterly tirzepatide plan names a 60 mg supply, and the pages say the period the medication lasts depends on the dose prescribed, so a quarter's supply covers a shorter span at a higher dose. 3. ## What the price includes The month-to-month semaglutide figure is $270 and six months is $1,620. Month-to-month tirzepatide is $299, or $1,794 over six months. The tirzepatide landing page offers $149 to start and then $249 a month billed quarterly, which is cheaper only for a buyer ready to pay three months at a time. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Same price at every dose, stated - Strength: Medicine included in the figure - Strength: Cancel anytime on the subscriptions - Strength: Coverage recorded across 42 states - Limitation: The tirzepatide landing page leads with a quarterly plan - Limitation: The monthly tirzepatide product sits on a separate page - Limitation: A quarterly supply's span depends on the dose - Limitation: Eight states are not served ## What the evidence says about this kind of treatment The assessment above is about PeterMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a cancel-anytime subscription on either molecule. Wrong for A reader planning from the tirzepatide landing page's $149 start figure. ## The evidence behind what PeterMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PeterMD compares | Seller | Who it suits | Go | | --- | --- | --- | | PlexusDx | A reader who will scroll past the entry card to find a product with a name | | | Ozari Health | A reader new to the drug class who will check the plan table before quarter two | | | Oria Meds | Readers who will commit six months and know which rung the headline is | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sipra](https://thisglp.com/reviews/sipra) [Sommar Club](https://thisglp.com/reviews/sommar-club) [StaveMD](https://thisglp.com/reviews/stavemd) [Steady State Health](https://thisglp.com/reviews/steady-state-health) [Super Healthy Rx](https://thisglp.com/reviews/super-healthy-rx) [Tablet Health](https://thisglp.com/reviews/tablet-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the $149 tirzepatide start the monthly price? No. It is the first charge, followed by $249 a month billed quarterly. Month-to-month tirzepatide is a separate product at $299. Does the semaglutide price rise with the dose? No. The subscription is stated as the same price at every dose, with medicine included. What does a month actually cost? $270 for semaglutide month to month and $299 for tirzepatide, each cancelable at any time. Is PeterMD legit? PeterMD is a GLP-1 telehealth sellers service. Its stated availability: 42 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is PeterMD expensive compared with other GLP-1 telehealth sellers? PeterMD publishes a starting figure of $270/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PeterMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Pillar Health reviews (2026): GLP-1 telehealth sellers | This GLP Pillar Health’s plan type affects both the care included and the payment commitment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pillar-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A clinician-reviewed GLP-1 storefront that distinguishes monthly ongoing care from other prescription purchases. # Does Pillar Health sell a GLP-1? Pillar Health’s plan type affects both the care included and the payment commitment. ## The verdict The distinction between monthly ongoing care and other purchases is useful. Confirm the actual follow-up process and renewal price rather than assuming a sale tile defines the whole treatment plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved Pillar Health offers online medical intake, independent clinical review and pharmacy fulfillment. Its weight-loss category names compounded semaglutide and a tirzepatide program. 1. ## Who writes the prescription, and what do they see? Independent licensed clinicians make prescribing decisions. Ask for the treating practice, the clinician responsible for follow-up and confirmation that care is available in your state. The terms say monthly plans include clinician review, prescribed medication and ongoing care; other plans include review and prescribed medication. Ongoing care still needs a practical definition: scheduled visits, messaging access and escalation arrangements. 2. ## What happens when the dose goes up? The weight-loss page discusses dose adjustments within clinician-supervised care. Confirm how prescription changes are authorized and whether a change affects fulfillment or cost for the selected product. 3. ## What the price includes The storefront shows sale prices alongside crossed-out regular figures, while the weight-loss page describes a recurring monthly program. Identify the promotion’s duration and the next charge before comparing it with a standing rate. 4. ## What it claims, and what it cites Compounded semaglutide is explicitly identified, and tirzepatide is listed as a separate program. Confirm the precise formulation, administration route and dispensing pharmacy; the overview does not establish every product detail. ## Where it holds up, and where it does not - Strength: Distinguishes monthly ongoing care from other plans - Strength: Uses independent clinician review - Limitation: Monitoring cadence is not fully specified - Limitation: Exact product and pharmacy details need confirmation ## What the evidence says about this kind of treatment The assessment above is about Pillar Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults who will choose a plan based on the actual ongoing clinical support included. Wrong for Anyone assuming all one-off and monthly purchases provide the same follow-up or that a sale price lasts indefinitely. ## The evidence behind what Pillar Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Pillar Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Teladoc Health](https://thisglp.com/reviews/teladoc-health) [Teleios Health](https://thisglp.com/reviews/teleios-health) [TeleWellnessMD](https://thisglp.com/reviews/telewellnessmd) [The Protocole](https://thisglp.com/reviews/the-protocole) [TideMedix](https://thisglp.com/reviews/tidemedix) [Tomorrow](https://thisglp.com/reviews/tomorrow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Do all plans include ongoing care? The terms explicitly include ongoing care in monthly plans. Other plans are described as clinician review and prescribed medication; clarify any further support. Can a sale tile establish the long-term treatment cost? No. Confirm the duration of the promotion and the price of subsequent orders. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://getpillarhealth.com/) - [Official program and terms](https://getpillarhealth.com/how-it-works/) - [Official program and terms](https://getpillarhealth.com/category/weight-loss/) - [Official program and terms](https://getpillarhealth.com/terms/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Piper reviews (2026): GLP-1 telehealth sellers | This GLP The brand has changed; the company behind it and the prices have not. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/piper Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Renamed, pharmacies named # Piper review The brand has changed; the company behind it and the prices have not. ## The verdict Piper now trades as Polly, and the old address redirects to the new one under the same corporate name. The catalog is unchanged: $135 a week for compounded semaglutide, $199 for compounded tirzepatide, with two compounding pharmacies named in the FAQ. That naming is the reason to read this one. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $146/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Polly is a cash-pay telehealth platform selling compounded semaglutide and compounded tirzepatide by weekly injection. Sermorelin, a lipotropic blend and two NAD+ formats sit beside them. Access is stated for all fifty states. The footer names the operating company and the trading name it now uses. 1. ## Who writes the prescription, and what do they see? The FAQ is unusually exact about the arrangement, and what it describes is a platform rather than a practice. Polly states it connects patients with independent licensed healthcare professionals, and that every medical evaluation, prescription and pharmacy service is provided by third parties. An independent provider reviews the intake and decides whether treatment is appropriate. No individual clinician or medical group is named. Three steps run from online intake to delivery, with free next-day air shipping stated on every order. No membership fee and no lock-in are advertised. Insurance is not billed, though HSA and FSA reimbursement is described as possible. A patient portal carries follow-up messaging. 2. ## What happens when the dose goes up? The catalog quotes one rate per molecule, with no dose tier beside it and no milligram figure anywhere. Treatment is described as adjusted by the provider as needed, which is a statement about oversight rather than about price. Whether the charge moves at a step up is not addressed on the page. Consistent pricing is advertised as a feature without being defined. 3. ## What the price includes Each product card carries a single figure and the word weekly beneath it: $135 for semaglutide, $199 for tirzepatide. The peptide and NAD+ lines are priced the same way. No multi-month plan, prepay tier or renewal rate is published. What the fill covers in weeks is on the card; what it costs across a calendar year is not. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded rather than manufactured. The FAQ names two 503A compounding pharmacies and states they are overseen by state boards of pharmacy. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. ## Where it holds up, and where it does not - Strength: Two compounding pharmacies are named - Strength: No membership fee and no lock-in - Strength: Free next-day shipping on every order - Strength: The platform's third-party role is stated plainly - Strength: Availability is claimed in all fifty states - Limitation: The brand name has changed under the buyer - Limitation: No multi-month or prepay rate is published - Limitation: The fill is weekly, not a calendar month - Limitation: No milligram dose appears on any card - Limitation: No individual clinician is named ## What the evidence says about this kind of treatment The assessment above is about Piper. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the compounding pharmacy named before handing over a card. Wrong for A buyer who wants one accountable practice rather than a platform of third parties. ## The evidence behind what Piper prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Piper compares | Seller | Who it suits | Go | | --- | --- | --- | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TotalRx](https://thisglp.com/reviews/totalrx) [Totara Health](https://thisglp.com/reviews/totara-health) [Trally Meds](https://thisglp.com/reviews/trally-meds) [Transcarent](https://thisglp.com/reviews/transcarent) [TRT Kingdom](https://thisglp.com/reviews/trt-kingdom) [Tummala Health](https://thisglp.com/reviews/tummala-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Polly the same company as Piper? Yes. The footer names one operating company trading under the Polly brand, and the Piper address redirects there. Which pharmacies fill these prescriptions? Polly names two 503A compounding pharmacies in its FAQ and states both are overseen by state boards of pharmacy. Who actually writes the prescription? An independent licensed provider, not Polly. Its FAQ states all clinical services are provided solely by third-party licensed professionals. Is Piper legit? Piper is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Piper expensive compared with other GLP-1 telehealth sellers? Piper publishes a starting figure of $146/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Piper below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PlexusDx reviews (2026): GLP-1 telehealth sellers | This GLP The lowest figure is a microdose protocol where the provider chooses both the molecule and the route. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/plexusdx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Entry plan picks your drug # PlexusDx review The lowest figure is a microdose protocol where the provider chooses both the molecule and the route. ## The verdict PlexusDx publishes a $129 microdose protocol, on which the provider selects the molecule and route. Its named semaglutide injection is $189 month to month and tirzepatide is $289. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $189/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states PlexusDx sells named semaglutide and tirzepatide injections across fifty states, plus an entry microdose protocol that is not molecule-specific. 1. ## Who writes the prescription, and what do they see? On the microdose protocol the prescriber decides what the plan contains. That is a real clinical choice and it means the $129 does not name a product a reader can compare. Two structures run side by side. The named product lines carry their own ladders. The entry protocol carries a lower figure and an unnamed drug, which is a different kind of purchase. 2. ## What happens when the dose goes up? The named lines publish term ladders rather than dose ladders. Nothing states what either figure does as milligrams rise, and the microdose protocol is a low weekly dose by design. 3. ## What the price includes Semaglutide injection is $189 month to month, $169 on three months and $149 on six. Tirzepatide is $289 month to month, $269 on three months and $249 on six. Six months of semaglutide at the monthly rate is $1,134, or $894 on the six-month rung. The $129 microdose figure is all-inclusive and is not one of these products. 4. ## What it claims, and what it cites All lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Three rungs published on both named lines - Strength: Coverage across all fifty states - Strength: The microdose protocol is labeled as one - Strength: All figures described as all-inclusive - Limitation: The entry figure names no molecule - Limitation: Its route is chosen by the provider - Limitation: No dose behavior is published - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about PlexusDx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a named product and will read past the entry card. Wrong for A reader comparing $129 against a named semaglutide price. ## The evidence behind what PlexusDx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PlexusDx compares | Seller | Who it suits | Go | | --- | --- | --- | | Onyx Weight Loss | A reader inside the eight-state footprint who reads what each card actually names | | | PeterMD | Readers who want a cancel-anytime subscription and will choose the monthly product over the quarterly offer | | | Prime Doctor RX | Readers who count charges rather than months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vea Health](https://thisglp.com/reviews/vea-health) [Vela Rx](https://thisglp.com/reviews/vela-rx) [Verge](https://thisglp.com/reviews/verge) [Vida Health](https://thisglp.com/reviews/vida-health) [Virgo-Meds](https://thisglp.com/reviews/virgo-meds) [Virta Health](https://thisglp.com/reviews/virta-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $129 buy? A microdose protocol on which the provider selects the molecule and the route. It is not a named product. What does the semaglutide injection cost? $189 month to month, $169 on three months and $149 on six. Is the $249 tirzepatide figure a monthly rate? It is the six-month rung. Month to month is $289 and three months is $269. Is PlexusDx legit? PlexusDx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is PlexusDx expensive compared with other GLP-1 telehealth sellers? PlexusDx publishes a starting figure of $189/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PlexusDx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PlushCare reviews (2026): GLP-1 telehealth sellers | This GLP The advertised cash-pay figure buys the 0.25 mg starting dose, and every maintenance dose is priced above it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/plushcare Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Starting dose only at $149 # PlushCare review The advertised cash-pay figure buys the 0.25 mg starting dose, and every maintenance dose is priced above it. ## The verdict PlushCare advertises compounded semaglutide at $149 a month cash-pay, and that figure covers the 0.25 mg starting dose only. Every higher dose is $299. No compounded tirzepatide price is published, and insurance is accepted on a separate basis. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $149/mo Prescription Required Compounded Yes — not FDA-approved PlushCare sells compounded semaglutide as a weekly injection across fifty states. The cash-pay figures read $149 at 0.25 mg and $299 at every dose from 0.5 mg to 2.4 mg. Its compounded tirzepatide page now redirects to a Mounjaro page with no compounded price. Insurance is accepted as a separate route to treatment. 1. ## Who writes the prescription, and what do they see? Treatment runs through a clinician visit rather than a form alone, and insurance is billed where it applies. That is a different model from a flat-fee compounding seller with no visit in it. What the visit covers, and how often it repeats, is not published. The two routes are priced separately and a reader chooses one at intake. Care is arranged remotely and the prescription follows the visit. The cash-pay figure and the insurance route answer different questions for different readers. A reader with coverage is comparing a copay against $149 rather than comparing sellers. A reader without coverage is comparing $149 against a market where most rates are flat. 2. ## What happens when the dose goes up? This is the seller's weak point and it is stated plainly. $149 buys 0.25 mg, and 0.25 mg is a four-week starting dose for almost everyone. Every dose from 0.5 mg to 2.4 mg is $299, printed in the same sentence as the entry figure. A reader planning a year should treat $149 as the first month and $299 as the standing rate. 3. ## What the price includes $149 is real and it is narrow. Sellers charging a flat $199 hold that figure at 2.4 mg, where PlushCare charges $299. No compounded tirzepatide figure is published at all. Insurance may change the semaglutide figure and is settled case by case rather than published. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded, so a pharmacy prepares it and no regulator reviews the finished vial. The published weight-change results for semaglutide came from the approved product at maintenance doses, not at 0.25 mg. A starting dose is a titration step rather than a treatment dose. What four weeks at 0.25 mg produces on its own was not measured as an endpoint. ## Where it holds up, and where it does not - Strength: Says what the entry figure buys - Strength: Insurance accepted as a separate route - Strength: Prescription follows a clinician visit - Limitation: Maintenance doses cost $299 a month - Limitation: No compounded tirzepatide price published ## What the evidence says about this kind of treatment The assessment above is about PlushCare. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. Wrong for A reader budgeting a year at one rate, because the advertised figure covers 0.25 mg and every dose above it is $299. ## The evidence behind what PlushCare prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PlushCare compares | Seller | Who it suits | Go | | --- | --- | --- | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Pallas Health | A reader past the opening quarter who wants check-ins priced in, not billed per visit. | | | Harper Meds | A reader who wants a clinician, a prescription and the medication under one charge, with no term to commit to before reaching the published rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vitakey](https://thisglp.com/reviews/vitakey) [Vital Step](https://thisglp.com/reviews/vital-step) [Vivanta Care](https://thisglp.com/reviews/vivanta-care) [VivioMD](https://thisglp.com/reviews/viviomd) [welludr.](https://thisglp.com/reviews/wellmedr)[Yes Clinic](https://thisglp.com/reviews/yes-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $149 what a maintenance dose costs? No. PlushCare states that the $149 cash-pay figure buys the 0.25 mg starting dose, and that 0.5 mg through 2.4 mg cost $299 a month. How long does anyone stay at 0.25 mg? The approved semaglutide schedule holds 0.25 mg for four weeks before the first increase. A reader on that schedule is past the advertised figure by month two. Does insurance change the price? Insurance is accepted on a separate basis from the cash-pay figure, and what it leaves a patient to pay is settled case by case rather than published. Is PlushCare expensive compared with other GLP-1 telehealth sellers? PlushCare publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PlushCare below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Pomegranate Health reviews (2026): GLP-1 telehealth sellers | This GLP Each product page quotes one starting figure; the pricing app behind it changes the price with the pharmacy, the dose tier and the package. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/pomegranate-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A starting price, then a pharmacy menu # Pomegranate Health review Each product page quotes one starting figure; the pricing app behind it changes the price with the pharmacy, the dose tier and the package. ## The verdict Pomegranate Health's product pages lead with compounded semaglutide from $119 a month and compounded tirzepatide from $159, but those are entry points rather than a rate a patient can count on. Its pricing app sets the charge by three choices made together, the dispensing pharmacy, a starter or advanced dose tier and the length of the package, and the monthly figures it returns sit both above and below the product-page lead. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $119/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Labs Not stated Pomegranate Health is an online clinic whose weight loss shelf carries compounded semaglutide and compounded tirzepatide beside oral Wegovy, orforglipron, Contrave and metformin. Longevity, hair, skin, men's and women's health catalogs share the same site. In the pricing app the compounded semaglutide is listed as semaglutide with cyanocobalamin, and the compounded tirzepatide as tirzepatide with pyridoxine, so both carry a B vitamin in the vial. 1. ## Who writes the prescription, and what do they see? After a short online assessment, a licensed physician is described as reviewing the patient's history, and the FAQ adds a virtual consultation with a licensed provider before anything is prescribed. Recent labs from the past twelve months or medical records may be requested before a prescription is written. No clinician, medical group or medical director is named anywhere on the pages, so a patient meets the prescriber only once the consultation begins. Once a prescription is issued it goes to a partner pharmacy, and the FAQ says many patients complete intake and receive a prescription within a few business days. The subscription renews automatically each period until it is canceled, and the terms ask for cancellation at least a day before the period ends. The same terms describe a fee for appointments canceled within 24 hours and state that medication fees are not refundable. There is no membership fee, which each product page repeats. 2. ## What happens when the dose goes up? The product page says the dose is increased gradually to support tolerability, and the pricing app is where that climb shows up in money. For semaglutide, moving from the starter tier to the advanced tier raises the monthly figure at every pharmacy listed, and at two of them the advanced tier adds a higher-strength vial priced on its own. A patient who starts cheaply at one pharmacy's starter tier should expect the charge to rise when the prescription steps up. 3. ## What the price includes Each product page writes its figure as a starting price: $119 a month for semaglutide and $159 for tirzepatide. Behind it, the pricing app lists up to eight pharmacies, and each one carries its own price for each tier and package, with some sold one month at a time and others only as multi-month bundles. The subscription terms add that asking for a specific pharmacy carries a separate coordination fee, which sits awkwardly beside an app that invites the patient to pick one. What a given patient will pay is settled only when those choices are made. 4. ## What it claims, and what it cites Both GLP-1 injections are compounded, and each product page carries the footnote that compounded medications have not been reviewed or approved by the FDA for safety, effectiveness or quality. The same page also displays a badge reading direct from FDA-licensed manufacturer, which describes a facility and not an approved drug. The pharmacies are named in the pricing app, among them Empower, Hallandale, Hyalo, NOVA, OptioRx and Redrock. ## Where it holds up, and where it does not - Strength: No membership fee on either molecule - Strength: Dispensing pharmacies are named in the pricing app - Strength: The B vitamin in each vial is disclosed - Strength: Labs are requested before prescribing when needed - Limitation: The lead figure is a starting price, not a set rate - Limitation: Price varies with pharmacy, dose tier and package - Limitation: A pharmacy-choice fee appears in the subscription terms - Limitation: Medication fees are not refundable - Limitation: No prescriber or medical director is named ## What the evidence says about this kind of treatment The assessment above is about Pomegranate Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who is willing to work through a pricing menu to find the pharmacy and package that suit a budget. Wrong for A buyer who wants one monthly figure that holds from the first fill through the dose increases that follow. ## The evidence behind what Pomegranate Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Pomegranate Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [YOURx Health](https://thisglp.com/reviews/yourx-health) [Youth & Soul](https://thisglp.com/reviews/youth-and-soul) [Zenbody](https://thisglp.com/reviews/zenbody) [Coby Health](https://thisglp.com/reviews/coby-health) [Form Health](https://thisglp.com/reviews/form-health) [Pepton Health](https://thisglp.com/reviews/pepton-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does compounded semaglutide cost at Pomegranate? The product page says it starts at $119 a month, but the pricing app sets the actual figure by pharmacy, dose tier and package, and some combinations cost more. Does the price go up as the dose goes up? For semaglutide, yes: the pricing app puts the advanced tier above the starter tier at every pharmacy listed, so a step up in dose is also a step up in the monthly charge. Are there fees beyond the medication price? No. Each product page states that there are no additional fees or membership costs, although the subscription terms describe separate fees for a pharmacy request and for an appointment canceled late. Is the medication FDA-approved? No. Both GLP-1 injections are compounded, and the product pages carry the seller's own footnote saying compounded medications have not been reviewed or approved by the FDA. Is Pomegranate Health expensive compared with other GLP-1 telehealth sellers? Pomegranate Health publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Pomegranate Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Potere Health MD reviews (2026): GLP-1 telehealth sellers | This GLP The clinic sells a vial and then divides its price by three to reach a monthly figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/potere-health-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A vial, priced as a month # Potere Health MD review The clinic sells a vial and then divides its price by three to reach a monthly figure. ## The verdict Potere Health MD charges $239 for a 10 mg vial of compounded semaglutide and $399 for 60 mg of tirzepatide, each described as twelve weeks of treatment at starter dosing. Twelve weeks is 2.76 calendar months rather than three, so the monthly rates are $87 and $145 rather than the $80 and $135 the page advertises. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 1 From From $87/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability Utah Potere Health MD is a physician-led weight-loss clinic in St. George, Utah, treating patients in person at the clinic or by telehealth anywhere in the state. It prescribes compounded semaglutide and tirzepatide, and lists FDA-approved brands such as Wegovy and Zepbound as alternatives when those are clinically appropriate. 1. ## Who writes the prescription, and what do they see? Care is managed throughout by a named physician rather than handed off after the first visit, which is a structural difference from an intake form reviewed by whichever clinician is on rota. The clinic states the same doctor handles dose adjustments, side effects, plateaus and long-term maintenance, and the initial consultation is free and does not require a purchase first. A complimentary consultation comes first, then medication is either collected at the St. George clinic or delivered. No recurring subscription is charged, and the clinic states that no monthly membership fee is required to be treated. Bundled care, treatment management and ongoing clinical support are described as sitting inside the vial price rather than being billed against each visit. 2. ## What happens when the dose goes up? This is the part the clinic handles more honestly than most, because it publishes the mechanism rather than a reassurance. A 10 mg vial lasts twelve weeks only at standard starter dosing, and the page adds that duration may vary when the dosing schedule changes. A patient who titrates upward therefore finishes the same vial sooner while its price stays exactly where it is. The monthly cost therefore rises through the ladder even though nothing on the invoice moves. 3. ## What the price includes The two figures in the largest type are monthly equivalents that the page itself flags as assuming twelve weeks. Reading them as calendar months understates semaglutide by $7 and tirzepatide by $10 at the starting dose alone, before any escalation shortens the vial further. What the clinic does publish, and many do not, is the milligram content behind each charge, which is what makes the arithmetic possible at all. 4. ## What it claims, and what it cites The compounded lines are prepared by an outside pharmacy rather than manufactured, and the clinic states that compounded formulations are not FDA-approved, have not been evaluated for safety or efficacy, and are not generic equivalents. It also says third-party certificates of analysis verify purity and potency, which is a check most sellers in this category do not mention. ## Where it holds up, and where it does not - Strength: The milligram content behind each charge is published - Strength: One named physician manages the whole course - Strength: The free consultation comes before any payment - Strength: No monthly membership fee - Strength: Third-party testing is described - Limitation: Monthly figures divide twelve weeks by three - Limitation: A higher dose empties the same vial sooner - Limitation: Treatment is limited to Utah - Limitation: The compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Potere Health MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Utah patient who wants one physician through the whole ladder and can price a vial rather than a month. Wrong for A buyer outside Utah, or one comparing $80 against another seller's calendar-month rate. ## The evidence behind what Potere Health MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Potere Health MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | Primary Clinic (Direct GLP) | Buyers who want unlimited primary care alongside the prescription and will use enough of it to earn the membership back | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Belle Health](https://thisglp.com/reviews/belle-health) [bmiMD](https://thisglp.com/reviews/bmimd) [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)[Collective](https://thisglp.com/reviews/collective) [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) [Direct Meds](https://thisglp.com/reviews/direct-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is the real monthly rate higher than the printed one? The printed figures assume twelve weeks is three calendar months. It is 2.76, which puts semaglutide at $87 and tirzepatide at $145 at starter dosing. Does the price rise as the dose rises? The vial price does not, but the vial empties faster. The clinic states that duration may vary if the dosing schedule is not followed, so the monthly cost climbs with the ladder. Who can be treated here? Patients in Utah, either in person in St. George or by telehealth anywhere in the state. Is Potere Health MD legit? Potere Health MD is a GLP-1 telehealth sellers service. Its stated availability: Utah. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Potere Health MD expensive compared with other GLP-1 telehealth sellers? Potere Health MD publishes a starting figure of $87/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Potere Health MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Precision Telemed reviews (2026): GLP-1 telehealth sellers | This GLP Both product pages publish the full dose range and name the clinicians, down to their NPI numbers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/precision-telemed Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Named clinicians, flat dose pricing # Precision Telemed review Both product pages publish the full dose range and name the clinicians, down to their NPI numbers. ## The verdict Precision Telemed charges $149.99 a month for compounded semaglutide, flat from the first month. Compounded tirzepatide is $199 for the first month and $249.99 after it. Both rates are stated to cover every dose in a published milligram range. The clinical team is named on the product pages. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $150/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Precision Telemed is a telehealth practice serving all 50 states. Its catalog runs from compounded semaglutide and tirzepatide to testosterone, sermorelin and NAD+. Each GLP-1 product page offers three programs: a monthly full program, a three-month supply and a low-dose maintenance tier. 1. ## Who writes the prescription, and what do they see? The product pages name a medical director, Joseph Palumbo, DO, with his NPI number. Several physicians and advanced practice nurses are listed beside him, each with an NPI. Consults are described as telehealth visits with a board-certified physician, often the same day. An optional Zoom consult with no medication is sold separately. An online assessment takes about five minutes. A physician consult follows, and medication ships cold-chain within 48 hours. Consult, medication and shipping sit inside the program price. No membership fee is charged, and HSA and FSA cards are accepted. 2. ## What happens when the dose goes up? Semaglutide is priced flat from 0.25 mg to 2.5 mg, and the page says the physician titrates gradually. Tirzepatide is priced flat from 2 mg to 15 mg after its first month. The maintenance tier holds the dose at 0.25 mg. A patient who needs to climb belongs on the full program. 3. ## What the price includes Semaglutide is $149.99 every month, and the page rules out first-month pricing in its own words. Tirzepatide is $199 for the first month, then $249.99. A three-month supply is billed in one payment on autoship for each molecule. Six months at the standing rates is $900 for semaglutide and $1,500 for tirzepatide. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded and dispensed by a 503A licensed pharmacy that is not named. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The product pages call the preparations human-grade and never research-grade, and both ship cold-chain. ## Where it holds up, and where it does not - Strength: Medical director and clinicians named with NPI numbers - Strength: Full milligram range published for both molecules - Strength: Semaglutide price is flat from month one - Strength: Every dose priced the same on the full program - Strength: No membership fee - Limitation: Tirzepatide's headline figure covers month one only - Limitation: The dispensing pharmacy is not named - Limitation: The lower program figures are a fixed low dose - Limitation: A three-month supply renews on autoship ## What the evidence says about this kind of treatment The assessment above is about Precision Telemed. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the prescribers named and the dose range published before paying. Wrong for A buyer comparing the tirzepatide headline against other sellers' standing rates. ## The evidence behind what Precision Telemed prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Precision Telemed compares | Seller | Who it suits | Go | | --- | --- | --- | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Eden](https://thisglp.com/reviews/eden) [Embody](https://thisglp.com/reviews/embody) [Enhance MD](https://thisglp.com/reviews/enhance-md) [Found](https://thisglp.com/reviews/found) [Gala](https://thisglp.com/reviews/gala) [HealthRX](https://thisglp.com/reviews/healthrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does tirzepatide cost after the first month? $249.99 a month. The $199 figure covers the first month only, and the same card says so. Does the semaglutide price change with the dose? No. The full program is $149.99 a month at every dose from 0.25 mg to 2.5 mg. What is the lower-priced semaglutide program? A maintenance tier held at 0.25 mg. It is not the full dose range. Who prescribes? Physicians and advanced practice nurses named on the product pages, under medical director Joseph Palumbo, DO. Is Precision Telemed legit? Precision Telemed is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Precision Telemed expensive compared with other GLP-1 telehealth sellers? Precision Telemed publishes a starting figure of $150/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Precision Telemed below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Premium Health reviews (2026): GLP-1 telehealth sellers | This GLP A monthly membership that includes medication. A higher dose adds a stated monthly charge. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/premium-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Base rate, dose surcharge # Premium Health review A monthly membership that includes medication. A higher dose adds a stated monthly charge. ## The verdict Premium Health charges $275 a month for compounded semaglutide and $445 for compounded tirzepatide. Both are month to month. A higher dose costs more. The FAQ adds $100 a month for semaglutide and $150 for tirzepatide. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $275/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Premium Health sells compounded semaglutide and tirzepatide as weight loss memberships. IV therapy and NAD+ infusions are sold on the same site. Medication, supplies and shipping are stated as included in the membership. 1. ## Who writes the prescription, and what do they see? Clinicians are described as US-licensed and trained in obesity medicine. The visit is a two-way video call on Doxy.me. The team schedules it after the intake forms. No clinician or medical director is named. Medication ships every 90 days, per the FAQ. The product page gives 30 to 90 days. Billing is month to month, with cancellation at any time. Medication cost is not refundable. Nutrition and fitness plans are listed as included. 2. ## What happens when the dose goes up? The FAQ prices the higher doses separately. Semaglutide goes up to 2 mg a week for $100 more each month. Tirzepatide goes up to 10 mg a week for $150 more. The provider decides when a higher dose applies. 3. ## What the price includes Semaglutide is $275 a month. Tirzepatide is $445 a month. Each product page shows one price and no prepay ladder. The dose surcharge is found only in the FAQ. The base step between molecules is $170 a month. 4. ## What it claims, and what it cites Both products are compounded. The FAQ names three pharmacies: Hallandale, Red Rock and Strive. The formula includes vitamin B12 or B6, which the site says reduces nausea. Compounded preparations are not FDA-approved. The FDA does not review them before dispensing. ## Where it holds up, and where it does not - Strength: Dose surcharge stated in dollars - Strength: Three dispensing pharmacies named - Strength: Video visit on a named platform - Strength: Month to month, cancel at any time - Limitation: A higher dose raises the monthly charge - Limitation: The surcharge appears only in the FAQ - Limitation: Shipping cadence is stated two ways - Limitation: No clinician or medical director named - Limitation: Medication cost is not refundable ## What the evidence says about this kind of treatment The assessment above is about Premium Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a video visit and the dose surcharge stated upfront. Wrong for A buyer who wants one price across the whole dose ladder. ## The evidence behind what Premium Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Premium Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HumeCare+](https://thisglp.com/reviews/humecare)[Live Vital](https://thisglp.com/reviews/live-vital) [Lttl](https://thisglp.com/reviews/lttl) [Luvo Health](https://thisglp.com/reviews/luvo-health) [MEDGm](https://thisglp.com/reviews/medgm) [Oak](https://thisglp.com/reviews/oak) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with the dose? Yes. The FAQ adds $100 a month for semaglutide up to 2 mg a week. It adds $150 a month for tirzepatide up to 10 mg a week. Is medication included? Yes. The FAQ says medication and supplies are included in the membership fee. How is the visit held? By two-way video on Doxy.me, scheduled after the intake forms. Which pharmacies fill the order? Hallandale Pharmacy, Red Rock Pharmacy and Strive Pharmacy are named in the FAQ. Is Premium Health expensive compared with other GLP-1 telehealth sellers? Premium Health publishes a starting figure of $275/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Premium Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PrescribedRX reviews (2026): GLP-1 telehealth sellers | This GLP Provider messaging and included supplies are described, but the three-month plan renews every ten weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/prescribedrx Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Refill timing needs clarification # PrescribedRX review Provider messaging and included supplies are described, but the three-month plan renews every ten weeks. ## The verdict PrescribedRX describes ongoing clinical messaging and dose adjustments within its compounded injection plans. The timing deserves clarification before starting: each offer advertises a three-month supply while setting renewal every ten weeks. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Dose published No Prescription Required Compounded Yes — not FDA-approved The platform offers several prescription treatment categories, including compounded semaglutide and tirzepatide. A clinician decides whether treatment fits after reviewing eligibility information. 1. ## Who writes the prescription, and what do they see? The product pages say a licensed provider reviews the application within 48 hours. PrescribedRX says it does not produce the medication. Ask which medical practice and pharmacy will handle your prescription before enrollment. The listed plans include injection supplies, priority shipping, and care-team messaging. Payment is collected before review, with a full refund stated when the provider finds treatment inappropriate. Renewal is described as recurring at the same package price. 2. ## What happens when the dose goes up? A provider directs dose increases. The pages promise a consistent price across doses, but do not publish a detailed milligram ladder. Ask how dose changes affect the amount dispensed and the timing of the next refill. 3. ## What the price includes Semaglutide requires $420 upfront, presented as $140 monthly; tirzepatide requires $597, presented as $199 monthly. Both are labeled three-month plans yet billed every ten weeks. No independently purchasable monthly option appeared in the rendered pages. 4. ## What it claims, and what it cites Both injection offers are compounded preparations. Their safety notices distinguish them from FDA-approved drugs. Evidence from branded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) or [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) trials does not verify these specific preparations. ## Where it holds up, and where it does not - Strength: Clinical messaging is included - Strength: Injection supplies and priority shipping listed - Strength: Dose changes do not change the stated package price - Limitation: Three-month supply and ten-week renewal differ - Limitation: No separate monthly payment displayed - Limitation: Specific dispensing pharmacy needs confirmation ## What the evidence says about this kind of treatment The assessment above is about PrescribedRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient comfortable with a prepaid supply after clarifying refill timing with the care team. Wrong for Someone who needs an unambiguous single-month trial of treatment. ## The evidence behind what PrescribedRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PrescribedRX compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PeterMD](https://thisglp.com/reviews/petermd) [RxSpan MD](https://thisglp.com/reviews/rxspan-md) [Sesame Care](https://thisglp.com/reviews/sesame-care) [ShedRx](https://thisglp.com/reviews/shedrx) [SkinnyRx](https://thisglp.com/reviews/skinnyrx) [SnagRx](https://thisglp.com/reviews/snagrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How often does PrescribedRX renew? The current injection pages say every ten weeks, despite describing a three-month plan. Confirm that schedule and the amount supplied before paying. Are the displayed monthly amounts monthly payments? The visible offers collect $420 for semaglutide or $597 for tirzepatide upfront. The smaller figures are package averages. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Prescriva reviews (2026): GLP-1 telehealth sellers | This GLP Prescriva separates standard weight-loss treatment from low-dose longevity programs and describes ongoing provider support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/prescriva Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Standard and microdose categories separated # Prescriva review Prescriva separates standard weight-loss treatment from low-dose longevity programs and describes ongoing provider support. ## The verdict Prescriva separates standard weight-loss treatment from microdose marketing and describes continuing provider support; verify the individual clinical relationship before choosing. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Prescriva markets online weight-loss care with compounded semaglutide and tirzepatide. Standard weight-loss programs and lower-dose longevity programs appear separately in the menu and should not be compared as identical treatment. 1. ## Who writes the prescription, and what do they see? Prescriva says independent U.S.-licensed clinicians in an affiliated network evaluate patients and retain the decision whether to prescribe. The specific medical practice and dispensing pharmacy should be confirmed before treatment begins. The offer includes licensed-clinician consultation, ongoing provider support and regular check-ins. A stated monthly dose-adjustment feature does not establish a compulsory increase. Ask how the clinician reviews response and how to obtain help between contacts. 2. ## What happens when the dose goes up? Prescriva markets monthly adjustments guided by a provider. The actual dose can remain stable or change according to the clinical plan. Keep standard and microdose programs separate when assessing supply, evidence and cost. 3. ## What the price includes The product pages distinguish month-to-month programs from discounted twenty-four-week plans. Consultation, medicine and shipping are described as included. Confirm the full prepaid or recurring amount and the refund cutoff before accepting a longer term; a cancellation slogan alone does not answer those questions. 4. ## What it claims, and what it cites The program pages identify compounded injections, which are not FDA-approved. A microdose category does not establish the outcomes of the higher-dose approved branded medicines studied in obesity trials. ## Where it holds up, and where it does not - Strength: Standard and microdose categories separated - Strength: Consultation and shipping described as included - Strength: Monthly clinical adjustments offered - Limitation: Individual clinician and pharmacy need confirming - Limitation: Longer discount terms require a full total - Limitation: Refund timing is not established by the product headline ## What the evidence says about this kind of treatment The assessment above is about Prescriva. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering a standard compounded prescription who wants to discuss continued monitoring rather than choose a dose by price. Wrong for Someone seeking an approved branded medicine or treating microdose and standard programs as clinically interchangeable. ## The evidence behind what Prescriva prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Prescriva compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Willow](https://thisglp.com/reviews/willow) [YourEra](https://thisglp.com/reviews/yourera) [EverPrime](https://thisglp.com/reviews/everprime) [MyDrHank](https://thisglp.com/reviews/mydrhank) [1st Optimal](https://thisglp.com/reviews/1st-optimal) [24hrDOC](https://thisglp.com/reviews/24hrdoc) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The offer includes licensed-clinician consultation, ongoing provider support and regular check-ins. A stated monthly dose-adjustment feature does not establish a compulsory increase. Ask how the clinician reviews response and how to obtain help between contacts. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Semaglutide program](https://prescriva.com/weight-loss/semaglutide) - [Tirzepatide program](https://prescriva.com/weight-loss/tirzepatide) - [Clinical process](https://prescriva.com/how-it-works) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PrescrYbe reviews (2026): GLP-1 telehealth sellers | This GLP PrescrYbe offers online GLP-1 assessment through independent clinical partners. Its program page and general terms describe recurring billing differently. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/prescrybe Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinical partners behind the platform # Does PrescrYbe sell a GLP-1? PrescrYbe offers online GLP-1 assessment through independent clinical partners. Its program page and general terms describe recurring billing differently. ## The verdict The intake and conditional real-time visit process are reasonably clear. Before starting, reconcile the no-automatic-billing language on the GLP-1 page with the subscription authorization in the terms, and identify the practice responsible for follow-up. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved PrescrYbe Health is a platform for prescription services, including GLP-1 weight management. The company states that it does not employ the clinical staff, prescribe or dispense medication. 1. ## Who writes the prescription, and what do they see? Independent licensed third-party clinicians make treatment decisions. The program describes a live phone or video visit when state requirements call for one; a questionnaire should not be mistaken for a guaranteed prescription. An online history is reviewed before a prescription, if appropriate, is sent to a pharmacy partner. The GLP-1 page includes ongoing check-ins and care coaching in its offer, without defining a universal appointment schedule. 2. ## What happens when the dose goes up? The site offers different formulations and program types rather than one published clinical escalation plan. Ask who reviews tolerance, whether changes require a synchronous visit and how a prescription adjustment affects the order. 3. ## What the price includes Starting figures appear for several program categories, but the reviewed page does not map every amount to a named drug, dose and recurring interval. The terms also say services are not billed to insurance. 4. ## What it claims, and what it cites Semaglutide and tirzepatide are named, alongside injection and oral categories that are not fully mapped to individual drugs. Compounded treatments are not FDA-approved; do not assume an oral category is an approved tablet. ## Where it holds up, and where it does not - Strength: Real-time visit requirements acknowledged - Strength: Independent clinicians control prescribing - Limitation: Care frequency not defined - Limitation: Automatic-billing language differs between pages ## What the evidence says about this kind of treatment The assessment above is about PrescrYbe. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone willing to verify the assigned clinical partner and an itemized treatment quote. Wrong for Someone requiring an unambiguous public recurring plan and complete formulation table. ## The evidence behind what PrescrYbe prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PrescrYbe compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AbundRX](https://thisglp.com/reviews/abundrx) [Actin](https://thisglp.com/reviews/actin) [AgelessRx](https://thisglp.com/reviews/agelessrx) [AHBARx](https://thisglp.com/reviews/ahbarx) [Alan Meds](https://thisglp.com/reviews/alan-meds) [Alegro Health](https://thisglp.com/reviews/alegro-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does PrescrYbe itself provide medical care? Its terms say clinical decisions belong to independent licensed partners, not the platform. Will every assessment include a live visit? The program describes live video or phone contact where required by the patient’s state; confirm the encounter format for your case. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://prescrybe.health/) - [Official program and terms](https://prescrybe.health/glp1) - [Official program and terms](https://prescrybe.health/terms-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PreventiveMD reviews (2026): GLP-1 telehealth sellers | This GLP It carries orforglipron alongside the usual pair, and its lowest figures are twelve-month plans paid up front. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/preventivemd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three molecules, not two # PreventiveMD review It carries orforglipron alongside the usual pair, and its lowest figures are twelve-month plans paid up front. ## The verdict PreventiveMD charges $119 for a one-month supply of compounded semaglutide and $139 for tirzepatide, both described as all-in. Its $83 and $97 headlines are twelve-month plans, and it also lists orforglipron from $149 — a third molecule most sellers in this category do not carry at all. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron · Semaglutide · Tirzepatide Form Injection · Oral States 36 Injection From $119/mo Oral From $198/mo Prescription Required Compounded Yes — not FDA-approved PreventiveMD sells compounded semaglutide and compounded tirzepatide by injection on one, three, six and twelve-month supplies, describing every figure as all-in. It also lists orforglipron from $149 plus a $49 monthly membership, which applies on brand plans. Thirty-six states are served. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely and a prescription precedes dispensing. The homepage carries the figures and the all-in claim rather than a description of the clinical process behind them, and the brand pathway is described as running through an approved oral tablet dispensed by a manufacturer's own service. Carrying three molecules is the unusual part. Orforglipron is an oral small-molecule agent rather than a peptide, and a seller offering it is offering a different route rather than another version of the same one. What that route costs here is stated, which is more than most sellers manage for the drugs they do carry. 2. ## What happens when the dose goes up? The price does not move with the dose; only the length of the supply moves it. That answers the question most sellers leave open, and it means the ladder a reader has to read is a ladder of terms rather than milligrams. 3. ## What the price includes Semaglutide is $119 for one month, $286 for three, $536 for six and $999 for twelve, which is where the $83 comes from. Tirzepatide is $139, $334, $626 and $1,168, the last of which is the $97. The all-in description is the claim doing the work — it says the number is not a medication rate with fees to follow. Orforglipron is the exception: $149 for the medication plus the $49 membership is $198 a month. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are compounded, prepared by a pharmacy rather than manufactured and reviewed as finished products, so neither is FDA-approved and neither is assessed for safety, efficacy or quality before dispensing. The orforglipron pathway is described as an approved tablet dispensed through a manufacturer's own service, which is a different regulatory footing and worth separating from the compounded lines. ## Where it holds up, and where it does not - Strength: Carries a third molecule most sellers do not - Strength: Both compounded figures described as all-in - Strength: Brand and compounded routes priced separately - Limitation: The headline figures need a year paid up front - Limitation: A $49 membership applies on brand plans - Limitation: Fourteen states are not served ## What the evidence says about this kind of treatment The assessment above is about PreventiveMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader interested in orforglipron, which most sellers in this category do not offer at all. Wrong for A reader comparing the $83 headline against a month-to-month rate elsewhere. ## The evidence behind what PreventiveMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PreventiveMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Alan Meds | A reader ready to prepay six months who wants the full-dose price in view before the intake. | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AHBARx](https://thisglp.com/reviews/ahbarx) [Alegro Health](https://thisglp.com/reviews/alegro-health) [Alinwell](https://thisglp.com/reviews/alinwell) [Allara Health](https://thisglp.com/reviews/allara-health) [Alloy](https://thisglp.com/reviews/alloy) [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is orforglipron? An oral small-molecule GLP-1 agent rather than a peptide, which makes it a different route from the injections most of this category sells. PreventiveMD lists it from $149. Does the $49 membership apply to me? It applies on brand plans, which here means orforglipron: $149 for the medication plus $49 is $198 a month. The compounded lines are described as all-in. Is $83 what I would actually pay? Only on the twelve-month plan, paid as $999 up front. One month of semaglutide is $119, and the price is the same at every dose. Is PreventiveMD expensive compared with other GLP-1 telehealth sellers? PreventiveMD publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PreventiveMD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PrideRx reviews (2026): GLP-1 telehealth sellers | This GLP Three approved products routed through the manufacturers' own channels, each with a required monthly membership beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/priderx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand drugs, plus a membership # PrideRx review Three approved products routed through the manufacturers' own channels, each with a required monthly membership beside it. ## The verdict PrideRx routes FDA-approved products through LillyDirect and NovoCare, at $149 to $299 in medication, plus a required $99 monthly membership. The all-in figures are $248 for the orals and $398 for the Zepbound pen. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron · Semaglutide · Tirzepatide Form Injection · Oral Injection From $398/mo Oral From $248/mo Prescription Required Compounded No PrideRx arranges access to brand orforglipron, brand oral semaglutide and the brand tirzepatide pen, rather than dispensing compounded preparations of its own. 1. ## Who writes the prescription, and what do they see? The membership is what the clinical relationship costs here, and it is stated: $25 for a first month and $99 a month after. What it buys is not described in the same detail as what it costs. This is a different business from most sellers a reader will meet. The medication comes from the manufacturer's channel at the manufacturer's price, and PrideRx charges for the access and the prescribing around it. That is a clearer separation than a bundled figure, and it means the two charges have to be added. 2. ## What happens when the dose goes up? All three lines are dose-tiered by the manufacturer and the pages say so. Foundayo runs from $149 at the starter dose to $299 at higher ones, and the Zepbound pen from $299 at 2.5 mg to $449 at 7.5 mg and above. A reader escalating pays the manufacturer's ladder plus the same membership throughout. 3. ## What the price includes At the entry doses the all-in figures are $248 a month for either oral and $398 for the Zepbound pen. At the top of the published ladders they become $398 and $548. Six months at the oral entry rate is $1,488 counting the $25 first month. Budgeting from the medication figure alone understates every one of these by $99 a month. 4. ## What it claims, and what it cites Foundayo, the [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) Pill and the [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) KwikPen are FDA-approved brand products dispensed through the manufacturers' own channels. Nothing here is compounded, so the caution about an unreviewed preparation does not apply. ## Where it holds up, and where it does not - Strength: FDA-approved products throughout - Strength: Manufacturer channels named explicitly - Strength: Dose ladders published on all three lines - Strength: The membership is disclosed in writing - Limitation: A $99 monthly membership is required - Limitation: The medication figure excludes it - Limitation: Top doses reach $449 before membership - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about PrideRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants an approved product and has added the membership to the ladder. Wrong for A reader comparing the medication figure against a compounded all-in price. ## The evidence behind what PrideRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PrideRx compares | Seller | Who it suits | Go | | --- | --- | --- | | NovoCare Pharmacy | Readers who want the approved product and will count thirteen boxes a year rather than twelve | | | PeterMD | Readers who want a cancel-anytime subscription and will choose the monthly product over the quarterly offer | | | Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [altRX](https://thisglp.com/reviews/altrx) [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) [AlyveRx](https://thisglp.com/reviews/alyverx) [AM Rx](https://thisglp.com/reviews/amrx) [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) [Amble](https://thisglp.com/reviews/amble) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month really cost? $248 for either oral at the entry dose and $398 for the Zepbound pen, because a $99 monthly membership sits on top of the medication figure. Are these compounded? No. Foundayo and Zepbound come through LillyDirect and the Wegovy Pill through NovoCare, all FDA-approved brand products. What happens as my dose rises? The manufacturer's ladder applies: Foundayo to $299 and the Zepbound pen to $449 at 7.5 mg and above, with the $99 membership unchanged throughout. Is PrideRx expensive compared with other GLP-1 telehealth sellers? PrideRx publishes a starting figure of $248/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts PrideRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Primary Clinic (Direct GLP) reviews (2026): GLP-1 telehealth sellers | This GLP The medication tables carry a condition printed across them: active members only. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/primary-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Members-only wholesale rate # Primary Clinic (Direct GLP) review The medication tables carry a condition printed across them: active members only. ## The verdict Primary Clinic sells compounded GLP-1s at pharmacy cost and charges $89 a month for the primary-care membership that unlocks them. Its own tables mark those rates as available only to active members, so the semaglutide floor is $174 and tirzepatide starts at $222. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 10 From From $174/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Included Primary Clinic trades as Direct GLP and runs a direct primary-care membership with weight management inside it. Compounded semaglutide and tirzepatide come from licensed 503A pharmacies. Routine labs and a long list of ordinary medications are covered by the same fee. 1. ## Who writes the prescription, and what do they see? The model is built around continuity rather than a single intake: unlimited virtual visits, direct text access to the provider, and same-day care with no copay. Labs are drawn near the patient's home and read before medication starts. The clinic argues that a GLP-1 belongs inside a primary-care relationship, and prices itself accordingly. A free virtual consult comes first, then the $89 membership, then labs, then medication if it is appropriate. Membership covers the visits, the messaging, the routine labs and the routine prescriptions. The GLP-1 itself is billed on top at the banded rate. 2. ## What happens when the dose goes up? Both molecules are priced by dose band rather than flat, and the bands are published in full. Semaglutide runs $85 at 0.25 to 0.75 mg, then $108, $145 and $183 as the dose climbs. Tirzepatide starts at $133 and reaches $258 by 8 to 10 mg, so escalation raises the medication line every time. 3. ## What the price includes Adding the membership is not optional arithmetic here, because the tables themselves state the rate is for active members only. At the starting bands a month is $174 for semaglutide and $222 for tirzepatide. A patient at the top of either ladder pays $272 or $347, and the membership is the same either way. 4. ## What it claims, and what it cites Both lines are compounded by licensed 503A pharmacies to patient-specific needs, and the clinic states plainly that they are not FDA-approved brand-name medications and not affiliated with them. The FDA does not review a compounded preparation before dispensing. No individual pharmacy is named. ## Where it holds up, and where it does not - Strength: Every dose band is published with its price - Strength: Medication is sold at cost rather than marked up - Strength: Unlimited visits, messaging and routine labs included - Strength: The members-only condition is printed on the tables - Limitation: The medication rate requires an $89 monthly membership - Limitation: The price rises at every dose band - Limitation: Membership spots are described as limited - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Primary Clinic (Direct GLP). These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants primary care and a GLP-1 from the same provider. Wrong for A buyer who wants medication alone and no membership beside it. ## The evidence behind what Primary Clinic (Direct GLP) prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Primary Clinic (Direct GLP) compares | Seller | Who it suits | Go | | --- | --- | --- | | Welling Health | Buyers who want bloodwork read by the prescriber and are comparing the medication line separately from the fee | | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | Potere Health MD | Utah patients who want one named physician through titration and can price a vial rather than a month | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Amble](https://thisglp.com/reviews/amble) [Andrew Meds](https://thisglp.com/reviews/andrew-meds) [Apex MD](https://thisglp.com/reviews/apex-md) [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) [Arc-1](https://thisglp.com/reviews/arc-1) [Ark Health](https://thisglp.com/reviews/ark-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I buy the medication without joining? No. The dose tables state the wholesale price is only available to active members of the $89 monthly membership. What does a month cost at the starting dose? $174 for semaglutide and $222 for tirzepatide, counting the membership that the rate depends on. Does the price change as the dose rises? Yes. Semaglutide climbs from $85 to $183 across four bands, and tirzepatide from $133 to $258. Is Primary Clinic (Direct GLP) expensive compared with other GLP-1 telehealth sellers? Primary Clinic (Direct GLP) publishes a starting figure of $174/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Primary Clinic (Direct GLP) below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Prime Doctor RX reviews (2026): GLP-1 telehealth sellers | This GLP The published figure is charged every four weeks, which is thirteen times a year rather than twelve. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/prime-doctor-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Billed every four weeks # Prime Doctor RX review The published figure is charged every four weeks, which is thirteen times a year rather than twelve. ## The verdict Prime Doctor RX publishes $249 every four weeks for compounded semaglutide. Thirteen fills a year make that $270 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $270/mo Oral From $302/mo Prescription Required Compounded Yes — not FDA-approved Prime Doctor RX sells semaglutide by injection and orally. The billing cycle is four weeks rather than a calendar month. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe the plan and its cycle. The clinician is not described and the intake is not documented. The cycle is the thing to notice. Four weeks and a month look alike on a page and differ by one charge a year. Nothing else about the structure is unusual. 2. ## What happens when the dose goes up? Nothing is published about what the figure does at a higher dose. The four-week cycle is a second unstated variable, because a dose increase can change what a fill contains without changing its interval. 3. ## What the price includes Thirteen charges at $249 is $3,237 a year, which is $270 a calendar month rather than $249. Over a year that is one extra charge. A reader comparing this against a monthly figure elsewhere is short by about $21 a month. 4. ## What it claims, and what it cites The lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The four-week cycle is recorded - Strength: Both an injection and an oral offered - Strength: A single clear figure per line - Limitation: Thirteen charges a year, not twelve - Limitation: About $21 a month more than it reads - Limitation: No dose behavior published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Prime Doctor RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who budgets by the charge, and knows there are thirteen of them. Wrong for A reader comparing $249 against another seller's calendar month. ## The evidence behind what Prime Doctor RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Prime Doctor RX compares | Seller | Who it suits | Go | | --- | --- | --- | | PlexusDx | A reader who will scroll past the entry card to find a product with a name | | | Oak | Readers who want a flat rate without a subscription and ignore the entry figure | | | PeterMD | Readers who want a cancel-anytime subscription and will choose the monthly product over the quarterly offer | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) [AskRx](https://thisglp.com/reviews/ask-rx) [Aspen](https://thisglp.com/reviews/aspen-health) [Aspire Health](https://thisglp.com/reviews/aspire-health) [Auren Rx](https://thisglp.com/reviews/auren-rx) [AVARA Rx](https://thisglp.com/reviews/avara-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $249 a monthly price? Not a calendar month. It is charged every four weeks, which is thirteen times a year, or $270 a month. How much does the cycle add? One extra charge a year, about $21 a month against a calendar-month reading. Does the price rise with the dose? Nothing is published either way. Is Prime Doctor RX expensive compared with other GLP-1 telehealth sellers? Prime Doctor RX publishes a starting figure of $270/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Prime Doctor RX above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Prime Health reviews (2026): GLP-1 telehealth sellers | This GLP The program ships four weeks at a time, which is one more charge a year than the figure implies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/prime-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four weeks, thirteen times # Prime Health review The program ships four weeks at a time, which is one more charge a year than the figure implies. ## The verdict Prime Health publishes $299 for compounded semaglutide and $399 for tirzepatide. Each ships a four-week supply, so thirteen charges a year make the real figures $324 and $432. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $324/mo Prescription Required Compounded Yes — not FDA-approved Prime Health sells both molecules by injection. Each program ships four weeks of medication. Both figures are stated flat across doses. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe programs rather than clinicians. The intake is not documented. The supply length is stated rather than hidden, which is the honest half. The consequence of it is not: nothing on the page converts four weeks into a calendar month. 2. ## What happens when the dose goes up? Both figures are flat across doses, so the rate holds as the dose rises. The extra cost here comes from the calendar rather than the milligrams, which makes it easy to miss. 3. ## What the price includes Thirteen charges at $299 is $3,887 a year, or $324 a calendar month. Tirzepatide at $399 comes to $5,187, or $432. Over a year that is one whole extra charge on each line, and a reader budgeting twelve months finds it in the thirteenth. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The four-week supply is stated plainly - Strength: Both figures flat across doses - Strength: Both molecules carry a price - Limitation: Billed thirteen times a year, not twelve - Limitation: About $25 and $33 a month more than it reads - Limitation: No state coverage list is recorded - Limitation: The compounding pharmacy goes unnamed ## What the evidence says about this kind of treatment The assessment above is about Prime Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who counts charges rather than months. Wrong for A reader comparing $299 against a calendar-month figure elsewhere. ## The evidence behind what Prime Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Prime Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | Regenics | Readers who will add the membership to the medication before comparing anything | | | Revive Meds | Readers who want to buy one order at a time and will get the price in writing | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Auren Rx](https://thisglp.com/reviews/auren-rx) [AVARA Rx](https://thisglp.com/reviews/avara-rx) [Avono Health](https://thisglp.com/reviews/avono-health) [AZ Health](https://thisglp.com/reviews/az-health) [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) [Bayan Health](https://thisglp.com/reviews/bayan-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $299 a monthly price? Not a calendar month. It buys four weeks, and thirteen of those fit into a year, so the real figure is $324. How much does the cycle add over a year? One extra charge on each line: $3,887 rather than $3,588 on semaglutide, and $5,187 rather than $4,788 on tirzepatide. Does the price rise with the dose? No. Both figures are stated flat across doses. Is Prime Health expensive compared with other GLP-1 telehealth sellers? Prime Health publishes a starting figure of $324/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Prime Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # PRIMO Health Partners reviews (2026): GLP-1 telehealth sellers | This GLP PRIMO offers online weight-loss plans alongside virtual primary and urgent care. Its semaglutide page describes monitoring but leaves the plan price and visit cadence unspecified. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/primo-health-partners Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Weight care within broader telehealth # Does PRIMO Health Partners sell a GLP-1? PRIMO offers online weight-loss plans alongside virtual primary and urgent care. Its semaglutide page describes monitoring but leaves the plan price and visit cadence unspecified. ## The verdict The broader clinical services may be relevant if you want more than prescription delivery. Confirm which are actually included in the chosen weight plan; the public page refers to multiple subscriptions and combinations rather than one uniform program. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved PRIMO Health Partners offers virtual care and a physician-directed GLP-1 pathway. Its website is operated by Cooper and Company, distinct from the treating clinician. 1. ## Who writes the prescription, and what do they see? The program describes evaluation by a board-certified physician and ongoing checks for side effects. Request the assigned practice and clinician; the general terms say the website itself is not a medical provider. Enrollment begins by phone, contact form or message, followed by an online consultation and medication shipment if prescribed. The page offers several program types, including combinations with other virtual care. 2. ## What happens when the dose goes up? The program says the doctor checks [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and can adjust the prescription. It does not publish a universal appointment frequency or response-time commitment, which should be clarified before starting. 3. ## What the price includes Asked about cost, the FAQ points to several subscriptions and combination plans rather than a complete quote. The dose, supply period, visits and other services need to be priced together for the selected option. 4. ## What it claims, and what it cites PRIMO states that compounding pharmacies fill prescriptions for semaglutide and tirzepatide. Those products are not FDA-approved; references to branded trials or large advertised weight-loss amounts do not establish the service’s own results. ## Where it holds up, and where it does not - Strength: Side-effect review described - Strength: Broader virtual-care options available - Limitation: No defined follow-up frequency - Limitation: Public cost answer lacks a full quote ## What the evidence says about this kind of treatment The assessment above is about PRIMO Health Partners. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking weight management alongside optional broader virtual-care services. Wrong for Someone needing a complete public medication price and scheduled follow-up calendar before contacting a sales or care team. ## The evidence behind what PRIMO Health Partners prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How PRIMO Health Partners compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [BeyondMD](https://thisglp.com/reviews/beyondmd) [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) [BiltRx](https://thisglp.com/reviews/biltrx) [Bionomy Health](https://thisglp.com/reviews/bionomy-health) [Bioverse](https://thisglp.com/reviews/bioverse) [Blis MD](https://thisglp.com/reviews/blis-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does every weight plan include primary care? The site describes combination plans but does not establish that all weight-loss plans include broader virtual care. Are the prescriptions compounded? The program explicitly says compounding pharmacies fill semaglutide and tirzepatide prescriptions. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://primohealthpartners.com/) - [Official program and terms](https://primohealthpartners.com/semaglutide-for-weight-loss/) - [Official program and terms](https://primohealthpartners.com/terms/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Push Health reviews (2026): GLP-1 telehealth sellers | This GLP Push Health connects patients with independent prescribers and sends approved prescriptions to a chosen pharmacy. Its GLP-1 pathway is not an all-inclusive medication subscription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/push-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Push Health review Push Health connects patients with independent prescribers and sends approved prescriptions to a chosen pharmacy. Its GLP-1 pathway is not an all-inclusive medication subscription. ## The verdict Push Health is strongest as a route to a clinician and a pharmacy prescription, rather than a bundled drug service. That flexibility makes the individual provider relationship important: consultation availability does not establish the continuity, follow-up fee or insurance work included after the first request. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Liraglutide · Orforglipron Form Injection · Oral Prescription Required The platform supports remote medical requests for weight management and other conditions. Its GLP-1 information covers semaglutide, tirzepatide, liraglutide and orforglipron, with both oral and injectable possibilities. The list is a set of options for discussion, not a promise that every patient can receive every product. 1. ## Who writes the prescription, and what do they see? A licensed medical provider reviews the request, medical history and suitability. The platform describes same-day consultations as available. The clinician, rather than the intake questionnaire alone, decides whether a prescription is appropriate and which treatment fits the medical indication. Patients enter weight history, medications and relevant medical conditions before connecting with a provider. If prescribed, medication can be sent to a pharmacy or manufacturer direct-to-patient program of the patient’s choice. That separation leaves dispensing, insurance and stock outside the initial consultation itself. 2. ## What happens when the dose goes up? The provider determines the dose and regimen. There is no single published platform-wide GLP-1 escalation or follow-up package. Before transferring care, clarify whether the same clinician handles refills, how often reassessment is needed and what happens if the chosen pharmacy cannot fill the next supply. 3. ## What the price includes Insurance and a subscription are not required to request a consultation. This does not mean medication is free or included. Consultation charges, subsequent clinical requests and pharmacy prices should be established separately; manufacturer savings depend on the specific product and eligibility. 4. ## What it claims, and what it cites The public pages distinguish approved product names and their ingredients. [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) and Wegovy both contain semaglutide but have different labeled uses; similar ingredient names do not make indications interchangeable. Push Health also excludes controlled weight-loss medicines such as phentermine from this service. ## Where it holds up, and where it does not - Strength: Patient chooses the dispensing pharmacy - Strength: Multiple prescription options can be discussed - Strength: No compulsory subscription is described - Limitation: Individual clinician arrangements shape continuity - Limitation: Consultation and medication are separate costs - Limitation: Controlled weight-loss prescriptions are excluded ## What the evidence says about this kind of treatment The assessment above is about Push Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a clinician-led prescription assessment while retaining a preferred retail pharmacy or manufacturer fulfillment route. Wrong for Someone wanting a single inclusive price or a guaranteed refill and follow-up schedule before meeting the provider. ## The evidence behind what Push Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. ## How Push Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Bliv](https://thisglp.com/reviews/bliv) [Bloom MD](https://thisglp.com/reviews/bloommd) [BloomWell Rx](https://thisglp.com/reviews/bloomwell-rx) [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) [Blue Sky MD](https://thisglp.com/reviews/blue-sky-md) [Bodi Envi](https://thisglp.com/reviews/bodi-envi) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Push Health sell a guaranteed GLP-1 prescription? No. A licensed provider must determine whether prescribing is appropriate. Can a preferred pharmacy be used? The GLP-1 page says prescriptions can be sent to a chosen pharmacy or manufacturer direct program when appropriate. Can phentermine be requested? The weight-loss service excludes controlled weight-loss medications such as phentermine. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.pushhealth.com/) - [GLP-1 care and prescribing options](https://www.pushhealth.com/drugs/glp-1-agonist) - [Weight-management program](https://www.pushhealth.com/services/weight-loss) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Queen RX reviews (2026): GLP-1 telehealth sellers | This GLP There is no monthly plan to choose, because the catalog holds a single quarterly one. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/queen-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One quarterly product # Queen RX review There is no monthly plan to choose, because the catalog holds a single quarterly one. ## The verdict Queen RX sells one GLP-1 product and it is quarterly: a single $299 charge covering three months of compounded semaglutide, which is where the hundred-dollar monthly framing comes from. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 45 From From $99.67/mo Prescription Required Compounded Yes — not FDA-approved Availability 45 states Queen RX is a compounded semaglutide seller with a deliberately short catalog, where the weight-care product sits beside a journal and a hat, and the treatment page offers one plan rather than a ladder of them. 1. ## Who writes the prescription, and what do they see? The purchase is stated to include a virtual doctor consultation and a prescription if one is approved, so the clinician review happens after payment rather than before it. Nothing on the pages names the clinician, describes what they see, or says what happens to the $299 if the prescription is declined. A buyer pays once and receives a quarter of treatment, and there is no membership charge layered on top. Simplicity is the selling point, and it is real, but it also removes the option of finding out whether the medication suits you before a quarter's money has moved. 2. ## What happens when the dose goes up? A three-month purchase spans most of a standard escalation, which usually runs from a starting dose up toward maintenance over the first sixteen weeks. Queen RX does not publish what the $299 contains in milligrams, nor whether a dose change inside the quarter is handled at no extra cost, so the part of treatment most likely to change is the part least described. 3. ## What the price includes $299 for three months works out at $99.67 a calendar month, and that arithmetic is honest as far as it goes. What it hides is the shape of the commitment: there is no smaller purchase available, so the minimum a buyer can spend to try this seller is a full quarter paid in one charge, with nothing published about refunds. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is a compounded preparation rather than a manufactured product, prepared by a pharmacy the site does not name, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: One product, priced without conditions - Strength: Consultation included in the purchase - Strength: No membership charge - Strength: Coverage stated across 45 states - Limitation: No monthly plan exists - Limitation: A full quarter is the smallest purchase - Limitation: No milligram dose beside the figure - Limitation: Nothing published about refunds ## What the evidence says about this kind of treatment The assessment above is about Queen RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer content to commit a quarter at a time in one payment. Wrong for A buyer who wants a month of medication before deciding whether to continue. ## The evidence behind what Queen RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Queen RX compares | Seller | Who it suits | Go | | --- | --- | --- | | MultiMedRx | A reader with insurance who needs a branded GLP-1 covered rather than sold | | | Alegro Health | Buyers trying a GLP-1 for two months before committing to a rate | | | Ivologist | Buyers who check a printed monthly equivalent against the term it covers | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Blue Sky MD](https://thisglp.com/reviews/blue-sky-md) [Bodi Envi](https://thisglp.com/reviews/bodi-envi) [Bon Health](https://thisglp.com/reviews/bon-health) [boostAGErx](https://thisglp.com/reviews/boostagerx) [Boston Medical Group](https://thisglp.com/reviews/boston-medical-group) [Breeze Meds](https://thisglp.com/reviews/breeze-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a monthly plan? No. The catalog holds one GLP-1 product, sold as a single $299 charge covering three months. What does that work out at per month? $99.67 a calendar month, though the money is taken in one payment rather than three. Is the consultation extra? No. Queen RX states the purchase includes a virtual doctor consultation and the prescription if it is approved. Is Queen RX legit? Queen RX is a GLP-1 telehealth sellers service. Its stated availability: 45 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Queen RX expensive compared with other GLP-1 telehealth sellers? Queen RX publishes a starting figure of $99.67/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Queen RX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # QuickMD reviews (2026): GLP-1 telehealth sellers | This GLP An online clinic that charges per visit and sends brand GLP-1 prescriptions to the patient's own pharmacy, after withdrawing its compounded versions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/quickmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A visit, not a program # QuickMD review An online clinic that charges per visit and sends brand GLP-1 prescriptions to the patient's own pharmacy, after withdrawing its compounded versions. ## The verdict QuickMD sells a consultation rather than a medication plan, so its clinicians can prescribe Wegovy, Zepbound, Mounjaro, Ozempic and other GLP-1s for a flat per-visit fee with no membership attached. The prescription then goes to a pharmacy the patient chooses, and that pharmacy, not QuickMD, sets what the medicine costs each month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose published No Prescription Required Compounded No QuickMD is a broad telemedicine practice whose larger lines are addiction treatment with buprenorphine, menopause hormone therapy, mental health and urgent care, and weight loss sits in that same menu as one more type of consultation. It does not accept health insurance, charges no membership, and lists its weight-loss consultation as unavailable in Louisiana. 1. ## Who writes the prescription, and what do they see? The pricing page promises a licensed doctor who assesses the patient and prescribes a GLP-1 if appropriate, and the weight-loss FAQ describes a review of health history, current medications and goals before that decision. No individual clinician is named on those pages, and the prescription goes either to the patient's pharmacy or to an eligible delivery service, depending on the drug. Each visit is bought on its own, so follow-up means a second booking rather than a feature of a plan, and the weight-loss page promises ongoing follow-up without saying how often it happens. Same-day appointments are advertised seven days a week, which suits a patient who needs a renewal quickly more than one who wants a standing care team. 2. ## What happens when the dose goes up? Because QuickMD does not sell the medication, a dose increase changes nothing on its own bill; the change shows up at the pharmacy counter, where the patient's chosen pharmacy prices each strength. The site publishes no [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule and leaves the step-by-step plan to the clinician in the visit, which means each step can also mean another paid visit. 3. ## What the price includes The only weight-loss price on the site is the consultation fee itself, published on the pricing page. Medication costs, the weight-loss page says, vary with the drug prescribed and the pharmacy chosen. QuickMD mentions savings on Ozempic and Mounjaro but prints no dollar figure for either, so the monthly total cannot be worked out before a visit. 4. ## What it claims, and what it cites The medication list still shows compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and compounded tirzepatide, but both of their pages now say the compounded versions are no longer available and point patients to Ozempic or Mounjaro instead. What remains is FDA-approved brand medicine: Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus and liraglutide, each filled by a pharmacy outside QuickMD. ## Where it holds up, and where it does not - Strength: No membership or subscription is required - Strength: Brand prescriptions go to any pharmacy - Strength: Same-day visits, seven days a week - Strength: The consultation fee is published - Limitation: Medication cost is left to the pharmacy - Limitation: Follow-up visits are booked and paid separately - Limitation: No clinician is named on the weight-loss pages - Limitation: Weight-loss visits are unavailable in Louisiana ## What the evidence says about this kind of treatment The assessment above is about QuickMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader with a pharmacy benefit or a brand savings program who only needs a prescriber, not a bundled program. Wrong for A reader looking for compounded medication, which QuickMD says it no longer offers. ## The evidence behind what QuickMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How QuickMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Calibrate Health | Insured buyers who want coaching and insurance handling alongside a prescription | | | Hims | Buyers set on brand Wegovy or Zepbound who accept a monthly membership on top | | | Knownwell | Insured patients who want ongoing care from one obesity-medicine clinician | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Breeze Meds](https://thisglp.com/reviews/breeze-meds) [Brello Health](https://thisglp.com/reviews/brello-health) [Brightmeds](https://thisglp.com/reviews/brightmeds) [Cabana](https://thisglp.com/reviews/cabana) [CaliberRx](https://thisglp.com/reviews/caliberrx) [California Trim Clinic](https://thisglp.com/reviews/california-trim-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does QuickMD still prescribe compounded semaglutide? No, its semaglutide page says compounded versions are no longer available now that the FDA has removed the drug from its shortage list, and it points existing patients toward Ozempic or another approved option. What does the medication cost through QuickMD? The site does not say, because QuickMD does not sell the medicine itself; the prescription goes to the patient's chosen pharmacy or a delivery service, and that pharmacy's price is what the patient ends up paying. Is there a membership at QuickMD? No, the weight-loss consultation is sold one visit at a time with no subscription behind it, and QuickMD does not bill any health insurance plan for the visit. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ravia Health reviews (2026): GLP-1 telehealth sellers | This GLP Ravia’s Florida psychiatric practice and its Lyv Health weight-care partnership are different routes. Confirm which team will manage the GLP-1 assessment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ravia-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Psychiatry and partner-delivered weight care # Does Ravia Health sell a GLP-1? Ravia’s Florida psychiatric practice and its Lyv Health weight-care partnership are different routes. Confirm which team will manage the GLP-1 assessment. ## The verdict The distinction between the local practice and partner program matters more than the broad nationwide banner. The site establishes access to GLP-1 evaluation, but not a specific molecule, dispensing pharmacy or complete treatment price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Ravia Health is an integrative psychiatric practice led by Raashida Portier, DNP, PMHNP-BC, FNP-BC. It separately advertises wellness and weight-care access through Lyv Health. 1. ## Who writes the prescription, and what do they see? The psychiatric route describes virtual appointments with Dr. Portier. The partner wellness route describes review by a licensed provider without establishing that the same clinician will manage both services. The site describes history-taking, lab evaluation and ongoing psychiatric management. Those features should not automatically be carried over to the separate GLP-1 partner program; ask what that specific intake and follow-up include. 2. ## What happens when the dose goes up? GLP-1 medication is described as conditional on clinical appropriateness. A dosing schedule, refill review interval and route for reporting treatment concerns were not established for the partner program. 3. ## What the price includes Psychiatric insurance acceptance and membership descriptions do not establish GLP-1 coverage or cost. Request a partner-program quote identifying medical visits, medication and any required labs. 4. ## What it claims, and what it cites The public page refers to GLP-1 medications generically. It does not establish a particular molecule, form or branded-versus-compounded selection, so those details remain unlisted rather than inferred. ## Where it holds up, and where it does not - Strength: Named clinician for the psychiatric practice - Strength: Partner relationship disclosed - Limitation: GLP-1 clinician assignment unresolved - Limitation: Specific medication not established ## What the evidence says about this kind of treatment The assessment above is about Ravia Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants to understand the relationship between psychiatric care and a separate weight-care referral. Wrong for Someone who needs a defined GLP-1 product and complete program terms before making contact. ## How Ravia Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Care Bare Rx](https://thisglp.com/reviews/care-bare-rx) [Care Clinics](https://thisglp.com/reviews/care-clinics) [Carocare Wellness](https://thisglp.com/reviews/carocare-wellness) [CeliaRx](https://thisglp.com/reviews/celia-rx) [Center for Medical Weight Loss (CMWL)](https://thisglp.com/reviews/center-for-medical-weight-loss)[Cielo](https://thisglp.com/reviews/cielo) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Dr. Portier necessarily prescribe through the weight program? The site distinguishes her psychiatric practice from the Lyv Health partnership; confirm the clinician assigned to the partner service. Is the entire practice nationwide? The site states Florida psychiatric care and separately advertises nationwide partner wellness access. Those scopes should not be merged. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://raviahealth.com/) - [Official program and terms](https://raviahealth.com/terms-conditions/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ReadyRx reviews (2026): GLP-1 telehealth sellers | This GLP A discounted first month, then a flat rate that ReadyRx applies to every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/readyrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat rate after month one # ReadyRx review A discounted first month, then a flat rate that ReadyRx applies to every dose. ## The verdict ReadyRx charges $249 a month for compounded semaglutide and $315 for compounded tirzepatide on its monthly plan. Both figures follow a discounted first month. Each card is labeled as covering every dose, which settles the titration question before it arises. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named ReadyRx is an online service selling compounded semaglutide and compounded tirzepatide. Brand Ozempic and Zepbound are listed beside them. Hormone and energy treatments share the site. No insurance is required, and each GLP-1 plan comes in a monthly or a quarterly version. 1. ## Who writes the prescription, and what do they see? The FAQ says board-certified physicians review health history and decide whether treatment is appropriate. The consultation is included in the program price. No physician is named, and neither is a medical group. What the intake asks, and whether the visit is live or written, is not described on the product pages. Every plan lists the same inclusions: personalized protocols, meal plans and coaching, free shipping, and unlimited physician messaging. The page also describes peer groups led by specialists. Refills are processed automatically. The billing FAQ says a subscription can be paused or canceled at any time. 2. ## What happens when the dose goes up? The semaglutide card is headed 'All Doses' and the tirzepatide card 'Every Dose'. Read plainly, the monthly rate does not rise as the dose climbs. No milligram strength is printed on either card, so the range those labels cover is not stated. Who approves each step is described only as the prescribing physician. 3. ## What the price includes On the monthly plan, semaglutide is $229 for the first month and $249 after. Tirzepatide is $295, then $315. The $66 step between the two drugs holds at the standing rate. A quarterly plan paid up front lowers both figures, and the page footnotes that condition. The hero banner leads with the quarterly first month rather than the monthly rate, and a site-wide discount code runs on top. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded, and the FAQ states that compounded GLP-1 medications are not FDA-approved. The [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) cross-sell card calls it 'The latest FDA-approved GLP-1'. That label fits the brand drug, not the compounded version the card sells. Pharmacies are described as FDA-registered and U.S.-based, and none is named. Four batch tests are listed: potency, sterility, pH and endotoxins. ## Where it holds up, and where it does not - Strength: The standing rate is printed beside the first-month figure - Strength: Each card is labeled as the same at every dose - Strength: Physician messaging is included without a cap - Strength: Four batch tests are named - Limitation: The hero figure is a quarterly first month - Limitation: One card calls compounded tirzepatide FDA-approved - Limitation: No physician, medical group or pharmacy is named - Limitation: No milligram strength is printed ## What the evidence says about this kind of treatment The assessment above is about ReadyRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who budgets from the month-two rate and expects to climb the dose ladder. Wrong for A reader who wants the prescribing physician or pharmacy named before paying. ## The evidence behind what ReadyRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How ReadyRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [CeliaRx](https://thisglp.com/reviews/celia-rx) [Center for Medical Weight Loss (CMWL)](https://thisglp.com/reviews/center-for-medical-weight-loss)[Cielo](https://thisglp.com/reviews/cielo) [Citizen Meds](https://thisglp.com/reviews/citizen-meds) [Claya](https://thisglp.com/reviews/claya) [Clinic Secret](https://thisglp.com/reviews/clinic-secret) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What will I pay after the first month? $249 a month for semaglutide and $315 for tirzepatide on the monthly plan. The first month is $229 and $295. Does a higher dose cost more? Not according to the cards, which are labeled 'All Doses' and 'Every Dose'. The milligram range those labels cover is not printed. Is the compounded tirzepatide FDA-approved? No. ReadyRx's own FAQ says compounded GLP-1 medications are not FDA-approved, whatever the cross-sell card's heading says. Is ReadyRx expensive compared with other GLP-1 telehealth sellers? ReadyRx publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ReadyRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Recovery Delivered reviews (2026): GLP-1 telehealth sellers | This GLP A seller that prints the expensive end of its own price ladder is telling you something about itself. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/recovery-delivered Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 It tells you the bad news # Recovery Delivered review A seller that prints the expensive end of its own price ladder is telling you something about itself. ## The verdict Recovery Delivered starts semaglutide at $199.99 a month and prints the two rungs above it, at $229.99 and $299.99. Tirzepatide opens at $219. Eighteen states are not served. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose States 32 Injection From $199/mo Oral From $249/mo Prescription Required Compounded Yes — not FDA-approved Availability 32 states Recovery Delivered sells semaglutide and tirzepatide by injection and semaglutide as drops or tablets. Its semaglutide line shows the whole escalation rather than the entry point. 1. ## Who writes the prescription, and what do they see? The provider consultation is named as part of each figure, so the clinician is inside the price rather than beside it. Printing your own worst number is a choice, and it is not a choice a seller makes when the number is embarrassing. Read it as a signal about the rest of the page. 2. ## What happens when the dose goes up? This is the disclosure to notice. Most sellers publish where a course begins; this one publishes where it can end. Nothing is left for month three to reveal. 3. ## What the price includes Six months at the entry rung is $1,199.94. At the top it is $1,799.94, a difference of $600 across the same period. Tirzepatide from $219 comes to $1,314, and the oral route from $249 to $1,494. 4. ## What it claims, and what it cites Every line is compounded. A pharmacy prepares them, and no regulator inspects the finished vial. How much of an oral dose is taken up is not addressed for either form. ## Where it holds up, and where it does not - Strength: The whole escalation is printed, not just its start - Strength: A provider consultation sits inside each figure - Strength: Both molecules and an oral route are priced - Limitation: Eighteen states go unserved - Limitation: The dearest rung is half again the entry one - Limitation: Neither oral form has absorption data - Limitation: No pharmacy is identified ## What the evidence says about this kind of treatment The assessment above is about Recovery Delivered. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who rewards a seller for publishing the number that costs it sales. Wrong for A reader outside the 32 states covered. ## The evidence behind what Recovery Delivered prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Recovery Delivered compares | Seller | Who it suits | Go | | --- | --- | --- | | Edessa | Readers who will read the plan table rather than the homepage banner | | | MedLeanRx | Readers who happen to live where this seller operates | | | Roboclinic | Readers ready to commit a full year and wanting the discount that buys | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Clume Health](https://thisglp.com/reviews/clume-health) [CLYR Health](https://thisglp.com/reviews/clyr-health) [Coivas](https://thisglp.com/reviews/coivas) [Concierge MD LA](https://thisglp.com/reviews/concierge-md-la) [Contour Health](https://thisglp.com/reviews/contour-health) [Cora Health](https://thisglp.com/reviews/cora-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Where does the semaglutide ladder end? $299.99 a month, printed on the page rather than discovered later. Is the provider visit billed separately? No. It is named inside each figure, along with delivery. How wide is the coverage? Thirty-two states, so eighteen are not served. Is Recovery Delivered legit? Recovery Delivered is a GLP-1 telehealth sellers service. Its stated availability: 32 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Recovery Delivered expensive compared with other GLP-1 telehealth sellers? Recovery Delivered publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Recovery Delivered above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Red Mountain Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP Red Mountain Weight Loss offers clinician-guided GLP-1 care through regional offices and telemedicine. Promotional pricing needs to be separated from the individual treatment plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/red-mountain-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Red Mountain Weight Loss sell a GLP-1? Red Mountain Weight Loss offers clinician-guided GLP-1 care through regional offices and telemedicine. Promotional pricing needs to be separated from the individual treatment plan. ## The verdict Red Mountain describes continuing check-ins and plan adjustments, which are more useful clinical details than a promotional starting figure. The key questions are the exact prescription, the chosen regional service and what monitoring continues after the introductory offer ends. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required The practice network provides medical weight management alongside hormone and aesthetic services. Its current site lists prescription GLP-1 care and other programs. A regional clinic or telemedicine pathway should be confirmed rather than interpreting the whole network as universal access. 1. ## Who writes the prescription, and what do they see? A licensed healthcare provider must assess medical suitability and issue any prescription. The practice describes medical oversight, laboratory-informed care and individualized planning. A consultation promotion does not guarantee the clinician will recommend a GLP-1. The public offer includes ongoing check-ins and plan adjustments. Regional offices and telemedicine are separately listed. Ask which clinician remains responsible, whether follow-up is in person or remote and how quickly clinical concerns can be raised between routine appointments. 2. ## What happens when the dose goes up? Dosing should evolve according to medical response rather than a promotional package name. The home page does not establish a universal [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule or a complete dose ladder. Obtain the next-review and refill process before beginning. 3. ## What the price includes Starting-price and consultation promotions appear alongside restrictions for new or returning patients. Laboratory fees are expressly excluded from the consultation promotion. A promotional saving should not be mistaken for the complete ongoing cost of medication and monitoring. 4. ## What it claims, and what it cites The public materials discuss compounded-treatment limitations and require prescribing, but the general home page does not fully specify a medicine and formulation for every plan. Ask for the actual product and dispenser; a GLP-1 category label is not a prescription specification. ## Where it holds up, and where it does not - Strength: Clinical oversight and ongoing adjustments are described - Strength: Office and telemedicine routes are distinguished - Strength: Promotional restrictions are disclosed - Limitation: The entry offer is not a complete dose-price schedule - Limitation: Labs can be outside a promotion - Limitation: Exact medicine and regional access need confirmation ## What the evidence says about this kind of treatment The assessment above is about Red Mountain Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone near a service location or eligible regional telemedicine pathway who wants continuing medically supervised weight care. Wrong for A buyer assuming the lowest promotion applies indefinitely or includes every medication and test. ## How Red Mountain Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) [DoctorAdam](https://thisglp.com/reviews/doctoradam) [Dollar Dad Club](https://thisglp.com/reviews/dollar-dad-club) [Dr. Arevitalize](https://thisglp.com/reviews/dr-arevitalize) [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) [DrBrainRx](https://thisglp.com/reviews/drbrainrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does a promotion guarantee treatment? No. Prescription treatment requires a licensed provider’s assessment and approval. Are laboratory fees waived with the consultation offer? The posted consultation-promotion conditions explicitly exclude lab fees. Can any patient use the promotion? The terms impose new or returning-patient conditions and exclude current patients from the stated offer. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.redmountainweightloss.com/) - [Official provider and care overview](https://www.redmountainweightloss.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Refills reviews (2026): GLP-1 telehealth sellers | This GLP Two compounded injections, a daily rate labeled as low as, and plans behind a date-of-birth question. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/refills Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Discount shown, plan withheld # Refills review Two compounded injections, a daily rate labeled as low as, and plans behind a date-of-birth question. ## The verdict Refills sells compounded semaglutide and a compounded GIP and GLP-1 injection. Its pages print a daily "as low as" rate beside a "40% OFF" badge. Monthly plans appear only after an intake that asks for a date of birth, and whether the daily rate outlasts a first order is not stated. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states except DC A technology platform connecting buyers with clinicians for weight loss, ED, hair and general wellness. It names its clinician partners: Beluga Health, Bask Health, Wasef Health and TelegraMD. It states it neither manufactures nor dispenses medication. 1. ## Who writes the prescription, and what do they see? Independent clinicians working through those four partners make every prescribing decision. No individual clinician is named, and a lab test may be ordered if the provider wants one. The first consultation usually follows within a few days of signup. The site advertises no membership or app fees, free shipping and round-the-clock support from a health concierge. Service covers all 50 states, excluding the District of Columbia. Plans, refills and prescriptions sit in one account. 2. ## What happens when the dose goes up? The homepage says every dosage costs the same and dose changes are not charged. The FAQ describes starting low and increasing every few weeks, though no milligram schedule is published. The flat-dose claim has no monthly figure to attach to before the intake. 3. ## What the price includes No monthly price appears on either product page, and the pricing FAQ says cost depends on the medication, the plan and the state. The daily rate carries an "as low as" label under a banner for new-patient offers. How long that rate lasts is not stated. 4. ## What it claims, and what it cites Both products are compounded, and the pharmacy partner page names Perfect Rx Pharmacy in Texas and Hallandale Pharmacy in Florida. Each batch is described as third-party tested, with a Certificate of Analysis on request. Compounded preparations are not FDA-approved, and the site says so. ## Where it holds up, and where it does not - Strength: Clinician partners and pharmacies are named - Strength: A Certificate of Analysis is offered on request - Strength: Same price at every dose is claimed - Strength: No membership or app fee - Limitation: No monthly price before the intake - Limitation: The daily rate may be a new-patient offer - Limitation: The intake asks for a date of birth - Limitation: No milligram schedule is published ## What the evidence says about this kind of treatment The assessment above is about Refills. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who will finish an intake to see a plan and wants batch testing documented. Wrong for A buyer comparing monthly prices before sharing personal details. ## The evidence behind what Refills prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Refills compares | Seller | Who it suits | Go | | --- | --- | --- | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) [DrBrainRx](https://thisglp.com/reviews/drbrainrx) [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) [DudeMeds](https://thisglp.com/reviews/dudemeds) [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) [Edessa](https://thisglp.com/reviews/edessa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Refills charge per month? The product pages do not say; the only figure is a daily "as low as" rate printed beside a discount badge. Who prescribes at Refills? Independent clinicians working through Beluga Health, Bask Health, Wasef Health and TelegraMD. Does a higher dose cost more? The homepage says every dosage costs the same, but no monthly base figure is published to check that against. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ReflexMD reviews (2026): GLP-1 telehealth sellers | This GLP Three products, three flat rates, and one of them never says what is in it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/reflexmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced on the front page # ReflexMD review Three products, three flat rates, and one of them never says what is in it. ## The verdict ReflexMD puts its entire catalog on the homepage as three cards, charging $297 a month for compounded semaglutide and $367 for compounded tirzepatide, which is dear for this shelf but published without a quiz. The third card, a $199 line called Weight Control, names no molecule at all. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $297/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named ReflexMD is a weight-management telehealth service selling two compounded injections and one line of oral tablets, and the three of them sit together in a block headed Let's Find Your Treatment Match. The company says more than seventy-five thousand patients have used it. A partner banner at the top of the page sells discounted peptide skincare through a separate brand, which is the only place the site sends a reader off-site. 1. ## Who writes the prescription, and what do they see? The intake asks for medical history, a body photograph and a photo identity document, and a United States based medical team then decides eligibility and which medication suits. That photo requirement is worth noticing, because most of this category asks for neither a picture nor an identity check before shipping a prescription drug. Beyond the phrase medical team, no clinician, medical group or medical director is named, and the site says a doctor can be messaged at any hour with a reply promised within hours. Everything happens remotely and ReflexMD states plainly that the program requires no in-person visits at any stage. Three telephone numbers appear across the page for wellness advisers, order support and general help, and advisers can be booked into a scheduled call rather than reached only by chat. Shipping is free and described as discreet, the pricing is labeled flat-rate, and purchases are eligible for flexible spending and health savings accounts. 2. ## What happens when the dose goes up? The pricing is labeled flat-rate on the homepage, which reads as a promise that the charge holds as the dose climbs, and nothing on the page contradicts it. What the page does not carry is a single milligram, for any of the three products, at any point in the escalation. A reader cannot see where a dose starts, how quickly it rises, or how long a rung is held, so the clinical half of the [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) question goes unanswered while the money half is settled. 3. ## What the price includes Compounded semaglutide is $297 a month and compounded tirzepatide is $367, both printed on a card before any medical question is asked, which is more than most sellers at any price will do. The third card is the one to read twice: it says Weight Control, oral tablets, $199 a month, and the page never states what the tablets contain. A fifteen percent code is offered on three-month plans, and the same discount reappears in an exit banner whose decline button reads that the reader wants to pay full price. 4. ## What it claims, and what it cites Both injections are compounded, which means no FDA review for safety, efficacy or quality before dispensing, and ReflexMD's footer states that compounded preparations are indicated only where a prescriber judges them meaningfully different from the approved product for that patient. The pharmacy is described as United States based and state-licensed rather than named. Whether the $199 tablets are a GLP-1, a different drug class or something that needs no prescription is left for the intake to reveal. ## Where it holds up, and where it does not - Strength: All three rates published before any intake - Strength: Flat-rate pricing stated on the homepage - Strength: Photo identity verification is part of the intake - Strength: Telephone support and scheduled adviser calls offered - Strength: No in-person visit required at any stage - Limitation: The $199 tablet line names no molecule - Limitation: Both injection rates sit high for compounded care - Limitation: No milligram is published for any product - Limitation: No clinician or medical group is named - Limitation: No state coverage list appears on the site ## What the evidence says about this kind of treatment The assessment above is about ReflexMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a compounded rate on the homepage and a person to call about it. Wrong for A reader who needs to know what is in a product before paying $199 a month for it. ## The evidence behind what ReflexMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How ReflexMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Kina | Women in menopause who want the medical group named and four routes priced up front | | | Transparent Meds | Buyers comparing a compounded GLP-1 against peptide programs sold by the same clinic | | | T2D.com | Buyers who already hold a GLP-1 prescription and want a dose-labeled cash rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Edessa](https://thisglp.com/reviews/edessa) [EdgeRx](https://thisglp.com/reviews/edgerx) [Effecty](https://thisglp.com/reviews/effecty) [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) [Elevate Health](https://thisglp.com/reviews/elevate-health) [Elevated Health](https://thisglp.com/reviews/elevated-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is in the $199 Weight Control tablets? Not stated. The card names the product and the price, and no molecule or ingredient appears anywhere on that page. Does the price rise as the dose rises? ReflexMD labels its pricing flat-rate and nothing on the page qualifies that. No milligram is published to measure it against. Is an in-person visit needed? No. ReflexMD states the program was designed so a prescription is issued virtually, with round-the-clock access to a licensed physician. Is ReflexMD expensive compared with other GLP-1 telehealth sellers? ReflexMD publishes a starting figure of $297/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ReflexMD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RegenCen reviews (2026): medical weight-loss clinics | This GLP RegenCen offers several weight-management and maintenance programs with clinician check-ins. Distinguish GLP-1 prescribing from the additional injections included in some packages. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/regencen Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does RegenCen sell a GLP-1? RegenCen offers several weight-management and maintenance programs with clinician check-ins. Distinguish GLP-1 prescribing from the additional injections included in some packages. ## The verdict RegenCen makes continuing supervision a visible part of its offer, including a separate maintenance pathway. The clinical question is which parts of a package are justified for the individual. Added NAD or vitamin injections should not be assumed necessary for a GLP-1 to work. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category medical weight-loss clinics Prescription Required The clinic network combines weight management with hormone and other wellness services. Its program menu includes semaglutide or tirzepatide, a four-month weight-and-wellness package, a shorter semaglutide program and continuing maintenance care. 1. ## Who writes the prescription, and what do they see? A provider assesses medical history and treatment goals before recommending medication. RegenCen describes medical oversight and laboratory evaluation. Confirm who at the chosen location manages the prescription and which tests are clinically needed rather than treating every marketed package as a standard protocol. Check-ins and ongoing symptom and progress monitoring are listed in both weight-loss and maintenance pathways. The four-month package adds comprehensive labs and other injections. Ask how the visit schedule, messaging access and responsibility for side effects differ between the offered programs. 2. ## What happens when the dose goes up? Maintenance care describes semaglutide or tirzepatide with dose adjustments and longer-term monitoring. It is not a promise that all patients can stop medication or maintain weight without it. Any decision to continue or reduce treatment should follow the provider’s assessment. 3. ## What the price includes Consultations are advertised as complimentary, but the public page does not establish a complete comparable medication-and-care price for every pathway. Obtain the total package payment and separate the cost of GLP-1 care from optional injectables or other services. 4. ## What it claims, and what it cites Semaglutide and tirzepatide are explicitly named. The precise finished product, formulation and dispensing pharmacy need to be confirmed for the selected prescription. A package’s broader claims about metabolism or energy do not establish evidence for every added treatment. ## Where it holds up, and where it does not - Strength: Maintenance care is separately described - Strength: Ongoing medical check-ins are included in the model - Strength: Different program lengths can be discussed - Limitation: Extra injections complicate the clinical and financial choice - Limitation: No complete public price for every pathway - Limitation: Prescription formulation needs clarification ## What the evidence says about this kind of treatment The assessment above is about RegenCen. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone wanting continuing clinic-based weight and maintenance support who can evaluate each component of the proposed plan. Wrong for A patient who wants only a clearly specified GLP-1 prescription without a wider wellness package. ## The evidence behind what RegenCen prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RegenCen compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EllieMD](https://thisglp.com/reviews/elliemd) [Eloria](https://thisglp.com/reviews/eloria) [Emerge Weight Loss](https://thisglp.com/reviews/emerge-weight-loss) [eMI Aesthetics](https://thisglp.com/reviews/emi-aesthetics) [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does RegenCen offer continuing maintenance care? Yes. It describes a program with semaglutide or tirzepatide, check-ins and continuing dose monitoring. Are additional injections always necessary? The page includes them in some packages; ask the clinician to explain their individual purpose and alternatives. Are consultations charged? The weight-loss page describes complimentary consultations, while treatment package costs require a quote. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://regencen.com/) - [Practice and clinical team](https://regencen.com/about-us/) - [Weight-management program](https://regencen.com/regencen-treatments-weight-loss/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Regenics reviews (2026): GLP-1 telehealth sellers | This GLP A required membership renews on a four-week clock, which is thirteen charges a year on top of the medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/regenics Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership renews every 28 days # Regenics review A required membership renews on a four-week clock, which is thirteen charges a year on top of the medication. ## The verdict Regenics publishes $119 a month for compounded semaglutide, with a mandatory membership at $79 every 28 days. Thirteen renewals a year make the all-in figure about $205. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $205/mo Prescription Required Compounded Yes — not FDA-approved Regenics sells both molecules by injection with medication priced separately from a required membership that runs on a different clock from the medication itself. 1. ## Who writes the prescription, and what do they see? The membership is described as covering provider consults and support alongside the medication, which is a real statement of what the clinical side costs. What it does not say is how often that support is available. Two clocks are running here and only one of them looks monthly. The medication is quoted per month and the membership renews every 28 days, so the two charges drift apart across a year in a way neither figure shows on its own. 2. ## What happens when the dose goes up? Nothing is published about what the medication figure does at a higher dose. With the membership already adding an unannounced thirteenth charge, a reader has two sources of unplanned cost rather than one. 3. ## What the price includes The membership is $79 every 28 days, which is thirteen renewals a year, or about $86 a calendar month rather than $79. Added to the $119 medication rate, semaglutide comes to roughly $205 a month and tirzepatide to $285. A first month is offered at $139 and $189. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Medication and membership priced separately - Strength: The membership names what it covers - Strength: Discounted first months are published - Limitation: The membership is mandatory, not optional - Limitation: It renews every 28 days, not monthly - Limitation: That adds a thirteenth charge a year - Limitation: The medication figure excludes all of it ## What the evidence says about this kind of treatment The assessment above is about Regenics. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will add the membership to the medication before comparing anything. Wrong for A reader budgeting from the $119. ## The evidence behind what Regenics prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Regenics compares | Seller | Who it suits | Go | | --- | --- | --- | | Rejuve Meds | Readers who will prepay a year and have read the footnote under the label | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | Prime Health | Readers who count charges rather than months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [eMI Aesthetics](https://thisglp.com/reviews/emi-aesthetics) [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus)[EverSlim](https://thisglp.com/reviews/everslim) [Eviora MD](https://thisglp.com/reviews/eviora-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month really cost? About $205 for semaglutide and $285 for tirzepatide, because a mandatory $79 membership renews every 28 days rather than monthly. Why is a $79 membership $86 a month? Because a 28-day cycle renews thirteen times a year rather than twelve, which spreads $1,027 across twelve calendar months. What is the medication price alone? $119 a month for semaglutide and $199 for tirzepatide, before the membership is added. Is Regenics expensive compared with other GLP-1 telehealth sellers? Regenics publishes a starting figure of $205/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Regenics above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rehydra+ Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Three dose tiers on each molecule, each with its own figure, and a separate price for buying without a subscription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rehydra-plus Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every dose tier priced # Rehydra+ Wellness review Three dose tiers on each molecule, each with its own figure, and a separate price for buying without a subscription. ## The verdict Rehydra+ Wellness publishes a three-tier dose ladder on both molecules: semaglutide at $119, $169 and $229 a month, and tirzepatide at $169, $289 and $419. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $119/mo Prescription Required Compounded Yes — not FDA-approved Rehydra+ Wellness sells both molecules by injection on a subscription with priced dose tiers, alongside one-time vials for buyers who do not want a standing order. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the clinician is not described. The tier structure implies a clinical decision at each step and the pages do not describe who makes it. Publishing what each dose costs is the substantive disclosure here, and it is rare enough to be the reason to look. Most sellers answer the escalation question with a single word or with silence; this one answers it with a number at every rung, which lets a reader cost out a year before starting one. 2. ## What happens when the dose goes up? This is the field Rehydra+ answers better than most. Semaglutide runs $119, $169 and $229 across three tiers, and tirzepatide $169, $289 and $419 — so reaching the top tier costs $110 and $250 more a month than the entry one. A buyer who expects to escalate knows the number today. 3. ## What the price includes Six months at the entry semaglutide tier is $714 and at the top tier $1,374. One-time non-subscription vials start at $149 and $219, so declining the standing order costs $30 and $50 more a month. A separate 2.5 mg listing runs $399 to $479, which is a different product line from the tiered ladder. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Three priced dose tiers on each molecule - Strength: One-time vials priced as an alternative - Strength: The cost of escalating is knowable today - Limitation: The top tirzepatide tier reaches $419 - Limitation: Declining the subscription costs more - Limitation: A separate listing runs to $479 - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Rehydra+ Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to price a full escalation before committing to a first dose. Wrong for A reader comparing entry figures as though they were rates, when the top tirzepatide tier is $419 and declining the subscription costs more. ## The evidence behind what Rehydra+ Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rehydra+ Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Rejuve Meds | Readers who will prepay a year and have read the footnote under the label | | | Regenics | Readers who will add the membership to the medication before comparing anything | | | RestorLife Med | Readers who want monitoring included rather than billed separately | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Factor Health MD](https://thisglp.com/reviews/factor-health-md) [Fella Health](https://thisglp.com/reviews/fella-health) [Fidelity Medical Clinic](https://thisglp.com/reviews/fidelity-medical-clinic) [Fierce Health](https://thisglp.com/reviews/fierce-health) [Fifty 410](https://thisglp.com/reviews/fifty-410) [FitFlow](https://thisglp.com/reviews/fitflow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What happens to the price as my dose rises? It rises with it and every step is published: semaglutide at $119, $169 and $229, and tirzepatide at $169, $289 and $419. Can I buy without subscribing? Yes. One-time vials start at $149 for semaglutide and $219 for tirzepatide, which is $30 and $50 above the entry subscription tiers. What is the 2.5 mg listing? A separate product running $399 to $479, distinct from the tiered ladder. Is Rehydra+ Wellness expensive compared with other GLP-1 telehealth sellers? Rehydra+ Wellness publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rehydra+ Wellness below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rejuve Meds reviews (2026): GLP-1 telehealth sellers | This GLP The label says Most Affordable and the figure under it needs twelve months paid up front. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rejuve-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Most Affordable, prepaid # Rejuve Meds review The label says Most Affordable and the figure under it needs twelve months paid up front. ## The verdict Rejuve Meds shows $165 a month for compounded semaglutide, which its own footnote ties to a twelve-month plan paid upfront. The FAQ's ongoing range starts at $205, and it names no tirzepatide injection figure at all. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $205/mo Prescription Required Compounded Yes — not FDA-approved Rejuve Meds sells both molecules by injection, labeling the semaglutide line Most Affordable and pricing it on a plan a reader has to read a footnote to identify. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. Free shipping is stated, which is a smaller disclosure than the one missing about what an ongoing month costs. A superlative label sitting on a prepaid figure is the shape to notice. Most Affordable describes the card, and the card describes a year paid in advance rather than a rate anyone is billed monthly. 2. ## What happens when the dose goes up? Nothing states what the figure does at a higher dose. The FAQ's ongoing range runs from $205 to $399, which may reflect dose or may reflect product, and the site does not say which. 3. ## What the price includes The twelve-month prepaid figure is $165 and the ongoing range starts at $205, so a reader paying monthly should plan from the higher number. An introductory first month from $85 is offered and a $120 summer discount is described as automatically applied. On tirzepatide the card reads $265 under the same prepaid footnote, and because the FAQ's range names no injection figure for it, no tirzepatide rate is published here. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The prepaid footnote is present - Strength: An ongoing range is published at all - Strength: Free shipping and an intro month stated - Limitation: The card figure needs twelve months upfront - Limitation: The ongoing rate starts $40 higher - Limitation: No tirzepatide monthly figure is published - Limitation: The range's driver is not explained ## What the evidence says about this kind of treatment The assessment above is about Rejuve Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will prepay a year and has read the footnote under the label. Wrong for A reader planning to pay month to month from the card figure. ## The evidence behind what Rejuve Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rejuve Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Regenics | Readers who will add the membership to the medication before comparing anything | | | Remote Pharmacy | Readers prepared to get the billing term confirmed in writing before paying anything | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Fitish](https://thisglp.com/reviews/fitish) [Fitness RX](https://thisglp.com/reviews/fitness-rx) [FitRx](https://thisglp.com/reviews/fitrx) [Fitstry](https://thisglp.com/reviews/fitstry) [FMmeds](https://thisglp.com/reviews/fmmeds) [FORM](https://thisglp.com/reviews/form) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $165 a monthly rate? It is tied to a twelve-month plan paid upfront by the site's own footnote. The FAQ's ongoing range starts at $205. What does tirzepatide cost monthly? Not established. The card shows $265 under the same prepaid footnote, and the FAQ's ongoing range names no figure for the tirzepatide injection. What is the ongoing range? $205 to $399, without the site stating whether the spread reflects dose, product or plan. Is Rejuve Meds expensive compared with other GLP-1 telehealth sellers? Rejuve Meds publishes a starting figure of $205/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rejuve Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Remedy Meds reviews (2026): GLP-1 telehealth sellers | This GLP A four-week fill billed monthly, and no figure a reader can see before the quiz. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/remedy-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week fill, price behind a quiz # Remedy Meds review A four-week fill billed monthly, and no figure a reader can see before the quiz. ## The verdict Remedy Meds sells compounded semaglutide and tirzepatide, but its public pages print no price for either. Every start button leads to a quiz that asks for height and weight first. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Remedy Meds sells both molecules by injection, plus a microdose line and a name-brand option. The homepage lists prepaid plans alongside month-to-month billing. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe plans and tiers. The clinician is not described anywhere a reader can reach. The homepage reads "Month-to-month · Cancel anytime · HSA/FSA accepted" and "No Memberships or Hidden Fees". Each fill is a four-week supply, so a year holds thirteen fills rather than twelve. 2. ## What happens when the dose goes up? The quiz's second screen reads "Your dose depends on your body." Nothing public states what the charge does at a higher dose. The microdose line is a separate product, not a lower rung. 3. ## What the price includes No figure appears on the homepage, even with every FAQ opened. The start buttons for semaglutide, tirzepatide, microdose and name brand all open the same quiz. A monthly charge, whenever it is shown, buys four weeks, not a calendar month. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Month-to-month billing is stated - Strength: No membership fee is claimed - Strength: Pays from HSA or FSA funds - Limitation: No price before the quiz - Limitation: The quiz asks for body measurements first - Limitation: Thirteen fills a year, not twelve - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Remedy Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to finish the quiz who will count thirteen fills a year. Wrong for A reader who wants a published price before giving out health details. ## The evidence behind what Remedy Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Remedy Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Prime Health | Readers who count charges rather than months | | | RestorLife Med | Readers who want monitoring included rather than billed separately | | | Revive Meds | Readers who want to buy one order at a time and will get the price in writing | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [FormBlends](https://thisglp.com/reviews/formblends) [FormidableMD](https://thisglp.com/reviews/formidablemd) [Framework](https://thisglp.com/reviews/framework) [Fresh Day Meds](https://thisglp.com/reviews/fresh-day) [Freya Meds](https://thisglp.com/reviews/freya-meds) [Fridays](https://thisglp.com/reviews/fridays) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is a price shown before the quiz? No. The public pages print none, and any figure appears only inside the quiz. Is a monthly charge a calendar month? No. Each fill is a four-week supply, so a year of monthly billing is thirteen fills. What is the microdose line? A separate lower-dose product with its own start button, not a lower rung of the standard plan. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # REMEVi reviews (2026): GLP-1 telehealth sellers | This GLP The advertised rates belong to a fifty-two week plan, and the site promises no titration hikes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/remevi Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Fifty-two weeks, not twelve months # REMEVi review The advertised rates belong to a fifty-two week plan, and the site promises no titration hikes. ## The verdict REMEVi publishes $199 a month for compounded semaglutide and $269 for tirzepatide on a 52-week plan. Month to month is $279 and $339. Coverage is 51 jurisdictions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 51 From From $279/mo Prescription Required Compounded Yes — not FDA-approved Availability 51 jurisdictions REMEVi sells both molecules by injection. Two plan lengths are priced. The site states the price does not rise with titration. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state plans and terms. The clinician is not described. Two commitments are published rather than one, which lets a reader price either path. The claim of no titration hikes is a real promise and it applies to both. 2. ## What happens when the dose goes up? The site states the same price every month with no [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) hikes. That answers the question directly. Nothing describes clinical support at a dose increase. 3. ## What the price includes Six months month to month is $1,674 on semaglutide. The 52-week plan is $199, so a year is $2,388 against $3,348 paid monthly. The saving is $80 a month on semaglutide and $70 on tirzepatide, for a year of commitment. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: No titration hikes, stated plainly - Strength: Both plan lengths published - Strength: Coverage in 51 jurisdictions - Limitation: The headline needs 52 weeks - Limitation: Month to month costs $80 more - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about REMEVi. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader committing a year who wants the rate fixed through titration. Wrong for A reader paying month to month from the advertised figure. ## The evidence behind what REMEVi prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How REMEVi compares | Seller | Who it suits | Go | | --- | --- | --- | | Rejuve Meds | Readers who will prepay a year and have read the footnote under the label | | | Renlo Health | Readers who want the flat claim shown at each tier rather than asserted once | | | Rewinding RX | Readers who want a fixed figure and the doses it covers listed | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) [Gaya Wellness](https://thisglp.com/reviews/gaya-wellness) [Genesis Health](https://thisglp.com/reviews/genesis) [Get Thin MD](https://thisglp.com/reviews/get-thin-md) [GetRelief Rx](https://thisglp.com/reviews/getrelief-rx) [Gimme Care](https://thisglp.com/reviews/gimme-care) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 a monthly rate? It belongs to the 52-week plan. Month to month is $279. Does the price rise as my dose goes up? No. The site states the same price every month with no titration hikes. Where does REMEVi ship? Fifty-one jurisdictions are recorded. Is REMEVi legit? REMEVi is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is REMEVi expensive compared with other GLP-1 telehealth sellers? REMEVi publishes a starting figure of $279/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts REMEVi above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Remi Meds reviews (2026): GLP-1 telehealth sellers | This GLP Two dose selectors, five priced steps on each, and every step up costs more. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/remi-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Five dose steps, five prices # Remi Meds review Two dose selectors, five priced steps on each, and every step up costs more. ## The verdict Remi Meds prices each dose separately. The GLP-1 line starts at $249 a month at 0.25 mg. The GLP-1/GIP + B12 line starts at $349 at 2.25 mg. Both are starting doses. Every later step costs more. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $249/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Remi Meds sells two compounded weight-loss injections, billed monthly. The pages call them Personalized GLP-1 and Personalized GLP-1/GIP + B12. Neither page names the molecule. The first line's weekly doses run 0.25 mg to 2.4 mg. Those are the semaglutide label's steps. The second line adds B vitamins to a GLP-1/GIP base. 1. ## Who writes the prescription, and what do they see? Remi Meds states that it is a patient management platform. Medical care comes from independent physician networks. Beluga Health is named as one of them. The licensed provider sets the dose on medical judgment. The intake is a questionnaire, then a consultation. Whether the consultation is live or written is not stated. The sequence has four steps. A questionnaire comes first, then a consultation. A prescription follows on eligibility. Check-ins continue after that. Medication ships from partner pharmacies. The first visit is described as free. The header's contact panel lists a Florida address and an email at another brand's domain. The footer lists Remi Meds' own email and phone. 2. ## What happens when the dose goes up? Here the price follows the dose. Each line has five steps. Each step up costs more than the one before. On both lines, the starting dose costs least. A patient on a standard escalation pays more at each increase. The step prices sit in each page's dose selector, not in a table. 3. ## What the price includes The listed figure is the starting-dose step. It is $249 for the GLP-1 line and $349 for the GLP-1/GIP + B12 line. The $100 gap applies at the first step. Higher steps appear only as selector options. No term discount is published. Billing is monthly. 4. ## What it claims, and what it cites Both lines are compounded by partner pharmacies. The GLP-1/GIP page cites Section 503A and states the blend is not affiliated with Eli Lilly. It also states the blend is not a substitute for FDA-approved products. Compounded drugs are not FDA-approved. The pharmacies are described as state-approved. None is named. ## Where it holds up, and where it does not - Strength: Every dose step is priced before intake - Strength: Milligram strengths are printed - Strength: A physician network partner is named - Strength: Monthly billing with no term - Limitation: The price rises at each dose step - Limitation: Neither page names the molecule - Limitation: No compounding pharmacy is named - Limitation: The contact panel carries another brand's email ## What the evidence says about this kind of treatment The assessment above is about Remi Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants each dose step priced before the first visit. Wrong for A buyer expecting one flat monthly rate through titration. ## The evidence behind what Remi Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Remi Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Go Vida Plena](https://thisglp.com/reviews/go-vida-plena) [GobyMeds](https://thisglp.com/reviews/gobymeds) [Goldspan Health](https://thisglp.com/reviews/goldspan-health) [Good Girl Rx](https://thisglp.com/reviews/good-girl-rx) [Good Life Meds](https://thisglp.com/reviews/good-life-meds) [GoodRx](https://thisglp.com/reviews/goodrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $249 the monthly price for the whole course? No. It is the 0.25 mg starting dose. Each of the four higher doses costs more. Which drug is the GLP-1 line? The page does not name it. Its five doses match the semaglutide label's weekly steps. Who prescribes? Independent physicians. Remi Meds names Beluga Health as one of its physician networks. Is Remi Meds expensive compared with other GLP-1 telehealth sellers? Remi Meds publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Remi Meds above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Remote Pharmacy reviews (2026): GLP-1 telehealth sellers | This GLP The same number appears on two of this seller's pages meaning two different things, so no rate can be established at all. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/remote-pharmacy Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same figure, two meanings # Remote Pharmacy review The same number appears on two of this seller's pages meaning two different things, so no rate can be established at all. ## The verdict Remote Pharmacy publishes no figure this desk can rank. Its injection page shows $167 with no term attached, while the identical $167 on its tablet page is a six-month prepay rung against a stated $296 a month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose Prescription Required Compounded Yes — not FDA-approved Remote Pharmacy sells both molecules as injections and as sublingual or tablet forms, on a cash-pay basis, with figures that do not resolve into rates. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the clinician is not described. The more immediate problem is upstream of care: a reader cannot establish what anything costs from the published pages. One number doing two jobs on one site is the whole finding. On the tablet page $167 is what six months of prepayment works out to, against $296 charged monthly. On the injection page the same $167 carries no term at all, so a reader has no way to know which of those two things it is. 2. ## What happens when the dose goes up? Nothing is published about dose on either line. With the billing term also unestablished, both of the variables that decide a year's cost are missing rather than merely unfavorable. 3. ## What the price includes There is nothing to rank. The tirzepatide line repeats the pattern: the injection page reads starts at $229.99 a month, and the same figure on the tablet page is stated as a first month followed by $349.99 a month thereafter. Treat every figure here as a quote to be confirmed rather than a price, and get the term in writing before paying. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Both molecules offered in two formats - Strength: Cash-pay terms stated plainly - Strength: A tablet page does publish its terms - Limitation: The injection figures carry no term - Limitation: The same number means two things - Limitation: No rate can be established at all - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Remote Pharmacy. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader prepared to get the billing term confirmed in writing before paying anything. Wrong for A reader comparing published figures, since neither of these is one. ## The evidence behind what Remote Pharmacy prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Remote Pharmacy compares | Seller | Who it suits | Go | | --- | --- | --- | | Rejuve Meds | Readers who will prepay a year and have read the footnote under the label | | | Rex MD | Readers who want an approved oral product with the clinician's cost stated inside it | | | RENN Health | Readers who will confirm which figure applies before paying | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [GoodRx](https://thisglp.com/reviews/goodrx) [Green Cap Health](https://thisglp.com/reviews/green-cap-health) [Harbor](https://thisglp.com/reviews/harbor) [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) [Harper Meds](https://thisglp.com/reviews/harper-meds) [He & She MD](https://thisglp.com/reviews/he-and-she-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost here? It cannot be established. The injection page shows $167 with no term, and the same figure on the tablet page is a six-month prepay rung against $296 a month. Is the tirzepatide figure a monthly rate? The injection page says starts at $229.99 a month. The same number on the tablet page is stated as a first month, with $349.99 a month after it. Why is no price shown for this seller? Because two of its own pages give the same figure different meanings, and publishing either reading as a rate would be this desk choosing one on the seller's behalf. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Renlo Health reviews (2026): GLP-1 telehealth sellers | This GLP Each dose tier is listed with the same price beside it, which is a stronger claim than the word flat. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/renlo-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same figure at every dose # Renlo Health review Each dose tier is listed with the same price beside it, which is a stronger claim than the word flat. ## The verdict Renlo Health publishes $199 a month for compounded semaglutide and $269 for tirzepatide. Each dose tier is listed separately at the same figure. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $199/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Renlo Health sells both molecules by injection across fifty states. Dose tiers are named and priced identically. Struck-through figures appear beside both. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages list doses and prices. The clinician is not described. Listing starting, mid and higher dose with $199 beside each is more convincing than the word flat. A reader can see the claim applied rather than asserted. 2. ## What happens when the dose goes up? This is answered as directly as it can be. The tirzepatide page states the price stays flat with zero increase at every dose. The semaglutide page lists the same figure at three named tiers. 3. ## What the price includes Six months at $199 is $1,194 and tirzepatide at $269 is $1,614. Both totals hold at any dose. Struck-through figures of $299 and $399 appear with no stated basis and should be ignored. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Each dose tier listed at the same price - Strength: Zero increase at every dose, stated - Strength: Coverage across all fifty states - Limitation: Struck-through figures have no basis - Limitation: No milligram thresholds published - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Renlo Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the flat claim shown at each tier rather than asserted once. Wrong for A reader who wants the flat claim tied to a published milligram threshold. ## The evidence behind what Renlo Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Renlo Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Rewinding RX | Readers who want a fixed figure and the doses it covers listed | | | Revel RX | A reader drawn to a low flat rate who also wants the handling described | | | REMEVi | Readers committing a year who want the rate fixed through titration | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Heally](https://thisglp.com/reviews/heally) [HealthHub](https://thisglp.com/reviews/healthhub) [Healthicare](https://thisglp.com/reviews/healthicare) [HealthOn](https://thisglp.com/reviews/healthon) [HealthSource](https://thisglp.com/reviews/healthsource) [HeliMeds](https://thisglp.com/reviews/helimeds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change by dose? No. The tiers are listed individually at $199, and the tirzepatide page states zero increase at every dose. What are the struck-through prices? $299 and $399, with no stated basis. Treat them as anchors. Where does Renlo ship? All fifty states are recorded. Is Renlo Health legit? Renlo Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Renlo Health expensive compared with other GLP-1 telehealth sellers? Renlo Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Renlo Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RENN Health reviews (2026): GLP-1 telehealth sellers | This GLP The homepage and the semaglutide page give different figures for the same product. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/renn-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Homepage and drug page differ # RENN Health review The homepage and the semaglutide page give different figures for the same product. ## The verdict RENN Health publishes semaglutide as low as $149 a month on its homepage and as low as $199 on its semaglutide page. Tirzepatide is $199 and both pages agree on that. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $149/mo Prescription Required Compounded Yes — not FDA-approved RENN Health sells both molecules by injection, with three and six-month bundles offered at stack discounts. Two of its pages disagree on one figure. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state prices and bundles. The clinician is not described. One product with two published prices is a disclosure problem before it is a pricing one. A reader who lands on the homepage plans from $149 and a reader who lands on the drug page plans from $199. 2. ## What happens when the dose goes up? Both figures use as-low-as wording, so each is a floor rather than a rate. Nothing states what raises either, and with two floors in play the range is wider than any single page suggests. 3. ## What the price includes The semaglutide figure fell to $149 on the homepage, while the drug-specific page still reads $199. Tirzepatide is $199 on both. Three and six-month bundles are described as carrying stack discounts without their figures being published. Confirm which semaglutide figure applies before ordering. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Both pages agree on tirzepatide - Strength: Bundles are described as available - Strength: Predictable monthly pricing is claimed - Limitation: Two pages give different semaglutide figures - Limitation: Both use as-low-as wording - Limitation: Bundle discounts are not quantified - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about RENN Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will confirm which figure applies before paying. Wrong for A reader planning from whichever page they happened to open. ## The evidence behind what RENN Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RENN Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Remote Pharmacy | Readers prepared to get the billing term confirmed in writing before paying anything | | | Renlo Health | Readers who want the flat claim shown at each tier rather than asserted once | | | Rejuve Meds | Readers who will prepay a year and have read the footnote under the label | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Hello Alpha](https://thisglp.com/reviews/hello-alpha) [HelloWellness](https://thisglp.com/reviews/hellowellness) [Henry Meds](https://thisglp.com/reviews/henry-meds) [Heros Health](https://thisglp.com/reviews/heros-health) [Hers](https://thisglp.com/reviews/hers) [Heva Health](https://thisglp.com/reviews/heva-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is semaglutide $149 or $199? The homepage says as low as $149 and the semaglutide page says as low as $199. Confirm which applies before ordering. Do the pages agree on anything? Yes. Tirzepatide is $199 on both the homepage and the tirzepatide page. What do the bundles cost? Three and six-month bundles are described as carrying stack discounts, without published figures. Is RENN Health expensive compared with other GLP-1 telehealth sellers? RENN Health publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RENN Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rese Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Rese combines portal support with a three-month medication shipment and no automatic reorder. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rese-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 No automatic billing or reorder # Rese Wellness review Rese combines portal support with a three-month medication shipment and no automatic reorder. ## The verdict Rese’s no-subscription model leaves the next order in the patient’s hands; active clinical monitoring still needs its own plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Rese Wellness offers compounded semaglutide and tirzepatide as three-month programs paid upfront. It says there is no subscription or automatic billing; patients decide whether to order again. 1. ## Who writes the prescription, and what do they see? A licensed provider must approve and prescribe before a medication charge is taken. The company’s founders and support staff are not automatically the clinician responsible for an individual patient. Ask for the treating practice and prescriber details. The program includes messaging through a patient portal and guidance around injection use. A fixed clinical appointment cadence is not established by the three-month purchase. Agree on check-ins and how the provider will handle symptoms between orders. 2. ## What happens when the dose goes up? Rese says the rate does not rise with dose and describes a standard schedule set by the provider. Clarify how that schedule can be slowed or changed, especially because the whole initial program is shipped together. 3. ## What the price includes The homepage publishes a monthly equivalent, but the first program requires three months paid upfront in one shipment. There is no automatic reorder. That removes subscription-renewal risk, but does not establish a refund right for unused medicine if treatment changes. 4. ## What it claims, and what it cites The medicines are compounded and are not FDA-approved. The public program includes the prescribed medication and injection guidance. Confirm which pharmacy fills the prescription, the vial labels and the usable dates for a single multi-month shipment. ## Where it holds up, and where it does not - Strength: No automatic billing or reorder - Strength: Three-month term clearly stated - Strength: Portal messaging is included - Limitation: Three months must be paid upfront - Limitation: Single shipment needs a usable-supply check - Limitation: No universal appointment cadence stated ## What the evidence says about this kind of treatment The assessment above is about Rese Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values deciding when to reorder and can arrange meaningful follow-up during a multi-month shipment. Wrong for Someone seeking a single month of medicine instead of one upfront three-month shipment. ## The evidence behind what Rese Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rese Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Independent Wellness](https://thisglp.com/reviews/independent-wellness) [Injectco](https://thisglp.com/reviews/injectco) [InstaRX](https://thisglp.com/reviews/instarx) [Intimate Rose](https://thisglp.com/reviews/intimate-rose) [Invigor Medical](https://thisglp.com/reviews/invigor-medical) [Invyncible](https://thisglp.com/reviews/invyncible) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The program includes messaging through a patient portal and guidance around injection use. A fixed clinical appointment cadence is not established by the three-month purchase. Agree on check-ins and how the provider will handle symptoms between orders. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Treatment and three-month purchase model](https://resewellness.com/) - [Clinical and service FAQ](https://resewellness.com/faq/) - [Care team background](https://resewellness.com/about/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Reset Solutions reviews (2026): GLP-1 telehealth sellers | This GLP A program fee and a separate medication bill, with an in-person start near The Woodlands. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/reset-solutions Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Local clinic, two bills # Reset Solutions review A program fee and a separate medication bill, with an in-person start near The Woodlands. ## The verdict Reset Solutions charges $99 a month for its program and prices medication on top, with compounded semaglutide starting at about $70, so the working figure for a new patient is $169 a month. What that buys is closer to a clinic than a mail-order service: a doctor's telehealth consultation, then an in-person kickoff near The Woodlands in Texas, and a local team that adjusts the dose from there. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 1 From From $169/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Reset Solutions is a medical weight-loss clinic in Shenandoah, Texas, near The Woodlands, running a GLP-1 program that pairs prescriptions with coaching, body-composition scans and metabolic testing. Its medication tab covers compounded semaglutide and compounded tirzepatide, and the clinic also helps patients order brand Wegovy and Zepbound through the manufacturers' own pharmacies. A separate page describes help for patients who qualify for the Medicare GLP-1 Bridge program. 1. ## Who writes the prescription, and what do they see? A patient begins with a telehealth consultation with the clinic's doctor, who decides whether GLP-1 treatment is appropriate and, if it is, writes the prescription. The home page refers to the clinic's physicians in the plural, but no physician is named on the pages a buyer sees before signing up. What the clinic does state clearly is the fallback, since a patient found not to be a medical candidate is fully refunded. The second step is what separates this from a shipped-box service, because the kickoff happens in person, where the team measures starting body composition, shows the patient how to use the medication, and sets goals for the months ahead. From then on, the monthly program fee covers all medical visits, coaching, check-ins, the 3D body-composition scans, program content and a progress-tracking app. There is no long-term contract. Once a patient is well established, a cheaper maintenance tier moves the check-ins and scans to a quarterly schedule and keeps the same care team. 2. ## What happens when the dose goes up? The clinic treats dose changes as its own job, saying its local team finds the right GLP-1 dose and adjusts it over time to balance results against [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The program fee does not change with the dose. Whether the medication price moves as the dose climbs is not spelled out. The page gives a starting figure for each compounded drug and says semaglutide is ordered about two months at a time, so the first medication bill is larger than the monthly figure suggests. 3. ## What the price includes Two charges make up the month. The program is $99, and compounded semaglutide is listed as starting at about $70, which puts a new semaglutide patient at $169 before any dose change. Compounded tirzepatide carries a higher starting figure on the same medication tab, and brand Wegovy and Zepbound are priced at the manufacturers' own cash rates through their direct pharmacies. 4. ## What it claims, and what it cites Both compounded lines are offered for eligible patients when commercially available medication is not the best fit or is not available, and each carries the statement that compounded medications are not FDA-approved. The pharmacy that prepares them is not named. The brand products are the manufacturers' own, filled through NovoCare Pharmacy and LillyDirect. ## Where it holds up, and where it does not - Strength: A doctor's consultation and an in-person kickoff - Strength: Program and medication are priced separately and plainly - Strength: A full refund for a patient who is not a medical candidate - Strength: A cheaper maintenance tier once a patient is established - Limitation: Medication is billed on top of the program fee - Limitation: The kickoff visit is in person, near The Woodlands - Limitation: Semaglutide is ordered about two months at a time - Limitation: No physician or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Reset Solutions. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient near The Woodlands who wants a local team and an in-person start. Wrong for A buyer far from the clinic, or one looking for a single all-in monthly figure. ## The evidence behind what Reset Solutions prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Reset Solutions compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | Rivas Medical Weight Loss | Buyers within reach of a clinic who want a clinician present every week | | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Invyncible](https://thisglp.com/reviews/invyncible) [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) [iThriveMD](https://thisglp.com/reviews/ithrivemd) [Ivim Health](https://thisglp.com/reviews/ivim-health) [Ivologist](https://thisglp.com/reviews/ivologist) [Ivy Rx](https://thisglp.com/reviews/ivy-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost with semaglutide? $169 at the start: the $99 program fee plus compounded semaglutide from about $70 a month. The medication is ordered about two months at a time. Do I have to visit the clinic? The first consultation is by telehealth, and the kickoff appointment that follows is in person at the clinic. What if I am not a candidate? The clinic states that a patient who is not a medical candidate is fully refunded. Is Reset Solutions expensive compared with other GLP-1 telehealth sellers? Reset Solutions publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Reset Solutions below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RestorLife Med reviews (2026): GLP-1 telehealth sellers | This GLP The figures are high and they include a quarterly blood test, which almost nothing else here does. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/restorlife-med Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A blood test each quarter # RestorLife Med review The figures are high and they include a quarterly blood test, which almost nothing else here does. ## The verdict RestorLife Med publishes $299 a month for compounded semaglutide and $399 for tirzepatide, each including B12 and one free blood test per quarter. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $299/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states RestorLife Med sells both molecules by injection with B12, across regular, six-month and microdose tiers, with lab work included in the figure. 1. ## Who writes the prescription, and what do they see? A quarterly blood test is included, which implies monitoring rather than only dispensing. Who reviews the result is not described, and that is the question the inclusion raises. Including labs is the substantive difference here. Most sellers in this category bill lab work separately or never mention it, so a quarterly test inside the price is worth something specific rather than being a marketing line. 2. ## What happens when the dose goes up? Nothing states what either figure does at a higher dose. A microdose entry tier is offered at $219 and $299, which is a separate product rather than a lower rung. 3. ## What the price includes Six months at $299 is $1,794 at the regular rate, or $1,194 on the six-month plan at $199. Tirzepatide is $2,394 regular and $1,590 at $265 on six months. A first month runs at half price, $149 and $199. The included quarterly blood test is worth counting against the higher figures. 4. ## What it claims, and what it cites Both lines are compounded with B12. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: One free blood test each quarter - Strength: B12 included in both formulations - Strength: Coverage across all fifty states - Strength: A half-price first month is published - Limitation: The regular rates sit high - Limitation: The lowest rates need six months - Limitation: The microdose tier is a different product - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about RestorLife Med. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants monitoring included rather than billed separately. Wrong for A reader shopping on headline price alone. ## The evidence behind what RestorLife Med prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RestorLife Med compares | Seller | Who it suits | Go | | --- | --- | --- | | Revive Meds | Readers who want to buy one order at a time and will get the price in writing | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | | Rehydra+ Wellness | Readers who want to price a full escalation before committing to a first dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ivologist](https://thisglp.com/reviews/ivologist) [Ivy Rx](https://thisglp.com/reviews/ivy-rx) [Jently](https://thisglp.com/reviews/jently) [Joey Med](https://thisglp.com/reviews/joey-med) [Joi + Blokes](https://thisglp.com/reviews/joi-and-blokes) [JRNYS](https://thisglp.com/reviews/jrnys) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is included in the price? B12 in the formulation and one free blood test per quarter, alongside the medication. What does the six-month plan cost? $199 a month for semaglutide and $265 for tirzepatide, against regular rates of $299 and $399. Is the first month cheaper? Yes, at half price: $149 for semaglutide and $199 for tirzepatide. Is RestorLife Med legit? RestorLife Med is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is RestorLife Med expensive compared with other GLP-1 telehealth sellers? RestorLife Med publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RestorLife Med above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Revel Health reviews (2026): GLP-1 telehealth sellers | This GLP The tablet undercuts the injection on both molecules, which is the reverse of the usual order. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/revel-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Oral is the cheaper route # Revel Health review The tablet undercuts the injection on both molecules, which is the reverse of the usual order. ## The verdict Revel Health prices its oral dissolving tablet below its own injection on both molecules: $149 against $199 for semaglutide, $199 against $249 for tirzepatide. Each line also opens with a reduced first month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 45 Injection From $199/mo Oral From $149/mo Prescription Required Compounded Yes — not FDA-approved Revel Health sells compounded semaglutide and compounded tirzepatide in two forms each, through an online service covering forty-five states. Injectable semaglutide is advertised at $199 a month and injectable tirzepatide at $249. The oral dissolving tablets are $149 and $199. Every line carries a lower first month: $99, $149, $99 and $149 respectively. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely and a prescription precedes shipping. Revel states that the rate covers consultation, medication, supplies and shipping. That is a claim about what is bundled, not a description of who conducts the consultation or what it involves. The service runs at a distance and every product is compounded. What distinguishes it is the direction of its own pricing. Most sellers charge a premium for an oral, on the reasoning that a daily tablet is the convenience option. Revel charges less for it, so a reader choosing the tablet here is not paying for the preference. 2. ## What happens when the dose goes up? The rates are stated as flat across doses. Escalation over the first sixteen weeks is the normal path, so a flat rate holds the monthly figure through the part that usually moves it. The seller does not describe what clinical support accompanies a step. 3. ## What the price includes The first-month figures are the part to read carefully. A reader comparing $99 against a competitor's standing rate is comparing one month against twelve. On the injection the difference is $100 in month one and nothing thereafter, so the annual figure is $2,388 for semaglutide rather than the $1,188 a $99 rate would imply. The all-in claim covers consultation, medication, supplies and shipping, which is a wider bundle than most sellers state. 4. ## What it claims, and what it cites Every product is compounded, prepared by a pharmacy rather than manufactured and reviewed as a finished product. A compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not FDA-approved and is not assessed for safety, efficacy or quality before dispensing. The published trial evidence for these molecules was generated with the approved products at labeled doses. ## Where it holds up, and where it does not - Strength: Oral priced below the injection on both molecules - Strength: Rate stated to include consultation and shipping - Strength: All four combinations carry a published figure - Limitation: Headline first-month rates apply once - Limitation: Five states are not served - Limitation: Support at a dose step is not described ## What the evidence says about this kind of treatment The assessment above is about Revel Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants an oral and expects to pay less for it, which on this seller is what happens. Wrong for A reader comparing on a first-month figure, which is not what the following eleven months cost. ## The evidence behind what Revel Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Revel Health compares | Seller | Who it suits | Go | | --- | --- | --- | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Alan Meds | A reader ready to prepay six months who wants the full-dose price in view before the intake. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) [Jyra Health](https://thisglp.com/reviews/jyra-health) [KERNX Health](https://thisglp.com/reviews/kernx-health) [Kin Meds](https://thisglp.com/reviews/kin-meds) [Kina](https://thisglp.com/reviews/kina) [Knownwell](https://thisglp.com/reviews/knownwell) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is the tablet cheaper than the injection here? That is how Revel prices it. The oral dissolving tablet is $149 against $199 for injectable semaglutide, and $199 against $249 on tirzepatide. What does the first-month price mean? It applies to the first month only. Injectable semaglutide opens at $99 and then runs at $199, so a twelve-month course is $2,288 rather than twelve times either figure. What is included in the rate? Revel states that consultation, medication, supplies and shipping are covered. That is a broader bundle than most sellers describe, and it is the seller's own claim. Is Revel Health expensive compared with other GLP-1 telehealth sellers? Revel Health publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Revel Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Revel RX reviews (2026): GLP-1 telehealth sellers | This GLP Two of the lowest flat figures published, with consultation and overnight cold shipping inside them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/revel-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Low, flat, cold-shipped # Revel RX review Two of the lowest flat figures published, with consultation and overnight cold shipping inside them. ## The verdict Revel RX publishes a flat $89 a month for compounded semaglutide and $155 for tirzepatide, at every dose tier. Consultation, medication and overnight cold shipping are included. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $89/mo Prescription Required Compounded Yes — not FDA-approved Revel RX sells both molecules by injection at one figure per molecule. Three things are named as included. Both rates are flat at every dose. 1. ## Who writes the prescription, and what do they see? A consultation is named as included in the figure. No clinician is described. The intake is not documented. Naming overnight cold shipping is unusual and specific. Compounded semaglutide needs cold handling, and most sellers do not say how theirs travels. 2. ## What happens when the dose goes up? Both figures are flat at every dose tier, which answers the question directly. Nothing describes clinical support at a step. 3. ## What the price includes Six months at $89 is $534 and tirzepatide at $155 is $930. Both totals hold at any dose. The three inclusions mean nothing obvious sits outside them. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Flat at every dose tier, both molecules - Strength: Overnight cold shipping named - Strength: Consultation inside the figure - Limitation: No milligram dose published - Limitation: No state coverage list is recorded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Revel RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a low flat rate with cold shipping stated. Wrong for A reader who needs a dose behind a figure. ## The evidence behind what Revel RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Revel RX compares | Seller | Who it suits | Go | | --- | --- | --- | | Rewinding RX | Readers who want a fixed figure and the doses it covers listed | | | Renlo Health | Readers who want the flat claim shown at each tier rather than asserted once | | | ReflexMD | Buyers who want the compounded rate on the homepage rather than after an intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Kina](https://thisglp.com/reviews/kina) [Knownwell](https://thisglp.com/reviews/knownwell) [Kongo](https://thisglp.com/reviews/kongo) [LaSara Medical Group](https://thisglp.com/reviews/lasara) [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) [Layla](https://thisglp.com/reviews/layla) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change with the dose? No. Both figures are flat at every dose tier. What is included? Consultation, medication and overnight cold shipping. Why does cold shipping matter? Compounded semaglutide needs cold handling, and most sellers do not state how theirs travels. Is Revel RX expensive compared with other GLP-1 telehealth sellers? Revel RX publishes a starting figure of $89/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Revel RX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Revive Longevity reviews (2026): GLP-1 telehealth sellers | This GLP Revive offers a tirzepatide program and separate wellness membership tiers. The named product is billed every four weeks, not every calendar month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/revive-longevity Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Four-week product, wider memberships # Does Revive Longevity sell a GLP-1? Revive offers a tirzepatide program and separate wellness membership tiers. The named product is billed every four weeks, not every calendar month. ## The verdict The product page provides a clearer treatment pathway than the wider optimization menu. Keep that specific GLP-1 program separate from general memberships, and ask what follow-up the chosen product includes before relying on platform-wide access claims. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved Revive Longevity offers weight, hormone and wellness telehealth. The reviewed tirzepatide product page describes clinical assessment and pharmacy fulfillment alongside ongoing support. 1. ## Who writes the prescription, and what do they see? An independent licensed provider reviews the patient’s information before prescribing. The site’s general physician-guided language should not replace confirmation of the assigned practice and clinician. The product page says the card is authorized at checkout and charged after clinical approval. The wider membership tiers include differing services, so confirm whether any of those tiers is required for the specific medication program. 2. ## What happens when the dose goes up? The tirzepatide page describes provider support and a flat plan charge, but does not establish a universal appointment interval. Ask how response is reviewed before renewal and whether a dose change affects supply quantity. 3. ## What the price includes The tirzepatide offer states every four weeks. Separate Foundation, Core and Private memberships also use four-week periods, but their product allowances do not automatically identify the same GLP-1 package. 4. ## What it claims, and what it cites The product page discusses compounded tirzepatide and contrasts it with FDA-approved branded trial products. Compounded drugs are not FDA-approved, and branded study results do not verify the outcomes of this particular service. ## Where it holds up, and where it does not - Strength: Conditional payment timing explained - Strength: Specific product interval stated - Limitation: Follow-up interval needs confirmation - Limitation: Program and membership scopes differ ## What the evidence says about this kind of treatment The assessment above is about Revive Longevity. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a specific GLP-1 program who can separate it from optional broader wellness services. Wrong for Someone who assumes a four-week charge creates only twelve payments in a full year. ## The evidence behind what Revive Longevity prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Revive Longevity compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lemonaid Health](https://thisglp.com/reviews/lemonaid-health) [LevelsRx](https://thisglp.com/reviews/levelsrx) [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) [Levers Health](https://thisglp.com/reviews/levers-health) [Liberty](https://thisglp.com/reviews/liberty) [LifeMD](https://thisglp.com/reviews/lifemd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the Foundation membership the tirzepatide program? The reviewed pages present them separately. Confirm which products and clinical services are included rather than treating the names as interchangeable. When is the initial payment captured? The tirzepatide page says authorization occurs at checkout and the charge follows provider approval. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://revivelongevity.com/) - [Official program and terms](https://revivelongevity.com/pricing/) - [Official program and terms](https://revivelongevity.com/how-it-works/) - [Official program and terms](https://revivelongevity.com/product/tirzepatide/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Revive Meds reviews (2026): GLP-1 telehealth sellers | This GLP No subscription and no membership fee, and no price a reader can see before handing over an email. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/revive-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 No subscription, no posted price # Revive Meds review No subscription and no membership fee, and no price a reader can see before handing over an email. ## The verdict Revive Meds sells compounded semaglutide and tirzepatide with no subscription, but its product cards print no price. The intake asks for a name and email on its first screen. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Revive Meds sells both molecules by injection alongside peptides and hormone support. Medication, vials and injection supplies are stated as included, and delivery is to the door. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state terms and inclusions. The clinician is not described. The site reads "No monthly subscriptions, no sign-up fees, no commitments. Pay only for what you order." A reader buys one order at a time, which several sellers here do not allow. 2. ## What happens when the dose goes up? No figure is shown for any dose. Whether the charge holds as the dose rises cannot be checked from the public pages. 3. ## What the price includes Each product card reads only "Start Weight Loss", with no figure beside it. The FAQ carries no price either. The first intake screen asks for first name, last name and email before anything else. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: No subscription required - Strength: No membership or sign-up fee stated - Strength: Supplies stated as included - Limitation: No price on any product card - Limitation: The intake asks for contact details first - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Revive Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to buy one order at a time and will ask for the price in writing. Wrong for A reader who needs a published price to compare before giving an email address. ## The evidence behind what Revive Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Revive Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | RestorLife Med | Readers who want monitoring included rather than billed separately | | | Prime Health | Readers who count charges rather than months | | | Remedy Meds | Readers willing to finish the quiz who count the fills rather than the months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Levers Health](https://thisglp.com/reviews/levers-health) [Liberty](https://thisglp.com/reviews/liberty) [LifeMD](https://thisglp.com/reviews/lifemd) [LifeRx.md](https://thisglp.com/reviews/liferx) [LifespanningRx](https://thisglp.com/reviews/lifespanningrx) [LillyDirect Foundayo](https://thisglp.com/reviews/lillydirect-foundayo) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Revive Meds cost? The product cards print no price. The intake asks for a name and email before showing anything further. Do I have to subscribe? No. The site states there are no monthly subscriptions, sign-up fees or commitments. Is a membership fee added? The site says there are no membership fees. The medication price itself is not published. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rewinding RX reviews (2026): GLP-1 telehealth sellers | This GLP A fixed figure at any dose, four strengths listed, and no membership. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rewinding-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Fixed price, any dose # Rewinding RX review A fixed figure at any dose, four strengths listed, and no membership. ## The verdict Rewinding RX publishes $139 a month for compounded semaglutide and $189 for tirzepatide. Both are fixed at any dose, with no hidden fees or memberships. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $139/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Rewinding RX sells both molecules by injection. Doses of 0.25, 1.5, 2 and 2.5 mg are listed, or a custom dose. Cancellation is stated as available anytime. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. A custom dose option implies a clinical decision. The clinician is not described. Three terms are stated together: fixed price, cancel anytime, no memberships. Each is checkable and each removes a common surprise. 2. ## What happens when the dose goes up? Four strengths are listed at one figure and a custom dose is offered. That answers the price question across the published range and leaves the custom case open. 3. ## What the price includes Six months at $139 is $834 and tirzepatide at $189 is $1,134. Both totals hold at any listed dose. Nothing is described as sitting outside either figure. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Fixed price at any listed dose - Strength: Four strengths published - Strength: No memberships or hidden fees - Strength: Coverage across all fifty states - Limitation: A custom dose is not priced - Limitation: No compounding pharmacy is named - Limitation: No first-month figure published ## What the evidence says about this kind of treatment The assessment above is about Rewinding RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a fixed figure and the doses it covers listed. Wrong for A reader needing a custom dose priced in advance. ## The evidence behind what Rewinding RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rewinding RX compares | Seller | Who it suits | Go | | --- | --- | --- | | Revel RX | A reader drawn to a low flat rate who also wants the handling described | | | Renlo Health | Readers who want the flat claim shown at each tier rather than asserted once | | | REMEVi | Readers committing a year who want the rate fixed through titration | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Liv Body](https://thisglp.com/reviews/liv-body) [LIV by WellNow](https://thisglp.com/reviews/liv-by-wellnow) [Livea](https://thisglp.com/reviews/livea) [50 Stars Health](https://thisglp.com/reviews/livv) [Longevixx](https://thisglp.com/reviews/longevixx) [Loop Health](https://thisglp.com/reviews/loop-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which doses does $139 cover? 0.25, 1.5, 2 and 2.5 mg are listed. A custom dose is offered without a published figure. Is there a membership? No. The site states no hidden fees or memberships, and cancellation at any time. What does tirzepatide cost? $189 a month on the same fixed-price terms. Is Rewinding RX legit? Rewinding RX is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Rewinding RX expensive compared with other GLP-1 telehealth sellers? Rewinding RX publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rewinding RX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rex MD reviews (2026): GLP-1 telehealth sellers | This GLP The tablet is an approved brand product with a published figure. The injection is too, and its price belongs to someone else. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rex-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand pill, priced; pen, not # Rex MD review The tablet is an approved brand product with a published figure. The injection is too, and its price belongs to someone else. ## The verdict Rex MD publishes $349 a month for the FDA-approved Wegovy pill including provider care, across four strengths. Its injectable is the brand Wegovy pen, for which it publishes no price and routes the buyer to a third party. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection · Oral Dose pricing Flat across doses States 50 From From $349/mo Prescription Required Compounded No Availability All 50 states Rex MD sells the approved oral semaglutide product with provider care bundled into one figure, alongside an injectable line it does not price itself. 1. ## Who writes the prescription, and what do they see? Provider care is named as inside the $349, which is a clearer statement of what the clinical relationship costs than most sellers make. What it covers in practice is not itemized. Two things separate this from most of the market. The product is approved rather than compounded, so the usual caution about an unreviewed preparation does not apply. And the seller declines to price its own injectable, sending a reader to the manufacturer's channel for a figure it does not control. 2. ## What happens when the dose goes up? The pill is priced across 1.5, 4, 9 and 25 mg at one figure, which answers the dose question directly for that line. The pen has no published figure at any dose here, so the question does not arise until a reader is on someone else's site. 3. ## What the price includes $349 a month is $2,094 over six months, with provider care inside it. The $499 a reader will meet for the pen is NovoCare's cash-pay rate rather than a Rex MD price, so it should not be attributed to this seller. A Zepbound vial product appears in the navigation with no published price at all. 4. ## What it claims, and what it cites The [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) pill and the Wegovy pen are FDA-approved brand products. Nothing here is compounded, which removes a category of risk and replaces it with a higher price. ## Where it holds up, and where it does not - Strength: An FDA-approved product, not compounded - Strength: One figure covers four strengths - Strength: Provider care named as included - Strength: Coverage across fifty states - Limitation: No price published for the injectable - Limitation: The $499 belongs to a third party - Limitation: A Zepbound product carries no figure - Limitation: The pill costs more than compounded lines ## What the evidence says about this kind of treatment The assessment above is about Rex MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants an approved oral product with the clinician's cost stated inside it. Wrong for A reader comparing against compounded prices, which describe a different product. ## The evidence behind what Rex MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Rex MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Remote Pharmacy | Readers prepared to get the billing term confirmed in writing before paying anything | | | Rejuve Meds | Readers who will prepay a year and have read the footnote under the label | | | Renlo Health | Readers who want the flat claim shown at each tier rather than asserted once | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LovelyMeds](https://thisglp.com/reviews/lovelymeds) [Luci](https://thisglp.com/reviews/luci) [Luma Health Co](https://thisglp.com/reviews/luma-health) [Luma Meds](https://thisglp.com/reviews/luma-meds) [Lumen Meds](https://thisglp.com/reviews/lumen-meds) [LumiMeds](https://thisglp.com/reviews/lumimeds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Rex MD charge for the injection? Nothing is published. It routes the buyer to NovoCare's own $499 cash-pay rate, which is a third party's charge rather than a Rex MD price. Is the pill compounded? No. It is the FDA-approved Wegovy pill, priced at $349 a month across 1.5, 4, 9 and 25 mg with provider care included. Why is it dearer than compounded sellers? Because it is a different product. An approved medicine carries trial evidence and a reviewed manufacturing chain that a compounded vial does not. Is Rex MD legit? Rex MD is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Rex MD expensive compared with other GLP-1 telehealth sellers? Rex MD publishes a starting figure of $349/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rex MD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rila reviews (2026): GLP-1 telehealth sellers | This GLP Rila names its medical group and pharmacy partners and describes check-ins during the first month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rila Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Medical group and pharmacies identified # Rila review Rila names its medical group and pharmacy partners and describes check-ins during the first month. ## The verdict Rila provides more specific first-month expectations and names its medical and pharmacy partners; clarify how that relationship continues after the first refill. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Rila offers online weight-management care with compounded GLP-1 injections and dissolving tablets. Its public timeline describes evaluation, treatment delivery and provider check-ins during the first month. 1. ## Who writes the prescription, and what do they see? The FAQ identifies Dr. TelX as an independent medical group. Providers licensed where care is offered make eligibility and prescribing decisions. Treatment is not guaranteed solely by completing the assessment. Rila’s first-month timeline places provider check-ins in weeks three and four, with support between refills. Ask whether those are scheduled clinical contacts and how monitoring changes once the initial plan is established. 2. ## What happens when the dose goes up? The timeline describes provider-directed adjustments as the patient responds. Confirm the formulation, milligram dose and reassessment process before comparing a tablet plan with an injection plan. 3. ## What the price includes Homepage starting equivalents require a six-month commitment. The terms say subscriptions renew until canceled and direct patients to a separate refund policy. A headline commitment price does not establish the upfront total or a refund for an already prepared shipment. 4. ## What it claims, and what it cites The site names [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and identifies EPIQ Scripts, Foothills Professional Pharmacy and Emerald Pharmacy as partners. The actual prescription can use a particular pharmacy from that network. Compounded preparations are not FDA-approved. ## Where it holds up, and where it does not - Strength: Medical group and pharmacies identified - Strength: Early check-in timeline described - Strength: Injection and oral categories are distinguished - Limitation: Headline figures require six months - Limitation: Continuing appointment cadence needs confirming - Limitation: Separate refund policy determines existing-order rights ## What the evidence says about this kind of treatment The assessment above is about Rila. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants an identified clinical network and a described early follow-up path before starting compounded treatment. Wrong for Someone who wants the lowest advertised equivalent without a six-month commitment. ## The evidence behind what Rila prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rila compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lyfe Rx](https://thisglp.com/reviews/lyfe-rx) [MadeMed](https://thisglp.com/reviews/mademed) [MANÜ Telehealth](https://thisglp.com/reviews/manu-telehealth) [Marek Health](https://thisglp.com/reviews/marek-health) [Maves](https://thisglp.com/reviews/maves) [Maximus](https://thisglp.com/reviews/maximus-tribe) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Rila’s first-month timeline places provider check-ins in weeks three and four, with support between refills. Ask whether those are scheduled clinical contacts and how monitoring changes once the initial plan is established. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Programs and first-month care](https://www.joinrila.com/) - [Pharmacy and medical-group FAQ](https://www.joinrila.com/faq) - [Subscription terms](https://www.joinrila.com/terms-of-service) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Risen Labs reviews (2026): regional GLP-1 care | This GLP Risen Labs requires a live video evaluation for compounded semaglutide or tirzepatide and identifies Olympia Pharmacy. The service is limited to New York and Colorado patients. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/risen-labs Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Risen Labs review Risen Labs requires a live video evaluation for compounded semaglutide or tirzepatide and identifies Olympia Pharmacy. The service is limited to New York and Colorado patients. ## The verdict Risen supplies unusually concrete process details: a live clinical encounter, a named pharmacy and a defined service region. Those disclosures help a patient ask specific questions. They do not independently verify a clinician’s license or guarantee treatment quality; the assigned professional and actual prescription still need confirmation. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category regional GLP-1 care Molecule Semaglutide · Tirzepatide Form Injection States 2 Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability New York and Colorado Risen Labs is a platform for medical weight-management assessment, with compounded semaglutide and tirzepatide injections described. The site limits patient access to New York and Colorado despite the company’s Texas name and legal address. 1. ## Who writes the prescription, and what do they see? A licensed provider makes treatment decisions independently of the platform. The service requires a synchronous video consultation and expressly says the intake questionnaire alone cannot produce a prescription. Confirm the clinician’s identity and authority to treat you in the state where the visit occurs. Intake gathers information without requesting payment. A live evaluation follows, with medication offered only when appropriate. The public pages describe the initial process more clearly than the ongoing visit cadence, so ask who manages refill reviews and symptoms after delivery. 2. ## What happens when the dose goes up? Both medicines are described as once-weekly subcutaneous injections. The clinician must determine the appropriate regimen and later adjustments. No public universal escalation or response-time schedule is established; obtain a specific plan for communicating intolerance or an interrupted course. 3. ## What the price includes The refund policy states that the consultation fee is charged after clinical approval and then becomes nonrefundable. Medication payment occurs at pharmacy fulfillment. A complete recurring medication price is not supplied by the weight page, so separate care and prescription charges before proceeding. 4. ## What it claims, and what it cites Olympia Pharmacy is identified as the partner dispensing compounded treatment. The named preparations are not FDA-approved. A pharmacy disclosure is useful for traceability but does not establish that a particular compounded formulation has the same evidence as a branded medicine. ## Where it holds up, and where it does not - Strength: Live video review is explicitly required - Strength: Partner pharmacy is identified - Strength: New York and Colorado eligibility is clear - Limitation: Ongoing follow-up cadence needs clarification - Limitation: Clinical and medication payments are separate - Limitation: Compounded products need formulation-specific questions ## What the evidence says about this kind of treatment The assessment above is about Risen Labs. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A New York or Colorado patient who prefers a stated live-video assessment process and a named dispensing pharmacy. Wrong for Someone outside the listed states or expecting an intake form alone to produce a prescription. ## The evidence behind what Risen Labs prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Risen Labs compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MaxLife](https://thisglp.com/reviews/maxlife) [MDExam](https://thisglp.com/reviews/mdexam) [Measured](https://thisglp.com/reviews/measured) [Medi-Weightloss](https://thisglp.com/reviews/medi-weightloss) [MediRX](https://thisglp.com/reviews/medirx) [MedLeanRx](https://thisglp.com/reviews/medleanrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Where can patients use Risen Labs? The site states New York and Colorado. A Texas company identity does not establish Texas patient access. Can intake alone issue a prescription? No. The site requires a live video consultation and clinical approval. Which pharmacy is named? The weight page identifies Olympia Pharmacy as the partner for compounded medication. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-loss eligibility, video review and pharmacy disclosure](https://risenlabstx.com/weight-loss) - [Independent-provider and platform terms](https://risenlabstx.com/terms) - [Consultation fees, refunds and cancellation](https://risenlabstx.com/refund-policy) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rivas Medical Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP The clinic gives the injection on site every seven days, and a telehealth program prices the same drugs by the month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rivas-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A weekly appointment, or telehealth # Rivas Medical Weight Loss review The clinic gives the injection on site every seven days, and a telehealth program prices the same drugs by the month. ## The verdict Rivas Medical Weight Loss runs two programs: a telehealth one at $399 a month for semaglutide and $599 for tirzepatide, and an in-clinic one where the injection is given on site at a weekly visit. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 3 From From $399/mo Prescription Required Compounded Yes — not FDA-approved Availability 3 states Rivas is a physical weight-loss practice rather than a mail-order brand, operating from clinics in a small number of states, and the injection is administered on site at a weekly appointment rather than shipped to a refrigerator at home. A telehealth program priced by the month sits beside it. 1. ## Who writes the prescription, and what do they see? The weekly visit is the whole point of the arrangement, because it puts a clinician in front of the patient every seven days rather than behind an intake form filled in once. What the clinic does not publish is who that clinician is, or what the appointment covers beyond the injection itself. A buyer books, attends, is injected and comes back a week later, and the charge covers all of it. There is no membership, no shipping and no subscription, because there is nothing to ship. The in-clinic model is also a geographic restriction, since a reader too far from a clinic has only the telehealth program to choose. 2. ## What happens when the dose goes up? The weekly rate is stated as covering any dose, so a step up from 0.25mg to a maintenance dose does not move the bill, and that is a genuinely unusual thing to find beside an in-person program. The clinical side of the escalation is not described anywhere on the pages, though a weekly visit is the setting in which a dose decision would normally be made. 3. ## What the price includes The telehealth program is $399 a month for semaglutide and $599 for tirzepatide, with the medication and a provider visit inside each figure, and its FAQ adds a $195 initial visit. Six months of semaglutide on that program is $2,394. The in-clinic route is priced by the week instead, at $115 for semaglutide and $165 for tirzepatide, and either figure buys a clinician's time as well as a drug. 4. ## What it claims, and what it cites Both lines are compounded preparations rather than manufactured products, prepared by a pharmacy the clinic does not name, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: A clinician visit every seven days - Strength: One rate at any dose - Strength: One charge covers the visit and the drug - Strength: No membership and no shipping fee - Limitation: In-clinic care needs weekly attendance - Limitation: Clinics operate in three states - Limitation: Telehealth tirzepatide is $599 a month - Limitation: No pharmacy is named for the compounding ## What the evidence says about this kind of treatment The assessment above is about Rivas Medical Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer near a clinic who wants supervision every week rather than a parcel. Wrong for A buyer after the lowest monthly figure, since both programs price a clinician's time into it. ## The evidence behind what Rivas Medical Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rivas Medical Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | Framework | Buyers who convert a weekly rate into a calendar month before comparing it | | | LaSara Medical Group | Buyers who can pay a full term at once and want the lowest rung | | | RxPepsDirect | Buyers at a starting dose who want per-vial pricing and no subscription | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MedLeanRx](https://thisglp.com/reviews/medleanrx) [Medro](https://thisglp.com/reviews/medro) [Medsol RX](https://thisglp.com/reviews/medsol-rx) [MEDVi](https://thisglp.com/reviews/medvi) [Metaboost Rx](https://thisglp.com/reviews/metaboost-rx) [Mevo Health](https://thisglp.com/reviews/mevo-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the medication arrive by post? Not on the in-clinic program, where injections are given on site at weekly visits and the weekly charge covers the appointment and the drug together. The telehealth program is the route for a patient who cannot attend. What does a month cost? $399 for semaglutide and $599 for tirzepatide on the telehealth program, with the medication and a provider visit included. The in-clinic program is charged by the week. Does a higher dose cost more? No. The weekly charge is stated as covering any dose, so escalation does not change it. Is Rivas Medical Weight Loss legit? Rivas Medical Weight Loss is a GLP-1 telehealth sellers service. Its stated availability: 3 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Rivas Medical Weight Loss expensive compared with other GLP-1 telehealth sellers? Rivas Medical Weight Loss publishes a starting figure of $399/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rivas Medical Weight Loss above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rivo Health reviews (2026): GLP-1 telehealth sellers | This GLP Four flat figures, all of them attributed to a seasonal sale that was still running out of season. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rivo-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four figures, all on a seasonal sale # Rivo Health review Four flat figures, all of them attributed to a seasonal sale that was still running out of season. ## The verdict Rivo Health publishes $149 a month for semaglutide and $199 for tirzepatide. Both orals carry the same figures. Coverage is 50 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 50 Injection From $149/mo Oral From $149/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states Rivo Health sells both molecules as an injection and as an oral. Each molecule carries one price across both formats. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages describe plans rather than people. No clinician is named. The rate is stated flat, which answers the question most sellers dodge. The sale framing is the part to discount. 2. ## What happens when the dose goes up? The price is recorded as flat, so a dose increase should not move it. Nothing describes support at a step. 3. ## What the price includes Six months at $149 is $894 and at $199 is $1,194. Longer plans are said to save more without publishing what. The sale claims up to half off retail, and no retail figure is shown. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. A pharmacy prepares them. The FDA does not review them before dispensing. ## Where it holds up, and where it does not - Strength: Flat across doses - Strength: Coverage in 50 states - Strength: Both formats carry a figure - Limitation: The rate is framed as a sale - Limitation: Multi-month savings are not published - Limitation: No retail figure backs the discount - Limitation: Nothing names the compounding pharmacy ## What the evidence says about this kind of treatment The assessment above is about Rivo Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a flat rate and can ignore the seasonal framing. Wrong for A reader deciding on the strength of a discount nobody has quantified. ## The evidence behind what Rivo Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rivo Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Luci | Readers who take an asterisk seriously and plan to ask what it hides | | | Tru2u | Readers who want a flat rate and will ask what the combined product contains | | | TelePeptide | Readers who want the whole commitment ladder priced in advance | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Mevo Health](https://thisglp.com/reviews/mevo-health) [Midi Health](https://thisglp.com/reviews/midi-health) [Mint Med](https://thisglp.com/reviews/mint-med) [Mint Medical Clinic](https://thisglp.com/reviews/mint-medical) [Mochi Health](https://thisglp.com/reviews/mochi-health) [Mojoon](https://thisglp.com/reviews/mojoon) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the sale price the real price? It is the only price on the page, months after the season it names. What do longer plans cost? The page says they save more. It does not say how much. Does the oral cost more? No. Each molecule carries one figure in both formats. Is Rivo Health legit? Rivo Health is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Rivo Health expensive compared with other GLP-1 telehealth sellers? Rivo Health publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rivo Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rixa Health reviews (2026): GLP-1 telehealth sellers | This GLP The price rises at each dose level, and the ladder is published in full. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rixa-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every dose has its own price # Rixa Health review The price rises at each dose level, and the ladder is published in full. ## The verdict Rixa Health prices by dose level rather than at one flat rate, and it prints the whole ladder with milligrams beside every charge. The charges cover four-week blocks, so the entry rungs work out at $211.25 and $303.33 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $211.25/mo Oral From $140/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability 45 states Rixa Health is a functional-medicine telehealth practice whose weight-loss line runs compounded semaglutide and compounded tirzepatide by weekly injection, plus orally dissolving tablets of both. Hormone care, testosterone and thyroid programs sit alongside it. Coverage is stated for forty-five states, with five listed as coming soon. 1. ## Who writes the prescription, and what do they see? Treatment starts from a booked appointment rather than a form dropped into a queue, and the practice publishes its providers on a page of their own. Its pricing page states that each figure includes the visit as well as the pass-through cost of the medication. What a provider assesses before writing a prescription is not set out. Each dose level is sold as its own plan with its own charge. The medication is described as shipped separately by the preparing compounding pharmacy rather than by the clinic. Ninety-day supplies of the tablets are offered beside the thirty-day ones. Partner pharmacies are listed on a page of their own. 2. ## What happens when the dose goes up? This is the part Rixa publishes better than most, and also where the cost sits. Semaglutide runs across five levels and tirzepatide across six, each naming its milligrams per week beside its charge, so a patient can price the whole climb before starting. The tablets escalate too, by strength rather than by level. 3. ## What the price includes Semaglutide starts at $195 for four weeks and tirzepatide at $280, which are $211.25 and $303.33 across a calendar month. Both ladders roughly double from bottom to top. Two of the five semaglutide levels are billed as five-week blocks, under a line stating that every price below covers four weeks. The semaglutide tablets start at $140 for thirty days. 4. ## What it claims, and what it cites Both injectable lines are compounded rather than manufactured, and the oral tablets pair the active ingredient with vitamin B12. The practice names its partner pharmacies on a dedicated page. Its weight-loss page lists three ninety-day tablet prices under a single repeated strength, where the pricing page lists three different strengths. ## Where it holds up, and where it does not - Strength: The price of every dose level is published in advance - Strength: Milligrams per week are printed beside each charge - Strength: The visit is stated to be inside the price - Strength: Partner pharmacies are listed on their own page - Strength: Ninety-day tablet supplies are priced openly - Limitation: The charge rises at every step up the dose ladder - Limitation: Two semaglutide levels are five-week blocks, not four - Limitation: Nothing is quoted as a calendar month - Limitation: Two pages disagree on the tablet strengths ## What the evidence says about this kind of treatment The assessment above is about Rixa Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the cost of the whole dose ladder before the first injection. Wrong for A buyer who wants one rate that holds as the dose climbs. ## The evidence behind what Rixa Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rixa Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | | Strut Health | A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MultiMedRx](https://thisglp.com/reviews/multimedrx) [MyFastRx](https://thisglp.com/reviews/myfastrx) [MyStart Health](https://thisglp.com/reviews/mystart-health) [Näky](https://thisglp.com/reviews/naky) [NativeMed](https://thisglp.com/reviews/nativemed) [Navio MD](https://thisglp.com/reviews/navio-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price go up with the dose? Yes. Semaglutide is priced across five levels and tirzepatide across six, and each step up carries its own higher charge. Is $195 a monthly figure? No. It buys four weeks, which is $211.25 spread across a calendar month. Two higher levels are billed as five-week blocks. Is the visit charged separately? No. The pricing page states each figure includes the visit and the pass-through cost of the medication. Is Rixa Health legit? Rixa Health is a GLP-1 telehealth sellers service. Its stated availability: 45 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Rixa Health expensive compared with other GLP-1 telehealth sellers? Rixa Health publishes a starting figure of $140/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rixa Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ro reviews (2026): GLP-1 telehealth sellers | This GLP Brand GLP-1s only, with the membership billed as a second monthly charge. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ro Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Brand pills and pens, plus membership # Ro review Brand GLP-1s only, with the membership billed as a second monthly charge. ## The verdict Ro sells FDA-approved GLP-1s only. Foundayo starts at $149 a month for the medication. The Ro Body membership is billed separately. On the monthly plan it is also $149. Medication is not included in the membership. Together that is $298 a month, the figure ranked here. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron Form Injection · Oral From From $298/mo Dose published Yes Prescription Required Compounded No Pharmacy Not named Ro is a telehealth company selling weight-loss care as the Ro Body membership. The shelf lists Wegovy pill and pen, Zepbound KwikPen and pen, Foundayo pill and Ozempic. No compounded GLP-1 is listed. Some products are cash-pay only. Others take insurance. 1. ## Who writes the prescription, and what do they see? A Ro-affiliated provider reviews an online visit. Eligibility is decided within two days, per the page. No prescribing clinician is named. A board-certified obesity physician is named for clinical content only. The membership covers an insurance concierge, provider messaging, side-effect support, dose logging and coaching. Cash-pay orders ship to the door. Insured prescriptions are collected at a pharmacy. The first membership month is refunded if the patient is not eligible. 2. ## What happens when the dose goes up? Foundayo's dose ladder is published. It runs 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, then 14.5 mg and 17.2 mg. The price rises with the dose. Two rungs carry a discount ending December 31, 2026. The top rungs keep their offer price only with a refill check-in inside 45 days. 3. ## What the price includes Every bill has two parts. The medication is priced by drug and dose. Foundayo starts at $149 a month. The membership is a separate charge. Its month-to-month rate is $149. So Foundayo at the starting dose costs $298 a month, medication plus the required membership. Ro prints the two parts apart, never the total. Prepaid plans lower the membership. The first month costs less. 4. ## What it claims, and what it cites Every GLP-1 here is an FDA-approved brand product. Ro states its cash prices match LillyDirect, NovoCare and TrumpRx. Ozempic is labeled as approved for type 2 diabetes. It may be prescribed off-label for weight loss. ## Where it holds up, and where it does not - Strength: Only FDA-approved products are sold - Strength: The Foundayo dose ladder is priced - Strength: Insurance checks are included - Strength: The first membership month is refundable if ineligible - Limitation: The membership is a second monthly charge - Limitation: Higher doses cost more - Limitation: Top-dose pricing depends on refill timing - Limitation: No prescribing clinician is named ## What the evidence says about this kind of treatment The assessment above is about Ro. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer set on a brand GLP-1 who wants insurance help and care in one account. Wrong for A buyer looking for compounded medication or one all-in price. ## The evidence behind what Ro prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. ## How Ro compares | Seller | Who it suits | Go | | --- | --- | --- | | Hims | Buyers set on brand Wegovy or Zepbound who accept a monthly membership on top | | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NEUVÉ Health](https://thisglp.com/reviews/neuve-md) [New Wave Health](https://thisglp.com/reviews/new-wave-health) [NewSelf](https://thisglp.com/reviews/newself) [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) [NexLife](https://thisglp.com/reviews/nexlife) [Next Vial](https://thisglp.com/reviews/next-vial) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How much is Foundayo through Ro? $149 a month at the starting dose, for the medication alone. The required membership adds $149 on the monthly plan, so $298 a month in all. Is the membership included in the medication price? No. Ro states medication is not included in the membership cost. Does Ro sell compounded GLP-1s? No. The shelf lists FDA-approved brand products only. Is Ro expensive compared with other GLP-1 telehealth sellers? Ro publishes a starting figure of $298/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ro above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Robinhood Telehealth reviews (2026): GLP-1 telehealth sellers | This GLP The program describes physician review and structured check-ins. Its dosing concentrations and cancellation language need careful reading. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/robinhood-telehealth Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Concentration needs context # Robinhood Telehealth review The program describes physician review and structured check-ins. Its dosing concentrations and cancellation language need careful reading. ## The verdict Robinhood describes continuing check-ins, but its two cancellation descriptions need reconciling before enrollment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Robinhood Telehealth markets compounded weight-loss and peptide programs through an online platform. Its treatment menu names semaglutide and tirzepatide injections as well as a separate microdose category. 1. ## Who writes the prescription, and what do they see? The platform says licensed U.S. physicians review eligibility. Its legal terms distinguish the platform from the medical groups and pharmacies that supply treatment. Ask for the name of the clinician and the pharmacy attached to the actual prescription. The semaglutide page describes structured check-ins and secure messaging between contacts. No single universal appointment interval is established. Clarify whether routine check-ins are clinician reviews or administrative follow-up. 2. ## What happens when the dose goes up? The program describes provider-directed adjustments. Confirm the weekly milligram prescription and the volume to administer with the clinician or pharmacist; do not convert a concentration label into a self-directed dose. 3. ## What the price includes The homepage’s starting offer does not establish every renewal bill. More importantly, the product FAQ asks for 30 days’ cancellation notice, while the terms describe switching off auto-refill up to 48 hours before monthly processing. Get the applicable deadline clarified in writing. 4. ## What it claims, and what it cites The advertised injections are compounded, not FDA-approved products. Published vial concentrations do not by themselves establish a patient’s weekly milligram dose or the usable duration of a shipment. ## Where it holds up, and where it does not - Strength: Compounded ingredients named - Strength: Provider messaging described - Strength: Concentrations visible on treatment menu - Limitation: Cancellation deadlines differ across pages - Limitation: Pharmacy assignment needs confirming - Limitation: Starting offer is not a complete renewal quote ## What the evidence says about this kind of treatment The assessment above is about Robinhood Telehealth. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone interested in a compounded injection who can confirm the actual care team, pharmacy and check-in schedule. Wrong for Someone who needs one clear cancellation deadline before agreeing to recurring care. ## The evidence behind what Robinhood Telehealth prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Robinhood Telehealth compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NextMeds](https://thisglp.com/reviews/nextmeds) [NiceRx](https://thisglp.com/reviews/nicerx) [Nirwana Health](https://thisglp.com/reviews/nirwana-health) [NoBsRx](https://thisglp.com/reviews/no-bs-rx) [Nolu](https://thisglp.com/reviews/nolu) [Noom](https://thisglp.com/reviews/noom) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The semaglutide page describes structured check-ins and secure messaging between contacts. No single universal appointment interval is established. Clarify whether routine check-ins are clinician reviews or administrative follow-up. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Treatment menu and care model](https://robinhoodtelehealth.online/) - [Semaglutide program](https://robinhoodtelehealth.online/treatments/semaglutide) - [Billing and cancellation terms](https://robinhoodtelehealth.online/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Roboclinic reviews (2026): GLP-1 telehealth sellers | This GLP All three headline figures require a year committed, and buying by the month costs a hundred dollars more. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/roboclinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Advertised at the annual rate # Roboclinic review All three headline figures require a year committed, and buying by the month costs a hundred dollars more. ## The verdict Roboclinic publishes $179 a month for injected semaglutide, $249 for the tablet and $299 for tirzepatide. Every one is a twelve-month plan rate. Bought monthly the same products are $299, $299 and $399. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $299/mo Oral From $299/mo Prescription Required Compounded Yes — not FDA-approved Roboclinic sells both molecules by injection and semaglutide as a tablet, with three plan lengths on each line and the longest advertised. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe plans and their strike-throughs rather than the clinical relationship. Publishing all three lengths is fair. Advertising only the twelve-month rate, against a struck-through figure, is the part that misleads a comparison. 2. ## What happens when the dose goes up? The rates are recorded as flat across doses, so a year committed is a year at one figure. No milligram appears beside any plan. 3. ## What the price includes Twelve months of injected semaglutide at $179 is $2,148; the same year bought monthly is $3,588. The tablet is $2,988 against $3,588, and tirzepatide $3,588 against $4,788. The three-month rungs sit between at $249, $279 and $349. 4. ## What it claims, and what it cites All three lines are compounded rather than manufactured. A pharmacy prepares them, and the FDA reviews none of them before dispensing. ## Where it holds up, and where it does not - Strength: All three plan lengths published - Strength: Flat across doses on every line - Strength: A tablet route priced separately - Limitation: Every advertised rate needs a year - Limitation: Monthly costs $100 to $120 more - Limitation: The strike-throughs are never charged - Limitation: Refunds inside a year are unstated ## What the evidence says about this kind of treatment The assessment above is about Roboclinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit a full year and wanting the discount that buys. Wrong for A reader comparing $179 against another seller's month-to-month figure. ## The evidence behind what Roboclinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Roboclinic compares | Seller | Who it suits | Go | | --- | --- | --- | | Edessa | Readers who will read the plan table rather than the homepage banner | | | Recovery Delivered | Readers who reward a seller for publishing the number that costs it sales | | | Nolu | Readers who count cycles rather than months and want a flat rate at any dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Noom](https://thisglp.com/reviews/noom) [Nova](https://thisglp.com/reviews/nova) [Nova MD](https://thisglp.com/reviews/nova-md) [Novi](https://thisglp.com/reviews/novi) [NovoCare Pharmacy](https://thisglp.com/reviews/novocare-pharmacy) [NowPatient](https://thisglp.com/reviews/nowpatient) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I pay monthly at $179? No. Month to month is $299 for the same injection. What does a year cost up front? $2,148 on injected semaglutide, or $3,588 on tirzepatide. Is there a middle option? Three-month plans at $249, $279 and $349. Is Roboclinic expensive compared with other GLP-1 telehealth sellers? Roboclinic publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Roboclinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Roen Rx reviews (2026): GLP-1 telehealth sellers | This GLP Insurance coordination for brand drugs, and a compounded bundle for everyone else. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/roen-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two routes, one membership # Roen Rx review Insurance coordination for brand drugs, and a compounded bundle for everyone else. ## The verdict RoenRx runs two routes. Insured patients get help pursuing brand coverage. Uninsured patients buy a compounded bundle. The Semaglutide Bundle is $217 for the first month, then $297. The Tirzepatide Bundle is $349, then $449. Those bundle rates are the all-in figures. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $449/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named RoenRx is a telehealth practice with several service lines. Primary care, mental health, hair loss, skin care and sexual health share the site. The weight-loss program has two routes. One coordinates insurance for brand GLP-1 drugs. The other sells compounded semaglutide and compounded tirzepatide. 1. ## Who writes the prescription, and what do they see? A licensed RoenRx provider reviews the sign-up form. The FAQ gives one to two business days for that review. The provider may send follow-up questions first. No provider is named. No medical group is named on the pages a buyer sees first. Membership is the base of the program. It covers medical care, one-on-one coaching and insurance coordination. It is billed monthly on the sign-up date. Cancellation is allowed at any time. Quarterly, semi-annual and annual memberships are offered at a discount. The program does not accept Medicare or Medicaid plans. 2. ## What happens when the dose goes up? The bundle rule has one exception. Standard [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) is inside the bundle price. A dose above standard titration schedules may add fees. The provider reviews any such change with the patient first. The amount of the extra fee is not published. 3. ## What the price includes Four figures appear on the site. Two are all-in. The $25 figure applies to brand drugs through insurance. The $106 figure is medication-only and needs a three-month supply. The $216 figure is tirzepatide's medication-only starting price. Membership is billed on top of both. The bundles combine medication and care: $297 a month for semaglutide and $449 for tirzepatide after the first month. 4. ## What it claims, and what it cites A pharmacy compounds the [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). Neither is manufactured. Compounded drugs are not FDA-approved. The pages describe semaglutide as the active ingredient in Ozempic and Wegovy. The compounding pharmacy is not named. A patient found ineligible for compounded medication is refunded under a 30-day guarantee. ## Where it holds up, and where it does not - Strength: An all-in bundle is published for each drug - Strength: Insurance coordination is offered for brand drugs - Strength: A refund if a patient is found ineligible - Strength: Membership can be canceled at any time - Limitation: The low headline figures exclude membership - Limitation: A dose beyond standard titration may cost extra - Limitation: Medicare and Medicaid plans are not accepted - Limitation: No provider or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Roen Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An insured buyer who wants help pursuing brand coverage, with a compounded fallback. Wrong for A buyer comparing headline figures without adding the membership. ## The evidence behind what Roen Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Roen Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | Fridays | Readers who will get the annual rate confirmed in writing before paying | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) [NuBloom](https://thisglp.com/reviews/nubloom) [Nucore Health](https://thisglp.com/reviews/nucore-health) [NuDay Rx](https://thisglp.com/reviews/nuday-rx) [NuuVim](https://thisglp.com/reviews/nuuvim) [NuviaRx](https://thisglp.com/reviews/nuviarx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is the $25 figure? A copay for brand drugs such as Wegovy when insurance covers them, after coordination. It does not apply to compounded medication. What does compounded semaglutide cost all-in? The Semaglutide Bundle is $217 for the first month, then $297 a month. It includes care, a provider review, the prescription and the medication. Does a higher dose cost more? Standard titration is inside the bundle. A dose beyond standard titration schedules may add fees. The amount is not published. Is Roen Rx expensive compared with other GLP-1 telehealth sellers? Roen Rx publishes a starting figure of $449/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Roen Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Royal Medical Center reviews (2026): GLP-1 telehealth sellers | This GLP Royal Medical Center describes a compounded GLP-1 weight-loss program with laboratory assessment, individualized dosing and follow-up. Confirm the precise medication and pharmacy. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/royal-medical-center Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Royal Medical Center review Royal Medical Center describes a compounded GLP-1 weight-loss program with laboratory assessment, individualized dosing and follow-up. Confirm the precise medication and pharmacy. ## The verdict Royal’s useful promise is an integrated clinical program rather than an isolated refill. Laboratory review, adjustments and continuing consultations are explicitly listed. The remaining work is to turn a broad compounded-GLP-1 offer into a named prescription, a practical follow-up schedule and a clearly identified dispensing pharmacy. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved The practice offers hormone and weight-management services for men and women. Its weight-loss page is titled for tirzepatide and describes compounded GLP-1 injections. That heading is relevant, but the actual prescribed ingredient and concentration still need to appear on the patient’s order. 1. ## Who writes the prescription, and what do they see? The service describes doctor-guided care and a comprehensive medical evaluation. A prescriber determines medical necessity. Ask which clinician would conduct the consultation and manage later dose changes; a general practice description does not assign a particular professional. The listed program includes health evaluation, laboratory testing, consultations, progress monitoring and lifestyle support. These are useful categories, but the frequency and contact method are not fully specified. Establish whether follow-ups are booked visits, messages or both. 2. ## What happens when the dose goes up? Royal describes customized dosing and adjustments according to response. It does not establish one public milligram schedule for every patient. Ask how [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) are assessed, what a delayed refill means for the course and which monitoring is needed before the next prescription. 3. ## What the price includes The treatment page publishes an entry monthly figure and says medication, supplies, physician consultations, follow-ups and lab monitoring are included. Confirm which prescription and supply duration qualify and whether a higher dose changes the bill. A general starting figure is not a complete [dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). 4. ## What it claims, and what it cites The offer is described as compounded treatment. Such preparations are not FDA-approved, and trial evidence for approved products does not establish the same performance for a specific compounded vial. Obtain the pharmacy identity, formulation and storage instructions before choosing the program. ## Where it holds up, and where it does not - Strength: Assessment and monitoring are listed together - Strength: Supplies and follow-up appear in the package - Strength: Dose decisions are individualized - Limitation: Public follow-up frequency is incomplete - Limitation: Precise prescription and pharmacy need confirmation - Limitation: Starting price does not establish all dose costs ## What the evidence says about this kind of treatment The assessment above is about Royal Medical Center. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a broader physician-guided weight-management program who can clarify the prescription and continuing-care arrangements. Wrong for A patient needing an approved branded product or a complete public clinical and dose-price schedule. ## The evidence behind what Royal Medical Center prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Royal Medical Center compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Obu Health](https://thisglp.com/reviews/obu-health) [Omnia TeleHealth](https://thisglp.com/reviews/omnia-telehealth) [Omzo](https://thisglp.com/reviews/omzo) [Ondra Health](https://thisglp.com/reviews/ondra-health) [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) [OnlyRx](https://thisglp.com/reviews/onlyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the service simply a pharmacy order? The page describes evaluation, labs, consultations and monitoring in addition to medication. Is a particular dose guaranteed? No. The program describes customized dosing subject to the prescriber’s clinical decision. Are compounded injections FDA-approved? No. A compounded preparation is not an FDA-approved finished product. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://royalmedicalcenters.com/) - [Practice and clinical team](https://royalmedicalcenters.com/about/) - [Weight-management program](https://royalmedicalcenters.com/weight-loss/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RX Bella reviews (2026): GLP-1 telehealth sellers | This GLP One monthly price per drug, sold from a storefront that shares its software with seven other brands. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rx-bella Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Monthly only, shared storefront # RX Bella review One monthly price per drug, sold from a storefront that shares its software with seven other brands. ## The verdict Compounded semaglutide costs $249 a month at RX Bella and compounded tirzepatide $299, billed every 30 days with shipping included and no longer term on offer. Those are plain figures, and the monthly-only structure means nobody pays ahead for a quarter they may not use. Before choosing it, a reader should also know that the same application runs eight storefronts, and this is one of them. Comparing it with those siblings is closer to comparing settings than companies. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states RX Bella is a telehealth brand selling compounded semaglutide and tirzepatide injections, with a lower-dose microdose program and an NAD+ line beside them and a peptide catalog reached from the footer. It gives Sheridan, Wyoming, as its base and says it serves all 50 states. Its disclaimer describes a platform that connects patients with independent licensed providers and state-licensed compounding pharmacies, and that does not itself practice medicine, write prescriptions or dispense drugs. 1. ## Who writes the prescription, and what do they see? Every clinical decision is attributed to independent, U.S.-licensed providers, and none of them, nor any medical group, is named on the pages a buyer sees before the intake. The FAQ describes that intake in some detail: a patient lists diagnoses, current medications and any past GLP-1 treatment, and a clinician uses those answers to decide whether treatment is appropriate and at what dose. Someone switching from another seller may continue at the same or an equivalent dose, while a new patient typically starts at the introductory one. After approval, the site describes a provider who checks in month after month and adjusts the plan, with care messaging seven days a week and shipping that takes two to three days. The terms add the practical details. A subscription is charged every 30 days until it is canceled, and auto-refill can be switched off in the portal up to 48 hours before the next processing date. A first order can be canceled within 24 hours, and only if the provider network has not yet received it. The software under all of this is shared, since the site runs the same compiled application, and shows the same member photographs, as seven other GLP-1 brands. 2. ## What happens when the dose goes up? The price does not move with the dose, which the treatment pages call flat-rate pricing, so a patient climbing from the introductory dose toward maintenance pays $249 or $299 at every step. The semaglutide page sketches that climb as [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) in month one and a therapeutic dose by month three, and the tirzepatide page speaks of careful escalation. No milligram strength appears on either page. The treatment pages carry no figure at all, and the prices appear in the home page's grid instead. 3. ## What the price includes Semaglutide is $249 a month and tirzepatide $299, each a monthly plan with free shipping and no prepaid rung. The banner's lower 'from' figure belongs to the microdose program, which the price grid does not show. A patient who is not approved is charged nothing. 4. ## What it claims, and what it cites Both injections are compounded, and the site's disclaimer states that compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are not FDA-approved and are not the same as the branded medications. The pharmacies are described as state-licensed and U.S.-based, and none is named. The home page's weight-loss chart quotes averages from the STEP and SURMOUNT-1 trials of the approved drugs, and those trials did not test the compounded versions sold here. ## Where it holds up, and where it does not - Strength: One monthly price per drug, flat across doses - Strength: No prepaid term is required - Strength: Nothing is charged if a patient is not approved - Strength: Care messaging seven days a week - Limitation: The storefront shares its application with seven other brands - Limitation: No provider, medical group or pharmacy is named - Limitation: No milligram strength is published - Limitation: Prices appear only in the home page grid ## What the evidence says about this kind of treatment The assessment above is about RX Bella. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants a flat monthly price and no prepaid term. Wrong for A buyer who wants to know which clinicians and pharmacy stand behind the brand before paying. ## The evidence behind what RX Bella prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RX Bella compares | Seller | Who it suits | Go | | --- | --- | --- | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) [OnlyRx](https://thisglp.com/reviews/onlyrx) [Onyx Weight Loss](https://thisglp.com/reviews/onyx-weight-loss) [Open Water Rx](https://thisglp.com/reviews/open-water-rx) [Optimized Health](https://thisglp.com/reviews/optimized-health) [Options Medical Weight Loss](https://thisglp.com/reviews/options-medical-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does RX Bella look like other GLP-1 sites? Its site runs the same compiled application as seven other brands' storefronts, down to the member photographs. Each brand sets its own products and prices inside that shared software. Does the price go up with the dose? The treatment pages describe flat-rate pricing, and the home page lists one figure per drug, semaglutide at $249 and tirzepatide at $299. How do I stop a subscription? Turn off auto-refill in the patient portal at least 48 hours before the next monthly processing date, according to the terms. Is RX Bella legit? RX Bella is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is RX Bella expensive compared with other GLP-1 telehealth sellers? RX Bella publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RX Bella above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rx.com reviews (2026): GLP-1 telehealth sellers | This GLP The figure set in the largest type is a six-month plan charged once. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rx-com Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Six months in the headline # Rx.com review The figure set in the largest type is a six-month plan charged once. ## The verdict Rx.com prices compounded semaglutide at $175 on the one-month plan and tirzepatide at $285. The $146 across its homepage is the six-month rung, taken as a single charge of $875. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 49 From From $190/mo Prescription Required Compounded Yes — not FDA-approved Availability 49 states Rx.com sells both molecules by injection. Coverage runs to 49 states. Alaska is excluded. A pharmacy discount card is a separate service on the same site. 1. ## Who writes the prescription, and what do they see? A licensed provider decides whether to prescribe, and the site states that payment does not guarantee one. Who the provider is, and what they review first, is not described anywhere. The visit is folded into the plan price rather than billed beside it. Three terms per molecule, each published as a billed total. The two longer terms are one payment each. Plans renew automatically at the same price until canceled. 2. ## What happens when the dose goes up? The rate is stated as holding at every dose. A step up therefore costs nothing extra. Nothing published says who approves the step or what they look at. A buyer on a six-month plan escalates inside a term already paid for. 3. ## What the price includes Three months of semaglutide is one charge of $495 and six months is $875, working out at $165 and $146. Month to month is $175. Tirzepatide runs $285, $795 and $1,550 on the same three terms. Reaching the headline rate means $875 committed before a second injection. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. A pharmacy prepares them to order. The FDA does not review a compounded preparation before it is dispensed. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Longer terms published as billed totals - Strength: One rate at every dose - Strength: The provider visit sits inside the price - Strength: Coverage stated across 49 states - Limitation: The headline figure is a six-month plan - Limitation: $875 is charged in a single payment - Limitation: Alaska is excluded - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Rx.com. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer ready to pay six months at once. Wrong for A buyer comparing $146 against another seller's monthly bill. ## The evidence behind what Rx.com prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rx.com compares | Seller | Who it suits | Go | | --- | --- | --- | | RxPros | A reader able to fund a year at signing and collect deliveries by the quarter | | | NexLife | Buyers committing a full year rather than starting month to month | | | LaSara Medical Group | Buyers who can pay a full term at once and want the lowest rung | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Oria Meds](https://thisglp.com/reviews/oria-meds) [OurView Health](https://thisglp.com/reviews/ourview-health) [Oxford's Medical Weight Loss (The Calibrate Clinic)](https://thisglp.com/reviews/the-calibrate-clinic)[Ozari Health](https://thisglp.com/reviews/ozari-health) [Pallas Health](https://thisglp.com/reviews/pallas-health) [PauseRX](https://thisglp.com/reviews/pauserx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $146 a monthly charge? No. It is the six-month plan expressed per month, and the actual charge is $875 taken once. What does the one-month plan cost? $175 for semaglutide and $285 for tirzepatide, billed monthly and renewing until canceled. Does a higher dose cost more? No. Rx.com states the same price applies at every dose, and no higher-dose figure is published. Is Rx.com legit? Rx.com is a GLP-1 telehealth sellers service. Its stated availability: 49 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Rx.com expensive compared with other GLP-1 telehealth sellers? Rx.com publishes a starting figure of $190/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rx.com right at the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RxION Health reviews (2026): GLP-1 telehealth sellers | This GLP The headline rate is the six-month rung, and the monthly plan asks for no term. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rxion-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Six-month headline, monthly plan beside it # RxION Health review The headline rate is the six-month rung, and the monthly plan asks for no term. ## The verdict With no term attached, RxION Health's compounded semaglutide is $199 a month and its compounded tirzepatide $299. The $99 and $183 headlines are the six-month rungs. Each is paid as one charge, $594 and $1,098. The price is stated as flat at every dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named RxION Health is an online service selling compounded semaglutide and tirzepatide injections. A separate microdose GLP-1 line is aimed at people with a BMI under 25. Sermorelin, NAD+, glutathione and PT-141 share the catalog. The product pages exclude New Jersey, Alaska and Mississippi. 1. ## Who writes the prescription, and what do they see? The FAQ says a licensed clinician reviews the online intake and decides eligibility. That clinician writes a treatment plan if treatment is appropriate. Plans are described as approved by U.S.-licensed medical professionals. None is named. What the intake asks beyond health history and goals is not stated. The page says its price reflects the consultation, with medication added if a provider prescribes it. Supplies, injection instructions and cold-pack overnight shipping are included. Ongoing clinical support is promised, without a stated schedule. The checkout itemizes a provider consultation and shipping, both marked as included. 2. ## What happens when the dose goes up? Both product pages state the same price at every dose, with no surprise increases. On the monthly plan, that means $199 or $299 through the climb. No milligram strength is printed beside the price. The pace of dose increases is left to the provider and not described. 3. ## What the price includes Three rungs are published for each drug. Semaglutide is $199 month to month, or $99 a month on a six-month supply billed as $594. Tirzepatide is $299, or $183 on the six-month supply billed as $1,098. A three-month rung sits between them. At checkout, the monthly semaglutide plan shows a struck $274 against $199, and tirzepatide a struck $374 against $299. 4. ## What it claims, and what it cites Both injections are compounded. Compounded drugs are not FDA-approved and are not reviewed by the FDA before dispensing. The pages describe the pharmacies as FDA-regulated and state-licensed, without naming one. Four batch tests are listed, with potency checked every three to six months against a 10 percent concentration band. ## Where it holds up, and where it does not - Strength: A month-to-month rung is published beside the prepaid ones - Strength: The price is stated as flat at every dose - Strength: Supplies and overnight cold shipping are included - Strength: Batch testing is described test by test - Limitation: The headline figure is a six-month prepay - Limitation: No clinician or pharmacy is named - Limitation: Not available in New Jersey, Alaska or Mississippi - Limitation: No milligram strength is printed ## What the evidence says about this kind of treatment The assessment above is about RxION Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a no-term monthly rate that holds through titration. Wrong for A reader in New Jersey, Alaska or Mississippi, or one reading the headline as a monthly bill. ## The evidence behind what RxION Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RxION Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PauseRX](https://thisglp.com/reviews/pauserx) [PCOS Sisters](https://thisglp.com/reviews/pcos-sisters) [Peak Wellness](https://thisglp.com/reviews/peak-wellness) [PepHaūs](https://thisglp.com/reviews/pephaus) [Pepti](https://thisglp.com/reviews/pepti) [Piper](https://thisglp.com/reviews/piper) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a month the regular semaglutide price? No. It is the six-month supply, billed once as $594. With no term, semaglutide is $199 a month. What does tirzepatide cost month to month? $299 a month. The six-month supply works out to $183 a month, billed once as $1,098. Does the price change with the dose? Both product pages state the same price at every dose. No milligram strength is printed beside it. Is RxION Health expensive compared with other GLP-1 telehealth sellers? RxION Health publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RxION Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RxPepsDirect reviews (2026): GLP-1 telehealth sellers | This GLP The vial price is the smaller half of what an order costs, because a visit fee lands on every one. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rxpepsdirect Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by the vial, billed by the order # RxPepsDirect review The vial price is the smaller half of what an order costs, because a visit fee lands on every one. ## The verdict RxPepsDirect sells semaglutide with B12 from $25 for a 1.2mg vial and tirzepatide with B12 from $45 for 12mg. A flat $39 medical visit is charged on every order and $15 FedEx shipping is billed separately, so a first semaglutide order is $79 delivered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 28 From From $79/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability 28 states RxPepsDirect prescribes compounded peptides dispensed by a named 503A pharmacy, across more than seventy formulations. GLP-1 lines sit inside that catalog rather than being the whole of it. 1. ## Who writes the prescription, and what do they see? Every prescription is stated to be written and countersigned by a licensed NP or PA in the patient's own state. The pharmacy that fills it is named on the site. Both facts are rarer than they should be in this category, and together they are the strongest thing here. There is no subscription. A buyer pays for a visit and for whatever vials the clinician approves, then pays again at the next order. No labs and no coaching are included. 2. ## What happens when the dose goes up? Because the model is per-vial, a dose increase changes the bill directly. A 1.2mg semaglutide vial covers roughly five weeks at 0.25mg a week, and a maintenance dose needs more of them in the same month. Milligram quantities sit beside every price, which is what makes that arithmetic possible at all. 3. ## What the price includes At the starting dose, one semaglutide vial, the visit and shipping come to $79. Tirzepatide comes to $99 on the same terms. The figures rise with the dose rather than holding flat, and every refill carries the $39 visit again, so an annual cost depends on how many orders a buyer places. 4. ## What it claims, and what it cites The GLP-1 lines are compounded preparations rather than manufactured products, so the FDA does not review them before dispensing. The compounding pharmacy is named, which is uncommon. ## Where it holds up, and where it does not - Strength: The compounding pharmacy is named - Strength: Prescriptions countersigned in the patient's state - Strength: Milligram quantity beside every price - Strength: No subscription and no membership - Limitation: A $39 visit fee on every order - Limitation: $15 shipping billed separately - Limitation: Cost rises as the dose rises - Limitation: No labs or coaching included ## What the evidence says about this kind of treatment The assessment above is about RxPepsDirect. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer at a starting dose who wants milligrams beside the price. Wrong for A buyer at a maintenance dose comparing against a flat monthly rate. ## The evidence behind what RxPepsDirect prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RxPepsDirect compares | Seller | Who it suits | Go | | --- | --- | --- | | Framework | Buyers who convert a weekly rate into a calendar month before comparing it | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | | Injectco | Buyers who want to pay month by month and keep a longer package as an option | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) [Potere Health MD](https://thisglp.com/reviews/potere-health-md) [Precision Telemed](https://thisglp.com/reviews/precision-telemed) [Premium Health](https://thisglp.com/reviews/premium-health) [PrescribedRX](https://thisglp.com/reviews/prescribedrx) [PreventiveMD](https://thisglp.com/reviews/preventivemd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $25 what a first order costs? No. A $39 visit fee applies to every order and shipping is $15, so a first semaglutide order is $79 delivered. Does the visit fee apply to refills? Yes. Each refill carries the $39 visit again, which is the part a per-vial price hides. How long does one vial last? A 1.2mg semaglutide vial covers about five weeks at a 0.25mg weekly starting dose. A higher dose needs more vials in the same month. Is RxPepsDirect legit? RxPepsDirect is a GLP-1 telehealth sellers service. Its stated availability: 28 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is RxPepsDirect expensive compared with other GLP-1 telehealth sellers? RxPepsDirect publishes a starting figure of $79/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RxPepsDirect below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RxPros reviews (2026): GLP-1 telehealth sellers | This GLP One advertised figure needs a year paid ahead, and the other is a first-month discount. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rxpros Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two rates, neither monthly # RxPros review One advertised figure needs a year paid ahead, and the other is a first-month discount. ## The verdict RxPros advertises compounded semaglutide at $99.99 and tirzepatide at $144.97. Both rates require annual prepayment and ship every three months. The larger figures on the homepage are a first-month introductory discount for new patients. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $99.99/mo Prescription Required Compounded Yes — not FDA-approved RxPros sells both molecules by injection and lists branded products beside them. Medication arrives quarterly. The doctor visit and overnight shipping are stated as included in the price. 1. ## Who writes the prescription, and what do they see? A doctor visit is inside the price rather than charged apart. RxPros does not say who conducts it or what it covers. Nothing describes a check between one quarterly shipment and the next. The model is buy-ahead. A year is the term behind the advertised rate. Medication arrives three months at a time rather than monthly, so the cadence of care is quarterly by construction. 2. ## What happens when the dose goes up? All doses are stated to cost the same, with no upcharge at a higher milligram. That is a real advantage. It also means a dose change arrives mid-consignment, and nothing published says how the remaining vials are handled. 3. ## What the price includes Twelve months of semaglutide at $99.99 is $1,199.88 committed before a first injection. Tirzepatide at $144.97 is $1,739.64. Neither figure is offered month to month. The introductory rate applies to a first month only, and to new patients only. 4. ## What it claims, and what it cites The two cheaper lines are compounded rather than manufactured. A pharmacy prepares them and is not named. The branded line is the manufacturer's product at a cash price. ## Where it holds up, and where it does not - Strength: Every dose at one price - Strength: Doctor visit included in the rate - Strength: Overnight delivery sits inside the price - Strength: Branded options priced beside compounded - Limitation: The advertised rate needs a year prepaid - Limitation: Shipments arrive three months at a time - Limitation: The second headline is a first-month rate - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about RxPros. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer prepared to pay a year ahead and take delivery quarterly. Wrong for A buyer who wants to stop after a month without money already spent. ## The evidence behind what RxPros prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RxPros compares | Seller | Who it suits | Go | | --- | --- | --- | | Rx.com | Buyers ready to pay six months at once for the figure in the headline | | | HeliMeds | Buyers converting a twelve-week plan into calendar months before comparing it | | | NexLife | Buyers committing a full year rather than starting month to month | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PreventiveMD](https://thisglp.com/reviews/preventivemd) [PrideRx](https://thisglp.com/reviews/priderx) [Primary Clinic (Direct GLP)](https://thisglp.com/reviews/primary-clinic)[Prime Doctor RX](https://thisglp.com/reviews/prime-doctor-rx) [Prime Health](https://thisglp.com/reviews/prime-health) [Queen RX](https://thisglp.com/reviews/queen-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99.99 a monthly subscription? No. It is the annual-prepay rate, and the medication ships in three-month consignments. What does a year cost? $1,199.88 for semaglutide at the advertised rate, or $1,739.64 for tirzepatide. Does a higher dose cost more? No. RxPros states all doses carry the same price, and no dose surcharge is published. Is RxPros expensive compared with other GLP-1 telehealth sellers? RxPros publishes a starting figure of $99.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RxPros below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RxSaludable reviews (2026): GLP-1 telehealth sellers | This GLP A Spanish and English telehealth brand whose semaglutide refill rate sits in its FAQ, not on its price cards. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rxsaludable Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Bilingual care, refill rate in the FAQ # RxSaludable review A Spanish and English telehealth brand whose semaglutide refill rate sits in its FAQ, not on its price cards. ## The verdict RxSaludable charges $179 a month for compounded semaglutide refills. The $99 on its card is the first month only. No refill rate for tirzepatide is printed. Care is offered in Spanish or English. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $179/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider RxSaludable LLC is a Palm Beach, Florida telehealth brand. It sells compounded semaglutide and tirzepatide by injection. A microdose GLP-1 plan, sermorelin, NAD+ and glutathione sit on the same site. The site is written for Hispanic patients in the United States. 1. ## Who writes the prescription, and what do they see? The FAQ names the clinical group: Wasef Health, PC, of Pinellas Park, Florida. Six physicians are listed with their schools or boards. The terms describe asynchronous visits with a board-certified physician licensed in the patient's state. Which physician signs a given prescription is not stated. The path has three steps. First, an online form. Second, a provider review. Third, shipment from a pharmacy if approved. Unlimited messaging is included. Cancellation is done in the patient portal. The FAQ states no cancellation fee and no long-term contract. All sales are final once dispensed. 2. ## What happens when the dose goes up? The FAQ states that the provider can change the medication or the dose based on progress. No milligram figure is published for either injection. No price is published for a higher dose. The microdose plan states the same price at every dose. The full-dose plans do not. 3. ## What the price includes Semaglutide is $99 for the first month, then $179 a month for refills. The FAQ says the refill price includes the physician review, the plan and the medication. The tirzepatide card leads with a first-order figure as well. Its refill rate is not published. No membership fee is stated. HSA and FSA cards are accepted. 4. ## What it claims, and what it cites Both injections are compounded. A compounding pharmacy prepares them, and the FDA does not approve or review them before dispensing. The FAQ names one pharmacy: Jungle Jim's Pharmacy in Fairfield, Ohio. The same answer states that this pharmacy cannot dispense sterile compounds. Which pharmacy fills an injection is not stated. ## Where it holds up, and where it does not - Strength: Consultations offered in Spanish - Strength: The semaglutide refill rate is published - Strength: Clinical group named with an address - Strength: No cancellation fee is stated - Limitation: Card figures are first-order prices - Limitation: No tirzepatide refill rate is printed - Limitation: No milligram dose is published - Limitation: The injection pharmacy is not identified ## What the evidence says about this kind of treatment The assessment above is about RxSaludable. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Spanish-speaking reader who wants the whole visit and follow-up in Spanish. Wrong for A reader comparing tirzepatide prices, since no ongoing tirzepatide rate is printed. ## The evidence behind what RxSaludable prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RxSaludable compares | Seller | Who it suits | Go | | --- | --- | --- | | Jently | Patients who want the compounding pharmacy named before they pay | | | TeleZen MD | Readers who want the monthly rate and every term discount on one card | | | Green Cap Health | Readers in Texas wanting the lowest published figures | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [QuickMD](https://thisglp.com/reviews/quickmd) [ReadyRx](https://thisglp.com/reviews/readyrx) [Recovery Delivered](https://thisglp.com/reviews/recovery-delivered) [Refills](https://thisglp.com/reviews/refills) [ReflexMD](https://thisglp.com/reviews/reflexmd) [Regenics](https://thisglp.com/reviews/regenics) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is semaglutide $99 a month? No. $99 is the first month. Refills are $179 a month, according to the FAQ. What does tirzepatide cost after the first order? Not stated. The card gives a first-order figure only. Can the visit be in Spanish? Yes. The site states that consultations and support are available in English or Spanish. Is RxSaludable expensive compared with other GLP-1 telehealth sellers? RxSaludable publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RxSaludable below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # RxSpan MD reviews (2026): GLP-1 telehealth sellers | This GLP The catalog leads with the standing rate, not the discounted one. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rxspan-md Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Regular price printed first # RxSpan MD review The catalog leads with the standing rate, not the discounted one. ## The verdict RxSpan MD prints "Regular Monthly Price $249" before it prints the discounted figure. Beside the low number it names the plan, the promotional code and the single upfront charge. That ordering is the reverse of the category habit, and it is the reason to read this catalog. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $249/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states LegitScript Claimed by provider RxSpan MD is a physician-founded telehealth practice running four lines: weight loss, longevity, hair loss and sexual health. The weight-loss line carries compounded and brand-name GLP-1 options plus a microdosing option. Care is stated for all fifty states, with availability varying by licensure. 1. ## Who writes the prescription, and what do they see? The medical group is named, and two supervising physicians are listed with their NPI numbers. The founder is named as a board-certified plastic surgeon. One FAQ answer is candid where most are vague. A conversation with a doctor is not always required. Many patients are approved on the written assessment alone. A telehealth visit is scheduled only when a clinician wants more information. Five steps are published, from intake to ongoing refills. Unlimited appointments and messaging are stated to be included. Four compounding pharmacies are named with their phone numbers. Which one fills a given prescription is not stated in advance. 2. ## What happens when the dose goes up? The plan price is quoted per month rather than per dose, and no dose tier appears in the catalog. Ongoing support and refills are described as part of the plan. No milligram figure is published beside any option. Nothing states who approves a step up the ladder. 3. ## What the price includes Compounded semaglutide is $249 a month at the regular rate and compounded tirzepatide is $329. Oral capsule versions of both are listed at their own rates. Each card then shows a twelve-month rate, the total billed upfront, and the promo code applied to reach it. Auto-renewal is disclosed on the card, and the final price is stated to be confirmed at checkout. 4. ## What it claims, and what it cites Compounded and brand-name GLP-1 plans are listed side by side under one heading. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The four named pharmacies are the transparency this category usually withholds. ## Where it holds up, and where it does not - Strength: The regular monthly price is printed first - Strength: Four compounding pharmacies are named - Strength: The medical group is named with NPI numbers - Strength: The upfront total is shown beside each rate - Strength: Auto-renewal is disclosed on the card - Limitation: The low figure needs a twelve-month prepay - Limitation: A promo code sits inside the advertised rate - Limitation: No milligram dose appears in the catalog - Limitation: Which pharmacy fills an order is not stated ## What the evidence says about this kind of treatment The assessment above is about RxSpan MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the standing rate, the pharmacy and the prescriber named up front. Wrong for A buyer who wants a live consultation before any prescription is written. ## The evidence behind what RxSpan MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How RxSpan MD compares | Seller | Who it suits | Go | | --- | --- | --- | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Remedy Meds](https://thisglp.com/reviews/remedy-meds) [REMEVi](https://thisglp.com/reviews/remevi) [Remi Meds](https://thisglp.com/reviews/remi-meds) [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) [Renlo Health](https://thisglp.com/reviews/renlo-health) [RENN Health](https://thisglp.com/reviews/renn-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $175 a month what a new patient pays? Only on the twelve-month plan, billed as one payment of $2,094 with a promo code applied. The regular monthly price is $249. Will a doctor call before prescribing? Not always. RxSpan MD states many patients are approved on the assessment alone, with a telehealth visit scheduled only if a clinician needs more. Which pharmacy fills the prescription? One of four named in the FAQ. The site lists each with a phone number but does not say which fills a given order. Is RxSpan MD legit? RxSpan MD is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is RxSpan MD expensive compared with other GLP-1 telehealth sellers? RxSpan MD publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts RxSpan MD above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Rylo Health reviews (2026): GLP-1 telehealth sellers | This GLP The no-contract rate holds at every dose, and the filling pharmacy is named. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/rylo-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One rate at every dose # Rylo Health review The no-contract rate holds at every dose, and the filling pharmacy is named. ## The verdict Rylo Health charges $139 a month for compounded semaglutide, month to month. Tirzepatide is $229 a month on the same no-contract terms. Neither figure moves when the physician raises the dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $139/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Rylo Health sells compounded semaglutide and tirzepatide as once-weekly injections. Each product page has a monthly tab and a quarterly tab. The quarterly tab opens first, and the monthly tab carries the no-contract rate. 1. ## Who writes the prescription, and what do they see? A US-licensed physician reviews each written intake within 24 hours. There is no video call at any point before prescribing. The FAQ names Lone Star Virtual Health PLLC as the clinical group. The reviewing physician is not named on the product pages. The intake is a written questionnaire that takes about five minutes. A physician decides from the answers and the health history given. An approved order ships free and arrives in about two days. The seller states its care team checks in with each patient every month. Payment is refundable until a prescription is written. 2. ## What happens when the dose goes up? The price does not change with the dose, and both product pages say so. The homepage shows a three-month ladder from 2.5 mg to 7.5 mg. Each month on that ladder costs $160, the quarterly tirzepatide rate. The seller states the physician adjusts the dose every month. No separate visit is described for a step up. 3. ## What the price includes Month to month, semaglutide is $139 and tirzepatide is $229. The quarterly tab bills $299 and $479 every three months instead. That works out to $100 and $160 a month on a commitment. No membership fee is charged, and canceling carries no fee. HSA and FSA cards are accepted at checkout. 4. ## What it claims, and what it cites Both drugs are compounded by a licensed 503A pharmacy. The FAQ names VialsRX in Houston as the pharmacy that fills them. Compounded drugs are not FDA-approved, and the FDA does not review them before dispensing. The seller states every batch is tested for sterility, endotoxin and potency. ## Where it holds up, and where it does not - Strength: No-contract monthly rate on both drugs - Strength: Price stated flat across every dose - Strength: Filling pharmacy named in the FAQ - Strength: Refundable until a prescription is written - Limitation: The quarterly tab is selected by default - Limitation: No live visit with the physician - Limitation: The reviewing physician is not named ## What the evidence says about this kind of treatment The assessment above is about Rylo Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants one monthly figure that holds through the dose ladder. Wrong for A reader who wants a live visit with a physician before a prescription is written. ## The evidence behind what Rylo Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Rylo Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Somira Health | Readers who want the pharmacy and the rate named before the intake | | | Rewinding RX | Readers who want a fixed figure and the doses it covers listed | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) [Renlo Health](https://thisglp.com/reviews/renlo-health) [RENN Health](https://thisglp.com/reviews/renn-health) [Reset Solutions](https://thisglp.com/reviews/reset-solutions) [RestorLife Med](https://thisglp.com/reviews/restorlife-med) [Revel Health](https://thisglp.com/reviews/revel-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Rylo Health charge each month? $139 for semaglutide and $229 for tirzepatide, month to month. Both figures hold at every dose on the ladder. Why does the page show $100 first? The quarterly tab opens by default and bills $299 every three months. The no-contract rate sits on the monthly tab beside it. Which pharmacy fills the order? VialsRX in Houston, according to the seller's FAQ. It is a licensed 503A compounding pharmacy. Is Rylo Health legit? Rylo Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Rylo Health expensive compared with other GLP-1 telehealth sellers? Rylo Health publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Rylo Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Ryze Rx reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide is sold vial by vial, and the price climbs with the strength the prescriber writes. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ryze-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Each vial strength priced # Ryze Rx review Semaglutide is sold vial by vial, and the price climbs with the strength the prescriber writes. ## The verdict Ryze Rx sells compounded semaglutide from $119 for its smallest vial up to $219 for its largest, and compounded tirzepatide from $199. The opening figure is the price of the first weeks of treatment, and the months after the dose rises cost more. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $119/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Ryze Rx is a cash-pay telehealth service that sells weight-loss, testosterone and peptide prescriptions from one catalog. Its injectable semaglutide and tirzepatide each appear as a grid of vial strengths, with a price printed beside every option on the product page. 1. ## Who writes the prescription, and what do they see? According to the product page, a licensed clinician reviews the intake within 24 hours and the prescribing physician chooses the molecule and the dose. The homepage describes its prescribers as board-certified physicians licensed in the patient's state, although none is named and nothing says whether the first visit is live or written. The path runs from a health assessment of under five minutes to physician review, a prescription, and shipping from a US compounding pharmacy, with the homepage promising monthly check-ins and dosage adjustments along the way. Treatment can be paused, adjusted or canceled from a patient dashboard, and the seller states there is no long-term contract to break. 2. ## What happens when the dose goes up? This is where the vial grid earns its place, because the semaglutide options run from a 1 mg vial at $119 to a 10 mg vial at $219. A patient whose dose rises through the usual escalation should expect the bill to rise with it. Tirzepatide is also sold as a three-month kit of 5, 10 and 15 mg vials for $499, the one place the catalog packages the climb instead of pricing each step. How many weeks any single vial is meant to last is not stated beside the grid. 3. ## What the price includes The semaglutide page preselects the $119 vial, and the banner across the site reads GLP-1s from $119 a month, so the headline and the default option agree. Shipping is described as free, the program is cash-pay with itemized receipts a patient can submit to an FSA or HSA, and no membership fee appears beside either drug. 4. ## What it claims, and what it cites Both drugs are compounded and dispensed by licensed 503A and 503B pharmacies that the seller does not name. Compounded preparations are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are dispensed. ## Where it holds up, and where it does not - Strength: Every vial strength carries a published price - Strength: Tirzepatide three-month kit priced in full - Strength: No membership fee beside either drug - Strength: Pause or cancel from the patient dashboard - Limitation: The price rises with the vial strength - Limitation: Weeks covered by each vial not stated - Limitation: Dispensing pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Ryze Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader early in treatment who wants to see what each step up the dose ladder will cost before starting. Wrong for A reader who wants the price fixed at every step, when each larger semaglutide vial here costs more than the last. ## The evidence behind what Ryze Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Ryze Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | SkyRx | Buyers ready to prepay a year who want the medication, visit and shipping in one figure | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Revel RX](https://thisglp.com/reviews/revel-rx) [Revive Meds](https://thisglp.com/reviews/revive-meds) [Rewinding RX](https://thisglp.com/reviews/rewinding-rx) [Rex MD](https://thisglp.com/reviews/rex-md) [Rivas Medical Weight Loss](https://thisglp.com/reviews/rivas-medical) [Rivo Health](https://thisglp.com/reviews/rivo-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $119 the monthly price? It is the price of the smallest semaglutide vial, which the site's banner presents as a monthly figure. Larger vials cost more, up to $219, and the grid does not say how long each one lasts. What does tirzepatide cost? The smallest tirzepatide vial is $199, and a three-month kit containing 5, 10 and 15 mg vials is $499. Can I stop treatment? The seller states there are no long-term contracts and that treatment can be paused, adjusted or canceled at any time from the patient dashboard. Is Ryze Rx legit? Ryze Rx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Ryze Rx expensive compared with other GLP-1 telehealth sellers? Ryze Rx publishes a starting figure of $119/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Ryze Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Science & Co reviews (2026): plans and ongoing care | This GLP Science & Co describes ongoing provider contact and dose adjustments, but its current headline prices require a twelve-month plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/science-and-co Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Follow-up described, monthly quote unresolved # Science & Co review Science & Co describes ongoing provider contact and dose adjustments, but its current headline prices require a twelve-month plan. ## The verdict Science & Co publishes a more specific care pathway than a price card alone: provider assessment, secure messaging and continued dose review. Its headline rates are attached to twelve-month plans. The outcome illustrations are not a reliable way to predict an individual patient’s results, and an ongoing month-to-month quote needs confirmation. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states and DC Science & Co is an online platform offering compounded semaglutide and tirzepatide injections alongside other treatment categories. It now also lists branded weight-loss products, whose availability and terms should be confirmed separately. The company states that it is not itself a compounding facility. Prescribing and medication preparation belong to independent licensed providers and pharmacies. 1. ## Who writes the prescription, and what do they see? A provider licensed in the patient’s state reviews the health questionnaire before deciding whether to prescribe. The FAQ says the same provider remains involved month to month. Its public care model includes health history, current medications, treatment response and labs when needed. These are service commitments; ask who your assigned clinician is and how to arrange a direct consultation. Science & Co advertises continuing messaging and regular check-ins. Its FAQ gives all fifty states and DC as its service area and describes a cash-pay service without insurance claims. Refills ship after clinical approval and pharmacy preparation. The shipping policy promises reshipment where a transit delay risks a temperature-sensitive product, so contact the care team promptly about a delivery problem. 2. ## What happens when the dose goes up? The medication pages say the price does not increase with prescribed dose. They describe monitoring tolerability and adjusting the schedule when [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) occur. A provider should decide whether to increase, hold or otherwise change treatment; the seller’s general discussion of nausea should not be read as advice to continue through every symptom. Confirm the check-in schedule and contact route before the first fill. 3. ## What the price includes The current compounded semaglutide headline is $59 per month on a twelve-month plan; tirzepatide is $99 on the same stated term. Those are commitment-based rates, not a verified month-to-month bill. Request the total charge, payment schedule and renewal amount in writing. The FAQ states no membership fee, but stopping future orders does not necessarily recover an earlier payment. 4. ## What it claims, and what it cites A licensed U.S. pharmacy prepares the compounded medication. Science & Co claims third-party testing and says patients can request a certificate of analysis. Ask for the dispensing pharmacy and documentation for the specific lot. Compounded preparations are not FDA-approved; testing claims and the website’s illustrative outcome panels do not establish equivalent results to a branded medicine. ## Where it holds up, and where it does not - Strength: Provider continuity described in the FAQ - Strength: Messaging and dose review included - Strength: Temperature-sensitive shipment problems addressed - Strength: No membership fee stated - Limitation: Headline rate requires a twelve-month plan - Limitation: Standing monthly price needs a separate quote - Limitation: Assigned pharmacy is not identified on the price card - Limitation: Illustrative outcome panels do not predict results ## What the evidence says about this kind of treatment The assessment above is about Science & Co. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants remote follow-up and can clarify the clinician, pharmacy and billing schedule before enrolling. Wrong for Someone seeking an independently established patient success rate or a fully specified month-to-month offer. ## The evidence behind what Science & Co prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Science & Co compares | Seller | Who it suits | Go | | --- | --- | --- | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ro](https://thisglp.com/reviews/ro) [Roboclinic](https://thisglp.com/reviews/roboclinic) [Roen Rx](https://thisglp.com/reviews/roen-rx) [RX Bella](https://thisglp.com/reviews/rx-bella) [Rx.com](https://thisglp.com/reviews/rx-com) [RxION Health](https://thisglp.com/reviews/rxion-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the headline rate available without a long plan? The current product FAQs tie $59 semaglutide and $99 tirzepatide to twelve months. Obtain a separate quote for a shorter arrangement. Can Science & Co treatment be paused? The FAQ allows a pause or cancellation through the account or support at least 72 hours before processing. It stops future orders, rather than reversing medication already prescribed, dispensed or shipped. Does the same provider stay involved? The FAQ says the same state-licensed provider follows the patient month to month and adjusts treatment based on response. What do the outcome graphics establish? They are labeled illustrative. They do not provide the methods or patient-level evidence needed to estimate your individual result. ## Sources for this review Provider information checked October 14, 2026. Terms can change. - [Semaglutide and plan term](https://science.co/weight-loss/semaglutide) - [Tirzepatide and plan term](https://science.co/weight-loss/tirzepatide) - [Care and cancellation FAQ](https://science.co/faq) - [Shipping and returns](https://science.co/shipping-returns) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Semaglutide Online reviews (2026): GLP-1 telehealth sellers | This GLP Four billing rungs sit in one table, and the headline figure belongs to the five-month commitment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/semaglutide-online Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four rungs in one table # Semaglutide Online review Four billing rungs sit in one table, and the headline figure belongs to the five-month commitment. ## The verdict Semaglutide Online charges $219 a month for compounded semaglutide on a month-to-month subscription. Compounded tirzepatide is $349 a month on the same terms. Both figures include the medication, the provider review and shipping. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $219/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability US except AL LegitScript Claimed by provider Semaglutide Online is a telehealth service selling compounded semaglutide and tirzepatide as injections or as oral drops. It also arranges brand-name Wegovy, Ozempic and Zepbound through a separate cash-pay or insurance program. The site states that it holds LegitScript certification and links to the listing. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the online intake within 12 hours of purchase, according to the seller. No appointment or video visit is required before that review. The provider's name and credential are not stated anywhere on the product pages. The seller says its providers favor FDA-approved products where they are appropriate. The intake is written rather than live, and a free 15-minute call with a care coordinator is offered first. Approved orders ship from the partner pharmacy within two to four business days. The service is not offered to patients in Alabama. If no treatment is appropriate, the seller states the charge is refunded in full. 2. ## What happens when the dose goes up? Each compounded rung is one price across every dose the provider prescribes. The tirzepatide page states its rate never rises when the provider adjusts the dose. The same page lists compounded semaglutide as a flat rate too. Support at each dose step is described only as the provider monitoring treatment and [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). 3. ## What the price includes Compounded semaglutide is sold on four rungs, each printed with its total. A five-month prescription is $179 a month, or $895 in total. Three months is $199 a month, or $597, and month to month is $219. A single month without a subscription is $229. Tirzepatide is $299 a month on the five-month rung, $1,495 in total. Its month-to-month rate is $349, and a single month costs $359. 4. ## What it claims, and what it cites The compounded products are shipped from a partner pharmacy that the site does not name. They are not FDA-approved, and the FDA does not review them before they are dispensed. Brand-name pens bought through the service carry a separate $44 monthly provider subscription on top of the medication. ## Where it holds up, and where it does not - Strength: Every billing rung printed with its total - Strength: Provider review and shipping included - Strength: Full refund if no treatment is appropriate - Strength: Flat tirzepatide rate across doses - Limitation: Headline figure needs a five-month commitment - Limitation: FAQ answers disagree on cancellation - Limitation: Compounding pharmacy is not named - Limitation: Not available in Alabama ## What the evidence says about this kind of treatment The assessment above is about Semaglutide Online. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to compare commitment lengths from a single table before choosing. Wrong for A reader who needs a clear cancellation rule before paying for more than one month. ## The evidence behind what Semaglutide Online prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Semaglutide Online compares | Seller | Who it suits | Go | | --- | --- | --- | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RxION Health](https://thisglp.com/reviews/rxion-health) [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) [RxPros](https://thisglp.com/reviews/rxpros) [RxSaludable](https://thisglp.com/reviews/rxsaludable) [Rylo Health](https://thisglp.com/reviews/rylo-health) [Ryze Rx](https://thisglp.com/reviews/ryze-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $179 the monthly price? Only on the five-month prescription, which is billed $895 in total. On a month-to-month subscription, compounded semaglutide is $219. What does tirzepatide cost? Compounded tirzepatide is $349 month to month, $359 for a single month, or $299 a month on the five-month rung. Can I cancel? The site answers two ways. One FAQ says patients can cancel anytime, while another says cancellation is unavailable once treatment begins. Is Semaglutide Online legit? Semaglutide Online is a GLP-1 telehealth sellers service. Its stated availability: US except AL. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Semaglutide Online expensive compared with other GLP-1 telehealth sellers? Semaglutide Online publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Semaglutide Online above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Sesame Care reviews (2026): GLP-1 telehealth sellers | This GLP The advertised introductory rate covers two months at the two lowest doses, and it is still displayed past the end date its own terms give. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/sesame-care Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Promo past its own end date # Sesame Care review The advertised introductory rate covers two months at the two lowest doses, and it is still displayed past the end date its own terms give. ## The verdict Sesame Care advertises $199 a month for compounded semaglutide, and three conditions sit on that figure. It applies to new self-pay patients, for the first two months only, and at the 0.25 and 0.5mg doses alone. The standing rate is $349. The promotion was still being advertised past the end date stated in its own FAQ terms. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose Injection From $358/mo Oral From $208/mo Prescription Required Compounded Yes — not FDA-approved Sesame Care sells both molecules by injection and semaglutide as a low-dose oral at $149. Its tirzepatide line is priced by dose rather than by a single figure, which is a fuller disclosure than most sellers offer. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing and the marketplace model puts a clinician between the buyer and the medication. What the pages do not settle is the eligibility question governing the advertised price. New self-pay patients qualify and returning or insured ones apparently do not, with the boundary drawn in FAQ terms rather than beside the figure. Three conditions on one advertised number is a lot to carry, and each is disclosed somewhere. The problem is where. A reader meets $199 on the marketing surface and the qualifications in a FAQ, which is the ordinary shape of this failure rather than an unusual one. 2. ## What happens when the dose goes up? The tirzepatide line is the strong disclosure here: $299 at the opening dose, $399 at 5mg, and $449 across 7.5, 10, 12.5 and 15mg. That is a published ladder with milligram figures attached, and it lets a reader price the escalation rather than guess at it. The semaglutide promotion runs the other way, restricting its rate to the two lowest doses. 3. ## What the price includes $199 describes two months at a starting dose, after which the rate is $349. Six months is therefore $398 plus four at $349, which is $1,794, and that assumes the dose does not move past 0.5mg. The tirzepatide ladder is more honest about the same problem: it says outright that the figure rises with the dose and prints what it rises to. 4. ## What it claims, and what it cites The compounded lines have not been through FDA review for safety or quality before dispensing. The oral [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is described as low-dose, so the $149 is not priced against a standard starting dose. ## Where it holds up, and where it does not - Strength: Tirzepatide priced by milligram dose - Strength: Every condition is disclosed somewhere - Strength: A low-dose oral is offered and labeled - Limitation: The promo was advertised past its end date - Limitation: Three conditions sit on one figure - Limitation: The standing rate is $150 higher - Limitation: Conditions live in FAQ terms, not beside the price ## What the evidence says about this kind of treatment The assessment above is about Sesame Care. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants tirzepatide priced by dose and will read the FAQ before the headline. Wrong for A reader taking the advertised semaglutide figure as a standing rate. ## The evidence behind what Sesame Care prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Sesame Care compares | Seller | Who it suits | Go | | --- | --- | --- | | Better U Care | Buyers in its listed states who want one monthly price from the first dose through maintenance | | | PlushCare | A reader with insurance who wants a clinician visit in the loop, and who reads $149 as a starting-dose figure rather than a standing one. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SexyMD](https://thisglp.com/reviews/sexymd) [ShapeIn Rx](https://thisglp.com/reviews/shapein-rx) [Shapely](https://thisglp.com/reviews/shapely) [Signos](https://thisglp.com/reviews/signos) [Silhouette MD](https://thisglp.com/reviews/silhouette-md) [SkyRx](https://thisglp.com/reviews/skyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who gets the $199? New self-pay patients, for the first two months, at the 0.25 and 0.5mg doses. The standing rate afterwards is $349. Is the promotion still running? It was still being advertised past the end date stated in its own FAQ terms when the pages were read, which is a reason to confirm it applies before ordering. What does tirzepatide cost at a higher dose? $399 at 5mg and $449 at 7.5mg and above, against $299 at the opening dose. Sesame publishes the ladder with the milligrams attached. Is Sesame Care expensive compared with other GLP-1 telehealth sellers? Sesame Care publishes a starting figure of $208/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Sesame Care above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # SexyMD reviews (2026): GLP-1 telehealth sellers | This GLP The no-commitment plan ships four weeks at a time, which is thirteen fills a year. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/sexymd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four-week fills, intro first # SexyMD review The no-commitment plan ships four weeks at a time, which is thirteen fills a year. ## The verdict SexyMD charges $149 per four-week fill of compounded GLP-1 on its no-commitment plan. Thirteen fills a year make that $161 a calendar month. The GLP-1 + GIP injection is $249 a fill, or $270 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $161/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability US except AR, MS, NJ SexyMD is a telehealth platform that markets its programs to women. It sells two compounded weight-loss injections from separate product pages. Those pages call them GLP-1 and GLP-1 + GIP. The terms name semaglutide and tirzepatide among the program's medicines. 1. ## Who writes the prescription, and what do they see? SexyMD does not prescribe; independent providers in affiliated medical groups do. The first visit may be video, phone or a written questionnaire. The terms say the patient's state decides which format applies. Refills and check-ins may be reviewed without a live visit. No provider is named anywhere on the product pages. The steps are an online intake, a provider review and shipping. Approved orders ship within three to five business days. The terms treat an order as final once it is submitted. Cancellation is honored only if support hears before provider review begins. A provider decline is refunded in full. Plans renew automatically unless canceled 48 hours before renewal. 2. ## What happens when the dose goes up? The product page promises a step-by-step dose-escalation schedule for each patient. It does not say whether the price changes as the dose rises. No milligram dose is published on either product page. No separate visit is described for a step up. 3. ## What the price includes Monthly Flex has no commitment and ships a four-week supply each time. The first fill is $69 for GLP-1 and $99 for GLP-1 + GIP. Later fills renew at $149 and $249, per the footnote. The struck $269 and $369 beside them carry no end date. The three-, six- and twelve-month plans print lower monthly figures. Each of those requires the longer commitment. 4. ## What it claims, and what it cites Both injections are compounded by pharmacies in the seller's network. The terms name 503A pharmacies and 503B outsourcing facilities, but no single pharmacy. The dispensing pharmacy can change without notice to the patient. Compounded drugs are not FDA-approved, and the FDA does not review them before dispensing. ## Where it holds up, and where it does not - Strength: No-commitment plan priced on the product page - Strength: Introductory fill labeled as introductory - Strength: A provider decline is refunded in full - Limitation: Four-week fills mean thirteen charges a year - Limitation: Product pages do not name the molecule - Limitation: Orders are final once review begins - Limitation: Dispensing pharmacy can change without notice ## What the evidence says about this kind of treatment The assessment above is about SexyMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to start without committing to a plan length. Wrong for A reader in Arkansas, Mississippi or New Jersey, which the footer excludes. ## The evidence behind what SexyMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How SexyMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Sprout Health | Readers taking the six-month plan, which is the one measured in calendar months | | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SkyRx](https://thisglp.com/reviews/skyrx) [Society of You](https://thisglp.com/reviews/society-of-you) [Somi Health](https://thisglp.com/reviews/somi-health) [Somira Health](https://thisglp.com/reviews/somira-health) [Southern Vitality and Weight Loss](https://thisglp.com/reviews/southern-vitality-weight-loss) [Spry](https://thisglp.com/reviews/spry) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $69 the monthly price? No. $69 is the introductory first Monthly Flex fill of GLP-1. Later fills renew at $149 each. Why is $149 shown as $161? Each fill covers four weeks, not a calendar month. Thirteen fills a year at $149 is $161 a calendar month. Can I cancel an order? Only before a provider starts review. After review begins, the terms treat the order as final. Is SexyMD legit? SexyMD is a GLP-1 telehealth sellers service. Its stated availability: US except AR, MS, NJ. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is SexyMD expensive compared with other GLP-1 telehealth sellers? SexyMD publishes a starting figure of $161/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts SexyMD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ShapeIn Rx reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide is priced in two dose bands, and the product page adds an appointment fee and a shipping charge. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/shapein-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced in dose bands # ShapeIn Rx review Semaglutide is priced in two dose bands, and the product page adds an appointment fee and a shipping charge. ## The verdict ShapeIn Rx lists compounded semaglutide with B12 at $179 for doses up to 1 mg and $299 for doses up to 2.5 mg. The product page adds $29 shipping, which makes a fill at the lower band $208, plus a one-time $45 appointment, although the homepage card for the same product calls shipping free. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Flat across doses From From $208/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named ShapeIn Rx is a Phoenix-based telehealth weight-loss clinic that sells compounded semaglutide blended with vitamin B12, compounded liraglutide, and brand-name GLP-1 pens, each from its own product page. 1. ## Who writes the prescription, and what do they see? The homepage describes a one-on-one virtual consultation with a licensed medical professional, and the product page prices that appointment at $45, paid once, for the doctor's prescription. Nothing on the site names the clinicians or says which credential the person on the call holds. After the consultation the plan runs as recurring shipments with follow-up from what the seller calls a full nursing team, reachable by email at any hour and by phone from Monday to Saturday. The homepage adds a free one-on-one session with a dietitian who writes a meal plan, and the FAQ says refills are processed automatically on the treatment plan's schedule. 2. ## What happens when the dose goes up? The price here follows the dose in bands rather than holding flat: the Quick Drop card covers doses up to 1 mg at $179, and the Shrink and Wink card covers doses up to 2.5 mg at $299. A patient escalating past 1 mg should expect to move to the second card, and the page does not describe how that step is decided beyond the prescriber's instructions. 3. ## What the price includes Read at the product page's own word, each fill up to 1 mg is $179 plus $29 shipping, or $208, and the first one also carries the $45 appointment. The homepage card for the same product promises free shipping, no hidden fees and no contracts, so which shipping terms apply is worth confirming before checkout. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded and blended with cyanocobalamin by a pharmacy the site does not name. The seller's own FAQ says these medications are not FDA-approved, and the FDA does not review compounded preparations before they are dispensed. ## Where it holds up, and where it does not - Strength: Both dose bands priced on the product page - Strength: Live consultation before the first prescription - Strength: Free dietitian consultation included - Strength: No contract or membership required - Limitation: Shipping charge conflicts with the homepage - Limitation: The price rises past 1 mg - Limitation: Compounding pharmacy is not named - Limitation: No state coverage list is published ## What the evidence says about this kind of treatment The assessment above is about ShapeIn Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a live consultation before the first prescription and a dose-banded price printed in advance. Wrong for A reader who needs the full monthly charge settled before checkout, given the conflicting shipping terms. ## The evidence behind what ShapeIn Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How ShapeIn Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sumbare Wellness](https://thisglp.com/reviews/sumbare-wellness) [Sunlight](https://thisglp.com/reviews/sunlight) [Superior Remedies](https://thisglp.com/reviews/superior-remedies) [Superpower](https://thisglp.com/reviews/superpower-health) [SurpassMD](https://thisglp.com/reviews/surpassmd) [SynergenX Health](https://thisglp.com/reviews/synergenx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the first month cost? The product page lists $179 for doses up to 1 mg, plus a one-time $45 appointment for the doctor's prescription and $29 shipping, although the homepage card describes shipping as free. Does the price change with the dose? Yes, by band: doses up to 1 mg are $179 and doses up to 2.5 mg are $299, according to the two cards on the product page. Which states are served? The FAQ says most US states and that eligibility is confirmed during the consultation, and no list of states is published. Is ShapeIn Rx expensive compared with other GLP-1 telehealth sellers? ShapeIn Rx publishes a starting figure of $208/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ShapeIn Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Shapely reviews (2026): GLP-1 telehealth sellers | This GLP The membership and the medication are two separate charges, and the site says so. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/shapely Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Insurance first, four states # Shapely review The membership and the medication are two separate charges, and the site says so. ## The verdict Shapely is an insurance-navigation service before it is a compounded GLP-1 seller. Its self-pay membership is $99 a month, and the panel listing what that membership covers also lists what it does not: medications and labs. A buyer paying cash for compounded semaglutide pays the medication rate and the membership, not one or the other. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 4 From From $198/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Extra cost Availability 4 states Shapely is a telehealth weight-loss practice in network with Medicare and major PPO plans. Its catalog leads with brand GLP-1s marked insurance-accepted, and lists compounded semaglutide and tirzepatide as cash-pay only. Video visits with a provider and a registered dietitian are the core of the service. Eligibility is stated for adults in four states. 1. ## Who writes the prescription, and what do they see? Care is delivered over video with an assigned provider, not through a questionnaire alone, and a dietitian visit is described monthly. The site states a provider may determine a compounded medication is clinically appropriate, which places the compounded route as a fallback rather than the default. Recent labs are strongly recommended but not required before starting most medications. Members get monthly video visits, unlimited chat, and a cellular scale that reports weight automatically, though the scale is excluded on two named insurers. Coverage is verified before any plan is chosen. Concierge support for locating medication at local pharmacies is stated to be part of the membership. Labs are offered at a flat rate for the uninsured. 2. ## What happens when the dose goes up? Compounded pricing is described as tiered by dose, with named ranges for low-mid and high doses. That is unusual disclosure, and it also means the medication charge rises as the dose climbs. Nothing states who signs off each step. No milligram figure appears beside any tier. 3. ## What the price includes Compounded semaglutide is $99 a month on both its starter and refill packages, billed $297 a quarter. Tirzepatide is $199 a month on the refill package, billed $597, after a $166 starter package; the high-dose package is $279. The membership is $99 a month, discounted for a first month, and is charged whether or not a plan covers the medication. Insurance copays for brand medications are described as typically $25, depending on the plan. Labs are $75 without insurance. 4. ## What it claims, and what it cites Brand [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review), Wegovy, [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), Mounjaro, Contrave and an orforglipron tablet are listed alongside the compounded lines. The compounded preparations come from a state-licensed pharmacy and are not FDA-approved. Shapely states it is not affiliated with either manufacturer's own patient program, while helping members reach them. ## Where it holds up, and where it does not - Strength: In network with Medicare and major PPO plans - Strength: Video visits with a provider and a dietitian - Strength: Brand and compounded routes sit side by side - Strength: Dose tiers are described rather than hidden - Strength: Lab cost is published for the uninsured - Limitation: Eligibility is limited to four states - Limitation: The membership excludes the medication - Limitation: Medication is billed three months at a time - Limitation: The medication charge rises with the dose - Limitation: Testimonials are compensated for usage rights ## What the evidence says about this kind of treatment The assessment above is about Shapely. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An insured buyer in one of its four states who wants coverage checked before paying cash. Wrong for A cash-pay buyer expecting the advertised medication rate to be the whole bill. ## The evidence behind what Shapely prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Shapely compares | Seller | Who it suits | Go | | --- | --- | --- | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SynergenX Health](https://thisglp.com/reviews/synergenx) [Synergy Rx](https://thisglp.com/reviews/synergy-rx) [T2D.com](https://thisglp.com/reviews/t2d) [TD Tele-Doc Weight Loss](https://thisglp.com/reviews/td-teledoc) [TeleCareSpot](https://thisglp.com/reviews/telecarespot) [TeleClinic](https://thisglp.com/reviews/teleclinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the $99 membership include medication? No. Shapely's own panel lists medications and labs among the things a membership does not include, so the two are billed separately. Which states does Shapely serve? Its eligibility answer names four: California, Florida, New York and Texas. The rest are described as coming. Is compounded the default here? No. Insurance-covered brand medication is the first route, and the site describes compounded as what a provider may determine is appropriate instead. Is Shapely legit? Shapely is a GLP-1 telehealth sellers service. Its stated availability: 4 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Shapely expensive compared with other GLP-1 telehealth sellers? Shapely publishes a starting figure of $198/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Shapely above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ShedRx reviews (2026): GLP-1 telehealth sellers | This GLP The same page quotes the medication at $149 and at $349-499, and the membership at $99 and at $125, without ever reconciling either pair. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/shedrx Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One page, two answers, twice # ShedRx review The same page quotes the medication at $149 and at $349-499, and the membership at $99 and at $125, without ever reconciling either pair. ## The verdict ShedRx publishes $149 for an oral line plus a membership its own page states as both $99 and $125 a month, which makes the all-in $274 on the higher of the two. Its microdose injections open at $149 and $199 and carry a stated two-month minimum. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Orforglipron · Semaglutide · Tirzepatide Form Injection · Oral Injection From $149/mo Oral From $274/mo Prescription Required Compounded Yes — not FDA-approved ShedRx routes some buyers to a manufacturer pharmacy and charges a membership alongside, sells its own compounded microdose injections of both molecules, and has added an orforglipron tablet — three quite different purchases sitting behind one storefront. 1. ## Who writes the prescription, and what do they see? The membership is described as covering a provider fee, so the clinical relationship is priced separately from the medicine, and on the manufacturer-pharmacy route the medication is paid to a third party rather than to ShedRx at all. A storefront that cannot state its own membership fee consistently on a single page is not a storefront a reader should assume has settled anything else, and the inconsistency is the most important fact recorded about it. 2. ## What happens when the dose goes up? The microdose lines sit below the doses the trials ran at and are described as microdose rather than by milligram, so a reader cannot tell where on the approved ladder either product sits. 3. ## What the price includes On the oral route, $149 paid to the dispensing pharmacy plus the $125 membership comes to $274 a month, or $1,644 over six. The same arithmetic applies to the new orforglipron tablet at the same two figures. The compounded microdose injections are $149 for semaglutide and $199 for tirzepatide, each committing a buyer to at least two months, and the hero's $349-499 medication range would put the all-in far above any of it. 4. ## What it claims, and what it cites The microdose lines are compounded and the manufacturer-pharmacy route is not, which puts two regulatory situations inside one catalog: a compounded preparation is not FDA-reviewed before dispensing, while the manufacturer's own pharmacy supplies the tested article. ## Where it holds up, and where it does not - Strength: Both a manufactured route and a compounded one are offered - Strength: The membership is disclosed rather than buried - Strength: An orforglipron tablet is priced openly - Strength: Cash-pay figures are published for new patients - Limitation: The membership is quoted at $99 and at $125 on one page - Limitation: The medication is quoted at $149 and at $349-499 on that same page - Limitation: Both microdose lines require a two-month minimum - Limitation: No milligram is published for either microdose product ## What the evidence says about this kind of treatment The assessment above is about ShedRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to telephone a seller and ask which of its two published membership fees is the real one. Wrong for A reader who needs one settled figure before enrolling, or who cannot commit two months at the outset. ## The evidence behind what ShedRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How ShedRx compares | Seller | Who it suits | Go | | --- | --- | --- | | TelePeptide | Readers who want the whole commitment ladder priced in advance | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | | TrimRx | Readers who already know which molecule they want and will hunt for which tile holds it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TeleClinic](https://thisglp.com/reviews/teleclinic) [TeleDocs360](https://thisglp.com/reviews/teledocs360) [TeleHealth Med](https://thisglp.com/reviews/telehealth-med) [TeleHealth Weight Solutions](https://thisglp.com/reviews/telehealth-weight-solutions) [TeleSlim Clinic](https://thisglp.com/reviews/teleslim-clinic) [TeleZen MD](https://thisglp.com/reviews/telezen-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the membership cost? The page states $99 in one place and $125 in another. This site uses $125 in its all-in arithmetic, because choosing the lower figure would be resolving the seller's own contradiction in the seller's favor. Can I cancel after a month? Not on the microdose lines. Both state a two-month minimum, so neither is the cancel-anytime monthly rate the figure resembles. What is the all-in on the oral route? $274 a month — $149 paid to the dispensing pharmacy plus the $125 membership — assuming the higher of the two membership figures is the operative one. Is ShedRx expensive compared with other GLP-1 telehealth sellers? ShedRx publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ShedRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Signos reviews (2026): GLP-1 telehealth sellers | This GLP A compounded GLP-1 comes bundled with a glucose sensor, sold only on three- or six-month terms. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/signos Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 GLP-1 with a glucose sensor # Signos review A compounded GLP-1 comes bundled with a glucose sensor, sold only on three- or six-month terms. ## The verdict Signos+ starts at $199 a month for compounded semaglutide or tirzepatide bundled with a glucose sensor and app. It is sold only on three- or six-month terms that renew automatically. Which of the two terms carries the $199 figure is not stated. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability US except LA Signos is a glucose-monitoring company whose app reads data from a wearable sensor. Signos+ adds a compounded GLP-1 prescription to that sensor and app. The 12-week plan includes two 15-day Stelo sensors, and the 24-week plan includes four. Medication for either plan ships once a month. 1. ## Who writes the prescription, and what do they see? Signos does not prescribe; clinicians from OpenLoop Health and other independent networks do. Those clinicians review the intake and choose both the drug and the dose. Residents of seven states and the District of Columbia, including Arkansas and West Virginia, must complete a video visit. The support page adds that updated lab work may be required before prescribing. Registered dietitians employed by Signos provide nutrition support inside the app. Clinical check-ins come from the prescribing network rather than from Signos staff. A refill may need a short clinician check-in before it ships. Signos states that a refill missed because a check-in was incomplete is not refunded. 2. ## What happens when the dose goes up? The prescribing clinician sets the starting dose during the medical intake. Signos publishes no dose schedule and does not say whether the price changes as the dose rises. The sensor's labeling says its readings are not a basis for medication changes without a clinician. 3. ## What the price includes The landing page prints $199 a month beside the words three- or six-month program. No month-to-month option appears anywhere in the Signos+ offer. All plans auto-renew, and canceling stops the next renewal without ending the current term. A full refund is issued if the member is found ineligible for the program. 4. ## What it claims, and what it cites All Signos+ medications are compounded, according to the seller's own program page. Compounded drugs are not FDA-approved, and the FDA does not review them before dispensing. The dispensing pharmacy is not named. Signos+ is not offered in Louisiana because of state rules on compounded medication. ## Where it holds up, and where it does not - Strength: Glucose sensor included in the monthly figure - Strength: Prescribing network is named - Strength: Full refund if found ineligible - Limitation: Three- or six-month term required - Limitation: Price by term is not published - Limitation: Refills missed over a check-in not refunded - Limitation: Not available in Louisiana ## What the evidence says about this kind of treatment The assessment above is about Signos. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants glucose data alongside a GLP-1 and can commit to three months. Wrong for A reader who wants to buy one month at a time. ## The evidence behind what Signos prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Signos compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Telos Rx](https://thisglp.com/reviews/telos-rx) [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) [The Edit](https://thisglp.com/reviews/the-edit) [The Virtual NP](https://thisglp.com/reviews/the-virtual-np) [TMates](https://thisglp.com/reviews/tmates) [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 a month-to-month price? No. It is a monthly rate on a three- or six-month term, and the page does not say which of the two terms it applies to. Who prescribes? Clinicians from OpenLoop Health and other independent networks write the prescriptions. Signos itself does not practice medicine or employ prescribers. Which states are covered? Signos+ covers 49 states and the District of Columbia. Louisiana is excluded, and seven states plus the District of Columbia require a video visit during the intake. Is Signos legit? Signos is a GLP-1 telehealth sellers service. Its stated availability: US except LA. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Signos expensive compared with other GLP-1 telehealth sellers? Signos publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Signos above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Silhouette MD reviews (2026): GLP-1 telehealth sellers | This GLP Both injections are advertised as a lowest tier. Both tablets cost substantially more and carry no such qualifier. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/silhouette-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Tablets cost far more # Silhouette MD review Both injections are advertised as a lowest tier. Both tablets cost substantially more and carry no such qualifier. ## The verdict Silhouette MD publishes as low as $149 a month for injected semaglutide and $299 for tirzepatide. The tablets are $263 and $325. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $149/mo Oral From $263/mo Prescription Required Compounded Yes — not FDA-approved Silhouette MD sells both molecules as an injection and as an oral. Four lines carry a figure. Only the injections are qualified. 1. ## Who writes the prescription, and what do they see? A prescription is issued before dispensing. Nothing describes who writes it or how often a case is reviewed. The gap between the two routes is the useful fact. A reader choosing the tablet pays a premium of $114 or $26 depending on molecule. 2. ## What happens when the dose goes up? Nothing published says what either injection becomes at a higher dose. The as-low-as wording implies movement without naming it. 3. ## What the price includes Six months at $149 is $894 at best, and at $299 is $1,794. The tablets are $1,578 and $1,950 over the same period, and neither carries a lowest-tier caveat. 4. ## What it claims, and what it cites Every line is compounded. A pharmacy prepares them. The FDA reviews none of them before they are dispensed. ## Where it holds up, and where it does not - Strength: Four lines all carry a figure - Strength: Tablet prices are unqualified - Strength: Both molecules in both routes - Limitation: Both injection figures are a floor - Limitation: The semaglutide tablet costs $114 more - Limitation: No milligram published anywhere - Limitation: The states served are not listed ## What the evidence says about this kind of treatment The assessment above is about Silhouette MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants an unqualified number and will pay the tablet premium to get one. Wrong for A reader assuming the tablet is the economical choice. ## The evidence behind what Silhouette MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Silhouette MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Somi Health | Readers who want the dose question answered in writing before anything else | | | Pepton Health | Readers who will create an account before deciding anything | | | Auren Rx | Readers who want a cancel-anytime subscription with the no-commitment rate printed beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) [Tonik Wellness](https://thisglp.com/reviews/tonik-wellness) [Transparent Meds](https://thisglp.com/reviews/transparent-meds) [Trava Health](https://thisglp.com/reviews/trava-health) [Trellis Vitality](https://thisglp.com/reviews/trellis-vitality) [Trillium Meds](https://thisglp.com/reviews/trillium-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why are the tablets dearer? The page does not say. It prices them higher and qualifies only the injections. Is $149 a real rate? It is the lowest advertised tier. What sits above it is unpublished. What does six tablet months cost? $1,578 for semaglutide and $1,950 for tirzepatide. Is Silhouette MD expensive compared with other GLP-1 telehealth sellers? Silhouette MD publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Silhouette MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Sipra reviews (2026): GLP-1 telehealth sellers | This GLP Sipra publishes the ingredients and formats in its compounded weight-loss range and describes ongoing side-effect support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/sipra Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Injection additives and oral formats disclosed # Sipra review Sipra publishes the ingredients and formats in its compounded weight-loss range and describes ongoing side-effect support. ## The verdict Sipra explains its formulations and ongoing support more clearly than a single generic GLP-1 label, while individual follow-up details still need confirming. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Sipra is an online platform offering compounded weight-management prescriptions alongside other care categories. Its weight-loss page names semaglutide and tirzepatide injections and dissolving oral products. 1. ## Who writes the prescription, and what do they see? A licensed U.S. physician reviews the online information and decides whether to prescribe. The platform describes physician visits and follow-ups, but the treating clinician and specific dispensing pharmacy need confirming for an individual order. Sipra describes regular check-ins, on-demand medical support, help with side effects and dose adjustments. It does not establish a fixed appointment frequency for every patient. Ask how the monitoring plan changes once a dose is stable. 2. ## What happens when the dose goes up? Doses are adjusted as treatment progresses under the clinician’s direction. Oral and injected preparations should not share an assumed dose schedule. Establish which symptoms warrant contacting the provider before the next shipment. 3. ## What the price includes The page lists different starting figures for injections and oral preparations. Those labels do not establish the selected ongoing plan total. Cancellation is online, but Sipra says canceling does not stop an order already sent to the pharmacy. 4. ## What it claims, and what it cites The injection listings include B12, while the [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) oral listing includes B6. The compounded treatments are not FDA-approved. Confirm the actual ingredient combination and route rather than comparing all formats as the same medicine. ## Where it holds up, and where it does not - Strength: Injection additives and oral formats disclosed - Strength: Provider follow-ups and side-effect support described - Strength: Online cancellation is available - Limitation: Starting figures are not a complete ongoing quote - Limitation: Assigned pharmacy needs confirming - Limitation: Pharmacy orders cannot simply be reversed by canceling ## What the evidence says about this kind of treatment The assessment above is about Sipra. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants a provider-guided comparison of compounded formats and can clarify the monitoring plan. Wrong for Someone who expects an account cancellation to reverse a prescription already sent to the pharmacy. ## The evidence behind what Sipra prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Sipra compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Trimi Health](https://thisglp.com/reviews/trimi-health) [TrimRx](https://thisglp.com/reviews/trimrx) [Trinity Meds](https://thisglp.com/reviews/trinity-meds) [TRT Nation](https://thisglp.com/reviews/trt-nation) [Tru2u](https://thisglp.com/reviews/tru2u) [TrueMe](https://thisglp.com/reviews/trueme) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Sipra describes regular check-ins, on-demand medical support, help with side effects and dose adjustments. It does not establish a fixed appointment frequency for every patient. Ask how the monitoring plan changes once a dose is stable. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-loss care, formats and billing](https://www.sipra.com/weight-loss) - [Semaglutide program](https://www.sipra.com/medications/semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # SkinnyRx reviews (2026): GLP-1 telehealth sellers | This GLP The semaglutide injection publishes an opening month and no standing rate anywhere, while tirzepatide publishes a standing rate after its first month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/skinnyrx Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A first month, and no second # SkinnyRx review The semaglutide injection publishes an opening month and no standing rate anywhere, while tirzepatide publishes a standing rate after its first month. ## The verdict SkinnyRx advertises $99 for a first month of injected semaglutide and $149 for a first month of the tablet, and publishes no standing rate for either. Tirzepatide is $299 a month after a $99 first month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral From From $299/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states claimed, branded availability may differ from compounded SkinnyRx sells both molecules by injection and semaglutide as a once-daily tablet, with a microdose option and free overnight shipping described. This site publishes no semaglutide figure for either form. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe promotions and shipping rather than the clinician or the review schedule. Advertising a first month without a second is the structural problem. A reader cannot total a course, and the standard single-month rate is described as not published before intake. 2. ## What happens when the dose goes up? Nothing published states what any figure does at a higher dose. On both semaglutide lines the more basic question is unanswered first: what month two costs. 3. ## What the price includes Six months of tirzepatide at $299 is $1,794. For either semaglutide form there is nothing to total, because the figure after the opening month does not appear on any rendered page. 4. ## What it claims, and what it cites The lines are compounded. A pharmacy prepares them to order, and the FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: Free overnight shipping described - Strength: A microdose option is offered - Strength: Tirzepatide carries a standing monthly rate - Limitation: No standing semaglutide rate is published - Limitation: The first month is not the rate - Limitation: The tablet shows a first month only - Limitation: The states served are not recorded ## What the evidence says about this kind of treatment The assessment above is about SkinnyRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a cheap first month and will ask what follows it in writing. Wrong for A reader who needs the second month priced before paying for the first. ## The evidence behind what SkinnyRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How SkinnyRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Nolu | Readers who count cycles rather than months and want a flat rate at any dose | | | Try Ageless | Readers willing to price the same product twice before buying it once | | | MedLeanRx | Readers who happen to live where this seller operates | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TRYM Health](https://thisglp.com/reviews/trym-health) [Tryozi](https://thisglp.com/reviews/tryozi) [Tuyo Health](https://thisglp.com/reviews/tuyo-health) [Tyde Wellness](https://thisglp.com/reviews/tyde-wellness) [UR Meds](https://thisglp.com/reviews/ur-meds) [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) Sponsored alternative ShedRx Readers willing to telephone a seller and ask which published fee is the real one ## Frequently asked What does the injection cost after month one? This site publishes no figure. No standing rate appears on any rendered page. What does tirzepatide cost after the first month? $299 a month on the one-month plan. The preselected six-month plan is $250 a month. What does the tablet cost? The page shows $149 for a first month and nothing after it, so this site publishes no figure. Is SkinnyRx expensive compared with other GLP-1 telehealth sellers? SkinnyRx publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts SkinnyRx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # SkyRx reviews (2026): GLP-1 telehealth sellers | This GLP The asterisk on $199 resolves at the foot of the page, among the citations. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/skyrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A year, priced as a month # SkyRx review The asterisk on $199 resolves at the foot of the page, among the citations. ## The verdict SkyRx advertises $199 a month and prints "No Hidden Fees. No Monthly Memberships. Cancel Anytime." beneath it. The asterisk resolves at the very bottom of the page, inside the reference list. The rate requires a twelve-month subscription paid upfront in full. That is $2,388 in one charge, and no month-to-month price is published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Flat across doses Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named SkyRx is a cash-pay telehealth storefront selling compounded semaglutide in two formats: a weekly injection and oral drops. Both are listed at the same rate. Generic ED products and NAD+ sit in a separate catalog. A Utah address and a support number are published. 1. ## Who writes the prescription, and what do they see? The site describes a quiz that returns instant pre-approval, followed by a free consultation with the team. Its own FAQ says a doctor approves the prescription before a pharmacy ships. No provider, medical group or supervising clinician is named. What a prescriber reads before approving is not described anywhere. One monthly figure is stated to cover the medication, supplies, the doctor visit and shipping. A money-back weight guarantee is offered subject to terms. Dosage is listed among the FAQ headings. The pharmacy is described only as U.S.-based compounding. 2. ## What happens when the dose goes up? No dose ladder is published, and no milligram figure appears beside the price. An FAQ heading asks what dosage a patient will take, which is where any answer would sit. Nothing on the page states whether the rate moves as the dose climbs. The starting dose is not named. 3. ## What the price includes One figure carries the whole catalog: $199 a month for the injection and $199 for the oral drops. The footnote fixing that figure to a twelve-month prepay sits among eight research citations, far below the price. A buyer unwilling to commit a year has no published rate to read. The total charge, $2,388, is not printed anywhere on the page. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded rather than manufactured, and the page states that compounded semaglutide is not approved or evaluated by the FDA. No compounding pharmacy is named. Tirzepatide appears only inside a citation title, not as a product. ## Where it holds up, and where it does not - Strength: One rate covers medication, visit and shipping - Strength: A weight guarantee is offered, subject to terms - Strength: Injection and oral drops cost the same - Strength: The compounding disclaimer is stated plainly - Limitation: The prepay condition sits among the citations - Limitation: No monthly rate appears on the page - Limitation: $2,388 is charged in a single payment - Limitation: No milligram dose appears on the page - Limitation: No prescriber or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about SkyRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer ready to prepay a year and wanting one figure to cover everything. Wrong for A buyer who wants to try a month before committing. ## The evidence behind what SkyRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How SkyRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vaylen](https://thisglp.com/reviews/vaylen) [Velvet Rx](https://thisglp.com/reviews/velvet-rx) [VevaRX](https://thisglp.com/reviews/vevarx) [VigorMeds](https://thisglp.com/reviews/vigormeds) [VirtualCare2Go](https://thisglp.com/reviews/virtualcare2go) [Vita Bella](https://thisglp.com/reviews/vita-bella) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can semaglutide be bought monthly here? No published rate covers it. The only figure on the page is fixed by its footnote to a twelve-month subscription paid upfront. What does the $199 actually buy? One month of a twelve-month plan. Paid upfront in full, that plan is $2,388, a total the page does not print. Do the oral drops cost less? No. SkyRx lists the injection and the oral drops at the same rate, both with the same footnote attached. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # SnagRx reviews (2026): GLP-1 sellers by price | This GLP Four billing cycles are published on each molecule, and the gap between the shortest and the longest is only thirty dollars a month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/snagrx Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A year buys thirty dollars # SnagRx review Four billing cycles are published on each molecule, and the gap between the shortest and the longest is only thirty dollars a month. ## The verdict SnagRx publishes compounded semaglutide at $99, $89, $79 and $69 a month across one, three, six and twelve-month cycles. Tirzepatide runs $149, $139, $129 and $119. Every rung holds at every dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 sellers by price Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $99/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states claimed, except Louisiana; Nebraska limited SnagRx sells both molecules by injection. There is no oral line. The whole ladder is published on the product page rather than revealed at checkout. 1. ## Who writes the prescription, and what do they see? A prescription is required before dispensing. The pages describe the plans rather than the clinician. Nothing states who writes it, or what the intake covers. A prescription is required before anything ships. The pricing page is the strong part of this seller: four terms, two molecules, and a stated flat rate at every dose on all eight combinations. 2. ## What happens when the dose goes up? Every rung is stated to hold at every dose, on both molecules. That covers all eight price-and-term combinations, so escalating through the first four months changes nothing about the bill. 3. ## What the price includes The one-month rate is $99 and $149, and those are the figures to budget from. Committing a full year takes $30 off each, reaching $69 and $119. That is a thinner reward for a year than most sellers offer, so the flexible rung costs little to keep. Six months at the one-month rate is $594 and $894. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. A pharmacy prepares them to order, and the FDA does not review a compounded preparation before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The whole ladder is published, not revealed at checkout - Strength: Flat at every dose on all eight combinations - Strength: Staying flexible costs only $30 a month - Limitation: A year of commitment buys very little - Limitation: Struck-through anchors nobody is charged - Limitation: No refund terms published - Limitation: No pharmacy named and no state list recorded ## What the evidence says about this kind of treatment The assessment above is about SnagRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to stay month to month without paying much for it. Wrong for A buyer hunting the steepest annual discount. ## The evidence behind what SnagRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How SnagRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | | EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 sellers by price reviews: [PeterMD](https://thisglp.com/reviews/petermd) [RxSpan MD](https://thisglp.com/reviews/rxspan-md) [Sesame Care](https://thisglp.com/reviews/sesame-care) [ShedRx](https://thisglp.com/reviews/shedrx) [SkinnyRx](https://thisglp.com/reviews/skinnyrx) [Sprout Health](https://thisglp.com/reviews/sprout-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost without committing? $99 for compounded semaglutide and $149 for tirzepatide, and both hold at every dose. Is the annual plan worth it? It saves $30 a month on either molecule. That is a smaller gap than most sellers offer for a year, so the flexibility is cheap to keep. What are the struck-through figures? $299 and $399 appear crossed out on the homepage. Nothing indicates either is a rate anyone is charged. Is SnagRx expensive compared with other GLP-1 sellers by price? SnagRx publishes a starting figure of $99/mo. Across the 402 GLP-1 sellers by price we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts SnagRx below the median, toward the cheaper end. The other 178 GLP-1 sellers by price we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller by price](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Society of You reviews (2026): GLP-1 telehealth sellers | This GLP Both injection cards lead with a first-month figure, and the standing rate is shown only after contact details are entered. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/society-of-you Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 First months only, rate behind the intake # Society of You review Both injection cards lead with a first-month figure, and the standing rate is shown only after contact details are entered. ## The verdict Society of You shows $149 and $249 as first-month figures for injected semaglutide and tirzepatide. The standing rate is not published before the intake. This site ranks no price for either line. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Society of You sells compounded semaglutide and compounded tirzepatide, both as weekly injections. Its one oral card is metformin, which is not a GLP-1. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages price products rather than describing the clinician behind them. The intake's first step asks for a name, email and phone number. The monthly rate comes after that step. The refund policy refers to introductory pricing. 2. ## What happens when the dose goes up? Nothing published says what either line does at a higher dose. No milligram appears on any card. 3. ## What the price includes A first-month figure is not a price. This site ranks a seller on the rate a buyer pays from month two. That rate is not shown before the intake, so both rows carry no figure. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them, and no agency reviews a compounded preparation before dispensing. ## Where it holds up, and where it does not - Strength: Semaglutide and tirzepatide from one seller - Strength: Both are weekly injections - Strength: The first-month figures are shown on the cards - Limitation: No standing rate is published - Limitation: Contact details come before the monthly price - Limitation: No milligram appears on any line - Limitation: Nothing lists the states served ## What the evidence says about this kind of treatment The assessment above is about Society of You. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to enter contact details before seeing the monthly rate. Wrong for A reader budgeting past month one from the opening figure. ## The evidence behind what Society of You prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Society of You compares | Seller | Who it suits | Go | | --- | --- | --- | | Bioverse | Readers who want semaglutide cheaply and ignore the struck figure beside it | | | Bionomy Health | Readers who want to be able to stop by doing nothing | | | Bodi Envi | Patients who value named care partners and can monitor refill notices | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [VitaFusions IV](https://thisglp.com/reviews/vitafusions-iv) [Vital Edge](https://thisglp.com/reviews/vital-edge) [Vitalex Health](https://thisglp.com/reviews/vitalex-health) [Vitara RX](https://thisglp.com/reviews/vitara-rx) [VitaStir](https://thisglp.com/reviews/vitastir) [Voxy](https://thisglp.com/reviews/voxy) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a tirzepatide tablet? No. Tirzepatide is sold by injection only, and the one oral card is not a GLP-1. What does month two cost? The site does not say before the intake. The $149 and $249 on the cards are first months. Why does this site show no price? It ranks the rate a buyer pays after month one. Society of You does not publish that rate before collecting contact details. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Somi Health reviews (2026): GLP-1 telehealth sellers | This GLP The seller states the flat-dose claim in its own capital letters, and prices its tablet at more than double the shot. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/somi-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 ANY DOSE, in capitals # Somi Health review The seller states the flat-dose claim in its own capital letters, and prices its tablet at more than double the shot. ## The verdict Somi Health publishes $135 a month for injected semaglutide on a three-month plan and $165 for tirzepatide. Both cards say ANY DOSE. The tablet is $279. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $135/mo Oral From $279/mo Prescription Required Compounded Yes — not FDA-approved Somi Health sells both molecules by injection and semaglutide as a tablet. The injections are priced by plan length. The tablet has one published plan. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages price plans rather than describe care. No clinician is named. Stating the dose claim in capitals is unusual and useful. It leaves no room to argue the figure was a starting rate. 2. ## What happens when the dose goes up? ANY DOSE is the whole answer, given plainly on both injection cards. Nothing states what the tablet does at a higher strength. 3. ## What the price includes Six months of injected semaglutide is $810 and tirzepatide $990, on the three-month plans. The tablet costs $279 a month, which is more than double the injection it replaces. Only the one-month tablet plan is published. 4. ## What it claims, and what it cites All three lines are compounded. A pharmacy makes them to order. No agency reviews them before they ship. ## Where it holds up, and where it does not - Strength: The flat-dose claim is stated emphatically - Strength: Both injections priced by plan length - Strength: A tablet route exists and is priced - Limitation: The tablet costs more than double the shot - Limitation: Only one tablet plan is published - Limitation: No milligram appears on any card - Limitation: Nothing lists the states served ## What the evidence says about this kind of treatment The assessment above is about Somi Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the dose question answered in writing before anything else. Wrong for A reader hoping the tablet is the cheaper way in here. ## The evidence behind what Somi Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Somi Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Silhouette MD | Readers who want an unqualified number and will pay the tablet premium for one | | | Auren Rx | Readers who want a cancel-anytime subscription with the no-commitment rate printed beside it | | | Pepton Health | Readers who will create an account before deciding anything | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Voxy](https://thisglp.com/reviews/voxy) [Vyora Wellness](https://thisglp.com/reviews/vyora-wellness) [VyrarX](https://thisglp.com/reviews/vyrarx) [Vytora Health](https://thisglp.com/reviews/vytora-health) [Walgreens Weight Management](https://thisglp.com/reviews/walgreens-weight-management) [WeightCare](https://thisglp.com/reviews/weightcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change with the dose? No. Both injection cards say ANY DOSE, in the seller's own capitals. What does the tablet cost? $279 a month, on the only tablet plan published. What does six months come to? $810 for semaglutide and $990 for tirzepatide on the three-month plans. Is Somi Health expensive compared with other GLP-1 telehealth sellers? Somi Health publishes a starting figure of $135/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Somi Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Somira Health reviews (2026): GLP-1 telehealth sellers | This GLP The price is stated as locked while the dose rises, on both plan lengths. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/somira-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Locked as you titrate # Somira Health review The price is stated as locked while the dose rises, on both plan lengths. ## The verdict Somira Health publishes $139.99 a month for compounded semaglutide and $159.99 for tirzepatide. Each renews at the same figure every month. The price is stated as locked during titration. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $139.99/mo Prescription Required Compounded Yes — not FDA-approved Somira Health sells both molecules by injection. Two billing options exist. The quarterly plan is billed as a single total. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state plans and totals. The clinician is not described. The titration guarantee is the claim to hold them to. It applies to both plan lengths and it is stated rather than implied. 2. ## What happens when the dose goes up? Price locked as you titrate is the seller's own wording. That answers the dose question directly. Nothing describes clinical support at a step. 3. ## What the price includes Six months month to month is $839.94 on semaglutide and $959.94 on tirzepatide. A quarterly plan bills in one charge at a lower monthly equivalent. The configurator shows its total before checkout. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Price stated as locked during titration - Strength: Quarterly totals published, not just rates - Strength: The pharmacy is named on the plan card - Limitation: The quarterly plan bills in one charge - Limitation: No milligram dose published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Somira Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the rate pinned across an escalation. Wrong for A reader who needs a monthly charge rather than a quarterly one. ## The evidence behind what Somira Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Somira Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | | SurpassMD | Readers who will ask what their own approved figure is | | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [WeightRx](https://thisglp.com/reviews/weightrx) [WeightWatchers Clinic](https://thisglp.com/reviews/weight-watchers) [Welling Health](https://thisglp.com/reviews/welling-health) [Wellspring Longevity Clinic](https://thisglp.com/reviews/wellspring-longevity-clinic) [WePeptideRx](https://thisglp.com/reviews/wepeptiderx) [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with the dose? No. The seller states the price is locked as you titrate. What does the quarterly plan cost? It bills once a quarter, below the monthly rate. The configurator shows the total before checkout. What does tirzepatide cost? $159.99 a month, renewing at the same figure each month. Is Somira Health expensive compared with other GLP-1 telehealth sellers? Somira Health publishes a starting figure of $139.99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Somira Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Sommar Club reviews (2026): GLP-1 telehealth sellers | This GLP Sommar markets online compounded care for women. Confirm the clinical follow-up and dispensing pharmacy for the chosen program. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/sommar-club Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Compounded ingredients identified # Sommar Club review Sommar markets online compounded care for women. Confirm the clinical follow-up and dispensing pharmacy for the chosen program. ## The verdict Sommar’s women-focused program may be convenient, but the treating relationship matters more than the audience-specific presentation. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Sommar Club markets online compounded weight-loss care for women. Its treatment pages name semaglutide and tirzepatide, with medical evaluation, medication fulfillment and support included in the program. 1. ## Who writes the prescription, and what do they see? Licensed U.S. clinicians review the assessment and decide whether prescribing is appropriate. Sommar says no payment is due unless treatment is approved. Confirm which medical practice provides the consultation and which pharmacy dispenses the chosen prescription. The program describes ongoing provider support without establishing one clinical appointment schedule for every patient. Ask whether routine contacts are clinical reviews and what to do if side effects occur before the next refill. 2. ## What happens when the dose goes up? The prescriber chooses dosing based on the patient’s response. The advertised program term should not determine how quickly a dose is increased. Confirm whether a changed prescription affects medicine already prepared. 3. ## What the price includes The offer uses a four-week equivalent while billing for a twelve-week term; a financing option is presented separately. Four-week and calendar-month figures are not the same. Check the full term payment, any financing obligation and cancellation timing rather than relying on the daily equivalent. 4. ## What it claims, and what it cites The injections are compounded prescriptions and are not FDA-approved. A program aimed at women still requires an individual clinical evaluation, including pregnancy-related plans and other medicines; the audience label does not establish suitability. ## Where it holds up, and where it does not - Strength: Compounded ingredients identified - Strength: Approval precedes payment under the public offer - Strength: Billing term is disclosed - Limitation: Headline equivalent differs from full term charge - Limitation: Financing needs separate review - Limitation: Assigned pharmacy and follow-up cadence need confirming ## What the evidence says about this kind of treatment The assessment above is about Sommar Club. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants online care and will establish a personal monitoring plan rather than rely on the program’s women-focused branding. Wrong for Someone who wants a shorter initial supply or needs to avoid committing to a twelve-week purchase. ## The evidence behind what Sommar Club prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Sommar Club compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) [Whoosh Wellness](https://thisglp.com/reviews/whoosh-wellness) [Wisp](https://thisglp.com/reviews/wisp) [Woodwork](https://thisglp.com/reviews/woodwork) [YourHealthRx](https://thisglp.com/reviews/yourhealthrx) [Yucca Health](https://thisglp.com/reviews/yucca-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The program describes ongoing provider support without establishing one clinical appointment schedule for every patient. Ask whether routine contacts are clinical reviews and what to do if side effects occur before the next refill. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Care model and full billing term](https://sommarclub.com/) - [Semaglutide program](https://sommarclub.com/semaglutide) - [Tirzepatide program](https://sommarclub.com/tirzepatide) - [Service terms](https://sommarclub.com/terms-and-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Southern Vitality and Weight Loss reviews (2026): GLP-1 telehealth sellers Every plan is a one-time package, and none of them renews on its own. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/southern-vitality-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Prepaid packages, no renewal # Southern Vitality and Weight Loss review Every plan is a one-time package, and none of them renews on its own. ## The verdict Southern Vitality sells compounded semaglutide at $199 for a one-month package. Tirzepatide is $299 for the same one-month package. Longer packages are prepaid in full and never renew. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Named LegitScript Claimed by provider Southern Vitality and Weight Loss is a clinic in Valdosta, Georgia, open since 2012. It also treats patients by telehealth from the same practice. It sells compounded semaglutide and tirzepatide as weekly injections. 1. ## Who writes the prescription, and what do they see? The medical director is Igor Ancor, MD, board-certified in internal medicine. The seller states he approves every patient plan before a prescription. The site lists his active medical licenses in 11 states. Of those 11, it names Georgia alone. The intake is an online form that a licensed provider reviews. The consultation is free, and no card is charged until approval. Check-ins run every two weeks for the length of the package. Approved orders ship cold and overnight within five to seven business days. 2. ## What happens when the dose goes up? Package prices on the page carry no dose qualifier. The seller states dosing follows physician-reviewed protocols. Its month-by-month outline has the physician adjusting the dose in month two. No separate visit is described for a step up. 3. ## What the price includes Semaglutide packages are $199 for one month, $399 for three, $534 for six and $948 for twelve. Tirzepatide packages are $299, $599, $894 and $1,440 on the same terms. A starter pack is $299 for semaglutide and $499 for tirzepatide. What the starter pack contains is not described. Shipping is free, and no membership fee applies. 4. ## What it claims, and what it cites Both drugs are compounded by partner pharmacies the site names. They are PerfectRX, The Pharmacy Hub and Rx Compounding Store. Compounded drugs are not FDA-approved, and the FDA does not review them before dispensing. ## Where it holds up, and where it does not - Strength: Every package priced with its total - Strength: No automatic renewal on any plan - Strength: Partner pharmacies named on the site - Strength: No charge before provider approval - Limitation: Sales are final once sent to the pharmacy - Limitation: Starter pack contents are not described - Limitation: No state coverage list is published ## What the evidence says about this kind of treatment The assessment above is about Southern Vitality and Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a prepaid package that ends without a cancellation step. Wrong for A reader who wants a refund option after the prescription reaches the pharmacy. ## The evidence behind what Southern Vitality and Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Southern Vitality and Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | TRYM Health | Buyers who will go looking for the plan table rather than price a program by the day | | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Zealthy](https://thisglp.com/reviews/zealthy) [Zera Health](https://thisglp.com/reviews/zera-health) [Zeuss](https://thisglp.com/reviews/zeuss) [ZipHealth](https://thisglp.com/reviews/ziphealth) [ZYP Medical](https://thisglp.com/reviews/zyp-medical) [10Rx](https://thisglp.com/reviews/10rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does a package renew? No. Every package is a one-time purchase, per the seller, with no automatic renewal. What does one month cost? $199 for semaglutide and $299 for tirzepatide, as one-time packages. When is the card charged? Only after a provider approves the plan. An optional card hold is released automatically if the plan is not approved. Is Southern Vitality and Weight Loss expensive compared with other GLP-1 telehealth sellers? Southern Vitality and Weight Loss publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Southern Vitality and Weight Loss above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Sprout Health reviews (2026): GLP-1 telehealth sellers | This GLP The monthly plan bills every four weeks and the six-month plan bills by the calendar, which are different years. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/sprout-health Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two clocks, one seller # Sprout Health review The monthly plan bills every four weeks and the six-month plan bills by the calendar, which are different years. ## The verdict Sprout Health publishes $299 a month for compounded semaglutide. That plan bills every four weeks, making it $324 a calendar month, while its six-month plan bills by the calendar at $169. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 44 From From $324/mo Prescription Required Compounded Yes — not FDA-approved Availability 44 states Sprout Health sells both molecules by injection across 44 states, running its monthly plan on a four-week cycle and its six-month plan on calendar months. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. The billing structure is where the published detail sits, and a reader has to compare two plans to notice that they are measured differently. One seller using two different definitions of a month is unusual and it makes the two plans harder to compare than the figures suggest. The monthly plan's thirteenth charge is invisible in its own price; the six-month plan has no such charge at all. 2. ## What happens when the dose goes up? Nothing is published about what either figure does at a higher dose. A checkout path also references a tirzepatide tablet, whose price is quiz-gated and therefore not published anywhere a reader can reach. 3. ## What the price includes Thirteen fills at $299 is $3,887 a year, or $324 a calendar month. The six-month semaglutide plan is $1,014 billed across calendar months, which is $169 — barely half. Tirzepatide runs the same shape: $349 on the four-week monthly plan, or $378 a calendar month, against $1,374 over six calendar months at $229. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Both plan structures are published - Strength: The six-month plan bills by the calendar - Strength: Coverage recorded across 44 states - Limitation: The monthly plan bills thirteen times a year - Limitation: The monthly plan runs on four-week fills - Limitation: An oral tirzepatide price is quiz-gated - Limitation: Six states are not served ## What the evidence says about this kind of treatment The assessment above is about Sprout Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader taking the six-month plan, which is the one measured in calendar months. Wrong for A reader comparing the monthly figure against another seller's calendar month. ## The evidence behind what Sprout Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Sprout Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Somira Health | Readers who want the pharmacy and the rate named before the intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AJ Peptide](https://thisglp.com/reviews/aj-peptide) [Ambiante Health & Wellness](https://thisglp.com/reviews/ambiante-health-wellness) [Aurelius Health Group](https://thisglp.com/reviews/aurelius-health-group) [AVArx](https://thisglp.com/reviews/avarx) [Basal Health](https://thisglp.com/reviews/basal-health) [Better MedSpa](https://thisglp.com/reviews/better-medspa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $299 a calendar month? No. The monthly plan is billed every four weeks for a four-week supply, which is thirteen charges a year, or $324 a calendar month. Does the six-month plan bill the same way? No. It is billed in calendar months, at $1,014 for six months of semaglutide, which is $169 a month. What does tirzepatide cost? $349 on the four-week monthly plan, which is $378 a calendar month, or $1,374 for six calendar months. Is Sprout Health legit? Sprout Health is a GLP-1 telehealth sellers service. Its stated availability: 44 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Sprout Health expensive compared with other GLP-1 telehealth sellers? Sprout Health publishes a starting figure of $324/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Sprout Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Spry reviews (2026): GLP-1 telehealth sellers | This GLP Two GLP-1 rates on the front page, billed on a four-week cycle the cards never mention. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/spry Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four weeks, not a month # Spry review Two GLP-1 rates on the front page, billed on a four-week cycle the cards never mention. ## The verdict Spry publishes $199 for semaglutide and $299 for tirzepatide with no contract. Its FAQ describes re-billing every four weeks, which is thirteen charges a year rather than twelve. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Spry sells five injectables from one screen: semaglutide and tirzepatide under weight loss, and BPC-157, NAD+ and sermorelin under anti-aging. Every figure is on the homepage before any intake. The catalog is small and the pages are short. 1. ## Who writes the prescription, and what do they see? A nurse practitioner reviews each file within twenty-four hours, and Spry says medication is ordered and shipped once that review approves it. Three co-founders are pictured by name. None carries a credential beside the name, and the team is described collectively as medical professionals with more than twenty years of experience. No medical director is identified. Nurses and staff are described as reaching out consistently to check on targets, with support hours of nine to five Eastern on weekdays. There are no contracts or commitment requirements. Insurance is not accepted, though Spry will supply a document for a patient to submit for reimbursement, and HSA plans often qualify. 2. ## What happens when the dose goes up? Spry says it works to titrate the dose to the level that suits the patient and that most [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) can be managed with over-the-counter medication. The billing cycle is built around the climb: a vial covers four weekly injections, then the next one ships. No milligram is published and nothing states whether the charge moves as the dose rises. 3. ## What the price includes The cards read $199 and $299. The FAQ explains what those figures buy: four weeks of medication, after which Spry re-bills and ships the next vial. Thirteen four-week cycles fall in a year, so the semaglutide rate works out at $215.58 a calendar month and tirzepatide at $323.92. That conversion is arithmetic on Spry's two published numbers, not a figure Spry prints. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded, so neither is FDA-approved and neither is reviewed by the FDA before dispensing. The compounding pharmacy is not named. Spry's FAQ also states that oral versions of these medications simply do not work as well as weekly injections, a comparative claim it attaches to no study. ## Where it holds up, and where it does not - Strength: Both GLP-1 rates on the homepage, before any intake - Strength: Review promised within twenty-four hours - Strength: No contract and no commitment requirement - Strength: Reimbursement paperwork offered for insurance claims - Limitation: The four-week cycle is in the FAQ, not on the price card - Limitation: Thirteen charges a year, not twelve - Limitation: No credential is attached to any named founder - Limitation: A comparative claim about oral GLP-1s carries no source - Limitation: No milligram and no compounding pharmacy is published ## What the evidence says about this kind of treatment The assessment above is about Spry. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who reads the billing cycle before comparing a price against a monthly one. Wrong for A buyer budgeting twelve payments a year against another seller's monthly rate. ## The evidence behind what Spry prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Spry compares | Seller | Who it suits | Go | | --- | --- | --- | | LumiMeds | Buyers who want the ingredient, route and pharmacy type labeled before they pay | | | Nova MD | Buyers who will read which plan is already selected before they press start | | | Omzo | Buyers who want the medication cost inside one fee rather than billed by a pharmacy | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [BodyLogicMD](https://thisglp.com/reviews/bodylogicmd) [Broose Wellness](https://thisglp.com/reviews/broose-wellness) [CAPO Health](https://thisglp.com/reviews/capo-health) [Chia](https://thisglp.com/reviews/chia-health) [Chronos Body Health & Wellness](https://thisglp.com/reviews/chronos-bhw) [CVS MinuteClinic](https://thisglp.com/reviews/cvs-minuteclinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 a monthly charge? No. Spry's FAQ describes four weekly injections, then a re-bill and the next vial, which is a four-week cycle. How many charges fall in a year? Thirteen, on a four-week cycle. Twelve monthly charges at $199 would be a different total. Who reviews the intake? Spry states a nurse practitioner reviews each file within twenty-four hours before medication is ordered. Is Spry expensive compared with other GLP-1 telehealth sellers? Spry publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Spry above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # StackMD reviews (2026): GLP-1 telehealth sellers | This GLP Five priced rungs on one molecule and six on the other, printed where a reader can find them before starting. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/stackmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Every rung on the page # StackMD review Five priced rungs on one molecule and six on the other, printed where a reader can find them before starting. ## The verdict StackMD publishes a per-dose ladder on both molecules: semaglutide from $125 at 1 mg to $225 at 10 mg, and tirzepatide from $199 at 5 mg to $449 at 30 mg. No membership or platform fee applies. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose States 50 From From $125/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states StackMD sells both molecules by injection across fifty states, with the price attached to the milligram rather than to a plan length, and a denial of any fee outside it. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. What the ladder does describe is the decision a clinician will make, because every rung on it has a number beside it before anyone starts. Publishing a price at every rung changes what a buyer can plan. Most sellers on this market answer the escalation question with a single word or with silence. The honest consequence of StackMD's approach is visible on its own page: a patient titrated to a high dose pays more than double the advertised starting price. 2. ## What happens when the dose goes up? This is the field StackMD answers better than almost anything a reader will meet. Semaglutide runs $125, $149, $175, $199 and $225 across 1, 2, 4, 6 and 10 mg. Tirzepatide runs $199, $249, $299, $349, $399 and $449 across 5 to 30 mg. All are 1 ml or 2 ml vials with B12 and glycine. 3. ## What the price includes Six months at the semaglutide entry rung is $750 and at the top rung $1,350. On tirzepatide the same spans are $1,194 and $2,694. The marquee reads transparent pricing with no memberships, and the product page backs it with a denial of any membership or platform fee on top. One gap remains: the injection vials state no supply duration, and only the oral tablets say thirty days. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Eleven priced dose rungs published in all - Strength: No membership or platform fee, stated - Strength: Coverage across all fifty states - Strength: Formulations described vial by vial - Limitation: The top tirzepatide rung is $449 - Limitation: The entry figure is the bottom rung only - Limitation: Injection vials state no supply duration - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about StackMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the cost of every dose stated before starting the lowest one. Wrong for A reader comparing the entry figure as though it were a rate. ## The evidence behind what StackMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How StackMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Telos Rx | Readers taking the longest plan, since no shorter term carries a published rate | | | Sprout Health | Readers taking the six-month plan, which is the one measured in calendar months | | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Defy Medical](https://thisglp.com/reviews/defy-medical) [Docberry](https://thisglp.com/reviews/docberry) [Elara MD](https://thisglp.com/reviews/elara-md) [EmbraceRX](https://thisglp.com/reviews/embrace-rx) [eMed](https://thisglp.com/reviews/emed) [Enara Health](https://thisglp.com/reviews/enara-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the price do as my dose rises? It rises with the milligram and every step is printed: semaglutide at $125, $149, $175, $199 and $225, and tirzepatide across six rungs from $199 to $449. Are there fees on top? The product page states no membership or platform fee on top, beside a marquee reading transparent pricing with no memberships. How long does a vial last? The injection vials state no supply duration. Only the oral tablets say thirty days, which leaves the billing cycle on the injections unestablished. Is StackMD legit? StackMD is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is StackMD expensive compared with other GLP-1 telehealth sellers? StackMD publishes a starting figure of $125/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts StackMD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # StaveMD reviews (2026): GLP-1 telehealth sellers | This GLP StaveMD advertises flat-dose treatment and a refund if no prescription is issued. Its introductory period and ongoing plan should be read separately. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/stavemd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A compounded GLP-1 platform with a clear distinction between free eligibility checking and paid clinical review. # Does StaveMD sell a GLP-1? StaveMD advertises flat-dose treatment and a refund if no prescription is issued. Its introductory period and ongoing plan should be read separately. ## The verdict The payment sequence and prescription-declined refund are useful disclosures. Confirm the clinician’s follow-up plan and exact formulation; a platform’s support claim is not proof of round-the-clock clinical care. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved StaveMD is a telehealth platform connecting adults with independent licensed providers and a US-licensed pharmacy. It expressly says it does not practice medicine or dispense medication. 1. ## Who writes the prescription, and what do they see? The initial eligibility check is not a medical consultation and does not guarantee a prescription. A licensed provider reviews the request after the paid checkout stage. The site advertises provider review and ongoing support. Ask who answers medication questions, how scheduled follow-up works and what response times apply to clinical messages. 2. ## What happens when the dose goes up? The semaglutide page says the price does not increase with dose. Treatment changes still depend on the clinician’s assessment, not the price structure or a desire to use a larger supply. 3. ## What the price includes The first semaglutide offer is described as a four-week introductory period, followed by a stated monthly renewal. Confirm the billing interval and renewal amount rather than treating those labels as identical. 4. ## What it claims, and what it cites Compounded semaglutide and tirzepatide are named. The semaglutide page explicitly distinguishes its compound from Ozempic and Wegovy. Compounded medicines are not FDA-approved substitutes for branded products. ## Where it holds up, and where it does not - Strength: Separates eligibility screening from prescribing - Strength: Explicitly distinguishes compounds from branded medicines - Limitation: Clinical response times need confirmation - Limitation: First-period and renewal intervals need careful reading ## What the evidence says about this kind of treatment The assessment above is about StaveMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults who want the approval and payment sequence explained before starting intake. Wrong for Anyone who assumes a free eligibility check is clinical approval or that a promotional first period is the continuing price. ## The evidence behind what StaveMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How StaveMD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Enara Health](https://thisglp.com/reviews/enara-health) [Enhanced](https://thisglp.com/reviews/enhanced) [EverFit Medical](https://thisglp.com/reviews/everfit-medical) [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) [Evernow](https://thisglp.com/reviews/evernow) [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the free check establish eligibility for a prescription? No. It is an initial screen. A licensed provider must still review the request and decide whether treatment is appropriate. Is compounded semaglutide the same as Wegovy? No. The product page expressly distinguishes its compound from branded semaglutide medicines. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://stavemd.com/) - [Official program and terms](https://stavemd.com/terms) - [Official program and terms](https://stavemd.com/semaglutide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Steady State Health reviews (2026): GLP-1 telehealth sellers | This GLP Steady State Health places GLP-1 treatment within Josie Cowburn’s women’s health practice in Oregon and Washington. Medication is billed separately from membership. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/steady-state-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named clinician, regional care # Steady State Health review Steady State Health places GLP-1 treatment within Josie Cowburn’s women’s health practice in Oregon and Washington. Medication is billed separately from membership. ## The verdict The practice provides a clearer ongoing relationship than an unnamed intake network: it identifies the clinician and monthly follow-up. The important limits are geographic access and separate charges for medication and any required lab work. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Steady State Health is a women’s telehealth practice addressing hormones, metabolism and related concerns. Its GLP-1 program names semaglutide and tirzepatide. 1. ## Who writes the prescription, and what do they see? The practice identifies Josie Cowburn, DNP, FNP-C. Its stated service area is Oregon and Washington; verify that your appointment location and treatment fall within the practice’s current availability. The program describes a comprehensive intake, monthly provider visits, weekly Zoom sessions and access to the clinician and medical assistant. Ask which sessions are individual and how urgent concerns are handled. 2. ## What happens when the dose goes up? Monthly visits create a stated review point for response and tolerance. Medication is ordered separately, so clarify who authorizes each refill and how a dose change affects the pharmacy order. 3. ## What the price includes The published membership and starting medication costs are separate. Recent metabolic labs are required; patients may bring existing results or purchase the offered panel. The starting estimate is not a universal drug-specific total. 4. ## What it claims, and what it cites The homepage describes delivery of compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) or [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). Compounded medication is not FDA-approved. The broader hormone-care offering does not establish suitability for a GLP-1. ## Where it holds up, and where it does not - Strength: Clinician identified by name - Strength: Monthly follow-up and group sessions described - Limitation: Limited stated region - Limitation: Medication and labs are separate ## What the evidence says about this kind of treatment The assessment above is about Steady State Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient in Oregon or Washington who values a named clinician and continuing metabolic care. Wrong for Someone outside the stated region or looking for a medication-only national storefront. ## The evidence behind what Steady State Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Steady State Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [FeelGood](https://thisglp.com/reviews/feelgood-meds) [Florida Weight Loss MD](https://thisglp.com/reviews/florida-weight-loss-md) [Found Youth](https://thisglp.com/reviews/found-youth) [Freeley](https://thisglp.com/reviews/freeley) [FuturHealth](https://thisglp.com/reviews/futurhealth) [G-Plans](https://thisglp.com/reviews/g-plans) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Where is the practice available? The GLP-1 program is described for Oregon and Washington. Confirm availability for your physical location when booking. Does membership cover medication? No. The program page says medication is ordered and billed separately. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://steadystatehealth.org/) - [Official program and terms](https://steadystatehealth.org/programs/glp1-program/) - [Official program and terms](https://steadystatehealth.org/terms-conditions/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Strut Health reviews (2026): GLP-1 telehealth sellers | This GLP Four advertised rates across two molecules, with an oral semaglutide at $99 a month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/strut-health Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Both molecules, both forms # Strut Health review Four advertised rates across two molecules, with an oral semaglutide at $99 a month. ## The verdict Strut Health prices both molecules in both forms. Compounded semaglutide is $149 a month by injection and $99 as an oral. Compounded tirzepatide is $199 either way. Each of those is an auto-refill rate, not a one-off price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 49 Injection From $149/mo Oral From $99/mo Prescription Required Compounded Yes — not FDA-approved Strut Health sells compounded semaglutide and compounded tirzepatide through an online service, and advertises a rate for all four combinations. Injectable semaglutide is $149 a month and the oral $99. Tirzepatide was $199 in either form. The service lists 49 states. Alaska is the exclusion. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely and a prescription is issued before shipping. The pricing page states the rates and the savings against them. It does not describe the clinician who writes the prescription. What the intake asks is not published. The service runs remotely, and every product here is compounded rather than the manufacturer's approved pen. The unusual fact is the breadth. Most sellers price one molecule in one form and route the rest through an enquiry. Strut publishes a rate for all four combinations, which lets a reader compare an oral against an injection without starting an intake. 2. ## What happens when the dose goes up? The advertised rates are auto-refill prices. Whether they hold as the dose rises is not stated beside them. Almost everyone escalates across the first sixteen weeks, so that is the question a reader should carry into the intake. The seller does not answer it. 3. ## What the price includes The oral semaglutide at $99 is the lowest advertised figure here. The page frames each rate as an auto-refill saving: 13 percent off the injectable semaglutide, 21 percent off the oral, 14 and 17 percent off the two tirzepatide lines. Two one-off prices sit beside them. Oral tirzepatide bought once is $239 rather than $199, and the injectable line shows a $325 compare-at figure. A reader who does not want a standing order pays the higher number. 4. ## What it claims, and what it cites Every product here is compounded, prepared by a pharmacy rather than manufactured and reviewed as a finished product. A compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not FDA-approved and is not assessed for safety, efficacy or quality before it is dispensed. The trial evidence quoted for these molecules was generated with the approved products at labeled doses. Whether a compounded preparation matches them is not measured. ## Where it holds up, and where it does not - Strength: Four advertised rates, both forms of both molecules - Strength: Oral semaglutide priced at $99 a month - Strength: One-off prices shown beside refill rates - Limitation: Advertised rates assume a standing auto-refill - Limitation: Not available in Alaska - Limitation: Dose-escalation pricing not stated ## What the evidence says about this kind of treatment The assessment above is about Strut Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to try an oral before committing to injections, since both molecules are priced in both forms. Wrong for A reader in Alaska, and a reader who wants a single month without a standing refill order. ## The evidence behind what Strut Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Strut Health compares | Seller | Who it suits | Go | | --- | --- | --- | | CoreAge Rx | A reader still at a starting dose, since that is the tier these rates price. | | | Care Bare Rx | A reader choosing between the two molecules on grounds other than price, since this seller charges the same for both. | | | Synergy Rx | A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Lifestyle Medicine](https://thisglp.com/reviews/genesis-lifestyle-medicine) [Gide Health](https://thisglp.com/reviews/gide-health) [Glow](https://thisglp.com/reviews/glow) [GOAL.MD](https://thisglp.com/reviews/goal-md) [GoodLife Health](https://thisglp.com/reviews/goodlife-health) [Happy Care Meds](https://thisglp.com/reviews/happy-care-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 the price of any semaglutide here? It is the oral semaglutide on auto-refill. The injectable is $149 on the same terms. What changes if I do not want auto-refill? Two rates are published for a single purchase. Oral tirzepatide is $239 rather than $199, and the injectable line carries a $325 compare-at figure. The other lines show only the refill rate. Does Strut Health ship to every state? The service lists 49 states. Alaska is excluded. That is what the service publishes. Is Strut Health expensive compared with other GLP-1 telehealth sellers? Strut Health publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Strut Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Sumbare Wellness reviews (2026): GLP-1 telehealth sellers | This GLP A single from-price covers two molecules and a microdose plan, so it describes none of them in particular. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/sumbare-wellness Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price for three products # Sumbare Wellness review A single from-price covers two molecules and a microdose plan, so it describes none of them in particular. ## The verdict Sumbare Wellness publishes one blended new-patient figure of $199 a month covering semaglutide, tirzepatide and a microdose plan alike. No per-molecule rate exists, so no price is ranked here. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Sumbare Wellness offers both molecules by injection on a site that is one of eight storefronts serving an identical compiled build, with a single flat figure standing in for three different products. 1. ## Who writes the prescription, and what do they see? The site states the plan is confirmed after provider review, which makes the published figure a from-price rather than a rate. The clinician who confirms it is not described. A blended price is a real structure and it has a real consequence. Tirzepatide costs more than semaglutide almost everywhere else on this market, so one figure covering both is either generous on one line or optimistic on the other, and a reader cannot tell which from the page. 2. ## What happens when the dose goes up? The plan is described as flat-rate with no consultation charge and no dose-change surcharge, which would be a strong claim if it were attached to a named product. Applied to three products at once it is harder to hold anyone to. 3. ## What the price includes Nothing per-molecule can be ranked. The figure is quoted as a new-patient from-price, confirmed after review, and the treatment pages beneath it carry the shared shell's defaults rather than rates this brand sets. Get a molecule-specific figure in writing before paying. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy none of the eight storefronts names, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: No consultation charge, as stated - Strength: No dose-change surcharge, as stated - Strength: The confirmation step is disclosed - Limitation: One figure covers three different products - Limitation: No per-molecule rate is published - Limitation: One of eight brands on one build - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Sumbare Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will get a molecule-specific figure confirmed before paying. Wrong for A reader comparing a tirzepatide price, since this seller publishes none. ## The evidence behind what Sumbare Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Sumbare Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Superior Remedies | Readers willing to book a consultation before learning any figure | | | Telos Rx | Readers taking the longest plan, since no shorter term carries a published rate | | | SurpassMD | Readers who will ask what their own approved figure is | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealFastRx](https://thisglp.com/reviews/healfast) [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) [Hone Health](https://thisglp.com/reviews/hone-health) [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) [KairoRx](https://thisglp.com/reviews/kairorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does tirzepatide cost here? No separate figure is published. One blended new-patient from-price covers semaglutide, tirzepatide and a microdose plan alike. Is the price flat across doses? The site says flat-rate with no dose-change surcharge, though it applies that to three products at once rather than to a named one. Is Sumbare its own company? It is one of eight storefronts running the same compiled application, matched byte for byte. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Sunlight reviews (2026): GLP-1 telehealth sellers | This GLP A price-forever guarantee attached to a four-week fill rather than a calendar month. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/sunlight Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same price forever, per fill # Sunlight review A price-forever guarantee attached to a four-week fill rather than a calendar month. ## The verdict Sunlight publishes $88 for compounded semaglutide and $157 for tirzepatide, with a stated guarantee of no price increases ever. Each buys a four-week fill, so the calendar-month figures are $95 and $170. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $95/mo Prescription Required Compounded Yes — not FDA-approved Sunlight sells both molecules by injection at a flat rate that includes the prescription. Both figures are guaranteed against increases. Each covers four weeks. 1. ## Who writes the prescription, and what do they see? The prescription is stated as included in the flat rate. The clinician is not described and the intake is not documented anywhere a reader can reach. The guarantee is the strongest claim here and it is worth reading precisely. Same price forever, no price increases ever, no hidden fees. That is a commitment about the rate rather than about the cycle, and the cycle is where the extra charge lives. 2. ## What happens when the dose goes up? Both lines are flat, so the rate holds as the dose rises. The guarantee reinforces it. What neither addresses is the thirteenth fill, which arrives because of the calendar rather than the milligrams. 3. ## What the price includes Thirteen fills at $88 is $1,144 a year, or $95 a calendar month rather than $88. Tirzepatide at $157 comes to $2,041, or $170. A banner frames $88 as a summer promotion, but the price-forever guarantee sits against that, so it is recorded as the standing rate rather than an introductory one. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: A stated guarantee against price increases - Strength: The prescription is inside the rate - Strength: Among the lower figures in the category - Strength: No hidden fees, stated plainly - Limitation: A four-week fill, not a calendar month - Limitation: Thirteen charges a year rather than twelve - Limitation: A promo banner sits against the guarantee - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Sunlight. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a rate guaranteed against increases and counts the fills. Wrong for A reader comparing $88 against another seller's calendar month. ## The evidence behind what Sunlight prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Sunlight compares | Seller | Who it suits | Go | | --- | --- | --- | | Sprout Health | Readers taking the six-month plan, which is the one measured in calendar months | | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | SurpassMD | Readers who will ask what their own approved figure is | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [KIN Health](https://thisglp.com/reviews/kin-health) [Klarity Health](https://thisglp.com/reviews/klarity-health) [Klinic](https://thisglp.com/reviews/klinic) [Kova](https://thisglp.com/reviews/kova) [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) [Lighter You](https://thisglp.com/reviews/lighter-you) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $88 a monthly price? It buys a four-week fill. Thirteen of those fit into a year, so the calendar-month figure is about $95. What does the guarantee cover? The site states same price forever, no price increases ever, and no hidden fees. That is a commitment about the rate, not about the billing cycle. Is $88 an introductory price? A banner frames it as a summer promotion, but the price-forever guarantee sits against that, so it is treated here as the standing rate. Is Sunlight expensive compared with other GLP-1 telehealth sellers? Sunlight publishes a starting figure of $95/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Sunlight below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Super Healthy Rx reviews (2026): GLP-1 telehealth sellers | This GLP Super Healthy Rx publishes compounded semaglutide and tirzepatide plans with physician review and ongoing support. The care relationship and subscription terms need equal attention. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/super-healthy-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Super Healthy Rx review Super Healthy Rx publishes compounded semaglutide and tirzepatide plans with physician review and ongoing support. The care relationship and subscription terms need equal attention. ## The verdict The useful feature is a stated route back to the provider, rather than a prescription-only checkout. The GLP-1 page also separates two medicines and promises the same price regardless of dose. That is a commercial promise, not a reason to increase a dose or evidence that treatment is suitable for everyone. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $199/mo Prescription Required Compounded Yes — not FDA-approved SuperHealthy Rx is operated by Natural Smart Health LLC as a telehealth platform. Its weight-care offering consists of compounded semaglutide and tirzepatide, with monthly and three-month plan choices. Other products marketed by the business are separate clinical decisions. 1. ## Who writes the prescription, and what do they see? The service describes assessment by licensed US physicians and says prescriptions remain their independent judgment. Its terms expressly decline to guarantee a prescription. They also allow the patient to direct a prescription to a pharmacy of their choice, even when a preferred pharmacy is offered. Patients supply health history online before the medical team reviews it. The treatment page includes ongoing provider support and injection supplies. Public descriptions do not establish one response deadline for every message; clarify who handles a problem between routine refills. 2. ## What happens when the dose goes up? Dose changes need clinician approval. The commercial statement that the price remains unchanged at different doses should be separated from a medical escalation plan. Ask what follow-up is required to move strength and how the service handles troublesome [nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) or an interrupted course. 3. ## What the price includes The GLP-1 page advertises semaglutide from $199 and tirzepatide from $249 monthly, alongside three-month choices. Confirm which billing selection those figures represent. The terms cover medical intake, review, messaging and care coordination; the final order should identify what is being supplied and when. 4. ## What it claims, and what it cites Both listed treatments are compounded, not FDA-approved versions of the branded products. The marketing describes free delivery from accredited pharmacies, but the clinical conversation should identify the actual dispensing pharmacy and formulation for the prescription being considered. ## Where it holds up, and where it does not - Strength: Two medicines and plan choices are distinguished - Strength: Ongoing provider support is listed - Strength: Terms acknowledge pharmacy choice - Limitation: Public messaging does not promise a response time - Limitation: Plan selection affects the purchasing comparison - Limitation: Compounded products require separate formulation scrutiny ## What the evidence says about this kind of treatment The assessment above is about Super Healthy Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded treatment who wants to discuss pharmacy choice and continued medical support before enrolling. Wrong for A person seeking a guaranteed prescription or clinical supervision defined by a published visit calendar. ## The evidence behind what Super Healthy Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Super Healthy Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lighter You](https://thisglp.com/reviews/lighter-you) [Livbetr](https://thisglp.com/reviews/livbetr) [Longevity Meds](https://thisglp.com/reviews/longevity-meds) [Loozy](https://thisglp.com/reviews/loozy) [Male Excel](https://thisglp.com/reviews/male-excel) [MangoRx](https://thisglp.com/reviews/mangorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is approval guaranteed? No. The terms reserve prescribing to the clinician’s professional judgment. Does a flat price mean a fixed dose? No. The stated price policy does not decide the dose, which remains a clinical question. Can another pharmacy be used? The terms say patients may direct their prescription to a pharmacy of their choosing; ask how that affects the quoted package. Is Super Healthy Rx expensive compared with other GLP-1 telehealth sellers? Super Healthy Rx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Super Healthy Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.superhealthyrx.com/) - [Terms of service and payment conditions](https://www.superhealthyrx.com/terms/) - [GLP-1 care and prescribing options](https://www.superhealthyrx.com/glp-1/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Superior Remedies reviews (2026): GLP-1 telehealth sellers | This GLP The only number on screen names neither a drug nor a term, and the figures in the page data belong to a shared template. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/superior-remedies Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One figure, no molecule # Superior Remedies review The only number on screen names neither a drug nor a term, and the figures in the page data belong to a shared template. ## The verdict Superior Remedies publishes no price a reader can act on. Its treatment pages read available by consultation, and the single on-screen figure is a limited-time offer of $149 a month attached to no molecule and no term. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 Prescription Required Compounded Yes — not FDA-approved Availability All 50 states Superior Remedies offers both molecules by injection and says in its FAQ that service is available across all 50 states, on a site that is one of eight storefronts serving an identical compiled build. 1. ## Who writes the prescription, and what do they see? A consultation precedes any figure, which the pages state directly. What they do not state is what the consultation will quote, so the clinical step and the pricing step arrive together and neither can be prepared for. The match against the other seven brands is byte for byte on the compiled application, which is a recorded hash rather than a resemblance. A reader shortlisting several of these believes they are comparing several companies when they are comparing one product's per-tenant configuration. 2. ## What happens when the dose goes up? Nothing can be said about dose where nothing is said about price. The limited-time figure names no molecule, so it cannot even be attached to a starting dose. 3. ## What the price includes There is nothing to rank. The $299 and $399 recorded against this seller appear only inside the page payload, where they are the shared shell's defaults rather than rates this brand charges — the same defaults that appear in sibling tenants' data. A buyer will meet a number at consultation and not before. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy none of the eight storefronts names, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: Both molecules are offered - Strength: The consultation requirement is stated - Strength: Service stated in all 50 states - Limitation: No price is published for either molecule - Limitation: The one on-screen figure names no drug - Limitation: One of eight brands on one build - Limitation: Canceling takes 30 days' notice ## What the evidence says about this kind of treatment The assessment above is about Superior Remedies. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to book a consultation before learning any figure. Wrong for A reader comparing published prices, since none exists here. ## The evidence behind what Superior Remedies prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Superior Remedies compares | Seller | Who it suits | Go | | --- | --- | --- | | Sumbare Wellness | Readers who will get a molecule-specific figure confirmed before paying | | | Telos Rx | Readers taking the longest plan, since no shorter term carries a published rate | | | Sprout Health | Readers taking the six-month plan, which is the one measured in calendar months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDLive](https://thisglp.com/reviews/mdlive) [MD Total Wellness](https://thisglp.com/reviews/mdtw) [Medical Health Institute](https://thisglp.com/reviews/medical-health-institute) [Medivive](https://thisglp.com/reviews/medivive) [MEDVidi](https://thisglp.com/reviews/medvidi) [Meli Health](https://thisglp.com/reviews/meli-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does treatment cost? The site does not say. Its treatment pages read available by consultation, and the only on-screen figure is a $149 limited-time offer attached to no molecule and no term. What about the $299 in its data? That figure appears in the page payload as the shared template's default, the same one carried by sibling tenants. It is not a rate this brand charges. Is Superior Remedies its own company? It is one of eight storefronts running the same compiled application, matched byte for byte. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Superpower reviews (2026): GLP-1 telehealth sellers | This GLP Semaglutide is sold only to members of a lab-testing service, and the membership fee is printed two different ways. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/superpower-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership before medication # Superpower review Semaglutide is sold only to members of a lab-testing service, and the membership fee is printed two different ways. ## The verdict Superpower lists compounded semaglutide at $229 a month as a member-only product, so the monthly figure is not the whole cost. The membership it requires is priced at $17 a month billed annually on the product page, which puts the least a member pays at $246 a month, while the homepage prices the same membership at $349 a year. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 42 From From $246/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Superpower is a membership health service built around lab testing, with two blood draws a year covering more than 150 biomarkers. Members can also buy prescriptions, peptides and supplements from its marketplace, and compounded semaglutide is one of those listings. 1. ## Who writes the prescription, and what do they see? The product page says a Superpower clinical team, described as a licensed physician, reviews the eligibility questionnaire and approves the prescription. No clinician is named, and the page does not say whether any part of that review happens live. Once a prescription is approved, the seller describes weekly check-ins, dose adjustments and provider access around the clock, and the membership adds a concierge team and an AI assistant that works from the member's own lab results. The FAQ refers to the next shipment as a 90-day supply. 2. ## What happens when the dose goes up? The FAQ is specific about the top of the ladder: the seller prescribes up to 2 mg a week. A patient who needs a higher dose than the schedule sets has the next 90-day supply adjusted, with no extra fees charged for it. That reads as a price that holds as the dose climbs, although the $229 figure itself carries no statement about the lower steps of the escalation. 3. ## What the price includes Taken at the product page's membership figure, a month costs $246, the $229 member price plus $17 for a membership billed once a year. The homepage's $349 a year for the same membership would push that to about $258, and the site never reconciles its two figures. Whether the medication is billed monthly or per 90-day shipment is not stated beside the price, so both points are worth settling before checkout. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded by a US-licensed pharmacy the page does not name. The page itself notes that compounded products are not FDA-approved and that the FDA does not verify their safety, effectiveness or quality before they are dispensed. ## Where it holds up, and where it does not - Strength: No extra fee for a higher dose - Strength: Weekly check-ins described after approval - Strength: Lab testing included with the membership - Limitation: Medication requires a paid membership - Limitation: Membership fee printed two different ways - Limitation: Billing cadence not stated beside the price - Limitation: Compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Superpower. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who already wants the lab membership and would add semaglutide to it rather than shop for medication alone. Wrong for A reader comparing medication prices, since the figure shown leaves out the membership it depends on. ## The evidence behind what Superpower prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Superpower compares | Seller | Who it suits | Go | | --- | --- | --- | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Metabolic Rx](https://thisglp.com/reviews/metabolic-rx) [Metabolyz](https://thisglp.com/reviews/metabolyz) [Mixx Health & Wellness](https://thisglp.com/reviews/mixx-health-and-wellness) [Modern Age](https://thisglp.com/reviews/modern-age) [Novera MD](https://thisglp.com/reviews/novera-md) [Nuform Health](https://thisglp.com/reviews/nuform-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $229 the whole monthly cost? No. Semaglutide is a member-only product, so the membership comes on top. At the product page's $17 a month, billed annually, the total is $246; the homepage prices the membership at $349 a year instead. Does the price rise with the dose? The FAQ says a patient who needs more than the schedule prescribes, up to 2 mg a week, is sent an adjusted 90-day supply with no extra fees. Is the semaglutide FDA-approved? No. It is compounded, and the product page states that compounded products have not been approved by the FDA. Is Superpower expensive compared with other GLP-1 telehealth sellers? Superpower publishes a starting figure of $246/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Superpower above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # SurpassMD reviews (2026): GLP-1 telehealth sellers | This GLP The figure depends on eligibility, medication, dose and provider approval, all stated. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/surpassmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three conditions on one figure # SurpassMD review The figure depends on eligibility, medication, dose and provider approval, all stated. ## The verdict SurpassMD publishes semaglutide as low as $114 a month and tirzepatide at $177, for eligible patients. The site states actual pricing depends on medication, dose and provider approval. Coverage is 51 jurisdictions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 51 From From $114/mo Prescription Required Compounded Yes — not FDA-approved Availability 51 jurisdictions SurpassMD sells both molecules by injection across 51 jurisdictions. Both figures carry stated conditions. Neither is a settled rate. 1. ## Who writes the prescription, and what do they see? Provider approval is named as one of the three things that moves the price. That makes the clinician part of the pricing, which the site says outright. Four conditions sit on one number: eligibility, medication, dose and approval. Listing them is honest. It also means the figure describes very little on its own. 2. ## What happens when the dose goes up? Dose is named as a variable that changes the price. What it changes it to is not published. Direction without a destination is half an answer. 3. ## What the price includes Six months at $114 is $684 at best. Tirzepatide at $177 is $1,062 at best. Both totals assume every condition resolves favorably. Ask what your own figure is before ordering. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The conditions are listed, not hidden - Strength: Coverage across 51 jurisdictions - Strength: Both molecules carry a figure - Limitation: Eligibility gates the published rate - Limitation: Dose changes it by an unstated amount - Limitation: Provider approval also moves it - Limitation: The pharmacy behind the vial is unnamed ## What the evidence says about this kind of treatment The assessment above is about SurpassMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will ask what their own approved figure is. Wrong for A reader planning six months from the published rate. ## The evidence behind what SurpassMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How SurpassMD compares | Seller | Who it suits | Go | | --- | --- | --- | | Somira Health | Readers who want the pharmacy and the rate named before the intake | | | Sunlight | Readers who want a rate guaranteed against increases and will count the fills | | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nurx](https://thisglp.com/reviews/nurx) [Olleve Care](https://thisglp.com/reviews/ollevecare) [Omada Health](https://thisglp.com/reviews/omada-health) [One80Rx](https://thisglp.com/reviews/one80rx) [Pillar Health](https://thisglp.com/reviews/pillar-health) [Prescriva](https://thisglp.com/reviews/prescriva) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Will I pay $114? Only if eligible, and the site states pricing also depends on medication, dose and provider approval. Does the price rise with the dose? Dose is named as a factor. What it raises the figure to is not published. Where does SurpassMD ship? Fifty-one jurisdictions are recorded. Is SurpassMD legit? SurpassMD is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is SurpassMD expensive compared with other GLP-1 telehealth sellers? SurpassMD publishes a starting figure of $114/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts SurpassMD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # SynergenX Health reviews (2026): GLP-1 telehealth sellers | This GLP A hormone clinic chain that sells compounded semaglutide online, with each visit priced apart from the medication. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/synergenx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Clinic chain, visit fees on top # SynergenX Health review A hormone clinic chain that sells compounded semaglutide online, with each visit priced apart from the medication. ## The verdict SynergenX lists compounded semaglutide from $150 for one month of treatment. Visits are billed apart from that figure. The first telehealth visit is regularly $100 before any discounts, and follow-ups run $40 each. Even at the longest stated gap between follow-ups, a month costs at least $163.33. What a higher dose costs is not published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 10 From From $163.33/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named SynergenX is a testosterone and hormone clinic chain with locations around Chicago, Dallas, Houston and San Antonio. Weight loss is one service line beside TRT, HRT and peptides. Compounded semaglutide is sold online through a live video appointment. A compounded tirzepatide card sits on the same page with its own starting figure. 1. ## Who writes the prescription, and what do they see? The provider directory lists 35 clinicians, and every credential shown is a nurse practitioner or physician assistant. No physician appears on that page, although its introduction says the team is led by doctors. The weight-loss pages say a licensed provider runs the video visit. Which clinician signs a given prescription is not stated. The online path begins with a scheduled video appointment rather than an asynchronous form. After the visit, a pharmacy partner ships the medication in refrigerated packaging. Follow-up appointments recur every one to three months, each carrying its own fee. The site also describes a free consultation and a paid in-clinic evaluation for patients near a location. 2. ## What happens when the dose goes up? The pricing block says medication starts as low as $150 for one month. It does not say at which dose, or what the next step costs. Dose changes are handled at the follow-up visits, so each step also passes through a paid appointment. No milligram figure appears on either semaglutide page. 3. ## What the price includes The online pricing block names three charges in one place. The first visit is regularly $100 before any discounts, and the size of the discount is not stated. Medication starts at $150 a month. Each follow-up is $40, due every one to three months. Spread over the longest stated gap, that adds at least $13.33 a month, for a floor of $163.33. The same page advertises a free online consultation above that block and does not reconcile the two. 4. ## What it claims, and what it cites The product is compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review), prepared by a compounding pharmacy rather than manufactured. It is not FDA-approved and is not reviewed by the FDA before dispensing. The page says it can be combined with B12 or other vitamins. No compounding pharmacy is named. ## Where it holds up, and where it does not - Strength: Visit fees are printed beside the medication price - Strength: A live video visit precedes any prescription - Strength: Physical clinics in four Texas and Illinois metros - Strength: Credentials listed for every named clinician - Limitation: Follow-up visits are billed on top - Limitation: The first-visit discount is not quantified - Limitation: No price published above the starting dose - Limitation: No compounding pharmacy is named - Limitation: No physician appears in the provider directory ## What the evidence says about this kind of treatment The assessment above is about SynergenX Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader near one of the clinic metros who wants a live visit and can budget for recurring visit fees. Wrong for A reader who wants one all-in monthly figure covering care and medication. ## The evidence behind what SynergenX Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How SynergenX Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | | Options Medical Weight Loss | Readers certain of a year who can pay the whole of it at once | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrescrYbe](https://thisglp.com/reviews/prescrybe) [PRIMO Health Partners](https://thisglp.com/reviews/primo-health-partners) [Push Health](https://thisglp.com/reviews/push-health) [Ravia Health](https://thisglp.com/reviews/ravia-health) [Red Mountain Weight Loss](https://thisglp.com/reviews/red-mountain-weight-loss) [RegenCen](https://thisglp.com/reviews/regencen) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the $150 the whole monthly cost? No. It covers the medication. Each follow-up is $40 and comes at least every three months, so a month costs at least $163.33. The first visit, regularly $100 before discounts, is extra. Who writes the prescription? A licensed provider after a video visit. The directory lists nurse practitioners and physician assistants, and no physician. How often are follow-up visits? Every one to three months, according to the online pricing block. Each one is billed separately. Is SynergenX Health expensive compared with other GLP-1 telehealth sellers? SynergenX Health publishes a starting figure of $163.33/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts SynergenX Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Synergy Rx reviews (2026): GLP-1 telehealth sellers | This GLP Both molecules are priced in both forms, which most sellers in this category do not do. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/synergy-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 All four rates published # Synergy Rx review Both molecules are priced in both forms, which most sellers in this category do not do. ## The verdict Synergy Rx publishes a rate for every combination it sells. Semaglutide is $199 by injection and $299 as an oral. Tirzepatide is $349 and $399. All fifty states are served. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $199/mo Oral From $299/mo Prescription Required Compounded Yes — not FDA-approved Synergy Rx sells compounded semaglutide and compounded tirzepatide, each as an injection and as an oral, and publishes a figure for all four. Semaglutide is $199 injectable and $299 oral. Tirzepatide was $349 injectable and $399 oral. The service lists all fifty states. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely and a prescription precedes shipping. The pricing page carries the four rates. It does not describe the clinician. What the intake asks before a prescription is written is not recorded here. The service is remote and every product is compounded. What distinguishes it is disclosure rather than price. Sellers commonly publish the injectable rate and route the oral through an enquiry form, which means a reader cannot compare the two without starting an intake. Here both are on the page. 2. ## What happens when the dose goes up? None of the four rates carries a statement about dose. Almost every patient escalates within the first sixteen weeks, and a rate that moves at each step changes the annual figure more than the gaps between sellers do. The seller does not establish whether these hold. 3. ## What the price includes The oral carries a $100 premium on semaglutide and a $50 premium on tirzepatide. That is the cost of a daily tablet over a weekly injection on this seller. The tirzepatide injection is $349 and the semaglutide injection $199. A reader choosing on price alone will find cheaper; a reader choosing on knowing the price before an intake will not find many. 4. ## What it claims, and what it cites All four products are compounded rather than manufactured and reviewed as finished products. None is FDA-approved, and none is assessed for safety, efficacy or quality before dispensing. The published trial evidence for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) was generated with the approved products at labeled doses, and a compounded preparation is not measured against it. ## Where it holds up, and where it does not - Strength: A published rate for all four combinations - Strength: Oral priced without requiring an intake - Strength: All fifty states served - Limitation: Tirzepatide injection priced at $349 - Limitation: Oral carries a premium on both molecules - Limitation: Dose-escalation pricing not stated ## What the evidence says about this kind of treatment The assessment above is about Synergy Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the oral and injectable rates for both molecules stated before starting an intake. Wrong for A reader shopping on the lowest injectable figure, which is not what this seller competes on. ## The evidence behind what Synergy Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Synergy Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Breeze Meds | A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. | | | Strut Health | A reader who wants to try an oral before committing to injections, since both molecules are offered in both forms at a stated rate. | | | Care Bare Rx | A reader choosing between the two molecules on grounds other than price, since this seller charges the same for both. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rese Wellness](https://thisglp.com/reviews/rese-wellness) [Revive Longevity](https://thisglp.com/reviews/revive-longevity) [Rila](https://thisglp.com/reviews/rila) [Risen Labs](https://thisglp.com/reviews/risen-labs) [Robinhood Telehealth](https://thisglp.com/reviews/robinhood-telehealth) [Royal Medical Center](https://thisglp.com/reviews/royal-medical-center) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does publishing four rates matter? Because most sellers publish one. The injectable rate goes on the page and the oral goes behind an intake form. A reader who wants to compare forms has to hand over details first. Is the oral worth the premium? That depends on whether a daily tablet suits you better than a weekly injection. The premium is $100 on semaglutide and $50 on tirzepatide. The seller does not compare the two clinically. Are these prices held through dose increases? Not stated. The seller publishes four advertised rates and no statement about what happens at a higher dose. Ask the intake. Is Synergy Rx expensive compared with other GLP-1 telehealth sellers? Synergy Rx publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Synergy Rx above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # T2D.com reviews (2026): GLP-1 telehealth sellers | This GLP One price includes the prescriber; a second, lower one is for buyers who already have a prescription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/t2d Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two doors, one priced by dose # T2D.com review One price includes the prescriber; a second, lower one is for buyers who already have a prescription. ## The verdict T2D.com offers two entry paths. Use its prescribers and compounded semaglutide is $170 a month, all-inclusive. Bring a prescription and the same drug is $99 a month at 0.25 and 0.50 milligrams. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 1 From From $170/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named T2D.com frames itself around type 2 diabetes and pre-diabetes rather than weight loss. Semaglutide and tirzepatide are both listed. The weight-loss program sits inside that framing. 1. ## Who writes the prescription, and what do they see? The $170 path includes a prescriber and ongoing support. The $99 path removes the prescriber; the buyer supplies one. That is an unusual choice to publish and it is published clearly. No individual clinician is named on either path. What a prescriber reviews before writing is not set out. Onboarding is described as fast, with no contract and cancellation at any time. On the bring-your-own path the telehealth consult is skipped and the pharmacy ships direct. Continued patient support is listed only against the higher tier. 2. ## What happens when the dose goes up? T2D states that medication is prescribed to the patient rather than to a preset [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) ladder. The $99 tier names 0.25 and 0.50 milligrams. What the higher doses cost on either path is not published, so the ladder stops where the marketing does. 3. ## What the price includes $170 a month covers the prescriber, the medication and support. $99 a month covers the medication at the two starting doses when the prescription comes from elsewhere. Those are the only two figures on the site. Neither tirzepatide nor any higher-dose rate is priced. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is compounded and therefore not FDA-approved and not reviewed by the FDA before dispensing. Tirzepatide is listed as available without a price. The compounding pharmacy is not named. The site also publishes an average weight reduction of 15 to 20 percent over 68 weeks. No study is named for it. ## Where it holds up, and where it does not - Strength: A milligram is printed beside the $99 tier - Strength: The all-inclusive $170 covers prescriber and medication - Strength: No contract and cancellation at any time - Strength: An existing prescription is accepted - Limitation: Tirzepatide is listed but never priced - Limitation: Higher-dose rates are not published on either path - Limitation: The compounding pharmacy is not named - Limitation: A 15 to 20 percent figure is quoted with no source ## What the evidence says about this kind of treatment The assessment above is about T2D.com. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer holding a current prescription who wants a dose-labeled cash rate. Wrong for A buyer who needs a tirzepatide price before starting. ## The evidence behind what T2D.com prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How T2D.com compares | Seller | Who it suits | Go | | --- | --- | --- | | NativeMed | Buyers who want to see the prepay arithmetic before deciding it is a saving | | | Omzo | Buyers who want the medication cost inside one fee rather than billed by a pharmacy | | | Kina | Women in menopause who want the medical group named and four routes priced up front | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sipra](https://thisglp.com/reviews/sipra) [Sommar Club](https://thisglp.com/reviews/sommar-club) [StaveMD](https://thisglp.com/reviews/stavemd) [Steady State Health](https://thisglp.com/reviews/steady-state-health) [Super Healthy Rx](https://thisglp.com/reviews/super-healthy-rx) [Tablet Health](https://thisglp.com/reviews/tablet-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $99 a month buy? Compounded semaglutide at 0.25 and 0.50 milligrams, when the buyer supplies the prescription and skips the consult. Is tirzepatide priced? No. It is listed as an available medication, and no figure is attached to it anywhere. What happens at a higher dose? Not published. The two stated milligrams are the starting ones, and no rate is given above them. Is T2D.com expensive compared with other GLP-1 telehealth sellers? T2D.com publishes a starting figure of $170/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts T2D.com below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tablet Health reviews (2026): GLP-1 telehealth sellers | This GLP Tablet Health lists oral and injected GLP-1 products. Its oral tirzepatide offering should not be mistaken for an FDA-approved version of an injectable brand. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tablet-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Formulation matters more than format # Tablet Health review Tablet Health lists oral and injected GLP-1 products. Its oral tirzepatide offering should not be mistaken for an FDA-approved version of an injectable brand. ## The verdict Tablet makes product formats and introductory-versus-later pricing visible, but choosing an oral product requires a careful evidence discussion. Convenience does not establish that compounded oral tirzepatide behaves like the injections studied in major trials. Ask the clinician about formulation-specific evidence and approved alternatives. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Tablet Health offers online clinical access and prescription fulfillment for weight management, alongside other treatments. Its catalog includes semaglutide and tirzepatide in oral and injection categories. A product menu does not establish equal effectiveness across those formulations. 1. ## Who writes the prescription, and what do they see? The terms require a provider to review health information, decide appropriateness and issue a valid prescription. Medical groups and dispensing pharmacies have separate responsibilities from the platform. Confirm the clinician and the pharmacy responsible for your particular product. The site describes consultation after checkout, personalized dosing and continued check-ins. Before paying, ask how the consultation is conducted and what happens financially if the product is unsuitable. General support and same-day dispatch claims do not answer clinical follow-up questions. 2. ## What happens when the dose goes up? Personalized dosing is advertised, but public format labels do not establish a safe conversion between oral and injected medicine. Discuss the actual formulation and planned dose with the clinician; do not substitute a product based on the ingredient name alone. 3. ## What the price includes The oral tirzepatide page explicitly separates a first-month offer from a higher continuing monthly amount and longer packages. Product-specific renewal terms matter: the homepage’s starting figure is not a permanent rate for every formulation. 4. ## What it claims, and what it cites The catalog includes compounded injections and oral GLP-1 preparations. There is no FDA-approved oral [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) medicine; ingredient or laboratory claims do not approve a finished compounded tablet. Ask for the prescribed ingredients, concentration and dispensing instructions. ## Where it holds up, and where it does not - Strength: Different formats identified in the catalog - Strength: A continuing oral-product price disclosed - Strength: Provider approval required in the terms - Limitation: Oral tirzepatide lacks an FDA-approved counterpart - Limitation: Consultation follows checkout - Limitation: Subscription cancellation has an advance deadline ## What the evidence says about this kind of treatment The assessment above is about Tablet Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient comparing formulations with a clinician and willing to examine product-specific evidence and terms. Wrong for Someone assuming every GLP-1 tablet is interchangeable with an approved injection. ## The evidence behind what Tablet Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Tablet Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Teladoc Health](https://thisglp.com/reviews/teladoc-health) [Teleios Health](https://thisglp.com/reviews/teleios-health) [TeleWellnessMD](https://thisglp.com/reviews/telewellnessmd) [The Protocole](https://thisglp.com/reviews/the-protocole) [TideMedix](https://thisglp.com/reviews/tidemedix) [Tomorrow](https://thisglp.com/reviews/tomorrow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is oral tirzepatide FDA approved? No. The evidence and approvals for injectable tirzepatide do not approve a compounded oral preparation. Can I choose a pharmacy? The terms allow a requested pharmacy if it can fulfill the prescription, with separate payment arrangements potentially applying. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://www.tablethealth.com/telehealth) - [Service and cancellation terms](https://www.tablethealth.com/terms-of-service) - [Treatment information](https://www.tablethealth.com/treatments/oral-tirzepatide) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TD Tele-Doc Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP A Richmond weight-loss practice that runs its GLP-1 prescribing through insurance and weekly video visits rather than a cash price list. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/td-teledoc Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Insurance first, Virginia physicians # TD Tele-Doc Weight Loss review A Richmond weight-loss practice that runs its GLP-1 prescribing through insurance and weekly video visits rather than a cash price list. ## The verdict TD Tele-Doc is an insurance-billed medical weight-loss practice out of Richmond, Virginia, and a reader who arrives expecting a cash price for compounded semaglutide will not find one displayed anywhere on its pages. What it does publish is who the doctors are, what the visits look like, and that Medicare and Medicaid are not accepted. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 2 Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability Virginia and Maryland TD Tele-Doc Weight Loss is a telehealth medical practice at 1801 Libbie Avenue in Richmond, built around preventive medicine and weight management and set up, by its founder's own account, with the help of Privia Health. Its medications page lists Wegovy, Zepbound, Ozempic and Mounjaro alongside compounded semaglutide injections, and the practice says it is in-network with most commercial insurance plans. 1. ## Who writes the prescription, and what do they see? Two physicians are named, each with a page of his own. Peter Wilbanks, MD, spent thirty years as an OB-GYN in Richmond before earning board certification in medical bariatrics, and Michael Perini, MD, is an internist certified by the American Board of Internal Medicine. The initial visit is a comprehensive evaluation with a licensed medical provider, held by video from the patient's home. The first contact is a free consultation, booked by phone or through an insurance-eligibility check on the site, and the program that follows is built on weekly virtual visits and remote monitoring. A starter box can include a biometric scale, a tape measure and a first month of the practice's own supplement blend, with the scale feeding readings back to the care team between appointments. 2. ## What happens when the dose goes up? Nothing on the site describes how a dose climbs or what a step up costs, and no milligram figure appears on the medications page. What the practice does describe is contact every week, so a patient in the third or fourth month would at least be seen by video before and after each change rather than messaging a queue. 3. ## What the price includes The pages display no cash price for any GLP-1, and the medications page ties the choice of drug to medical history and insurance coverage. Commercial insurance is the stated path, and the practice says it may cover the virtual visits and the monitoring equipment as well. Medicare and Medicaid are excluded in so many words, so anyone relying on either plan should know that before the free consultation, not after it. 4. ## What it claims, and what it cites Both brand-name GLP-1 drugs and compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) are offered. The brands are FDA-approved; the compounded injections are prepared by a pharmacy, are not FDA-approved, and are not reviewed by the FDA before they are dispensed. No compounding pharmacy is named anywhere on the site. ## Where it holds up, and where it does not - Strength: Two physicians named with their training - Strength: In-network with most commercial insurance - Strength: Weekly video visits with remote monitoring - Strength: A free first consultation - Limitation: No cash price is displayed - Limitation: Medicare and Medicaid are not accepted - Limitation: Coverage limited to Virginia and Maryland - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about TD Tele-Doc Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Virginia or Maryland patient with commercial insurance who wants a physician-led program with a weekly video check-in rather than a prescription-only storefront. Wrong for Someone on Medicare or Medicaid, or a cash buyer who wants to compare a published monthly price before calling anyone. ## The evidence behind what TD Tele-Doc Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How TD Tele-Doc Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | SynergenX Health | Readers near a clinic metro who want a live video visit and can budget for visit fees | | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TotalRx](https://thisglp.com/reviews/totalrx) [Totara Health](https://thisglp.com/reviews/totara-health) [Trally Meds](https://thisglp.com/reviews/trally-meds) [Transcarent](https://thisglp.com/reviews/transcarent) [TRT Kingdom](https://thisglp.com/reviews/trt-kingdom) [Tummala Health](https://thisglp.com/reviews/tummala-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked How much does compounded semaglutide cost here? No price is displayed on the site. The practice routes the choice of medication through a consultation and the patient's insurance coverage, so the figure comes out of that first call. Does TD Tele-Doc take Medicare? No. The site states that it cannot currently accept Medicare or Medicaid. Where does it operate? The medications page describes telemedicine for Virginia residents, and the locations page lists towns in both Virginia and Maryland. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Teladoc Health reviews (2026): virtual weight-management care | This GLP Teladoc Health combines weight-management support with GLP-1 assessment where the member’s program includes prescribing. Coverage and care eligibility must be checked first. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/teladoc-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Teladoc Health sell a GLP-1? Teladoc Health combines weight-management support with GLP-1 assessment where the member’s program includes prescribing. Coverage and care eligibility must be checked first. ## The verdict Teladoc’s useful distinction is between weight-support membership and access to a prescribing clinician. Some programs include both, while others expect the member to discuss medication with an existing primary-care provider. Confirm the actual benefit before assuming a connected scale and coaching also include prescription management. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category virtual weight-management care Prescription Required The weight-management offering combines a connected scale, behavior support and coaching. Its GLP-1 pathway adds clinical assessment when available under the member’s program. The platform is a care service, not a direct promise of a particular drug supply. 1. ## Who writes the prescription, and what do they see? A care provider reviews medical history and existing medicines before recommending treatment. Where the benefit includes provider visits, a Teladoc clinician can assess a prescription. Otherwise the member may need their usual primary-care clinician to make that decision. Program features can include a scale with automatic uploads, food and activity tracking, coaching and an app. The public FAQ says the app is helpful but not mandatory for participation. Verify the clinician access and communication routes attached to the benefit, not just the general feature list. 2. ## What happens when the dose goes up? If medication is prescribed, the care provider explains use, possible [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), expected effects and monitoring. Insurance approval can take several weeks and need further paperwork. Ask how monitoring and refills will continue during an appeal, a shortage or a denied prescription. 3. ## What the price includes Costs vary with health-plan or employer benefits, deductibles and medication coverage. Coverage does not mean that the drug is free. A single public monthly amount cannot represent every member’s clinical service and pharmacy obligation. 4. ## What it claims, and what it cites The GLP-1 information describes a medication-assessment process rather than establishing one guaranteed product or pharmacy for every member. The prescriber may propose an alternative if coverage is denied. A program’s published outcomes should not be treated as a prediction for an individual starting treatment. ## Where it holds up, and where it does not - Strength: Coaching and tracking support are described - Strength: Medication instructions and monitoring are addressed - Strength: The site explains insurance-approval delays - Limitation: Prescriber access is benefit-dependent - Limitation: Drug cost-sharing can remain substantial - Limitation: Approval and dispensing can take several weeks ## What the evidence says about this kind of treatment The assessment above is about Teladoc Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A person with access through an employer or health plan who wants structured weight support alongside appropriately supervised medication. Wrong for Someone needing an immediate guaranteed prescription or a nationally uniform cash price. ## How Teladoc Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vea Health](https://thisglp.com/reviews/vea-health) [Vela Rx](https://thisglp.com/reviews/vela-rx) [Verge](https://thisglp.com/reviews/verge) [Vida Health](https://thisglp.com/reviews/vida-health) [Virgo-Meds](https://thisglp.com/reviews/virgo-meds) [Virta Health](https://thisglp.com/reviews/virta-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does every program include a prescriber? No. Teladoc says members should check whether their program includes care-provider visits; some may use their regular clinician. How quickly is an insured prescription filled? The public FAQ warns that authorization and administrative steps can take several weeks. Is the app compulsory? The weight-management FAQ says it is not required, though it provides tracking and coaching tools. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.teladochealth.com/) - [GLP-1 care and prescribing options](https://www.teladochealth.com/individuals/glp-1) - [Weight-management program](https://www.teladochealth.com/expert-care/condition-management/weight-management) - [How assessment and follow-up work](https://www.teladochealth.com/start/how-it-works) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleCareSpot reviews (2026): GLP-1 telehealth sellers | This GLP A separate consult fee applies and is credited toward the package if the patient is approved. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/telecarespot Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Consult fee, credited back # TeleCareSpot review A separate consult fee applies and is credited toward the package if the patient is approved. ## The verdict TeleCareSpot publishes $299 a month for semaglutide and $399 for tirzepatide, flat at all doses with everything included. A separate $79 consult fee may be credited toward the package on approval. Coverage is 48 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 48 From From $299/mo Prescription Required Compounded Yes — not FDA-approved Availability 48 states TeleCareSpot sells both molecules by injection across 48 states. Both rates are flat at all doses. Oral tirzepatide and phentermine are also offered. 1. ## Who writes the prescription, and what do they see? The consult is charged separately and then credited if approved. That prices the clinical step explicitly rather than folding it away. Crediting the consult against the package is a fair structure. A reader who is declined pays for the assessment; a reader who is approved does not pay twice. 2. ## What happens when the dose goes up? Both rates are flat at all doses, which answers the question directly. Nothing describes clinical support at a step. 3. ## What the price includes Six months at $299 is $1,794 and tirzepatide at $399 is $2,394. Both totals hold at any dose. The consult is a $79 one-time fee, which the seller says may be applied toward an eligible program. A declined applicant is out $79. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Flat at all doses on both molecules - Strength: The consult fee is credited on approval - Strength: Coverage across 48 states - Strength: Everything included, no hidden fees stated - Limitation: The credit applies only to an eligible program - Limitation: A declined applicant pays it regardless - Limitation: Oral tirzepatide is priced at intake only - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about TeleCareSpot. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader confident of approval who wants a flat all-in rate. Wrong for A reader who will not pay $79 before learning whether treatment is possible. ## The evidence behind what TeleCareSpot prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TeleCareSpot compares | Seller | Who it suits | Go | | --- | --- | --- | | TeleClinic | Readers who want the standard rate stated beside the introductory one before they sign up | | | SurpassMD | Readers who will ask what their own approved figure is | | | TMates | Readers choosing between formats who do not want the choice priced | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vitakey](https://thisglp.com/reviews/vitakey) [Vital Step](https://thisglp.com/reviews/vital-step) [Vivanta Care](https://thisglp.com/reviews/vivanta-care) [VivioMD](https://thisglp.com/reviews/viviomd) [welludr.](https://thisglp.com/reviews/wellmedr)[Yes Clinic](https://thisglp.com/reviews/yes-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Do I pay for the consult? It is charged separately and credited toward the package if you are approved. How much is the consult? $79, one time. The seller says the fee may be applied toward an eligible treatment program. Does the price rise with the dose? No. Both rates are stated flat at all doses. Is TeleCareSpot legit? TeleCareSpot is a GLP-1 telehealth sellers service. Its stated availability: 48 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is TeleCareSpot expensive compared with other GLP-1 telehealth sellers? TeleCareSpot publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TeleCareSpot above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleClinic reviews (2026): GLP-1 telehealth sellers | This GLP Each molecule starts on a discounted first quarter billed quarterly, and the standard monthly rate is stated beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/teleclinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Intro quarter, then the standard rate # TeleClinic review Each molecule starts on a discounted first quarter billed quarterly, and the standard monthly rate is stated beside it. ## The verdict TeleClinic publishes standard member rates of $199 a month for semaglutide and $299 for tirzepatide. Each starts on an introductory first quarter, billed quarterly. Coverage is 47 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 47 From From $199/mo Prescription Required Compounded Yes — not FDA-approved Availability 47 states TeleClinic sells both molecules by injection. Each has an introductory first-quarter rate and a standard monthly rate, and both are stated in one FAQ answer. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The member framing implies a continuing relationship rather than a transaction. What that membership includes beyond the medication is not itemized. Stating the standard rate beside the introductory one is the useful part. A buyer can see month four's bill before paying for month one. The introductory rate is billed as a quarter, so it is a three-month commitment. 2. ## What happens when the dose goes up? Nothing is published about what the standard rate does at a higher dose. No milligram figure appears beside either rate. 3. ## What the price includes Semaglutide is $139 a month for the first quarter, billed quarterly, then $199 a month. Tirzepatide is $219 a month for the first quarter, then $299. Six months of semaglutide at those rates is $1,014. Tirzepatide costs $100 a month more at the standard rate. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The standard rate is stated beside the intro rate - Strength: Both molecules priced in one answer - Strength: Coverage across 47 states - Limitation: The introductory rate needs a quarter billed at once - Limitation: What membership includes is not itemized - Limitation: No dose behavior is published - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about TeleClinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the standard rate stated before signing up for the introductory quarter. Wrong for A reader who needs the rate at a higher dose established first. ## The evidence behind what TeleClinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TeleClinic compares | Seller | Who it suits | Go | | --- | --- | --- | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | | The Edit | Readers who read the standing rate beside the first-order figure | | | TMates | Readers choosing between formats who do not want the choice priced | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [YOURx Health](https://thisglp.com/reviews/yourx-health) [Youth & Soul](https://thisglp.com/reviews/youth-and-soul) [Zenbody](https://thisglp.com/reviews/zenbody) [Coby Health](https://thisglp.com/reviews/coby-health) [Form Health](https://thisglp.com/reviews/form-health) [Pepton Health](https://thisglp.com/reviews/pepton-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does tirzepatide cost more? Yes. The standard rate is $299 a month for tirzepatide against $199 for semaglutide. What does the first quarter cost? $139 a month for semaglutide and $219 a month for tirzepatide, billed quarterly. The standard rate applies after that. Where does TeleClinic operate? Forty-seven states are recorded in its coverage list. Is TeleClinic legit? TeleClinic is a GLP-1 telehealth sellers service. Its stated availability: 47 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is TeleClinic expensive compared with other GLP-1 telehealth sellers? TeleClinic publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TeleClinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleDocs360 reviews (2026): GLP-1 telehealth sellers | This GLP TeleDocs360 describes the evaluation and follow-up pathway, with a higher tirzepatide price at the top two doses. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/teledocs360 Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinical portal, dose-based tier # TeleDocs360 review TeleDocs360 describes the evaluation and follow-up pathway, with a higher tirzepatide price at the top two doses. ## The verdict TeleDocs360 has resumed a public weight-management offering. Its clinical portal gives patients a stated route for dosing and side-effect questions. The clearest limitation is that the published refund language is inconsistent, so confirm it before paying. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $299/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named The service coordinates enrollment, billing, appointments, and patient support. Licensed healthcare professionals make treatment decisions independently. The public programs include compounded semaglutide and tirzepatide injections. 1. ## Who writes the prescription, and what do they see? Enrollment includes selecting a provider and arranging an appointment. The clinician reviews the medical intake and decides whether to prescribe. Transfer patients can request continuation, but the same drug or dose is not guaranteed. Payment is taken during enrollment, followed by access to Teledocs.app for intake and clinical communication. Patients are directed there for adverse effects, dosing questions, and refill requests. Administrative support is handled by TeleDocs360. 2. ## What happens when the dose goes up? Semaglutide is advertised at $299 every 30 days across available doses. Tirzepatide is $399 through 10 mg and $549 at 12.5 mg or 15 mg. The provider selects the dose; the service says patients are notified before a higher recurring charge. 3. ## What the price includes The program includes evaluation, medication when prescribed, supplies where applicable, and standard shipping. A $99 physician fee is included rather than added. Detailed terms make that fee nonrefundable after evaluation, although a separate semaglutide banner still promises a full refund if not approved. 4. ## What it claims, and what it cites These are compounded preparations, not FDA-approved versions of the branded drugs. The product pages describe U.S. pharmacy dispensing. Confirm the dispensing pharmacy for the proposed prescription before ordering. ## Where it holds up, and where it does not - Strength: Clinical questions routed through a patient portal - Strength: Evaluation and standard delivery included - Strength: Higher-dose tirzepatide tier disclosed - Limitation: Refund statements conflict on the semaglutide page - Limitation: Included physician fee becomes nonrefundable after evaluation - Limitation: Upper tirzepatide doses increase the price ## What the evidence says about this kind of treatment The assessment above is about TeleDocs360. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants a stated process for contacting the clinical team between prescriptions. Wrong for A patient needing an unqualified full-refund promise or one tirzepatide rate at every dose. ## The evidence behind what TeleDocs360 prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TeleDocs360 compares | Seller | Who it suits | Go | | --- | --- | --- | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | Ro | Buyers set on a brand GLP-1 who want insurance help and care in one account | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Belle Health](https://thisglp.com/reviews/belle-health) [bmiMD](https://thisglp.com/reviews/bmimd) [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)[Collective](https://thisglp.com/reviews/collective) [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) [Direct Meds](https://thisglp.com/reviews/direct-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does TeleDocs360 charge more at higher doses? Its tirzepatide offer rises from $399 through 10 mg to $549 at 12.5 mg and 15 mg, each billed every 30 days. Semaglutide is listed at $299 across available doses. Is the physician fee extra? The $99 fee is included. Detailed terms say it becomes nonrefundable once the evaluation occurs; confirm the conflicting refund wording before enrollment. Is TeleDocs360 expensive compared with other GLP-1 telehealth sellers? TeleDocs360 publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TeleDocs360 above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleHealth Med reviews (2026): GLP-1 telehealth sellers | This GLP A compounded GLP-1 storefront that promises one price for every dose and shows no figure before checkout. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/telehealth-med Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat price promised, not printed # TeleHealth Med review A compounded GLP-1 storefront that promises one price for every dose and shows no figure before checkout. ## The verdict TeleHealth Med sells compounded semaglutide and tirzepatide. It states one price for every dose. It does not print that price on either site. A buyer learns it only inside the questionnaire. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named TeleHealth Med, Inc. runs a cash-pay telehealth storefront for compounded GLP-1 injections. Its page title places it in Evans, Georgia. Orders run through a second storefront at v2.telehealthmed.com. Sublingual forms are described in the FAQ. No insurance is required. 1. ## Who writes the prescription, and what do they see? A licensed clinician reviews the intake. The site says the review happens after payment. Some patients are then called for a video visit. Others receive a prescription within one day. No clinician is named. The storefront says board-certified physicians review each plan. The process has three steps: questionnaire, clinician review, delivery. Payment is taken before the review. An ineligible buyer is refunded in full within 24 to 48 hours. Refills require a check-in when the supply runs low. Future months can be canceled before the next shipment is prepared. 2. ## What happens when the dose goes up? The storefront lists milligram strengths for both molecules. It states the same price for all dosages. A step up therefore should not change the charge. That price is not shown, so the claim cannot be checked before purchase. Dose changes go through the provider. 3. ## What the price includes No figure is printed for either molecule. The storefront states no membership fee and no hidden fees. It also runs a banner reading "Sale: Live for 24 Hrs" with no end date or amount beside it. The refund terms say promotional discounts can reduce a refund. 4. ## What it claims, and what it cites Both lines are compounded by 503A pharmacies. The site states that the FDA has not approved or evaluated compounded medications for safety, quality or efficacy. No pharmacy is named. The footer states the website is not a pharmacy or a healthcare provider. ## Where it holds up, and where it does not - Strength: The site promises the same price at all dosages - Strength: Full refund if found ineligible - Strength: Milligram strengths are listed - Strength: No membership fee is stated - Limitation: Neither drug shows a figure - Limitation: Payment is taken before clinician review - Limitation: No clinician or pharmacy is named - Limitation: A sale banner carries no terms ## What the evidence says about this kind of treatment The assessment above is about TeleHealth Med. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a flat price across the dose ladder and will learn it at checkout. Wrong for A reader who needs a published figure to compare against other sellers. ## The evidence behind what TeleHealth Med prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How TeleHealth Med compares | Seller | Who it suits | Go | | --- | --- | --- | | TeleZen MD | Readers who want the monthly rate and every term discount on one card | | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Eden](https://thisglp.com/reviews/eden) [Embody](https://thisglp.com/reviews/embody) [Enhance MD](https://thisglp.com/reviews/enhance-md) [Found](https://thisglp.com/reviews/found) [Gala](https://thisglp.com/reviews/gala) [HealthRX](https://thisglp.com/reviews/healthrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does it cost? The site does not say. It states one price for all dosages and prints no figure. Is the price the same at a higher dose? The storefront says so. The figure itself is not published. What if I do not qualify? The FAQ states a full refund within 24 to 48 hours. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleHealth Weight Solutions reviews (2026): GLP-1 telehealth sellers | This GLP The opening charge buys about ten weeks, and refills afterwards depend on vial size. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/telehealth-weight-solutions Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Ten weeks, then refills # TeleHealth Weight Solutions review The opening charge buys about ten weeks, and refills afterwards depend on vial size. ## The verdict TeleHealth Weight Solutions charges $650 for an initial supply of about ten weeks of compounded semaglutide, which is roughly $325 a month. Refills start near $60 a month depending on vial size. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved TeleHealth Weight Solutions sells both molecules by injection as an initial block followed by refills, with the refill cost tied to the vial rather than to a plan. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe supplies and fees rather than clinicians. The intake is not documented. The structure front-loads the cost heavily. A buyer pays most of the money before knowing whether they tolerate the drug, and then pays very little afterwards if the vial size suits them. 2. ## What happens when the dose goes up? Refill cost is stated to depend on vial size, which is the closest thing to a dose ladder here without being one. A larger vial means a higher refill, so escalation moves the figure without the pages saying by how much. 3. ## What the price includes $650 across about ten weeks is roughly $325 a month, and ten weeks is 2.3 calendar months rather than three. Refills from about $60 a month change the picture entirely after the opening block. Tirzepatide opens at $750, about $375 a month, and carries a one-time transfer fee of $125 that sits outside the supply cost. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Refills are far cheaper than the opening block - Strength: The initial supply length is stated - Strength: The transfer fee is disclosed - Limitation: Most of the cost lands before month three - Limitation: Refill cost depends on unpublished vial sizes - Limitation: A one-time $125 transfer fee on tirzepatide - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about TeleHealth Weight Solutions. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who can carry a large opening charge and wants cheap refills after it. Wrong for A reader who wants to spread cost evenly, or to stop cheaply in month two. ## The evidence behind what TeleHealth Weight Solutions prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TeleHealth Weight Solutions compares | Seller | Who it suits | Go | | --- | --- | --- | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | | TeleClinic | Readers who want the standard rate stated beside the introductory one before they sign up | | | Somira Health | Readers who want the pharmacy and the rate named before the intake | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HumeCare+](https://thisglp.com/reviews/humecare)[Live Vital](https://thisglp.com/reviews/live-vital) [Lttl](https://thisglp.com/reviews/lttl) [Luvo Health](https://thisglp.com/reviews/luvo-health) [MEDGm](https://thisglp.com/reviews/medgm) [Oak](https://thisglp.com/reviews/oak) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the opening charge buy? About ten weeks of supply for $650 on semaglutide, which is roughly $325 a calendar month. Ten weeks is 2.3 months rather than three. What do refills cost? From about $60 a month, with the figure depending on vial size — so a higher dose costs more without the pages stating how much. Is there a fee on the tirzepatide line? Yes. A one-time $125 transfer fee sits outside the $750 initial supply. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Teleios Health reviews (2026): GLP-1 telehealth sellers | This GLP Teleios Health advertises continuing support, but its exact monitoring schedule and narrow refund window need attention before treatment starts. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/teleios-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A platform arranging compounded semaglutide and tirzepatide injections with independent clinician review and pharmacy delivery. # Teleios Health review Teleios Health advertises continuing support, but its exact monitoring schedule and narrow refund window need attention before treatment starts. ## The verdict The two named weekly injection options and separated platform, clinician and pharmacy roles are useful. Confirm the actual medical team, follow-up cadence and prescription-specific total rather than relying on a generic starting offer. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Teleios Health is a technology platform connecting patients with independent healthcare providers and pharmacies. It explicitly says the platform itself does not diagnose or treat patients. 1. ## Who writes the prescription, and what do they see? A provider-patient relationship begins only after mutual acceptance with an independent clinician. Ask who is assigned, how that clinician is licensed for your location and which practice manages questions after the first review. The homepage describes clinical review, pharmacy fulfillment and regular check-ins. It also advertises continuous support, but does not define a guaranteed clinical response time. Establish how scheduled reviews and between-visit concerns are handled. 2. ## What happens when the dose goes up? Weekly compounded semaglutide and tirzepatide injections are listed. The clinician should set the regimen and any adjustments; the homepage’s general progress timeline is not an individualized prediction or dosing instruction. 3. ## What the price includes The terms divide the professional fee into provider and partner-pharmacy components. Both treatment cards have starting prices, but a full quote needs the actual prescription and supply period. The service does not participate in insurance, Medicare or Medicaid networks. 4. ## What it claims, and what it cites The named offers are compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) injections. The site states these are not FDA-approved. Results cited from studies of GLP-1 medicines should not be taken as proof of an equivalent result with a particular dispensed compound. ## Where it holds up, and where it does not - Strength: Names both compounded weekly injection options - Strength: Explains that care comes from independent providers - Limitation: Clinical follow-up frequency needs clarification - Limitation: Treatment quotes require prescription-specific detail ## What the evidence says about this kind of treatment The assessment above is about Teleios Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults comfortable with independent online care who will confirm the clinician, pharmacy and monitoring arrangements. Wrong for Anyone needing guaranteed refunds after dispensing or assuming a marketing progress timeline predicts their response. ## The evidence behind what Teleios Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Teleios Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PeterMD](https://thisglp.com/reviews/petermd) [Sesame Care](https://thisglp.com/reviews/sesame-care) [SnagRx](https://thisglp.com/reviews/snagrx) [Sprout Health](https://thisglp.com/reviews/sprout-health) [Strut Health](https://thisglp.com/reviews/strut-health) [Wellorithm](https://thisglp.com/reviews/wellorithm) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who provides the medical care? Independent healthcare providers, not Teleios Health itself. Confirm the treating practice and clinician before beginning treatment. Does the homepage timeline predict my result? No. The published sequence is general marketing. Your clinician should discuss realistic expectations and review your individual response. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://www.teleioshealth.care/) - [Official program and terms](https://www.teleioshealth.care/terms) - [Official program and terms](https://www.teleioshealth.care/refund-policy) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TelePeptide reviews (2026): GLP-1 telehealth sellers | This GLP Every line publishes a month-to-month figure and three commitment rates, each stated as covering the evaluation, the prescription, the medication and the shipping — and no figure anywhere states a dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/telepeptide Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four terms, four lines, no dose # TelePeptide review Every line publishes a month-to-month figure and three commitment rates, each stated as covering the evaluation, the prescription, the medication and the shipping — and no figure anywhere states a dose. ## The verdict TelePeptide publishes sixteen figures across four lines, opening at $199 a month for injected semaglutide bought a month at a time and falling to $169 on an annual commitment. Every tier is stated as all-inclusive. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $199/mo Oral From $229/mo Prescription Required Compounded Yes — not FDA-approved TelePeptide sells both molecules as an injection and as a dissolvable sublingual tablet, and prices each of those four lines at four different commitment lengths, so a buyer meets sixteen published figures where a single starting price would normally stand. 1. ## Who writes the prescription, and what do they see? The physician evaluation is named as part of what each figure covers, which is a more specific claim than the usual promise that a prescription will be issued, though no individual clinician is described anywhere on the pages read. Stating plainly that a figure already contains the evaluation, the prescription, the medication and the shipping removes the four charges that most commonly appear after a purchase, and it is why this seller carries no fee correction on this site. 2. ## What happens when the dose goes up? Nothing in sixteen published figures says what happens when a dose goes up, and on a sublingual formulation the silence matters more than usual, because a reader cannot even infer the answer from a pen strength they can see. 3. ## What the price includes Injected semaglutide is $199 month to month, $189 on three months, $179 on six and $169 on an annual prepay, so a year at the monthly rate costs $360 more than the same year committed in advance. The dissolvable semaglutide tablet runs $229, $219, $209 and $199, injected tirzepatide $249, $237, $224 and $214, and the tirzepatide tablet $249, $239, $229 and $219. Month to month the two tirzepatide formats cost the same, and at every other term the tablet costs more than the injection of the same molecule. 4. ## What it claims, and what it cites All four lines are compounded, prepared by a pharmacy the site does not name, and the FDA reviews none of them before dispensing — a caveat with particular force for a sublingual tablet, a format no approved product comes in. ## Where it holds up, and where it does not - Strength: Four commitment lengths published on every line - Strength: Each tier stated as covering evaluation, prescription, medication and shipping - Strength: The month-to-month option is priced rather than withheld - Strength: Both molecules available in both formats - Limitation: No milligram dose appears beside any of the sixteen figures - Limitation: The annual rate requires a year committed in advance - Limitation: The tablets never cost less than the injections - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about TelePeptide. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the whole commitment ladder priced in advance and is content to ask about dose separately. Wrong for A reader who needs to know what any of these sixteen figures becomes once the dose starts climbing. ## The evidence behind what TelePeptide prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TelePeptide compares | Seller | Who it suits | Go | | --- | --- | --- | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | | Pepti | Readers who want labs and physician care inside one figure and count fills rather than months | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Strut Health](https://thisglp.com/reviews/strut-health) [Wellorithm](https://thisglp.com/reviews/wellorithm) [Willow](https://thisglp.com/reviews/willow) [YourEra](https://thisglp.com/reviews/yourera) [EverPrime](https://thisglp.com/reviews/everprime) [MyDrHank](https://thisglp.com/reviews/mydrhank) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does all-inclusive mean here? The seller states that each tier covers the physician evaluation, the prescription, the medication and the shipping, which is why this site applies no fee correction to any of its figures. What does committing to a year save? On injected semaglutide it is $30 a month against the month-to-month rate, or $360 over the year that the commitment lasts. Is the tablet cheaper than the injection? No. The sublingual semaglutide tablet runs $30 a month above the injection at every term. The two tirzepatide formats cost the same month to month, and the tablet costs more on every commitment. Is TelePeptide expensive compared with other GLP-1 telehealth sellers? TelePeptide publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TelePeptide above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleSlim Clinic reviews (2026): GLP-1 telehealth sellers | This GLP A Chicago obesity-medicine practice that sells a monthly doctor subscription and sends the prescription to whichever pharmacy the patient chooses. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/teleslim-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Obesity doctors, drug billed apart # TeleSlim Clinic review A Chicago obesity-medicine practice that sells a monthly doctor subscription and sends the prescription to whichever pharmacy the patient chooses. ## The verdict TeleSlim Clinic sells access to board-certified obesity-medicine physicians for $99 a month, and the medication is a separate bill that its own FAQ puts anywhere from $10 to $900 a month. That makes it a doctor's subscription with a pharmacy receipt beside it, not a single GLP-1 price a reader can rank. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Flat across doses States 6 Prescription Required Pharmacy Named Availability IL, TX, CO, MI, PA and AZ TeleSlim Clinic is a subscription-based, all-online weight-loss practice headquartered on North Michigan Avenue in Chicago, serving Illinois and offering telemedicine in Texas, Colorado, Michigan, Pennsylvania and Arizona. Its medication list runs from semaglutide and tirzepatide to the Wegovy pill, orforglipron, phentermine and metformin, which is a far wider shelf than a GLP-1 storefront carries. 1. ## Who writes the prescription, and what do they see? Every visit, the site says, is with a board-certified obesity-medicine doctor, never a nurse or physician assistant, and three physicians are named with their boards. Dr. Jihad Kudsi, the founder, is a bariatric surgeon with dual certification in general surgery and obesity medicine, and Dr. Diala Alatassi and Dr. Katie E. Rosenfeld each hold two board certifications. A patient starts with a 45-minute video consultation, reviews a treatment plan with the doctor, and then pays a monthly subscription that includes a follow-up with that doctor every month. Weekly sessions with a registered dietitian or an exercise specialist are sold separately, and the practice says plainly that anyone after a quick fix may be at the wrong clinic. 2. ## What happens when the dose goes up? The subscription does not move as a dose rises, because it pays for the doctor rather than the drug. The medication is where the dose shows up, and its cost is set by whichever pharmacy fills it and by the patient's insurance. The monthly follow-up is where a step up is decided, so each change passes through a physician visit that the subscription already covers. 3. ## What the price includes The doctor's subscription is $99 a month, with prepaid terms at $269 for three months, $499 for six and $899 for a year. The first consultation is its own charge, currently discounted for a limited time. Medication is extra, and the FAQ gives the range as $10 to $900 a month depending on the drug and on whether insurance pays for it. 4. ## What it claims, and what it cites The practice prescribes FDA-approved medications and sends each prescription to the patient's preferred pharmacy, with help on prior authorization where insurance applies. It also names a partner pharmacy, Rush Pharmacy in Oviedo, Florida, with a street address. Nothing on the current pages describes a compounded preparation. ## Where it holds up, and where it does not - Strength: Board-certified obesity-medicine physicians only - Strength: Three physicians named with their certifications - Strength: A monthly doctor follow-up is included - Strength: A partner pharmacy named with an address - Limitation: Medication is billed separately - Limitation: The medication range is very wide - Limitation: The first consultation costs extra - Limitation: Dietitian and exercise sessions cost extra ## What the evidence says about this kind of treatment The assessment above is about TeleSlim Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient with insurance that may cover a brand GLP-1 who wants a specialist physician managing the dose every month. Wrong for A cash buyer looking for one monthly figure that already includes the medication. ## The evidence behind what TeleSlim Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How TeleSlim Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | SynergenX Health | Readers near a clinic metro who want a live video visit and can budget for visit fees | | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | Jently | Patients who want the compounding pharmacy named before they pay | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MyDrHank](https://thisglp.com/reviews/mydrhank) [1st Optimal](https://thisglp.com/reviews/1st-optimal) [24hrDOC](https://thisglp.com/reviews/24hrdoc) [AbundRX](https://thisglp.com/reviews/abundrx) [Actin](https://thisglp.com/reviews/actin) [AgelessRx](https://thisglp.com/reviews/agelessrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the $99 a month include the medication? No. It covers the monthly physician follow-up. The FAQ says medication costs are separate and can run from $10 to $900 a month. Is a longer plan cheaper? Yes. The subscription is $269 for three months, $499 for six and $899 for a year. Which states does TeleSlim serve? Illinois, with telemedicine coverage in Texas, Colorado, Michigan, Pennsylvania and Arizona. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleWellnessMD reviews (2026): GLP-1 telehealth sellers | This GLP TeleWellnessMD offers a GLP-1 assessment and a location-dependent formulary. Its terms allow patients to request an outside pharmacy before completing an order. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/telewellnessmd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 State-dependent prescription access # Does TeleWellnessMD sell a GLP-1? TeleWellnessMD offers a GLP-1 assessment and a location-dependent formulary. Its terms allow patients to request an outside pharmacy before completing an order. ## The verdict The pharmacy-transfer option is useful, but the public catalog does not establish a complete dose-and-supply quote. Start by confirming availability in your state and the clinical contact schedule, rather than interpreting an unqualified catalog amount as a monthly plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required TeleWellnessMD is an online medical-provider network with a prescription catalog and patient portal. Its GLP-1 section lists semaglutide and tirzepatide options, including explicitly oral entries. 1. ## Who writes the prescription, and what do they see? The terms assign clinical decisions to licensed providers and say a consultation does not guarantee treatment. State-specific notices identify some clinicians, but do not establish who will receive an individual case. Patients select their location to determine available prescriptions and begin an assessment. The reviewed public material does not specify the recurring visit frequency for each GLP-1 plan. 2. ## What happens when the dose goes up? A catalog entry is not a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) schedule. Ask the provider how tolerance, current medication and refill eligibility are reassessed, and obtain the prescribed formulation and directions from the pharmacy. 3. ## What the price includes The public formulary does not consistently expose supply duration and dose with its amounts. A comparable standing monthly GLP-1 price therefore remains unestablished. The terms describe self-pay service and restrict reimbursement requests. 4. ## What it claims, and what it cites The catalog names semaglutide and tirzepatide, including oral formulations. It does not establish that every listing is a branded FDA-approved product; confirm the formulation and approval status before ordering. ## Where it holds up, and where it does not - Strength: Outside-pharmacy requests allowed - Strength: Location affects availability explicitly - Limitation: Follow-up cadence not specified - Limitation: Catalog amounts lack dose and interval context ## What the evidence says about this kind of treatment The assessment above is about TeleWellnessMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values the option to request a pharmacy transfer and will confirm the available state-specific program. Wrong for Someone expecting a public catalog figure to establish a complete monthly supply and care schedule. ## The evidence behind what TeleWellnessMD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TeleWellnessMD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Alinwell](https://thisglp.com/reviews/alinwell) [Allara Health](https://thisglp.com/reviews/allara-health) [Alloy](https://thisglp.com/reviews/alloy) [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) [altRX](https://thisglp.com/reviews/altrx) [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I use my own pharmacy? The terms say to contact support before completing the order if you want a prescription transferred to a pharmacy of your choice. Does a catalog listing mean it is available in my state? No. The catalog asks for location to determine prescription availability. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://telewellnessmd.com/) - [Official program and terms](https://telewellnessmd.com/pages/termsofuse) - [Official program and terms](https://telewellnessmd.com/rx_browser/glp-1-therapies) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TeleZen MD reviews (2026): GLP-1 telehealth sellers | This GLP A four-rung plan ladder on both molecules, with the month-to-month rate printed at the bottom of each card. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/telezen-md Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four rungs, one price per dose # TeleZen MD review A four-rung plan ladder on both molecules, with the month-to-month rate printed at the bottom of each card. ## The verdict TeleZen MD charges $168 a month for compounded semaglutide on its Monthly Plan. Tirzepatide is $268. Longer plans cost less per month. All doses are stated to cost the same. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $168/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named TeleZen MD sells compounded semaglutide and tirzepatide by weekly injection. It is cash-pay only, with no insurance billing. Each molecule has a four-rung card: annual, semi-annual, quarterly and monthly. 1. ## Who writes the prescription, and what do they see? The page names four physicians. Each entry lists a board certification or a medical school. The page states that a U.S. board-certified doctor reviews every prescription. Approval is stated to take about 24 hours. The first step is a five-minute health questionnaire. A licensed physician then reviews it and approves a prescription if the patient qualifies. Medication ships overnight from a 503A pharmacy. Plans are paused or canceled in the patient portal. No contract or membership fee is stated. A nutrition protocol and coaching program come with every plan. 2. ## What happens when the dose goes up? The buyer chooses at checkout. One option is a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) plan that rises over time. The other holds one dose. The FAQ states that all doses are the same price. A step up therefore does not change the charge. Dose changes are raised at check-ins. 3. ## What the price includes The monthly rungs are $168 and $268. The quarterly rungs are $149 and $233 a month. They bill $448 and $698 every three months. The semi-annual and annual rungs cost less again. The hero figure is the annual rung. The card also prints the rate without a commitment. 4. ## What it claims, and what it cites Both lines are compounded in 503A pharmacies. They are not FDA-approved. The FDA does not review them before dispensing. No pharmacy is named. Syringes and alcohol swabs are included. ## Where it holds up, and where it does not - Strength: Month-to-month rate printed on each card - Strength: Same price at every dose - Strength: Four physicians named with certifications - Strength: Pause or cancel in the portal - Limitation: The hero figure needs twelve months - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published - Limitation: No state coverage list is published ## What the evidence says about this kind of treatment The assessment above is about TeleZen MD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the monthly rate and the term discounts on one card. Wrong for A reader who will not buy until the 503A pharmacy behind the overnight shipment is named. ## The evidence behind what TeleZen MD prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TeleZen MD compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Belle Health | Someone who wants included nutrition and clinical support and can choose an appropriate supply commitment after discussing treatment. | | | Good Girl Rx | A reader who will read the one-month rung rather than the headline, and wants microdoses labeled as such | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [altRX](https://thisglp.com/reviews/altrx) [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) [AlyveRx](https://thisglp.com/reviews/alyverx) [AM Rx](https://thisglp.com/reviews/amrx) [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) [Amble](https://thisglp.com/reviews/amble) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost without a commitment? $168 a month on the Monthly Plan. Tirzepatide is $268. Does the price rise with the dose? No. The FAQ states all doses are the same price. What does the quarterly plan bill? $448 every three months for semaglutide. $698 for tirzepatide. Is TeleZen MD expensive compared with other GLP-1 telehealth sellers? TeleZen MD publishes a starting figure of $168/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TeleZen MD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tell Her Doc reviews (2026): GLP-1 telehealth sellers | This GLP Four physicians listed by NPI and four pharmacies by phone, beside one starting figure whose billing period is never given. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tellherdoc Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Clinicians by NPI, price term unstated # Tell Her Doc review Four physicians listed by NPI and four pharmacies by phone, beside one starting figure whose billing period is never given. ## The verdict Tell Her Doc advertises compounded semaglutide and tirzepatide starting at $269. The page does not say whether that buys a month, a fill or a longer plan. It is unusually specific about who prescribes and who compounds, and silent on what a given dose costs. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection States 50 Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Tell Her Doc is a single-page storefront for compounded semaglutide and tirzepatide. Both come as weekly injections, as pills, and in microdoses. Ozempic and Zepbound are listed beside them as limited stock, without a price. The site's own terms name the operator as TellHerDoc, Inc., a Delaware corporation in Alpharetta, Georgia. 1. ## Who writes the prescription, and what do they see? The FAQ names the medical team, Lion MD, led by Dr. Ana Lisa Carr and Dr. Kelly Tenbrink. Each lead physician's NPI number is printed, as are two supporting physicians'. A licensed clinician reviews the intake and writes the prescription if appropriate. The page says the whole flow typically takes one to two weeks. Care starts with an online quiz covering weight, pregnancy and a long medical history. Insurance is not required, and buy-now-pay-later financing is offered. Cancellation is by message or through the patient portal. All sales are final once medication leaves the pharmacy. 2. ## What happens when the dose goes up? Microdoses are offered for both injectable molecules. No milligram amount is published for any strength. No price is attached to any step. What a dose increase costs is therefore not stated anywhere before enrollment. 3. ## What the price includes The hero figure reads starting at $269 and names both molecules together. It carries no period, dose or form. A footnote says pricing is paid upfront in full and depends on the product and plan. That footnote sits under a first-order discount section, not under the $269. The FAQ says the price includes the consult, the prescription and shipping. The page states no monthly membership. 4. ## What it claims, and what it cites Both lines are compounded, and the page states that compounded drugs are not approved or evaluated by the FDA for safety, effectiveness or quality. Four compounding pharmacies are named with phone numbers: Belmar, Strive, Epiq Scripts and Casa Pharma Rx. Which one fills a given order is not stated. ## Where it holds up, and where it does not - Strength: Four physicians listed with NPI numbers - Strength: Four compounding pharmacies listed with phone numbers - Strength: The page states no monthly membership - Strength: Service in all 50 states - Limitation: The one figure has no stated period - Limitation: No price for any dose step - Limitation: No price before a date-of-birth screen - Limitation: All sales final once dispensed ## What the evidence says about this kind of treatment The assessment above is about Tell Her Doc. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the prescribing physicians and compounding pharmacies named before starting. Wrong for A reader who needs a monthly cost at a specific dose before sharing personal details. ## The evidence behind what Tell Her Doc prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Tell Her Doc compares | Seller | Who it suits | Go | | --- | --- | --- | | MaxLife | Readers who will ask what the starter kit covers and what follows it | | | Clinic Secret | Buyers who budget from the standing rate rather than the first-month figure | | | WeightRx | Readers wanting tirzepatide who will confirm the figure before ordering | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Amble](https://thisglp.com/reviews/amble) [Andrew Meds](https://thisglp.com/reviews/andrew-meds) [Apex MD](https://thisglp.com/reviews/apex-md) [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) [Arc-1](https://thisglp.com/reviews/arc-1) [Ark Health](https://thisglp.com/reviews/ark-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $269 a monthly price? Not stated. The figure covers both molecules and gives no period, dose or form. A footnote says pricing is paid upfront in full. Who prescribes? A medical team the FAQ calls Lion MD. Four physicians are listed with NPI numbers. Who runs Tell Her Doc? The site's terms name TellHerDoc, Inc., a Delaware corporation based in Alpharetta, Georgia. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Telos Rx reviews (2026): GLP-1 telehealth sellers | This GLP The advertised figures belong to the longest plan, and no monthly rate is published for either molecule. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/telos-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Longest plan, no monthly rate # Telos Rx review The advertised figures belong to the longest plan, and no monthly rate is published for either molecule. ## The verdict Telos Rx publishes $99 a month for compounded semaglutide as its lowest plan-length tier, against a $299 comparison price. No month-to-month rate is published, and standard tirzepatide is $139. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $99/mo Prescription Required Compounded Yes — not FDA-approved Availability Not published by the provider Telos Rx sells both molecules by injection on plan-length tiers, with a separate microdosed tirzepatide product priced below the standard line. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. The plan structure is the only thing the pages set out in detail, and it omits the rung most readers would start on. A ladder with no top rung is an unusual shape. A reader can see what the longest commitment costs and cannot see what a single month costs, which reverses the usual disclosure problem — here the cheap figure is real and the expensive one is missing. 2. ## What happens when the dose goes up? Nothing states what either figure does at a higher dose. The microdosed tirzepatide product at $116 is a different treatment rather than a lower rung of the standard $139 line, and the pages keep the two apart. 3. ## What the price includes Six months at $99 is $594 if the longest plan is taken, and nothing on the site establishes what six months costs otherwise. The comparison prices of $299 and $279 sit beside the figures with no stated basis, so they are anchors rather than rates. Standard compounded tirzepatide is $139 a month against a $399 comparison. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The microdosed product is priced separately - Strength: The plan-tier structure is stated - Strength: Both molecules carry a standard figure - Limitation: No month-to-month rate is published - Limitation: The advertised figure needs the longest plan - Limitation: Comparison prices have no stated basis - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Telos Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader taking the longest plan, since no shorter term carries a published rate. Wrong for A reader who wants to know what a single month costs. ## The evidence behind what Telos Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Telos Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Sumbare Wellness | Readers who will get a molecule-specific figure confirmed before paying | | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | The Edit | Readers who read the standing rate beside the first-order figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [ARSYNL Rx](https://thisglp.com/reviews/arsynl-rx) [Ascend Medical](https://thisglp.com/reviews/ascend-medical) [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) [AskRx](https://thisglp.com/reviews/ask-rx) [Aspen](https://thisglp.com/reviews/aspen-health) [Aspire Health](https://thisglp.com/reviews/aspire-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does one month cost? Not published. The $99 is the lowest plan-length tier and no month-to-month rate appears on the site. Is $116 the tirzepatide price? That is the separate microdosed product. Standard compounded tirzepatide is listed at $139 a month. What are the $299 and $399 figures? Comparison prices with no stated basis. Treat them as anchors rather than rates anyone is charged. Is Telos Rx expensive compared with other GLP-1 telehealth sellers? Telos Rx publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Telos Rx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # The Aesthetic Concierge reviews (2026): GLP-1 telehealth sellers | This GLP A physician-led practice that bills semaglutide in five-week cycles, after a kick-off appointment that carries its own price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/the-aesthetic-concierge Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Five-week cycles, physician-led # The Aesthetic Concierge review A physician-led practice that bills semaglutide in five-week cycles, after a kick-off appointment that carries its own price. ## The verdict The Aesthetic Concierge bills compounded semaglutide at $414 every five weeks, beside a struck $479. Five weeks is longer than a month, so the calendar-month equivalent is $360. Every patient starts with a $579 kick-off appointment that includes the first five weeks. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 14 From From $360/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Included Availability 14 states The Aesthetic Concierge is a medical weight-loss practice that also offers hormone therapy, NAD+ and longevity care. It lists virtual care in fourteen states. Semaglutide and tirzepatide are sold as injections, and an oral semaglutide is offered on a maintenance plan. 1. ## Who writes the prescription, and what do they see? The site names Dr. Evan Blum as co-founder and medical director, and a physician associate beside him. The home page describes a team of doctors and nurse practitioners under his lead. Which clinician writes a given prescription is not stated. The first appointment reviews bloodwork and health history before a plan is set. Care begins with the kick-off appointment, which includes basic bloodwork and the first five weeks of medication. After that, patients move to a five-week subscription with unlimited access to the medical team. The pricing page calls the kick-off an in-person discussion. The home page calls it a virtual appointment. 2. ## What happens when the dose goes up? The semaglutide subscription is one figure per five-week cycle, and no milligram tiers are published beside it. Tirzepatide starts at $479 every five weeks, and 'starting at' is not explained. Dose changes are described as part of regular check-ins. A separate maintenance plan applies after the goal weight is reached. 3. ## What the price includes $414 every five weeks is the standing semaglutide rate, and nothing on the page says the struck $479 returns. A five-week cycle does not line up with calendar months, so the figure does not compare directly with monthly rates. At $414 per five weeks, a calendar month comes to $360. The $579 kick-off is a separate first charge, and a microdosing tier is priced lower. 4. ## What it claims, and what it cites Both injectable lines are compounded, sourced from a 503A pharmacy the site does not name. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. The oral [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) on the maintenance plan comes from the same kind of 503A pharmacy. ## Where it holds up, and where it does not - Strength: Medical director named on the pricing page - Strength: Basic bloodwork included in the kick-off - Strength: Standing rate printed beside the struck anchor - Strength: Unlimited team access on the subscription - Limitation: Billing cycle is five weeks, not monthly - Limitation: A kick-off appointment is charged first - Limitation: No compounding pharmacy is named - Limitation: No milligram dose published beside a price ## What the evidence says about this kind of treatment The assessment above is about The Aesthetic Concierge. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in one of the listed states who wants a named physician lead and bloodwork up front. Wrong for A reader comparing monthly figures who does not want to convert a five-week cycle. ## The evidence behind what The Aesthetic Concierge prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How The Aesthetic Concierge compares | Seller | Who it suits | Go | | --- | --- | --- | | Wellspring Longevity Clinic | Readers who want a custom blend and will ask what theirs costs | | | Concierge MD LA | Readers who want one number covering care and medication and can commit four months | | | Silhouette MD | Readers who want an unqualified number and will pay the tablet premium for one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Auren Rx](https://thisglp.com/reviews/auren-rx) [AVARA Rx](https://thisglp.com/reviews/avara-rx) [Avono Health](https://thisglp.com/reviews/avono-health) [AZ Health](https://thisglp.com/reviews/az-health) [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) [Bayan Health](https://thisglp.com/reviews/bayan-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost per month? $414 buys five weeks. A calendar month at that rate is $360. What is the kick-off appointment? A $579 first charge covering the consultation, basic bloodwork and the first five weeks of medication. Is the struck $479 charged later? Nothing on the page says so. It sits beside the $414 with no end date attached. Is The Aesthetic Concierge legit? The Aesthetic Concierge is a GLP-1 telehealth sellers service. Its stated availability: 14 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is The Aesthetic Concierge expensive compared with other GLP-1 telehealth sellers? The Aesthetic Concierge publishes a starting figure of $360/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts The Aesthetic Concierge above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Oxford's Medical Weight Loss (The Calibrate Clinic) reviews (2026) | This GLP A Lafayette practice that quotes a new-patient first month, then bills a flat rate that it says covers every dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/the-calibrate-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Local clinic, first month discounted # Oxford's Medical Weight Loss (The Calibrate Clinic) review A Lafayette practice that quotes a new-patient first month, then bills a flat rate that it says covers every dose. ## The verdict The Calibrate Clinic is a weight loss practice on South College Drive in Lafayette, Louisiana, and its pricing cards lead with a new-patient first month of $145 for its GLP-1 program and $199 for its GLP-1+GIP program. The FAQ is plain about what follows: from the second month the regular rate is $215 or $329, and it is stated to cover every dose on the way up. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $215/mo Dose published No Prescription Required Pharmacy Not named The Calibrate Clinic runs two weight loss programs, one built on a GLP-1 medication and one on a combined GLP-1+GIP medication, and the footer names them as semaglutide and tirzepatide. Consultations happen by phone, medication can be collected from the Lafayette office three days a week, and the practice says it ships nationwide to anyone who would rather stay home. No state list is published for where its providers prescribe. It is a separate business from the national telehealth company with a similar name. 1. ## Who writes the prescription, and what do they see? The first conversation is a free phone call of about ten minutes with a member of the medical team, who reviews health history and goals and decides which medication fits. The site says every program is overseen by a licensed provider who writes the prescription and monitors progress remotely, and describes that care as concierge provider access. No clinician, medical director or credential is named anywhere on the pages, so a patient learns who prescribes only after the call. Starting takes a small consultation deposit paid online, and the site says the medication itself is billed only after the prescription is approved, when a staff member calls to take payment. Prescriptions are filled through a local pharmacy that the clinic says turns them around in one to two business days. After that the team is reachable by phone on weekdays and describes regular check-ins, with a patient portal of ten tools included. There are no contracts, and the pricing cards say a patient can cancel at any time. 2. ## What happens when the dose goes up? Both cards say all doses are covered at the monthly rate with no per-dose fees, and the FAQ repeats that the regular rate holds no matter where a patient sits in [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). One line under the cards reads differently, saying exact pricing is based on the prescribed dose and offering a personalized quote. The two statements cannot both describe the same bill, and the quote is the place a patient would learn which one applies to them. Dose adjustments are described as part of the regular check-ins, handled by the same team. 3. ## What the price includes The GLP-1 program is $145 for the first month and $215 a month after it. The GLP-1+GIP program is $199 for the first month and $329 a month after it. Both figures are labeled on the cards as all-inclusive, covering medication, provider care and shipping, and the FAQ says there are no membership or consultation fees on top. Six months on the GLP-1 program at the regular rate comes to $1,290, and the step from one program to the other is $114 a month. 4. ## What it claims, and what it cites The site names [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) in its footer but does not say anywhere whether the medication is compounded or a manufacturer's branded pen. That matters, because a compounded preparation is not FDA-approved and is not reviewed by the FDA before it is dispensed, and a buyer cannot tell from these pages which one is being sold. The dispensing pharmacy is described only as local and is not named. ## Where it holds up, and where it does not - Strength: The regular rate is stated in the FAQ - Strength: No membership or consultation fee on top - Strength: Medication billed only after approval - Strength: Office pickup or nationwide shipping - Strength: No contract, cancel at any time - Limitation: The headline figure is a first month only - Limitation: Compounded or branded is never stated - Limitation: No prescriber or medical director named - Limitation: Dose-pricing wording contradicts itself on one page - Limitation: The pharmacy is described but not named ## What the evidence says about this kind of treatment The assessment above is about Oxford's Medical Weight Loss (The Calibrate Clinic). These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient near Lafayette who wants a phone consultation, office pickup and a flat monthly rate after the first month. Wrong for A buyer who needs to know before paying whether the medication is compounded, or who prescribes it. ## The evidence behind what Oxford's Medical Weight Loss (The Calibrate Clinic) prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Oxford's Medical Weight Loss (The Calibrate Clinic) compares | Seller | Who it suits | Go | | --- | --- | --- | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Believe Health](https://thisglp.com/reviews/believe-health) [Better U Care](https://thisglp.com/reviews/better-u-care) [BetterMe Rx](https://thisglp.com/reviews/betterme-rx) [BeyondMD](https://thisglp.com/reviews/beyondmd) [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) [BiltRx](https://thisglp.com/reviews/biltrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the program cost after the first month? The FAQ names $215 a month for the GLP-1 program and $329 for the GLP-1+GIP program, and says that regular rate begins once the new-patient first month ends. Is this the same company as the national Calibrate program? No. This is The Calibrate Clinic, a medical weight loss practice with an office in Lafayette, Louisiana, and a website of its own. Does the rate rise with the dose? The cards and the FAQ say every dose is covered at the monthly rate, although one line beneath the cards says exact pricing depends on the prescribed dose. Is the medication compounded? The site does not say. It names semaglutide and tirzepatide, but it never states whether either is compounded or branded, so that is a question for the phone consultation. Is Oxford's Medical Weight Loss (The Calibrate Clinic) expensive compared with other GLP-1 telehealth sellers? Oxford's Medical Weight Loss (The Calibrate Clinic) publishes a starting figure of $215/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Oxford's Medical Weight Loss (The Calibrate Clinic) above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # The Edit reviews (2026): GLP-1 telehealth sellers | This GLP The first month is priced below the standing rate for a limited time, and only once. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/the-edit Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A first-month price, once # The Edit review The first month is priced below the standing rate for a limited time, and only once. ## The verdict The Edit publishes $259 a month for compounded semaglutide, with a limited-time first month at $200. Tirzepatide is $349 after a $300 first month. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $259/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states The Edit sells both molecules by injection across fifty states, with prepay tiers billed once upfront and a limited-time first-month price. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state rates and tiers. The clinician is not described and the intake is not documented. A first-month price is a discount, not a rate. The figure a buyer meets first is not the one they will pay. The standing rate is published beside it, which is the part that matters. 2. ## What happens when the dose goes up? Both lines are stated flat, so the rate holds as the dose rises. The prepay tiers are about term rather than dose, so neither variable is left unstated. 3. ## What the price includes Six months of semaglutide at the standing rate is $1,554. Prepaying brings it to $575 for three months, about $192 a month, or $1,065 for six, about $178. Tirzepatide is $349 a month, or $855 and $1,575 prepaid, about $285 and $263 a month. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The first-month price is labeled limited time - Strength: Standing rates published beside it - Strength: Prepay totals stated, not just rates - Strength: Coverage across all fifty states - Limitation: The first figure is a one-time discount - Limitation: Tirzepatide costs $90 more a month - Limitation: Prepaid tiers bill in one charge - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about The Edit. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who reads the standing rate beside the first-order figure. Wrong for A reader budgeting six months from the first-month figure. ## The evidence behind what The Edit prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How The Edit compares | Seller | Who it suits | Go | | --- | --- | --- | | TMates | Readers choosing between formats who do not want the choice priced | | | TeleClinic | Readers who want the standard rate stated beside the introductory one before they sign up | | | Telos Rx | Readers taking the longest plan, since no shorter term carries a published rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Bionomy Health](https://thisglp.com/reviews/bionomy-health) [Bioverse](https://thisglp.com/reviews/bioverse) [Blis MD](https://thisglp.com/reviews/blis-md) [Bliv](https://thisglp.com/reviews/bliv) [Bloom MD](https://thisglp.com/reviews/bloommd) [BloomWell Rx](https://thisglp.com/reviews/bloomwell-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $200 the ongoing price? No. It is a limited-time first month. The standing rate is $259 a month. What do the prepay tiers cost? $575 for three months and $1,065 for six, billed once upfront, which is about $192 and $178 a month. Does the price rise with the dose? No. Both lines are stated flat across doses. Is The Edit legit? The Edit is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is The Edit expensive compared with other GLP-1 telehealth sellers? The Edit publishes a starting figure of $259/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts The Edit above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # The Protocole reviews (2026): GLP-1 telehealth sellers | This GLP The Protocole lists compounded semaglutide and tirzepatide as four-week supplies, with a consultation credited toward an order if treatment proceeds. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/the-protocole Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A consultation before the protocol # The Protocole review The Protocole lists compounded semaglutide and tirzepatide as four-week supplies, with a consultation credited toward an order if treatment proceeds. ## The verdict The Protocole gives patients a longer advertised consultation option and names a pharmacy, but does not publish one standardized vial quantity. Its wellness positioning should not obscure the practical questions: who prescribes, what amount is supplied and how care continues after that first discussion. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved The Protocole markets physician-guided compounded treatments, including separate standard and microdose GLP-1 products. Its broader peptide catalog is not evidence that combining products is necessary or clinically supported for weight management. 1. ## Who writes the prescription, and what do they see? A physician consultation is presented as the route to a personalized plan. The site names a clinical and scientific board, but those advisors are not necessarily the professional prescribing for an individual patient. Ask for the treating practice’s details. The advertised consultation lasts forty-five minutes and its fee is credited if an order proceeds. The site names VialsRX as its dispensing partner. Clarify repeat visits, between-visit messaging and who handles an adverse reaction, since initial consultation length does not establish continued access. 2. ## What happens when the dose goes up? Product pages leave total vial content, concentration and vial size to the individual prescription. That is a reason to request the actual label and quantity, not a published dose ladder. Discuss how a strength change affects both supplied medicine and the next order. 3. ## What the price includes Semaglutide and tirzepatide are priced as four-week supplies. A consultation charge and possible membership-related terms also need explanation. Four-week purchasing creates a different annual cost from calendar-month billing; request a complete quote for the regimen. 4. ## What it claims, and what it cites The GLP-1 injections are compounded, with separate lower-dose listings. Such preparations are not FDA approved. Product-specific pharmacy instructions should govern handling; broad wellness or testimonial claims do not establish outcomes for a particular mixture. ## Where it holds up, and where it does not - Strength: Consultation duration stated - Strength: Pharmacy partner identified - Strength: Four-week supply labels visible - Limitation: Vial quantity determined only by prescription - Limitation: Membership language needs clarification - Limitation: Broader peptide claims need separate evidence ## What the evidence says about this kind of treatment The assessment above is about The Protocole. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking a substantive initial discussion and prepared to obtain a detailed prescription and follow-up plan. Wrong for A patient expecting every product’s exact dose and full continuing cost to be settled by the storefront. ## The evidence behind what The Protocole prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How The Protocole compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Bon Health](https://thisglp.com/reviews/bon-health) [boostAGErx](https://thisglp.com/reviews/boostagerx) [Boston Medical Group](https://thisglp.com/reviews/boston-medical-group) [Breeze Meds](https://thisglp.com/reviews/breeze-meds) [Brello Health](https://thisglp.com/reviews/brello-health) [Brightmeds](https://thisglp.com/reviews/brightmeds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the consultation an extra drug charge? The site says the consultation fee is deducted from an order if treatment proceeds. Ask how that credit and any membership fee apply. Are microdose and standard products the same? No. They are listed separately and should be evaluated by their actual prescribed regimens. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://theprotocole.com/) - [Treatment information](https://theprotocole.com/products/semaglutide) - [Treatment information](https://theprotocole.com/products/tirzepatide) - [Service and cancellation terms](https://theprotocole.com/terms-and-conditions) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # The Virtual NP reviews (2026): GLP-1 telehealth sellers | This GLP A nurse practitioner's telehealth practice that charges for the visit and bills brand-name medication separately. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/the-virtual-np Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One named NP, brand drugs only # The Virtual NP review A nurse practitioner's telehealth practice that charges for the visit and bills brand-name medication separately. ## The verdict The Virtual NP charges $75 for its weight-loss care, as a visit or a monthly membership. The medication is extra. It prescribes brand Wegovy and Zepbound. Compounded versions are no longer offered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 7 Prescription Required Compounded No Availability TX, FL, NY, AZ, NV, NM and KS The Virtual NP is a Texas-based telehealth practice near Dallas-Fort Worth. Weight loss is one service beside urgent care, refills, ED and hair loss. Visits are offered in seven states. Those are Texas, Florida, New York, Arizona, Nevada, New Mexico and Kansas. 1. ## Who writes the prescription, and what do they see? The prescriber is a board-certified family nurse practitioner. The site names her: Sandra Jordan, MSN, APRN, FNP-C. She founded the practice. Every visit is a one-to-one video consultation with a nurse practitioner. No physician is named. The buyer pays first, then books a visit from the receipt email. Recent lab work is required before the consultation. The prescriber then writes a plan. If approved, a payment link covers the drug. A monthly progress report and refill payment follow. 2. ## What happens when the dose goes up? The FAQ tells a new patient to select the Month 1 option, the lowest dose. Later months follow in order. Dose changes are made at follow-up. The site publishes no price for any dose step. 3. ## What the price includes The weight-loss visit is $75. A month-to-month membership is also $75 a month. A pay-as-you-go plan without membership is charged per visit. The medication is billed separately and varies by drug and pharmacy. For cash buyers, the site points to NovoCare and LillyDirect. Insurance can be checked for coverage. 4. ## What it claims, and what it cites The practice prescribes brand [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), which are FDA-approved. Ozempic and other diabetes medications appear on the service page. Prescriptions go to a local pharmacy or a partner pharmacy. The FAQ states that compounded GLP-1 medications are no longer offered. ## Where it holds up, and where it does not - Strength: The prescriber is named with credentials - Strength: Brand FDA-approved medications only - Strength: Visit fee published up front - Strength: Manufacturer cash programs are named - Limitation: The medication price is not published - Limitation: Seven states only - Limitation: Lab work needed before the first visit - Limitation: No physician is named ## What the evidence says about this kind of treatment The assessment above is about The Virtual NP. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in one of the seven states who wants brand medication and a named prescriber. Wrong for A buyer looking for one monthly figure that includes the medication. ## The evidence behind what The Virtual NP prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How The Virtual NP compares | Seller | Who it suits | Go | | --- | --- | --- | | SynergenX Health | Readers near a clinic metro who want a live video visit and can budget for visit fees | | | Care Clinics | Readers who will do the division themselves and want the week counts published to do it with | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Breeze Meds](https://thisglp.com/reviews/breeze-meds) [Brello Health](https://thisglp.com/reviews/brello-health) [Brightmeds](https://thisglp.com/reviews/brightmeds) [Cabana](https://thisglp.com/reviews/cabana) [CaliberRx](https://thisglp.com/reviews/caliberrx) [Calibrate Health](https://thisglp.com/reviews/calibrate-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $75 include the medication? No. It covers the visit or a month of membership. The medication is paid separately. Is compounded semaglutide available? No. The FAQ states compounded GLP-1 medications are no longer offered. Do I need labs? Yes. The FAQ requires recent lab work before the consultation. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TideMedix reviews (2026): GLP-1 telehealth sellers | This GLP TideMedix offers online GLP-1 assessment with semaglutide and tirzepatide pathways. Clinical approval, the actual formulation and ongoing costs must be confirmed after the opening offer. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tidemedix Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does TideMedix sell a GLP-1? TideMedix offers online GLP-1 assessment with semaglutide and tirzepatide pathways. Clinical approval, the actual formulation and ongoing costs must be confirmed after the opening offer. ## The verdict TideMedix clearly separates applying from being approved, which is useful. The harder questions concern the prescription and ongoing care. The public FAQ routes people toward different forms without one universal medicine, follow-up calendar or renewal charge. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required The direct-pay platform advertises weight-management assessment for semaglutide and tirzepatide. Its FAQ describes oral and injection pathways for education and assessment routing, with availability determined by provider review rather than guaranteed by the menu. 1. ## Who writes the prescription, and what do they see? A licensed professional reviews the health information before treatment is considered. TideMedix expressly says a prescription is not guaranteed. The public materials should be followed by confirmation of the medical practice and clinician responsible for the actual patient. The process begins with an online assessment, followed by clinical review and possible fulfillment. The FAQ says review and shipping times vary with the workflow and will be shown during the patient and checkout process. There is no universal response or dispatch deadline. 2. ## What happens when the dose goes up? If prescribing is appropriate, the provider should explain monitoring, risks, interactions and contraindications. Obtain the dose-adjustment and refill-contact plan directly. An assessment-routing choice does not supply instructions for using an oral preparation or weekly injection. 3. ## What the price includes The homepage advertises an introductory first-month offer. That is not a standing renewal price or a dose-price ladder. The FAQ describes a direct-pay path without an insurance requirement; the specific plan and later charges need to be shown before checkout. 4. ## What it claims, and what it cites Semaglutide and tirzepatide are named, but the finished product and formulation are not universal across the assessment paths. Confirm brand or compounding status and the dispensing pharmacy before accepting any comparison with approved-product trial results. ## Where it holds up, and where it does not - Strength: Provider approval is explicitly required - Strength: Clinical screening is separated from applying - Strength: The introductory nature of the offer is visible - Limitation: Renewal costs are not fully public - Limitation: Forms shown for routing do not guarantee availability - Limitation: Provider and pharmacy details need confirmation ## What the evidence says about this kind of treatment The assessment above is about TideMedix. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone comfortable beginning with an assessment while withholding payment until the specific prescription and continuing-care terms are clear. Wrong for A buyer needing a fully specified medicine and flat continuing price before entering the service. ## The evidence behind what TideMedix prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TideMedix compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Care Bare Rx](https://thisglp.com/reviews/care-bare-rx) [Care Clinics](https://thisglp.com/reviews/care-clinics) [Carocare Wellness](https://thisglp.com/reviews/carocare-wellness) [CeliaRx](https://thisglp.com/reviews/celia-rx) [Center for Medical Weight Loss (CMWL)](https://thisglp.com/reviews/center-for-medical-weight-loss)[Cielo](https://thisglp.com/reviews/cielo) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is treatment approval guaranteed? No. TideMedix says a licensed provider must review suitability first. Does the first-month price recur? The offer is explicitly introductory; obtain the later payment schedule. Are all listed forms available to everyone? No. The FAQ frames them as assessment pathways, with availability and appropriateness determined clinically. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://tidemedix.com/) - [Terms of service and payment conditions](https://tidemedix.com/files/terms.html) - [Patient questions and care arrangements](https://tidemedix.com/files/faq.html) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TMates reviews (2026): GLP-1 telehealth sellers | This GLP The format does not change the price, and every rung of the term ladder is published with its total. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tmates Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Oral or injection, one price # TMates review The format does not change the price, and every rung of the term ladder is published with its total. ## The verdict TMates publishes $249 a month for semaglutide and $297 for tirzepatide, falling to $158 and $167 on twelve months. Injectable and oral cost the same. Fifty states are covered. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $249/mo Prescription Required Compounded Yes — not FDA-approved Availability All 50 states TMates sells both molecules by injection or orally at one price per molecule. Four term lengths are published on each. Shipping is free. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. Ongoing support is named as included. The clinician is not described. Pricing an oral at the injection rate removes a decision most sellers charge for. Cancellation is stated as available at any time. 2. ## What happens when the dose goes up? Both lines are flat across doses. Nothing describes clinical support at a step. The ladder is about term rather than dose. 3. ## What the price includes Semaglutide runs $249 for one month and $217 on three, billed $650. Six months is $175 at $1,050 and twelve is $158 at $1,900. Tirzepatide runs $297, $267 at $800, $217 at $1,299 and $167 at $1,999. Every total is published beside its rate. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Oral and injection at the same price - Strength: All four rungs published with totals - Strength: Free shipping and cancel anytime - Strength: Coverage across all fifty states - Limitation: The best rate needs a $1,900 prepay - Limitation: No milligram dose published - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about TMates. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader choosing between formats who does not want the choice priced. Wrong for A reader unwilling to prepay for the lowest rung. ## The evidence behind what TMates prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TMates compares | Seller | Who it suits | Go | | --- | --- | --- | | The Edit | Readers who read the standing rate beside the first-order figure | | | TeleClinic | Readers who want the standard rate stated beside the introductory one before they sign up | | | TeleCareSpot | Readers confident of approval who want a flat all-in rate | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [CeliaRx](https://thisglp.com/reviews/celia-rx) [Center for Medical Weight Loss (CMWL)](https://thisglp.com/reviews/center-for-medical-weight-loss)[Cielo](https://thisglp.com/reviews/cielo) [Citizen Meds](https://thisglp.com/reviews/citizen-meds) [Claya](https://thisglp.com/reviews/claya) [Clinic Secret](https://thisglp.com/reviews/clinic-secret) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the oral cost more? No. Injectable and oral carry the same price on both molecules. What is billed on the annual plan? $1,900 for semaglutide and $1,999 for tirzepatide, which is $158 and $167 a month. Can I cancel? Cancellation is stated as available at any time, with free shipping on all plans. Is TMates legit? TMates is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is TMates expensive compared with other GLP-1 telehealth sellers? TMates publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TMates above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TOM Weight Loss reviews (2026): GLP-1 telehealth sellers | This GLP A one-physician obesity medicine practice in Texas and Utah, with medication inside the monthly price. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tom-weight-loss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One doctor, two states # TOM Weight Loss review A one-physician obesity medicine practice in Texas and Utah, with medication inside the monthly price. ## The verdict TOM Weight Loss charges $199 a month for compounded semaglutide. Tirzepatide is $249. Both include the medication and the physician. Any dose up to the stated maximum costs the same. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 2 From From $199/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability Texas and Utah TOM Weight Loss is an online medical practice. It serves patients located in Texas and Utah only. It prescribes compounded semaglutide and tirzepatide, oral options, and brand-name GLP-1s. 1. ## Who writes the prescription, and what do they see? One physician is named: Dr. Tran Le, MD. The site states she is board-certified in obesity, addiction and occupational medicine. Her NPI is printed in the footer. The practice states the same doctor sees a patient at every visit. It describes itself as deliberately small. New patients start in a patient portal. The first visit with the doctor is complimentary. The doctor selects the medication and the starting dose. A licensed pharmacy ships it to the patient's door. Regular check-ins follow, and the dose is adjusted at those visits. 2. ## What happens when the dose goes up? The semaglutide plan covers any dose up to 2.4 mg a week. The tirzepatide plan covers up to 15 mg a week. The price does not move within those limits. The tirzepatide plan also covers high-dose semaglutide. Dose steps are made at check-ins. 3. ## What the price includes The pricing page opens on monthly billing. Semaglutide is $199 a month and tirzepatide is $249. The gap is $50. Quarterly billing is offered as a toggle. A separate à la carte plan covers physician care only. Under it, the pharmacy bills the medication per fill. 4. ## What it claims, and what it cites The included medication is compounded by state-licensed pharmacies. Compounded drugs are not FDA-approved. The FDA does not review them before dispensing. The à la carte table names five pharmacies and prices each dose. Brand-name GLP-1s require the à la carte plan. ## Where it holds up, and where it does not - Strength: Medication included in the monthly price - Strength: Maximum weekly dose stated for each plan - Strength: One named physician at every visit - Strength: Pharmacies named in the à la carte table - Limitation: Patients in Texas and Utah only - Limitation: Brand-name drugs need a separate plan - Limitation: Included-plan pharmacy is not specified ## What the evidence says about this kind of treatment The assessment above is about TOM Weight Loss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in Texas or Utah who wants one physician and one flat monthly price. Wrong for A reader outside Texas and Utah. ## The evidence behind what TOM Weight Loss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TOM Weight Loss compares | Seller | Who it suits | Go | | --- | --- | --- | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | Get Thin MD | Readers taking the three-month plan who read what the sale actually covers | | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Clume Health](https://thisglp.com/reviews/clume-health) [CLYR Health](https://thisglp.com/reviews/clyr-health) [Coivas](https://thisglp.com/reviews/coivas) [Concierge MD LA](https://thisglp.com/reviews/concierge-md-la) [Contour Health](https://thisglp.com/reviews/contour-health) [Cora Health](https://thisglp.com/reviews/cora-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does a higher dose cost more? No. Semaglutide up to 2.4 mg a week is $199. Tirzepatide up to 15 mg a week is $249. Is the medication included? Yes, on both plans. There is no separate pharmacy bill. Who is the doctor? Dr. Tran Le, MD. The site lists three board certifications and her NPI. Is TOM Weight Loss legit? TOM Weight Loss is a GLP-1 telehealth sellers service. Its stated availability: Texas and Utah. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is TOM Weight Loss expensive compared with other GLP-1 telehealth sellers? TOM Weight Loss publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TOM Weight Loss above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tomorrow reviews (2026): GLP-1 telehealth sellers | This GLP Tomorrow names its compounded preparations and separates monthly from quarterly semaglutide purchases. Its order-cancellation terms deserve equal attention. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tomorrow Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A clear product, tighter terms # Tomorrow review Tomorrow names its compounded preparations and separates monthly from quarterly semaglutide purchases. Its order-cancellation terms deserve equal attention. ## The verdict Tomorrow gives useful product detail, including glycine in its compounded semaglutide. The unresolved care question is how follow-up works for your state and treatment. Its public cancellation language is more restrictive for an initial order than the general cancel-anytime message suggests. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral From From $199/mo Prescription Required Compounded Yes — not FDA-approved Tomorrow offers compounded GLP-1 injections, lower-dose options and sublingual products, plus branded medicines. These are separate preparations, not interchangeable ways to obtain the same clinical result. 1. ## Who writes the prescription, and what do they see? An independent medical group evaluates health information. A live phone or video consultation may be necessary depending on state requirements. A pharmacy, including VialsRX or another assigned dispenser, fills an appropriate prescription. The site describes ongoing clinician oversight and account-based communication. Ask what follow-up is included before a refill, and which channel reaches the prescriber if side effects develop. The application cannot establish a guaranteed prescription. 2. ## What happens when the dose goes up? The public offer describes clinician monitoring, but a lower-dose or sublingual preparation should not be substituted for a conventional injection without individual advice. Clarify the expected adjustment and refill schedule, including what happens during a treatment pause. 3. ## What the price includes Semaglutide has separate monthly billing and a lower quarterly equivalent that requires an upfront package. Care and delivery are included in the stated product plan. Confirm the rate at your later prescribed dose and whether changing preparations changes the bundle. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) injection page identifies a compounded preparation with glycine. The broader catalog includes compounded [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and branded products. Finished compounded medicines are not FDA approved; evidence for an approved injection does not validate the sublingual alternatives. ## Where it holds up, and where it does not - Strength: Specific semaglutide formulation disclosed - Strength: Independent medical review described - Strength: Monthly and quarterly options separated - Limitation: Initial order may become noncancelable at medical review - Limitation: Product formats need distinct evidence - Limitation: Follow-up timing not universal ## What the evidence says about this kind of treatment The assessment above is about Tomorrow. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient seeking a clearly described prescription option and willing to clarify ongoing clinical access. Wrong for Someone assuming a canceled subscription reverses an initial medical-review charge. ## The evidence behind what Tomorrow prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Tomorrow compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) [DoctorAdam](https://thisglp.com/reviews/doctoradam) [Dollar Dad Club](https://thisglp.com/reviews/dollar-dad-club) [Dr. Arevitalize](https://thisglp.com/reviews/dr-arevitalize) [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) [DrBrainRx](https://thisglp.com/reviews/drbrainrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can a submitted initial order always be canceled? The terms say it cannot be canceled once submitted for medical review. Future renewals have separate cancellation controls. Does the quarterly equivalent offer monthly flexibility? No. The product page distinguishes quarterly upfront billing from its monthly purchase. Is Tomorrow expensive compared with other GLP-1 telehealth sellers? Tomorrow publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Tomorrow above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://trytomorrow.com/) - [Service and cancellation terms](https://trytomorrow.com/terms) - [Treatment information](https://trytomorrow.com/products/semaglutide) - [Consultation and care process](https://trytomorrow.com/how-it-works) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tonik Wellness reviews (2026): GLP-1 telehealth sellers | This GLP A hormone and longevity clinic that prices both molecules on three terms, with a month-to-month card beside the yearly one it advertises. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tonik-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three terms, lab work first # Tonik Wellness review A hormone and longevity clinic that prices both molecules on three terms, with a month-to-month card beside the yearly one it advertises. ## The verdict Tonik Wellness charges $225 a month for semaglutide and $349 for tirzepatide on its month-to-month plans, and both fall on a quarterly or annual commitment. The product page leads with the annual rung, so a buyer who reads only that line is looking at a twelve-month price. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $225/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Not stated Tonik Wellness is a telehealth clinic founded in 2024 and headquartered in Hamilton, New Jersey, selling testosterone, bioidentical hormones, sexual health and longevity treatments alongside weight loss. Semaglutide and tirzepatide are sold as weekly injections, and the footer states that the company itself provides no medical or pharmacy services. 1. ## Who writes the prescription, and what do they see? Prescriptions are written by what the footer calls Tonik-affiliated independent healthcare providers, and the about page names a medical director, Joel Jones, DO, and a clinical director who is a family nurse practitioner. Before anything is prescribed, a patient orders lab work and then has a call with a Tonik provider to go over symptoms and results, which is a longer path than a form-only intake. The first step is a free consultation that matches a new patient with a dedicated concierge, who then steers the lab order, the provider call and the start of treatment. Every plan lists the medication, injection supplies, provider oversight, concierge support and a patient portal. The page also lists ongoing provider check-ins and access to metabolic support protocols and coaching. 2. ## What happens when the dose goes up? The program description promises dose adjustments based on progress and clear dosing instructions, but no milligram amount is printed on either plan and the page never says whether a higher dose changes the monthly charge. A patient who steps up in the third month would have to ask the concierge, because none of the three price cards mentions a dose at all. 3. ## What the price includes Semaglutide is $225 a month on the monthly card, $165 a month on the quarterly card billed as $495 every three months, and $149 a month on the annual card billed as $1,788 a year. Tirzepatide runs $349, then $249 billed as $747 a quarter, then $229 a month on the yearly plan. The semaglutide product page opens on the $149 annual figure, and the cost of the lab work is not stated anywhere on the weight-loss pages. 4. ## What it claims, and what it cites The how-it-works page states that all medications are compounded and shipped from licensed U.S. pharmacies, none of which is named. Compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are not FDA-approved and are not reviewed by the FDA before they are dispensed. ## Where it holds up, and where it does not - Strength: Month-to-month rate printed beside the commitments - Strength: Lab work and a provider call first - Strength: Medical director named on the about page - Strength: Injection supplies included on every plan - Limitation: The product page leads with the annual rate - Limitation: The cost of lab work is not stated - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published ## What the evidence says about this kind of treatment The assessment above is about Tonik Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a lab-based start and a named medical director, and who is prepared to decide between a monthly, quarterly and yearly commitment at the outset. Wrong for A reader who needs the full first-month cost, lab work included, before starting a consultation. ## The evidence behind what Tonik Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Tonik Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Elevated Health | Readers who want to see every rung before choosing a term | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | Corsica Health | Readers who want the monthly rate and the prepay discount on one selector | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) [DrBrainRx](https://thisglp.com/reviews/drbrainrx) [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) [DudeMeds](https://thisglp.com/reviews/dudemeds) [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) [Edessa](https://thisglp.com/reviews/edessa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost without a commitment? $225 a month on the monthly card, which the page labels month-to-month access. The quarterly and annual cards bring it down to $165 and $149 a month. Why does the product page show a lower figure? The semaglutide product page leads with the $149 annual rate, which is billed as $1,788 for the year rather than month by month. Is lab work part of the price? The page describes ordering lab work as the first step before the provider call, but it does not say what the labs cost or whether a plan covers them. Is Tonik Wellness expensive compared with other GLP-1 telehealth sellers? Tonik Wellness publishes a starting figure of $225/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Tonik Wellness above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TotalRx reviews (2026): GLP-1 telehealth sellers | This GLP TotalRx describes a medication-inclusive program with independent prescribing networks and ongoing support. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/totalrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Selected-rate renewal promise is explicit # TotalRx review TotalRx describes a medication-inclusive program with independent prescribing networks and ongoing support. ## The verdict TotalRx distinguishes its clinical network from the storefront and describes ongoing support; agree on the actual monitoring schedule before starting. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved TotalRx is an online prescription platform whose weight-loss guide describes compounded semaglutide and tirzepatide injections. The offer includes clinician review, medication, supplies, shipping and ongoing support within the selected plan. 1. ## Who writes the prescription, and what do they see? Independent affiliated healthcare providers make all prescribing decisions. TotalRx says completing an assessment does not itself create a provider-patient relationship. The licensed clinician must decide whether treatment is appropriate after reviewing the health information. The program describes ongoing care and support rather than only the first shipment. A fixed clinical appointment interval and guaranteed response deadline are not established by the pricing guide. Ask how regular dose reviews and side-effect questions reach the treating clinician. 2. ## What happens when the dose goes up? TotalRx says the chosen price remains the same at renewal and as doses change. That is a billing claim, not an instruction to increase. Confirm the prescribed dose and how the clinician adjusts the plan when tolerance or response changes. 3. ## What the price includes The guide gives different equivalents according to plan length while claiming the selected rate stays constant across renewals and doses. The terms require automatic renewal unless canceled and generally exclude returning dispensed medicine. Confirm the full chosen term, billing date and pharmacy cutoff. 4. ## What it claims, and what it cites The injections are compounded and are not FDA-approved. The site names independent provider networks including OpenLoop; the individual prescription and dispensing pharmacy must still be established for each patient. ## Where it holds up, and where it does not - Strength: Selected-rate renewal promise is explicit - Strength: Medication and basic supplies included in the described plan - Strength: Independent prescribing networks identified - Limitation: Lowest equivalents depend on plan length - Limitation: Subscriptions renew until canceled - Limitation: Dispensed medicine is generally nonreturnable ## What the evidence says about this kind of treatment The assessment above is about TotalRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded treatment who will confirm the clinician, pharmacy and dose-review plan rather than rely solely on pricing assurances. Wrong for Someone who does not want to manage an automatically renewing treatment plan. ## The evidence behind what TotalRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TotalRx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) [Elevate Health](https://thisglp.com/reviews/elevate-health) [Elevated Health](https://thisglp.com/reviews/elevated-health) [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) [ElixaMD](https://thisglp.com/reviews/elixamd) [ElleS](https://thisglp.com/reviews/elles) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The program describes ongoing care and support rather than only the first shipment. A fixed clinical appointment interval and guaranteed response deadline are not established by the pricing guide. Ask how regular dose reviews and side-effect questions reach the treating clinician. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Current weight-loss pricing and inclusions](https://totalrx.com/guides/weight-loss/pricing) - [Medical, payment and refill terms](https://totalrx.com/terms) - [Assessment and treatment pathway](https://totalrx.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Totara Health reviews (2026): GLP-1 telehealth sellers | This GLP Oral and injectable programs sit inside a broader telehealth marketplace. The intake format depends on the patient’s state. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/totara-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 State-dependent video visits described # Totara Health review Oral and injectable programs sit inside a broader telehealth marketplace. The intake format depends on the patient’s state. ## The verdict Totara’s state-dependent consultation model is worth clarifying before choosing an oral or injectable plan. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Totara is a telehealth marketplace with women’s health, weight management and other services. Its weight-loss offering includes compounded semaglutide and tirzepatide, with both oral and injectable options marketed publicly. 1. ## Who writes the prescription, and what do they see? A physician reviews the medical intake and decides whether treatment is suitable. Totara says video is added when required by the patient’s state. Its terms distinguish the platform from the independent healthcare professionals providing the care. Totara describes online evaluation and pharmacy fulfillment, but the reviewed program pages do not establish a fixed follow-up appointment cadence or clinical response deadline. Ask who receives a side-effect report and whether a new dose requires another evaluation. 2. ## What happens when the dose goes up? The weight-loss page advertises flat-price programs and several supply lengths. That is a billing claim, not an individualized [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) plan. The prescriber should decide when to hold, increase or change treatment. 3. ## What the price includes One-month and longer plans are listed separately. Longer terms show full package prices; confirm whether the order is prepaid, what renews and what can be refunded. A lower long-term equivalent does not establish a monthly cancelable medicine bill. 4. ## What it claims, and what it cites The site describes compounded formulations from licensed pharmacies. These are not FDA-approved medicines. An oral compounded treatment is not interchangeable with an approved branded pill simply because the active ingredient has a familiar name. ## Where it holds up, and where it does not - Strength: State-dependent video visits described - Strength: Oral and injectable options distinguished - Strength: Multiple plan lengths disclosed - Limitation: Clinical follow-up interval is not specified - Limitation: Individual dispensing pharmacy needs confirming - Limitation: Longer plans require a separate commitment comparison ## What the evidence says about this kind of treatment The assessment above is about Totara Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone comfortable with online evaluation who wants to compare formulations and will establish the follow-up relationship before ordering. Wrong for Someone seeking an FDA-approved brand or a guaranteed schedule of live follow-up visits. ## The evidence behind what Totara Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Totara Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [EllieMD](https://thisglp.com/reviews/elliemd) [Eloria](https://thisglp.com/reviews/eloria) [Emerge Weight Loss](https://thisglp.com/reviews/emerge-weight-loss) [eMI Aesthetics](https://thisglp.com/reviews/emi-aesthetics) [EOS Health](https://thisglp.com/reviews/eos) [Eve](https://thisglp.com/reviews/eve) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Totara describes online evaluation and pharmacy fulfillment, but the reviewed program pages do not establish a fixed follow-up appointment cadence or clinical response deadline. Ask who receives a side-effect report and whether a new dose requires another evaluation. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-loss plans](https://totara.health/weight-loss) - [Platform and medical terms](https://totara.health/legal/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Trally Meds reviews (2026): GLP-1 telehealth sellers | This GLP Trally describes clinical approval before the first charge and check-ins before later treatment orders. The public price and dose cards need careful confirmation for the actual prescription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trally-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Confirm the actual prescription # Trally Meds review Trally describes clinical approval before the first charge and check-ins before later treatment orders. The public price and dose cards need careful confirmation for the actual prescription. ## The verdict Trally’s approval-based charging model is a useful starting point, but the individual clinical relationship still needs establishing. Confirm the prescriber, pharmacy and exact dose rather than treating the displayed sales cards as instructions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Trally Meds offers compounded GLP-1 weight-management treatment through an online assessment and provider review. The page names semaglutide and tirzepatide, with consultation and delivery advertised as included and no membership charge. 1. ## Who writes the prescription, and what do they see? A medical provider reviews the assessment and decides whether to issue a prescription. The pages reviewed do not clearly name a specific independent medical practice for a new patient. Ask which clinician is responsible for the prescription and continued care. Trally says the initial payment is authorized at checkout and charged after prescribing. Later orders follow an ongoing check-in and provider approval. Clarify whether those reviews are clinician contacts, how symptoms are assessed and how to reach the provider between refills. 2. ## What happens when the dose goes up? Dose adjustment must follow the actual clinician’s prescription, not the sales page’s dose labels. Ask the provider to confirm the ingredient, weekly milligrams, concentration and usable quantity, particularly when comparing the one- and three-month options. 3. ## What the price includes The page shows one- and three-month supply cards with dose labels. Those displayed groupings do not establish a complete, unambiguous price schedule for each medicine. Confirm a written drug-specific quote and the plan for any dose change before paying. 4. ## What it claims, and what it cites The weight-management page identifies compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). Neither preparation is FDA-approved. The public materials do not establish which pharmacy will dispense a particular patient’s medicine; verify that information before the first order. ## Where it holds up, and where it does not - Strength: First charge follows clinical prescribing - Strength: Refill check-ins are described - Strength: Consultation is included in the advertised offer - Limitation: The responsible clinical practice needs confirmation - Limitation: Public dose and price cards require clarification - Limitation: The assigned pharmacy is not established ## What the evidence says about this kind of treatment The assessment above is about Trally Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants clinical review before charging and will clarify the actual prescription and monitoring arrangement. Wrong for Someone ready to use the public sales-card dose labels as a personal medication schedule. ## The evidence behind what Trally Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Trally Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus)[EverSlim](https://thisglp.com/reviews/everslim) [Eviora MD](https://thisglp.com/reviews/eviora-md) [Factor Health MD](https://thisglp.com/reviews/factor-health-md) [Fella Health](https://thisglp.com/reviews/fella-health) [Fidelity Medical Clinic](https://thisglp.com/reviews/fidelity-medical-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked When does the first Trally charge occur? The page describes a temporary card authorization at checkout, followed by a charge only if the provider issues a prescription. How are repeat orders described? Trally says ongoing check-ins and provider approval precede later charges. Confirm the clinical review process and next order date for the chosen plan. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Treatment, dose labels and provider approval](https://www.trallymeds.com/weight-management) - [Recurring billing and clinical check-ins](https://www.trallymeds.com/billing-terms) - [Prescription returns and fulfillment](https://www.trallymeds.com/return-and-refund-policy) - [Service terms](https://www.trallymeds.com/terms-of-use) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Transcarent reviews (2026): GLP-1 telehealth sellers | This GLP Transcarent provides weight-management support through employer and benefit arrangements. GLP-1 medication management depends on both clinical suitability and the coverage selected for the program. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/transcarent Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Benefit-dependent weight care # Does Transcarent sell a GLP-1? Transcarent provides weight-management support through employer and benefit arrangements. GLP-1 medication management depends on both clinical suitability and the coverage selected for the program. ## The verdict Transcarent can be a useful route for an eligible member seeking coordinated weight care. Check the benefit before assuming medication access, and distinguish a coverage decision from the treating clinician’s assessment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Transcarent’s Weight Health service combines clinical guidance, lifestyle and behavioral support, medication management and possible surgical pathways. Organizations configure the benefit, so it is not a universal direct-purchase GLP-1 subscription. 1. ## Who writes the prescription, and what do they see? The clinical team evaluates the member and guides treatment within the applicable benefit. A public obesity-medicine specialist profile does not identify every member’s treating clinician. Confirm who will make prescribing decisions and how that relationship connects with an existing doctor. The public service describes ongoing clinician-guided support, nutrition, behavioral coaching and medication management. The patient’s care path can also include pharmacy assistance or a bariatric evaluation. Ask which contacts are included in the employer’s selected version of the program. 2. ## What happens when the dose goes up? Medication changes belong to the clinician and should account for the individual response, history and benefit constraints. Coaching and pharmacy navigation support the plan but do not replace the clinical decision about dose or whether a GLP-1 is appropriate. 3. ## What the price includes There is no universal public medication-inclusive monthly amount. Access, drug coverage and out-of-pocket costs depend on the sponsoring benefit. Obtain the plan’s actual rules rather than using another member’s experience to infer your own coverage. 4. ## What it claims, and what it cites The Weight Health page includes GLP-1 management when covered and appropriate. It does not establish one ingredient, formulation or pharmacy for all members. Confirm the actual prescription and coverage requirements with the care team. ## Where it holds up, and where it does not - Strength: Clinical and behavioral support are connected - Strength: Medication coverage is explicitly conditional - Strength: Several weight-care pathways are available - Limitation: Eligibility depends on the sponsoring benefit - Limitation: No single treatment or cost applies to every member - Limitation: The individual clinical contact schedule needs confirming ## What the evidence says about this kind of treatment The assessment above is about Transcarent. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An eligible member who wants coordinated weight care and can clarify the employer’s medication coverage and clinical pathway. Wrong for Someone looking for unrestricted cash enrollment or guaranteed coverage of a requested GLP-1 medicine. ## How Transcarent compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Fierce Health](https://thisglp.com/reviews/fierce-health) [Fifty 410](https://thisglp.com/reviews/fifty-410) [FitFlow](https://thisglp.com/reviews/fitflow) [Fitish](https://thisglp.com/reviews/fitish) [Fitness RX](https://thisglp.com/reviews/fitness-rx) [FitRx](https://thisglp.com/reviews/fitrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can every Transcarent member receive a GLP-1? No. The public service makes medication management conditional on coverage and clinical appropriateness. Is Weight Health only a prescribing service? No. It also describes lifestyle, behavioral, pharmacy and surgical support depending on the member’s needs and benefit. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight Health benefit and medication management](https://transcarent.com/weight-health) - [Member access](https://transcarent.com/members) - [Clinical-service terms](https://transcarent.com/terms-of-service) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Transparent Meds reviews (2026): GLP-1 telehealth sellers | This GLP Two GLP-1 lines priced beside four peptide programs, each card carrying its own pair of figures. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/transparent-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Six programs, one row # Transparent Meds review Two GLP-1 lines priced beside four peptide programs, each card carrying its own pair of figures. ## The verdict Transparent Meds charges $99 a month for compounded semaglutide and $199 for compounded tirzepatide, each shown against a struck-through higher figure, and the footnote beneath them says these are monthly program fees when prescribed. Four peptide cards sit alongside with prices of their own. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $99/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Transparent Meds is a telehealth clinic selling six injectable programs from a single band of cards, of which only two are GLP-1 medicines: the rest are NAD+, tesamorelin, sermorelin and an erectile dysfunction line. All six sit in one horizontal band and every card carries both a struck-through figure and a live one. Read down the page rather than across it and the figures come in an order the eye never sees, which is how a peptide's rate ends up attached to a GLP-1. 1. ## Who writes the prescription, and what do they see? A licensed medical provider reviews a secure online quiz and intake form with no appointment, and the site is specific that titration and dosage are set by the prescribing doctor rather than chosen at checkout. Where most sellers leave the dose decision ambiguous, this one puts it in the product description itself, twice. No clinician, medical group or medical director is named anywhere, and no list of licensed states is published. The flow is a quiz, a clinician review, then a tracked and discreetly packaged shipment with cold-pack handling and syringes included in the box. Transparent Meds states there are no monthly memberships, no hidden fees and cancellation at any time, and it repeats that the final cost is determined after clinician review rather than fixed by the card. Follow-up questions and dose adjustments run through the same care team. 2. ## What happens when the dose goes up? Each product's information panel says the same thing in the same words: [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) and dosage are determined by the prescribing doctor based on medical history and response. That is the clinical half answered as well as this category usually answers it. The money half is left ambiguous. A footnote saying the final cost is set after clinician review reads either as a formality or as a warning that $99 is a starting rate, and nothing on the page settles which. 3. ## What the price includes Semaglutide is $99 a month against a struck-through $229, and tirzepatide is $199 against a struck-through $349. Neither figure carries a first-month qualifier, and the only footnote calls both of them monthly program fees. The four peptide cards are priced the same way, which is what makes that band easy to misread: the semaglutide discount and the NAD+ discount sit two columns apart and differ by fourteen dollars. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded at a 503A pharmacy, shipped with a cold pack and syringes, and are not FDA-approved, which the information panel states rather than hides. Naming the pharmacy type is a real disclosure and more than most peers offer, though the pharmacy itself is never named. The peptide cards specify a single concentration of 3 mg per milliliter, so the site is capable of printing a strength when it wants to. ## Where it holds up, and where it does not - Strength: Both GLP-1 rates published before the quiz - Strength: The 503A pharmacy type is named for each product - Strength: Titration stated to be the doctor's decision - Strength: Syringes and cold-pack shipping listed inside the price - Strength: No membership and no cancellation charge - Limitation: Six cards share one row, so prices are easy to mispair - Limitation: The footnote leaves final cost open after review - Limitation: No milligram is published for either GLP-1 line - Limitation: No clinician, medical group or state list is named ## What the evidence says about this kind of treatment The assessment above is about Transparent Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader comparing a compounded GLP-1 against peptide programs sold by one clinic. Wrong for A reader who wants the price fixed before a clinician has looked at anything. ## The evidence behind what Transparent Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Transparent Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Tuyo Health | Buyers weighing a compounded plan against brand Wegovy or Zepbound at the same clinic | | | ReflexMD | Buyers who want the compounded rate on the homepage rather than after an intake | | | Omzo | Buyers who want the medication cost inside one fee rather than billed by a pharmacy | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Fitish](https://thisglp.com/reviews/fitish) [Fitness RX](https://thisglp.com/reviews/fitness-rx) [FitRx](https://thisglp.com/reviews/fitrx) [Fitstry](https://thisglp.com/reviews/fitstry) [FMmeds](https://thisglp.com/reviews/fmmeds) [FORM](https://thisglp.com/reviews/form) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a first-month rate? Nothing on the page says so. The only footnote calls the figures monthly program fees when prescribed, with final cost set after review. What does the struck-through $229 mean? It is the anchor figure shown above the live $99. Both appear on the same card, with no term attached to either. Is the compounding pharmacy named? Only by type. Each information panel says the medication is compounded at a licensed 503A pharmacy without naming it. Is Transparent Meds expensive compared with other GLP-1 telehealth sellers? Transparent Meds publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Transparent Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Trava Health reviews (2026): GLP-1 telehealth sellers | This GLP Each product page prints a monthly price for every dose on the ladder, so the cost of titration is visible before intake. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trava-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A published price at every dose # Trava Health review Each product page prints a monthly price for every dose on the ladder, so the cost of titration is visible before intake. ## The verdict Trava prices compounded semaglutide at $117.96 a month at 0.25 mg and tirzepatide at $178.98 at 2.5 mg. The price rises at each dose step, and every step is published. At the top of each ladder the monthly figures are $187.96 and $319.98. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $117.96/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Trava is an online seller of compounded semaglutide and tirzepatide, alongside NAD+, sermorelin, skincare and other wellness products. There is no membership. Each GLP-1 has its own product page with a dose selector and a monthly or quarterly purchase. 1. ## Who writes the prescription, and what do they see? The providers page names six physicians, drawn from a partnership with Wasef Health and Bask Health. Each is listed with a specialty. The site says licensed, board-certified providers review every intake. The evaluation is free, and a card hold for the full amount is charged only if the order is approved. A buyer picks a product and a dose, then completes an online intake. A provider reviews it and, if prescribing, sets the dosing plan. The doctor visit is stated to be included in the product price. Refills and dose questions go through a patient portal, with replies promised within 24 hours. 2. ## What happens when the dose goes up? The semaglutide page lists five doses from 0.25 mg to 2.5 mg, and the price changes at each. Tirzepatide lists six, from 2.5 mg to 15 mg. The FAQ advises new patients against a three-month supply of one dose. It describes a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) plan instead, with dosing instructions adjusted if a higher strength arrives before the patient needs it. 3. ## What the price includes The monthly figure depends on the prescribed dose, and the page shows it before intake. Semaglutide runs from $117.96 to $187.96 across its five doses. Tirzepatide runs from $178.98 to $319.98 across six. A quarterly package lowers the cost, and the page states the saving at each dose. The site banner advertises a lower 'as low as' figure that the product pages do not lead with. 4. ## What it claims, and what it cites Both products are compounded and are not FDA-approved or reviewed by the FDA before dispensing, as the product pages state. The FAQ names Optimal Balance Pharmacy and Greenwich RX as the dispensing pharmacies. The next answer compares Optimal with VialsRx instead, so the pharmacy list is not consistent. ## Where it holds up, and where it does not - Strength: A monthly price published at every dose - Strength: No membership and no visit fee - Strength: Six physicians named on the providers page - Strength: Card charged only after approval - Limitation: The price rises at each dose step - Limitation: Pharmacy names differ between two FAQ answers - Limitation: Banner figure differs from the product pages ## What the evidence says about this kind of treatment The assessment above is about Trava Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to cost a full titration ladder before starting an intake. Wrong for A reader who wants one flat price regardless of dose. ## The evidence behind what Trava Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Trava Health compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Rehydra+ Wellness | Readers who want to price a full escalation before committing to a first dose | | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [FormBlends](https://thisglp.com/reviews/formblends) [FormidableMD](https://thisglp.com/reviews/formidablemd) [Framework](https://thisglp.com/reviews/framework) [Fresh Day Meds](https://thisglp.com/reviews/fresh-day) [Freya Meds](https://thisglp.com/reviews/freya-meds) [Fridays](https://thisglp.com/reviews/fridays) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price change with the dose? Yes. Semaglutide runs from $117.96 to $187.96 a month across five doses. Tirzepatide runs from $178.98 to $319.98 across six. Is there a fee for the doctor visit? No. The FAQ states the visit is included in the product price, and there is no membership. When is my card charged? A hold is placed for the full amount and charged only if a provider approves the order. Is Trava Health legit? Trava Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Trava Health expensive compared with other GLP-1 telehealth sellers? Trava Health publishes a starting figure of $117.96/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Trava Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Trellis Vitality reviews (2026): GLP-1 telehealth sellers | This GLP A three-term price table at one price per dose, with the pharmacy and the medical group both named. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trellis-vitality Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Named pharmacy, named medical group # Trellis Vitality review A three-term price table at one price per dose, with the pharmacy and the medical group both named. ## The verdict Trellis Vitality charges $150 a month for compounded semaglutide. Tirzepatide is $199. Three- and six-month plans cost less per month. Every dose costs the same. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $150/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Labs Not stated LegitScript Claimed by provider Trellis Vitality is an online longevity clinic. It was founded in 2026 in Austin, Texas. It sells a weight and metabolic program alongside NAD+, tesamorelin and other protocols. 1. ## Who writes the prescription, and what do they see? Trellis states it is not a medical group. Prescribing is done by Arora Health & Aesthetics, LLC. The site names that group's medical director, Dr. Sean Arora, with his NPI. It also names a chief medical officer. A clinician licensed in the patient's state reviews the intake and labs. The program starts with a free clinical assessment. A home lab kit sets a baseline. Monitoring continues, with a re-test at 90 days. Medication is one part of the program. The site states no membership and no consult fee. 2. ## What happens when the dose goes up? The table is headed with one rule: all dosages, same price. A dose step therefore does not change the monthly charge. No milligram amounts are published on the program page. The clinician sets the dose and the formulation. 3. ## What the price includes Semaglutide is $150 on one month, $140 on three and $133 on six. Tirzepatide is $199, $189 and $179. Each figure is per month. The cost of the lab kit is not stated on the program page. 4. ## What it claims, and what it cites Both lines are compounded by Vials Rx, a state-licensed pharmacy in Houston. The site lists four batch tests. Compounded drugs are not FDA-approved. The program page states that plainly. ## Where it holds up, and where it does not - Strength: The compounding pharmacy is named - Strength: The medical group and director are named - Strength: Same price at every dose - Strength: Month-to-month rate leads the table - Limitation: State coverage claims conflict on the site - Limitation: Lab kit cost not stated - Limitation: No milligram amount appears on the page ## What the evidence says about this kind of treatment The assessment above is about Trellis Vitality. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the pharmacy and medical group named before starting. Wrong for A reader in Connecticut, Ohio or South Carolina. ## The evidence behind what Trellis Vitality prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Trellis Vitality compares | Seller | Who it suits | Go | | --- | --- | --- | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | FitFlow | Buyers who read the plan table before the page title and want the whole ladder in one place | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Health](https://thisglp.com/reviews/genesis) [Get Thin MD](https://thisglp.com/reviews/get-thin-md) [GetRelief Rx](https://thisglp.com/reviews/getrelief-rx) [Gimme Care](https://thisglp.com/reviews/gimme-care) [Glam Health](https://thisglp.com/reviews/glam-health) [Go Vida Plena](https://thisglp.com/reviews/go-vida-plena) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Do higher doses cost more on this program? No. The table states all dosages cost the same. Which pharmacy fills the prescription? Vials Rx, a state-licensed pharmacy in Houston. Is it available in every state? No. The FAQ excludes Connecticut, Ohio and South Carolina at minimum. No state list is published. Is Trellis Vitality expensive compared with other GLP-1 telehealth sellers? Trellis Vitality publishes a starting figure of $150/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Trellis Vitality below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Trillium Meds reviews (2026): GLP-1 telehealth sellers | This GLP A pharmacy picker with its own table of plan totals under every pharmacy it lists. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trillium-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Pick the pharmacy, then the plan # Trillium Meds review A pharmacy picker with its own table of plan totals under every pharmacy it lists. ## The verdict Trillium Meds is a storefront that asks a buyer to choose the compounding pharmacy before choosing a plan, and each pharmacy carries its own table of plan totals rather than a single house price. For semaglutide a one-month plan is $159 at either pharmacy listed, while a month of tirzepatide costs $199 or $249 depending on which pharmacy fills the vial. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 52 From From $159/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states and Puerto Rico LegitScript Claimed by provider Trillium Meds describes itself as a subscription-based telehealth access service that connects adults with licensed providers and regulated pharmacies, and it takes care to add, in its footer, that it is not a medical provider. Its weight-management page sells compounded semaglutide and compounded tirzepatide by the vial, self-pay only, to buyers in all fifty states and Puerto Rico. The company publishes a Portland, Oregon address and puts its Trustpilot rating beside the button that starts an intake. 1. ## Who writes the prescription, and what do they see? The FAQ names the prescribers as Wasef Health providers, licensed to serve patients in all fifty states and Puerto Rico, which is more than most storefronts of this kind are willing to put in writing. The process it lays out runs from a secure health intake to an independent provider's review, and a prescription is issued only if that provider decides treatment may be appropriate. What the provider reads beyond the intake itself is not described, and no individual clinician is named anywhere on the site. An approved patient lands in the Trillium portal, which the home page describes as holding provider chat, dose tracking, goal tracking and shipment details together across the whole course of care. Every customer is offered a ninety-day free trial of a dietitian membership, no membership fee is listed for the medical service itself, and pausing is described as available at any time. A banner across the top of every page asks buyers to allow seven to ten business days for delivery, because the pharmacies do not work weekends. 2. ## What happens when the dose goes up? Every standard plan on the page is marked any dose, so a patient stepping up from one strength to the next inside a plan does not step into a different price along with it. The exception is the three-month starter plan, offered only to people new to GLP-1s, which ships three vials covering the first three titrated doses. After that first quarter the page leaves unstated which plan a patient moves onto, and it says nothing about who decides the next step or how quickly. 3. ## What the price includes Every figure on the page is a plan total rather than a monthly rate, which keeps the arithmetic honest but leaves the division to the buyer. Semaglutide is $159 for one month, $357 for three months at any dose, which works out to $119 a month, and $257 for the three-month starter plan. Tirzepatide from Hyalo Technologies or Nova Specialty is $199 for one month and $499 for three, while Hallandale and VialsRx charge $249 for the single month. 4. ## What it claims, and what it cites Both drugs are compounded, and the page says so without softening it: compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are marketed. What sets this storefront apart is that each card names the pharmacy, the formulation, the beyond-use date, the shipping carrier and the states it ships to, so a buyer knows before paying exactly who will prepare the vial. ## Where it holds up, and where it does not - Strength: The dispensing pharmacy is named on every card - Strength: Every plan is priced as a total - Strength: Standard plans cover any dose at one price - Strength: Prescribers are named as Wasef Health providers - Strength: No membership fee is listed - Limitation: Tirzepatide costs more at two of the pharmacies - Limitation: The starter plan is for new patients only - Limitation: No milligram dose appears beside any plan - Limitation: Delivery can take seven to ten business days - Limitation: No individual clinician is named ## What the evidence says about this kind of treatment The assessment above is about Trillium Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to choose the pharmacy that fills the vial before paying for it. Wrong for A buyer who wants one house price and no comparison to make. ## The evidence behind what Trillium Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Trillium Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [GobyMeds](https://thisglp.com/reviews/gobymeds) [Goldspan Health](https://thisglp.com/reviews/goldspan-health) [Good Girl Rx](https://thisglp.com/reviews/good-girl-rx) [Good Life Meds](https://thisglp.com/reviews/good-life-meds) [GoodRx](https://thisglp.com/reviews/goodrx) [Green Cap Health](https://thisglp.com/reviews/green-cap-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a single month of semaglutide cost? It is $159 at either pharmacy the page lists for semaglutide, and the three-month plan brings the same vials down to $119 a month on a total of $357 paid at once. Why does tirzepatide show two different one-month prices? Because the price belongs to the pharmacy rather than to the storefront, so a month of tirzepatide is $199 at Hyalo Technologies or Nova Specialty and $249 at Hallandale or VialsRx. Who writes the prescription? The FAQ says Trillium partners with Wasef Health providers licensed across all fifty states and Puerto Rico, although no individual clinician is named on any page of the site. Is Trillium Meds legit? Trillium Meds is a GLP-1 telehealth sellers service. Its stated availability: All 50 states and Puerto Rico. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Trillium Meds expensive compared with other GLP-1 telehealth sellers? Trillium Meds publishes a starting figure of $159/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Trillium Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Trimi Health reviews (2026): GLP-1 telehealth sellers | This GLP Both monthly figures here are an annual plan divided by twelve, charged in a single payment at the start. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trimi-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Annual plan, billed up front # Trimi Health review Both monthly figures here are an annual plan divided by twelve, charged in a single payment at the start. ## The verdict Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide. Both are annual plans billed at once, at $1,188 and $1,500, or split through a buy-now-pay-later provider. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 Prescription Required Compounded Yes — not FDA-approved Trimi Health sells compounded semaglutide and compounded tirzepatide by injection, shipping to all fifty states. The figures on its page are the advertised headline rates, and both describe a twelve-month plan. Semaglutide is billed as $1,188 for the year and tirzepatide as $1,500. Affirm, Klarna and Afterpay are offered as ways to spread that charge. 1. ## Who writes the prescription, and what do they see? Care is arranged remotely and a prescription is required before the first vial ships. The page prices a twelve-month plan rather than a course of clinician contact. How often a patient is seen across that year, and by whom, is not published. The annual charge is described as the cost of the plan, not as a fee for a visit. Care is arranged remotely and the plan runs for a year from the first payment. The rate is stated as flat across doses, so a titration does not move the figure. That matters most between month one and month four, when the dose usually rises. Whether a plan can be ended early, and on what terms, is not published. 2. ## What happens when the dose goes up? The rate is stated as flat across doses, so an escalation leaves the figure alone. That claim is worth more here than at a month-to-month seller, because the whole year is already paid for. A reader who reaches a maintenance dose in month four is still on the rate agreed in month one. What happens if a clinician moves a patient to the other molecule mid-plan is not stated. 3. ## What the price includes The monthly framing and the billing are different things here, and the second one is what a card is charged. $99 a month reads like a month-to-month rate and is an annual commitment of $1,188. The tirzepatide plan is $1,500, which works out at $125 across twelve months. A buy-now-pay-later arrangement spreads the payment without shortening the term. 4. ## What it claims, and what it cites Both products are compounded, which means a pharmacy prepares them rather than a manufacturer. A compounded preparation is not FDA-approved and is not reviewed before it is dispensed. The published trial evidence for these molecules used the approved products at the doses on their labels. Whether a compounded vial matches those products in content or purity is not measured. ## Where it holds up, and where it does not - Strength: Rate stated as flat across doses - Strength: Annual cost published as a total - Strength: Ships to all fifty states - Limitation: Monthly figure is an annual plan - Limitation: Full year is charged at the start - Limitation: Financing spreads payment, not the term ## What the evidence says about this kind of treatment The assessment above is about Trimi Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who can pay a year at once, or finance it, and wants the monthly figure to stop moving as the dose rises. Wrong for A reader who wants to stop after a month or two, because the plan behind both figures is a twelve-month one charged up front. ## The evidence behind what Trimi Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Trimi Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Lean Meds | Readers willing to clarify the prescription and renewal details | | | Collective | A reader who will stay on treatment for a full twelve months, which is the term the annual membership is priced against. | | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Harbor](https://thisglp.com/reviews/harbor) [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) [Harper Meds](https://thisglp.com/reviews/harper-meds) [He & She MD](https://thisglp.com/reviews/he-and-she-md) [Heally](https://thisglp.com/reviews/heally) [HealthHub](https://thisglp.com/reviews/healthhub) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a month what the card is charged? No. The plan is annual and the charge is $1,188 at the start, which is $99 across twelve months. Affirm, Klarna and Afterpay are offered to spread that payment. Does the tirzepatide plan work the same way? It does. The advertised $125 a month is a $1,500 annual plan billed on the same terms as the semaglutide one. Will the price change as the dose goes up? Trimi Health states a flat rate across doses. The figure therefore holds through the escalation, which is where many sellers in this category reprice. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TrimRx reviews (2026): GLP-1 telehealth sellers | This GLP The compounded tiles name a mechanism rather than a drug, the bundle prices have gone behind a quiz, and the first-month discount lands on the same figure as the standing rate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trimrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Sold by mechanism, not molecule # TrimRx review The compounded tiles name a mechanism rather than a drug, the bundle prices have gone behind a quiz, and the first-month discount lands on the same figure as the standing rate. ## The verdict TrimRx publishes $179 a month for its compounded GLP-1 line and $259 for the GLP-1 plus GIP line. The rate after the advertised first month is the same $179, and the site no longer sells any branded medication. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $179/mo Prescription Required Compounded Yes — not FDA-approved TrimRx sells two compounded injections, labeled by receptor rather than by the molecule in the vial, with only the hero mockup naming tirzepatide. A patient prescribed a branded product fills it at a pharmacy of their own choosing. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing, but the pages describe products and tiers rather than the clinical relationship behind them. Naming a product by its mechanism obstructs comparison shopping, because a reader who wants tirzepatide cannot find it from the tile, and the three bundle figures that once showed the term structure now sit behind a quiz. 2. ## What happens when the dose goes up? The compounded rates are recorded as flat across doses, which is the answer a reader wants, though no milligram appears beside either tile to say what the flat rate is flat across. 3. ## What the price includes Six months of the compounded GLP-1 line at $179 is $1,074, and the GLP-1 plus GIP line at $259 is $1,554. The struck-through $299 in the checkout mockup implies a first-month saving that the standing rate then erases, since $179 is what is charged either way. 4. ## What it claims, and what it cites The two mechanism-named lines are compounded, prepared by a pharmacy the site does not name. The footer states that TrimRx does not sell, dispense or ship any branded medication, so a manufactured product is not an option here. ## Where it holds up, and where it does not - Strength: Compounded rates are stated flat across doses - Strength: Both compounded lines carry a published rate - Strength: The standing rate is not an introductory one - Strength: The first-month figure matches what follows it - Limitation: Products are named by mechanism rather than molecule - Limitation: The three bundle prices are now quiz-gated - Limitation: A strike-through implies a discount that does not persist - Limitation: States served are not published ## What the evidence says about this kind of treatment The assessment above is about TrimRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who already knows which molecule they want and will read the hero mockup to find out which tile contains it. Wrong for A reader shopping by molecule name, or one hoping the struck-through figure means the first month costs less than the second. ## The evidence behind what TrimRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TrimRx compares | Seller | Who it suits | Go | | --- | --- | --- | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | NowPatient | Readers who want a named manufactured product and will read the buy box first | | | Navio MD | Readers who want the branded and compounded routes priced side by side | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealthHub](https://thisglp.com/reviews/healthhub) [Healthicare](https://thisglp.com/reviews/healthicare) [HealthOn](https://thisglp.com/reviews/healthon) [HealthSource](https://thisglp.com/reviews/healthsource) [HeliMeds](https://thisglp.com/reviews/helimeds) [Hello Alpha](https://thisglp.com/reviews/hello-alpha) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is in the GLP-1 plus GIP line? Tirzepatide, according to the hero mockup on the homepage. The tile itself names only the mechanism, so the molecule appears nowhere a buyer would look first. Is $179 an introductory price? No. The checkout mockup strikes $299 through to $179 for a first month, and $179 is also the rate charged after it, so nothing changes at month two. Where did the bundle prices go? $316, $299 and $283 were published and are now reachable only by completing a quiz. That is a withdrawal rather than a change, and this site records it as one. Is TrimRx expensive compared with other GLP-1 telehealth sellers? TrimRx publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TrimRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Trinity Meds reviews (2026): GLP-1 telehealth sellers | This GLP A flat monthly rate at every dose, printed beside a countdown and a promise of pricing for life. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trinity-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One rate, every dose # Trinity Meds review A flat monthly rate at every dose, printed beside a countdown and a promise of pricing for life. ## The verdict Trinity Meds charges $99 a month for compounded semaglutide and $149 for compounded tirzepatide. The page states that the rate holds at every dose and every month. A banner names an end date for the offer, and a countdown runs beside the price. The home page also promises flat monthly pricing for life, and no later rate is published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $99/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Trinity Meds is a self-pay telehealth membership selling compounded semaglutide and compounded tirzepatide as weekly injections. The site describes Trinity HealthCare Supply as the provider of the technology platform and administrative services. It states that Trinity HealthCare Supply makes no prescribing decisions. Membership is described as open to residents of all 50 states. 1. ## Who writes the prescription, and what do they see? Clinical evaluation and prescribing are attributed to OpenLoop Healthcare Partners, PC and its affiliated practices. Those providers are said to apply clinical protocols and exclusionary criteria before prescribing. The consultation may be live video or an asynchronous review, as the provider and state law decide. The site says many patients are prescribed immediately after the assessment. What the provider reads beyond the intake is not described. The membership covers telehealth consultations, a personalized care plan, prescription fulfillment where appropriate, and shipping. Unlimited check-ins and 24/7 support are listed as included. Processing and delivery are quoted at about four to five business days after evaluation. Pausing or canceling is described as available at any time. No insurance is required, and FSA payment is accepted. 2. ## What happens when the dose goes up? The page states the same price at every dose, so the charge does not move as the dose climbs. No dose schedule or milligram figure is published beside either product. Who approves a step up, and on what evidence, is not described. The FAQ does say a provider may recommend a taper if treatment stops. It adds that weight regain after stopping is common. 3. ## What the price includes Semaglutide is $99 a month and tirzepatide is $149, billed month to month. The hero card prints $299 struck through beside the $99. A promo bar gives an end date, and a timer reads "Price increases in" above the button. The home page headlines "Flat Monthly Pricing For Life!" in the same view. No figure is published for what the rate becomes after that date. 4. ## What it claims, and what it cites Both products are compounded rather than manufactured. The FAQ states that the compounded versions are not FDA approved and have not been independently evaluated by the FDA. Prescriptions are filled by state-licensed 503A compounding pharmacies. Four are named with addresses: RedRock Pharmacy, Health Warehouse, Precision Medicine and Triad Rx. ## Where it holds up, and where it does not - Strength: One monthly rate at every dose - Strength: Month-to-month billing with cancellation anytime - Strength: Four filling pharmacies named with addresses - Strength: The prescribing medical group is named - Strength: No membership fee on top of the rate - Limitation: A countdown sits beside the headline rate - Limitation: No rate is stated for after the deadline - Limitation: No milligram dose appears on the page - Limitation: No individual clinician is named - Limitation: Prescribing may follow the questionnaire alone ## What the evidence says about this kind of treatment The assessment above is about Trinity Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants one monthly figure that does not climb with the dose. Wrong for A buyer who wants a live consultation guaranteed before any prescription. ## The evidence behind what Trinity Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Trinity Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | VevaRX | Buyers who will read a product page twice before believing the number on the card | | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Hello Alpha](https://thisglp.com/reviews/hello-alpha) [HelloWellness](https://thisglp.com/reviews/hellowellness) [Henry Meds](https://thisglp.com/reviews/henry-meds) [Heros Health](https://thisglp.com/reviews/heros-health) [Hers](https://thisglp.com/reviews/hers) [Heva Health](https://thisglp.com/reviews/heva-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise as the dose goes up? No. The page states the same price at every dose: $99 a month for semaglutide and $149 for tirzepatide. What does the countdown mean for the price? The banner names an end date and the timer counts down to it. No post-deadline rate is published, and the home page promises flat monthly pricing for life. Who prescribes? Providers within the OpenLoop Healthcare Partners, PC network, according to the site. No individual clinician is named. Is Trinity Meds legit? Trinity Meds is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Trinity Meds expensive compared with other GLP-1 telehealth sellers? Trinity Meds publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Trinity Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TRT Kingdom reviews (2026): GLP-1 telehealth sellers | This GLP TRT Kingdom offers lab-informed weight-management care alongside hormone services. Its compounded GLP-1 categories need a named prescription and clear continuing-care terms. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trt-kingdom Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does TRT Kingdom sell a GLP-1? TRT Kingdom offers lab-informed weight-management care alongside hormone services. Its compounded GLP-1 categories need a named prescription and clear continuing-care terms. ## The verdict The useful feature is a described clinical process built around history, testing and follow-up. The limitation is the menu’s generic class wording: compounded GLP-1 and GLP-1/GIP do not by themselves identify an ingredient or formulation. Ask for that detail before evaluating the plan’s evidence or cost. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved TRT Kingdom provides telehealth hormone, wellness and weight-management pathways. Its weight menu includes compounded GLP-1 categories and microdosing options alongside other therapies. A broad catalog is not evidence that a lower-dose or combined protocol is appropriate for a particular patient. 1. ## Who writes the prescription, and what do they see? Licensed medical providers, rather than the technology company, are responsible for care under the terms. Medical history and relevant laboratory information shape the treatment decision. Confirm the prescriber’s identity and the practice responsible for ongoing management. The public journey includes a questionnaire, provider contact, laboratory work when required and continuing check-ins. Testing may use home collection or local laboratory arrangements. Ask which monitoring is mandatory for the proposed weight treatment and how between-visit concerns reach the clinician. 2. ## What happens when the dose goes up? Treatment duration and dose depend on medical assessment and response. A microdosing menu item should not be interpreted as a proven obesity-treatment regimen. Obtain an explanation of the exact prescription, evidence, escalation or reduction plan and follow-up requirements. 3. ## What the price includes The weight-management page does not establish one complete recurring medication price. HSA/FSA payment options are described, but account eligibility does not establish affordability or drug coverage. Laboratory and care fees should be separated from medication in the quote. 4. ## What it claims, and what it cites The menu uses compounded GLP-1 and GLP-1/GIP class labels without clearly establishing the active ingredient for each option in the reviewed page. Compounded preparations are not FDA-approved. Confirm the medicine, formulation and supplying pharmacy before making comparisons. ## Where it holds up, and where it does not - Strength: Clinical and laboratory assessment are described - Strength: Continuing provider oversight is part of the model - Strength: Medical responsibility is separated from the platform - Limitation: Generic medicine categories leave key details unresolved - Limitation: Microdosing claims need individual evidence discussion - Limitation: No complete public recurring quote ## What the evidence says about this kind of treatment The assessment above is about TRT Kingdom. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone seeking broader metabolic assessment who is willing to require a named prescription and a clear monitoring plan. Wrong for A patient choosing a microdosing or generic GLP-1 category without knowing the actual drug and evidence. ## How TRT Kingdom compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Independent Wellness](https://thisglp.com/reviews/independent-wellness) [Injectco](https://thisglp.com/reviews/injectco) [InstaRX](https://thisglp.com/reviews/instarx) [Intimate Rose](https://thisglp.com/reviews/intimate-rose) [Invigor Medical](https://thisglp.com/reviews/invigor-medical) [Invyncible](https://thisglp.com/reviews/invyncible) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the class label identify the medicine? No. A GLP-1 or GLP-1/GIP label does not replace the ingredient and formulation on a prescription. Is laboratory work part of the process? The service describes lab-informed care, with requirements determined by the treatment and clinician. Who provides clinical care? The terms distinguish licensed medical providers from the company’s administrative and technology services. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://trtkingdom.com/) - [Weight-management program](https://trtkingdom.com/categories/weight-loss) - [Terms of service and payment conditions](https://trtkingdom.com/legal/terms-of-service) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TRT Nation reviews (2026): GLP-1 telehealth sellers | This GLP One tirzepatide rate, fixed at every dose, sold in three-month blocks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trt-nation Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Three months, one rate # TRT Nation review One tirzepatide rate, fixed at every dose, sold in three-month blocks. ## The verdict TRT Nation sells compounded tirzepatide at $219 a month. The rate holds at every dose. A three-month minimum purchase applies. That is $657 before a buyer can stop. No month-to-month rate is published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Tirzepatide Form Injection From From $219/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability US except AL, AK, AR, HI, MO TRT Nation is a Tampa testosterone clinic that also sells weight-loss therapy online. Its weight-loss page lists two products. Tirzepatide is the injectable. Phentermine is an oral tablet. Semaglutide is not offered. The clinic serves every state except Alabama, Alaska, Arkansas, Missouri and Hawaii. 1. ## Who writes the prescription, and what do they see? Licensed healthcare providers prescribe after a medical screening and a consultation. No provider or medical group is named. Candidates are described as adults 25 and over with a BMI over 25. Eligibility is stated to be the provider's decision. What the provider reviews is not described. Enrollment starts with an online intake form. A provider consultation follows. If a prescription is written, the medication ships by FedEx. No in-person visit is required. Providers are said to offer nutritional guidance. New patients are offered 10% off the first treatment. 2. ## What happens when the dose goes up? The FAQ answers the dose question in writing. Tirzepatide costs $219 a month regardless of dosage. No dose ladder or milligram figure is published. Who approves a step up is not stated. The starting dose is not named. 3. ## What the price includes One figure covers tirzepatide: $219 a month. An asterisk under the card reads "3 months minimum purchase." The minimum commitment is therefore $657. No single-month rate appears on the page. The FAQ contrasts this with clinics that raise prices as treatment progresses. 4. ## What it claims, and what it cites The [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is compounded. The FAQ says every prescription is compounded with vitamin B12. The pharmacy is described only as a regulated U.S. pharmacy. Compounded preparations are not FDA-approved. The FDA does not review them before dispensing. ## Where it holds up, and where it does not - Strength: One rate applies at every dose - Strength: The dose question is answered in writing - Strength: Eligibility criteria are published on the page - Strength: New patients get 10% off the first treatment - Limitation: A three-month minimum purchase applies - Limitation: $657 is committed before a buyer can stop - Limitation: No semaglutide option is offered - Limitation: No prescriber or pharmacy is named - Limitation: No milligram dose is published ## What the evidence says about this kind of treatment The assessment above is about TRT Nation. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer ready to commit three months to tirzepatide at one rate. Wrong for A buyer who wants to try a single month first. ## The evidence behind what TRT Nation prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TRT Nation compares | Seller | Who it suits | Go | | --- | --- | --- | | Maximus | A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. | | | Hello Alpha | A reader set on brand Wegovy or Zepbound with a pharmacy quote already in hand | | | Rex MD | Readers who want an approved oral product with the clinician's cost stated inside it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Invigor Medical](https://thisglp.com/reviews/invigor-medical) [Invyncible](https://thisglp.com/reviews/invyncible) [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) [iThriveMD](https://thisglp.com/reviews/ithrivemd) [Ivim Health](https://thisglp.com/reviews/ivim-health) [Ivologist](https://thisglp.com/reviews/ivologist) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can tirzepatide be bought for one month? No. The card carries a three-month minimum purchase. The smallest outlay is $657. Does the price rise with the dose? No. The FAQ states $219 a month regardless of dosage. Is semaglutide available? No. The weight-loss page lists tirzepatide and phentermine only. Is TRT Nation legit? TRT Nation is a GLP-1 telehealth sellers service. Its stated availability: US except AL, AK, AR, HI, MO. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is TRT Nation expensive compared with other GLP-1 telehealth sellers? TRT Nation publishes a starting figure of $219/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TRT Nation above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tru2u reviews (2026): GLP-1 telehealth sellers | This GLP Flat pricing across four lines, plus a combined product that pairs both molecules for $275. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tru2u Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two molecules in one vial # Tru2u review Flat pricing across four lines, plus a combined product that pairs both molecules for $275. ## The verdict Tru2u publishes $225 a month for semaglutide and $345 for tirzepatide. Orals match the injections. A combined product is $275. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $225/mo Oral From $225/mo Prescription Required Compounded Yes — not FDA-approved Tru2u sells both molecules by injection and as tablets. A fifth product, GLP Squared, combines the two. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. No clinician is described on the pages read. Four of the five products are priced conventionally and flat. The fifth pairs two molecules in one purchase, which is unusual and untested. 2. ## What happens when the dose goes up? Prices are recorded as flat across doses. No milligram appears beside any of the five products. 3. ## What the price includes Six months of semaglutide is $1,350 and of tirzepatide is $2,070. The combined product sits between them at $275 a month, or $1,650 over six. 4. ## What it claims, and what it cites Every line is compounded. A pharmacy prepares them to order. The FDA does not review a compounded preparation before it is dispensed, and no trial has tested the two molecules paired. ## Where it holds up, and where it does not - Strength: Flat across doses on every line - Strength: Both formats carry a figure - Strength: The combination is priced openly - Limitation: The combination has no trial behind it - Limitation: No milligram dose published anywhere - Limitation: Nothing publishes a list of states - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Tru2u. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a flat rate and will ask what the combined product contains. Wrong for A reader treating GLP Squared as a studied treatment rather than a product. ## The evidence behind what Tru2u prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Tru2u compares | Seller | Who it suits | Go | | --- | --- | --- | | Luci | Readers who take an asterisk seriously and plan to ask what it hides | | | Rivo Health | Readers who want a flat rate and can ignore the seasonal framing | | | Navio MD | Readers who want the branded and compounded routes priced side by side | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Ivologist](https://thisglp.com/reviews/ivologist) [Ivy Rx](https://thisglp.com/reviews/ivy-rx) [Jently](https://thisglp.com/reviews/jently) [Joey Med](https://thisglp.com/reviews/joey-med) [Joi + Blokes](https://thisglp.com/reviews/joi-and-blokes) [JRNYS](https://thisglp.com/reviews/jrnys) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What is GLP Squared? A combined semaglutide and tirzepatide product at $275 a month. No dose is published for either part. Do the tablets cost more? No. Each molecule is one figure in both formats. Has the combination been studied? No trial has tested the two molecules paired. Is Tru2u expensive compared with other GLP-1 telehealth sellers? Tru2u publishes a starting figure of $225/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Tru2u above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TrueMe reviews (2026): GLP-1 telehealth sellers | This GLP The product page says no intake form is required before payment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trueme Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Pay first, intake after # TrueMe review The product page says no intake form is required before payment. ## The verdict TrueMe puts a line directly under its semaglutide price that most of this category would never print: no intake form is required before you pay, with a full refund if a provider does not approve. The order of operations is the finding, and the second one is geography, because the same page names six states and nothing outside them. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 6 From From $151/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 6 states TrueMe sells compounded semaglutide and compounded tirzepatide by weekly injection, both prepared with added B vitamins, alongside NAD+ and sermorelin on the same four-card home page. The rate is described as covering the consultation, the medication, shipping, supplies and ongoing provider support, with the phrase no membership or hidden fees repeated across the top of the site. Coverage is the constraint rather than the price, and the company says more states are coming. 1. ## Who writes the prescription, and what do they see? A provider decides whether treatment is appropriate, and the refund promise is what carries the weight here, since a buyer has already paid by the time that decision is made. The site does not name a provider, a medical group or a medical director, and the four-step explainer describes questions being answered rather than a clinician reading anything in particular. Ongoing provider support is listed inside the price on both product pages. What happens between payment and approval is never described. Everything runs through a patient portal, with a four-step path from choosing a treatment to receiving it, and the company publishes a free guide plus three calculators alongside the catalog. The price is stated to be all-inclusive on every card, and the product pages repeat that in capitals beneath the plan table. Cancellation is offered at any time. Shipping and injection supplies sit inside the figure rather than beside it. 2. ## What happens when the dose goes up? The site advertises the same price at any dose in its scrolling banner, which means the rate a buyer starts on holds as the weekly dose climbs. Neither product page prints a milligram figure, so the ladder that rate covers is not published anywhere a buyer can check. Nothing states who approves a step up, or how long the first dose is held. The banner is the whole of the disclosure. 3. ## What the price includes Each molecule has two rungs: a month-to-month figure and a three-month plan billed as one payment, with the three-month rung marked most popular and its single charge printed beside the monthly equivalent. Tirzepatide sits one tier above semaglutide on both rungs. The home page shows the same two figures per product as a small table before a buyer clicks through. Nothing longer than three months is offered. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, and TrueMe states plainly that it is neither a state-licensed pharmacy nor a drug manufacturer. The dispensing pharmacy is described as licensed and third-party but is not named. Compounded preparations are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality. ## Where it holds up, and where it does not - Strength: The refund condition is printed beside the price - Strength: The three-month charge is shown as one payment - Strength: Same price at every titration dose - Strength: Shipping and supplies sit inside the rate - Strength: No membership fee is charged - Limitation: Payment comes before the intake form - Limitation: Only six states are served - Limitation: The dispensing pharmacy goes unnamed - Limitation: No prescriber or medical group is named - Limitation: No milligram dose appears on either page ## What the evidence says about this kind of treatment The assessment above is about TrueMe. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer in one of its six states who wants refund terms stated before the intake. Wrong for A buyer who expects a clinical review before any money changes hands. ## The evidence behind what TrueMe prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TrueMe compares | Seller | Who it suits | Go | | --- | --- | --- | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | | FMmeds | Buyers who want one all-in figure and the compounding pharmacy named beside it | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) [Jyra Health](https://thisglp.com/reviews/jyra-health) [KERNX Health](https://thisglp.com/reviews/kernx-health) [Kin Meds](https://thisglp.com/reviews/kin-meds) [Kina](https://thisglp.com/reviews/kina) [Knownwell](https://thisglp.com/reviews/knownwell) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which states does TrueMe serve? Six: Arizona, Texas, Pennsylvania, Colorado, Missouri and Wisconsin. The product pages list them by name and the home page by abbreviation. Is there a medical review before payment? No. The semaglutide page states no intake form is required before you pay, with a full refund promised if a provider does not approve. Does the price rise with the dose? No. TrueMe advertises the same price at any dose, though it publishes no milligram figure to show what that ladder covers. Is TrueMe legit? TrueMe is a GLP-1 telehealth sellers service. Its stated availability: 6 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is TrueMe expensive compared with other GLP-1 telehealth sellers? TrueMe publishes a starting figure of $151/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TrueMe below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Try Ageless reviews (2026): GLP-1 telehealth sellers | This GLP The same product carries one price in the shop and a different one in the plan funnel, and which is cheaper depends on the line. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/try-ageless Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two doors, two prices # Try Ageless review The same product carries one price in the shop and a different one in the plan funnel, and which is cheaper depends on the line. ## The verdict Try Ageless leads injected semaglutide at $99 a month in its shop, with $229 struck beside it. A separate plan funnel quotes the same product at $279 month-to-month, down to $199 on an annual commitment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $99/mo Oral From $199/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Try Ageless sells both molecules by injection and orally, through two routes that price the same products differently: a shop with per-dose ladders, and a plan funnel with commitment rates. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. Neither route describes the clinician, and the two do not reference each other anywhere a buyer would notice. Running two pricing systems for one catalog means no published figure is the price without also naming the door it came through. On oral tirzepatide the funnel is the cheaper route, which makes the pattern impossible to generalize. 2. ## What happens when the dose goes up? The shop publishes a genuine ladder: its spec table runs $119 to $229 across 0.25 to 2.5 mg on the injection, and $199 to $249 on the oral. The injection's $99 headline sits below that table, and the page says the final amount depends on the prescribed dose. The plan funnel states no dose at all. 3. ## What the price includes Six months of injected semaglutide is $594 at the shop's headline, $1,194 on the annual plan rate and $1,674 month-to-month in the funnel. Oral tirzepatide reverses it: $1,494 to $1,794 at the shop against $954 to $1,194 in the funnel. Intro coupons take $50 off a first order on three lines. 4. ## What it claims, and what it cites All four lines are compounded rather than manufactured. A pharmacy prepares them, and no agency reviews a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: The shop publishes real per-dose ladders - Strength: Milligram ranges are stated on both molecules - Strength: Annual and monthly funnel rates both published - Strength: Intro coupons are named openly - Limitation: Two routes quote different prices - Limitation: The two doors never reference each other - Limitation: The cheaper door changes by line - Limitation: The funnel states no dose at all ## What the evidence says about this kind of treatment The assessment above is about Try Ageless. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to price the same product twice before buying it once. Wrong for A reader who assumes the first figure they are shown is the seller's price. ## The evidence behind what Try Ageless prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Try Ageless compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | Nolu | Readers who count cycles rather than months and want a flat rate at any dose | | | He & She MD | A reader with a year's cost available who wants the annual total printed | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Kongo](https://thisglp.com/reviews/kongo) [LaSara Medical Group](https://thisglp.com/reviews/lasara) [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) [Layla](https://thisglp.com/reviews/layla) [Lean Meds](https://thisglp.com/reviews/leanmeds) [Lean Rx](https://thisglp.com/reviews/lean-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which route is cheaper? It depends on the line. The shop is cheaper on injected semaglutide; the funnel is cheaper on oral tirzepatide. Is there a published dose ladder? In the shop, yes: its table runs $119 to $229 across 0.25 to 2.5 mg on the injection, beside a $99 headline. The funnel states no dose. What do the coupons save? $50 off a first order, on three of the four lines. Is Try Ageless expensive compared with other GLP-1 telehealth sellers? Try Ageless publishes a starting figure of $99/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Try Ageless below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # TRYM Health reviews (2026): GLP-1 telehealth sellers | This GLP The menu leads to a daily rate, and the daily rate belongs to a twelve-month plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/trym-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by the day # TRYM Health review The menu leads to a daily rate, and the daily rate belongs to a twelve-month plan. ## The verdict TRYM advertises plans from $3.20 a day for semaglutide and $4.20 for tirzepatide. Neither is a rate TRYM charges by the month. Both are the twelve-month prepayments, $1,150 and $1,500 for the year, and the month-to-month plans are $150 and $180. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $150/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states TRYM Health is a subscription management platform offering compounded semaglutide and tirzepatide alongside NAD+, a growth-hormone peptide and an amino blend. It states that it does not itself provide medical or pharmacy services. Programs are available in all fifty states. 1. ## Who writes the prescription, and what do they see? There is no consultation step in the sign-up TRYM describes. A member registers, completes an intake form, pays, and is then matched with a partner provider for review. The platform presents skipping appointments as a convenience, so what the provider sees before approving an order is the form and nothing else. Programs are bought as terms of one, three, six or twelve months, each shipped in insulated packaging with a temperature sensor. The twelve-month plan arrives as two shipments rather than one. A patient already on a higher dose is told they will not have to start over. 2. ## What happens when the dose goes up? Each program states that it fills enough supply to move up every four weeks on a regular dosing schedule. That is a clear commitment to covering the ladder inside one price. The pricing page also says both programs cover up to a maximum dose of 15 mg a week. That ceiling belongs to tirzepatide; the semaglutide entry carries the same sentence, and TRYM's services page caps semaglutide far lower. 3. ## What the price includes The full table is published only on a pricing page the site's own navigation does not link to. That is the heart of the problem, because the menu reaches per-day figures and an account wall. Reached directly, it lists semaglutide at $150 a month, $375 a quarter, $650 for six months and $1,150 for a year, with tirzepatide at $180, $450, $800 and $1,500. TRYM states there are no membership fees, shipping costs or hidden charges. 4. ## What it claims, and what it cites Both lines are compounded and described as additive free with a one-year expiry. TRYM states that compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality. The dispensing pharmacy is not named. ## Where it holds up, and where it does not - Strength: The month-to-month rate is published, once the page is found - Strength: No membership fee or shipping charge - Strength: Supply is stated as covering a step every four weeks - Strength: A patient on a higher dose is not made to restart - Strength: Shipments are temperature-monitored - Limitation: The advertised daily rate is the twelve-month plan - Limitation: The pricing page is not linked from the navigation - Limitation: The semaglutide program states a tirzepatide dose ceiling - Limitation: Payment comes before any provider review ## What the evidence says about this kind of treatment The assessment above is about TRYM Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who will find the plan table and compare terms rather than days. Wrong for A buyer pricing a program from the per-day figure on the homepage. ## The evidence behind what TRYM Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How TRYM Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | | Fifty 410 | Buyers who want no card charged until a prescription exists and will check which product a headline belongs to | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Lean Rx](https://thisglp.com/reviews/lean-rx) [LeanDose](https://thisglp.com/reviews/leandose) [Lemonaid Health](https://thisglp.com/reviews/lemonaid-health) [LevelsRx](https://thisglp.com/reviews/levelsrx) [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) [Levers Health](https://thisglp.com/reviews/levers-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $3.20 a day the real rate? Only on the twelve-month plan. Month to month, semaglutide is $150 and tirzepatide is $180. Where is the full price list? On the pricing page, which the site's navigation does not link to. The menu leads instead to per-day figures and an account wall. What dose do the programs cover? The pricing page states both cover up to 15 mg a week. That is the tirzepatide ceiling, and TRYM's services page gives semaglutide a much lower one. Is TRYM Health legit? TRYM Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is TRYM Health expensive compared with other GLP-1 telehealth sellers? TRYM Health publishes a starting figure of $150/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts TRYM Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tryozi reviews (2026): GLP-1 telehealth sellers | This GLP The opening figure is the first four weeks, at half the standing rate. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tryozi Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Half off, once # Tryozi review The opening figure is the first four weeks, at half the standing rate. ## The verdict Tryozi opens on $139 and doubles it a screen later. The pricing block states the arrangement in full: $139 for the first four weeks, then $279 a month for compounded semaglutide. Tirzepatide runs $189 then $379. The standing rate is never concealed, only placed second. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 50 From From $279/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states LegitScript Claimed by provider Tryozi is a cash-pay telehealth storefront selling compounded semaglutide and compounded tirzepatide by weekly injection. Both are described as prepared by a licensed 503A U.S. pharmacy. Nothing else is listed. The platform states LegitScript certification and links its own listing. 1. ## Who writes the prescription, and what do they see? Every request is stated to be reviewed by a licensed U.S. clinician rather than a bot, which the site says in those words. Eligibility is checked through a free two-minute assessment before any charge. No individual clinician, medical group or medical director is named. What a clinician reads before prescribing is not described. Multi-week plans are billed once and ship every four weeks, so a fill arrives thirteen times a year rather than twelve. Discounts on the twelve-, twenty-four- and fifty-two-week terms are published as percentages off. The full total is stated to be shown before payment. Ongoing support is described without a stated cadence. 2. ## What happens when the dose goes up? No dose tier is published and no milligram figure appears beside either product. Each card explains what its molecule acts on, with semaglutide described as one appetite pathway and tirzepatide as two. Nothing states whether the rate moves as the dose climbs. Who approves a step up is not addressed. 3. ## What the price includes Semaglutide is $139 for the first four weeks and $279 a month after. Tirzepatide is $189 then $379, on the same halving. Longer terms are billed in one charge at published percentage discounts, each shipping every four weeks. The recurring figure sits directly beneath the promotional one on the same card. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, and the preparing pharmacy is described as a licensed 503A facility without being named. Compounded preparations are not FDA-approved and are not reviewed by the FDA before dispensing. Each product card sets out the mechanism claimed for its molecule. ## Where it holds up, and where it does not - Strength: The recurring rate sits under the promotional one - Strength: Every plan discount is published as a percentage - Strength: The pharmacy type is stated as licensed 503A - Strength: LegitScript certification is stated and linked - Strength: Eligibility is checked before any charge - Limitation: The headline is a first-fill rate, not the price - Limitation: The standing rate is double the opening one - Limitation: Fills arrive every four weeks, not monthly - Limitation: No milligram dose appears on either card - Limitation: No clinician or medical group is named ## What the evidence says about this kind of treatment The assessment above is about Tryozi. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants the recurring rate and the discount ladder on one screen. Wrong for A buyer budgeting from the figure in the headline. ## The evidence behind what Tryozi prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Tryozi compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LifeMD](https://thisglp.com/reviews/lifemd) [LifeRx.md](https://thisglp.com/reviews/liferx) [LifespanningRx](https://thisglp.com/reviews/lifespanningrx) [LillyDirect Foundayo](https://thisglp.com/reviews/lillydirect-foundayo) [Liv Body](https://thisglp.com/reviews/liv-body) [LIV by WellNow](https://thisglp.com/reviews/liv-by-wellnow) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What happens after the first four weeks? The rate doubles. Semaglutide moves from $139 to $279 a month and tirzepatide from $189 to $379, as printed on the same card. Is a monthly plan billed every month? Multi-week plans are billed once and ship every four weeks, which is thirteen fills across a year rather than twelve. Does the price change with the dose? Nothing on the page says. No dose tier or milligram figure is published beside either product. Is Tryozi legit? Tryozi is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Tryozi expensive compared with other GLP-1 telehealth sellers? Tryozi publishes a starting figure of $279/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Tryozi above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tummala Health reviews (2026): GLP-1 telehealth sellers | This GLP Tummala offers compounded semaglutide with nutrition guidance and support. The treating practice and monitoring schedule need confirming. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tummala-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Introductory and later pricing separated # Tummala Health review Tummala offers compounded semaglutide with nutrition guidance and support. The treating practice and monitoring schedule need confirming. ## The verdict Tummala’s injection offer gives a recognizable treatment pathway, but the medical-practice identity and follow-up plan need confirming before enrollment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Prescription Required Compounded Yes — not FDA-approved Tummala Health markets online weight management and other prescription care. Its semaglutide injection page describes personalized protocols, nutrition support and ongoing care, with a first-month offer that differs from later months. 1. ## Who writes the prescription, and what do they see? Tummala describes provider-guided care and a medical evaluation before treatment. The public product and terms do not identify the individual clinician who will treat a new patient. Ask which medical practice is responsible for clinical decisions and follow-up. The semaglutide offer describes continuing support and nutrition guidance. A universal appointment interval and promised clinical response time were not established. Confirm who handles nausea, missed doses or a treatment change before the next order. 2. ## What happens when the dose goes up? The product page says pricing does not rise with dose. That does not establish a dose schedule appropriate for every patient. Confirm the prescribed milligrams and monitoring plan with the clinician. 3. ## What the price includes The product page separates the first-month offer from the later monthly figure and claims all-[dose pricing](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). The terms generally make prescription orders final and nonreturnable. Ask for the exact renewal, included supplies, shipment length and cancellation cutoff. 4. ## What it claims, and what it cites The [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) injection is a compounded preparation rather than an FDA-approved branded product. Other medicines appear in the wider menu, but the specific formulation, pharmacy and prescribing decision should be confirmed for the selected treatment. ## Where it holds up, and where it does not - Strength: Introductory and later pricing separated - Strength: All-dose pricing claim is stated - Strength: Nutrition and ongoing support described - Limitation: Treating practice needs confirming - Limitation: Prescription orders are generally final - Limitation: Follow-up cadence is not specified ## What the evidence says about this kind of treatment The assessment above is about Tummala Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded semaglutide who will confirm the treating practice, pharmacy and continued support before ordering. Wrong for Someone who needs the responsible medical practice and a fixed monitoring interval identified before enrollment. ## The evidence behind what Tummala Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Tummala Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [50 Stars Health](https://thisglp.com/reviews/livv) [Longevixx](https://thisglp.com/reviews/longevixx) [Loop Health](https://thisglp.com/reviews/loop-health) [LovelyMeds](https://thisglp.com/reviews/lovelymeds) [Luci](https://thisglp.com/reviews/luci) [Luma Health Co](https://thisglp.com/reviews/luma-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The semaglutide offer describes continuing support and nutrition guidance. A universal appointment interval and promised clinical response time were not established. Confirm who handles nausea, missed doses or a treatment change before the next order. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Semaglutide program and renewal figure](https://tummalahealth.com/product/semaglutide-injection/) - [Service and prescription terms](https://tummalahealth.com/terms-of-use/) - [Current treatment categories](https://tummalahealth.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tuyo Health reviews (2026): GLP-1 telehealth sellers | This GLP Two columns, compounded against brand-name, with the membership fee attached to only one of them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tuyo-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Compounded beside brand # Tuyo Health review Two columns, compounded against brand-name, with the membership fee attached to only one of them. ## The verdict Tuyo Health starts compounded semaglutide at $155 a month and tirzepatide at $279, with no membership charge. Brand Wegovy starts at $499 and Zepbound at $399, each with a $99 membership added. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Rises with dose From From $155/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Included Tuyo Health is a telehealth clinic whose weight-loss page sets compounded and brand-name GLP-1 care side by side. Sexual health, primary care, testosterone, birth control, peptides and hair loss share the platform. The comparison table is the page's main structure, and it runs the same rows down both columns. 1. ## Who writes the prescription, and what do they see? A board-certified provider reviews the intake and prescribes. The co-founder and chief executive is named as a physician, which is more than most of this shelf offers. Beyond him, no individual clinician is named. Eligibility is published rather than implied: a BMI of 30, or 27 with a related condition, or a transfer with a valid prescription. The compounded plan includes the consultation, clinical support, free same-week shipping and lab work every three months. The brand plan halves that lab frequency to every six months and adds the membership. Habit tracking tools for shots and weight come with either. Prior-authorization help is offered on the insurance route. 2. ## What happens when the dose goes up? Tuyo publishes a [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) step in its own three-step flow, describing a gradual increase in medication toward the goal. The pricing header beside the two starting figures says cash-pay pricing varies by dose and is available upon evaluation. Read together, those two lines mean the rate can move as the dose climbs, and the page does not say by how much. 3. ## What the price includes Semaglutide starts at $155 and tirzepatide at $279 on the compounded side, with no membership fee. Wegovy starts at $499 and Zepbound at $399 on the brand side, plus $99 a month. For buyers whose insurance covers the medication, Tuyo quotes plans from $25 a month. Every figure is a starting one. 4. ## What it claims, and what it cites The compounded formulations are prepared by licensed compounding pharmacies, are not FDA-approved, and Tuyo repeats that disclosure three times on one page. The brand products are the FDA-approved originals. Separating the two columns this clearly is the most useful thing the page does. No pharmacy is named on either side. ## Where it holds up, and where it does not - Strength: Compounded and brand priced on one screen - Strength: The membership fee is attached to the column it applies to - Strength: Lab work included, quarterly on the compounded plan - Strength: Eligibility thresholds published in the FAQ - Strength: The chief executive is named as a physician - Limitation: Both GLP-1 figures are starting rates, not flat ones - Limitation: Pricing is stated to vary by dose without a ladder - Limitation: Neither column identifies the compounding pharmacy - Limitation: The $25 insurance figure depends on a plan nobody can check ## What the evidence says about this kind of treatment The assessment above is about Tuyo Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer weighing a compounded plan against brand Zepbound at the same clinic. Wrong for A buyer who needs the rate at a higher dose fixed before starting. ## The evidence behind what Tuyo Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Tuyo Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Kina | Women in menopause who want the medical group named and four routes priced up front | | | Transparent Meds | Buyers comparing a compounded GLP-1 against peptide programs sold by the same clinic | | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Luci](https://thisglp.com/reviews/luci) [Luma Health Co](https://thisglp.com/reviews/luma-health) [Luma Meds](https://thisglp.com/reviews/luma-meds) [Lumen Meds](https://thisglp.com/reviews/lumen-meds) [LumiMeds](https://thisglp.com/reviews/lumimeds) [Lumora](https://thisglp.com/reviews/lumora) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the $99 membership apply to the compounded plan? No. It sits in the brand-name column beside Wegovy and Zepbound. The compounded column states there are no membership fees. Is $155 a flat monthly rate? It is a starting rate. The same panel says cash-pay pricing varies by dose and is set after evaluation. Is lab work extra? No. Lab work every three months is listed inside the compounded cost, and every six months on the brand plan. Is Tuyo Health expensive compared with other GLP-1 telehealth sellers? Tuyo Health publishes a starting figure of $155/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Tuyo Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Tyde Wellness reviews (2026): GLP-1 telehealth sellers | This GLP A women's weight-loss program that names every compounding pharmacy it uses and prices each molecule with a single floor across two strengths. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/tyde-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Five pharmacies named, two strengths # Tyde Wellness review A women's weight-loss program that names every compounding pharmacy it uses and prices each molecule with a single floor across two strengths. ## The verdict Tyde Wellness lists compounded semaglutide starting at $88 a month and tirzepatide starting at $125, each offered as a microdose or at full strength, and names all five pharmacies that may fill the order. What the page does not say is which of the two strengths those floors buy, so a patient planning past the first month is planning around a starting figure rather than a rate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $88/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states Tyde Wellness is an online weight-loss program aimed at women, run as a subscription through a physician-owned practice, Tyde Medical Center, LLC, with Tyde Wellness, LLC handling administration. It sells compounded semaglutide and tirzepatide injections, a low-dose naltrexone tablet as an add-on for plateaus, and three named programs, from a full-strength plan to a coaching plan without medication. 1. ## Who writes the prescription, and what do they see? The site describes board-certified clinicians and says a licensed clinician reviews each intake within 24 to 48 hours before deciding whether to prescribe. The membership terms put every prescription, diagnosis and treatment decision with providers affiliated with Tyde Medical Center. No clinician is listed by name or credential. A patient either books a free consultation or goes straight to an online questionnaire with no appointment, and the approved prescription ships from a compounding pharmacy to the door. The consultation path adds labs and weekly check-ins through the portal, where doses are adjusted, and plans are sold as a subscription that the site says can be canceled at any time. 2. ## What happens when the dose goes up? Both injections come in two strengths, and dosing is described as tailored to BMI and goals, but no milligram amount appears and no price is attached to either strength. A woman who starts on the microdose and moves to full strength in the second or third month cannot tell from the page whether her bill moves with her, and that is the question to put to the clinician first. 3. ## What the price includes The two cards read starting at $88 a month for semaglutide and starting at $125 a month for tirzepatide, and a separate section offers a discount on the first month for patients who only need medication. The membership terms authorize a recurring fee at an interval set by the plan, every four weeks or every calendar month, without printing the amount, so the billing cycle is worth confirming before checkout. 4. ## What it claims, and what it cites Both injections are compounded, and Tyde says plainly that they are made by independent FDA-registered pharmacies, not by Tyde, and that they are not FDA-approved and have not been reviewed by the FDA for safety, efficacy or quality. Its pharmacy page names five: Belmar Pharma Solutions, Casa Pharma, Olympia Pharmacy, Red Rock Home Pharmacy and Beaker Pharmacy, each with an address and phone number. ## Where it holds up, and where it does not - Strength: Five compounding pharmacies named with addresses - Strength: Microdose and full-strength options - Strength: Clinician review within two days - Strength: Weekly portal check-ins on the consultation path - Limitation: One floor covers two strengths - Limitation: No milligram dose is published - Limitation: The membership fee amount is not printed - Limitation: No clinician is named ## What the evidence says about this kind of treatment The assessment above is about Tyde Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A woman who wants to know which pharmacies may compound her medication and would like the option of starting on a microdose. Wrong for A buyer who needs a full-strength monthly rate in writing before comparing sellers. ## The evidence behind what Tyde Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Tyde Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Jently | Patients who want the compounding pharmacy named before they pay | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | Piper | Buyers who want the compounding pharmacy named before they hand over a card | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [LVNG RX](https://thisglp.com/reviews/lvng-rx) [Lyfe Rx](https://thisglp.com/reviews/lyfe-rx) [MadeMed](https://thisglp.com/reviews/mademed) [MANÜ Telehealth](https://thisglp.com/reviews/manu-telehealth) [Marek Health](https://thisglp.com/reviews/marek-health) [Maves](https://thisglp.com/reviews/maves) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $88 buy a full-strength semaglutide dose? The page does not say. The card offers a microdose and full strength under one starting figure of $88 a month. Which pharmacies make the medication? The pharmacy page names Belmar Pharma Solutions, Casa Pharma, Olympia Pharmacy, Red Rock Home Pharmacy and Beaker Pharmacy, and says the choice depends on location and prescription. Can I cancel? The site says plans are a subscription that can be canceled at any time. The membership terms say charges continue automatically until the patient cancels. Is Tyde Wellness legit? Tyde Wellness is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Tyde Wellness expensive compared with other GLP-1 telehealth sellers? Tyde Wellness publishes a starting figure of $88/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Tyde Wellness below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # UR Meds reviews (2026): GLP-1 telehealth sellers | This GLP A single starting figure for GLP-1 care, labeled limited-time, with no drug, dose or end date attached to it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ur-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One figure, no drug named # UR Meds review A single starting figure for GLP-1 care, labeled limited-time, with no drug, dose or end date attached to it. ## The verdict UR Meds puts one figure, $179, at the top of its weight-loss page under a banner that calls the pricing limited-time, and it never says which drug, dose or length of supply that figure buys. A reader can finish the page knowing the starting number and the refund rules, but not what the first box on the doorstep will contain. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Flat across doses From From $179/mo Dose published No Prescription Required Pharmacy Not named UR Meds is an online clinic whose menu runs from medical weight loss and microdosing to men's hormones, menopause care, hair, peptides and longevity, all reached through the same short online assessment. The weight-loss page describes GLP-1 care in general terms and prices it as a single program rather than as semaglutide or tirzepatide. 1. ## Who writes the prescription, and what do they see? The site says a licensed provider reviews every assessment before any treatment decision, and that finishing the assessment does not guarantee a prescription. Who that provider is stays unnamed, because the providers page describes the review without listing a clinician and the footer says care may come from independent providers, affiliated medical groups or clinical partners. The path runs from a two-minute online evaluation through a provider's review to medication shipped to the door, with shipping stated as free once a prescription is written. The weight-loss page repeats that a buyer is only charged if prescribed, while the cancellation policy says the first month is charged when the intake form is completed and refunded in full after a medical disqualification. Canceling takes a request at least 72 hours before the billing date, and outside a disqualification the policy rules out any refund on cancellation. 2. ## What happens when the dose goes up? Nothing on the weight-loss page describes a dose schedule, a step up, or what happens to the bill when a provider raises the dose after the first month. The FAQ says the cost depends on eligibility, the treatment plan and the provider's review, which leaves room for the charge to move once treatment is underway, and the site does not say which way it moves. 3. ## What the price includes Every page that carries a price carries the same one: the home page banner reads "GLP-1 Programs Starting at $179", and the weight-loss page repeats the figure in its hero box beside "No monthly membership". The banner on that page calls this limited-time pricing but gives no end date and no figure the price returns to afterward, so a reader has nothing to plan a third or fourth month against. The cancellation policy, for its part, describes the purchase as membership in a subscription program billed by the month. 4. ## What it claims, and what it cites The weight-loss page names no molecule, no dose and no pharmacy, and it does not say whether a prescription would be filled with a brand-name product or a compounded preparation. Its disclaimer mentions compounded medications only where applicable, and compounded GLP-1 preparations are not FDA-approved and are not reviewed by the FDA before they are dispensed. ## Where it holds up, and where it does not - Strength: Full refund after a medical disqualification - Strength: The starting figure appears on every page - Strength: Shipping stated as free once prescribed - Strength: No separate membership fee is advertised - Limitation: The $179 names no drug or dose - Limitation: Limited-time label with no end date - Limitation: First month charged when intake is done - Limitation: No prescriber or pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about UR Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader comfortable letting a provider choose the drug, who wants a refund promise if the assessment ends in a disqualification. Wrong for Anyone who needs to know before paying whether the starting figure buys semaglutide or tirzepatide, and for how many weeks. ## The evidence behind what UR Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How UR Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | TeleZen MD | Readers who want the monthly rate and every term discount on one card | | | Factor Health MD | Buyers expecting to climb the dose ladder who want one price throughout | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Maximus](https://thisglp.com/reviews/maximus-tribe) [MaxLife](https://thisglp.com/reviews/maxlife) [MDExam](https://thisglp.com/reviews/mdexam) [Measured](https://thisglp.com/reviews/measured) [Medi-Weightloss](https://thisglp.com/reviews/medi-weightloss) [MediRX](https://thisglp.com/reviews/medirx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does UR Meds charge for GLP-1 care? The site says care starts at $179 and that the final figure depends on eligibility, the treatment plan and a provider's review, without tying it to a drug, a dose or a supply length. When is the card charged? The weight-loss page says a buyer is only charged if prescribed, while the cancellation policy says the first month is charged once the intake form is complete and refunded in full after a medical disqualification. How long does the limited-time price last? The banner does not say, and the weight-loss page shows neither an end date nor a later monthly figure. Is UR Meds expensive compared with other GLP-1 telehealth sellers? UR Meds publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts UR Meds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Valhalla Vitality reviews (2026): GLP-1 telehealth sellers | This GLP A broad telehealth catalog that shows its GLP-1 prices only to account holders, after sign-up. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/valhalla-vitality Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A free account is needed to see prices # Valhalla Vitality review A broad telehealth catalog that shows its GLP-1 prices only to account holders, after sign-up. ## The verdict Valhalla Vitality sells an injectable and an oral GLP-1 therapy and publishes no price for either. Pricing, dosing and product details open only after a free account is created. The site says this is deliberate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose published No Prescription Required Pharmacy Not named Availability All 50 states Valhalla Vitality is an online wellness store with a licensed-provider step in front of each prescription. Its catalog covers weight loss, hormones, peptides, sexual health, lab tests and supplements. The GLP-1 shelf holds two listings, one injectable and one oral. Both are marked as available by subscription. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews the eligibility check, typically within one business day, according to the home page. That provider decides whether a GLP-1, a "GLP-1+" option or an alternative is appropriate. No provider, medical group or credential is named on the GLP-1 pages. The home page describes provider consultations as free. The eligibility questionnaire takes five to seven minutes and asks for no photo ID at that step. An approved prescription goes to a pharmacy and ships to the patient, with tracking in the account. Two AI assistants handle product questions, billing and habit coaching. Subscriptions renew automatically and end at the close of the paid term once canceled. 2. ## What happens when the dose goes up? No dose, dose schedule or step-up plan appears on any public GLP-1 page. The product pages place dosing behind the account wall, alongside the price. Whether the charge changes as the dose rises is therefore not stated publicly. 3. ## What the price includes Neither GLP-1 listing shows a figure. The GLP-1 care page answers its own question directly: detailed options and pricing are shown only to patients inside the portal. Opening an account requires contact details, so the figures cannot be read anonymously. Two standing discounts are described: 5% off for subscribing, and a rewards tier worth 1% to 10%. The home page states that no membership fee is charged. 4. ## What it claims, and what it cites The footer states that compounded drug products are not FDA-approved or evaluated for safety, effectiveness or quality. The public pages do not say which molecule either listing contains. They also do not say whether a brand product is ever dispensed. The care page mentions compounded options where appropriate, and no pharmacy is named. ## Where it holds up, and where it does not - Strength: Free provider consultation before any purchase - Strength: No membership fee, per the home page - Strength: Subscriptions can be canceled in the account - Strength: Short eligibility check, no ID upfront - Limitation: No GLP-1 price shown without an account - Limitation: Molecule and dose hidden behind sign-in - Limitation: No provider or pharmacy named publicly - Limitation: Dispensed medication is not refundable ## What the evidence says about this kind of treatment The assessment above is about Valhalla Vitality. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader willing to open an account before seeing a price, who also wants hormone or peptide care from the same store. Wrong for Anyone comparing GLP-1 prices before handing over contact details. ## The evidence behind what Valhalla Vitality prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Valhalla Vitality compares | Seller | Who it suits | Go | | --- | --- | --- | | Henry Meds | Patients who want a fixed monthly bill and can read dose as milligrams per shipment | | | Maximus | A reader weighing a compounded preparation against the manufacturer's own pen, with both priced on one seller's pages. | | | Fridays | Readers who will get the annual rate confirmed in writing before paying | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Medro](https://thisglp.com/reviews/medro) [Medsol RX](https://thisglp.com/reviews/medsol-rx) [MEDVi](https://thisglp.com/reviews/medvi) [Metaboost Rx](https://thisglp.com/reviews/metaboost-rx) [Mevo Health](https://thisglp.com/reviews/mevo-health) [Midi Health](https://thisglp.com/reviews/midi-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Valhalla Vitality charge for a GLP-1? The price is not published. The site shows pricing and dosing only to signed-in account holders. Is it semaglutide or tirzepatide? The public pages do not say. The two listings are named by route, injectable or oral, and the molecule is not stated. Can a subscription be canceled? Yes, through the account. The terms say the cancellation takes effect at the end of the current paid term. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vaylen reviews (2026): GLP-1 telehealth sellers | This GLP Every figure on the page is a twelve-month program paid upfront. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vaylen Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced only by the year # Vaylen review Every figure on the page is a twelve-month program paid upfront. ## The verdict Vaylen publishes three prices and all three are twelve-month programs billed in one payment. Its own footnote says so. The same footnote states that shorter and monthly plans exist, and prints no figure for any of them. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $83.25/mo Oral From $99/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Vaylen sells compounded semaglutide and compounded tirzepatide as weekly injections, plus a daily dissolvable semaglutide tablet. Weight loss is the only line open. Men's health, women's health, hair loss and longevity are listed as pre-launch waitlists. 1. ## Who writes the prescription, and what do they see? Clinical services are provided through a named external clinician network rather than by Vaylen itself. The site states a board-certified US clinician reads each intake within twenty-four hours and that no approval is automated. A declined patient is refunded in full. No individual clinician is named. A program covers the prescription, the medication, provider check-ins and shipping. Monthly check-ins, dose adjustments and safety labs are listed as part of it. The site states there is no membership fee underneath. Payment can be split through two financing providers. 2. ## What happens when the dose goes up? Dose is stated to be matched to the goal and adjusted monthly as the body responds. Safety labs are named as part of that. No milligram figure appears beside any plan. Nothing published says what a step up costs inside a twelve-month term. 3. ## What the price includes Semaglutide, tirzepatide and the oral tablet each carry a monthly-looking figure. The footnote attached to all three states the figure is the per-month cost of a twelve-month program billed upfront. A separate first-month price appears in the weight-loss panel. No month-to-month rate is published anywhere. 4. ## What it claims, and what it cites Both molecules are offered compounded. The footer states that compounded medications are not FDA-approved finished products and have not been evaluated by the FDA. It also states FDA-approved medication may be prescribed where clinically appropriate. Pharmacies are described as licensed United States facilities and not named. ## Where it holds up, and where it does not - Strength: The commitment term is printed in the footnote, not hidden - Strength: A declined patient is refunded in full - Strength: Monthly check-ins and safety labs are named - Strength: The clinician network is named in the footer - Strength: Financing is offered on the upfront payment - Limitation: Every published rate requires a twelve-month prepayment - Limitation: No month-to-month figure appears anywhere - Limitation: No milligram dose is published - Limitation: Four of the five advertised lines are waitlists ## What the evidence says about this kind of treatment The assessment above is about Vaylen. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer ready to pay twelve months at once for the lowest stated rate. Wrong for A buyer who wants to compare a monthly bill against another monthly bill. ## The evidence behind what Vaylen prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vaylen compares | Seller | Who it suits | Go | | --- | --- | --- | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | Big Easy Weight Loss | Readers who can pay a block up front and want the new-patient reduction | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Midi Health](https://thisglp.com/reviews/midi-health) [Mint Med](https://thisglp.com/reviews/mint-med) [Mint Medical Clinic](https://thisglp.com/reviews/mint-medical) [Mochi Health](https://thisglp.com/reviews/mochi-health) [Mojoon](https://thisglp.com/reviews/mojoon) [Mondae](https://thisglp.com/reviews/mondae) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I pay monthly? The footnote says shorter programs and monthly plans are available. No figure is published for either. What happens if the clinician declines me? The site states a full refund. Prescriptions are issued only after an individual clinical evaluation. Who provides the care? A named external network of licensed US clinicians. Vaylen states it is not itself a medical provider. Is Vaylen expensive compared with other GLP-1 telehealth sellers? Vaylen publishes a starting figure of $83.25/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Vaylen below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vea Health reviews (2026): GLP-1 telehealth sellers | This GLP Vea lists standard and microdose GLP-1 options alongside an iPhone app. Its own terms make the independent clinical practice responsible for prescribing decisions. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vea-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 App features versus clinical care # Vea Health review Vea lists standard and microdose GLP-1 options alongside an iPhone app. Its own terms make the independent clinical practice responsible for prescribing decisions. ## The verdict Vea’s product selection and tracking app may appeal to someone who wants a digital care interface. Assess the medical service separately from the technology. A device or app does not establish suitability for a compounded prescription. A microdose listing does not carry the evidence of a standard obesity regimen. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Vea Health combines online medical access, prescription products and health-tracking software. Its weight-loss collection lists semaglutide and tirzepatide in standard and microdose categories. App access is offered with treatment; hardware shown on waitlists should not be mistaken for an included device. 1. ## Who writes the prescription, and what do they see? An independent professional practice supplies the care under Vea’s terms. A licensed clinician reviews the intake and determines medical necessity. The platform states that a consultation does not guarantee prescribing; ask which practice and clinician will manage your treatment. Public pages describe evaluation, pharmacy shipment if approved and an app for continued tracking. The app is presented as iPhone-only at the time checked, with Android still forthcoming. Confirm how to contact the medical team if the app is unsuitable for your device. 2. ## What happens when the dose goes up? Vea markets tailored dosing, but standard and microdose entries need separate assessment. Obtain the actual prescription strength and monitoring plan from the clinician. Neither an app trend nor an advertised category is a reason to adjust an injection yourself. 3. ## What the price includes The collection establishes treatment choices but not one complete, recurring weight-care price for every product. The selected offer must disclose its recurring amount, cadence and any minimum term. Ask separately about clinical follow-up, prescribed supply and testing before comparing totals. 4. ## What it claims, and what it cites Its terms explicitly discuss compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and explain that finished compounded drugs are not FDA approved. They also permit asking about an approved alternative where clinically appropriate. Confirm the pharmacy, preparation and reason for the proposed option. ## Where it holds up, and where it does not - Strength: Independent practice role stated - Strength: Compounded status explained in terms - Strength: Current app limitations disclosed - Limitation: Android access not yet established - Limitation: Product categories do not settle an individual regimen - Limitation: Complete recurring treatment total requires confirmation ## What the evidence says about this kind of treatment The assessment above is about Vea Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for An iPhone user seeking a digital tracking interface who also wants direct clarification of the clinical plan. Wrong for Someone expecting the tracking app or microdose marketing to prove medication effectiveness or clinical suitability. ## The evidence behind what Vea Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vea Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MyFastRx](https://thisglp.com/reviews/myfastrx) [MyStart Health](https://thisglp.com/reviews/mystart-health) [Näky](https://thisglp.com/reviews/naky) [NativeMed](https://thisglp.com/reviews/nativemed) [Navio MD](https://thisglp.com/reviews/navio-md) [Neo Soma Healthcare](https://thisglp.com/reviews/neo-soma-healthcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the app prescribe a treatment? No. The terms place treatment decisions with licensed clinicians in an independent practice. Is there a five-business-day cancellation cutoff? The October clarification says no such cutoff applies to stopping a future renewal. Cancellation before renewal is still necessary. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://www.veahealth.co/) - [Service and cancellation terms](https://www.veahealth.co/terms-and-conditions) - [Treatment information](https://www.veahealth.co/shop/collections/weight-loss) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vela Rx reviews (2026): GLP-1 telehealth sellers | This GLP Vela offers compounded injections and provider messaging. Its product FAQ and terms disagree about cancellation notice. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vela-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clarify clinical follow-up # Vela Rx review Vela offers compounded injections and provider messaging. Its product FAQ and terms disagree about cancellation notice. ## The verdict Vela names the platform operator and describes continued check-ins, but its cancellation descriptions need resolving before treatment begins. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Vela Rx markets online compounded semaglutide and tirzepatide injections through a platform operated by TBF Supplements LLC. Independent medical providers evaluate patients, with medication fulfillment handled through pharmacies. 1. ## Who writes the prescription, and what do they see? The terms distinguish the platform company from the medical groups providing care. A licensed provider must review the patient and decide whether treatment is appropriate. A no-prescription payment promise is not a guarantee of clinical eligibility. The product page describes structured check-ins and secure messaging between visits. It does not establish a single appointment interval for all patients. Confirm who reviews the check-ins and how to obtain clinical advice before the next refill. 2. ## What happens when the dose goes up? The program describes provider-directed adjustments. Ask whether the next pharmacy order waits for a review of symptoms and response, and what happens if the current dose should be maintained longer. 3. ## What the price includes The product FAQ asks for 30 days’ notice before cancellation, while the legal terms describe disabling auto-refill 48 hours before processing. Discounted starting figures also appear beside higher reference prices. Get one written renewal quote and cancellation deadline before enrolling. 4. ## What it claims, and what it cites The medicines are compounded and are not FDA-approved. The storefront identifies the ingredients but does not establish which pharmacy will fill a particular patient’s prescription. Request the pharmacy name and product label before the first shipment. ## Where it holds up, and where it does not - Strength: Compounded ingredients named - Strength: Provider messaging and check-ins described - Strength: Platform company identified - Limitation: Cancellation windows differ across pages - Limitation: Discounted figures need a renewal quote - Limitation: Dispensing pharmacy needs confirming ## What the evidence says about this kind of treatment The assessment above is about Vela Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded care who can establish a clear clinical follow-up plan and confirm the dispensing pharmacy. Wrong for Someone who cannot enroll until the two different cancellation notice periods are reconciled. ## The evidence behind what Vela Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vela Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NEUVÉ Health](https://thisglp.com/reviews/neuve-md) [New Wave Health](https://thisglp.com/reviews/new-wave-health) [NewSelf](https://thisglp.com/reviews/newself) [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) [NexLife](https://thisglp.com/reviews/nexlife) [Next Vial](https://thisglp.com/reviews/next-vial) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The product page describes structured check-ins and secure messaging between visits. It does not establish a single appointment interval for all patients. Confirm who reviews the check-ins and how to obtain clinical advice before the next refill. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Semaglutide care and cancellation FAQ](https://getvelarx.com/treatments/semaglutide) - [Platform and subscription terms](https://getvelarx.com/terms) - [Current treatment offers](https://getvelarx.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Velvet Rx reviews (2026): GLP-1 telehealth sellers | This GLP Three GLP-1 cards priced for the first four weeks, with no renewal rate printed beside any of them. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/velvet-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 First fill priced, renewal not # Velvet Rx review Three GLP-1 cards priced for the first four weeks, with no renewal rate printed beside any of them. ## The verdict Velvet Rx prices only the first fill. Semaglutide is $99 today against a struck $299. Tirzepatide is $179 against $359. No renewal price is published. This site does not rank a first-fill figure. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Dose published No Prescription Required Pharmacy Named Velvet Rx is a cash-pay telehealth brand. Its terms name Rocket Health Inc of Oceanside, California, as the platform operator. The menu has two weekly injections and a daily GLP-1 tablet. It also sells NAD+, sermorelin and a GHK-Cu cream. 1. ## Who writes the prescription, and what do they see? A two-minute quiz starts the process. The terms say Rocket Health does not provide medical care. Care comes from a provider employed by or contracted with an affiliated physician practice. That practice is not named. No individual clinician is named either. The site advertises same-day doctor visits. Each card lists what the price covers. That is a doctor consult, one-to-one medical support, the prescription and free shipping. The intake asks for height, weight and date of birth. Payment is cash only, by card or Apple Pay. The terms allow subscriptions that renew until canceled. The interval is shown at checkout, not on the page. 2. ## What happens when the dose goes up? No dose is printed on any card. No step-up schedule is published. Whether the charge changes at a higher dose is not stated. The tablet card does not name its molecule. The home page says semaglutide or tirzepatide. 3. ## What the price includes A first-fill price is not treated as the price on this site. Velvet Rx prints three, each marked "today". Semaglutide is $99, struck from $299. Tirzepatide is $179, struck from $359. The tablet is $149, struck from $349. Injection cards cover four weeks of medicine. The tablet card covers four packs. No card states the second-month charge. The struck figure is not described as the renewal rate. 4. ## What it claims, and what it cites The hero reads "FDA-Approved medication." The cards do not say whether a fill is brand or compounded. The terms list four partner pharmacies. One is Precision Compounding Pharmacy in Bellmore, New York. The others are RedRock Pharmacy, Health Warehouse and Triad Rx. Compounded preparations are not FDA-approved. ## Where it holds up, and where it does not - Strength: Each card lists what the price covers - Strength: Four partner pharmacies named in the terms - Strength: Operating company and address are published - Strength: Injection and tablet options offered - Limitation: Only first-fill prices are published - Limitation: No renewal rate on any card - Limitation: Prescribing practice is not named - Limitation: Brand or compounded is not stated ## What the evidence says about this kind of treatment The assessment above is about Velvet Rx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who will confirm the renewal charge with the seller before month two bills. Wrong for Anyone budgeting past the first four weeks from the page alone. ## The evidence behind what Velvet Rx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Velvet Rx compares | Seller | Who it suits | Go | | --- | --- | --- | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | TrueMe | Buyers in one of the six states it serves who want refund terms stated before the intake | | | Tryozi | Buyers who want the recurring rate and the discount ladder on one screen before starting | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) [NexLife](https://thisglp.com/reviews/nexlife) [Next Vial](https://thisglp.com/reviews/next-vial) [NextMeds](https://thisglp.com/reviews/nextmeds) [NiceRx](https://thisglp.com/reviews/nicerx) [Nirwana Health](https://thisglp.com/reviews/nirwana-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Velvet Rx charge? The first fill is $99 for semaglutide, $179 for tirzepatide and $149 for the tablet. The renewal price is not published. Is the struck price the renewal price? The page does not say. Each card shows a struck figure beside the price marked for today. Who operates Velvet Rx? Rocket Health Inc of Oceanside, California, according to the terms of use. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Verge reviews (2026): GLP-1 telehealth sellers | This GLP Verge names Telegra MD as its clinical group. Pharmacy transmission creates an important deadline for changing a prescription. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/verge Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Review before dispensing # Verge review Verge names Telegra MD as its clinical group. Pharmacy transmission creates an important deadline for changing a prescription. ## The verdict Verge identifies its clinical group, but early refill processing makes a timely clinical review especially important. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved Verge offers online prescription weight-management and other wellness programs. Its weight-loss page describes a GLP-1 injection containing semaglutide and a separate GLP-1/GIP injection category, with subscription and one-time order options. 1. ## Who writes the prescription, and what do they see? The terms identify Telegra MD, LLC and its affiliated professional entities as the independent provider group. A licensed clinician evaluates the patient and makes the prescribing decision; Verge supplies the platform and order process. The offer describes online provider review and access to support. The public pages do not establish one scheduled follow-up interval or guaranteed clinical response time. Ask how a needed dose adjustment is handled before a prescription reaches the pharmacy. 2. ## What happens when the dose goes up? The terms say orders cannot be changed, canceled or re-scripted after being sent to the partner pharmacy. That makes the timing of a dose review particularly important. Confirm the prescription before each order is transmitted. 3. ## What the price includes The page distinguishes subscriptions from one-time purchases. Its one-month subscription renews every 25 days, and the three-month subscription every 80 days; those are earlier than the labels might suggest. Compare the actual charge dates and full order amount. Prescription and consultation charges are generally final. 4. ## What it claims, and what it cites The weight-loss treatments are compounded and are not FDA-approved. The exact formulation and dispensing pharmacy should be confirmed on the prescription. A generic GLP-1/GIP category alone should not substitute for the named active ingredient. ## Where it holds up, and where it does not - Strength: Medical group identified - Strength: One-time orders are offered - Strength: Actual renewal intervals are disclosed - Limitation: Renewals occur before the labeled calendar terms - Limitation: Pharmacy-transmitted orders cannot be revised - Limitation: Universal follow-up schedule is not stated ## What the evidence says about this kind of treatment The assessment above is about Verge. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who can coordinate dose reviews before pharmacy transmission and wants to compare subscription with one-time ordering. Wrong for Someone who needs to revise or cancel a prescription after it has already been transmitted to the pharmacy. ## The evidence behind what Verge prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Verge compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nova](https://thisglp.com/reviews/nova) [Nova MD](https://thisglp.com/reviews/nova-md) [Novi](https://thisglp.com/reviews/novi) [NovoCare Pharmacy](https://thisglp.com/reviews/novocare-pharmacy) [NowPatient](https://thisglp.com/reviews/nowpatient) [NP2GO](https://thisglp.com/reviews/np2go) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? The offer describes online provider review and access to support. The public pages do not establish one scheduled follow-up interval or guaranteed clinical response time. Ask how a needed dose adjustment is handled before a prescription reaches the pharmacy. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Weight-loss products and exact renewal timing](https://startverge.com/weight-loss/) - [Medical group and order-finality terms](https://startverge.com/terms-conditions/) - [Program overview](https://startverge.com/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # VevaRX reviews (2026): GLP-1 telehealth sellers | This GLP The cards and the paragraph beneath them quote different numbers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vevarx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One page, two prices # VevaRX review The cards and the paragraph beneath them quote different numbers. ## The verdict VevaRX prices compounded semaglutide at $189 a month on the card at the top of its product page. A Program Details paragraph lower on the same page quotes $167 a month and a $467 three-month total instead. The cards say $399 for three months. Both blocks are internally consistent and they contradict each other. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 36 From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named VevaRX is a cash-pay telehealth storefront selling compounded semaglutide and compounded tirzepatide by weekly injection. Sermorelin, PT-141, NAD+ and glutathione sit beside them. Nothing is billed to insurance. The site publishes no state list. 1. ## Who writes the prescription, and what do they see? A free assessment goes to a licensed doctor, and the site states that not everyone is approved. Who reviews it, and under what standing order, is never named. The homepage says care is led by experienced U.S. licensed doctors and stops there. No medical group, medical director or supervising physician appears anywhere. Three steps are published: assessment, treatment choice, then delivery with follow-up. Each medication has its own product page carrying its own plan cards. Renewal is automatic on the term chosen. Canceling and pausing are handled by contacting support rather than in an account. 2. ## What happens when the dose goes up? Semaglutide is sold as same-price-at-every-dose, so a step up costs nothing extra. Tirzepatide is written the same way. No milligram figure appears beside either plan. Nothing published describes who signs off a dose increase, or what a provider looks at first. 3. ## What the price includes Semaglutide has a monthly card at $189 and a three-month card at $399, which the card itself converts to $133 a month. The paragraph under those cards names $167 a month and $467 for three months. Tirzepatide is three-month only, at $467 every three months, billed again each term. The card beside it calls that $149 per month. Three into $467 is $155.67. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, and VevaRX states plainly that it is neither the compounder nor the manufacturer. No compounding pharmacy is named. Its FAQ goes further than most. Effectiveness and safety claims are said to describe the active ingredients in general. They are not said to describe the formulations dispensed here. ## Where it holds up, and where it does not - Strength: A refund is stated if treatment is not approved - Strength: The three-month total is printed, not implied - Strength: Same price at every titration dose - Strength: The compounding disclaimer is unusually direct - Limitation: Two price blocks on one page disagree - Limitation: A card's own per-month conversion is off - Limitation: Tirzepatide has no month-to-month option - Limitation: No compounding pharmacy is named - Limitation: No prescriber or medical group is named ## What the evidence says about this kind of treatment The assessment above is about VevaRX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who checks a product page against itself before entering a card number. Wrong for A buyer who needs one number they can rely on at checkout. ## The evidence behind what VevaRX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How VevaRX compares | Seller | Who it suits | Go | | --- | --- | --- | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [NP2GO](https://thisglp.com/reviews/np2go) [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) [NuBloom](https://thisglp.com/reviews/nubloom) [Nucore Health](https://thisglp.com/reviews/nucore-health) [NuDay Rx](https://thisglp.com/reviews/nuday-rx) [NuuVim](https://thisglp.com/reviews/nuuvim) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which semaglutide price is the real one? The cards are the newer block: $189 monthly, $399 for three months. The paragraph below them quotes $167 and $467, which the cards do not offer. Can tirzepatide be bought month to month? No. The page states a three-month minimum at $467, rebilled every three months until canceled. Does a higher dose cost more? No. VevaRX states the same price applies at every dose on both programs. Is VevaRX expensive compared with other GLP-1 telehealth sellers? VevaRX publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts VevaRX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vida Health reviews (2026): virtual metabolic care | This GLP Vida Health combines clinical assessment, dietitian care and behavioral support. GLP-1 prescribing depends on the available program, benefits and individual medical assessment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vida-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Vida Health sell a GLP-1? Vida Health combines clinical assessment, dietitian care and behavioral support. GLP-1 prescribing depends on the available program, benefits and individual medical assessment. ## The verdict Vida’s strength is a team-based metabolic-care model rather than a medication-only service. Its public materials include prescribing, nutrition and behavior support, but access is tied to the actual program available to the member. Confirm what your benefit includes before assuming that a coaching enrollment also supplies a prescriber. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category virtual metabolic care Prescription Required Vida Health provides a virtual platform for weight, diabetes and other cardiometabolic care. Its weight and metabolic pages include GLP-1 medicines when appropriate, combined with dietary guidance, activity tracking and behavior support. They do not promise one drug or regimen for every participant. 1. ## Who writes the prescription, and what do they see? Clinical services are provided through the separately identified Vida Medical professional practices. The terms distinguish clinical professionals from health coaches, who do not provide medical services. Ask who makes prescription decisions and where medication questions are escalated. The program describes physician or advanced-practitioner care, registered dietitians, coaching and app-based monitoring. Tools can track weight and other relevant health measures. The precise team and included services depend on the program, so verify the actual arrangement rather than relying on the full platform feature list. 2. ## What happens when the dose goes up? Clinicians assess medication suitability as part of a broader plan. The public descriptions do not define a universal GLP-1 escalation timetable or refill interval. Agree on how [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), progress and treatment interruptions are reviewed and how the care team communicates with an existing clinician. 3. ## What the price includes Employer and health-plan arrangements can affect access and patient charges. The public pages do not establish one retail medication-inclusive monthly price. Program participation and a covered clinical service do not by themselves guarantee insurance coverage of the prescription. 4. ## What it claims, and what it cites The GLP-1 class is discussed without one named molecule or formulation promised to every member. Obtain the actual medication, indication and pharmacy from the clinical team. Reported program averages describe groups and should not be treated as an individual forecast. ## Where it holds up, and where it does not - Strength: Medical and lifestyle support are combined - Strength: Professional practice identities are disclosed - Strength: Coaching is distinguished from clinical care - Limitation: Benefit configuration determines available care - Limitation: No universal public drug package - Limitation: A program average does not predict individual response ## What the evidence says about this kind of treatment The assessment above is about Vida Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A person eligible for Vida care who wants coordinated nutrition, behavioral and medical support for metabolic health. Wrong for Someone seeking a guaranteed specific GLP-1 or assuming a coaching benefit includes every clinical and pharmacy service. ## How Vida Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Obu Health](https://thisglp.com/reviews/obu-health) [Omnia TeleHealth](https://thisglp.com/reviews/omnia-telehealth) [Omzo](https://thisglp.com/reviews/omzo) [Ondra Health](https://thisglp.com/reviews/ondra-health) [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) [OnlyRx](https://thisglp.com/reviews/onlyrx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does Vida Health itself provide the medical care? The terms identify separate Vida Medical professional practices as the providers of clinical services. Can a health coach make prescription decisions? The terms distinguish nonclinical coaching from professional medical care. Prescription decisions require the appropriate clinician. Is medication guaranteed with enrollment? No. The clinician assesses appropriateness, while program and benefit rules determine access and coverage. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Member treatment programs and prescribing access](https://www.vida.com/what-we-treat/) - [Metabolic care model and GLP-1 support](https://www.vida.com/metabolic-care/) - [Clinical practices, benefits and payment terms](https://www.vida.com/terms-of-use/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # VigorMeds reviews (2026): GLP-1 telehealth sellers | This GLP Taking it under the tongue costs less here than taking it by injection. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vigormeds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The needle is the premium # VigorMeds review Taking it under the tongue costs less here than taking it by injection. ## The verdict VigorMeds charges $199 a month for semaglutide by weekly injection and $139 for the sublingual, and the gap on tirzepatide is wider still at $299 against $159, which makes the needle the expensive choice on both molecules. The customer reviews propping up those pages are worth weighing carefully, because all twelve on the semaglutide injection page carry the same month and the same count of people who found them helpful. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Injection From $199/mo Oral From $139/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named VigorMeds is a telehealth catalog whose weight-management line sells compounded semaglutide and compounded tirzepatide as weekly injections and as daily sublinguals, with microdosing versions of both, liraglutide and a naltrexone combination listed as coming soon. Anti-aging, hair loss and erectile dysfunction programs sit in the same storefront. 1. ## Who writes the prescription, and what do they see? The site describes the medication as dispensed following professional review and according to established medical standards, which is a sentence about process rather than about a person. No prescriber, medical group or medical director is named anywhere on the product pages. Nothing published describes what a clinician looks at before approving a plan, or how long that takes. Each product is sold as a one-month or a three-month plan, and the product page arrives with the one-month plan already chosen rather than the longer one, which is the less common way around. A site-wide promotional code takes a fixed amount off, and because it is a first-order discount the standing figure is what a patient keeps paying. An interactive estimator on the page turns a current weight into a projected loss under three different assumptions. 2. ## What happens when the dose goes up? Nothing on the product page states what happens to the price as the dose climbs, and no milligram figure appears beside the entry rate for either molecule. Every rate is written as a starting figure rather than a ceiling, which leaves the step up unpriced. Microdosing versions are sold as separate products rather than as a rung on the same ladder. 3. ## What the price includes Semaglutide is $199 injected and $139 sublingual; tirzepatide is $299 injected and $159 sublingual, so the non-injectable route saves $60 on one molecule and $140 on the other. The product page confirms the entry figure as a one-month plan rather than a prepaid term, which is worth knowing before comparing it with sellers whose headline is a year. The promotional code applies to a first order only. 4. ## What it claims, and what it cites Both molecules are sold in compounded form, prepared to order by a pharmacy rather than manufactured, which means the FDA does not review the preparation before it is dispensed. No compounding pharmacy is named on the product pages. No LegitScript certification is claimed. ## Where it holds up, and where it does not - Strength: The sublingual costs less than the injection on both molecules - Strength: The product page defaults to a one-month plan - Strength: Four format prices are published in one grid - Strength: Microdosing versions are priced separately and openly - Strength: A projected-loss estimator is offered in three modes - Limitation: Every testimonial carries the same date and helpful count - Limitation: No prescriber or medical group is named - Limitation: No compounding pharmacy is named - Limitation: Each rate is a starting figure with no dose attached ## What the evidence says about this kind of treatment The assessment above is about VigorMeds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who would rather take a daily sublingual than a weekly injection. Wrong for A buyer who weighs a seller by the testimonials on its product pages. ## The evidence behind what VigorMeds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How VigorMeds compares | Seller | Who it suits | Go | | --- | --- | --- | | Breeze Meds | A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. | | | CoreAge Rx | A reader still at a starting dose, since that is the tier these rates price. | | | Embody | Readers who will establish the care arrangements and recurring agreement before enrollment | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Onyx Weight Loss](https://thisglp.com/reviews/onyx-weight-loss) [Open Water Rx](https://thisglp.com/reviews/open-water-rx) [Optimized Health](https://thisglp.com/reviews/optimized-health) [Options Medical Weight Loss](https://thisglp.com/reviews/options-medical-weight-loss) [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) [Oria Meds](https://thisglp.com/reviews/oria-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the sublingual really cheaper than the shot? Yes, on both molecules. Semaglutide is $139 against $199, and tirzepatide is $159 against $299. Is the entry price a prepaid term? No. The semaglutide product page shows the one-month plan selected at the same figure the catalog card quotes. What should I make of the reviews? Weigh them carefully. All twelve on the semaglutide injection page share one month and one identical count of helpful votes. Is VigorMeds expensive compared with other GLP-1 telehealth sellers? VigorMeds publishes a starting figure of $139/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts VigorMeds below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Virgo-Meds reviews (2026): GLP-1 telehealth sellers | This GLP Virgo names OpenLoop and describes four-week check-ins while the dose is being established. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/virgo-meds Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinical group identified # Virgo-Meds review Virgo names OpenLoop and describes four-week check-ins while the dose is being established. ## The verdict Virgo describes both the clinical network and an early check-in cadence; clarify how monitoring changes once the dose is stable. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Virgo-Meds offers online compounded weight-loss prescriptions with injectable and oral options. The public process describes a medical assessment, state-dependent consultation, pharmacy delivery and check-ins while the dose is being established. 1. ## Who writes the prescription, and what do they see? The terms identify OpenLoop and affiliated professional medical groups as clinical providers. Most evaluations are asynchronous, with a live video visit where required. The clinician decides whether prescribing is appropriate after reviewing the full health history. Virgo describes check-ins every four weeks while the dose settles, then less often, with messaging or video contact available. Ask what triggers the reduced review frequency and how to obtain a clinical response if symptoms arise between contacts. 2. ## What happens when the dose goes up? The program describes dose adjustments based on response. Agree on the exact ingredient, route and milligrams with the prescriber rather than using a shared schedule for oral and injectable products. 3. ## What the price includes The current homepage promotes a discount, but the full selected plan and renewal total need confirming. The terms govern subscriptions and refund timing. The stated no-approval refund should not be mistaken for a refund of medication already prepared or shipped. 4. ## What it claims, and what it cites The site markets [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) in different formulations. Compounded medicines are not FDA-approved; a dissolving oral product should not be assumed to share an injection’s absorption, dose or clinical evidence. ## Where it holds up, and where it does not - Strength: Clinical group identified - Strength: Four-week early check-ins described - Strength: State-dependent video visits explained - Limitation: Review frequency becomes less specific after stabilization - Limitation: Discount does not establish the full recurring bill - Limitation: Oral and injected formats need separate comparison ## What the evidence says about this kind of treatment The assessment above is about Virgo-Meds. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants online prescribing with a described early monitoring period and can confirm when a live visit is needed. Wrong for Someone who needs the same fixed clinical review frequency throughout treatment rather than less frequent contact after stabilization. ## The evidence behind what Virgo-Meds prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Virgo-Meds compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [OurView Health](https://thisglp.com/reviews/ourview-health) [Oxford's Medical Weight Loss (The Calibrate Clinic)](https://thisglp.com/reviews/the-calibrate-clinic)[Ozari Health](https://thisglp.com/reviews/ozari-health) [Pallas Health](https://thisglp.com/reviews/pallas-health) [PauseRX](https://thisglp.com/reviews/pauserx) [PCOS Sisters](https://thisglp.com/reviews/pcos-sisters) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Virgo describes check-ins every four weeks while the dose settles, then less often, with messaging or video contact available. Ask what triggers the reduced review frequency and how to obtain a clinical response if symptoms arise between contacts. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Clinical process and check-ins](https://virgo-meds.com/pages/how-it-works) - [Medical group and subscription terms](https://virgo-meds.com/policies/terms-of-service) - [Weight-loss treatments](https://virgo-meds.com/pages/weight-loss) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Virta Health reviews (2026): metabolic care programs | This GLP Virta Health offers nutrition-centered metabolic care with GLP-1 prescribing in selected programs. Its medication and deprescribing pathways depend on the individual care plan. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/virta-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 # Does Virta Health sell a GLP-1? Virta Health offers nutrition-centered metabolic care with GLP-1 prescribing in selected programs. Its medication and deprescribing pathways depend on the individual care plan. ## The verdict Virta treats food habits and metabolic monitoring as central parts of care, rather than simply supplying refills. That can be useful for patients seeking support beyond a prescription. Its advertised medication off-ramp is a clinical pathway for suitable members, not a guarantee that everyone can stop a GLP-1 without regaining weight. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category metabolic care programs Prescription Required Virta provides metabolic care for weight management and type 2 diabetes. Its GLP-1 materials distinguish companion support from Weight Loss+ prescribing with oral or injectable treatment. Access and services depend on the program purchased by an employer or health plan. 1. ## Who writes the prescription, and what do they see? Medical decisions sit with the clinical team. The company describes a personalized nutrition approach, regular monitoring and medication changes when appropriate. Before enrolling, establish whether your benefit includes prescribing or only support for medication managed by another clinician. The app connects members to care-team guidance and practical nutrition tools. Virta describes proactive check-ins rather than a purely self-directed content library. That support should be matched to the patient’s existing diabetes or weight treatment, particularly when food intake and medication needs change together. 2. ## What happens when the dose goes up? The service describes deprescribing when medically appropriate and continued nutrition support afterward. This should be an individually monitored decision. Ask which measures guide a dose reduction, who authorizes it and what follow-up would happen if appetite, weight or glucose control worsens. 3. ## What the price includes The public treatment pages do not establish one standing cash price including medication for every individual. Employer and health-plan arrangements shape access. Confirm clinical services, pharmacy coverage and any patient cost-sharing rather than assuming an organizational savings claim describes your own bill. 4. ## What it claims, and what it cites The program page offers oral and injectable GLP-1 prescribing but does not establish one medicine for every member. Product choice remains clinical. Outcomes reported for selected Virta cohorts should be interpreted with their population and study design, not presented as a promise of personal success. ## Where it holds up, and where it does not - Strength: Nutrition and medical monitoring are integrated - Strength: Medication reduction is framed as clinically conditional - Strength: Support continues beyond the initial prescription - Limitation: Benefit details determine service access - Limitation: No single public inclusive cash price - Limitation: An advertised off-ramp is not a personal guarantee ## What the evidence says about this kind of treatment The assessment above is about Virta Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient eligible for a Virta benefit who wants continuing nutrition and metabolic support with medication decisions made by a care team. Wrong for Someone seeking a guaranteed prescription or a promise that medication can safely be stopped on a set calendar. ## How Virta Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Peak Wellness](https://thisglp.com/reviews/peak-wellness) [PepHaūs](https://thisglp.com/reviews/pephaus) [Pepti](https://thisglp.com/reviews/pepti) [Piper](https://thisglp.com/reviews/piper) [PlexusDx](https://thisglp.com/reviews/plexusdx) [PlushCare](https://thisglp.com/reviews/plushcare) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does every Virta program prescribe GLP-1s? The site distinguishes companion care from Weight Loss+ prescribing. Verify the specific program available to you. Will Virta definitely stop my medication? No. Its materials describe deprescribing when clinically appropriate, not an instruction or guarantee for everyone. Is nutrition support still relevant while taking a GLP-1? Virta’s model deliberately combines nutrition and clinical monitoring; ask how that plan fits your health needs. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official provider and care overview](https://www.virtahealth.com/) - [GLP-1 care and prescribing options](https://www.virtahealth.com/weight-loss-and-glp-1s) - [How assessment and follow-up work](https://www.virtahealth.com/how-it-works) - [Terms of service and payment conditions](https://www.virtahealth.com/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # VirtualCare2Go reviews (2026): GLP-1 telehealth sellers | This GLP One card covers three different molecules and tells you outright that which one arrives depends on what is in stock — a disclosure almost nobody else in this market volunteers. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/virtualcare2go Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Supply picks the drug, and says so # VirtualCare2Go review One card covers three different molecules and tells you outright that which one arrives depends on what is in stock — a disclosure almost nobody else in this market volunteers. ## The verdict VirtualCare2Go publishes $279 a month for a compounded semaglutide injection, $599 for tablets and $629 for an injection card naming three molecules at once. Consultation and shipping are stated as included throughout, across 50 states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $279/mo Oral From $599/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states VirtualCare2Go sells compounded weight-loss treatment as three all-inclusive monthly products, one of which does not commit to a molecule: the card lists semaglutide, liraglutide or tirzepatide and states that what is prescribed will depend on current supply at the time. 1. ## Who writes the prescription, and what do they see? A consultation is named as part of every price rather than charged beside it, so the clinical relationship is inside the figure, though nothing describes who conducts it or how often a case is revisited once treatment is running. Telling a buyer that stock decides the molecule is a genuinely unusual act of candor, and it is simultaneously a warning. A person who has researched one drug may receive another, and the three named here differ in schedule, in strength and in what their trials measured. 2. ## What happens when the dose goes up? The tablet card publishes its strengths — 3, 7, 14 and 21 mg — which is more than most oral sellers manage anywhere on their sites, but no card states what a figure does when a buyer moves between those strengths. 3. ## What the price includes Six months of the compounded semaglutide injection is $1,674, the tablets $3,594 and the three-molecule injection card $3,774. Consultation and shipping sit inside all three, and no contract or insurance is required, so what is quoted is what is charged for a month. 4. ## What it claims, and what it cites Every line is compounded rather than manufactured, prepared to order by a pharmacy the pages do not name, and the FDA does not review a compounded preparation before it is dispensed. On the card that names three molecules, the regulatory caveat applies without the buyer knowing which drug it applies to. ## Where it holds up, and where it does not - Strength: Consultation and shipping stated as included - Strength: The tablet strengths are published in milligrams - Strength: The supply caveat is disclosed rather than hidden - Strength: Coverage across 50 states - Limitation: One card does not commit to a molecule - Limitation: Stock decides which drug is prescribed - Limitation: The tablet route is more than double the injection - Limitation: No pharmacy is identified on any line ## What the evidence says about this kind of treatment The assessment above is about VirtualCare2Go. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who values a seller willing to write down an uncomfortable fact, and who is genuinely indifferent between three molecules. Wrong for A reader who has researched one drug and expects to receive that drug rather than whichever one is in stock. ## The evidence behind what VirtualCare2Go prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How VirtualCare2Go compares | Seller | Who it suits | Go | | --- | --- | --- | | WeightWatchers Clinic | Readers who want a familiar brand and will add the membership at its ceiling | | | Balanced Hormone Health | Readers who would rather see a dose increase priced than hidden in a monthly figure | | | Silhouette MD | Readers who want an unqualified number and will pay the tablet premium for one | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PlexusDx](https://thisglp.com/reviews/plexusdx) [PlushCare](https://thisglp.com/reviews/plushcare) [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) [Potere Health MD](https://thisglp.com/reviews/potere-health-md) [Precision Telemed](https://thisglp.com/reviews/precision-telemed) [Premium Health](https://thisglp.com/reviews/premium-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which molecule does the $629 card supply? Whichever is available. The card names semaglutide, liraglutide or tirzepatide, and states that what is prescribed will depend on current supply. Is anything charged on top of these figures? Not according to the pages: consultation and shipping are stated as included, no insurance is required and no contract is described. Are the tablet strengths published? Yes, at 3, 7, 14 and 21 mg, which is a fuller disclosure than most oral sellers on this site provide. Is VirtualCare2Go legit? VirtualCare2Go is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is VirtualCare2Go expensive compared with other GLP-1 telehealth sellers? VirtualCare2Go publishes a starting figure of $279/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts VirtualCare2Go above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vita Bella reviews (2026): GLP-1 telehealth sellers | This GLP The hero figure carries an asterisk, and the asterisk names two charges beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vita-bella Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 The asterisk does the work # Vita Bella review The hero figure carries an asterisk, and the asterisk names two charges beside it. ## The verdict Vita Bella advertises compounded semaglutide from $109 a month and tirzepatide from $159, with an asterisk resolving on the same page to membership, consult and provider approval. The Performance membership is $129 a month and a one-time consultation fee is $99, so a month starts at $238 and $288. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 46 From From $238/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Extra cost Vita Bella is a telehealth membership platform selling hormone therapy, weight management, anti-aging, sexual wellness, cognitive health, hair loss and skin care from one account. Its GLP-1 products are compounded semaglutide and tirzepatide, each formulated with B-6. The company is registered in Scottsdale, Arizona, and states that treatment decisions rest with independent licensed providers. 1. ## Who writes the prescription, and what do they see? A member joins first and meets a provider afterwards, in a scheduled one-to-one video visit that reviews health history, labs and goals before anything is prescribed. Quarterly check-ins with a provider are described as part of the membership rather than as separate appointments, which is a more continuous arrangement than a single intake form. Labs are required to confirm eligibility for some programs and are stated as not included in the fee. The membership is the product and the medication is bought through it at what the company calls wholesale pricing, so the two charges are always separate and always both payable. A three-month minimum applies to the first quarter. The membership rate is higher in California than elsewhere, which the company prints rather than discovers at checkout. 2. ## What happens when the dose goes up? Neither product page ties a figure to a milligram, and no dose ladder is published for either molecule. Dose adjustment is described as something a provider handles at the quarterly check-in rather than as a priced event. Whether the medication line moves with the ladder is therefore not established anywhere a buyer can read before joining. 3. ## What the price includes Printing the membership on the same page as the medication is what makes this arithmetic possible, and plenty of sellers in this category do not. The floor is $109 plus $129 for semaglutide and $159 plus $129 for tirzepatide, with the $99 consultation landing once at the start and a first quarter committed before anything can be canceled. A member in California meets a membership of $179 instead. 4. ## What it claims, and what it cites Both GLP-1 lines are compounded rather than manufactured, prepared with B-6 to a patient-specific formula, and the company states that its prescription products require an online evaluation with a licensed professional. The FDA does not review a compounded preparation before it is dispensed. Pharmacy partners are referred to but never named. ## Where it holds up, and where it does not - Strength: The membership and the medication are priced separately and both shown - Strength: Quarterly provider check-ins are included - Strength: The California rate is disclosed up front - Strength: A ten-minute pre-purchase consult is offered free - Limitation: The advertised figure excludes a required membership - Limitation: A one-time $99 consultation fee applies - Limitation: The first quarter is a minimum commitment - Limitation: No milligram dose or dose ladder is published ## What the evidence says about this kind of treatment The assessment above is about Vita Bella. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who will use more of the catalog than a GLP-1 and can carry a membership alongside it. Wrong for A buyer who wants one charge a month and nothing else attached. ## The evidence behind what Vita Bella prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vita Bella compares | Seller | Who it suits | Go | | --- | --- | --- | | Welling Health | Buyers who want bloodwork read by the prescriber and are comparing the medication line separately from the fee | | | Joi + Blokes | Buyers who want coaching bundled in and are budgeting for the quarter rather than the first month | | | Primary Clinic (Direct GLP) | Buyers who want unlimited primary care alongside the prescription and will use enough of it to earn the membership back | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrescribedRX](https://thisglp.com/reviews/prescribedrx) [PreventiveMD](https://thisglp.com/reviews/preventivemd) [PrideRx](https://thisglp.com/reviews/priderx) [Prime Doctor RX](https://thisglp.com/reviews/prime-doctor-rx) [Prime Health](https://thisglp.com/reviews/prime-health) [Queen RX](https://thisglp.com/reviews/queen-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $109 what a month costs? No. The asterisk beside it names a $129 monthly membership and a provider consult, which puts the semaglutide floor at $238. What is the $99 for? A one-time consultation fee charged at the start of a plan, in addition to the monthly membership and the medication. Can I cancel after one month? Not on the first quarter. Vita Bella states a three-month minimum commitment when a plan begins. Is Vita Bella expensive compared with other GLP-1 telehealth sellers? Vita Bella publishes a starting figure of $238/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Vita Bella above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # VitaFusions IV reviews (2026): GLP-1 telehealth sellers | This GLP A Dallas IV practice selling two injectables across Texas, one price per drug at any dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vitafusions-iv Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Texas only, any dose # VitaFusions IV review A Dallas IV practice selling two injectables across Texas, one price per drug at any dose. ## The verdict VitaFusions IV is a Dallas mobile IV practice that now sells compounded semaglutide at $149 and compounded tirzepatide at $189, each printed with the words any dose and a short list of charges it promises not to make. It serves Texas only, so for a buyer anywhere else the question of how that price compares never arises. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 1 From From $149/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability Texas only The business began as a mobile IV and hydration service in the Dallas-Fort Worth area. Most of the reviews on its home page still describe a nurse arriving at the door with a drip, rather than a vial arriving in the mail. Its medical weight-loss page now sells two compounded injectables, semaglutide and tirzepatide, after a telehealth visit, and the practice says in plain words that it serves the Dallas-Fort Worth area and all of Texas. 1. ## Who writes the prescription, and what do they see? The first conversation is a free consultation with a patient-care advisor, booked online, and the clinical step comes after it as a telehealth call with a clinician who sets the treatment plan. No clinician is named on the weight-loss page, and nothing on it describes what that clinician reviews before prescribing, whether labs are requested, or how often the plan is revisited once the first vial has shipped. Once the telehealth visit is done the medication is mailed to the patient's door, and the FAQ puts delivery at two to three business days from the conversation with the provider. Each program box lists no hidden fees, no insurance needed, no memberships, no monthly contracts and no autodrafts, which, read literally, means no refill is charged to a card automatically and each month is a fresh decision. 2. ## What happens when the dose goes up? Both program boxes say any dose, so the figure a patient pays at the starting strength is the figure they pay months later at a maintenance dose. That removes the dose-driven price step some sellers build into the third or fourth month of a course. The page publishes no milligram figures and no schedule, and it does not say who decides when the dose goes up or how that step is supervised. 3. ## What the price includes Semaglutide is $149 and tirzepatide is $189, and the home page describes the semaglutide figure as a month of treatment at any dose. The program page frames semaglutide as a starting price and tirzepatide as the only price, yet neither page prints a second rung, a term discount or a first-month offer that would complicate either number. 4. ## What it claims, and what it cites Both drugs are compounded, which the FAQ confirms when it says every medication is made in a compounding pharmacy, and compounded preparations are not FDA-approved or reviewed by the FDA before they are dispensed. Unusually for a practice of this size, the FAQ names the dispensing pharmacy as New Solutions Functional Wellness Pharmacy and prints its telephone number beside the name. ## Where it holds up, and where it does not - Strength: One price per drug at any dose - Strength: The dispensing pharmacy is named - Strength: No membership or monthly contract - Strength: The first consultation is free - Strength: Delivery is quoted at two to three days - Limitation: Serves Texas residents only - Limitation: No clinician is named on the page - Limitation: No milligram dose is published - Limitation: Semaglutide is labeled a starting price - Limitation: Labs are not mentioned anywhere ## What the evidence says about this kind of treatment The assessment above is about VitaFusions IV. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A Texas buyer who wants one price per drug and no subscription behind it. Wrong for Anyone living outside Texas. ## The evidence behind what VitaFusions IV prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How VitaFusions IV compares | Seller | Who it suits | Go | | --- | --- | --- | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | | California Trim Clinic | Buyers who want a free call with a clinician, and a prescriber's name on the site, before paying anything | | | Big Easy Weight Loss | Readers who can pay a block up front and want the new-patient reduction | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [ReadyRx](https://thisglp.com/reviews/readyrx) [Recovery Delivered](https://thisglp.com/reviews/recovery-delivered) [Refills](https://thisglp.com/reviews/refills) [ReflexMD](https://thisglp.com/reviews/reflexmd) [Regenics](https://thisglp.com/reviews/regenics) [Rehydra+ Wellness](https://thisglp.com/reviews/rehydra-plus) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does VitaFusions IV serve patients outside Texas? No. The practice says it serves the Dallas-Fort Worth area and the rest of Texas, and no other state is mentioned anywhere on the site as a place it will treat or ship to. Does the price go up as the dose increases? Both program boxes print any dose beside the figure, $149 for semaglutide and $189 for tirzepatide, so the page gives no reason to expect a higher charge at a higher strength. Which pharmacy fills the prescription? The FAQ names New Solutions Functional Wellness Pharmacy as the source of the medication that is mailed to the patient's door after the telehealth visit with a clinician. Is VitaFusions IV legit? VitaFusions IV is a GLP-1 telehealth sellers service. Its stated availability: Texas only. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is VitaFusions IV expensive compared with other GLP-1 telehealth sellers? VitaFusions IV publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts VitaFusions IV below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vitakey reviews (2026): GLP-1 telehealth sellers | This GLP Vitakey promises continuity with the same provider. Verify the responsible practice, prescription and follow-up arrangements. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vitakey Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Same-provider continuity is described # Does Vitakey sell a GLP-1? Vitakey promises continuity with the same provider. Verify the responsible practice, prescription and follow-up arrangements. ## The verdict Vitakey’s same-provider promise is potentially useful, but it needs confirming against the medical practice and follow-up plan for the actual treatment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Vitakey markets online prescription weight management and wellness care. It describes a medical assessment, a licensed-provider review, pharmacy delivery and continued contact with the same provider. 1. ## Who writes the prescription, and what do they see? A licensed provider decides whether to prescribe after reviewing the intake. The homepage’s sample provider messages and outcome graphics should not be treated as an introduction to the clinician who will actually treat a new patient. Request the medical practice and assigned provider details. Vitakey promises continued access to the same provider and says refills and check-ins can be arranged through the patient account. The reviewed pages do not establish a universal follow-up interval or response deadline. Confirm that continuity applies to the selected program. 2. ## What happens when the dose goes up? The treating clinician and pharmacist should identify the ingredient, route, concentration and dose. Do not build a dosing plan from a generic category or promotional result graphic. 3. ## What the price includes The homepage emphasizes easy cancellation. The terms say clinical work and medicine already ordered or prepared are generally nonrefundable, and only the portion disclosed at checkout is refundable after a prescribing denial. Obtain the full recurring bill and order cutoff before enrolling. 4. ## What it claims, and what it cites The site says compounded medicines may be prescribed. The exact GLP-1 product, formulation and pharmacy for an individual plan are not established by the broad homepage categories. Compounded medicines are not FDA-approved, and a treatment category does not identify a completed prescription. ## Where it holds up, and where it does not - Strength: Same-provider continuity is described - Strength: Clinical review can decline treatment - Strength: Refund limits are addressed in the terms - Limitation: Exact medicine and pharmacy need confirming - Limitation: No universal follow-up deadline stated - Limitation: Cancellation does not reverse all existing charges ## What the evidence says about this kind of treatment The assessment above is about Vitakey. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who values continuity and will verify the actual provider, medicine and monitoring arrangement before paying. Wrong for Someone who needs the exact drug, dispensing pharmacy and assigned prescriber established entirely from the public offer. ## How Vitakey compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) [Remedy Meds](https://thisglp.com/reviews/remedy-meds) [REMEVi](https://thisglp.com/reviews/remevi) [Remi Meds](https://thisglp.com/reviews/remi-meds) [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) [Renlo Health](https://thisglp.com/reviews/renlo-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Vitakey promises continued access to the same provider and says refills and check-ins can be arranged through the patient account. The reviewed pages do not establish a universal follow-up interval or response deadline. Confirm that continuity applies to the selected program. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Current care process](https://www.vitakeywellness.com/) - [Clinical, subscription and refund terms](https://www.vitakeywellness.com/terms.html) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vital Edge reviews (2026): GLP-1 telehealth sellers | This GLP The daily capsule costs $151 less a month than the weekly injection. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vital-edge Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Capsule undercuts the shot # Vital Edge review The daily capsule costs $151 less a month than the weekly injection. ## The verdict Vital Edge prices compounded semaglutide at $350 injected and $199 as a capsule. Tirzepatide runs $450 injected and $269 as a capsule. A feature panel higher up the page calls the treatments FDA-approved, which the compounded cards cannot support. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses Injection From $350/mo Oral From $199/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Vital Edge is a physician-supervised weight-loss service sold direct to the patient. Its catalog runs compounded semaglutide and tirzepatide alongside branded Ozempic, Mounjaro, Wegovy and Rybelsus. Lipotropic injections and three-month bundles sit in the same list. 1. ## Who writes the prescription, and what do they see? A five-minute online intake is followed by a virtual meeting with a licensed weight-loss specialist. The site describes that meeting as determining the treatment rather than confirming it. No prescriber is named. What the specialist reviews before writing is not set out. Each product is a flat monthly fee that includes the consult, the medication and shipping. Refills arrive monthly in discreet packaging. Three-month bundles are sold as one charge. Ongoing support is offered but not described in detail. 2. ## What happens when the dose goes up? Every card states a flat monthly fee with no upcharge based on dosage. That holds for the compounded and the branded lines alike. No milligram figure appears on any card. Nothing published names who authorizes a dose increase. 3. ## What the price includes The four compounded rates are $350 and $199 for semaglutide, $450 and $269 for tirzepatide. Branded products are priced separately and far higher. The semaglutide three-month bundle is $899, which works out below the monthly rate. Each card repeats its figure as the renewal price. 4. ## What it claims, and what it cites Two cards are labeled compounded and four carry brand names. A compounded preparation is made to order by a pharmacy and the FDA does not review it before dispensing. No compounding pharmacy is named. No LegitScript certification is claimed. ## Where it holds up, and where it does not - Strength: Compounded and branded routes are priced side by side - Strength: A flat fee applies at every dose - Strength: Consult, medication and shipping sit inside the rate - Strength: Three-month bundles are priced openly - Strength: Both molecules are sold in two formats - Limitation: A feature panel calls compounded treatments FDA-approved - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published - Limitation: The injection costs far more than the capsule ## What the evidence says about this kind of treatment The assessment above is about Vital Edge. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer weighing a daily capsule against a weekly injection on price. Wrong for A buyer who wants only an FDA-approved product and needs the label to be exact. ## The evidence behind what Vital Edge prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vital Edge compares | Seller | Who it suits | Go | | --- | --- | --- | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | | June Health | A reader who wants the cost of escalating known at enrollment, not at month three | | | Found | Readers who will commit to a longer term and want coaching and membership inside one figure | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RENN Health](https://thisglp.com/reviews/renn-health) [Reset Solutions](https://thisglp.com/reviews/reset-solutions) [RestorLife Med](https://thisglp.com/reviews/restorlife-med) [Revel Health](https://thisglp.com/reviews/revel-health) [Revel RX](https://thisglp.com/reviews/revel-rx) [Revive Meds](https://thisglp.com/reviews/revive-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is the capsule so much cheaper? The site does not explain the gap. It prices compounded oral semaglutide at $199 and the compounded injection at $350. Are the medications FDA-approved? The branded products are. The two compounded cards are not, whatever the feature panel above them says. Does a higher dose cost more? No. Every card states a flat monthly fee with no upcharge based on dosage. Is Vital Edge expensive compared with other GLP-1 telehealth sellers? Vital Edge publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Vital Edge above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vital Step reviews (2026): GLP-1 telehealth sellers | This GLP Vital Step identifies Dr. TelX as a clinical group and offers oral and injectable compounded treatment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vital-step Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinician-selected formats # Vital Step review Vital Step identifies Dr. TelX as a clinical group and offers oral and injectable compounded treatment. ## The verdict Vital Step identifies its clinical network, but a specific monitoring plan still needs agreeing before treatment starts. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Vital Step markets online weight-loss programs with compounded semaglutide and tirzepatide in injectable and rapidly dissolving oral formats. Longer plans are prepaid rather than monthly installments. 1. ## Who writes the prescription, and what do they see? The terms identify Dr. TelX as the medical group through which clinical services may be provided. The licensed provider, rather than the platform, decides whether treatment is appropriate and which formulation to prescribe. Vital Step describes online medical evaluation and a clinician-guided treatment plan. A universal scheduled follow-up interval and guaranteed clinical response time were not established on the reviewed pages. Confirm how continued monitoring works after delivery. 2. ## What happens when the dose goes up? The site says the clinician selects the medication and dose. Discuss tolerance before increasing and ask how a changed prescription affects remaining prepaid medicine. 3. ## What the price includes The homepage distinguishes one-month prices from annual prepaid equivalents. Longer terms are paid together. It also refers patients to checkout for final renewal and refund conditions; the legal terms generally exclude refunds for partially used subscription periods. 4. ## What it claims, and what it cites Compounded oral and injectable products differ in formulation and evidence. They are not FDA-approved. The clinician should identify the exact medicine and route; an injection and an oral preparation are not interchangeable at an advertised price. ## Where it holds up, and where it does not - Strength: Medical group identified - Strength: Prepaid terms distinguished from installments - Strength: Oral and injectable formats separated - Limitation: Longer plans require upfront commitment - Limitation: Final terms depend on selected checkout plan - Limitation: Follow-up cadence is not established ## What the evidence says about this kind of treatment The assessment above is about Vital Step. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants to discuss oral and injectable options with a licensed provider and can confirm continued follow-up. Wrong for Someone who needs longer-term savings without paying the extended plan upfront. ## The evidence behind what Vital Step prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vital Step compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rewinding RX](https://thisglp.com/reviews/rewinding-rx) [Rex MD](https://thisglp.com/reviews/rex-md) [Rivas Medical Weight Loss](https://thisglp.com/reviews/rivas-medical) [Rivo Health](https://thisglp.com/reviews/rivo-health) [Rixa Health](https://thisglp.com/reviews/rixa-health) [RNK Health](https://thisglp.com/reviews/myrnk) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Vital Step describes online medical evaluation and a clinician-guided treatment plan. A universal scheduled follow-up interval and guaranteed clinical response time were not established on the reviewed pages. Confirm how continued monitoring works after delivery. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Plans, formulation and billing FAQ](https://vitalstep.com/) - [Medical and subscription terms](https://vitalstep.com/policies/terms-of-service) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vitalex Health reviews (2026): GLP-1 telehealth sellers | This GLP One starting figure covers both molecules, and the site says the plan price is confirmed after provider review. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vitalex-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One price, either molecule # Vitalex Health review One starting figure covers both molecules, and the site says the plan price is confirmed after provider review. ## The verdict Vitalex Health's only published figure reads "Plans from $159/mo · confirmed after provider review". It sits under a new-patient offer banner, and neither drug page names a price. What a plan costs is settled only after intake. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Vitalex Health sells both molecules by injection under one starting figure. Per-drug pricing is not itemized. The home page shows that figure beneath a banner labeled as a new-patient offer. 1. ## Who writes the prescription, and what do they see? The provider review is what confirms the price, which the site states directly. That makes the clinician part of the pricing and the published figure a starting point. One figure for two molecules removes a decision and hides a difference. Tirzepatide normally carries a premium, so a single rate is either generous on one line or optimistic on the other. 2. ## What happens when the dose goes up? Nothing is published about dose. The confirmation step covers both the molecule and the plan, so neither is settled before intake. 3. ## What the price includes The home page says plans start from $159 a month and are confirmed after provider review. The banner above it calls this a new-patient offer, and no standing rate is printed beside it. Whether $159 holds past the first month is not stated. No figure is ranked for it here. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The confirmation step is disclosed - Strength: One starting figure covers either molecule - Limitation: Per-drug pricing is not itemized - Limitation: $159 is a starting figure on a new-patient banner - Limitation: No dose behavior is published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Vitalex Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader wanting tirzepatide who will confirm the figure applies to it. Wrong for A reader who needs a settled monthly price before intake. ## The evidence behind what Vitalex Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vitalex Health compares | Seller | Who it suits | Go | | --- | --- | --- | | VyrarX | Readers who will ask what maintenance costs before starting | | | Wellspring Longevity Clinic | Readers who want a custom blend and will ask what theirs costs | | | Voxy | Readers who want check-ins included and will pick a cadence deliberately | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rivo Health](https://thisglp.com/reviews/rivo-health) [Rixa Health](https://thisglp.com/reviews/rixa-health) [RNK Health](https://thisglp.com/reviews/myrnk) [Ro](https://thisglp.com/reviews/ro) [Roboclinic](https://thisglp.com/reviews/roboclinic) [Roen Rx](https://thisglp.com/reviews/roen-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does tirzepatide cost more? The page does not say. One starting figure covers either molecule, and per-drug pricing is not itemized. Is $159 settled? No. The page reads "Plans from $159/mo · confirmed after provider review", under a new-patient offer banner, so it is a starting point rather than a rate. Where is the per-drug price? Behind the intake. The eligibility steps ask for a name before any plan or price is shown. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vitara RX reviews (2026): GLP-1 telehealth sellers | This GLP Three figures for one semaglutide program on one site, and nothing that says which of them a buyer will be charged. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vitara-rx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat by dose, unclear by plan # Vitara RX review Three figures for one semaglutide program on one site, and nothing that says which of them a buyer will be charged. ## The verdict VitaraRx makes a clear promise about dose, that the price does not change as the milligrams climb, and an unclear one about the price itself. Its cards say semaglutide from $99 a month and tirzepatide from $149, the banner above them says plans start at $179.99, and the intake form lists semaglutide at $212 at every dose. The order form is what a buyer is actually charged, so $212 is the semaglutide figure ranked here. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses States 49 From From $212/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability US except AK VitaraRx is a cash-pay telehealth storefront for compounded semaglutide and tirzepatide, and it describes itself as a marketplace connecting patients with independently licensed providers rather than as a clinic or a pharmacy. It does not dispense medication, does not accept insurance, and bills for the medication when a shipment goes out. 1. ## Who writes the prescription, and what do they see? The FAQ names the provider network as MD Integrations and says a US-based doctor reviews the questionnaire and replies within about 24 hours. In some states the doctor asks for a video consultation or a live chat before prescribing, and the intake form asks for a photo ID and a picture of the patient. No individual clinician is named anywhere on the site. A patient picks a therapy, answers the medical questions and waits for the doctor's reply, and if a prescription is written the order goes to the dispensing pharmacy and ships with instructions. Refills are handled through the account, where a patient can reorder or cancel at any time, and the FAQ says the patient is contacted before each refill is billed. Once medication arrives the FAQ treats every sale as final, so canceling stops the next shipment but does not return the one already on the shelf. 2. ## What happens when the dose goes up? This is where VitaraRx is most specific. Each card prints the dose range it covers, 0.25 mg to 2.5 mg for semaglutide and 2.5 mg to 15 mg for tirzepatide, above the words "All doses. Same Price.", and a section headed "Your Dose, One Price" says the monthly rate follows the medication prescribed rather than the dose. A patient stepping up the ladder every few weeks should see the same charge at each step, whichever figure that charge turns out to be. 3. ## What the price includes The cards and the banner sit a few inches apart and do not agree, with "From $99 / Month" for semaglutide and "From $149 / Month" for tirzepatide printed under a heading of "Doctor-Led Weight Loss Plans Starting at $179.99/Month". The intake form adds a third number, offering compounded semaglutide at $212 from the starting dose up to 2.4 mg weekly, and it prints no tirzepatide price at all. The word "From" on the cards and the FAQ's note that billing follows the chosen treatment plan both point to a plan ladder. No plan lengths or terms are shown, though, so the cards cannot be read as a month-to-month charge. The intake form is the one place a buyer is quoted for an order, which is why its $212 is the semaglutide figure ranked here. Tirzepatide is not ranked at all: the form's medication question offers only semaglutide, so the card's $149 has no order behind it. 4. ## What it claims, and what it cites Both molecules are compounded, and the site says so beside the banner: compounded medications are not FDA-approved, and the FDA has not verified their safety or effectiveness. The FAQ names the dispensing pharmacy as Manifest Pharmacy in Greer, South Carolina, and the footer says compounded prescriptions are prepared by licensed pharmacies under Section 503A. ## Where it holds up, and where it does not - Strength: Same price at every dose, stated in writing - Strength: Dose ranges printed on each card - Strength: Dispensing pharmacy and provider network named - Strength: Patient contacted before each refill is billed - Limitation: Cards, banner and intake quote different prices - Limitation: No plan lengths or terms are shown - Limitation: No tirzepatide price in the intake form - Limitation: All sales final once medication arrives ## What the evidence says about this kind of treatment The assessment above is about Vitara RX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient expecting several dose increases who wants the charge fixed across the whole ladder, and who will confirm the plan price with the seller first. Wrong for Anyone who needs one settled monthly figure before starting, since the site's own pages give three of them. ## The evidence behind what Vitara RX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vitara RX compares | Seller | Who it suits | Go | | --- | --- | --- | | Good Girl Rx | A reader who will read the one-month rung rather than the headline, and wants microdoses labeled as such | | | Eden | Buyers comparing what the two molecules actually cost | | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [RxION Health](https://thisglp.com/reviews/rxion-health) [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) [RxPros](https://thisglp.com/reviews/rxpros) [RxSaludable](https://thisglp.com/reviews/rxsaludable) [Rylo Health](https://thisglp.com/reviews/rylo-health) [Ryze Rx](https://thisglp.com/reviews/ryze-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does semaglutide cost at VitaraRx? The card says from $99 a month and the banner says plans start at $179.99 a month, but the intake form lists $212 at every dose, and that order-form figure is the one ranked here. The site does not explain which plan the other two belong to. Will a higher dose cost more? No, both cards say every dose costs the same, and the pricing section says the monthly rate depends on the medication rather than the milligrams. Which pharmacy fills the prescription? The FAQ names Manifest Pharmacy in Greer, South Carolina, and names MD Integrations as the network of prescribing providers. Is Vitara RX legit? Vitara RX is a GLP-1 telehealth sellers service. Its stated availability: US except AK. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Vitara RX expensive compared with other GLP-1 telehealth sellers? Vitara RX publishes a starting figure of $212/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Vitara RX above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # VitaStir reviews (2026): GLP-1 telehealth sellers | This GLP The lowest listing covers one week, and the ladder above it climbs to nearly four hundred dollars. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vitastir Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A kit, not a month # VitaStir review The lowest listing covers one week, and the ladder above it climbs to nearly four hundred dollars. ## The verdict VitaStir lists a $99 single-dose kit, which covers one week. Its lowest published month is $125 for four injections, or $135 a calendar month, and the ladder climbs to $395. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $135/mo Prescription Required Compounded Yes — not FDA-approved VitaStir sells both molecules by injection in kits, with a titration ladder priced upward from the entry month. The lowest-priced listing is a one-week supply. 1. ## Who writes the prescription, and what do they see? A prescription precedes dispensing. The pages describe kits and doses. The clinician is not described anywhere a reader can reach. Selling by the kit rather than the month makes the entry figure look like a rate. Four injections is a month; one is a week, and the two listings sit close together. 2. ## What happens when the dose goes up? This is where the real cost lives. The semaglutide ladder runs $125, $245, $295, $345 and $395 as the dose climbs, so the top rung is over three times the entry one. A reader escalating should price the rung they expect to reach. 3. ## What the price includes Four injections at $125 is a four-week supply, and thirteen of those a year makes $135 a calendar month. Tirzepatide starts at $145 for four, or $157 a month, climbing to $299 and beyond. The $99 kit is a week and should not enter a monthly comparison. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The full titration ladder is published - Strength: Both molecules carry an entry figure - Strength: Kit contents are described by dose count - Limitation: The lowest listing covers one week - Limitation: The top rung is over three times the entry - Limitation: Four-week supplies bill thirteen times a year - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about VitaStir. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will price the rung they expect to reach rather than the entry one. Wrong for A reader comparing the $99 kit against a monthly figure. ## The evidence behind what VitaStir prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How VitaStir compares | Seller | Who it suits | Go | | --- | --- | --- | | Voxy | Readers who want check-ins included and will pick a cadence deliberately | | | Woodwork | Readers ready to commit forty-eight weeks who read asterisks | | | Vitalex Health | Readers wanting tirzepatide who will confirm the figure applies to it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rylo Health](https://thisglp.com/reviews/rylo-health) [Ryze Rx](https://thisglp.com/reviews/ryze-rx) [Science & Co](https://thisglp.com/reviews/science-and-co) [Semaglutide Online](https://thisglp.com/reviews/semaglutide-online) [SexyMD](https://thisglp.com/reviews/sexymd) [ShapeIn Rx](https://thisglp.com/reviews/shapein-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $99 a month? No. It is a single-dose kit covering one week. Its lowest published month is $125 for four injections. What does the ladder cost at the top? $395 a month on semaglutide, against $125 at the entry rung. Is a four-injection supply a calendar month? No. Four weekly injections is 28 days, so thirteen of those fit into a year and $125 becomes $135 a month. Is VitaStir expensive compared with other GLP-1 telehealth sellers? VitaStir publishes a starting figure of $135/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts VitaStir below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vivanta Care reviews (2026): GLP-1 telehealth sellers | This GLP Vivanta identifies a consultation step and a pharmacy partner. The public GLP-1 category leaves the actual treatment to be confirmed. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vivanta-care Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clinical evaluation precedes prescribing # Does Vivanta Care sell a GLP-1? Vivanta identifies a consultation step and a pharmacy partner. The public GLP-1 category leaves the actual treatment to be confirmed. ## The verdict Vivanta identifies a consultation step and pharmacy partner, while leaving several treatment-specific details for the intake. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Vivanta offers clinician-guided wellness programs through an online platform. Its GLP-1 program describes medical intake, an independent clinical evaluation, pharmacy fulfillment and ongoing contact with the care team. 1. ## Who writes the prescription, and what do they see? An independent medical group provides the clinical services. A state-licensed clinician reviews the intake and determines eligibility; browsing the website or submitting information does not itself create a treating relationship. Vivanta says patients can message the care team and adjust the plan through the program. A fixed monitoring schedule, guaranteed response time and complete state-specific availability list were not established on the reviewed pages. 2. ## What happens when the dose goes up? The selected medicine, concentration and dose remain clinical decisions. Because the public category does not establish the exact formulation, obtain those details before comparing it with another GLP-1 offer. 3. ## What the price includes The program discloses a separate clinician consultation charge before intake. Medication pricing is not established as a single public standing total. The terms say subscriptions renew until canceled and refer to a separate refund policy. 4. ## What it claims, and what it cites The program uses the general GLP-1 category rather than establishing the exact ingredient and formulation in the public material reviewed. It identifies DiRx as a pharmacy partner. Confirm the actual prescription and dispensing pharmacy before accepting a plan. ## Where it holds up, and where it does not - Strength: Clinical evaluation precedes prescribing - Strength: Pharmacy partner identified - Strength: Consultation charge disclosed separately - Limitation: Exact GLP-1 ingredient is not established publicly - Limitation: Ongoing medication total needs confirming - Limitation: Follow-up cadence and state list remain unclear ## What the evidence says about this kind of treatment The assessment above is about Vivanta Care. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone prepared to clarify the medical group, exact treatment and follow-up arrangements before a consultation or purchase. Wrong for Someone unwilling to pay an evaluation charge before the actual medication and continuing total are established. ## How Vivanta Care compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [SkyRx](https://thisglp.com/reviews/skyrx) [Society of You](https://thisglp.com/reviews/society-of-you) [Somi Health](https://thisglp.com/reviews/somi-health) [Somira Health](https://thisglp.com/reviews/somira-health) [Southern Vitality and Weight Loss](https://thisglp.com/reviews/southern-vitality-weight-loss) [Spry](https://thisglp.com/reviews/spry) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What should I confirm about ongoing care? Vivanta says patients can message the care team and adjust the plan through the program. A fixed monitoring schedule, guaranteed response time and complete state-specific availability list were not established on the reviewed pages. Ask who makes clinical decisions between refills and how to reach that person. Is a prescription guaranteed? No. An independent licensed clinician must decide whether treatment is appropriate; a product page or completed intake does not establish eligibility. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [GLP-1 program and consultation fee](https://vivantacare.com/programs/glp-1) - [Medical and subscription terms](https://vivantacare.com/legal/terms) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # VivioMD reviews (2026): GLP-1 telehealth sellers | This GLP VivioMD names its pharmacy partners and offers care-team messaging. Its clinical follow-up schedule is less specific than the promise of access. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/viviomd Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named pharmacies, follow-up questions # Does VivioMD sell a GLP-1? VivioMD names its pharmacy partners and offers care-team messaging. Its clinical follow-up schedule is less specific than the promise of access. ## The verdict The named pharmacy network is useful transparency, and VivioMD describes ongoing provider access. The missing detail to settle is who will actively monitor your progress, rather than simply being available when you send a message. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required Compounded Yes — not FDA-approved Pharmacy Named VivioMD is an online platform connecting patients with independent medical providers for personalized weight-loss prescriptions. Its homepage presents GLP-1 tablets, GLP-1 injections and GLP-1/GIP injections. 1. ## Who writes the prescription, and what do they see? An independent licensed provider evaluates the online medical history and decides whether a prescription is appropriate. VivioMD itself supplies the platform. The terms distinguish the platform from the medical groups and do not guarantee that a prescription will be written. The homepage promises ongoing clinician access and 24/7 care-team messaging. It does not establish a universal scheduled follow-up interval or clinical response deadline. Before starting, ask how symptom reports reach a prescriber and how a dose change is approved. 2. ## What happens when the dose goes up? VivioMD claims the price does not rise as doses increase. The reviewed homepage does not establish a patient-specific milligram schedule. Discuss whether the current dose should change with the prescriber rather than following a sales sequence. 3. ## What the price includes The homepage gives separate starting prices for GLP-1 tablets, GLP-1 injections and GLP-1/GIP injections and claims flat pricing as doses rise. The terms also permit subscriptions and promotional commitments. Confirm the exact ingredient, formulation, full billed term and renewal amount before choosing. 4. ## What it claims, and what it cites VivioMD markets compounded and personalized treatment. Its terms identify RedRock Pharmacy, Health Warehouse and Triad Rx as fulfillment partners, with different roles. A listed partner does not establish which pharmacy or formulation will be assigned to a particular patient. Compounded drugs are not FDA-approved. ## Where it holds up, and where it does not - Strength: Pharmacy partners identified in the terms - Strength: Independent clinician review before prescribing - Strength: Messaging and flat-dose pricing described - Limitation: Scheduled clinical follow-up interval not established - Limitation: Messaging availability is not a response-time guarantee - Limitation: Subscription details are broader than the homepage summary ## What the evidence says about this kind of treatment The assessment above is about VivioMD. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone considering compounded care who will confirm the dispensing pharmacy and a practical follow-up plan before paying. Wrong for Someone who wants a specific FDA-approved branded medicine or a publicly guaranteed appointment schedule. ## How VivioMD compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [StackMD](https://thisglp.com/reviews/stackmd) [Sumbare Wellness](https://thisglp.com/reviews/sumbare-wellness) [Sunlight](https://thisglp.com/reviews/sunlight) [Superior Remedies](https://thisglp.com/reviews/superior-remedies) [Superpower](https://thisglp.com/reviews/superpower-health) [SurpassMD](https://thisglp.com/reviews/surpassmd) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does VivioMD itself provide the medical care? Its terms describe a platform through which independent medical groups and providers supply clinical services. Does 24/7 messaging mean an immediate clinician reply? The homepage offers messaging access, but the reviewed pages do not establish an immediate clinical response guarantee. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Treatment options and public FAQ](https://viviomd.com/) - [Medical, pharmacy and subscription terms](https://viviomd.com/terms-of-use) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Voxy reviews (2026): GLP-1 telehealth sellers | This GLP The figure in the headline belongs to the twelve-month plan, and every other rung is published beside it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/voxy Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Headline is the annual tier # Voxy review The figure in the headline belongs to the twelve-month plan, and every other rung is published beside it. ## The verdict Voxy publishes $179 a month for compounded semaglutide, with a headline of starting at $129 that belongs to the annual prepay tier. Every rung of the ladder is published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $179/mo Prescription Required Compounded Yes — not FDA-approved Voxy sells both molecules by injection across four billing cadences. The price covers the provider visit, medication, injection supplies, shipping and monthly check-ins. 1. ## Who writes the prescription, and what do they see? Monthly check-ins are named as included, which is a specific commitment about the clinical relationship rather than a general one. The clinician is not otherwise described. Five things inside one figure is a broad inclusion list, and monthly check-ins in particular are rare. The headline choosing the lowest rung is the usual pattern, and the other rungs being published beside it is not. 2. ## What happens when the dose goes up? Nothing states what any rung does at a higher dose. The ladder is about billing cadence rather than milligrams, so the escalation question is unanswered on all four rungs equally. 3. ## What the price includes Semaglutide runs $179 month to month, $159 billed quarterly, $149 billed every six months and $129 billed annually. Tirzepatide runs $299, $269, $239 and $199. The annual rung is 28 percent below the monthly on semaglutide and 33 percent on tirzepatide. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: All four cadences published - Strength: Monthly check-ins named as included - Strength: Visit, supplies and shipping inside the price - Limitation: The headline is the annual tier - Limitation: Month to month costs $50 more - Limitation: No dose behavior is published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Voxy. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants check-ins included and will pick a cadence deliberately. Wrong for A reader planning monthly from the headline figure. ## The evidence behind what Voxy prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Voxy compares | Seller | Who it suits | Go | | --- | --- | --- | | VitaStir | Readers who will price the rung they expect to reach rather than the entry one | | | Whoosh Wellness | Readers unsure of eligibility who do not want to risk a consultation fee | | | VyrarX | Readers who will ask what maintenance costs before starting | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Superior Remedies](https://thisglp.com/reviews/superior-remedies) [Superpower](https://thisglp.com/reviews/superpower-health) [SurpassMD](https://thisglp.com/reviews/surpassmd) [SynergenX Health](https://thisglp.com/reviews/synergenx) [Synergy Rx](https://thisglp.com/reviews/synergy-rx) [T2D.com](https://thisglp.com/reviews/t2d) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $129 a monthly rate? It is the twelve-month prepay tier. Month to month is $179 for semaglutide. What is included? The provider visit, medication, injection supplies, shipping and monthly check-ins. What are the middle rungs? $159 billed quarterly and $149 billed every six months on semaglutide. Is Voxy expensive compared with other GLP-1 telehealth sellers? Voxy publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Voxy below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vyora Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Two monthly figures, one per molecule, and a written promise that neither moves with the dose. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vyora-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One rate through the dose ladder # Vyora Wellness review Two monthly figures, one per molecule, and a written promise that neither moves with the dose. ## The verdict Vyora Wellness charges $299 a month for compounded semaglutide. Compounded tirzepatide is $399 a month. The FAQ states the cost stays the same as doses change. Refunds after dispensing are paid as account credit, not cash. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $299/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named LegitScript Claimed by provider Vyora Wellness is an online clinic selling compounded GLP-1 medicines and longevity peptides. The weight shelf lists semaglutide, tirzepatide, a microdose tirzepatide and daily tablets. The two weekly injections are the lines priced here. Insurance is not accepted. 1. ## Who writes the prescription, and what do they see? A licensed provider reviews a written health assessment before anything is prescribed. The FAQ states no video visit is used. A phone call is occasionally required. Most decisions are stated to arrive within 24 hours. The team page names two physicians under medical leadership. Each is captioned as family medicine, while the bio beneath names another specialty. The plan is a subscription billed each month. Coaching at any hour, nutrition guidance and a private member community are included. The refund policy sets shipping for monthly subscriptions at every three weeks. Shipping fees are shown at checkout, not on the product page. 2. ## What happens when the dose goes up? The semaglutide page lists six doses, from 0.25 mg to 2.4 mg. The tirzepatide page lists six, from 2.5 mg to 15 mg. The FAQ states the monthly cost does not change as the dose rises. The provider sets each step. [Side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) are handled first with low-dose protocols, by the FAQ's account. 3. ## What the price includes Semaglutide is $299 a month and tirzepatide is $399. The step between them is $100. Six months comes to $1,794 on semaglutide and $2,394 on tirzepatide. Each product is labeled a four-week subscription. Its price is written per month. The page does not reconcile the two units. 4. ## What it claims, and what it cites Both injections are compounded by 503A pharmacies. Neither is FDA-approved. The FAQ says Vyora works with 25 compounding pharmacies and names none of them. The FDA does not review a compounded preparation before it is dispensed. ## Where it holds up, and where it does not - Strength: Price stated as flat at every dose - Strength: Doses listed on both product pages - Strength: No video visit required - Strength: Coaching and community included in the price - Limitation: Refunds after dispensing come as store credit - Limitation: No compounding pharmacy is named - Limitation: Shipping fees appear only at checkout - Limitation: Four-week label beside a monthly price ## What the evidence says about this kind of treatment The assessment above is about Vyora Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants one figure that holds through the whole dose ladder. Wrong for A buyer who wants a cash refund option once the medication ships. ## The evidence behind what Vyora Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vyora Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | Elevated Health | Readers who want to see every rung before choosing a term | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TeleCareSpot](https://thisglp.com/reviews/telecarespot) [TeleClinic](https://thisglp.com/reviews/teleclinic) [TeleDocs360](https://thisglp.com/reviews/teledocs360) [TeleHealth Med](https://thisglp.com/reviews/telehealth-med) [TeleHealth Weight Solutions](https://thisglp.com/reviews/telehealth-weight-solutions) [TelePeptide](https://thisglp.com/reviews/telepeptide) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with the dose? No. Vyora's FAQ states the cost remains the same as doses change, on both molecules. Is a video visit required? No. A written assessment goes to a licensed provider. A phone call is occasionally added. How are refunds paid? As account credit that does not expire. A card refund applies only when a provider does not approve the order. Is Vyora Wellness expensive compared with other GLP-1 telehealth sellers? Vyora Wellness publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Vyora Wellness above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # VyrarX reviews (2026): GLP-1 telehealth sellers | This GLP Both figures are entry-tier, and maintenance-dose pricing is not disclosed. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vyrarx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Entry tier, no ceiling # VyrarX review Both figures are entry-tier, and maintenance-dose pricing is not disclosed. ## The verdict VyrarX publishes from $179 a month for compounded semaglutide and from $329 for tirzepatide. Both are entry-tier figures. Maintenance-dose pricing is not publicly disclosed. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 47 From From $179/mo Prescription Required Compounded Yes — not FDA-approved VyrarX sells both molecules by injection. Free shipping and provider messaging are included. Two entry figures are published. 1. ## Who writes the prescription, and what do they see? One-to-one provider messaging is named as included. No clinician is described. The intake is not documented. The inclusion of direct messaging is a real disclosure. The omission of maintenance pricing is a bigger one, and the pages state it rather than hiding it. 2. ## What happens when the dose goes up? Entry-tier is the seller's own word. Maintenance-dose pricing is not disclosed, so the figure a reader will pay at a therapeutic dose is unknown. 3. ## What the price includes Six months at $179 is $1,074 at the entry tier, and tirzepatide at $329 is $1,974. Both totals apply only while a reader stays at the entry dose. Ask what maintenance costs before ordering. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: One-to-one provider messaging included - Strength: Free shipping on both lines - Strength: The entry-tier limit is stated - Limitation: Maintenance pricing is not disclosed - Limitation: Both figures also use from wording - Limitation: No milligram dose published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about VyrarX. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will ask what maintenance costs before starting. Wrong for A reader budgeting a year from the entry figure. ## The evidence behind what VyrarX prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How VyrarX compares | Seller | Who it suits | Go | | --- | --- | --- | | Vitalex Health | Readers wanting tirzepatide who will confirm the figure applies to it | | | Wellspring Longevity Clinic | Readers who want a custom blend and will ask what theirs costs | | | WeightRx | Readers wanting tirzepatide who will confirm the figure before ordering | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TelePeptide](https://thisglp.com/reviews/telepeptide) [TeleSlim Clinic](https://thisglp.com/reviews/teleslim-clinic) [TeleZen MD](https://thisglp.com/reviews/telezen-md) [Tell Her Doc](https://thisglp.com/reviews/tellherdoc) [Telos Rx](https://thisglp.com/reviews/telos-rx) [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a maintenance dose cost? Not disclosed. Both published figures are entry-tier. What is included? Free shipping and one-to-one provider messaging. Is $179 a rate? It uses from wording at the entry tier, so it is a floor twice over. Is VyrarX expensive compared with other GLP-1 telehealth sellers? VyrarX publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts VyrarX below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Vytora Health reviews (2026): GLP-1 telehealth sellers | This GLP A monthly price that stays put as the dose climbs, with prescribing handled by a named Florida medical group. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/vytora-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Same bill at every dose # Vytora Health review A monthly price that stays put as the dose climbs, with prescribing handled by a named Florida medical group. ## The verdict Vytora Health charges $179 a month for compounded semaglutide and $249 for compounded tirzepatide on its month-to-month plan, and both product pages say that figure holds at every dose a provider prescribes. The prescribing belongs to a named Florida medical group, and the cheaper three-month option collects a full quarter in a single charge. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 51 From From $179/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states and DC LegitScript Claimed by provider Vytora Health is a storefront selling compounded semaglutide and compounded tirzepatide as weekly injections, with NAD+ and sermorelin on the same pricing grid, and it calls itself a marketing and administrative company rather than a medical provider or a pharmacy. Mounjaro and Zepbound cards also appear on the homepage at $1,399 a month, an odd sight beside a footer line saying Vytora does not offer brand-name products. 1. ## Who writes the prescription, and what do they see? The prescribing sits with Wasef Health, PC, a licensed medical group in Pinellas Park, Florida, and every product page repeats that all prescribing decisions are made by its clinicians alone. A new patient answers an online questionnaire and a provider reviews it, with no video call needed in most states. Kansas, Louisiana, Mississippi, New Mexico and West Virginia require a brief video or audio visit before treatment starts. The reviewers are described as board-certified, though no individual clinician is named on the product pages. One monthly charge covers the medication, the physician consultation, supplies, shipping and unlimited messaging with the provider, with a progress-tracking portal alongside it. The plan renews on its own each billing cycle until the patient emails the support address to cancel. The refund policy says all sales are final, so the decision to stop is best made before a renewal date comes around rather than after the vial is in the refrigerator. 2. ## What happens when the dose goes up? A patient who starts semaglutide at the lowest dose and steps up over the first four months pays the same $179 in the fifth month as in the first. Both product pages carry the line "Same price at every dose", and the FAQ repeats it. Dose increases are described as gradual and made under provider supervision, and [dose escalation](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) guidance is listed among the things every plan includes. How often a provider checks in before approving the next step is the part the pages leave out. 3. ## What the price includes Month to month, semaglutide is $179 and tirzepatide is $249, a $70 gap that holds at every dose. The three-month plan brings semaglutide down to $149 a month, billed as $447 each quarter, and tirzepatide to $199 a month, billed as $599. A pricing table lower on the homepage lists tirzepatide's one-month rate at $199 as well, which disagrees with the $249 printed on the card above it and on the tirzepatide page itself. 4. ## What it claims, and what it cites Both injections come from a network of licensed U.S. compounding pharmacies that the site never names, and every page says compounded medications are not FDA-approved and have not been evaluated by the agency for safety, efficacy or quality. The shipping answer adds a practical warning. Boxes often arrive with the ice packs melted, the medication is described as stable for up to 56 days at up to 86°F, and a warm arrival does not typically qualify for a refund. ## Where it holds up, and where it does not - Strength: Price stated as unchanged at every dose - Strength: Prescribing medical group named on every page - Strength: One-month and three-month terms priced side by side - Strength: Shipping included on every refill - Limitation: Homepage table misstates the tirzepatide month - Limitation: No individual clinician named before checkout - Limitation: Refund policy treats all sales as final - Limitation: Compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Vytora Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who expects to climb several doses and wants the monthly bill to stay where it started. Wrong for A buyer who wants a refund route if the first month does not suit them. ## The evidence behind what Vytora Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Vytora Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | | Liberty | A reader who wants to know what kind of facility made the vial, and will accept a mid-market rate to get that in writing. | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TMates](https://thisglp.com/reviews/tmates) [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) [Tonik Wellness](https://thisglp.com/reviews/tonik-wellness) [Transparent Meds](https://thisglp.com/reviews/transparent-meds) [Trava Health](https://thisglp.com/reviews/trava-health) [Trellis Vitality](https://thisglp.com/reviews/trellis-vitality) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Who writes the prescription? A clinician with Wasef Health, PC, a licensed medical group in Florida, while Vytora describes its own role as marketing and administration only. What happens to the price when the dose goes up? Nothing, according to both product pages, so semaglutide stays at $179 a month and tirzepatide at $249 on the month-to-month plan whatever the provider prescribes. Is a video visit needed? Only in Kansas, Louisiana, Mississippi, New Mexico and West Virginia, where a brief video or audio visit comes first; elsewhere the questionnaire and a provider's review are enough to begin. Is Vytora Health legit? Vytora Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states and DC. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Vytora Health expensive compared with other GLP-1 telehealth sellers? Vytora Health publishes a starting figure of $179/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Vytora Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Walgreens Weight Management reviews (2026): GLP-1 telehealth sellers | This GLP The pharmacy states each fill is a 28-day supply, which is thirteen fills a year rather than twelve. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/walgreens-weight-management Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A fill is twenty-eight days # Walgreens Weight Management review The pharmacy states each fill is a 28-day supply, which is thirteen fills a year rather than twelve. ## The verdict Walgreens Weight Management publishes $349 per fill for brand Wegovy after the first two fills. Each fill is a 28-day supply, so the calendar-month figure is $378, with a $49 online visit billed separately. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection · Oral Dose pricing Rises with dose States 28 Injection From $378/mo Oral From $149/mo Prescription Required Compounded No Walgreens dispenses brand Wegovy through its virtual-care program in the states the page lists, with the first two fills discounted and limited to the 0.25 and 0.5 milligram doses. Nothing here is compounded. 1. ## Who writes the prescription, and what do they see? An online visit precedes the prescription and is billed at $49 outside the medication price, which is a clearer separation of the clinical cost than most sellers manage. Buying an approved product from a national pharmacy chain removes the questions that dominate this category — no unnamed compounder, no unreviewed preparation, no ambiguity about what is in the pen. What replaces them is arithmetic about the calendar. 2. ## What happens when the dose goes up? The discounted fills cover only the first two doses, 0.25 and 0.5 milligrams, so the price rises the moment [titration](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) begins. That is stated rather than implied, and it means the introductory figure describes the weeks nobody stays in. 3. ## What the price includes Thirteen 28-day fills at $349 is $4,537 a year, or $378 a calendar month rather than $349. The $49 visit sits outside that. A separate oral product is listed at $149 for a 1.5 milligram 30-day supply, with a ladder running to $349 at the top. That product is orforglipron rather than semaglutide, so its figures do not describe the same drug at all. 4. ## What it claims, and what it cites [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review) is an FDA-approved brand product dispensed by a licensed pharmacy, so the caution about a preparation the FDA has not reviewed does not apply here. The oral line is a different approved molecule. ## Where it holds up, and where it does not - Strength: An FDA-approved product from a national chain - Strength: Pickup at a local Walgreens or another pharmacy - Strength: The visit fee is stated separately - Strength: A fill's length is published as 28 days - Limitation: Thirteen fills a year, not twelve - Limitation: The discount covers only the first two doses - Limitation: A $49 visit sits outside the price - Limitation: The oral ladder is a different molecule ## What the evidence says about this kind of treatment The assessment above is about Walgreens Weight Management. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants the approved product and counts fills rather than months. Wrong for A reader comparing $349 against a compounded monthly figure. ## The evidence behind what Walgreens Weight Management prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Walgreens Weight Management compares | Seller | Who it suits | Go | | --- | --- | --- | | Wellorithm | Readers who will read the checkout catalog rather than the landing page | | | Whoosh Wellness | Readers unsure of eligibility who do not want to risk a consultation fee | | | YourEra | Readers committing six months who have read which figure belongs to which plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Trillium Meds](https://thisglp.com/reviews/trillium-meds) [Trimi Health](https://thisglp.com/reviews/trimi-health) [TrimRx](https://thisglp.com/reviews/trimrx) [Trinity Meds](https://thisglp.com/reviews/trinity-meds) [TRT Nation](https://thisglp.com/reviews/trt-nation) [Tru2u](https://thisglp.com/reviews/tru2u) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $349 a monthly price? Not a calendar month. Walgreens states each fill is a 28-day supply, which is thirteen fills a year, or $378 a month. What does the discount cover? The first two fills only, at the 0.25 and 0.5 milligram doses. The price rises as soon as titration moves beyond them. Is the oral product the same drug? No. The oral ladder recorded here is orforglipron, a different molecule from semaglutide, so its figures describe a different medicine. Is Walgreens Weight Management expensive compared with other GLP-1 telehealth sellers? Walgreens Weight Management publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Walgreens Weight Management below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # WeightWatchers Clinic reviews (2026): GLP-1 telehealth sellers | This GLP Every self-pay figure is footnoted to a separate membership the buyer cannot decline and whose price is given as a span rather than a number. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/weight-watchers Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A membership quoted as a range # WeightWatchers Clinic review Every self-pay figure is footnoted to a separate membership the buyer cannot decline and whose price is given as a span rather than a number. ## The verdict WeightWatchers Clinic publishes self-pay figures of $199 for the Wegovy injection, $149 for the pill and $299 for Zepbound. Each requires a separate Med+ membership quoted at $74 to $84 a month, putting the real cost at $283, $233 and $383. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 50 Injection From $283/mo Oral From $233/mo Prescription Required Compounded No Availability 50 states WeightWatchers Clinic arranges approved brand medicines rather than compounded preparations, charging a self-pay medication rate alongside a required membership of its own, with coverage across 50 states. 1. ## Who writes the prescription, and what do they see? The membership is where the clinical relationship is priced, and the pages state that it is required. What it includes is described in less detail than the medication rates beside it, and the range it is quoted in is never explained. Footnoting a mandatory charge rather than adding it is the structural problem here, and the footnote is present and accurate, so nothing is concealed. Every headline is nonetheless a number no buyer is charged, and the membership's span makes even the corrected total an upper bound. 2. ## What happens when the dose goes up? Nothing published states what any of the three self-pay figures becomes at a higher dose, which matters here because the approved products these pages sell are themselves priced in tiers by the manufacturers. 3. ## What the price includes Taking the membership at its $84 ceiling, a month comes to $283 for the Wegovy injection, $233 for the pill and $383 for Zepbound, or $1,698, $1,398 and $2,298 over six months. At the $74 floor each falls by $60 over that period, and nothing published lets a buyer work out in advance which end applies to them. 4. ## What it claims, and what it cites [Wegovy](https://thisglp.com/research/semaglutide-cochrane-review), Ozempic and [Zepbound](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are FDA-approved manufactured products, so the caution this site applies to compounded preparations is not relevant here: what arrives is the article that was tested, at the strength printed on it. ## Where it holds up, and where it does not - Strength: Approved brand products throughout - Strength: The membership requirement is footnoted plainly - Strength: Both an injection and a pill are priced - Strength: Coverage across 50 states - Limitation: Every headline excludes the membership - Limitation: The membership is a span, not a figure - Limitation: Nothing on the page adds the two up - Limitation: Dose tiers are not published ## What the evidence says about this kind of treatment The assessment above is about WeightWatchers Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants an approved product from a familiar brand and will add the membership at its ceiling before comparing anything. Wrong for A reader comparing the $199 against a compounded seller's all-in rate, which is between $74 and $84 adrift before anything else is counted. ## The evidence behind what WeightWatchers Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How WeightWatchers Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | VirtualCare2Go | Readers genuinely indifferent between three molecules who value plain speaking | | | Corsica Health | Readers who want the monthly rate and the prepay discount on one selector | | | Aspire Health | Readers who want the dose stated beside the vial and will do the arithmetic | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TrueMe](https://thisglp.com/reviews/trueme) [Try Ageless](https://thisglp.com/reviews/try-ageless) [TRYM Health](https://thisglp.com/reviews/trym-health) [Tryozi](https://thisglp.com/reviews/tryozi) [Tuyo Health](https://thisglp.com/reviews/tuyo-health) [Tyde Wellness](https://thisglp.com/reviews/tyde-wellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month really cost? Between $273 and $283 for the Wegovy injection, depending where in its stated range the required membership lands, and this site uses the upper bound throughout. Can the membership be declined? No. The pages footnote it as required beside every self-pay figure, which is why none of those figures is a number anybody is actually charged. Are these compounded medicines? No. They are FDA-approved manufactured products, so the warnings this site attaches to compounded preparations do not apply to any line here. Is WeightWatchers Clinic legit? WeightWatchers Clinic is a GLP-1 telehealth sellers service. Its stated availability: 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is WeightWatchers Clinic expensive compared with other GLP-1 telehealth sellers? WeightWatchers Clinic publishes a starting figure of $233/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts WeightWatchers Clinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # WeightCare reviews (2026): GLP-1 telehealth sellers | This GLP The monthly plan carries no commitment, and the longer tirzepatide terms cap the dose they cover. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/weightcare Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Four terms, one without commitment # WeightCare review The monthly plan carries no commitment, and the longer tirzepatide terms cap the dose they cover. ## The verdict WeightCare charges $399 a month for compounded semaglutide and $499 for compounded tirzepatide with no commitment. Six-month terms lower those to $215 and $275. On tirzepatide, the six-month rate covers doses up to 7.5 mg a week. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $399/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named WeightCare is a telehealth program selling compounded semaglutide and tirzepatide by weekly injection. Microdose programs, B12, NAD+ and sermorelin sit on the same site. Each GLP-1 page prints four payment options, from month to month through twelve months. 1. ## Who writes the prescription, and what do they see? Payment for the first month comes before the medical questionnaire. A board-certified physician then reviews the answers and connects through the telehealth platform. The site describes that visit as same-day. No prescriber is named on the product pages. A buyer judged not to be a candidate is refunded in full, by the FAQ's own terms. Messaging with the physician is unlimited, and monthly check-ins are part of the program. Before each renewal the patient completes a refill questionnaire. That form is where a dose is held, lowered or raised. Anti-nausea medication is listed as provided where required. Cancellation is by email with CANCEL in the subject line. 2. ## What happens when the dose goes up? The two molecules are covered differently. Semaglutide's comparison table marks all doses as included on every term. Tirzepatide's monthly plan also includes all doses. Its three-month starter titrates up from the lowest dose, and its six-month plan stops at 7.5 mg a week. Doses from 10 to 15 mg a week are sold as separate high-dose programs. A longer tirzepatide term fixes the rate, not the dose ceiling. 3. ## What the price includes The no-commitment rates are $399 and $499, a $100 step between molecules. Six-month rates are $215 and $275, and twelve-month rates are $139 and $216. Held for a year, the twelve-month rates total $1,668 on semaglutide and $2,592 on tirzepatide. The three-month rung is stated as payable at the start. Whether the longer rungs bill monthly or upfront is not stated beside them. 4. ## What it claims, and what it cites Both products are compounded, and each product page states in capitals that neither is FDA-approved. The FDA does not evaluate compounded products for safety, effectiveness or quality. The dispensing pharmacy is described as accredited but is not named. The trial results for these molecules were measured on the approved products, not on these preparations. ## Where it holds up, and where it does not - Strength: A no-commitment rate on both pages - Strength: Tirzepatide dose limits stated per term - Strength: Unlimited physician messaging on every plan - Strength: Full refund if judged not a candidate - Limitation: First month paid before the medical questionnaire - Limitation: Six-month tirzepatide stops at 7.5 mg weekly - Limitation: Compounding pharmacy is not named - Limitation: State exclusions differ between two answers ## What the evidence says about this kind of treatment The assessment above is about WeightCare. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants a month without commitment before choosing a longer term. Wrong for A tirzepatide buyer expecting to reach 10 mg or more inside a six-month plan. ## The evidence behind what WeightCare prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How WeightCare compares | Seller | Who it suits | Go | | --- | --- | --- | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | | DreamHug Medical | A reader signing for the longest term who needs a broad list of served states | | | Amble | Buyers who want a multi-month rate that holds at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [UR Meds](https://thisglp.com/reviews/ur-meds) [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) [Vaylen](https://thisglp.com/reviews/vaylen) [Velvet Rx](https://thisglp.com/reviews/velvet-rx) [VevaRX](https://thisglp.com/reviews/vevarx) [VigorMeds](https://thisglp.com/reviews/vigormeds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does a month cost without a commitment? $399 for semaglutide and $499 for tirzepatide, on the Monthly plan both product pages describe as flexible and month to month. Does the six-month tirzepatide plan cover every dose? No. It covers doses up to 7.5 mg a week. Doses from 10 to 15 mg a week are sold as separate high-dose programs. Which states are served? All except Alaska, Hawaii, Louisiana and Mississippi, per the FAQ. One product-page answer also excludes Alabama. Is WeightCare expensive compared with other GLP-1 telehealth sellers? WeightCare publishes a starting figure of $399/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts WeightCare above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # WeightlessRx reviews (2026): GLP-1 telehealth sellers | This GLP Every plan is a three-month supply, and the card is charged only after a clinician approves. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/weightlessrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Quarterly supply, charged after approval # WeightlessRx review Every plan is a three-month supply, and the card is charged only after a clinician approves. ## The verdict WeightlessRx sells compounded semaglutide at $500 and compounded tirzepatide at $700. Each price buys a three-month supply. The cards print those as $167 and $233 a month. The card is charged only after a clinician approves. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses From From $167/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Named Availability All 50 states LegitScript Claimed by provider WeightlessRx is a cash-pay telehealth service with two products. Both are compounded weekly injections: semaglutide and tirzepatide. There is no membership fee and no consult fee. HSA and FSA cards are accepted. 1. ## Who writes the prescription, and what do they see? A U.S.-licensed clinician in the patient's state writes the prescription. The clinicians are described as independent of the company. The intake takes about 90 seconds. A telehealth visit with the clinician follows. No prescribing clinician is named on the public pages. The order runs in a fixed sequence. First, the card is authorized, not charged. Next, a clinician reviews the intake. If approved, the card is charged and the order ships. Refills then renew automatically. Cancellation needs five business days' notice before the billing date. A pause of up to 90 days is available. 2. ## What happens when the dose goes up? Each supply covers every dose level at one price. The FAQ states dose adjustments cost nothing extra. The separate molecule prices still differ; a switch requires a new price confirmation. A patient arriving from another program can continue near their current dose. The clinician makes that call. 3. ## What the price includes Semaglutide is $500 for three months, shown as $167 a month. Tirzepatide is $700, shown as $233. The step between the monthly figures is $66. No one-month price is published. The plan introduction mentions monthly or three-month options. The FAQ states every plan is a three-month supply. 4. ## What it claims, and what it cites Both products are compounded and neither is FDA-approved. The FAQ states compounded medications are not reviewed by the FDA for safety, quality or efficacy. The partner pharmacy is named as VitaScripts Pharmacy. LegitScript certification is stated. ## Where it holds up, and where it does not - Strength: No charge before a clinician approves - Strength: Every dose included at one price - Strength: Compounding pharmacy named in the FAQ - Strength: No membership or consult fee - Limitation: No one-month plan is offered - Limitation: Monthly option mentioned without a separate price - Limitation: Cancellation needs five business days' notice - Limitation: No prescribing clinician named ## What the evidence says about this kind of treatment The assessment above is about WeightlessRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer ready to pay for three months at once, with nothing charged before approval. Wrong for A buyer who wants to try a single month before committing to three. ## The evidence behind what WeightlessRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How WeightlessRx compares | Seller | Who it suits | Go | | --- | --- | --- | | Brello Health | Readers who can prepay a quarter and want the billing cycle read before the price tag | | | MaxLife | Readers who will ask what the starter kit covers and what follows it | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [VirtualCare2Go](https://thisglp.com/reviews/virtualcare2go) [Vita Bella](https://thisglp.com/reviews/vita-bella) [VitaFusions IV](https://thisglp.com/reviews/vitafusions-iv) [Vital Edge](https://thisglp.com/reviews/vital-edge) [Vitalex Health](https://thisglp.com/reviews/vitalex-health) [Vitara RX](https://thisglp.com/reviews/vitara-rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is there a monthly plan? No. The FAQ states every plan is a three-month supply: $500 for semaglutide and $700 for tirzepatide. When is the card charged? Only after a clinician approves the prescription. Until then it is authorized, not charged. Which pharmacy compounds the medication? The FAQ names VitaScripts Pharmacy as the partner. Is WeightlessRx legit? WeightlessRx is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is WeightlessRx expensive compared with other GLP-1 telehealth sellers? WeightlessRx publishes a starting figure of $167/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts WeightlessRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # WeightRx reviews (2026): GLP-1 telehealth sellers | This GLP Tirzepatide costs $83 and semaglutide costs $250, which reverses the usual order. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/weightrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Tirzepatide is the cheap one # WeightRx review Tirzepatide costs $83 and semaglutide costs $250, which reverses the usual order. ## The verdict WeightRx publishes $83 a month for compounded tirzepatide and $250 for semaglutide. Both figures appear on the homepage. The tirzepatide line is the cheaper of the two. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $83/mo Prescription Required Compounded Yes — not FDA-approved WeightRx sells both molecules by injection. Two figures are published together. The dual agonist is priced below the single one. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The homepage carries the prices. No clinician is described. Tirzepatide normally carries a premium of fifty to a hundred dollars. Here it is a third of the semaglutide figure, and nothing on the pages explains the inversion. 2. ## What happens when the dose goes up? Nothing is published about dose on either line. With the molecule pricing already inverted, a reader has no way to check whether the pattern holds as the dose rises. 3. ## What the price includes Six months of tirzepatide at $83 is $498 and semaglutide at $250 is $1,500. A three-fold gap in the unusual direction is worth confirming with the seller before ordering, because a transposition would explain it too. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Both figures published on one page - Strength: Tirzepatide is unusually cheap here - Strength: Both molecules are offered - Limitation: The molecule pricing is inverted - Limitation: Nothing explains the inversion - Limitation: No milligram dose published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about WeightRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader wanting tirzepatide who will confirm the figure before ordering. Wrong for A reader shopping the semaglutide line on price. ## The evidence behind what WeightRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How WeightRx compares | Seller | Who it suits | Go | | --- | --- | --- | | VyrarX | Readers who will ask what maintenance costs before starting | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | | Wellspring Longevity Clinic | Readers who want a custom blend and will ask what theirs costs | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vitalex Health](https://thisglp.com/reviews/vitalex-health) [Vitara RX](https://thisglp.com/reviews/vitara-rx) [VitaStir](https://thisglp.com/reviews/vitastir) [Voxy](https://thisglp.com/reviews/voxy) [Vyora Wellness](https://thisglp.com/reviews/vyora-wellness) [Vytora Health](https://thisglp.com/reviews/vytora-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is tirzepatide cheaper? Nothing on the pages explains it. Tirzepatide is $83 and semaglutide $250, which reverses the usual order. Should I confirm it? Yes. A three-fold gap in the unusual direction is worth checking with the seller before ordering. What dose do these buy? No milligram figure is published beside either price. Is WeightRx expensive compared with other GLP-1 telehealth sellers? WeightRx publishes a starting figure of $83/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts WeightRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Welling Health reviews (2026): GLP-1 telehealth sellers | This GLP The medication carries no markup, and the margin is charged as a separate track. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/welling-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 At cost, plus a membership # Welling Health review The medication carries no markup, and the margin is charged as a separate track. ## The verdict Welling sells compounded semaglutide from $94 a month and tirzepatide from $135 with the markup stated as zero, then charges $36 a month for the prescription track that makes either possible. The floor a buyer actually meets is $130 and $171, and both medication figures are labeled as the starting dose. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $130/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Labs Included LegitScript Claimed by provider Welling is a membership clinic built around three tracks a member assembles for themselves: bloodwork read by a clinician, a prescription catalog billed at the pharmacy's own cost, and body composition with a dietitian and trainer. Twenty-seven treatments span weight, hormones, peptides and hair. Each track is priced separately and adding more than one reduces the rate on each. 1. ## Who writes the prescription, and what do they see? The clinician who reads a member's bloodwork is the one who writes the prescription, which is an unusual arrangement in a category where an intake form and a dispensing decision rarely meet the same person. A hundred-plus biomarker panel is drawn twice a year, at baseline and again six months later, so a dose decision has a before and an after behind it. What that clinician must see before prescribing a GLP-1 specifically is not set out. Membership is assembled from tracks rather than sold as one bundle, so a member who wants only a prescription pays only for that track. Medication is invoiced at the dispensing pharmacy's own cost with nothing added. Two DEXA scans a year, a dietitian and a trainer belong to a separate track, and the mobile app is free whether or not anyone is a member. 2. ## What happens when the dose goes up? Every price on the treatments page is marked as the direct cost of the starting dose, which is a warning printed rather than a detail left out. Semaglutide is described as titrated over five dose steps and tirzepatide over six, so a member should expect the medication line to climb as the ladder does. Nothing published says what each subsequent step costs, so the size of that climb cannot be worked out in advance. 3. ## What the price includes Splitting the bill into a zero-markup medication line and a flat membership is the clearest structure in this category, because it lets a buyer see exactly what the clinic earns. It also means the advertised $94 is never what a month costs: the Rx track at $36 is a condition of being prescribed at all, putting the semaglutide floor at $130 and tirzepatide at $171. Adding a second track cuts the per-track rate by a fifth. 4. ## What it claims, and what it cites The GLP-1 lines are compounded rather than manufactured, and the site describes them as carrying the same active molecule as the brand. A compounded preparation is not reviewed by the FDA before it is dispensed. The dispensing pharmacy is not named, though the clinic states it is LegitScript certified. ## Where it holds up, and where it does not - Strength: Medication is billed at pharmacy cost with no markup - Strength: The prescriber is the clinician who read the labs - Strength: A hundred-plus biomarker panel twice a year - Strength: The starting-dose caveat is printed on the price - Strength: LegitScript certified - Limitation: The advertised figure excludes a required membership - Limitation: Prices are the starting dose only - Limitation: No cost is published for later dose steps - Limitation: The dispensing pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Welling Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants bloodwork read by the prescriber and can separate the medication line from the fee. Wrong for A buyer comparing $94 against another seller's all-in monthly rate. ## The evidence behind what Welling Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Welling Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Primary Clinic (Direct GLP) | Buyers who want unlimited primary care alongside the prescription and will use enough of it to earn the membership back | | | Vita Bella | Buyers who will use the wider catalog the membership unlocks rather than a GLP-1 alone | | | MyStart Health | Buyers who titrate quickly and want the rate frozen before the dose climbs | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [WeightlessRx](https://thisglp.com/reviews/weightlessrx) [WeightRx](https://thisglp.com/reviews/weightrx) [WeightWatchers Clinic](https://thisglp.com/reviews/weight-watchers) [Wellspring Longevity Clinic](https://thisglp.com/reviews/wellspring-longevity-clinic) [WePeptideRx](https://thisglp.com/reviews/wepeptiderx) [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I buy the medication without the membership? No. The Rx track at $36 a month is what makes a prescription possible, so the semaglutide floor is $130 and tirzepatide $171. What does at direct cost mean here? Welling states the medication is invoiced at what the pharmacy charges, with a markup of zero, and takes its margin in the membership instead. Do the prices hold as the dose rises? The figures are labeled as the starting dose, and semaglutide is described as titrated over five steps. No cost is published for the later ones. Is Welling Health expensive compared with other GLP-1 telehealth sellers? Welling Health publishes a starting figure of $130/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Welling Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # welludr. reviews (2026): GLP-1 telehealth sellers | This GLP The wellmedr.com site now presents itself as welludr. Its weight-care offering includes compounded semaglutide and tirzepatide, with important differences between membership and medication-plan cancellation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/wellmedr Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Two subscriptions need attention # welludr. review The wellmedr.com site now presents itself as welludr. Its weight-care offering includes compounded semaglutide and tirzepatide, with important differences between membership and medication-plan cancellation. ## The verdict The welludr service describes clinician messaging and continued dose review, but the purchase needs careful clarification. The terms allow separate membership and medication plans: stopping the drug plan alone does not stop membership billing. Confirm both the clinical follow-up route and every recurring charge before enrolling. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Prescription Required Compounded Yes — not FDA-approved The welludr service is an online health platform offering prescription weight care through independent clinicians and pharmacy partners. Current pages on wellmedr.com distinguish the active GLP-1 service from several other treatments marked coming soon. A broad catalog should not be read as proof each service is available. 1. ## Who writes the prescription, and what do they see? The terms distinguish the administrative platform from the medical groups and prescribers delivering care. Its program describes individual clinical assessment and access to licensed clinicians. Confirm your assigned practice, supported state and clinician contact route before accepting a treatment plan. The program advertises intake review, ongoing messaging and adjustments according to response. A patient should distinguish general support or an AI-assisted interface from the clinician responsible for medication decisions. The terms and current homepage do not establish guaranteed approval or delivery for every applicant. 2. ## What happens when the dose goes up? The tirzepatide offer says pricing does not change with dose and describes four-week shipments. Confirm that promise for the selected medication and the actual next prescription. Regular dispatch is not a substitute for clinical review when tolerance or health status changes. 3. ## What the price includes The weight-care landing page carries sale and starting-price language rather than a stable dose-by-dose continuation quote. General terms say membership excludes medication unless the purchase states otherwise. Ask for a written renewal total and supply period before treating either advertised amount as all-inclusive. 4. ## What it claims, and what it cites Current material explicitly offers compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) and acknowledges that these preparations are not FDA approved. A pharmacy list includes multiple possible dispensers; the actual pharmacy and formulation depend on the prescription and location. ## Where it holds up, and where it does not - Strength: Separate clinical and platform roles explained - Strength: Compounded-drug status disclosed - Strength: Clinician messaging advertised - Limitation: Medication cancellation can leave membership active - Limitation: Promotional prices obscure continuation cost - Limitation: Exact pharmacy varies by order ## What the evidence says about this kind of treatment The assessment above is about welludr.. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants online compounded weight care and will first confirm the clinician, renewal total and subscription structure. Wrong for A patient expecting one cancellation to stop every charge without checking which subscription was ended. ## The evidence behind what welludr. prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How welludr. compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) [Whoosh Wellness](https://thisglp.com/reviews/whoosh-wellness) [Wisp](https://thisglp.com/reviews/wisp) [Woodwork](https://thisglp.com/reviews/woodwork) [YourHealthRx](https://thisglp.com/reviews/yourhealthrx) [Yucca Health](https://thisglp.com/reviews/yucca-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does ending the medication plan end membership? The terms say it does not. Canceling membership also ends the medication plan, but the reverse is not true. Are the compounded prescriptions FDA approved? No. The current site explicitly distinguishes compounded preparations from FDA-approved finished drugs. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Provider program](https://www.wellmedr.com/) - [Service and cancellation terms](https://www.wellmedr.com/pages/terms-conditions) - [Treatment information](https://www.wellmedr.com/pages/get-started-weight-loss) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Wellorithm reviews (2026): GLP-1 telehealth sellers | This GLP The landing page and the checkout catalog publish different figures, and the bundle price is a first cycle only. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/wellorithm Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Marketing and checkout differ # Wellorithm review The landing page and the checkout catalog publish different figures, and the bundle price is a first cycle only. ## The verdict Wellorithm lists $247 a month for compounded semaglutide in its own checkout catalog, while its marketing page advertises starting at $249. The product is four weekly injections, making the real figure $268 a calendar month. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 49 From From $268/mo Prescription Required Compounded Yes — not FDA-approved Availability 50 states + DC Wellorithm sells both molecules by injection in 50 states plus D.C., as its own FAQ puts it, with its prices published in the checkout catalog rather than on the marketing pages a reader arrives at. 1. ## Who writes the prescription, and what do they see? A telehealth consult precedes the prescription, and the checkout catalog describes its price as including the consult along with the medication and shipping, so the clinical step is not billed as a separate line. Two surfaces of one business disagree, and the one that bills is the one to believe. The checkout catalog is where the figures actually live, and it is not the page anybody lands on first. 2. ## What happens when the dose goes up? The product is described as four weekly subcutaneous injections, which sets the cycle rather than the dose. Nothing states what the figure does as the milligrams rise, so the calendar is the only variable the pages resolve. 3. ## What the price includes Thirteen four-week cycles at $247 is $3,211 a year, or $268 a calendar month. A first month is $147 with $100 off. The three-month bundle is $645 for the first cycle only and renews at $747, which is $249 a month — so the bundle's advertised saving applies once rather than continuously. Tirzepatide runs the same shape at $347, or $376 a calendar month, with its bundle at $947 renewing to $1,047. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The checkout catalog publishes real figures - Strength: The consult is included in the listed price - Strength: Available in 50 states plus D.C. - Strength: Both first and renewal bundle prices given - Limitation: Marketing and checkout publish different figures - Limitation: Four-weekly billing adds a thirteenth charge - Limitation: The bundle discount applies to one cycle only - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about Wellorithm. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will read the checkout catalog rather than the landing page. Wrong for A reader taking the marketing figure or the bundle's first-cycle price as recurring. ## The evidence behind what Wellorithm prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Wellorithm compares | Seller | Who it suits | Go | | --- | --- | --- | | Walgreens Weight Management | Readers who want the approved product and count fills rather than months | | | YourEra | Readers committing six months who have read which figure belongs to which plan | | | Whoosh Wellness | Readers unsure of eligibility who do not want to risk a consultation fee | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Zealthy](https://thisglp.com/reviews/zealthy) [Zera Health](https://thisglp.com/reviews/zera-health) [Zeuss](https://thisglp.com/reviews/zeuss) [ZipHealth](https://thisglp.com/reviews/ziphealth) [ZYP Medical](https://thisglp.com/reviews/zyp-medical) [10Rx](https://thisglp.com/reviews/10rx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is it $247 or $249? The checkout catalog says $247 and the marketing page says starting at $249. The checkout is what bills, and four-weekly cycles make either figure about $268 a calendar month. Does the bundle keep its price? No. The three-month semaglutide bundle is $645 for the first cycle and renews at $747, which is $249 a month. Is the consult extra? The checkout catalog says the price includes the consult, the medication and shipping, so no separate consult charge is listed beside it. Is Wellorithm legit? Wellorithm is a GLP-1 telehealth sellers service. Its stated availability: 50 states + DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Wellorithm expensive compared with other GLP-1 telehealth sellers? Wellorithm publishes a starting figure of $268/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Wellorithm above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Wellspring Longevity Clinic reviews (2026): GLP-1 telehealth sellers | This GLP Both lines are described as personalized and both figures say starts at. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/wellspring-longevity-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two starting figures # Wellspring Longevity Clinic review Both lines are described as personalized and both figures say starts at. ## The verdict Wellspring Longevity Clinic publishes a personalized GLP-1 starting at $199 a month. A GLP-1 and GIP blend starts at $249. Both are starting figures. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $199/mo Prescription Required Compounded Yes — not FDA-approved Wellspring Longevity Clinic sells both molecules by injection as custom formulations. The tirzepatide line is enriched with B vitamins. 1. ## Who writes the prescription, and what do they see? The word personalized implies a clinician sets the formulation. No clinician is described and the intake is not documented. Custom formulation is the claim on both lines. What varies between patients, and what that does to the price, is not published. 2. ## What happens when the dose goes up? Nothing is published about dose. Starts at leaves the ceiling unstated on a product described as personalized, so two variables move together. 3. ## What the price includes Six months at $199 is $1,194 at the floor and tirzepatide at $249 is $1,494. Both totals assume the starting figure holds. On a personalized formulation that is a larger assumption than usual. 4. ## What it claims, and what it cites Both lines are compounded, with the [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) blend carrying B vitamins. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Both molecules carry a figure - Strength: The tirzepatide formulation is described - Strength: Personalization is stated up front - Limitation: Both figures are a floor - Limitation: Personalization is not priced - Limitation: No milligram dose published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Wellspring Longevity Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a custom blend and will ask what theirs costs. Wrong for A reader who needs a settled figure before intake. ## The evidence behind what Wellspring Longevity Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Wellspring Longevity Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | WeightRx | Readers wanting tirzepatide who will confirm the figure before ordering | | | VyrarX | Readers who will ask what maintenance costs before starting | | | Vitalex Health | Readers wanting tirzepatide who will confirm the figure applies to it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [AJ Peptide](https://thisglp.com/reviews/aj-peptide) [Ambiante Health & Wellness](https://thisglp.com/reviews/ambiante-health-wellness) [Aurelius Health Group](https://thisglp.com/reviews/aurelius-health-group) [AVArx](https://thisglp.com/reviews/avarx) [Basal Health](https://thisglp.com/reviews/basal-health) [Better MedSpa](https://thisglp.com/reviews/better-medspa) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $199 a rate? It is a starting figure on a product described as personalized, so the ceiling is unstated. What is the premium blend? A GLP-1 and GIP formulation enriched with B vitamins, starting at $249. What dose does it buy? No milligram figure is published beside either price. Is Wellspring Longevity Clinic expensive compared with other GLP-1 telehealth sellers? Wellspring Longevity Clinic publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Wellspring Longevity Clinic above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # WePeptideRx reviews (2026): GLP-1 telehealth sellers | This GLP The starting price is the first dose tier, and the monthly figure climbs with each step up the ladder. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/wepeptiderx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Priced by the dose tier # WePeptideRx review The starting price is the first dose tier, and the monthly figure climbs with each step up the ladder. ## The verdict WePeptideRx lists compounded semaglutide at $149 and compounded tirzepatide at $159 for a 30-day supply, each beside a struck-through list price and a $40 saving applied automatically at checkout. Both figures belong to the first dose tier, and the pricing page takes semaglutide to $259 at its top dose and tirzepatide to $349, so the bill in the fourth month can look quite different from the first. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $149/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 48 states LegitScript Claimed by provider WePeptideRx is a Florida telehealth storefront selling compounded semaglutide and tirzepatide, each bundled with B12 in a single weekly injection, beside brand Wegovy, Ozempic, Zepbound and Mounjaro and a shelf of peptide, sexual-health and urgent-care prescriptions. The weight-loss screen asks the buyer to choose a treatment rather than a strength, and says a licensed provider sets the dose at the visit. 1. ## Who writes the prescription, and what do they see? The prescribing happens over secure video, usually within 24 hours according to the treatment screen, through a third-party telemedicine network. The treating provider is licensed in the patient's state and is identified to the patient before and during the consultation. A medical director is named on the site, a board-certified internal medicine physician who oversees clinical protocols and the prescribing workflows the treating providers follow. Payment is taken at checkout, before any provider has looked at the case. The refund policy says a treatment the provider declines is refunded in full to the card, normally within five business days, rather than turned into store credit. After that the plan runs as a subscription that can be paused or canceled by email before the next billing cycle, and medication that has been dispensed cannot be returned. 2. ## What happens when the dose goes up? This is the part of the page worth reading twice. Semaglutide comes in five weekly tiers from 0.25 mg to 2.5 mg, priced from $149 at the first to $259 at the top, and tirzepatide in six tiers from 2.5 mg to 15 mg, priced from $159 to $349. A patient who steps up once a month will cross several of those tiers in the first half year, and the page prints the two ends of each ladder without pricing the rungs in between. 3. ## What the price includes The $40 comes off automatically at checkout, and nothing on the page gives it an end date or ties it to a first order. The struck $189 and $199 therefore read as list prices rather than a deal about to expire. Each molecule also has a 90-day program, and the page notes a small difference in what goes into it: the monthly doses include glycine and the 90-day version does not. 4. ## What it claims, and what it cites Both compounded lines are prepared by state-licensed compounding pharmacies the site does not name, and every page says compounded drugs are not FDA-approved and are not evaluated by the FDA for safety or efficacy. The brand pens on the same screen are the manufacturers' FDA-approved products, and the site is careful to say that [Ozempic](https://thisglp.com/research/semaglutide-cochrane-review) and [Mounjaro](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) are approved for type 2 diabetes rather than for weight management. ## Where it holds up, and where it does not - Strength: Price at the top dose is published - Strength: Named medical director on the site - Strength: Full card refund if not approved - Strength: Brand and compounded lines priced together - Limitation: The headline figure is the lowest dose tier - Limitation: Middle dose tiers are not priced - Limitation: Charged before a provider reviews the case - Limitation: Compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about WePeptideRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants to know the top-dose price before starting, not only the entry figure. Wrong for A buyer who reads the starting price as the price for the whole course. ## The evidence behind what WePeptideRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How WePeptideRx compares | Seller | Who it suits | Go | | --- | --- | --- | | StackMD | Readers who want the cost of every dose stated before starting the lowest one | | | Rehydra+ Wellness | Readers who want to price a full escalation before committing to a first dose | | | Zappy Health | Buyers comparing a compounded plan against the brand routes on the same catalog page | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [BodyLogicMD](https://thisglp.com/reviews/bodylogicmd) [Broose Wellness](https://thisglp.com/reviews/broose-wellness) [CAPO Health](https://thisglp.com/reviews/capo-health) [Chia](https://thisglp.com/reviews/chia-health) [Chronos Body Health & Wellness](https://thisglp.com/reviews/chronos-bhw) [CVS MinuteClinic](https://thisglp.com/reviews/cvs-minuteclinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does $149 cover every dose? No, it is the first semaglutide tier, and the pricing page lists the top tier at $259 a month, while tirzepatide runs from $159 at the first tier to $349 at the sixth. What happens if the provider says no? The refund policy says the item is refunded in full to the original card, normally within five business days of the decision, and never converted into store credit. Is the $40 discount temporary? The page gives it no end date and describes it as applied automatically at checkout, beside struck list prices of $189 for semaglutide and $199 for tirzepatide. Is WePeptideRx legit? WePeptideRx is a GLP-1 telehealth sellers service. Its stated availability: 48 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is WePeptideRx expensive compared with other GLP-1 telehealth sellers? WePeptideRx publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts WePeptideRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Wholesome Clinic reviews (2026): GLP-1 telehealth sellers | This GLP Four products, each with its dose ladder printed rather than a single opening figure. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/wholesome-clinic Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Publishes the whole ladder # Wholesome Clinic review Four products, each with its dose ladder printed rather than a single opening figure. ## The verdict Wholesome Clinic publishes what each dose step costs rather than one headline, which is the disclosure most sellers in this category leave out, and it serves only seven states. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Rises with dose States 7 Injection From $159/mo Oral From $159/mo Prescription Required Compounded Yes — not FDA-approved Wholesome Clinic sells compounded semaglutide and compounded tirzepatide in both forms on a self-pay basis, and prices every one of them as a ladder. Injectable semaglutide runs $159, $189, $219 and $249 across four dose stages, while the oral runs $159, $189 and $229. Injectable tirzepatide runs $349, $449 and $549, and the oral $249, $299 and $349. The service covers seven states. 1. ## Who writes the prescription, and what do they see? Care is arranged through the clinic and a prescription precedes the first fill. Every plan is described as self-pay, so no insurance pathway is offered, and the pages state the dose tiers rather than describing the clinician who sets them. The distinguishing feature is candor about escalation. Almost every patient moves up the ladder inside the first sixteen weeks, and most sellers publish only the bottom rung, which means a reader cannot know the shape of the cost until they are already on it. Here every rung is printed for each product before anyone commits. 2. ## What happens when the dose goes up? The price scales with the dose, and the clinic says so. That is more expensive than a flat rate for a patient who escalates, and it is also the honest description of what is being sold. A reader can calculate a year at the top rung before starting, which is not possible at a seller that publishes one number. 3. ## What the price includes The tirzepatide ladder is the figure to plan against: $349 at the bottom and $549 at the top, against $159 to $249 for injected semaglutide. The oral tirzepatide sits below the injection at $249 to $349, so the form decision moves real money here. Self-pay throughout means no insurance offsets any of it, and seven states is a narrow footprint that decides eligibility before price does. 4. ## What it claims, and what it cites All four products are compounded rather than manufactured and reviewed as finished products, so none is FDA-approved and none is assessed for safety, efficacy or quality before it is dispensed. The published results readers may have seen for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) were generated with the approved products at labeled doses. ## Where it holds up, and where it does not - Strength: Every dose rung published before you start - Strength: Oral tirzepatide below the injection - Strength: Self-pay terms stated plainly - Limitation: Seven states only - Limitation: Price rises with the dose - Limitation: Tirzepatide reaches $549 at the top rung ## What the evidence says about this kind of treatment The assessment above is about Wholesome Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants to see what a higher dose costs before starting, rather than discovering it in month three. Wrong for A reader outside the seven states served, and a reader who needs a rate that does not move. ## The evidence behind what Wholesome Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Wholesome Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | Nova | A reader in one of the two states Nova covers who wants a figure with the service fee already inside it. | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Defy Medical](https://thisglp.com/reviews/defy-medical) [Docberry](https://thisglp.com/reviews/docberry) [Elara MD](https://thisglp.com/reviews/elara-md) [EmbraceRX](https://thisglp.com/reviews/embrace-rx) [eMed](https://thisglp.com/reviews/emed) [Enara Health](https://thisglp.com/reviews/enara-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why does the price go up? Because the clinic prices by dose plan and publishes each rung rather than quoting one figure. A higher dose costs more here, and the amount it costs is printed before you start. Is a rising price worse than a flat one? Over a full year a flat rate usually costs less for a patient who escalates. What this seller offers instead is the ability to work out the whole year in advance, which a single opening figure does not allow. Which states are covered? Seven. That is the narrowest footprint among the sellers assessed here, and it settles eligibility before any price comparison matters. Is Wholesome Clinic expensive compared with other GLP-1 telehealth sellers? Wholesome Clinic publishes a starting figure of $159/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Wholesome Clinic below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Whoosh Wellness reviews (2026): GLP-1 telehealth sellers | This GLP Nothing is billed unless a prescription is approved, and the prepay tabs print totals where monthly rates appear. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/whoosh-wellness Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 No charge until prescribed # Whoosh Wellness review Nothing is billed unless a prescription is approved, and the prepay tabs print totals where monthly rates appear. ## The verdict Whoosh Wellness publishes $169 a month for compounded semaglutide and $249 for tirzepatide, as the monthly rungs of a three-tab ladder. Its pricing page states no charge until prescribed. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $169/mo Prescription Required Compounded Yes — not FDA-approved Whoosh Wellness sells both molecules by injection with physician review, injection supplies and free shipping inside every figure, across monthly and prepaid tabs. 1. ## Who writes the prescription, and what do they see? The no-charge-until-prescribed policy is the clearest statement of clinical risk-sharing a reader will find in this category. A buyer who is declined pays nothing, which most sellers do not commit to. That single policy changes the shape of the decision. Elsewhere a reader risks a consultation fee to find out whether they are eligible; here the seller carries that cost, and the published figures already contain the review, the supplies and the shipping. 2. ## What happens when the dose goes up? Nothing states what the monthly figures do at a higher dose. A microdose injection starts at $149 and a microdose tirzepatide at $199, which are separate products rather than lower rungs of the standard lines. 3. ## What the price includes The published $169 and $249 are the top of the ladder rather than a prepay rung, so they are what a reader without a commitment pays. The prepay tabs are the part to read twice: they print plan totals of $499 and $699 for six months with a per-month suffix attached, and the seller's own product pages resolve those as about $83 and $116 effective monthly. Tablets are also $249. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: No charge until prescribed, stated plainly - Strength: Physician review and supplies included - Strength: Free shipping inside every figure - Strength: Monthly rungs published, not just prepay - Limitation: Prepay tabs print totals with a per-month suffix - Limitation: Microdose lines are separate products - Limitation: No dose behavior is published - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Whoosh Wellness. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader unsure of eligibility who does not want to risk a consultation fee. Wrong for A reader reading the six-month tab's figure as a monthly rate. ## The evidence behind what Whoosh Wellness prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Whoosh Wellness compares | Seller | Who it suits | Go | | --- | --- | --- | | Wellorithm | Readers who will read the checkout catalog rather than the landing page | | | Walgreens Weight Management | Readers who want the approved product and count fills rather than months | | | Voxy | Readers who want check-ins included and will pick a cadence deliberately | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Enhanced](https://thisglp.com/reviews/enhanced) [EverFit Medical](https://thisglp.com/reviews/everfit-medical) [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) [Evernow](https://thisglp.com/reviews/evernow) [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) [FeelGood](https://thisglp.com/reviews/feelgood-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What happens if I am not approved? Nothing is charged. The pricing page states no charge until prescribed, which is unusual in this category. What do the six-month tabs mean? They print plan totals of $499 and $699 with a per-month suffix. The seller's own product pages resolve those as about $83 and $116 a month. What is included in $169? Physician review, injection supplies and free shipping, all stated as inside the figure. Is Whoosh Wellness expensive compared with other GLP-1 telehealth sellers? Whoosh Wellness publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Whoosh Wellness below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Willow reviews (2026): GLP-1 telehealth sellers | This GLP Four compounded GLP-1 products at two monthly prices, with a dozen named physicians and a program aimed at women. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/willow Updated: 2026-10-28 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Two prices, four products # Willow review Four compounded GLP-1 products at two monthly prices, with a dozen named physicians and a program aimed at women. ## The verdict Willow charges $299 a month for compounded semaglutide and $399 for compounded tirzepatide, by injection or tablet. The plan renews monthly, and the prescribing physicians are named on the site. What happens to the price as the dose rises is not stated. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $299/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Willow is a cash-pay telehealth program run by Willow Health Services, Inc., which says it is not itself a healthcare provider. It connects patients with independent licensed physicians who prescribe compounded GLP-1 medication. Its mission statement addresses women's weight loss specifically. The menu also includes NAD+. 1. ## Who writes the prescription, and what do they see? The physicians page lists twelve doctors, MDs and DOs, led by a chief medical officer who is an OB/GYN. A physician reviews each health history and writes the prescription, and the site says this happens the same day. The terms assign that physician from a medical practice licensed in the patient's state. Government-issued photo ID is required. After approval the order goes to a partner pharmacy, which takes two to four business days to process it. Delivery by FedEx or UPS takes two to three more days, and shipping is free. The monthly plan includes unlimited physician messaging and 24/7 support from a care team. It renews automatically until canceled. 2. ## What happens when the dose goes up? The product pages say the doctor raises the dose gradually and adjusts the plan if [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) appear. Generic ondansetron, an anti-nausea drug, can be prescribed if needed. No milligram schedule is published. Whether the monthly charge changes at a higher dose is not stated. For stopping, the FAQ recommends a gradual taper with the physician. 3. ## What the price includes Each product page prints one figure: $299 a month for semaglutide, as injection or tablet, and $399 for tirzepatide in either form. The FAQ calls this a monthly subscription starting at $299, covering medication, the evaluation, physician access and shipping. The words "starting at" are not explained further, and no longer plan or term discount is shown. A prescription can go to an outside pharmacy, but a platform fee then applies and the medication is paid separately. 4. ## What it claims, and what it cites All four products are compounded. The site says compounded medications are not FDA-approved and not reviewed by the FDA for safety, effectiveness or quality. They are prepared by state-licensed compounding pharmacies, which are not named. The injections are weekly, and the [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) tablet dissolves in the mouth once a day. ## Where it holds up, and where it does not - Strength: Twelve prescribing physicians named on the site - Strength: Same price for injection and tablet - Strength: Free two-day shipping is included - Strength: Full refund if canceled before the pharmacy - Limitation: Price at higher doses not stated - Limitation: No milligram dose schedule is published - Limitation: Compounding pharmacy is not named - Limitation: Renews automatically each month ## What the evidence says about this kind of treatment The assessment above is about Willow. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a named physician roster and the choice of a daily tablet at the same price as the weekly injection. Wrong for Anyone who needs the monthly charge at a maintenance dose before signing up. ## The evidence behind what Willow prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Willow compares | Seller | Who it suits | Go | | --- | --- | --- | | Hers | Readers who want a wide catalog and will budget the membership as the main charge | | | Layla | Readers set on a needle-free option who will ask about dose at intake | | | Midi Health | Readers who want every rung costed, with its milligram, before choosing a first dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Florida Weight Loss MD](https://thisglp.com/reviews/florida-weight-loss-md) [Found Youth](https://thisglp.com/reviews/found-youth) [Freeley](https://thisglp.com/reviews/freeley) [FuturHealth](https://thisglp.com/reviews/futurhealth) [G-Plans](https://thisglp.com/reviews/g-plans) [Gatlan](https://thisglp.com/reviews/gatlan) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does Willow cost? $299 a month for compounded semaglutide and $399 for compounded tirzepatide. The tablet versions carry the same prices as the injections. How is a Willow plan canceled? By messaging the care team at least two business days before the next processing date. A cancellation made before the prescription reaches the pharmacy is refunded in full. Does Willow take insurance? No. The program is cash-pay, and the site says it is HSA and FSA eligible. Is Willow expensive compared with other GLP-1 telehealth sellers? Willow publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Willow above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Wisp reviews (2026): GLP-1 telehealth sellers | This GLP A daily sublingual drop at $225 a month, which the seller says has not yet been tested in the human body. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/wisp Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Daily drops, untested in people # Wisp review A daily sublingual drop at $225 a month, which the seller says has not yet been tested in the human body. ## The verdict Wisp sells compounded semaglutide as a daily sublingual drop at $225 a month for a 28-day bottle. Its own FAQ says the formulation has not yet been tested within the human body. A $99 monthly check-in appears separately in the program FAQ. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Oral States 27 From From $225/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability 26 states and DC Wisp is a telehealth company focused on sexual and reproductive health, with a weight care section. Its GLP-1 is a 15 mL bottle of compounded semaglutide drops, taken under the tongue once daily. The weight care shop page lists no injection and no tirzepatide. The drops are sold for delivery only. 1. ## Who writes the prescription, and what do they see? A provider reviews a medical history submitted through the platform before prescribing. The seller says patients hear from a provider 24 to 72 hours after the consult request. Providers are described as board-certified. One physician, a DO, is named on the weight care team panel. The prescribing clinician for a given patient is not named in advance. The program FAQ describes a monthly cycle. After three weeks the card is authorized for the check-in, and the provider reviews progress before the refill. The check-in is then charged, together with the medication when delivery is chosen. The same process repeats each month. 2. ## What happens when the dose goes up? The bottle is labeled 0.3 mg to 1.0 mg, a 28-day supply taken once daily. The lowest dose goes into the cart first, and the provider adjusts from there. The directions let the patient self-advance to the next dose if it is tolerated, per the prescription. A price for higher doses is not stated. 3. ## What the price includes The drops are $225 a month, and six months at that rate is $1,350. The weight care FAQ adds a $99 check-in charged each month. The product page does not say whether $225 already includes it. That question is worth settling before the first refill. 4. ## What it claims, and what it cites The drops are compounded by a 503A pharmacy that Wisp does not name. The FAQ states compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) is not FDA-approved. No approved semaglutide product is a sublingual drop. The weight-loss trials of semaglutide tested a weekly injection and a daily tablet, so their results were not measured in this form. The seller's absorption data come from lab tests on human-derived tissue. ## Where it holds up, and where it does not - Strength: Seller discloses the drops are untested in people - Strength: No refrigeration needed for the drops - Strength: Dose range printed on the product page - Limitation: No human testing of this formulation - Limitation: Monthly check-in charge sits beside the price - Limitation: Served in 26 states and DC - Limitation: No tirzepatide or injection on the shop page ## What the evidence says about this kind of treatment The assessment above is about Wisp. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who will not inject and accepts a formulation without human data. Wrong for A reader who wants the form the semaglutide trials actually tested. ## The evidence behind what Wisp prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Wisp compares | Seller | Who it suits | Go | | --- | --- | --- | | Revel Health | A reader who wants an oral and expects to pay less for it, which on this seller is what happens. | | | Zera Health | A reader who budgets from the monthly rate printed beside the first-month offer. | | | HealthSource | Readers who want the compounding source identified and the contents itemized | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Genesis Lifestyle Medicine](https://thisglp.com/reviews/genesis-lifestyle-medicine) [Gide Health](https://thisglp.com/reviews/gide-health) [Glow](https://thisglp.com/reviews/glow) [GOAL.MD](https://thisglp.com/reviews/goal-md) [GoodLife Health](https://thisglp.com/reviews/goodlife-health) [Happy Care Meds](https://thisglp.com/reviews/happy-care-meds) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Has this drop been tested in people? Not according to Wisp. Its FAQ says lab tests on human-derived tissue suggest absorption, but the formulation has not yet been tested within the human body. Is there a charge besides the $225? The weight care FAQ describes a $99 monthly check-in. The product page does not say whether $225 already includes it. Which states are served? Twenty-six states and Washington, D.C., as listed in the product page FAQ. Is Wisp legit? Wisp is a GLP-1 telehealth sellers service. Its stated availability: 26 states and DC. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Wisp expensive compared with other GLP-1 telehealth sellers? Wisp publishes a starting figure of $225/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Wisp above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Woodwork reviews (2026): GLP-1 telehealth sellers | This GLP The advertised figure carries an asterisk, and the asterisk says forty-eight weeks. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/woodwork Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Forty-eight weeks in an asterisk # Woodwork review The advertised figure carries an asterisk, and the asterisk says forty-eight weeks. ## The verdict Woodwork advertises compounded semaglutide from $127 a month, with an asterisk stating the price applies to a 48-week plan. Tirzepatide is $199 under the same condition. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $127/mo Prescription Required Compounded Yes — not FDA-approved Woodwork sells semaglutide as injections or oral tablets and tirzepatide by injection. Both advertised figures belong to a near-year commitment. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages name products and terms. The clinician is not described. The condition is disclosed and it is disclosed in an asterisk, which is the smallest place a forty-eight week commitment can be put. Nothing is hidden and nothing is prominent either. 2. ## What happens when the dose goes up? Nothing is published about dose on either line. The from wording leaves a floor as well, so two variables sit behind a figure that already requires most of a year. 3. ## What the price includes Forty-eight weeks at $127 is about $1,406 committed, and that is the only path to the advertised rate. No shorter term is published, so a reader wanting three months cannot price it. Tirzepatide at $199 across the same term is about $2,203. 4. ## What it claims, and what it cites Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: The 48-week condition is disclosed - Strength: An oral option exists on semaglutide - Strength: Both molecules carry a figure - Limitation: The condition sits in an asterisk - Limitation: No shorter term is published at all - Limitation: Both figures also use from wording - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about Woodwork. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader ready to commit forty-eight weeks who reads asterisks. Wrong for A reader wanting a shorter term, which is not priced. ## The evidence behind what Woodwork prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Woodwork compares | Seller | Who it suits | Go | | --- | --- | --- | | YourEra | Readers committing six months who have read which figure belongs to which plan | | | VitaStir | Readers who will price the rung they expect to reach rather than the entry one | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [HealFastRx](https://thisglp.com/reviews/healfast) [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) [Hone Health](https://thisglp.com/reviews/hone-health) [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) [KairoRx](https://thisglp.com/reviews/kairorx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does the asterisk say? That the price applies to the 48-week semaglutide injection plan. It is the condition on the advertised figure. Is a shorter plan available? None is published, so a reader wanting three months cannot price it from the site. What does the commitment total? About $1,406 for semaglutide across 48 weeks, or about $2,203 for tirzepatide. Is Woodwork expensive compared with other GLP-1 telehealth sellers? Woodwork publishes a starting figure of $127/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Woodwork below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Yes Clinic reviews (2026): GLP-1 telehealth sellers | This GLP Yes Clinic makes the product and price structure relatively easy to identify. Clinical follow-up still deserves a direct conversation. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/yes-clinic Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A semaglutide program with a clearly identified compounded injectable and a choice of monthly or longer supply purchases. # Yes Clinic review Yes Clinic makes the product and price structure relatively easy to identify. Clinical follow-up still deserves a direct conversation. ## The verdict The named semaglutide and vitamin B12 formulation, flat-dose statement and separate plan lengths are useful disclosures. They do not establish the quality or frequency of ongoing care. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Yes Clinic provides an online route to independent medical review and pharmacy fulfillment. Its semaglutide page describes a compounded injectable containing semaglutide and vitamin B12. 1. ## Who writes the prescription, and what do they see? An independent licensed clinician decides whether treatment is appropriate. Ask which medical practice is responsible for follow-up and how to reach it after medication arrives. Consultation is included on the product page, but the public offer does not fully specify scheduled follow-up or response times. Clarify how symptoms, laboratory needs and prescription changes are handled. 2. ## What happens when the dose goes up? The product page says pricing remains the same at every dose. A flat price is a financial term, not a reason to increase a dose; changes still require individualized clinical guidance. 3. ## What the price includes Monthly, three-month and six-month purchases are displayed separately. Longer options involve a larger upfront purchase, while terms distinguish recurring subscriptions from plans that do not renew. 4. ## What it claims, and what it cites The reviewed product is compounded [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) with vitamin B12, administered by injection. It is not an FDA-approved version of a branded semaglutide medicine. ## Where it holds up, and where it does not - Strength: Identifies the compounded formulation - Strength: States that price does not rise with dose - Limitation: Follow-up frequency needs confirmation - Limitation: Longer supplies increase the upfront commitment ## What the evidence says about this kind of treatment The assessment above is about Yes Clinic. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults seeking a clearly identified semaglutide formulation and willing to confirm the follow-up plan. Wrong for Anyone choosing primarily on a longer-supply discount before understanding treatment tolerance or refund limits. ## The evidence behind what Yes Clinic prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How Yes Clinic compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [KairoRx](https://thisglp.com/reviews/kairorx) [KIN Health](https://thisglp.com/reviews/kin-health) [Klarity Health](https://thisglp.com/reviews/klarity-health) [Klinic](https://thisglp.com/reviews/klinic) [Kova](https://thisglp.com/reviews/kova) [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does flat pricing determine the dose? No. The flat-price statement concerns cost. The clinician must decide the appropriate prescription. What formulation is listed? The reviewed product page describes injectable compounded semaglutide with vitamin B12, not an FDA-approved branded pen. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://yesclinic.com/) - [Official program and terms](https://yesclinic.com/terms-of-use/) - [Official program and terms](https://yesclinic.com/product/semaglutide/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # YourEra reviews (2026): GLP-1 telehealth sellers | This GLP Both advertised figures need six months, and no month-to-month rate is published for either. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/yourera Updated: 2026-10-26 Partner By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Six months behind the headline # YourEra review Both advertised figures need six months, and no month-to-month rate is published for either. ## The verdict YourEra advertises from $79.20 a month for compounded semaglutide, and its own page states that figure reflects the six-month plan. Tirzepatide reads as low as $159.20 on the same plan, and neither month-to-month rate is published. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection Dose pricing Flat across doses Prescription Required Compounded Yes — not FDA-approved Availability Not published by the provider YourEra sells both molecules by injection at the same price at every dose, with a six-month plan behind the advertised figure and a separate month-to-month path. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping and the clinician is not described. What the pages do describe carefully is which figure belongs to which plan, at least on the semaglutide line. The semaglutide disclosure is good: the six-month condition is written out in a sentence rather than hidden in an asterisk. The tirzepatide card labels its figure the same way. What neither discloses is the rate a buyer pays month to month. 2. ## What happens when the dose goes up? Same price at every dose is confirmed on the semaglutide line, so escalation does not move that figure. On tirzepatide the pages say nothing about dose, and the prior question is what the line costs off the six-month plan. 3. ## What the price includes Six months of semaglutide at $79.20 is $475.20, and tirzepatide at $159.20 is $955.20, each paid on the plan the figure belongs to. The month-to-month rate on either line is higher and not published, so a reader who wants to stop early has no figure to plan against. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured, prepared by a pharmacy the site does not name, and not reviewed by the FDA before dispensing as an approved product is. ## Where it holds up, and where it does not - Strength: The six-month condition is stated in a sentence - Strength: Same price at every dose on semaglutide - Strength: Both cards name the plan behind the figure - Limitation: The advertised figure needs six months - Limitation: No month-to-month rate is published - Limitation: Tirzepatide also needs six months - Limitation: No state coverage list is recorded ## What the evidence says about this kind of treatment The assessment above is about YourEra. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader committing six months who has read which figure belongs to which plan. Wrong for A reader who wants to pay month to month, since no rate for it is published. ## The evidence behind what YourEra prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How YourEra compares | Seller | Who it suits | Go | | --- | --- | --- | | Wellorithm | Readers who will read the checkout catalog rather than the landing page | | | Woodwork | Readers ready to commit forty-eight weeks who read asterisks | | | YourHealthRx | Readers in any jurisdiction wanting a flat rate with little to decide | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Livbetr](https://thisglp.com/reviews/livbetr) [Longevity Meds](https://thisglp.com/reviews/longevity-meds) [Loozy](https://thisglp.com/reviews/loozy) [Male Excel](https://thisglp.com/reviews/male-excel) [MangoRx](https://thisglp.com/reviews/mangorx) [MD Trim Clinic](https://thisglp.com/reviews/md-trim-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Can I pay $79.20 a month? Only on the six-month plan, which the page states in so many words. The month-to-month rate is higher and not published. What does tirzepatide cost? As low as $159.20 a month on the six-month plan, the label printed on its own card. No month-to-month rate is published. Does the price rise with the dose? Not on semaglutide — the same price at every dose is confirmed on that line. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # YourHealthRx reviews (2026): GLP-1 telehealth sellers | This GLP One flat price regardless of dose, an oral option, and coverage in every jurisdiction. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/yourhealthrx Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Flat, wide coverage # YourHealthRx review One flat price regardless of dose, an oral option, and coverage in every jurisdiction. ## The verdict YourHealthRx publishes $140 a month for a weekly semaglutide injection with B12, flat regardless of dose. The rate needs a code and is locked while a patient stays enrolled. Tirzepatide is $190. Coverage is 51 jurisdictions. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 51 From From $140/mo Prescription Required Compounded Yes — not FDA-approved Availability 51 jurisdictions YourHealthRx sells semaglutide and tirzepatide as weekly injections with B12, and each as an oral dissolving tablet. All carry a flat price. 1. ## Who writes the prescription, and what do they see? A prescription precedes shipping. The pages state prices and plans. No clinician is described. Flat regardless of dose is the useful claim. A rate locked for as long as a patient stays enrolled removes a second decision. 2. ## What happens when the dose goes up? The price is stated flat regardless of dose, which answers the question directly. Nothing describes clinical support at a step. 3. ## What the price includes Six months at $140 is $840, and tirzepatide at $190 is $1,140. Both rates need a code at checkout. The semaglutide dissolving tablet is a separate product at $170 a month. 4. ## What it claims, and what it cites Both lines are compounded with B12. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named. ## Where it holds up, and where it does not - Strength: Flat regardless of dose - Strength: Coverage in 51 jurisdictions - Strength: An oral option priced separately - Strength: Rate locked while enrolled - Limitation: Both rates need a code - Limitation: No milligram dose published - Limitation: No compounding pharmacy is named ## What the evidence says about this kind of treatment The assessment above is about YourHealthRx. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader in any jurisdiction wanting a flat rate with little to decide. Wrong for A reader who needs a milligram stated beside the flat price. ## The evidence behind what YourHealthRx prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How YourHealthRx compares | Seller | Who it suits | Go | | --- | --- | --- | | WeightRx | Readers wanting tirzepatide who will confirm the figure before ordering | | | Woodwork | Readers ready to commit forty-eight weeks who read asterisks | | | YourEra | Readers committing six months who have read which figure belongs to which plan | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [MDLive](https://thisglp.com/reviews/mdlive) [MD Total Wellness](https://thisglp.com/reviews/mdtw) [Medical Health Institute](https://thisglp.com/reviews/medical-health-institute) [Medivive](https://thisglp.com/reviews/medivive) [MEDVidi](https://thisglp.com/reviews/medvidi) [Meli Health](https://thisglp.com/reviews/meli-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does the price rise with the dose? No. It is stated flat regardless of dose. What does the rate lock mean? The $140 rate is stated as locked while you stay enrolled, billed monthly, with a code. What does the oral cost? $170 a month for the semaglutide dissolving tablet. Is YourHealthRx legit? YourHealthRx is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is YourHealthRx expensive compared with other GLP-1 telehealth sellers? YourHealthRx publishes a starting figure of $140/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts YourHealthRx below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # YOURx Health reviews (2026): GLP-1 telehealth sellers | This GLP YOURx offers physician-directed semaglutide within a wider longevity service. Its public pages describe different consultation formats, a detail worth resolving before enrollment. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/yourx-health Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Clarify the consultation format # Does YOURx Health sell a GLP-1? YOURx offers physician-directed semaglutide within a wider longevity service. Its public pages describe different consultation formats, a detail worth resolving before enrollment. ## The verdict YOURx makes sense to investigate if you want weight care alongside broader health services. The unresolved point is how you actually see a clinician: the homepage describes questionnaire review without video, while its process page describes a video appointment. Confirm which applies to your treatment. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Prescription Required YOURx Health connects adults with licensed medical professionals and pharmacy fulfillment. Semaglutide appears in its weight-loss offering; the broader catalog also includes hormone and other wellness services. Those separate treatments should not be assumed necessary for GLP-1 care. 1. ## Who writes the prescription, and what do they see? The homepage identifies the Dr. Telx network and describes physician review of health information. The terms reserve treatment decisions to the treating professional. Neither enrollment nor choosing a product establishes that a prescription will be issued. Its process page describes health intake, testing when relevant, a physician consultation and pharmacy shipment. Monthly check-ins and care-team messaging are advertised. Ask whether those messages reach the prescriber directly and which tests apply to weight management rather than other services. 2. ## What happens when the dose goes up? The process page promises protocol adjustments and ongoing monitoring, but does not publish a semaglutide dose ladder with matching charges. Clarify who approves a refill or dose change, the response time for [side effects](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1), and whether either decision changes the bill. 3. ## What the price includes The pages reviewed do not establish one comparable continuing semaglutide-and-care total. Billing terms allow consultation, medication, laboratory and shipping charges depending on the chosen service. Obtain an itemized quote instead of treating a broad promise of transparent pricing as an all-inclusive plan. 4. ## What it claims, and what it cites Semaglutide is named on the weight-loss section. The reviewed material does not settle the exact brand, formulation or dispensing pharmacy for an individual order. Ask for those details before accepting treatment; evidence about approved semaglutide products does not validate every preparation. ## Where it holds up, and where it does not - Strength: A named clinician network - Strength: Published follow-up and messaging options - Strength: Separate billing terms available - Limitation: Consultation descriptions differ between pages - Limitation: No complete public dose-and-cost ladder - Limitation: Individual pharmacy assignment needs confirmation ## What the evidence says about this kind of treatment The assessment above is about YOURx Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient who wants to discuss weight management within a broader physician-directed service and can clarify the appointment arrangements first. Wrong for Someone who needs a confirmed video appointment and a complete medication-inclusive quote before providing payment details. ## The evidence behind what YOURx Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. ## How YOURx Health compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Meli Health](https://thisglp.com/reviews/meli-health) [Metabolic Rx](https://thisglp.com/reviews/metabolic-rx) [Metabolyz](https://thisglp.com/reviews/metabolyz) [Mixx Health & Wellness](https://thisglp.com/reviews/mixx-health-and-wellness) [Modern Age](https://thisglp.com/reviews/modern-age) [Novera MD](https://thisglp.com/reviews/novera-md) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is video consultation required at YOURx? The homepage says video is unnecessary, while the process page describes a physician video visit. Ask which route your chosen program uses. Does canceling guarantee a refund? No. Billing terms distinguish stopping a future renewal from reversing an existing charge; service-specific refund conditions still apply. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official program](https://yourxhealth.com/) - [Service and cancellation terms](https://yourxhealth.com/terms-of-service/) - [Billing and subscription conditions](https://yourxhealth.com/billing-terms-and-conditions/) - [Consultation and care process](https://yourxhealth.com/how-it-works/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Youth & Soul reviews (2026): GLP-1 telehealth sellers | This GLP Youth & Soul brings injections, lozenges and a spray into one menu. They are not interchangeable versions of a single medicine. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/youth-and-soul Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 A broad GLP-1 storefront with branded pens, compounded options and several administration formats. The specific prescription matters more than the shared weight-loss category. # Youth & Soul review Youth & Soul brings injections, lozenges and a spray into one menu. They are not interchangeable versions of a single medicine. ## The verdict A useful place to compare formats, provided the clinician explains the exact product and its evidence. Clarify renewal terms: no membership fee does not mean no subscription. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Youth & Soul is a platform connecting patients with independent healthcare providers and pharmacies. Its storefront combines weight-loss treatments with skincare and other wellness products. 1. ## Who writes the prescription, and what do they see? The assessment alone does not establish a clinician-patient relationship. A licensed provider must review the request and determine whether to prescribe; the platform does not itself provide healthcare or dispense medication. The site advertises doctor-led plans and coaching. Before enrolling, ask who handles adverse effects, whether follow-up is scheduled and how quickly clinical messages are answered. A broad product menu does not answer those questions. 2. ## What happens when the dose goes up? Confirm the formulation, concentration and instructions for the actual prescription. The menu includes lozenges and a tirzepatide spray as well as injections; a clinician should explain why a particular route is appropriate without treating them as equivalent. 3. ## What the price includes Product and bundle prices have different scopes, including a promotional skincare and microdose bundle. The terms promise a full refund if treatment is not approved, but subscription cancellation requires thirty days’ notice. 4. ## What it claims, and what it cites The menu names [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better), including compounded formats and branded Wegovy, Ozempic and Zepbound. Brand approval does not extend to compounded lozenges or sprays, and a listing does not guarantee that a clinician will prescribe it. ## Where it holds up, and where it does not - Strength: Names multiple formulations and branded options - Strength: Publishes a refund condition for declined treatment - Limitation: Follow-up cadence needs clarification - Limitation: Compounded formats cannot inherit brand evidence ## What the evidence says about this kind of treatment The assessment above is about Youth & Soul. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Adults who want to ask a clinician about clearly identified product and format choices. Wrong for Anyone assuming a spray or lozenge has the same approval, dosing or evidence as a branded injection. ## The evidence behind what Youth & Soul prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Youth & Soul compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Nuform Health](https://thisglp.com/reviews/nuform-health) [Nurx](https://thisglp.com/reviews/nurx) [Olleve Care](https://thisglp.com/reviews/ollevecare) [Omada Health](https://thisglp.com/reviews/omada-health) [One80Rx](https://thisglp.com/reviews/one80rx) [Pillar Health](https://thisglp.com/reviews/pillar-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does no membership fee mean no recurring billing? No. The terms discuss subscription programs and require thirty days’ cancellation notice. Confirm whether the selected order renews. Are the listed formats interchangeable? No. Confirm the exact formulation, route and prescription instructions with the clinician. A branded injection’s approval does not establish approval for a compounded lozenge or spray. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Official service overview](https://youthnsoul.com/) - [Official program and terms](https://youthnsoul.com/terms-of-service) - [Official program and terms](https://youthnsoul.com/safety-info/glp1) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Yucca Health reviews (2026): GLP-1 telehealth sellers | This GLP A banner promises a rate for life, and the asterisk names the plan it belongs to. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/yucca-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Lifetime rate, six-month term # Yucca Health review A banner promises a rate for life, and the asterisk names the plan it belongs to. ## The verdict Yucca Health runs a sticky banner offering $125 a month for life. The asterisk says which plan: the six-month semaglutide one, billed as $750 every six months. Without a commitment, semaglutide is $146 and tirzepatide is $258. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 50 From From $146/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability All 50 states Yucca Health sells compounded semaglutide and compounded tirzepatide as weekly injections. Longevity treatments sit beside them. Licensed providers are stated across all fifty states. 1. ## Who writes the prescription, and what do they see? A clinical intake goes to a licensed provider, who decides whether treatment is appropriate before any plan begins. The site says a plan starts with a provider review rather than a checkout. The provider stays involved as the dose is adjusted. Three plan lengths sit in one selector on the treatment page. Each prints its billed total and its per-month equivalent. The consultation, injection kit and two-day shipping are stated as included. 2. ## What happens when the dose goes up? The price is stated as flat at every dose level, and the promise is repeated as lasting for life. A step up therefore costs nothing extra. Who signs off the step is described only as the provider who wrote the prescription. 3. ## What the price includes Semaglutide is $146 a month with no commitment. Three months is $420, or $140 a month, and six months is $750, or $125. The whole ladder sits on the treatment page rather than behind the intake, which is the part worth crediting. 4. ## What it claims, and what it cites Both lines are compounded rather than manufactured. The FAQ answers the approval question directly. Compounded medications are not FDA-approved, and do not undergo FDA review for safety or effectiveness. ## Where it holds up, and where it does not - Strength: The full plan ladder is published before intake - Strength: The price is stated as flat at every dose - Strength: Free consultation and injection kit - Strength: Compounded status answered directly in the FAQ - Limitation: The banner rate needs $750 in one charge - Limitation: The lifetime promise is tied to a six-month plan - Limitation: No compounding pharmacy is named - Limitation: No milligram dose is published ## What the evidence says about this kind of treatment The assessment above is about Yucca Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants every rung visible before starting an intake. Wrong for A buyer taking the banner figure as a monthly bill. ## The evidence behind what Yucca Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Yucca Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Ondra Health | Buyers who want the billed total printed beside the monthly figure before they choose a term | | | CoraDoc | Buyers who would rather pay a program once than carry a subscription they have to remember to cancel | | | TRYM Health | Buyers who will go looking for the plan table rather than price a program by the day | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [PrescrYbe](https://thisglp.com/reviews/prescrybe) [PRIMO Health Partners](https://thisglp.com/reviews/primo-health-partners) [Push Health](https://thisglp.com/reviews/push-health) [Ravia Health](https://thisglp.com/reviews/ravia-health) [Red Mountain Weight Loss](https://thisglp.com/reviews/red-mountain-weight-loss) [RegenCen](https://thisglp.com/reviews/regencen) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does $125 a month for life require? The six-month semaglutide plan, billed as $750 every six months. The no-commitment rung on the same selector is $146. Does the rate change when the dose goes up? Yucca states the price stays flat at every dose level, and repeats that as holding for life. Are these products FDA-approved? No. Yucca's own FAQ says its compounded medications are not FDA-approved and do not undergo FDA review. Is Yucca Health legit? Yucca Health is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is Yucca Health expensive compared with other GLP-1 telehealth sellers? Yucca Health publishes a starting figure of $146/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Yucca Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Zappy Health reviews (2026): GLP-1 telehealth sellers | This GLP Its lowest-priced plan holds the starting dose for three months. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/zappy-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 A starter dose, for a quarter # Zappy Health review Its lowest-priced plan holds the starting dose for three months. ## The verdict Zappy Health headlines compounded semaglutide at $159 a month, and the two conditions attached to that figure sit in smaller type on the same product page. It is a three-month Starter Pack billed once at $477, held at the 0.25 mg starting dose, and sold in select states only. The plan table beneath it is where the rest of the catalog lives, and the rung with no term attached is $249 a month across all doses. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 42 From From $249/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Zappy Health is a cash-pay telehealth clinic whose weight-loss shelf carries compounded semaglutide and compounded tirzepatide beside three brand routes: Wegovy tablets, Wegovy injections and Zepbound vials through the manufacturers' own direct programs. Anti-aging, strength and skin lines share the site, and a women's health category is marked as coming. No insurance is billed and no membership is charged. The brand routes are marked cash-pay only, and two of them are restricted to patients new to that manufacturer. 1. ## Who writes the prescription, and what do they see? Treatment is described as clinically supervised with monthly virtual visits included in every plan, and an AI assistant is listed beside those visits as part of the same package. No clinician, medical group or medical director is named on the product page or the catalog. What a provider reads before approving a starting dose is not described, which matters more here than usual, because the starter pack commits a patient to that dose for three months. Premium customer support is named on every tier. Every plan bundles monthly virtual visits, access to the AI assistant and support, so the difference between rungs is term length and dose freedom rather than the care attached. Multi-month plans ship all vials together in one delivery and are billed once, which is worth knowing before a fridge is planned around it. The catalog sits on a single pricing page that prices the compounded and brand routes side by side. A separate helpdesk carries the rest. 2. ## What happens when the dose goes up? This is where the cheap rung stops being cheap in the way it looks. The starter packs are written as a starting dose determined appropriate by a provider, and the semaglutide pack names 0.25 mg while the tirzepatide pack names 2.5 mg. The plan and the clinical decision are describing the same number from two directions. A patient who needs to climb inside those three months is on the wrong plan, and the all-doses rungs above are stated to be flat across the ladder. Nothing published says what happens if a provider raises the dose mid-pack. 3. ## What the price includes Semaglutide runs from the starter pack at the bottom to a month-to-month rung at $249, with two multi-month tiers in between, each billed as a single upfront charge. Tirzepatide is built the same way from $279 to $349. The brand routes are priced per month on the same shelf, and one of them undercuts the compounded semaglutide rate the page leads with. Every multi-month figure is shown as a per-month equivalent with its total printed beside it. 4. ## What it claims, and what it cites The compounded lines are prepared rather than manufactured, and the page repeats that compounded drugs are not FDA-approved and are not evaluated by the FDA. The brand products are the manufacturers' own, routed through their direct programs and marked as such. The compounding pharmacy is not named. ## Where it holds up, and where it does not - Strength: Brand and compounded routes are priced together - Strength: Every multi-month total is printed, not just the rate - Strength: The all-doses rungs are flat across the ladder - Strength: Monthly virtual visits sit inside every plan - Strength: The starter pack's dose limit is disclosed - Limitation: The headline plan holds the starting dose - Limitation: The headline rate is limited to select states - Limitation: $477 is charged in a single payment - Limitation: No clinician or medical group is named - Limitation: The compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Zappy Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer comparing a compounded plan against the brand routes on one catalog page. Wrong for A buyer who expects to climb the dose ladder inside the first three months. ## The evidence behind what Zappy Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Zappy Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Shapely | Insured buyers in one of its four states who want a plan checked before paying cash | | | CLYR Health | Buyers who want the cost of each dose tier published before the first injection | | | Cielo | Buyers who want the commitment behind a headline rate spelled out in the asterisk under it | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Rese Wellness](https://thisglp.com/reviews/rese-wellness) [Revive Longevity](https://thisglp.com/reviews/revive-longevity) [Rila](https://thisglp.com/reviews/rila) [Risen Labs](https://thisglp.com/reviews/risen-labs) [Robinhood Telehealth](https://thisglp.com/reviews/robinhood-telehealth) [Royal Medical Center](https://thisglp.com/reviews/royal-medical-center) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is $159 a month available to everyone? No. It is a three-month Starter Pack billed once at $477, restricted to first-time users at the 0.25 mg dose and to select states. What does a plan with no term cost? Semaglutide is $249 a month and tirzepatide is $349, both stated to cover all doses with no commitment attached. Can brand medication be bought here? Yes. Wegovy tablets, Wegovy injections and Zepbound vials are listed through the manufacturers' own direct programs, cash-pay only. Is Zappy Health expensive compared with other GLP-1 telehealth sellers? Zappy Health publishes a starting figure of $249/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Zappy Health above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Zealthy reviews (2026): GLP-1 telehealth sellers | This GLP The ranked figure adds a recurring membership to a medication rate bought three months at a time. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/zealthy Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Membership plus medication # Zealthy review The ranked figure adds a recurring membership to a medication rate bought three months at a time. ## The verdict Zealthy's compounded semaglutide comes to $286 a month and tirzepatide to $351. Each figure is two charges added together. One is a recurring membership. The other is a medication rate available on a three-month purchase. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection States 34 From From $286/mo Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Zealthy is a telehealth company covering weight loss, primary care, mental health and other services. Its weight program prescribes brand GLP-1s through insurance where covered. Compounded semaglutide and tirzepatide are the cash-pay route. Membership is recurring. 1. ## Who writes the prescription, and what do they see? A Zealthy provider reviews an online health assessment before prescribing. The membership includes refills, dose updates and unlimited messaging with the provider. The site lists access to licensed providers at any hour at no extra cost. No prescriber is named on the pricing page. The program is billed in two parts. The membership is charged monthly, on the same day as the first charge. The medication is charged on its own. Insurance coordinators work on brand coverage. A coach is included in the membership. Cancellation is allowed at any time. 2. ## What happens when the dose goes up? Dose updates are listed inside the membership. The medication figures are written as 'as low as'. Whether the medication price changes by dose is not stated on the pricing page. 3. ## What the price includes The rule applied here is that a required fee is part of the price. Zealthy describes its weight loss memberships as recurring while a patient is on medication. Both charges are therefore counted: $286 for semaglutide and $351 for tirzepatide. The $65 step between them is the medication difference alone. The medication part is the three-month purchase rate. A month-to-month medication price is not published before intake. First-month offers are promotional and are not counted. 4. ## What it claims, and what it cites Compounded drugs are prepared by a state-licensed sterile compounding pharmacy. Zealthy states they are not FDA-approved. The pharmacy is not named. Brand products are prescribed separately, often through insurance. ## Where it holds up, and where it does not - Strength: Brand coverage help included in membership - Strength: Unlimited provider messaging on the membership - Strength: Cancellation allowed at any time - Limitation: Membership is charged on top of medication - Limitation: Medication rate requires a three-month purchase - Limitation: No month-to-month medication price published - Limitation: Compounding pharmacy is not named ## What the evidence says about this kind of treatment The assessment above is about Zealthy. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who may use insurance for a brand GLP-1 and wants coordination included. Wrong for A cash buyer who wants a medication price without a membership. ## The evidence behind what Zealthy prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Zealthy compares | Seller | Who it suits | Go | | --- | --- | --- | | Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | | | Mochi Health | Buyers who want the dose ladder priced in milligrams before they commit | | | Yucca Health | Buyers who want the whole ladder visible before intake and may not stay six months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Sipra](https://thisglp.com/reviews/sipra) [Sommar Club](https://thisglp.com/reviews/sommar-club) [StaveMD](https://thisglp.com/reviews/stavemd) [Steady State Health](https://thisglp.com/reviews/steady-state-health) [Super Healthy Rx](https://thisglp.com/reviews/super-healthy-rx) [Tablet Health](https://thisglp.com/reviews/tablet-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Why is the figure $286 and not the medication price? The membership is charged every month alongside the medication. Both are counted. Is the medication rate available month to month? Not as published. The medication rates are stated for three-month purchases. Does the first-month offer change the price? No. It applies to the first month only, so it is not counted here. Is Zealthy expensive compared with other GLP-1 telehealth sellers? Zealthy publishes a starting figure of $286/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Zealthy above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Zenbody reviews (2026): GLP-1 telehealth sellers | This GLP Zenbody identifies different pharmacies for its injections and tablets and describes continuing clinical contact. Route and monitoring deserve as much attention as the first-month discount. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/zenbody Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Named route-specific pharmacies # Zenbody review Zenbody identifies different pharmacies for its injections and tablets and describes continuing clinical contact. Route and monitoring deserve as much attention as the first-month discount. ## The verdict Zenbody provides useful pharmacy transparency and distinguishes oral from injectable treatment. Before starting, confirm the medical professional responsible for follow-up and how the chosen formulation will be reviewed as your response changes. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Prescription Required Compounded Yes — not FDA-approved Zenbody is an online platform for clinician-prescribed compounded semaglutide and tirzepatide. Its treatment pages offer an injected vial and a daily oral tablet, with evaluation, medicine and delivery described as included. 1. ## Who writes the prescription, and what do they see? The legal terms identify independent professional organizations, including Remedora Inc., PC, whose licensed providers supply clinical services. Zenbody is separate from those practitioners. Confirm the individual clinician and the consent applicable to the patient’s state. The product pages describe progress tracking, clinical-team messaging and check-ins. They do not establish one scheduled appointment interval or guaranteed clinical reply time for every patient. Ask how a symptom report reaches the prescriber before a new refill is prepared. 2. ## What happens when the dose goes up? Zenbody says dose adjustments are included. Oral and injected compounded products use different routes and schedules, so the clinician should select and reassess the actual prescription rather than transpose a dose between formats. 3. ## What the price includes Introductory and later prices differ by ingredient and format. Injection listings describe a four-week supply, while tablets are listed as thirty-day supplies. The clinical and fulfillment scope is included in the offer, but the actual continuing order should be confirmed before treatment begins. 4. ## What it claims, and what it cites The injections are identified as filled by Rx Route in Tomball, Texas, and tablets by Epiq Scripts in Richardson, Texas. These compounded products are not FDA-approved. A named dispenser is useful information, but does not make a compounded tablet clinically interchangeable with an approved brand. ## Where it holds up, and where it does not - Strength: Injection and tablet pharmacies are named - Strength: Clinical contact continues after dispensing - Strength: Different supply formats are described - Limitation: Follow-up frequency needs an individual agreement - Limitation: First-month discounts do not describe later bills - Limitation: Oral and injection evidence should not be conflated ## What the evidence says about this kind of treatment The assessment above is about Zenbody. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for Someone who wants a named pharmacy and can discuss the route, dose and monitoring plan before choosing compounded treatment. Wrong for Someone seeking an FDA-approved branded product or a guaranteed fixed interval of live appointments. ## The evidence behind what Zenbody prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Zenbody compares | Seller | Who it suits | Go | | --- | --- | --- | | SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | | | ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | | | RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Tablet Health](https://thisglp.com/reviews/tablet-health) [Teladoc Health](https://thisglp.com/reviews/teladoc-health) [Teleios Health](https://thisglp.com/reviews/teleios-health) [TeleWellnessMD](https://thisglp.com/reviews/telewellnessmd) [The Protocole](https://thisglp.com/reviews/the-protocole) [TideMedix](https://thisglp.com/reviews/tidemedix) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Which pharmacy fills Zenbody prescriptions? The product pages identify Rx Route for injections and Epiq Scripts for tablets. Confirm the pharmacy shown on the individual prescription. Does included messaging establish an immediate clinician response? No universal response guarantee was established in the reviewed public terms. Agree on the appropriate contact route before starting. ## Sources for this review Provider information checked October 26, 2026. Terms can change. - [Semaglutide formats and pharmacy](https://www.zenbody.com/products/semaglutide/) - [Tirzepatide formats and continuing prices](https://www.zenbody.com/products/tirzepatide/) - [Pharmacy-order refund cutoff](https://www.zenbody.com/refund-policy/) - [Medical groups and service terms](https://www.zenbody.com/terms-of-service/) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Zera Health reviews (2026): GLP-1 telehealth sellers | This GLP Each product page leads with a first-month figure and prints the monthly rate that follows it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/zera-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Standing rates behind a first-month offer # Zera Health review Each product page leads with a first-month figure and prints the monthly rate that follows it. ## The verdict Zera Health charges $179 a month for compounded semaglutide and $255 for compounded tirzepatide, billed monthly. Both pages lead with a lower first-month figure. A separate low-dose line starts at $129. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 50 Injection From $179/mo Oral From $169/mo Prescription Required Compounded Yes — not FDA-approved Zera Health sells compounded semaglutide and compounded tirzepatide through an online service covering all fifty states. Standard semaglutide is $179 a month and tirzepatide $255. A microdose semaglutide line, described by the seller as low-dose, starts at $129. A daily dissolving tablet is listed at $169. 1. ## Who writes the prescription, and what do they see? Treatment is arranged remotely and a prescription is issued before shipping. The product pages carry the rates and a one-line description of the form. They do not describe the clinician or what the intake asks. The service runs at a distance and every product is compounded. The useful detail is that each page prints two figures. The first month is discounted, and the monthly rate that follows is stated beside it. A reader can see the second bill before paying the first. 2. ## What happens when the dose goes up? The monthly rates are tied to named vial strengths: 2.5 mg or 5 mg for semaglutide, 5 mg or 10 mg for tirzepatide. What a higher strength costs is not printed on the same card. That is the question to settle at the intake. 3. ## What the price includes Semaglutide is $149 for the first month, then $179. Tirzepatide is $199 for the first month, then $255, or $215 a month billed every three months. Six months of standard semaglutide at the monthly rate is $1,074. The $76 step from semaglutide to tirzepatide is narrower than several sellers charge. 4. ## What it claims, and what it cites Both molecules are compounded, prepared by a pharmacy rather than manufactured and reviewed as finished products. Neither is FDA-approved and neither is assessed for safety, efficacy or quality before dispensing. The trial evidence quoted for these drugs came from the approved products at labeled doses. ## Where it holds up, and where it does not - Strength: The monthly rate is printed beside the offer - Strength: All fifty states served - Strength: Narrow step between the two molecules - Limitation: The lead figure is a first month only - Limitation: Prices above the named vial strengths are not shown - Limitation: The tablet's standing rate is not stated ## What the evidence says about this kind of treatment The assessment above is about Zera Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who budgets from the monthly rate rather than the first-month figure. Wrong for A reader expecting the first-month price to hold, or wanting every dose priced before the intake. ## The evidence behind what Zera Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Zera Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Alan Meds | A reader ready to prepay six months who wants the full-dose price in view before the intake. | | | DoctorAdam | A reader weighing a tablet against an injection who wants the decision to be about the routine rather than the cost. | | | Revel Health | A reader who wants an oral and expects to pay less for it, which on this seller is what happens. | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [TotalRx](https://thisglp.com/reviews/totalrx) [Totara Health](https://thisglp.com/reviews/totara-health) [Trally Meds](https://thisglp.com/reviews/trally-meds) [Transcarent](https://thisglp.com/reviews/transcarent) [TRT Kingdom](https://thisglp.com/reviews/trt-kingdom) [Tummala Health](https://thisglp.com/reviews/tummala-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is the first-month price what I would keep paying? No. Semaglutide is $149 for the first month and $179 after it. Tirzepatide is $199 for the first month and $255 after it. What is the $129 line? A separate microdose semaglutide product the seller describes as low-dose. It is not the standard semaglutide program. Does Zera serve my state? All fifty are listed. Is Zera Health expensive compared with other GLP-1 telehealth sellers? Zera Health publishes a starting figure of $169/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Zera Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Zeuss reviews (2026): GLP-1 telehealth sellers | This GLP Two compounded injections sold as single 60-day purchases, with nothing renewed unless the buyer orders again. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/zeuss Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Sixty days at a time # Zeuss review Two compounded injections sold as single 60-day purchases, with nothing renewed unless the buyer orders again. ## The verdict Zeuss sells its compounded GLP-1 injection at $125 a month and its compounded GIP/GLP-1 injection at $199, each bought as a single 60-day supply for $250 or $398, and nothing renews unless the buyer places the next order. That gives a patient control over every charge, and it also hands the patient the job of remembering the refill before the last dose runs out. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection From From $125/mo Dose published No Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Zeuss is a telehealth brand with weight, skin, hair and hormone lines for men and women, and its weight-loss page labels the two injections by drug class, GLP-1 and GIP/GLP-1, without printing the molecule names semaglutide or tirzepatide anywhere. The FAQ confirms only that both are compounded and prescribed on the strength of an intake and a medical history. 1. ## Who writes the prescription, and what do they see? A licensed Zeuss provider reads the intake, confirms eligibility and writes what the page calls a personalized dosing plan, and the FAQ says a prescription is issued only when medically appropriate. The page does not name that provider, does not say whether a video or phone visit is part of the review, and does not say how long approval takes before the pharmacy's two to three business days of processing begin. Everything the price covers is listed in a single FAQ answer: the provider review, the medication, and cold-chain shipping in temperature-controlled packaging to the door, with no membership and no hidden fees. The card is never charged for a refill unless the patient authorizes it, so at the end of each 60-day supply the next vial arrives only if someone has ordered it early enough to cover the pharmacy's processing time. 2. ## What happens when the dose goes up? The page promises a personalized dosing plan and says the product suits maintenance dosing, yet it prints no milligram strength beside either price and does not say whether the $125 or the $199 changes when the provider raises the dose. For a patient in the first four months, when labeled schedules step the dose up every four weeks, that leaves the second and third orders unpriced until the provider has written them. 3. ## What the price includes A 60-day supply costs $250 on the GLP-1 line and $398 on the GIP/GLP-1 line, which the page divides into $125 and $199 a month. Three purchases cover six months, which comes to $750 and $1,194 respectively. The $74 gap between the two monthly figures holds for as long as neither price moves, and neither total is a commitment, because nothing carries over from one order to the next. 4. ## What it claims, and what it cites Both injections are compounded by state-licensed 503A and 503B pharmacies, none of them named. The footnote on the page says compounded medications have not been approved by the FDA and that the agency does not verify their safety, effectiveness or quality. ## Where it holds up, and where it does not - Strength: No automatic refills or recurring charges - Strength: Provider review and cold-chain shipping included - Strength: No membership fee on either line - Strength: Each order stands alone - Limitation: No milligram dose beside either price - Limitation: Molecules named only by drug class - Limitation: Refills depend on the patient reordering - Limitation: Compounding pharmacies are not named ## What the evidence says about this kind of treatment The assessment above is about Zeuss. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A buyer who wants every charge to be one they placed themselves. Wrong for A patient who wants refills to arrive without placing each order. ## The evidence behind what Zeuss prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Zeuss compares | Seller | Who it suits | Go | | --- | --- | --- | | Alegro Health | Buyers trying a GLP-1 for two months before committing to a rate | | | Amble | Buyers who want a multi-month rate that holds at every dose | | | TRYM Health | Buyers who will go looking for the plan table rather than price a program by the day | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vea Health](https://thisglp.com/reviews/vea-health) [Vela Rx](https://thisglp.com/reviews/vela-rx) [Verge](https://thisglp.com/reviews/verge) [Vida Health](https://thisglp.com/reviews/vida-health) [Virgo-Meds](https://thisglp.com/reviews/virgo-meds) [Virta Health](https://thisglp.com/reviews/virta-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Is Zeuss a subscription? No, the FAQ says there are no recurring charges or automatic refills, and the card is charged for a refill only when the patient authorizes it. What does one order buy? A 60-day supply, at $250 for the GLP-1 injection or $398 for the GIP/GLP-1 injection, with the provider review and cold-chain shipping included in that figure. Does a higher dose cost more? The page does not say, because it prints no milligram strength beside either price and names no dose tiers for either injection. Is Zeuss expensive compared with other GLP-1 telehealth sellers? Zeuss publishes a starting figure of $125/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Zeuss below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ZipHealth reviews (2026): GLP-1 telehealth sellers | This GLP Four brand-name GLP-1 medicines with starting estimates, a separate clinical fee and final pricing from the pharmacy. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/ziphealth Updated: 2026-10-26 By [This GLP Editorial Team](https://thisglp.com/about) · Updated October 2026 Brands with provisional prices # ZipHealth review Four brand-name GLP-1 medicines with starting estimates, a separate clinical fee and final pricing from the pharmacy. ## The verdict ZipHealth sells brand-name GLP-1 medicines only. The four are Wegovy, the Wegovy pill, Zepbound and Foundayo. The public catalog gives starting estimates; it does not establish a final price for each prescribed dose. A $79 clinical service and support fee is added per treatment. The site calls every price an estimate. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide · Orforglipron Form Injection · Oral Dose published Yes Prescription Required Compounded No Availability 19 states LegitScript Claimed by provider ZipHealth is an online pharmacy and prescribing service in Delray Beach, Florida. It also treats erectile dysfunction, migraine, herpes and other common conditions. It is cash-pay and does not bill insurance for these medicines. Brand orders ship from partner pharmacies. 1. ## Who writes the prescription, and what do they see? Two clinicians are named with their NPI numbers. One is a board-certified nurse practitioner, the other a board-certified DO. A provider reviews the online consultation and picks the dose. Most decisions are stated to come within 24 hours. Some states require a video call first. The patient answers a questionnaire, and a provider reviews it. If prescribed, the order goes to a partner pharmacy. Shipping from ZipHealth itself is free. A partner pharmacy sets its own shipping fee. There is no lock-in contract or subscription. A brand order can be canceled only before the pharmacy processes it. 2. ## What happens when the dose goes up? A licensed provider selects the dose after reviewing the consultation. The current Zepbound, Wegovy pill and Foundayo pages show a starting estimate. A consultation is required to see prices. Ask for the charge at your prescribed dose and at any planned increase, including the separate $79 service fee. 3. ## What the price includes Every figure is labeled "Starting at". A footnote says each is provisional. The dispensing pharmacy sets what is actually charged when it fills the order. The $79 fee is charged on top. No insurance or coupon condition is attached to the figures. The FAQ also mentions lower-priced personalized programs, but every treatment it lists is a brand medicine. 4. ## What it claims, and what it cites Every medicine on offer is an FDA-approved brand. For [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) that means Wegovy, as a pen or a pill. [Tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) is sold as Zepbound. Orforglipron is sold as Foundayo. None is compounded. Wegovy devices differ by presentation. Confirm the exact pen and number of doses with the dispensing pharmacy. ## Where it holds up, and where it does not - Strength: Brand-name medicines only, all FDA-approved - Strength: Clinical-service fee is disclosed separately - Strength: Two clinicians named with NPI numbers - Strength: No subscription or lock-in contract - Limitation: No figure is final until the pharmacy fills it - Limitation: $79 fee added per treatment - Limitation: Public starting estimates do not price every dose - Limitation: Delivery limited to listed states ## What the evidence says about this kind of treatment The assessment above is about ZipHealth. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A cash buyer seeking a branded GLP-1 who can confirm the pharmacy charge before fulfillment. Wrong for Anyone who wants compounded medication, or a settled figure before an order is filled. ## The evidence behind what ZipHealth prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. - [What Is Orforglipron? A Daily GLP-1 Tablet That Is Not a Peptide](https://thisglp.com/research/what-is-orforglipron) A small-molecule daily tablet, not a peptide. Over 72 weeks in 3,127 adults, weight fell 11.2% on the top dose against 2.1% on placebo. No trial has compared it against an injection. ## How ZipHealth compares | Seller | Who it suits | Go | | --- | --- | --- | | FORM | A reader who has priced the manufacturer already and wants a prescriber named | | | NovoCare Pharmacy | Readers who want the approved product and will count thirteen boxes a year rather than twelve | | | Walgreens Weight Management | Readers who want the approved product and count fills rather than months | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [Vitakey](https://thisglp.com/reviews/vitakey) [Vital Step](https://thisglp.com/reviews/vital-step) [Vivanta Care](https://thisglp.com/reviews/vivanta-care) [VivioMD](https://thisglp.com/reviews/viviomd) [welludr.](https://thisglp.com/reviews/wellmedr)[Yes Clinic](https://thisglp.com/reviews/yes-clinic) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked Does ZipHealth sell compounded semaglutide? No. Its weight-loss treatments are Wegovy, the Wegovy pill, Zepbound and Foundayo. All are brand-name and FDA-approved. What is the $79 fee? A clinical service and support fee, charged per treatment on top of the medication. It applies to new and repeat patients. Is the listed price final? No. The site treats it as provisional. What is charged is fixed by the pharmacy when it fills the order. Is ZipHealth legit? ZipHealth is a GLP-1 telehealth sellers service. Its stated availability: 19 states. It displays a LegitScript certification claim, which we record as a claim and not as a verified fact: LegitScript's public checker is gated and returns the same page for any domain put into it, so no one can reproduce a check from it. What our record does not establish: a single monthly price you can check before an intake, whether it bills insurance and how its intake works. Ask for those in writing before you pay. ## Sources for this review Provider information checked October 15, 2026. Terms can change. - [Treatment choices and clinical support](https://www.ziphealth.co/clinics/weight-loss) - [Zepbound consultation details](https://www.ziphealth.co/clinics/weight-loss/zepbound) - [Oral Wegovy care pathway](https://www.ziphealth.co/clinics/weight-loss/wegovy-pill) - [Foundayo assessment information](https://www.ziphealth.co/clinics/weight-loss/foundayo) - [Prescribing and pharmacy questions](https://www.ziphealth.co/faq) - [Official Wegovy pen presentations](https://www.novo-pi.com/wegovy.pdf) Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # ZYP Medical reviews (2026): GLP-1 telehealth sellers | This GLP A one-provider clinic near Omaha that prices each order by how long the vial will last, and prints the arithmetic. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/zyp-medical Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 One named prescriber, seven states # ZYP Medical review A one-provider clinic near Omaha that prices each order by how long the vial will last, and prints the arithmetic. ## The verdict ZYP Medical is a small practice built around one family nurse practitioner, and it is unusually frank that the price of a refill moves with the dose. Its starter plans are $399 for ten weeks of compounded semaglutide and $450 for two months of tirzepatide, and every new patient books a paid consult first. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral States 7 From From $250/mo Dose published Yes Prescription Required Compounded Yes — not FDA-approved Pharmacy Not named Availability Nebraska, Iowa, South Dakota, Minnesota, Kansas, Colorado and Arizona ZYP Medical is a clinic based in Gretna, Nebraska, that sees patients in person near Omaha and by telehealth in Nebraska, Iowa, South Dakota, Minnesota, Kansas, Colorado and Arizona. Alongside weight loss it offers testosterone therapy, urgent care, NAD+, peptides, IV hydration and lab testing, and its GLP-1 menu covers injectable semaglutide and tirzepatide plus two needle-free tirzepatide tablets. 1. ## Who writes the prescription, and what do they see? The prescriber is named on the page: Josh Peterson, a family nurse practitioner, who reviews the intake ahead of the visit and writes a prescription only when he judges treatment appropriate. Patients text him directly rather than going through a call center, and the site says the consult fee pays for his clinical time, not for a prescription. Treatment starts with a booked consult, either an hour-long Deep Dive for people new to these drugs or a thirty-minute Power Consult for those who have taken them before, and a prescription can go out the same day. Medication ships from licensed 503A compounding pharmacies in three to five business days, with supplies, cold-pack shipping and unlimited messaging counted inside the medication price. All sales are final, consult fees are not returned once the visit has happened, and a prepaid plan canceled before a later vial ships carries only a capped partial refund. 2. ## What happens when the dose goes up? The tirzepatide starter covers four weeks at 2.5 mg and four at 5 mg, with a check-in at week seven before the reorder. The semaglutide starter steps from 0.25 mg to 0.5 mg to 1 mg across ten weeks, all drawn from a single vial. After the starter, the FAQ explains that a higher dose empties the same vial sooner, so each order is priced on how long it will actually last. A dose change made mid-supply is explained to the patient before it happens, not after. The page also offers in-between doses, giving 3.5 mg of tirzepatide as its example. 3. ## What the price includes The product page prices the semaglutide starter at "$160/month" and "$399 for the 10-week starter plan, paid in full", and the tirzepatide starter at "$225/month" and "$450 for the 2-month starter plan". Both are opening fills for a new patient, so neither is ranked here as the monthly price someone pays by month four. The dissolving tirzepatide tablet is $250 a month for a 30-day supply. Refills are priced by dose and quantity rather than at a flat rate, with semaglutide capped at $350 per order, and the consult adds a one-time $50 for the Deep Dive or $29.99 for the Power Consult. The hero banner still shows a lower starting figure than the plan cards beneath it, and Affirm financing costs more in total than paying up front. 4. ## What it claims, and what it cites Both injectables and both tablets are compounded and used off-label, and the site says plainly that none of them is FDA-approved and that the brand products are considered first-line treatment for obesity. The standard formulation includes vitamin B6, which the page says is there for nausea and plays no part in the weight loss, with a B12 and glycine version available at extra cost. The pharmacies are described as licensed 503A compounders that test each batch for potency, though none is named. ## Where it holds up, and where it does not - Strength: Prescribing nurse practitioner named, reachable by text - Strength: Dose-based pricing explained with its arithmetic - Strength: In-between doses available, not just fixed steps - Strength: Month-to-month supplies offered at every dose - Limitation: Paid consult required before any prescription - Limitation: Refill prices depend on dose, not published - Limitation: Serves seven states, per the page - Limitation: All sales final and no pharmacy named ## What the evidence says about this kind of treatment The assessment above is about ZYP Medical. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A patient in one of the seven states who wants a named clinician on text and is willing to pay per order as the dose changes. Wrong for Someone living outside the seven listed states, or anyone who wants one flat monthly charge that holds as the dose rises. ## The evidence behind what ZYP Medical prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How ZYP Medical compares | Seller | Who it suits | Go | | --- | --- | --- | | Dr. Gillis' Wellness Center | Maine patients who want a named physician and in-person follow-up | | | Big Easy Weight Loss | Readers who can pay a block up front and want the new-patient reduction | | | Center for Medical Weight Loss (CMWL) | Buyers who want a named medical director and a rate that holds at every dose | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [YOURx Health](https://thisglp.com/reviews/yourx-health) [Youth & Soul](https://thisglp.com/reviews/youth-and-soul) [Zenbody](https://thisglp.com/reviews/zenbody) [Coby Health](https://thisglp.com/reviews/coby-health) [Form Health](https://thisglp.com/reviews/form-health) [Pepton Health](https://thisglp.com/reviews/pepton-health) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does ZYP Medical charge to start? The semaglutide starter is $399 for ten weeks, paid in full, and the tirzepatide starter is $450 for two months, with a one-time consult first at $50 for the hour-long visit or $29.99 for the shorter one. Why does the price change after the starter plan? Each order is priced on how long the vial will last at the patient's dose, so a higher dose makes the same order cover fewer weeks, and semaglutide orders are capped at $350. Is there a needle-free option? Yes, a tirzepatide tablet that dissolves under the tongue costs $250 a month, and a chewable tirzepatide tablet is sold as well. Is ZYP Medical legit? ZYP Medical is a GLP-1 telehealth sellers service. Its stated availability: Nebraska, Iowa, South Dakota, Minnesota, Kansas, Colorado and Arizona. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay. Is ZYP Medical expensive compared with other GLP-1 telehealth sellers? ZYP Medical publishes a starting figure of $250/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts ZYP Medical above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). --- # Terms of Use | This GLP The terms for using This GLP — what the site is, what it isn't, and the ground rules for reading and linking to it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/terms Updated: 2026-09-16 Legal # Terms of Use Effective September 15, 2026 These Terms set out the agreement between you and This GLP (“we,” “us”) covering the website, the calculators, and anything else we publish here — together, the “Services.” They are binding, so they are worth reading before you rely on anything on the site. Using any part of the Services means you accept them and our [Privacy Policy](https://thisglp.com/privacy); if that does not suit you, the right course is simply not to use the site. ## 1\. Acceptance of Terms Reading a review, running a cost calculation, comparing two sellers or following a link out all count as use. In doing any of them you are confirming that you are 18 or older, or the age of majority where you live, and that these Terms are understood and accepted. Anyone acting for a company rather than themselves is confirming they can commit that company to them. ## 2\. Description of Service We publish research and reviews about GLP-1 medication and the telehealth sellers and pharmacies that supply it: what a month really costs, what the trials measured, and how sellers differ from one another. Nothing on this site is a clinical service. We hold no pharmacy license, employ no prescribers, write no prescriptions, dispense nothing, diagnose nobody, and form no doctor–patient relationship with anyone who reads us. ## 3\. Not Medical Advice Everything here is background reading. It is not a diagnosis, not a treatment plan, and not a substitute for either. Starting a GLP-1, stopping one, changing a dose or adding anything alongside it are all decisions for a licensed prescriber or pharmacist who knows your history — take them there, and take any question about a symptom there too. Do not put off advice, or set advice aside, because of something you read on this site. In an emergency, contact a doctor or your local emergency number rather than a website. ⛔ GLP-1 receptor agonists carry real risks — the labeled warnings include pancreatitis, gallbladder disease, kidney injury following dehydration, and a boxed warning about thyroid C-cell tumors seen in rodents — and they are not suitable for everyone. Much of what this site covers is compounded rather than FDA-approved, which means it has not been reviewed for safety, efficacy or quality before being dispensed. Acting on anything you read here is your own decision and your own risk. ## 4\. User Conduct You agree to use the Services only for lawful purposes and in a way that does not infringe the rights of, restrict, or inhibit anyone else's use of the Site. Prohibited conduct includes, without limitation: attempting to gain unauthorized access to any portion of the Site, its servers, or related systems; scraping or mass-copying content without permission; interfering with or disrupting the operation of the Site; uploading viruses, malware, or harmful code; harvesting email addresses or other contact information; and using the Site to harass, defame, or harm any person or entity. ## 5\. Intellectual Property All content on the Site that we create — including text, graphics, logos, research methodology, reviews, rankings, tools, charts, and the design and “look and feel” of the Site — is owned by This GLP or its licensors and is protected by United States and international copyright, trademark, and other intellectual property laws. You may view, download, and print content from the Site for your own personal, non-commercial use, and you may quote brief excerpts with attribution, provided you do not remove any copyright or other notices. You may not republish, scrape, sell, license, or otherwise commercially exploit substantial portions of our content without our prior written permission. Provider names, brand names, logos, and trademarks referenced on the Site — including Geref® (EMD Serono), the discontinued branded form of GLP-1 acetate, and others — are the property of their respective owners. Their mention on the Site does not imply any affiliation with, endorsement by, or sponsorship from those companies unless we explicitly state otherwise. ## 6\. Affiliate Links and Advertising This GLP is a reader-supported publication. Many of the outbound links to providers on this Site are affiliate links, meaning that if you click a link and sign up or make a purchase we may earn a commission at no additional cost to you. Our commercial relationships may influence which providers we feature prominently, but they never influence our editorial assessments, scores, or safety statements. For full details, please see our [Disclosures](https://thisglp.com/disclosures) and [Methodology](https://thisglp.com/methodology). ## 7\. Third-Party Links and Providers The Site contains links to third-party websites, including provider sign-up pages, pharmaceutical manufacturer websites, scientific literature, and news sources. We do not control and are not responsible for the content, availability, privacy practices, or business practices of any third-party site. A link to a provider does not constitute an endorsement beyond what our review states. Before entering into any transaction with a third party, you should independently verify pricing, product availability, licensing, shipping terms, and applicable refund or cancellation policies. ## 8\. Disclaimers THE SERVICES ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. TO THE FULLEST EXTENT PERMITTED BY LAW, This GLP DISCLAIMS ALL WARRANTIES, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, AND ACCURACY. We make no warranty that (a) the Services will meet your requirements, (b) the Services will be uninterrupted, timely, secure, or error-free, (c) pricing information, availability, ingredient lists, clinical claims, or any other provider data will be accurate or current, or (d) any defects in the Services will be corrected. GLP-1 provider pricing and product offerings change frequently, and the science evolves; we do our best to keep information up to date, but you should verify every material detail directly with the provider before acting on it. ## 9\. Limitation of Liability TO THE MAXIMUM EXTENT PERMITTED BY LAW, IN NO EVENT SHALL This GLP, ITS AFFILIATES, OFFICERS, EMPLOYEES, AGENTS, OR LICENSORS BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY, OR PUNITIVE DAMAGES — INCLUDING WITHOUT LIMITATION LOST PROFITS, LOST REVENUE, LOST DATA, LOSS OF GOODWILL, PERSONAL INJURY, OR EMOTIONAL DISTRESS — ARISING OUT OF OR RELATED TO YOUR USE OF OR INABILITY TO USE THE SERVICES, WHETHER BASED ON WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), STATUTE, OR ANY OTHER LEGAL THEORY, AND WHETHER OR NOT WE HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. In jurisdictions that do not allow the exclusion or limitation of certain damages, our liability will be limited to the maximum extent permitted by law. In no event shall our aggregate liability to you for all claims arising out of or related to the Services exceed one hundred U.S. dollars (US$100). ## 10\. Indemnification You agree to defend, indemnify, and hold harmless This GLP, its affiliates, and their respective officers, directors, employees, and agents from and against any claims, liabilities, damages, losses, and expenses, including reasonable attorneys' fees, arising out of or in any way connected with your access to or use of the Services, your violation of these Terms, or your violation of any third-party right, including any intellectual property or privacy right. ## 11\. Termination We reserve the right, in our sole discretion and without notice, to suspend or terminate your access to all or any part of the Services at any time, with or without cause. Upon termination, all provisions of these Terms that by their nature should survive termination — including ownership provisions, warranty disclaimers, indemnification, and limitations of liability — will survive. ## 12\. Changes to These Terms We may revise these Terms from time to time. When we do, we will update the “Effective” date at the top of this page and, for material changes, take reasonable steps to notify users (for example, by posting a notice on the Site or sending an email to newsletter subscribers). Your continued use of the Services after changes become effective constitutes acceptance of the revised Terms. ## 13\. Governing Law and Dispute Resolution These Terms, and anything arising from them or from your use of the Services, are governed by the laws of the State of Florida, without regard to its conflict-of-law rules. Any claim between us belongs in the state or federal courts sitting in Florida, and by using the Services you agree those courts may exercise personal jurisdiction over you. Nothing here limits a right you hold under the consumer-protection law of the state you live in, where that law says it cannot be waived. ## 14\. Miscellaneous These Terms, together with our [Privacy Policy](https://thisglp.com/privacy) and [Disclosures](https://thisglp.com/disclosures), constitute the entire agreement between you and This GLP regarding the Services. If any provision of these Terms is held to be invalid or unenforceable, the remaining provisions will remain in full force and effect. Our failure to enforce any right or provision of these Terms will not be considered a waiver of that right or provision. ## 15\. Contact Questions about these Terms can be sent to [notices@thisglp.com](mailto:notices@thisglp.com) or by mail to: **This GLP** [notices@thisglp.com](mailto:notices@thisglp.com) --- # Tools | This GLP Ten GLP-1 tools: a true monthly cost from any headline, the approved dose ladder, the five marks every seller is scored on, which of them publish a full dose ladder, and how many reach your state. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools Updated: 2026-09-16 Built from the literature # Tools 10 calculators, each doing one conversion by itself rather than asking you to trust a seller’s math: what a “starting at” price actually totals over its term, and what the approved dose ladder costs to climb. Neither recommends a dose or a seller — each computes what the numbers you enter imply, and shows the work. [The scorecard behind every ranking ## What Sellers Publish Nothing here is ranked on opinion. The five marks every seller is scored on — price transparency, honest headline, dose-ladder pricing, state coverage and catalog breadth — for all of them at once, so you can disagree with the weighting and still use the marks. Open the calculator →](https://thisglp.com/tools/what-sellers-publish)[A census of what is missing ## Questions They Leave Open Counted across every ranked seller: how many publish nothing about what the price does at a higher dose, nothing about where they ship, nothing about a second format — with the sentence worth sending before a first order. Open the calculator →](https://thisglp.com/tools/questions-they-leave-open)[Thirteen bills, not twelve ## When a Month Is Not a Month A price quoted monthly but billed every four weeks arrives thirteen times a year. Every seller whose own note names an interval other than a calendar month, with the charges a year it implies. Open the calculator →](https://thisglp.com/tools/billing-cadence-check)[Not that it rises — what it rises to ## Published Dose Ladders Saying the price climbs with the dose is one disclosure; printing the numbers it climbs to is another. Every seller publishing three or more rungs, so month six can be priced before enrolling. Open the calculator →](https://thisglp.com/tools/published-dose-ladders)[The constraint that beats price ## Coverage by State A seller that cannot ship to you is not an option at any price. How many ranked sellers — and how many with a full review here — record coverage in each state, and which states have almost none. Open the calculator →](https://thisglp.com/tools/coverage-by-state)[Before you compare on price ## Molecule and Format Finder A cheaper seller is no use if it does not carry what you came for. What each ranked seller lists by molecule and by form, so a reader wanting a tablet can skip the ones that only inject. Open the calculator →](https://thisglp.com/tools/molecule-and-format-finder)[What “starting at” hides ## Cost Calculator Enter a seller's own monthly figure, its plan term and any up-front fee, and see the true cost per month and the total for the term — checked against real published GLP-1 prices with their verification dates. Open the calculator →](https://thisglp.com/tools/glp1-cost-calculator)[Dose and cost ## Titration Planner The approved week-by-week ladder for semaglutide and tirzepatide, read off the current labels — and what climbing it costs at a seller that holds one price against one that re-prices at every step. Open the calculator →](https://thisglp.com/tools/glp1-titration-planner)[What the trials found ## Expected Weight Loss Enter a starting weight and see the published distribution from STEP 1 and SURMOUNT-1 applied to it — not the arm mean every landing page quotes, but how many participants reached each threshold and how many did not. Open the calculator →](https://thisglp.com/tools/glp1-expected-weight-loss)[Is that a normal price? ## Price Check Enter the monthly figure a seller quoted you and see where it lands among every published price on this site — corrected for fees and four-week terms — with the median, the range and how many are lower. Open the calculator →](https://thisglp.com/tools/glp1-price-check) ## Or read the boards For questions a single conversion can’t answer — which seller, which format, whether the evidence holds up — these boards answer them with the working shown. --- # When a GLP-1 'month' is not a month | This GLP A seller billing every four weeks charges thirteen times a year, not twelve. Every seller whose own pricing note names an interval other than a calendar month, with how many charges a year that implies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/billing-cadence-check Updated: 2026-10-26 [← Tools](https://thisglp.com/tools)Thirteen bills, not twelve # When a month is not a month A price quoted “monthly” but billed every four weeks arrives thirteen times a year. That is an eight percent premium invisible on the price tag and obvious on a bank statement. 34 sellers here record an interval that is not a calendar month, and 24 of them are on the four-week cycle. By [This GLP Editorial Team](https://thisglp.com/about) 34 sellers whose own pricing note names the interval [Framework](https://thisglp.com/reviews/framework) billed every a week · about 52 charges a year Framework prices per WEEK, not per month: 'GLP 1s For As Low as $25/Week'. Fifty-two weeks is $1,300 a year, so the calendar month is $108.33, not $100. '$0 membership fees.' Our conversion: Framework prints "As low as $25/Week", and $25 × 52 ÷ 12 is $108.33 a month. A second Framework page prints "As low as $19/Week", and neither names a molecule, dose or term. [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) billed every a week · about 52 charges a year 'Starting at $149 — GLP-1 Injections — one simple injection per week', with no insurance required, free shipping and no membership fee. Iron Med RX does not say which GLP-1 medication this is. Re-read September 18, 2026: unchanged. [Pepton Health](https://thisglp.com/reviews/pepton-health) billed every a week · about 52 charges a year Card reads 'Starting at $179 / GLP-1 Injections / One simple injection per week' and names no molecule. Refill pricing is behind account creation. [Aspire Health](https://thisglp.com/reviews/aspire-health) billed every four weeks · about 13 charges a year Verbatim from weight-loss page: '$249' for 5-week supply of compounded tirzepatide/B6 (2.5 mg) + $75/month LoseIt program fee = ~$289/month total. 15-week supply at $699 (~$202/mo for medication alone). 'Medication costs are not included in either program fee.' Re-read September 14, 2026: now $149, was $289. $149 buys a four-week vial at 2.5 mg weekly, which is $161 a calendar month, plus the same $49/month medical-care fee. [boostAGErx](https://thisglp.com/reviews/boostagerx) billed every four weeks · about 13 charges a year GLP-1 'starting at $95/mo' on 12-month plan paid upfront; actual price varies by product/plan Re-read September 18, 2026: unchanged. $95 is the 3-month plan paid upfront; one month is the $225 four-week plan, and thirteen fills a year is $243.75. [Contour Health](https://thisglp.com/reviews/contour-health) billed every four weeks · about 13 charges a year Starting package $500 covers medical assessment, tailored plan, and 8-10 weeks of medication/supplies (20-120mg vials). Ongoing cost is pay-per-vial; site-published 'Average Monthly Cost' is $300/mo at a typical 2.5-5mg/week dose. Source: contourhealthrx.com/weight-loss. Re-read October 14, 2026: now $null, was $300. A weekly starting estimate does not specify a four-week refill bill; the cost depends on vial size and dose. [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) billed every four weeks · about 13 charges a year Sold in WEEK BLOCKS: '4 weeks $200, 8 weeks $350, 10 weeks $400, 12 weeks $500, 20 weeks $650'. ⚠ A $250 one-time consultation and a $50/month follow-up fee are charged on top. Re-read September 18, 2026: the seller publishes $200. $200 per four-week block is $216.67 a calendar month, plus the $50/month follow-up subscription stated to exclude medication. [DrBrainRx](https://thisglp.com/reviews/drbrainrx) billed every four weeks · about 13 charges a year Verbatim from /products/semaglutide: 'The monthly price is the same for all doses and does not increase as your dose goes up.' Includes 4-week vial (0.25–2.5 mg/week range). Plus $25/month provider care fee for dose titration and support (cancellable anytime). Re-read September 18, 2026: unchanged. $199 medication plus the $25/month Care Access plan the product page states is required. [Goldspan Health](https://thisglp.com/reviews/goldspan-health) billed every four weeks · about 13 charges a year ⛔ Same 4-week cycle: 'a new monthly supply arrives automatically every 4 weeks' — about $3,887/yr across 13 charges, not $3,588. Price published only on the altroapp.com storefront. Re-read September 17, 2026: unchanged. $299 on the same four-week cycle is $3,887 a year, or $323.92 a calendar month. [Harper Meds](https://thisglp.com/reviews/harper-meds) billed every four weeks · about 13 charges a year Flat price at every dose; all-inclusive (consult, prescription, medication, shipping). Re-read September 18, 2026: unchanged. $196 on the same four-week fill is $212.33 a calendar month. [HealthSource](https://thisglp.com/reviews/healthsource) billed every four weeks · about 13 charges a year Verbatim from product page: 'From: $199.00 every 4 weeks.' Medication is compounded semaglutide+B12 in vial form with syringes and alcohol pads. Multiple dose tiers available (Full Dose, Starter 4-week, Starter 6-week, 8-week); $199 is entry-tier price. Re-read September 18, 2026: unchanged. $199 every four weeks is thirteen fills a year — $216 a calendar month. [HeliMeds](https://thisglp.com/reviews/helimeds) billed every four weeks · about 13 charges a year Paid upfront as a 12-week plan, not a subscription. Any dose is $199/mo. Re-read September 17, 2026: unchanged. The $99 headline is the starter dose; any dose is a $597 twelve-week block labeled $199/mo, and twelve weeks is 2.76 calendar months, so $216. The same footnote prices the next four-week supply at $239. [Joey Med](https://thisglp.com/reviews/joey-med) billed every four weeks · about 13 charges a year Re-read September 18, 2026: unchanged. Joey Med sells GLP-1 Core as a "4 Week" fill at $199, and thirteen fills a year is $215.58 a calendar month. [Lean Rx](https://thisglp.com/reviews/lean-rx) billed every four weeks · about 13 charges a year Re-read September 18, 2026: the seller publishes $450. $450 buys four weeks of medication with no commitment ("4 Weeks Pay in full today"), plus a required $35 shipping charge, which is $485 per four-week fill. Thirteen fills fall in a year, so a calendar month costs $525.42. [Lttl](https://thisglp.com/reviews/lttl) billed every four weeks · about 13 charges a year Low-dose line marketed for tolerability. Month-to-month, was $179. Ladder: $129 quarterly, $119 every 6mo, $109 annually. First Month Special $119. Re-read September 18, 2026: unchanged. The microdose line: $149 buys a four-week supply, and thirteen fills a year is $161.42 a calendar month. [Luma Health Co](https://thisglp.com/reviews/luma-health) billed every four weeks · about 13 charges a year Re-read September 18, 2026: unchanged. Luma prices semaglutide as a "(4 week supply)" at $115, and thirteen fills a year is $124.58 a calendar month. [Midi Health](https://thisglp.com/reviews/midi-health) billed every four weeks · about 13 charges a year From /glp1-pricing, headed 'No membership fees. No surprises.' ⚠ EVERY table is labeled '4-week supply', NOT a calendar month, so this is 13 cycles a year and must never be restated as '/mo'. Ladder runs $165.90 (0.1–0.5 mg) to $355.00 (2.5 mg). Re-read September 18, 2026: unchanged. $165.90 buys a four-week supply, and thirteen fills a year is $179.73 a calendar month. [MyStart Health](https://thisglp.com/reviews/mystart-health) billed every four weeks · about 13 charges a year Homepage FAQ verbatim: program 'starts at $299/month, excluding any discounts,' all-inclusive (consults, unlimited clinician access, meds, labs, shipping). Promo banner '$150 Off + Lifetime 25% Off' (coupon SELFLOVE25 in funnel URL) but no final promo dollar price published pre-quiz — plan-selection pricing is gated behind a signed medical attestation, so not published. Re-read September 18, 2026: unchanged. The monthly plan is auto-billed each month and ships a four-week supply, and thirteen four-week fills a year on a flat $299 is $324 a calendar month. [Piper](https://thisglp.com/reviews/piper) billed every four weeks · about 13 charges a year Re-read September 17, 2026: unchanged. $135 buys a four-week dosage, and thirteen fills a year is $146.25 a calendar month. [Prime Health](https://thisglp.com/reviews/prime-health) billed every four weeks · about 13 charges a year A four-week supply, not a calendar month — 13 charges a year. Re-read September 17, 2026: unchanged. The $299 program ships a four-week supply, so a year takes thirteen charges: $324 a calendar month. [Rx.com](https://thisglp.com/reviews/rx-com) billed every four weeks · about 13 charges a year '1 month $285 per month'. Longer plans are one upfront charge: 3 months $795 ($265/mo), 6 months $1,550 ($259/mo). Checkout fine print says billing continues every 28 days. The same four-week cycle on the tirzepatide rung: $308.75, or $309 a calendar month. [SexyMD](https://thisglp.com/reviews/sexymd) billed every four weeks · about 13 charges a year Re-read September 18, 2026: now $149, was $199. $149 buys one four-week Monthly Flex fill, and thirteen fills a year is $161 a calendar month. [Sprout Health](https://thisglp.com/reviews/sprout-health) billed every four weeks · about 13 charges a year Homepage hero product card, confirmed on two independent surfaces, with no intro or promo qualifier attached. Re-read September 15, 2026: now $299, was $149. $299 Monthly Plan is billed every four weeks for a four-week supply, so thirteen fills a year is $324 a calendar month; its six-month plan at $1,014 is billed in calendar months instead, at $169. [Sunlight](https://thisglp.com/reviews/sunlight) billed every four weeks · about 13 charges a year Treatment card reads 'Semaglutide (Compounded) $88' and the FAQ confirms 'semaglutide starts at $88 and tirzepatide at $157. Each flat monthly rate includes your prescription'. A banner frames it as 'Summer Promo! As low as $88', but the site also promises 'Same price forever. No price increases ever. No hidden Fees.', so it is recorded as the standing rate rather than an intro price. Re-read September 18, 2026: unchanged. $88 buys one four-week fill, and thirteen fills a year is $95 a calendar month. [TrueMe](https://thisglp.com/reviews/trueme) billed every four weeks · about 13 charges a year Dual-action compounded tirzepatide with added B vitamins. A 3-month plan works out to $139/mo but is billed as a single $417 payment. Re-read September 15, 2026: now $149, was $189. $149 on the same four-week cycle is $161 a calendar month. [VitaStir](https://thisglp.com/reviews/vitastir) billed every four weeks · about 13 charges a year Single-dose-vial kit, 30-day supply. Re-read September 17, 2026: unchanged. The $99 listing is a one-week home kit; the cheapest published month is $125 for four injections, and thirteen four-week fills a year is $135. Its titration ladder then climbs to $245, $295, $345 and $395. [Basal Health](https://thisglp.com/reviews/basal-health) billed every four weeks · about 13 charges a year Published recurring four-week treatment rate after introductory offer, not a calendar-month bill. https://basal.health/ Official basal.health offer read October 26, 2026: recurring treatment is $299 every four weeks after the introductory period, not a calendar month. Thirteen four-week bills per year cost $3,887, or $323.92 per calendar month (G4: $299 × 13 ÷ 12). This is arithmetic on the advertised bill, not a walked checkout. [Alegro Health](https://thisglp.com/reviews/alegro-health) billed every eight weeks · about 6.50 charges a year 199 dollars total for the full 8-week starter with B12 (about two months), select states, no monthly fees The $199 is the total for an eight-week starter course with B12, about two months of treatment, rather than a monthly rate — and no ongoing monthly price is published. [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) billed every twelve weeks · about 4.33 charges a year 'Zepbound® Prescription — Starting at $139'. No period stated. Re-read September 18, 2026: the seller publishes $144. The compounded starter is 60 mg total as a twelve-week supply at $499, and twelve weeks is 2.76 calendar months. [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) billed every twelve weeks · about 4.33 charges a year Sold only in 12-week packages: 'Semaglutide Compounded Treatment — Starting at $495 for 12 weeks', discounted to $399 for new patients. $495 over 12 weeks is $165 a calendar month; the starter price works out at $133. Re-read September 18, 2026: the seller publishes $495. The $495 is a twelve-week package, and twelve weeks is 2.76 calendar months rather than three — $179 a month, not the $165 a division by three would give. [Clume Health](https://thisglp.com/reviews/clume-health) billed every twelve weeks · about 4.33 charges a year The $200/mo figure requires a 12-week prepaid term. Re-read September 14, 2026: now $259, was $219. [Good Life Meds](https://thisglp.com/reviews/good-life-meds) billed every twelve weeks · about 4.33 charges a year 'Patients Continuing GLP-1 Therapy: Standard Dose Levels: Monthly = $297, Quarterly = $822, 6 Month Supply = $1494' — so $274/mo on the quarterly and $249/mo on the six-month, both prepaid. The $197 promo is the same first-order $100 off with code NEWME100. ⚠ A separate NEW-PATIENTS-ONLY option exists: 'New GL JumpStart Bundle! 3 Month Supply = $599 — Initial 12 Week Supply: 2.5mg → 5mg → 7.5mg (4 weeks each)', i.e. $199.67/mo but only for patients new to GLP-1 therapy and only across the titration doses. Re-read September 18, 2026: unchanged. [Noom](https://thisglp.com/reviews/noom) billed every twelve weeks · about 4.33 charges a year Footnote 2 verbatim: 'Initial 3 week subscription and 4 weeks of medication from $79 plus tax and $199 per month plus tax for 12 week subscription thereafter.' Same three-clock structure as the main program. ⚠ A SITE-WIDE BANNER ADVERTISES A THIRD FIGURE THAT RECONCILES WITH NEITHER: '$49 Limited-Time Offer: Microdose GLP-1Rx Program (Compounded Semaglutide). Price includes medication.' The $49 is not explained anywhere on the page and does not match the $79 intro in the footnote — treat it as an unverified promotional entry price. Re-read September 18, 2026: now $179, was $199. $179 is billed per month against a twelve-week subscription, so three payments of $537 buy 84 days — 2.76 calendar months — which is $195 a month. [Tryozi](https://thisglp.com/reviews/tryozi) billed every twelve weeks · about 4.33 charges a year First 4 weeks $139 (50% off), then $279/mo. Multi-week plans are billed once and ship every 4 weeks: 12-week -22%, 24-week -29%, 52-week -47%. Re-read September 17, 2026: unchanged. ## Where this list comes from From each seller’s own recorded pricing note, matched on the interval it names. There is no billing-interval field on this roster, and a seller absent from this list has not been shown to bill by the calendar month — it has simply not written the interval down anywhere this site has read. That makes the list a floor. --- # GLP-1 coverage by state: providers and reviews | This GLP Find GLP-1 providers with recorded coverage in your state. Filter by medication, read reviews and check source disclosures before enrolling. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/coverage-by-state Updated: 2026-10-26 [← Tools](https://thisglp.com/tools)The constraint that beats price # Coverage by state Every other comparison on this site assumes the seller can reach you. Across 51 jurisdictions, choice is not evenly spread: TX has 177 ranked sellers recording coverage, and the five thinnest have DC (40), MS (130), AR (134), AK (136), AL (138). By [This GLP Editorial Team](https://thisglp.com/about) 51 jurisdictions, from each seller's own recorded coverage list Choose your stateMedication listed These are recorded coverage lists, not a guarantee of prescribing or shipping. Medication availability can depend on the program, pharmacy and your clinical assessment. Alaska — 136 sellers · AK · Alabama — 138 sellers · AL · Arkansas — 134 sellers · AR · Arizona — 170 sellers · AZ · California — 154 sellers · CA · Colorado — 173 sellers · CO · Connecticut — 156 sellers · CT · District of Columbia — 40 sellers · DC · Delaware — 152 sellers · DE · Florida — 176 sellers · FL · Georgia — 159 sellers · GA · Hawaii — 142 sellers · HI · Iowa — 160 sellers · IA · Idaho — 156 sellers · ID · Illinois — 161 sellers · IL · Indiana — 154 sellers · IN · Kansas — 153 sellers · KS · Kentucky — 154 sellers · KY · Louisiana — 142 sellers · LA · Massachusetts — 154 sellers · MA · Maryland — 161 sellers · MD · Maine — 155 sellers · ME · Michigan — 158 sellers · MI · Minnesota — 157 sellers · MN · Missouri — 154 sellers · MO · Mississippi — 130 sellers · MS · Montana — 154 sellers · MT · North Carolina — 156 sellers · NC · North Dakota — 147 sellers · ND · Nebraska — 155 sellers · NE · New Hampshire — 155 sellers · NH · New Jersey — 148 sellers · NJ · New Mexico — 154 sellers · NM · Nevada — 158 sellers · NV · New York — 168 sellers · NY · Ohio — 157 sellers · OH · Oklahoma — 156 sellers · OK · Oregon — 154 sellers · OR · Pennsylvania — 162 sellers · PA · Rhode Island — 149 sellers · RI · South Carolina — 141 sellers · SC · South Dakota — 147 sellers · SD · Tennessee — 152 sellers · TN · Texas — 177 sellers · TX · Utah — 161 sellers · UT · Virginia — 162 sellers · VA · Vermont — 154 sellers · VT · Washington — 164 sellers · WA · Wisconsin — 155 sellers · WI · West Virginia — 143 sellers · WV · Wyoming — 155 sellers · WY Recorded sellers in the state 40–148 sellers 149–154 sellers 155–158 sellers 159–177 sellers Shades compare recorded seller counts; the legend gives each range. A darker state does not mean a particular treatment is available to you. Select a state for its alphabetical list. Find a state, or a seller 51 jurisdictions ## Before you enroll Unknown coverage is excluded from every state. Recorded coverage can also become outdated, so these counts are neither a minimum nor a complete list of current options. A source-check date applies only to the provider disclosure beside it; it is not license verification. - Confirm care is offered at your current address for the medication and program you want. - Ask which clinician and dispensing pharmacy would serve you, and whether they can do so in your state. - Check dose, supply, required fees, total due today, renewal price and cancellation terms before paying. --- # GLP-1 Cost Calculator: True Monthly Price | This GLP See what a 'starting at' headline hides. Enter a monthly price, plan term and any up-front fee to get the true cost per month and total for the term — checked against real published GLP-1 prices. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/glp1-cost-calculator Updated: 2026-10-28 [← Tools](https://thisglp.com/tools)True cost # GLP-1 Cost Calculator A “starting at $X/mo” headline can hide a lot: a term commitment, a one-time consult or lab fee, a price that only applies to the first month. Enter a seller’s own numbers to see the true cost per month and the total for the term — then check it against 402 real published GLP-1 prices below. By [This GLP Editorial Team](https://thisglp.com/about) 402 published prices, with verification dates The headline Example figures — not any single seller’s stated terms. Replace them with a seller’s own numbers. “Starting at” price ($/mo)Plan termUp-front fee ($, one-time) Headline says $149/mo True cost per month $182/mo $33/mo (22.1%) more than the headline, once the up-front fee is spread across the term. Total for the term $546 $149 × 3 months + $99 up front. Against the 857 published seller-format prices we hold below ($49–$687/mo), a $149/mo headline is inside the range we've verified. The real published range ## 402 sellers publish a GLP-1 price Sellers price oral and injectable independently, and the direction is not consistent — on our own roster, Try Ageless charges _more_ for its oral product ($199) than for its own injection ($99), and lists a $199 nasal option on top. Sort by seller, not by format: a column being lower here is not a claim that the format is generally cheaper. Search sellers by name Showing 25 of 402 sellers | Seller | Semaglutide, inj. | Tirzepatide, inj. | Semaglutide, oral | Tirzepatide, oral | Verified | | --- | --- | --- | --- | --- | --- | | 50 Stars Health | $146 | $220 | — | — | Sep 18, 2026 | | Actin | $169 | $269 | — | — | Sep 17, 2026 | | AgelessRx | $239 | $349 | — | — | Sep 18, 2026 | | AHBARx | $249 | $349 | — | — | Sep 18, 2026 | | Alan Meds | $315 | $325 | $215 | — | Sep 18, 2026 | | Alloy | $169 | $199 | — | — | Sep 18, 2026 | | Alternate Health Club | $129 | $169 | — | — | Sep 17, 2026 | | altRX | $89 | $149 | — | — | Oct 13, 2026 | | Always Wellness and Recovery | $210 | $280 | — | — | Sep 18, 2026 | | AlyveRx | $183 | $283 | — | — | Sep 17, 2026 | | Amble | $179 | $329 | — | — | Sep 18, 2026 | | Andrew Meds | $199 | $299 | — | — | Sep 18, 2026 | | Apex MD | $299 | $399 | — | — | Sep 17, 2026 | | AquaVita NextGen | $215 | $320 | — | — | Sep 18, 2026 | | Arc-1 | $199.99 | $199.99 | — | — | Sep 17, 2026 | | Ark Health | $169 | $249 | $125 | — | Sep 18, 2026 | | ARSYNL Rx | $219 | $269 | — | — | Sep 14, 2026 | | Ascend Vitality | $199 | $299 | $199 | $199 | Sep 17, 2026 | | AskRx | $299 | $399 | — | — | Sep 18, 2026 | | Aspen | $179 | $179 | — | — | Sep 18, 2026 | | Aspire Health | $161 | $210 | — | — | Sep 14, 2026 | | Auren Rx | $149 | $229 | — | — | Sep 18, 2026 | | AVARA Rx | $229 | $279 | — | — | Sep 17, 2026 | | Avono Health | $219 | $299 | — | — | Sep 18, 2026 | | AZ Health | $179 | $199 | — | — | Sep 17, 2026 | ## Why so few sellers publish a price We track 120 GLP-1 sellers. 402 of them publish a clean price up front; the rest require a consult, a quote, or an account before any number appears — which is itself worth knowing before you start that process. Where a seller does publish a price, we record it by format and by the date we last verified it, because a compounding pharmacy’s pricing page changes without notice more often than a retail one. --- # Expected Weight Loss on a GLP-1: the Spread, Not the Average | This GLP Enter a starting weight and see the published distribution from STEP 1 and SURMOUNT-1 applied to it — how many participants reached each threshold, and how many did not. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/glp1-expected-weight-loss Updated: 2026-09-16 [← Tools](https://thisglp.com/tools)What the trials found # Expected Weight Loss Almost every page selling one of these drugs is quoting the same two figures, −14.9% and −20.9%, and both are arm means. A mean is the least informative number a trial produces and the only one that reaches a landing page. Both trials also published where their participants actually landed, and that distribution is what this tool renders. By [This GLP Editorial Team](https://thisglp.com/about) Distributions read from the published trial reports Starting weight Trial arm The arm mean, which is the figure you have already seen **33 lb** — 14.9% of 220 lb over 68 weeks, ending near **187 lb**. The placebo arm of the same trial averaged 5 lb, and both arms received lifestyle support. ### Where 1,961 people actually landed STEP 1 published the distribution, not only the average. Each row is a threshold the trial reported, the share of this arm that reached it, and the share that did not. Semaglutide 2.4 mg once weekly: share of participants reaching each weight-loss threshold in STEP 1 | Threshold | At your weight | Reached it | Did not | | --- | --- | --- | --- | | 5% or more | 11 lb | 86.4%placebo 31.5% | 13.6% | | 10% or more | 22 lb | 69.1%placebo 12% | 30.9% | | 15% or more | 33 lb | 50.5%placebo 4.9% | 49.5% | STEP 1 reported 5% and 10% and 15% thresholds. The two trials did not publish the same rungs, so the rows differ between molecules. Missing rungs are absent from the papers rather than from this page. Source: STEP 1, [PMID 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/). ### Nothing at baseline told anyone which row they would be in The trial reported the distribution; it did not report a way to place a given person inside it. Starting weight, age and sex did not sort participants into the group that reached a threshold and the group that did not. The rows above describe 1,961 adults with a body-mass index of 30 or higher, or 27 with a weight-related condition, and no diabetes, under 68 weeks of free drug and a full dose escalation, which is not the same arrangement as a monthly subscription. [the cost calculator](https://thisglp.com/tools/glp1-cost-calculator) covers what 68 weeks of it is priced at. ## Why an average is the wrong thing to plan around In STEP 1, 50.5% of the semaglutide arm reached 15% or more. Turned the other way, almost half did not, and 30.9% did not reach 10%. In SURMOUNT-1, 57% of the highest tirzepatide arm reached 20% — so more than two in five people who spent 72 weeks at the top approved dose did not. Neither trial reported anything measured at baseline that separated those groups in advance. One hundred squares standing for one hundred people in the STEP 1 semaglutide 2.4 mg arm: sixty-nine filled for the share who reached 10 percent body weight loss or more, thirty-one left open for the share who did not. · STEP 1 SEMAGLUTIDE 2.4 MG · 69 reached 10% or more · 31 did not Each square is one person in every hundred of the STEP 1 semaglutide 2.4 mg arm. STEP 1 randomized 1,961 people; the open squares are the share the headline figure does not describe. That matters financially as well as clinically, because the decision a reader is making is whether to start paying monthly. A year of this costs four figures at almost every seller on this site, and the trial that produced the headline gave the drug away. Neither figure above is a forecast of what a year of paying for it looks like, and neither describes what happens when the curve flattens. One more gap between the trial and the purchase: both trials ran the approved products at a full, supervised escalation. Most sellers on this site dispense a compounded preparation, which is not FDA-approved and is not reviewed by the FDA for safety, efficacy or quality before dispensing. The figures above describe semaglutide and tirzepatide as studied, not as sold. --- # GLP-1 Price Check: Is What You Were Quoted Normal? | This GLP Enter the monthly price a seller quoted you and see where it sits against every published GLP-1 price we hold — corrected for fees and terms, with the median and the range. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/glp1-price-check Updated: 2026-10-28 [← Tools](https://thisglp.com/tools)Is that a normal price? # GLP-1 Price Check A seller quotes you a monthly figure and you have nothing to set it against. This places it among 848 published prices — every seller on this site that publishes one, with any membership or program fee already added in and any four-week term already converted to a calendar month. By [This GLP Editorial Team](https://thisglp.com/about) Prices recorded from each seller's own page What you were quoted for Monthly price you were quoted Against 374 published prices for semaglutide, injection $249 a month is higher than **82%** of them. The median is **$190**, and the published range runs **$49** to **$525.42**. $49$525.42 **291** published prices are lower. Against the median you would pay **$708** more across a year. ### What this number is not - **Cheaper is not better.** Some of the lowest figures here are microdoses, which are a smaller dose rather than a discount on the same product, and some are opening prices that rise at the next step of the ladder. - **Every figure is all-in as far as we can establish it.** Where a seller charges a membership or a program fee outside its headline, we add it before ranking. Your quote may not be on the same basis — check what it excludes before comparing. - **A month must be a month.** Several sellers price a four-week supply and print it with a monthly symbol. Thirteen of those land in a year, not twelve. - **These are advertised prices, not walked checkouts.** They are what each seller publishes, corrected for fees and terms — not what a completed purchase charged. [Turn a headline into a true monthly figure](https://thisglp.com/tools/glp1-cost-calculator) · [How these prices are recorded](https://thisglp.com/methodology) ## Why a median is more useful here than a lowest price Injectable semaglutide runs from $49 to $525.42 a month across 374 sellers, and the median sits at $190. A spread that wide on one molecule is not a quality gradient — the cheapest and the dearest are frequently the same compounded preparation from similar pharmacies. It is a spread in what sellers think they can charge. That is why the floor is a poor benchmark. Chasing it leads to microdose products priced against other sellers’ standard doses, and to opening rates that step up as you titrate. The median tells you whether a quote is inside the market at all, which is the question a reader actually has. The same arithmetic across twelve months, and the sellers whose figure does not move as the dose does, are the two things worth checking next. Every price here is what a seller publishes, corrected — not a walked checkout. That distinction is the whole discipline of this site and it is set out in [the methodology](https://thisglp.com/methodology). Most of these products are compounded, which means they are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed; price says nothing about which preparation is which. --- # GLP-1 Titration Planner: the Ladder, and What It Costs | This GLP The approved week-by-week dose schedules for semaglutide and tirzepatide, read off the current labels — with the cost of climbing them at a flat seller against a dose-indexed one. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/glp1-titration-planner Updated: 2026-09-16 [← Tools](https://thisglp.com/tools)Dose and cost # GLP-1 Titration Planner Both of these drugs start below the dose that was studied and climb for months. That has a clinical consequence and a financial one, and the financial one is the part nobody puts in a headline: the opening dose is the dose you are on for the fewest weeks of the year, so a seller’s price at the top of the ladder matters more than its price at the bottom. By [This GLP Editorial Team](https://thisglp.com/about) Schedules read from the current prescribing information The Wegovy label ladder plotted against time: five four-week blocks climbing from 0.25 mg at week one to 2.4 mg at week seventeen, with 0.25, 0.5 and 1 mg drawn as open squares because the label lists them only as stepping doses and not as maintenance options. · WEGOVY LABEL LADDER · 0.25 · 0.5 · 1 · 1.7 · 2.4 · 1 · 5 · 9 · 13 · 17 · Week. Filled = a maintenance dose; open = a stepping dose. Wegovy escalation schedule, week by week | Weeks | Dose | What the label calls it | | --- | --- | --- | | 1–4 | 0.25 mg | initiationStarting dose. Not intended to produce weight loss — it is there to let the gut adjust. | | 5–8 | 0.5 mg | escalation | | 9–12 | 1 mg | escalation | | 13–16 | 1.7 mg | escalation | | 17+ | 2.4 mg | maintenanceThe dose STEP 1 studied, where the −14.9% mean change was measured. | Reaching 7.2 mg takes **1 weeks** on this schedule, so a buyer spends roughly **0%** of a first year below the top dose. Source: [Wegovy prescribing information, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b). ### What the ladder costs, two ways The same escalation, priced by a seller that holds one figure across every dose and by one that raises it at each step. Put in any two numbers you are comparing. Flat at every dose Monthly price $1,788 across a first year Priced by dose Opening price Rise per step $2,351 across a first year On these figures the dose-indexed seller costs **$563** more across the year, despite opening $50 lower a month. ## These are the approved products’ schedules Every step above comes from the prescribing information for Wegovy and Zepbound, not from a seller’s page. Most sellers on this site dispense a compounded preparation, and a compounding pharmacy is free to supply a different ladder entirely — which is exactly what a microdose protocol is. If a seller does not publish the strengths it dispenses, this schedule tells you what the approved product does and not what will arrive in your vial. It is also not a prescription. Escalation is decided by a clinician against how you are tolerating the drug, and both labels allow holding a dose longer or stepping back down. The schedule here is the default path, not an instruction — escalation is a clinical decision, and the ladder exists because of how the drug is tolerated on the way up. --- # Which GLP-1 sellers offer a tablet, and which only inject | This GLP Not every seller carries both molecules, and most carry one format. What each ranked seller lists by molecule and by form, so a reader wanting a tablet or wanting tirzepatide can stop reading the ones that cannot supply it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/molecule-and-format-finder Updated: 2026-10-26 [← Tools](https://thisglp.com/tools)Before you compare on price # Molecule and format finder A cheaper seller is no use if it does not carry what you came for. Of 580 ranked sellers, 475 list more than one molecule and only 113 list more than one format. Narrow by what you need before you sort by anything else. By [This GLP Editorial Team](https://thisglp.com/about) 580 ranked sellers, by catalog rather than by price [Push Health](https://thisglp.com/reviews/push-health) Semaglutide, Tirzepatide, Liraglutide, Orforglipron · as injection and tablet [FuturHealth](https://thisglp.com/reviews/futurhealth) Semaglutide, Tirzepatide, Orforglipron · as injection and tablet [Hers](https://thisglp.com/reviews/hers) Orforglipron, Semaglutide, Tirzepatide · as injection and tablet [Kin Meds](https://thisglp.com/reviews/kin-meds) Orforglipron, Semaglutide, Tirzepatide · as injection and tablet [Klinic](https://thisglp.com/reviews/klinic) Semaglutide, Tirzepatide, Orforglipron · as injection and tablet [NowPatient](https://thisglp.com/reviews/nowpatient) Liraglutide, Semaglutide, Tirzepatide · as injection and tablet [PreventiveMD](https://thisglp.com/reviews/preventivemd) Orforglipron, Semaglutide, Tirzepatide · as injection and tablet [PrideRx](https://thisglp.com/reviews/priderx) Orforglipron, Semaglutide, Tirzepatide · as injection and tablet [ShedRx](https://thisglp.com/reviews/shedrx) Orforglipron, Semaglutide, Tirzepatide · as injection and tablet [ZipHealth](https://thisglp.com/reviews/ziphealth) Semaglutide, Tirzepatide, Orforglipron · as injection and tablet [24hrDOC](https://thisglp.com/reviews/24hrdoc) Semaglutide, Tirzepatide · as injection and tablet [Alan Meds](https://thisglp.com/reviews/alan-meds) Semaglutide, Tirzepatide · as injection and tablet [Apex MD](https://thisglp.com/reviews/apex-md) Semaglutide, Tirzepatide · as injection and tablet [Ark Health](https://thisglp.com/reviews/ark-health) Semaglutide, Tirzepatide · as injection and tablet [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) Semaglutide, Tirzepatide · as injection and tablet [Bayan Health](https://thisglp.com/reviews/bayan-health) Semaglutide, Tirzepatide · as injection and tablet [BetterMe Rx](https://thisglp.com/reviews/betterme-rx) Semaglutide, Tirzepatide · as injection and tablet [Breeze Meds](https://thisglp.com/reviews/breeze-meds) Semaglutide, Tirzepatide · as injection and tablet [Broose Wellness](https://thisglp.com/reviews/broose-wellness) Semaglutide, Tirzepatide · as injection and tablet [CeliaRx](https://thisglp.com/reviews/celia-rx) Semaglutide, Tirzepatide · as injection and tablet [Claya](https://thisglp.com/reviews/claya) Semaglutide, Tirzepatide · as injection and tablet [CVS MinuteClinic](https://thisglp.com/reviews/cvs-minuteclinic) Semaglutide, Tirzepatide · as injection and tablet [Direct Meds](https://thisglp.com/reviews/direct-meds) Semaglutide, Tirzepatide · as injection and tablet [DoctorAdam](https://thisglp.com/reviews/doctoradam) Semaglutide, Tirzepatide · as injection and tablet [Dr. Arevitalize](https://thisglp.com/reviews/dr-arevitalize) Semaglutide, Tirzepatide · as injection and tablet [Edessa](https://thisglp.com/reviews/edessa) Semaglutide, Tirzepatide · as injection and tablet [ElleS](https://thisglp.com/reviews/elles) Semaglutide, Tirzepatide · as injection and tablet [Embody](https://thisglp.com/reviews/embody) Semaglutide, Tirzepatide · as injection and tablet [EmbraceRX](https://thisglp.com/reviews/embrace-rx) Semaglutide, Tirzepatide · as injection and tablet [Eve](https://thisglp.com/reviews/eve) Semaglutide, Tirzepatide · as injection and tablet [FORM](https://thisglp.com/reviews/form) Semaglutide, Tirzepatide · as injection and tablet [Glow](https://thisglp.com/reviews/glow) Semaglutide, Tirzepatide · as injection and tablet [Good Girl Rx](https://thisglp.com/reviews/good-girl-rx) Semaglutide, Tirzepatide · as injection and tablet [GoodRx](https://thisglp.com/reviews/goodrx) Orforglipron, Tirzepatide · as injection and tablet [He & She MD](https://thisglp.com/reviews/he-and-she-md) Semaglutide, Tirzepatide · as injection and tablet [HealthHub](https://thisglp.com/reviews/healthhub) Semaglutide, Tirzepatide · as injection and tablet [Healthicare](https://thisglp.com/reviews/healthicare) Semaglutide, Tirzepatide · as injection and tablet [HealthSource](https://thisglp.com/reviews/healthsource) Semaglutide, Tirzepatide · as injection and tablet [Henry Meds](https://thisglp.com/reviews/henry-meds) Semaglutide, Tirzepatide · as injection and tablet [HumeCare+](https://thisglp.com/reviews/humecare)Semaglutide, Tirzepatide · as injection and tablet [Idgie Health](https://thisglp.com/reviews/idgie-health) Semaglutide, Tirzepatide · as injection and tablet [June Health](https://thisglp.com/reviews/june-health) Semaglutide, Tirzepatide · as injection and tablet [Kina](https://thisglp.com/reviews/kina) Semaglutide, Tirzepatide · as injection and tablet [Layla](https://thisglp.com/reviews/layla) Semaglutide, Tirzepatide · as injection and tablet [LifeMD](https://thisglp.com/reviews/lifemd) Semaglutide, Tirzepatide · as injection and tablet [LifespanningRx](https://thisglp.com/reviews/lifespanningrx) Semaglutide, Tirzepatide · as injection and tablet [Lttl](https://thisglp.com/reviews/lttl) Semaglutide, Tirzepatide · as injection and tablet [Luci](https://thisglp.com/reviews/luci) Semaglutide, Tirzepatide · as injection and tablet [Luvo Health](https://thisglp.com/reviews/luvo-health) Semaglutide, Tirzepatide · as injection and tablet [MadeMed](https://thisglp.com/reviews/mademed) Semaglutide, Tirzepatide · as injection and tablet [Male Excel](https://thisglp.com/reviews/male-excel) Semaglutide, Tirzepatide · as injection and tablet [MEDGm](https://thisglp.com/reviews/medgm) Semaglutide, Tirzepatide · as injection and tablet [MediRX](https://thisglp.com/reviews/medirx) Semaglutide, Tirzepatide · as injection and tablet [MedLeanRx](https://thisglp.com/reviews/medleanrx) Semaglutide, Tirzepatide · as injection and tablet [MEDVi](https://thisglp.com/reviews/medvi) Semaglutide, Tirzepatide · as injection and tablet [Midi Health](https://thisglp.com/reviews/midi-health) Semaglutide, Tirzepatide · as injection and tablet [MyDrHank](https://thisglp.com/reviews/mydrhank) Semaglutide, Tirzepatide · as injection and tablet [Näky](https://thisglp.com/reviews/naky) Semaglutide, Tirzepatide · as injection and tablet [NEUVÉ Health](https://thisglp.com/reviews/neuve-md) Semaglutide, Tirzepatide · as injection and tablet [NoBsRx](https://thisglp.com/reviews/no-bs-rx) Semaglutide, Tirzepatide · as injection and tablet [Nolu](https://thisglp.com/reviews/nolu) Semaglutide, Tirzepatide · as injection and tablet [Nova](https://thisglp.com/reviews/nova) Semaglutide, Tirzepatide · as injection and tablet [Nu Image Medical](https://thisglp.com/reviews/nu-image-medical) Semaglutide, Tirzepatide · as injection and tablet [Nucore Health](https://thisglp.com/reviews/nucore-health) Semaglutide, Tirzepatide · as injection and tablet [Nuform Health](https://thisglp.com/reviews/nuform-health) Semaglutide, Tirzepatide · as injection and tablet [NuuVim](https://thisglp.com/reviews/nuuvim) Semaglutide, Tirzepatide · as injection and tablet [OnlyRx](https://thisglp.com/reviews/onlyrx) Semaglutide, Tirzepatide · as injection and tablet [Pepti](https://thisglp.com/reviews/pepti) Semaglutide, Tirzepatide · as injection and tablet [Pepton Health](https://thisglp.com/reviews/pepton-health) Semaglutide, Tirzepatide · as injection and tablet [Prime Doctor RX](https://thisglp.com/reviews/prime-doctor-rx) Semaglutide, Tirzepatide · as injection and tablet [Raeliva](https://thisglp.com/reviews/onlinesemaglutideorg) Semaglutide, Tirzepatide · as injection and tablet [Recovery Delivered](https://thisglp.com/reviews/recovery-delivered) Semaglutide, Tirzepatide · as injection and tablet [Revel Health](https://thisglp.com/reviews/revel-health) Semaglutide, Tirzepatide · as injection and tablet [Rila](https://thisglp.com/reviews/rila) Semaglutide, Tirzepatide · as injection and tablet [Rivo Health](https://thisglp.com/reviews/rivo-health) Semaglutide, Tirzepatide · as injection and tablet [Rixa Health](https://thisglp.com/reviews/rixa-health) Semaglutide, Tirzepatide · as injection and tablet [Roboclinic](https://thisglp.com/reviews/roboclinic) Semaglutide, Tirzepatide · as injection and tablet [Sesame Care](https://thisglp.com/reviews/sesame-care) Semaglutide, Tirzepatide · as injection and tablet [Silhouette MD](https://thisglp.com/reviews/silhouette-md) Semaglutide, Tirzepatide · as injection and tablet [Sipra](https://thisglp.com/reviews/sipra) Semaglutide, Tirzepatide · as injection and tablet [SkinnyRx](https://thisglp.com/reviews/skinnyrx) Semaglutide, Tirzepatide · as injection and tablet [Society of You](https://thisglp.com/reviews/society-of-you) Semaglutide, Tirzepatide · as injection and tablet [Somi Health](https://thisglp.com/reviews/somi-health) Semaglutide, Tirzepatide · as injection and tablet [Strut Health](https://thisglp.com/reviews/strut-health) Semaglutide, Tirzepatide · as injection and tablet [Synergy Rx](https://thisglp.com/reviews/synergy-rx) Semaglutide, Tirzepatide · as injection and tablet [Tablet Health](https://thisglp.com/reviews/tablet-health) Semaglutide, Tirzepatide · as injection and tablet [TelePeptide](https://thisglp.com/reviews/telepeptide) Semaglutide, Tirzepatide · as injection and tablet [Tomorrow](https://thisglp.com/reviews/tomorrow) Semaglutide, Tirzepatide · as injection and tablet [Totara Health](https://thisglp.com/reviews/totara-health) Semaglutide, Tirzepatide · as injection and tablet [Tru2u](https://thisglp.com/reviews/tru2u) Semaglutide, Tirzepatide · as injection and tablet [Try Ageless](https://thisglp.com/reviews/try-ageless) Semaglutide, Tirzepatide · as injection and tablet [Vaylen](https://thisglp.com/reviews/vaylen) Semaglutide, Tirzepatide · as injection and tablet [Velvet Rx](https://thisglp.com/reviews/velvet-rx) Semaglutide, Tirzepatide · as injection and tablet [VigorMeds](https://thisglp.com/reviews/vigormeds) Semaglutide, Tirzepatide · as injection and tablet [Virgo-Meds](https://thisglp.com/reviews/virgo-meds) Semaglutide, Tirzepatide · as injection and tablet [VirtualCare2Go](https://thisglp.com/reviews/virtualcare2go) Semaglutide, Tirzepatide · as injection and tablet [Vital Edge](https://thisglp.com/reviews/vital-edge) Semaglutide, Tirzepatide · as injection and tablet [Vital Step](https://thisglp.com/reviews/vital-step) Semaglutide, Tirzepatide · as injection and tablet [WeightWatchers Clinic](https://thisglp.com/reviews/weight-watchers) Semaglutide, Tirzepatide · as injection and tablet [Wholesome Clinic](https://thisglp.com/reviews/wholesome-clinic) Semaglutide, Tirzepatide · as injection and tablet [Youth & Soul](https://thisglp.com/reviews/youth-and-soul) Semaglutide, Tirzepatide · as injection and tablet [Zenbody](https://thisglp.com/reviews/zenbody) Semaglutide, Tirzepatide · as injection and tablet [Zera Health](https://thisglp.com/reviews/zera-health) Semaglutide, Tirzepatide · as injection and tablet [ZYP Medical](https://thisglp.com/reviews/zyp-medical) Semaglutide, Tirzepatide · as injection and tablet [Alloy](https://thisglp.com/reviews/alloy) Liraglutide, Semaglutide, Tirzepatide · as injection [Bloom MD](https://thisglp.com/reviews/bloommd) Liraglutide, Semaglutide, Tirzepatide · as injection [Enara Health](https://thisglp.com/reviews/enara-health) Semaglutide, Tirzepatide, Liraglutide · as injection [Form Health](https://thisglp.com/reviews/form-health) Semaglutide, Tirzepatide, Liraglutide · as injection [JM Integrated Health](https://thisglp.com/reviews/jm-integrated-health) Semaglutide, Tirzepatide, Liraglutide · as injection [Klarity Health](https://thisglp.com/reviews/klarity-health) Semaglutide, Tirzepatide, Liraglutide · as injection [MDLive](https://thisglp.com/reviews/mdlive) Semaglutide, Tirzepatide, Liraglutide · as injection [Nurx](https://thisglp.com/reviews/nurx) Semaglutide, Tirzepatide, Liraglutide · as injection [10Rx](https://thisglp.com/reviews/10rx) Semaglutide, Tirzepatide · as injection [50 Stars Health](https://thisglp.com/reviews/livv) Semaglutide, Tirzepatide · as injection [AbundRX](https://thisglp.com/reviews/abundrx) Semaglutide, Tirzepatide · as injection [Actin](https://thisglp.com/reviews/actin) Semaglutide, Tirzepatide · as injection [AgelessRx](https://thisglp.com/reviews/agelessrx) Semaglutide, Tirzepatide · as injection [AHBARx](https://thisglp.com/reviews/ahbarx) Semaglutide, Tirzepatide · as injection [Alinwell](https://thisglp.com/reviews/alinwell) Semaglutide, Tirzepatide · as injection [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) Semaglutide, Tirzepatide · as injection [altRX](https://thisglp.com/reviews/altrx) Semaglutide, Tirzepatide · as injection [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) Semaglutide, Tirzepatide · as injection [AlyveRx](https://thisglp.com/reviews/alyverx) Semaglutide, Tirzepatide · as injection [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) Orforglipron · as injection and tablet [Ambiante Health & Wellness](https://thisglp.com/reviews/ambiante-health-wellness) Semaglutide, Tirzepatide · as injection [Amble](https://thisglp.com/reviews/amble) Semaglutide, Tirzepatide · as injection [Andrew Meds](https://thisglp.com/reviews/andrew-meds) Semaglutide, Tirzepatide · as injection [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) Semaglutide, Tirzepatide · as injection [Arc-1](https://thisglp.com/reviews/arc-1) Semaglutide, Tirzepatide · as injection [ARSYNL Rx](https://thisglp.com/reviews/arsynl-rx) Semaglutide, Tirzepatide · as injection [Ascend Medical](https://thisglp.com/reviews/ascend-medical) Semaglutide, Tirzepatide · as injection [AskRx](https://thisglp.com/reviews/ask-rx) Semaglutide, Tirzepatide · as injection [Aspen](https://thisglp.com/reviews/aspen-health) Semaglutide, Tirzepatide · as injection [Aspire Health](https://thisglp.com/reviews/aspire-health) Semaglutide, Tirzepatide · as injection [Auren Rx](https://thisglp.com/reviews/auren-rx) Semaglutide, Tirzepatide · as injection [AVARA Rx](https://thisglp.com/reviews/avara-rx) Semaglutide, Tirzepatide · as injection [AVArx](https://thisglp.com/reviews/avarx) Semaglutide, Tirzepatide · as injection [Avono Health](https://thisglp.com/reviews/avono-health) Semaglutide, Tirzepatide · as injection [AZ Health](https://thisglp.com/reviews/az-health) Semaglutide, Tirzepatide · as injection [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) Semaglutide, Tirzepatide · as injection [Believe Health](https://thisglp.com/reviews/believe-health) Semaglutide, Tirzepatide · as injection [Belle Health](https://thisglp.com/reviews/belle-health) Semaglutide, Tirzepatide · as injection [Better U Care](https://thisglp.com/reviews/better-u-care) Semaglutide, Tirzepatide · as injection [BeyondMD](https://thisglp.com/reviews/beyondmd) Semaglutide, Tirzepatide · as injection [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) Semaglutide, Tirzepatide · as injection [BiltRx](https://thisglp.com/reviews/biltrx) Semaglutide, Tirzepatide · as injection [Bionomy Health](https://thisglp.com/reviews/bionomy-health) Semaglutide, Tirzepatide · as injection [Bioverse](https://thisglp.com/reviews/bioverse) Semaglutide, Tirzepatide · as injection [Blis MD](https://thisglp.com/reviews/blis-md) Semaglutide, Tirzepatide · as injection [Bliv](https://thisglp.com/reviews/bliv) Semaglutide, Tirzepatide · as injection [BloomWell Rx](https://thisglp.com/reviews/bloomwell-rx) Semaglutide, Tirzepatide · as injection [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) Semaglutide, Tirzepatide · as injection [Blue Sky MD](https://thisglp.com/reviews/blue-sky-md) Semaglutide, Tirzepatide · as injection [bmiMD](https://thisglp.com/reviews/bmimd) Semaglutide, Tirzepatide · as injection [Bodi Envi](https://thisglp.com/reviews/bodi-envi) Semaglutide, Tirzepatide · as injection [Bodybuilding Health+](https://thisglp.com/reviews/bodybuilding-health-plus)Semaglutide, Tirzepatide · as injection [Bon Health](https://thisglp.com/reviews/bon-health) Semaglutide, Tirzepatide · as injection [boostAGErx](https://thisglp.com/reviews/boostagerx) Semaglutide, Tirzepatide · as injection [Boston Medical Group](https://thisglp.com/reviews/boston-medical-group) Semaglutide, Tirzepatide · as injection [Brello Health](https://thisglp.com/reviews/brello-health) Semaglutide, Tirzepatide · as injection [Brightmeds](https://thisglp.com/reviews/brightmeds) Semaglutide, Tirzepatide · as injection [CaliberRx](https://thisglp.com/reviews/caliberrx) Semaglutide, Tirzepatide · as injection [California Trim Clinic](https://thisglp.com/reviews/california-trim-clinic) Semaglutide, Tirzepatide · as injection [Call-On-Doc](https://thisglp.com/reviews/call-on-doc) Semaglutide, Tirzepatide · as injection [Candor Rx](https://thisglp.com/reviews/candor-rx) Semaglutide, Tirzepatide · as injection [CAPO Health](https://thisglp.com/reviews/capo-health) Semaglutide, Tirzepatide · as injection [Care Bare Rx](https://thisglp.com/reviews/care-bare-rx) Semaglutide, Tirzepatide · as injection [Care Clinics](https://thisglp.com/reviews/care-clinics) Semaglutide, Tirzepatide · as injection [Carocare Wellness](https://thisglp.com/reviews/carocare-wellness) Semaglutide, Tirzepatide · as injection [Center for Medical Weight Loss (CMWL)](https://thisglp.com/reviews/center-for-medical-weight-loss)Semaglutide, Tirzepatide · as injection [Chia](https://thisglp.com/reviews/chia-health) Semaglutide, Tirzepatide · as injection [Cielo](https://thisglp.com/reviews/cielo) Semaglutide, Tirzepatide · as injection [Citizen Meds](https://thisglp.com/reviews/citizen-meds) Semaglutide, Tirzepatide · as injection [Clinic Secret](https://thisglp.com/reviews/clinic-secret) Semaglutide, Tirzepatide · as injection [Clume Health](https://thisglp.com/reviews/clume-health) Semaglutide, Tirzepatide · as injection [CLYR Health](https://thisglp.com/reviews/clyr-health) Semaglutide, Tirzepatide · as injection [Coby Health](https://thisglp.com/reviews/coby-health) Semaglutide, Tirzepatide · as injection [Coivas](https://thisglp.com/reviews/coivas) Semaglutide, Tirzepatide · as injection [Collective](https://thisglp.com/reviews/collective) Semaglutide, Tirzepatide · as injection [Concierge MD LA](https://thisglp.com/reviews/concierge-md-la) Semaglutide, Tirzepatide · as injection [Contour Health](https://thisglp.com/reviews/contour-health) Semaglutide, Tirzepatide · as injection [Cora Health](https://thisglp.com/reviews/cora-health) Semaglutide, Tirzepatide · as injection [CoraDoc](https://thisglp.com/reviews/coradoc) Semaglutide, Tirzepatide · as injection [CoreAge Rx](https://thisglp.com/reviews/coreage-rx) Semaglutide, Tirzepatide · as injection [Corsica Health](https://thisglp.com/reviews/corsica-health) Semaglutide, Tirzepatide · as injection [Curex](https://thisglp.com/reviews/curex) Semaglutide, Tirzepatide · as tablet [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) Semaglutide, Tirzepatide · as injection [Dollar Dad Club](https://thisglp.com/reviews/dollar-dad-club) Semaglutide · as injection and tablet [Dr. Gillis' Wellness Center](https://thisglp.com/reviews/dr-gillis-wellness-center) Semaglutide, Tirzepatide · as injection [DrBrainRx](https://thisglp.com/reviews/drbrainrx) Semaglutide, Tirzepatide · as injection [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) Semaglutide, Tirzepatide · as injection [DudeMeds](https://thisglp.com/reviews/dudemeds) Semaglutide, Tirzepatide · as injection [Eden](https://thisglp.com/reviews/eden) Semaglutide, Tirzepatide · as injection [EdgeRx](https://thisglp.com/reviews/edgerx) Semaglutide, Tirzepatide · as injection [Effecty](https://thisglp.com/reviews/effecty) Semaglutide, Tirzepatide · as injection [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) Semaglutide, Tirzepatide · as injection [Elevate Health](https://thisglp.com/reviews/elevate-health) Semaglutide, Tirzepatide · as injection [Elevated Health](https://thisglp.com/reviews/elevated-health) Semaglutide, Tirzepatide · as injection [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) Semaglutide, Tirzepatide · as injection [EllieMD](https://thisglp.com/reviews/elliemd) Semaglutide, Tirzepatide · as injection [Eloria](https://thisglp.com/reviews/eloria) Semaglutide · as injection and tablet [Enhance MD](https://thisglp.com/reviews/enhance-md) Semaglutide, Tirzepatide · as injection [EOS Health](https://thisglp.com/reviews/eos) Semaglutide, Tirzepatide · as injection [Evernow](https://thisglp.com/reviews/evernow) Semaglutide, Tirzepatide · as injection [EverPrime](https://thisglp.com/reviews/everprime) Semaglutide, Tirzepatide · as injection [EverSlim](https://thisglp.com/reviews/everslim) Semaglutide, Tirzepatide · as injection [Eviora MD](https://thisglp.com/reviews/eviora-md) Semaglutide, Tirzepatide · as injection [Factor Health MD](https://thisglp.com/reviews/factor-health-md) Semaglutide, Tirzepatide · as injection [Fella Health](https://thisglp.com/reviews/fella-health) Semaglutide, Tirzepatide · as injection [Fidelity Medical Clinic](https://thisglp.com/reviews/fidelity-medical-clinic) Semaglutide, Tirzepatide · as injection [Fierce Health](https://thisglp.com/reviews/fierce-health) Semaglutide, Tirzepatide · as injection [Fifty 410](https://thisglp.com/reviews/fifty-410) Semaglutide, Tirzepatide · as injection [FitFlow](https://thisglp.com/reviews/fitflow) Semaglutide, Tirzepatide · as injection [Fitish](https://thisglp.com/reviews/fitish) Semaglutide, Tirzepatide · as injection [Fitness RX](https://thisglp.com/reviews/fitness-rx) Semaglutide, Tirzepatide · as injection [Fitstry](https://thisglp.com/reviews/fitstry) Semaglutide, Tirzepatide · as injection [FMmeds](https://thisglp.com/reviews/fmmeds) Semaglutide, Tirzepatide · as injection [FormBlends](https://thisglp.com/reviews/formblends) Semaglutide, Tirzepatide · as injection [FormidableMD](https://thisglp.com/reviews/formidablemd) Semaglutide, Tirzepatide · as injection [Found](https://thisglp.com/reviews/found) Semaglutide, Tirzepatide · as injection [Found Youth](https://thisglp.com/reviews/found-youth) Semaglutide, Tirzepatide · as injection [Framework](https://thisglp.com/reviews/framework) Semaglutide, Tirzepatide · as injection [Fresh Day Meds](https://thisglp.com/reviews/fresh-day) Semaglutide, Tirzepatide · as injection [Freya Meds](https://thisglp.com/reviews/freya-meds) Semaglutide, Tirzepatide · as injection [Fridays](https://thisglp.com/reviews/fridays) Semaglutide, Tirzepatide · as injection [Gala](https://thisglp.com/reviews/gala) Semaglutide, Tirzepatide · as injection [Gaya Wellness](https://thisglp.com/reviews/gaya-wellness) Semaglutide, Tirzepatide · as injection [Genesis Health](https://thisglp.com/reviews/genesis) Semaglutide, Tirzepatide · as injection [Get Thin MD](https://thisglp.com/reviews/get-thin-md) Semaglutide, Tirzepatide · as injection [GetRelief Rx](https://thisglp.com/reviews/getrelief-rx) Semaglutide, Tirzepatide · as tablet [Gimme Care](https://thisglp.com/reviews/gimme-care) Semaglutide, Tirzepatide · as injection [Glam Health](https://thisglp.com/reviews/glam-health) Semaglutide, Tirzepatide · as injection [Go Vida Plena](https://thisglp.com/reviews/go-vida-plena) Semaglutide, Tirzepatide · as injection [GOAL.MD](https://thisglp.com/reviews/goal-md) Semaglutide, Tirzepatide · as injection [GobyMeds](https://thisglp.com/reviews/gobymeds) Semaglutide, Tirzepatide · as injection [Goldspan Health](https://thisglp.com/reviews/goldspan-health) Semaglutide, Tirzepatide · as injection [Good Life Meds](https://thisglp.com/reviews/good-life-meds) Semaglutide, Tirzepatide · as injection [GoodLife Health](https://thisglp.com/reviews/goodlife-health) Semaglutide, Tirzepatide · as injection [Green Cap Health](https://thisglp.com/reviews/green-cap-health) Semaglutide, Tirzepatide · as injection [Happy Care Meds](https://thisglp.com/reviews/happy-care-meds) Semaglutide, Tirzepatide · as injection [Harbor](https://thisglp.com/reviews/harbor) Semaglutide, Tirzepatide · as injection [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) Semaglutide, Tirzepatide · as injection [Harper Meds](https://thisglp.com/reviews/harper-meds) Semaglutide, Tirzepatide · as injection [HealFastRx](https://thisglp.com/reviews/healfast) Semaglutide, Tirzepatide · as injection [Heally](https://thisglp.com/reviews/heally) Semaglutide, Tirzepatide · as injection [HealthOn](https://thisglp.com/reviews/healthon) Semaglutide, Tirzepatide · as injection [HealthRX](https://thisglp.com/reviews/healthrx) Semaglutide, Tirzepatide · as injection [HeliMeds](https://thisglp.com/reviews/helimeds) Semaglutide, Tirzepatide · as injection [Helix Wellness Rx](https://thisglp.com/reviews/helix-wellness-rx) Semaglutide, Tirzepatide · as injection [HelloWellness](https://thisglp.com/reviews/hellowellness) Semaglutide, Tirzepatide · as injection [Heros Health](https://thisglp.com/reviews/heros-health) Semaglutide, Tirzepatide · as injection [Heva Health](https://thisglp.com/reviews/heva-health) Semaglutide, Tirzepatide · as injection [Hims](https://thisglp.com/reviews/hims) Semaglutide, Tirzepatide · as injection [Immortals](https://thisglp.com/reviews/immortals) Semaglutide, Tirzepatide · as injection [Independent Wellness](https://thisglp.com/reviews/independent-wellness) Semaglutide, Tirzepatide · as injection [Injectco](https://thisglp.com/reviews/injectco) Semaglutide, Tirzepatide · as injection [InstaRX](https://thisglp.com/reviews/instarx) Semaglutide, Tirzepatide · as injection [Intimate Rose](https://thisglp.com/reviews/intimate-rose) Semaglutide, Tirzepatide · as injection [Invigor Medical](https://thisglp.com/reviews/invigor-medical) Semaglutide, Tirzepatide · as injection [Invyncible](https://thisglp.com/reviews/invyncible) Semaglutide, Tirzepatide · as injection [Iron Med RX](https://thisglp.com/reviews/iron-med-rx) Semaglutide · as injection and tablet [iThriveMD](https://thisglp.com/reviews/ithrivemd) Semaglutide, Tirzepatide · as injection [Ivim Health](https://thisglp.com/reviews/ivim-health) Semaglutide, Tirzepatide · as injection [Ivologist](https://thisglp.com/reviews/ivologist) Semaglutide, Tirzepatide · as injection [Ivy Rx](https://thisglp.com/reviews/ivy-rx) Semaglutide, Tirzepatide · as injection [Jently](https://thisglp.com/reviews/jently) Semaglutide, Tirzepatide · as injection [Joey Med](https://thisglp.com/reviews/joey-med) Semaglutide, Tirzepatide · as injection [Joi + Blokes](https://thisglp.com/reviews/joi-and-blokes) Semaglutide, Tirzepatide · as injection [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) Semaglutide, Tirzepatide · as injection [Jyra Health](https://thisglp.com/reviews/jyra-health) Semaglutide, Tirzepatide · as injection [KairoRx](https://thisglp.com/reviews/kairorx) Semaglutide, Tirzepatide · as injection [KERNX Health](https://thisglp.com/reviews/kernx-health) Semaglutide, Tirzepatide · as injection [Kongo](https://thisglp.com/reviews/kongo) Semaglutide, Tirzepatide · as injection [Kova](https://thisglp.com/reviews/kova) Semaglutide, Tirzepatide · as injection [LaSara Medical Group](https://thisglp.com/reviews/lasara) Semaglutide, Tirzepatide · as injection [Lavender Sky Health](https://thisglp.com/reviews/lavender-sky-health) Semaglutide, Tirzepatide · as injection [Lean Meds](https://thisglp.com/reviews/leanmeds) Semaglutide, Tirzepatide · as injection [Lean Rx](https://thisglp.com/reviews/lean-rx) Semaglutide, Tirzepatide · as injection [LeanDose](https://thisglp.com/reviews/leandose) Semaglutide, Tirzepatide · as injection [Lemonaid Health](https://thisglp.com/reviews/lemonaid-health) Semaglutide, Tirzepatide · as injection [LevelsRx](https://thisglp.com/reviews/levelsrx) Semaglutide, Tirzepatide · as injection [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) Semaglutide, Tirzepatide · as injection [Levers Health](https://thisglp.com/reviews/levers-health) Semaglutide, Tirzepatide · as injection [Liberty](https://thisglp.com/reviews/liberty) Semaglutide, Tirzepatide · as injection [LifeRx.md](https://thisglp.com/reviews/liferx) Semaglutide, Tirzepatide · as injection [Lighter You](https://thisglp.com/reviews/lighter-you) Semaglutide, Tirzepatide · as injection [LillyDirect Foundayo](https://thisglp.com/reviews/lillydirect-foundayo) Orforglipron · as injection and tablet [Liv Body](https://thisglp.com/reviews/liv-body) Semaglutide, Tirzepatide · as injection [Livbetr](https://thisglp.com/reviews/livbetr) Semaglutide, Tirzepatide · as injection [Live Vital](https://thisglp.com/reviews/live-vital) Semaglutide, Tirzepatide · as injection [Livea](https://thisglp.com/reviews/livea) Semaglutide, Tirzepatide · as injection [Longevity Meds](https://thisglp.com/reviews/longevity-meds) Semaglutide, Tirzepatide · as injection [Longevixx](https://thisglp.com/reviews/longevixx) Semaglutide, Tirzepatide · as injection [LovelyMeds](https://thisglp.com/reviews/lovelymeds) Semaglutide, Tirzepatide · as injection [Luma Health Co](https://thisglp.com/reviews/luma-health) Semaglutide, Tirzepatide · as injection [Luma Meds](https://thisglp.com/reviews/luma-meds) Semaglutide, Tirzepatide · as injection [LumiMeds](https://thisglp.com/reviews/lumimeds) Semaglutide, Tirzepatide · as injection [Lumora](https://thisglp.com/reviews/lumora) Semaglutide, Tirzepatide · as injection [LVNG RX](https://thisglp.com/reviews/lvng-rx) Semaglutide, Tirzepatide · as injection [Lyfe Rx](https://thisglp.com/reviews/lyfe-rx) Semaglutide, Tirzepatide · as injection [MANÜ Telehealth](https://thisglp.com/reviews/manu-telehealth) Semaglutide, Tirzepatide · as injection [Maves](https://thisglp.com/reviews/maves) Semaglutide, Tirzepatide · as injection [Maximus](https://thisglp.com/reviews/maximus-tribe) Semaglutide, Tirzepatide · as injection [MaxLife](https://thisglp.com/reviews/maxlife) Semaglutide, Tirzepatide · as injection [MD Total Wellness](https://thisglp.com/reviews/mdtw) Semaglutide, Tirzepatide · as injection [MD Trim Clinic](https://thisglp.com/reviews/md-trim-clinic) Semaglutide, Tirzepatide · as injection [MDExam](https://thisglp.com/reviews/mdexam) Semaglutide, Tirzepatide · as injection [Measured](https://thisglp.com/reviews/measured) Semaglutide, Tirzepatide · as injection [Medivive](https://thisglp.com/reviews/medivive) Semaglutide, Tirzepatide · as injection [Medro](https://thisglp.com/reviews/medro) Semaglutide, Tirzepatide · as injection [Medsol RX](https://thisglp.com/reviews/medsol-rx) Semaglutide, Tirzepatide · as injection [Meli Health](https://thisglp.com/reviews/meli-health) Semaglutide, Tirzepatide · as injection [Metabolic Rx](https://thisglp.com/reviews/metabolic-rx) Semaglutide, Tirzepatide · as injection [Metabolyz](https://thisglp.com/reviews/metabolyz) Semaglutide, Tirzepatide · as injection [Metaboost Rx](https://thisglp.com/reviews/metaboost-rx) Semaglutide, Tirzepatide · as injection [Mevo Health](https://thisglp.com/reviews/mevo-health) Semaglutide, Tirzepatide · as injection [Mint Med](https://thisglp.com/reviews/mint-med) Semaglutide, Tirzepatide · as injection [Mint Medical Clinic](https://thisglp.com/reviews/mint-medical) Semaglutide, Tirzepatide · as injection [Mochi Health](https://thisglp.com/reviews/mochi-health) Semaglutide, Tirzepatide · as injection [Mondae](https://thisglp.com/reviews/mondae) Semaglutide, Tirzepatide · as injection [MyFastRx](https://thisglp.com/reviews/myfastrx) Semaglutide, Tirzepatide · as injection [MyStart Health](https://thisglp.com/reviews/mystart-health) Semaglutide, Tirzepatide · as injection [NativeMed](https://thisglp.com/reviews/nativemed) Semaglutide, Tirzepatide · as injection [Navio MD](https://thisglp.com/reviews/navio-md) Semaglutide, Tirzepatide · as injection [Neo Soma Healthcare](https://thisglp.com/reviews/neo-soma-healthcare) Semaglutide, Tirzepatide · as injection [New Wave Health](https://thisglp.com/reviews/new-wave-health) Semaglutide, Tirzepatide · as injection [NewSelf](https://thisglp.com/reviews/newself) Semaglutide, Tirzepatide · as injection [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) Semaglutide, Tirzepatide · as injection [NexLife](https://thisglp.com/reviews/nexlife) Semaglutide, Tirzepatide · as injection [Next Vial](https://thisglp.com/reviews/next-vial) Semaglutide, Tirzepatide · as injection [NextMeds](https://thisglp.com/reviews/nextmeds) Semaglutide, Tirzepatide · as injection [NiceRx](https://thisglp.com/reviews/nicerx) Semaglutide, Tirzepatide · as injection [Nirwana Health](https://thisglp.com/reviews/nirwana-health) Semaglutide, Tirzepatide · as injection [Noom](https://thisglp.com/reviews/noom) Semaglutide, Tirzepatide · as injection [Nova MD](https://thisglp.com/reviews/nova-md) Semaglutide, Tirzepatide · as injection [Novi](https://thisglp.com/reviews/novi) Semaglutide, Tirzepatide · as injection [NovoCare Pharmacy](https://thisglp.com/reviews/novocare-pharmacy) Semaglutide · as injection and tablet [NP2GO](https://thisglp.com/reviews/np2go) Semaglutide, Tirzepatide · as injection [NuBloom](https://thisglp.com/reviews/nubloom) Semaglutide, Tirzepatide · as injection [NuDay Rx](https://thisglp.com/reviews/nuday-rx) Semaglutide, Tirzepatide · as injection [NuviaRx](https://thisglp.com/reviews/nuviarx) Semaglutide, Tirzepatide · as injection [Oak](https://thisglp.com/reviews/oak) Semaglutide, Tirzepatide · as injection [Obu Health](https://thisglp.com/reviews/obu-health) Semaglutide, Tirzepatide · as injection [Omzo](https://thisglp.com/reviews/omzo) Semaglutide, Tirzepatide · as injection [Ondra Health](https://thisglp.com/reviews/ondra-health) Semaglutide, Tirzepatide · as injection [Onyx Weight Loss](https://thisglp.com/reviews/onyx-weight-loss) Semaglutide, Tirzepatide · as injection [Open Water Rx](https://thisglp.com/reviews/open-water-rx) Semaglutide, Tirzepatide · as injection [Optimized Health](https://thisglp.com/reviews/optimized-health) Semaglutide, Tirzepatide · as injection [Options Medical Weight Loss](https://thisglp.com/reviews/options-medical-weight-loss) Semaglutide, Tirzepatide · as injection [OrderlyMeds](https://thisglp.com/reviews/orderlymeds) Semaglutide, Tirzepatide · as injection [Oria Meds](https://thisglp.com/reviews/oria-meds) Semaglutide, Tirzepatide · as injection [OurView Health](https://thisglp.com/reviews/ourview-health) Semaglutide, Tirzepatide · as injection [Oxford's Medical Weight Loss (The Calibrate Clinic)](https://thisglp.com/reviews/the-calibrate-clinic)Semaglutide, Tirzepatide · as injection [Ozari Health](https://thisglp.com/reviews/ozari-health) Semaglutide, Tirzepatide · as injection [Pallas Health](https://thisglp.com/reviews/pallas-health) Semaglutide, Tirzepatide · as injection [PauseRX](https://thisglp.com/reviews/pauserx) Semaglutide, Tirzepatide · as injection [PCOS Sisters](https://thisglp.com/reviews/pcos-sisters) Semaglutide, Tirzepatide · as injection [Peak Wellness](https://thisglp.com/reviews/peak-wellness) Semaglutide, Tirzepatide · as injection [PepHaūs](https://thisglp.com/reviews/pephaus) Semaglutide, Tirzepatide · as injection [PeterMD](https://thisglp.com/reviews/petermd) Semaglutide, Tirzepatide · as injection [Piper](https://thisglp.com/reviews/piper) Semaglutide, Tirzepatide · as injection [PlexusDx](https://thisglp.com/reviews/plexusdx) Semaglutide, Tirzepatide · as injection [PlushCare](https://thisglp.com/reviews/plushcare) Semaglutide, Tirzepatide · as injection [Pomegranate Health](https://thisglp.com/reviews/pomegranate-health) Semaglutide, Tirzepatide · as injection [Potere Health MD](https://thisglp.com/reviews/potere-health-md) Semaglutide, Tirzepatide · as injection [Precision Telemed](https://thisglp.com/reviews/precision-telemed) Semaglutide, Tirzepatide · as injection [Premium Health](https://thisglp.com/reviews/premium-health) Semaglutide, Tirzepatide · as injection [PrescribedRX](https://thisglp.com/reviews/prescribedrx) Semaglutide, Tirzepatide · as injection [Prescriva](https://thisglp.com/reviews/prescriva) Semaglutide, Tirzepatide · as injection [Primary Clinic (Direct GLP)](https://thisglp.com/reviews/primary-clinic)Semaglutide, Tirzepatide · as injection [Prime Health](https://thisglp.com/reviews/prime-health) Semaglutide, Tirzepatide · as injection [ReadyRx](https://thisglp.com/reviews/readyrx) Semaglutide, Tirzepatide · as injection [Refills](https://thisglp.com/reviews/refills) Semaglutide, Tirzepatide · as injection [ReflexMD](https://thisglp.com/reviews/reflexmd) Semaglutide, Tirzepatide · as injection [Regenics](https://thisglp.com/reviews/regenics) Semaglutide, Tirzepatide · as injection [Rehydra+ Wellness](https://thisglp.com/reviews/rehydra-plus) Semaglutide, Tirzepatide · as injection [Rejuve Meds](https://thisglp.com/reviews/rejuve-meds) Semaglutide, Tirzepatide · as injection [Remedy Meds](https://thisglp.com/reviews/remedy-meds) Semaglutide, Tirzepatide · as injection [REMEVi](https://thisglp.com/reviews/remevi) Semaglutide, Tirzepatide · as injection [Remi Meds](https://thisglp.com/reviews/remi-meds) Semaglutide, Tirzepatide · as injection [Remote Pharmacy](https://thisglp.com/reviews/remote-pharmacy) Semaglutide, Tirzepatide · as injection [Renlo Health](https://thisglp.com/reviews/renlo-health) Semaglutide, Tirzepatide · as injection [RENN Health](https://thisglp.com/reviews/renn-health) Semaglutide, Tirzepatide · as injection [Rese Wellness](https://thisglp.com/reviews/rese-wellness) Semaglutide, Tirzepatide · as injection [Reset Solutions](https://thisglp.com/reviews/reset-solutions) Semaglutide, Tirzepatide · as injection [RestorLife Med](https://thisglp.com/reviews/restorlife-med) Semaglutide, Tirzepatide · as injection [Revel RX](https://thisglp.com/reviews/revel-rx) Semaglutide, Tirzepatide · as injection [Revive Meds](https://thisglp.com/reviews/revive-meds) Semaglutide, Tirzepatide · as injection [Rewinding RX](https://thisglp.com/reviews/rewinding-rx) Semaglutide, Tirzepatide · as injection [Rex MD](https://thisglp.com/reviews/rex-md) Semaglutide · as injection and tablet [Risen Labs](https://thisglp.com/reviews/risen-labs) Semaglutide, Tirzepatide · as injection [Rivas Medical Weight Loss](https://thisglp.com/reviews/rivas-medical) Semaglutide, Tirzepatide · as injection [RNK Health](https://thisglp.com/reviews/myrnk) Semaglutide, Tirzepatide · as injection [Ro](https://thisglp.com/reviews/ro) Orforglipron · as injection and tablet [Robinhood Telehealth](https://thisglp.com/reviews/robinhood-telehealth) Semaglutide, Tirzepatide · as injection [Roen Rx](https://thisglp.com/reviews/roen-rx) Semaglutide, Tirzepatide · as injection [RX Bella](https://thisglp.com/reviews/rx-bella) Semaglutide, Tirzepatide · as injection [Rx.com](https://thisglp.com/reviews/rx-com) Semaglutide, Tirzepatide · as injection [RxION Health](https://thisglp.com/reviews/rxion-health) Semaglutide, Tirzepatide · as injection [RxPepsDirect](https://thisglp.com/reviews/rxpepsdirect) Semaglutide, Tirzepatide · as injection [RxPros](https://thisglp.com/reviews/rxpros) Semaglutide, Tirzepatide · as injection [RxSaludable](https://thisglp.com/reviews/rxsaludable) Semaglutide, Tirzepatide · as injection [RxSpan MD](https://thisglp.com/reviews/rxspan-md) Semaglutide, Tirzepatide · as injection [Rylo Health](https://thisglp.com/reviews/rylo-health) Semaglutide, Tirzepatide · as injection [Ryze Rx](https://thisglp.com/reviews/ryze-rx) Semaglutide, Tirzepatide · as injection [Science & Co](https://thisglp.com/reviews/science-and-co) Semaglutide, Tirzepatide · as injection [Semaglutide Online](https://thisglp.com/reviews/semaglutide-online) Semaglutide, Tirzepatide · as injection [SexyMD](https://thisglp.com/reviews/sexymd) Semaglutide, Tirzepatide · as injection [Shapely](https://thisglp.com/reviews/shapely) Semaglutide, Tirzepatide · as injection [Signos](https://thisglp.com/reviews/signos) Semaglutide, Tirzepatide · as injection [SnagRx](https://thisglp.com/reviews/snagrx) Semaglutide, Tirzepatide · as injection [Somira Health](https://thisglp.com/reviews/somira-health) Semaglutide, Tirzepatide · as injection [Sommar Club](https://thisglp.com/reviews/sommar-club) Semaglutide, Tirzepatide · as injection [Southern Vitality and Weight Loss](https://thisglp.com/reviews/southern-vitality-weight-loss) Semaglutide, Tirzepatide · as injection [Sprout Health](https://thisglp.com/reviews/sprout-health) Semaglutide, Tirzepatide · as injection [Spry](https://thisglp.com/reviews/spry) Semaglutide, Tirzepatide · as injection [StackMD](https://thisglp.com/reviews/stackmd) Semaglutide, Tirzepatide · as injection [Steady State Health](https://thisglp.com/reviews/steady-state-health) Semaglutide, Tirzepatide · as injection [Sumbare Wellness](https://thisglp.com/reviews/sumbare-wellness) Semaglutide, Tirzepatide · as injection [Sunlight](https://thisglp.com/reviews/sunlight) Semaglutide, Tirzepatide · as injection [Super Healthy Rx](https://thisglp.com/reviews/super-healthy-rx) Semaglutide, Tirzepatide · as injection [Superior Remedies](https://thisglp.com/reviews/superior-remedies) Semaglutide, Tirzepatide · as injection [SurpassMD](https://thisglp.com/reviews/surpassmd) Semaglutide, Tirzepatide · as injection [SynergenX Health](https://thisglp.com/reviews/synergenx) Semaglutide, Tirzepatide · as injection [TeleCareSpot](https://thisglp.com/reviews/telecarespot) Semaglutide, Tirzepatide · as injection [TeleClinic](https://thisglp.com/reviews/teleclinic) Semaglutide, Tirzepatide · as injection [TeleDocs360](https://thisglp.com/reviews/teledocs360) Semaglutide, Tirzepatide · as injection [TeleHealth Weight Solutions](https://thisglp.com/reviews/telehealth-weight-solutions) Semaglutide, Tirzepatide · as injection [Teleios Health](https://thisglp.com/reviews/teleios-health) Semaglutide, Tirzepatide · as injection [TeleZen MD](https://thisglp.com/reviews/telezen-md) Semaglutide, Tirzepatide · as injection [Telos Rx](https://thisglp.com/reviews/telos-rx) Semaglutide, Tirzepatide · as injection [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) Semaglutide, Tirzepatide · as injection [The Edit](https://thisglp.com/reviews/the-edit) Semaglutide, Tirzepatide · as injection [The Protocole](https://thisglp.com/reviews/the-protocole) Semaglutide, Tirzepatide · as injection [The Virtual NP](https://thisglp.com/reviews/the-virtual-np) Semaglutide, Tirzepatide · as injection [TMates](https://thisglp.com/reviews/tmates) Semaglutide, Tirzepatide · as injection [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss) Semaglutide, Tirzepatide · as injection [Tonik Wellness](https://thisglp.com/reviews/tonik-wellness) Semaglutide, Tirzepatide · as injection [TotalRx](https://thisglp.com/reviews/totalrx) Semaglutide, Tirzepatide · as injection [Trally Meds](https://thisglp.com/reviews/trally-meds) Semaglutide, Tirzepatide · as injection [Transparent Meds](https://thisglp.com/reviews/transparent-meds) Semaglutide, Tirzepatide · as injection [Trava Health](https://thisglp.com/reviews/trava-health) Semaglutide, Tirzepatide · as injection [Trellis Vitality](https://thisglp.com/reviews/trellis-vitality) Semaglutide, Tirzepatide · as injection [Trillium Meds](https://thisglp.com/reviews/trillium-meds) Semaglutide, Tirzepatide · as injection [Trimi Health](https://thisglp.com/reviews/trimi-health) Semaglutide, Tirzepatide · as injection [TrimRx](https://thisglp.com/reviews/trimrx) Semaglutide, Tirzepatide · as injection [Trinity Meds](https://thisglp.com/reviews/trinity-meds) Semaglutide, Tirzepatide · as injection [TrueMe](https://thisglp.com/reviews/trueme) Semaglutide, Tirzepatide · as injection [TRYM Health](https://thisglp.com/reviews/trym-health) Semaglutide, Tirzepatide · as injection [Tryozi](https://thisglp.com/reviews/tryozi) Semaglutide, Tirzepatide · as injection [Tuyo Health](https://thisglp.com/reviews/tuyo-health) Semaglutide, Tirzepatide · as injection [Tyde Wellness](https://thisglp.com/reviews/tyde-wellness) Semaglutide, Tirzepatide · as injection [Valhalla Vitality](https://thisglp.com/reviews/valhalla-vitality) Semaglutide, Tirzepatide · as injection [Vea Health](https://thisglp.com/reviews/vea-health) Semaglutide, Tirzepatide · as injection [Vela Rx](https://thisglp.com/reviews/vela-rx) Semaglutide, Tirzepatide · as injection [Verge](https://thisglp.com/reviews/verge) Semaglutide, Tirzepatide · as injection [VevaRX](https://thisglp.com/reviews/vevarx) Semaglutide, Tirzepatide · as injection [Vita Bella](https://thisglp.com/reviews/vita-bella) Semaglutide, Tirzepatide · as injection [VitaFusions IV](https://thisglp.com/reviews/vitafusions-iv) Semaglutide, Tirzepatide · as injection [Vitalex Health](https://thisglp.com/reviews/vitalex-health) Semaglutide, Tirzepatide · as injection [Vitara RX](https://thisglp.com/reviews/vitara-rx) Semaglutide, Tirzepatide · as injection [VitaStir](https://thisglp.com/reviews/vitastir) Semaglutide, Tirzepatide · as injection [Voxy](https://thisglp.com/reviews/voxy) Semaglutide, Tirzepatide · as injection [Vyora Wellness](https://thisglp.com/reviews/vyora-wellness) Semaglutide, Tirzepatide · as injection [VyrarX](https://thisglp.com/reviews/vyrarx) Semaglutide, Tirzepatide · as injection [Vytora Health](https://thisglp.com/reviews/vytora-health) Semaglutide, Tirzepatide · as injection [Walgreens Weight Management](https://thisglp.com/reviews/walgreens-weight-management) Semaglutide · as injection and tablet [WeightCare](https://thisglp.com/reviews/weightcare) Semaglutide, Tirzepatide · as injection [WeightlessRx](https://thisglp.com/reviews/weightlessrx) Semaglutide, Tirzepatide · as injection [WeightRx](https://thisglp.com/reviews/weightrx) Semaglutide, Tirzepatide · as injection [Welling Health](https://thisglp.com/reviews/welling-health) Semaglutide, Tirzepatide · as injection [Wellorithm](https://thisglp.com/reviews/wellorithm) Semaglutide, Tirzepatide · as injection [Wellspring Longevity Clinic](https://thisglp.com/reviews/wellspring-longevity-clinic) Semaglutide, Tirzepatide · as injection [welludr.](https://thisglp.com/reviews/wellmedr)Semaglutide, Tirzepatide · as injection [WePeptideRx](https://thisglp.com/reviews/wepeptiderx) Semaglutide, Tirzepatide · as injection [Whoosh Wellness](https://thisglp.com/reviews/whoosh-wellness) Semaglutide, Tirzepatide · as injection [Willow](https://thisglp.com/reviews/willow) Semaglutide, Tirzepatide · as injection [Woodwork](https://thisglp.com/reviews/woodwork) Semaglutide, Tirzepatide · as injection [YourEra](https://thisglp.com/reviews/yourera) Semaglutide, Tirzepatide · as injection [YourHealthRx](https://thisglp.com/reviews/yourhealthrx) Semaglutide, Tirzepatide · as injection [Yucca Health](https://thisglp.com/reviews/yucca-health) Semaglutide, Tirzepatide · as injection [Zappy Health](https://thisglp.com/reviews/zappy-health) Semaglutide, Tirzepatide · as injection [Zealthy](https://thisglp.com/reviews/zealthy) Semaglutide, Tirzepatide · as injection [Zeuss](https://thisglp.com/reviews/zeuss) Semaglutide, Tirzepatide · as injection [1st Optimal](https://thisglp.com/reviews/1st-optimal) Semaglutide · as injection [Alegro Health](https://thisglp.com/reviews/alegro-health) Semaglutide · as injection [Allara Health](https://thisglp.com/reviews/allara-health) Semaglutide · as injection [AM Rx](https://thisglp.com/reviews/amrx) Semaglutide · as injection [Aurelius Health Group](https://thisglp.com/reviews/aurelius-health-group) Tirzepatide · as injection [Basal Health](https://thisglp.com/reviews/basal-health) Tirzepatide · as injection [Cabana](https://thisglp.com/reviews/cabana) Semaglutide · as injection [Calibrate Health](https://thisglp.com/reviews/calibrate-health) Semaglutide · as injection [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) Semaglutide · as injection [ElixaMD](https://thisglp.com/reviews/elixamd) Semaglutide · as injection [Emerge Weight Loss](https://thisglp.com/reviews/emerge-weight-loss) Tirzepatide · as injection [eMI Aesthetics](https://thisglp.com/reviews/emi-aesthetics) Semaglutide · as injection [Everlywell (Weight Care+)](https://thisglp.com/reviews/everlywell-weight-care-plus)Semaglutide · as injection [FitRx](https://thisglp.com/reviews/fitrx) Semaglutide · as injection [Florida Weight Loss MD](https://thisglp.com/reviews/florida-weight-loss-md) Tirzepatide · as injection [Garcia Weight Loss, Aesthetics & Hormone Therapy](https://thisglp.com/reviews/garcia-weight-loss) Semaglutide · as injection [Hello Alpha](https://thisglp.com/reviews/hello-alpha) Semaglutide · as injection [Hone Health](https://thisglp.com/reviews/hone-health) Liraglutide · as injection [JRNYS](https://thisglp.com/reviews/jrnys) Semaglutide · as injection [JumpstartMD](https://thisglp.com/reviews/jumpstartmd) Semaglutide · as injection [Knownwell](https://thisglp.com/reviews/knownwell) Tirzepatide · as injection [LIV by WellNow](https://thisglp.com/reviews/liv-by-wellnow) Semaglutide · as injection [Loop Health](https://thisglp.com/reviews/loop-health) Tirzepatide · as injection [Lumen Meds](https://thisglp.com/reviews/lumen-meds) Tirzepatide · as injection [LunaRx](https://thisglp.com/reviews/lunarx-health) Semaglutide · as injection [MangoRx](https://thisglp.com/reviews/mangorx) Semaglutide · as tablet [Marek Health](https://thisglp.com/reviews/marek-health) Semaglutide · as injection [Medi-Weightloss](https://thisglp.com/reviews/medi-weightloss) Semaglutide · as injection [Mojoon](https://thisglp.com/reviews/mojoon) Semaglutide · as injection [MultiMedRx](https://thisglp.com/reviews/multimedrx) Semaglutide · as injection [Omnia TeleHealth](https://thisglp.com/reviews/omnia-telehealth) Semaglutide · as injection [Queen RX](https://thisglp.com/reviews/queen-rx) Semaglutide · as injection [QuickMD](https://thisglp.com/reviews/quickmd) Semaglutide · as injection [Royal Medical Center](https://thisglp.com/reviews/royal-medical-center) Tirzepatide · as injection [ShapeIn Rx](https://thisglp.com/reviews/shapein-rx) Semaglutide · as injection [SkyRx](https://thisglp.com/reviews/skyrx) Semaglutide · as injection [Superpower](https://thisglp.com/reviews/superpower-health) Semaglutide · as injection [T2D.com](https://thisglp.com/reviews/t2d) Semaglutide · as injection [TD Tele-Doc Weight Loss](https://thisglp.com/reviews/td-teledoc) Semaglutide · as injection [TeleHealth Med](https://thisglp.com/reviews/telehealth-med) Semaglutide · as injection [TeleSlim Clinic](https://thisglp.com/reviews/teleslim-clinic) Semaglutide · as injection [Tell Her Doc](https://thisglp.com/reviews/tellherdoc) Semaglutide · as injection [TRT Nation](https://thisglp.com/reviews/trt-nation) Tirzepatide · as injection [Tummala Health](https://thisglp.com/reviews/tummala-health) Semaglutide · as injection [UR Meds](https://thisglp.com/reviews/ur-meds) Semaglutide · as injection [Wisp](https://thisglp.com/reviews/wisp) Semaglutide · as tablet [Yes Clinic](https://thisglp.com/reviews/yes-clinic) Semaglutide · as injection [AJ Peptide](https://thisglp.com/reviews/aj-peptide) · as [Better MedSpa](https://thisglp.com/reviews/better-medspa) · as [BodyLogicMD](https://thisglp.com/reviews/bodylogicmd) · as [Chronos Body Health & Wellness](https://thisglp.com/reviews/chronos-bhw) · as [Defy Medical](https://thisglp.com/reviews/defy-medical) · as [Docberry](https://thisglp.com/reviews/docberry) · as [Elara MD](https://thisglp.com/reviews/elara-md) · as [eMed](https://thisglp.com/reviews/emed) · as [Enhanced](https://thisglp.com/reviews/enhanced) · as [EverFit Medical](https://thisglp.com/reviews/everfit-medical) · as [Evergreen Telehealth](https://thisglp.com/reviews/evergreen-telehealth) · as [Evolve Telemed](https://thisglp.com/reviews/evolve-telemed) · as [FeelGood](https://thisglp.com/reviews/feelgood-meds) · as [Freeley](https://thisglp.com/reviews/freeley) · as [G-Plans](https://thisglp.com/reviews/g-plans) · as [Gatlan](https://thisglp.com/reviews/gatlan) · as [Genesis Lifestyle Medicine](https://thisglp.com/reviews/genesis-lifestyle-medicine) · as [Gide Health](https://thisglp.com/reviews/gide-health) · as [Hormonally Balanced](https://thisglp.com/reviews/hormonally-balanced) · as [KIN Health](https://thisglp.com/reviews/kin-health) · as [LifeVine Wellness](https://thisglp.com/reviews/lifevine-wellness) · as [Loozy](https://thisglp.com/reviews/loozy) · as [Medical Health Institute](https://thisglp.com/reviews/medical-health-institute) · as [MEDVidi](https://thisglp.com/reviews/medvidi) · as [Mixx Health & Wellness](https://thisglp.com/reviews/mixx-health-and-wellness) · as [Modern Age](https://thisglp.com/reviews/modern-age) · as [Novera MD](https://thisglp.com/reviews/novera-md) · as [Olleve Care](https://thisglp.com/reviews/ollevecare) · as [Omada Health](https://thisglp.com/reviews/omada-health) · as [One80Rx](https://thisglp.com/reviews/one80rx) · as [Pillar Health](https://thisglp.com/reviews/pillar-health) · as [PrescrYbe](https://thisglp.com/reviews/prescrybe) · as [PRIMO Health Partners](https://thisglp.com/reviews/primo-health-partners) · as [Ravia Health](https://thisglp.com/reviews/ravia-health) · as [Red Mountain Weight Loss](https://thisglp.com/reviews/red-mountain-weight-loss) · as [RegenCen](https://thisglp.com/reviews/regencen) · as [Revive Longevity](https://thisglp.com/reviews/revive-longevity) · as [StaveMD](https://thisglp.com/reviews/stavemd) · as [Teladoc Health](https://thisglp.com/reviews/teladoc-health) · as [TeleWellnessMD](https://thisglp.com/reviews/telewellnessmd) · as [TideMedix](https://thisglp.com/reviews/tidemedix) · as [Transcarent](https://thisglp.com/reviews/transcarent) · as [TRT Kingdom](https://thisglp.com/reviews/trt-kingdom) · as [Vida Health](https://thisglp.com/reviews/vida-health) · as [Virta Health](https://thisglp.com/reviews/virta-health) · as [Vitakey](https://thisglp.com/reviews/vitakey) · as [Vivanta Care](https://thisglp.com/reviews/vivanta-care) · as [VivioMD](https://thisglp.com/reviews/viviomd) · as [YOURx Health](https://thisglp.com/reviews/yourx-health) · as ## Listing is not pricing This counts what a seller lists, not what it publishes a figure for. A service can carry two molecules in two formats and price only one of them, and several do — the catalog is a different disclosure from the price list, and crediting one for the other would be the kind of shortcut this site exists to catch. --- # Which GLP-1 sellers publish the whole dose ladder | This GLP Saying a price rises with the dose is one disclosure; publishing what it rises to is another. Every seller whose own pricing note prints three or more rungs, so a buyer can price month six before enrolling. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/published-dose-ladders Updated: 2026-10-28 [← Tools](https://thisglp.com/tools)Not that it rises — what it rises to # Published dose ladders Plenty of sellers will tell you the price goes up with the dose. Far fewer print the numbers it goes up to, which is the only version of that disclosure a buyer can plan against. 216 of 580 sellers publish three or more rungs on at least one line. By [This GLP Editorial Team](https://thisglp.com/about) 216 sellers printing three or more rungs, quoted from their own notes [24hrDOC](https://thisglp.com/reviews/24hrdoc) Tirzepatide $239/mo sale (regular $339/mo); semaglutide $149/mo Re-read September 18, 2026: now $null, was $239. [Actin](https://thisglp.com/reviews/actin) Month-to-month. Actin prints all three cadences on the product page: 1-Month $169, 3-Month $143, 6-Month $116, flat at every dose. Re-read September 17, 2026: unchanged. [AgelessRx](https://thisglp.com/reviews/agelessrx) $1,695/month full cash price incl. consult and delivery Re-read September 14, 2026: now $349, was $1695. $349 of Wegovy billed through NovoCare plus the $65/month AgelessRx membership billed alongside it, which the page totals itself. [Alloy](https://thisglp.com/reviews/alloy) $115 medication + mandatory $99/mo Alloy Weight Care fee = $214/mo effective Re-read September 18, 2026: the seller publishes $115. $115 a month for the medication plus the mandatory $99 Alloy Weight Care fee. [Amazon One Medical](https://thisglp.com/reviews/amazon-one-medical) The same approved orforglipron tablet, recorded as a compounded injection by the sweep. No pharmacy compounds this molecule. The $25 is an insurance copay; the cash figure is "Rx from $149 with coupon if eligible", conditional on the coupon, with care billed separately ("Care from $39"), so no unconditional cash price is published. [Amble](https://thisglp.com/reviews/amble) Range up to $329/mo Re-read September 18, 2026: now $329, was $289. [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) First month only (originally $499); ongoing/steady-state monthly price not published. 'Pricing is subject to change.' Re-read September 18, 2026: now $215, was $375. [ARSYNL Rx](https://thisglp.com/reviews/arsynl-rx) "Doctor-Led Semaglutide Weight Loss Plans Starting at $233.00/Month". First-time orders advertise $50 off with code NEWROOTS50. Re-read September 14, 2026: now $219, was $199.99. [AskRx](https://thisglp.com/reviews/ask-rx) Re-read September 18, 2026: unchanged. $199 is the Wegovy 0.25 mg medication line; the $100 monthly care fee ($90 physician visit plus $10 fulfillment) is required on every order, so $299 all in. AskRx prescribes brand-name Wegovy only, never compounded semaglutide. [Aspire Health](https://thisglp.com/reviews/aspire-health) Verbatim from weight-loss page: '$149' for 5-week supply of compounded semaglutide/B6 (low dose 0.25–0.5 mg) + $75/month LoseIt program fee = ~$205/month total. 'Medication costs are not included in either program fee.' 15-week supply listed at $399 (~$115/mo for medication alone). program fee enrollment fee $200 ($175 online). Re-read September 14, 2026: now $129, was $205. $129 buys a five-week vial at 0.5 mg weekly, which is $112 a calendar month, plus the $49/month medical-care fee charged apart from medication. [Auren Rx](https://thisglp.com/reviews/auren-rx) $129/mo on Subscribe & save, $149/mo no-commitment. Re-read September 18, 2026: now $149, was $129. [Balanced Hormone Health](https://thisglp.com/reviews/balanced-hormone-health) 'Zepbound® Prescription — Starting at $139'. No period stated. Re-read September 18, 2026: the seller publishes $144. The compounded starter is 60 mg total as a twelve-week supply at $499, and twelve weeks is 2.76 calendar months. [Basal Health](https://thisglp.com/reviews/basal-health) Published recurring four-week treatment rate after introductory offer, not a calendar-month bill. https://basal.health/ Official basal.health offer read October 26, 2026: recurring treatment is $299 every four weeks after the introductory period, not a calendar month. Thirteen four-week bills per year cost $3,887, or $323.92 per calendar month (G4: $299 × 13 ÷ 12). This is arithmetic on the advertised bill, not a walked checkout. [Believe Health](https://thisglp.com/reviews/believe-health) Flat across all dosages. Shown against a struck-through $249 anchor. Re-read September 14, 2026: now $129, was $149. [BetterMe Rx](https://thisglp.com/reviews/betterme-rx) 3-month plan $597 sale price (regular $747 = $249/mo). Headline $199/mo is sale-dependent. The $199 is a sale price on the three-month plan; the regular price of that same plan is $747, which is $249 a month. [Big Easy Weight Loss](https://thisglp.com/reviews/big-easy-weight-loss) Sold only in 12-week packages: 'Semaglutide Compounded Treatment — Starting at $495 for 12 weeks', discounted to $399 for new patients. $495 over 12 weeks is $165 a calendar month; the starter price works out at $133. Re-read September 18, 2026: the seller publishes $495. The $495 is a twelve-week package, and twelve weeks is 2.76 calendar months rather than three — $179 a month, not the $165 a division by three would give. [BiltRx](https://thisglp.com/reviews/biltrx) starting price per month Re-read September 17, 2026: now $81, was $125. $81 a month for the medication plus the mandatory "9.99 monthly membership" is at least $90.99 a month; the consultation fee is billed separately and its amount is not published. [Bloom MD](https://thisglp.com/reviews/bloommd) From $395/mo, scales to $595. Re-read September 17, 2026: now $375.25, was $395. [Blue Haven RX](https://thisglp.com/reviews/blue-haven-rx) Flat rate incl. consult + medication + free shipping; intro from $149/mo on a 3-month plan Re-read September 18, 2026: unchanged. $179 buys four weeks by the card's own definition, and thirteen fills a year is $193.92 a calendar month. [bmiMD](https://thisglp.com/reviews/bmimd) Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/. Re-read September 17, 2026: now $119, was $99. [Bodi Envi](https://thisglp.com/reviews/bodi-envi) $179 standing, flat at every dose, with a $155 intro rate. ⚠ That intro is sold on a timer — 'Your $155 intro rate is reserved for 29:49' — which counts down from thirty minutes on every visit. Re-read October 14, 2026: now $155, was $179. [Bon Health](https://thisglp.com/reviews/bon-health) Annual plan; $195 (6-mo), $225/mo (quarterly, popular), $330 month-to-month Re-read September 18, 2026: now $95, was $170. The $95 is the annual plan, billed $1,140 a year. The same ladder runs $115 at six months and $140 quarterly, and a buyer who does not commit pays "Monthly billed monthly $220". [boostAGErx](https://thisglp.com/reviews/boostagerx) GLP-1 'starting at $95/mo' on 12-month plan paid upfront; actual price varies by product/plan Re-read September 18, 2026: unchanged. $95 is the 3-month plan paid upfront; one month is the $225 four-week plan, and thirteen fills a year is $243.75. [Brello Health](https://thisglp.com/reviews/brello-health) ⛔ THE MONTH IS NOT A MONTH — IT IS ELEVEN WEEKS. The card advertises '$133 Per Month Special', but the checkout reads 'Billed $399 Today. Then $399 Every 11 Weeks.' Eleven weeks is 2.53 calendar months, so the true cost is $399/2.53 = about $158 per calendar month, not $133 — the advertised figure understates it by roughly 18%. $599 is a strikethrough anchor that is never charged. There is NO 1-month option; the 3-month prepay is mandatory. Re-read September 17, 2026: now $133, was $158. [Brightmeds](https://thisglp.com/reviews/brightmeds) Flat across doses. $50 off the first order. Re-read September 14, 2026: now $129, was $189. [Candor Rx](https://thisglp.com/reviews/candor-rx) Compounded semaglutide as low as $99/mo, flat pricing marketed as '$95/month, any dose, forever' (no dosage upcharge). Re-read September 17, 2026: now $99, was $190. [Care Clinics](https://thisglp.com/reviews/care-clinics) Re-read September 18, 2026: the seller publishes $399. Our conversion: $399 buys sixteen weeks at 1.5 mg, which is 3.68 calendar months, or $108 a month. The same $399 buys ten weeks at 2.5 mg — $173 a month — so the charge holds while the supply shrinks. [CeliaRx](https://thisglp.com/reviews/celia-rx) Site displays this as "$499.00 $125.00/mo, ~4 month supply 1 vial" -- a single $499 charge for the whole vial, not a recurring $125 monthly charge. The $399 vial is one charge, and the "$125/mo" label does not divide out of it; a 10 mg vial is four to forty weekly injections depending on the dose. [Cielo](https://thisglp.com/reviews/cielo) The stored $115 is on no page. The semaglutide page prints "6 Month Plan … Now $89/Month", "3 Month Plan $99/Month" and "Monthly Plan $139/Month" beside "Regularly $199/month", and Cielo states it has no contracts, so $139 is the rate without a term commitment. [Citizen Meds](https://thisglp.com/reviews/citizen-meds) Per-dose ladder: 0.5mg $245, 1.0mg $295, 1.7/2.4mg $345, 2.5mg $395. Re-read September 17, 2026: unchanged. The $125 kit is four weekly injections sold as a one-month supply, and thirteen fills a year is $135.42. [Clinic Secret](https://thisglp.com/reviews/clinic-secret) $297 standing with $197 for a first month. The site-wide banner names the mechanism — 'New Member Promo — $100 Off 1st Month' — and $297 minus $100 is exactly $197. No membership fee. Re-read September 18, 2026: unchanged. [Clume Health](https://thisglp.com/reviews/clume-health) The $200/mo figure requires a 12-week prepaid term. Re-read September 14, 2026: now $259, was $219. [CLYR Health](https://thisglp.com/reviews/clyr-health) Flat any-dose $229/mo; 3-month prepay $189/mo ($567 billed once) Re-read September 18, 2026: now $169, was $229. [Coby Health](https://thisglp.com/reviews/coby-health) Standing monthly rung, excluding the $159 first month and prepaid bundles. Month 2 at 0.5 mg is $199; 1 mg is $229 and 1.7–2.4 mg is $249. Consultation, medication, support and shipping included. https://www.cobyhealth.com/treatments/weight-loss/semaglutide Re-read October 14, 2026: unchanged. [Collective](https://thisglp.com/reviews/collective) Verbatim: 'Compounded Semaglutide: $59/month. Same price, every dose. Cancel anytime.' ⛔ EXCLUDES the required membership — the site states 'What does it cost? $59/month + $199 annual membership.' First-year total is $907 ($75.58/mo equivalent). Re-read September 17, 2026: unchanged. $59 a month plus the required $199 annual membership spread over twelve months. [Cora Health](https://thisglp.com/reviews/cora-health) Re-read September 18, 2026: unchanged. $99 is the annual Essential Plan rung ($1,188 billed yearly); the plans page prices the no-commitment monthly plan at $175. [CoraDoc](https://thisglp.com/reviews/coradoc) Re-read September 17, 2026: unchanged. The $99 is the six-month program paid in one charge; the seller states there is no subscription option. Its shortest commitment is the three-month Semaglutide Starter at $165, and the three-month maintenance tier is $199. [DadVantage Men's Health](https://thisglp.com/reviews/dadvantage-mens-health) Sold in WEEK BLOCKS: '4 weeks $200, 8 weeks $350, 10 weeks $400, 12 weeks $500, 20 weeks $650'. ⚠ A $250 one-time consultation and a $50/month follow-up fee are charged on top. Re-read September 18, 2026: the seller publishes $200. $200 per four-week block is $216.67 a calendar month, plus the $50/month follow-up subscription stated to exclude medication. [Direct Meds](https://thisglp.com/reviews/direct-meds) 'As low as $399.00 or $12.87 per day'; the '$9.58 per day' string on the public /products/tirzepatide marketing page is a copy error (matches sema math). Unchanged vs our data. Re-read September 18, 2026: unchanged. [DrBrainRx](https://thisglp.com/reviews/drbrainrx) Verbatim from /products/tirzepatide: flat $299 per 4-week vial at all weekly doses (2.5–15 mg). Plus $25/month provider care fee for dose titration and support (cancellable anytime). Re-read September 18, 2026: unchanged. $299 for one month of medication ("Monthly Flex | $299"; the $249 is the monthly equivalent of the "6-Month Premier | $1,494 upfront" bundle) plus the same required $25/month Care Access plan. [DudeMeds](https://thisglp.com/reviews/dudemeds) $175/mo (orig $295 struck), Total Billed $525 (Orig. $885); 503B compounded; cheapest product on site — advertised '$149+' price not found on any product page Re-read September 18, 2026: the seller publishes $295. [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) '3-Month Starter Program $500' — evaluation, baseline labs, three months of follow-up care. ⚠ That is $166.67 a month for CARE; the medication is billed separately and is not priced. The $500 three-month starter buys the evaluation, baseline labs and follow-up care, which is $166.67 a month of care; the medication is paid separately to the pharmacy, which the practice's resource page lists at $249 a month for compounded semaglutide. [Eden](https://thisglp.com/reviews/eden) Re-read September 14, 2026: now $99, was $198. $99 medication plus the $99/month Eden Membership its GLP-1 page states is required and not included. [Edessa](https://thisglp.com/reviews/edessa) Plan table on myedessa.com/product-glp-1-injection.html: 1 month $179, 3 month $160/mo, 6 month $135/mo. The homepage's 'Start for just $135' is the six-month prepay rate, not the month-to-month price. [Effecty](https://thisglp.com/reviews/effecty) $60 first month, then $160/mo on the 12-month plan. Re-read September 17, 2026: now $170, was $160. [Elara Health and Wellness](https://thisglp.com/reviews/elara-health-and-wellness) The seller's card reads "$249 billed monthly"; its $179 equivalent requires $2,327 paid in one charge covering thirteen months. The stored $117 is on no page. [Elevated Health](https://thisglp.com/reviews/elevated-health) $196 first month, $296/mo after on the monthly plan; lower on longer plans (3-mo $242, 6-mo $229, 12-mo $187/mo) Re-read September 18, 2026: unchanged. [ElitePhysiqMD](https://thisglp.com/reviews/elitephysiqmd) Compounded semaglutide injection subscription. A $49 required telehealth visit is added per order. Re-read September 14, 2026: now $199, was $145. $179.10 is the member rate and membership is $89.00 a month, which the page totals at $268.10; without it every order comes to $278.00. [Embody](https://thisglp.com/reviews/embody) Checkout: '$79/mo flat forever' (strikethrough $299); bundles $76/$73/$69 per month on 3/6/12-mo. CAVEAT: T&C list price is $199/mo — the $79 depends on the auto-applied SUMMER promo marketed as permanently locked; Trustpilot complaints allege the lock was not always honored. Re-read October 13, 2026: the seller publishes $199. [Enhance MD](https://thisglp.com/reviews/enhance-md) $212/mo is the 12-month-plan rate (billed every 48 weeks). 6-mo $224/mo, 3-mo $237/mo, 1-mo $249/mo. First month $112 = $100 off first order on 3+ month plans (code SUMMER100); $50 off 1-month (SUMMER50). Flat price at all doses; labs, consult, 2-day shipping included. Re-read September 18, 2026: the seller publishes $249. The one-month plan bills $249 every four weeks, so thirteen fills a calendar year is $269.75 a month. [EOS Health](https://thisglp.com/reviews/eos) $179.99 for a first month, then $279.99 recurring. Each price is all-in: consultation, medication, shipping and injection supplies, and it does not change with your dose. Re-read September 14, 2026: now $169, was $279.99. [EverPrime](https://thisglp.com/reviews/everprime) Official product calculators checked October 28, 2026. Selected one-month standard medicine rates: semaglutide $249; tirzepatide $329. Member medication rates $150/$230 exclude the separate $99 Core subscription. Visit-fee inclusions and upfront terms need a personal quote; no verified all-in monthly total. https://joineverprime.com/products/glp-1-semaglutide Re-read October 28, 2026: unchanged. Medication-only rate; the membership page also lists nonmember visit charges. Ask for the combined medication, visits and lab quote, with renewal dates, before treating this as a monthly or six-month care total. [Fidelity Medical Clinic](https://thisglp.com/reviews/fidelity-medical-clinic) Maintenance is '$199 — Semaglutide and supplies for 4 doses (4 weeks)', which is 13 fills a year, or $215.75 a calendar month. The intro is '$99 — Initial Prescription — 2 month order required — supplies for 8 doses (2 months)', i.e. $49.50 a month for the first two. Re-read September 17, 2026: now $199, was $215.75. $199 every four weeks, converted by month length rather than a 13/12 approximation. [FitFlow](https://thisglp.com/reviews/fitflow) Month-to-month; drops to $145/mo (quarterly), $120/mo (6-month), or $99/mo on annual prepay. Same active ingredient as Wegovy. Re-read September 17, 2026: unchanged. The $99 card price is the twelve-month prepay rung ($1,188 upfront); month to month the same vial is $175. [Fitstry](https://thisglp.com/reviews/fitstry) 'Starting at $149 — Compounded semaglutide — the GLP-1 most people have in mind. A weekly shot you do at home.' Re-read September 17, 2026: unchanged. The FAQ's month-to-month rate is $249 every four weeks, and thirteen cycles a year is $269.75 a calendar month. [FMmeds](https://thisglp.com/reviews/fmmeds) Standing month-to-month rate. Prepay cadences work out to $129/mo (3-month), $119/mo (6-month) and $95/mo (12-month) — the homepage currently headlines the $95 figure, which is the 12-month prepay equivalent. Re-read September 17, 2026: unchanged. [FormBlends](https://thisglp.com/reviews/formblends) Published offer price via rx.formscripts.com; may be intro — confirm at checkout Re-read September 18, 2026: unchanged. $99 buys the first month only; the standing month-to-month rate is $190, or $165 with the Subscribe and Save credit. [FormidableMD](https://thisglp.com/reviews/formidablemd) Dose-tiered: 1mg $169, 2mg $189, 5mg $209, 10mg $269/mo. Compounded or FDA-approved options. Separate $199 initial consult + $99 follow-up visits Re-read September 17, 2026: unchanged. $169 at 1 mg plus the required visit schedule — a $199 initial consultation and six $99 follow-ups in year one, $793, or $66.08 a month. [Found](https://thisglp.com/reviews/found) $169/mo cash-pay on 12-month prepaid plan, medication+membership+coaching included; promo\_price 99 = $99/mo WITH insurance (12-mo prepaid). Month-to-month: $199/mo insurance, $289/mo cash. Site-wide '$100 off today' checkout promo running. Re-read September 18, 2026: the seller publishes $289. Found bills $289 per 28-day cycle on the month-to-month cash plan; thirteen cycles a year is $313.08 a calendar month. [Framework](https://thisglp.com/reviews/framework) Framework prices per WEEK, not per month: 'GLP 1s For As Low as $25/Week'. Fifty-two weeks is $1,300 a year, so the calendar month is $108.33, not $100. '$0 membership fees.' Our conversion: Framework prints "As low as $25/Week", and $25 × 52 ÷ 12 is $108.33 a month. A second Framework page prints "As low as $19/Week", and neither names a molecule, dose or term. [Fridays](https://thisglp.com/reviews/fridays) The month-to-month rate, stated on /weight-loss as 'Starting at $150/mo ($249/mo for month-to-month plan)'. ⚠ FRIDAYS' TWO PAGES DISAGREE: /pricing simultaneously advertises 'Starting at $117/mo' with '$279/mo with an annual plan' and 'SAVE 58% use code NYNY12', while /weight-loss puts the plan rate at $150. The $117 recorded as the promo is COUPON-GATED, not a standing rate, and the two pages cannot both be right about the annual figure ($150 vs $279). Re-read September 17, 2026: unchanged. [Genesis Health](https://thisglp.com/reviews/genesis) Compounded semaglutide injection. Monthly: $175/mo. Quarterly: $145/mo ($435 billed every 3 months). Bi-Annual: $120/mo ($720 every 6 months). Annual: $99/mo ($1,188/yr). Includes physician consult, medication, and free shipping. Re-read September 18, 2026: unchanged. [Gimme Care](https://thisglp.com/reviews/gimme-care) Re-read September 18, 2026: unchanged. The month-to-month rung is $160 ("1 month $ 160"), and refills are "Shipped every 28 days", which is thirteen fills a year, or $173.33 a calendar month. The $130 is the three-month plan, billed every three months. [Go Vida Plena](https://thisglp.com/reviews/go-vida-plena) Spanish-first GLP-1 program from $199/mo; pay in installments (Klarna/Afterpay/Affirm). Tirzepatide and oral semaglutide also offered (prices not published). Re-read September 15, 2026: now $179, was $199. $179 is the twelve-month rung billed at $2,148; month to month the same injection is $269. [GobyMeds](https://thisglp.com/reviews/gobymeds) $299 total for 12 weeks incl. medication, shipping, consultation, injection kit; JUMPSTART20 promo $279 total ($93/mo) — promo end-dated Dec 31 2025 but still displayed July 2026 Re-read September 18, 2026: the seller publishes $169. [Goldspan Health](https://thisglp.com/reviews/goldspan-health) ⛔ ADVERTISED '/month' BUT SHIPS EVERY 4 WEEKS — verbatim: 'a new monthly supply arrives automatically every 4 weeks'. That is 13 charges a year, not 12: about $2,977/yr, not $2,748. Price is not on goldspanhealth.com — it appears only on the altroapp.com storefront the product links to. Re-read September 17, 2026: unchanged. $229 buys four weeks behind a monthly label; thirteen renewals a year is $2,977, or $248.08 a calendar month. [Good Life Meds](https://thisglp.com/reviews/good-life-meds) 'Same Price at Every Dose Level: 1 Month Supply = $199'. The $99 promo is a FIRST-ORDER discount only — '$100 Off First Order ... Must use promo code NEWME100 at checkout' — not a standing rate. Good Life states 'No additional fees or membership costs', so $199 is genuinely all-in. Re-read September 18, 2026: unchanged. [GoodRx](https://thisglp.com/reviews/goodrx) Re-read September 18, 2026: unchanged. Orforglipron is the approved tablet Foundayo, so this row prices a tablet rather than the weekly injection the sweep recorded. Foundayo is "As low as $149 per month" at the 0.8 mg and 2.5 mg doses, plus the required $39 monthly membership, which is $188 all in. [Green Cap Health](https://thisglp.com/reviews/green-cap-health) Re-read September 17, 2026: unchanged. The $79 is a first month. The standing month-to-month rate is $179, falling to $149 on three months and $129 on six, with medication at any dose and no separate membership charge. [Harmony Wellness Clinic](https://thisglp.com/reviews/harmony-wellness-clinic) Verbatim from services page: '$200' at Level 1 through '$300' at Level 5. GLP-1 + B12 formulation. Five dose tiers ($200/$225/$250/$275/$300/month); $200 is entry-tier price. Re-read September 18, 2026: unchanged. [He & She MD](https://thisglp.com/reviews/he-and-she-md) Annual plan: billed $1,188 upfront. Advertised as a limited-time rate (banner: 'Injectable Semaglutide $199/month from just $99/month'). Re-read September 17, 2026: unchanged. The $99 is the annual plan, billed $1,188 in one charge up front; the plans page now also publishes a MONTHLY PLAN at $199/mo billed monthly, which is what a buyer pays without committing a year. [Healthicare](https://thisglp.com/reviews/healthicare) $174/mo billed monthly; $147.90/mo on the 3-month plan ($443.70 billed every 3 months) Re-read September 18, 2026: now $126, was $174. [HealthOn](https://thisglp.com/reviews/healthon) Starting at $189; lowest on the 12-month plan Re-read September 17, 2026: unchanged. $189 is charged by no plan; the semaglutide subscription bills $155 for the first order and $255 for every order after. HealthOn's product page ties the $189 to a 12-month plan paid upfront, while its program page labels the same figure a monthly plan. [HealthRX](https://thisglp.com/reviews/healthrx) Flat rate, same price at every dose; 3-month plan from $133/mo, 12-month plan from $99/mo Re-read September 17, 2026: unchanged. $133 is the three-month prepay rate; the published month-to-month renewal is $165. [HeliMeds](https://thisglp.com/reviews/helimeds) Paid upfront as a 12-week plan, not a subscription. Any dose is $199/mo. Re-read September 17, 2026: unchanged. The $99 headline is the starter dose; any dose is a $597 twelve-week block labeled $199/mo, and twelve weeks is 2.76 calendar months, so $216. The same footnote prices the next four-week supply at $239. [HelloWellness](https://thisglp.com/reviews/hellowellness) Re-read September 18, 2026: unchanged. The $133 a month is the seller's three-month charge of $399 divided by three, but the plan is "Billed $399 today · Then $399 every 11 weeks" — 52 ÷ 11 charges a year, which is $157.18 a calendar month. [Henry Meds](https://thisglp.com/reviews/henry-meds) Re-read September 17, 2026: unchanged. The $249 a month is the sublingual tablet plan; the same page prices six months at $1,074 ($1,014 if paid in full), which is not six times $249. [Hers](https://thisglp.com/reviews/hers) Medication only. A Hers Weight Loss Membership is MANDATORY on top — $39 the first month, then $149/mo — and Hers states plainly that 'Medication is not available without a membership', so the all-in standing cost is this figure plus $149. Re-read September 17, 2026: unchanged. $199 medication plus the mandatory $149 membership. [Heva Health](https://thisglp.com/reviews/heva-health) Tirzepatide on hevahealth.com/weight-loss: the 3-Month Program card reads "$399/mo $339/mo" with the $399 struck and "Save $60/month vs. month-to-month", so month-to-month is $399. "Any dose — same price". Tirzepatide is not dispensed in AK, AR, IN or SC. [Hims](https://thisglp.com/reviews/hims) Re-read September 18, 2026: unchanged. $199 is Hims' medication-only price for Wegovy Pen, and the Hims Weight Loss Membership is a required $149 a month on top, which is $348 all in. Hims no longer lists a compounded semaglutide. [Idgie Health](https://thisglp.com/reviews/idgie-health) 'Semaglutide Compounded Microdose', '1 Month · Billed monthly, flexible · $134/mo'; or $377 charged today for 3 months (shown as $125/mo). The site calls microdosing an off-label approach. [Immortals](https://thisglp.com/reviews/immortals) A microdose tier is $167. Brand Wegovy is $1,550. Re-read September 17, 2026: unchanged. The $196 a month is "Billed quarterly with a three-month commitment paid up front"; no month-to-month semaglutide rate is published. [Invigor Medical](https://thisglp.com/reviews/invigor-medical) Includes the doctor consult and supplies. Micro-dose plan starts at $149/mo. Re-read September 18, 2026: unchanged. The Compounded GLP-1 subscription bills "$225.00 every 4 weeks", which is thirteen fills a year, or $244 a calendar month. [Invyncible](https://thisglp.com/reviews/invyncible) Standard formula, down from $300. A B12 version is listed at $180. Re-read September 18, 2026: unchanged. Every rung of the Tirzepatide Injection Program is labeled "(4 weeks)", so $210 is thirteen fills a year, or $228 a calendar month. [Ivologist](https://thisglp.com/reviews/ivologist) $124 for a first month, then $149/month. Paying three months up front instead costs $397 in one charge. Re-read September 17, 2026: unchanged. [JumpstartMD](https://thisglp.com/reviews/jumpstartmd) ⛔ A PROGRAM START FEE, not a monthly medication cost. 'Get started for $49 ($379) for a limited time only!' — $379 regular, $49 promotional. The GLP-1 medication is not priced on any public page. The $379 is a program start fee advertised against a limited-time $99 ("Get started for $99 ($379) for a limited time only!"), not a monthly medication cost. [June Health](https://thisglp.com/reviews/june-health) Semaglutide with (B12 or Glycine) injectable solution, lowest published tier of 5 dose tiers. Re-read September 17, 2026: now $279, was $179. The stored $179 appears nowhere on the storefront, whose injectable semaglutide prices run from $149 on a separate line to $319. [JustAnswer Weight Loss](https://thisglp.com/reviews/justanswer-weight-loss) Monthly plan $149.97/mo; 6-month $130.00/mo; 12-month $112.49/mo. Semaglutide + B12. Free shipping, automatic refills. Re-read September 17, 2026: now $112.49, was $149.97. The $112.49 a month is "\*With purchase of annual plan"; the month-to-month rate is not published outside an identity intake. [KERNX Health](https://thisglp.com/reviews/kernx-health) Founding rate; standard rate is $249/mo once founding membership closes. A provider consultation fee is charged separately and only when treatment is approved: $25 message-based review, $35 standard live visit, $60 complex live visit. Re-read September 17, 2026: now $209, was $129. [Kin Meds](https://thisglp.com/reviews/kin-meds) Entry pricing — likely insured/savings-card tier; cash-pay LillyDirect vials run $299-$449/mo Re-read September 17, 2026: unchanged. The $149 is the Zepbound card's consultation fee; the medication ships via LillyDirect at a price Kin Meds does not publish. [Kina](https://thisglp.com/reviews/kina) $199/month standing, $169 for a first month. A $25 physician consultation fee is covered, not added. Re-read September 17, 2026: unchanged. [LaSara Medical Group](https://thisglp.com/reviews/lasara) Month-to-month, and the same figure whether you subscribe or buy once. Longer plans: 3 months $849 ($283/mo), 6 months $1,495 ($249/mo), 12 months $2,795 ($233/mo). Re-read September 15, 2026: now $289, was $299. [Lean Meds](https://thisglp.com/reviews/leanmeds) Standing month-to-month rate. The advertised $69 is the 12-month prepay tier; 3-month is $76 and 6-month is $73. Read October 13, 2026: leanmeds.com now advertises a generic $49/month starting offer beside a countdown (data-end-epoch 1792209600). The public consultation starts with health questions and exposes no molecule-specific standing price. The earlier $79 monthly rate and prepay ladder were not found; withhold until a current standing semaglutide rate is public. [Lean Rx](https://thisglp.com/reviews/lean-rx) Re-read September 18, 2026: the seller publishes $450. $450 buys four weeks of medication with no commitment ("4 Weeks Pay in full today"), plus a required $35 shipping charge, which is $485 per four-week fill. Thirteen fills fall in a year, so a calendar month costs $525.42. [Lemonaid Health](https://thisglp.com/reviews/lemonaid-health) Re-read September 18, 2026: the seller publishes $299. Lemonaid bills compounded semaglutide at $299 a month and requires its $49 monthly membership beside it, so the lowest monthly cost is $348. [LevelUp Rx](https://thisglp.com/reviews/levelup-rx) 1-month $249.97/mo; 6-month $1349.82; 12-month $2349.88. Flat across all doses. Re-read September 17, 2026: unchanged. [Levers Health](https://thisglp.com/reviews/levers-health) Marketed as '$123/mo' but billed and shipped as $246 every other month. The catalog card reads 'Low and Microdose GLP-1 — From $246'. Levers prices its semaglutide subscription at $247 for the Regular rung the product page selects by default, capped at 1.25mg a week; the Max rung at 2.5mg a week is $297. The stored $123 is half of a $246 two-month microdose line, and the $296 filed here previously belongs to the tirzepatide plan. [Liberty](https://thisglp.com/reviews/liberty) Compounded semaglutide weekly injection, flat $199/mo; drops to about $171/mo on a 3-month supply. Sourced from a 503B outsourcing facility; Rx after clinician review. Re-read September 17, 2026: now $129, was $199. [LifeMD](https://thisglp.com/reviews/lifemd) Medication only (starting); plus the program fee. As low as $0-$25/mo with insurance. Re-read September 18, 2026: unchanged. $199 Wegovy pen plus the $149/mo program and provider fee stated in the pricing footnote. [Live Vital](https://thisglp.com/reviews/live-vital) Sold as a 10-week protocol at $299 total, which works out to about $130 a calendar month — not the '3 month program' the page's own framing suggests. Re-read September 18, 2026: the seller publishes $99. The $99 a month divides a $299 ten-week protocol by three; ten weeks is 2.3 calendar months, so it is $130 a calendar month. [Loop Health](https://thisglp.com/reviews/loop-health) Membership fee only — medication is NOT included. Loop sells one plan: '$1,500 / yr', which is $125 a month, and the page states 'Annual plan only at launch'. It includes a '$180/mo research credit applied to peptides, panels, and add-on packages'. Re-read September 18, 2026: now $null, was $125. The $125 is a membership fee only, billed as $1,500 a year on the single annual plan, and the medication is not included in it. [Lttl](https://thisglp.com/reviews/lttl) Low-dose line marketed for tolerability. Month-to-month, was $179. Ladder: $129 quarterly, $119 every 6mo, $109 annually. First Month Special $119. Re-read September 18, 2026: unchanged. The microdose line: $149 buys a four-week supply, and thirteen fills a year is $161.42 a calendar month. [Luma Meds](https://thisglp.com/reviews/luma-meds) Amortized per-month rate on 3-month plan. Re-read September 15, 2026: now $99, was $140. $99 is both a new-patient rate and the three-month rung; a continuing patient billed monthly pays $149, with $119 on three months. [Lumen Meds](https://thisglp.com/reviews/lumen-meds) Semaglutide is advertised at $0 for the first month; no ongoing rate is published. Re-read September 18, 2026: now $191.99, was $195.82. [Luvo Health](https://thisglp.com/reviews/luvo-health) Published as $249 per 4 weeks ($62/week). Longer commitments cut the weekly rate: $657/12wk, $1,194/24wk, $2,327/52wk. Re-read September 18, 2026: unchanged. $249 per four weeks is thirteen fills a year — $271 a calendar month. [MadeMed](https://thisglp.com/reviews/mademed) Quarterly plan $239/mo (billed $717/3mo); 6-month plan drops to $199/mo (the site's 'From $199/mo'). Re-read September 18, 2026: unchanged. [Maves](https://thisglp.com/reviews/maves) The seller's card reads "$89 first month, then $189/mo after", with the $100 discount auto-applied at checkout. The stored $99 matches neither figure. [MaxLife](https://thisglp.com/reviews/maxlife) Starter Kit: $100/mo for 3 months, 'billed $300 now, then $155/mo' ('$165 Total Savings'). Monthly Plan: $155/mo, which MaxLife calls a 'Guaranteed Fee'. Medication + supplies included in the membership. Re-read September 17, 2026: now $89, was $155. [MediRX](https://thisglp.com/reviews/medirx) $149 to start, with $120 off a first month and as little as $70 for the first month on the 6-month plan. No insurance required. ⚠ MediRX's homepage also prints $179 for the same product in a second grid. Re-read September 17, 2026: unchanged. [MedLeanRx](https://thisglp.com/reviews/medleanrx) $269/mo standard; intro bundle: 2-month supply at 2 mg weekly for $325 (~$163/mo), Texas clients only, while supplies last Re-read September 17, 2026: unchanged. [Medro](https://thisglp.com/reviews/medro) Month-to-month; drops to $179/mo (3-month), $159/mo (6-month), or $149/mo (12-month). Illustrative — final price shown before checkout, may vary by dose/pharmacy/eligibility. Re-read September 17, 2026: now $99, was $149. $99 is $199 less the flat one-time first-order code; $199 is the figure the page strikes through. [Medsol RX](https://thisglp.com/reviews/medsol-rx) 12-mo plan; $229 (6-mo), $249 (3-mo), or $199 first month then $279 month-to-month Re-read September 15, 2026: now $199, was $209. [Midi Health](https://thisglp.com/reviews/midi-health) From /glp1-pricing, headed 'No membership fees. No surprises.' ⚠ EVERY table is labeled '4-week supply', NOT a calendar month, so this is 13 cycles a year and must never be restated as '/mo'. Ladder runs $165.90 (0.1–0.5 mg) to $355.00 (2.5 mg). Re-read September 18, 2026: unchanged. $165.90 buys a four-week supply, and thirteen fills a year is $179.73 a calendar month. [Mochi Health](https://thisglp.com/reviews/mochi-health) Re-read September 17, 2026: the seller publishes $60. The $60 is medication only and the Mochi membership is a standing $79 a month that the seller states does not include medication, which is $139 all in. [Mondae](https://thisglp.com/reviews/mondae) Same $115 whether the 1-month or 3-month plan is selected; a struck-through $600 is shown as an anchor price. Re-read September 17, 2026: now $87, was $115. [MyStart Health](https://thisglp.com/reviews/mystart-health) Homepage FAQ verbatim: program 'starts at $299/month, excluding any discounts,' all-inclusive (consults, unlimited clinician access, meds, labs, shipping). Promo banner '$150 Off + Lifetime 25% Off' (coupon SELFLOVE25 in funnel URL) but no final promo dollar price published pre-quiz — plan-selection pricing is gated behind a signed medical attestation, so not published. Re-read September 18, 2026: unchanged. The monthly plan is auto-billed each month and ships a four-week supply, and thirteen four-week fills a year on a flat $299 is $324 a calendar month. [New Wave Health](https://thisglp.com/reviews/new-wave-health) Checkout: 'Monthly Plan - $100 off first month', $249/mo struck to $149/mo; 'Total today: $149'. 3-month plan is one $657 charge; 6-month is one $1,134 charge. Re-read September 18, 2026: now $null, was $249. [Nex Gen Health Rx](https://thisglp.com/reviews/nex-gen-health-rx) Verbatim: 'Doctor-led weight loss plans starting at $190' with '0.5 mg · 30 Day Supply' selected. Longer supplies quote $171 (90-day), $426 (180-day) and $1,092 (360-day), but the site never states whether those are totals or per-month rates, so they are not recorded. Re-read September 17, 2026: unchanged. The $171, $426 and $1,092 in the note are the seller's "Total savings:" lines, not prices: the 90-, 180- and 360-day plans total $399, $714 and $1,188, and the strength each figure buys (0.5 mg) is printed beside it. [NexLife](https://thisglp.com/reviews/nexlife) The 12-month-plan rate. The homepage prints it as 'As low as $119/mo\*', footnoted '\*On a 12-month plan.' Month-to-month is $139. Re-read September 18, 2026: unchanged. $119 is the twelve-month plan charged $1,428 in a single payment at signup; the cancel-anytime monthly rate on the same ladder is $139. [Next Vial](https://thisglp.com/reviews/next-vial) nextvial.com/product/glp-1-medications/ with Tirzepatide Injection selected: "1 Month billed monthly $249 /mo · 3 Months $687 total $229 /mo · 6 Months $1,194 total $199 /mo · 12 Months MOST POPULAR $1,788 total $149 /mo". Showing 120 of 216. ## How a row qualifies By printing three or more distinct figures in one recorded pricing note — a ladder rather than a headline and an asterisk. That is a deliberately mechanical test, and it will miss a seller that publishes its ladder as a table this site recorded only the opening rung of. It will not, however, credit a seller that merely says the price changes. --- # The questions GLP-1 sellers leave you to ask | This GLP Counted across every seller ranked on this site: how many publish nothing about what the price does at a higher dose, nothing about where they ship, nothing about a second format — and the question to put to each one before ordering. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/questions-they-leave-open Updated: 2026-10-28 [← Tools](https://thisglp.com/tools)A census of what is missing # Questions they leave open Most of what a buyer needs to know is not on a pricing page, and the gaps are consistent enough to count. Across 580 ranked sellers, here is how often each question goes unanswered — and the sentence worth sending before a first order. By [This GLP Editorial Team](https://thisglp.com/about) Counted across 580 ranked sellers 1. 467 of 580 sellers ## Sells one format only Ask: “Is there a tablet as well as an injection, and what does it cost?” This is the most common silence on the roster, and the most expensive one: almost everyone escalates inside sixteen weeks, so a figure that says nothing about a higher dose describes the cheapest month of a course rather than the course. 2. 379 of 580 sellers ## Records no list of states it ships to Ask: “Can you ship to my state, and is that list published anywhere?” 3. 370 of 580 sellers ## Says nothing about what the price does at a higher dose Ask: “Does this figure hold when my dose goes up, and if not, what does it become?” 4. 178 of 580 sellers ## Publishes no figure this site can rank Ask: “What does a month cost, before I create an account?” 5. 105 of 580 sellers ## Sells one molecule only Ask: “Do you offer tirzepatide as well, and at what price?” ## Silence is not a verdict Every count above is “published nothing on this point”. It is not a finding that a seller is hiding something, and it is not evidence that the answer is bad. A seller that has simply never written the sentence down will usually answer it in a message, and the answer is worth having in writing before money changes hands. --- # What each GLP-1 seller actually publishes | This GLP The five things this site scores every seller on — whether a price exists before you make an account, whether the headline is the billed figure, whether it holds across the dose ladder, where it ships and what it sells — as a single scorecard. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/tools/what-sellers-publish Updated: 2026-10-26 [← Tools](https://thisglp.com/tools)The scorecard behind every ranking # What sellers publish Nothing on this site is ranked on opinion. Every seller is marked out of ten on five things it either did or did not put on its own pages, and those marks are what order the boards. Here they are for all 580 sellers, so a reader can disagree with the weighting and still use the marks. By [This GLP Editorial Team](https://thisglp.com/about) 580 sellers, five marks each, all read off the sellers' own pages ## What each mark means Price transparency · weighted 30% Can you find what a month costs — for the molecule and the form you want — before creating an account, and does the seller's own site agree with itself? Honest headline · weighted 10% Is the figure the seller leads with the figure it bills? A price that needs a twelve-month prepay, or that is struck through from an anchor nobody pays, is a different number from a standing monthly rate. Dose-ladder pricing · weighted 10% Does the price hold as your dose escalates, or is it re-set at every step? This is the difference most buyers only discover in month three. State coverage · weighted 25% How much of the country the seller actually ships to. A seller that does not operate where you live is not an option, whatever it charges. Molecule and form breadth · weighted 25% Whether the seller carries both molecules, and whether it offers an oral as well as an injection. Breadth is what lets you change course without changing provider. Search sellers by name Showing 25 of 580 sellers | Seller | Price | Honest | Dose-ladder | State | Molecule | States | | --- | --- | --- | --- | --- | --- | --- | | [Actin](https://thisglp.com/reviews/actin) | 8.5 | 3.0 | 2.0 | 2.0 | 5.0 | — | | [AgelessRx](https://thisglp.com/reviews/agelessrx) | 8.5 | 3.0 | 2.0 | 2.0 | 5.0 | — | | [AHBARx](https://thisglp.com/reviews/ahbarx) | 8.5 | 5.0 | 2.0 | 2.0 | 5.0 | — | | [Alloy](https://thisglp.com/reviews/alloy) | 8.5 | 3.0 | 2.0 | 2.0 | 8.0 | — | | [Alternate Health Club](https://thisglp.com/reviews/alternate-health-club) | 8.5 | 5.0 | 10.0 | 2.0 | 5.0 | — | | [altRX](https://thisglp.com/reviews/altrx) | 8.5 | 5.0 | 10.0 | 2.0 | 5.0 | — | | [Always Wellness and Recovery](https://thisglp.com/reviews/always-wellness-and-recovery) | 8.5 | 5.0 | 2.0 | 2.0 | 5.0 | — | | [AlyveRx](https://thisglp.com/reviews/alyverx) | 8.5 | 10.0 | 10.0 | 2.0 | 5.0 | — | | [Amble](https://thisglp.com/reviews/amble) | 8.5 | 3.0 | 10.0 | 10.0 | 5.0 | 50 | | [Andrew Meds](https://thisglp.com/reviews/andrew-meds) | 8.5 | 5.0 | 2.0 | 10.0 | 5.0 | 51 | | [AquaVita NextGen](https://thisglp.com/reviews/aquavita-nextgen) | 8.5 | 3.0 | 2.0 | 1.0 | 5.0 | 5 | | [Arc-1](https://thisglp.com/reviews/arc-1) | 8.5 | 5.0 | 4.0 | 2.0 | 5.0 | — | | [ARSYNL Rx](https://thisglp.com/reviews/arsynl-rx) | 8.5 | 3.0 | 2.0 | 2.0 | 5.0 | — | | [Ascend Vitality](https://thisglp.com/reviews/ascend-vitality) | 8.5 | 5.0 | 2.0 | 2.0 | 7.0 | — | | [AskRx](https://thisglp.com/reviews/ask-rx) | 8.5 | 5.0 | 2.0 | 10.0 | 5.0 | 50 | | [Aspen](https://thisglp.com/reviews/aspen-health) | 8.5 | 10.0 | 10.0 | 10.0 | 5.0 | 51 | | [Aspire Health](https://thisglp.com/reviews/aspire-health) | 8.5 | 3.0 | 2.0 | 2.0 | 5.0 | — | | [Auren Rx](https://thisglp.com/reviews/auren-rx) | 8.5 | 3.0 | 2.0 | 10.0 | 5.0 | 50 | | [AVARA Rx](https://thisglp.com/reviews/avara-rx) | 8.5 | 3.0 | 2.0 | 10.0 | 5.0 | 50 | | [Avono Health](https://thisglp.com/reviews/avono-health) | 8.5 | 10.0 | 2.0 | 2.0 | 5.0 | — | | [AZ Health](https://thisglp.com/reviews/az-health) | 8.5 | 5.0 | 2.0 | 2.0 | 5.0 | — | | [Bayan Health](https://thisglp.com/reviews/bayan-health) | 8.5 | 10.0 | 10.0 | 2.0 | 7.0 | — | | [Believe Health](https://thisglp.com/reviews/believe-health) | 8.5 | 3.0 | 10.0 | 2.0 | 5.0 | — | | [Belle Health](https://thisglp.com/reviews/belle-health) | 8.5 | 5.0 | 10.0 | 10.0 | 5.0 | 50 | | [Better U Care](https://thisglp.com/reviews/better-u-care) | 8.5 | 10.0 | 10.0 | 4.2 | 5.0 | 21 | ## What a low mark is not A low mark is a statement about what a seller published, not about the medicine it dispenses or the clinicians it works with. A seller can run an excellent service and score badly here by keeping its prices behind an account, and several do. The marks measure one thing: how much a reader can find out before handing over their details. --- # Trademarks | This GLP Third-party product and company names on This GLP belong to their respective owners. Our use is nominative, for identification and comparison. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/trademarks Updated: 2026-09-16 Legal # Trademarks Effective September 15, 2026 This GLP discusses branded medications and products in the course of its research and reviews. We use those names only to identify and describe the products in question — a nominative, descriptive use. All trademarks, service marks, and trade names referenced on this Site are the property of their respective owners, and their appearance here does not imply any affiliation with, endorsement by, or sponsorship from those owners. ## 1\. Trademark Attributions The following attributions apply to marks frequently referenced on This GLP: - **GLP-1** and **GLP-1 acetate** are International Nonproprietary Names for the underlying compound, not trademarks of any party. - The names and logos of the telehealth providers and compounding pharmacies we review belong to those companies. All other product names, brand names, logos, and marks referenced on this Site are trademarks of their respective owners. ## 2\. Non-Affiliation Statement **This GLP is not affiliated with, endorsed by, or sponsored by any manufacturer, compounding pharmacy or telehealth provider it reviews.** References to any company, product, or brand are for identification and editorial commentary only and do not signify any relationship, partnership, or approval unless we explicitly state otherwise. ## 3\. Our Own Marks “This GLP”, the This GLP logo, and the look and feel of this Site are marks and property of This GLP and its publisher. Please do not use them in a way that suggests affiliation or endorsement without our written permission. See our [Terms of Use](https://thisglp.com/terms) for details on intellectual property. ## 4\. Corrections If you are a rights holder and believe a mark has been attributed incorrectly, please contact us at [notices@thisglp.com](mailto:notices@thisglp.com) and we will review and correct it promptly through our [corrections](https://thisglp.com/corrections) process. For our full trademark and affiliate-disclosure context, see our [Disclosures](https://thisglp.com/disclosures).